<SEC-DOCUMENT>0001840199-24-000006.txt : 20240116
<SEC-HEADER>0001840199-24-000006.hdr.sgml : 20240116
<ACCEPTANCE-DATETIME>20240116064118
ACCESSION NUMBER:		0001840199-24-000006
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		135
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20240116
DATE AS OF CHANGE:		20240116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Waldencast plc
		CENTRAL INDEX KEY:			0001840199
		STANDARD INDUSTRIAL CLASSIFICATION:	PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40207
		FILM NUMBER:		24533588

	BUSINESS ADDRESS:	
		STREET 1:		10 BANK STREET, SUITE 560
		CITY:			WHITE PLAINS
		STATE:			NY
		ZIP:			10606
		BUSINESS PHONE:		(917) 546-6828

	MAIL ADDRESS:	
		STREET 1:		10 BANK STREET, SUITE 560
		CITY:			WHITE PLAINS
		STATE:			NY
		ZIP:			10606

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Waldencast Acquisition Corp.
		DATE OF NAME CHANGE:	20210112
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>wald-20221231.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2024 Workiva--><!--r:cb24ed7e-6299-4643-a980-910da3dfa7bf,g:f940d8a8-f49a-452c-b5e1-83817ee3c0b3,d:f2fc25067f8b45fc8cc165df93f3be1c--><html xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:wald="http://www.waldencast.com/20221231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>wald-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-43">0001840199</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-44">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-45">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-46">2022</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" id="f-47">US</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" id="f-48">Y9</ix:nonNumeric><ix:nonFraction unitRef="shares" contextRef="c-96" decimals="4" name="wald:StockholdersEquityNumberOfSharesInEachUnit" scale="0" id="f-579">0.3333</ix:nonFraction><ix:nonNumeric contextRef="c-361" name="wald:ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption" format="ixt-sec:durday" id="f-1576">3</ix:nonNumeric><ix:nonNumeric contextRef="c-390" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod" format="ixt-sec:duryear" id="f-1814">10</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-401" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="f-1815">0.33</ix:nonFraction><ix:nonNumeric contextRef="c-501" name="wald:TransitionServicesAgreementPeriod" id="f-2134">P12M</ix:nonNumeric><ix:nonNumeric contextRef="c-501" name="wald:TransitionServicesAgreementExtensionPeriod" id="f-2135">P12M</ix:nonNumeric><ix:nonNumeric contextRef="c-516" name="wald:ForwardPurchaseAgreementHurdleRateAccrualPeriod" format="ixt-sec:duryear" id="f-2150">5</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="c-15" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-2183">one</ix:nonFraction><ix:nonFraction unitRef="segment" contextRef="c-15" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-2184">one</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="wald-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">us-gaap:SupplyCommitmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="distributor"><xbrli:measure>wald:distributor</xbrli:measure></xbrli:unit><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfDistributorServiceFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfDistributorServiceFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfRevenueRecognitionTimingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:SADistributorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfRevenueRecognitionTimingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:SADistributorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:PhysicianChannelProviderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:PhysicianChannelProviderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfDistributorRevenueNonstandardPaymentTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:USOnlineMarketplaceDistributorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfDistributorRevenueNonstandardPaymentTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:USOnlineMarketplaceDistributorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:OtherMisstatementAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:OtherMisstatementAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfRevenueRecognitionTimingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:SADistributorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:PhysicianChannelProviderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:USOnlineMarketplaceDistributorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:USOnlineMarketplaceDistributorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:USOnlineMarketplaceDistributorAndSADistributorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfDistributorRevenueNonstandardPaymentTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfDistributorServiceFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfDistributorServiceFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfCapitalizedComputerSoftwareExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfCapitalizedComputerSoftwareExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:OtherMisstatementAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfCapitalizedMarketingExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfCapitalizedInternalUseSoftwareCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfAccruedDistributionServiceFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">wald:VendorOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">wald:InventoryPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">wald:VendorOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">wald:InventoryPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">wald:InventoryPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">wald:VendorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">wald:InventoryPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">wald:VendorThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">wald:VendorOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">wald:InventoryPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">wald:InventoryPurchasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">wald:VendorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">wald:VendorOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:LenderConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">wald:VendorTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:LenderConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">wald:VendorOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:LenderConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">wald:ComputerHardwareSoftwareAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">wald:GondolasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wald:FounderAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>wald:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wald:LimitedPartnershipUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="director"><xbrli:measure>wald:director</xbrli:measure></xbrli:unit><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiChinaBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:CedarwalkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiChinaBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiChinaBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiChinaBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:TretinoinDistributionAndSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:TretinoinDistributionAndSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:TretinoinDistributionAndSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:TretinoinDistributionAndSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:FormulationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:FormulationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:FormulationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:FormulationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:PhysicianChannelProviderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:PhysicianChannelProviderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:PhysicianChannelProviderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:PhysicianChannelProviderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:SpaChannelDistributorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:SpaChannelDistributorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:SpaChannelDistributorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:SpaChannelDistributorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wald:RestOfTheWorldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wald:RestOfTheWorldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wald:RestOfTheWorldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wald:RestOfTheWorldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:VN</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:VN</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:VN</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:VN</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:TretinoinDistributionAndSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:FormulationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:TretinoinDistributionAndSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:FormulationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2018TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2018TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2018RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2018RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:PPPLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:PPPLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="wald:VariableRateComponentAxis">wald:VariableRateComponentOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">wald:AlternateBaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">wald:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="wald:VariableRateComponentAxis">wald:VariableRateComponentTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">wald:ApplicableRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="wald:VariableRateComponentAxis">wald:VariableRateComponentThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="wald:VariableRateComponentAxis">wald:VariableRateComponentOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">wald:AlternateBaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2018TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2018TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:PPPLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:PPPLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="operatinglease"><xbrli:measure>wald:operatingLease</xbrli:measure></xbrli:unit><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:InterestRateCollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:InterestRateCollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:SponsorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BurwellMountainTrustAndZenoInvestmentMasterFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-20</xbrli:startDate><xbrli:endDate>2021-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:SponsorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BurwellMountainTrustAndZenoInvestmentMasterFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-20</xbrli:startDate><xbrli:endDate>2021-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BeautyVenturesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:SponsorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BeautyVenturesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BeautyVenturesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:SponsorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:InterestRateCollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:InterestRateCollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:InterestRateCollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:PublicDerivativeWarrantLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:PublicDerivativeWarrantLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:PublicDerivativeWarrantLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:PublicDerivativeWarrantLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:PrivateDerivativeWarrantLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:PrivateDerivativeWarrantLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:PrivateDerivativeWarrantLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:PrivateDerivativeWarrantLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">wald:ComputerHardwareSoftwareAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">wald:GondolasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:A2022IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:A2022IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-27</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-27</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-27</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-27</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-27</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">wald:ShareBasedPaymentArrangementFounderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-12</xbrli:startDate><xbrli:endDate>2022-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-12</xbrli:startDate><xbrli:endDate>2022-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="individual"><xbrli:measure>wald:individual</xbrli:measure></xbrli:unit><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">wald:ShareBasedPaymentArrangementFounderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-12</xbrli:startDate><xbrli:endDate>2022-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">wald:ShareBasedPaymentArrangementFounderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-12</xbrli:startDate><xbrli:endDate>2022-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:LongTermIncentiveAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:OneTimStockGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:OneTimStockGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wald:FounderAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wald:ReplacementAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wald:FounderAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wald:FounderAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:PredecessorIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:PredecessorIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:PredecessorIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:PredecessorIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:PredecessorIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:PredecessorIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:PredecessorIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:PredecessorIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:InvestorDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorAndInvestorDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BurwellMountainTrustAndZenoInvestmentMasterFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:SponsorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BurwellMountainTrustAndZenoInvestmentMasterFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BurwellMountainTrustAndZenoInvestmentMasterFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BeautyVenturesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:SponsorWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BeautyVenturesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BeautyVenturesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-18</xbrli:startDate><xbrli:endDate>2021-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:InvestorDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:AaronChatterleyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">wald:ForwardPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PrivatePlacementWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:JanuaryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:JanuaryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:ConvertibleWorkingCapitalNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:ConvertibleWorkingCapitalNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:ConvertibleWorkingCapitalNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:ConvertibleWorkingCapitalNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:NonConvertibleWorkingCapitalNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:NonConvertibleWorkingCapitalNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:NonConvertibleWorkingCapitalNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:NonConvertibleWorkingCapitalNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-15</xbrli:startDate><xbrli:endDate>2021-03-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tradingday"><xbrli:measure>wald:tradingDay</xbrli:measure></xbrli:unit><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiChinaBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">us-gaap:SupplyCommitmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiChinaBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiChinaBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiChinaBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiShanghaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiShanghaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiShanghaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiShanghaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiShanghaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:CedarwalkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:CedarwalkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">wald:SkintrinsiqDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">wald:SkintrinsiqDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">wald:SkintrinsiqDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">wald:SkintrinsiqDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wald:StockGrowthIncentiveAwardsSGIAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>wald:lease</xbrli:measure></xbrli:unit><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:WarehouseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">wald:ObagiBlueSeaHoldingLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:SADistributorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:VietnamPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:SADistributorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:VietnamPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840199</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-27</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">20-F</ix:nonNumeric></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One) </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentRegistrationStatement" format="ixt:fixed-false" id="f-2">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-3">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: </span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-5"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-6">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentShellCompanyReport" format="ixt:fixed-false" id="f-7">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-8">001-40207</ix:nonNumeric></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-9">Waldencast plc</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jersey</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Translation of Registrant&#8217;s name into English)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Jurisdiction of incorporation or organization)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">10 Bank Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-11">Suite 560</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">White Plains</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-13">NY</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">10606</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(917) 546-6828 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:ContactPersonnelName" id="f-15">Michel Brousset</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:EntityAddressAddressLine1" id="f-16">10 Bank Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c-2" name="dei:EntityAddressAddressLine2" id="f-17">Suite 560</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:EntityAddressCityOrTown" id="f-18">White Plains</ix:nonNumeric>, <ix:nonNumeric contextRef="c-2" name="dei:EntityAddressStateOrProvince" id="f-19">NY</ix:nonNumeric> <ix:nonNumeric contextRef="c-2" name="dei:EntityAddressPostalZipCode" id="f-20">10606</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-2" name="dei:CityAreaCode" id="f-21">917</ix:nonNumeric>) <ix:nonNumeric contextRef="c-2" name="dei:LocalPhoneNumber" id="f-22">546-6828</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person) </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered or to be registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of exchange</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-23">Class A ordinary shares, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-24">WALD</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-25">Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-4" name="dei:Security12bTitle" id="f-26">Redeemable warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-4" name="dei:TradingSymbol" id="f-27">WALDW</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-4" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-28">Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered or to be registered pursuant to Section 12(g) of the Act: None </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the report: </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2022, the issuer had 107,564,785 ordinary shares outstanding, consisting of <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-29">86,460,560</ix:nonFraction> outstanding Waldencast plc Class A ordinary shares, par value $0.0001 per share, and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">21,104,225</ix:nonFraction>. outstanding Waldencast plc Class B ordinary shares, par value $0.0001 per share. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-31">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-32">No</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-33">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-34">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-35">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-36">x</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-37">o</ix:nonNumeric></span></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4pt">The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting over Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-38">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-true" id="f-39">x</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtRestatementRecoveryAnalysisFlag" format="ixt:fixed-false" id="f-40">o</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAccountingStandard" id="f-41">U.S. GAAP</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International Financial Reporting Standards as issued by the International Accounting Standards Board</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If &#8220;Other&#8221; has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow. Item 17 </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Item 18 </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-42">x</ix:nonNumeric></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_10">INTRODUCTION AND USE OF CERTAIN TERMS </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_10">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_13">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_13">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_16">PART I </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_16">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_19">ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_19">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_22">ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_22">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_25">ITEM 3. KEY INFORMATION </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_25">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_28">ITEM 4. INFORMATION ON THE COMPANY</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_28">62</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_31">ITEM 4A. UNRESOLVED STAFF COMMENTS </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_31">92</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_34">ITEM 5. </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_34">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_34">92</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_91">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_91">122</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_94">ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_94">131</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_97">ITEM 8. FINANCIAL INFORMATION </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_97">141</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_193">ITEM 9. THE OFFER AND LISTING </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_193">207</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_196">ITEM 10. ADDITIONAL INFORMATION </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_196">207</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_199">ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_199">220</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_202">ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_202">221</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_205">PART II </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_205">221</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_208">ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_208">221</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_211">ITEM 14. MATERIAL MODIFICATIONS TO RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_211">221</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_214">ITEM 15. CONTROLS AND PROCEDURES </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_214">221</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_220">ITEM 16A. AUDIT COMMITTEE AND FINANCIAL EXPERTS </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_220">223</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_223">ITEM 16B. CODE OF ETHICS </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_223">223</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_226">ITEM 16C. PRINCIPAL ACCOUNT FEES AND SERVICES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_226">223</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_229">ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_229">224</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_232">ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_232">224</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_235">ITEM 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_235">224</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_238">ITEM 16G. CORPORATE GOVERNANCE </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_238">224</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_241">ITEM 16H. MINE SAFETY DISCLOSURE </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_241">225</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_244">ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_244">225</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_247">ITEM 16J. INSIDER TRADING POLICIES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_247">225</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_250">PART III </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_250">225</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_253">ITEM 17. FINANCIAL STATEMENTS </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_253">225</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_256">ITEM 18. FINANCIAL STATEMENTS </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_256">225</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_259">ITEM 19. EXHIBITS </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_259">225</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_262">EXHIBIT INDEX </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_262">226</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_265">SIGNATURE </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_265">230</a></span></div></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION AND USE OF CERTAIN TERMS </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast plc publishes consolidated financial statements expressed in U.S. dollars. Our consolidated financial statements responsive to Item 18 of this Annual Report filed on Form 20-F (including information incorporated by reference herein, this &#8220;Report&#8221;) with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) are prepared in accordance with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context requires otherwise, the words &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Company,&#8221; &#8220;Waldencast&#8221; and similar words or phrases in this Report refer to Waldencast plc (formerly known as Waldencast Acquisition Corp.), a public limited company incorporated under the laws of Jersey, and its consolidated subsidiaries, including, but not limited to, Obagi Global Holdings Limited, a Cayman Islands exempted company, and its subsidiaries (collectively, &#8220;Obagi&#8221;) and Milk Makeup LLC, a Delaware limited liability company, and its subsidiaries (collectively, &#8220;Milk&#8221;), which Waldencast acquired on July 27, 2022 (the &#8220;Closing Date&#8221;), as more fully described in &#8220;Item 4. Information on the Company&#8221; and &#8220;Item 10. Additional Information&#8212;C. Material Contracts&#8221; in this Report (the &#8220;Business Combination&#8221;).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accounting for the Business Combination, Waldencast plc was deemed to be the accounting acquirer, and Obagi was deemed to be the predecessor entity for purposes of financial reporting. As a result, when reading our financial statements and information about historical financial results in this Report, you should note there is a clear division between the &#8220;predecessor&#8221; periods that include financial statements up to the Closing Date (the &#8220;Predecessor Periods&#8221;), and successor periods that include all periods after the close of the Business Combination (the &#8220;Successor Periods&#8221;). The predecessor and successor results shown are not comparable, as the Predecessor Periods include only the financial statements of Obagi (which prior to the Business Combination also included its business in the China Region (as defined below), which was not acquired by Waldencast) and the Successor Periods include the consolidated financial statements of Waldencast, which include Obagi and Milk as well. The Successor Periods reflect that since the Closing Date, we have organized our business into two reportable segments - the business of Obagi, which we refer to as our &#8220;Obagi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Skincare&#8221; segment and the business of Milk, which we refer to as our &#8220;Milk Makeup&#8482;&#8221; segment. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December 31, 2023, management of the Company and the audit committee of Waldencast&#8217;s Board of Directors (the &#8220;Board&#8221;), with the assistance of legal and accounting advisors, conducted an internal review of certain accounting issues related to the recognition of revenue in the Predecessor Periods, including issues related to the recognition of revenue from sales of Obagi products to Obagi&#8217;s Southeast Asia Distributor (the &#8220;SA Distributor&#8221;) in Vietnam, transactions with other Obagi distributors both within and outside the U.S., as well as certain other accounting items. As a result of the review, the Board, upon the recommendation of the audit committee, concluded that the financial statements for certain Predecessor Periods should no longer be relied upon. On that basis, this Report contains a restated consolidated balance sheet as of December 31, 2021 and consolidated statements of operations and comprehensive income (loss), cash flows and shareholders&#8217; equity for the years ended December 31, 2021 and 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Report, in addition to the terms already defined above, unless stated otherwise or the context otherwise required, all references to:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;2022 Credit Agreement&#8221; means the Credit Agreement, dated as of June 24, 2022, by and among the Borrower, Parent Guarantor, the Lenders and the Administrative Agent, as amended, restated or otherwise modified from time to time;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Administrative Agent&#8221; means JPMorgan Chase Bank, N.A. in its capacity as the administrative agent under the 2022 Credit Agreement;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;affiliate&#8221; means, with respect to any specified Person, any Person that, directly or indirectly, controls, is controlled by, or is under common control with, such specified Person, whether through one or more intermediaries or otherwise. The term &#8220;control&#8221; (including the terms &#8220;controlling,&#8221; &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Borrower&#8221; means Waldencast Finco Limited, a wholly-owned subsidiary of Waldencast;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;CARES Act&#8221; means Coronavirus Aid, Relief, and Economic Security Act;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Class A ordinary shares&#8221; means our Class&#160;A ordinary shares, par value $0.0001 per share;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Class B ordinary shares&#8221; means our Class&#160;B ordinary shares, par value $0.0001 per share;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;cGMP&#8221; means current Good Manufacturing Practice regulations enforced by the FDA;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;China Region&#8221; means the People&#8217;s Republic of China (&#8220;PRC&#8221;), including the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Code&#8221; means </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the U.S. Internal Revenue Code of 1986, as amended;</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;COVID-19&#8221; means SARS-CoV-2 or COVID-19, and any evolutions or mutations thereof or related or associated epidemics, pandemics or disease outbreaks;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;EMA&#8221; means the European Medicines Agency, an agency of the European Union (&#8220;EU&#8221;);</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Equityholder Representative&#8221; means Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as representative of the Milk Members;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Exchange Act&#8221; means the Securities Exchange Act of 1934, as amended;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;FDA&#8221; means the U.S. Food and Drug Administration;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;FDCA&#8221; means the Federal Food, Drug, and Cosmetic Act;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Holdco 1&#8221; means Obagi Holdco 1 Limited, a private limited company incorporated under the laws of Jersey and a wholly-owned subsidiary of Waldencast plc;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;International&#8221; means the entire world except the U.S.;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;IRS&#8221; means the U.S. Internal Revenue Service;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Jersey&#8221; means the Bailiwick of Jersey, Channel Islands, a British crown dependency;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Jersey Companies Law&#8221; means the Companies (Jersey) Law 1991, as amended;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Lenders&#8221; means the lenders party to the 2022 Credit Agreement;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;MoCRA&#8221; means the </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Modernization of Cosmetics Regulation Act of 2022;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Merger Sub&#8221; means Obagi Merger Sub, Inc., a Cayman Islands exempted company;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Milk Members&#8221; m</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eans the holders of the common and preferred membership units of Milk Makeup LLC prior to the Business Combination;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Milk Purchase Agreement&#8221; means the Equity Purchase Agreement, dated as of November&#160;15, 2021, by and among Waldencast, Waldencast LP, Holdco 1, Milk, the Milk Members and the Equityholder Representative;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Nasdaq&#8221; means The Nasdaq Stock Market LLC;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Obagi China Business&#8221; means all sales of Obagi products in the China Region prior to the Business Combination.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Obagi Merger Agreement&#8221; means the Agreement and Plan of Merger, dated as of November&#160;15, 2021, by and among Waldencast, Merger Sub and Obagi;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Ordinary Shares&#8221; means our Class A ordinary shares and Class B ordinary shares, collectively;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Parent Guarantor&#8221; means Waldencast LP in its capacity as parent guarantor under the 2022 Credit Agreement;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Person&#8221; means any individual, firm, corporation, partnership, exempted limited partnership, limited liability company, exempted company, incorporated or unincorporated association, joint venture, joint stock company, governmental authority or instrumentality or other entity of any kind; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Securities Act&#8221; means the Securities Act of 1933, as amended; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Sponsor&#8221; means Waldencast Long-Term Capital LLC, a Cayman Islands limited liability company;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;United States dollars,&#8221; &#8220;U.S. dollars,&#8221; &#8220;USD&#8221; or &#8220;$&#8221; are to the lawful currency of the U.S.; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Waldencast LP&#8221; means Waldencast Partners LP, a Cayman Islands exempted limited partnership and indirect subsidiary of Waldencast plc; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Waldencast Purchasers&#8221; means Holdco 1 and Waldencast LP.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All product and/or brand names, whether designated by notice or not (&#174;/&#8482;), are trademarks of Waldencast plc and/or its affiliates. This Report also contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Report may appear without the&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;or&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reference in this Report to the websites maintained by Waldencast, Obagi, Milk or any other company is not deemed to incorporate by reference any information available on such websites into this Report and such information does not form part of this Report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Report contains certain industry and market data that was obtained from third-party sources, such as industry surveys and industry publications, including, but not limited to, those issued by the U.S. Census Bureau, the American Society of Plastic Surgeons, Euromonitor International and others. In addition, the Report also contains other industry and market data, including market size estimates, growth and other projections and information regarding our competitive </span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">position, prepared by our management on the basis of such industry sources and our management's knowledge of and experience in the industry and markets in which we operate (including management's estimates and assumptions relating to such industry and markets based on that knowledge). Our management has developed its knowledge of such industry and markets through its experience and participation in these markets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, industry surveys and industry publications generally state that the information they contain has been obtained from sources believed to be reliable but that the accuracy and completeness of such information is not guaranteed and that any projections they contain are based on a number of significant assumptions. Forecasts, projections and other forward-looking information obtained from these sources involve risks and uncertainties and are subject to change based on various factors, including those discussed in the section &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; below. You should not place undue reliance on these statements.</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Report, as well as our other public filings or public statements, include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements. These forward-looking statements are often identified by terms and phrases such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;continue,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;predict,&#8221; &#8220;will&#8221; and variations of such words and similar expressions but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements include assumptions and relate to our future prospects, developments and business strategies. Factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the material weaknesses in our internal control over financial reporting, our efforts to remediate such material weakness and the timing of remediation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the impact of the restatement of our consolidated financial statements with respect to the Predecessor Periods;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to retain the listing of our securities on The Nasdaq Capital Market and our ability to meet Nasdaq&#8217;s continued listing standards;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to achieve the anticipated benefits from any acquired business, including the Obagi and Milk acquisitions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to successfully implement our management&#8217;s plans and strategies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the overall economic and market conditions, sales forecasts and other information about our possible or assumed future results of operations or our performance;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the general impact of geopolitical events, including the impact of current wars, conflicts and other hostilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the impact of any legal proceedings or investigations, including the outcome of any litigation or investigation related to or arising out of the restatement of our financial results or material weakness in internal control over financial reporting;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to manage expenses, our liquidity and our investments in working capital;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">any failure to obtain governmental and regulatory approvals related to our business and products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">risks related to Class A ordinary shares and warrants, including continued price volatility;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the impact of any international trade or foreign exchange restrictions, increased tariffs, foreign currency exchange fluctuations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to raise additional capital or complete desired acquisitions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to comply with financial covenants imposed by the 2022 Credit Agreement and the impact of debt service obligations and restrictive debt covenants;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the impact of any unfavorable publicity on our business or products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our ability to implement our strategic initiatives and continue to innovate Obagi&#8217;s and Milk&#8217;s existing products and anticipate and respond to market trends and changes in consumer preferences;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">changes in future exchange or interest rates or credit ratings, changes in tax laws, regulations, rates and policies; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">other risks and uncertainties described from time to time in our filings with the SEC.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We undertake no obligation to update or revise the forward-looking statements included in this Report, whether as a result of new information, future events or otherwise, after the date of this Report. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Factors that could cause or contribute to such differences are discussed in &#8220;Item 5. Waldencast&#8217;s Operating and Financial Review and Prospects&#8221; as well as in &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8221; included herein. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I </span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_19"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Directors and Senior Management</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Advisers</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Auditors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Not applicable. </span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_22"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. KEY INFORMATION </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Selected Financial Data</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserved.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Capitalization and Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Reasons for the Offer and Use of Proceeds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Risk Factors </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">In evaluating our business, you should carefully consider the following discussion of material risks, events and uncertainties that make an investment in us speculative or risky, in addition to the other information in this Report. A manifestation of any of the following risks and uncertainties could, in circumstances we may or may not be able to accurately predict, materially and adversely affect our business and operations, growth, reputation (including the commercial reputation of our products), prospects, product pipeline and sales, operating and financial results, financial condition, cash flows, liquidity and share price. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. It is not possible to predict or identify all such factors; our operations could also be affected by factors, events or uncertainties that are not presently known to us or that we currently do not consider to present significant risks to our operations. Therefore, you should not consider the following risks to be a complete statement of all the potential risks or uncertainties that we face.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF KEY RISKS</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks Related to Internal Controls and Financial Reporting</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o We are subject to an investigation by the SEC and may face litigation and other risks as a result of the restatement of our financial results and material weaknesses in our internal control over financial reporting.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o We have identified material weaknesses in our internal control over financial reporting. If we are unable to develop and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results in a timely manner, which may adversely affect investor confidence in us and materially and adversely affect our business and operating results.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks Relating to our Business Operations and Financial Condition</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o We may not be able to successfully implement our growth strategy, which includes among other things, expanding international sales, and the historical growth of our Obagi Skincare and Milk Makeup Businesses may not be indicative of our future performance.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o Failure to comply with any of the covenants under our 2022 Credit Agreement could result in an event of default, which may accelerate our outstanding indebtedness and have a material adverse effect on our business, liquidity position and financial position.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o If we fail to maintain compliance with the continued listing standards of Nasdaq, our securities may be delisted and the price of our Class A ordinary shares and our ability to access the capital markets could be negatively impacted.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o Any legal proceedings, investigations or claims against us could be costly and time-consuming to defend, and, if adversely decided or settled, could materially and adversely affect our business, financial condition and results of operations and could harm our reputation regardless of the outcome. In addition, our business and operations could be negatively affected if they become subject to any securities litigation or shareholder activism, which could cause us to incur significant expense, hinder execution of business and growth strategy and impact our share price.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o We rely on a number of third-party suppliers, distributors and other vendors for our business, and they may not continue to produce products or provide services that are consistent with our standards or applicable regulatory </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements, which could harm our brand, cause consumer dissatisfaction and require us to find alternative suppliers of our products.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks Related to the Ownership of our Securities</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o We may issue additional securities without your approval, or conduct future resales, which would dilute your ownership interests and may depress the market price of our Class A ordinary shares even if our business is doing well.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o We may be exposed to unknown or contingent liabilities and may be required to subsequently take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on our financial condition, results of operations and the price of our securities, which could cause you to lose some or all of your investment.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o Warrants will be exercisable for our Class A ordinary shares, which would increase the number of shares eligible for future resale in the public market and result in dilution to our shareholders, and a sale of a substantial number of our securities in the public market could cause the price of our securities to decline.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o A significant number of our shares are held by our sponsors and the former owner of Obagi.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks Related to Global Economic, Political and Social Conditions</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o Our sales and profitability may suffer if current economic conditions in any of our major markets inhibit people from spending their disposable income on beauty and wellness products.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks Related to our Obagi Skincare Business</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o We are dependent on one main provider in the U.S. who is considered our customer, and the loss of the services of such provider, or their inability to pay invoices in accordance with agreed-upon payment terms, could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o Our Obagi Skincare business faces intense competition, in some cases from companies that have significantly greater resources than we do, which could limit our ability to generate sales and/or render our products obsolete.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o The loss of a significant customer or inability of a large customer to pay invoices in accordance with agreed-upon payment terms could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Legal and Regulatory Risks That Could Adversely Impact our Obagi Skincare Business</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o  Laws, regulations, enforcement trends or changes in existing regulations governing the introduction, approval, marketing and sale of our over-the-counter (&#8220;OTC&#8221;) drug, device and cosmetic products to consumers could harm our business.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks Related to our Milk Makeup Business</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o The loss of a significant reseller could materially and adversely affect the business, financial condition and results of operations for our Milk Makeup business.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Legal and Regulatory Risks That Could Adversely Impact our Milk Makeup Business</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o New laws, regulations, enforcement trends or changes in existing regulations governing the introduction, marketing and sale of Milk Makeup products to consumers could harm our business.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks Related to the Business &amp; Wellness Industry</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o Any damage to our reputation or brands, whether stemming from our use of social media or otherwise, may materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o The design, development, manufacture and sale of our products involve the risk of product liability and other claims by consumers and other third parties, and our insurance may be insufficient to cover any such claims.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Internal Controls and Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to an investigation by the SEC and may face litigation and other risks as a result of the restatement of our financial results and material weaknesses in our internal control over financial reporting.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of the restatement of our financial results for the Predecessor Periods, the associated material weaknesses in our internal control over financial reporting described below, and other matters raised or that may in the future be raised by the SEC, we are subject to an investigation by the SEC and may be exposed to a number of additional risks and uncertainties, including (i) potential litigation or other disputes that may include, among others, claims invoking the federal and state securities laws, contractual claims or other claims arising from the material weaknesses in our internal control over financial reporting and preparation and/or restatement of our financial statements; (ii) unanticipated costs for accounting, advisory and legal fees in connection with or related to the restatement and/or investigation; (iii) diversion of the efforts and attention of management and other personnel from our business operations; and (iv) fines, penalties or other actions required as the outcome of government investigations, all of which could result in a potential loss of investor confidence and/or a negative impact on the price of our securities.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As previously disclosed, we proactively and voluntarily self-reported our review of the historical accounting used by Obagi to the SEC. In connection with this matter, we received a document subpoena in September 2023. Although we are fully cooperating with the SEC&#8217;s investigation and continue to respond to requests related to this matter, we cannot predict when such matters will be completed or the outcome or potential impact of this matter on our business, investor confidence or the price of our securities. Any remedial measures, sanctions, fines or penalties, including, but not limited to, financial penalties and awards, injunctive relief and compliance conditions, which may be imposed on us in connection with this matter could have a material adverse effect on our business, financial condition and results of operations. Additionally, the investigation has resulted in substantial costs and we are likely to continue to incur substantial costs, regardless of the outcome of the investigation.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of the date of this Report, other than the investigation, we have no knowledge of any litigation or dispute arising from the material weaknesses in our internal control over financial reporting, the preparation of our financial statements and/or the restatement of our financial results. However, we cannot assure you that such litigation or dispute will not arise in the future. Any such litigation or dispute, whether successful or not, could have a material adverse effect on our business, results of operations and financial condition. We cannot assure you that the SEC or another regulatory body will not make further regulatory inquiries or pursue action against us and our senior officers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have identified material weaknesses in our internal control over financial reporting. If we are unable to develop and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results in a timely manner, which may adversely affect investor confidence in us and materially and adversely affect our business and operating results.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the preparation of our consolidated financial statements as of December 31, 2022, we identified material weaknesses in our internal control over financial reporting related to insufficient segregation of duties and review procedures, insufficient resources with appropriate levels of understanding of US GAAP and insufficient policies and procedures regarding internal controls over financial reporting.  A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis. As part of our plan to remediate these material weaknesses, we performed, with the assistance of expert advisors, a full review of our internal control procedures and have begun to implement new controls and processes, hired additional qualified personnel in our finance and legal departments and established more robust processes to support our internal control over financial reporting, including clearly defined policies, roles, responsibilities, and appropriate segregation of duties, and we plan to continue these efforts. Notwithstanding the identified material weaknesses, our management has concluded that the consolidated financial statements included in this Report present fairly, in all material respects, our financial position, results of operations and cash flows for the periods disclosed in conformity with GAAP. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Item 15- Controls and Procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; for further information. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, earlier in 2022 we reevaluated the classification of our Class A ordinary shares subject to possible redemption. After consultation with our advisors, our management and our audit committee concluded that the previously issued financial statements as of March 18, 2021, March 31, 2021 and June 30, 2021 and for the periods from January 1, 2021 through March 31, 2021, and the three months and six months ended June 30, 2021 contained misstatements for such classification and, accordingly, we restated them to report all Class A ordinary shares subject to possible redemption as temporary equity. We identified a deficiency in our accounting for warrants, which resulted in the restatement of our audited opening balance sheet as of March 18, 2021. We determined that these deficiencies constituted a material weakness in accounting for complex financial instruments.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective internal controls are necessary for us to provide reliable financial reports and prevent fraud. As noted above, we have taken a number of measures to remediate the material weaknesses and continue to evaluate steps to enhance our internal controls. However, these remediation measures have been and may continue to be time consuming and costly and we cannot assure you that these initiatives will ultimately have the intended effects. If we are unable to remediate our material weaknesses in a timely manner or identify additional material weaknesses, we may be unable to provide required financial information in a timely and reliable manner and may incorrectly report financial information. If our financial statements continue to not be filed on a timely basis, we could be subject to sanctions or additional investigations by Nasdaq, the SEC or other regulatory authorities. Failure to timely file has caused us to be ineligible to utilize short form registration statements on Form F-3 or Form F-4, which may impair our ability to obtain capital in a timely fashion, to provide liquidity to our employees and shareholders, to execute our business strategies or issue shares to effect an acquisition. Any of these events, whether they have or were to occur, could have a material adverse effect on our business.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the existence of material weaknesses in internal control over financial reporting could adversely affect our reputation or investor perceptions of us, which could have a negative effect on the trading price of our securities.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We cannot assure you that the measures we have taken and plan to take in the future will remediate the material weaknesses identified or that any additional material weaknesses or restatements of financial results will not arise in the future due to a failure to implement and maintain adequate internal control over financial reporting. Even if we are successful in strengthening our controls and procedures, in the future those controls and procedures may not be adequate to prevent or identify irregularities or errors or to facilitate the fair presentation of our financial statements.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Relating to our Business Operations and Financial Condition</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may not be able to successfully implement our growth strategy, and the historical growth of our Obagi Skincare and Milk Makeup Businesses may not be indicative of our future performance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The future growth, profitability and cash flows of our Obagi Skincare and Milk Makeup businesses depend upon our ability to successfully implement our growth strategy, which, in turn, is dependent upon a number of key initiatives, including our ability to:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">grow awareness, relevance and trial of the Obagi and Milk brands and products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">maintain a regular supply of core existing products and execute effective go-to-market strategies to grow them;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">maintain and further strengthen our relationships with our physician customers, international distributors and retail partners in each geographic market where we sell products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">maintain and enhance our reputation as a provider of high-quality products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">secure new points of distribution in new markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">maintain the ability to sell our products within our existing retail partners for Milk products and operate and ship from our own e-commerce platforms without interruption;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">enhance the productivity of our brands within our points of distribution;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">maintain and enhance our digital platforms and capabilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">execute our go-to-market strategies effectively;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">protect our key talent from leaving;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">ensure that we are able to sell our products with attractive margins that deliver profit;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">achieve our growth targets with the financial investments outlined in our plans for each business; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">predict our growth and manage our financial investments appropriately to reach our targets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We cannot assure you that we will successfully achieve any or all of the above initiatives in the manner or time period that we expect. Further, achieving these objectives will require investments that may result in short-term cost increases with net sales materializing on a longer-term horizon and therefore may be dilutive to our earnings. We cannot assure you that we will realize, in full or in part, the anticipated benefits we expect our growth strategy will achieve. The failure to realize those benefits could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may not be successful in executing our growth strategy, and even if we achieve our strategic plan, we may not be able to achieve or sustain profitability in our business. You should not regard the historical growth rates of our Obagi Skincare and Milk Makeup businesses as indicative of future performance. In the future our revenue from our Obagi Skincare and/or Milk Makeup business could be reduced or grow more slowly than we expect. We also may incur significant losses in the future for a number of reasons, including the following risks and the other risks described in this Report, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may lose one or more significant customers or key retailers, or sales of our products through these customers or retailers may decrease;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our products may be the subject of regulatory actions, including, but not limited to, actions by the FDA, the Federal Trade Commission (&#8220;FTC&#8221;) and the Consumer Product Safety Commission (&#8220;CPSC&#8221;) in the U.S. and comparable foreign authorities outside the U.S.;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the ability of our third-party suppliers to produce our products and of our distributors to distribute our products could be disrupted, particularly if they are not able to comply with the new regulations promulgated by the FDA under MoCRA;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the integration of the companies may be more costly or take longer than anticipated;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may be unable to introduce new products that appeal to consumers or otherwise successfully compete with our competitors in the skincare or cosmetics industries; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">we may be unsuccessful in enhancing the recognition and reputation of the Obagi and Milk brands, and our brands may be damaged as a result of, among other reasons, our failure, or alleged failure, to comply with applicable ethical, social, product, labor or environmental standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are able to successfully acquire additional companies and/or expand our Obagi Skincare and Milk Makeup businesses, we will experience growth in the number of our employees and the scope of our operations. To the extent that we acquire and launch additional products, the resulting growth and expansion of the required sales force to sell those products will place a significant demand on our financial, managerial and operational resources. Since many of the new products we are working on may involve new technologies or entering new geographical markets, we may not be able to accurately forecast the number of employees required and the timing of their hire or the associated costs. The extent of any expansion we may experience will be driven largely by the success of our new products and expanded distribution channels. As a result, management&#8217;s ability to project the size of any such expansion and its cost to Waldencast is limited by the following uncertainties: (a) we will not have previously sold any of the new products and the ultimate success of these new products is unknown; (b) we may be entering new geographic markets and/or distribution channels; and (c) the costs associated with any expansion will be partially driven by factors that may not be fully in our control (e.g., timing of hire, market salary rates). Due to the uncertainty surrounding the timing of our strategic initiatives, new product lines or the stabilization of the global markets, our costs to hire significant numbers of new employees could be higher than anticipated. Our success will also depend on the ability of our executive officers and senior management team to continue to implement and improve our operational, information management and financial control systems, and to expand, train and manage our employee base. Our inability to manage growth effectively could cause our operating costs to grow even faster than we currently anticipate and adversely affect our results of operations.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are subject to risks associated with doing business internationally.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A significant component of our growth strategy involves expanding sales of our Obagi Skincare and Milk Makeup products internationally. We generate an increasing share of our revenue from international sales and maintain international operations, including supply and distribution chains that are, and will continue to be, an increasingly significant part of our business. International sales of our Obagi Skincare products currently depend upon the marketing efforts of and sales by certain distributors and licensees. The SA Distributor accounted for</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> a significant portion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> of our net revenue for the period from July 28 to December 31, 2022 (the &#8220;2022 Successor Period&#8221;), the period from January 1 to July 27, 2022 (the &#8220;2022 Predecessor Period&#8221;) and year ended December 31, 2021 (&#8220;2021 Predecessor Period&#8221;). In March 2023, we acquired a majority interest in Obagi Vietnam Import Export Trading MTV Company Limited, a company incorporated in accordance with the laws of Vietnam and formed by the SA Distributor to conduct its business in Vietnam (&#8220;Obagi Vietnam&#8221;). Given the distribution in Vietnam was previously conducted by the SA Distributor, our management has little experience in directly selling and distributing products in this country and is currently setting up its own operations in Vietnam with senior local management to oversee such operations. During the course of 2023, we also began to establish our own entities in various other countries in Southeast Asia to distribute products directly in those countries as well, which requires an initial investment in facilities, personnel and registration of products and other start-up costs. We may experience significant delays between incurring these costs and the sale of products in these countries as a result of required business or regulatory licenses or product approvals and the time required to establish a market presence in a new geographic region. We cannot assure you that we will be able to successfully promote, distribute and sell our products in each of these new markets.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our success in executing on our international expansion strategy will depend upon our ability to, among other things:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">secure all required product and business licenses to operate the business in its jurisdiction;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">develop relationships with sub-distributors, retailers, customers and other business partners in the country;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">attract and retain talent and create processes and systems;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">expand brand awareness, adjust our products to accommodate local consumer preferences and expand our distribution channels and networks within the country.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our future business operations in new countries are subject to the economic, political and legal environment in such geographic areas. In particular, Vietnam&#8217;s economy differs from the economies of the countries in which we currently </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">operate in many respects such as governmental involvement, level of development, growth rate, allocation of resources and inflation rate. The regulatory landscape in Vietnam is also complex and we may encounter difficulties obtaining and maintaining authorizations required by the governmental authorities to import, market and sell our products in this country. Relevant laws and regulations, as well as their interpretations, may be unclear or may evolve in Vietnam. This can make it difficult for us to assess which licenses and approvals are necessary to operate the business of Obagi Vietnam or the processes for obtaining such licenses in Vietnam. For these reasons, we also cannot be certain that we will be able to maintain the licenses and approvals that we have previously obtained, or that once they expire, we will be able to renew them. We cannot be sure that our interpretations of the rules and their exemptions have been or will be consistent with those of the local regulators. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As we expand the business of Obagi in Southeast Asia, we may be required to obtain new licenses in other countries, which could be a complex and timely process, and comply with additional laws and regulations in the new markets in which we plan to operate. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. In addition, many countries from time to time evaluate the regulatory status of various products and ingredients. We may not obtain foreign regulatory approvals on a timely basis, if at all, or may choose not to implement a country&#8217;s labeling requirements if to do so would have a negative impact on our international or domestic operations.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The intellectual property laws in Vietnam and the other countries in Southeast Asia may not be as protective as those in the U.S. and we may encounter difficulties asserting rights against those who misappropriate our intellectual property to sell counterfeit products using our trade names. Moreover, the laws and regulations in these jurisdictions have in the past, and may in the future, change rapidly, and we may not be able to adapt quickly to such changes, which could disrupt our operations. The legal systems of Vietnam and other countries in Southeast Asia differ from most common law jurisdictions. For instance, in Vietnam, previously decided legal cases have little precedential value. The laws and regulations are subject to broad and varying interpretations by government officials and courts. For vague regulations, the courts of Vietnam have the power to read implied terms into contracts, adding a further layer of uncertainty. As a result, government officials and courts often express different views from lawyers on the legality, validity and effect of a particular legal document. In addition, the views of a governmental authority received on a particular issue may have no binding effect or finality, so there is no guarantee that similar issues will be dealt with in a similar way by other governmental authorities. Furthermore, recognition and enforcement of legal rights through Vietnam courts, arbitration centers and administrative agencies in the event of a dispute is uncertain.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our ability to execute our international growth strategy will depend, in part, on our ability to penetrate new international markets and increase the localization of our products and services. We expect to continue to increase our sales and presence outside the U.S., particularly in markets we believe to have high-growth potential. The substantial up-front investment required, the lack of consumer awareness of our products in certain jurisdictions outside of the U.S., differences in consumer preferences and trends between the U.S. and other jurisdictions, the risk of inadequate intellectual property protections and differences in packaging, labeling and related laws, rules and regulations are all substantial matters that need to be evaluated prior to doing business in new jurisdictions and make the success of our international efforts uncertain.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As we continue to expand our international sales, our business will increasingly be subject to certain risks inherent in international business, many of which are beyond our control. These risks include:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">local political and economic instability;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">increased expenses for developing, testing and making localized versions of our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">difficulties in hiring and retaining employees;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">differing employment practices and laws and labor;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">difficulties in registering products in multiple jurisdictions with varying regulatory requirements and in maintaining such registrations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">risks of noncompliance by our distributors, retailers or partners or agents with, and burdens of complying with, a wide variety of extraterritorial, regional and local laws, including competition laws and anti-bribery laws such as the Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) and the U.K. Bribery Act 2010 (the &#8220;Bribery Act&#8221;), despite our compliance efforts and activities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the impact of government-led initiatives to encourage the purchase or support of domestic vendors, which can affect the willingness of customers to purchase products from, or collaborate to promote interoperability of products with, companies whose headquarters or primary operations are not domestic;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">adverse changes in tariff and trade protection measures;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">unexpected changes or differences in foreign regulatory requirements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">potentially negative consequences from changes in tax laws;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the potential business failure of one or more of our distribution partners;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">exchange rate risks;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">potential natural disasters in countries where our products are sold;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">differing degrees of protection for intellectual property; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">difficulties in coordinating foreign distribution.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any of these factors could adversely affect our business, financial condition and results of operations. We cannot assure you that we can successfully manage these risks or avoid their effects.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we fail to generate sufficient cash flow from our operations, we will be unable to continue to develop and commercialize new products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect capital and operating expenditures to increase over the next several years as we expand the infrastructure, international footprint, distribution channels and our commercialization, clinical trial, research and development (&#8220;R&amp;D&#8221;) and manufacturing activities for our Obagi Skincare and Milk Makeup businesses. In order to fund these activities and our growth strategy, in September 2023, we entered into subscription agreements with certain investors for the issuance and sale of 14,000,000 Class A ordinary shares in a private placement to (i) one stakeholder of Beauty Ventures LLC (&#8220;Beauty Ventures&#8221;), which is a beneficial owner of 21.6%  of our Class A ordinary shares (ii) certain other existing equityholders, who qualified as accredited investors, including certain members of the Sponsor, and (iii) Michel Brousset, Waldencast&#8217;s founder and Chief Executive Officer, and Hind Sebti, founder and Chief Growth Officer, at a purchase price of $5.00 each per share, for aggregate gross proceeds of $70 million (the &#8220;2023 PIPE Investment&#8221;).</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe that net cash provided by operating activities and existing cash and cash equivalents, including proceeds received from the 2023 PIPE Investment and the 2022 Credit Agreement will be sufficient for our current needs. However, our present and future funding requirements will depend on many factors, including, among other things:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">acquisitions of additional businesses in the beauty and wellness industry;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the level of R&amp;D investment required to maintain and improve our competitive positions in the skincare and makeup markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the success of our product sales and related collections of accounts receivable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">our need or decision to acquire or license complementary products or technologies for our Obagi Skincare and/or Milk Makeup businesses;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">costs relating to the expansion of our distribution channels and setting up direct distribution channels in certain international markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">costs relating to the expansion of the sales force, management and operational support;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">competing technological and market developments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">costs relating to regulatory investigations or litigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">costs relating to changes in regulatory policies or laws that affect our operations; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">working capital needs driven by inventory and account receivables relating to our U.S. and international expansion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the extent we are unable to generate sufficient cash flow, we may be forced to cancel, reduce or delay marketing initiatives, investments or acquisitions. Alternatively, we may need to draw down on the revolving loan facility under the 2022 Credit Agreement or raise additional funds, and we cannot be certain that such funds will be available on acceptable terms when needed, if at all. The incurrence of additional indebtedness would result in increased debt service obligations and operating and financing covenants that could restrict our operations and the issuance of any additional equity could result in dilution to our existing shareholders.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Failure to comply with any of the covenants under our 2022 Credit Agreement could result in an event of default, which may accelerate our outstanding indebtedness and have a material adverse effect on our business, liquidity position and financial position.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to various financial covenants under the 2022 Credit Agreement. Our ability to comply with the financial covenants under the 2022 Credit Agreement will depend on the success of our businesses, our operating results, and our ability to achieve our financial forecasts. Various risks, uncertainties and events beyond our control, including general or industry-specific economic downturns, could affect our ability to comply with the financial covenants and terms of the 2022 Credit Agreement. In addition, the 2022 Credit Agreement also requires us, among other things, to timely deliver certain financial statements to the Lenders. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Failure to comply with the covenants and other terms could result in an event of default and the acceleration of amounts owing under the 2022 Credit Agreement unless we are able to negotiate a waiver. The Lenders could condition any such waiver on an amendment to the 2022 Credit Agreement on terms that may be unfavorable to us. We could also be blocked from borrowing or obtaining letters of credit under the 2022 Credit Agreement, and the 2022 Credit Agreement could be terminated by the Lenders. Under these circumstances, other sources of capital may not be available or may be available only on unfavorable terms. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we fail to comply with the covenants and other terms under the 2022 Credit Agreement and we are unable to negotiate a covenant waiver or replace or refinance the credit agreement on favorable terms, our business, financial condition and results of operations could be materially and adversely impacted. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">If we fail to maintain compliance with the continued listing standards of Nasdaq, our securities may be delisted and the price of our Class A ordinary shares and our ability to access the capital markets could be negatively impacted.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our securities are listed on The Nasdaq Capital Market. If we fail to maintain compliance with the continued listing standards of Nasdaq, our securities may be delisted and the price of our Class A ordinary shares and our ability to access the capital markets could be negatively impacted. On May 4, 2023, we received a written notice from Nasdaq indicating that, as a result of not having timely filed our Annual Report on Form 20-F for the fiscal year ended December 31, 2022, we were not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the SEC. On July 6, 2023, we obtained an extension from Nasdaq permitting us to regain compliance provided we filed this Report no later than October 30, 2023. On October 31, 2023, we received a written notice from the Listing Qualifications Staff of Nasdaq (the &#8220;Listing Qualifications Staff&#8221;) indicating that, based upon our non-compliance with the filing requirement as of October 30, 2023, the Listing Qualifications Staff had determined to delist our securities from Nasdaq by opening of business on November 9, 2023 unless we timely requested a hearing before the Nasdaq Hearings Panel. On November 7, 2023, by requesting a hearing (the &#8220;Hearing&#8221;) before the Nasdaq Hearings Panel (the &#8220;Panel&#8221;), we appealed the determination of the Listing Qualifications Staff to the Panel and requested that the stay of delisting, which otherwise would have expired on November 22, 2023, be extended until the Panel issued a final decision on the matter. On November 22, 2023, Nasdaq granted our request to extend the stay. Accordingly, our securities will continue to trade on The Nasdaq Capital Market until the Panel issues a final decision regarding our listing status following the Hearing scheduled for February 8, 2024, or, if earlier, upon receipt of confirmation from Nasdaq that we have regained compliance with Nasdaq&#8217;s continued listing standards. On January 3, 2024, we received an additional notice of non-compliance from the Listing Qualifications Staff because we had not filed interim financial statements for the period ended June 30, 2023 with the SEC by December 31, 2023, as required by Nasdaq Listing Rule 5250(c)(2). The notice indicated that the Panel will consider this additional notice as part of its determination regarding the Company&#8217;s continued listing on The Nasdaq Capital Market. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have not regained compliance with Nasdaq&#8217;s continued listing standards and the Panel does not grant us a further extension or we fail to satisfy the terms of any extension granted, our securities may be delisted from The Nasdaq Capital Market. In addition, our Board may determine that the cost of maintaining the listing on a national securities exchange outweighs the benefits of such listing. A delisting of our securities would materially impair our shareholders&#8217; ability to buy and sell our Class A ordinary shares and/or our warrants and could have an adverse effect on the market price of, and the efficiency of the trading market for, our securities. The delisting of our securities could significantly impair our ability to raise capital and the value of your investment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our Class A ordinary shares are delisted from The Nasdaq Capital Market, we expect that in the event that any dividends were paid on such shares, they would not be eligible for preferential tax rates, and no mark-to-market election would be available if we are a passive foreign investment company (&#8220;PFIC&#8221;). See &#8220;Item 10. Additional Information&#8212;E. Taxation&#8212;U.S. Federal Income Tax Considerations&#8221; for more information regarding the U.S. federal income tax considerations of the ownership and disposition of Class A ordinary shares, including if such shares are delisted from The Nasdaq Capital Market.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may make investments into or acquire other companies, which could divert our management&#8217;s attention, result in dilution to our shareholders and otherwise disrupt our operations, and we may have difficulty integrating any such acquisitions successfully or realizing the anticipated benefits therefrom, any of which could have an adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we may seek to acquire or invest in additional businesses that we believe could complement or expand our existing and future offerings or otherwise offer growth opportunities. The success of any attempts to grow our business through acquisitions to complement our business depends in part on the availability of, our ability to identify and our ability to engage and pursue suitable acquisition candidates. We may not be able to find suitable acquisition candidates, and we may not be able to complete acquisitions on favorable terms, if at all. If we are able to complete future acquisitions, we cannot assure you that they will ultimately strengthen our competitive position or that they will be viewed positively by customers, financial markets or investors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;padding-left:4.5pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pursuit of potential acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated, and the costs incurred likely would not be recoverable. In addition, we have limited experience in acquiring other businesses and may have difficulty integrating acquired businesses or assets, or otherwise realizing any of the anticipated benefits of acquisitions. If we acquire additional businesses, we may not be able to integrate the acquired operations and technologies successfully, or effectively manage the combined business following the acquisition. Integration may prove to be difficult due to the necessity of integrating personnel with disparate business backgrounds, different geographical locations and who may be accustomed to different corporate cultures. Additionally, with multiple business combinations, we could face additional risks, including additional burdens and costs with respect to possible multiple negotiations and due diligence investigations (if there are multiple sellers) and the additional risks associated with the subsequent assimilation of the operations and services or products of multiple acquired companies with different businesses in a single operating business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may not achieve the anticipated benefits from any acquired business due to a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to integrate or benefit from acquired products or technologies in a profitable manner;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated costs or liabilities, including legal liabilities, associated with any such acquisition, or other accounting consequences;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management&#8217;s attention or resources from other business concerns;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse effects on our business relationships with existing customers, members or strategic partners as a result of the acquisition;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential loss of the acquired company&#8217;s customers;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to develop further the acquired company&#8217;s technology;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities associated with managing the geographic separation of acquired businesses and consolidating multiple physical locations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">becoming subject to new regulations as a result of an acquisition, including if we acquire a business serving customers in a regulated industry or acquire a business with customers or operations in a country in which we do not already operate;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coordination of product development and sales and marketing functions;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential loss of key employees;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquisition targets not having as robust internal controls over financial reporting as would be expected of a public company;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible cash flow interruption or loss of revenue as a result of transitional matters; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">use of substantial portions of our available cash or issuance of dilutive equity to consummate an acquisition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue equity securities or incur indebtedness to pay for any such acquisition or investment, which could adversely affect our business, financial condition or results of operations. Any such issuances of additional capital stock may cause shareholders to experience significant dilution of their ownership interests.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may not realize benefits from any business combination that we undertake. If we fail to successfully integrate such businesses, or the technologies associated with such business combinations into our company, the revenue and operating results of the combined company could be adversely affected. If our customers are uncertain about our ability to operate on a combined basis, they could delay or cancel orders for our products. We may not successfully evaluate or utilize the acquired technology or accurately forecast the financial impact of a combination, including accounting charges or volatility in the stock price of the combined entity.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any legal proceedings, investigations or claims against us could be costly and time-consuming to defend, and, if adversely decided or settled, could materially and adversely affect our business, financial condition and results of operations and could harm our reputation regardless of the outcome. In addition, our business and operations could be negatively affected if they become subject to any securities litigation or shareholder activism, which could cause us to incur significant expense, hinder execution of business and growth strategy and impact our share price.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are and may in the future become subject to legal proceedings, investigations, such as the SEC investigation described elsewhere herein, and claims, including claims that arise in the ordinary course of business, such as claims by </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customers, claims or investigations brought by regulators or employment claims made by our current or former employees and independent contractors. Such claims may also involve our directors or management. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, claims made by or against us in disputes and other legal or regulatory proceedings can be expensive and time-consuming to bring or defend against, requiring us to expend significant resources and divert the efforts and attention of our management and other personnel from our business operations. These potential claims include, but are not limited to, personal injury claims, class action lawsuits, intellectual property claims, employment litigation and regulatory investigations and causes of action relating to the advertising and promotional claims about our products. Any adverse determination against us in these proceedings, or even the allegations contained in the claims, regardless of whether they are ultimately found to be without merit, may also result in settlements, injunctions or damages that could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any pending or, to our knowledge, threatened litigation that will or could be expected to have a material impact on our business, financial condition and results of operations, other than the SEC investigation described in &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Legal Proceedings&#8221; and &#8220;Item 8. Financial Information&#8212;Note 21. Subsequent Events&#8221;. Any litigation, investigation or claim, whether meritorious or not, could harm our reputation, will increase our costs and may divert management&#8217;s attention, time and resources, which may in turn harm our business, financial condition and results of operations. Insurance might not cover such claims, might not provide sufficient payments to cover all the costs to resolve one or more such claims and might not continue to be available on terms acceptable to us. A claim brought against us for which we are uninsured or underinsured could result in unanticipated costs, potentially harming our business, financial position and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been brought against that company. Shareholder activism, which could take many forms or arise in a variety of situations, as well as the frequency of lawsuits against special purpose acquisition companies (&#8220;SPAC&#8221;) sponsors, has been increasing recently, especially in the context of SPAC business combinations. Volatility in the share price of our Class A ordinary shares, impediments to our securityholders&#8217; ability to trade our restricted securities, the restatement of our financial statements or other reasons may in the future cause us to become the target of securities litigation or shareholder activism. Securities litigation and shareholder activism, including potential proxy contests, could result in substantial costs and divert management&#8217;s and our Board&#8217;s attention and resources from our business. Additionally, such securities litigation and shareholder activism could give rise to perceived uncertainties as to our future, adversely affect our relationships with suppliers and service providers and make it more difficult to attract and retain qualified personnel. Also, we may be required to incur significant legal fees and other expenses related to any securities litigation and activist shareholder matters. Further, our share price could be subject to significant fluctuation or otherwise be adversely affected by the events, risks and uncertainties of any securities litigation and shareholder activism.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to the U.K. Bribery Act, the FCPA and other anti-corruption laws and anti-money laundering laws. Failure to comply with these laws could subject us to penalties and other adverse consequence.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to anti-corruption laws, including the Bribery Act, the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, and other anti-corruption laws and anti-money laundering laws that apply in countries where we conduct activities or may conduct activities in the future. The Bribery Act, the FCPA and these other anti-corruption laws generally prohibit us and our employees, agents, representatives, distributors, retailers, other business partners, and third-party intermediaries from authorizing, promising, offering, providing, soliciting, or receiving, directly or indirectly, improper or prohibited payments, or anything else of value, to or from recipients in the public or private sector in order to obtain or retain business or gain some other business advantage. These laws have been enforced aggressively in recent years and are interpreted broadly. Under the Bribery Act, we may also be liable for failing to prevent a person associated with us from committing a bribery offense. Additionally, we are required to comply with all applicable economic and financial sanctions and trade embargoes, and export/import control laws.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our products in several countries outside of the U.S. and will continue to rely on local distributors and partners to expand and build out our operations in relevant markets. We, or any of our local distributors and other third parties may have direct or indirect interactions with officials and employees of government agencies or state-owned or affiliated entities. We can be held liable for the corrupt or other illegal activities of these local distributors and partners, even if we do not explicitly authorize or have actual knowledge of such activities. While we strive to put in place the relevant controls to identify high-risk individuals and entities before contracting with them, we will be operating in a number of jurisdictions that pose a high risk of potential Bribery Act or FCPA violations. The Bribery Act and FCPA </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">present particular challenges in the prescription product industry, because, in many countries, hospitals and clinics are run by the government, and doctors and other hospital or clinic employees may therefore be considered foreign officials. We cannot assure you that all of our local distributors or other third parties will comply with all applicable laws, for which we may be ultimately held responsible. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted and as we increase our international sales and business, our risks under these laws may increase.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these anti-corruption laws also require that we keep accurate books and records and maintain internal controls and compliance procedures reasonably designed to prevent any corrupt conduct. While we have policies and procedures to address compliance with those laws, we cannot assure you that none of our employees, agents, representatives, business partners or third-party intermediaries will take actions that violate our policies and applicable law, for which we may be ultimately held responsible. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any violations of these anti-corruption laws, or even allegations of such violations, can lead to an investigation and/or enforcement action, which could disrupt our operations, involve significant management distraction and lead to significant costs and expenses, including legal fees. If we, or our local distributors or other third parties, are found to have engaged in practices that violate these laws and regulations, we could suffer hefty fines and severe penalties, profit disgorgement, injunctions on future conduct, securities litigation, bans on transacting government business, delisting from securities exchanges and other consequences that could have a material adverse effect on our business, financial condition and results of operations. In addition, our brand and reputation, our sales activities or our stock price could be adversely affected if we become the subject of any negative publicity related to actual or potential violations of anti-corruption, anti-bribery or trade control laws and regulations.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to the Ownership of our Securities</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results are variable, and future operating results may be difficult to predict.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly results of operations have varied in the past and are likely to vary significantly in the future due to a number of factors, many of which are outside of our control, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">weakness in consumer spending as a result of a slowdown in the global, U.S. or other economies;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher manufacturing costs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in geographic, channel, or product mix;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in demand for and market acceptance of our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the development of new competitive products by others;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulatory classifications of our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in physician or customer acceptance of our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in treatment practices of physicians who currently prescribe our prescription-strength Obagi products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limited visibility into, and difficulty predicting the level of activity in our customers&#8217; practices and retailers&#8217; businesses;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our customers and distributors to timely pay in full their invoices for product orders;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced demand for our products during the summer months due to variability of patient compliance resulting from travel and other disruptive activities, particularly during July and August;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the technology or advertising landscape that increase costs for consumer reach, engagement, acquisition or conversion;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays between our expenditures to acquire new product lines or expand into new distribution channels and the generation of revenues from those new products or distribution channels;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated delays and disruptions in the manufacturing process caused by insufficient capacity or availability of raw materials, turnover in the labor force or the introduction of new production processes, power outages or natural or other disasters beyond our control;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capital investments and expenditures to support strategic initiatives;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in the cost of raw materials used to manufacture our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of operating expenses;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased competition;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legal costs and settlement expenses associated with litigation and related reimbursements from insurance carriers, if any, or related to regulatory matters; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to our effective tax rate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To respond to these and other factors, we may make business decisions that adversely affect our operating results such as modifications to our pricing policy, promotions, development efforts, product releases, business structure or operations. Most of our expenses, such as employee compensation and rent for our facilities, are relatively fixed in the short term. Moreover, our expense levels are based, in part, on our expectations regarding future revenue levels. As a result, if our net revenues for a particular period fall below expectations, we may be unable to adjust spending quickly enough to offset such shortfall. Due to these and other factors, we believe that quarter-to-quarter comparisons of our operating results may not be meaningful. You should not rely on our results for any one quarter as an indication of our future performance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we generally anticipate seeing some seasonality in our product sales, with higher sales in the last quarter of the year and lower sales during the summer months. It is also possible that in future periods, our results of operations will not meet the expectations of investors or analysts, or any published reports or analyses regarding our company. In that event, the price of our common stock could decline, perhaps substantially.</span></div><div style="padding-left:4.5pt;text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The historical financial results of our Obagi Skincare and Milk Makeup businesses may not be indicative of our future performance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The historical financial results of our Obagi Skincare and Milk Makeup businesses included in this Report do not reflect the financial condition, results of operations or cash flows each would have achieved as a standalone company during the periods presented or those we will achieve in the future. This is primarily the result of the following factors: (a) we incurred significant costs as a result of the Business Combination and the restatement of our financial statements, including legal, financial advisory and accounting fees, (b) we will continue to incur additional costs related to public company reporting, investor relations and compliance with the Sarbanes-Oxley Act that neither Obagi nor Milk had as they were not public companies; and (c) our capital structure is different from that reflected in historical financial statements for the Predecessor Periods, which include only the business of Obagi. Our financial condition and future results of operations could be materially different from amounts reflected in the historical financial statements included elsewhere in this Report, so it may be difficult for investors to compare our future results to historical results or to evaluate our relative performance or trends in our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our securities may be volatile.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price of our securities, may fluctuate due to a variety of factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the volume of our Class A ordinary shares available for public sale;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our shareholders to trade restricted securities pursuant to Rule 144 or a shelf registration statement;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the markets in which we and our customers operate;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments involving our competitors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in laws and regulations affecting our Obagi Skincare and/or Milk Makeup businesses;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in operating performance and the performance of competitors in general;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated fluctuations in our quarterly or annual operating results;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publication of research reports by securities analysts about us or our competitors or our industry;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the public&#8217;s reaction to our press releases, our other public announcements and our filings with the SEC;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions by shareholders, including the sale by any of our significant shareholders of any of their Class A ordinary shares or the perception that such sales by our significant shareholders may occur;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions and departures of key personnel;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commencement of, or involvement in, litigation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our capital structure, such as future issuances of securities or the incurrence of additional debt; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic and political conditions, such as the effects of, recessions, interest rates, local and national elections, prices for fuel and consumer goods, international currency fluctuations, corruption, political instability, acts of war or terrorism, or a pandemic or epidemic.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These market and industry factors may materially reduce the market price of our Class A ordinary shares and warrants regardless of our operating performance.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may issue additional securities without your approval, which would dilute your ownership interests and may depress the market price of our Class A ordinary shares.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain directors, key employees and consultants of the Company and of our subsidiaries have been granted equity awards under the Waldencast 2022 Incentive Award Plan. You will experience additional dilution when those equity awards vest and are settled or exercisable, as applicable, for our Class A ordinary shares.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, in connection with the 2023 PIPE Investment, we entered into subscription agreements with certain investors for the issuance and sale of 14,000,000 Class A ordinary shares in a private placement to (i) one stakeholder of Beauty Ventures, (ii) certain other existing equityholders, including certain members of the Sponsor, and (iii) Michel Brousset and Hind Sebti at a purchase price of $5.00 each per share, for aggregate gross proceeds of $70.0 million. The 2023 PIPE Investment resulted in dilution of the equity interests of other existing holders of our securities who did not participate in the transaction. In the future, we may issue additional Class A ordinary shares or other equity securities of equal or senior rank in connection with, among other things, acquisitions or repayment of outstanding indebtedness, without shareholder approval, in a number of circumstances. The issuance of additional Class A ordinary shares or other equity securities could significantly dilute the equity interests of existing holders of our securities and may adversely affect prevailing market prices for our Class A ordinary shares or warrants.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be exposed to unknown or contingent liabilities and may be required to subsequently take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on our financial condition, results of operations and the price of our securities, which could cause you to lose some or all of your investment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that the due diligence conducted in relation to Obagi and Milk has identified all material issues or risks associated with Obagi Skincare and Milk Makeup businesses or the industries in which they compete. Furthermore, we cannot assure you that factors outside of Obagi&#8217;s, Milk&#8217;s and our control will not later arise. As a result of these factors, we may be exposed to liabilities and incur additional costs and expenses and we may be forced to later write down or write off assets, restructure our operations, or incur impairment or other charges that could result in our reporting losses. Even if our due diligence has identified certain risks, unexpected risks may arise and previously known risks may materialize in a manner not consistent with our preliminary risk analysis. In connection with the restatement of our financial statements for the Predecessor Periods, we determined that the reporting unit fair value for our Obagi Skincare business was more likely than not less than its carrying amount due to the fact that restated actual results of the business following the Closing Date were less than the projected results at the time of the acquisition. As a result, during the Successor Period ended December 31, 2022, the Company recorded a non-cash impairment charge of $68.7 million within the Obagi Skincare reportable segment. If any of these unexpected or unidentified risks materialize, including any other future write downs or charges, it could have a material adverse effect on our financial condition and results of operations and could contribute to negative market perceptions about our securities. Additionally, we have no indemnification rights against Obagi or former Obagi shareholders or against Milk or the former owners of Milk under our acquisition agreements with Obagi and Milk. Accordingly, our equityholders could suffer a reduction in the value of their securities. Such equityholders are unlikely to have a remedy for such reduction in value unless they are able to successfully claim that the reduction was due to the breach by our directors or officers of a duty of care or other fiduciary duty owed to them, or if they are able to successfully bring a private claim under securities laws that the registration statement or proxy statement/prospectus relating to the Business Combination contained an actionable material misstatement or material omission.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants will be exercisable for our Class A ordinary shares, which would increase the number of shares eligible for future resale in the public market and result in dilution to our shareholders, and a sale of a substantial number of our securities in the public market could cause the price of our securities to decline.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding warrants to purchase an aggregate of 29,533,282 Class A ordinary shares are exercisable in accordance with the terms of the warrant agreement, dated March 15, 2021, between Waldencast Acquisition Corp. and Continental Stock Transfer &amp; Trust Company (the &#8220;Warrant Agreement&#8221;) governing those securities at an exercise price of $11.50 per share. These warrants will expire five years after the completion of our the Business Combination (July 27, 2027), at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. To the extent such warrants are exercised, additional Class A ordinary shares will be issued, which will result in dilution to our existing Class A ordinary shareholders and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market or the fact that such warrants may be exercised could adversely affect the market price of our Class A ordinary shares. However, there is no guarantee that the public warrants will ever be in the money prior to their expiration and as such, the warrants may expire worthless. In addition, our shareholders who exercised their redemption rights with respect to their public shares in connection with the Business Combination retained their public warrants, which may be exercised by such redeeming shareholders for our Class A ordinary shares resulting in further dilution.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant number of our shares are held by our sponsors and the former owner of Obagi.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Members of the Sponsor and its affiliates own a combined ownership interest of 50.8% of our Class A ordinary shares, comprised of the following: (i) Burwell Mountain Trust (&#8220;Burwell&#8221;) holds an ownership interest of 11.2% of the  Class A ordinary shares, (ii) Zeno Investment Master Fund (f/k/a Dynamo Master Fund) (&#8220;Zeno&#8221;) holds an ownership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest of 19.1% of the Class A ordinary shares, (iii) Waldencast Ventures LP holds an ownership interest of 5.0% of the  Class A ordinary shares, and (iv) Beauty Ventures holds an ownership interest of 21.6% of the Class A ordinary shares. In addition, Cedarwalk Skincare Ltd., the owner of Obagi immediately prior to the close of the Business Combination (&#8220;Cedarwalk&#8221;), holds an ownership interest of 28.3% of the  Class A ordinary shares.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of such ownership, members of the Sponsor and their affiliates and Cedarwalk exercise significant influence over all matters requiring shareholder approval, including the election and removal of directors, appointment and removal of officers, any amendment of our memorandum and articles of association (the &#8220;Constitutional Document&#8221;), and any approval of significant corporate transactions. Additionally, the interests of the Sponsor and its affiliates and/or Cedarwalk may differ from those of other shareholders. As a result, the concentration of voting power with members of the Sponsor and their affiliates and Cedarwalk may have an adverse effect on the price of our securities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future resales of our Class A ordinary shares may cause the market price of our securities to drop significantly, even if our business is doing well.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions, in connection with the 2023 PIPE Investment, the participating investors agreed not to transfer or sell, during the respective lock-up period, any Class A ordinary shares (i) subscribed by such participating investor in connection with the 2023 PIPE Investment and (ii) held by such participating investor at or prior to the applicable PIPE Closing Date (as defined below) (the &#8220;Lock-Up Shares&#8221;). For 75% of the Lock-Up Shares, the applicable lock-up period means the period beginning on September 14, 2023 for investors in 13,600,000 Class A ordinary shares (the &#8220;First PIPE Closing Date&#8221;) or November 8, 2023 for investors in 400,000 Class A ordinary shares (the &#8220;Second PIPE Closing Date&#8221; and together with the First PIPE Closing Date, the &#8220;PIPE Closing Dates&#8221;, and individually, each a &#8220;PIPE Closing Date&#8221;), and ending on the one-year anniversary of the applicable PIPE Closing Date. For 25% of the Lock-Up Shares, the applicable lock-up period means the period beginning on the applicable PIPE Closing Date and ending on the six-month anniversary of the applicable PIPE Closing Date. There are no other contractual lock-up restrictions currently in place, as those entered into in connection with the Business Combination have expired. See &#8220;Item 5. Waldencast&#8217;s Operating and Financial Review and Prospects&#8212;Recent Events&#8212;Lock-Up Restrictions&#8221; for more information on the Lock-Up Agreements (as defined below). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the expiration of each applicable lock-up period, the applicable shareholders will not be contractually restricted from selling our Class A ordinary shares, however other restrictions may apply as a result of applicable securities laws. Additionally, certain of the Class A ordinary shares held by the Sponsor and its affiliates and former members of Milk, who acquired the shares in a private placement, are not contractually restricted from selling any of their Class A ordinary shares, other than by applicable securities laws, including those requiring us to be timely in our reporting obligations. See &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks Related to our Organization and Corporate Structure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;As a former shell company, resales of shares of our restricted Class A ordinary shares in reliance on Rule 144 of the Securities Act are subject to the requirements of Rule 144(i).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; As such, sales of a substantial number of our Class A ordinary shares in the public market could occur at any time subject to applicable securities laws. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our Class A ordinary shares.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the applicable lock-up periods expire and registration statements are available for use, the sale or possibility of sale of these shares could have the effect of increasing the volatility in our share price or the market price of our Class A ordinary shares could decline if the holders of currently restricted shares sell them or are perceived by the market as intending to sell them.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Global Economic, Political and Social Conditions</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our sales and profitability may suffer if current economic conditions in any of our major markets inhibit people from spending their disposable income on beauty and wellness products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Virtually all of our products are purchased based on consumer choice due to the fact that they are generally considered cosmetic in nature and not covered by health insurance policies. As a result, they are typically paid for directly by the customer out of disposable income and are not subject to reimbursement by third-party payors such as health insurers. Adverse changes in the economy, such as continuing increases in prices for consumer goods in the U.S. and many other countries, an economic slow-down or recession, or ongoing economic uncertainties, could accordingly have a significant negative effect on consumer spending for these products. If consumers reassess their spending choices, the demand for these products could decline significantly, which would have a material adverse effect on our sales and profitability. In addition, inflation, rising interest rates and other economic uncertainties may cause our suppliers, distributors, contractors or other third-party partners to suffer financial or operational difficulties that they cannot overcome, resulting in their inability to provide us with the materials and services we need, in which case our business and results of operations could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global or regional conflicts or uncertainties may adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse changes in global or regional conditions periodically occur, including changes or uncertainty in fiscal, monetary or trade policy, geopolitical and security issues, such as armed conflict and civil or military unrest, political instability, human rights concerns and terrorist activity, catastrophic events such as natural disasters and public health issues (including the COVID-19 pandemic), supply chain interruptions, new or revised export, import or doing-business regulations, including trade sanctions and tariffs or other global or regional occurrences.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global or regional conflicts could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions. Additionally, military actions and any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets, particularly if current or new sanctions continue for an extended period of time or if geopolitical tensions result in expanded military operations on a global scale.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, tensions between the U.S. and China have led to increased tariffs and trade restrictions. The U.S. has imposed economic sanctions on certain Chinese individuals and entities and restrictions on the export of U.S.-regulated products and technology to certain Chinese technology companies. These and other global and regional conditions may adversely impact our business strategy to continue to expand sales of Obagi and Milk products in China.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public health emergencies, epidemics or pandemics, such as COVID-19, have had, and could in the future have, an adverse impact on our operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health emergencies, epidemics or pandemics have had, and could in the future have, an adverse impact on our operations and financial condition. The emergence of COVID-19 in 2020 caused many countries, including the U.S., to declare national emergencies and implement preventive measures such as travel bans and shelter in place or total lock-down orders. The net revenue derived from our Obagi Skincare and Milk Makeup businesses were materially and adversely affected in the first two quarters of 2020, as many of Obagi&#8217;s physician customers and Milk&#8217;s primary reseller, Sephora, were required to close their businesses for several weeks, which greatly diminished demand for Obagi and Milk products. Any re-implementation of similar restrictions in response to a new variant of COVID-19 or another pandemic or epidemic could have a material impact on our future net revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of COVID-19 on the global supply chain caused a number of challenges for our Milk Makeup business that were in many cases beyond our control, including among others, availability of raw materials and components, production and transport delays, loss of productivity in warehousing and shipping, reduction in Sephora&#8217;s ability to ship from their warehouses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to stores, and reductions in their stores&#8217; ability to properly offer advice and service and to supply </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk products and service our gondolas in the same way that was done prior to COVID-19. This impact in-store is particularly challenging for prestige cosmetics where consumers are paying a premium price to be able to access advice and samples that justify paying more instead of purchasing a product in a self-serve environment. In addition, although the impact of COVID-19 on Obagi&#8217;s manufacturing and supply chain to date has not been material, temporary or permanent closures of Obagi&#8217;s direct and indirect suppliers could result in adverse effects to the supply chain. Any supply disruptions would adversely affect our ability to procure sufficient inventory of Obagi and Milk products to support customer orders.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we also modified some of our business practices, including accelerating the launch of a redesigned Obagi website to enable us to sell Obagi products directly to consumers, creating an e-commerce platform to enable Obagi&#8217;s physician customers to sell the products online to their patients, designing a Door-Step Delivery Program for Obagi customers&#8217; patients, and investing in the Obagi Helping Hands program to provide free hand sanitizer to healthcare professionals. All of these changes required significant investments of financial and management resources.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the COVID-19 Public Health Emergency declared under the Public Health Service Act expired in May 2023, any future pandemic, epidemic, natural disaster or other unanticipated event could require us to make similar unplanned investments or adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business operations involve doing business in the People&#8217;s Republic of China, which exposes us to risks inherent in doing business in that country</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup currently sources components in the People&#8217;s Republic of China and does not have substantial alternatives to those suppliers. Milk Makeup and Obagi Hong Kong Limited, a subsidiary of Cedarwalk (&#8220;Obagi Hong Kong&#8221;) also utilize warehouse services provided third-party distributors in that region. The results of operations of our business will be materially and adversely affected if the cost for components or third-party warehouse services increase significantly. Additionally, the Chinese government may impose regulations regarding ingredients and composition of cosmetics and skincare products and these regulations may affect our ability to sell our Obagi Skincare and Milk Makeup products in the PRC.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Doing business in China exposes us to political, legal and economic risks. In particular, the political, legal and economic climate in China, both nationally and regionally, is fluid and unpredictable. Our ability to operate in China may be adversely affected by changes in U.S. and Chinese laws and regulations such as those related to, among other things, taxation, import and export tariffs, environmental regulations, land use rights, intellectual property, currency controls, network security and other matters. In addition, we or our suppliers and distributors, including Obagi Hong Kong,  may not obtain or retain the requisite legal permits to continue to operate in China, and costs or operational limitations may be imposed in connection with obtaining and complying with such permits. In addition, Chinese trade regulations are in a state of flux, and we may become subject to other forms of taxation, tariffs and duties in China. Furthermore, the third parties we rely on in China may disclose our confidential information or intellectual property to competitors or third parties, which could result in the illegal distribution and sale of counterfeit versions of our products. If any of these events occur, our business, financial condition and results of operations could be materially and adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. government has imposed increased tariffs on certain imports from China. We currently source important components for some Milk Makeup products from third-party suppliers in China, and, as such, current tariffs may increase the cost of such goods, which may result in lower gross margin on affected products. In any case, increased tariffs on imports from China could materially and adversely affect the business, financial condition and results of operations of our Milk Makeup business. In retaliation for the current U.S. tariffs, China has implemented tariffs on a wide range of American products. There is also a concern that the imposition of additional tariffs by the U.S. could result in the adoption of tariffs by other countries as well, leading to a global trade war. Trade restrictions implemented by the U.S. or other countries in connection with a global trade war could materially and adversely affect our business, financial condition and results of operations</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Obagi Skincare Business</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on one main provider in the U.S. who is considered our customer, and the loss of the services of such a provider could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We sell Obagi products in the U.S. to healthcare professionals in the physician-dispensed channel through an authorized wholesale distributor (the &#8220;Physician Channel Provider&#8221;), who also serves as our only distributor with respect to sales of Obagi products to retail and spa customers in the U.S. Under this model, we sell the products to the Physician Channel Provider, which then sells the products through to Obagi&#8217;s physician customers when they order them. Although the Physician Channel Provider purchases products from us for sale to our physician customers in the U.S. and customers who purchase our products on our e-commerce platforms, we maintain control of the product  inventory at their warehouse and continue to manage the relationships with the end customers, until immediately prior to the sale of the product to the end customer.  As a result, control of the products does not shift to the Physician Channel Provider, and we do not recognize revenue from products sold to the Physician Channel Provider, until immediately prior to their sale to the physician or e-commerce customer.  On the other hand, we recognize revenue for products sold to the Physician Channel Provider for our retail and spa customers upon transfer of the products to the Physician Channel Provider.  See &#8220;Item 5. Waldencast&#8217;s Operating and Financial Review and Prospects&#8221; and &#8220;Item 8. Financial Information - Note 2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restatement and Reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further information on revenue recognition for products sold to the Physician Channel Provider.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Physician Channel Provider accounted for a significant portion of our net revenue in the 2022 Successor Period, 2022 Predecessor Period, 2021 Predecessor Period and the year ended December 31, 2020 (the &#8220;2020 Predecessor Period&#8221;). Our agreement with the Physician Channel Provider does not contain any minimum purchase requirements. Accordingly, Obagi does not have any guarantees regarding the quantity of each of the products that Physician Channel Provider will order. Obagi provides the Physician Channel Provider with forecasts of demand for its products from physician customers, however, these forecasts may not always accurately assess demand for one or more products during any given quarter, which many affect subsequent orders for the affected products from them. Our agreement with the Physician Channel Provider expires in September 2024 we may not be able to extend the agreement on its current terms or renegotiate the terms on a commercially reasonable basis, or at all.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Physician Channel Provider operates and manages the ordering portal for our customers, receives and fulfills product orders, and provides customer service functions (including call center services), processes product returns, runs customer credential and credit checks, and offers invoicing, and collection, accounts receivable and chargeback services. The failure of the Physician Channel Provider to provide the expected services on a timely basis, or at all, at the prices we expect, or the costs and disruption incurred in changing our main U.S. distributor could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Obagi Skincare business faces intense competition, in some cases from companies that have significantly greater resources than we do, which could limit our ability to generate sales and/or render our products obsolete.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for aesthetic and therapeutic skin health products is highly competitive and we expect the intensity of competition to increase in the future. We also expect to encounter increased competition as Obagi enters new markets and/or distribution channels, attempts to penetrate existing markets with new products and expands into new distribution channels. We may not be able to compete effectively in these markets, may face significant pricing pressure from our competitors and may lose market share to our competitors. The principal competitors for our Obagi Skincare business are large, well-established companies in the fields of pharmaceuticals, cosmetics, medical devices and health care. Our largest direct competitors include SkinCeuticals and Skinbetter Science, each a division of L&#8217;Or&#233;al S.A., SkinMedica, Inc., a division of Allergan, Inc., ZO Skin Health, a majority of which is owned by Blackstone Tactical Opportunities, and PCA Skin and EltaMD, each a division of Colgate-Palmolive.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indirect competitors for Obagi Medical&#174; products sell skincare products directly to consumers, and generally consist of large well known cosmetic companies, including, but not limited to, La Roche-Posay Laboratoire Dermatologique SAS, Dermalogica, Inc., Murad Inc. and dermatologist backed brands, such as Dr. Dennis Gross Skincare, LLC. Our Obagi Clinical line faces competition from Eucerin, La Roche Posay and Vichy in Southeast Asia.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We also face competition from medical device companies offering products to physicians that are used to enhance the skin&#8217;s appearance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of these competitors have significantly greater resources than we have. This enables them, among other things, to make greater investments in research and development and spread their research and development costs, as well as their marketing and promotional costs, over a broader revenue base. It is also possible that developments by our competitors could make Obagi products or technologies less competitive or obsolete. The treatment of skin conditions and the enhancement of the appearance of skin are the subjects of active research and development by many potential competitors, including major pharmaceutical companies and specialized biotechnology firms, such as those listed above, as well as universities and other research institutions. Competitive advances may also include the potential development of new laser </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or radio frequency therapies to treat hyperpigmentation and photodamaged skin. While we intend to expand our technological capabilities to remain competitive, research and development by others may result in the introduction of new products by competitors that represent substantial improvements over existing Obagi products. If that occurs, sales of our existing products could decline rapidly. Similarly, if we fail to make sufficient investments in research and development programs, our current and planned products could be surpassed by more effective or advanced products developed by our competitors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenues and financial results depend significantly on sales of our Obagi Nu-Derm&#174; products. If we are unable to manufacture or sell the Nu-Derm products in sufficient quantities and in a timely manner, or maintain physician and/or patient acceptance of Nu-Derm products, our business will be materially and adversely impacted.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, a substantial portion of our Obagi Skincare revenues have resulted from sales of our principal product line, the Obagi Nu-Derm System and related products. Nu-Derm products accounted for a significant portion of the total products shipped in the 2022 Successor Period, 2022 Predecessor Period, 2021 Predecessor Period and the 2020 Predecessor Period. Although we currently offer other products such as Obagi-C&#174; Rx, Professional-C&#174;, ELASTIderm&#174;, CLENZIderm&#174;, Blue Peel&#174; products and our Obagi Clinical line, and intend to introduce additional new products, we still expect sales of our Obagi Nu-Derm System and related products to account for a substantial portion of sales for the Obagi Skincare business for the foreseeable future. Because this business is highly dependent on Nu-Derm products, factors adversely affecting the pricing of, or demand for, these products could have a material and adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of Obagi Nu-Derm products also experience seasonality. We believe this is due to variability in patient compliance that relates to several factors such as a tendency to travel and/or engage in other disruptive activities during the summer months. Additionally, our commercial success depends in large part on our ability to sustain market acceptance of the Nu-Derm System. If existing users of our products determine that Obagi products do not satisfy their requirements, if our competitors develop a product that is perceived by patients or physicians to better satisfy their respective requirements or if state or federal regulations or enforcement actions prohibit sales of the Nu-Derm System, individual products within the system or any related products, sales of these products may decline and our total net revenue may correspondingly decline. We cannot assure you that we will be able to continue to manufacture these products in commercial quantities at acceptable costs. Our inability to do so would adversely affect our operating results and cause our business to suffer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on third parties to manufacture our products, which exposes us to risks we would not face if we manufactured the products ourselves, including capacity constraints, delay in product deliveries, and the inability to directly control regulatory compliance and quality assurance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently outsource all of the manufacturing of Obagi products to third-party contract manufacturers (&#8220;CMOs&#8221;). We have two or more qualified CMOs for some of our key products, however, certain products, including some of our sun protection products, are currently supplied by a single source. In the event that such a sole source supplier or any of our other CMOs terminates its supply arrangement with us, experiences financial difficulties, encounters regulatory or quality assurance issues, experiences a significant disruption in supply of raw materials or components for our products or suffers any damage to its facilities, we may experience delays in securing sufficient amounts of our products, which could harm our business, reputation and relationships with customers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch Health, which formerly owned the Obagi Skincare business, is our only supplier and manufacturer of our tretinoin products. Obagi has a contract with Bausch Health that has an initial termination date in 2027. While there are several other CMOs of generic tretinoin, the termination of this agreement or any loss of services under the agreement could be difficult for us to replace on the same or similarly favorable terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to rely on third parties to produce materials required for clinical trials and for the commercial production of our Obagi products. However, there are a limited number of third-party CMOs that operate under the FDA&#8217;s current cGMPs regulations and that have the necessary expertise and capacity to manufacture our products. During the 2022 Successor Period, the 2022 Predecessor Period, the 2021 Predecessor Period and the 2020 Predecessor Period, we purchased a significant portion of inventory from two CMOs. During the 2022 Predecessor Period, we also purchased a considerable amount of inventory from  a company in Japan that produces a separate line of products using the brand name Obagi under a license agreement with us, which products we purchased from them for sale in China prior to the Closing Date. In the event one of these suppliers terminates its arrangement with Obagi, it may be difficult for us to locate alternate CMOs for our anticipated future needs. If we are unable to arrange for third-party manufacturing of our Obagi </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, or to do so on commercially reasonable terms, we may not be able to complete development of, market and sell new products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reliance on third-party CMOs entails risks to which we would not be subject if we manufactured products ourselves, including reliance on the third party for regulatory compliance and quality assurance. To the extent that any of our CMOs fails to comply with regulatory requirements or encounters quality assurance issues, we may experience an interruption in the supply of products, which could impair our customer relationships and adversely affect our business, financial condition and results of operations. In addition, reliance on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third-party CMOs subjects us to the possibility of breach of the applicable manufacturing agreement by the third party, and the possibility of termination or non-renewal of the agreement by the third party. The process of transferring products to a new CMO is time consuming and can take 6 to 18 months, which could result in a delay in supply of affected products until the technical transfer is completed. Dependence upon third parties for the manufacture of our products may also reduce our profit margins and may limit our ability to develop and deliver products on a timely and competitive basis. Using third-party CMOs also entails the following risks, among others:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of the third-party to manufacture our products on schedule, or at all, including if our CMOs give greater priority to the supply of other products over our products or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the reduction or termination of production or deliveries, or the raising of prices or renegotiation of terms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of third-party CMOs  to comply with applicable regulatory requirements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">raw material or labor shortages that delay production of our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in raw material or labor costs that may adversely affect our procurement costs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an inability to reduce production quickly in response to changes in market demand due to binding purchase orders with the third-party CMO or the incurrence of liabilities when negotiating modifications to or cancellation of outstanding purchase orders;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inadvertent or intentional disclosure of our confidential information or intellectual property to competitors or other third parties; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of a third party to produce our products according to our specifications.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The loss of a significant customer or inability of a large customer to pay invoices in accordance with agreed-upon payment terms could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our e-commerce partners and international distributors purchase our products directly from us. The SA Distributor, accounted for a material portion of our net revenue for the Obagi Skincare business in the 2022 Successor Period, 2022 Predecessor Period and 2021 Predecessor Period. The agreement with the SA Distributor granted the SA Distributor a right to distribute Obagi products in Vietnam, Cambodia, Laos, Myanmar and South Korea, contained minimum purchase requirements and had a term that would have expired on December 31, 2026. In January and October 2022, we executed amendments with the SA Distributor to, among other things, expand the countries within Southeast Asia in which it may distribute our products. During the COVID pandemic, the SA Distributor was not able to ship and sell products into Vietnam due to import restrictions issued by that country, and thus was unable to generate any revenue from product sales. As a result, the SA Distributor was not able to make payments on any invoices to us for several months in 2020. The SA Distributor subsequently experienced a prolonged delay from June 2022 through June 2023 (following our  acquisition of Obagi Vietnam from the SA Distributor in March 2023), in obtaining relevant product licenses required to continue importing and distributing Obagi products in Vietnam. During this period, there were a number of long outstanding invoices that remained unpaid by the SA Distributor and we did not recognize any revenue on those invoices during the entirety of that period. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the restatement of our financial results for Predecessor Periods, we determined that revenue for product orders received from the SA Distributor should be recognized under  ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;) only when the SA Distributor had paid the entire invoice for such product order in full, which often took a prolonged period of time (several moths) to occur. See &#8220;Item 5. Waldencast&#8217;s Operating and Financial Review and Prospects&#8221; and &#8220;Item 8. Financial Information&#8212;Note 2. Restatement and Reclassifications.&#8221;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, as part of our strategy to internalize distribution channels in key markets, certain of Obagi&#8217;s subsidiaries entered into and consummated a Purchase Agreement (the &#8220;Vietnam Purchase Agreement&#8221;) with Obagi Vietnam and the SA Distributor, pursuant to which, among other terms, Obagi acquired certain assets of Obagi Vietnam, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the SA Distributor and in return, the SA Distributor received forty percent (40%) of the outstanding equity of Obagi Blue Sea Holding, LLC, an indirect subsidiary of Obagi and the parent company of Obagi Vietnam.  The Vietnam Purchase Agreement also provided the SA Distributor with a potential earnout payment based upon the net revenue of the business of Obagi Vietnam during the twelve months ending December 31, 2026, subject to setoff for any owed obligations. We currently do not anticipate that any such earnout payment will be payable. The SA Distributor does not currently have any active participation in the Obagi Vietnam business other than as a silent shareholder. Due to non-performance by the SA Distributor of its obligations pursuant to the Vietnam Purchase Agreement and certain other matters, we took further steps in 2023 to restructure the business of Obagi Vietnam by hiring a new local management, finance and sales team to replace the previous SA Distributor team, entering into new online and offline distribution agreements with reputable partners and re-applying for all product registrations, which were obtained in June 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, Obagi had also agreed to amendments in payment terms with certain customers, including the exclusive distributor of Obagi products on Amazon and Walmart e-commerce platforms in the U.S. (the &#8220;U.S. Online Marketplace Distributor&#8221;), that allowed for progress payments on invoices that resulted in a gap of more than 365 days between the shipment of products to the customer and receipt of payment in full for the invoice for such products. In such instances, a portion of the invoice to the customer was considered to constitute a financing component and a corresponding portion of the revenue attributable to the product order was recognized as interest income. See &#8220;Item 5. Waldencast&#8217;s Operating and Financial Review and Prospects&#8221; and &#8220;Item 8. Financial Information&#8212;Note 2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restatement and Reclassifications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; In the fourth quarter of 2023, we terminated our relationship with the U.S. Online Marketplace Distributor and began selling products on Amazon directly. See &#8220;Item 8. Financial Information&#8212;Note 21. Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;U.S. Online Marketplace Distributor Contract Termination.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented additional internal controls related to prolonged payment terms, the amendment of payment terms or deviation from agreed-upon payment terms by customers, however, we cannot assure you that we will not encounter issues with delayed payments from customers in the future. Any inability of a significant customer to maintain their payment terms with us could adversely affect our revenue, capital resources and ability to predict cash flow from operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on third parties to store, distribute and deliver products to our international customers and for other essential services.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on other third-party logistics providers to store and fulfill product orders from our international distributors. Obagi is not party to long-term contracts with any of these parties, and upon expiration of these existing agreements, we may not be able to renegotiate the terms on a commercially reasonable basis, or at all.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, these third-party providers may:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have economic or business interests or goals that are inconsistent with ours;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">take actions contrary to our instructions, requests, policies or objectives;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be unable or unwilling to fulfill their obligations to comply with applicable regulations, including those regarding the storage and handling of our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have financial difficulties;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disclose our confidential information or intellectual property to competitors or third parties;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engage in activities or employ practices that may harm our reputation; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">work with, be acquired by, or come under control of, our competitors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of these events, alone or together, could have a material adverse effect on our business, financial condition and results of operations. In addition, such problems may require us to find new third-party service providers, and we cannot assure you that we would be successful in finding financially viable alternatives that meet our standards.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The management and oversight of the engagement and activities of our third-party service providers require substantial time and effort from our employees, and we may be unable to successfully manage and oversee such activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to manage our inventory of Obagi products effectively, our results of operations, financial condition and liquidity may be materially and adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Obagi Skincare business requires us to manage large volumes of inventory effectively. We depend on our forecasts of demand for, and popularity of, various products to make purchase decisions and to manage our inventory of stock-keeping units (&#8220;SKUs&#8221;). Demand for products, however, can change significantly between the time inventory or components are ordered and the date of sale due to the long lead times required to manufacture our products. Demand may be affected by new product launches, changes in customer preferences, demand or spending patterns, changes in product cycles and pricing, product defects and promotions. It may be difficult to accurately forecast demand and determine appropriate levels of products or components. Our ability to accurately forecast demand may be further hindered in the future as we expand the percentage of our sales made outside of the U.S. because we depend on our international distributors to provide us with forecasts for demand for our products in their respective territories.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our distributors overestimate demand, our distributors may not be able to sell their existing inventory to their customers, which may affect their ability to timely pay us and their demand for products in the future. Moreover, costs of goods sold increased in the 2022 Successor Period, in part as a result of inventory reserve provisions and write-offs. We may be required to recognize additional inventory write-offs and increase our reserves for product returns in future, particularly if our estimates relating to demand in certain of our markets or with respect to certain of our product lines are incorrect. On the other hand, if we or our distributors underestimate demand, we may not have sufficient inventory of products to ship to our customers. Obagi products have expiration dates that generally range from 24 to 36 months from the date of manufacture. We estimate the amount of potentially excess, dated or otherwise impaired inventories that we may have to write down. Although our estimates are reviewed quarterly for reasonableness, our product return activity could differ significantly from our estimates. Judgment is required in estimating the amount of inventory that may be written down and we rely on data from third parties, including, but not limited to, distributor forecasts and independent market research reports. The actual amounts could be different from our estimates, and differences are accounted for in the period in which they become known. If we determine that the actual amounts exceed our reserve amounts, we will record a charge to earnings to approximate the difference. A material reduction in earnings resulting from a charge would have a material adverse effect on our net income, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obagi licenses intellectual property to third parties in certain international markets and our net income would be adversely affected if any of these third parties terminate or breach their license agreements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi licenses certain trademarks for the retail drug store channel in Japan to Rohto, from whom we receive royalties.  We also license our trademarks and product formulas to Obagi Hong Kong, for commercialization in the China Region. Because incremental costs associated with these agreements are minimal, a material decline in licensing revenues from or termination of our relationships with Rohto and/or Obagi Hong Kong could have an adverse effect on our gross margin. In addition, the failure of Rohto, Obagi Hong Kong, or any other entity that licenses our product formulas to comply with our quality standards and other controls, could materially and adversely affect our financial condition and operating results. Our licensees or others may dispute the scope of their rights under any of these licenses. Our licensees under these licenses may breach the terms of their respective agreements. Loss or breach of any of these licenses for any reason could materially and adversely affect our financial condition and operating results. Any dispute with a licensee could be complex, expensive and time-consuming, and an outcome adverse to us could materially and adversely affect our business and impair our ability to commercialize our licensed products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obagi and our CMOs and suppliers license certain product and device technologies from third parties. If these licenses are breached, terminated or disputed, our ability to commercialize products dependent on these technologies and patents may be compromised.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi has licensed certain products and proprietary</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology for various products, including our SUZANOBAGIMD&#174; products, Obagi Nu-Cil&#8482; Eyelash Enhancing Serum, Obagi Nu-Cil&#8482; Eyebrow Boosting Serum and the Skintrinsiq&#8482; device. If one or more of the licenses that we have with the parties who own these formulas or technologies terminate, or if we violate the terms of our licenses or otherwise lose our rights to these products or technology, we may be unable to continue developing and selling the Obagi products that are covered by these licenses. Our licensors or others may dispute the scope of our rights under any of these licenses. The licensors under these licenses may breach the terms of their respective agreements or fail to prevent infringement of the licensed formulas or technology by third parties. Loss of any of these licenses for any reason could materially and adversely affect our financial condition and operating results.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we purchase Obagi products from manufacturers and suppliers who have licensed patent rights to use and sell these products from third-party licensors, and if any dispute arises as to these licensed rights, the third-party licensors may bring legal actions against us, our respective licensees, suppliers, customers or collaborators, and claim damages and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seek to enjoin the manufacturing and marketing of such products. In addition, if we determine that our products do not incorporate the patented technology that we have licensed from third parties, or that one or more of the patents that we have licensed are not valid, we may dispute our obligation to pay royalties to our licensors. Any dispute with a licensor could be complex, expensive and time-consuming and an outcome adverse to us could materially and adversely affect our business and impair our ability to commercialize our patent-licensed products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to successfully in-license or acquire additional products and technologies would impair our ability to grow the Obagi Skincare business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to in-license, acquire, develop and market new products and technologies. Because we have limited internal research capabilities, our business model depends in part on our ability to license patents, products and/or technologies from third parties. The success of this strategy also depends upon our ability and the ability of our third-party formulators to formulate products under such licenses, as well as our ability to manufacture, market and sell such licensed products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to successfully identify any new products to in-license, acquire or internally develop. Moreover, negotiating and implementing an economically viable acquisition is a lengthy and complex process. Other companies, including those with substantially greater financial, marketing and sales resources, may compete with us for the acquisition of products or technologies. We may not be able to acquire or in-license the rights to such products on terms that we find acceptable, or at all. As a result, our ability to grow the Obagi Skincare business or increase our profits could be adversely impacted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obagi received a Paycheck Protection Program loan, and its application for such loan could in the future be determined to have been impermissible or could result in damage to our reputation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Obagi applied for and received an unsecured $6.8 million loan under the Paycheck Protection Program (the &#8220;PPP Loan&#8221;). In June 2021, the PPP Loan was fully forgiven. The Paycheck Protection Program was established under the CARES Act, and is administered by the U.S. Small Business Administration (the &#8220;SBA&#8221;). If Obagi is later determined to have been ineligible to receive the PPP Loan or loan forgiveness, we may be subject to significant penalties, including significant civil, criminal and administrative penalties, we could be required to repay the PPP Loan in its entirety, and our reputation could suffer. A review or audit by the SBA or other government entity or claims under the U.S. False Claims Act could consume significant financial and management resources. In February 2023, we were notified by our lender that the SBA had requested additional documents relating to our PPP Loan. The lender has questioned the amount of our loan request, however, the SBA review is ongoing and we cannot determine if the SBA will ultimately challenge the PPP Loan, in which case we may be required to repay all or a portion of the loan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal and Regulatory Risks That Could Adversely Impact our Obagi Skincare Business</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws, regulations, enforcement trends or changes in existing regulations governing the introduction, marketing and sale of our over-the-counter (&#8220;OTC&#8221;) drug, device and cosmetic products to consumers could harm our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi products are subject to regulation by the FDA, FTC and comparable state, local and foreign regulatory authorities, including the European Commission, and, over time, the regulatory landscape for our products has become more complex with increasingly strict requirements. If the laws and regulations governing our products continue to change, we may find it necessary to alter some of the ways we have traditionally marketed our products to stay in compliance with applicable regulations, and this could add to the costs of our operations and have a material adverse effect on our business. To the extent federal, state, local or foreign regulatory requirements regarding consumer protection, or the ingredients, claims or safety of our products continue to change in the future, such changes could require us to reformulate or discontinue certain products, apply for new or different marketing authorizations, revise product packaging or labeling, or adjust operations and systems, any of which could result in, among other things, increased costs, delays in product launches, product returns or recalls and lower net sales, and therefore could have a material adverse effect on our business, financial condition and results of operations. Noncompliance with applicable regulations could result in enforcement action by the FDA, FTC or other regulatory authorities within or outside the U.S., including, but not limited to, product seizures, injunctions, product recalls, and criminal or civil monetary penalties, all of which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDCA defines cosmetics, in relevant part, as &#8220;articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness, or altering </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the appearance.&#8221; The term &#8220;drug,&#8221; in contrast, is defined by reference to its intended use, as &#8220;articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease&#8221; and &#8220;articles (other than food) intended to affect the structure or any function of the body of man or other animals.&#8221; Therefore, almost any ingested or topical or injectable product that, through its label or labeling (including Internet websites, promotional pamphlets, and other marketing material), is claimed to be beneficial for such uses will be regulated by the FDA as a drug. This definition also includes components of drugs, such as active pharmaceutical ingredients. Drug products must generally either receive premarket approval from the FDA or conform to a &#8220;monograph&#8221; for a particular drug category, as established by the FDA&#8217;s OTC Drug Review process, which has been subject to recent reforms pursuant to the CARES Act. The statutory and regulatory requirements applicable to drugs are extensive and require significant resources and time to ensure compliance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MoCRA, enacted by Congress in late December 2022, introduced new compliance obligations for manufacturers of cosmetic products in the U.S. and significantly expanded the FDA&#8217;s authority to regulate cosmetic products. Under MoCRA, companies will be obligated to adhere to new requirements for cosmetics, such as new labeling standards for spe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cific products, safety substantiation, facility registration, product listing, adverse event reporting, compliance with cGMPs, mandatory recalls and record-keeping requirements for such products and the manufacturing facilities in which they are produced, among other things. Companies will need to be in compliance with many of the new requirements no later than July 1, 2024. MoCRA requires the FDA to issue regulations governing cGMP for cosmetic manufacturers by December 2025 and additional labeling requirements as expected to go into effect in 2024. Our operations could be harmed if regulatory authorities make determinations that our CMOs are not in compliance with regulations. We cannot assure you that the CMOs of all of our products will be able to comply with all of these new regulations in a timely manner or that they will not decide to pass the increased costs of having to comply with the regulations onto us, which would increase our costs and negatively impact net income. In addition, with the exception of color additives, the FDA does not currently require premarket approval for, or premarket review of, products intended to be sold as cosmetics in the U.S. However, the FDA may in the future require premarket approval or clearance of such products as well.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market certain products, such as eyelash serums and chemical peels, as cosmetics (i.e., not pursuant to an FDA approval or OTC monograph), but the FDA may disagree with our determination that these products do not require FDA premarket review and approval or that they adhere to the applicable OTC monograph. We also market the Skintrisiq device for use in connection with certain of our cosmetic and OTC skin care products. We believe that, based on its intended use, the Skintrinsiq device does not meet the FDCA&#8217;s definition of a medical device and have not sought FDA premarket review of this product. However, the FDA may disagree with our determination and subject the Skintrinsiq device to medical device regulations. Similar risks may apply in foreign jurisdictions where we market our products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inquiry into the regulatory status of our cosmetics and related products, including the Skintrinsiq device, and any related interruption in the marketing and sale of these products could damage our reputation and image in the marketplace. In recent years, the FDA has issued warning letters to several cosmetic companies alleging improper claims regarding their cosmetic products. The FDA has also historically taken action against manufacturers of some light-emitting products used to alter or improve appearance on the grounds that those products are medical devices that require clearance or approval. If the FDA or any other regulatory authorities determine that we have made inappropriate drug or medical device claims regarding Obagi products, we could receive a warning or untitled letter, be required to modify our product claims, pay fines or penalties, or take other actions to satisfy the FDA or any other regulatory authorities. In addition, plaintiffs&#8217; lawyers have filed class action lawsuits against cosmetic companies after receipt of these types of FDA warning letters. We cannot assure you that we will not be subject to state, federal or foreign government actions or class action lawsuits, which could harm our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the Obagi products we intend to sell as cosmetics or for use with our cosmetic products were to be regulated as drugs or medical devices, we might be required to conduct, among other things, lengthy clinical trials to demonstrate the safety and efficacy of these products and/or submit applications to the FDA in order to obtain required marketing authorizations for such products, and we may be required to cease distribution of or recall these products until such authorizations are obtained. We may</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not have sufficient resources to conduct any required clinical trials or to ensure compliance with the manufacturing requirements applicable to drugs or medical devices. If the FDA or any other regulatory authorities determine that any of our products intended to be sold as cosmetics or for use with our cosmetic products should be classified and regulated as drug products or medical devices, or were to ban or restrict the use of certain ingredients in such cosmetic products, and we are unable to comply with applicable requirements for those products, we may be unable to continue to market those products and may be subject to enforcement action.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we sell products, such as sunscreens, that are subject to the FDA&#8217;s OTC drug monograph regulatory requirements. The FDA regulates the formulation, manufacturing, packaging and labeling of OTC drug products. Certain </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our products, such as some of our sunscreen and acne drug products, are regulated pursuant to the FDA&#8217;s OTC drug monographs that specify acceptable active drug ingredients and acceptable product claims that are generally recognized as safe and effective for particular uses. If any of these products that are marketed as OTC drugs pursuant to an OTC monograph are not in compliance with the applicable FDA monograph or the FDA changes the list of active ingredients that are covered under the monograph, we may be required to reformulate the product, stop making claims relating to such product or stop selling the product until we are able to obtain costly and time-consuming FDA approvals. We are also required to submit adverse event reports to the FDA for our OTC drug products, and failure to comply with this requirement may subject us to FDA regulatory action. Moreover, the FDA&#8217;s process for establishing, amending, and finalizing monographs has recently been reformed pursuant to the CARES Act. If these reforms affect the regulatory requirements to which we or our products are subject, or if we do not comply, we could be subject to enforcement action, which could materially adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to FTC rules and regulations as well as state consumer protection laws. If we are unable to show adequate substantiation for our product claims, our claims are otherwise perceived to be unlawful or deceptive, our promotional materials make claims that exceed the scope of allowed claims for the classification of the specific product, or we do not adhere to certain disclosures, the FDA, the FTC or other regulatory authorities could take enforcement action or impose penalties or fines, require us to revise our marketing materials, amend our claims or stop selling certain products, all of which could harm our business, financial condition and results of operations. Any regulatory action or penalty could lead to private party actions, or private parties could seek to challenge our claims even in the absence of formal regulatory actions, which could harm our business, financial condition and results of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products may also be subject to regulation by the CPSC in the U.S. under the provisions of the Consumer Product Safety Act, as amended by the Consumer Product Safety Improvement Act of 2008. These statutes and the related regulations ban consumer products that fail to comply with applicable product safety laws, regulations and standards. The CPSC has the authority to require the recall, repair, replacement or refund of any such banned products or products that otherwise create a substantial risk of injury and may seek penalties for regulatory noncompliance under certain circumstances. The CPSC also requires manufacturers of consumer products to report certain types of information regarding products that fail to comply with applicable regulations. Certain state laws also address the safety of consumer products, and mandate reporting requirements, and noncompliance may result in penalties or other regulatory action.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, new or revised government laws, regulations or guidelines could result in additional compliance costs and, in the event of non-compliance, civil remedies, including fines, injunctions, withdrawals, recalls or seizures and confiscations, as well as potential criminal sanctions, any of which could have an adverse effect on our business, financial condition, results of operations and prospects. We cannot, for example, predict additional costs or other impacts of MoCRA, which among other things, requires FDA rulemaking for the implementation of key provisions. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products containing the active ingredient, hydroquinone, are marketed as prescription-use only drugs but have not received required premarket authorization from the FDA or other regulatory authorities, and the FDA could require us to remove these products from the market until we obtain approval of the required NDA, and we could be found to be marketing and selling these products in violation of the law.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market Obagi products that contain hydroquinone (&#8220;HQ&#8221;) on a prescription-only (i.e., not OTC) basis, and we have not sought nor obtained premarket approval from the FDA to market these products in the U.S., nor have we sought marketing authorizations in other jurisdictions. Sales of Obagi products containing HQ accounted for a significant portion of total products in the 2022 Successor Period, 2022 Predecessor Period, 2021 Predecessor Period and 2020 Predecessor Period, respectively. Although, to date, neither the FDA nor any other regulators have taken action against us for selling our prescription HQ products in the U.S. and in other jurisdictions without marketing approval, there can be no assurance the FDA or any other regulatory authorities will not take enforcement action against us, or otherwise require us to obtain premarket approval or similar authorization of our prescription HQ products, and we may be required to suspend marketing of our prescription HQ products unless and until such products are approved.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the historical evolution of the legal and regulatory framework applicable to drugs in the U.S., the FDA acknowledges that there are some drugs on the market that lack required FDA approval for marketing. The FDA has historically utilized a risk-based enforcement approach with respect to drugs marketed without required approvals. In 2003, the FDA issued a Compliance Policy Guide (&#8220;CPG&#8221;), which was finalized in 2006 and subsequently amended in 2011, in which it announced a drug safety initiative to remove unapproved drugs from the market and established enforcement priorities and a policy of enforcement discretion with respect to marketed unapproved products. Under this policy, the FDA indicated that it intended to give higher priority to enforcement actions involving unapproved drug </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products in certain categories, including drugs with potential safety risks and ineffective drugs that could be used in lieu of effective treatments. Although this CPG was withdrawn and the drug safety initiative was terminated on the basis of a Federal Register notice in 2020, a subsequent Federal Register notice in May 2021 withdrew the prior notice terminating the program and the CPG, and the FDA indicated that it plans to continue to prioritize enforcement based on its existing general approach, which involves risk-based prioritization in light of all the facts of a given circumstance, and issue new guidance on this topic.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our prescription-only HQ products do not fall within the previously established categories of unapproved drugs for which the FDA has indicated it prioritizes enforcement. We have not received any communications from the FDA or any similar regulatory authority regarding these HQ products or any of our other products. However, the FDA has issued a Warning Letter to at least one contract manufacturer of prescription-only HQ that cited and objected to another company&#8217;s sale of prescription-only HQ on grounds that the product was both an unapproved drug and failed to comply with cGMPs in violation of the FDCA. In addition, although our prescription-only HQ products are made with 4% HQ, the FDA has expressed concerns regarding the safety of 2% HQ products marketed OTC. In addition, the CARES Act implemented a number of changes to regulation of OTC drugs, one of which prohibited the sale of any drug without an approved monograph, including HQ (at any concentration level), from being marked in the U.S. as an OTC drug without FDA approval effective September 2020. In April 2022, the FDA announced that it had issued warning letters to 12 companies for continuing to sell 2% HQ products on an OTC basis in violation of the CARES Act. The FDA&#8217;s announcement also cited reports describing serious side effects associated with the use of skin lightening products containing HQ, including reports of skin rashes, facial swelling, and skin discoloration. See &#8220;Item 3. Key Information&#8212;D.  Risk Factors&#8212;Risks Related to our Obagi Skincare Business&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our products may cause adverse events or side effects, or could be associated with safety issues, that could result in recalls, withdrawals, or regulatory enforcement action. For example, the FDA has historically expressed concerns regarding the safety of HQ products, including risks for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">potentially serious side effects, including skin rashes, facial swelling, skin discoloration, carcinogenicity and reproductive toxicity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in June and July of 2022, the FDA issued warning letters to two other manufacturers of products containing HQ. In the future the FDA may pursue an enforcement action against us or suspend marketing of our prescription HQ products until we obtain approval of an NDA (as defined below).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required to seek FDA approval or foreign authorities&#8217; authorization of these products, our attention and resources will be dedicated to the clinical development and regulatory approval processes, which will be time-consuming and very expensive. We may also not successfully obtain such approvals or may be delayed in obtaining such approvals if one of our competitors obtains approval and non-patent marketing exclusivity for the same uses for which we intend to seek approvals. In addition, if we are determined to be marketing our prescription HQ products unlawfully, or if patients experience adverse events from using our prescription HQ products, we may be required to recall or cease distribution of these products and may be subject to product liability claims or enforcement action. If we are required to suspend or cease marketing of our prescription HQ products for any reason, our business would be materially adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we obtain regulatory approvals for any of our prescription HQ products, such approvals will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. In addition, if the FDA or foreign regulatory authorities approve our products, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements, any of which may materially increase our costs and limit our ability to maintain profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The drug regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are required to seek and obtain any regulatory approvals that may be required for our products, we may be unable to obtain or maintain such regulatory approvals, which would substantially harm our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any products that are regulated by the FDA as drugs must generally obtain premarket approval from the FDA, unless subject to the OTC monograph process or subject to other limited exceptions. The FDA approves new drugs through the New Drug Application (&#8220;NDA&#8221;) or Abbreviated New Drug Application (&#8220;ANDA&#8221;) processes before they may be legally marketed in the U.S. In the NDA process, an applicant must generally demonstrate through well-controlled clinical trials that a drug is safe and effective for its intended uses. The Hatch-Waxman Act established the ANDA process, which is an abbreviated FDA approval procedure for drugs that are shown to be bioequivalent to proprietary drugs previously approved by the FDA through its NDA process. Premarket applications for generic drugs are termed &#8220;abbreviated&#8221; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">because such applications generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, an ANDA applicant must demonstrate that its product is bioequivalent to the innovator drug. In certain situations, an applicant may obtain ANDA approval of a generic drug with a strength or dosage form that differs from a referenced innovator drug pursuant to the filing and approval of an ANDA Suitability Petition. Similar requirements apply in foreign jurisdictions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain Obagi products, including our tretinoin-based products, are marketed pursuant to an ANDA held by Bausch Health or dispensed under the category of unlicensed medicines in the United Kingdom (the &#8220;U.K.&#8221;). However, we have not sought or obtained FDA premarket approval or foreign regulatory authorities&#8217; authorization for any of our products. The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or any foreign regulatory authorities can delay, limit or deny approval or require us to conduct additional nonclinical or clinical testing or abandon a program for, among others, the following reasons:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of any clinical trials we may be required to conduct;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product is safe and effective for its proposed indication or bioequivalent to a listed drug;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that a product&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials may not be acceptable or sufficient to support the submission of an NDA, ANDA or other submission or to obtain regulatory approval in the U.S. or elsewhere, and we may be required to conduct additional clinical studies;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA&#8217;s or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party CMOs with which we contract for clinical and commercial supplies; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for any approvals.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approvals to market our products, which could significantly harm our business, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in laws, regulations, enforcement trends in international markets could harm our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, cosmetics are subject to notification through the Cosmetic Products Notification Portal by the company responsible for placing them on the EU market. A cosmetic is defined as &#8220;any substance or mixture intended to be placed in contact with the external parts of the human body (epidermis, hair, nails, lips and external genital organs) or with the teeth and the mucous membranes of the oral cavity with a view exclusively or mainly to cleaning them, perfuming them, changing their appearance, protecting them, keeping them in good condition or correcting body odours.&#8221; Consequently, a product is notably considered to be a cosmetic if it is presented as protecting the skin, maintaining the skin in good condition or improving the appearance of the skin, provided that it is not a medicinal product due to its composition or intended use. In the EU, the composition of a cosmetic may not be such that it has a significant effect on the body through a pharmacological, immunological or metabolic mode of action. No test has been determined yet for the significance of the effect. Indeed, by contrast, a medicinal product is defined as &#8220;any substance or combination of substances presented as having properties for treating or preventing disease in human beings; or any substance or combination of substances </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which may be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis.&#8221; A similar position was adopted by the U.K. following Brexit.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many countries, including the U.S., EU, Canada, Australia and Japan, where HQ is regulated as a drug and requires a prescription, we have not sought nor obtained regulatory approval to distribute our HQ products, and instead offer our Nu-Derm Fx and Obagi-C Fx solutions, which contain the skin brightening agent arbutin, for these markets. The effects of arbutin on the skin could be attributed to their gradual hydrolysis and release of HQ. In the EU, the safety of alpha- and beta-arbutin has been previously assessed by the European Commission&#8217;s Scientific Committee on Consumer Products (&#8220;SCCS&#8221;) in 2015 and 2008 respectively, which concluded that the use of alpha-arbutin is safe for consumers in cosmetic products in a concentration up to 2% in face creams and up to 0.5% in body lotions, and the use of beta-arbutin is safe for consumers in cosmetic products in a concentration up to 7% in face creams provided that the contamination of hydroquinone in the cosmetic formulations remain below 1 ppm. Nevertheless, the SCCS highlighted in both opinions that a potential combined use of HQ releasing substances in cosmetic products has not been evaluated. HQ is listed in Annex II to the Cosmetic Regulation, which means that, with certain exceptions not applicable to us, HQ is a prohibited cosmetic ingredient in the EU. In the last couple of years, concerns have been raised within the European Commission on the HQ content, its release, as well as on the aggregate exposure from cosmetic products containing alpha-arbutin and/or beta-arbutin. This led to additional consultation with the SCCS and resulted in the identification of a number of issues in the previous submissions, in particular the stability and dermal absorption of alpha-arbutin and/or beta-arbutin, the release rate of HQ and the aggregate exposure calculation from cosmetics exposure.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this, a call for data was launched from July 2020 to April 2021 during which interested parties were asked to contribute with data/information relevant to the stability of alpha- and beta-arbutin, their dermal absorption, the HQ release rate (including biotransformation) and the aggregate exposure. On March 15 and March 16, 2022, the SCCS issued its preliminary opinion on the safety of alpha-arbutin and beta-arbutin in cosmetic products dated March 15-16, 2022, the SCCS considered that it cannot conclude on the safety of alpha-arbutin (when used in face creams up to a maximum concentration of 2% and in body lotions up to a maximum concentration of 0.5%) or beta-arbutin (when used in face cream up to a maximum concentration of 7%) because not all relevant scientific data which are required for the safety assessment, e.g., data on the degradation/metabolism of arbutin when exposed to the skin microbiome/enzymes and the release and final fate of HQ, are available. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2023, the SCCS issued its final opinion. The main conclusions in this opinion were:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) alpha-arbutin used in face creams up to a maximum concentration of 2% and in body lotions up to a concentration of 0.5% is safe, also when used together;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) beta-arbutin used in face creams up to a maximum concentration of 7% is safe;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) hydroquinone should remain as low as possible in formulations containing alpha-or beta-arbutin and should not be higher than the unavoidable traces in both arbutins. In the new studies, submitted by the applicant, 3ppm was the LOQ for hydroquinone and 1ppm for the LOD;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv) aggregate exposure of alpha-arbutin (2% in face cream and 0.5% in body lotion with beta-arbutin (7% in face cream)) are considered safe.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No amendments were made to the EU Cosmetics Regulation prohibiting or restricting the use of alpha- and/or beta-arbutin following this final opinion. Further, to the best of our knowledge, no such amendments to the Cosmetics Regulations are planned to be made in the near future. In addition, Obagi&#8217;s arbutin products are permitted to be sold in the Asia-Pacific region countries in which Obagi distributes such products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some countries may impose import or export restrictions that limit or temporarily halt our ability to import products to some of the international regions in which we distribute products in response to pandemics, natural disasters, geopolitical issues or regulatory compliance issues. For instance, in response to the COVID-19 pandemic, certain South Asian countries including Vietnam imposed restrictions on imports from countries that were deemed at high risk for the disease and our SA Distributor was unable to import products into Vietnam for several months as a result. Subsequently, in June 2022, the SA Distributor experienced a delay in obtaining renewals of licenses from the Vietnam drug administration to distribute products into that country, which prohibited its ability to import our products into Vietnam until such licenses were obtained in June 2023. Similarly, in response to the ongoing conflict between Russian </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Ukraine, the U.S. president adopted executive orders that prohibit the import of various products, including ours, into the Russian Federation. While our net sales into that territory are not material, it is possible that other countries in which we have more significant sales may become involved in the conflict and similar executive orders may be issued in the future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products may cause adverse events or side effects, or could be associated with safety issues, that could result in recalls, withdrawals, or regulatory enforcement action. For example, the FDA has historically expressed concerns regarding the safety of HQ products, including risks for potentially serious side effects, including skin rashes, facial swelling, skin discoloration, carcinogenicity and reproductive toxicity.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events or other undesirable side effects caused by our products could cause us or regulatory authorities to issue warnings about our products or could lead to recalls or regulatory enforcement action. For example, our HQ products could be subject to enforcement action and/or recalls based on the FDA&#8217;s concerns regarding OTC HQ-based products. Specifically, in August 2006, the FDA issued a proposed rule that cited certain preclinical evidence suggesting that HQ may be a carcinogen, if orally administered, may present fertility risks and may be related to a skin condition called ochronosis, which results in the darkening and thickening of the skin and the appearance of small bumps and grayish-brown spots, after use of concentrations as low as 1 to 2 percent. The FDA also concluded that it could not rule out the potential carcinogenic risk from topically applied HQ. Accordingly, the FDA recommended that additional studies be conducted to determine if there is a risk to humans from the use of HQ. The FDA nominated HQ for further study by the National Toxicology Program (the &#8220;NTP&#8221;), and in December 2009, the NTP Board of Scientific Counselors approved the nomination and has been conducting studies related to HQ.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi Nu-Derm Clear, Blender and Sunfader products, and the Obagi-C Rx C-Clarifying Serum and Obagi-C Rx C-Night Therapy Cream products, which are part of Obagi&#8217;s Obagi-C Rx Systems, contain HQ at 4% concentration. Until the completion of the NTP studies, the FDA recommended classifying OTC skin-bleaching drug products, including HQ, as not generally recognized as safe and effective (&#8220;GRASE&#8221;), as misbranded, and as new drugs within the meaning of the FDCA, meaning that such products would need to be approved through the NDA process in order to be legally marketed in the U.S.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although this proposed rule was never finalized, in March 2020, Congress passed the CARES Act, which among other things, amended the FDCA to incorporate FDA&#8217;s proposed rulemaking with respect to OTC drugs into final OTC monograph determinations. In particular, the CARES Act deemed any OTC drugs that were identified as not GRASE in the FDA&#8217;s most recent proposed rulemaking for such OTC drugs to be &#8220;new drugs&#8221; and misbranded within the meaning of the FDCA, meaning that as of September 23, 2020, such drugs required an approved drug application before they could be lawfully marketed. As a result, products containing HQ were prohibited from being marketed in the U.S. as OTC drug products without an approved NDA. Subsequently, in April 2022, the FDA announced that it had issued warning letters to 12 companies for continuing to sell 2% HQ products on an OTC basis in violation of the CARES Act. The FDA&#8217;s announcement also cited reports describing serious side effects associated with the use of skin lightening products containing HQ, including reports of skin rashes, facial swelling, and skin discoloration. Furthermore, in June and July of 2022, the FDA issued warning letters to two manufacturers of products containing HQ.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the legal framework with respect to HQ products marketed OTC does not directly affect the regulatory status of our prescription-only HQ products, the FDA&#8217;s cited concerns regarding the safety of HQ in OTC products at concentrations as low as 1% or 2% could nevertheless trigger regulatory scrutiny of our prescription-only HQ products. To the extent that the FDA were to determine that our prescription-use only HQ products present safety concerns, the FDA could determine that the products should be recalled, and such determination could trigger the FDA to require marketing authorization for these products based on the FDA&#8217;s established enforcement priorities for drugs marketed without an approved NDA. See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks Related to our Obagi Skincare Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Our products containing the active ingredient, hydroquinone, are marketed as prescription-use only drugs but have not received required premarket authorization from the FDA or other regulatory authorities, and the FDA could require us to remove these products from the market until we obtain approval of the required NDA, and we could be found to be marketing and selling these products in violation of the law</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our products are associated with undesirable side effects or adverse events, a number of potentially significant negative consequences could result, including, but not limited to:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may suspend, limit or withdraw approvals of such products (to the extent subject to such approvals), or seek an injunction against its manufacture or distribution;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require warnings or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the products are administered or conduct clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to fines, injunctions or the imposition of criminal penalties;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could seriously harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulations could prohibit physicians from dispensing Obagi prescription-only products directly or through their e-commerce websites.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our primary market, the U.S., we market prescription-only Obagi products and systems directly to physicians to dispense in their offices. Although several of our systems contain prescription-strength HQ products and we sell different strengths of tretinoin, all of which require a prescription, our products are not currently available in pharmacies. Certain states, including Massachusetts, Montana, New Hampshire, New York and Texas, prohibit physicians from dispensing prescription products without a pharmacy or other license or authorization, permitting physicians to dispense such products only in certain limited circumstances for &#8220;immediate need&#8221; until a patient can get to a pharmacy or in rural areas with a small population. For these states Obagi offers alternate products under our Obagi Nu-Derm Fx and Obagi-C Fx product lines that contain the skin brightening ingredient arbutin rather than 4% HQ. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware that the State of Texas and Puerto Rico, as well as certain credit card authorization vendors, have taken action against physician customers who sell Obagi prescription products to patients over the Internet, questioning whether these practices are consistent with such states&#8217; pharmacy licensure and physician dispensing rules and requiring them to either obtain the proper licenses or to cease selling our prescription products through their e-commerce sites. Most of these physicians ceased selling the prescription products online, offering them only in office to patients, and/or chose to sell our alternate arbutin products online instead. These actions did not have a material impact on our sales or net revenue. However, in the future there may be additional states that take similar enforcement actions against our customers. In the event that occurs, affected customers may be unable to continue selling our prescription-strength products over the Internet or at all, or be required to incur additional costs to obtain the required licensure to be able to dispense the products, which may discourage such customers from continuing to purchase them. Moreover, in the event state regulations change or the interpretation of existing regulations change that limit or prohibit the ability of physicians to dispense prescription products directly to patients in their offices,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or limit or prevent our ability to distribute products directly through physicians, patients may be unable to obtain our prescription-strength products, as they are not currently available in pharmacies, which would have a material effect on our business and on both customers&#8217; and patients&#8217; ability to purchase HQ products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to commercially distribute Obagi products may be significantly harmed if we or our CMOs fail to comply with applicable laws and regulations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have the infrastructure or internal capability to manufacture our products. We rely, and expect to continue to rely, on third-party CMOs for the production of Obagi drug, OTC and cosmetic products. Our products and the facilities in which they are manufactured are generally subject to regulation under the FDCA and FDA implementing regulations, state laws and comparable regulatory frameworks in foreign markets. Federal, state and foreign authorities may inspect the facilities of our CMOs periodically to determine if we and our CMOs are complying with applicable provisions of the FDCA, FDA and foreign regulations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing facilities for drug products are required to comply with the FDA&#8217;s cGMPs and with similar requirements outside the U.S., which require manufacturers to maintain, among other things, stringent vendor qualifications, ingredient identification procedures, manufacturing controls and record keeping processes. Following the passage of the MoCRA, the FDA is required to promulgate additional regulations relating to cGMPs for cosmetics by December 2025. Subsequently, compliance with such cGMP requirements will become mandatory for manufacturers of cosmetic products. If the FDA finds a violation of cGMPs, it may enjoin our CMOs operations, seize our products, restrict importation of goods, impose administrative, civil or criminal penalties, among other things. In addition to the new cGMP requirements, cosmetic manufacturing and processing facilities will be required to be registered with FDA. The MoCRA also requires manufacturers to list their cosmetic products with FDA and to report serious adverse events associated with the use of their cosmetic products in the U.S. to the FDA. Adulterated or misbranded cosmetic products will be subject to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recalls that are mandated by FDA, similar to medical devices. Our operations could be harmed if regulatory authorities make determinations that our CMOs are not in compliance with these regulations as they take effect. We cannot assure you that the CMOS of all of our products will be able to comply with all of these new regulations in a timely manner or that they will not decide to pass the increased costs of having to comply with the regulations onto us, which would increase our costs and negatively impact net income. In addition, FDA regulations prohibit or otherwise restrict the use of certain ingredients in cosmetic products. Similar or stricter requirements may apply in foreign jurisdictions. For instance, in the EU, cosmetic products must be manufactured in compliance with good manufacturing practice and EU regulations equally prohibit or otherwise restrict the use of certain ingredients in cosmetic products, including tretinoin.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties to manufacture Obagi products in accordance with our specifications and in compliance with applicable laws and regulations, including the MoCRA and FDA guidelines and applicable cGMPs or similar requirements for drug products. Compliance with these standards can increase the cost of manufacturing our products as we work with our vendors to assure they are qualified and in compliance. For our tretinoin-based products, which we distribute pursuant to an ANDA held by Bausch Health or which we dispense under the category of unlicensed medicines in the U.K., we also rely on our contract manufacturers to maintain appropriate regulatory clearances or approvals, or otherwise qualify for exemptions from FDA premarket review requirements for such products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP and similar regulations. Our contract manufacturing partners may be found in violation of applicable requirements, which could have a material adverse effect on us and our business. If we or our CMOs fail to comply with these applicable standards, laws, and regulations, it could lead to customer complaints, adverse events, product withdrawal or recall, or increase the likelihood that our products are rendered adulterated or misbranded, any of which could result in negative publicity, remedial costs, or regulatory enforcement that could impact our ability to continue selling certain products. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products and harm our business and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain regulatory approvals or to comply with regulations in foreign jurisdictions would prevent us from marketing our products internationally.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key part of the growth strategy for our Obagi Skincare business is to expand the sale of Obagi products in international markets. To market our products in many non-U.S. jurisdictions, we must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. In some countries, we do not have to obtain prior regulatory approval but do have to comply with other regulatory restrictions on the manufacture, importation, distribution, marketing and sale of our products. We may be unable to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval procedure varies among countries and can involve additional testing and data review. The time required to obtain approval in non-U.S. jurisdictions may differ from that required to obtain FDA approval and could be lengthy. For instance, in June 2022, the SA Distributor encountered a prolonged delay in obtaining required approvals from the drug administration in Vietnam, which prevented it from importing and selling our products into the country. After the acquisition of Obagi Vietnam, Obagi Vietnam applied for and finally received the required approvals to distribute Obagi products in that country in June 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. In addition, many countries from time to time evaluate the regulatory status of various products and ingredients. We may not obtain foreign regulatory approvals on a timely basis, if at all, or may choose not to implement a country&#8217;s labeling requirements if to do so would have a negative impact on our international or domestic operations. If any of our products receives FDA approval, such approvals do not ensure approval by regulatory agencies in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory agencies in other foreign countries or by the FDA. The failure to obtain any required approvals could materially harm our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some jurisdictions, the entity that obtains approval from the applicable regulatory authority must be a domestic company. In those cases, we are required to rely on the distributor in such country to obtain the appropriate regulatory approvals, which subjects us to additional risks, such as their potential inability to effectively obtain and maintain required </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory approvals. Furthermore, in the event that an exclusive distributor in a country terminates its agreement with us, it may not be able to transfer the approvals to a successor that we appoint, and we may face significant delays in our ability to import products to that country while the new distributor applies for the appropriate approvals, which it may not be able to obtain.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.K., certain of Obagi products may be deemed medicinal products and therefore subject to regulation by the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) under the medicines regime. We have not obtained a marketing authorization for such products in the U.K., however the U.K.&#8217;s Human Medicines Regulations 2012 allow for supply of medicinal products that have not been authorized for marketing to patients with special needs at the request of the healthcare professional responsible for the treatment of individual patients. Obagi&#8217;s tretinoin products are currently supplied in the U.K. under the category of an unlicensed medicine or &#8220;special.&#8221; Unlicensed medicines should not, however, be supplied where an equivalent licensed medicinal product can meet special needs of the patient. The responsibility for deciding whether an individual patient has &#8220;special needs,&#8221; that a licensed product cannot meet, is a matter for the healthcare professional. Examples of &#8220;special needs&#8221; include an intolerance or allergy to a particular ingredient, or an inability to ingest solid oral dosage forms. The MHRA has a wide range of enforcement powers and failure to comply with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory restrictions or obtain regulatory approvals if required could harm our business. If the MHRA were to decide that our products do not meet the &#8220;specials&#8221; requirements, we may need to cease supply of these products and obtain a marketing authorization in the U.K.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if foreign regulatory authorities were to ban or restrict the use of certain ingredients in cosmetic products, and we are unable to comply with the applicable requirements and regulations for those products, we may be unable to continue to market those products and may be subject to enforcement action. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with governmental regulations, we could face substantial penalties and our business, financial condition and results of operations could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry in and outside the U.S. is heavily regulated and closely scrutinized by federal, state, local and foreign authorities. Although our offerings are not currently covered by any commercial third-party payor or government healthcare program, our business activities may nonetheless be subject to regulation and enforcement by the U.S. Department of Justice, the Department of Health and Human Services and other federal, state and foreign governmental authorities. Federal, state and foreign laws and regulations that may affect our ability to conduct business include, without limitation:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, or arranging for or recommending the purchase, lease or order of, any item or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws and civil monetary penalty laws, such as the federal False Claims Act, which impose criminal and civil penalties and authorize civil whistleblower or qui tam actions, against individuals or entities for, among other things: knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent; making a false statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act, manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims;  </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Civil Monetary Penalties Law, which prohibits, among other things, an individual or entity from offering remuneration to a federal healthcare program beneficiary that the individual or entity knows or should know is likely to influence the beneficiary to order or receive healthcare items or services from a particular provider any item or service for which payment may be made by the federal healthcare program;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the criminal healthcare fraud provisions of HIPAA and related rules that prohibit knowingly and willfully executing a scheme or artifice to defraud any healthcare benefit program or falsifying, concealing or covering up a material fact or making any material false, fictitious or fraudulent statement in connection with the delivery of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologicals, and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare &amp; Medicaid Services under the Open Payments Program, information related to payments or other transfers of value made to teaching hospitals, physicians (as defined by statute) and certain non-physician practitioners including physician assistants and nurse practitioners, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal consumer protection and unfair competition laws, which broadly regulate platform activities and activities that potentially harm consumers; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state and foreign law equivalents of each of the above federal laws, such as anti-kickback, self-referral and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and self-pay patients.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition HIPAA, as amended by HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information, may apply to us in certain circumstances. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Achieving and sustaining compliance with these laws may prove costly. The risk of our being found in violation of these laws and regulations is increased by the fact that many of them have not been fully interpreted by regulatory authorities or the courts, and their provisions are sometimes complex and open to a variety of interpretations. Failure to comply with these laws and other laws can result in significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations and exclusion from participation in federal, state and foreign healthcare programs and imprisonment. Our failure to accurately anticipate the application of these laws and regulations to our business or any other failure to comply with regulatory requirements could create liability for us and negatively affect our business. In addition, any action against us for violation of these laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management&#8217;s attention from the operation of our business and result in adverse publicity, or otherwise result in a material adverse effect on our business, results of operations, financial condition, cash flows and/or reputation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Milk Makeup Business</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The loss of a significant reseller could materially and adversely affect the business, financial condition and results of operations for our Milk Makeup business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., Sephora accounted for a large majority of net revenue for our Milk Makeup business during the 2022 Successor Period. Our contract with Sephora does not require them to purchase any minimum amount of Milk Makeup products. In addition, in line with industry practice, our contract with Sephora allows Sephora to terminate with no prior notice. Accordingly, they could reduce their purchasing levels or cease buying products from us at any time and for any reason. The loss of our relationship with Sephora or any of our other distributors could have a material and adverse impact on our future operating results. If we lose a significant reseller or if sales of our products to a significant retailer materially decrease, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because a high percentage of our sales are made through our retailers, our results are subject to risks relating to the general business performance of our retailers, with significant exposure to Sephora. Factors that adversely affect our retailers&#8217; businesses could also have a material adverse effect on our business, financial condition and results of operations. These factors may include:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any reduction in consumer traffic and demand at our retailers as a result of economic downturns, pandemics or other health crises, changes in consumer preferences or reputational damage as a result of, among other developments, data privacy breaches, regulatory investigations or employee misconduct;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any disruption to their ability to properly receive, deliver, service, promote or market the Milk Makeup brand and products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any credit risks associated with the financial condition of our retailers; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of consolidation or weakness in the retail industry or at certain retailers, including store closures and the resulting uncertainty.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The cosmetics industry is highly competitive, and if we are unable to compete effectively, our results will suffer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk faces vigorous competition from companies throughout the world, including large multinational consumer products companies that have many cosmetics brands under ownership and standalone beauty and cosmetics brands, including those that may target the latest trends or specific distribution channels. Competition in the cosmetics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">industry is based on the introduction of new products, pricing of products, quality of products, quality of packaging, brand awareness, perceived value and quality, innovation, distribution and in-store presence and visibility, promotional activities, advertising, editorials, e-commerce and mobile commerce initiatives and other activities. We must compete with a high volume of new product introductions and existing products by diverse companies across several different distribution channels.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many multinational consumer companies have greater financial, technical or marketing resources, longer operating histories, greater brand recognition or larger customer bases than we do and may be able to respond more effectively to changing business and economic conditions than we can. Our competitors may attempt to gain market share by offering products at prices at or below the prices at which our products are typically offered, including through the use of large percentage discounts. Competitive pricing may require us to reduce our prices, which would decrease our profitability or result in lost sales. Our competitors, many of whom have greater resources than we do, may be better able to withstand these price reductions and lost sales. Our competitors may also leverage their scale for advantageous in-store support at retailers or for advantages in procuring raw materials or using up capacity at CMOs or warehouses that we cannot replicate given our size.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is difficult for us to predict the timing and scale of our competitors&#8217; activities in these areas or whether new competitors will emerge in the cosmetics industry. In recent years, numerous online, &#8220;indie&#8221; and influencer-backed cosmetics companies have emerged and garnered significant followings. In addition, further technological breakthroughs, including new and enhanced technologies that increase competition in the online retail market, new product offerings by competitors and the strength and success of our competitors&#8217; marketing programs may impede our growth and the implementation of our business strategy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete also depends on the continued strength of the Milk brand and products, the success of our marketing, innovation and execution strategies, the continued diversity of our product offerings, the successful management of new product introductions and innovations, strong operational execution, including in order fulfillment, and our success in entering new markets and expanding our business in existing geographies. If we are unable to continue to compete effectively, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Milk Makeup business has a history of net losses and may experience future operating losses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup has a history of net losses and may not be able to establish profitable operations. The Milk Makeup business reported a net loss of $13.8 million during the 2022 Successor Period. Our Milk Makeup business may incur additional operating losses in the future. Furthermore, our strategic plan will require a significant investment in product development, sales, marketing, personnel, technology and administrative programs, which may not result in the accelerated net revenue growth that we anticipate for this business. As a result, there can be no assurance that this business will ever generate substantial net revenue or achieve or sustain profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milk&#8217;s new product introductions may not be as successful as we anticipate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cosmetics industry is driven in part by beauty trends, which may shift quickly. The continued success of our Milk Makeup business depends on our ability to anticipate, gauge and react in a timely and cost-effective manner to changes in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consumer preferences for cosmetics products, consumer attitudes toward the cosmetics industry and brand and where and how consumers shop for and use these products. We must continually work to develop, produce and market new products, maintain and enhance the recognition of the Milk brand, maintain a favorable mix of products and develop our approach as to how and where we market and sell our products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an established process for the development of our new products. Nonetheless, each new product launch involves risks, as well as the possibility of unexpected consequences. For example, the acceptance of new product launches and sales to our retailers may not be as high as we anticipate due to factors such as lack of acceptance of the products themselves or their price, or limited effectiveness of our marketing strategies. In addition, our ability to launch new products may be limited by delays or difficulties affecting the ability of our suppliers or CMOs to timely manufacture, distribute and ship new products. We may also experience a decrease in sales of certain existing products as a result of newly launched products. Any of these occurrences could delay or impede our ability to achieve our sales objectives, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any damage to our reputation or the Milk brand or dilution of our brand&#8217;s uniqueness may materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that developing and maintaining Milk&#8217;s unique brand position and strong reputation is critical and that the financial success of the Milk Makeup business is directly dependent on consumer perception of our brand. Furthermore, the importance of brand recognition and perceived uniqueness may become even greater as competitors offer more products similar to our products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk has relatively low brand awareness among consumers when compared to other cosmetics brands and maintaining and enhancing the recognition and reputation of our brand is critical to our business and future growth.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many factors, some of which are beyond our control, are important to maintaining Milk&#8217;s reputation and brand. These factors include our ability to comply with ethical, social, product, labor and environmental standards. Any actual or perceived failure in compliance with such standards could damage Milk&#8217;s reputation and brand.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The growth of our brand depends largely on our ability to provide a high-quality consumer experience, which in turn depends on Milk&#8217;s ability to bring innovative products to the market at competitive prices that respond to consumer demands and preferences. Additional factors affecting our consumer experience include a reliable and user-friendly website interface and mobile applications for our consumers to browse and purchase products on our e-commerce website. If we are unable to preserve our reputation, enhance our brand recognition or increase positive awareness of our products and Internet platforms, it may be difficult for us to maintain and grow the consumer base for Milk Makeup products, and our business, financial condition and results of operations may be materially and adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our brand may also suffer if our marketing plans or product initiatives do not have the desired impact on our brand&#8217;s image or our ability to attract consumers. Further, our brand value could diminish significantly due to a number of factors, including consumer perception that we have acted in an irresponsible manner, adverse publicity about Milk products, our failure to maintain the quality of our products, product contamination, the failure of our products to deliver consistently positive consumer experiences, or our products becoming unavailable to consumers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Milk Makeup business may experience declines in average selling prices, which may decrease our net sales.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup may experience a reduction in the average selling price of its products for a myriad of reasons, including, but not limited to, voluntary introduction of price reductions or consumer rebate programs, competition, customer demand and shifts in geographic, channel or product mix to lower priced products. Additionally, in response to current global economic conditions, we may find we need to discount the price our Milk products to facilitate sales in uncertain times. If any of the foregoing were to occur, the net sales, operating income and net income of our Milk Makeup business may be reduced.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on a number of third-party suppliers, distributors and other vendors for our Milk Makeup business, and they may not continue to produce products or provide services that are consistent with our standards or applicable regulatory requirements, which could harm our brand, cause consumer dissatisfaction and require us to find alternative suppliers of our products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use multiple third-party suppliers based in the U.S. and overseas to source substantially all of our Milk Makeup products. Certain of these third-party suppliers manufacture components and packaging while other third-party suppliers </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will fill and assemble the products. We engage our third-party suppliers on a purchase order basis and are not party to long-term contracts with any of them. The ability of these third parties to supply our products may be affected by competing orders placed by other companies and their demands. If we experience significant increases in demand or need to replace a significant number of existing suppliers, we cannot assure you that additional supply capacity will be available when required on terms that are acceptable to us, or at all, or that any supplier will allocate sufficient capacity to us in order to meet our requirements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on a limited number of suppliers for certain components that are integral to our finished products. If these or other suppliers encounter financial, operating or other difficulties or if our relationship with them changes, we may be unable to quickly establish or qualify replacement sources of supply and we could face production interruptions, delays and inefficiencies. In addition, technology changes by our vendors could disrupt access to required manufacturing capacity or require expensive, time-consuming development efforts to adapt and integrate new equipment or processes. Our growth may exceed the capacity of one or more of these suppliers to produce the needed equipment and materials in sufficient quantities to support our growth. Any one of these factors could harm our business and growth prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, quality control problems or supply chain issues, such as the use of ingredients and delivery of products that do not meet our quality control standards and specifications or comply with applicable laws or regulations, including the Controlled Substances Act and the FDCA, could harm our business. We cannot assure you that our CMOs will continue to meet all requirements of the new FDA regulations promulgated under the MoCRA, in which case we will need to seek qualified alternatives that may not be available or available on terms acceptable to us. Any quality control or supply chain problems could result in regulatory action, such as restrictions on importation, legal prohibitions on the sale of Milk Makeup products or other penalties, or result in products of inferior quality or product stock outages or shortages, harming our sales and creating inventory write-downs for unusable products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">To deepen our market penetration and raise awareness of our brand and products, we have increased the amount we spend on marketing activities, which may not ultimately prove successful or an effective use of our resources.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To increase awareness of our Milk Makeup products and services domestically and internationally, we have increased, and plan to continue to increase, the amount we spend on marketing activities. Our marketing efforts and costs are significant and include national and regional campaigns involving outdoor media, social media, additional placements and alliances with strategic partners. We attempt to structure our advertising/marketing campaigns in ways we believe most likely to increase brand awareness and adoption; however, our campaigns may not achieve the returns on advertising spend desired or successfully increase brand or product awareness sufficiently to sustain or increase our growth goals, which could have an adverse effect on our gross margin and business overall.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely heavily on a third-party agency and direct sales forces to sell Milk Makeup products in the U.S. and internationally, and any failure to train and maintain our third-party agency and direct sales forces could harm our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to sell Milk Makeup products and generate revenues depends in part upon a third-party agency and direct sales forces within the U.S. and internationally. We do not have any long-term employment contracts with our third-party agency and direct sales forces and the loss of the services provided by these key personnel may harm our business. In order to provide more comprehensive sales and service coverage, we continue to increase the size of the sales force for the Milk Makeup business to pursue growth opportunities within and outside of our existing geographic markets. To adequately train new representatives to successfully market and sell our products and for them to establish strong customer relationships takes time. As a result, our net revenues, our gross margin and ability to maintain market share could be materially harmed if we are unable to (a) retain our third-party agency and direct sales personnel, (b) quickly replace them with individuals of equivalent technical expertise and qualifications if they leave, (c) successfully instill technical expertise in new and existing sales representatives, or (d) establish and maintain strong relationships with our customers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal and Regulatory Risks That Could Adversely Impact our Milk Makeup Business</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New laws, regulations, enforcement trends or changes in existing regulations governing the introduction, marketing and sale of Milk Makeup products to consumers could harm our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Milk Makeup products are subject to regulation by the FDA, the FTC, the CPSC, and comparable state, local and foreign regulatory authorities, including the European Commission, and over time, the regulatory landscape for our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products has become more complex with increasingly strict requirements. There has been an increase in regulatory activity and activism in the U.S. and abroad, including the adoption of the MoCRA, which significantly expanded the FDA&#8217;s enforcement authorities over cosmetics products and imposes new obligations on the cosmetics industry, including requirements relating to cGMP, labeling, safety substantiation, facility registration and product listing with the FDA, adverse event reporting and recordkeeping, among others. Pursuant to MoCRA, the FDA promulgated several regulations relating to cosmetics, which companies must be in compliance with no later than July 1, 2024, and will adopt additional regulations in 2024 and cGMP requirements in 2025. As a result, the regulatory landscape for Milk Makeup products is becoming more complex with increasingly strict requirements. If this trend continues, we may find it necessary to alter some of the ways we have traditionally manufactured and marketed Milk Makeup products to stay in compliance with a changing regulatory landscape, and this could add to the costs of our operations and have an adverse impact on our business. To the extent federal, state, local or foreign regulatory changes regarding consumer protection, or the ingredients, claims or safety of our products, occurs in the future, they could require us to reformulate or discontinue certain of our products, revise the product packaging or labeling, change the manufacturers at which our products are made, or adjust operations and systems, any of which could result in, among other things, increased costs, delays in product launches, product returns or recalls and lower net sales, and therefore could have a material adverse effect on the business, financial condition and results of operations of our Milk Makeup business. Noncompliance with applicable regulations could result in enforcement action by regulatory authorities within or outside the U.S., including, but not limited to, product seizures, injunctions, product recalls and criminal or civil monetary penalties, all of which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., with the exception of color additives, the FDA does not currently require pre-market approval for products intended to be sold as cosmetics. However, the FDA may in the future require pre-market approval, clearance or registration/notification of cosmetic products. Moreover, such products could also be regulated as both drugs and cosmetics simultaneously, as the categories are not mutually exclusive. The statutory and regulatory requirements applicable to drugs are extensive and require significant resources and time to ensure compliance. For example, if any of our products intended to be sold as cosmetics were to be regulated as drugs, we might be required to conduct, among other things, clinical trials to demonstrate the safety and efficacy of these products. We may not have sufficient resources to conduct any required clinical trials or to ensure compliance with the manufacturing requirements applicable to drugs. If the FDA determines that any of our products intended to be sold as cosmetics should be classified and regulated as drug products and we are unable to comply with applicable drug requirements, we may be unable to continue to market those products. Any inquiry into the regulatory status of our cosmetics and any related interruption in the marketing and sale of these products could damage our reputation and image in the marketplace.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, the FDA has issued warning letters to several cosmetic companies alleging improper claims regarding their cosmetic products, including improper drug claims. If the FDA determines that we have made inappropriate drug claims regarding our products intended to be sold as cosmetics, we could receive a warning or untitled letter, be required to modify our product claims or take other actions to satisfy the FDA, including the recall of products from the market. In addition, plaintiffs&#8217; lawyers have filed class action lawsuits against cosmetic companies after receipt of these types of FDA warning letters. There can be no assurance that we will not be subject to state and federal government actions or class action lawsuits, which could harm our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are also subject to regulation by the CPSC in the U.S. under the provisions of the Consumer Product Safety Act, as amended by the Consumer Product Safety Improvement Act of 2008. These statutes and the related regulations ban from the market consumer products that fail to comply with applicable product safety laws, regulations and standards. The CPSC has the authority to require the recall, repair, replacement or refund of any such banned products or products that otherwise create a substantial risk of injury, and may seek penalties for regulatory noncompliance under certain circumstances. The CPSC also requires manufacturers of consumer products to report certain types of information to the CPSC regarding products that fail to comply with applicable regulations. Certain state laws also address the safety of consumer products, and mandate reporting requirements, and noncompliance may result in penalties or other regulatory action.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products and facilities are subject to regulation by federal and state regulators.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and the facilities in which they are manufactured are generally subject to regulation under the FDCA and the FDA implementing regulations and state laws. The FDA or state authorities may inspect any or all of our CMOs&#8217; facilities periodically to determine if such facilities comply with the FDCA and FDA regulations and state laws. In addition, our facilities for manufacturing OTC drug products must comply with the FDA&#8217;s cGMP that require our CMOs </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to maintain, among other things, good manufacturing processes, including stringent vendor qualifications, ingredient identification, manufacturing controls and record keeping.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to MoCRA, the FDA also is required to promulgate regulations relating to cGMPs for cosmetics. In addition to cGMP requirements, cosmetic manufacturing and processing facilities are required to be registered with FDA. The MoCRA also requires manufacturers to list their cosmetic products with FDA and to report serious adverse events associated with the use of their cosmetic products in the U.S. to the FDA. Adulterated or misbranded cosmetic products will be subject to recalls that are mandated by FDA, similar to medical devices. In addition, FDA regulations prohibit or otherwise restrict the use of certain ingredients in cosmetic products. Similar or stricter requirements may apply in foreign jurisdictions. For instance, in the EU, cosmetic products must be manufactured in compliance with good manufacturing practice and EU regulations equally prohibit or otherwise restrict the use of certain ingredients in cosmetic products, including tretinoin.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties to manufacture Milk products in accordance with our specifications and in compliance with applicable laws and regulations, including the MoCRA and FDA cosmetic guidelines and applicable cGMPs and other requirements for drug products. Compliance with these standards can increase the cost of manufacturing our products as we work with our vendors to assure they are qualified and in compliance. We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP and similar regulations. Our contract manufacturing partners may be found in violation of applicable requirements, which could have a material adverse effect on us and our business. If we or our CMOs fail to comply with these applicable standards, laws, and regulations, it could lead to customer complaints, adverse events, product withdrawal or recall, or increase the likelihood that our products are rendered adulterated or misbranded, any of which could result in negative publicity, remedial costs, or regulatory enforcement that could impact our ability to continue selling certain products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA, FTC or particular states may ultimately prohibit or limit the sale of some or all cosmetics containing U.S. hemp and U.S. hemp-derived ingredients, including cannabidiol (&#8220;CBD&#8221;) and other cannabinoids.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Agricultural Improvement Act of 2018, the FDA has retained authority over drugs, cosmetics and other FDA-regulated products that contain U.S. hemp and U.S. hemp-derived ingredients, including CBD, even if those products are not otherwise controlled substances regulated by the Drug Enforcement Administration. The FDA has consistently taken the position that CBD, whether derived from U.S. hemp or U.S. Schedule I cannabis, is prohibited from use as an ingredient in food and dietary supplements. With regard to cosmetics, the FDA has stated that ingredients not specifically addressed by regulation must nonetheless comply with all applicable requirements, and no ingredient &#8211; including a cannabis or cannabis-derived ingredient &#8211; can be used in a cosmetic if it causes the product to be adulterated or misbranded in any way. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the FDA and FTC have issued warning letters to companies that, in many cases, asserted that the manufacturer made unsubstantiated health claims or sold CBD products in a form that appeals to children. In addition, the FTC has entered settlements with companies to resolve claims that those companies made unsubstantiated health claims to market their CBD products. Until the FDA and FTC formally adopt regulations with respect to CBD or other U.S. hemp-derived cannabinoid products or announce an official position with respect to CBD or other U.S. hemp-derived cannabinoid products in cosmetic products, there is a risk that the FDA or FTC could take enforcement action against us  in respect of U.S. hemp-derived cosmetic products, such as some of our KUSH and Hydro products, sold in the U.S.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA could in the future take the position that our cosmetic products are intended for use in diagnosing, treating, mitigating or preventing disease or for use in affecting the structure or any function of the body and, therefore, seek to regulate our cosmetic products containing U.S. hemp-derived ingredients under its authorities for drug products. Though we do not market our cosmetics containing U.S. hemp-derived ingredients as drugs, the FDA could still assert that the products are intended for use as drugs, including based on the understood or presumed physical effects of cannabinoids. Thus, we may not have the ability to successfully respond to such allegations simply by modifying labeling or advertising claims. If we cannot or elect not to comply with the onerous regulatory requirements applicable to FDA-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulated drugs, we could be prevented from producing, marketing and selling cosmetic products containing U.S. hemp-derived ingredients, including CBD or other cannabinoids.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, states have retained regulatory authority through their own analogues to the FDCA and the states may diverge from the federal treatment of the use of U.S. hemp in cosmetic products. The FDA or applicable states may ultimately not permit the sale of products containing U.S. hemp-derived ingredients, including CBD and other cannabinoids, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government regulations and private party actions relating to the marketing and advertising of our products and services may restrict, inhibit or delay our ability to sell our products and harm our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governmental authorities, including the FTC, regulate advertising and product claims regarding the performance and benefits of our products. These regulatory authorities typically require a reasonable basis to support any marketing claims. What constitutes adequate substantiation can vary widely from market to market, and there is no assurance that the efforts that we undertake to support our claims will be deemed adequate for any particular product or claim. A significant area of risk for such activities relates to improper or unsubstantiated claims about our products and their use or safety. If we are unable to show adequate substantiation for our product claims, or our promotional materials make claims that exceed the scope of allowed claims for the classification of the specific product, the FDA, the FTC or other regulatory authorities could take enforcement action or impose penalties, such as monetary consumer redress, requiring us to revise our marketing materials, amend our claims or stop selling certain products, all of which could harm our business, financial condition and results of operations. Any regulatory action or penalty could lead to private party actions, or private parties could seek to challenge our claims even in the absence of formal regulatory actions, which could harm our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Business &amp; Wellness Industry</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any damage to our reputation or brands may materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that developing and maintaining our brands is critical and that our financial success is directly dependent on consumer perception of our brands. Furthermore, the importance of brand recognition may become even greater as competitors offer more products similar to ours.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many factors, some of which are beyond our control, are important to maintaining our reputation and the Obagi and Milk brands. These factors include our ability to comply with ethical, social, product, labor and environmental standards, which have become increasingly important to consumers. Any actual or perceived failure in compliance with such standards could damage our reputation and brands. The growth of our brands depends largely on our ability to provide a high-quality consumer experience, which in turn depends on our ability to bring innovative, effective products to the market at competitive prices that respond to consumer demands and preferences. If we are unable to preserve our reputation, enhance our brand recognition or increase positive awareness of our products, it may be difficult for us to maintain and grow our consumer base, and our business, financial condition and results of operations may be materially and adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our brands may also suffer if our marketing plans or product initiatives do not have the desired impact on our brands&#8217; image or our ability to attract consumers. Further, our brand value could diminish significantly due to a number of factors, including consumer perception that our products are not safe or that we have acted in an irresponsible manner, adverse publicity about our products, our failure to maintain the quality of our products, product contamination, the failure of our products to deliver consistently positive consumer experiences, or the products becoming unavailable to consumers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends, in part, on the quality, efficacy and safety of our products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any loss of confidence on the part of consumers in the ingredients used in our Obagi Skincare or Milk Makeup products, whether related to product contamination or product safety or quality failures, actual or perceived, or inclusion of prohibited ingredients, could tarnish the image of the applicable brand and could cause consumers to choose other products. Allegations of contamination or other adverse effects on product safety or suitability for use by a particular consumer, even if untrue, may require us to expend significant time and resources responding to such allegations and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could, from time to time, result in a recall of a product from any or all of the markets in which the affected product was distributed. Any such issues or recalls could negatively affect our profitability and brand image.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our products are found or perceived to be defective or unsafe, or if they otherwise fail to meet consumers&#8217; expectations, our relationships with consumers could suffer, the appeal of our brands could be diminished, we may need to recall some of our products and/or become subject to regulatory action and we could lose sales or market share or become subject to boycotts or liability claims. In addition, third parties may sell counterfeit versions of some of our products. These counterfeit products may pose safety risks, may fail to meet consumers&#8217; expectations, and may have a negative impact on our business. Any of these outcomes could result in a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The design, development, manufacture and sale of our products involve the risk of product liability and other claims by consumers and other third parties, and our insurance may be insufficient to cover any such claims.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design, development, manufacture and sale of skincare and cosmetic products involves an inherent risk of product liability claims and the associated adverse publicity. A product may be safe for the general population when used as directed but could cause an adverse reaction for a person who has a health condition or allergies, or who is taking a prescription medication. If we discover that any of our products are causing adverse reactions, we could suffer adverse publicity or regulatory/government sanctions. We regularly monitor the use of our products for trends or increases in reports of adverse events or product complaints. In some, but not all, cases, an increase in adverse event reports may be an indication that there has been a change in a product&#8217;s specifications or efficacy. Such changes could lead to a recall of the product in question or, in some cases, increases in product liability claims related to the product in question. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, potential product liability risks may arise from the testing, manufacture and sale of our Obagi Skincare and/or Milk Makeup products, including that any of the products fail to meet quality or manufacturing specifications, contain contaminants, include inadequate instructions as to their proper use, include inadequate warnings concerning side effects and interactions with other substances or for persons with health conditions or allergies, or cause adverse reactions or side effects. Product liability claims could increase our costs, and adversely affect our business, financial condition and results of operations. As we continue to offer an increasing number of new products, our product liability risk may increase. In the past, plaintiffs have received substantial damage awards from other cosmetic and drug companies based upon claims for injuries allegedly caused by the use of their products. Although we currently maintain general liability and product liability insurance, any claims brought against us may exceed our existing or future insurance policy coverage or limits. In addition, there may be liability risks, including, without limitation, product liability risks, for which we do not maintain or procure insurance coverage or for which the insurance coverage may not cover or be adequate. To the extent that any judgment against us that is in excess of our policy limits or is not covered by our insurance policies, the judgment would have to be paid from our cash reserves, which would reduce our capital resources. In addition, we may be required to pay higher premiums and accept higher deductibles in order to secure adequate insurance coverage in the future. Further, we may not have sufficient capital resources to pay a judgment, in which case our creditors could levy against our assets. Any product liability claim or series of claims brought against us could harm our business significantly, particularly if a claim were to result in adverse publicity or damage awards that are in excess of our insurance policy limits or not covered, in whole or in part, by our insurance policies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also be subject to a variety of other types of claims, proceedings, investigations and litigation initiated by government agencies or third parties. Such claims or proceedings could include those related to compliance matters, product regulation or safety, taxes, employee benefit plans, employment discrimination, health and safety, environmental, antitrust, customs, import/export, government contract compliance, financial controls or reporting, intellectual property, allegations of misrepresentation, false claims or false statements, commercial claims, claims regarding promotion of our products and services, shareholder derivative suits or other similar matters. Negative publicity, whether accurate or inaccurate, about the efficacy, safety or side effects of our products or the type of products we make, whether involving us or a competitor, could materially reduce market acceptance of our products, cause consumers to seek alternatives to our products, result in product withdrawals and cause our stock price to decline. Negative publicity could also result in an increased number of product liability claims, whether or not these claims have a basis in scientific fact. Any such claims, proceedings, investigations or litigation, regardless of the merits, might result in substantial costs, restrictions on product use or sales, or otherwise injure our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of social media may materially and adversely affect our reputation or subject us to fines or other penalties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely to a large extent on our online presence to reach consumers, and we, along with our e-commerce partners, retailers and distributors, offer consumers the opportunity to rate and comment on our products on their websites. Negative commentary or false statements regarding us or our products may be posted on these e-commerce websites or social media platforms and may harm our reputation or business. Our target consumers often value readily available information and often act on such information without further investigation and without regard to its accuracy. The harm may be immediate without affording us an opportunity to redress or correct the information. In addition, we may face claims relating to information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that is published or made available through the interactive features of our e-commerce website. For example, we may receive third-party complaints that the comments or other content posted by users on our platforms infringe third-party intellectual property rights or otherwise infringe the legal rights of others. While the Communications Decency Act and Digital Millennium Copyright Act generally protect online service providers from claims of copyright infringement or other legal liability for the self-directed activities of its users, if it were determined that we did not meet the relevant safe harbor requirements under either law, we could be exposed to claims related to advertising practices, defamation, intellectual property rights, rights of publicity and privacy, and personal injury torts. We could incur significant costs investigating and defending such claims and, if we are found liable, significant damages. If any of these events occur, our business, financial condition and results of operations could be materially and adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use third-party social media platforms as marketing tools. For example, Obagi and Milk maintain Snapchat, Facebook, TikTok, Instagram and/or YouTube accounts. As e-commerce and social media platforms continue to rapidly evolve, we must continue to maintain a presence on these platforms and establish a presence on new or emerging popular social media platforms. If we are unable to cost-effectively use social media platforms as marketing tools, our ability to acquire new consumers and our financial condition may suffer. Furthermore, as laws and regulations rapidly evolve to govern the use of these platforms and devices, the failure by us, our employees or third parties acting at our direction to abide by applicable laws and regulations in the use of these platforms and devices could subject us to regulatory investigations, class action lawsuits, liability, fines or other penalties and could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, an increase in the use of social media for product promotion and marketing may cause an increase in the burden on us to monitor compliance of such materials and increase the risk that such materials could contain problematic product or marketing claims in violation of applicable regulations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A disruption in the operations of any of our freight carriers or higher shipping costs could cause a decline in our net revenues or a reduction in our earnings.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on commercial freight carriers to deliver our products both within the U.S. and internationally. If the operations of these carriers are disrupted for any reason, we may be unable to timely deliver our products to our customers. If we cannot deliver our products on time and cost effectively, our customers may choose competitive offerings, causing our net revenues and gross margins to decline, possibly materially. In a rising fuel cost environment, our freight costs may increase. In addition, we earn an increasingly larger portion of our net revenues from international sales. International sales carry higher shipping costs, which could negatively impact our gross margin and results of operations. If freight costs materially increase and we are unable to pass that increase along to our customers for any reason or otherwise offset such increases in our cost of sales, our gross margin and financial results could be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A disruption in our operations could materially and adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company engaged in distribution on a global scale, our operations, including those of our third-party suppliers, brokers and delivery service providers, are subject to the risks inherent in such activities, including industrial accidents, environmental events, strikes and other labor disputes, disruptions in information systems, product quality control, safety, licensing requirements and other regulatory issues, as well as natural disasters, pandemics (such as the COVID-19 pandemic), border disputes, acts of terrorism and other external factors over which we and our third-party suppliers, brokers and delivery service providers have no control. The loss of, or damage to, the manufacturing facilities or distribution centers of our third-party suppliers, brokers and delivery service providers could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend heavily on contracted third-party delivery service providers to deliver our products to our distribution facilities and logistics retailers, and from there to our customers, distributors and/or retailers. Interruptions to or failures in these delivery services could prevent the timely or successful delivery of our products. These interruptions or failures may be due to unforeseen events that are beyond our control or the control of our third-party delivery service providers, such as inclement weather, natural disasters or labor unrest. If our products are not delivered on time or are delivered in a damaged state, retailers and customers may refuse to accept our products and have less confidence in our services.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to meet the needs of our customers depends on the proper operation of our third-party distribution facilities, where most of our inventory that is not in transit is housed. Our insurance coverage may not be sufficient to cover the full extent of any loss or damage to our inventory or distribution facilities, and any loss, damage or disruption of the facilities, or loss or damage of the inventory stored there, could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign currency exchange rate fluctuations and restrictions on the repatriation of cash could adversely affect our results of operations, financial position and cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is exposed to fluctuations in exchange rates. Although our reporting currency is the U.S. dollar, we operate in different geographical areas and transact in a range of currencies in addition to the U.S. dollar, such as the British pound, the Canadian dollar, the Chinese yuan, the EU euro and the Vietnamese dong. As a result, movements in exchange rates may cause our revenue and expenses to fluctuate, impacting our profitability, financial position and cash flows. Future business operations and opportunities, including our planned expansion of our business outside the U.S., may further increase the risk that cash flows resulting from these activities may be adversely affected by changes in currency exchange rates. In the event we are unable to offset these risks, there could be a material adverse effect on our business and operations. In appropriate circumstances where we are unable to naturally offset our exposure to these currency risks, we may enter into derivative transactions to reduce such exposures. Even where we implement hedging strategies to mitigate foreign currency risk, these strategies might not eliminate our exposure to foreign exchange rate fluctuations and involve costs and risks of their own, such as ongoing management time and expertise, external costs to implement the strategies and potential accounting implications. Nevertheless, exchange rate fluctuations may either increase or decrease our revenues and expenses as reported in U.S. dollars. Moreover, foreign governments may restrict transfers of cash out of the country and control exchange rates. There can be no assurance that we will be able to repatriate earnings generated, or cash held, by us and our subsidiaries due to exchange control restrictions or the requirements to hold cash locally to meet regulatory solvency requirements. This could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Technology and Cyber Security</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on information technology systems and infrastructure; if we, or the third parties we rely on, fail to protect sensitive information of our consumers and information technology systems against security breaches, it could damage our reputation and brand and substantially harm our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely to a large extent on our information technology systems and infrastructure, which may be the subject of breakdowns, malicious intrusion and attacks. We rely on these networks and systems to market and sell our products, process electronic and financial information, assist with sales tracking and reporting, manage a variety of business processes and activities and comply with regulatory, legal and tax requirements. We are also increasingly dependent on a variety of information systems and third-party partners to effectively process consumer orders from our e-commerce websites for Obagi Skincare and Milk Makeup products. A key component of our growth strategy entails expanding our e-commerce efforts both in the U.S. and internationally. Our e-commerce websites serve as an effective extension of our marketing strategies by introducing potential new consumers to our brands, product offerings, retailers and enhanced content. Due to the increasing importance of our e-commerce operations, we are vulnerable to website downtime and other technical failures. Our failure to successfully respond to these risks in a timely manner could reduce e-commerce sales and damage our brands&#8217; reputations. We collect, maintain, transmit and store data about our customers, suppliers and others, including personal data, financial information, such as consumer payment information, as well as other confidential and proprietary information important to our business. We also frequently employ third-party service providers that collect, store, process and transmit personal data, and confidential, proprietary and financial information on our behalf, such as credit card processing vendors and logistics providers, and as a result a number of third-party vendors may or could have access to our confidential information. If our third-party service providers fail to protect their information technology systems and our confidential and proprietary information, we may be vulnerable to disruptions in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service and unauthorized access to our confidential or proprietary information and we could incur liability and reputational damage.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in place certain technical and organizational measures to maintain the security and safety of critical proprietary, personal, employee, customer and financial data that we continue to maintain and upgrade to industry standards. However, advances in technology, the increasing ingenuity of criminals, new exposures via cryptography, acts or omissions by our employees, contractors or service providers or other events or developments could result in a compromise or breach in the security of confidential or personal data. Further, attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. We and our service providers may not be able to prevent third parties, including criminals, competitors or others, from breaking into or altering our systems, disrupting business operations or communications infrastructure through denial-of-service attacks, attempting to gain access to our systems, information or monetary funds through phishing or social engineering campaigns, installing viruses or malicious software on our e-commerce websites or mobile applications or devices used by our employees or contractors, or carrying out other activity intended to disrupt our systems or gain access to confidential or sensitive information in our or our service providers&#8217; systems. We may also face increased cybersecurity risks due to our reliance on Internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Actual or anticipated attacks may cause us to incur increasing costs, including costs to deploy additional personnel and protection technologies, train employees and engage third-party experts and consultants. If a material security breach were to occur, our reputation and brands could be damaged, and we could be required to expend significant capital and other resources to alleviate problems caused by such breaches, including exposure of litigation or regulatory action and a risk of loss and possible liability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payment methods used on our e-commerce websites subject us to third-party payment processing-related risks.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accept payments from our consumers using a variety of methods, including online payments with credit cards and debit cards issued by major banks, payments made with gift cards processed by third-party providers and payment through third-party online payment platforms such as Afterpay. We also rely on third parties to provide payment processing services. For certain payment methods, including credit and debit cards, we pay interchange and other fees, which may increase over time and raise our operating costs and lower our profit margins. We may also be subject to fraud and other illegal activities in connection with the various payment methods we offer, including online payment options and gift cards. Transactions on our e-commerce websites and mobile applications are card-not-present transactions, so they present a greater risk of fraud. Criminals are using increasingly sophisticated methods to engage in illegal activities such as unauthorized use of credit or debit cards and bank account information. Requirements relating to consumer authentication and fraud detection with respect to online sales are complex. We may ultimately be held liable for the unauthorized use of a cardholder&#8217;s card number in an illegal activity and be required by card issuers to pay charge-back fees. Chargebacks result not only in our loss of fees earned with respect to the payment, but also leave us liable for the underlying money transfer amount. If our chargeback rate becomes excessive, card associations also may require us to pay fines or refuse to process our transactions. In addition, we may be subject to additional fraud risk if third-party service providers or our employees fraudulently use consumer information for their own gain or facilitate the fraudulent use of such information. Overall, we may have little recourse if we process a criminally fraudulent transaction.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to adopt new technologies or adapt our e-commerce website and systems to changing consumer requirements or emerging industry standards, our business may be materially and adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To remain competitive, we must continue to enhance and improve the responsiveness, functionality and features of our information technology networks and systems, including our e-commerce websites. Our competitors are continually innovating and introducing new products to increase their consumer base and enhance user experience. As a result, to attract and retain consumers and compete in the skincare and cosmetic markets, we must continue to invest resources to enhance our information technology and improve our existing products and services for our consumers. The Internet and the online retail industry are characterized by rapid technological evolution, changes in consumer requirements and preferences, frequent introductions of new products and services embodying new technologies and the emergence of new industry standards and practices, any of which could render our existing technologies and systems obsolete. Our success will depend, in part, on our ability to identify, develop, acquire or license leading technologies useful in our business, and respond to technological advances and emerging industry standards and practices in a cost-effective and timely way. The </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development of our e-commerce websites and other proprietary technology entails significant technical and business risks. There can be no assurance that we will be able to properly implement or use new technologies effectively or adapt our e-commerce websites and systems to meet consumer requirements or emerging industry standards. If we are unable to adapt in a cost-effective and timely manner in response to changing market conditions or consumer requirements, whether for technical, legal, financial or other reasons, our business, financial condition and results of operations may be materially and adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to complex and evolving U.S. and foreign laws and regulations regarding privacy and data protection. Many of these laws and regulations are subject to change and uncertain interpretation, and any failure or perceived failure to comply could result in claims, changes to our business practices, monetary penalties or increased costs of operations, or otherwise could harm our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a variety of laws and regulations in the U.S. and abroad regarding privacy and data protection, some of which can be enforced by private parties or government entities and some of which provide for significant penalties for noncompliance. Such laws and regulations govern the collection, use, disclosure, retention, and security of personal information, such as information that we may collect in connection with sales on our e-commerce websites or during clinical trials of our products. Implementation standards, interpretations and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business, affect our ability to operate in certain jurisdictions or to collect, store, transfer, use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, or result in additional liability for us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, claims by third parties, government investigations and enforcement actions, including injunctions, fines and/or criminal penalties if we knowingly obtain or disclose individually identifiable health information from a covered entity in a manner that is not authorized or permitted by HIPAA or applicable state laws, any of which could have a material adverse effect on our operations, financial performance and business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., numerous federal and state laws and regulations, including federal and state health information privacy laws, state data breach notification laws, and federal and state consumer protection laws that govern the collection, use, disclosure and protection of health-related and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other personal information could apply to our operations or the operations of our collaborators and third-party providers. For example, the California Consumer Privacy Act (the &#8220;CCPA&#8221;), which went into effect on January 1, 2020, creates individual privacy rights for California consumers, including the right to opt out of certain disclosures of personal information, increases the privacy and security obligations of entities handling certain personal information, and also establishes significant penalties for noncompliance. The CCPA also provides for a private right of action for data breaches, which is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Additionally, in November 2020, California voters passed the California Privacy Rights Act (the &#8220;CPRA&#8221;). The CPRA, which went into effect on January 1, 2023, significantly expands the CCPA, including by introducing additional obligations such as data minimization and storage limitations, granting additional rights to consumers such as correction of personal information and additional opt-out rights and creating a new entity, the California Privacy Protection Agency, to implement and enforce the law. The CPRA may require us to modify our data collection or processing practices and policies, cause us to incur substantial costs and expenses to comply, and increase our potential exposure to regulatory enforcement and/or litigation. Other U.S. states have also enacted or are considering enacting stricter data privacy laws. For example, in March 2021, Virginia enacted the Virginia Consumer Data Protection Act and, in March 2022, Utah enacted the Utah Consumer Privacy Act, comprehensive privacy statutes that are similar to the CCPA and CPRA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the FTC and many state Attorneys General continue to enforce federal and state consumer protection laws against companies for online collection, use, dissemination and security practices that appear to be unfair or deceptive. For example, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure can constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions. For example, the EU&#8217;s General Data Protection Regulation 2016/679 (the &#8220;EU GDPR&#8221;) and the U.K. General Data Protection </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation and the U.K.&#8217;s Data Protection Act 2018 (the &#8220;U.K. GDPR&#8221;; and together with the EU GDPR, the &#8220;GDPR&#8221;) governs certain collection and other processing activities involving personal data about data subjects in the European Economic Area (&#8220;EEA&#8221;) and U.K. respectively. The U.K. GDPR is likely to be subject to divergence from the EU GDPR over time. Among other things, the GDPR imposes requirements regarding the security of personal data and the rights of data subjects to access and delete personal data, requires having lawful bases on which personal data can be processed, includes requirements relating to the consent of individuals to whom the personal data relates (such consent relates to the lawful processing of personal data under the GDPR and is distinct from others consents obtained from individuals in connection with clinical trial participation), requires detailed notices for clinical trial participants and investigators and regulates transfers of personal data from the EEA to third countries that have not been found to provide adequate protection to such personal data, including the U.S. (and these restrictions have heightened in light of recent case law and regulatory guidance). In addition, the EU GDPR imposes substantial administrative fines for breaches and violations ranging from &#8364;10.0 million to &#8364;20.0 million or 2% to 4% of our annual global revenue, whichever is higher and the U.K. GDPR imposes separate and additional fines ranging from &#163;8.7 million to &#163;17.5 million or 2% to 4% of total worldwide annual revenue, whichever is higher. The GDPR also confers a private right of action on data subjects to lodge complaints with supervisory authorities, seek judicial remedies (including data subject-led class actions and injunctions) and obtain compensation for damages resulting from violations of the GDPR.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to EEA and U.K. rules with respect to cross-border transfers of personal data outside of the EEA and U.K. to third countries. The GDPR generally prohibits the transfer of EEA and U.K. personal data to third countries whose laws do not ensure an adequate level of protection, unless a valid data transfer mechanism has been implemented or an Article 49 GDPR derogation applies. Legal developments in the EEA and U.K. have created complexity and uncertainty regarding transfers of personal data. As supervisory authorities issue further guidance on personal data transfer mechanisms, transfer risk assessments, and supplementary measures for the security of transferred personal data or start taking enforcement action, we could be subject to additional costs, complaints or regulatory investigations or fines, or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we operate our business and could harm our business, financial condition and results of operations. In October 2022, President Biden signed an Executive Order on &#8220;Enhancing Safeguards for United States Signals Intelligence Activities&#8221; which introduced new binding safeguards to address the concerns raised by the Court of Justice of the European Union in its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Schrems II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> judgement. Although this Executive Order is intended to form the basis of a new EU-US Data Privacy Framework (the &#8220;Framework&#8221;), the Framework is still in development and its route to implementation remains uncertain. In June 2021, the European Commission published a new set of modular standard contractual clauses (the &#8220;New SCCs&#8221;). The New SCCs must be used for all relevant transfers of personal data outside the EEA (since December 2022) and organizations must ensure that all new and existing contracts involving the transfer of personal data outside the EEA contain New SCCs. Although the European Commission adopted an adequacy decision for the U.K. in June 2021 allowing the continued flow of personal data from the EEA to the U.K., this decision will automatically expire in June 2025 unless the European Commission re-assesses and renews or extends that decision. The decision will be regularly reviewed by the European Commission going forward and may be revoked if the U.K. diverges from its current data protection laws and the European Commission deems the U.K. to no longer provide adequate protection of personal data.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the U.K. implemented its own U.K.-specific international data transfer agreement (&#8220;IDTA&#8221;) and addendum to the New SCCs (&#8220;U.K. Addendum&#8221;). For all contracts involving transfers of U.K.-originated data entered into after September 2022, organizations that transfer U.K. personal data are required to use the IDTA, or the New SCCs together with the U.K. Addendum. Existing contracts involving transfers of U.K.-originated data relying on standard contractual clauses must be migrated to the IDTA, or the New SCCs together with the U.K. Addendum by March 2024. The cross-border data transfer landscape in the EEA and U.K. is continually developing, and we are monitoring these developments. We may, in addition to other impacts, experience additional costs associated with increased compliance burdens and be required to engage in new contract negotiations with third parties that aid in processing data on our behalf or localize certain data. We may experience reluctance or refusal by current or prospective European customers to use our products, and we may find it necessary or desirable to make further changes to our handling of personal data of EEA and U.K.-based data subjects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cross-border data transfer landscape globally (including in the EEA, U.K. and U.S.) is continually evolving, and other countries outside of Europe have enacted or are considering enacting cross-border data transfer restrictions and laws requiring data localization, which may affect our ability to process or transfer personal data from Europe or elsewhere. Inability to import personal data to the U.S. may significantly and negatively impact our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators in the EEA and the U.K. are increasingly focusing on compliance with requirements in cookies and tracking technologies and the online behavioral advertising ecosystem, with a notable rise in enforcement activity from supervisory authorities across the EEA in relation to cookies-related violations, resulting in significant fines as supervisory authorities increasing adopt a fact-based approach. National laws in the EEA that implement the ePrivacy Directive are likely to be replaced by the ePrivacy Regulation, which, though still in development, will if adopted, impose new obligations on the use of personal data in the context of electronic communications, particularly in relation to online tracking technologies and direct marketing, and will significantly increase fines for noncompliance, although it will not have effect in the U.K. In the U.K., it is possible that we will be subject to separate and additional legal regimes with respect to ePrivacy, which may result in further costs and may necessitate changes to our business practices. The GDPR requires opt-in, informed consent for the placement of cookies on a customer&#8217;s device, and imposes conditions on obtaining valid consent (e.g., a prohibition on prechecked consents). Increased regulation of cookies tracking technologies and online behavioral advertising may lead to broader restrictions and impairments on our online activities, including our ability to identify and potentially target users, lead to substantial costs, require significant systems changes, negatively impact our efforts to understand our customers and subject us to additional liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with existing, not yet effective, and proposed privacy and data protection laws and regulations can be costly and can delay or impede our ability to market and sell our products, affect our ability to conduct business through websites and mobile applications we and our partners may operate, require us to modify or amend our information practices and policies, change and limit the way we use consumer information in operating our business, increase our operating costs, or require significant management time and attention. Failure to comply could result in negative publicity or subject us to inquiries or investigations, claims or other remedies, including significant fines and penalties, or demands that we modify or cease existing business practices. We may also face civil claims, including representative actions and other class action type litigation (where individuals have suffered harm), potentially amounting to significant compensation or damages liabilities, as well as associated costs, and diversion of internal resources. Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our proprietary rights, we may not be able to compete effectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends significantly on our ability to protect our proprietary rights to the formulas and technologies used for our Obagi Skincare and Milk Makeup products. We rely primarily on maintaining the confidentiality of our trade secrets and the protection of trade secret laws, as well as a combination of patent, copyright, trademark and trade dress (including common law trademark and trade dress) laws, and nondisclosure, confidentiality and other contractual restrictions, to protect our proprietary formulas and technologies. However, these legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. For example, our trade secrets may be misappropriated by current or former employees, contractors or parties with whom we partner, or may be inadvertently disclosed or obtained by breach of a confidentiality agreement or other confidentiality obligation. Although we have taken steps to protect our intellectual property and proprietary formulas and technologies, including entering into confidentiality agreements and intellectual property assignment agreements with our employees, consultants and advisors, such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements. Further, the parties with whom we enter into confidentiality and intellectual property assignment agreements could dispute the ownership of intellectual property developed under these agreements. In addition, the laws of some foreign countries may not protect our intellectual property rights to the same extent as the laws of the U.S.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are involved in intellectual property claims and litigation, the proceedings may divert our resources and subject us to significant liability for damages, substantial litigation expense and the loss of our proprietary rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to protect or enforce our intellectual property rights, we may initiate litigation. In addition, others may initiate litigation related to intellectual property against us. Companies against whom we might initiate litigation or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">who might initiate litigation against us may be better able to sustain the costs of litigation because they have substantially greater resources. We may become subject to interference proceedings conducted in patent and trademark offices to determine the priority of inventions or uses. There are numerous issued and pending patents in the skincare product field. The validity and breadth of such patents may involve complex legal and factual questions for which important legal principles may remain unresolved. If third parties file oppositions to our patent applications in foreign countries, we may also have to participate in opposition proceedings in foreign tribunals to defend the patentability of our filed foreign patent applications. We also have worked with consultants in developing our intellectual property portfolio. To the extent any of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these consultants are engaged in litigation involving intellectual property related to us, we may also become a party to such actions or otherwise be adversely affected by virtue of our relationships with the consultants.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation may be necessary for us to assert or defend against infringement claims, enforce our issued and licensed patents, protect our trade secrets or know-how or determine the enforceability, scope and validity of the proprietary rights of others. Our involvement in intellectual property claims and litigation could:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divert existing management, scientific and financial resources;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subject us to significant liabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">result in a ruling that allows our competitors to market competitive products without obtaining a license from us;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to enter into royalty or licensing agreements, which may not be available on terms acceptable to us, if at all; or</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">force us to discontinue selling or modify our products, or to develop new products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, our business could be materially and adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our intellectual property, the value of our brands and other intangible assets may be diminished, and our business may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a combination of trademark, copyright, trade secret, trade dress, patent and other laws protecting proprietary rights, nondisclosure and confidentiality agreements and other practices to protect the brands of our Obagi Skincare and Milk Makeup businesses and proprietary information, formulas, technologies and processes. Our trademarks are valuable assets that support our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">brands and consumers&#8217; perceptions of our products. Although we have certain existing and pending trademark registrations for our various brands in the U.S. and in some of the foreign countries in which we operate, we may not be successful in asserting trademark or trade name protection in all jurisdictions. We also have not applied for trademark protection for all of our marks or in all relevant foreign jurisdictions and cannot be certain whether our pending trademark applications will be approved in full, modifications or at all. We rely on common law trademark protections for certain of our marks. Third parties may also attempt to register our trademarks abroad in jurisdictions where we have not yet applied for trademark protection, oppose our trademark applications domestically or abroad, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products in some parts of the world, which could result in the loss of brand recognition and could require us to devote resources to advertising and marketing new brands.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that we regard as our own. Our assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims third parties may bring against us, to determine the ownership of what we regard as our intellectual property. We may be subject to claims challenging the inventorship or ownership of our intellectual property. We also rely upon unpatented trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position, which we seek to protect, in part, through confidentiality agreements with our employees and our collaborators and consultants. It is possible that technology relevant to our business will be developed independently by a person that is not a party to such an agreement, and that person could be an employee of or otherwise associated with one of our competitors. Furthermore, if the employees and consultants who are parties to these agreements breach or violate the terms of these agreements, we may not have adequate remedies for or sufficient resources to litigate any such breach or violation, and we could lose our trade secrets through such breaches or violations. Further, our trade secrets could otherwise become known or independently discovered by our competitors. If we are unable to obtain, maintain and enforce intellectual property protection directed to our technology and any future technologies that we develop, others may be able to make, use, import or sell products that are the same or substantially the same as ours, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may not be able to protect our intellectual property rights throughout the world. Filing, prosecuting and defending intellectual property rights in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal or state laws in the U.S. Consequently, we may not be able to prevent third parties from utilizing our intellectual property in all countries outside the U.S., or from selling or importing products similar to ours in and into the U.S. or other jurisdictions. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may use our intellectual property in jurisdictions where we have not obtained protection to develop their own products and, further, may export otherwise infringing products to territories where we have protection, but enforcement is not as strong as that in the U.S. These products may compete with our products, and our intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to correctly estimate or control our future operating expenses in relation to obtaining intellectual property, enforcing intellectual property and/or defending intellectual property, which could affect operating expenses. Our operating expenses may fluctuate significantly in the future as a result of a variety of factors, including the costs of preparing, filing, prosecuting, defending, and enforcing intellectual property claims and other intellectual property-related costs, including adverse proceedings (such as litigation) costs. If we fail to protect our intellectual property or other proprietary rights, our business, financial condition and results of operations may be materially and adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on our ability to operate our business without infringing, misappropriating or otherwise violating the trademarks, patents, copyrights and other proprietary rights of third parties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to operate without infringing, misappropriating or otherwise violating the trademarks, patents, copyrights, trade secrets and other proprietary rights of others. We cannot be certain that the conduct of our business does not and will not infringe, misappropriate or otherwise violate such rights. From time to time, we receive allegations of trademark infringement, and third parties have filed claims against us with allegations of intellectual property infringement. In addition, third parties may involve us in intellectual property disputes as part of a business model or strategy to gain competitive advantage. We may also be required to pay substantial damages or be subject to an order prohibiting us and our customers, distributors or retailers from importing or selling certain products or engaging in certain activities. Our inability to operate our business without infringing, misappropriating or otherwise violating the trademarks, patents, copyrights and proprietary rights of others could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we gain greater visibility and market exposure as a public company or otherwise, we may also face a greater risk of being the subject of such claims and litigation. For these and other reasons, third parties may allege that our products or activities infringe, misappropriate or otherwise violate their trademark, patent, copyright or other proprietary rights. Defending against allegations and litigation could be expensive, occupy significant amounts of time, divert management&#8217;s attention from other business concerns and have an adverse impact on our ability to bring products to market. In addition, if we are found to infringe, misappropriate or otherwise violate third-party trademark, patent, copyright or other proprietary rights, our ability to use our brands to the fullest extent may be limited, we may need to obtain a license, which may not be available on commercially reasonable terms, or at all, or we may need to redesign or rebrand our marketing strategies or products, which may not be possible.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Organization and Corporate Structure</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to risks related to our dependency on our directors and officers and on key personnel, as well as risks related to attracting, retaining and developing human capital in a highly competitive market.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are dependent upon a relatively small group of individuals and in particular, Michel Brousset and Hind Sebti, our Chief Growth Officer. We believe that our success depends on the continued service of our directors and officers. We do not have key-man insurance on the life of any of our directors or officers. The unexpected loss of the services of one or more of our directors or officers could have a detrimental effect on us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our success and future growth depend upon the services of Obagi&#8217;s and Milk&#8217;s management teams and other key employees, including highly skilled experts in their respective fields. In 2023, we made extensive changes to senior management at Obagi, finding seasoned experts to join Obagi as the new President, Chief Financial Officer and Chief Marketing Officer with in-depth expertise in their respective fields. However, these new executives have only recently taken on these roles and we cannot assure you that they will integrate well into the Obagi business, that we will be able to retain them, or that they will be able to successfully manage and operate the business, maintain our existing relationships with key suppliers and customers and retain other highly skilled key employees of Obagi. The loss of one or more members of Obagi&#8217;s or Milk&#8217;s management teams or key employees could harm our business, and we may not be able to find adequate replacements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on our continued ability to attract, retain and motivate highly qualified management, business development, sales and marketing, product development and other personnel for our Obagi Skincare and Milk Makeup businesses. We may have difficulty recruiting and retaining such qualified personnel due to current market conditions, their inability to trade their equity awards and the existence of many similar competitive job openings. There is intense competition in our industry particularly for senior sales and marketing and research and product development positions. The failure to attract and retain qualified personnel could have a significant negative impact on our future product sales and business results.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, prospective and existing employees and independent contractors often consider the value of the equity awards they receive in connection with their employment. If the perceived value of our equity awards declines, experiences significant volatility or increases such that prospective employees or independent contractors believe there is limited or less upside to the value of such equity awards, it may adversely affect our ability to recruit and retain key employees and independent contractors. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects would be harmed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we currently maintain directors&#8217; and officers&#8217; liability insurance coverage, such coverage may not be sufficient to cover the types or extent of claims or loss that may be incurred or received. Our inability to obtain and maintain appropriate insurance coverage could cause a substantial business disruption, adverse reputational impact and regulatory scrutiny. If we incur any loss that is not covered by our directors&#8217; and officers&#8217; liability insurance policy, or the compensated amount is significantly less than our actual loss, our business, financial condition and results of operations could be materially and adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our only material asset is our indirect interest in Waldencast LP, and we are accordingly dependent upon distributions from Waldencast LP to pay dividends, taxes and other expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a holding company with no material assets other than indirect equity interests in Waldencast LP. As such, we do not have any independent means of generating revenue or cash flow, and our ability to pay taxes and operating expenses or declare and pay dividends in the future, if any, will be dependent upon the results of operations and cash flows of Waldencast LP and its subsidiaries, including Obagi and Milk. We intend to cause Waldencast LP to make distributions to its members, including Holdco 1, in an amount at least sufficient to allow for the payment of all applicable taxes, and to pay our corporate and other overhead expenses and those of Holdco 1. We cannot assure you, however, that Waldencast LP and its subsidiaries will generate sufficient cash flow to distribute funds to Holdco 1, or that applicable legal and contractual restrictions, including negative covenants in Waldencast LP&#8217;s debt instruments, will permit such distributions. It could materially and adversely affect our liquidity and financial condition if Waldencast LP is restricted from, or otherwise unable to, distribute sufficient cash to us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our warrants are accounted for as liabilities and the changes in value of our warrants could have a material effect on our financial results.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the SEC together issued a statement regarding the accounting and reporting considerations for warrants issued by SPACs entitled &#8220;Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies&#8221; (the &#8220;SEC Statement&#8221;). Specifically, the SEC Statement focused on certain settlement terms and provisions related to tender offers following a business combination, which terms are similar to those contained in the Warrant Agreement. As a result of the SEC Statement, we reevaluated the accounting treatment of our 11,500,000 public warrants and 5,933,333 private placement warrants and determined to classify the warrants as derivative liabilities measured at fair value, with changes in fair value each period reported in earnings.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we have included derivative liabilities related to embedded features contained within our warrant in our balance sheet as of December 31, 2022. Accounting Standards Codification (&#8220;ASC&#8221;) Topic 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 815&#8221;), provides for the remeasurement of the fair value of such derivatives at each balance sheet date, with a resulting non-cash gain or loss related to the change in the fair value being recognized in earnings in the statement of operations. As a result of the recurring fair value measurement, our financial statements and results of operations may fluctuate quarterly based on factors that are outside of our control. Due to the recurring fair value measurement, we expect that we will recognize non-cash gains or losses on our warrants each reporting period and that the amount of such gains or losses could be material.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of our significant intangible assets may reduce our profitability.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values at the acquisition date of our goodwill, acquired trademarks and trade names, customer and distributor relationships, supply agreement and product formulations are recorded as intangible assets and all, except for goodwill, are amortized over the period that we expect to benefit from the applicable assets. </span><span style="color:#232a31;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value estimates result from a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions that have been deemed reasonable by management as of the measurement date. Accordingly, such estimates and assumptions may not be accurate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, acquired net intangible assets and goodwill comprised approximately 89.3% of our consolidated total assets. We evaluate goodwill for impairment on an annual basis on October 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and at an interim date if indicators of a potential impairment exist. The annual impairment test for the 2021 Predecessor Period did not indicate an impairment of goodwill at the time it was performed. However, subsequent to the Business Combination, we concluded that relevant events and circumstances indicated it was more likely than not that the fair value of the Obagi Skincare reporting segment was less than its carrying amount. This included a decline in financial performance of the Obagi Skincare reporting unit compared to results projected at the time of acquisition, primarily as a result of the subsequent identification of the matters underlying the restatement adjustments. As result, we recorded a non-cash impairment charge of $68.7 million in the period ended December 31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Obagi Skincare reportable segment had a goodwill balance of $199.5 million after an  impairment charge of $68.7 million was recorded following an impairment test conducted in July 2022. As a result, the fair value of the Obagi Skincare reportable segment currently equals the carrying value. The Obagi business continues to face challenges with respect to meeting the forecasts for the business created at the time it was acquired. If we are not successful in addressing these challenges, the projected revenue growth rates or operating margins could fail to grow in accordance with current expectations and result in a further decrease in the fair value of the Obagi Skincare reportable segment below the carrying value. In addition, the fair value of the Obagi Skincare reportable segment could also be negatively impacted by market conditions including inflation, the valuation of its competitors and/or a market capitalization decrease as a result of the restatement of our financial statements for certain Predecessor Periods or other factors, which could result in an additional indicator of impairment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Milk Makeup segment had a goodwill balance of $135.1 million as of December 31, 2022. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not performed a quantitative review of the reporting segment since the Business Combination, as qualitative factors and circumstances did not indicate that the fair value of the reporting unit was less than the carrying value and on that basis management concluded that there was no change in the fair value. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the goodwill balance for the reporting unit has not changed. However, if our Milk Makeup business is unable to meet projected future results, as compared to the forecasts for the business created at the time of the Business Combination, there could be a possibility of an impairment of the goodwill. The fair value of the segment could also be negatively impacted by a shift in gross margin of the business as a result of competition or inflation, or could be negatively impacted by the valuation of its competitors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any further impairment of our intangible assets could reduce our profitability and have a material adverse effect on our results of operations and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a former shell company, resales of shares of our restricted Class A ordinary shares in reliance on Rule 144 of the Securities Act are subject to the requirements of Rule 144(i).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the closing of the Business Combination, we were deemed a &#8220;shell company&#8221; under applicable SEC rules and regulations because we had no or nominal operations and either no or nominal assets, assets consisting solely of cash and cash equivalents, or assets consisting of any amount of cash and cash equivalents and nominal other assets. As a result, sales of our securities pursuant to Rule 144 under the Securities Act cannot be made unless, among other things, at the time of a proposed sale, we are subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act and have filed all reports and other materials required to be filed by Section 13 or 15(d) of the Securities Exchange Act, as applicable, during the preceding 12 months, other than Form 6-K reports. Because, as a former shell company, the reporting requirements of Rule 144(i) will apply regardless of holding period, restrictive legends on our securities cannot be removed except in connection with an actual sale that is subject to an effective registration statement under, or an applicable exemption from the registration requirements of, the Securities Act. We do not currently have an effective registration statement and any registration statement would require us to be current in our filings and to have filed additional information required in order to become effective. In addition, because our unregistered securities cannot be sold pursuant to Rule 144 unless we continue to meet such requirements, any unregistered securities we issue will have limited liquidity unless we can comply with such requirements. In addition, our previous status as a shell company could also limit our use of our securities to pay for any acquisitions we may seek to pursue in the future. The lack of liquidity of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our securities as a result of the inability to sell under Rule 144 for a longer period of time than a non-former shell company could cause the market price of our securities to decline.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Your rights and responsibilities as a shareholder are governed by Jersey law, which differs in some material respects with respect to the rights and responsibilities of shareholders of U.S. companies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are organized under the laws of the Bailiwick of Jersey, Channel Islands, a British crown dependency that is an island located off the coast of Normandy, France. Jersey is not a member of the EU. Jersey legislation regarding companies is largely based on English corporate law principles. The rights and responsibilities of the holders of our Class A ordinary shares are governed by the Constitutional Document and by Jersey law, including the provisions of the Jersey Companies Law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders in U.S. corporations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, Jersey law significantly limits the circumstances under which shareholders of companies may bring derivative actions and, in most cases, only the corporation may be the proper claimant or plaintiff for the purposes of maintaining proceedings in respect of any wrongful act committed against it. Neither an individual nor any group of shareholders has any right of action in such circumstances. Jersey law also does not afford appraisal rights to dissenting shareholders in the form typically available to shareholders of a U.S. corporation. However, we cannot assure you that Jersey law will not change in the future or that it will serve to protect our investors in a similar fashion afforded under corporate law principles in the U.S., which could adversely affect your rights.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It may be difficult to enforce a U.S. judgment against us or our directors and officers outside the U.S., or to assert U.S. securities law claims outside the U.S.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors may have difficulties pursuing an original action brought in a court in a jurisdiction outside the U.S., including Jersey, for liabilities under the securities laws of the U.S. The U.S. and Jersey currently do not have a treaty providing for the reciprocal recognition and enforcement of judgments (as opposed to arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment rendered by any federal or state court in the U.S. based on civil liability, whether or not predicated solely upon U.S. federal securities laws, would not automatically be recognized and is not directly enforceable in Jersey. Rather, a judgment of a U.S. court constitutes a cause of action which may be enforced by Jersey courts provided that:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">the applicable U.S. courts had jurisdiction over the case, as recognized under Jersey law;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the judgment is given on the merits and is final, conclusive and non-appealable;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the judgment relates to the payment of a sum of money, not being taxes, fines or similar governmental penalties;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the defendant is not immune under the principles of public international law;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the same matters at issue in the case were not previously the subject of a judgment or disposition in a separate court;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the judgment was not obtained by fraud; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recognition and enforcement of the judgment is not contrary to public policy in Jersey.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the foregoing, investors may be able to enforce in Jersey judgments in civil and commercial matters that have been obtained from U.S. federal or state courts. However, it is doubtful that an original action based on U.S. federal or state securities laws could be brought before Jersey courts. In addition, a plaintiff who is not resident in Jersey may be required to provide a security bond in advance to cover the potential of the expected costs of any case initiated in Jersey.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The obligations associated with being the publicly traded entity in the &#8220;Up-C&#8221; structure involve significant expenses and will require significant resources and management attention, which may divert from our business operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the publicly traded entity in an Up-C structure, we are subject to the reporting requirements of the Exchange Act and the Sarbanes-Oxley Act. The Exchange Act requires the filing of annual, quarterly and current reports with respect to a public company&#8217;s business and financial condition. The Sarbanes-Oxley Act requires, among other things, that a public company establish and maintain effective internal control over financial reporting. As a result, we will incur significant legal, accounting and other expenses that our Obagi Skincare and Milk Makeup businesses did not previously incur. Our entire management team and many of our other employees will need to devote substantial time to compliance matters related to the Up-C structure and regulatory requirements associated with being a publicly traded entity. We will bear all </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the internal and external costs of preparing and distributing periodic public reports in compliance with our obligations under the securities laws.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act, and the related rules and regulations implemented by the SEC and Nasdaq, have increased legal and financial compliance costs and will make some compliance activities more time-consuming. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us, and our business may be harmed. In the future, it may be more expensive or more difficult for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified people to serve on our Board, our Board committees or as executive officers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may amend the terms of the warrants in a manner that may be adverse to holders with the approval by the holders of at least 65% of the then outstanding public warrants.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our public warrants were issued in registered form under a Warrant Agreement between our transfer agent for our warrants and Waldencast. The Warrant Agreement provides that (a) the terms of the warrants may be amended without the consent of any holder for the purpose of (i) curing any ambiguity or correcting any mistake, including to conform the provisions of the Warrant Agreement to the description of the terms of the warrants and the Warrant Agreement set forth in this Report, or defective provision or (ii) adding or changing any provisions with respect to matters or questions arising under the Warrant Agreement as the parties to the Warrant Agreement may deem necessary or desirable and that the parties deem to not adversely affect the rights of the registered holders of the warrants under the Warrant Agreement and (b) all other modifications or amendments require the vote or written consent of at least 65% of the then outstanding public warrants; provided that any amendment that solely affects the terms of the private placement warrants or any provision of the Warrant Agreement solely with respect to the private placement warrants will also require at least 65% of the then outstanding private placement warrants. Accordingly, we may amend the terms of the public warrants in a manner adverse to a holder if holders of at least 65% of the then outstanding public warrants approve of such amendment. Although our ability to amend the terms of the public warrants with the consent of at least 65% of the then outstanding public warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the warrants, shorten the exercise period or decrease the number of our Class A ordinary shares purchasable upon exercise of a warrant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may redeem your unexpired warrants prior to their exercise at a time that is disadvantageous to you, thereby making your warrants worthless.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have the ability to redeem the outstanding public warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per warrant if, among other things, the last reported sale price of our Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders equals or exceeds $18.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like). Redemption of the outstanding warrants as described above could force you to: (1) exercise your warrants and pay the exercise price therefor at a time when it may be disadvantageous for you to do so; (2) sell your warrants at the then current market price when you might otherwise wish to hold your warrants; or (3) accept the nominal redemption price which, at the time the outstanding warrants are called for redemption, we expect would be substantially less than the market value of your warrants. None of the private placement warrants will be redeemable by us (subject to limited exceptions) so long as they are held by the Sponsor or its permitted transferees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have the ability to redeem the outstanding warrants at any time after they become exercisable and prior to their expiration, at a price of $0.10 per warrant if, among other things, the last reported sale price of our Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders equals or exceeds $10.00 per share (as adjusted for share splits, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like). In such a case, the holders will be able to exercise their warrants prior to redemption for a number of our Class A ordinary shares determined based on the redemption date and the fair market value of our Class A ordinary shares. The value received upon exercise of the warrants (1) may be less than the value the holders would have received if they had exercised their warrants at a later time where the underlying share price is higher and (2) may not compensate the holders for the value of the warrants, because the number of Class A ordinary shares received is capped at 0.361 Class A ordinary shares per warrant (subject to adjustment) irrespective of the remaining life of the warrants.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay cash dividends for the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently intend to retain our future earnings, if any, to finance the further development and expansion of our business and do not intend to pay cash dividends in the foreseeable future. Any future determination to pay dividends will be at the discretion of our Board and will depend on our financial condition, results of operations, capital requirements, restrictions contained in any future agreements and financing instruments, business prospects and such other factors as our Board deems relevant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If analysts do not publish research about our business or if they publish inaccurate or unfavorable research, our stock price and trading volume could decline.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our Class A ordinary shares will depend in part on the research and reports that analysts publish about us. We do not have any control over these analysts. If one or more of the analysts who cover us downgrade our Class A ordinary shares or publish inaccurate or unfavorable research about our businesses, the price of our Class A ordinary shares could decline. If few analysts cover us, the demand for our shares could decrease and our stock price and trading volume may decline. Similar results may occur if one or more of these analysts stop covering us in the future or fail to publish reports on us regularly.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently an emerging growth company within the meaning of the Securities Act, and to the extent we have taken advantage of certain exemptions from disclosure requirements available to emerging growth companies, this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently an &#8220;emerging growth company&#8221; within the meaning of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As a result, our shareholders may not have access to certain information they may deem important. We cannot predict whether investors will find our securities less attractive because we will rely on these exemptions. If some investors find our securities less attractive as a result of our reliance on these exemptions, the trading prices of our securities may be lower than they otherwise would be, there may be a less active trading market for our securities and the trading prices of our securities may be more volatile.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cease to be an emerging growth company, we will no longer be able to take advantage of certain exemptions from reporting, and, absent other exemptions or relief available from the SEC, we will also be required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act. We will incur additional expenses in connection with such compliance and our management will need to devote additional time and effort to implement and comply with such requirements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and are permitted to file less information with the SEC than a U.S. company. This may limit the information available to holders of the Ordinary Shares.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that we are a foreign private issuer, as such term is defined in Rule 405 under the Securities Act, however, under Rule 405, the determination of foreign private issuer status is made annually on the last business day of an issuer&#8217;s most recently completed second fiscal quarter and, accordingly, the next determination regarding our status will be made on June 30, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a foreign private issuer, we are not subject to all of the disclosure requirements applicable to public companies organized within the U.S. For example, we are exempt from certain rules under the Exchange Act that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorizations applicable to a security registered under the Exchange Act, including the U.S. proxy rules under Section 14 of the Exchange Act (including the requirement applicable to emerging growth companies to disclose the compensation of our Chief Executive Officer and the other two most highly compensated executive officers on an individual, rather than an aggregate, basis). In addition, our officers and directors are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, while we may elect to voluntarily submit quarterly interim consolidated financial data to the SEC under cover of the SEC&#8217;s Form 6-K, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies and are not required to file quarterly reports on Form 10-Q or current reports on Form 6-K under the Exchange Act. We also are exempt from the requirements to obtain shareholder approval for certain issuances of securities, including shareholder approval of share option plans. In addition, as a foreign private issuer, we are exempt from the provisions of Regulation FD, which prohibits issuers from making selective disclosure of material nonpublic information.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our Ordinary Shares are not listed and we do not currently intend to list our Ordinary Shares on any market in the Bailiwick of Jersey, our home country. As a result, we are not subject to the reporting and other requirements of companies listed in the Bailiwick of Jersey. For instance, we are not required to publish quarterly or semi-annual financial statements (although we are required to comply with Nasdaq&#8217;s continued listing standards to publicly disclose an interim balance sheet and income statement as of the end of our second quarter each fiscal year). Accordingly, there may be less publicly available information concerning our business than there would be if we were a U.S. public company and you may not be afforded the same protections or information that would be made available to you were you investing in a U.S. domestic issuer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a public limited company incorporated under the laws of Jersey, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from Nasdaq corporate governance listing standards. These practices may afford less protection to securityholders than they would enjoy if we complied fully with Nasdaq corporate governance listing standards.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public limited company incorporated under the laws of Jersey and listed on Nasdaq, we are subject to Nasdaq corporate governance listing standards. However, Nasdaq rules permit a foreign private issuer like us to follow the corporate governance practices of its home country. Certain corporate governance practices in Jersey, which is our home country, may differ significantly from Nasdaq corporate governance listing standards. Currently, we follow our home country practice in lieu of the provisions under Rule 5620(a), Rule 5635(c), Rule 5635(d) and Rule 5250(b)(3) of the Nasdaq Stock Market Marketplace Rules (the &#8220;Rules&#8221;) by relying on the exemption provided for foreign private issuers under Rule 5615(a)(3) of the Rules. Rule 5620(a) of the Rules requires that the Company hold an annual meeting of shareholders no later than one year after the end of the Company&#8217;s fiscal year-end; Rule 5635(c) of the Rules requires shareholder approval for share incentive plans; Rule 5635(d) of the Rules requires shareholder approval for the issuance of securities, other than in a public offering, equal to 20% or more of the voting power outstanding before the issuance for less than the greater of book or market value of the stock; and Rule 5250(b)(3) of the Rules requires disclosure of third-party director and nominee compensation. The corporate governance practice in our home country, Jersey, does not require the Company to follow or comply with the requirements of Rule 5620(a), Rule 5635(c), Rule 5635(d) and Rule 5250(b)(3). We will continue to comply with other corporate governance requirements of the Rules. However, in the future, we may consider following home country practice in lieu of additional requirements under the Rules with respect to certain corporate governance standards. Any foreign private issuer exemptions we avail ourselves of in the future may reduce the scope of information and protection to which you are otherwise entitled as an investor. As a result, there may be less publicly available information concerning our business than there would be if we were a U.S. public company and you may not be afforded the same protections or information that would be made available to you were you investing in a U.S. domestic issuer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may lose our foreign private issuer status in the future, which could result in significant additional cost and expense.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to maintain our current status as a foreign private issuer, either (a) more than 50% of our outstanding voting securities must be either directly or indirectly owned of record by non-residents of the U.S. or (b)(i) a majority of our executive officers or directors may not be U.S. citizens or residents, (ii) more than 50% of our assets cannot be located in the U.S. and (iii) our business must be administered principally outside the U.S. On an annual basis, we are required to assess whether we meet these criteria as of the last business day of our second fiscal quarter. Although we have elected to comply with certain U.S. regulatory provisions, our loss of foreign private issuer status would make such provisions mandatory. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly higher. If we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive than the forms available to a foreign private issuer. For example, the annual report on Form 10-K requires domestic issuers to disclose executive compensation information on an individual basis with specific disclosure regarding the domestic compensation philosophy, objectives, annual total compensation (base salary, bonus, and equity compensation) and potential payments in connection with change in control, retirement, death or disability, while this Report permits us to disclose compensation information on an aggregate basis. We would also have to mandatorily comply with U.S. federal proxy requirements, and our officers, directors, and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions of Section 16 of the Exchange Act. We may also be required to modify certain of our policies to comply with good governance practices associated with U.S. domestic issuers. The additional requirements that we would become subject to and any modification of our policies if we were to lose our foreign private issuer status could lead us to incur significant additional legal, accounting and other expenses. In addition, we may lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jersey law and our Constitutional Document contain certain provisions, including anti-takeover provisions that limit the ability of shareholders to take certain actions and could delay or discourage takeover attempts that shareholders may consider favorable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jersey law and our Constitutional Document contain provisions that could have the effect of rendering more difficult, delaying or preventing an acquisition that shareholders may consider favorable, including transactions in which shareholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for our Ordinary Shares, and therefore depress the trading price of our Class A ordinary shares. These provisions could also make it difficult for shareholders to take certain actions, including electing directors who are not nominated by the current members of our Board or taking other corporate actions, including effecting changes in our management. Among other things, the Constitutional Document includes provisions regarding:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">providing for a classified board of directors with staggered, three-year terms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our Board to issue shares of preferred stock, and to determine the price and other terms of those shares, including preferences and voting rights, without shareholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our Board will have the exclusive right to elect directors to fill a vacancy created by the expansion of our Board or the resignation, death or removal of a director, which will prevent shareholders from being able to fill vacancies on our Board; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limitation of the liability of, and the indemnification of, our directors and officers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our Board or management.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Constitutional Document limits the liability of our non-employee directors, Cedarwalk and the Sponsor and their respective affiliates and representatives&#8217; liability to us for breach of fiduciary duty and could also prevent us from benefiting from corporate opportunities that might otherwise have been available to us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Constitutional Document provides that, to the fullest extent permitted by law, and other than corporate opportunities that are expressly presented to one of our directors or officers in his or her capacity as such, our non-employee directors, Cedarwalk and the Sponsor and their respective affiliates and representatives:</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">will not have any fiduciary duty to refrain from (i) engaging in and possessing interests in other business ventures of every type and description, including those engaged in the same or similar business activities or lines of business in which we or any of our subsidiaries now engages or proposes to engage or (ii) competing with us </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or any of our affiliates, subsidiaries or representatives, on its own account, or in partnership with, or as an employee, officer, director or shareholder of any other Person (other than us or any of our subsidiaries);</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">will have no duty to communicate or present such transaction or matter to us or any of our subsidiaries, as the case may be; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">will not be liable to us or our shareholders or to any of our subsidiaries for breach of any duty (fiduciary, contractual or otherwise) as a shareholder or director of us by reason of the fact that such Person, directly or indirectly, pursues or acquires such opportunity for itself, herself or himself, directs such opportunity to another Person or does not present such opportunity to us or any of our subsidiaries, affiliates or representatives.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Taxation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any disparity between the U.S. corporate tax rate and the U.S. tax rate applicable to non-corporate Members of Waldencast LP may complicate our ability to maintain its intended capital structure, which could impose transaction costs on it and require management attention.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast LP is treated as a partnership for U.S. federal income tax purposes and, as such, generally is not subject to U.S. federal income tax. Instead, its taxable income is generally allocated to its members, including Holdco 1. If and when Waldencast LP generates taxable income, it will generally make cash distributions, or tax distributions, to each of its members, including Holdco 1, based on each member&#8217;s allocable share of net taxable income (calculated under certain assumptions) multiplied by an assumed tax rate. The assumed tax rate for this purpose will be the highest effective marginal combined federal, state, and local income tax rate applicable to an individual or corporate member (whichever is higher). In the event of any disparity between the tax rates applicable to corporate and non-corporate taxpayers, Holdco 1 could receive tax distributions from Waldencast LP in excess of its actual tax liability, which could result in it accumulating cash in excess of its tax liability. This would complicate our ability to maintain certain aspects of our capital structure. Such cash, if retained, could cause the value of a Waldencast LP Unit to deviate from the value of a Class A ordinary share. In addition, such cash, if used to purchase additional Waldencast LP Units, could result in deviation from the one-to-one relationship between our Class A ordinary shares outstanding and Waldencast LP Units unless a corresponding number of additional Class A ordinary shares are distributed as a stock dividend. We may, if permitted under our debt agreements, choose to pay dividends to all holders of our Class A ordinary shares with any excess cash. These considerations could have unintended impacts on the pricing of our Class A ordinary shares and may impose transaction costs and require management efforts to address on a recurring basis. To the extent that we do not distribute such excess cash as dividends on our Class A ordinary shares and instead, for example, hold such cash balances or lend them to Waldencast LP, holders of Waldencast LP Units during a period in which we hold such cash balances could benefit from the value attributable to such cash balances as a result of redeeming or exchanging their Waldencast LP Units and obtaining ownership of our Class A ordinary shares (or a cash payment based on the value of our Class A ordinary shares). In such case, these holders of Waldencast LP Units could receive disproportionate value for their Waldencast LP Units exchanged during this time frame.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with applicable transfer pricing and similar regulations could harm our business and financial results.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many countries, including the U.S., we are subject to transfer pricing and other tax regulations designed to ensure that appropriate levels of income are reported as earned in each jurisdiction and are taxed accordingly. Although we believe that we are in substantial compliance with all applicable regulations and restrictions, we are subject to the risk that governmental authorities could audit our transfer pricing and related practices and assert that additional taxes are owed. In the event that the audits or assessments are concluded adversely to us, we may or may not be able to offset or mitigate the consolidated effect.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be a PFIC, which could result in adverse U.S. federal income tax consequences to U.S. Holders.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are a PFIC for any taxable year, or portion thereof, that is included in the holding period of a U.S. Holder (as defined herein), such U.S. Holder may be subject to certain adverse U.S. federal income tax consequences and may be subject to additional reporting requirements. We are not expected to be treated as a PFIC for the taxable year ending on December 31, 2022, or the foreseeable future. However, the facts on which any determination of PFIC status are based may not be known until the close of each taxable year in question. Additionally, there is uncertainty regarding the application of the start-up exception. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be treated as a corporation resident in the U.S. for U.S. federal income tax purposes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A corporation is generally considered a tax resident in the jurisdiction of its organization or incorporation. Thus, as a corporation incorporated under the laws of Jersey, we should generally be classified as a non-U.S. corporation (and therefore as a non-U.S. tax resident) for U.S. federal income tax purposes. In certain circumstances, however, under section 7874 of the Code, a corporation organized outside the U.S. will be treated as a U.S. corporation (and, therefore, as a U.S. tax resident).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the rules in effect currently, we do not expect to be treated as a U.S. corporation for U.S. federal income tax purposes by virtue of section 7874. Nevertheless, because the section 7874 rules and exceptions are complex, subject to factual and legal uncertainties, and may change in the future (possibly with retroactive effect), there can be no assurance that we will not be treated as a U.S. corporation for U.S. federal income tax purposes. In addition, it is possible that a future acquisition of the stock or assets of a U.S. corporation could result in our being treated as a U.S. corporation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We continue to operate so as to be treated exclusively as a resident of Jersey for tax purposes, but the tax authorities of other jurisdictions may treat us as also being a resident of, or as having a taxable presence in, another jurisdiction for tax purposes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our residence for tax purposes (including, for the avoidance of doubt, withholding tax and tax treaty eligibility purposes) is exclusively in Jersey and we have no taxable presence in the form of a fixed place of business or permanent establishment in any other jurisdiction. Because we are incorporated under Jersey law and have our registered office in Jersey, we are considered to be resident in Jersey for Jersey tax purposes. In addition, we maintain our management, organizational and operational structures in such a manner that we should not be regarded as a tax resident of any other jurisdiction either for domestic law purposes or for the purposes of any applicable tax treaty (notably any applicable tax treaty with Jersey) and should be deemed resident only in Jersey and that we should not have a fixed place of business or permanent establishment outside Jersey.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, the determination of our tax residence, which primarily depends upon our place of effective management, as well as the characterization of fixed places of business or permanent establishments outside our jurisdiction of incorporation, are questions of fact based on all circumstances. Because such determinations are highly fact-sensitive, no assurance can be given regarding their outcome. A failure to maintain exclusive tax residence in Jersey or not to maintain a fixed place of business or permanent establishment outside Jersey could result in significant adverse tax consequences to us. A failure to maintain exclusive tax residence in Jersey could also result in significant adverse tax consequences for shareholders. The impact of this risk would differ based on the views taken by each relevant tax authority and, in respect of the taxation of shareholders, on their specific situation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future amend our management, organizational and operational structures in such a manner that we may be regarded as a tax resident of another jurisdiction either for domestic law purposes or for the purposes of any applicable tax treaty. A change in tax residence could result in significant adverse tax consequences to us and our shareholders, and we may opt to make such changes without consideration of the tax consequences for shareholders.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law could significantly affect our reported earnings and cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have business operations and assets in different jurisdictions, which are subject to different tax regimes. Changes in tax regimes, such as the reduction or elimination of tax benefits, or limitations on the deductibility of interest expense, could have a material adverse effect on our results and cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, countries in which we operate have agreed to implement aspects of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the &#8220;Two Pillars Solution,&#8221; an OECD/G20 Inclusive Framework initiative, which aims to reform the international taxation policies and ensure that multinational companies pay taxes wherever they operate and generate profits. &#8220;Pillar Two&#8221; of this initiative generally provides for an effective global minimum corporate tax rate of 15% on profits generated by multinational companies with consolidated revenues of at least &#8364;750 million, calculated on a country-by-country basis. This minimum tax would be applied on profits in any jurisdiction wherever the effective tax rate, determined on a jurisdictional basis, is below 15%. The OECD and its members are still working on the coordinated implementation of the minimum tax. Although this initiative is subject to further developments in the countries where we operate, it is expected to be in force in various jurisdictions, including the U.K. and the EU, for fiscal years commencing on January 1, 2024. Any minimum tax may have a negative impact on our financial condition, results of operations and cash flows.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. INFORMATION ON THE COMPANY </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">History and Development of the Company </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast plc was a blank check company that was incorporated on December 8, 2020 as Waldencast Acquisition Corp., a Cayman Islands exempted company formed as a SPAC for the purpose of entering into a merger, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses in the beauty and wellness industry. On March 18, 2021, we consummated an Initial Public Offering (&#8220;IPO&#8221;) of 34,500,000 units, with each unit consisting of one Class A ordinary share (a &#8220;Public Share&#8221;) and one-third of one redeemable warrant to acquire one Class A ordinary share (together, a &#8220;Unit&#8221;), at $10.00 per Unit. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Business Combination, on July 26, 2022, with the approval of the Company&#8217;s shareholders, and in accordance with the Cayman Companies Act (the &#8220;Cayman Act&#8221;), the Jersey Companies Law and the Company&#8217;s Constitutional Document, the Company&#8217;s jurisdiction of incorporation was changed from the Cayman Islands to Jersey and its name changed to Waldencast plc (the &#8220;Domestication&#8221;). </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Domestication, (i) each then issued and outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Waldencast Acquisition Corp.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Class A ordinary share was converted automatically, on a one-for-one basis, into a Class A ordinary share of Waldencast plc, (ii) each then issued and outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast Acquisition Corp. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class B ordinary share was converted automatically, on a one-for-one basis, into a Class A ordinary share of Waldencast plc, (iii) each then issued and outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast Acquisition Corp. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrant was converted automatically into a warrant to purchase Class A ordinary shares of Waldencast plc and (iv) each then issued and outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast Acquisition Corp. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unit was canceled and the holders thereof were entitled to one Class A ordinary share of Waldencast plc and one-third of one warrant.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Closing Date, pursuant to the Obagi Merger Agreement, Merger Sub merged with and into Obagi, with Obagi surviving as an indirect subsidiary of Waldencast LP. In addition, on the Closing Date, pursuant to the Milk Purchase Agreement, Waldencast LP acquired from the Milk Members all of their equity in Milk in exchange for cash, Waldencast LP common units (&#8220;Waldencast LP Units&#8221;) and Waldencast plc Class B ordinary shares, which are non-economic voting shares. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Waldencast LP Units are redeemable at the option of the holder of such units into an equal number of Waldencast plc Class A ordinary shares or cash, at the sole discretion of Waldencast. The equity interests of Obagi and Milk are held by Waldencast LP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We, in turn, hold our interests in Obagi and Milk through Waldencast LP and Holdco 1. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Business Combination, we are organized as an &#8220;Up-C&#8221; structure, whereby the Milk Members retain a direct equity ownership in Waldencast LP, an entity that is classified as a partnership for U.S. federal income tax purposes, in the form of their Waldencast LP Units. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material terms of the Business Combination are described in &#8220;Item 10. Additional Information&#8212;C. Material Contracts&#8221; of this Report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each holder of a Public Share was entitled to redeem such share in connection with the consummation of the Business Combination </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a pro rata portion of the cash then on deposit in the trust account created in connection with our IPO. Such pro rata portion was calculated as of two business days prior to the consummation of the Business Combination including interest earned on the funds held in the trust account and not previously released to us (net of taxes payable). A total of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,021,946 Public Shares were redeemed in connection with the Business Combination.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast plc&#8217;s registered office is 2nd Floor Sir Walter Raleigh House, 48-50 Esplanade, St. Helier, Jersey JE2 3QB, and its principal executive office is 10 Bank Street, Suite 560, White Plains, NY 10606, and its telephone number is (917) 546-6828.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC which is accessible at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Since Waldencast plc is a &#8220;foreign private issuer,&#8221; it is exempt from the rules and regulations under the Exchange Act prescribing the furnishing and content of proxy statements, and its officers, directors and principal shareholders are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions contained in Section 16 of the Exchange Act with respect to their purchase and sale of our shares. In addition, we are not required to file reports and financial statements with the SEC as frequently or as promptly as U.S. public companies whose securities are registered under the Exchange Act. However, we are required to file with the SEC an Annual Report on Form 20-F containing financial statements audited by an independent accounting firm.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast plc&#8217;s principal website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.waldencast.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The information contained on Waldencast plc&#8217;s website does not form a part of, and is not incorporated by reference into, this Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Business Overview </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Unless the context otherwise requires, all references in this section to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; or &#8220;Waldencast&#8221; generally refer to Waldencast plc.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Founded by Michel Brousset and Hind Sebti, our ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Our vision is fundamentally underpinned by our brand-led business model that ensures proximity to our customers, business agility and market responsiveness, while maintaining each brand&#8217;s distinct DNA. The first step in realizing our vision was the Business Combination with Obagi and Milk. As part of the Waldencast platform, our brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset light efficiency; and the market responsiveness and speed of entrepreneurial indie brands.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Facilities</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our executive offices are at 10 Bank Street, Suite 560, White Plains, NY 10606. The cost for this space is included in the $0.01 million per month fee that we paid an affiliate of the Sponsor for office space, administrative and support services up until the Closing Date. See &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;7.B. Related Party Transactions&#8221; for a description of the agreement. We consider our current office space adequate for our current operations.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Employees</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We currently have three executive officers and 269 full-time employees, consisting of 180 in sales and marketing, 17 in R&amp;D, 31 in operations and 41 in general and administrative positions. We are dedicated to hiring and nurturing diverse talent and believe this is one of the keys to our current and future success. Approximately 29% of our employee base identifies as black, indigenous or people of color (&#8220;BIOPIC&#8221;). In addition, over 83% of our employees identifies as female. Our employees are all non-unionized, and we believe our relations with our employees are good.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are not involved in any material litigation nor, to management&#8217;s knowledge, was any material litigation threatened against us, which if adversely determined could have a material adverse effect on the Company other than routine litigation arising in the ordinary course of business, except as described below.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">SEC Investigation</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As previously disclosed, we proactively and voluntarily self-reported our review of the historical accounting used by Obagi to the SEC. In connection with this matter, we received a document subpoena in September 2023. Although we are fully cooperating with the SEC&#8217;s investigation and continue to respond to requests related to this matter, we cannot predict when such matters will be completed or the outcome or potential impact of this matter on our business, investor confidence or the price of our securities. Any remedial measures, sanctions, fines or penalties, including, but not limited to, financial penalties and awards, injunctive relief and compliance conditions, which may be imposed on us in connection with this matter could have a material adverse effect on our business, financial condition and results of operations. Additionally, the investigation has resulted in substantial costs and is likely to continue to incur substantial costs, regardless of the outcome of the investigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Emerging Growth Company</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hareholder approval of any golden parachute payments not previously approved.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with certain other public companies difficult or impossible because of the potential differences in accounting standards used.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain an emerging growth company until the earlier of: (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of our initial public offering, (b) in which we have total annual gross revenue of at least $1,235.0 million or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common equity that is held by non-affiliates exceeds $700.0 million as of the end of the prior fiscal year&#8217;s second fiscal quarter; and (2) the date on which we have issued more than $1,000 million in non-convertible debt securities during the prior three-year period. References herein to &#8220;emerging growth company&#8221; shall have the meaning associated with it in the JOBS Act.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Private Issuer</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a &#8220;foreign private issuer&#8221; under SEC rules and will report under the Exchange Act as a non-U.S. company with &#8220;foreign private issuer&#8221; status and will be subject to the reporting requirements under the Exchange Act applicable to foreign private issuers. This means that, even after we no longer qualify as an &#8220;emerging growth company,&#8221; as long as we qualify as a &#8220;foreign private issuer&#8221; under the Exchange Act, we will be exempt from certain provisions of and intend to take advantage of certain exemptions from the Exchange Act that are applicable to U.S. public companies. Such exemptions include the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act and the sections of the Exchange Act requiring insiders to file public reports of their stock ownership.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we will not be required to file our annual report on Form 20-F until 120 days after the end of each fiscal year and we will furnish reports on Form 6-K to the SEC regarding certain information required to be publicly disclosed by us in Jersey or that is distributed or required to be distributed by us to our shareholders. Further, based on our foreign private issuer status, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as a U.S. company whose securities are registered under the Exchange Act. We will also not be required to comply with Regulation FD, which addresses certain restrictions on the selective disclosure of material information. In addition, among other matters, our officers, directors and principal shareholders will be exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions of Section 16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our Class A ordinary shares.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may take advantage of these reporting exemptions until such time as we are no longer a &#8220;foreign private issuer.&#8221; We could lose our status as a &#8220;foreign private issuer&#8221; under current SEC rules and regulations if more than 50% of our outstanding voting securities become directly or indirectly held of record by U.S. Holders and any one of the following is true: (i) the majority of our directors or executive officers are U.S. citizens or residents; (ii) more than 50% of our assets are located in the U.S.; or (iii) our business is administered principally in the U.S.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may choose to take advantage of some but not all of these reduced burdens. We have taken advantage of reduced reporting requirements in this Report. Accordingly, the information contained in this Report may be different from the information you receive from our competitors that are public companies, or other public companies in which you have made an investment. See &#8220;Item 3. Key Information&#8212;Risk Factors&#8212;Risks Related to our Organization and Corporate Structure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and are permitted to file less information with the SEC than a U.S. company. This may limit the information available to holders of the Ordinary Shares.&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Professional Skincare Segment: Obagi</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our professional skincare segment consists of the Obagi business. Unless the context otherwise requires, all references in this section to &#8220;Obagi,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;company&#8221; refer to the business of Obagi and its subsidiaries.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi&#8217;s Purpose and Ambition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi exists to create the future of skincare so every face is cared for, everywhere. We offer transformative solutions at every stage of the skincare journey to help you greet the future with confidence. Our ambition is to be the top dermo-credentialed brand in the world, driving strong growth through channel and geographic diversification, and to continue to progress the industry that we pioneered with devices, new indications, and new product categories.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi launched in 1988 under the name Worldwide Product Distribution, Inc. and subsequently changed its name to Obagi Medical Products, Inc. in December 1997. In October 2007, the company completed an initial public offering of its common stock and was traded on Nasdaq under the trading symbol &#8220;OMPI.&#8221; In April 2013, the company merged with and into Odysseus Acquisition Corp., with the company as the surviving corporation in the merger, becoming a wholly-owned subsidiary of Bausch Health. In November 2017, Bausch Health sold substantially all of the assets of Obagi Medical Products, Inc. and its subsidiaries to Obagi Holdings Company Limited (&#8220;Obagi Holdco&#8221;), (a wholly-owned subsidiary of Obagi), and Obagi Cosmeceuticals LLC (&#8220;Obagi Cosmeceuticals&#8221;), (a wholly-owned subsidiary of Obagi Holdco). We acquired Obagi through the Business Combination in July 2022.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi is a global skincare products company that is rooted in research and skin biology. We develop, market and sell innovative skin health products in more than 65 countries around the world. Every product we develop stems from a deep understanding of the skin and how healthy skin functions. We believe the result is a highly compelling product portfolio designed to prevent or improve the most common, visible skin concerns such as fine lines and wrinkles, elasticity, photodamage, hyperpigmentation (spots or patches of skin that are darker than surrounding areas of skin), acne, oxidative stress, environmental damage and hydration.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Centered on our rich history in selling products to medical professionals who then dispense the products in-office directly to their patients, a distribution model referred to as the physician-dispensed channel, our portfolio today includes two distinct brands, with more than 200 cosmetic, OTC and prescription products, and a device sold throughout the medical, spa and retail channels:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Obagi Medical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Products within our flagship brand were historically designed for professional recommendation in a clinical setting.  We now sell the entire Obagi Medical line through physicians, and our OTC and cosmetic products within the line online directly to consumers (&#8220;DTC&#8221;) via our website and through other e-commerce channels. This line of professional systems and products is targeted to consumers looking for the most advanced product formulations in a customized skincare regimen. None of our products, including our prescription products, have been approved by the FDA or other similar regulatory authorities.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Obagi Clinical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Targeted towards the Southeast Asia market, this product line was specifically designed to prevent and reduce the early signs of aging. We built this line for the &#8217;skin-tellectual&#8217; consumer who knows high-quality ingredients and is increasingly focused on product efficacy and quality, but may not yet regularly visit a dermatologist or skincare professional.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Skintrinsiq device</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Used in facial treatments offered by physicians&#8217; offices, spas and aestheticians.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Skincare Market</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the American Society of Plastic Surgeons, there were 2.6 million cosmetic procedures performed in the U.S. in 2022, which represents a 19% increase in cosmetic surgery procedures since 2019. We believe this reflects a growing desire and acceptance among the population to seek assistance from physicians to improve their appearance, including the appearance of their skin. One key driver of this trend is the aging of the &#8220;baby boomer&#8221; segment of the U.S. population, as well as the &#8220;millennial&#8221; segment, whose oldest members are now over 40. As a result, the average age of the country&#8217;s population has increased over the last decade to a median age of 38.9. With the older population&#8217;s strong desire to reduce the signs of premature aging, we expect the market opportunity for skincare products to continue to grow. In particular, women tend to demonstrate a higher motivation than men to improve their personal appearances. The U.S. Census Bureau estimated that the number of women between the ages of 35 and 69, the primary users of our products, grew 21.7% between 2000 and 2018. In addition, during the recent COVID-19 pandemic, as in-person meetings shifted to video calls and virtual meetings, we believe adult consumers of all ages were progressively seeing themselves more on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">screen and began focusing more on their appearances. We believe that these trends will continue to drive an increased market demand for skincare products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to industry sources, in 2021, there were approximately 12,767 physicians practicing dermatology and 7,228 practicing plastic surgeons in the U.S. Based on physicians who have opened accounts with us, we believe multi-specialty physicians are also dedicating resources in their practices to skin care in response to the rapid increase in consumer demand for non-invasive skincare treatments. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last ten years, consumers have become increasingly knowledgeable about skincare science, ingredients and formulations. According to industry sources, consumers are shifting desire for quality over price and looking for higher performance products. Certain large retailers have been expanding brand assortments to capitalize on the fast-growing premium beauty skincare category. Specifically, they are trying to attract and maintain customers seeking more advanced products than offered by mass brands, but also looking for the purchasing convenience and accessibility of retail outlets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., the physician-dispensed skincare market varies by country due to cultural differences and regulatory requirements. Cultural desires for skin with lighter and more even pigmentation have created large and growing aesthetic skincare demands throughout Asia, particularly Japan, China, Korea, Vietnam and India. European and certain South American countries such as Brazil also present large skincare markets due to the complementary growth in cosmetic procedures and willingness on the part of their consumers to spend discretionary income on aesthetic enhancements. Industry sources estimate that in 2021 the global market for beauty and personal care was approximately $530 billion, with skincare representing approximately $155 billion. The physician- dispensed skincare market percentage growth was approximately 2.5 times the percentage growth of the premium skincare market from 2018-2020. The premium skincare market, defined as buyers who prefer luxury brands, accounted for $63 billion of the total global skincare market, with approximately 47% of premium skincare buyers, versus approximately 20% of non-premium buyers, using 8-14 skincare products weekly. The global market for skincare is estimated to reach approximately $204 billion by 2025, with premium skincare expected to grow at a compound annual growth rate of approximately 11% from 2021 through 2025.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our comprehensive portfolio of products is designed to meet the needs of users no matter what their skin tone or where they are in their skincare journey.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obagi Medical</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our flagship brand, launched in 1988, is among the most respected and most recognized brands in the professional skincare category. We believe the strength of Obagi Medical&#8217;s reputation lies in the exacting standards and formulas we have developed to support our products including more than 30 studies across thousands of subjects and all six skin types on the Fitzpatrick scale, which classifies skin type according to the amount of pigment a person&#8217;s skin has and the skin&#8217;s reaction to sun exposure. None of these studies have been used to support an application for marketing approval with the FDA or other similar regulatory authority. Consequently, they were not designed to fulfill the specific requirements of such regulatory application process and should not be viewed as a substitute for clinical trials that would be conducted in connection with the application to the FDA or similar regulatory authority. Products within the Obagi Medical portfolio are developed using formulations specifically designed for the physician-dispensed market and stringent ingredient standards. Furthermore, Obagi conducts extensive testing to evaluate the performance of all products in the Obagi Medical portfolio, including the portfolio&#8217;s cosmetic, OTC drug and prescription-strength drug product.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi Medical is anchored by the Obagi Nu-Derm System, which we believe is the leading prescription-based topical skin health system on the market. The Obagi Nu-Derm System and related products accounted for a significant portion of the total products shipped in the 2022 Successor Period, 2022 Predecessor Period, 2021 Predecessor Period and 2020 Predecessor Period. Sales of Obagi Nu-Derm products experience seasonality. We believe this is due to variability in patient compliance that relates to several factors such as a tendency to travel and/or engage in other disruptive activities during the summer months. While we have earned a strong reputation for offering premier hyperpigmentation solutions, our portfolio has expanded over time to include a line of Vitamin C powered antioxidant products, our Professional-C&#174; line, as well as the ELASTIderm&#174; line, which leverages a patented Bi-Mineral Contour Complex&#8482; technology to address elasticity and firmness in the skin. Other products within the comprehensive Obagi Medical franchise include products to address hydration, sun protection and acne. These solutions incorporate a range of individual prescription and non-prescription therapeutic agents, as well as cosmetic ingredients to address the needs of consumers who seek advanced skincare in a customized skincare regimen designed by a professional.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-indent:18pt"><img src="wald-20221231_g1.jpg" alt="Medical-R03.jpg" style="height:821px;margin-bottom:5pt;vertical-align:text-bottom;width:636px"/></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products listed above, including Nu-Derm Clear, Blender&#174; and Sunfader, as well as Obagi-C&#174; Rx C-Clarifying Serum and Obagi-C Rx C-Night Therapy Cream, which are part of the Obagi-C Rx Systems, contain 4% HQ. These products are marketed as prescription-only drugs, however, we have not sought nor obtained the required premarket approval from the FDA to market these products in the U.S. The FDA has historically utilized a risk-based enforcement approach with respect to drugs marketed without approval in accordance with its active CPG, issued in 2006 and subsequently amended in 2011, in which the FDA announced a drug safety initiative to remove unapproved drugs from the market and established enforcement priorities and a policy of enforcement discretion with respect to marketed unapproved products. While the FDA has expressed its view that all prescription HQ products should be reviewed and approved by the FDA, we believe our prescription-only HQ products do not fall within the previously established categories of unapproved drugs for which the FDA has indicated it prioritizes enforcement. We have not received any communications from the FDA or any similar regulatory authorities regarding our Nu-Derm HQ or any other products. However, whether due to safety concerns or otherwise, in the future the FDA may choose to pursue an enforcement action against us and determine that our HQ products should be removed from the market until we obtain approval of an NDA. For example, although our prescription-only HQ products are made with 4% HQ, the FDA has historically expressed concerns regarding the safety of 2% HQ products, sold on an OTC basis. In particular, in August 2006, the FDA issued a proposed rule that cited certain preclinical evidence suggesting that HQ may be carcinogenic, if orally administered, and may be related to a skin condition called ochronosis, which results in the darkening and thickening of the skin, and the appearance of small bumps and grayish-brown spots, after use of concentrations as low as 1 to 2 percent. The FDA also concluded that it could not rule out the potential carcinogenic risk from topically applied HQ, and classified OTC skin-bleaching drug products, including HQ, as not GRASE, as misbranded, and as new drugs within the meaning of the FDCA, meaning that such products would need to be approved through the NDA process in order to be legally marketed in the U.S. Although this proposed rule was never finalized, in March 2020 the CARES Act was enacted, which among other things deemed any OTC drugs that were identified as not GRASE in the FDA&#8217;s most recent proposed rulemaking for such OTC drugs to be &#8220;new drugs&#8221; and misbranded within the meaning of the FDCA, meaning that such drugs could not be marketed without an approved drug application as of September 23, 2020. As a result, products containing HQ are prohibited from being marketed in the U.S. as OTC drug products without an approved NDA. Subsequently, on April 19, 2022, the FDA announced that it had issued warning letters to 12 companies for continuing to sell 2% HQ products on an OTC basis, citing violations of the applicable CARES Act provisions. Furthermore, in June and July of 2022, the FDA issued warning letters to two other manufacturers of products containing HQ.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s announcement also cited reports describing serious side effects associated with the use of skin lightening products containing HQ, including reports of skin rashes, facial swelling, and skin discoloration. The FDA&#8217;s safety concerns regarding these lower-concentration OTC HQ products could prompt the FDA to assert that our higher-concentration, prescription-only HQ products represent a higher priority for enforcement pursuant to the active CPG. In many countries, including the EU, Canada, Australia and Japan, HQ is regulated as a drug and requires a prescription. We have not sought nor obtained regulatory approval to distribute our HQ products in these countries, and instead offer our Nu-Derm Fx and Obagi-C Fx solutions, which contain the skin brightening agent arbutin, for these markets. In the EU, the European Commission has expressed concerns on the potential use of (alpha and beta) arbutin in cosmetic products this has led to additional consultation with the SCCS (Scientific Committee on Consumer Safety), further to which call for data was launched which ended in April 2021. In January 2023, the SCCS issued its final opinion on the safety of alpha arbutin and beta arbutin in cosmetic products. The main conclusions in this opinion were that: (i) that alpha-arbutin used in face creams up to a maximum concentration of 2% and in body lotions up to a concentration of 0.5% is safe, also when used together; (ii) beta-arbutin used in face creams up to a maximum concentration of 7% is safe; (iii) HQ should remain as low as possible in formulations containing alpha-or beta-arbutin and should not be higher than the unavoidable traces in both arbutins, and (iv) aggregate exposure of alpha-arbutin (2% in face cream and 0.5% in body lotion) with beta-arbutin (7% in face cream) are considered safe. No amendments were made to the EU Cosmetics Regulation prohibiting or restricting the use of alpha- and/or beta-arbutin following this final opinion. See &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Legal and Regulatory Risks That Could Adversely Impact our Obagi Skincare Business.&#8221; In addition, Obagi&#8217;s arbutin products are permitted to be sold in the Asia-Pacific region countries in which Obagi distributes such products.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obagi Clinical</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Obagi Clinical line, launched in December 2018, was designed to meet the needs of &#8220;skin-tellectual&#8221; consumers who may not yet regularly visit a dermatologist or skincare professional. The product line is primarily targeted for Southeast Asian markets. This retail skincare brand leverages the over 30-year legacy of Obagi Medical to incorporate </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinically proven ingredients in cosmetic and OTC solutions that maintain healthy, more youthful-looking skin, mitigate environmental damage and address the emerging signs of skin aging. This line includes the following:</span></div><div style="margin-top:12pt;text-align:center"><img src="wald-20221231_g2.jpg" alt="Clinical R02.jpg" style="height:464px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of Obagi Clinical products have accounted for an insignificant portion of our net revenue for the 2022 Successor Period, 2022 Predecessor Period and 2021 Predecessor Period and for less than 20% of revenue for the 2020 Predecessor Period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Skintrinsiq</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, facial services saw the greatest increase in demand among minimally invasive procedures. Capitalizing on this trend, Obagi, in collaboration with Theravent, Inc., was the first professional skincare company to market a professional-use facial device offering consumers an advanced delivery system for Obagi&#8217;s transformational products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leveraging our expansive knowledge as a leader in the skincare market, we began distributing the Skintrinsiq device powered by Obagi InfuseIQ&#8482; technology to physician&#8217;s offices and medical spas in July 2021. The device features a small footprint and easy-to-use interface designed to minimize training time and maximize time for skin care. Additionally, the Skintrinsiq device offers physicians another opportunity to consult with consumers about their at- home skincare regimens and creates a mechanism for patient retention. We believe the Skintrinsiq pricing allows physicians to quickly recoup their initial expense while offering facial treatments to patients at a reasonable price. Based on the intended use of the product, we do not believe that the Skintrinsiq device meets the FDA&#8217;s definition of a medical device, and therefore we believe this product is exempt from FDA premarket review requirements. However, the FDA may disagree with our determination and require us to cease marketing the Skintrinsiq device unless and until we obtain marketing authorization from the FDA. We are aware that manufacturers of light emitting products that make express acne treatment claims have sought clearance through the 510(k) pathway and that the FDA has taken action against manufacturers of some light-emitting products used to alter or improve appearance on the grounds that those products are unapproved medical devices. In addition, regulators in other markets in which the Skintrinsiq device may be sold may have a different interpretation of whether it may constitute a medical device, including in light of rapidly evolving legislation on this matter, which means that it is possible that regulators in other markets, such as the U.K., will consider the devices as a medical device.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Skintrinsiq device uses innovative technology designed to extract debris and impurities from the skin, infuse Obagi skincare products exactly where they are needed most and then lock them in so they can continue working even after the treatment ends. We have also incorporated an optional simultaneous LED light to provide red and/or blue light to help meet a wide variety of skin health goals. We believe customized Skintrinsiq protocols can accelerate patients&#8217; transformations and take Obagi skincare results to the next level. By improving results, we believe the Skintrinsiq device will help attract new consumers to physician practices and medical spas.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obagi Science</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Innovative Research and Development</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the course of our over 30-year legacy, Obagi has amassed more than 80 global patents on product and technology innovations, which we believe sets us apart from our competitors. The table below sets forth a description of the material patents owned by Obagi Cosmeceuticals and/or its affiliates and the jurisdictions in which they are valid:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:31.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2f5496;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of Patent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2f5496;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jurisdictions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2f5496;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expiration Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Anti-Aging Treatment Using Copper and Zinc Compositions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Australia, Canada, Czech Republic, France, Germany, Great Britain Hungary, Italy, Japan, Mexico, Poland, South Korea, Spain, Turkey, U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">June 2026</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chemical Compositions and Methods of Making Them</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">France, Germany, Great Britain, Italy, Japan, Mexico, Poland, South Korea, Spain, U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jan.2026-Feb. 2027</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Methods for Lightening Skin Using Arbutin Compositions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Nov. 2028</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Skin Lightening Compositions Comprising Arbutin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Canada</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Nov. 2028</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Skin Treatment Compositions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">France, Germany, Great Britain, Japan, Mexico, Netherlands, Norway, Poland, South Korea, Spain, Sweden</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Nov. 2028-Aug. 2030</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stable Organic Peroxide Compositions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Belgium, Canada, Czech Republic, Estonia, France, Germany Great Britain, Hungary, Ireland, Italy, Japan, Liechtenstein, Luxembourg, Mexico, Monaco, Netherlands, Romania, South Korea, Slovak Republic, Slovenia, Switzerland, U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Mar.-June 2026</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a number of these patents will expire over the next five years, we do not believe the expiration of such patents will have a material effect on our business or results of operations because the formulations for the products covered by such patents are still treated as trade secrets, which are known only by a limited number of need-to-know employees, CMOs of the products who are bound by strict confidentiality provisions, and regulatory authorities as required. In addition, we are aware that other solubilized versions of benzoyl peroxide are already currently available on the market using different technologies than ours and, as a result, the expiration of the related patents will likely not have an impact on the availability of competitor products.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">World Class Research and Development (R&amp;D) Program</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&amp;D program aims to design products and execute studies that demonstrate the high-quality design of our formulas and powerful performance of our products. We apply a scientific approach to all of our products, from inception to development and testing. After formulation, all of our products are tested for integrity, safety and performance. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch Health, the manufacturer of our tretinoin products, holds an ANDA for such products, meaning the FDA has found such products to be bioequivalent to other tretinoin products approved through the NDA process. To approve an NDA for a product, the FDA generally requires applicants to demonstrate the safety and efficacy of the product through successful completion of well-controlled clinical trials usually employing several hundred to a few thousand subjects. None of our other products are distributed under an NDA or ANDA approved by the FDA. However, the FDA may require us to conduct well-controlled clinical trials to establish the safety and efficacy of our prescription strength HQ products and to obtain an NDA to continue marketing our HQ products. See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;The Skincare Market&#8212;Government Regulation&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Regulation of Drug Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for more information on potential FDA requirements. Nonetheless, we do conduct thorough testing of all of products, whether they are cosmetics, OTC drugs or prescription-strength products, to evaluate their safety and performance. Prior to launch, our products undergo several </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety tests, including, but not limited to, human repeat insult patch tests, used to help predict the likelihood for induced allergic contact dermatitis, comedogenicity tests, to ensure the product does not clog pores, and cumulative irritation tests. In addition to these safety and tolerability studies, we have conducted more than 30 studies with the leading academic institutions and key independent experts in dermatology and aesthetic medicine for our products, including, but not limited to, the following:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.484%"><tr><td style="width:1.0%"></td><td style="width:31.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Product</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Study</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Principal  Investigator</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Obagi Nu-Derm System</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(hydroquinone)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have conducted 10 studies on our Nu-Derm System that included a total of over 500 patients with Fitzpatrick skin types I-IV to assess (a) how well the system addresses hyperpigmentation and photodamage; (b) how well the system works as compared to other skincare regimens; and (c) how well the system works when used in conjunction with other skincare solutions.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">James H. Herndon, Jr., MD</span></div><div style="padding-right:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">M.L. Sigler, PhD Marta I. Rendon, MD FAAD</span></div><div style="padding-right:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Michael Gold, MD Suzanne Bruce, MD David Pariser, MD Pearl Grimes, MD Joel Schelssinger, MD</span></div><div style="padding-right:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Mitchel P Goldman, MD Suzanne Bruce, MD </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Obagi-C Rx System</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(hydroquinone)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have conducted two studies on the Obagi-C Rx System, including (a) one that involved 30 patients to assess how well the system addresses photodamage and fine lines and wrinkles and (b) an in vitro study that evaluated how well the L-ascorbic acid in the system absorbs into and remains in the skin.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Suzanne Bruce, MD Paul A. Lehman, MSc</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CLENZIderm System</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(OTC monograph for topical acne products)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have conducted 3 studies on our CLENZIderm System that included a total of 90 patients to assess (a) how well the system addresses acne, (b) how well the solubilized BPO in the system enters skin follicles and (c) how well the system works as compared to other acne regimens.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Leonard Swinyer, MD Suzzanne Bruce, MD Mary C. Spellman</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our HQ studies have reported serious adverse events (&#8220;SAEs&#8221;). A number of participants in the Obagi Nu-Derm System studies reported adverse events (&#8220;AEs&#8221;), which included dry skin, erythema (superficial reddening of the skin), pruritus (itchy skin) and skin exfoliation. No participants that received Obagi Nu-Derm discontinued any of the studies due to the occurrence of an AE. Specifically:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the Herdon Study, in which 71 participants of a total of 301 received Obagi Nu-Derm, there were no severe side effects, SAEs or AEs reported in the Obagi Nu-Derm arm of the study, however some participants experienced mild erythema, scaling, burning and itching.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the Rendon study, 21 of the 38 participants that received Obagi Nu-Derm reported AEs that were related to the trial material, with such AEs including moderate dry skin, redness, itching and peeling and one reported case of severe dryness and peeling. No SAEs were reported in this study.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the Grimes study, 3 of the 20 participants that received Obagi Nu-Derm reported AEs that were related to the trial material, with such AEs including 2 participants that experienced mild dry skin, redness, itching and peeling, and 1 participant that experienced moderate redness. No severe side effects or SAEs were reported in this study.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the Nu-Derm Botox study and Nu-Derm IPL study, some participants experienced transient dryness, redness and irritation, but by the end of the studies those levels had returned to baseline. No participants in these studies reported severe side effects and no SAEs were reported.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the study assessing how the Obagi-C Rx System, our other HQ product, addressed photodamage, of the 30 participants, 16 reported in the first week AEs that were at least probably related to the trial material, including 5 reported </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cases of dryness, 2 redness, 2 peeling, 2 milia (tiny white bumps on the skin), 1 rash, 1 pruritus, 1 contact dermatitis and 1 burning session and 5 reported cases in the second week of dryness and peeling. No SAEs were reported in this study.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the CLENZIderm studies, of the 55 participants in these studies, only one participant reported AEs of dryness and peeling. No SAEs were reported in these studies and no participants that received the CLENZIderm System discontinued any of the studies due to the occurrence of an AE.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also help to demonstrate the craftsmanship of our formulas through stability tests, penetration studies, head-to-head comparative studies and consumer perception studies. We constantly seek new protocols and testing methods that analyze and demonstrate the power of our products. For example, Obagi-commissioned head-to-head studies have indicated the Obagi Nu-Derm System, Obagi Nu-Cil&#8482; and Hydrate Luxe&#174; products outperform competitors across certain key attributes and a consumer preference survey commissioned by Obagi in 2019 highlighted consumer preference for Obagi&#8217;s Professional-C Serum 20% over a leading competitor&#8217;s product. We continue to expand our collaborations with leading dermatologists and institutions to coordinate additional studies for new product uses and formulations. In alignment with our value of promoting and representing diversity and inclusion in skincare, Obagi was the first physician-dispensed skincare brand to design clinical research protocols to cover all six skin types across the Fitzpatrick scale. Today, we remain focused on that commitment to ensure we deliver on our promise of providing high-quality products for every stage of the skincare journey, no matter your age or skin tone.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, products that are regulated solely as cosmetic products are not intended to have a pharmacological effect on the body, and our studies are not intended to suggest or establish such an effect for such products. Further, our studies are substantially smaller in scale (generally using over 30 but under 200 subjects) and rigor than FDA required studies, including only one phase of testing rather than the three phases typically required by the FDA. None of these studies have been used to support an application for marketing approval with the FDA or other similar regulatory authority. Consequently, they were not designed to fulfill the specific requirements of such regulatory application process and should not be viewed as a substitute for clinical trials that would be conducted in connection with the application to the FDA or similar regulatory authority.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SKINCLUSION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Initiative</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we launched our SKINCLUSION initiative, designed to elevate the global dialogue about diversity and how we can all make conscious choices to see the beauty in all our differences. Born from the insight that more than 70% of consumers do not see themselves represented in beauty marketing and advertising, we aimed to change the narrative. Leading with our conviction to provide transformative skincare for every face, everywhere, we built a communication platform to discuss why representation matters, show how lack of inclusivity stems from unconscious bias, and inspire other industry leaders to follow suit. Since then, we have continued to progress this initiative by incorporating more diversity in our model photography, our social media content, and our brand ambassadors. We champion new areas to represent diversity such as partnering with a woman who became the first model with Down syndrome to represent a skincare brand.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The campaign mirrors Obagi&#8217;s commitment to diversity and inclusion in all aspects of its business &#8211; from corporate culture to product development. With ambassadors ranging from celebrities and renowned dermatologists to a Down Syndrome advocate, role model and model, the global awareness initiative also includes donations supporting organizations like the International Cultural Diversity Organization and Project Implicit.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Marketing</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Domestic</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., we sell our Obagi Medical systems and related products to physicians, including physicians on site at medical spas, through our direct sales force. The medical professionals we sell to then dispense our products in-office, directly to their patients, a distribution method commonly referred to as the &#8220;physician-dispensed&#8221; channel. We also sell the Skintrinsiq device through the physician-dispensed channel as well as to licensed aestheticians. We believe that the physician-dispensed distribution model ultimately results in higher patient satisfaction because it is better suited to the provision of system-based skin care than traditional distribution channels. Our physician customer base consists primarily of plastic surgeons and dermatologists, but also includes physicians from other practice areas, such as general practice, family practice, internal medicine, dental and OBGYNs who are adding skin care to their practices.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had a large healthcare professional account base consisting of more than 5,000 active medical provider accounts, and estimate there are approximately 6,100 licensed physicians, resulting in broad distribution of Obagi products in the majority of dispensing aesthetic clinics. Our sales and marketing team consisted of 128 sales, marketing and education specialists, including 85 dedicated sales representatives and managers, as of December 31, 2022. In addition to providing our accounts with products, we also offer turn-key practice building programs and patient events to help these physicians grow their practices, as well as in-office materials on our products for their patients.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Obagi products for the physician-dispensed channel are sold through the Physician Channel Provider, which purchases products from us to maintain a sufficient inventory for this channel and operates and manages the ordering portal for our physician customers, receives and fulfills orders, and provides customer service functions (including call center services), processes product returns, runs customer credit checks, and offers invoicing, and collection, accounts receivable and chargeback services. Although the Physician Channel Provider is considered to be our customer as they purchase products from us for  physicians and customers who purchase products from us on our e-commerce platform, we maintain control of the product inventory in their warehouse and manage the relationship with the end customer until immediately prior to their sale and do not recognize revenue for sales to the Physician Channel Provider until sell through to the end customer.  See &#8220;Item 5. Waldencast&#8217;s Operating and Financial Review and Prospects&#8221; and &#8220;Item 8. Financial Information&#8212;Note 2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restatement and Reclassifications&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information on the recognition of revenue from the Physician Channel Provider.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we launched a collaboration with Massage Envy to carry select Obagi Medical products throughout their national franchised spas, including our larger professional sized products for facial services offered at the spas. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also sell Obagi Clinical products to consumers via e-commerce platforms through our online store at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.obagi.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.amazon.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and through Target&#8217;s online store at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.target.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as a number of other e-retailers and distributors and we intend to increasingly develop this sales channel to capture additional margin opportunities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The North American market accounted for 61.3%, 60.3%, 55.5% and 67.8% of our net revenue for the 2022 Successor Period, 2022 Predecessor Period, 2021 Predecessor Period and 2020 Predecessor Period, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International markets accounted for approximately 36.5%, 35.6%, 40.5% and 25.9% of our net revenue for the 2022 Successor Period, 2022 Predecessor Period, 2021 Predecessor Period and 2020 Predecessor Period, respectively. We address international markets through 26 international distribution partners that have sales and marketing activities in over 65 countries outside of the U.S., and a trademark and know-how license agreement and a license distribution agreement for the retail drug store channel in Japan. We target distribution partners who are capable and willing to mirror our sales and distribution model in the U.S. and who have an established business and reputation with physicians. The products that we sell internationally are generally the same formulations as those sold in the U.S.; however, in some instances, formulations have been modified to comply with the regulatory requirements of certain countries, particularly in the U.K., Europe and Asia. These distributors use a model similar to our business model in the U.S., addressing their territories through direct sales representatives who sell to physicians, or through alternative distribution channels, depending on regulatory requirements and industry practices. Our distribution agreements typically grant distributors the right to distribute and sell our products to licensed medical professionals and skincare clinics within a specified territory, require them to purchase a specified minimum amount of our products each year and have a term of two to five years. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to our domestic sales channels, we intend to increasingly develop our online and e-commerce distribution channels and generally reserve the rights to distribute our products through other channels and e-commerce in such territories.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have a broad base of international distributors, our SA Distributor historically accounted for a significant portion of Obagi&#8217;s net revenue for the 2022 Successor Period, 2022 Predecessor Period and 2021 Predecessor Period. See &#8220;Item 5. Waldencast&#8217;s Operating and Financial Review and Prospects&#8221; and &#8220;Item 8. Financial Information&#8212;Note 2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restatement and Reclassifications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for more information regarding net revenue from Obagi&#8217;s SA Distributor. Obagi&#8217;s agreement with the SA Distributor granted the SA Distributor a non-exclusive right to distribute our products in Vietnam and South Korea, contained minimum purchase requirements and had a term that expired on December 31, 2026. In January and October 2022, we executed amendments with the SA Distributor to, among other things, expand the countries within Southeast Asia in which it may distribute Obagi products. In March 2023, as part of our strategy to internalize </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distribution channels in key markets, certain of Obagi&#8217;s subsidiaries entered into and consummated the Vietnam Purchase Agreement, pursuant to which, among other terms, Obagi acquired certain assets of Obagi Vietnam from the SA Distributor and, in return, the SA Distributor received forty percent (40%) of the outstanding equity of Obagi Blue Sea Holding, LLC, an indirect subsidiary of Obagi and the parent company of Obagi Vietnam. The Vietnam Purchase Agreement also provides the SA Distributor with a potential earnout payment based upon the net revenue of the business of Obagi Vietnam during the twelve-month period ending on December 31, 2026, subject to setoff for any owed obligations. We currently do not anticipate that any such earnout payment shall be payable. The SA Distributor does not currently have any active participation in the Obagi Vietnam business other than as a silent shareholder. Due to non-performance by the SA Distributor of its obligations pursuant to the Vietnam Purchase Agreement and certain other matters, we took further steps in 2023 to further restructure the business of Obagi Vietnam by hiring a new local management, finance and sales teams to replace the previous SA Distributor team, entering into new online and offline distribution agreements with reputable partners and re-applying for all product registrations, which were obtained in June 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue expanding our international presence in key locations, such as Asia, Europe and South America, by entering into strategic relationships or building our own distribution structure. We believe that there is potential for significant sales growth of our products in international markets, particularly in Southeast Asia, Europe and Brazil, due to cultural emphasis on overall skin health and appearance, and the continued development and acceptance of surgical and non-surgical cosmetic procedures throughout many countries of the world.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Licensing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Japan, we built an alternative model to build a presence and brand awareness for our products. For example, in Japan we launched a formal long-term relationship by entering into a Trademark and Know-How License Agreement with Rohto to market and sell products in Japan using the Obagi brand name. Under our current agreement, Rohto is licensed to manufacture and sell a series of OTC and cosmetic products developed by it under the Obagi brand name in the Japanese drug store channel, for which it pays us a license fee. In 2008, we expanded that relationship to provide for collaboration on the development of new products and to pursue the higher end department store channel in Japan. Our strategic partner in Japan has engaged in aggressive direct-to-consumer advertising, which we believe has raised consumer demand in Japan, creating greater brand awareness in the physician channel to the benefit of our core prescription lines. In April 2019, we entered into a Distribution and Supply Agreement with Rohto that gave us the exclusive right to sell their Obagi branded products in the cross-border e-commerce channel in the PRC, which agreement was assigned to Obagi Hong Kong in connection with the Business Combination.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the Business Combination, on the Closing Date we entered into an Intellectual Property License Agreement (the &#8220;IP License Agreement&#8221;) and Global Supply Services Agreement (the &#8220;Supply Agreement&#8221;) with Obagi Hong Kong for the sale of Obagi products throughout the China Region. Under these agreements, we will supply, or cause to be supplied through certain CMOs (as defined in the Supply Agreement), Obagi products to Obagi Hong Kong and its affiliates, and Obagi Hong Kong will purchase such products, with the exclusive right to distribute and sell such products in the China Region. In return, Obagi Hong Kong will pay us a royalty of five and a half percent (5.5%) of gross sales of licensed products, subject to certain deductions. See &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;7.B. Related Party Transactions&#8221; for a description of these related party transactions. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to look for credible partners to address new geographies, and to evaluate alternative channel opportunities in Japan and other countries to drive brand awareness and accelerate overall market penetration.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategic Initiatives for Driving Growth</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ambition is to be the top dermo credentialed brand in the world, driving strong growth through channel and geographic diversification. Obagi plans to focus on three key initiatives to achieve this goal:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Brand Expansion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We plan to continue building upon the highly respected reputation of the Obagi brand. We see significant market opportunity to build broad brand awareness in consumer segments beyond those who receive their skincare from healthcare professionals. In July 2021, we launched the Skintrinsiq device for use in spas as well as medical offices. We have also experienced positive sales increases following the endorsement of our products by celebrities and popular publications. In particular, we recognize the opportunity to reach a younger consumer base that is increasingly interested in clinically proven skincare products. Complementary to these efforts, we are engaging in efforts to enhance our brands&#8217; aesthetic appeal by refreshing our packaging and in-clinic merchandising.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Channel Expansion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;While we continue undertaking significant efforts to further our market penetration within the physician-dispensed channel, we intend to also focus on continuing to implement our omni-channel strategy to expand our distribution beyond this market segment. In December 2020, in tandem with the redesign of our own website, we launched our first e-commerce store to enable us to sell our Obagi Medical OTC and cosmetic products directly to consumers through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.obagi.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We see particular adjacent opportunity in the spa channel, where consumer demand for medical grade skin solutions has increased. In 2018, we launched a collaboration with Massage Envy to carry select Obagi Medical products throughout their national franchised spas, including our professionally sized products for facial services offered at the spas. We have launched the Skintrinsiq device in several practices as of December 31, 2022, with 73% of our aesthetic practice partners and 80% of initial consumers recommending the device treatments. </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">International Growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Finally, we intend to continue expanding our international presence. As we continue to enhance our own U.S. online web store, we plan to build and execute a global e-commerce strategy that will enable us to reach consumers in several international markets, including some in which we may not have a distribution partner. At the same time, we will focus on growing our network of third-party distributors in key large international markets, such as Europe, Brazil, Southeast Asia and the Middle East, or expanding through the acquisition of distributors, such as our acquisition of Obagi Vietnam from the SA Distributor, and building out our own sales infrastructure to distribute products directly into new geographic areas such as Southeast Asia. We also plan to drive distribution of our products through strategic relationships in other countries, including Japan and China.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competitive Strengths</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we are well-positioned to achieve our strategic initiatives as a result of the following competitive strengths:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Market leading brand</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi has been a leader in the physician-dispensed market from inception, being one of the first companies to offer skincare products in the physician-dispensed market over 30 years ago. Recent ratings from an industry source rank Obagi as being particularly well regarded by physicians for our marketing and innovation, customer service and education among large brands in the physician-dispensed market.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Robust portfolio of high-quality, innovative products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product portfolio currently consists of over 200 products. While some of the competitors in the skincare market also offer a broad spectrum of products, only one other competitor offers both prescription strength and non-prescription products. In addition, many competitors in our primary market, physician-dispensed, generally have more narrowly focused offerings, addressing only targeted skincare problems, while our portfolio addresses all of the most common visible skin disorders.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Diversified, omni-channel market with global geographic coverage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our diversified, omni-channel strategy gives us a competitive advantage over many skincare companies that choose to focus only on the physician-dispensed market. By offering a skincare line developed specifically for physicians as well a device that can also be used in the spa and wellness channels, we believe we are able to expand our brand recognition and meet the consumer where they are in their skincare journeys. In addition, our global breadth into over 65 countries positions us well to achieve worldwide brand recognition. Our strategic relationship with Rohto and agreements with Obagi Hong Kong allow us to penetrate the markets in Japan and China, as well as the development of our operations in Vietnam through the acquisition of Obagi Vietnam from the SA Distributor and build out of a direct sales infrastructure in Southeast Asia, which represents a large growing market for skincare, and we intend to continue expanding our network of distributors and strategic partners.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Specialized and efficient global sales force</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our domestic internal sales force of 128 professional representatives and education specialists as of December 31, 2022 allows us to develop close relationships with the physicians who dispense our products throughout the U.S. In addition, our global sales force consists of 26 international distributors who sell our products in over 65 countries throughout the world. We believe the breadth and experience of our internal and global sales network provide us with a competitive advantage.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for aesthetic and therapeutic skin health products is highly competitive and we expect the intensity of competition to increase in the future. We also expect to encounter increased competition as we enter new markets and/or distribution channels, attempt to penetrate existing markets with new products and expand into new distribution channels. Our principal competitors are large, well established companies in the fields of pharmaceuticals, cosmetics, medical devices and health care. Our largest direct competitors include SkinCeuticals and Skinbetter Science, divisions of L&#8217;Or&#233;al S.A., SkinMedica, Inc., a division of Allergan, Inc., ZO Skin Health, and PCA Skin and EltaMD, each a division of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Colgate-Palmolive. Our indirect competitors for Obagi Medical&#174; products sell skin care products directly to consumers, and generally consist of large well known cosmetic companies, including, but not limited to, La Roche-Posay, Dermalogica, Murad and dermatologist backed brands, such as Dr. Dennis Gross. Our Obagi Clinical line competes with Eucerin, La Roche Posay and Vichy in Southeast Asia markets</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face competition from medical device companies offering products to physicians, aestheticians and spa and wellness centers that are used in facial treatments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitive factors in our market include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product efficacy, uniqueness, quality, reliability of performance and convenience of use;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">brand awareness and recognition;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">breadth of product offerings;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales and marketing capabilities and methods of distribution;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">resources devoted to product education and technical support;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">speed of introducing new competitive products and existing product upgrades; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effectiveness.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face and will continue to face intense competition. A number of our competitors have greater research and development and marketing capabilities, more diverse distribution channels and greater financial resources than we do. These competitors may have developed, or could in the future develop, new technologies that compete with our products or render our products obsolete. We are also likely to encounter increased competition as we enter new markets and as we attempt to further penetrate existing markets.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently outsource all our product manufacturing to third-party CMOs. We have two or more qualified CMOs for some of our key products, however, certain products, including some of our sun protection products, are currently supplied by a single source. The termination of our agreement with a single source supplier or any loss or disruption of services under such agreement could be difficult for us to replace upon the same favorable terms. The transfer of technology required to begin using a new CMO is also a lengthy process, which can take six to 18 months to achieve. We believe our manufacturing processes provide us with a competitive advantage, which we have developed through years of experience formulating skin care products. For all of our proprietary product concepts, we believe we own the related manufacturing processes, methods and formulations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., we use FDA-compliant CMOs who specialize in the manufacture of prescription and OTC pharmaceutical and/or cosmetic products. The CMOs manufacture products pursuant to our specifications. All of our CMOs are required by law to comply with cGMPs. We require all CMOs with whom we have agreements to represent and warrant to us that the products they produce for us are made in accordance with cGMPs, including documentation, recordkeeping, building and facility design, equipment maintenance and personnel requirements. We pre-qualify and continually monitor our CMOs for quality and compliance. We also require documentation of compliance and quality from those CMOs for whom we act as representative in connection with the promotion and sale of their products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch Health, which formerly owned the business of Obagi, is our only supplier and manufacturer of tretinoin. We have a contract with Bausch Health that has an initial termination date in 2027. While there are several other manufacturers of generic tretinoin, the termination of this agreement or any loss of services under the agreement could be difficult for us to replace upon the same or similar favorable terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we entered into development and production agreement with Theravant, Inc., under which Theravant has agreed to work collaboratively with us to develop and manufacture the Skintrinsiq device exclusively for Obagi. We serve as the exclusive distributor of the device under the agreement. The term of the agreement expires at the end of December 2024.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design of our systems and products is generally proprietary to us, and we hold approximately 80 provisional and issued patents worldwide for the composition of many of these products. Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to protect our proprietary position by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development of our business when appropriate. We also rely on trade secrets, trade dress, know-how, continuing technological innovation and in-licensing opportunities to develop and maintain our proprietary position.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have pursued an aggressive trademark registration policy aimed at achieving brand recognition and product differentiation in the market. We own over 1,000 U.S. and foreign trademark registrations and applications and common law marks.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also acquired rights to market, distribute, sell and, in some cases, make products pursuant to license agreements with other third parties that grant us the right to use the product formulas, trademarks and other trade secrets; these agreements do not include products that have underlying patents. For instance, in December 2016, Obagi entered into an exclusive license and distribution agreement with Nextcell Medical Company, under which we have the exclusive right to market, sell and distribute the SUZANOBAGIMD line of products in the U.S. and all U.S. territories. The term of the agreement expires at the end of January 2024 and we are currently negotiating an extention of that agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we entered into a master supply and distribution agreement with Maxey Cosmetics LLC (&#8220;Maxey&#8221;), under which we purchase our Obagi Nu-Cil&#8482; products from Maxey and have been granted the right to market, sell and distribute them throughout the world, with such right being (i) exclusive in Asia and (ii) shared with Maxey, which is permitted to sell similar products under its own brand name, through any of its current distribution channels (except for certain specified major cosmetic retail outlets) in the U.S., Europe, Africa and the Middle East. The agreement has an initial term through April 2026.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Obagi, we are committed to hiring and nurturing diverse talent and believe this is one of the keys to our current and future success. More than 20% of our employee base identifies as BIPOC. Additionally, our leadership team consists of a diverse group of professionals, over 60% of whom are women, dedicated to promoting inclusivity. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The team has built a culture that combines a fast moving and outcome-oriented mindset with a tight knit sense of community, winning both a Top Workplaces USA Award and a Top Workplace Led by Women Award in 2022. Obagi is mindful of diversity during the recruiting and retaining process and believes that diversity is key to its culture and long-term success, with 84% of our employee base being women. As of December 31, 2022, we had 187 employees. Our employees include 125 in sales and marketing, 17 in research, development and quality control, 25 in operations and distribution and 20 in administrative functions. Our employees are all non-unionized, and we believe our relations with our employees are good.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Properties</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi&#8217;s corporate headquarters were located in Long Beach, California until September 2022, when we temporarily moved our headquarters to Houston, Texas. In January 2024, Obagi will relocate its headquarters back to its Long Beach offices, where it occupies facilities totaling approximately 28,300 rentable square feet under a lease that expires in June 2026. In September 2022, we temporarily relocated our headquarters to The Woodlands, Texas, where we rent approximately 16,460 square feet of additional office space under a lease that will expire in July 2032.  We have entered into a sublease for this space for when we relocate that will run through December 2025. We also lease warehouse facilities located in Conroe, Texas under a lease that will expire in February 2031 and plan to sublease those facilities as well. The warehouse space includes approximately 35,000 square feet of warehouse space and 4,200 square feet of office space. We use our office spaces primarily for our management, research and development, sales, marketing, operations, finance, legal, human resources and general administrative teams. We believe that our Long Beach office  space is adequate for our current needs and should we need additional space, we believe we will be able to obtain additional space on commercially reasonable terms.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi products are subject to regulation by the FDA the FTC and comparable state, local and foreign regulatory authorities and, over time, the regulatory landscape for our products has become more complex with increasingly strict requirements. These laws and regulations govern, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, disposal, record-keeping, promotion, advertising, distribution, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing, export and import of drugs and cosmetic products. Noncompliance with applicable regulations could result in enforcement action by the FDA, FTC, or other regulatory authorities within or outside the U.S., including, but not limited to, product seizures, injunctions, product recalls, and criminal or civil monetary penalties, all of which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Regulation of Cosmetics Products</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our products are cosmetics. The FDCA defines cosmetics as articles or components of articles intended for application to the human body to cleanse, beautify, promote attractiveness, or alter the appearance. The labeling of cosmetic products is subject to the requirements of the FDCA, the Fair Packaging and Labeling Act, and other laws and regulations. Cosmetics are not subject to pre-market approval by the FDA; however certain ingredients, such as color additives, must be pre-approved for the specific intended use in the product and are subject to certain restrictions on their use. The FDA may, by regulation, require warning statements on certain cosmetic products for specified hazards associated with such products. FDA regulations also prohibit or otherwise restrict the use of certain types of ingredients in cosmetic products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA requires that cosmetic labeling and claims be truthful and not misleading. Moreover, cosmetics may not be marketed or labeled for their use in treating, preventing, mitigating, or curing diseases or other conditions or in affecting the structure or function of the body, as such claims would render the product to be a drug and subject to regulation as a drug. The FDA evaluates the &#8220;intended use&#8221; of a product to determine whether it is a drug, cosmetic product, or both. The FDA may also consider labeling claims in determining the intended use of a product. If the FDA considers label claims for cosmetic products to be claims affecting the structure or function of the human body, or intended for a disease condition, then such products may be regulated as &#8220;new drugs&#8221; within the meaning of the FDCA, meaning that such products would generally require premarket review and approval by the FDA to be legally marketed in the U.S. In addition to FDA requirements, state consumer protection laws and regulations can subject a cosmetics company to a range of requirements and theories of liability, including similar standards regarding false and misleading product claims, under which state enforcement or class- action lawsuits may be brought.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market certain products, such chemical peels, as cosmetics, with the stronger peels sold only to licensed healthcare providers for professional use only. However, the FDA may disagree with our determination that these products do not require FDA premarket review and approval. Similar risks may apply in foreign jurisdictions. If any of our products we intend to sell as cosmetics were to be regulated as drugs, we might be required to conduct, among other things, clinical trials to demonstrate the safety and efficacy of these products and to apply for pre-market approval of such products from the FDA.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant changes to the regulatory landscape for cosmetic products are anticipated for the coming years as a result of the enactment of MoCRA. Under MoCRA, companies will be obligated to adhere to new requirements for cosmetics, such as new labeling standards for specific products, safety substantiation, facility registration, product listing, adverse event reporting, compliance with cGMPs, mandatory recalls and record-keeping requirements for such products and the manufacturing facilities in which they are produced, among other things. Companies will need to be in compliance with many of the new requirements no later than July 1, 2024. MoCRA requires the FDA to issue regulations governing cGMP for cosmetic manufacturers by December 2025 and additional labeling requirements are expected to go into effect in 2024. We already require all third-party CMOs who enter into agreements to produce our products to represent and warrant to us that the products are made in accordance with cGMPs, including documentation, recordkeeping, building and facility design, equipment maintenance and personnel requirements. We have written agreements in place with all such U.S. CMOs except one.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are also subject to regulation by the CPSC under the provisions of the Consumer Product Safety Act, as amended by the Consumer Product Safety Improvement Act of 2008. These statutes and the related regulations ban consumer products that fail to comply with applicable product safety laws, regulations and standards. The CPSC has the authority to require the recall, repair, replacement or refund of any such banned products or products that otherwise create a substantial risk of injury and may seek penalties for regulatory noncompliance under certain circumstances. The CPSC also requires manufacturers of consumer products to report certain types of information regarding products that fail to comply with applicable regulations. Certain state laws also address the safety of consumer products, and mandate reporting requirements, and noncompliance may result in penalties or other regulatory action.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Regulation of Drug Products</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the FDA regulates drugs under the FDCA and its implementing regulations. Our prescription-only products containing hydroquinone are regulated as drugs, however, to date, we have not sought or obtained required NDAs or other FDA approvals for these products. Based on the historical evolution of the legal and regulatory framework applicable to drugs in the U.S., the FDA acknowledges that there are some drugs on the market that lack required FDA approval for marketing. The FDA has historically utilized a risk-based enforcement approach with respect to drugs marketed without required approvals. In 2003, the FDA issued a Compliance Policy Guide, or CPG, which was finalized in 2006 and subsequently amended in 2011, in which the FDA announced a drug safety initiative to remove unapproved drugs from the market and established enforcement priorities and a policy of enforcement discretion with respect to marketed unapproved products. Under this policy, the FDA indicated that it intended to give higher priority to enforcement actions involving unapproved drug products in certain categories, including drugs with potential safety risks and ineffective dugs that could be used in lieu of effective treatments. Although this CPG was withdrawn and the drug safety initiative was terminated on the basis of a Federal Register notice in 2020, a subsequent Federal Register notice in May 2021 withdrew the prior notice terminating the program and the CPG, and the FDA indicated that it plans to continue to prioritize enforcement based on its existing general approach, which involves risk-based prioritization in light of all the facts of a given circumstance. We believe our prescription-only HQ products do not fall within the previously established categories of unapproved drugs for which the FDA has indicated it prioritizes enforcement. To date, we have not received any communications from the FDA or any similar regulatory authorities regarding our Nu-Derm HQ or any other products and neither the FDA nor any other regulators have prohibited us from selling our prescription HQ products in the U.S. or in other jurisdictions. However, there can be no assurance the FDA or any other regulatory authorities will not take enforcement action against us, or otherwise require us to obtain premarket approval or similar authorization of our prescription HQ products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources, and generally involves the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with the FDA&#8217;s Good Laboratory Practice requirements and other applicable regulations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an Investigational New Drug application requesting authorization from the FDA to administer an investigational biologic to humans which must become effective before human clinical trials may begin;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an independent Institutional Review Board or ethics committee at each clinical site before each trial may be initiated;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices (&#8220;GCPs&#8221;), to establish the safety and efficacy of the proposed drug for its intended use. Clinical trials generally include the following:</span></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1: the product is initially introduced into healthy human subjects or patients with the target disease or condition to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2: the product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3: the product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In some cases, the FDA may require, or sponsors may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies, may be conducted after initial marketing approval, and may be used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA, including:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparation of and submission to the FDA of an NDA after completion of all pivotal trials;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination by the FDA within 60 days of its receipt of an NDA to file the application for review</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA advisory committee review, if applicable;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity, and of selected clinical investigation sites to assess compliance with GCPs; and</span></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the U.S.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hatch-Waxman Act</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 505(j) of the FDCA establishes an abbreviated approval process for a generic version of approved drug products through the submission of an ANDA. Certain of our products, including tretinoin products, are marketed pursuant to an ANDA held by Bausch Health. An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics and intended use, among other things, to a previously approved product.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Over-the-Counter Drug Products</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently market certain non-prescription drug products, including certain products that are intended to treat acne or be used as sunscreens, which are regulated as OTC drug products by the FDA. Certain OTC drug products are subject to regulation pursuant to the FDA&#8217;s &#8220;monographs,&#8221; which provide rules applicable to each therapeutic category of non-prescription drug, and establishes conditions, such as active ingredients, uses (indications), doses, labeling, and testing procedures, under which an OTC drug within that particular category may be GRASE, and therefore can be marketed without obtaining pre-market approval of an NDA or ANDA. To be legally marketed, among other things, OTC drug products marketed under an OTC monograph must be manufactured in compliance with the FDA&#8217;s cGMP requirements for drug products, and the failure to maintain compliance with these requirements could lead to FDA enforcement action. Moreover, a failure to comply with the OTC monograph requirements could lead the FDA to determine that the drug is not GRASE, and thus is a &#8220;new drug&#8221; requiring approval in accordance with the NDA process described above.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Regulation of Medical Devices</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical devices are subject to extensive and rigorous regulation by the FDA and by other federal, state and local authorities. The Federal Food, Drug, and Cosmetic Act and related regulations govern the conditions of safety, efficacy, clearance, approval, manufacturing, quality system requirements, labeling, packaging, distribution, storage, recordkeeping, reporting, marketing, advertising, and promotion of medical devices. Unless an exemption applies, each medical device commercially distributed in the U.S. requires either FDA clearance of a 510(k) premarket notification or approval of a premarket approval application (a &#8220;PMA&#8221;). Under the FDCA, medical devices are classified into one of three classes&#8212;Class I, Class II or Class III&#8212;depending on the degree of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness. Class I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA&#8217;s General Controls for medical devices, which include facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising and promotional materials. Class II devices are subject to the FDA&#8217;s General Controls, and special controls, which can include performance standards, post-market surveillance, patient registries and FDA guidance documents. While most Class I devices are exempt from the 510(k) premarket notification requirement, manufacturers of most Class II devices are required to submit to the FDA a premarket notification under Section 510(k) of the FDCA requesting permission to commercially distribute the device. Devices deemed by the FDA to pose the greatest risks, such as life-sustaining, life- supporting or some implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, are placed in Class III, requiring approval of a PMA. Some pre-amendment devices are unclassified but are subject to the FDA&#8217;s premarket notification and clearance process in order to be commercially distributed. We believe that, based on its intended use, our Skintrinsiq device does not meet the FDCA&#8217;s definition of a medical device and have not sought FDA premarket review of this product. However, the FDA may disagree with our determination and subject the Skintrinsiq device to medical device regulations. Similar risks may apply in foreign jurisdictions where we market our products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Government Regulation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key part of the growth strategy for our Obagi Skincare business is to expand the sale of Obagi products in international markets. To market our products in many non-U.S. jurisdictions we must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. In some countries, we do not have to obtain prior regulatory approval but instead may need to comply with a notification system and/or do have to comply with other regulatory restrictions on the manufacture, importation, distribution, marketing and sale of our products. We may be unable to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market. In several countries, we rely on distributors or other third parties to comply with and obtain any relevant approvals, licenses or registrations. The approval procedure varies among countries and can involve additional testing and data review. The time required to obtain approval in non-U.S. jurisdictions may differ from that required to obtain FDA approval and could be lengthy. For instance, in June 2022, the SA Distributor encountered a prolonged delay in obtaining required approvals from the drug administration in Vietnam, which prevented it from importing and selling our products into the country for an extended period of time. After the acquisition of Obagi Vietnam from the SA Distributor, Obagi Vietnam applied for and received the required approvals to distribute our products in that country in June 2023. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. In addition, many countries from time to time evaluate the regulatory status of various products and ingredients. We may not obtain foreign regulatory approvals on a timely basis, if at all, or may choose not to implement a country&#8217;s labeling requirements if to do so would have a negative impact on our international or domestic operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the regulatory requirements related to our products, see &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Legal and Regulatory Risks That Could Adversely Impact our Obagi Skincare Business&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in laws, regulations, enforcement trends in international markets could harm our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi is not involved in any material litigation nor, to management&#8217;s knowledge, was any material litigation threatened against Obagi which if adversely determined could have a material adverse effect on Obagi other than routine litigation arising in the ordinary course of business. See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Legal Proceedings&#8221; and &#8220;Item 8. Financial Information&#8212;Note 21. Subsequent Events&#8221; for more information on legal proceedings and investigations, including the SEC investigation, involving the Company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our &#8220;Clean&#8221; Makeup Segment: Milk </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our &#8220;clean&#8221; Makeup Segment consists of the Milk Makeup business. Unless the context otherwise requires, all references in this section to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; the &#8220;company,&#8221; or &#8220;Milk Makeup&#8221; generally refer to Milk and its consolidated subsidiaries.</span></div><div style="margin-top:12pt;text-align:center"><img src="wald-20221231_g3.jpg" alt="Image_5.jpg" style="height:336px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"/></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8201;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk Makeup&#8217;s Dream and Mission</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ambition at Milk is to build the top global makeup brand of the next generation. Our mission is to serve and empower our&#160;community&#160;to live their look by creating effective, easy to use, vegan, clean cruelty-free beauty products.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup is a leading, award-winning clean prestige makeup brand with unique products, a strong following among Gen-Z consumers and an emerging global presence. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our inclusive brand values, &#8220;clean&#8221; product philosophy (see &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Values and Commitments&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8216;Clean&#8217; Products&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and commitments to sustainability and philanthropy are at the zeitgeist of what will motivate the next generation of beauty consumers around the world. These values and product attributes will only become more relevant over time. We believe that our ability to authentically connect with youth culture while developing unique, effective and easy to use products that are also 100% vegan, clean and cruelty-free sets us apart from other brands.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup was launched in 2016 with the goal of building a global movement to challenge and broaden the definition of beauty. Community and self-expression are at the heart of everything we do. We believe that it&#8217;s not how you wear your makeup, it&#8217;s what you do in it that matters. This ethos is captured in our brand signature, &#8220;Live Your Look.&#8221; All aspects of the brand are designed in-house at our downtown NYC home.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, Milk was the #2 clean brand in Sephora in the U.S., with our Hydro Grip face primer and  Lip + Cheek as category leading best-sellers. We are a &#8220;hybrid&#8221; brand, offering an innovative selection of both makeup and skincare products. This allows us to play a broader role in our community&#8217;s beauty routine and also positions us for expansion into new categories both within and outside of makeup and skincare. Our other top products include Matte Bronzer, Hydro Grip Set + Refresh Spray, Kush Mascara,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kush Brow and Pore Eclipse Primer. We currently have strong positions within Sephora in the primer, mascara, blush and bronzer categories. We believe we have opportunities in large segments of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cosmetics market such as foundation, concealer, brow, liner and lip color. Outside of cosmetics, we believe that we have untapped opportunities in skincare and potentially other categories such as haircare, fragrance, bath and shower which, as illustrated in the chart below, are significant markets. We believe that Milk Makeup has the ability to build a premier cross-category beauty brand.</span></div><div style="margin-top:12pt;text-align:center"><img src="wald-20221231_g4.jpg" alt="Image_6.jpg" style="height:272px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Source: Euromonitor International; Beauty &amp; Personal Care, 2022 ed, retail value sales, current prices, 2021 fixed ex rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The brand is currently distributed online via </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.milkmakeup.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in omni-channel retail through Sephora (in the U.S. (including Sephora at Kohl&#8217;s), Canada, EU, Middle East and Australia), on Amazon, in the U.K. at Sephora, Space NK and online at Cult Beauty and ASOS and cross-border to China through SuperOrdinary. We have opportunities to accelerate within our existing footprint and grow in both new channels and regions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup is anchored by a strong community with significant room for growth as awareness and distribution continue to build. As of November&#160;2023, Milk Makeup had 2,300,000 followers on Instagram, 13,500,000 likes and 945,000,000 hash-tagged video views on TikTok, 1,320,000 monthly views on Pinterest, 108,000 followers on Facebook, 88,000 subscribers on YouTube and 64,000 followers on X (formerly known as Twitter).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have strong awareness among Gen-Z with opportunities to build across all other age groups. A</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ccording to a July-August 2022 survey conducted by Sephora of female participants aged 16-64 who have purchased beauty products for themselves in the past three months, Milk Makeup has 84% awareness among &#8220;Gen-Z&#8221; participants, 78% awareness among &#8220;Millennial&#8221; participants, 70% awareness among &#8220;Gen-X&#8221; participants and 47% awareness among &#8220;Boomer&#8221; participants. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">his awareness and resonance with the younger core audience is a key strength of the brand and, we believe, a key differentiator from the large legacy brands. Our plan is to continuously renew relevance with our younger core demographic while expanding into more mature demographics, who tend to have higher disposable income, through awareness building and product storytelling. This will create strong future growth potential for the brand.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk Makeup&#8217;s strategy to building a top clean make-up brand of the new generation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is based on three goals:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Grow our consumer base</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: drive more awareness and trial of our products by reinvesting in operational efficiencies, increasing marketing spend and leveraging our owned ecosystem to increase awareness, trial and topline growth. Additionally, we plan to broaden our brand footprint to recruit more Millennials while continuing to build on our strong position with Gen-Z consumers.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Brand expansion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: expand our make-up assortment and enter into new sub- categories by accelerating and scaling product innovation and building on hero products to create category champions (products in the top 5 of their respective categories) with global resonance. We plan to continue evolving our margin by optimizing our hero product lines and focusing on higher margin products.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Internationalize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: build global brand awareness by continuing to utilize, strengthen and maximize our distribution relationship throughout the Sephora ecosystem, while expanding our presence in key markets, such as the UK and Latin America, leveraging our brand success to develop a highly efficient international and direct-to-consumer model.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Industry Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup operates within a subsector of the cosmetics industry known as color cosmetics. The global color cosmetics market is valued at approximately $66.0 billion with an expected compound annual growth rate (&#8220;CAGR&#8221;) of 7.0% from 2021 to 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cosmetics industry is comprised primarily of face makeup, eye makeup, lip products, nail products and cosmetics sets/kits. According to industry sources, global sales of face makeup were $24.0 billion in 2020. Cosmetics sets/kits are combinations of products that are packaged together and often offered with a promotional incentive relative to buying the products separately.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cosmetics industry is large and fragmented. There are established multi-national competitors such as Unilever P.L.C., Coty Inc., L&#8217;Or&#233;al S.A., The Est&#233;e Lauder Companies, Inc., P&amp;G, Revlon Inc., Shiseido Company, Limited, Puig and e.l.f, Beauty Inc., in addition to independent companies such as Rare Beauty, Anastasia Beverly Hills, Pat McGrath Labs, Huda Beauty, Ilia, Kosas, Saie,Tower 28 and Forma. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there is a clear opportunity for Milk Makeup to gain share within this market. We believe that our advantage lies in our ability to build a strong community, our agility in responding to emerging trends and speed to market, as well as our ability to connect deeply with and meet the needs of the next generation of consumers. In addition, we believe that many of the barriers to entry that previously prevented younger brands from gaining scale, such as the need to have robust research and development capabilities, heavy traditional media investment and broad distribution are no longer critical to succeeding in the market today due to the availability of high quality third-party CMOs, the strength of social media in driving awareness and relevance, and the weight of e-commerce within beauty and the consumer&#8217;s desire for high performance products and a premium brand experience.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup offers an exciting portfolio of over 330 makeup and skincare SKUs. We currently have bestselling products at Sephora in the U.S. in the primer and mascara categories with our Hydro Grip primer and Lip + Cheek. We also have strong positions in  the bronzer category with Matte Bronzer, mascara category with Kush Mascara and brow category with Kush Brow, and the showcasing the versatility of the brand. These products are part of a $5.0 billion prestige color cosmetics category in the U.S. alone, much of which we have yet to truly address. We currently have limited offerings in the foundation and concealer categories as well as brow, liner, eyeshadow and lip color. We also believe that we can expand further into other beauty categories such as skincare, haircare, bath/shower and fragrance. The chart below highlights the market breakdown and demonstrates where we have both existing strengths and future opportunities.</span></div><div style="margin-top:12pt;text-align:center"><img src="wald-20221231_g5.jpg" alt="Image_8.jpg" style="height:246px;margin-bottom:5pt;vertical-align:text-bottom;width:600px"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Market sizes reflect 2021E data for the U.S. market; Euromonitor International; Beauty &amp; Personal Care and Color Cosmetics in the U.S., 2022ed, retail value sales, current prices, 2021 fixed ex rates.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Areas where management believes product offering expansions or introduction of new categories are possible.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Primer refers to EMI&#8217;s category BB/CC creams and skin tints refers to EMI&#8217;s premium foundation/ concealer.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond strong rankings, our products have won multiple prestigious awards including the 2023 </span><span style="background-color:#ffffff;color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cosmopolitan Reader&#8217;s Choice Beauty Award; Sculpt Stick, which won the 2023 Allure Best of Beauty Award; Pore Eclipse Matte Setting Spray, which won both the 2023 Allure Best of Beauty Award and the 2023 Elle Canada/Quebec Beauty Grand Prix Award; Future Fluid All Over Cream Concealer, which won the 2023 Cosmopolitan Holy Grail Award and the 2023 Elle Canada/Quebec Beauty Grand Prix Award; and Kush Brow Lamination Gel, which won the 2023 Cosmopolitan Beauty Award. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Distribution Strategy</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup has had a strong exclusive relationship with Sephora covering most markets, including the U.S., Canada, Europe, the Middle East, Australia and New Zealand. This has allowed the Milk Makeup brand to quickly rise within the category ranks through exceptional launch support and visibility both in-store and online. In a crowded and fragmented market, our partnership with Sephora has allowed us to break through despite limited marketing spend. Selling through Sephora has also allowed us to internationalize efficiently due to the synergies within the Sephora ecosystem in terms of common management, terms, and merchandising.</span></div><div style="margin-top:12pt;text-align:center"><img src="wald-20221231_g6.jpg" alt="Image_10.jpg" style="height:393px;margin-bottom:5pt;vertical-align:text-bottom;width:590px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup has an established distribution footprint across Sephora North America. In 2019, Milk Makeup began expanding internationally into Cult Beauty and Sephora Europe, then in 2020 into Sephora Middle East, Selfridges and cross-border into China, and finally in 2021 into Sephora Australia and New Zealand. We believe that we have significant opportunities to increase our sales within our existing footprint, including gains in productivity and distribution expansion, such as Sephora at Kohl&#8217;s, while expanding into high growth international markets such as India. For the 2022 Successor Period, Milk Makeup&#8217;s international retail revenue accounted for a substantial portion of its total net revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup has entered into distribution or vendor agreements with Sephora North America, Sephora Canada, Sephora Middle East and Sephora Australia and New Zealand. Pursuant to those agreements, we grant Sephora the exclusive right to import and distribute our selected products within the territories described in the agreements. In addition, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">those agreements contain a term of exclusivity of up to three years, which can be automatically renewed by either party. Each of these agreements can be terminated without penalty by either party by giving advance written notice to the other party. None of our agreements with Sephora contain any minimum purchase requirements. In early 2023, Milk entered into new amendments with respect to the Sephora agreements that updated certain terms and extended the exclusivity of the Milk brand with Sephora through 2024 in certain of the above regions.   </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November 2023, Milk Makeup was present in approximately 1,400 Sephora locations in the U.S. and 100 in Canada, including Sephora inside JCPenney and Sephora at Kohl&#8217;s locations. In Europe, Milk Makeup was present through Sephora in France, Germany, Spain, Sweden, Denmark, Italy, Poland, Portugal, Switzerland, Greece, the Czech Republic and the Balkans and Turkey. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our e-commerce site, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.milkmakeup.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is a direct-to-consumer, platform that currently ships across the U.S. For the three months ended December 31, 2022, milkmakeup.com accounted for an insignificant portion of our net revenue, and Milk Makeup management currently expects this to increase substantially by 2025 as a percent of overall net sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are actively gauging other e-commerce expansion opportunities across other regions and exploring other channels.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our main competitors are Unilever P.L.C., Coty Inc., e.l.f. Beauty Inc., L&#8217;Or&#233;al S.A., LVMH Moet Hennessy Louis Vuitton SE, The Est&#233;e Lauder Companies Inc., P&amp;G, Revlon Inc. and Shiseido Company, Limited. These companies own both legacy brands as well as younger previously independent brands. Milk Makeup also competes directly with privately held brands, including Pat McGrath Labs, Ilia, Kosas, Rare Beauty, Anastasia Beverly Hills, Huda Beauty, Forma, Saie, Tarte and Tower 28. Ilia, Saie, Kosas and Tarte, which are also clean beauty brands and have partnerships with Sephora, are the key competitors of Milk Makeup. Among other areas, Milk Makeup believes that it competes against other cosmetics brands on price, quality of products and packaging, perceived value, innovation, in-store presence and visibility, and e-commerce and mobile commerce initiatives. Milk Makeup is focused on expanding its market share in the color cosmetics industry and continuing to be a leader in clean make-up.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competitive Strengths</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Authentic Brand with Innovative, Iconic Products</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup is an authentic, culturally relevant brand with an impactful message of empowering our community to live their look and offering effective, vegan, clean, easy-to-use products. Our cruelty-free, globally compliant formulas allow diverse consumers to experiment with their color and find a look that they truly love. Milk Makeup products are designed to have unique and innovative packaging, formula and delivery systems and have proven to have strong market retention and growth, even in an industry that is constantly evolving. We believe that the desire for shared values and effective, clean products will only grow and will position our brand for considerable future growth.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Engaged, Desirable Community</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our community is the heart, soul and inspiration of our brand and a key point of differentiation, both in terms of our ability to resonate with the younger demographic and our content and community capabilities in social media. Our community has been built organically, with fans and users advocating for our brand and products across various social media platforms and introducing others to our products. Since launching, Milk Makeup has built an impressive, inclusive and diverse social media presence, with 2,300,000 followers on Instagram, 13,500,000 likes and 945,000,000 hash-tagged video views on TikTok. 1,320,000 monthly views on Pinterest, 108,000 followers on Facebook, 88,000 subscribers on YouTube and 64,000 followers on X (formerly known as Twitter) as of November 2023. These accounts keep our community engaged with the brand, alert them to new product offerings and allow us to interact directly with our consumers, monitoring any feedback they may have and adjusting our content and investments in accordance. In an age where social media and influencer marketing provide tangible results, we believe that our unique and engaged social media presence provides a competitive edge.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Established Domestic Omni-Channel Platform with Proof Points Internationally</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., Milk Makeup has a leading market position among clean brands in Sephora and a burgeoning direct-to-consumer presence through milkmakeup.com. We also have a growing retail presence across Europe, the Middle East, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Australia, New Zealand and the U.K. We have plans to continue the aggressive expansion of our international footprint. We believe there is considerable opportunity to further increase penetration across all of the markets in which we are currently competing while entering large untapped markets including  Brazil, Mexico and South Asia. Currently, outside of North America, international retail sales of Milk Makeup are highly diversified. For the 2022 Successor Period, Milk Makeup&#8217;s international revenue accounted for a significant portion of its total revenue.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strong Historical Sales Growth with Potential for Future Growth and Gross Margin Expansion</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup historically has experienced strong, double-digit yearly growth in net revenue, including during the years ended December 31, 2022, 2021 and 2020, while improving product margins. We plan to execute margin expansion initiatives, including boosting direct-to-consumer sales and introducing higher margin products. See &#8220;Item 4. Information on the Company&#8212;Growth Opportunities&#8212;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improve Operational Efficiency and Profitability&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for details.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth Opportunities</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grow Customer Base and Brand Awareness</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup has a significant opportunity to increase our customer base and drive higher brand awareness and first purchase as consumers become more educated about our high-quality product offering and strong values around inclusivity and social responsibility. Put into context in terms of ranking, Milk Makeup is one of the top 15 makeup brands today within Sephora U.S. and we believe we can become a strong top 10 brand. Incremental opportunities also exist with Milk Makeup&#8217;s other retail partners such as Cult Beauty and at new potential retailers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several strategic initiatives to drive brand awareness. We plan to leverage the strength of our current media ecosystem (for which we were recognized with multiple awards from various publications) and reinvest in operational efficiencies to increase and improve marketing spend behind further expanding reach. Further, we plan to create collaborations with non-beauty brands to broaden our reach and increase brand appeal to new audiences. These efforts have the ultimate aim of attracting new Millennial customers while building upon the existing resonance with Gen-Z customers.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accelerate Direct-to-Consumer Channel</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To build and accelerate a substantial direct-to-consumer business, Milk Makeup has undertaken several initiatives that we believe will drive increased reach and improved repeat purchase rates and marketing efficiency. These strategic developments will also position the business with a diversified sales mix between e-commerce and retail sales channels. Our core direct-to-consumer initiatives include technological improvements (including website enhancement), optimization of the marketing funnel, development of the e-commerce team, rollout of direct-to-consumer exclusive offerings and building out operations to expand into new markets. We also plan to leverage the Waldencast platform and e-commerce expertise to further accelerate our direct-to-consumer growth.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expand Distribution to New Geographies and, Over Time, Potential New Retailers Domestically and Internationally</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there are several large and meaningful potential retail partnerships in international markets for us to pursue. As compared to our current 100% Sephora door penetration in North America, we have less than 50% door penetration in Sephora stores located in Europe, the Middle East and Australia/New Zealand and have not yet entered Sephora Asia, or Latin America. Entering more Sephora doors internationally and enhancing this key relationship is a significant focus area. Further, Milk Makeup can potentially expand upon our Sephora European brick-and-mortar presence to address untapped opportunities with new channels. New market opportunities also exist for our direct-to-consumer platform, as currently milkmakeup.com only ships products in the U.S. In alignment with our strategy to drive brand awareness, we plan to develop international capabilities that will allow us to service international markets over time. Finally, we have opportunities to expand our retail distribution network over time.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Extend Product Offerings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup plans to leverage our relevance and appeal to introduce new offerings in our product portfolio that both build on existing category strengths such as primer and mascara while addressing new categories. As previously noted, we have established positions in Mascara, Primer, Blush and Bronzer, but also significant opportunity to enter into other categories such as foundation/concealer, lash and brow, lip color and eyeshadow. Further, we are exploring expanding </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further into skincare and possibly entering other categories such as haircare, body, bath and shower and Fragrance over time. Currently, our product portfolio consists of over 330 SKUs. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Improve Operational Efficiency and Profitability</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our clean makeup business gains scale, there are several initiatives in place to drive improved operational efficiency and profitability. Our new cost-of-goods-sold framework, featuring annual negotiations and value analysis on hero SKUs as well as gross margin targets for new products, will facilitate gross margin expansion. Other strategic tactics include annual price increases on key SKUs, further expansion into higher margin categories (complexion and skincare) and an evolving channel mix that is more accretive. To help address rising operating costs, Milk Makeup will continue to undergo forecasting and supply chain optimization projects. With these key developments, we believe that we can continue to scale rapidly and profitably. While the global supply chain disruption is impacting the overall market, we have taken a proactive approach to protect ourselves including increasing stock coverage on our hero products.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leverage Favorable Industry Tailwinds</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup is well-positioned to capitalize on strong and favorable industry tailwinds. With consumer desires shifting towards quality clean, natural and vegan products, over price considerations, we believe that our brand position as an authentic and innovative provider of vegan, clean, cruelty-free products provides us an advantage in addressing these evolving customer dynamics. Additionally, in accordance with broader consumer sentiment focusing on environmental and other environmental, social and governance (&#8220;ESG&#8221;) concerns, we constantly evaluate our packaging for more sustainable options, further reinforcing our credibility as a desirable brand for consumers searching for those attributes. We believe that these consumer desires will only increase over time and that they will help to propel our business as we scale globally.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Values and Commitments </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that a key strength and point of differentiation for us with our community are our shared values and the commitments that we have made to uphold them. Strong ESG scores and values are table stakes for young consumers and mandatory for modern brands. These are present in everything that we do.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8220;Clean&#8221; Products</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From day one, we have always strived to create breakthrough, effective products that are also clean, vegan and cruelty-free. When we launched, we called our product ethos &#8220;cool, clean beauty that works.&#8221; At Milk Makeup, we use the word &#8220;clean&#8221; to describe how we formulate our products. We define &#8220;clean&#8221; using the following five factors:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">No Animal Products and Byproducts: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our products are Leaping Bunny Certified, which means that Milk Makeup does not test on animals at any stage in its supply chain. Additionally, our products have no animal derivatives and are 100% vegan.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Clean&#8221; Ingredients</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;We are dedicated to creating natural products, which means our products will never contain any of the over 2,500 controversial and potentially harmful or irritating ingredients, including parabens, sulfates, BHA, BPA, plastic microbeads, talc, urea, retinyl palmitate, mercury or mercury-containing ingredients, resorcinol, formaldehyde, aluminum salts, and mineral oil. We publish a complete and growing list of ingredients it will never use in our &#8220;Ingredient No List.&#8221;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Natural Products:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Milk Makeup follows ISO 16128 guidelines, where &#8220;natural&#8221; means plant, mineral, and/or microbiologically derived ingredients. We want to bring products that are as natural as possible to our community, while also not compromising on quality and performance. We are always striving to improve, and are currently working toward making new formulas that are over 80% natural.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Ethically Sourced Ingredients</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have committed to ethical and responsible sourcing for our formulas from start to finish. For any products containing mica or palm-derived ingredients, we only use ethically sourced and sustainable mica and sustainability certified palm-derived ingredients. Milk Makeup also exclusively works with cGMP compliant factories.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dedication to More Sustainable Packaging</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our launch, we have focused on creating packaging that is iconic, innovative, easy to use, and pairs perfectly with our formulas. We are also committed to reducing our overall impact on the environment. We recognize that we have a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lot of work to do in this area and are constantly striving to make our packaging more sustainable, starting with new products and continuing on to shipping and partnerships. We are focusing on the following 4 sustainability initiatives:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">More Sustainable Shipping</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Starting in January 2021, we redesigned our e-commerce shipping system and started transporting our products in a new, sustainable shipping box and bag. Our new shipping box is printed with petroleum-free plant-based inks and its inner bag is made from 100% post-consumer waste, both of which are made in the U.S. Both the new box and bag are both 100% recyclable once the adhesive strip on the packaging is removed.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Environmentally Friendly In-Store Packaging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Milk Makeup is working to use less plastic, offer more refills and use more post-consumer resin and recyclable materials on packaging and in-store merchandising, which includes launching new product display systems that use 63% less plastic on average than previous displays, introducing refills where possible, and exploring the use of mono plastic to make recycling easier.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitment to Diversity and Inclusion</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup&#8217;s mission is to empower our community to live their look. We believe in beauty for all, which means we are committed to the importance of diversity, equity and inclusion (&#8220;DE&amp;I&#8221;). This commitment starts by striving to create a workplace where everyone can thrive. We have made five commitments with respect to DE&amp;I within our teams, consumers and partners and we have, and intend to continue to update them on our progress with respect to these commitments every year. These include increasing representation among our teams and partners, educating, communicating and taking action internally to support our DE&amp;I objectives, giving back 1% of our sales from our website to The Center NYC and 1% to the Fashion Scholarship Fund and being accountable by providing updates on our progress every June and December.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Properties</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup&#8217;s corporate headquarters are located in New York, New York, where Milk Makeup occupies facilities totaling approximately 17,500 rentable square feet under a lease that expires November&#160;30, 2030. We primarily use these facilities for corporate offices and as an in-house studio. Additionally, we sublease from Milk Studios Los Angeles LLC certain space in Los Angeles, CA for a fee of $0.015 million per month. We primarily use these facilities for corporate offices and as an in-house studio. Milk Makeup does not own any real property.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of the Milk Makeup business depends on its employees and the culture that attracts them. Milk Makeup has built a team of industry professionals focused on promoting beauty for all. Milk Makeup&#8217;s culture focuses on creativity, self-expression, inclusion, respect and trust. As of December 31, 2022, Milk Makeup had 89 full time employees. None of Milk Makeup&#8217;s employees are represented by a labor organization or are a party to any collective bargaining agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our DE&amp;I initiatives, we are committed to inclusive hiring and interviewing practices Milk Makeup and work with recruitment agencies who represent talent who identify as BIPOC. 38% of Milk Makeup&#8217;s employees identify as BIPOC. Milk Makeup considers its relationships with employees to be vital, and is focused on creating a great place to work through the effective attraction, development, retention of and compensation to human resource talent.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup believes that our intellectual property has substantial value and has contributed significantly to the success of our business. We rely on a combination of trademark, trade dress, copyright and trade secret protection to protect our brands, formulas and other intellectual property. Milk Makeup&#8217;s primary intellectual property includes our brands and trademark rights, including the Milk Makeup brand, which has significant consumer recognition. Milk Makeup&#8217;s trademarks are valuable assets that reinforce the distinctiveness of our brand and customers&#8217; favorable perception of our products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have trademarks registered and applications pending throughout the world for our stylized logos in Australia, Bahrain, Brazil, Canada, China, the EU, Hong Kong, India, Indonesia, Israel, Japan, Kuwait, Malaysia, Mexico, Qatar, Russia, Saudi Arabia, Singapore, South Korea, Thailand, the UAE, the U.K. and the U.S. From time to time, we apply to register trademarks for our other brands in the U.S. and other countries. The registrations of these trademarks in the U.S. and foreign jurisdictions are generally effective for terms of ten years and require periodic renewals, which for our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trademark registrations in the U.S., are presently scheduled between 2027 and 2031. In addition to trademark protection, Milk Makeup owns numerous domain name registrations, including milkmakeup.com. We do not have any issued patents or pending patent applications.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality and Quarterly Results</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup&#8217;s business is subject to moderate seasonal fluctuations driven by retail consumer purchasing habits and timing of purchases by our retail customers. Additionally, the COVID-19 pandemic had an impact on consumer behavior that resulted in temporary changes in the seasonal fluctuations of Milk Makeup&#8217;s business. As a result of moderate seasonal fluctuations, results for any interim period are not necessarily indicative of the results that may be achieved for the full fiscal year. Additionally, because a significant percentage of our net sales are currently concentrated in a limited number of customers, a change in the order pattern or product restocking by one or more of our large retail customers driven by new product launches, new store openings and/or promotions could cause a significant fluctuation of our quarterly results or impact our liquidity.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and products are subject to regulation by governmental authorities including by the U.S. FDA, FTC, CPSC, as well as various other federal, state, local and foreign regulatory authorities. These laws and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulations principally relate to the design, development, manufacturing, processing, handling, testing, holding, storage, quality, safety, shipment, sale, ingredients, labeling, advertising, packaging, marketing, and disposal of our products. Noncompliance with applicable regulations could result in enforcement action by the FDA, FTC, or other regulatory authorities within or outside the U.S., including, but not limited to, product seizures, injunctions, product recalls, and criminal or civil monetary penalties, all of which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FDCA, cosmetics (including personal care products) are defined as articles or components of articles that are applied to the human body and intended to cleanse, beautify, promote attractiveness or alter its appearance, with the exception of &#8220;soap&#8221; as defined by FDA, the regulation of which varies based on its intended use. The labeling of cosmetic products is also subject to the requirements of the FDCA, the&#160;Fair Packaging and Labeling Act, the&#160;Poison Prevention Packaging Act&#160;and other federal, state, and local laws and regulations. Cosmetics are not subject to pre-market approval by the FDA, however, certain ingredients, such as color additives, must be pre-authorized. Significant changes to the regulatory landscape for cosmetic products are anticipated for the coming years as a result of the enactment of MoCRA. Under MoCRA, we will be obligated to adhere to new requirements for cosmetics, such as new labeling standards for specific products, safety substantiation, facility registration, product listing, adverse event reporting, compliance with cGMPs, mandatory recalls and record-keeping requirements for such products and the manufacturing facilities in which they are produced, among other things. We or our CMOs will need to be in compliance with many of the new requirements no later than July 1, 2024. MoCRA requires the FDA to issue regulations governing cGMP for cosmetic manufacturers by December 2025 and additional labeling requirements are expected to go into effect in 2024. We cannot assure you we or that CMOS for all of our products will be able to comply with all of these new regulations in a timely manner or that our CMOs will not decide to pass the increased costs of having to comply with the regulations onto us, which would increase our costs and negatively impact net income.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FTC, FDA and other governmental authorities also regulate advertising and product claims regarding the safety, performance and benefits of our products. These regulatory authorities typically require a safety assessment of the product or ingredient, and reasonable basis to support any marketing claims. As such, product claims must be adequately substantiated. What constitutes a reasonable basis for substantiation of claims can vary widely from market to market, and we cannot assure you that our efforts to support our claims will be considered sufficient. The most significant area of risk for such activities relates to improper or unsubstantiated claims about the use and safety of our products. If the products or any ingredient is or is alleged to be adulterated or misbranded, or if the safety or effectiveness of the products or ingredients has not been adequately substantiated, or if any other product claims lack adequate substantiation or are alleged to be false or misleading, regulators may take enforcement action or impose penalties, such as monetary consumer redress, or consumer lawyers can bring claims or an action against us, including, among other things, seeking damages, an amendment of the claims, and/or injunctive or other equitable relief, such as requiring us to revise our marketing materials, preventing us from making certain claims about the products or ingredients, stop selling certain products, or requiring us to add a specific warning label or disclaimer about the products or ingredients. Any of which could harm our business, financial condition and results of operations. Other warnings or disclaimers may also be mandated pursuant to federal or state laws and regulations. We may also be subject to regulatory action if the FDA or other regulators determine our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, product ingredients, or operations do not comply with any applicable laws or regulations, and we could be required to stop selling, withdraw, recall, re-label or re-package any products on the market.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our advertising for products is also regulated by the FTC under the Federal Trade Commission Act. Cosmetics and personal care products must be advertised and promoted truthfully and otherwise in compliance with state consumer protection laws prohibiting false advertising and unfair or deceptive trade practices. Also, under the federal Lanham Act, competitors and others can initiate litigation relating to advertising claims. A company that is found to have violated these laws may be subject to significant liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities monitor cosmetic products&#8217; regulatory compliance through market surveillance and inspection of cosmetics manufacturers and distributors to ensure, among other things, that the products&#8217; labeling and advertising is not false nor misleading and is compliant with legal requirements, that the products do not contain false nor misleading labeling or harmful ingredients, that they are manufactured under sanitary conditions, or pursuant to cGMPs. Inspections also may arise from consumer or competitor complaints filed with or brought to the attention of regulatory authorities, including FDA or FTC. In the event a regulatory authority or a court identifies false or misleading labeling, unsanitary conditions, harmful ingredients, or otherwise a failure to comply with cGMPs or legal requirements, we may be requested or required by a regulatory authority or required by a court, or we may independently decide to conduct a recall or market withdrawal of our product or to make changes to our manufacturing processes or product formulations, labeling or marketing, which could result in an insufficient amount of our products in the market, impact our sales and/or harm our reputation. Fines or other payments may also be required by a regulator or a court.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the passage of MoCRA, we are also subject to mandatory adverse event reporting requirements for certain of our products, including cosmetics. If we fail to comply with our reporting or adverse event recordkeeping obligations, the FDA could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, seizure of products or delay in approval or clearance of future products. We may also be required to conduct a recall of the products at issue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or other regulators may determine that our products cannot be marketed as is or do not meet the regulatory requirements, including, without limitation with respect to labeling, marketing, or ingredient formulation, for the classification of product in which they are marketed. The FDA may take the position that we failed to satisfy premarket requirements for color additives, or that our products contain otherwise impermissible ingredients, in which case some or all of our products may be deemed adulterated or misbranded in violation of the FDCA. Furthermore, the FDA may determine that one or more of our products has not been accurately classified as cosmetics and should be regulated as a drug, which would require lengthy and expensive clinical trials and be cost prohibitive. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to a number of federal, state and foreign laws and regulations that affect companies conducting business on the Internet, or advertising on social media, including consumer protection regulations that regulate retailers and govern the promotion and sale of merchandise, including by third parties. Many of these laws and regulations are still evolving and being tested in courts, and could be interpreted in ways that could harm our business. These may involve user privacy, data protection, content, intellectual property, distribution, electronic contracts and other communications, competition, protection of minors, consumer protection, telecommunications, product liability, taxation, economic or other trade prohibitions or sanctions and online payment services. In particular, we are subject to federal, state and foreign laws regarding privacy and protection of people&#8217;s data. U.S. federal and state and foreign laws and regulations are constantly evolving and can be subject to significant change. In addition, the application, interpretation and enforcement of these laws and regulations are often uncertain, and may be interpreted and applied inconsistently from country to country and inconsistently with our current policies and practices.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to regulation by the CPSC under the&#160;Consumer Product Safety Act, as amended by the&#160;Consumer Product Safety Improvement Act of 2008. These statutes and the related regulations ban from the market consumer products that fail to comply with applicable product safety laws, regulations, and standards. The CPSC has the authority to require the recall, repair, replacement or refund of any such banned products or products that otherwise create a substantial risk of injury and may seek penalties for regulatory noncompliance under certain circumstances. CPSC regulations also require manufacturers of consumer products to report to the CPSC certain types of information regarding products that fail to comply with applicable regulations. Certain state laws also address the safety of consumer products, and mandate reporting requirements, and noncompliance may result in penalties or other regulatory action.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup is not involved in any material litigation, nor, to management&#8217;s knowledge, was any material litigation threatened against Milk Makeup which if adversely determined could have a material adverse effect on Milk Makeup other than routine litigation arising in the ordinary course of business. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Organizational Structure </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon consummation of the Business Combination, Waldencast became organized in an &#8220;Up-C&#8221; structure, whereby the equity interests of Obagi and Milk are held by Waldencast LP, which is an indirect subsidiary of Waldencast plc. Obagi Holdco 1, a wholly owned subsidiary of Waldencast plc, owns 82.6% of the partnership units in Waldencast LP.  The following table sets out the subsidiaries of Waldencast plc, as of the date hereof. </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Company Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Country of Incorporation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Proportion of Ownership Interest</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Blue Sea Administration Vietnam Company Limited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vietnam</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup Europe, S.L.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Barcelona</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S., Delaware</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup UK Limited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">England &amp; Wales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi AsiaPac Limited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hong Kong</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi Blue Sea Holding, LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cayman Islands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi Cosmeceuticals LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S., Delaware</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi Global Holdings Limited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cayman Islands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi Holdco 1 Limited </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jersey</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi Holdco 2 Limited </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jersey</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi Holdings Company Limited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cayman Islands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi Netherlands B.V.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Netherlands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi Viet Nam Import Export Trading MTV Company Limited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vietnam</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast Cayman LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cayman Islands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast Finco Limited </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jersey</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast Malaysia SDN. BHD.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Malaysia</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast Partners LP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cayman Islands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast Singapore Pte. Ltd.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Singapore</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast UK Operations Limited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">England &amp; Wales</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.6%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Property, Plants and Equipment </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast plc&#8217;s property, plants and equipment are held directly and through Obagi and Milk. Information regarding Waldencast plc, Obagi and Milk&#8217;s property, plants and equipment is described above.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_31"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4A. UNRESOLVED STAFF COMMENTS </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None / Not applicable.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_34"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. WALDENCAST&#8217;S OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis should be read in conjunction with the other sections of this Report, including &#8220;Item 4. Information on the Company,&#8221; and our audited consolidated financial statements and notes thereto found in &#8220;Item 8. Financial Information.&#8221; For purposes of this section, the &#8220;Company,&#8221; &#8220;we,&#8221; or &#8220;our&#8221; refer to (i) Waldencast plc, and its subsidiaries (&#8220;Waldencast&#8221; or the &#8220;Successor&#8221;) for the 2022 Successor Period (July 28, 2022 to December 31, 2022) after the consummation of the Business Combination, unless the context otherwise requires and (ii) Obagi Global Holdings Limited and its subsidiaries (&#8220;Predecessor&#8221;) for the 2022 Predecessor Period (January 1, 2022 to July 27, 2022 ) and the years ended December 31, 2021 and 2020 (each referred to herein as a &#8220;Predecessor Period&#8221;) prior to the consummation of the Business Combination.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion contains forward-looking statements that reflect future plans, estimates, beliefs and expected performance. The forward-looking statements are dependent upon events, risks and uncertainties that may be outside of our control. Our actual results may differ significantly from those projected in the forward-looking statements. Factors that might cause future results to differ materially from those projected in the forward-looking statements include, but are not limited to, those discussed in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; included elsewhere in this Report. Certain amounts may not foot due to rounding. </span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_37"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast, formerly known as Waldencast Acquisition Corp., is a Jersey company. Waldencast, together with its consolidated subsidiaries, is a global multi-brand beauty and wellness platform whose ambition is to build a global best-in-class beauty and wellness multi-brand platform by creating, acquiring and accelerating the next generation of high-growth, purpose-driven brands that can benefit from the Company&#8217;s strong product and brand development capabilities. The first step in realizing our vision was the Business Combination with Obagi and Milk. Our business is organized into two reportable segments&#8212;Obagi Skincare and Milk Makeup.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi Skincare is an industry-leading, advanced skin care line rooted in research and skin biology, refined with a legacy of over 30 years&#8217; experience. Obagi products are designed to diminish the appearance of premature aging, photodamage, skin discoloration, acne, and sun damage. Obagi offers over 200 products through physicians and its website www.obagi.com throughout the U.S. as well as in over 65 countries through international distributors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup is known for its innovative formulas and clean ingredients. The brand creates vegan, cruelty-free, clean formulas from its headquarters in downtown New York City. Currently, Milk offers over 300 products through its U.S. website </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.milkmakeup.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and its retail partners including Sephora in North America, Europe, the Middle East, Australia, Cult Beauty, and ASOS online.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restatement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, management of the Company and the audit committee of Waldencast&#8217;s Board, with the assistance of legal and accounting advisors, conducted an internal review of certain accounting issues related to the recognition of revenue in the Predecessor Periods, including issues related to the recognition of revenue from sales of Obagi products to the SA Distributor in Vietnam, transactions with other Obagi distributors both within and outside the U.S., as well as certain other accounting items. As a result of the review, the Board, upon the recommendation of the audit committee, concluded that financial statements for the years ended December 31, 2020 and 2021, filed with the SEC on August 3, 2022 on Form 20-F (Commission File Number: 001-40207) and amended on Form 20-F/A on August 24, 2022 (Registration Statement No. 333-267053) should no longer be relied upon. For additional information and a detailed discussion of the restatement, see &#8220;Item 8. Financial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information&#8212;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_1097">Not</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_1097">e 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Restatement and Reclassifications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;   </span></div><div><span><br/></span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_40"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Global Events</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the fact that our products are generally considered cosmetic in nature and not covered by health insurance policies, they are typically paid for directly by the consumer out of disposable income. Adverse changes in the economy, such as the increased rates of inflation experienced in the U.S. and many other countries over the past few years, an economic slow-down or recession, or ongoing economic uncertainties, could have a significant negative effect on consumer spending for our products. If consumers reassess their spending choices, the demand for our products could decline significantly.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared COVID-19, a global pandemic and recommended containment and mitigation measures worldwide. During the next two years, COVID-19 disrupted everyday life and markets worldwide, leading to significant business and supply-chain disruptions, as well as broad-based changes in supply and demand. During the first half of 2020, our manufacturing and supply chain for Milk Makeup products and sales of Obagi Skincare and Milk Makeup products were adversely affected because many of our physician customers and retailers such as Sephora remained closed. While most quarantine, social distancing and other regulatory measures instituted or recommended in response to COVID-19 were temporary, the impact of future developments related to COVID-19 or a similar pandemic or epidemic cannot be estimated.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, global or regional conflicts could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions. Military actions and any resulting sanctions could also adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets, particularly if current or new sanctions continue for an extended period of time or if geopolitical tensions result in expanded military operations on a global scale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the impact of current ongoing conflicts have not been material to date,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">long-term effects are uncertain and cannot be predicted with confidence. For additional information on the risks presented by global or regional conflicts, see also &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risk Related to Global Economic, Political and Social Conditions&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global or regional conflicts or uncertainties may adversely affect our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combination</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2022 we consummated the Business Combination with (i) Obagi and Merger Sub pursuant to the Obagi Merger Agreement and (ii), Milk, Holdco 1, Waldencast LP, the Milk Members, and the Equityholder Representative, pursuant to the Milk Equity Purchase Agreement (together with the Obagi Merger Agreement and related ancillary agreements contemplated in such agreement, the &#8220;Transaction Agreements&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the consummation of the Business Combination, Merger Sub merged with and into Obagi and the separate corporate existence of Merger Sub ceased, with Obagi surviving as our indirect subsidiary. At the effective time of the Business Combination all outstanding ordinary shares of Obagi, $0.50 par value (&#8220;Obagi common stock&#8221;) were canceled and exchanged for (i) 28,237,506 Class A ordinary shares of Waldencast and (ii) cash in the amount of $345.4 million.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, upon consummation of the Business Combination, we acquired from the Milk Members all of their equity in Milk in exchange for (i) 21,104,225 Waldencast LP Units (ii) 21,104,225 Class B ordinary shares, which are non-economic voting shares of Waldencast, and (iii) cash in the amount $121.6 million. Each Waldencast LP Unit and Class B ordinary share held by a Milk Member is redeemable at the option of the holder, and, if such option is exercised, exchangeable at the option of Waldencast into one Waldencast Class A ordinary share or cash, in accordance with the terms of our Amended and Restated Waldencast Partners LP Agreement. Upon consummation of the Business Combination, Waldencast became organized in an &#8220;Up-C&#8221; structure, whereby the equity interests of Obagi and Milk are held by Waldencast LP, which is an indirect subsidiary of Waldencast plc. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the consummation of the Business Combination, following the approval of our shareholders, and in accordance with the Cayman Act, the Jersey Companies Laws and our Constitutional Document, we effected a deregistration under the Cayman Act and a domestication under Part 18C of the Jersey Companies Laws (by means of filing a memorandum and articles of association with the Registrar of Companies in Jersey), pursuant to which our jurisdiction of incorporation was changed from the Cayman Islands to Jersey. Upon the effective time of the Domestication, we were renamed &#8220;Waldencast plc.&#8221;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Business Combination, Waldencast was deemed to be the accounting acquirer and has continued as the SEC registrant. Obagi and Milk are the accounting acquirees, however Obagi was considered the predecessor entity for purposes of financial reporting. Accordingly, Obagi&#8217;s financial statements for previous periods are included in this Report as the financial statements of the Company for Predecessor Periods. Under the acquisition method of accounting, Waldencast&#8217;s assets and liabilities retained their carrying values and the assets and liabilities associated with Obagi and Milk have been recorded at their fair values measured as of the acquisition date, which created a new basis of accounting. The excess of the purchase price over the estimated fair values of the net assets acquired has been recorded as goodwill. This change in accounting basis is represented in the accompanying consolidated financial statements by a black line, which appears between the columns entitled &#8220;Successor&#8221; and &#8220;Predecessor&#8221; in the financial statements and in the relevant accompanying notes. The black line signifies that the consolidated financial statements presented for Successor Periods after the acquisition are presented on a measurement basis different from Predecessor Periods. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statement presentation distinguishes Waldencast as the &#8220;Successor&#8221; for reporting periods following the acquisition, or 2022 Successor Period from July 28, 2022 to December 31, 2022, and Obagi as the &#8220;Predecessor&#8221; for the periods prior to the acquisition, including the 2022 Predecessor Period from January 1, 2022 to July 27, 2022 and the years ended December 31, 2021 and 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the Business Combination, Obagi carved out and distributed 100% of the Obagi China Business to its shareholder, Cedarwalk (the &#8220;Obagi China Distribution&#8221;). The Obagi China Distribution did not represent a strategic shift that had major effect on the operational and financial results of Obagi and thus was not reported as a discontinued operation. See &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;7.B. Related Party </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transactions&#8221; for a description of the Obagi China Distribution. Following the Obagi China Distribution, the Obagi China Business continues to be held by Cedarwalk, which also owned 24.5% of the fully diluted Waldencast plc Class A ordinary shares as of the closing of the Business Combination. In connection with the Obagi China Distribution, Obagi Hong Kong, owned by Cedarwalk, entered into the Supply Agreement and IP License Agreement with us, under which it pays us royalties based on its sales of Obagi branded products in the China Region. See &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;7.B. Related Party Transactions&#8221; and &#8220;Item 8. Financial Information&#8212;Note 17. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; to the financial statements for more information regarding related party transactions with Cedarwalk. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Credit Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, the Borrower and Parent Guarantor entered into the 2022 Credit Agreement with the Lenders led by the Administrative Agent. The 2022 Credit Agreement provides the Company with access to a term loan of $175.0 million (the &#8220;2022 Term Loan&#8221;), and a revolving credit capacity with borrowing capacity of up to $50.0 million (the &#8220;2022 Revolving Credit Facility&#8221;), of which an aggregate principal amount of up to $7.5 million may be available, at the Borrower&#8217;s option, to be drawn in the form of letters of credit (&#8220;2022 Letter of Credit&#8221;). A total principal amount of $186.1 million was outstanding under the 2022 Credit Agreement as of the Closing Date (July 27, 2022). </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Borrower entered into a technical amendment to the 2022 Credit Agreement to cure a technical error and clarify when the first amortization payment under the 2022 Credit Agreement is due and payable.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Borrower entered into a waiver and consent agreement with JPMorgan and the required Lenders to, among other things, waive certain defaults or events of default that had or would have resulted from the failure to deliver certain financial information and related reports. In June 2023, the Borrower entered into a subsequent waiver and consent agreement with JPMorgan and the required Lenders, pursuant to which they agreed to, among other things, (a) continue to waive certain defaults or events of default that had or would have resulted from the failure to deliver certain financial information and related reports and (b) suspend the testing of certain financial covenants in the 2022 Credit Agreement.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Borrower entered into a subsequent waiver and consent agreement with JPMorgan and the required Lenders, pursuant to which they agreed to, among other things, (i) waive any default or event of default that has or would result from the failure to deliver the financial information and related reports with respect to the fiscal year of the Borrower ended December 31, 2022 and the fiscal quarters of the Borrower ended March 31, 2023 and June 30, 2023, respectively and (ii) suspend the testing of certain financial covenants set forth in the 2022 Credit Agreement. Such waiver would remain in effect until September 15, 2023.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Borrower and Waldencast Partners LP entered into the second amendment and waiver to the 2022 Credit Agreement (the &#8220;Amendment&#8221;) with JPMorgan and the required Lenders, pursuant to which they agreed to (i) waive any default or event of default that has or would result from (a) the failure to deliver the financial information and related reports with respect to the fiscal year of the Borrower ended December 31, 2022 and the fiscal quarters of the Borrower ended March 31, 2023 and June 30, 2023, respectively, (b) any inaccuracy or misrepresentation in certain historical financial statements previously delivered to JPMorgan and (c) certain historical breaches of the financial covenants and (ii) amend the 2022 Credit Agreement to, among other things, modify the existing financial covenant tests. The Borrower is required to deliver certain of the financial information described in (i)(a) above by December 31, 2023 (the &#8220;Waiver Expiration Date&#8221;). Failure to deliver the required audited financial information and certain other deliverables on or prior to the Waiver Expiration Date will result in an event of default under the 2022 Credit Agreement (unless otherwise waived or extended). The Amendment also (i) included additional restrictions on the Borrower&#8217;s, Waldencast Partners LP's and certain of their subsidiaries&#8217; ability to incur certain types of additional indebtedness, make certain acquisitions and investments, create certain liens, dispose of certain assets and make certain types of restricted payments, (ii) established a minimum liquidity covenant of $15.0 million, which is certified on a monthly basis, and (iii) introduced additional financial reporting obligations, in each case until the earlier of September 30, 2024 or such earlier time that the Borrower elects to test the financial covenants in the same manner as prior to giving effect to the Amendment. As of the date of the issuance of these financial statements, the Company was in compliance with all financial covenants.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Borrower subsequently delivered unaudited financial information and related reports with respect to the fiscal quarters of the Borrower ended March 31, 2023 and June 30, 2023. In December 2023, the Borrower entered into a subsequent waiver and consent agreement with JPMorgan and the required Lenders, pursuant to which they agreed, among </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other things, to waive any default or event of default that has or would result from the failure to deliver the financial information and related reports with respect to the fiscal year of the Borrower ended December 31, 2022. Such waiver shall remain in effect until January 15, 2024. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we fail to comply with the covenants and other terms under the 2022 Credit Agreement and we are unable to negotiate a covenant waiver or replace or refinance the credit agreement on favorable terms, our business, financial condition and results of operations could be materially and adversely impacted. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Term Loan and the 2022 Revolving Credit Facility will mature on July 27, 2026. Borrowings under the 2022 Term Loan were used to, among other things, repay outstanding amounts under, and terminate, the predecessor credit facilities of Obagi and Milk discussed below. For a full discussion of the 2022 Credit Agreement, please see &#8220;Liquidity and Capital Resources.&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Predecessor Credit Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, Obagi entered into a credit agreement (the &#8220;Predecessor 2018 Credit Agreement&#8221;) with a syndicate of lenders including Wells Fargo Bank, National Association (&#8220;Wells Fargo&#8221;) as administrative agent for the lenders. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Obagi replaced the Predecessor 2018 Credit Agreement for a new financing agreement with a syndicate of lenders, including TCW Asset Management Company LLC as administrative agent for the lenders (the &#8220;Predecessor 2021 Credit Agreement&#8221;). The outstanding debt under the Predecessor 2021 Credit Agreement was paid in full in connection with the closing of the Business Combination. For a further discussion of the Predecessor credit agreements, please see &#8220;Item 5. Waldencast&#8217;s Operating and Financial Review and Prospects&#8212;Liquidity and Capital Resources.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PPP Loan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Predecessor received loan proceeds in the amount of $6.8 million under the PPP from MUFG Union Bank. In June 2021, the Predecessor received approval from the SBA and MUFG Union Bank for forgiveness of the full amount of the PPP Loan. In February 2023, we were notified by our lender that the SBA had requested additional documents relating to the PPP Loan. We provided the required documentation and no further communication has been received in response. For further discussion of the PPP Loan, please see &#8220;Liquidity and Capital Resources.&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 PIPE Transaction</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we entered into subscription agreements (the &#8220;2023 Subscription Agreements&#8221;) with certain investors (collectively, the &#8220;2023 PIPE Investors&#8221;), pursuant to, and on the terms and subject to the conditions of which, the 2023 PIPE Investors collectively subscribed for 14,000,000 Class A ordinary shares (the &#8220;2023 PIPE Shares&#8221;) in a private placement at a purchase price of $5.00 each per share, for aggregate gross proceeds of $70.0 million. The 2023 PIPE Investment was anchored by a $50.0 million investment by a Beauty Ventures stakeholder. The remainder of the 2023 PIPE Investors were certain existing shareholders including Cedarwalk, and certain members of the Sponsor, Mr. Brousset and Ms. Sebti. The 2023 Subscription Agreements relating to approximately $68.0 million of proceeds was consummated in September 2023, with the closing of the 2023 Subscription Agreements relating to the remaining approximately $2.0 million occurring in November 2023. For additional information, see &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;7.B. Related Party Transactions.&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction with the SA Distributor and Restatement of Revenues</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, as part of our strategy to internalize distribution channels in key markets, certain of Obagi&#8217;s subsidiaries entered into and consummated the Vietnam Purchase Agreement pursuant to which, among other things, Obagi acquired certain assets of Obagi Vietnam from the SA Distributor and in return, the SA Distributor received forty percent (40%) of the outstanding equity of Obagi Blue Sea Holding, LLC, a subsidiary of Obagi and the parent company of Obagi Vietnam. The Vietnam Purchase Agreement also provided the SA Distributor with a potential earnout payment based upon the net revenue of the business of Obagi Vietnam during the twelve-month period ending on December 31, 2026, subject to setoff for any owed obligations. We currently do not anticipate that any such earnout payment will be payable. The SA Distributor does not currently have any active participation in the Obagi Vietnam business other than as a silent shareholder. Due to non-performance by the SA Distributor of its obligations pursuant to the Vietnam Purchase Agreement and certain other matters, we took further steps in 2023 to restructure the business of Obagi Vietnam by hiring a new local management, finance and sales team to replace the previous SA Distributor team, entering into new online and offline </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distribution agreements with reputable partners and re-applying for all product registrations, which were obtained in June 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the fact that we had a written legal agreement with the SA Distributor, for accounting purposes, it was determined that the SA Distributor revenue should have been recognized when Obagi had no remaining obligations and received substantially all of the consideration related to each purchase order placed by the SA Distributor in accordance with ASC 606. For additional information and a detailed discussion, see &#8220;Item 8. Financial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information&#8212;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_1097">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restatement and Reclassifications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;   </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lock-Up Restrictions</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to a Letter Agreement, dated March 15, 2021, between us and the initial shareholders of Waldencast (as amended, the &#8220;Letter Agreement&#8221;), such shareholders agreed not to transfer, assign or sell any of their sponsor shares until the earlier to occur of: (A) one year after the Closing Date; and (B) following the Closing Date,(x) if the last reported sale price of our Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share sub-divisions, share dividends, rights issuances, consolidations, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within any 30-trading day period commencing at least 150 days after our initial business combination or (y) the date on which we complete a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of our public shareholders having the right to exchange their Ordinary Shares for cash, securities or other property (except with respect to permitted transferees) (the &#8220;Letter Agreement Lock-Up Provisions&#8221;). Any permitted transferees would be subject to the same restrictions and other agreements of the initial shareholders of Waldencast Acquisition Corp. with respect to any sponsor shares. Such Letter Agreement Lock-Up Provisions expired on July 27, 2023. See &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;7.B. Related Party Transactions&#8221; for a description of the Lock-Up restrictions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to the Sponsor FPA (as defined below), Burwell and Zeno agreed not to transfer, assign or sell any of their Class A ordinary shares according to the same Letter Agreement Lock-Up Provisions. Any permitted transferees would be subject to the same restrictions and other agreements as a purchaser under the Sponsor FPA. The Sponsor FPA lock-up period expired on July 27, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Transaction Agreements, at the Closing Date, certain Obagi Shareholders entered into lock-up agreements (the &#8220;Obagi Lock-Up Agreement&#8221;) and certain Milk Members entered into lock-up agreements (the &#8220;Milk Lock-Up Agreements&#8221; and together with the Obagi Lock-Up Agreement, the &#8220;Lock-Up Agreements&#8221;), pursuant to which they agreed not to transfer, assign or sell during the respective Lock-Up Periods, which expired on January 27, 2023 and July 27, 2023, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2023 PIPE Investment, the participating investors agreed to a lock-up of all of their Class A ordinary shares (including those acquired as part of the placement and any shares previously held) pursuant to which 75% of their shares will be locked-up for a one-year period following the applicable PIPE Closing Date and 25% of their shares will be locked-up for a six-month period following the applicable PIPE Closing Date (the &#8220;PIPE Lock-ups&#8221;). See &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;7.B. Related Party Transactions&#8221; for a description of the Lock-Up restrictions.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue is generated through both of our operating segments. Obagi Skincare generates net revenue primarily through product sales and royalties, while Milk Makeup generates net revenue primarily through product sales.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Obagi Skincare segment primarily sells its products to physicians or to consumers via e-commerce platforms (which are considered direct to consumer (&#8220;DTC&#8221;)) or indirectly via our distributors. Product sales revenue is recognized net of provisions for estimated volume rebates and discounts, markdowns, margin adjustments, early-payment discounts, returns and payments to distributors under ASC 606.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., our Obagi Skincare segment sells products to physicians through the Physician Channel Provider, which accounted for a substantial part of our net revenue for the 2022 Successor Period, 2022 Predecessor Period, 2021 Predecessor Period and 2020 Predecessor Period. Under this model, we sell the products to the Physician Channel Provider (&#8220;sell in&#8221;), which then sells the products through to our physician customers when they order them (&#8220;sell through&#8221;). Although the Physician Channel Provider purchases products from us for our physician customers and customers who purchase our products on our e-commerce platform, we maintain control of the product inventory at the Physician Channel Provider&#8217;s warehouse and continue to manage the relationships with these customers, until immediately prior to the sale of the product to the end customer. As a result, control of the products does not transfer to the Physician Channel Provider, and we do not recognize revenue from products sold to the Physician Channel Provider, until immediately prior to sell through to the end customer. See &#8220;Item 8. Financial Information - Note 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restatement and Reclassification</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s&#8221; for more information on recognition of revenue for sales to the Physician Channel Provider. Net revenue from the Physician Channel Provider is considered direct sales revenue. Products sold DTC in the U.S. via our e-commerce platform also represent direct sales revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To a more limited extent, our Obagi Skincare segment also sells products to other distributors in the U.S. for resale to spas and on third-party e-commerce websites. We recognize revenue for product sales to our distributors on a sell in basis upon transfer of the products to such distributors. Sales to other distributors are considered distributor revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internationally, our Obagi Skincare segment sells our products through distributors in over 65 countries across Asia, Europe, Latin America and the Middle East. We typically recognize revenue for product sales to our international distributors upon transfer of the products to the distributors. Sales to international distributors are considered distributor revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Milk Makeup segment sells our products directly to retailers and to distributors who resell products to retailers. Sales directly to retailers are considered direct sales revenue, and sales to distributors are considered distributors revenue. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Obagi China Distribution, we entered into the IP License Agreement, the Supply Agreement, and a Transition Services Agreement (the &#8220;Transition Services Agreement&#8221;) with the Obagi China Business. See &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;7.B. Related Party Transactions&#8221; for a description of the IP License, Supply and Transition Services Agreements. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      Under the IP License Agreement, we granted an exclusive license to certain intellectual property relating to the Obagi brand to Obagi Hong Kong, and we retain the rights to such intellectual property to conduct the Obagi-branded business worldwide except for the China Region. Obagi Hong Kong purchases inventory from the U.S. for resale in the China Region. Additionally, Obagi Hong Kong pays us a royalty of 5.5% of gross sales of licensed products. During the 2022 Successor Period, royalties generated from related party license agreement was $0.2 million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Supply Agreement, we supply, or cause to be supplied through certain of our CMOs, products to Obagi Hong Kong for distribution and sale in the China Region. The term of the Supply Agreement is perpetual, subject to termination for material breach and failure to cure or termination in the event that the IP License Agreement is terminated. We anticipate supplying Obagi Hong Kong directly with products at an agreed-upon markup, until such time as Obagi Hong Kong has been added as a party to our CMO agreements, after which it will obtain products directly from our CMOs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Business Combination, we recognized $22.1 million of a related party liability for the unfavorable discounts provided in the Supply Agreement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The fair value was determined using the present value of after-tax cash flows related to the unfavorable discount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s provided to Obagi Hong Kong. The related party liability is amortized into net product revenue as products are supplied to Obagi Hong Kong. During the 2022 Successor Period, net product revenue generated from supplying products to the Obagi Hong Kong was $17.0 million. See &#8220;Item 8. Financial Information&#8212;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_172">Note </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_172">17</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Transactions.&#8221;</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Obagi Skincare segment also generates royalty revenue from the sale of products in Japan through a strategic licensing agreement with Rohto, a Japanese pharmaceutical manufacturer and distributor that sells a series of OTC and cosmetic products under the Obagi brand name in the Japanese retail skincare channels. Revenue for royalty income is recognized in the period that corresponds to the related Rohto net sales.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold consists primarily of expenses related to inventory, and promotional product costs, including when inventory and promotional products are sold or written down, and product-related intangible asset amortization and depreciation expenses. We allocate product-related intangible asset amortization expense to cost of goods sold. We expect that cost of goods sold will increase in absolute dollars as our revenue grows. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the 2022 Successor Period, cost of goods sold incurred from supplying products to the Obagi China Business was $5.1 million.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General, and Administrative</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative costs (&#8220;SG&amp;A&#8221;) include expenses we incur in the ordinary course of business relating to personnel, including salaries, bonuses and benefits, marketing, office supplies, computer and technology, rent and utilities, insurance, legal and professional fees, city, state and property taxes, and advertising expenses. We expect SG&amp;A expenses to increase in absolute dollars as we continue to invest in building and maintaining our customer base, growing our business, enhancing our brand awareness, hiring additional personnel and upgrading and expanding our systems, processes, and controls to support the growth in our business, as well as our increased compliance and reporting requirements as a public company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Business Combination, we incurred incremental one-time expenses that were SG&amp;A in nature, including legal, consulting, regulatory, accounting, insurance, investor relations and other expenses related to professional fees and certain filing and listing fees. The Sarbanes-Oxley Act, as well as rules adopted by the SEC and Nasdaq, require public companies to implement specified corporate governance practices that have and will likely continue to increase our legal, regulatory, financial and insurance compliance costs following the Business Combination. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all R&amp;D expenses are related to new product development and design improvements in current products. R&amp;D costs consist primarily of employee-related costs, including salaries, bonuses, and benefits, as well as clinical testing and consumer validation testing. We plan to continue to invest in our R&amp;D efforts. As a result, we expect that R&amp;D expenses will remain stable or increase in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Depreciation and Amortization</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses are related to our property and equipment and intangible assets. Product-related intangible asset amortization is presented in cost of goods sold in the consolidated statement of operations and comprehensive loss. Depreciation and amortization expenses not classified in cost of goods sold are presented in SG&amp;A expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on Impairment of Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of goodwill recognizes the difference between the carrying value and fair value of goodwill. The process of evaluating goodwill for impairment is subjective and requires significant judgment and estimates. At least annually, and more frequently if events and circumstances exist that would more likely than not reduce the fair value of a reporting unit below its carrying amount, we test goodwill for impairment. This is performed first though an optional qualitative assessment and then, if indicators of impairment exist, through a quantitative assessment. When performing the optional qualitative analysis, we consider many factors including general economic conditions, industry and market conditions, financial performance, key business drivers, and long-term operating plans. </span></div><div style="text-align:justify"><span><br/></span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_58"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The 2022 Successor Period, 2022 Predecessor Period and 2021 Predecessor Period</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When reading our financial statements and information on historical financial results in this Report, you should note there is a clear division between the Predecessor Periods and Successor Periods. The predecessor and successor results shown are not comparable as the Predecessor Periods include only Obagi, which includes the Obagi China Business that was not acquired by Waldencast. The Successor Period includes the consolidated financial statements of Waldencast, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which include Obagi and Milk. In addition, the 2022 Successor Period includes only five months of operations, whereas the 2022 Predecessor Period includes seven months of operations (the &#8220;2022 Period Time Discrepancy&#8221;). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our consolidated statements of operations data, in dollars for the 2022 Successor Period, 2022 Predecessor Period and fiscal year ended December 31, 2021 Predecessor Period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.997%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.986%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Waldencast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Obagi)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From July 28,<br/>2022 to<br/>December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From January 1,<br/>2022 to July 27, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue (including related party net revenue of $17,219 in the Successor Period)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">92,373</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">73,760</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">142,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold (including related party costs of $5,128 in the Successor Period)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">31,716</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">42,892</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,435</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">159,437</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">58,155</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">89,060</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(127,721)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(15,263)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,625)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,793)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on PPP Loan forgiveness</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on write-off of loan receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(971)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total other (income) expenses, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,361)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5,681</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,349</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(126,360)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(20,944)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(120,557)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(21,057)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,576)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Revenue</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide our disaggregated revenue for the periods presented:</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Waldencast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Obagi)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From July 28, 2022 to<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From January 1,<br/>2022 to July 27, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Sales Channel</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,729&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,759&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,760&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue (including related party net revenue of $17.2 million in distributor sales) was $92.4 million for the 2022 Successor Period. Net revenue for the 2022 Predecessor Period and 2021 Predecessor Period was $73.8 million and $142.5 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in direct sales in the 2022 Successor Period as compared to the 2022 Predecessor Period was primarily attributable to net revenue of $30.2 million generated by the Milk Makeup segment, which was acquired in the 2022 Successor Period and therefore, not presented in the 2022 Predecessor Period. The increase was offset partially by the 2022 Period Time Discrepancy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in distributor sales in the 2022 Successor Period was primarily due to the 2022 Period Time Discrepancy. In addition, sales to the SA distributor decreased in the 2022 Successor period as a result of various challenges it faced during that period. Other factors such as pricing and customers composition have remained relatively consistently between the two periods.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi Skincare also generates royalty revenue from products sold under the Obagi name in Japan and Hong Kong through license agreements. The decrease in royalty revenue in the 2022 Successor Period as compared to the 2022 Predecessor Period was attributable to the 2022 Period Time Discrepancy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in sales across all channels in the 2022 Predecessor Period as compared to the 2021 Predecessor Period was attributable to the fact that the 2022 Predecessor period only includes seven months, whereas the 2021 Predecessor Period includes twelve months.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the decrease in distributor revenue was driven by lower demand by spa customers and lower sales to the SA Distributor.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Waldencast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Obagi)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From July 28, 2022 to<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From January 1,<br/>2022 to July 27,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Geographic Region</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">North America</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of the World</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,729&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,759&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,760&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from North America was $56.6 million for the 2022 Successor Period, $44.4 million for the 2022 Predecessor Period and $79.1 million for the 2021 Predecessor Period. Net revenue from the Rest of the World was $33.8 million for the 2022 Successor Period, $26.3 million for the 2022 Predecessor Period, and $57.6 million for the 2021 Predecessor Period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in net revenue from North America and the Rest of the World in the 2022 Successor Period as compared to the 2022 Predecessor Period was primarily attributable to the net revenue generated in the Milk Makeup segment from North America and the Rest of the World of $22.6 million and $8.7 million, respectively. As Milk Makeup was acquired in the 2022 Successor Period, its revenue is not included in the 2022 Predecessor Period. The increase was offset partially by the 2022 Period Time Discrepancy. Net revenue to the Physician Channel Provider in North America remained consistent. Net Revenue to the SA Distributor in the Rest of the World decreased in the 2022 Successor Period due to various challenges it faced during that time period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in net revenue from North America and the Rest of the World in the 2022 Predecessor Period as compared to the 2021 Predecessor Period was primarily attributable to the 2022 Predecessor Period representing seven months of operations and the 2021 Predecessor Period representing twelve months of operations.  In addition, the decrease was driven by lower sales to the SA Distributor.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Waldencast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Obagi)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From July 28, 2022 to<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From January 1,<br/>2022 to July 27,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold (including related party costs of $5.1 million in the Successor Period)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">as a percentage of net revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold (including related party costs of $5.1 million for supplying products to the Obagi China Business) was $60.7 million for the 2022 Successor Period. Cost of goods sold for the 2022 Predecessor Period and 2021 Predecessor Period was $30.9 million and $55.0 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold for the 2022 Successor Period of $60.7 million primarily consisted of (i) standard cost of goods sold to customers of $34.8 million (ii) depreciation and amortization of product-related assets and supply agreements of $4.8 million, (iii) freight and inventory inspection costs of $1.7 million, (iv) amortization of the inventory fair value step-up related to the Business Combination of $10.0 million; and (v) inventory reserve provisions and write-offs of $8.1 million. Cost of goods sold in the 2022 Predecessor Period of $30.9 million primarily consisted of (i) standard cost of goods sold to customers of $23.5 million, (ii) depreciation and amortization of product-related assets and supply agreements of $2.7 million, and (iii) freight and inventory inspection costs of $2.3 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in cost of goods sold from the 2022 Predecessor Period to the 2022 Successor Period was primarily attributable to the acquisition of Milk Makeup. In addition, a significant  fair value step up in inventory was recognized in cost of goods sold over inventory turns for both reporting segments in the 2022 Successor Period. This contributed to a $10.0 million increase in cost of goods sold and any remaining unamortized fair value step up will be fully recognized in the first three months of 2023. Further, we recorded an inventory write-down of $8.1 million in the 2022 Successor Period for excess inventory.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, cost of goods sold as a percentage of revenue for the 2022 Successor Period increased significantly as a result of higher shipments to the SA Distributor as cost of goods sold was recognized based on shipping terms while revenue was only recognized when the cash payments related to completed purchase orders were collected in full.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold for the 2021 Predecessor Period of $55.0 million primarily consisted of (i) standard cost of goods sold to customers of $47.0 million, (ii) depreciation and amortizations of product-related assets and supply agreements of $4.7 million, and (iii) freight and inventory inspection costs of $3.0 million. The decrease in cost of goods sold in the 2022 Predecessor Period as compared to the 2021 Predecessor Period was attributable to the fact that the 2022 Predecessor Period included only seven months of operations as compared to the 2021 Predecessor Period, which included twelve months of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Waldencast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Obagi)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From July 28, 2022 to<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From January 1,<br/>2022 to July 27,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">as a percentage of net revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expense was $88.9 million for the 2022 Successor Period, $55.5 million for the 2022 Predecessor Period and $83.0 million for the 2021 Predecessor Period.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expense for the 2022 Successor Period of $88.9 million primarily consisted of (i) employee related compensation including stock-based compensation of $33.0 million (ii) depreciation and amortization expense of $22.2 million, (iii) office and administrative expenses of $10.8 million (iv) transaction costs of $9.4 million (v) selling, marketing, and distribution costs of $8.3 million, and (vi) professional consulting and legal services of $4.4 million. This is compared to SG&amp;A expense for the 2022 Predecessor Period of $55.5 million, which primarily consisted of (i) employee related compensation of $27.0 million, (ii) selling, marketing, and distribution costs of $8.5 million, (iii) depreciation and amortization expense of $5.5 million, (iv) office and administrative expenses of $6.1 million (v) transaction costs associated with executing the Business Combination of $5.2 million and (vi) professional consulting and legal services of $2.4 million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in SG&amp;A expense in 2022 Successor Period as compared to the 2022 Predecessor Period was primarily attributable to the acquisition of Milk Makeup in the 2022 Successor Period, which resulted in (i) an increase in depreciation and amortization as a result of new fair value basis of long-lived assets following the Business Combination, (ii) increase in salaries and other employee costs, (iii)  increase in office and administrative expenses from additional costs related to product liability insurance for the additional operating segment, and (iv) one time transaction costs including legal and other professional expenses. The increase was further driven by stock based compensation recorded in the 2022 Successor Period that was not present in the 2022 Predecessor Period. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expense for the 2021 Predecessor Period of $83.0 million primarily consisted of (i) employee related compensation of $45.0 million, (ii) selling, marketing, and distribution costs of $9.6 million, (iii) depreciation and amortization expense of $9.2 million, (iv) transaction costs and other professional fees of $9.1 million, and (v) office and administrative expenses of $8.9 million. The decrease in SG&amp;A expense in the 2022 Predecessor Period as compared to the 2021 Predecessor Period was primarily attributable to the 2022 Predecessor Period including only seven months of operations as compared to the 2021 Predecessor Period that included twelve months of operations. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Waldencast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Obagi)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From July 28, 2022 to<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From January 1,<br/>2022 to July 27,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">as a percentage of net revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expense for the 2022 Successor Period of $1.8 million primarily consisted of salaries and other employee related costs of $0.9 million and R&amp;D expenses, including product development and licensing costs of $0.5 million as compared to R&amp;D expense in the 2022 Predecessor Period of $2.6 million, which primarily consisted of salaries and other employee related costs of $1.3 million and R&amp;D expenses including product development and licensing costs of $0.6 million. The decrease was primarily driven by 2022 Period Time Discrepancy.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> R&amp;D expense in the 2021 Predecessor Period of $6.1 million primarily consisted of salaries and other employee related costs of $2.2 million and R&amp;D expenses including product development and licensing cost of $3.3 million. The decrease in R&amp;D expense in the 2022 Predecessor Period as compared to the 2021 Predecessor Period was driven by a decrease in R&amp;D spend prior to the Business Combination and the fact that the 2022 Predecessor Period includes only seven months of operations as compared to the 2021 Predecessor Period that includes twelve months of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on Impairment of Goodwill</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Waldencast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Obagi)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From July 28, 2022 to<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From January 1,<br/>2022 to July 27,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on Impairment of Goodwill</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of goodwill recognizes the difference between the carrying value and fair value of goodwill. The process of evaluating goodwill for impairment is subjective and requires significant judgment and estimates. At least annually, and more frequently if events and circumstances exist that would more likely than not reduce the fair value of a reporting unit below its carrying amount, we test goodwill for impairment. This is performed first through an optional qualitative assessment and then, if indicators of impairment exist, through a quantitative assessment. When performing the optional qualitative analysis, we consider many factors including general economic conditions, industry and market conditions, financial performance, key business drivers, and long-term operating plans. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Successor Period, in addition to the factors mentioned above, management considered whether the restated historical financial performance of the Obagi Skincare segment as well as the resulting changes to its projected future cash flows as compared to the projections used when we consummated the Business Combination, provided additional indicators that the fair value of the Obagi Skincare segment was less than its carrying value immediately following the Business Combination. Through a qualitative analysis, we determined that it was more likely than not that the fair value of the reporting unit associated with the Obagi Skincare segment was less than its carrying amount and a quantitative analysis was performed, at an interim date. As a result, the Company recorded a non-cash goodwill impairment charge of $68.7 million during the 2022 Successor Period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, net</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Waldencast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Obagi)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From July 28, 2022 to<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From January 1,<br/>2022 to July 27,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">as a percentage of net revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $6.2 million for the 2022 Successor Period, $6.7 million for the 2022 Predecessor Period, and $11.1 million in the 2021 Predecessor Period. Interest expense remained consistent in the 2022 Successor and 2022 Predecessor Period. The decrease in interest expense in the 2022 Predecessor Period as compared to the 2021 Predecessor Period was attributable to the fact that the 2022 Predecessor Period represents only seven months of operations as compared to the 2021 Predecessor Period that represents twelve months of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had unpaid principal of $170.7 million and $14.1 million on the 2022 Term Loan and the 2022 Revolving Credit Facility, respectively, with a weighted average interest rate of 6.6% outstanding under the 2022 Credit Agreement. As of July 27, 2022, Obagi had unpaid principal of $128.8 million, with an interest rate of 8.5% outstanding under the Predecessor 2021 Credit Agreement, which was paid in full in connection with the closing of the Business Combination. As of December&#160;31, 2021 (Predecessor Period), the Company had unpaid principal of $124.2 million with an interest rate of 8.5%.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on Extinguishment of Debt</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Waldencast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Obagi)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From July 28, 2022 to<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From January 1,<br/>2022 to July 27,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No loss on extinguishment of debt was recorded in the 2022 Successor Period or the 2022 Predecessor Period. Loss on extinguishment of debt for the 2021 Predecessor Period was $2.3 million related to the write-off of previously deferred financing costs due to the refinancing of Obagi&#8217;s debt in March 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Derivative Warrant Liabilities </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Waldencast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Obagi)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From July 28, 2022 to<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From January 1,<br/>2022 to July 27,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,793)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities for the 2022 Successor Period was $6.8 million related to the remeasurement of the fair value of the warrants at the end of the reporting period following the Business Combination. No change in fair value of derivative warrant liabilities was recorded for 2022 Predecessor Period or for the 2021 Predecessor Period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on PPP Loan Forgiveness</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Waldencast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Obagi)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From July 28, 2022 to<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From January 1,<br/>2022 to July 27,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on PPP loan forgiveness</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,824)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No gain on PPP Loan forgiveness was recorded for the 2022 Successor Period and 2022 Predecessor Period. For the 2021 Predecessor Period, the Predecessor recognized a gain of $6.8 million associated with the forgiveness of the PPP Loan borrowed in 2020. See &#8220;Item 8. Financial Information&#8212;Note 8. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on Write-off of Loan Receivable</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Waldencast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Obagi)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From July 28, 2022 to<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From January 1,<br/>2022 to July 27,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on write-off of loan receivable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No Loss on write-off of loan receivable was recorded for the 2022 Successor Period and the 2022 Predecessor Period and $2.6 million was recorded for the 2021 Predecessor Period.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Waldencast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Obagi)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From July 28, 2022 to<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From January 1,<br/>2022 to July 27,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(798)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(971)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(817)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense (income), net was $0.8 million for the 2022 Successor Period and $1.0 million for the 2022 Predecessor Period. These amounts consisted primarily of losses related to foreign currency translation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offset by general interest income. Other expense (income) remained consistent from the 2022 Predecessor Period to the 2022 Successor Period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax (Benefit) Expense </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Waldencast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Obagi)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From July 28, 2022 to<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From January 1,<br/>2022 to July 27,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (benefit) expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,803)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effective tax rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(96.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit was $5.8 million for the 2022 Successor Period, with a corresponding effective tax rate of 4.6% compared to an income tax expense of $0.1 million for the 2022 Predecessor Period, with a corresponding effective tax rate of (0.6)%. The change in the effective tax rate was driven by the change in pre-tax earnings. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense was $9.6 million for the 2021 Predecessor Period, with a corresponding effective tax rate of (96.3)%. During the 2022 Predecessor Period, the Company recognized a valuation allowance of $14.1 million to account for the portion of the deferred tax asset that was more likely than not to not be realized due to a cumulative loss incurred in Obagi&#8217;s U.S. subsidiary over the three-year period ended July 27, 2022 (Predecessor Period), change in pre-tax earnings, and non-deductible transaction costs.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_61"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December 31, 2021 and 2020 (Predecessor Periods)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize our consolidated statements of operations data, in dollars for the 2021 Predecessor Period and the 2020 Predecessor Period, and the dollar and percentage change between the respective years.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Obagi)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 v. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net revenue </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">142,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">94,428</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">48,044</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">50.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">87,435</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">65,332</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22,103</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">33.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">89,060</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">64,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">24,256</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">37.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating (loss) income </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,625)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,153)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(407.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,118&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,837&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on PPP Loan forgiveness</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on write-off of loan receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n.m.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total other (income) expenses, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,349</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,057</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">32.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4,210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">73.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (benefit) expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(382.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,576)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,370)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(17,206)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">726.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n.m. = not meaningful</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide our revenue by sales channel, as well as by revenue source and geographic region (based on the location of the end customer), for the periods presented.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor <br/>(Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 v. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Sales Channel</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,759&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,524&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,235&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue was $142.5 million and $94.4 million for the 2021 Predecessor Period and 2020 Predecessor Period, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in direct sales in the 2021 Predecessor Period as compared to the 2020 Predecessor Period was primarily attributable to an increase in sales to the Physician Channel Provider and DTC in the U.S. via our e-commerce platform as many restrictions imposed by the COVID-19 pandemic were no longer in place. The increase in distributor sales was primarily driven by an increase in sales to the SA Distributor and other international distributors as well as lower sales in the 2020 Predecessor Period due to COVID-19. The Predecessor also generated royalty revenue from products sold under the Obagi name in Japan through license agreements. Royalty revenue was consistent in the 2021 Predecessor Period as compared to the 2020 Predecessor Period.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor<br/>(Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 v. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Geographic Region</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">North America</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of the World</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,759&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,524&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,235&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,044&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from North America was $79.1 million and $64.0 million for the 2021 Predecessor Period and 2020 Predecessor Period, respectively. Net revenue from the Rest of the World was $57.6 million and $24.5 million for the 2021 Predecessor Period and the 2020 Predecessor Period, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in net revenue from North America and the Rest of the World in the 2021 Predecessor Period as compared to the 2020 Predecessor Period was primarily attributable to an increase in sales to the Physician Channel Provider and DTC via our e-commerce platform in North America and an increase in sales to the SA Distributor and other international distributors in the Rest of the World.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor<br/>(Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 v. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">as a percentage of net revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold was $55.0 million and $29.1 million for the 2021 Predecessor Period and 2020 Predecessor Period, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold for the 2021 Predecessor Period of $55.0 million primarily consisted of (i) inventory cost of goods sold to customers of $47.0 million (ii) depreciation and amortization of product-related assets and supply agreements of $4.7 million, and (iii) freight and inventory inspection costs of $3.0 million. This compares to cost of goods sold in the 2020 Predecessor Period of $29.1 million, which primarily consisted of (w) inventory cost of goods sold to customers of $20.1 million, (x) depreciation and amortization of product-related assets and supply agreements of $4.7 million, (y) freight and inspection of inventory costs of $1.9 million and (z) inventory reserve provisions and write-offs of $1.3 million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in cost of goods sold was primarily attributable to the increase in customer demand in 2021 Predecessor Period. In addition, cost of goods sold as a percentage of revenue increased significantly due to the increase in cost of goods sold and the decrease in revenue related to the SA distributor as the Predecessor only recognized revenue to the SA distributor when the cash payments related to completed purchase orders were collected in full. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor<br/>(Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">as a percentage of net revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expense was $83.0 million and $60.4 million for the 2021 Predecessor Period and the 2020 Predecessor Period, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expense for the 2021 Predecessor Period of $83.0 million primarily consisted of (i) employee related compensation of $45.0 million, (ii) selling, marketing, and distribution costs of $9.6 million, (iii) depreciation and amortization expense of $9.2 million, (iv) transaction costs and other professional fees of $9.1 million, and (v) office and administrative expenses of $8.9 million. This is compared to SG&amp;A expense for the 2020 Predecessor Period of $60.4 million, which primarily consisted of (i) employee related compensation of $35.5 million, (ii) depreciation and amortization expense of $8.8 million, (iii) selling, marketing, and distribution costs of $6.8 million (iv) office and administrative expenses of $5.2 million  and (v) professional fees of $1.8 million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in SG&amp;A expense in 2021 Predecessor Period as compared to the 2020 Predecessor Period was primarily attributable to the increase in selling, marketing and distribution costs and transaction costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor<br/>(Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,092&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">as a percentage of net revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> R&amp;D expense was $6.1 million and $4.4 million for the 2021 Predecessor Period and the 2020 Predecessor Period, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expense for the 2021 Predecessor Period of $6.1 million primarily consisted of salaries and other employee related costs of $2.2 million and R&amp;D expenses including product development and licensing cost of $3.3 million as compared to R&amp;D expense in the 2020 Predecessor Period of $4.4 million, which primarily consisted of salaries and other employee related costs of $2.4 million and R&amp;D expenses including product development and licensing cost of $1.6 million. The increase was primarily driven by an increase in R&amp;D spend in the 2021 Predecessor Period.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, net</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor<br/>(Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">as a percentage of net revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased by $4.8 million or 77.0% for the 2021 Predecessor Period compared to the 2020 Predecessor Period. The increase was primarily due to refinancing of Obagi&#8217;s debt in March 2021 at higher interest rates, as well as additional borrowings incurred from Wells Fargo in the latter half of the 2020 fiscal year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on Extinguishment of Debt</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor<br/>(Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,317&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss on extinguishment of debt for the 2021 Predecessor Period was primarily related to the write-off of previously deferred financing costs due to the refinancing of Obagi&#8217;s debt in March 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on PPP Loan Forgiveness</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor<br/>(Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on PPP Loan Forgiveness</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,824)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,824)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the 2021 Predecessor Period, we recognized a gain of $6.8 million associated with the forgiveness of the PPP Loan borrowed in 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on Write-off of Loan Receivable</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor<br/>(Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on write-off of loan receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,555&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the 2021 Predecessor Period, we recognized a loss on write-off of loan receivable of $2.6 million and did not recognize a loss in the 2020 Predecessor Period.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Income) Expense, Net</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor<br/>(Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(817)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(828)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n.m.</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income was $0.8 million for the year ended December 31, 2021. This amount consisted primarily of $0.2 million of losses related to foreign currency translation and $1.0 million of general interest income.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses for the year ended December 31, 2020 was immaterial.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income for the year ended December 31, 2021 increased by $0.8 million compared to the same period in 2020, primarily driven by an increase in general interest income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax (Benefit) Expense </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor<br/>(Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (benefit) expense </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,394)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(382.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effective tax rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(96.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense was $9.6 million for the 2021 Predecessor Period, with a corresponding effective tax rate of (96.3)%, compared to an income tax benefit of $3.4 million for the 2020 Predecessor Period, with a corresponding effective tax rate of 58.9%. The change in effective tax rate was primarily driven by the change in pre-tax earnings, change in valuation allowance, and forgiveness of our Paycheck Protection Program loan.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our results of operations and measures of performance determined in accordance with U.S. GAAP, we believe that certain non-GAAP financial measures are useful in evaluating and comparing our financial and operational performance over multiple periods, identifying trends affecting our business, formulating business plans, and making strategic decisions, as they are similar to measures reported by our public competitors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted gross margin and adjusted EBITDA are key performance measures that our management uses to assess our financial performance and for internal planning and forecasting purposes. Adjusted gross margin and adjusted EBITDA are not intended to be substitutes for any GAAP financial measures and, as calculated, may not be comparable to other similarly titled measures of performance of other companies in other industries or within the same industry. Additionally, investors should not solely rely on our non-GAAP financial measures as they do not reflect our current or future cash requirements and working capital needs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are limitations to non-GAAP financial measures because they exclude charges and credits that are required to be included in GAAP financial presentation. The items excluded from GAAP financial measures such as net income/loss to arrive at non-GAAP financial measures are significant components for understanding and assessing our financial performance. Non-GAAP financial measures should be considered together with, and not alternatives to, financial measures prepared in accordance with GAAP.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adjusted Gross Profit and Adjusted Gross Margin</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define and calculate Adjusted gross profit as GAAP gross profit which excludes the impact of inventory fair value adjustments and the amortization of the fair value of the related party liability to Obagi China, which management believes is not reflective of core operating performance given the nature, size and non-recurring nature of the Business Combination, see &#8220;Item 8. Financial Information&#8212;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_127">Note </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_127">4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. We define and calculate Adjusted Gross Margin as Adjusted gross profit as a percentage of net revenue. We adjust for these items because we do not believe they reflect normal, recurring activity, may obscure underlying business trends and make comparisons of long-term performance challenging. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents our Adjusted gross profit and Adjusted gross margin reconciled to our gross profit and gross margin, the closest GAAP measures for the periods indicated:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Period from July 28<br/>to December 31<br/>(Successor)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands except for percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Obagi</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Milk</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Waldencast (Total)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net revenue (including related party net revenue of $17,219) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross Profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross Margin %</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross Margin Adjustments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of the fair value of the related party liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of the inventory fair value adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted Gross Profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted Gross Margin %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adjusted EBITDA and Adjusted EBITDA Margin </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define and calculate adjusted EBITDA as GAAP net income (loss) before interest income or expense, income tax (benefit) expense, depreciation and amortization, and further adjusted for the items as described in the reconciliation below. We believe this information will be useful for investors to facilitate comparisons of our operating performance and better identify trends in our business. We define and calculate adjusted EBITDA Margin as adjusted EBITDA as a percentage of net revenue. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA excludes certain expenses that are required to be presented in accordance with GAAP because management believes they are non-core to our regular business. These include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.2pt">Non-cash expenses, such as depreciation and amortization, stock-based compensation, inventory fair value adjustments, the amortization of fair value of the related party liability to Obagi China, change in fair value of financial instruments, loss on impairment of goodwill, and foreign currency transaction loss (gain); </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interest expense and income tax expense;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expenses that are not related to our underlying business performance, such as:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Transaction-related costs which includes mainly legal expenses in connection with the Business Combination, including creating and maintaining the Up-C structure, as well as advisory and consulting fees;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The gain on PPP Loan forgiveness which relates to the forgiveness of the full amount of a PPP Loan in June 2021; </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Loss on extinguishment of debt, and loss on write-off of loan receivables which relates to the write-off of previously deferred financing costs due to the refinancing of Obagi&#8217;s debt in March 2021 and the write-off of a loan receivable in 2021 that was later deemed uncollectible;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Gains/losses on disposal of assets; </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.17pt">Restructuring costs which relates to the relocation costs associated with the relocation of Obagi&#8217;s headquarters from California to Texas in 2022.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents our adjusted EBITDA reconciled to our net income (loss), the closest GAAP measure for the periods indicated:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.839%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.842%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Period from July 28<br/>to December 31<br/>(Successor)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Period from January 1 to July 27 (Predecessor)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year ended December 31 (Predecessor)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands except for percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Obagi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Milk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Central costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Waldencast (Total)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Obagi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Obagi</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(93,757)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(13,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(13,027)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(120,557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(21,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(19,576)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted For:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income tax (benefit) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transaction-related costs (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">COGS impact related to Inventory fair value adjustment (2) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities (3) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,793)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,793)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value of interest rate collar (4) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of  related party liability (5) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12,186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency transaction loss (gain) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(510)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Gain) loss on disposal of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restructuring costs (6) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on extinguishment of debt (7) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gain on PPP Loan forgiveness (8) </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on write-off of loan receivable (9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on impairment of goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,857)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(241)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,929)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16,027)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">95&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net Loss % of Net Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(153.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(44.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(130.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(28.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(13.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Adjusted EBITDA Margin</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(17.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes mainly legal expenses in connection with the Business Combination, including creating and maintaining the Up-C structure, as well as advisory and consulting fees.</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the amortization of the inventory fair value step-up as a result of the Business Combination.</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to change in fair value of warrant liabilities and not definitively related to operations.</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Relates to interest rate collar and not definitively related to operations.</span></div><div style="margin-top:2pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the fair value of the related party liability for the unfavorable discount to Obagi China as part of the Business Combination.</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the relocation costs associated with the relocation of Obagi&#8217;s headquarters from California to Texas.</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the write-off of previously deferred financing costs due to the refinancing of Obagi&#8217;s debt in March 2021.</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the forgiveness of the full amount of a PPP Loan in June 2021.</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the write-off of a loan receivable in 2021 that was later deemed uncollectible.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure liquidity in terms of our ability to fund the cash requirements of our business operations, including working capital needs, capital expenditures, contractual obligations, debt service, acquisitions, and other commitments with cash flows from operations and other sources of funding. Our principal sources of capital and liquidity are proceeds from the Business Combination, including additional financing and 2022 PIPE Investment, as well as our borrowings from banks and cash flows from operations. In June 2022, the Borrower entered into the 2022 Credit Agreement with the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lenders led by the Administrative Agent. See &#8220;Item 5. Waldencast&#8217;s Operating and Financial Review and Prospects&#8212;Recent Events&#8221; for further information on the 2022 Credit Agreement. The 2022 Credit Agreement provides the Company with the 2022 Term Loan of $175.0 million and 2022 Revolving Credit Facility of $14.1 million, with a borrowing capacity up to $50.0 million, for a total outstanding balance of $186.1 million at the Closing Date (July 27, 2022). The proceeds from the FPA and PIPE investments, along with the proceeds from the Term Loan and Revolving Credit Facility, were primarily used for the $587.7 million of consideration paid, net of cash acquired, for the Obagi and Milk Business Combinations, as well as for debt issuance costs of $6.3 million, to settle the outstanding balance on the Predecessor 2021 Credit Agreement of $4.3 million, and for cash used for working capital needs, including transaction-related expenses. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the temporary loss in demand for Obagi products and drop in revenue early in the COVID pandemic, Obagi drew on the Predecessor 2018 Revolving Credit Facility, (as defined below) and increased its borrowing capacity by $10.0 million. Obagi also secured a $6.8 million PPP Loan, which was used in accordance with the PPP requirements and for which forgiveness was obtained in the second quarter of 2021. Overall, these financing activities resulted in net cash inflow of approximately $16.4 million in 2020 (excluding $2.0 million of dividends to Obagi&#8217;s then shareholder). In March 2021, Obagi was able to access additional credit by replacing the Predecessor 2018 Credit Agreement with the Predecessor 2021 Credit Agreement from a new syndicate of lenders. The Predecessor 2021 Credit Agreement included a term loan of $110.0 million and a revolving credit facility with borrowing capacity of up to $40.0 million. Obagi recorded a loss on termination of the Predecessor 2018 Credit Agreement of $2.3 million to loss on extinguishment of debt in the accompanying consolidated statement of operations and comprehensive loss during the 2021 Predecessor Period, which consisted of expensing unamortized debt issuance costs. The outstanding balance under the Predecessor 2021 Credit Agreement was paid in full upon the completion of the Business Combination. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect capital and operating expenditures to increase over the next several years as we expand our infrastructure, distribution channels and our commercialization, clinical trial, research and development and manufacturing activities. We believe that net cash provided by our operating activities and existing cash and cash equivalents, including access to credit facilities, will be sufficient to fund our operations for the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we entered into the 2023 Subscription Agreements with the 2023 PIPE Investors pursuant to, and on the terms and subject to the conditions of which, the 2023 PIPE Investors collectively subscribed for 14,000,000 Class A ordinary shares in a private placement at a purchase price of $5.00 each per share, for aggregate gross proceeds of $70.0 million. The 2023 PIPE Investment was anchored by a $50.0 million investment by a stakeholder in Beauty Ventures, which was the beneficial holder of 21.6% of our Class A ordinary shares as of December 31, 2023. The remainder of the 2023 PIPE Investors were certain existing shareholders including Cedarwalk, certain members of the Sponsor, and Mr. Brousset and Ms. Sebti. The 2023 Subscription Agreements relating to approximately $68.0 million of proceeds were consummated on the First PIPE Closing Date, and the closings of Subscription Agreements relating to the remaining approximately $2.0 million occurred on the Second PIPE Closing Date, following receipt of regulatory approvals (the &#8220;PIPE Closings&#8221;). Following the PIPE Closings, we had a total of 122,152,112 Class A Shares issued and outstanding. No Class B ordinary shares, warrants or other securities of the Company were issued in connection with the 2023 PIPE Investment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Subscription Agreements for the 2023 PIPE Investors included the PIPE Lock-up pursuant to which the 2023 PIPE Investors agreed not to transfer or sell, during the respective lock-up period, any (i) 2023 PIPE Shares or (ii) the Lock-Up Shares. For 75% of the Lock-Up Shares, the lock-up period means the period beginning on the applicable PIPE Closing Date and ending on the one-year anniversary of the applicable PIPE Closing Date. For 25% of the Lock-Up Shares, the lock-up period means the period beginning on the applicable PIPE Closing Date and ending on the six-month anniversary of the applicable PIPE Closing Date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our net cash provided by operating activities and existing cash and cash equivalents are not sufficient to fund our operations in the future, or if we seek to expand or diversify through accretive acquisitions, we may need to seek additional credit or raise additional funds, and we cannot be certain that such funds will be available to us on acceptable terms when needed, if at all. If we are required to seek additional credit, our ability to in-license new technologies, develop future products or expand our pipeline of products could all be negatively impacted, which would have an adverse effect on our ability to grow our business and remain competitive. Further, we may decide to raise additional proceeds by issuing equity securities or securities that are convertible into our equity. If we sell such securities, investors may be materially diluted as a result of such offerings. In addition, if we raise additional funds through collaboration, licensing or other similar arrangements, we may be required to relinquish potentially valuable rights to our future products or proprietary technologies or grant licenses on terms that are not favorable to us. If we cannot raise funds on acceptable terms, we may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not be able to expand our operations, develop new products, take advantage of future opportunities or respond to competitive pressures or unanticipated customer requirements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 we had cash and cash equivalents of $8.7 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Credit Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Borrower entered into the 2022 Credit Agreement with the Lenders led by the Administrative Agent. The 2022 Credit Agreement provides us with the 2022 Term Loan of $175.0 million and the 2022 Revolving Credit Facility, which an aggregate principal amount of up to $7.5 million may be available, at Borrower&#8217;s option, in the form of letters of credit. A total principal amount of $186.1 million was outstanding under the 2022 Credit Agreement at the Closing Date (July 27, 2022). The Term Loan and the Revolving Credit Facility will mature in July 2026. In September 2022, the Borrower entered into a Technical Amendment to Credit Agreement with the Administrative Agent to cure a technical error and clarify when the first amortization payment under the 2022 Credit Agreement is due and payable. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for a description of waivers granted and amendments to the 2022 Credit Agreement after the 2022 Successor Period.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan and the Revolving Credit Facility will mature in July 2026. We may elect to borrow either alternate base rate borrowings or term benchmark borrowings. Each Term Loan or Revolving Credit Facility draw that is an alternate base rate borrowing bears interest at an Alternate Base Rate (as defined in the 2022 Credit Agreement) plus the Applicable Rate (as defined in the 2022 Credit Agreement) of 2.5% per annum. Each Term Loan or Revolving Credit Facility that is a term benchmark borrowing bears interest at the Term SOFR Rate (as defined in the 2022 Credit Agreement), which resets monthly, plus 0.1% and the Applicable Rate of 3.5% per annum. In connection with the issuance of the 2022 Credit Agreement, we incurred $6.3 million of debt issuance costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had an unpaid principal amount of $170.7 million, and unamortized debt issuance costs of $4.2 million on the Term Loan. The interest rate on the 2022 Term Loan was 7.9% and there was no accrued interest as of December 31, 2022 (Successor Period).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the current portion of the Term Loan and Revolver was $8.4 million and $14.1 million, respectively. The current portion of the unamortized debt issuance costs on the Term Loan and Revolver was $1.2 million and $1.2 million, respectively. The weighted-average interest rate on the Term Loan and Revolver was 6.6% and there was $0.1 million of accrued interest as of December 31, 2022 (Successor Period). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Predecessor 2021 Credit Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Obagi settled the Predecessor 2018 Credit Agreement and entered into the Predecessor 2021 Credit Agreement with a new syndicate of lenders, including TCW Asset Management Company LLC as administrative agent for the lenders. The Predecessor 2021 Credit Agreement included a term loan of $110.0 million (the &#8220;Predecessor 2021 Term Loan&#8221;) and a revolving credit facility with borrowing capacity of up to $40.0 million (the &#8220;Predecessor 2021 Revolving Credit Facility&#8221;). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both the Predecessor 2021 Term Loan and the Predecessor 2021 Revolving Credit Facility were due to mature in March 2026. The Predecessor 2021 Credit Agreement interest rate was calculated based on LIBOR plus applicable margin, as determined by Obagi&#8217;s leverage ratios, and was subject to LIBOR succession provisions. In connection with the issuance of the Predecessor 2021 Credit Agreement, Obagi incurred $6.4 million of debt issuance costs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 (Predecessor Period), Obagi had an unpaid principal amount of $109.2 million, and unamortized debt issuance costs of $3.9 million on the Predecessor 2021 Term Loan. The interest rate on the Predecessor 2021 Term Loan was 8.50% and there was no accrued interest as of December 31, 2021 (Predecessor Period). The outstanding balance under the Predecessor 2021 Credit Agreement was paid in full upon the completion of the Business Combination. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Predecessor 2018 Credit Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, Obagi entered into the Predecessor 2018 Credit Agreement with a syndicate of lenders, including Wells Fargo as administrative agent for the lenders. The Predecessor 2018 Credit Agreement included a term loan of $90.0 million (the &#8220;Predecessor 2018 Term Loan&#8221;) and a revolving credit facility with borrowing capacity of up to $35.0 million </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;Predecessor 2018 Revolving Credit Facility&#8221;) which was due to mature in December 2023. In March 2021, Obagi replaced the Predecessor 2018 Credit Agreement with the Predecessor 2021 Credit Agreement from a new syndicate of lenders.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PPP Loan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Obagi received loan proceeds in the amount of $6.8 million under the PPP from MUFG Union Bank. The PPP, established as part of the CARES Act, provided for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The PPP Loan accrued interest at a rate of 1.00% as of December 31, 2020 (Predecessor Period). The accrued interest was $67,000 as of December 31, 2020 (Predecessor Period). The loan and accrued interest were forgivable after eight or twenty-four weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities and maintains its payroll levels. Obagi used the proceeds for purposes consistent with the PPP and received approval from MUFG Union Bank for forgiveness of the full amount of the loan. In June 2021, Predecessor received approval from the Small Business Administration and MUFG Union Bank for forgiveness of the full amount of the PPP Loan. In February 2023, we were informed that the SBA wished to receive additional documentation regarding the PPP Loan. The PPP Loan is currently being reviewed by the SBA and we cannot predict the outcome of the review at this time. See &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8212;Risks Related to our Obagi Skincare Business&#8221; for further discussion. </span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Cash Flow Data</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The period from July 28, 2022 to December 31, 2022 (Successor Period) and the period from January 1, 2022 to July 27, 2022 (Predecessor Period):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Waldencast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor      (Obagi)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From July 28, 2022 to<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From January 1, 2022 to July 27, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(74,977)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,037)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(544,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">629,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Operating Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $75.0 million for the 2022 Successor Period, primarily driven by following: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Net loss of $120.6 million resulting from the impact of higher operating expenses during the Successor Period primarily due to SG&amp;A expenses and cost of goods sold following the Business Combination, partially offset by the revenue generated in the Milk Makeup segment, which was acquired in the 2022 Successor Period, although a large portion of this loss resulted from non-cash reconciling charges and did not impact the cash-flow, related to: (i) depreciation and amortization expenses of $27.0 million, (ii) stock based compensation of $7.7 million following the Business Combination and (iii) loss on impairment of $68.7 million subsequent to the Business Combination.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cash outflows resulting from the net change in operating assets and liabilities of $35.1 million, primarily driven by increases in inventories, the settlement of transaction expenses of $36.4 million related to the Business Combination, and an increase to accounts receivable due to extended payment terms granted to certain customers. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Non-cash reconciling credits related to derivative warrant liabilities of $6.8 million and deferred income taxes of $5.8 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $10.0 million for the 2022 Predecessor Period and was primarily driven by following: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss of $21.1 million resulting from the impact of significant operating expenses in excess of gross profit during the 2022 Predecessor Period;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These were offset primarily due to: (i) non-cash reconciling item related to depreciation and amortization expenses of $8.2&#160;million and (ii) cash inflows resulting the net change in operating assets and liabilities of $1.9 million, primarily driven by increase decrease in inventories, other assets, accounts payable and other liabilities. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Investing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $544.4 million for the 2022 Successor Period, primarily driven by cash paid in the amount of $587.7 million as part of our acquisition of Obagi Skincare and Milk Makeup, net of cash acquired. This amount was partially offset by the proceeds of $44.9 million from our trust account, which was released to us as part of the Business Combination. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $0.9 million for the 2022 Predecessor Period, primarily driven by the increases in capital expenditures of $0.9 million. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $629.5 million for the 2022 Successor Period. The change was primarily driven by: (i) proceeds from the FPA and PIPE investments of $451.0 million, (ii) an increase in proceeds of $189.1 million from the 2022 Term Loan and Revolving Credit Facility, (iii) a decrease in repayment of $4.3 million for the Predecessor 2021 Term Loan, and (iv) a decrease in payment of $6.3 million for debt issuance cost.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $3.9 million for the 2022 Predecessor Period. The increase was primarily driven by an increase in proceeds of $6.0 million from the Predecessor 2021 Revolving Credit Facility, decrease in repayment of $1.4 million for the Predecessor 2021 Term Loan and decrease in payment of $0.7 million for debt issuance cost.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">For the fiscal years ended 2021 and 2020 (Predecessor Period):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except percentages)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,431)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(147.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,787)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,707)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(63.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Operating Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) operating activities increased by $11.0 million, or 147.5%, for the year ended December 31, 2021 (Predecessor Period) compared to the same period in 2020, primarily due to a net increase of $16.8 million in cash provided in connection with operating assets and liabilities, primarily resulting from: (i) favorable changes in accounts receivable due to new customers in China, (ii) increased sales and the timing of payments received from customers and (iii) favorable changes in accounts payable as a result of the timing of payments. These were partially offset by net cash used related to: (i) increases in inventory to meet the higher forecasted sales for the 2021 Predecessor Period, (ii) higher net loss of $17.2 million resulting from the impact of higher operating expenses during the period due to higher SG&amp;A expenses, which was partially offset by the net effect of non-cash items of $11.3 million, primarily including, (a) gain related to the forgiveness of the PPP Loan borrowed in 2020 (See &#8220;Item 8. Financial Information&#8212; Note 8. Debt&#8221;), (b) loss on extinguishment of debt related to the write-off of previously deferred financing costs due to the refinancing of Obagi&#8217;s debt in March 2021, (c) loss on write-off of loan receivable (See &#8220;Item 8. Financial Information&#8212;Note 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restatement and Reclassifications&#8221;) and (d) changes in deferred income taxes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Investing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net cash used in investing activities increased by $2.1 million, or 121.9%, for the year ended December 31, 2021 compared to the same period in 2020, which was attributable primarily to a non-recourse, uncollateralized short-term promissory note of $2.5 million lending to a third party (see &#8220;Item 8. Financial Information&#8212;Note 12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental Balance Sheet Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) as well as increases in capital expenditures of $0.2 million to build our online sales </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capabilities to reduce the impact caused by the closure of businesses due to COVID-19. Property, plant and equipment expenditures decreased $0.6 million year over year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities decreased by $9.2 million, or 63.9%, for the year ended December 31, 2021 compared to the same period in 2020, primarily due to the increase in (i)  repayments of our 2018 Revolving Credit Facility of $35.0 million; (ii) repayments of the 2018 Term Loan of $63.1 million; (iii) payment of debt issuance costs of $5.4 million for the 2021 Credit Agreement; (iv) decreased borrowings under the 2018 Revolving Credit Facility of $9.0 million and (v) the PPP Loan of $6.8 million as a result of partial recovery from COVID-19 as discussed above, which were partially offset by the 2021 Credit Agreement that included term loan proceeds of $110.0 million. </span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our audited annual consolidated financial statements and related notes requires us to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances at the time. We periodically review our estimates and make adjustments when facts and circumstances dictate. Due to the inherent uncertainty involved in making assumptions and estimates, changes in circumstances could result in actual results differing from those estimates, and such differences could be material to the Company&#8217;s consolidated balance sheets, consolidated statements of operations and comprehensive loss, consolidated statements of shareholders&#8217; equity, and consolidated statements of cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An accounting estimate policy is considered to be critical if it requires an estimate to be made based on assumptions about matters that are highly uncertain at the time it is made. An accounting estimate policy is also considered critical if our audited consolidated financial statements could be materially impacted by (i) reasonable, alternative estimates or (ii) changes in the accounting estimates that are reasonably likely to occur on a periodic basis. We believe that our critical accounting policies reflect the more significant estimates and assumptions used in the preparation of our audited consolidated financial statements. The critical accounting policies, judgments and estimates should be read in conjunction with the financial statements and the notes thereto within this Report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the following critical accounting policies, estimates and assumptions may have a material impact on our reported financial condition and operating performance and may involve significant levels of judgment to account for highly uncertain matters or are matters susceptible to significant change.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which establishes principles for recognizing revenue at an amount that reflects the consideration to which an entity expects to be entitled in exchange for transferring goods or services to a customer. Our revenue is derived from two main sources: (1) product sales and (2) royalties from brand name licensing. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the sale of products to customers is recognized at a point in time when control of the product transfers to the customer, based on assessment of payment and shipping terms impacting our right to payment, transfer of legal title, physical possession, and assumption of risks and rewards. When promotional products, such as samples and testers, are provided by the Company to its customers at the same time as a related saleable product, the cost of these promotional products are recognized as cost of sales at the same time as the revenue for the related product is recognized.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Royalty revenue from the licensing arrangements is recognized when the product sale occurs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell products directly to consumers via our e-commerce platforms, to distributors in the U.S. and internationally, and through retailers. Our distributors may resell products to retailers, spas or other end consumers. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine when to recognize revenue under ASC 606, in cases where we sell products to the Physician Channel Provider or distributors who then resell the products to end customers, we use judgment to determine which party controls the products and when that control transfers from us to the distributor. We analyze various factors including our ability to direct products physically held by distributors, when title and risk of loss transfers, and who ultimately manages the relationship with the end customer. When we are able to direct products physically held by a distributor &#8211; such as </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determining which end customers&#8217; orders are fulfilled when there is limited product inventory &#8211; we conclude that the distributor does not control the product for purposes of ASC 606 until we relinquish those abilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Obagi&#8217;s distributors charge fees for certain services that they render to us. The services provided are in connection with the distribution of our products and include packing and shipping, marketing and advertising, monitoring product reviews, providing customer service, and generating data and analytical reports on product sales. Fees to distributors for these services are recognized as a reduction to revenue because the services provided are typically not distinct from the distributors&#8217; purchase of products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, customers are required to pay either in advance or between 30 and 90 days from delivery of the product or invoicing. However, in certain circumstances, we offer extended payment terms to customers. In addition, certain customers may not comply with formal payment terms specified in their written agreements with us. When the period between the transfer of control of the products and payment is expected to be greater than one year, we adjust the promised amount of consideration for the effects of a significant financing component. When contracts contain a significant financing component in which we are effectively financing the customer, a portion of the transaction price is recognized as interest income rather than revenue using a discount rate that reflects the rate that would be used in a separate financing transaction between us and the customer. We exercise judgement to determine an appropriate interest rate considering the customer&#8217;s credit characteristics and current economic conditions. For the periods included in the financial statements in this Report, a 5% change in the discount rate would not have had a material impact on the amount of net revenue or interest income recorded. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When payment terms are significantly extended after the execution of a written agreement or a customer has a pattern of late or insufficient payments, we perform an assessment to determine whether it is probable that we will collect substantially all of the consideration owed to us from that customer. When making this assessment, we consider various factors including our history with the customer and the customer&#8217;s payment history, credit rating, current financial condition, and any known facts that could otherwise impact the customer&#8217;s intent or ability to pay us. If we determine that it is not probable that we will collect substantially all of the consideration owed by the customer, we record an impairment of the customer&#8217;s accounts receivable balance. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers place orders for products through separate purchase orders under our written agreements with them. If the written agreement with a customer does not meet all of the criteria for a contract under ASC 606, each purchase order for products is regarded as a separate contract between us and the customer. If we determine that it is not probable that we will collect substantially all of the consideration from the customer, we generally recognize revenue for each purchase order only after we have transferred the related products and received all or substantially all of the payment for that purchase order. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess goodwill annually on October 1st each year for impairment and at an interim date if indicators of a potential impairment exist. We have two goodwill reporting units, which we test for impairment at the reporting unit level.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our initial review for impairment of goodwill includes considering qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill, as a basis for determining whether it is necessary to perform a quantitative analysis. If we determine that it is more likely than not that the fair value of reporting unit is less than its carrying amount, a quantitative analysis is then performed to identify goodwill impairment. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining the fair value of a reporting unit involves the use of significant estimates and assumptions. The fair value of our reporting units is determined using a combination of the discounted cash flow method under the income approach and the guideline public company method under the market approach. Fair value estimates result from a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions that have been deemed reasonable by our management as of the measurement date. Under the discounted cash flow method, fair value is determined by discounting the estimated future cash flows of each reporting unit, which includes the most recent projected long-term financial forecasts for revenue, earnings, capital expenditures and working capital. The discount rate used is intended to reflect the risks inherent in the future cash flows of the applicable reporting unit. Under the guideline public company method, we estimate fair value by using market multiples of various financial metrics observed for comparable public companies to the reporting unit.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual impairment test performed for the 2021 Predecessor Period and 2020 Predecessor Period did not indicate an impairment of goodwill when they were performed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the closing of the Business Combination during the Successor Period, we concluded that qualitative factors and circumstances indicated it was more likely than not that the fair value for our Obagi Skincare reporting unit was less than its carrying amount. As part of the restatement of historical financial results and reassessment of projected revenue and earnings from the Obagi Skincare reporting unit, management determined there was a decline in financial performance compared to previously projected results at the time of the acquisition. See &#8220;Item 8. Financial Information&#8212;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_1097">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restatement and Reclassifications.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Therefore, we performed a quantitative goodwill impairment test for the associated reporting unit immediately after the acquisition date. As a result, we recorded a non-cash impairment charge of $68.7 million within the Obagi Skincare reportable segment in the 2022 Successor Period, as reflected in the financial statements. Management further determined that there was no additional impairment analysis needed for the October 1 annual impairment test.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, the Obagi Skincare reportable segment had a goodwill balance of $199.5 million after an impairment charge of $68.7 million was recorded following an impairment test conducted in July 2022. As a result, the fair value of the Obagi Skincare reportable segment currently equals the carrying value. The Obagi business continues to face challenges with respect to meeting the forecasts for the business created at the time it was acquired. If we are not successful in addressing these challenges, the projected revenue growth rates or operating margins could fail to grow in accordance with current expectations and result in a further decrease in the fair value of the Obagi Skincare reportable segment below the carrying value. In addition, the fair value of the Obagi Skincare reportable segment could also be negatively impacted by market conditions including inflation, the valuation of its competitors and/or a market capitalization decrease as a result of the restatement of our financial statements for certain Predecessor Periods or other factors, which could result in an additional indicator of impairment. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Milk M</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">akeup segment had a goodwill balance of $135.1 million as of December&#160;31, 2022.  We have not performed a quantitative review of the reporting segment since the Business Combination, as qualitative factors and circumstances did not indicate that the fair value of the reporting unit was less than the carrying value and on that basis management concluded that there was no change in the fair value. As a result, the goodwill balance for the reporting unit has not changed. However, if our Milk Makeup business is unable to meet projected future results, as compared to the forecasts for the business created at the time of the Business Combination, there could be a possibility of an impairment of the goodwill. The fair value of the segment could also be negatively impacted by a shift in gross margin of the business as a result of competition or inflation or could be negatively impacted by the valuation of its competitors.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further impairment charges, if any, may be material to our results of operations and financial position. See Item 3A, "Risk Factors&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Impairment of our significant intangible assets may reduce our profitabilit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">y." </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Tax Assets (and Related Valuation Allowance)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize net deferred tax assets to the extent that we believe these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If we determine that deferred tax assets may be able to be recognized in the future in excess of their net recorded amount, we adjust the deferred tax asset valuation allowance, which would reduce the provision for income taxes. We record uncertain tax positions on the basis of a two-step process whereby (i) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (ii) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. This requires management to make judgments and estimates regarding: (i) the timing and amount of the reversal of taxable temporary differences; (ii) expected future taxable income; and (iii) the impact of tax planning strategies. Future changes to tax rates would also impact the amounts of deferred tax assets and liabilities and could adversely affect our financial statements. A valuation allowance of $7.9 million was recorded as of December 31, 2022 (Successor Period) and has been provided for on the deferred tax assets related to the Company&#8217;s investment in Waldencast Partners LP. As of December 31, 2021 (Predecessor Period), the Company had recorded a valuation allowance of $14.1 million. See &#8220;Item 8. Financial Information&#8212;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_169">Note 16</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Benefit.&#8221;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance will be reduced at such time as management believes it is more-likely-than-not that the deferred tax assets will be realized. The exact timing and amount of a valuation allowance release are subject to change on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the basis of the future level of profitability and changes in tax laws. Release of the valuation allowance would result in the recognition of certain deferred tax assets and a decrease in income tax expense for the period the release is recorded.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we acquire a business, the total purchase consideration provided is allocated to the identifiable assets and liabilities of the acquired business at their estimated respective fair values. Any excess consideration of the fair value of purchase consideration over the fair values of assets acquired and liabilities assumed is recognized as goodwill. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgments and assumptions are required in determining the fair value of assets acquired and liabilities assumed. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows, useful lives and discount rates. Measurement period adjustments are reflected at the time identified, up through the conclusion of the measurement period, which is the time at which all information for determination of the values of assets acquired and liabilities assumed is received and may not exceed one year from the acquisition date. We may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with a corresponding offset to goodwill. If outside of the measurement period, any subsequent adjustments are recorded in our consolidated statements of operations and comprehensive loss.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_82"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Accounting Election</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can choose not to take advantage of the extended transition period and comply with the requirements that apply to non-emerging growth companies, and any such election to not take advantage of the extended transition period is irrevocable. We are an &#8220;emerging growth company&#8221; as defined in Section 2(a) of the Securities Act, and have elected to take advantage of the benefits of this extended transition period, which means that when a standard is issued or revised and has different application dates for public or private companies, we, for so long as we remain an emerging growth company, may adopt the new or revised standard at the time private companies are required to adopt the new or revised standard. </span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_85"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Item 8. Financial Information&#8212;<span id="if92f84ba5af0421f9152717f35be8332_176"></span></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_124">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for more information regarding recent accounting pronouncements.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business, which primarily relate to fluctuations in interest rates, foreign exchange and inflation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have interest rate risk with respect to our indebtedness. As of December 31, 2022 (Successor Period), we had an aggregate face value of $184.8 million of outstanding indebtedness, all of which has variable interest rates. A one percent increase or decrease in the annual interest rate on our variable rate borrowings of $184.8 million would have increased or decreased our annual cash interest expense by approximately $1.8 million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To mitigate interest rate risk in connection with the variable rate loans under the 2022 Credit Agreement, we entered into an interest rate collar with Wells Fargo for a notional value of $160.0 million and a fixed cash payment of $0.8 million. Under the terms of the interest rate collar, we are required to pay Wells Fargo if the monthly secured overnight financing rate (&#8220;SOFR&#8221;)-based interest rate falls below the defined interest rate floor of 2.55%; conversely, we are entitled to receive payment from Wells Fargo if the SOFR-based interest rate rises above the defined interest rate cap of 5.25%. Settlement in cash occurs, if contractually required, until termination of the agreement in October 2024, and the variable interest rate is reset on the last day of each month. See &#8220;Item 8. Financial Information&#8212;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_145">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8212;Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more details on the interest rate collar.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange Fluctuations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We transact business in multiple currencies worldwide, of which the most significant currency for the 2022 Predecessor Period, 2021 Predecessor Period and 2020 Predecessor Period was the U.S. dollar. Our international revenue, as well as costs and expenses dominated in foreign currencies, expose us to the risk of fluctuations in foreign currency exchange rates against the U.S. dollar. As of December 31, 2022, the effect of a hypothetical 10% change in foreign currency exchange rates would not have been material to our financial condition or results of operations. To date, we have not entered into any hedging arrangements with respect to foreign currency risk. As our international operations grow, we will continue to reassess our approach to manage our risk relating to fluctuations in currency rates. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that inflation has had a material effect on our business, financial condition, or results of operations to date; however, we continue to monitor the effects of the global macroeconomic environment, including inflationary pressures. Generally, we have been able to introduce new products at higher prices, increase prices on select products and implement other operating efficiencies to sufficiently offset cost increases.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trend Information </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as disclosed elsewhere in this Report, we are not aware of any trends, uncertainties, demands, commitments or events for the year ended December 31, 2022 that are reasonably likely to have a material effect on our net sales or revenues, income, profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative of future results of operations or financial condition.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES </span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Directors and Senior Management </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the names, ages and positions of our current directors and executive officers as of the date of this Report:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Position</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Officers/Directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michel Brousset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer and Class III Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hind Sebti</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Growth Officer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Philippe Gautier</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer and Chief Operating Officer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Employee Directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Felipe Dutra</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class III Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cristiano Souza</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class II Director</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sarah Brown</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class I Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Juliette Hickman</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class II Director</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lindsay Pattison</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class I Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zack Werner</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class I Director</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aaron Chatterley</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class II Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simon Dai</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class III Director</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Michel Brousset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as a director on our Board and our Chief Executive Officer since January 2021. Mr. Brousset has more than 25 years of experience leading, operating and building global brands at L&#8217;Or&#233;al (PAR: OR) and Procter &amp; Gamble (NYSE: PG) where he worked to launch and build iconic brands across multiple geographies. Most recently, Mr. Brousset founded Waldencast Ventures LP (&#8220;Waldencast Ventures&#8221;), a holding company and investment vehicle, in 2019 and has been the Chief Executive Officer since its inception. Waldencast Ventures partners with, creates, incubates and accelerates next-generation and early-stage beauty and wellness brands. Mr. Brousset has led investments in the current and former Waldencast Ventures portfolio companies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to founding Waldencast Ventures, Mr. Brousset was the Group President of L&#8217;Or&#233;al&#8217;s Consumer Products Division in North America from July 2016 to April 2019. In this role, Mr. Brousset managed each of the Presidents of key L&#8217;Or&#233;al brands and the Presidents and cross-functional teams of L&#8217;Or&#233;al Canada CPD and L&#8217;Or&#233;al Caribe, as well as the heads of supply chain, finance, human resources (&#8220;HR&#8221;), information technology (&#8220;IT&#8221;), legal, research and development (&#8220;R&amp;D&#8221;) and consumer and market intelligence (&#8220;CMI&#8221;). As the Group President of L&#8217;Or&#233;al&#8217;s Consumer Products Division in North America, Mr. Brousset led multiple strategic initiatives and acquisitions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Mr. Brousset was the Chief Executive Officer and Managing Director of L&#8217;Or&#233;al U.K. &amp; Ireland between July 2013 and July 2016, where he managed a broad portfolio of brands and all the divisions of L&#8217;Or&#233;al for the U.K, and Ireland. In addition, he managed across all functional areas including supply chain, finance, HR, IT, CMI, legal and regulatory. Mr. Brousset also spent nearly 14 years at Procter &amp; Gamble in various marketing and brand management roles across North America and Western Europe.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Brousset currently serves as a member of the board of directors of several Waldencast Ventures portfolio companies. Our Board has implemented guidelines, pursuant to which, unless and until we and Waldencast Ventures merge or otherwise become affiliated entities, Mr. Brousset will spend on average at least 90% of his monthly average working time providing services to us, such that a maximum of 10% may be spent to provide services to Waldencast Ventures. Mr. Brousset holds a B.S. in Economics from the Universidad del Pac&#237;fico in Peru and an M.B.A. from the University of North Carolina - Kenan-Flagler Business School.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hind Sebti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as our Chief Operating Officer since February 2021. Ms. Sebti has more than 20 years of experience leading and managing beauty brands across multiple categories and stages during her tenures at L&#8217;Or&#233;al (PAR: OR) and Procter &amp; Gamble (NYSE: PG). Ms. Sebti co-founded Waldencast Ventures alongside Mr. Brousset in 2019. Ms. Sebti brings in-depth knowledge and understanding of the beauty industry as well as consumer insights to identify and invest in the next-generation beauty brands. Importantly, Ms. Sebti plays a key role in helping portfolio brands scale, leveraging her extensive multi-category and brand management experience. Previously, Ms. Sebti  also served as Chief Executive Officer of Waldencast Brands, a subsidiary of Waldencast Ventures, to incubate and commercialize new brands, where she led the brand creation process, with a focus on creative and operational optimization, through all stages from conception and product development to go-to-market strategy. She remains involved in the business, however pursuant to guidelines implemented by the Board, unless and until we and Waldencast Ventures merge or otherwise become affiliated entities, Ms. Sebti will spend on average at least 80% of her monthly average working time providing services to us, such that a maximum of 20% may be spent to provide services to Waldencast Ventures.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to Waldencast Ventures, Ms. Sebti held various leadership positions at L&#8217;Or&#233;al from April 2013 to December 2018. She was the General Manager for Maybelline and Essie in the U.K. from July 2017 to December 2018. She also held the position of General Manager of professional haircare brands Redken, Pureology and Mizani from September 2015 to July 2017, where she focused on digitalization and consumer centricity to drive growth. Ms. Sebti began her tenure at L&#8217;Or&#233;al as the Marketing Director of L&#8217;Or&#233;al Paris and Consumer Division Category Director. Prior to L&#8217;Or&#233;al, Ms. Sebti held various Business Leader and Brand Manager positions at Procter &amp; Gamble in the U.K., Ireland and France across brands such as Olay Skin Care and Gillette Venus from January 2002 to March 2013. Ms. Sebti serves as a member of the board of directors of Cosmetic Executive Women U.K. and holds a Master&#8217;s. Ms. Sebti currently serves as Chairperson of the board of directors of Kjaer Weis, a Waldencast Ventures portfolio company. Degree in Industrial Engineering from The National Institute of Applied Science of Lyon.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Philippe Gautier </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Gautier joined the Company in October 2022. Prior to that, he most recently served as Group Chief Financial Officer at Selecta, a KKR portfolio company. Prior to Selecta, he spent five years as Group Chief Financial Officer and Operations, for SMCP, previously a KKR portfolio company and parent company of Parisian fashion labels Sandro, Maje, Claudie Pierlot and De Fursac. For more than a decade, Mr. Gautier served as Chief Financial Officer within the Kering Group for global brands Sergio Rossi and Puma in North America. Mr. Gautier began his career at HSBC asset management in Tokyo. Mr. Gautier holds a Master of Science in Management from HEC Paris.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Employee Directors</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Felipe Dutra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been a director and the executive chairman of the board of directors of Waldencast Acquisition Corp. since January 2021. Mr. Dutra served as the Chief Financial Officer at Anheuser-Busch InBev (Euronext: ABI) (NYSE: BUD) (MEXBOL: ANB) (JSE: ANH) from January 2005 to April 2020 and played an instrumental role in building AB InBev from a regional Brazilian brewer into the world&#8217;s largest brewer and a top five global consumer goods company according to sales through numerous landmark acquisitions. Mr. Dutra&#8217;s contributions to AmBev, AB InBev&#8217;s current </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsidiary, stretch back to 1990. He held multiple leadership positions in Treasury and Finance at AmBev before being appointed to Chief Financial Officer in 2000.  In addition to being a seasoned deal maker, over the course of his 15-year tenure as Chief Financial Officer of AB InBev, Mr. Dutra took on the additional role of Chief Technology Officer in 2014 to lead the company&#8217;s adoption of digital technology and implementation of data analytics. Mr. Dutra also served as a Board Director of AmBev (BOVESPA: ABEV) (NYSE: ABEV) from January 2005 to May 2020, Grupo Modelo from December 2010 to June 2013 and Budweiser APAC from September 2019 to June 2020. He holds a degree in Economics from Universidade Candido Mendes and an M.B.A. from Universidade de S&#227;o Paulo in Brazil.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cristiano Souza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has been a director of Waldencast plc since January 2021. Mr. Souza is the managing partner at Zeno Equity Partners LLP (&#8220;ZEP&#8221;). Based out of the United Kingdom, ZEP is the investment manager of the Zeno Investment Fund (ZIF) (f/k/a Dynamo Investment Fund) an investment fund focused on long-term equity investments. Prior to becoming managing partner at ZEP, Mr. Souza spent 29 years as a partner of Dynamo Administra&#231;&#227;o de Recursos and nine years as a partner of Dynamo Capital LLC, where he was an analyst and portfolio manager of funds managed and advised by both entities. Mr. Souza has a Bachelor&#8217;s degree in Economics from Candido Mendes University in Rio de Janeiro.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarah Brown</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as an independent director on our Board since March 2021. Ms. Brown&#8217;s work brings together the worlds of business, philanthropy, non-profit activism, and youth campaigning. She is the Founder and Chair of Theirworld, a global children&#8217;s charity based in London. She also serves as the Executive Chair of the U.S. non-profit Global Business Coalition for Education. Ms. Brown serves on the global board of UNICEF Executive Director&#8217;s Generation Unlimited. She is the Chief Executive Officer of the Office of Gordon and Sarah Brown established in 2010 following Gordon Brown&#8217;s Premiership in the U.K. Ms. Brown served as a Non-Executive Director of Harrods Group Holdings Ltd from 2012 until 2022. She holds a Bachelor&#8217;s of Science degree in Psychology from the University of Bristol.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Juliette Hickman&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as an independent director on our Board since March 2021. Ms. Hickman is a former investment analyst and investor at Capital World Investors, part of The Capital Group Companies. She joined The Capital Group in 1998 and held the role of investment analyst and investor initially focusing on the Global Beverage industry until 2020. Ms. Hickman has served as an independent director for Montanya Distillers since 2019 and an independent director for Keurig Dr. Pepper since January 2021. Ms. Hickman holds a Bachelor&#8217;s of Arts degree in Politics and Public Administration from the Nottingham Trent University and in 2022 gained a Postgraduate Certificate in Sustainable Business qualification from Cambridge University.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lindsay Pattison</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as an independent director on our Board since March 2021. Ms. Pattison has years of experience in the fields of marketing, advertising and business-transformation. She was appointed in 2018 as the global Chief Client Officer at WPP PLC (&#8220;WPP&#8221;), a leading marketing services organization. Previously, Ms. Pattison was GroupM&#8217;s, and then WPP&#8217;s, Chief Transformation Officer. She was the Global Chief Executive Officer of Maxus, a WPP media agency, from 2014 until 2021. Her experience also includes roles at Young and Rubicam and PHD Media, as well as a client-side role with Sony Ericsson. She serves on the board of directors at the communications company Chime Ltd and at the international design agency Design Bridge. She served twice on the WEF Global Agenda Council on the Future of Media. As a passionate and vocal campaigner for gender equality, she launched &#8216;Walk the Talk,&#8217; an initiative to help senior women at Maxus to thrive and make progress in their careers - a program now adopted globally by WPP. She sits on WPP&#8217;s Inclusion Council and Risk Committee. Ms. Pattison holds a Bachelor&#8217;s of Arts in English Literature from the University of Stirling and completed the TLC Leaders Program, a leadership course delivered by members of the faculty of Harvard Business School.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zack Werner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as an independent director on our Board since March 2021. Mr. Werner founded The Maze Group in 2016, a highly technical strategic consultancy focused on data architecture and driving growth through digital marketing. Maze partners with private equity owned and public clients such as LVMH, HelloFresh, JC Penney, General Electric, and Pat McGrath Labs to optimize customer acquisition, conversion rate, and retention as well as provide strategies around technology platform and infrastructure transformation. The Maze Group also partners with private equity clients to co-invest in consumer companies. Mr. Werner also started his career at Universal Music Group from 2011 until 2013, where he focused on digital distribution deals, customer relationship management and integrated marketing systems. In addition, in 2017, Mr. Werner became an advisor for Stadium Goods, a sneaker and streetwear marketplace, to oversee e-commerce and growth.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Simon Dai</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as a director on our Board since the consummation of the Business Combination. Mr. Dai has served on the board of directors of Obagi since September 2019, including as its Chairman since July 2020, and has led several investments in the healthcare space. Since January 2020, Mr. Dai has served as the Co-Chairman and Chief Executive Officer of Presbia PLC, a medical device company focused on the development of the presbyopia-correcting </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lens, an innovative solution for the common age-related loss of the ability to read or focus on near objects. He also co-founded Oxford MEStar in October 2013, a spin-out company from the Institute of Biomedical Engineering of Oxford University specializing in automation solution, serving as its Chief Executive Officer from October 2016 until August 2020. Previously, Mr. Dai focused on impact investing at Bill &amp; Melinda Gates Foundation, where he was a Liaison Officer based in Ethiopia. Mr. Dai received a BA in Sociology from Manchester University, an MSc. in Finance from the London School of Economics and an MBA from the UCLA Anderson School of Management.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Dai has been appointed to our Board of by Cedarwalk pursuant to the Investor Rights Agreement, dated as of July 27, 2022, by and among us, Cedarwalk and CWC Skincare Ltd. as guarantor of Cedarwalk&#8217;s obligations thereunder (the &#8220;Investor Rights Agreement&#8221;). For additional information regarding the Investor Rights Agreement, see &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;7.B. Related Party Transactions&#8221; in this Report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aaron Chatterley</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;has served as an independent director on our Board since December 2021. Mr. Chatterley founded the web development company SP New Media in 1996, where he served as the Chief Executive Officer until selling the company in 2000. In 2005, Mr. Chatterley co-founded the online beauty retailer, feel unique, where he served as the Chief Executive Officer until April 2014. Mr. Chatterley led the partial sale of feel unique to Palamon Capital Partners in December 2012, as well as the sale of feel unique to LVMH/Sephora in September 2021. In addition, since 2016 Mr. Chatterley has served as a Non-Executive Director of Digital Jersey, an economic development agency, and currently serves as an audit and risk committee member. Mr. Chatterley also serves as an Ambassador for The Prince&#8217;s Trust Women Supporting Women, a youth charity organization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Family Relationships</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no family relationships between any of our executive officers and directors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Diversity </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast&#8217;s mission is to build a global best-in-class beauty and wellness operating platform by creating, nurturing, and scaling conscious, high growth, purpose-driven brands.   Brands that aim to make the beauty industry a little better every day:  more sustainable, more inclusive and more transparent.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For that reason, it is fundamental that our Board of Directors not only reflects our commitment to economic performance, but also our desire to create, nurture, and scale brands with a soul. Brands that marry purpose, art, beauty, and design with science, industry, and commerce to make the planet and the lives of those in it better.  Our Board includes a variety of skills, professional and industry backgrounds, geographical experience and expertise, gender, tenure, ethnicity, and diversity of thought.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We firmly believe that a diverse Board with a range of views, insights, perspectives, and opinions will support good decision making and be of benefit to the Company&#8217;s shareholders and all other stakeholders. We are committed to reviewing objectives to further increase our Board diversity over time through annual performance reviews and the support of the Nominations and Corporate Governance Committee. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Diversity Matrix (as of December 31, 2023)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Country of Principal Executive Offices:</span></div></td><td colspan="12" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United Kingdom</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign Private Issuer</span></td><td colspan="12" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure Prohibited under Home Country Law</span></td><td colspan="12" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Number of Directors</span></td><td colspan="12" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I: Gender Identity</span></td><td colspan="12" style="background-color:#dbdbdb;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Female</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Male</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Binary</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Did not Disclose</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Directors</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II: Demographic Background</span></td><td colspan="12" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Underrepresented in Home Country Jurisdiction</span></td><td colspan="12" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LGBTQ+</span></td><td colspan="12" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Did Not Disclose Demographic Background</span></td><td colspan="12" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Compensation </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year 2022 Executive Officer and Director Compensation </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate compensation paid and share-based compensation and other payments expensed by us and our subsidiaries to our executive officers with respect to the year ended December 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $3.5 million. For so long as we qualify as a foreign private issuer, we are not required to comply with the proxy rule</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s applicable to U.S. domestic companies, including the requirement applicable to emerging growth companies to disclose the compensation of our Chief Executive Officer and other two most highly compensated executive officers on an individual, rather than an aggregate, basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Sponsor purchased 7,187,500 Class B ordinary shares for an aggregate purchase price of $0.025 million, or approximately $0.003 per share (the &#8220;sponsor shares&#8221;). In February 2021, the Sponsor transferred 20,000 Class B ordinary shares to each of our then-serving independent directors, Ms. Sarah Brown, Ms. Juliette Hickman, Ms. Lindsay Pattison and Mr. Zack Werner (the &#8220;Investor Directors&#8221;), resulting in the Sponsor holding 7,107,500 Class B ordinary shares. In March 2021, we effected a share capitalization resulting in the Sponsor holding an aggregate of 8,545,000 Class B ordinary shares. As such, the Sponsor and the Investor Directors collectively owned 20% of our issued and outstanding shares upon consummation of our IPO. In connection with the Business Combination, 8,625,000 sponsor shares held by the Sponsor and Investor Directors converted automatically, on a one-for-one basis, into one Class A ordinary share in accordance with their terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issued to Mr. Aaron Chatterley 20,000 Class A ordinary shares in a private placement exempt from registration pursuant to Section 4(a)(2) of the Securities Act, and Rule 506 of Regulation D promulgated thereunder, in connection with the consummation of the Business Combination.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended on December 31, 2022, none of our directors received any cash compensation for services rendered to us.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our 2022 Incentive Award Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2022 Incentive Award Plan (the &#8220;2022 Plan&#8221;) became effective upon the closing of the Business Combination. Under the 2022 Plan we may grant eligible officers, employees, non-employee directors and consultants restricted share units (&#8220;RSUs&#8221;) and performance-vested share units (&#8220;PSUs&#8221;), restricted stock, non-qualified options or &#8220;Incentive stock options,&#8221; share appreciation rights (&#8220;SARs&#8221;), other stock-based awards (valued in whole or in part by reference to, or otherwise based on, our ordinary shares, including divided equivalents) and bonuses payable in fully vested ordinary shares and awards that are payable solely in cash. No award will be granted pursuant to the 2022 Plan on or after July 27, 2032, but awards granted before that date may extend beyond that date. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 we had reserved a total of 16,134,716  Class A ordinary shares for issuance under the 2022 Plan subject to adjustment for changes in capitalization as provided under the 2022 Plan. The share reserve under the 2022 Plan will automatically increase on January 1st of each calendar year (each, an &#8220;Evergreen Date&#8221;), prior to the tenth anniversary of the Effective Date (as such term is defined in the 2022 Plan), in an amount equal to the lesser of (i) 3% of the total number of our Class A ordinary shares issued and outstanding on the December 31st immediately preceding the applicable Evergreen Date and (ii) a number of our Class A ordinary shares determined by the plan administrator, including zero. All of our ordinary shares reserved for issuance under the 2022 Plan as of the Effective Date may be granted as incentive stock options. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2022 Plan is administered by our Board, unless the Board appoints a committee of directors to administer certain aspects of the 2022 Plan. In August 2022, the Board appointed the Compensation Committee as the &#8220;plan administrator&#8221; of the 2022 Plan. Under the terms of the 2022 Plan, the exercise price of all options and stock appreciation granted under the 2022 Plan will be determined by the plan administrator, but in no event may the exercise price be less than 100% of the fair market value of our related Class A ordinary shares on the date of grant, unless otherwise set forth in the applicable award agreement. Each stock option and free-standing SAR will vest and become exercisable (including in the event of the optionee&#8217;s termination of employment or service) at such time and subject to such terms and conditions as determined by the plan administrator in the applicable individual option agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plan administrator may grant RSUs, PSUs, restricted stock awards, stock options and SARs that are subject to vesting, forfeiture and other terms and conditions as determined by the plan administrator in the applicable award </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement. The applicable individual award agreement may provide for the lapse of restrictions in installments or the acceleration or waiver of restrictions (in whole or part) under certain circumstances as set forth in the applicable individual award agreement, including the attainment of certain performance goals, a recipients&#8217; termination of employment or service, or a recipient&#8217;s death or disability. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that a &#8220;change in control&#8221; (as such term is defined in the 2022 Plan) occurs, each award granted under the 2022 Plan will continue to operate in accordance with its terms, subject to adjustment (including, without limitation, assumption or conversion into equivalent awards of the acquirer&#8217;s equity).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as provided in the applicable award agreement, if (i) a change in control occurs and (ii) either (x) an outstanding award is not assumed or substituted in connection with such change in control or (y) an outstanding award is assumed or substituted in connection with such change in control and a recipient&#8217;s employment or service is terminated without cause or by the recipient for good reason (if applicable) within 12 months following the change in control, then (i) any unvested or unexercisable portion of an award carrying a right to exercise will become fully vested and exercisable and (ii) the restrictions, deferral limitations, payment conditions and forfeiture conditions applicable to any other award granted under the 2022 Plan will lapse, the awards will vest in full and any performance conditions will be deemed to be achieved at target performance levels.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Plan provides the Board with the authority to amend, alter or terminate the 2022 Plan, but no such action may adversely affect the rights of any recipient with respect to outstanding awards without the recipient&#8217;s consent. The plan administrator may amend an award, prospectively or retroactively, but no such amendment may adversely affect the rights of any recipient without the recipient&#8217;s consent. Shareholder approval of any such action will be obtained if required to comply with applicable law.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All awards will be subject to the provisions of any clawback policy implemented by us (including the policy adopted by us in November 2023 in accordance with the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act) to the extent set forth in such clawback policy, and will be further subject to such deductions and clawback as may be required to be made pursuant to any law, government regulation or stock exchange listing standard.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grants Made to Executive Officers of the Company under the 2022 Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company granted our founders, Mr. Brousset and Ms. Sebti, stock options to purchase, in an aggregate, up to 11,500,000 Class A ordinary shares (the &#8220;Founder Options&#8221;). The Founder Options vest over a period of six years as follows: (a) 1,916,666 of such shares will vest on the first anniversary of the date of grant with an exercise price of $10.70 per share; (b) 1,916,666 of such shares will vest on the second anniversary of the date of grant with an exercise price of $11.45 per share; (c) 1,916,668 of such shares will vest on the third anniversary of the date of grant with an exercise price of $12.25 per share; and (d) the remaining 5,750,000 shares will vest on the sixth anniversary of the date of grant with an exercise price of $15.01 per share; in each case, subject to the recipient&#8217;s continued employment with the Company through the applicable vesting date unless otherwise provided in connection with certain terminations of employment. To the extent vested, Founder Options may be exercised at any time prior to the fifth (5th) anniversary of the applicable vesting date, unless otherwise provided in connection with certain terminations of employment. Upon exercise of any vested Founder Options with an exercise price of $10.70, $11.45 and $12.25, the respective founder will be required to hold the Class A ordinary shares for a minimum of twelve (12) months following the date of exercise, unless the respective founder&#8217;s employment is terminated on account of death or disability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our founders were also awarded RSUs in August 2022 with respect to 692,000 Class A ordinary shares, respectively (the &#8220;Founder RSUs&#8221;). The Founder RSUs will vest in full on the third anniversary of the date of grant, subject to their continued employment with the Company. In November 2022, the Company also granted RSUs with respect to 270,137 Class A ordinary shares to our executive officers, including our founders, in connection with the long-term incentive award program established for our employees for the year ended December 31, 2022 (the &#8220;2022 RSUs&#8221;). The 2022 RSUs were subject to achievement of either the net revenue or EBITDA goal established by the Compensation Committee for the year ended December 31, 2022. In June 2023, upon a recommendation of the Compensation Committee, the Board determined to waive the performance goals applicable to the 2022 RSUs held by certain of our employees, including those held by Mr. Gautier. Accordingly, Mr. Gautier&#8217;s 2022 RSUs will vest in three equal installments in 2023, 2024 and 2025, subject to the recipient&#8217;s continued employment with the Company, unless otherwise provided in connection with certain terminations of employment. With respect to the 2022 RSUs granted to our founders, the Board determined not to waive the performance goals applicable to the founders&#8217; 2022 RSUs. Based on the financials prepared by the Company for the period ended </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022, the Board has certified that the applicable performance goals have not been met and, accordingly, that the 2022 RSUs granted to our founders will not vest.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Board Practices</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Composition of the Board of Directors</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and affairs are managed under the direction of our Board. As of the date of this Report, our Board consists of nine directors. Subject to the terms of the Investor Rights Agreement, our Constitutional Document provides that the number of directors on our Board will be fixed by our Board.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When considering whether directors and director nominees have the experience, qualifications, attributes and skills, taken as a whole, to enable our Board to satisfy its oversight responsibilities effectively in light of its business and structure, our Board focuses primarily on each person&#8217;s background and experience in order to provide an appropriate mix of experience and skills relevant to the size and nature of the business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our Investor Rights Agreement with Cedarwalk, the Sponsor and CWC Skincare Ltd., the guarantor of Cedarwalk&#8217;s obligation thereunder, we have agreed to take all necessary action to cause our Board to be comprised of one director nominated by Cedarwalk for as long as Cedarwalk owns 5% of our then outstanding Ordinary Shares. Mr. Simon Dai has been elected as the initial director nominee of Cedarwalk, and serves as a Class III director. See &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;7.B. Related Party Transactions&#8221; for more information on the Investor Rights Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Classified Board of Directors</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the terms of our Constitutional Document, our Board may consist of no less than five, but no more than 15 natural persons, such number to be set by the Board by resolution from time to time. Our Board is divided into classes of directors that will serve staggered three-year terms. At each annual meeting of shareholders, a class of directors will be elected for a three-year term to succeed the same class whose term is then expiring. As a result, only one class of directors will be elected at each annual meeting of our shareholders, with the other classes continuing for the remainder of their respective three-year terms. Our Board is divided among the three classes as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Class I directors, which are Lindsay Pattison, Zack Werner and Sarah Brown, and their terms will expire at the first annual meeting of shareholders to be held after the consummation of the Business Combination, which is expected to be held January 18, 2024;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Class II directors, which are Aaron Chatterley, Juliette Hickman and Cristiano Souza, and their terms will expire at the second annual meeting of shareholders to be held after the consummation of the Business Combination; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Class III directors, which are Michel Brousset, Felipe Dutra and Simon Dai, and their terms will expire at the third annual meeting of shareholders to be held after the consummation of the Business Combination.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each director&#8217;s term will continue until the election and qualification of his or her successor, or his or her earlier death, resignation or removal. Any increase or decrease in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. This classification of our Board may have the effect of delaying or preventing changes in control our company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Independence</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our common stock being listed on The Nasdaq Capital Market, we are required to comply with the applicable rules of the exchange in determining whether a director is independent. We believe that each of Ms. Sarah Brown, Ms. Juliette Hickman, Ms. Lindsay Pattison, Mr. Zack Werner and Mr. Aaron Chatterley qualifies as &#8220;independent&#8221; as defined under the applicable Nasdaq rules.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Private Issuer Status</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For so long as we qualify as a foreign private issuer, we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and imposing liability for insiders who profit from trades made within a short period of time;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rules under the Exchange Act requiring the filing with the SEC of an annual report on Form 10-K (although we will file annual reports on a corresponding form for foreign private issuers), quarterly reports on Form 10-Q containing unaudited financial and other specified information (although we will file semi-annual financial information on a current reporting form for foreign private issuers), or current reports on Form 8-K, upon the occurrence of specified significant events; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulation Fair Disclosure or Regulation FD, which regulates selective disclosure of material non-public information by issuers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, there may be less publicly available information concerning our business, executive compensation and other matters than there would be if we were a U.S. public company. Additionally, certain accommodations in the Nasdaq corporate governance standards allow foreign private issuers, such as us, to follow &#8220;home country&#8221; corporate governance practices in lieu of the otherwise applicable corporate governance standards.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Committees of the Board of Directors</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board directs the management of our business and affairs, as provided by Jersey law, and conducts its business through meetings of our Board and standing committees. We have three standing committees - an audit committee, a compensation committee and a nominating and governance committee.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, from time to time, special committees may be established under the direction of our Board when it deems it necessary or advisable to address specific issues. Copies of the charters for each committee are available on our website, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.waldencast.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as required by applicable SEC and Nasdaq rules. The information on or available through our website is not deemed incorporated in this Report and does not form part of this Report.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The audit committee&#8217;s responsibilities include, among other things:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assisting board oversight of (i) the integrity of our financial statements, (ii) our compliance with legal and regulatory requirements, (iii) our independent auditor&#8217;s qualifications and independence and (iv) the performance of our internal audit function and independent auditors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the appointment, compensation, retention, replacement and oversight of the work of the independent auditors and any other independent registered public accounting firm engaged by us;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pre-approving all audit and non-audit services to be provided by the independent auditors or any other registered public accounting firm engaged by us, and establishing pre-approval policies and procedures; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and discussing with the independent auditors all relationships the auditors have with us in order to evaluate their continued independence;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">monitoring compliance by the independent auditors with the audit partner rotation requirements contained in applicable laws and regulations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">monitoring our compliance with the employee conflict of interest requirements contained in applicable laws and regulations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and reviewing a report from the independent auditors describing (i) all critical accounting policies and practices to be used; (ii) any critical audit matters arising from the current period audit; (iii) all alternative treatments of financial information that have been discussed by the independent auditors and management, ramifications of the use of such alternative disclosures and treatments, and the treatment preferred by the independent auditors; (iv) all other material written communications between the independent auditors and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management, such as any management letter and any schedule of unadjusted audit differences; and (v) any material financial arrangements which do not appear on our financial statements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing the adequacy and effectiveness of our accounting and internal control policies and procedures on a regular basis;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and reviewing a report, at least annually, from our management, attested to by the independent auditors, assessing the effectiveness of our internal control over financial reporting and stating management&#8217;s responsibility for establishing and maintaining adequate internal control over financial reporting prior to its inclusion in our Annual Report on Form 20-F or Form 10-K, as applicable;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">meeting to review and discuss our annual audited financial statements and quarterly financial statements with management and the independent auditor;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing with our legal advisors, when appropriate, any legal, regulatory matters, including any matters (i) that may have a material impact on our financial statements and (ii) involving potential or ongoing material violations of law or breaches of fiduciary duty by us or any of our directors, officers, employees, or agents or breaches of fiduciary duty to us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The audit committee consists of Juliette Hickman, Sarah Brown and Zack Werner, with Juliette Hickman serving as chair. Our Board has determined that each of the members of the audit committee qualifies as independent under the Nasdaq rules applicable to members of our Board generally and under the Nasdaq rules and Exchange Act Rule 10A-3 specific to audit committee members and that each of the members of the audit committee meets the requirements for financial sophistication under the applicable Nasdaq rules. In addition, our Board has determined that Juliette Hickman qualifies as an &#8220;audit committee financial expert,&#8221; as such term is defined in Item 407(d)(5) of Regulation S-K.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functions of the compensation committee include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and approving compensation plans for the Company&#8217;s executive officers and recommending to the Board for approval. </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluating on an annual basis the performance of the Company&#8217;s executive officers, taking into consideration, among other things the short-term and long-term goals and objectives of the Company&#8217;s executive compensation plans and determining and approving the remuneration of our executive officers (other than our Chief Executive Officer and our Chief Growth Officer) and recommending to our Board the remuneration of our Chief Executive Officer and our Chief Growth Officer; in each case, based on such evaluations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and making recommendations to our Board with respect to the compensation, and any incentive-compensation and equity-based plans that are subject to the Board&#8217;s approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determining and approving any grants of equity awards to be made to eligible participants (other than our Chief Executive Officer and our Chief Growth Officer) and recommending to the Board for approval any equity awards to be made to our Chief Executive Officer and our Chief Growth Officer.</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implementing and administering our incentive compensation and equity-based remuneration plans;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assisting management in complying with our proxy statement and annual report disclosure requirements and recommending to the Board for approval, if necessary;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">producing a report on executive compensation to be included in our annual report on Form 20-F or Form 10-K, as applicable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing and approving the terms of any compensation &#8220;clawback&#8221; or similar policy or agreement between the Company and our executive officers or other employees, as deemed necessary or as required by applicable law; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing, evaluating and recommending changes, if appropriate, to the remuneration for non-employee directors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation committee consists of Lindsay Pattison, Zack Warner and Juliette Hickman, with Lindsay Pattison serving as chair. Our Board has determined that each of the members of the compensation committee meets the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independence requirements under Nasdaq and SEC rules. Our Board has determined that each member of this committee will also be a &#8220;non-employee director&#8221; within the meaning of Rule 16b-3 under the Exchange Act.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition and function of the compensation committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and regulations. We will comply with future requirements to the extent they become applicable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nominating and Corporate Governance Committee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functions of the nominating and corporate governance committee include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identifying, screening and reviewing individuals qualified to serve as directors, consistent with criteria approved by our Board, and recommending to our Board candidates for nomination for appointment at the annual general meeting or to fill vacancies on our Board;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and recommending to our Board, and overseeing implementation of, our corporate governance guidelines;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coordinating and overseeing the annual evaluation of our Board, as whole, and management, and evaluating and reporting to our Board on the performance and effectiveness of our Board and each of our committees; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewing on a regular basis our overall corporate governance and recommending improvements as and when necessary.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nominating and corporate governance committee consists of Sarah Brown, Aaron Chatterley and Lindsay Pattison, with Sarah Brown serving as the chair. Our Board has determined that each of the members of the nominating and governance committee meet the independence requirements under Nasdaq and SEC rules.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition and function of the nominating and governance committee comply with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and regulations. We will comply with future requirements to the extent they become applicable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Committee Interlocks and Insider Participation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the members of the compensation committee is currently, or has been at any time, one of our officers or employees. None of our executive officers currently serves, or has served during the last year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our Board or compensation committee.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Employees </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information pertaining to Waldencast plc&#8217;s employees is set forth in &#8220;Item 4 Information on the Company&#8212;4.B. Business Overview&#8221; of this Report.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Share Ownership </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information pertaining to Waldencast plc&#8217;s share ownership is set forth in &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;7.A. Major Shareholders&#8221; of this Report.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.4pt">Disclosure of a Registrant&#8217;s Action to Recover Erroneously Awarded Compensation</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS </span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Major Shareholders </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information regarding the beneficial ownership of Ordinary Shares as of December 31, 2023 by: </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each person known by us to be the beneficial owner of more than 5% of Ordinary Shares; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our directors and executive officers; and </span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all our directors and executive officers as a group. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if that person possesses sole or shared voting or investment power over that security. A person is also deemed to be a beneficial owner of securities that such person has a right to acquire within 60 days including, without limitation, through the exercise of any option, warrant or other right or the conversion of any other security. Such securities, however, are deemed to be outstanding only for the purpose of computing the percentage beneficial ownership of that person but are not deemed to be outstanding for the purpose of computing the percentage beneficial ownership of any other person. Under these rules, more than one person may be deemed to be a beneficial owner of the same securities. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2023, (the &#8220;record date&#8221;), there were 103,152,281 Class A ordinary shares (including 1,916,666 Class A ordinary shares subject to outstanding stock options held by our executive officers that are currently exercisable or exercisable within 60 days of the record date, and 6,758 Class A ordinary shares subject to restricted stock units that are vested or will vest within 60 days of the record date, but have not yet been settled) and 20,847,553 Waldencast plc Class B ordinary shares issued and outstanding.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, we believe that all persons named in the table below have sole voting and investment power with respect to all voting shares beneficially owned by them.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name and Address of Beneficial Owner</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class A<br/>ordinary shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% of <br/>Class A<br/>ordinary<br/>shares<br/>outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class B</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ordinary</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Combined</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Voting</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Power</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(12)</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5% Holders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast Long-Term Capital LLC (the Sponsor)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,066,666</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cedarwalk Skincare Ltd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,637,506</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zeno Investment Master Fund</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,500,709</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Burwell Mountain Trust</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,826,110</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Santa Venerina Inv. &amp; Arbitrage Ltd.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,000,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TRUXT Investimentos Ltda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,871,957</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Main Post Growth Capital, L.P.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,090,058</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Directors and Executive Officers</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sarah Brown</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aaron Chatterley</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Juliette Hickman</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lindsay Pattison</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zack Werner</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michel Brousset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,592,780</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simon Dai</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hind Sebtia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">553,333</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Philippe Gautier</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,758</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cristiano Souza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,500,709</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Felipe Dutra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Waldencast plc directors and executive officers as a group (10 individuals)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,753,580</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Less than one percent. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.13pt">Unless otherwise noted, the business address for each of those listed in the table above is c/o Waldencast plc, 10 Bank Street, Suite 560, White Plains, NY 10606.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.13pt">Reflects securities held directly by Beauty Ventures consisting of (i) 17,300,000 Class A ordinary shares and (ii) 5,766,666 Class A ordinary shares issuable upon exercise of warrants held by Beauty Ventures. Waldencast Long-Term Capital LLC, (the &#8220;Sponsor&#8221;), is the managing member of Beauty Ventures. The voting and investment power of the Sponsor is exercised jointly by Waldencast Ventures, LP, Burwell Mountain Trust, and Zeno Investment Master Fund (f/k/a Dynamo Master Fund). Waldencast Ventures, LP is controlled by Michel Brousset. See </span><span style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">footnote 8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for further details. Burwell Mountain PTC LLC is the trustee of Burwell Mountain Trust, a non-grantor, fully discretionary dynasty trust duly organized under Wyoming law. See </span><span style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">footnote 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for further details. Zeno Investment Master Fund is controlled by Cristiano Souza. See </span><span style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">footnote 4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for further details.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.13pt">This information is based on a Schedule 13D filed with the SEC on August 5, 2022 by Cedarwalk Skincare Ltd. (&#8220;Cedarwalk&#8221;). According to this Schedule 13D, Cedarwalk directly holds 28,237,500 Class A ordinary shares. CWC Skincare Ltd. (&#8220;CWC&#8221;) is the sole shareholder of Cedarwalk, and Sijue Dai is the sole shareholder of CWC and the Director of each of Cedarwalk and CWC. Each of CWC and Mr. Dai may be deemed to be the beneficial owner of 28,237,500 Waldencast Class A ordinary shares. The business address of each is c/o Cedarwalk Skincare Limited, Rm 3001-3010, 30/F, China Resource Building, 26 Harbour Road, Wanchai, Hong Kong.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.13pt">This information is based on a Schedule 13D/A filed with the SEC on December 1, 2023 by Zeno Investment Master Fund, (f/k/a Dynamo Master Fund) who beneficially owns 20,500,709 Class A ordinary shares. Zeno Equity Partners LLP, a British limited liability partnership, is the investment manager of Zeno Investment Master Fund. Cristiano Souza is the controlling shareholder of Zeno Equity Partners LLP. The business address of Zeno Equity Partners LLP, Zeno Investment Master Fund is 272 Kings Road, College House 3rd floor, London SW3 5AW.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.13pt">This information is based on a Schedule 13D filed with the SEC on August 8, 2022 by Burwell Mountain Trust. According to this Schedule 13D, Burwell Mountain Trust directly holds 7,848,333 Class A ordinary shares and Private Placement Warrants exercisable for 3,977,777 Class A ordinary shares. Burwell Mountain PTC LLC, as trustee of Burwell Mountain Trust, has the sole voting and dispositive power over the shares held on behalf of the Burwell Mountain Trust, a non-grantor, fully discretionary dynasty trust duly organized under Wyoming law of which Felipe Dutra and his descendants are eligible beneficiaries. Burwell Mountain PTC LLC is an independent trustee over which Mr. Dutra has no control. The business address of each is 270 W. Pearl, Suite 103, Jackson, WY 83001. Burwell Mountain PTC LLC, as trustee of the Burwell Mountain Trust, pledged substantially all of the reported securities held by it pursuant to a loan agreement with customary default provisions. In the event of a default under the loan agreement, following such securities respective lock-up periods, the secured parties may foreclose upon any and all securities pledged to them.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.13pt">The business address of Santa Venerina Inv. &amp; Arbitrage Ltd. is East Bay Street, Nassau, Bahamas.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.13pt">This information is based on a Schedule 13G filed with the SEC on January 31, 2023 by TRUXT Investimentos Ltda. According to this Schedule 13G, TRUXT Investimentos Ltda. may be deemed to have shared voting power with regard to 5,269,543 Waldencast Class A ordinary shares and shared dispositive power with regard to 5,871,957 Class A ordinary shares and Bruno de Godoy Garcia may be deemed to have shared voting and dispositive power with regard to 3,473,053 Waldencast Class A ordinary shares. Mr. Garcia is the Chief Investment Officer and a controlling person of TRUXT Investimentos Ltda. The business address of each is Av. Ataulfo de Paiva, 153, 6 floor, Leblon, Rio de Janeiro, RJ, 22440-032 Brazil.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.59pt">Waldencast Ventures, LP holds (i) 2,848,334 Class A ordinary shares, (ii) 1,977,779 Class A ordinary shares issuable upon exercise of the private placement warrants and (iii) 333,334 Class A ordinary shares issuable upon exercise of the Working Capital Loan warrants. Mr. Brousset is the chief executive officer of Waldencast Management, LLC, the general partner of Waldencast Ventures, LP. As such, Mr. Brousset may be deemed to beneficially own the shares held by Waldencast Ventures, LP. Mr. Brousset also holds (i) 50,000 Class A ordinary shares and (ii) 1,383,333 stock options that are exercisable within 60 days of the record date for Class A ordinary shares, subject to a per share exercise price of $10.70 and an expiration date of August 12, 2028.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.59pt">Ms. Sebti holds (i) 20,000 Class A ordinary shares and (ii) 533,333 stock options that are exercisable within 60 days of the record date for Class A ordinary shares, subject to a per share exercise price of $10.70 and an expiration date of August 12, 2028.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.88pt">Mr. Gautier holds 6,758 Class A ordinary shares subject to restricted stock units that are vested or scheduled to vest within 60 days of the record date, but have not yet been settled as of the record date.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.88pt">Class B ordinary shares are non-economic voting shares and may be exchanged, together with an equal amount of Waldencast LP Units, for Class A ordinary shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:9.88pt">Includes both Class A ordinary shares and Class B ordinary shares.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Related Party Transactions </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Waldencast</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sponsor Shares</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Sponsor purchased 7,187,500 Class B ordinary shares for an aggregate purchase price of $0.025 million, or approximately $0.003 per share. In February 2021, the Sponsor transferred 20,000 Class B ordinary shares to each of the Investor Directors, resulting in the Sponsor holding 7,107,500 Class B ordinary shares. In March 2021, we effected a share capitalization resulting in the Sponsor holding an aggregate of 8,545,000 Class B ordinary shares. As such, the Sponsor and the Investor Directors collectively owned 20% of our issued and outstanding shares upon consummation of our IPO.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Business Combination, 8,625,000 sponsor shares held by the Sponsor and Investor Directors converted automatically, on a one-for-one basis, into one Class A ordinary share in accordance with their terms.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Forward Purchase Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our IPO, on February 22, 2021, we, the Sponsor and Zeno entered into a Forward Purchase Agreement (the &#8220;Sponsor FPA&#8221;), which was subsequently amended by the assignment and assumption agreement entered into by and between the Sponsor and Burwell on December 20, 2021. Under the assignment and assumption agreement, Sponsor assigned, and Burwell assumed, all of the Sponsor&#8217;s rights and benefits under the Forward Purchase Agreement, pursuant to which, Burwell and Zeno committed to subscribe for and purchase 16,000,000 Class A ordinary shares and 5,333,333 warrants for an aggregate commitment amount of $160.0 million in connection with the closing of our initial business combination. In addition, we and Beauty Ventures entered into a Forward Purchase Agreement on March 1, 2021 (the &#8220;Third-Party FPA&#8221;, and together with the Sponsor FPA, the &#8220;FPAs,&#8221;) pursuant to which Beauty Ventures committed to subscribe for and purchase up to 17,300,000 Class A ordinary shares and up to 5,766,666 warrants for an aggregate commitment amount of $173.0 million, in connection with the closing of our initial business combination. Members of our Sponsor or their affiliates will begin to receive a twenty percent (20%) performance fee allocation on the return of the forward purchase securities in excess of the hurdle rate, calculated on the total return generated from forward purchase securities (whether by dividend, transfer or increase in value as measured from date of issuance), when the return of such securities (less the expenses of Beauty Ventures) underlying the Third-Party FPA exceeds a hurdle rate of five percent (5%) accrued annually until the fifth anniversary of the issuance of such securities. In the event of a transfer and subsequent sale of any forward purchase securities prior to such fifth anniversary, the performance fee for the period between such transfer and such fifth anniversary will be calculated based on the proceeds generated by such sale.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The FPA investments were consummated substantially concurrently with the consummation of the Business Combination. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the FPAs and the transactions contemplated thereby is not complete and is subject to and qualified in its entirety by reference thereto, copies of which are attached as Exhibits 4.26-4.28 to this Report and the terms of which are incorporated by reference herein.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneously with the consummation of our IPO, the Sponsor purchased 5,933,333 private placement warrants at a purchase price of $1.50 per private placement warrant, or $8.9 million in the aggregate. Each private placement warrant entitles the holder to purchase one Class A ordinary share for $11.50 per share. The private placement warrants may not be redeemed by us so long as they are held by the Sponsor or its permitted transferees. If the private placement warrants are held by holders other than the Sponsor or its permitted transferees, the private placement warrants will be redeemable by us and exercisable by the holders on the same basis as the warrants included in the Units that were sold as part of our IPO. The Sponsor, or its permitted transferees, has the option to exercise the private placement warrants on a cashless basis.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The private placement warrants are identical to the warrants included in the Units sold in our IPO, except that the private placement warrants: (i) are not redeemable by us, (ii) may be exercised for cash or on a cashless basis so long as they are held by the Sponsor or any of its permitted transferees and (iii) are entitled to registration rights (including the Class A ordinary shares issuable upon exercise of the private placement warrants). Additionally, the purchasers have agreed not to transfer, assign or sell any of the private placement warrants, including our Class A ordinary shares issuable upon exercise of the private placement warrants (except to certain permitted transferees), until 30 days after the completion of our initial business combination.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Business Combination, each of the 5,933,333 private placement warrants converted automatically into a warrant to acquire one Class A ordinary share. The foregoing description of the private placement warrants is not complete and is subject to and qualified in its entirety by reference thereto, a copy of which is attached as Exhibit 4.14 to this Report and the terms of which are incorporated by reference herein.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registration Rights</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the sponsor shares, private placement warrants, and warrants that were issued upon conversion of the Working Capital Loan (as defined below) (and any Class&#160;A ordinary shares issuable upon (i) the exercise of the private placement warrants, including the Working Capital Warrants (as defined below) and (ii) the conversion of the sponsor shares) are entitled to registration rights pursuant to a registration rights agreement dated March&#160;15, 2021 (the &#8220;Legacy Registration Rights Agreement&#8221;) requiring us to register such securities for resale (in the case of the sponsor shares, only after conversion to our Class&#160;A ordinary shares). The holders of these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of the Business Combination and rights to require us to register for resale such securities pursuant to Rule 415 under the Securities Act. We will bear the expenses incurred in connection with the filing of any such registration statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, the Sponsor, the members of the Sponsor and certain of our shareholders, Obagi and Milk and certain of their respective affiliates entered into an amended and restated registration rights agreement, dated July 27, 2022 (the &#8220;Registration Rights Agreement&#8221;), pursuant to which we agreed to register for resale, pursuant to Rule 415 under the Securities Act, certain of our Class&#160;A ordinary shares and our other securities that are held by the parties thereto from time to time, subject to the restrictions on transfer therein. The Registration Rights Agreement amended and restated the Legacy Registration Rights Agreement and terminates with respect to any party thereto, on the date that such party no longer holds any Registrable Securities (as defined therein). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we filed a registration statement on Form F-1 to register up to 121,120,063 Class A ordinary shares, consisting of (i) 8,545,000 Class A ordinary shares converted from the sponsor shares; (ii) 80,000 Class A ordinary shares converted from the founder shares held by the Investor Directors; (iii) 20,000 Class A ordinary shares issued to Aaron Chatterley in a private placement exempt from registration pursuant to Section 4(a)(2) of the Securities Act, and Rule 506 of Regulation D promulgated thereunder, in connection with the consummation of the Business Combination; (iv) 28,237,506 Class A ordinary shares issued pursuant to the Obagi Merger Agreement; (v) 21,104,225 Class A ordinary shares issuable in exchange for 21,104,225 Class B ordinary shares pursuant to the Milk Equity Purchase Agreement; (vi) 11,800,000 Class A ordinary shares issued in the PIPE Investments; (vii) 33,300,000 Class A ordinary shares issued pursuant to the FPAs; and (viii) 18,033,332 Class A ordinary shares issuable in respect of the private placement warrants, pursuant to the Registration Rights Agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Registration Rights Agreement and the transactions contemplated thereby is not complete and is subject to and qualified in its entirety by reference thereto, a copy of which is attached as Exhibit 4.9 to this Report and the terms of which are incorporated by reference herein.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Notes and Advances</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;12, 2021, we issued a promissory note to the Sponsor (the &#8220;January Note&#8221;), pursuant to which we could borrow an aggregate principal amount of $0.3 million. The note was non-interest bearing and payable on the completion of the IPO. There were no borrowings outstanding under the note at the closing of the IPO.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;18, 2021, we issued a promissory note to the Sponsor, pursuant to which we could borrow up to an aggregate principal amount of $1,500,000 from the Sponsor (the &#8220;Working Capital Loan&#8221;). The note was non-interest bearing, unsecured and due and payable in full on the earlier of (x)&#160;March 18, 2023 and (y) the date we consummated our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initial business combination. On October&#160;28, 2021, we drew down the entire available balance of the Promissory Note and the Sponsor deposited $1,500,000 in our operating bank account. As of July 27, 2022, we had a total aggregate principal amount of $1,500,000 in outstanding borrowings under the Convertible Working Capital Note. In connection with the closing of Business Combination, the Sponsor elected to convert $1,500,000 of the Working Capital Loan balance into warrants at a price of $1.50 per warrant for a total of 1,000,000 warrants (the &#8220;Working Capital Warrants&#8221;). The Working Capital Warrants issuance was exempt from registration pursuant to Section 4(a)(2) of the Securities Act, and Rule 506 of Regulation D promulgated thereunder. Borrowings under the Convertible Working Capital Note are no longer available.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we issued working capital promissory notes to the Sponsor on (i) May 20, 2022, for up to $600,000 (&#8220;May Working Capital Note&#8221;) and (ii) July 15, 2022, for up to $450,000 (&#8220;July Working Capital Note&#8221; and, together with May Working Capital Note, the &#8220;Non-Convertible Working Capital Notes&#8221;), in each case, for working capital purposes. As of July 27, 2022, we had a total aggregate principal amount of $1,050,000 in outstanding borrowings under the Non-Convertible Working Capital Notes. In connection with the closing of Business Combination, the aggregate outstanding balance under the Non-Convertible Working Capital Notes of $1,050,000 was repaid to the Sponsor. Borrowings under the Non-Convertible Working Capital Notes are no longer available.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the January Note, Working Capital Loan, May Working Capital Note and July Working Capital Note and the transactions contemplated thereby is not complete and is subject to and qualified in its entirety by reference thereto, copies of which are attached as Exhibits 4.24, 4.25, 4.30 and 4.31, respectively, to this Report and the terms of which are incorporated by reference herein.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Administrative Services Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into an agreement whereby, commencing on March&#160;15, 2021, through the earlier of the consummation of a business combination or our liquidation, we agreed to pay the Sponsor a monthly fee of $0.01&#160;million for office space, administrative, financial and support services. We incurred approximately $0.065&#160;million in administrative expenses under the agreement through the Closing Date, but ceased to incur these fees following the completion of the Business Combination. As of December 31, 2022, there was no outstanding balance under the administrative services agreement.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lock-Up Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to a Letter Agreement, dated March 15, 2021, between us and the initial shareholders of Waldencast Acquisition Corp., such shareholders agreed not to transfer, assign or sell any of their sponsor shares until the earlier to occur of: (A) one year after the Closing Date; and (B) following the Closing Date, (x) if the last reported sale price of our Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share sub-divisions, share dividends, rights issuances, consolidations, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within any 30-trading day period commencing at least 150 days after our initial business combination or (y) the date on which we complete a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of our public shareholders having the right to exchange their Ordinary Shares for cash, securities or other property (except with respect to permitted transferees). Any permitted transferees would be subject to the same restrictions and other agreements of the initial shareholders of Waldencast Acquisition Corp. with respect to any sponsor shares. Such Letter Agreement Lock-Up Provisions expired on July 27, 2023. See &#8220;Item 5. Waldencast&#8217;s Operating and Financial Review and Prospects&#8212;Recent Events&#8212;Lock-Up Restrictions&#8221; for more information on the Lock-Up Agreements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to the Sponsor FPA, Burwell and Zeno agreed not to transfer, assign or sell any of their Class A ordinary shares according to the same Letter Agreement Lock-Up Provisions. Any permitted transferees would be subject to the same restrictions and other agreements as a purchaser under the Sponsor FPA. The Sponsor FPA lock-up period expired on July 27, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the 2023 Subscription Agreements, the 2023 PIPE Investors agreed not to transfer or sell, during the respective lock-up period, any (i) 2023 PIPE Shares or (ii) Class A shares held by such holder at or prior to the respective PIPE Closing Dates. For 75% of the Lock-Up Shares, the applicable lock-up period means the period beginning on the applicable PIPE Closing Date and ending on the one-year anniversary of the applicable PIPE Closing Date. For 25% of the Lock-Up Shares, the applicable lock-up period means the period beginning on the applicable PIPE Closing Date and ending on the six-month anniversary of the applicable PIPE Closing Date.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Waiver and Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the consummation of the Business Combination, we waived those certain provisions as contemplated by the Letter Agreement and certain other agreements related thereto (collectively, the &#8220;Waiver&#8221;), with respect to any securities held by an Insider (as defined in the Letter Agreement) as of the closing the Business Combination (the &#8220;Lock-Up Securities&#8221;) that would disallow a pledge by such Insider of the Lock-Up Securities in a transaction for the purpose of financing such Insider&#8217;s payment obligations owed in connection with the closing of the Business Combination.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with such Waiver, we entered into that certain Waiver and Agreement, dated as of July 25, 2022, by and between us and Burwell (the &#8220;Waiver and Agreement&#8221;), to permit a pledge by Burwell of its Lock-Up Securities to be used as a portion of the collateral under a loan to finance Burwell&#8217;s payment obligations under the Sponsor FPA in connection with the closing of the Business Combination. Pursuant to the terms of the Waiver and Agreement, in the event of a foreclosure, any such lenders or a collateral agents will be required to execute a joinder to the Letter Agreement pursuant to which they will be bound by the transfer restrictions of the Lock-Up Securities (including the foreclosure of or other exercise of remedies under any such loan documentation) in the Letter Agreement for the duration of such agreement. We also agreed to provide any such lender or collateral agent with customary registration rights in the event of default, foreclosure or other exercise of remedies following the respective Lock-Up Periods (as defined in the Letter Agreement).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Waiver and Agreement and the transactions contemplated thereby is not complete and is subject to and qualified in its entirety by reference thereto, a copy of which is attached as Exhibit 4.33 to this Report and the terms of which are incorporated by reference herein.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Business Combination, we entered into indemnification agreements with each of our directors. The indemnification agreements provide, to the fullest extent permitted under law, indemnification against all expenses, judgments, fines and amounts paid in settlement relating to, arising out of or resulting from indemnitee&#8217;s status as a director, officer, employee, fiduciary or agent of the Company or any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other entity which such person is or was serving at the Company&#8217;s request as a director, officer, employee or agent. In addition, the indemnification agreements provide that the Company will advance, to the extent not prohibited by law, the expenses incurred by the indemnitee in connection with any proceeding, and such advancement will be made within thirty (30) days after the receipt by the Company of a statement requesting such advances from time to time, whether prior to or after final disposition of any proceeding. The foregoing description of the indemnification agreements and the transactions contemplated thereby is not complete and is subject to and qualified in its entirety by reference thereto, copies of which are attached as Exhibits 4.15 to 4.23 to this Report and the terms of which are incorporated by reference herein.</span></div><div style="margin-top:12pt;padding-right:13.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director Interests</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Article 75 of the Jersey Companies Law and the Constitutional Document, any director of the Company who has, directly or indirectly, an interest in a transaction entered into or proposed to be entered into by the Company or by a subsidiary of the Company which to a material extent conflicts or may conflict with the interests of the Company and of which the director is aware, is required to disclose to the Company the nature and extent of the director&#8217;s interest.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mr. Dutra and his descendants are eligible beneficiaries of Burwell Mountain Trust and should be regarded as interested&#160;accordingly in any transaction involving Burwell and its affiliates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Investor Directors and Mr. Chatterley each owns 20,000 Class A ordinary shares and should be regarded as interested accordingly in any transaction involving such Class A ordinary shares;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Simon Dai was nominated for appointment to our Board by Cedarwalk, pursuant to the Investor Rights Agreement, and should be regarded as interested accordingly&#160;in any transaction involving Cedarwalk and its affiliates; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mr. Brousset is the chief executive officer of Waldencast Management, LLC, the general partner of Waldencast Ventures. Waldencast Ventures holds (a) 2,848,334 Class A ordinary shares; (b) 1,977,779 Class A ordinary shares issuable upon exercise of the private placement warrants; and (c) 333,334 Class A ordinary shares issuable upon exercise of the Working Capital Loan warrants. Mr. Brousset should be regarded as interested accordingly in any transaction involving such Class A ordinary shares, Waldencast Ventures and its affiliates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a matter of Jersey law, each director of the Company is under a duty to act honestly and in good faith with a view to acting in the best interests of the Company, regardless of any other directorship such director may hold. Each director is responsible for advising the board of directors in advance of any potential conflicts of interest.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2023 PIPE Transaction</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 PIPE Transaction</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, we entered into the 2023 Subscription Agreements with the 2023 PIPE Investors, pursuant to, and on the terms and subject to the conditions of which, the 2023 PIPE Investors collectively subscribed for 14,000,000 Class A ordinary shares in a private placement at a purchase price of $5.00 each per share, for aggregate gross proceeds of $70.0 million. The 2023 PIPE Investment was anchored by a $50 million investment by a Beauty Ventures stakeholder. The remainder of the 2023 PIPE Investors were certain existing shareholders, certain members of the Sponsor, Mr. Brousset and Ms. Sebti. The 2023 Subscription Agreements relating to approximately $68 million of proceeds was consummated in September 2023, with the closings of Subscription Agreements relating to the remaining approximately $2 million consummated in November 2023 (the &#8220;Closing Date&#8221;). The Subscription Agreements for the 2023 PIPE Investors provided for certain lock-up restrictions as described above under &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lock-up Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Subscription Agreements provide for certain registration rights pursuant to which Waldencast is required to, as soon as practicable but no later than 60 days following the SEC notice that the post-effective amendment filed in connection with the Company&#8217;s Registration Statement on Form F-1, has been declared effective, submit to or file with the SEC a registration statement registering the resale of such shares. Additionally, Waldencast is required to use its commercially reasonable efforts to have the registration statement declared effective as soon as practicable after the filing thereof, but no later than the earlier of (i) the 90th calendar day following the filing date thereof if the SEC notifies us that it will review the registration statement and (ii) the 10th business day after the date we are notified (orally or in writing, whichever is earlier) by the SEC that the registration statement will not be &#8220;reviewed&#8221; or will not be subject to further review. We must use commercially reasonable efforts to keep the registration statement effective until the earliest of: (i) the date the 2023 PIPE Investors no longer hold any registrable shares, (ii) the date all registrable shares held by the 2023 PIPE Investors may be sold without restriction under Rule 144 under the Securities Act and (iii) two years from the date of effectiveness of the registration statement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the 2023 Subscription Agreements and the transactions contemplated thereby is not complete and is subject to, and qualified in its entirety by, the full text of the form of Subscription Agreement, the form of which is attached as Exhibit 4.38 to this Report on Form 20-F and incorporated by reference herein.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operational Support Services Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, Obagi Cosmeceuticals entered into an operational support services agreement with Obagi Holdco, Obagi Hong Kong and Obagi Shanghai Cosmeceuticals Co. Ltd., a subsidiary of Obagi Hong Kong (&#8220;Obagi Shanghai&#8221;), pursuant to which Obagi Cosmeceuticals provided certain services, including administrative and product related services, to the other signatories party thereto. The agreement terminated with respect to Obagi Hong Kong and Obagi Shanghai in connection with the Obagi China Distribution (as defined below). Under the agreement, which automatically renewed for a one-year term on January&#160;1, 2021, Obagi Cosmeceuticals receives service fees in an amount equal to the sum of its costs incurred in the performance of such services plus five percent (5%). Total service fees paid to Obagi Cosmeceuticals were $1.1, $3.5 and $4.6 million for the 2022 Successor Period, 2022 Predecessor Period, and for the year ended December 31, 2021 (Predecessor Period), respectively.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Exclusive Marketing Services Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Obagi Holdco and Obagi Shanghai entered into a non-exclusive marketing services agreement, pursuant to which Obagi Shanghai provided certain sales and marketing services to Obagi Holdco in the PRC. Under the agreement, which terminated upon closing of the Business Combination, Obagi Shanghai received service fees in an amount equal to the sum of its costs incurred in the performance of such services plus five percent (5%). Total service fees paid to Obagi Shanghai were  $2.1 and $2.6 million for the 2022 Predecessor Period, and for the year ended December 31, 2021 (Predecessor Period), respectively.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shareholder Loan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, Obagi paid approximately $2.0 million in accrued interest to a shareholder related to a shareholder loan, the principal of which was repaid in 2018 upon refinancing with a third-party syndicate of banks.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registration with National Medical Products Administration in China</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Cedarwalk paid approximately $4.1 million to register Obagi&#8217;s products with the National Medical Products Administration in China in exchange for 8,000,000 shares of Obagi common stock. This non-cash capital contribution was recorded as additional paid-in capital in Obagi&#8217;s consolidated statements of shareholders&#8217; equity for the year ended December&#160;31, 2020.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obagi China Distribution</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition to the Obagi Merger Agreement, prior to the Closing Date, Obagi Holdco distributed to Obagi and then Obagi distributed to Cedarwalk of all of the issued and outstanding shares of capital stock of Obagi Hong Kong and certain related assets pursuant to distribution agreements in the Obagi China Distribution. Prior to the Business Combination, the Obagi China Business had been conducted through Obagi Hong Kong and its subsidiaries. The following agreements were entered into in connection with the closing of the Business Combination: (a) that certain Transition Services Agreement, dated as of July 27, 2022, by and among Obagi certain of Obagi&#8217;s affiliates and Obagi Hong Kong, pursuant to which Obagi and certain of its affiliates will provide transition services to Obagi Hong Kong, (b) that certain IP License Agreement, dated as of July 27, 2022, by and among Obagi and Obagi Hong Kong pursuant to which Obagi will exclusively license intellectual property relating to the Obagi brand to Obagi Hong Kong with respect to the China Region, and (c) that certain Supply Agreement, dated as of July 27, 2022, by and between Obagi and Obagi Hong Kong pursuant to which Obagi will supply products to Obagi Hong Kong for distribution and sale in the China Region.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the consummation of the Business Combination, we entered into the Investor Rights Agreement (together with the Transition Services Agreement, Intellectual Property License Agreement, and Supply Agreement, the &#8220;Obagi China Related Party Agreements&#8221;).</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transition Services Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Transition Services Agreement, Obagi and certain of its affiliates will provide to Obagi Hong Kong and its affiliates certain transition services to enable Obagi Hong Kong to conduct Obagi-branded business as a going concern in the China Region. Obagi and certain of its affiliates will provide the transition services set forth under the Transition Services Agreement for up to twelve (12) months following the Closing Date, with an option for Obagi Hong Kong, in its sole discretion, to extend the service period for up to an additional twelve (12) months solely with respect to certain services relating to research and development. Obagi Hong Kong did not elect to extend the service period for such services and as a result the Transition Services Agreement expired in July 2023. Services were to be charged at the reasonable, fully-loaded costs of providing the services, once the value of the services provided exceeded a specified amount. Because the specified amount had not been exceeded, Obagi Hong Kong paid $0 in fees during the 2022 Predecessor Period and the 2022 Successor Period. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IP License Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the IP License Agreement, Obagi will exclusively license intellectual property relating to the Obagi brand to Obagi Hong Kong with respect to the China Region, and Obagi will retain the rights to such intellectual property to conduct the Obagi-branded business worldwide except for the China Region. The license from Obagi to Obagi Hong Kong will include future intellectual property of Obagi relating to the Obagi brand in the worldwide business, including, but not limited to: (i)&#160;trademarks; (ii)&#160;domain names; (iii)&#160;patents; (iv)&#160;trade secrets and know-how; (v)&#160;copyrights; and (vi)&#160;product specifications and formulas.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The license will be perpetual, irrevocable, non-transferable and sublicensable, subject to: (x)&#160;a limited right of Obagi to terminate for an uncured material breach by Obagi Hong Kong that materially and adversely affects Obagi or the Obagi brand, in which case Obagi will purchase Obagi Hong Kong at a discount to fair market value based on an independent valuation procedure; (y) the right of either party to transfer the Intellectual Property License Agreement without consent of the other party to an affiliate or to a successor in interest in connection with any merger, business combination or other change of control transaction, or sale of a product or service line; and (z) a right of Obagi Hong Kong to sublicense to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affiliates, Approved CMOs (as defined in the Supply Agreement) and other approved third parties. Upon the termination of the Intellectual Property License Agreement, at the written request of, Obagi Hong Kong shall promptly cease, and shall cause its sublicensees to promptly cease, all use of the Licensed IP Rights (as defined in the Intellectual Property License Agreement), subject to a non-exclusive right to use the Licensed IP Rights for a period of up to nine complete calendar months following the effective date of termination, in a manner consistent with past practice and in compliance with the terms and conditions of this Agreement, to sell off all inventory of China Products (as defined in the Intellectual Property License Agreement) to consumers in the China Region (and subject to the terms relating to royalties in the Intellectual Property License Agreement).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the IP License Agreement, Obagi Hong Kong will be obligated to pay Obagi a royalty of five and a half percent (5.5%) of gross sales of licensed products, subject to certain deductions. Obagi Hong Kong paid royalty fees of $0.2 million during the 2022 Successor Period.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Obagi Supply Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Obagi Supply Agreement, Obagi will supply, or cause to be supplied through certain CMOs, products to Obagi Hong Kong and its affiliates, and Obagi Hong Kong may purchase such products for distribution and sale in the China Region. The term of the Obagi Supply Agreement is perpetual, subject to termination for uncured material breach or termination in the event that the Intellectual Property License Agreement is terminated.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investor Rights Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Investor Rights Agreement, Cedarwalk has the right to nominate one director for election or appointment to the Board for so long as Cedarwalk owns 5% of the then-outstanding common stock of Waldencast, and such appointee is initially Simon Dai, who serves as a director of Obagi, Obagi Holdco and Obagi Hong Kong. Upon such termination of the Supply Agreement:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Obagi Hong Kong shall promptly refrain from using the Product Information File, the Specifications and the Confidential Information of Obagi (each as defined in the Supply Agreement);</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Obagi Hong Kong shall return to Obagi all documents relating to the Product Information File, Specifications and Confidential Information of Obagi Cosmeceuticals. The relevant costs shall be borne by the party who is responsible for the termination or the non-renewal of the Supply Agreement; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unless the Supply Agreement is terminated by Obagi Hong Kong due to Obagi&#8217;s breach of its obligations related to the quality of the products, Obagi Cosmeceuticals shall complete the manufacturing of all products covered by firm orders and deliver them to the applicable recipient.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Investor Rights Agreement and the transactions contemplated thereby is not complete and is subject to and qualified in its entirety by reference thereto, a copy of which is filed as Exhibit 4.29 to this Report and the terms of which are incorporated by reference herein.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk receives certain administrative services from affiliated companies related through common ownership. Such amounts are included in rent and management fee expenses and amounted to $0.05 million for the 2022 Successor Period.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Interests of Experts and Counsel </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. FINANCIAL INFORMATION</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Waldencast plc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_100">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (PCAOB ID No. <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-49">34</ix:nonNumeric>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_100">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_100">142</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_103">Consolidated Balance Sheets as of December 31, 2022 (Successor</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_103">) and December 31, 2021 (Restated)  (Predecessor</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_103">)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_103">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_103">143</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_106">Consolidated Statements of Operations and Comprehensive Loss for the period from July 28, 2022 to December 31, 2022 (Successor</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_106">), for the period from January 1, 2022 to July 27, 2022 (Predecessor</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_106">), for the year ended December 31, 2021 (Restated) (Predecessor</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_106">), and for the year ended December 31, 2020 (Restated) (Predecessor</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_106">)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_106">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_106">144</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_109">Consolidated Statements of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_109">Shareholders</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_109">&#8217;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_109"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_109">Equity for the period from July 28, 2022 to December 31, 2022 (Successor</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_109">), for the period from January 1, 2022 to July 27, 2022 (Predecessor</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_109">), for the year ended December 31, 2021 (Restated) (Predecessor</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_109">), and for the year ended December 31, 2020 (Restated) (Predecessor</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_109">)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_109">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_109">145</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_112">Consolidated Statements of Cash Flows for the period from July 28, 2022 to December 31, 2022 (Successor</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_112">), for the period from January 1, 2022 to July 27, 2022 (Predecessor</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_112">), for the year ended December 31, 2021 (Restated) (Predecessor</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_112">), and for the year ended December 31, 2020 (Restated) (Predecessor</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_112">)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_112">F-</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_112">146</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_115">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#if2fc25067f8b45fc8cc165df93f3be1c_115">148</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-141</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div><span><br/></span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">REPORT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the shareholders and the Board of Directors of Waldencast plc</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Opinion on the Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated balance sheets of Waldencast plc and subsidiaries (the "Company") as of December 31, 2022 (Successor) and December 31, 2021 (Predecessor), the related consolidated statements of operations and comprehensive loss, shareholders&#8217; equity, and cash flows, for the period from July 28, 2022 to December 31, 2022 (Successor), January 1, 2022 to July 27, 2022 (Predecessor), the year ended December 31, 2021 (Predecessor), and the year ended December 31, 2020 (Predecessor), and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 (Successor) and  December 31, 2021 (Predecessor) and the results of its operations and its cash flows for the periods from July 28, 2022 through December 31, 2022 (Successor), January 1, 2022 through July 27, 2022 (Predecessor), and for each of the two years in the period ended December 31, 2021 (Predecessor) in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Restatement of the 2021 and 2020 Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_1097">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to the financial statements, the accompanying 2021 (Predecessor) and 2020 (Predecessor) financial statements have been restated to correct misstatements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Change in Accounting Principle </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_124">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to the financial statements, the Company changed its method of accounting for leases in 2022 due to the adoption of Accounting Standards Update No. 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-50">Deloitte &amp; Touche LLP</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-51">Costa Mesa, California</ix:nonNumeric>  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 15, 2024</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company&#8217;s auditor since 2018.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-142</span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.174%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Successor (Waldencast)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-52">8,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-53">12,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-54">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-55">650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">19,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">18,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Related party accounts receivable (Note 17)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="f-58">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-60">54,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-61">21,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">6,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">4,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-64">679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-65">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">91,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">59,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-68">8,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-69">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-70">639,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-71">79,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-72">334,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-73">44,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use asset, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-74">16,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="f-75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-76">535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-77">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TOTAL ASSETS</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-78">1,090,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-79">184,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">CURRENT LIABILITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-80">23,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-81">12,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Related party accounts payable (Note 17)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-82">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">2,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-86">20,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-87">15,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current liabilities (including related party liability of $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-88">9,914</ix:nonFraction> as of December 31, 2022)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-89">26,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-90">12,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-91">72,505</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-92">40,805</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-93">159,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-94">103,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivative warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-95">18,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="f-96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-97">17,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-99">22,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="f-100">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="f-101">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-102">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TOTAL LIABILITIES</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-103">290,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-104">145,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">COMMITMENTS AND CONTINGENCIES (NOTE 18)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-7" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-105"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-8" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-106"></ix:nonFraction></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SHAREHOLDERS' EQUITY:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Predecessor common shares, <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-107">25,000,000</ix:nonFraction> shares authorized; $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-108">0.50</ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-109"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-110">8,000,002</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-111">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Successor preferred shares, <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-112">25,000,000</ix:nonFraction> shares authorized, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="4" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-113">0.0001</ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-114"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-115">none</ix:nonFraction></ix:nonFraction> issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Successor Class A ordinary shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-116">0.0001</ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-117">1,000,000,000</ix:nonFraction> shares authorized; and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-118">86,460,560</ix:nonFraction> outstanding as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-119">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Successor Class B ordinary shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-120">0.0001</ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-121">100,000,000</ix:nonFraction> shares authorized; and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-122">21,104,225</ix:nonFraction> outstanding as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-123">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-124">796,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-125">100,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-126">156,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-127">64,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-128">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-129">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TOTAL CONTROLLING SHAREHOLDERS' EQUITY</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-130">639,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-131">39,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-132">160,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:fixed-zero" scale="3" id="f-133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TOTAL SHAREHOLDERS' EQUITY</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-134">799,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-135">39,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-136">1,090,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-137">184,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-143</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28, 2022 to<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from<br/>January 1, 2022 to<br/>July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor (Waldencast)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue (including related party net revenue of $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-138">17,219</ix:nonFraction> in the Successor period)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-139">92,373</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-140">73,760</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-141">142,472</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-142">94,428</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold (including related party costs of $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-143">5,128</ix:nonFraction> in the Successor period)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-144">60,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-145">30,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-146">55,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-147">29,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-148">31,716</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-149">42,892</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-150">87,435</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-151">65,332</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-152">88,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-153">55,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-154">82,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-155">60,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-156">1,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-157">2,606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-158">6,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-159">4,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-160">68,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-161">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-163">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-164">159,437</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-165">58,155</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-166">89,060</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-167">64,804</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-168">127,721</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-169">15,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-170">1,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="f-171">528</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-172">6,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-173">6,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-174">11,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-175">6,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities (Note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-176">6,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="3" id="f-177">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="3" id="f-178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="3" id="f-179">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt (Note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-180">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-181">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-182">2,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-183">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on PPP Loan forgiveness (Note 8)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="wald:GainOnPPPLoanForgiveness" format="ixt:fixed-zero" scale="3" id="f-184">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="wald:GainOnPPPLoanForgiveness" format="ixt:fixed-zero" scale="3" id="f-185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="wald:GainOnPPPLoanForgiveness" format="ixt:num-dot-decimal" scale="3" id="f-186">6,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="wald:GainOnPPPLoanForgiveness" format="ixt:fixed-zero" scale="3" id="f-187">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on write-off of loan receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="wald:GainLossOnNoteReceivableWriteoff" format="ixt:fixed-zero" scale="3" id="f-188">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="wald:GainLossOnNoteReceivableWriteoff" format="ixt:fixed-zero" scale="0" id="f-189">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="wald:GainLossOnNoteReceivableWriteoff" format="ixt:num-dot-decimal" scale="3" id="f-190">2,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="wald:GainLossOnNoteReceivableWriteoff" format="ixt:fixed-zero" scale="0" id="f-191">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-192">798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-193">971</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-194">817</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-195">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total other (income) expenses, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-196">1,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-197">5,681</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-198">8,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-199">6,292</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-200">126,360</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-201">20,944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-202">9,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-203">5,764</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-204">5,803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-205">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-206">9,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-207">3,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-208">120,557</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-209">21,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-210">19,576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-211">2,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-212">24,990</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="f-213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="f-214">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="f-215">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss attributable to Class A shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-216">95,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-217">21,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-218">19,576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-219">2,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share attributable to Class A shareholders (Note 15):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-220"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-221">1.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-222"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-223">2.63</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-224"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-225">2.45</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-226"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-227">0.30</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares used in computing net loss per share (Note 15):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-228"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-229">86,460,560</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-230"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-231">8,000,002</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-232"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-233">8,000,002</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-234"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-235">8,000,002</ix:nonFraction></ix:nonFraction></span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-236">120,557</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-237">21,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-238">19,576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-239">2,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-240">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-241">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-242">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-243">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-244">120,593</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-245">20,961</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-246">19,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-247">2,354</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-248">24,997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive loss attributable to Class A shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-252">95,596</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-253">20,961</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-254">19,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-255">2,354</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-144</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share data)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.796%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="54" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shareholders' Equity<br/>Waldencast plc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:29pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Class A Ordinary Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Class B Ordinary Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional <br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Other Comprehensive<br/>&#160;Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Noncontrolling Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Shareholders&#8217; Equity</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BALANCE&#8212;July 28, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-256">8,645,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-257">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-258">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-259">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-260">174</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-261">61,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-262">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-263">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-264">61,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of Class A ordinary shares upon release of Trust proceeds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="wald:StockIssuedDuringPeriodSharesTrustProceeds" format="ixt:num-dot-decimal" scale="0" id="f-265">4,478,054</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="wald:StockIssuedDuringPeriodValueTrustProceeds" format="ixt:num-dot-decimal" scale="3" id="f-266">44,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="wald:StockIssuedDuringPeriodValueTrustProceeds" format="ixt:num-dot-decimal" scale="3" id="f-267">44,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;Issuance of common shares in connection with the FPA investment </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="wald:StockIssuedDuringPeriodSharesForeignPurchaseAgreements" format="ixt:num-dot-decimal" scale="0" id="f-268">33,300,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="wald:StockIssuedDuringPeriodValueForeignPurchaseAgreements" scale="3" id="f-269">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="wald:StockIssuedDuringPeriodValueForeignPurchaseAgreements" format="ixt:num-dot-decimal" scale="3" id="f-270">332,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="wald:StockIssuedDuringPeriodValueForeignPurchaseAgreements" format="ixt:num-dot-decimal" scale="3" id="f-271">333,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;Issuance of common shares in connection with the PIPE investment </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="wald:StockIssuedDuringPeriodSharesSubscriptionAgreements" format="ixt:num-dot-decimal" scale="0" id="f-272">11,800,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="wald:StockIssuedDuringPeriodValueSubscriptionAgreements" scale="3" id="f-273">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="wald:StockIssuedDuringPeriodValueSubscriptionAgreements" format="ixt:num-dot-decimal" scale="3" id="f-274">117,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="wald:StockIssuedDuringPeriodValueSubscriptionAgreements" format="ixt:num-dot-decimal" scale="3" id="f-275">118,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;Issuance of common shares in connection with the Obagi and Milk Business Combination </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-276">28,237,506</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="f-277">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="f-278">21,104,225</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="f-279">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-280">292,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-281">185,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-282">477,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-283">95,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-284">24,990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-285">120,557</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-286">7,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-287">7,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-288">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-289">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-290">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BALANCE&#8212;December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-291">86,460,560</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-292">8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-293">21,104,225</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-294">2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-295">796,038</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-296">156,780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-297">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-298">160,659</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-299">799,898</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="54" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shareholders' Equity <br/>Obagi Global Holdings Limited</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Predecessor</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BALANCE&#8212;January 1, 2020 (as reported)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-300">8,000,002</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-301">4,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-302">96,055</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-303">1,513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-304">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-305">98,533</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Opening balance sheet restatement adjustments (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-306">37,346</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-307">37,346</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BALANCE&#8212;January 1, 2020 (as restated)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-308">8,000,002</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-309">4,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-310">96,055</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-311">38,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-312">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-313">61,187</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss (as restated)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-314">2,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-315">2,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-316">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-317">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-cash contribution of trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" format="ixt:num-dot-decimal" scale="3" id="f-318">4,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" format="ixt:num-dot-decimal" scale="3" id="f-319">4,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-320">0.26</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="3" id="f-321">2,044</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="3" id="f-322">2,044</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BALANCE&#8212;December 31, 2020 (as restated)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-323">8,000,002</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-324">4,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-325">100,113</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-326">43,273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-327">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-328">60,847</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss (as restated)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-329">19,576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-330">19,576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-331">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-332">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-333">0.25</ix:nonFraction> per share)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="3" id="f-334">2,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="3" id="f-335">2,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BALANCE&#8212;December 31, 2021 (as restated)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-63" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-336">8,000,002</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-337">4,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-338">100,113</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-339">64,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-340">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-341">39,239</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-342">21,057</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-343">21,057</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-344">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-345">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Distribution of Obagi China Business</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="wald:DistributionOfBusiness" format="ixt:num-dot-decimal" scale="3" id="f-346">13,113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="wald:DistributionOfBusiness" scale="3" id="f-347">188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="wald:DistributionOfBusiness" scale="3" id="f-348">71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="wald:DistributionOfBusiness" format="ixt:num-dot-decimal" scale="3" id="f-349">13,372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BALANCE&#8212;July 27, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-350">8,000,002</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-351">4,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-352">87,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-353">86,094</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-354">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-355">4,906</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="6" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-145</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars)</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Period from<br/>January 1 to<br/>July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year ended<br/>December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year ended<br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Successor (Waldencast)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-356">120,557</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-357">21,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-358">19,576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-359">2,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-360">7,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-362">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="wald:DepreciationDepletionAndAmortizationOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-364">26,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="wald:DepreciationDepletionAndAmortizationOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-365">8,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="wald:DepreciationDepletionAndAmortizationOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-366">13,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="wald:DepreciationDepletionAndAmortizationOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-367">13,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="f-368">740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:fixed-zero" scale="3" id="f-369">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:fixed-zero" scale="3" id="f-370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:fixed-zero" scale="3" id="f-371">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-372">6,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities" format="ixt:fixed-zero" scale="3" id="f-373">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities" format="ixt:fixed-zero" scale="3" id="f-374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities" format="ixt:fixed-zero" scale="3" id="f-375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-cash loss from change in fair value on interest rate collar</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="wald:NonCashLossFromChangeInFairValueOnInterestRateCollar" scale="3" id="f-376">592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="wald:NonCashLossFromChangeInFairValueOnInterestRateCollar" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="wald:NonCashLossFromChangeInFairValueOnInterestRateCollar" format="ixt:fixed-zero" scale="3" id="f-378">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="wald:NonCashLossFromChangeInFairValueOnInterestRateCollar" format="ixt:fixed-zero" scale="3" id="f-379">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-382">2,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gain on PPP Loan forgiveness</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="wald:GainOnPPPLoanForgiveness" format="ixt:fixed-zero" scale="3" id="f-384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="wald:GainOnPPPLoanForgiveness" format="ixt:fixed-zero" scale="3" id="f-385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="wald:GainOnPPPLoanForgiveness" format="ixt:num-dot-decimal" scale="3" id="f-386">6,824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="wald:GainOnPPPLoanForgiveness" format="ixt:fixed-zero" scale="3" id="f-387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-388">677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-389">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-390">1,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-391">798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of related party liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="wald:AmortizationOfRelatedPartyLiability" format="ixt:num-dot-decimal" scale="3" id="f-392">12,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="wald:AmortizationOfRelatedPartyLiability" format="ixt:fixed-zero" scale="3" id="f-393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="wald:AmortizationOfRelatedPartyLiability" format="ixt:fixed-zero" scale="3" id="f-394">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="wald:AmortizationOfRelatedPartyLiability" format="ixt:fixed-zero" scale="3" id="f-395">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-396">5,823</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-397">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-398">9,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-399">3,044</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on impairment of goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-400">68,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-402">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Gain) Loss on disposal of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-404">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-405">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-406">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="f-407">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on write-off of loan receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="wald:GainLossOnNoteReceivableWriteoff" format="ixt:fixed-zero" scale="3" id="f-408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="wald:GainLossOnNoteReceivableWriteoff" format="ixt:fixed-zero" scale="3" id="f-409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="wald:GainLossOnNoteReceivableWriteoff" format="ixt:num-dot-decimal" scale="3" id="f-410">2,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="wald:GainLossOnNoteReceivableWriteoff" format="ixt:fixed-zero" scale="3" id="f-411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities, net of impact of business combinations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-412">204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-413">3,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-414">5,057</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-415">16,661</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Related party accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" scale="3" id="f-416">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" format="ixt:fixed-zero" scale="3" id="f-417">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" format="ixt:fixed-zero" scale="3" id="f-418">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" format="ixt:fixed-zero" scale="3" id="f-419">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-420">6,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-421">13,008</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-422">6,010</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-423">4,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="f-424">213</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="f-425">658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-426">1,097</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-427">1,919</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-428">250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-429">352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-430">612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-431">1,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-432">1,021</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-433">9,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-434">9,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-435">7,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Related party accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="3" id="f-436">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" format="ixt:fixed-zero" scale="3" id="f-437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" format="ixt:fixed-zero" scale="3" id="f-438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" format="ixt:fixed-zero" scale="3" id="f-439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-440">724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current liabilities and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-444">39,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-445">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-446">2,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-447">4,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash (used in) provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-448">74,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-449">10,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-450">3,529</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-451">7,431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditure on intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="f-452">247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="f-453">248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="f-454">863</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="f-455">653</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditure on property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-456">1,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-457">661</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-458">424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-459">1,054</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Advances for note receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="wald:AdvancesForNoteReceivable" format="ixt:fixed-zero" scale="3" id="f-460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="wald:AdvancesForNoteReceivable" format="ixt:fixed-zero" scale="3" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="wald:AdvancesForNoteReceivable" format="ixt:num-dot-decimal" scale="3" id="f-462">2,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="wald:AdvancesForNoteReceivable" format="ixt:fixed-zero" scale="3" id="f-463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from trust account</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="wald:ProceedsFromTrustAccount" format="ixt:num-dot-decimal" scale="3" id="f-464">44,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="wald:ProceedsFromTrustAccount" format="ixt:fixed-zero" scale="3" id="f-465">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="wald:ProceedsFromTrustAccount" format="ixt:fixed-zero" scale="3" id="f-466">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="wald:ProceedsFromTrustAccount" format="ixt:fixed-zero" scale="3" id="f-467">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisition of Obagi Business Combinations, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-468">465,010</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-469">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-470">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-471">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisition of Milk Business Combinations, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-472">122,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-473">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-474">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-475">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-476">544,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-477">909</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-478">3,787</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-479">1,707</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from PIPE investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="3" id="f-480">118,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:fixed-zero" scale="3" id="f-481">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:fixed-zero" scale="3" id="f-482">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:fixed-zero" scale="3" id="f-483">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from FPA investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="wald:ProceedsFromForwardPurchaseAgreements" format="ixt:num-dot-decimal" scale="3" id="f-484">333,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="wald:ProceedsFromForwardPurchaseAgreements" format="ixt:fixed-zero" scale="3" id="f-485">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="wald:ProceedsFromForwardPurchaseAgreements" format="ixt:fixed-zero" scale="3" id="f-486">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="wald:ProceedsFromForwardPurchaseAgreements" format="ixt:fixed-zero" scale="3" id="f-487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-488">175,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:fixed-zero" scale="3" id="f-489">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-490">110,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:fixed-zero" scale="3" id="f-491">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment of term loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-492">4,348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-493">1,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-494">72,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-495">9,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-146</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from revolving credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-496">14,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-497">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-498">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-499">29,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Repayment of revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-500">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-501">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-502">44,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-503">9,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from PPP Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromOtherDebt" format="ixt:fixed-zero" scale="3" id="f-504">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromOtherDebt" format="ixt:fixed-zero" scale="3" id="f-505">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProceedsFromOtherDebt" format="ixt:fixed-zero" scale="3" id="f-506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ProceedsFromOtherDebt" format="ixt:num-dot-decimal" scale="3" id="f-507">6,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-508">6,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="f-509">742</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-510">6,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-511">1,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payment of dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:fixed-zero" scale="3" id="f-512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:fixed-zero" scale="3" id="f-513">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="f-514">2,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="f-515">2,044</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-516">629,465</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-517">3,883</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-518">5,162</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-519">14,319</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-520">10,121</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-521">7,063</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-522">4,904</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-523">5,181</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-524">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-525">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-526">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-527">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;Beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-528">78</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-529">13,444</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-530">8,572</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-531">3,391</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;End of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-532">10,163</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-533">6,477</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-534">13,444</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-535">8,572</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SUPPLEMENTAL CASH FLOW DATA &#8211; CASH PAID:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-536">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-537">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="f-538">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-539">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-540">5,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-541">5,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-542">10,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-543">5,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NON-CASH INVESTING AND FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures in accounts payable and accruals</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-544">406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-545">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-546">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-547">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital contribution of trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="wald:CapitalContribution" format="ixt:fixed-zero" scale="3" id="f-548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="wald:CapitalContribution" format="ixt:fixed-zero" scale="3" id="f-549">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="wald:CapitalContribution" format="ixt:fixed-zero" scale="3" id="f-550">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="wald:CapitalContribution" format="ixt:num-dot-decimal" scale="3" id="f-551">4,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Obagi China Distribution to shareholder</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="wald:DistributionToShareholderForDispositionOfBusiness" format="ixt:fixed-zero" scale="3" id="f-552">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="wald:DistributionToShareholderForDispositionOfBusiness" format="ixt:num-dot-decimal" scale="3" id="f-553">13,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="wald:DistributionToShareholderForDispositionOfBusiness" format="ixt:fixed-zero" scale="3" id="f-554">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="wald:DistributionToShareholderForDispositionOfBusiness" format="ixt:fixed-zero" scale="3" id="f-555">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;Issuance of ordinary shares for Obagi Business Combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-556">277,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:fixed-zero" scale="3" id="f-557">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:fixed-zero" scale="3" id="f-558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:fixed-zero" scale="3" id="f-559">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of ordinary shares for Milk Business Combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-560">200,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:fixed-zero" scale="3" id="f-561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:fixed-zero" scale="3" id="f-562">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:fixed-zero" scale="3" id="f-563">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Conversion of promissory note to warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="f-564">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="3" id="f-565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="3" id="f-566">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="3" id="f-567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-147</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Waldencast plc</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In U.S. dollars, except share and per share data)</span></div></td></tr></table></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_118"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="f-568" continuedAt="f-568-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">ORGANIZATION AND DESCRIPTION OF BUSINESS</span></ix:nonNumeric></div><ix:continuation id="f-568-1" continuedAt="f-568-2"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-14" name="us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList" id="f-569">Successor</ix:nonNumeric></span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast plc (&#8220;Waldencast&#8221;), formerly known as Waldencast Acquisition Corp., is a Jersey company. Waldencast was originally incorporated on December 8, 2020 as a Cayman Islands exempted company and a blank check company solely for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. On March&#160;18, 2021, Waldencast consummated an initial public offering of <ix:nonFraction unitRef="shares" contextRef="c-89" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-570">34,500,000</ix:nonFraction> units (the &#8220;IPO&#8221;), with each unit consisting of <ix:nonFraction unitRef="shares" contextRef="c-90" decimals="INF" name="wald:StockholdersEquityNumberOfSharesInEachUnit" format="ixt-sec:numwordsen" scale="0" id="f-571">one</ix:nonFraction> Class A ordinary share and one-third of one redeemable warrant (&#8220;Public Warrant&#8221;) to acquire <ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-572">one</ix:nonFraction> Class A ordinary share (together, a &#8220;Unit&#8221;), at $<ix:nonFraction unitRef="usdPerShare" contextRef="c-92" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-573">10.00</ix:nonFraction> per Unit.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Business Combination (as defined below), on July 26, 2022, with the approval of Waldencast&#8217;s shareholders, and in accordance with the Cayman Companies Act (the &#8220;Cayman Act&#8221;), the Companies (Jersey) Law 1991, as amended (the &#8220;Jersey Companies Law&#8221;) and Waldencast&#8217;s amended and restated memorandum and articles of association, Waldencast effected a deregistration under the Cayman Act and a domestication under Part 18C of the Jersey Companies Law (by means of filing a memorandum and articles of association with the Registrar of Companies in Jersey), pursuant to which Waldencast&#8217;s jurisdiction of incorporation was changed from the Cayman Islands to Jersey (the &#8220;Domestication&#8221;). Upon the effective time of the Domestication, Waldencast Acquisition Corp. was renamed Waldencast plc.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2022 (the &#8220;Closing Date&#8221;), Waldencast acquired Obagi Global Holdings Limited, a Cayman Islands exempted company, and its subsidiaries (collectively, &#8220;Obagi&#8221;) and Milk Makeup LLC, a Delaware limited liability company, and its subsidiaries (collectively &#8220;Milk&#8221;) (the &#8220;Business Combination&#8221;), as described below in &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_127">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Business Combinations.&#8221; Following the Business Combination, the Company (as defined below) conducts its business through the following reportable segments: (i) Obagi Skincare and (ii) Milk Makeup. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi is a global skincare company that develops, markets, and sells proprietary-topical aesthetic and therapeutic prescription-strength skincare systems and related products primarily in the physician-dispensed market. Obagi provides cosmetic, over-the-counter (&#8220;OTC&#8221;) and prescription products. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup develops and sells cosmetic, skin care and other beauty products. The brand creates vegan, cruelty-free, clean formulas from its Milk headquarters in downtown New York City. Milk&#8217;s products are offered through its U.S. website, www.milkmakeup.com, and its retail partners including Sephora in North America, Europe, the Middle East, Australia, Cult Beauty, and ASOS online.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Business Combination, Waldencast is organized as an &#8220;Up-C&#8221; structure, whereby the equity interests of Obagi and Milk are held by Waldencast Partners LP (&#8220;Waldencast Partners LP&#8221;), a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cayman Islands exempted limited partnership and indirect </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsidiary of Waldencast, which is an entity that is classified as a partnership for U.S. federal income tax purposes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Predecessor</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi Global Holdings Limited is a holding company incorporated in the Cayman Islands that conducts all operations through its wholly-owned subsidiaries. Obagi is a global skincare company that develops, markets, and sells proprietary-topical aesthetic and therapeutic prescription-strength skincare systems and related products primarily in the physician-dispensed market. Obagi provides cosmetic, OTC and prescription products. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Board of Directors of Obagi approved (i) an increase in the number of Obagi&#8217;s authorized ordinary shares from <ix:nonFraction unitRef="shares" contextRef="c-93" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-574">50,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-575">25,000,000</ix:nonFraction>, (ii) an issuance of <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-576">4,000,000</ix:nonFraction> ordinary shares to ZhongHua Finance Acquisition Fund I, L.P. (&#8220;ZhongHua&#8221;), and (iii) a <ix:nonFraction unitRef="number" contextRef="c-95" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" format="ixt-sec:numwordsen" scale="0" id="f-577">two</ix:nonFraction>-for-one stock split of Obagi&#8217;s issued and outstanding ordinary shares (in combination with the share issuance to ZhongHua, the &#8220;Stock Split&#8221;), all of which became effective on December 2, 2020. Obagi was held by a single shareholder, and the share issuance to ZhongHua was deemed akin to a </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-148</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-568-2"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock split. All share, per share amounts and related shareholders&#8217; equity balances presented herein have been retroactively adjusted to reflect the impact of the Stock Split.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2021, ZhongHua, Obagi&#8217;s sole shareholder, transferred its shares to its affiliate, Cedarwalk Skincare Ltd. (&#8220;Cedarwalk&#8221;), which became the new sole shareholder of Obagi. This transfer between affiliates did not result in any change of control.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the Business Combination, Obagi carved out and distributed all of the outstanding shares of its subsidiary, Obagi Hong Kong Limited (&#8220;Obagi Hong Kong&#8221; or &#8220;Obagi HK&#8221;) to its shareholder, Cedarwalk (the &#8220;Obagi China Distribution&#8221;). All sales of Obagi products in the People&#8217;s Republic of China, inclusive of the Hong Kong Special Administrative Region, the Macau Special Administrative Region, and Taiwan (the &#8220;China Region&#8221;) prior to the Business Combination had been conducted through Obagi Hong Kong and its subsidiaries (the &#8220;Obagi China Business&#8221;), which were not acquired by Waldencast in the Business Combination.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-578" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast has prepared the accompanying consolidated financial statements pursuant to generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for the Business Combination, Waldencast was deemed to be the legal and the accounting acquirer (referred to as the &#8220;Successor&#8221;), however, Obagi was deemed to be the predecessor entity for financial reporting purposes (referred to as the &#8220;Predecessor&#8221;). Under the acquisition method of accounting, Waldencast&#8217;s assets and liabilities retained their carrying values and the assets and liabilities associated with Obagi and Milk were recorded at their fair values measured as of the acquisition date, which created a new basis of accounting.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This change in accounting basis is represented in the accompanying consolidated financial statements by a black line, which appears between the columns entitled Successor and Predecessor in the financial statements and in the relevant accompanying notes. The black line signifies that the consolidated financial statements presented for the Company after the Closing Date (the &#8220;Successor Period&#8221;) are presented on a measurement basis different from those for the period prior to the Closing Date (the &#8220;Predecessor Periods&#8221;). As a result of the application of the acquisition method of accounting as of the Closing Date, the financial statements for the Predecessor Periods (which only includes Obagi, including the Obagi China Business, through July 27, 2022) and for the Successor Period (which includes Waldencast and its subsidiaries from July 28, 2022 to December 31, 2022) are presented on a different basis of accounting and are, therefore, not comparable.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context requires otherwise, the &#8220;Company&#8221; refers to Obagi for periods prior to the Business Combination and to Waldencast together with its consolidated subsidiaries, as the Successor for periods after the Business Combination.</span></div></ix:nonNumeric></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_1097"></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:ErrorCorrectionTextBlock" id="f-580" continuedAt="f-580-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">RESTATEMENT AND RECLASSIFICATIONS</span></ix:nonNumeric></div><ix:continuation id="f-580-1" continuedAt="f-580-2"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restatement of Previously Issued Financial Statements</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, management of the Company (&#8220;Management&#8221;) and the audit committee of the Company&#8217;s Board of Directors (&#8220;the Board&#8221;), conducted an internal review, with the assistance of legal and accounting advisors, pertaining to certain accounting practices used by Obagi in connection with the recognition of revenue from sales of Obagi products to its Southeast Asia Distributor (the &#8220;SA Distributor&#8221;) in Vietnam, transactions with other Obagi distributors, both within and outside the U.S., as well as other accounting issues. Management and the audit committee identified misstatements in the previously issued consolidated financial statements as of December 31, 2021 and for the years ended December 31, 2021 and 2020 (Predecessor Periods) as described below.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the Company has restated the accompanying consolidated balance sheet as of December 31, 2021 (Predecessor Period) and consolidated statements of operations and comprehensive loss, cash flows, and shareholders&#8217; equity for the years ended December 31, 2021 and 2020 (Predecessor Periods) from amounts previously reported.</span></div></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-149</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-580-2" continuedAt="f-580-3"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Restatement Adjustments</span></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A summary of the restatement adjustments are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:6.91pt">Net revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; The Company identified misstatements primarily relating to distributor fees and the recognition of revenue from <ix:nonFraction unitRef="distributor" contextRef="c-86" decimals="INF" name="wald:MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors" format="ixt-sec:numwordsen" scale="0" id="f-581"><ix:nonFraction unitRef="distributor" contextRef="c-8" decimals="INF" name="wald:MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors" format="ixt-sec:numwordsen" scale="0" id="f-582">three</ix:nonFraction></ix:nonFraction> of Obagi&#8217;s distributors: the SA Distributor, Obagi&#8217;s exclusive supplier for the physician-dispensed channel in the U.S. (&#8220;Physician Channel Provider&#8221;), and the distributor for Obagi&#8217;s U.S. e-commerce platforms (&#8220;U.S. Online Marketplace Distributor&#8221;). <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" id="f-583" continuedAt="f-583-1" escape="true">The following table summarizes the impact of the restatement to net revenue:</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-583-1" continuedAt="f-583-2"><div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributor fees for services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-584">39,146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SA Distributor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-586">14,220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-587">1,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physician Channel Provider </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-588">8,191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-589">8,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US Online Marketplace Distributor </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-590">1,773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-591">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-592">267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-593">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total net revenue adjustments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-594">63,597</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-595">10,283</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Distributor fees for services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; Obagi&#8217;s distributors charge fees for certain services they render. The Predecessor (Obagi) had recorded these service fees as selling, general and administrative (&#8220;SG&amp;A&#8221;) and research and development (&#8220;R&amp;D&#8221;) expenses. Management subsequently determined these service fees should have been recognized as a reduction to net revenue, as the additional services provided by distributors were not distinct from the distributors&#8217; purchase of Obagi products. This resulted in an overstatement of net revenue of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-596">39.1</ix:nonFraction> million and corresponding overstatements of SG&amp;A expenses and R&amp;D expenses of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-597">37.1</ix:nonFraction> million $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" sign="-" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-598">2.0</ix:nonFraction> million, respectively, for the year ended December 31, 2021 (Predecessor Period). The misstatement had no impact to net income or cash flows for the year ended December 31, 2021 (Predecessor Period). There was no similar accounting misstatement identified for the year ended December 31, 2020 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:10.5pt">SA Distributor </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211; The Predecessor historically recognized revenue for products sold to Obagi&#8217;s SA Distributor upon shipment of the products. Management determined that the SA Distributor revenue should have been recognized when Obagi had no remaining performance obligations and received substantially all of the consideration related to each purchase order in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">(&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">606&#8221;). This resulted in an overstatement of accounts receivable of $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" sign="-" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-599">24.8</ix:nonFraction> million as of December 31, 2021 (Predecessor Period), an overstatement of net revenue of $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-600">14.2</ix:nonFraction> million for the year ended December 31, 2021 (Predecessor Period), and an understatement of net revenue of $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-601">1.7</ix:nonFraction> million for the year ended December 31, 2020 (Predecessor Period). </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Physician Channel Provider</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> - The Predecessor historically recognized revenue for products sold in the physician dispensed, or Direct-to-Physician (&#8220;DTP&#8221;), channel upon the transfer of products to the Physician Channel Provider. Management determined that although the products were transferred to the Physician Channel Provider, the Physician Channel Provider did not obtain actual control of the products until immediately prior to selling through to the physician customer. Therefore, revenue should have been recognized only immediately prior to transfer of products to physicians (i.e., when the products were sold to the physicians) rather than when they were transferred to the Physician Channel Provider. In addition, the Physician Channel Provider charged fees for certain services rendered by it (as discussed above) and the Predecessor recorded these service fees as SG&amp;A and R&amp;D expenses, instead of as a reduction to net revenue. As a result of these items, there was an overstatement of net revenue of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-602">8.2</ix:nonFraction> million, an understatement of cost of goods sold of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-603">0.4</ix:nonFraction> million, an overstatement of SG&amp;A of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-604">7.1</ix:nonFraction> million, an overstatement of accounts receivable of $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" sign="-" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-605">14.8</ix:nonFraction> million, and an understatement of inventory of $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-606">2.0</ix:nonFraction> million as of and for the year ended December 31, 2021 (Predecessor Period). For the year ended December 31, 2020 (Predecessor Period) this resulted in an understatement of revenue of $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-607">8.6</ix:nonFraction> million, an understatement of cost of goods sold of $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-608">2.6</ix:nonFraction> million, and an overstatement of SG&amp;A of $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-609">4.9</ix:nonFraction> million.  </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">U.S. Online Marketplace Distributor &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> The Predecessor agreed to nonstandard payment terms in its contracts with the U.S. Online Marketplace Distributor and allowed for payments over a period of time that exceeded <ix:nonNumeric contextRef="c-111" name="wald:MinimumThresholdPeriodForContractRepaymentOverTime" format="ixt-sec:durday" id="f-610"><ix:nonNumeric contextRef="c-112" name="wald:MinimumThresholdPeriodForContractRepaymentOverTime" format="ixt-sec:durday" id="f-611">365</ix:nonNumeric></ix:nonNumeric> days until final payment of an invoice. Management subsequently identified misstatements to revenue recognition relating to the significant financing component of such </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-150</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-580-3" continuedAt="f-580-4"><ix:continuation id="f-583-2" continuedAt="f-583-3"><div style="padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">arrangement, timing of revenue, and incorrect accounting of shipping activities. The net impact of these misstatements resulted in an overstatement of net revenue of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-612">1.8</ix:nonFraction> million, an understatement of other income of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:OtherNonoperatingIncome" scale="6" id="f-613">1.0</ix:nonFraction> million and an understatement of deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-614">0.7</ix:nonFraction> million as of and for the year ended December 31, 2021 (Predecessor Period) and an understatement of net revenue of $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-615">0.1</ix:nonFraction> million for the year ended December 31, 2020 (Predecessor Period).</span></div></ix:continuation><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><ix:continuation id="f-583-3" continuedAt="f-583-4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Other net revenue adjustments &#8211; </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"><ix:continuation id="f-583-4" continuedAt="f-583-5">Other net revenue adjustments were individually and in the aggregate insignificant for the years ended December 31, 2021 and 2020 (Predecessor Periods).</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:6.34pt">Cost of goods sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; <ix:continuation id="f-583-5" continuedAt="f-583-6">The following table summarizes the impact of the restatement to cost of goods sold:</ix:continuation></span></div><ix:continuation id="f-583-6" continuedAt="f-583-7"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:39.749%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physician Channel Provider</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="f-616">374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-617">2,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory obsolescence provision </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" sign="-" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="f-618">583</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="f-619">665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other - adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-620">1,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-621">1,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total net cost of goods sold adjustments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-622">1,673</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-623">4,471</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Physician Channel Provider </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; As described above in (a)3, Management determined that it should have recognized revenue and cost of goods sold for products sold to the Physician Channel Provider immediately prior to the transfer of products to the physicians, which resulted in understatements of costs of goods sold as set forth in the table above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Inventory obsolescence provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; The Company did not appropriately adjust the inventory reserve for obsolete inventory. In connection with the restatement, the Company corrected its historical inventory obsolescence provision. This resulted in an overstatement of cost of goods sold of $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" sign="-" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-624">0.6</ix:nonFraction> million for the year ended December 31, 2021 (Predecessor Period) and an understatement of $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-625">0.7</ix:nonFraction> million for the year ended December 31, 2020 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:10.5pt">Other net cost of goods sold adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; The Predecessor historically recorded certain promotional products in marketing expenses. Management determined that it should have recorded such promotional products in inventory and cost of goods sold, which resulted in understatements of costs of goods sold as set forth in the table above. The other net cost of goods sold adjustments related to the understatement of cost of goods sold were insignificant both individually and in the aggregate for the years ended December 31, 2021 and 2020 (Predecessor Periods).</span></div></ix:continuation><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:6.91pt">SG&amp;A </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; <ix:continuation id="f-583-7" continuedAt="f-583-8">The following table summarizes the impact of the restatement to SG&amp;A expenses:</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-583-8" continuedAt="f-583-9"><div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributor fees for services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-626">37,075</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:fixed-zero" scale="3" id="f-627">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physician Channel Provider </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-628">7,065</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-629">4,891</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-630">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="f-631">472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="f-632">732</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-633">1,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other - adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="f-634">974</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="f-635">546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total SG&amp;A adjustments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-636">44,523</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-637">3,138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Distributor fees for services &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described above in (a)1, the Predecessor had incorrectly recorded certain payments to distributors for services on a gross basis in net revenue which caused an overstatement of SG&amp;A expenses.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Physician Channel Provider &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> As described above in (a)3, the Predecessor had recorded fees for certain services to the Physician Channel Provider in SG&amp;A expenses as opposed to a reduction to net revenue, which cause an overstatement of SG&amp;A expenses. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Computer software &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> As described below in (j), the Predecessor historically capitalized certain computer software expenses that should have been expensed as incurred. This adjustment resulted in </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-151</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-580-4" continuedAt="f-580-5"><ix:continuation id="f-583-9" continuedAt="f-583-10"><div style="padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">understatements of SG&amp;A expenses of $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-638">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-639">0.5</ix:nonFraction> million for the years ended December 31, 2021 and 2020 (Predecessor Periods), respectively.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Prepaid expenses &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described below in (h)1 through (h)2, the Predecessor historically capitalized certain expenses primarily related to marketing and advertising activities. Obagi should have expensed these items in the period in which the expenses were incurred. These misstatements resulted in an overstatement of SG&amp;A expenses of $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-640">0.7</ix:nonFraction> million for the year ended December 31, 2021 (Predecessor Period) and an understatement of $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-641">1.8</ix:nonFraction> million for the year ended December 31, 2020 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:10.5pt">Other SG&amp;A adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> As described in (b)3, management determined that it should have recorded certain promotional products in cost of goods sold instead of marketing expenses, which resulted in an overstatement of SG&amp;A expenses as set forth in the table above. The other SG&amp;A adjustments were individually and in the aggregate insignificant for the years ended December 31, 2021 and 2020 (Predecessor Periods). </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:6.34pt">R&amp;D </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Distributor fees for services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; As described above in (a)1, the Predecessor had incorrectly recorded fees for certain services in R&amp;D expenses as opposed to a reduction to net revenue, which caused an overstatement of R&amp;D expenses.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Prepaid expenses &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described below in (h), Obagi should have expensed certain costs that were previously capitalized related to R&amp;D activities. These misstatements resulted in understatements of R&amp;D expenses of $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-642">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-643">0.5</ix:nonFraction> million for the years ended December 31, 2021 and 2020 (Predecessor Periods), respectively.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Other R&amp;D expense &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The other R&amp;D expense misstatements were individually and in the aggregate insignificant for the years ended December 31, 2021 and 2020 (Predecessor Periods).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:6.91pt">Other expenses (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> - As described above in (a)4, the Predecessor did not adjust the transaction price for a significant financing component in its contract with the U.S. Online Marketplace Distributor. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:8.01pt">Accounts receivable, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; <ix:continuation id="f-583-10" continuedAt="f-583-11">The following table summarizes the impact of the restatement to accounts receivable, net:</ix:continuation></span></div><ix:continuation id="f-583-11" continuedAt="f-583-12"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:69.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SA Distributor </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" sign="-" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-644">24,821</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physician Channel Provider</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" sign="-" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-645">14,796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncollectible loan receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" sign="-" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-646">2,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" sign="-" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-647">2,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total accounts receivable, net adjustments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" sign="-" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-648">44,629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">SA Distributor &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described above in (a)2, the Company restated revenue for products sold to the SA Distributor and adjusted the overstatement of accounts receivable, net. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Physician Channel Provider</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; As described above in (a)3, the Company restated revenue for products sold in the DTP channel and adjusted the overstatement of accounts receivable, net.  </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Uncollectible loan receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; The Predecessor did not record the loss on the write-off of a one-time uncollectible loan receivable related to the Obagi China Business in the period it was deemed uncollectible. This resulted in an overstatement of accounts receivable, net of $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" sign="-" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-649">2.5</ix:nonFraction> million as of December 31, 2021 (Predecessor Period) and an understatement of a loss on the write-off of the loan receivable of $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" sign="-" name="wald:GainLossOnNoteReceivableWriteoff" scale="6" id="f-650">2.6</ix:nonFraction> million for the year ended December 31, 2021 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; The Company identified misstatements related to certain distributor receivables, aged accounts receivable and other accounts receivable. The aggregate impact of these misstatements resulted in an overstatement of accounts receivable, net of $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" sign="-" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-651">2.5</ix:nonFraction> million as of December 31, 2021 (Predecessor Period).</span></div></ix:continuation><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:6.34pt">Inventories </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; <ix:continuation id="f-583-12" continuedAt="f-583-13">The following table summarizes the impact of the restatement to inventories:</ix:continuation></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-152</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-580-5" continuedAt="f-580-6"><ix:continuation id="f-583-13" continuedAt="f-583-14"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:69.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physician Channel Provider </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-652">2,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory obsolescence provision </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" sign="-" name="us-gaap:InventoryNet" scale="3" id="f-653">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other adjustments  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:InventoryNet" scale="3" id="f-654">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total net inventory adjustments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-655">2,272</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Physician Channel Provider </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; As described above in (a)3, the Predecessor historically recognized cost of goods sold for products sold in the DTP channel upon transfer of the products to the Physician Channel Provider instead of immediately prior to transfer of the products to physician customers, which resulted in an understatement of inventory. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Inventory obsolescence provision </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; As described above in (b)2, as a result of misstatements in inventory, the Company had an overstatement of inventory of $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-5" sign="-" name="us-gaap:InventoryNet" scale="6" id="f-656">0.1</ix:nonFraction> million as of December 31, 2021 (Predecessor Period). </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; As described in (b)3, management determined that it should have recorded certain promotional products in inventory and cost of goods sold instead of marketing expenses, which resulted in an understatement of inventory of $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-657">0.3</ix:nonFraction> million as of December 31, 2021 (Predecessor Period).</span></div></ix:continuation><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:106%;padding-left:6.34pt"> Prepaid Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Marketing costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; The Predecessor capitalized and amortized certain expenses related to marketing activities that did not meet the criteria for capitalization. Obagi should have expensed these items in the periods in which the expenses were incurred. This resulted in an overstatement to prepaid expenses of $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-6" sign="-" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="f-658">2</ix:nonFraction> million as of December 31, 2021 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">R&amp;D &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> The Predecessor capitalized and amortized certain expenses related to R&amp;D activities. Obagi should have expensed these items in the periods in which the expenses were incurred. This resulted in an overstatement of prepaid expenses of $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" sign="-" name="us-gaap:PrepaidExpenseCurrent" scale="6" id="f-659">1.1</ix:nonFraction> million as of December 31, 2021 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Other prepaid expense adjustments &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The other prepaid expense misstatements were individually and in the aggregate insignificant as of December 31, 2021 (Predecessor Period). </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:8.57pt">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The ot</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">her current assets misstatements were individually and in the aggregate insignificant as of December 31, 2021 (Predecessor Period). </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(j)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:8.57pt">Property and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; The Predecessor historically capitalized certain internal use software costs that did not meet the criteria for capitalization. Obagi should have recorded these expenses in the periods in which they were incurred. This resulted in an overstatement of property and equipment, net of $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" sign="-" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-660">2.4</ix:nonFraction> million as of December 31, 2021 (Predecessor Period), however it had an insignificant impact on depreciation expense for the years ended December 31, 2021 and 2020 (Predecessor Periods).</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(k)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:6.34pt">Other non-current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; As described above in (h), the Predecessor historically capitalized prepaid expenses and included the long-term portion of such expenses in other non-current assets. Obagi should have recognized these expenses in the periods in which they were incurred. This resulted in an overstatement of other non-current assets of $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" sign="-" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-661">1.2</ix:nonFraction> million as of December 31, 2021 (Predecessor Period). </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(l)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:8.57pt">Accounts payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; The Predecessor historically did not appropriately accrue for certain costs incurred in the period. These misstatements were individually insignificant, but in the aggregate resulted in an understatement of accounts payable of $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-662">1.3</ix:nonFraction> million as of December 31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(m)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:3.57pt">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">   </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:106%;padding-left:10.5pt">Deferred revenue &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">As described above in (a)4, the Company identified misstatements to revenue recognized for the SA Distributor and the U.S. Online Marketplace Distributor. Obagi should have recorded deferred revenue for payments received in advance of the revenue recognition. These adjustments resulted in an understatement of other current liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-663">0.7</ix:nonFraction> million as of December 31, 2021 (Predecessor Period).</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-153</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-580-6" continuedAt="f-580-7"><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Accrued payroll and related expenses &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company identified misstatements to accrued liabilities for employee related compensation matters and other expenses. This resulted in an understatement of other current liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-664">0.2</ix:nonFraction> million as of December 31, 2021 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Accrued distribution service fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> The Company identified misstatements to accrued distribution service fees which should have been classified as contra-accounts receivable. This resulted in an overstatement of other current liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" sign="-" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-665">1.2</ix:nonFraction> million as of December 31, 2021 (Predecessor Period).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(n)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Tax Accounting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; The Company recalculated its income tax expense and related liabilities as a result of the restatements. The tax impact of the restatements was a decrease to income tax expense of $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-666">1.7</ix:nonFraction> million and an increase to income tax expense of $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-667">1.7</ix:nonFraction> million for the years ended December 31, 2021 and 2020 (Predecessor Periods), respectively. There was no impact to the balance sheet as of December 31, 2021 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(o)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">&#160;&#160;&#160;&#160;Accumulated Deficit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; The cumulative impact of the restatement adjustments for the previously reported periods increased accumulated deficit by approximately $<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-668">37.3</ix:nonFraction> million as of January 1, 2020. The effects of the restatement adjustment to opening accumulated deficit as of January 1, 2020 primarily relates to restatement adjustments associated with the SA Distributor, the Physician Channel Provider, U.S. Online Marketplace Distributor, and prepaid expenses as described above in (a)2, (a)3, (a)4, and (h), respectively. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to enhance the clarity of financial information for users of these financial statements, the Company has elected to make certain reclassifications to its consolidated statements of operations and comprehensive loss. As such, certain amounts in the prior periods presented have been reclassified to conform to the current period financial statement presentation. These reclassification changes do not constitute errors because they represent changes in presentation from one acceptable method to another acceptable method under U.S. GAAP. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Reclassifications</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categories of the reclassification adjustments and their impact on previously reported consolidated financial statements are described below: </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(p) The Company chose to reclassify depreciation and amortization expenses presented historically in the Predecessor Periods as a separate line item to cost of goods sold and SG&amp;A expenses. Depreciation expense of property and equipment was reclassified to SG&amp;A expenses and amortization expense of product-related intangible assets (e.g., supply agreement, formulations) was reclassified to cost of goods sold. These reclassifications align the historical presentation in the Predecessor Periods to the Successor Period presentation in the consolidated statement of operations and comprehensive loss.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Cost of goods sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; <ix:continuation id="f-583-14" continuedAt="f-583-15">The following table summarizes the impact of the reclassification adjustments to cost of goods sold:</ix:continuation></span></div><ix:continuation id="f-583-15" continuedAt="f-583-16"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-669">4,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-670">4,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(q) The Company chose to reclassify amounts related to the effect of foreign exchange rates on cash and cash equivalents and present them as a separate line item from the change in cash, cash equivalents and restricted cash. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(r) The Company previously did not present gross profit. The Company has changed the presentation in its statement of operations to present gross profit, which resulted in cost of goods sold being reclassified from being grouped with other operating expenses to being part of the separate gross profit presentation.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-154</span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_1203"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-580-7" continuedAt="f-580-8"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Consolidated Financial Statement Adjustments Tables</span></div><ix:continuation id="f-583-16" continuedAt="f-583-17"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the effects of the restatement and reclassification adjustments to the previously issued consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEET</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.479%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">As Reported</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Restatement Adjustments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Restatement Reference</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-671">12,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="f-672">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-673">12,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-674">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="f-675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-676">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-677">63,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" sign="-" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-678">44,629</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">f</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-679">18,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-680">19,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-681">2,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">g</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-682">21,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-683">7,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" sign="-" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-684">2,979</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">h</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-685">4,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-686">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" sign="-" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-687">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">i</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-688">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-689">104,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" sign="-" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-690">45,392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-691">59,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-692">3,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" sign="-" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-693">2,386</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-694">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-695">79,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="f-696">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-697">79,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-698">44,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="f-699">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-700">44,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-701">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" sign="-" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-702">1,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">k</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-703">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">TOTAL ASSETS</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-704">233,573</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" sign="-" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-705">48,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-706">184,586</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CURRENT LIABILITIES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-707">11,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-708">1,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">l</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-709">12,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-710">15,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-711">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">n.m.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-712">15,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-713">12,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" sign="-" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-714">300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">m</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-715">12,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-716">39,740</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-717">1,065</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-718">40,805</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Long-term debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-719">103,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="3" id="f-720">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-721">103,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="f-722">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-723">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="f-724">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-725">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" sign="-" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-726">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">n.m.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="f-727">571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">TOTAL LIABILITIES</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-728">144,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-729">1,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-730">145,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">SHAREHOLDERS' EQUITY:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Predecessor common shares, <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-731">25,000,000</ix:nonFraction> shares authorized; $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-732">0.50</ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-733"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-734">8,000,002</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-735">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="f-736">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="f-737">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-738">100,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:fixed-zero" scale="3" id="f-739">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-740">100,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-741">14,798</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-742">50,051</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-743">64,849</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-744">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="f-745">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-746">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">TOTAL SHAREHOLDERS' EQUITY</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-747">89,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-748">50,051</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-749">39,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-750">233,573</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" sign="-" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-751">48,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-752">184,586</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n.m. - not meaningful</span></div></ix:continuation></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-155</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-583-17" continuedAt="f-583-18"><ix:continuation id="f-580-8" continuedAt="f-580-9"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE (LOSS)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restatement Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restatement Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-753">206,069</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-754">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-755">63,597</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-756">142,472</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-757">53,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-758">1,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b,p,r</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-759">55,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross profit </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-760">87,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-761">48,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" sign="-" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-762">48,708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-763">118,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-764">9,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-765">44,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c,p</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-766">82,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-767">6,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="3" id="f-768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-769">899</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d,a(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-770">6,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-771">14,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" sign="-" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-772">13,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-773">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">j,p</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="3" id="f-774">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating expenses </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="wald:OperatingExpensesAndCostOfGoodSold" format="ixt:num-dot-decimal" scale="3" id="f-775">187,995</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" sign="-" name="wald:OperatingExpensesAndCostOfGoodSold" format="ixt:num-dot-decimal" scale="3" id="f-776">53,364</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-777">45,571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-778">89,060</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-779">18,074</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:fixed-zero" scale="3" id="f-780">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-781">19,699</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-782">1,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-783">11,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="f-784">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:InterestExpense" scale="3" id="f-785">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n.m.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-786">11,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-787">2,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-788">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-789">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-790">2,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on PPP Loan forgiveness</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="wald:GainOnPPPLoanForgiveness" format="ixt:num-dot-decimal" scale="3" id="f-791">6,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="wald:GainOnPPPLoanForgiveness" format="ixt:fixed-zero" scale="3" id="f-792">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="wald:GainOnPPPLoanForgiveness" format="ixt:fixed-zero" scale="3" id="f-793">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="wald:GainOnPPPLoanForgiveness" format="ixt:num-dot-decimal" scale="3" id="f-794">6,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on write-off of loan receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="wald:GainLossOnNoteReceivableWriteoff" format="ixt:fixed-zero" scale="3" id="f-795">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="wald:GainLossOnNoteReceivableWriteoff" format="ixt:fixed-zero" scale="3" id="f-796">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="wald:GainLossOnNoteReceivableWriteoff" format="ixt:num-dot-decimal" scale="3" id="f-797">2,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="wald:GainLossOnNoteReceivableWriteoff" format="ixt:num-dot-decimal" scale="3" id="f-798">2,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses (income), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-799">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-800">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-801">1,011</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-802">817</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total other (income) expenses, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-803">6,843</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-804">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-805">1,506</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-806">8,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Loss) income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-807">11,231</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-808">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-809">21,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-810">9,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-811">11,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-812">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-813">1,699</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-814">9,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="f-815">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="3" id="f-816">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-817">19,506</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-818">19,576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-139" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-819"><ix:nonFraction unitRef="usdPerShare" contextRef="c-139" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-820">0.01</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-107" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-821"><ix:nonFraction unitRef="usdPerShare" contextRef="c-107" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-822">2.44</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-823"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-824">2.45</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares used in computing net loss per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-825"><ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-826">8,000,002</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-827"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-828">8,000,002</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="f-829">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="3" id="f-830">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-831">19,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-832">19,576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-833">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="f-834">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="f-835">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-836">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-837">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-838">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-839">19,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-840">19,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n.m. - not meaningful</span></div></ix:continuation></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-156</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-583-18" continuedAt="f-583-19"><ix:continuation id="f-580-9" continuedAt="f-580-10"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restatement Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restatement Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-841">84,145</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-842">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-843">10,283</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-844">94,428</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-845">24,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-846">4,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b,p,r</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-847">29,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross profit </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-848">65,332</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-849">19,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" sign="-" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-850">19,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-851">54,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-852">8,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-853">3,138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c,p</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-854">60,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-855">3,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:fixed-zero" scale="3" id="f-856">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-857">454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-858">4,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-859">13,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" sign="-" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-860">13,421</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" sign="-" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-861">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">j,p</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="3" id="f-862">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating expenses </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="wald:OperatingExpensesAndCostOfGoodSold" format="ixt:num-dot-decimal" scale="3" id="f-863">92,118</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" sign="-" name="wald:OperatingExpensesAndCostOfGoodSold" format="ixt:num-dot-decimal" scale="3" id="f-864">24,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" sign="-" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-865">2,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-866">64,804</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-867">7,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:fixed-zero" scale="3" id="f-868">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-869">8,501</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="f-870">528</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-871">6,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="f-872">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="f-873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-874">6,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-875">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-876">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-877">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-878">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total other (income) expenses, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-879">6,292</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-880">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-881">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-882">6,292</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Loss) income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-883">14,265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-884">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-885">8,501</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-886">5,764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-887">5,094</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-889">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-890">3,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-891">9,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="3" id="f-892">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-893">6,801</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-894">2,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-142" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-895"><ix:nonFraction unitRef="usdPerShare" contextRef="c-142" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-896">1.14</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-108" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-897"><ix:nonFraction unitRef="usdPerShare" contextRef="c-108" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-898">0.84</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-899"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-900">0.30</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares used in computing net loss per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-901"><ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-902">8,000,002</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-903"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-904">8,000,002</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-905">9,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:fixed-zero" scale="3" id="f-906">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-907">6,801</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-908">2,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-909">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="f-910">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="f-911">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-912">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-913">9,155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-914">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-915">6,801</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-916">2,354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-157</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-583-19" continuedAt="f-583-20"><ix:continuation id="f-580-10" continuedAt="f-580-11"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CONSOLIDATED STATEMENT OF CASH FLOWS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars)</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restatement Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restatement Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="f-917">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-918">19,506</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-919">19,576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="wald:DepreciationDepletionAndAmortizationOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-920">14,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="wald:DepreciationDepletionAndAmortizationOperatingActivities" scale="3" id="f-921">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="wald:DepreciationDepletionAndAmortizationOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-922">13,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-923">2,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-925">2,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gain on PPP Loan forgiveness</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="wald:GainOnPPPLoanForgiveness" format="ixt:num-dot-decimal" scale="3" id="f-926">6,824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="wald:GainOnPPPLoanForgiveness" format="ixt:fixed-zero" scale="3" id="f-927">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="wald:GainOnPPPLoanForgiveness" format="ixt:num-dot-decimal" scale="3" id="f-928">6,824</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-929">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-930">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n.m.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-931">1,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-932">11,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-933">1,699</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-934">9,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on disposal of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-935">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="f-936">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-937">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on write-off of loan receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="wald:GainLossOnNoteReceivableWriteoff" format="ixt:fixed-zero" scale="3" id="f-938">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="wald:GainLossOnNoteReceivableWriteoff" format="ixt:num-dot-decimal" scale="3" id="f-939">2,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">f</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="wald:GainLossOnNoteReceivableWriteoff" format="ixt:num-dot-decimal" scale="3" id="f-940">2,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-941">23,790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-942">18,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">f</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-943">5,057</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-944">5,359</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-945">651</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">g</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-946">6,010</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-947">2,654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-948">1,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">h</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-949">1,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-950">2,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-951">1,711</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">i,k</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-952">612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-953">8,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-954">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">l, q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-955">9,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current liabilities and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-956">4,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-957">1,782</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">m</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-958">2,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash (used in) provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-959">5,070</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-960">1,541</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-961">3,529</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditure on intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="f-962">937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="f-963">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n.m.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="f-964">863</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditure on property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-965">1,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-966">1,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-967">424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Advances for note receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="wald:AdvancesForNoteReceivable" format="ixt:num-dot-decimal" scale="3" id="f-968">2,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="wald:AdvancesForNoteReceivable" format="ixt:fixed-zero" scale="3" id="f-969">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="wald:AdvancesForNoteReceivable" format="ixt:num-dot-decimal" scale="3" id="f-970">2,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash used in investing activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-971">5,360</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-972">1,573</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-973">3,787</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash provided by financing activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-974">5,162</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-975">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-976">5,162</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-977">4,872</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="f-978">32</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-979">4,904</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-980">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-981">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">q</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-982">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;Beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-983">8,572</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-984">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-985">8,572</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;End of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-986">13,444</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-987">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-988">13,444</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SUPPLEMENTAL CASH FLOW DATA &#8211; CASH PAID:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="f-989">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="f-990">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="f-991">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-992">10,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-993">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-994">10,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NON-CASH INVESTING AND FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures in accounts payable and accruals</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-995">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" sign="-" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-996">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-997">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-158</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-583-20"><ix:continuation id="f-580-11"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENT OF CASH FLOWS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars)</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restatement Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restatement Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-998">9,171</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-999">6,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-1000">2,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="wald:DepreciationDepletionAndAmortizationOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1001">13,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" sign="-" name="wald:DepreciationDepletionAndAmortizationOperatingActivities" scale="3" id="f-1002">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="wald:DepreciationDepletionAndAmortizationOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1003">13,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-1004">798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="f-1005">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-1006">798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1007">4,743</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1008">1,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1009">3,044</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-1010">961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-1011">15,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">f</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-1012">16,661</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-1013">1,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-1014">2,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">g</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-1015">4,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-1016">2,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="f-1017">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">h</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-1018">1,919</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="f-1019">998</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-1020">2,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">i,k</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-1021">1,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" sign="-" name="wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-1022">7,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties" scale="3" id="f-1023">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">l</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-1024">7,391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current liabilities and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1025">2,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1026">1,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">m</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1027">4,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash (used in) provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1028">7,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="f-1029">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1030">7,431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditure on intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="f-1031">652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="f-1032">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="f-1033">653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditure on property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1034">1,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" sign="-" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-1035">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1036">1,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash used in investing activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1037">1,887</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-1038">180</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1039">1,707</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash provided by financing activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1040">14,319</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-1041">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1042">14,319</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-1043">5,181</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:fixed-zero" scale="3" id="f-1044">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-1045">5,181</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;Beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1046">3,391</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-1047">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1048">3,391</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;End of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1049">8,572</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-1050">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1051">8,572</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SUPPLEMENTAL CASH FLOW DATA &#8211; CASH PAID:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-1052">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="f-1053">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-1054">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-1055">5,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-1056">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-1057">5,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NON-CASH INVESTING AND FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures in accounts payable and accruals</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-1058">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" sign="-" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-1059">186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-1060">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital contribution of trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="wald:CapitalContribution" format="ixt:num-dot-decimal" scale="3" id="f-1061">4,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="wald:CapitalContribution" format="ixt:fixed-zero" scale="3" id="f-1062">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="wald:CapitalContribution" format="ixt:num-dot-decimal" scale="3" id="f-1063">4,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div id="if2fc25067f8b45fc8cc165df93f3be1c_124"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-1064" continuedAt="f-1064-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></ix:nonNumeric></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-1065" escape="true"><ix:continuation id="f-1064-1" continuedAt="f-1064-2"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The accompanying consolidated financial statements include the accounts of Waldencast and its consolidated subsidiaries. The Company consolidates entities in which the Company has a majority voting interest. The Company eliminates intercompany transactions and accounts in consolidation. The Company separately presents within equity on the consolidated balance sheets the ownership interests attributable to parties with noncontrolling interests in the Company's consolidated subsidiaries, and separately presents net income attributable to such parties on the consolidated statements of operations and comprehensive loss.</span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-159</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1064-2" continuedAt="f-1064-3"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a registration statement declared effective under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or do not have a class of securities registered under the Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This may make comparison of the Company&#8217;s consolidated financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-1066" escape="true"><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Significant estimates and assumptions reflected in the financial statements include, but are not limited to, revenue recognition, fair value of assets acquired and liabilities assumed in business combinations, stock-based compensation, and valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and assumptions that it believes are reasonable at the time. Due to the inherent uncertainty involved in making assumptions and estimates, changes in circumstances could result in actual results differing from those estimates, and such differences could be material to the Company&#8217;s consolidated balance sheets and consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-1067" continuedAt="f-1067-1" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company maintains its cash balances in accounts held by major banks and financial institutions located primarily in the U.S. and considers such risk to be minimal. Such bank deposits from time to time may be exposed to credit risk in excess of the Federal Deposit Insurance Corporation insurance limit.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable primarily represent amounts due from distributors, and third-party logistics companies, directly and indirectly from major retailers, and from group purchasing organizations located both inside and outside the U.S. The Company mitigates its credit risks by performing ongoing credit evaluations of its customers&#8217; financial conditions, requiring customer advance payments in certain circumstances. The Company generally does not require collateral. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 (Successor Period), two U.S. customers accounted for <ix:nonFraction unitRef="number" contextRef="c-149" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1068">50</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-150" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1069">19</ix:nonFraction>% of accounts receivable, respectively. As of December&#160;31, 2021 (Predecessor Period), three U.S. customers accounted for <ix:nonFraction unitRef="number" contextRef="c-151" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1070">41</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-152" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1071">14</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="c-153" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1072">10</ix:nonFraction>% of accounts receivable, respectively. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period from July 28, 2022 to December&#160;31, 2022 (Successor Period), one vendor exceeded 10% of inventory purchases. During the period from January 1, 2022 to July&#160;27, 2022 (Predecessor Period), three vendors exceeded 10% of inventory purchases. During the period from July 28, 2022 to December&#160;31, 2022 (Successor Period), the Company purchased approximately <ix:nonFraction unitRef="number" contextRef="c-154" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1073">27</ix:nonFraction>% of inventory from one vendor. During the period from January 1, 2022 to July&#160;27, 2022 (Predecessor Period), the Company purchased approximately <ix:nonFraction unitRef="number" contextRef="c-155" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1074">23</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-156" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1075">12</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="c-157" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1076">12</ix:nonFraction>% of inventory, respectively, from three vendors. During the year ended December&#160;31, 2021 (Predecessor Period), two vendors exceeded 10% of inventory purchases. In 2021 (Predecessor Period), the Company purchased approximately <ix:nonFraction unitRef="number" contextRef="c-158" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1077">45</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-159" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1078">11</ix:nonFraction>% of inventory, respectively, from two vendors.</span></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><ix:continuation id="f-1067-1" continuedAt="f-1067-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 (Successor Period), two</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vendors accounted for</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-160" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1079">15</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-161" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1080">12</ix:nonFraction>%,</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1067-2">respectively, of accounts payable. As of December&#160;31, 2021 (Predecessor Period), one vendor accounted for <ix:nonFraction unitRef="number" contextRef="c-162" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1081">24</ix:nonFraction>% of accounts payable.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-1082" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company considers highly liquid investments with an initial maturity of three months or less to be cash and cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-1083" continuedAt="f-1083-1" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company&#8217;s restricted cash represents funds that were not accessible for general purpose cash needs due to contractual limitations. As of December&#160;31, 2022 (Successor Period), the Company&#8217;s cash, cash </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-160</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1064-3" continuedAt="f-1064-4"><ix:continuation id="f-1083-1" continuedAt="f-1083-2"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equivalents, and restricted cash balance of $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1084">10.2</ix:nonFraction> million shown on the consolidated statements of cash flows consisted of $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="f-1085">1.5</ix:nonFraction>&#160;million of restricted cash and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-1086">8.7</ix:nonFraction>&#160;million of cash and cash equivalents. The restricted cash balance represented cash in a savings account held by a major bank located in the U.S. and provides collateral for corporate credit cards obtained by the Predecessor for its employees. The Company is required to hold the restricted cash in the bank&#8217;s savings account. Following the acquisition of Milk, the Company had an additional $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" format="ixt:num-dot-decimal" scale="6" id="f-1087">0.8</ix:nonFraction> million in restricted cash held with a financial institution as collateral for a lease deposit. The deposit is refundable at the end of the lease in November 2030, provided that Milk does not default on its lease payments. </span></div></ix:continuation><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1083-2">As of December&#160;31, 2021 (Predecessor Period) the Company&#8217;s cash, cash equivalents, and restricted cash balance of $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-1088">13.4</ix:nonFraction> million as shown on the consolidated statements of cash flows consisted of $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="f-1089">0.6</ix:nonFraction> million restricted cash and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-1090">12.8</ix:nonFraction> million in cash and cash equivalents.</ix:continuation> </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-1091" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company&#8217;s products are produced by third-party contract manufacturers (&#8220;CMOs). Inventories consist of finished goods, work-in-process products and promotional products, valued at the lower of cost or net realizable value using the standard cost method, which approximates actual costs determined on a first-in, first-out (&#8220;FIFO&#8221;) basis. In order to track inventory quantities, the Company uses a perpetual inventory system. Promotional product is charged to cost of goods sold at the time the product is shipped to the Company&#8217;s customer.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has in-transit inventory at any given period. Assessment of in-transit inventory is required to determine inventory balances accurately at period-end. Inventory is recognized when the Company holds title and bears substantially all of the risks and rewards of ownership. In many transactions, the transfer of title and the risks and rewards of ownership are dictated by contractually specified shipping terms, which may take the form of free-on-board (&#8220;FOB&#8221;) shipping point or FOB destination point.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If historical costs exceed the net realizable value at the balance sheet date, the Company adjusts the inventory to net realizable value (i.e., if impairment is identified, the Company records write-downs of inventories to cost of goods sold in the period in which it occurs). The Company evaluates the carrying value of inventories on a regular basis and determines the need to write down carrying values by considering historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost, and the remaining shelf life of goods on hand. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Obsolete, Scrap and Expired Inventory</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inventory provision is set up for inventory that is expected to become obsolete or have a decreased value due to market trends or product upgrades. It accounts for losses that may occur when the inventory cannot be sold at its full cost. The Company regularly monitors any inventory that is not expected to be sold prior to the expiration date and historically slow-moving inventory based on the remaining shelf life and incorporates these considerations into its reserve analysis. Additionally, each period, Management will evaluate whether any additional write downs are required in addition to the calculated reserve amount (generally, by stock keeping unit (&#8220;SKU&#8221;) and/or lot). Specific reserves may relate to known matters, such as quality concerns or a discontinued product.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Sales Returns</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the Company has not experienced a material amount of product returns. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain arrangements may give the Company&#8217;s customers the right to return products. In addition, when customer arrangements do not give the Company&#8217;s customer the explicit right to return products, the Company may accept returns on a discretionary basis. The Company records a return asset for products returned by customers measured at the former carrying amount of the inventory, less any expected costs to recover the goods and potential decreases in value. If the returned inventory is not considered re-sellable, it will be written off to cost of goods sold. When customers have the right to receive a refund for defective or damaged products (as opposed to a replacement product), the right is accounted for as a right of return under ASC 606. When customers have the right to receive a replacement product for defective or damaged products, the right is accounted for as a warranty under ASC 460-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Company accrues for replacement costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesPolicyTextBlock" id="f-1092" continuedAt="f-1092-1" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivatives </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accounts for derivative instruments in accordance with ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 815&#8221;), which requires additional disclosures about the Company&#8217;s objectives and strategies for using </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-161</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1064-4" continuedAt="f-1064-5"><ix:continuation id="f-1092-1"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">derivative instruments, how the derivative instruments and related hedged items are accounted for, and how the derivative instruments and related hedging items affect the consolidated financial statements. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses interest rate collars to mitigate interest risk associated with its variable rate credit agreements. See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_145">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Financial Instruments&#8221; for further discussion of the interest rate collar. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Terms of debt instruments are reviewed to determine whether they contain embedded derivative instruments that are required to be accounted for separately from the host contract and recorded on the consolidated balance sheets at fair value under ASC 815. An evaluation of specifically identified conditions is made to determine whether the fair value of warrants issued is required to be classified as equity or as a derivative liability. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Liabilities</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for Public Warrants and Private Placement Warrants (each as defined below) as liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 480&#8221;) and ASC 815. Specifically, the Public and Private Placement Warrants meet the definition of a derivative but do not qualify for an exception from derivative accounting since the warrants are not indexed to the Company&#8217;s stock and, therefore, are precluded from equity classification. Since the Public and Private Placement Warrants meet the definition of a derivative under ASC 815, the Company measures the warrants at fair value at inception and at each reporting date, with changes in fair value recognized in change in fair value of derivative warrant liabilities in the consolidated statements of operations and comprehensive loss in the period of change. See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_145">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Financial Instruments&#8221; for further discussion of the warrants, including the FPA Warrants (as defined below).</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-1093" continuedAt="f-1093-1" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the interest rate collar and warrant liabilities were estimated using inputs based on management&#8217;s judgment and conditions that existed at each reporting date. See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_151">Note 1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_151">1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for further details.</span></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1093-1">The fair values of the Company&#8217;s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and all other current liabilities approximate their carrying values because of the short maturities of these instruments. Additionally, the carrying amount of debt approximates fair value due to the adjusting interest rates of the Company&#8217;s term loan, which approximate current market rates.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="f-1094" continuedAt="f-1094-1" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Capitalized Software and Website Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212; The Company capitalizes costs related to (i) internal-use software (ii) cloud computing arrangement (&#8220;CCA&#8221;) implementation costs, and (iii) other software-related costs (e.g., website development costs).</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For internal-use software, both internal and external costs incurred during the preliminary project stage are expensed as incurred, and qualifying costs incurred during the application development state are capitalized. Capitalization ceases no later than the point at which a software project is substantially completed and ready for its intended use. </span></div></ix:nonNumeric></ix:continuation><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-162</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1064-5" continuedAt="f-1064-6"><ix:continuation id="f-1094-1"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For CCAs, or hosting arrangements, the Company evaluates if the CCA includes a software license that will be accounted for in addition to a hosting service. The cost of the arrangement (i.e., license or service cost) of a CCA that includes a software license will be capitalized as an acquisition of an asset (similar to internal-use software) and amortized over its useful economic life, whereas the costs of a service contract are expensed as incurred.  </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs related to website development are expensed as incurred during the planning stage, content development stage, and operating stage. The Company generally capitalizes costs incurred for activities during the website application and infrastructure development stage, and graphics development stage. Costs incurred for website hosting services from a third-party vendor are expensed over the period the services are received.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Internal-use software costs and website development costs are amortized on a straight-line basis over their estimated useful lives, which is generally <ix:nonNumeric contextRef="c-164" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-1095">three years</ix:nonNumeric> or less. Management evaluates the useful lives of these assets and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets.</span></div></ix:continuation><div style="padding-left:18pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="wald:PrepaidExpensesPolicyTextBlock" id="f-1096" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; At initial recognition, the Company measures prepaid assets based on cost (i.e., amount paid). In the accounting period or periods in which a good or service is used or received, the asset will be reduced by a proportionate amount and an associated asset (e.g., inventory) or expense (e.g., marketing) will be recorded.   </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Prepaid Inventory</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prepayments are required to begin production of inventory at certain of the Company&#8217;s CMOs and inventory suppliers. Vendors are tracked to determine prepayments that have been made and when the associated inventory is expected to be delivered to the Company (i.e., when the Company takes ownership of the inventory). Prepaid inventory is triggered by invoices received from CMOs (i.e., the vendor). When the Company submits purchase orders, the CMOs may request a prepayment amount (deposit) based on agreed-upon percentage in the vendor contracts to start the production process.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Prepaid Marketing and Advertising</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally expenses the costs of advertising and marketing as costs are incurred, except for costs associated with producing advertising. While production costs (i.e., costs to develop promotions for a specific campaign associated with an identified new brand or new product) are incurred during the process of production, the Company has elected to expense certain costs when the associated advertising takes place. In the event that the advertising is not expected to occur (e.g., decision has been made to not launch a promotion) or a <ix:nonNumeric contextRef="c-1" name="wald:RecognitionPeriodForDeferredAdvertisingCostsMaximum" format="ixt-sec:durwordsen" id="f-1097">12-month</ix:nonNumeric> period elapses without the associated advertising occurring, the associated production costs will be expensed.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-1098" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Property and equipment are stated at cost, net of accumulated depreciation. In the case of a business combination, acquired property and equipment are recognized at their fair value as of the date of acquisition. Following initial recognition, property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of respective assets. No depreciation is charged to construction in progress. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-1099" continuedAt="f-1099-1" escape="true">The estimated useful lives of the Company&#8217;s assets are as follows:</ix:nonNumeric></span></div><ix:continuation id="f-1099-1" continuedAt="f-1099-2"><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ESTIMATED&#160;USEFUL&#160;LIVES</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-165" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-1100">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-166" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-1101">3</ix:nonNumeric> - <ix:nonNumeric contextRef="c-167" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-1102">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-168" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-1103">3</ix:nonNumeric> - <ix:nonNumeric contextRef="c-169" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-1104">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gondolas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-170" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-1105">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lesser of useful life or term of lease</span></td></tr></table></div></ix:continuation><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="f-1106" continuedAt="f-1106-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets, Net</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1106-1">&#8212;Intangible assets consist primarily of trademarks and trade names, a supply agreement, customer relationships, formulations, and developed technology. Intangible assets acquired in a business combination are recognized at their fair value as of the date of acquisition. Following initial recognition, intangible assets are carried at cost less accumulated amortization and impairment losses, if any, and are amortized on a straight-line basis over the estimated useful life of the asset.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-163</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1064-6" continuedAt="f-1064-7"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-1107" continuedAt="f-1107-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1107-1">&#8212;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, for each asset group held for use with indicators of impairment, the Company compares the expected future cash flows generated by the asset group, which represents the lowest level at which cash flows are identifiable, with its associated net carrying value. If the net carrying value of the asset group exceeds expected undiscounted cash flows, the excess of the net book value over estimated fair value is charged to impairment loss.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-1108" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; When the Company acquires a business, the total purchase consideration provided is allocated to the identifiable assets and liabilities of the acquired business at their estimated respective fair values. Any excess consideration of the fair value of purchase consideration over the fair values of assets acquired and liabilities assumed is recognized as goodwill.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgments and assumptions are required in determining the fair value of assets acquired and liabilities assumed. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows, useful lives and discount rates. Measurement period adjustments are reflected at the time identified, up through the conclusion of the measurement period, which is the time at which all information for determination of the values of assets acquired and liabilities assumed is received, which may not exceed one year from the acquisition date. The Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with a corresponding offset to goodwill. If outside of the measurement period, any subsequent adjustments are recorded in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-1109" continuedAt="f-1109-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Goodwill represents the difference between the purchase price and the fair value of assets and liabilities acquired in a business combination. The Company reviews goodwill for impairment annually on October 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1109-1"> and at an interim date if events or changes in circumstances indicate the occurrence of a triggering event. The Company reviews goodwill for impairment by initially considering qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill, as a basis for determining whether it is necessary to perform a quantitative analysis. If it is determined that it is more likely than not that the fair value of reporting unit is less than its carrying amount, a quantitative analysis is performed to identify goodwill impairment. Determining the fair value of a reporting unit involves the use of significant estimates and assumptions.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtPolicyTextBlock" id="f-1110" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company capitalizes costs related to the issuance of debt instruments, as applicable. Such costs are initially recorded as a direct deduction from the applicable debt instrument and amortized over the contractual term of the related debt instrument in interest expense, net using the straight-line method, which approximates the effective interest method, in the consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-1111" continuedAt="f-1111-1" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Trade accounts receivable are stated at net realizable value. Receivables are unsecured and represent amounts billed to and currently due from customers that have yet to be collected. Payment terms are generally short-term in nature and are less than one year. In certain circumstances, the Company offers extended payment terms to customers. When the period between the transfer of control of the products and payment is greater than one year, the Company adjusts the promised amount of consideration for the effects of a significant financing component. </span></div></ix:nonNumeric><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1111-1">The Company maintains an allowance for doubtful accounts, which represents allowances for customer trade accounts receivable that are both probable and estimated to be partially or entirely uncollectible. These allowances are used to reduce gross trade receivables to their net realizable value. The Company records these allowances based on estimates related to the following factors: (i)&#160;customer-specific allowances, based upon past collection history, historical trends, and identification of specific customer risk and (ii)&#160;formula-based general allowances using an aging schedule. Determining such allowances involves the use of significant estimates and assumptions. Payments of accounts receivable are allocated to the specific invoices identified on the customer&#8217;s remittance advice or to the customer&#8217;s account, if unspecified, until an invoice can be determined by the customer. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to trade accounts receivable.</ix:continuation>  </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-1112" continuedAt="f-1112-1" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company recognizes revenue when control of the promised goods or services is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to for those goods or services. In that determination, under ASC 606 the Company follows a five-step model that includes: (1) determination of whether a contract or an agreement between two or more parties that creates legally enforceable </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-164</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1112-1" continuedAt="f-1112-2"><ix:continuation id="f-1064-7" continuedAt="f-1064-8"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rights and obligations exists; (2) identification of the performance obligations in the contract; (3) determination of the transaction price; (4) allocation of the transaction price to the performance obligations in the contract; and (5) recognition of revenue when (or as) performance obligations are satisfied. Net revenue excludes taxes collected by us on behalf of governmental authorities.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue is primarily generated from product sales to distributors, retailers, physicians and directly to consumers (&#8220;DTC&#8221;) via its e-commerce platforms. Distributors may resell products to retailers, physicians, or end consumers. To determine when to recognize revenue under ASC 606 in cases where products are sold to distributors, the Company analyzes various factors including its ability to direct products physically held by the distributors, when title and risk of loss transfers, and who ultimately manages the relationship with the end consumer. The Company does not recognize revenue until control of the products is transferred to the distributor.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, and when facts and circumstances change, the Company assesses whether it is probable that the Company will collect substantially all of the consideration it will be entitled to from a customer. If the Company determines that it is not probable that the Company will collect substantially all of the consideration from the customer, the Company recognizes revenue only when one or more of the following events occur: (i) the Company has no remaining obligations to transfer goods or services to the customer, and all, or substantially all, of the consideration promised by the customer has been received by the Company and is nonrefundable, (ii) the contract has been terminated, and the consideration received from the customer is nonrefundable, or (iii) the Company has transferred control of the goods or services to which the consideration that has been received relates, the Company has stopped transferring goods or services to the customer (if applicable) and has no obligation under the contract to transfer additional goods or services, and the consideration received from the customer is nonrefundable.  </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that each of its products is distinct and represents a separate performance obligation. The transaction price is equal to the consideration the Company is entitled to &#8211; which could be either a distributor, retailer, physician, or e-commerce end consumer. When measuring revenue and determining the consideration the Company is entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Product sales revenue is recognized net of provisions for estimated volume rebates and discounts, markdowns, margin adjustments, early-payment discounts and returns. The Company estimates variable consideration using the expected value method and adjusts the transaction price when control of the related product is transferred to the customer. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s distributors charge fees for certain services rendered by the distributors, including packing and shipping, marketing and advertising the Company&#8217;s products, monitoring product reviews, regulatory services, providing customer service, and generating data and analytical reports on product sales. Distributor fees for services are recognized as a reduction to revenue because the services provided are typically not distinct from the distributors&#8217; purchase of products.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, customers are required to pay either in advance or between <ix:nonNumeric contextRef="c-171" name="wald:CustomerPaymentPeriod" format="ixt-sec:durday" id="f-1113">30</ix:nonNumeric> and <ix:nonNumeric contextRef="c-172" name="wald:CustomerPaymentPeriod" format="ixt-sec:durday" id="f-1114">90</ix:nonNumeric> days from delivery or invoicing. However, in certain circumstances, the Company offers extended payment terms to customers. When the period between the transfer of control of the products and payment is greater than one year, the Company adjusts the promised amount of consideration for the effects of a significant financing component. When contracts contain a significant financing component in which the Company is effectively financing the customer, a portion of the transaction price is recognized as other income.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price to each performance obligation based on its relative standalone selling price. Standalone selling price is the price at which the Company would sell a promised product separately to a customer. The Company typically has an observable standalone selling price for each of its products.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has different contracted shipping terms with different customers that dictate the timing of payment, passage of legal title, transfer of physical possession, and assumption of the risks and rewards occur. For distributors, other than the Physician Channel Provider, and retailers, depending on the contract, the Company considers transfer of control to have occurred either once the delivery of the product has occurred or once the product has been picked up from the Company&#8217;s designated warehouse/distribution center by the customer&#8217;s shipping agent, unless the Company is responsible for shipping the goods, in which case transfer of control passes upon delivery to the customer. For DTC </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-165</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1064-8" continuedAt="f-1064-9"><ix:continuation id="f-1112-2" continuedAt="f-1112-3"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales and sales to physicians through the Physician Channel Provider, control transfers upon shipment to the end consumer or physician. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shipping and Handling </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for shipping and handling activities as fulfillment activities instead of as performance obligations and recognizes these costs as SG&amp;A expenses. Costs related to shipping and handling for the period from July&#160;28 to December&#160;31, 2022 (Successor Period), and the period from January&#160;1 to July&#160;27, 2022 (Predecessor Period), and the years ended December&#160;31, 2021 and 2020 (Predecessor Periods) were $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="wald:ShippingAndHandlingCosts" scale="6" id="f-1115">2.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="wald:ShippingAndHandlingCosts" scale="6" id="f-1116">0.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="wald:ShippingAndHandlingCosts" scale="6" id="f-1117">1.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="wald:ShippingAndHandlingCosts" scale="6" id="f-1118">0.2</ix:nonFraction> million, respectively. Amounts billed to customers for shipping and handling are included in revenue.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Promotional Products</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In situations where promotional products, such as samples and testers, are provided by the Company to its customers at the same time as a related saleable product, the cost of these promotional products are recognized as cost of sales at the same time as the revenue for the related product is recognized.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates royalty revenue from products sold under the Obagi brand name in Japan and Hong Kong through license agreements with local operators. Under these agreements, the Company provides the local operators with a license of intellectual property and receives a royalty based upon a percentage of net sales of Obagi-branded products sold in Japan and Hong Kong. Because the license is the predominant item to which the sales-based royalty relates, the Company recognizes revenue for the sales-based royalty when the local operators make sales of the products.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs to Obtain a Contract with a Customer</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the incremental costs of obtaining a customer contract as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. The incremental costs to obtain contracts primarily relate to sales commission and sales-based bonuses. Total capitalizable costs to obtain a contract were immaterial during the periods presented.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div></ix:continuation><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1112-3">The Company&#8217;s contracts do not typically give rise to material contract assets or contract liabilities because (i) payment is typically closely aligned with the timing of the Company&#8217;s performance or (ii) the Company performs prior to customer payment, and the Company has an unconditional right to payment that represents an account receivable. Similarly, the Company does not recognize material revenue in reporting periods from performance obligations satisfied in previous periods. The Company applies the exemption in ASC 606-10-50-14(a) related to disclosure of the amount of transaction price allocated to unsatisfied performance obligations for royalty contracts. Because of the short-term nature of product sales contracts, the Company typically does not have other material amounts to disclose related to the transaction price allocated to unsatisfied performance obligations.</ix:continuation> </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-1119" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cost of Goods Sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;Cost of goods sold consists of inventory and promotional product costs, including when inventory and promotional products are sold or written down, and product-related intangible asset amortization and depreciation expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-1120" continuedAt="f-1120-1" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;R&amp;D costs are expensed as incurred. Costs associated with research and development activities may include materials, equity and facility costs, personnel costs, contracted services (i.e., the costs of services performed by third parties in connection with the Company&#8217;s R&amp;D activities), and direct costs (e.g., appropriate allocations for general and administrative costs). Substantially all R&amp;D expenses are related to new product development and design improvements or increased functionality in current products. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may capitalize acquired assets associated with R&amp;D activities (e.g., materials, equipment) if both of the following criteria are met: (i) the Company reasonably expects that the acquired assets will be used in an alternative manner and anticipates an economic benefit from the alternative future use and (ii) the use of the acquired asset is not </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-166</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1064-9" continuedAt="f-1064-10"><ix:continuation id="f-1120-1"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contingent on the further development of the asset after acquisition date (i.e., the asset can be used in an alternative manner in the condition in which it existed at the acquisition date).</span></div></ix:continuation><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="f-1121" continuedAt="f-1121-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1121-1">&#8212;Advertising costs are expensed in the period in which they are incurred.</ix:continuation> Total advertising costs, included in SG&amp;A expense on the consolidated statements of operations and comprehensive loss, were $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="f-1122">11.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="f-1123">6.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="f-1124">9.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:AdvertisingExpense" scale="6" id="f-1125">5.9</ix:nonFraction> million for the period from July&#160;28 to December&#160;31, 2022 (Successor Period), the period from January&#160;1 to July&#160;27, 2022 (Predecessor Period) and the years ended December&#160;31, 2021 and 2020 (Predecessor Periods), respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-1126" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company measures the cost of share-based awards granted to eligible employees, directors, and consultants based on the grant-date fair value of the awards. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Replacement Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Closing Date, in connection with the Business Combination, the Company assumed Obagi and Milk&#8217;s legacy incentive award plans and outstanding unvested options granted under those plans (&#8220;Replacement Options&#8221;). Because the options were deemed in the money on the replacement date, a Hull-White lattice pricing model was used to estimate their fair value to capture the optimal timing of exercise. This pricing model requires the use of assumptions including the volatility of the underlying stock, the fair value of the stock, dividend yield, risk-free rate, and exercise multiple. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Founder Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value and derived service period of the stock options issued to founders (&#8220;Founder Awards&#8221;) in August 2022 based on the Monte Carlo simulation, as they were deemed out of the money on the grant date. The Monte Carlo simulation model requires the use of assumptions including the option&#8217;s expected term, the volatility of the underlying stock, dividend yield rate, risk-free rate, and expected exercise behavior. For expected exercise behavior, the Company assumes that the options are exercised after <ix:nonFraction unitRef="number" contextRef="c-173" decimals="2" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent" scale="-2" id="f-1127">50</ix:nonFraction>% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock is equal to the price of the Company&#8217;s ordinary shares on the grant date.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to recognize the effect of forfeitures in the period in which they occur. Share-based awards are classified as equity, unless the underlying shares are classified as liabilities or the Company is required to settle the awards by transferring cash or other assets.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for awards with service or performance conditions using the straight-line method over the requisite service period, which is generally the award&#8217;s vesting period. Compensation expense for employee stock-based awards whose vesting is subject to the fulfillment of both a service condition and the occurrence of a performance condition is recognized on a graded-vesting basis at the time the achievement of the performance condition becomes probable.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-1128" continuedAt="f-1128-1" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accounts for income taxes using the asset and liability approach. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes represents income taxes paid or payable for the current period plus the change in deferred taxes during the period. Deferred taxes result from differences between the financial and tax basis of the Company&#8217;s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether a valuation allowance is required often requires significant judgment including the long-range forecasting of future taxable income and the evaluation of planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made. A valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-1129">7.9</ix:nonFraction> million was recorded as of December&#160;31, 2022 (Successor Period), a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-1130">14.1</ix:nonFraction> million was recorded as of December&#160;31, 2021 (Predecessor Period), and <ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:fixed-zero" scale="0" id="f-1131">no</ix:nonFraction> valuation allowance was recorded as of December&#160;31, 2020 (Predecessor Period).</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-167</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1064-10" continuedAt="f-1064-11"><ix:continuation id="f-1128-1" continuedAt="f-1128-2"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for a tax benefit from an uncertain position in the consolidated financial statements only if it is more likely than not that the position is sustainable, based solely on its technical merits and consideration of the relevant taxing authority&#8217;s widely understood administrative practices and precedents. If the recognition threshold for the tax position is met, the Company records only the portion of the tax benefit that is greater than 50% likely to be realized. As of December&#160;31, 2022 (Successor Period), 2021 (Predecessor Period), and 2020 (Predecessor Period), the Company had <ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="f-1132"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="f-1133"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="f-1134">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> uncertain positions in the consolidated financial statements.</span></div></ix:continuation><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1128-2">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="3" id="f-1135"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="3" id="f-1136"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="3" id="f-1137">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> amounts accrued for interest and penalties as of December&#160;31, 2022 (Successor Period), or December 31, 2021 and 2020 (Predecessor Periods).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-1138" continuedAt="f-1138-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Income (Loss) Per Share</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1138-1">&#8212;Basic net income (loss) per share attributable to shareholders of ordinary shares is computed by dividing the Company&#8217;s net income (loss) attributable to holders of ordinary shares by the weighted-average number of ordinary shares used in the income (loss) per share calculation during the period. Diluted net income (loss) per share attributable to holders of ordinary shares is computed by giving effect to all potentially dilutive securities. The net income (loss) per share that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="f-1139" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Noncontrolling interests represent the portion of Waldencast Partners LP that the Company controls and consolidates but does not own. The Company recognizes each noncontrolling holder&#8217;s respective share of the estimated fair value of the net assets at the date of formation or acquisition. Noncontrolling interests are subsequently adjusted for the noncontrolling holder&#8217;s share of additional contributions, distributions and their share of the net earnings or losses of each respective consolidated entity. The Company allocates net income or loss to noncontrolling interests based on the weighted average ownership interest during the period. The net income (loss) that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss. The Company does not recognize a gain or loss on transactions with a consolidated entity in which it does not own 100% of the equity, but the Company reflects the difference in cash received or paid from the noncontrolling interests carrying amount as additional paid-in-capital.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-1140" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and incur expenses and about which separate financial information is regularly evaluated by the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) in deciding how to allocate resources. Similar operating segments can be aggregated into a single operating segment if the businesses are similar. Management has determined that, following the Business Combination, the Successor has <ix:nonFraction unitRef="segment" contextRef="c-14" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-1141"><ix:nonFraction unitRef="segment" contextRef="c-14" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1142">two</ix:nonFraction></ix:nonFraction> operating and reportable segments: Obagi Skincare and Milk Makeup, reflecting the manner in which the CODM operates the Company. The Company&#8217;s CODM is its Chief Executive Officer. The Predecessor had <ix:nonFraction unitRef="segment" contextRef="c-15" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1143"><ix:nonFraction unitRef="segment" contextRef="c-15" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-1144">one</ix:nonFraction></ix:nonFraction> operating and reportable segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-1145" continuedAt="f-1145-1" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;) using the modified retrospective transition method on the date of the Business Combination. The Predecessor planned to adopt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 842 during the annual period ended December&#160;31, 2022. Waldencast had no capital or operating lease obligations prior to the Business Combination. The Company elected the package of practical expedients available upon transition to ASC 842 that allow (i) historical lease classification of existing leases, (ii) no reassessment of any expired or existing contracts containing leases, and (iii) no reassessment of initial direct costs for any existing leases. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of the new standard impacted the Company&#8217;s accounting for operating leases. Upon adoption, the Company established an operating right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-1146">13.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and a corresponding operating lease liability of $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-1147">16.6</ix:nonFraction> million. The Company does not have any finance leases. See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_142">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further detail.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of ASC 842, the Company recognized rent expense for operating leases on a straight&#8209;line basis (including the effect of reduced or free rent and rent escalations) over the lease term. The difference between the cash paid to the landlord and the amount recognized as rent expense on a straight&#8209;line basis was recognized as an adjustment to deferred rent in the consolidated balance sheets.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Debt-Debt with Conversion and Other Options&#8221; (Subtopic 470-20) and &#8220;Derivatives and Hedging-Contracts in an Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-168</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1145-1" continuedAt="f-1145-2"><ix:continuation id="f-1064-11" continuedAt="f-1064-12"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 also removes certain settlement conditions that are required for equity-linked contracts to qualify for scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company adopted ASU 2020-06 on January 1, 2021. Adoption of the ASU did not impact the Company&#8217;s financial position, results of operations or cash flows.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU No.&#160;2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic&#160;848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was effective for the Company in the annual period ended December&#160;31, 2022. This ASU provides relief that, if elected, will require less accounting analysis and less accounting recognition for modifications related to reference rate reform. This update provides optional guidance for a limited period of time to ease the potential burden in accounting for reference rate reform on financial reporting. The amendments in the update apply only to contracts, hedging relationships, and other transactions that reference the London Inter-Bank Offered Rate (&#8220;LIBOR&#8221;) or another reference rate expected to be discontinued because of reference rate reform. Waldencast adopted this ASU prospectively effective January 1, 2022, which did not have a material effect on its consolidated financial position, results of operations and cash flows.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022, Waldencast adopted ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes&#8212;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2019-12&#8221;). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. Waldencast adopted this ASU prospectively, which did not have a material effect on its consolidated financial position, results of operations and cash flows.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards, Not Yet Adopted</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU No.&#160;2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements&#8212;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU adds an impairment model known as current expected credit loss that is based on expected losses rather than incurred losses. It recognizes an allowance as an estimate of expected credit losses, which may result in more timely recognition of such losses. In 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 326), which defers the effective date for entities in the &#8220;all other&#8221; category and public not-for-profit entities that have not yet issued their financial statements reflecting the adoption of credit losses. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, and early adoption is permitted. This guidance is effective for the Company for the annual period beginning on January 1, 2023, and interim periods within the annual period beginning on January 1, 2023, with earlier adoption permitted. The adoption of this new standard will not have a material effect on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The guidance requires an acquirer to, at the date of acquisition, recognize and measure the acquired contract assets and contract liabilities acquired in the same manner that they were recognized and measured in the acquiree&#8217;s financial statements before the acquisition. This guidance is effective for interim and annual periods beginning after December 15, 2022, with early adoption permitted. The amendments in this update should be applied prospectively to business combinations occurring on or after the effective date. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements, but does not expect it to have a material impact.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The guidance expands public entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. The guidance also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. This guidance is effective for interim periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. The amendments in this update should be applied retrospectively to all periods presented in the financial statements. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements but does not expect it to have a material impact.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-169</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1145-2"><ix:continuation id="f-1064-12"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2025, with early adoption permitted. The amendments should be applied prospectively however, retrospective application is also permitted. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements.</span></div></ix:continuation></ix:continuation><div id="if2fc25067f8b45fc8cc165df93f3be1c_127"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-1148" continuedAt="f-1148-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">BUSINESS COMBINATIONS</span></ix:nonNumeric></div><ix:continuation id="f-1148-1" continuedAt="f-1148-2"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2022, Waldencast consummated its initial business combination with (i) Obagi, pursuant to an Agreement and Plan of Merger dated November 15, 2021, by and among Waldencast, Obagi Merger Sub, Inc., a Cayman Islands exempted company limited by shares and an indirect wholly-owned subsidiary of Waldencast (&#8220;Merger Sub&#8221;), and Obagi (the &#8220;Obagi Merger Agreement&#8221;), and (ii), Milk, pursuant to an Equity Purchase Agreement dated November 15, 2021, by and among Waldencast, Obagi Holdco 1 Limited, a limited company incorporated under the laws of Jersey (&#8220;Holdco Purchaser&#8221;) and a subsidiary of Waldencast, Waldencast Partners LP together with Holdco Purchaser, (the &#8220;Purchasers&#8221;), certain members of Milk (the &#8220;Milk Members&#8221;), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as representative of the Milk Members (the &#8220;Equityholder Representative&#8221;) (the &#8220;Milk Equity Purchase Agreement&#8221; and together with the Obagi Merger Agreement, the &#8220;Transaction Agreements&#8221;).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Obagi Merger Agreement, at the effective time of the Obagi Merger (the &#8220;Obagi Merger Effective Time&#8221;) Merger Sub merged with and into Obagi (the &#8220;Obagi Merger&#8221;) and the separate corporate existence of Merger Sub ceased, with Obagi surviving as an indirect subsidiary of the Company. At the Obagi Merger Effective Time, all outstanding ordinary shares of Obagi, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-175" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1149">0.50</ix:nonFraction> par value (&#8220;Obagi common shares&#8221;) were canceled and exchanged for (i) <ix:nonFraction unitRef="shares" contextRef="c-176" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-1150">28,237,506</ix:nonFraction> Class A ordinary shares of Waldencast and (ii) cash in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1151">345.4</ix:nonFraction> million.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Milk Equity Purchase Agreement, at the effective time of the Milk Transaction (the &#8220;Milk Purchase Effective Time&#8221;) the Purchasers acquired from the Milk Members all of their equity in Milk in exchange for (i) <ix:nonFraction unitRef="shares" contextRef="c-178" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-1152">21,104,225</ix:nonFraction> limited partnership units in Waldencast Partners LP (&#8220;Waldencast LP Units&#8221;) (ii) <ix:nonFraction unitRef="shares" contextRef="c-179" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-1153">21,104,225</ix:nonFraction> Class B ordinary shares, which are non-economic voting shares of Waldencast and (iii) cash in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-1154">121.6</ix:nonFraction> million </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;Milk Transaction&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Waldencast LP Unit and Class B ordinary share held by a Milk Member is redeemable at the option of the holder, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, if such option is exercised, exchangeable at the option of Waldencast </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into <ix:nonFraction unitRef="shares" contextRef="c-181" decimals="INF" name="wald:CommonStockConvertibleConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-1155">one</ix:nonFraction> Waldencast Class A ordinary share or cash, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accordance with the terms of the Amended and Restated Waldencast Partners LP Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon consummation of the Business Combination </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast became organized in an &#8220;Up-C&#8221; structure, whereby the equity interests of Obagi and Milk are held by Waldencast Partners LP, which is an indirect subsidiary of Waldencast plc.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Business Combination, Waldencast was deemed to be the accounting acquirer and continues as the SEC registrant. Obagi and Milk were deemed to be the accounting acquirees, however Obagi is considered the predecessor entity for purposes of financial reporting. Waldencast was determined to be the accounting acquirer based on evaluation of the following factors:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">The owners of Waldencast have the largest voting interest in the combined company;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">The original owner of Waldencast, Waldencast Long-Term Capital LLC (the &#8220;Sponsor&#8221;), and its affiliates nominated the majority of the initial members who will serve on the board of directors of Waldencast (the former owner of Obagi nominated <ix:nonFraction unitRef="director" contextRef="c-175" decimals="INF" name="wald:NumberOfNominatedDirectors" format="ixt-sec:numwordsen" scale="0" id="f-1156">one</ix:nonFraction> director, and Milk nominated <ix:nonFraction unitRef="director" contextRef="c-182" decimals="INF" name="wald:NumberOfNominatedDirectors" format="ixt:fixed-zero" scale="0" id="f-1157">no</ix:nonFraction> directors); and</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Waldencast&#8217;s existing management holds executive management roles for the post-combination company, whilst Obagi and Milk management team members report into the current Waldencast executive team.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the Obagi Merger Effective Time, Obagi carved out and distributed the Obagi China Business to Cedarwalk pursuant to the Obagi China Distribution. Following the Obagi China Distribution, the Obagi China Business continues to be held by Cedarwalk, which also owned <ix:nonFraction unitRef="number" contextRef="c-183" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-1158">24.5</ix:nonFraction>% of the fully diluted Waldencast plc Class A ordinary shares as of the Obagi Merger Effective Time. Prior to the Obagi China Distribution, the pre-tax losses for the Obagi China Business were $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1159">8.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1160">3.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1161">2.3</ix:nonFraction> million for the period from January 1 to July 27, 2022 (Predecessor Period), the year ended December 31, 2021 (Predecessor Period) and the year ended December 31, 2020 (Predecessor Period), respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-170</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1148-2" continuedAt="f-1148-3"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_172">Note 17</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Transactions&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on ongoing transactions with the Obagi China Business following the close of the Obagi Merger. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurement period adjustments will be recognized in the reporting period in which the adjustments are determined.  </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-1162" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obagi and Milk Purchase Price Allocation:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Purchase Price:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-1163">345,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-1164">121,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-1165">467,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="f-1166">277,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="f-1167">200,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="f-1168">477,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash repayment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="wald:BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-1169">136,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="wald:BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-1170">3,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="wald:BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-1171">140,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="f-1172">22,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:fixed-zero" scale="3" id="f-1173">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="f-1174">22,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total purchase consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="f-1175">781,434</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="f-1176">325,651</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="f-1177">1,107,085</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1178">15,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1179">2,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1180">17,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" scale="3" id="f-1181">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" scale="3" id="f-1182">819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-1183">1,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Account receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="f-1184">15,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="f-1185">3,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="f-1186">19,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty" scale="3" id="f-1187">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty" scale="3" id="f-1188">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty" scale="3" id="f-1189">526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="3" id="f-1190">31,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="3" id="f-1191">30,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="3" id="f-1192">61,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-1193">4,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="f-1194">520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-1195">4,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" id="f-1196">359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" format="ixt:fixed-zero" scale="3" id="f-1197">-</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" id="f-1198">359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1199">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1200">8,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1201">9,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1202">505,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1203">157,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1204">662,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1205">4,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1206">8,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-1207">13,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="3" id="f-1208">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:fixed-zero" scale="3" id="f-1209">-</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="3" id="f-1210">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total identifiable assets acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="f-1211">579,316</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="f-1212">212,609</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="f-1213">791,925</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-1214">18,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-1215">6,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-1216">25,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="f-1217">12,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="f-1218">5,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="f-1219">18,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="f-1220">6,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="f-1221">10,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="f-1222">16,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1223">28,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-1224">-</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1225">28,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities assumed:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1226">66,145</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1227">22,030</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1228">88,175</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net assets acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-1229">513,171</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-1230">190,579</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-1231">703,750</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="f-1232">781,434</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="f-1233">325,651</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="f-1234">1,107,085</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1235">268,263</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1236">135,072</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1237">403,335</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill recognized for these acquisitions is attributable to improving the product offerings, expanding into additional markets and the expected cash flows resulting from these efforts, and assembled workforce. Goodwill recognized is not expected to be deductible for local tax purposes. During the Successor Period ended December 31, 2022, the Company recorded a non-cash impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-1238">68.7</ix:nonFraction> million within the Obagi Skincare reportable segment. See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_133">Note 6</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Goodwill&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional details.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_178">Note 19</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Segment Reporting&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for amounts related to revenue and earnings associated with Obagi Skincare and Milk Makeup subsequent to the acquisition date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related party liability</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company recognized a liability with respect to a related party supply contract executed on the Closing Date between Obagi and Obagi Hong Kong. The fair value of the related party liability was determined using the present value of after-tax cash flows related to unfavorable discounts provided to the Obagi China Business included in the supply agreement. As of the Obagi Merger Effective Time, the Company recognized a related party liability of $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="f-1239">22.1</ix:nonFraction> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-171</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1148-3" continuedAt="f-1148-4"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million. During the period from July 28 to December 31, 2022 (Successor Period), the Company amortized $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1240">12.2</ix:nonFraction> million of the related party liability into the related party revenue recognized on the sale of products to the Obagi China Business. The Company had a remaining related party liability of $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="f-1241">9.9</ix:nonFraction> million, included in Other current liabilities, as of December 31, 2022.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" id="f-1242" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Useful Life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks and Trade Name</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1243">414,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1244">145,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1245">559,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-201" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-1246">14</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer/distributor relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1247">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1248">11,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1249">36,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-205" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-1250">11</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tretinoin distribution and supply agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1251">38,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-1252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1253">38,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-209" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-1254">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formulations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1255">27,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1256">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1257">28,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-213" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-1258">8</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Intangible Assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1259">505,300</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1260">157,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1261">662,800</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible assets acquired in connection with the Business Combination are classified as Level 3 in the fair value hierarchy. The estimate of the fair values of the acquired amortizable intangible assets were determined using a multi-period excess earnings income approach by discounting the incremental after-tax cash flows over multiple periods. Significant estimates used in the determination include estimating future cash flows over multiple periods, terminal value, and discounting such cash flows at a rate of return that reflects the relative risk of the cash flows.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction Costs </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Business Combination, Waldencast incurred transactions costs of $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="f-1262">9.4</ix:nonFraction> million which was incurred during the period from July&#160;28, 2022 to December&#160;31, 2022 (Successor Period). Transaction costs consisted of advisory, legal, accounting and management fees, which are included in SG&amp;A expenses on the consolidated statements of operations and comprehensive loss. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unaudited ASC 805 Pro Forma </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="f-1263" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma combined financial information presents the Company&#8217;s results as though the Business Combination had occurred on January 1, 2021, for the years ended December&#160;31, 2021 and 2022. The unaudited pro forma consolidated financial information has been prepared using the acquisition method of accounting in accordance with U.S. GAAP.</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma net revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1264">200,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="f-1265">162,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1266">86,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1267">145,152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Pro forma net income (loss) attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" sign="-" name="wald:BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1268">25,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" sign="-" name="wald:BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1269">26,519</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma net income (loss) attributable to Waldencast plc</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" sign="-" name="wald:BusinessAcquisitionProFormaNetIncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1270">61,790</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" sign="-" name="wald:BusinessAcquisitionProFormaNetIncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1271">118,633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited pro forma results include adjustments such as inventory step-up, amortization of acquired intangible assets, and interest expense on debt financing in connection with the Business Combination. Material, nonrecurring pro forma adjustments directly attributable to the Business Combination include:&#160;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; Cost of goods sold related to acquired inventory step-up of $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1272">10.0</ix:nonFraction> million was removed from net income for the year ended December&#160;31, 2022 and recognized as an incremental cost of goods sold in the year ended December&#160;31, 2021. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-172</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1148-4" continuedAt="f-1148-5"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; Transaction related costs of $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="f-1273">66.1</ix:nonFraction> million were removed from net income for the year ended December&#160;31, 2022 and recognized as an expense in the year ended December&#160;31, 2021. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated pro forma financial information was prepared in accordance with accounting standards and is not necessarily indicative of the results of operations that would have occurred if the Business Combination had been completed on the date indicated, nor is it indicative of the future operating results of the Company.&#160;</span></div></ix:continuation><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1148-5">The unaudited pro forma results do not reflect events that either have occurred or may occur after the Business Combination, including, but not limited to, the anticipated realization of operating synergies in subsequent periods. They also do not give effect to certain charges that the Company expects to incur in connection with these acquisitions, including, but not limited to, additional professional fees and employee integration.</ix:continuation>&#160;</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_130"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-1274" continuedAt="f-1274-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">REVENUE</span></ix:nonNumeric></div><ix:continuation id="f-1274-1" continuedAt="f-1274-2"><div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates its revenue from customers by sales channel, as well as by revenue source and geographic region, based on the location of the end customer, as it believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Sales Channel</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue is primarily generated from product sales. Direct Sales revenue listed in the table below includes (i) sales to physicians through the Physician Channel Provider, (ii) DTC sales via the Company&#8217;s e-commerce platforms, and (iii) sales directly to retailers. Distributors revenue includes products sold through distributors other than the Physician Channel Provider.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="f-1275" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue by sales channel was as follows for the periods indicated: </span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Skincare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk  Makeup</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Sales Channel</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1276">30,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1277">30,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1278">60,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1279">28,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1280">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1281">29,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1282">59,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1283">31,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1284">90,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1285">1,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1286">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1287">1,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1288">61,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1289">31,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1290">92,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1 to July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Sales Channel</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1291">39,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1292">68,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1293">54,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1294">31,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1295">68,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1296">34,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1297">70,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1298">136,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1299">88,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1300">3,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1301">5,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1302">5,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1303">73,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1304">142,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1305">94,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period from July 28 to December 31, 2022 (Successor Period), three customers accounted for <ix:nonFraction unitRef="number" contextRef="c-244" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1306">29</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-245" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1307">18</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-246" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1308">16</ix:nonFraction>% of the Company&#8217;s revenue, respectively. During the period from January 1 to July 27, 2022, (Predecessor Period), two customers accounted for <ix:nonFraction unitRef="number" contextRef="c-247" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1309">44</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-248" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1310">20</ix:nonFraction>% of the Company&#8217;s revenue. For the year ended December 31, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-173</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1274-2" continuedAt="f-1274-3"><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 (Predecessor Period), two customers accounted for <ix:nonFraction unitRef="number" contextRef="c-249" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1311">44</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-250" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1312">17</ix:nonFraction>% of the Company&#8217;s revenue. For the year ended December 31, 2020 (Predecessor Period), one customer accounted for <ix:nonFraction unitRef="number" contextRef="c-251" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1313">57</ix:nonFraction>% of the Company&#8217;s revenue.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Physician Channel Provider is an authorized wholesale distributor and service provider for the Company in the U.S. Revenue from sales to physicians and e-commerce customers made through this provider are considered direct sales revenue. The Physician Channel Provider is also a distributor of the Company&#8217;s products to other channels, such as the spa channel, and the related sales are considered distributor revenue (in which instances it is referred to as the &#8220;Spa Channel Distributor&#8221;). Revenue generated from products sold to physicians and the DTC channel via the Company&#8217;s e-commerce platform through the Physician Channel Provider was $<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1314">26.3</ix:nonFraction> million during the period from July 28 to December 31, 2022 (Successor Period), $<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1315">32.2</ix:nonFraction> million during the period from January 1 to July 27, 2022, (Predecessor Period), $<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1316">58.8</ix:nonFraction> million during the year ended December 31, 2021 (Predecessor Period), and $<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1317">51.6</ix:nonFraction> million during the year ended December 31, 2020 (Predecessor Period). Revenue generated from products sold to the Spa Channel Distributor was $<ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1318">0.3</ix:nonFraction> million during the period from July 28 to December 31, 2022 (Successor Period), $<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1319">0.4</ix:nonFraction> million during the period from January 1 to July 27, 2022, (Predecessor Period), $<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1320">3.6</ix:nonFraction> million during the year ended December 31, 2021 (Predecessor Period), and $<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1321">2.5</ix:nonFraction> million during the year ended December 31, 2020 (Predecessor Period). </span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Geographic Region</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-1322" escape="true"><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue by geographic region, based on the location of the end customer, was as follows for the periods indicated: </span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:82.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.095%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Geographic Region&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">North America</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1323">56,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of the World</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1324">33,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1325">90,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1326">1,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1327">92,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:49.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1 to July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Geographic Region&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">North America</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1328">44,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1329">79,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1330">64,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of the World</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1331">26,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1332">57,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1333">24,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1334">70,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1335">136,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1336">88,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1337">3,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1338">5,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1339">5,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1340">73,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1341">142,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1342">94,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period from July&#160;28 to December&#160;31, 2022 (Successor Period), the two countries that accounted for more than <ix:nonFraction unitRef="number" contextRef="c-272" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1343"><ix:nonFraction unitRef="number" contextRef="c-273" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1344">10</ix:nonFraction></ix:nonFraction>% of the Company&#8217;s total revenues were the United States and China, respectively, with net product sales amounting to $<ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1345">54.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1346">17.0</ix:nonFraction> million, respectively. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-174</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1274-3"><div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period from January&#160;1 to July 27, 2022, (Predecessor Period) the two countries that accounted for more than <ix:nonFraction unitRef="number" contextRef="c-276" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1347"><ix:nonFraction unitRef="number" contextRef="c-277" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1348">10</ix:nonFraction></ix:nonFraction>% of the Company&#8217;s total revenues were the United States and Vietnam, with net product sales amounting to $<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1349">43.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1350">14.9</ix:nonFraction> million, respectively. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2021 (Predecessor Period), the countries that accounted for more than <ix:nonFraction unitRef="number" contextRef="c-280" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1351"><ix:nonFraction unitRef="number" contextRef="c-281" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1352"><ix:nonFraction unitRef="number" contextRef="c-282" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1353">10</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the Company&#8217;s total revenues were the United States, China, and Vietnam, with net product sales amounting to $<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1354">76.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1355">16.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1356">18.6</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020 (Predecessor Period), the United States was the country that accounted for more than <ix:nonFraction unitRef="number" contextRef="c-286" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1357">10</ix:nonFraction>% of the Company&#8217;s total revenues, amounting to net product sales of $<ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-1358">63.4</ix:nonFraction> million.</span></div></ix:continuation><div id="if2fc25067f8b45fc8cc165df93f3be1c_133"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillDisclosureTextBlock" id="f-1359" continuedAt="f-1359-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">GOODWILL</span></ix:nonNumeric></div><ix:continuation id="f-1359-1"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated goodwill acquired in the Obagi Merger to its Obagi Skincare reportable segment and goodwill acquired in the Milk Transaction to its Milk Makeup segment. The fair value of each reporting unit was determined as of the Closing Date as part of the Business Combination (see &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_127">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-1360" continuedAt="f-1360-1" escape="true">The following table presents changes in goodwill by reportable segment:</ix:nonNumeric></span></div><ix:continuation id="f-1360-1"><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Skincare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk Makeup</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Goodwill</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance as of December 31, 2021 and 2020 (Predecessor)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1361"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1362">44,489</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="f-1363"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="f-1364">&#8212;</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1365"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1366">44,489</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elimination of Predecessor goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:GoodwillPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-1367">44,489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:GoodwillPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="3" id="f-1368">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GoodwillPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-1369">44,489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi and Milk Business Combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1370">268,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1371">135,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1372">403,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-1373">68,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-1374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-1375">68,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance as of December 31, 2022 (Successor)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1376">199,548</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1377">135,072</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1378">334,620</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates goodwill for impairment on an annual basis on October 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and at an interim date if indicators of a potential impairment exist. The goodwill impairment test is conducted at the reporting unit level. The fair value of the Company&#8217;s reporting units is determined using a combination of the discounted cash flow method under the income approach and the guideline public company method under the market approach. Fair value estimates result from a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions that have been deemed reasonable by management as of the measurement date. Under the discounted cash flow method, fair value is determined by discounting the estimated future cash flows of each reporting unit, which includes the Company&#8217;s most recent projected long-term financial forecasts for revenue, earnings, capital expenditures and working capital. The discount rate used is intended to reflect the risks inherent in the future cash flows of the respective reporting unit. Under the guideline public company method, fair value is estimated using market multiples of various financial metrics observed for the reporting unit&#8217;s comparable public companies. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual impairment test performed for fiscal 2020 and 2021 (Predecessor Period) and fiscal 2022 (Successor Period) did not indicate an impairment of goodwill at the time they were performed. However, subsequent to the Business Combination (see &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_127">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Business Combinations&#8221;), the Company concluded that qualitative factors and relevant events and circumstances indicated it was more likely than not that the fair value of the Obagi Skincare reporting segment was less than its carrying amount. This included a decline in financial performance of the Obagi Skincare reporting unit compared to results projected at the time of acquisition, primarily as a result of the subsequent identification of the matters underlying the restatements adjustments, see &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_1097">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restatement and Reclassifications.&#8221; Therefore, the Company performed a quantitative goodwill impairment test for the associated reporting unit. As a result, during the Successor Period ended December 31, 2022, the Company recorded a non-cash impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="f-1379">68.7</ix:nonFraction> million within the Obagi Skincare reportable segment.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-175</span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="f-1380" continuedAt="f-1380-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">INTANGIBLE ASSETS&#8212;NET</span></ix:nonNumeric></div><ix:continuation id="f-1380-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-1381" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following as of December&#160;31, 2022 (Successor Period):</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:34.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average Useful<br/>Lives (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademark and trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-296" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1382">14</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1383">559,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1384">17,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1385">541,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-297" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1386">11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1387">36,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1388">1,349</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1389">34,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supply agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-298" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1390">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1391">38,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1392">3,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1393">35,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formulations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-299" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1394">8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1395">28,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1396">1,526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1397">27,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-300" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1398">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-1399">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-1400">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-1401">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1402">663,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1403">24,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1404">639,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following as of December&#160;31, 2021 (Predecessor Period):</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:34.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average Useful<br/>Lives (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademark and trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-301" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1405">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1406">46,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1407">17,842</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1408">28,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-302" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1409">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1410">39,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1411">16,404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1412">22,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supply agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-303" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1413">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1414">25,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1415">10,654</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1416">14,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formulations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-304" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1417">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1418">22,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1419">9,592</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1420">13,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-305" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1421">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-1422">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-1423">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-1424">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1425">134,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1426">54,503</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1427">79,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the period from July 28 to December&#160;31, 2022 (Successor Period), period from January&#160;1, 2022 to July&#160;27, 2022 (Predecessor Period), and the years ended December&#160;31, 2021 and 2020 (Predecessor Period), was $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1428">24.0</ix:nonFraction> million,</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1429">7.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1430">13.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1431">13.3</ix:nonFraction> million, respectively. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-1432" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected amortization for each of the years between 2023 through 2027, and thereafter are as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ending December 31</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1433">56,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1434">56,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1435">56,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1436">56,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1437">53,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1438">359,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1439">639,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-176</span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-1440" continuedAt="f-1440-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">DEBT</span></ix:nonNumeric></div><ix:continuation id="f-1440-1" continuedAt="f-1440-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-1441" escape="true"><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.226%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.383%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.119%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Successor)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Predecessor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 Term Loan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1442">170,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-1443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1444">14,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-1445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Predecessor 2021 Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-1446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1447">109,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Predecessor 2021 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-1448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1449">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Predecessor 2018 Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-1450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-1451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Predecessor 2018 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-1452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-1453">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Predecessor PPP Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-1454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-1455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-1456">5,445</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-1457">5,310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1458">179,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1459">118,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1460">20,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1461">15,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1462">159,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1463">103,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Successor 2022 Credit Agreement </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Borrower, a wholly-owned subsidiary of the Company, together with Waldencast Partners LP and certain of its subsidiaries as guarantors, entered into the 2022 Credit Agreement with the Lenders and JPMorgan, as administrative agent for the Lenders. The 2022 Credit Agreement provides the Company with access to a term loan of $<ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1464">175.0</ix:nonFraction> million (the &#8220;2022 Term Loan&#8221;) and a revolving credit capacity with borrowing capacity of up to $<ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1465">50.0</ix:nonFraction> million (the &#8220;2022 Revolving Credit Facility&#8221;), of which up to $<ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-1466">7.5</ix:nonFraction> million may be available, at Borrower&#8217;s option, to be drawn in form of letters of credit (&#8220;2022 Letter of Credit&#8221;). The 2022 Credit Agreement is secured by the assets of the Company. The 2022 Credit Agreement restricts the Company&#8217;s ability to make certain distributions or dividends, subject to a number of enumerated exceptions, which restrictions will not apply at any time the Company&#8217;s Leverage Ratio is below <ix:nonFraction unitRef="number" contextRef="c-322" decimals="INF" name="wald:DebtInstrumentCovenantLeverageRatioMaximum" scale="0" id="f-1467">2.5</ix:nonFraction>X.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Credit Agreement matures on July 27, 2026, <ix:nonNumeric contextRef="c-323" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1468">four years</ix:nonNumeric> following the funding date. The Company may elect to borrow either alternate base rate borrowings or term benchmark borrowings. Each draw that is an alternate base rate borrowing bears interest at&#160;an Alternate Base Rate (as defined in the 2022 Credit Agreement) plus the applicable rate of <ix:nonFraction unitRef="number" contextRef="c-324" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1469">2.5</ix:nonFraction>% per annum. Each draw that is a term benchmark borrowing bears interest at the Term SOFR Rate (as defined in the 2022 Credit Agreement), which resets periodically, plus <ix:nonFraction unitRef="number" contextRef="c-325" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1470">0.1</ix:nonFraction>% and the applicable rate of <ix:nonFraction unitRef="number" contextRef="c-326" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1471">3.5</ix:nonFraction>% per annum. As of December&#160;31, 2022, borrowings under the 2022 Credit Agreement consisted entirely of term benchmark borrowings at a borrowing rate of <ix:nonFraction unitRef="number" contextRef="c-327" decimals="3" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1472">7.9</ix:nonFraction>%. The carrying amount of debt approximates fair value due to the adjusting interest rates of the term loan, which approximate current market rates.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2022 Credit Agreement, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="f-1473">6.3</ix:nonFraction> million of debt issuance costs. As of December&#160;31, 2022, the Company had unpaid principal of $<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="f-1474">170.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="f-1475">14.1</ix:nonFraction> million on the 2022 Term Loan and the 2022 Revolving Credit Facility, respectively. The 2022 Term Loan and the 2022 Revolving Credit Facility had total unamortized debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="f-1476">5.4</ix:nonFraction> million as of December&#160;31, 2022. As of December 31, 2022, the weighted average interest rate was <ix:nonFraction unitRef="number" contextRef="c-329" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="f-1477"><ix:nonFraction unitRef="number" contextRef="c-308" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="f-1478">6.6</ix:nonFraction></ix:nonFraction>% for the 2022 Term Loan and the 2022 Revolving Credit Facility. The current portion of the 2022 Term Loan and the 2022 Revolving Credit Facility was $<ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-1479">8.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-1480">14.1</ix:nonFraction> million, respectively. The current portion of the unamortized debt issuance costs on the 2022 Term Loan and the 2022 Revolving Credit Facility was $<ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-5" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="6" id="f-1481">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-5" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="6" id="f-1482">1.2</ix:nonFraction> million, respectively. The accrued interest was $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="6" id="f-1483">0.1</ix:nonFraction> million as of December&#160;31, 2022. Unamortized debt issuance costs on the 2022 Letter of Credit is $<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-1484">0.2</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="f-1485">51,000</ix:nonFraction> was recognized in other current assets and $<ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-1486">0.1</ix:nonFraction> million was recognized in other assets in the consolidated balance sheets.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-177</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1440-2" continuedAt="f-1440-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-1487" escape="true"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled maturities under the Company&#8217;s 2022 Credit Agreement as of December&#160;31, 2022 (Successor Period) are as follows :</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1488">22,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1489">7,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1490">11,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1491">143,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:fixed-zero" scale="3" id="f-1492">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unpaid principal</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1493">184,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Waiver and Consent and Amendment to the 2022 Credit Agreement</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Borrower entered into a technical amendment to the 2022 Credit Agreement to cure a technical error and clarify when the first amortization payment under the 2022 Credit Agreement is due and payable.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Borrower entered into a waiver and consent agreement with JPMorgan and the required Lenders to, among other things, waive certain defaults or events of default that had or would have resulted from the failure to deliver certain financial information and related reports. In June 2023, the Borrower entered into a subsequent waiver and consent agreement with JPMorgan and the required Lenders, pursuant to which they agreed to, among other things, (a) continue to waive certain defaults or events of default that had or would have resulted from the failure to deliver certain financial information and related reports and (b) suspend the testing of certain financial covenants in the 2022 Credit Agreement.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Borrower entered into a subsequent waiver and consent agreement with JPMorgan and the required Lenders, pursuant to which they agreed to, among other things, (i) waive any default or event of default that has or would result from the failure to deliver the financial information and related reports with respect to the fiscal year of the Borrower ended December 31, 2022 and the fiscal quarters of the Borrower ended March 31, 2023 and June 30, 2023, respectively and (ii) suspend the testing of certain financial covenants set forth in the 2022 Credit Agreement. Such waiver would remain in effect until September 15, 2023.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Borrower and Waldencast Partners LP entered into the second amendment and waiver to the 2022 Credit Agreement (the &#8220;Amendment&#8221;) with JPMorgan and the required Lenders, pursuant to which they agreed to (i) waive any default or event of default that has or would result from (a) the failure to deliver the financial information and related reports with respect to the fiscal year of the Borrower ended December 31, 2022 and the fiscal quarters of the Borrower ended March 31, 2023 and June 30, 2023, respectively, (b) any inaccuracy or misrepresentation in certain historical financial statements previously delivered to JPMorgan and (c) certain historical breaches of the financial covenants and (ii) amend the 2022 Credit Agreement to, among other things, modify the existing financial covenant tests. The Borrower is required to deliver certain of the financial information described in (i)(a) above by December 31, 2023 (the &#8220;Waiver Expiration Date&#8221;). Failure to deliver the required audited financial information and certain other deliverables on or prior to the Waiver Expiration Date will result in an event of default under the 2022 Credit Agreement (unless otherwise waived or extended). The Amendment also (i) included additional restrictions on the Borrower&#8217;s, Waldencast Partners LP's and certain of their subsidiaries&#8217; ability to incur certain types of additional indebtedness, make certain acquisitions and investments, create certain liens, dispose of certain assets and make certain types of restricted payments, (ii) established a minimum liquidity covenant of $<ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-5" name="wald:LineOfCreditCovenantTermsMinimumLiquidity" scale="6" id="f-1494">15.0</ix:nonFraction> million, which is certified on a monthly basis, and (iii) introduced additional financial reporting obligations, in each case until the earlier of September 30, 2024 or such earlier time that the Borrower elects to test the financial covenants in the same manner as prior to giving effect to the Amendment. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Borrower subsequently delivered unaudited financial information and related reports with respect to the fiscal quarters of the Borrower ended March 31, 2023 and June 30, 2023. In December 2023, the Borrower entered into a subsequent waiver and consent agreement with JPMorgan and the required Lenders, pursuant to which they agreed, among other things, to waive any default or event of default that has or would result from the failure to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-178</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1440-3" continuedAt="f-1440-4"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deliver the financial information and related reports with respect to the fiscal year of the Borrower ended December 31, 2022. Such waiver shall remain in effect until January 15, 2024.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Predecessor 2021 Credit Agreement </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Obagi replaced its Predecessor 2018 Credit Agreement (described below) for a new financing agreement with a syndicate of lenders, including TCW Asset Management Company LLC as administrative agent for the lenders (the &#8220;2021 Credit Agreement&#8221;). The terms and conditions of the 2018 Credit Agreement and the 2021 Credit Agreement limited the ability of Obagi and its wholly-owned subsidiaries to declare dividends or make other distributions, directly or indirectly, to its shareholder, subject to certain enumerated exceptions, including, but not limited to, dividends up to a specified amount if Obagi was able to achieve certain &#8220;Consolidated Total Leverage Ratios&#8221; thresholds. Due to the aforementioned restrictions, substantially all of the net assets of Obagi&#8217;s subsidiaries were restricted.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Credit Agreement included a term loan of $<ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1495">110.0</ix:nonFraction> million (the &#8220;2021 Term Loan&#8221;) and a revolving credit facility with borrowing capacity of up to $<ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1496">40.0</ix:nonFraction> million (&#8220;2021 Revolving Credit Facility&#8221;). Both the 2021 Term Loan and the 2021 Revolving Credit Facility were due to mature in March 2026. The 2021 Term Loan and 2021 Revolving Credit Facility bore interest at the LIBOR plus an applicable margin, as determined by the Company&#8217;s leverage ratios, and were subject to LIBOR succession provisions. In connection with the issuance of the 2021 Credit Agreement, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="f-1497">6.4</ix:nonFraction> million of debt issuance costs. The 2021 Credit Agreement was secured by the assets of the Company. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 (Predecessor Period), the Company had unpaid principal of $<ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-1498">109.2</ix:nonFraction> million, and unamortized debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="f-1499">3.9</ix:nonFraction> million on the 2021 Term Loan. The interest rate was <ix:nonFraction unitRef="number" contextRef="c-340" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="f-1500">8.5</ix:nonFraction>% and there was <ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-5" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" format="ixt:fixed-zero" scale="0" id="f-1501">no</ix:nonFraction> accrued interest as of December&#160;31, 2021 (Predecessor Period). The current portion of the 2021 Term Loan and 2021 Revolving Credit Facility was $<ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-1502">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-1503">15.0</ix:nonFraction> million, respectively. The current portion of the unamortized debt issuance costs on the 2021 Term Loan and 2021 Revolving Credit Facility was $<ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-5" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="6" id="f-1504">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-5" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="6" id="f-1505">1.4</ix:nonFraction> million, respectively. The outstanding debt under the Predecessor 2021 Credit Agreement was paid in full as part of Waldencast&#8217;s acquisition of Obagi. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Predecessor 2018 Credit Agreement </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, and subject to amendments in March 2020 and November  2020, Obagi entered into a credit agreement (the &#8220;2018 Credit Agreement&#8221;) with a syndicate of banks, including Wells Fargo Bank, National Association (&#8220;Wells Fargo&#8221;) as administrative agent for the banks (the &#8220;Syndicate of Banks&#8221;). The 2018 Credit Agreement included a term loan of $<ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1506">90.0</ix:nonFraction> million (the &#8220;2018 Term Loan&#8221;) and a revolving credit facility with borrowing capacity of up to $<ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1507">35.0</ix:nonFraction> million (&#8220;2018 Revolving Credit Facility&#8221;). Both the 2018 Term Loan and the 2018 Revolving Credit Facility were due to mature in December 2023. In connection with the issuance of the 2018 Credit Agreement, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="f-1508">2.9</ix:nonFraction> million of debt issuance costs.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon settlement of the debt with proceeds from the Predecessor 2021 Credit Agreement, the Company recorded a loss on extinguishment of the 2018 Credit Agreement of $<ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-1509">2.3</ix:nonFraction> million to loss on extinguishment of debt in the accompanying consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2021 (Predecessor Period), which consisted of expensing unamortized debt issuance costs.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Predecessor PPP Loan</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company received loan proceeds in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1510">6.8</ix:nonFraction> million under the Paycheck Protection Program (&#8220;PPP&#8221;) from MUFG Union Bank (the &#8220;PPP Loan&#8221;). The PPP, established as part of the Coronavirus aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;), provided for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The PPP Loan accrued interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-319" decimals="2" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="f-1511">1</ix:nonFraction>%. The PPP Loan and accrued interest were forgivable after eight or twenty-four weeks as long as the borrower used the proceeds for eligible purposes, including payroll, benefits, rent and utilities and maintains its payroll levels. The Company used the proceeds for purposes consistent with the PPP, and in 2021, received approval from MUFG Union Bank and the Small Business Administration (&#8220;SBA&#8221;) for forgiveness of the full amount of its PPP Loan, inclusive of accrued interest of $<ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-3" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" format="ixt:num-dot-decimal" scale="0" id="f-1512">74,000</ix:nonFraction>. The Company recognized a gain on PPP Loan forgiveness of $<ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-5" name="us-gaap:LineOfCreditFacilityDecreaseForgiveness1" scale="6" id="f-1513">6.8</ix:nonFraction> million for the year ended December&#160;31, 2021 (Predecessor Period). </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-179</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1440-4"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Company was notified by its lender that the SBA had requested additional documents relating to the Company&#8217;s PPP Loan. The Company provided the required documentation and no further communication has been received in response.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-180</span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-1514" continuedAt="f-1514-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">LEASES</span></ix:nonNumeric></div><ix:continuation id="f-1514-1" continuedAt="f-1514-2"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for real estate properties for office and warehouse space with initial terms of approximately <ix:nonNumeric contextRef="c-349" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-1515">8</ix:nonNumeric> and <ix:nonNumeric contextRef="c-350" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-1516">11</ix:nonNumeric> years, respectively.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s lease contracts include options to extend the leases for up to <ix:nonNumeric contextRef="c-7" name="wald:LesseeOperatingLeaseExtensionTerm" format="ixt-sec:duryear" id="f-1517">5</ix:nonNumeric> years. Our lease agreements generally do not contain any residual value guarantees or restrictive covenants.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if a contract contains a lease at inception of the arrangement based on whether the Company has the right to obtain substantially all of the economic benefits from the use of an identified asset and whether the Company has the right to direct the use of an identified asset in exchange for consideration, which relates to an asset that the Company does not own. Right of use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of any changes in market conditions but generally, these termination options are not exercised and not considered in the determination of the lease term. Lease liabilities are recognized at the present value of the future lease payments at the lease commencement date. ROU assets are recognized on the balance sheet based on the lease liability adjusted for any initial direct costs, lease incentives received, and prepaid rent. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate used to determine the present value of the future lease payments is the Company&#8217;s incremental borrowing rate (&#8220;IBR&#8221;), because the interest rate implicit in most of the Company&#8217;s leases is not readily determinable. The IBR is a hypothetical rate based on the Company&#8217;s understanding of what its credit rating would be, and resulting interest the Company would pay, to borrow an amount equal to the lease payments in a similar economic environment over the lease term on a collateralized basis. Lease payments may be fixed or variable, however, only fixed payments or in-substance fixed payments are included in the Company&#8217;s lease liability calculation. Variable lease payments may include costs such as common area maintenance, utilities, or other costs. Variable lease payments are recognized in operating expenses in the period in which the obligation for those payments is incurred. The Company has elected not to separate non-lease components from lease components and accounts for them as a single lease component. The Company has also elected the short-term lease recognition exemption for all leases that qualify.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company historically accounted for leases in accordance with ASC 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under which operating leases were not recorded on the balance sheet. Adoption of ASC 842 was not required in interim periods preceding December&#160;31, 2022. Upon consummation of the Business Combination, Obagi and Milk adopted ASC 842 as a matter of policy alignment. The period from January 1 to July 27, 2022 (Predecessor Period) does not reflect the impact of ASC 842 adoption, as the Company did not adopt the standard as of an interim 2022 period.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease expenses of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-1518">1.4</ix:nonFraction> million were composed of operating lease costs. The Company does not have any finance leases, short-term lease costs or variable lease costs. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-181</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1514-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-1519" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company&#8217;s operating leases was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:77.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022<br/>(Successor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-1520">1,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for new operating lease liabilities:</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1521">4,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:77.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022<br/>(Successor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-7" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1522">7.75</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1523">5.9</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-1524" continuedAt="f-1524-1" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliation of the undiscounted future minimal lease payments under non-cancelable operating leases to the total operating lease liability recognized on the consolidated balance sheet as of December 31, 2022 was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:77.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1525">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1526">3,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1527">3,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1528">2,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1529">2,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1530">9,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-1531">24,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed Interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-1532">4,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total reported lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1533">19,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosures Related to Periods Prior to the Adoption of ASC 842 </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Obagi China Distribution, the Company leased office space under <ix:nonFraction unitRef="operatinglease" contextRef="c-88" decimals="INF" name="wald:NumberOfOperatingLeases" format="ixt-sec:numwordsen" scale="0" id="f-1534">three</ix:nonFraction> non-cancelable operating leases expiring between September 2023 and February 2032. Rent expense related to the Company&#8217;s operating leases was $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:LeaseAndRentalExpense" scale="6" id="f-1535">0.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:LeaseAndRentalExpense" scale="6" id="f-1536">1.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:LeaseAndRentalExpense" scale="6" id="f-1537">1.1</ix:nonFraction> million for the period from January 1 to July&#160;27, 2022 (Predecessor Period) and the years ended December&#160;31, 2021 and 2020 (Predecessor Period), respectively.</span></div><ix:continuation id="f-1524-1"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments as of December 31, 2021 were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1538">1,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" format="ixt:num-dot-decimal" scale="3" id="f-1539">1,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" format="ixt:num-dot-decimal" scale="3" id="f-1540">1,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" format="ixt:num-dot-decimal" scale="3" id="f-1541">1,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="3" id="f-1542">844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" format="ixt:num-dot-decimal" scale="3" id="f-1543">1,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-1544">8,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div id="if2fc25067f8b45fc8cc165df93f3be1c_145"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="f-1545" continuedAt="f-1545-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">FINANCIAL INSTRUMENTS</span></ix:nonNumeric></div><ix:continuation id="f-1545-1" continuedAt="f-1545-2"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Collar</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To mitigate interest rate risk in connection with the variable rate loans under the 2022 Credit Agreement, the Company entered into an interest rate collar with Wells Fargo for a notional value of $<ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="f-1546">160.0</ix:nonFraction> million and a fixed cash payment of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-182</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1545-2" continuedAt="f-1545-3"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-5" name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" scale="6" id="f-1547">0.8</ix:nonFraction> million. Under the terms of the interest rate collar, the Company is required to pay Wells Fargo if the monthly SOFR-based interest falls below the defined interest rate floor of <ix:nonFraction unitRef="number" contextRef="c-351" decimals="4" name="us-gaap:DerivativeFloorInterestRate" scale="-2" id="f-1548">2.55</ix:nonFraction>%; conversely, the Company is entitled to receive payment from Wells Fargo if the monthly SOFR-based interest rate rises above the defined interest rate cap of <ix:nonFraction unitRef="number" contextRef="c-351" decimals="4" name="us-gaap:DerivativeCapInterestRate" scale="-2" id="f-1549">5.25</ix:nonFraction>%. Settlement in cash occurs monthly, if contractually required, until termination of the agreement in October 2024, and the variable interest rate is reset on the last day of each month. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This derivative instrument has not been designated for hedge accounting, therefore the change in fair value is recognized in current period earnings. The fair value of these contracts, included in other non-current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $<ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="f-1550">0.2</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of December&#160;31, 2022 (Successor Period). The non-cash loss from change in fair value during the period from July 28 to December&#160;31, 2022 (Successor Period) was $<ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-5" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="f-1551">0.6</ix:nonFraction> million, recognized in other expenses, net. No payments or receipts were exchanged on the interest rate collar contract during the period from July 28 to December&#160;31, 2022 (Successor Period) aside from the initial fixed cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-5" name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" scale="6" id="f-1552">0.8</ix:nonFraction> million. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liabilities </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Waldencast&#8217;s IPO, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-353" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1553">11,499,950</ix:nonFraction> Public Warrants to third-party investors. Simultaneously with the closing of the IPO, Waldencast completed the private sale of <ix:nonFraction unitRef="shares" contextRef="c-354" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1554">5,933,333</ix:nonFraction> warrants (the &#8220;Sponsor Warrants&#8221;) to the Sponsor. Also, in connection with the IPO, on February 22, 2021, Waldencast, the Sponsor and Zeno Investment Master Fund (f/k/a Dynamo Master Fund, a member of the Sponsor (&#8220;Zeno&#8221;), entered into a Forward Purchase Agreement (the &#8220;Sponsor FPA&#8221;), which was subsequently amended by the assignment and assumption agreement entered into by and between the Sponsor and Burwell Mountain Trust (&#8220;Burwell&#8221;) on December 20, 2021. Under the assignment and assumption agreement, Sponsor assigned, and Burwell assumed, all of the Sponsor&#8217;s rights and benefits under the Sponsor FPA, pursuant to which, Burwell and Zeno committed to subscribe for and purchase <ix:nonFraction unitRef="shares" contextRef="c-355" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1555">16,000,000</ix:nonFraction> Waldencast Class A ordinary shares and <ix:nonFraction unitRef="shares" contextRef="c-356" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1556">5,333,333</ix:nonFraction> warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;Sponsor FPA Warrants&#8221;) in connection with the closing of the Business Combination. In addition, Waldencast and Beauty Ventures LLC (&#8220;Beauty Ventures&#8221;) entered into a Forward Purchase Agreement on March&#160;1, 2021 (the &#8220;Third-Party FPA&#8221;, and together with the Sponsor FPA, the &#8220;FPAs&#8221;), pursuant to which Beauty Ventures committed to subscribe for and purchase up to <ix:nonFraction unitRef="shares" contextRef="c-357" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1557">17,300,000</ix:nonFraction> Class A ordinary shares and <ix:nonFraction unitRef="shares" contextRef="c-358" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1558">5,766,666</ix:nonFraction> warrants (the &#8220;Third-Party FPA Warrants&#8221; and together with the Sponsor FPA Warrants, the &#8220;FPA Warrants&#8221;) for an aggregate commitment amount of $<ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-1559">173.0</ix:nonFraction> million, in connection with the closing of Waldencast&#8217;s initial business combination. Finally, in connection with the Business Combination, Waldencast issued <ix:nonFraction unitRef="shares" contextRef="c-360" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1560">1,000,000</ix:nonFraction> warrants to settle $<ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-1561">1.5</ix:nonFraction> million working capital loans with its Sponsor, the terms of which are identical to the Sponsor FPA Warrants (the &#8220;Sponsor Loan Warrants&#8221;). The Sponsor Loan Warrants and Third-Party FPA Warrants are collectively referred to as the &#8220;Private Placement Warrants&#8221;.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, all of the above-noted warrants, totaling <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1562">29,533,282</ix:nonFraction>, remained issued and outstanding. For the period from July 28 to December&#160;31, 2022 (Successor Period), the Company recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="f-1563">6.8</ix:nonFraction> million from the change in fair value of the Public Warrants and Private Placement Warrants in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Domestication, Public Warrants and Private Placement Warrants each entitle the holder to purchase <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-1564">one</ix:nonFraction> share of the Company&#8217;s Class A ordinary shares at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-1565">11.50</ix:nonFraction> per share. Public Warrants may only be exercised for a whole number of shares. No fractional warrants will be issued and only whole warrants can trade. The Public Warrants became exercisable <ix:nonNumeric contextRef="c-361" name="wald:ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination" format="ixt-sec:durday" id="f-1566">30</ix:nonNumeric> days after the completion of the Business Combination. The Public Warrants will expire June 27, 2027 or earlier upon redemption or liquidation.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem the Public Warrants:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">in whole and not in part;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">upon a minimum of <ix:nonNumeric contextRef="c-361" name="wald:ClassOfWarrantOrRightRedemptionPeriod" format="ixt-sec:durday" id="f-1567">30</ix:nonNumeric> days&#8217; prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption, based on the redemption date and the &#8220;fair market value&#8221; of the Class A ordinary shares;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-362" decimals="2" name="wald:ClassOfWarrantOrRightRedemptionPricePerShare" scale="0" id="f-1568">0.01</ix:nonFraction> per warrant if, and only if, the reported last sale price of the Class A ordinary shares for any <ix:nonNumeric contextRef="c-361" name="wald:ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice" format="ixt-sec:durday" id="f-1569">20</ix:nonNumeric> trading days within a <ix:nonNumeric contextRef="c-361" name="wald:ClassOfWarrantOrRightRedemptionTradingPeriod" format="ixt-sec:durday" id="f-1570">30</ix:nonNumeric>-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption the warrant holders (the &#8220;Reference Value&#8221;) equals or exceeds $<ix:nonFraction unitRef="usdPerShare" contextRef="c-362" decimals="2" name="wald:ClassOfWarrantOrRightRedemptionStockPriceTrigger" scale="0" id="f-1571">18.00</ix:nonFraction> per share (as adjusted).</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">At a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-363" decimals="2" name="wald:ClassOfWarrantOrRightRedemptionPricePerShare" scale="0" id="f-1572">0.01</ix:nonFraction> per warrant if, and only if, the Reference Value equals or exceeds $<ix:nonFraction unitRef="usdPerShare" contextRef="c-363" decimals="2" name="wald:ClassOfWarrantOrRightRedemptionStockPriceTrigger" scale="0" id="f-1573">10.00</ix:nonFraction> per share (as adjusted); and</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-183</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1545-3" continuedAt="f-1545-4"><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">if the Reference Value is less than $<ix:nonFraction unitRef="usdPerShare" contextRef="c-364" decimals="2" name="wald:ClassOfWarrantOrRightRedemptionStockPriceTrigger" scale="0" id="f-1574">18.00</ix:nonFraction> per share (as adjusted), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price and number of Class A ordinary shares issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants.</span></div></ix:continuation><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1545-4">The terms of the Third-Party FPA Warrants are identical to the Public Warrants. The Sponsor Loan Warrants and Sponsor FPA Warrants are also identical to the Public Warrants, except that they and the Class A ordinary shares issuable upon the exercise of such warrants were not transferable, assignable or salable until <ix:nonNumeric contextRef="c-365" name="wald:ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination" format="ixt-sec:durday" id="f-1575">30</ix:nonNumeric> days after the completion of the Business Combination, subject to certain limited exceptions. Additionally, the Sponsor Loan Warrants and Sponsor FPA Warrants will be exercisable on a cashless basis and be non-redeemable, except as described above, so long as they are held by the initial purchasers or their permitted transferees, thereafter they will be redeemable by the Company and exercisable by such holders on the same basis as Public Warrants.</ix:continuation> </span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_151"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-1577" continuedAt="f-1577-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">FAIR VALUE MEASUREMENTS</span></ix:nonNumeric></div><ix:continuation id="f-1577-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-1578" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s financial instruments that are measured at fair value on a recurring basis by level within the fair value hierarchy as of December&#160;31, 2022 (Successor Period): </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quoted Prices in Active Market</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Other Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Other Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate collar</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="f-1579">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-1580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-3" name="us-gaap:DerivativeAssets" scale="3" id="f-1581">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-1582">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities - Public</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1583">7,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1584">7,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="f-1585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="f-1586">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities - Private</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1587">11,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="f-1588">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-375" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1589">11,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="f-1590">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private derivative warrants are classified as Level 2 financial instruments. The fair value of the Level 2 Private Placement Warrant liabilities has been measured based on the fair value of Public Warrant liabilities. The interest rate collar has been measured at net present value by projecting future cash flows and discounting the future amounts to a present value using market-based observable inputs including interest rate curves and credit spreads.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For goodwill (see &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_133">Note 6</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Goodwill&#8221;), fair value assessments of the reporting units and the reporting units&#8217; net assets performed for goodwill impairment tests are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain long-lived and intangible assets at fair value on a nonrecurring basis when events occur that indicate an asset group may not be recoverable. If the carrying amount of an asset group is not recoverable, an impairment charge is recorded to reduce the carrying amount by the excess over its fair value. Except for the initial valuation of long-lived assets in connection with the Business Combination (see &#8220;</span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_127">Note 4</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business Combinations&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and impairment of goodwill discussed above, no long-lived assets were remeasured at fair value on a nonrecurring basis during the periods presented.</span></div></ix:continuation><div id="if2fc25067f8b45fc8cc165df93f3be1c_154"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-1591" continuedAt="f-1591-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">SUPPLEMENTAL BALANCE SHEET DISCLOSURES</span></ix:nonNumeric></div><ix:continuation id="f-1591-1" continuedAt="f-1591-2"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Net</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 (Successor Period), accounts receivable, net consisted of accounts receivable of $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="wald:AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent" scale="6" id="f-1592">20.3</ix:nonFraction> million, less allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-1593">1.0</ix:nonFraction> million. As of December&#160;31, 2021 (Predecessor Period), accounts receivable, net consisted of accounts receivable of $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="wald:AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent" scale="6" id="f-1594">19.4</ix:nonFraction> million, less allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-1595">0.7</ix:nonFraction> million. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-184</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1591-2" continuedAt="f-1591-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="f-1596" escape="true"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the allowance for doubtful accounts were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:57.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.270%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">July 28 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1<br/>to July 27,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1597">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="f-1598">671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="f-1599">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for bad debts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-1600">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-1601">390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="f-1602">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-off of uncollectible accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:fixed-zero" scale="3" id="f-1603">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:fixed-zero" scale="3" id="f-1604">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:fixed-zero" scale="3" id="f-1605">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="f-1606">994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1607">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="f-1608">671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, and as amended in December 2021 and April 2022, Obagi Cosmeceuticals LLC, a wholly-owned subsidiary of Obagi, entered into a non-recourse, uncollateralized short-term promissory note, not in the ordinary course of business, lending a third party $<ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-5" name="us-gaap:IncreaseDecreaseInNotesReceivableCurrent" scale="6" id="f-1609">2.5</ix:nonFraction> million (the &#8220;Predecessor Loan Receivable&#8221;). This Predecessor Loan Receivable had a maturity date of December&#160;31, 2022 and carried an interest rate of <ix:nonFraction unitRef="number" contextRef="c-378" decimals="4" name="us-gaap:LoansReceivableBasisSpreadOnVariableRate" scale="-2" id="f-1610">1.00</ix:nonFraction>% from July 30, 2021 to September 29, 2021 and <ix:nonFraction unitRef="number" contextRef="c-8" decimals="4" name="us-gaap:LoansReceivableBasisSpreadOnVariableRate" scale="-2" id="f-1611">8.00</ix:nonFraction>% from September&#160;30, 2021 through maturity. The outstanding principal and accrued interest were due upon maturity. As discussed in &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_1097">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Restatement and Reclassifications,&#8221; the Company wrote-off the $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInNotesReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1612">2.5</ix:nonFraction>&#160;million loan receivable in 2021 when it was determined to be uncollectible. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-1613" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Successor)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Predecessor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-1614">11,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-1615">1,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-1616">43,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-1617">20,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-1618">54,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-1619">21,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><ix:continuation id="f-1099-2"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Successor)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Predecessor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer hardware, software and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-1620">944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-1621">752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-1622">724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="f-1623">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-1624">608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-1625">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internally developed software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-1626">889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1627">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gondolas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1628">6,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="f-1629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1630">2,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-1631">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1632">11,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1633">1,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1634">2,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-1635">678</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1636">8,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1637">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-185</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1591-3" continuedAt="f-1591-4"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for property and equipment for the period from July 28 to December&#160;31, 2022 (Successor Period) and the period from January 1 to July 27, 2022 (Predecessor Period) were $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1638">2.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1639">0.5</ix:nonFraction> million, respectively. Depreciation expense for property and equipment for the years ended December&#160;31, 2021 and 2020 (Predecessor Period) were $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1640">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1641">0.1</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense pertains to property and equipment utilized as part of the Company&#8217;s SG&amp;A activities and therefore has not been allocated to cost of goods sold.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="f-1642" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Successor)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Predecessor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued salaries and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1643">9,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1644">6,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued sales returns and damages</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="wald:AccruedSalesReturnsAndDamagesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1645">2,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="wald:AccruedSalesReturnsAndDamagesCurrent" format="ixt:fixed-zero" scale="3" id="f-1646">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued marketing expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedMarketingCostsCurrent" scale="3" id="f-1647">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccruedMarketingCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1648">2,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued distribution fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="wald:AccruedDistributionFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1649">1,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="wald:AccruedDistributionFeesCurrent" scale="3" id="f-1650">760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1651">9,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="f-1652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1653">2,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1654">2,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1655">26,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1656">12,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><ix:continuation id="f-1591-4" continuedAt="f-1591-5"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accrued distribution fees related to service charges such as e-commerce shipping and handling costs. The related party liability of $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="6" id="f-1657">9.9</ix:nonFraction> million as of December 31, 2022 reflects the remaining unamortized fair value of the related party inventory contract executed on the acquisition date between Obagi and the Obagi China Business (see &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_127">Note 4</a></span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1591-5">. Business Combinations&#8221;). This related party liability will be amortized into related party revenue upon the sale of products to the Obagi China Business in subsequent periods.</ix:continuation> </span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_157"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-1658" continuedAt="f-1658-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">STOCK-BASED COMPENSATION</span></ix:nonNumeric></div><ix:continuation id="f-1658-1" continuedAt="f-1658-2"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Successor Incentive Plan</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2022 Incentive Award Plan (the &#8220;Plan&#8221;) provides for incentives to be provided to selected officers, employees, non-employee directors and consultants of the Company in the form of options, stock appreciation rights, restricted stock, restricted stock units, stock bonuses or other stock-based awards granted under the Plan. The Plan was adopted by Waldencast&#8217;s Board of Directors in June 2022, was approved by its shareholders in July, 2022, and became effective on July 27, 2022 in connection with the closing of the Business Combination. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum number of ordinary shares available for issuance under the Plan as of December 31, 2022 was <ix:nonFraction unitRef="shares" contextRef="c-389" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1659">16,134,716</ix:nonFraction></span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;Share Reserve&#8221;); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Share Reserve automatically increases on January 1st of each calendar year (each, an &#8220;Evergreen Date&#8221;), prior to the tenth anniversary of the effective date of the Plan in an amount equal to the lesser of (i) <ix:nonFraction unitRef="number" contextRef="c-390" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-1660">3</ix:nonFraction>% of the total number of ordinary shares issued and outstanding on the December&#160;31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> immediately preceding the applicable Evergreen Date and (ii) a number of ordinary shares determined by the Board, including zero. All and up to the number of ordinary shares reserved for issuance under the Plan as of the effective date of the Plan (subject to an equitable adjustment in the event of a change in capitalization or change in control event) may be granted as an incentive stock options. As of December&#160;31, 2022 (Successor Period), the Company had <ix:nonFraction unitRef="shares" contextRef="c-389" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-1661">2,749,579</ix:nonFraction></span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares reserved for future issuances under the Plan.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combination</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Closing Date, in connection with the Business Combination, the Company assumed Obagi and Milk&#8217;s legacy incentive award plans and outstanding unvested awards granted under those plans. The Company assumed <ix:nonFraction unitRef="shares" contextRef="c-391" decimals="INF" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1662">5,906,300</ix:nonFraction> stock options and <ix:nonFraction unitRef="shares" contextRef="c-392" decimals="INF" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1663">1,776,827</ix:nonFraction> restricted stock units as replacement awards pursuant to the Obagi Merger Agreement, as </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-186</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1658-2" continuedAt="f-1658-3"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">well as <ix:nonFraction unitRef="shares" contextRef="c-393" decimals="INF" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1664">237,724</ix:nonFraction> stock options and <ix:nonFraction unitRef="shares" contextRef="c-394" decimals="INF" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1665">2,808,131</ix:nonFraction> share appreciation rights as replacement awards pursuant to the Milk Merger Agreement. The total post-combination incremental stock-based compensation was $<ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-5" name="wald:ShareBasedPaymentArrangementBusinessCombinationIncrementalCost" scale="6" id="f-1666">18.3</ix:nonFraction> million, which is expected to be recognized over the remaining requisite service periods, where $<ix:nonFraction unitRef="usd" contextRef="c-396" decimals="-5" name="us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure" scale="6" id="f-1667">47.7</ix:nonFraction> million represents the fair value of the equity awards as part of the equity purchase consideration. The awards that were replaced had been contingent on a performance condition and as such, the Company is required to use an attribution model in which compensation cost for each vesting tranche is recognized as if each vesting tranche were a separate award.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Founder Awards</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022 the Company granted a total of <ix:nonFraction unitRef="shares" contextRef="c-397" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-1668">11,500,000</ix:nonFraction> stock options to the <ix:nonFraction unitRef="individual" contextRef="c-398" decimals="INF" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals" format="ixt-sec:numwordsen" scale="0" id="f-1669">two</ix:nonFraction> founders of Waldencast that vest based on service over the <ix:nonNumeric contextRef="c-399" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1670">six-year</ix:nonNumeric> period from August 2022 through August 2028. The options were granted with <ix:nonFraction unitRef="segment" contextRef="c-397" decimals="INF" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-1671">four</ix:nonFraction> vesting tranches, each tranche with a different exercise price, subject to their continued employment with the Company. Additionally, the Company granted <ix:nonFraction unitRef="shares" contextRef="c-400" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1672">692,000</ix:nonFraction> founders service-based restricted stock units that cliff vest in August 2025, subject to their continued employment with the Company. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incentive Awards</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company approved incentive awards to employees of Waldencast, Milk, and Obagi. The long-term incentive awards (the &#8220;LTI Awards&#8221;) are restricted stock units that vest based on both a service condition and meeting either a net sales or earnings before interest, taxes, depreciation and amortization (&#8220;EBITDA&#8221;) target in calendar year 2022. These LTI Awards were granted to employees in November 2022. The performance targets for the LTI Awards</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were met for Milk in 2022. The Company granted LTI Awards will vest one-third each year beginning on February 15, 2023, subject to continued service through such dates. As of December&#160;31, 2022 (Successor Period),</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-401" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1673">694,537</ix:nonFraction> restricted stock units had been granted. In May 2023, the Board approved a modification to the LTI Awards by waiving the performance conditions for most Obagi and Waldencast employees, other than the former Chief Executive Officer of Obagi and the Chief Executive Officer and Chief Growth Officer of Waldencast. See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_187">Note 21</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Waldencast One-Time Stock Grant</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company approved a one-time stock grant for certain Milk employees that were not eligible to participate in the LTI award program. A total of <ix:nonFraction unitRef="shares" contextRef="c-402" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1674">10,000</ix:nonFraction> awards were approved under this program. These awards are service-based restricted stock units that will cliff vest <ix:nonNumeric contextRef="c-403" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1675">three years</ix:nonNumeric> from the grant date, subject to continued employment with the Company. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock" id="f-1676" continuedAt="f-1676-1" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the period from July 28 to December&#160;31, 2022 (Successor Period) was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of<br/>Common<br/>Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>intrinsic<br/>Value (in<br/>thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of July 28, 2022 (Successor)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:fixed-zero" scale="0" id="f-1677">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-24" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-1678">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-1679">20,452,155</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1680">9.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-27" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="f-1681">8.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-1682">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-1683">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="f-1684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-27" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-1685">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2022 (Successor)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1686">20,452,155</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-38" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1687">9.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-27" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1688">8.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1689">39,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable as of December 31, 2022 (Successor)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-1690">4,451,538</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-38" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-1691">4.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-27" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1692">7.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1693">21,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest as of December 31, 2022 (Successor)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1694">20,452,155</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-38" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-1695">9.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-27" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1696">8.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1697">39,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value per share of the awards granted for stock options during the period from July 28 to December&#160;31, 2022 (Successor Period) is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1698">3.58</ix:nonFraction>.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-187</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1658-3" continuedAt="f-1658-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-1699" continuedAt="f-1699-1" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock option awards was determined on the grant date using the Monte Carlo simulation model for Founder Awards and the Hull-White lattice pricing model was used for replacement awards based on the following weighted-average assumptions:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:57.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28<br/>to December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Founder Awards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Replacement Awards</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-404" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-1700">2.87</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-404" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-1701">2.92</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonFraction unitRef="number" contextRef="c-405" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-1702">2.79</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-405" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-1703">2.80</ix:nonFraction>% </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-406" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1704">4.7</ix:nonNumeric> - <ix:nonNumeric contextRef="c-407" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1705">9.9</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-405" decimals="2" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple" scale="0" id="f-1706">2.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-404" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-1707">39.77</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-404" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-1708">44.76</ix:nonFraction>%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-405" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1709">50.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The risk-free rate is based on U.S. Treasury securities with maturities equivalent to the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The expected term for founder awards is based on the assumption that the options are exercised after <ix:nonFraction unitRef="number" contextRef="c-14" decimals="2" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent" scale="-2" id="f-1710">50</ix:nonFraction>% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The exercise multiple is selected from the commonly used exercise multiple range of <ix:nonFraction unitRef="number" contextRef="c-408" decimals="1" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple" scale="0" id="f-1711">2.0</ix:nonFraction>x to <ix:nonFraction unitRef="number" contextRef="c-409" decimals="1" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple" scale="0" id="f-1712">2.5</ix:nonFraction>x assuming on average the options holders would exercise the options when the ratio of underlying stock price to the exercise price reaches <ix:nonFraction unitRef="number" contextRef="c-14" decimals="1" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple" scale="0" id="f-1713">2.3</ix:nonFraction>x.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">For founder awards, the expected stock price volatility is the median historical volatility of Waldencast&#8217;s volatility peer group with a look-back period equal to the contractual term using daily stock prices; for replacement awards, the expected stock price volatility is estimated by adjusting the observed equity volatility for leverage.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.43pt">Waldencast has not paid any dividends historically and does not plan to declare dividends in the foreseeable future and therefore assumed a dividend yield of <ix:nonFraction unitRef="usd" contextRef="c-14" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="0" id="f-1714">zero</ix:nonFraction>.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="f-1715" continuedAt="f-1715-1" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity for the period from July 28 to December&#160;31, 2022 (Successor Period) was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant Date Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of July 28, 2022 (Successor)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-410" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="f-1716">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-410" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-1717">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-411" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1718">3,173,364</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-411" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1719">9.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-411" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1720">370,945</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-411" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1721">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-411" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-1722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-411" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-1723">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2022 (Successor)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-412" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1724">2,802,419</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-412" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1725">9.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized compensation cost as of December 31, 2022 (Successor Period) for stock options and restricted stock was $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-1726">32.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-1727">11.4</ix:nonFraction> million, respectively. These costs are expected to be recognized over a weighted-average service period of <ix:nonNumeric contextRef="c-414" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1728">4.8</ix:nonNumeric> and <ix:nonNumeric contextRef="c-415" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1729">2.9</ix:nonNumeric> years for stock options and restricted stock, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Predecessor Incentive Plan</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Predecessor established a Stock Incentive Plan (the &#8220;Predecessor Incentive Plan&#8221;), under which stock options, stock awards, and restricted stock units (&#8220;Predecessor Restricted Stock&#8221;) of the Company could be granted to eligible employees, directors, and consultants. Under the Predecessor Incentive Plan, the Company was authorized to issue of a maximum number of <ix:nonFraction unitRef="shares" contextRef="c-416" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1730">1,500,000</ix:nonFraction> shares of Obagi common stock. Incentive stock options were required to have an exercise price at or above the fair market value of the stock on the date of the grant. The Company&#8217;s stock options and Predecessor Restricted Stock granted during the period from January 1 to July 27, 2022 (Predecessor Period) and the year ended December&#160;31, 2021 (Predecessor Period) had service-based and performance-based vesting conditions. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-188</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1658-4" continuedAt="f-1658-5"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options vested over <ix:nonNumeric contextRef="c-417" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1731">five years</ix:nonNumeric>, with <ix:nonFraction unitRef="number" contextRef="c-418" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-1732">25</ix:nonFraction>% of options vesting in <ix:nonFraction unitRef="segment" contextRef="c-419" decimals="INF" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments" format="ixt-sec:numwordsen" scale="0" id="f-1733">four</ix:nonFraction> equal quarterly installments at the end of each <ix:nonNumeric contextRef="c-418" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1734">three-month</ix:nonNumeric> period through the first anniversary of the grant, and the remaining <ix:nonFraction unitRef="number" contextRef="c-420" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-1735">75</ix:nonFraction>% vesting in a series of <ix:nonFraction unitRef="segment" contextRef="c-421" decimals="INF" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" format="ixt-sec:numwordsen" scale="0" id="f-1736">five</ix:nonFraction> equal annual installments over the <ix:nonNumeric contextRef="c-420" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1737">five-year</ix:nonNumeric> period measured from the grant date. The Predecessor Restricted Stock vested in <ix:nonFraction unitRef="segment" contextRef="c-422" decimals="INF" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" format="ixt-sec:numwordsen" scale="0" id="f-1738">five</ix:nonFraction> equal annual installments at the end of each year, over the <ix:nonNumeric contextRef="c-423" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1739">five-year</ix:nonNumeric> period from the grant date. Award holders had a <ix:nonNumeric contextRef="c-423" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-1740">ten-year</ix:nonNumeric> period to exercise the options before they expire. Notwithstanding achievement of the service-based condition, the options and the Predecessor Restricted Stock did not vest or become exercisable until a qualifying transaction was consummated prior to the expiration date. A qualifying transaction consisted of either a change in control event or an underwritten initial public offering by the Company of its equity securities on a U.S. or foreign exchange, which occurred upon Waldencast&#8217;s acquisition of Obagi. </span></div><ix:continuation id="f-1676-1"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the period from January 1 to July 27, 2022 (Predecessor Period) was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of<br/>Common Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>intrinsic<br/>Value (in<br/>thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of January 1, 2022 (Predecessor) </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-67" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1741">800,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-67" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1742">41.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-61" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1743">9.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1744">16,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-69" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-1745">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-69" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-1746">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-69" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-1747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-69" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-1748">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-69" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1749">25,200</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-69" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1750">41.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-69" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="f-1751">8.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" scale="3" id="f-1752">639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-69" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:fixed-zero" scale="0" id="f-1753">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-69" decimals="2" name="wald:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-1754">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of July 27, 2022 (Predecessor)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-76" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1755">774,800</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-76" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1756">41.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-69" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1757">8.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1758">19,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the year ended December&#160;31, 2021 (Predecessor Period) was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of<br/>Common Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>intrinsic<br/>Value (in<br/>thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of January 1, 2021 (Predecessor)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:fixed-zero" scale="0" id="f-1759">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-59" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-1760">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-1761">800,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-61" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1762">41.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-61" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="f-1763">9.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1764">16,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-1765">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-61" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-1766">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="f-1767">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-61" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-1768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:fixed-zero" scale="0" id="f-1769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-61" decimals="2" name="wald:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-1770">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2021 (Predecessor)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-67" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1771">800,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-67" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1772">41.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-61" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1773">9.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1774">16,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value per share of the awards granted during from January 1 to July 27, 2022 (Predecessor Period) was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1775">15.55</ix:nonFraction> for stock options and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-424" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1776">38.90</ix:nonFraction> for Predecessor Restricted Stock. The weighted average fair value per share of the awards granted during the year ended December&#160;31, 2021 (Predecessor Period) was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1777">15.55</ix:nonFraction> for stock options and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-425" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1778">38.68</ix:nonFraction> for Predecessor Restricted Stock. The unrecognized compensation cost as of December&#160;31, 2021 (Predecessor Period) for stock options and Predecessor Restricted Stock was $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-1779">9.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-426" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-1780">12.4</ix:nonFraction> million, respectively. Prior to Waldencast&#8217;s acquisition of Obagi, the Company did not expect the occurrence of a qualifying transaction event to be &#8220;probable&#8221;, and therefore no expense had been recorded.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-189</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1658-5"><ix:continuation id="f-1699-1"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock option awards was determined on the grant date using the Black-Scholes valuation model based on the following weighted-average assumptions:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1<br/>to July 27, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended <br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-427" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:fixed-zero" scale="0" id="f-1781">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-428" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1782">0.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-428" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1783">6.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-427" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" format="ixt:fixed-zero" scale="0" id="f-1784">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-428" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-1785">43.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-427" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="0" id="f-1786">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock per share value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-429" decimals="2" name="us-gaap:SharePrice" format="ixt:fixed-zero" scale="0" id="f-1787">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-430" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-1788">38.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The risk-free rate is based on U.S. Treasury securities with maturities equivalent to the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The expected term is the estimated length of time the grants are expected to be outstanding before it is exercised or terminated. This number is calculated as the midpoint between the requisite service period and the contractual term of the award, as the Company does not have any historical data that would provide a reasonable basis to estimate the expected term for the option.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The expected price volatility is based on the average of the historical volatility of comparable public companies over a period consistent with the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The Predecessor historically made distributions to its shareholder but the Company does not plan to declare dividends in the foreseeable future and therefore assumed a dividend yield of <ix:nonFraction unitRef="usd" contextRef="c-427" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" format="ixt:fixed-zero" scale="0" id="f-1789">zero</ix:nonFraction>.</span></div></ix:continuation><ix:continuation id="f-1715-1"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Predecessor Restricted Stock activity for the period from January 1 to July&#160;27, 2022 (Predecessor Period) was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant Date Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of January 1, 2022 (Predecessor)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-431" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1790">243,307</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-431" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1791">38.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-432" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1792">1,754</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-432" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1793">68.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-432" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" format="ixt:fixed-zero" scale="0" id="f-1794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-69" decimals="2" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-1795">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-432" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1796">10,219</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-432" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1797">38.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-432" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="f-1798">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-432" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-1799">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of July 27, 2022 (Predecessor)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-433" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1800">234,842</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-433" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1801">38.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Restricted Stock activity for the year ended December&#160;31, 2021 (Predecessor Period) was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant Date Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of January 1, 2021 (Predecessor)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-434" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="f-1802">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-434" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-1803">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-435" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1804">243,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-435" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1805">38.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-435" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" format="ixt:fixed-zero" scale="0" id="f-1806">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-61" decimals="2" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-1807">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-435" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-1808">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-435" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-1809">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-435" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="0" id="f-1810">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-435" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-1811">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2021 (Predecessor)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-431" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1812">243,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-431" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1813">38.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-190</span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_163"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1816" continuedAt="f-1816-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">SHAREHOLDERS&#8217; EQUITY</span></ix:nonNumeric></div><ix:continuation id="f-1816-1"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successor&#8217;s Share Capital</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s Memorandum of Association (the &#8220;Constitutional Document&#8221;), its authorized share capital consists of <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1817">1,000,000,000</ix:nonFraction> Class A ordinary shares, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1818">100,000,000</ix:nonFraction> Class B ordinary shares and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1819">25,000,000</ix:nonFraction> Preference Shares, each having a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="4" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1820"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1821"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1822">0.0001</ix:nonFraction></ix:nonFraction></ix:nonFraction>. As of December&#160;31, 2022 (Successor Period), there were&#160;<ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1823"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1824">86,460,560</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1825"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1826">21,104,225</ix:nonFraction></ix:nonFraction> Class A and Class B ordinary shares, respectively, issued and outstanding. The Company did <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-1827"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-1828">no</ix:nonFraction></ix:nonFraction>t have any Preference Shares issued and outstanding as of December&#160;31, 2022 (Successor Period).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Class A ordinary share is entitled to <ix:nonNumeric contextRef="c-436" name="us-gaap:CommonStockVotingRights" id="f-1829">one</ix:nonNumeric> vote per share. The Company can, at the discretion of its Board of Directors, declare dividends and distributions out of the funds of the Company lawfully available therefor. In the event of a voluntary or involuntary liquidation or wind-up, assets available for distribution among the holders of Class A ordinary shares will be distributed on a pro rata basis.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Class B ordinary share is entitled to <ix:nonNumeric contextRef="c-437" name="us-gaap:CommonStockVotingRights" id="f-1830">one</ix:nonNumeric> vote per share and will vote together with holders of Class&#160;A ordinary shares as a single class. Class B ordinary shares are non-economic shares that are not entitled to dividends. Upon a liquidation, dissolution or winding up the Company, the holders of Class B ordinary shares will not be entitled to receive any assets of the Company, except to the extent of the par value of their shares, pro rata with the distributions that the Class A ordinary shares.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As outlined in &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_127">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Business Combinations,&#8221; Class B ordinary shares were issued by the Company to the Milk Members in connection with the Business Combination, giving rise to noncontrolling interest in the Company&#8217;s controlled subsidiary, Waldencast Partners LP. As such, the Constitutional Document prohibits issuances of additional shares of Class B ordinary shares, unless issued to a noncontrolling interest in connection with the Company&#8217;s Up-C structure. Class B ordinary shares are convertible into Class A ordinary shares on a <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="wald:CommonStockConvertibleConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-1831">one</ix:nonFraction>-to-one basis at the option of the holder. If such option is exercised, the exchanged Class B ordinary shares will automatically be surrendered and retired for no consideration. If the Company issues or redeems Class B ordinary shares, Waldencast Partners LP is obligated to issue or redeem a corresponding number of Waldencast LP partnership units, such that the number of issued and outstanding partnership units at any time will correspond and be equivalent to the then number of issued and outstanding Class B ordinary shares.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Predecessor&#8217;s Share Capital</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Predecessor&#8217;s equity structure consisted of a single class of ordinary shares. In November  2020, the Obagi Board of Directors approved (i) an increase in the number of the Company&#8217;s authorized common shares from <ix:nonFraction unitRef="shares" contextRef="c-93" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1832">50,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1833">25,000,000</ix:nonFraction>, (ii) an issuance of <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1834">4,000,000</ix:nonFraction> common shares to ZhongHua, and (iii) a <ix:nonFraction unitRef="number" contextRef="c-95" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" format="ixt-sec:numwordsen" scale="0" id="f-1835">two</ix:nonFraction>-for-one split of the Company&#8217;s issued and outstanding common shares  all of which became effective in December  2020. The Company was held by a single shareholder, and the share issuance to ZhongHua was deemed akin to a stock split. All share, per share amounts and related shareholders&#8217; equity balances presented for Predecessor Periods have been retroactively adjusted to reflect the impact of the Stock Split. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December&#160;31, 2021 the Predecessor had <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1836">25,000,000</ix:nonFraction> ordinary shares authorized and <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1837"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1838">8,000,002</ix:nonFraction></ix:nonFraction> shares issued and outstanding. Predecessor&#8217;s ordinary shares had a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1839">0.50</ix:nonFraction> per share and each share was entitled to <ix:nonNumeric contextRef="c-16" name="us-gaap:CommonStockVotingRights" id="f-1840">one</ix:nonNumeric> vote.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Predecessor was able to, at the discretion of its Board of Directors, declare dividends and distributions out of the funds of the Company lawfully available therefor. Payments of dividends and distributions were limited to realized or unrealized profits of the Company. The Company did <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="0" id="f-1841">no</ix:nonFraction>t pay any dividends during the period from January 1 to July 27, 2022 (Predecessor Period). In the years ended December&#160;31, 2021 and 2020 (Predecessor Period), Obagi, through a wholly-owned subsidiary, paid $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-1842">2.0</ix:nonFraction> million (approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-1843">0.25</ix:nonFraction> per share) and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-1844">2.0</ix:nonFraction> million (approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-1845">0.26</ix:nonFraction> per share), respectively, in dividends to its shareholder.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-191</span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_166"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1846" continuedAt="f-1846-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">NET LOSS PER SHARE </span></ix:nonNumeric></div><ix:continuation id="f-1846-1"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the weighted average ownership percentages during the period to calculate the net loss per share attributable to public shareholders and the noncontrolling interest holders. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-1847" continuedAt="f-1847-1" escape="true">The following table sets forth the computation of basic and diluted net income (loss) using the treasury stock method: </ix:nonNumeric></span></div><ix:continuation id="f-1847-1"><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.950%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from<br/>January 1 to <br/>July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except for share and per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-1848">120,557</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-1849">21,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-1850">19,576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-1851">2,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1852">24,990</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-1853">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-1854">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-1855">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributed to Class A shareholders - basic and diluted EPS</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-1856"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1857">95,567</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-1858"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1859">21,057</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1860"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-1861">19,576</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-1862"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1863">2,370</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1864">86,460,560</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1865">8,000,002</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1866">8,000,002</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1867">8,000,002</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="f-1868">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="0" id="f-1869">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="0" id="f-1870">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="0" id="f-1871">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average diluted shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1872">86,460,560</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1873">8,000,002</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1874">8,000,002</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1875">8,000,002</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1876"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1877">1.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1878"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1879">2.63</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1880"><ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1881">2.45</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1882"><ix:nonFraction unitRef="usdPerShare" contextRef="c-17" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1883">0.30</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-1884" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents potential ordinary shares outstanding that were excluded from the computation of diluted net loss per share of common share because their effect would have been anti-dilutive:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:41.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from<br/>July 28 to December 31, <br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from<br/>January 1 to<br/>July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended <br/>December 31, <br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended <br/>December 31, <br/>2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-438" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1885">29,533,282</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-439" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-1886">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-440" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-1887">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-441" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-1888">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-442" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1889">20,452,155</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-443" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1890">774,800</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-444" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1891">800,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-445" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-1892">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-446" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1893">2,802,419</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-447" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1894">234,842</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-448" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1895">243,307</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-449" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-1896">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1897">52,787,856</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1898">1,009,642</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1899">1,043,307</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-1900">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="if2fc25067f8b45fc8cc165df93f3be1c_169"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1901" continuedAt="f-1901-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">INCOME TAX BENEFIT</span></ix:nonNumeric></div><ix:continuation id="f-1901-1" continuedAt="f-1901-2"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Predecessor was domiciled in the Cayman Islands. Following the Business Combination, the Company, domiciled in the Bailiwick of Jersey, is subject to taxation in the U.S. and various states jurisdictions. ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 740&#8221;) indicates that the federal statutory income tax rate of a foreign reporting entity be used when preparing the rate reconciliation disclosure. As such, the Company and its wholly-owned subsidiaries use the statutory income tax rate in the Bailiwick of Jersey for the Successor Period and the Cayman Islands for the Predecessor Period, which was <ix:nonFraction unitRef="number" contextRef="c-15" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1902"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1903">0</ix:nonFraction></ix:nonFraction>%. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-1904" continuedAt="f-1904-1" escape="true">The Company&#8217;s consolidated pretax income (loss) for the period from July 28 to December&#160;31, 2022 (Successor Period), the period from January 1 to July 27, 2022 (Predecessor Period), the year ended December&#160;31, </ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-192</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1901-2" continuedAt="f-1901-3"><ix:continuation id="f-1904-1"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 (Predecessor Period) and the year ended December&#160;31, 2020 (Predecessor Period) were generated by domestic and foreign operations as follows:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:41.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from<br/>July 28 to December 31, <br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1 to July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1905">125,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1906">17,676</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1907">15,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-1908">13,243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1909">1,079</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1910">3,268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1911">5,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-1912">7,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1913">126,360</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1914">20,944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1915">9,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1916">5,764</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-1917" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the period from July 28 to December&#160;31, 2022 (Successor Period), the period from January 1 to July 27, 2022 (Predecessor Period), the year ended December&#160;31, 2021 (Predecessor Period) and the year ended December&#160;31, 2020 (Predecessor Period) consisted of the following:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:39.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1 to July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current provision (benefit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1918">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1919">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1920">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="f-1921">363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1922">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1923">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1924">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1925">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1926">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-1927">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-1928">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-1929">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-1930">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-1931">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-1932">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-1933">350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred (income) expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1934">4,557</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="f-1935">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1936">7,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1937">2,473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1938">1,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-1939">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1940">1,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-1941">571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1942">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1943">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1944">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1946">5,823</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-1947">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1948">9,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1949">3,044</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income tax (benefit) provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1950">5,803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1951">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1952">9,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1953">3,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-193</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1901-3" continuedAt="f-1901-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1954" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income tax expense related to the following:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:41.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1 to July 27,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit at Bailiwick of Jersey for Successor and Income tax benefit at Cayman Islands for Predecessor statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" format="ixt:fixed-zero" scale="-2" id="f-1955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" format="ixt:fixed-zero" scale="-2" id="f-1956">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" format="ixt:fixed-zero" scale="-2" id="f-1957">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" format="ixt:fixed-zero" scale="-2" id="f-1958">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S./foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1959">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1960">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1961">30.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1962">47.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State income tax benefit, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1963">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1964">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1965">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1966">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Permanent Items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-1967">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-1968">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-1969">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-1970">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="f-1971">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="f-1972">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="f-1973">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="f-1974">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1975">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1976">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1977">141.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1978">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction bonuses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="wald:EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent" format="ixt:fixed-zero" scale="-2" id="f-1979">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="wald:EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent" scale="-2" id="f-1980">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="wald:EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent" format="ixt:fixed-zero" scale="-2" id="f-1981">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="wald:EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent" format="ixt:fixed-zero" scale="-2" id="f-1982">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="wald:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" format="ixt:fixed-zero" scale="-2" id="f-1983">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="wald:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" scale="-2" id="f-1984">11.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="wald:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" format="ixt:fixed-zero" scale="-2" id="f-1985">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="wald:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" format="ixt:fixed-zero" scale="-2" id="f-1986">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PPP Loan forgiveness  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="wald:EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent" format="ixt:fixed-zero" scale="-2" id="f-1987">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="wald:EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent" format="ixt:fixed-zero" scale="-2" id="f-1988">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="wald:EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent" scale="-2" id="f-1989">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="wald:EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent" format="ixt:fixed-zero" scale="-2" id="f-1990">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">True-Ups</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="wald:EffectiveIncomeTaxRateReconciliationTrueUpsPercent" format="ixt:fixed-zero" scale="-2" id="f-1991">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="wald:EffectiveIncomeTaxRateReconciliationTrueUpsPercent" format="ixt:fixed-zero" scale="-2" id="f-1992">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" sign="-" name="wald:EffectiveIncomeTaxRateReconciliationTrueUpsPercent" scale="-2" id="f-1993">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="wald:EffectiveIncomeTaxRateReconciliationTrueUpsPercent" scale="-2" id="f-1994">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" format="ixt:fixed-zero" scale="-2" id="f-1995">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" format="ixt:fixed-zero" scale="-2" id="f-1996">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" format="ixt:fixed-zero" scale="-2" id="f-1997">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1998">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="wald:EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent" scale="-2" id="f-1999">11.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="wald:EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent" format="ixt:fixed-zero" scale="-2" id="f-2000">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" name="wald:EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent" format="ixt:fixed-zero" scale="-2" id="f-2001">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="wald:EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent" format="ixt:fixed-zero" scale="-2" id="f-2002">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax (benefit) expense </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-2003">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-2004">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-2005">96.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-17" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-2006">58.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of each reporting date, the Company considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As part of the Business Combination, the Company determined that there was sufficient positive evidence to conclude that it was more likely than not that additional deferred taxes of $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="f-2007">28.1</ix:nonFraction> million would be realizable through the reversal of existing deferred tax liabilities listed below. It therefore reduced the valuation allowance accordingly. As of December 31, 2022, a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-2008">7.9</ix:nonFraction> million has been provided for on the deferred tax assets related to the Company&#8217;s investment in Waldencast Partners LP. If or when recognized, the tax benefits related to any reversal of valuation allowance will be accounted for as a reduction of income tax expense.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-2009" continuedAt="f-2009-1" escape="true">The tax effects of temporary differences that give rise to portions of the deferred tax assets and deferred tax liabilities as of December&#160;31, 2022 (Successor Period) and December&#160;31, 2021 (Predecessor Period) are presented below:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-194</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1901-4" continuedAt="f-1901-5"><ix:continuation id="f-2009-1"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest to foreign related parties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="wald:DeferredTaxAssetsAccruedInterestToForeignRelatedParties" format="ixt:num-dot-decimal" scale="3" id="f-2010">1,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="wald:DeferredTaxAssetsAccruedInterestToForeignRelatedParties" scale="3" id="f-2011">581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="wald:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2012">2,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="wald:DeferredTaxAssetsLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-2013">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-2014">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-2015">4,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="wald:DeferredTaxAssetsFormationCosts" format="ixt:num-dot-decimal" scale="3" id="f-2016">1,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="wald:DeferredTaxAssetsFormationCosts" format="ixt:num-dot-decimal" scale="3" id="f-2017">1,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-2018">13,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-2019">4,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="3" id="f-2020">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="f-2021">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="wald:DeferredTaxAssetsTransactionCosts" format="ixt:fixed-zero" scale="3" id="f-2022">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="wald:DeferredTaxAssetsTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="f-2023">1,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other temporary differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-2024">646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-2025">1,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" format="ixt:num-dot-decimal" scale="3" id="f-2026">1,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" id="f-2027">831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="f-2028">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="f-2029">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-deductible interest carryover</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetInterestCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-2030">3,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetInterestCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-2031">1,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below market contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="wald:DeferredTaxAssetsBelowMarketLeaseContract" format="ixt:num-dot-decimal" scale="3" id="f-2032">2,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="wald:DeferredTaxAssetsBelowMarketLeaseContract" format="ixt:fixed-zero" scale="3" id="f-2033">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-2034">2,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="f-2035">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in Waldencast LP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-2036">3,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsInvestments" format="ixt:fixed-zero" scale="3" id="f-2037">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-2038">34,580</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-2039">16,532</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" scale="3" id="f-2040">285</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-2041">2,794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed asset basis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-2042">370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-2043">226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-2044">2,025</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:fixed-zero" scale="3" id="f-2045">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-2046">46,206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-2047">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" format="ixt:fixed-zero" scale="3" id="f-2048">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" format="ixt:fixed-zero" scale="3" id="f-2049">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2050">48,886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2051">3,020</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net deferred tax (liabilities) assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="wald:DeferredTaxAssetsNetBeforeValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-2052">14,306</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="wald:DeferredTaxAssetsNetBeforeValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-2053">13,512</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-2054">7,944</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-2055">14,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2056">22,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="f-2057">548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="wald:SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock" id="f-2058" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses and tax credit carryforwards as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Successor Period) and  December&#160;31, 2021 (Predecessor Period) were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:49.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.805%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.805%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.585%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expiration Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expiration Year</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, federal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-2059">50,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-451" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-2060">20,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, state</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-452" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-2061">39,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2039-2042</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-2062">9,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2039-2041</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax Credits, federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="f-2063">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2038-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-451" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="f-2064">283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2038-2039</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax Credits, state</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-452" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="f-2065">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="f-2066">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#8220;IRC&#8221;) annual use of the Company&#8217;s net operating losses (&#8220;NOLs&#8221;) and R&amp;D credit carryforwards may be limited in the event a cumulative change in ownership of more than 50.0% occurs within a three-year period. The Company has not undergone an analysis to determine whether this limitation would apply to the utilization of the NOL carryforward. However, as the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-195</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-1901-5"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal NOLs do not expire, the Company does not believe that any potential limitations to federal or state NOL&#8217;s, or federal credit carryforwards, if applicable, would be material to the financial statements.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits, and uncertain income tax positions must meet a more likely than not recognition threshold to be recognized. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line in the consolidated statements of operations and comprehensive loss. There were <ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="f-2067"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="f-2068">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022 (Successor Period)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or December&#160;31, 2021 (Predecessor Period). The Company does not expect material changes to its unrecognized tax benefits for the twelve month period following the reporting date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (Successor Period) there were no active taxing authority examinations in any of the Company's major tax jurisdictions. The Company remains subject to examination for federal and state income tax purposes for the tax years ending 2018 through 2022 (Successor Period).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the tax years beginning on or after January 1, 2022, the Tax Cuts and Jobs Act of 2017 eliminates the option to currently deduct R&amp;D expenses and requires taxpayers to capitalize and amortize them over five years for research activities performed in the U.S. and 15 years for research activities performed outside the U.S. pursuant to IRC Section 174. Although Congress is considering legislation that would repeal or defer this capitalization and amortization requirement, it is not certain that this provision will be repealed or otherwise modified. If the requirement is not repealed or replaced, it will decrease our tax deduction for research and development expense in future years.</span></div></ix:continuation><div id="if2fc25067f8b45fc8cc165df93f3be1c_172"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-2069" continuedAt="f-2069-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">RELATED PARTY TRANSACTIONS</span></ix:nonNumeric></div><ix:continuation id="f-2069-1" continuedAt="f-2069-2"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Waldencast</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Prior to the Business Combination</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sponsor Shares</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Sponsor purchased <ix:nonFraction unitRef="shares" contextRef="c-454" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-2070">7,187,500</ix:nonFraction> Class B ordinary shares for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-2071">0.025</ix:nonFraction> million, or approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="c-455" decimals="3" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-2072">0.003</ix:nonFraction> per share (the &#8220;sponsor shares&#8221;). In February 2021, the Sponsor transferred <ix:nonFraction unitRef="shares" contextRef="c-456" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2073">20,000</ix:nonFraction> Class B ordinary shares to each of the Company&#8217;s then-serving independent directors, Ms. Sarah Brown, Ms. Juliette Hickman, Ms. Lindsay Pattison and Mr. Zack Werner (the &#8220;Investor Directors&#8221;), resulting in the Sponsor holding <ix:nonFraction unitRef="shares" contextRef="c-457" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2074">7,107,500</ix:nonFraction> Class B ordinary shares. In March 2021, Waldencast effected a share capitalization resulting in the Sponsor holding an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-458" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2075">8,545,000</ix:nonFraction> Class B ordinary shares. As such, the Sponsor and the Investor Directors collectively owned <ix:nonFraction unitRef="number" contextRef="c-459" decimals="2" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="f-2076">20</ix:nonFraction>% of Waldencast&#8217;s issued and outstanding shares upon consummation of its IPO. In connection with the Business Combination, <ix:nonFraction unitRef="shares" contextRef="c-460" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2077">8,625,000</ix:nonFraction> sponsor shares held by the Sponsor and Investor Directors converted automatically, on a <ix:nonFraction unitRef="number" contextRef="c-460" decimals="INF" name="wald:ConversionOfStockToCommonStockConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-2078">one</ix:nonFraction>-for-one basis, into one Class A ordinary share in accordance with their terms.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Agreements</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with Waldencast&#8217;s IPO, in February  2021, the Sponsor and Zeno (a member of the Sponsor) entered into the Sponsor FPA, which was subsequently amended by the assignment and assumption agreement entered into by and between the Sponsor and Burwell in December 2021. Under the assignment and assumption agreement, Sponsor assigned, and Burwell assumed, all of the Sponsor&#8217;s rights and benefits under the Sponsor FPA, pursuant to which, Burwell and Zeno committed to subscribe for and purchase <ix:nonFraction unitRef="shares" contextRef="c-461" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-2079">16,000,000</ix:nonFraction> Class A ordinary shares and <ix:nonFraction unitRef="shares" contextRef="c-462" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-2080">5,333,333</ix:nonFraction> warrants for an aggregate commitment amount of $<ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-2081">160.0</ix:nonFraction> million in connection with the closing of Waldencast&#8217;s initial business combination. In addition, Beauty Ventures entered into the Third-Party FPA with Waldencast in March 2021, pursuant to which Beauty Ventures committed to subscribe for and purchase up to <ix:nonFraction unitRef="shares" contextRef="c-464" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-2082">17,300,000</ix:nonFraction> Class A ordinary shares and up to <ix:nonFraction unitRef="shares" contextRef="c-465" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-2083">5,766,666</ix:nonFraction> warrants for an aggregate commitment amount of $<ix:nonFraction unitRef="usd" contextRef="c-466" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-2084">173.0</ix:nonFraction> million, in connection with the closing of the Company&#8217;s initial business combination. Members of the Sponsor or their affiliates will begin to receive a twenty percent (<ix:nonFraction unitRef="number" contextRef="c-467" decimals="2" name="wald:ForwardPurchaseAgreementPerformanceFeeAllocationPercentage" scale="-2" id="f-2085">20</ix:nonFraction>%) performance fee allocation on the return of the forward purchase securities in excess of the hurdle rate, calculated on the total return generated from forward purchase securities (whether by dividend, transfer or increase in value as measured from date of issuance), when the return of such securities (less the expenses of Beauty Ventures) underlying the Third-Party FPA exceeds a hurdle rate of five percent (<ix:nonFraction unitRef="number" contextRef="c-467" decimals="2" name="wald:ForwardPurchaseAgreementHurdleRate" scale="-2" id="f-2086">5</ix:nonFraction>%) accrued annually until the fifth anniversary of the issuance of such securities. In the event of a transfer and subsequent sale of any forward purchase securities prior to such fifth anniversary, the performance fee for the period between such transfer and such fifth </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-196</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-2069-2" continuedAt="f-2069-3"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anniversary will be calculated based on the proceeds generated by such sale. The FPA investments were consummated substantially concurrently with the consummation of the Business Combination.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Placement Warrants</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneously with the consummation of the IPO, the Sponsor purchased <ix:nonFraction unitRef="shares" contextRef="c-468" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-2087">5,933,333</ix:nonFraction> Private Placement Warrants at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-469" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-2088">1.50</ix:nonFraction> per private placement warrant, or $<ix:nonFraction unitRef="usd" contextRef="c-468" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="f-2089">8.9</ix:nonFraction> million in the aggregate. Each Private Placement Warrant entitles the holder to purchase <ix:nonFraction unitRef="number" contextRef="c-469" decimals="INF" name="wald:ConversionOfStockToCommonStockConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-2090">one</ix:nonFraction> Class A ordinary share for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-469" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-2091">11.50</ix:nonFraction> per share. The Private Placement Warrants may not be redeemed by the Company so long as they are held by the Sponsor or its permitted transferees. If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the  Private Placement Warrants will be redeemable by the Company and exercisable by the holders on the same basis as the Public Warrants. The Sponsor, or its permitted transferees, has the option to exercise the Private Placement Warrants on a cashless basis. The Private Placement Warrants are identical to the Public Warrants, except that the Private Placement Warrants: (i) are not redeemable by the Company, (ii) may be exercised for cash or on a cashless basis so long as they are held by the Sponsor or any of its permitted transferees and (iii) are entitled to registration rights (including the Class A ordinary shares issuable upon exercise of the private placement warrants). Additionally, the purchasers agreed not to transfer, assign or sell any of the Private Placement Warrants, including the Class A ordinary shares issuable upon exercise of the Private Placement Warrants (except to certain permitted transferees), until <ix:nonNumeric contextRef="c-468" name="wald:ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination" format="ixt-sec:durday" id="f-2092">30</ix:nonNumeric> days after the completion of the Business Combination. In connection with the Business Combination, each of the <ix:nonFraction unitRef="shares" contextRef="c-470" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-2093">5,933,333</ix:nonFraction> Private Placement Warrants converted automatically into a warrant to acquire <ix:nonFraction unitRef="number" contextRef="c-471" decimals="INF" name="wald:ConversionOfStockToCommonStockConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-2094">one</ix:nonFraction> Class A ordinary share.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Registration Rights</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the sponsor shares, Private Placement Warrants, and warrants that were issued upon conversion of the Working Capital Loan (as defined below) (and any Class A ordinary shares issuable upon (i) the exercise of the Private Placement Warrants, including the Working Capital Warrants (as defined below) and (ii) the conversion of the sponsor shares) are entitled to registration rights pursuant to a registration rights agreement dated March 15, 2021 (the &#8220;Legacy Registration Rights Agreement&#8221;) requiring the Company to register such securities for resale (in the case of the sponsor shares, only after conversion to Class A ordinary shares). The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of the Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company is responsible for the expenses incurred in connection with the filing of any such registration statements.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sponsor, the members of the Sponsor and certain of the Company&#8217;s shareholders, Obagi and Milk and certain of their respective affiliates entered into an amended and restated registration rights agreement, dated July 27, 2022, with the Company (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company agreed to register for resale, pursuant to Rule 415 under the Securities Act, certain Class A ordinary shares and our other securities that are held by the parties thereto from time to time, subject to the restrictions on transfer therein. The Registration Rights Agreement amended and restated the Legacy Registration Rights Agreement and terminates with respect to any party thereto, on the date that such party no longer holds any Registrable Securities (as defined therein).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company filed a registration statement on Form F-1 to register up to <ix:nonFraction unitRef="shares" contextRef="c-472" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-2095">121,120,063</ix:nonFraction> Class A ordinary shares, consisting of (i) <ix:nonFraction unitRef="shares" contextRef="c-473" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-2096">8,545,000</ix:nonFraction> Class A ordinary shares converted from the sponsor shares; (ii) <ix:nonFraction unitRef="shares" contextRef="c-474" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-2097">80,000</ix:nonFraction> Class A ordinary shares converted from the sponsor shares held by the Investor Directors; (iii) <ix:nonFraction unitRef="shares" contextRef="c-475" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-2098">20,000</ix:nonFraction> Class A ordinary shares issued to Aaron Chatterley in a private placement exempt from registration pursuant to Section 4(a)(2) of the Securities Act, and Rule 506 of Regulation D promulgated thereunder, in connection with the consummation of the Business Combination; (iv) <ix:nonFraction unitRef="shares" contextRef="c-476" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-2099">28,237,506</ix:nonFraction> Class A ordinary shares issued pursuant to the Obagi Merger Agreement; (v) <ix:nonFraction unitRef="shares" contextRef="c-477" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-2100">21,104,225</ix:nonFraction> Class A ordinary shares issuable in exchange for <ix:nonFraction unitRef="shares" contextRef="c-478" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-2101">21,104,225</ix:nonFraction> Class B ordinary shares pursuant to the Milk Equity Purchase Agreement; (vi) <ix:nonFraction unitRef="shares" contextRef="c-479" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-2102">11,800,000</ix:nonFraction> Class A ordinary shares issued in the PIPE investments; (vii) <ix:nonFraction unitRef="shares" contextRef="c-480" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-2103">33,300,000</ix:nonFraction> Class A ordinary shares issued pursuant to the FPAs; and (viii) <ix:nonFraction unitRef="shares" contextRef="c-481" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-2104">18,033,332</ix:nonFraction> Class A ordinary shares issuable in respect of the private placement warrants, pursuant to the Registration Rights Agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-197</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-2069-3" continuedAt="f-2069-4"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Notes and Advances</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, Waldencast issued a promissory note to the Sponsor (the &#8220;January Note&#8221;), pursuant to which Waldencast could borrow an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-482" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-2105">0.3</ix:nonFraction> million. The note was non-interest bearing and payable on the completion of the IPO. There were <ix:nonFraction unitRef="usd" contextRef="c-483" decimals="-3" name="us-gaap:ShortTermBorrowings" format="ixt:fixed-zero" scale="0" id="f-2106">no</ix:nonFraction> borrowings outstanding under the note at the closing of the IPO.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Waldencast issued a promissory note to the Sponsor, pursuant to which it could borrow up to an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-484" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="f-2107">1,500,000</ix:nonFraction> from the Sponsor (the &#8220;Working Capital Loan&#8221;). The note was non-interest bearing, unsecured and due and payable in full on the earlier of (x) March 18, 2023 and (y) the date Waldencast consummated its initial business combination. In October 2021, Waldencast drew down the entire available balance of the promissory note and the Sponsor deposited $<ix:nonFraction unitRef="usd" contextRef="c-485" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="0" id="f-2108">1,500,000</ix:nonFraction> in Waldencast&#8217;s operating bank account. As of the Closing Date, there was a total aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="0" id="f-2109">1,500,000</ix:nonFraction> in outstanding borrowings under the Convertible Working Capital Note. In connection with the closing of Business Combination, the Sponsor elected to convert $<ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="0" id="f-2110">1,500,000</ix:nonFraction> of the Working Capital Loan balance into warrants at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-486" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-2111">1.50</ix:nonFraction> per warrant for a total of <ix:nonFraction unitRef="shares" contextRef="c-486" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-2112">1,000,000</ix:nonFraction> warrants (the &#8220;Working Capital Warrants&#8221;). The Working Capital Warrants issuance was exempt from registration pursuant to Section 4(a)(2) of the Securities Act, and Rule 506 of Regulation D promulgated thereunder. Borrowings under the Convertible Working Capital Note are <ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:fixed-zero" scale="0" id="f-2113">no</ix:nonFraction> longer available.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Waldencast issued working capital promissory notes to the Sponsor on (i) in May 2022, for up to $<ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="f-2114">600,000</ix:nonFraction> (&#8220;May Working Capital Note&#8221;) and (ii) July 2022, for up to $<ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="f-2115">450,000</ix:nonFraction> (&#8220;July Working Capital Note&#8221; and, together with May Working Capital Note, the &#8220;Non-Convertible Working Capital Notes&#8221;), in each case, for working capital purposes. As of the Closing Date, there was a total aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="0" id="f-2116">1,050,000</ix:nonFraction> in outstanding borrowings under the Non-Convertible Working Capital Notes. In connection with the closing of Business Combination, the aggregate outstanding balance under the Non-Convertible Working Capital Notes of $<ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="0" id="f-2117">1,050,000</ix:nonFraction> was repaid to the Sponsor. Borrowings under the Non-Convertible Working Capital Notes are <ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:fixed-zero" scale="0" id="f-2118">no</ix:nonFraction> longer available.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Administrative Services Agreement</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast entered into an agreement whereby, commencing on March 15, 2021, through the earlier of the consummation of a business combination or a liquidation, Waldencast agreed to pay the Sponsor a monthly fee of $<ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-3" name="us-gaap:AdministrativeFeesExpense" format="ixt:num-dot-decimal" scale="0" id="f-2119">10,000</ix:nonFraction> for office space, administrative, financial and support services. Waldencast incurred approximately $<ix:nonFraction unitRef="usd" contextRef="c-493" decimals="-3" name="us-gaap:AdministrativeFeesExpense" format="ixt:num-dot-decimal" scale="0" id="f-2120">65,000</ix:nonFraction> in administrative expenses under the agreement through the Closing Date, but ceased to incur these fees following the completion of the Business Combination. As of December 31, 2022 (Successor Period), the Company had $<ix:nonFraction unitRef="usd" contextRef="c-494" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-2121">0.4</ix:nonFraction> million in related party accounts payable in consolidated balance sheets. The Company ceased to incur these fees following the completion of the Business Combination.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lock-Up Agreements</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to a Letter Agreement, dated March 15, 2021, between the initial shareholders of Waldencast Acquisition Corp. and Waldencast (the &#8220;Letter Agreement&#8221;), such shareholders agreed not to transfer, assign or sell any of their sponsor shares until the earlier to occur of: (A) <ix:nonNumeric contextRef="c-492" name="wald:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod" format="ixt-sec:durwordsen" id="f-2122">one year</ix:nonNumeric> after the Closing Date; and (B) following the Closing Date, (x) if the last reported sale price of the Class A ordinary shares equals or exceeds $<ix:nonFraction unitRef="usdPerShare" contextRef="c-495" decimals="2" name="wald:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" scale="0" id="f-2123">12.00</ix:nonFraction> per share (as adjusted for share sub-divisions, share dividends, rights issuances, consolidations, reorganizations, recapitalizations and other similar transactions) for any <ix:nonFraction unitRef="tradingday" contextRef="c-492" decimals="INF" name="wald:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays" scale="0" id="f-2124">20</ix:nonFraction> trading days within any <ix:nonFraction unitRef="tradingday" contextRef="c-492" decimals="INF" name="wald:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays" scale="0" id="f-2125">30</ix:nonFraction>-trading day period commencing at least <ix:nonNumeric contextRef="c-492" name="wald:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays" format="ixt-sec:durday" id="f-2126">150</ix:nonNumeric> days after the Company&#8217;s initial business combination or (y) the date on which it completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of its public shareholders having the right to exchange their ordinary shares for cash, securities or other property (except with respect to permitted transferees) (the &#8220;Letter Agreement Lock-Up Provisions&#8221;). Any permitted transferees would be subject to the same restrictions and other agreements of the initial shareholders of Waldencast Acquisition Corp. with respect to any sponsor shares. Such Letter Agreement Lock-Up Provisions expired on July 27, 2023.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to the Sponsor FPA, Burwell and Zeno agreed not to transfer, assign or sell any of their Class A ordinary shares according to the same Letter Agreement Lock-Up Provisions. Any permitted transferees would be subject to the same restrictions and other agreements as a purchaser under the Sponsor FPA. The Sponsor FPA lock-up period expired on July 27, 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-198</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-2069-4" continuedAt="f-2069-5"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Waiver and Agreement</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the consummation of the Business Combination, the Company waived certain provisions as contemplated by the Letter Agreement and certain other agreements related thereto (collectively, the &#8220;Waiver&#8221;), with respect to any securities held by an Insider (as defined in the Letter Agreement) as of the closing the Business Combination (the &#8220;Lock-Up Securities&#8221;) that would disallow a pledge by such Insider of the Lock-Up Securities in a transaction for the purpose of financing such Insider&#8217;s payment obligations owed in connection with the closing of the Business Combination. In connection with such Waiver, the Company entered into that certain Waiver and Agreement, dated as of July 25, 2022, with Burwell (the &#8220;Waiver and Agreement&#8221;), to permit a pledge by Burwell of its Lock-Up Securities to be used as a portion of the collateral under a loan to finance Burwell&#8217;s payment obligations under the Sponsor FPA in connection with the closing of the Business Combination. Pursuant to the terms of the Waiver and Agreement, in the event of a foreclosure, any such lenders or a collateral agents will be required to execute a joinder to the Letter Agreement pursuant to which they will be bound by the transfer restrictions of the Lock-Up Securities (including the foreclosure of or other exercise of remedies under any such loan documentation) in the Letter Agreement for the duration of such agreement. We also agreed to provide any such lender or collateral agent with customary registration rights in the event of default, foreclosure or other exercise of remedies following the respective Lock-Up Periods (as defined in the Letter Agreement).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnification Agreements</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Business Combination, the Company entered into indemnification agreements with each of its directors. The indemnification agreements provide, to the fullest extent permitted under law, indemnification against all expenses, judgments, fines and amounts paid in settlement relating to, arising out of or resulting from an indemnitee&#8217;s status as a director, officer, employee, fiduciary or agent of the Company or any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other entity which such person is or was serving at the Company&#8217;s request as a director, officer, employee or agent. In addition, the indemnification agreements provide that the Company will advance, to the extent not prohibited by law, the expenses incurred by the indemnitee in connection with any proceeding, and such advancement will be made within thirty (<ix:nonNumeric contextRef="c-496" name="wald:IndemnificationAgreementAdvanceExpensePeriod" format="ixt-sec:durday" id="f-2127">30</ix:nonNumeric>) days after the receipt by the Company of a statement requesting such advances from time to time, whether prior to or after final disposition of any proceeding. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transactions with Cedarwalk in connection with the Business Combination</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Obagi China Distribution, the Company entered into an Intellectual Property License Agreement (the &#8220;IP License Agreement&#8221;), a Global Supply Services Agreement (the &#8220;Supply Agreement&#8221;), and a Transition Services Agreement (the &#8220;Transition Services Agreement&#8221;) with Obagi Hong Kong, which is owned by Cedarwalk, the former owner of Obagi and a beneficial holder of <ix:nonFraction unitRef="number" contextRef="c-183" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-2128">24.5</ix:nonFraction>% of the Company&#8217;s fully diluted Class A ordinary shares as of the closing of the Business Combination.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the IP License Agreement, the Company exclusively licenses intellectual property relating to the Obagi brand to the Obagi China Business, and the Company retains the rights to such intellectual property to conduct the Obagi-branded business worldwide except for the China Region. The Obagi China Business pays the Company a royalty of <ix:nonFraction unitRef="number" contextRef="c-497" decimals="3" name="wald:RoyaltyPercentageOfGrossSales" scale="-2" id="f-2129">5.5</ix:nonFraction>% of gross sales of licensed products. During the period from July 28 to December&#160;31, 2022 (Successor Period) net revenue generated from related party royalties was $<ix:nonFraction unitRef="usd" contextRef="c-498" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2130">0.2</ix:nonFraction> million. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Supply Agreement, the Company supplies or causes to be supplied through certain Obagi CMOs products for distribution and sale in the China Region by the Obagi China Business. The term of the Supply Agreement is perpetual, subject to termination for material breach and failure to cure or termination in the event that the IP License Agreement is terminated. The Company anticipates it will continue supplying the Obagi China Business with products at an agreed-upon markup, net of agreed-upon discounts as applicable until the Obagi China Business has been added as a party to Obagi&#8217;s CMO agreements, at which time it will then order directly from the CMOs. During the period from July 28 to December&#160;31, 2022 (Successor Period) net revenue generated from supplying products to the Obagi China Business was $<ix:nonFraction unitRef="usd" contextRef="c-499" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-2131">17.0</ix:nonFraction> million</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the related cost of goods sold was $<ix:nonFraction unitRef="usd" contextRef="c-499" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-2132">5.1</ix:nonFraction> million.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 (Successor Period), the Company had $<ix:nonFraction unitRef="usd" contextRef="c-500" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-2133">0.3</ix:nonFraction></span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million in related party accounts receivable from the Obagi China Business in the consolidated balance sheet. </span></div></ix:continuation><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-199</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-2069-5" continuedAt="f-2069-6"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Transition Services Agreement, the Company provided Obagi Hong Kong and its affiliates certain transition services to enable them to conduct the Obagi China Business as a going concern in the China Region. The transition services were provided for an initial term of up to <span style="-sec-ix-hidden:f-2134">twelve</span> (12) months, with an option for Obagi China Business to extend the service period for up to an additional <span style="-sec-ix-hidden:f-2135">twelve</span> (12) months solely as to certain R&amp;D services. Obagi Hong Kong did not elect to extend the services and as a result the Transition Services Agreement expired on July 27, 2023. Services under the agreement were to be charged at the reasonable, fully-loaded costs of providing the services, but such services were to be provided at no charge for a certain period of time or up to a specified dollar value of services (the &#8220;Threshold Amount&#8221;). The Company determined that the Threshold Amount may be applied towards a combination of the Company&#8217;s services or inventory purchases made by the Obagi China Business under the Supply Agreement. Due to the fact that the Threshold Amount had not been reached at the time of expiration, the Company received no fees from the Obagi China Business during the period ended December 31, 2022 (Successor Period).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Predecessor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operational Support Services Agreement</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, Obagi Cosmeceuticals LLC (&#8220;Obagi Cosmeceuticals&#8221;) entered into an operational support services agreement with Obagi Holdings Company Limited (&#8220;Obagi Holdco&#8221;), Obagi Hong Kong and Obagi Shanghai Cosmeceuticals Co. Ltd., a subsidiary of Obagi Hong Kong (&#8220;Obagi Shanghai&#8221;), pursuant to which Obagi Cosmeceuticals provided certain services, including administrative and product related services, to the other signatories party thereto. The agreement terminated with respect to Obagi Hong Kong and Obagi Shanghai in connection with the Obagi China Distribution (as defined below). Under the agreement, which automatically renewed for a <ix:nonNumeric contextRef="c-502" name="wald:ServicesAgreementRenewalTerm" format="ixt-sec:durwordsen" id="f-2136">one-year</ix:nonNumeric> term on January 1, 2021, Obagi Cosmeceuticals received service fees in an amount equal to the sum of its costs incurred in the performance of such services plus five percent (<ix:nonFraction unitRef="number" contextRef="c-503" decimals="2" name="wald:ServicesAgreementFeePercentageOfIncurredCosts" scale="-2" id="f-2137">5</ix:nonFraction>%). Total service fees paid to Obagi Cosmeceuticals were $<ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-5" name="wald:PaymentsForServicesAgreementFees" scale="6" id="f-2138">1.1</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-5" name="wald:PaymentsForServicesAgreementFees" scale="6" id="f-2139">3.5</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-5" name="wald:PaymentsForServicesAgreementFees" scale="6" id="f-2140">4.6</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-507" decimals="-5" name="wald:PaymentsForServicesAgreementFees" scale="6" id="f-2141">0.9</ix:nonFraction> million for the 2022 Successor Period, 2022 Predecessor Period, for the year ended December 31, 2021 (Predecessor Period), and for the year ended December 31, 2020 (Predecessor Period), respectively. There were <ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-5" name="wald:PaymentsForServicesAgreementFees" format="ixt:fixed-zero" scale="0" id="f-2142">no</ix:nonFraction> service fees paid to Obagi Shanghai in the 2022 Successor Period, as the agreement was terminated upon closing of the Business Combination.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Exclusive Marketing Services Agreement</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Obagi Holdco and Obagi Shanghai entered into a non-exclusive marketing services agreement, pursuant to which Obagi Shanghai provided certain sales and marketing services to Obagi Holdco in the People&#8217;s Republic of China. Under the agreement, which terminated upon closing of the Business Combination, Obagi Shanghai received service fees in an amount equal to the sum of its costs incurred in the performance of such services plus five percent (<ix:nonFraction unitRef="number" contextRef="c-509" decimals="2" name="wald:ServicesAgreementFeePercentageOfIncurredCosts" scale="-2" id="f-2143">5</ix:nonFraction>%). Total service fees paid to Obagi Shanghai were $<ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-5" name="wald:PaymentsForServicesAgreementFees" scale="6" id="f-2144">2.1</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-5" name="wald:PaymentsForServicesAgreementFees" scale="6" id="f-2145">2.6</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-5" name="wald:PaymentsForServicesAgreementFees" scale="6" id="f-2146">0.6</ix:nonFraction> million for the 2022 Predecessor Period, for the year ended December 31, 2021 (Predecessor Period), and for the year ended December 31, 2020 (Predecessor Period), respectively. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registration with National Medical Products Administration in China</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Cedarwalk paid approximately $<ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-5" name="us-gaap:PaymentsForFees" scale="6" id="f-2147">4.1</ix:nonFraction> million to register Obagi&#8217;s products with the National Medical Products Administration in China in exchange for <ix:nonFraction unitRef="shares" contextRef="c-514" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-2148">8,000,000</ix:nonFraction> shares of Obagi common stock. This non-cash capital contribution was recorded as additional paid-in capital in Obagi&#8217;s consolidated statements of shareholders&#8217; equity for the year ended December 31, 2020.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Obagi China Distribution</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition to the Obagi Merger Agreement, prior to the Closing Date, Obagi Holdco distributed to Obagi and then Obagi distributed to Cedarwalk all of the issued and outstanding shares of capital stock of Obagi Hong Kong and certain related assets pursuant to distribution agreements in the Obagi China Distribution, as discussed in &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_127">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Business Combinations.&#8221; The Obagi China Business had been conducted through Obagi Hong Kong and its subsidiaries. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milk</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk subleases from Milk Studios Los Angeles LLC certain space in Los Angeles, CA on a month-to-month basis. Milk primarily uses these facilities for corporate offices and as an in-house studio. During the period from July 28 to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-200</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><ix:continuation id="f-2069-6"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022 (Successor Period), the Company incurred administrative fees of $<ix:nonFraction unitRef="usd" contextRef="c-515" decimals="-5" name="us-gaap:AdministrativeFeesExpense" scale="6" id="f-2149">0.1</ix:nonFraction> million, which is recorded in SG&amp;A expenses in consolidated statements of operations and comprehensive loss.</span></ix:continuation><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_175"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-2151" continuedAt="f-2151-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">COMMITMENTS AND CONTINGENCIES</span></ix:nonNumeric></div><ix:continuation id="f-2151-1" continuedAt="f-2151-2"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Commitments</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase commitments represent unconditional purchase obligations to purchase goods or services, primarily inventory, that are enforceable and legally binding on the Company and specify all significant terms, including fixed or minimum quantities to be purchased, price provisions, and the approximate timing of the transaction. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into a certain development and production agreement with a third-party vendor in which the Company is committed to purchase from the vendor certain units of Skintrinsiq devices totaling $<ix:nonFraction unitRef="usd" contextRef="c-517" decimals="-5" name="us-gaap:LongTermPurchaseCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="f-2152">5.7</ix:nonFraction>&#160;million. As of December 31, 2022, the Company&#8217;s associated future minimum payment was $<ix:nonFraction unitRef="usd" contextRef="c-518" decimals="-5" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="6" id="f-2153">1.4</ix:nonFraction> million over the next <ix:nonNumeric contextRef="c-519" name="us-gaap:LongtermPurchaseCommitmentPeriod" format="ixt-sec:durmonth" id="f-2154">12</ix:nonNumeric>-<ix:nonNumeric contextRef="c-520" name="us-gaap:LongtermPurchaseCommitmentPeriod" format="ixt-sec:durmonth" id="f-2155">18</ix:nonNumeric> months. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into an unconditional purchase order with third-party product manufacturers for the delivery of inventory in which the Company is committed to purchase from the manufacturers certain product inventory totaling $<ix:nonFraction unitRef="usd" contextRef="c-521" decimals="-5" name="us-gaap:LongTermPurchaseCommitmentAmount" scale="6" id="f-2156">8.2</ix:nonFraction> million. As of December 31, 2022, the Company&#8217;s associated future minimum payment was $<ix:nonFraction unitRef="usd" contextRef="c-522" decimals="-5" name="us-gaap:PurchaseObligation" scale="6" id="f-2157">7.0</ix:nonFraction> million over the next <ix:nonNumeric contextRef="c-523" name="us-gaap:LongtermPurchaseCommitmentPeriod" format="ixt-sec:durmonth" id="f-2158">12</ix:nonNumeric>-<ix:nonNumeric contextRef="c-524" name="us-gaap:LongtermPurchaseCommitmentPeriod" format="ixt-sec:durmonth" id="f-2159">18</ix:nonNumeric> months. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div></ix:continuation><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><ix:continuation id="f-2151-2" continuedAt="f-2151-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Except for the SEC investigation described in &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_187">Note 21</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Subsequent Events</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-2151-3">.&#8221; the Company is not involved in any material litigation nor, to management&#8217;s knowledge, was any material litigation threatened against the Company, which if adversely determined could have a material adverse impact on the Company other than routine litigation arising in the ordinary course of business,</ix:continuation> </span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_178"></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-2160" continuedAt="f-2160-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">SEGMENT REPORTING</span></ix:nonNumeric></div><ix:continuation id="f-2160-1" continuedAt="f-2160-2"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports segment information based on the management approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of our reportable segments. Prior to the consummation of the Business Combination, the Predecessor operated its business and reported its results through a single operating and reportable segment. Following the Business Combination, the Company determined that it has <ix:nonFraction unitRef="segment" contextRef="c-14" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-2161"><ix:nonFraction unitRef="segment" contextRef="c-14" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-2162">two</ix:nonFraction></ix:nonFraction> operating and reportable segments: Obagi Skincare and Milk Makeup. See. &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_127">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obagi Skincare </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- this segment consists of the business of Obagi. Obagi&#8217;s business activities include developing, marketing, and selling skin health products. These assets and activities are conducted by Obagi Global Holdings Limited and its wholly-owned subsidiaries.  </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milk Makeup</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - this segment consists of the business of Milk. Milk&#8217;s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Milk generates revenue from the sale of cosmetics to retailers, including off-price retailers, and sales DTC via its website. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Central costs include operating expenses related to corporate overhead expenses such as personnel-related costs, professional fees, interest expense related to the 2022 Credit Agreement, and the change in the fair value of derivatives. These costs are not used in evaluating the results of, or in allocating resources to, the Company&#8217;s segments.  </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the segments are the same as those described in &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_124">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-201</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-2160-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-2163" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of financial measures of the Company&#8217;s segments to the consolidated totals:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022<br/>(Successor):</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Skincare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk Makeup</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-2164">61,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-2165">31,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-2166">92,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-2167">44,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-2168">15,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-2169">60,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-2170">16,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-2171">15,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-2172">31,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the performance of its reportable segments based on segment gross profit. Segment gross profit is segment revenue less segment cost of goods sold.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="f-2173" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles segment gross profit to net income (loss) before income taxes for the period from July 28 to December&#160;31, 2022 (Successor Period):</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"><tr><td style="width:1.0%"></td><td style="width:85.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from<br/>July 28 to December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-2174">31,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-2175">88,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-2176">1,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-2177">68,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-2178">6,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="f-2179">6,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-2180">798</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-2181">126,360</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-2182">120,557</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not evaluate performance or allocate resources based on segment asset data, and therefore such information is not presented. All of the Company&#8217;s and the Predecessor&#8217;s long-lived assets are located in the U.S.</span></div></ix:continuation><div id="if2fc25067f8b45fc8cc165df93f3be1c_184"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="f-2185" continuedAt="f-2185-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">EMPLOYEE BENEFIT PLAN</span></ix:nonNumeric></div><ix:continuation id="f-2185-1"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a Section&#160;401(k)&#160;retirement plan and pension plans for employees in the U.S. and the United Kingdom. During the period from July 28 to December&#160;31, 2022 (Successor Period), the period from January 1 to July&#160;27, 2022 (Predecessor Period), and the years ended December&#160;31, 2021 and 2020 (Predecessor Periods) the Company&#8217;s contributions to the plan were $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-2186">0.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-2187">0.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-2188">0.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-2189">0.5</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="if2fc25067f8b45fc8cc165df93f3be1c_187"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-2190" continuedAt="f-2190-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">SUBSEQUENT EVENTS </span></ix:nonNumeric></div><ix:continuation id="f-2190-1" continuedAt="f-2190-2"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023,</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company granted an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-525" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-2191">2,290,000</ix:nonFraction> stock growth incentive awards</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;SGI Awards&#8221;) in performance share units to certain Waldencast employees, in an amount up to <ix:nonFraction unitRef="number" contextRef="c-525" decimals="2" name="wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent" scale="-2" id="f-2192">200</ix:nonFraction>% of the target share units allocated to the program, which are based on meeting the respective Company&#8217;s net revenue and EBITDA targets for the year ended December 31, 2025. The SGI Awards had a grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-525" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-2193">8.88</ix:nonFraction> and require a <ix:nonNumeric contextRef="c-525" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:durwordsen" id="f-2194">one-year</ix:nonNumeric> post vesting holding period once the shares have been awarded.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-202</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-2190-2" continuedAt="f-2190-3"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Incentive (&#8220;LTI&#8221;) Awards</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the LTI Awards were modified to waive the performance conditions for most Obagi and Waldencast employees, other than the Chief Executive Officer of Obagi and the Chief Executive Officer and Chief Growth Officer of Waldencast. Based on the financial statements prepared by the Company for the period ended December 31, 2022, the Board has certified that the applicable performance goals have not been met and, accordingly, that the 2022 RSUs granted to our founders will not vest.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Leases</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Obagi entered into <ix:nonFraction unitRef="lease" contextRef="c-526" decimals="INF" name="wald:NumberOfLeaseAgreements" format="ixt-sec:numwordsen" scale="0" id="f-2195">two</ix:nonFraction> leases for office and warehouse space in Texas as part of their plans to  relocate the headquarters from California. Obagi&#8217;s corporate headquarters were located in Long Beach, California until September 2022, when Obagi moved its headquarters to Houston, Texas under a lease that will expire in July 2032. In January 2024, Obagi will relocate its headquarters back to its Long Beach offices, where it occupies facilities totaling approximately <ix:nonFraction unitRef="sqft" contextRef="c-527" decimals="0" name="us-gaap:NetRentableArea" format="ixt:num-dot-decimal" scale="0" id="f-2196">28,300</ix:nonFraction> rentable square feet under a lease that expires in June 2026.  Obagi entered into a sublease for the office space in Texas once Obagi relocates to California that will run through December 2025. The Obagi warehouse facilities located in Conroe, Texas are subject to a lease that will expire in February 2031 and Obagi plans to sublease those facilities subject to finding a tenant. ROU assets as of December 31, 2022 associated with the office and warehouse were $<ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-2197">4.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-529" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-2198">2.5</ix:nonFraction> million, respectively. The Company is in the process of assessing whether or not impairment exists.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction with the SA Distributor</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, as part of the Company&#8217;s strategy to internalize distribution channels in key markets, certain of Obagi&#8217;s subsidiaries entered into and consummated a Purchase Agreement (the &#8220;Vietnam Purchase Agreement&#8221;) with Obagi Vietnam and the SA Distributor, pursuant to which, among other terms, Obagi acquired certain assets of Obagi Vietnam from the SA Distributor and in return, the SA Distributor received forty percent (<ix:nonFraction unitRef="number" contextRef="c-530" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="f-2199">40</ix:nonFraction>%) of the outstanding equity of Obagi Blue Sea Holding, LLC, a subsidiary of Obagi and the parent company of Obagi Vietnam. The Vietnam Purchase Agreement also provided the SA Distributor with a potential earnout payment based upon the net revenue of the business of Obagi Vietnam during the <ix:nonNumeric contextRef="c-531" name="wald:BusinessAcquisitionEarnoutPeriod" format="ixt-sec:durwordsen" id="f-2200">twelve-month</ix:nonNumeric> period ending on December 31, 2026, subject to setoff for any owed obligations. The Company currently does not anticipate that any such earnout payment will be payable. The SA Distributor does not currently have any active participation in the Obagi Vietnam business other than as a silent shareholder. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Credit Agreement</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_139">Note 8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; Borrower and Waldencast Partners LP and JPMorgan, entered into a waiver and consent to the 2022 Credit Agreement in May 2023, August 2023 and December 2023. The 2022 Credit Agreement was amended in September 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subscription Agreement with PIPE Investors</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Company entered into subscription agreements (the &#8220;Subscription Agreements&#8221;) with certain investors (collectively, the &#8220;2023 PIPE Investors&#8221;), pursuant to, and on the terms and subject to the conditions of which, the 2023 PIPE Investors collectively subscribed for <ix:nonFraction unitRef="shares" contextRef="c-532" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-2201">14,000,000</ix:nonFraction> Class A ordinary shares (the &#8220;PIPE Shares&#8221;), in a private placement at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-533" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-2202">5.00</ix:nonFraction> each per share, for aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-534" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-2203">70.0</ix:nonFraction>&#160;million (the &#8220;2023 PIPE Investment&#8221;). The Subscription Agreements relating to approximately $<ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-2204">68.0</ix:nonFraction>&#160;million of proceeds were consummated in September 2023, and the closings of Subscription Agreements relating to the remaining approximately $<ix:nonFraction unitRef="usd" contextRef="c-535" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-2205">2.0</ix:nonFraction>&#160;million occurred in November 2023, following receipt of regulatory approvals (the &#8220;2023 PIPE Closings&#8221; and the date on which such Closing occurred, the &#8220;PIPE Closing Date&#8221;).&#8221; <ix:nonFraction unitRef="shares" contextRef="c-536" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-2206">No</ix:nonFraction> Class B ordinary shares, warrants or other securities of the Company were issued in connection with the 2023 PIPE Investment. As a result, the Company had a total of <ix:nonFraction unitRef="shares" contextRef="c-537" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2207"><ix:nonFraction unitRef="shares" contextRef="c-537" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2208">122,076,410</ix:nonFraction></ix:nonFraction> ordinary shares issued and outstanding, including <ix:nonFraction unitRef="shares" contextRef="c-538" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2209"><ix:nonFraction unitRef="shares" contextRef="c-538" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2210">101,228,857</ix:nonFraction></ix:nonFraction> Class A ordinary shares issued and outstanding and <ix:nonFraction unitRef="shares" contextRef="c-539" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2211"><ix:nonFraction unitRef="shares" contextRef="c-539" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2212">20,847,553</ix:nonFraction></ix:nonFraction> class B ordinary shares issued and outstanding, as of December 31, 2023. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-203</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-2190-3"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SEC Investigation</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, the audit committee of the Board, engaged in a review of certain accounting practices applied to the Company&#8217;s financial statements for the Predecessor Period and Successor Period through December 31, 2022. The Company proactively and voluntarily self-reported the review to the SEC. In connection with this matter, the Company  received a document subpoena from the SEC in September 2023. Although the Company is fully cooperating with the SEC&#8217;s investigation and continues to voluntarily respond to requests related to this matter, it cannot predict when the SEC will complete its investigation or its outcome and potential impact such outcome may have on the Company&#8217;s business. Any remedial measures, sanctions, fines or penalties, including, but not limited to, financial penalties and awards, injunctive relief and compliance conditions, imposed on the Company could have a material adverse effect on its business, financial condition and results of operations.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Nasdaq Capital Market Listing</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s securities are listed on The Nasdaq Capital Market. In May 2023, the Company received written notice from Nasdaq indicating that, as a result of not having timely filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, it was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the SEC. In July 2023, the Company obtained an extension from Nasdaq permitting it to regain compliance provided it filed this Report no later than October 30, 2023. On October 31, 2023, the Company received a written notice from the Listing Qualifications Staff of Nasdaq (the &#8220;Listing Qualifications Staff&#8221;) indicating that, based upon its non-compliance with the filing requirement as of October 30, 2023, the Listing Qualifications Staff had determined to delist the Company&#8217;s securities from Nasdaq by opening of business on November 9, 2023 unless the Company timely requested a hearing before the Nasdaq Hearings Panel. On November 7, 2023, by requesting a hearing (the &#8220;Hearing&#8221;) before the Nasdaq Hearings Panel (the &#8220;Panel&#8221;), the Company appealed the determination of the Listing Qualifications Staff to the Panel and requested that the stay of delisting, which otherwise would have expired on November 22, 2023, be extended until the Panel issued a final decision on the matter. On November 22, 2023, Nasdaq granted the Company&#8217;s request to extend the stay. Accordingly, the Company&#8217;s securities will continue to trade on The Nasdaq Capital Market until the Panel issues a final decision regarding its listing status following the Hearing scheduled for February 8, 2024, or, if earlier, upon receipt of confirmation from Nasdaq that the Company has regained compliance with Nasdaq&#8217;s continued listing standards. On January 3, 2024, we received an additional notice of non-compliance from the Listing Qualifications Staff due to the Company not having filed interim financial statements for the period ended June 30, 2023 with the SEC by December 31, 2023, as required by Nasdaq Listing Rule 5250(c)(2). The notice indicated that the Panel will consider this additional notice as part of its determination regarding the Company&#8217;s continued listing on The Nasdaq Capital Market. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Online Marketplace Distributor Contract Termination</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Company entered into a termination agreement with the U.S. Online Marketplace Distributor. The termination agreement provides the U.S. Online Marketplace Distributor with a termination fee in exchange for the return of all existing inventory purchased from Obagi, deactivation of all online marketplace listings by the U.S. Online Marketplace Distributor, and full satisfaction of the remaining outstanding accounts receivable balance within defined payment terms. The termination agreement includes contractual protections designed to ensure that the Company is only providing a return credit for valuable inventory which excludes short-dated or damaged products. The termination of the U.S. Online Marketplace Distributor shall enable the Company to fully control the online marketplace distribution of Obagi products, including both product quality and customer service.</span></div></ix:continuation><div id="if2fc25067f8b45fc8cc165df93f3be1c_190"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21.</span><ix:nonNumeric contextRef="c-1" name="us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" id="f-2213" continuedAt="f-2213-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) </span></ix:nonNumeric></div><ix:continuation id="f-2213-1" continuedAt="f-2213-2"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parent company financial statements for Waldencast Plc should be read in conjunction with the Company&#8217;s Consolidated Financial Statements and the accompanying notes thereto. For purposes of this condensed financial information, the Company&#8217;s wholly owned and majority owned subsidiaries are recorded based upon its proportionate share of its subsidiaries&#8217; net assets (similar to presenting them on the equity method). Waldencast plc has no material operations of its own and conducts substantially all of its activities through its wholly owned subsidiaries. Waldencast plc has no significant assets or liabilities other than derivative warrant liabilities and cash, most expenditures paid by Waldencast plc are allocated to its subsidiaries. Waldencast Finco Limited, a wholly-owned indirect subsidiary of Waldencast plc, is the borrower under the 2022 Credit Agreement. The terms and conditions of the 2022 Credit </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-204</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-2213-2" continuedAt="f-2213-3"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_139">Note 8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for definition) limit the ability of Waldencast plc&#8217;s wholly owned subsidiaries to make certain distributions or dividends, subject to a number of enumerated exceptions. Due to the aforementioned restrictions, substantially all of the Successor period net assets of Waldencast Plc&#8217;s subsidiaries are restricted. Since the restricted net assets of consolidated subsidiaries exceed 25% of the consolidated net assets of the Company and its subsidiaries, the accompanying condensed parent company financial statements have been prepared in accordance with Rule 12-04, Schedule 1 of Regulation S-X. This information should be read in conjunction with the accompanying Consolidated Financial Statements.</span></div><ix:nonNumeric contextRef="c-1" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock" id="f-2214" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following condensed financial statements have been presented on a &#8220;parent-only&#8221; basis. Under a parent-only presentation, Waldencast plc&#8217;s investment in its subsidiaries is presented under the equity method of accounting. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC<br/>(PARENT COMPANY ONLY)<br/>CONDENSED BALANCE SHEET</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-2215">3,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-2216">3,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in subsidiary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-3" name="wald:InvestmentInSubsidiary" format="ixt:num-dot-decimal" scale="3" id="f-2217">823,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL ASSETS</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-2218">827,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CURRENT LIABILITIES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intercompany payables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-3" name="wald:IntercompanyPayables" format="ixt:num-dot-decimal" scale="3" id="f-2219">8,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-2220">18,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL LIABILITIES</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-2221">27,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHAREHOLDERS&#8217; EQUITY:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successor Class A ordinary shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-541" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-2222">0.0001</ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-541" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-2223">1,000,000,000</ix:nonFraction> shares authorized; and <ix:nonFraction unitRef="shares" contextRef="c-541" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2224">86,460,560</ix:nonFraction> outstanding as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-541" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-2225">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successor Class B ordinary shares, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-542" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-2226">0.0001</ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-542" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-2227">1,000,000,000</ix:nonFraction> shares authorized; and <ix:nonFraction unitRef="shares" contextRef="c-542" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2228">21,104,225</ix:nonFraction> outstanding as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-542" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-2229">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-2230">796,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-2231">156,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-2232">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL CONTROLLING SHAREHOLDERS&#8217; EQUITY</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2233">639,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-2234">160,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL SHAREHOLDERS&#8217; EQUITY</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-2235">799,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2236">827,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-205</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><ix:continuation id="f-2213-3"><ix:nonNumeric contextRef="c-1" name="srt:ScheduleOfCondensedIncomeStatementTableTextBlock" id="f-2237" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC<br/>(PARENT COMPANY ONLY)<br/>CONDENSED STATEMENT OF OPERATIONS </span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the period from July 28 to December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-2238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:fixed-zero" scale="3" id="f-2239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:fixed-zero" scale="3" id="f-2240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="f-2241">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-2242">6,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-2243">6,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-2244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before equity in undistributed earnings of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-2245">6,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity in undistributed earnings of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" sign="-" name="us-gaap:IncomeLossFromSubsidiariesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-2246">102,379</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2247">95,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-2248">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-2249">95,596</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="srt:ScheduleOfCondensedCashFlowStatementTableTextBlock" id="f-2250" escape="true"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC<br/>(PARENT COMPANY ONLY)<br/>CONDENSED STATEMENT OF CASH FLOW </span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-2251">95,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity in income of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" sign="-" name="us-gaap:IncomeLossFromSubsidiariesNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-2252">102,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" name="us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2253">6,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="f-2254">19</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from trust</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" name="wald:ProceedsFromTrustAccount" format="ixt:num-dot-decimal" scale="3" id="f-2255">6,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2256">6,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfers from subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" name="us-gaap:ProceedsFromContributionsFromAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-2257">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfers to subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" name="us-gaap:PaymentsOfDistributionsToAffiliates" scale="3" id="f-2258">300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses paid on behalf of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" name="wald:PaymentsOfExpensesOnBehalfOfSubsidiaries" format="ixt:num-dot-decimal" scale="3" id="f-2259">8,982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2260">3,282</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-2261">3,137</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH - Beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-2262">78</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH - end of period</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2263">3,215</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-206</span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_193"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. THE OFFER AND LISTING </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Offer and Listing Details </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nasdaq Listing of Waldencast plc Class A Ordinary Shares and Waldencast plc Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast plc Class A ordinary shares and Waldencast plc Warrants are listed on the Nasdaq Capital Market under the symbols &#8220;WALD&#8221; and &#8220;WALDW,&#8221; respectively. Holders of Waldencast plc Class A ordinary shares and Waldencast plc Warrants should obtain current market quotations for their securities. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Plan of Distribution </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Markets </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast plc Class A ordinary shares and Waldencast plc Warrants are listed on the Nasdaq Capital Market under the symbols &#8220;WALD&#8221; and &#8220;WALDW,&#8221; respectively. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Selling Shareholders </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Dilution </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.4pt">Expenses of the Issue </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_196"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10. ADDITIONAL INFORMATION </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Share Capital </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Memorandum and Articles of Association</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth in our Registration Statement on Form F-1 (File No. 333-267053), as amended, initially filed with the SEC on August 24, 2022, under the heading &#8220;Description of Share Capital&#8221; is incorporated herein by reference.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Material Contracts</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Material Contracts Relating to Waldencast Plc&#8217;s Operations </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we entered into the 2022 Credit Agreement by and among Borrower, Parent Guarantor, the Lenders and the  Administrative Agent. The 2022 Credit Agreement provides us with access to the Term Loan of $175.0 million, the Revolving Credit Facility with borrowing capacity of up to $50.0 million, of which an aggregate principal amount of up to $7.5 million may be available, at the Borrower&#8217;s option to be drawn in the form of letters credit (collectively, the &#8220;2022 Credit Facilities&#8221;). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Borrower entered into a technical amendment to the 2022 Credit Agreement to cure a technical error and clarify when the first amortization payment under the 2022 Credit Agreement is due and payable.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">207</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Borrower entered into a waiver and consent agreement with JPMorgan and the required Lenders to, among other things, waive certain defaults or events of default that had or would have resulted from the failure to deliver certain financial information and related reports. In June 2023, the Borrower entered into a subsequent waiver and consent agreement with JPMorgan and the required Lenders, pursuant to which they agreed to, among other things, (a) continue to waive certain defaults or events of default that had or would have resulted from the failure to deliver certain financial information and related reports and (b) suspend the testing of certain financial covenants in the 2022 Credit Agreement.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Borrower entered into a subsequent waiver and consent agreement with JPMorgan and the required Lenders, pursuant to which they agreed to, among other things, (i) waive any default or event of default that has or would result from the failure to deliver the financial information and related reports with respect to the fiscal year of the Borrower ended December 31, 2022 and the fiscal quarters of the Borrower ended March 31, 2023 and June 30, 2023, respectively and (ii) suspend the testing of certain financial covenants set forth in the 2022 Credit Agreement. Such waiver would remain in effect until September 15, 2023.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Borrower and Waldencast Partners LP entered into the second amendment and waiver to the 2022 Credit Agreement (the &#8220;Amendment&#8221;) with JPMorgan and the required Lenders, pursuant to which they agreed to (i) waive any default or event of default that has or would result from (a) the failure to deliver the financial information and related reports with respect to the fiscal year of the Borrower ended December 31, 2022 and the fiscal quarters of the Borrower ended March 31, 2023 and June 30, 2023, respectively, (b) any inaccuracy or misrepresentation in certain historical financial statements previously delivered to JPMorgan and (c) certain historical breaches of the financial covenants and (ii) amend the 2022 Credit Agreement to, among other things, modify the existing financial covenant tests. The Borrower is required to deliver certain of the financial information described in (i)(a) above by December 31, 2023 (the &#8220;Waiver Expiration Date&#8221;). Failure to deliver the required audited financial information and certain other deliverables on or prior to the Waiver Expiration Date will result in an event of default under the 2022 Credit Agreement (unless otherwise waived or extended). The Amendment also (i) included additional restrictions on the Borrower&#8217;s, Waldencast Partners LP's and certain of their subsidiaries&#8217; ability to incur certain types of additional indebtedness, make certain acquisitions and investments, create certain liens, dispose of certain assets and make certain types of restricted payments, (ii) established a minimum liquidity covenant of $15.0 million, which is certified on a monthly basis, and (iii) introduced additional financial reporting obligations, in each case until the earlier of September 30, 2024 or such earlier time that the Borrower elects to test the financial covenants in the same manner as prior to giving effect to the Amendment. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Borrower subsequently delivered unaudited financial information and related reports with respect to the fiscal quarters of the Borrower ended March 31, 2023 and June 30, 2023. In December 2023, the Borrower entered into a subsequent waiver and consent agreement with JPMorgan and the required Lenders, pursuant to which they agreed, among other things, to waive any default or event of default that has or would result from the failure to deliver the financial information and related reports with respect to the fiscal year of the Borrower ended December 31, 2022. Such waiver shall remain in effect until January 15, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Credit Agreement restricts our ability to make certain distributions or dividends, subject to a number of enumerated exceptions. The 2022 Credit Agreement matures on July 27, 2026, four years following the funding date. Borrowings under the Term Loan were used, among other things, to repay outstanding amounts under, and terminate, the existing credit facilities of Obagi and Milk in connection with the closing of the Business Combination. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Credit Facilities will accrue interest at a rate per annum equal to, at Borrower&#8217;s option, the Alternate Base Rate or the Adjusted Term SOFR Rate (each, as defined in the 2022 Credit Agreement) plus an applicable margin of 2.50% for Alternate Base Rate borrowings and 3.50% for Adjusted Term SOFR Rate borrowings. Borrowings under the 2022 Revolving Credit Facility may be prepaid without premium or penalty, subject to applicable notice requirements and the payment of customary &#8220;breakage&#8221; costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations under the 2022 Credit Agreement are (i) guaranteed by certain existing and future subsidiaries of Waldencast plc and (ii) secured by a first priority lien on substantially all of the assets of Waldencast LP, the Borrower and the subsidiary guarantors, in the case of each of clauses (i) and (ii) above, subject to customary exceptions and limitations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Credit Agreement contains customary representations and warranties, affirmative covenants and events of default and also contains customary negative covenants including, among other things, limitations on the ability of Waldencast LP, Borrower and certain of their subsidiaries to incur indebtedness, create liens, make investments, enter into mergers, consolidations and other similar transactions, dispose of assets, declare dividends, enter into certain transactions </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">208</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with their affiliates and enter into sale and leaseback transactions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the Waivers described above and the Second Amendment (i) provided additional restrictions on the Borrower&#8217;s, Parent Guarantor&#8217;s and certain of their subsidiaries&#8217; ability to incur certain types of additional indebtedness, make certain acquisitions and investments, create certain liens, dispose of certain assets and make certain types of restricted payments, (ii) established a minimum liquidity covenant of $15 million, which is certified on a monthly basis and (iii) introduced additional financial reporting obligations, in each case until the earlier of September 30, 2024 or such earlier time that the Borrower elects to test the financial covenants in the same manner as prior to giving effect to the Second Amendment (the period to and including such date, the &#8220;Covenant Relief Period&#8221;). Additionally, the 2022 Credit Agreement requires Parent Guarantor, the Borrower and certain of their subsidiaries to comply with specified financial covenants, including maintaining (i) a maximum Total Leverage Ratio of (a) during the Covenant Relief Period, 5.75 to 1.00 and (b) upon and after the termination of the Covenant Relief Period, 4.25 to 1.00, in each case, which steps down over time to 3.75 to 1.00 and (ii) a minimum Interest Coverage Ratio of (a) during the Covenant Relief Period, 1.75 to 1.00, which steps up over time to 2.75 to 1.00, and (b) upon and after the termination of the Covenant Relief Period, 3.00 to 1.00 (each, as defined in the 2022 Credit Agreement). The foregoing descriptions of the 2022 Credit Agreement, the First Amendment, the Second Amendment and the Waivers are qualified in its entirety by reference to the full and complete terms thereof and are attached as Exhibit 4.32 and Exhibit 4.37, respectively, to this Report and is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contracts Material to Our Obagi Skincare and Milk Makeup Businesses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to agreements that are material to our Obagi Skincare business and Milk Makeup business can be found in &#8220;Item 4. &#8220;Information on the Company&#8212;4.B. Business Overview&#8221; of this Report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Contracts with Directors, Executive Officers, Major Shareholders and Related Parties</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information relating to material agreements with our directors and executive officers, major shareholders and related parties can be found in &#8220;Item 7 Major Shareholders and Related Party Transactions&#8212;7.B. Related Party Transactions&#8221; of this Report. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Material Contracts Relating to the Business Combination </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contracts Entered Into Prior to the Business Combination</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PIPE Subscriptions</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the execution of the Transaction Agreements, we entered into Subscription Agreements, executed on or prior to November 14, 2021, pursuant to which the investors (the &#8220;Initial PIPE Investors&#8221;) agreed to purchase, in the aggregate, 10,500,000 Class&#160;A ordinary shares at $10.00 per share for an aggregate commitment amount of $105.0 million. The Transaction Agreements provided that we could enter into additional subscription agreements with investors to participate in the purchase of our shares after November 15, 2021 but prior to the Closing Date. On June 14, 2022, we entered into Subscription Agreements with additional investors on the same terms as the Initial PIPE Investors, pursuant to which such investors agreed to acquire an aggregate of 800,000 shares of Class A ordinary shares for an aggregate purchase price equal to $8.0 million. On July 15, 2022, we entered additional Subscription Agreements on the same terms as the Initial PIPE Investors, pursuant to which such investors subscribed for 500,000 Class A ordinary shares for an aggregate purchase price equal to $5.0 million (collectively, the &#8220;PIPE Investments&#8221;). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Subscription Agreements and the transactions contemplated thereby is not complete and is subject to and qualified in its entirety by reference thereto, a copy of which is filed as Exhibits 4.6 to this Report and the terms of which are incorporated by reference herein.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FPAs and Agreements with the Sponsor and its Affiliates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to material agreements with related parties entered into prior to and in contemplation of the Business Combination can be found in &#8220;Item 7 Major Shareholders and Related Party Transactions&#8212;7.B. Related Party Transactions&#8221;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transaction Agreements </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following summary describes the material provisions of the Obagi Merger Agreement and the Milk Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">but does not purport to describe all of the terms of such agreements and is qualified in its entirety by reference </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">209</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">to the complete text of the Obagi Merger Agreement and Milk Purchase Agreement, copies of which are attached as Exhibits 4.1 and 4.2, respectively, of this Report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Obagi Merger Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2022, we entered into the Obagi Merger Agreement pursuant to which Merger Sub merged with and into Obagi, with Obagi as the surviving corporation and an indirect subsidiary of Waldencast as of the Closing Date (the &#8220;Obagi Merger&#8221;). At the effective time of the Obagi Merger, all outstanding ordinary shares of Obagi common stock were canceled and exchanged for (i) 28,237,506 Class A ordinary shares of Waldencast and (ii) cash in the amount of $317.5 million. At the effective time of the Obagi Merger, all options to purchase Obagi common stock granted under the 2021 Obagi Stock Incentive Plan (&#8220;Obagi Options&#8221;) were converted into options to purchase Waldencast plc Class A ordinary shares, subject to substantially the same terms and conditions as were in effect with respect to such Obagi Option immediately prior to the Obagi Merger Effective Time. Each Obagi Option to purchase one share of Obagi common stock converted into the right to purchase 7.62 Waldencast plc Class A ordinary shares. Similarly, all restricted stock units issued in respect of Obagi common stock granted (&#8220;Obagi RSUs&#8221;) were converted into restricted stock units with respect to Waldencast plc Class A ordinary shares, subject to substantially the same terms and conditions as were in effect with respect to such Obagi RSU immediately prior to the effective time. Each Obagi RSU with respect to one share of Obagi common stock converted into an RSU with respect to 7.62 Waldencast plc Class A ordinary shares. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition to the merger, immediately prior to the closing, Obagi effected the Obagi China Distribution. For a description of that transaction as well as the agreement related thereto, see &#8220;Item 7. Major Shareholders and Related Party Transactions&#8212;7.B. Related Party Transactions&#8221; in this Report.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Obagi Merger Agreement contains certain post-closing covenants of Waldencast, pursuant to which the Company agreed:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">as soon as practicable following the date that is 60 days after the Closing Date and subject to applicable securities laws, file an effective registration statement on Form S-8 (or other applicable form) with respect to Waldencast plc&#8217;s Class A ordinary shares issuable under the 2022 Plan and use commercially reasonable efforts to maintain the effectiveness of such registration statement(s) (and maintain the current status of the prospectus or prospectuses contained therein) for so long as awards granted pursuant to the 2022 Plan remain outstanding;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for a period of twelve (12) months following the Closing Date, provide, or cause its affiliates to provide, each Obagi employee continuing employment with Waldencast or Obagi with (i) an annual base salary or hourly wage rate, as applicable, that is no less favorable than the annual base salary or hourly wage rate, as applicable, provided to such employee immediately prior to the Closing Date, (ii) target cash incentive opportunity that is no less favorable than the target cash incentive opportunity provided to such employee immediately prior to the Closing Date and (iii) health, retirement, welfare and other employee and fringe benefits that are no less favorable, in the aggregate, than those provided to such employee immediately prior to the Closing Date;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for the purposes of determining eligibility, vesting, participation and benefits accrual under Waldencast and its affiliate&#8217;s&#8217; plans and programs providing employee benefits, credit each Obagi employee continuing employment with Waldencast or Obagi with his or her years of service with Obagi prior to the Closing Date to the same extent as such employee was (or would have been) entitled prior to the Closing Date;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cause (i) each Obagi employee continuing employment with Waldencast plc or Obagi to be immediately eligible to participate in any and all Waldencast benefit plans; (ii) all pre-existing condition exclusions and actively-at-work requirements of such Waldencast benefit plan to be waived for such employee and his or her covered dependents; and (iii) any co-payments, deductibles and other eligible expenses incurred by such employee to be credited for purposes of satisfying all deductible, coinsurance and maximum out-of-pocket requirements applicable to such employee and his or her covered dependents for the applicable plan year of each comparable Waldencast benefit plan;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">indemnify and hold harmless each present and former director and officer of Obagi and Waldencast and each of their respective subsidiaries against any costs, expenses, judgments, fines, losses, claims, damages or liabilities incurred in connection with any legal proceeding arising out of or pertaining to matters existing or occurring at or prior to the Closing Date to the fullest extent that would have been permitted under applicable law and the applicable governing documents to indemnify such person;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain for a period of not less than six years from the Closing Date provisions in its governing documents and those of its subsidiaries concerning the indemnification and exoneration (including provisions relating to expense advancement) of its and its subsidiaries&#8217; former and current officers, directors and employees, no less favorable to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">210</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">those persons than the provisions of the governing documents of Obagi, Waldencast or their respective subsidiaries, as applicable, in each case, as of the date of the Obagi Merger Agreement and (ii) not amend, repeal or otherwise modify such provisions in any respect that would adversely affect the rights of those persons thereunder; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for a period of six years from the Closing Date, maintain in effect directors&#8217; and officers&#8217; liability, employment practices liability and fiduciary liability insurance covering those persons who are currently covered by Waldencast&#8217;s, Obagi&#8217;s or their respective subsidiaries&#8217; directors&#8217; and officers&#8217; liability, employment practices liability and fiduciary liability insurance policies on terms not less favorable to the insureds than the terms of such current insurance coverage.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Milk Purchase Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2022, we also entered into the Milk Purchase Agreement pursuant to which the Waldencast Purchasers acquired from the Milk Members all of their equity in Milk in exchange for (i) 21,104,225 Waldencast LP Units (ii) 21,104,225 Class B ordinary shares, which are non-economic voting shares of Waldencast and (iii) cash in the amount of $112.5 million (the &#8220;Milk Transaction&#8221;). Each Waldencast LP Unit and Class B ordinary share held by a Milk Member is redeemable at the option of the holder, and, if such option is exercised, exchangeable at the option of Waldencast into one Waldencast Class A ordinary share or cash, in accordance with the terms of the Amended and Restated Waldencast Partners LP Agreement. Upon consummation of the Business Combination Waldencast became organized in an &#8220;Up-C&#8221; structure, whereby the equity interests of Obagi and Milk are held by Waldencast LP, which is an indirect subsidiary of Waldencast plc. We, in turn, hold our interests in Obagi and Milk through Waldencast LP and Holdco 1.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Milk Purchase Effective Time (the &#8220;Milk Closing&#8221;), all options to purchase Milk common stock (&#8220;Milk Options&#8221;) were converted into options to purchase Waldencast plc Class A ordinary shares, subject to substantially the same terms and conditions as were in effect with respect to such Milk Option immediately prior to the Milk Transaction effective time. Each Milk Option to purchase one Milk common unit converted into an option to purchase 1.47 Waldencast plc Class A ordinary shares. Similarly, all unit appreciation rights issued in respect of Milk common stock (&#8220;Milk UARs&#8221;) were converted into SARs with respect to Waldencast plc Class A ordinary shares, subject to substantially the same terms and conditions as are in effect with respect to such Milk UAR immediately prior to the effective time. Each Milk UAR with respect to one Milk common unit converted into a SAR with respect to 1.47 Waldencast plc Class A ordinary shares.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Milk Purchase Agreement contains certain post-closing covenants of Waldencast, pursuant to which the Company agreed:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">as soon as practicable following the date that is 60 days after the Closing Date and subject to applicable securities laws, file an effective registration statement on Form S-8 (or other applicable form) with respect to Waldencast plc&#8217;s Class A ordinary shares issuable under the Waldencast plc 2022 Plan and use commercially reasonable efforts to maintain the effectiveness of such registration statement(s) (and maintain the current status of the prospectus or prospectuses contained therein) for so long as awards granted pursuant to the 2022 Plan remain outstanding;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for a period of twelve (12) months following the Closing Date, provide, or cause its affiliates to provide, each Milk employee continuing employment with Waldencast or Milk with (i) an annual base salary or hourly wage rate, as applicable, that is no less favorable than the annual base salary or hourly wage rate, as applicable, provided to such employee immediately prior to the Closing Date, (ii) target cash incentive opportunity that is no less favorable than the target cash incentive opportunity provided to such employee immediately prior to the Closing Date and (iii) health, retirement, welfare and other employee and fringe benefits that are no less favorable, in the aggregate, than those provided to such employee immediately prior to the Closing Date;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for the purposes of determining eligibility, vesting, participation and benefit accrual under Waldencast and its affiliate&#8217;s&#8217; plans and programs providing employee benefits, credit each Milk employee continuing employment with Waldencast or Milk with his or her years of service with Milk prior to the Closing Date to the same extent as such employee was (or would have been) entitled prior to the Closing Date;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cause (i) each Milk employee continuing employment with Waldencast plc or Milk to be immediately eligible to participate in any and all Waldencast benefit plans; (ii) all pre-existing condition exclusions and actively-at-work requirements of such Waldencast benefit plan to be waived for such employee and his or her covered dependents; and (iii) any co-payments, deductibles and other eligible expenses incurred by such employee to be credited for purposes of satisfying all deductible, coinsurance and maximum out-of-pocket requirements applicable to such </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">211</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employee and his or her covered dependents for the applicable plan year of each comparable Waldencast benefit plan;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">indemnify and hold harmless each present and former director and officer of Milk and Waldencast and each of their respective subsidiaries against any costs, expenses, judgments, fines, losses, claims, damages or liabilities incurred in connection with any legal proceeding arising out of or pertaining to matters existing or occurring at or prior to the Closing Date to the fullest extent that would have been permitted under applicable law and the applicable governing documents to indemnify such person;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain for a period of not less than six years from the Closing Date provisions in its governing documents and those of its subsidiaries concerning the indemnification and exoneration (including provisions relating to expense advancement) of its and its subsidiaries&#8217; former and current officers, directors and employees, no less favorable to those persons than the provisions of the governing documents of Milk, Waldencast or their respective subsidiaries, as applicable, in each case, as of the date of the Milk Purchase Agreement and (ii) not amend, repeal or otherwise modify such provisions in any respect that would adversely affect the rights of those persons thereunder; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for a period of six years from the Closing Date, maintain in effect directors&#8217; and officers&#8217; liability, employment practices liability and fiduciary liability insurance covering those persons who are currently covered by Waldencast&#8217;s, Milk&#8217;s or their respective subsidiaries&#8217; directors&#8217; and officers&#8217; liability, employment practices liability and fiduciary liability insurance policies on terms not less favorable to the insureds than the terms of such current insurance coverage.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Related Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lock-Up Agreements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Transaction Agreements, on the Closing Date, certain of the Obagi shareholders entered and certain of the Milk Members entered into Lock-Up Agreements, pursuant to which they agreed not to transfer, assign or sell during the respective Lock-Up Period (as defined in the Letter Agreement), (I)&#160;in the case of any of our Class&#160;A ordinary shares and the Waldencast LP Units, as applicable, received as consideration in connection with the Business Combination, until the earlier of (A) one year after the Closing Date and (B) (x)&#160;if the last reported sale price of our Class&#160;A ordinary shares equals or exceeds $12.00&#160;per share (as adjusted for share sub-divisions, share dividends, rights issuances, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the Closing Date or (y) the date on which we complete a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of our shareholders having the right to exchange their Class&#160;A ordinary shares for cash, securities or other property; and (II) in the event that a certain portion of the Obagi Cash Consideration (as defined in the Obagi Merger Agreement) or the Milk Cash Consideration (as defined in the Milk Purchase Agreement) is paid in our equity of Waldencast as a result of the occurrence of certain events set forth in the Obagi Merger Agreement and the Milk Purchase Agreement, as applicable, such equity of Waldencast received by Obagi or Milk, for the same period as set forth in clause (I) above, provided that solely for the purpose of this clause (II), the term &#8220;one-year&#8221; in clause&#160;(I)(A) shall be replaced with the term &#8220;six months.&#8221; The foregoing description of the Lock-Up Agreements and the transactions contemplated thereby is not complete and is subject to and qualified in its entirety by reference thereto, a copy of the form which is filed as Exhibits 4.7 to this Report and the terms of which are incorporated by reference herein. Each Lock-Up Period expired on January 27, 2023 and July 27, 2023, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amended and Restated Exempted Limited Partnership Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of immediately before the consummation of the Milk Transaction, the initial exempted limited partnership agreement of Waldencast LP was amended and restated in its entirety to provide that each Waldencast LP Unit will have identical economic rights and Holdco 1 was admitted as the general partner of Waldencast LP. The Waldencast LP Units have no voting rights. The Amended and Restated Waldencast Partners LP Agreement prohibits transfers of Waldencast LP Units held by the Milk Members and will require the prior consent of Holdco 1 for such transfers, subject to certain exceptions set forth in the Amended and Restated Waldencast Partners LP Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the expiration of any applicable Lock-Up Period, each holder of the Waldencast LP Unit (other than Holdco 1) shall be entitled at any time, to cause Waldencast LP to redeem (each, a &#8220;Unit Redemption&#8221;), all or a portion of its Waldencast LP Units, in which case, we may at our option, acquire such Waldencast LP Units in exchange for cash or new Waldencast plc Class A ordinary shares on a one-for-one basis. In connection with any Unit Redemption, a number of Waldencast plc Class B ordinary shares equal to the number of redeemed Waldencast LP Units will be surrendered and canceled. Once the Milk Members have caused Unit Redemptions to have occurred that cause the aggregate Waldencast LP </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">212</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Units held by the Milk Members to be equal to or less than 20% of the total Waldencast LP Units held by the Milk Members as of the Closing Date of the Milk Transaction, Waldencast LP will have the right to acquire all or a portion of the remaining Waldencast LP Units that remain outstanding in exchange for cash or Waldencast plc Class A ordinary shares on a one-for-one basis, at Waldencast LP&#8217;s sole discretion, subject to certain limitations set forth in the Amended and Restated Waldencast Partners LP Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Amended and Restated Waldencast Partners LP Agreement, Waldencast LP is obligated to make pro rata tax distributions to holders of Waldencast LP Units at certain assumed tax rates unless such distribution would not be permitted under applicable law.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sponsor Support Agreements </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Obagi Merger Agreement and Milk Purchase Agreement, Waldencast entered into a (i) Sponsor Support Agreement dated November 15, 2021 with the Sponsor, Obagi, and the Investor Directors and (ii) Sponsor Support Agreement dated November 15, 2021 with the Sponsor, the representative of the Milk Members and the Investor Directors (together the &#8220;Sponsor Support Agreements&#8221;). Pursuant to the Sponsor Support Agreements, the Sponsor and the Investor Directors agreed to, among other things, vote in favor of the Obagi Merger Agreement and the Milk Purchase Agreement and transactions contemplated thereby, in each case, subject to the terms and conditions contemplated by the Sponsor Support Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sponsor and the Investor Directors also agreed not to (a) sell or otherwise dispose of, or agree to sell or dispose of, directly or indirectly, any Waldencast Class A ordinary shares or any Waldencast warrants held by the Sponsor and the Investor Directors immediately after the Closing Date, (b) deposit any Waldencast Class A ordinary shares into a voting trust or enter into a voting agreement that is inconsistent with the Obagi Sponsor Support Agreement, (c) enter into any swap, engage in hedging or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any of such Waldencast Class A ordinary shares or Waldencast warrants or (d) publicly announce any intention to effect any transaction specified in clause (a)&#8211;(c). </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sponsor Support Agreements terminated upon closing of the Business Combination. The foregoing description of the Sponsor Supports Agreements and the transactions contemplated thereby is not complete and is subject to and qualified in its entirety by reference thereto, copies of which is filed as Exhibits 4.3 and 4.4 to this Report and the terms of which are incorporated by reference herein.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholder Support Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Obagi Merger Agreement, Waldencast entered into a Support Agreement dated November 15, 2021 with Obagi and Cedarwalk (the &#8220;Stockholder Support Agreement&#8221;). Pursuant to the Stockholder Support Agreement, Cedarwalk agreed to, among other things, vote to adopt and approve, upon the effectiveness of the Registration Statement being declared effective and delivered or otherwise made available to stockholders, the Obagi Merger Agreement and the transactions contemplated thereby, in each case, subject to the terms and conditions of the Stockholder Support Agreement. Cedarwalk also agreed not to (a) sell or otherwise dispose of, or agree to sell or dispose of, directly or indirectly, any shares of Obagi common stock held by Cedarwalk immediately after the consummation of the Obagi Merger (b) enter into any swap or other arrangements that transfers to another, in whole or in part, any of the economic consequences of ownership of any of such Obagi common stock, or (c) publicly announce any intention to effect any transaction specified in clause (a) or (b). The Stockholder Support Agreement terminated upon closing of the Business Combination. The foregoing description of the Stockholder Support Agreement and the transactions contemplated thereby is not complete and is subject to and qualified in its entirety by reference thereto, a copy of which is filed as Exhibit 4.5 this Report and the terms of which are incorporated by reference herein.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Exchange Controls</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no governmental laws, decrees, regulations or other legislation in Jersey that may affect the import or export of capital, including the availability of cash and cash equivalents for use by the Company, or that may affect the remittance of dividends, interest, or other payments by the Company to non-resident holders of its ordinary shares. There is no limitation imposed by the laws of Jersey or in the Company&#8217;s articles of association on the right of non-residents to hold or vote shares.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">213</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Taxation </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Federal Income Tax Considerations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a discussion of U.S. federal income tax considerations generally applicable to the ownership and disposition of Class A ordinary shares by U.S. Holders. This discussion addresses only those holders of Class A ordinary shares that hold their ordinary shares as capital assets (generally, property held for investment) and assumes that any distributions made (or deemed made) by us and any consideration received (or deemed received) by a holder in consideration for the sale or other disposition of Class A ordinary shares will be in U.S. dollars. This discussion does not discuss all aspects of U.S. federal income taxation that may be relevant to holders in light of their particular circumstances or status including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Sponsor or Waldencast&#8217;s officers or directors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">financial institutions or financial services entities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">broker-dealers;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">taxpayers that are subject to the mark-to-market accounting rules;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tax-exempt entities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governments or agencies or instrumentalities thereof;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">insurance companies;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulated investment companies or real estate investment trusts;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expatriates or former long-term residents of the U.S.;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons that actually or constructively own five percent or more of our voting shares or five percent or more of the total value of any class of our shares;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons that acquired our ordinary shares pursuant to an exercise of employee share options, in connection with employee share incentive plans or otherwise as compensation or in connection with the performance of services;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons that hold our ordinary shares as part of a straddle, constructive sale, hedging, conversion or other integrated or similar transaction; or</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persons whose functional currency is not the U.S. dollar.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion is based on the Code, proposed, temporary and final Treasury Regulations promulgated under the Code, and judicial and administrative interpretations thereof, all as of the date hereof. All of the foregoing is subject to change, which change could apply retroactively and could affect the tax considerations described herein. This discussion does not address U.S. federal taxes other than those pertaining to U.S. federal income taxation (such as estate or gift taxes, the alternative minimum tax or the Medicare tax on investment income), nor does it address any aspects of U.S. state or local or non-U.S. taxation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not and do not intend to seek any rulings from the IRS regarding any of the U.S. federal income tax considerations described herein. There can be no assurance that the IRS will not take positions inconsistent with the considerations discussed below or that any such positions would not be sustained by a court.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion does not consider the tax treatment of partnerships or other pass-through entities or persons who hold our ordinary shares through such entities. If a partnership (or any entity or arrangement so characterized for U.S. federal income tax purposes) holds our ordinary shares, the tax treatment of such partnership and a person treated as a partner of such partnership will generally depend on the status of the partner and the activities of the partnership. Partnerships holding any of our ordinary shares and persons that are treated as partners of such partnerships should consult their tax advisors as to the particular U.S. federal income tax consequences of the ownership and disposition of Class A ordinary shares. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EACH HOLDER SHOULD CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES OF THE OWNERSHIP AND DISPOSITION OF CLASS A ORDINARY SHARES, INCLUDING THE EFFECTS OF U.S. FEDERAL, STATE AND LOCAL AND NON-U.S. TAX LAWS.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used herein, a &#8220;U.S. Holder&#8221; is a beneficial owner of Class A ordinary shares who or that is, for U.S. federal income tax purposes:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">an individual citizen or resident of the U.S.,</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">a corporation (or other entity that is treated as a corporation for U.S. federal income tax purposes) that is created or organized (or treated as created or organized) in or under the laws of the U.S. or any state thereof or the District of Columbia,</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">an estate whose income is subject to U.S. federal income tax regardless of its source, or</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">a trust if (i) a U.S. court can exercise primary supervision over the administration of such trust and one or more U.S. persons have the authority to control all substantial decisions of the trust or (ii) it has a valid election in place to be treated as a U.S. person.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Residence of Waldencast Plc for U.S. Federal Income Tax Purposes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A corporation is generally considered for U.S. federal income tax purposes to be a tax resident in the jurisdiction of its organization or incorporation. Section 7874 of the Code provides an exception to this general rule, under which a non-U.S. incorporated entity may, in certain circumstances, be treated as a U.S. corporation for U.S. federal income tax purposes. These rules are complex and there is limited guidance regarding their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the rules currently in effect, we do not expect to be treated as a U.S. corporation for U.S. federal income tax purposes by virtue of Section 7874 of the Code as a result of the Business Combination. Nevertheless, because the rules and exceptions under Section 7874 of the Code are complex, subject to factual and legal uncertainties, and may change in the future (possibly with retroactive effect), there can be no assurance that we will not be treated as a U.S. corporation for U.S. federal income tax purposes. In addition, it is possible that a future acquisition of the stock or assets of a U.S. corporation could result in our being treated as a U.S. corporation at the time of the Business Combination.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to be treated as a U.S. corporation for U.S. federal income tax purposes, it could be subject to liability for additional U.S. income taxes, and the gross amount of any dividend payments to its non-U.S. shareholders could be subject to 30% U.S. withholding tax, depending on the application of any income tax treaty that might apply to reduce the withholding tax. If Holdco 1 were to be disregarded, or we were otherwise to be treated as a direct partner in Waldencast LP, dividend payments by us could be treated as wholly or partially U.S.-source for foreign tax credit and other U.S. federal income tax purposes even if we are treated as a non-U.S. corporation under Section 7874 of the Code.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remainder of this discussion assumes that Waldencast plc will not be treated as a U.S. corporation for U.S. federal income tax purposes under Section 7874 of the Code.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Federal Income Tax Considerations of Owning Class A Ordinary Shares</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Taxation of Dividends and Other Distributions on Class A Ordinary Shares</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the passive foreign investment company (&#8220;PFIC&#8221;) rules discussed below, any distribution of cash or other property to a U.S. Holder of Class A ordinary shares, will generally be treated as a dividend for U.S. federal income tax purposes to the extent the distribution is paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Such dividends will be taxable to a corporate U.S. Holder at regular rates and will not be eligible for the dividends-received deduction generally allowed to domestic corporations in respect of dividends received from other domestic corporations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributions in excess of such earnings and profits will generally be applied against and reduce the U.S. Holder&#8217;s basis in its Class A ordinary shares (but not below zero) and, to the extent in excess of such basis, will be treated as gain from the sale or exchange of such Class A ordinary shares. We may not determine our earnings and profits on the basis of U.S. federal income tax principles, however, in which case any distribution paid by us will be treated as a dividend.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to non-corporate U.S. Holders, dividends will generally be taxed at preferential long-term capital gains rates only if (i) Class A ordinary shares are readily tradable on an established securities market in the U.S. or (ii) we are eligible for the benefits of an applicable income tax treaty, in each case provided that we are is not treated as a PFIC in the taxable year in which the dividend was paid or in any previous year and certain holding period or other requirements are met. If our Class A ordinary shares are delisted from The Nasdaq Capital Market and are not otherwise readily tradable on an established securities market in the U.S., and provided that we remain ineligible for the benefits of an applicable tax treaty with the U.S., dividends received on our Class A ordinary shares would generally not be eligible to be taxed at preferential rates. U.S. Holders should consult their tax advisors regarding the availability of the lower rate for any dividends paid with respect to Class A ordinary shares. See &#8220;Item 8. Financial Information&#8212;Note 21. Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;The Nasdaq Capital Market Listing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">215</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxation on the Disposition of Class A Ordinary Shares</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the PFIC rules discussed below, upon a sale or other taxable disposition of Class A ordinary shares, a U.S. Holder will generally recognize capital gain or loss. The amount of gain or loss recognized will generally be equal to the difference between (i) the sum of the amount of cash and the fair market value of any property received in such disposition and (ii) the U.S. Holder&#8217;s adjusted tax basis in such ordinary shares.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under tax law currently in effect, long-term capital gains recognized by non-corporate U.S. Holders are generally subject to U.S. federal income tax at a reduced rate of tax. Capital gain or loss will constitute long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the ordinary shares exceeds one year. However, it is unclear whether the redemption rights with respect to the Class A ordinary shares may have prevented the holding period of the Class A ordinary shares from commencing prior to the termination of such rights in connection with the Business Combination. The deductibility of capital losses is subject to various limitations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PFIC Considerations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Definition of a PFIC</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A foreign (i.e., non-U.S.) corporation will be a PFIC for U.S. federal income tax purposes if at least 75% of its gross income in a taxable year of the foreign corporation, including its pro rata share of the gross income of any corporation in which it is considered to own at least 25% of the shares by value, is passive income. Alternatively, a foreign corporation will be a PFIC if at least 50% of its assets in a taxable year of the foreign corporation, ordinarily determined based on fair market value and averaged quarterly over the year, including its pro rata share of the assets of any corporation in which it is considered to own at least 25% of the shares by value, are held for the production of, or produce, passive income. Passive income generally includes dividends, interest, rents and royalties (other than certain rents or royalties derived from the active conduct of a trade or business) and gains from the disposition of passive assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to a start-up exception, a corporation will not be a PFIC for the first taxable year the corporation has gross income, if (1) no predecessor of the foreign corporation was a PFIC; (2) the corporation satisfies the IRS that it will not be a PFIC for either of the first two taxable years following the start-up year; and (3) the corporation is not in fact a PFIC for either of those years.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">PFIC Status of Waldencast and Waldencast Plc</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a foreign corporation&#8217;s PFIC determination will be made annually, absent certain elections described below, a determination that Waldencast Acquisition Corp., our predecessor (&#8220;WAC&#8221;) was or Waldencast plc is a PFIC will continue to apply to subsequent years in which a U.S. Holder continues to hold shares in such entity (including a successor entity), whether or not such entity is a PFIC in those subsequent years. Because, following the Domestication, Waldencast is treated as the successor to WAC for U.S. federal income tax purposes, any Class A ordinary shares treated as received in exchange for WAC Class A ordinary shares in the Domestication may, in the absence of certain elections described below, be treated as stock of a PFIC if WAC or Waldencast was treated as a PFIC during the holding period of a U.S. Holder.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the timing of the Business Combination, the anticipated assets and income of the combined company and the application of the start-up exception, we do not expect WAC to be treated as a PFIC for the taxable year ending on December 31, 2021 (the &#8220;Start-Up Year&#8221;), nor do we expect Waldencast to be treated as a PFIC for the taxable year ending on December 31, 2022, or the foreseeable future. However, as further discussed below, the facts on which any determination of PFIC status are based may not be known until the close of each taxable year in question, and, in the case of the Start-Up Year, until as late as the close of our taxable years ended on December 31, 2023. Additionally, there is uncertainty regarding the application of the start-up exception.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although WAC likely met the PFIC income or asset tests for the Start-Up Year, the start-up exception is expected to apply to prevent such entity from being treated as a PFIC for the Start-Up Year provided that the combined company does not meet either test in the two subsequent taxable years. Based on the timing of the Business Combination and the assets and income of the combined company, we do not believe we met either test for our taxable year ended December 31, 2022, and do not expect to meet either test in the foreseeable future. However, because PFIC status is an annual factual determination, we may become a PFIC in future if the composition of our income or assets, or the market price of our Class A ordinary shares, were to change. Accordingly, there can be no assurance with respect to the PFIC status of WAC for the Start-Up Year or Waldencast for any future taxable year.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">216</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Application of PFIC Rules to Ordinary Shares</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If (i) WAC or Waldencast is determined to be a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S. Holder and (ii) the U.S. Holder did not make a timely and effective QEF Election (as defined below) for the first year in its holding period in which WAC or Waldencast (as the case may be)(was or) is a PFIC (such taxable year as it relates to each U.S. Holder, the &#8220;First PFIC Holding Year&#8221;), a QEF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Election along with a purging election, or a &#8220;mark-to-market&#8221; election, each as described below under &#8220;QEF Election, Mark-to-Market Election and Purging Election,&#8221; then such holder will generally be subject to special rules (the &#8220;Default PFIC Regime&#8221;) with respect to:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any gain recognized by the U.S. Holder on the sale or other disposition of its ordinary shares; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any &#8220;excess distribution&#8221; made to the U.S. Holder (generally, any distributions to such U.S. Holder during a taxable year of the U.S. Holder that are greater than 125% of the average annual distributions received by such U.S. Holder in respect of its ordinary shares during the three preceding taxable years of such U.S. Holder or, if shorter, such U.S. Holder&#8217;s holding period for such ordinary shares).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Default PFIC Regime:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Holder&#8217;s gain or excess distribution will be allocated ratably over the U.S. Holder&#8217;s holding period for its ordinary shares (taking into account the relevant holding period of the WAC Class A ordinary share treated as exchanged therefor);</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of gain allocated to the U.S. Holder&#8217;s taxable year in which the U.S. Holder recognized the gain or received the excess distribution, or to the period in the U.S. Holder&#8217;s holding period before the first day of the first taxable year in which WAC was or Waldencast is a PFIC, will be taxed as ordinary income;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of gain allocated to other taxable years (or portions thereof) of the U.S. Holder and included in such U.S. Holder&#8217;s holding period will be taxed at the highest tax rate in effect for that year and applicable to the U.S. Holder; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an additional tax equal to the interest charge generally applicable to underpayments of tax will be imposed on the U.S. Holder in respect of the tax attributable to each such other taxable year of such U.S. Holder.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that owns (or is deemed to own) shares in a PFIC during any taxable year of the U.S. Holder may be required to file an IRS Form 8621 (whether or not the U.S. Holder makes one or more of the elections described below with respect to such shares) with such U.S. Holder&#8217;s U.S. federal income tax return and provide such other information as may be required by the U.S. Treasury Department.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">QEF Election, Mark-to-Market Election and Purging Election</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, if WAC or Waldencast is determined to be a PFIC, a U.S. Holder may avoid the Default PFIC Regime with respect to its ordinary shares by making a timely and effective &#8220;qualified electing fund&#8221; (&#8220;QEF&#8221;) election under Section 1295 of the Code (a &#8220;QEF Election&#8221;) for such holder&#8217;s First PFIC Holding Year. In order to comply with the requirements of a QEF Election with respect to Class A ordinary shares, a U.S. Holder must receive a PFIC Annual Information Statement from us. If we determine we are a PFIC for any taxable year, we may endeavor to provide to a U.S. Holder such information as the IRS may require, including a PFIC Annual Information Statement, in order to enable the U.S. Holder to make and maintain a QEF Election. However, there is no assurance that we will so endeavor, or that we will have timely knowledge of our status as a PFIC in the future or of the required information to be provided. U.S. Holders are urged to consult their tax advisors with respect to any QEF Election previously made with respect to Waldencast shares.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alternatively, if a U.S. Holder, at the close of its taxable year, owns (or is deemed to own) shares in a PFIC that are treated as marketable shares, the U.S. Holder may make a mark-to-market election with respect to such shares for such taxable year. If the U.S. Holder makes a valid mark-to-market election for such holder&#8217;s First PFIC Holding Year, such holder will generally not be subject to the Default PFIC Regime in respect of its ordinary shares as long as such shares continue to be treated as marketable shares. Instead, the U.S. Holder will generally include as ordinary income for each year in its holding period that Waldencast or WAC is treated as a PFIC the excess, if any, of the fair market value of its ordinary shares at the end of its taxable year over the adjusted basis in its ordinary shares. The U.S. Holder also will be allowed to take an ordinary loss in respect of the excess, if any, of the adjusted basis of its Class A ordinary shares over the fair market value of its ordinary shares at the end of its</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taxable year (but only to the extent of the net amount of previously included income as a result of the mark-to-market election). The U.S. Holder&#8217;s basis in its ordinary shares will be adjusted to reflect any such income or loss amounts, and any further gain recognized on a sale or other taxable disposition of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">217</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ordinary shares in a taxable year in which WAC was or Waldencast is treated as a PFIC will be treated as ordinary income. Special tax rules may also apply if a U.S. Holder makes a mark-to-market election for a taxable year after such holder&#8217;s First PFIC Holding Year.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The mark-to-market election is available only for &#8220;marketable stock,&#8221; which generally includes stock that is regularly traded on a national securities exchange that is registered with the Securities and Exchange Commission, including The Nasdaq Capital Market. If our Class A ordinary shares are delisted from The Nasdaq Capital Market (and are not otherwise regularly traded on another national securities exchange that is registered with the SEC), our Class A ordinary shares would generally not be treated as &#8220;marketable stock&#8221; for such purposes, and a U.S. Holder would not be eligible to make a mark-to-market election with respect to our Class A ordinary shares. Any mark-to-market election that is otherwise in effect with respect to our Class A ordinary shares at the time that they are delisted will generally terminate automatically, effective as of the beginning of the U.S. Holder&#8217;s taxable year in which the delisting occurs. U.S. Holders should consult their own tax advisors regarding the availability and tax consequences of a mark-to-market election in respect of WAC Class A ordinary shares or the Class A ordinary shares under their particular circumstances, as well as regarding any mark-to-market elections previously made with respect to WAC Class A ordinary shares or our Class A ordinary shares. See &#8220;Item 8. Financial Information&#8212;Note 21. Subsequent Events&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Nasdaq Capital Market Listing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class A ordinary shares treated as stock of a PFIC under the Default PFIC Regime (including Class A ordinary shares treated as received in exchange for WAC Class A ordinary shares that were so treated at the time of the Domestication) will continue to be treated as stock of a PFIC, including in taxable years in which we cease to be a PFIC, unless the applicable U.S. Holder makes a &#8220;purging election&#8221; with respect to such shares. Under one type of purging election, the U.S. Holder will be deemed to have sold such shares at their fair market value on the last day of the last year in which WAC or Waldencast, as applicable, is treated as a PFIC, and any gain recognized on such deemed sale will be treated as an excess distribution, as described above. As a result of this election, the U.S. Holder will have additional basis (to the extent of any gain recognized in the deemed sale) and, solely for purposes of the PFIC rules, a new holding period in such holder&#8217;s Class A ordinary shares. U.S. Holders should consult their tax advisors regarding the application of the purging elections rules to their particular circumstances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are a PFIC and, at any time, have foreign subsidiary that is a PFIC, U.S. Holders would be deemed to own a portion of the shares of such lower-tier PFIC, and could incur liability for the deferred tax and interest charge described above if we receive a distribution from, or disposes of all or part of our interest in, the lower-tier PFIC or the U.S. Holders otherwise were deemed to have disposed of an interest in the lower-tier PFIC. A mark-to-market election would not be available with respect to such lower-tier PFIC. U.S. Holders should consult their own tax advisors regarding the tax issues raised by lower-tier PFICs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with PFICs and with the QEF and mark-to-market elections are very complex and are affected by various factors in addition to those described above. Accordingly, U.S. Holders of Class A ordinary shares should consult their own tax advisors concerning the application of the PFIC rules to Class A ordinary shares under their particular circumstances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE RULES DEALING WITH PFICS ARE COMPLEX AND ARE IMPACTED BY VARIOUS FACTORS IN ADDITION TO THOSE DESCRIBED ABOVE. U.S. HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS REGARDING THE CONSEQUENCES TO THEM OF THE PFIC RULES, INCLUDING, WITHOUT LIMITATION, WHETHER A QEF ELECTION, A MARK-TO-MARKET ELECTION OR ANY OTHER ELECTION IS AVAILABLE AND THE CONSEQUENCES TO THEM OF ANY SUCH ELECTION, AND THE IMPACT OF ANY PROPOSED OR FINAL PFIC TREASURY REGULATIONS.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jersey Tax Considerations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary of Jersey taxation issues can only provide a general overview of this area and it is not a description of all the tax considerations that may be relevant to a decision to invest in our Class A ordinary shares. The following summary of the anticipated treatment of Waldencast plc and holders of Class A ordinary shares (other than residents of Jersey) is based on Jersey taxation law and practice as it is understood to apply at the date of this document and may be subject to any changes in Jersey law occurring after such date. It does not constitute legal or tax advice and does not address all aspects of Jersey tax law and practice (including such tax law and practice as it applies to any land or building situate in Jersey). Legal advice should be taken with regard to individual circumstances. Prospective investors in our Class A ordinary shares should consult their professional advisers on the implications of acquiring, buying, selling or otherwise disposing of Waldencast plc common stock under the laws of any jurisdiction in which they may be liable to taxation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">218</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders should note that tax law and interpretation can change and that, in particular, the levels and basis of, and reliefs from, taxation may change and may alter the benefits of investment in our Class A ordinary shares.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any person who is in any doubt about their tax position or who is subject to taxation in a jurisdiction other than Jersey should consult their own professional adviser.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company Residence</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Income Tax (Jersey) Law 1961 (as amended) (&#8220;Tax Law&#8221;), a company shall be regarded as resident in Jersey if it is incorporated under the Jersey Companies Law unless:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">its business is centrally managed and controlled outside Jersey in a country or territory where the highest rate at which any company may be charged to tax on any part of its income is 10% or higher; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the company is resident for tax purposes in that country or territory.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are resident for tax purposes in Jersey and subject to tax in Jersey.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under current Jersey law, there are no capital gains, capital transfer, gift, wealth or inheritance taxes, or any death or estate duties. No capital or stamp duty is levied in Jersey on the issue, conversion, redemption, or transfer of ordinary shares. On the death of an individual holder of ordinary shares (whether or not such individual was domiciled in Jersey), duty at rates of up to 0.75% of the value of the relevant ordinary shares may be payable on the registration of any Jersey probate or letters of administration which may be required in order to transfer, convert, redeem, or make payments in respect of, ordinary shares held by a deceased individual sole shareholder, subject to a cap of &#163;100,000.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The general rate of income tax under the Tax Law on the profits of companies regarded as resident in Jersey or having a permanent establishment in Jersey is 0% (&#8220;zero tax rating&#8221;), though certain exceptions from zero tax rating might apply.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Withholding Tax </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For so long as we are subject to a zero tax rating, or are deemed to be resident for tax purposes in Jersey, no withholding in respect of Jersey taxation will be required on payments in respect of our Class A ordinary shares to any holder of our Class A ordinary shares not resident in Jersey.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stamp Duty</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Jersey, no stamp duty is levied on the issue or transfer of our Class A ordinary shares except that stamp duty is payable on Jersey grants of probate and letters of administration, which will generally be required to transfer ordinary shares on the death of a holder of such ordinary shares if such holder was entered as the holder of the shares on the register maintained in Jersey. In the case of a grant of probate or letters of administration, stamp duty is levied according to the size of the estate (wherever situated in respect of a holder of ordinary shares domiciled in Jersey, or situated in Jersey in respect of a holder of ordinary shares domiciled outside Jersey) and is payable on a sliding scale at a rate of up to 0.75% on the value of an estate up to a maximum stamp duty charge of &#163;100,000. The rules for joint holders through a nominee are different and advice relating to this form of holding should be obtained from a professional adviser.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jersey does not otherwise levy taxes upon capital, inheritances, capital gains or gifts nor are there otherwise estate duties.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goods and Services Tax</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Goods and Services Tax (Jersey) Law 2007 (&#8220;GST Law&#8221;), a tax rate which is currently 5% applies to the supply of goods and services (&#8220;GST&#8221;), unless the supply is regarded as exempt or zero rated, or the relevant supplier or recipient of such goods and services is registered as an &#8220;international services entity.&#8221;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company must register for GST if its turnover is greater than &#163;300,000 in any 12-month period, and will then need to charge GST to its customers. Companies can also choose to register voluntarily.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company may apply to be registered as an International Services Entity (&#8220;ISE&#8221;) if it mainly serves non-Jersey residents. By virtue of a company being an ISE, it will not have to register for GST, will not charge GST on its supplies, and will not be charged GST on its purchases.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be an ISE within the meaning of the GST Law, as we satisfy the requirements of the Goods and Services Tax (International Services Entities) (Jersey) Regulations 2008, as amended. As long as we continue to be such an entity, a supply of goods or of a service made by or to us shall not be a taxable supply for the purposes of the GST Law.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Substance Legislation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With effect from January 1, 2019, Jersey has implemented legislation to meet EU demands for companies to have substance in certain circumstances. Broadly, part of the legislation is intended to apply to holding companies managed and controlled in Jersey. As we are tax resident in Jersey, this legislation applies to us on this basis.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.4pt">Dividends and Paying Agents </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">G.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.73pt">Statement by Experts</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.73pt">Documents on Display </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain of the informational filing requirements of the Exchange Act. Since the Company is a &#8220;foreign private issuer,&#8221; the Company is exempt from the rules and regulations under the Exchange Act prescribing the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions contained in Section 16 of the Exchange Act, with respect to their purchase and sale of our shares. In addition, the Company is not required to file reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we are required to file with the SEC an Annual Report on Form 20-F containing financial statements audited by an independent accounting firm. The Company may, but is not required, to furnish to the SEC, on Form 6-K, unaudited financial information after each of our first three fiscal quarters. Information filed with or furnished to the SEC by us will be available on our website. The SEC also maintains a website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">http://www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that contains reports and other information that we file with or furnish electronically with the SEC. You may read and copy any report or document we file, including the exhibits, at the SEC&#8217;s public reference room located at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.61pt">Subsidiary Information </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_199"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain market risks in the ordinary course of its business, including fluctuations in interest rates, foreign exchange and inflation. Currently, these risks are not material to the Company&#8217;s financial condition or results of operations, but they may be in the future.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further information regarding quantitative and qualitative disclosure about market risk is included in &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8221; of this Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">220</span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_202"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022 there were 11,500,000 warrants that had been issued in our initial public offering outstanding (the &#8220;Public Warrants&#8221;). The Public Warrants entitle the holder to purchase one Waldencast plc Class A ordinary share at an exercise price of $11.50 per share. The Public Warrants will expire on July 27, 2027 (i.e., five years after the completion of the Business Combination), at 5:00 p.m., New York City time, or earlier upon redemption or liquidation in accordance with their terms. As of December 31, 2022 there were also 11,099,999 private placement warrants held by Beauty Ventures, Burwell as trustee of Burwell, and Zeno Investment Master Fund. The private placements warrants are identical to the Public Warrants in all material respects. </span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_205"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II </span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_208"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None/not applicable.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_211"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None/not applicable.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_214"></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15. CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A. Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures, pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act, are required to be designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that information relating to the Company is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2022 (the end of the period covered by this Report). Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of December 31, 2022 were not effective because of material weaknesses in internal control over financial reporting as described below.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Material Weaknesses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously reported in the Company&#8217;s Quarterly Report on Form 10-Q as filed with the SEC on May 25, 2021, and due to the restatements of our March 23, 2021, March 31, 2021, and June 30, 2021 financial statements, and as updated in our most recent Annual Report on Form 10-K for the year ended and as of December 31, 2021, management of the Company prior to the Business Combination had identified a material weakness due to the material restatement of redeemable Class A Shares in the previously issued financial statements. As described below under &#8220;Remediation Plan,&#8221; we continue to enhance our processes and procedures to identify and appropriately apply applicable accounting requirements to better evaluate and understand the nuances of the complex accounting standards that apply to our financial statements. Our remediation efforts regarding this material weakness remain ongoing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with the preparation of our consolidated financial statements as of December 31, 2022, we identified material weaknesses in our internal control over financial reporting when considering the criteria set forth by the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">221</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013 Framework). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon the conclusions of our Chief Executive Officer and Chief Financial Officer, we have concluded that we have material weaknesses in each of the components of the 2013 Framework due to a lack of sufficient controls around the Company&#8217;s Control Environment, Risk Assessment, Control Activities, Information and Communication, and Monitoring of controls. This formed the basis for the statement of non-reliance on the financial statements for certain Predecessor Periods and Successor Periods as described in the Form 6-K filed with the SEC on July 5, 2023 and Form 6-K/A filed on November 25, 2022, respectively. The material weaknesses identified were caused by the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.07pt">Insufficient Segregation of Duties and Review Procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Control deficiencies were identified in segregation of duties and more specifically the lack of review and approval of manual journal entries. The Company identified that certain journal entries were either not reviewed or lacked the necessary supporting details for a reviewer to critically evaluate the accuracy of the entry. </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Insufficient Resources with Appropriate level of Understanding of Generally Accepted Accounting Principles (&#8220;GAAP"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was an insufficient number of personnel with an appropriate level of GAAP knowledge and experience to create the proper environment for effective internal control over financial reporting, with an emphasis on the sufficient understanding of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and to ensure that (a) the consolidated financial statements were prepared timely and accurately, (b) there were adequate processes for oversight, (c) there was accountability for the performance of internal control over financial reporting responsibilities, and (d) corrective activities were appropriately applied, prioritized, and implemented in a timely manner. </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.07pt">Policies and Procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: There was a lack of sufficient policies and procedures in place for the Obagi reporting segment to ensure that all relevant information was provided by former Obagi management to Company management to ensure the segment results portrayed an accurate picture of the financial position of the segment. There was also insufficient monitoring of the internal control environment of the Company, and the Company did not perform an appropriate risk assessment to design control activities to be responsive to risks of material misstatement. The Company additionally did not have a formal delegation of authority in place allowing for the appropriate monitoring of material financial and business decisions nor have processes in place to monitor the control environment to ensure that the financial statements were accurate and complete. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remediation Plan and Status</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has been actively engaged in remediation efforts to address the material weaknesses identified above. We have been making enhancements to our control environment since the calendar year-ended December 31, 2022 by improving oversight, communication of expectations and emphasizing the importance of internal controls. In addition, we made improvements to the level of detail in our risk assessment including the linkage between risks and internal controls. We plan to continue improving upon the design of our internal controls over financial reporting and the timeliness of those procedures during the calendar year-ended December 31, 2024 and beyond. We have made progress towards addressing the material weaknesses by implementing processes to better identify, document, and assess systems and information used when performing internal controls, including the enhancement of established accounting policies, procedures and controls. The remediation efforts also include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">hiring additional qualified accounting, finance and legal personnel, to provide additional capacity and expertise to enhance our accounting and reporting review procedures;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">engaging consultants to provide additional technical accounting expertise;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">engaging third-party specialists to help assess and document </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our internal controls for complying with Sarbanes-Oxley Act of 2002; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">engaging third-party specialists with whom we consult regarding complex accounting applications;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">identifying relevant controls and establishing clear roles, responsibilities and segregation of duties, including supervisory reviews performed by our financial management team at an appropriate level based upon our risk assessment. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above, during fiscal year-ended December 31, 2023, the Company also (1) hired a new seasoned executive leadership team at Obagi including a new President, Chief Financial Officer and Chief Marketing Officer (2) reinforced the senior leadership team based in Southeast Asia with the appointment of a new President and Chief Financial </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Officer and (3) reinforced its legal and finance functions by hiring a new General Counsel and Senior Vice President of Accounting. Management continues to be closely involved in monitoring the Obagi segment of the business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we had begun implementing the activities noted above, management has concluded that the material weaknesses were not remediated as of December 31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the identified material weaknesses, management has concluded that the consolidated financial statements included in this Report present fairly, in all material respects, our financial position, results of operations and cash flows for the periods disclosed in conformity with U.S. generally accepted accounting principles (U.S. GAAP).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B. Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Report does not include a report of management&#8217;s assessment regarding our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) in accordance with guidance issued by the SEC where companies are permitted to exclude management&#8217;s report on internal controls over financial reporting in the first Annual Report filed after the close of a material acquisition. On July 27, 2022, we consummated a merger with (i) Obagi and (ii) Milk, as discussed in &#8220;4. Business Combinations,&#8221; of the Notes to the Consolidated Financial Statements, where the Company was determined to be the accounting acquirer, however Obagi was determined to be the accounting predecessor for the purpose of financial reporting. The assets, liabilities, and operations of the Company prior to the acquisitions are insignificant when compared to the consolidated company post-acquisitions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C. Attestation Report of the Registered Public Accounting Firm</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we are an "emerging growth company" under the JOBS Act, our independent registered public accounting firm is not required to attest to the effectiveness of our internal control over financial reporting for so long as we are an emerging growth company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D. Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as described above and under &#8220;Remediation Plan,&#8221; there were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the fiscal year-ended December 31, 2022, which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_217"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16. [RESERVED]</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_220"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board has determined that each of the members of the audit committee qualifies as independent under the Nasdaq rules applicable to members of our Board generally and under the Nasdaq rules and Exchange Act Rule 10A-3 specific to audit committee members and that each of the members of the audit committee meets the requirements for financial sophistication under the applicable Nasdaq rules. In addition, our Board has determined that Juliette Hickman qualifies as an &#8220;audit committee financial expert,&#8221; as such term is defined in Item 407(d)(5) of Regulation S-K.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_223"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16B. CODE OF ETHICS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a code of ethics and business conduct that applies to all of our directors, officers and employees. The code of ethics is available on our website, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.waldencast.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The information on or available through our website is not deemed incorporated in this Report and does not form part of this Report. We intend to make any legally required disclosures regarding amendments to, or waivers of, the provisions of its code of ethics on our website rather than by filing a Current Report on Form 6-K.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_226"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the 2022 Successor Period (July 28, 2022 to December 31, 2022), Deloitte &amp; Touche LLP (&#8220;Deloitte&#8221;) has served as our company&#8217;s independent registered public accounting firm. For the Predecessor Periods, Deloitte served as Obagi&#8217;s </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">223</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent registered public accounting firm. The following table sets out the aggregate fees for professional audit services and other services rendered by Deloitte for each of the periods presented.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Waldencast)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Obagi)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From July 28, 2022 to<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">From January 1,<br/>2022 to July 27,<br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended<br/>December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Audit fees (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Audit-related fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax fees (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fees</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,509&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,738&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,166&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Audit fees consist of professional services provided in connection with the audit of our annual financial statements and other audit or interim review services provided in connection with regulatory filings or engagements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Tax fees consist of fees for professional services for tax compliance, tax advice, and tax audits.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_229"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None/not applicable.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_232"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16E. ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None/not applicable.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_235"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANTS</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None/not applicable.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_238"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16G. CORPORATE GOVERNANCE</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a foreign private issuer, we are not subject to all of the corporate governance requirements applicable to public companies organized within the U.S. For example, we are exempt from certain rules under the&#160;Exchange Act&#160;that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">authorizations applicable to a security registered under the&#160;Exchange Act, including the U.S. proxy rules under Section 14 of the Exchange Act (including the requirement applicable to emerging growth companies to disclose the compensation of our Chief Executive Officer and the other two most highly compensated executive officers on an individual, rather than an aggregate, basis). In addition, our officers and directors are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. Moreover, while we submit quarterly interim consolidated financial data to the SEC under cover of the SEC&#8217;s Form 6-K, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public companies and are not required to file quarterly reports on Form 10-Q or current reports on Form 6-K under the&#160;Exchange Act. We also are exempt from the requirements to obtain shareholder approval for certain issuances of securities, including shareholder approval of share option plans. In addition, as a foreign private issuer, we are exempt from the provisions of&#160;Regulation FD, which prohibits issuers from making selective disclosure of material nonpublic information.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated under the laws of Jersey and our corporate governance practices are governed by applicable Jersey law, including the provisions of the Jersey Companies Law, and the Constitutional Document. In addition, because our securities are listed on The Nasdaq Capital Market, we are subject to Nasdaq&#8217;s corporate governance listing standards.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rule 5615(a)(3) of the Rules permits a foreign private issuer like us to follow home country practices in lieu of certain requirements of Listing Rule 5600, provided that such foreign private issuer discloses in its annual report filed with the SEC each requirement of Rule 5600 that it does not follow and describes the home country practice followed in lieu of such requirement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">224</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently follow our home country practice in lieu of the requirements of the 5600 Series of the Rules to be exempt from the requirements as follows: (i) Rule 5620(a) of the Rules which provides that (with certain exceptions not relevant to the conclusions expressed herein) each company listing common stock or voting preferred stock, and their equivalents, shall hold an annual meeting of shareholders no later than one year after the end of the company&#8217;s fiscal year-end; (ii) Rule 5635(c) of the Rules which sets forth the circumstances under which shareholder approval is required prior to an issuance of securities of the Company in connection with equity-based compensation of officers, directors, employees or consultants; (iii) Rule 5635(d) of the Rules which sets forth the circumstances under which shareholder approval is required prior to an issuance of securities, other than in a public offering, equal to 20% or more of the voting power outstanding at a price less than the lower of: (x) the Nasdaq Official Closing Price (as reflected on Nasdaq.com) immediately preceding the signing of the binding agreement; or (y) the average Nasdaq Official Closing Price of the common stock (as reflected on Nasdaq.com) for the five trading days immediately preceding the signing of the binding agreement; and (iv) Rule 5250(b)(3) of the Rules which requires disclosure of third-party director and nominee compensation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we choose to follow additional home country practice in the future, our shareholders may be afforded less protection than they would otherwise enjoy under the Nasdaq corporate governance requirements applicable to U.S. domestic issuers. See &#8220;Item 3. Key Information&#8212;Risk Factors&#8212;Risks Related to our Organization and Corporate Structure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;As a public limited company incorporated under the laws of Jersey, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from Nasdaq corporate governance listing standards. These practices may afford less protection to securityholders than they would enjoy if we complied fully with Nasdaq corporate governance listing standards.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_241"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16H. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None/not applicable.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_244"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None/not applicable.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_247"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16J. INSIDER TRADING POLICY</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted an Insider Trading Policy that applies to all directors, officers and employees of Waldencast and (a) their spouses, minor children, adult family members sharing the same house, and (b) any other person or entity over whom a person subject to the policy has substantial influence or control when it relates to decisions to purchase or sell securities. The Insider Trading Policy, which applies to any purchases and sales of our securities (including</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ordinary shares, warrants, shares issued under stock options, RSUs or other equity awards, and if we ever issue them preferred shares, bonds or debt securities or convertible debentures and warrants) is designed to promote compliance with applicable insider trading laws, rules and regulations, and the Nasdaq listing standards. The foregoing description of the Insider Trading Policy is not complete and is subject to and qualified in its entirety by reference thereto, a copy of which is filed as Exhibit 4.39 to this Report and the terms of which are incorporated by reference herein.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_250"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III </span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_253"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 17. FINANCIAL STATEMENTS </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Item 18. Financial Statements.&#8221; </span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_256"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 18. FINANCIAL STATEMENTS </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements and the related notes required by this Item are included in this annual report on Form 20-F beginning on page F-1.</span></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_259"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 19. EXHIBITS </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">225</span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_262"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Memorandum and Articles of Association of Waldencast plc. (incorporated by reference to Exhibit 1.1 to the <a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022044277/f20f2022ex1-1_walden.htm">Report on Form 20-F (Reg. No. 001-40207), filed with the SEC on August 3, 2022).</a> </span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000114036122016071/ny20001615x19_ex4-5.htm">Specimen ordinary share certificate of Waldencast plc (incorporated by reference to Exhibit 4.5 to Amendment No. 3 to the Registration Statement on Form F-4 (Reg. No. 333-262692), filed with the SEC on April 27, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390021016417/ea137924ex4-1_waldencast.htm">Warrant Agreement, dated March 15, 2021, between Waldencast Acquisition Corp. and Continental Stock Transfer &amp; Trust Company (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K (Reg. No. 001-40207), filed with the SEC on March 18, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000114036122024822/ny20001615x31_f4a.htm#tAA">Agreement and Plan of Merger, dated as of November 15, 2021, by and among the Company, Merger Sub and Obagi (incorporated by reference to Annex A to Amendment No. 7 to the Registration Statement on Form F-4 (Reg. No. 333-262692), filed with the SEC on July 1, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390021060377/ea150570ex2-2_waldencast.htm">Equity Purchase Agreement, dated as of November 15, 2021, by and among the Company, Waldencast LP, Holdco Purchaser, Milk, the Milk Members and the Equityholder Representative (incorporated by reference to Exhibit 2.2 to Amendment No. 1 to the Current Report on Form 8-K (Reg. No. 001-40207), filed with the SEC on November 17, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000114036122023159/ny20001615x25_f4a.htm#tAC">Sponsor Support Agreement, dated November 15, 2021, by and among the Sponsor, the Company, certain directors of the Company and Obagi (incorporated by reference to Annex C to Amendment No. 5 to the Registration Statement on Form F-4 (Reg. No. 333-262692), filed with the SEC on June 16, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000114036122023159/ny20001615x25_f4a.htm#tAD">Sponsor Support Agreement, dated November 15, 2021, by and among the Sponsor, the Company and Milk (incorporated by reference to Annex D to Amendment No. 5 to the Registration Statement on Form F-4 (Reg. No. 333-262692), filed with the SEC on June 16, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000114036122023159/ny20001615x25_f4a.htm#tAE">Stockholder Support Agreement, dated November 15, 2021, by and among the Company, Cedarwalk Skincare Ltd. and Obagi (incorporated by reference to Annex E to Amendment No. 5 to the Registration Statement on Form F-4 (Reg. No. 333-262692), filed with the SEC on June 16, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390021060377/ea150570ex10-1_waldencast.htm">Form of Subscription Agreement, by and between the Company and the undersigned subscriber party thereto (incorporated by reference to Exhibit 10.1 to Amendment No. 1 to the Current Report on Form 8-K (Reg. No. 001-40207), filed with the SEC on November 17, 2021 ). </a></span></div></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390021060381/ea150570ex10-7_waldencast.htm">Form of </a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390021060381/ea150570ex10-7_waldencast.htm">Milk Lock-Up Agreement (incorporated by reference to Exhibit 10.7 to Amendment No. 1 to the Current Report on Form 8-K (Reg. No. 001-40207), filed with the SEC on November 18, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390021060377/ea150570ex10-6_waldencast.htm">Form of Obagi Lock-Up Agreement (incorporated by reference to Exhibit 10.6 to Amendment No. 1 to the Current Report on Form 8-K (Reg. No. 001-40207), filed with the SEC on November 18, 2021).</a>T</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022044277/f20f2022ex4-8_walden.htm">Amended and Restated Registration Rights Agreement, by and among the Company, the Sponsor, certain former shareholders of Obagi and certain former members of Milk (incorporated by reference to Exhibit 4.8 to the Report on Form 20-F (Reg. No. 001-40207), filed with the SEC on August 3, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">226</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022044277/f20f2022ex4-9_walden.htm">Waldencast plc 2022 Incentive Award Plan (incorporated by reference to Exhibit 4.9 to the Report on Form 20-F (Reg. No. 001-40207), filed with the SEC on August 3, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390021016417/ea137924ex10-1_waldencast.htm">Letter Agreement, dated March 15, 2021, among the Company, the Sponsor and the Sponsor&#8217;s officers and directors (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K (Reg No. 001-40207) filed with the SEC on March 18, 2021). </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390021016417/ea137924ex10-2_waldencast.htm">Investment Management Trust Agreement, dated March 15, 2021, between the Registrant and Continental Stock Transfer &amp; Trust Company, as trustee (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K (Reg No. 001-40207) filed with the SEC on March 18, 2021). </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390021016417/ea137924ex10-4_waldencast.htm">Administrative Services Agreement, dated March 15, 2021, between the Company and the Sponsor (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K (Reg No. 001-40207) filed with the SEC on March 18, 2021). </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390021016417/ea137924ex10-5_waldencast.htm">Sponsor Warrants Purchase Agreement, dated March 15, 2021, between the Company and the Sponsor (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K (Reg No. 001-40207) filed with the SEC on March 18, 2021). </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022044277/f20f2022ex4-14_walden.htm">Indemnity Agreement, dated July 27, 2022, between the Company and Michel Brousset (incorporated by reference to Exhibit 4.14 to the Report on Form 20-F (Reg. No. 001-40207), filed with the SEC on August 3, 2022). </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022044277/f20f2022ex4-15_walden.htm">Indemnity Agreement, dated July 27, 2022, between the Company and Felipe Dutra ((incorporated by reference to Exhibit 4.15 to the Report on Form 20-F (Reg. No. 001-40207), filed with the SEC on August 3, 2022). </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022044277/f20f2022ex4-16_walden.htm">Indemnity Agreement, dated July 27, 2022, between the Company and Cristiano Souza (incorporated by reference to Exhibit 4.16 to the Report on Form 20-F (Reg. No. 001-40207), filed with the SEC on August 3, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022044277/f20f2022ex4-17_walden.htm">Indemnity Agreement, dated July 27, 2022, between the Company and Sarah J. Brown (incorporated by reference to Exhibit 4.17 to the Report on Form 20-F (Reg. No. 001-40207), filed with the SEC on August 3, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022044277/f20f2022ex4-18_walden.htm">Indemnity Agreement, dated July 27, 2022, between the Company and Juliette Hickman (incorporated by reference to Exhibit 4.18 to the Report on Form 20-F (Reg. No. 001-40207), filed with the SEC on August 3, 2022). </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022044277/f20f2022ex4-19_walden.htm">Indemnity Agreement, dated July 27, 2022, between the Company and Lindsay Pattison (incorporated by reference to Exhibit 4.19 to the Report on Form 20-F (Reg No. 001-40207), filed with the SEC on August 3, 2022). </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022044277/f20f2022ex4-20_walden.htm">Indemnity Agreement, dated July 27, 2022, between the Company and Zack Werner (incorporated by reference to Exhibit 4.20 to the Report on Form 20-F (Reg. No. 001-40207), filed with the SEC on August 3, 2022). </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022044277/f20f2022ex4-21_walden.htm">Indemnity Agreement, dated July 27, 2022, between the Company and Aaron Chatterley(incorporated by reference to Exhibit 4.21 to the Report on Form 20-F (Reg. No. 001-40207), filed with the SEC on August 3, 2022). </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022044277/f20f2022ex4-22_walden.htm">Indemnity Agreement, dated July 27, 2022, between the Company and Simon Dai (incorporated by reference to Exhibit 4.22 to the Report on Form 20-F (Reg. No. 001-40207), filed with the SEC on August 3, 2022). </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390021010884/fs12021ex10-1_waldencast.htm">Promissory Note, dated January 12, 2021, issued to the Sponsor (incorporated by reference to Exhibit 10.1 to the Registration Statement on Form S-1 (Reg. No. 333-253370), filed with the SEC on February 22, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000114036122005047/ny20001615x3_ex10-20.htm">Promissory Note, dated August 18, 2021, issued to the Sponsor (incorporated by reference to Exhibit 10.20 to the Registration Statement on Form F-4 (Reg. No. 333-262692), filed with the SEC on February 14, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390021010884/fs12021ex10-9_waldencast.htm">Forward Purchase Agreement, dated February 22, 2021, by and among the Company, the Sponsor and </a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390021010884/fs12021ex10-9_waldencast.htm">Zeno Investment Master Fund</a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390021010884/fs12021ex10-9_waldencast.htm"> (f/k/a D</a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390021010884/fs12021ex10-9_waldencast.htm">ynamo Master Fund</a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390021010884/fs12021ex10-9_waldencast.htm">)</a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390021010884/fs12021ex10-9_waldencast.htm"> (incorporated by reference to Exhibit 10.9 to the Registration Statement on Form S-1 (Reg. No. 333-253370), filed with the SEC on February 22, 2021). </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390021012598/fs12021a1ex10-10_waldencast.htm">Forward Purchase Agreement, dated March 1, 2021, between the Company and Beauty Ventures (incorporated by reference to Exhibit 10.10 to Amendment No. 1 to the Registration Statement on Form S-1 (Reg. No. 333-253370), filed with the SEC on March 1, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000114036121042643/ny20001615x2_ex1-1.htm">Assignment, Assumption and Joinder Agreement to the Forward Purchase Agreement, dated December 20, 2021, between the Sponsor and Burwell Mountain Trust (incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K (Reg. No. 001-40207), filed with the SEC on December 22, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000114036122005047/ny20001615x3_ex10-28.htm">Investor Rights Agreement, by and among the Company, Cedarwalk Skincare Ltd., the Sponsor and CWC Skincare Ltd., the guarantor of Cedarwalk Skincare Ltd.&#8217;s obligations thereunder (incorporated by reference to Exhibit 10.28 to the Registration Statement on Form F-4 (Reg No. 333-262692), filed with the SEC on February 14, 2022. </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022029291/ea160427ex10-1_walden.htm">Promissory Note, dated May 20, 2022, issued to the Sponsor (incorporated by reference to Exhibit 10.1 to </a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022029291/ea160427ex10-1_walden.htm">the Current Report on Form 8-K (Reg No. 001-40207), filed with the SEC on May 24, 2022.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022039705/ea162926ex10-2_walden.htm">Promissory Note, dated July 15, 2022, issued to the Sponsor (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K (Reg. No. 001-40207), filed with the SEC on July 15, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022044277/f20f2022ex4-31_walden.htm">Credit Agreement, dated June 24, 2022, by and among Waldencast Finco Limited, Waldencast Partners LP, as the parent guarantor, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (incorporated by reference to Exhibit 4.31 to the Report on Form 20-F (Reg. No. 001-40207), filed with the SEC on August 3, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022044277/f20f2022ex4-32_walden.htm">Waiver and Agreement, dated as of July 25, 2022, by and between Waldencast Acquisition Corp. and Burwell Mountain PTC LLC, as trustee of Burwell Mountain Trust (incorporated by reference to Exhibit 4.32 to the Report on Form 20-F (Reg. No. 001-40207), filed with the SEC on August 3, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022044277/f20f2022ex4-33_walden.htm">Joinder to the Letter Agreement, dated as of July 7, 2022, by and between the Company and Burwell Mountain PTC LLC, as trustee of Burwell Mountain Trust (incorporated by reference to Exhibit 4.33 to the Report on Form 20-F (Reg. No. 001-40207), filed with the SEC on August 3, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022044277/f20f2022ex4-34_walden.htm">Joinder to the Letter Agreement, dated as of December 16, 2021, by and between the Company and Aaron Chatterley (incorporated by reference to Exhibit 4.34 to the Report on Form 20-F (Reg. No. 001-40207), filed with the SEC on August 3, 2022).</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">228</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.113%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000121390022044277/f20f2022ex4-35_walden.htm">Joinder to the Letter Agreement, dated as of July 27, 2022, by and between the Company and Simon Dai (incorporated by reference to Exhibit 4.35 to the Report on Form 20-F (Reg. No. 001-40207), filed with the SEC on August 3, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000184019923000022/wald_ex993part2xsept2023.htm">Second Amendment and Waiver to the Credit Agreement, dated September 15, 2023</a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000184019923000022/wald_ex993part2xsept2023.htm">,</a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000184019923000022/wald_ex993part2xsept2023.htm"> </a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000184019923000022/wald_ex993part2xsept2023.htm">by and among Waldencast Finco Limited,</a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000184019923000022/wald_ex993part2xsept2023.htm"> </a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000184019923000022/wald_ex993part2xsept2023.htm">Waldencast Partners LP, as the parent guarantor, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent (incorporated by reference to Exhibit </a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000184019923000022/wald_ex993part2xsept2023.htm">99.3 </a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000184019923000022/wald_ex993part2xsept2023.htm">to the Report on Form </a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000184019923000022/wald_ex993part2xsept2023.htm">6</a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000184019923000022/wald_ex993part2xsept2023.htm">-</a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000184019923000022/wald_ex993part2xsept2023.htm">K</a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000184019923000022/wald_ex993part2xsept2023.htm"> (Reg. No. 001-40207), </a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000184019923000022/wald_ex993part2xsept2023.htm">filed with the SEC on September 18, 2023)</a><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000184019923000022/wald_ex993part2xsept2023.htm">.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.38</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1840199/000184019923000022/wald_992xsubscriptionagree.htm">Form of Subscription Agreement, by and between the Company and the undersigned subscriber party thereto (incorporated by reference to Exhibit 99.2 to the Report on Form 6-K (Reg. No. 001-40207), filed with the SEC on September 18, 2023).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.39*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="wald_20221231-20fxex439.htm">Insider Trading Policy</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="wald-20221231xexhibit81.htm">Subsidiaries of Waldencast plc.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="wald-20221231x20fxex121.htm">Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="wald-20221231x20fxex122.htm">Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="wald-20221231x20fxex131.htm">Certification of the Principal Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="wald-20221231x20fxex132.htm">Certification of the Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File<br/>because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded as Inline XBRL and contained in Exhibit 101).</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Filed herewith.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.37pt">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K on the basis that the Company customarily and actually treats that information as private or confidential and the omitted information is not material.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">229</span></div></div></div><div id="if2fc25067f8b45fc8cc165df93f3be1c_265"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if2fc25067f8b45fc8cc165df93f3be1c_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this report on its behalf. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January&#160;16, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Philippe Gautier</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name: Philippe Gautier</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title: Chief Financial Officer and Chief Operating Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">230</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.39
<SEQUENCE>2
<FILENAME>wald_20221231-20fxex439.htm
<DESCRIPTION>EX-4.39
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i083fbb24fe3c4338811ad4b466ece5da_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 4.39</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">WALDENCAST PLC </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">INSIDER TRADING POLICY</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Adopted on September 16, 2022</font></div><div style="text-indent:158.7pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As a director, officer or employee of Waldencast plc or one of its subsidiaries (together, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">we</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">us</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Waldencast</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), you will probably become aware of material information about our business or other companies that we do business with or are interested in acquiring (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">other entities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) that is not available to the investing public (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">material nonpublic information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;). You have a legal and ethical obligation to maintain the confidentiality of material nonpublic information. In addition, it is illegal and a violation of Company policy to purchase or sell any securities of the Company (including selling shares issued under stock options, restricted stock units (&#8220;RSUs&#8221;) or other equity awards) or in any other entities while you are in possession of material nonpublic information about the Company or those other entities.  The Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) has adopted this Insider Trading Policy (this &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) to ensure compliance with the law and to avoid even the appearance of improper conduct by anyone associated with Waldencast. We have all worked hard to establish the Company&#8217;s reputation for integrity and ethical conduct, and we are all responsible for preserving and enhancing this reputation.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:11.9pt">WHO IS COVERED BY THE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">POLICY</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Policy applies to all Waldencast directors, officers and employees, wherever located and whether they work on a full- or part-time basis, and (a) their spouses, minor children, adult family members sharing the same house, and (b) any other person or entity over whom a person subject to the Policy has substantial influence or control when it relates to decisions to purchase or sell securities (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Related Insiders</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;). This Policy also applies to any trust or other estate in which you have a substantial beneficial interest or for which you serve as trustee or in a similar fiduciary capacity. We may also determine that the Policy should apply to other people, such as contractors or consultants who have access to material nonpublic information about the Company.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">II.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:8.85pt">TRANSACTIONS COVERED BY THE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">POLICY</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:98%">This Policy applies to purchases and sales of securities, including Waldencast ordinary shares, warrants, shares issued under stock options, RSUs or other equity awards, and if we ever issue them preferred shares, bonds or debt securities or convertible debentures and warrants (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:98%">Waldencast Securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:98%">&#8221;). The Policy also applies to purchases and sales of derivative securities, such as exchange-traded put or call options or swaps relating to Waldencast Securities, as well as securities of other entities, to the extent you become aware of material nonpublic information about the other entities by virtue of your employment at or service with Waldencast. The Policy does not apply, however, to trading in funds that may hold Waldencast Securities, such as exchange-traded funds or mutual funds.</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If you are a director, officer or an employee that we identify as having regular access to material nonpublic information about our business, then there are additional restrictions that apply to you that are set forth in the Addendum to Insider Trading Policy that is attached to this Policy (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Addendum</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;). We will notify you if the Addendum applies to you. The Addendum</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-indent:18pt"><font><br></font></div><div id="i083fbb24fe3c4338811ad4b466ece5da_38"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">contains restrictions about trading in our securities during &#8220;blackout periods&#8221; and requires pre- clearance for transactions in Waldencast Securities.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">III.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:5.8pt">INDIVIDUAL</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">RESPONSIBILITY</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You are responsible for complying with this Policy and ensuring that your Related Insiders also comply with the Policy. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">As </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">a result, you should make sure that your family and others that live in your home are aware that they need to confer with you before they trade in any Waldencast Securities. You should treat all transactions by your Related Insiders as if they were your own transactions for purposes of this Policy and U.S. securities laws. In all cases, the responsibility </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">for </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">determining whether someone has material nonpublic information rests with that individual. Any action taken by the Company or any other employee pursuant to this Policy does not in any way constitute legal advice or insulate you </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">your Related Insiders from liability under applicable securities</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">laws.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">IV.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:4.57pt">WHAT IS CONSIDERED MATERIAL NONPUBLIC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">INFORMATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">What Does Material Mean&#63;</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You may wonder what is considered &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">material</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; information under the Policy&#63; Under our policies and U.S. securities law, information is material if&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%;padding-left:14.15pt">there </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">is </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">a substantial likelihood that a reasonable investor would consider the information important in determining whether </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">purchase </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">sell a security&#59;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%"> or</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">the information, if made public, likely would affect the market price of a</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">company&#8217;s securities.</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Information may be material even if it relates to future, speculative or contingent events and even if it is significant only when considered in combination with already publicly available information. Material information can be positive or negative. Information can be material even with respect to companies that are not publicly traded, such as those with outstanding bonds.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Whether information is considered material depends on the facts and circumstances of each situation. It is impossible to list all the information that could be considered material, but some of the more common examples include&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%;padding-left:14.15pt">earnings announcements or guidance on future earnings, or changes to previously released announcements </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">guidance&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">other unpublished financial</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">results&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">development of a significant new product, process, or service, or new significant contracts or</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">customers&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">the loss of a significant contract or</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">customer&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">expansion </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">shrinking of our operations </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">major business</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">disruptions&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">changes </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">our management team or the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Board&#59;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">a cybersecurity incident </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">risk that may negatively impact our business, reputation or share</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">value&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">pending or threatened significant litigation or government action, or the resolution of any of these types of</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">matters&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%;padding-left:14.15pt">a pending or proposed merger, acquisition, tender offer, joint venture, restructuring</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">or change in</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">assets&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">changes </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">analyst recommendations or debt</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ratings&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">events related to Waldencast Securities (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">e.g</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">., stock splits, dividends, changes to the rights of securityholders, an offering of additional securities, stock</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">repurchases)&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">significant changes </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the Company&#8217;s pricing </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or cost </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">structure&#59;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%;padding-left:14.15pt">extraordinary borrowing </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">other financing transactions out of the ordinary course of business&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">write-downs and additions </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">reserves </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">for </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">bad</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">debts&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">liquidity problems </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">impending bankruptcy&#59;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%;padding-left:14.15pt">changes </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">auditors or auditor notification that </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">Company may no longer rely </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">an audit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">report.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">What Does Nonpublic Mean&#63;</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">What is &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Nonpublic</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; information&#63; Information is considered to be nonpublic unless and until it has been fully disclosed to the public </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">sufficient time has passed for the stock market to digest the information.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">It is important to note that information is not necessarily public just because it has been discussed in the press or on social media, which will sometimes report rumors. You should presume that information is nonpublic until it has been officially released by the Company in at least one of the following ways&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">publicly available filings with the U.S. Securities and Exchange Commission</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">SEC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) or securities regulatory authorities&#59; or</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:127%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:127%;padding-left:14.15pt">issuance of press releases via major</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:127%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:127%">newswire.</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You may not attempt to &#8220;beat the market&#8221; by trading simultaneously with, or shortly after, the official release of material information. Although there is no fixed period for how long it takes the market to absorb information, as a general rule a person who has material nonpublic information should not engage in any trading activities for one (1) full trading day following its official release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">What if I have questions about Information&#63;</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If the SEC decides to investigate a transaction, they are likely to view it after-the-fact with the benefit of hindsight. As a result, before engaging in any transaction you should carefully consider how the transaction may be construed in the bright light of hindsight. If you have any</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">questions or uncertainties about this Policy, the Addendum </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">whether information you may have may be considered Material </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Nonpublic, please ask a member of Waldencast management or the Company&#8217;s legal department (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">Legal</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8221;). Please note, however, that neither the Company nor Legal can provide legal advice to you </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">a specific proposed transaction (Legal represents the Company not directors, officers </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">employees, so you may want </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">talk to your own legal advisor) and asking the Company </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Legal will not insulate you from liability under applicable securities laws.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">V.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:7.62pt">&#8220;TIPPING&#8221; MATERIAL NONPUBLIC INFORMATION IS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">PROHIBITED</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition to trading while </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">possession of material nonpublic information, it </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">is </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">also illegal and a violation of this Policy to give that information to another person (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">tipping</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) if you know </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">have reason to believe that the person will misuse the information by trading in securities or will pass it </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">to others who will trade on it. This applies regardless of whether the &#8220;tippee&#8221; is related to you </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or is </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">an entity, such as a trust or a corporation, and regardless of whether you receive any monetary benefit from the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">tippee.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">VI.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:4.57pt">GIFTS OF</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">SECURITIES</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">True or &#8220;bona fide&#8221; gifts of Waldencast Securities are not subject to this Policy, unless (a) you have a reason to believe that </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">recipient intends to sell the securities while you are aware of material nonpublic information, or (b) you are subject to the Addendum (in which case you will have to have the gift pre-cleared). Gifts of securities may include gifts to trusts for estate planning purposes, as well </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">donations to a charitable organization. Whether a gift </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">is </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;bona fide&#8221; may depend on various circumstances surrounding the gift. For example, a gift may not be considered bona fide if you receive a monetary benefit such as a tax deduction by donating shares to a charity before you believe the share price will drop because of material nonpublic information you have. Accordingly, you are encouraged to consult Company management </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Legal when contemplating a gift.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">VII.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:1.52pt">PROHIBITED</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">TRANSACTIONS</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%;padding-left:7.62pt">Short Sales. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You may not engage </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">short sales of Waldencast Securities. A short sale is a sale of securities when you (i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">do </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">not own the securities sold </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(ii) do own the securities sold, but </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">do </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">not deliver them within 20 days </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">place them in the mail within five days of the sale. Short sales may reduce your incentive to seek to improve the Company&#8217;s performance and often have the potential to signal to the market that you lack confidence in the Company&#8217;s</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">prospects.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%;padding-left:7.62pt">Margin Accounts and Pledges. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Because a margin sale </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">foreclosure sale may occur at a time when you are aware of material nonpublic information (or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">for </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">those subject to the Addendum </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">a blackout period) you may not hold Waldencast Securities </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">a margin account or otherwise pledge them </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">collateral </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">for </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">a loan without prior approval in writing from the Company. You will need to get written approval from either Company management or Legal. However, if you are an executive officer </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">director, you will need to obtain written approval from the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Board.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%;padding-left:7.01pt">Hedging Transactions. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You may not engage (directly or indirectly) in hedging transactions, or otherwise engage in transactions that hedge or offset, or are designed to hedge or offset, any decrease in the market value of Waldencast Securities. Hedging transactions include (but are not limited to) collars, equity swaps, exchange funds and prepaid variable forward sale contracts. Hedging transactions may allow you to continue to own Waldencast Securities, but without the full risks and rewards of ownership. This may lead you to no longer having the same objectives as the Company&#8217;s other shareholders.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">VIII.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:16.47pt">SAFEGUARDING CONFIDENTIAL</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">INFORMATION</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If material information about Waldencast has not been disclosed to the general public, you must keep that information in strict confidence and discuss it only with authorized persons and other employees who have a &#8220;need to know&#8221; the information for a legitimate business purpose. You are required to use the utmost care in protecting the Company&#8217;s confidential information. You should follow the guidelines below to help prevent the misuse of our confidential information&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">Avoid discussing confidential information with colleagues in places where you may</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">be overheard by people who do not have a valid need to know that information, such as on elevators, in lobbies, common areas, restaurants and on</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">airplanes.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">Be very careful when discussing confidential information </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">speaker phones </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">cell phones </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">locations where you may be overheard. Do not discuss such information with relatives or social</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">acquaintances.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Do not give your computer IDs and passwords to any other person. Password protect your computers and log off when they are not in</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">use.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Always put confidential documents away when you are not using them and, based upon the sensitivity of the material, keep them in a locked desk </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">office. Do not leave documents containing confidential information where they may be seen by people who do not have a need to know the content of the</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">documents.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.15pt">Be aware that </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Internet and other external electronic mail carriers are not secure environments for the transmission of confidential information. If available, use Company-authorized encryption software to protect confidential electronic communications.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Comply with the specific terms of any confidentiality agreements of which you</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">are aware.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Upon termination of your employment, you must return to the Company all physical (including electronic) copies of confidential information as well </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">all other material in any physical or electronic form that is based </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">or derived from such information, without retaining any</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">copies.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">You may not bring the confidential information of any former employer to the Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">IX.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:3.34pt">RESPONDING TO REQUESTS FOR</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">INFORMATION</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">People may ask you questions about various activities of the Company. Questions can come from the media, securities analysts and others asking about our business, rumors about us, trading activity, current and future prospects and plans for the Company, whether we are acquiring or selling companies and other similar important information. Do </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">not </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">attempt to handle these inquiries without prior authorization from Waldencast management. Only Waldencast management or our investor relations or public relations employees or agencies are specifically authorized to answer questions about or disclose information about the Company.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Refer questions or requests for information from </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">financial community, such </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">securities analysts, brokers or investors, to the Company&#8217;s Chief Executive Officer </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Chief Financial</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Officer.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">Refer requests </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">for </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">information about the Company from the media </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">press to Waldencast</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">management.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%;padding-left:14.15pt">Refer requests </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">for </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">information from the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">SEC or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">other regulators to Waldencast management or</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">Legal.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Please see our Corporate Disclosure Policy for additional guidelines.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">X.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:7.62pt">REPORTING VIOLATIONS&#47;SEEKING</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">ADVICE</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If you suspect someone has violated this Policy, you should report it to Company management or Legal through the reporting procedures set forth in our Code of Ethics and Business Conduct. In addition, if you receive&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%;padding-left:14.15pt">material nonpublic information that you are not authorized </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">receive </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:101%">that you do not need to know to perform your employment responsibilities&#59;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:101%"> or</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:14.15pt">confidential information and are unsure if it </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">is </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">within the definition of material nonpublic information </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">whether its release might be contrary to a fiduciary or other duty or</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">obligation,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">you should not share it with anyone. Consulting your colleagues can have the effect of making the problem worse. Containment of the information is critical until you have talked to Company management or Legal about the situation.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">XI.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:4.57pt">POST-TERMINATION TRANSACTIONS</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Policy and the Addendum continue to apply to transactions in Waldencast Securities even after you are no longer employed by the Company, or if you are a director after your service on the Board ends. If you have material nonpublic information when your employment&#47;service with the Company ends, you may not trade in Waldencast Securities until that information has become public or is no longer material. Questions or concerns on whether any continuing nonpublic information remains material should be directed to Company management or Legal. If you are subject to the Addendum, the Policy will cease to apply to your transactions in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Waldencast Securities upon the expiration of any blackout period or other Company-imposed trading restrictions applicable at the time your employment&#47;service ended.</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">XII.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:1.52pt">PENALTIES FOR VIOLATIONS OF THE INSIDER TRADING POLICY AND</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">LAWS</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The personal consequences to you of illegal insider trading can be severe. Any person who &#8220;willfully&#8221; violates any provision of U.S. securities laws may be fined up to $5 million ($25 million for entities) and&#47;or imprisoned for up to twenty years.</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition, U.S. law empowers the government to seek significant civil penalties against anyone found liable of insider trading, including as tippers or tippees. The amount of a penalty could total three times the profits made or losses avoided. All those who violate U.S. insider trading laws, including tippers and tippees could be subject to the maximum penalty. The maximum penalty may be assessed even against tippers for the profits made or losses avoided by all people you gave the information to or anyone they then passed the information on to. In addition, civil penalties of the greater of $2 million or three times the profits made or losses avoided can be imposed on any person who &#8220;controls&#8221; a person who engages in illegal insider trading.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Subject to applicable law, Company employees who violate this Policy may also be subject to discipline by the Company, up to and including termination of employment. Needless to say, a violation of law, or even a governmental or regulatory investigation that does not result in prosecution, can tarnish your reputation and irreparably damage your career.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If you are located or engaged in dealings outside the U.S., you should be aware that laws regarding insider trading and similar offenses differ from country to country. You must abide by the laws in the country where you are located in addition to the U.S. securities laws. If a local law conflicts with this Policy, you should consult Company management or Legal.</font></div><div><font><br></font></div><div style="text-align:center;text-indent:55.9pt"><font><br></font></div><div id="i083fbb24fe3c4338811ad4b466ece5da_46"></div><div style="text-align:center;text-indent:55.9pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center;text-indent:55.9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">WALDENCAST PLC</font></div><div><font><br></font></div><div style="text-align:center;text-indent:196.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">ADDENDUM TO </font></div><div style="text-align:center;text-indent:196.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">INSIDER TRADING POLICY</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">INTRODUCTION</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Addendum explains requirements and procedures that apply to all directors and officers of Waldencast plc or one of its subsidiaries (together, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">we</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">us</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">,&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), as well as designated Company employees who have access to material nonpublic information about the Company (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Covered Persons</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), and is in addition to and supplements the Company&#8217;s Insider Trading Policy (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;). Please note that this Addendum applies to all Waldencast Securities that you hold or may acquire in the future during your employment with the Company. Any capitalized terms used in this Addendum but not defined in it, have the meanings given to them in the Policy.</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Please read this Addendum carefully. When you have completed your review, please sign the attached acknowledgment form and return it to Legal.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">PRE-CLEARANCE PROCEDURES</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As a Covered Person, you and your Related Insiders may not engage in any transaction involving Waldencast Securities (including the exercise of stock options or warrants, sales of shares issued under stock options, RSUs or other equity awards, gifts of shares, loans using Waldencast Securities as collateral, contributions of shares to a trust, or any other transfers) without first obtaining pre-clearance of the transaction from Legal or, if you are not a member of Company management, Company management. Each proposed transaction will be evaluated to determine if it raises insider trading concerns or other concerns under applicable laws and regulations. Any advice you receive from Company management or Legal will relate solely to the restraints imposed by law and will not constitute advice regarding the investment aspects of any transaction. Clearance of a transaction is valid only for a 48-hour period. If you do not place the transaction order within that 48-hour period, you must re-request clearance of the transaction. If clearance is denied, the fact of such denial must be kept confidential by you.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">When a request for pre-clearance is made, you should carefully consider whether you may be aware of any material nonpublic information about the Company and should fully describe your circumstances to the appropriate member of Company management or Legal. You should also be prepared to comply with applicable securities laws at the time of any</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">sale.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">BLACKOUT PERIODS</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As a Covered Person, you and your Related Insiders are subject to the following blackout periods, during which you&#47;they may not trade in Waldencast Securities (except by means of pre-arranged 10b5-1 Plans established in compliance with this Addendum). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Remember to cancel any &#8220;limit&#8221; orders or other pending trading orders you have in place during a blackout period (unless the orders were made pursuant to your 10b5-1 Plan).</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Quarterly Blackout</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Because the announcement of the Company&#8217;s quarterly financial results will almost always have the potential to have a material effect on the market for the Company&#8217;s securities, all Covered Persons are prohibited from trading in the Company&#8217;s securities during the period (i) beginning on the fifteenth (15</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:112%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">) day of the third month of the quarter (March 15, June 15, September 15 and December 15 each year) and (ii) ending after the first full trading day following the release of the Company&#8217;s earnings for that quarter. For example, if we issue an earnings release on a Wednesday, you may not trade in Waldencast Securities until open of markets on Friday.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Interim Earnings Guidance Blackout</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Company may on occasion issue interim earnings guidance or other potentially material information by means of a press release, SEC filing on Form 6-K or Form 8-K, as applicable, or other means designed to achieve public dissemination of the information. You should expect that trading will be blacked out while the Company is in the process of assembling the information to be released until after the first full trading day following the release of the information.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Event Specific Blackout</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. From time to time, an event may occur that is material to the Company and is known by only a few directors, officers or employees.  The existence of an event-specific blackout will not be announced generally, but you will be informed if you are subject to the event specific blackout. If you are informed that the Company has implemented a special blackout, you </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">may not</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">disclose the fact that trading has been suspended to anyone, including other Company employees (who may themselves not be subject to the special blackout), family members (other than those subject to this Policy who would be prohibited from trading because you are), friends or brokers. You should treat the imposition of a special blackout period as material nonpublic information.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">NOTE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#58; Even if a blackout period is not in effect, at no time may you trade in Waldencast Securities if you have material nonpublic information about the Company. The failure of the Company to notify you of an event specific blackout will not relieve you of the obligation not to trade while in possession of material nonpublic information.</font></div><div style="text-indent:18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">RULE 10B5-1 TRADING PLANS</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">SEC Rule 10b5-1 provides an affirmative defense against insider trading liability. This does not protect you from having any transactions you engage in investigated by the SEC, but can provide a defense for you if you are subject to an investigation. You can rely on this defense and trade in Waldencast Securities, regardless of whether you have material nonpublic information about the Company, if your trade is made under a written trading plan adopted by you in good faith when you were not aware of any material nonpublic information and that plan complies with the requirements of Rule 10b5-1 (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">10b5-1 Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;). Our shareholder services provider, Fidelity, our your own personal broker can help you with creating a 10b5-1 Plan.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">If you want to enter into a 10b5-1 Plan, you must submit a copy of your proposed 10b5-1 Plan to Company management or Legal for approval at least five (5) business days before you want to adopt the 10b5-1 Plan. You may not adopt a 10b5-1 Plan during a blackout period or when you are aware of material nonpublic information about the Company.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Once the 10b5-1 Plan is adopted, you must not exercise any subsequent influence or control over the amount of securities to be traded, the price at which they are to be traded or the date of the trade. Trades should happen automatically under the 10b5-1 Plan according to the provisions of the plan. You may amend, replace, or terminate your 10b5-1 Plan only during periods when trading is permitted in accordance with this Policy, and you must submit any proposed amendment, replacement or termination of your 10b5-1 Plan to Company management or Legal for approval at least five (5) business days prior to adoption. You should understand that frequent changes </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">terminations of a 10b5-1 Plan may call into question whether you entered into </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">plan in good faith (and therefore may jeopardize your ability to use the affirmative defense against insider trading</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">allegations).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">ACKNOWLEDGEMENT</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">All directors, officers and other employees subject to the procedures set forth in this Addendum must acknowledge their understanding of, and intent to comply with, the Policy and this Addendum on the form attached to this Addendum.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">INSIDER TRADING POLICY ADDENDUM ACKNOWLEDGMENT FORM</font></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">I have read and understand the Company&#8217;s Insider Trading Policy and the Addendum attached to it (together, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:112%">Insider Trading Policy</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;). I agree to comply fully with all policies and procedures contained in the Insider Trading Policy </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">for as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">long </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">I am subject to the Insider Trading Policy. If I am an employee of Waldencast plc, I acknowledge that the Insider Trading Policy </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">is </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">a statement of policies and procedures and does not, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%">any way, constitute an employment contract or an assurance of continued employment.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.645%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Printed Name</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:275.1pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-4</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>3
<FILENAME>wald-20221231xexhibit81.htm
<DESCRIPTION>EX-8.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i596a39d73b444982a62ff998ee3a7af1_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 8.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Waldencast plc</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">List of Subsidiaries</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:48.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Blue Sea Administration Vietnam Company Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vietnam</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milk Makeup LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S., Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milk Makeup Europe, S.L.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barcelona</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milk Makeup UK Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England &#38; Wales</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obagi AsiaPac Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obagi Blue Sea Holding, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obagi Cosmeceuticals LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S., Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obagi Global Holdings Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obagi Holdco 1 Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obagi Holdco 2 Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obagi Holdings Company Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obagi Netherlands B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amsterdam</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Obagi Viet Nam Import Export Trading MTV Company Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vietnam</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Waldencast Cayman LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Waldencast Finco Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Waldencast Malaysia SDN. BHD.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Waldencast Singapore Pte. Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Waldencast Partners LP</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Waldencast UK Operations Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England &#38; Wales</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>wald-20221231x20fxex121.htm
<DESCRIPTION>EX-12.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7fca161737c24f5bb11f65c665d5e666_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 12.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Certification</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michel Brousset, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form 20&#8211;F of Waldencast plc&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) &#91;language omitted in accordance with Exchange Act Rule 13a-14(a)&#93; for the company and have&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;b)&#160;&#160;&#160;&#160;&#91;paragraph omitted in accordance with Exchange Act Rule 13a-14(a)&#93;&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January&#160;16, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michel Brousset</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Michel Brousset</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Chief Executive Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>5
<FILENAME>wald-20221231x20fxex122.htm
<DESCRIPTION>EX-12.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i26d889d5a4d74348b7fb4baa5eb24fa4_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 12.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Certification</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Philippe Gautier, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form 20&#8211;F of Waldencast plc&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) &#91;language omitted in accordance with Exchange Act Rule 13a-14(a)&#93; for the company and have&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;b)&#160;&#160;&#160;&#160;&#91;paragraph omitted in accordance with Exchange Act Rule 13a-14(a)&#93;&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January&#160;16, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Philippe Gautier</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Philippe Gautier</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Chief Financial Officer and Chief Operating Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>6
<FILENAME>wald-20221231x20fxex131.htm
<DESCRIPTION>EX-13.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0444ed1fdc3a4cbdbd08001aaf15549f_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 13.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18 U.S.C. Section 1350</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2022 (the &#8220;Report&#8221;) by Waldencast plc (the &#8220;Company&#8221;), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div><font><br></font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (1)&#160;&#160;&#160;&#160;the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2)&#160;&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January&#160;16, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michel Brousset</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Michel Brousset</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Chief Executive Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>7
<FILENAME>wald-20221231x20fxex132.htm
<DESCRIPTION>EX-13.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i196f5d4c27a84f2bb9090fa53c6bd583_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 13.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18 U.S.C. Section 1350</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2022 (the &#8220;Report&#8221;) by Waldencast plc (the &#8220;Company&#8221;), the undersigned, as the Chief Financial Officer and Chief Operating Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;</font></div><div><font><br></font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (1)&#160;&#160;&#160;&#160;the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2)&#160;&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:4.5pt;text-indent:-49.5pt"><font><br></font></div><div style="padding-left:49.5pt;text-indent:-49.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January&#160;16, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Philippe Gautier</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Philippe Gautier</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Chief Financial Officer and Chief Operating Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>wald-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cb24ed7e-6299-4643-a980-910da3dfa7bf,g:f940d8a8-f49a-452c-b5e1-83817ee3c0b3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:wald="http://www.waldencast.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.waldencast.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wald-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wald-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wald-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="wald-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="COVER" roleURI="http://www.waldencast.com/role/COVER">
        <link:definition>0000001 - Document - COVER</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.waldencast.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" roleURI="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" roleURI="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYParenthetical" roleURI="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYParenthetical">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESS" roleURI="http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS">
        <link:definition>0000010 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTATEMENTANDRECLASSIFICATIONS" roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONS">
        <link:definition>0000011 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONS" roleURI="http://www.waldencast.com/role/BUSINESSCOMBINATIONS">
        <link:definition>0000013 - Disclosure - BUSINESS COMBINATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUE" roleURI="http://www.waldencast.com/role/REVENUE">
        <link:definition>0000014 - Disclosure - REVENUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILL" roleURI="http://www.waldencast.com/role/GOODWILL">
        <link:definition>0000015 - Disclosure - GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSNET" roleURI="http://www.waldencast.com/role/INTANGIBLEASSETSNET">
        <link:definition>0000016 - Disclosure - INTANGIBLE ASSETS&#8212;NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://www.waldencast.com/role/DEBT">
        <link:definition>0000017 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.waldencast.com/role/LEASES">
        <link:definition>0000018 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTS" roleURI="http://www.waldencast.com/role/FINANCIALINSTRUMENTS">
        <link:definition>0000019 - Disclosure - FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.waldencast.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>0000020 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALBALANCESHEETDISCLOSURES" roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURES">
        <link:definition>0000021 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.waldencast.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>0000022 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREHOLDERSEQUITY" roleURI="http://www.waldencast.com/role/SHAREHOLDERSEQUITY">
        <link:definition>0000023 - Disclosure - SHAREHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARE" roleURI="http://www.waldencast.com/role/NETLOSSPERSHARE">
        <link:definition>0000024 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXBENEFIT" roleURI="http://www.waldencast.com/role/INCOMETAXBENEFIT">
        <link:definition>0000025 - Disclosure - INCOME TAX BENEFIT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>0000026 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000027 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTREPORTING" roleURI="http://www.waldencast.com/role/SEGMENTREPORTING">
        <link:definition>0000028 - Disclosure - SEGMENT REPORTING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLAN" roleURI="http://www.waldencast.com/role/EMPLOYEEBENEFITPLAN">
        <link:definition>0000029 - Disclosure - EMPLOYEE BENEFIT PLAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.waldencast.com/role/SUBSEQUENTEVENTS">
        <link:definition>0000030 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLY" roleURI="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLY">
        <link:definition>0000031 - Disclosure - SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationConsolidationandPresentationofFinancialStatementsPolicies" roleURI="http://www.waldencast.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies">
        <link:definition>9954471 - Disclosure - Organization, Consolidation and Presentation of Financial Statements (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTATEMENTANDRECLASSIFICATIONSTables" roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSTables">
        <link:definition>9954473 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9954474 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONSTables" roleURI="http://www.waldencast.com/role/BUSINESSCOMBINATIONSTables">
        <link:definition>9954475 - Disclosure - BUSINESS COMBINATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUETables" roleURI="http://www.waldencast.com/role/REVENUETables">
        <link:definition>9954476 - Disclosure - REVENUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLTables" roleURI="http://www.waldencast.com/role/GOODWILLTables">
        <link:definition>9954477 - Disclosure - GOODWILL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSNETTables" roleURI="http://www.waldencast.com/role/INTANGIBLEASSETSNETTables">
        <link:definition>9954478 - Disclosure - INTANGIBLE ASSETS&#8212;NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTTables" roleURI="http://www.waldencast.com/role/DEBTTables">
        <link:definition>9954479 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.waldencast.com/role/LEASESTables">
        <link:definition>9954480 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>9954481 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALBALANCESHEETDISCLOSURESTables" roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESTables">
        <link:definition>9954482 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>9954483 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHARETables" roleURI="http://www.waldencast.com/role/NETLOSSPERSHARETables">
        <link:definition>9954484 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXBENEFITTables" roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITTables">
        <link:definition>9954485 - Disclosure - INCOME TAX BENEFIT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTREPORTINGTables" roleURI="http://www.waldencast.com/role/SEGMENTREPORTINGTables">
        <link:definition>9954486 - Disclosure - SEGMENT REPORTING (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables" roleURI="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables">
        <link:definition>9954487 - Disclosure - SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" roleURI="http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails">
        <link:definition>9954488 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails" roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails">
        <link:definition>9954489 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Summary of Net Revenue Restatement Adjustments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails" roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails">
        <link:definition>9954490 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Summary of Cost of Goods Sold Restatement Adjustments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails" roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails">
        <link:definition>9954491 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Summary of SG&amp;A Expenses Restatement Adjustments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails" roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails">
        <link:definition>9954492 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails" roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails">
        <link:definition>9954493 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Summary of Accounts Receivable, Net Restatement Adjustments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails" roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails">
        <link:definition>9954494 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Summary of Inventory Restatement Adjustments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTATEMENTANDRECLASSIFICATIONSSummaryofReclassificationAdjustmentsDetails" roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofReclassificationAdjustmentsDetails">
        <link:definition>9954495 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Summary of Reclassification Adjustments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails" roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails">
        <link:definition>9954496 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsParentheticalDetails" roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsParentheticalDetails">
        <link:definition>9954497 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Consolidated Balance Sheets (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails" roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails">
        <link:definition>9954498 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Consolidated Statements of Operations and Comprehensive (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails" roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails">
        <link:definition>9954499 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Consolidated Statement of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>9954500 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails" roleURI="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails">
        <link:definition>9954501 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONSNarrativeDetails" roleURI="http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails">
        <link:definition>9954502 - Disclosure - BUSINESS COMBINATIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" roleURI="http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails">
        <link:definition>9954503 - Disclosure - BUSINESS COMBINATIONS - Summary of Purchase Price Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails" roleURI="http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails">
        <link:definition>9954504 - Disclosure - BUSINESS COMBINATIONS - Schedule of Intangible Assets Acquired in Business Combination (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails" roleURI="http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails">
        <link:definition>9954505 - Disclosure - BUSINESS COMBINATIONS - Unaudited Pro Forma Consolidated Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERevenuebySalesChannelDetails" roleURI="http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails">
        <link:definition>9954506 - Disclosure - REVENUE - Revenue by Sales Channel (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUENarrativeDetails" roleURI="http://www.waldencast.com/role/REVENUENarrativeDetails">
        <link:definition>9954507 - Disclosure - REVENUE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERevenuebyGeographicRegionDetails" roleURI="http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails">
        <link:definition>9954508 - Disclosure - REVENUE - Revenue by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLScheduleofGoodwillDetails" roleURI="http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails">
        <link:definition>9954509 - Disclosure - GOODWILL - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLNarrativeDetails" roleURI="http://www.waldencast.com/role/GOODWILLNarrativeDetails">
        <link:definition>9954510 - Disclosure - GOODWILL - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" roleURI="http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails">
        <link:definition>9954511 - Disclosure - INTANGIBLE ASSETS&#8212;NET - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSNETNarrativeDetails" roleURI="http://www.waldencast.com/role/INTANGIBLEASSETSNETNarrativeDetails">
        <link:definition>9954512 - Disclosure - INTANGIBLE ASSETS&#8212;NET - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSNETExpectedAmortizationDetails" roleURI="http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails">
        <link:definition>9954513 - Disclosure - INTANGIBLE ASSETS&#8212;NET - Expected Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTLongtermDebtDetails" roleURI="http://www.waldencast.com/role/DEBTLongtermDebtDetails">
        <link:definition>9954514 - Disclosure - DEBT - Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTLongtermDebtDetails_1" roleURI="http://www.waldencast.com/role/DEBTLongtermDebtDetails_1">
        <link:definition>9954514 - Disclosure - DEBT - Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTNarrativeDetails" roleURI="http://www.waldencast.com/role/DEBTNarrativeDetails">
        <link:definition>9954515 - Disclosure - DEBT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTScheduledMaturitiesDetails" roleURI="http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails">
        <link:definition>9954516 - Disclosure - DEBT - Scheduled Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://www.waldencast.com/role/LEASESNarrativeDetails">
        <link:definition>9954517 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESSupplementalCashFlowInformationDetails" roleURI="http://www.waldencast.com/role/LEASESSupplementalCashFlowInformationDetails">
        <link:definition>9954518 - Disclosure - LEASES - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESOperatingLeaseMaturityScheduleDetails" roleURI="http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails">
        <link:definition>9954519 - Disclosure - LEASES - Operating Lease Maturity Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESOperatingLeaseMaturityScheduleDetails_1" roleURI="http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails_1">
        <link:definition>9954519 - Disclosure - LEASES - Operating Lease Maturity Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details" roleURI="http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details">
        <link:definition>9954520 - Disclosure - LEASES - Operating Lease Maturity Schedule Prior to the Adoption of ASC 842 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCIALINSTRUMENTSDetails" roleURI="http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails">
        <link:definition>9954521 - Disclosure - FINANCIAL INSTRUMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSDetails" roleURI="http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails">
        <link:definition>9954522 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails" roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails">
        <link:definition>9954523 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails" roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails">
        <link:definition>9954524 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Change in Allowance for Doubtful Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails" roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails">
        <link:definition>9954525 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails">
        <link:definition>9954526 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails">
        <link:definition>9954527 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>9954528 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONStockOptionActivityDetails" roleURI="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails">
        <link:definition>9954529 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails" roleURI="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails">
        <link:definition>9954530 - Disclosure - STOCK-BASED COMPENSATION - Fair Value of Stock Options Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" roleURI="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails">
        <link:definition>9954531 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREHOLDERSEQUITYDetails" roleURI="http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails">
        <link:definition>9954532 - Disclosure - SHAREHOLDERS&#8217; EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails" roleURI="http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails">
        <link:definition>9954533 - Disclosure - NET LOSS PER SHARE - Basic and Diluted Net Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" roleURI="http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
        <link:definition>9954534 - Disclosure - NET LOSS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXBENEFITNarrativeDetails" roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails">
        <link:definition>9954535 - Disclosure - INCOME TAX BENEFIT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails" roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails">
        <link:definition>9954536 - Disclosure - INCOME TAX BENEFIT - Schedule of Consolidated Pretax Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails" roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails">
        <link:definition>9954537 - Disclosure - INCOME TAX BENEFIT - Schedule of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails" roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails">
        <link:definition>9954538 - Disclosure - INCOME TAX BENEFIT - Schedule of Components of Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails">
        <link:definition>9954539 - Disclosure - INCOME TAX BENEFIT - Summary of Deferred Tax Assets and Deferred Tax Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails" roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails">
        <link:definition>9954540 - Disclosure - INCOME TAX BENEFIT - Summary of Net Operating Losses and Tax Credit Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>9954541 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>9954542 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTREPORTINGNarrativeDetails" roleURI="http://www.waldencast.com/role/SEGMENTREPORTINGNarrativeDetails">
        <link:definition>9954543 - Disclosure - SEGMENT REPORTING - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" roleURI="http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails">
        <link:definition>9954544 - Disclosure - SEGMENT REPORTING - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTREPORTINGReconciliationofSegmentGrossProfittoNetIncomeLossBeforeIncomeTaxesDetails" roleURI="http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentGrossProfittoNetIncomeLossBeforeIncomeTaxesDetails">
        <link:definition>9954545 - Disclosure - SEGMENT REPORTING - Reconciliation of Segment Gross Profit to Net Income (Loss) Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANDetails" roleURI="http://www.waldencast.com/role/EMPLOYEEBENEFITPLANDetails">
        <link:definition>9954546 - Disclosure - EMPLOYEE BENEFIT PLAN (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>9954547 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails" roleURI="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails">
        <link:definition>9954548 - Disclosure - SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails" roleURI="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails">
        <link:definition>9954549 - Disclosure - SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails" roleURI="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails">
        <link:definition>9954550 - Disclosure - SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Cash Flow (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="wald_ApplicableRateMember" abstract="true" name="ApplicableRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_BusinessAcquisitionEarnoutPeriod" abstract="false" name="BusinessAcquisitionEarnoutPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_ShippingAndHandlingCosts" abstract="false" name="ShippingAndHandlingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember" abstract="true" name="MisstatementOfCapitalizedInternalUseSoftwareCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_A2022IncentiveAwardPlanMember" abstract="true" name="A2022IncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember" abstract="true" name="MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements" abstract="false" name="StockIssuedDuringPeriodSharesForeignPurchaseAgreements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember" abstract="true" name="BurwellMountainTrustAndZenoInvestmentMasterFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_CustomerTwoMember" abstract="true" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_A2021RevolvingCreditFacilityMember" abstract="true" name="A2021RevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_ShareBasedPaymentArrangementFounderMember" abstract="true" name="ShareBasedPaymentArrangementFounderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent" abstract="false" name="BusinessAcquisitionProFormaNetIncomeLossAttributableToParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_MilkTransactionMember" abstract="true" name="MilkTransactionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_DistributionToShareholderForDispositionOfBusiness" abstract="false" name="DistributionToShareholderForDispositionOfBusiness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="wald_RoyaltyPercentageOfGrossSales" abstract="false" name="RoyaltyPercentageOfGrossSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements" abstract="false" name="StockIssuedDuringPeriodValueForeignPurchaseAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination" abstract="false" name="ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_FormulationsMember" abstract="true" name="FormulationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_CustomerPaymentPeriod" abstract="false" name="CustomerPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_ObagiMergerMember" abstract="true" name="ObagiMergerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="wald_SponsorWarrantsMember" abstract="true" name="SponsorWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_DeferredTaxAssetsNetBeforeValuationAllowance" abstract="false" name="DeferredTaxAssetsNetBeforeValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember" abstract="true" name="MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_DeferredTaxAssetsFormationCosts" abstract="false" name="DeferredTaxAssetsFormationCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_ForwardPurchaseAgreementHurdleRate" abstract="false" name="ForwardPurchaseAgreementHurdleRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum" abstract="false" name="RecognitionPeriodForDeferredAdvertisingCostsMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_MisstatementOfRevenueRecognitionTimingMember" abstract="true" name="MisstatementOfRevenueRecognitionTimingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_StockIssuedDuringPeriodValueSubscriptionAgreements" abstract="false" name="StockIssuedDuringPeriodValueSubscriptionAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_InventoryPurchasesMember" abstract="true" name="InventoryPurchasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_ObagiAndMilkBusinessCombinationsMember" abstract="true" name="ObagiAndMilkBusinessCombinationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors" abstract="false" name="MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="wald_ProceedsFromTrustAccount" abstract="false" name="ProceedsFromTrustAccount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_PhysicianChannelProviderMember" abstract="true" name="PhysicianChannelProviderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_AdvancesForNoteReceivable" abstract="false" name="AdvancesForNoteReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_ClassOfWarrantOrRightRedemptionTradingPeriod" abstract="false" name="ClassOfWarrantOrRightRedemptionTradingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_SADistributorMember" abstract="true" name="SADistributorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_LimitedPartnershipUnitsMember" abstract="true" name="LimitedPartnershipUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_MisstatementOfResearchAndDevelopmentExpenseMember" abstract="true" name="MisstatementOfResearchAndDevelopmentExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_CustomerThreeMember" abstract="true" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_VariableRateComponentOneMember" abstract="true" name="VariableRateComponentOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_LineOfCreditCovenantTermsMinimumLiquidity" abstract="false" name="LineOfCreditCovenantTermsMinimumLiquidity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_ObagiCosmeceuticalsLLCMember" abstract="true" name="ObagiCosmeceuticalsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_StockIssuedDuringPeriodValueTrustProceeds" abstract="false" name="StockIssuedDuringPeriodValueTrustProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="wald_SponsorAndInvestorDirectorsMember" abstract="true" name="SponsorAndInvestorDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_ObagiSkincareMember" abstract="true" name="ObagiSkincareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_NumberOfLeaseAgreements" abstract="false" name="NumberOfLeaseAgreements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="wald_FounderAwardsMember" abstract="true" name="FounderAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_MisstatementOfDistributorServiceFeesMember" abstract="true" name="MisstatementOfDistributorServiceFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_StockIssuedDuringPeriodSharesSubscriptionAgreements" abstract="false" name="StockIssuedDuringPeriodSharesSubscriptionAgreements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="wald_PPPLoanMember" abstract="true" name="PPPLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_GondolasMember" abstract="true" name="GondolasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_PublicWarrantsMember" abstract="true" name="PublicWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_AaronChatterleyMember" abstract="true" name="AaronChatterleyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_ReplacementAwardsMember" abstract="true" name="ReplacementAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_ConversionOfStockToCommonStockConversionRatio" abstract="false" name="ConversionOfStockToCommonStockConversionRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="wald_LesseeOperatingLeaseExtensionTerm" abstract="false" name="LesseeOperatingLeaseExtensionTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_DeferredTaxAssetsBelowMarketLeaseContract" abstract="false" name="DeferredTaxAssetsBelowMarketLeaseContract" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties" abstract="false" name="DeferredTaxAssetsAccruedInterestToForeignRelatedParties" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_MisstatementOfInventoryMember" abstract="true" name="MisstatementOfInventoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_USOnlineMarketplaceDistributorAndSADistributorMember" abstract="true" name="USOnlineMarketplaceDistributorAndSADistributorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_SponsorMember" abstract="true" name="SponsorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_OperatingExpensesAndCostOfGoodSold" abstract="false" name="OperatingExpensesAndCostOfGoodSold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_LongTermIncentiveAwardsMember" abstract="true" name="LongTermIncentiveAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_IndemnificationAgreementAdvanceExpensePeriod" abstract="false" name="IndemnificationAgreementAdvanceExpensePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_VariableRateComponentAxis" abstract="true" name="VariableRateComponentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="wald_SecuredOvernightFinancingRateSOFRMember" abstract="true" name="SecuredOvernightFinancingRateSOFRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_NonCashLossFromChangeInFairValueOnInterestRateCollar" abstract="false" name="NonCashLossFromChangeInFairValueOnInterestRateCollar" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays" abstract="false" name="ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="wald_AccruedSalesReturnsAndDamagesCurrent" abstract="false" name="AccruedSalesReturnsAndDamagesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_ClassOfWarrantOrRightRedemptionPricePerShare" abstract="false" name="ClassOfWarrantOrRightRedemptionPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="wald_GainLossOnNoteReceivableWriteoff" abstract="false" name="GainLossOnNoteReceivableWriteoff" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_VietnamPurchaseAgreementMember" abstract="true" name="VietnamPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="wald_ObagiChinaBusinessMember" abstract="true" name="ObagiChinaBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_VariableRateComponentTwoMember" abstract="true" name="VariableRateComponentTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember" abstract="true" name="MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock" abstract="false" name="SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="wald_RestOfTheWorldMember" abstract="true" name="RestOfTheWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_SkintrinsiqDevicesMember" abstract="true" name="SkintrinsiqDevicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_VendorTwoMember" abstract="true" name="VendorTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_ForwardPurchaseAgreementMember" abstract="true" name="ForwardPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_OtherMisstatementAdjustmentsMember" abstract="true" name="OtherMisstatementAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_A2022RevolvingCreditFacilityMember" abstract="true" name="A2022RevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="wald_A2022TermLoanMember" abstract="true" name="A2022TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_PrivateDerivativeWarrantLiabilitiesMember" abstract="true" name="PrivateDerivativeWarrantLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember" abstract="true" name="MisstatementOfDistributorRevenueNonstandardPaymentTermsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember" abstract="true" name="MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger" abstract="false" name="ClassOfWarrantOrRightRedemptionStockPriceTrigger" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost" abstract="false" name="ShareBasedPaymentArrangementBusinessCombinationIncrementalCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_CapitalContribution" abstract="false" name="CapitalContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_ObagiBlueSeaHoldingLLCMember" abstract="true" name="ObagiBlueSeaHoldingLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_ProceedsFromForwardPurchaseAgreements" abstract="false" name="ProceedsFromForwardPurchaseAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="wald_DeferredTaxAssetsTransactionCosts" abstract="false" name="DeferredTaxAssetsTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_PrivatePlacementWarrantsMember" abstract="true" name="PrivatePlacementWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties" abstract="false" name="IncreaseDecreaseInAccountsPayableExcludingRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_DepreciationDepletionAndAmortizationOperatingActivities" abstract="false" name="DepreciationDepletionAndAmortizationOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_ClassOfWarrantOrRightRedemptionPeriod" abstract="false" name="ClassOfWarrantOrRightRedemptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_NumberOfNominatedDirectors" abstract="false" name="NumberOfNominatedDirectors" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="wald_MisstatementOfCapitalizedMarketingExpensesMember" abstract="true" name="MisstatementOfCapitalizedMarketingExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_StockholdersEquityNumberOfSharesInEachUnit" abstract="false" name="StockholdersEquityNumberOfSharesInEachUnit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice" abstract="false" name="ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_NonConvertibleWorkingCapitalNotesMember" abstract="true" name="NonConvertibleWorkingCapitalNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_GainOnPPPLoanForgiveness" abstract="false" name="GainOnPPPLoanForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_WaldencastPlcMember" abstract="true" name="WaldencastPlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_TransitionServicesAgreementExtensionPeriod" abstract="false" name="TransitionServicesAgreementExtensionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_InvestorDirectorsMember" abstract="true" name="InvestorDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest" abstract="false" name="BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_ComputerHardwareSoftwareAndEquipmentMember" abstract="true" name="ComputerHardwareSoftwareAndEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_ServicesAgreementFeePercentageOfIncurredCosts" abstract="false" name="ServicesAgreementFeePercentageOfIncurredCosts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="wald_AccruedDistributionFeesCurrent" abstract="false" name="AccruedDistributionFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays" abstract="false" name="ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="wald_ConvertibleWorkingCapitalNoteMember" abstract="true" name="ConvertibleWorkingCapitalNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_VariableRateComponentDomain" abstract="true" name="VariableRateComponentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_OneTimStockGrantMember" abstract="true" name="OneTimStockGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_BeautyVenturesLLCMember" abstract="true" name="BeautyVenturesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_ObagiShanghaiMember" abstract="true" name="ObagiShanghaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_PrepaidExpensesPolicyTextBlock" abstract="false" name="PrepaidExpensesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="wald_A2021TermLoanMember" abstract="true" name="A2021TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_TretinoinDistributionAndSupplyAgreementMember" abstract="true" name="TretinoinDistributionAndSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_USOnlineMarketplaceDistributorMember" abstract="true" name="USOnlineMarketplaceDistributorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_SpaChannelDistributorMember" abstract="true" name="SpaChannelDistributorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" abstract="false" name="ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="wald_PaymentsOfExpensesOnBehalfOfSubsidiaries" abstract="false" name="PaymentsOfExpensesOnBehalfOfSubsidiaries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod" abstract="false" name="ForwardPurchaseAgreementHurdleRateAccrualPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_JanuaryNoteMember" abstract="true" name="JanuaryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_DistributionOfBusiness" abstract="false" name="DistributionOfBusiness" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember" abstract="true" name="MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember" abstract="true" name="MisstatementOfCapitalizedComputerSoftwareExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt" abstract="false" name="BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_MinimumThresholdPeriodForContractRepaymentOverTime" abstract="false" name="MinimumThresholdPeriodForContractRepaymentOverTime" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_MilkMakeupMember" abstract="true" name="MilkMakeupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_StockGrowthIncentiveAwardsSGIAwardsMember" abstract="true" name="StockGrowthIncentiveAwardsSGIAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_IntercompanyPayables" abstract="false" name="IntercompanyPayables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_MilkMember" abstract="true" name="MilkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_DebtInstrumentCovenantLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="wald_AlternateBaseRateMember" abstract="true" name="AlternateBaseRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_A2018RevolvingCreditFacilityMember" abstract="true" name="A2018RevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod" abstract="false" name="ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_PublicDerivativeWarrantLiabilitiesMember" abstract="true" name="PublicDerivativeWarrantLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption" abstract="false" name="ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_TransitionServicesAgreementPeriod" abstract="false" name="TransitionServicesAgreementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage" abstract="false" name="ForwardPurchaseAgreementPerformanceFeeAllocationPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_VariableRateComponentThreeMember" abstract="true" name="VariableRateComponentThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays" abstract="false" name="ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_PredecessorIncentivePlanMember" abstract="true" name="PredecessorIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_ServicesAgreementRenewalTerm" abstract="false" name="ServicesAgreementRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="wald_PaymentsForServicesAgreementFees" abstract="false" name="PaymentsForServicesAgreementFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_MisstatementOfAccruedDistributionServiceFeesMember" abstract="true" name="MisstatementOfAccruedDistributionServiceFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_InterestRateCollarMember" abstract="true" name="InterestRateCollarMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_VendorOneMember" abstract="true" name="VendorOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_NumberOfOperatingLeases" abstract="false" name="NumberOfOperatingLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="wald_AmortizationOfRelatedPartyLiability" abstract="false" name="AmortizationOfRelatedPartyLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="wald_A2018TermLoanMember" abstract="true" name="A2018TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent" abstract="false" name="AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_StockIssuedDuringPeriodSharesTrustProceeds" abstract="false" name="StockIssuedDuringPeriodSharesTrustProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="wald_CommonStockConvertibleConversionRatio" abstract="false" name="CommonStockConvertibleConversionRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="wald_A2022CreditAgreementMember" abstract="true" name="A2022CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="wald_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationTrueUpsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="wald_InvestmentInSubsidiary" abstract="false" name="InvestmentInSubsidiary" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember" abstract="true" name="MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="wald_VendorThreeMember" abstract="true" name="VendorThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="wald_CedarwalkMember" abstract="true" name="CedarwalkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>wald-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cb24ed7e-6299-4643-a980-910da3dfa7bf,g:f940d8a8-f49a-452c-b5e1-83817ee3c0b3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="wald-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_708da656-7951-4573-b403-2a495a9056b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b1c7efbd-74a3-4c59-9027-632ac894e4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_708da656-7951-4573-b403-2a495a9056b0" xlink:to="loc_us-gaap_AssetsCurrent_b1c7efbd-74a3-4c59-9027-632ac894e4cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3a4b3b18-377f-40f9-8ca4-4b790f57a046" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_708da656-7951-4573-b403-2a495a9056b0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3a4b3b18-377f-40f9-8ca4-4b790f57a046" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_13e6824c-1693-4567-bd7e-f6cf6b54aa3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_708da656-7951-4573-b403-2a495a9056b0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_13e6824c-1693-4567-bd7e-f6cf6b54aa3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bf050e62-3ac4-40de-943a-9aa1d7ff2ece" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_708da656-7951-4573-b403-2a495a9056b0" xlink:to="loc_us-gaap_Goodwill_bf050e62-3ac4-40de-943a-9aa1d7ff2ece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f2aebf1a-e99c-40f2-aef5-c556e0a33641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_708da656-7951-4573-b403-2a495a9056b0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f2aebf1a-e99c-40f2-aef5-c556e0a33641" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_00e1759c-7841-42d9-8236-36138d31bb01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_708da656-7951-4573-b403-2a495a9056b0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_00e1759c-7841-42d9-8236-36138d31bb01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_090664e4-9dc0-4acf-a287-16e335c1600f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_627172a0-ee5a-455c-afec-304dd7c2a2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_090664e4-9dc0-4acf-a287-16e335c1600f" xlink:to="loc_us-gaap_MinorityInterest_627172a0-ee5a-455c-afec-304dd7c2a2b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0747e5ef-b1e2-4d81-a183-37f3d32da094" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_090664e4-9dc0-4acf-a287-16e335c1600f" xlink:to="loc_us-gaap_StockholdersEquity_0747e5ef-b1e2-4d81-a183-37f3d32da094" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_07e10076-0fa8-4289-879b-5fcd92706658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_910f0151-4bc1-4437-80b1-f00904ea189b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_07e10076-0fa8-4289-879b-5fcd92706658" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_910f0151-4bc1-4437-80b1-f00904ea189b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_e4aa1713-a874-4f50-900f-4dcceeab4f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_07e10076-0fa8-4289-879b-5fcd92706658" xlink:to="loc_us-gaap_OtherAssetsCurrent_e4aa1713-a874-4f50-900f-4dcceeab4f9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a93219ba-626e-4d87-80a8-2bff7b57a9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_07e10076-0fa8-4289-879b-5fcd92706658" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a93219ba-626e-4d87-80a8-2bff7b57a9a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b95ffa45-9f51-4734-8336-debdcdbc886e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_07e10076-0fa8-4289-879b-5fcd92706658" xlink:to="loc_us-gaap_InventoryNet_b95ffa45-9f51-4734-8336-debdcdbc886e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5c176693-16f3-42cc-b0cb-ec6a9cab671b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_07e10076-0fa8-4289-879b-5fcd92706658" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_5c176693-16f3-42cc-b0cb-ec6a9cab671b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_1a3a4c4f-68ef-48a6-9590-b6bdb2649884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_07e10076-0fa8-4289-879b-5fcd92706658" xlink:to="loc_us-gaap_RestrictedCash_1a3a4c4f-68ef-48a6-9590-b6bdb2649884" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_73462e92-9537-46ff-9bde-e16772336d97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_52919759-89e8-4379-8a6e-3e1228597eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_73462e92-9537-46ff-9bde-e16772336d97" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_52919759-89e8-4379-8a6e-3e1228597eb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f56d7d02-772b-4b6e-8342-f2e089e2fff6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_73462e92-9537-46ff-9bde-e16772336d97" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f56d7d02-772b-4b6e-8342-f2e089e2fff6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_44c5ee0f-364b-441c-b3b6-10373a746b56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_73462e92-9537-46ff-9bde-e16772336d97" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_44c5ee0f-364b-441c-b3b6-10373a746b56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_790f1e2f-d884-459e-9a01-420ead65b615" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_73462e92-9537-46ff-9bde-e16772336d97" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_790f1e2f-d884-459e-9a01-420ead65b615" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_23e32a46-7229-43a5-8c78-9c20426ee5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_73462e92-9537-46ff-9bde-e16772336d97" xlink:to="loc_us-gaap_LiabilitiesCurrent_23e32a46-7229-43a5-8c78-9c20426ee5fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_57240733-2bbc-4144-9386-707f26f09312" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_73462e92-9537-46ff-9bde-e16772336d97" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_57240733-2bbc-4144-9386-707f26f09312" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9d46a5cb-0b55-42ae-84a6-fc006e471a83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f096a500-986d-42e1-aebb-6b2ce02e7436" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9d46a5cb-0b55-42ae-84a6-fc006e471a83" xlink:to="loc_us-gaap_LongTermDebtCurrent_f096a500-986d-42e1-aebb-6b2ce02e7436" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a1e5e3c7-2a93-4d13-933d-54b113c821a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9d46a5cb-0b55-42ae-84a6-fc006e471a83" xlink:to="loc_us-gaap_AccountsPayableCurrent_a1e5e3c7-2a93-4d13-933d-54b113c821a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_540f1136-a594-42cb-8836-d116a724a318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9d46a5cb-0b55-42ae-84a6-fc006e471a83" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_540f1136-a594-42cb-8836-d116a724a318" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_11b09420-a54b-4410-b4cc-4e820047485c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9d46a5cb-0b55-42ae-84a6-fc006e471a83" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_11b09420-a54b-4410-b4cc-4e820047485c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f22defe5-2e78-4c32-ab01-54c3a5c046be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7fa73b88-898e-476f-928a-ee7fa67e22d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f22defe5-2e78-4c32-ab01-54c3a5c046be" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7fa73b88-898e-476f-928a-ee7fa67e22d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_843d88d8-2e33-4311-8b0c-08d7db749ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f22defe5-2e78-4c32-ab01-54c3a5c046be" xlink:to="loc_us-gaap_Liabilities_843d88d8-2e33-4311-8b0c-08d7db749ed7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1fcec1ac-5fe9-4c31-b6e8-17046a2eefc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_072e71cc-3c25-4cbf-8a7a-35e90a4fc5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1fcec1ac-5fe9-4c31-b6e8-17046a2eefc5" xlink:to="loc_us-gaap_CommonStockValue_072e71cc-3c25-4cbf-8a7a-35e90a4fc5fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_879fc918-33e6-4353-a429-a01e1d168163" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1fcec1ac-5fe9-4c31-b6e8-17046a2eefc5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_879fc918-33e6-4353-a429-a01e1d168163" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2cd5e213-7e3d-4755-a201-7df42e680e99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1fcec1ac-5fe9-4c31-b6e8-17046a2eefc5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2cd5e213-7e3d-4755-a201-7df42e680e99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d176f1f7-9426-41e2-8b2d-fd67c11aa224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_1fcec1ac-5fe9-4c31-b6e8-17046a2eefc5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d176f1f7-9426-41e2-8b2d-fd67c11aa224" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="wald-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d1f6dcac-31ef-4a88-bca8-bc2ba195b82c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5ba04c61-9474-46b0-a52d-1710a6d804e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d1f6dcac-31ef-4a88-bca8-bc2ba195b82c" xlink:to="loc_us-gaap_ProfitLoss_5ba04c61-9474-46b0-a52d-1710a6d804e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_50b076a0-0a21-4182-bd57-f7035293f56e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d1f6dcac-31ef-4a88-bca8-bc2ba195b82c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_50b076a0-0a21-4182-bd57-f7035293f56e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5a26cb95-26a0-4093-ba05-cecb3afcb793" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7616f7fb-5363-4d84-8be0-0adc9d3d632f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5a26cb95-26a0-4093-ba05-cecb3afcb793" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7616f7fb-5363-4d84-8be0-0adc9d3d632f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_13f50aab-73b5-40d0-b973-544d43848d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5a26cb95-26a0-4093-ba05-cecb3afcb793" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_13f50aab-73b5-40d0-b973-544d43848d3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_52b95be9-df67-4f51-b2a6-df9a7defb771" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_87b8c2ef-c050-4ff0-a85e-61fa0b477ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_52b95be9-df67-4f51-b2a6-df9a7defb771" xlink:to="loc_us-gaap_OperatingIncomeLoss_87b8c2ef-c050-4ff0-a85e-61fa0b477ee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7874100e-079c-41bc-898f-b4d9897a66fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_52b95be9-df67-4f51-b2a6-df9a7defb771" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7874100e-079c-41bc-898f-b4d9897a66fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_6197cd87-f061-4725-a929-c89a5d09ce96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e12947b8-df90-4eb0-8ca9-c7d95745e48c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_6197cd87-f061-4725-a929-c89a5d09ce96" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e12947b8-df90-4eb0-8ca9-c7d95745e48c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_dbc320eb-b149-4be9-bb61-80c78c9c88c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_6197cd87-f061-4725-a929-c89a5d09ce96" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_dbc320eb-b149-4be9-bb61-80c78c9c88c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5c776cd6-931e-4e71-b918-7b702d7a31ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8fc520ec-8749-4160-a44e-c77984d84fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5c776cd6-931e-4e71-b918-7b702d7a31ac" xlink:to="loc_us-gaap_ProfitLoss_8fc520ec-8749-4160-a44e-c77984d84fe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a76ff666-eb5d-4adb-8346-e5f6faff84f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5c776cd6-931e-4e71-b918-7b702d7a31ac" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a76ff666-eb5d-4adb-8346-e5f6faff84f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_41f77476-5bcc-4ece-a25e-ec395179f46b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e7b943ec-c647-4489-8bc2-36460297752d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_41f77476-5bcc-4ece-a25e-ec395179f46b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e7b943ec-c647-4489-8bc2-36460297752d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7c23f83d-9b71-4ee1-b25e-aab7dce92ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_41f77476-5bcc-4ece-a25e-ec395179f46b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7c23f83d-9b71-4ee1-b25e-aab7dce92ae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_cea98760-a0f7-4ee8-a27a-a8acd8b245d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_41f77476-5bcc-4ece-a25e-ec395179f46b" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_cea98760-a0f7-4ee8-a27a-a8acd8b245d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_96e4c5b3-06f8-4ddc-8935-92c77bcb57ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cb194676-e413-48c0-8c0a-dd0fa9ce7d65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_96e4c5b3-06f8-4ddc-8935-92c77bcb57ee" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cb194676-e413-48c0-8c0a-dd0fa9ce7d65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1ad1a6ce-ae5f-4b68-a02f-7f72f3ecad5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_96e4c5b3-06f8-4ddc-8935-92c77bcb57ee" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1ad1a6ce-ae5f-4b68-a02f-7f72f3ecad5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f08544a3-5904-4e3b-9641-4976373d4c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e212c6b8-8056-46d8-8310-a5ac72957307" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f08544a3-5904-4e3b-9641-4976373d4c9c" xlink:to="loc_us-gaap_InterestExpense_e212c6b8-8056-46d8-8310-a5ac72957307" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5e2db8e5-2ce8-4362-91de-679dccac0d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f08544a3-5904-4e3b-9641-4976373d4c9c" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5e2db8e5-2ce8-4362-91de-679dccac0d5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1af91135-cd26-44c5-8421-a6ab7696df4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f08544a3-5904-4e3b-9641-4976373d4c9c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1af91135-cd26-44c5-8421-a6ab7696df4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainOnPPPLoanForgiveness_d3bf0d9a-24e1-4a8e-8df6-bb8c0d3ef822" xlink:href="wald-20221231.xsd#wald_GainOnPPPLoanForgiveness"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f08544a3-5904-4e3b-9641-4976373d4c9c" xlink:to="loc_wald_GainOnPPPLoanForgiveness_d3bf0d9a-24e1-4a8e-8df6-bb8c0d3ef822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainLossOnNoteReceivableWriteoff_76a00858-5fd7-4a46-9c67-4870372d0672" xlink:href="wald-20221231.xsd#wald_GainLossOnNoteReceivableWriteoff"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f08544a3-5904-4e3b-9641-4976373d4c9c" xlink:to="loc_wald_GainLossOnNoteReceivableWriteoff_76a00858-5fd7-4a46-9c67-4870372d0672" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5a5eaebe-d4d3-4a6d-9afe-36b1c73bf483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f08544a3-5904-4e3b-9641-4976373d4c9c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5a5eaebe-d4d3-4a6d-9afe-36b1c73bf483" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e836c0ef-aca1-4578-a2d6-3b1029e56c80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_2279949b-08f5-4dc8-ba3d-5c3aa311b419" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e836c0ef-aca1-4578-a2d6-3b1029e56c80" xlink:to="loc_us-gaap_GrossProfit_2279949b-08f5-4dc8-ba3d-5c3aa311b419" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f6d369fb-8f85-4662-aaea-439b28e9eca8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e836c0ef-aca1-4578-a2d6-3b1029e56c80" xlink:to="loc_us-gaap_OperatingExpenses_f6d369fb-8f85-4662-aaea-439b28e9eca8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="wald-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98d622ae-3a58-4298-93fd-466620c2432d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ProceedsFromTrustAccount_6b366791-8265-43ea-8bb5-cc9a1e97725a" xlink:href="wald-20221231.xsd#wald_ProceedsFromTrustAccount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98d622ae-3a58-4298-93fd-466620c2432d" xlink:to="loc_wald_ProceedsFromTrustAccount_6b366791-8265-43ea-8bb5-cc9a1e97725a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AdvancesForNoteReceivable_0806199d-a8c6-46d2-9d81-7830a58498dc" xlink:href="wald-20221231.xsd#wald_AdvancesForNoteReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98d622ae-3a58-4298-93fd-466620c2432d" xlink:to="loc_wald_AdvancesForNoteReceivable_0806199d-a8c6-46d2-9d81-7830a58498dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_58d30009-83c5-427a-947f-646b5ae76d55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98d622ae-3a58-4298-93fd-466620c2432d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_58d30009-83c5-427a-947f-646b5ae76d55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_85d88cec-f532-4905-bebf-dacdd01af8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98d622ae-3a58-4298-93fd-466620c2432d" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_85d88cec-f532-4905-bebf-dacdd01af8f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_085bc044-5128-40cc-a8f5-090bab602a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_98d622ae-3a58-4298-93fd-466620c2432d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_085bc044-5128-40cc-a8f5-090bab602a6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties_b879d8df-fcf8-4fd0-a066-b7d4af7e411d" xlink:href="wald-20221231.xsd#wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties_b879d8df-fcf8-4fd0-a066-b7d4af7e411d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c9e3e9a5-9941-41ea-8344-df78aec6bbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c9e3e9a5-9941-41ea-8344-df78aec6bbdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_cf7901e4-dcc3-4210-a8d4-eef2679e56c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_cf7901e4-dcc3-4210-a8d4-eef2679e56c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_214e4adf-cfb9-44ae-90d6-855d51abb6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_214e4adf-cfb9-44ae-90d6-855d51abb6ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_82a34840-d566-4a68-b837-3b5dd458ba6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_82a34840-d566-4a68-b837-3b5dd458ba6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9767bf81-f6b9-46cd-be2c-bda55e24074a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9767bf81-f6b9-46cd-be2c-bda55e24074a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b10a7a3c-3c0d-4ef7-88ce-7d97bd2dfaff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_us-gaap_ShareBasedCompensation_b10a7a3c-3c0d-4ef7-88ce-7d97bd2dfaff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9290d9aa-f116-44d6-b6a1-a9c9de21ee2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_us-gaap_ProfitLoss_9290d9aa-f116-44d6-b6a1-a9c9de21ee2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2df84fd1-d3f4-4104-a8a8-8028f23852eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2df84fd1-d3f4-4104-a8a8-8028f23852eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_6257d757-f075-4ffb-93d3-0e36b8d9c85c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_us-gaap_OperatingLeaseExpense_6257d757-f075-4ffb-93d3-0e36b8d9c85c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_6770d770-2c80-4a6b-8bdb-a8123df9ec1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_6770d770-2c80-4a6b-8bdb-a8123df9ec1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DepreciationDepletionAndAmortizationOperatingActivities_89277b96-7060-407b-969b-60004d7b1f56" xlink:href="wald-20221231.xsd#wald_DepreciationDepletionAndAmortizationOperatingActivities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_wald_DepreciationDepletionAndAmortizationOperatingActivities_89277b96-7060-407b-969b-60004d7b1f56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cd78a0f1-1b00-43a0-8867-af3d288b796b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cd78a0f1-1b00-43a0-8867-af3d288b796b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_4ca85ae3-b1d2-40d7-9ff1-f3d0a02d6a01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_4ca85ae3-b1d2-40d7-9ff1-f3d0a02d6a01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_NonCashLossFromChangeInFairValueOnInterestRateCollar_be8ad19d-63a2-4a0e-ad02-9db5de4cc326" xlink:href="wald-20221231.xsd#wald_NonCashLossFromChangeInFairValueOnInterestRateCollar"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_wald_NonCashLossFromChangeInFairValueOnInterestRateCollar_be8ad19d-63a2-4a0e-ad02-9db5de4cc326" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_55f2a986-0713-47aa-a872-8c855244c843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_55f2a986-0713-47aa-a872-8c855244c843" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainLossOnNoteReceivableWriteoff_a02b846d-fa9b-408b-8df6-4f4ec815173c" xlink:href="wald-20221231.xsd#wald_GainLossOnNoteReceivableWriteoff"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_wald_GainLossOnNoteReceivableWriteoff_a02b846d-fa9b-408b-8df6-4f4ec815173c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_ff82e4e8-f1a7-44ed-829b-4f7b365016b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_ff82e4e8-f1a7-44ed-829b-4f7b365016b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b56fdb87-32e4-4e91-9356-3fc9783c1d38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b56fdb87-32e4-4e91-9356-3fc9783c1d38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_2921fdf4-549d-4665-b2c7-3be88dd47f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_2921fdf4-549d-4665-b2c7-3be88dd47f0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AmortizationOfRelatedPartyLiability_689222df-5361-4d1e-addb-87bd3948ccca" xlink:href="wald-20221231.xsd#wald_AmortizationOfRelatedPartyLiability"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_wald_AmortizationOfRelatedPartyLiability_689222df-5361-4d1e-addb-87bd3948ccca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_74ac02c7-5942-40af-89d2-089438b49546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="22" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_74ac02c7-5942-40af-89d2-089438b49546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainOnPPPLoanForgiveness_9227094b-b6a7-4d6a-9616-f189e5b39654" xlink:href="wald-20221231.xsd#wald_GainOnPPPLoanForgiveness"/>
    <link:calculationArc order="23" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94e7e91f-25ed-46db-b6c7-fedd6f4328ec" xlink:to="loc_wald_GainOnPPPLoanForgiveness_9227094b-b6a7-4d6a-9616-f189e5b39654" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_8e8ed5ea-7d39-45ff-a3c8-1ffe9b251d23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0533b958-62e3-409f-bf83-4c948b407f62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_8e8ed5ea-7d39-45ff-a3c8-1ffe9b251d23" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0533b958-62e3-409f-bf83-4c948b407f62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59036630-ccca-4094-bf42-d35f6a5732e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_8e8ed5ea-7d39-45ff-a3c8-1ffe9b251d23" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59036630-ccca-4094-bf42-d35f6a5732e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_329748ba-1d5b-4052-8460-6853237f8f89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_8e8ed5ea-7d39-45ff-a3c8-1ffe9b251d23" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_329748ba-1d5b-4052-8460-6853237f8f89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_05f37eab-a616-44f0-bf23-85e5774df4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_ecbf9e4a-ee8c-4583-8862-debd43014b81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_05f37eab-a616-44f0-bf23-85e5774df4c8" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_ecbf9e4a-ee8c-4583-8862-debd43014b81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_942eae49-0f9b-4897-8b13-0e8a12d35d51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_05f37eab-a616-44f0-bf23-85e5774df4c8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_942eae49-0f9b-4897-8b13-0e8a12d35d51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_15cd4c4e-bc02-41b6-bdd5-64d3456d8c47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_05f37eab-a616-44f0-bf23-85e5774df4c8" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_15cd4c4e-bc02-41b6-bdd5-64d3456d8c47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_214638ec-7181-481c-b827-828a217cb2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_05f37eab-a616-44f0-bf23-85e5774df4c8" xlink:to="loc_us-gaap_PaymentsOfDividends_214638ec-7181-481c-b827-828a217cb2ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_01467393-e4ed-41b1-bf07-3a9fb947efcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_05f37eab-a616-44f0-bf23-85e5774df4c8" xlink:to="loc_us-gaap_RepaymentsOfDebt_01467393-e4ed-41b1-bf07-3a9fb947efcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_cad57fa4-249b-4e56-b952-a51651daa3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_05f37eab-a616-44f0-bf23-85e5774df4c8" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_cad57fa4-249b-4e56-b952-a51651daa3eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherDebt_04874e32-88cb-41a0-a840-68a19c629454" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherDebt"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_05f37eab-a616-44f0-bf23-85e5774df4c8" xlink:to="loc_us-gaap_ProceedsFromOtherDebt_04874e32-88cb-41a0-a840-68a19c629454" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_912a4f32-22aa-4c10-a595-ec75f66ec050" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_05f37eab-a616-44f0-bf23-85e5774df4c8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_912a4f32-22aa-4c10-a595-ec75f66ec050" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ProceedsFromForwardPurchaseAgreements_8b6564af-9171-420d-9a33-5eb1abcd64ad" xlink:href="wald-20221231.xsd#wald_ProceedsFromForwardPurchaseAgreements"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_05f37eab-a616-44f0-bf23-85e5774df4c8" xlink:to="loc_wald_ProceedsFromForwardPurchaseAgreements_8b6564af-9171-420d-9a33-5eb1abcd64ad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_11cd3831-f7b2-4544-bc3d-5134f409237e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ff198fec-03ca-4a3d-ba68-7091b6643f93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11cd3831-f7b2-4544-bc3d-5134f409237e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ff198fec-03ca-4a3d-ba68-7091b6643f93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cc3c0e9c-dbbd-47e4-acdf-572dbe7bdcdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11cd3831-f7b2-4544-bc3d-5134f409237e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cc3c0e9c-dbbd-47e4-acdf-572dbe7bdcdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5ab7e075-fdda-457a-846b-9adfd0b176f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_11cd3831-f7b2-4544-bc3d-5134f409237e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5ab7e075-fdda-457a-846b-9adfd0b176f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OperatingExpensesAndCostOfGoodSold_8bbff089-7d6b-423f-889a-8b5f748a12c4" xlink:href="wald-20221231.xsd#wald_OperatingExpensesAndCostOfGoodSold"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7098288d-fb1a-42c2-8a03-c9290230db7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_wald_OperatingExpensesAndCostOfGoodSold_8bbff089-7d6b-423f-889a-8b5f748a12c4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7098288d-fb1a-42c2-8a03-c9290230db7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f4f01f65-a1ec-4b99-bea5-11cb93da67ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_wald_OperatingExpensesAndCostOfGoodSold_8bbff089-7d6b-423f-889a-8b5f748a12c4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f4f01f65-a1ec-4b99-bea5-11cb93da67ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_95f36cb9-194a-4f78-bf06-897933191a18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_wald_OperatingExpensesAndCostOfGoodSold_8bbff089-7d6b-423f-889a-8b5f748a12c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_95f36cb9-194a-4f78-bf06-897933191a18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_36572bfd-dadc-4caa-aa64-e914ecdebe29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_wald_OperatingExpensesAndCostOfGoodSold_8bbff089-7d6b-423f-889a-8b5f748a12c4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_36572bfd-dadc-4caa-aa64-e914ecdebe29" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e44ea8bb-d12c-43ca-aa35-eafff5bea86c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_908691ff-4ef1-4de9-a57c-ce6f55e73aae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e44ea8bb-d12c-43ca-aa35-eafff5bea86c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_908691ff-4ef1-4de9-a57c-ce6f55e73aae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_101fafdd-3a2e-41d4-966d-45465ca56bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e44ea8bb-d12c-43ca-aa35-eafff5bea86c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_101fafdd-3a2e-41d4-966d-45465ca56bf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt_fa3e2a35-2faa-44ee-b7cd-975e440f1280" xlink:href="wald-20221231.xsd#wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e44ea8bb-d12c-43ca-aa35-eafff5bea86c" xlink:to="loc_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt_fa3e2a35-2faa-44ee-b7cd-975e440f1280" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_75ce074c-5b20-4f42-a2ea-9cf5b4ddb445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_e44ea8bb-d12c-43ca-aa35-eafff5bea86c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_75ce074c-5b20-4f42-a2ea-9cf5b4ddb445" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_426aa8e0-367e-47e3-a7c5-dd52d9c5aca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a02821b6-2727-43df-bbfe-a57ac2b95e47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_426aa8e0-367e-47e3-a7c5-dd52d9c5aca7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a02821b6-2727-43df-bbfe-a57ac2b95e47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3b0b034e-d594-4c57-9efb-46f9e914f229" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_426aa8e0-367e-47e3-a7c5-dd52d9c5aca7" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3b0b034e-d594-4c57-9efb-46f9e914f229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_d7a207c7-2ee2-4b3a-aa55-62891008eecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty_e6f94558-055a-4bd6-bb88-48ec887333b4" xlink:href="wald-20221231.xsd#wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_d7a207c7-2ee2-4b3a-aa55-62891008eecc" xlink:to="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty_e6f94558-055a-4bd6-bb88-48ec887333b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d9cf6700-f972-4e29-873e-7c9b7002ab82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_d7a207c7-2ee2-4b3a-aa55-62891008eecc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d9cf6700-f972-4e29-873e-7c9b7002ab82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1d299817-d768-41d2-bf17-0dd84d259cca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_d7a207c7-2ee2-4b3a-aa55-62891008eecc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_1d299817-d768-41d2-bf17-0dd84d259cca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_8ce5263a-fc14-46bb-b95a-218bd454f012" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_d7a207c7-2ee2-4b3a-aa55-62891008eecc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_8ce5263a-fc14-46bb-b95a-218bd454f012" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ba0b3723-8db5-4adc-b19c-8501cdc77347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_d7a207c7-2ee2-4b3a-aa55-62891008eecc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_ba0b3723-8db5-4adc-b19c-8501cdc77347" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_7d04c26c-8929-475e-8130-05df29b59ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_d7a207c7-2ee2-4b3a-aa55-62891008eecc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_7d04c26c-8929-475e-8130-05df29b59ffd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e2ba4025-40f9-46e8-98a0-13a586732330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_d7a207c7-2ee2-4b3a-aa55-62891008eecc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e2ba4025-40f9-46e8-98a0-13a586732330" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets_cb98fc02-6453-480b-85fa-4fde7f2aeaa6" xlink:href="wald-20221231.xsd#wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_d7a207c7-2ee2-4b3a-aa55-62891008eecc" xlink:to="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets_cb98fc02-6453-480b-85fa-4fde7f2aeaa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_3b1f34dd-b436-45f2-8a2a-3aafd03decd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_d7a207c7-2ee2-4b3a-aa55-62891008eecc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_3b1f34dd-b436-45f2-8a2a-3aafd03decd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_386d5cfc-bd4a-499f-b370-12baa9774d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_d7a207c7-2ee2-4b3a-aa55-62891008eecc" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_386d5cfc-bd4a-499f-b370-12baa9774d2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_4e012f62-cf71-432b-9be4-8b0d3241fed4" xlink:href="wald-20221231.xsd#wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_d7a207c7-2ee2-4b3a-aa55-62891008eecc" xlink:to="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_4e012f62-cf71-432b-9be4-8b0d3241fed4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_4a93683c-1b53-425f-9d8c-f02f0535171a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_74c6f717-7c2a-4fe4-b65c-305935c16435" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_4a93683c-1b53-425f-9d8c-f02f0535171a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_74c6f717-7c2a-4fe4-b65c-305935c16435" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_30e62737-1793-4c2d-a69c-12fd350c4d83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_4a93683c-1b53-425f-9d8c-f02f0535171a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_30e62737-1793-4c2d-a69c-12fd350c4d83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_3b6763f8-b834-4f87-806b-3650352076bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_4a93683c-1b53-425f-9d8c-f02f0535171a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_3b6763f8-b834-4f87-806b-3650352076bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_bd00b0fe-ca96-4e57-a18e-6355a7dac674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_4a93683c-1b53-425f-9d8c-f02f0535171a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_bd00b0fe-ca96-4e57-a18e-6355a7dac674" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4a673b39-a614-4adf-a769-a2f7ff3487fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent_a730f52b-ac19-4633-b930-5447c2da6fbb" xlink:href="wald-20221231.xsd#wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4a673b39-a614-4adf-a769-a2f7ff3487fd" xlink:to="loc_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent_a730f52b-ac19-4633-b930-5447c2da6fbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest_21c2b110-c2d8-4f8a-8086-a1ee63699487" xlink:href="wald-20221231.xsd#wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_4a673b39-a614-4adf-a769-a2f7ff3487fd" xlink:to="loc_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest_21c2b110-c2d8-4f8a-8086-a1ee63699487" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a209cbdb-7efd-49ab-8e4b-1e177e9d362f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_98ca1c39-a053-45a0-8386-38eefe316f50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a209cbdb-7efd-49ab-8e4b-1e177e9d362f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_98ca1c39-a053-45a0-8386-38eefe316f50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5ecb4922-b2c4-4139-8f82-be36d904f6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a209cbdb-7efd-49ab-8e4b-1e177e9d362f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5ecb4922-b2c4-4139-8f82-be36d904f6e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#INTANGIBLEASSETSNETExpectedAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_66aea4af-2c7e-414c-be2c-270d233758ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b0e3d788-8160-4308-9b87-6aa10cd23575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_66aea4af-2c7e-414c-be2c-270d233758ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b0e3d788-8160-4308-9b87-6aa10cd23575" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_86bfc1a4-fd0c-4bfb-b2f4-999d2e005927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_66aea4af-2c7e-414c-be2c-270d233758ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_86bfc1a4-fd0c-4bfb-b2f4-999d2e005927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7cbc6b7b-d27f-4309-95a0-270990da6220" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_66aea4af-2c7e-414c-be2c-270d233758ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_7cbc6b7b-d27f-4309-95a0-270990da6220" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e53bb4fb-d47e-4626-96fb-083da454438f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_66aea4af-2c7e-414c-be2c-270d233758ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e53bb4fb-d47e-4626-96fb-083da454438f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_f11fbfea-fa01-4602-b9ac-782f2cb340b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_66aea4af-2c7e-414c-be2c-270d233758ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_f11fbfea-fa01-4602-b9ac-782f2cb340b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_6581490a-6713-4d7a-9459-7448ac5362a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_66aea4af-2c7e-414c-be2c-270d233758ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_6581490a-6713-4d7a-9459-7448ac5362a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/DEBTLongtermDebtDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#DEBTLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/DEBTLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0a97183e-0610-403d-87ad-f5bd8c593a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_caebd64e-af95-4ead-9bd6-5a2a634966a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_0a97183e-0610-403d-87ad-f5bd8c593a4a" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_caebd64e-af95-4ead-9bd6-5a2a634966a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e56e84d4-7b34-460f-a7e4-18bf4573ccd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_0a97183e-0610-403d-87ad-f5bd8c593a4a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e56e84d4-7b34-460f-a7e4-18bf4573ccd9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/DEBTLongtermDebtDetails_1" xlink:type="simple" xlink:href="wald-20221231.xsd#DEBTLongtermDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/DEBTLongtermDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ff474468-4ced-4ad7-96c0-fed5bf33abdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_6ae3f1e8-fcb8-496f-9097-d970d291228d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ff474468-4ced-4ad7-96c0-fed5bf33abdc" xlink:to="loc_us-gaap_LongTermDebtCurrent_6ae3f1e8-fcb8-496f-9097-d970d291228d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_dbf355f9-acd0-4fd4-bb52-461ca2cc01e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ff474468-4ced-4ad7-96c0-fed5bf33abdc" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_dbf355f9-acd0-4fd4-bb52-461ca2cc01e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#DEBTScheduledMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_7a3af132-96a7-4a5e-80e1-1610bbe5c8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_31866cf4-47a4-40ad-8999-6e711be8f215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_7a3af132-96a7-4a5e-80e1-1610bbe5c8c9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_31866cf4-47a4-40ad-8999-6e711be8f215" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_595bb692-3bc9-49a7-bbc4-871d1f71518c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_7a3af132-96a7-4a5e-80e1-1610bbe5c8c9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_595bb692-3bc9-49a7-bbc4-871d1f71518c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_28595e07-5148-4f25-8b8e-41cf00af5fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_7a3af132-96a7-4a5e-80e1-1610bbe5c8c9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_28595e07-5148-4f25-8b8e-41cf00af5fa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2010d7cc-b771-4351-b8cf-004a9aedff5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_7a3af132-96a7-4a5e-80e1-1610bbe5c8c9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2010d7cc-b771-4351-b8cf-004a9aedff5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_cc04e9a0-1d3a-4e27-8826-9b5b1b813088" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_7a3af132-96a7-4a5e-80e1-1610bbe5c8c9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_cc04e9a0-1d3a-4e27-8826-9b5b1b813088" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#LEASESOperatingLeaseMaturityScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4fdaea77-e053-406e-a3d9-7e9fc3e686b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6e12cac0-cded-43ff-929c-942a00ea2124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4fdaea77-e053-406e-a3d9-7e9fc3e686b4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6e12cac0-cded-43ff-929c-942a00ea2124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_df42c084-d24f-4386-a89d-fbdbb1ec176a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4fdaea77-e053-406e-a3d9-7e9fc3e686b4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_df42c084-d24f-4386-a89d-fbdbb1ec176a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bf65a254-0e6b-4db3-8a2a-315554a0006d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4fdaea77-e053-406e-a3d9-7e9fc3e686b4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bf65a254-0e6b-4db3-8a2a-315554a0006d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_88a2d5bc-ff9f-4c36-84c8-33e2e4bbf40d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4fdaea77-e053-406e-a3d9-7e9fc3e686b4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_88a2d5bc-ff9f-4c36-84c8-33e2e4bbf40d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c6d28cea-dbe0-400c-b09a-6dde3e252acb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4fdaea77-e053-406e-a3d9-7e9fc3e686b4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c6d28cea-dbe0-400c-b09a-6dde3e252acb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b7695e63-e49c-4548-be6e-dffc8a954542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4fdaea77-e053-406e-a3d9-7e9fc3e686b4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b7695e63-e49c-4548-be6e-dffc8a954542" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails_1" xlink:type="simple" xlink:href="wald-20221231.xsd#LEASESOperatingLeaseMaturityScheduleDetails_1"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_83b1bc5d-0b4a-4b5c-96bb-42a4cb06eeab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fbc8ee52-d3ed-4964-b142-b420781ab4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_83b1bc5d-0b4a-4b5c-96bb-42a4cb06eeab" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fbc8ee52-d3ed-4964-b142-b420781ab4cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_16a603d5-7682-4a1c-909b-ab7526fa98cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_83b1bc5d-0b4a-4b5c-96bb-42a4cb06eeab" xlink:to="loc_us-gaap_OperatingLeaseLiability_16a603d5-7682-4a1c-909b-ab7526fa98cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details" xlink:type="simple" xlink:href="wald-20221231.xsd#LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_b9da9455-7605-4441-a0ee-038a8a193d72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_37cc7f32-0b0b-4486-8253-336860db51a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_b9da9455-7605-4441-a0ee-038a8a193d72" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_37cc7f32-0b0b-4486-8253-336860db51a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_80a19c65-215f-4f93-83a3-b4d5dfe6a487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_b9da9455-7605-4441-a0ee-038a8a193d72" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_80a19c65-215f-4f93-83a3-b4d5dfe6a487" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_0fbc92c4-e00d-4862-94c6-714eee1a754e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_b9da9455-7605-4441-a0ee-038a8a193d72" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_0fbc92c4-e00d-4862-94c6-714eee1a754e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_4c9b7bb7-2901-4a4c-ae6d-d773f5194400" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_b9da9455-7605-4441-a0ee-038a8a193d72" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_4c9b7bb7-2901-4a4c-ae6d-d773f5194400" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_c673cdc5-6fdc-4c33-b6b2-688f638b04c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_b9da9455-7605-4441-a0ee-038a8a193d72" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_c673cdc5-6fdc-4c33-b6b2-688f638b04c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_c0fdc8af-5059-4cde-8e89-e4c545068139" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_b9da9455-7605-4441-a0ee-038a8a193d72" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_c0fdc8af-5059-4cde-8e89-e4c545068139" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2a5d499b-2e92-4232-a144-8c0108e17994" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_53899933-1b05-4f80-856f-fc20ecf85b48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_2a5d499b-2e92-4232-a144-8c0108e17994" xlink:to="loc_us-gaap_InventoryWorkInProcess_53899933-1b05-4f80-856f-fc20ecf85b48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_7951a083-f59d-4a4b-a212-b89f58a683cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_2a5d499b-2e92-4232-a144-8c0108e17994" xlink:to="loc_us-gaap_InventoryFinishedGoods_7951a083-f59d-4a4b-a212-b89f58a683cf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5f0fb7ef-eaea-4dda-9279-93aa9b9662e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7a02057b-1680-4e06-b1e7-66f8ea920153" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5f0fb7ef-eaea-4dda-9279-93aa9b9662e0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7a02057b-1680-4e06-b1e7-66f8ea920153" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5f19b453-587b-44b5-bda3-78b6ceca2638" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5f0fb7ef-eaea-4dda-9279-93aa9b9662e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5f19b453-587b-44b5-bda3-78b6ceca2638" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_e1be6a3f-36ca-48cc-9bc7-8566210d9331" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_a6a70897-87cb-4246-afbc-5b7281429fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_e1be6a3f-36ca-48cc-9bc7-8566210d9331" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_a6a70897-87cb-4246-afbc-5b7281429fd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AccruedDistributionFeesCurrent_377e245d-5177-4fe2-8861-706b426b3709" xlink:href="wald-20221231.xsd#wald_AccruedDistributionFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_e1be6a3f-36ca-48cc-9bc7-8566210d9331" xlink:to="loc_wald_AccruedDistributionFeesCurrent_377e245d-5177-4fe2-8861-706b426b3709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_ecc5ac44-2185-44bb-ba44-92c311adb672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_e1be6a3f-36ca-48cc-9bc7-8566210d9331" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_ecc5ac44-2185-44bb-ba44-92c311adb672" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AccruedSalesReturnsAndDamagesCurrent_8da9afaa-c8ac-4e8d-a3fc-824d7bc88b90" xlink:href="wald-20221231.xsd#wald_AccruedSalesReturnsAndDamagesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_e1be6a3f-36ca-48cc-9bc7-8566210d9331" xlink:to="loc_wald_AccruedSalesReturnsAndDamagesCurrent_8da9afaa-c8ac-4e8d-a3fc-824d7bc88b90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_dca28fca-6e87-44a5-9b5c-0811721cd0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_e1be6a3f-36ca-48cc-9bc7-8566210d9331" xlink:to="loc_us-gaap_AccruedSalariesCurrent_dca28fca-6e87-44a5-9b5c-0811721cd0ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_a9888010-d8b6-4692-ac6e-4e28ff473c88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cd1f397c-ba16-4771-87b4-c2c4ea715b74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_a9888010-d8b6-4692-ac6e-4e28ff473c88" xlink:to="loc_us-gaap_ProfitLoss_cd1f397c-ba16-4771-87b4-c2c4ea715b74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_09135df7-a695-4b69-bfe1-43f4ca06c0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_a9888010-d8b6-4692-ac6e-4e28ff473c88" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_09135df7-a695-4b69-bfe1-43f4ca06c0ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_978f8398-e640-470a-9d8f-a1d136209397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_a213fd72-4d43-452a-821d-3da511240d40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_978f8398-e640-470a-9d8f-a1d136209397" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_a213fd72-4d43-452a-821d-3da511240d40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f6bad3f3-ac68-4a3b-ac20-02887fb7d403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_978f8398-e640-470a-9d8f-a1d136209397" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f6bad3f3-ac68-4a3b-ac20-02887fb7d403" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_462ceb37-afd8-4282-979f-6b24d25eaf6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dc8df196-90d1-4501-b650-ecc596f7c143" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_462ceb37-afd8-4282-979f-6b24d25eaf6f" xlink:to="loc_us-gaap_ProfitLoss_dc8df196-90d1-4501-b650-ecc596f7c143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ea1c7ec5-71c7-4323-989f-bd67f7e520da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_462ceb37-afd8-4282-979f-6b24d25eaf6f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ea1c7ec5-71c7-4323-989f-bd67f7e520da" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15f1d14a-2885-417c-b0d5-3922332eeb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_45e99f85-6bc5-43f9-ad90-3c0626c6f7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15f1d14a-2885-417c-b0d5-3922332eeb3d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_45e99f85-6bc5-43f9-ad90-3c0626c6f7f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e1253e1d-e66f-4046-bb55-30bd94dbfc82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15f1d14a-2885-417c-b0d5-3922332eeb3d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e1253e1d-e66f-4046-bb55-30bd94dbfc82" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c1e578ef-22e5-409a-9fb1-85a0ea4e9f42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_44bef604-1c23-4025-b12f-ee79e0833150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c1e578ef-22e5-409a-9fb1-85a0ea4e9f42" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_44bef604-1c23-4025-b12f-ee79e0833150" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_99cd5615-7833-462d-92e8-67c9542b855c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c1e578ef-22e5-409a-9fb1-85a0ea4e9f42" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_99cd5615-7833-462d-92e8-67c9542b855c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_611451d6-09c6-4d4a-b81d-7c3b80299acc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c1e578ef-22e5-409a-9fb1-85a0ea4e9f42" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_611451d6-09c6-4d4a-b81d-7c3b80299acc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_af9a8270-1bc5-420a-9e21-8675682f95e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6ce0dd34-30cb-4e3a-81d0-4d25d3e56cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_af9a8270-1bc5-420a-9e21-8675682f95e0" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6ce0dd34-30cb-4e3a-81d0-4d25d3e56cdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3491bf73-47ef-4b97-9c37-d49d7386e7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_af9a8270-1bc5-420a-9e21-8675682f95e0" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_3491bf73-47ef-4b97-9c37-d49d7386e7d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b90b4bf0-2092-444d-840d-4b89ba8db9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_af9a8270-1bc5-420a-9e21-8675682f95e0" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_b90b4bf0-2092-444d-840d-4b89ba8db9c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ef36d575-96d8-44c3-995c-faa654d5fc07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_39ee91fb-c5cd-41ba-ab38-679b7daeaa89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ef36d575-96d8-44c3-995c-faa654d5fc07" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_39ee91fb-c5cd-41ba-ab38-679b7daeaa89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_181a58bd-b19b-4733-b676-d59519c732f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ef36d575-96d8-44c3-995c-faa654d5fc07" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_181a58bd-b19b-4733-b676-d59519c732f6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3050edc7-6302-4e42-ad65-0b7aca2e75df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4fb1072c-0c7b-4be0-b964-aff32802c5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3050edc7-6302-4e42-ad65-0b7aca2e75df" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4fb1072c-0c7b-4be0-b964-aff32802c5cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_11bb713b-ea52-47b5-b2f3-8544865afb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3050edc7-6302-4e42-ad65-0b7aca2e75df" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_11bb713b-ea52-47b5-b2f3-8544865afb6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b498781b-c7b0-4c4a-afb0-3a0db1d8a2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3050edc7-6302-4e42-ad65-0b7aca2e75df" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b498781b-c7b0-4c4a-afb0-3a0db1d8a2b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_59f1e6b8-54b4-4e51-81bc-ffa14f4b7d45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3050edc7-6302-4e42-ad65-0b7aca2e75df" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_59f1e6b8-54b4-4e51-81bc-ffa14f4b7d45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_e8833a3d-aace-429a-a615-03b84486055a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3050edc7-6302-4e42-ad65-0b7aca2e75df" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_e8833a3d-aace-429a-a615-03b84486055a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_664c155f-ff28-457c-922d-7379aa6c09ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3050edc7-6302-4e42-ad65-0b7aca2e75df" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_664c155f-ff28-457c-922d-7379aa6c09ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent_11a51d52-c922-44e5-bc5a-32190f0e831f" xlink:href="wald-20221231.xsd#wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3050edc7-6302-4e42-ad65-0b7aca2e75df" xlink:to="loc_wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent_11a51d52-c922-44e5-bc5a-32190f0e831f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_0f8418d7-8f59-4eef-80af-10fc54328032" xlink:href="wald-20221231.xsd#wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3050edc7-6302-4e42-ad65-0b7aca2e75df" xlink:to="loc_wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_0f8418d7-8f59-4eef-80af-10fc54328032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent_ed78632c-9a21-48d6-a9cc-a5085731cc0d" xlink:href="wald-20221231.xsd#wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3050edc7-6302-4e42-ad65-0b7aca2e75df" xlink:to="loc_wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent_ed78632c-9a21-48d6-a9cc-a5085731cc0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent_33f46749-0da2-41bf-807d-785a4593c208" xlink:href="wald-20221231.xsd#wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3050edc7-6302-4e42-ad65-0b7aca2e75df" xlink:to="loc_wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent_33f46749-0da2-41bf-807d-785a4593c208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_4d3a9b57-5906-45ef-aebb-b003c3c9054d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3050edc7-6302-4e42-ad65-0b7aca2e75df" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_4d3a9b57-5906-45ef-aebb-b003c3c9054d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent_1f8b9969-6f72-4805-a3b1-2b1cfd2dfe06" xlink:href="wald-20221231.xsd#wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3050edc7-6302-4e42-ad65-0b7aca2e75df" xlink:to="loc_wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent_1f8b9969-6f72-4805-a3b1-2b1cfd2dfe06" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_wald_DeferredTaxAssetsNetBeforeValuationAllowance_0d7aaad3-66a6-4804-ae75-ec2f616afed5" xlink:href="wald-20221231.xsd#wald_DeferredTaxAssetsNetBeforeValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7907c93c-5b4e-4ef3-8381-7a5fd0544019" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_wald_DeferredTaxAssetsNetBeforeValuationAllowance_0d7aaad3-66a6-4804-ae75-ec2f616afed5" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_7907c93c-5b4e-4ef3-8381-7a5fd0544019" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b04a3268-47f4-4829-92f8-8a22545a9227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_wald_DeferredTaxAssetsNetBeforeValuationAllowance_0d7aaad3-66a6-4804-ae75-ec2f616afed5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b04a3268-47f4-4829-92f8-8a22545a9227" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_72cca4bc-1ac9-4d56-add0-a9b6e4fc4402" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3bdebb92-991e-469c-832c-9a1eb8faadb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72cca4bc-1ac9-4d56-add0-a9b6e4fc4402" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3bdebb92-991e-469c-832c-9a1eb8faadb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DeferredTaxAssetsLeaseLiabilities_07c0fc1c-8abd-46a4-9404-7fd7942d189e" xlink:href="wald-20221231.xsd#wald_DeferredTaxAssetsLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72cca4bc-1ac9-4d56-add0-a9b6e4fc4402" xlink:to="loc_wald_DeferredTaxAssetsLeaseLiabilities_07c0fc1c-8abd-46a4-9404-7fd7942d189e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_27e9f894-e3ff-4334-b266-c73d5c67eeca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72cca4bc-1ac9-4d56-add0-a9b6e4fc4402" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_27e9f894-e3ff-4334-b266-c73d5c67eeca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties_4325ae58-c42d-4475-a89c-8952ff2ed621" xlink:href="wald-20221231.xsd#wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72cca4bc-1ac9-4d56-add0-a9b6e4fc4402" xlink:to="loc_wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties_4325ae58-c42d-4475-a89c-8952ff2ed621" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DeferredTaxAssetsFormationCosts_f17938ff-8d1e-444d-aedb-4aab2d2f9343" xlink:href="wald-20221231.xsd#wald_DeferredTaxAssetsFormationCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72cca4bc-1ac9-4d56-add0-a9b6e4fc4402" xlink:to="loc_wald_DeferredTaxAssetsFormationCosts_f17938ff-8d1e-444d-aedb-4aab2d2f9343" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4e8edc58-da8c-42fd-be22-c331bebff932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72cca4bc-1ac9-4d56-add0-a9b6e4fc4402" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4e8edc58-da8c-42fd-be22-c331bebff932" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DeferredTaxAssetsTransactionCosts_acaa77e0-8903-4962-84cf-7016a6c059f5" xlink:href="wald-20221231.xsd#wald_DeferredTaxAssetsTransactionCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72cca4bc-1ac9-4d56-add0-a9b6e4fc4402" xlink:to="loc_wald_DeferredTaxAssetsTransactionCosts_acaa77e0-8903-4962-84cf-7016a6c059f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8d1bbf5c-313a-494c-92fb-b0252cd3f224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72cca4bc-1ac9-4d56-add0-a9b6e4fc4402" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8d1bbf5c-313a-494c-92fb-b0252cd3f224" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_9ea1b85c-2b08-49e4-abc8-c5fdd4aaaa92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72cca4bc-1ac9-4d56-add0-a9b6e4fc4402" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_9ea1b85c-2b08-49e4-abc8-c5fdd4aaaa92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DeferredTaxAssetsBelowMarketLeaseContract_5e9f2e1d-654d-4fc0-bd28-fd27f5c0465f" xlink:href="wald-20221231.xsd#wald_DeferredTaxAssetsBelowMarketLeaseContract"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72cca4bc-1ac9-4d56-add0-a9b6e4fc4402" xlink:to="loc_wald_DeferredTaxAssetsBelowMarketLeaseContract_5e9f2e1d-654d-4fc0-bd28-fd27f5c0465f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_7e7f0a99-b1f4-496f-83f3-ea62b062250c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72cca4bc-1ac9-4d56-add0-a9b6e4fc4402" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_7e7f0a99-b1f4-496f-83f3-ea62b062250c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_fa5a1ed6-5656-4e73-a919-79809a6aa8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72cca4bc-1ac9-4d56-add0-a9b6e4fc4402" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_fa5a1ed6-5656-4e73-a919-79809a6aa8bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_23cc4d91-39c7-4699-b5f9-3057969578b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72cca4bc-1ac9-4d56-add0-a9b6e4fc4402" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_23cc4d91-39c7-4699-b5f9-3057969578b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_c29bce34-fa33-4f70-8653-63d660bd349d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72cca4bc-1ac9-4d56-add0-a9b6e4fc4402" xlink:to="loc_us-gaap_DeferredTaxAssetInterestCarryforward_c29bce34-fa33-4f70-8653-63d660bd349d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_91ca0688-841e-4c8b-a337-6c734d05fca3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_738689e8-13a8-4c9b-8726-cf2c49081d00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_91ca0688-841e-4c8b-a337-6c734d05fca3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_738689e8-13a8-4c9b-8726-cf2c49081d00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_d2547375-2381-4365-8f9c-c07af72b4488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_91ca0688-841e-4c8b-a337-6c734d05fca3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_d2547375-2381-4365-8f9c-c07af72b4488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_0435bb22-48b8-46c8-8ca8-0e9fb94627e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_91ca0688-841e-4c8b-a337-6c734d05fca3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_0435bb22-48b8-46c8-8ca8-0e9fb94627e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_e6ee8fb4-ce67-409e-83be-1b3975e3e9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_91ca0688-841e-4c8b-a337-6c734d05fca3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_e6ee8fb4-ce67-409e-83be-1b3975e3e9cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5bfaee61-5dc2-4539-9ae1-1a21197e7118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_91ca0688-841e-4c8b-a337-6c734d05fca3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5bfaee61-5dc2-4539-9ae1-1a21197e7118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_185d2b1d-ae09-4ea5-a3fb-2ba77752d3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_559fbf19-c8d5-4b98-9be5-802528023785" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_185d2b1d-ae09-4ea5-a3fb-2ba77752d3c6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_559fbf19-c8d5-4b98-9be5-802528023785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_06083a45-36e4-45d4-97d7-2cf31734a647" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_185d2b1d-ae09-4ea5-a3fb-2ba77752d3c6" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_06083a45-36e4-45d4-97d7-2cf31734a647" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b22b7867-a243-4086-9782-25bd1c4b670e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_185d2b1d-ae09-4ea5-a3fb-2ba77752d3c6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b22b7867-a243-4086-9782-25bd1c4b670e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_10087d18-98ba-4d77-bb82-f19879a78e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_IntercompanyPayables_9487ea46-bfbc-4b76-8f7a-45f341e7ca9c" xlink:href="wald-20221231.xsd#wald_IntercompanyPayables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_10087d18-98ba-4d77-bb82-f19879a78e5a" xlink:to="loc_wald_IntercompanyPayables_9487ea46-bfbc-4b76-8f7a-45f341e7ca9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_f262b194-172e-4de2-81bb-200181a3aaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_10087d18-98ba-4d77-bb82-f19879a78e5a" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_f262b194-172e-4de2-81bb-200181a3aaa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_376301ee-fcd2-46d5-960f-06057ebb3a63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_45034cd4-25d9-4318-9828-a67eba9f268e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_376301ee-fcd2-46d5-960f-06057ebb3a63" xlink:to="loc_us-gaap_AssetsCurrent_45034cd4-25d9-4318-9828-a67eba9f268e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_InvestmentInSubsidiary_f5af2909-6160-43df-b27d-09f560812631" xlink:href="wald-20221231.xsd#wald_InvestmentInSubsidiary"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_376301ee-fcd2-46d5-960f-06057ebb3a63" xlink:to="loc_wald_InvestmentInSubsidiary_f5af2909-6160-43df-b27d-09f560812631" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_63ee5baf-f73f-4a6d-bf1c-b332159c8c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c5a6129a-4eca-4d8c-87a8-5a8a81224de1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_63ee5baf-f73f-4a6d-bf1c-b332159c8c3f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c5a6129a-4eca-4d8c-87a8-5a8a81224de1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ec5cdf9b-5805-4bb3-8d61-1b0201ea84d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_63ee5baf-f73f-4a6d-bf1c-b332159c8c3f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ec5cdf9b-5805-4bb3-8d61-1b0201ea84d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9842f20b-0743-40ea-8020-e00d8cd4baad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_94d5947d-7ca9-4b56-a422-337dea5c79ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9842f20b-0743-40ea-8020-e00d8cd4baad" xlink:to="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_94d5947d-7ca9-4b56-a422-337dea5c79ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_dfa2d093-659e-4c53-89c2-402a603d893c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9842f20b-0743-40ea-8020-e00d8cd4baad" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_dfa2d093-659e-4c53-89c2-402a603d893c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"/>
  <link:calculationLink xlink:role="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce8be453-ec92-4776-8098-a656aa1455e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3bcdb135-fd10-49f5-8a13-f94987b19387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce8be453-ec92-4776-8098-a656aa1455e0" xlink:to="loc_us-gaap_ProfitLoss_3bcdb135-fd10-49f5-8a13-f94987b19387" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_ce1a4503-9642-48df-a578-b3296c4560c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce8be453-ec92-4776-8098-a656aa1455e0" xlink:to="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_ce1a4503-9642-48df-a578-b3296c4560c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_25d69313-6c37-42d1-9815-29391b1ff5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce8be453-ec92-4776-8098-a656aa1455e0" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_25d69313-6c37-42d1-9815-29391b1ff5cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_924bd7be-e6fc-434c-ba56-0c2ce8529fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_d8fa646f-cb6d-4b24-8fb5-1b5eb09d66d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_924bd7be-e6fc-434c-ba56-0c2ce8529fc6" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_d8fa646f-cb6d-4b24-8fb5-1b5eb09d66d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates_0928aeec-6a81-4068-aa52-d4a3b09788e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_924bd7be-e6fc-434c-ba56-0c2ce8529fc6" xlink:to="loc_us-gaap_PaymentsOfDistributionsToAffiliates_0928aeec-6a81-4068-aa52-d4a3b09788e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PaymentsOfExpensesOnBehalfOfSubsidiaries_68a3500a-6306-4b28-8ac3-1444d6aa9119" xlink:href="wald-20221231.xsd#wald_PaymentsOfExpensesOnBehalfOfSubsidiaries"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_924bd7be-e6fc-434c-ba56-0c2ce8529fc6" xlink:to="loc_wald_PaymentsOfExpensesOnBehalfOfSubsidiaries_68a3500a-6306-4b28-8ac3-1444d6aa9119" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>wald-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cb24ed7e-6299-4643-a980-910da3dfa7bf,g:f940d8a8-f49a-452c-b5e1-83817ee3c0b3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.waldencast.com/role/COVER" xlink:type="simple" xlink:href="wald-20221231.xsd#COVER"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/COVER" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e453eabb-70ae-4a77-8637-027984e308cf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentType_e453eabb-70ae-4a77-8637-027984e308cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_a65c3aab-eaff-45bf-ae6e-d5f6489ff3df" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentRegistrationStatement_a65c3aab-eaff-45bf-ae6e-d5f6489ff3df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_71823cc5-9136-493f-9aa8-eb4f30d22190" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentAnnualReport_71823cc5-9136-493f-9aa8-eb4f30d22190" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_22172f92-fde8-49f9-a143-1be9abaac24a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_CurrentFiscalYearEndDate_22172f92-fde8-49f9-a143-1be9abaac24a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7061331d-9eca-4f0c-9d78-796ff24ad7ff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentPeriodEndDate_7061331d-9eca-4f0c-9d78-796ff24ad7ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_84b2905b-0fde-44aa-83af-7cd7890db0e8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentTransitionReport_84b2905b-0fde-44aa-83af-7cd7890db0e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_4e1e58cf-0b18-443d-b188-4cb7f22474f2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentShellCompanyReport_4e1e58cf-0b18-443d-b188-4cb7f22474f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_eaedd807-1c2d-4dce-8d29-8d4541d3c712" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityFileNumber_eaedd807-1c2d-4dce-8d29-8d4541d3c712" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b17281de-b427-4bf0-bfa5-ca4e16d1dda5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityRegistrantName_b17281de-b427-4bf0-bfa5-ca4e16d1dda5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e8112ba2-2e43-4470-a9a4-b67b43d7e972" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityAddressAddressLine1_e8112ba2-2e43-4470-a9a4-b67b43d7e972" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_26bbb315-5141-42f4-a07d-f43b639d43af" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityAddressAddressLine2_26bbb315-5141-42f4-a07d-f43b639d43af" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b0b503eb-744d-44b1-8151-9e6d4c2acc21" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityAddressCityOrTown_b0b503eb-744d-44b1-8151-9e6d4c2acc21" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_403b4b74-a009-46f2-a964-b792370d96c0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityAddressStateOrProvince_403b4b74-a009-46f2-a964-b792370d96c0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a18f7e16-6cc0-4749-8447-64c289a63362" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityAddressPostalZipCode_a18f7e16-6cc0-4749-8447-64c289a63362" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_84abb777-e201-482c-8650-997601e29aa8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_ContactPersonnelName_84abb777-e201-482c-8650-997601e29aa8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1d3a544e-7a79-4448-8344-9cb5e208553a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_CityAreaCode_1d3a544e-7a79-4448-8344-9cb5e208553a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_36df013e-a0a6-4d1d-8c57-8cb7a4bc8404" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_LocalPhoneNumber_36df013e-a0a6-4d1d-8c57-8cb7a4bc8404" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e5e158e9-206a-4996-81fb-eb2bb9314dcb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_Security12bTitle_e5e158e9-206a-4996-81fb-eb2bb9314dcb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a2b2f1f6-ac11-477c-a4ee-afdb91f881d9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_TradingSymbol_a2b2f1f6-ac11-477c-a4ee-afdb91f881d9" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c9918042-57bb-4021-bb24-39707b95680c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_SecurityExchangeName_c9918042-57bb-4021-bb24-39707b95680c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_03aaf512-e28e-40c0-a313-2fcec05077e5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_03aaf512-e28e-40c0-a313-2fcec05077e5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_1f9f1098-ccc8-47e4-9363-55cb67af6092" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_1f9f1098-ccc8-47e4-9363-55cb67af6092" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_563d5d0b-d864-415c-8806-96c251f6d81c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityVoluntaryFilers_563d5d0b-d864-415c-8806-96c251f6d81c" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c6d123cd-e525-498e-856c-54779f8b757e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityCurrentReportingStatus_c6d123cd-e525-498e-856c-54779f8b757e" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_4cce6197-c0c2-49b0-b19c-2adcc8864322" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityInteractiveDataCurrent_4cce6197-c0c2-49b0-b19c-2adcc8864322" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_5a4de90b-504c-4a2f-b66b-c67625025dd5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityFilerCategory_5a4de90b-504c-4a2f-b66b-c67625025dd5" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_42054e03-f700-4ab4-bcfb-e440a67b79ff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityEmergingGrowthCompany_42054e03-f700-4ab4-bcfb-e440a67b79ff" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_24950017-7d2d-4969-a509-af0495b66047" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityExTransitionPeriod_24950017-7d2d-4969-a509-af0495b66047" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_db55b9f5-7704-481f-9309-3ac1477026a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_IcfrAuditorAttestationFlag_db55b9f5-7704-481f-9309-3ac1477026a1" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_30990195-b8b2-4cca-a4ec-5dcd7fab021f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_30990195-b8b2-4cca-a4ec-5dcd7fab021f" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_7611b238-ea85-4fe5-8039-63026792ab07" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtRestatementRecoveryAnalysisFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_7611b238-ea85-4fe5-8039-63026792ab07" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_0c9e68ec-4de5-4793-b761-4d9ba60f9fd6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentAccountingStandard_0c9e68ec-4de5-4793-b761-4d9ba60f9fd6" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_886a883a-3805-4c4e-acc6-efca8abe16b2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityShellCompany_886a883a-3805-4c4e-acc6-efca8abe16b2" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a78e7c28-5a43-413f-bebd-8d6688fc8194" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityCentralIndexKey_a78e7c28-5a43-413f-bebd-8d6688fc8194" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a933844a-d1db-4f17-9abf-83a6dba61921" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_AmendmentFlag_a933844a-d1db-4f17-9abf-83a6dba61921" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ff5536be-f6bf-427c-b76e-7d7ea4c545a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ff5536be-f6bf-427c-b76e-7d7ea4c545a1" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d28f2fca-6482-4b46-86f9-68ca296107ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentFiscalYearFocus_d28f2fca-6482-4b46-86f9-68ca296107ec" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_0b90b412-2300-4fc7-91a5-4201dc2fb3fe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityAddressCountry_0b90b412-2300-4fc7-91a5-4201dc2fb3fe" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8a73a5bf-a33c-431d-96df-3200f3e25746" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8a73a5bf-a33c-431d-96df-3200f3e25746" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_e0db228d-3143-48f5-b397-394f0c9ee6ed" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentInformationTable_e0db228d-3143-48f5-b397-394f0c9ee6ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_894d7354-c234-4d79-89d9-9062f9fba2fc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_e0db228d-3143-48f5-b397-394f0c9ee6ed" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_894d7354-c234-4d79-89d9-9062f9fba2fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_894d7354-c234-4d79-89d9-9062f9fba2fc_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_894d7354-c234-4d79-89d9-9062f9fba2fc" xlink:to="loc_dei_AddressTypeDomain_894d7354-c234-4d79-89d9-9062f9fba2fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_69875783-fcbe-44c6-b0ef-13d63d203ba9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_894d7354-c234-4d79-89d9-9062f9fba2fc" xlink:to="loc_dei_AddressTypeDomain_69875783-fcbe-44c6-b0ef-13d63d203ba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_835e8a6e-2739-45cf-b971-63280a641e54" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_69875783-fcbe-44c6-b0ef-13d63d203ba9" xlink:to="loc_dei_BusinessContactMember_835e8a6e-2739-45cf-b971-63280a641e54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_46c207d7-e260-4de9-92a2-71c3c3d9797a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_e0db228d-3143-48f5-b397-394f0c9ee6ed" xlink:to="loc_us-gaap_StatementClassOfStockAxis_46c207d7-e260-4de9-92a2-71c3c3d9797a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_46c207d7-e260-4de9-92a2-71c3c3d9797a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_46c207d7-e260-4de9-92a2-71c3c3d9797a" xlink:to="loc_us-gaap_ClassOfStockDomain_46c207d7-e260-4de9-92a2-71c3c3d9797a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ff706955-1993-4c85-a0ed-d6e2a49ea1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_46c207d7-e260-4de9-92a2-71c3c3d9797a" xlink:to="loc_us-gaap_ClassOfStockDomain_ff706955-1993-4c85-a0ed-d6e2a49ea1ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_59efe353-8d42-4e07-8309-fe46bdd5e487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ff706955-1993-4c85-a0ed-d6e2a49ea1ed" xlink:to="loc_us-gaap_CommonClassAMember_59efe353-8d42-4e07-8309-fe46bdd5e487" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_d6a4b7ad-2d64-4311-9840-324ea48043e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ff706955-1993-4c85-a0ed-d6e2a49ea1ed" xlink:to="loc_us-gaap_WarrantMember_d6a4b7ad-2d64-4311-9840-324ea48043e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_47b5b2d4-2a6e-401d-8487-17ce2188ed72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ff706955-1993-4c85-a0ed-d6e2a49ea1ed" xlink:to="loc_us-gaap_CommonClassBMember_47b5b2d4-2a6e-401d-8487-17ce2188ed72" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="wald-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_edf1051c-cc8a-4439-bf3b-3732a73ac052" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8f4b9b87-fc67-4217-b124-d766222b33b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_edf1051c-cc8a-4439-bf3b-3732a73ac052" xlink:to="loc_us-gaap_AssetsAbstract_8f4b9b87-fc67-4217-b124-d766222b33b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f6e1ca22-0ccb-4d19-97aa-03350a7d3dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8f4b9b87-fc67-4217-b124-d766222b33b3" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f6e1ca22-0ccb-4d19-97aa-03350a7d3dfc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3cfdd94d-9863-4890-9aca-3a6bd94cb20b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e1ca22-0ccb-4d19-97aa-03350a7d3dfc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3cfdd94d-9863-4890-9aca-3a6bd94cb20b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_d7e375b8-8c55-4943-846e-688a10937261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e1ca22-0ccb-4d19-97aa-03350a7d3dfc" xlink:to="loc_us-gaap_RestrictedCash_d7e375b8-8c55-4943-846e-688a10937261" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7b5e7bb2-d5d1-4750-8c44-81fb7d5bcf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e1ca22-0ccb-4d19-97aa-03350a7d3dfc" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7b5e7bb2-d5d1-4750-8c44-81fb7d5bcf9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7841ffcc-dc8e-4d88-95de-80a121509269" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e1ca22-0ccb-4d19-97aa-03350a7d3dfc" xlink:to="loc_us-gaap_InventoryNet_7841ffcc-dc8e-4d88-95de-80a121509269" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_903b718a-2373-48dd-af58-f723b43064c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e1ca22-0ccb-4d19-97aa-03350a7d3dfc" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_903b718a-2373-48dd-af58-f723b43064c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_6d1a6ad5-93f9-458b-a152-e5c3556e3941" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e1ca22-0ccb-4d19-97aa-03350a7d3dfc" xlink:to="loc_us-gaap_OtherAssetsCurrent_6d1a6ad5-93f9-458b-a152-e5c3556e3941" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a871219d-3122-4aa3-8a0f-5f0bf3b7db0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e1ca22-0ccb-4d19-97aa-03350a7d3dfc" xlink:to="loc_us-gaap_AssetsCurrent_a871219d-3122-4aa3-8a0f-5f0bf3b7db0b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_beae68ef-23ec-4b39-b093-eeb70e319d05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8f4b9b87-fc67-4217-b124-d766222b33b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_beae68ef-23ec-4b39-b093-eeb70e319d05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_abe70299-8cfb-428d-af8e-316a285a12bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8f4b9b87-fc67-4217-b124-d766222b33b3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_abe70299-8cfb-428d-af8e-316a285a12bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_757e1c3a-b84e-453e-91f6-94222279fcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8f4b9b87-fc67-4217-b124-d766222b33b3" xlink:to="loc_us-gaap_Goodwill_757e1c3a-b84e-453e-91f6-94222279fcaf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_beea02be-c73a-47be-8fe1-b9290aa1f7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8f4b9b87-fc67-4217-b124-d766222b33b3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_beea02be-c73a-47be-8fe1-b9290aa1f7ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9a971200-5b33-46c3-ab5f-28021a247861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8f4b9b87-fc67-4217-b124-d766222b33b3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9a971200-5b33-46c3-ab5f-28021a247861" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e869836d-50c4-497e-b7a9-5295ce581ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_8f4b9b87-fc67-4217-b124-d766222b33b3" xlink:to="loc_us-gaap_Assets_e869836d-50c4-497e-b7a9-5295ce581ad0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_edf1051c-cc8a-4439-bf3b-3732a73ac052" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f32a90be-627b-495e-bbd5-95ae8565cdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f32a90be-627b-495e-bbd5-95ae8565cdcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a79d576-03b8-4a96-bef4-4eb868b27bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f32a90be-627b-495e-bbd5-95ae8565cdcc" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a79d576-03b8-4a96-bef4-4eb868b27bc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_629d8ea5-e085-4553-ac71-2c43dd159fde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f32a90be-627b-495e-bbd5-95ae8565cdcc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_629d8ea5-e085-4553-ac71-2c43dd159fde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7ed9c06f-835a-4a06-837a-ab84e0b9094e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f32a90be-627b-495e-bbd5-95ae8565cdcc" xlink:to="loc_us-gaap_LongTermDebtCurrent_7ed9c06f-835a-4a06-837a-ab84e0b9094e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_299fdca3-1ef5-454d-ada6-2e2885af9626" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f32a90be-627b-495e-bbd5-95ae8565cdcc" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_299fdca3-1ef5-454d-ada6-2e2885af9626" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b5cd269d-e0dc-40d7-bfdb-e1eee4053afe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f32a90be-627b-495e-bbd5-95ae8565cdcc" xlink:to="loc_us-gaap_LiabilitiesCurrent_b5cd269d-e0dc-40d7-bfdb-e1eee4053afe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e10bcbe8-807f-4058-ac8a-670849d11258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e10bcbe8-807f-4058-ac8a-670849d11258" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_321fc6ee-da44-4a73-81e2-d84ecd73b399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_321fc6ee-da44-4a73-81e2-d84ecd73b399" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0036db84-69be-4784-96be-cea70c3d943d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0036db84-69be-4784-96be-cea70c3d943d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_783d7578-d845-4226-a9bb-f7c650195f49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_783d7578-d845-4226-a9bb-f7c650195f49" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a2cf3a9f-2b8a-42c7-a6ce-b2d9d2abdc42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a2cf3a9f-2b8a-42c7-a6ce-b2d9d2abdc42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0a3a9519-bd81-4930-b1fc-efc44ea1dde5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_Liabilities_0a3a9519-bd81-4930-b1fc-efc44ea1dde5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f87e6315-3319-40ec-a867-3408f86d9900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f87e6315-3319-40ec-a867-3408f86d9900" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9f31635a-54e9-4bba-bf49-7457f731eabb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_EquityAbstract_9f31635a-54e9-4bba-bf49-7457f731eabb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_80d5f501-75ec-4960-b7dd-1d8158ecaa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_9f31635a-54e9-4bba-bf49-7457f731eabb" xlink:to="loc_us-gaap_CommonStockValue_80d5f501-75ec-4960-b7dd-1d8158ecaa3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_06a5bf3e-ba45-485a-973d-2e9cba2266fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_9f31635a-54e9-4bba-bf49-7457f731eabb" xlink:to="loc_us-gaap_AdditionalPaidInCapital_06a5bf3e-ba45-485a-973d-2e9cba2266fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b736647f-efe3-4ca7-a9b3-5e1ab953b2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_9f31635a-54e9-4bba-bf49-7457f731eabb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b736647f-efe3-4ca7-a9b3-5e1ab953b2c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_59ae7b6e-28c0-4ae2-b2a7-c1d4914cb83e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_9f31635a-54e9-4bba-bf49-7457f731eabb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_59ae7b6e-28c0-4ae2-b2a7-c1d4914cb83e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_17307018-8153-48d9-abfb-dad4c2ccdb98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_9f31635a-54e9-4bba-bf49-7457f731eabb" xlink:to="loc_us-gaap_StockholdersEquity_17307018-8153-48d9-abfb-dad4c2ccdb98" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_6b2d1826-f873-44da-8c2c-c5ff888ec8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_9f31635a-54e9-4bba-bf49-7457f731eabb" xlink:to="loc_us-gaap_MinorityInterest_6b2d1826-f873-44da-8c2c-c5ff888ec8bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_609ff63b-f38c-4672-a5cd-fcf4a45b5080" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_9f31635a-54e9-4bba-bf49-7457f731eabb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_609ff63b-f38c-4672-a5cd-fcf4a45b5080" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_87e454c1-3a88-4caa-80e8-7986ac0bab58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_87e454c1-3a88-4caa-80e8-7986ac0bab58" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8d72545d-5a33-4284-80c3-3004428d1989" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_edf1051c-cc8a-4439-bf3b-3732a73ac052" xlink:to="loc_us-gaap_StatementTable_8d72545d-5a33-4284-80c3-3004428d1989" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_53d1aa94-38ad-4837-93e1-ec82595a0e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8d72545d-5a33-4284-80c3-3004428d1989" xlink:to="loc_us-gaap_StatementClassOfStockAxis_53d1aa94-38ad-4837-93e1-ec82595a0e16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_53d1aa94-38ad-4837-93e1-ec82595a0e16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_53d1aa94-38ad-4837-93e1-ec82595a0e16" xlink:to="loc_us-gaap_ClassOfStockDomain_53d1aa94-38ad-4837-93e1-ec82595a0e16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_69cb069a-8a62-44e8-b002-c6f256db3b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_53d1aa94-38ad-4837-93e1-ec82595a0e16" xlink:to="loc_us-gaap_ClassOfStockDomain_69cb069a-8a62-44e8-b002-c6f256db3b2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_4e008dcd-a7bc-4808-9f78-9e12c4afc404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_69cb069a-8a62-44e8-b002-c6f256db3b2c" xlink:to="loc_us-gaap_CommonClassAMember_4e008dcd-a7bc-4808-9f78-9e12c4afc404" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_8216bb53-28d8-4b9f-93fc-33f44e1c7071" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_69cb069a-8a62-44e8-b002-c6f256db3b2c" xlink:to="loc_us-gaap_CommonClassBMember_8216bb53-28d8-4b9f-93fc-33f44e1c7071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad4fa5d4-908f-4c9d-b00e-0aba79fab88a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8d72545d-5a33-4284-80c3-3004428d1989" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad4fa5d4-908f-4c9d-b00e-0aba79fab88a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ad4fa5d4-908f-4c9d-b00e-0aba79fab88a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad4fa5d4-908f-4c9d-b00e-0aba79fab88a" xlink:to="loc_us-gaap_RelatedPartyDomain_ad4fa5d4-908f-4c9d-b00e-0aba79fab88a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c8d9ed24-66ec-4eee-b356-124782504c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad4fa5d4-908f-4c9d-b00e-0aba79fab88a" xlink:to="loc_us-gaap_RelatedPartyDomain_c8d9ed24-66ec-4eee-b356-124782504c9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_d8b92ee4-a117-4fed-8b10-3d2e2d73f9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c8d9ed24-66ec-4eee-b356-124782504c9b" xlink:to="loc_us-gaap_NonrelatedPartyMember_d8b92ee4-a117-4fed-8b10-3d2e2d73f9f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_5d242a44-54b9-4ad4-9bde-53fe3e530cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c8d9ed24-66ec-4eee-b356-124782504c9b" xlink:to="loc_us-gaap_RelatedPartyMember_5d242a44-54b9-4ad4-9bde-53fe3e530cc5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="wald-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_80afe06b-b28c-46ac-b640-295f82a78dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_80afe06b-b28c-46ac-b640-295f82a78dc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_686d5873-770f-4d06-8251-5b9b34f9c79f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_686d5873-770f-4d06-8251-5b9b34f9c79f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0f9c0edd-e958-400a-8d0d-2086d60fd89f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0f9c0edd-e958-400a-8d0d-2086d60fd89f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_21aa7b30-83b3-4880-a736-43ea72fde1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_CommonStockSharesIssued_21aa7b30-83b3-4880-a736-43ea72fde1e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b2f01d4e-8323-45d5-b1aa-ca6499ec1c78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b2f01d4e-8323-45d5-b1aa-ca6499ec1c78" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_56bb9b4e-ed18-4c46-b752-592bb9acb061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_56bb9b4e-ed18-4c46-b752-592bb9acb061" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1dd8dd28-3b4b-470a-bc79-bbcf4a95c302" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1dd8dd28-3b4b-470a-bc79-bbcf4a95c302" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_aff68090-39e9-4c17-82a6-bb2ba68b445c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_PreferredStockSharesIssued_aff68090-39e9-4c17-82a6-bb2ba68b445c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2e715a46-794b-462f-a72c-df961853fe50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2e715a46-794b-462f-a72c-df961853fe50" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1b616adb-31df-433b-bea3-32106860473f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_StatementTable_1b616adb-31df-433b-bea3-32106860473f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0a43b24f-eef4-4c89-a0b4-bf39630579f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1b616adb-31df-433b-bea3-32106860473f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0a43b24f-eef4-4c89-a0b4-bf39630579f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0a43b24f-eef4-4c89-a0b4-bf39630579f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0a43b24f-eef4-4c89-a0b4-bf39630579f6" xlink:to="loc_us-gaap_ClassOfStockDomain_0a43b24f-eef4-4c89-a0b4-bf39630579f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a7a8defc-138e-4c11-b7fa-ac255d80463a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0a43b24f-eef4-4c89-a0b4-bf39630579f6" xlink:to="loc_us-gaap_ClassOfStockDomain_a7a8defc-138e-4c11-b7fa-ac255d80463a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_0f4b2d9e-d16b-4915-9d2a-69189183d3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a7a8defc-138e-4c11-b7fa-ac255d80463a" xlink:to="loc_us-gaap_CommonClassAMember_0f4b2d9e-d16b-4915-9d2a-69189183d3e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_ab4c3267-4047-41e2-ae40-483b6dd7459f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a7a8defc-138e-4c11-b7fa-ac255d80463a" xlink:to="loc_us-gaap_CommonClassBMember_ab4c3267-4047-41e2-ae40-483b6dd7459f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f0766699-298a-433d-a3a8-c5ab186db9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1b616adb-31df-433b-bea3-32106860473f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f0766699-298a-433d-a3a8-c5ab186db9d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f0766699-298a-433d-a3a8-c5ab186db9d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f0766699-298a-433d-a3a8-c5ab186db9d5" xlink:to="loc_us-gaap_RelatedPartyDomain_f0766699-298a-433d-a3a8-c5ab186db9d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6bf1b3d0-1be9-4e66-8199-96f4e52b0108" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f0766699-298a-433d-a3a8-c5ab186db9d5" xlink:to="loc_us-gaap_RelatedPartyDomain_6bf1b3d0-1be9-4e66-8199-96f4e52b0108" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_9eebc5a8-3463-4f94-8fd5-d321f9c4e1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6bf1b3d0-1be9-4e66-8199-96f4e52b0108" xlink:to="loc_us-gaap_RelatedPartyMember_9eebc5a8-3463-4f94-8fd5-d321f9c4e1ff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="simple" xlink:href="wald-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3baf014a-5baf-40b4-850c-90197c9989a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33d854c0-15f8-445b-8965-f6013ce1fdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3baf014a-5baf-40b4-850c-90197c9989a1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33d854c0-15f8-445b-8965-f6013ce1fdc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d088287d-db27-44c1-88a1-2633bd9088ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3baf014a-5baf-40b4-850c-90197c9989a1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d088287d-db27-44c1-88a1-2633bd9088ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6ec677ee-7a0a-48d6-9b9b-7b63aab99a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3baf014a-5baf-40b4-850c-90197c9989a1" xlink:to="loc_us-gaap_StatementTable_6ec677ee-7a0a-48d6-9b9b-7b63aab99a0e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2186a706-c70e-46b8-9ba2-eff2f45ad50b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6ec677ee-7a0a-48d6-9b9b-7b63aab99a0e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2186a706-c70e-46b8-9ba2-eff2f45ad50b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2186a706-c70e-46b8-9ba2-eff2f45ad50b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2186a706-c70e-46b8-9ba2-eff2f45ad50b" xlink:to="loc_us-gaap_RelatedPartyDomain_2186a706-c70e-46b8-9ba2-eff2f45ad50b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_09dac033-03df-4c9d-a3d7-bfb006af475a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2186a706-c70e-46b8-9ba2-eff2f45ad50b" xlink:to="loc_us-gaap_RelatedPartyDomain_09dac033-03df-4c9d-a3d7-bfb006af475a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_f02a5bdd-a0aa-4b6f-9085-1904bd2c5980" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_09dac033-03df-4c9d-a3d7-bfb006af475a" xlink:to="loc_us-gaap_RelatedPartyMember_f02a5bdd-a0aa-4b6f-9085-1904bd2c5980" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_22ea68d0-d78c-459e-aa62-bc2112b362cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6ec677ee-7a0a-48d6-9b9b-7b63aab99a0e" xlink:to="loc_us-gaap_SupplyCommitmentAxis_22ea68d0-d78c-459e-aa62-bc2112b362cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_22ea68d0-d78c-459e-aa62-bc2112b362cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_22ea68d0-d78c-459e-aa62-bc2112b362cc" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_22ea68d0-d78c-459e-aa62-bc2112b362cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_28a0cbcd-3435-4bbb-88b1-908e9cf2bb41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_22ea68d0-d78c-459e-aa62-bc2112b362cc" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_28a0cbcd-3435-4bbb-88b1-908e9cf2bb41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentMember_e7523d97-31f8-4905-9d8f-bee1c7b9a49e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_28a0cbcd-3435-4bbb-88b1-908e9cf2bb41" xlink:to="loc_us-gaap_SupplyCommitmentMember_e7523d97-31f8-4905-9d8f-bee1c7b9a49e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="wald-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_eb36be64-4f40-460a-b50c-6cf9e83ccf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_eb36be64-4f40-460a-b50c-6cf9e83ccf6b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6c32179d-51cc-4d07-a84c-8cd5a2ea74a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6c32179d-51cc-4d07-a84c-8cd5a2ea74a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7eef98df-0df0-4d09-a3f2-17b6c556b923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7eef98df-0df0-4d09-a3f2-17b6c556b923" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockIssuedDuringPeriodSharesTrustProceeds_18e3d8a0-dab3-45eb-9326-46da3ec02d9c" xlink:href="wald-20221231.xsd#wald_StockIssuedDuringPeriodSharesTrustProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_wald_StockIssuedDuringPeriodSharesTrustProceeds_18e3d8a0-dab3-45eb-9326-46da3ec02d9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockIssuedDuringPeriodValueTrustProceeds_bf9d511e-0aae-4319-a6f3-014470904fa3" xlink:href="wald-20221231.xsd#wald_StockIssuedDuringPeriodValueTrustProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_wald_StockIssuedDuringPeriodValueTrustProceeds_bf9d511e-0aae-4319-a6f3-014470904fa3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements_b3cacb8d-5988-4cf3-b631-94884791e1c4" xlink:href="wald-20221231.xsd#wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements_b3cacb8d-5988-4cf3-b631-94884791e1c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements_a23cc6ab-5508-413f-b6b1-9277d4c9b245" xlink:href="wald-20221231.xsd#wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements_a23cc6ab-5508-413f-b6b1-9277d4c9b245" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockIssuedDuringPeriodSharesSubscriptionAgreements_7c585979-55f2-48bc-a07c-5c88cdceb8cb" xlink:href="wald-20221231.xsd#wald_StockIssuedDuringPeriodSharesSubscriptionAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_wald_StockIssuedDuringPeriodSharesSubscriptionAgreements_7c585979-55f2-48bc-a07c-5c88cdceb8cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockIssuedDuringPeriodValueSubscriptionAgreements_94a863f7-f86d-4a5b-9da8-70ab3e264083" xlink:href="wald-20221231.xsd#wald_StockIssuedDuringPeriodValueSubscriptionAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_wald_StockIssuedDuringPeriodValueSubscriptionAgreements_94a863f7-f86d-4a5b-9da8-70ab3e264083" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d62cbb59-de25-4cc1-b22c-40dfca375540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d62cbb59-de25-4cc1-b22c-40dfca375540" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_baf8a79d-3651-4022-a814-3d15690ff23a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_baf8a79d-3651-4022-a814-3d15690ff23a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_13889adb-54b5-4691-9aa8-63985264ef9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_ProfitLoss_13889adb-54b5-4691-9aa8-63985264ef9c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d4d7bfe7-02fe-479e-9ed2-342f8d175cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d4d7bfe7-02fe-479e-9ed2-342f8d175cb0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b1a2762e-fe83-4632-9bbb-58925fdfb290" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b1a2762e-fe83-4632-9bbb-58925fdfb290" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_2c93a08c-55d8-422d-b4a5-4a45cc8d9ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_2c93a08c-55d8-422d-b4a5-4a45cc8d9ba4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_97f946c6-8565-4529-9824-86549255ec8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_DividendsCommonStockCash_97f946c6-8565-4529-9824-86549255ec8f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DistributionOfBusiness_012ba9cf-fb12-4d3c-bb62-88fb37ce11b7" xlink:href="wald-20221231.xsd#wald_DistributionOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_wald_DistributionOfBusiness_012ba9cf-fb12-4d3c-bb62-88fb37ce11b7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e28fdaf9-b650-44bf-98d2-ac7822846209" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f0ec8957-f911-4683-a0ea-6adc2b395fda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_26d40751-2f6b-4c80-874b-263506a59b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_eb36be64-4f40-460a-b50c-6cf9e83ccf6b" xlink:to="loc_us-gaap_StatementTable_26d40751-2f6b-4c80-874b-263506a59b5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fc39e37a-965b-41f8-b2fb-e9da7a8cd413" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_26d40751-2f6b-4c80-874b-263506a59b5f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fc39e37a-965b-41f8-b2fb-e9da7a8cd413" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fc39e37a-965b-41f8-b2fb-e9da7a8cd413_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fc39e37a-965b-41f8-b2fb-e9da7a8cd413" xlink:to="loc_us-gaap_EquityComponentDomain_fc39e37a-965b-41f8-b2fb-e9da7a8cd413_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1eca69aa-e89e-4db2-94eb-6a61017e690a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fc39e37a-965b-41f8-b2fb-e9da7a8cd413" xlink:to="loc_us-gaap_EquityComponentDomain_1eca69aa-e89e-4db2-94eb-6a61017e690a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fa85f83b-06e4-41ff-bc95-9b4b86e2bd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1eca69aa-e89e-4db2-94eb-6a61017e690a" xlink:to="loc_us-gaap_CommonStockMember_fa85f83b-06e4-41ff-bc95-9b4b86e2bd5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_29779239-ea62-4db0-b588-e5f26aed670a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1eca69aa-e89e-4db2-94eb-6a61017e690a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_29779239-ea62-4db0-b588-e5f26aed670a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_dddff235-0e94-483b-ad6e-8dec09669670" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1eca69aa-e89e-4db2-94eb-6a61017e690a" xlink:to="loc_us-gaap_RetainedEarningsMember_dddff235-0e94-483b-ad6e-8dec09669670" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2453ab4b-d955-43cc-987f-e5ebc0c74aae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1eca69aa-e89e-4db2-94eb-6a61017e690a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2453ab4b-d955-43cc-987f-e5ebc0c74aae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_049f9b74-5d05-47d2-aede-800cf545f29f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1eca69aa-e89e-4db2-94eb-6a61017e690a" xlink:to="loc_us-gaap_NoncontrollingInterestMember_049f9b74-5d05-47d2-aede-800cf545f29f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1a8f92e5-b8a1-4d31-a883-a8fe21336b54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_26d40751-2f6b-4c80-874b-263506a59b5f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1a8f92e5-b8a1-4d31-a883-a8fe21336b54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1a8f92e5-b8a1-4d31-a883-a8fe21336b54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1a8f92e5-b8a1-4d31-a883-a8fe21336b54" xlink:to="loc_us-gaap_ClassOfStockDomain_1a8f92e5-b8a1-4d31-a883-a8fe21336b54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9ee2f13c-b7e3-48ec-880f-db8c66c012e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1a8f92e5-b8a1-4d31-a883-a8fe21336b54" xlink:to="loc_us-gaap_ClassOfStockDomain_9ee2f13c-b7e3-48ec-880f-db8c66c012e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_4458e8c4-55dc-4d1f-aca4-7342ed7a5c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9ee2f13c-b7e3-48ec-880f-db8c66c012e2" xlink:to="loc_us-gaap_CommonClassAMember_4458e8c4-55dc-4d1f-aca4-7342ed7a5c6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_3405f262-8c14-4732-ac99-66bae0dda415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9ee2f13c-b7e3-48ec-880f-db8c66c012e2" xlink:to="loc_us-gaap_CommonClassBMember_3405f262-8c14-4732-ac99-66bae0dda415" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4ce1e1b2-826d-4064-9d6d-62ab4b90f112" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_26d40751-2f6b-4c80-874b-263506a59b5f" xlink:to="loc_dei_LegalEntityAxis_4ce1e1b2-826d-4064-9d6d-62ab4b90f112" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4ce1e1b2-826d-4064-9d6d-62ab4b90f112_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4ce1e1b2-826d-4064-9d6d-62ab4b90f112" xlink:to="loc_dei_EntityDomain_4ce1e1b2-826d-4064-9d6d-62ab4b90f112_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_20dfcfb2-0936-4ca5-828c-07e5de321c43" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4ce1e1b2-826d-4064-9d6d-62ab4b90f112" xlink:to="loc_dei_EntityDomain_20dfcfb2-0936-4ca5-828c-07e5de321c43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_WaldencastPlcMember_ce089e44-f941-45c0-81c2-3b1335296cdf" xlink:href="wald-20221231.xsd#wald_WaldencastPlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_20dfcfb2-0936-4ca5-828c-07e5de321c43" xlink:to="loc_wald_WaldencastPlcMember_ce089e44-f941-45c0-81c2-3b1335296cdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiCosmeceuticalsLLCMember_0892f097-a37c-4e5c-a364-81a97fd2670b" xlink:href="wald-20221231.xsd#wald_ObagiCosmeceuticalsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_20dfcfb2-0936-4ca5-828c-07e5de321c43" xlink:to="loc_wald_ObagiCosmeceuticalsLLCMember_0892f097-a37c-4e5c-a364-81a97fd2670b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_2818ab50-ccc5-4c3b-8b6c-0a6dc33d9820" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_26d40751-2f6b-4c80-874b-263506a59b5f" xlink:to="loc_srt_RestatementAxis_2818ab50-ccc5-4c3b-8b6c-0a6dc33d9820" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_2818ab50-ccc5-4c3b-8b6c-0a6dc33d9820_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_2818ab50-ccc5-4c3b-8b6c-0a6dc33d9820" xlink:to="loc_srt_RestatementDomain_2818ab50-ccc5-4c3b-8b6c-0a6dc33d9820_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_1a1ed8ef-4ec3-47e4-9951-4e276b542d3a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_2818ab50-ccc5-4c3b-8b6c-0a6dc33d9820" xlink:to="loc_srt_RestatementDomain_1a1ed8ef-4ec3-47e4-9951-4e276b542d3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_c09f83c1-c4b6-44b3-a8d0-b51263588976" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1a1ed8ef-4ec3-47e4-9951-4e276b542d3a" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_c09f83c1-c4b6-44b3-a8d0-b51263588976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_7e0a24a0-8e4d-4720-b39f-9fa3cc8e4f06" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1a1ed8ef-4ec3-47e4-9951-4e276b542d3a" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_7e0a24a0-8e4d-4720-b39f-9fa3cc8e4f06" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="wald-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6084452a-4601-44d2-a771-e22ddd1d04f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6084452a-4601-44d2-a771-e22ddd1d04f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_389de8a0-4064-49a4-adff-f1dfa3727f47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6084452a-4601-44d2-a771-e22ddd1d04f3" xlink:to="loc_us-gaap_ProfitLoss_389de8a0-4064-49a4-adff-f1dfa3727f47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0afa66bb-9a36-4503-a5fd-cc986a8ddae7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6084452a-4601-44d2-a771-e22ddd1d04f3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0afa66bb-9a36-4503-a5fd-cc986a8ddae7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0afa66bb-9a36-4503-a5fd-cc986a8ddae7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_40b8d3c2-812c-44a0-8f8a-26fc8dd06d36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_ShareBasedCompensation_40b8d3c2-812c-44a0-8f8a-26fc8dd06d36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DepreciationDepletionAndAmortizationOperatingActivities_710334e8-ef35-44ab-a0dd-212dac15a85a" xlink:href="wald-20221231.xsd#wald_DepreciationDepletionAndAmortizationOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_wald_DepreciationDepletionAndAmortizationOperatingActivities_710334e8-ef35-44ab-a0dd-212dac15a85a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_e356fe21-cc51-403b-9af5-994f2314ba57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_OperatingLeaseExpense_e356fe21-cc51-403b-9af5-994f2314ba57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_d15314e6-0505-402b-b20e-23e464321f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_d15314e6-0505-402b-b20e-23e464321f3e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_NonCashLossFromChangeInFairValueOnInterestRateCollar_deb14f2f-395c-4479-90bb-bfb10234f619" xlink:href="wald-20221231.xsd#wald_NonCashLossFromChangeInFairValueOnInterestRateCollar"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_wald_NonCashLossFromChangeInFairValueOnInterestRateCollar_deb14f2f-395c-4479-90bb-bfb10234f619" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d2c3ebb9-ab15-4dd2-9f3c-05fbc6bdfac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d2c3ebb9-ab15-4dd2-9f3c-05fbc6bdfac1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainOnPPPLoanForgiveness_2d4b753a-6d43-46ba-9497-380251ecb3ed" xlink:href="wald-20221231.xsd#wald_GainOnPPPLoanForgiveness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_wald_GainOnPPPLoanForgiveness_2d4b753a-6d43-46ba-9497-380251ecb3ed" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_96075ced-47a5-4e17-981b-e367cd8a42ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_96075ced-47a5-4e17-981b-e367cd8a42ae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AmortizationOfRelatedPartyLiability_3d2bdd07-7cb4-48d8-9afb-fbde3f3c181e" xlink:href="wald-20221231.xsd#wald_AmortizationOfRelatedPartyLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_wald_AmortizationOfRelatedPartyLiability_3d2bdd07-7cb4-48d8-9afb-fbde3f3c181e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8c6ad2be-b37b-4872-a03c-a72ca50b6806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8c6ad2be-b37b-4872-a03c-a72ca50b6806" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_ee004331-312b-42c0-83a1-ff6aa17904c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_ee004331-312b-42c0-83a1-ff6aa17904c4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_52173d2e-eee1-4e19-85ec-586f95fa0e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_52173d2e-eee1-4e19-85ec-586f95fa0e6a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainLossOnNoteReceivableWriteoff_9ebe31a0-095e-4fda-9e4d-29872a731930" xlink:href="wald-20221231.xsd#wald_GainLossOnNoteReceivableWriteoff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_wald_GainLossOnNoteReceivableWriteoff_9ebe31a0-095e-4fda-9e4d-29872a731930" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_46b7eb43-2b25-43ca-9ebe-d8adf4ea55c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_46b7eb43-2b25-43ca-9ebe-d8adf4ea55c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_ac0f4396-24d6-49c5-89f5-addc09c26703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_ac0f4396-24d6-49c5-89f5-addc09c26703" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_7b1e1113-105b-4e15-a262-8cf44b3efa8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_7b1e1113-105b-4e15-a262-8cf44b3efa8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_3a18b680-9730-4042-a0ed-8495075e3ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_3a18b680-9730-4042-a0ed-8495075e3ed2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c70a1a98-311a-471a-81ef-b27389dd6e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c70a1a98-311a-471a-81ef-b27389dd6e9b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties_726aa537-5aa9-4766-9f2a-4bb3853c8b48" xlink:href="wald-20221231.xsd#wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:to="loc_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties_726aa537-5aa9-4766-9f2a-4bb3853c8b48" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_1b20ccdc-734e-497c-a5a2-470dca189470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_1b20ccdc-734e-497c-a5a2-470dca189470" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ba33d0d1-3541-495b-891c-ec3c97d0f0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ba33d0d1-3541-495b-891c-ec3c97d0f0e4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2e72c291-750c-48d9-a5fc-852ce38757f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2e72c291-750c-48d9-a5fc-852ce38757f4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ebf38345-02cf-4eaf-9acd-04897e39c51d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ebf38345-02cf-4eaf-9acd-04897e39c51d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2cb258-54ff-4a6a-9f8d-f098b1ee39ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2cb258-54ff-4a6a-9f8d-f098b1ee39ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5bc97e67-137c-40f1-b701-a973654f39d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2cb258-54ff-4a6a-9f8d-f098b1ee39ae" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5bc97e67-137c-40f1-b701-a973654f39d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_919c7a7a-c202-459a-8f8b-97a43b8766db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2cb258-54ff-4a6a-9f8d-f098b1ee39ae" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_919c7a7a-c202-459a-8f8b-97a43b8766db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AdvancesForNoteReceivable_55e27415-ac0f-4d00-a610-551c922b87f4" xlink:href="wald-20221231.xsd#wald_AdvancesForNoteReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2cb258-54ff-4a6a-9f8d-f098b1ee39ae" xlink:to="loc_wald_AdvancesForNoteReceivable_55e27415-ac0f-4d00-a610-551c922b87f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ProceedsFromTrustAccount_2c32bd32-c15d-4c56-be2e-fab012e73702" xlink:href="wald-20221231.xsd#wald_ProceedsFromTrustAccount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2cb258-54ff-4a6a-9f8d-f098b1ee39ae" xlink:to="loc_wald_ProceedsFromTrustAccount_2c32bd32-c15d-4c56-be2e-fab012e73702" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_74428bd6-1e24-4715-bbf4-ec8953caa875" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2cb258-54ff-4a6a-9f8d-f098b1ee39ae" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_74428bd6-1e24-4715-bbf4-ec8953caa875" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e203aea0-8989-4b48-891a-5ca255885c63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2cb258-54ff-4a6a-9f8d-f098b1ee39ae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e203aea0-8989-4b48-891a-5ca255885c63" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_18cd5332-09c9-451d-87df-9955916db758" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_18cd5332-09c9-451d-87df-9955916db758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ProceedsFromForwardPurchaseAgreements_056ab344-93dc-4168-8bce-3d4510c1a2c2" xlink:href="wald-20221231.xsd#wald_ProceedsFromForwardPurchaseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_wald_ProceedsFromForwardPurchaseAgreements_056ab344-93dc-4168-8bce-3d4510c1a2c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_2e3fcada-ac13-44e2-8dc8-21bc59fe94eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_2e3fcada-ac13-44e2-8dc8-21bc59fe94eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_9db05496-f651-409c-93cb-639178590a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_us-gaap_RepaymentsOfDebt_9db05496-f651-409c-93cb-639178590a2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_9384a862-b880-43b1-9aa8-980b783aa71c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_9384a862-b880-43b1-9aa8-980b783aa71c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_af812e0d-81f7-458d-b24f-1fcc1d3a0cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_af812e0d-81f7-458d-b24f-1fcc1d3a0cc0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherDebt_838b22ab-b148-4476-96a7-a7f1486b2379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_us-gaap_ProceedsFromOtherDebt_838b22ab-b148-4476-96a7-a7f1486b2379" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9e8b73eb-abb7-4e81-ba43-df37aa3a27ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9e8b73eb-abb7-4e81-ba43-df37aa3a27ca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_35f0f6ed-ef70-42b6-bea6-fa7d18723307" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_us-gaap_PaymentsOfDividends_35f0f6ed-ef70-42b6-bea6-fa7d18723307" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54709743-56d8-4da0-8e46-75c82555cae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54709743-56d8-4da0-8e46-75c82555cae6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_327c67ad-8822-46d9-b58f-4477ef16c797" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_327c67ad-8822-46d9-b58f-4477ef16c797" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e2916ee7-eaba-4fd0-bf53-8cf3c76776fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e2916ee7-eaba-4fd0-bf53-8cf3c76776fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c5b4710e-0502-4c06-84a7-22f2fb27d148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c5b4710e-0502-4c06-84a7-22f2fb27d148" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c420458b-11a8-4eae-a92b-00024b082881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_02b5bc80-284d-4193-b7dc-31ae8f8b86d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_02b5bc80-284d-4193-b7dc-31ae8f8b86d5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_4106226d-1301-42b1-ab4f-9d8199dfed24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_02b5bc80-284d-4193-b7dc-31ae8f8b86d5" xlink:to="loc_us-gaap_IncomeTaxesPaid_4106226d-1301-42b1-ab4f-9d8199dfed24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_845af3ff-28e0-468b-b366-be4194249879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_02b5bc80-284d-4193-b7dc-31ae8f8b86d5" xlink:to="loc_us-gaap_InterestPaidNet_845af3ff-28e0-468b-b366-be4194249879" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a5eb6e23-b366-4a8c-abe8-4a8a0c485d98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a5eb6e23-b366-4a8c-abe8-4a8a0c485d98" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_48055545-489f-430f-a3d7-16543fda0fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a5eb6e23-b366-4a8c-abe8-4a8a0c485d98" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_48055545-489f-430f-a3d7-16543fda0fa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CapitalContribution_3bab0387-1431-4190-9147-bc4241b75b4d" xlink:href="wald-20221231.xsd#wald_CapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a5eb6e23-b366-4a8c-abe8-4a8a0c485d98" xlink:to="loc_wald_CapitalContribution_3bab0387-1431-4190-9147-bc4241b75b4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DistributionToShareholderForDispositionOfBusiness_3b666767-e131-4df7-9cfe-e41c684a2799" xlink:href="wald-20221231.xsd#wald_DistributionToShareholderForDispositionOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a5eb6e23-b366-4a8c-abe8-4a8a0c485d98" xlink:to="loc_wald_DistributionToShareholderForDispositionOfBusiness_3b666767-e131-4df7-9cfe-e41c684a2799" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_bde4cebd-459f-4b06-9aa5-fb7f510dbd96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a5eb6e23-b366-4a8c-abe8-4a8a0c485d98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_bde4cebd-459f-4b06-9aa5-fb7f510dbd96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_3c813138-d597-4f82-bbac-93869e958f88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a5eb6e23-b366-4a8c-abe8-4a8a0c485d98" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_3c813138-d597-4f82-bbac-93869e958f88" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a3ca9851-2f98-4d44-b703-771cb17bd71d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:to="loc_us-gaap_StatementTable_a3ca9851-2f98-4d44-b703-771cb17bd71d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_59638e30-135d-43d5-9015-2123f99d780a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a3ca9851-2f98-4d44-b703-771cb17bd71d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_59638e30-135d-43d5-9015-2123f99d780a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_59638e30-135d-43d5-9015-2123f99d780a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_59638e30-135d-43d5-9015-2123f99d780a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_59638e30-135d-43d5-9015-2123f99d780a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eea409a8-bb67-47f4-9b97-3f066041a018" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_59638e30-135d-43d5-9015-2123f99d780a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eea409a8-bb67-47f4-9b97-3f066041a018" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiMergerMember_46a1febe-9151-4ac7-a72f-e87dfaf00135" xlink:href="wald-20221231.xsd#wald_ObagiMergerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eea409a8-bb67-47f4-9b97-3f066041a018" xlink:to="loc_wald_ObagiMergerMember_46a1febe-9151-4ac7-a72f-e87dfaf00135" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkTransactionMember_e9b254cb-5119-4bed-bb72-858850992f10" xlink:href="wald-20221231.xsd#wald_MilkTransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eea409a8-bb67-47f4-9b97-3f066041a018" xlink:to="loc_wald_MilkTransactionMember_e9b254cb-5119-4bed-bb72-858850992f10" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList_6cd9439b-6ed9-4b81-b167-47f5615fe6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:to="loc_us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList_6cd9439b-6ed9-4b81-b167-47f5615fe6ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5833b981-08cc-41e2-9d29-2c9be5e0c387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5833b981-08cc-41e2-9d29-2c9be5e0c387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockholdersEquityNumberOfSharesInEachUnit_08bda3c8-aeea-4e7d-88bc-95d3ace4dcf3" xlink:href="wald-20221231.xsd#wald_StockholdersEquityNumberOfSharesInEachUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:to="loc_wald_StockholdersEquityNumberOfSharesInEachUnit_08bda3c8-aeea-4e7d-88bc-95d3ace4dcf3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_d01825fb-15c6-4423-9bf3-0c14c8ae6380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_d01825fb-15c6-4423-9bf3-0c14c8ae6380" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_de929045-faba-497f-9154-2ea266fc0eec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_de929045-faba-497f-9154-2ea266fc0eec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1a361002-be96-4a31-b26c-15ddaa59d034" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1a361002-be96-4a31-b26c-15ddaa59d034" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ffd68439-cd98-4b7c-8d03-5466dca6ee47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:to="loc_us-gaap_CommonStockSharesIssued_ffd68439-cd98-4b7c-8d03-5466dca6ee47" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_d6ada9bd-77d4-4e37-bf4a-123186584a57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_d6ada9bd-77d4-4e37-bf4a-123186584a57" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_53bc9c53-8f97-4699-b6d6-8b6d6accc492" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_53bc9c53-8f97-4699-b6d6-8b6d6accc492" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c06add68-0b63-4ea2-bbb7-3e1c4a790e82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53bc9c53-8f97-4699-b6d6-8b6d6accc492" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c06add68-0b63-4ea2-bbb7-3e1c4a790e82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c06add68-0b63-4ea2-bbb7-3e1c4a790e82_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c06add68-0b63-4ea2-bbb7-3e1c4a790e82" xlink:to="loc_us-gaap_EquityComponentDomain_c06add68-0b63-4ea2-bbb7-3e1c4a790e82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_79df5983-ffb2-4512-a308-97895460ef90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c06add68-0b63-4ea2-bbb7-3e1c4a790e82" xlink:to="loc_us-gaap_EquityComponentDomain_79df5983-ffb2-4512-a308-97895460ef90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_475c9c82-26a5-445c-8f83-4d20b1493924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_79df5983-ffb2-4512-a308-97895460ef90" xlink:to="loc_us-gaap_CommonStockMember_475c9c82-26a5-445c-8f83-4d20b1493924" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_23518025-487a-4302-807a-794da19ffea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_79df5983-ffb2-4512-a308-97895460ef90" xlink:to="loc_us-gaap_WarrantMember_23518025-487a-4302-807a-794da19ffea8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_775ed692-4ef2-44e3-91d8-fe193ab6412e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53bc9c53-8f97-4699-b6d6-8b6d6accc492" xlink:to="loc_us-gaap_StatementClassOfStockAxis_775ed692-4ef2-44e3-91d8-fe193ab6412e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_775ed692-4ef2-44e3-91d8-fe193ab6412e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_775ed692-4ef2-44e3-91d8-fe193ab6412e" xlink:to="loc_us-gaap_ClassOfStockDomain_775ed692-4ef2-44e3-91d8-fe193ab6412e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1c90073c-6ff7-4a1c-be17-dae56b714c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_775ed692-4ef2-44e3-91d8-fe193ab6412e" xlink:to="loc_us-gaap_ClassOfStockDomain_1c90073c-6ff7-4a1c-be17-dae56b714c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_1be97771-958e-4284-a7c3-5485d9d4f485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1c90073c-6ff7-4a1c-be17-dae56b714c7d" xlink:to="loc_us-gaap_CommonClassAMember_1be97771-958e-4284-a7c3-5485d9d4f485" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4bb504c2-3730-4bda-b614-b4738cb5f6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53bc9c53-8f97-4699-b6d6-8b6d6accc492" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4bb504c2-3730-4bda-b614-b4738cb5f6ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4bb504c2-3730-4bda-b614-b4738cb5f6ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4bb504c2-3730-4bda-b614-b4738cb5f6ee" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4bb504c2-3730-4bda-b614-b4738cb5f6ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d4e4c58-2180-42cd-bcbd-d5276fe3bde6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4bb504c2-3730-4bda-b614-b4738cb5f6ee" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d4e4c58-2180-42cd-bcbd-d5276fe3bde6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_7e778ffa-2932-4699-a0e1-b97f94ce868d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d4e4c58-2180-42cd-bcbd-d5276fe3bde6" xlink:to="loc_us-gaap_IPOMember_7e778ffa-2932-4699-a0e1-b97f94ce868d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_036d72e2-4e3a-4994-96f8-499af97a416d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_036d72e2-4e3a-4994-96f8-499af97a416d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_feab4608-144e-45b0-9fc9-b68520cff193" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_feab4608-144e-45b0-9fc9-b68520cff193" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e2ca4e5f-e88a-457b-8f57-24e5d865a299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e2ca4e5f-e88a-457b-8f57-24e5d865a299" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bd059f1a-4b5a-4c22-8acc-3b9e697eebc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bd059f1a-4b5a-4c22-8acc-3b9e697eebc6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fa0ff8fb-e36b-4aeb-abaa-898adef80d72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fa0ff8fb-e36b-4aeb-abaa-898adef80d72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8d55280b-db68-497c-9b68-10835c59d57a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_us-gaap_InventoryNet_8d55280b-db68-497c-9b68-10835c59d57a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MinimumThresholdPeriodForContractRepaymentOverTime_1c494493-4f8f-4312-b29d-26eb3247fbeb" xlink:href="wald-20221231.xsd#wald_MinimumThresholdPeriodForContractRepaymentOverTime"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_wald_MinimumThresholdPeriodForContractRepaymentOverTime_1c494493-4f8f-4312-b29d-26eb3247fbeb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_346b9460-509f-4664-9f88-52b283750313" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_us-gaap_OtherNonoperatingIncome_346b9460-509f-4664-9f88-52b283750313" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a26c303a-b2e7-4c61-aa6d-ab26114aeb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a26c303a-b2e7-4c61-aa6d-ab26114aeb6c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_2cb905bc-f810-4d7c-8c76-2fcc6e617bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_2cb905bc-f810-4d7c-8c76-2fcc6e617bbb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_bc8e6da4-1fe4-44c8-9151-76036daffeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_2cb905bc-f810-4d7c-8c76-2fcc6e617bbb" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_bc8e6da4-1fe4-44c8-9151-76036daffeb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_bc8e6da4-1fe4-44c8-9151-76036daffeb8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_bc8e6da4-1fe4-44c8-9151-76036daffeb8" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_bc8e6da4-1fe4-44c8-9151-76036daffeb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_4c1a5f56-e017-4953-84f5-85b8ebbb7219" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_bc8e6da4-1fe4-44c8-9151-76036daffeb8" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_4c1a5f56-e017-4953-84f5-85b8ebbb7219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfDistributorServiceFeesMember_6d56a1de-4c86-4902-b88d-3e08113401f0" xlink:href="wald-20221231.xsd#wald_MisstatementOfDistributorServiceFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_4c1a5f56-e017-4953-84f5-85b8ebbb7219" xlink:to="loc_wald_MisstatementOfDistributorServiceFeesMember_6d56a1de-4c86-4902-b88d-3e08113401f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfRevenueRecognitionTimingMember_d592cd2e-3eb8-45ba-ba7c-3bac74652af4" xlink:href="wald-20221231.xsd#wald_MisstatementOfRevenueRecognitionTimingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_4c1a5f56-e017-4953-84f5-85b8ebbb7219" xlink:to="loc_wald_MisstatementOfRevenueRecognitionTimingMember_d592cd2e-3eb8-45ba-ba7c-3bac74652af4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_94843cb1-a6d4-45b5-8326-76ab05f71f28" xlink:href="wald-20221231.xsd#wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_4c1a5f56-e017-4953-84f5-85b8ebbb7219" xlink:to="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_94843cb1-a6d4-45b5-8326-76ab05f71f28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember_b4208fd4-7ff8-49b4-b3d5-57824df8ed20" xlink:href="wald-20221231.xsd#wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_4c1a5f56-e017-4953-84f5-85b8ebbb7219" xlink:to="loc_wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember_b4208fd4-7ff8-49b4-b3d5-57824df8ed20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OtherMisstatementAdjustmentsMember_5b78bcae-6baf-4871-b877-76e66833f5f4" xlink:href="wald-20221231.xsd#wald_OtherMisstatementAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_4c1a5f56-e017-4953-84f5-85b8ebbb7219" xlink:to="loc_wald_OtherMisstatementAdjustmentsMember_5b78bcae-6baf-4871-b877-76e66833f5f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_495da122-2f6f-48d0-9b41-254b2d164470" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_2cb905bc-f810-4d7c-8c76-2fcc6e617bbb" xlink:to="loc_srt_RestatementAxis_495da122-2f6f-48d0-9b41-254b2d164470" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_495da122-2f6f-48d0-9b41-254b2d164470_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_495da122-2f6f-48d0-9b41-254b2d164470" xlink:to="loc_srt_RestatementDomain_495da122-2f6f-48d0-9b41-254b2d164470_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_48280cd2-eb7e-409a-9a15-2c6dbdd883a0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_495da122-2f6f-48d0-9b41-254b2d164470" xlink:to="loc_srt_RestatementDomain_48280cd2-eb7e-409a-9a15-2c6dbdd883a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_efff0555-59f9-480f-84fc-a59d8baaa0dc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_48280cd2-eb7e-409a-9a15-2c6dbdd883a0" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_efff0555-59f9-480f-84fc-a59d8baaa0dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_bf89e837-868c-48cf-b834-3f1f5ab25f72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_2cb905bc-f810-4d7c-8c76-2fcc6e617bbb" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_bf89e837-868c-48cf-b834-3f1f5ab25f72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_bf89e837-868c-48cf-b834-3f1f5ab25f72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_bf89e837-868c-48cf-b834-3f1f5ab25f72" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_bf89e837-868c-48cf-b834-3f1f5ab25f72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_61b443f4-be91-4881-917f-025f723a1a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_bf89e837-868c-48cf-b834-3f1f5ab25f72" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_61b443f4-be91-4881-917f-025f723a1a8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember_3c08d7fc-55c1-4e54-b2bc-408a73366c53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_61b443f4-be91-4881-917f-025f723a1a8d" xlink:to="loc_us-gaap_SalesChannelThroughIntermediaryMember_3c08d7fc-55c1-4e54-b2bc-408a73366c53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SADistributorMember_77c3ea77-bb0d-42f5-a3e6-3628415e502d" xlink:href="wald-20221231.xsd#wald_SADistributorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_61b443f4-be91-4881-917f-025f723a1a8d" xlink:to="loc_wald_SADistributorMember_77c3ea77-bb0d-42f5-a3e6-3628415e502d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PhysicianChannelProviderMember_4a997c32-4fd4-47a8-bc72-325dd331e8a4" xlink:href="wald-20221231.xsd#wald_PhysicianChannelProviderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_61b443f4-be91-4881-917f-025f723a1a8d" xlink:to="loc_wald_PhysicianChannelProviderMember_4a997c32-4fd4-47a8-bc72-325dd331e8a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_USOnlineMarketplaceDistributorMember_2e4604d0-9b9f-4d62-b994-0ad55d04b883" xlink:href="wald-20221231.xsd#wald_USOnlineMarketplaceDistributorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_61b443f4-be91-4881-917f-025f723a1a8d" xlink:to="loc_wald_USOnlineMarketplaceDistributorMember_2e4604d0-9b9f-4d62-b994-0ad55d04b883" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_499910f3-09bd-4c81-82ac-c8b0b9cc29c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f277346d-d3f0-4989-8cb8-a791a84ec132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_499910f3-09bd-4c81-82ac-c8b0b9cc29c5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f277346d-d3f0-4989-8cb8-a791a84ec132" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_3f6b1265-6dce-4552-ae34-d74d72e68160" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_499910f3-09bd-4c81-82ac-c8b0b9cc29c5" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_3f6b1265-6dce-4552-ae34-d74d72e68160" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_bba640ca-d043-4b09-b168-a955a99ee58e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_3f6b1265-6dce-4552-ae34-d74d72e68160" xlink:to="loc_srt_RestatementAxis_bba640ca-d043-4b09-b168-a955a99ee58e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_bba640ca-d043-4b09-b168-a955a99ee58e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_bba640ca-d043-4b09-b168-a955a99ee58e" xlink:to="loc_srt_RestatementDomain_bba640ca-d043-4b09-b168-a955a99ee58e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_66a0fa32-2945-4e55-a651-9ab8f81a53b9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_bba640ca-d043-4b09-b168-a955a99ee58e" xlink:to="loc_srt_RestatementDomain_66a0fa32-2945-4e55-a651-9ab8f81a53b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_52866c45-b5c3-430d-a630-73eb638526df" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_66a0fa32-2945-4e55-a651-9ab8f81a53b9" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_52866c45-b5c3-430d-a630-73eb638526df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_ebd1433f-231c-4947-8027-67dcd39c22b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_3f6b1265-6dce-4552-ae34-d74d72e68160" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_ebd1433f-231c-4947-8027-67dcd39c22b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_ebd1433f-231c-4947-8027-67dcd39c22b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_ebd1433f-231c-4947-8027-67dcd39c22b2" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_ebd1433f-231c-4947-8027-67dcd39c22b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_0405b221-708f-4105-99ab-50b9a083485a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_ebd1433f-231c-4947-8027-67dcd39c22b2" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_0405b221-708f-4105-99ab-50b9a083485a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PhysicianChannelProviderMember_9ff68f12-3b25-4dad-a195-eb10a7785777" xlink:href="wald-20221231.xsd#wald_PhysicianChannelProviderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_0405b221-708f-4105-99ab-50b9a083485a" xlink:to="loc_wald_PhysicianChannelProviderMember_9ff68f12-3b25-4dad-a195-eb10a7785777" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_16fbcca1-17e0-4456-ad08-240724854d53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_3f6b1265-6dce-4552-ae34-d74d72e68160" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_16fbcca1-17e0-4456-ad08-240724854d53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_16fbcca1-17e0-4456-ad08-240724854d53_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_16fbcca1-17e0-4456-ad08-240724854d53" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_16fbcca1-17e0-4456-ad08-240724854d53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_7002d101-8e23-4b3a-b1b4-6fbfa577e86c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_16fbcca1-17e0-4456-ad08-240724854d53" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_7002d101-8e23-4b3a-b1b4-6fbfa577e86c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_560efcb7-f64b-49f4-b64b-b047eae16175" xlink:href="wald-20221231.xsd#wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_7002d101-8e23-4b3a-b1b4-6fbfa577e86c" xlink:to="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_560efcb7-f64b-49f4-b64b-b047eae16175" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfInventoryMember_db55d2eb-fb41-4a9c-9592-b31cab2467c2" xlink:href="wald-20221231.xsd#wald_MisstatementOfInventoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_7002d101-8e23-4b3a-b1b4-6fbfa577e86c" xlink:to="loc_wald_MisstatementOfInventoryMember_db55d2eb-fb41-4a9c-9592-b31cab2467c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OtherMisstatementAdjustmentsMember_633df691-c2e4-4ba9-9336-74dd965819d9" xlink:href="wald-20221231.xsd#wald_OtherMisstatementAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_7002d101-8e23-4b3a-b1b4-6fbfa577e86c" xlink:to="loc_wald_OtherMisstatementAdjustmentsMember_633df691-c2e4-4ba9-9336-74dd965819d9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_8256eff1-aa81-4443-ac47-d0eaea9e1967" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6fd4c36b-fc6b-40d5-9a79-a79d0c0b7dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_8256eff1-aa81-4443-ac47-d0eaea9e1967" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6fd4c36b-fc6b-40d5-9a79-a79d0c0b7dbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_5114dc05-0f37-43bc-b454-def4cbcc388d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_8256eff1-aa81-4443-ac47-d0eaea9e1967" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_5114dc05-0f37-43bc-b454-def4cbcc388d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_27a197d3-ee02-4d0b-9c94-a5702c1be200" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_5114dc05-0f37-43bc-b454-def4cbcc388d" xlink:to="loc_srt_RestatementAxis_27a197d3-ee02-4d0b-9c94-a5702c1be200" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_27a197d3-ee02-4d0b-9c94-a5702c1be200_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_27a197d3-ee02-4d0b-9c94-a5702c1be200" xlink:to="loc_srt_RestatementDomain_27a197d3-ee02-4d0b-9c94-a5702c1be200_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_ccc760e4-f6e7-4f34-98a6-65877996c52d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_27a197d3-ee02-4d0b-9c94-a5702c1be200" xlink:to="loc_srt_RestatementDomain_ccc760e4-f6e7-4f34-98a6-65877996c52d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_aa352e07-1fcd-4dee-a89b-ea07b1b8d5dd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_ccc760e4-f6e7-4f34-98a6-65877996c52d" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_aa352e07-1fcd-4dee-a89b-ea07b1b8d5dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1ae7e2f5-b95b-4449-9602-1f144322ec2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_5114dc05-0f37-43bc-b454-def4cbcc388d" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1ae7e2f5-b95b-4449-9602-1f144322ec2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1ae7e2f5-b95b-4449-9602-1f144322ec2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1ae7e2f5-b95b-4449-9602-1f144322ec2e" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_1ae7e2f5-b95b-4449-9602-1f144322ec2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_e3d1b501-3cea-4028-9bc7-9e6db1c9b1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1ae7e2f5-b95b-4449-9602-1f144322ec2e" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_e3d1b501-3cea-4028-9bc7-9e6db1c9b1ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfDistributorServiceFeesMember_a1d26634-e7d2-452b-93ee-dbcee039f562" xlink:href="wald-20221231.xsd#wald_MisstatementOfDistributorServiceFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_e3d1b501-3cea-4028-9bc7-9e6db1c9b1ea" xlink:to="loc_wald_MisstatementOfDistributorServiceFeesMember_a1d26634-e7d2-452b-93ee-dbcee039f562" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_4784f247-58bd-45b6-b1ae-5b5640ea7e9d" xlink:href="wald-20221231.xsd#wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_e3d1b501-3cea-4028-9bc7-9e6db1c9b1ea" xlink:to="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_4784f247-58bd-45b6-b1ae-5b5640ea7e9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember_0f69e296-7469-477c-be63-597646579066" xlink:href="wald-20221231.xsd#wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_e3d1b501-3cea-4028-9bc7-9e6db1c9b1ea" xlink:to="loc_wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember_0f69e296-7469-477c-be63-597646579066" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember_65592543-3899-4608-abc5-c4984f778bd9" xlink:href="wald-20221231.xsd#wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_e3d1b501-3cea-4028-9bc7-9e6db1c9b1ea" xlink:to="loc_wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember_65592543-3899-4608-abc5-c4984f778bd9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OtherMisstatementAdjustmentsMember_f152d728-11d5-4742-84ee-3ea46eb1c6fd" xlink:href="wald-20221231.xsd#wald_OtherMisstatementAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_e3d1b501-3cea-4028-9bc7-9e6db1c9b1ea" xlink:to="loc_wald_OtherMisstatementAdjustmentsMember_f152d728-11d5-4742-84ee-3ea46eb1c6fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_65544ca3-936f-4f48-a5f0-2d571dcdd749" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_5114dc05-0f37-43bc-b454-def4cbcc388d" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_65544ca3-936f-4f48-a5f0-2d571dcdd749" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_65544ca3-936f-4f48-a5f0-2d571dcdd749_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_65544ca3-936f-4f48-a5f0-2d571dcdd749" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_65544ca3-936f-4f48-a5f0-2d571dcdd749_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_e8a17638-e546-46ca-b7e3-7afac905cf89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_65544ca3-936f-4f48-a5f0-2d571dcdd749" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_e8a17638-e546-46ca-b7e3-7afac905cf89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PhysicianChannelProviderMember_26ce278d-50fe-4048-b9fb-e5dcbfcddb75" xlink:href="wald-20221231.xsd#wald_PhysicianChannelProviderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_e8a17638-e546-46ca-b7e3-7afac905cf89" xlink:to="loc_wald_PhysicianChannelProviderMember_26ce278d-50fe-4048-b9fb-e5dcbfcddb75" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors_29ee09ca-ab7c-44e9-8fc1-f1b828cd7ce6" xlink:href="wald-20221231.xsd#wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors_29ee09ca-ab7c-44e9-8fc1-f1b828cd7ce6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cd80a446-c302-48f6-93f3-dc92e30087ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cd80a446-c302-48f6-93f3-dc92e30087ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2e749ff9-221d-4424-ae23-bcb5e88bec72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2e749ff9-221d-4424-ae23-bcb5e88bec72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6119b283-89d4-416b-a694-8ec4b6789e76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6119b283-89d4-416b-a694-8ec4b6789e76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_af295b6a-fb0c-4ef9-9868-3a04cf7c4f88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_af295b6a-fb0c-4ef9-9868-3a04cf7c4f88" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_68db9b45-38f9-43a4-ba75-ba8b3442e766" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_AccountsPayableCurrent_68db9b45-38f9-43a4-ba75-ba8b3442e766" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2c38c021-529f-4c1b-8208-7e316b3ccc66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2c38c021-529f-4c1b-8208-7e316b3ccc66" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_50d00822-a8cc-4f52-8af7-ce9e2f15749b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_50d00822-a8cc-4f52-8af7-ce9e2f15749b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_501992ae-2510-46e9-90e6-d9bdcc0635f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_501992ae-2510-46e9-90e6-d9bdcc0635f4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4e689ae8-ca06-40db-9a92-13b96938f94c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_ProfitLoss_4e689ae8-ca06-40db-9a92-13b96938f94c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_a11caf87-099b-4cc6-93dc-a0a09c460106" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_a11caf87-099b-4cc6-93dc-a0a09c460106" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_c3c4aaf0-b574-44e8-a7d9-12033bffe325" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_a11caf87-099b-4cc6-93dc-a0a09c460106" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_c3c4aaf0-b574-44e8-a7d9-12033bffe325" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_c3c4aaf0-b574-44e8-a7d9-12033bffe325_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_c3c4aaf0-b574-44e8-a7d9-12033bffe325" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_c3c4aaf0-b574-44e8-a7d9-12033bffe325_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_c3c4aaf0-b574-44e8-a7d9-12033bffe325" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember_9c988559-ba16-401f-8ace-0f11bee65d08" xlink:href="wald-20221231.xsd#wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:to="loc_wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember_9c988559-ba16-401f-8ace-0f11bee65d08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfCapitalizedMarketingExpensesMember_ab9c131f-f8b1-4d86-8f94-f9508d1efd6d" xlink:href="wald-20221231.xsd#wald_MisstatementOfCapitalizedMarketingExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:to="loc_wald_MisstatementOfCapitalizedMarketingExpensesMember_ab9c131f-f8b1-4d86-8f94-f9508d1efd6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfResearchAndDevelopmentExpenseMember_6eda3e6b-4294-4828-b930-d27e362dccf0" xlink:href="wald-20221231.xsd#wald_MisstatementOfResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:to="loc_wald_MisstatementOfResearchAndDevelopmentExpenseMember_6eda3e6b-4294-4828-b930-d27e362dccf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember_e11edf31-3fcd-4ab9-820a-afac655b8c26" xlink:href="wald-20221231.xsd#wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:to="loc_wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember_e11edf31-3fcd-4ab9-820a-afac655b8c26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OtherMisstatementAdjustmentsMember_7485e989-2bb5-4223-9d9e-8b5fbac50d8a" xlink:href="wald-20221231.xsd#wald_OtherMisstatementAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:to="loc_wald_OtherMisstatementAdjustmentsMember_7485e989-2bb5-4223-9d9e-8b5fbac50d8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember_e8bcb066-a65a-4ee1-a1cd-606f4326b44c" xlink:href="wald-20221231.xsd#wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:to="loc_wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember_e8bcb066-a65a-4ee1-a1cd-606f4326b44c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember_00c9f1f3-6f88-4faf-9759-c3b8ae684148" xlink:href="wald-20221231.xsd#wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:to="loc_wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember_00c9f1f3-6f88-4faf-9759-c3b8ae684148" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfAccruedDistributionServiceFeesMember_b159f616-40a6-4496-b23b-4500e6d45485" xlink:href="wald-20221231.xsd#wald_MisstatementOfAccruedDistributionServiceFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:to="loc_wald_MisstatementOfAccruedDistributionServiceFeesMember_b159f616-40a6-4496-b23b-4500e6d45485" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember_7f395a1c-a601-4009-a630-2b56a6714d55" xlink:href="wald-20221231.xsd#wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:to="loc_wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember_7f395a1c-a601-4009-a630-2b56a6714d55" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_ebb2dd1b-7118-40c6-8a70-4806bae9e3ad" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_a11caf87-099b-4cc6-93dc-a0a09c460106" xlink:to="loc_srt_RestatementAxis_ebb2dd1b-7118-40c6-8a70-4806bae9e3ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_ebb2dd1b-7118-40c6-8a70-4806bae9e3ad_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_ebb2dd1b-7118-40c6-8a70-4806bae9e3ad" xlink:to="loc_srt_RestatementDomain_ebb2dd1b-7118-40c6-8a70-4806bae9e3ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_f7101d92-4f69-4e51-9a72-2c97cde79ea5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_ebb2dd1b-7118-40c6-8a70-4806bae9e3ad" xlink:to="loc_srt_RestatementDomain_f7101d92-4f69-4e51-9a72-2c97cde79ea5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_afd54fd2-658f-4c76-b5d1-7d620ba8653e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_f7101d92-4f69-4e51-9a72-2c97cde79ea5" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_afd54fd2-658f-4c76-b5d1-7d620ba8653e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_0f097afb-dada-426d-98ec-ac5345949b21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_a11caf87-099b-4cc6-93dc-a0a09c460106" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_0f097afb-dada-426d-98ec-ac5345949b21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_0f097afb-dada-426d-98ec-ac5345949b21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_0f097afb-dada-426d-98ec-ac5345949b21" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_0f097afb-dada-426d-98ec-ac5345949b21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_dba3bb4c-e1c7-405c-bc90-30efb1e16710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_0f097afb-dada-426d-98ec-ac5345949b21" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_dba3bb4c-e1c7-405c-bc90-30efb1e16710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_USOnlineMarketplaceDistributorMember_222a0b34-534c-45e8-8084-05c96c39c81d" xlink:href="wald-20221231.xsd#wald_USOnlineMarketplaceDistributorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_dba3bb4c-e1c7-405c-bc90-30efb1e16710" xlink:to="loc_wald_USOnlineMarketplaceDistributorMember_222a0b34-534c-45e8-8084-05c96c39c81d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_USOnlineMarketplaceDistributorAndSADistributorMember_8f4e1756-36ce-4d7a-8171-556f7112ffab" xlink:href="wald-20221231.xsd#wald_USOnlineMarketplaceDistributorAndSADistributorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_dba3bb4c-e1c7-405c-bc90-30efb1e16710" xlink:to="loc_wald_USOnlineMarketplaceDistributorAndSADistributorMember_8f4e1756-36ce-4d7a-8171-556f7112ffab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bd6bb6ec-3686-484e-ad62-ae18926c1453" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_a11caf87-099b-4cc6-93dc-a0a09c460106" xlink:to="loc_dei_LegalEntityAxis_bd6bb6ec-3686-484e-ad62-ae18926c1453" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bd6bb6ec-3686-484e-ad62-ae18926c1453_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_bd6bb6ec-3686-484e-ad62-ae18926c1453" xlink:to="loc_dei_EntityDomain_bd6bb6ec-3686-484e-ad62-ae18926c1453_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_68018df6-5b0e-4db6-855d-e7931bdd461e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_bd6bb6ec-3686-484e-ad62-ae18926c1453" xlink:to="loc_dei_EntityDomain_68018df6-5b0e-4db6-855d-e7931bdd461e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiCosmeceuticalsLLCMember_f7f179e8-1848-43e2-b6b2-5ee5c87dcc22" xlink:href="wald-20221231.xsd#wald_ObagiCosmeceuticalsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_68018df6-5b0e-4db6-855d-e7931bdd461e" xlink:to="loc_wald_ObagiCosmeceuticalsLLCMember_f7f179e8-1848-43e2-b6b2-5ee5c87dcc22" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3a4560c4-abc5-4cd4-a135-3f1443df7bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_22d5e3d6-5f5c-48c8-9de9-baac09b40ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3a4560c4-abc5-4cd4-a135-3f1443df7bc7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_22d5e3d6-5f5c-48c8-9de9-baac09b40ffb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainLossOnNoteReceivableWriteoff_50bf6da8-c51f-48b5-8be2-9fce6a48eb53" xlink:href="wald-20221231.xsd#wald_GainLossOnNoteReceivableWriteoff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3a4560c4-abc5-4cd4-a135-3f1443df7bc7" xlink:to="loc_wald_GainLossOnNoteReceivableWriteoff_50bf6da8-c51f-48b5-8be2-9fce6a48eb53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_aa68663d-b179-485c-8e9a-3d448047ee0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3a4560c4-abc5-4cd4-a135-3f1443df7bc7" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_aa68663d-b179-485c-8e9a-3d448047ee0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_88584c8f-02b5-499f-8eb2-778414123ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_aa68663d-b179-485c-8e9a-3d448047ee0c" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_88584c8f-02b5-499f-8eb2-778414123ae8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_88584c8f-02b5-499f-8eb2-778414123ae8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_88584c8f-02b5-499f-8eb2-778414123ae8" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_88584c8f-02b5-499f-8eb2-778414123ae8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_ff0dfac2-7dc7-42f5-89a4-e5d26499a2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_88584c8f-02b5-499f-8eb2-778414123ae8" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_ff0dfac2-7dc7-42f5-89a4-e5d26499a2a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfRevenueRecognitionTimingMember_c62d3a10-a3a1-49bb-870b-9f92332ba102" xlink:href="wald-20221231.xsd#wald_MisstatementOfRevenueRecognitionTimingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_ff0dfac2-7dc7-42f5-89a4-e5d26499a2a5" xlink:to="loc_wald_MisstatementOfRevenueRecognitionTimingMember_c62d3a10-a3a1-49bb-870b-9f92332ba102" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_c2b52498-a04f-40e2-8b77-189bc8fc95c1" xlink:href="wald-20221231.xsd#wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_ff0dfac2-7dc7-42f5-89a4-e5d26499a2a5" xlink:to="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_c2b52498-a04f-40e2-8b77-189bc8fc95c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember_666a19c6-ee5a-4a8c-aa46-e2579b33831a" xlink:href="wald-20221231.xsd#wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_ff0dfac2-7dc7-42f5-89a4-e5d26499a2a5" xlink:to="loc_wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember_666a19c6-ee5a-4a8c-aa46-e2579b33831a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OtherMisstatementAdjustmentsMember_c8ab9318-64c5-4f82-a580-9aef13eea4d0" xlink:href="wald-20221231.xsd#wald_OtherMisstatementAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_ff0dfac2-7dc7-42f5-89a4-e5d26499a2a5" xlink:to="loc_wald_OtherMisstatementAdjustmentsMember_c8ab9318-64c5-4f82-a580-9aef13eea4d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_92e8292f-b471-4f91-97f5-282ee1b6f791" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_aa68663d-b179-485c-8e9a-3d448047ee0c" xlink:to="loc_srt_RestatementAxis_92e8292f-b471-4f91-97f5-282ee1b6f791" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_92e8292f-b471-4f91-97f5-282ee1b6f791_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_92e8292f-b471-4f91-97f5-282ee1b6f791" xlink:to="loc_srt_RestatementDomain_92e8292f-b471-4f91-97f5-282ee1b6f791_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_9b5e91f6-67cc-4630-89cd-3f4ebaa9eef1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_92e8292f-b471-4f91-97f5-282ee1b6f791" xlink:to="loc_srt_RestatementDomain_9b5e91f6-67cc-4630-89cd-3f4ebaa9eef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_43e7a675-0486-443c-81fd-a635d3d571cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_9b5e91f6-67cc-4630-89cd-3f4ebaa9eef1" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_43e7a675-0486-443c-81fd-a635d3d571cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_33be940c-5621-4d02-ac90-683da1e1ebfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_aa68663d-b179-485c-8e9a-3d448047ee0c" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_33be940c-5621-4d02-ac90-683da1e1ebfd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_33be940c-5621-4d02-ac90-683da1e1ebfd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_33be940c-5621-4d02-ac90-683da1e1ebfd" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_33be940c-5621-4d02-ac90-683da1e1ebfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_da4f0700-5890-4d6e-a8bb-170149c3acf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_33be940c-5621-4d02-ac90-683da1e1ebfd" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_da4f0700-5890-4d6e-a8bb-170149c3acf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SADistributorMember_4df03d8e-7932-4210-b86a-a71df227f67f" xlink:href="wald-20221231.xsd#wald_SADistributorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_da4f0700-5890-4d6e-a8bb-170149c3acf9" xlink:to="loc_wald_SADistributorMember_4df03d8e-7932-4210-b86a-a71df227f67f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PhysicianChannelProviderMember_7b379788-b62f-4b6a-96f9-0063df51e253" xlink:href="wald-20221231.xsd#wald_PhysicianChannelProviderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_da4f0700-5890-4d6e-a8bb-170149c3acf9" xlink:to="loc_wald_PhysicianChannelProviderMember_7b379788-b62f-4b6a-96f9-0063df51e253" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e4d5286b-ef74-4929-8bda-293e5bcef054" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_017e6c77-7eb2-45fa-9bfd-08977988593b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e4d5286b-ef74-4929-8bda-293e5bcef054" xlink:to="loc_us-gaap_InventoryNet_017e6c77-7eb2-45fa-9bfd-08977988593b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_81329e61-4985-4915-93a4-49edd8836359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e4d5286b-ef74-4929-8bda-293e5bcef054" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_81329e61-4985-4915-93a4-49edd8836359" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_c1891ade-86ce-4c25-8d54-772a7c089640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_81329e61-4985-4915-93a4-49edd8836359" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_c1891ade-86ce-4c25-8d54-772a7c089640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_c1891ade-86ce-4c25-8d54-772a7c089640_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_c1891ade-86ce-4c25-8d54-772a7c089640" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_c1891ade-86ce-4c25-8d54-772a7c089640_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_79ae423e-0410-4f15-9958-3951d3be5b90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_c1891ade-86ce-4c25-8d54-772a7c089640" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_79ae423e-0410-4f15-9958-3951d3be5b90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_d97500c5-cf4b-4ea1-b433-3873579a677e" xlink:href="wald-20221231.xsd#wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_79ae423e-0410-4f15-9958-3951d3be5b90" xlink:to="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_d97500c5-cf4b-4ea1-b433-3873579a677e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfInventoryMember_3f192b78-6efc-48de-9e94-4af61326a6c7" xlink:href="wald-20221231.xsd#wald_MisstatementOfInventoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_79ae423e-0410-4f15-9958-3951d3be5b90" xlink:to="loc_wald_MisstatementOfInventoryMember_3f192b78-6efc-48de-9e94-4af61326a6c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OtherMisstatementAdjustmentsMember_c7854a7b-8150-46c7-8668-c4062808c906" xlink:href="wald-20221231.xsd#wald_OtherMisstatementAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_79ae423e-0410-4f15-9958-3951d3be5b90" xlink:to="loc_wald_OtherMisstatementAdjustmentsMember_c7854a7b-8150-46c7-8668-c4062808c906" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_7f6a21d2-5f96-4991-a62a-49575658f6a4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_81329e61-4985-4915-93a4-49edd8836359" xlink:to="loc_srt_RestatementAxis_7f6a21d2-5f96-4991-a62a-49575658f6a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_7f6a21d2-5f96-4991-a62a-49575658f6a4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_7f6a21d2-5f96-4991-a62a-49575658f6a4" xlink:to="loc_srt_RestatementDomain_7f6a21d2-5f96-4991-a62a-49575658f6a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_5b497840-3c86-4a85-b6eb-17f4c338d85c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_7f6a21d2-5f96-4991-a62a-49575658f6a4" xlink:to="loc_srt_RestatementDomain_5b497840-3c86-4a85-b6eb-17f4c338d85c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_2be7fee6-949e-477c-b7eb-4f93aafb2e60" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_5b497840-3c86-4a85-b6eb-17f4c338d85c" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_2be7fee6-949e-477c-b7eb-4f93aafb2e60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_452a6d7b-107b-430f-8925-21e8f397b399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_81329e61-4985-4915-93a4-49edd8836359" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_452a6d7b-107b-430f-8925-21e8f397b399" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_452a6d7b-107b-430f-8925-21e8f397b399_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_452a6d7b-107b-430f-8925-21e8f397b399" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_452a6d7b-107b-430f-8925-21e8f397b399_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_02796102-7b3c-412d-88be-18f24275daf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_452a6d7b-107b-430f-8925-21e8f397b399" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_02796102-7b3c-412d-88be-18f24275daf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PhysicianChannelProviderMember_57db139d-31fc-4f26-a03a-d1ebfed05104" xlink:href="wald-20221231.xsd#wald_PhysicianChannelProviderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_02796102-7b3c-412d-88be-18f24275daf4" xlink:to="loc_wald_PhysicianChannelProviderMember_57db139d-31fc-4f26-a03a-d1ebfed05104" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofReclassificationAdjustmentsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSSummaryofReclassificationAdjustmentsDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofReclassificationAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationLineItems_59ab163f-2701-4279-ab20-6156c51beba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_89ba3771-9a04-430d-99ba-cd903b615f08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationLineItems_59ab163f-2701-4279-ab20-6156c51beba4" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_89ba3771-9a04-430d-99ba-cd903b615f08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTable_6179af61-2f96-46c4-8131-0a62ca2f924f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationLineItems_59ab163f-2701-4279-ab20-6156c51beba4" xlink:to="loc_us-gaap_ReclassificationTable_6179af61-2f96-46c4-8131-0a62ca2f924f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_057e5503-4698-4973-ad58-b3ac3ef6b2a4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationTable_6179af61-2f96-46c4-8131-0a62ca2f924f" xlink:to="loc_srt_RestatementAxis_057e5503-4698-4973-ad58-b3ac3ef6b2a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_057e5503-4698-4973-ad58-b3ac3ef6b2a4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_057e5503-4698-4973-ad58-b3ac3ef6b2a4" xlink:to="loc_srt_RestatementDomain_057e5503-4698-4973-ad58-b3ac3ef6b2a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_d194af9b-659e-47b5-9de8-8c6739fb719d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_057e5503-4698-4973-ad58-b3ac3ef6b2a4" xlink:to="loc_srt_RestatementDomain_d194af9b-659e-47b5-9de8-8c6739fb719d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_91b58377-38f9-40db-aaf7-36ef6082f407" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_d194af9b-659e-47b5-9de8-8c6739fb719d" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_91b58377-38f9-40db-aaf7-36ef6082f407" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_aedd5399-7c5f-48eb-a908-8f6171cc4366" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_2bd42bf5-3325-400f-be45-639f949b74c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_aedd5399-7c5f-48eb-a908-8f6171cc4366" xlink:to="loc_us-gaap_AssetsAbstract_2bd42bf5-3325-400f-be45-639f949b74c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_bd48ff7c-6d3b-48a7-9e7a-a7d1546600fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2bd42bf5-3325-400f-be45-639f949b74c9" xlink:to="loc_us-gaap_AssetsCurrentAbstract_bd48ff7c-6d3b-48a7-9e7a-a7d1546600fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_80a41c26-9b12-434d-9c53-4a5c1328be81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd48ff7c-6d3b-48a7-9e7a-a7d1546600fe" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_80a41c26-9b12-434d-9c53-4a5c1328be81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_1b7ba2bb-cb88-4f16-9955-7da66c827c49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd48ff7c-6d3b-48a7-9e7a-a7d1546600fe" xlink:to="loc_us-gaap_RestrictedCash_1b7ba2bb-cb88-4f16-9955-7da66c827c49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6b705161-1a10-443a-9941-89fd3a3dccc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd48ff7c-6d3b-48a7-9e7a-a7d1546600fe" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6b705161-1a10-443a-9941-89fd3a3dccc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_3d7b3568-e488-43e5-a1b2-a0faabf74640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd48ff7c-6d3b-48a7-9e7a-a7d1546600fe" xlink:to="loc_us-gaap_InventoryNet_3d7b3568-e488-43e5-a1b2-a0faabf74640" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_e8162c0f-94ff-4d64-91a9-c818c2ed80fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd48ff7c-6d3b-48a7-9e7a-a7d1546600fe" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_e8162c0f-94ff-4d64-91a9-c818c2ed80fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_dc490bdd-07e9-4aa8-93fa-1e9f3182f718" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd48ff7c-6d3b-48a7-9e7a-a7d1546600fe" xlink:to="loc_us-gaap_OtherAssetsCurrent_dc490bdd-07e9-4aa8-93fa-1e9f3182f718" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0c63bdbb-d0e6-4fb2-997f-dfa27871ebaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd48ff7c-6d3b-48a7-9e7a-a7d1546600fe" xlink:to="loc_us-gaap_AssetsCurrent_0c63bdbb-d0e6-4fb2-997f-dfa27871ebaa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_252d9784-ee0c-47da-8d6d-25d88f1d88e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2bd42bf5-3325-400f-be45-639f949b74c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_252d9784-ee0c-47da-8d6d-25d88f1d88e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_651a5bfc-92ce-4f9c-82f8-b6d226576651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2bd42bf5-3325-400f-be45-639f949b74c9" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_651a5bfc-92ce-4f9c-82f8-b6d226576651" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_46f5270a-632c-49f9-9271-ba0282e14555" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2bd42bf5-3325-400f-be45-639f949b74c9" xlink:to="loc_us-gaap_Goodwill_46f5270a-632c-49f9-9271-ba0282e14555" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3fbec805-540d-4cb7-88ea-d40e1521ea1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2bd42bf5-3325-400f-be45-639f949b74c9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3fbec805-540d-4cb7-88ea-d40e1521ea1b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cbb98d93-e014-40dd-8b75-50e4048f91de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2bd42bf5-3325-400f-be45-639f949b74c9" xlink:to="loc_us-gaap_Assets_cbb98d93-e014-40dd-8b75-50e4048f91de" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e1c08bb-c1c8-4ef8-9519-76dd3a386fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_aedd5399-7c5f-48eb-a908-8f6171cc4366" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e1c08bb-c1c8-4ef8-9519-76dd3a386fa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_96938cf8-010d-417c-b261-752cdd8536fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e1c08bb-c1c8-4ef8-9519-76dd3a386fa3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_96938cf8-010d-417c-b261-752cdd8536fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_dc3a7039-22b9-4ade-a9b2-be38471455ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96938cf8-010d-417c-b261-752cdd8536fd" xlink:to="loc_us-gaap_AccountsPayableCurrent_dc3a7039-22b9-4ade-a9b2-be38471455ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b283c6a8-4ead-4c89-8525-c6f63126beb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96938cf8-010d-417c-b261-752cdd8536fd" xlink:to="loc_us-gaap_LongTermDebtCurrent_b283c6a8-4ead-4c89-8525-c6f63126beb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_02112075-0912-4c8c-b607-c7759594aa11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96938cf8-010d-417c-b261-752cdd8536fd" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_02112075-0912-4c8c-b607-c7759594aa11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2693a926-b1c0-4a35-858f-7c28d708d10b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96938cf8-010d-417c-b261-752cdd8536fd" xlink:to="loc_us-gaap_LiabilitiesCurrent_2693a926-b1c0-4a35-858f-7c28d708d10b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0abb1b6e-d24d-4a95-9577-cbf69b5bf6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e1c08bb-c1c8-4ef8-9519-76dd3a386fa3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0abb1b6e-d24d-4a95-9577-cbf69b5bf6b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_db4b8e56-041c-4a57-95f2-69a46d60b46a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e1c08bb-c1c8-4ef8-9519-76dd3a386fa3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_db4b8e56-041c-4a57-95f2-69a46d60b46a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_91be534d-be71-4998-9279-145e0c33ad80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e1c08bb-c1c8-4ef8-9519-76dd3a386fa3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_91be534d-be71-4998-9279-145e0c33ad80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8a4584b3-872b-464d-ab5f-f22c963fb7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e1c08bb-c1c8-4ef8-9519-76dd3a386fa3" xlink:to="loc_us-gaap_Liabilities_8a4584b3-872b-464d-ab5f-f22c963fb7f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4f8f93f9-e8a9-4c58-90de-3080d95616da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e1c08bb-c1c8-4ef8-9519-76dd3a386fa3" xlink:to="loc_us-gaap_EquityAbstract_4f8f93f9-e8a9-4c58-90de-3080d95616da" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ce96621c-d2f6-48c1-a367-7d8ac4179dda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_4f8f93f9-e8a9-4c58-90de-3080d95616da" xlink:to="loc_us-gaap_CommonStockValue_ce96621c-d2f6-48c1-a367-7d8ac4179dda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b2e1004b-c228-4608-a6d8-b13e83c56ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_4f8f93f9-e8a9-4c58-90de-3080d95616da" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b2e1004b-c228-4608-a6d8-b13e83c56ee6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c2f00ea7-14ab-4df2-89f5-dff806cfe9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_4f8f93f9-e8a9-4c58-90de-3080d95616da" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c2f00ea7-14ab-4df2-89f5-dff806cfe9d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b5863e13-8562-4493-a179-a6d01b9796ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_4f8f93f9-e8a9-4c58-90de-3080d95616da" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b5863e13-8562-4493-a179-a6d01b9796ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d3f163e4-511d-4dae-8dde-5a13a999a323" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_4f8f93f9-e8a9-4c58-90de-3080d95616da" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d3f163e4-511d-4dae-8dde-5a13a999a323" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4fb82062-d4ec-40f3-8e3a-3afeb30ef5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e1c08bb-c1c8-4ef8-9519-76dd3a386fa3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4fb82062-d4ec-40f3-8e3a-3afeb30ef5b1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_26d65f8f-341d-47c8-8ab5-d444ff17eafd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_aedd5399-7c5f-48eb-a908-8f6171cc4366" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_26d65f8f-341d-47c8-8ab5-d444ff17eafd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_bba56f4f-0002-4d4b-81d8-d8ca5da540e0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_26d65f8f-341d-47c8-8ab5-d444ff17eafd" xlink:to="loc_srt_RestatementAxis_bba56f4f-0002-4d4b-81d8-d8ca5da540e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_bba56f4f-0002-4d4b-81d8-d8ca5da540e0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_bba56f4f-0002-4d4b-81d8-d8ca5da540e0" xlink:to="loc_srt_RestatementDomain_bba56f4f-0002-4d4b-81d8-d8ca5da540e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_6246a7ed-21e4-4d2f-aafa-0b496940f0f2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_bba56f4f-0002-4d4b-81d8-d8ca5da540e0" xlink:to="loc_srt_RestatementDomain_6246a7ed-21e4-4d2f-aafa-0b496940f0f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_916ec335-114a-4439-834d-3d6853e7204e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_6246a7ed-21e4-4d2f-aafa-0b496940f0f2" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_916ec335-114a-4439-834d-3d6853e7204e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_f27eb789-35c1-43b0-a4d8-0c65b499a2bd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_6246a7ed-21e4-4d2f-aafa-0b496940f0f2" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_f27eb789-35c1-43b0-a4d8-0c65b499a2bd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0108afae-2130-4581-b24d-5867b1dda4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0108afae-2130-4581-b24d-5867b1dda4f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_87f52212-04f0-4966-be9f-11d62943effa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_87f52212-04f0-4966-be9f-11d62943effa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_de6e3325-f80a-46e8-8887-f9222145f606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_GrossProfit_de6e3325-f80a-46e8-8887-f9222145f606" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cfeed560-3743-4a97-bff8-8299e8d06c11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cfeed560-3743-4a97-bff8-8299e8d06c11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_52dd4a9c-2a27-4785-a2ad-244ce268b6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_52dd4a9c-2a27-4785-a2ad-244ce268b6cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_30e8a54e-8ed7-4a66-ac1b-852a1d828470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_30e8a54e-8ed7-4a66-ac1b-852a1d828470" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OperatingExpensesAndCostOfGoodSold_9741201f-1e9b-4383-9989-1c7653d3ca89" xlink:href="wald-20221231.xsd#wald_OperatingExpensesAndCostOfGoodSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_wald_OperatingExpensesAndCostOfGoodSold_9741201f-1e9b-4383-9989-1c7653d3ca89" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_86a55333-b4bb-4107-9e42-ebb3b780d1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_OperatingExpenses_86a55333-b4bb-4107-9e42-ebb3b780d1a0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5f6b496d-6f44-4dfc-9cb5-ca78c43c0042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_OperatingIncomeLoss_5f6b496d-6f44-4dfc-9cb5-ca78c43c0042" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_dad610ba-222e-40e0-aae5-8d70b134a045" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_InterestExpense_dad610ba-222e-40e0-aae5-8d70b134a045" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_222b4aa8-aa1d-4633-a122-0e7bc437d70e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_222b4aa8-aa1d-4633-a122-0e7bc437d70e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainOnPPPLoanForgiveness_e9dfc898-2ccb-4305-80c2-c856281091e5" xlink:href="wald-20221231.xsd#wald_GainOnPPPLoanForgiveness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_wald_GainOnPPPLoanForgiveness_e9dfc898-2ccb-4305-80c2-c856281091e5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainLossOnNoteReceivableWriteoff_8f06c9e0-0188-4611-822a-50b027d094e0" xlink:href="wald-20221231.xsd#wald_GainLossOnNoteReceivableWriteoff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_wald_GainLossOnNoteReceivableWriteoff_8f06c9e0-0188-4611-822a-50b027d094e0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_762ff668-2337-45a7-930b-328d2ea75a23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_762ff668-2337-45a7-930b-328d2ea75a23" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d9b7df23-fc0c-433a-9b3c-f241f2ba4301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d9b7df23-fc0c-433a-9b3c-f241f2ba4301" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_88249a4e-b706-4fb8-abeb-8a3d7682f1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_88249a4e-b706-4fb8-abeb-8a3d7682f1cb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9a8481f2-2632-4f8f-8855-f1ea261c0080" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9a8481f2-2632-4f8f-8855-f1ea261c0080" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1070a09f-07fb-483d-974c-1caf99440d55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_ProfitLoss_1070a09f-07fb-483d-974c-1caf99440d55" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_532645aa-4b9a-48cc-b7c6-555ab3b7e101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_EarningsPerShareAbstract_532645aa-4b9a-48cc-b7c6-555ab3b7e101" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_78d50737-2441-42da-a661-3683c8b50044" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_532645aa-4b9a-48cc-b7c6-555ab3b7e101" xlink:to="loc_us-gaap_EarningsPerShareBasic_78d50737-2441-42da-a661-3683c8b50044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_cc8f4239-d70d-4b37-a869-7fd74c3adbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_532645aa-4b9a-48cc-b7c6-555ab3b7e101" xlink:to="loc_us-gaap_EarningsPerShareDiluted_cc8f4239-d70d-4b37-a869-7fd74c3adbb6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_e68bf5a5-8edc-4afe-b640-7ec2f06b3ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_e68bf5a5-8edc-4afe-b640-7ec2f06b3ca2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c201e125-06a4-4e84-840e-bfb95a70e00b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_e68bf5a5-8edc-4afe-b640-7ec2f06b3ca2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c201e125-06a4-4e84-840e-bfb95a70e00b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8dcea809-63f2-45f9-a447-ab4aa3bd24ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_e68bf5a5-8edc-4afe-b640-7ec2f06b3ca2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8dcea809-63f2-45f9-a447-ab4aa3bd24ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_84c99e23-55f2-4284-a41b-995933a61eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_84c99e23-55f2-4284-a41b-995933a61eb1" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ccaafcd5-337d-4239-acde-5a8184f6b45b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ccaafcd5-337d-4239-acde-5a8184f6b45b" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_88f0fcf8-13eb-437e-a4cc-4763d69661da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_88f0fcf8-13eb-437e-a4cc-4763d69661da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_71948914-c056-4e5f-94be-6d84091ef1d7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_88f0fcf8-13eb-437e-a4cc-4763d69661da" xlink:to="loc_srt_RestatementAxis_71948914-c056-4e5f-94be-6d84091ef1d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_71948914-c056-4e5f-94be-6d84091ef1d7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_71948914-c056-4e5f-94be-6d84091ef1d7" xlink:to="loc_srt_RestatementDomain_71948914-c056-4e5f-94be-6d84091ef1d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_008c19e0-b386-4987-aadf-bfef74a9863d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_71948914-c056-4e5f-94be-6d84091ef1d7" xlink:to="loc_srt_RestatementDomain_008c19e0-b386-4987-aadf-bfef74a9863d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_23f458ce-9a23-4535-a5b9-a92edb67db9d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_008c19e0-b386-4987-aadf-bfef74a9863d" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_23f458ce-9a23-4535-a5b9-a92edb67db9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_f1ef1208-d4f6-4e39-811d-ff85e7059a0f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_008c19e0-b386-4987-aadf-bfef74a9863d" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_f1ef1208-d4f6-4e39-811d-ff85e7059a0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_ba00e5a7-010c-4e28-85a4-bf35b5bce0bb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_008c19e0-b386-4987-aadf-bfef74a9863d" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_ba00e5a7-010c-4e28-85a4-bf35b5bce0bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b11cdcba-bc7d-4694-ab31-57a4fe5c15ea" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_88f0fcf8-13eb-437e-a4cc-4763d69661da" xlink:to="loc_dei_LegalEntityAxis_b11cdcba-bc7d-4694-ab31-57a4fe5c15ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b11cdcba-bc7d-4694-ab31-57a4fe5c15ea_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_b11cdcba-bc7d-4694-ab31-57a4fe5c15ea" xlink:to="loc_dei_EntityDomain_b11cdcba-bc7d-4694-ab31-57a4fe5c15ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b4829862-89f5-4831-927f-f80b4688df7c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_b11cdcba-bc7d-4694-ab31-57a4fe5c15ea" xlink:to="loc_dei_EntityDomain_b4829862-89f5-4831-927f-f80b4688df7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiCosmeceuticalsLLCMember_654d069e-0d39-4fd2-9556-2df9d48322e0" xlink:href="wald-20221231.xsd#wald_ObagiCosmeceuticalsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b4829862-89f5-4831-927f-f80b4688df7c" xlink:to="loc_wald_ObagiCosmeceuticalsLLCMember_654d069e-0d39-4fd2-9556-2df9d48322e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_787e4f6c-7772-4cd2-b1a7-2f76a47fb6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_787e4f6c-7772-4cd2-b1a7-2f76a47fb6f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_aa8b333a-3787-4aae-a9ce-726dd92a926e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_787e4f6c-7772-4cd2-b1a7-2f76a47fb6f1" xlink:to="loc_us-gaap_ProfitLoss_aa8b333a-3787-4aae-a9ce-726dd92a926e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f46d1e6-8870-4481-a9ec-9cd034968204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_787e4f6c-7772-4cd2-b1a7-2f76a47fb6f1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f46d1e6-8870-4481-a9ec-9cd034968204" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f46d1e6-8870-4481-a9ec-9cd034968204" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DepreciationDepletionAndAmortizationOperatingActivities_2304a22e-3ee7-4ad0-9133-deb0d852150f" xlink:href="wald-20221231.xsd#wald_DepreciationDepletionAndAmortizationOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:to="loc_wald_DepreciationDepletionAndAmortizationOperatingActivities_2304a22e-3ee7-4ad0-9133-deb0d852150f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f4c03da4-f0b8-45af-b177-2d231685a609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f4c03da4-f0b8-45af-b177-2d231685a609" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainOnPPPLoanForgiveness_5194c4c2-0c03-4c3c-ad90-5e93e7877a7b" xlink:href="wald-20221231.xsd#wald_GainOnPPPLoanForgiveness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:to="loc_wald_GainOnPPPLoanForgiveness_5194c4c2-0c03-4c3c-ad90-5e93e7877a7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_78dbd2dd-3971-4ac3-8b44-70f8893ea4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_78dbd2dd-3971-4ac3-8b44-70f8893ea4bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5ed999d0-58c8-401e-8887-d602057543b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5ed999d0-58c8-401e-8887-d602057543b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8d4b3c03-745f-432a-bf03-5e98f55e49b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8d4b3c03-745f-432a-bf03-5e98f55e49b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainLossOnNoteReceivableWriteoff_0c857fa4-8f23-4262-b6b5-3c062038ed1b" xlink:href="wald-20221231.xsd#wald_GainLossOnNoteReceivableWriteoff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:to="loc_wald_GainLossOnNoteReceivableWriteoff_0c857fa4-8f23-4262-b6b5-3c062038ed1b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_126348af-248e-46af-bfe0-3472e47991bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_126348af-248e-46af-bfe0-3472e47991bf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ad0462a8-21e6-4e2a-afd6-99b9ed94c6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_126348af-248e-46af-bfe0-3472e47991bf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ad0462a8-21e6-4e2a-afd6-99b9ed94c6f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_30b31233-ac21-4959-82c1-2926dd387594" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_126348af-248e-46af-bfe0-3472e47991bf" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_30b31233-ac21-4959-82c1-2926dd387594" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1efb5261-5a67-4f5e-9a84-effb144a898e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_126348af-248e-46af-bfe0-3472e47991bf" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1efb5261-5a67-4f5e-9a84-effb144a898e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8216999c-693b-4aef-b951-9132ae94ebb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_126348af-248e-46af-bfe0-3472e47991bf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8216999c-693b-4aef-b951-9132ae94ebb0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties_97c6d652-08d9-4d27-adf9-8e8267115384" xlink:href="wald-20221231.xsd#wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_126348af-248e-46af-bfe0-3472e47991bf" xlink:to="loc_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties_97c6d652-08d9-4d27-adf9-8e8267115384" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_905163ab-1f01-45ac-8f69-b1d6047518cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_126348af-248e-46af-bfe0-3472e47991bf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_905163ab-1f01-45ac-8f69-b1d6047518cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_956840cd-f108-4f9e-b1d1-c4c111c977ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_956840cd-f108-4f9e-b1d1-c4c111c977ff" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6ae429c0-71da-45ef-86e1-2c505774390f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6ae429c0-71da-45ef-86e1-2c505774390f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5d7e3036-12ac-4568-a66f-4f162afbd940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6ae429c0-71da-45ef-86e1-2c505774390f" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5d7e3036-12ac-4568-a66f-4f162afbd940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_64f8b004-6494-4bd1-9983-ab6f4444ebef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6ae429c0-71da-45ef-86e1-2c505774390f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_64f8b004-6494-4bd1-9983-ab6f4444ebef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AdvancesForNoteReceivable_8fca1d63-d8a8-4b69-83a6-473dc0fcb9b9" xlink:href="wald-20221231.xsd#wald_AdvancesForNoteReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6ae429c0-71da-45ef-86e1-2c505774390f" xlink:to="loc_wald_AdvancesForNoteReceivable_8fca1d63-d8a8-4b69-83a6-473dc0fcb9b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ae6de3fb-1077-4593-aa54-dc37c83f7acf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6ae429c0-71da-45ef-86e1-2c505774390f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ae6de3fb-1077-4593-aa54-dc37c83f7acf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4c16a955-a847-4943-9f04-04d952e2b026" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4c16a955-a847-4943-9f04-04d952e2b026" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3bfe49dd-571e-4305-af34-5f9b89f75d03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4c16a955-a847-4943-9f04-04d952e2b026" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3bfe49dd-571e-4305-af34-5f9b89f75d03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_aad0c152-fac3-47f4-88da-d7e17c0d0046" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_aad0c152-fac3-47f4-88da-d7e17c0d0046" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf3a4e33-4de1-4f24-b927-8cc15a1514ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf3a4e33-4de1-4f24-b927-8cc15a1514ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aea6b243-0be7-4f85-a2fa-0cc472e84893" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aea6b243-0be7-4f85-a2fa-0cc472e84893" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3e01d558-1412-465b-b6ca-382ebabc174c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_e5ed122e-f53c-43d5-ba82-57bfb3dc6c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_e5ed122e-f53c-43d5-ba82-57bfb3dc6c3c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_e4ce72de-8c31-4877-9477-3319a3fb69b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_e5ed122e-f53c-43d5-ba82-57bfb3dc6c3c" xlink:to="loc_us-gaap_IncomeTaxesPaid_e4ce72de-8c31-4877-9477-3319a3fb69b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_89397538-1e88-42ba-8490-1c2ea1a34db3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_e5ed122e-f53c-43d5-ba82-57bfb3dc6c3c" xlink:to="loc_us-gaap_InterestPaidNet_89397538-1e88-42ba-8490-1c2ea1a34db3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86c1c15c-1673-4331-a75a-ae87f9d08cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86c1c15c-1673-4331-a75a-ae87f9d08cc8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f82558dc-14b0-46f2-85ef-e48afa2fc036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86c1c15c-1673-4331-a75a-ae87f9d08cc8" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f82558dc-14b0-46f2-85ef-e48afa2fc036" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CapitalContribution_d4ebe5e3-2cc5-479a-acae-c696c5264c99" xlink:href="wald-20221231.xsd#wald_CapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86c1c15c-1673-4331-a75a-ae87f9d08cc8" xlink:to="loc_wald_CapitalContribution_d4ebe5e3-2cc5-479a-acae-c696c5264c99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_d708688e-724e-4a0b-8ed2-1294f6d6c9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_d708688e-724e-4a0b-8ed2-1294f6d6c9ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_a329d779-1e71-4be0-8822-ca91b548d992" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_d708688e-724e-4a0b-8ed2-1294f6d6c9ae" xlink:to="loc_srt_RestatementAxis_a329d779-1e71-4be0-8822-ca91b548d992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_a329d779-1e71-4be0-8822-ca91b548d992_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_a329d779-1e71-4be0-8822-ca91b548d992" xlink:to="loc_srt_RestatementDomain_a329d779-1e71-4be0-8822-ca91b548d992_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_d16c86a0-e340-476b-b14a-1e8e732b552c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_a329d779-1e71-4be0-8822-ca91b548d992" xlink:to="loc_srt_RestatementDomain_d16c86a0-e340-476b-b14a-1e8e732b552c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_b5d61ddc-b87a-4e73-9d89-e380ed8ea53a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_d16c86a0-e340-476b-b14a-1e8e732b552c" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_b5d61ddc-b87a-4e73-9d89-e380ed8ea53a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_08592172-8fcd-48ff-85fa-94731990fe97" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_d16c86a0-e340-476b-b14a-1e8e732b552c" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_08592172-8fcd-48ff-85fa-94731990fe97" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_96eb546f-66a5-4578-bf19-ef541b9c8d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_96eb546f-66a5-4578-bf19-ef541b9c8d6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37b40424-2a50-43ef-9ce3-f6887a0f40c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37b40424-2a50-43ef-9ce3-f6887a0f40c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_2c6c2d7b-00b2-422a-8087-2ca5cec32e89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_RestrictedCash_2c6c2d7b-00b2-422a-8087-2ca5cec32e89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a8894492-ecbc-4f27-8d9f-b3469793c705" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a8894492-ecbc-4f27-8d9f-b3469793c705" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_dfd8697d-b96e-42bf-9e46-dc07e941a936" xlink:href="wald-20221231.xsd#wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_dfd8697d-b96e-42bf-9e46-dc07e941a936" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a5020791-cc02-4098-9bee-eb644a1711d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a5020791-cc02-4098-9bee-eb644a1711d4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum_8dc7146b-e2ac-4525-9209-a67e3636a714" xlink:href="wald-20221231.xsd#wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum_8dc7146b-e2ac-4525-9209-a67e3636a714" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CustomerPaymentPeriod_1342c31a-5d77-4c6c-a919-1d1639b1db13" xlink:href="wald-20221231.xsd#wald_CustomerPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_wald_CustomerPaymentPeriod_1342c31a-5d77-4c6c-a919-1d1639b1db13" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShippingAndHandlingCosts_bcb76703-1a37-4565-8129-16d399a8d330" xlink:href="wald-20221231.xsd#wald_ShippingAndHandlingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_wald_ShippingAndHandlingCosts_bcb76703-1a37-4565-8129-16d399a8d330" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_84e254d7-02a2-4cf7-b183-6c23a7693140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_AdvertisingExpense_84e254d7-02a2-4cf7-b183-6c23a7693140" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent_77e03749-e81e-4c60-912f-3ad003df0933" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent_77e03749-e81e-4c60-912f-3ad003df0933" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4888a8da-9578-45ec-af94-3ac4952b0aec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4888a8da-9578-45ec-af94-3ac4952b0aec" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_4297b78d-dd5c-4320-8a6f-8aba9ce2839b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_4297b78d-dd5c-4320-8a6f-8aba9ce2839b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a01784f1-cc83-4682-bed4-fddd27a387ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a01784f1-cc83-4682-bed4-fddd27a387ea" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_4b84c206-8673-4207-a49b-d86cd1dfe5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_NumberOfReportableSegments_4b84c206-8673-4207-a49b-d86cd1dfe5c5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_321822ae-35df-4373-9597-c085d6ef43a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_NumberOfOperatingSegments_321822ae-35df-4373-9597-c085d6ef43a5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_21d9dcae-a7a6-4b05-866f-922de31720a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_21d9dcae-a7a6-4b05-866f-922de31720a6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c593fe2d-acd5-4a6b-94fd-083b74eaaf8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_OperatingLeaseLiability_c593fe2d-acd5-4a6b-94fd-083b74eaaf8c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c351e16b-0bbe-4b8a-8016-96781d5d04b7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_srt_MajorCustomersAxis_c351e16b-0bbe-4b8a-8016-96781d5d04b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c351e16b-0bbe-4b8a-8016-96781d5d04b7_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_c351e16b-0bbe-4b8a-8016-96781d5d04b7" xlink:to="loc_srt_NameOfMajorCustomerDomain_c351e16b-0bbe-4b8a-8016-96781d5d04b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_583733db-3e4e-42c2-ad80-229e5520cfa7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_c351e16b-0bbe-4b8a-8016-96781d5d04b7" xlink:to="loc_srt_NameOfMajorCustomerDomain_583733db-3e4e-42c2-ad80-229e5520cfa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CustomerOneMember_91f31eaa-7dde-4981-be18-b0fe04bc1e05" xlink:href="wald-20221231.xsd#wald_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_583733db-3e4e-42c2-ad80-229e5520cfa7" xlink:to="loc_wald_CustomerOneMember_91f31eaa-7dde-4981-be18-b0fe04bc1e05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CustomerTwoMember_cad31d16-46e6-48f5-b32f-a1cc3786f161" xlink:href="wald-20221231.xsd#wald_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_583733db-3e4e-42c2-ad80-229e5520cfa7" xlink:to="loc_wald_CustomerTwoMember_cad31d16-46e6-48f5-b32f-a1cc3786f161" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CustomerThreeMember_73fe906b-676f-442d-9950-66a76e08dbf9" xlink:href="wald-20221231.xsd#wald_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_583733db-3e4e-42c2-ad80-229e5520cfa7" xlink:to="loc_wald_CustomerThreeMember_73fe906b-676f-442d-9950-66a76e08dbf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9ba038fc-d524-41f5-ad99-8abe37c35867" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9ba038fc-d524-41f5-ad99-8abe37c35867" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9ba038fc-d524-41f5-ad99-8abe37c35867_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9ba038fc-d524-41f5-ad99-8abe37c35867" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9ba038fc-d524-41f5-ad99-8abe37c35867_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_46085d0c-5e50-4319-a3da-176b35df7e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9ba038fc-d524-41f5-ad99-8abe37c35867" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_46085d0c-5e50-4319-a3da-176b35df7e7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_47dd1cec-8e4f-4627-adda-6b61fd89ff89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_46085d0c-5e50-4319-a3da-176b35df7e7c" xlink:to="loc_us-gaap_AccountsReceivableMember_47dd1cec-8e4f-4627-adda-6b61fd89ff89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_InventoryPurchasesMember_3cc54b60-b5e8-4394-b71f-19f6fcd93cef" xlink:href="wald-20221231.xsd#wald_InventoryPurchasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_46085d0c-5e50-4319-a3da-176b35df7e7c" xlink:to="loc_wald_InventoryPurchasesMember_3cc54b60-b5e8-4394-b71f-19f6fcd93cef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember_607d8b6e-605a-4cdf-93c2-0d5929efd1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_46085d0c-5e50-4319-a3da-176b35df7e7c" xlink:to="loc_us-gaap_AccountsPayableMember_607d8b6e-605a-4cdf-93c2-0d5929efd1b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c2bcbd47-03f9-48bb-83cd-82333e9f5a16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c2bcbd47-03f9-48bb-83cd-82333e9f5a16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c2bcbd47-03f9-48bb-83cd-82333e9f5a16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c2bcbd47-03f9-48bb-83cd-82333e9f5a16" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c2bcbd47-03f9-48bb-83cd-82333e9f5a16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_36fdfea9-07a4-45ad-94bd-38d700677ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c2bcbd47-03f9-48bb-83cd-82333e9f5a16" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_36fdfea9-07a4-45ad-94bd-38d700677ac3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_530c99f6-aaf4-4ee7-895b-9c14b891ff67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_36fdfea9-07a4-45ad-94bd-38d700677ac3" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_530c99f6-aaf4-4ee7-895b-9c14b891ff67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_af8954f1-c334-4e50-be75-4961a7b4930b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_36fdfea9-07a4-45ad-94bd-38d700677ac3" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_af8954f1-c334-4e50-be75-4961a7b4930b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LenderConcentrationRiskMember_a9f70be9-c66b-49e3-9525-38b3d0b0ff50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LenderConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_36fdfea9-07a4-45ad-94bd-38d700677ac3" xlink:to="loc_us-gaap_LenderConcentrationRiskMember_a9f70be9-c66b-49e3-9525-38b3d0b0ff50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_0f3a3730-a6a5-45e9-b3fa-4d7dbd0e4fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_0f3a3730-a6a5-45e9-b3fa-4d7dbd0e4fa3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0f3a3730-a6a5-45e9-b3fa-4d7dbd0e4fa3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_0f3a3730-a6a5-45e9-b3fa-4d7dbd0e4fa3" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0f3a3730-a6a5-45e9-b3fa-4d7dbd0e4fa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_de304cb0-d32d-4657-9638-69bd0bddffd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_0f3a3730-a6a5-45e9-b3fa-4d7dbd0e4fa3" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_de304cb0-d32d-4657-9638-69bd0bddffd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VendorOneMember_8e55364e-5c2f-401a-8f21-47d004d35882" xlink:href="wald-20221231.xsd#wald_VendorOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_de304cb0-d32d-4657-9638-69bd0bddffd1" xlink:to="loc_wald_VendorOneMember_8e55364e-5c2f-401a-8f21-47d004d35882" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VendorTwoMember_7d1d81a0-ba8b-4876-8fbf-bf46643ce8d2" xlink:href="wald-20221231.xsd#wald_VendorTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_de304cb0-d32d-4657-9638-69bd0bddffd1" xlink:to="loc_wald_VendorTwoMember_7d1d81a0-ba8b-4876-8fbf-bf46643ce8d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VendorThreeMember_f88d2bdd-badf-4594-a02c-9a2f4cca79a1" xlink:href="wald-20221231.xsd#wald_VendorThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_de304cb0-d32d-4657-9638-69bd0bddffd1" xlink:to="loc_wald_VendorThreeMember_f88d2bdd-badf-4594-a02c-9a2f4cca79a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_22e20052-147e-4d17-aebf-acdb36c25b58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_us-gaap_AwardTypeAxis_22e20052-147e-4d17-aebf-acdb36c25b58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_22e20052-147e-4d17-aebf-acdb36c25b58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_22e20052-147e-4d17-aebf-acdb36c25b58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_22e20052-147e-4d17-aebf-acdb36c25b58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5e2697d-a0d8-41ac-9c0b-168d7232ba61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_22e20052-147e-4d17-aebf-acdb36c25b58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5e2697d-a0d8-41ac-9c0b-168d7232ba61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_FounderAwardsMember_0f21b0c1-d89b-42f5-8d69-7f2cf067d2d8" xlink:href="wald-20221231.xsd#wald_FounderAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5e2697d-a0d8-41ac-9c0b-168d7232ba61" xlink:to="loc_wald_FounderAwardsMember_0f21b0c1-d89b-42f5-8d69-7f2cf067d2d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_59c7bfa0-71dc-4bce-a1ff-9115d1fa1b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_59c7bfa0-71dc-4bce-a1ff-9115d1fa1b8c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_59c7bfa0-71dc-4bce-a1ff-9115d1fa1b8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_59c7bfa0-71dc-4bce-a1ff-9115d1fa1b8c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_59c7bfa0-71dc-4bce-a1ff-9115d1fa1b8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd5f0c0f-193b-44fa-86d3-12170c9431e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_59c7bfa0-71dc-4bce-a1ff-9115d1fa1b8c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd5f0c0f-193b-44fa-86d3-12170c9431e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkMember_e5b20d2d-e7c4-4142-b2dd-992cc149f5a0" xlink:href="wald-20221231.xsd#wald_MilkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd5f0c0f-193b-44fa-86d3-12170c9431e7" xlink:to="loc_wald_MilkMember_e5b20d2d-e7c4-4142-b2dd-992cc149f5a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a9292949-f62d-4583-b6a9-fa0f3989af68" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a9292949-f62d-4583-b6a9-fa0f3989af68" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a9292949-f62d-4583-b6a9-fa0f3989af68_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a9292949-f62d-4583-b6a9-fa0f3989af68" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a9292949-f62d-4583-b6a9-fa0f3989af68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_53421b0c-ab0a-4d27-984f-a2cbe915ea87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a9292949-f62d-4583-b6a9-fa0f3989af68" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_53421b0c-ab0a-4d27-984f-a2cbe915ea87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2ecb52a7-fb73-4eae-b7fe-5879615f7370" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_53421b0c-ab0a-4d27-984f-a2cbe915ea87" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2ecb52a7-fb73-4eae-b7fe-5879615f7370" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f93d03bb-a183-417a-9f1f-bff77397b00d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f93d03bb-a183-417a-9f1f-bff77397b00d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f93d03bb-a183-417a-9f1f-bff77397b00d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f93d03bb-a183-417a-9f1f-bff77397b00d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f93d03bb-a183-417a-9f1f-bff77397b00d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a44deb08-022a-41c5-92b3-1f802310a2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f93d03bb-a183-417a-9f1f-bff77397b00d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a44deb08-022a-41c5-92b3-1f802310a2ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_c8afe513-4b00-405d-89d1-327f214c2a34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a44deb08-022a-41c5-92b3-1f802310a2ef" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_c8afe513-4b00-405d-89d1-327f214c2a34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7705f823-de36-434b-8e6c-f1cd60e6adb8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_srt_RangeAxis_7705f823-de36-434b-8e6c-f1cd60e6adb8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7705f823-de36-434b-8e6c-f1cd60e6adb8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7705f823-de36-434b-8e6c-f1cd60e6adb8" xlink:to="loc_srt_RangeMember_7705f823-de36-434b-8e6c-f1cd60e6adb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7e54d978-867d-4be4-9bb0-afd8fd973f49" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7705f823-de36-434b-8e6c-f1cd60e6adb8" xlink:to="loc_srt_RangeMember_7e54d978-867d-4be4-9bb0-afd8fd973f49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0aa73bf3-53b4-4cae-825b-d65133cbd761" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7e54d978-867d-4be4-9bb0-afd8fd973f49" xlink:to="loc_srt_MaximumMember_0aa73bf3-53b4-4cae-825b-d65133cbd761" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ab9dd93e-3b74-4a1b-91fd-d4768236b47a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7e54d978-867d-4be4-9bb0-afd8fd973f49" xlink:to="loc_srt_MinimumMember_ab9dd93e-3b74-4a1b-91fd-d4768236b47a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05aa3b33-6896-48eb-bfad-bd186c93a7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c5877468-355c-46a1-91dd-970b7c12f8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05aa3b33-6896-48eb-bfad-bd186c93a7f9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c5877468-355c-46a1-91dd-970b7c12f8c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd57b224-213f-4998-b957-666c02e94bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05aa3b33-6896-48eb-bfad-bd186c93a7f9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd57b224-213f-4998-b957-666c02e94bcd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9ceb5255-2a9c-4d46-8060-7606832ce314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd57b224-213f-4998-b957-666c02e94bcd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9ceb5255-2a9c-4d46-8060-7606832ce314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ceb5255-2a9c-4d46-8060-7606832ce314_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9ceb5255-2a9c-4d46-8060-7606832ce314" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9ceb5255-2a9c-4d46-8060-7606832ce314_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_85be408e-7772-4485-a94b-df82b7bddc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9ceb5255-2a9c-4d46-8060-7606832ce314" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_85be408e-7772-4485-a94b-df82b7bddc9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ComputerHardwareSoftwareAndEquipmentMember_0adc2264-f917-49ca-bee9-f0e6d43e1175" xlink:href="wald-20221231.xsd#wald_ComputerHardwareSoftwareAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_85be408e-7772-4485-a94b-df82b7bddc9d" xlink:to="loc_wald_ComputerHardwareSoftwareAndEquipmentMember_0adc2264-f917-49ca-bee9-f0e6d43e1175" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_a19c16aa-3fc8-4d9d-b95b-33934bef96fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_85be408e-7772-4485-a94b-df82b7bddc9d" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_a19c16aa-3fc8-4d9d-b95b-33934bef96fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_a524c30d-ec61-44e5-bd5f-b7be2a1794d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_85be408e-7772-4485-a94b-df82b7bddc9d" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_a524c30d-ec61-44e5-bd5f-b7be2a1794d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GondolasMember_11044ec8-be3a-4dda-adf0-639a69d0c83e" xlink:href="wald-20221231.xsd#wald_GondolasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_85be408e-7772-4485-a94b-df82b7bddc9d" xlink:to="loc_wald_GondolasMember_11044ec8-be3a-4dda-adf0-639a69d0c83e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_613a7fa1-04f4-4ee1-b75e-baf8c830a16a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd57b224-213f-4998-b957-666c02e94bcd" xlink:to="loc_srt_RangeAxis_613a7fa1-04f4-4ee1-b75e-baf8c830a16a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_613a7fa1-04f4-4ee1-b75e-baf8c830a16a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_613a7fa1-04f4-4ee1-b75e-baf8c830a16a" xlink:to="loc_srt_RangeMember_613a7fa1-04f4-4ee1-b75e-baf8c830a16a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b75f9018-b1c5-4c9b-8507-c113dac332bd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_613a7fa1-04f4-4ee1-b75e-baf8c830a16a" xlink:to="loc_srt_RangeMember_b75f9018-b1c5-4c9b-8507-c113dac332bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f39a7076-23d6-4ecc-9362-8e187b6b6542" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b75f9018-b1c5-4c9b-8507-c113dac332bd" xlink:to="loc_srt_MinimumMember_f39a7076-23d6-4ecc-9362-8e187b6b6542" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9db33d7a-e731-479c-8d16-08f02d63f531" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b75f9018-b1c5-4c9b-8507-c113dac332bd" xlink:to="loc_srt_MaximumMember_9db33d7a-e731-479c-8d16-08f02d63f531" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#BUSINESSCOMBINATIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_71e1ebef-8116-4a8f-84cb-00b4bf44d2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_71e1ebef-8116-4a8f-84cb-00b4bf44d2a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8bde9649-9665-4c0a-b954-0482b0d18ada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8bde9649-9665-4c0a-b954-0482b0d18ada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_187209e3-0127-4cde-b2da-c9720005fbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_187209e3-0127-4cde-b2da-c9720005fbd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CommonStockConvertibleConversionRatio_c0eaf445-f385-45b7-8871-8feccf007dfb" xlink:href="wald-20221231.xsd#wald_CommonStockConvertibleConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_wald_CommonStockConvertibleConversionRatio_c0eaf445-f385-45b7-8871-8feccf007dfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_NumberOfNominatedDirectors_9253b10e-15f3-44c1-bae2-be8d5e73564e" xlink:href="wald-20221231.xsd#wald_NumberOfNominatedDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_wald_NumberOfNominatedDirectors_9253b10e-15f3-44c1-bae2-be8d5e73564e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_b30bcafe-8777-4784-83e5-4d8e6101a93f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_b30bcafe-8777-4784-83e5-4d8e6101a93f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0e1684a8-7b1c-45f7-a37f-3e802449f8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0e1684a8-7b1c-45f7-a37f-3e802449f8e3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b9b9f2da-7b7f-42dd-9c19-535de5a064b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b9b9f2da-7b7f-42dd-9c19-535de5a064b7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_5040a31e-698a-4354-835a-663f17392eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_5040a31e-698a-4354-835a-663f17392eee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d9673048-e866-42cc-83c9-36787b922357" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d9673048-e866-42cc-83c9-36787b922357" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_42f69ac6-1ec5-4abe-afe8-8bf2ebbae17d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_42f69ac6-1ec5-4abe-afe8-8bf2ebbae17d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_d42c6c7a-c1fd-4e7b-8dbd-f3838b1fcaae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_d42c6c7a-c1fd-4e7b-8dbd-f3838b1fcaae" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_cc0ee79b-36b7-4af7-a2a3-061cda3d256a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_cc0ee79b-36b7-4af7-a2a3-061cda3d256a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2b7b7075-ea86-4a40-80c1-d569570eebf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2b7b7075-ea86-4a40-80c1-d569570eebf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2b7b7075-ea86-4a40-80c1-d569570eebf1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2b7b7075-ea86-4a40-80c1-d569570eebf1" xlink:to="loc_us-gaap_SegmentDomain_2b7b7075-ea86-4a40-80c1-d569570eebf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_11cf7f5a-2e60-4267-b518-fc7298d81867" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2b7b7075-ea86-4a40-80c1-d569570eebf1" xlink:to="loc_us-gaap_SegmentDomain_11cf7f5a-2e60-4267-b518-fc7298d81867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiSkincareMember_bf7dfb2b-a224-42a9-8bac-9b5029156bf7" xlink:href="wald-20221231.xsd#wald_ObagiSkincareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_11cf7f5a-2e60-4267-b518-fc7298d81867" xlink:to="loc_wald_ObagiSkincareMember_bf7dfb2b-a224-42a9-8bac-9b5029156bf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_543fdab0-14d7-43e3-8dc6-6c1235a5283c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_543fdab0-14d7-43e3-8dc6-6c1235a5283c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_543fdab0-14d7-43e3-8dc6-6c1235a5283c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_543fdab0-14d7-43e3-8dc6-6c1235a5283c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_543fdab0-14d7-43e3-8dc6-6c1235a5283c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_366930b0-75a0-4ff7-8e62-ae81c62d8b53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_543fdab0-14d7-43e3-8dc6-6c1235a5283c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_366930b0-75a0-4ff7-8e62-ae81c62d8b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiAndMilkBusinessCombinationsMember_c1d981ac-6f56-4e87-9eb7-0e5fbe20952c" xlink:href="wald-20221231.xsd#wald_ObagiAndMilkBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_366930b0-75a0-4ff7-8e62-ae81c62d8b53" xlink:to="loc_wald_ObagiAndMilkBusinessCombinationsMember_c1d981ac-6f56-4e87-9eb7-0e5fbe20952c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiMergerMember_0c3ec57b-8ca0-4972-b3be-6a1452f2332a" xlink:href="wald-20221231.xsd#wald_ObagiMergerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_366930b0-75a0-4ff7-8e62-ae81c62d8b53" xlink:to="loc_wald_ObagiMergerMember_0c3ec57b-8ca0-4972-b3be-6a1452f2332a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkTransactionMember_a07762c8-f221-4d9b-97dc-4d4a61dea0fe" xlink:href="wald-20221231.xsd#wald_MilkTransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_366930b0-75a0-4ff7-8e62-ae81c62d8b53" xlink:to="loc_wald_MilkTransactionMember_a07762c8-f221-4d9b-97dc-4d4a61dea0fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_977118da-91e8-45af-9538-760c824d08a9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:to="loc_srt_OwnershipAxis_977118da-91e8-45af-9538-760c824d08a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_977118da-91e8-45af-9538-760c824d08a9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_977118da-91e8-45af-9538-760c824d08a9" xlink:to="loc_srt_OwnershipDomain_977118da-91e8-45af-9538-760c824d08a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b5d9b63f-2d90-4b2f-b203-29c9e702a215" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_977118da-91e8-45af-9538-760c824d08a9" xlink:to="loc_srt_OwnershipDomain_b5d9b63f-2d90-4b2f-b203-29c9e702a215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_WaldencastPlcMember_63d38fe6-61f5-4731-b3c4-8a3d76ffd386" xlink:href="wald-20221231.xsd#wald_WaldencastPlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_b5d9b63f-2d90-4b2f-b203-29c9e702a215" xlink:to="loc_wald_WaldencastPlcMember_63d38fe6-61f5-4731-b3c4-8a3d76ffd386" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_34a498e3-d78f-4797-ae8e-772015c49c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:to="loc_us-gaap_StatementClassOfStockAxis_34a498e3-d78f-4797-ae8e-772015c49c0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_34a498e3-d78f-4797-ae8e-772015c49c0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_34a498e3-d78f-4797-ae8e-772015c49c0e" xlink:to="loc_us-gaap_ClassOfStockDomain_34a498e3-d78f-4797-ae8e-772015c49c0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3988fd97-8d41-42cf-a0ca-e43213288750" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_34a498e3-d78f-4797-ae8e-772015c49c0e" xlink:to="loc_us-gaap_ClassOfStockDomain_3988fd97-8d41-42cf-a0ca-e43213288750" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_86660aa2-524e-40b2-9d9e-00991bb2ec0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3988fd97-8d41-42cf-a0ca-e43213288750" xlink:to="loc_us-gaap_CommonClassAMember_86660aa2-524e-40b2-9d9e-00991bb2ec0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_LimitedPartnershipUnitsMember_49a30760-95a5-453a-9ca3-c571b7de976c" xlink:href="wald-20221231.xsd#wald_LimitedPartnershipUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3988fd97-8d41-42cf-a0ca-e43213288750" xlink:to="loc_wald_LimitedPartnershipUnitsMember_49a30760-95a5-453a-9ca3-c571b7de976c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_816ae6b6-11fe-47a9-99f6-f87b49b2fdde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3988fd97-8d41-42cf-a0ca-e43213288750" xlink:to="loc_us-gaap_CommonClassBMember_816ae6b6-11fe-47a9-99f6-f87b49b2fdde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3de9506a-0176-4e92-a39b-c8dd2c223fbb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:to="loc_dei_LegalEntityAxis_3de9506a-0176-4e92-a39b-c8dd2c223fbb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3de9506a-0176-4e92-a39b-c8dd2c223fbb_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_3de9506a-0176-4e92-a39b-c8dd2c223fbb" xlink:to="loc_dei_EntityDomain_3de9506a-0176-4e92-a39b-c8dd2c223fbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e51e84eb-2252-49a8-bfbc-f666a053ae97" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_3de9506a-0176-4e92-a39b-c8dd2c223fbb" xlink:to="loc_dei_EntityDomain_e51e84eb-2252-49a8-bfbc-f666a053ae97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiChinaBusinessMember_a90639dc-0a2a-4c87-a985-4e9ae233b9e7" xlink:href="wald-20221231.xsd#wald_ObagiChinaBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e51e84eb-2252-49a8-bfbc-f666a053ae97" xlink:to="loc_wald_ObagiChinaBusinessMember_a90639dc-0a2a-4c87-a985-4e9ae233b9e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6f238e5-fcb0-48cc-aa5f-3b57815b6775" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6f238e5-fcb0-48cc-aa5f-3b57815b6775" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b6f238e5-fcb0-48cc-aa5f-3b57815b6775_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6f238e5-fcb0-48cc-aa5f-3b57815b6775" xlink:to="loc_us-gaap_RelatedPartyDomain_b6f238e5-fcb0-48cc-aa5f-3b57815b6775_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8f1c69e1-2239-472d-b5d8-30da0709999e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6f238e5-fcb0-48cc-aa5f-3b57815b6775" xlink:to="loc_us-gaap_RelatedPartyDomain_8f1c69e1-2239-472d-b5d8-30da0709999e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_fef90b73-8a7f-4a9f-80a2-4a0745da93ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8f1c69e1-2239-472d-b5d8-30da0709999e" xlink:to="loc_us-gaap_RelatedPartyMember_fef90b73-8a7f-4a9f-80a2-4a0745da93ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3dc50360-bf72-42f8-8ee3-479e48774efc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:to="loc_srt_CounterpartyNameAxis_3dc50360-bf72-42f8-8ee3-479e48774efc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3dc50360-bf72-42f8-8ee3-479e48774efc_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3dc50360-bf72-42f8-8ee3-479e48774efc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3dc50360-bf72-42f8-8ee3-479e48774efc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b87e5f78-2c04-4dd3-8750-3e6a7794e512" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3dc50360-bf72-42f8-8ee3-479e48774efc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b87e5f78-2c04-4dd3-8750-3e6a7794e512" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CedarwalkMember_2e95f131-bedd-42ab-b922-0380b9b8d27e" xlink:href="wald-20221231.xsd#wald_CedarwalkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b87e5f78-2c04-4dd3-8750-3e6a7794e512" xlink:to="loc_wald_CedarwalkMember_2e95f131-bedd-42ab-b922-0380b9b8d27e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_977cc537-a066-488a-942b-c05e0ddec6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_5099f75e-91cb-44ee-ba4b-b20703c4f086" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_977cc537-a066-488a-942b-c05e0ddec6c0" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_5099f75e-91cb-44ee-ba4b-b20703c4f086" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_f7e71f65-21f4-4ba1-89d6-5e5b9063b514" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_5099f75e-91cb-44ee-ba4b-b20703c4f086" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_f7e71f65-21f4-4ba1-89d6-5e5b9063b514" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_99f5b478-0868-42d1-a4c5-5a804511048a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_5099f75e-91cb-44ee-ba4b-b20703c4f086" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_99f5b478-0868-42d1-a4c5-5a804511048a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt_cce7ed21-f0f0-479d-b539-301a2b938690" xlink:href="wald-20221231.xsd#wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_5099f75e-91cb-44ee-ba4b-b20703c4f086" xlink:to="loc_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt_cce7ed21-f0f0-479d-b539-301a2b938690" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_be3c5602-acaa-4336-ade2-1efcdd40e001" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_5099f75e-91cb-44ee-ba4b-b20703c4f086" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_be3c5602-acaa-4336-ade2-1efcdd40e001" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_329c9645-0a23-4ef0-a0ad-c9fdf61fdd73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_5099f75e-91cb-44ee-ba4b-b20703c4f086" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_329c9645-0a23-4ef0-a0ad-c9fdf61fdd73" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_977cc537-a066-488a-942b-c05e0ddec6c0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_22986f80-9143-4541-b628-a5632197e15a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_22986f80-9143-4541-b628-a5632197e15a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_21b57bff-edc1-4257-adab-78d8df43495c" xlink:href="wald-20221231.xsd#wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_21b57bff-edc1-4257-adab-78d8df43495c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_21d21e04-1bfa-449e-8e25-8f0fd0160bba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_21d21e04-1bfa-449e-8e25-8f0fd0160bba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty_6fcd1d3c-e579-4f0b-8dd5-6fc2aadf5482" xlink:href="wald-20221231.xsd#wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty_6fcd1d3c-e579-4f0b-8dd5-6fc2aadf5482" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1f445c5b-4783-438c-bae4-6b6daff773fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1f445c5b-4783-438c-bae4-6b6daff773fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_7e852c92-7476-432f-9fc3-6a3895274978" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_7e852c92-7476-432f-9fc3-6a3895274978" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_66941308-88b7-4b70-8c24-bc09b9a2434c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_66941308-88b7-4b70-8c24-bc09b9a2434c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_4759bc40-610b-404c-aedd-04b6bf3bb5df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_4759bc40-610b-404c-aedd-04b6bf3bb5df" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_aac846eb-bf3a-43da-92b8-20414203a985" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_aac846eb-bf3a-43da-92b8-20414203a985" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets_1071908e-8392-4fdd-a465-1104f4b557dd" xlink:href="wald-20221231.xsd#wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets_1071908e-8392-4fdd-a465-1104f4b557dd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_bae6be9e-7f03-4433-a7fb-b1f8fccddaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_bae6be9e-7f03-4433-a7fb-b1f8fccddaa3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_ff156119-211b-43a7-84b3-fd11332e7fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_ff156119-211b-43a7-84b3-fd11332e7fa1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_131a1ba1-558b-4b4b-ad8d-e6bfcd7b4c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_977cc537-a066-488a-942b-c05e0ddec6c0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_131a1ba1-558b-4b4b-ad8d-e6bfcd7b4c05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_dc269151-2269-4408-9aca-6b182efe782a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_131a1ba1-558b-4b4b-ad8d-e6bfcd7b4c05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_dc269151-2269-4408-9aca-6b182efe782a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_5cbf2d55-2253-46d9-8d21-b9b9e38a9bea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_131a1ba1-558b-4b4b-ad8d-e6bfcd7b4c05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_5cbf2d55-2253-46d9-8d21-b9b9e38a9bea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_52a6efae-4d5f-4c36-aca8-139cc9f5e960" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_131a1ba1-558b-4b4b-ad8d-e6bfcd7b4c05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_52a6efae-4d5f-4c36-aca8-139cc9f5e960" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_68b0f87f-1c1c-4b19-84c4-d8d2778820d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_131a1ba1-558b-4b4b-ad8d-e6bfcd7b4c05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_68b0f87f-1c1c-4b19-84c4-d8d2778820d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2364f616-568a-4ff8-8436-e63330ea25de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_131a1ba1-558b-4b4b-ad8d-e6bfcd7b4c05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2364f616-568a-4ff8-8436-e63330ea25de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_cfb7939c-6fc4-40d9-b851-72bafc0946a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_977cc537-a066-488a-942b-c05e0ddec6c0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_cfb7939c-6fc4-40d9-b851-72bafc0946a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_74d9f788-ec81-424a-9490-384116594596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_04a02f1b-076c-4ed0-9f66-5917faf75bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_977cc537-a066-488a-942b-c05e0ddec6c0" xlink:to="loc_us-gaap_Goodwill_04a02f1b-076c-4ed0-9f66-5917faf75bbd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_de5cea9a-86ef-4a8a-93f1-d73349829865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_977cc537-a066-488a-942b-c05e0ddec6c0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_de5cea9a-86ef-4a8a-93f1-d73349829865" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e636bdb6-3f20-46d6-8952-b877b84c401b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_de5cea9a-86ef-4a8a-93f1-d73349829865" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e636bdb6-3f20-46d6-8952-b877b84c401b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e636bdb6-3f20-46d6-8952-b877b84c401b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e636bdb6-3f20-46d6-8952-b877b84c401b" xlink:to="loc_us-gaap_SegmentDomain_e636bdb6-3f20-46d6-8952-b877b84c401b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f05d7789-5827-4bc0-84e6-b3066cdabee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e636bdb6-3f20-46d6-8952-b877b84c401b" xlink:to="loc_us-gaap_SegmentDomain_f05d7789-5827-4bc0-84e6-b3066cdabee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiSkincareMember_ee15c73a-819f-4b85-a5fc-fcf606450ce2" xlink:href="wald-20221231.xsd#wald_ObagiSkincareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f05d7789-5827-4bc0-84e6-b3066cdabee0" xlink:to="loc_wald_ObagiSkincareMember_ee15c73a-819f-4b85-a5fc-fcf606450ce2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkMakeupMember_228484d0-363a-436e-8bd6-7b3981bc5147" xlink:href="wald-20221231.xsd#wald_MilkMakeupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f05d7789-5827-4bc0-84e6-b3066cdabee0" xlink:to="loc_wald_MilkMakeupMember_228484d0-363a-436e-8bd6-7b3981bc5147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0d75b4c8-ed8c-41a8-b3b5-3b39aa0da346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_de5cea9a-86ef-4a8a-93f1-d73349829865" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0d75b4c8-ed8c-41a8-b3b5-3b39aa0da346" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0d75b4c8-ed8c-41a8-b3b5-3b39aa0da346_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0d75b4c8-ed8c-41a8-b3b5-3b39aa0da346" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0d75b4c8-ed8c-41a8-b3b5-3b39aa0da346_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3ec37ec-153f-4d09-bd26-1244fae2c1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0d75b4c8-ed8c-41a8-b3b5-3b39aa0da346" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3ec37ec-153f-4d09-bd26-1244fae2c1a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiAndMilkBusinessCombinationsMember_abb34a12-d55f-4fc0-92b6-7f83a9d12e1b" xlink:href="wald-20221231.xsd#wald_ObagiAndMilkBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3ec37ec-153f-4d09-bd26-1244fae2c1a3" xlink:to="loc_wald_ObagiAndMilkBusinessCombinationsMember_abb34a12-d55f-4fc0-92b6-7f83a9d12e1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c67e0da-eb36-4a7f-bb67-f73ec71d35ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_de5cea9a-86ef-4a8a-93f1-d73349829865" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c67e0da-eb36-4a7f-bb67-f73ec71d35ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2c67e0da-eb36-4a7f-bb67-f73ec71d35ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c67e0da-eb36-4a7f-bb67-f73ec71d35ce" xlink:to="loc_us-gaap_RelatedPartyDomain_2c67e0da-eb36-4a7f-bb67-f73ec71d35ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5a4a6752-f263-4aed-a069-9a0a283f72cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c67e0da-eb36-4a7f-bb67-f73ec71d35ce" xlink:to="loc_us-gaap_RelatedPartyDomain_5a4a6752-f263-4aed-a069-9a0a283f72cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_53a4812e-2a3e-4bc4-8ccc-7baa568c7641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5a4a6752-f263-4aed-a069-9a0a283f72cb" xlink:to="loc_us-gaap_RelatedPartyMember_53a4812e-2a3e-4bc4-8ccc-7baa568c7641" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_ad6484ef-a1bd-4ec7-ab92-f3d8fd2caae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5738f648-af6f-4826-bc58-60d6a1cd506a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_ad6484ef-a1bd-4ec7-ab92-f3d8fd2caae1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5738f648-af6f-4826-bc58-60d6a1cd506a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_b3ccd524-04f1-4c6d-9d10-f631d3a9f32f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_ad6484ef-a1bd-4ec7-ab92-f3d8fd2caae1" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_b3ccd524-04f1-4c6d-9d10-f631d3a9f32f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_db12ab8d-dd66-47bb-892e-ea848bfce049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_ad6484ef-a1bd-4ec7-ab92-f3d8fd2caae1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_db12ab8d-dd66-47bb-892e-ea848bfce049" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_68d16e86-3926-4f27-8efa-c080dedc1131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_db12ab8d-dd66-47bb-892e-ea848bfce049" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_68d16e86-3926-4f27-8efa-c080dedc1131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_68d16e86-3926-4f27-8efa-c080dedc1131_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_68d16e86-3926-4f27-8efa-c080dedc1131" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_68d16e86-3926-4f27-8efa-c080dedc1131_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62096649-57b0-4f2d-a106-d5ec8b8eafbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_68d16e86-3926-4f27-8efa-c080dedc1131" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62096649-57b0-4f2d-a106-d5ec8b8eafbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_01acfe17-90c7-4beb-b2be-22a95215e3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62096649-57b0-4f2d-a106-d5ec8b8eafbb" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_01acfe17-90c7-4beb-b2be-22a95215e3a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_b6ee2e57-c588-4c5a-9d7d-a7ac7b4a24c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62096649-57b0-4f2d-a106-d5ec8b8eafbb" xlink:to="loc_us-gaap_CustomerRelationshipsMember_b6ee2e57-c588-4c5a-9d7d-a7ac7b4a24c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_TretinoinDistributionAndSupplyAgreementMember_d6106389-0eed-4ae2-b38f-48e65a73ca14" xlink:href="wald-20221231.xsd#wald_TretinoinDistributionAndSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62096649-57b0-4f2d-a106-d5ec8b8eafbb" xlink:to="loc_wald_TretinoinDistributionAndSupplyAgreementMember_d6106389-0eed-4ae2-b38f-48e65a73ca14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_FormulationsMember_011fbeac-1307-4ca1-aa2b-dafe024e4860" xlink:href="wald-20221231.xsd#wald_FormulationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62096649-57b0-4f2d-a106-d5ec8b8eafbb" xlink:to="loc_wald_FormulationsMember_011fbeac-1307-4ca1-aa2b-dafe024e4860" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_75423bf8-3384-4e91-972e-34d78818e706" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_db12ab8d-dd66-47bb-892e-ea848bfce049" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_75423bf8-3384-4e91-972e-34d78818e706" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_75423bf8-3384-4e91-972e-34d78818e706_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_75423bf8-3384-4e91-972e-34d78818e706" xlink:to="loc_us-gaap_SegmentDomain_75423bf8-3384-4e91-972e-34d78818e706_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_95521600-ea2b-4ee1-95e0-0e8242fb59bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_75423bf8-3384-4e91-972e-34d78818e706" xlink:to="loc_us-gaap_SegmentDomain_95521600-ea2b-4ee1-95e0-0e8242fb59bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiSkincareMember_d61790a8-e20d-440c-ba7a-62c79e9f9835" xlink:href="wald-20221231.xsd#wald_ObagiSkincareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_95521600-ea2b-4ee1-95e0-0e8242fb59bf" xlink:to="loc_wald_ObagiSkincareMember_d61790a8-e20d-440c-ba7a-62c79e9f9835" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkMakeupMember_e8b2907a-ae9b-4ea6-b095-f363b3213e18" xlink:href="wald-20221231.xsd#wald_MilkMakeupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_95521600-ea2b-4ee1-95e0-0e8242fb59bf" xlink:to="loc_wald_MilkMakeupMember_e8b2907a-ae9b-4ea6-b095-f363b3213e18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c4acf90f-9d7a-4941-9eac-a3acf4f83196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_db12ab8d-dd66-47bb-892e-ea848bfce049" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c4acf90f-9d7a-4941-9eac-a3acf4f83196" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4acf90f-9d7a-4941-9eac-a3acf4f83196_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c4acf90f-9d7a-4941-9eac-a3acf4f83196" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4acf90f-9d7a-4941-9eac-a3acf4f83196_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b1a8e10-b615-4b47-9f5b-9c4c4b7e74fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c4acf90f-9d7a-4941-9eac-a3acf4f83196" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b1a8e10-b615-4b47-9f5b-9c4c4b7e74fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiAndMilkBusinessCombinationsMember_97d8fb16-f8f9-4a49-af60-b873d6015ecc" xlink:href="wald-20221231.xsd#wald_ObagiAndMilkBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b1a8e10-b615-4b47-9f5b-9c4c4b7e74fb" xlink:to="loc_wald_ObagiAndMilkBusinessCombinationsMember_97d8fb16-f8f9-4a49-af60-b873d6015ecc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e0e4e137-c883-4504-b8f3-dc0414b5ae24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_0dc04414-cd64-42a3-8e3f-7d1e7b96ecd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e4e137-c883-4504-b8f3-dc0414b5ae24" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_0dc04414-cd64-42a3-8e3f-7d1e7b96ecd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_356e08ee-2ce4-4445-8a88-ad155b05e57e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e4e137-c883-4504-b8f3-dc0414b5ae24" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_356e08ee-2ce4-4445-8a88-ad155b05e57e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest_577fe895-f0a2-40a8-bbe7-8786cfb93ae6" xlink:href="wald-20221231.xsd#wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e4e137-c883-4504-b8f3-dc0414b5ae24" xlink:to="loc_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest_577fe895-f0a2-40a8-bbe7-8786cfb93ae6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent_1e837d17-f298-47c4-b9d1-9efa5586980b" xlink:href="wald-20221231.xsd#wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e4e137-c883-4504-b8f3-dc0414b5ae24" xlink:to="loc_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent_1e837d17-f298-47c4-b9d1-9efa5586980b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_52c23059-4483-4180-af6f-9d1123bf7d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e4e137-c883-4504-b8f3-dc0414b5ae24" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_52c23059-4483-4180-af6f-9d1123bf7d3e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_299510bc-a228-4c6c-bb69-47b303bf259f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_52c23059-4483-4180-af6f-9d1123bf7d3e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_299510bc-a228-4c6c-bb69-47b303bf259f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_299510bc-a228-4c6c-bb69-47b303bf259f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_299510bc-a228-4c6c-bb69-47b303bf259f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_299510bc-a228-4c6c-bb69-47b303bf259f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14ca9312-469f-4a35-8073-ccca9c114834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_299510bc-a228-4c6c-bb69-47b303bf259f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14ca9312-469f-4a35-8073-ccca9c114834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiAndMilkBusinessCombinationsMember_90524529-f1b4-4452-a5fb-2370dc92b09d" xlink:href="wald-20221231.xsd#wald_ObagiAndMilkBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14ca9312-469f-4a35-8073-ccca9c114834" xlink:to="loc_wald_ObagiAndMilkBusinessCombinationsMember_90524529-f1b4-4452-a5fb-2370dc92b09d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#REVENUERevenuebySalesChannelDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4a62c306-dab7-4e4d-a34b-aad55712b252" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a292ab26-2848-4c24-aec9-af9f4c0c0d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4a62c306-dab7-4e4d-a34b-aad55712b252" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a292ab26-2848-4c24-aec9-af9f4c0c0d9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1ae80736-ff8b-47da-87f9-9fc81173fc73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4a62c306-dab7-4e4d-a34b-aad55712b252" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1ae80736-ff8b-47da-87f9-9fc81173fc73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8419d7cc-5627-4ec8-824f-7f080cda73e9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1ae80736-ff8b-47da-87f9-9fc81173fc73" xlink:to="loc_srt_ProductOrServiceAxis_8419d7cc-5627-4ec8-824f-7f080cda73e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8419d7cc-5627-4ec8-824f-7f080cda73e9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8419d7cc-5627-4ec8-824f-7f080cda73e9" xlink:to="loc_srt_ProductsAndServicesDomain_8419d7cc-5627-4ec8-824f-7f080cda73e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_244a7976-1aaf-4fca-9453-2a6ea68991b0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8419d7cc-5627-4ec8-824f-7f080cda73e9" xlink:to="loc_srt_ProductsAndServicesDomain_244a7976-1aaf-4fca-9453-2a6ea68991b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_338bd741-ee69-4e0f-81a1-b41868e84d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_244a7976-1aaf-4fca-9453-2a6ea68991b0" xlink:to="loc_us-gaap_ProductMember_338bd741-ee69-4e0f-81a1-b41868e84d2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_779412e3-bf71-404d-bb43-4491ae0b3479" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_244a7976-1aaf-4fca-9453-2a6ea68991b0" xlink:to="loc_us-gaap_RoyaltyMember_779412e3-bf71-404d-bb43-4491ae0b3479" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_be449fc0-3813-40ae-bfbb-c51a97ba4a22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1ae80736-ff8b-47da-87f9-9fc81173fc73" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_be449fc0-3813-40ae-bfbb-c51a97ba4a22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_be449fc0-3813-40ae-bfbb-c51a97ba4a22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_be449fc0-3813-40ae-bfbb-c51a97ba4a22" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_be449fc0-3813-40ae-bfbb-c51a97ba4a22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_beeee759-ac9b-443b-a7f4-ee773800ee83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_be449fc0-3813-40ae-bfbb-c51a97ba4a22" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_beeee759-ac9b-443b-a7f4-ee773800ee83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember_da85c5c6-f99a-455f-b46d-b20cab10f03b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_beeee759-ac9b-443b-a7f4-ee773800ee83" xlink:to="loc_us-gaap_SalesChannelDirectlyToConsumerMember_da85c5c6-f99a-455f-b46d-b20cab10f03b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember_f977a74d-a445-4db1-8abf-b731af3f8214" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_beeee759-ac9b-443b-a7f4-ee773800ee83" xlink:to="loc_us-gaap_SalesChannelThroughIntermediaryMember_f977a74d-a445-4db1-8abf-b731af3f8214" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_53cbd5ef-4322-435e-bbe1-c75099a5e66c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1ae80736-ff8b-47da-87f9-9fc81173fc73" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_53cbd5ef-4322-435e-bbe1-c75099a5e66c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_53cbd5ef-4322-435e-bbe1-c75099a5e66c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_53cbd5ef-4322-435e-bbe1-c75099a5e66c" xlink:to="loc_us-gaap_SegmentDomain_53cbd5ef-4322-435e-bbe1-c75099a5e66c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7f737db1-c522-4110-9158-0930b1c58e01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_53cbd5ef-4322-435e-bbe1-c75099a5e66c" xlink:to="loc_us-gaap_SegmentDomain_7f737db1-c522-4110-9158-0930b1c58e01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiSkincareMember_5c81a34d-21e2-4824-bef5-6012744d4272" xlink:href="wald-20221231.xsd#wald_ObagiSkincareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7f737db1-c522-4110-9158-0930b1c58e01" xlink:to="loc_wald_ObagiSkincareMember_5c81a34d-21e2-4824-bef5-6012744d4272" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkMakeupMember_a1dd2a54-77fa-46dd-9e48-e0a8995f47c8" xlink:href="wald-20221231.xsd#wald_MilkMakeupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7f737db1-c522-4110-9158-0930b1c58e01" xlink:to="loc_wald_MilkMakeupMember_a1dd2a54-77fa-46dd-9e48-e0a8995f47c8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/REVENUENarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#REVENUENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/REVENUENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_161b3e66-59e5-4148-b656-fdd67f8d6591" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_117b3891-e70f-4b18-93b6-83c9a2f02740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_161b3e66-59e5-4148-b656-fdd67f8d6591" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_117b3891-e70f-4b18-93b6-83c9a2f02740" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e3249d90-1a3f-4176-a5ef-287d50d2bfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_161b3e66-59e5-4148-b656-fdd67f8d6591" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e3249d90-1a3f-4176-a5ef-287d50d2bfcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_fd8c5d4d-a79f-4bf0-8d47-b54d2d744651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_161b3e66-59e5-4148-b656-fdd67f8d6591" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_fd8c5d4d-a79f-4bf0-8d47-b54d2d744651" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8e57b8c7-30e0-42d3-b9b4-8adb2545fe49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fd8c5d4d-a79f-4bf0-8d47-b54d2d744651" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8e57b8c7-30e0-42d3-b9b4-8adb2545fe49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8e57b8c7-30e0-42d3-b9b4-8adb2545fe49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8e57b8c7-30e0-42d3-b9b4-8adb2545fe49" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8e57b8c7-30e0-42d3-b9b4-8adb2545fe49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a06f053-3916-4ac2-8731-913dd32a0df8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8e57b8c7-30e0-42d3-b9b4-8adb2545fe49" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a06f053-3916-4ac2-8731-913dd32a0df8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_b2d9d645-828e-4d3e-83fc-5e3d879434be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a06f053-3916-4ac2-8731-913dd32a0df8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_b2d9d645-828e-4d3e-83fc-5e3d879434be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c8022caf-eccd-45d9-9db9-692ed17d06eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fd8c5d4d-a79f-4bf0-8d47-b54d2d744651" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c8022caf-eccd-45d9-9db9-692ed17d06eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c8022caf-eccd-45d9-9db9-692ed17d06eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c8022caf-eccd-45d9-9db9-692ed17d06eb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c8022caf-eccd-45d9-9db9-692ed17d06eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_181c8daf-85bf-4894-9261-2d023534b486" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c8022caf-eccd-45d9-9db9-692ed17d06eb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_181c8daf-85bf-4894-9261-2d023534b486" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c6271f21-2b7b-4514-92d6-a2aebff04cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_181c8daf-85bf-4894-9261-2d023534b486" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c6271f21-2b7b-4514-92d6-a2aebff04cf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_a15d1bc4-2a37-4bc8-822d-1f47447334b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_181c8daf-85bf-4894-9261-2d023534b486" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_a15d1bc4-2a37-4bc8-822d-1f47447334b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_795e8e3f-a433-4886-9f67-27eb09597cfc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fd8c5d4d-a79f-4bf0-8d47-b54d2d744651" xlink:to="loc_srt_MajorCustomersAxis_795e8e3f-a433-4886-9f67-27eb09597cfc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_795e8e3f-a433-4886-9f67-27eb09597cfc_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_795e8e3f-a433-4886-9f67-27eb09597cfc" xlink:to="loc_srt_NameOfMajorCustomerDomain_795e8e3f-a433-4886-9f67-27eb09597cfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b43debfd-6065-4d90-9117-8febc79a2abb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_795e8e3f-a433-4886-9f67-27eb09597cfc" xlink:to="loc_srt_NameOfMajorCustomerDomain_b43debfd-6065-4d90-9117-8febc79a2abb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CustomerOneMember_b8ede068-b11f-41cd-88cd-e663c55069ec" xlink:href="wald-20221231.xsd#wald_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b43debfd-6065-4d90-9117-8febc79a2abb" xlink:to="loc_wald_CustomerOneMember_b8ede068-b11f-41cd-88cd-e663c55069ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CustomerTwoMember_0c0df606-ec59-4a66-9965-5acb9943e4f7" xlink:href="wald-20221231.xsd#wald_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b43debfd-6065-4d90-9117-8febc79a2abb" xlink:to="loc_wald_CustomerTwoMember_0c0df606-ec59-4a66-9965-5acb9943e4f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CustomerThreeMember_52b1e684-e551-4775-88ad-4d60b6e25f15" xlink:href="wald-20221231.xsd#wald_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b43debfd-6065-4d90-9117-8febc79a2abb" xlink:to="loc_wald_CustomerThreeMember_52b1e684-e551-4775-88ad-4d60b6e25f15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_2249cbb2-bdef-4fe1-9839-71e312e17b95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fd8c5d4d-a79f-4bf0-8d47-b54d2d744651" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_2249cbb2-bdef-4fe1-9839-71e312e17b95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_2249cbb2-bdef-4fe1-9839-71e312e17b95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_2249cbb2-bdef-4fe1-9839-71e312e17b95" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_2249cbb2-bdef-4fe1-9839-71e312e17b95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_4c296f46-4084-4cc3-957c-e0d2b7f85bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_2249cbb2-bdef-4fe1-9839-71e312e17b95" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_4c296f46-4084-4cc3-957c-e0d2b7f85bc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PhysicianChannelProviderMember_72f69f16-9dc6-47aa-940c-d0f83a86fd6d" xlink:href="wald-20221231.xsd#wald_PhysicianChannelProviderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_4c296f46-4084-4cc3-957c-e0d2b7f85bc5" xlink:to="loc_wald_PhysicianChannelProviderMember_72f69f16-9dc6-47aa-940c-d0f83a86fd6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SpaChannelDistributorMember_d2c9aa00-5532-434c-b399-824d6d302bb7" xlink:href="wald-20221231.xsd#wald_SpaChannelDistributorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_4c296f46-4084-4cc3-957c-e0d2b7f85bc5" xlink:to="loc_wald_SpaChannelDistributorMember_d2c9aa00-5532-434c-b399-824d6d302bb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4a6dc5ee-f2b4-4c6a-9198-a49bde3454f8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fd8c5d4d-a79f-4bf0-8d47-b54d2d744651" xlink:to="loc_srt_StatementGeographicalAxis_4a6dc5ee-f2b4-4c6a-9198-a49bde3454f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4a6dc5ee-f2b4-4c6a-9198-a49bde3454f8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4a6dc5ee-f2b4-4c6a-9198-a49bde3454f8" xlink:to="loc_srt_SegmentGeographicalDomain_4a6dc5ee-f2b4-4c6a-9198-a49bde3454f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7f41c763-b0c6-41f7-8b74-dcc2689f8f1a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4a6dc5ee-f2b4-4c6a-9198-a49bde3454f8" xlink:to="loc_srt_SegmentGeographicalDomain_7f41c763-b0c6-41f7-8b74-dcc2689f8f1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1f408352-18be-4e79-912d-a73025c3af9a" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7f41c763-b0c6-41f7-8b74-dcc2689f8f1a" xlink:to="loc_country_US_1f408352-18be-4e79-912d-a73025c3af9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_02ddb324-be66-41fb-a518-bc9147ec5f43" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7f41c763-b0c6-41f7-8b74-dcc2689f8f1a" xlink:to="loc_country_CN_02ddb324-be66-41fb-a518-bc9147ec5f43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_VN_448445bf-456f-42a3-9845-027d5484cf15" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_VN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7f41c763-b0c6-41f7-8b74-dcc2689f8f1a" xlink:to="loc_country_VN_448445bf-456f-42a3-9845-027d5484cf15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_35bc183d-88c6-4aa3-b079-e316c02f2ebb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fd8c5d4d-a79f-4bf0-8d47-b54d2d744651" xlink:to="loc_srt_ProductOrServiceAxis_35bc183d-88c6-4aa3-b079-e316c02f2ebb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_35bc183d-88c6-4aa3-b079-e316c02f2ebb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_35bc183d-88c6-4aa3-b079-e316c02f2ebb" xlink:to="loc_srt_ProductsAndServicesDomain_35bc183d-88c6-4aa3-b079-e316c02f2ebb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5357cc52-9f3e-421d-b859-f456de31fc10" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_35bc183d-88c6-4aa3-b079-e316c02f2ebb" xlink:to="loc_srt_ProductsAndServicesDomain_5357cc52-9f3e-421d-b859-f456de31fc10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ab091ec4-3030-4e1e-ac68-c6e3ca72b7da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5357cc52-9f3e-421d-b859-f456de31fc10" xlink:to="loc_us-gaap_ProductMember_ab091ec4-3030-4e1e-ac68-c6e3ca72b7da" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#REVENUERevenuebyGeographicRegionDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_319df5dc-4c99-44f3-a072-836b79e4ab35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_404c7a7e-ef06-4884-9cea-613292481c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_319df5dc-4c99-44f3-a072-836b79e4ab35" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_404c7a7e-ef06-4884-9cea-613292481c8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_efdd04e9-451e-4ac9-8524-286cc9d402d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_319df5dc-4c99-44f3-a072-836b79e4ab35" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_efdd04e9-451e-4ac9-8524-286cc9d402d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aae298db-2a38-4f7d-a77c-f252eb155bc2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_efdd04e9-451e-4ac9-8524-286cc9d402d8" xlink:to="loc_srt_ProductOrServiceAxis_aae298db-2a38-4f7d-a77c-f252eb155bc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_aae298db-2a38-4f7d-a77c-f252eb155bc2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_aae298db-2a38-4f7d-a77c-f252eb155bc2" xlink:to="loc_srt_ProductsAndServicesDomain_aae298db-2a38-4f7d-a77c-f252eb155bc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_034603dd-b3fa-4c4b-8a7a-b2ceac297c65" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_aae298db-2a38-4f7d-a77c-f252eb155bc2" xlink:to="loc_srt_ProductsAndServicesDomain_034603dd-b3fa-4c4b-8a7a-b2ceac297c65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_17ad1927-c8ce-4f40-95c1-504191321662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_034603dd-b3fa-4c4b-8a7a-b2ceac297c65" xlink:to="loc_us-gaap_ProductMember_17ad1927-c8ce-4f40-95c1-504191321662" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_39667b0d-1d31-4746-a077-7d5493ce7ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_034603dd-b3fa-4c4b-8a7a-b2ceac297c65" xlink:to="loc_us-gaap_RoyaltyMember_39667b0d-1d31-4746-a077-7d5493ce7ea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7f8e2619-779f-41ca-b53a-3fcf3e6a295a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_efdd04e9-451e-4ac9-8524-286cc9d402d8" xlink:to="loc_srt_StatementGeographicalAxis_7f8e2619-779f-41ca-b53a-3fcf3e6a295a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7f8e2619-779f-41ca-b53a-3fcf3e6a295a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7f8e2619-779f-41ca-b53a-3fcf3e6a295a" xlink:to="loc_srt_SegmentGeographicalDomain_7f8e2619-779f-41ca-b53a-3fcf3e6a295a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d34df2f7-85d4-4fe1-a43a-1a0eacfd3e28" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7f8e2619-779f-41ca-b53a-3fcf3e6a295a" xlink:to="loc_srt_SegmentGeographicalDomain_d34df2f7-85d4-4fe1-a43a-1a0eacfd3e28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_25e4cf86-e42c-4a40-90b2-5212ac8c8e75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d34df2f7-85d4-4fe1-a43a-1a0eacfd3e28" xlink:to="loc_srt_NorthAmericaMember_25e4cf86-e42c-4a40-90b2-5212ac8c8e75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_RestOfTheWorldMember_6251d00f-16d0-4aa5-99d7-ac24cf6f0254" xlink:href="wald-20221231.xsd#wald_RestOfTheWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d34df2f7-85d4-4fe1-a43a-1a0eacfd3e28" xlink:to="loc_wald_RestOfTheWorldMember_6251d00f-16d0-4aa5-99d7-ac24cf6f0254" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#GOODWILLScheduleofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_fae39809-13d9-40b7-b39e-6c15fd6211cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_7ebf9e89-0792-4994-a837-f7212bf0eaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_fae39809-13d9-40b7-b39e-6c15fd6211cf" xlink:to="loc_us-gaap_GoodwillRollForward_7ebf9e89-0792-4994-a837-f7212bf0eaa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1ab59c82-c406-40e5-b2bb-740d5be1484c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_7ebf9e89-0792-4994-a837-f7212bf0eaa8" xlink:to="loc_us-gaap_Goodwill_1ab59c82-c406-40e5-b2bb-740d5be1484c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_6f9bcf5b-9d0c-4028-8c89-4980fd665b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_7ebf9e89-0792-4994-a837-f7212bf0eaa8" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_6f9bcf5b-9d0c-4028-8c89-4980fd665b1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_033bf2fd-ff26-4325-9f94-0ae84b6973ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_7ebf9e89-0792-4994-a837-f7212bf0eaa8" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_033bf2fd-ff26-4325-9f94-0ae84b6973ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_fc647889-ea62-4fe2-a65a-1d244250bab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_7ebf9e89-0792-4994-a837-f7212bf0eaa8" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_fc647889-ea62-4fe2-a65a-1d244250bab2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d2fd7497-5b62-491d-bcd4-402ef7d8da31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_118763f4-a436-4a1c-a5d9-93ff11cf3657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_fae39809-13d9-40b7-b39e-6c15fd6211cf" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_118763f4-a436-4a1c-a5d9-93ff11cf3657" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7182f429-7930-444f-b7cd-f1a1862ccc99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_118763f4-a436-4a1c-a5d9-93ff11cf3657" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7182f429-7930-444f-b7cd-f1a1862ccc99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7182f429-7930-444f-b7cd-f1a1862ccc99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7182f429-7930-444f-b7cd-f1a1862ccc99" xlink:to="loc_us-gaap_SegmentDomain_7182f429-7930-444f-b7cd-f1a1862ccc99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_50693782-e546-4de9-98b8-5e0f6ba9aa35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7182f429-7930-444f-b7cd-f1a1862ccc99" xlink:to="loc_us-gaap_SegmentDomain_50693782-e546-4de9-98b8-5e0f6ba9aa35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiSkincareMember_3dab6e2c-d802-4edf-a8a2-bf7700d740ab" xlink:href="wald-20221231.xsd#wald_ObagiSkincareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_50693782-e546-4de9-98b8-5e0f6ba9aa35" xlink:to="loc_wald_ObagiSkincareMember_3dab6e2c-d802-4edf-a8a2-bf7700d740ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkMakeupMember_5548abcd-4e6d-4834-9182-acfb3ca0c94f" xlink:href="wald-20221231.xsd#wald_MilkMakeupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_50693782-e546-4de9-98b8-5e0f6ba9aa35" xlink:to="loc_wald_MilkMakeupMember_5548abcd-4e6d-4834-9182-acfb3ca0c94f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/GOODWILLNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#GOODWILLNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/GOODWILLNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_93155f56-ac82-4418-bc04-39dbcd5f0258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_f7a34ec4-1a07-448a-af79-8303b38ad9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_93155f56-ac82-4418-bc04-39dbcd5f0258" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_f7a34ec4-1a07-448a-af79-8303b38ad9e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_a2a12314-8e32-45fe-a394-2a787888fc95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_93155f56-ac82-4418-bc04-39dbcd5f0258" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_a2a12314-8e32-45fe-a394-2a787888fc95" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0e3268ba-0bb4-4c0f-a41a-7928a6840f45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a2a12314-8e32-45fe-a394-2a787888fc95" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0e3268ba-0bb4-4c0f-a41a-7928a6840f45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0e3268ba-0bb4-4c0f-a41a-7928a6840f45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0e3268ba-0bb4-4c0f-a41a-7928a6840f45" xlink:to="loc_us-gaap_SegmentDomain_0e3268ba-0bb4-4c0f-a41a-7928a6840f45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_307c9dab-d737-4d8c-bb4d-00ac007778b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0e3268ba-0bb4-4c0f-a41a-7928a6840f45" xlink:to="loc_us-gaap_SegmentDomain_307c9dab-d737-4d8c-bb4d-00ac007778b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiSkincareMember_ef74c3cf-d3f1-4f50-af8e-419ffc8a71b2" xlink:href="wald-20221231.xsd#wald_ObagiSkincareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_307c9dab-d737-4d8c-bb4d-00ac007778b9" xlink:to="loc_wald_ObagiSkincareMember_ef74c3cf-d3f1-4f50-af8e-419ffc8a71b2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df97a5a5-1025-4b28-84d0-3c37bb9d032a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3580d86f-f69c-4349-b09f-187fe752fb66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df97a5a5-1025-4b28-84d0-3c37bb9d032a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3580d86f-f69c-4349-b09f-187fe752fb66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e4262357-7d4b-4d6c-b521-b10d9c785199" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df97a5a5-1025-4b28-84d0-3c37bb9d032a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e4262357-7d4b-4d6c-b521-b10d9c785199" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_963a803d-ce74-4ee4-88b2-a5ac8e0a3850" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df97a5a5-1025-4b28-84d0-3c37bb9d032a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_963a803d-ce74-4ee4-88b2-a5ac8e0a3850" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0c3f53c2-b423-4d64-ac33-bc063fc07082" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df97a5a5-1025-4b28-84d0-3c37bb9d032a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0c3f53c2-b423-4d64-ac33-bc063fc07082" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_826fdce2-42cb-4279-871a-da6f66689805" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df97a5a5-1025-4b28-84d0-3c37bb9d032a" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_826fdce2-42cb-4279-871a-da6f66689805" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ba2dc6a-0a0f-4d42-8f4f-2caca9c63189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_826fdce2-42cb-4279-871a-da6f66689805" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ba2dc6a-0a0f-4d42-8f4f-2caca9c63189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8ba2dc6a-0a0f-4d42-8f4f-2caca9c63189_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ba2dc6a-0a0f-4d42-8f4f-2caca9c63189" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8ba2dc6a-0a0f-4d42-8f4f-2caca9c63189_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_01ac9f08-b3fa-489c-afca-8ea846414a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ba2dc6a-0a0f-4d42-8f4f-2caca9c63189" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_01ac9f08-b3fa-489c-afca-8ea846414a9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_e9f0f07b-0f8f-4573-8683-4a84a34e0a99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_01ac9f08-b3fa-489c-afca-8ea846414a9e" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_e9f0f07b-0f8f-4573-8683-4a84a34e0a99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_f9853fea-b3ad-4f92-b414-07ff6ca48aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_01ac9f08-b3fa-489c-afca-8ea846414a9e" xlink:to="loc_us-gaap_CustomerRelationshipsMember_f9853fea-b3ad-4f92-b414-07ff6ca48aeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_TretinoinDistributionAndSupplyAgreementMember_ba9b296a-e3fd-47ac-bf7d-6ba28d64eb1a" xlink:href="wald-20221231.xsd#wald_TretinoinDistributionAndSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_01ac9f08-b3fa-489c-afca-8ea846414a9e" xlink:to="loc_wald_TretinoinDistributionAndSupplyAgreementMember_ba9b296a-e3fd-47ac-bf7d-6ba28d64eb1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_FormulationsMember_174848f2-39cc-40d3-9f39-0f7a416f4e7e" xlink:href="wald-20221231.xsd#wald_FormulationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_01ac9f08-b3fa-489c-afca-8ea846414a9e" xlink:to="loc_wald_FormulationsMember_174848f2-39cc-40d3-9f39-0f7a416f4e7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_6870056a-4335-43e5-85da-748cc818e66c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_01ac9f08-b3fa-489c-afca-8ea846414a9e" xlink:to="loc_us-gaap_PatentsMember_6870056a-4335-43e5-85da-748cc818e66c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/DEBTLongtermDebtDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#DEBTLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/DEBTLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b4fbd31b-6e43-4a24-b87a-6aa61611d97a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_416142d4-d16b-42b1-940d-67f75477e380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4fbd31b-6e43-4a24-b87a-6aa61611d97a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_416142d4-d16b-42b1-940d-67f75477e380" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_483fd6da-3d95-43e5-a5c4-1bd4fe839bec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4fbd31b-6e43-4a24-b87a-6aa61611d97a" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_483fd6da-3d95-43e5-a5c4-1bd4fe839bec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6c0c737a-e05c-4759-b275-e208088530e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4fbd31b-6e43-4a24-b87a-6aa61611d97a" xlink:to="loc_us-gaap_LongTermDebt_6c0c737a-e05c-4759-b275-e208088530e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_beb0097c-bbef-44db-9e56-ed8ba48744e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4fbd31b-6e43-4a24-b87a-6aa61611d97a" xlink:to="loc_us-gaap_LongTermDebtCurrent_beb0097c-bbef-44db-9e56-ed8ba48744e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e44842cf-ff31-41a2-bfb5-64f7d04606d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4fbd31b-6e43-4a24-b87a-6aa61611d97a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e44842cf-ff31-41a2-bfb5-64f7d04606d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f54307ee-4b4d-4c0f-b26f-99113e53c805" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4fbd31b-6e43-4a24-b87a-6aa61611d97a" xlink:to="loc_us-gaap_DebtInstrumentTable_f54307ee-4b4d-4c0f-b26f-99113e53c805" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cfe10c2b-8a9a-4264-ade2-c9a00ba700dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f54307ee-4b4d-4c0f-b26f-99113e53c805" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cfe10c2b-8a9a-4264-ade2-c9a00ba700dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cfe10c2b-8a9a-4264-ade2-c9a00ba700dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cfe10c2b-8a9a-4264-ade2-c9a00ba700dc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cfe10c2b-8a9a-4264-ade2-c9a00ba700dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_86f1c4ed-be87-40c6-acff-9c340b6a2510" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cfe10c2b-8a9a-4264-ade2-c9a00ba700dc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_86f1c4ed-be87-40c6-acff-9c340b6a2510" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_25b91a47-f631-46c3-9266-4f06415788dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_86f1c4ed-be87-40c6-acff-9c340b6a2510" xlink:to="loc_us-gaap_LineOfCreditMember_25b91a47-f631-46c3-9266-4f06415788dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e520b408-2061-46bb-87a6-7132ee8fdfe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f54307ee-4b4d-4c0f-b26f-99113e53c805" xlink:to="loc_us-gaap_DebtInstrumentAxis_e520b408-2061-46bb-87a6-7132ee8fdfe7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e520b408-2061-46bb-87a6-7132ee8fdfe7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e520b408-2061-46bb-87a6-7132ee8fdfe7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e520b408-2061-46bb-87a6-7132ee8fdfe7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8b193c41-5da9-4bad-b5aa-16ae75010468" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e520b408-2061-46bb-87a6-7132ee8fdfe7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8b193c41-5da9-4bad-b5aa-16ae75010468" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2022TermLoanMember_6771b603-de27-4c9a-a597-9a547bb08086" xlink:href="wald-20221231.xsd#wald_A2022TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b193c41-5da9-4bad-b5aa-16ae75010468" xlink:to="loc_wald_A2022TermLoanMember_6771b603-de27-4c9a-a597-9a547bb08086" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2022RevolvingCreditFacilityMember_c4a4c043-0cc1-44ef-8a1a-e7f59f5514ad" xlink:href="wald-20221231.xsd#wald_A2022RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b193c41-5da9-4bad-b5aa-16ae75010468" xlink:to="loc_wald_A2022RevolvingCreditFacilityMember_c4a4c043-0cc1-44ef-8a1a-e7f59f5514ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2021TermLoanMember_2c4a7e02-20e4-428d-aaff-7630f9e22789" xlink:href="wald-20221231.xsd#wald_A2021TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b193c41-5da9-4bad-b5aa-16ae75010468" xlink:to="loc_wald_A2021TermLoanMember_2c4a7e02-20e4-428d-aaff-7630f9e22789" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2021RevolvingCreditFacilityMember_8a255ce8-4405-41e2-bcb7-b9f0ebe8e39f" xlink:href="wald-20221231.xsd#wald_A2021RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b193c41-5da9-4bad-b5aa-16ae75010468" xlink:to="loc_wald_A2021RevolvingCreditFacilityMember_8a255ce8-4405-41e2-bcb7-b9f0ebe8e39f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2018TermLoanMember_d2a349d8-ebaf-418d-8dcb-e81c74c9fb33" xlink:href="wald-20221231.xsd#wald_A2018TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b193c41-5da9-4bad-b5aa-16ae75010468" xlink:to="loc_wald_A2018TermLoanMember_d2a349d8-ebaf-418d-8dcb-e81c74c9fb33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2018RevolvingCreditFacilityMember_9aa19878-eb14-429d-860c-90088180f1d1" xlink:href="wald-20221231.xsd#wald_A2018RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b193c41-5da9-4bad-b5aa-16ae75010468" xlink:to="loc_wald_A2018RevolvingCreditFacilityMember_9aa19878-eb14-429d-860c-90088180f1d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PPPLoanMember_12d91516-98dc-4776-a089-755b1d3ebda8" xlink:href="wald-20221231.xsd#wald_PPPLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b193c41-5da9-4bad-b5aa-16ae75010468" xlink:to="loc_wald_PPPLoanMember_12d91516-98dc-4776-a089-755b1d3ebda8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_aea88243-ce8e-4b55-9601-688add861880" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f54307ee-4b4d-4c0f-b26f-99113e53c805" xlink:to="loc_us-gaap_CreditFacilityAxis_aea88243-ce8e-4b55-9601-688add861880" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_aea88243-ce8e-4b55-9601-688add861880_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_aea88243-ce8e-4b55-9601-688add861880" xlink:to="loc_us-gaap_CreditFacilityDomain_aea88243-ce8e-4b55-9601-688add861880_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_59224a07-e9a6-44b4-ba21-6eac7ad43a70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_aea88243-ce8e-4b55-9601-688add861880" xlink:to="loc_us-gaap_CreditFacilityDomain_59224a07-e9a6-44b4-ba21-6eac7ad43a70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_81f2e5b4-ddd6-47db-81c8-313db93d42da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_59224a07-e9a6-44b4-ba21-6eac7ad43a70" xlink:to="loc_us-gaap_SecuredDebtMember_81f2e5b4-ddd6-47db-81c8-313db93d42da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_e641d9b3-3637-482e-89d3-3ac3dcc5d3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_59224a07-e9a6-44b4-ba21-6eac7ad43a70" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_e641d9b3-3637-482e-89d3-3ac3dcc5d3e2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#DEBTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/DEBTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_99bb64d5-0f4e-4917-a7d7-07b3901ef670" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_99bb64d5-0f4e-4917-a7d7-07b3901ef670" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4ecd9b82-54fc-4ed8-bbf9-f2b7840d128f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4ecd9b82-54fc-4ed8-bbf9-f2b7840d128f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DebtInstrumentCovenantLeverageRatioMaximum_fd0f8a5e-8afc-4470-8e03-12e17ef99293" xlink:href="wald-20221231.xsd#wald_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_wald_DebtInstrumentCovenantLeverageRatioMaximum_fd0f8a5e-8afc-4470-8e03-12e17ef99293" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_bbcd1346-a4a8-45c2-9074-d8ece0f31835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_DebtInstrumentTerm_bbcd1346-a4a8-45c2-9074-d8ece0f31835" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_087222dc-1784-463c-ab2b-8e8e981e4bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_087222dc-1784-463c-ab2b-8e8e981e4bd8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_6a7f1ea0-b190-4c16-abcb-62cce3a16700" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_6a7f1ea0-b190-4c16-abcb-62cce3a16700" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_89619dc4-a0f0-4f84-8cf3-a3f158e03e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_89619dc4-a0f0-4f84-8cf3-a3f158e03e7d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_81ac6638-e367-4e9c-9904-fefb18b4f69b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_81ac6638-e367-4e9c-9904-fefb18b4f69b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_0311d512-01ad-4a33-94e1-db1cccb5aeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_LongTermDebtCurrent_0311d512-01ad-4a33-94e1-db1cccb5aeb8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_471bf096-fa67-4e1c-a02d-9a73fca0a7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_471bf096-fa67-4e1c-a02d-9a73fca0a7a8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_f4b2e252-0115-4861-89ae-a1e480c603d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_f4b2e252-0115-4861-89ae-a1e480c603d3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_LineOfCreditCovenantTermsMinimumLiquidity_fb0de4d2-c9c9-4f15-be4b-e142409a1b39" xlink:href="wald-20221231.xsd#wald_LineOfCreditCovenantTermsMinimumLiquidity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_wald_LineOfCreditCovenantTermsMinimumLiquidity_fb0de4d2-c9c9-4f15-be4b-e142409a1b39" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e949f10f-24dd-46d9-bd5c-013b24c9471c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_LongTermDebt_e949f10f-24dd-46d9-bd5c-013b24c9471c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2495e0c7-8fd0-4c00-a744-f5a66a2239b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2495e0c7-8fd0-4c00-a744-f5a66a2239b9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityDecreaseForgiveness1_59d23eb9-4a43-41b2-9e40-e8137f4251dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityDecreaseForgiveness1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_LineOfCreditFacilityDecreaseForgiveness1_59d23eb9-4a43-41b2-9e40-e8137f4251dd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_65f7f7e4-b287-4906-969b-67117156ef5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:to="loc_us-gaap_CreditFacilityAxis_65f7f7e4-b287-4906-969b-67117156ef5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_65f7f7e4-b287-4906-969b-67117156ef5d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_65f7f7e4-b287-4906-969b-67117156ef5d" xlink:to="loc_us-gaap_CreditFacilityDomain_65f7f7e4-b287-4906-969b-67117156ef5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f52f9ec1-9e65-4b18-849d-e6b6c7f264b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_65f7f7e4-b287-4906-969b-67117156ef5d" xlink:to="loc_us-gaap_CreditFacilityDomain_f52f9ec1-9e65-4b18-849d-e6b6c7f264b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_673ff672-9a97-475a-a83a-53ceff62ba0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_f52f9ec1-9e65-4b18-849d-e6b6c7f264b4" xlink:to="loc_us-gaap_SecuredDebtMember_673ff672-9a97-475a-a83a-53ceff62ba0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1a338235-0c98-4ee2-8895-1891b3b20fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_f52f9ec1-9e65-4b18-849d-e6b6c7f264b4" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1a338235-0c98-4ee2-8895-1891b3b20fd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a0439cc2-23aa-4e43-afce-e7c5027cf1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:to="loc_us-gaap_DebtInstrumentAxis_a0439cc2-23aa-4e43-afce-e7c5027cf1bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a0439cc2-23aa-4e43-afce-e7c5027cf1bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a0439cc2-23aa-4e43-afce-e7c5027cf1bb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a0439cc2-23aa-4e43-afce-e7c5027cf1bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b7acc551-3019-443c-ae79-285d60aa6663" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a0439cc2-23aa-4e43-afce-e7c5027cf1bb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b7acc551-3019-443c-ae79-285d60aa6663" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2022CreditAgreementMember_384254d3-2d15-445b-aa5c-2a883ec3e956" xlink:href="wald-20221231.xsd#wald_A2022CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7acc551-3019-443c-ae79-285d60aa6663" xlink:to="loc_wald_A2022CreditAgreementMember_384254d3-2d15-445b-aa5c-2a883ec3e956" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2022TermLoanMember_0fc52e73-c6fe-4e14-834e-a47d55b30a1c" xlink:href="wald-20221231.xsd#wald_A2022TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7acc551-3019-443c-ae79-285d60aa6663" xlink:to="loc_wald_A2022TermLoanMember_0fc52e73-c6fe-4e14-834e-a47d55b30a1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2022RevolvingCreditFacilityMember_c0daf40a-c004-448e-8c4b-f764d362513b" xlink:href="wald-20221231.xsd#wald_A2022RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7acc551-3019-443c-ae79-285d60aa6663" xlink:to="loc_wald_A2022RevolvingCreditFacilityMember_c0daf40a-c004-448e-8c4b-f764d362513b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2021TermLoanMember_72fba302-552d-4c80-b666-8740c3cdec42" xlink:href="wald-20221231.xsd#wald_A2021TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7acc551-3019-443c-ae79-285d60aa6663" xlink:to="loc_wald_A2021TermLoanMember_72fba302-552d-4c80-b666-8740c3cdec42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2021RevolvingCreditFacilityMember_1c6e1a50-fbb5-4e83-9905-967b8dfce4f6" xlink:href="wald-20221231.xsd#wald_A2021RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7acc551-3019-443c-ae79-285d60aa6663" xlink:to="loc_wald_A2021RevolvingCreditFacilityMember_1c6e1a50-fbb5-4e83-9905-967b8dfce4f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2018TermLoanMember_28fe2747-5af0-4af9-ab08-2ad5a91ea015" xlink:href="wald-20221231.xsd#wald_A2018TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7acc551-3019-443c-ae79-285d60aa6663" xlink:to="loc_wald_A2018TermLoanMember_28fe2747-5af0-4af9-ab08-2ad5a91ea015" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PPPLoanMember_2b187012-e31c-45e1-a8a9-e9c2ebf83ea4" xlink:href="wald-20221231.xsd#wald_PPPLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7acc551-3019-443c-ae79-285d60aa6663" xlink:to="loc_wald_PPPLoanMember_2b187012-e31c-45e1-a8a9-e9c2ebf83ea4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c9305185-6348-457e-9f24-d246817bc352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c9305185-6348-457e-9f24-d246817bc352" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c9305185-6348-457e-9f24-d246817bc352_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c9305185-6348-457e-9f24-d246817bc352" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c9305185-6348-457e-9f24-d246817bc352_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_acef8abe-c9e1-4494-a490-5d2dff383c72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c9305185-6348-457e-9f24-d246817bc352" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_acef8abe-c9e1-4494-a490-5d2dff383c72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_4d4aa120-0573-4300-8dae-85a9d654d6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_acef8abe-c9e1-4494-a490-5d2dff383c72" xlink:to="loc_us-gaap_LineOfCreditMember_4d4aa120-0573-4300-8dae-85a9d654d6d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e6143eca-4a77-4d5e-8d43-e5442af862ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_acef8abe-c9e1-4494-a490-5d2dff383c72" xlink:to="loc_us-gaap_SeniorNotesMember_e6143eca-4a77-4d5e-8d43-e5442af862ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VariableRateComponentAxis_256861d6-36d7-4ae7-a786-2a69fad90f8e" xlink:href="wald-20221231.xsd#wald_VariableRateComponentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:to="loc_wald_VariableRateComponentAxis_256861d6-36d7-4ae7-a786-2a69fad90f8e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VariableRateComponentDomain_256861d6-36d7-4ae7-a786-2a69fad90f8e_default" xlink:href="wald-20221231.xsd#wald_VariableRateComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_wald_VariableRateComponentAxis_256861d6-36d7-4ae7-a786-2a69fad90f8e" xlink:to="loc_wald_VariableRateComponentDomain_256861d6-36d7-4ae7-a786-2a69fad90f8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VariableRateComponentDomain_6887ec86-b3b4-4d02-9d21-4ae6622f2a24" xlink:href="wald-20221231.xsd#wald_VariableRateComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_wald_VariableRateComponentAxis_256861d6-36d7-4ae7-a786-2a69fad90f8e" xlink:to="loc_wald_VariableRateComponentDomain_6887ec86-b3b4-4d02-9d21-4ae6622f2a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VariableRateComponentOneMember_a6e1e864-3c1f-4ddc-8bfa-d8f77e0e6d78" xlink:href="wald-20221231.xsd#wald_VariableRateComponentOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wald_VariableRateComponentDomain_6887ec86-b3b4-4d02-9d21-4ae6622f2a24" xlink:to="loc_wald_VariableRateComponentOneMember_a6e1e864-3c1f-4ddc-8bfa-d8f77e0e6d78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VariableRateComponentTwoMember_65a54fa6-2849-4313-85dc-85f4544b7382" xlink:href="wald-20221231.xsd#wald_VariableRateComponentTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wald_VariableRateComponentDomain_6887ec86-b3b4-4d02-9d21-4ae6622f2a24" xlink:to="loc_wald_VariableRateComponentTwoMember_65a54fa6-2849-4313-85dc-85f4544b7382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VariableRateComponentThreeMember_689df6ac-7c84-49ee-9457-993605fd0f80" xlink:href="wald-20221231.xsd#wald_VariableRateComponentThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_wald_VariableRateComponentDomain_6887ec86-b3b4-4d02-9d21-4ae6622f2a24" xlink:to="loc_wald_VariableRateComponentThreeMember_689df6ac-7c84-49ee-9457-993605fd0f80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_54164e59-4d81-4365-a255-8e76ed641ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:to="loc_us-gaap_VariableRateAxis_54164e59-4d81-4365-a255-8e76ed641ab6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_54164e59-4d81-4365-a255-8e76ed641ab6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_54164e59-4d81-4365-a255-8e76ed641ab6" xlink:to="loc_us-gaap_VariableRateDomain_54164e59-4d81-4365-a255-8e76ed641ab6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_80202654-be94-4992-b89b-ee65dfb1c378" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_54164e59-4d81-4365-a255-8e76ed641ab6" xlink:to="loc_us-gaap_VariableRateDomain_80202654-be94-4992-b89b-ee65dfb1c378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AlternateBaseRateMember_c37976e6-8291-4260-a7dd-364d41bef671" xlink:href="wald-20221231.xsd#wald_AlternateBaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_80202654-be94-4992-b89b-ee65dfb1c378" xlink:to="loc_wald_AlternateBaseRateMember_c37976e6-8291-4260-a7dd-364d41bef671" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SecuredOvernightFinancingRateSOFRMember_bc4305cf-58f2-4247-ad56-685b7be6add2" xlink:href="wald-20221231.xsd#wald_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_80202654-be94-4992-b89b-ee65dfb1c378" xlink:to="loc_wald_SecuredOvernightFinancingRateSOFRMember_bc4305cf-58f2-4247-ad56-685b7be6add2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ApplicableRateMember_e1498f7f-f856-48a4-b29a-73a33db44a2a" xlink:href="wald-20221231.xsd#wald_ApplicableRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_80202654-be94-4992-b89b-ee65dfb1c378" xlink:to="loc_wald_ApplicableRateMember_e1498f7f-f856-48a4-b29a-73a33db44a2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f1c2a324-1de2-49f7-8205-924b38afcd08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f1c2a324-1de2-49f7-8205-924b38afcd08" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f1c2a324-1de2-49f7-8205-924b38afcd08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f1c2a324-1de2-49f7-8205-924b38afcd08" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f1c2a324-1de2-49f7-8205-924b38afcd08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_700e3e6c-9265-4912-9ac3-9e30d06521a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f1c2a324-1de2-49f7-8205-924b38afcd08" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_700e3e6c-9265-4912-9ac3-9e30d06521a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_2c11e190-dbcf-4840-bfb6-1622985a272c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_700e3e6c-9265-4912-9ac3-9e30d06521a0" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_2c11e190-dbcf-4840-bfb6-1622985a272c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_d9f41ab5-6216-46a9-9f9f-ddd64ad2dbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_700e3e6c-9265-4912-9ac3-9e30d06521a0" xlink:to="loc_us-gaap_OtherAssetsMember_d9f41ab5-6216-46a9-9f9f-ddd64ad2dbd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c6cf17ba-cec7-4f61-99c3-4b3eb7d8bd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c6cf17ba-cec7-4f61-99c3-4b3eb7d8bd8e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c6cf17ba-cec7-4f61-99c3-4b3eb7d8bd8e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c6cf17ba-cec7-4f61-99c3-4b3eb7d8bd8e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c6cf17ba-cec7-4f61-99c3-4b3eb7d8bd8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e0bd6976-751b-4644-8426-a6bd6c1f24df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c6cf17ba-cec7-4f61-99c3-4b3eb7d8bd8e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e0bd6976-751b-4644-8426-a6bd6c1f24df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d49f84dc-c6a4-404d-b6fd-a10d97fea7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e0bd6976-751b-4644-8426-a6bd6c1f24df" xlink:to="loc_us-gaap_SubsequentEventMember_d49f84dc-c6a4-404d-b6fd-a10d97fea7bd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#DEBTScheduledMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_40807477-e1e2-4a2f-a041-4fb5136d3540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e8414355-ef90-4640-b64c-8c671d4ea54e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40807477-e1e2-4a2f-a041-4fb5136d3540" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e8414355-ef90-4640-b64c-8c671d4ea54e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5c6bc43a-f928-4e1b-9f68-cd9d99137ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40807477-e1e2-4a2f-a041-4fb5136d3540" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5c6bc43a-f928-4e1b-9f68-cd9d99137ae1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7f3611f4-74f4-43b7-b269-e9f8020d84f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40807477-e1e2-4a2f-a041-4fb5136d3540" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7f3611f4-74f4-43b7-b269-e9f8020d84f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f06dd8f1-f3db-4a47-b2d0-e293a1927722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40807477-e1e2-4a2f-a041-4fb5136d3540" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f06dd8f1-f3db-4a47-b2d0-e293a1927722" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_94eb9574-309f-4af5-b725-2892d624b372" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40807477-e1e2-4a2f-a041-4fb5136d3540" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_94eb9574-309f-4af5-b725-2892d624b372" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5b249773-afd2-4fda-b909-0579c54281ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40807477-e1e2-4a2f-a041-4fb5136d3540" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5b249773-afd2-4fda-b909-0579c54281ed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_260a1a74-a30b-4944-9831-c47d1a5c022c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40807477-e1e2-4a2f-a041-4fb5136d3540" xlink:to="loc_us-gaap_DebtInstrumentTable_260a1a74-a30b-4944-9831-c47d1a5c022c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8d74899b-3d89-4c74-a3a9-13f6cea20085" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_260a1a74-a30b-4944-9831-c47d1a5c022c" xlink:to="loc_us-gaap_DebtInstrumentAxis_8d74899b-3d89-4c74-a3a9-13f6cea20085" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8d74899b-3d89-4c74-a3a9-13f6cea20085_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8d74899b-3d89-4c74-a3a9-13f6cea20085" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8d74899b-3d89-4c74-a3a9-13f6cea20085_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b3787205-a67c-4b29-a8c4-58e5e1375aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8d74899b-3d89-4c74-a3a9-13f6cea20085" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b3787205-a67c-4b29-a8c4-58e5e1375aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2022CreditAgreementMember_b2a5197f-5338-4993-b233-f8948d4efa49" xlink:href="wald-20221231.xsd#wald_A2022CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3787205-a67c-4b29-a8c4-58e5e1375aaf" xlink:to="loc_wald_A2022CreditAgreementMember_b2a5197f-5338-4993-b233-f8948d4efa49" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#LEASESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_91789b78-551b-4526-bcd1-967e807f0c35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_06d57d06-4e73-49e6-a7dc-1116f8ffd2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91789b78-551b-4526-bcd1-967e807f0c35" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_06d57d06-4e73-49e6-a7dc-1116f8ffd2b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_LesseeOperatingLeaseExtensionTerm_91bf1136-36ab-4de1-86e7-d021c42e75e2" xlink:href="wald-20221231.xsd#wald_LesseeOperatingLeaseExtensionTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91789b78-551b-4526-bcd1-967e807f0c35" xlink:to="loc_wald_LesseeOperatingLeaseExtensionTerm_91bf1136-36ab-4de1-86e7-d021c42e75e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_515d435d-9653-4dff-ace0-95aebeb271a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91789b78-551b-4526-bcd1-967e807f0c35" xlink:to="loc_us-gaap_OperatingLeaseCost_515d435d-9653-4dff-ace0-95aebeb271a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_NumberOfOperatingLeases_e65e9b67-fa16-4de1-ae8c-719a75175a54" xlink:href="wald-20221231.xsd#wald_NumberOfOperatingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91789b78-551b-4526-bcd1-967e807f0c35" xlink:to="loc_wald_NumberOfOperatingLeases_e65e9b67-fa16-4de1-ae8c-719a75175a54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_076287c7-1798-46e1-b48d-13d066974c45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91789b78-551b-4526-bcd1-967e807f0c35" xlink:to="loc_us-gaap_LeaseAndRentalExpense_076287c7-1798-46e1-b48d-13d066974c45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_544a8bbd-d25e-46c6-9dc6-79a77fab263a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91789b78-551b-4526-bcd1-967e807f0c35" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_544a8bbd-d25e-46c6-9dc6-79a77fab263a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ce3402dc-ae7e-40c7-a96a-a2cec1fbf9cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_544a8bbd-d25e-46c6-9dc6-79a77fab263a" xlink:to="loc_srt_RangeAxis_ce3402dc-ae7e-40c7-a96a-a2cec1fbf9cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ce3402dc-ae7e-40c7-a96a-a2cec1fbf9cd_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ce3402dc-ae7e-40c7-a96a-a2cec1fbf9cd" xlink:to="loc_srt_RangeMember_ce3402dc-ae7e-40c7-a96a-a2cec1fbf9cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c8e450b4-d879-41f1-b3ea-e733f250642d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ce3402dc-ae7e-40c7-a96a-a2cec1fbf9cd" xlink:to="loc_srt_RangeMember_c8e450b4-d879-41f1-b3ea-e733f250642d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d7c50a27-3d51-45b3-adaa-5c231e2d2c75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c8e450b4-d879-41f1-b3ea-e733f250642d" xlink:to="loc_srt_MinimumMember_d7c50a27-3d51-45b3-adaa-5c231e2d2c75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6b458dda-cc0b-4481-ad81-a803a7f848ba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c8e450b4-d879-41f1-b3ea-e733f250642d" xlink:to="loc_srt_MaximumMember_6b458dda-cc0b-4481-ad81-a803a7f848ba" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#FINANCIALINSTRUMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_d4a0fc85-9513-464f-9e66-84f270a9e7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_d4a0fc85-9513-464f-9e66-84f270a9e7b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_f75e7a1e-8498-4c06-8587-0a7f325351a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_f75e7a1e-8498-4c06-8587-0a7f325351a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFloorInterestRate_cb47e9c0-19ca-48b0-b66b-b906ee150205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFloorInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_DerivativeFloorInterestRate_cb47e9c0-19ca-48b0-b66b-b906ee150205" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCapInterestRate_722aeebd-e837-4bb7-be56-643183185b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCapInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_DerivativeCapInterestRate_722aeebd-e837-4bb7-be56-643183185b5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_38009d44-421b-41fc-bb4b-8a199547d2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_38009d44-421b-41fc-bb4b-8a199547d2b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_43e3daa3-f3c6-4f65-8110-bee1682215e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_43e3daa3-f3c6-4f65-8110-bee1682215e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ee46adff-cef2-4d63-976b-325a463d5e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ee46adff-cef2-4d63-976b-325a463d5e4d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bccae863-40af-4c6c-9a36-3d9681ccfb49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bccae863-40af-4c6c-9a36-3d9681ccfb49" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_dba98cba-33a9-4eef-8d95-77ab7e19f7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_dba98cba-33a9-4eef-8d95-77ab7e19f7c5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c6a70b72-3c4c-4a30-a360-b6a9c9c906f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c6a70b72-3c4c-4a30-a360-b6a9c9c906f4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_47ebc537-4186-4673-b2b9-87a503ccd983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_47ebc537-4186-4673-b2b9-87a503ccd983" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6d061099-1c09-4c99-877a-ef776eed6cba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6d061099-1c09-4c99-877a-ef776eed6cba" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination_a31e8e97-973b-4f0f-90d7-3de2938d1280" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination_a31e8e97-973b-4f0f-90d7-3de2938d1280" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightRedemptionPeriod_e04bcb74-9f0e-4fef-abb7-60ef739f57ae" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightRedemptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_wald_ClassOfWarrantOrRightRedemptionPeriod_e04bcb74-9f0e-4fef-abb7-60ef739f57ae" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightRedemptionPricePerShare_09eb764d-ddd2-4cb6-a953-1dc74cdfb4a6" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightRedemptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_wald_ClassOfWarrantOrRightRedemptionPricePerShare_09eb764d-ddd2-4cb6-a953-1dc74cdfb4a6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice_350d3093-ba1c-4c3f-b8dd-24dd87365ece" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice_350d3093-ba1c-4c3f-b8dd-24dd87365ece" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightRedemptionTradingPeriod_53d4849e-572e-46dd-aec2-c3b96bfe175a" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightRedemptionTradingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_wald_ClassOfWarrantOrRightRedemptionTradingPeriod_53d4849e-572e-46dd-aec2-c3b96bfe175a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption_409c9d20-e1ad-45cd-954a-2243d36579fe" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption_409c9d20-e1ad-45cd-954a-2243d36579fe" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger_209495ea-2b1a-4fc1-bf3a-a7847f5af028" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger_209495ea-2b1a-4fc1-bf3a-a7847f5af028" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_ba9ee043-27b2-4e82-b440-7d0c40173495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_DerivativeTable_ba9ee043-27b2-4e82-b440-7d0c40173495" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a728d029-c482-43e3-9a6f-85cdc938a82d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_ba9ee043-27b2-4e82-b440-7d0c40173495" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a728d029-c482-43e3-9a6f-85cdc938a82d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a728d029-c482-43e3-9a6f-85cdc938a82d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a728d029-c482-43e3-9a6f-85cdc938a82d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a728d029-c482-43e3-9a6f-85cdc938a82d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1465013f-2f7d-420a-ade8-548ce56c357e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a728d029-c482-43e3-9a6f-85cdc938a82d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1465013f-2f7d-420a-ade8-548ce56c357e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_InterestRateCollarMember_2c8fdb45-2ec9-4ba5-903f-70384d1e0a10" xlink:href="wald-20221231.xsd#wald_InterestRateCollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1465013f-2f7d-420a-ade8-548ce56c357e" xlink:to="loc_wald_InterestRateCollarMember_2c8fdb45-2ec9-4ba5-903f-70384d1e0a10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9ae61402-f9a3-43ce-b00c-5a78f3829e03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_ba9ee043-27b2-4e82-b440-7d0c40173495" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9ae61402-f9a3-43ce-b00c-5a78f3829e03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9ae61402-f9a3-43ce-b00c-5a78f3829e03_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9ae61402-f9a3-43ce-b00c-5a78f3829e03" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9ae61402-f9a3-43ce-b00c-5a78f3829e03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ece7b15f-381e-4af9-9e2a-aa7a7a7cdf34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9ae61402-f9a3-43ce-b00c-5a78f3829e03" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ece7b15f-381e-4af9-9e2a-aa7a7a7cdf34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PublicWarrantsMember_bcae7624-4192-45d6-a7b7-996b3b184881" xlink:href="wald-20221231.xsd#wald_PublicWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ece7b15f-381e-4af9-9e2a-aa7a7a7cdf34" xlink:to="loc_wald_PublicWarrantsMember_bcae7624-4192-45d6-a7b7-996b3b184881" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SponsorWarrantsMember_ff5035fb-079c-47b6-af03-4ec2c5e41fd8" xlink:href="wald-20221231.xsd#wald_SponsorWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ece7b15f-381e-4af9-9e2a-aa7a7a7cdf34" xlink:to="loc_wald_SponsorWarrantsMember_ff5035fb-079c-47b6-af03-4ec2c5e41fd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PrivatePlacementWarrantsMember_32d9a6f2-0989-41f6-9ef1-00e53fc685f9" xlink:href="wald-20221231.xsd#wald_PrivatePlacementWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ece7b15f-381e-4af9-9e2a-aa7a7a7cdf34" xlink:to="loc_wald_PrivatePlacementWarrantsMember_32d9a6f2-0989-41f6-9ef1-00e53fc685f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_25093e67-c6e9-460c-a302-46332a89b4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_ba9ee043-27b2-4e82-b440-7d0c40173495" xlink:to="loc_us-gaap_StatementClassOfStockAxis_25093e67-c6e9-460c-a302-46332a89b4b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_25093e67-c6e9-460c-a302-46332a89b4b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_25093e67-c6e9-460c-a302-46332a89b4b1" xlink:to="loc_us-gaap_ClassOfStockDomain_25093e67-c6e9-460c-a302-46332a89b4b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_411b394e-a307-4a82-8351-ebb52cc72f33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_25093e67-c6e9-460c-a302-46332a89b4b1" xlink:to="loc_us-gaap_ClassOfStockDomain_411b394e-a307-4a82-8351-ebb52cc72f33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_9cb033a1-d95a-4394-942b-472c926c7c22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_411b394e-a307-4a82-8351-ebb52cc72f33" xlink:to="loc_us-gaap_CommonClassAMember_9cb033a1-d95a-4394-942b-472c926c7c22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_d2c90df1-6187-4bf6-84dd-7b90ec699f02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_ba9ee043-27b2-4e82-b440-7d0c40173495" xlink:to="loc_us-gaap_VestingAxis_d2c90df1-6187-4bf6-84dd-7b90ec699f02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d2c90df1-6187-4bf6-84dd-7b90ec699f02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_d2c90df1-6187-4bf6-84dd-7b90ec699f02" xlink:to="loc_us-gaap_VestingDomain_d2c90df1-6187-4bf6-84dd-7b90ec699f02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_2e4186af-4e72-48d8-911b-b4352af24b73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_d2c90df1-6187-4bf6-84dd-7b90ec699f02" xlink:to="loc_us-gaap_VestingDomain_2e4186af-4e72-48d8-911b-b4352af24b73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fb79933a-3295-4c9e-8d7d-a223b980c226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2e4186af-4e72-48d8-911b-b4352af24b73" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fb79933a-3295-4c9e-8d7d-a223b980c226" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a5cdca71-bfe9-49fd-a14c-a2fd37a7ce2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_2e4186af-4e72-48d8-911b-b4352af24b73" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a5cdca71-bfe9-49fd-a14c-a2fd37a7ce2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6ed7cf85-28ba-402a-9ee6-99e47629bcbd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_ba9ee043-27b2-4e82-b440-7d0c40173495" xlink:to="loc_srt_CounterpartyNameAxis_6ed7cf85-28ba-402a-9ee6-99e47629bcbd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ed7cf85-28ba-402a-9ee6-99e47629bcbd_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6ed7cf85-28ba-402a-9ee6-99e47629bcbd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6ed7cf85-28ba-402a-9ee6-99e47629bcbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f201a16c-567b-486e-8624-10fcc7aa2e4c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6ed7cf85-28ba-402a-9ee6-99e47629bcbd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f201a16c-567b-486e-8624-10fcc7aa2e4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember_6ce09af0-01e8-4eaf-b6ec-cb9f03a75b09" xlink:href="wald-20221231.xsd#wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f201a16c-567b-486e-8624-10fcc7aa2e4c" xlink:to="loc_wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember_6ce09af0-01e8-4eaf-b6ec-cb9f03a75b09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BeautyVenturesLLCMember_028ae6a3-8754-4faa-8a9c-1c97c02c4d85" xlink:href="wald-20221231.xsd#wald_BeautyVenturesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f201a16c-567b-486e-8624-10fcc7aa2e4c" xlink:to="loc_wald_BeautyVenturesLLCMember_028ae6a3-8754-4faa-8a9c-1c97c02c4d85" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e6a495f7-ea7d-4705-9c8d-eb528a61bccb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_76b3d898-d428-4f77-bf6a-21309a5d779e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e6a495f7-ea7d-4705-9c8d-eb528a61bccb" xlink:to="loc_us-gaap_DerivativeAssets_76b3d898-d428-4f77-bf6a-21309a5d779e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_bc617528-3fc9-45c2-bcd6-87d4aa2760d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e6a495f7-ea7d-4705-9c8d-eb528a61bccb" xlink:to="loc_us-gaap_DerivativeLiabilities_bc617528-3fc9-45c2-bcd6-87d4aa2760d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0fa05798-d607-42e1-a73e-580791bb1588" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e6a495f7-ea7d-4705-9c8d-eb528a61bccb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0fa05798-d607-42e1-a73e-580791bb1588" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bfc208fd-acba-4a20-8bea-fc005af514b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0fa05798-d607-42e1-a73e-580791bb1588" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bfc208fd-acba-4a20-8bea-fc005af514b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bfc208fd-acba-4a20-8bea-fc005af514b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bfc208fd-acba-4a20-8bea-fc005af514b8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bfc208fd-acba-4a20-8bea-fc005af514b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db2d07ff-daef-4c7a-bca1-85582fa0a600" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bfc208fd-acba-4a20-8bea-fc005af514b8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db2d07ff-daef-4c7a-bca1-85582fa0a600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1e36cc5e-059c-4284-91ad-f4866726fcbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db2d07ff-daef-4c7a-bca1-85582fa0a600" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1e36cc5e-059c-4284-91ad-f4866726fcbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_334dd52e-550a-4f8e-9402-54eabbad9d66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db2d07ff-daef-4c7a-bca1-85582fa0a600" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_334dd52e-550a-4f8e-9402-54eabbad9d66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2e21ca76-a46b-408b-917b-cbbc4d341707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db2d07ff-daef-4c7a-bca1-85582fa0a600" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2e21ca76-a46b-408b-917b-cbbc4d341707" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4043d003-bdff-4f3c-879f-cecfbf486d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0fa05798-d607-42e1-a73e-580791bb1588" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4043d003-bdff-4f3c-879f-cecfbf486d85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4043d003-bdff-4f3c-879f-cecfbf486d85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4043d003-bdff-4f3c-879f-cecfbf486d85" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4043d003-bdff-4f3c-879f-cecfbf486d85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_556062a6-f0cf-4494-ace3-ec6df5cd677a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4043d003-bdff-4f3c-879f-cecfbf486d85" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_556062a6-f0cf-4494-ace3-ec6df5cd677a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_InterestRateCollarMember_42900320-047c-4f82-997e-14b3cbd8dfdd" xlink:href="wald-20221231.xsd#wald_InterestRateCollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_556062a6-f0cf-4494-ace3-ec6df5cd677a" xlink:to="loc_wald_InterestRateCollarMember_42900320-047c-4f82-997e-14b3cbd8dfdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PublicDerivativeWarrantLiabilitiesMember_bd941de8-cf16-46f1-a761-f0885f08e6e8" xlink:href="wald-20221231.xsd#wald_PublicDerivativeWarrantLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_556062a6-f0cf-4494-ace3-ec6df5cd677a" xlink:to="loc_wald_PublicDerivativeWarrantLiabilitiesMember_bd941de8-cf16-46f1-a761-f0885f08e6e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PrivateDerivativeWarrantLiabilitiesMember_3f957e4d-8310-4d5d-bf79-12a656b0d66e" xlink:href="wald-20221231.xsd#wald_PrivateDerivativeWarrantLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_556062a6-f0cf-4494-ace3-ec6df5cd677a" xlink:to="loc_wald_PrivateDerivativeWarrantLiabilitiesMember_3f957e4d-8310-4d5d-bf79-12a656b0d66e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_00dd570d-d2db-4f24-b112-1151f771b78a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent_34cdb519-42a0-4345-8630-3d44215bf97a" xlink:href="wald-20221231.xsd#wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_00dd570d-d2db-4f24-b112-1151f771b78a" xlink:to="loc_wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent_34cdb519-42a0-4345-8630-3d44215bf97a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_f88f158b-065b-4e8f-9f0d-64623b74e490" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_00dd570d-d2db-4f24-b112-1151f771b78a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_f88f158b-065b-4e8f-9f0d-64623b74e490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent_245512fe-7cce-4f2f-92a6-ba95dba343af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInNotesReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_00dd570d-d2db-4f24-b112-1151f771b78a" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent_245512fe-7cce-4f2f-92a6-ba95dba343af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansReceivableBasisSpreadOnVariableRate_72e33a61-b60c-44d7-8fe3-1cc1a2ac20db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_00dd570d-d2db-4f24-b112-1151f771b78a" xlink:to="loc_us-gaap_LoansReceivableBasisSpreadOnVariableRate_72e33a61-b60c-44d7-8fe3-1cc1a2ac20db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ba9efd47-f78a-49dc-b385-b1945430cbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_00dd570d-d2db-4f24-b112-1151f771b78a" xlink:to="loc_us-gaap_Depreciation_ba9efd47-f78a-49dc-b385-b1945430cbc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_532144bd-ca2a-4a6b-87f4-91687f89e38d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_00dd570d-d2db-4f24-b112-1151f771b78a" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_532144bd-ca2a-4a6b-87f4-91687f89e38d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_05ec497a-e54a-4cff-baa1-9dd5f03612de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_00dd570d-d2db-4f24-b112-1151f771b78a" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_05ec497a-e54a-4cff-baa1-9dd5f03612de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_77b54dc9-4adf-4655-afb5-b04421f88cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_05ec497a-e54a-4cff-baa1-9dd5f03612de" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_77b54dc9-4adf-4655-afb5-b04421f88cfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_77b54dc9-4adf-4655-afb5-b04421f88cfd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_77b54dc9-4adf-4655-afb5-b04421f88cfd" xlink:to="loc_us-gaap_RelatedPartyDomain_77b54dc9-4adf-4655-afb5-b04421f88cfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c576151a-cb91-4948-8abe-a03b974e2b37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_77b54dc9-4adf-4655-afb5-b04421f88cfd" xlink:to="loc_us-gaap_RelatedPartyDomain_c576151a-cb91-4948-8abe-a03b974e2b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_e5a8fb92-1ff4-4404-899d-238ed3252332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c576151a-cb91-4948-8abe-a03b974e2b37" xlink:to="loc_us-gaap_RelatedPartyMember_e5a8fb92-1ff4-4404-899d-238ed3252332" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_f134499c-61ab-4c98-9e6c-1398ffe96ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e8d6151d-2efc-42df-a5a5-f7ea200ec9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_f134499c-61ab-4c98-9e6c-1398ffe96ce2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e8d6151d-2efc-42df-a5a5-f7ea200ec9ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_cf377188-7d94-43c4-9b3a-162d2c31495a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e8d6151d-2efc-42df-a5a5-f7ea200ec9ce" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_cf377188-7d94-43c4-9b3a-162d2c31495a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_37e88256-856b-41ee-9ae0-e025f942226e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e8d6151d-2efc-42df-a5a5-f7ea200ec9ce" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_37e88256-856b-41ee-9ae0-e025f942226e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_183f8dd1-5ee6-4f80-a2b6-b621fe772d48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e8d6151d-2efc-42df-a5a5-f7ea200ec9ce" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_183f8dd1-5ee6-4f80-a2b6-b621fe772d48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_8d0cffc1-3d74-4c8f-afb5-191766532de3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_db445879-b050-4f50-8ec9-f5c8d339cd70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_f134499c-61ab-4c98-9e6c-1398ffe96ce2" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_db445879-b050-4f50-8ec9-f5c8d339cd70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ba573ed2-d86e-440c-92ea-552ae78ac6ce" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_db445879-b050-4f50-8ec9-f5c8d339cd70" xlink:to="loc_dei_LegalEntityAxis_ba573ed2-d86e-440c-92ea-552ae78ac6ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ba573ed2-d86e-440c-92ea-552ae78ac6ce_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ba573ed2-d86e-440c-92ea-552ae78ac6ce" xlink:to="loc_dei_EntityDomain_ba573ed2-d86e-440c-92ea-552ae78ac6ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2891a6b2-28ad-424b-a638-270896e14395" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ba573ed2-d86e-440c-92ea-552ae78ac6ce" xlink:to="loc_dei_EntityDomain_2891a6b2-28ad-424b-a638-270896e14395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_WaldencastPlcMember_50862704-a1b0-47df-a4b2-d916c4073f37" xlink:href="wald-20221231.xsd#wald_WaldencastPlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2891a6b2-28ad-424b-a638-270896e14395" xlink:to="loc_wald_WaldencastPlcMember_50862704-a1b0-47df-a4b2-d916c4073f37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiCosmeceuticalsLLCMember_93744f80-b1ce-447a-81f4-e3a2f4e7e582" xlink:href="wald-20221231.xsd#wald_ObagiCosmeceuticalsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2891a6b2-28ad-424b-a638-270896e14395" xlink:to="loc_wald_ObagiCosmeceuticalsLLCMember_93744f80-b1ce-447a-81f4-e3a2f4e7e582" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01882e8c-dfd0-48cf-b23a-9801f38bac6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_cd62bbbf-dcb3-49f2-a51e-c0f8ba840781" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01882e8c-dfd0-48cf-b23a-9801f38bac6d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_cd62bbbf-dcb3-49f2-a51e-c0f8ba840781" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1fc9dc76-4601-466c-8a4f-a92a469bce71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01882e8c-dfd0-48cf-b23a-9801f38bac6d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1fc9dc76-4601-466c-8a4f-a92a469bce71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dff3248b-05d6-4eaa-954f-3d586c32bd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01882e8c-dfd0-48cf-b23a-9801f38bac6d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_dff3248b-05d6-4eaa-954f-3d586c32bd7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_46d86041-48e8-4527-b86a-f524217ea73b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01882e8c-dfd0-48cf-b23a-9801f38bac6d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_46d86041-48e8-4527-b86a-f524217ea73b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c611c114-9e19-4a5a-ad35-c620e518f759" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_46d86041-48e8-4527-b86a-f524217ea73b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c611c114-9e19-4a5a-ad35-c620e518f759" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c611c114-9e19-4a5a-ad35-c620e518f759_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c611c114-9e19-4a5a-ad35-c620e518f759" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c611c114-9e19-4a5a-ad35-c620e518f759_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d98a4421-1eae-460a-a2e1-a43572a682d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c611c114-9e19-4a5a-ad35-c620e518f759" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d98a4421-1eae-460a-a2e1-a43572a682d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ComputerHardwareSoftwareAndEquipmentMember_9e53953e-5a19-4ab0-91c8-9c5a0a0e87ca" xlink:href="wald-20221231.xsd#wald_ComputerHardwareSoftwareAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d98a4421-1eae-460a-a2e1-a43572a682d1" xlink:to="loc_wald_ComputerHardwareSoftwareAndEquipmentMember_9e53953e-5a19-4ab0-91c8-9c5a0a0e87ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0046bd21-937c-4232-8477-11b53579a417" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d98a4421-1eae-460a-a2e1-a43572a682d1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0046bd21-937c-4232-8477-11b53579a417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_e2ebbe84-b4fb-4385-9152-50681ed43732" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d98a4421-1eae-460a-a2e1-a43572a682d1" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_e2ebbe84-b4fb-4385-9152-50681ed43732" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_1081b009-0340-4eac-8e6c-707f1334255b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d98a4421-1eae-460a-a2e1-a43572a682d1" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_1081b009-0340-4eac-8e6c-707f1334255b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GondolasMember_15f5242e-27cd-4734-9bb8-8944044dc1d0" xlink:href="wald-20221231.xsd#wald_GondolasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d98a4421-1eae-460a-a2e1-a43572a682d1" xlink:to="loc_wald_GondolasMember_15f5242e-27cd-4734-9bb8-8944044dc1d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_f495dd67-aeb4-4327-ac75-466264580341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d98a4421-1eae-460a-a2e1-a43572a682d1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_f495dd67-aeb4-4327-ac75-466264580341" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2b62a736-677a-4ead-9017-eb13a917d699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_e4fd811f-3c8c-40aa-a661-cf15e3fe1e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b62a736-677a-4ead-9017-eb13a917d699" xlink:to="loc_us-gaap_AccruedSalariesCurrent_e4fd811f-3c8c-40aa-a661-cf15e3fe1e2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AccruedSalesReturnsAndDamagesCurrent_ada5e361-9367-4420-b9bc-3eef74849c57" xlink:href="wald-20221231.xsd#wald_AccruedSalesReturnsAndDamagesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b62a736-677a-4ead-9017-eb13a917d699" xlink:to="loc_wald_AccruedSalesReturnsAndDamagesCurrent_ada5e361-9367-4420-b9bc-3eef74849c57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_742c1dab-6d66-4f6c-b204-5b7ebf6fc136" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b62a736-677a-4ead-9017-eb13a917d699" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_742c1dab-6d66-4f6c-b204-5b7ebf6fc136" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AccruedDistributionFeesCurrent_e4dad95a-eb6b-4231-b2b4-0bd3fc2d0c44" xlink:href="wald-20221231.xsd#wald_AccruedDistributionFeesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b62a736-677a-4ead-9017-eb13a917d699" xlink:to="loc_wald_AccruedDistributionFeesCurrent_e4dad95a-eb6b-4231-b2b4-0bd3fc2d0c44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_3f04d37a-a618-4fe4-b207-1a9f9589e1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b62a736-677a-4ead-9017-eb13a917d699" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_3f04d37a-a618-4fe4-b207-1a9f9589e1fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_55f8ba47-5255-4861-b12f-a617f22cbe0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b62a736-677a-4ead-9017-eb13a917d699" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_55f8ba47-5255-4861-b12f-a617f22cbe0f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e6c7b29a-6305-450e-8699-e70e891836d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b62a736-677a-4ead-9017-eb13a917d699" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e6c7b29a-6305-450e-8699-e70e891836d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1ae71f00-a74b-4413-b1a8-4d5a907ca5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e6c7b29a-6305-450e-8699-e70e891836d8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1ae71f00-a74b-4413-b1a8-4d5a907ca5f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1ae71f00-a74b-4413-b1a8-4d5a907ca5f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1ae71f00-a74b-4413-b1a8-4d5a907ca5f3" xlink:to="loc_us-gaap_RelatedPartyDomain_1ae71f00-a74b-4413-b1a8-4d5a907ca5f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a015e1b1-8aaf-45e0-b54c-17960b8dafbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1ae71f00-a74b-4413-b1a8-4d5a907ca5f3" xlink:to="loc_us-gaap_RelatedPartyDomain_a015e1b1-8aaf-45e0-b54c-17960b8dafbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_bdedf96f-c6dc-435f-a6fe-37bd70bddde0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a015e1b1-8aaf-45e0-b54c-17960b8dafbc" xlink:to="loc_us-gaap_RelatedPartyMember_bdedf96f-c6dc-435f-a6fe-37bd70bddde0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_71cd151f-49d6-4f80-af3d-d36077bdb991" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a015e1b1-8aaf-45e0-b54c-17960b8dafbc" xlink:to="loc_us-gaap_NonrelatedPartyMember_71cd151f-49d6-4f80-af3d-d36077bdb991" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bf8cea99-31b8-49ae-9527-24b8f00e76ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bf8cea99-31b8-49ae-9527-24b8f00e76ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod_7ec8b778-8da6-49a7-b877-e4c62c310f6a" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod_7ec8b778-8da6-49a7-b877-e4c62c310f6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_cf5dc0a5-0bcd-45bf-b82d-975e8a91cdad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_cf5dc0a5-0bcd-45bf-b82d-975e8a91cdad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8d65294d-a17f-4839-a7ad-c8310498f9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8d65294d-a17f-4839-a7ad-c8310498f9e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod_e8b284f0-62a0-442c-a7b6-deb6ba6eb15f" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod_e8b284f0-62a0-442c-a7b6-deb6ba6eb15f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod_9fc6b969-7ae1-4cd5-a4c6-a9e442c98d9a" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod_9fc6b969-7ae1-4cd5-a4c6-a9e442c98d9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost_95407d35-f59b-4d7e-999a-a19acac27460" xlink:href="wald-20221231.xsd#wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost_95407d35-f59b-4d7e-999a-a19acac27460" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_45ce0564-7515-4d05-a279-cd18dd624330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_45ce0564-7515-4d05-a279-cd18dd624330" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_96ce1cbb-df50-4064-afea-bd0d9a29123d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_96ce1cbb-df50-4064-afea-bd0d9a29123d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals_1c7dd0c4-b8f3-4f3c-8363-b28fe4813da1" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals_1c7dd0c4-b8f3-4f3c-8363-b28fe4813da1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d8490c42-c546-4775-9731-c5bfda1ff81c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d8490c42-c546-4775-9731-c5bfda1ff81c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches_4b68d7ff-acbe-4442-a81a-e55160ddae3c" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches_4b68d7ff-acbe-4442-a81a-e55160ddae3c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f910aa13-ebba-4634-b8c5-d2ad093e1246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f910aa13-ebba-4634-b8c5-d2ad093e1246" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_305f8b71-f071-4553-85f6-44429d63071e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_305f8b71-f071-4553-85f6-44429d63071e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_fa03711e-d62c-4718-84c8-be0bbce48dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_fa03711e-d62c-4718-84c8-be0bbce48dd9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b75b1cfb-e7bb-4afd-ac02-659062140017" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b75b1cfb-e7bb-4afd-ac02-659062140017" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4d6b1000-d032-450c-86d4-2904fcf008fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4d6b1000-d032-450c-86d4-2904fcf008fc" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_3f2c4619-b693-4a47-8a41-67a58ed06cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_3f2c4619-b693-4a47-8a41-67a58ed06cb8" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments_8acd80ab-4c8c-4202-a6c3-1337f2465a93" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments_8acd80ab-4c8c-4202-a6c3-1337f2465a93" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_ede2cd81-5e6d-451d-99ca-c2fcf8e85341" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_ede2cd81-5e6d-451d-99ca-c2fcf8e85341" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_af2f96c2-eaff-4fe2-bd58-fff3047cc855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_af2f96c2-eaff-4fe2-bd58-fff3047cc855" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cad63094-bc9b-427f-9288-8af877633fac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cad63094-bc9b-427f-9288-8af877633fac" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07ae11b3-628f-46da-bda5-c293a7273fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07ae11b3-628f-46da-bda5-c293a7273fe1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c36aace9-5cd3-438b-8a8f-980a036e77d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07ae11b3-628f-46da-bda5-c293a7273fe1" xlink:to="loc_us-gaap_AwardTypeAxis_c36aace9-5cd3-438b-8a8f-980a036e77d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c36aace9-5cd3-438b-8a8f-980a036e77d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c36aace9-5cd3-438b-8a8f-980a036e77d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c36aace9-5cd3-438b-8a8f-980a036e77d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53832bc2-a179-46e3-bc22-2a0fb4db0a23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c36aace9-5cd3-438b-8a8f-980a036e77d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53832bc2-a179-46e3-bc22-2a0fb4db0a23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_61679e4d-714e-403c-87cc-5576e6d513a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53832bc2-a179-46e3-bc22-2a0fb4db0a23" xlink:to="loc_us-gaap_EmployeeStockMember_61679e4d-714e-403c-87cc-5576e6d513a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1fea53f8-c844-4ca8-845b-3132173bf06a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53832bc2-a179-46e3-bc22-2a0fb4db0a23" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1fea53f8-c844-4ca8-845b-3132173bf06a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_cda28bd8-7912-4d6f-a50a-4dd951af02bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53832bc2-a179-46e3-bc22-2a0fb4db0a23" xlink:to="loc_us-gaap_RestrictedStockMember_cda28bd8-7912-4d6f-a50a-4dd951af02bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_8abca6fe-b787-4b61-9d13-81e2e18e8b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53832bc2-a179-46e3-bc22-2a0fb4db0a23" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_8abca6fe-b787-4b61-9d13-81e2e18e8b2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5e41a7e4-1950-424b-a4b6-9b51830192d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53832bc2-a179-46e3-bc22-2a0fb4db0a23" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5e41a7e4-1950-424b-a4b6-9b51830192d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fc5a9b54-c9c4-4467-a005-37d826d66266" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07ae11b3-628f-46da-bda5-c293a7273fe1" xlink:to="loc_us-gaap_PlanNameAxis_fc5a9b54-c9c4-4467-a005-37d826d66266" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fc5a9b54-c9c4-4467-a005-37d826d66266_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_fc5a9b54-c9c4-4467-a005-37d826d66266" xlink:to="loc_us-gaap_PlanNameDomain_fc5a9b54-c9c4-4467-a005-37d826d66266_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e9678ceb-b66a-4b4b-b7b4-b3e27370c627" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_fc5a9b54-c9c4-4467-a005-37d826d66266" xlink:to="loc_us-gaap_PlanNameDomain_e9678ceb-b66a-4b4b-b7b4-b3e27370c627" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2022IncentiveAwardPlanMember_fb26c0ff-3578-4c5d-a8df-9f74209c2079" xlink:href="wald-20221231.xsd#wald_A2022IncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e9678ceb-b66a-4b4b-b7b4-b3e27370c627" xlink:to="loc_wald_A2022IncentiveAwardPlanMember_fb26c0ff-3578-4c5d-a8df-9f74209c2079" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_LongTermIncentiveAwardsMember_747ab54f-a662-4779-a80f-56a58ae8a2b7" xlink:href="wald-20221231.xsd#wald_LongTermIncentiveAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e9678ceb-b66a-4b4b-b7b4-b3e27370c627" xlink:to="loc_wald_LongTermIncentiveAwardsMember_747ab54f-a662-4779-a80f-56a58ae8a2b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OneTimStockGrantMember_775a219c-696b-4fe9-9bc0-84a0e285a2ad" xlink:href="wald-20221231.xsd#wald_OneTimStockGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e9678ceb-b66a-4b4b-b7b4-b3e27370c627" xlink:to="loc_wald_OneTimStockGrantMember_775a219c-696b-4fe9-9bc0-84a0e285a2ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PredecessorIncentivePlanMember_9bb0b309-117e-4b41-9302-334e12a09ead" xlink:href="wald-20221231.xsd#wald_PredecessorIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e9678ceb-b66a-4b4b-b7b4-b3e27370c627" xlink:to="loc_wald_PredecessorIncentivePlanMember_9bb0b309-117e-4b41-9302-334e12a09ead" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_3c289190-d40e-442e-990f-7863da6ca65d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07ae11b3-628f-46da-bda5-c293a7273fe1" xlink:to="loc_srt_TitleOfIndividualAxis_3c289190-d40e-442e-990f-7863da6ca65d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3c289190-d40e-442e-990f-7863da6ca65d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_3c289190-d40e-442e-990f-7863da6ca65d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3c289190-d40e-442e-990f-7863da6ca65d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_98fdecf1-b1dc-4551-92cc-f9f8c66cad0d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_3c289190-d40e-442e-990f-7863da6ca65d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_98fdecf1-b1dc-4551-92cc-f9f8c66cad0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_a476846c-643f-488c-b80b-129802999d95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07ae11b3-628f-46da-bda5-c293a7273fe1" xlink:to="loc_us-gaap_GranteeStatusAxis_a476846c-643f-488c-b80b-129802999d95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_a476846c-643f-488c-b80b-129802999d95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_a476846c-643f-488c-b80b-129802999d95" xlink:to="loc_us-gaap_GranteeStatusDomain_a476846c-643f-488c-b80b-129802999d95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_40c0c726-1bc0-457d-acc5-5ab7934484ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_a476846c-643f-488c-b80b-129802999d95" xlink:to="loc_us-gaap_GranteeStatusDomain_40c0c726-1bc0-457d-acc5-5ab7934484ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedPaymentArrangementFounderMember_795a0ac2-b448-4ce4-aec1-30a07f6a71c5" xlink:href="wald-20221231.xsd#wald_ShareBasedPaymentArrangementFounderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_40c0c726-1bc0-457d-acc5-5ab7934484ca" xlink:to="loc_wald_ShareBasedPaymentArrangementFounderMember_795a0ac2-b448-4ce4-aec1-30a07f6a71c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_93012524-3ab8-483c-a0f3-f74f3b0cd92b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07ae11b3-628f-46da-bda5-c293a7273fe1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_93012524-3ab8-483c-a0f3-f74f3b0cd92b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93012524-3ab8-483c-a0f3-f74f3b0cd92b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_93012524-3ab8-483c-a0f3-f74f3b0cd92b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93012524-3ab8-483c-a0f3-f74f3b0cd92b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1bc2a3bc-e745-41ba-97dd-3b82e330e52d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_93012524-3ab8-483c-a0f3-f74f3b0cd92b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1bc2a3bc-e745-41ba-97dd-3b82e330e52d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiAndMilkBusinessCombinationsMember_078a1607-f8bd-4284-83a6-96e30daf43cd" xlink:href="wald-20221231.xsd#wald_ObagiAndMilkBusinessCombinationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1bc2a3bc-e745-41ba-97dd-3b82e330e52d" xlink:to="loc_wald_ObagiAndMilkBusinessCombinationsMember_078a1607-f8bd-4284-83a6-96e30daf43cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiMergerMember_2e71fb5b-03b6-4fac-a343-320babd4358e" xlink:href="wald-20221231.xsd#wald_ObagiMergerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1bc2a3bc-e745-41ba-97dd-3b82e330e52d" xlink:to="loc_wald_ObagiMergerMember_2e71fb5b-03b6-4fac-a343-320babd4358e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkTransactionMember_be76f6db-494c-4d80-9a59-4a2a030b338e" xlink:href="wald-20221231.xsd#wald_MilkTransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1bc2a3bc-e745-41ba-97dd-3b82e330e52d" xlink:to="loc_wald_MilkTransactionMember_be76f6db-494c-4d80-9a59-4a2a030b338e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_9d3b543c-c2ae-4dee-8412-e582d1893af1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07ae11b3-628f-46da-bda5-c293a7273fe1" xlink:to="loc_us-gaap_VestingAxis_9d3b543c-c2ae-4dee-8412-e582d1893af1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_9d3b543c-c2ae-4dee-8412-e582d1893af1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_9d3b543c-c2ae-4dee-8412-e582d1893af1" xlink:to="loc_us-gaap_VestingDomain_9d3b543c-c2ae-4dee-8412-e582d1893af1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a6001448-fc71-4395-b4e8-19321dc2d490" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_9d3b543c-c2ae-4dee-8412-e582d1893af1" xlink:to="loc_us-gaap_VestingDomain_a6001448-fc71-4395-b4e8-19321dc2d490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3933cfdc-4f2f-40aa-af30-ce1e8fe1a0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a6001448-fc71-4395-b4e8-19321dc2d490" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3933cfdc-4f2f-40aa-af30-ce1e8fe1a0d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5b9023e7-f3e3-446a-84c1-f6ce34dfa786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_a6001448-fc71-4395-b4e8-19321dc2d490" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5b9023e7-f3e3-446a-84c1-f6ce34dfa786" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#STOCKBASEDCOMPENSATIONStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61778696-82d7-4da9-8b46-846280bb6f71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f6403b7-5d0e-466e-81f8-13883fa991b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61778696-82d7-4da9-8b46-846280bb6f71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f6403b7-5d0e-466e-81f8-13883fa991b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0def3808-48da-4636-8e7e-1fe69d38689a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f6403b7-5d0e-466e-81f8-13883fa991b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0def3808-48da-4636-8e7e-1fe69d38689a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_63c06634-c5b1-42ef-b4bb-215b737a37c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f6403b7-5d0e-466e-81f8-13883fa991b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_63c06634-c5b1-42ef-b4bb-215b737a37c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9fca2cae-3d8b-497d-9904-073aba273768" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f6403b7-5d0e-466e-81f8-13883fa991b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9fca2cae-3d8b-497d-9904-073aba273768" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d0c8fcba-e0bd-4f4a-b3cf-4f2186bce894" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f6403b7-5d0e-466e-81f8-13883fa991b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d0c8fcba-e0bd-4f4a-b3cf-4f2186bce894" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_13e3c50c-ee99-4eda-bdbe-2ff049e6aa7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f6403b7-5d0e-466e-81f8-13883fa991b7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_13e3c50c-ee99-4eda-bdbe-2ff049e6aa7c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1d6bca1a-a756-47f2-88ef-3bcc3a15ebe9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_a2a88858-d49a-4a24-8acf-b1d574a2dffa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61778696-82d7-4da9-8b46-846280bb6f71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_a2a88858-d49a-4a24-8acf-b1d574a2dffa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4fa474f1-22d8-4385-8cf0-31de7cacb618" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61778696-82d7-4da9-8b46-846280bb6f71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4fa474f1-22d8-4385-8cf0-31de7cacb618" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f022e6d-451c-40a2-884c-3f9aa74f42bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61778696-82d7-4da9-8b46-846280bb6f71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f022e6d-451c-40a2-884c-3f9aa74f42bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8022f094-3dc0-4917-90db-c73d38fee253" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f022e6d-451c-40a2-884c-3f9aa74f42bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8022f094-3dc0-4917-90db-c73d38fee253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9d7fea1e-ce16-4011-b12d-87448fc0e369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f022e6d-451c-40a2-884c-3f9aa74f42bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9d7fea1e-ce16-4011-b12d-87448fc0e369" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8ca82110-081f-4450-ac54-d15335d02575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f022e6d-451c-40a2-884c-3f9aa74f42bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8ca82110-081f-4450-ac54-d15335d02575" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5a63acb0-fe23-4108-aaf3-f6016b4940b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f022e6d-451c-40a2-884c-3f9aa74f42bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5a63acb0-fe23-4108-aaf3-f6016b4940b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_30cc9c74-b537-463f-b743-f2243088d3f0" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f022e6d-451c-40a2-884c-3f9aa74f42bf" xlink:to="loc_wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_30cc9c74-b537-463f-b743-f2243088d3f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7eea813c-c11e-4eeb-ad09-3bc6b56e4d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_35548f35-45a3-4680-b713-70c415be61cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61778696-82d7-4da9-8b46-846280bb6f71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_35548f35-45a3-4680-b713-70c415be61cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4ad30a71-ddab-45a6-a104-350f6999ce36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61778696-82d7-4da9-8b46-846280bb6f71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4ad30a71-ddab-45a6-a104-350f6999ce36" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61778696-82d7-4da9-8b46-846280bb6f71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a25afeef-d673-4a07-b91e-c72987f6419b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a25afeef-d673-4a07-b91e-c72987f6419b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm_d4d16e9f-ea99-43ae-a5cd-e4fb24800840" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm_d4d16e9f-ea99-43ae-a5cd-e4fb24800840" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm_a715b576-2983-4a95-8796-d6324c96cb76" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm_a715b576-2983-4a95-8796-d6324c96cb76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_448cea7c-a1fd-4a9c-9532-09ad6df54977" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_448cea7c-a1fd-4a9c-9532-09ad6df54977" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b584fccf-e49c-4ced-abaf-58726bee328f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b584fccf-e49c-4ced-abaf-58726bee328f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d2cffcde-9af1-4f94-8ac8-8dc5c9a1b5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d2cffcde-9af1-4f94-8ac8-8dc5c9a1b5a1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_d277d6a1-b458-45ec-a0a4-fd5f7ea64f3f" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_d277d6a1-b458-45ec-a0a4-fd5f7ea64f3f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue_ddbdffb2-76c6-4102-88a3-c90f992d6627" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue_ddbdffb2-76c6-4102-88a3-c90f992d6627" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_bc1ff2f3-71fc-4080-808a-251bcde4d671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_bc1ff2f3-71fc-4080-808a-251bcde4d671" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8f2e5511-3c5b-4314-b7db-766d21576eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8f2e5511-3c5b-4314-b7db-766d21576eb7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52db308f-6f35-4023-95ef-8f58df779620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61778696-82d7-4da9-8b46-846280bb6f71" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52db308f-6f35-4023-95ef-8f58df779620" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_995a2391-118e-4bc9-878f-a81619f611a5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52db308f-6f35-4023-95ef-8f58df779620" xlink:to="loc_dei_LegalEntityAxis_995a2391-118e-4bc9-878f-a81619f611a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_995a2391-118e-4bc9-878f-a81619f611a5_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_995a2391-118e-4bc9-878f-a81619f611a5" xlink:to="loc_dei_EntityDomain_995a2391-118e-4bc9-878f-a81619f611a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d6941957-307a-432d-98f1-0e321ac32662" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_995a2391-118e-4bc9-878f-a81619f611a5" xlink:to="loc_dei_EntityDomain_d6941957-307a-432d-98f1-0e321ac32662" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_WaldencastPlcMember_e56097e3-8661-4038-b6ee-2f0837fbba95" xlink:href="wald-20221231.xsd#wald_WaldencastPlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d6941957-307a-432d-98f1-0e321ac32662" xlink:to="loc_wald_WaldencastPlcMember_e56097e3-8661-4038-b6ee-2f0837fbba95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiCosmeceuticalsLLCMember_168437a5-93b8-4d72-9987-2fb6167782c3" xlink:href="wald-20221231.xsd#wald_ObagiCosmeceuticalsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d6941957-307a-432d-98f1-0e321ac32662" xlink:to="loc_wald_ObagiCosmeceuticalsLLCMember_168437a5-93b8-4d72-9987-2fb6167782c3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_79ec7034-263b-46f0-bbe4-43d31ecb507d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_79ec7034-263b-46f0-bbe4-43d31ecb507d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_071726c9-acff-46ba-a4a3-522b3f2f3b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_071726c9-acff-46ba-a4a3-522b3f2f3b5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_32f0ef17-9059-42ee-add6-958a25d2ae79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_32f0ef17-9059-42ee-add6-958a25d2ae79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple_ba37a32d-9e3b-4b98-8dcf-3fd3bb2a897a" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple_ba37a32d-9e3b-4b98-8dcf-3fd3bb2a897a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8b11aa8e-76ff-45c9-b701-79a301ac878b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8b11aa8e-76ff-45c9-b701-79a301ac878b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9534807e-24d3-4d2e-8fc9-b4cd1cd7e3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9534807e-24d3-4d2e-8fc9-b4cd1cd7e3f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3506694a-48e4-4170-ae47-0f8a9cf83f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3506694a-48e4-4170-ae47-0f8a9cf83f5d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent_940da8c3-89b5-4320-8f57-b1330aeaab5f" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent_940da8c3-89b5-4320-8f57-b1330aeaab5f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_b0c675c9-68c4-4788-b4db-1b3a3c765ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_b0c675c9-68c4-4788-b4db-1b3a3c765ea5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fa784984-c0f0-42d3-b2d0-8fb73810d407" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fa784984-c0f0-42d3-b2d0-8fb73810d407" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_8c7d619e-4a8f-4d69-a3c6-0526235c2c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_8c7d619e-4a8f-4d69-a3c6-0526235c2c1a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_7307c641-2d9e-440d-83d7-dffefce86bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_SharePrice_7307c641-2d9e-440d-83d7-dffefce86bb6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3921cbef-d4a7-4e5b-97da-0bd4086dd944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3921cbef-d4a7-4e5b-97da-0bd4086dd944" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_123ac13c-f6cf-434e-b758-7fe2f5753174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3921cbef-d4a7-4e5b-97da-0bd4086dd944" xlink:to="loc_us-gaap_AwardTypeAxis_123ac13c-f6cf-434e-b758-7fe2f5753174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_123ac13c-f6cf-434e-b758-7fe2f5753174_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_123ac13c-f6cf-434e-b758-7fe2f5753174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_123ac13c-f6cf-434e-b758-7fe2f5753174_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c9e3871-6794-4b69-8aae-784892443d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_123ac13c-f6cf-434e-b758-7fe2f5753174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c9e3871-6794-4b69-8aae-784892443d8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_FounderAwardsMember_9f4753b1-0abc-4407-85a5-9beb5160394d" xlink:href="wald-20221231.xsd#wald_FounderAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c9e3871-6794-4b69-8aae-784892443d8e" xlink:to="loc_wald_FounderAwardsMember_9f4753b1-0abc-4407-85a5-9beb5160394d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ReplacementAwardsMember_34ac5a69-74a1-4af4-9de3-fb4a7eca9f75" xlink:href="wald-20221231.xsd#wald_ReplacementAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c9e3871-6794-4b69-8aae-784892443d8e" xlink:to="loc_wald_ReplacementAwardsMember_34ac5a69-74a1-4af4-9de3-fb4a7eca9f75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c29a8de9-970b-4da7-8666-b7faa9bcdb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c9e3871-6794-4b69-8aae-784892443d8e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c29a8de9-970b-4da7-8666-b7faa9bcdb9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fdccc677-4bb0-45b5-8eab-a39744a3cdd4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3921cbef-d4a7-4e5b-97da-0bd4086dd944" xlink:to="loc_srt_RangeAxis_fdccc677-4bb0-45b5-8eab-a39744a3cdd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fdccc677-4bb0-45b5-8eab-a39744a3cdd4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fdccc677-4bb0-45b5-8eab-a39744a3cdd4" xlink:to="loc_srt_RangeMember_fdccc677-4bb0-45b5-8eab-a39744a3cdd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_023a29eb-aef0-4111-a607-c3fa4fcf83fe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fdccc677-4bb0-45b5-8eab-a39744a3cdd4" xlink:to="loc_srt_RangeMember_023a29eb-aef0-4111-a607-c3fa4fcf83fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bda1c313-ab8a-40b1-8192-f1d4cc6ea2fb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_023a29eb-aef0-4111-a607-c3fa4fcf83fe" xlink:to="loc_srt_MinimumMember_bda1c313-ab8a-40b1-8192-f1d4cc6ea2fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3c0ba716-0005-40dd-9251-c2242aa61d2e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_023a29eb-aef0-4111-a607-c3fa4fcf83fe" xlink:to="loc_srt_MaximumMember_3c0ba716-0005-40dd-9251-c2242aa61d2e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_839a47bd-9cbd-4536-896d-4b5ba13c77f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2ff87066-2fc8-4c48-aaa5-d2e0e44da2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_839a47bd-9cbd-4536-896d-4b5ba13c77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2ff87066-2fc8-4c48-aaa5-d2e0e44da2d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ef3b7c8d-ec61-4565-939e-9c524195ae7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2ff87066-2fc8-4c48-aaa5-d2e0e44da2d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ef3b7c8d-ec61-4565-939e-9c524195ae7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6fb745dc-299e-4901-b4c6-297c27b755ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2ff87066-2fc8-4c48-aaa5-d2e0e44da2d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6fb745dc-299e-4901-b4c6-297c27b755ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60f03bf3-0dad-46d7-8010-d042e1534cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2ff87066-2fc8-4c48-aaa5-d2e0e44da2d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60f03bf3-0dad-46d7-8010-d042e1534cd7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2074eb35-a4bb-4605-b1d9-69841c95f1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2ff87066-2fc8-4c48-aaa5-d2e0e44da2d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2074eb35-a4bb-4605-b1d9-69841c95f1d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a63c375b-2c5e-496d-933a-be0d8f1185df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2ff87066-2fc8-4c48-aaa5-d2e0e44da2d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a63c375b-2c5e-496d-933a-be0d8f1185df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8bb8729c-8a86-4b7e-a744-e72eab34ff73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba668247-737e-473d-bebb-f8e72de2bf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_839a47bd-9cbd-4536-896d-4b5ba13c77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba668247-737e-473d-bebb-f8e72de2bf9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aa61a695-3411-4179-b83f-04042cf0b43a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba668247-737e-473d-bebb-f8e72de2bf9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aa61a695-3411-4179-b83f-04042cf0b43a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5a3935ef-a11b-492f-8200-cf4a233adbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba668247-737e-473d-bebb-f8e72de2bf9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5a3935ef-a11b-492f-8200-cf4a233adbb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue_84f3a36f-7171-4a63-bbad-ce83a417d4ca" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba668247-737e-473d-bebb-f8e72de2bf9e" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue_84f3a36f-7171-4a63-bbad-ce83a417d4ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_72be211a-7fba-4d1e-99fc-ead977149531" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba668247-737e-473d-bebb-f8e72de2bf9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_72be211a-7fba-4d1e-99fc-ead977149531" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0a531c29-ec3d-4027-b7ef-441abd567024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba668247-737e-473d-bebb-f8e72de2bf9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0a531c29-ec3d-4027-b7ef-441abd567024" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_273db657-3144-4aa6-b949-9e90a2dfdfca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f331fc42-fa88-47cd-bc4b-422436a73b14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_839a47bd-9cbd-4536-896d-4b5ba13c77f6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f331fc42-fa88-47cd-bc4b-422436a73b14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_aececf21-2e8e-4131-a231-608aaa3bdef3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f331fc42-fa88-47cd-bc4b-422436a73b14" xlink:to="loc_us-gaap_AwardTypeAxis_aececf21-2e8e-4131-a231-608aaa3bdef3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aececf21-2e8e-4131-a231-608aaa3bdef3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_aececf21-2e8e-4131-a231-608aaa3bdef3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aececf21-2e8e-4131-a231-608aaa3bdef3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f885ec1b-58dd-49da-bc2f-1729665e9faa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_aececf21-2e8e-4131-a231-608aaa3bdef3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f885ec1b-58dd-49da-bc2f-1729665e9faa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_edb1a520-e5ba-4913-a953-4a1a29fc424c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f885ec1b-58dd-49da-bc2f-1729665e9faa" xlink:to="loc_us-gaap_RestrictedStockMember_edb1a520-e5ba-4913-a953-4a1a29fc424c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5f265fdc-3949-499e-ab5b-fd8604779725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f885ec1b-58dd-49da-bc2f-1729665e9faa" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5f265fdc-3949-499e-ab5b-fd8604779725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_fdacdaf0-59f6-4920-a82a-02b04c444b8c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f331fc42-fa88-47cd-bc4b-422436a73b14" xlink:to="loc_dei_LegalEntityAxis_fdacdaf0-59f6-4920-a82a-02b04c444b8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fdacdaf0-59f6-4920-a82a-02b04c444b8c_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_fdacdaf0-59f6-4920-a82a-02b04c444b8c" xlink:to="loc_dei_EntityDomain_fdacdaf0-59f6-4920-a82a-02b04c444b8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b54402d4-e764-4813-a432-15cbbd85a35c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_fdacdaf0-59f6-4920-a82a-02b04c444b8c" xlink:to="loc_dei_EntityDomain_b54402d4-e764-4813-a432-15cbbd85a35c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_WaldencastPlcMember_4380dbdd-7c78-48e0-8677-466a7ef38914" xlink:href="wald-20221231.xsd#wald_WaldencastPlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b54402d4-e764-4813-a432-15cbbd85a35c" xlink:to="loc_wald_WaldencastPlcMember_4380dbdd-7c78-48e0-8677-466a7ef38914" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiCosmeceuticalsLLCMember_6fa6dccb-c1f4-494f-b8b7-f2488e5d358e" xlink:href="wald-20221231.xsd#wald_ObagiCosmeceuticalsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b54402d4-e764-4813-a432-15cbbd85a35c" xlink:to="loc_wald_ObagiCosmeceuticalsLLCMember_6fa6dccb-c1f4-494f-b8b7-f2488e5d358e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SHAREHOLDERSEQUITYDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_45e6a3a4-90c9-4fd7-a3a0-5227c58e2b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_45e6a3a4-90c9-4fd7-a3a0-5227c58e2b8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4fa248af-f52e-450f-a466-a07d140928a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4fa248af-f52e-450f-a466-a07d140928a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6c0cdb86-e3fe-4a02-8527-cff176ce417b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6c0cdb86-e3fe-4a02-8527-cff176ce417b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_95a331e2-5bb4-4844-ac45-337f3b7e6227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_95a331e2-5bb4-4844-ac45-337f3b7e6227" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3a17c7ef-f13d-4d5d-a477-3216bc849040" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_CommonStockSharesIssued_3a17c7ef-f13d-4d5d-a477-3216bc849040" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_26b7023b-3d6c-45de-a067-d3de23ec3f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_26b7023b-3d6c-45de-a067-d3de23ec3f0f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b601de23-0f80-47b1-b558-e2ae779960fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b601de23-0f80-47b1-b558-e2ae779960fa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_153bb194-8bac-4bcb-9f3e-ed3a47024a19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_153bb194-8bac-4bcb-9f3e-ed3a47024a19" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockVotingRights_4b5b435d-e396-42ce-afff-863f22ebfc79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_CommonStockVotingRights_4b5b435d-e396-42ce-afff-863f22ebfc79" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CommonStockConvertibleConversionRatio_3c36dc5e-3ae7-40f7-86db-4e450eefb6c3" xlink:href="wald-20221231.xsd#wald_CommonStockConvertibleConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_wald_CommonStockConvertibleConversionRatio_3c36dc5e-3ae7-40f7-86db-4e450eefb6c3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_074b9b1f-d24c-4a1b-ae9a-f140d4528512" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_074b9b1f-d24c-4a1b-ae9a-f140d4528512" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_84965b89-46ab-42c5-807f-d90bd040b156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_DividendsCommonStockCash_84965b89-46ab-42c5-807f-d90bd040b156" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_7d22ddeb-bebc-48d8-9f6e-48b8bc09066a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_7d22ddeb-bebc-48d8-9f6e-48b8bc09066a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9418d3e1-a04c-472b-b841-6dd6848b0471" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9418d3e1-a04c-472b-b841-6dd6848b0471" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b3c2d1f0-c155-4bef-b44f-9ddb5be913ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9418d3e1-a04c-472b-b841-6dd6848b0471" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b3c2d1f0-c155-4bef-b44f-9ddb5be913ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b3c2d1f0-c155-4bef-b44f-9ddb5be913ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b3c2d1f0-c155-4bef-b44f-9ddb5be913ea" xlink:to="loc_us-gaap_ClassOfStockDomain_b3c2d1f0-c155-4bef-b44f-9ddb5be913ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c236d5d5-9dd5-4748-9b47-299706c9dbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b3c2d1f0-c155-4bef-b44f-9ddb5be913ea" xlink:to="loc_us-gaap_ClassOfStockDomain_c236d5d5-9dd5-4748-9b47-299706c9dbfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_9b259997-3118-49d6-a45e-59de4febed00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c236d5d5-9dd5-4748-9b47-299706c9dbfb" xlink:to="loc_us-gaap_CommonClassAMember_9b259997-3118-49d6-a45e-59de4febed00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_303eec19-2b84-436b-9d98-525a800ab55f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c236d5d5-9dd5-4748-9b47-299706c9dbfb" xlink:to="loc_us-gaap_CommonClassBMember_303eec19-2b84-436b-9d98-525a800ab55f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9cbce61a-8aa9-4996-b305-4546a25117ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5201161f-96c6-48a5-b9e4-3557d6599085" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9cbce61a-8aa9-4996-b305-4546a25117ae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5201161f-96c6-48a5-b9e4-3557d6599085" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ac71c5f-7ec3-4eb3-a227-1a499fc6ac42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9cbce61a-8aa9-4996-b305-4546a25117ae" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ac71c5f-7ec3-4eb3-a227-1a499fc6ac42" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aa4b5e04-4d7b-4b35-962a-577ed465cac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ac71c5f-7ec3-4eb3-a227-1a499fc6ac42" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aa4b5e04-4d7b-4b35-962a-577ed465cac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aa4b5e04-4d7b-4b35-962a-577ed465cac1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aa4b5e04-4d7b-4b35-962a-577ed465cac1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_aa4b5e04-4d7b-4b35-962a-577ed465cac1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_518e2fe1-9cbd-4754-9469-9dc4f70ec42b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aa4b5e04-4d7b-4b35-962a-577ed465cac1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_518e2fe1-9cbd-4754-9469-9dc4f70ec42b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_fff78e20-799d-4301-b7ed-f3879013381e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_518e2fe1-9cbd-4754-9469-9dc4f70ec42b" xlink:to="loc_us-gaap_WarrantMember_fff78e20-799d-4301-b7ed-f3879013381e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ef06076d-35d6-40d8-a65e-0bd7b9dbef70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_518e2fe1-9cbd-4754-9469-9dc4f70ec42b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ef06076d-35d6-40d8-a65e-0bd7b9dbef70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1cf727b4-a24e-4ecb-8fb1-48c762489855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_518e2fe1-9cbd-4754-9469-9dc4f70ec42b" xlink:to="loc_us-gaap_RestrictedStockMember_1cf727b4-a24e-4ecb-8fb1-48c762489855" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_ad73dda6-dd49-4e13-bbf9-1e7b70624b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_347aaad0-bd8d-4dfe-9e7e-5021b0b09cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ad73dda6-dd49-4e13-bbf9-1e7b70624b2d" xlink:to="loc_us-gaap_OperatingLossCarryforwards_347aaad0-bd8d-4dfe-9e7e-5021b0b09cfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_adc45768-3a37-4de4-8a1a-4843781f0dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ad73dda6-dd49-4e13-bbf9-1e7b70624b2d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_adc45768-3a37-4de4-8a1a-4843781f0dbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_f2d87620-3965-4efc-8b33-b3b9768df7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ad73dda6-dd49-4e13-bbf9-1e7b70624b2d" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_f2d87620-3965-4efc-8b33-b3b9768df7e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5ef5c062-d70c-48be-8cc1-69e0ebd50582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_f2d87620-3965-4efc-8b33-b3b9768df7e5" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5ef5c062-d70c-48be-8cc1-69e0ebd50582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5ef5c062-d70c-48be-8cc1-69e0ebd50582_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5ef5c062-d70c-48be-8cc1-69e0ebd50582" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5ef5c062-d70c-48be-8cc1-69e0ebd50582_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_354af83e-a441-44ac-9686-8e1e435ae7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5ef5c062-d70c-48be-8cc1-69e0ebd50582" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_354af83e-a441-44ac-9686-8e1e435ae7bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_4c4361ca-8a85-4458-a7d2-0ad0a4fea02a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_354af83e-a441-44ac-9686-8e1e435ae7bb" xlink:to="loc_us-gaap_DomesticCountryMember_4c4361ca-8a85-4458-a7d2-0ad0a4fea02a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_458f0e10-8664-42f8-8b27-e60241dbb2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_354af83e-a441-44ac-9686-8e1e435ae7bb" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_458f0e10-8664-42f8-8b27-e60241dbb2a2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1c5281bf-cb2a-41b4-a872-2dd6c3e7c4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1c5281bf-cb2a-41b4-a872-2dd6c3e7c4d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_78d968f8-2e12-432a-bf53-9e6d7366e556" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_78d968f8-2e12-432a-bf53-9e6d7366e556" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4e06dbc3-18b0-4452-a593-a5067d4217d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4e06dbc3-18b0-4452-a593-a5067d4217d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d7658460-998d-4d3a-9fc2-3cc1f1f960b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d7658460-998d-4d3a-9fc2-3cc1f1f960b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_a0205b6b-46c3-47dd-9c25-235afd2cfe77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_a0205b6b-46c3-47dd-9c25-235afd2cfe77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ConversionOfStockToCommonStockConversionRatio_d16bb2cf-312c-497a-a73a-dfd393ff9967" xlink:href="wald-20221231.xsd#wald_ConversionOfStockToCommonStockConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ConversionOfStockToCommonStockConversionRatio_d16bb2cf-312c-497a-a73a-dfd393ff9967" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage_0c2e412f-9a76-4711-839d-9a1aee8f9f67" xlink:href="wald-20221231.xsd#wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage_0c2e412f-9a76-4711-839d-9a1aee8f9f67" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ForwardPurchaseAgreementHurdleRate_ee8773ef-d198-4411-b8d0-9c4f3f128b6d" xlink:href="wald-20221231.xsd#wald_ForwardPurchaseAgreementHurdleRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ForwardPurchaseAgreementHurdleRate_ee8773ef-d198-4411-b8d0-9c4f3f128b6d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod_00f6246d-13ec-4a03-98b2-c5eb0a88c2f3" xlink:href="wald-20221231.xsd#wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod_00f6246d-13ec-4a03-98b2-c5eb0a88c2f3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d5c0a68f-f092-4171-bb76-c3d670d8ac09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d5c0a68f-f092-4171-bb76-c3d670d8ac09" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination_20da3878-fd14-4beb-a113-571fa1b56ac9" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination_20da3878-fd14-4beb-a113-571fa1b56ac9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3276ef2f-ccae-49e1-b8ff-f5ccbe847b14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3276ef2f-ccae-49e1-b8ff-f5ccbe847b14" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6e29b0f1-f43c-4598-9856-7f0c4a26593d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6e29b0f1-f43c-4598-9856-7f0c4a26593d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_3b944226-5950-4c49-885c-53542ae20fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_ShortTermBorrowings_3b944226-5950-4c49-885c-53542ae20fe1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7816f7fe-918d-49a6-b034-fff1bc744575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7816f7fe-918d-49a6-b034-fff1bc744575" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_bdf347f2-5f4a-4ba0-ba19-ee69df00f184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_LongTermDebt_bdf347f2-5f4a-4ba0-ba19-ee69df00f184" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6a98b52d-2e8f-4dbf-95cb-2b0ff4db50e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6a98b52d-2e8f-4dbf-95cb-2b0ff4db50e8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdministrativeFeesExpense_35bff9ff-0cc4-4466-b21e-3544ba8d692f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdministrativeFeesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_AdministrativeFeesExpense_35bff9ff-0cc4-4466-b21e-3544ba8d692f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5a7ba784-8511-442a-9250-01d09713dc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_AccountsPayableCurrent_5a7ba784-8511-442a-9250-01d09713dc3b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod_76ead271-aa20-4791-8406-9f61dadae0e6" xlink:href="wald-20221231.xsd#wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod_76ead271-aa20-4791-8406-9f61dadae0e6" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger_a84c996f-bd77-48b1-9804-6a53fa50c7eb" xlink:href="wald-20221231.xsd#wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger_a84c996f-bd77-48b1-9804-6a53fa50c7eb" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays_678b97ca-83b1-43cb-a975-ba78055e6d5c" xlink:href="wald-20221231.xsd#wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays_678b97ca-83b1-43cb-a975-ba78055e6d5c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays_1cc671b2-8d75-4867-9c13-9a81bea59c03" xlink:href="wald-20221231.xsd#wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays_1cc671b2-8d75-4867-9c13-9a81bea59c03" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays_c331ee4a-be25-4e39-a9d4-3f61cf0a5413" xlink:href="wald-20221231.xsd#wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays_c331ee4a-be25-4e39-a9d4-3f61cf0a5413" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_IndemnificationAgreementAdvanceExpensePeriod_f6cd682e-3fbc-4437-9bee-71dcb1aa54c6" xlink:href="wald-20221231.xsd#wald_IndemnificationAgreementAdvanceExpensePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_IndemnificationAgreementAdvanceExpensePeriod_f6cd682e-3fbc-4437-9bee-71dcb1aa54c6" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_49d81760-bb27-417c-9e25-8a476e178693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_49d81760-bb27-417c-9e25-8a476e178693" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_RoyaltyPercentageOfGrossSales_0f28f3b3-9b33-467f-81ff-49a0f4464747" xlink:href="wald-20221231.xsd#wald_RoyaltyPercentageOfGrossSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_RoyaltyPercentageOfGrossSales_0f28f3b3-9b33-467f-81ff-49a0f4464747" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7881f13e-5d94-4466-9140-ba083a31f71a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7881f13e-5d94-4466-9140-ba083a31f71a" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3a5bcebb-9d68-4d1e-af53-d7ee4abc83d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3a5bcebb-9d68-4d1e-af53-d7ee4abc83d7" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_56d1dbb9-d9bc-4889-a8ff-14e4e68262d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_56d1dbb9-d9bc-4889-a8ff-14e4e68262d8" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_TransitionServicesAgreementPeriod_689aee1e-1955-4d57-97e1-d3e626969379" xlink:href="wald-20221231.xsd#wald_TransitionServicesAgreementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_TransitionServicesAgreementPeriod_689aee1e-1955-4d57-97e1-d3e626969379" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_TransitionServicesAgreementExtensionPeriod_858f9d4d-37fc-4ac8-8c11-3274bf705536" xlink:href="wald-20221231.xsd#wald_TransitionServicesAgreementExtensionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_TransitionServicesAgreementExtensionPeriod_858f9d4d-37fc-4ac8-8c11-3274bf705536" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ServicesAgreementRenewalTerm_e1d31be7-58a7-400b-b2d9-55e9d6cd1260" xlink:href="wald-20221231.xsd#wald_ServicesAgreementRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ServicesAgreementRenewalTerm_e1d31be7-58a7-400b-b2d9-55e9d6cd1260" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ServicesAgreementFeePercentageOfIncurredCosts_8c90efb5-8f89-474f-936e-efad440830df" xlink:href="wald-20221231.xsd#wald_ServicesAgreementFeePercentageOfIncurredCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ServicesAgreementFeePercentageOfIncurredCosts_8c90efb5-8f89-474f-936e-efad440830df" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PaymentsForServicesAgreementFees_6aae8833-abaa-49df-be2a-84939c6ef672" xlink:href="wald-20221231.xsd#wald_PaymentsForServicesAgreementFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_PaymentsForServicesAgreementFees_6aae8833-abaa-49df-be2a-84939c6ef672" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_90a8eeb8-1858-44b3-bd5e-3168df8d2d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_PaymentsForFees_90a8eeb8-1858-44b3-bd5e-3168df8d2d85" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7f910a11-18f0-49f0-b65f-aa2a81ec4d75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_srt_CounterpartyNameAxis_7f910a11-18f0-49f0-b65f-aa2a81ec4d75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7f910a11-18f0-49f0-b65f-aa2a81ec4d75_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7f910a11-18f0-49f0-b65f-aa2a81ec4d75" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7f910a11-18f0-49f0-b65f-aa2a81ec4d75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7f910a11-18f0-49f0-b65f-aa2a81ec4d75" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SponsorMember_724d2b25-de2b-4fd4-bfa0-36b50846811e" xlink:href="wald-20221231.xsd#wald_SponsorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_SponsorMember_724d2b25-de2b-4fd4-bfa0-36b50846811e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_InvestorDirectorsMember_f11bb593-eae9-47d2-889c-3b4bdf18ab1e" xlink:href="wald-20221231.xsd#wald_InvestorDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_InvestorDirectorsMember_f11bb593-eae9-47d2-889c-3b4bdf18ab1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SponsorAndInvestorDirectorsMember_e20ba65d-02f9-49d6-8f3e-ff5778465f64" xlink:href="wald-20221231.xsd#wald_SponsorAndInvestorDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_SponsorAndInvestorDirectorsMember_e20ba65d-02f9-49d6-8f3e-ff5778465f64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember_242bf527-04f7-4c17-9012-b0495d60904e" xlink:href="wald-20221231.xsd#wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember_242bf527-04f7-4c17-9012-b0495d60904e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BeautyVenturesLLCMember_9d9896b2-2b56-44be-9fb4-9d0d6dcf004b" xlink:href="wald-20221231.xsd#wald_BeautyVenturesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_BeautyVenturesLLCMember_9d9896b2-2b56-44be-9fb4-9d0d6dcf004b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AaronChatterleyMember_8ea2bb78-46ef-4788-b118-021757eecc9f" xlink:href="wald-20221231.xsd#wald_AaronChatterleyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_AaronChatterleyMember_8ea2bb78-46ef-4788-b118-021757eecc9f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CedarwalkMember_75f56a6d-37d3-414c-b0e5-d9b80bbdde67" xlink:href="wald-20221231.xsd#wald_CedarwalkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_CedarwalkMember_75f56a6d-37d3-414c-b0e5-d9b80bbdde67" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiChinaBusinessMember_911ba3c4-5c6f-4246-b004-af9e288b1cd3" xlink:href="wald-20221231.xsd#wald_ObagiChinaBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_ObagiChinaBusinessMember_911ba3c4-5c6f-4246-b004-af9e288b1cd3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiCosmeceuticalsLLCMember_83701f4a-70e5-4997-ae52-71abcb42e6f4" xlink:href="wald-20221231.xsd#wald_ObagiCosmeceuticalsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_ObagiCosmeceuticalsLLCMember_83701f4a-70e5-4997-ae52-71abcb42e6f4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiShanghaiMember_560dc0e6-4465-4b40-9b2c-0779136749a4" xlink:href="wald-20221231.xsd#wald_ObagiShanghaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_ObagiShanghaiMember_560dc0e6-4465-4b40-9b2c-0779136749a4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_711e1253-1e2c-4fa0-b6fb-ae641202a289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_711e1253-1e2c-4fa0-b6fb-ae641202a289" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_711e1253-1e2c-4fa0-b6fb-ae641202a289_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_711e1253-1e2c-4fa0-b6fb-ae641202a289" xlink:to="loc_us-gaap_RelatedPartyDomain_711e1253-1e2c-4fa0-b6fb-ae641202a289_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_66849acf-a6cc-42d1-82e4-aae2f7867487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_711e1253-1e2c-4fa0-b6fb-ae641202a289" xlink:to="loc_us-gaap_RelatedPartyDomain_66849acf-a6cc-42d1-82e4-aae2f7867487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_b07f4052-c884-4d94-83fc-ab403334d8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_66849acf-a6cc-42d1-82e4-aae2f7867487" xlink:to="loc_us-gaap_RelatedPartyMember_b07f4052-c884-4d94-83fc-ab403334d8c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e85913f3-c036-4ba9-88de-a37ac6b3d3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e85913f3-c036-4ba9-88de-a37ac6b3d3b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e85913f3-c036-4ba9-88de-a37ac6b3d3b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e85913f3-c036-4ba9-88de-a37ac6b3d3b0" xlink:to="loc_us-gaap_ClassOfStockDomain_e85913f3-c036-4ba9-88de-a37ac6b3d3b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a1d497a2-fdff-461d-b5df-e5cf7541cc51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e85913f3-c036-4ba9-88de-a37ac6b3d3b0" xlink:to="loc_us-gaap_ClassOfStockDomain_a1d497a2-fdff-461d-b5df-e5cf7541cc51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_eda328cb-f83e-4a7f-b8ca-47b2fdb0dec9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a1d497a2-fdff-461d-b5df-e5cf7541cc51" xlink:to="loc_us-gaap_CommonClassBMember_eda328cb-f83e-4a7f-b8ca-47b2fdb0dec9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_e3e6fe26-79cc-4113-b9ec-f78abb6f23ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a1d497a2-fdff-461d-b5df-e5cf7541cc51" xlink:to="loc_us-gaap_CommonClassAMember_e3e6fe26-79cc-4113-b9ec-f78abb6f23ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bc6c3e00-77b3-4e1f-bb41-4ee417955175" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a1d497a2-fdff-461d-b5df-e5cf7541cc51" xlink:to="loc_us-gaap_CommonStockMember_bc6c3e00-77b3-4e1f-bb41-4ee417955175" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f88aa414-e56e-4edb-9f73-2ef730744542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f88aa414-e56e-4edb-9f73-2ef730744542" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f88aa414-e56e-4edb-9f73-2ef730744542_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f88aa414-e56e-4edb-9f73-2ef730744542" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f88aa414-e56e-4edb-9f73-2ef730744542_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_61128086-c29b-440e-bc96-8dba2ccfe2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f88aa414-e56e-4edb-9f73-2ef730744542" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_61128086-c29b-440e-bc96-8dba2ccfe2e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SponsorWarrantsMember_a49af21a-8332-498f-a8ef-9b95dd3f0fd1" xlink:href="wald-20221231.xsd#wald_SponsorWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_61128086-c29b-440e-bc96-8dba2ccfe2e5" xlink:to="loc_wald_SponsorWarrantsMember_a49af21a-8332-498f-a8ef-9b95dd3f0fd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PrivatePlacementWarrantsMember_3a1b4d4a-56bb-4864-a9a5-33ce3047f1a2" xlink:href="wald-20221231.xsd#wald_PrivatePlacementWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_61128086-c29b-440e-bc96-8dba2ccfe2e5" xlink:to="loc_wald_PrivatePlacementWarrantsMember_3a1b4d4a-56bb-4864-a9a5-33ce3047f1a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9aa209db-acc7-4277-a416-0db4fc0282de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9aa209db-acc7-4277-a416-0db4fc0282de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9aa209db-acc7-4277-a416-0db4fc0282de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9aa209db-acc7-4277-a416-0db4fc0282de" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9aa209db-acc7-4277-a416-0db4fc0282de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6bdc95d-e4a5-4cac-8e09-5aab84245ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9aa209db-acc7-4277-a416-0db4fc0282de" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6bdc95d-e4a5-4cac-8e09-5aab84245ab0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiMergerMember_d72b0772-f599-4be3-83c7-aafdf0b63053" xlink:href="wald-20221231.xsd#wald_ObagiMergerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6bdc95d-e4a5-4cac-8e09-5aab84245ab0" xlink:to="loc_wald_ObagiMergerMember_d72b0772-f599-4be3-83c7-aafdf0b63053" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkTransactionMember_36b8a3a7-030d-40ca-9c95-0d0ea548fc47" xlink:href="wald-20221231.xsd#wald_MilkTransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6bdc95d-e4a5-4cac-8e09-5aab84245ab0" xlink:to="loc_wald_MilkTransactionMember_36b8a3a7-030d-40ca-9c95-0d0ea548fc47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_17516ffe-61a2-4939-87dc-ebf8c1489691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_17516ffe-61a2-4939-87dc-ebf8c1489691" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17516ffe-61a2-4939-87dc-ebf8c1489691_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_17516ffe-61a2-4939-87dc-ebf8c1489691" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_17516ffe-61a2-4939-87dc-ebf8c1489691_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbdf3679-7775-4b87-bcae-7b70c1eadf7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_17516ffe-61a2-4939-87dc-ebf8c1489691" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbdf3679-7775-4b87-bcae-7b70c1eadf7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_bb2b6d93-31e0-4cc5-914a-53505481308f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbdf3679-7775-4b87-bcae-7b70c1eadf7d" xlink:to="loc_us-gaap_PrivatePlacementMember_bb2b6d93-31e0-4cc5-914a-53505481308f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_99f753fb-d25a-4f57-9018-c491e7533fab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_99f753fb-d25a-4f57-9018-c491e7533fab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_99f753fb-d25a-4f57-9018-c491e7533fab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_99f753fb-d25a-4f57-9018-c491e7533fab" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_99f753fb-d25a-4f57-9018-c491e7533fab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ccc9b68d-37ff-4659-9635-1525164599c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_99f753fb-d25a-4f57-9018-c491e7533fab" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ccc9b68d-37ff-4659-9635-1525164599c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ForwardPurchaseAgreementMember_9fa31d7c-4ae1-4ff8-b111-96c9eaf43178" xlink:href="wald-20221231.xsd#wald_ForwardPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ccc9b68d-37ff-4659-9635-1525164599c0" xlink:to="loc_wald_ForwardPurchaseAgreementMember_9fa31d7c-4ae1-4ff8-b111-96c9eaf43178" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6a7bf695-9d83-483f-b9f5-3e2da80ddd63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_DebtInstrumentAxis_6a7bf695-9d83-483f-b9f5-3e2da80ddd63" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6a7bf695-9d83-483f-b9f5-3e2da80ddd63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6a7bf695-9d83-483f-b9f5-3e2da80ddd63" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6a7bf695-9d83-483f-b9f5-3e2da80ddd63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_df6613e9-271d-4402-b1cb-cc0500cdf2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6a7bf695-9d83-483f-b9f5-3e2da80ddd63" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_df6613e9-271d-4402-b1cb-cc0500cdf2aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_JanuaryNoteMember_dd5835a1-d183-402f-a931-a7394c3b745e" xlink:href="wald-20221231.xsd#wald_JanuaryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_df6613e9-271d-4402-b1cb-cc0500cdf2aa" xlink:to="loc_wald_JanuaryNoteMember_dd5835a1-d183-402f-a931-a7394c3b745e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ConvertibleWorkingCapitalNoteMember_cd77d1cf-402a-4922-b5eb-69cc768063d4" xlink:href="wald-20221231.xsd#wald_ConvertibleWorkingCapitalNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_df6613e9-271d-4402-b1cb-cc0500cdf2aa" xlink:to="loc_wald_ConvertibleWorkingCapitalNoteMember_cd77d1cf-402a-4922-b5eb-69cc768063d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_NonConvertibleWorkingCapitalNotesMember_c66cd392-f617-4137-86e0-60e9250cc084" xlink:href="wald-20221231.xsd#wald_NonConvertibleWorkingCapitalNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_df6613e9-271d-4402-b1cb-cc0500cdf2aa" xlink:to="loc_wald_NonConvertibleWorkingCapitalNotesMember_c66cd392-f617-4137-86e0-60e9250cc084" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_3bfedfae-e92f-4583-9619-d5f2842dd1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_3bfedfae-e92f-4583-9619-d5f2842dd1c3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_3bfedfae-e92f-4583-9619-d5f2842dd1c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_3bfedfae-e92f-4583-9619-d5f2842dd1c3" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_3bfedfae-e92f-4583-9619-d5f2842dd1c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_4ebe502c-5ac0-4bb7-b988-7c43dfc86dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_3bfedfae-e92f-4583-9619-d5f2842dd1c3" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_4ebe502c-5ac0-4bb7-b988-7c43dfc86dbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_9b0136aa-0251-4b12-b6e5-fad7705323f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_4ebe502c-5ac0-4bb7-b988-7c43dfc86dbe" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_9b0136aa-0251-4b12-b6e5-fad7705323f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f22f7a5b-f6a4-4232-84bc-62878f3dd5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f22f7a5b-f6a4-4232-84bc-62878f3dd5ce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f22f7a5b-f6a4-4232-84bc-62878f3dd5ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f22f7a5b-f6a4-4232-84bc-62878f3dd5ce" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f22f7a5b-f6a4-4232-84bc-62878f3dd5ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_42c85618-49dc-474e-8f51-c2eb0bbedbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f22f7a5b-f6a4-4232-84bc-62878f3dd5ce" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_42c85618-49dc-474e-8f51-c2eb0bbedbe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_1f104deb-70a0-4901-ba32-fb1a0db8ca83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_42c85618-49dc-474e-8f51-c2eb0bbedbe6" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_1f104deb-70a0-4901-ba32-fb1a0db8ca83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_cea27d56-7690-47fa-95de-51e1b832c323" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_srt_OwnershipAxis_cea27d56-7690-47fa-95de-51e1b832c323" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_cea27d56-7690-47fa-95de-51e1b832c323_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_cea27d56-7690-47fa-95de-51e1b832c323" xlink:to="loc_srt_OwnershipDomain_cea27d56-7690-47fa-95de-51e1b832c323_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_cb0e09ec-bc77-44c9-9d39-751ff57ff224" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_cea27d56-7690-47fa-95de-51e1b832c323" xlink:to="loc_srt_OwnershipDomain_cb0e09ec-bc77-44c9-9d39-751ff57ff224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_WaldencastPlcMember_476917cb-e370-4413-a33c-b19d1256e2e3" xlink:href="wald-20221231.xsd#wald_WaldencastPlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_cb0e09ec-bc77-44c9-9d39-751ff57ff224" xlink:to="loc_wald_WaldencastPlcMember_476917cb-e370-4413-a33c-b19d1256e2e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_16f0ea15-6b12-434e-a839-cf09dfab5bb0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_dei_LegalEntityAxis_16f0ea15-6b12-434e-a839-cf09dfab5bb0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_16f0ea15-6b12-434e-a839-cf09dfab5bb0_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_16f0ea15-6b12-434e-a839-cf09dfab5bb0" xlink:to="loc_dei_EntityDomain_16f0ea15-6b12-434e-a839-cf09dfab5bb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a77272a9-4edb-41eb-a761-190c4e3aa1f7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_16f0ea15-6b12-434e-a839-cf09dfab5bb0" xlink:to="loc_dei_EntityDomain_a77272a9-4edb-41eb-a761-190c4e3aa1f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiChinaBusinessMember_850abee3-d14d-4927-ae11-d58229b2c7a0" xlink:href="wald-20221231.xsd#wald_ObagiChinaBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a77272a9-4edb-41eb-a761-190c4e3aa1f7" xlink:to="loc_wald_ObagiChinaBusinessMember_850abee3-d14d-4927-ae11-d58229b2c7a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CedarwalkMember_f317005e-6972-4295-8335-2a508962c038" xlink:href="wald-20221231.xsd#wald_CedarwalkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a77272a9-4edb-41eb-a761-190c4e3aa1f7" xlink:to="loc_wald_CedarwalkMember_f317005e-6972-4295-8335-2a508962c038" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9985637f-030e-4bba-a5fe-6c128673ee48" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_srt_ProductOrServiceAxis_9985637f-030e-4bba-a5fe-6c128673ee48" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9985637f-030e-4bba-a5fe-6c128673ee48_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9985637f-030e-4bba-a5fe-6c128673ee48" xlink:to="loc_srt_ProductsAndServicesDomain_9985637f-030e-4bba-a5fe-6c128673ee48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f03abf69-2691-49cb-973e-02628476ccce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9985637f-030e-4bba-a5fe-6c128673ee48" xlink:to="loc_srt_ProductsAndServicesDomain_f03abf69-2691-49cb-973e-02628476ccce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c1c74cde-f60f-430d-902e-dc0446e4dd30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f03abf69-2691-49cb-973e-02628476ccce" xlink:to="loc_us-gaap_ProductMember_c1c74cde-f60f-430d-902e-dc0446e4dd30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_908f3306-ec7a-494d-af7c-95b7298c7736" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_SupplyCommitmentAxis_908f3306-ec7a-494d-af7c-95b7298c7736" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_908f3306-ec7a-494d-af7c-95b7298c7736_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SupplyCommitmentAxis_908f3306-ec7a-494d-af7c-95b7298c7736" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_908f3306-ec7a-494d-af7c-95b7298c7736_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_e0800229-ee9a-4703-a2e6-fa5e3b52021a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SupplyCommitmentAxis_908f3306-ec7a-494d-af7c-95b7298c7736" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_e0800229-ee9a-4703-a2e6-fa5e3b52021a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentMember_03dd0b5a-1ea2-4c1d-b66f-e7ae3de799e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_e0800229-ee9a-4703-a2e6-fa5e3b52021a" xlink:to="loc_us-gaap_SupplyCommitmentMember_03dd0b5a-1ea2-4c1d-b66f-e7ae3de799e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7d513702-984b-4e7c-be3a-3203668c0cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7d513702-984b-4e7c-be3a-3203668c0cd2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7d513702-984b-4e7c-be3a-3203668c0cd2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7d513702-984b-4e7c-be3a-3203668c0cd2" xlink:to="loc_us-gaap_SegmentDomain_7d513702-984b-4e7c-be3a-3203668c0cd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b44c974a-78b7-4049-9b80-0222b2ec53f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7d513702-984b-4e7c-be3a-3203668c0cd2" xlink:to="loc_us-gaap_SegmentDomain_b44c974a-78b7-4049-9b80-0222b2ec53f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkMakeupMember_439e335f-94a7-405a-bc4a-bb4964496190" xlink:href="wald-20221231.xsd#wald_MilkMakeupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b44c974a-78b7-4049-9b80-0222b2ec53f8" xlink:to="loc_wald_MilkMakeupMember_439e335f-94a7-405a-bc4a-bb4964496190" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_b2972272-cfdb-4baf-954a-764e33d18009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_f5ad0646-1350-4efe-93fe-01491cdfd3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_b2972272-cfdb-4baf-954a-764e33d18009" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_f5ad0646-1350-4efe-93fe-01491cdfd3c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_f85a25d4-43e4-4e2e-84f2-3ebb0baa3e76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_b2972272-cfdb-4baf-954a-764e33d18009" xlink:to="loc_us-gaap_PurchaseObligation_f85a25d4-43e4-4e2e-84f2-3ebb0baa3e76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_1ddd051b-48e1-4080-8564-0359de799809" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_b2972272-cfdb-4baf-954a-764e33d18009" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_1ddd051b-48e1-4080-8564-0359de799809" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_a3ae4352-7925-4bf4-ab01-2a1eb6189d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_b2972272-cfdb-4baf-954a-764e33d18009" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_a3ae4352-7925-4bf4-ab01-2a1eb6189d7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c64f13d1-9860-4707-9d0d-9bd96834a42b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_a3ae4352-7925-4bf4-ab01-2a1eb6189d7f" xlink:to="loc_srt_RangeAxis_c64f13d1-9860-4707-9d0d-9bd96834a42b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c64f13d1-9860-4707-9d0d-9bd96834a42b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c64f13d1-9860-4707-9d0d-9bd96834a42b" xlink:to="loc_srt_RangeMember_c64f13d1-9860-4707-9d0d-9bd96834a42b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_71fb95c0-406b-4be7-a3f1-dcff9ab35dc2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c64f13d1-9860-4707-9d0d-9bd96834a42b" xlink:to="loc_srt_RangeMember_71fb95c0-406b-4be7-a3f1-dcff9ab35dc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_434fb6ec-483b-4441-b073-cd56f2720b55" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_71fb95c0-406b-4be7-a3f1-dcff9ab35dc2" xlink:to="loc_srt_MinimumMember_434fb6ec-483b-4441-b073-cd56f2720b55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_97c8a949-c63f-4793-a2cd-8852409f0313" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_71fb95c0-406b-4be7-a3f1-dcff9ab35dc2" xlink:to="loc_srt_MaximumMember_97c8a949-c63f-4793-a2cd-8852409f0313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_f104c372-f891-43aa-9722-2df5e9804f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_a3ae4352-7925-4bf4-ab01-2a1eb6189d7f" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_f104c372-f891-43aa-9722-2df5e9804f3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_f104c372-f891-43aa-9722-2df5e9804f3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_f104c372-f891-43aa-9722-2df5e9804f3a" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_f104c372-f891-43aa-9722-2df5e9804f3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_00c08310-f32e-49da-9ed2-a00dc19b8c84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_f104c372-f891-43aa-9722-2df5e9804f3a" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_00c08310-f32e-49da-9ed2-a00dc19b8c84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SkintrinsiqDevicesMember_eef86319-494f-484c-8b8a-ffb35dca1068" xlink:href="wald-20221231.xsd#wald_SkintrinsiqDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_00c08310-f32e-49da-9ed2-a00dc19b8c84" xlink:to="loc_wald_SkintrinsiqDevicesMember_eef86319-494f-484c-8b8a-ffb35dca1068" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_ccc093aa-62d7-4443-881c-bbd85d2cb3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_00c08310-f32e-49da-9ed2-a00dc19b8c84" xlink:to="loc_us-gaap_InventoriesMember_ccc093aa-62d7-4443-881c-bbd85d2cb3b4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_51bb09e3-d2b0-4837-8e6e-6a74c06ac85a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c482e811-5ca6-449e-bd89-8d81ecf5fb83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_51bb09e3-d2b0-4837-8e6e-6a74c06ac85a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c482e811-5ca6-449e-bd89-8d81ecf5fb83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_602b8592-4fc2-4d1d-b1cf-ba24a5e74508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_51bb09e3-d2b0-4837-8e6e-6a74c06ac85a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_602b8592-4fc2-4d1d-b1cf-ba24a5e74508" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_f07c6a9a-2742-4e22-8a6b-28ded64190a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_51bb09e3-d2b0-4837-8e6e-6a74c06ac85a" xlink:to="loc_us-gaap_GrossProfit_f07c6a9a-2742-4e22-8a6b-28ded64190a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_003dc6c2-b517-47aa-8dac-e00a82b333cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_51bb09e3-d2b0-4837-8e6e-6a74c06ac85a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_003dc6c2-b517-47aa-8dac-e00a82b333cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_07998a70-4dec-48f8-bf72-7b5cee50cf55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_003dc6c2-b517-47aa-8dac-e00a82b333cc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_07998a70-4dec-48f8-bf72-7b5cee50cf55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_07998a70-4dec-48f8-bf72-7b5cee50cf55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_07998a70-4dec-48f8-bf72-7b5cee50cf55" xlink:to="loc_us-gaap_SegmentDomain_07998a70-4dec-48f8-bf72-7b5cee50cf55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_51610ccd-86dd-4239-9813-e4df10c87bce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_07998a70-4dec-48f8-bf72-7b5cee50cf55" xlink:to="loc_us-gaap_SegmentDomain_51610ccd-86dd-4239-9813-e4df10c87bce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiSkincareMember_31b9301c-6fff-4edb-8e96-c4451a5d3ee8" xlink:href="wald-20221231.xsd#wald_ObagiSkincareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_51610ccd-86dd-4239-9813-e4df10c87bce" xlink:to="loc_wald_ObagiSkincareMember_31b9301c-6fff-4edb-8e96-c4451a5d3ee8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkMakeupMember_56d2998a-b02f-409c-9673-70285998aeef" xlink:href="wald-20221231.xsd#wald_MilkMakeupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_51610ccd-86dd-4239-9813-e4df10c87bce" xlink:to="loc_wald_MilkMakeupMember_56d2998a-b02f-409c-9673-70285998aeef" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f720ce8b-1e25-4047-880c-c18d163ce938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f720ce8b-1e25-4047-880c-c18d163ce938" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent_2187732f-08f5-41ac-a5ff-63ccf027e6cf" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent_2187732f-08f5-41ac-a5ff-63ccf027e6cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_61c05417-a47b-4762-9b1d-d5c350e4a8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_61c05417-a47b-4762-9b1d-d5c350e4a8ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d4b0f45c-6459-48bf-a85d-70e06e8af2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d4b0f45c-6459-48bf-a85d-70e06e8af2ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_NumberOfLeaseAgreements_e868eeb2-6ada-4b0f-8821-75e27304010b" xlink:href="wald-20221231.xsd#wald_NumberOfLeaseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_wald_NumberOfLeaseAgreements_e868eeb2-6ada-4b0f-8821-75e27304010b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_ecd452f7-5ebd-4781-a6b7-8ef2063172d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_NetRentableArea_ecd452f7-5ebd-4781-a6b7-8ef2063172d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_357c9bee-fead-4489-89fe-0f4c00986ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_357c9bee-fead-4489-89fe-0f4c00986ee6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9572abe9-902b-4f39-aef6-44c44cfa78fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9572abe9-902b-4f39-aef6-44c44cfa78fa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessAcquisitionEarnoutPeriod_8c3b7472-9c6e-4926-8d0b-b2476f8bcae2" xlink:href="wald-20221231.xsd#wald_BusinessAcquisitionEarnoutPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_wald_BusinessAcquisitionEarnoutPeriod_8c3b7472-9c6e-4926-8d0b-b2476f8bcae2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7652fbed-d282-4b41-bb41-3580d5d4cc39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7652fbed-d282-4b41-bb41-3580d5d4cc39" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_5ac0c1fb-cfea-47f2-94ac-d6b2fc771fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_5ac0c1fb-cfea-47f2-94ac-d6b2fc771fe4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7bf0720e-bf23-4da9-823c-6e1da18fb3db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7bf0720e-bf23-4da9-823c-6e1da18fb3db" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_92a2de3a-0369-4892-a939-fd4cdecad1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_CommonStockSharesIssued_92a2de3a-0369-4892-a939-fd4cdecad1b1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2f0c758e-8a02-445f-98f8-fc5f9a2cdbff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2f0c758e-8a02-445f-98f8-fc5f9a2cdbff" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_63e4d7ef-17c0-46d5-98bc-75549d4c6b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_63e4d7ef-17c0-46d5-98bc-75549d4c6b2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_63e4d7ef-17c0-46d5-98bc-75549d4c6b2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_63e4d7ef-17c0-46d5-98bc-75549d4c6b2e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_63e4d7ef-17c0-46d5-98bc-75549d4c6b2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_49abcbf1-f388-484f-9c95-9d86235c3b11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_63e4d7ef-17c0-46d5-98bc-75549d4c6b2e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_49abcbf1-f388-484f-9c95-9d86235c3b11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_70e12530-a12e-4451-a47b-ce46fc2db3af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_49abcbf1-f388-484f-9c95-9d86235c3b11" xlink:to="loc_us-gaap_SubsequentEventMember_70e12530-a12e-4451-a47b-ce46fc2db3af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_73fa550c-2425-43fe-baef-c165e23d90b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_us-gaap_AwardTypeAxis_73fa550c-2425-43fe-baef-c165e23d90b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73fa550c-2425-43fe-baef-c165e23d90b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_73fa550c-2425-43fe-baef-c165e23d90b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73fa550c-2425-43fe-baef-c165e23d90b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_481391de-dc5e-4f56-89f6-7821c78a0325" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_73fa550c-2425-43fe-baef-c165e23d90b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_481391de-dc5e-4f56-89f6-7821c78a0325" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockGrowthIncentiveAwardsSGIAwardsMember_3389bdfe-b054-4208-896d-1132705bb75c" xlink:href="wald-20221231.xsd#wald_StockGrowthIncentiveAwardsSGIAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_481391de-dc5e-4f56-89f6-7821c78a0325" xlink:to="loc_wald_StockGrowthIncentiveAwardsSGIAwardsMember_3389bdfe-b054-4208-896d-1132705bb75c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2ce8ade5-bc65-4145-b531-6012ab5d2808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2ce8ade5-bc65-4145-b531-6012ab5d2808" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2ce8ade5-bc65-4145-b531-6012ab5d2808_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2ce8ade5-bc65-4145-b531-6012ab5d2808" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2ce8ade5-bc65-4145-b531-6012ab5d2808_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66c4b0fc-ef07-4da3-807a-6bd0141586b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2ce8ade5-bc65-4145-b531-6012ab5d2808" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66c4b0fc-ef07-4da3-807a-6bd0141586b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VietnamPurchaseAgreementMember_ba42b998-1a63-4ab8-a2c5-6d04a1cfe3b6" xlink:href="wald-20221231.xsd#wald_VietnamPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66c4b0fc-ef07-4da3-807a-6bd0141586b6" xlink:to="loc_wald_VietnamPurchaseAgreementMember_ba42b998-1a63-4ab8-a2c5-6d04a1cfe3b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_488fce32-5564-4121-9308-21d0da457964" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_srt_OwnershipAxis_488fce32-5564-4121-9308-21d0da457964" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_488fce32-5564-4121-9308-21d0da457964_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_488fce32-5564-4121-9308-21d0da457964" xlink:to="loc_srt_OwnershipDomain_488fce32-5564-4121-9308-21d0da457964_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_0a2b76b6-4752-460f-974c-511af2dbc7c5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_488fce32-5564-4121-9308-21d0da457964" xlink:to="loc_srt_OwnershipDomain_0a2b76b6-4752-460f-974c-511af2dbc7c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiBlueSeaHoldingLLCMember_48a2db78-28c4-42cf-8651-c81b1dd500df" xlink:href="wald-20221231.xsd#wald_ObagiBlueSeaHoldingLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_0a2b76b6-4752-460f-974c-511af2dbc7c5" xlink:to="loc_wald_ObagiBlueSeaHoldingLLCMember_48a2db78-28c4-42cf-8651-c81b1dd500df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_60826397-aea9-4f76-aa8a-064e59ba991e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_dei_LegalEntityAxis_60826397-aea9-4f76-aa8a-064e59ba991e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_60826397-aea9-4f76-aa8a-064e59ba991e_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_60826397-aea9-4f76-aa8a-064e59ba991e" xlink:to="loc_dei_EntityDomain_60826397-aea9-4f76-aa8a-064e59ba991e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9cfbe12d-782f-4f1c-aec7-08a51373c107" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_60826397-aea9-4f76-aa8a-064e59ba991e" xlink:to="loc_dei_EntityDomain_9cfbe12d-782f-4f1c-aec7-08a51373c107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SADistributorMember_f58a7f51-fb54-4bfe-8b93-f1764c081c9d" xlink:href="wald-20221231.xsd#wald_SADistributorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9cfbe12d-782f-4f1c-aec7-08a51373c107" xlink:to="loc_wald_SADistributorMember_f58a7f51-fb54-4bfe-8b93-f1764c081c9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a9a839ca-1edb-4e93-bed8-62871e8e587e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_srt_StatementGeographicalAxis_a9a839ca-1edb-4e93-bed8-62871e8e587e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a9a839ca-1edb-4e93-bed8-62871e8e587e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a9a839ca-1edb-4e93-bed8-62871e8e587e" xlink:to="loc_srt_SegmentGeographicalDomain_a9a839ca-1edb-4e93-bed8-62871e8e587e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4fc3f154-72a6-4cd4-a678-708d4120378d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a9a839ca-1edb-4e93-bed8-62871e8e587e" xlink:to="loc_srt_SegmentGeographicalDomain_4fc3f154-72a6-4cd4-a678-708d4120378d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX_5df5566b-a46b-432e-90c0-2ffe31660ade" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_TX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4fc3f154-72a6-4cd4-a678-708d4120378d" xlink:to="loc_stpr_TX_5df5566b-a46b-432e-90c0-2ffe31660ade" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_1f5fc1fe-6b41-4e71-91c3-bc39cfc11014" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4fc3f154-72a6-4cd4-a678-708d4120378d" xlink:to="loc_stpr_CA_1f5fc1fe-6b41-4e71-91c3-bc39cfc11014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_4f16192d-ee32-48c8-9356-f411f3d34bb3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_4f16192d-ee32-48c8-9356-f411f3d34bb3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_4f16192d-ee32-48c8-9356-f411f3d34bb3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_4f16192d-ee32-48c8-9356-f411f3d34bb3" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_4f16192d-ee32-48c8-9356-f411f3d34bb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_8d6752f1-17a9-4489-b6ce-535cd06697f4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_4f16192d-ee32-48c8-9356-f411f3d34bb3" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_8d6752f1-17a9-4489-b6ce-535cd06697f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_c1789e85-073d-4427-89f6-b1083610d7ee" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_8d6752f1-17a9-4489-b6ce-535cd06697f4" xlink:to="loc_srt_OfficeBuildingMember_c1789e85-073d-4427-89f6-b1083610d7ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WarehouseMember_9225fd1f-5c17-4e3b-802b-86726df74525" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WarehouseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_8d6752f1-17a9-4489-b6ce-535cd06697f4" xlink:to="loc_srt_WarehouseMember_9225fd1f-5c17-4e3b-802b-86726df74525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9d484b30-0f37-4352-819b-fb401265ad27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9d484b30-0f37-4352-819b-fb401265ad27" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9d484b30-0f37-4352-819b-fb401265ad27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9d484b30-0f37-4352-819b-fb401265ad27" xlink:to="loc_us-gaap_ClassOfStockDomain_9d484b30-0f37-4352-819b-fb401265ad27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b8d814c8-7025-4c2b-8aad-3e6bff2dac01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9d484b30-0f37-4352-819b-fb401265ad27" xlink:to="loc_us-gaap_ClassOfStockDomain_b8d814c8-7025-4c2b-8aad-3e6bff2dac01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_c8b939b9-e756-4ea0-ba10-5e24d7d85b74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b8d814c8-7025-4c2b-8aad-3e6bff2dac01" xlink:to="loc_us-gaap_CommonClassAMember_c8b939b9-e756-4ea0-ba10-5e24d7d85b74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_1b9bdda7-19b4-411e-a185-be71d374a032" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b8d814c8-7025-4c2b-8aad-3e6bff2dac01" xlink:to="loc_us-gaap_CommonClassBMember_1b9bdda7-19b4-411e-a185-be71d374a032" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ba173dec-a897-4573-9533-dea578eb8379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ba173dec-a897-4573-9533-dea578eb8379" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ba173dec-a897-4573-9533-dea578eb8379_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ba173dec-a897-4573-9533-dea578eb8379" xlink:to="loc_us-gaap_EquityComponentDomain_ba173dec-a897-4573-9533-dea578eb8379_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2cbfff04-d9df-49ed-b809-f7ded4ebc660" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ba173dec-a897-4573-9533-dea578eb8379" xlink:to="loc_us-gaap_EquityComponentDomain_2cbfff04-d9df-49ed-b809-f7ded4ebc660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_17927107-4467-43c7-960b-92a2086d2d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2cbfff04-d9df-49ed-b809-f7ded4ebc660" xlink:to="loc_us-gaap_WarrantMember_17927107-4467-43c7-960b-92a2086d2d4d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedBalanceSheetStatementsCaptionsLineItems_6d6c1000-3ccb-4032-9f22-8fef8404b920" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_23eb76a2-85b5-421d-aea1-a903026c5ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedBalanceSheetStatementsCaptionsLineItems_6d6c1000-3ccb-4032-9f22-8fef8404b920" xlink:to="loc_us-gaap_AssetsAbstract_23eb76a2-85b5-421d-aea1-a903026c5ca7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1d3d8071-e9b2-4702-a8cd-4117ea59f2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_23eb76a2-85b5-421d-aea1-a903026c5ca7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1d3d8071-e9b2-4702-a8cd-4117ea59f2a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_734af6fe-5518-4bf2-aea5-f9c1e17dcbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d3d8071-e9b2-4702-a8cd-4117ea59f2a5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_734af6fe-5518-4bf2-aea5-f9c1e17dcbd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_544ceb34-b7c1-48af-b3b7-5a6b2bd94acf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d3d8071-e9b2-4702-a8cd-4117ea59f2a5" xlink:to="loc_us-gaap_AssetsCurrent_544ceb34-b7c1-48af-b3b7-5a6b2bd94acf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_InvestmentInSubsidiary_da4927e2-9333-4f4f-9333-5faa1e047b1b" xlink:href="wald-20221231.xsd#wald_InvestmentInSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_23eb76a2-85b5-421d-aea1-a903026c5ca7" xlink:to="loc_wald_InvestmentInSubsidiary_da4927e2-9333-4f4f-9333-5faa1e047b1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_88d99d4b-b93a-4eca-92b5-6117b6ee3954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_23eb76a2-85b5-421d-aea1-a903026c5ca7" xlink:to="loc_us-gaap_Assets_88d99d4b-b93a-4eca-92b5-6117b6ee3954" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_550ef399-a227-4555-953b-064c48df6bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedBalanceSheetStatementsCaptionsLineItems_6d6c1000-3ccb-4032-9f22-8fef8404b920" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_550ef399-a227-4555-953b-064c48df6bfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d8433788-4284-4876-b900-e086654661a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_550ef399-a227-4555-953b-064c48df6bfd" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d8433788-4284-4876-b900-e086654661a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_IntercompanyPayables_8ec5a3d6-0e2a-4ce4-85e7-4ef5c5709fc3" xlink:href="wald-20221231.xsd#wald_IntercompanyPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d8433788-4284-4876-b900-e086654661a4" xlink:to="loc_wald_IntercompanyPayables_8ec5a3d6-0e2a-4ce4-85e7-4ef5c5709fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_76e35175-5554-4d07-a115-3571e8bc1689" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_550ef399-a227-4555-953b-064c48df6bfd" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_76e35175-5554-4d07-a115-3571e8bc1689" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bc865f3c-cf4b-45d6-bb9f-8d07d4e6569d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_550ef399-a227-4555-953b-064c48df6bfd" xlink:to="loc_us-gaap_Liabilities_bc865f3c-cf4b-45d6-bb9f-8d07d4e6569d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_550ef399-a227-4555-953b-064c48df6bfd" xlink:to="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ebe985d8-0819-4097-8e40-3ef2becb7f90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ebe985d8-0819-4097-8e40-3ef2becb7f90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_40babbc0-6ac0-4a50-84f4-fb4a8a7bd845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_40babbc0-6ac0-4a50-84f4-fb4a8a7bd845" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ae3227fe-fdbe-4a04-b27c-89ef4ee6994d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ae3227fe-fdbe-4a04-b27c-89ef4ee6994d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_164fb41d-9a59-4d65-a377-07b47bd9697b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_CommonStockValue_164fb41d-9a59-4d65-a377-07b47bd9697b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f9747b6e-adac-450f-85c4-fe39cd0a27a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f9747b6e-adac-450f-85c4-fe39cd0a27a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cddd9636-5b06-461a-bf0e-2de7f9d7273e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cddd9636-5b06-461a-bf0e-2de7f9d7273e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d283608f-8bda-4a46-a7f0-718bb26e4274" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d283608f-8bda-4a46-a7f0-718bb26e4274" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f98b97ac-1af2-4910-8dfa-d5264494a2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_StockholdersEquity_f98b97ac-1af2-4910-8dfa-d5264494a2dc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_fe9c7336-b17f-41a8-a36a-85f22d357265" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_MinorityInterest_fe9c7336-b17f-41a8-a36a-85f22d357265" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b64f7c40-9af4-4201-b8a6-558df69e8c81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b64f7c40-9af4-4201-b8a6-558df69e8c81" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2a3f94a4-c207-4dfe-9c13-1f76b0c286a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_550ef399-a227-4555-953b-064c48df6bfd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2a3f94a4-c207-4dfe-9c13-1f76b0c286a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedBalanceSheetStatementTable_ee52a159-b0b4-4f8e-955b-618fbffa5e2f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedBalanceSheetStatementsCaptionsLineItems_6d6c1000-3ccb-4032-9f22-8fef8404b920" xlink:to="loc_srt_CondensedBalanceSheetStatementTable_ee52a159-b0b4-4f8e-955b-618fbffa5e2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_bcfcafed-747f-44ff-a1f4-6cee85c7b380" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_CondensedBalanceSheetStatementTable_ee52a159-b0b4-4f8e-955b-618fbffa5e2f" xlink:to="loc_srt_ConsolidatedEntitiesAxis_bcfcafed-747f-44ff-a1f4-6cee85c7b380" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_bcfcafed-747f-44ff-a1f4-6cee85c7b380_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_bcfcafed-747f-44ff-a1f4-6cee85c7b380" xlink:to="loc_srt_ConsolidatedEntitiesDomain_bcfcafed-747f-44ff-a1f4-6cee85c7b380_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_2c7d8206-f37b-4d6d-a72a-ae0d3947f2ae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_bcfcafed-747f-44ff-a1f4-6cee85c7b380" xlink:to="loc_srt_ConsolidatedEntitiesDomain_2c7d8206-f37b-4d6d-a72a-ae0d3947f2ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_fda0879a-bb76-4502-b2cf-bff656fb082b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_2c7d8206-f37b-4d6d-a72a-ae0d3947f2ae" xlink:to="loc_srt_ParentCompanyMember_fda0879a-bb76-4502-b2cf-bff656fb082b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f77ebae8-5f4e-4f82-9c1d-997d3983197b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_CondensedBalanceSheetStatementTable_ee52a159-b0b4-4f8e-955b-618fbffa5e2f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f77ebae8-5f4e-4f82-9c1d-997d3983197b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f77ebae8-5f4e-4f82-9c1d-997d3983197b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f77ebae8-5f4e-4f82-9c1d-997d3983197b" xlink:to="loc_us-gaap_ClassOfStockDomain_f77ebae8-5f4e-4f82-9c1d-997d3983197b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_947e5ee1-1d6d-45c8-a73f-70a6fcbc326b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f77ebae8-5f4e-4f82-9c1d-997d3983197b" xlink:to="loc_us-gaap_ClassOfStockDomain_947e5ee1-1d6d-45c8-a73f-70a6fcbc326b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_f78ca44a-69b2-4a2b-b838-fb073a955aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_947e5ee1-1d6d-45c8-a73f-70a6fcbc326b" xlink:to="loc_us-gaap_CommonClassAMember_f78ca44a-69b2-4a2b-b838-fb073a955aa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_40092241-e326-426d-8350-24a964a7df81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_947e5ee1-1d6d-45c8-a73f-70a6fcbc326b" xlink:to="loc_us-gaap_CommonClassBMember_40092241-e326-426d-8350-24a964a7df81" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4bbfb8b6-368b-4bcc-88a2-924584be49e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4bbfb8b6-368b-4bcc-88a2-924584be49e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a1b877ef-5bc5-4f0f-85e8-802a81078936" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a1b877ef-5bc5-4f0f-85e8-802a81078936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_472b1703-e4fa-4d6c-8a73-f91f6cd2351f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_OperatingIncomeLoss_472b1703-e4fa-4d6c-8a73-f91f6cd2351f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_f87a85ca-5250-4fdc-a496-00e3945849a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeDisclosureNonoperatingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_f87a85ca-5250-4fdc-a496-00e3945849a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_0a223372-7505-40e3-9136-af9cb641b548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_f87a85ca-5250-4fdc-a496-00e3945849a0" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_0a223372-7505-40e3-9136-af9cb641b548" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1396b652-3045-408a-8a3a-7b2fd4942442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_f87a85ca-5250-4fdc-a496-00e3945849a0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1396b652-3045-408a-8a3a-7b2fd4942442" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c7943de2-6434-404f-98ce-24629149960e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c7943de2-6434-404f-98ce-24629149960e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ec4a2293-2444-4122-b806-a3eadb35dd65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ec4a2293-2444-4122-b806-a3eadb35dd65" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_87b0c140-8b26-436a-baa9-900d179975b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_87b0c140-8b26-436a-baa9-900d179975b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_d37237ac-fe8a-4fe1-a945-fae526fc041a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_d37237ac-fe8a-4fe1-a945-fae526fc041a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_948af752-d1b1-4fe6-a3ce-c37db3fd991c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_NetIncomeLoss_948af752-d1b1-4fe6-a3ce-c37db3fd991c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a6c07ee1-b77a-4a5f-8976-16bcd8c6e0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a6c07ee1-b77a-4a5f-8976-16bcd8c6e0a0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6aa8a0f7-44af-4d66-8926-52187501bd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6aa8a0f7-44af-4d66-8926-52187501bd2a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedIncomeStatementTable_72dc01d5-ac1b-4125-9953-71b217307c5e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_srt_CondensedIncomeStatementTable_72dc01d5-ac1b-4125-9953-71b217307c5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_0371cfb7-791b-4a5f-83e5-4c6b330214f3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_CondensedIncomeStatementTable_72dc01d5-ac1b-4125-9953-71b217307c5e" xlink:to="loc_srt_ConsolidatedEntitiesAxis_0371cfb7-791b-4a5f-83e5-4c6b330214f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_0371cfb7-791b-4a5f-83e5-4c6b330214f3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0371cfb7-791b-4a5f-83e5-4c6b330214f3" xlink:to="loc_srt_ConsolidatedEntitiesDomain_0371cfb7-791b-4a5f-83e5-4c6b330214f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_a4e6ae4f-41c3-41b9-bd1a-c852e77ffe7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0371cfb7-791b-4a5f-83e5-4c6b330214f3" xlink:to="loc_srt_ConsolidatedEntitiesDomain_a4e6ae4f-41c3-41b9-bd1a-c852e77ffe7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_c762f13a-d31a-4f5d-9c5e-676eae3cb068" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_a4e6ae4f-41c3-41b9-bd1a-c852e77ffe7c" xlink:to="loc_srt_ParentCompanyMember_c762f13a-d31a-4f5d-9c5e-676eae3cb068" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"/>
  <link:definitionLink xlink:role="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_efa69bf5-4a22-4dba-8064-8ada55099fdc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7ff0e5ec-4715-4b70-b260-c4fc49152a93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_efa69bf5-4a22-4dba-8064-8ada55099fdc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7ff0e5ec-4715-4b70-b260-c4fc49152a93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e79b1446-f02c-44ca-ae03-ea0728012a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7ff0e5ec-4715-4b70-b260-c4fc49152a93" xlink:to="loc_us-gaap_ProfitLoss_e79b1446-f02c-44ca-ae03-ea0728012a1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_095a008c-0695-496a-b601-65382f8f3859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7ff0e5ec-4715-4b70-b260-c4fc49152a93" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_095a008c-0695-496a-b601-65382f8f3859" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a758f18b-f95d-423b-bfa5-4f533bdd23bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_095a008c-0695-496a-b601-65382f8f3859" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a758f18b-f95d-423b-bfa5-4f533bdd23bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_8f182387-7608-4b1f-aa0f-bb76d34cbfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a758f18b-f95d-423b-bfa5-4f533bdd23bb" xlink:to="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_8f182387-7608-4b1f-aa0f-bb76d34cbfdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_9872a0bf-54aa-44e4-8bd5-752ba23bf444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a758f18b-f95d-423b-bfa5-4f533bdd23bb" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_9872a0bf-54aa-44e4-8bd5-752ba23bf444" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_58dc9c5e-93d7-434c-ae20-fc473fb9b373" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7ff0e5ec-4715-4b70-b260-c4fc49152a93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_58dc9c5e-93d7-434c-ae20-fc473fb9b373" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_df2af54c-a002-4f16-b5b2-da62a83ea5de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_efa69bf5-4a22-4dba-8064-8ada55099fdc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_df2af54c-a002-4f16-b5b2-da62a83ea5de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ProceedsFromTrustAccount_921d25e0-d8b1-4942-88c2-5a42598c0df1" xlink:href="wald-20221231.xsd#wald_ProceedsFromTrustAccount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_df2af54c-a002-4f16-b5b2-da62a83ea5de" xlink:to="loc_wald_ProceedsFromTrustAccount_921d25e0-d8b1-4942-88c2-5a42598c0df1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_728e538c-4b45-4a7a-b39a-f36bb97f0354" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_df2af54c-a002-4f16-b5b2-da62a83ea5de" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_728e538c-4b45-4a7a-b39a-f36bb97f0354" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_880cc435-b488-4400-965d-87a07b2dc695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_efa69bf5-4a22-4dba-8064-8ada55099fdc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_880cc435-b488-4400-965d-87a07b2dc695" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_1eeca15c-52e3-4ec4-86e3-52c907f25d26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_880cc435-b488-4400-965d-87a07b2dc695" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_1eeca15c-52e3-4ec4-86e3-52c907f25d26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates_5cf99c68-1c04-4194-9754-832e81a2ba12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_880cc435-b488-4400-965d-87a07b2dc695" xlink:to="loc_us-gaap_PaymentsOfDistributionsToAffiliates_5cf99c68-1c04-4194-9754-832e81a2ba12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PaymentsOfExpensesOnBehalfOfSubsidiaries_f52763e5-6748-4c18-aef5-9e69cf223ac1" xlink:href="wald-20221231.xsd#wald_PaymentsOfExpensesOnBehalfOfSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_880cc435-b488-4400-965d-87a07b2dc695" xlink:to="loc_wald_PaymentsOfExpensesOnBehalfOfSubsidiaries_f52763e5-6748-4c18-aef5-9e69cf223ac1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_07077d0a-6a94-4f3c-a5a0-e681db3ce04f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_880cc435-b488-4400-965d-87a07b2dc695" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_07077d0a-6a94-4f3c-a5a0-e681db3ce04f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_f9920a20-1260-43c2-8b90-b9ff151386d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_efa69bf5-4a22-4dba-8064-8ada55099fdc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_f9920a20-1260-43c2-8b90-b9ff151386d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22545a24-ca06-45a7-9e4b-c67581c9a54b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_efa69bf5-4a22-4dba-8064-8ada55099fdc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22545a24-ca06-45a7-9e4b-c67581c9a54b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a45484f2-2b9e-4e75-9569-8d3c36343efb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementTable_9b9cbefa-14eb-4995-bd2f-dba0460ffff0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedCashFlowStatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_efa69bf5-4a22-4dba-8064-8ada55099fdc" xlink:to="loc_srt_CondensedCashFlowStatementTable_9b9cbefa-14eb-4995-bd2f-dba0460ffff0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_919e981d-6ed3-42d3-8727-08feed452901" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_CondensedCashFlowStatementTable_9b9cbefa-14eb-4995-bd2f-dba0460ffff0" xlink:to="loc_srt_ConsolidatedEntitiesAxis_919e981d-6ed3-42d3-8727-08feed452901" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_919e981d-6ed3-42d3-8727-08feed452901_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_919e981d-6ed3-42d3-8727-08feed452901" xlink:to="loc_srt_ConsolidatedEntitiesDomain_919e981d-6ed3-42d3-8727-08feed452901_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_d7ef17fd-45a9-42e8-8136-7db14d0ebe36" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_919e981d-6ed3-42d3-8727-08feed452901" xlink:to="loc_srt_ConsolidatedEntitiesDomain_d7ef17fd-45a9-42e8-8136-7db14d0ebe36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_7515ccf2-a225-4b0d-b928-3a2ea3c734dd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_d7ef17fd-45a9-42e8-8136-7db14d0ebe36" xlink:to="loc_srt_ParentCompanyMember_7515ccf2-a225-4b0d-b928-3a2ea3c734dd" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>wald-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cb24ed7e-6299-4643-a980-910da3dfa7bf,g:f940d8a8-f49a-452c-b5e1-83817ee3c0b3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_73a4d05e-fc81-43da-a789-023ec6c2f006_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_38997e21-36ce-40da-876b-1ec56be744f8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_954ccae8-37d5-483b-9dfa-feb5d0290fcf_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1a72cbf3-cf9a-4469-9754-d2681c71c93d_negatedLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_5316c91a-ecb9-4d25-a18e-83a1372b50a7_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D expense adjustments</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a61c919c-a92e-447d-90a4-110d1c5f77ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of impact of business combinations:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ddada51c-cbce-413c-aebb-fa8a029d00d1_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_0a635d1a-62c0-47ec-8fd3-38c4c09bc771_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_73cef557-cb2e-4a07-8b47-ebf737a337cd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent_05341647-0f30-452c-9cb7-fe0ee17b79c8_terseLabel_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum allocated target share units, percent</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent_label_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Allocated Target Share Units, Percent</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent_documentation_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Allocated Target Share Units, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent" xlink:to="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_68233e9d-2bfc-4904-8db4-f2961d29e023_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by Sales Channel</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b54c6f3-38e3-400c-8778-238b4466a4ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_CustomerTwoMember_cae17d2e-5775-492f-b533-c39e2abddb5a_terseLabel_en-US" xlink:label="lab_wald_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two</link:label>
    <link:label id="lab_wald_CustomerTwoMember_label_en-US" xlink:label="lab_wald_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label id="lab_wald_CustomerTwoMember_documentation_en-US" xlink:label="lab_wald_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CustomerTwoMember" xlink:href="wald-20221231.xsd#wald_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_CustomerTwoMember" xlink:to="lab_wald_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage_5d39ef4f-64b4-4af8-872d-ee50446c40d3_terseLabel_en-US" xlink:label="lab_wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance fee allocation percentage</link:label>
    <link:label id="lab_wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage_label_en-US" xlink:label="lab_wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Purchase Agreement, Performance Fee Allocation Percentage</link:label>
    <link:label id="lab_wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage_documentation_en-US" xlink:label="lab_wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Purchase Agreement, Performance Fee Allocation Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage" xlink:href="wald-20221231.xsd#wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage" xlink:to="lab_wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_8faa24ed-d7c7-456e-98a3-757f48690bba_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_ad88cd0b-ecbb-414d-a1c2-aa3e739121c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Purchase Price Allocation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_ee47cff6-be11-42b6-8ec9-2453a7dbf7a1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_AlternateBaseRateMember_47b92c44-4da7-403f-a929-d453c1eea4c9_terseLabel_en-US" xlink:label="lab_wald_AlternateBaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate Base Rate</link:label>
    <link:label id="lab_wald_AlternateBaseRateMember_label_en-US" xlink:label="lab_wald_AlternateBaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate Base Rate [Member]</link:label>
    <link:label id="lab_wald_AlternateBaseRateMember_documentation_en-US" xlink:label="lab_wald_AlternateBaseRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate Base Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AlternateBaseRateMember" xlink:href="wald-20221231.xsd#wald_AlternateBaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_AlternateBaseRateMember" xlink:to="lab_wald_AlternateBaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_5be2aa77-71f2-4936-9794-9b6b4538f0ec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LenderConcentrationRiskMember_c9ade7ca-518a-412b-b850-26ede690bfaa_terseLabel_en-US" xlink:label="lab_us-gaap_LenderConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Concentration Risk</link:label>
    <link:label id="lab_us-gaap_LenderConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_LenderConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LenderConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LenderConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LenderConcentrationRiskMember" xlink:to="lab_us-gaap_LenderConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1293db86-cb18-40e4-913e-a5dfc84e1669_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_PrivatePlacementWarrantsMember_850388d7-fe16-44b7-ae68-f5381110915f_terseLabel_en-US" xlink:label="lab_wald_PrivatePlacementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement Warrants</link:label>
    <link:label id="lab_wald_PrivatePlacementWarrantsMember_label_en-US" xlink:label="lab_wald_PrivatePlacementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement Warrants [Member]</link:label>
    <link:label id="lab_wald_PrivatePlacementWarrantsMember_documentation_en-US" xlink:label="lab_wald_PrivatePlacementWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PrivatePlacementWarrantsMember" xlink:href="wald-20221231.xsd#wald_PrivatePlacementWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_PrivatePlacementWarrantsMember" xlink:to="lab_wald_PrivatePlacementWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_95e48b04-ecb9-46f9-aa19-45ac948a9ac7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_4401674a-07d8-4f5d-a7d5-6accc1f07f7a_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_e5f0ee47-a680-4484-b1c8-e80f2724a272_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9aa97056-a19e-4b85-92c5-8d042a3dc3cb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5ba36d43-5771-4415-bc5f-329bff514c10_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_86c3f7b5-0975-41f5-b876-6b312197442e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1970043-4fb3-4e43-b850-fd8a3081a7cc_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty_d76842ba-5aa3-4630-88ce-38129dc5df5a_terseLabel_en-US" xlink:label="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party receivable</link:label>
    <link:label id="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty_label_en-US" xlink:label="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables, Related Party</link:label>
    <link:label id="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty_documentation_en-US" xlink:label="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables, Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty" xlink:href="wald-20221231.xsd#wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty" xlink:to="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_3c19b40d-f1bf-41a9-9e8d-c223157e1d0a_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_441cd7bf-ca55-49b7-829b-d20bb11f0152_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_cf0d906c-2464-40f5-8cb0-258fe21ea4bb_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5d86d1f9-2b65-4689-a7ce-14d3e0ecfcec_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e798de61-2104-4760-9f88-f1b17a49c851_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_GainLossOnNoteReceivableWriteoff_18047eb6-f47e-4412-a73e-b66778d9cac8_negatedTerseLabel_en-US" xlink:label="lab_wald_GainLossOnNoteReceivableWriteoff" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on write-off of loan receivable</link:label>
    <link:label id="lab_wald_GainLossOnNoteReceivableWriteoff_0aaa5d11-84fe-4a54-9915-23248bd9bea0_negatedLabel_en-US" xlink:label="lab_wald_GainLossOnNoteReceivableWriteoff" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on write-off of loan receivable</link:label>
    <link:label id="lab_wald_GainLossOnNoteReceivableWriteoff_label_en-US" xlink:label="lab_wald_GainLossOnNoteReceivableWriteoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Note Receivable Writeoff</link:label>
    <link:label id="lab_wald_GainLossOnNoteReceivableWriteoff_documentation_en-US" xlink:label="lab_wald_GainLossOnNoteReceivableWriteoff" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Note Receivable Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainLossOnNoteReceivableWriteoff" xlink:href="wald-20221231.xsd#wald_GainLossOnNoteReceivableWriteoff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_GainLossOnNoteReceivableWriteoff" xlink:to="lab_wald_GainLossOnNoteReceivableWriteoff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_27902a0b-cecf-4ab2-96cb-14594289820d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_89996793-ac1a-452b-a1d8-dcc3f473cba1_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7b502b33-f395-4d25-b4bb-f6eda4819be2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_a9918d87-a08a-416b-8865-c82a9038a1e1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_61e987ab-ae09-41e4-9ffa-4af279c87764_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a5b23cb6-58bf-4009-b4be-64efd3968949_negatedLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e61a8e65-5079-4fa1-8802-8993aee3f082_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts receivable, net adjustments</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_edf729a7-e8a1-4ff4-944e-639c57b5687a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_75143d53-d05b-4d3c-a1a6-966441ca70e7_netLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_52906f3c-82f5-40bd-a0b8-6ed119629288_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL CASH FLOW DATA &#8211; CASH PAID:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_TX_8744c176-12e6-4be0-a766-99ef3850a6d7_terseLabel_en-US" xlink:label="lab_stpr_TX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TEXAS</link:label>
    <link:label id="lab_stpr_TX_label_en-US" xlink:label="lab_stpr_TX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TEXAS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_TX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_TX" xlink:to="lab_stpr_TX" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ConvertibleWorkingCapitalNoteMember_2fd520db-9692-4036-b9a4-382e1b870ae3_terseLabel_en-US" xlink:label="lab_wald_ConvertibleWorkingCapitalNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Working Capital Note</link:label>
    <link:label id="lab_wald_ConvertibleWorkingCapitalNoteMember_label_en-US" xlink:label="lab_wald_ConvertibleWorkingCapitalNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Working Capital Note [Member]</link:label>
    <link:label id="lab_wald_ConvertibleWorkingCapitalNoteMember_documentation_en-US" xlink:label="lab_wald_ConvertibleWorkingCapitalNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Working Capital Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ConvertibleWorkingCapitalNoteMember" xlink:href="wald-20221231.xsd#wald_ConvertibleWorkingCapitalNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ConvertibleWorkingCapitalNoteMember" xlink:to="lab_wald_ConvertibleWorkingCapitalNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ObagiBlueSeaHoldingLLCMember_8e2406bf-96f6-4be8-8197-f83b6aa3b9db_terseLabel_en-US" xlink:label="lab_wald_ObagiBlueSeaHoldingLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi Blue Sea Holding, LLC</link:label>
    <link:label id="lab_wald_ObagiBlueSeaHoldingLLCMember_label_en-US" xlink:label="lab_wald_ObagiBlueSeaHoldingLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi Blue Sea Holding, LLC [Member]</link:label>
    <link:label id="lab_wald_ObagiBlueSeaHoldingLLCMember_documentation_en-US" xlink:label="lab_wald_ObagiBlueSeaHoldingLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi Blue Sea Holding, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiBlueSeaHoldingLLCMember" xlink:href="wald-20221231.xsd#wald_ObagiBlueSeaHoldingLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ObagiBlueSeaHoldingLLCMember" xlink:to="lab_wald_ObagiBlueSeaHoldingLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_b6b5dca8-199d-4741-bce9-c8378553ecb0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_DistributionToShareholderForDispositionOfBusiness_c1ecd921-4c8e-4c8a-a225-5b0387544ac2_terseLabel_en-US" xlink:label="lab_wald_DistributionToShareholderForDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi China Distribution to shareholder</link:label>
    <link:label id="lab_wald_DistributionToShareholderForDispositionOfBusiness_label_en-US" xlink:label="lab_wald_DistributionToShareholderForDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution To Shareholder For Disposition Of Business</link:label>
    <link:label id="lab_wald_DistributionToShareholderForDispositionOfBusiness_documentation_en-US" xlink:label="lab_wald_DistributionToShareholderForDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution To Shareholder For Disposition Of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DistributionToShareholderForDispositionOfBusiness" xlink:href="wald-20221231.xsd#wald_DistributionToShareholderForDispositionOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_DistributionToShareholderForDispositionOfBusiness" xlink:to="lab_wald_DistributionToShareholderForDispositionOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_9ab49686-2eae-4008-b8b3-0c3c8a5ab844_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1911c1f7-37da-4da3-9885-c8ad1c547be0_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdministrativeFeesExpense_f9e9aefb-435d-4cbf-945c-b2a00dd981f8_terseLabel_en-US" xlink:label="lab_us-gaap_AdministrativeFeesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative expenses</link:label>
    <link:label id="lab_us-gaap_AdministrativeFeesExpense_label_en-US" xlink:label="lab_us-gaap_AdministrativeFeesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Fees Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdministrativeFeesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdministrativeFeesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdministrativeFeesExpense" xlink:to="lab_us-gaap_AdministrativeFeesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_PaymentsForServicesAgreementFees_13e71552-5f34-4f7d-a7d1-083197214565_terseLabel_en-US" xlink:label="lab_wald_PaymentsForServicesAgreementFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total service fees paid</link:label>
    <link:label id="lab_wald_PaymentsForServicesAgreementFees_label_en-US" xlink:label="lab_wald_PaymentsForServicesAgreementFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Services Agreement Fees</link:label>
    <link:label id="lab_wald_PaymentsForServicesAgreementFees_documentation_en-US" xlink:label="lab_wald_PaymentsForServicesAgreementFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Services Agreement Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PaymentsForServicesAgreementFees" xlink:href="wald-20221231.xsd#wald_PaymentsForServicesAgreementFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_PaymentsForServicesAgreementFees" xlink:to="lab_wald_PaymentsForServicesAgreementFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3729830c-3da4-42e7-b0a3-8473c55d27ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_12d4fed5-71ea-4b18-94ab-6ca9f5180f06_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDistributionsToAffiliates_48a48bba-ed2b-48b0-9328-464d4884708b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers to subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDistributionsToAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Distributions to Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:to="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_e2e55168-55cc-471c-91c0-83671ac7d6cc_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent_367f21bb-cfc2-4ec3-89b9-e22b1223800a_terseLabel_en-US" xlink:label="lab_wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True-Ups</link:label>
    <link:label id="lab_wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent_label_en-US" xlink:label="lab_wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, True-Ups, Percent</link:label>
    <link:label id="lab_wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent_documentation_en-US" xlink:label="lab_wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, True-Ups, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent" xlink:href="wald-20221231.xsd#wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent" xlink:to="lab_wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_eeadb43f-a921-4419-bd5d-f76fdf725d96_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_3f6274c4-dc51-4236-a4cd-842f38751d8a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_StockIssuedDuringPeriodSharesSubscriptionAgreements_bc9900eb-1c93-4d1c-8ef8-834b07d977da_terseLabel_en-US" xlink:label="lab_wald_StockIssuedDuringPeriodSharesSubscriptionAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares in connection with the PIPE investment (in shares)</link:label>
    <link:label id="lab_wald_StockIssuedDuringPeriodSharesSubscriptionAgreements_label_en-US" xlink:label="lab_wald_StockIssuedDuringPeriodSharesSubscriptionAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Subscription Agreements</link:label>
    <link:label id="lab_wald_StockIssuedDuringPeriodSharesSubscriptionAgreements_documentation_en-US" xlink:label="lab_wald_StockIssuedDuringPeriodSharesSubscriptionAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Subscription Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockIssuedDuringPeriodSharesSubscriptionAgreements" xlink:href="wald-20221231.xsd#wald_StockIssuedDuringPeriodSharesSubscriptionAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_StockIssuedDuringPeriodSharesSubscriptionAgreements" xlink:to="lab_wald_StockIssuedDuringPeriodSharesSubscriptionAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_cac08fbd-25d4-4e9f-a802-0455e946cbe6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_c3312884-4eef-4e0d-ac67-9b83fe7e819f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Axis]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelAxis_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2173b0e7-bc3c-428d-8348-8fffc707903e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod_daa2eb53-9eeb-4c3f-a401-7256c9131729_terseLabel_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anniversary period, annual increase in shares issued under plan</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod_label_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares, Anniversary Period</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod_documentation_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares, Anniversary Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod" xlink:to="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_b201c351-4be0-478b-b603-43f2ea4bf0df_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0b8b8e5f-53b6-4966-b843-6d3392ae45b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6ea478bc-d68d-4604-afb9-5ddad49888c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ObagiAndMilkBusinessCombinationsMember_0d61b979-afcf-4478-b932-80531d5500a3_terseLabel_en-US" xlink:label="lab_wald_ObagiAndMilkBusinessCombinationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi and Milk Business Combinations</link:label>
    <link:label id="lab_wald_ObagiAndMilkBusinessCombinationsMember_label_en-US" xlink:label="lab_wald_ObagiAndMilkBusinessCombinationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi and Milk Business Combinations [Member]</link:label>
    <link:label id="lab_wald_ObagiAndMilkBusinessCombinationsMember_documentation_en-US" xlink:label="lab_wald_ObagiAndMilkBusinessCombinationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi and Milk Business Combinations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiAndMilkBusinessCombinationsMember" xlink:href="wald-20221231.xsd#wald_ObagiAndMilkBusinessCombinationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ObagiAndMilkBusinessCombinationsMember" xlink:to="lab_wald_ObagiAndMilkBusinessCombinationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_4cb84dd5-decc-462e-9e4d-bfc45f270948_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives of Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0197d121-e43a-4afb-8e7b-01c7afa9f24b_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7bb599e4-9a73-46f2-bccb-9956b4f6523e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4afe0862-4fc0-4d07-b8db-364a7c571172_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5ed7150e-fd0e-44ac-99aa-a9d86efb6a78_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedBalanceSheetStatementsCaptionsLineItems_977029e8-6690-41d6-8aab-8035faa003ce_terseLabel_en-US" xlink:label="lab_srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Balance Sheet Statements, Captions [Line Items]</link:label>
    <link:label id="lab_srt_CondensedBalanceSheetStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Balance Sheet Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_b0ef5863-0b3f-4601-b063-5250b301de49_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_58fa48f9-f164-4f7a-bc3f-f7b3d4ec2161_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7d8f6676-2462-4085-8138-59b0aeb4af80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_be419c2e-f17a-4b0d-9b90-c0c89460386c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_4388f43a-d5b5-4f07-bd13-587938e2de0b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d463c010-64ef-4f60-a095-4a5b7c222433_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_805cb86e-102e-4b6b-bb13-0e74b4612700_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_VariableRateComponentTwoMember_0cfb5ef8-dc92-4c5c-9f39-9d0bede62960_terseLabel_en-US" xlink:label="lab_wald_VariableRateComponentTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component Two</link:label>
    <link:label id="lab_wald_VariableRateComponentTwoMember_label_en-US" xlink:label="lab_wald_VariableRateComponentTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component Two [Member]</link:label>
    <link:label id="lab_wald_VariableRateComponentTwoMember_documentation_en-US" xlink:label="lab_wald_VariableRateComponentTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VariableRateComponentTwoMember" xlink:href="wald-20221231.xsd#wald_VariableRateComponentTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_VariableRateComponentTwoMember" xlink:to="lab_wald_VariableRateComponentTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_dd7f4901-0077-4afe-a86f-9938064fac44_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_VariableRateComponentAxis_58948d65-fe6f-4bed-9833-293e99d03962_terseLabel_en-US" xlink:label="lab_wald_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Axis]</link:label>
    <link:label id="lab_wald_VariableRateComponentAxis_label_en-US" xlink:label="lab_wald_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Axis]</link:label>
    <link:label id="lab_wald_VariableRateComponentAxis_documentation_en-US" xlink:label="lab_wald_VariableRateComponentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VariableRateComponentAxis" xlink:href="wald-20221231.xsd#wald_VariableRateComponentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_VariableRateComponentAxis" xlink:to="lab_wald_VariableRateComponentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_6d0b41b7-06dd-4998-a2fe-fa3ce290a46b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_0c776259-282e-423b-9936-f0dfbecb7c37_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForFees_b007b63b-56b2-4a1e-b7ff-126e53a96749_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product registration payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForFees_label_en-US" xlink:label="lab_us-gaap_PaymentsForFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Other Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForFees" xlink:to="lab_us-gaap_PaymentsForFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_77a22f4d-5e5f-4650-a805-9461b6ba83c5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches_b5087933-cce8-454d-9de1-4527149694c3_terseLabel_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches_label_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Tranches</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches_documentation_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches" xlink:to="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ObagiCosmeceuticalsLLCMember_7065b357-10b3-4eff-9019-2ddd3f9d0b52_verboseLabel_en-US" xlink:label="lab_wald_ObagiCosmeceuticalsLLCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi Global Holdings Limited</link:label>
    <link:label id="lab_wald_ObagiCosmeceuticalsLLCMember_eedb7165-f508-4be9-a24c-017c00cff273_terseLabel_en-US" xlink:label="lab_wald_ObagiCosmeceuticalsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi Cosmeceuticals</link:label>
    <link:label id="lab_wald_ObagiCosmeceuticalsLLCMember_label_en-US" xlink:label="lab_wald_ObagiCosmeceuticalsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi Cosmeceuticals LLC [Member]</link:label>
    <link:label id="lab_wald_ObagiCosmeceuticalsLLCMember_documentation_en-US" xlink:label="lab_wald_ObagiCosmeceuticalsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi Cosmeceuticals LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiCosmeceuticalsLLCMember" xlink:href="wald-20221231.xsd#wald_ObagiCosmeceuticalsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ObagiCosmeceuticalsLLCMember" xlink:to="lab_wald_ObagiCosmeceuticalsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a913bc86-e1e2-4096-913b-2a22fdce1579_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of units issued in IPO (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_bc278cf0-145a-439c-ae17-ac1386916f06_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0eb249cd-bba2-48c7-9410-7ce7819553a4_netLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in private placement (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_511f7d03-fd08-42df-a84d-6413d11f70a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod_fbaf455e-cb41-4e9d-bb83-7353156b0dba_terseLabel_en-US" xlink:label="lab_wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hurdle rate accrual period</link:label>
    <link:label id="lab_wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod_label_en-US" xlink:label="lab_wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Purchase Agreement, Hurdle Rate Accrual Period</link:label>
    <link:label id="lab_wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod_documentation_en-US" xlink:label="lab_wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Purchase Agreement, Hurdle Rate Accrual Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod" xlink:href="wald-20221231.xsd#wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod" xlink:to="lab_wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_3493e6bf-ca0d-48e0-a93f-b7fc707f6c6b_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_SADistributorMember_4ef75c4c-1345-4590-a7f5-61e3c6f5b9b0_terseLabel_en-US" xlink:label="lab_wald_SADistributorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SA Distributor</link:label>
    <link:label id="lab_wald_SADistributorMember_label_en-US" xlink:label="lab_wald_SADistributorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SA Distributor [Member]</link:label>
    <link:label id="lab_wald_SADistributorMember_documentation_en-US" xlink:label="lab_wald_SADistributorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SA Distributor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SADistributorMember" xlink:href="wald-20221231.xsd#wald_SADistributorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_SADistributorMember" xlink:to="lab_wald_SADistributorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_634455ab-6eab-41c8-8cf8-4cccdb0c819e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_LimitedPartnershipUnitsMember_3418b0fe-041c-4a7b-b720-9ac51b8d656f_terseLabel_en-US" xlink:label="lab_wald_LimitedPartnershipUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Partnership Units</link:label>
    <link:label id="lab_wald_LimitedPartnershipUnitsMember_label_en-US" xlink:label="lab_wald_LimitedPartnershipUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Partnership Units [Member]</link:label>
    <link:label id="lab_wald_LimitedPartnershipUnitsMember_documentation_en-US" xlink:label="lab_wald_LimitedPartnershipUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Partnership Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_LimitedPartnershipUnitsMember" xlink:href="wald-20221231.xsd#wald_LimitedPartnershipUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_LimitedPartnershipUnitsMember" xlink:to="lab_wald_LimitedPartnershipUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2b7ec3b9-e0e0-4521-a3bc-a3d675dcf5eb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total antidilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_ec8c9d56-42bd-4a18-8e58-c21dd8b2b70e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAccountingStandard_85275e0d-de2c-4c0b-bcd7-18a0d4d89a01_terseLabel_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:label id="lab_dei_DocumentAccountingStandard_label_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard" xlink:to="lab_dei_DocumentAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_db96d0cc-3a3f-4d3f-9e73-1a6cf1cd5282_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_74006595-4d21-4b70-a83c-2a3a88d0f576_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_SponsorWarrantsMember_dbcc5787-6b09-4ca1-87de-53e7c6d91d91_terseLabel_en-US" xlink:label="lab_wald_SponsorWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sponsor Warrants</link:label>
    <link:label id="lab_wald_SponsorWarrantsMember_label_en-US" xlink:label="lab_wald_SponsorWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sponsor Warrants [Member]</link:label>
    <link:label id="lab_wald_SponsorWarrantsMember_documentation_en-US" xlink:label="lab_wald_SponsorWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sponsor Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SponsorWarrantsMember" xlink:href="wald-20221231.xsd#wald_SponsorWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_SponsorWarrantsMember" xlink:to="lab_wald_SponsorWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d2032755-3a7c-4224-967e-f90d382f1cc9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_0c265825-f6e7-4eb9-bb62-0abc664b8de8_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_c8e0eaeb-1a20-4938-a7ac-932b4a61df35_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_eb695203-98de-4d3b-90c1-912db9766f16_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9a4b8e2b-f400-494e-a339-c56f7e7318de_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities:</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_d49ec219-e9e3-497b-bb67-309aec38f306_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_4dbfaf76-6eea-4f15-bb68-ccc1a43cfd28_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a6dbf9ef-1481-472b-b296-5817b411406e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationLineItems_b1d8bcc1-ea30-4fe6-a761-a299866497ae_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationLineItems" xlink:to="lab_us-gaap_ReclassificationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7d453bdc-9657-4b08-9f19-49fadac7b892_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f408b743-06ce-4fd0-b891-25568746596b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_d93f2ada-032f-483e-8000-5b0c8ceb0cdd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_13a4f031-95a4-4177-a901-ae53a0dd454b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_c1de1b30-7bb5-4d9d-8162-c6cbebf5ddd9_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_aeaa76f1-e87a-4094-9141-e6fd32833f09_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses adjustments</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_SponsorMember_a8665561-747a-4d25-8db5-6ae9ee24eee0_terseLabel_en-US" xlink:label="lab_wald_SponsorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sponsor</link:label>
    <link:label id="lab_wald_SponsorMember_label_en-US" xlink:label="lab_wald_SponsorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sponsor [Member]</link:label>
    <link:label id="lab_wald_SponsorMember_documentation_en-US" xlink:label="lab_wald_SponsorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sponsor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SponsorMember" xlink:href="wald-20221231.xsd#wald_SponsorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_SponsorMember" xlink:to="lab_wald_SponsorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_a8d8854b-546f-402a-bcb4-19dceddd6a21_terseLabel_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate [Domain]</link:label>
    <link:label id="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_label_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ee35d124-a5da-4f62-8e69-d5b0e699d1ee_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_8fce8abc-64ac-49d6-be78-a8621aeda350_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_6710b8c0-77c7-46cb-b758-d370e22df482_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_955714d0-245c-4c11-b09a-3fb91526ef49_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recently Issued Accounting Standards, Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_9353b240-3c98-4404-96ef-7ca367eecf41_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_PredecessorIncentivePlanMember_d4575a41-b895-4dda-b36a-a59760ee6934_terseLabel_en-US" xlink:label="lab_wald_PredecessorIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Predecessor Incentive Plan</link:label>
    <link:label id="lab_wald_PredecessorIncentivePlanMember_label_en-US" xlink:label="lab_wald_PredecessorIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Predecessor Incentive Plan [Member]</link:label>
    <link:label id="lab_wald_PredecessorIncentivePlanMember_documentation_en-US" xlink:label="lab_wald_PredecessorIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Predecessor Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PredecessorIncentivePlanMember" xlink:href="wald-20221231.xsd#wald_PredecessorIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_PredecessorIncentivePlanMember" xlink:to="lab_wald_PredecessorIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_GainOnPPPLoanForgiveness_da1f316f-c93f-4cfb-b6eb-b56cd1e3fd65_negatedLabel_en-US" xlink:label="lab_wald_GainOnPPPLoanForgiveness" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on PPP Loan forgiveness (Note 8)</link:label>
    <link:label id="lab_wald_GainOnPPPLoanForgiveness_44cab6f6-b011-4d37-9638-834dbcfe3263_negatedTerseLabel_en-US" xlink:label="lab_wald_GainOnPPPLoanForgiveness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on PPP Loan forgiveness</link:label>
    <link:label id="lab_wald_GainOnPPPLoanForgiveness_label_en-US" xlink:label="lab_wald_GainOnPPPLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on PPP Loan Forgiveness</link:label>
    <link:label id="lab_wald_GainOnPPPLoanForgiveness_documentation_en-US" xlink:label="lab_wald_GainOnPPPLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on PPP Loan Forgiveness</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainOnPPPLoanForgiveness" xlink:href="wald-20221231.xsd#wald_GainOnPPPLoanForgiveness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_GainOnPPPLoanForgiveness" xlink:to="lab_wald_GainOnPPPLoanForgiveness" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_c8192e2d-058b-417a-b4b1-76b2fa03693a_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cc52c4f6-d32a-4b36-9d0b-1387f68a34e0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f847d609-060f-4852-ae3f-255509617960_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_c7dffbe5-ff60-46dc-b240-c3e71852247d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Consolidated Pretax Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_0b875543-f99b-46c3-9a1f-832a02e79467_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_eef8af5d-1eba-4fb2-861e-e6d8dca4074a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per unit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_3900ca70-f273-40a0-b9d6-19e246d11bce_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b96f46b9-c7b9-4ae0-a081-87b53c7c15dd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MilkMember_872b1db0-fbf5-4848-859b-c3fa04d38ecb_terseLabel_en-US" xlink:label="lab_wald_MilkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milk</link:label>
    <link:label id="lab_wald_MilkMember_label_en-US" xlink:label="lab_wald_MilkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milk [Member]</link:label>
    <link:label id="lab_wald_MilkMember_documentation_en-US" xlink:label="lab_wald_MilkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkMember" xlink:href="wald-20221231.xsd#wald_MilkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MilkMember" xlink:to="lab_wald_MilkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_73ee68a5-2a6f-4bdb-a3cc-a26c77469249_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_bc3d9446-c930-4bd9-b7bd-193d3f82fb3e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_5af039dc-1666-4f59-873a-7c7251c023f9_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_4ac3f3b4-e82e-475a-9dae-9a2c203949aa_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f6d7c001-a162-4d4b-8ce2-59422d043933_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions, Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6cd0e1cb-1cb4-4a82-bddc-afab13cfd468_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_23ae0bee-ba8e-408e-ac91-2767bab5e93a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0a0fc981-2853-4875-9fd3-ae5f062c88b7_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_8d82a9ca-e5df-4887-99d7-2137b76497fd_negatedLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SG&amp;A expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_c13f3408-a06a-4e3a-9dac-280dcbbf072b_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total SG&amp;A adjustments</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6ff2aa79-e442-4a93-ae24-8f6d0bcc72e3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_54ee2734-3360-4787-9287-dc5cc20a2113_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_db537248-b4a0-4b8c-8975-a00fdcf958c0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d13bd970-9c11-448b-ad2d-0a4151a88284_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_bfecf0ee-8b44-4eb0-8c18-1d5a0e6d3f6d_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ede04311-4bc0-4772-abbf-a7d6a74b66cc_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_AccruedSalesReturnsAndDamagesCurrent_248462d0-415d-46f9-bdf5-4cc3a037d105_terseLabel_en-US" xlink:label="lab_wald_AccruedSalesReturnsAndDamagesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued sales returns and damages</link:label>
    <link:label id="lab_wald_AccruedSalesReturnsAndDamagesCurrent_label_en-US" xlink:label="lab_wald_AccruedSalesReturnsAndDamagesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Returns And Damages, Current</link:label>
    <link:label id="lab_wald_AccruedSalesReturnsAndDamagesCurrent_documentation_en-US" xlink:label="lab_wald_AccruedSalesReturnsAndDamagesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Returns And Damages, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AccruedSalesReturnsAndDamagesCurrent" xlink:href="wald-20221231.xsd#wald_AccruedSalesReturnsAndDamagesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_AccruedSalesReturnsAndDamagesCurrent" xlink:to="lab_wald_AccruedSalesReturnsAndDamagesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_f05505fd-b286-4159-acd8-ba7c7be998c8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi and Milk Business Combinations</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_4d7c8a93-c10d-4a48-9abd-d75ac0b61eda_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ErrorCorrectionTextBlock_59d7ec4a-9e08-4e6f-86ed-e5240dbd91d1_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTATEMENT AND RECLASSIFICATIONS</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionTextBlock_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Correction [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionTextBlock" xlink:to="lab_us-gaap_ErrorCorrectionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_1023b70d-b41d-468a-9214-c823a5ba51e0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_269752a3-5722-4f06-be65-30c01e202757_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_VariableRateComponentThreeMember_4e8ee4ad-0040-42a2-898c-2039355e0334_terseLabel_en-US" xlink:label="lab_wald_VariableRateComponentThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component Three</link:label>
    <link:label id="lab_wald_VariableRateComponentThreeMember_label_en-US" xlink:label="lab_wald_VariableRateComponentThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component Three [Member]</link:label>
    <link:label id="lab_wald_VariableRateComponentThreeMember_documentation_en-US" xlink:label="lab_wald_VariableRateComponentThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VariableRateComponentThreeMember" xlink:href="wald-20221231.xsd#wald_VariableRateComponentThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_VariableRateComponentThreeMember" xlink:to="lab_wald_VariableRateComponentThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_19006cbf-7090-446e-a27b-0826b687d921_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_TransitionServicesAgreementPeriod_313d1d90-cc67-4ead-bb70-390d805f9c9e_terseLabel_en-US" xlink:label="lab_wald_TransitionServicesAgreementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services, initial term</link:label>
    <link:label id="lab_wald_TransitionServicesAgreementPeriod_label_en-US" xlink:label="lab_wald_TransitionServicesAgreementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Services Agreement Period</link:label>
    <link:label id="lab_wald_TransitionServicesAgreementPeriod_documentation_en-US" xlink:label="lab_wald_TransitionServicesAgreementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Services Agreement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_TransitionServicesAgreementPeriod" xlink:href="wald-20221231.xsd#wald_TransitionServicesAgreementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_TransitionServicesAgreementPeriod" xlink:to="lab_wald_TransitionServicesAgreementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_90a51a92-8d2d-4c7c-805c-60bd0ebd384d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_6f52193b-58b5-43e3-a914-1a9ca5d3c038_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties_9e667086-6107-4c81-b58e-a1f69f5f0911_terseLabel_en-US" xlink:label="lab_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties_label_en-US" xlink:label="lab_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Excluding Related Parties</link:label>
    <link:label id="lab_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties_documentation_en-US" xlink:label="lab_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Excluding Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties" xlink:href="wald-20221231.xsd#wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties" xlink:to="lab_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_45e390c9-a185-4318-a155-25775f6bdc4c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract_1eadef28-ff7a-47ce-a949-33b676f8807e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Purchase Price:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_SkintrinsiqDevicesMember_c3671606-ebb2-40f4-9515-18b6cc5c671c_terseLabel_en-US" xlink:label="lab_wald_SkintrinsiqDevicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skintrinsiq Devices</link:label>
    <link:label id="lab_wald_SkintrinsiqDevicesMember_label_en-US" xlink:label="lab_wald_SkintrinsiqDevicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skintrinsiq Devices [Member]</link:label>
    <link:label id="lab_wald_SkintrinsiqDevicesMember_documentation_en-US" xlink:label="lab_wald_SkintrinsiqDevicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skintrinsiq Devices</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SkintrinsiqDevicesMember" xlink:href="wald-20221231.xsd#wald_SkintrinsiqDevicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_SkintrinsiqDevicesMember" xlink:to="lab_wald_SkintrinsiqDevicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_44fc1361-6a7a-412e-9faa-67d3c1a3c750_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_e15a2561-633e-45f8-a11f-ee1cc804a434_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_c7a7362b-6505-4e81-894a-7135e6b19f9f_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_d359e6d9-4889-47a0-8c82-0c762581eeb7_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_2a97fa4f-ea3c-4abb-908c-b141228dbf29_verboseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Name</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_2457f704-64f4-44d9-a118-c62f55655707_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademark and trade name</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_d4b65206-477d-441d-8dfe-e0722f3aa641_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_9255f522-da3c-414c-b522-cd6967350ab5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_94b2ac5b-c885-4916-bad3-f06bdf67e6df_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_5e337309-b311-4e56-ac02-d9a425b6b28f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_7b76e798-a4ea-43dc-b4f8-9dbc691d4346_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7fd9e8db-e56d-4c1c-90c1-21a24f780a72_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_98c145a8-2c15-4160-b0aa-ae387f0575d7_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_7dab4328-e57d-4270-afdc-2579ac7da53c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BUSINESS COMBINATIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_3bf1de3d-3075-464d-9dc7-b540ca7c26a5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0b8d17e5-513d-422e-af3a-5dff0f3aacf2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares called by each warrant</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_ae41a09f-473e-42d2-a248-3997946ef9e0_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest in fully diluted Class A ordinary shares (percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_085f2e09-9dae-4f29-b854-2a6d2636f429_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding beginning balance, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55341091-3509-4f75-8534-cb8d643bbc1c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding ending balance, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_RestOfTheWorldMember_163c8d9d-f5d4-4356-b718-0d700685d076_terseLabel_en-US" xlink:label="lab_wald_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of the World</link:label>
    <link:label id="lab_wald_RestOfTheWorldMember_label_en-US" xlink:label="lab_wald_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of the World [Member]</link:label>
    <link:label id="lab_wald_RestOfTheWorldMember_documentation_en-US" xlink:label="lab_wald_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of the World</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_RestOfTheWorldMember" xlink:href="wald-20221231.xsd#wald_RestOfTheWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_RestOfTheWorldMember" xlink:to="lab_wald_RestOfTheWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_AccruedDistributionFeesCurrent_b75ac208-6bd9-4f44-8469-4e11f4dc46ef_terseLabel_en-US" xlink:label="lab_wald_AccruedDistributionFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued distribution fees</link:label>
    <link:label id="lab_wald_AccruedDistributionFeesCurrent_label_en-US" xlink:label="lab_wald_AccruedDistributionFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Distribution Fees, Current</link:label>
    <link:label id="lab_wald_AccruedDistributionFeesCurrent_documentation_en-US" xlink:label="lab_wald_AccruedDistributionFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Distribution Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AccruedDistributionFeesCurrent" xlink:href="wald-20221231.xsd#wald_AccruedDistributionFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_AccruedDistributionFeesCurrent" xlink:to="lab_wald_AccruedDistributionFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_PublicWarrantsMember_0b817b56-1dd0-4e2d-b163-9fea6a4b8c69_terseLabel_en-US" xlink:label="lab_wald_PublicWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Warrants</link:label>
    <link:label id="lab_wald_PublicWarrantsMember_label_en-US" xlink:label="lab_wald_PublicWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Warrants [Member]</link:label>
    <link:label id="lab_wald_PublicWarrantsMember_documentation_en-US" xlink:label="lab_wald_PublicWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PublicWarrantsMember" xlink:href="wald-20221231.xsd#wald_PublicWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_PublicWarrantsMember" xlink:to="lab_wald_PublicWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_c64302eb-a2ba-4f55-930a-523119597ff4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory reserve</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_1850e642-6a97-4aa4-95ac-7d775d4860ca_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_587a0ebb-ae9e-499c-b54b-8a1e44709ea3_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_04cb2328-0c6c-44b7-9b83-7941f6ca8575_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_1744e8d4-e535-46c2-a4d8-c41370b0a7de_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_19b96f18-3515-491e-95fc-71b1b97f7f81_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_39f381ff-4c5e-47bd-a394-82b28d90d1df_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_StockIssuedDuringPeriodValueTrustProceeds_52b0833e-15a8-4564-85a0-3ce88b6ee85a_terseLabel_en-US" xlink:label="lab_wald_StockIssuedDuringPeriodValueTrustProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A ordinary shares upon release of Trust proceeds</link:label>
    <link:label id="lab_wald_StockIssuedDuringPeriodValueTrustProceeds_label_en-US" xlink:label="lab_wald_StockIssuedDuringPeriodValueTrustProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Trust Proceeds</link:label>
    <link:label id="lab_wald_StockIssuedDuringPeriodValueTrustProceeds_documentation_en-US" xlink:label="lab_wald_StockIssuedDuringPeriodValueTrustProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Trust Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockIssuedDuringPeriodValueTrustProceeds" xlink:href="wald-20221231.xsd#wald_StockIssuedDuringPeriodValueTrustProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_StockIssuedDuringPeriodValueTrustProceeds" xlink:to="lab_wald_StockIssuedDuringPeriodValueTrustProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_USOnlineMarketplaceDistributorMember_099b245b-36bd-4fb8-a4e4-791eb7960ea7_terseLabel_en-US" xlink:label="lab_wald_USOnlineMarketplaceDistributorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Online Marketplace Distributor</link:label>
    <link:label id="lab_wald_USOnlineMarketplaceDistributorMember_label_en-US" xlink:label="lab_wald_USOnlineMarketplaceDistributorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Online Marketplace Distributor [Member]</link:label>
    <link:label id="lab_wald_USOnlineMarketplaceDistributorMember_documentation_en-US" xlink:label="lab_wald_USOnlineMarketplaceDistributorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Online Marketplace Distributor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_USOnlineMarketplaceDistributorMember" xlink:href="wald-20221231.xsd#wald_USOnlineMarketplaceDistributorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_USOnlineMarketplaceDistributorMember" xlink:to="lab_wald_USOnlineMarketplaceDistributorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_StockholdersEquityNumberOfSharesInEachUnit_a66f3acd-50ff-4fb2-bf4a-f35ebef38bc8_terseLabel_en-US" xlink:label="lab_wald_StockholdersEquityNumberOfSharesInEachUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares in each IPO unit</link:label>
    <link:label id="lab_wald_StockholdersEquityNumberOfSharesInEachUnit_label_en-US" xlink:label="lab_wald_StockholdersEquityNumberOfSharesInEachUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Number Of Shares In Each Unit</link:label>
    <link:label id="lab_wald_StockholdersEquityNumberOfSharesInEachUnit_documentation_en-US" xlink:label="lab_wald_StockholdersEquityNumberOfSharesInEachUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Number Of Shares In Each Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockholdersEquityNumberOfSharesInEachUnit" xlink:href="wald-20221231.xsd#wald_StockholdersEquityNumberOfSharesInEachUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_StockholdersEquityNumberOfSharesInEachUnit" xlink:to="lab_wald_StockholdersEquityNumberOfSharesInEachUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_fa4ff085-7f3d-4bb2-80b6-fa24c56e4e30_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_29b754b7-2682-4448-ba33-2b779a5d5679_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensed products</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors_18d59794-cc06-406f-a790-178fb8e294e2_terseLabel_en-US" xlink:label="lab_wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distributors</link:label>
    <link:label id="lab_wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors_label_en-US" xlink:label="lab_wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement Adjustments, Revenue Recognition, Number of Distributors</link:label>
    <link:label id="lab_wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors_documentation_en-US" xlink:label="lab_wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement Adjustments, Revenue Recognition, Number of Distributors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors" xlink:href="wald-20221231.xsd#wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors" xlink:to="lab_wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_7cdd062e-05b9-4c6b-a833-f974186490dc_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_2b1f22dc-4153-448f-a3e9-d625de6b89a1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_6879f088-504f-4734-b29e-db50e03ff55e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a0b69aad-5907-4a35-a717-885e18628be7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9b757f90-c943-41f4-a852-ffe443133e0c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7b10bf5f-8432-4480-bcda-664186a333e3_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent_49fb4d4e-dac7-4f71-ac68-16ef37a69f88_terseLabel_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of award vesting period</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent_label_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period, Percent</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent_documentation_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent" xlink:to="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_517fc519-45d0-4900-877e-3ef358552a8d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_d7cccc90-aeb9-4702-8a14-9185d72c6e50_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_16d420ab-0529-439b-89aa-6117a6e33715_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Deferred Tax Assets and Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_7f14833d-038b-4f91-b4c9-efad0b5c2d59_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_934cbeb0-f431-4bdb-80c1-4840b4a053a2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6f367295-0069-44c0-80be-6467fc1218cb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9679be03-27b4-4a47-a911-e52a653a2df7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_NumberOfNominatedDirectors_81cd9d6d-924a-4516-9da2-c3474a078083_terseLabel_en-US" xlink:label="lab_wald_NumberOfNominatedDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of nominated directors</link:label>
    <link:label id="lab_wald_NumberOfNominatedDirectors_label_en-US" xlink:label="lab_wald_NumberOfNominatedDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Nominated Directors</link:label>
    <link:label id="lab_wald_NumberOfNominatedDirectors_documentation_en-US" xlink:label="lab_wald_NumberOfNominatedDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Nominated Directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_NumberOfNominatedDirectors" xlink:href="wald-20221231.xsd#wald_NumberOfNominatedDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_NumberOfNominatedDirectors" xlink:to="lab_wald_NumberOfNominatedDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_a37e15ff-acbd-401b-9f8f-7ad3f1d84a16_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_c0971503-c8c3-403d-9ebd-b7e565e84a0d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities:</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f6cd23ae-f23d-4f54-9d72-948c5c1aa4ca_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ac2f78b6-78da-43bc-8e89-dfecc32fd4e3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_61c0d296-2bce-4f50-8dc9-7accefd7d6e2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_PrivateDerivativeWarrantLiabilitiesMember_287494e9-131f-43c3-8a43-d1d886c34c22_terseLabel_en-US" xlink:label="lab_wald_PrivateDerivativeWarrantLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative warrant liabilities - Private</link:label>
    <link:label id="lab_wald_PrivateDerivativeWarrantLiabilitiesMember_label_en-US" xlink:label="lab_wald_PrivateDerivativeWarrantLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Derivative Warrant Liabilities [Member]</link:label>
    <link:label id="lab_wald_PrivateDerivativeWarrantLiabilitiesMember_documentation_en-US" xlink:label="lab_wald_PrivateDerivativeWarrantLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Derivative Warrant Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PrivateDerivativeWarrantLiabilitiesMember" xlink:href="wald-20221231.xsd#wald_PrivateDerivativeWarrantLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_PrivateDerivativeWarrantLiabilitiesMember" xlink:to="lab_wald_PrivateDerivativeWarrantLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_887e99c2-0261-467b-9fe1-98483d2a4da1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_c684e877-2a9c-40fc-9e9f-481bae65d3e3_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm_f10be8b2-aee2-4f20-80ca-948863e70a45_terseLabel_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, weighted average remaining contractual life</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeiture In Period, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeiture In Period, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm" xlink:to="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays_666ffb63-316f-4993-ab9b-af92371bc01a_terseLabel_en-US" xlink:label="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lock-up shares, threshold trading days</link:label>
    <link:label id="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays_label_en-US" xlink:label="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Trading Days</link:label>
    <link:label id="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays_documentation_en-US" xlink:label="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays" xlink:href="wald-20221231.xsd#wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays" xlink:to="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_8e980906-0f49-4b3a-a74e-dbbb859e953e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_7f87087c-45d2-4fe5-bab4-7ac808f140e8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays_26275228-2a64-4a47-8227-5554288d1f0c_terseLabel_en-US" xlink:label="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lock-up shares, threshold consecutive trading days</link:label>
    <link:label id="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays_label_en-US" xlink:label="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays_documentation_en-US" xlink:label="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays" xlink:href="wald-20221231.xsd#wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays" xlink:to="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_InvestorDirectorsMember_2fc46f4a-5f55-4135-8579-6decaa697f52_terseLabel_en-US" xlink:label="lab_wald_InvestorDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor Directors</link:label>
    <link:label id="lab_wald_InvestorDirectorsMember_label_en-US" xlink:label="lab_wald_InvestorDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor Directors [Member]</link:label>
    <link:label id="lab_wald_InvestorDirectorsMember_documentation_en-US" xlink:label="lab_wald_InvestorDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investor Directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_InvestorDirectorsMember" xlink:href="wald-20221231.xsd#wald_InvestorDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_InvestorDirectorsMember" xlink:to="lab_wald_InvestorDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6f8dfb6c-0d19-48ec-95e8-b72b6d1cf4da_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember_5e945e62-0dda-49d5-a2b3-0a455342c508_terseLabel_en-US" xlink:label="lab_wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Revenue, Nonstandard Payment Terms</link:label>
    <link:label id="lab_wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember_label_en-US" xlink:label="lab_wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Distributor Revenue, Nonstandard Payment Terms [Member]</link:label>
    <link:label id="lab_wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember_documentation_en-US" xlink:label="lab_wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Distributor Revenue, Nonstandard Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember" xlink:href="wald-20221231.xsd#wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember" xlink:to="lab_wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_aa0012a6-1723-4c85-8432-f477506d289c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_NumberOfOperatingLeases_fd4e34cd-d182-477a-bca8-f815da4e7894_terseLabel_en-US" xlink:label="lab_wald_NumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of non-cancelable operating leases</link:label>
    <link:label id="lab_wald_NumberOfOperatingLeases_label_en-US" xlink:label="lab_wald_NumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Leases</link:label>
    <link:label id="lab_wald_NumberOfOperatingLeases_documentation_en-US" xlink:label="lab_wald_NumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_NumberOfOperatingLeases" xlink:href="wald-20221231.xsd#wald_NumberOfOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_NumberOfOperatingLeases" xlink:to="lab_wald_NumberOfOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_bebd0e22-bba0-400e-b0f8-fe0cc94c0767_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elimination of Predecessor goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_6b5eb27b-8492-417c-bdd6-3f4474b0ca93_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative warrant liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_1f223f02-2546-4731-8460-a035bade9f58_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of term loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_6b4597b4-2039-4169-8e53-38a0d3596262_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_f3fa3edd-9890-4a29-87bb-afbef6db2a3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_71874b73-e755-4f47-a6d6-5b95d87ea56f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_8dbfd0e7-4779-4f18-a45b-1d1298a28e76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_90bb5536-a1de-4307-b0eb-7ac5193c0ec2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LIABILITIES</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_9c499786-0327-4f12-8258-d9445f5359b5_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provision (benefit), total</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5775741c-85ff-4daf-acac-17a0595ba2c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentShellCompanyReport_e1a6472a-0e82-43f9-b50b-64944051540a_terseLabel_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:label id="lab_dei_DocumentShellCompanyReport_label_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport" xlink:to="lab_dei_DocumentShellCompanyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9b09f5e7-14d3-4351-bdc9-ecc5a69eb801_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_4675aadb-fa1c-46ae-875d-0abafe558825_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableMember_44ae547c-6ba9-4adf-94ed-ef8dfce3e6c7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableMember_label_en-US" xlink:label="lab_us-gaap_AccountsPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableMember" xlink:to="lab_us-gaap_AccountsPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_66cce11a-74f4-49cc-b8e2-93d2ee0e6f3a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NorthAmericaMember_221b1d7b-1067-4754-acee-0c8aef9d5f6e_terseLabel_en-US" xlink:label="lab_srt_NorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">North America</link:label>
    <link:label id="lab_srt_NorthAmericaMember_label_en-US" xlink:label="lab_srt_NorthAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">North America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NorthAmericaMember" xlink:to="lab_srt_NorthAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_fb5aa0bc-aa1e-4e72-bd73-2c9066f6a8be_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income:</link:label>
    <link:label id="lab_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income, Nonoperating [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeDisclosureNonoperatingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:to="lab_us-gaap_OtherIncomeDisclosureNonoperatingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_a1d22419-25d3-449e-8041-3907d7b6d3cc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_PaymentsOfExpensesOnBehalfOfSubsidiaries_122c6ca3-c29c-4331-81b1-8ffcb823baf2_negatedTerseLabel_en-US" xlink:label="lab_wald_PaymentsOfExpensesOnBehalfOfSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses paid on behalf of subsidiaries</link:label>
    <link:label id="lab_wald_PaymentsOfExpensesOnBehalfOfSubsidiaries_label_en-US" xlink:label="lab_wald_PaymentsOfExpensesOnBehalfOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Expenses On Behalf Of Subsidiaries</link:label>
    <link:label id="lab_wald_PaymentsOfExpensesOnBehalfOfSubsidiaries_documentation_en-US" xlink:label="lab_wald_PaymentsOfExpensesOnBehalfOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Expenses On Behalf Of Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PaymentsOfExpensesOnBehalfOfSubsidiaries" xlink:href="wald-20221231.xsd#wald_PaymentsOfExpensesOnBehalfOfSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_PaymentsOfExpensesOnBehalfOfSubsidiaries" xlink:to="lab_wald_PaymentsOfExpensesOnBehalfOfSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_e1b2b5a1-ef96-4767-8573-44504e330ee5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_34a27179-17f2-40e3-b6bf-6278f894fb81_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Software and Website Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_f2389d13-4705-4772-925e-9b56135a2e97_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue_8f73d142-05fc-4096-a9f8-3fb9e39e48a0_terseLabel_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercised, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercised, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue" xlink:to="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_IndemnificationAgreementAdvanceExpensePeriod_f0752fb2-0b08-476d-83eb-81320a962f24_terseLabel_en-US" xlink:label="lab_wald_IndemnificationAgreementAdvanceExpensePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification agreement, advancement period</link:label>
    <link:label id="lab_wald_IndemnificationAgreementAdvanceExpensePeriod_label_en-US" xlink:label="lab_wald_IndemnificationAgreementAdvanceExpensePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Agreement, Advance Expense Period</link:label>
    <link:label id="lab_wald_IndemnificationAgreementAdvanceExpensePeriod_documentation_en-US" xlink:label="lab_wald_IndemnificationAgreementAdvanceExpensePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Agreement, Advance Expense Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_IndemnificationAgreementAdvanceExpensePeriod" xlink:href="wald-20221231.xsd#wald_IndemnificationAgreementAdvanceExpensePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_IndemnificationAgreementAdvanceExpensePeriod" xlink:to="lab_wald_IndemnificationAgreementAdvanceExpensePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_NonConvertibleWorkingCapitalNotesMember_7175d765-c8bb-4a20-9eb2-5e97c1d2bcf4_terseLabel_en-US" xlink:label="lab_wald_NonConvertibleWorkingCapitalNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Convertible Working Capital Notes</link:label>
    <link:label id="lab_wald_NonConvertibleWorkingCapitalNotesMember_label_en-US" xlink:label="lab_wald_NonConvertibleWorkingCapitalNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Convertible Working Capital Notes [Member]</link:label>
    <link:label id="lab_wald_NonConvertibleWorkingCapitalNotesMember_documentation_en-US" xlink:label="lab_wald_NonConvertibleWorkingCapitalNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Convertible Working Capital Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_NonConvertibleWorkingCapitalNotesMember" xlink:href="wald-20221231.xsd#wald_NonConvertibleWorkingCapitalNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_NonConvertibleWorkingCapitalNotesMember" xlink:to="lab_wald_NonConvertibleWorkingCapitalNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_548ca3c8-9db1-445d-981f-cc648e19ffb6_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_850ca289-2107-48d8-a005-983a99a4f8a7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_64191b92-fa1b-42dd-bd8d-713770ce311c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_a2c8e34a-9692-4656-a850-ecc46d726220_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum payment</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_d0fa6d65-9869-4028-b5ee-2f100e3ff981_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_d0d14745-d0f4-4401-93b5-059dc912ae49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_01bb46ce-d044-4328-929f-2aa345f9f62b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments_33aa7181-6293-4c0c-9d10-1c01c7362d42_terseLabel_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of quarterly installments</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments_label_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Quarterly Installments</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments_documentation_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Quarterly Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments" xlink:to="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_SecuredOvernightFinancingRateSOFRMember_753a2334-b906-42cc-951b-6a4efc390403_terseLabel_en-US" xlink:label="lab_wald_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:label id="lab_wald_SecuredOvernightFinancingRateSOFRMember_label_en-US" xlink:label="lab_wald_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:label id="lab_wald_SecuredOvernightFinancingRateSOFRMember_documentation_en-US" xlink:label="lab_wald_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SecuredOvernightFinancingRateSOFRMember" xlink:href="wald-20221231.xsd#wald_SecuredOvernightFinancingRateSOFRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_SecuredOvernightFinancingRateSOFRMember" xlink:to="lab_wald_SecuredOvernightFinancingRateSOFRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_fbf46196-5d9e-4a6d-9989-c231d896ef7a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_184bb7b9-96fd-448e-8cc5-497f2790f622_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provision (benefit):</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_684132ce-e1d6-4add-a286-1eaf0007a9e3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_f157709d-7d31-464f-a8eb-1f22606da006_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax benefit, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc93ef99-937d-4aea-97f2-a32f239fd9d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination_42cf1b71-4215-42f0-bd78-76175305520a_terseLabel_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise period</link:label>
    <link:label id="lab_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination_label_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Period After Completion of Business Combination</link:label>
    <link:label id="lab_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination_documentation_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Period After Completion of Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination" xlink:to="lab_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6005218c-fe57-4b01-a26d-4effc9324dd5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_40d0cf8e-e907-4e5c-9dbf-8d3a470cc50f_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_A2021TermLoanMember_072ac635-a4c8-419d-9cf5-a472d85069f8_terseLabel_en-US" xlink:label="lab_wald_A2021TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Predecessor 2021 Term Loan</link:label>
    <link:label id="lab_wald_A2021TermLoanMember_label_en-US" xlink:label="lab_wald_A2021TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Term Loan [Member]</link:label>
    <link:label id="lab_wald_A2021TermLoanMember_documentation_en-US" xlink:label="lab_wald_A2021TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2021TermLoanMember" xlink:href="wald-20221231.xsd#wald_A2021TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_A2021TermLoanMember" xlink:to="lab_wald_A2021TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_55390a57-0cda-49b7-9dde-1e5c545fb149_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_6a255a39-1c21-4071-8840-a3c7bf793e1c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_35a40ce7-5513-4c34-9c63-020f5b9e40b5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_LineOfCreditCovenantTermsMinimumLiquidity_1a116c75-43a3-4c3e-aeda-bb532e41d601_terseLabel_en-US" xlink:label="lab_wald_LineOfCreditCovenantTermsMinimumLiquidity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum liquidity covenant</link:label>
    <link:label id="lab_wald_LineOfCreditCovenantTermsMinimumLiquidity_label_en-US" xlink:label="lab_wald_LineOfCreditCovenantTermsMinimumLiquidity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Covenant Terms, Minimum Liquidity</link:label>
    <link:label id="lab_wald_LineOfCreditCovenantTermsMinimumLiquidity_documentation_en-US" xlink:label="lab_wald_LineOfCreditCovenantTermsMinimumLiquidity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Covenant Terms, Minimum Liquidity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_LineOfCreditCovenantTermsMinimumLiquidity" xlink:href="wald-20221231.xsd#wald_LineOfCreditCovenantTermsMinimumLiquidity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_LineOfCreditCovenantTermsMinimumLiquidity" xlink:to="lab_wald_LineOfCreditCovenantTermsMinimumLiquidity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromOtherDebt_ba935048-c974-476b-9c9f-ee9ca6c43fb3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from PPP Loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromOtherDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Other Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherDebt" xlink:to="lab_us-gaap_ProceedsFromOtherDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_3d74ac5b-37ef-4d0e-b5c7-aa8f52d7dc72_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued salaries and related expenses</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_51cf6296-a0c9-4d41-ae8a-520f0a2ff03b_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_1c77f539-9a1b-4d3d-be30-b2800d583b37_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityDecreaseForgiveness1_39184190-3700-4877-928b-5dfbc4e8e284_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityDecreaseForgiveness1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, forgiveness</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityDecreaseForgiveness1_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityDecreaseForgiveness1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Decrease, Forgiveness</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityDecreaseForgiveness1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityDecreaseForgiveness1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityDecreaseForgiveness1" xlink:to="lab_us-gaap_LineOfCreditFacilityDecreaseForgiveness1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_be7b3af3-1468-4564-bb02-87e2f56a27c9_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_21fcc551-038b-42e9-9f13-5ca7f32f1574_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma net revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_a9f85f88-80d5-4346-bb07-21096361b119_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_b0442cda-50df-4f5b-833c-3f47e4526943_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_4d668bc2-d71e-4f7f-97ce-74106c904435_negatedNetLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_96530b78-d859-4701-a968-18deba28bee9_netLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_8c7cbe3c-52cb-4a78-a6ca-561f93166af1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Waldencast LP</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_e5d0d354-67d9-4a1b-b30d-2f8a2886952e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_4f1af56f-f56e-431b-af5c-5414bb5e9298_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91930226-6da1-433a-8fdd-75fa5d2ed654_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_RoyaltyPercentageOfGrossSales_581d8fce-b998-4bbb-ac6c-28d68aefb61d_terseLabel_en-US" xlink:label="lab_wald_RoyaltyPercentageOfGrossSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty percentage</link:label>
    <link:label id="lab_wald_RoyaltyPercentageOfGrossSales_label_en-US" xlink:label="lab_wald_RoyaltyPercentageOfGrossSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Percentage of Gross Sales</link:label>
    <link:label id="lab_wald_RoyaltyPercentageOfGrossSales_documentation_en-US" xlink:label="lab_wald_RoyaltyPercentageOfGrossSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Percentage of Gross Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_RoyaltyPercentageOfGrossSales" xlink:href="wald-20221231.xsd#wald_RoyaltyPercentageOfGrossSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_RoyaltyPercentageOfGrossSales" xlink:to="lab_wald_RoyaltyPercentageOfGrossSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_592ac782-0dda-426c-beb2-f7f968add9b6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_911a2b2b-c4bb-4389-a7da-b5ff6f52a465_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_4f69ec86-6dab-4e34-a5e2-4d714695d4e2_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Statement of Cash Flow</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Cash Flow Statement [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:to="lab_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a82498c5-c02b-430d-a39c-05757598f61b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_95f6b9f1-d283-4671-bbd0-be100273418a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_90191eca-485b-48fc-9c0e-998a2e067607_terseLabel_en-US" xlink:label="lab_wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_label_en-US" xlink:label="lab_wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Transaction Costs, Percent</link:label>
    <link:label id="lab_wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_documentation_en-US" xlink:label="lab_wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Transaction Costs, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" xlink:href="wald-20221231.xsd#wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" xlink:to="lab_wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_185989bc-7067-4741-95e2-bf11ed3b4783_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per share (Note 15):</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_e043497b-5694-4de7-8f1e-d49e2b741b6c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7d8616fa-b629-44f7-87bd-5a3232255d53_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_71856930-1d63-449d-8ae1-b940ac332d8d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_96efdcb8-306b-46a3-8889-bb5c36b030ee_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities assumed:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_CustomerThreeMember_439bf817-134f-40e5-820a-3ac1d1ab8321_terseLabel_en-US" xlink:label="lab_wald_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Three</link:label>
    <link:label id="lab_wald_CustomerThreeMember_label_en-US" xlink:label="lab_wald_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:label id="lab_wald_CustomerThreeMember_documentation_en-US" xlink:label="lab_wald_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CustomerThreeMember" xlink:href="wald-20221231.xsd#wald_CustomerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_CustomerThreeMember" xlink:to="lab_wald_CustomerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8d514f06-04a5-4075-a9db-5faa645c45d5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_8c559ab4-311c-43dc-b0dc-7809f3e8fc95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_913ad4e4-5852-4876-aae9-db869c9469a5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_cd89c467-7d0f-4168-ac5e-bd6098cad696_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_fbb5ed16-c3f0-440b-885a-5eb2a660b643_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_1b7cb08d-40d9-43d6-b3f7-1313855f1746_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ParentCompanyMember_4fd7f9ba-7164-4f3e-89fa-0fe46f25ff5c_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company</link:label>
    <link:label id="lab_srt_ParentCompanyMember_label_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember" xlink:to="lab_srt_ParentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7b01bd23-8292-4628-a50f-d1003aa6f977_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b15215fb-227f-42e9-b4cb-ddde68dd42ea_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_291b63b7-e04c-4992-9d02-9433445a5e9f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e511ce3c-a762-4a35-95f7-fee761cee7fa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_3a833dc9-2159-4b38-bf4d-10365867872f_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_86cc231a-56b4-49d5-8735-ce5566ab9a50_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of derivative asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_bd62869b-bfbe-48bc-8e26-1f8e5c85a531_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_2a8d3c0c-f427-45fa-8704-987f86470c46_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7666bc0f-aa4d-481f-b129-60337fb0c04e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b1aad966-475c-49c5-b44d-63dd187a885e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bf1187fa-e4de-4c30-95b8-855600f7e1c3_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0b22035e-df01-477e-950b-cfb472aabfaf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accumulated deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MilkTransactionMember_773301ea-122f-4009-bc22-8ed3ce039d80_verboseLabel_en-US" xlink:label="lab_wald_MilkTransactionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milk</link:label>
    <link:label id="lab_wald_MilkTransactionMember_1a246655-ae0e-419a-81de-6af29789c257_terseLabel_en-US" xlink:label="lab_wald_MilkTransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milk Transaction</link:label>
    <link:label id="lab_wald_MilkTransactionMember_label_en-US" xlink:label="lab_wald_MilkTransactionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milk Transaction [Member]</link:label>
    <link:label id="lab_wald_MilkTransactionMember_documentation_en-US" xlink:label="lab_wald_MilkTransactionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milk Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkTransactionMember" xlink:href="wald-20221231.xsd#wald_MilkTransactionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MilkTransactionMember" xlink:to="lab_wald_MilkTransactionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_98317776-5f52-4bc4-ba6b-337d76a9990a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_61bddd08-43e8-492f-817f-62c12e4b1e86_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0453af3b-0751-46d1-a98e-6cc5f7b64141_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ee94aa9b-3c60-4b95-ac09-0ed37a325c90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net adjustments</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_873cf947-1c8e-4611-ac21-3e113f344509_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedBalanceSheetStatementTable_e40e4434-da70-4955-87cb-8c820d1380df_terseLabel_en-US" xlink:label="lab_srt_CondensedBalanceSheetStatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Balance Sheet Statement [Table]</link:label>
    <link:label id="lab_srt_CondensedBalanceSheetStatementTable_label_en-US" xlink:label="lab_srt_CondensedBalanceSheetStatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Balance Sheet Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedBalanceSheetStatementTable" xlink:to="lab_srt_CondensedBalanceSheetStatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesChannelDirectlyToConsumerMember_0368909b-4c39-49c1-8da2-b97d0cbaf28f_terseLabel_en-US" xlink:label="lab_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct sales</link:label>
    <link:label id="lab_us-gaap_SalesChannelDirectlyToConsumerMember_label_en-US" xlink:label="lab_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Channel, Directly to Consumer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:to="lab_us-gaap_SalesChannelDirectlyToConsumerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_18ecc380-459a-4dc7-925a-55d33fef188b_terseLabel_en-US" xlink:label="lab_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Revenue Recognition Timing and Payments Recorded for Services</link:label>
    <link:label id="lab_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_label_en-US" xlink:label="lab_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Revenue Recognition Timing and Payments Recorded for Services [Member]</link:label>
    <link:label id="lab_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_documentation_en-US" xlink:label="lab_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Revenue Recognition Timing and Payments Recorded for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember" xlink:href="wald-20221231.xsd#wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember" xlink:to="lab_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_ace517e2-94fc-4304-b9f0-38b37196e83a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue_6aac9f51-191a-4aea-bf7e-9fa9a4375c5b_terseLabel_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, aggregate intrinsic value</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue_label_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Intrinsic Value</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue_documentation_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" xlink:to="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_BusinessContactMember_b01cee2a-08bb-4f1b-a5f0-72daa28c75b3_terseLabel_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Contact</link:label>
    <link:label id="lab_dei_BusinessContactMember_label_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Contact [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c32fdf4e-9eea-4400-a537-b88ecdbf67d6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e1e5a90b-4cca-4e25-82d0-e85a61d42a4c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory note</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_d45818a9-dc5c-4d28-ad1a-973d8557fbe4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c045686b-8dec-497d-8b17-0a421f412fc9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_291d30df-1912-4e09-8065-d49638c63852_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other temporary differences</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ReplacementAwardsMember_29c91913-6264-480c-a514-3ba6506467b9_terseLabel_en-US" xlink:label="lab_wald_ReplacementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Replacement Awards</link:label>
    <link:label id="lab_wald_ReplacementAwardsMember_label_en-US" xlink:label="lab_wald_ReplacementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Replacement Awards [Member]</link:label>
    <link:label id="lab_wald_ReplacementAwardsMember_documentation_en-US" xlink:label="lab_wald_ReplacementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Replacement Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ReplacementAwardsMember" xlink:href="wald-20221231.xsd#wald_ReplacementAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ReplacementAwardsMember" xlink:to="lab_wald_ReplacementAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_b51b482e-5c6d-47f9-a40a-5c6c9f8db374_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8f55b114-6996-4871-94d5-c8637772aef5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_421f0df3-6469-4f91-b551-44461467ab79_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_20d73f09-7c43-4b56-9a46-cfe0556921f7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_cbc43122-3ee9-4779-9872-f8e1f46eec1e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_216dc501-c781-453c-bf85-03b122a65d7d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_b0eb4185-6c47-401c-8297-23dde1878cd2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_2e9a2cb8-209f-4bd1-8764-595cea414b90_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_462fea04-ec35-411c-94b5-92cca340d31a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_606b991e-5b2d-4bdd-a3de-6c0cb6bd1078_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_DeferredTaxAssetsFormationCosts_de4e9309-ab17-40f0-9e11-dd18b6441301_terseLabel_en-US" xlink:label="lab_wald_DeferredTaxAssetsFormationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Formation costs</link:label>
    <link:label id="lab_wald_DeferredTaxAssetsFormationCosts_label_en-US" xlink:label="lab_wald_DeferredTaxAssetsFormationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Formation Costs</link:label>
    <link:label id="lab_wald_DeferredTaxAssetsFormationCosts_documentation_en-US" xlink:label="lab_wald_DeferredTaxAssetsFormationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Formation Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DeferredTaxAssetsFormationCosts" xlink:href="wald-20221231.xsd#wald_DeferredTaxAssetsFormationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_DeferredTaxAssetsFormationCosts" xlink:to="lab_wald_DeferredTaxAssetsFormationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_49f63a0b-cf3b-4c4f-8906-858f9410d73d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_797487e3-b1af-4918-b087-1125460b5ccb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b3935fd9-0ff7-4f78-8089-4132c0bf584f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_b80d4602-3767-431b-864b-a5ee341cfba1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MilkMakeupMember_5a096085-e3ea-4f68-8345-0991ac7b1330_verboseLabel_en-US" xlink:label="lab_wald_MilkMakeupMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milk&#160;</link:label>
    <link:label id="lab_wald_MilkMakeupMember_d2ec3bf7-2f50-4851-8e2c-ec663bf5e70c_terseLabel_en-US" xlink:label="lab_wald_MilkMakeupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milk Makeup</link:label>
    <link:label id="lab_wald_MilkMakeupMember_label_en-US" xlink:label="lab_wald_MilkMakeupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milk Makeup [Member]</link:label>
    <link:label id="lab_wald_MilkMakeupMember_documentation_en-US" xlink:label="lab_wald_MilkMakeupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milk Makeup</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkMakeupMember" xlink:href="wald-20221231.xsd#wald_MilkMakeupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MilkMakeupMember" xlink:to="lab_wald_MilkMakeupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_DeferredTaxAssetsTransactionCosts_fb8444f9-23c0-4147-a016-f35821ce16fd_terseLabel_en-US" xlink:label="lab_wald_DeferredTaxAssetsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_wald_DeferredTaxAssetsTransactionCosts_label_en-US" xlink:label="lab_wald_DeferredTaxAssetsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Transaction Costs</link:label>
    <link:label id="lab_wald_DeferredTaxAssetsTransactionCosts_documentation_en-US" xlink:label="lab_wald_DeferredTaxAssetsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DeferredTaxAssetsTransactionCosts" xlink:href="wald-20221231.xsd#wald_DeferredTaxAssetsTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_DeferredTaxAssetsTransactionCosts" xlink:to="lab_wald_DeferredTaxAssetsTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1c55a53f-f973-4a54-868f-2e78c1616b10_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent_ae2270a1-0dc8-4b08-b85c-54d58a2f94ac_terseLabel_en-US" xlink:label="lab_wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and notes receivable, before allowance for doubtful accounts</link:label>
    <link:label id="lab_wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent_label_en-US" xlink:label="lab_wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable and Notes Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:label id="lab_wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent_documentation_en-US" xlink:label="lab_wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable and Notes Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent" xlink:href="wald-20221231.xsd#wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent" xlink:to="lab_wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_bf04fe17-4007-4fc5-bb21-58035fa476ca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_e84dc011-c6e7-4e9e-94fb-bc25027af022_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_f7b5fa0c-73bb-4a71-bfb1-eec94a1e4589_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_29e4e260-f488-480d-ba80-c60486d07681_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from term loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_57ced496-c868-4de8-afa4-262b6b4230cd_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesChannelThroughIntermediaryMember_c5050ad3-f319-4222-8385-c1f1bc7e9975_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor fees for services</link:label>
    <link:label id="lab_us-gaap_SalesChannelThroughIntermediaryMember_80ed6955-4018-4d68-b885-49623a73b408_terseLabel_en-US" xlink:label="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributors</link:label>
    <link:label id="lab_us-gaap_SalesChannelThroughIntermediaryMember_label_en-US" xlink:label="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Channel, Through Intermediary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesChannelThroughIntermediaryMember" xlink:to="lab_us-gaap_SalesChannelThroughIntermediaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_873d361d-202a-4871-8452-a6f8691aff62_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_b0feba3d-2b7a-442d-89bc-dbc1d1c2e173_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ConversionOfStockToCommonStockConversionRatio_47b0aa6a-d214-4886-897e-93a24e286db2_terseLabel_en-US" xlink:label="lab_wald_ConversionOfStockToCommonStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock conversion ratio</link:label>
    <link:label id="lab_wald_ConversionOfStockToCommonStockConversionRatio_label_en-US" xlink:label="lab_wald_ConversionOfStockToCommonStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock to Common Stock, Conversion Ratio</link:label>
    <link:label id="lab_wald_ConversionOfStockToCommonStockConversionRatio_documentation_en-US" xlink:label="lab_wald_ConversionOfStockToCommonStockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock to Common Stock, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ConversionOfStockToCommonStockConversionRatio" xlink:href="wald-20221231.xsd#wald_ConversionOfStockToCommonStockConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ConversionOfStockToCommonStockConversionRatio" xlink:to="lab_wald_ConversionOfStockToCommonStockConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ClassOfWarrantOrRightRedemptionTradingPeriod_82e7b64f-55e3-4d22-b851-b51c183a9013_terseLabel_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightRedemptionTradingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant redemption, trading period</link:label>
    <link:label id="lab_wald_ClassOfWarrantOrRightRedemptionTradingPeriod_label_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightRedemptionTradingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Redemption, Trading Period</link:label>
    <link:label id="lab_wald_ClassOfWarrantOrRightRedemptionTradingPeriod_documentation_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightRedemptionTradingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Redemption, Trading Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightRedemptionTradingPeriod" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightRedemptionTradingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ClassOfWarrantOrRightRedemptionTradingPeriod" xlink:to="lab_wald_ClassOfWarrantOrRightRedemptionTradingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedPaymentArrangementFounderMember_831918ce-2306-446b-b2f0-4a207ab36eb3_terseLabel_en-US" xlink:label="lab_wald_ShareBasedPaymentArrangementFounderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Founder</link:label>
    <link:label id="lab_wald_ShareBasedPaymentArrangementFounderMember_label_en-US" xlink:label="lab_wald_ShareBasedPaymentArrangementFounderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Founder [Member]</link:label>
    <link:label id="lab_wald_ShareBasedPaymentArrangementFounderMember_documentation_en-US" xlink:label="lab_wald_ShareBasedPaymentArrangementFounderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Founder</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedPaymentArrangementFounderMember" xlink:href="wald-20221231.xsd#wald_ShareBasedPaymentArrangementFounderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedPaymentArrangementFounderMember" xlink:to="lab_wald_ShareBasedPaymentArrangementFounderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e8a417f3-b4c7-4e7c-ac4f-4b838f280ac9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_a8a4d3a8-8d29-4e40-9834-6b9c08efadf2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_47a08e7e-fdf6-448d-8532-7e8fb9548ad4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_129bc76d-2486-4d20-b2ea-7d27a15e1c1e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WarehouseMember_f40a40c3-51a7-492d-9069-0b0402af68c4_terseLabel_en-US" xlink:label="lab_srt_WarehouseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse</link:label>
    <link:label id="lab_srt_WarehouseMember_label_en-US" xlink:label="lab_srt_WarehouseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WarehouseMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WarehouseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WarehouseMember" xlink:to="lab_srt_WarehouseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_f038a7d8-8d4d-47a7-a9f5-8b0217b56897_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_b2913154-1aa0-4ed7-9fdc-076a61c9d75d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_57197d89-9d1d-4c02-9990-e34331fdaa81_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unpaid principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_044d16c4-9275-48b9-a4d7-58275f8adf0f_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unpaid principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ApplicableRateMember_aa026f25-3fd3-422d-88d7-7b283de70c85_terseLabel_en-US" xlink:label="lab_wald_ApplicableRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Rate</link:label>
    <link:label id="lab_wald_ApplicableRateMember_label_en-US" xlink:label="lab_wald_ApplicableRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Rate [Member]</link:label>
    <link:label id="lab_wald_ApplicableRateMember_documentation_en-US" xlink:label="lab_wald_ApplicableRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ApplicableRateMember" xlink:href="wald-20221231.xsd#wald_ApplicableRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ApplicableRateMember" xlink:to="lab_wald_ApplicableRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_b550188a-4ebd-4b46-afd8-04dec43fe9ff_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk</link:label>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierConcentrationRiskMember" xlink:to="lab_us-gaap_SupplierConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_c5890e23-f8fc-48e1-9c46-9f82cdce4f8a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_d0cafabf-2d7c-4749-909c-30b011d330f7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock split conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_255657dc-2563-4ec4-83d8-e51a10e9ce89_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for bad debts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_6bd08ba4-1995-427f-81b6-609db2eda52e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_11a8908e-95c5-465c-9ff2-211586348dbf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_9ae5b26e-8fb8-4b4d-9bd2-ed9ce019f6c8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_6a9ac00a-b37a-4452-bbe8-a1be7283a9fd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_ccd8a724-1cc8-471a-b135-b09c78178b6c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred (income) expense, total</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_1946a238-b465-4a8a-8703-4a3975a18de8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_A2018RevolvingCreditFacilityMember_0d2d3cc9-3a5c-4e00-86f2-e58ce3fe91dd_terseLabel_en-US" xlink:label="lab_wald_A2018RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Predecessor 2018 Revolving Credit Facility</link:label>
    <link:label id="lab_wald_A2018RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_wald_A2018RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_wald_A2018RevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_wald_A2018RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Revolving Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2018RevolvingCreditFacilityMember" xlink:href="wald-20221231.xsd#wald_A2018RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_A2018RevolvingCreditFacilityMember" xlink:to="lab_wald_A2018RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple_e373d461-8083-479b-ad11-12fa430235b5_terseLabel_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise multiple</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple_label_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Multiple</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple_documentation_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple" xlink:to="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_CommonStockConvertibleConversionRatio_3504585d-50ec-4092-9da7-dbfb1df73971_terseLabel_en-US" xlink:label="lab_wald_CommonStockConvertibleConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock conversion ratio (in shares)</link:label>
    <link:label id="lab_wald_CommonStockConvertibleConversionRatio_label_en-US" xlink:label="lab_wald_CommonStockConvertibleConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Convertible, Conversion Ratio</link:label>
    <link:label id="lab_wald_CommonStockConvertibleConversionRatio_documentation_en-US" xlink:label="lab_wald_CommonStockConvertibleConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CommonStockConvertibleConversionRatio" xlink:href="wald-20221231.xsd#wald_CommonStockConvertibleConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_CommonStockConvertibleConversionRatio" xlink:to="lab_wald_CommonStockConvertibleConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7abe639b-b270-48ad-8375-b1a6ff0228bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited. weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_e2e44a8f-7cfc-42db-baf3-785f3a7f302a_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_81c1779a-ce47-4bb5-8f19-f6429db09c23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_18d67709-8967-4c64-9f17-bd70cb8495a5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_675c5414-350d-4637-b66f-931a912fdc21_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock per share value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_VietnamPurchaseAgreementMember_d81468fc-7f95-430d-9a9e-13a7f5766ff1_terseLabel_en-US" xlink:label="lab_wald_VietnamPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vietnam Purchase Agreement</link:label>
    <link:label id="lab_wald_VietnamPurchaseAgreementMember_label_en-US" xlink:label="lab_wald_VietnamPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vietnam Purchase Agreement [Member]</link:label>
    <link:label id="lab_wald_VietnamPurchaseAgreementMember_documentation_en-US" xlink:label="lab_wald_VietnamPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vietnam Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VietnamPurchaseAgreementMember" xlink:href="wald-20221231.xsd#wald_VietnamPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_VietnamPurchaseAgreementMember" xlink:to="lab_wald_VietnamPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_fefc0f67-f94f-489c-93e7-ca9403fc83aa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_PPPLoanMember_74145839-9dbe-45b4-a68a-91108ba6cba2_terseLabel_en-US" xlink:label="lab_wald_PPPLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Predecessor PPP Loan</link:label>
    <link:label id="lab_wald_PPPLoanMember_label_en-US" xlink:label="lab_wald_PPPLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP Loan [Member]</link:label>
    <link:label id="lab_wald_PPPLoanMember_documentation_en-US" xlink:label="lab_wald_PPPLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PPPLoanMember" xlink:href="wald-20221231.xsd#wald_PPPLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_PPPLoanMember" xlink:to="lab_wald_PPPLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_fa7b5d0b-98d1-4af8-a9ae-1c20d07466fb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedCashFlowStatementsCaptionsLineItems_df80e746-51b6-4f92-8042-bc3ca948d3de_terseLabel_en-US" xlink:label="lab_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Cash Flow Statements, Captions [Line Items]</link:label>
    <link:label id="lab_srt_CondensedCashFlowStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Cash Flow Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_e3b5416f-272d-4108-a3ba-5d86c2f4f610_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares in connection with the Obagi and Milk Business Combination (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_VendorOneMember_4771eba8-0354-4387-98cb-3789ef65def9_terseLabel_en-US" xlink:label="lab_wald_VendorOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor One</link:label>
    <link:label id="lab_wald_VendorOneMember_label_en-US" xlink:label="lab_wald_VendorOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor One [Member]</link:label>
    <link:label id="lab_wald_VendorOneMember_documentation_en-US" xlink:label="lab_wald_VendorOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VendorOneMember" xlink:href="wald-20221231.xsd#wald_VendorOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_VendorOneMember" xlink:to="lab_wald_VendorOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_05956a25-099a-4ab3-adb6-7bddf1a6b05c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_BeautyVenturesLLCMember_ce709c5a-569c-4f88-8802-9055e0787c37_terseLabel_en-US" xlink:label="lab_wald_BeautyVenturesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beauty Ventures LLC</link:label>
    <link:label id="lab_wald_BeautyVenturesLLCMember_label_en-US" xlink:label="lab_wald_BeautyVenturesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beauty Ventures LLC [Member]</link:label>
    <link:label id="lab_wald_BeautyVenturesLLCMember_documentation_en-US" xlink:label="lab_wald_BeautyVenturesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beauty Ventures LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BeautyVenturesLLCMember" xlink:href="wald-20221231.xsd#wald_BeautyVenturesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_BeautyVenturesLLCMember" xlink:to="lab_wald_BeautyVenturesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_10e88a46-8177-43da-b4be-b5ef36140b5d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_e1058b7d-3b53-4640-bedf-abd306d08276_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_DeferredTaxAssetsLeaseLiabilities_cce73194-628e-4cd1-80af-3c14ba3420f7_terseLabel_en-US" xlink:label="lab_wald_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_wald_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_wald_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:label id="lab_wald_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_wald_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DeferredTaxAssetsLeaseLiabilities" xlink:href="wald-20221231.xsd#wald_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_wald_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_938e75fc-4b42-4476-96e5-4eabce41fb2c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_6936898d-dbb2-4d82-9363-ec0e7faa2b9c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Pro Forma Consolidated Financial Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_5bbc07e6-f4f6-4d02-8b69-8188bddbd973_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_b9b1c823-686d-4caa-b8c0-fe1782d6adb2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_a95d7592-0eb4-475c-bcdc-5aa60abe5cd9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_33c21ab2-d96a-47d1-9e1a-55b1a06b36fa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) Loss on disposal of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5e68b9d4-ba26-4046-8067-18f08b44bfcf_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_5bec209c-b8b3-468b-8cb9-9fcdf70be375_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4a7f820d-d2b6-421b-95fa-616591d1d9e4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_fc5a2107-0e6f-4f37-8f16-31d18c090403_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense adjustment</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_12b95bce-bdd1-4145-8320-af7ff7c4e51b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1f918cfd-0097-4379-bab3-6e27a4a169fa_negatedNetLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_528da1e5-b8df-410a-b413-8151209a6574_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post vesting holding period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_75e6abf1-abc4-44d6-9ebd-b0dff8a15da9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of uncollectible accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ClassOfWarrantOrRightRedemptionPeriod_c95b1c79-5ff4-463e-b7c5-9912d606188f_terseLabel_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightRedemptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant redemption period</link:label>
    <link:label id="lab_wald_ClassOfWarrantOrRightRedemptionPeriod_label_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightRedemptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Redemption Period</link:label>
    <link:label id="lab_wald_ClassOfWarrantOrRightRedemptionPeriod_documentation_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightRedemptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Redemption Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightRedemptionPeriod" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightRedemptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ClassOfWarrantOrRightRedemptionPeriod" xlink:to="lab_wald_ClassOfWarrantOrRightRedemptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_85804021-72e6-441a-8164-c7299faf09c5_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_2d0455ee-1920-4195-98a6-d29135ebb296_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_30b1750a-baf1-4bcc-b898-b852f80316eb_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_631e2a56-51a2-40cb-8a5a-2f0025f89bc4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS' EQUITY:</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_764765a8-2074-4ad1-9b19-92816f08fe14_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY:</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f544b2ef-25da-4913-adff-bf534ad8e343_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_907aac9f-d4ce-4028-9951-d989cbe6ba94_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_c7a0cad5-e04b-4164-a578-e1eb43de0d29_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_dda6c290-b4bb-4f7e-b4c0-212b46e6a837_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1309a1be-c418-4737-923f-18365bfb86fe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Business Combinations, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_043c7182-73e3-495d-8356-c772b0e57cfb_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_VariableRateComponentOneMember_14aa02d1-202a-48fe-b174-0ff01e6227bf_terseLabel_en-US" xlink:label="lab_wald_VariableRateComponentOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component One</link:label>
    <link:label id="lab_wald_VariableRateComponentOneMember_label_en-US" xlink:label="lab_wald_VariableRateComponentOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component One [Member]</link:label>
    <link:label id="lab_wald_VariableRateComponentOneMember_documentation_en-US" xlink:label="lab_wald_VariableRateComponentOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VariableRateComponentOneMember" xlink:href="wald-20221231.xsd#wald_VariableRateComponentOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_VariableRateComponentOneMember" xlink:to="lab_wald_VariableRateComponentOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_f1bd89bf-e260-447e-a638-84b214019fa4_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent_6aa4f0d7-11a0-45c5-8a6d-40bb1cea42a6_terseLabel_en-US" xlink:label="lab_wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction bonuses</link:label>
    <link:label id="lab_wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent_label_en-US" xlink:label="lab_wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Transaction Bonuses, Percent</link:label>
    <link:label id="lab_wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent_documentation_en-US" xlink:label="lab_wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Transaction Bonuses, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent" xlink:href="wald-20221231.xsd#wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent" xlink:to="lab_wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_527ccff3-1b69-4084-a199-38b3a323ed4a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_df3edcd4-030d-433e-9c8d-9362317acaec_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_8a07e5d9-900a-4394-9cbf-a2d45f42c85c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESTIMATED&#160;USEFUL&#160;LIVES</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_country_VN_f9e1d2e5-eede-4d60-9a6a-ebcff600f8e1_terseLabel_en-US" xlink:label="lab_country_VN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIET NAM</link:label>
    <link:label id="lab_country_VN_label_en-US" xlink:label="lab_country_VN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIET NAM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_VN" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_VN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_VN" xlink:to="lab_country_VN" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember_ad4b1e5c-f1a3-4d0e-bfa1-10d4037806aa_terseLabel_en-US" xlink:label="lab_wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Capitalized Computer Software Expenses</link:label>
    <link:label id="lab_wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember_label_en-US" xlink:label="lab_wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Capitalized Computer Software Expenses [Member]</link:label>
    <link:label id="lab_wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember_documentation_en-US" xlink:label="lab_wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Capitalized Computer Software Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember" xlink:href="wald-20221231.xsd#wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember" xlink:to="lab_wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_PhysicianChannelProviderMember_6fab08c3-93df-447d-bba7-b833be70ae0a_terseLabel_en-US" xlink:label="lab_wald_PhysicianChannelProviderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physician Channel Provider</link:label>
    <link:label id="lab_wald_PhysicianChannelProviderMember_label_en-US" xlink:label="lab_wald_PhysicianChannelProviderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physician Channel Provider [Member]</link:label>
    <link:label id="lab_wald_PhysicianChannelProviderMember_documentation_en-US" xlink:label="lab_wald_PhysicianChannelProviderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physician Channel Provider</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PhysicianChannelProviderMember" xlink:href="wald-20221231.xsd#wald_PhysicianChannelProviderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_PhysicianChannelProviderMember" xlink:to="lab_wald_PhysicianChannelProviderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_beeb453e-8707-48ce-8d8e-559856b63621_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_b49be728-10b0-44ef-8c6d-ce6031e841eb_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internally developed software</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_c8b8babf-c562-4967-813f-b2ef036fa8b2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_c3a70857-6d9d-4e94-948d-4ade8b23e8d1_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Intangible Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5e18da05-eeb8-4b41-8bb7-e787081d6f3e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_InventoryPurchasesMember_d559c6b4-7f88-46ef-b521-c358ed7b1ed6_terseLabel_en-US" xlink:label="lab_wald_InventoryPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Purchases</link:label>
    <link:label id="lab_wald_InventoryPurchasesMember_label_en-US" xlink:label="lab_wald_InventoryPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Purchases [Member]</link:label>
    <link:label id="lab_wald_InventoryPurchasesMember_documentation_en-US" xlink:label="lab_wald_InventoryPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_InventoryPurchasesMember" xlink:href="wald-20221231.xsd#wald_InventoryPurchasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_InventoryPurchasesMember" xlink:to="lab_wald_InventoryPurchasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1fa79887-7d00-4c18-be07-b0b55f079ab7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_bd7bc3db-77f7-44c0-b0e0-5a2311395868_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_180b399d-e3b9-4d70-8801-9f1df2d4651e_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_TransitionServicesAgreementExtensionPeriod_8e66f2e0-1f7c-4be9-a502-7b09d09b5216_terseLabel_en-US" xlink:label="lab_wald_TransitionServicesAgreementExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services, optional extension term</link:label>
    <link:label id="lab_wald_TransitionServicesAgreementExtensionPeriod_label_en-US" xlink:label="lab_wald_TransitionServicesAgreementExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Services Agreement, Extension Period</link:label>
    <link:label id="lab_wald_TransitionServicesAgreementExtensionPeriod_documentation_en-US" xlink:label="lab_wald_TransitionServicesAgreementExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Services Agreement, Extension Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_TransitionServicesAgreementExtensionPeriod" xlink:href="wald-20221231.xsd#wald_TransitionServicesAgreementExtensionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_TransitionServicesAgreementExtensionPeriod" xlink:to="lab_wald_TransitionServicesAgreementExtensionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_StockIssuedDuringPeriodValueSubscriptionAgreements_8aaa4d9a-9280-491e-b40b-a65119c8a09a_terseLabel_en-US" xlink:label="lab_wald_StockIssuedDuringPeriodValueSubscriptionAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares in connection with the PIPE investment</link:label>
    <link:label id="lab_wald_StockIssuedDuringPeriodValueSubscriptionAgreements_label_en-US" xlink:label="lab_wald_StockIssuedDuringPeriodValueSubscriptionAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Subscription Agreements</link:label>
    <link:label id="lab_wald_StockIssuedDuringPeriodValueSubscriptionAgreements_documentation_en-US" xlink:label="lab_wald_StockIssuedDuringPeriodValueSubscriptionAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Subscription Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockIssuedDuringPeriodValueSubscriptionAgreements" xlink:href="wald-20221231.xsd#wald_StockIssuedDuringPeriodValueSubscriptionAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_StockIssuedDuringPeriodValueSubscriptionAgreements" xlink:to="lab_wald_StockIssuedDuringPeriodValueSubscriptionAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_9c0e9049-0bff-4655-952d-f76be6f280ea_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_9d9d6672-db85-452b-8b04-b99eddc8d245_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Category of Item Purchased [Axis]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Category of Item Purchased [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_3f0932e1-6161-4336-92ef-45a1d28e9033_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_4cd92c12-6351-458c-afae-41ee199b74d4_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_843031a0-f813-4c8b-8216-13a0e79c3ac2_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_27ab91c6-5d1c-4619-94db-173cb28c87e3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_bfbab64a-823e-4331-b953-1e0ee7eaea8e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of dividends</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_b5d081c1-b97d-47b6-983f-bba8321bd69a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger_789af568-88f2-462a-82fa-dfbdd9c38c8f_terseLabel_en-US" xlink:label="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lock-up shares, stock price trigger</link:label>
    <link:label id="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger_label_en-US" xlink:label="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Stock Price Trigger</link:label>
    <link:label id="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger_documentation_en-US" xlink:label="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" xlink:href="wald-20221231.xsd#wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" xlink:to="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_14cb8221-6d47-455c-916b-49562a76b361_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_646490c6-4e72-4911-bdd2-a5ceedbe8a61_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMPLOYEE BENEFIT PLAN</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_797ff3de-4e9f-4fe1-9101-67fc5e61c0a1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_8cf47c22-4d77-4d33-92d1-99746ad5f513_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_c042afe9-ae01-4c23-92c1-199a2fa606f8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT REPORTING</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_c131b109-5039-4dfa-9dde-64404356fcc5_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_5422c832-5774-43ae-9fc1-da7e109b2c60_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_3d5a58e5-cda6-43c2-ae96-09b83ba7c7b7_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MisstatementOfInventoryMember_7b67bce1-bb4b-4171-82ec-d11a927dc3b8_terseLabel_en-US" xlink:label="lab_wald_MisstatementOfInventoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory obsolescence provision</link:label>
    <link:label id="lab_wald_MisstatementOfInventoryMember_label_en-US" xlink:label="lab_wald_MisstatementOfInventoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Inventory [Member]</link:label>
    <link:label id="lab_wald_MisstatementOfInventoryMember_documentation_en-US" xlink:label="lab_wald_MisstatementOfInventoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfInventoryMember" xlink:href="wald-20221231.xsd#wald_MisstatementOfInventoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MisstatementOfInventoryMember" xlink:to="lab_wald_MisstatementOfInventoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d0503017-2fd3-4247-bcfd-c9473b416b14_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_3f86932e-e344-4986-8727-65316e70b05b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ForwardPurchaseAgreementMember_f3315dc1-a278-44a9-a875-bcd2dc6f98c3_terseLabel_en-US" xlink:label="lab_wald_ForwardPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Purchase Agreement</link:label>
    <link:label id="lab_wald_ForwardPurchaseAgreementMember_label_en-US" xlink:label="lab_wald_ForwardPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Purchase Agreement [Member]</link:label>
    <link:label id="lab_wald_ForwardPurchaseAgreementMember_documentation_en-US" xlink:label="lab_wald_ForwardPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ForwardPurchaseAgreementMember" xlink:href="wald-20221231.xsd#wald_ForwardPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ForwardPurchaseAgreementMember" xlink:to="lab_wald_ForwardPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7e340dd5-e133-4932-b465-43fd387bad2a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating (loss) income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MisstatementOfDistributorServiceFeesMember_577bd5ba-1315-4a9a-8353-0ff91bc85e8b_terseLabel_en-US" xlink:label="lab_wald_MisstatementOfDistributorServiceFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Distributor Service Fees</link:label>
    <link:label id="lab_wald_MisstatementOfDistributorServiceFeesMember_label_en-US" xlink:label="lab_wald_MisstatementOfDistributorServiceFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Distributor Service Fees [Member]</link:label>
    <link:label id="lab_wald_MisstatementOfDistributorServiceFeesMember_documentation_en-US" xlink:label="lab_wald_MisstatementOfDistributorServiceFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Distributor Service Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfDistributorServiceFeesMember" xlink:href="wald-20221231.xsd#wald_MisstatementOfDistributorServiceFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MisstatementOfDistributorServiceFeesMember" xlink:to="lab_wald_MisstatementOfDistributorServiceFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_b9f2896a-e92c-42fc-9f41-c8a08dc52207_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_81dbbf0a-66c7-4912-b8ff-321d25a5ddad_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCapInterestRate_53d4917e-ed44-40b2-8327-14a118c7448a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCapInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate cap (percent)</link:label>
    <link:label id="lab_us-gaap_DerivativeCapInterestRate_label_en-US" xlink:label="lab_us-gaap_DerivativeCapInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Cap Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCapInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCapInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCapInterestRate" xlink:to="lab_us-gaap_DerivativeCapInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_3860f5d9-5a85-4ab5-9bff-8b2c15cc6281_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFloorInterestRate_1ab78431-62b5-494a-ab69-fa937c74b959_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFloorInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate floor (percent)</link:label>
    <link:label id="lab_us-gaap_DerivativeFloorInterestRate_label_en-US" xlink:label="lab_us-gaap_DerivativeFloorInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Floor Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFloorInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFloorInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFloorInterestRate" xlink:to="lab_us-gaap_DerivativeFloorInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c02f722b-9289-47b3-82da-07e127977bec_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OfficeBuildingMember_f34c156f-2490-4297-87a4-72ea2c6d3633_terseLabel_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office</link:label>
    <link:label id="lab_srt_OfficeBuildingMember_label_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OfficeBuildingMember" xlink:to="lab_srt_OfficeBuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e8097af9-2702-4df2-84b4-3fae57c1baf5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_6af9b598-7efa-4de0-a77b-73574119208f_verboseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer/distributor relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_69ae8cc9-a741-43d9-b4fa-9f6e8bdffefd_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_967b4811-9479-485a-81a7-d07a3b02f7b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_8de5efa3-ba94-45a4-8e14-6f15de15f9d3_terseLabel_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate, Type of Property [Axis]</link:label>
    <link:label id="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_label_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate, Type of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_60f6ddb4-1ed5-4fd9-97a7-38462056c46f_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_14aac3a5-cabe-47d8-928a-152892c8fcd0_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9b518ba5-67f6-43c3-ac94-913e54310890_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_00b977fa-e471-4cd1-9f1b-269b145555a6_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c437f213-dc87-4171-9c29-4ee991a94320_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative warrant liabilities (Note 10)</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_47e0595d-46ea-468c-851d-9147439a86ac_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_3a510635-8132-4844-8fd4-e168d30f0ee4_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_cdf4d88d-5b06-4491-87f1-51f66efc5d83_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_04f9a648-05b4-4d25-bf5b-f556eb6f24c0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative notional value</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_OtherMisstatementAdjustmentsMember_c2c74441-45e4-4595-81c0-8779c3f7c7a5_terseLabel_en-US" xlink:label="lab_wald_OtherMisstatementAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_wald_OtherMisstatementAdjustmentsMember_label_en-US" xlink:label="lab_wald_OtherMisstatementAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Misstatement Adjustments [Member]</link:label>
    <link:label id="lab_wald_OtherMisstatementAdjustmentsMember_documentation_en-US" xlink:label="lab_wald_OtherMisstatementAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Misstatement Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OtherMisstatementAdjustmentsMember" xlink:href="wald-20221231.xsd#wald_OtherMisstatementAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_OtherMisstatementAdjustmentsMember" xlink:to="lab_wald_OtherMisstatementAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_0d70aff2-8ba4-4e6b-aaa2-490a2616b719_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f06a74b6-6d43-4f74-a39a-cd2a45d83463_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_17bced16-f2bb-405d-882c-dca01749c869_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_74717cef-fa9b-43ca-b0f8-2bfc0b49c97c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease remaining term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_8857cf2a-e59c-481e-9df3-b0c6a56dadee_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_a77e02c4-b3ec-4e35-8c61-6ae98986205c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentArrangementMember_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment Arrangement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember" xlink:to="lab_us-gaap_SupplyCommitmentArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_5362d868-242a-4420-b55d-6b621e25feb4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_IntercompanyPayables_e068fc47-fa13-48f9-9f61-8bf3d7ff2249_terseLabel_en-US" xlink:label="lab_wald_IntercompanyPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercompany payables</link:label>
    <link:label id="lab_wald_IntercompanyPayables_label_en-US" xlink:label="lab_wald_IntercompanyPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercompany Payables</link:label>
    <link:label id="lab_wald_IntercompanyPayables_documentation_en-US" xlink:label="lab_wald_IntercompanyPayables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercompany Payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_IntercompanyPayables" xlink:href="wald-20221231.xsd#wald_IntercompanyPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_IntercompanyPayables" xlink:to="lab_wald_IntercompanyPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_3e141b4a-ff95-4d6c-9c09-161844d0d230_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_509f6684-eb43-45ba-a99c-04a34ebb762f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_c0836749-e128-4f8e-b915-cc164ccf3e4f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_d6666e2a-543a-4eea-a6d0-9c2b21a5936b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable adjustments</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a7d22fa0-e7c3-472a-921d-bd07ed090328_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_f465b7f1-6ec7-4a7e-8c07-c9514533e5b6_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (income) expenses, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_54e555f6-788e-4fd0-b921-87a92c2a5b41_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0253f6d8-68e6-4703-b52d-935c0f8f6465_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit at Bailiwick of Jersey for Successor and Income tax benefit at Cayman Islands for Predecessor statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_A2021RevolvingCreditFacilityMember_1f911c78-2f56-4e29-8809-1578aeb3f7be_terseLabel_en-US" xlink:label="lab_wald_A2021RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Predecessor 2021 Revolving Credit Facility</link:label>
    <link:label id="lab_wald_A2021RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_wald_A2021RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_wald_A2021RevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_wald_A2021RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Revolving Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2021RevolvingCreditFacilityMember" xlink:href="wald-20221231.xsd#wald_A2021RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_A2021RevolvingCreditFacilityMember" xlink:to="lab_wald_A2021RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_8bc3cbe6-dcf3-4b72-8e0d-1f1ca31ba5fa_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (NOTE 18)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_dff18549-94e0-410c-a2e7-0463c50e1923_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">As Reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_SponsorAndInvestorDirectorsMember_4b5e3c51-15e2-4eaf-a602-5df334e62fb5_terseLabel_en-US" xlink:label="lab_wald_SponsorAndInvestorDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sponsor and Investor Directors</link:label>
    <link:label id="lab_wald_SponsorAndInvestorDirectorsMember_label_en-US" xlink:label="lab_wald_SponsorAndInvestorDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sponsor and Investor Directors [Member]</link:label>
    <link:label id="lab_wald_SponsorAndInvestorDirectorsMember_documentation_en-US" xlink:label="lab_wald_SponsorAndInvestorDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sponsor and Investor Directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SponsorAndInvestorDirectorsMember" xlink:href="wald-20221231.xsd#wald_SponsorAndInvestorDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_SponsorAndInvestorDirectorsMember" xlink:to="lab_wald_SponsorAndInvestorDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_VariableRateComponentDomain_1f63bed3-8232-48c6-b447-f9ebc84aa22a_terseLabel_en-US" xlink:label="lab_wald_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:label id="lab_wald_VariableRateComponentDomain_label_en-US" xlink:label="lab_wald_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:label id="lab_wald_VariableRateComponentDomain_documentation_en-US" xlink:label="lab_wald_VariableRateComponentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VariableRateComponentDomain" xlink:href="wald-20221231.xsd#wald_VariableRateComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_VariableRateComponentDomain" xlink:to="lab_wald_VariableRateComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_2a0a8610-9b66-4c56-b4f9-b057c89b1313_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial commitment amount of purchase commitments</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_daaf0514-b5b9-456a-8357-e71843f2b8cf_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_AaronChatterleyMember_c4456941-ba11-4333-adfb-6e89da27ec85_terseLabel_en-US" xlink:label="lab_wald_AaronChatterleyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aaron Chatterley</link:label>
    <link:label id="lab_wald_AaronChatterleyMember_label_en-US" xlink:label="lab_wald_AaronChatterleyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aaron Chatterley [Member]</link:label>
    <link:label id="lab_wald_AaronChatterleyMember_documentation_en-US" xlink:label="lab_wald_AaronChatterleyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aaron Chatterley</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AaronChatterleyMember" xlink:href="wald-20221231.xsd#wald_AaronChatterleyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_AaronChatterleyMember" xlink:to="lab_wald_AaronChatterleyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_2141dea6-91df-464f-8dad-65cc298af80e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_820b1498-1734-43da-bb0b-93866cf5ec4c_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_a3070928-2666-4005-b1b1-6a965deadd88_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAX BENEFIT</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_JanuaryNoteMember_bc86d748-9492-4300-9180-38d5f7478209_terseLabel_en-US" xlink:label="lab_wald_JanuaryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January Note</link:label>
    <link:label id="lab_wald_JanuaryNoteMember_label_en-US" xlink:label="lab_wald_JanuaryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January Note [Member]</link:label>
    <link:label id="lab_wald_JanuaryNoteMember_documentation_en-US" xlink:label="lab_wald_JanuaryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_JanuaryNoteMember" xlink:href="wald-20221231.xsd#wald_JanuaryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_JanuaryNoteMember" xlink:to="lab_wald_JanuaryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_cbada1fb-76be-4d0a-ae12-0a2f4759c2bf_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember_3ebabbae-6e10-4587-8419-1dde9a669c17_terseLabel_en-US" xlink:label="lab_wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Burwell and Zeno</link:label>
    <link:label id="lab_wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember_label_en-US" xlink:label="lab_wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Burwell Mountain Trust and Zeno Investment Master Fund [Member]</link:label>
    <link:label id="lab_wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember_documentation_en-US" xlink:label="lab_wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Burwell Mountain Trust and Zeno Investment Master Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember" xlink:href="wald-20221231.xsd#wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember" xlink:to="lab_wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_b844f978-1502-4247-91d5-bf7a1b7041a8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_VendorThreeMember_99c845f5-6b26-4b82-941a-c44a5096627d_terseLabel_en-US" xlink:label="lab_wald_VendorThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor Three</link:label>
    <link:label id="lab_wald_VendorThreeMember_label_en-US" xlink:label="lab_wald_VendorThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor Three [Member]</link:label>
    <link:label id="lab_wald_VendorThreeMember_documentation_en-US" xlink:label="lab_wald_VendorThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VendorThreeMember" xlink:href="wald-20221231.xsd#wald_VendorThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_VendorThreeMember" xlink:to="lab_wald_VendorThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_19d09b6b-0c72-41ae-ab14-3c6d750d832d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets Acquired in Business Combination</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_A2022IncentiveAwardPlanMember_7f5e2ae5-5392-441b-9971-ae3b49a1e6c0_terseLabel_en-US" xlink:label="lab_wald_A2022IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Incentive Award Plan</link:label>
    <link:label id="lab_wald_A2022IncentiveAwardPlanMember_label_en-US" xlink:label="lab_wald_A2022IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Incentive Award Plan [Member]</link:label>
    <link:label id="lab_wald_A2022IncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_wald_A2022IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Incentive Award Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2022IncentiveAwardPlanMember" xlink:href="wald-20221231.xsd#wald_A2022IncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_A2022IncentiveAwardPlanMember" xlink:to="lab_wald_A2022IncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_87ae288b-9b0c-4eca-a049-6d136d658551_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_3ec08241-6a08-40db-aa6b-2aba64888370_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105e43f2-1d07-4565-b28c-3c38b7bf4998_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7c1c71ee-2104-4724-97c2-cee7d87314dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_LongTermIncentiveAwardsMember_299170b7-8d76-4b4b-8486-194d62cdca8e_terseLabel_en-US" xlink:label="lab_wald_LongTermIncentiveAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Awards</link:label>
    <link:label id="lab_wald_LongTermIncentiveAwardsMember_label_en-US" xlink:label="lab_wald_LongTermIncentiveAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Awards [Member]</link:label>
    <link:label id="lab_wald_LongTermIncentiveAwardsMember_documentation_en-US" xlink:label="lab_wald_LongTermIncentiveAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_LongTermIncentiveAwardsMember" xlink:href="wald-20221231.xsd#wald_LongTermIncentiveAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_LongTermIncentiveAwardsMember" xlink:to="lab_wald_LongTermIncentiveAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_57fc4abe-ddb6-4698-ac59-2e17668d28ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_d77a411b-8aaf-4b03-ae98-d057c20defb4_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentAxis" xlink:to="lab_us-gaap_SupplyCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_c59c77c6-b905-4b22-a947-79fd2505e955_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0e9e3f82-92c1-48ea-a05b-75ce05b9c7f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_e2308aa2-2d95-46a7-8218-63dfd50de712_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedCashFlowStatementTable_709f3e48-f665-46a3-8a28-529a47a5411e_terseLabel_en-US" xlink:label="lab_srt_CondensedCashFlowStatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Cash Flow Statement [Table]</link:label>
    <link:label id="lab_srt_CondensedCashFlowStatementTable_label_en-US" xlink:label="lab_srt_CondensedCashFlowStatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Cash Flow Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedCashFlowStatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedCashFlowStatementTable" xlink:to="lab_srt_CondensedCashFlowStatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0d5549f3-ad0d-4872-8928-cb6ef93c4c48_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_76120331-ca87-40f9-8e93-3d82d2bbe1f2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_USOnlineMarketplaceDistributorAndSADistributorMember_5da92e22-1749-4871-9adf-cd9785cd8586_terseLabel_en-US" xlink:label="lab_wald_USOnlineMarketplaceDistributorAndSADistributorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Online Marketplace Distributor and SA Distributor</link:label>
    <link:label id="lab_wald_USOnlineMarketplaceDistributorAndSADistributorMember_label_en-US" xlink:label="lab_wald_USOnlineMarketplaceDistributorAndSADistributorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Online Marketplace Distributor and SA Distributor [Member]</link:label>
    <link:label id="lab_wald_USOnlineMarketplaceDistributorAndSADistributorMember_documentation_en-US" xlink:label="lab_wald_USOnlineMarketplaceDistributorAndSADistributorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Online Marketplace Distributor and SA Distributor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_USOnlineMarketplaceDistributorAndSADistributorMember" xlink:href="wald-20221231.xsd#wald_USOnlineMarketplaceDistributorAndSADistributorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_USOnlineMarketplaceDistributorAndSADistributorMember" xlink:to="lab_wald_USOnlineMarketplaceDistributorAndSADistributorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_OperatingExpensesAndCostOfGoodSold_e53f4ae0-d9f0-4c98-bd4a-fffc474af0bd_totalLabel_en-US" xlink:label="lab_wald_OperatingExpensesAndCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_wald_OperatingExpensesAndCostOfGoodSold_label_en-US" xlink:label="lab_wald_OperatingExpensesAndCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses and Cost of Good Sold</link:label>
    <link:label id="lab_wald_OperatingExpensesAndCostOfGoodSold_documentation_en-US" xlink:label="lab_wald_OperatingExpensesAndCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses and Cost of Good Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OperatingExpensesAndCostOfGoodSold" xlink:href="wald-20221231.xsd#wald_OperatingExpensesAndCostOfGoodSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_OperatingExpensesAndCostOfGoodSold" xlink:to="lab_wald_OperatingExpensesAndCostOfGoodSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c6e5e07c-5427-4ac6-8842-f7fe2e17cd23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average fair value of options granted in period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_0b3cad5e-3f0a-48f8-ba32-acb9b11693e1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Class A shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9b374d08-5867-4063-8984-7f1d03ad4f13_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_2bbe58b6-f462-43e4-858f-f5442d04354f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_InterestRateCollarMember_e367ff9e-2e7f-455f-ac2d-0ca3ea2fd910_terseLabel_en-US" xlink:label="lab_wald_InterestRateCollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate collar</link:label>
    <link:label id="lab_wald_InterestRateCollarMember_label_en-US" xlink:label="lab_wald_InterestRateCollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Collar [Member]</link:label>
    <link:label id="lab_wald_InterestRateCollarMember_documentation_en-US" xlink:label="lab_wald_InterestRateCollarMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Collar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_InterestRateCollarMember" xlink:href="wald-20221231.xsd#wald_InterestRateCollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_InterestRateCollarMember" xlink:to="lab_wald_InterestRateCollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_49562fa1-da3f-40a9-bfbd-b36cd471be23_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_3650b20a-d1f3-4bce-a7ae-8c777d71617d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5b5a80ec-62d5-4237-9f0b-5ed139413628_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3cc80c0b-2859-44c7-b254-f9ab005f8485_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_7ad2de8c-f423-4cff-8b18-3aad0374a304_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_a372eeb8-32ae-40f9-974d-903ac8a29099_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_d31e345b-b9b6-481a-9f63-5784d1ec2197_terseLabel_en-US" xlink:label="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY)</link:label>
    <link:label id="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information of Parent Company Only Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_093c41f8-23cd-4185-813e-f1cc66df2b03_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_StockGrowthIncentiveAwardsSGIAwardsMember_ca367cf5-660f-45fb-bcfe-62cc30effd44_terseLabel_en-US" xlink:label="lab_wald_StockGrowthIncentiveAwardsSGIAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SGI Awards</link:label>
    <link:label id="lab_wald_StockGrowthIncentiveAwardsSGIAwardsMember_label_en-US" xlink:label="lab_wald_StockGrowthIncentiveAwardsSGIAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Growth Incentive Awards (SGI Awards) [Member]</link:label>
    <link:label id="lab_wald_StockGrowthIncentiveAwardsSGIAwardsMember_documentation_en-US" xlink:label="lab_wald_StockGrowthIncentiveAwardsSGIAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Growth Incentive Awards (SGI Awards)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockGrowthIncentiveAwardsSGIAwardsMember" xlink:href="wald-20221231.xsd#wald_StockGrowthIncentiveAwardsSGIAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_StockGrowthIncentiveAwardsSGIAwardsMember" xlink:to="lab_wald_StockGrowthIncentiveAwardsSGIAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6443915b-031b-4ebd-90dd-fd4acfb42d40_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7e0c879a-ebfb-4cbe-9c59-ab09f783e91c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_5833febb-aa73-422f-af60-b597d20783f5_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold (including related party costs of $5,128 in the Successor period)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_8fb1a21e-4c8e-4735-9c71-4374725b3c8c_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_3a560cb5-dcaa-432b-b8c2-8049eac0f7ab_netLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net cost of goods sold adjustments</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9bb83e59-d17c-4bdc-a734-8b39e4f003eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_ce458f48-fa7f-4957-93ad-9e439ae93efc_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Useful Life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassBMember_bc9fd3b4-ed0b-4b40-baf8-8db74b99a120_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class B Ordinary Shares</link:label>
    <link:label id="lab_us-gaap_CommonClassBMember_label_en-US" xlink:label="lab_us-gaap_CommonClassBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent_951d76b8-6bdb-452a-824b-7d49cff2dc4d_terseLabel_en-US" xlink:label="lab_wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP Loan forgiveness</link:label>
    <link:label id="lab_wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent_label_en-US" xlink:label="lab_wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, PPP Loan Forgiveness, Percent</link:label>
    <link:label id="lab_wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent_documentation_en-US" xlink:label="lab_wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, PPP Loan Forgiveness, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent" xlink:href="wald-20221231.xsd#wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent" xlink:to="lab_wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_bdc7eeff-d2b6-4f7e-a4d7-a8d8383904c0_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_FounderAwardsMember_cf4e8c2a-040a-4f0e-b891-b5d548883d51_terseLabel_en-US" xlink:label="lab_wald_FounderAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founder Awards</link:label>
    <link:label id="lab_wald_FounderAwardsMember_label_en-US" xlink:label="lab_wald_FounderAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founder Awards [Member]</link:label>
    <link:label id="lab_wald_FounderAwardsMember_documentation_en-US" xlink:label="lab_wald_FounderAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founder Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_FounderAwardsMember" xlink:href="wald-20221231.xsd#wald_FounderAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_FounderAwardsMember" xlink:to="lab_wald_FounderAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_fe28d84b-6f2b-4f22-b533-6780b1854b20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_17671cd7-5e48-49f8-a127-502b344c1b3b_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_a35adf03-df97-4f69-9fde-78f344830334_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_bbe38f2b-e2d0-4b25-b88e-f5bfc1e224b0_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_c24ff37c-3c0c-4e72-a5f8-2548acd49f4f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5caf900e-8ec4-4e25-8df9-6d2bb1fd63b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ComputerHardwareSoftwareAndEquipmentMember_706232dd-51dc-4e47-abd1-c4c81b7d1263_verboseLabel_en-US" xlink:label="lab_wald_ComputerHardwareSoftwareAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware and software</link:label>
    <link:label id="lab_wald_ComputerHardwareSoftwareAndEquipmentMember_02066863-aa5a-4546-a976-2585a98b5be2_terseLabel_en-US" xlink:label="lab_wald_ComputerHardwareSoftwareAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware, software and equipment</link:label>
    <link:label id="lab_wald_ComputerHardwareSoftwareAndEquipmentMember_label_en-US" xlink:label="lab_wald_ComputerHardwareSoftwareAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Hardware, Software And Equipment [Member]</link:label>
    <link:label id="lab_wald_ComputerHardwareSoftwareAndEquipmentMember_documentation_en-US" xlink:label="lab_wald_ComputerHardwareSoftwareAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Hardware, Software And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ComputerHardwareSoftwareAndEquipmentMember" xlink:href="wald-20221231.xsd#wald_ComputerHardwareSoftwareAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ComputerHardwareSoftwareAndEquipmentMember" xlink:to="lab_wald_ComputerHardwareSoftwareAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_a2a76168-40a6-4300-bebe-dc9cf5d2d422_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share</link:label>
    <link:label id="lab_us-gaap_WarrantMember_064f6865-2be5-470d-89c1-b6c6fd5a7fda_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2b205d32-eaca-4efc-9118-14bfb5531f8a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_cd6e7de9-5d91-49c9-ac39-713763fa5667_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_d0d55108-345b-449a-8c6b-30290295dcfd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_6f8b8723-a78a-400c-8d03-4cf099a290d7_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_88368d05-729e-4f5c-a57f-c03459179659_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_AuditInformationAbstract_label_en-US" xlink:label="lab_wald_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_wald_AuditInformationAbstract_documentation_en-US" xlink:label="lab_wald_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AuditInformationAbstract" xlink:href="wald-20221231.xsd#wald_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_AuditInformationAbstract" xlink:to="lab_wald_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_CapitalContribution_9b9fd50e-aeb2-47d7-bc85-c19467abfc8f_terseLabel_en-US" xlink:label="lab_wald_CapitalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contribution of trademarks</link:label>
    <link:label id="lab_wald_CapitalContribution_label_en-US" xlink:label="lab_wald_CapitalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Contribution</link:label>
    <link:label id="lab_wald_CapitalContribution_documentation_en-US" xlink:label="lab_wald_CapitalContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CapitalContribution" xlink:href="wald-20221231.xsd#wald_CapitalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_CapitalContribution" xlink:to="lab_wald_CapitalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays_d6b1db2c-a898-4373-954a-8286a723cc1d_terseLabel_en-US" xlink:label="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lock-up shares, threshold period before commencement of consecutive trading days</link:label>
    <link:label id="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays_label_en-US" xlink:label="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Period Before Commencement of Consecutive Trading Days</link:label>
    <link:label id="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays_documentation_en-US" xlink:label="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Period Before Commencement of Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays" xlink:href="wald-20221231.xsd#wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays" xlink:to="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_d631e9c7-5a9a-4d05-97e0-daee1609e3ce_terseLabel_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_label_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Reclassification, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6b68465a-057d-4a99-ba82-c22d532025c9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_32c78d69-336c-48e7-ae9a-3bbc3fd1e298_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_0b38c4fa-9df7-4209-b5c4-ad122fe80186_terseLabel_en-US" xlink:label="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_label_en-US" xlink:label="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</link:label>
    <link:label id="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_documentation_en-US" xlink:label="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:href="wald-20221231.xsd#wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:to="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_a3699a5b-0048-4388-800c-6c6d0664060f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_13e037f9-2990-4ba4-87ad-26aece836ab3_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_5cf51658-6937-4609-a3e9-4311f517e492_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_cace41ca-b0b4-4c26-a735-47b36c7cd868_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed cash payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Derivative Instrument, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:to="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_bb80c63e-c177-4e2c-8f22-899ba9b5d777_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Cash Flow and Other Information Related to Leases</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_579ac148-1a0e-4825-9bf6-e66a9373b60f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5c13ddb2-c097-495e-80c2-b233d5e66742_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_4c24765e-b25f-4395-ac64-ce8d53fd581a_terseLabel_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, aggregate intrinsic value</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_label_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Intrinsic Value</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_documentation_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:to="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_8c963115-2c04-4bbf-977e-43274ddc8e0b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_68b5e1ef-c60e-473a-a2dd-04e7ec429d07_terseLabel_en-US" xlink:label="lab_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of equity awards in business combination</link:label>
    <link:label id="lab_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Issued in Business Combination, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:to="lab_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_4475eb49-61bd-4836-b928-3d8f6fb3d4ed_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9aeeb48e-f8dd-48e6-9d5c-1ae2d1e3650c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock, unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d48d0f25-e8e3-446b-b657-99cb115812e8_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures in accounts payable and accruals</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_f592f178-daaa-4e81-a8b1-c38f162b9866_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt (Note 8)</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_c4645198-8fb3-4764-9673-3755f07dae33_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_4d5c6120-d0d9-43a5-b121-4ffdcf106eb7_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_64b6554e-2ad6-4424-b1d7-b7fab1d92060_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares available for issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_444598a4-e274-477a-bc06-c2ff43b4959a_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5bc2136d-1d59-4383-b9d8-da392e08d257_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_46ef832d-8978-400b-a4c7-2035da7ce976_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash contribution of trademarks</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_1ded4bc3-7d60-421b-8ed4-710d5075e43b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_3cd86133-fbfd-4ab9-a3d6-1df8b42901ee_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_83427f51-b30a-45bf-8516-c741a1e72f72_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6a0dc752-3cae-481b-9bd8-c44b4186f42f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_A2022CreditAgreementMember_28afd2a6-7bb4-4af7-88cf-db7238a1e46e_terseLabel_en-US" xlink:label="lab_wald_A2022CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Credit Agreement</link:label>
    <link:label id="lab_wald_A2022CreditAgreementMember_label_en-US" xlink:label="lab_wald_A2022CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Credit Agreement [Member]</link:label>
    <link:label id="lab_wald_A2022CreditAgreementMember_documentation_en-US" xlink:label="lab_wald_A2022CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2022CreditAgreementMember" xlink:href="wald-20221231.xsd#wald_A2022CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_A2022CreditAgreementMember" xlink:to="lab_wald_A2022CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d147d4b7-b4bd-491e-8a4d-67a5ec9b2dc8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_5e475bb1-5467-4b3f-900d-bddcb3254084_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_ad7e7ffa-6f56-4478-9580-eb6239f90330_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_e331f5e8-c93a-40bb-b1e6-1823ac357c45_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_652c9296-af0d-489d-92f6-8ae8b19d865c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ProceedsFromTrustAccount_1a7119c4-36fc-4fec-871f-4a6817a55bbd_terseLabel_en-US" xlink:label="lab_wald_ProceedsFromTrustAccount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from trust account</link:label>
    <link:label id="lab_wald_ProceedsFromTrustAccount_80415144-a22f-4b27-b327-b42c739e2dba_verboseLabel_en-US" xlink:label="lab_wald_ProceedsFromTrustAccount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from trust</link:label>
    <link:label id="lab_wald_ProceedsFromTrustAccount_label_en-US" xlink:label="lab_wald_ProceedsFromTrustAccount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Trust Account</link:label>
    <link:label id="lab_wald_ProceedsFromTrustAccount_documentation_en-US" xlink:label="lab_wald_ProceedsFromTrustAccount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Trust Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ProceedsFromTrustAccount" xlink:href="wald-20221231.xsd#wald_ProceedsFromTrustAccount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ProceedsFromTrustAccount" xlink:to="lab_wald_ProceedsFromTrustAccount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_028a936e-ffc4-4daa-9334-9edfb293420e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1b8c93d7-02c2-4977-93e5-1944891ec50d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_23981616-0b3c-416f-96e6-adb198273409_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_02d71638-d963-4d15-8258-4c511da34577_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26af7c61-95c9-4de1-8dd6-2cb03e562e4d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;Beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cd0caf5e-b9d6-4f76-bf53-f64670d0248d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;End of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3d9f42ac-28b2-45d4-8ffd-f1978358149a_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember_27869eb9-ab0c-432c-9c4e-d70114d28d29_terseLabel_en-US" xlink:label="lab_wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Capitalized Internal Use Software Costs</link:label>
    <link:label id="lab_wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember_label_en-US" xlink:label="lab_wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Capitalized Internal Use Software Costs [Member]</link:label>
    <link:label id="lab_wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember_documentation_en-US" xlink:label="lab_wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Capitalized Internal Use Software Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember" xlink:href="wald-20221231.xsd#wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember" xlink:to="lab_wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_43a5df78-7514-4238-b9ac-584006c9163e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_328dccd2-d414-4490-aafa-f62ed9dc2e8e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ffc15277-467f-47b3-905d-dc9948f1fd19_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_ee94ad69-b8d1-4e9f-8b8c-d1d62fe9894a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b88c661c-66cd-4b58-8121-76b62da70354_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_GondolasMember_96c9370a-9dcc-486e-a6b1-d715f9f125a3_terseLabel_en-US" xlink:label="lab_wald_GondolasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gondolas</link:label>
    <link:label id="lab_wald_GondolasMember_label_en-US" xlink:label="lab_wald_GondolasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gondolas [Member]</link:label>
    <link:label id="lab_wald_GondolasMember_documentation_en-US" xlink:label="lab_wald_GondolasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gondolas</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GondolasMember" xlink:href="wald-20221231.xsd#wald_GondolasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_GondolasMember" xlink:to="lab_wald_GondolasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ProceedsFromForwardPurchaseAgreements_1e2768fc-ee7f-4ddb-9de0-415c66d066e1_terseLabel_en-US" xlink:label="lab_wald_ProceedsFromForwardPurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from FPA investments</link:label>
    <link:label id="lab_wald_ProceedsFromForwardPurchaseAgreements_label_en-US" xlink:label="lab_wald_ProceedsFromForwardPurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Forward Purchase Agreements</link:label>
    <link:label id="lab_wald_ProceedsFromForwardPurchaseAgreements_documentation_en-US" xlink:label="lab_wald_ProceedsFromForwardPurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Forward Purchase Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ProceedsFromForwardPurchaseAgreements" xlink:href="wald-20221231.xsd#wald_ProceedsFromForwardPurchaseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ProceedsFromForwardPurchaseAgreements" xlink:to="lab_wald_ProceedsFromForwardPurchaseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInNotesReceivableCurrent_852db053-be66-41d1-b8f9-a7866dde6cfb_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in loan receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInNotesReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Notes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInNotesReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:to="lab_us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_60b7e60c-85d7-42de-916a-5723f9f9adae_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_db91675a-c83e-40ff-99bf-88b9ad26bdb3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_d8f378f9-3564-4182-99bd-1b73e0a3e21e_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding borrowings</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7875f6e2-82c2-485f-b8e8-def35ef7161c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4bc23b27-bf77-493f-a5da-e206e7dddc78_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subscription agreement proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_41281bb5-4ad0-4b8a-92d4-74140c667bba_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_94a62eeb-3b74-4683-b43a-87ccaafc3837_terseLabel_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Vested In Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Vested In Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:to="lab_wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_BusinessAcquisitionEarnoutPeriod_a04acd47-f2cc-4fde-bb24-33339c08f7e1_terseLabel_en-US" xlink:label="lab_wald_BusinessAcquisitionEarnoutPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnout period</link:label>
    <link:label id="lab_wald_BusinessAcquisitionEarnoutPeriod_label_en-US" xlink:label="lab_wald_BusinessAcquisitionEarnoutPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Earnout Period</link:label>
    <link:label id="lab_wald_BusinessAcquisitionEarnoutPeriod_documentation_en-US" xlink:label="lab_wald_BusinessAcquisitionEarnoutPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Earnout Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessAcquisitionEarnoutPeriod" xlink:href="wald-20221231.xsd#wald_BusinessAcquisitionEarnoutPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_BusinessAcquisitionEarnoutPeriod" xlink:to="lab_wald_BusinessAcquisitionEarnoutPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MisstatementOfAccruedDistributionServiceFeesMember_6cd60502-91b5-49b1-9452-952fd562c008_terseLabel_en-US" xlink:label="lab_wald_MisstatementOfAccruedDistributionServiceFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Accrued Distribution Service Fees</link:label>
    <link:label id="lab_wald_MisstatementOfAccruedDistributionServiceFeesMember_label_en-US" xlink:label="lab_wald_MisstatementOfAccruedDistributionServiceFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Accrued Distribution Service Fees [Member]</link:label>
    <link:label id="lab_wald_MisstatementOfAccruedDistributionServiceFeesMember_documentation_en-US" xlink:label="lab_wald_MisstatementOfAccruedDistributionServiceFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Accrued Distribution Service Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfAccruedDistributionServiceFeesMember" xlink:href="wald-20221231.xsd#wald_MisstatementOfAccruedDistributionServiceFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MisstatementOfAccruedDistributionServiceFeesMember" xlink:to="lab_wald_MisstatementOfAccruedDistributionServiceFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_60dec4a9-122b-41fd-a305-1f013fd1d049_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Ordinary Shares</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9c7947f9-042d-4e75-8fb7-d5ff39cd58b6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation cost, weighted average service period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ObagiSkincareMember_87acef6f-f023-413b-9731-efd6111eea54_terseLabel_en-US" xlink:label="lab_wald_ObagiSkincareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi Skincare</link:label>
    <link:label id="lab_wald_ObagiSkincareMember_546f1a07-5acf-4869-b049-3dad18e47e89_verboseLabel_en-US" xlink:label="lab_wald_ObagiSkincareMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi</link:label>
    <link:label id="lab_wald_ObagiSkincareMember_label_en-US" xlink:label="lab_wald_ObagiSkincareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi Skincare [Member]</link:label>
    <link:label id="lab_wald_ObagiSkincareMember_documentation_en-US" xlink:label="lab_wald_ObagiSkincareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi Skincare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiSkincareMember" xlink:href="wald-20221231.xsd#wald_ObagiSkincareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ObagiSkincareMember" xlink:to="lab_wald_ObagiSkincareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_c62f1209-4f5d-4a4a-97c3-991882fb2bec_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Class A shareholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelName_cd33c95d-f553-4154-a1cb-a2ecbffdaebf_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:label id="lab_dei_ContactPersonnelName_label_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_34856f1d-7e77-493f-89be-0d33d7257235_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_ecbc98ae-1912-4c96-9669-d77940e085eb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares in connection with the Obagi and Milk Business Combination</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_5b659a75-1909-4f7e-af71-1cc6a38ee737_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of ordinary shares for Business Combinations</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentRegistrationStatement_51968393-2625-4ee1-ad42-a1d1b8b51fac_terseLabel_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Registration Statement</link:label>
    <link:label id="lab_dei_DocumentRegistrationStatement_label_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_49117c42-fe40-4516-8f93-ea82dc9b900d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_246915b5-0f0c-49cd-a704-2c6c5dc6e830_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_4fced2f0-8b86-4da8-a995-229d3b6fdcab_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_aa9f05d2-651c-4a0e-9d16-2b488d49b0ed_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f5a4ef84-2ce8-46cd-aac5-cc4fa00c90c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption_d8e0e179-2548-4116-b045-57ede7faf234_terseLabel_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant redemption, period between end of trading and notice of redemption</link:label>
    <link:label id="lab_wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption_label_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Period Between End of Trading and Notice of Redemption</link:label>
    <link:label id="lab_wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption_documentation_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Period Between End of Trading and Notice of Redemption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption" xlink:to="lab_wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember_59dd8b68-4318-410f-b647-b8f605d782ca_terseLabel_en-US" xlink:label="lab_wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Loss On Forgiveness of Uncollectible Loan Receivable</link:label>
    <link:label id="lab_wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember_label_en-US" xlink:label="lab_wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Loss On Forgiveness of Uncollectible Loan Receivable [Member]</link:label>
    <link:label id="lab_wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember_documentation_en-US" xlink:label="lab_wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Loss On Forgiveness of Uncollectible Loan Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember" xlink:href="wald-20221231.xsd#wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember" xlink:to="lab_wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_b8e4c411-daff-420e-bed9-f06fc1396f25_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_45079e8c-70af-464c-91c8-372bdaf9edaa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_d886313e-9b93-4237-b44f-dd46330baa4f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_941d25eb-8ef2-4e04-bb3f-921aa3511e50_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, accrued interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_71c5b77f-3fbc-4f7f-9705-c9ae614f1fc4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_9347ddcd-aa8f-4acb-b364-f98e7cdda314_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities (including related party liability of $9,914 as of December 31, 2022)</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_2c08ed0b-b442-42d7-94b3-fff41da5811e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party liability</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_23d5bfe8-1166-4f39-b637-78d6fc363f07_netLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_0ec03fee-d000-4d27-bdc0-a86ee4d7267f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetInterestCarryforward_63d6eb36-669d-4d1c-8359-b54e85489202_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible interest carryover</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetInterestCarryforward_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Interest Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_47930e24-4b2a-4a09-9aef-c0485dac3dd4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fef990dd-41e9-4533-b45b-8c68f63f3533_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock registered (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum_dd8ff96e-8f53-4171-aab4-b5b894e853c3_terseLabel_en-US" xlink:label="lab_wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period after which production costs will be expensed for advertising that has not yet occurred</link:label>
    <link:label id="lab_wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum_label_en-US" xlink:label="lab_wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition Period for Deferred Advertising Costs, Maximum</link:label>
    <link:label id="lab_wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum_documentation_en-US" xlink:label="lab_wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition Period for Deferred Advertising Costs, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum" xlink:href="wald-20221231.xsd#wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum" xlink:to="lab_wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_af532472-7e19-492d-9f74-817e67d4b9b1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_d2e8b882-53f9-42c9-9004-2fa3bcb35f04_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma net income (loss)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest_e418a243-e479-43b1-9e42-0e098f2eff9f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Increase, Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_52e050a8-76f1-4ae6-aeba-d10a3c0d3477_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_e65f3734-54bb-4c12-9ef7-8479609f3854_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_DebtInstrumentCovenantLeverageRatioMaximum_7bea78c2-c3fa-4f0d-b734-c08dcaee1926_terseLabel_en-US" xlink:label="lab_wald_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage ratio, maximum</link:label>
    <link:label id="lab_wald_DebtInstrumentCovenantLeverageRatioMaximum_label_en-US" xlink:label="lab_wald_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:label id="lab_wald_DebtInstrumentCovenantLeverageRatioMaximum_documentation_en-US" xlink:label="lab_wald_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DebtInstrumentCovenantLeverageRatioMaximum" xlink:href="wald-20221231.xsd#wald_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_DebtInstrumentCovenantLeverageRatioMaximum" xlink:to="lab_wald_DebtInstrumentCovenantLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_a3a89cf7-1eb8-4260-bbc4-7708e61115ff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of promissory note to warrants</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_0a219599-e364-42ff-b0cb-ceeb012fa567_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_fa1fee89-b85f-4615-83c3-e593e1cac953_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_ca60086d-a472-45ce-bb53-6a5f87962088_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_d0af1023-2fb3-4a88-b8dc-fad0e9a8c325_netLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net inventory adjustments</link:label>
    <link:label id="lab_us-gaap_InventoryNet_c67c008e-d526-417b-a716-3606596fd505_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember_e8b7f6cc-c83b-44fa-a1ac-9239d9dce451_terseLabel_en-US" xlink:label="lab_wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Capitalized Marketing and Advertising Expenses</link:label>
    <link:label id="lab_wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember_label_en-US" xlink:label="lab_wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Capitalized Marketing and Advertising Expenses [Member]</link:label>
    <link:label id="lab_wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember_documentation_en-US" xlink:label="lab_wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Capitalized Marketing and Advertising Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember" xlink:href="wald-20221231.xsd#wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember" xlink:to="lab_wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ObagiShanghaiMember_6cfaa74d-cca4-4bea-b7f7-f8298ab3d40c_terseLabel_en-US" xlink:label="lab_wald_ObagiShanghaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi Shanghai</link:label>
    <link:label id="lab_wald_ObagiShanghaiMember_label_en-US" xlink:label="lab_wald_ObagiShanghaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi Shanghai [Member]</link:label>
    <link:label id="lab_wald_ObagiShanghaiMember_documentation_en-US" xlink:label="lab_wald_ObagiShanghaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi Shanghai</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiShanghaiMember" xlink:href="wald-20221231.xsd#wald_ObagiShanghaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ObagiShanghaiMember" xlink:to="lab_wald_ObagiShanghaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_70449d68-ebd1-4089-aeba-ae2671864dbe_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from PIPE investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_29f4f7b7-acb9-41a3-994a-cd68685b9e0b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_73bafe62-4a59-4590-9e36-f54954abf80a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MisstatementOfCapitalizedMarketingExpensesMember_28fcf9db-a8a8-4ef3-b64b-7cd721dc3ec4_terseLabel_en-US" xlink:label="lab_wald_MisstatementOfCapitalizedMarketingExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Capitalized Marketing Expenses</link:label>
    <link:label id="lab_wald_MisstatementOfCapitalizedMarketingExpensesMember_label_en-US" xlink:label="lab_wald_MisstatementOfCapitalizedMarketingExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Capitalized Marketing Expenses [Member]</link:label>
    <link:label id="lab_wald_MisstatementOfCapitalizedMarketingExpensesMember_documentation_en-US" xlink:label="lab_wald_MisstatementOfCapitalizedMarketingExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Capitalized Marketing Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfCapitalizedMarketingExpensesMember" xlink:href="wald-20221231.xsd#wald_MisstatementOfCapitalizedMarketingExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MisstatementOfCapitalizedMarketingExpensesMember" xlink:to="lab_wald_MisstatementOfCapitalizedMarketingExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_7b0be523-23e4-428c-afd8-56c86f633415_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_f61fba40-25bd-4b76-aa04-287bca65f0d1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative warrant liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Assets and Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_1b937563-1904-4b75-b3f5-9e64f4b6bf00_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_2305dc14-97bc-4efa-937b-3c5c4b8c7fe3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_45b4d3e5-45b1-41f3-8016-1a9eb37f99e1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_92ee5b49-17a3-41d6-abf3-998adb5f7b1b_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_29260ba4-5ae3-456e-a9a1-d1ff14365f78_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Balance Sheet</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Balance Sheet [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_cde37ce4-60f0-451d-bd04-4575074a2050_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d5d22488-366b-4339-8e5d-729e2ebb6cd7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_AmortizationOfRelatedPartyLiability_1716a45b-87bb-4a2a-85f8-d0d10168fdb6_negatedTerseLabel_en-US" xlink:label="lab_wald_AmortizationOfRelatedPartyLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of related party liability</link:label>
    <link:label id="lab_wald_AmortizationOfRelatedPartyLiability_label_en-US" xlink:label="lab_wald_AmortizationOfRelatedPartyLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Related Party Liability</link:label>
    <link:label id="lab_wald_AmortizationOfRelatedPartyLiability_documentation_en-US" xlink:label="lab_wald_AmortizationOfRelatedPartyLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Related Party Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AmortizationOfRelatedPartyLiability" xlink:href="wald-20221231.xsd#wald_AmortizationOfRelatedPartyLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_AmortizationOfRelatedPartyLiability" xlink:to="lab_wald_AmortizationOfRelatedPartyLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c3e01870-3f12-446c-bf32-cfd1fee25216_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_f63bb502-0be0-4b57-b507-755289c7c81d_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Correction, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Correction, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_826b40ad-4fc1-4a39-a6c5-9e74fb333f8d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_86e0f280-8c13-4eb1-b76a-4df725443b63_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_113398d5-a8a8-441c-83b5-d7d1697eb2f7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5a9ac805-4c2a-4861-a3bd-2e9000388312_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_DeferredTaxAssetsBelowMarketLeaseContract_473ad12e-9b12-476e-842a-3f9dbd87a57c_terseLabel_en-US" xlink:label="lab_wald_DeferredTaxAssetsBelowMarketLeaseContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below market contract</link:label>
    <link:label id="lab_wald_DeferredTaxAssetsBelowMarketLeaseContract_label_en-US" xlink:label="lab_wald_DeferredTaxAssetsBelowMarketLeaseContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Below Market Lease Contract</link:label>
    <link:label id="lab_wald_DeferredTaxAssetsBelowMarketLeaseContract_documentation_en-US" xlink:label="lab_wald_DeferredTaxAssetsBelowMarketLeaseContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Below Market Lease Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DeferredTaxAssetsBelowMarketLeaseContract" xlink:href="wald-20221231.xsd#wald_DeferredTaxAssetsBelowMarketLeaseContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_DeferredTaxAssetsBelowMarketLeaseContract" xlink:to="lab_wald_DeferredTaxAssetsBelowMarketLeaseContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_943e9216-d23d-4c1b-b0b6-c29385fbabd7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_660a42ad-e613-47b2-aeac-e7003498c3c6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_40406b04-169a-429a-b702-4fda14819f9a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_9cbdad57-e537-4e6a-9df4-ca9e78146070_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent_e0860d67-41cb-497b-94e7-b7c6177f9d5a_terseLabel_en-US" xlink:label="lab_wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent_label_en-US" xlink:label="lab_wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Goodwill Impairment, Percent</link:label>
    <link:label id="lab_wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent_documentation_en-US" xlink:label="lab_wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Goodwill Impairment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent" xlink:href="wald-20221231.xsd#wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent" xlink:to="lab_wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_0d502c3d-ab69-49a0-8d26-5b0b72260843_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_74ee24eb-adce-4be9-bb26-57f435fc8a34_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance cost, current</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Current, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod_033d6a44-54f3-4783-8ce9-b11318ef800e_terseLabel_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity instruments assumed in business combination (in shares)</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod_label_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Business Combination, Assumed In Period</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod_documentation_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Business Combination, Assumed In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod" xlink:to="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals_f70a1c59-cc2b-4ab2-af08-448e553f0d1d_terseLabel_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of founders</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals_label_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Number Of Individuals</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals_documentation_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Number Of Individuals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals" xlink:to="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_432e7b61-2970-4775-992c-39924f2ebe9f_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock_4c3597d4-47dd-41c7-9447-07df26bb4764_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Statement of Operations</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Income Statement [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_5efc0dd2-0bed-425b-bbb0-14bb6f63480e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_71e8bec2-459f-412d-88d1-e5e879fa4fee_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before equity in undistributed earnings of subsidiaries</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_0d64ee18-e1e5-4a14-8fe6-74c634e11e1d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_ed34f3c6-de1c-493e-9c6e-4de25367e079_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_89f2d562-a300-47fc-bdb1-9295c6819f65_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributed to Class A shareholders - basic EPS</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_93b8a2bf-2342-4b7f-899f-32f3db5e48e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList_a8199bc4-b920-4224-9fb2-d8d85b70e9a4_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Designation, Predecessor and Successor [Fixed List]</link:label>
    <link:label id="lab_us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList_label_en-US" xlink:label="lab_us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Designation, Predecessor and Successor [Fixed List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList" xlink:to="lab_us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_937de496-8b12-4f39-abab-43d50af4ee7f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Common Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember_ce3caea6-aa7c-4716-b193-2c7866886808_terseLabel_en-US" xlink:label="lab_wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Employee Related Compensation Matters and Other Expenses</link:label>
    <link:label id="lab_wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember_label_en-US" xlink:label="lab_wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Employee Related Compensation Matters and Other Expenses [Member]</link:label>
    <link:label id="lab_wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember_documentation_en-US" xlink:label="lab_wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Employee Related Compensation Matters and Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember" xlink:href="wald-20221231.xsd#wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember" xlink:to="lab_wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_7e9fc813-4f13-49a7-9ee4-3df022d6fab5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restatement and Reclassification Adjustments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ac75cf9f-1fe4-42e5-89ab-0ec5e67b8f78_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b729e623-1b5e-4de2-8864-48c6edf26798_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_4fae787a-2b50-473a-a652-ba1a91785eee_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reported lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_7db37335-8475-4111-9902-3e4c5c2016d5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_12757ba3-5411-4816-887e-0e9181ac85c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_6858921b-f27f-4148-8af6-0118521139ee_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b0bc6ba6-ea83-4b1e-8a5c-cf9bc4c644f1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember_6061b535-b3a8-4233-8dc1-1190568600a9_terseLabel_en-US" xlink:label="lab_wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Income Tax Expense and Related Liabilities</link:label>
    <link:label id="lab_wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember_label_en-US" xlink:label="lab_wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Income Tax Expense and Related Liabilities [Member]</link:label>
    <link:label id="lab_wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember_documentation_en-US" xlink:label="lab_wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Income Tax Expense and Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember" xlink:href="wald-20221231.xsd#wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember" xlink:to="lab_wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_8ea35c30-52b4-4537-b963-9a05c3d6b514_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company 401(k) retirement plan contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_b229821c-9b58-47c4-b3da-e36710858c83_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_LesseeOperatingLeaseExtensionTerm_f21fd3a1-45f5-44a8-8c87-2362fd046c40_terseLabel_en-US" xlink:label="lab_wald_LesseeOperatingLeaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease extension term</link:label>
    <link:label id="lab_wald_LesseeOperatingLeaseExtensionTerm_label_en-US" xlink:label="lab_wald_LesseeOperatingLeaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Extension Term</link:label>
    <link:label id="lab_wald_LesseeOperatingLeaseExtensionTerm_documentation_en-US" xlink:label="lab_wald_LesseeOperatingLeaseExtensionTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Extension Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_LesseeOperatingLeaseExtensionTerm" xlink:href="wald-20221231.xsd#wald_LesseeOperatingLeaseExtensionTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_LesseeOperatingLeaseExtensionTerm" xlink:to="lab_wald_LesseeOperatingLeaseExtensionTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_FormulationsMember_14a7e4ad-acff-4e07-a772-52d11b30f6f8_verboseLabel_en-US" xlink:label="lab_wald_FormulationsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Formulations</link:label>
    <link:label id="lab_wald_FormulationsMember_ad9a159b-0d7e-46fb-bc31-a849b087b7cb_terseLabel_en-US" xlink:label="lab_wald_FormulationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Formulations</link:label>
    <link:label id="lab_wald_FormulationsMember_label_en-US" xlink:label="lab_wald_FormulationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Formulations [Member]</link:label>
    <link:label id="lab_wald_FormulationsMember_documentation_en-US" xlink:label="lab_wald_FormulationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Formulations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_FormulationsMember" xlink:href="wald-20221231.xsd#wald_FormulationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_FormulationsMember" xlink:to="lab_wald_FormulationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock_c511c04d-718e-4f7a-acc3-fc740a0b9082_terseLabel_en-US" xlink:label="lab_wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Net Operating Losses and Tax Credit Carryforwards</link:label>
    <link:label id="lab_wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock_label_en-US" xlink:label="lab_wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Operating Loss Carryforwards and Tax Credit Carryforwards [Table Text Block]</link:label>
    <link:label id="lab_wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock_documentation_en-US" xlink:label="lab_wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Operating Loss Carryforwards and Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock" xlink:href="wald-20221231.xsd#wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock" xlink:to="lab_wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_b92040ec-4acf-4759-89d8-b4ab426aad23_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_69b1bbb0-e1a4-49ae-b535-3a3407a415ae_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to Class A shareholders (Note 15):</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_6d7f0328-01a8-4bb8-976d-255d3a0cfb54_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_8a0d6039-1bfe-428b-821e-246da7a18359_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_2cfa829e-129d-4d17-88c2-eb25ca61e454_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Predecessor common shares, 25,000,000 shares authorized; $0.50 par value, 8,000,002 shares issued and outstanding as of December 31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_e6d7d5ad-c961-4b81-a99b-3fbe56b4387c_netLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Successor ordinary shares</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_98112783-ec7d-4bda-9de8-6c2f6413838c_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_4232ffd8-1754-4dbb-8f4c-aba9aeda3768_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred (income) expense:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_3b7bf1c5-ec62-4299-8ba4-085696611401_terseLabel_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of annual installments</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_label_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Annual Installments</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_documentation_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Annual Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:to="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_46590239-21c4-4e62-9094-1134d27faa52_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ObagiMergerMember_930aaf71-5f5f-42bf-a398-04b527eb9f75_verboseLabel_en-US" xlink:label="lab_wald_ObagiMergerMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi</link:label>
    <link:label id="lab_wald_ObagiMergerMember_87ab3efd-e879-447b-a36d-53afc17dbf4d_terseLabel_en-US" xlink:label="lab_wald_ObagiMergerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi Merger</link:label>
    <link:label id="lab_wald_ObagiMergerMember_label_en-US" xlink:label="lab_wald_ObagiMergerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi Merger [Member]</link:label>
    <link:label id="lab_wald_ObagiMergerMember_documentation_en-US" xlink:label="lab_wald_ObagiMergerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi Merger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiMergerMember" xlink:href="wald-20221231.xsd#wald_ObagiMergerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ObagiMergerMember" xlink:to="lab_wald_ObagiMergerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_CedarwalkMember_7fef422a-11ff-424d-b330-f55b9df4ab64_terseLabel_en-US" xlink:label="lab_wald_CedarwalkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cedarwalk</link:label>
    <link:label id="lab_wald_CedarwalkMember_label_en-US" xlink:label="lab_wald_CedarwalkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cedarwalk [Member]</link:label>
    <link:label id="lab_wald_CedarwalkMember_documentation_en-US" xlink:label="lab_wald_CedarwalkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cedarwalk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CedarwalkMember" xlink:href="wald-20221231.xsd#wald_CedarwalkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_CedarwalkMember" xlink:to="lab_wald_CedarwalkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_NumberOfLeaseAgreements_45061079-a0d4-4fbd-a14d-028bb0123683_terseLabel_en-US" xlink:label="lab_wald_NumberOfLeaseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of leases</link:label>
    <link:label id="lab_wald_NumberOfLeaseAgreements_label_en-US" xlink:label="lab_wald_NumberOfLeaseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Lease Agreements</link:label>
    <link:label id="lab_wald_NumberOfLeaseAgreements_documentation_en-US" xlink:label="lab_wald_NumberOfLeaseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Lease Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_NumberOfLeaseAgreements" xlink:href="wald-20221231.xsd#wald_NumberOfLeaseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_NumberOfLeaseAgreements" xlink:to="lab_wald_NumberOfLeaseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_d21c0b32-0806-4666-867d-6ae68ac6e368_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f179cdec-2131-4383-abb6-f618b70d37ef_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses (income), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_dfb143b3-ed15-41d8-84bb-e3eca837db07_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8577b464-8db2-49ba-9f7b-d9ccc56f9741_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5df54a59-6240-45bb-8e59-3aef5c1f3db2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ae2d48dd-9b7b-4e01-93b2-c4a8eecc8e18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ForwardPurchaseAgreementHurdleRate_4e2a320c-1dc6-4daa-b26a-3bbabe8d354e_terseLabel_en-US" xlink:label="lab_wald_ForwardPurchaseAgreementHurdleRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hurdle rate (percent)</link:label>
    <link:label id="lab_wald_ForwardPurchaseAgreementHurdleRate_label_en-US" xlink:label="lab_wald_ForwardPurchaseAgreementHurdleRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Purchase Agreement, Hurdle Rate</link:label>
    <link:label id="lab_wald_ForwardPurchaseAgreementHurdleRate_documentation_en-US" xlink:label="lab_wald_ForwardPurchaseAgreementHurdleRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward Purchase Agreement, Hurdle Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ForwardPurchaseAgreementHurdleRate" xlink:href="wald-20221231.xsd#wald_ForwardPurchaseAgreementHurdleRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ForwardPurchaseAgreementHurdleRate" xlink:to="lab_wald_ForwardPurchaseAgreementHurdleRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_412242fc-12c6-4218-8205-b1aaf96f88e9_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_48b495ad-2d30-40e5-ac24-ba20a1049e4b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_749ce6be-1423-415c-8724-06d04f5ceded_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_99f1694e-e9de-40b8-bbcc-9b4ac4fbf644_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_03fc0230-63ff-49af-889f-f766d61ffa0b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_1c9b0a32-aa57-4a73-8c0b-2efccc0f8ae3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party liability</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_53219074-23b0-4f78-afd8-a97759837d86_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_c44eddf0-fd5d-4aad-b461-b22d02a0172f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_label_en-US" xlink:label="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ad485cf7-9c28-4d17-a401-923e5fcaeed6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_8c63657f-32f2-4d27-8a53-34d860f19a02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod_87976e6f-111f-44df-91dd-a72fca0f5611_terseLabel_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options assumed in business combination (in shares)</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod_label_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Business Combination, Assumed In Period</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod_documentation_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Business Combination, Assumed In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod" xlink:to="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_0691146a-623a-4048-b436-3f737ef51a9e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_6b5b59a5-2064-41c8-bb60-580c8afe17b5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase commitment period</link:label>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_label_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_bb32f4fb-9607-4fb1-9f8f-dae5745a51a5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in undistributed earnings of subsidiaries</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_a99d0698-7ee5-4ae8-8765-26025d42d47a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in income of subsidiaries</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Subsidiaries, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_CustomerOneMember_1873597a-2404-4ac3-9501-256f570f2fd9_terseLabel_en-US" xlink:label="lab_wald_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One</link:label>
    <link:label id="lab_wald_CustomerOneMember_label_en-US" xlink:label="lab_wald_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_wald_CustomerOneMember_documentation_en-US" xlink:label="lab_wald_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CustomerOneMember" xlink:href="wald-20221231.xsd#wald_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_CustomerOneMember" xlink:to="lab_wald_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ObagiChinaBusinessMember_e2545f02-9f9c-42bd-94b4-7f0728624120_terseLabel_en-US" xlink:label="lab_wald_ObagiChinaBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi China Business</link:label>
    <link:label id="lab_wald_ObagiChinaBusinessMember_label_en-US" xlink:label="lab_wald_ObagiChinaBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi China Business [Member]</link:label>
    <link:label id="lab_wald_ObagiChinaBusinessMember_documentation_en-US" xlink:label="lab_wald_ObagiChinaBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obagi China Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiChinaBusinessMember" xlink:href="wald-20221231.xsd#wald_ObagiChinaBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ObagiChinaBusinessMember" xlink:to="lab_wald_ObagiChinaBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties_6321d8bb-88bb-4b22-811b-550f9e46b22b_terseLabel_en-US" xlink:label="lab_wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest to foreign related parties</link:label>
    <link:label id="lab_wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties_label_en-US" xlink:label="lab_wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Accrued Interest to Foreign Related Parties</link:label>
    <link:label id="lab_wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties_documentation_en-US" xlink:label="lab_wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Accrued Interest to Foreign Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties" xlink:href="wald-20221231.xsd#wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties" xlink:to="lab_wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_95d6e0b2-aea9-4620-b850-168e8b4d6120_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative warrant liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_08570784-62ad-407c-b126-5c8f38217f11_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_fa74e3e1-f34d-4a36-a4ff-137da5ea8f16_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL CONTROLLING SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e91da0ee-11c6-44af-964d-6aaa2785833f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_418821bb-519b-4391-96e2-f510c887ff83_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_abf22dfa-c7f5-45db-b53c-95eefafe0680_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_e1cd9411-8a5d-4321-91f3-0d146b57c26c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_5d6eaa23-2d7c-4818-9fe2-f6ad1e6e0955_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0b1f3262-7196-403b-b9d1-dac400130a5f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_63dc6e62-ce95-4b1e-9630-b193361c67c8_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ac47c10d-8c41-4f12-8aef-bd9234c3a150_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b710105f-3403-41f1-b7aa-8257de5b824a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax losses</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_86effaea-dc7b-48d5-b10d-6c6b90342440_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_14d7b1b9-8c6f-4be8-a1a7-501f39bc4e8a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditure on intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MinimumThresholdPeriodForContractRepaymentOverTime_d9bb5330-5c9a-4af1-80d8-9eb20316274d_terseLabel_en-US" xlink:label="lab_wald_MinimumThresholdPeriodForContractRepaymentOverTime" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold repayment period</link:label>
    <link:label id="lab_wald_MinimumThresholdPeriodForContractRepaymentOverTime_label_en-US" xlink:label="lab_wald_MinimumThresholdPeriodForContractRepaymentOverTime" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Threshold Period for Contract Repayment Over Time</link:label>
    <link:label id="lab_wald_MinimumThresholdPeriodForContractRepaymentOverTime_documentation_en-US" xlink:label="lab_wald_MinimumThresholdPeriodForContractRepaymentOverTime" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Threshold Period for Contract Repayment Over Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MinimumThresholdPeriodForContractRepaymentOverTime" xlink:href="wald-20221231.xsd#wald_MinimumThresholdPeriodForContractRepaymentOverTime"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MinimumThresholdPeriodForContractRepaymentOverTime" xlink:to="lab_wald_MinimumThresholdPeriodForContractRepaymentOverTime" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_865a4933-3aed-4f67-af5d-d6979384bd00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8b8d3a47-9229-485f-a384-9fbaedfcb516_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares exchanged (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2ffd7c15-e809-41e2-8153-4e88f541ac41_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ServicesAgreementRenewalTerm_987d47e0-9302-4b08-8c68-8bacb69e5e01_terseLabel_en-US" xlink:label="lab_wald_ServicesAgreementRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services agreement, renewal term</link:label>
    <link:label id="lab_wald_ServicesAgreementRenewalTerm_label_en-US" xlink:label="lab_wald_ServicesAgreementRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreement, Renewal Term</link:label>
    <link:label id="lab_wald_ServicesAgreementRenewalTerm_documentation_en-US" xlink:label="lab_wald_ServicesAgreementRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreement, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ServicesAgreementRenewalTerm" xlink:href="wald-20221231.xsd#wald_ServicesAgreementRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ServicesAgreementRenewalTerm" xlink:to="lab_wald_ServicesAgreementRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_SpaChannelDistributorMember_6416b576-1678-4606-ba47-14d1456ad254_terseLabel_en-US" xlink:label="lab_wald_SpaChannelDistributorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spa Channel Distributor</link:label>
    <link:label id="lab_wald_SpaChannelDistributorMember_label_en-US" xlink:label="lab_wald_SpaChannelDistributorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spa Channel Distributor [Member]</link:label>
    <link:label id="lab_wald_SpaChannelDistributorMember_documentation_en-US" xlink:label="lab_wald_SpaChannelDistributorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spa Channel Distributor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SpaChannelDistributorMember" xlink:href="wald-20221231.xsd#wald_SpaChannelDistributorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_SpaChannelDistributorMember" xlink:to="lab_wald_SpaChannelDistributorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplyCommitmentMember_df31d3d4-e7dc-48f0-b72c-09b18f2627b1_terseLabel_en-US" xlink:label="lab_us-gaap_SupplyCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment</link:label>
    <link:label id="lab_us-gaap_SupplyCommitmentMember_label_en-US" xlink:label="lab_us-gaap_SupplyCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Commitment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplyCommitmentMember" xlink:to="lab_us-gaap_SupplyCommitmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_bb5a4b7d-ebbc-4594-81e3-a08334ba9af3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedIncomeStatementTable_4c90f936-92b1-4eef-87d0-760b022cba19_terseLabel_en-US" xlink:label="lab_srt_CondensedIncomeStatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Income Statement [Table]</link:label>
    <link:label id="lab_srt_CondensedIncomeStatementTable_label_en-US" xlink:label="lab_srt_CondensedIncomeStatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Income Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedIncomeStatementTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedIncomeStatementTable" xlink:to="lab_srt_CondensedIncomeStatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8f7ee794-f035-4f36-9214-8629c49c2475_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_DeferredTaxAssetsNetBeforeValuationAllowance_447f0df5-9fa6-4530-89ab-bea7667a9509_totalLabel_en-US" xlink:label="lab_wald_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax (liabilities) assets</link:label>
    <link:label id="lab_wald_DeferredTaxAssetsNetBeforeValuationAllowance_label_en-US" xlink:label="lab_wald_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, Before Valuation Allowance</link:label>
    <link:label id="lab_wald_DeferredTaxAssetsNetBeforeValuationAllowance_documentation_en-US" xlink:label="lab_wald_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, Before Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:href="wald-20221231.xsd#wald_DeferredTaxAssetsNetBeforeValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:to="lab_wald_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_97845c46-32ad-4a4e-801e-d286eedfb649_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_9fd4d4a8-cf71-41b9-a91d-6e9d14ce4c46_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Useful Lives (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_042a589e-65cf-4a4e-91da-3b03240e7c92_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0c18c875-87ac-4a39-9409-ae4085086ba8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ef92cd52-6562-4b9d-8b6e-d777ed628217_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_8051164e-e479-40ec-aaae-4457d774aa43_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d44a4763-34a9-4dbb-bc5c-d0618a60e4c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_dfa98a91-5d1a-42e1-821a-925cb2acf2ce_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by Geographic Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4e7f6849-5770-4967-b717-7a78721115c8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_A2022TermLoanMember_adba0877-aacd-4750-8306-0f1ce0aeb9af_terseLabel_en-US" xlink:label="lab_wald_A2022TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Term Loan</link:label>
    <link:label id="lab_wald_A2022TermLoanMember_label_en-US" xlink:label="lab_wald_A2022TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Term Loan [Member]</link:label>
    <link:label id="lab_wald_A2022TermLoanMember_documentation_en-US" xlink:label="lab_wald_A2022TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2022TermLoanMember" xlink:href="wald-20221231.xsd#wald_A2022TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_A2022TermLoanMember" xlink:to="lab_wald_A2022TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_bf13620a-d593-488e-9c9b-c9d14efc9b39_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_3b1136ca-991b-4bbf-81bf-942946dac168_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedIncomeStatementsCaptionsLineItems_ebfb28fc-03e2-4843-8803-d7b63a51e8df_terseLabel_en-US" xlink:label="lab_srt_CondensedIncomeStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Income Statements, Captions [Line Items]</link:label>
    <link:label id="lab_srt_CondensedIncomeStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedIncomeStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Income Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedIncomeStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7146ab32-b1aa-433b-b00e-d5c69ba6d01f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_1f04725b-8620-4045-8426-fdb20f5e854e_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_210ed1b4-dc94-432b-8ce6-4eb0194a9d61_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Restatement Recovery Analysis [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Restatement Recovery Analysis [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtRestatementRecoveryAnalysisFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:to="lab_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_753aa90e-e4b3-4b6d-a458-e422df392793_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued marketing expenses</link:label>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Marketing Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:to="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_54f25017-c14e-4cd7-92e8-73cb98b75593_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-Use Software and Website Development Costs</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_4be9e8bf-349f-45a3-b209-34d67e6407a0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_OneTimStockGrantMember_3cdd33bf-c55d-4897-b743-7094884976cb_terseLabel_en-US" xlink:label="lab_wald_OneTimStockGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-Tim Stock Grant</link:label>
    <link:label id="lab_wald_OneTimStockGrantMember_label_en-US" xlink:label="lab_wald_OneTimStockGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-Tim Stock Grant [Member]</link:label>
    <link:label id="lab_wald_OneTimStockGrantMember_documentation_en-US" xlink:label="lab_wald_OneTimStockGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-Tim Stock Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OneTimStockGrantMember" xlink:href="wald-20221231.xsd#wald_OneTimStockGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_OneTimStockGrantMember" xlink:to="lab_wald_OneTimStockGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0f6cf2a9-4194-4d58-a263-af32c0355d8a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_c5a11844-2b8d-446d-80f4-6df0485bcfb3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from change in fair value on derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_96072fcd-7d06-4129-898a-39c514d43a33_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_b2789c5f-277f-4a6c-9a65-c16ceed908a5_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_VendorTwoMember_99864c08-c3a3-4f0a-b30f-a69d99c9927e_terseLabel_en-US" xlink:label="lab_wald_VendorTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor Two</link:label>
    <link:label id="lab_wald_VendorTwoMember_label_en-US" xlink:label="lab_wald_VendorTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor Two [Member]</link:label>
    <link:label id="lab_wald_VendorTwoMember_documentation_en-US" xlink:label="lab_wald_VendorTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vendor Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VendorTwoMember" xlink:href="wald-20221231.xsd#wald_VendorTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_VendorTwoMember" xlink:to="lab_wald_VendorTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ServicesAgreementFeePercentageOfIncurredCosts_3b6ce837-517d-40bd-9f2a-b510cac5777a_terseLabel_en-US" xlink:label="lab_wald_ServicesAgreementFeePercentageOfIncurredCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service fee percentage</link:label>
    <link:label id="lab_wald_ServicesAgreementFeePercentageOfIncurredCosts_label_en-US" xlink:label="lab_wald_ServicesAgreementFeePercentageOfIncurredCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreement Fee, Percentage of Incurred Costs</link:label>
    <link:label id="lab_wald_ServicesAgreementFeePercentageOfIncurredCosts_documentation_en-US" xlink:label="lab_wald_ServicesAgreementFeePercentageOfIncurredCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreement Fee, Percentage of Incurred Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ServicesAgreementFeePercentageOfIncurredCosts" xlink:href="wald-20221231.xsd#wald_ServicesAgreementFeePercentageOfIncurredCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ServicesAgreementFeePercentageOfIncurredCosts" xlink:to="lab_wald_ServicesAgreementFeePercentageOfIncurredCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockVotingRights_78ed588d-504e-4635-a82a-c518fd7871ca_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockVotingRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, voting rights</link:label>
    <link:label id="lab_us-gaap_CommonStockVotingRights_label_en-US" xlink:label="lab_us-gaap_CommonStockVotingRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Voting Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockVotingRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockVotingRights" xlink:to="lab_us-gaap_CommonStockVotingRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_aabd4a02-f947-4a12-be4f-8b839baed759_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_e8bc3522-4845-4e08-bfe1-33553d0f3099_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_014de39c-198d-467a-bebf-2a3059241d74_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_b51e5cd5-5d08-40e7-b17b-5d3de96e8050_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_17661c63-0ac7-4940-b10a-bc39002188d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_ec8f3e4e-065b-4e1f-a0b3-ccd2c732e350_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_165cdddd-64d1-476d-a39a-450028d2effc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShippingAndHandlingCosts_ac0ce6d9-96a2-454c-b950-0985fed0f47c_terseLabel_en-US" xlink:label="lab_wald_ShippingAndHandlingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and handling costs</link:label>
    <link:label id="lab_wald_ShippingAndHandlingCosts_label_en-US" xlink:label="lab_wald_ShippingAndHandlingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping And Handling Costs</link:label>
    <link:label id="lab_wald_ShippingAndHandlingCosts_documentation_en-US" xlink:label="lab_wald_ShippingAndHandlingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping And Handling Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShippingAndHandlingCosts" xlink:href="wald-20221231.xsd#wald_ShippingAndHandlingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShippingAndHandlingCosts" xlink:to="lab_wald_ShippingAndHandlingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_f88bfeb3-4e74-414e-b4eb-5dcf8bfc554c_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Segment Gross Profit to Net Income (Loss) Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_68186925-1d91-4571-863c-a58674440ae5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_24ee8ba3-00f7-47cc-b8e5-6be5a7c147e1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c0c9bcb5-d306-4075-9dde-811f6af8bff5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets adjustments</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_f8a7d0c5-3c74-4cdd-95ea-31dfe89488d9_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice_479db410-f84e-4a0f-9d43-cc62e46accef_terseLabel_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant redemption, number of trading days at or above trigger price</link:label>
    <link:label id="lab_wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice_label_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Redemption, Number of Trading Days At or Above Trigger Price</link:label>
    <link:label id="lab_wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice_documentation_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Redemption, Number of Trading Days At or Above Trigger Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice" xlink:to="lab_wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6db2727a-2f49-42af-a0e7-69b253b87b20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk -free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_19c4cc58-aa97-40e9-848b-f47ad34fb4a1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_f11116d2-34ae-4f07-9f2b-2365a39eaed5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d50187e0-36d1-488e-8aac-6b38cd73a18c_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_12b90c8d-6a01-47a5-8d06-666ec54d3823_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_StockIssuedDuringPeriodSharesTrustProceeds_e50d8dca-7c9e-43e0-9107-555212468eca_terseLabel_en-US" xlink:label="lab_wald_StockIssuedDuringPeriodSharesTrustProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Class A ordinary shares upon release of Trust proceeds (in shares)</link:label>
    <link:label id="lab_wald_StockIssuedDuringPeriodSharesTrustProceeds_label_en-US" xlink:label="lab_wald_StockIssuedDuringPeriodSharesTrustProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Trust Proceeds</link:label>
    <link:label id="lab_wald_StockIssuedDuringPeriodSharesTrustProceeds_documentation_en-US" xlink:label="lab_wald_StockIssuedDuringPeriodSharesTrustProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Trust Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockIssuedDuringPeriodSharesTrustProceeds" xlink:href="wald-20221231.xsd#wald_StockIssuedDuringPeriodSharesTrustProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_StockIssuedDuringPeriodSharesTrustProceeds" xlink:to="lab_wald_StockIssuedDuringPeriodSharesTrustProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod_f1bd80b4-5668-48e3-977f-a41dc4c0fd54_terseLabel_en-US" xlink:label="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lock-up shares, earnout period</link:label>
    <link:label id="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod_label_en-US" xlink:label="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period</link:label>
    <link:label id="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod_documentation_en-US" xlink:label="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod" xlink:href="wald-20221231.xsd#wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod" xlink:to="lab_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_824c5255-4e0e-4bf5-9c18-f1f443345734_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_DistributionOfBusiness_062991ab-b758-4a9c-8869-21858301456e_negatedTerseLabel_en-US" xlink:label="lab_wald_DistributionOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution of Obagi China Business</link:label>
    <link:label id="lab_wald_DistributionOfBusiness_label_en-US" xlink:label="lab_wald_DistributionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution of Business</link:label>
    <link:label id="lab_wald_DistributionOfBusiness_documentation_en-US" xlink:label="lab_wald_DistributionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DistributionOfBusiness" xlink:href="wald-20221231.xsd#wald_DistributionOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_DistributionOfBusiness" xlink:to="lab_wald_DistributionOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_f554d2e2-9afc-4008-8797-b27f34b1a95c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_b9fd890b-36f0-4cf6-baa9-385ec76059a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_72627e7c-8ca2-4ff5-af28-b4d3a2bf40cd_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributed to Class A shareholders - diluted EPS</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_640b48fb-9876-4deb-8ba4-9515d9eb3905_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_A2022RevolvingCreditFacilityMember_a090be39-accb-4882-b3fd-cdc44b7d0755_terseLabel_en-US" xlink:label="lab_wald_A2022RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Revolving Credit Facility</link:label>
    <link:label id="lab_wald_A2022RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_wald_A2022RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_wald_A2022RevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_wald_A2022RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Revolving Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2022RevolvingCreditFacilityMember" xlink:href="wald-20221231.xsd#wald_A2022RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_A2022RevolvingCreditFacilityMember" xlink:to="lab_wald_A2022RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_c79595e2-9383-454d-8b1a-270daf82e4b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Financial Measures of Segments to Consolidated Totals</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_c6f28ffc-6f99-4271-a466-f6c33bbc01ea_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_194fb356-25a3-4029-b2bd-7ddadaa2d41c_terseLabel_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Adjustments</link:label>
    <link:label id="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_label_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Error Correction, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_ff9dce54-e056-4ce9-a16f-79485440d9f6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements_23908634-312f-4fcb-b167-2b4078c85891_terseLabel_en-US" xlink:label="lab_wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares in connection with the FPA investment (in shares)</link:label>
    <link:label id="lab_wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements_label_en-US" xlink:label="lab_wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Foreign Purchase Agreements</link:label>
    <link:label id="lab_wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements_documentation_en-US" xlink:label="lab_wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Foreign Purchase Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements" xlink:href="wald-20221231.xsd#wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements" xlink:to="lab_wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_975fe541-56f5-4de2-8878-c649fbe6e386_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL BALANCE SHEET DISCLOSURES</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_AdvancesForNoteReceivable_49304182-c4e2-4b69-a4d4-61665476fb60_negatedTerseLabel_en-US" xlink:label="lab_wald_AdvancesForNoteReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances for note receivable</link:label>
    <link:label id="lab_wald_AdvancesForNoteReceivable_label_en-US" xlink:label="lab_wald_AdvancesForNoteReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances For Note Receivable</link:label>
    <link:label id="lab_wald_AdvancesForNoteReceivable_documentation_en-US" xlink:label="lab_wald_AdvancesForNoteReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances For Note Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AdvancesForNoteReceivable" xlink:href="wald-20221231.xsd#wald_AdvancesForNoteReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_AdvancesForNoteReceivable" xlink:to="lab_wald_AdvancesForNoteReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_f2416de7-a2c0-4f95-b718-9524714a93d6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_9e32383b-7fd1-435c-8e42-5dc294b6a5ad_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_2358050a-2b70-4a33-bb2d-b9896520b97f_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding borrowings</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets_3d767ae5-4977-40f2-b690-834416dfa8e2_terseLabel_en-US" xlink:label="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets_label_en-US" xlink:label="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Leases, Right-of-Use Assets</link:label>
    <link:label id="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets_documentation_en-US" xlink:label="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Leases, Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets" xlink:href="wald-20221231.xsd#wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets" xlink:to="lab_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_12b06462-6f8d-4ee2-a9e6-25a565ec3dde_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromContributionsFromAffiliates_af4aa70d-59ca-4efd-871f-cb7d911bb036_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers from subsidiaries</link:label>
    <link:label id="lab_us-gaap_ProceedsFromContributionsFromAffiliates_label_en-US" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Contributions from Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_237cdd01-1fb9-479c-8f99-d2f4ea026e53_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_a74bd529-413d-4695-8544-750fd6d40b35_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_98372204-9ab3-421c-a71d-07f63963bcb5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage increase in shares available for issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_67dacdd4-172a-400d-9a0d-21493187b245_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_fe31d1dd-4db9-43a2-b6cd-c0fe694443c0_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_abce6783-9bd6-407f-bbbd-06190ac2861e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_124a0f7b-960f-4e16-922f-1909055fdf83_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_NonCashLossFromChangeInFairValueOnInterestRateCollar_052b3c57-e47d-4b5c-9b32-05f78a329eb7_terseLabel_en-US" xlink:label="lab_wald_NonCashLossFromChangeInFairValueOnInterestRateCollar" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash loss from change in fair value on interest rate collar</link:label>
    <link:label id="lab_wald_NonCashLossFromChangeInFairValueOnInterestRateCollar_label_en-US" xlink:label="lab_wald_NonCashLossFromChangeInFairValueOnInterestRateCollar" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Loss From Change In Fair Value On Interest Rate Collar</link:label>
    <link:label id="lab_wald_NonCashLossFromChangeInFairValueOnInterestRateCollar_documentation_en-US" xlink:label="lab_wald_NonCashLossFromChangeInFairValueOnInterestRateCollar" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Loss From Change In Fair Value On Interest Rate Collar</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_NonCashLossFromChangeInFairValueOnInterestRateCollar" xlink:href="wald-20221231.xsd#wald_NonCashLossFromChangeInFairValueOnInterestRateCollar"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_NonCashLossFromChangeInFairValueOnInterestRateCollar" xlink:to="lab_wald_NonCashLossFromChangeInFairValueOnInterestRateCollar" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_eebb20f8-6d74-40b0-8305-066d301d3696_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationTable_36a956cc-c44c-412a-a9f3-6db6d399371b_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationTable" xlink:to="lab_us-gaap_ReclassificationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_PrepaidExpensesPolicyTextBlock_a6ef9626-ddc5-4ab5-b252-1a83c4dc17fd_terseLabel_en-US" xlink:label="lab_wald_PrepaidExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses</link:label>
    <link:label id="lab_wald_PrepaidExpensesPolicyTextBlock_label_en-US" xlink:label="lab_wald_PrepaidExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses [Policy Text Block]</link:label>
    <link:label id="lab_wald_PrepaidExpensesPolicyTextBlock_documentation_en-US" xlink:label="lab_wald_PrepaidExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PrepaidExpensesPolicyTextBlock" xlink:href="wald-20221231.xsd#wald_PrepaidExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_PrepaidExpensesPolicyTextBlock" xlink:to="lab_wald_PrepaidExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_3025f873-ff9b-4498-ad8a-e801ba96830e_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_11fadec5-c17e-4654-a9b4-b50774fa2a93_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party liability from merger</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_176db1a6-3ffa-49f5-820e-8b10e41cd158_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MisstatementOfRevenueRecognitionTimingMember_e596f1f8-0283-4473-9c86-3471284e0de5_terseLabel_en-US" xlink:label="lab_wald_MisstatementOfRevenueRecognitionTimingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Revenue Recognition Timing</link:label>
    <link:label id="lab_wald_MisstatementOfRevenueRecognitionTimingMember_label_en-US" xlink:label="lab_wald_MisstatementOfRevenueRecognitionTimingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Revenue Recognition Timing [Member]</link:label>
    <link:label id="lab_wald_MisstatementOfRevenueRecognitionTimingMember_documentation_en-US" xlink:label="lab_wald_MisstatementOfRevenueRecognitionTimingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Revenue Recognition Timing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfRevenueRecognitionTimingMember" xlink:href="wald-20221231.xsd#wald_MisstatementOfRevenueRecognitionTimingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MisstatementOfRevenueRecognitionTimingMember" xlink:to="lab_wald_MisstatementOfRevenueRecognitionTimingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_97a5da5c-2701-44c7-af3c-5977b5211ae3_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost_77b2ad70-00fb-44bb-91de-d3f3ae248115_terseLabel_en-US" xlink:label="lab_wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental stock based compensation expense</link:label>
    <link:label id="lab_wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost_label_en-US" xlink:label="lab_wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Business Combination, Incremental Cost</link:label>
    <link:label id="lab_wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost_documentation_en-US" xlink:label="lab_wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Business Combination, Incremental Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost" xlink:href="wald-20221231.xsd#wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost" xlink:to="lab_wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_d0cf99ca-bbf6-4119-9151-8cf76c99f0c6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_8eb59f9a-62f2-44c2-b7e3-010e2a607937_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_65cdae91-b679-4a2e-95ee-b7d96c52e270_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_WaldencastPlcMember_e728331e-c96c-4d70-bb8d-14450631d7c5_terseLabel_en-US" xlink:label="lab_wald_WaldencastPlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waldencast plc</link:label>
    <link:label id="lab_wald_WaldencastPlcMember_label_en-US" xlink:label="lab_wald_WaldencastPlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waldencast plc [Member]</link:label>
    <link:label id="lab_wald_WaldencastPlcMember_documentation_en-US" xlink:label="lab_wald_WaldencastPlcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Waldencast plc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_WaldencastPlcMember" xlink:href="wald-20221231.xsd#wald_WaldencastPlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_WaldencastPlcMember" xlink:to="lab_wald_WaldencastPlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MisstatementOfResearchAndDevelopmentExpenseMember_1d4a231e-e348-4534-a980-8f4253767773_terseLabel_en-US" xlink:label="lab_wald_MisstatementOfResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement Of Research And Development Expense</link:label>
    <link:label id="lab_wald_MisstatementOfResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_wald_MisstatementOfResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement Of Research And Development Expense [Member]</link:label>
    <link:label id="lab_wald_MisstatementOfResearchAndDevelopmentExpenseMember_documentation_en-US" xlink:label="lab_wald_MisstatementOfResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement Of Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfResearchAndDevelopmentExpenseMember" xlink:href="wald-20221231.xsd#wald_MisstatementOfResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MisstatementOfResearchAndDevelopmentExpenseMember" xlink:to="lab_wald_MisstatementOfResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c946141b-b54a-4c56-8338-6ad9c37fc965_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_04c35328-f1a8-46db-bc72-9d8e924a3e98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_fbd98499-a085-4e29-9345-7c102c46454e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c3a8933a-f3e4-46d2-b11a-585bf467c6e8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_b91e4870-83dd-46b7-9c3f-32594f9dc57d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S./foreign tax rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bc3a9c3c-99d2-40c4-851f-8efa15b92f40_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_052ceed4-1dcc-41cd-b74b-80daa481cedb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_4d3ddb62-20b2-466e-8cc7-49833009f289_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_8ad23d38-6571-46f8-a720-12da2b64aba7_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_976fa30c-de46-4970-b554-8c3d79095783_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_b1cf0bd2-6997-400c-80a1-40c4fc372bae_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from revolving credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6540cef9-10a4-4647-b5f5-03e7b2574120_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_PublicDerivativeWarrantLiabilitiesMember_12e188be-30c0-42c7-8074-69fdfd6d7765_terseLabel_en-US" xlink:label="lab_wald_PublicDerivativeWarrantLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative warrant liabilities - Public</link:label>
    <link:label id="lab_wald_PublicDerivativeWarrantLiabilitiesMember_label_en-US" xlink:label="lab_wald_PublicDerivativeWarrantLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Derivative Warrant Liabilities [Member]</link:label>
    <link:label id="lab_wald_PublicDerivativeWarrantLiabilitiesMember_documentation_en-US" xlink:label="lab_wald_PublicDerivativeWarrantLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Derivative Warrant Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PublicDerivativeWarrantLiabilitiesMember" xlink:href="wald-20221231.xsd#wald_PublicDerivativeWarrantLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_PublicDerivativeWarrantLiabilitiesMember" xlink:to="lab_wald_PublicDerivativeWarrantLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_810c7976-4cb3-4c3d-88cd-ed22f25f966f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7b69f74d-c441-4743-b4fa-b6185fe13adb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_TretinoinDistributionAndSupplyAgreementMember_e8023b7f-f3dc-47b4-8d66-42f15cf84711_verboseLabel_en-US" xlink:label="lab_wald_TretinoinDistributionAndSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tretinoin distribution and supply agreement</link:label>
    <link:label id="lab_wald_TretinoinDistributionAndSupplyAgreementMember_d547707a-0c62-4652-b1f1-54327ec0369c_terseLabel_en-US" xlink:label="lab_wald_TretinoinDistributionAndSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply agreement</link:label>
    <link:label id="lab_wald_TretinoinDistributionAndSupplyAgreementMember_label_en-US" xlink:label="lab_wald_TretinoinDistributionAndSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tretinoin Distribution and Supply Agreement [Member]</link:label>
    <link:label id="lab_wald_TretinoinDistributionAndSupplyAgreementMember_documentation_en-US" xlink:label="lab_wald_TretinoinDistributionAndSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tretinoin Distribution and Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_TretinoinDistributionAndSupplyAgreementMember" xlink:href="wald-20221231.xsd#wald_TretinoinDistributionAndSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_TretinoinDistributionAndSupplyAgreementMember" xlink:to="lab_wald_TretinoinDistributionAndSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansReceivableBasisSpreadOnVariableRate_209f49a6-b4f2-45f1-a40a-d56d2709de8a_terseLabel_en-US" xlink:label="lab_us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_LoansReceivableBasisSpreadOnVariableRate_label_en-US" xlink:label="lab_us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Receivable, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:to="lab_us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_9231bce0-d2f4-4a57-aff7-8fadba7b5949_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_195a5f27-5516-4079-a8ee-e59db282bd7b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent Items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_5bc86ea3-fede-46b4-85d8-0189f8c16d89_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Account receivable, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_9a18500b-73b8-4bc1-9c04-6bf915d121ea_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_57270a58-85cf-47fd-bc79-18e8c9abd766_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenue (including related party net revenue of $17,219 in the Successor period)</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_13198d2b-876b-42a0-bd6a-3621ec1b22f0_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8c285889-5519-4fb5-a817-06b080b9a353_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net revenue adjustments</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_25f4524d-e737-4506-8ec0-fd8c82099435_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetRentableArea_ceab9bb0-99aa-41af-8728-67708bb011fd_terseLabel_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rentable square feet</link:label>
    <link:label id="lab_us-gaap_NetRentableArea_label_en-US" xlink:label="lab_us-gaap_NetRentableArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Rentable Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetRentableArea" xlink:to="lab_us-gaap_NetRentableArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_6aaf6212-be5e-46e1-8b44-ed1a1786af29_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3a19d67a-b73e-451c-b392-da8b72cfe7b4_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent_b4f62376-ce8d-451d-bf9d-01afe3a5f0de_terseLabel_en-US" xlink:label="lab_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro forma net income (loss) attributable to Waldencast plc</link:label>
    <link:label id="lab_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent_label_en-US" xlink:label="lab_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss), Attributable to Parent</link:label>
    <link:label id="lab_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent_documentation_en-US" xlink:label="lab_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss), Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent" xlink:href="wald-20221231.xsd#wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent" xlink:to="lab_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_9d980fc2-ad51-4fcb-b464-e972f854dad3_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLE ASSETS&#8212;NET</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_5620703b-aa15-461b-8686-d65f90be6652_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_371816a2-2af0-4c06-a6f8-73cb5e2c63da_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember_381b6d9b-b73b-46a1-a722-49914a3d420b_terseLabel_en-US" xlink:label="lab_wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Capitalized Research and Development Expenses</link:label>
    <link:label id="lab_wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember_label_en-US" xlink:label="lab_wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Capitalized Research and Development Expenses [Member]</link:label>
    <link:label id="lab_wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember_documentation_en-US" xlink:label="lab_wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Misstatement of Capitalized Research and Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember" xlink:href="wald-20221231.xsd#wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember" xlink:to="lab_wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ClassOfWarrantOrRightRedemptionPricePerShare_1ac5d12f-d0f0-4443-8840-ef40eba7b176_terseLabel_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant redemption price (in dollars per share)</link:label>
    <link:label id="lab_wald_ClassOfWarrantOrRightRedemptionPricePerShare_label_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Redemption Price Per Share</link:label>
    <link:label id="lab_wald_ClassOfWarrantOrRightRedemptionPricePerShare_documentation_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Redemption Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightRedemptionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:to="lab_wald_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a3645f4b-9a6f-4b3b-a3cc-0023d2647ef6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_86632f0c-6a74-4b9b-a5ee-4ded2b87d55c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_43059f56-c8c5-482a-b40f-c3b7d7fca781_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger_590dc0df-3302-44a6-99b1-351830f5eeef_terseLabel_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant redemption, stock price trigger (in dollars per share)</link:label>
    <link:label id="lab_wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger_label_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Redemption, Stock Price Trigger</link:label>
    <link:label id="lab_wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger_documentation_en-US" xlink:label="lab_wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Redemption, Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger" xlink:to="lab_wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_cf3cf02e-5de7-4d0c-b332-a3298e993ef2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_A2018TermLoanMember_38647f1d-d08e-4526-ad9f-ba0095e9d3fc_terseLabel_en-US" xlink:label="lab_wald_A2018TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Predecessor 2018 Term Loan</link:label>
    <link:label id="lab_wald_A2018TermLoanMember_label_en-US" xlink:label="lab_wald_A2018TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Term Loan [Member]</link:label>
    <link:label id="lab_wald_A2018TermLoanMember_documentation_en-US" xlink:label="lab_wald_A2018TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2018TermLoanMember" xlink:href="wald-20221231.xsd#wald_A2018TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_A2018TermLoanMember" xlink:to="lab_wald_A2018TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillDisclosureTextBlock_3dba3133-39f8-43a0-9c49-29948d9a955c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL</link:label>
    <link:label id="lab_us-gaap_GoodwillDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_234f1231-ac44-4482-822d-75be660240c8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_9e7725ce-fbb3-4921-a244-10390aa98a1f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_00b574bf-1632-48cf-a582-e4fc29fd8ccd_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a252fbe4-0ab9-47bd-a6fd-09f3db559cf6_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b2b33801-c916-4413-894e-f52fe6f61119_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average diluted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_c495b0d0-868c-45e0-9f99-266212a87adc_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent_2ed67f97-6760-43ba-a40b-1e1720083658_terseLabel_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise term, percent</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent_label_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Exercise Term, Percent</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent_documentation_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Exercise Term, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent" xlink:to="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9c948350-5d5f-4167-8ce5-ed6a17007138_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditure on property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_47e93747-6956-4a4b-9277-d77ab0efa05a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1f08d3df-6fc8-40fc-925d-82df9ef2b3af_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_870919d6-2aad-4696-950f-6d7d9d013712_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_222852df-d6f5-48bc-9600-8e375c22e30a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ee23fc9d-b299-4ee2-b33e-d4c2b2b8f508_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_InvestmentInSubsidiary_c5905bdf-a350-4f56-ace6-d2c6b795056d_terseLabel_en-US" xlink:label="lab_wald_InvestmentInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in subsidiary</link:label>
    <link:label id="lab_wald_InvestmentInSubsidiary_label_en-US" xlink:label="lab_wald_InvestmentInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Subsidiary</link:label>
    <link:label id="lab_wald_InvestmentInSubsidiary_documentation_en-US" xlink:label="lab_wald_InvestmentInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_InvestmentInSubsidiary" xlink:href="wald-20221231.xsd#wald_InvestmentInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_InvestmentInSubsidiary" xlink:to="lab_wald_InvestmentInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_20385935-6faf-4846-bdf0-e1ffd82606ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fac1c7c8-8f32-4ded-8d13-56db50ec9cff_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_ba6a7452-6e30-4fb7-a645-d18d321de8bc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_ce9f8ab4-904d-4480-88de-15f9f6fc4784_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest_8cc32539-08fa-4d5d-86df-52b528aaeea3_terseLabel_en-US" xlink:label="lab_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Pro forma net income (loss) attributable to noncontrolling interest</link:label>
    <link:label id="lab_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss), Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest_documentation_en-US" xlink:label="lab_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss), Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest" xlink:href="wald-20221231.xsd#wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_c4fc114a-4833-4af5-a50c-24badc7f4bc1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_136b65de-cc2f-4132-a5ee-13e178e62229_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b8b53815-cee5-4f54-a713-4ffad1a7010e_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0436404d-e7aa-4f4d-a73e-f4f13dba6511_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average basic shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_de79ae00-681f-4345-a438-ef47898c0a99_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed asset basis</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_09f6c4b0-543e-43ef-bd5e-6ca3f7202e41_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_DepreciationDepletionAndAmortizationOperatingActivities_d90c2ac4-7854-44f7-81ce-a0c65755588c_verboseLabel_en-US" xlink:label="lab_wald_DepreciationDepletionAndAmortizationOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_wald_DepreciationDepletionAndAmortizationOperatingActivities_d01ae649-4452-4239-87be-52de9f1a65bd_terseLabel_en-US" xlink:label="lab_wald_DepreciationDepletionAndAmortizationOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_wald_DepreciationDepletionAndAmortizationOperatingActivities_label_en-US" xlink:label="lab_wald_DepreciationDepletionAndAmortizationOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Operating Activities</link:label>
    <link:label id="lab_wald_DepreciationDepletionAndAmortizationOperatingActivities_documentation_en-US" xlink:label="lab_wald_DepreciationDepletionAndAmortizationOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DepreciationDepletionAndAmortizationOperatingActivities" xlink:href="wald-20221231.xsd#wald_DepreciationDepletionAndAmortizationOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_DepreciationDepletionAndAmortizationOperatingActivities" xlink:to="lab_wald_DepreciationDepletionAndAmortizationOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt_423ae635-abac-4b25-8da4-0e521534fa97_terseLabel_en-US" xlink:label="lab_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash repayment of debt</link:label>
    <link:label id="lab_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt_label_en-US" xlink:label="lab_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Cash Repayments of Debt</link:label>
    <link:label id="lab_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt_documentation_en-US" xlink:label="lab_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Cash Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt" xlink:href="wald-20221231.xsd#wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt" xlink:to="lab_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForErrorCorrectionDomain_16b2eac2-1781-4e96-b427-89e12396f3e4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Correction, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForErrorCorrectionDomain_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Correction, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:to="lab_us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_00521604-b8a5-4b71-a3b6-95498d94bd23_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash (used in) provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_37c414c7-6420-4868-b598-c5fc0cfd859b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_cdcf11f5-00bf-4321-8253-1db7e4a5603e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares exchanged</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_f66c1b3d-277e-477e-800b-762b4dfa28a1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3ac9ae7a-2642-4f76-81ac-c7cbde7ac615_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements_a9932adc-13f9-47d4-938d-1edb6eb41bc8_terseLabel_en-US" xlink:label="lab_wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common shares in connection with the FPA investment</link:label>
    <link:label id="lab_wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements_label_en-US" xlink:label="lab_wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Foreign Purchase Agreements</link:label>
    <link:label id="lab_wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements_documentation_en-US" xlink:label="lab_wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Foreign Purchase Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements" xlink:href="wald-20221231.xsd#wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements" xlink:to="lab_wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm_780bb6e2-80e3-4451-838c-4cbfc8d5aafa_terseLabel_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, weighted average remaining contractual life</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighed Average Remaining Contractual Term</link:label>
    <link:label id="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighed Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm" xlink:to="lab_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_73f444b8-7a2d-4635-aaec-894b786fc2fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_wald_CustomerPaymentPeriod_50e848e4-e664-482f-a66a-b9fb6995a7f3_terseLabel_en-US" xlink:label="lab_wald_CustomerPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer payment period</link:label>
    <link:label id="lab_wald_CustomerPaymentPeriod_label_en-US" xlink:label="lab_wald_CustomerPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Payment Period</link:label>
    <link:label id="lab_wald_CustomerPaymentPeriod_documentation_en-US" xlink:label="lab_wald_CustomerPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CustomerPaymentPeriod" xlink:href="wald-20221231.xsd#wald_CustomerPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_wald_CustomerPaymentPeriod" xlink:to="lab_wald_CustomerPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_2686e2da-9451-4483-971d-f7f64faa9cbd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Domain]</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerSalesChannelDomain_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Sales Channel [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:to="lab_us-gaap_ContractWithCustomerSalesChannelDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_41b92afe-5c62-420f-a8bd-a77168e3bfd2_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>wald-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:cb24ed7e-6299-4643-a980-910da3dfa7bf,g:f940d8a8-f49a-452c-b5e1-83817ee3c0b3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.waldencast.com/role/COVER" xlink:type="simple" xlink:href="wald-20221231.xsd#COVER"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/COVER" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_133d607e-2525-4663-974d-f257978b2450" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_e0db228d-3143-48f5-b397-394f0c9ee6ed" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_133d607e-2525-4663-974d-f257978b2450" xlink:to="loc_dei_DocumentInformationTable_e0db228d-3143-48f5-b397-394f0c9ee6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_894d7354-c234-4d79-89d9-9062f9fba2fc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_e0db228d-3143-48f5-b397-394f0c9ee6ed" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_894d7354-c234-4d79-89d9-9062f9fba2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_69875783-fcbe-44c6-b0ef-13d63d203ba9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_894d7354-c234-4d79-89d9-9062f9fba2fc" xlink:to="loc_dei_AddressTypeDomain_69875783-fcbe-44c6-b0ef-13d63d203ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_835e8a6e-2739-45cf-b971-63280a641e54" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_69875783-fcbe-44c6-b0ef-13d63d203ba9" xlink:to="loc_dei_BusinessContactMember_835e8a6e-2739-45cf-b971-63280a641e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_46c207d7-e260-4de9-92a2-71c3c3d9797a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_e0db228d-3143-48f5-b397-394f0c9ee6ed" xlink:to="loc_us-gaap_StatementClassOfStockAxis_46c207d7-e260-4de9-92a2-71c3c3d9797a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ff706955-1993-4c85-a0ed-d6e2a49ea1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_46c207d7-e260-4de9-92a2-71c3c3d9797a" xlink:to="loc_us-gaap_ClassOfStockDomain_ff706955-1993-4c85-a0ed-d6e2a49ea1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_59efe353-8d42-4e07-8309-fe46bdd5e487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ff706955-1993-4c85-a0ed-d6e2a49ea1ed" xlink:to="loc_us-gaap_CommonClassAMember_59efe353-8d42-4e07-8309-fe46bdd5e487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_d6a4b7ad-2d64-4311-9840-324ea48043e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ff706955-1993-4c85-a0ed-d6e2a49ea1ed" xlink:to="loc_us-gaap_WarrantMember_d6a4b7ad-2d64-4311-9840-324ea48043e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_47b5b2d4-2a6e-401d-8487-17ce2188ed72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ff706955-1993-4c85-a0ed-d6e2a49ea1ed" xlink:to="loc_us-gaap_CommonClassBMember_47b5b2d4-2a6e-401d-8487-17ce2188ed72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_e0db228d-3143-48f5-b397-394f0c9ee6ed" xlink:to="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e453eabb-70ae-4a77-8637-027984e308cf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentType_e453eabb-70ae-4a77-8637-027984e308cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_a65c3aab-eaff-45bf-ae6e-d5f6489ff3df" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentRegistrationStatement_a65c3aab-eaff-45bf-ae6e-d5f6489ff3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_71823cc5-9136-493f-9aa8-eb4f30d22190" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentAnnualReport_71823cc5-9136-493f-9aa8-eb4f30d22190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_22172f92-fde8-49f9-a143-1be9abaac24a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_CurrentFiscalYearEndDate_22172f92-fde8-49f9-a143-1be9abaac24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7061331d-9eca-4f0c-9d78-796ff24ad7ff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentPeriodEndDate_7061331d-9eca-4f0c-9d78-796ff24ad7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_84b2905b-0fde-44aa-83af-7cd7890db0e8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentTransitionReport_84b2905b-0fde-44aa-83af-7cd7890db0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_4e1e58cf-0b18-443d-b188-4cb7f22474f2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentShellCompanyReport_4e1e58cf-0b18-443d-b188-4cb7f22474f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_eaedd807-1c2d-4dce-8d29-8d4541d3c712" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityFileNumber_eaedd807-1c2d-4dce-8d29-8d4541d3c712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b17281de-b427-4bf0-bfa5-ca4e16d1dda5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityRegistrantName_b17281de-b427-4bf0-bfa5-ca4e16d1dda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e8112ba2-2e43-4470-a9a4-b67b43d7e972" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityAddressAddressLine1_e8112ba2-2e43-4470-a9a4-b67b43d7e972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_26bbb315-5141-42f4-a07d-f43b639d43af" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityAddressAddressLine2_26bbb315-5141-42f4-a07d-f43b639d43af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b0b503eb-744d-44b1-8151-9e6d4c2acc21" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityAddressCityOrTown_b0b503eb-744d-44b1-8151-9e6d4c2acc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_403b4b74-a009-46f2-a964-b792370d96c0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityAddressStateOrProvince_403b4b74-a009-46f2-a964-b792370d96c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_a18f7e16-6cc0-4749-8447-64c289a63362" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityAddressPostalZipCode_a18f7e16-6cc0-4749-8447-64c289a63362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_84abb777-e201-482c-8650-997601e29aa8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_ContactPersonnelName_84abb777-e201-482c-8650-997601e29aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1d3a544e-7a79-4448-8344-9cb5e208553a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_CityAreaCode_1d3a544e-7a79-4448-8344-9cb5e208553a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_36df013e-a0a6-4d1d-8c57-8cb7a4bc8404" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_LocalPhoneNumber_36df013e-a0a6-4d1d-8c57-8cb7a4bc8404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e5e158e9-206a-4996-81fb-eb2bb9314dcb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_Security12bTitle_e5e158e9-206a-4996-81fb-eb2bb9314dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a2b2f1f6-ac11-477c-a4ee-afdb91f881d9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_TradingSymbol_a2b2f1f6-ac11-477c-a4ee-afdb91f881d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c9918042-57bb-4021-bb24-39707b95680c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_SecurityExchangeName_c9918042-57bb-4021-bb24-39707b95680c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_03aaf512-e28e-40c0-a313-2fcec05077e5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_03aaf512-e28e-40c0-a313-2fcec05077e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_1f9f1098-ccc8-47e4-9363-55cb67af6092" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_1f9f1098-ccc8-47e4-9363-55cb67af6092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_563d5d0b-d864-415c-8806-96c251f6d81c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityVoluntaryFilers_563d5d0b-d864-415c-8806-96c251f6d81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c6d123cd-e525-498e-856c-54779f8b757e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityCurrentReportingStatus_c6d123cd-e525-498e-856c-54779f8b757e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_4cce6197-c0c2-49b0-b19c-2adcc8864322" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityInteractiveDataCurrent_4cce6197-c0c2-49b0-b19c-2adcc8864322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_5a4de90b-504c-4a2f-b66b-c67625025dd5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityFilerCategory_5a4de90b-504c-4a2f-b66b-c67625025dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_42054e03-f700-4ab4-bcfb-e440a67b79ff" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityEmergingGrowthCompany_42054e03-f700-4ab4-bcfb-e440a67b79ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_24950017-7d2d-4969-a509-af0495b66047" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityExTransitionPeriod_24950017-7d2d-4969-a509-af0495b66047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_db55b9f5-7704-481f-9309-3ac1477026a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_IcfrAuditorAttestationFlag_db55b9f5-7704-481f-9309-3ac1477026a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_30990195-b8b2-4cca-a4ec-5dcd7fab021f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_30990195-b8b2-4cca-a4ec-5dcd7fab021f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_7611b238-ea85-4fe5-8039-63026792ab07" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtRestatementRecoveryAnalysisFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_7611b238-ea85-4fe5-8039-63026792ab07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_0c9e68ec-4de5-4793-b761-4d9ba60f9fd6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentAccountingStandard_0c9e68ec-4de5-4793-b761-4d9ba60f9fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_886a883a-3805-4c4e-acc6-efca8abe16b2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityShellCompany_886a883a-3805-4c4e-acc6-efca8abe16b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a78e7c28-5a43-413f-bebd-8d6688fc8194" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityCentralIndexKey_a78e7c28-5a43-413f-bebd-8d6688fc8194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a933844a-d1db-4f17-9abf-83a6dba61921" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_AmendmentFlag_a933844a-d1db-4f17-9abf-83a6dba61921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_ff5536be-f6bf-427c-b76e-7d7ea4c545a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_ff5536be-f6bf-427c-b76e-7d7ea4c545a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d28f2fca-6482-4b46-86f9-68ca296107ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_DocumentFiscalYearFocus_d28f2fca-6482-4b46-86f9-68ca296107ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_0b90b412-2300-4fc7-91a5-4201dc2fb3fe" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityAddressCountry_0b90b412-2300-4fc7-91a5-4201dc2fb3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8a73a5bf-a33c-431d-96df-3200f3e25746" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_564cc62e-5922-4aa9-a279-e1ccd9c05dd1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8a73a5bf-a33c-431d-96df-3200f3e25746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/AuditInformation" xlink:type="simple" xlink:href="wald-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_wald_AuditInformationAbstract_274ebad3-a615-4414-87d7-ab2e3c66aedd" xlink:href="wald-20221231.xsd#wald_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_7bb9a3c0-3ff2-4cf0-92a1-a0a6eac2215a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wald_AuditInformationAbstract_274ebad3-a615-4414-87d7-ab2e3c66aedd" xlink:to="loc_dei_AuditorFirmId_7bb9a3c0-3ff2-4cf0-92a1-a0a6eac2215a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_b899023b-f4c7-42a7-a182-583cc1877627" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wald_AuditInformationAbstract_274ebad3-a615-4414-87d7-ab2e3c66aedd" xlink:to="loc_dei_AuditorName_b899023b-f4c7-42a7-a182-583cc1877627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_0fda9545-3e0b-410f-bf29-147d09536d7b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wald_AuditInformationAbstract_274ebad3-a615-4414-87d7-ab2e3c66aedd" xlink:to="loc_dei_AuditorLocation_0fda9545-3e0b-410f-bf29-147d09536d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="wald-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_90ce9637-4096-41e5-8d69-28438407506d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8d72545d-5a33-4284-80c3-3004428d1989" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_90ce9637-4096-41e5-8d69-28438407506d" xlink:to="loc_us-gaap_StatementTable_8d72545d-5a33-4284-80c3-3004428d1989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_53d1aa94-38ad-4837-93e1-ec82595a0e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8d72545d-5a33-4284-80c3-3004428d1989" xlink:to="loc_us-gaap_StatementClassOfStockAxis_53d1aa94-38ad-4837-93e1-ec82595a0e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_69cb069a-8a62-44e8-b002-c6f256db3b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_53d1aa94-38ad-4837-93e1-ec82595a0e16" xlink:to="loc_us-gaap_ClassOfStockDomain_69cb069a-8a62-44e8-b002-c6f256db3b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_4e008dcd-a7bc-4808-9f78-9e12c4afc404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_69cb069a-8a62-44e8-b002-c6f256db3b2c" xlink:to="loc_us-gaap_CommonClassAMember_4e008dcd-a7bc-4808-9f78-9e12c4afc404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_8216bb53-28d8-4b9f-93fc-33f44e1c7071" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_69cb069a-8a62-44e8-b002-c6f256db3b2c" xlink:to="loc_us-gaap_CommonClassBMember_8216bb53-28d8-4b9f-93fc-33f44e1c7071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad4fa5d4-908f-4c9d-b00e-0aba79fab88a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8d72545d-5a33-4284-80c3-3004428d1989" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad4fa5d4-908f-4c9d-b00e-0aba79fab88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c8d9ed24-66ec-4eee-b356-124782504c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ad4fa5d4-908f-4c9d-b00e-0aba79fab88a" xlink:to="loc_us-gaap_RelatedPartyDomain_c8d9ed24-66ec-4eee-b356-124782504c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_d8b92ee4-a117-4fed-8b10-3d2e2d73f9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c8d9ed24-66ec-4eee-b356-124782504c9b" xlink:to="loc_us-gaap_NonrelatedPartyMember_d8b92ee4-a117-4fed-8b10-3d2e2d73f9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_5d242a44-54b9-4ad4-9bde-53fe3e530cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c8d9ed24-66ec-4eee-b356-124782504c9b" xlink:to="loc_us-gaap_RelatedPartyMember_5d242a44-54b9-4ad4-9bde-53fe3e530cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_edf1051c-cc8a-4439-bf3b-3732a73ac052" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8d72545d-5a33-4284-80c3-3004428d1989" xlink:to="loc_us-gaap_StatementLineItems_edf1051c-cc8a-4439-bf3b-3732a73ac052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8f4b9b87-fc67-4217-b124-d766222b33b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_edf1051c-cc8a-4439-bf3b-3732a73ac052" xlink:to="loc_us-gaap_AssetsAbstract_8f4b9b87-fc67-4217-b124-d766222b33b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f6e1ca22-0ccb-4d19-97aa-03350a7d3dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8f4b9b87-fc67-4217-b124-d766222b33b3" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f6e1ca22-0ccb-4d19-97aa-03350a7d3dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3cfdd94d-9863-4890-9aca-3a6bd94cb20b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e1ca22-0ccb-4d19-97aa-03350a7d3dfc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3cfdd94d-9863-4890-9aca-3a6bd94cb20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_d7e375b8-8c55-4943-846e-688a10937261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e1ca22-0ccb-4d19-97aa-03350a7d3dfc" xlink:to="loc_us-gaap_RestrictedCash_d7e375b8-8c55-4943-846e-688a10937261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7b5e7bb2-d5d1-4750-8c44-81fb7d5bcf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e1ca22-0ccb-4d19-97aa-03350a7d3dfc" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7b5e7bb2-d5d1-4750-8c44-81fb7d5bcf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7841ffcc-dc8e-4d88-95de-80a121509269" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e1ca22-0ccb-4d19-97aa-03350a7d3dfc" xlink:to="loc_us-gaap_InventoryNet_7841ffcc-dc8e-4d88-95de-80a121509269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_903b718a-2373-48dd-af58-f723b43064c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e1ca22-0ccb-4d19-97aa-03350a7d3dfc" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_903b718a-2373-48dd-af58-f723b43064c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_6d1a6ad5-93f9-458b-a152-e5c3556e3941" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e1ca22-0ccb-4d19-97aa-03350a7d3dfc" xlink:to="loc_us-gaap_OtherAssetsCurrent_6d1a6ad5-93f9-458b-a152-e5c3556e3941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a871219d-3122-4aa3-8a0f-5f0bf3b7db0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f6e1ca22-0ccb-4d19-97aa-03350a7d3dfc" xlink:to="loc_us-gaap_AssetsCurrent_a871219d-3122-4aa3-8a0f-5f0bf3b7db0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_beae68ef-23ec-4b39-b093-eeb70e319d05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8f4b9b87-fc67-4217-b124-d766222b33b3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_beae68ef-23ec-4b39-b093-eeb70e319d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_abe70299-8cfb-428d-af8e-316a285a12bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8f4b9b87-fc67-4217-b124-d766222b33b3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_abe70299-8cfb-428d-af8e-316a285a12bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_757e1c3a-b84e-453e-91f6-94222279fcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8f4b9b87-fc67-4217-b124-d766222b33b3" xlink:to="loc_us-gaap_Goodwill_757e1c3a-b84e-453e-91f6-94222279fcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_beea02be-c73a-47be-8fe1-b9290aa1f7ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8f4b9b87-fc67-4217-b124-d766222b33b3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_beea02be-c73a-47be-8fe1-b9290aa1f7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9a971200-5b33-46c3-ab5f-28021a247861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8f4b9b87-fc67-4217-b124-d766222b33b3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9a971200-5b33-46c3-ab5f-28021a247861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e869836d-50c4-497e-b7a9-5295ce581ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8f4b9b87-fc67-4217-b124-d766222b33b3" xlink:to="loc_us-gaap_Assets_e869836d-50c4-497e-b7a9-5295ce581ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_edf1051c-cc8a-4439-bf3b-3732a73ac052" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f32a90be-627b-495e-bbd5-95ae8565cdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f32a90be-627b-495e-bbd5-95ae8565cdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a79d576-03b8-4a96-bef4-4eb868b27bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f32a90be-627b-495e-bbd5-95ae8565cdcc" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a79d576-03b8-4a96-bef4-4eb868b27bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_629d8ea5-e085-4553-ac71-2c43dd159fde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f32a90be-627b-495e-bbd5-95ae8565cdcc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_629d8ea5-e085-4553-ac71-2c43dd159fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7ed9c06f-835a-4a06-837a-ab84e0b9094e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f32a90be-627b-495e-bbd5-95ae8565cdcc" xlink:to="loc_us-gaap_LongTermDebtCurrent_7ed9c06f-835a-4a06-837a-ab84e0b9094e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_299fdca3-1ef5-454d-ada6-2e2885af9626" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f32a90be-627b-495e-bbd5-95ae8565cdcc" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_299fdca3-1ef5-454d-ada6-2e2885af9626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b5cd269d-e0dc-40d7-bfdb-e1eee4053afe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f32a90be-627b-495e-bbd5-95ae8565cdcc" xlink:to="loc_us-gaap_LiabilitiesCurrent_b5cd269d-e0dc-40d7-bfdb-e1eee4053afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e10bcbe8-807f-4058-ac8a-670849d11258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e10bcbe8-807f-4058-ac8a-670849d11258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_321fc6ee-da44-4a73-81e2-d84ecd73b399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_321fc6ee-da44-4a73-81e2-d84ecd73b399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0036db84-69be-4784-96be-cea70c3d943d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0036db84-69be-4784-96be-cea70c3d943d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_783d7578-d845-4226-a9bb-f7c650195f49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_783d7578-d845-4226-a9bb-f7c650195f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a2cf3a9f-2b8a-42c7-a6ce-b2d9d2abdc42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a2cf3a9f-2b8a-42c7-a6ce-b2d9d2abdc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0a3a9519-bd81-4930-b1fc-efc44ea1dde5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_Liabilities_0a3a9519-bd81-4930-b1fc-efc44ea1dde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f87e6315-3319-40ec-a867-3408f86d9900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f87e6315-3319-40ec-a867-3408f86d9900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9f31635a-54e9-4bba-bf49-7457f731eabb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_EquityAbstract_9f31635a-54e9-4bba-bf49-7457f731eabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_80d5f501-75ec-4960-b7dd-1d8158ecaa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9f31635a-54e9-4bba-bf49-7457f731eabb" xlink:to="loc_us-gaap_CommonStockValue_80d5f501-75ec-4960-b7dd-1d8158ecaa3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_06a5bf3e-ba45-485a-973d-2e9cba2266fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9f31635a-54e9-4bba-bf49-7457f731eabb" xlink:to="loc_us-gaap_AdditionalPaidInCapital_06a5bf3e-ba45-485a-973d-2e9cba2266fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b736647f-efe3-4ca7-a9b3-5e1ab953b2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9f31635a-54e9-4bba-bf49-7457f731eabb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b736647f-efe3-4ca7-a9b3-5e1ab953b2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_59ae7b6e-28c0-4ae2-b2a7-c1d4914cb83e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9f31635a-54e9-4bba-bf49-7457f731eabb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_59ae7b6e-28c0-4ae2-b2a7-c1d4914cb83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_17307018-8153-48d9-abfb-dad4c2ccdb98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9f31635a-54e9-4bba-bf49-7457f731eabb" xlink:to="loc_us-gaap_StockholdersEquity_17307018-8153-48d9-abfb-dad4c2ccdb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_6b2d1826-f873-44da-8c2c-c5ff888ec8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9f31635a-54e9-4bba-bf49-7457f731eabb" xlink:to="loc_us-gaap_MinorityInterest_6b2d1826-f873-44da-8c2c-c5ff888ec8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_609ff63b-f38c-4672-a5cd-fcf4a45b5080" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9f31635a-54e9-4bba-bf49-7457f731eabb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_609ff63b-f38c-4672-a5cd-fcf4a45b5080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_87e454c1-3a88-4caa-80e8-7986ac0bab58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bff03e-1713-40e3-94db-5c5d149d5968" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_87e454c1-3a88-4caa-80e8-7986ac0bab58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="wald-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2c9e60ba-cc3b-415d-8d3d-9f5d224c2a31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1b616adb-31df-433b-bea3-32106860473f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2c9e60ba-cc3b-415d-8d3d-9f5d224c2a31" xlink:to="loc_us-gaap_StatementTable_1b616adb-31df-433b-bea3-32106860473f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0a43b24f-eef4-4c89-a0b4-bf39630579f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1b616adb-31df-433b-bea3-32106860473f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0a43b24f-eef4-4c89-a0b4-bf39630579f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a7a8defc-138e-4c11-b7fa-ac255d80463a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0a43b24f-eef4-4c89-a0b4-bf39630579f6" xlink:to="loc_us-gaap_ClassOfStockDomain_a7a8defc-138e-4c11-b7fa-ac255d80463a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_0f4b2d9e-d16b-4915-9d2a-69189183d3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a7a8defc-138e-4c11-b7fa-ac255d80463a" xlink:to="loc_us-gaap_CommonClassAMember_0f4b2d9e-d16b-4915-9d2a-69189183d3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_ab4c3267-4047-41e2-ae40-483b6dd7459f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a7a8defc-138e-4c11-b7fa-ac255d80463a" xlink:to="loc_us-gaap_CommonClassBMember_ab4c3267-4047-41e2-ae40-483b6dd7459f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f0766699-298a-433d-a3a8-c5ab186db9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1b616adb-31df-433b-bea3-32106860473f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f0766699-298a-433d-a3a8-c5ab186db9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6bf1b3d0-1be9-4e66-8199-96f4e52b0108" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f0766699-298a-433d-a3a8-c5ab186db9d5" xlink:to="loc_us-gaap_RelatedPartyDomain_6bf1b3d0-1be9-4e66-8199-96f4e52b0108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_9eebc5a8-3463-4f94-8fd5-d321f9c4e1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6bf1b3d0-1be9-4e66-8199-96f4e52b0108" xlink:to="loc_us-gaap_RelatedPartyMember_9eebc5a8-3463-4f94-8fd5-d321f9c4e1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1b616adb-31df-433b-bea3-32106860473f" xlink:to="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_80afe06b-b28c-46ac-b640-295f82a78dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_80afe06b-b28c-46ac-b640-295f82a78dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_686d5873-770f-4d06-8251-5b9b34f9c79f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_686d5873-770f-4d06-8251-5b9b34f9c79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0f9c0edd-e958-400a-8d0d-2086d60fd89f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0f9c0edd-e958-400a-8d0d-2086d60fd89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_21aa7b30-83b3-4880-a736-43ea72fde1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_CommonStockSharesIssued_21aa7b30-83b3-4880-a736-43ea72fde1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b2f01d4e-8323-45d5-b1aa-ca6499ec1c78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b2f01d4e-8323-45d5-b1aa-ca6499ec1c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_56bb9b4e-ed18-4c46-b752-592bb9acb061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_56bb9b4e-ed18-4c46-b752-592bb9acb061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1dd8dd28-3b4b-470a-bc79-bbcf4a95c302" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1dd8dd28-3b4b-470a-bc79-bbcf4a95c302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_aff68090-39e9-4c17-82a6-bb2ba68b445c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_PreferredStockSharesIssued_aff68090-39e9-4c17-82a6-bb2ba68b445c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2e715a46-794b-462f-a72c-df961853fe50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_df9b6f73-a3db-4bae-a1e2-08b2fe5a3a26" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2e715a46-794b-462f-a72c-df961853fe50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="wald-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f0cdb5b7-7fe0-4782-ab27-de04f15c03ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f0cdb5b7-7fe0-4782-ab27-de04f15c03ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3e57e890-e60a-4a61-985c-163641174b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3e57e890-e60a-4a61-985c-163641174b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_768a350b-142a-4fe7-9116-f4ff1326dc4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_GrossProfit_768a350b-142a-4fe7-9116-f4ff1326dc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c7a16125-583e-4e24-bd4d-ad22333c13be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c7a16125-583e-4e24-bd4d-ad22333c13be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d850b711-7d38-4955-ad74-0b8d8fc0620b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d850b711-7d38-4955-ad74-0b8d8fc0620b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_d2b48b5d-86ee-4ea6-9b00-750a013bdfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_d2b48b5d-86ee-4ea6-9b00-750a013bdfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_51f117cb-10c3-4d5e-afed-316183d3d225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_OperatingExpenses_51f117cb-10c3-4d5e-afed-316183d3d225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3f67531d-1da0-41da-b447-b812daeeb1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_OperatingIncomeLoss_3f67531d-1da0-41da-b447-b812daeeb1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3ff77732-59a4-4428-8850-970ce929f7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_InterestExpense_3ff77732-59a4-4428-8850-970ce929f7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_48e4baf2-b2ca-4181-9137-ff9d1b740936" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_48e4baf2-b2ca-4181-9137-ff9d1b740936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b5bec430-a413-48b9-aad2-9ca1ac8146b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b5bec430-a413-48b9-aad2-9ca1ac8146b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainOnPPPLoanForgiveness_593b7543-7790-4ac0-88ec-b4305984ecac" xlink:href="wald-20221231.xsd#wald_GainOnPPPLoanForgiveness"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_wald_GainOnPPPLoanForgiveness_593b7543-7790-4ac0-88ec-b4305984ecac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainLossOnNoteReceivableWriteoff_c8b030d2-8f76-4004-ab6a-cbe957ecab09" xlink:href="wald-20221231.xsd#wald_GainLossOnNoteReceivableWriteoff"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_wald_GainLossOnNoteReceivableWriteoff_c8b030d2-8f76-4004-ab6a-cbe957ecab09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6f47f8a2-ff6c-4df0-9856-2054ed66971a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6f47f8a2-ff6c-4df0-9856-2054ed66971a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8f077045-8cf2-4e72-90a9-e14e5d07b2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8f077045-8cf2-4e72-90a9-e14e5d07b2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f050c996-dc8a-49b0-a66d-313491fc72d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f050c996-dc8a-49b0-a66d-313491fc72d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_df20131e-277b-4b14-80fd-212af49fb20f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_df20131e-277b-4b14-80fd-212af49fb20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5390444d-ac5e-4e2c-a2a1-78db2ce8c12f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_ProfitLoss_5390444d-ac5e-4e2c-a2a1-78db2ce8c12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_80bc7877-d5d8-4770-9d43-4cc9060b1486" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_80bc7877-d5d8-4770-9d43-4cc9060b1486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_499c9731-fc4b-4ac0-b0fe-d400158beae9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_NetIncomeLoss_499c9731-fc4b-4ac0-b0fe-d400158beae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_28290f6a-c0c3-4783-8ac3-4ac7e2d9bdda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_EarningsPerShareAbstract_28290f6a-c0c3-4783-8ac3-4ac7e2d9bdda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_43a4e46a-767c-41ae-90bb-1cda8627f8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_28290f6a-c0c3-4783-8ac3-4ac7e2d9bdda" xlink:to="loc_us-gaap_EarningsPerShareBasic_43a4e46a-767c-41ae-90bb-1cda8627f8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f5307754-10ec-4cc8-87ca-34aa79223661" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_28290f6a-c0c3-4783-8ac3-4ac7e2d9bdda" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f5307754-10ec-4cc8-87ca-34aa79223661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_f802c28a-783a-4632-b4a8-c51fa5111f76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_f802c28a-783a-4632-b4a8-c51fa5111f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4164484c-1caa-473e-85c4-cfbd3b7c16c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_f802c28a-783a-4632-b4a8-c51fa5111f76" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4164484c-1caa-473e-85c4-cfbd3b7c16c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_81334618-5994-46b2-9ddb-424b2c3d6198" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_f802c28a-783a-4632-b4a8-c51fa5111f76" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_81334618-5994-46b2-9ddb-424b2c3d6198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9da8426b-17bf-4f9c-a56d-307369fe2943" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9da8426b-17bf-4f9c-a56d-307369fe2943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dba890ce-5fb7-4253-a928-b1a5f0875258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_dba890ce-5fb7-4253-a928-b1a5f0875258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_9c7a7672-4be0-49ad-946b-929c56aefafa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_9c7a7672-4be0-49ad-946b-929c56aefafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5550d377-0aa5-4a5a-be9d-a94bc9a807d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90ad28cc-4eb1-4f93-9589-da70cce9f712" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5550d377-0aa5-4a5a-be9d-a94bc9a807d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="simple" xlink:href="wald-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8930b651-2f25-4320-9cc5-bb34347e14d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6ec677ee-7a0a-48d6-9b9b-7b63aab99a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8930b651-2f25-4320-9cc5-bb34347e14d7" xlink:to="loc_us-gaap_StatementTable_6ec677ee-7a0a-48d6-9b9b-7b63aab99a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2186a706-c70e-46b8-9ba2-eff2f45ad50b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6ec677ee-7a0a-48d6-9b9b-7b63aab99a0e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2186a706-c70e-46b8-9ba2-eff2f45ad50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_09dac033-03df-4c9d-a3d7-bfb006af475a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2186a706-c70e-46b8-9ba2-eff2f45ad50b" xlink:to="loc_us-gaap_RelatedPartyDomain_09dac033-03df-4c9d-a3d7-bfb006af475a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_f02a5bdd-a0aa-4b6f-9085-1904bd2c5980" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_09dac033-03df-4c9d-a3d7-bfb006af475a" xlink:to="loc_us-gaap_RelatedPartyMember_f02a5bdd-a0aa-4b6f-9085-1904bd2c5980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_22ea68d0-d78c-459e-aa62-bc2112b362cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6ec677ee-7a0a-48d6-9b9b-7b63aab99a0e" xlink:to="loc_us-gaap_SupplyCommitmentAxis_22ea68d0-d78c-459e-aa62-bc2112b362cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_28a0cbcd-3435-4bbb-88b1-908e9cf2bb41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentAxis_22ea68d0-d78c-459e-aa62-bc2112b362cc" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_28a0cbcd-3435-4bbb-88b1-908e9cf2bb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentMember_e7523d97-31f8-4905-9d8f-bee1c7b9a49e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_28a0cbcd-3435-4bbb-88b1-908e9cf2bb41" xlink:to="loc_us-gaap_SupplyCommitmentMember_e7523d97-31f8-4905-9d8f-bee1c7b9a49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3baf014a-5baf-40b4-850c-90197c9989a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6ec677ee-7a0a-48d6-9b9b-7b63aab99a0e" xlink:to="loc_us-gaap_StatementLineItems_3baf014a-5baf-40b4-850c-90197c9989a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33d854c0-15f8-445b-8965-f6013ce1fdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3baf014a-5baf-40b4-850c-90197c9989a1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33d854c0-15f8-445b-8965-f6013ce1fdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d088287d-db27-44c1-88a1-2633bd9088ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3baf014a-5baf-40b4-850c-90197c9989a1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d088287d-db27-44c1-88a1-2633bd9088ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="wald-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d2cb9546-a427-4d3b-a485-f99ccaaeb7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_26d40751-2f6b-4c80-874b-263506a59b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d2cb9546-a427-4d3b-a485-f99ccaaeb7f7" xlink:to="loc_us-gaap_StatementTable_26d40751-2f6b-4c80-874b-263506a59b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fc39e37a-965b-41f8-b2fb-e9da7a8cd413" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_26d40751-2f6b-4c80-874b-263506a59b5f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fc39e37a-965b-41f8-b2fb-e9da7a8cd413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1eca69aa-e89e-4db2-94eb-6a61017e690a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fc39e37a-965b-41f8-b2fb-e9da7a8cd413" xlink:to="loc_us-gaap_EquityComponentDomain_1eca69aa-e89e-4db2-94eb-6a61017e690a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_fa85f83b-06e4-41ff-bc95-9b4b86e2bd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1eca69aa-e89e-4db2-94eb-6a61017e690a" xlink:to="loc_us-gaap_CommonStockMember_fa85f83b-06e4-41ff-bc95-9b4b86e2bd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_29779239-ea62-4db0-b588-e5f26aed670a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1eca69aa-e89e-4db2-94eb-6a61017e690a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_29779239-ea62-4db0-b588-e5f26aed670a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_dddff235-0e94-483b-ad6e-8dec09669670" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1eca69aa-e89e-4db2-94eb-6a61017e690a" xlink:to="loc_us-gaap_RetainedEarningsMember_dddff235-0e94-483b-ad6e-8dec09669670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2453ab4b-d955-43cc-987f-e5ebc0c74aae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1eca69aa-e89e-4db2-94eb-6a61017e690a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2453ab4b-d955-43cc-987f-e5ebc0c74aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_049f9b74-5d05-47d2-aede-800cf545f29f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1eca69aa-e89e-4db2-94eb-6a61017e690a" xlink:to="loc_us-gaap_NoncontrollingInterestMember_049f9b74-5d05-47d2-aede-800cf545f29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1a8f92e5-b8a1-4d31-a883-a8fe21336b54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_26d40751-2f6b-4c80-874b-263506a59b5f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1a8f92e5-b8a1-4d31-a883-a8fe21336b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9ee2f13c-b7e3-48ec-880f-db8c66c012e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1a8f92e5-b8a1-4d31-a883-a8fe21336b54" xlink:to="loc_us-gaap_ClassOfStockDomain_9ee2f13c-b7e3-48ec-880f-db8c66c012e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_4458e8c4-55dc-4d1f-aca4-7342ed7a5c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9ee2f13c-b7e3-48ec-880f-db8c66c012e2" xlink:to="loc_us-gaap_CommonClassAMember_4458e8c4-55dc-4d1f-aca4-7342ed7a5c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_3405f262-8c14-4732-ac99-66bae0dda415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9ee2f13c-b7e3-48ec-880f-db8c66c012e2" xlink:to="loc_us-gaap_CommonClassBMember_3405f262-8c14-4732-ac99-66bae0dda415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4ce1e1b2-826d-4064-9d6d-62ab4b90f112" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_26d40751-2f6b-4c80-874b-263506a59b5f" xlink:to="loc_dei_LegalEntityAxis_4ce1e1b2-826d-4064-9d6d-62ab4b90f112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_20dfcfb2-0936-4ca5-828c-07e5de321c43" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4ce1e1b2-826d-4064-9d6d-62ab4b90f112" xlink:to="loc_dei_EntityDomain_20dfcfb2-0936-4ca5-828c-07e5de321c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_WaldencastPlcMember_ce089e44-f941-45c0-81c2-3b1335296cdf" xlink:href="wald-20221231.xsd#wald_WaldencastPlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_20dfcfb2-0936-4ca5-828c-07e5de321c43" xlink:to="loc_wald_WaldencastPlcMember_ce089e44-f941-45c0-81c2-3b1335296cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiCosmeceuticalsLLCMember_0892f097-a37c-4e5c-a364-81a97fd2670b" xlink:href="wald-20221231.xsd#wald_ObagiCosmeceuticalsLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_20dfcfb2-0936-4ca5-828c-07e5de321c43" xlink:to="loc_wald_ObagiCosmeceuticalsLLCMember_0892f097-a37c-4e5c-a364-81a97fd2670b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_2818ab50-ccc5-4c3b-8b6c-0a6dc33d9820" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_26d40751-2f6b-4c80-874b-263506a59b5f" xlink:to="loc_srt_RestatementAxis_2818ab50-ccc5-4c3b-8b6c-0a6dc33d9820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_1a1ed8ef-4ec3-47e4-9951-4e276b542d3a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_2818ab50-ccc5-4c3b-8b6c-0a6dc33d9820" xlink:to="loc_srt_RestatementDomain_1a1ed8ef-4ec3-47e4-9951-4e276b542d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_c09f83c1-c4b6-44b3-a8d0-b51263588976" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1a1ed8ef-4ec3-47e4-9951-4e276b542d3a" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_c09f83c1-c4b6-44b3-a8d0-b51263588976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_7e0a24a0-8e4d-4720-b39f-9fa3cc8e4f06" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1a1ed8ef-4ec3-47e4-9951-4e276b542d3a" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_7e0a24a0-8e4d-4720-b39f-9fa3cc8e4f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_eb36be64-4f40-460a-b50c-6cf9e83ccf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_26d40751-2f6b-4c80-874b-263506a59b5f" xlink:to="loc_us-gaap_StatementLineItems_eb36be64-4f40-460a-b50c-6cf9e83ccf6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_eb36be64-4f40-460a-b50c-6cf9e83ccf6b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6c32179d-51cc-4d07-a84c-8cd5a2ea74a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6c32179d-51cc-4d07-a84c-8cd5a2ea74a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7eef98df-0df0-4d09-a3f2-17b6c556b923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7eef98df-0df0-4d09-a3f2-17b6c556b923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockIssuedDuringPeriodSharesTrustProceeds_18e3d8a0-dab3-45eb-9326-46da3ec02d9c" xlink:href="wald-20221231.xsd#wald_StockIssuedDuringPeriodSharesTrustProceeds"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_wald_StockIssuedDuringPeriodSharesTrustProceeds_18e3d8a0-dab3-45eb-9326-46da3ec02d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockIssuedDuringPeriodValueTrustProceeds_bf9d511e-0aae-4319-a6f3-014470904fa3" xlink:href="wald-20221231.xsd#wald_StockIssuedDuringPeriodValueTrustProceeds"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_wald_StockIssuedDuringPeriodValueTrustProceeds_bf9d511e-0aae-4319-a6f3-014470904fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements_b3cacb8d-5988-4cf3-b631-94884791e1c4" xlink:href="wald-20221231.xsd#wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements_b3cacb8d-5988-4cf3-b631-94884791e1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements_a23cc6ab-5508-413f-b6b1-9277d4c9b245" xlink:href="wald-20221231.xsd#wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements_a23cc6ab-5508-413f-b6b1-9277d4c9b245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockIssuedDuringPeriodSharesSubscriptionAgreements_7c585979-55f2-48bc-a07c-5c88cdceb8cb" xlink:href="wald-20221231.xsd#wald_StockIssuedDuringPeriodSharesSubscriptionAgreements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_wald_StockIssuedDuringPeriodSharesSubscriptionAgreements_7c585979-55f2-48bc-a07c-5c88cdceb8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockIssuedDuringPeriodValueSubscriptionAgreements_94a863f7-f86d-4a5b-9da8-70ab3e264083" xlink:href="wald-20221231.xsd#wald_StockIssuedDuringPeriodValueSubscriptionAgreements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_wald_StockIssuedDuringPeriodValueSubscriptionAgreements_94a863f7-f86d-4a5b-9da8-70ab3e264083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d62cbb59-de25-4cc1-b22c-40dfca375540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_d62cbb59-de25-4cc1-b22c-40dfca375540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_baf8a79d-3651-4022-a814-3d15690ff23a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_baf8a79d-3651-4022-a814-3d15690ff23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_13889adb-54b5-4691-9aa8-63985264ef9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_ProfitLoss_13889adb-54b5-4691-9aa8-63985264ef9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d4d7bfe7-02fe-479e-9ed2-342f8d175cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d4d7bfe7-02fe-479e-9ed2-342f8d175cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b1a2762e-fe83-4632-9bbb-58925fdfb290" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b1a2762e-fe83-4632-9bbb-58925fdfb290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_2c93a08c-55d8-422d-b4a5-4a45cc8d9ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_2c93a08c-55d8-422d-b4a5-4a45cc8d9ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_97f946c6-8565-4529-9824-86549255ec8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_DividendsCommonStockCash_97f946c6-8565-4529-9824-86549255ec8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DistributionOfBusiness_012ba9cf-fb12-4d3c-bb62-88fb37ce11b7" xlink:href="wald-20221231.xsd#wald_DistributionOfBusiness"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_wald_DistributionOfBusiness_012ba9cf-fb12-4d3c-bb62-88fb37ce11b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e28fdaf9-b650-44bf-98d2-ac7822846209" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e28fdaf9-b650-44bf-98d2-ac7822846209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f0ec8957-f911-4683-a0ea-6adc2b395fda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a22c9549-b387-49b4-ade9-c158e2d95336" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f0ec8957-f911-4683-a0ea-6adc2b395fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="wald-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_81226fb0-304c-4e1a-ba2c-fa64597ed87c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_3afe1079-a9bc-4908-9b6c-eadf7db4a1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_81226fb0-304c-4e1a-ba2c-fa64597ed87c" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_3afe1079-a9bc-4908-9b6c-eadf7db4a1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="wald-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d24dc80c-d2bb-4c79-85ce-7f303396ce20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a3ca9851-2f98-4d44-b703-771cb17bd71d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d24dc80c-d2bb-4c79-85ce-7f303396ce20" xlink:to="loc_us-gaap_StatementTable_a3ca9851-2f98-4d44-b703-771cb17bd71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_59638e30-135d-43d5-9015-2123f99d780a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a3ca9851-2f98-4d44-b703-771cb17bd71d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_59638e30-135d-43d5-9015-2123f99d780a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eea409a8-bb67-47f4-9b97-3f066041a018" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_59638e30-135d-43d5-9015-2123f99d780a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eea409a8-bb67-47f4-9b97-3f066041a018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiMergerMember_46a1febe-9151-4ac7-a72f-e87dfaf00135" xlink:href="wald-20221231.xsd#wald_ObagiMergerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eea409a8-bb67-47f4-9b97-3f066041a018" xlink:to="loc_wald_ObagiMergerMember_46a1febe-9151-4ac7-a72f-e87dfaf00135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkTransactionMember_e9b254cb-5119-4bed-bb72-858850992f10" xlink:href="wald-20221231.xsd#wald_MilkTransactionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eea409a8-bb67-47f4-9b97-3f066041a018" xlink:to="loc_wald_MilkTransactionMember_e9b254cb-5119-4bed-bb72-858850992f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a3ca9851-2f98-4d44-b703-771cb17bd71d" xlink:to="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6084452a-4601-44d2-a771-e22ddd1d04f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6084452a-4601-44d2-a771-e22ddd1d04f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_389de8a0-4064-49a4-adff-f1dfa3727f47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6084452a-4601-44d2-a771-e22ddd1d04f3" xlink:to="loc_us-gaap_ProfitLoss_389de8a0-4064-49a4-adff-f1dfa3727f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0afa66bb-9a36-4503-a5fd-cc986a8ddae7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6084452a-4601-44d2-a771-e22ddd1d04f3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0afa66bb-9a36-4503-a5fd-cc986a8ddae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0afa66bb-9a36-4503-a5fd-cc986a8ddae7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_40b8d3c2-812c-44a0-8f8a-26fc8dd06d36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_ShareBasedCompensation_40b8d3c2-812c-44a0-8f8a-26fc8dd06d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DepreciationDepletionAndAmortizationOperatingActivities_710334e8-ef35-44ab-a0dd-212dac15a85a" xlink:href="wald-20221231.xsd#wald_DepreciationDepletionAndAmortizationOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_wald_DepreciationDepletionAndAmortizationOperatingActivities_710334e8-ef35-44ab-a0dd-212dac15a85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_e356fe21-cc51-403b-9af5-994f2314ba57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_OperatingLeaseExpense_e356fe21-cc51-403b-9af5-994f2314ba57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_d15314e6-0505-402b-b20e-23e464321f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_d15314e6-0505-402b-b20e-23e464321f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_NonCashLossFromChangeInFairValueOnInterestRateCollar_deb14f2f-395c-4479-90bb-bfb10234f619" xlink:href="wald-20221231.xsd#wald_NonCashLossFromChangeInFairValueOnInterestRateCollar"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_wald_NonCashLossFromChangeInFairValueOnInterestRateCollar_deb14f2f-395c-4479-90bb-bfb10234f619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d2c3ebb9-ab15-4dd2-9f3c-05fbc6bdfac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d2c3ebb9-ab15-4dd2-9f3c-05fbc6bdfac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainOnPPPLoanForgiveness_2d4b753a-6d43-46ba-9497-380251ecb3ed" xlink:href="wald-20221231.xsd#wald_GainOnPPPLoanForgiveness"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_wald_GainOnPPPLoanForgiveness_2d4b753a-6d43-46ba-9497-380251ecb3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_96075ced-47a5-4e17-981b-e367cd8a42ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_96075ced-47a5-4e17-981b-e367cd8a42ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AmortizationOfRelatedPartyLiability_3d2bdd07-7cb4-48d8-9afb-fbde3f3c181e" xlink:href="wald-20221231.xsd#wald_AmortizationOfRelatedPartyLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_wald_AmortizationOfRelatedPartyLiability_3d2bdd07-7cb4-48d8-9afb-fbde3f3c181e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8c6ad2be-b37b-4872-a03c-a72ca50b6806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8c6ad2be-b37b-4872-a03c-a72ca50b6806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_ee004331-312b-42c0-83a1-ff6aa17904c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_ee004331-312b-42c0-83a1-ff6aa17904c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_52173d2e-eee1-4e19-85ec-586f95fa0e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_52173d2e-eee1-4e19-85ec-586f95fa0e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainLossOnNoteReceivableWriteoff_9ebe31a0-095e-4fda-9e4d-29872a731930" xlink:href="wald-20221231.xsd#wald_GainLossOnNoteReceivableWriteoff"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_wald_GainLossOnNoteReceivableWriteoff_9ebe31a0-095e-4fda-9e4d-29872a731930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_46b7eb43-2b25-43ca-9ebe-d8adf4ea55c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_46b7eb43-2b25-43ca-9ebe-d8adf4ea55c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_ac0f4396-24d6-49c5-89f5-addc09c26703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_ac0f4396-24d6-49c5-89f5-addc09c26703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_7b1e1113-105b-4e15-a262-8cf44b3efa8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_7b1e1113-105b-4e15-a262-8cf44b3efa8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_3a18b680-9730-4042-a0ed-8495075e3ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_3a18b680-9730-4042-a0ed-8495075e3ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c70a1a98-311a-471a-81ef-b27389dd6e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c70a1a98-311a-471a-81ef-b27389dd6e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties_726aa537-5aa9-4766-9f2a-4bb3853c8b48" xlink:href="wald-20221231.xsd#wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:to="loc_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties_726aa537-5aa9-4766-9f2a-4bb3853c8b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_1b20ccdc-734e-497c-a5a2-470dca189470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_1b20ccdc-734e-497c-a5a2-470dca189470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ba33d0d1-3541-495b-891c-ec3c97d0f0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ba33d0d1-3541-495b-891c-ec3c97d0f0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2e72c291-750c-48d9-a5fc-852ce38757f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70d9bfc9-1771-44eb-8667-a7ca0eccc52a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2e72c291-750c-48d9-a5fc-852ce38757f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ebf38345-02cf-4eaf-9acd-04897e39c51d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_af30565b-3192-4605-8421-623641d5e82d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ebf38345-02cf-4eaf-9acd-04897e39c51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2cb258-54ff-4a6a-9f8d-f098b1ee39ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2cb258-54ff-4a6a-9f8d-f098b1ee39ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5bc97e67-137c-40f1-b701-a973654f39d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2cb258-54ff-4a6a-9f8d-f098b1ee39ae" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5bc97e67-137c-40f1-b701-a973654f39d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_919c7a7a-c202-459a-8f8b-97a43b8766db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2cb258-54ff-4a6a-9f8d-f098b1ee39ae" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_919c7a7a-c202-459a-8f8b-97a43b8766db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AdvancesForNoteReceivable_55e27415-ac0f-4d00-a610-551c922b87f4" xlink:href="wald-20221231.xsd#wald_AdvancesForNoteReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2cb258-54ff-4a6a-9f8d-f098b1ee39ae" xlink:to="loc_wald_AdvancesForNoteReceivable_55e27415-ac0f-4d00-a610-551c922b87f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ProceedsFromTrustAccount_2c32bd32-c15d-4c56-be2e-fab012e73702" xlink:href="wald-20221231.xsd#wald_ProceedsFromTrustAccount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2cb258-54ff-4a6a-9f8d-f098b1ee39ae" xlink:to="loc_wald_ProceedsFromTrustAccount_2c32bd32-c15d-4c56-be2e-fab012e73702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_74428bd6-1e24-4715-bbf4-ec8953caa875" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2cb258-54ff-4a6a-9f8d-f098b1ee39ae" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_74428bd6-1e24-4715-bbf4-ec8953caa875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e203aea0-8989-4b48-891a-5ca255885c63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7f2cb258-54ff-4a6a-9f8d-f098b1ee39ae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e203aea0-8989-4b48-891a-5ca255885c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_18cd5332-09c9-451d-87df-9955916db758" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_18cd5332-09c9-451d-87df-9955916db758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ProceedsFromForwardPurchaseAgreements_056ab344-93dc-4168-8bce-3d4510c1a2c2" xlink:href="wald-20221231.xsd#wald_ProceedsFromForwardPurchaseAgreements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_wald_ProceedsFromForwardPurchaseAgreements_056ab344-93dc-4168-8bce-3d4510c1a2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_2e3fcada-ac13-44e2-8dc8-21bc59fe94eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_2e3fcada-ac13-44e2-8dc8-21bc59fe94eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_9db05496-f651-409c-93cb-639178590a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_us-gaap_RepaymentsOfDebt_9db05496-f651-409c-93cb-639178590a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_9384a862-b880-43b1-9aa8-980b783aa71c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_9384a862-b880-43b1-9aa8-980b783aa71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_af812e0d-81f7-458d-b24f-1fcc1d3a0cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_af812e0d-81f7-458d-b24f-1fcc1d3a0cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherDebt_838b22ab-b148-4476-96a7-a7f1486b2379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromOtherDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_us-gaap_ProceedsFromOtherDebt_838b22ab-b148-4476-96a7-a7f1486b2379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9e8b73eb-abb7-4e81-ba43-df37aa3a27ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_9e8b73eb-abb7-4e81-ba43-df37aa3a27ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_35f0f6ed-ef70-42b6-bea6-fa7d18723307" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_us-gaap_PaymentsOfDividends_35f0f6ed-ef70-42b6-bea6-fa7d18723307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54709743-56d8-4da0-8e46-75c82555cae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3cd7dcb1-da6f-4433-ba4a-1545d6b68d84" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_54709743-56d8-4da0-8e46-75c82555cae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_327c67ad-8822-46d9-b58f-4477ef16c797" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_327c67ad-8822-46d9-b58f-4477ef16c797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e2916ee7-eaba-4fd0-bf53-8cf3c76776fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e2916ee7-eaba-4fd0-bf53-8cf3c76776fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c5b4710e-0502-4c06-84a7-22f2fb27d148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c5b4710e-0502-4c06-84a7-22f2fb27d148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c420458b-11a8-4eae-a92b-00024b082881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c420458b-11a8-4eae-a92b-00024b082881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_02b5bc80-284d-4193-b7dc-31ae8f8b86d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_02b5bc80-284d-4193-b7dc-31ae8f8b86d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_4106226d-1301-42b1-ab4f-9d8199dfed24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_02b5bc80-284d-4193-b7dc-31ae8f8b86d5" xlink:to="loc_us-gaap_IncomeTaxesPaid_4106226d-1301-42b1-ab4f-9d8199dfed24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_845af3ff-28e0-468b-b366-be4194249879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_02b5bc80-284d-4193-b7dc-31ae8f8b86d5" xlink:to="loc_us-gaap_InterestPaidNet_845af3ff-28e0-468b-b366-be4194249879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a5eb6e23-b366-4a8c-abe8-4a8a0c485d98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15e4477f-19c1-4fdd-bc2e-ad97a01fd5c5" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a5eb6e23-b366-4a8c-abe8-4a8a0c485d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_48055545-489f-430f-a3d7-16543fda0fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a5eb6e23-b366-4a8c-abe8-4a8a0c485d98" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_48055545-489f-430f-a3d7-16543fda0fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CapitalContribution_3bab0387-1431-4190-9147-bc4241b75b4d" xlink:href="wald-20221231.xsd#wald_CapitalContribution"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a5eb6e23-b366-4a8c-abe8-4a8a0c485d98" xlink:to="loc_wald_CapitalContribution_3bab0387-1431-4190-9147-bc4241b75b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DistributionToShareholderForDispositionOfBusiness_3b666767-e131-4df7-9cfe-e41c684a2799" xlink:href="wald-20221231.xsd#wald_DistributionToShareholderForDispositionOfBusiness"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a5eb6e23-b366-4a8c-abe8-4a8a0c485d98" xlink:to="loc_wald_DistributionToShareholderForDispositionOfBusiness_3b666767-e131-4df7-9cfe-e41c684a2799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_bde4cebd-459f-4b06-9aa5-fb7f510dbd96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a5eb6e23-b366-4a8c-abe8-4a8a0c485d98" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_bde4cebd-459f-4b06-9aa5-fb7f510dbd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_3c813138-d597-4f82-bbac-93869e958f88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a5eb6e23-b366-4a8c-abe8-4a8a0c485d98" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_3c813138-d597-4f82-bbac-93869e958f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="wald-20221231.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dfb7bd73-4da4-473c-ac92-fcbc3cbdba3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_aa0a7698-5fbc-4dff-885a-269791188575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dfb7bd73-4da4-473c-ac92-fcbc3cbdba3f" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_aa0a7698-5fbc-4dff-885a-269791188575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONS" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONS"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_0bfc58fb-6d58-4105-93be-2cb784ae1f17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionTextBlock_91261c07-291a-444a-9e5c-9b555565f3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_0bfc58fb-6d58-4105-93be-2cb784ae1f17" xlink:to="loc_us-gaap_ErrorCorrectionTextBlock_91261c07-291a-444a-9e5c-9b555565f3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="wald-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2dc0fe51-b37f-42f4-9339-871e353dbc45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_cdd08a27-21df-4102-85e5-8d1252e107ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2dc0fe51-b37f-42f4-9339-871e353dbc45" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_cdd08a27-21df-4102-85e5-8d1252e107ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/BUSINESSCOMBINATIONS" xlink:type="simple" xlink:href="wald-20221231.xsd#BUSINESSCOMBINATIONS"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/BUSINESSCOMBINATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_06c97314-1dc7-4a1b-8dd1-98238b0275f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_d9f954a2-cfcc-4edc-a5e6-965ff85ad381" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_06c97314-1dc7-4a1b-8dd1-98238b0275f5" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_d9f954a2-cfcc-4edc-a5e6-965ff85ad381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/REVENUE" xlink:type="simple" xlink:href="wald-20221231.xsd#REVENUE"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/REVENUE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4d55e36f-d387-447c-bda9-007121b048bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_2a9c7a03-c920-4a08-97f1-7353858e0624" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4d55e36f-d387-447c-bda9-007121b048bb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_2a9c7a03-c920-4a08-97f1-7353858e0624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/GOODWILL" xlink:type="simple" xlink:href="wald-20221231.xsd#GOODWILL"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/GOODWILL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_27761f3e-bc44-45a9-9506-d8a84b8c96bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock_67c29493-cf47-4e93-9233-631e56eefda1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_27761f3e-bc44-45a9-9506-d8a84b8c96bd" xlink:to="loc_us-gaap_GoodwillDisclosureTextBlock_67c29493-cf47-4e93-9233-631e56eefda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INTANGIBLEASSETSNET" xlink:type="simple" xlink:href="wald-20221231.xsd#INTANGIBLEASSETSNET"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/INTANGIBLEASSETSNET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6ed7be2a-86e2-4be4-bafe-eea9c574622f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_f8518e01-f26e-4e0a-be29-c81ee94550c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6ed7be2a-86e2-4be4-bafe-eea9c574622f" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_f8518e01-f26e-4e0a-be29-c81ee94550c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/DEBT" xlink:type="simple" xlink:href="wald-20221231.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ca8e2703-051e-4bef-91b6-72e81bfcedf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_e47cc579-c2ed-4515-96be-11d20285633d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ca8e2703-051e-4bef-91b6-72e81bfcedf5" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_e47cc579-c2ed-4515-96be-11d20285633d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/LEASES" xlink:type="simple" xlink:href="wald-20221231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8d246d41-d586-4f06-977e-ed5865f902c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_d22d6632-532a-4f4e-a8b7-b13fae1fbcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d246d41-d586-4f06-977e-ed5865f902c1" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_d22d6632-532a-4f4e-a8b7-b13fae1fbcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/FINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="wald-20221231.xsd#FINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/FINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e4ebe4df-0069-4875-8a8b-bf1b0481289e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_96760f25-4610-49fe-9f6c-3b6cc807af2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e4ebe4df-0069-4875-8a8b-bf1b0481289e" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_96760f25-4610-49fe-9f6c-3b6cc807af2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="wald-20221231.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e50c0449-1e45-414e-84a0-638a8ea694aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_100c98d9-3272-4b3c-8154-bb311c545b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e50c0449-1e45-414e-84a0-638a8ea694aa" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_100c98d9-3272-4b3c-8154-bb311c545b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURES" xlink:type="simple" xlink:href="wald-20221231.xsd#SUPPLEMENTALBALANCESHEETDISCLOSURES"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb78eda5-c185-4a32-bf7b-82b47c7e1595" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_774ddd54-91a2-4a8a-94c8-63c9bc51c08f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eb78eda5-c185-4a32-bf7b-82b47c7e1595" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_774ddd54-91a2-4a8a-94c8-63c9bc51c08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="wald-20221231.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9098548f-4a4a-49e7-aea0-a68042a427d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1cf7fe5a-f37a-4fc9-b902-3d5131d997f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9098548f-4a4a-49e7-aea0-a68042a427d6" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1cf7fe5a-f37a-4fc9-b902-3d5131d997f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="wald-20221231.xsd#SHAREHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_06ffd172-25db-4aae-951a-fa59674f8b13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8b903ac4-e054-405b-a40f-0c790d3e6a32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_06ffd172-25db-4aae-951a-fa59674f8b13" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8b903ac4-e054-405b-a40f-0c790d3e6a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/NETLOSSPERSHARE" xlink:type="simple" xlink:href="wald-20221231.xsd#NETLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/NETLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b7309dde-554d-48d6-82df-e6bc729db06e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_799b805b-1202-4c93-bcd3-c91ebc3c12b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b7309dde-554d-48d6-82df-e6bc729db06e" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_799b805b-1202-4c93-bcd3-c91ebc3c12b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INCOMETAXBENEFIT" xlink:type="simple" xlink:href="wald-20221231.xsd#INCOMETAXBENEFIT"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/INCOMETAXBENEFIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f6317109-5aa0-4765-ad53-faad8fc48a67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4b9e520c-e71f-4a79-8e97-495134869a93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f6317109-5aa0-4765-ad53-faad8fc48a67" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4b9e520c-e71f-4a79-8e97-495134869a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="wald-20221231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_e2dcb622-cd7c-4d6b-be38-5b55484b2a29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2ddd8975-91ee-4ac1-b8aa-1df8683b7b39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_e2dcb622-cd7c-4d6b-be38-5b55484b2a29" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2ddd8975-91ee-4ac1-b8aa-1df8683b7b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="wald-20221231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b38d56db-1f7f-4d97-ae3a-56cded8a1e61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bb9e1d2d-d4d8-4aaa-a5ec-03e0987e87ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b38d56db-1f7f-4d97-ae3a-56cded8a1e61" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bb9e1d2d-d4d8-4aaa-a5ec-03e0987e87ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SEGMENTREPORTING" xlink:type="simple" xlink:href="wald-20221231.xsd#SEGMENTREPORTING"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SEGMENTREPORTING" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_426212f1-0b9f-4280-b165-3fe944782c56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_dcae577b-5a4a-4d06-bb3b-29e3b466017f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_426212f1-0b9f-4280-b165-3fe944782c56" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_dcae577b-5a4a-4d06-bb3b-29e3b466017f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/EMPLOYEEBENEFITPLAN" xlink:type="simple" xlink:href="wald-20221231.xsd#EMPLOYEEBENEFITPLAN"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/EMPLOYEEBENEFITPLAN" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_949738a1-f53c-4ad8-9f65-efa69fbddcdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_bcccb69f-3656-4765-bd68-f5ef2fa4cc67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_949738a1-f53c-4ad8-9f65-efa69fbddcdd" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_bcccb69f-3656-4765-bd68-f5ef2fa4cc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="wald-20221231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_99ea988f-8d6d-4605-9d60-f5a2c1678516" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_7dbd7d64-4f53-41a7-8cbf-189676e031a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_99ea988f-8d6d-4605-9d60-f5a2c1678516" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_7dbd7d64-4f53-41a7-8cbf-189676e031a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLY" xlink:type="simple" xlink:href="wald-20221231.xsd#SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLY"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_50a34959-5391-440e-aa5a-d369aba2b58c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_521903c9-1f58-4af0-9c72-1d059d73bb34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_50a34959-5391-440e-aa5a-d369aba2b58c" xlink:to="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_521903c9-1f58-4af0-9c72-1d059d73bb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies" xlink:type="simple" xlink:href="wald-20221231.xsd#OrganizationConsolidationandPresentationofFinancialStatementsPolicies"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/OrganizationConsolidationandPresentationofFinancialStatementsPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2e5d6f71-b726-4528-98b1-4a8d0f2f7422" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="wald-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2715c38f-fc22-4f1c-8bd1-144b9ed8e7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2715c38f-fc22-4f1c-8bd1-144b9ed8e7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_8f24bdfc-4ee9-4667-9744-176889449989" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_8f24bdfc-4ee9-4667-9744-176889449989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_0332bdbb-c01e-42b6-ab8d-0710389c30a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_UseOfEstimates_0332bdbb-c01e-42b6-ab8d-0710389c30a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_ec4341ed-fb82-42f8-8bd8-b97dafc268d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_ec4341ed-fb82-42f8-8bd8-b97dafc268d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_bef839f0-fbad-4d84-a33d-6138570ca58b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_bef839f0-fbad-4d84-a33d-6138570ca58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ba8ff0fb-0880-4d20-9edb-6a910fe2e84b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_ba8ff0fb-0880-4d20-9edb-6a910fe2e84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_242a71dc-f160-4a3a-ad69-f2f2aa4f955b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_242a71dc-f160-4a3a-ad69-f2f2aa4f955b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_0008455d-98c9-49bd-b762-100fcd865543" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_0008455d-98c9-49bd-b762-100fcd865543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_13ae76e7-86ac-43b1-926c-bedb4d85fa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_13ae76e7-86ac-43b1-926c-bedb4d85fa4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_79e605f7-4b95-4658-ac74-55ee5e1a0d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_79e605f7-4b95-4658-ac74-55ee5e1a0d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PrepaidExpensesPolicyTextBlock_4b008eb1-fcf2-4fbe-b203-7acc530541a1" xlink:href="wald-20221231.xsd#wald_PrepaidExpensesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_wald_PrepaidExpensesPolicyTextBlock_4b008eb1-fcf2-4fbe-b203-7acc530541a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f47ea44c-65da-4c21-83cf-ad096f1e2428" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f47ea44c-65da-4c21-83cf-ad096f1e2428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_ee30d47c-767e-42cd-ad76-fad6829cc69c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_ee30d47c-767e-42cd-ad76-fad6829cc69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_90f3563a-205d-4771-8823-96005983ed24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_90f3563a-205d-4771-8823-96005983ed24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_5bcc7f54-e1ac-4016-9c65-b23161292952" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_5bcc7f54-e1ac-4016-9c65-b23161292952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_191a14ef-b094-4af5-8ada-f430e13b3c75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_191a14ef-b094-4af5-8ada-f430e13b3c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_3986a46d-111e-4e33-91c6-fa8be11e7c04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_DebtPolicyTextBlock_3986a46d-111e-4e33-91c6-fa8be11e7c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_9d4e9b7f-bc6f-4946-9a30-768664aba90b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_9d4e9b7f-bc6f-4946-9a30-768664aba90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_57facc16-adae-48cc-a45b-1f3dcc8328e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_57facc16-adae-48cc-a45b-1f3dcc8328e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_a0ef7c35-dc69-4d64-bea8-efed92732d99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_a0ef7c35-dc69-4d64-bea8-efed92732d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_07710e36-db4c-49f9-9b85-79712643c84d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_07710e36-db4c-49f9-9b85-79712643c84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_0273b851-40b9-4b97-ba0b-bc95fafbdd25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_0273b851-40b9-4b97-ba0b-bc95fafbdd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e8d36ccb-4233-4501-8bff-fe110e93ef5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e8d36ccb-4233-4501-8bff-fe110e93ef5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_00ed6a1c-1abd-45f2-b00c-1315fbd5aa6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_00ed6a1c-1abd-45f2-b00c-1315fbd5aa6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_5b617f44-6b8c-4575-9a71-39ba11867288" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_5b617f44-6b8c-4575-9a71-39ba11867288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_e327c8b4-d255-40a1-9e5a-5e22e7afabdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_e327c8b4-d255-40a1-9e5a-5e22e7afabdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_da5311aa-67fb-4352-9328-d4af7bb06264" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_da5311aa-67fb-4352-9328-d4af7bb06264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_edb7541d-1399-4c50-9100-837c1b840bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae424706-0882-42d0-9b44-5ae78c36e055" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_edb7541d-1399-4c50-9100-837c1b840bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSTables" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSTables"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_8901f75c-89e6-49e1-aeb1-881a0800dbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_adf5f155-a01f-4c79-bb3c-7b08976e61c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_8901f75c-89e6-49e1-aeb1-881a0800dbd8" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_adf5f155-a01f-4c79-bb3c-7b08976e61c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="wald-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2057448b-31c4-432b-af4c-b0b6605f5077" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b3d5aedd-539e-4b18-afae-b8513bce3c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2057448b-31c4-432b-af4c-b0b6605f5077" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b3d5aedd-539e-4b18-afae-b8513bce3c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/BUSINESSCOMBINATIONSTables" xlink:type="simple" xlink:href="wald-20221231.xsd#BUSINESSCOMBINATIONSTables"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/BUSINESSCOMBINATIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5c29bb6f-0787-4063-9940-7e8543e0ffa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_34e83ef9-5a94-4f24-ac54-43deb23fbec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5c29bb6f-0787-4063-9940-7e8543e0ffa4" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_34e83ef9-5a94-4f24-ac54-43deb23fbec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_1fb72dfb-4eff-4741-a9b9-0ec628cbaca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5c29bb6f-0787-4063-9940-7e8543e0ffa4" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_1fb72dfb-4eff-4741-a9b9-0ec628cbaca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_c18bdbee-0531-481d-99b0-c04190c5ee4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_5c29bb6f-0787-4063-9940-7e8543e0ffa4" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_c18bdbee-0531-481d-99b0-c04190c5ee4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/REVENUETables" xlink:type="simple" xlink:href="wald-20221231.xsd#REVENUETables"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/REVENUETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_abe7f3a1-d358-4652-af61-2ddd08f6d679" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_3add071a-7a3a-4194-a9b7-66e7ffd12dee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_abe7f3a1-d358-4652-af61-2ddd08f6d679" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_3add071a-7a3a-4194-a9b7-66e7ffd12dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_66a755a7-1685-40bc-85de-2aba4e6860fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_abe7f3a1-d358-4652-af61-2ddd08f6d679" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_66a755a7-1685-40bc-85de-2aba4e6860fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/GOODWILLTables" xlink:type="simple" xlink:href="wald-20221231.xsd#GOODWILLTables"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/GOODWILLTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d95fef10-328f-4fea-95a4-edf6d7bcc665" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_e2259b50-64e1-4535-a473-3119ea30a2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d95fef10-328f-4fea-95a4-edf6d7bcc665" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_e2259b50-64e1-4535-a473-3119ea30a2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INTANGIBLEASSETSNETTables" xlink:type="simple" xlink:href="wald-20221231.xsd#INTANGIBLEASSETSNETTables"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/INTANGIBLEASSETSNETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c63fc8a9-9efc-44c3-95e6-fad699f3c0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_01f5a06d-a529-43ed-aaa9-2945b6a566b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c63fc8a9-9efc-44c3-95e6-fad699f3c0e6" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_01f5a06d-a529-43ed-aaa9-2945b6a566b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_77c8fcd6-ee79-4303-b640-7009bac22d34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c63fc8a9-9efc-44c3-95e6-fad699f3c0e6" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_77c8fcd6-ee79-4303-b640-7009bac22d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/DEBTTables" xlink:type="simple" xlink:href="wald-20221231.xsd#DEBTTables"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/DEBTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e68c226b-40e8-4330-a865-73412ece88bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_6239882d-82c6-4f38-a486-53dfaa10c84a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e68c226b-40e8-4330-a865-73412ece88bc" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_6239882d-82c6-4f38-a486-53dfaa10c84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_07810be4-54c4-41f2-883a-03b5abd89971" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e68c226b-40e8-4330-a865-73412ece88bc" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_07810be4-54c4-41f2-883a-03b5abd89971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/LEASESTables" xlink:type="simple" xlink:href="wald-20221231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c3bf2064-c46d-4e40-bb4c-c69fdf4aa844" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_7a4a7e4f-c64c-4d4b-a089-0c3f4f3ce7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3bf2064-c46d-4e40-bb4c-c69fdf4aa844" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_7a4a7e4f-c64c-4d4b-a089-0c3f4f3ce7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f0ff5eb5-c864-40a4-aad6-9be0ae7a8c80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c3bf2064-c46d-4e40-bb4c-c69fdf4aa844" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f0ff5eb5-c864-40a4-aad6-9be0ae7a8c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="wald-20221231.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ca0cf127-f651-4588-868a-385dd2beb616" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_636935f7-9594-4321-aa51-2129cbeecd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ca0cf127-f651-4588-868a-385dd2beb616" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_636935f7-9594-4321-aa51-2129cbeecd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESTables" xlink:type="simple" xlink:href="wald-20221231.xsd#SUPPLEMENTALBALANCESHEETDISCLOSURESTables"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_001d23ca-7410-467a-a581-cd2ff195f0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_9b3fef21-78be-4ada-99c0-55284798fe12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_001d23ca-7410-467a-a581-cd2ff195f0cc" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_9b3fef21-78be-4ada-99c0-55284798fe12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_491a78f8-3f9b-4961-983e-90dba9b5b54b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_001d23ca-7410-467a-a581-cd2ff195f0cc" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_491a78f8-3f9b-4961-983e-90dba9b5b54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ed380bfe-fee9-4df7-b1f1-2407a740d1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_001d23ca-7410-467a-a581-cd2ff195f0cc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ed380bfe-fee9-4df7-b1f1-2407a740d1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_4585d3b4-0acd-44f8-86a1-6b8d1f1e40e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_001d23ca-7410-467a-a581-cd2ff195f0cc" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_4585d3b4-0acd-44f8-86a1-6b8d1f1e40e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="wald-20221231.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a2afdc4d-4661-47f4-b0d1-4038011a4b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_a01d2eb4-0a2d-4821-80b7-a896198af25e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a2afdc4d-4661-47f4-b0d1-4038011a4b3b" xlink:to="loc_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_a01d2eb4-0a2d-4821-80b7-a896198af25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ceff5262-7d6b-4158-9c52-1a1e4653521b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a2afdc4d-4661-47f4-b0d1-4038011a4b3b" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ceff5262-7d6b-4158-9c52-1a1e4653521b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_2e6fba27-66ca-4098-883f-7309de563e63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a2afdc4d-4661-47f4-b0d1-4038011a4b3b" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_2e6fba27-66ca-4098-883f-7309de563e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/NETLOSSPERSHARETables" xlink:type="simple" xlink:href="wald-20221231.xsd#NETLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/NETLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_427542b8-027c-4e8f-a0ed-2ca945918257" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4aa6fc5a-0734-4e23-a25d-ea8f95af25ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_427542b8-027c-4e8f-a0ed-2ca945918257" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4aa6fc5a-0734-4e23-a25d-ea8f95af25ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6994209d-0b21-4ce6-bf8d-2404850d0c66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_427542b8-027c-4e8f-a0ed-2ca945918257" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6994209d-0b21-4ce6-bf8d-2404850d0c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITTables" xlink:type="simple" xlink:href="wald-20221231.xsd#INCOMETAXBENEFITTables"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/INCOMETAXBENEFITTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_21d415b4-252f-4f69-b5ff-8d870d782241" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_93f65495-86fa-4681-8794-e0af7f85d19e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_21d415b4-252f-4f69-b5ff-8d870d782241" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_93f65495-86fa-4681-8794-e0af7f85d19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_4404c9dc-f0b1-43e9-abc8-51d1498a331c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_21d415b4-252f-4f69-b5ff-8d870d782241" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_4404c9dc-f0b1-43e9-abc8-51d1498a331c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6db6dfbd-edfc-4d45-8eb9-d68baed4c14b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_21d415b4-252f-4f69-b5ff-8d870d782241" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6db6dfbd-edfc-4d45-8eb9-d68baed4c14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b4ee8ffb-108a-4493-8015-e9342660d6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_21d415b4-252f-4f69-b5ff-8d870d782241" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b4ee8ffb-108a-4493-8015-e9342660d6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock_f78ee0e9-eb28-43f6-89f8-3aff5d32aed8" xlink:href="wald-20221231.xsd#wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_21d415b4-252f-4f69-b5ff-8d870d782241" xlink:to="loc_wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock_f78ee0e9-eb28-43f6-89f8-3aff5d32aed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SEGMENTREPORTINGTables" xlink:type="simple" xlink:href="wald-20221231.xsd#SEGMENTREPORTINGTables"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SEGMENTREPORTINGTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e6f5146a-7c23-4242-a992-991d4be46d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_5d8dff41-0e6c-4ec6-89cc-2d2e0e84d441" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e6f5146a-7c23-4242-a992-991d4be46d0a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_5d8dff41-0e6c-4ec6-89cc-2d2e0e84d441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_79792c05-0841-40a8-b2bd-8a7b2880ffae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e6f5146a-7c23-4242-a992-991d4be46d0a" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_79792c05-0841-40a8-b2bd-8a7b2880ffae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables" xlink:type="simple" xlink:href="wald-20221231.xsd#SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_c626ca31-4708-4ed7-be16-7191c447ffb6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_3680aa44-a025-4d4b-80f9-0c8b64ad22be" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_c626ca31-4708-4ed7-be16-7191c447ffb6" xlink:to="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_3680aa44-a025-4d4b-80f9-0c8b64ad22be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedIncomeStatementTableTextBlock_7ee2c58f-fc6d-4dcc-8165-e44daa9d2fd1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_c626ca31-4708-4ed7-be16-7191c447ffb6" xlink:to="loc_srt_ScheduleOfCondensedIncomeStatementTableTextBlock_7ee2c58f-fc6d-4dcc-8165-e44daa9d2fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_5045363e-98f4-4823-8905-ad125212f3a2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_c626ca31-4708-4ed7-be16-7191c447ffb6" xlink:to="loc_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_5045363e-98f4-4823-8905-ad125212f3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20912b63-317d-4ad8-89a7-3b37dbb53449" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_53bc9c53-8f97-4699-b6d6-8b6d6accc492" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20912b63-317d-4ad8-89a7-3b37dbb53449" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_53bc9c53-8f97-4699-b6d6-8b6d6accc492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c06add68-0b63-4ea2-bbb7-3e1c4a790e82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53bc9c53-8f97-4699-b6d6-8b6d6accc492" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c06add68-0b63-4ea2-bbb7-3e1c4a790e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_79df5983-ffb2-4512-a308-97895460ef90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c06add68-0b63-4ea2-bbb7-3e1c4a790e82" xlink:to="loc_us-gaap_EquityComponentDomain_79df5983-ffb2-4512-a308-97895460ef90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_475c9c82-26a5-445c-8f83-4d20b1493924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_79df5983-ffb2-4512-a308-97895460ef90" xlink:to="loc_us-gaap_CommonStockMember_475c9c82-26a5-445c-8f83-4d20b1493924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_23518025-487a-4302-807a-794da19ffea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_79df5983-ffb2-4512-a308-97895460ef90" xlink:to="loc_us-gaap_WarrantMember_23518025-487a-4302-807a-794da19ffea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_775ed692-4ef2-44e3-91d8-fe193ab6412e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53bc9c53-8f97-4699-b6d6-8b6d6accc492" xlink:to="loc_us-gaap_StatementClassOfStockAxis_775ed692-4ef2-44e3-91d8-fe193ab6412e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1c90073c-6ff7-4a1c-be17-dae56b714c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_775ed692-4ef2-44e3-91d8-fe193ab6412e" xlink:to="loc_us-gaap_ClassOfStockDomain_1c90073c-6ff7-4a1c-be17-dae56b714c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_1be97771-958e-4284-a7c3-5485d9d4f485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1c90073c-6ff7-4a1c-be17-dae56b714c7d" xlink:to="loc_us-gaap_CommonClassAMember_1be97771-958e-4284-a7c3-5485d9d4f485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4bb504c2-3730-4bda-b614-b4738cb5f6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53bc9c53-8f97-4699-b6d6-8b6d6accc492" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4bb504c2-3730-4bda-b614-b4738cb5f6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d4e4c58-2180-42cd-bcbd-d5276fe3bde6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4bb504c2-3730-4bda-b614-b4738cb5f6ee" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d4e4c58-2180-42cd-bcbd-d5276fe3bde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_7e778ffa-2932-4699-a0e1-b97f94ce868d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4d4e4c58-2180-42cd-bcbd-d5276fe3bde6" xlink:to="loc_us-gaap_IPOMember_7e778ffa-2932-4699-a0e1-b97f94ce868d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_53bc9c53-8f97-4699-b6d6-8b6d6accc492" xlink:to="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList_6cd9439b-6ed9-4b81-b167-47f5615fe6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:to="loc_us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList_6cd9439b-6ed9-4b81-b167-47f5615fe6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5833b981-08cc-41e2-9d29-2c9be5e0c387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5833b981-08cc-41e2-9d29-2c9be5e0c387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockholdersEquityNumberOfSharesInEachUnit_08bda3c8-aeea-4e7d-88bc-95d3ace4dcf3" xlink:href="wald-20221231.xsd#wald_StockholdersEquityNumberOfSharesInEachUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:to="loc_wald_StockholdersEquityNumberOfSharesInEachUnit_08bda3c8-aeea-4e7d-88bc-95d3ace4dcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_d01825fb-15c6-4423-9bf3-0c14c8ae6380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_d01825fb-15c6-4423-9bf3-0c14c8ae6380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_de929045-faba-497f-9154-2ea266fc0eec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_de929045-faba-497f-9154-2ea266fc0eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1a361002-be96-4a31-b26c-15ddaa59d034" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1a361002-be96-4a31-b26c-15ddaa59d034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ffd68439-cd98-4b7c-8d03-5466dca6ee47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:to="loc_us-gaap_CommonStockSharesIssued_ffd68439-cd98-4b7c-8d03-5466dca6ee47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_d6ada9bd-77d4-4e37-bf4a-123186584a57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c4be7a71-16f8-4180-bf6f-e820f3a74fc5" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_d6ada9bd-77d4-4e37-bf4a-123186584a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_d0745eea-6a3e-4632-b93c-a19591ba9d80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_2cb905bc-f810-4d7c-8c76-2fcc6e617bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_d0745eea-6a3e-4632-b93c-a19591ba9d80" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_2cb905bc-f810-4d7c-8c76-2fcc6e617bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_bc8e6da4-1fe4-44c8-9151-76036daffeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_2cb905bc-f810-4d7c-8c76-2fcc6e617bbb" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_bc8e6da4-1fe4-44c8-9151-76036daffeb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_4c1a5f56-e017-4953-84f5-85b8ebbb7219" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_bc8e6da4-1fe4-44c8-9151-76036daffeb8" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_4c1a5f56-e017-4953-84f5-85b8ebbb7219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfDistributorServiceFeesMember_6d56a1de-4c86-4902-b88d-3e08113401f0" xlink:href="wald-20221231.xsd#wald_MisstatementOfDistributorServiceFeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_4c1a5f56-e017-4953-84f5-85b8ebbb7219" xlink:to="loc_wald_MisstatementOfDistributorServiceFeesMember_6d56a1de-4c86-4902-b88d-3e08113401f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfRevenueRecognitionTimingMember_d592cd2e-3eb8-45ba-ba7c-3bac74652af4" xlink:href="wald-20221231.xsd#wald_MisstatementOfRevenueRecognitionTimingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_4c1a5f56-e017-4953-84f5-85b8ebbb7219" xlink:to="loc_wald_MisstatementOfRevenueRecognitionTimingMember_d592cd2e-3eb8-45ba-ba7c-3bac74652af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_94843cb1-a6d4-45b5-8326-76ab05f71f28" xlink:href="wald-20221231.xsd#wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_4c1a5f56-e017-4953-84f5-85b8ebbb7219" xlink:to="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_94843cb1-a6d4-45b5-8326-76ab05f71f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember_b4208fd4-7ff8-49b4-b3d5-57824df8ed20" xlink:href="wald-20221231.xsd#wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_4c1a5f56-e017-4953-84f5-85b8ebbb7219" xlink:to="loc_wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember_b4208fd4-7ff8-49b4-b3d5-57824df8ed20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OtherMisstatementAdjustmentsMember_5b78bcae-6baf-4871-b877-76e66833f5f4" xlink:href="wald-20221231.xsd#wald_OtherMisstatementAdjustmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_4c1a5f56-e017-4953-84f5-85b8ebbb7219" xlink:to="loc_wald_OtherMisstatementAdjustmentsMember_5b78bcae-6baf-4871-b877-76e66833f5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_495da122-2f6f-48d0-9b41-254b2d164470" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_2cb905bc-f810-4d7c-8c76-2fcc6e617bbb" xlink:to="loc_srt_RestatementAxis_495da122-2f6f-48d0-9b41-254b2d164470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_48280cd2-eb7e-409a-9a15-2c6dbdd883a0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_495da122-2f6f-48d0-9b41-254b2d164470" xlink:to="loc_srt_RestatementDomain_48280cd2-eb7e-409a-9a15-2c6dbdd883a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_efff0555-59f9-480f-84fc-a59d8baaa0dc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_48280cd2-eb7e-409a-9a15-2c6dbdd883a0" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_efff0555-59f9-480f-84fc-a59d8baaa0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_bf89e837-868c-48cf-b834-3f1f5ab25f72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_2cb905bc-f810-4d7c-8c76-2fcc6e617bbb" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_bf89e837-868c-48cf-b834-3f1f5ab25f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_61b443f4-be91-4881-917f-025f723a1a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_bf89e837-868c-48cf-b834-3f1f5ab25f72" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_61b443f4-be91-4881-917f-025f723a1a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember_3c08d7fc-55c1-4e54-b2bc-408a73366c53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_61b443f4-be91-4881-917f-025f723a1a8d" xlink:to="loc_us-gaap_SalesChannelThroughIntermediaryMember_3c08d7fc-55c1-4e54-b2bc-408a73366c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SADistributorMember_77c3ea77-bb0d-42f5-a3e6-3628415e502d" xlink:href="wald-20221231.xsd#wald_SADistributorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_61b443f4-be91-4881-917f-025f723a1a8d" xlink:to="loc_wald_SADistributorMember_77c3ea77-bb0d-42f5-a3e6-3628415e502d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PhysicianChannelProviderMember_4a997c32-4fd4-47a8-bc72-325dd331e8a4" xlink:href="wald-20221231.xsd#wald_PhysicianChannelProviderMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_61b443f4-be91-4881-917f-025f723a1a8d" xlink:to="loc_wald_PhysicianChannelProviderMember_4a997c32-4fd4-47a8-bc72-325dd331e8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_USOnlineMarketplaceDistributorMember_2e4604d0-9b9f-4d62-b994-0ad55d04b883" xlink:href="wald-20221231.xsd#wald_USOnlineMarketplaceDistributorMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_61b443f4-be91-4881-917f-025f723a1a8d" xlink:to="loc_wald_USOnlineMarketplaceDistributorMember_2e4604d0-9b9f-4d62-b994-0ad55d04b883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_2cb905bc-f810-4d7c-8c76-2fcc6e617bbb" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_036d72e2-4e3a-4994-96f8-499af97a416d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_036d72e2-4e3a-4994-96f8-499af97a416d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_feab4608-144e-45b0-9fc9-b68520cff193" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_feab4608-144e-45b0-9fc9-b68520cff193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e2ca4e5f-e88a-457b-8f57-24e5d865a299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e2ca4e5f-e88a-457b-8f57-24e5d865a299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bd059f1a-4b5a-4c22-8acc-3b9e697eebc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bd059f1a-4b5a-4c22-8acc-3b9e697eebc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fa0ff8fb-e36b-4aeb-abaa-898adef80d72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fa0ff8fb-e36b-4aeb-abaa-898adef80d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8d55280b-db68-497c-9b68-10835c59d57a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_us-gaap_InventoryNet_8d55280b-db68-497c-9b68-10835c59d57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MinimumThresholdPeriodForContractRepaymentOverTime_1c494493-4f8f-4312-b29d-26eb3247fbeb" xlink:href="wald-20221231.xsd#wald_MinimumThresholdPeriodForContractRepaymentOverTime"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_wald_MinimumThresholdPeriodForContractRepaymentOverTime_1c494493-4f8f-4312-b29d-26eb3247fbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_346b9460-509f-4664-9f88-52b283750313" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_us-gaap_OtherNonoperatingIncome_346b9460-509f-4664-9f88-52b283750313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a26c303a-b2e7-4c61-aa6d-ab26114aeb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_58d0c576-d1f6-4694-b7ce-4cb9a5d9d6e4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a26c303a-b2e7-4c61-aa6d-ab26114aeb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_2f8979be-6170-4be7-9418-c30cd3f55f87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_3f6b1265-6dce-4552-ae34-d74d72e68160" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_2f8979be-6170-4be7-9418-c30cd3f55f87" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_3f6b1265-6dce-4552-ae34-d74d72e68160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_bba640ca-d043-4b09-b168-a955a99ee58e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_3f6b1265-6dce-4552-ae34-d74d72e68160" xlink:to="loc_srt_RestatementAxis_bba640ca-d043-4b09-b168-a955a99ee58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_66a0fa32-2945-4e55-a651-9ab8f81a53b9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_bba640ca-d043-4b09-b168-a955a99ee58e" xlink:to="loc_srt_RestatementDomain_66a0fa32-2945-4e55-a651-9ab8f81a53b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_52866c45-b5c3-430d-a630-73eb638526df" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_66a0fa32-2945-4e55-a651-9ab8f81a53b9" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_52866c45-b5c3-430d-a630-73eb638526df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_ebd1433f-231c-4947-8027-67dcd39c22b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_3f6b1265-6dce-4552-ae34-d74d72e68160" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_ebd1433f-231c-4947-8027-67dcd39c22b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_0405b221-708f-4105-99ab-50b9a083485a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_ebd1433f-231c-4947-8027-67dcd39c22b2" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_0405b221-708f-4105-99ab-50b9a083485a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PhysicianChannelProviderMember_9ff68f12-3b25-4dad-a195-eb10a7785777" xlink:href="wald-20221231.xsd#wald_PhysicianChannelProviderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_0405b221-708f-4105-99ab-50b9a083485a" xlink:to="loc_wald_PhysicianChannelProviderMember_9ff68f12-3b25-4dad-a195-eb10a7785777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_16fbcca1-17e0-4456-ad08-240724854d53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_3f6b1265-6dce-4552-ae34-d74d72e68160" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_16fbcca1-17e0-4456-ad08-240724854d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_7002d101-8e23-4b3a-b1b4-6fbfa577e86c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_16fbcca1-17e0-4456-ad08-240724854d53" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_7002d101-8e23-4b3a-b1b4-6fbfa577e86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_560efcb7-f64b-49f4-b64b-b047eae16175" xlink:href="wald-20221231.xsd#wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_7002d101-8e23-4b3a-b1b4-6fbfa577e86c" xlink:to="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_560efcb7-f64b-49f4-b64b-b047eae16175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfInventoryMember_db55d2eb-fb41-4a9c-9592-b31cab2467c2" xlink:href="wald-20221231.xsd#wald_MisstatementOfInventoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_7002d101-8e23-4b3a-b1b4-6fbfa577e86c" xlink:to="loc_wald_MisstatementOfInventoryMember_db55d2eb-fb41-4a9c-9592-b31cab2467c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OtherMisstatementAdjustmentsMember_633df691-c2e4-4ba9-9336-74dd965819d9" xlink:href="wald-20221231.xsd#wald_OtherMisstatementAdjustmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_7002d101-8e23-4b3a-b1b4-6fbfa577e86c" xlink:to="loc_wald_OtherMisstatementAdjustmentsMember_633df691-c2e4-4ba9-9336-74dd965819d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_499910f3-09bd-4c81-82ac-c8b0b9cc29c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_3f6b1265-6dce-4552-ae34-d74d72e68160" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_499910f3-09bd-4c81-82ac-c8b0b9cc29c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f277346d-d3f0-4989-8cb8-a791a84ec132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_499910f3-09bd-4c81-82ac-c8b0b9cc29c5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f277346d-d3f0-4989-8cb8-a791a84ec132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_8050bbcf-ab59-4825-8f81-0f9d4c5b32cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_5114dc05-0f37-43bc-b454-def4cbcc388d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_8050bbcf-ab59-4825-8f81-0f9d4c5b32cd" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_5114dc05-0f37-43bc-b454-def4cbcc388d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_27a197d3-ee02-4d0b-9c94-a5702c1be200" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_5114dc05-0f37-43bc-b454-def4cbcc388d" xlink:to="loc_srt_RestatementAxis_27a197d3-ee02-4d0b-9c94-a5702c1be200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_ccc760e4-f6e7-4f34-98a6-65877996c52d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_27a197d3-ee02-4d0b-9c94-a5702c1be200" xlink:to="loc_srt_RestatementDomain_ccc760e4-f6e7-4f34-98a6-65877996c52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_aa352e07-1fcd-4dee-a89b-ea07b1b8d5dd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_ccc760e4-f6e7-4f34-98a6-65877996c52d" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_aa352e07-1fcd-4dee-a89b-ea07b1b8d5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1ae7e2f5-b95b-4449-9602-1f144322ec2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_5114dc05-0f37-43bc-b454-def4cbcc388d" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1ae7e2f5-b95b-4449-9602-1f144322ec2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_e3d1b501-3cea-4028-9bc7-9e6db1c9b1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1ae7e2f5-b95b-4449-9602-1f144322ec2e" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_e3d1b501-3cea-4028-9bc7-9e6db1c9b1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfDistributorServiceFeesMember_a1d26634-e7d2-452b-93ee-dbcee039f562" xlink:href="wald-20221231.xsd#wald_MisstatementOfDistributorServiceFeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_e3d1b501-3cea-4028-9bc7-9e6db1c9b1ea" xlink:to="loc_wald_MisstatementOfDistributorServiceFeesMember_a1d26634-e7d2-452b-93ee-dbcee039f562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_4784f247-58bd-45b6-b1ae-5b5640ea7e9d" xlink:href="wald-20221231.xsd#wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_e3d1b501-3cea-4028-9bc7-9e6db1c9b1ea" xlink:to="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_4784f247-58bd-45b6-b1ae-5b5640ea7e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember_0f69e296-7469-477c-be63-597646579066" xlink:href="wald-20221231.xsd#wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_e3d1b501-3cea-4028-9bc7-9e6db1c9b1ea" xlink:to="loc_wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember_0f69e296-7469-477c-be63-597646579066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember_65592543-3899-4608-abc5-c4984f778bd9" xlink:href="wald-20221231.xsd#wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_e3d1b501-3cea-4028-9bc7-9e6db1c9b1ea" xlink:to="loc_wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember_65592543-3899-4608-abc5-c4984f778bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OtherMisstatementAdjustmentsMember_f152d728-11d5-4742-84ee-3ea46eb1c6fd" xlink:href="wald-20221231.xsd#wald_OtherMisstatementAdjustmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_e3d1b501-3cea-4028-9bc7-9e6db1c9b1ea" xlink:to="loc_wald_OtherMisstatementAdjustmentsMember_f152d728-11d5-4742-84ee-3ea46eb1c6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_65544ca3-936f-4f48-a5f0-2d571dcdd749" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_5114dc05-0f37-43bc-b454-def4cbcc388d" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_65544ca3-936f-4f48-a5f0-2d571dcdd749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_e8a17638-e546-46ca-b7e3-7afac905cf89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_65544ca3-936f-4f48-a5f0-2d571dcdd749" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_e8a17638-e546-46ca-b7e3-7afac905cf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PhysicianChannelProviderMember_26ce278d-50fe-4048-b9fb-e5dcbfcddb75" xlink:href="wald-20221231.xsd#wald_PhysicianChannelProviderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_e8a17638-e546-46ca-b7e3-7afac905cf89" xlink:to="loc_wald_PhysicianChannelProviderMember_26ce278d-50fe-4048-b9fb-e5dcbfcddb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_8256eff1-aa81-4443-ac47-d0eaea9e1967" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_5114dc05-0f37-43bc-b454-def4cbcc388d" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_8256eff1-aa81-4443-ac47-d0eaea9e1967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6fd4c36b-fc6b-40d5-9a79-a79d0c0b7dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_8256eff1-aa81-4443-ac47-d0eaea9e1967" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6fd4c36b-fc6b-40d5-9a79-a79d0c0b7dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_986359e5-3d4f-49f9-8e93-e817a000037e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_a11caf87-099b-4cc6-93dc-a0a09c460106" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_986359e5-3d4f-49f9-8e93-e817a000037e" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_a11caf87-099b-4cc6-93dc-a0a09c460106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_c3c4aaf0-b574-44e8-a7d9-12033bffe325" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_a11caf87-099b-4cc6-93dc-a0a09c460106" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_c3c4aaf0-b574-44e8-a7d9-12033bffe325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_c3c4aaf0-b574-44e8-a7d9-12033bffe325" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember_9c988559-ba16-401f-8ace-0f11bee65d08" xlink:href="wald-20221231.xsd#wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:to="loc_wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember_9c988559-ba16-401f-8ace-0f11bee65d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfCapitalizedMarketingExpensesMember_ab9c131f-f8b1-4d86-8f94-f9508d1efd6d" xlink:href="wald-20221231.xsd#wald_MisstatementOfCapitalizedMarketingExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:to="loc_wald_MisstatementOfCapitalizedMarketingExpensesMember_ab9c131f-f8b1-4d86-8f94-f9508d1efd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfResearchAndDevelopmentExpenseMember_6eda3e6b-4294-4828-b930-d27e362dccf0" xlink:href="wald-20221231.xsd#wald_MisstatementOfResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:to="loc_wald_MisstatementOfResearchAndDevelopmentExpenseMember_6eda3e6b-4294-4828-b930-d27e362dccf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember_e11edf31-3fcd-4ab9-820a-afac655b8c26" xlink:href="wald-20221231.xsd#wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:to="loc_wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember_e11edf31-3fcd-4ab9-820a-afac655b8c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OtherMisstatementAdjustmentsMember_7485e989-2bb5-4223-9d9e-8b5fbac50d8a" xlink:href="wald-20221231.xsd#wald_OtherMisstatementAdjustmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:to="loc_wald_OtherMisstatementAdjustmentsMember_7485e989-2bb5-4223-9d9e-8b5fbac50d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember_e8bcb066-a65a-4ee1-a1cd-606f4326b44c" xlink:href="wald-20221231.xsd#wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:to="loc_wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember_e8bcb066-a65a-4ee1-a1cd-606f4326b44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember_00c9f1f3-6f88-4faf-9759-c3b8ae684148" xlink:href="wald-20221231.xsd#wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:to="loc_wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember_00c9f1f3-6f88-4faf-9759-c3b8ae684148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfAccruedDistributionServiceFeesMember_b159f616-40a6-4496-b23b-4500e6d45485" xlink:href="wald-20221231.xsd#wald_MisstatementOfAccruedDistributionServiceFeesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:to="loc_wald_MisstatementOfAccruedDistributionServiceFeesMember_b159f616-40a6-4496-b23b-4500e6d45485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember_7f395a1c-a601-4009-a630-2b56a6714d55" xlink:href="wald-20221231.xsd#wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_65ecf807-75fc-4e90-9e74-a4c409f1da53" xlink:to="loc_wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember_7f395a1c-a601-4009-a630-2b56a6714d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_ebb2dd1b-7118-40c6-8a70-4806bae9e3ad" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_a11caf87-099b-4cc6-93dc-a0a09c460106" xlink:to="loc_srt_RestatementAxis_ebb2dd1b-7118-40c6-8a70-4806bae9e3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_f7101d92-4f69-4e51-9a72-2c97cde79ea5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_ebb2dd1b-7118-40c6-8a70-4806bae9e3ad" xlink:to="loc_srt_RestatementDomain_f7101d92-4f69-4e51-9a72-2c97cde79ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_afd54fd2-658f-4c76-b5d1-7d620ba8653e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_f7101d92-4f69-4e51-9a72-2c97cde79ea5" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_afd54fd2-658f-4c76-b5d1-7d620ba8653e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_0f097afb-dada-426d-98ec-ac5345949b21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_a11caf87-099b-4cc6-93dc-a0a09c460106" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_0f097afb-dada-426d-98ec-ac5345949b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_dba3bb4c-e1c7-405c-bc90-30efb1e16710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_0f097afb-dada-426d-98ec-ac5345949b21" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_dba3bb4c-e1c7-405c-bc90-30efb1e16710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_USOnlineMarketplaceDistributorMember_222a0b34-534c-45e8-8084-05c96c39c81d" xlink:href="wald-20221231.xsd#wald_USOnlineMarketplaceDistributorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_dba3bb4c-e1c7-405c-bc90-30efb1e16710" xlink:to="loc_wald_USOnlineMarketplaceDistributorMember_222a0b34-534c-45e8-8084-05c96c39c81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_USOnlineMarketplaceDistributorAndSADistributorMember_8f4e1756-36ce-4d7a-8171-556f7112ffab" xlink:href="wald-20221231.xsd#wald_USOnlineMarketplaceDistributorAndSADistributorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_dba3bb4c-e1c7-405c-bc90-30efb1e16710" xlink:to="loc_wald_USOnlineMarketplaceDistributorAndSADistributorMember_8f4e1756-36ce-4d7a-8171-556f7112ffab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bd6bb6ec-3686-484e-ad62-ae18926c1453" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_a11caf87-099b-4cc6-93dc-a0a09c460106" xlink:to="loc_dei_LegalEntityAxis_bd6bb6ec-3686-484e-ad62-ae18926c1453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_68018df6-5b0e-4db6-855d-e7931bdd461e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_bd6bb6ec-3686-484e-ad62-ae18926c1453" xlink:to="loc_dei_EntityDomain_68018df6-5b0e-4db6-855d-e7931bdd461e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiCosmeceuticalsLLCMember_f7f179e8-1848-43e2-b6b2-5ee5c87dcc22" xlink:href="wald-20221231.xsd#wald_ObagiCosmeceuticalsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_68018df6-5b0e-4db6-855d-e7931bdd461e" xlink:to="loc_wald_ObagiCosmeceuticalsLLCMember_f7f179e8-1848-43e2-b6b2-5ee5c87dcc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_a11caf87-099b-4cc6-93dc-a0a09c460106" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors_29ee09ca-ab7c-44e9-8fc1-f1b828cd7ce6" xlink:href="wald-20221231.xsd#wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors_29ee09ca-ab7c-44e9-8fc1-f1b828cd7ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cd80a446-c302-48f6-93f3-dc92e30087ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cd80a446-c302-48f6-93f3-dc92e30087ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2e749ff9-221d-4424-ae23-bcb5e88bec72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2e749ff9-221d-4424-ae23-bcb5e88bec72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6119b283-89d4-416b-a694-8ec4b6789e76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6119b283-89d4-416b-a694-8ec4b6789e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_af295b6a-fb0c-4ef9-9868-3a04cf7c4f88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_af295b6a-fb0c-4ef9-9868-3a04cf7c4f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_68db9b45-38f9-43a4-ba75-ba8b3442e766" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_AccountsPayableCurrent_68db9b45-38f9-43a4-ba75-ba8b3442e766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2c38c021-529f-4c1b-8208-7e316b3ccc66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2c38c021-529f-4c1b-8208-7e316b3ccc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_50d00822-a8cc-4f52-8af7-ce9e2f15749b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_50d00822-a8cc-4f52-8af7-ce9e2f15749b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_501992ae-2510-46e9-90e6-d9bdcc0635f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_501992ae-2510-46e9-90e6-d9bdcc0635f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4e689ae8-ca06-40db-9a92-13b96938f94c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_690b5612-3d16-4299-bfb0-c4db49933353" xlink:to="loc_us-gaap_ProfitLoss_4e689ae8-ca06-40db-9a92-13b96938f94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_c289af0e-244d-482f-a13e-89c90c8abe6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_aa68663d-b179-485c-8e9a-3d448047ee0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_c289af0e-244d-482f-a13e-89c90c8abe6c" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_aa68663d-b179-485c-8e9a-3d448047ee0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_88584c8f-02b5-499f-8eb2-778414123ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_aa68663d-b179-485c-8e9a-3d448047ee0c" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_88584c8f-02b5-499f-8eb2-778414123ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_ff0dfac2-7dc7-42f5-89a4-e5d26499a2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_88584c8f-02b5-499f-8eb2-778414123ae8" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_ff0dfac2-7dc7-42f5-89a4-e5d26499a2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfRevenueRecognitionTimingMember_c62d3a10-a3a1-49bb-870b-9f92332ba102" xlink:href="wald-20221231.xsd#wald_MisstatementOfRevenueRecognitionTimingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_ff0dfac2-7dc7-42f5-89a4-e5d26499a2a5" xlink:to="loc_wald_MisstatementOfRevenueRecognitionTimingMember_c62d3a10-a3a1-49bb-870b-9f92332ba102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_c2b52498-a04f-40e2-8b77-189bc8fc95c1" xlink:href="wald-20221231.xsd#wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_ff0dfac2-7dc7-42f5-89a4-e5d26499a2a5" xlink:to="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_c2b52498-a04f-40e2-8b77-189bc8fc95c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember_666a19c6-ee5a-4a8c-aa46-e2579b33831a" xlink:href="wald-20221231.xsd#wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_ff0dfac2-7dc7-42f5-89a4-e5d26499a2a5" xlink:to="loc_wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember_666a19c6-ee5a-4a8c-aa46-e2579b33831a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OtherMisstatementAdjustmentsMember_c8ab9318-64c5-4f82-a580-9aef13eea4d0" xlink:href="wald-20221231.xsd#wald_OtherMisstatementAdjustmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_ff0dfac2-7dc7-42f5-89a4-e5d26499a2a5" xlink:to="loc_wald_OtherMisstatementAdjustmentsMember_c8ab9318-64c5-4f82-a580-9aef13eea4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_92e8292f-b471-4f91-97f5-282ee1b6f791" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_aa68663d-b179-485c-8e9a-3d448047ee0c" xlink:to="loc_srt_RestatementAxis_92e8292f-b471-4f91-97f5-282ee1b6f791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_9b5e91f6-67cc-4630-89cd-3f4ebaa9eef1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_92e8292f-b471-4f91-97f5-282ee1b6f791" xlink:to="loc_srt_RestatementDomain_9b5e91f6-67cc-4630-89cd-3f4ebaa9eef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_43e7a675-0486-443c-81fd-a635d3d571cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_9b5e91f6-67cc-4630-89cd-3f4ebaa9eef1" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_43e7a675-0486-443c-81fd-a635d3d571cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_33be940c-5621-4d02-ac90-683da1e1ebfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_aa68663d-b179-485c-8e9a-3d448047ee0c" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_33be940c-5621-4d02-ac90-683da1e1ebfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_da4f0700-5890-4d6e-a8bb-170149c3acf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_33be940c-5621-4d02-ac90-683da1e1ebfd" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_da4f0700-5890-4d6e-a8bb-170149c3acf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SADistributorMember_4df03d8e-7932-4210-b86a-a71df227f67f" xlink:href="wald-20221231.xsd#wald_SADistributorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_da4f0700-5890-4d6e-a8bb-170149c3acf9" xlink:to="loc_wald_SADistributorMember_4df03d8e-7932-4210-b86a-a71df227f67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PhysicianChannelProviderMember_7b379788-b62f-4b6a-96f9-0063df51e253" xlink:href="wald-20221231.xsd#wald_PhysicianChannelProviderMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_da4f0700-5890-4d6e-a8bb-170149c3acf9" xlink:to="loc_wald_PhysicianChannelProviderMember_7b379788-b62f-4b6a-96f9-0063df51e253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3a4560c4-abc5-4cd4-a135-3f1443df7bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_aa68663d-b179-485c-8e9a-3d448047ee0c" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3a4560c4-abc5-4cd4-a135-3f1443df7bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_22d5e3d6-5f5c-48c8-9de9-baac09b40ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3a4560c4-abc5-4cd4-a135-3f1443df7bc7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_22d5e3d6-5f5c-48c8-9de9-baac09b40ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainLossOnNoteReceivableWriteoff_50bf6da8-c51f-48b5-8be2-9fce6a48eb53" xlink:href="wald-20221231.xsd#wald_GainLossOnNoteReceivableWriteoff"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3a4560c4-abc5-4cd4-a135-3f1443df7bc7" xlink:to="loc_wald_GainLossOnNoteReceivableWriteoff_50bf6da8-c51f-48b5-8be2-9fce6a48eb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_ff69507c-c319-4a9d-857f-c0edf8d80e78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_81329e61-4985-4915-93a4-49edd8836359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_ff69507c-c319-4a9d-857f-c0edf8d80e78" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_81329e61-4985-4915-93a4-49edd8836359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_c1891ade-86ce-4c25-8d54-772a7c089640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_81329e61-4985-4915-93a4-49edd8836359" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_c1891ade-86ce-4c25-8d54-772a7c089640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_79ae423e-0410-4f15-9958-3951d3be5b90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_c1891ade-86ce-4c25-8d54-772a7c089640" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_79ae423e-0410-4f15-9958-3951d3be5b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_d97500c5-cf4b-4ea1-b433-3873579a677e" xlink:href="wald-20221231.xsd#wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_79ae423e-0410-4f15-9958-3951d3be5b90" xlink:to="loc_wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember_d97500c5-cf4b-4ea1-b433-3873579a677e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MisstatementOfInventoryMember_3f192b78-6efc-48de-9e94-4af61326a6c7" xlink:href="wald-20221231.xsd#wald_MisstatementOfInventoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_79ae423e-0410-4f15-9958-3951d3be5b90" xlink:to="loc_wald_MisstatementOfInventoryMember_3f192b78-6efc-48de-9e94-4af61326a6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OtherMisstatementAdjustmentsMember_c7854a7b-8150-46c7-8668-c4062808c906" xlink:href="wald-20221231.xsd#wald_OtherMisstatementAdjustmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_79ae423e-0410-4f15-9958-3951d3be5b90" xlink:to="loc_wald_OtherMisstatementAdjustmentsMember_c7854a7b-8150-46c7-8668-c4062808c906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_7f6a21d2-5f96-4991-a62a-49575658f6a4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_81329e61-4985-4915-93a4-49edd8836359" xlink:to="loc_srt_RestatementAxis_7f6a21d2-5f96-4991-a62a-49575658f6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_5b497840-3c86-4a85-b6eb-17f4c338d85c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_7f6a21d2-5f96-4991-a62a-49575658f6a4" xlink:to="loc_srt_RestatementDomain_5b497840-3c86-4a85-b6eb-17f4c338d85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_2be7fee6-949e-477c-b7eb-4f93aafb2e60" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_5b497840-3c86-4a85-b6eb-17f4c338d85c" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_2be7fee6-949e-477c-b7eb-4f93aafb2e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_452a6d7b-107b-430f-8925-21e8f397b399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_81329e61-4985-4915-93a4-49edd8836359" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_452a6d7b-107b-430f-8925-21e8f397b399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_02796102-7b3c-412d-88be-18f24275daf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_452a6d7b-107b-430f-8925-21e8f397b399" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_02796102-7b3c-412d-88be-18f24275daf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PhysicianChannelProviderMember_57db139d-31fc-4f26-a03a-d1ebfed05104" xlink:href="wald-20221231.xsd#wald_PhysicianChannelProviderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_02796102-7b3c-412d-88be-18f24275daf4" xlink:to="loc_wald_PhysicianChannelProviderMember_57db139d-31fc-4f26-a03a-d1ebfed05104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e4d5286b-ef74-4929-8bda-293e5bcef054" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_81329e61-4985-4915-93a4-49edd8836359" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e4d5286b-ef74-4929-8bda-293e5bcef054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_017e6c77-7eb2-45fa-9bfd-08977988593b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e4d5286b-ef74-4929-8bda-293e5bcef054" xlink:to="loc_us-gaap_InventoryNet_017e6c77-7eb2-45fa-9bfd-08977988593b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofReclassificationAdjustmentsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSSummaryofReclassificationAdjustmentsDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofReclassificationAdjustmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_87c1db74-46fc-44ce-b780-9add59b2ab80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTable_6179af61-2f96-46c4-8131-0a62ca2f924f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_87c1db74-46fc-44ce-b780-9add59b2ab80" xlink:to="loc_us-gaap_ReclassificationTable_6179af61-2f96-46c4-8131-0a62ca2f924f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_057e5503-4698-4973-ad58-b3ac3ef6b2a4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTable_6179af61-2f96-46c4-8131-0a62ca2f924f" xlink:to="loc_srt_RestatementAxis_057e5503-4698-4973-ad58-b3ac3ef6b2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_d194af9b-659e-47b5-9de8-8c6739fb719d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_057e5503-4698-4973-ad58-b3ac3ef6b2a4" xlink:to="loc_srt_RestatementDomain_d194af9b-659e-47b5-9de8-8c6739fb719d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_91b58377-38f9-40db-aaf7-36ef6082f407" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_d194af9b-659e-47b5-9de8-8c6739fb719d" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_91b58377-38f9-40db-aaf7-36ef6082f407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationLineItems_59ab163f-2701-4279-ab20-6156c51beba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTable_6179af61-2f96-46c4-8131-0a62ca2f924f" xlink:to="loc_us-gaap_ReclassificationLineItems_59ab163f-2701-4279-ab20-6156c51beba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_89ba3771-9a04-430d-99ba-cd903b615f08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationLineItems_59ab163f-2701-4279-ab20-6156c51beba4" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_89ba3771-9a04-430d-99ba-cd903b615f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_07752719-b468-4504-8765-679d0b2e1951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_26d65f8f-341d-47c8-8ab5-d444ff17eafd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_07752719-b468-4504-8765-679d0b2e1951" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_26d65f8f-341d-47c8-8ab5-d444ff17eafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_bba56f4f-0002-4d4b-81d8-d8ca5da540e0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_26d65f8f-341d-47c8-8ab5-d444ff17eafd" xlink:to="loc_srt_RestatementAxis_bba56f4f-0002-4d4b-81d8-d8ca5da540e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_6246a7ed-21e4-4d2f-aafa-0b496940f0f2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_bba56f4f-0002-4d4b-81d8-d8ca5da540e0" xlink:to="loc_srt_RestatementDomain_6246a7ed-21e4-4d2f-aafa-0b496940f0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_916ec335-114a-4439-834d-3d6853e7204e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_6246a7ed-21e4-4d2f-aafa-0b496940f0f2" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_916ec335-114a-4439-834d-3d6853e7204e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_f27eb789-35c1-43b0-a4d8-0c65b499a2bd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_6246a7ed-21e4-4d2f-aafa-0b496940f0f2" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_f27eb789-35c1-43b0-a4d8-0c65b499a2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_aedd5399-7c5f-48eb-a908-8f6171cc4366" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_26d65f8f-341d-47c8-8ab5-d444ff17eafd" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_aedd5399-7c5f-48eb-a908-8f6171cc4366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_2bd42bf5-3325-400f-be45-639f949b74c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_aedd5399-7c5f-48eb-a908-8f6171cc4366" xlink:to="loc_us-gaap_AssetsAbstract_2bd42bf5-3325-400f-be45-639f949b74c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_bd48ff7c-6d3b-48a7-9e7a-a7d1546600fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2bd42bf5-3325-400f-be45-639f949b74c9" xlink:to="loc_us-gaap_AssetsCurrentAbstract_bd48ff7c-6d3b-48a7-9e7a-a7d1546600fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_80a41c26-9b12-434d-9c53-4a5c1328be81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd48ff7c-6d3b-48a7-9e7a-a7d1546600fe" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_80a41c26-9b12-434d-9c53-4a5c1328be81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_1b7ba2bb-cb88-4f16-9955-7da66c827c49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd48ff7c-6d3b-48a7-9e7a-a7d1546600fe" xlink:to="loc_us-gaap_RestrictedCash_1b7ba2bb-cb88-4f16-9955-7da66c827c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6b705161-1a10-443a-9941-89fd3a3dccc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd48ff7c-6d3b-48a7-9e7a-a7d1546600fe" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6b705161-1a10-443a-9941-89fd3a3dccc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_3d7b3568-e488-43e5-a1b2-a0faabf74640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd48ff7c-6d3b-48a7-9e7a-a7d1546600fe" xlink:to="loc_us-gaap_InventoryNet_3d7b3568-e488-43e5-a1b2-a0faabf74640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_e8162c0f-94ff-4d64-91a9-c818c2ed80fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd48ff7c-6d3b-48a7-9e7a-a7d1546600fe" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_e8162c0f-94ff-4d64-91a9-c818c2ed80fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_dc490bdd-07e9-4aa8-93fa-1e9f3182f718" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd48ff7c-6d3b-48a7-9e7a-a7d1546600fe" xlink:to="loc_us-gaap_OtherAssetsCurrent_dc490bdd-07e9-4aa8-93fa-1e9f3182f718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0c63bdbb-d0e6-4fb2-997f-dfa27871ebaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bd48ff7c-6d3b-48a7-9e7a-a7d1546600fe" xlink:to="loc_us-gaap_AssetsCurrent_0c63bdbb-d0e6-4fb2-997f-dfa27871ebaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_252d9784-ee0c-47da-8d6d-25d88f1d88e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2bd42bf5-3325-400f-be45-639f949b74c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_252d9784-ee0c-47da-8d6d-25d88f1d88e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_651a5bfc-92ce-4f9c-82f8-b6d226576651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2bd42bf5-3325-400f-be45-639f949b74c9" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_651a5bfc-92ce-4f9c-82f8-b6d226576651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_46f5270a-632c-49f9-9271-ba0282e14555" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2bd42bf5-3325-400f-be45-639f949b74c9" xlink:to="loc_us-gaap_Goodwill_46f5270a-632c-49f9-9271-ba0282e14555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3fbec805-540d-4cb7-88ea-d40e1521ea1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2bd42bf5-3325-400f-be45-639f949b74c9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3fbec805-540d-4cb7-88ea-d40e1521ea1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cbb98d93-e014-40dd-8b75-50e4048f91de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2bd42bf5-3325-400f-be45-639f949b74c9" xlink:to="loc_us-gaap_Assets_cbb98d93-e014-40dd-8b75-50e4048f91de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e1c08bb-c1c8-4ef8-9519-76dd3a386fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_aedd5399-7c5f-48eb-a908-8f6171cc4366" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e1c08bb-c1c8-4ef8-9519-76dd3a386fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_96938cf8-010d-417c-b261-752cdd8536fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e1c08bb-c1c8-4ef8-9519-76dd3a386fa3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_96938cf8-010d-417c-b261-752cdd8536fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_dc3a7039-22b9-4ade-a9b2-be38471455ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96938cf8-010d-417c-b261-752cdd8536fd" xlink:to="loc_us-gaap_AccountsPayableCurrent_dc3a7039-22b9-4ade-a9b2-be38471455ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b283c6a8-4ead-4c89-8525-c6f63126beb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96938cf8-010d-417c-b261-752cdd8536fd" xlink:to="loc_us-gaap_LongTermDebtCurrent_b283c6a8-4ead-4c89-8525-c6f63126beb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_02112075-0912-4c8c-b607-c7759594aa11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96938cf8-010d-417c-b261-752cdd8536fd" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_02112075-0912-4c8c-b607-c7759594aa11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2693a926-b1c0-4a35-858f-7c28d708d10b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_96938cf8-010d-417c-b261-752cdd8536fd" xlink:to="loc_us-gaap_LiabilitiesCurrent_2693a926-b1c0-4a35-858f-7c28d708d10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0abb1b6e-d24d-4a95-9577-cbf69b5bf6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e1c08bb-c1c8-4ef8-9519-76dd3a386fa3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0abb1b6e-d24d-4a95-9577-cbf69b5bf6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_db4b8e56-041c-4a57-95f2-69a46d60b46a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e1c08bb-c1c8-4ef8-9519-76dd3a386fa3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_db4b8e56-041c-4a57-95f2-69a46d60b46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_91be534d-be71-4998-9279-145e0c33ad80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e1c08bb-c1c8-4ef8-9519-76dd3a386fa3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_91be534d-be71-4998-9279-145e0c33ad80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8a4584b3-872b-464d-ab5f-f22c963fb7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e1c08bb-c1c8-4ef8-9519-76dd3a386fa3" xlink:to="loc_us-gaap_Liabilities_8a4584b3-872b-464d-ab5f-f22c963fb7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4f8f93f9-e8a9-4c58-90de-3080d95616da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e1c08bb-c1c8-4ef8-9519-76dd3a386fa3" xlink:to="loc_us-gaap_EquityAbstract_4f8f93f9-e8a9-4c58-90de-3080d95616da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ce96621c-d2f6-48c1-a367-7d8ac4179dda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4f8f93f9-e8a9-4c58-90de-3080d95616da" xlink:to="loc_us-gaap_CommonStockValue_ce96621c-d2f6-48c1-a367-7d8ac4179dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b2e1004b-c228-4608-a6d8-b13e83c56ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4f8f93f9-e8a9-4c58-90de-3080d95616da" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b2e1004b-c228-4608-a6d8-b13e83c56ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c2f00ea7-14ab-4df2-89f5-dff806cfe9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4f8f93f9-e8a9-4c58-90de-3080d95616da" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c2f00ea7-14ab-4df2-89f5-dff806cfe9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b5863e13-8562-4493-a179-a6d01b9796ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4f8f93f9-e8a9-4c58-90de-3080d95616da" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b5863e13-8562-4493-a179-a6d01b9796ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d3f163e4-511d-4dae-8dde-5a13a999a323" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4f8f93f9-e8a9-4c58-90de-3080d95616da" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d3f163e4-511d-4dae-8dde-5a13a999a323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4fb82062-d4ec-40f3-8e3a-3afeb30ef5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e1c08bb-c1c8-4ef8-9519-76dd3a386fa3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4fb82062-d4ec-40f3-8e3a-3afeb30ef5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsParentheticalDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsParentheticalDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsParentheticalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_3dd09fc4-f941-4fd1-81a3-a22050e90bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8a043c1a-40d7-490f-9bd1-e6b8ca50ea0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_3dd09fc4-f941-4fd1-81a3-a22050e90bf5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8a043c1a-40d7-490f-9bd1-e6b8ca50ea0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f9a14ba2-8a2c-4a4e-97ba-39b6c10f4f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_3dd09fc4-f941-4fd1-81a3-a22050e90bf5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f9a14ba2-8a2c-4a4e-97ba-39b6c10f4f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f5becc06-7adf-4ff2-9503-2ea2d8fa4ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_3dd09fc4-f941-4fd1-81a3-a22050e90bf5" xlink:to="loc_us-gaap_CommonStockSharesIssued_f5becc06-7adf-4ff2-9503-2ea2d8fa4ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_93f0aaf3-b9f2-4b8c-8e20-9094bb4bbef5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_3dd09fc4-f941-4fd1-81a3-a22050e90bf5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_93f0aaf3-b9f2-4b8c-8e20-9094bb4bbef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_5653ed90-52cb-40d5-9075-554ab248ad87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_88f0fcf8-13eb-437e-a4cc-4763d69661da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_5653ed90-52cb-40d5-9075-554ab248ad87" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_88f0fcf8-13eb-437e-a4cc-4763d69661da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_71948914-c056-4e5f-94be-6d84091ef1d7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_88f0fcf8-13eb-437e-a4cc-4763d69661da" xlink:to="loc_srt_RestatementAxis_71948914-c056-4e5f-94be-6d84091ef1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_008c19e0-b386-4987-aadf-bfef74a9863d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_71948914-c056-4e5f-94be-6d84091ef1d7" xlink:to="loc_srt_RestatementDomain_008c19e0-b386-4987-aadf-bfef74a9863d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_23f458ce-9a23-4535-a5b9-a92edb67db9d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_008c19e0-b386-4987-aadf-bfef74a9863d" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_23f458ce-9a23-4535-a5b9-a92edb67db9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_f1ef1208-d4f6-4e39-811d-ff85e7059a0f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_008c19e0-b386-4987-aadf-bfef74a9863d" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_f1ef1208-d4f6-4e39-811d-ff85e7059a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_ba00e5a7-010c-4e28-85a4-bf35b5bce0bb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_008c19e0-b386-4987-aadf-bfef74a9863d" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_ba00e5a7-010c-4e28-85a4-bf35b5bce0bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b11cdcba-bc7d-4694-ab31-57a4fe5c15ea" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_88f0fcf8-13eb-437e-a4cc-4763d69661da" xlink:to="loc_dei_LegalEntityAxis_b11cdcba-bc7d-4694-ab31-57a4fe5c15ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b4829862-89f5-4831-927f-f80b4688df7c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_b11cdcba-bc7d-4694-ab31-57a4fe5c15ea" xlink:to="loc_dei_EntityDomain_b4829862-89f5-4831-927f-f80b4688df7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiCosmeceuticalsLLCMember_654d069e-0d39-4fd2-9556-2df9d48322e0" xlink:href="wald-20221231.xsd#wald_ObagiCosmeceuticalsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b4829862-89f5-4831-927f-f80b4688df7c" xlink:to="loc_wald_ObagiCosmeceuticalsLLCMember_654d069e-0d39-4fd2-9556-2df9d48322e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_88f0fcf8-13eb-437e-a4cc-4763d69661da" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0108afae-2130-4581-b24d-5867b1dda4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0108afae-2130-4581-b24d-5867b1dda4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_87f52212-04f0-4966-be9f-11d62943effa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_87f52212-04f0-4966-be9f-11d62943effa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_de6e3325-f80a-46e8-8887-f9222145f606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_GrossProfit_de6e3325-f80a-46e8-8887-f9222145f606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cfeed560-3743-4a97-bff8-8299e8d06c11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cfeed560-3743-4a97-bff8-8299e8d06c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_52dd4a9c-2a27-4785-a2ad-244ce268b6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_52dd4a9c-2a27-4785-a2ad-244ce268b6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_30e8a54e-8ed7-4a66-ac1b-852a1d828470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_30e8a54e-8ed7-4a66-ac1b-852a1d828470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OperatingExpensesAndCostOfGoodSold_9741201f-1e9b-4383-9989-1c7653d3ca89" xlink:href="wald-20221231.xsd#wald_OperatingExpensesAndCostOfGoodSold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_wald_OperatingExpensesAndCostOfGoodSold_9741201f-1e9b-4383-9989-1c7653d3ca89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_86a55333-b4bb-4107-9e42-ebb3b780d1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_OperatingExpenses_86a55333-b4bb-4107-9e42-ebb3b780d1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5f6b496d-6f44-4dfc-9cb5-ca78c43c0042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_OperatingIncomeLoss_5f6b496d-6f44-4dfc-9cb5-ca78c43c0042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_dad610ba-222e-40e0-aae5-8d70b134a045" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_InterestExpense_dad610ba-222e-40e0-aae5-8d70b134a045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_222b4aa8-aa1d-4633-a122-0e7bc437d70e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_222b4aa8-aa1d-4633-a122-0e7bc437d70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainOnPPPLoanForgiveness_e9dfc898-2ccb-4305-80c2-c856281091e5" xlink:href="wald-20221231.xsd#wald_GainOnPPPLoanForgiveness"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_wald_GainOnPPPLoanForgiveness_e9dfc898-2ccb-4305-80c2-c856281091e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainLossOnNoteReceivableWriteoff_8f06c9e0-0188-4611-822a-50b027d094e0" xlink:href="wald-20221231.xsd#wald_GainLossOnNoteReceivableWriteoff"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_wald_GainLossOnNoteReceivableWriteoff_8f06c9e0-0188-4611-822a-50b027d094e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_762ff668-2337-45a7-930b-328d2ea75a23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_762ff668-2337-45a7-930b-328d2ea75a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d9b7df23-fc0c-433a-9b3c-f241f2ba4301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d9b7df23-fc0c-433a-9b3c-f241f2ba4301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_88249a4e-b706-4fb8-abeb-8a3d7682f1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_88249a4e-b706-4fb8-abeb-8a3d7682f1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9a8481f2-2632-4f8f-8855-f1ea261c0080" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9a8481f2-2632-4f8f-8855-f1ea261c0080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1070a09f-07fb-483d-974c-1caf99440d55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_ProfitLoss_1070a09f-07fb-483d-974c-1caf99440d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_532645aa-4b9a-48cc-b7c6-555ab3b7e101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_EarningsPerShareAbstract_532645aa-4b9a-48cc-b7c6-555ab3b7e101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_78d50737-2441-42da-a661-3683c8b50044" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_532645aa-4b9a-48cc-b7c6-555ab3b7e101" xlink:to="loc_us-gaap_EarningsPerShareBasic_78d50737-2441-42da-a661-3683c8b50044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_cc8f4239-d70d-4b37-a869-7fd74c3adbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_532645aa-4b9a-48cc-b7c6-555ab3b7e101" xlink:to="loc_us-gaap_EarningsPerShareDiluted_cc8f4239-d70d-4b37-a869-7fd74c3adbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_e68bf5a5-8edc-4afe-b640-7ec2f06b3ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_e68bf5a5-8edc-4afe-b640-7ec2f06b3ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c201e125-06a4-4e84-840e-bfb95a70e00b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_e68bf5a5-8edc-4afe-b640-7ec2f06b3ca2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c201e125-06a4-4e84-840e-bfb95a70e00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8dcea809-63f2-45f9-a447-ab4aa3bd24ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_e68bf5a5-8edc-4afe-b640-7ec2f06b3ca2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8dcea809-63f2-45f9-a447-ab4aa3bd24ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_84c99e23-55f2-4284-a41b-995933a61eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_84c99e23-55f2-4284-a41b-995933a61eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ccaafcd5-337d-4239-acde-5a8184f6b45b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_da25e239-7e4a-4d3d-809d-18e2c94f7694" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ccaafcd5-337d-4239-acde-5a8184f6b45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_f4d51959-6ed2-448d-aec8-bf30be81953a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_d708688e-724e-4a0b-8ed2-1294f6d6c9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_f4d51959-6ed2-448d-aec8-bf30be81953a" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_d708688e-724e-4a0b-8ed2-1294f6d6c9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_a329d779-1e71-4be0-8822-ca91b548d992" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_d708688e-724e-4a0b-8ed2-1294f6d6c9ae" xlink:to="loc_srt_RestatementAxis_a329d779-1e71-4be0-8822-ca91b548d992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_d16c86a0-e340-476b-b14a-1e8e732b552c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_a329d779-1e71-4be0-8822-ca91b548d992" xlink:to="loc_srt_RestatementDomain_d16c86a0-e340-476b-b14a-1e8e732b552c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_b5d61ddc-b87a-4e73-9d89-e380ed8ea53a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_d16c86a0-e340-476b-b14a-1e8e732b552c" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_b5d61ddc-b87a-4e73-9d89-e380ed8ea53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_08592172-8fcd-48ff-85fa-94731990fe97" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_d16c86a0-e340-476b-b14a-1e8e732b552c" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_08592172-8fcd-48ff-85fa-94731990fe97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_d708688e-724e-4a0b-8ed2-1294f6d6c9ae" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_787e4f6c-7772-4cd2-b1a7-2f76a47fb6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_787e4f6c-7772-4cd2-b1a7-2f76a47fb6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_aa8b333a-3787-4aae-a9ce-726dd92a926e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_787e4f6c-7772-4cd2-b1a7-2f76a47fb6f1" xlink:to="loc_us-gaap_ProfitLoss_aa8b333a-3787-4aae-a9ce-726dd92a926e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f46d1e6-8870-4481-a9ec-9cd034968204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_787e4f6c-7772-4cd2-b1a7-2f76a47fb6f1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f46d1e6-8870-4481-a9ec-9cd034968204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f46d1e6-8870-4481-a9ec-9cd034968204" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DepreciationDepletionAndAmortizationOperatingActivities_2304a22e-3ee7-4ad0-9133-deb0d852150f" xlink:href="wald-20221231.xsd#wald_DepreciationDepletionAndAmortizationOperatingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:to="loc_wald_DepreciationDepletionAndAmortizationOperatingActivities_2304a22e-3ee7-4ad0-9133-deb0d852150f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f4c03da4-f0b8-45af-b177-2d231685a609" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f4c03da4-f0b8-45af-b177-2d231685a609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainOnPPPLoanForgiveness_5194c4c2-0c03-4c3c-ad90-5e93e7877a7b" xlink:href="wald-20221231.xsd#wald_GainOnPPPLoanForgiveness"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:to="loc_wald_GainOnPPPLoanForgiveness_5194c4c2-0c03-4c3c-ad90-5e93e7877a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_78dbd2dd-3971-4ac3-8b44-70f8893ea4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_78dbd2dd-3971-4ac3-8b44-70f8893ea4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5ed999d0-58c8-401e-8887-d602057543b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5ed999d0-58c8-401e-8887-d602057543b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8d4b3c03-745f-432a-bf03-5e98f55e49b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8d4b3c03-745f-432a-bf03-5e98f55e49b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GainLossOnNoteReceivableWriteoff_0c857fa4-8f23-4262-b6b5-3c062038ed1b" xlink:href="wald-20221231.xsd#wald_GainLossOnNoteReceivableWriteoff"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:to="loc_wald_GainLossOnNoteReceivableWriteoff_0c857fa4-8f23-4262-b6b5-3c062038ed1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_126348af-248e-46af-bfe0-3472e47991bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_126348af-248e-46af-bfe0-3472e47991bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ad0462a8-21e6-4e2a-afd6-99b9ed94c6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_126348af-248e-46af-bfe0-3472e47991bf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ad0462a8-21e6-4e2a-afd6-99b9ed94c6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_30b31233-ac21-4959-82c1-2926dd387594" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_126348af-248e-46af-bfe0-3472e47991bf" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_30b31233-ac21-4959-82c1-2926dd387594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1efb5261-5a67-4f5e-9a84-effb144a898e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_126348af-248e-46af-bfe0-3472e47991bf" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1efb5261-5a67-4f5e-9a84-effb144a898e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8216999c-693b-4aef-b951-9132ae94ebb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_126348af-248e-46af-bfe0-3472e47991bf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8216999c-693b-4aef-b951-9132ae94ebb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties_97c6d652-08d9-4d27-adf9-8e8267115384" xlink:href="wald-20221231.xsd#wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_126348af-248e-46af-bfe0-3472e47991bf" xlink:to="loc_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties_97c6d652-08d9-4d27-adf9-8e8267115384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_905163ab-1f01-45ac-8f69-b1d6047518cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_126348af-248e-46af-bfe0-3472e47991bf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_905163ab-1f01-45ac-8f69-b1d6047518cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_956840cd-f108-4f9e-b1d1-c4c111c977ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_03a97f33-4b15-408a-b0ff-8afda8a1f63f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_956840cd-f108-4f9e-b1d1-c4c111c977ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6ae429c0-71da-45ef-86e1-2c505774390f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6ae429c0-71da-45ef-86e1-2c505774390f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5d7e3036-12ac-4568-a66f-4f162afbd940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6ae429c0-71da-45ef-86e1-2c505774390f" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_5d7e3036-12ac-4568-a66f-4f162afbd940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_64f8b004-6494-4bd1-9983-ab6f4444ebef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6ae429c0-71da-45ef-86e1-2c505774390f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_64f8b004-6494-4bd1-9983-ab6f4444ebef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AdvancesForNoteReceivable_8fca1d63-d8a8-4b69-83a6-473dc0fcb9b9" xlink:href="wald-20221231.xsd#wald_AdvancesForNoteReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6ae429c0-71da-45ef-86e1-2c505774390f" xlink:to="loc_wald_AdvancesForNoteReceivable_8fca1d63-d8a8-4b69-83a6-473dc0fcb9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ae6de3fb-1077-4593-aa54-dc37c83f7acf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6ae429c0-71da-45ef-86e1-2c505774390f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ae6de3fb-1077-4593-aa54-dc37c83f7acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4c16a955-a847-4943-9f04-04d952e2b026" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4c16a955-a847-4943-9f04-04d952e2b026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3bfe49dd-571e-4305-af34-5f9b89f75d03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4c16a955-a847-4943-9f04-04d952e2b026" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3bfe49dd-571e-4305-af34-5f9b89f75d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_aad0c152-fac3-47f4-88da-d7e17c0d0046" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_aad0c152-fac3-47f4-88da-d7e17c0d0046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf3a4e33-4de1-4f24-b927-8cc15a1514ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf3a4e33-4de1-4f24-b927-8cc15a1514ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aea6b243-0be7-4f85-a2fa-0cc472e84893" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aea6b243-0be7-4f85-a2fa-0cc472e84893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3e01d558-1412-465b-b6ca-382ebabc174c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3e01d558-1412-465b-b6ca-382ebabc174c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_e5ed122e-f53c-43d5-ba82-57bfb3dc6c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_e5ed122e-f53c-43d5-ba82-57bfb3dc6c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_e4ce72de-8c31-4877-9477-3319a3fb69b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_e5ed122e-f53c-43d5-ba82-57bfb3dc6c3c" xlink:to="loc_us-gaap_IncomeTaxesPaid_e4ce72de-8c31-4877-9477-3319a3fb69b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_89397538-1e88-42ba-8490-1c2ea1a34db3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_e5ed122e-f53c-43d5-ba82-57bfb3dc6c3c" xlink:to="loc_us-gaap_InterestPaidNet_89397538-1e88-42ba-8490-1c2ea1a34db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86c1c15c-1673-4331-a75a-ae87f9d08cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_96ba8983-550b-4655-8f33-78915221c7e2" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86c1c15c-1673-4331-a75a-ae87f9d08cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f82558dc-14b0-46f2-85ef-e48afa2fc036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86c1c15c-1673-4331-a75a-ae87f9d08cc8" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_f82558dc-14b0-46f2-85ef-e48afa2fc036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CapitalContribution_d4ebe5e3-2cc5-479a-acae-c696c5264c99" xlink:href="wald-20221231.xsd#wald_CapitalContribution"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_86c1c15c-1673-4331-a75a-ae87f9d08cc8" xlink:to="loc_wald_CapitalContribution_d4ebe5e3-2cc5-479a-acae-c696c5264c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cf6cdaaa-30cc-4b78-b022-470ee79baff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cf6cdaaa-30cc-4b78-b022-470ee79baff7" xlink:to="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c351e16b-0bbe-4b8a-8016-96781d5d04b7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_srt_MajorCustomersAxis_c351e16b-0bbe-4b8a-8016-96781d5d04b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_583733db-3e4e-42c2-ad80-229e5520cfa7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_c351e16b-0bbe-4b8a-8016-96781d5d04b7" xlink:to="loc_srt_NameOfMajorCustomerDomain_583733db-3e4e-42c2-ad80-229e5520cfa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CustomerOneMember_91f31eaa-7dde-4981-be18-b0fe04bc1e05" xlink:href="wald-20221231.xsd#wald_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_583733db-3e4e-42c2-ad80-229e5520cfa7" xlink:to="loc_wald_CustomerOneMember_91f31eaa-7dde-4981-be18-b0fe04bc1e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CustomerTwoMember_cad31d16-46e6-48f5-b32f-a1cc3786f161" xlink:href="wald-20221231.xsd#wald_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_583733db-3e4e-42c2-ad80-229e5520cfa7" xlink:to="loc_wald_CustomerTwoMember_cad31d16-46e6-48f5-b32f-a1cc3786f161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CustomerThreeMember_73fe906b-676f-442d-9950-66a76e08dbf9" xlink:href="wald-20221231.xsd#wald_CustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_583733db-3e4e-42c2-ad80-229e5520cfa7" xlink:to="loc_wald_CustomerThreeMember_73fe906b-676f-442d-9950-66a76e08dbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9ba038fc-d524-41f5-ad99-8abe37c35867" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9ba038fc-d524-41f5-ad99-8abe37c35867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_46085d0c-5e50-4319-a3da-176b35df7e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9ba038fc-d524-41f5-ad99-8abe37c35867" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_46085d0c-5e50-4319-a3da-176b35df7e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_47dd1cec-8e4f-4627-adda-6b61fd89ff89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_46085d0c-5e50-4319-a3da-176b35df7e7c" xlink:to="loc_us-gaap_AccountsReceivableMember_47dd1cec-8e4f-4627-adda-6b61fd89ff89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_InventoryPurchasesMember_3cc54b60-b5e8-4394-b71f-19f6fcd93cef" xlink:href="wald-20221231.xsd#wald_InventoryPurchasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_46085d0c-5e50-4319-a3da-176b35df7e7c" xlink:to="loc_wald_InventoryPurchasesMember_3cc54b60-b5e8-4394-b71f-19f6fcd93cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableMember_607d8b6e-605a-4cdf-93c2-0d5929efd1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_46085d0c-5e50-4319-a3da-176b35df7e7c" xlink:to="loc_us-gaap_AccountsPayableMember_607d8b6e-605a-4cdf-93c2-0d5929efd1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c2bcbd47-03f9-48bb-83cd-82333e9f5a16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c2bcbd47-03f9-48bb-83cd-82333e9f5a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_36fdfea9-07a4-45ad-94bd-38d700677ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c2bcbd47-03f9-48bb-83cd-82333e9f5a16" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_36fdfea9-07a4-45ad-94bd-38d700677ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_530c99f6-aaf4-4ee7-895b-9c14b891ff67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_36fdfea9-07a4-45ad-94bd-38d700677ac3" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_530c99f6-aaf4-4ee7-895b-9c14b891ff67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_af8954f1-c334-4e50-be75-4961a7b4930b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_36fdfea9-07a4-45ad-94bd-38d700677ac3" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_af8954f1-c334-4e50-be75-4961a7b4930b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LenderConcentrationRiskMember_a9f70be9-c66b-49e3-9525-38b3d0b0ff50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LenderConcentrationRiskMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_36fdfea9-07a4-45ad-94bd-38d700677ac3" xlink:to="loc_us-gaap_LenderConcentrationRiskMember_a9f70be9-c66b-49e3-9525-38b3d0b0ff50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_0f3a3730-a6a5-45e9-b3fa-4d7dbd0e4fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_0f3a3730-a6a5-45e9-b3fa-4d7dbd0e4fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_de304cb0-d32d-4657-9638-69bd0bddffd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_0f3a3730-a6a5-45e9-b3fa-4d7dbd0e4fa3" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_de304cb0-d32d-4657-9638-69bd0bddffd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VendorOneMember_8e55364e-5c2f-401a-8f21-47d004d35882" xlink:href="wald-20221231.xsd#wald_VendorOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_de304cb0-d32d-4657-9638-69bd0bddffd1" xlink:to="loc_wald_VendorOneMember_8e55364e-5c2f-401a-8f21-47d004d35882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VendorTwoMember_7d1d81a0-ba8b-4876-8fbf-bf46643ce8d2" xlink:href="wald-20221231.xsd#wald_VendorTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_de304cb0-d32d-4657-9638-69bd0bddffd1" xlink:to="loc_wald_VendorTwoMember_7d1d81a0-ba8b-4876-8fbf-bf46643ce8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VendorThreeMember_f88d2bdd-badf-4594-a02c-9a2f4cca79a1" xlink:href="wald-20221231.xsd#wald_VendorThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_de304cb0-d32d-4657-9638-69bd0bddffd1" xlink:to="loc_wald_VendorThreeMember_f88d2bdd-badf-4594-a02c-9a2f4cca79a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_22e20052-147e-4d17-aebf-acdb36c25b58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_us-gaap_AwardTypeAxis_22e20052-147e-4d17-aebf-acdb36c25b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5e2697d-a0d8-41ac-9c0b-168d7232ba61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_22e20052-147e-4d17-aebf-acdb36c25b58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5e2697d-a0d8-41ac-9c0b-168d7232ba61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_FounderAwardsMember_0f21b0c1-d89b-42f5-8d69-7f2cf067d2d8" xlink:href="wald-20221231.xsd#wald_FounderAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5e2697d-a0d8-41ac-9c0b-168d7232ba61" xlink:to="loc_wald_FounderAwardsMember_0f21b0c1-d89b-42f5-8d69-7f2cf067d2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_59c7bfa0-71dc-4bce-a1ff-9115d1fa1b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_59c7bfa0-71dc-4bce-a1ff-9115d1fa1b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd5f0c0f-193b-44fa-86d3-12170c9431e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_59c7bfa0-71dc-4bce-a1ff-9115d1fa1b8c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd5f0c0f-193b-44fa-86d3-12170c9431e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkMember_e5b20d2d-e7c4-4142-b2dd-992cc149f5a0" xlink:href="wald-20221231.xsd#wald_MilkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd5f0c0f-193b-44fa-86d3-12170c9431e7" xlink:to="loc_wald_MilkMember_e5b20d2d-e7c4-4142-b2dd-992cc149f5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a9292949-f62d-4583-b6a9-fa0f3989af68" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a9292949-f62d-4583-b6a9-fa0f3989af68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_53421b0c-ab0a-4d27-984f-a2cbe915ea87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_a9292949-f62d-4583-b6a9-fa0f3989af68" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_53421b0c-ab0a-4d27-984f-a2cbe915ea87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2ecb52a7-fb73-4eae-b7fe-5879615f7370" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_53421b0c-ab0a-4d27-984f-a2cbe915ea87" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_2ecb52a7-fb73-4eae-b7fe-5879615f7370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f93d03bb-a183-417a-9f1f-bff77397b00d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f93d03bb-a183-417a-9f1f-bff77397b00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a44deb08-022a-41c5-92b3-1f802310a2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f93d03bb-a183-417a-9f1f-bff77397b00d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a44deb08-022a-41c5-92b3-1f802310a2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_c8afe513-4b00-405d-89d1-327f214c2a34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a44deb08-022a-41c5-92b3-1f802310a2ef" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_c8afe513-4b00-405d-89d1-327f214c2a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7705f823-de36-434b-8e6c-f1cd60e6adb8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_srt_RangeAxis_7705f823-de36-434b-8e6c-f1cd60e6adb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7e54d978-867d-4be4-9bb0-afd8fd973f49" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7705f823-de36-434b-8e6c-f1cd60e6adb8" xlink:to="loc_srt_RangeMember_7e54d978-867d-4be4-9bb0-afd8fd973f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0aa73bf3-53b4-4cae-825b-d65133cbd761" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7e54d978-867d-4be4-9bb0-afd8fd973f49" xlink:to="loc_srt_MaximumMember_0aa73bf3-53b4-4cae-825b-d65133cbd761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ab9dd93e-3b74-4a1b-91fd-d4768236b47a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7e54d978-867d-4be4-9bb0-afd8fd973f49" xlink:to="loc_srt_MinimumMember_ab9dd93e-3b74-4a1b-91fd-d4768236b47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e73a2c94-dc72-47dd-8ea8-4ac3508dd5b4" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_96eb546f-66a5-4578-bf19-ef541b9c8d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_96eb546f-66a5-4578-bf19-ef541b9c8d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37b40424-2a50-43ef-9ce3-f6887a0f40c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_37b40424-2a50-43ef-9ce3-f6887a0f40c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_2c6c2d7b-00b2-422a-8087-2ca5cec32e89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_RestrictedCash_2c6c2d7b-00b2-422a-8087-2ca5cec32e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a8894492-ecbc-4f27-8d9f-b3469793c705" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a8894492-ecbc-4f27-8d9f-b3469793c705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_dfd8697d-b96e-42bf-9e46-dc07e941a936" xlink:href="wald-20221231.xsd#wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_dfd8697d-b96e-42bf-9e46-dc07e941a936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a5020791-cc02-4098-9bee-eb644a1711d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a5020791-cc02-4098-9bee-eb644a1711d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum_8dc7146b-e2ac-4525-9209-a67e3636a714" xlink:href="wald-20221231.xsd#wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum_8dc7146b-e2ac-4525-9209-a67e3636a714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CustomerPaymentPeriod_1342c31a-5d77-4c6c-a919-1d1639b1db13" xlink:href="wald-20221231.xsd#wald_CustomerPaymentPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_wald_CustomerPaymentPeriod_1342c31a-5d77-4c6c-a919-1d1639b1db13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShippingAndHandlingCosts_bcb76703-1a37-4565-8129-16d399a8d330" xlink:href="wald-20221231.xsd#wald_ShippingAndHandlingCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_wald_ShippingAndHandlingCosts_bcb76703-1a37-4565-8129-16d399a8d330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_84e254d7-02a2-4cf7-b183-6c23a7693140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_AdvertisingExpense_84e254d7-02a2-4cf7-b183-6c23a7693140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent_77e03749-e81e-4c60-912f-3ad003df0933" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent_77e03749-e81e-4c60-912f-3ad003df0933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4888a8da-9578-45ec-af94-3ac4952b0aec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4888a8da-9578-45ec-af94-3ac4952b0aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_4297b78d-dd5c-4320-8a6f-8aba9ce2839b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_4297b78d-dd5c-4320-8a6f-8aba9ce2839b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a01784f1-cc83-4682-bed4-fddd27a387ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_a01784f1-cc83-4682-bed4-fddd27a387ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_4b84c206-8673-4207-a49b-d86cd1dfe5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_NumberOfReportableSegments_4b84c206-8673-4207-a49b-d86cd1dfe5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_321822ae-35df-4373-9597-c085d6ef43a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_NumberOfOperatingSegments_321822ae-35df-4373-9597-c085d6ef43a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_21d9dcae-a7a6-4b05-866f-922de31720a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_21d9dcae-a7a6-4b05-866f-922de31720a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c593fe2d-acd5-4a6b-94fd-083b74eaaf8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_32dd1b63-ea9d-4f85-9534-ae78e6caba71" xlink:to="loc_us-gaap_OperatingLeaseLiability_c593fe2d-acd5-4a6b-94fd-083b74eaaf8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b73edffb-8e9c-4b61-9de0-9124a00e3210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd57b224-213f-4998-b957-666c02e94bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b73edffb-8e9c-4b61-9de0-9124a00e3210" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd57b224-213f-4998-b957-666c02e94bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9ceb5255-2a9c-4d46-8060-7606832ce314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd57b224-213f-4998-b957-666c02e94bcd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9ceb5255-2a9c-4d46-8060-7606832ce314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_85be408e-7772-4485-a94b-df82b7bddc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9ceb5255-2a9c-4d46-8060-7606832ce314" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_85be408e-7772-4485-a94b-df82b7bddc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ComputerHardwareSoftwareAndEquipmentMember_0adc2264-f917-49ca-bee9-f0e6d43e1175" xlink:href="wald-20221231.xsd#wald_ComputerHardwareSoftwareAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_85be408e-7772-4485-a94b-df82b7bddc9d" xlink:to="loc_wald_ComputerHardwareSoftwareAndEquipmentMember_0adc2264-f917-49ca-bee9-f0e6d43e1175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_a19c16aa-3fc8-4d9d-b95b-33934bef96fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_85be408e-7772-4485-a94b-df82b7bddc9d" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_a19c16aa-3fc8-4d9d-b95b-33934bef96fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_a524c30d-ec61-44e5-bd5f-b7be2a1794d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_85be408e-7772-4485-a94b-df82b7bddc9d" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_a524c30d-ec61-44e5-bd5f-b7be2a1794d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GondolasMember_11044ec8-be3a-4dda-adf0-639a69d0c83e" xlink:href="wald-20221231.xsd#wald_GondolasMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_85be408e-7772-4485-a94b-df82b7bddc9d" xlink:to="loc_wald_GondolasMember_11044ec8-be3a-4dda-adf0-639a69d0c83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_613a7fa1-04f4-4ee1-b75e-baf8c830a16a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd57b224-213f-4998-b957-666c02e94bcd" xlink:to="loc_srt_RangeAxis_613a7fa1-04f4-4ee1-b75e-baf8c830a16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b75f9018-b1c5-4c9b-8507-c113dac332bd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_613a7fa1-04f4-4ee1-b75e-baf8c830a16a" xlink:to="loc_srt_RangeMember_b75f9018-b1c5-4c9b-8507-c113dac332bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f39a7076-23d6-4ecc-9362-8e187b6b6542" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b75f9018-b1c5-4c9b-8507-c113dac332bd" xlink:to="loc_srt_MinimumMember_f39a7076-23d6-4ecc-9362-8e187b6b6542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9db33d7a-e731-479c-8d16-08f02d63f531" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b75f9018-b1c5-4c9b-8507-c113dac332bd" xlink:to="loc_srt_MaximumMember_9db33d7a-e731-479c-8d16-08f02d63f531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05aa3b33-6896-48eb-bfad-bd186c93a7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd57b224-213f-4998-b957-666c02e94bcd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05aa3b33-6896-48eb-bfad-bd186c93a7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c5877468-355c-46a1-91dd-970b7c12f8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_05aa3b33-6896-48eb-bfad-bd186c93a7f9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c5877468-355c-46a1-91dd-970b7c12f8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#BUSINESSCOMBINATIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0d7739c0-813a-4902-9786-4f94550cbaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0d7739c0-813a-4902-9786-4f94550cbaf1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2b7b7075-ea86-4a40-80c1-d569570eebf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2b7b7075-ea86-4a40-80c1-d569570eebf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_11cf7f5a-2e60-4267-b518-fc7298d81867" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2b7b7075-ea86-4a40-80c1-d569570eebf1" xlink:to="loc_us-gaap_SegmentDomain_11cf7f5a-2e60-4267-b518-fc7298d81867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiSkincareMember_bf7dfb2b-a224-42a9-8bac-9b5029156bf7" xlink:href="wald-20221231.xsd#wald_ObagiSkincareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_11cf7f5a-2e60-4267-b518-fc7298d81867" xlink:to="loc_wald_ObagiSkincareMember_bf7dfb2b-a224-42a9-8bac-9b5029156bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_543fdab0-14d7-43e3-8dc6-6c1235a5283c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_543fdab0-14d7-43e3-8dc6-6c1235a5283c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_366930b0-75a0-4ff7-8e62-ae81c62d8b53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_543fdab0-14d7-43e3-8dc6-6c1235a5283c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_366930b0-75a0-4ff7-8e62-ae81c62d8b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiAndMilkBusinessCombinationsMember_c1d981ac-6f56-4e87-9eb7-0e5fbe20952c" xlink:href="wald-20221231.xsd#wald_ObagiAndMilkBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_366930b0-75a0-4ff7-8e62-ae81c62d8b53" xlink:to="loc_wald_ObagiAndMilkBusinessCombinationsMember_c1d981ac-6f56-4e87-9eb7-0e5fbe20952c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiMergerMember_0c3ec57b-8ca0-4972-b3be-6a1452f2332a" xlink:href="wald-20221231.xsd#wald_ObagiMergerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_366930b0-75a0-4ff7-8e62-ae81c62d8b53" xlink:to="loc_wald_ObagiMergerMember_0c3ec57b-8ca0-4972-b3be-6a1452f2332a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkTransactionMember_a07762c8-f221-4d9b-97dc-4d4a61dea0fe" xlink:href="wald-20221231.xsd#wald_MilkTransactionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_366930b0-75a0-4ff7-8e62-ae81c62d8b53" xlink:to="loc_wald_MilkTransactionMember_a07762c8-f221-4d9b-97dc-4d4a61dea0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_977118da-91e8-45af-9538-760c824d08a9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:to="loc_srt_OwnershipAxis_977118da-91e8-45af-9538-760c824d08a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b5d9b63f-2d90-4b2f-b203-29c9e702a215" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_977118da-91e8-45af-9538-760c824d08a9" xlink:to="loc_srt_OwnershipDomain_b5d9b63f-2d90-4b2f-b203-29c9e702a215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_WaldencastPlcMember_63d38fe6-61f5-4731-b3c4-8a3d76ffd386" xlink:href="wald-20221231.xsd#wald_WaldencastPlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_b5d9b63f-2d90-4b2f-b203-29c9e702a215" xlink:to="loc_wald_WaldencastPlcMember_63d38fe6-61f5-4731-b3c4-8a3d76ffd386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_34a498e3-d78f-4797-ae8e-772015c49c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:to="loc_us-gaap_StatementClassOfStockAxis_34a498e3-d78f-4797-ae8e-772015c49c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3988fd97-8d41-42cf-a0ca-e43213288750" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_34a498e3-d78f-4797-ae8e-772015c49c0e" xlink:to="loc_us-gaap_ClassOfStockDomain_3988fd97-8d41-42cf-a0ca-e43213288750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_86660aa2-524e-40b2-9d9e-00991bb2ec0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3988fd97-8d41-42cf-a0ca-e43213288750" xlink:to="loc_us-gaap_CommonClassAMember_86660aa2-524e-40b2-9d9e-00991bb2ec0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_LimitedPartnershipUnitsMember_49a30760-95a5-453a-9ca3-c571b7de976c" xlink:href="wald-20221231.xsd#wald_LimitedPartnershipUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3988fd97-8d41-42cf-a0ca-e43213288750" xlink:to="loc_wald_LimitedPartnershipUnitsMember_49a30760-95a5-453a-9ca3-c571b7de976c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_816ae6b6-11fe-47a9-99f6-f87b49b2fdde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3988fd97-8d41-42cf-a0ca-e43213288750" xlink:to="loc_us-gaap_CommonClassBMember_816ae6b6-11fe-47a9-99f6-f87b49b2fdde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3de9506a-0176-4e92-a39b-c8dd2c223fbb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:to="loc_dei_LegalEntityAxis_3de9506a-0176-4e92-a39b-c8dd2c223fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e51e84eb-2252-49a8-bfbc-f666a053ae97" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_3de9506a-0176-4e92-a39b-c8dd2c223fbb" xlink:to="loc_dei_EntityDomain_e51e84eb-2252-49a8-bfbc-f666a053ae97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiChinaBusinessMember_a90639dc-0a2a-4c87-a985-4e9ae233b9e7" xlink:href="wald-20221231.xsd#wald_ObagiChinaBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e51e84eb-2252-49a8-bfbc-f666a053ae97" xlink:to="loc_wald_ObagiChinaBusinessMember_a90639dc-0a2a-4c87-a985-4e9ae233b9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6f238e5-fcb0-48cc-aa5f-3b57815b6775" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6f238e5-fcb0-48cc-aa5f-3b57815b6775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8f1c69e1-2239-472d-b5d8-30da0709999e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b6f238e5-fcb0-48cc-aa5f-3b57815b6775" xlink:to="loc_us-gaap_RelatedPartyDomain_8f1c69e1-2239-472d-b5d8-30da0709999e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_fef90b73-8a7f-4a9f-80a2-4a0745da93ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8f1c69e1-2239-472d-b5d8-30da0709999e" xlink:to="loc_us-gaap_RelatedPartyMember_fef90b73-8a7f-4a9f-80a2-4a0745da93ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3dc50360-bf72-42f8-8ee3-479e48774efc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:to="loc_srt_CounterpartyNameAxis_3dc50360-bf72-42f8-8ee3-479e48774efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b87e5f78-2c04-4dd3-8750-3e6a7794e512" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3dc50360-bf72-42f8-8ee3-479e48774efc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b87e5f78-2c04-4dd3-8750-3e6a7794e512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CedarwalkMember_2e95f131-bedd-42ab-b922-0380b9b8d27e" xlink:href="wald-20221231.xsd#wald_CedarwalkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b87e5f78-2c04-4dd3-8750-3e6a7794e512" xlink:to="loc_wald_CedarwalkMember_2e95f131-bedd-42ab-b922-0380b9b8d27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_543d0412-8240-4e5f-bd03-c131c79c4633" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_71e1ebef-8116-4a8f-84cb-00b4bf44d2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_71e1ebef-8116-4a8f-84cb-00b4bf44d2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8bde9649-9665-4c0a-b954-0482b0d18ada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8bde9649-9665-4c0a-b954-0482b0d18ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_187209e3-0127-4cde-b2da-c9720005fbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_187209e3-0127-4cde-b2da-c9720005fbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CommonStockConvertibleConversionRatio_c0eaf445-f385-45b7-8871-8feccf007dfb" xlink:href="wald-20221231.xsd#wald_CommonStockConvertibleConversionRatio"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_wald_CommonStockConvertibleConversionRatio_c0eaf445-f385-45b7-8871-8feccf007dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_NumberOfNominatedDirectors_9253b10e-15f3-44c1-bae2-be8d5e73564e" xlink:href="wald-20221231.xsd#wald_NumberOfNominatedDirectors"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_wald_NumberOfNominatedDirectors_9253b10e-15f3-44c1-bae2-be8d5e73564e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_b30bcafe-8777-4784-83e5-4d8e6101a93f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_b30bcafe-8777-4784-83e5-4d8e6101a93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0e1684a8-7b1c-45f7-a37f-3e802449f8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0e1684a8-7b1c-45f7-a37f-3e802449f8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b9b9f2da-7b7f-42dd-9c19-535de5a064b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b9b9f2da-7b7f-42dd-9c19-535de5a064b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_5040a31e-698a-4354-835a-663f17392eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_5040a31e-698a-4354-835a-663f17392eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d9673048-e866-42cc-83c9-36787b922357" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d9673048-e866-42cc-83c9-36787b922357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_42f69ac6-1ec5-4abe-afe8-8bf2ebbae17d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_42f69ac6-1ec5-4abe-afe8-8bf2ebbae17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_d42c6c7a-c1fd-4e7b-8dbd-f3838b1fcaae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_d42c6c7a-c1fd-4e7b-8dbd-f3838b1fcaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_cc0ee79b-36b7-4af7-a2a3-061cda3d256a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8d8fea94-91d7-41d0-9b96-70948f6f6f54" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_cc0ee79b-36b7-4af7-a2a3-061cda3d256a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_773d696c-4a08-4ccf-96ee-528454bef53d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_de5cea9a-86ef-4a8a-93f1-d73349829865" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_773d696c-4a08-4ccf-96ee-528454bef53d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_de5cea9a-86ef-4a8a-93f1-d73349829865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e636bdb6-3f20-46d6-8952-b877b84c401b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_de5cea9a-86ef-4a8a-93f1-d73349829865" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e636bdb6-3f20-46d6-8952-b877b84c401b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f05d7789-5827-4bc0-84e6-b3066cdabee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e636bdb6-3f20-46d6-8952-b877b84c401b" xlink:to="loc_us-gaap_SegmentDomain_f05d7789-5827-4bc0-84e6-b3066cdabee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiSkincareMember_ee15c73a-819f-4b85-a5fc-fcf606450ce2" xlink:href="wald-20221231.xsd#wald_ObagiSkincareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f05d7789-5827-4bc0-84e6-b3066cdabee0" xlink:to="loc_wald_ObagiSkincareMember_ee15c73a-819f-4b85-a5fc-fcf606450ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkMakeupMember_228484d0-363a-436e-8bd6-7b3981bc5147" xlink:href="wald-20221231.xsd#wald_MilkMakeupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f05d7789-5827-4bc0-84e6-b3066cdabee0" xlink:to="loc_wald_MilkMakeupMember_228484d0-363a-436e-8bd6-7b3981bc5147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0d75b4c8-ed8c-41a8-b3b5-3b39aa0da346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_de5cea9a-86ef-4a8a-93f1-d73349829865" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0d75b4c8-ed8c-41a8-b3b5-3b39aa0da346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3ec37ec-153f-4d09-bd26-1244fae2c1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0d75b4c8-ed8c-41a8-b3b5-3b39aa0da346" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3ec37ec-153f-4d09-bd26-1244fae2c1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiAndMilkBusinessCombinationsMember_abb34a12-d55f-4fc0-92b6-7f83a9d12e1b" xlink:href="wald-20221231.xsd#wald_ObagiAndMilkBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f3ec37ec-153f-4d09-bd26-1244fae2c1a3" xlink:to="loc_wald_ObagiAndMilkBusinessCombinationsMember_abb34a12-d55f-4fc0-92b6-7f83a9d12e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c67e0da-eb36-4a7f-bb67-f73ec71d35ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_de5cea9a-86ef-4a8a-93f1-d73349829865" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c67e0da-eb36-4a7f-bb67-f73ec71d35ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5a4a6752-f263-4aed-a069-9a0a283f72cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c67e0da-eb36-4a7f-bb67-f73ec71d35ce" xlink:to="loc_us-gaap_RelatedPartyDomain_5a4a6752-f263-4aed-a069-9a0a283f72cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_53a4812e-2a3e-4bc4-8ccc-7baa568c7641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5a4a6752-f263-4aed-a069-9a0a283f72cb" xlink:to="loc_us-gaap_RelatedPartyMember_53a4812e-2a3e-4bc4-8ccc-7baa568c7641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_977cc537-a066-488a-942b-c05e0ddec6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_de5cea9a-86ef-4a8a-93f1-d73349829865" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_977cc537-a066-488a-942b-c05e0ddec6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_5099f75e-91cb-44ee-ba4b-b20703c4f086" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_977cc537-a066-488a-942b-c05e0ddec6c0" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_5099f75e-91cb-44ee-ba4b-b20703c4f086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_f7e71f65-21f4-4ba1-89d6-5e5b9063b514" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_5099f75e-91cb-44ee-ba4b-b20703c4f086" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_f7e71f65-21f4-4ba1-89d6-5e5b9063b514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_99f5b478-0868-42d1-a4c5-5a804511048a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_5099f75e-91cb-44ee-ba4b-b20703c4f086" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_99f5b478-0868-42d1-a4c5-5a804511048a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt_cce7ed21-f0f0-479d-b539-301a2b938690" xlink:href="wald-20221231.xsd#wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_5099f75e-91cb-44ee-ba4b-b20703c4f086" xlink:to="loc_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt_cce7ed21-f0f0-479d-b539-301a2b938690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_be3c5602-acaa-4336-ade2-1efcdd40e001" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_5099f75e-91cb-44ee-ba4b-b20703c4f086" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_be3c5602-acaa-4336-ade2-1efcdd40e001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_329c9645-0a23-4ef0-a0ad-c9fdf61fdd73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_5099f75e-91cb-44ee-ba4b-b20703c4f086" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_329c9645-0a23-4ef0-a0ad-c9fdf61fdd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_977cc537-a066-488a-942b-c05e0ddec6c0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_22986f80-9143-4541-b628-a5632197e15a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_22986f80-9143-4541-b628-a5632197e15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_21b57bff-edc1-4257-adab-78d8df43495c" xlink:href="wald-20221231.xsd#wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_21b57bff-edc1-4257-adab-78d8df43495c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_21d21e04-1bfa-449e-8e25-8f0fd0160bba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_21d21e04-1bfa-449e-8e25-8f0fd0160bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty_6fcd1d3c-e579-4f0b-8dd5-6fc2aadf5482" xlink:href="wald-20221231.xsd#wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty_6fcd1d3c-e579-4f0b-8dd5-6fc2aadf5482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1f445c5b-4783-438c-bae4-6b6daff773fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1f445c5b-4783-438c-bae4-6b6daff773fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_7e852c92-7476-432f-9fc3-6a3895274978" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_7e852c92-7476-432f-9fc3-6a3895274978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_66941308-88b7-4b70-8c24-bc09b9a2434c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_66941308-88b7-4b70-8c24-bc09b9a2434c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_4759bc40-610b-404c-aedd-04b6bf3bb5df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_4759bc40-610b-404c-aedd-04b6bf3bb5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_aac846eb-bf3a-43da-92b8-20414203a985" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_aac846eb-bf3a-43da-92b8-20414203a985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets_1071908e-8392-4fdd-a465-1104f4b557dd" xlink:href="wald-20221231.xsd#wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets_1071908e-8392-4fdd-a465-1104f4b557dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_bae6be9e-7f03-4433-a7fb-b1f8fccddaa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_bae6be9e-7f03-4433-a7fb-b1f8fccddaa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_ff156119-211b-43a7-84b3-fd11332e7fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6991bd29-ef0b-4ce7-ab69-6112a2962cf3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_ff156119-211b-43a7-84b3-fd11332e7fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_131a1ba1-558b-4b4b-ad8d-e6bfcd7b4c05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_977cc537-a066-488a-942b-c05e0ddec6c0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_131a1ba1-558b-4b4b-ad8d-e6bfcd7b4c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_dc269151-2269-4408-9aca-6b182efe782a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_131a1ba1-558b-4b4b-ad8d-e6bfcd7b4c05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_dc269151-2269-4408-9aca-6b182efe782a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_5cbf2d55-2253-46d9-8d21-b9b9e38a9bea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_131a1ba1-558b-4b4b-ad8d-e6bfcd7b4c05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_5cbf2d55-2253-46d9-8d21-b9b9e38a9bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_52a6efae-4d5f-4c36-aca8-139cc9f5e960" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_131a1ba1-558b-4b4b-ad8d-e6bfcd7b4c05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_52a6efae-4d5f-4c36-aca8-139cc9f5e960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_68b0f87f-1c1c-4b19-84c4-d8d2778820d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_131a1ba1-558b-4b4b-ad8d-e6bfcd7b4c05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_68b0f87f-1c1c-4b19-84c4-d8d2778820d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2364f616-568a-4ff8-8436-e63330ea25de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_131a1ba1-558b-4b4b-ad8d-e6bfcd7b4c05" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2364f616-568a-4ff8-8436-e63330ea25de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_cfb7939c-6fc4-40d9-b851-72bafc0946a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_977cc537-a066-488a-942b-c05e0ddec6c0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_cfb7939c-6fc4-40d9-b851-72bafc0946a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_74d9f788-ec81-424a-9490-384116594596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_977cc537-a066-488a-942b-c05e0ddec6c0" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_74d9f788-ec81-424a-9490-384116594596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_04a02f1b-076c-4ed0-9f66-5917faf75bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_977cc537-a066-488a-942b-c05e0ddec6c0" xlink:to="loc_us-gaap_Goodwill_04a02f1b-076c-4ed0-9f66-5917faf75bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ff84fde3-6e10-4b2a-a1c6-236817f45e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_db12ab8d-dd66-47bb-892e-ea848bfce049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ff84fde3-6e10-4b2a-a1c6-236817f45e44" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_db12ab8d-dd66-47bb-892e-ea848bfce049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_68d16e86-3926-4f27-8efa-c080dedc1131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_db12ab8d-dd66-47bb-892e-ea848bfce049" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_68d16e86-3926-4f27-8efa-c080dedc1131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62096649-57b0-4f2d-a106-d5ec8b8eafbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_68d16e86-3926-4f27-8efa-c080dedc1131" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62096649-57b0-4f2d-a106-d5ec8b8eafbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_01acfe17-90c7-4beb-b2be-22a95215e3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62096649-57b0-4f2d-a106-d5ec8b8eafbb" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_01acfe17-90c7-4beb-b2be-22a95215e3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_b6ee2e57-c588-4c5a-9d7d-a7ac7b4a24c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62096649-57b0-4f2d-a106-d5ec8b8eafbb" xlink:to="loc_us-gaap_CustomerRelationshipsMember_b6ee2e57-c588-4c5a-9d7d-a7ac7b4a24c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_TretinoinDistributionAndSupplyAgreementMember_d6106389-0eed-4ae2-b38f-48e65a73ca14" xlink:href="wald-20221231.xsd#wald_TretinoinDistributionAndSupplyAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62096649-57b0-4f2d-a106-d5ec8b8eafbb" xlink:to="loc_wald_TretinoinDistributionAndSupplyAgreementMember_d6106389-0eed-4ae2-b38f-48e65a73ca14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_FormulationsMember_011fbeac-1307-4ca1-aa2b-dafe024e4860" xlink:href="wald-20221231.xsd#wald_FormulationsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_62096649-57b0-4f2d-a106-d5ec8b8eafbb" xlink:to="loc_wald_FormulationsMember_011fbeac-1307-4ca1-aa2b-dafe024e4860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_75423bf8-3384-4e91-972e-34d78818e706" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_db12ab8d-dd66-47bb-892e-ea848bfce049" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_75423bf8-3384-4e91-972e-34d78818e706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_95521600-ea2b-4ee1-95e0-0e8242fb59bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_75423bf8-3384-4e91-972e-34d78818e706" xlink:to="loc_us-gaap_SegmentDomain_95521600-ea2b-4ee1-95e0-0e8242fb59bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiSkincareMember_d61790a8-e20d-440c-ba7a-62c79e9f9835" xlink:href="wald-20221231.xsd#wald_ObagiSkincareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_95521600-ea2b-4ee1-95e0-0e8242fb59bf" xlink:to="loc_wald_ObagiSkincareMember_d61790a8-e20d-440c-ba7a-62c79e9f9835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkMakeupMember_e8b2907a-ae9b-4ea6-b095-f363b3213e18" xlink:href="wald-20221231.xsd#wald_MilkMakeupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_95521600-ea2b-4ee1-95e0-0e8242fb59bf" xlink:to="loc_wald_MilkMakeupMember_e8b2907a-ae9b-4ea6-b095-f363b3213e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c4acf90f-9d7a-4941-9eac-a3acf4f83196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_db12ab8d-dd66-47bb-892e-ea848bfce049" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c4acf90f-9d7a-4941-9eac-a3acf4f83196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b1a8e10-b615-4b47-9f5b-9c4c4b7e74fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c4acf90f-9d7a-4941-9eac-a3acf4f83196" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b1a8e10-b615-4b47-9f5b-9c4c4b7e74fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiAndMilkBusinessCombinationsMember_97d8fb16-f8f9-4a49-af60-b873d6015ecc" xlink:href="wald-20221231.xsd#wald_ObagiAndMilkBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2b1a8e10-b615-4b47-9f5b-9c4c4b7e74fb" xlink:to="loc_wald_ObagiAndMilkBusinessCombinationsMember_97d8fb16-f8f9-4a49-af60-b873d6015ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_ad6484ef-a1bd-4ec7-ab92-f3d8fd2caae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_db12ab8d-dd66-47bb-892e-ea848bfce049" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_ad6484ef-a1bd-4ec7-ab92-f3d8fd2caae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5738f648-af6f-4826-bc58-60d6a1cd506a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_ad6484ef-a1bd-4ec7-ab92-f3d8fd2caae1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5738f648-af6f-4826-bc58-60d6a1cd506a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_b3ccd524-04f1-4c6d-9d10-f631d3a9f32f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_ad6484ef-a1bd-4ec7-ab92-f3d8fd2caae1" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_b3ccd524-04f1-4c6d-9d10-f631d3a9f32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9aebe6e5-0795-4649-895b-573dd433a8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_52c23059-4483-4180-af6f-9d1123bf7d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9aebe6e5-0795-4649-895b-573dd433a8b6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_52c23059-4483-4180-af6f-9d1123bf7d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_299510bc-a228-4c6c-bb69-47b303bf259f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_52c23059-4483-4180-af6f-9d1123bf7d3e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_299510bc-a228-4c6c-bb69-47b303bf259f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14ca9312-469f-4a35-8073-ccca9c114834" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_299510bc-a228-4c6c-bb69-47b303bf259f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14ca9312-469f-4a35-8073-ccca9c114834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiAndMilkBusinessCombinationsMember_90524529-f1b4-4452-a5fb-2370dc92b09d" xlink:href="wald-20221231.xsd#wald_ObagiAndMilkBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_14ca9312-469f-4a35-8073-ccca9c114834" xlink:to="loc_wald_ObagiAndMilkBusinessCombinationsMember_90524529-f1b4-4452-a5fb-2370dc92b09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e0e4e137-c883-4504-b8f3-dc0414b5ae24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_52c23059-4483-4180-af6f-9d1123bf7d3e" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_e0e4e137-c883-4504-b8f3-dc0414b5ae24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_0dc04414-cd64-42a3-8e3f-7d1e7b96ecd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e4e137-c883-4504-b8f3-dc0414b5ae24" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_0dc04414-cd64-42a3-8e3f-7d1e7b96ecd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_356e08ee-2ce4-4445-8a88-ad155b05e57e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e4e137-c883-4504-b8f3-dc0414b5ae24" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_356e08ee-2ce4-4445-8a88-ad155b05e57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest_577fe895-f0a2-40a8-bbe7-8786cfb93ae6" xlink:href="wald-20221231.xsd#wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e4e137-c883-4504-b8f3-dc0414b5ae24" xlink:to="loc_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest_577fe895-f0a2-40a8-bbe7-8786cfb93ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent_1e837d17-f298-47c4-b9d1-9efa5586980b" xlink:href="wald-20221231.xsd#wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e0e4e137-c883-4504-b8f3-dc0414b5ae24" xlink:to="loc_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent_1e837d17-f298-47c4-b9d1-9efa5586980b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#REVENUERevenuebySalesChannelDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_799b7f21-a6c0-4ca6-89b8-bf1304fe8270" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1ae80736-ff8b-47da-87f9-9fc81173fc73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_799b7f21-a6c0-4ca6-89b8-bf1304fe8270" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1ae80736-ff8b-47da-87f9-9fc81173fc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8419d7cc-5627-4ec8-824f-7f080cda73e9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1ae80736-ff8b-47da-87f9-9fc81173fc73" xlink:to="loc_srt_ProductOrServiceAxis_8419d7cc-5627-4ec8-824f-7f080cda73e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_244a7976-1aaf-4fca-9453-2a6ea68991b0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8419d7cc-5627-4ec8-824f-7f080cda73e9" xlink:to="loc_srt_ProductsAndServicesDomain_244a7976-1aaf-4fca-9453-2a6ea68991b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_338bd741-ee69-4e0f-81a1-b41868e84d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_244a7976-1aaf-4fca-9453-2a6ea68991b0" xlink:to="loc_us-gaap_ProductMember_338bd741-ee69-4e0f-81a1-b41868e84d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_779412e3-bf71-404d-bb43-4491ae0b3479" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_244a7976-1aaf-4fca-9453-2a6ea68991b0" xlink:to="loc_us-gaap_RoyaltyMember_779412e3-bf71-404d-bb43-4491ae0b3479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_be449fc0-3813-40ae-bfbb-c51a97ba4a22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1ae80736-ff8b-47da-87f9-9fc81173fc73" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_be449fc0-3813-40ae-bfbb-c51a97ba4a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_beeee759-ac9b-443b-a7f4-ee773800ee83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_be449fc0-3813-40ae-bfbb-c51a97ba4a22" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_beeee759-ac9b-443b-a7f4-ee773800ee83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelDirectlyToConsumerMember_da85c5c6-f99a-455f-b46d-b20cab10f03b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesChannelDirectlyToConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_beeee759-ac9b-443b-a7f4-ee773800ee83" xlink:to="loc_us-gaap_SalesChannelDirectlyToConsumerMember_da85c5c6-f99a-455f-b46d-b20cab10f03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesChannelThroughIntermediaryMember_f977a74d-a445-4db1-8abf-b731af3f8214" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesChannelThroughIntermediaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_beeee759-ac9b-443b-a7f4-ee773800ee83" xlink:to="loc_us-gaap_SalesChannelThroughIntermediaryMember_f977a74d-a445-4db1-8abf-b731af3f8214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_53cbd5ef-4322-435e-bbe1-c75099a5e66c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1ae80736-ff8b-47da-87f9-9fc81173fc73" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_53cbd5ef-4322-435e-bbe1-c75099a5e66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7f737db1-c522-4110-9158-0930b1c58e01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_53cbd5ef-4322-435e-bbe1-c75099a5e66c" xlink:to="loc_us-gaap_SegmentDomain_7f737db1-c522-4110-9158-0930b1c58e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiSkincareMember_5c81a34d-21e2-4824-bef5-6012744d4272" xlink:href="wald-20221231.xsd#wald_ObagiSkincareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7f737db1-c522-4110-9158-0930b1c58e01" xlink:to="loc_wald_ObagiSkincareMember_5c81a34d-21e2-4824-bef5-6012744d4272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkMakeupMember_a1dd2a54-77fa-46dd-9e48-e0a8995f47c8" xlink:href="wald-20221231.xsd#wald_MilkMakeupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7f737db1-c522-4110-9158-0930b1c58e01" xlink:to="loc_wald_MilkMakeupMember_a1dd2a54-77fa-46dd-9e48-e0a8995f47c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4a62c306-dab7-4e4d-a34b-aad55712b252" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1ae80736-ff8b-47da-87f9-9fc81173fc73" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_4a62c306-dab7-4e4d-a34b-aad55712b252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a292ab26-2848-4c24-aec9-af9f4c0c0d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4a62c306-dab7-4e4d-a34b-aad55712b252" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a292ab26-2848-4c24-aec9-af9f4c0c0d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/REVENUENarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#REVENUENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/REVENUENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0df19d7e-d508-4c0f-b361-4d7f4b7c2f63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_fd8c5d4d-a79f-4bf0-8d47-b54d2d744651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0df19d7e-d508-4c0f-b361-4d7f4b7c2f63" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_fd8c5d4d-a79f-4bf0-8d47-b54d2d744651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8e57b8c7-30e0-42d3-b9b4-8adb2545fe49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fd8c5d4d-a79f-4bf0-8d47-b54d2d744651" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8e57b8c7-30e0-42d3-b9b4-8adb2545fe49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a06f053-3916-4ac2-8731-913dd32a0df8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8e57b8c7-30e0-42d3-b9b4-8adb2545fe49" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a06f053-3916-4ac2-8731-913dd32a0df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_b2d9d645-828e-4d3e-83fc-5e3d879434be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2a06f053-3916-4ac2-8731-913dd32a0df8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_b2d9d645-828e-4d3e-83fc-5e3d879434be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c8022caf-eccd-45d9-9db9-692ed17d06eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fd8c5d4d-a79f-4bf0-8d47-b54d2d744651" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c8022caf-eccd-45d9-9db9-692ed17d06eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_181c8daf-85bf-4894-9261-2d023534b486" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c8022caf-eccd-45d9-9db9-692ed17d06eb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_181c8daf-85bf-4894-9261-2d023534b486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c6271f21-2b7b-4514-92d6-a2aebff04cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_181c8daf-85bf-4894-9261-2d023534b486" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c6271f21-2b7b-4514-92d6-a2aebff04cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_a15d1bc4-2a37-4bc8-822d-1f47447334b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_181c8daf-85bf-4894-9261-2d023534b486" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_a15d1bc4-2a37-4bc8-822d-1f47447334b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_795e8e3f-a433-4886-9f67-27eb09597cfc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fd8c5d4d-a79f-4bf0-8d47-b54d2d744651" xlink:to="loc_srt_MajorCustomersAxis_795e8e3f-a433-4886-9f67-27eb09597cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b43debfd-6065-4d90-9117-8febc79a2abb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_795e8e3f-a433-4886-9f67-27eb09597cfc" xlink:to="loc_srt_NameOfMajorCustomerDomain_b43debfd-6065-4d90-9117-8febc79a2abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CustomerOneMember_b8ede068-b11f-41cd-88cd-e663c55069ec" xlink:href="wald-20221231.xsd#wald_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b43debfd-6065-4d90-9117-8febc79a2abb" xlink:to="loc_wald_CustomerOneMember_b8ede068-b11f-41cd-88cd-e663c55069ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CustomerTwoMember_0c0df606-ec59-4a66-9965-5acb9943e4f7" xlink:href="wald-20221231.xsd#wald_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b43debfd-6065-4d90-9117-8febc79a2abb" xlink:to="loc_wald_CustomerTwoMember_0c0df606-ec59-4a66-9965-5acb9943e4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CustomerThreeMember_52b1e684-e551-4775-88ad-4d60b6e25f15" xlink:href="wald-20221231.xsd#wald_CustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b43debfd-6065-4d90-9117-8febc79a2abb" xlink:to="loc_wald_CustomerThreeMember_52b1e684-e551-4775-88ad-4d60b6e25f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelAxis_2249cbb2-bdef-4fe1-9839-71e312e17b95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fd8c5d4d-a79f-4bf0-8d47-b54d2d744651" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelAxis_2249cbb2-bdef-4fe1-9839-71e312e17b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerSalesChannelDomain_4c296f46-4084-4cc3-957c-e0d2b7f85bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerSalesChannelDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelAxis_2249cbb2-bdef-4fe1-9839-71e312e17b95" xlink:to="loc_us-gaap_ContractWithCustomerSalesChannelDomain_4c296f46-4084-4cc3-957c-e0d2b7f85bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PhysicianChannelProviderMember_72f69f16-9dc6-47aa-940c-d0f83a86fd6d" xlink:href="wald-20221231.xsd#wald_PhysicianChannelProviderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_4c296f46-4084-4cc3-957c-e0d2b7f85bc5" xlink:to="loc_wald_PhysicianChannelProviderMember_72f69f16-9dc6-47aa-940c-d0f83a86fd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SpaChannelDistributorMember_d2c9aa00-5532-434c-b399-824d6d302bb7" xlink:href="wald-20221231.xsd#wald_SpaChannelDistributorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerSalesChannelDomain_4c296f46-4084-4cc3-957c-e0d2b7f85bc5" xlink:to="loc_wald_SpaChannelDistributorMember_d2c9aa00-5532-434c-b399-824d6d302bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4a6dc5ee-f2b4-4c6a-9198-a49bde3454f8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fd8c5d4d-a79f-4bf0-8d47-b54d2d744651" xlink:to="loc_srt_StatementGeographicalAxis_4a6dc5ee-f2b4-4c6a-9198-a49bde3454f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7f41c763-b0c6-41f7-8b74-dcc2689f8f1a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4a6dc5ee-f2b4-4c6a-9198-a49bde3454f8" xlink:to="loc_srt_SegmentGeographicalDomain_7f41c763-b0c6-41f7-8b74-dcc2689f8f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1f408352-18be-4e79-912d-a73025c3af9a" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7f41c763-b0c6-41f7-8b74-dcc2689f8f1a" xlink:to="loc_country_US_1f408352-18be-4e79-912d-a73025c3af9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_02ddb324-be66-41fb-a518-bc9147ec5f43" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7f41c763-b0c6-41f7-8b74-dcc2689f8f1a" xlink:to="loc_country_CN_02ddb324-be66-41fb-a518-bc9147ec5f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_VN_448445bf-456f-42a3-9845-027d5484cf15" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_VN"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7f41c763-b0c6-41f7-8b74-dcc2689f8f1a" xlink:to="loc_country_VN_448445bf-456f-42a3-9845-027d5484cf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_35bc183d-88c6-4aa3-b079-e316c02f2ebb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fd8c5d4d-a79f-4bf0-8d47-b54d2d744651" xlink:to="loc_srt_ProductOrServiceAxis_35bc183d-88c6-4aa3-b079-e316c02f2ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5357cc52-9f3e-421d-b859-f456de31fc10" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_35bc183d-88c6-4aa3-b079-e316c02f2ebb" xlink:to="loc_srt_ProductsAndServicesDomain_5357cc52-9f3e-421d-b859-f456de31fc10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ab091ec4-3030-4e1e-ac68-c6e3ca72b7da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5357cc52-9f3e-421d-b859-f456de31fc10" xlink:to="loc_us-gaap_ProductMember_ab091ec4-3030-4e1e-ac68-c6e3ca72b7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_161b3e66-59e5-4148-b656-fdd67f8d6591" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fd8c5d4d-a79f-4bf0-8d47-b54d2d744651" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_161b3e66-59e5-4148-b656-fdd67f8d6591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_117b3891-e70f-4b18-93b6-83c9a2f02740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_161b3e66-59e5-4148-b656-fdd67f8d6591" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_117b3891-e70f-4b18-93b6-83c9a2f02740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e3249d90-1a3f-4176-a5ef-287d50d2bfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_161b3e66-59e5-4148-b656-fdd67f8d6591" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e3249d90-1a3f-4176-a5ef-287d50d2bfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#REVENUERevenuebyGeographicRegionDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5f249ef0-ee1c-4dab-91fd-b907ffc1ff2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_efdd04e9-451e-4ac9-8524-286cc9d402d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5f249ef0-ee1c-4dab-91fd-b907ffc1ff2e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_efdd04e9-451e-4ac9-8524-286cc9d402d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_aae298db-2a38-4f7d-a77c-f252eb155bc2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_efdd04e9-451e-4ac9-8524-286cc9d402d8" xlink:to="loc_srt_ProductOrServiceAxis_aae298db-2a38-4f7d-a77c-f252eb155bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_034603dd-b3fa-4c4b-8a7a-b2ceac297c65" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_aae298db-2a38-4f7d-a77c-f252eb155bc2" xlink:to="loc_srt_ProductsAndServicesDomain_034603dd-b3fa-4c4b-8a7a-b2ceac297c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_17ad1927-c8ce-4f40-95c1-504191321662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_034603dd-b3fa-4c4b-8a7a-b2ceac297c65" xlink:to="loc_us-gaap_ProductMember_17ad1927-c8ce-4f40-95c1-504191321662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_39667b0d-1d31-4746-a077-7d5493ce7ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_034603dd-b3fa-4c4b-8a7a-b2ceac297c65" xlink:to="loc_us-gaap_RoyaltyMember_39667b0d-1d31-4746-a077-7d5493ce7ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7f8e2619-779f-41ca-b53a-3fcf3e6a295a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_efdd04e9-451e-4ac9-8524-286cc9d402d8" xlink:to="loc_srt_StatementGeographicalAxis_7f8e2619-779f-41ca-b53a-3fcf3e6a295a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d34df2f7-85d4-4fe1-a43a-1a0eacfd3e28" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7f8e2619-779f-41ca-b53a-3fcf3e6a295a" xlink:to="loc_srt_SegmentGeographicalDomain_d34df2f7-85d4-4fe1-a43a-1a0eacfd3e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NorthAmericaMember_25e4cf86-e42c-4a40-90b2-5212ac8c8e75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d34df2f7-85d4-4fe1-a43a-1a0eacfd3e28" xlink:to="loc_srt_NorthAmericaMember_25e4cf86-e42c-4a40-90b2-5212ac8c8e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_RestOfTheWorldMember_6251d00f-16d0-4aa5-99d7-ac24cf6f0254" xlink:href="wald-20221231.xsd#wald_RestOfTheWorldMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d34df2f7-85d4-4fe1-a43a-1a0eacfd3e28" xlink:to="loc_wald_RestOfTheWorldMember_6251d00f-16d0-4aa5-99d7-ac24cf6f0254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_319df5dc-4c99-44f3-a072-836b79e4ab35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_efdd04e9-451e-4ac9-8524-286cc9d402d8" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_319df5dc-4c99-44f3-a072-836b79e4ab35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_404c7a7e-ef06-4884-9cea-613292481c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_319df5dc-4c99-44f3-a072-836b79e4ab35" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_404c7a7e-ef06-4884-9cea-613292481c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#GOODWILLScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637fb02d-b17e-43bd-a56d-10be96ae4c17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_118763f4-a436-4a1c-a5d9-93ff11cf3657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637fb02d-b17e-43bd-a56d-10be96ae4c17" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_118763f4-a436-4a1c-a5d9-93ff11cf3657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7182f429-7930-444f-b7cd-f1a1862ccc99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_118763f4-a436-4a1c-a5d9-93ff11cf3657" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7182f429-7930-444f-b7cd-f1a1862ccc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_50693782-e546-4de9-98b8-5e0f6ba9aa35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7182f429-7930-444f-b7cd-f1a1862ccc99" xlink:to="loc_us-gaap_SegmentDomain_50693782-e546-4de9-98b8-5e0f6ba9aa35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiSkincareMember_3dab6e2c-d802-4edf-a8a2-bf7700d740ab" xlink:href="wald-20221231.xsd#wald_ObagiSkincareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_50693782-e546-4de9-98b8-5e0f6ba9aa35" xlink:to="loc_wald_ObagiSkincareMember_3dab6e2c-d802-4edf-a8a2-bf7700d740ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkMakeupMember_5548abcd-4e6d-4834-9182-acfb3ca0c94f" xlink:href="wald-20221231.xsd#wald_MilkMakeupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_50693782-e546-4de9-98b8-5e0f6ba9aa35" xlink:to="loc_wald_MilkMakeupMember_5548abcd-4e6d-4834-9182-acfb3ca0c94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_fae39809-13d9-40b7-b39e-6c15fd6211cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_118763f4-a436-4a1c-a5d9-93ff11cf3657" xlink:to="loc_us-gaap_GoodwillLineItems_fae39809-13d9-40b7-b39e-6c15fd6211cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_7ebf9e89-0792-4994-a837-f7212bf0eaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_fae39809-13d9-40b7-b39e-6c15fd6211cf" xlink:to="loc_us-gaap_GoodwillRollForward_7ebf9e89-0792-4994-a837-f7212bf0eaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1ab59c82-c406-40e5-b2bb-740d5be1484c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7ebf9e89-0792-4994-a837-f7212bf0eaa8" xlink:to="loc_us-gaap_Goodwill_1ab59c82-c406-40e5-b2bb-740d5be1484c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPeriodIncreaseDecrease_6f9bcf5b-9d0c-4028-8c89-4980fd665b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7ebf9e89-0792-4994-a837-f7212bf0eaa8" xlink:to="loc_us-gaap_GoodwillPeriodIncreaseDecrease_6f9bcf5b-9d0c-4028-8c89-4980fd665b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_033bf2fd-ff26-4325-9f94-0ae84b6973ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7ebf9e89-0792-4994-a837-f7212bf0eaa8" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_033bf2fd-ff26-4325-9f94-0ae84b6973ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_fc647889-ea62-4fe2-a65a-1d244250bab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7ebf9e89-0792-4994-a837-f7212bf0eaa8" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_fc647889-ea62-4fe2-a65a-1d244250bab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d2fd7497-5b62-491d-bcd4-402ef7d8da31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7ebf9e89-0792-4994-a837-f7212bf0eaa8" xlink:to="loc_us-gaap_Goodwill_d2fd7497-5b62-491d-bcd4-402ef7d8da31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/GOODWILLNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#GOODWILLNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/GOODWILLNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_eb38ba4c-6258-49fd-a29b-a0782f9e673a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_a2a12314-8e32-45fe-a394-2a787888fc95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_eb38ba4c-6258-49fd-a29b-a0782f9e673a" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_a2a12314-8e32-45fe-a394-2a787888fc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0e3268ba-0bb4-4c0f-a41a-7928a6840f45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a2a12314-8e32-45fe-a394-2a787888fc95" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0e3268ba-0bb4-4c0f-a41a-7928a6840f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_307c9dab-d737-4d8c-bb4d-00ac007778b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0e3268ba-0bb4-4c0f-a41a-7928a6840f45" xlink:to="loc_us-gaap_SegmentDomain_307c9dab-d737-4d8c-bb4d-00ac007778b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiSkincareMember_ef74c3cf-d3f1-4f50-af8e-419ffc8a71b2" xlink:href="wald-20221231.xsd#wald_ObagiSkincareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_307c9dab-d737-4d8c-bb4d-00ac007778b9" xlink:to="loc_wald_ObagiSkincareMember_ef74c3cf-d3f1-4f50-af8e-419ffc8a71b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_93155f56-ac82-4418-bc04-39dbcd5f0258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a2a12314-8e32-45fe-a394-2a787888fc95" xlink:to="loc_us-gaap_GoodwillLineItems_93155f56-ac82-4418-bc04-39dbcd5f0258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_f7a34ec4-1a07-448a-af79-8303b38ad9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_93155f56-ac82-4418-bc04-39dbcd5f0258" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_f7a34ec4-1a07-448a-af79-8303b38ad9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c05c66fc-8b99-46a2-af29-5d8dc0c8e91e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_826fdce2-42cb-4279-871a-da6f66689805" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c05c66fc-8b99-46a2-af29-5d8dc0c8e91e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_826fdce2-42cb-4279-871a-da6f66689805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ba2dc6a-0a0f-4d42-8f4f-2caca9c63189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_826fdce2-42cb-4279-871a-da6f66689805" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ba2dc6a-0a0f-4d42-8f4f-2caca9c63189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_01ac9f08-b3fa-489c-afca-8ea846414a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8ba2dc6a-0a0f-4d42-8f4f-2caca9c63189" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_01ac9f08-b3fa-489c-afca-8ea846414a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_e9f0f07b-0f8f-4573-8683-4a84a34e0a99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_01ac9f08-b3fa-489c-afca-8ea846414a9e" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_e9f0f07b-0f8f-4573-8683-4a84a34e0a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_f9853fea-b3ad-4f92-b414-07ff6ca48aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_01ac9f08-b3fa-489c-afca-8ea846414a9e" xlink:to="loc_us-gaap_CustomerRelationshipsMember_f9853fea-b3ad-4f92-b414-07ff6ca48aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_TretinoinDistributionAndSupplyAgreementMember_ba9b296a-e3fd-47ac-bf7d-6ba28d64eb1a" xlink:href="wald-20221231.xsd#wald_TretinoinDistributionAndSupplyAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_01ac9f08-b3fa-489c-afca-8ea846414a9e" xlink:to="loc_wald_TretinoinDistributionAndSupplyAgreementMember_ba9b296a-e3fd-47ac-bf7d-6ba28d64eb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_FormulationsMember_174848f2-39cc-40d3-9f39-0f7a416f4e7e" xlink:href="wald-20221231.xsd#wald_FormulationsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_01ac9f08-b3fa-489c-afca-8ea846414a9e" xlink:to="loc_wald_FormulationsMember_174848f2-39cc-40d3-9f39-0f7a416f4e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_6870056a-4335-43e5-85da-748cc818e66c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_01ac9f08-b3fa-489c-afca-8ea846414a9e" xlink:to="loc_us-gaap_PatentsMember_6870056a-4335-43e5-85da-748cc818e66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df97a5a5-1025-4b28-84d0-3c37bb9d032a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_826fdce2-42cb-4279-871a-da6f66689805" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df97a5a5-1025-4b28-84d0-3c37bb9d032a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3580d86f-f69c-4349-b09f-187fe752fb66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df97a5a5-1025-4b28-84d0-3c37bb9d032a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3580d86f-f69c-4349-b09f-187fe752fb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e4262357-7d4b-4d6c-b521-b10d9c785199" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df97a5a5-1025-4b28-84d0-3c37bb9d032a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e4262357-7d4b-4d6c-b521-b10d9c785199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_963a803d-ce74-4ee4-88b2-a5ac8e0a3850" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df97a5a5-1025-4b28-84d0-3c37bb9d032a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_963a803d-ce74-4ee4-88b2-a5ac8e0a3850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0c3f53c2-b423-4d64-ac33-bc063fc07082" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_df97a5a5-1025-4b28-84d0-3c37bb9d032a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0c3f53c2-b423-4d64-ac33-bc063fc07082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INTANGIBLEASSETSNETNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#INTANGIBLEASSETSNETNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/INTANGIBLEASSETSNETNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f9026280-30f8-4c24-8f22-30b572dc00b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c6a94f5c-1ec1-4eec-8105-7b11339331f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f9026280-30f8-4c24-8f22-30b572dc00b2" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c6a94f5c-1ec1-4eec-8105-7b11339331f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#INTANGIBLEASSETSNETExpectedAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85415f31-ad36-4e10-a45e-96804d66093b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0e60d7ce-6738-482a-a07e-d0dc5bec27a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85415f31-ad36-4e10-a45e-96804d66093b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0e60d7ce-6738-482a-a07e-d0dc5bec27a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_20fbe3bf-fef7-4221-ae1d-f1dc805900b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85415f31-ad36-4e10-a45e-96804d66093b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_20fbe3bf-fef7-4221-ae1d-f1dc805900b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c4372492-503e-4cf1-a6db-c9319b4be3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85415f31-ad36-4e10-a45e-96804d66093b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_c4372492-503e-4cf1-a6db-c9319b4be3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5ab32756-cbb0-4f56-b389-f500f9a4d1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85415f31-ad36-4e10-a45e-96804d66093b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5ab32756-cbb0-4f56-b389-f500f9a4d1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_b6a6058c-df4b-47d7-80fc-757b5d7487b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85415f31-ad36-4e10-a45e-96804d66093b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_b6a6058c-df4b-47d7-80fc-757b5d7487b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_eb0df2b7-4a93-46b5-b502-a6a2d4773af3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85415f31-ad36-4e10-a45e-96804d66093b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_eb0df2b7-4a93-46b5-b502-a6a2d4773af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b96bd080-1c49-4f68-842c-549d233869b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_85415f31-ad36-4e10-a45e-96804d66093b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b96bd080-1c49-4f68-842c-549d233869b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/DEBTLongtermDebtDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#DEBTLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/DEBTLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_de1add59-7f70-421c-8535-ef86d9e6e3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f54307ee-4b4d-4c0f-b26f-99113e53c805" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_de1add59-7f70-421c-8535-ef86d9e6e3f5" xlink:to="loc_us-gaap_DebtInstrumentTable_f54307ee-4b4d-4c0f-b26f-99113e53c805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_cfe10c2b-8a9a-4264-ade2-c9a00ba700dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f54307ee-4b4d-4c0f-b26f-99113e53c805" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_cfe10c2b-8a9a-4264-ade2-c9a00ba700dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_86f1c4ed-be87-40c6-acff-9c340b6a2510" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_cfe10c2b-8a9a-4264-ade2-c9a00ba700dc" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_86f1c4ed-be87-40c6-acff-9c340b6a2510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_25b91a47-f631-46c3-9266-4f06415788dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_86f1c4ed-be87-40c6-acff-9c340b6a2510" xlink:to="loc_us-gaap_LineOfCreditMember_25b91a47-f631-46c3-9266-4f06415788dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e520b408-2061-46bb-87a6-7132ee8fdfe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f54307ee-4b4d-4c0f-b26f-99113e53c805" xlink:to="loc_us-gaap_DebtInstrumentAxis_e520b408-2061-46bb-87a6-7132ee8fdfe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8b193c41-5da9-4bad-b5aa-16ae75010468" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e520b408-2061-46bb-87a6-7132ee8fdfe7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8b193c41-5da9-4bad-b5aa-16ae75010468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2022TermLoanMember_6771b603-de27-4c9a-a597-9a547bb08086" xlink:href="wald-20221231.xsd#wald_A2022TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b193c41-5da9-4bad-b5aa-16ae75010468" xlink:to="loc_wald_A2022TermLoanMember_6771b603-de27-4c9a-a597-9a547bb08086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2022RevolvingCreditFacilityMember_c4a4c043-0cc1-44ef-8a1a-e7f59f5514ad" xlink:href="wald-20221231.xsd#wald_A2022RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b193c41-5da9-4bad-b5aa-16ae75010468" xlink:to="loc_wald_A2022RevolvingCreditFacilityMember_c4a4c043-0cc1-44ef-8a1a-e7f59f5514ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2021TermLoanMember_2c4a7e02-20e4-428d-aaff-7630f9e22789" xlink:href="wald-20221231.xsd#wald_A2021TermLoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b193c41-5da9-4bad-b5aa-16ae75010468" xlink:to="loc_wald_A2021TermLoanMember_2c4a7e02-20e4-428d-aaff-7630f9e22789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2021RevolvingCreditFacilityMember_8a255ce8-4405-41e2-bcb7-b9f0ebe8e39f" xlink:href="wald-20221231.xsd#wald_A2021RevolvingCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b193c41-5da9-4bad-b5aa-16ae75010468" xlink:to="loc_wald_A2021RevolvingCreditFacilityMember_8a255ce8-4405-41e2-bcb7-b9f0ebe8e39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2018TermLoanMember_d2a349d8-ebaf-418d-8dcb-e81c74c9fb33" xlink:href="wald-20221231.xsd#wald_A2018TermLoanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b193c41-5da9-4bad-b5aa-16ae75010468" xlink:to="loc_wald_A2018TermLoanMember_d2a349d8-ebaf-418d-8dcb-e81c74c9fb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2018RevolvingCreditFacilityMember_9aa19878-eb14-429d-860c-90088180f1d1" xlink:href="wald-20221231.xsd#wald_A2018RevolvingCreditFacilityMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b193c41-5da9-4bad-b5aa-16ae75010468" xlink:to="loc_wald_A2018RevolvingCreditFacilityMember_9aa19878-eb14-429d-860c-90088180f1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PPPLoanMember_12d91516-98dc-4776-a089-755b1d3ebda8" xlink:href="wald-20221231.xsd#wald_PPPLoanMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b193c41-5da9-4bad-b5aa-16ae75010468" xlink:to="loc_wald_PPPLoanMember_12d91516-98dc-4776-a089-755b1d3ebda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_aea88243-ce8e-4b55-9601-688add861880" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f54307ee-4b4d-4c0f-b26f-99113e53c805" xlink:to="loc_us-gaap_CreditFacilityAxis_aea88243-ce8e-4b55-9601-688add861880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_59224a07-e9a6-44b4-ba21-6eac7ad43a70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_aea88243-ce8e-4b55-9601-688add861880" xlink:to="loc_us-gaap_CreditFacilityDomain_59224a07-e9a6-44b4-ba21-6eac7ad43a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_81f2e5b4-ddd6-47db-81c8-313db93d42da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_59224a07-e9a6-44b4-ba21-6eac7ad43a70" xlink:to="loc_us-gaap_SecuredDebtMember_81f2e5b4-ddd6-47db-81c8-313db93d42da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_e641d9b3-3637-482e-89d3-3ac3dcc5d3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_59224a07-e9a6-44b4-ba21-6eac7ad43a70" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_e641d9b3-3637-482e-89d3-3ac3dcc5d3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b4fbd31b-6e43-4a24-b87a-6aa61611d97a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f54307ee-4b4d-4c0f-b26f-99113e53c805" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b4fbd31b-6e43-4a24-b87a-6aa61611d97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_416142d4-d16b-42b1-940d-67f75477e380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4fbd31b-6e43-4a24-b87a-6aa61611d97a" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_416142d4-d16b-42b1-940d-67f75477e380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_483fd6da-3d95-43e5-a5c4-1bd4fe839bec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4fbd31b-6e43-4a24-b87a-6aa61611d97a" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_483fd6da-3d95-43e5-a5c4-1bd4fe839bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6c0c737a-e05c-4759-b275-e208088530e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4fbd31b-6e43-4a24-b87a-6aa61611d97a" xlink:to="loc_us-gaap_LongTermDebt_6c0c737a-e05c-4759-b275-e208088530e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_beb0097c-bbef-44db-9e56-ed8ba48744e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4fbd31b-6e43-4a24-b87a-6aa61611d97a" xlink:to="loc_us-gaap_LongTermDebtCurrent_beb0097c-bbef-44db-9e56-ed8ba48744e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e44842cf-ff31-41a2-bfb5-64f7d04606d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b4fbd31b-6e43-4a24-b87a-6aa61611d97a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e44842cf-ff31-41a2-bfb5-64f7d04606d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/DEBTLongtermDebtDetails_1" xlink:type="simple" xlink:href="wald-20221231.xsd#DEBTLongtermDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/DEBTLongtermDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.waldencast.com/role/DEBTNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#DEBTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/DEBTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3d03a09f-1f80-4f64-84c9-0151558aa329" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3d03a09f-1f80-4f64-84c9-0151558aa329" xlink:to="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_65f7f7e4-b287-4906-969b-67117156ef5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:to="loc_us-gaap_CreditFacilityAxis_65f7f7e4-b287-4906-969b-67117156ef5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f52f9ec1-9e65-4b18-849d-e6b6c7f264b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_65f7f7e4-b287-4906-969b-67117156ef5d" xlink:to="loc_us-gaap_CreditFacilityDomain_f52f9ec1-9e65-4b18-849d-e6b6c7f264b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_673ff672-9a97-475a-a83a-53ceff62ba0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_f52f9ec1-9e65-4b18-849d-e6b6c7f264b4" xlink:to="loc_us-gaap_SecuredDebtMember_673ff672-9a97-475a-a83a-53ceff62ba0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_1a338235-0c98-4ee2-8895-1891b3b20fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_f52f9ec1-9e65-4b18-849d-e6b6c7f264b4" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_1a338235-0c98-4ee2-8895-1891b3b20fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a0439cc2-23aa-4e43-afce-e7c5027cf1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:to="loc_us-gaap_DebtInstrumentAxis_a0439cc2-23aa-4e43-afce-e7c5027cf1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b7acc551-3019-443c-ae79-285d60aa6663" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a0439cc2-23aa-4e43-afce-e7c5027cf1bb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b7acc551-3019-443c-ae79-285d60aa6663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2022CreditAgreementMember_384254d3-2d15-445b-aa5c-2a883ec3e956" xlink:href="wald-20221231.xsd#wald_A2022CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7acc551-3019-443c-ae79-285d60aa6663" xlink:to="loc_wald_A2022CreditAgreementMember_384254d3-2d15-445b-aa5c-2a883ec3e956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2022TermLoanMember_0fc52e73-c6fe-4e14-834e-a47d55b30a1c" xlink:href="wald-20221231.xsd#wald_A2022TermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7acc551-3019-443c-ae79-285d60aa6663" xlink:to="loc_wald_A2022TermLoanMember_0fc52e73-c6fe-4e14-834e-a47d55b30a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2022RevolvingCreditFacilityMember_c0daf40a-c004-448e-8c4b-f764d362513b" xlink:href="wald-20221231.xsd#wald_A2022RevolvingCreditFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7acc551-3019-443c-ae79-285d60aa6663" xlink:to="loc_wald_A2022RevolvingCreditFacilityMember_c0daf40a-c004-448e-8c4b-f764d362513b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2021TermLoanMember_72fba302-552d-4c80-b666-8740c3cdec42" xlink:href="wald-20221231.xsd#wald_A2021TermLoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7acc551-3019-443c-ae79-285d60aa6663" xlink:to="loc_wald_A2021TermLoanMember_72fba302-552d-4c80-b666-8740c3cdec42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2021RevolvingCreditFacilityMember_1c6e1a50-fbb5-4e83-9905-967b8dfce4f6" xlink:href="wald-20221231.xsd#wald_A2021RevolvingCreditFacilityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7acc551-3019-443c-ae79-285d60aa6663" xlink:to="loc_wald_A2021RevolvingCreditFacilityMember_1c6e1a50-fbb5-4e83-9905-967b8dfce4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2018TermLoanMember_28fe2747-5af0-4af9-ab08-2ad5a91ea015" xlink:href="wald-20221231.xsd#wald_A2018TermLoanMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7acc551-3019-443c-ae79-285d60aa6663" xlink:to="loc_wald_A2018TermLoanMember_28fe2747-5af0-4af9-ab08-2ad5a91ea015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PPPLoanMember_2b187012-e31c-45e1-a8a9-e9c2ebf83ea4" xlink:href="wald-20221231.xsd#wald_PPPLoanMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7acc551-3019-443c-ae79-285d60aa6663" xlink:to="loc_wald_PPPLoanMember_2b187012-e31c-45e1-a8a9-e9c2ebf83ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c9305185-6348-457e-9f24-d246817bc352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c9305185-6348-457e-9f24-d246817bc352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_acef8abe-c9e1-4494-a490-5d2dff383c72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c9305185-6348-457e-9f24-d246817bc352" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_acef8abe-c9e1-4494-a490-5d2dff383c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_4d4aa120-0573-4300-8dae-85a9d654d6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_acef8abe-c9e1-4494-a490-5d2dff383c72" xlink:to="loc_us-gaap_LineOfCreditMember_4d4aa120-0573-4300-8dae-85a9d654d6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e6143eca-4a77-4d5e-8d43-e5442af862ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_acef8abe-c9e1-4494-a490-5d2dff383c72" xlink:to="loc_us-gaap_SeniorNotesMember_e6143eca-4a77-4d5e-8d43-e5442af862ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VariableRateComponentAxis_256861d6-36d7-4ae7-a786-2a69fad90f8e" xlink:href="wald-20221231.xsd#wald_VariableRateComponentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:to="loc_wald_VariableRateComponentAxis_256861d6-36d7-4ae7-a786-2a69fad90f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VariableRateComponentDomain_6887ec86-b3b4-4d02-9d21-4ae6622f2a24" xlink:href="wald-20221231.xsd#wald_VariableRateComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wald_VariableRateComponentAxis_256861d6-36d7-4ae7-a786-2a69fad90f8e" xlink:to="loc_wald_VariableRateComponentDomain_6887ec86-b3b4-4d02-9d21-4ae6622f2a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VariableRateComponentOneMember_a6e1e864-3c1f-4ddc-8bfa-d8f77e0e6d78" xlink:href="wald-20221231.xsd#wald_VariableRateComponentOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wald_VariableRateComponentDomain_6887ec86-b3b4-4d02-9d21-4ae6622f2a24" xlink:to="loc_wald_VariableRateComponentOneMember_a6e1e864-3c1f-4ddc-8bfa-d8f77e0e6d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VariableRateComponentTwoMember_65a54fa6-2849-4313-85dc-85f4544b7382" xlink:href="wald-20221231.xsd#wald_VariableRateComponentTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wald_VariableRateComponentDomain_6887ec86-b3b4-4d02-9d21-4ae6622f2a24" xlink:to="loc_wald_VariableRateComponentTwoMember_65a54fa6-2849-4313-85dc-85f4544b7382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VariableRateComponentThreeMember_689df6ac-7c84-49ee-9457-993605fd0f80" xlink:href="wald-20221231.xsd#wald_VariableRateComponentThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_wald_VariableRateComponentDomain_6887ec86-b3b4-4d02-9d21-4ae6622f2a24" xlink:to="loc_wald_VariableRateComponentThreeMember_689df6ac-7c84-49ee-9457-993605fd0f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_54164e59-4d81-4365-a255-8e76ed641ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:to="loc_us-gaap_VariableRateAxis_54164e59-4d81-4365-a255-8e76ed641ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_80202654-be94-4992-b89b-ee65dfb1c378" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_54164e59-4d81-4365-a255-8e76ed641ab6" xlink:to="loc_us-gaap_VariableRateDomain_80202654-be94-4992-b89b-ee65dfb1c378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AlternateBaseRateMember_c37976e6-8291-4260-a7dd-364d41bef671" xlink:href="wald-20221231.xsd#wald_AlternateBaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_80202654-be94-4992-b89b-ee65dfb1c378" xlink:to="loc_wald_AlternateBaseRateMember_c37976e6-8291-4260-a7dd-364d41bef671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SecuredOvernightFinancingRateSOFRMember_bc4305cf-58f2-4247-ad56-685b7be6add2" xlink:href="wald-20221231.xsd#wald_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_80202654-be94-4992-b89b-ee65dfb1c378" xlink:to="loc_wald_SecuredOvernightFinancingRateSOFRMember_bc4305cf-58f2-4247-ad56-685b7be6add2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ApplicableRateMember_e1498f7f-f856-48a4-b29a-73a33db44a2a" xlink:href="wald-20221231.xsd#wald_ApplicableRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_80202654-be94-4992-b89b-ee65dfb1c378" xlink:to="loc_wald_ApplicableRateMember_e1498f7f-f856-48a4-b29a-73a33db44a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f1c2a324-1de2-49f7-8205-924b38afcd08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f1c2a324-1de2-49f7-8205-924b38afcd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_700e3e6c-9265-4912-9ac3-9e30d06521a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f1c2a324-1de2-49f7-8205-924b38afcd08" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_700e3e6c-9265-4912-9ac3-9e30d06521a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_2c11e190-dbcf-4840-bfb6-1622985a272c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_700e3e6c-9265-4912-9ac3-9e30d06521a0" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_2c11e190-dbcf-4840-bfb6-1622985a272c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_d9f41ab5-6216-46a9-9f9f-ddd64ad2dbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_700e3e6c-9265-4912-9ac3-9e30d06521a0" xlink:to="loc_us-gaap_OtherAssetsMember_d9f41ab5-6216-46a9-9f9f-ddd64ad2dbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c6cf17ba-cec7-4f61-99c3-4b3eb7d8bd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c6cf17ba-cec7-4f61-99c3-4b3eb7d8bd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e0bd6976-751b-4644-8426-a6bd6c1f24df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c6cf17ba-cec7-4f61-99c3-4b3eb7d8bd8e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e0bd6976-751b-4644-8426-a6bd6c1f24df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d49f84dc-c6a4-404d-b6fd-a10d97fea7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e0bd6976-751b-4644-8426-a6bd6c1f24df" xlink:to="loc_us-gaap_SubsequentEventMember_d49f84dc-c6a4-404d-b6fd-a10d97fea7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e1ad6e9c-2d08-492b-8eef-97dc67941ec1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_99bb64d5-0f4e-4917-a7d7-07b3901ef670" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_99bb64d5-0f4e-4917-a7d7-07b3901ef670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4ecd9b82-54fc-4ed8-bbf9-f2b7840d128f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4ecd9b82-54fc-4ed8-bbf9-f2b7840d128f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DebtInstrumentCovenantLeverageRatioMaximum_fd0f8a5e-8afc-4470-8e03-12e17ef99293" xlink:href="wald-20221231.xsd#wald_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_wald_DebtInstrumentCovenantLeverageRatioMaximum_fd0f8a5e-8afc-4470-8e03-12e17ef99293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_bbcd1346-a4a8-45c2-9074-d8ece0f31835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_DebtInstrumentTerm_bbcd1346-a4a8-45c2-9074-d8ece0f31835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_087222dc-1784-463c-ab2b-8e8e981e4bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_087222dc-1784-463c-ab2b-8e8e981e4bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_6a7f1ea0-b190-4c16-abcb-62cce3a16700" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_6a7f1ea0-b190-4c16-abcb-62cce3a16700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_89619dc4-a0f0-4f84-8cf3-a3f158e03e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_89619dc4-a0f0-4f84-8cf3-a3f158e03e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_81ac6638-e367-4e9c-9904-fefb18b4f69b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_81ac6638-e367-4e9c-9904-fefb18b4f69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_0311d512-01ad-4a33-94e1-db1cccb5aeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_LongTermDebtCurrent_0311d512-01ad-4a33-94e1-db1cccb5aeb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_471bf096-fa67-4e1c-a02d-9a73fca0a7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_471bf096-fa67-4e1c-a02d-9a73fca0a7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_f4b2e252-0115-4861-89ae-a1e480c603d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_f4b2e252-0115-4861-89ae-a1e480c603d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_LineOfCreditCovenantTermsMinimumLiquidity_fb0de4d2-c9c9-4f15-be4b-e142409a1b39" xlink:href="wald-20221231.xsd#wald_LineOfCreditCovenantTermsMinimumLiquidity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_wald_LineOfCreditCovenantTermsMinimumLiquidity_fb0de4d2-c9c9-4f15-be4b-e142409a1b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e949f10f-24dd-46d9-bd5c-013b24c9471c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_LongTermDebt_e949f10f-24dd-46d9-bd5c-013b24c9471c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2495e0c7-8fd0-4c00-a744-f5a66a2239b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2495e0c7-8fd0-4c00-a744-f5a66a2239b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityDecreaseForgiveness1_59d23eb9-4a43-41b2-9e40-e8137f4251dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityDecreaseForgiveness1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d0be21-af23-408d-a3dd-13597fb0bf1d" xlink:to="loc_us-gaap_LineOfCreditFacilityDecreaseForgiveness1_59d23eb9-4a43-41b2-9e40-e8137f4251dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#DEBTScheduledMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3c977ef5-c7d7-479c-bd6d-3bc75e25aeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_260a1a74-a30b-4944-9831-c47d1a5c022c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3c977ef5-c7d7-479c-bd6d-3bc75e25aeb9" xlink:to="loc_us-gaap_DebtInstrumentTable_260a1a74-a30b-4944-9831-c47d1a5c022c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8d74899b-3d89-4c74-a3a9-13f6cea20085" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_260a1a74-a30b-4944-9831-c47d1a5c022c" xlink:to="loc_us-gaap_DebtInstrumentAxis_8d74899b-3d89-4c74-a3a9-13f6cea20085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b3787205-a67c-4b29-a8c4-58e5e1375aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8d74899b-3d89-4c74-a3a9-13f6cea20085" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b3787205-a67c-4b29-a8c4-58e5e1375aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2022CreditAgreementMember_b2a5197f-5338-4993-b233-f8948d4efa49" xlink:href="wald-20221231.xsd#wald_A2022CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3787205-a67c-4b29-a8c4-58e5e1375aaf" xlink:to="loc_wald_A2022CreditAgreementMember_b2a5197f-5338-4993-b233-f8948d4efa49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_40807477-e1e2-4a2f-a041-4fb5136d3540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_260a1a74-a30b-4944-9831-c47d1a5c022c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_40807477-e1e2-4a2f-a041-4fb5136d3540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e8414355-ef90-4640-b64c-8c671d4ea54e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40807477-e1e2-4a2f-a041-4fb5136d3540" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e8414355-ef90-4640-b64c-8c671d4ea54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5c6bc43a-f928-4e1b-9f68-cd9d99137ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40807477-e1e2-4a2f-a041-4fb5136d3540" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5c6bc43a-f928-4e1b-9f68-cd9d99137ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7f3611f4-74f4-43b7-b269-e9f8020d84f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40807477-e1e2-4a2f-a041-4fb5136d3540" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_7f3611f4-74f4-43b7-b269-e9f8020d84f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f06dd8f1-f3db-4a47-b2d0-e293a1927722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40807477-e1e2-4a2f-a041-4fb5136d3540" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f06dd8f1-f3db-4a47-b2d0-e293a1927722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_94eb9574-309f-4af5-b725-2892d624b372" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40807477-e1e2-4a2f-a041-4fb5136d3540" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_94eb9574-309f-4af5-b725-2892d624b372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5b249773-afd2-4fda-b909-0579c54281ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_40807477-e1e2-4a2f-a041-4fb5136d3540" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5b249773-afd2-4fda-b909-0579c54281ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f05eeea9-af6c-4202-9be6-79a838c79f32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_544a8bbd-d25e-46c6-9dc6-79a77fab263a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f05eeea9-af6c-4202-9be6-79a838c79f32" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_544a8bbd-d25e-46c6-9dc6-79a77fab263a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ce3402dc-ae7e-40c7-a96a-a2cec1fbf9cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_544a8bbd-d25e-46c6-9dc6-79a77fab263a" xlink:to="loc_srt_RangeAxis_ce3402dc-ae7e-40c7-a96a-a2cec1fbf9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c8e450b4-d879-41f1-b3ea-e733f250642d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ce3402dc-ae7e-40c7-a96a-a2cec1fbf9cd" xlink:to="loc_srt_RangeMember_c8e450b4-d879-41f1-b3ea-e733f250642d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d7c50a27-3d51-45b3-adaa-5c231e2d2c75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c8e450b4-d879-41f1-b3ea-e733f250642d" xlink:to="loc_srt_MinimumMember_d7c50a27-3d51-45b3-adaa-5c231e2d2c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6b458dda-cc0b-4481-ad81-a803a7f848ba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c8e450b4-d879-41f1-b3ea-e733f250642d" xlink:to="loc_srt_MaximumMember_6b458dda-cc0b-4481-ad81-a803a7f848ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_91789b78-551b-4526-bcd1-967e807f0c35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_544a8bbd-d25e-46c6-9dc6-79a77fab263a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_91789b78-551b-4526-bcd1-967e807f0c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_06d57d06-4e73-49e6-a7dc-1116f8ffd2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91789b78-551b-4526-bcd1-967e807f0c35" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_06d57d06-4e73-49e6-a7dc-1116f8ffd2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_LesseeOperatingLeaseExtensionTerm_91bf1136-36ab-4de1-86e7-d021c42e75e2" xlink:href="wald-20221231.xsd#wald_LesseeOperatingLeaseExtensionTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91789b78-551b-4526-bcd1-967e807f0c35" xlink:to="loc_wald_LesseeOperatingLeaseExtensionTerm_91bf1136-36ab-4de1-86e7-d021c42e75e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_515d435d-9653-4dff-ace0-95aebeb271a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91789b78-551b-4526-bcd1-967e807f0c35" xlink:to="loc_us-gaap_OperatingLeaseCost_515d435d-9653-4dff-ace0-95aebeb271a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_NumberOfOperatingLeases_e65e9b67-fa16-4de1-ae8c-719a75175a54" xlink:href="wald-20221231.xsd#wald_NumberOfOperatingLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91789b78-551b-4526-bcd1-967e807f0c35" xlink:to="loc_wald_NumberOfOperatingLeases_e65e9b67-fa16-4de1-ae8c-719a75175a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_076287c7-1798-46e1-b48d-13d066974c45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_91789b78-551b-4526-bcd1-967e807f0c35" xlink:to="loc_us-gaap_LeaseAndRentalExpense_076287c7-1798-46e1-b48d-13d066974c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/LEASESSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#LEASESSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/LEASESSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3b51c606-e176-42cc-896c-3982ddc6143d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_36a39af8-0899-4d0d-9aec-3ef304ffcf56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3b51c606-e176-42cc-896c-3982ddc6143d" xlink:to="loc_us-gaap_OperatingLeasePayments_36a39af8-0899-4d0d-9aec-3ef304ffcf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_514ab8d7-f396-40f4-85b2-5b51f2b61321" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3b51c606-e176-42cc-896c-3982ddc6143d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_514ab8d7-f396-40f4-85b2-5b51f2b61321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c6d5f402-5898-4dc5-83ef-4bfbc91801b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3b51c606-e176-42cc-896c-3982ddc6143d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c6d5f402-5898-4dc5-83ef-4bfbc91801b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ae40bfde-11ab-4ef9-9d27-83b4ae82e653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3b51c606-e176-42cc-896c-3982ddc6143d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ae40bfde-11ab-4ef9-9d27-83b4ae82e653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#LEASESOperatingLeaseMaturityScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0320476c-8646-4703-a721-e78e6d0f1dad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0d8bfdd7-99b5-4402-bc39-a1dbac803d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0320476c-8646-4703-a721-e78e6d0f1dad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0d8bfdd7-99b5-4402-bc39-a1dbac803d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_af9fad07-ba72-4880-a0c6-8911de53f244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0320476c-8646-4703-a721-e78e6d0f1dad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_af9fad07-ba72-4880-a0c6-8911de53f244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7217aef6-743f-49ee-876c-8578de939b77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0320476c-8646-4703-a721-e78e6d0f1dad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7217aef6-743f-49ee-876c-8578de939b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_aa261b89-2cb6-4ae7-96cf-8ac6b2b93b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0320476c-8646-4703-a721-e78e6d0f1dad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_aa261b89-2cb6-4ae7-96cf-8ac6b2b93b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f64344af-545c-4bc3-b212-a16f0061555a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0320476c-8646-4703-a721-e78e6d0f1dad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f64344af-545c-4bc3-b212-a16f0061555a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_21373345-7c9b-4057-9d26-d2253f120e94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0320476c-8646-4703-a721-e78e6d0f1dad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_21373345-7c9b-4057-9d26-d2253f120e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_04c95e98-3284-464d-8b59-5796cc52a428" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0320476c-8646-4703-a721-e78e6d0f1dad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_04c95e98-3284-464d-8b59-5796cc52a428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c14e10f5-efab-4524-942d-28394c42df89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0320476c-8646-4703-a721-e78e6d0f1dad" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c14e10f5-efab-4524-942d-28394c42df89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_83354e2d-c577-4735-8560-ea0ab2bced88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0320476c-8646-4703-a721-e78e6d0f1dad" xlink:to="loc_us-gaap_OperatingLeaseLiability_83354e2d-c577-4735-8560-ea0ab2bced88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails_1" xlink:type="simple" xlink:href="wald-20221231.xsd#LEASESOperatingLeaseMaturityScheduleDetails_1"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details" xlink:type="simple" xlink:href="wald-20221231.xsd#LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_88b94140-8cba-4fba-b728-57da07ddbdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_b05491a0-0a0c-48f0-9aea-57ead2a4fe65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_88b94140-8cba-4fba-b728-57da07ddbdbf" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_b05491a0-0a0c-48f0-9aea-57ead2a4fe65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_54294869-b67f-40d8-8e4e-8ccf7c5dd3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_88b94140-8cba-4fba-b728-57da07ddbdbf" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_54294869-b67f-40d8-8e4e-8ccf7c5dd3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_71096864-663f-4f58-8a54-71548fbd4eed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_88b94140-8cba-4fba-b728-57da07ddbdbf" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_71096864-663f-4f58-8a54-71548fbd4eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_f355ce6e-e63b-48f7-a28f-75530485cbfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_88b94140-8cba-4fba-b728-57da07ddbdbf" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_f355ce6e-e63b-48f7-a28f-75530485cbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_a4c5512f-614b-446a-ac7a-1685f87a5367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_88b94140-8cba-4fba-b728-57da07ddbdbf" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_a4c5512f-614b-446a-ac7a-1685f87a5367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_a1df1ede-e09f-4f13-9ee7-0c7d15ada5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_88b94140-8cba-4fba-b728-57da07ddbdbf" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_a1df1ede-e09f-4f13-9ee7-0c7d15ada5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_f1dce505-8713-43c5-a156-be656f907fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_88b94140-8cba-4fba-b728-57da07ddbdbf" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_f1dce505-8713-43c5-a156-be656f907fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#FINANCIALINSTRUMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b60eb276-cca2-4f6a-a1d9-f6987f5ca753" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_ba9ee043-27b2-4e82-b440-7d0c40173495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b60eb276-cca2-4f6a-a1d9-f6987f5ca753" xlink:to="loc_us-gaap_DerivativeTable_ba9ee043-27b2-4e82-b440-7d0c40173495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a728d029-c482-43e3-9a6f-85cdc938a82d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_ba9ee043-27b2-4e82-b440-7d0c40173495" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a728d029-c482-43e3-9a6f-85cdc938a82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1465013f-2f7d-420a-ade8-548ce56c357e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a728d029-c482-43e3-9a6f-85cdc938a82d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1465013f-2f7d-420a-ade8-548ce56c357e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_InterestRateCollarMember_2c8fdb45-2ec9-4ba5-903f-70384d1e0a10" xlink:href="wald-20221231.xsd#wald_InterestRateCollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1465013f-2f7d-420a-ade8-548ce56c357e" xlink:to="loc_wald_InterestRateCollarMember_2c8fdb45-2ec9-4ba5-903f-70384d1e0a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9ae61402-f9a3-43ce-b00c-5a78f3829e03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_ba9ee043-27b2-4e82-b440-7d0c40173495" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9ae61402-f9a3-43ce-b00c-5a78f3829e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ece7b15f-381e-4af9-9e2a-aa7a7a7cdf34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9ae61402-f9a3-43ce-b00c-5a78f3829e03" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ece7b15f-381e-4af9-9e2a-aa7a7a7cdf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PublicWarrantsMember_bcae7624-4192-45d6-a7b7-996b3b184881" xlink:href="wald-20221231.xsd#wald_PublicWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ece7b15f-381e-4af9-9e2a-aa7a7a7cdf34" xlink:to="loc_wald_PublicWarrantsMember_bcae7624-4192-45d6-a7b7-996b3b184881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SponsorWarrantsMember_ff5035fb-079c-47b6-af03-4ec2c5e41fd8" xlink:href="wald-20221231.xsd#wald_SponsorWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ece7b15f-381e-4af9-9e2a-aa7a7a7cdf34" xlink:to="loc_wald_SponsorWarrantsMember_ff5035fb-079c-47b6-af03-4ec2c5e41fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PrivatePlacementWarrantsMember_32d9a6f2-0989-41f6-9ef1-00e53fc685f9" xlink:href="wald-20221231.xsd#wald_PrivatePlacementWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ece7b15f-381e-4af9-9e2a-aa7a7a7cdf34" xlink:to="loc_wald_PrivatePlacementWarrantsMember_32d9a6f2-0989-41f6-9ef1-00e53fc685f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_25093e67-c6e9-460c-a302-46332a89b4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_ba9ee043-27b2-4e82-b440-7d0c40173495" xlink:to="loc_us-gaap_StatementClassOfStockAxis_25093e67-c6e9-460c-a302-46332a89b4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_411b394e-a307-4a82-8351-ebb52cc72f33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_25093e67-c6e9-460c-a302-46332a89b4b1" xlink:to="loc_us-gaap_ClassOfStockDomain_411b394e-a307-4a82-8351-ebb52cc72f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_9cb033a1-d95a-4394-942b-472c926c7c22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_411b394e-a307-4a82-8351-ebb52cc72f33" xlink:to="loc_us-gaap_CommonClassAMember_9cb033a1-d95a-4394-942b-472c926c7c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_d2c90df1-6187-4bf6-84dd-7b90ec699f02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_ba9ee043-27b2-4e82-b440-7d0c40173495" xlink:to="loc_us-gaap_VestingAxis_d2c90df1-6187-4bf6-84dd-7b90ec699f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_2e4186af-4e72-48d8-911b-b4352af24b73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_d2c90df1-6187-4bf6-84dd-7b90ec699f02" xlink:to="loc_us-gaap_VestingDomain_2e4186af-4e72-48d8-911b-b4352af24b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fb79933a-3295-4c9e-8d7d-a223b980c226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2e4186af-4e72-48d8-911b-b4352af24b73" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fb79933a-3295-4c9e-8d7d-a223b980c226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a5cdca71-bfe9-49fd-a14c-a2fd37a7ce2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_2e4186af-4e72-48d8-911b-b4352af24b73" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a5cdca71-bfe9-49fd-a14c-a2fd37a7ce2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6ed7cf85-28ba-402a-9ee6-99e47629bcbd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_ba9ee043-27b2-4e82-b440-7d0c40173495" xlink:to="loc_srt_CounterpartyNameAxis_6ed7cf85-28ba-402a-9ee6-99e47629bcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f201a16c-567b-486e-8624-10fcc7aa2e4c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6ed7cf85-28ba-402a-9ee6-99e47629bcbd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f201a16c-567b-486e-8624-10fcc7aa2e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember_6ce09af0-01e8-4eaf-b6ec-cb9f03a75b09" xlink:href="wald-20221231.xsd#wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f201a16c-567b-486e-8624-10fcc7aa2e4c" xlink:to="loc_wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember_6ce09af0-01e8-4eaf-b6ec-cb9f03a75b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BeautyVenturesLLCMember_028ae6a3-8754-4faa-8a9c-1c97c02c4d85" xlink:href="wald-20221231.xsd#wald_BeautyVenturesLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f201a16c-567b-486e-8624-10fcc7aa2e4c" xlink:to="loc_wald_BeautyVenturesLLCMember_028ae6a3-8754-4faa-8a9c-1c97c02c4d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_ba9ee043-27b2-4e82-b440-7d0c40173495" xlink:to="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_d4a0fc85-9513-464f-9e66-84f270a9e7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_d4a0fc85-9513-464f-9e66-84f270a9e7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_f75e7a1e-8498-4c06-8587-0a7f325351a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_f75e7a1e-8498-4c06-8587-0a7f325351a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFloorInterestRate_cb47e9c0-19ca-48b0-b66b-b906ee150205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFloorInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_DerivativeFloorInterestRate_cb47e9c0-19ca-48b0-b66b-b906ee150205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCapInterestRate_722aeebd-e837-4bb7-be56-643183185b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeCapInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_DerivativeCapInterestRate_722aeebd-e837-4bb7-be56-643183185b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_38009d44-421b-41fc-bb4b-8a199547d2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_38009d44-421b-41fc-bb4b-8a199547d2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_43e3daa3-f3c6-4f65-8110-bee1682215e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_43e3daa3-f3c6-4f65-8110-bee1682215e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ee46adff-cef2-4d63-976b-325a463d5e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ee46adff-cef2-4d63-976b-325a463d5e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bccae863-40af-4c6c-9a36-3d9681ccfb49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_bccae863-40af-4c6c-9a36-3d9681ccfb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_dba98cba-33a9-4eef-8d95-77ab7e19f7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_dba98cba-33a9-4eef-8d95-77ab7e19f7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c6a70b72-3c4c-4a30-a360-b6a9c9c906f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c6a70b72-3c4c-4a30-a360-b6a9c9c906f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_47ebc537-4186-4673-b2b9-87a503ccd983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_47ebc537-4186-4673-b2b9-87a503ccd983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6d061099-1c09-4c99-877a-ef776eed6cba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6d061099-1c09-4c99-877a-ef776eed6cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination_a31e8e97-973b-4f0f-90d7-3de2938d1280" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination_a31e8e97-973b-4f0f-90d7-3de2938d1280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightRedemptionPeriod_e04bcb74-9f0e-4fef-abb7-60ef739f57ae" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightRedemptionPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_wald_ClassOfWarrantOrRightRedemptionPeriod_e04bcb74-9f0e-4fef-abb7-60ef739f57ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightRedemptionPricePerShare_09eb764d-ddd2-4cb6-a953-1dc74cdfb4a6" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightRedemptionPricePerShare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_wald_ClassOfWarrantOrRightRedemptionPricePerShare_09eb764d-ddd2-4cb6-a953-1dc74cdfb4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice_350d3093-ba1c-4c3f-b8dd-24dd87365ece" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice_350d3093-ba1c-4c3f-b8dd-24dd87365ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightRedemptionTradingPeriod_53d4849e-572e-46dd-aec2-c3b96bfe175a" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightRedemptionTradingPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_wald_ClassOfWarrantOrRightRedemptionTradingPeriod_53d4849e-572e-46dd-aec2-c3b96bfe175a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption_409c9d20-e1ad-45cd-954a-2243d36579fe" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption_409c9d20-e1ad-45cd-954a-2243d36579fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger_209495ea-2b1a-4fc1-bf3a-a7847f5af028" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_e343c335-8a69-4e6b-90cd-d2eb2f5f8d53" xlink:to="loc_wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger_209495ea-2b1a-4fc1-bf3a-a7847f5af028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7f424388-1e98-4229-a152-4d752ffced8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0fa05798-d607-42e1-a73e-580791bb1588" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7f424388-1e98-4229-a152-4d752ffced8d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0fa05798-d607-42e1-a73e-580791bb1588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bfc208fd-acba-4a20-8bea-fc005af514b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0fa05798-d607-42e1-a73e-580791bb1588" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bfc208fd-acba-4a20-8bea-fc005af514b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db2d07ff-daef-4c7a-bca1-85582fa0a600" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bfc208fd-acba-4a20-8bea-fc005af514b8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db2d07ff-daef-4c7a-bca1-85582fa0a600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1e36cc5e-059c-4284-91ad-f4866726fcbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db2d07ff-daef-4c7a-bca1-85582fa0a600" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1e36cc5e-059c-4284-91ad-f4866726fcbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_334dd52e-550a-4f8e-9402-54eabbad9d66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db2d07ff-daef-4c7a-bca1-85582fa0a600" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_334dd52e-550a-4f8e-9402-54eabbad9d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2e21ca76-a46b-408b-917b-cbbc4d341707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db2d07ff-daef-4c7a-bca1-85582fa0a600" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2e21ca76-a46b-408b-917b-cbbc4d341707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4043d003-bdff-4f3c-879f-cecfbf486d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0fa05798-d607-42e1-a73e-580791bb1588" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4043d003-bdff-4f3c-879f-cecfbf486d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_556062a6-f0cf-4494-ace3-ec6df5cd677a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4043d003-bdff-4f3c-879f-cecfbf486d85" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_556062a6-f0cf-4494-ace3-ec6df5cd677a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_InterestRateCollarMember_42900320-047c-4f82-997e-14b3cbd8dfdd" xlink:href="wald-20221231.xsd#wald_InterestRateCollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_556062a6-f0cf-4494-ace3-ec6df5cd677a" xlink:to="loc_wald_InterestRateCollarMember_42900320-047c-4f82-997e-14b3cbd8dfdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PublicDerivativeWarrantLiabilitiesMember_bd941de8-cf16-46f1-a761-f0885f08e6e8" xlink:href="wald-20221231.xsd#wald_PublicDerivativeWarrantLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_556062a6-f0cf-4494-ace3-ec6df5cd677a" xlink:to="loc_wald_PublicDerivativeWarrantLiabilitiesMember_bd941de8-cf16-46f1-a761-f0885f08e6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PrivateDerivativeWarrantLiabilitiesMember_3f957e4d-8310-4d5d-bf79-12a656b0d66e" xlink:href="wald-20221231.xsd#wald_PrivateDerivativeWarrantLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_556062a6-f0cf-4494-ace3-ec6df5cd677a" xlink:to="loc_wald_PrivateDerivativeWarrantLiabilitiesMember_3f957e4d-8310-4d5d-bf79-12a656b0d66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e6a495f7-ea7d-4705-9c8d-eb528a61bccb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0fa05798-d607-42e1-a73e-580791bb1588" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e6a495f7-ea7d-4705-9c8d-eb528a61bccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_76b3d898-d428-4f77-bf6a-21309a5d779e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e6a495f7-ea7d-4705-9c8d-eb528a61bccb" xlink:to="loc_us-gaap_DerivativeAssets_76b3d898-d428-4f77-bf6a-21309a5d779e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_bc617528-3fc9-45c2-bcd6-87d4aa2760d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e6a495f7-ea7d-4705-9c8d-eb528a61bccb" xlink:to="loc_us-gaap_DerivativeLiabilities_bc617528-3fc9-45c2-bcd6-87d4aa2760d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5c3e8c14-505b-4035-8c2f-7a6d0ea577e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_05ec497a-e54a-4cff-baa1-9dd5f03612de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5c3e8c14-505b-4035-8c2f-7a6d0ea577e2" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_05ec497a-e54a-4cff-baa1-9dd5f03612de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_77b54dc9-4adf-4655-afb5-b04421f88cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_05ec497a-e54a-4cff-baa1-9dd5f03612de" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_77b54dc9-4adf-4655-afb5-b04421f88cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c576151a-cb91-4948-8abe-a03b974e2b37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_77b54dc9-4adf-4655-afb5-b04421f88cfd" xlink:to="loc_us-gaap_RelatedPartyDomain_c576151a-cb91-4948-8abe-a03b974e2b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_e5a8fb92-1ff4-4404-899d-238ed3252332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c576151a-cb91-4948-8abe-a03b974e2b37" xlink:to="loc_us-gaap_RelatedPartyMember_e5a8fb92-1ff4-4404-899d-238ed3252332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_00dd570d-d2db-4f24-b112-1151f771b78a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_05ec497a-e54a-4cff-baa1-9dd5f03612de" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_00dd570d-d2db-4f24-b112-1151f771b78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent_34cdb519-42a0-4345-8630-3d44215bf97a" xlink:href="wald-20221231.xsd#wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_00dd570d-d2db-4f24-b112-1151f771b78a" xlink:to="loc_wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent_34cdb519-42a0-4345-8630-3d44215bf97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_f88f158b-065b-4e8f-9f0d-64623b74e490" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_00dd570d-d2db-4f24-b112-1151f771b78a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_f88f158b-065b-4e8f-9f0d-64623b74e490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent_245512fe-7cce-4f2f-92a6-ba95dba343af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInNotesReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_00dd570d-d2db-4f24-b112-1151f771b78a" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent_245512fe-7cce-4f2f-92a6-ba95dba343af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansReceivableBasisSpreadOnVariableRate_72e33a61-b60c-44d7-8fe3-1cc1a2ac20db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_00dd570d-d2db-4f24-b112-1151f771b78a" xlink:to="loc_us-gaap_LoansReceivableBasisSpreadOnVariableRate_72e33a61-b60c-44d7-8fe3-1cc1a2ac20db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ba9efd47-f78a-49dc-b385-b1945430cbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_00dd570d-d2db-4f24-b112-1151f771b78a" xlink:to="loc_us-gaap_Depreciation_ba9efd47-f78a-49dc-b385-b1945430cbc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_532144bd-ca2a-4a6b-87f4-91687f89e38d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_00dd570d-d2db-4f24-b112-1151f771b78a" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_532144bd-ca2a-4a6b-87f4-91687f89e38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a726f919-8f12-4163-b02b-531a45265ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_db445879-b050-4f50-8ec9-f5c8d339cd70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a726f919-8f12-4163-b02b-531a45265ef7" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_db445879-b050-4f50-8ec9-f5c8d339cd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ba573ed2-d86e-440c-92ea-552ae78ac6ce" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_db445879-b050-4f50-8ec9-f5c8d339cd70" xlink:to="loc_dei_LegalEntityAxis_ba573ed2-d86e-440c-92ea-552ae78ac6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2891a6b2-28ad-424b-a638-270896e14395" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ba573ed2-d86e-440c-92ea-552ae78ac6ce" xlink:to="loc_dei_EntityDomain_2891a6b2-28ad-424b-a638-270896e14395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_WaldencastPlcMember_50862704-a1b0-47df-a4b2-d916c4073f37" xlink:href="wald-20221231.xsd#wald_WaldencastPlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2891a6b2-28ad-424b-a638-270896e14395" xlink:to="loc_wald_WaldencastPlcMember_50862704-a1b0-47df-a4b2-d916c4073f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiCosmeceuticalsLLCMember_93744f80-b1ce-447a-81f4-e3a2f4e7e582" xlink:href="wald-20221231.xsd#wald_ObagiCosmeceuticalsLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2891a6b2-28ad-424b-a638-270896e14395" xlink:to="loc_wald_ObagiCosmeceuticalsLLCMember_93744f80-b1ce-447a-81f4-e3a2f4e7e582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_f134499c-61ab-4c98-9e6c-1398ffe96ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_db445879-b050-4f50-8ec9-f5c8d339cd70" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_f134499c-61ab-4c98-9e6c-1398ffe96ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e8d6151d-2efc-42df-a5a5-f7ea200ec9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_f134499c-61ab-4c98-9e6c-1398ffe96ce2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e8d6151d-2efc-42df-a5a5-f7ea200ec9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_cf377188-7d94-43c4-9b3a-162d2c31495a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e8d6151d-2efc-42df-a5a5-f7ea200ec9ce" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_cf377188-7d94-43c4-9b3a-162d2c31495a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_37e88256-856b-41ee-9ae0-e025f942226e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e8d6151d-2efc-42df-a5a5-f7ea200ec9ce" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_37e88256-856b-41ee-9ae0-e025f942226e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_183f8dd1-5ee6-4f80-a2b6-b621fe772d48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e8d6151d-2efc-42df-a5a5-f7ea200ec9ce" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_183f8dd1-5ee6-4f80-a2b6-b621fe772d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_8d0cffc1-3d74-4c8f-afb5-191766532de3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e8d6151d-2efc-42df-a5a5-f7ea200ec9ce" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_8d0cffc1-3d74-4c8f-afb5-191766532de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_addc1cc3-ac56-4d58-bc84-511c25927a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_4c708f9b-f101-423b-af60-976a4688f3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_addc1cc3-ac56-4d58-bc84-511c25927a2b" xlink:to="loc_us-gaap_InventoryWorkInProcess_4c708f9b-f101-423b-af60-976a4688f3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_877a853d-6767-4070-b2c4-b0cf2bc9c699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_addc1cc3-ac56-4d58-bc84-511c25927a2b" xlink:to="loc_us-gaap_InventoryFinishedGoods_877a853d-6767-4070-b2c4-b0cf2bc9c699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6ae580ca-65df-49df-a054-fcaa5d80187e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_addc1cc3-ac56-4d58-bc84-511c25927a2b" xlink:to="loc_us-gaap_InventoryNet_6ae580ca-65df-49df-a054-fcaa5d80187e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d372c350-6c13-444b-b956-36584d2cd259" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_46d86041-48e8-4527-b86a-f524217ea73b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d372c350-6c13-444b-b956-36584d2cd259" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_46d86041-48e8-4527-b86a-f524217ea73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c611c114-9e19-4a5a-ad35-c620e518f759" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_46d86041-48e8-4527-b86a-f524217ea73b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c611c114-9e19-4a5a-ad35-c620e518f759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d98a4421-1eae-460a-a2e1-a43572a682d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c611c114-9e19-4a5a-ad35-c620e518f759" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d98a4421-1eae-460a-a2e1-a43572a682d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ComputerHardwareSoftwareAndEquipmentMember_9e53953e-5a19-4ab0-91c8-9c5a0a0e87ca" xlink:href="wald-20221231.xsd#wald_ComputerHardwareSoftwareAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d98a4421-1eae-460a-a2e1-a43572a682d1" xlink:to="loc_wald_ComputerHardwareSoftwareAndEquipmentMember_9e53953e-5a19-4ab0-91c8-9c5a0a0e87ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0046bd21-937c-4232-8477-11b53579a417" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d98a4421-1eae-460a-a2e1-a43572a682d1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0046bd21-937c-4232-8477-11b53579a417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_e2ebbe84-b4fb-4385-9152-50681ed43732" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d98a4421-1eae-460a-a2e1-a43572a682d1" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_e2ebbe84-b4fb-4385-9152-50681ed43732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_1081b009-0340-4eac-8e6c-707f1334255b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d98a4421-1eae-460a-a2e1-a43572a682d1" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_1081b009-0340-4eac-8e6c-707f1334255b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_GondolasMember_15f5242e-27cd-4734-9bb8-8944044dc1d0" xlink:href="wald-20221231.xsd#wald_GondolasMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d98a4421-1eae-460a-a2e1-a43572a682d1" xlink:to="loc_wald_GondolasMember_15f5242e-27cd-4734-9bb8-8944044dc1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_f495dd67-aeb4-4327-ac75-466264580341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d98a4421-1eae-460a-a2e1-a43572a682d1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_f495dd67-aeb4-4327-ac75-466264580341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01882e8c-dfd0-48cf-b23a-9801f38bac6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_46d86041-48e8-4527-b86a-f524217ea73b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01882e8c-dfd0-48cf-b23a-9801f38bac6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_cd62bbbf-dcb3-49f2-a51e-c0f8ba840781" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01882e8c-dfd0-48cf-b23a-9801f38bac6d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_cd62bbbf-dcb3-49f2-a51e-c0f8ba840781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1fc9dc76-4601-466c-8a4f-a92a469bce71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01882e8c-dfd0-48cf-b23a-9801f38bac6d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1fc9dc76-4601-466c-8a4f-a92a469bce71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dff3248b-05d6-4eaa-954f-3d586c32bd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_01882e8c-dfd0-48cf-b23a-9801f38bac6d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_dff3248b-05d6-4eaa-954f-3d586c32bd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20a52fb1-b856-4a09-ac92-44a0e4c20e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e6c7b29a-6305-450e-8699-e70e891836d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20a52fb1-b856-4a09-ac92-44a0e4c20e6d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e6c7b29a-6305-450e-8699-e70e891836d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1ae71f00-a74b-4413-b1a8-4d5a907ca5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e6c7b29a-6305-450e-8699-e70e891836d8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1ae71f00-a74b-4413-b1a8-4d5a907ca5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a015e1b1-8aaf-45e0-b54c-17960b8dafbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1ae71f00-a74b-4413-b1a8-4d5a907ca5f3" xlink:to="loc_us-gaap_RelatedPartyDomain_a015e1b1-8aaf-45e0-b54c-17960b8dafbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_bdedf96f-c6dc-435f-a6fe-37bd70bddde0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a015e1b1-8aaf-45e0-b54c-17960b8dafbc" xlink:to="loc_us-gaap_RelatedPartyMember_bdedf96f-c6dc-435f-a6fe-37bd70bddde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_71cd151f-49d6-4f80-af3d-d36077bdb991" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a015e1b1-8aaf-45e0-b54c-17960b8dafbc" xlink:to="loc_us-gaap_NonrelatedPartyMember_71cd151f-49d6-4f80-af3d-d36077bdb991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2b62a736-677a-4ead-9017-eb13a917d699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e6c7b29a-6305-450e-8699-e70e891836d8" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_2b62a736-677a-4ead-9017-eb13a917d699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_e4fd811f-3c8c-40aa-a661-cf15e3fe1e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b62a736-677a-4ead-9017-eb13a917d699" xlink:to="loc_us-gaap_AccruedSalariesCurrent_e4fd811f-3c8c-40aa-a661-cf15e3fe1e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AccruedSalesReturnsAndDamagesCurrent_ada5e361-9367-4420-b9bc-3eef74849c57" xlink:href="wald-20221231.xsd#wald_AccruedSalesReturnsAndDamagesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b62a736-677a-4ead-9017-eb13a917d699" xlink:to="loc_wald_AccruedSalesReturnsAndDamagesCurrent_ada5e361-9367-4420-b9bc-3eef74849c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_742c1dab-6d66-4f6c-b204-5b7ebf6fc136" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b62a736-677a-4ead-9017-eb13a917d699" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_742c1dab-6d66-4f6c-b204-5b7ebf6fc136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AccruedDistributionFeesCurrent_e4dad95a-eb6b-4231-b2b4-0bd3fc2d0c44" xlink:href="wald-20221231.xsd#wald_AccruedDistributionFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b62a736-677a-4ead-9017-eb13a917d699" xlink:to="loc_wald_AccruedDistributionFeesCurrent_e4dad95a-eb6b-4231-b2b4-0bd3fc2d0c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_3f04d37a-a618-4fe4-b207-1a9f9589e1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b62a736-677a-4ead-9017-eb13a917d699" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_3f04d37a-a618-4fe4-b207-1a9f9589e1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_55f8ba47-5255-4861-b12f-a617f22cbe0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b62a736-677a-4ead-9017-eb13a917d699" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_55f8ba47-5255-4861-b12f-a617f22cbe0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eaff40b3-881e-454a-a38d-b828bef01083" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07ae11b3-628f-46da-bda5-c293a7273fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eaff40b3-881e-454a-a38d-b828bef01083" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07ae11b3-628f-46da-bda5-c293a7273fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c36aace9-5cd3-438b-8a8f-980a036e77d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07ae11b3-628f-46da-bda5-c293a7273fe1" xlink:to="loc_us-gaap_AwardTypeAxis_c36aace9-5cd3-438b-8a8f-980a036e77d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53832bc2-a179-46e3-bc22-2a0fb4db0a23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c36aace9-5cd3-438b-8a8f-980a036e77d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53832bc2-a179-46e3-bc22-2a0fb4db0a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_61679e4d-714e-403c-87cc-5576e6d513a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53832bc2-a179-46e3-bc22-2a0fb4db0a23" xlink:to="loc_us-gaap_EmployeeStockMember_61679e4d-714e-403c-87cc-5576e6d513a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1fea53f8-c844-4ca8-845b-3132173bf06a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53832bc2-a179-46e3-bc22-2a0fb4db0a23" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1fea53f8-c844-4ca8-845b-3132173bf06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_cda28bd8-7912-4d6f-a50a-4dd951af02bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53832bc2-a179-46e3-bc22-2a0fb4db0a23" xlink:to="loc_us-gaap_RestrictedStockMember_cda28bd8-7912-4d6f-a50a-4dd951af02bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember_8abca6fe-b787-4b61-9d13-81e2e18e8b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53832bc2-a179-46e3-bc22-2a0fb4db0a23" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember_8abca6fe-b787-4b61-9d13-81e2e18e8b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5e41a7e4-1950-424b-a4b6-9b51830192d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53832bc2-a179-46e3-bc22-2a0fb4db0a23" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5e41a7e4-1950-424b-a4b6-9b51830192d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fc5a9b54-c9c4-4467-a005-37d826d66266" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07ae11b3-628f-46da-bda5-c293a7273fe1" xlink:to="loc_us-gaap_PlanNameAxis_fc5a9b54-c9c4-4467-a005-37d826d66266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e9678ceb-b66a-4b4b-b7b4-b3e27370c627" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_fc5a9b54-c9c4-4467-a005-37d826d66266" xlink:to="loc_us-gaap_PlanNameDomain_e9678ceb-b66a-4b4b-b7b4-b3e27370c627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_A2022IncentiveAwardPlanMember_fb26c0ff-3578-4c5d-a8df-9f74209c2079" xlink:href="wald-20221231.xsd#wald_A2022IncentiveAwardPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e9678ceb-b66a-4b4b-b7b4-b3e27370c627" xlink:to="loc_wald_A2022IncentiveAwardPlanMember_fb26c0ff-3578-4c5d-a8df-9f74209c2079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_LongTermIncentiveAwardsMember_747ab54f-a662-4779-a80f-56a58ae8a2b7" xlink:href="wald-20221231.xsd#wald_LongTermIncentiveAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e9678ceb-b66a-4b4b-b7b4-b3e27370c627" xlink:to="loc_wald_LongTermIncentiveAwardsMember_747ab54f-a662-4779-a80f-56a58ae8a2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_OneTimStockGrantMember_775a219c-696b-4fe9-9bc0-84a0e285a2ad" xlink:href="wald-20221231.xsd#wald_OneTimStockGrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e9678ceb-b66a-4b4b-b7b4-b3e27370c627" xlink:to="loc_wald_OneTimStockGrantMember_775a219c-696b-4fe9-9bc0-84a0e285a2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PredecessorIncentivePlanMember_9bb0b309-117e-4b41-9302-334e12a09ead" xlink:href="wald-20221231.xsd#wald_PredecessorIncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e9678ceb-b66a-4b4b-b7b4-b3e27370c627" xlink:to="loc_wald_PredecessorIncentivePlanMember_9bb0b309-117e-4b41-9302-334e12a09ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_3c289190-d40e-442e-990f-7863da6ca65d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07ae11b3-628f-46da-bda5-c293a7273fe1" xlink:to="loc_srt_TitleOfIndividualAxis_3c289190-d40e-442e-990f-7863da6ca65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_98fdecf1-b1dc-4551-92cc-f9f8c66cad0d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_3c289190-d40e-442e-990f-7863da6ca65d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_98fdecf1-b1dc-4551-92cc-f9f8c66cad0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_a476846c-643f-488c-b80b-129802999d95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07ae11b3-628f-46da-bda5-c293a7273fe1" xlink:to="loc_us-gaap_GranteeStatusAxis_a476846c-643f-488c-b80b-129802999d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_40c0c726-1bc0-457d-acc5-5ab7934484ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_a476846c-643f-488c-b80b-129802999d95" xlink:to="loc_us-gaap_GranteeStatusDomain_40c0c726-1bc0-457d-acc5-5ab7934484ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedPaymentArrangementFounderMember_795a0ac2-b448-4ce4-aec1-30a07f6a71c5" xlink:href="wald-20221231.xsd#wald_ShareBasedPaymentArrangementFounderMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_40c0c726-1bc0-457d-acc5-5ab7934484ca" xlink:to="loc_wald_ShareBasedPaymentArrangementFounderMember_795a0ac2-b448-4ce4-aec1-30a07f6a71c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_93012524-3ab8-483c-a0f3-f74f3b0cd92b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07ae11b3-628f-46da-bda5-c293a7273fe1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_93012524-3ab8-483c-a0f3-f74f3b0cd92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1bc2a3bc-e745-41ba-97dd-3b82e330e52d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_93012524-3ab8-483c-a0f3-f74f3b0cd92b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1bc2a3bc-e745-41ba-97dd-3b82e330e52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiAndMilkBusinessCombinationsMember_078a1607-f8bd-4284-83a6-96e30daf43cd" xlink:href="wald-20221231.xsd#wald_ObagiAndMilkBusinessCombinationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1bc2a3bc-e745-41ba-97dd-3b82e330e52d" xlink:to="loc_wald_ObagiAndMilkBusinessCombinationsMember_078a1607-f8bd-4284-83a6-96e30daf43cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiMergerMember_2e71fb5b-03b6-4fac-a343-320babd4358e" xlink:href="wald-20221231.xsd#wald_ObagiMergerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1bc2a3bc-e745-41ba-97dd-3b82e330e52d" xlink:to="loc_wald_ObagiMergerMember_2e71fb5b-03b6-4fac-a343-320babd4358e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkTransactionMember_be76f6db-494c-4d80-9a59-4a2a030b338e" xlink:href="wald-20221231.xsd#wald_MilkTransactionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1bc2a3bc-e745-41ba-97dd-3b82e330e52d" xlink:to="loc_wald_MilkTransactionMember_be76f6db-494c-4d80-9a59-4a2a030b338e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_9d3b543c-c2ae-4dee-8412-e582d1893af1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07ae11b3-628f-46da-bda5-c293a7273fe1" xlink:to="loc_us-gaap_VestingAxis_9d3b543c-c2ae-4dee-8412-e582d1893af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a6001448-fc71-4395-b4e8-19321dc2d490" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_9d3b543c-c2ae-4dee-8412-e582d1893af1" xlink:to="loc_us-gaap_VestingDomain_a6001448-fc71-4395-b4e8-19321dc2d490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3933cfdc-4f2f-40aa-af30-ce1e8fe1a0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a6001448-fc71-4395-b4e8-19321dc2d490" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3933cfdc-4f2f-40aa-af30-ce1e8fe1a0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5b9023e7-f3e3-446a-84c1-f6ce34dfa786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_a6001448-fc71-4395-b4e8-19321dc2d490" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5b9023e7-f3e3-446a-84c1-f6ce34dfa786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_07ae11b3-628f-46da-bda5-c293a7273fe1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bf8cea99-31b8-49ae-9527-24b8f00e76ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bf8cea99-31b8-49ae-9527-24b8f00e76ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod_7ec8b778-8da6-49a7-b877-e4c62c310f6a" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod_7ec8b778-8da6-49a7-b877-e4c62c310f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_cf5dc0a5-0bcd-45bf-b82d-975e8a91cdad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_cf5dc0a5-0bcd-45bf-b82d-975e8a91cdad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8d65294d-a17f-4839-a7ad-c8310498f9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8d65294d-a17f-4839-a7ad-c8310498f9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod_e8b284f0-62a0-442c-a7b6-deb6ba6eb15f" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod_e8b284f0-62a0-442c-a7b6-deb6ba6eb15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod_9fc6b969-7ae1-4cd5-a4c6-a9e442c98d9a" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod_9fc6b969-7ae1-4cd5-a4c6-a9e442c98d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost_95407d35-f59b-4d7e-999a-a19acac27460" xlink:href="wald-20221231.xsd#wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost_95407d35-f59b-4d7e-999a-a19acac27460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_45ce0564-7515-4d05-a279-cd18dd624330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_45ce0564-7515-4d05-a279-cd18dd624330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_96ce1cbb-df50-4064-afea-bd0d9a29123d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_96ce1cbb-df50-4064-afea-bd0d9a29123d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals_1c7dd0c4-b8f3-4f3c-8363-b28fe4813da1" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals_1c7dd0c4-b8f3-4f3c-8363-b28fe4813da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d8490c42-c546-4775-9731-c5bfda1ff81c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d8490c42-c546-4775-9731-c5bfda1ff81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches_4b68d7ff-acbe-4442-a81a-e55160ddae3c" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches_4b68d7ff-acbe-4442-a81a-e55160ddae3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f910aa13-ebba-4634-b8c5-d2ad093e1246" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f910aa13-ebba-4634-b8c5-d2ad093e1246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_305f8b71-f071-4553-85f6-44429d63071e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_305f8b71-f071-4553-85f6-44429d63071e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_fa03711e-d62c-4718-84c8-be0bbce48dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_fa03711e-d62c-4718-84c8-be0bbce48dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b75b1cfb-e7bb-4afd-ac02-659062140017" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_b75b1cfb-e7bb-4afd-ac02-659062140017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4d6b1000-d032-450c-86d4-2904fcf008fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4d6b1000-d032-450c-86d4-2904fcf008fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_3f2c4619-b693-4a47-8a41-67a58ed06cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_3f2c4619-b693-4a47-8a41-67a58ed06cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments_8acd80ab-4c8c-4202-a6c3-1337f2465a93" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments_8acd80ab-4c8c-4202-a6c3-1337f2465a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_ede2cd81-5e6d-451d-99ca-c2fcf8e85341" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_ede2cd81-5e6d-451d-99ca-c2fcf8e85341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_af2f96c2-eaff-4fe2-bd58-fff3047cc855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_af2f96c2-eaff-4fe2-bd58-fff3047cc855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cad63094-bc9b-427f-9288-8af877633fac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e46c0c11-3255-4239-8993-a426bae9e1bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cad63094-bc9b-427f-9288-8af877633fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#STOCKBASEDCOMPENSATIONStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7871093e-cc32-4a67-931a-f86160287159" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52db308f-6f35-4023-95ef-8f58df779620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7871093e-cc32-4a67-931a-f86160287159" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52db308f-6f35-4023-95ef-8f58df779620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_995a2391-118e-4bc9-878f-a81619f611a5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52db308f-6f35-4023-95ef-8f58df779620" xlink:to="loc_dei_LegalEntityAxis_995a2391-118e-4bc9-878f-a81619f611a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d6941957-307a-432d-98f1-0e321ac32662" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_995a2391-118e-4bc9-878f-a81619f611a5" xlink:to="loc_dei_EntityDomain_d6941957-307a-432d-98f1-0e321ac32662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_WaldencastPlcMember_e56097e3-8661-4038-b6ee-2f0837fbba95" xlink:href="wald-20221231.xsd#wald_WaldencastPlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d6941957-307a-432d-98f1-0e321ac32662" xlink:to="loc_wald_WaldencastPlcMember_e56097e3-8661-4038-b6ee-2f0837fbba95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiCosmeceuticalsLLCMember_168437a5-93b8-4d72-9987-2fb6167782c3" xlink:href="wald-20221231.xsd#wald_ObagiCosmeceuticalsLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d6941957-307a-432d-98f1-0e321ac32662" xlink:to="loc_wald_ObagiCosmeceuticalsLLCMember_168437a5-93b8-4d72-9987-2fb6167782c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61778696-82d7-4da9-8b46-846280bb6f71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52db308f-6f35-4023-95ef-8f58df779620" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61778696-82d7-4da9-8b46-846280bb6f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f6403b7-5d0e-466e-81f8-13883fa991b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61778696-82d7-4da9-8b46-846280bb6f71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f6403b7-5d0e-466e-81f8-13883fa991b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0def3808-48da-4636-8e7e-1fe69d38689a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f6403b7-5d0e-466e-81f8-13883fa991b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0def3808-48da-4636-8e7e-1fe69d38689a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_63c06634-c5b1-42ef-b4bb-215b737a37c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f6403b7-5d0e-466e-81f8-13883fa991b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_63c06634-c5b1-42ef-b4bb-215b737a37c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9fca2cae-3d8b-497d-9904-073aba273768" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f6403b7-5d0e-466e-81f8-13883fa991b7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9fca2cae-3d8b-497d-9904-073aba273768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d0c8fcba-e0bd-4f4a-b3cf-4f2186bce894" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f6403b7-5d0e-466e-81f8-13883fa991b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d0c8fcba-e0bd-4f4a-b3cf-4f2186bce894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_13e3c50c-ee99-4eda-bdbe-2ff049e6aa7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f6403b7-5d0e-466e-81f8-13883fa991b7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_13e3c50c-ee99-4eda-bdbe-2ff049e6aa7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1d6bca1a-a756-47f2-88ef-3bcc3a15ebe9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f6403b7-5d0e-466e-81f8-13883fa991b7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1d6bca1a-a756-47f2-88ef-3bcc3a15ebe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_a2a88858-d49a-4a24-8acf-b1d574a2dffa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61778696-82d7-4da9-8b46-846280bb6f71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_a2a88858-d49a-4a24-8acf-b1d574a2dffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4fa474f1-22d8-4385-8cf0-31de7cacb618" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61778696-82d7-4da9-8b46-846280bb6f71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4fa474f1-22d8-4385-8cf0-31de7cacb618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f022e6d-451c-40a2-884c-3f9aa74f42bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61778696-82d7-4da9-8b46-846280bb6f71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f022e6d-451c-40a2-884c-3f9aa74f42bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8022f094-3dc0-4917-90db-c73d38fee253" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f022e6d-451c-40a2-884c-3f9aa74f42bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8022f094-3dc0-4917-90db-c73d38fee253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9d7fea1e-ce16-4011-b12d-87448fc0e369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f022e6d-451c-40a2-884c-3f9aa74f42bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9d7fea1e-ce16-4011-b12d-87448fc0e369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8ca82110-081f-4450-ac54-d15335d02575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f022e6d-451c-40a2-884c-3f9aa74f42bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8ca82110-081f-4450-ac54-d15335d02575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5a63acb0-fe23-4108-aaf3-f6016b4940b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f022e6d-451c-40a2-884c-3f9aa74f42bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5a63acb0-fe23-4108-aaf3-f6016b4940b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_30cc9c74-b537-463f-b743-f2243088d3f0" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f022e6d-451c-40a2-884c-3f9aa74f42bf" xlink:to="loc_wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice_30cc9c74-b537-463f-b743-f2243088d3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7eea813c-c11e-4eeb-ad09-3bc6b56e4d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1f022e6d-451c-40a2-884c-3f9aa74f42bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7eea813c-c11e-4eeb-ad09-3bc6b56e4d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_35548f35-45a3-4680-b713-70c415be61cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61778696-82d7-4da9-8b46-846280bb6f71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_35548f35-45a3-4680-b713-70c415be61cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4ad30a71-ddab-45a6-a104-350f6999ce36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61778696-82d7-4da9-8b46-846280bb6f71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4ad30a71-ddab-45a6-a104-350f6999ce36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_61778696-82d7-4da9-8b46-846280bb6f71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a25afeef-d673-4a07-b91e-c72987f6419b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a25afeef-d673-4a07-b91e-c72987f6419b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm_d4d16e9f-ea99-43ae-a5cd-e4fb24800840" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm_d4d16e9f-ea99-43ae-a5cd-e4fb24800840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm_a715b576-2983-4a95-8796-d6324c96cb76" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm_a715b576-2983-4a95-8796-d6324c96cb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_448cea7c-a1fd-4a9c-9532-09ad6df54977" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_448cea7c-a1fd-4a9c-9532-09ad6df54977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b584fccf-e49c-4ced-abaf-58726bee328f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b584fccf-e49c-4ced-abaf-58726bee328f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d2cffcde-9af1-4f94-8ac8-8dc5c9a1b5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d2cffcde-9af1-4f94-8ac8-8dc5c9a1b5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_d277d6a1-b458-45ec-a0a4-fd5f7ea64f3f" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue_d277d6a1-b458-45ec-a0a4-fd5f7ea64f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue_ddbdffb2-76c6-4102-88a3-c90f992d6627" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue_ddbdffb2-76c6-4102-88a3-c90f992d6627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_bc1ff2f3-71fc-4080-808a-251bcde4d671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_bc1ff2f3-71fc-4080-808a-251bcde4d671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8f2e5511-3c5b-4314-b7db-766d21576eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47ca5126-2708-4c7e-934c-d738fe3a1c68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8f2e5511-3c5b-4314-b7db-766d21576eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0602a39f-adac-45d6-9409-c2e063ac5787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3921cbef-d4a7-4e5b-97da-0bd4086dd944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0602a39f-adac-45d6-9409-c2e063ac5787" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3921cbef-d4a7-4e5b-97da-0bd4086dd944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_123ac13c-f6cf-434e-b758-7fe2f5753174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3921cbef-d4a7-4e5b-97da-0bd4086dd944" xlink:to="loc_us-gaap_AwardTypeAxis_123ac13c-f6cf-434e-b758-7fe2f5753174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c9e3871-6794-4b69-8aae-784892443d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_123ac13c-f6cf-434e-b758-7fe2f5753174" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c9e3871-6794-4b69-8aae-784892443d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_FounderAwardsMember_9f4753b1-0abc-4407-85a5-9beb5160394d" xlink:href="wald-20221231.xsd#wald_FounderAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c9e3871-6794-4b69-8aae-784892443d8e" xlink:to="loc_wald_FounderAwardsMember_9f4753b1-0abc-4407-85a5-9beb5160394d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ReplacementAwardsMember_34ac5a69-74a1-4af4-9de3-fb4a7eca9f75" xlink:href="wald-20221231.xsd#wald_ReplacementAwardsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c9e3871-6794-4b69-8aae-784892443d8e" xlink:to="loc_wald_ReplacementAwardsMember_34ac5a69-74a1-4af4-9de3-fb4a7eca9f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c29a8de9-970b-4da7-8666-b7faa9bcdb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c9e3871-6794-4b69-8aae-784892443d8e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c29a8de9-970b-4da7-8666-b7faa9bcdb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fdccc677-4bb0-45b5-8eab-a39744a3cdd4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3921cbef-d4a7-4e5b-97da-0bd4086dd944" xlink:to="loc_srt_RangeAxis_fdccc677-4bb0-45b5-8eab-a39744a3cdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_023a29eb-aef0-4111-a607-c3fa4fcf83fe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fdccc677-4bb0-45b5-8eab-a39744a3cdd4" xlink:to="loc_srt_RangeMember_023a29eb-aef0-4111-a607-c3fa4fcf83fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bda1c313-ab8a-40b1-8192-f1d4cc6ea2fb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_023a29eb-aef0-4111-a607-c3fa4fcf83fe" xlink:to="loc_srt_MinimumMember_bda1c313-ab8a-40b1-8192-f1d4cc6ea2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3c0ba716-0005-40dd-9251-c2242aa61d2e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_023a29eb-aef0-4111-a607-c3fa4fcf83fe" xlink:to="loc_srt_MaximumMember_3c0ba716-0005-40dd-9251-c2242aa61d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3921cbef-d4a7-4e5b-97da-0bd4086dd944" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_79ec7034-263b-46f0-bbe4-43d31ecb507d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_79ec7034-263b-46f0-bbe4-43d31ecb507d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_071726c9-acff-46ba-a4a3-522b3f2f3b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_071726c9-acff-46ba-a4a3-522b3f2f3b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_32f0ef17-9059-42ee-add6-958a25d2ae79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_32f0ef17-9059-42ee-add6-958a25d2ae79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple_ba37a32d-9e3b-4b98-8dcf-3fd3bb2a897a" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple_ba37a32d-9e3b-4b98-8dcf-3fd3bb2a897a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8b11aa8e-76ff-45c9-b701-79a301ac878b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8b11aa8e-76ff-45c9-b701-79a301ac878b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9534807e-24d3-4d2e-8fc9-b4cd1cd7e3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9534807e-24d3-4d2e-8fc9-b4cd1cd7e3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3506694a-48e4-4170-ae47-0f8a9cf83f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3506694a-48e4-4170-ae47-0f8a9cf83f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent_940da8c3-89b5-4320-8f57-b1330aeaab5f" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent_940da8c3-89b5-4320-8f57-b1330aeaab5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_b0c675c9-68c4-4788-b4db-1b3a3c765ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_b0c675c9-68c4-4788-b4db-1b3a3c765ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fa784984-c0f0-42d3-b2d0-8fb73810d407" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fa784984-c0f0-42d3-b2d0-8fb73810d407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_8c7d619e-4a8f-4d69-a3c6-0526235c2c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_8c7d619e-4a8f-4d69-a3c6-0526235c2c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_7307c641-2d9e-440d-83d7-dffefce86bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc62e842-29f3-42fb-b829-e59f66982fc4" xlink:to="loc_us-gaap_SharePrice_7307c641-2d9e-440d-83d7-dffefce86bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4ebf90a5-a5ed-4bb0-abf8-33042072e968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f331fc42-fa88-47cd-bc4b-422436a73b14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4ebf90a5-a5ed-4bb0-abf8-33042072e968" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f331fc42-fa88-47cd-bc4b-422436a73b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_aececf21-2e8e-4131-a231-608aaa3bdef3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f331fc42-fa88-47cd-bc4b-422436a73b14" xlink:to="loc_us-gaap_AwardTypeAxis_aececf21-2e8e-4131-a231-608aaa3bdef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f885ec1b-58dd-49da-bc2f-1729665e9faa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_aececf21-2e8e-4131-a231-608aaa3bdef3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f885ec1b-58dd-49da-bc2f-1729665e9faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_edb1a520-e5ba-4913-a953-4a1a29fc424c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f885ec1b-58dd-49da-bc2f-1729665e9faa" xlink:to="loc_us-gaap_RestrictedStockMember_edb1a520-e5ba-4913-a953-4a1a29fc424c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5f265fdc-3949-499e-ab5b-fd8604779725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f885ec1b-58dd-49da-bc2f-1729665e9faa" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5f265fdc-3949-499e-ab5b-fd8604779725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_fdacdaf0-59f6-4920-a82a-02b04c444b8c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f331fc42-fa88-47cd-bc4b-422436a73b14" xlink:to="loc_dei_LegalEntityAxis_fdacdaf0-59f6-4920-a82a-02b04c444b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b54402d4-e764-4813-a432-15cbbd85a35c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_fdacdaf0-59f6-4920-a82a-02b04c444b8c" xlink:to="loc_dei_EntityDomain_b54402d4-e764-4813-a432-15cbbd85a35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_WaldencastPlcMember_4380dbdd-7c78-48e0-8677-466a7ef38914" xlink:href="wald-20221231.xsd#wald_WaldencastPlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b54402d4-e764-4813-a432-15cbbd85a35c" xlink:to="loc_wald_WaldencastPlcMember_4380dbdd-7c78-48e0-8677-466a7ef38914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiCosmeceuticalsLLCMember_6fa6dccb-c1f4-494f-b8b7-f2488e5d358e" xlink:href="wald-20221231.xsd#wald_ObagiCosmeceuticalsLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b54402d4-e764-4813-a432-15cbbd85a35c" xlink:to="loc_wald_ObagiCosmeceuticalsLLCMember_6fa6dccb-c1f4-494f-b8b7-f2488e5d358e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_839a47bd-9cbd-4536-896d-4b5ba13c77f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f331fc42-fa88-47cd-bc4b-422436a73b14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_839a47bd-9cbd-4536-896d-4b5ba13c77f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2ff87066-2fc8-4c48-aaa5-d2e0e44da2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_839a47bd-9cbd-4536-896d-4b5ba13c77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2ff87066-2fc8-4c48-aaa5-d2e0e44da2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ef3b7c8d-ec61-4565-939e-9c524195ae7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2ff87066-2fc8-4c48-aaa5-d2e0e44da2d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ef3b7c8d-ec61-4565-939e-9c524195ae7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6fb745dc-299e-4901-b4c6-297c27b755ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2ff87066-2fc8-4c48-aaa5-d2e0e44da2d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6fb745dc-299e-4901-b4c6-297c27b755ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60f03bf3-0dad-46d7-8010-d042e1534cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2ff87066-2fc8-4c48-aaa5-d2e0e44da2d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_60f03bf3-0dad-46d7-8010-d042e1534cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2074eb35-a4bb-4605-b1d9-69841c95f1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2ff87066-2fc8-4c48-aaa5-d2e0e44da2d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2074eb35-a4bb-4605-b1d9-69841c95f1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a63c375b-2c5e-496d-933a-be0d8f1185df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2ff87066-2fc8-4c48-aaa5-d2e0e44da2d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a63c375b-2c5e-496d-933a-be0d8f1185df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8bb8729c-8a86-4b7e-a744-e72eab34ff73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2ff87066-2fc8-4c48-aaa5-d2e0e44da2d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8bb8729c-8a86-4b7e-a744-e72eab34ff73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba668247-737e-473d-bebb-f8e72de2bf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_839a47bd-9cbd-4536-896d-4b5ba13c77f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba668247-737e-473d-bebb-f8e72de2bf9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aa61a695-3411-4179-b83f-04042cf0b43a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba668247-737e-473d-bebb-f8e72de2bf9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aa61a695-3411-4179-b83f-04042cf0b43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5a3935ef-a11b-492f-8200-cf4a233adbb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba668247-737e-473d-bebb-f8e72de2bf9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5a3935ef-a11b-492f-8200-cf4a233adbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue_84f3a36f-7171-4a63-bbad-ce83a417d4ca" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba668247-737e-473d-bebb-f8e72de2bf9e" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue_84f3a36f-7171-4a63-bbad-ce83a417d4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_72be211a-7fba-4d1e-99fc-ead977149531" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba668247-737e-473d-bebb-f8e72de2bf9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_72be211a-7fba-4d1e-99fc-ead977149531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0a531c29-ec3d-4027-b7ef-441abd567024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba668247-737e-473d-bebb-f8e72de2bf9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0a531c29-ec3d-4027-b7ef-441abd567024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_273db657-3144-4aa6-b949-9e90a2dfdfca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba668247-737e-473d-bebb-f8e72de2bf9e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_273db657-3144-4aa6-b949-9e90a2dfdfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SHAREHOLDERSEQUITYDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b0454d56-7e81-435f-a590-5fc542cd5f76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9418d3e1-a04c-472b-b841-6dd6848b0471" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b0454d56-7e81-435f-a590-5fc542cd5f76" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9418d3e1-a04c-472b-b841-6dd6848b0471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b3c2d1f0-c155-4bef-b44f-9ddb5be913ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9418d3e1-a04c-472b-b841-6dd6848b0471" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b3c2d1f0-c155-4bef-b44f-9ddb5be913ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c236d5d5-9dd5-4748-9b47-299706c9dbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b3c2d1f0-c155-4bef-b44f-9ddb5be913ea" xlink:to="loc_us-gaap_ClassOfStockDomain_c236d5d5-9dd5-4748-9b47-299706c9dbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_9b259997-3118-49d6-a45e-59de4febed00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c236d5d5-9dd5-4748-9b47-299706c9dbfb" xlink:to="loc_us-gaap_CommonClassAMember_9b259997-3118-49d6-a45e-59de4febed00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_303eec19-2b84-436b-9d98-525a800ab55f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c236d5d5-9dd5-4748-9b47-299706c9dbfb" xlink:to="loc_us-gaap_CommonClassBMember_303eec19-2b84-436b-9d98-525a800ab55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9418d3e1-a04c-472b-b841-6dd6848b0471" xlink:to="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_45e6a3a4-90c9-4fd7-a3a0-5227c58e2b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_45e6a3a4-90c9-4fd7-a3a0-5227c58e2b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4fa248af-f52e-450f-a466-a07d140928a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4fa248af-f52e-450f-a466-a07d140928a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6c0cdb86-e3fe-4a02-8527-cff176ce417b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6c0cdb86-e3fe-4a02-8527-cff176ce417b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_95a331e2-5bb4-4844-ac45-337f3b7e6227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_95a331e2-5bb4-4844-ac45-337f3b7e6227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3a17c7ef-f13d-4d5d-a477-3216bc849040" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_CommonStockSharesIssued_3a17c7ef-f13d-4d5d-a477-3216bc849040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_26b7023b-3d6c-45de-a067-d3de23ec3f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_26b7023b-3d6c-45de-a067-d3de23ec3f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_b601de23-0f80-47b1-b558-e2ae779960fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_PreferredStockSharesIssued_b601de23-0f80-47b1-b558-e2ae779960fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_153bb194-8bac-4bcb-9f3e-ed3a47024a19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_153bb194-8bac-4bcb-9f3e-ed3a47024a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockVotingRights_4b5b435d-e396-42ce-afff-863f22ebfc79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockVotingRights"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_CommonStockVotingRights_4b5b435d-e396-42ce-afff-863f22ebfc79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CommonStockConvertibleConversionRatio_3c36dc5e-3ae7-40f7-86db-4e450eefb6c3" xlink:href="wald-20221231.xsd#wald_CommonStockConvertibleConversionRatio"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_wald_CommonStockConvertibleConversionRatio_3c36dc5e-3ae7-40f7-86db-4e450eefb6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_074b9b1f-d24c-4a1b-ae9a-f140d4528512" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_074b9b1f-d24c-4a1b-ae9a-f140d4528512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_84965b89-46ab-42c5-807f-d90bd040b156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_DividendsCommonStockCash_84965b89-46ab-42c5-807f-d90bd040b156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_7d22ddeb-bebc-48d8-9f6e-48b8bc09066a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_cedbf84a-9357-4b8c-a3f9-8a51dee8ab34" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_7d22ddeb-bebc-48d8-9f6e-48b8bc09066a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b7d2782c-80b8-45ac-8075-9af7dcf5d52c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_2bc0051b-a783-4412-859c-158a1fe00744" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b7d2782c-80b8-45ac-8075-9af7dcf5d52c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_2bc0051b-a783-4412-859c-158a1fe00744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2604d09d-a140-402f-b4a6-d2099b7a00e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_2bc0051b-a783-4412-859c-158a1fe00744" xlink:to="loc_us-gaap_ProfitLoss_2604d09d-a140-402f-b4a6-d2099b7a00e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0d2a662d-e6d3-4b80-93d9-737b42f2910e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_2bc0051b-a783-4412-859c-158a1fe00744" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0d2a662d-e6d3-4b80-93d9-737b42f2910e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9c509cd3-cc5b-49f3-9671-473c05837b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_2bc0051b-a783-4412-859c-158a1fe00744" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_9c509cd3-cc5b-49f3-9671-473c05837b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ff0bbb7b-220b-42fc-8190-2553c07a2667" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_2bc0051b-a783-4412-859c-158a1fe00744" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ff0bbb7b-220b-42fc-8190-2553c07a2667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_18636fe7-2103-470c-abef-f5857e8bce51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b7d2782c-80b8-45ac-8075-9af7dcf5d52c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_18636fe7-2103-470c-abef-f5857e8bce51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f947cca9-c29a-44a9-aa7b-3e95ed1ca4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_18636fe7-2103-470c-abef-f5857e8bce51" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f947cca9-c29a-44a9-aa7b-3e95ed1ca4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_907e6910-f3fd-497e-b1e6-494aecac50e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_18636fe7-2103-470c-abef-f5857e8bce51" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_907e6910-f3fd-497e-b1e6-494aecac50e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_50d463ab-fd0b-4a90-800a-7d2ef31bb945" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_18636fe7-2103-470c-abef-f5857e8bce51" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_50d463ab-fd0b-4a90-800a-7d2ef31bb945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_748d94ce-ddc4-4a38-aa97-64cd456ce669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b7d2782c-80b8-45ac-8075-9af7dcf5d52c" xlink:to="loc_us-gaap_EarningsPerShareBasic_748d94ce-ddc4-4a38-aa97-64cd456ce669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b8e2df9a-99ff-458d-8e8c-750438985fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b7d2782c-80b8-45ac-8075-9af7dcf5d52c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b8e2df9a-99ff-458d-8e8c-750438985fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_53f4e649-e9a6-4a30-bcf9-eabcf7c919e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ac71c5f-7ec3-4eb3-a227-1a499fc6ac42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_53f4e649-e9a6-4a30-bcf9-eabcf7c919e4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ac71c5f-7ec3-4eb3-a227-1a499fc6ac42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aa4b5e04-4d7b-4b35-962a-577ed465cac1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ac71c5f-7ec3-4eb3-a227-1a499fc6ac42" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aa4b5e04-4d7b-4b35-962a-577ed465cac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_518e2fe1-9cbd-4754-9469-9dc4f70ec42b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_aa4b5e04-4d7b-4b35-962a-577ed465cac1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_518e2fe1-9cbd-4754-9469-9dc4f70ec42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_fff78e20-799d-4301-b7ed-f3879013381e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_518e2fe1-9cbd-4754-9469-9dc4f70ec42b" xlink:to="loc_us-gaap_WarrantMember_fff78e20-799d-4301-b7ed-f3879013381e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ef06076d-35d6-40d8-a65e-0bd7b9dbef70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_518e2fe1-9cbd-4754-9469-9dc4f70ec42b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ef06076d-35d6-40d8-a65e-0bd7b9dbef70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1cf727b4-a24e-4ecb-8fb1-48c762489855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_518e2fe1-9cbd-4754-9469-9dc4f70ec42b" xlink:to="loc_us-gaap_RestrictedStockMember_1cf727b4-a24e-4ecb-8fb1-48c762489855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9cbce61a-8aa9-4996-b305-4546a25117ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8ac71c5f-7ec3-4eb3-a227-1a499fc6ac42" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9cbce61a-8aa9-4996-b305-4546a25117ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5201161f-96c6-48a5-b9e4-3557d6599085" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9cbce61a-8aa9-4996-b305-4546a25117ae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5201161f-96c6-48a5-b9e4-3557d6599085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#INCOMETAXBENEFITNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_eb68c156-de5b-483d-9051-a3044718efbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1e2899c6-8302-445f-bc1d-4ee56380e770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eb68c156-de5b-483d-9051-a3044718efbe" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1e2899c6-8302-445f-bc1d-4ee56380e770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3082d4f0-a6dc-4493-a1bf-49a53f9b588f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eb68c156-de5b-483d-9051-a3044718efbe" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3082d4f0-a6dc-4493-a1bf-49a53f9b588f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_199f8eb1-a2d8-4474-90d1-5dadedf43694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eb68c156-de5b-483d-9051-a3044718efbe" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_199f8eb1-a2d8-4474-90d1-5dadedf43694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_827a33f8-bbd3-409e-96b4-ede49151b62f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_eb68c156-de5b-483d-9051-a3044718efbe" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_827a33f8-bbd3-409e-96b4-ede49151b62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_06574d0a-fb01-4685-b753-cf38a51b5633" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e8bfd0b1-962e-4391-8802-d37a745085f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_06574d0a-fb01-4685-b753-cf38a51b5633" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e8bfd0b1-962e-4391-8802-d37a745085f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_cc6e233e-2980-44c8-bb22-0e80a152d8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_06574d0a-fb01-4685-b753-cf38a51b5633" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_cc6e233e-2980-44c8-bb22-0e80a152d8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e6a1436e-0fec-4b49-bf3b-65e52d8ab3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_06574d0a-fb01-4685-b753-cf38a51b5633" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e6a1436e-0fec-4b49-bf3b-65e52d8ab3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_393d3935-2d94-405e-9832-6726bed948d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_83a8b832-9fbf-4527-908a-ee8e33f07245" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_393d3935-2d94-405e-9832-6726bed948d6" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_83a8b832-9fbf-4527-908a-ee8e33f07245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_059456c5-d646-4be8-865a-f870c9457db0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_83a8b832-9fbf-4527-908a-ee8e33f07245" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_059456c5-d646-4be8-865a-f870c9457db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_131c26e5-e7c9-4239-bbed-9e25ef6ff462" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_83a8b832-9fbf-4527-908a-ee8e33f07245" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_131c26e5-e7c9-4239-bbed-9e25ef6ff462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5a3df670-beee-4580-a23f-10439f543c74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_83a8b832-9fbf-4527-908a-ee8e33f07245" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5a3df670-beee-4580-a23f-10439f543c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0b598c32-cd6e-4257-8979-537fa07087b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_83a8b832-9fbf-4527-908a-ee8e33f07245" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0b598c32-cd6e-4257-8979-537fa07087b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_57a920e4-edc9-4d0b-84ea-616ae695fd28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_393d3935-2d94-405e-9832-6726bed948d6" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_57a920e4-edc9-4d0b-84ea-616ae695fd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_9e7d1d05-42ed-4745-8d5e-3b2fca729974" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_57a920e4-edc9-4d0b-84ea-616ae695fd28" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_9e7d1d05-42ed-4745-8d5e-3b2fca729974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_33a19060-7842-44e6-a2de-e945580ab856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_57a920e4-edc9-4d0b-84ea-616ae695fd28" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_33a19060-7842-44e6-a2de-e945580ab856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_d24ffe19-7d5f-44a5-9f1a-1ae082823707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_57a920e4-edc9-4d0b-84ea-616ae695fd28" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_d24ffe19-7d5f-44a5-9f1a-1ae082823707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b496bc91-98a6-4d6e-a660-c5918eda5300" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_57a920e4-edc9-4d0b-84ea-616ae695fd28" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b496bc91-98a6-4d6e-a660-c5918eda5300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_91a79ca7-83dc-4f4c-871c-fab02363f5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_393d3935-2d94-405e-9832-6726bed948d6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_91a79ca7-83dc-4f4c-871c-fab02363f5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d061286f-8784-40d9-bb1b-35f145faa392" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_eea59c47-ba2f-479c-adeb-39d256ffa11f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d061286f-8784-40d9-bb1b-35f145faa392" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_eea59c47-ba2f-479c-adeb-39d256ffa11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4f5623e1-c12c-4c65-92fa-0db07a61fc56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d061286f-8784-40d9-bb1b-35f145faa392" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4f5623e1-c12c-4c65-92fa-0db07a61fc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c3f4bb72-a332-4e20-8d7c-c79ce2b9fb89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d061286f-8784-40d9-bb1b-35f145faa392" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c3f4bb72-a332-4e20-8d7c-c79ce2b9fb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_e178edad-6cc8-4eda-b1ba-d1fc44e47ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d061286f-8784-40d9-bb1b-35f145faa392" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_e178edad-6cc8-4eda-b1ba-d1fc44e47ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_88812429-bc75-45c1-961a-e73d32b0afde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d061286f-8784-40d9-bb1b-35f145faa392" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_88812429-bc75-45c1-961a-e73d32b0afde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6d25d62c-fdff-4e71-8c0d-af597efc4584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d061286f-8784-40d9-bb1b-35f145faa392" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6d25d62c-fdff-4e71-8c0d-af597efc4584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent_d781ff53-41d5-494e-8f67-987759c21002" xlink:href="wald-20221231.xsd#wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d061286f-8784-40d9-bb1b-35f145faa392" xlink:to="loc_wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent_d781ff53-41d5-494e-8f67-987759c21002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_3c5b7de2-15e0-4f79-bf2a-88e9c79d773f" xlink:href="wald-20221231.xsd#wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d061286f-8784-40d9-bb1b-35f145faa392" xlink:to="loc_wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent_3c5b7de2-15e0-4f79-bf2a-88e9c79d773f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent_97245d42-1e94-444b-befa-66c368f9803c" xlink:href="wald-20221231.xsd#wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d061286f-8784-40d9-bb1b-35f145faa392" xlink:to="loc_wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent_97245d42-1e94-444b-befa-66c368f9803c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent_3511f932-9f55-4832-be90-561c198bb34d" xlink:href="wald-20221231.xsd#wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d061286f-8784-40d9-bb1b-35f145faa392" xlink:to="loc_wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent_3511f932-9f55-4832-be90-561c198bb34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a9ff684a-1a35-43e2-946b-1d1e711ca2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d061286f-8784-40d9-bb1b-35f145faa392" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a9ff684a-1a35-43e2-946b-1d1e711ca2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent_53aff2f9-31fb-4dd0-8809-d4c53e3b9523" xlink:href="wald-20221231.xsd#wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d061286f-8784-40d9-bb1b-35f145faa392" xlink:to="loc_wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent_53aff2f9-31fb-4dd0-8809-d4c53e3b9523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0db147a2-c69c-415b-a64d-bc0385eb9590" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d061286f-8784-40d9-bb1b-35f145faa392" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0db147a2-c69c-415b-a64d-bc0385eb9590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6c305988-770e-48b5-91dd-d5ff560657a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cbe7d652-2b6a-46b3-aa88-3c2f5d8a9e36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6c305988-770e-48b5-91dd-d5ff560657a2" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cbe7d652-2b6a-46b3-aa88-3c2f5d8a9e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties_257007c6-f758-402a-96af-33171ee65dfb" xlink:href="wald-20221231.xsd#wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cbe7d652-2b6a-46b3-aa88-3c2f5d8a9e36" xlink:to="loc_wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties_257007c6-f758-402a-96af-33171ee65dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DeferredTaxAssetsLeaseLiabilities_3178118d-cc02-42cb-b263-71ed57b53001" xlink:href="wald-20221231.xsd#wald_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cbe7d652-2b6a-46b3-aa88-3c2f5d8a9e36" xlink:to="loc_wald_DeferredTaxAssetsLeaseLiabilities_3178118d-cc02-42cb-b263-71ed57b53001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_96bd4721-52a8-4f5a-886b-d0ec72b935c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cbe7d652-2b6a-46b3-aa88-3c2f5d8a9e36" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_96bd4721-52a8-4f5a-886b-d0ec72b935c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DeferredTaxAssetsFormationCosts_086c5921-75e9-4a8b-af92-8ab60e7570d9" xlink:href="wald-20221231.xsd#wald_DeferredTaxAssetsFormationCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cbe7d652-2b6a-46b3-aa88-3c2f5d8a9e36" xlink:to="loc_wald_DeferredTaxAssetsFormationCosts_086c5921-75e9-4a8b-af92-8ab60e7570d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_41ba400d-0467-4ddc-bb4f-720238d478ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cbe7d652-2b6a-46b3-aa88-3c2f5d8a9e36" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_41ba400d-0467-4ddc-bb4f-720238d478ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_bb15ad98-951e-4608-9121-a96e39475bba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cbe7d652-2b6a-46b3-aa88-3c2f5d8a9e36" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_bb15ad98-951e-4608-9121-a96e39475bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DeferredTaxAssetsTransactionCosts_81e873d2-5f74-45f7-9a29-2b899f218466" xlink:href="wald-20221231.xsd#wald_DeferredTaxAssetsTransactionCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cbe7d652-2b6a-46b3-aa88-3c2f5d8a9e36" xlink:to="loc_wald_DeferredTaxAssetsTransactionCosts_81e873d2-5f74-45f7-9a29-2b899f218466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_42751858-151f-4722-8211-93e55867cc76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cbe7d652-2b6a-46b3-aa88-3c2f5d8a9e36" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_42751858-151f-4722-8211-93e55867cc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_4a96714b-3f50-424c-8614-4dcfb0f1b51f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cbe7d652-2b6a-46b3-aa88-3c2f5d8a9e36" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_4a96714b-3f50-424c-8614-4dcfb0f1b51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5d67a3b1-fd64-4396-9196-995566e49eec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cbe7d652-2b6a-46b3-aa88-3c2f5d8a9e36" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_5d67a3b1-fd64-4396-9196-995566e49eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_11f88abe-4698-46ef-8262-fa786c2b1195" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cbe7d652-2b6a-46b3-aa88-3c2f5d8a9e36" xlink:to="loc_us-gaap_DeferredTaxAssetInterestCarryforward_11f88abe-4698-46ef-8262-fa786c2b1195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DeferredTaxAssetsBelowMarketLeaseContract_557cf614-2a5e-4657-8e6b-f704f63be2f9" xlink:href="wald-20221231.xsd#wald_DeferredTaxAssetsBelowMarketLeaseContract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cbe7d652-2b6a-46b3-aa88-3c2f5d8a9e36" xlink:to="loc_wald_DeferredTaxAssetsBelowMarketLeaseContract_557cf614-2a5e-4657-8e6b-f704f63be2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_c873f711-9cea-4660-a8fc-53db0c4b48d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cbe7d652-2b6a-46b3-aa88-3c2f5d8a9e36" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_c873f711-9cea-4660-a8fc-53db0c4b48d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_c11a21ad-e55c-4c31-badc-f72cb83d042d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cbe7d652-2b6a-46b3-aa88-3c2f5d8a9e36" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_c11a21ad-e55c-4c31-badc-f72cb83d042d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_72da2672-8b72-4434-8786-a84613636790" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_cbe7d652-2b6a-46b3-aa88-3c2f5d8a9e36" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_72da2672-8b72-4434-8786-a84613636790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_69a0cabe-f18c-4ae3-abdc-b99f6d250cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6c305988-770e-48b5-91dd-d5ff560657a2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_69a0cabe-f18c-4ae3-abdc-b99f6d250cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_92466654-6a09-4889-9f28-6ee4eda3c524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_69a0cabe-f18c-4ae3-abdc-b99f6d250cdd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill_92466654-6a09-4889-9f28-6ee4eda3c524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_be9493ba-eda1-491c-bb26-0a4503bd856f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_69a0cabe-f18c-4ae3-abdc-b99f6d250cdd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_be9493ba-eda1-491c-bb26-0a4503bd856f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_b2699d7b-b435-4b08-a006-4033a47ff5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_69a0cabe-f18c-4ae3-abdc-b99f6d250cdd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_b2699d7b-b435-4b08-a006-4033a47ff5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_dbbc0291-6f2b-4d34-b27a-16788d03f37e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_69a0cabe-f18c-4ae3-abdc-b99f6d250cdd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_dbbc0291-6f2b-4d34-b27a-16788d03f37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_04398874-38a3-4bae-ad7c-958d2459172e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_69a0cabe-f18c-4ae3-abdc-b99f6d250cdd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_04398874-38a3-4bae-ad7c-958d2459172e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_58059e66-95d9-49c7-b7b3-fc4e9666ebd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_69a0cabe-f18c-4ae3-abdc-b99f6d250cdd" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_58059e66-95d9-49c7-b7b3-fc4e9666ebd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_DeferredTaxAssetsNetBeforeValuationAllowance_5bef4e59-62c3-4063-8027-d732e70b3146" xlink:href="wald-20221231.xsd#wald_DeferredTaxAssetsNetBeforeValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6c305988-770e-48b5-91dd-d5ff560657a2" xlink:to="loc_wald_DeferredTaxAssetsNetBeforeValuationAllowance_5bef4e59-62c3-4063-8027-d732e70b3146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5fbbc224-90b3-43e4-91e8-a75db6c07bca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6c305988-770e-48b5-91dd-d5ff560657a2" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5fbbc224-90b3-43e4-91e8-a75db6c07bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_2a328ef3-312f-4922-a149-90ae9acf307d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6c305988-770e-48b5-91dd-d5ff560657a2" xlink:to="loc_us-gaap_DeferredTaxLiabilities_2a328ef3-312f-4922-a149-90ae9acf307d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_29c64eda-3a59-4b90-8050-82025cb0a0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_f2d87620-3965-4efc-8b33-b3b9768df7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_29c64eda-3a59-4b90-8050-82025cb0a0fc" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_f2d87620-3965-4efc-8b33-b3b9768df7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5ef5c062-d70c-48be-8cc1-69e0ebd50582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_f2d87620-3965-4efc-8b33-b3b9768df7e5" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5ef5c062-d70c-48be-8cc1-69e0ebd50582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_354af83e-a441-44ac-9686-8e1e435ae7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5ef5c062-d70c-48be-8cc1-69e0ebd50582" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_354af83e-a441-44ac-9686-8e1e435ae7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_4c4361ca-8a85-4458-a7d2-0ad0a4fea02a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_354af83e-a441-44ac-9686-8e1e435ae7bb" xlink:to="loc_us-gaap_DomesticCountryMember_4c4361ca-8a85-4458-a7d2-0ad0a4fea02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_458f0e10-8664-42f8-8b27-e60241dbb2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_354af83e-a441-44ac-9686-8e1e435ae7bb" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_458f0e10-8664-42f8-8b27-e60241dbb2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_ad73dda6-dd49-4e13-bbf9-1e7b70624b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_f2d87620-3965-4efc-8b33-b3b9768df7e5" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_ad73dda6-dd49-4e13-bbf9-1e7b70624b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_347aaad0-bd8d-4dfe-9e7e-5021b0b09cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ad73dda6-dd49-4e13-bbf9-1e7b70624b2d" xlink:to="loc_us-gaap_OperatingLossCarryforwards_347aaad0-bd8d-4dfe-9e7e-5021b0b09cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_adc45768-3a37-4de4-8a1a-4843781f0dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ad73dda6-dd49-4e13-bbf9-1e7b70624b2d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_adc45768-3a37-4de4-8a1a-4843781f0dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_f7bc84f3-80a6-4c42-8213-df71ed4f56a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_f7bc84f3-80a6-4c42-8213-df71ed4f56a7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7f910a11-18f0-49f0-b65f-aa2a81ec4d75" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_srt_CounterpartyNameAxis_7f910a11-18f0-49f0-b65f-aa2a81ec4d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7f910a11-18f0-49f0-b65f-aa2a81ec4d75" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SponsorMember_724d2b25-de2b-4fd4-bfa0-36b50846811e" xlink:href="wald-20221231.xsd#wald_SponsorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_SponsorMember_724d2b25-de2b-4fd4-bfa0-36b50846811e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_InvestorDirectorsMember_f11bb593-eae9-47d2-889c-3b4bdf18ab1e" xlink:href="wald-20221231.xsd#wald_InvestorDirectorsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_InvestorDirectorsMember_f11bb593-eae9-47d2-889c-3b4bdf18ab1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SponsorAndInvestorDirectorsMember_e20ba65d-02f9-49d6-8f3e-ff5778465f64" xlink:href="wald-20221231.xsd#wald_SponsorAndInvestorDirectorsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_SponsorAndInvestorDirectorsMember_e20ba65d-02f9-49d6-8f3e-ff5778465f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember_242bf527-04f7-4c17-9012-b0495d60904e" xlink:href="wald-20221231.xsd#wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember_242bf527-04f7-4c17-9012-b0495d60904e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BeautyVenturesLLCMember_9d9896b2-2b56-44be-9fb4-9d0d6dcf004b" xlink:href="wald-20221231.xsd#wald_BeautyVenturesLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_BeautyVenturesLLCMember_9d9896b2-2b56-44be-9fb4-9d0d6dcf004b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_AaronChatterleyMember_8ea2bb78-46ef-4788-b118-021757eecc9f" xlink:href="wald-20221231.xsd#wald_AaronChatterleyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_AaronChatterleyMember_8ea2bb78-46ef-4788-b118-021757eecc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CedarwalkMember_75f56a6d-37d3-414c-b0e5-d9b80bbdde67" xlink:href="wald-20221231.xsd#wald_CedarwalkMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_CedarwalkMember_75f56a6d-37d3-414c-b0e5-d9b80bbdde67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiChinaBusinessMember_911ba3c4-5c6f-4246-b004-af9e288b1cd3" xlink:href="wald-20221231.xsd#wald_ObagiChinaBusinessMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_ObagiChinaBusinessMember_911ba3c4-5c6f-4246-b004-af9e288b1cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiCosmeceuticalsLLCMember_83701f4a-70e5-4997-ae52-71abcb42e6f4" xlink:href="wald-20221231.xsd#wald_ObagiCosmeceuticalsLLCMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_ObagiCosmeceuticalsLLCMember_83701f4a-70e5-4997-ae52-71abcb42e6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiShanghaiMember_560dc0e6-4465-4b40-9b2c-0779136749a4" xlink:href="wald-20221231.xsd#wald_ObagiShanghaiMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_451fc6d9-443c-4b24-84db-fd1b730dad8e" xlink:to="loc_wald_ObagiShanghaiMember_560dc0e6-4465-4b40-9b2c-0779136749a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_711e1253-1e2c-4fa0-b6fb-ae641202a289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_711e1253-1e2c-4fa0-b6fb-ae641202a289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_66849acf-a6cc-42d1-82e4-aae2f7867487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_711e1253-1e2c-4fa0-b6fb-ae641202a289" xlink:to="loc_us-gaap_RelatedPartyDomain_66849acf-a6cc-42d1-82e4-aae2f7867487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_b07f4052-c884-4d94-83fc-ab403334d8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_66849acf-a6cc-42d1-82e4-aae2f7867487" xlink:to="loc_us-gaap_RelatedPartyMember_b07f4052-c884-4d94-83fc-ab403334d8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e85913f3-c036-4ba9-88de-a37ac6b3d3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e85913f3-c036-4ba9-88de-a37ac6b3d3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a1d497a2-fdff-461d-b5df-e5cf7541cc51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e85913f3-c036-4ba9-88de-a37ac6b3d3b0" xlink:to="loc_us-gaap_ClassOfStockDomain_a1d497a2-fdff-461d-b5df-e5cf7541cc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_eda328cb-f83e-4a7f-b8ca-47b2fdb0dec9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a1d497a2-fdff-461d-b5df-e5cf7541cc51" xlink:to="loc_us-gaap_CommonClassBMember_eda328cb-f83e-4a7f-b8ca-47b2fdb0dec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_e3e6fe26-79cc-4113-b9ec-f78abb6f23ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a1d497a2-fdff-461d-b5df-e5cf7541cc51" xlink:to="loc_us-gaap_CommonClassAMember_e3e6fe26-79cc-4113-b9ec-f78abb6f23ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bc6c3e00-77b3-4e1f-bb41-4ee417955175" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a1d497a2-fdff-461d-b5df-e5cf7541cc51" xlink:to="loc_us-gaap_CommonStockMember_bc6c3e00-77b3-4e1f-bb41-4ee417955175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f88aa414-e56e-4edb-9f73-2ef730744542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f88aa414-e56e-4edb-9f73-2ef730744542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_61128086-c29b-440e-bc96-8dba2ccfe2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f88aa414-e56e-4edb-9f73-2ef730744542" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_61128086-c29b-440e-bc96-8dba2ccfe2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SponsorWarrantsMember_a49af21a-8332-498f-a8ef-9b95dd3f0fd1" xlink:href="wald-20221231.xsd#wald_SponsorWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_61128086-c29b-440e-bc96-8dba2ccfe2e5" xlink:to="loc_wald_SponsorWarrantsMember_a49af21a-8332-498f-a8ef-9b95dd3f0fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PrivatePlacementWarrantsMember_3a1b4d4a-56bb-4864-a9a5-33ce3047f1a2" xlink:href="wald-20221231.xsd#wald_PrivatePlacementWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_61128086-c29b-440e-bc96-8dba2ccfe2e5" xlink:to="loc_wald_PrivatePlacementWarrantsMember_3a1b4d4a-56bb-4864-a9a5-33ce3047f1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9aa209db-acc7-4277-a416-0db4fc0282de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9aa209db-acc7-4277-a416-0db4fc0282de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6bdc95d-e4a5-4cac-8e09-5aab84245ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9aa209db-acc7-4277-a416-0db4fc0282de" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6bdc95d-e4a5-4cac-8e09-5aab84245ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiMergerMember_d72b0772-f599-4be3-83c7-aafdf0b63053" xlink:href="wald-20221231.xsd#wald_ObagiMergerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6bdc95d-e4a5-4cac-8e09-5aab84245ab0" xlink:to="loc_wald_ObagiMergerMember_d72b0772-f599-4be3-83c7-aafdf0b63053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkTransactionMember_36b8a3a7-030d-40ca-9c95-0d0ea548fc47" xlink:href="wald-20221231.xsd#wald_MilkTransactionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d6bdc95d-e4a5-4cac-8e09-5aab84245ab0" xlink:to="loc_wald_MilkTransactionMember_36b8a3a7-030d-40ca-9c95-0d0ea548fc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_17516ffe-61a2-4939-87dc-ebf8c1489691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_17516ffe-61a2-4939-87dc-ebf8c1489691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbdf3679-7775-4b87-bcae-7b70c1eadf7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_17516ffe-61a2-4939-87dc-ebf8c1489691" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbdf3679-7775-4b87-bcae-7b70c1eadf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_bb2b6d93-31e0-4cc5-914a-53505481308f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fbdf3679-7775-4b87-bcae-7b70c1eadf7d" xlink:to="loc_us-gaap_PrivatePlacementMember_bb2b6d93-31e0-4cc5-914a-53505481308f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_99f753fb-d25a-4f57-9018-c491e7533fab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_99f753fb-d25a-4f57-9018-c491e7533fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ccc9b68d-37ff-4659-9635-1525164599c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_99f753fb-d25a-4f57-9018-c491e7533fab" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ccc9b68d-37ff-4659-9635-1525164599c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ForwardPurchaseAgreementMember_9fa31d7c-4ae1-4ff8-b111-96c9eaf43178" xlink:href="wald-20221231.xsd#wald_ForwardPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ccc9b68d-37ff-4659-9635-1525164599c0" xlink:to="loc_wald_ForwardPurchaseAgreementMember_9fa31d7c-4ae1-4ff8-b111-96c9eaf43178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6a7bf695-9d83-483f-b9f5-3e2da80ddd63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_DebtInstrumentAxis_6a7bf695-9d83-483f-b9f5-3e2da80ddd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_df6613e9-271d-4402-b1cb-cc0500cdf2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6a7bf695-9d83-483f-b9f5-3e2da80ddd63" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_df6613e9-271d-4402-b1cb-cc0500cdf2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_JanuaryNoteMember_dd5835a1-d183-402f-a931-a7394c3b745e" xlink:href="wald-20221231.xsd#wald_JanuaryNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_df6613e9-271d-4402-b1cb-cc0500cdf2aa" xlink:to="loc_wald_JanuaryNoteMember_dd5835a1-d183-402f-a931-a7394c3b745e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ConvertibleWorkingCapitalNoteMember_cd77d1cf-402a-4922-b5eb-69cc768063d4" xlink:href="wald-20221231.xsd#wald_ConvertibleWorkingCapitalNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_df6613e9-271d-4402-b1cb-cc0500cdf2aa" xlink:to="loc_wald_ConvertibleWorkingCapitalNoteMember_cd77d1cf-402a-4922-b5eb-69cc768063d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_NonConvertibleWorkingCapitalNotesMember_c66cd392-f617-4137-86e0-60e9250cc084" xlink:href="wald-20221231.xsd#wald_NonConvertibleWorkingCapitalNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_df6613e9-271d-4402-b1cb-cc0500cdf2aa" xlink:to="loc_wald_NonConvertibleWorkingCapitalNotesMember_c66cd392-f617-4137-86e0-60e9250cc084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_3bfedfae-e92f-4583-9619-d5f2842dd1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_3bfedfae-e92f-4583-9619-d5f2842dd1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_4ebe502c-5ac0-4bb7-b988-7c43dfc86dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_3bfedfae-e92f-4583-9619-d5f2842dd1c3" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_4ebe502c-5ac0-4bb7-b988-7c43dfc86dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_9b0136aa-0251-4b12-b6e5-fad7705323f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_4ebe502c-5ac0-4bb7-b988-7c43dfc86dbe" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_9b0136aa-0251-4b12-b6e5-fad7705323f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f22f7a5b-f6a4-4232-84bc-62878f3dd5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f22f7a5b-f6a4-4232-84bc-62878f3dd5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_42c85618-49dc-474e-8f51-c2eb0bbedbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f22f7a5b-f6a4-4232-84bc-62878f3dd5ce" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_42c85618-49dc-474e-8f51-c2eb0bbedbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_1f104deb-70a0-4901-ba32-fb1a0db8ca83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_42c85618-49dc-474e-8f51-c2eb0bbedbe6" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_1f104deb-70a0-4901-ba32-fb1a0db8ca83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_cea27d56-7690-47fa-95de-51e1b832c323" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_srt_OwnershipAxis_cea27d56-7690-47fa-95de-51e1b832c323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_cb0e09ec-bc77-44c9-9d39-751ff57ff224" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_cea27d56-7690-47fa-95de-51e1b832c323" xlink:to="loc_srt_OwnershipDomain_cb0e09ec-bc77-44c9-9d39-751ff57ff224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_WaldencastPlcMember_476917cb-e370-4413-a33c-b19d1256e2e3" xlink:href="wald-20221231.xsd#wald_WaldencastPlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_cb0e09ec-bc77-44c9-9d39-751ff57ff224" xlink:to="loc_wald_WaldencastPlcMember_476917cb-e370-4413-a33c-b19d1256e2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_16f0ea15-6b12-434e-a839-cf09dfab5bb0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_dei_LegalEntityAxis_16f0ea15-6b12-434e-a839-cf09dfab5bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a77272a9-4edb-41eb-a761-190c4e3aa1f7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_16f0ea15-6b12-434e-a839-cf09dfab5bb0" xlink:to="loc_dei_EntityDomain_a77272a9-4edb-41eb-a761-190c4e3aa1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiChinaBusinessMember_850abee3-d14d-4927-ae11-d58229b2c7a0" xlink:href="wald-20221231.xsd#wald_ObagiChinaBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a77272a9-4edb-41eb-a761-190c4e3aa1f7" xlink:to="loc_wald_ObagiChinaBusinessMember_850abee3-d14d-4927-ae11-d58229b2c7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_CedarwalkMember_f317005e-6972-4295-8335-2a508962c038" xlink:href="wald-20221231.xsd#wald_CedarwalkMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a77272a9-4edb-41eb-a761-190c4e3aa1f7" xlink:to="loc_wald_CedarwalkMember_f317005e-6972-4295-8335-2a508962c038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9985637f-030e-4bba-a5fe-6c128673ee48" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_srt_ProductOrServiceAxis_9985637f-030e-4bba-a5fe-6c128673ee48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f03abf69-2691-49cb-973e-02628476ccce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9985637f-030e-4bba-a5fe-6c128673ee48" xlink:to="loc_srt_ProductsAndServicesDomain_f03abf69-2691-49cb-973e-02628476ccce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_c1c74cde-f60f-430d-902e-dc0446e4dd30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f03abf69-2691-49cb-973e-02628476ccce" xlink:to="loc_us-gaap_ProductMember_c1c74cde-f60f-430d-902e-dc0446e4dd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentAxis_908f3306-ec7a-494d-af7c-95b7298c7736" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentAxis"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_SupplyCommitmentAxis_908f3306-ec7a-494d-af7c-95b7298c7736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentArrangementMember_e0800229-ee9a-4703-a2e6-fa5e3b52021a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentAxis_908f3306-ec7a-494d-af7c-95b7298c7736" xlink:to="loc_us-gaap_SupplyCommitmentArrangementMember_e0800229-ee9a-4703-a2e6-fa5e3b52021a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplyCommitmentMember_03dd0b5a-1ea2-4c1d-b66f-e7ae3de799e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplyCommitmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentArrangementMember_e0800229-ee9a-4703-a2e6-fa5e3b52021a" xlink:to="loc_us-gaap_SupplyCommitmentMember_03dd0b5a-1ea2-4c1d-b66f-e7ae3de799e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7d513702-984b-4e7c-be3a-3203668c0cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7d513702-984b-4e7c-be3a-3203668c0cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b44c974a-78b7-4049-9b80-0222b2ec53f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7d513702-984b-4e7c-be3a-3203668c0cd2" xlink:to="loc_us-gaap_SegmentDomain_b44c974a-78b7-4049-9b80-0222b2ec53f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkMakeupMember_439e335f-94a7-405a-bc4a-bb4964496190" xlink:href="wald-20221231.xsd#wald_MilkMakeupMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b44c974a-78b7-4049-9b80-0222b2ec53f8" xlink:to="loc_wald_MilkMakeupMember_439e335f-94a7-405a-bc4a-bb4964496190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9f78fb6c-d6df-4223-866a-9612b949902d" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1c5281bf-cb2a-41b4-a872-2dd6c3e7c4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1c5281bf-cb2a-41b4-a872-2dd6c3e7c4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_78d968f8-2e12-432a-bf53-9e6d7366e556" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_78d968f8-2e12-432a-bf53-9e6d7366e556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4e06dbc3-18b0-4452-a593-a5067d4217d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4e06dbc3-18b0-4452-a593-a5067d4217d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d7658460-998d-4d3a-9fc2-3cc1f1f960b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d7658460-998d-4d3a-9fc2-3cc1f1f960b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_a0205b6b-46c3-47dd-9c25-235afd2cfe77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_a0205b6b-46c3-47dd-9c25-235afd2cfe77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ConversionOfStockToCommonStockConversionRatio_d16bb2cf-312c-497a-a73a-dfd393ff9967" xlink:href="wald-20221231.xsd#wald_ConversionOfStockToCommonStockConversionRatio"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ConversionOfStockToCommonStockConversionRatio_d16bb2cf-312c-497a-a73a-dfd393ff9967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage_0c2e412f-9a76-4711-839d-9a1aee8f9f67" xlink:href="wald-20221231.xsd#wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage_0c2e412f-9a76-4711-839d-9a1aee8f9f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ForwardPurchaseAgreementHurdleRate_ee8773ef-d198-4411-b8d0-9c4f3f128b6d" xlink:href="wald-20221231.xsd#wald_ForwardPurchaseAgreementHurdleRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ForwardPurchaseAgreementHurdleRate_ee8773ef-d198-4411-b8d0-9c4f3f128b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod_00f6246d-13ec-4a03-98b2-c5eb0a88c2f3" xlink:href="wald-20221231.xsd#wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod_00f6246d-13ec-4a03-98b2-c5eb0a88c2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d5c0a68f-f092-4171-bb76-c3d670d8ac09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d5c0a68f-f092-4171-bb76-c3d670d8ac09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination_20da3878-fd14-4beb-a113-571fa1b56ac9" xlink:href="wald-20221231.xsd#wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination_20da3878-fd14-4beb-a113-571fa1b56ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3276ef2f-ccae-49e1-b8ff-f5ccbe847b14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3276ef2f-ccae-49e1-b8ff-f5ccbe847b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6e29b0f1-f43c-4598-9856-7f0c4a26593d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6e29b0f1-f43c-4598-9856-7f0c4a26593d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_3b944226-5950-4c49-885c-53542ae20fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_ShortTermBorrowings_3b944226-5950-4c49-885c-53542ae20fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7816f7fe-918d-49a6-b034-fff1bc744575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7816f7fe-918d-49a6-b034-fff1bc744575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_bdf347f2-5f4a-4ba0-ba19-ee69df00f184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_LongTermDebt_bdf347f2-5f4a-4ba0-ba19-ee69df00f184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6a98b52d-2e8f-4dbf-95cb-2b0ff4db50e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6a98b52d-2e8f-4dbf-95cb-2b0ff4db50e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdministrativeFeesExpense_35bff9ff-0cc4-4466-b21e-3544ba8d692f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdministrativeFeesExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_AdministrativeFeesExpense_35bff9ff-0cc4-4466-b21e-3544ba8d692f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5a7ba784-8511-442a-9250-01d09713dc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_AccountsPayableCurrent_5a7ba784-8511-442a-9250-01d09713dc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod_76ead271-aa20-4791-8406-9f61dadae0e6" xlink:href="wald-20221231.xsd#wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod_76ead271-aa20-4791-8406-9f61dadae0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger_a84c996f-bd77-48b1-9804-6a53fa50c7eb" xlink:href="wald-20221231.xsd#wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger_a84c996f-bd77-48b1-9804-6a53fa50c7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays_678b97ca-83b1-43cb-a975-ba78055e6d5c" xlink:href="wald-20221231.xsd#wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays_678b97ca-83b1-43cb-a975-ba78055e6d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays_1cc671b2-8d75-4867-9c13-9a81bea59c03" xlink:href="wald-20221231.xsd#wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays_1cc671b2-8d75-4867-9c13-9a81bea59c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays_c331ee4a-be25-4e39-a9d4-3f61cf0a5413" xlink:href="wald-20221231.xsd#wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays_c331ee4a-be25-4e39-a9d4-3f61cf0a5413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_IndemnificationAgreementAdvanceExpensePeriod_f6cd682e-3fbc-4437-9bee-71dcb1aa54c6" xlink:href="wald-20221231.xsd#wald_IndemnificationAgreementAdvanceExpensePeriod"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_IndemnificationAgreementAdvanceExpensePeriod_f6cd682e-3fbc-4437-9bee-71dcb1aa54c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_49d81760-bb27-417c-9e25-8a476e178693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_49d81760-bb27-417c-9e25-8a476e178693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_RoyaltyPercentageOfGrossSales_0f28f3b3-9b33-467f-81ff-49a0f4464747" xlink:href="wald-20221231.xsd#wald_RoyaltyPercentageOfGrossSales"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_RoyaltyPercentageOfGrossSales_0f28f3b3-9b33-467f-81ff-49a0f4464747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7881f13e-5d94-4466-9140-ba083a31f71a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7881f13e-5d94-4466-9140-ba083a31f71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3a5bcebb-9d68-4d1e-af53-d7ee4abc83d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3a5bcebb-9d68-4d1e-af53-d7ee4abc83d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_56d1dbb9-d9bc-4889-a8ff-14e4e68262d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_56d1dbb9-d9bc-4889-a8ff-14e4e68262d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_TransitionServicesAgreementPeriod_689aee1e-1955-4d57-97e1-d3e626969379" xlink:href="wald-20221231.xsd#wald_TransitionServicesAgreementPeriod"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_TransitionServicesAgreementPeriod_689aee1e-1955-4d57-97e1-d3e626969379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_TransitionServicesAgreementExtensionPeriod_858f9d4d-37fc-4ac8-8c11-3274bf705536" xlink:href="wald-20221231.xsd#wald_TransitionServicesAgreementExtensionPeriod"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_TransitionServicesAgreementExtensionPeriod_858f9d4d-37fc-4ac8-8c11-3274bf705536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ServicesAgreementRenewalTerm_e1d31be7-58a7-400b-b2d9-55e9d6cd1260" xlink:href="wald-20221231.xsd#wald_ServicesAgreementRenewalTerm"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ServicesAgreementRenewalTerm_e1d31be7-58a7-400b-b2d9-55e9d6cd1260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ServicesAgreementFeePercentageOfIncurredCosts_8c90efb5-8f89-474f-936e-efad440830df" xlink:href="wald-20221231.xsd#wald_ServicesAgreementFeePercentageOfIncurredCosts"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_ServicesAgreementFeePercentageOfIncurredCosts_8c90efb5-8f89-474f-936e-efad440830df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PaymentsForServicesAgreementFees_6aae8833-abaa-49df-be2a-84939c6ef672" xlink:href="wald-20221231.xsd#wald_PaymentsForServicesAgreementFees"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_wald_PaymentsForServicesAgreementFees_6aae8833-abaa-49df-be2a-84939c6ef672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_90a8eeb8-1858-44b3-bd5e-3168df8d2d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_aff73cd9-8a9f-4670-b578-d68c0b553779" xlink:to="loc_us-gaap_PaymentsForFees_90a8eeb8-1858-44b3-bd5e-3168df8d2d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_25ab18c1-1542-4e5f-bb1b-d4c852df132c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_a3ae4352-7925-4bf4-ab01-2a1eb6189d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_25ab18c1-1542-4e5f-bb1b-d4c852df132c" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_a3ae4352-7925-4bf4-ab01-2a1eb6189d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c64f13d1-9860-4707-9d0d-9bd96834a42b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_a3ae4352-7925-4bf4-ab01-2a1eb6189d7f" xlink:to="loc_srt_RangeAxis_c64f13d1-9860-4707-9d0d-9bd96834a42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_71fb95c0-406b-4be7-a3f1-dcff9ab35dc2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c64f13d1-9860-4707-9d0d-9bd96834a42b" xlink:to="loc_srt_RangeMember_71fb95c0-406b-4be7-a3f1-dcff9ab35dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_434fb6ec-483b-4441-b073-cd56f2720b55" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_71fb95c0-406b-4be7-a3f1-dcff9ab35dc2" xlink:to="loc_srt_MinimumMember_434fb6ec-483b-4441-b073-cd56f2720b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_97c8a949-c63f-4793-a2cd-8852409f0313" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_71fb95c0-406b-4be7-a3f1-dcff9ab35dc2" xlink:to="loc_srt_MaximumMember_97c8a949-c63f-4793-a2cd-8852409f0313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_f104c372-f891-43aa-9722-2df5e9804f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_a3ae4352-7925-4bf4-ab01-2a1eb6189d7f" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_f104c372-f891-43aa-9722-2df5e9804f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_00c08310-f32e-49da-9ed2-a00dc19b8c84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_f104c372-f891-43aa-9722-2df5e9804f3a" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_00c08310-f32e-49da-9ed2-a00dc19b8c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SkintrinsiqDevicesMember_eef86319-494f-484c-8b8a-ffb35dca1068" xlink:href="wald-20221231.xsd#wald_SkintrinsiqDevicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_00c08310-f32e-49da-9ed2-a00dc19b8c84" xlink:to="loc_wald_SkintrinsiqDevicesMember_eef86319-494f-484c-8b8a-ffb35dca1068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_ccc093aa-62d7-4443-881c-bbd85d2cb3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_00c08310-f32e-49da-9ed2-a00dc19b8c84" xlink:to="loc_us-gaap_InventoriesMember_ccc093aa-62d7-4443-881c-bbd85d2cb3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_b2972272-cfdb-4baf-954a-764e33d18009" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_a3ae4352-7925-4bf4-ab01-2a1eb6189d7f" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_b2972272-cfdb-4baf-954a-764e33d18009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_f5ad0646-1350-4efe-93fe-01491cdfd3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_b2972272-cfdb-4baf-954a-764e33d18009" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_f5ad0646-1350-4efe-93fe-01491cdfd3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_f85a25d4-43e4-4e2e-84f2-3ebb0baa3e76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_b2972272-cfdb-4baf-954a-764e33d18009" xlink:to="loc_us-gaap_PurchaseObligation_f85a25d4-43e4-4e2e-84f2-3ebb0baa3e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_1ddd051b-48e1-4080-8564-0359de799809" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_b2972272-cfdb-4baf-954a-764e33d18009" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_1ddd051b-48e1-4080-8564-0359de799809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SEGMENTREPORTINGNarrativeDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SEGMENTREPORTINGNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SEGMENTREPORTINGNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_179054a2-9bc0-43db-9359-c3618bec5e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_9df8bc54-ebb3-431b-9c63-cf8fc82f6dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_179054a2-9bc0-43db-9359-c3618bec5e2d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_9df8bc54-ebb3-431b-9c63-cf8fc82f6dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_da97aa50-e672-494e-904d-14503c77a485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_179054a2-9bc0-43db-9359-c3618bec5e2d" xlink:to="loc_us-gaap_NumberOfReportableSegments_da97aa50-e672-494e-904d-14503c77a485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4a8c4f10-dda1-4d05-9e50-9be2e1a5d531" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_003dc6c2-b517-47aa-8dac-e00a82b333cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4a8c4f10-dda1-4d05-9e50-9be2e1a5d531" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_003dc6c2-b517-47aa-8dac-e00a82b333cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_07998a70-4dec-48f8-bf72-7b5cee50cf55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_003dc6c2-b517-47aa-8dac-e00a82b333cc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_07998a70-4dec-48f8-bf72-7b5cee50cf55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_51610ccd-86dd-4239-9813-e4df10c87bce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_07998a70-4dec-48f8-bf72-7b5cee50cf55" xlink:to="loc_us-gaap_SegmentDomain_51610ccd-86dd-4239-9813-e4df10c87bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiSkincareMember_31b9301c-6fff-4edb-8e96-c4451a5d3ee8" xlink:href="wald-20221231.xsd#wald_ObagiSkincareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_51610ccd-86dd-4239-9813-e4df10c87bce" xlink:to="loc_wald_ObagiSkincareMember_31b9301c-6fff-4edb-8e96-c4451a5d3ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_MilkMakeupMember_56d2998a-b02f-409c-9673-70285998aeef" xlink:href="wald-20221231.xsd#wald_MilkMakeupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_51610ccd-86dd-4239-9813-e4df10c87bce" xlink:to="loc_wald_MilkMakeupMember_56d2998a-b02f-409c-9673-70285998aeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_51bb09e3-d2b0-4837-8e6e-6a74c06ac85a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_003dc6c2-b517-47aa-8dac-e00a82b333cc" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_51bb09e3-d2b0-4837-8e6e-6a74c06ac85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c482e811-5ca6-449e-bd89-8d81ecf5fb83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_51bb09e3-d2b0-4837-8e6e-6a74c06ac85a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c482e811-5ca6-449e-bd89-8d81ecf5fb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_602b8592-4fc2-4d1d-b1cf-ba24a5e74508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_51bb09e3-d2b0-4837-8e6e-6a74c06ac85a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_602b8592-4fc2-4d1d-b1cf-ba24a5e74508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_f07c6a9a-2742-4e22-8a6b-28ded64190a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_51bb09e3-d2b0-4837-8e6e-6a74c06ac85a" xlink:to="loc_us-gaap_GrossProfit_f07c6a9a-2742-4e22-8a6b-28ded64190a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentGrossProfittoNetIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SEGMENTREPORTINGReconciliationofSegmentGrossProfittoNetIncomeLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentGrossProfittoNetIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e8ea2ade-5c47-4183-aa57-a10e123ee12a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_ea1635b4-e788-4d04-8788-2dff20180a00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e8ea2ade-5c47-4183-aa57-a10e123ee12a" xlink:to="loc_us-gaap_GrossProfit_ea1635b4-e788-4d04-8788-2dff20180a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0dc85155-60b0-4f50-88de-29a7edd01a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e8ea2ade-5c47-4183-aa57-a10e123ee12a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0dc85155-60b0-4f50-88de-29a7edd01a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1f396dc6-048f-4444-9e8f-083a06b4ac8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e8ea2ade-5c47-4183-aa57-a10e123ee12a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1f396dc6-048f-4444-9e8f-083a06b4ac8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_8695f228-d27d-4ca3-875d-7d8b700941f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e8ea2ade-5c47-4183-aa57-a10e123ee12a" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_8695f228-d27d-4ca3-875d-7d8b700941f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2e3e780b-5c85-42d1-82fa-f71560305514" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e8ea2ade-5c47-4183-aa57-a10e123ee12a" xlink:to="loc_us-gaap_InterestExpense_2e3e780b-5c85-42d1-82fa-f71560305514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_163c1f46-9d9a-4a0e-9bb2-1864d904868a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e8ea2ade-5c47-4183-aa57-a10e123ee12a" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_163c1f46-9d9a-4a0e-9bb2-1864d904868a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fc815b4f-3388-4c63-821a-44d3e281d551" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e8ea2ade-5c47-4183-aa57-a10e123ee12a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fc815b4f-3388-4c63-821a-44d3e281d551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8d424b6c-e342-4441-b518-44eeaab58034" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e8ea2ade-5c47-4183-aa57-a10e123ee12a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8d424b6c-e342-4441-b518-44eeaab58034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c5aef289-21b1-43c8-80c2-21577b27eb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e8ea2ade-5c47-4183-aa57-a10e123ee12a" xlink:to="loc_us-gaap_ProfitLoss_c5aef289-21b1-43c8-80c2-21577b27eb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/EMPLOYEEBENEFITPLANDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#EMPLOYEEBENEFITPLANDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/EMPLOYEEBENEFITPLANDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9b7843ce-9231-453d-baf8-cf9def18ba7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_89f8f11d-ab80-42d6-be07-cd0715bf4803" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9b7843ce-9231-453d-baf8-cf9def18ba7f" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_89f8f11d-ab80-42d6-be07-cd0715bf4803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_75818721-65b5-4343-9e4c-f5769e699c55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_75818721-65b5-4343-9e4c-f5769e699c55" xlink:to="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_63e4d7ef-17c0-46d5-98bc-75549d4c6b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_63e4d7ef-17c0-46d5-98bc-75549d4c6b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_49abcbf1-f388-484f-9c95-9d86235c3b11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_63e4d7ef-17c0-46d5-98bc-75549d4c6b2e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_49abcbf1-f388-484f-9c95-9d86235c3b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_70e12530-a12e-4451-a47b-ce46fc2db3af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_49abcbf1-f388-484f-9c95-9d86235c3b11" xlink:to="loc_us-gaap_SubsequentEventMember_70e12530-a12e-4451-a47b-ce46fc2db3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_73fa550c-2425-43fe-baef-c165e23d90b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_us-gaap_AwardTypeAxis_73fa550c-2425-43fe-baef-c165e23d90b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_481391de-dc5e-4f56-89f6-7821c78a0325" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_73fa550c-2425-43fe-baef-c165e23d90b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_481391de-dc5e-4f56-89f6-7821c78a0325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_StockGrowthIncentiveAwardsSGIAwardsMember_3389bdfe-b054-4208-896d-1132705bb75c" xlink:href="wald-20221231.xsd#wald_StockGrowthIncentiveAwardsSGIAwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_481391de-dc5e-4f56-89f6-7821c78a0325" xlink:to="loc_wald_StockGrowthIncentiveAwardsSGIAwardsMember_3389bdfe-b054-4208-896d-1132705bb75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2ce8ade5-bc65-4145-b531-6012ab5d2808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2ce8ade5-bc65-4145-b531-6012ab5d2808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66c4b0fc-ef07-4da3-807a-6bd0141586b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2ce8ade5-bc65-4145-b531-6012ab5d2808" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66c4b0fc-ef07-4da3-807a-6bd0141586b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_VietnamPurchaseAgreementMember_ba42b998-1a63-4ab8-a2c5-6d04a1cfe3b6" xlink:href="wald-20221231.xsd#wald_VietnamPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66c4b0fc-ef07-4da3-807a-6bd0141586b6" xlink:to="loc_wald_VietnamPurchaseAgreementMember_ba42b998-1a63-4ab8-a2c5-6d04a1cfe3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_488fce32-5564-4121-9308-21d0da457964" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_srt_OwnershipAxis_488fce32-5564-4121-9308-21d0da457964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_0a2b76b6-4752-460f-974c-511af2dbc7c5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_488fce32-5564-4121-9308-21d0da457964" xlink:to="loc_srt_OwnershipDomain_0a2b76b6-4752-460f-974c-511af2dbc7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ObagiBlueSeaHoldingLLCMember_48a2db78-28c4-42cf-8651-c81b1dd500df" xlink:href="wald-20221231.xsd#wald_ObagiBlueSeaHoldingLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_0a2b76b6-4752-460f-974c-511af2dbc7c5" xlink:to="loc_wald_ObagiBlueSeaHoldingLLCMember_48a2db78-28c4-42cf-8651-c81b1dd500df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_60826397-aea9-4f76-aa8a-064e59ba991e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_dei_LegalEntityAxis_60826397-aea9-4f76-aa8a-064e59ba991e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9cfbe12d-782f-4f1c-aec7-08a51373c107" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_60826397-aea9-4f76-aa8a-064e59ba991e" xlink:to="loc_dei_EntityDomain_9cfbe12d-782f-4f1c-aec7-08a51373c107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_SADistributorMember_f58a7f51-fb54-4bfe-8b93-f1764c081c9d" xlink:href="wald-20221231.xsd#wald_SADistributorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9cfbe12d-782f-4f1c-aec7-08a51373c107" xlink:to="loc_wald_SADistributorMember_f58a7f51-fb54-4bfe-8b93-f1764c081c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a9a839ca-1edb-4e93-bed8-62871e8e587e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_srt_StatementGeographicalAxis_a9a839ca-1edb-4e93-bed8-62871e8e587e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4fc3f154-72a6-4cd4-a678-708d4120378d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a9a839ca-1edb-4e93-bed8-62871e8e587e" xlink:to="loc_srt_SegmentGeographicalDomain_4fc3f154-72a6-4cd4-a678-708d4120378d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX_5df5566b-a46b-432e-90c0-2ffe31660ade" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_TX"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4fc3f154-72a6-4cd4-a678-708d4120378d" xlink:to="loc_stpr_TX_5df5566b-a46b-432e-90c0-2ffe31660ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_1f5fc1fe-6b41-4e71-91c3-bc39cfc11014" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4fc3f154-72a6-4cd4-a678-708d4120378d" xlink:to="loc_stpr_CA_1f5fc1fe-6b41-4e71-91c3-bc39cfc11014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_4f16192d-ee32-48c8-9356-f411f3d34bb3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_4f16192d-ee32-48c8-9356-f411f3d34bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_8d6752f1-17a9-4489-b6ce-535cd06697f4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_4f16192d-ee32-48c8-9356-f411f3d34bb3" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_8d6752f1-17a9-4489-b6ce-535cd06697f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_c1789e85-073d-4427-89f6-b1083610d7ee" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficeBuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_8d6752f1-17a9-4489-b6ce-535cd06697f4" xlink:to="loc_srt_OfficeBuildingMember_c1789e85-073d-4427-89f6-b1083610d7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WarehouseMember_9225fd1f-5c17-4e3b-802b-86726df74525" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WarehouseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_8d6752f1-17a9-4489-b6ce-535cd06697f4" xlink:to="loc_srt_WarehouseMember_9225fd1f-5c17-4e3b-802b-86726df74525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9d484b30-0f37-4352-819b-fb401265ad27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9d484b30-0f37-4352-819b-fb401265ad27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b8d814c8-7025-4c2b-8aad-3e6bff2dac01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9d484b30-0f37-4352-819b-fb401265ad27" xlink:to="loc_us-gaap_ClassOfStockDomain_b8d814c8-7025-4c2b-8aad-3e6bff2dac01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_c8b939b9-e756-4ea0-ba10-5e24d7d85b74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b8d814c8-7025-4c2b-8aad-3e6bff2dac01" xlink:to="loc_us-gaap_CommonClassAMember_c8b939b9-e756-4ea0-ba10-5e24d7d85b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_1b9bdda7-19b4-411e-a185-be71d374a032" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b8d814c8-7025-4c2b-8aad-3e6bff2dac01" xlink:to="loc_us-gaap_CommonClassBMember_1b9bdda7-19b4-411e-a185-be71d374a032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ba173dec-a897-4573-9533-dea578eb8379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ba173dec-a897-4573-9533-dea578eb8379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2cbfff04-d9df-49ed-b809-f7ded4ebc660" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ba173dec-a897-4573-9533-dea578eb8379" xlink:to="loc_us-gaap_EquityComponentDomain_2cbfff04-d9df-49ed-b809-f7ded4ebc660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_17927107-4467-43c7-960b-92a2086d2d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2cbfff04-d9df-49ed-b809-f7ded4ebc660" xlink:to="loc_us-gaap_WarrantMember_17927107-4467-43c7-960b-92a2086d2d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1cfeb785-c1f8-44e7-80a8-1ed5f0206634" xlink:to="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f720ce8b-1e25-4047-880c-c18d163ce938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f720ce8b-1e25-4047-880c-c18d163ce938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent_2187732f-08f5-41ac-a5ff-63ccf027e6cf" xlink:href="wald-20221231.xsd#wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent_2187732f-08f5-41ac-a5ff-63ccf027e6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_61c05417-a47b-4762-9b1d-d5c350e4a8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_61c05417-a47b-4762-9b1d-d5c350e4a8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d4b0f45c-6459-48bf-a85d-70e06e8af2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d4b0f45c-6459-48bf-a85d-70e06e8af2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_NumberOfLeaseAgreements_e868eeb2-6ada-4b0f-8821-75e27304010b" xlink:href="wald-20221231.xsd#wald_NumberOfLeaseAgreements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_wald_NumberOfLeaseAgreements_e868eeb2-6ada-4b0f-8821-75e27304010b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetRentableArea_ecd452f7-5ebd-4781-a6b7-8ef2063172d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetRentableArea"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_NetRentableArea_ecd452f7-5ebd-4781-a6b7-8ef2063172d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_357c9bee-fead-4489-89fe-0f4c00986ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_357c9bee-fead-4489-89fe-0f4c00986ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9572abe9-902b-4f39-aef6-44c44cfa78fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9572abe9-902b-4f39-aef6-44c44cfa78fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_BusinessAcquisitionEarnoutPeriod_8c3b7472-9c6e-4926-8d0b-b2476f8bcae2" xlink:href="wald-20221231.xsd#wald_BusinessAcquisitionEarnoutPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_wald_BusinessAcquisitionEarnoutPeriod_8c3b7472-9c6e-4926-8d0b-b2476f8bcae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7652fbed-d282-4b41-bb41-3580d5d4cc39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_7652fbed-d282-4b41-bb41-3580d5d4cc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_5ac0c1fb-cfea-47f2-94ac-d6b2fc771fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_5ac0c1fb-cfea-47f2-94ac-d6b2fc771fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7bf0720e-bf23-4da9-823c-6e1da18fb3db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7bf0720e-bf23-4da9-823c-6e1da18fb3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_92a2de3a-0369-4892-a939-fd4cdecad1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_CommonStockSharesIssued_92a2de3a-0369-4892-a939-fd4cdecad1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2f0c758e-8a02-445f-98f8-fc5f9a2cdbff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_4d3019eb-87ef-4c07-8bf5-0d32d5a419f0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2f0c758e-8a02-445f-98f8-fc5f9a2cdbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_9905fcce-cf04-4ed3-b6f0-93db82ca0969" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedBalanceSheetStatementTable_ee52a159-b0b4-4f8e-955b-618fbffa5e2f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_9905fcce-cf04-4ed3-b6f0-93db82ca0969" xlink:to="loc_srt_CondensedBalanceSheetStatementTable_ee52a159-b0b4-4f8e-955b-618fbffa5e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_bcfcafed-747f-44ff-a1f4-6cee85c7b380" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedBalanceSheetStatementTable_ee52a159-b0b4-4f8e-955b-618fbffa5e2f" xlink:to="loc_srt_ConsolidatedEntitiesAxis_bcfcafed-747f-44ff-a1f4-6cee85c7b380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_2c7d8206-f37b-4d6d-a72a-ae0d3947f2ae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_bcfcafed-747f-44ff-a1f4-6cee85c7b380" xlink:to="loc_srt_ConsolidatedEntitiesDomain_2c7d8206-f37b-4d6d-a72a-ae0d3947f2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_fda0879a-bb76-4502-b2cf-bff656fb082b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_2c7d8206-f37b-4d6d-a72a-ae0d3947f2ae" xlink:to="loc_srt_ParentCompanyMember_fda0879a-bb76-4502-b2cf-bff656fb082b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f77ebae8-5f4e-4f82-9c1d-997d3983197b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedBalanceSheetStatementTable_ee52a159-b0b4-4f8e-955b-618fbffa5e2f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f77ebae8-5f4e-4f82-9c1d-997d3983197b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_947e5ee1-1d6d-45c8-a73f-70a6fcbc326b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f77ebae8-5f4e-4f82-9c1d-997d3983197b" xlink:to="loc_us-gaap_ClassOfStockDomain_947e5ee1-1d6d-45c8-a73f-70a6fcbc326b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_f78ca44a-69b2-4a2b-b838-fb073a955aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_947e5ee1-1d6d-45c8-a73f-70a6fcbc326b" xlink:to="loc_us-gaap_CommonClassAMember_f78ca44a-69b2-4a2b-b838-fb073a955aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassBMember_40092241-e326-426d-8350-24a964a7df81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonClassBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_947e5ee1-1d6d-45c8-a73f-70a6fcbc326b" xlink:to="loc_us-gaap_CommonClassBMember_40092241-e326-426d-8350-24a964a7df81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedBalanceSheetStatementsCaptionsLineItems_6d6c1000-3ccb-4032-9f22-8fef8404b920" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedBalanceSheetStatementTable_ee52a159-b0b4-4f8e-955b-618fbffa5e2f" xlink:to="loc_srt_CondensedBalanceSheetStatementsCaptionsLineItems_6d6c1000-3ccb-4032-9f22-8fef8404b920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_23eb76a2-85b5-421d-aea1-a903026c5ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedBalanceSheetStatementsCaptionsLineItems_6d6c1000-3ccb-4032-9f22-8fef8404b920" xlink:to="loc_us-gaap_AssetsAbstract_23eb76a2-85b5-421d-aea1-a903026c5ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1d3d8071-e9b2-4702-a8cd-4117ea59f2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23eb76a2-85b5-421d-aea1-a903026c5ca7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1d3d8071-e9b2-4702-a8cd-4117ea59f2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_734af6fe-5518-4bf2-aea5-f9c1e17dcbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d3d8071-e9b2-4702-a8cd-4117ea59f2a5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_734af6fe-5518-4bf2-aea5-f9c1e17dcbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_544ceb34-b7c1-48af-b3b7-5a6b2bd94acf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1d3d8071-e9b2-4702-a8cd-4117ea59f2a5" xlink:to="loc_us-gaap_AssetsCurrent_544ceb34-b7c1-48af-b3b7-5a6b2bd94acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_InvestmentInSubsidiary_da4927e2-9333-4f4f-9333-5faa1e047b1b" xlink:href="wald-20221231.xsd#wald_InvestmentInSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23eb76a2-85b5-421d-aea1-a903026c5ca7" xlink:to="loc_wald_InvestmentInSubsidiary_da4927e2-9333-4f4f-9333-5faa1e047b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_88d99d4b-b93a-4eca-92b5-6117b6ee3954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23eb76a2-85b5-421d-aea1-a903026c5ca7" xlink:to="loc_us-gaap_Assets_88d99d4b-b93a-4eca-92b5-6117b6ee3954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_550ef399-a227-4555-953b-064c48df6bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedBalanceSheetStatementsCaptionsLineItems_6d6c1000-3ccb-4032-9f22-8fef8404b920" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_550ef399-a227-4555-953b-064c48df6bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d8433788-4284-4876-b900-e086654661a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_550ef399-a227-4555-953b-064c48df6bfd" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d8433788-4284-4876-b900-e086654661a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_IntercompanyPayables_8ec5a3d6-0e2a-4ce4-85e7-4ef5c5709fc3" xlink:href="wald-20221231.xsd#wald_IntercompanyPayables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d8433788-4284-4876-b900-e086654661a4" xlink:to="loc_wald_IntercompanyPayables_8ec5a3d6-0e2a-4ce4-85e7-4ef5c5709fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_76e35175-5554-4d07-a115-3571e8bc1689" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_550ef399-a227-4555-953b-064c48df6bfd" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_76e35175-5554-4d07-a115-3571e8bc1689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bc865f3c-cf4b-45d6-bb9f-8d07d4e6569d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_550ef399-a227-4555-953b-064c48df6bfd" xlink:to="loc_us-gaap_Liabilities_bc865f3c-cf4b-45d6-bb9f-8d07d4e6569d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_550ef399-a227-4555-953b-064c48df6bfd" xlink:to="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ebe985d8-0819-4097-8e40-3ef2becb7f90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ebe985d8-0819-4097-8e40-3ef2becb7f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_40babbc0-6ac0-4a50-84f4-fb4a8a7bd845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_40babbc0-6ac0-4a50-84f4-fb4a8a7bd845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ae3227fe-fdbe-4a04-b27c-89ef4ee6994d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ae3227fe-fdbe-4a04-b27c-89ef4ee6994d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_164fb41d-9a59-4d65-a377-07b47bd9697b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_CommonStockValue_164fb41d-9a59-4d65-a377-07b47bd9697b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f9747b6e-adac-450f-85c4-fe39cd0a27a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f9747b6e-adac-450f-85c4-fe39cd0a27a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cddd9636-5b06-461a-bf0e-2de7f9d7273e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cddd9636-5b06-461a-bf0e-2de7f9d7273e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d283608f-8bda-4a46-a7f0-718bb26e4274" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d283608f-8bda-4a46-a7f0-718bb26e4274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f98b97ac-1af2-4910-8dfa-d5264494a2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_StockholdersEquity_f98b97ac-1af2-4910-8dfa-d5264494a2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_fe9c7336-b17f-41a8-a36a-85f22d357265" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_MinorityInterest_fe9c7336-b17f-41a8-a36a-85f22d357265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b64f7c40-9af4-4201-b8a6-558df69e8c81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f4cd32ca-02d0-436a-b4ba-3ac7e36a1055" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b64f7c40-9af4-4201-b8a6-558df69e8c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2a3f94a4-c207-4dfe-9c13-1f76b0c286a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_550ef399-a227-4555-953b-064c48df6bfd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2a3f94a4-c207-4dfe-9c13-1f76b0c286a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_8cb741f7-328f-4668-822f-028276d74eed" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedIncomeStatementTable_72dc01d5-ac1b-4125-9953-71b217307c5e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_8cb741f7-328f-4668-822f-028276d74eed" xlink:to="loc_srt_CondensedIncomeStatementTable_72dc01d5-ac1b-4125-9953-71b217307c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_0371cfb7-791b-4a5f-83e5-4c6b330214f3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementTable_72dc01d5-ac1b-4125-9953-71b217307c5e" xlink:to="loc_srt_ConsolidatedEntitiesAxis_0371cfb7-791b-4a5f-83e5-4c6b330214f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_a4e6ae4f-41c3-41b9-bd1a-c852e77ffe7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0371cfb7-791b-4a5f-83e5-4c6b330214f3" xlink:to="loc_srt_ConsolidatedEntitiesDomain_a4e6ae4f-41c3-41b9-bd1a-c852e77ffe7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_c762f13a-d31a-4f5d-9c5e-676eae3cb068" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_a4e6ae4f-41c3-41b9-bd1a-c852e77ffe7c" xlink:to="loc_srt_ParentCompanyMember_c762f13a-d31a-4f5d-9c5e-676eae3cb068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementTable_72dc01d5-ac1b-4125-9953-71b217307c5e" xlink:to="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4bbfb8b6-368b-4bcc-88a2-924584be49e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4bbfb8b6-368b-4bcc-88a2-924584be49e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a1b877ef-5bc5-4f0f-85e8-802a81078936" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a1b877ef-5bc5-4f0f-85e8-802a81078936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_472b1703-e4fa-4d6c-8a73-f91f6cd2351f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_OperatingIncomeLoss_472b1703-e4fa-4d6c-8a73-f91f6cd2351f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_f87a85ca-5250-4fdc-a496-00e3945849a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeDisclosureNonoperatingAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_f87a85ca-5250-4fdc-a496-00e3945849a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_0a223372-7505-40e3-9136-af9cb641b548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_f87a85ca-5250-4fdc-a496-00e3945849a0" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_0a223372-7505-40e3-9136-af9cb641b548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1396b652-3045-408a-8a3a-7b2fd4942442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeDisclosureNonoperatingAbstract_f87a85ca-5250-4fdc-a496-00e3945849a0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1396b652-3045-408a-8a3a-7b2fd4942442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c7943de2-6434-404f-98ce-24629149960e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c7943de2-6434-404f-98ce-24629149960e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ec4a2293-2444-4122-b806-a3eadb35dd65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ec4a2293-2444-4122-b806-a3eadb35dd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_87b0c140-8b26-436a-baa9-900d179975b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_87b0c140-8b26-436a-baa9-900d179975b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_d37237ac-fe8a-4fe1-a945-fae526fc041a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_d37237ac-fe8a-4fe1-a945-fae526fc041a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_948af752-d1b1-4fe6-a3ce-c37db3fd991c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_NetIncomeLoss_948af752-d1b1-4fe6-a3ce-c37db3fd991c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a6c07ee1-b77a-4a5f-8976-16bcd8c6e0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a6c07ee1-b77a-4a5f-8976-16bcd8c6e0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6aa8a0f7-44af-4d66-8926-52187501bd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedIncomeStatementsCaptionsLineItems_8a63617f-8be5-4eb6-b806-dc931aa46213" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6aa8a0f7-44af-4d66-8926-52187501bd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails" xlink:type="simple" xlink:href="wald-20221231.xsd#SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"/>
  <link:presentationLink xlink:role="http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_47f537eb-4734-4455-a0f6-5f989f26fc76" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementTable_9b9cbefa-14eb-4995-bd2f-dba0460ffff0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedCashFlowStatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_47f537eb-4734-4455-a0f6-5f989f26fc76" xlink:to="loc_srt_CondensedCashFlowStatementTable_9b9cbefa-14eb-4995-bd2f-dba0460ffff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_919e981d-6ed3-42d3-8727-08feed452901" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementTable_9b9cbefa-14eb-4995-bd2f-dba0460ffff0" xlink:to="loc_srt_ConsolidatedEntitiesAxis_919e981d-6ed3-42d3-8727-08feed452901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_d7ef17fd-45a9-42e8-8136-7db14d0ebe36" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_919e981d-6ed3-42d3-8727-08feed452901" xlink:to="loc_srt_ConsolidatedEntitiesDomain_d7ef17fd-45a9-42e8-8136-7db14d0ebe36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_7515ccf2-a225-4b0d-b928-3a2ea3c734dd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_d7ef17fd-45a9-42e8-8136-7db14d0ebe36" xlink:to="loc_srt_ParentCompanyMember_7515ccf2-a225-4b0d-b928-3a2ea3c734dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_efa69bf5-4a22-4dba-8064-8ada55099fdc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementTable_9b9cbefa-14eb-4995-bd2f-dba0460ffff0" xlink:to="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_efa69bf5-4a22-4dba-8064-8ada55099fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7ff0e5ec-4715-4b70-b260-c4fc49152a93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_efa69bf5-4a22-4dba-8064-8ada55099fdc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7ff0e5ec-4715-4b70-b260-c4fc49152a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e79b1446-f02c-44ca-ae03-ea0728012a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7ff0e5ec-4715-4b70-b260-c4fc49152a93" xlink:to="loc_us-gaap_ProfitLoss_e79b1446-f02c-44ca-ae03-ea0728012a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_095a008c-0695-496a-b601-65382f8f3859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7ff0e5ec-4715-4b70-b260-c4fc49152a93" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_095a008c-0695-496a-b601-65382f8f3859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a758f18b-f95d-423b-bfa5-4f533bdd23bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_095a008c-0695-496a-b601-65382f8f3859" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a758f18b-f95d-423b-bfa5-4f533bdd23bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_8f182387-7608-4b1f-aa0f-bb76d34cbfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a758f18b-f95d-423b-bfa5-4f533bdd23bb" xlink:to="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_8f182387-7608-4b1f-aa0f-bb76d34cbfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_9872a0bf-54aa-44e4-8bd5-752ba23bf444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_a758f18b-f95d-423b-bfa5-4f533bdd23bb" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities_9872a0bf-54aa-44e4-8bd5-752ba23bf444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_58dc9c5e-93d7-434c-ae20-fc473fb9b373" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7ff0e5ec-4715-4b70-b260-c4fc49152a93" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_58dc9c5e-93d7-434c-ae20-fc473fb9b373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_df2af54c-a002-4f16-b5b2-da62a83ea5de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_efa69bf5-4a22-4dba-8064-8ada55099fdc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_df2af54c-a002-4f16-b5b2-da62a83ea5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_ProceedsFromTrustAccount_921d25e0-d8b1-4942-88c2-5a42598c0df1" xlink:href="wald-20221231.xsd#wald_ProceedsFromTrustAccount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_df2af54c-a002-4f16-b5b2-da62a83ea5de" xlink:to="loc_wald_ProceedsFromTrustAccount_921d25e0-d8b1-4942-88c2-5a42598c0df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_728e538c-4b45-4a7a-b39a-f36bb97f0354" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_df2af54c-a002-4f16-b5b2-da62a83ea5de" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_728e538c-4b45-4a7a-b39a-f36bb97f0354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_880cc435-b488-4400-965d-87a07b2dc695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_efa69bf5-4a22-4dba-8064-8ada55099fdc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_880cc435-b488-4400-965d-87a07b2dc695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_1eeca15c-52e3-4ec4-86e3-52c907f25d26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_880cc435-b488-4400-965d-87a07b2dc695" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_1eeca15c-52e3-4ec4-86e3-52c907f25d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates_5cf99c68-1c04-4194-9754-832e81a2ba12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_880cc435-b488-4400-965d-87a07b2dc695" xlink:to="loc_us-gaap_PaymentsOfDistributionsToAffiliates_5cf99c68-1c04-4194-9754-832e81a2ba12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_wald_PaymentsOfExpensesOnBehalfOfSubsidiaries_f52763e5-6748-4c18-aef5-9e69cf223ac1" xlink:href="wald-20221231.xsd#wald_PaymentsOfExpensesOnBehalfOfSubsidiaries"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_880cc435-b488-4400-965d-87a07b2dc695" xlink:to="loc_wald_PaymentsOfExpensesOnBehalfOfSubsidiaries_f52763e5-6748-4c18-aef5-9e69cf223ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_07077d0a-6a94-4f3c-a5a0-e681db3ce04f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_880cc435-b488-4400-965d-87a07b2dc695" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_07077d0a-6a94-4f3c-a5a0-e681db3ce04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_f9920a20-1260-43c2-8b90-b9ff151386d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_efa69bf5-4a22-4dba-8064-8ada55099fdc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_f9920a20-1260-43c2-8b90-b9ff151386d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22545a24-ca06-45a7-9e4b-c67581c9a54b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_efa69bf5-4a22-4dba-8064-8ada55099fdc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22545a24-ca06-45a7-9e4b-c67581c9a54b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a45484f2-2b9e-4e75-9569-8d3c36343efb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_efa69bf5-4a22-4dba-8064-8ada55099fdc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a45484f2-2b9e-4e75-9569-8d3c36343efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>wald-20221231_g1.jpg
<TEXT>
begin 644 wald-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $MA>6QE92!(
M97)N86YD97H    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,Y
M,@  DI(  @    ,Y,@  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M***^@.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVL44&1ZA 2/P+$5R_P#,1\B_LGIGP2A^T_!36(/,CB\VXN4\R5MJ)F%!ECV
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>YA54CO+^S\R8!>%W,"-^  /G#5RE%#C%A=EO5=4O-;U6XU+4YC/=7+[Y)"
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M^&<?"/\ T$=:_P"_\7_QJC_AG'PC_P!!'6O^_P#%_P#&J/K5,.1GS117TO\
M\,X^$?\ H(ZU_P!_XO\ XU1_PSCX1_Z".M?]_P"+_P"-4?6J8<C/FBBOI?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUC:62UNLG?@9(!(4@XYP0.*S]E/EYK:#YE>QZ!11168PHHHH **** "BBB@
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M""Q!PS''WVZ8ZT>&O"&A^$+::W\.V/V.*=P\B^<\FY@,9^=CBG.K&7-;K;\
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M-U)M6;_K<+(****S&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;"#40]Q<3&"#$,FR9P"2$?;M8#:<D$@' SDBJFH:#>W&H>$6CCQ'IS2BZ=7
M,0:U>,$>OS$#C/7TK LM!\1I'X/TF;0XHX/#UTOG7ZW$965%A= Z+G=AL@L"
M <D<$9(.6#U_KJ%V==IWC+0=5U);&POC)/)N\K=!(B3;?O>6[*%DQ@_=)Z53
M\6^)#X>UKP[YUSY%C=74T=UB/>9 ('9%  +9+A<!>2<#OBL3PSHOB/2-;L+6
M&UO+72+=W$T-W=07%M&FU@HMR )@<D??Q\I(]*V/&6GZK/K'AS4=(TY-1_LV
M\DFGA:54^0PNN1N(&[)X]\9P,D'+%2MT#6QIKXKT5M";6!?*+)7\MF,;!P^<
M;#&1OWYXVXS[4R/QAH4FDSZD+[;;V\@BE$D3I(CG&$,94/N.1A<9.>*Y*^\)
M:QJ6FW.I2V;0W<VMQZH-,BO3"_EI"(=GFQD!9" 7R&QG SUJ*[\&WM]8O?6V
MBWEI<1ZA;W7V:XUR62YNDC1T(,WF,(SB0[=K_P (R13Y(=PNSKSXV\/+I+ZE
M)J(BM8YUMY#+$Z-%(Q 571E#+G(Z@<<]*MZ-XBTS7Q/_ &7<-(]NP6:*2%XI
M(\C(RC@, >QQ@XXKBSX4O;FV\^#0[BSDDU?3YY4O=4:[GDAAE!9G9Y'48!.%
M5B2!]!740:7=Q_$:]U3RMME-I4%N) P^:5996(QUX5EY([_6IE&%M!ZF=J'C
M^UT[QVFB317)MQ9R2RO'IUQ(_FAXPH7:A!3:S98 C.!D=#H2^./#\6L2:5]L
MDDO8IQ;R10VDTGEN0" Q5" #N')..O/!Q6UJUU.S\:V&O:=IDFJ0K8364L,$
ML:2(6DC</^\901\A!&<]*L^&-*NM-OO$4EY$(UO=6:X@8,#OC,,2@\=.588/
M/%%H6N&HUO'WAI=02R.I?OI+E;2,BWE,<DQ8+L63;M8[C@X)QSG&#2'Q_P"&
M1>R6IU(AXKEK25S;R^7%*&V%'DV[5.?4C/!'!%<K'H7B2'0= \-C0U>+2-4M
M9I-1^TQ[)88YPV]5SNWE>2"!_%@DD5>O/"^JR_#7Q7I26H-[J-Y?36T7F+^\
M629F0YS@9&#R1COBJY(=_P 179T=[XRT'3M5.G7E]Y=PCHDA\F1HXF;&T/(%
MV(3D<,1U'K7,ZEXKFU/XAG0+#5]3TJ"&V3YK;26=I)VE9#N,D3 1@*,/PIR?
MFXINN:+XDM_$&H3^&+2\@:\F67='=P/93-M52T\4@WJ<+@^7G( .<].B&D7;
M_$*^U)D*6<VCPVJ3*XSY@EE9@!U& RG/3GZTDHQ5PU);+QCH-YJ2:;;:CYMP
MSM$C&)PDSK]Y4DVA'88.0I/0U%:^/?#E[>FUM+Z2:17D1BEI,41DSN#/LVKC
M:>I&1@CJ,\]8:%KS:1X?\-7.DQVUOHMU;R2:FLZ&.9(#E2B [PSX .X#&YN3
M6WX9T2]T[P'/IEW"([MY+TA-P.1)/*R'(XY5E/MGFAQ@@U"#XD>%+F)9(M4)
M22,21%K69?/' Q'E/WC98 JN2.XXI\OBFVOUT>?1=2@6&YU/[).L\,BNQ$4C
M&+:5RCY53\VW@>X!S=/\-ZC!9_#Y);15.C1 7R[U/E-]C:/U^;YR!QGKGIS5
M>Z\+ZM)XUDOHK4?9&\0V]Z&\Q1^Z2Q,3/C.?]8<8ZGKC'-'+"^@:F];>//#=
MY?1VEOJ.Z66=K=&,$BQF4,5\O>5VAL@X7.3P1D$5)K'C7P_H%Q+!JM_Y+P1>
M;-MADD6)><;V52%)QP"03V!S7.CPMJJ_# :2MJHU$:K]I""1>%_M#S=^[./]
M7SUSVZ\5C^-+F?2=/\=VEO!:7\>I1^:\QNHPUJQMT3RW0G>3A04V@Y+#IUIJ
M$6[(+L]$UC6[?2= EU1O,DB6/>GE0/*6R,K\J G'OCBN.D^(9NO VC:Q%*]G
M,]SIPU%WLY(HE65U\T(9%PRXW#<I; P<\@UVD-G)+X9CLG_=R-9B(Y'W24Q7
M&P:/KEUX*T'1+K19+>;1KO31([W$3QW$<+KYCIALX 3.& /. ":4.7KW!W.I
MLO%NB7]E>74%\$BL1FZ^T1O T(QD%E<!@" <''/:I-'\2Z5KSRIIMP[RP@,\
M4T$D,@4]&V.H.#V.,5S'B[PCJ6O:OK36B*D-UI5I'$YFV"6:&Y>782IW+D;1
MN_VN#Q5SPKH\T6NS:E<Z'>Z:XM?LXDU#6)+V5\L&*J#(ZA!@<Y!SV'-)QARW
M'J:FH^,M!TG4FL;^^,4T>WS2()&CAW?=\R0*53/^T15"W\5)8ZYXG&MWBQV5
MA>6\-LOEY;Y[>-]BA1N=BS$@<GG K(\2Z+XB3Q#J%WX9M+V.6]5#YD5W;M:3
M,$"9N(I1N' V_N\Y4#O3)/"FN6OC_5_%EK;0W<@FB\BRF==L\?V>-':(G_52
M;E(!;J!@X!#52C"V_3_(5V;Z^*K73Y->N]:U*"+3[&XMT7]S(KVPDBBP),J.
M2TF>,@ \D8(%[3/%>BZO)<1V=X1);1B65+B%X&5/[^)%4E>/O#CWKE=5\-:Q
MJ,'B=X[$HVIZEIMQ!')+'DI$+?S,X8@;=C\9YV\9R,W_ !7X5OO$&O7/D8AM
MKKP_=Z>;@L/DEDDC*@CJ1A6Z>A]12Y8/K_6@:FI:>.?#EZEP\.I*BVT!N)&G
MB>$&(=9%+J-R]/F7(Y'K4=OX_P##=R;D1W\BO:V<E],DMI-&Z0)C=)M9 <?,
M,<<\XS@UC:O8^(O$^@R6$OAZWTQ[>%'1Y[A'$LJ2QN(TV$[8V\O!+8/(^6J>
MM:7XD\1ZCJMV_AXV"2^&;W3H5DNH7DDGD*%5.UB IP<'/8YQQEJ$.OYH+LZF
MS\<>'K^UNKFWOV^S6L8EEN)+>6.+8>A5V4*V>VTG-7-'\1:9KWG#39W=X-OF
MQ3020R)N^Z2CJ&P<'!Q@X-97B7P]=ZQX"CTN# NX1;RB,S-&)&B='*;UY7.T
M@,.AP>U1>%-(E@UFZU&XT2\TUFMU@5[_ %:2]FD&XL1S(ZJ@/3G))/ [Q:'*
MVAZEFZ\3VVCZSK3ZUJ=M#IUC!:-M$;[X&E=TRYVX(8A<8)Q@DX')N:9XLT75
MI+A+.\*O;1^;*EQ"\#+'_?Q(JDKQ]X<>]<QXD\+ZMJ.I>(I+6U$D=]_9/D$R
M*-WD7+/+U/&U2#SU[9/%6_%GA6_U_7;G[/MBM[GP]=Z?]H+#"2R21E01UP0K
M=!V/J*KE@^O]60M1%\=V>H^--)M=)ORUA)9W<]TCV[1[@GE&.0;U!*\O@K\I
MYZXXZ-?$&F/9Z7=K=?N-69%LGV,/-+QF11C&5RJD\X].O%<G'INO:YXLTNZU
M+0ETJTM--NK2607$;L7D$8^4*3\GRG;GGKD#C+-(T;Q!/!X6T?4](%E;^'72
M22^^U(Z7)B@>)!&H^8;M^X[@,8[TW&-OZ\PU.CL?&N@:C??9+.^:24AS'_H\
MBK-LSN\MBNV3&#]PGI6/HGQ)TZ_FULW_ -H@@T^XE\N3^SKE0((X5D9I"4PK
M??\ E.#C;@<C-+PSHOB/2-;L+6&UO+72+=W$T-W=07%M&FU@HMR )@<D??Q\
MI(]*DO\ 1];AL_&FDVVD274>NBYGM;R.>)45GM5C$;*S!@=R8R 1\P)(YP<L
M+V_4+LW+/Q]X<OI(DM;V5A-+'#'(;.98W=_N .4"G..#G'3U%;,6I6DVJ7&G
M12[KJVC269 I^17+!<G&,G:>,YXSW%9&NZ/'>_#VXTZ_E6V*60)F)X@DC4,K
MY_V64'\*K?#VTO/^$<_MC6%"ZIK3_;KD#^ ,H$:#T"H%&.QS4-1M=#U.JHHH
MK,84444 %%%% !1110 4444 %%%% !1110!%<?ZO\:SI3C-5/&/BW3?"&F0W
MFK^=Y4LOE+Y2;CNP3ZCL#7!S?''PKVBU(_2W7_XJMHTIM<R6A-U>QUNMD#2Y
M_P#<-;FB'_BE-._Z](O_ $$5Y!J?QK\*36,D>W4%+#'S0#_XJO2;?Q'8Z1\+
MK'7;HR?8ELK>3*IEMK;0./\ @0I.$KI6%=+4U93UK/NSB%_]TUQ,WQQ\*<XC
MU%OI O\ \56?<_&_PHT+@QZBN0>MNO\ \55>RFMT%TSTOP8V?"Z8[2R_^AFK
MLE<YX#\16%W\,Y-<@,ALH_M$Q)3#;5))X]>#7.3?'#PF"<)J#?[L"_\ Q5*-
M.<KM(=TM#N)CP:K>"CE]5_Z^1_Z#7!2_'#PH0<QZBOUMU_\ BJZ;X3^)M.\4
M6NKW>E&4Q+<JK>:FT@[:4H2BM4"W/0:*0D#J0/K0&#?=(/T-9%"T44W>O]Y?
MSH =112%@O4@?4T +12!@WW2#]*6@ HI ZDX##\Z6@ H)P,FD+*O5@/J:;)A
MX6[C% "^8OK1YB>M>8^*O'DOAOQ NFI;>;N1&5B^,[B1CK[5UHU>T#%'OH R
MG!!F4$?K6LJ4HI-]2%--M=CH?,3^]2@AAD<BL!KJ"XMVFMYTF5<@M&X8 ^G%
M:VEEFTR!W.2Z[OSYK-JQ5RU1112&%%%% !1110 4444 %%%% !1110 4444
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MD6#$1P8<_=V\#N V:TI?#.E:WXF\=W&IV2W,T,D(@=B<Q-]CC.4Y^5LXY'/
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M7[?B%SV2BJ5IJUK?:CJ%C;LQGT^1([@%2 "R!Q@]_E85=K'8H**** "BBB@
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M&51@\9RW)/RD$>E0H+FLQWT.D379/^$WNM(D$*V<&EQ7HE.0P+22*V3G&W"
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MDC!^4#L#7=UE/<J.P4445!04444 %%%% !1110 4444 %%%% !1110 4444
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M"%-P1@+_  ]:/9,+GH5%<$OB#Q.^HRZ;<7&FY;4)-)6:WM9$(D-HUPDXS(P
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M!;7.^6?[1Y:[&&[R)!'+U'\+D#W[9%:%>6Z5X!O%UN&.X@UJTM[4:EF[36'
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M-H*JH8$'.#@KG--L/B)9:UX=-YH\^FO?K<B,V3ZA'N6+[4(?,)R,94AAZEE
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M$%C<RVK1GS+6VBF545AC( 4%SZ;VS7IM5Y[ZUMKJUMKB98YKMV2!">9&52Q
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MTM8<;8TG4DD*/NJ.<]A7.7OAN9OAGXQ6/2'.HW.I7]Q !;GSI#Y[&-UXR3@
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MFQG'*#&.G?&>:7/'L%F</::[XEB\,1>*;K6A/ NJFV?3_LL81H3>&#[P&[>
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M=..H">66[6)9'58@OR('!7)+CD@\*:L:1H#6?B?6];NQ#]HU!XXXO*R=L$:
M*&R!\Q8L3[;1GBKNKZ%IVNP1Q:I;F40OYD3I(T;QMC&5="&4X)'!I.4>8>MC
MS\:YXH9#IW]OI]I_X2HZ7]L6TC/[C[)YF-F,;MW.?7V^6M/6[WQ'I5]I/A^T
MU#4=1N+N.>YFO8(+19RL90!$639%_'DG!;';G(Z&Q\&Z!IL<266GB)8KW[>@
M\US_ *1Y?E^8<GD[>N>">>O-6]8T'3=>ABCU.W,GDOOBDCE>*2-L8RKH0R\<
M<'FGSQOM^ K,J^$[O5[K1/\ BH(3%>PS/$2S1[I%!^5F$;,JL1C(!ZY[8K;J
MIIFEV6C:>EEID"P6Z$D*"3DDY))/)))R2>35NLI.[NB@HHHI %%%% !1110!
M3U#1],U;RO[4TZTO?).Z/[3 LFP^HW XJ!]*T*?7/M$EAI\FJPJDOFM"AG0?
M,J-G&X#A@#[''>L+7%\<'XAZ.=">V'AH(/MXD";B<G=U^;IMV[>_7BI+JQUU
M_B'>W.D7%M9P-I5K&TMW8O.DC"6X.U2LB8(# D<_>'3OI;3<1HR>'?#^K037
MEM9V?F7\3?\ $PM(T$KJZX++*!DY&.<G(]:J^&_ 6A^&;5HK:#[4[7"W'FW4
M<999%78I4*JJI"Y *@'D^M<UX8N/$>FQ^%_#Q#Q1W6G6T[F2)0]FD"@7$3*1
MGYB85!/(\R3!&U:H:/XE\97_ (-%_82ZAJ$\UA#--)<Z>(/)D:5 WD;8OWH\
MHR-D+)@JN <[*OEELGH*Z/3VTRP?[7OLK9OMP"W68E/V@!=N'X^;Y>.<\<5#
M+I>C6]U!?S6-C%<6ZK!!<O"@:,$[516QD DX 'KBN2T.7Q9JMSI<6HWU]8V_
MDW4LLT5J@:4K+$(ED,L"[25:3HB$[<X%8N@ZWXFUSPW8W#M?:HMPEC/<M>:6
MD:Q2&[BSY(\L"1/+WL7^;;M5@03PO9ON%STS4M)T[6;9;?5]/M;^%7#K%=0K
M*H;!&0&!&<$C/N:CET+2)]+739M+LI+!3E;5[=#$/HF,?I7F:>)/%E[J*6=G
MJ6H"[N+59)XQIL9BM7-[!&Q@<Q_O4$;R_,2PP-V?3<>7QII]Y/\ 9[J\U3RK
M^6T@BN;6)(YHOL;3)*S)&I'[[;'N!"X&,9YH]G)=0NCLUT;3$CN$33K14N8E
M@G40*!+& 5",,?,H!( /&":A?2]#:9[22QT\R7,:,\#0INE2$C82N/F5"RX[
M*2,8S7":+?\ CC4H;6WN[J^M%EOXDFNA9#S8X_(F:0?O+:-0N]8@&V, 6QN;
MI39$\3)K&G:K-/JCWL=G?VD2"R0QRRI<1K$)-L1,:3+&'9B5 Q\K*.IR.]FP
MN>ESW$-M'YES+'"FY4W2,%&YB%49/<D@ =R0*S9- \/7YDCETG3+DQ7#2.K6
MT;[)FPS,1CASE23U.0:\_N_^$CUO2=3BDOM?EMK233+J)YM)2"9F6<M.J)Y.
M7V!58  G*J/F!.Z])?:_;?:V@;58;*6[9A>V^D*UU,1:6_EEXO*Z,_F!F* @
MH%RHZ'LVMF%SOYM-L;B=IKBRMY96A-NTCQ*S&(G)3)'W20,CI5)?"OAY+*2S
M70=,6UE*M) +./8Y484E<8.!T]*YO2[SQ>=9@N=5-RL4E^EM/8I;H8(HOL(D
M:17";SB?*;BQ7MC-:>I:AJ&N:3X<NO#=S=V5OJEQ')-/% CR1V[6\D@R'5E7
MYA&,X."<=ZGE:TN,U;CPWH=X\+W>C:?.T"".)I;5&,:@Y"KD< $9P*<VGZ,+
M7^Q&M+$6\R/)]@,2;'7<"[>7C!&Y@2<=6&>37#&_\=V>EW)B:ZU"ZDMKK9Y]
MHD8B:&Z6)&7;'RSPEI I#9*_*,';5&*Z\72S6VI3PWK2Q6]Q +M+-FE2!KFS
MW-L:&/=($$Q4>4,[.%;O7(^XKGILFF6$NI1ZA+96SWL2E([EHE,B*>H#8R!S
MTIBZ-I:VMK;+IMF+>SD$MM$(%V0.,X9!C"D9/(]37GMUK7C"+P]87-N^K32>
M?>AE;3O+GN%6;$&]1;N$R@Z%8P<Y+KCG0*>,;BZC?^V-2MH[O5+VW:);& BU
M@3S3 X)C)Y\N,98D,)..<&ER-=0N=_17F[:YXNFNM)DF34K.:>33B]G;Z;YD
M#12;#<F60H3&RDR+C<I 4'!R2-SQ!K5_?>";'5_#+74'VLPS?);EY1$RYQ@1
MRE3R.1&^/3^(+V;T'<ZRBN&?6?$V^UB^SWL<MY;:8\2FSW"-S,?M@D<*50B/
M'WB/]GFI_!\OB99=*_X2"YO+L7^E&YN1<6J1"TN%:/\ =C8BXR)&X;)_=G'>
MCD:5[A<[*BO+]6\1^*M.CU\RRZA&D=U"MM<+9!EB1[Q(PD:M" [&-^SR@XSE
M"0*M3:MXF%K%NN=:CL=]UY%[#I(>[G*B/R1+#Y7R*29AG8F0B$E<\OV3[A<]
M"6XA>X>W26-IHU5WC# LJMG:2.H!VM@]\'TJ2O,+R/Q+8ZUJ&H-=ZI!J-YI-
MHRQV]@MQ;B53,98]ZPM@)NRN26);I)PM=OX4NKZ]\,VL^K).ET3('^T)M=@'
M8*Q&Q.J@'E$//*CI2E"RN%S8HHHK,84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% $5U,UO:2S1P27#1H6$,6W?(0/NC<0,GW
M(%>;>&=;\^XUGQ#XC3Q!;)8WUUM>6\Q;(JR>6D ACE(9QD#[I!8'YCQGTZN0
M'@VYE\)ZOI4UU%'/>:I-J$$J LL9-QYT6X'&<$+D?4 ]ZT@TE9B9-+X^L+33
M]1N-3T_4M/ET^U^UO:W,2"62+.-R8<J>>,9!!(SBFW'CZWL]/>^OM"UJUMQ-
M##$TMN@:<R-M78H?=[D$ ^V>*S-:\'Z_XFL]5FU:33;:^GTM].M(K:21XEWL
MKL[L5!Y**, ' !ZYKI/$^C3ZW:6$5J\:-;:E:W;>82 4BE5V P#S@''OZ57N
M:"U,P?$" S3VPT#7#?6RA[FS%O&9(8R,B0G?L(/. K%OE/'%:NF>*-.UC44M
M-/9Y?,L(M0CEVX1XI&95QSG.4.01W'OAMAHT]IXRUG5W>,P7]O:Q1J"=RF+S
M=V>,8^=<<^OX\OHW@[Q)X8@TJ?1Y=+NKR'2H].NXKJ21(_D=G#HRJ2>788*C
MMTI6@]@U+T7B3^V/&7AN;3Y;B*QN(-322%SM#M#+%'N*@D'!#8/7![9(J:'X
MBZ;/=V$46G:F8=3F:*PNC"HBN<*S;E);('R\;@"<@@8R1#I/@BYT^YT S7,,
MT=A;WZW14%2\ES(CG8/[H(<<G.,>^*MIX0\21'PUI]Q=::VE^'[I7CD0OYUQ
M&D3QH2NW"L P! )!R3D8P:]Q_P!>H:DWA?QI?7U_KHUC2]0M[2TOI%%Q,L"Q
MV<201OLDVR%B<ECD!OOCGTU++QQ87,R+>6=]ID<T#W%O/?1*B3QH-S,I#$C"
M_-A@IQVJI_PB^HB[\0Z>WV231=?>62:4RNMQ 9(%B*A-I5AE <[AU/7'.7IO
MP[E-N]EJ.D^&K*(V4MH][IMH!<S[XS'OR4'E\$D@%LYQG%'N/4-1VI>-'U+5
M_"T5E9ZMIT5YJBLLMQ'Y:7<'DRYZ,3C)0[7 /0XXXO?$C6K_ $S2K.UT^TU%
MOMU[;V\ES8M&K(C2J&169P5=@2 <8&>HZU#_ ,([XKOK[P\-5GTE;31;I9G:
MW:0O<XB= V"N$/S?=R1R3G@ [_B?1I];M+"*U>-&MM2M;MO,) *12J[ 8!YP
M#CW]*+Q4D&MC'M?$%GX;M$LX]-\075R\9O+BVGF^USVL6=NYV>5@%.TX56).
M#@9S5J[\>646HPV6FZ9J>L2364=_&VGPHR&&1F"MN9U ^[T/J,9YP:MHVN0^
M(;C5O#4ECYE]:):W"7I8",H7*2KM4[B/,8%#@'CD4WP[X0?P]K<,L,ZR6=OH
MMMIL>[/F,T;R,6(Q@ AQWZYI>Y:[#4W;_5K;2M%DU/4=\$$48=U*Y<$X 7 S
MELD# SDUA/X^L;6"X?4]-U+3I+98Y9(+F) XA=PGF_*Y!12?FP<@=JTO%F@K
MXF\+WFDLZ1F<(R-(F]0Z.'7<O==RC([C-8NA^#1&;Y=4T+P[IT%U:-:/%I%O
MAI5;[Y:0HI /'RX/KDU,>2UV/4UM4\7:;I%]<VMV)RUK:I<2O%'N WR>7''P
M<EW;.T8[=15"X^(%A8Z?>W&IZ;JEE/9>2TEE+"AF9)9!&CH%<JPW'!P<C'3.
M <JV^'5W+X)O=-UJ^M[S5;J>*7[3)'YD;" J(5=3C<I6,;AZN_7K36\!WMQI
M5W$FE^&]&EFDM=B:9 1E8[A)7+2;%)R$P%VXSU/<6HT^XM3H(O&"!;9M1T75
M=,2YO%LT>[CC #L"5)VNQ"D@+GU8"EO?&>GV5S>6X@N[B:UN(K14@16-Q.Z;
M_*CRPRP7#-G  /7KA?'<5I+X#UC[>YCBCMFE61?O)(OS(R_[0<*1[XK'L_".
MJ0^&='N8YH/^$AM+MM2G-P2(YIY582HQ4' Q(5! .-J\5*46KL>I?G\?:=!I
MMO<M9:BTTU__ &<UDD*F>*XV,^QEW8Z+U!(^8'.,D2Q>.-.-CJ,]];7NGSZ:
M8UN+.YB'G9D.(]H0L&WG@8)YXK.C\':G+>6>HWT]K]N?7%U2\6,MY:(MNT*Q
MQG +$#9R0,_,?04NO>!I=<OM?EDEMA'J$5B;82H9 )+=W?$B$8*-N4$9.06]
MJ=J8M3<T;Q'%J]Y/92V-YIM[ BRM:WJ*',;$@."C,I&5(X/!'.*V*XK3/#.L
M:9::E<:7I?A?1M1EMQ%:K86YV;LY+22;%8CI\H7C'4UVM1))/0:"BBBH&%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6'J/B5K/6I-+M-%U'4YXK9+F0VA@"HCLZ
MK_K)$).8VX /:LO7/ ":W\0]'\4MJUS;MI:!1:QCY9,$G[V?ESNPW!R..*DU
MSP6==U_4+V34+NR2XTR*T@DLKR6%XW5YF+,JD*X_>+@-GHW [Z)1ZL6IO:9/
M8:M:6NMV,:,+RV1HYS& YB8;E4GKCG./6K5O;PVEO';VL4<,,2A(XXU"JBCH
M !P![5P:>!]3.I65P]OI,;Q-9LMS%(_F:>D&W?!;@IS&X4CEEXD;(; JE?\
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MD:/:65S-8W<T4EC*U\SR>:BP31NT R"#& AVXV\D97)+4*,;7;"[/1R RE6
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MK+9F\MGNUB7[3&&1/EPYP=TL8^?;]X'IDB;2OASH>E:M>7L<<K+-=QW,-O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ>M2V]^BW(:W$>HVMN<[DY^^_3#8_O>G%OP7K=JVO7%G;>)?$!=[1F_LKQ#
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M6 N()DF%L92<.0">RG&?Z4J^'O$7A/[3J&F^(K_6[9+*9Y;+4V\UWF5"4,;
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MU;2R)G#9R67<5/M]"::H-[,.8]XHHHKG*"BBB@ HHHH **** "BBB@ HHHH
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M./8I:H****D HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKO**?M9?TD%D<-J7@37-1O-%U$^+3'JVE+.HO/[-C/FB7C[F[:,+QW]:FN/
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M'=0\7W-QH$)^:QALTA,HW;]ID!+8R:]+HIJK-;!9'%ZKX$U"7Q8NN^'?$/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME>"CN\$:0?6U3^5<N+H0HM*)TTYN2U-RBBBN$U"BBB@ HHHH **** "BBB@
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M4 %%%% !1110 4444 %%%% !39?]2_\ NFG4R;_4O_NG^5 &3+''+;QLZ*_
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M.N8)4D'JC TU.,MF2XRCNB2BBBJ)"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "F3?ZB3_ '3_ "I]1W!Q:RG_ &#_
M "H QQA+5 33/#"[8;GT-PY_6JS:M;QVR!H[P>_V*;_XBF^']1AA2<M#>[6F
M9@193'(/_ :8%NY*K?W.2/O*3]-IJ6*XA&FS?O$ QCK[5GW5U#J%S=V\:7"E
MTY\ZVDC&"".K**AT[08H;.2154%3NX9O7=Z^O-4K-:B.O7[H^E+2)]Q?I2U
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M@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX.6Y=F.2QK*US2)#B2QN7@+'YE))7\!VHN!SD[J5CBC27"OG+1E1CGVQ6[H
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M<4V.UMXGW101HWJJ &@ NCMM7/M7.79RIKJ*38IZJ/RH S/#K9T6,?W68?\
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MA2<#L#Z5)7F&IS>)9]?L=D.H37EE?SR6]BUCBR5!:S+#(9PG5BR@@OP7(VC
M-)H]]X[U..UM[JZOK1);^%);H60\V./R)FE'[RVC4+O6(!MC %L;VI>STO<=
MSU"JEQJVG6E_!8W5_:PW=S_J+>295DE_W5)R?PKBY8?&#ZT88]:U2.U.K+9;
M_L5N<6PM!(9\^5C)E!7=]W+$!<XK%?P)XH\47>EZY=ZM)8?;;2W;4K5F>)DD
M1!_RS PQ5OG4$C8Q)YZ4*FNK"YZS4=Q<P6L7FW4T<,>Y5WR,%&YB%49/<D@#
MU) KE/$]]KEOXBMXK*74+>R,"M"UC8+<B>?S,,DI(^1 F#G*=6^;Y<5S$\_B
MS5K5+6^BU&X8RV\M];RV BBM9DOX"JP.$'FIY8D);<_"!B1G%*-.^MPN>I6]
MS!=1>;:S1S1[F7?&P8;E)5AD=P00?0@BBXN8+.VDN+N:."")2TDLK!511U))
MX KR>&Y\;Z3=6MEI=I<0VK74\B*UNS)*SZA,6$A$+[5,90@EXAALAFZ"SJ$?
MB?Q#X+UZSO+C6!?-I\IFL_[-CCB67+#R89"F9$([KN)P#O4G::]EKOH%SU".
M>*626.*5'>%@LBJP)0D X(['!!^A%/KS5+S788;^:UFU@6DNJQB34?[&47K0
M?9!\WD^0-_[T*FXH2%'H,B73KKQR\B7^HS749CO-/@DTY+2,Q/')%#]H?=MW
M_*\CG(;"[".1T7LWW"YZ+17%>(M1\1VOCG3XM.^V/ILGV=7BAM\HV92)69_)
M<8"8.#)%C&1OSBN6T?Q+XXO_  ?]OL9-0U"673X9I9+C3U@\F4S*"(-L7[T&
M(NV0LF"JD9)V4*FVKW"YZ]5"ZUW2+***6\U6RMXYI#%&\MPB!W!(*@D\L"""
M.N17G]CK'C606W]J2:E;Q$-]EDM-,$S73^=@+.'B3RP$Q\VV'.2<C&*EL]&U
MJZ\0:/=S->6BVZZMNBBLX4B'^EC8"#'_ ,M4ZG.6"Y!!+$GL[;L+GH\,T5Q!
M'-;R)+%(H=)$8,KJ1D$$=01WJ*\U"STZ$2ZA=P6L9) >>0(#A2QY)[*K'Z G
MM7FECJ/C*WT1(X8M0AU&+3HOLFG1Z4@M6_T)22S[%$;B;<NP,,;5&P@YK/\
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MV1N567;+*L>\+U(&XGISCJ*W*Y'4_!5S?ZS)<0ZI##9S:G;:G- ]GOE,D(C
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MA;P?9"'7[5,)7W.7(;!! PJ\&L^S^&0L]3TZZ_M>69+5+3SHY/._>R6Z*BN
M)0@SM!(9'/7!&:MJF]F+4U;_ ,:VMKXP_L&&;2]\,"SW;W6HB%HD.XD*FUM[
M!%+D$KA2I)P<UI?\)3X?_L[[?_;NF_8_,\K[3]LC\O?C.W=G&<$''7%4M9\)
MKJ]YJ-P;PQ->6EM @\K<(V@F>56//S LX!7C(!&>>,R#P+J$%Q/J":S:'4YK
MN>=I&TW, 66**-E\KS,Y_<J0V[NP(.3E6@T/4ZG^U]-&J+IIU"U^WNGF+:^>
MOFLO]X)G...N*AN]4T/PW:V\%]?:?I,&W;!'-,D"[5P,*"0,#(Z=,BN1U?P!
M>0WM[K&BZ@SW*Q_:+:U*L +I+?RHV \Q80/E7@QD]1D# '57VA)J&N6.HSR*
M3:VEQ;&)H]P;SO+RV<\8$9&,<[OS5HZ:AJ6GUC38]2AT^34;1+V=-\-LTZB2
M1>>57.2.#R/0UG3^+=,%]8V^GW5K?FXOC93F"Y5OLS"&63+ 9Y_=$8..OM7/
MVGPQ%KJ6GW)U>6:.V2T\]'\X>;);HJ*ZA90BYV@D,CD<X(S27/PP_M'2-.TO
M5-622TTTQI;^18JDABCBD15=F9MY_> G(V':1L^8T[4^XM3KY==TB'2EU.;5
M+*/3WQMNWN$$39.!A\XZ^],'B/0VNK:V76=/-Q>(LEM$+I-\ZM]UD&<L#@X(
MZU2U#0+^^TW2Q_:5LFHZ;/YT=P;(F%SY;Q<Q!Q_#(>C#D ].*R[/X>BTTV*U
M_M+>8[;3(!)Y&/\ CSF,N<;OX\XQVZ\TDH6U8]33@\0Z0_C,:1IC65Q>7$,T
MUY);S(9(FB,:!9 .<D2$#)&-F/IJRZOIL,)FFU"UCB#R(7>90NZ,,7&<]5".
M2.VTYZ&N?T+P;<:-J]C.^IPSV>G6DUI:PK:;)-DCHV9)-YWL/+ SM&<DGG.<
M[Q!X$O;K2-5AM;Q+B$I?W%C9B#9)]IN8I5(:4O@KF9\#:N-PR>*=H-VN&IT_
M_"4^'_[/-_\ V[IOV,2^2;C[9'Y?F8SLW9QNQSCKBIGUW2$ELXGU2R62^ :T
M0W" W /0H,_-U'3/6N-N_!.MBXTJ[@OK.74([^"2686(2"&*&WG128?,RS;I
M,$A@>5P %I[_  O1KFTD&K2;$C1+N,K*JS%9WGRJI*JK\TC8#"0*-N ,$DY8
M=PU.OTW7=(UGS?['U6RO_)QYOV6X27R\YQNVDXS@]?0UEW_CG0[/^SY4U/3Y
MK*ZO&M);Q;U/*MV$+R?,V<9.P+@D?>'T-C3_  S#9^!8?#,D[/"EA]B>:,>6
MS#9M+#K@GD]^:IVGA.Z6]TVZU+4;:>33[@2*+>P$"N@MY(54_,QS^\)SG'&
MHI+DNPU-J76M+@N+6"?4K.*:\&;:-YU#3_[@)RW4=*R=9\<Z'I6E/>QZGI]R
ML=Y#:2!;U!L9Y K9.3@JI9R/1#TY(Q&^& /]DK_:SF.RL;6RN$*RJ)U@8LK
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MS(VBF>)XVP1E70A@<,PX/()'0TFX-W#4P8/B'I]RUF8M/U V]U;VD[7!6()
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M)TUT%J;T+%H(V;DE03^5/I%4(H5> !@4M9%!1110 4444 %%%% '">/?'/\
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MVDF,PAH@=CL#)&0Q4XXY&WC<LM/M=/69;.+RQ/,\\AW%B[N<L23S^'0  #
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M3(8N PY&=BC-=%H_CO3[FSO#JTOV6XM)KH./LTJH\<5PT0*,1B0X\L$(2=S
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MNWN[;3K:^O+>?3FAMX[.^6W6.<L=S3 NOF(5V@#YL8;@;LC5M_'%C-JNH9F
MTVTL[>7>8)!,)I)IHC&8R-V[=&H";=V3CG(JS<>./#]K!:S37D@CNDDD0BTF
M;8L;!9#)A/W85B V_;@]<8-%YJ2=@T.0U/0O'4_B#5'BO+T6\KRF)K:;8C0D
M#RXUS< *XP,D1QDX;]X,YI)+?Q=I^@O<7TES96]O:7(D,EZ=Y4S6[#),TI1S
M&)PKF1@F<EES@=4?&^EV,1_M>[4.9KL*;6UGD5(X)C&S.0AV;<J&8X7.<''-
M71XLT8ZTFE+<R-=23&!"MM*8FD"%RGF[=FX*"2-V1BCFGV"R."\+Z?J/B>XE
MGCO-;BT(7-Z(#_;3L_W+81?O4D.]0RSXPS '().>9H](^(LVJPSR7<EO.UI%
MB3>&@B?[*%='03;2?.W-D1,>F' X'J%%3[5WV"QQ7@S2-0L_$6H7M[8:E:13
M6%K &U&_6Z>25&E+E6$CD+\ZX'RCDX Z5VM%%1*3D[C6@4445(PHHHH ****
M .!\2:)KDWC*]OM'M;\23V5K#:7MO?+%##*DDI8S1[P9% =>-K9Y QG(CO\
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M.ZJ50L2.&(-'-/L%D<Y:^&]=U#48UO9=:L-(7[6T,#:NWVB/*6XC$DB2DO\
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MD>MWWC;5SIW]I_Z-JT2"Y:_Q:10"WB:2+R"_+'<<$)P6!W#!%:.I>+-3\/\
MVJVU46MS/:S6#F>UMI KP7%P8FQ%N9MZ['P 6SE>.HK2N_'GARQL8[RXOI!
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M;@7P0AY8$;<$U*GA+Q3;:'9O#?:P^I+HTDDRRZN[+_:*F,Q#!DVE3F4$?<(
MSS@UU[^-_#Z-: WKM]K\ORREM*P7?(8T#D*?+)<%</MY!'8U0NO&4UE\/-3\
M03VX>XM9+V.*.*&1U)AFEC3=MR0"(QN8X R>13YI]@T.>U71/'DNLZX]K=W6
MR:*Z%JT,^R,JT9$"+F?".K;?F$2\@G><\W]8\)ZC<:7?6H&IW<%KJ]K<V$8U
M23S9(%\AI0':4$G<LNW>PVGE2.#6[I7BJU+V]CJFH"6_F8 %-,GM$4MG8CB3
M=Y;D X5F!;@@<BK>E>*=+UO39=0TPWDUK%&)/,.GSKYBX)S&&0&3H>$SV]12
M<IKIL%D8WB2PU:XATO[!:ZM):1VDJ26MKJ0@N(YR$\II)#(-X4"0-\S9)!P]
M/\&^&KW2-3U>^U>2:6\NY8B9/M<CQ3'[/")'$98JO[Q7 R 0H"C"X%)X?^(%
MCJ6@Z//J"7::AJ%L)3!!IERP) 3>RX0_NP9%&_)7GJ>:T5\:Z R7#B]?;;@$
MDVTH\T%Q&#%\O[T%R%^3=R0.XI/G2Y;!IN<A#HWC074Y']II+]@D2ZFDU,-%
M=3^?$Q,";SY.Z(2A3A=NX<#&39OM \0WEF3IZZU9+#I]\UI!/K):1;HF/[.)
M&60AQQ(0&9U .">PUT\>V5WXETFRT];F:TOH;DO)_9UQN26.6.,*?D^4 F0-
MN'RX4DJ",R1?$CPO-"LT=[<F)HO/#G3K@*8N\N3'_JQW?[JY&2,BJO/L&AC6
MECXUL_&E[J-QY]Y:J9Y(X$E"PSIL_=0C=.55@VT;O)7D$ER#SZ""2H)&#CD>
ME8=UXTT"RGNXKF^9#:)(\K_9Y#'^[7<ZJX7:[*O)526&#QP:S]8\>65II,-Y
MIRW,Q.HP6<L;Z=<;XM\D8<,FP,K;),J"/F)7 ;.##4I6T'HCK:*R=1\3:7I-
MO;2WTD\?VF,RQQK:2O)L4 LS(JEE"[ADL!C(!Q63;>*IM4\=OI&FR*ME;VT4
MSR/IL[^?O,GW9LJB+A%PQ#!LD#.#4*+:N%SK****D84444 %%%% !1110 44
M44 %8&K>$;75]1GNY;V\@^T0Q1310&,*YB9GB?)0L&1W+#! R!D'I6_7*W/C
M&>'Q4-,CTV-[47OV![EKHK()?LIN<B/8<KMP,[ASVQUJ/-?W1,NIX4M?["U?
M3;F\N[HZP)!>74I02OOC$61M4*,(J@87''0\YS;SX;Z7J5F8]3O+R^N/,B=;
MNZ6"5U$:LJ)M:/RV4"1_O(3EB<YP13M?B+=2:9:7%WHT,4VH6EO=64<5\9%8
M32QQ*)6\L>7AI5[-P&QDJ15K3_&>J:I=V5G::+9BZF-YYXDU%A'$+:=86VL(
M27R6R,A:TM40M#4E\)VAT73=/M+FYL3ICA[6YMA&)(VV,A."A3E78$;<<\ 8
M&,Y?AUI\<$=M'J6I+:"P@T^>V#Q;+J&'=M5SLW<[V!VE<@XIW@F^UV[\,W<M
M_;VSW"W=XMONOG?S"MQ*-C,8P45<!00&^4 X'W:P_!>L:VMCHJ?88[R^UJQ;
M4)I[O6YV01KY7S*C1L$8F?[B * H^8]BTU?4-#=?X>:4U_J%X+F[2>^=9-\?
ME*8G642JX(3+L'4$&3?@<="0;VE^$[/2]5&IK<W5S>E)EEGG9<S&4Q%F8*H&
M0(8U&   .E81^(MPUO \.C1,U^(GT]6O2-Z27"09FQ&?*8&13MPW1AG*D5>T
MCQC?7VI6D%_I$-I!=7=Q81S17IE;SX-^\;?+7Y#Y4F&SG@949H:J6U#0KK\,
M-*;1TTR]U#4;ZV@M1:VJW31-]F0.DGR@1@-\T4?WPPPN,8)!<WPRTM=+EL;.
M_OK%+FV>UNWM%@C^TQ,6.UE$6Q<;FQL52-Q]:M7'BZX7Q))I=KIL4BBY-C'+
M)=%"US]F^T@%0AQ'LXWY)!_A(YKEM"U[Q2;+P?(MM#>S3:-<RR12ZFZB<*+8
MB61C$?WF68;<-C<?FZTU[1]0T.ZUCP[%JWV9UO;NPN+9'BCN;1D#^6X =#N5
MA@[5/3(*@@BJ-EX%TNPTD:?%+=-")[.XR[J26MEA6,?=Z$0)GUR<8XQEV/Q,
MCU+6;>WL])N'LYA"#<E9,HTL"S+G]WY8&'4',@;/\)')V-%US6=8\(IK']EV
M-O)=6R7-I#]O=PRNH8;V\D;2 >P:IM.*U'HQ-$\&VVAZE;W<6I:A<K:6;6-K
M;W#QF.WA+(=J[4!./+498DX')-9MC\/8VL-0AUJ_N)VO!?0HD3($MH;F<R-Y
M?R [B F2V[!!QQUPO#/BN_T?PQ;SWEBUV5TRUU/4+B;6)IG:.8$*T:2(1O)1
MR8U*J#M +$\;O_"::U*ML]IH-E)'>ZI-IMKOU-E8F(S!G<>20H_<,< L>15-
M5$Q:&MK'A*TUJ^EN)KN[@2Y@2VO+>!D$=W$C,RH^5) ^=Q\I4D,02:J/X TV
M6ZNWGN[Z6VN8+N 6;.@BB6Y</,4(0-DL,\L<=JS4^(=\+1I;C0$5WAN6MXHK
MTNSR6\Z02HW[L8&]_E*[BP'W02%K3@\9A_"-SK$UF%GMYQ;/:J[KMD+JJAC)
M&C(/G4DL@P#G!'56J(-!W_"$0"1KI-8U--3>5Y)-20PB9PR)&RD>7L"[8H^B
M Y0'.<FFZ;\/]&TGQ,VMV:N+AG>3:T<3'>XPS&39YI)R3@N1DDXK#UG6]9UR
M^TG3H;*.W_XFTMG>I!J\T&]TMI)-JRQQABF-K9X.Y=I7J1T%UXI&G>(XO#_V
M)WNIG@%IF8GSH6#>9(21D>6(WR.<G9R-XP/GM8- ?P+I#^,3XD*L+QG61E\J
M(AG5-@;>4,@X X#A<C.,DYM:=X6L=,&D"!YW&DV+V, D8'=&WEY+<<G]TO3
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M9^;Y,N=OG0O$W!(.4<!AR.X]ZLT@"BBB@ HHHH **** "BBB@ HHHH ****
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MHI78$<%O#;(R6T,<*L[2,L:A068EF;CN222>Y)-2444@"BBB@ HHHH ****
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M+>PO[6YGM6VW$4,RNT)Y&& .5/!Z^E%F!;HHHI %%%% !1110 4444 %%%%
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M_P"![M^.GR[?>J2N!N7&IZ#I^H&QN[W3K6\OV#&WEEC22X) 0':3ECA0O?@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC!(YRSQJQ/J2*135B:BBB@04444 %%%% !1110 4444 %%%% !1110 4444
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MY]\_E[U5M!&EY\HQDQCG'0U:K(60RWT$8/&[/Y<UKU(PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBD?[O% "T5YGXK\2ZQIUX'T^8%Q>")8C&I5AYFW'..H[Y'U%=IX;;6FL9V\0
MJB7#3DQHA7"IM&!QGOGJ2:;5A7N;%%%%(84444 %%%% !1110 4444 %%%%
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M 94VP+AB:Q;M<7"X';O6])&ZYQ&=W^[65-:WES=+MMY& [[,"D!T6B+MT2T
M&/W8/Y\U?JMI\+6^FV\4@PZ1@,/0XJS3 **** "BBB@ HHHH **** "BBB@
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M45!04444 %%%% !1110 4444 %%%% !1110 4444 %%%>6:R-+,?B(:AY?\
MPF7VF;^RMW_'UT_T7R.^S&W.WY<[]W\57&/,)L]3HKR?2_&.H:*=6M[.33]2
M>/4M6?\ LN*-_M481IYED8[CE"RA.$_C7#$\5IP>/KZ33YW.JZ%)#'JRV/\
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MT;QAXALKA[%6>Z20WLT$J0W,HLX<01J&;8QP#RS'^ZK'.W=\$^*;_P 5:7J
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M*YU0R,P2ZD-P),2LL@\I\C<3@-A<'@/DC;<5V=[?Z?:ZI9M:7\7FP,RLR%B
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M:.1=PN>@65_;:C"\MG)YB1S20,=I&'C<HXY]&4C\*L5RO@G0Y= _M6UFMKY
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MG+-/8P375N;6>2-6D@+AS$Q&2NX<'!XR.#BIJR&%%%% !1110 4444 %%%%
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MEUC&QH0;=(2 <]<)G/'7VH:A;<-1P\7^&C:R7(\0Z48(F5))1>Q[49LX!.[
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M-/\ [:Q_:/V6/[7MQCS=HW]./O9Z<5=K(84444 %%%% !1110 4444 %%%%
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MBSOK>\MPJM:2(GF/(9%3REPY5FS)$>#C$J'/)QHR>$-#EL;:T>Q_<VEK]D@
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M$8 %=O%/B8)I[ZC<WUA>/)ID9M(=/5H9/.:,3><Y1C$^6<!=R' 7&<\>J
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M6\UT9(#&GF.#N49_B!4Y7ME?6MJBBLWJQA1112 **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>9:WXL\00'Q%KMG?QPV'A^_2T_LHVZL;H?N]S,Y^8%O,^7
M'''.:]-K#O/!GA[4->36;S3(Y+]"K>868!F7[K,@.UB.Q()%:0E%/43.,L_B
M9?:1+JDOB2R>?2XM:O;*&^BD3<GE;V2/R@ 2-J$;B<YZ^M2GXK:A%?6MA<^%
MO*O=0AMY;"(:@K"7SF8*&;9\F C$]>1C!ZUT2>"?"%KX@-R;"W_M&\DGN1'-
M<._FLW^M<1LQ4_? ) X# <<5SNL>!? RB;2--U"PTG56$*[9KLS2(H<%%$;2
M!EY8!2I4\@ XX.J=)O86IE:E\3_$%Y-=C2=,:SFTVVNVN+-'6=IFCN(H<ABO
MR[ SOGD<<@BM_2O%6M7OPIU_6+E&MKRQANC:3LT<OF!(MRR;E4(^&R,A=IV]
M*UO!_@#3?",:31EKG4=LJ/='<H*R.'90FX@#*KUR>.M=!JEO97>CWEMJNS[#
M- \=SO?8OEE2&RV1@8)YR,5,I0VB@2?4\I\/_$;5=/AU2_UJZOM3L+'2X;B8
M7ME'9R1W,KA8T7 &4;).XC' -37'Q8U"[U+3)=%LX;A(OMZW]E#>1O'+Y,<4
MBND^WD!7)& ,G@],UW]QX/T&[.;G3DDS9"P(+MAH 054C/.",@GD'H15&Y^&
MWA6\MK>"ZTV25+8R&,O>3%OW@4/EM^6R%4<D\#%/GI-W:"S,B7XIB35K*#3M
M%>XLKB>P@DNI+D1M$UVH=/DVG=A2">1SQ[U@Z;\7-4M_"=W=RZ2=9ETM7EO[
MAKA+?:&N98XE50AW?*@R<#IW-=A?^'O S^)()KY;"'5;%(KF.(7AB:-(>4D,
M88 A0.I& ..E5K?P'\/O$6G V%K:W]HH:(O:7SLK9<R%69'^8AG)&<XSQBFG
M22U0:E9/BEY6K74.HZ*]O8PW%_;I=QW(D,C6BL[_ +O:",JI(YZ\>]-O/BA<
MZ;I%I=:KH,=C-J#K]C6XU.-89(VC+[FDQ\A  &"O5@ 3U'3KX.T%;A9_[/5G
M6YN+H;I'8&2=2LI()P0P8C!X&> *SH? '@Y89=,@T^)71DG=4NI!-%PRH0X;
M>BX#@ $#&X#O4WI=OZ^\-3+UWQ;JNJ>%= U;PFMRD&I$R7"VT44MVB!"<1QR
M':Q#<'KQR*P[GXGWFE1^&IYKJ2_%R;ZVN+=K5;:26XC:-8DD#9\I@SX8@[>2
M<=!7HE]X3T34M*MM.O+%7M[3!M]LC(\1 QE74A@??.35*Z\$^$X=+C2]TVW2
MRL8)QF65@B)* 968D\D[02S9(QG(HC*GLT%F<S:>/]?&O7-H=*BO;BYU273[
M:Q6Z$:VY@MDD<^:4RX8L3R!C'?I4GB7QO>7G@7PSK6@SWFG#5]0BBE%O;+<S
M*ACE+*J%6W'<@Z#/%=3IO@KP_I<]M<6%DRRV\[W,4C7,LA$CQ")F)9CG* #G
M/KUYI)_ _A^Y\/6.AR6+C3]/D$MK$ES*C1, P!#JP;H[=3WHYJ=T[!9G%Z#\
M0=:74I]&^S7&N7LEXT=HMZB6$XC2%))#*FWY>7 7Y1NSVJYH/Q2U#Q##/<67
MAE!;VEDEY<R-J('EJZN0 /+^8_NS_GKT!^'/A4V8MFTK<HF\_P QKB4RE]NT
MDR;MY!7C!.,5-H7A/PUIVF3#0;6/['J%JD+M'</(LL(#;<,6/&';D=<]>E#E
M3:V"S..O?B;JMJN@ZMJ6F#3-,N[*YOVACN%N&N8UA1D7.T;#ND'Y<]>+-E\6
M9M4N;6PTC1+>]U&>ZDMS%%J:F$;8?-#+*$(88R#P""IZUU%[X=\+"/3++48+
M8+9VCV=E!/.?]2PCC90"WS_\LUR<G)7G)Y-)\)^&[62TN]*@$CV4TK03?:Y)
MBDA4Q."S,<X&5P<X(/ -'-3ML&IS?Q%\2:OH^J>'H+6_O=,ANX+J6\%A9)>2
M QK&1PRG@;FR1CCDUGQ_%V70_#VC'Q#;13WUS8_;[AS<) 3 9"L;(G(>1E&[
M8".AY[5Z3<Z18WFJ6>HW,&^[LED2"0L1L$@ <8S@Y"CJ#TXK'/P^\,&&TB&F
ME4LPRPA+B5=JEMQ0D-\R9YV'*CL*(SIV2D@LS&O/B:]M%JE]%H,UQI-A</:"
M\2Y0-).I5=OEGD*68*&R?4@"F7'Q2_LN9X]>T<V'V2Z-M?L+H2+;L8/.B((4
M;@X!'\.#CKFMO4/!'A)KB^U74],M09HW:ZEF<B, KAW()VJ=HY< ' ZU)_P@
MGAE_#\VCG3$DL+F59Y4>5V:1P00Q<MN)X'?IQTI7I=@U.1MOC1;R72076E1P
M2,FUH_MP:5)O)\W:4V@[/X"_][C'>M$?$JZLM!TO7/$&@KIVE:B PG2^$IC5
MH3(A*A!]X@KU'4>N*Z&?P7X?N=4FU&73Q]IG4K*5F=4?*[<E P7=MXW8S[U6
M\2^%=,OO!4.AS3Q6&CV9@,OFC<HMX2K;-S-\O" ;B3QG.:=Z3:T#4R]4\1ZW
MJ \)Z?8LF@W7B!))II65;AK94B#[%# *6.0.1QAN*6V\4Z]9ZY:>&_LMGX@O
MC!)/-?0W0MU6-)0GS)M8;P&&0#U]!TZ?6O#VE^(K)+76+1;B*-P\?S,C1L.Z
MLI#*?<$5#IGA31-&NH+C2[!+:6WMFM8RC-Q&SAV!&<$E@"6//O4\T+;#LSAH
M/C?87<_V>TTU9Y[IPFG11WJ$SL91&!+Q^Y)R&YW?+[\5,WQ6U)9GME\*AKR*
MXO8)8?[14!?LT<4C,&V8.1*0!_LCUXZ?_A7OA<Q747]E+Y5W_K(_.DVK\V_Y
M!NQ'\P!^3%%E\/O#&G_\>FFE#F=LFXE8DS(J2DDL<EE1?RR,$FKYJ7;^OO%[
MQ7\*^-I/$>I?8[G2FL#-I\.I6K&<2^;;R$A2V -K9'3GZUROAGXKWDT&C6NJ
MVD4L]\BRM<SW26Q<22N%6)2H638H /S*2>Q)KT+3_#FE:7=07-A:^5-!8QZ?
M&WF.VVWC)*)@DYP2>>OO6:GPZ\+1QVL::7B.T"+'']HEV$(VY=Z[L28/(W9J
M5*GKH&IC:QXXO]+\;ZA8PP?:TB%E96ECN6,37-QYK[VD(R@"1XQ@]*PH/B_<
MZ/:W:Z];1S7JW]Z6ADNHX?(@BD"B-&VXE<9( ZMM)S7H.H^#M!U66]EU"P$L
ME\83._FNI)BSY94@C85W'E<'FJ2_#?PHEK%;QZ642*1Y$*7,JMER"X+!MQ4X
M&5)QQTIJ5*VJ"S.>F^*DMY>/;:7I3)9SF\@MM1:X&[S((#(3Y6T\9  R??VH
MUWQ1XGB^&_A.\TCRWO\ 6!917%VS(C+)*J?=4HR_,2><87T-=,WP_P###:PV
MJ?V4JW;"3+)-(J_/&8W.P-M!*G!.,]^HS5]_#FE2:7IVG/:YM-+>&2TC\Q_W
M30X\LYSDXP.I.>^:.:FK6069Q<?Q.GTV.YM[_39KG['%>1K>/<(&N;FUB\R5
M"JH J\$!@.<?=%='H?BG4-0&F#4_#MU9G4P\D,EO(+B**-45P9G 7RRV[ &#
MDCK4T_@;PY<:A?7LVEQM<7\4D-PPD<!ED7:^ #A68<%E )]:N'P[I;7NEW9M
M?W^D1O%9/YC?NE=0C#&<-E5 YS4N4'L@U-.BBBLB@HHHH P?'&I7VC^!=8U#
M25S>6]J[Q';G:<?>QWP,G\*\N\1ZW>:%I^JVWASQ1>:K9C3K.\:]FOC(8)FO
M(TQY@Y170L2O8 \8->WD @@C(/4&LI]#\/6.DW4,FEZ9;:<W[ZY1K>-(3M^;
M>XQCC&<GIC-:TYJ.Z$U<X$?$K7&UK^P0VA+>+=21MJ;NXLF185EVCYLA_FQ]
MXXP3@]*S8OB[X@N=&BO8X=&@>*WM))XIQ)ON&GF*?N5W]% YR3S^5>G'1/#@
MMX=*;3-+$+LUQ#9FWCVL5QF14QC(W+E@.,CUK(U7X:>']6U*RN98I((;-56.
MSMPB0X5]X &W*C(R0A7/?-6IT^J%9F?X)\37TNBVDUWI^K:E)JE_<N]Q"%>"
MT'VEXPN6<,J*%!P V!GZ5A>'M3O;_2X=8'BRX'BB\DNHAHLTP:$RKY@6'R?^
M6>W:IW^V22#7JMI9VUA;+;V-O%;0*25BA0(H))).!QR22?<U#'I&FPZE)J,6
MGVL=](-KW2P*)7'H7QDU/.M= L<=X D\1-JU^-5BOTL0\JJ;[?N;#+Y3#>2=
MS*7WA<1@A=H&37!^"]2\1R7'A)OMFL6]QJ1E=KW5-3-S:72*C941;B0V=N 2
MIX./4>[)-'*TBQ2([1-LD"L"4; .#Z'!!QZ$53?0=(DT^&PDTJQ:SMSNAMFM
MD,<9YY5<8'4]/4TU46MUN%CC/!?CG5/%EGK+W,FFV7]FPF(O &DWRX;_ $A<
MG_4G'RC!)P>>.>6\/^(_$&G;UANIM1U.;2Y;JW+ZF+^TO6CVLS!!M>$D$@#@
M9.#TKV"VTK3[.9)K2PM8)4A%NCQ0JK+$.0@('"CTZ5#%H6EV7VJ73K&VT^>Y
M0B6YM8$CD.>Y8#DCKSFCVD5?0+,\WN_BKK$NF0:MIEI9QZ7>W,ZVT\\$LK+%
M$BY9D1MQ!<N-RC"!>0<U6MO'6NZ7<^,-9N;ZPO[:WBM)K>TC\XJ/-BC\MHP6
MR$PX+_+DG)XZ5Z+IOACP]_PBFFZ7'9VFI:9;0H;9KA$G5QC(D!Q@DYSD>M6'
ML?#TEU-<R6NF/<*!8RRM'&7 8+B%CUY#+\AZ[AQR*?/#9(+,\Y7XG>);O[/;
MZ?::<+@?;C+-=6L\4<RP1QR*R(Q#+D2%2#GD9SVKI?!OB_5M;UA+/6+>R1;O
M2+?5K8VN_,<<I(\M]QY88ZC ]JZ6'P]HMM%%%;Z/811PJZQI':HH0. '  '
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MF(0S1_9Y!&7D3:LF45LH?XA\V,^H([5/4@%%%4]+U2#5K:6>V615BN9K9A(
M#NBD:-CP3QE3CVH N4444 %%%% !1110 4444 5-6%\=%O1HYC&H>0_V4R_=
M$NT[<^V<5QEM;>,+GX-:W;>,$6XUR:QNT2.W52[@QL$4B/Y2V>/E[8[YKOJ0
MD*I+'  R35*5EL*QP.I:=XM76[*Y6]M);B'2;P6TT%@T,<<F^W81REY)!A]A
M'\) #$<],VY\5Z]>?V-=K>:GI]MK,%[>06]AIR7,L<:"$0*PV.<'<6)]9,9
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MM;A@K$COBMDZBL+0P(?AU<+IFE&\TK0KZYT^_DE%O,J+&8'C=?++I  <.X?
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MJ(R5R%02Q*K  X3H!Q77:KXPT71;][/4;F:.:.-)'V6DLB(KL53<ZJ5!9E(
M)R3P*@N/'GAZUT_[9<7<Z1YEWI]BG,D?EX\PO&$WH%W+DL !N7U%'/4?0+(I
M^-?"%QXIO+ HUN;:%#'<13%AYBFYMI2. <Y2!Q]2/<BK:?#Y--UL7VEV]A:*
MFIO/'Y2[62T:U,9A&%X'G,9-@^7G/7BM*;QOI>GWUW;ZG<Y9)W2".TM)YGV)
M##(Y<*AY'F@Y'&UEYR#B.V\<V4OB;4K.4R)86EC#=I=_8YA'@^:SLTA78$VQ
MJ5;@-\P!.,!+VBC9;!I<P=/^%YTZ&P:UATV&ZM+735$L2E2)X9MUS("%ZR(
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MAAM"UE,@826\<BB1F7:CEF8!6VG@#&>NMI'B32M<DD33+AI61%D^>%X]Z,2
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ML%%%%0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;(8X\WWEQPG++DF-D!*AMH.X\X!V_#OC*U\1R0+%I]_8_:K3[9:F[6,"XBR
M678[8P67(;!^88S2<)(+HZ*BBBH&%%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% $5U=0V5K)<73B.*,99B.@KG9?B+X:A?;+?.OOY#X_E5[Q;_P BI?\ _7,?
MS%>$:J/F'TKNPV'A5BW(QJ5'%V1]%VUS%>6L5S;.)(9D$D;C^)2,@_E4M8_A
M(Y\%Z-_UXP_^@"MBN*2LVC9;!1112 **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0D#J0*-Z_P!X?G0
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MKO#' YQ6%93S222"8.H"J0'QGOZ >E:%[\MC;KW))_S^= %J._,G/E #_?\
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M /7HG\JW:\Z?Q,Z%L%%%%0,**** "BBB@ HHHH **** "BBB@ HHHH ****
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MU%VQJI). !DG)-.I@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %-=@L;,QP "2:=4=RI>UE5>
M"R$#/TH \YN_B7X.2S2)M=@#J>1M?_"NE\"ZM8ZUHD]WI=RES ;IEWIG&0J\
M<UX7>_ ?79(A-_:FG88],R?_ !->M_!WPU<^%?!<^G7LT,TGVZ23="3MP50=
MP/2@#I_%7_(KWO\ N#_T(5X9JIC_ +F?EXY->Y^*P3X6O@HR=@QC_>%>':I#
M-GB-N!SQ7JX'X6<M;XD>V>"O^1'T?_KT3^5;E8?@K_D1]'_Z]$_E6Y7FS^-G
M2M@HHHJ!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 >>ZW:&XU[4%558.PWAANS
M@#'%>=ZAH%K'(?M-O$&VG($8.&)([>F.G/Z5Z3?S2V_B34'7[OF+T..N!6!=
M:EYDLCM9LPV#*O\ W2Q&>G;D_C7YW5KU88NKRZJ[_,]R,8\D4^QD:?IUM%S8
MHDB' FV JHYQV&#VXKUWPLP;PO8%22/*XSZ9XKA'NHYK'8(-H58SA>P../J!
M7=^%AM\+V*A-@$> O]WD\5Z^0U95*TW+L<^,M[.-C6HHHKZT\L**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ -8LFKS(.WY5
MLG[I^E<M<'"YH UFNY)])CF^ZS.0<?C_ (5@>(KIXM#ED.Y]KH=H(R?F'KQ5
MFSU&-]/6!Y478Q.,C/6H+NZMQ V^X4*.OS 4".5LY0(9YA;LK&$9&%R?_'C6
MIJ0'V@&6W,JX!^Z#BMG2C%-IX= K DC=CJ*L.<O\V"?I3#?1F?9R'R<HN".-
MI./Y5,TKO;R,R[>,<UP%Q\6M+L[B5)M+OD(E92Q*;2P.#CFNE3Q-!>>"5UU8
M9(X)5W",X+ ;]OT]ZUE1G%*ZW(<XI-M[$N_$@-3:E/?KIL?V#*.TF"Z1^:57
M!P=IQU;:#[$_4<8/&&EK('$=X6[ MQ^6[%=II-__ &AIEO<VP7RW!X=L,.2.
MV:F5.<%>2,J>)HUFXTY79FZ[=ZG'=62PV@E:0A9RA&(QQD\L.,D],]*MZ7+=
MF8+=1@#/#  =_P#>/^16%XYUN/1Q;374+3%I" (F  .PCOUX8USFA^/;"+48
MQ%9W.XNL9W. !DX[&M(X>K4AS1CH5*M3A+EE+4]2O;J\A?\ T9$=<=U).<-Z
M>^W]:);JYDT6Y?RB9U7Y(PI7<<# ^;'>JDXD34Y7DFG,+*@2.-#A6YR<C]?P
MK5M9]R;@",_WA@UAL;'.V(UR:-'N+=;<[1O#Q9Y[X*N:VQ),MHWV<*9<_*'X
M%:2R9K,\1+=R:;(--G%O=;04D\KS,8.?NY&<CCK1NPV0VUO;Q[E%GB 0DY*H
MW3'Z<UEWNJ7!\07%E#92.(X_,$SY5&.0-H;!&>:U;!VD8LYF';9)MQ]1CFLK
M5DN1>236\K#^$(JY[]>3C^M/03-2QD=@ID 5L<@'./QJM<ZCJD%U(([>)H06
MVD!B2.W3WQQZ9IFD/*P_?[]V3PX Q^54UNKU=0N(;N]2(&X81+'&22A V]5Z
M\\T(8WQC>3-H%F^YHV:<Y RO&#BI])\^6&UE0 JJG+-CKDX]ZH>.Y"-$M3UQ
M+R?PK1\,KOTJ$L6_U;'&?>NF5OJZ]3)?Q&;UB\D<FZ2"-<,"/+8G/Z"N*^+W
MC'5]$72I=(>*W1VD24S*&R<*1QCCH?SKMK8YD%<Q\0M'TW5[2+^UUD=('+IY
M;@%>.3SP:YX-*5V:M-['G.G_ !/UZ]U[2;+[3;/#<7\,,H\A02K2(#CD]B>:
M[V2:>[\6WVR)&"7=Q&K%L= 1Z>HK"TGP%H$NCZ3KXBN)5N46XAAN'5@N<=0%
M'KGKVKMM,TBUEUZ2$@B,Q-(P'&6+<D_7)S3G*+^$$FMRCXKD:#Q5<,@)^=,A
M<9(\L>ON*L:7*3(&F#Q(1R9"#CE>>/K63XKF6UU93)YDF^/.XR $;691R2.P
MJS::A$UB<1MD 9+3!QC(_P!HGK[5'09Z+_:=A_S^VW_?U?\ &IH9X;A-]O*D
MJ@XW(P89_"O-S<(2I6)1N(P?+&#FN[T*$0Z4FT ;B2<#'.<?TJ0-&BBBF 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !39/]6WT-.ILG^J?_=- '!7.H11:?'$]E/)( OS YW<=>OT_
M.N@\&DG1)"P*G[0^5)R5Z<55N8I5TN(*\>%P!F,^GUJ[X34II<P)R?M#DD#'
M7!H D\5G'A6^_P"N8_\ 0A7B&JL Q.\YVCD'_P"O7M_BS_D5;_\ ZYC^8KPG
M5>H^E>K@5>+]3EK/WCW+P7_R(^C_ /7I'_*MRL/P7_R(^C_]>D?\JW*\V?QL
MZ8[!1114#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XBZ0CQ+?<\-)UW=/E':L
MB_39=SX&0(00-Q^;G)'\OS'M6KJ4<3:Y>O*R_*YR=G3@<9[USVHSH+J\$2QG
M; H9MX7;R><^P)XZ#K7YCBH\V-J6[O\ ,]Z#M3B_)&UJ&PV&%8L^Y< ?45U7
MA=2GA>Q4L&*QX+*, \FN1F6V:'*!&D7D@G(&.G'ZUV7A[(\/V@.,A#G'U->S
MPUI4FO)'-C?@7J:5%%%?:GE!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 (QPA)]*XZ[NH/L^[SX]N.#O%=A+_J7_P!TUXM=
M2"6SW1W(*@?=#>WIB@#32]M61LW4(#MA277!P><9ZUG7]PEMIL[/.C\''W1Z
M>GTK3\&Z5:7WAE9Y(R[F5QUX.#[U+K^@6ITN96615([/UIZ"NS<\-6[6_AZU
M)E$GFQK+R,8W '%7)6VG)*XSVS7+Z;FWT>)825544 ;L<<56ENIW1]Y9>>GF
M;NXI#/._$WP_\3W>K7<EEIBR6INII(9/M$:[E9R0<%N*]234EBT^*WN=.BCC
MV#,(V[%/<8QC@T?;?*TU2"2WE852?E)WGG%%UIL=WB(7>Q]F_:8_7\>>E=GM
ME4LJFR]3@Q4*ZC>AO\OU,F\U#P\S#[1HD1P>&6-1G\L5JVJZ,+*+[-;B&-L2
M!5!&"?I6#-X;NKRUC%K<V[#YBI<E6(!P<C!QU'YUHZ;IEU'I,$),<LL;,C,C
MC'!/'./:N2O.2C[FIT4(+24U9V.<^*#6ITG3TMP1B<D]?[M>;Z22=24*VUC,
MF&QG!W5[?=>#K3Q#:-#JS31&%MR&!UR"1WX/;%4+'X2Z':70F:\OY2KAPN5
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MB@ HHHH **** "BBB@ ILO\ J7_W33J;+_J7_P!TT ><7VKZQ'8^7_HSE9
MR6\S#;@\<#&3QW_G75>#C,=#8W)0R^<=YCSMS@=,]JR;W1+9X$G9F)+*0NQ"
M% !X!VYQ^-;'A*-(M)ECB4(BSL H& !A: )?%O\ R*E__P!<Q_Z$*\)U7[P^
ME>Z^+?\ D5+_ /ZYC_T(5X7JL4A;B-NG]VO6P/POU.2M\2/<O!?_ "(^C_\
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M]9,W6P4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHQY]*L4@"BBB@ HJA)KFG1:-<ZL]R!8VHE,TP5CL\IF5^ ,G!5AP.W%7Z=F
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M79-&6X']H1VZW+0;3D1EBH;.,'D$=>/Q%5XO$VD3^'9]=AO ^F6XE:2X5&(
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M  FPS>:,G,1)))\S'%0>,;?Q/8ZAK^J6<E\MBNGW,BS"Z*QP 6C!=BB;[WF
M''DYR2?,_AKN6\1Z(M]-9-K&GBZ@QYL!ND\R/)"C<N<C)91SW8>M7HYX9I)4
MBE1WA?9*JL"8VVAL-Z':RG![$'O1SM.[06/-9-(\83://_9:ZI9PN;0O;7NH
M?:+B8KYGG&.19UVJV8N/,C^XW"YP;6A:3XKM[JV_MO\ M2ZE&WR;B._6**"(
M YCFB\QO,?\ VOWA.5^<$%J[>'6M+N-4ETVWU*SEOX1NEM4G5I4'')0'(ZCJ
M.XJ)O$6B)?2V3ZQIZW4./-@-T@>/) &Y<Y&2RCGN1ZT^>3TL*R.%3PAX@%C>
M7^_4!K3^&+:VCE&J.-UZL<RN"/,VG!9""?EW$L/F)-79]+\3L=5$*:F+N228
M_:?[2403PF<%(X8]Q\J3R<INPF&Y);K76W?B+1-/N1;W^L:?:SM)Y8BFND1B
M^%.W!.<X=#CT9?44^XUW2+2]:SN]4LH+I(C,T$MPBNL8!)<J3G: "<].#1SR
M?0+(\VG\*>);^UU<-8WPCFL]3M[*'4-02XE19HK41H7,C<%HY?XCCN><GJ/"
M":I)KFJ+>WTES8:3(]A:.96;S]S"1F?/WF13'%DYY23GYC6P?%_AH6(O3XAT
MK[*TAB$_VV/87 !*[MV,X(..N#0WB;3;:YGBU2^L;#;<_9X#->Q@SGRT?@9R
M#^\QM/.,'HPH<I-6:"R.3E\):E87VI75G'JTUO<:P)9;>VU>1);BU^RHORLT
MH"L)@,DLK%4VYVX4M7PUXHN-*U22]NM1%\FCB/3%BU1TVW!-Q@/L<*[A3 "[
M#!(R#UK?A\<Z=<ZOJ6FVLUG+=6-_#:>4+Z,,ZOY0>3!_NM*5V\DLFT<G%;EI
MJVG7]S<6UC?VMS/:MMN(H9E=H3SPP!RIX/7TH<YI:H+(XV3POK5EJ4DFFWFK
M2Q0M826PGU620%O.Q=A@S_,/*"G#9 ).S!)JM?Z+XJOY(+66*Z>"SOGE>26Z
M0QW*MJ,$T14;R?W<*./F"XZ+G-;5CX_T_4O"-KK-BUM<32M9I/9PW2NULUQ*
MD>'(&05WDX(&=IZ5M'Q'H86[8ZSIX%BP2Z)ND_T=B=H#\_*2>,''-'--/5!H
M<)J7A?Q)K%UK5G=+J0BN[+48O/;4R+:5WD4VH2)9,H%0%6^4 \@[@3EUUHWB
MU]3TEM)35+"QCBB'E7%[Y[P2"9C(96^TX=64KC(FP!@*AZ]7K/C31=)\*7&N
MQZE87,"PRM;;;Q MU(BD^6C9(+$C&!D^U:=[K&GZ79)=ZM?6MA Y $ES,L:Y
M(SC+$#-/GGV"R..\-Z)KD/C*ROM8M;\R065U#=WMQ?++#-*\D14PQ[R8U(1N
M-JXX!SC)@U?1?'3ZQ>G2=0D6SBF=;/=<#]Y'<@^8[ G.8'(9 ?X05'I6^GC*
MWN_&Q\/Z9+IMPT,223NVH!9,L7RL<85MY4("P)7 9?6NFI.<D[M!9'GMMX7U
M2#Q#I&HW\6J7OV6XOH"4U1MT<3W*O;NV95#($7YEY)&T%6V@"WX&\-ZKX;BT
M:"9KOR/[(V7\4]X9DBN5,>P(I8A1@RCY/EPH]J[>BI=1M6'8****S&%%%% !
M7$2^&=0N/ Z:5+"ZS-KING$<^QEA.HF8N'4@@^6=W!W#MS76:K>G3='N[Y8T
MD-O"TH1YEB5L#."[<*/<\"H$\1Z))>7%I'K&GO<VRNT\*W2%X@APQ9<Y4 ]<
M]*N+:U0CC+W1/%IL1;P3:AY<27B*4OLR.OVV)H,DR*S$P*XR75L$@NI.:O7N
M@ZOJ_P (KS2K^&X_M5[:=8HOMC*S-E_+#OYC9R"N59W'8EL9K1U#Q]X?L;G2
M%&KZ;+!J4SQBX%]&$C54=M^<X(W($ZCEAWXK47Q)H;374*ZSI[2V:L]R@NDW
M0*IPQ<9^4#(R3TJW*>FGF+0Y'5-"\00>(+=-+&K36T=[9O!<+JS>5#;*ZF=)
MD>3=*Q^<Y(;*E1D8P5T32_$\-QI!N8]4B>&X0ZI+<ZD)HKAA!.'>--Y*QF1H
MSM^7^'Y!MS6UJ7C[P_IXTJ1=6TV:VU&Z:W^T"^C"1A8V=GSG! *JIY&"Z\]
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MF;!!Y"].>-8N5M%_6HM#EK;PEXKT;PA866BS7B3MI,:7D<M^T@2=)824BS(
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M0J5)=BS<2EP-V2 !U&*EN_%,QT?0;S1[!+F37)$2&*[G, C#0/-EBJ.<@)C
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M]T:P@BAD:WNK>)B1Y%Y*[%T=L+B%3D%CE-N!DFK=A\4-*U6.,:587U[<RSK
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M).:GL/$0U+6KNPMM,O?+LY!%->L8A"',:2;0-^\_+(O\.,]ZPM%\=+'97O\
MPD$=S$;9M1G6Z9(_+F@M[AD.P(V[*J47YE!)Z9ZTO?:L/0@T[X;36NFV5I>:
MQ%/_ &?%;P6S0V7D_NX[B.<[QO.]B8@ >,9)P23F.R^%<5HKQ-JCS0J8E@$J
MRR,L:7,<Y1M\K*<^6%RBH.22#5ZR^)FE:E#_ ,2RRO;VZ#/FTM6@E<(JJS/N
M64QE1O4<.3D@8S61'X]U.\U.TGTRTO+RQO-5A6*&-8%<0/IJSB([W7YB[;\Y
MZ(PW= ;_ 'NHM#2UOX>S:E-JDMEJT=J^I"YB<2V?FK'%/% CA0'7#9@#!O\
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MG4%<_,H8@$9&X ],U#:>#Y/^$?\ $.G:IJ"3R:]++)--;6WD"/S(5B(52S=
MF<D\YY]\.S^)T>F:&D_B>TNH;B:]O(X/,EM8_-2*>0$ F4+^[4(AR02<;=_6
MM#6_':OX;UFYT"VO9/LUA)+'J*0H889?LWGH&4G=]UD.2A7Y@"<Y%'+43L&@
M^'P9J44S7[:Q:-JG]I?;TE&GLL"G[+]F*&+S<GY<G.\<^W!I7?@"ZTRPAN=
MOV>]TRPABLXVA4EY(+>YC0DE@.3<@\C V8[\:(\>Q1B&WGT35AJ,LT4*616'
MS7\R.1U?/F; I$4@Y8$%3D"G'XA:;Y'G)8Z@\,,(FOG"1XL%\QXSYN7SPT4@
M.S=C83TP2[U T+GBGPLGBJQM[:YNF@6+S@YC3)826\L!QSQCS=W?ICO6=%X,
MU)'>]?6+1M3.I#4(Y5T]E@4BV^S[3%YN3\F3G>.?R,&F>/5@L;C^TX+N[:UG
MN7O+F".,1VD NYHHV?Y@2-L1^Z&.$)/J;<_Q#TZVNIDEL-0%O$)V%X$C,3K!
M,D4S#Y]V$9\DE1PK$9XRK5%H@T,J?X6EI-5N+?6$BNM4M3:3,U@AC6)K=(FV
M("-ARF[*D#D!@V 1J7/@<W6J3227\9LI;EKQK<VNY_.-I]E^\6VE-G.TIG/?
M'%3:[XE8^!/$6JZ,9(I=/BN4AG=%*M)$I!91R" X*\CJIXQU0^.K<,\ T?5&
MU&.1TDTY5A,R!(TD9R?,V%=LL?1B<N!C/%%ZC#0I6?@.]MM'N+1];$LS7-K<
M6[/#*\<)@=74;9)F<@E0" Z@#H!SFC=?"QKR;4'GUDD7J7+8\N8B.:>,H[*I
MF*!?F8A=N[&!O..=.'XCV5QIUYJ-OH^JR6%E:)=7%T%A"HK6ZW 7!E#%MKJ.
M 1D]<<TW4?B=I&D0D:G:W5I>+.T#64\EO'(I6-)"=QE$9&V1#PY)W 8SG#3J
MWT#0[+ITHKE(OB'I$^JM8PQ7+D6PN4<>7F1#")@5B+^:WRG&0FW=D9S5.;XK
M:!!HUMJ$BR+]ID>..$W-MN.Q59CO\WR^ R\;]V3C&<UG[.78=T=O17-:?X[T
MK4_$4>D6B3&26)98Y7:-0ZM$)00A?S"-I^]LVYR,Y%=+4M-;C"BBBD 4444
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M;Y<_P_,P;//0CO5FBH;;=QA1112 **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K$N?!^AW<UY)<6;O]M21)X_M$@C;>-KD(&VJS#@LH#'GGFMNO
M*M:\77OA6_\ %#V<UA; WEQ<K+J",R2R16=ILMUPZ_.^YB.3]PX!YQI",I.T
M1,[V3PIHLL<Z/9 K<17,,H\U_F2Y</,.O&Y@#[=L4R?P?HEQ D+VLB*DDT@,
M5S+&Q,S;Y065@2K-R5)VG XX%<#XI\:7]Y:^*-#NS:>7_9UV(H[= 9%"Q9#.
M?-+C//6)5Y&&;C.QK/C;6M$TZ[2Y6REN;354L9+Q(1' B/;+,'*23J!RP3F4
M#)!SG"F^2>FHKHZ%_ WAZ2>[E:Q<_:X9H)8_M,OE[)2#*%3=M3<0"2H!)YI9
MO"&GR:SI=ZB(D>G7%S=K$4W%IYCDON)X&6<XQU*D8VX//:#X\U/4O%&F:=J$
M-G;I>VZOY,6'DR8F<OGS<A,KP1&R\@>9GBK%[XSOK?Q]'HJRZ?'$UY]F%I)&
MQN9(_LAF^T*=X&S>/+^Z>0><\!<L[VN&ALZWX1LO$&M6E[J;2206]K-;FV21
MXQ+YC1D[BK#<N(R"A!4[N>E79/#^F2Z5/IKVW^BW$SW$B"1@?,:3S2X8'*G>
M=P((P<8Q@5QMEXYUP>'VNM1&G>=)I^G7Z3) \<5LEU(R,9%,A+",*7)#+D9^
M[UJO#<&Y^!7B:X-S#=&7^U7\^W&(Y<S3'<@R<*>HY/'<T<LMF^H71V</A'0X
M'LG6Q#R6,[W,$LTCR.)7&&=F8DN2#U8GH/08:W@[1'NI+A[60M),+@H;F7RU
MD$BR[UCW;5)=0Q( R<YSDYYG3/%GB#6]8M]-TN^T61&:Y)U-+226"X6-+<@Q
MJ)A_%.R'YR,QGW 5_'6KB^U5(8+.<6"W$TEHB-YUM'!<*F)#NY:6(N\> .@X
M<<T<L[[A='83:#IMQ9ZG:S6VZ'52S7B[V'FDQK&><Y'RHHXQT]:JWOA32KO3
M7M/LRJ#)<3(6RX66=9%D8J3AL^:_RGCGITKCH_B%XAN;6]>+3;2V-O;M?+)<
M*VPVTA3[,2=P 8@R;LD &(Y*@Y%^+Q/)K?@%=0N(X+F1-6M;=BB[(V_TN(!E
M,<K@XW _+(PR,'NM')-!=%[PYX!M]'OY=0U"X-_>M+%)')NF"QF..2-<>9+(
MQ.V:0<L1R, 8K6?PIHTMY<W,EHSFZ#B:)IY#"^]=KGRMVS<PR"P7)R>>36/X
M>\2ZM?Z]%;ZB+,VMX=0\@00NCQ"UN5A&YB[!]P;/ 7&.]9MWX\U.'Q5_9T4F
ME@FXNX?[.DCD^TQK%!)(DK,&(VN44CY/NL,9.<%IM[AH=%:^!O#UI=M=)923
M3L06DNKN:<MB.2, ^8[9&R61<'C#>PQ/8^%-(T^:"6W@F:2VD\R%Y[N68QGR
MVC !=CA0KN O09.!FN5_X22X\3?!_P 475TT#S0V5U"7ME41M_H^[Y2LLBG[
MV,ASTY .0,[4[ZZA\2V]TE]IFE6EKX@,;W%Y"[KO.F##NQF4#(;8%&WG:>3D
M,^63O=A='=Q>$M&@^R^1:R1K:VGV*-$N) IA (".H;#@!CC=G!.1S5K2M%L=
M&MYH;&.3;/)YDK3SO,\C;0N6>1BQ^55')X  KS&UU"_L%@2>YM-3O;#Q)?3'
M3[2$Q3!C%?.-P,C<2<%!@8!ZMUKK/ 'BV_\ %-M>OJ$5L?L_EE)+8I@EE)*$
M++* RD=V!^895>ZE"25[@FC4A\%Z%!9-:+:RO ;26R"2W<TFV"0('C4LQ*KB
M-< 8QCC&34D?A+18M<CU>.U=;N*1I8R+B3RT=D*,PCW; Q4D$XR>IYK@XOB9
MK$MA<S+<:*S1PV<T@"%?L33&4/#+OF53(GEJ/F:(9/KA3K>(=<_MCX6V-[-]
MG OKBW$K7'[JUVK,&<2MEPL3A"N06!WC!8');C-.S871UEGX>TRQTB?2X+=F
ML)PRO;S3/*FUA@HH<G:F.-HP!V%1V'A;2=.N4N+>&9IT22-9;B[EF?:^S<NY
MV)Q^[3Z8XQDUS/A2XNX/ NM7?A^VLFE2[GELK2V8R6>%"X2!AMW(V#R  '9N
M,#%5+?XCZQ>&Z:TT99(Q:7&JV@VONGLE1EB^DCRA3CGY#]W/-+EG=V871V%K
MX4T6SL1:6UD$@$MO,$\US\\"QK$<DY^411_7;SG)S!:>"- L6<VUE(-S0, ]
MU*X3R'\R)5#,0BJQR%7 [8Q7"/\ %/7%TF.=;:P9'N'C_M','D<1JP0C[7L5
MB21_KB<+]W/%:7A+Q)>2^+]2MKJ*#38KZ]BN";@,_G2-90$V\;#"AUQN)))(
MZ*>2KY)I/4+HZV7P?H<LJR-9NK"625O+N)$$A>0RL' 8;U+DG:V5Y/%6+/P[
MIMAJDNH6L,B3RL[,#<2&,,YR[+&6V*6/)( )).>IK N/%.IMXXDT*U:QC)F,
M$<,D+/,J_9O-%V<. 8M_[K&!D_Q@\5E^%&E\-?"FSUQ8-/:[NUM+B[GCM#$S
M1.Z>8\S;B7=5>5B_ _V1SF>65M7_ $PT.F@\'Z>#K1O42<ZQ=+<3&-3$5V!1
M& 5.05*!MP(.XD\4LG@G0);5+>2TE*+YFYOM<V^428\P2/OW2*VU<JY(.T9'
M KE-;^)%]9E[O3WTU]+^U3);W.!)]J1(X3^[S,@<[VF7Y"[?( $;DU(_BC5_
M$/BW4?"NQ=/BD:>".1'5+BW"+E+CY9M[*Q P/+488#<>0:Y9[W"Z.^M;"VLI
MKJ6UB\M[N;SYSDG>^Q4SST^5%&!QQ5'_ (1C1MFQK%&3R[F,J[,P*W#AY@03
MR&89YZ=!@4SPY:6^AV,7AY+^2\N+&!78S,Q?RV9@A))/]PCCCY> !@5LUDVT
MRC ?P3H<EH+>2"Z<*Y82M?W!EY7:5\TOOVE>-N=OM3E\&:%'IXLH;.2&%7BD
M4PW,L;HT<2PH5=6#*1&H7@\C.<Y.=VBCFEW%9&3+X;T\VJI;V\:2133W,#2;
MI%2:82!W*EOF!\U\J3CGC'&)?#^BV_AWP]8Z19\PV<*Q*Q&"Q Y8^Y.2?K6C
M12YFU89AR^#-!F:(R61_=N[X6>11)OE,K!P&PZER6VME1G@4K^#]#D>_:2R+
M?VA'+%<*9Y-I60YD"KNPF\\MLQDC)R:VZ*?-+N%C"/@KP^9UE&G[2LGF(BS2
M!(V,D<A*H&VKEX8V( &2.>IS2\2^"(M:C<Z?<)87$T[S3S%96+LT2Q'!25&'
MRHHQNVG'*FNJHH4Y)WN*R*FE:=#I&C66FVQ8PV=O';QECDE44*,^^!5NBBIW
M&%%%% %>^L;;4[&6SOHA-!,NUT)(S]".00>01R#R*R9O!6A7%I%;SVLLJ1ES
MN>[F9Y ^-ZR.7W2*VU<JY(.T C@4GCN&ZN/A[K\-@5$[Z?.%!C+[AL.5 !')
M&0#V)!P<8/%G7M4M=2U'7],U/2-3M[/0+:XN7AMW*7*I/<_)'B4[& # DEOF
M X'0:PBVKIB9Z'_8.F_;/M7V;]]]L^W;][?Z[R?)WXSC_5_+CIWQGFL:/X?:
M,NJ"=TD:TCL[:T@LA/*L:K"SD;P'Q*#O'#@XV^]4/#_C74]6\=WNC7%I!';P
M27"; 4$L(C?:CL!*S$..>8T'(P6'-9;?$+67NM2AL7TJ^NH+G4+:+3(8G^T1
M"!93'+(=_*LT:*0% S(,-GY::C-:7%='8_\ "':(+F.=+62.1'9SY=S*@D+2
MM*0X# .-[NP# @;C@#-)%X,T&%XWBL-KH48MYTF9&242J[G=^\8.-VYLGEN<
M,<\_/XVO]4U>VM?"MQIDUI<W%O;K?-&T\:NT-Q+*N%=<LHBBXR,;^?:@/B!X
M@CU_4M,EL[$RV<5P K!8SNBBW+,5$S2>6[#IY8 #CYV(Y.6?<+HZ^'P9H,$K
M21V1R98Y5#3R,(RD@E4("V$4. VU<*<<BKMIHFGV-T+BU@,<H,YSYC$9FD$D
MAP3CEP#[=!@<5YM)XIU'6#H&JSZOI%E!::O) ]U-:CR0QLY""62Z9""'V8#G
MYB.004KH_%.F3:O\0= M+E=/N=.%I<SM:WECYX9D>$$C+A0VU\*2/E^;AL\#
MB[V;"YT;>'],:R^R&U_<_:S>@"1@5F,AE+ALY!WDG@XY(Z<55'@S0OLU[;-9
MN]O>Q/#+ ]S*T:HQRRHI;$8)Y^0+R!Z"N1T[QWX@U>2PMK)M*6>]GMT>7[/(
MZ69DAN))+=U$@)EC\A0>5^^,JO&;U]XB\4V]_?1PS:08+/4;/326LI=SO.D.
M91^]P%5YL[.<@8W \T<LT[7"Z.FE\+Z/->6ER]GB2S2-(0DKJFV,[HPR A7V
M'E=P.T\C!J"7P7H,S(7LW 5G8JES*JR;Y3*P<!@)%+LQVMD#)P,5S"^/]474
M]%M[E;%%NYWM9PJ9>61+IK=C&K2A@OR[OE64@'YMH&XZ/BKQ??:'KC6ELUB@
MCMHIX;:X1C-J3O(RF& A@ RA5[-S(N0!S1RSO:X:&Z?#&DMK@U<P2_:Q-YXQ
M<R^7YGE^5O\ +W;-VSY<[<XJ*U\'Z'90M%;V1"&6&4!IY&VF%]\2KECM1&Y"
M#"C)XY-8'AO2KZ3Q/XKU*<Z3/J,=V;>WN6T]E=#]F@*C?YA/E\C*#J=QR,X%
M>U\3ZEXBU#2)%L(;+_37M(VN8Y&:&Z2SG,QVAU#*KXCP>NUSGE2"TNC#0Z&_
M\"^'=2A>*[L7*2&4RB.ZEC\WS)#(X?:PW N2V#D G@"I-8\*66I^%[W0X0+:
MVOI6DGRIDSOE\R4C)X+$M@_PD@@<8KSNQ\;:CX:^&NE+#JFBF2VTV4LT\+82
M6".+;9,!-_KR78YXX7A*Z:?Q+XDFUY[6QDTN*W?55TR+SK21V0_9!<F1B)0&
M'WEV@#L<\8+<9KJ%T=C<Z99W=K#;3P*8()(I8XURH1HV#H1C'1E!QTXK+'@O
M0A',OV68F9D8N;R8O'L+%!&^_=&%+M@(5 W'UKDK7Q;JNHZMILNEVUC:W>LV
MFG>;+<)+*L8DBO)2-H=0=IBXZ$[CDGC%KQ-JKZM\)9+O5(;,NFHPP7*2MY=N
MYBU!(W+%MVV-MA)SNPIYS2Y))I7"Z-9?AWHHUH7C)(UNEK';I:^?*%)6625F
MD._][N:3)#@\C)SDUH2^#M$FD#FUD1O,DD8Q7,L?F&20R.'VL-ZER3M;*\GB
MO/+"YT#&MK/%H-OI;26;1VUA>YTMY<2_+-,L04$[!N!3;Q$.2W/8?#Z^MD\.
M6=CYD:S3/>3V\,66C$"W+ >4V!F(!XPIXRI4@ <!R4DKW!6-V/0-,B:!DM0#
M;W4UY'\[';++O\QNO.?-?@\#=P.!6?'X%\/1K9J;.65+(%;>.>[FE1%)0[-K
M.04!C0A3E05! !KDM-U:^;QXGB=[&\&E:G<'34NS)&8#;Y5;=E4.7R9@Y!*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117%:I\0SI]_J#QZ/
M)<:+I5PEMJ&I"X5?)D;;G;&1EPN]=QR,9X!Q51BY; =K17(:1\2=%U#5+[3K
MZ9-/N[2^N;54E9BL@A)RV\J%!(!;;G('K3X_BAX/ECD=-7XC1'(-M,"P=MJ[
M04R^3T"Y)'/3FG[.?85T=917+:9X]TO7?$5IIF@$WR2PW$L\^&C^SB)D3[K*
M-V6?''3&>E8C?%NV1/$$;Z8R7>CWPMDA:? NH_M"P&56V\88Y*X..!GGAJG-
M] NCT2BL>#Q9HMS?PV4%[NN)KN>SC3RG&Z:$$R+DC' !YZ'L353Q!XIN=-UF
MUT;1-);5]4N('N3#]H6!8X5(4LSD'JQ  QR?2IY7>P7.CHK@]6^)<FEQR>9H
M,R3QZ?;7C07,WE,IEN?(V'"MC!^;/.1VJE/\5KS3;-;S6/#L<%M_:<FGR-;W
MYF9/*W^=)CRER%$>0.X],<TJ4WT"Z/2:*XRW^(7F^!;#7I=(E2]U"[-C;Z:L
MP+-/YKQA2Y  ^X23C@9ZU:7QQ#IUB9/&%E)H5SYQA2$DW(F^7=NC*+EU ZG
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP=M(+;[)#JL@M3)8.5,.7(MBY(W;AR_F'G'R^AJ/3_@Y'86K?\3V>2\A-O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNE#W-K*H$BJ2501N)R'>0@,JJ&"JP)+?+O@L/B9K5U'J+7%E9VOD!,^;L/\
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ME6.\@174%FX(4'J>M2HR2O<=T=A9:#ING&R-E;>4;"U-G;?.Q\N$E"5Y//\
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M9978RB,.2SL221#'U_N^YS#_ ,(-X>$MDZV+I]A$'D(EU*J PX\HLH;:Y7
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M-J]I>33I<6@@+"1MZNI#1LIQO8'(W9')SFAQBMF&I=;Q%HB7#V[:QIZS1RK
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MAM[>-I99&Z(JC))^@%8$OC33]0^'^J>)?#%S%?16=K/+&61E4R1H6VLIPPY
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M'A6P\*6<T&GDMYSAW<PPQ9P, ;8D1?QQGGDUMUG*U]!A1112 **** "BBB@
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>wald-20221231_g2.jpg
<TEXT>
begin 644 wald-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $MA>6QE92!(
M97)N86YD97H    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,W
M.0  DI(  @    ,W.0  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M5)N$;K<FC!3E:3LCF)[>>UD\NYADA?&=LBE3CZ&HZ[7Q_996UOD'K$Y_5?\
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M:49*_P _\CC68LQ9B22<DGO7=ZI_R3>#_KE#_,5QNI0I;:M=P0C$<4[HHSG
M#$"NRU3_ ))O!_URA_F*RKN[@_,UPZLJB\F<'11178<(4444 %%%% $]G>2V
M4_F0[3D%61QE74]01W%33ZDTMJUO#;P6L3MN=80WSD=,EB3@>G2GZ/IHU*Z9
M'=5148G]ZJMD*2, ]1D<_P!*G@T=I=+NB%B:XAEC&\3KM52&S\V[;Z=ZQE*"
M>OD;PC4<?=V=_P M1DVOSS%W^SVR3-'Y7GHIWA<8QUQTXSC-%KKT]J8'%O;2
MS0+LCFD4E@OIP<?IFJ_]E7GVJ2W,.V2(;GWNJJH]2Q.,?C4%Q;2VDQBN$V.
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MM[=)B#)Y0;YL=."2!^ %,MM+O+R,201 JS;5W2*I<^B@D9/TIT>CWTLDJ+"
M87\M]TBJ-W]T$GD^PIODV?0E>TW2W'MK$QG@N%BA6XA"CS@&RX QAAG'3VJ0
MZ[*L<<<%K:P)'.MP%C5N6'KECQ49TV2"WO$N8)!<0/&O#+M3=G@\]^.E-N=&
MO[..1[B$*(B!(!(K%,],@'('O2_=O^OZ[E?O5_7R_08FHS(MT$"@W+!F(!RI
M#;AC\:LOKLSQW %K:H]TFV:54.Y_?K@'Z"HAHFH&$RB ;5C\QAYB[E7&<E<Y
M'Y5%8P+<-.'C=]D#N-A P0.ISV_6FU3:N).JFO/^OU))M6GFCF1DC FCCC;
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ME20>/05AZA<?:M0FF\QI=[9\QD"EO? X%5J*F%-0V*J5I5-PHHHK4Q"BBB@
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M)#([;L[SC X[8'\Z'3=_Z\_\P]M'JOZLO\ON+.CQ*RWDWE+--!!OBC==P)R
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M'-)W=PHHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7I=@_LZ'\P4445YYZ84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4O:SWANK6]M!M@O;*8Q31CT##M]145A\.M"TWPSJ>C6HN0NJHR7EV\N^XEW
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MI>=J&H3V@Q:"_NC*ML/]@8&/UK6TSPE8:5XKU;Q!;RW#7>JA!.CLIC78,#:
M 1^)-:>U2=[WT?XVM^1GRNUEY?AN6M.TRV\->&X]/TQ'\BR@*PJ[;B0,G&>]
M>'6'A^#Q%\']<\;:IJ=XVN3+<,THN6"JH./)*9QM(XP?48KZ$K@+SX->&+R:
M^(DU*WM[XL\EG!=%8 Y_C"8QD'D9R!Z5G">LFWJ^OY_>:6222Z/^ON.)O_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9_\ ?#?_ !5<O16GU>E_*<_]H8K^=G4?\+ U7_GWL_\ OAO_ (JC_A8&J_\
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M?;5+;U*G0P<&TX[>3?Y>A=_X3G4O^>%I_P!\-_\ %4?\)SJ7_/"T_P"^&_\
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MRXO"4(4)2C%7L=[7(WOBN^MK^X@2*W*QRL@)5LX!QZUUU>:ZK_R&+S_KN_\
MZ$:]7/<36P].#I2M=GS$4F:O_"9:A_SQMO\ OEO_ (JC_A,M0_YXVW_?+?\
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MJ'_/&V_[Y;_XJC_A,M0_YXVW_?+?_%5@44?VIC?^?C#E1O\ _"9:A_SQMO\
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MV!M!7I[51TJ2ZD^(DQOU"S!7!4=,!>,>V,5R,T\UQ,99Y7ED/5W8DG\34O\
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M ,SB?^%=?]13_P E_P#[*C_A77_44_\ )?\ ^RKMJ*/K5;O^0?V5@_Y/Q?\
MF<3_ ,*Z_P"HI_Y+_P#V5'_"NO\ J*?^2_\ ]E7;44?6JW?\@_LK!_R?B_\
M,XG_ (5U_P!13_R7_P#LJ/\ A77_ %%/_)?_ .RKMJ*/K5;O^0?V5@_Y/Q?^
M9Q/_  KK_J*?^2__ -E1_P *Z_ZBG_DO_P#95VU%'UJMW_(/[*P?\GXO_,XG
M_A77_44_\E__ +*C_A77_44_\E__ +*NVHH^M5N_Y!_96#_D_%_YG$_\*Z_Z
MBG_DO_\ 94?\*Z_ZBG_DO_\ 95VU%'UJMW_(/[*P?\GXO_,XG_A77_44_P#)
M?_[*C_A77_44_P#)?_[*NVHH^M5N_P"0?V5@_P"3\7_F<3_PKK_J*?\ DO\
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MG"[?F_\ ,]FGC\13BH1EHO)?Y''_ /" _P#42_\ ('_V5'_" _\ 42_\@?\
MV5=A16?]D8+^3\7_ )E_VEBOYOP7^1Q__" _]1+_ ,@?_94?\(#_ -1+_P @
M?_95V%%']D8+^3\7_F']I8K^;\%_D<?_ ,(#_P!1+_R!_P#94?\ " _]1+_R
M!_\ 95V%%']D8+^3\7_F']I8K^;\%_D<?_P@/_42_P#('_V5'_" _P#42_\
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M_42_\@?_ &5=A11_9&"_D_%_YA_:6*_F_!?Y''_\(#_U$O\ R!_]E1_P@/\
MU$O_ "!_]E7844?V1@OY/Q?^8?VEBOYOP7^1Q_\ P@/_ %$O_('_ -E1_P (
M#_U$O_('_P!E7844?V1@OY/Q?^8?VEBOYOP7^1Q__" _]1+_ ,@?_94?\(#_
M -1+_P @?_95V%%']D8+^3\7_F']I8K^;\%_D<?_ ,(#_P!1+_R!_P#94?\
M" _]1+_R!_\ 95V%%']D8+^3\7_F']I8K^;\%_D<?_P@/_42_P#('_V5'_"
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M'_" _P#42_\ ('_V5=A11_9&"_D_%_YA_:6*_F_!?Y''_P#" _\ 42_\@?\
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M@?\ V5'_  @/_42_\@?_ &5=A11_9&"_D_%_YA_:6*_F_!?Y''_\(#_U$O\
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MPA/_ %$/_(/_ -E7544?V+@/^??XO_,.9G*_\(3_ -1#_P @_P#V5'_"$_\
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M\(3_ -1#_P @_P#V5'_"$_\ 40_\@_\ V5=511_8N _Y]_B_\PYF<K_PA/\
MU$/_ "#_ /94?\(3_P!1#_R#_P#95U5%']BX#_GW^+_S#F9RO_"$_P#40_\
M(/\ ]E1_PA/_ %$/_(/_ -E7544?V+@/^??XO_,.9G*_\(3_ -1#_P @_P#V
M5=+:P?9K.&#=N\J-4W8QG QFI:*ZL-@,/A6Y48VOYO\ 5B;;W"BBBNT04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %)2TE !1110 4444 %%%% !1110 4444 ***!10 4449H **,T9H **
M,T9H **,T9H **,T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M)0 4444 %
M%%% !1110 4444 %%%% "BB@44 !I*4TE !1110 4444 %%%% !2BDI10 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %)2TE !1110 444O% "44O%)0 4444 %%
M%% "BB@44 !I*4TE !1110 4444 %%%% !2BDI10 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %)2TE !44DI1\ "IA5:;_7#Z4 2"0GTHW&F+3^V: (WGVYZ5 V
MH^7P0*2;!)^M49>M:))F;99;60O55J6UU+[0X&T#)QQ6)*,]N]7=,^61!C^*
MJY58CF=S>HHHK$W%%% HH #24II* "DW"EJ')IH3)2P R:B-U$OWFQ]:9("5
MS6?.#M.?U%-(3;-#^T+8MM$@)]*L @C(Y%<DBI]L&?T%=5;X$"X]*J44D3&3
M;)*44E**S- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "@T4&@!**** "BBB@ HHHH ****
M "E%)2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HI"<#-1K,[/@P2*/[S;<?H: ):*;N/I
M4;7 7KC\Z )J*JM?QIUQ^=1'5[<'&]<_[W_UJ5T!?HJ*&X6;H",C(SW'J/SJ
M6F 4444 %%%% !1110 4444 %%%!..M !13=WM1N]J '45$UPJ?>_K_A4+:C
M"GWFQ^!_PH MT5G/KEFGWI /P/\ A5BVOH;KF)LC\: +-%%% !1110 4E+24
M  JO,?WWX58/]:JR?Z\T /'2GC[E,'2GC[E %*;J?K5.7K5R;J?K5.7K6D3*
M12E_K5S3O]<G^\*IR_UJYIW^N3_>%7+8F.YNFEI#2US]3<444"BF &DI324
M%0U-4-4A,'_U=9]Q]TU??[M4IQ\IJEN0]C'7_C\%=/!_J%KF1_Q^"NF@_P!0
MM54V%3W):44E**Q-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "@T4&@!*7%)39"0.* '49
MJ,'BFL3GBJL!-02/6J<KL%ZXK+NYYD4X<CTP:+ ;^ZEKS35?$5Y:2;8YG_.N
MP\*7\NHZ0LT[EFZ'--QL!MTHI*45GU ****8!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,E^Z/]X5#
M_$:FD^Z/J*CQR:3&A*J3#YC5W%59AR:0S.N!UK,9?]('UK6G'!K,=?WP^M '
M1:=C:O'S!3@^G-7ZS]/X"_2M"FB0HHHI@%%%% !1110 4444 %1S?P_7^AJ2
MHY?X?K_0T (*6@"EJ1E*X'S&LZX'RFM.X')K.N!\II@85V/FK<T+_5#ZC^=8
MUV/F_&MO1!B'_@2_SJF)&]1112 **** "DI:2@ JO+_KC5D56E_UM "CI3Q]
MRF#I3Q]R@"E-U/UJG+UJY-U/UJG+UK2)E(HR]*NV/6+_ 'A5.7D5=L1_J_\
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MPU?R:GX:L+R;_62P@OQU-#5G8HU****0"BB@44 %%%% !5"\59+K;(BNH12
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M_6@L=<S?N\<=,UGVB>;J$8/3<#^M27,F?RQ2Z.-UX">QJ6!T8I:!12 ****
M"BBB@ HHHH **** "D-+2&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *6DI: *DW$Q''.#_2H'&*GNA^_0@=5.3].@_6J,T*2W
MCF0$A8UP-Q'K3L(E%*!ZFJ_V6W_NG_OL_P"-0^1"-0V[6V^43C>?4>]%@+-S
M(%P 1T]:SK"0W6NQQ*2?*!D8_I_6H=2"075NT0*Y+ _,>>*G\((9)KRZ;J3L
M!]O\BG;2XKZG44445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %!HH- "4V7[M.ILI^2@",=!0>E Z4'I5D%><90U@:J/W9KH)
MCA#FL'5.8S]*T@2SRKQ'_P ?9^M>I_#C_D65/O7F'B1?]*->G_#G_D5T^M:5
MOA*B=;2BDSGI2BN0L**** "@T4&@!**** &X)^O:ODCQ@N?BEJP/>=LU]<9%
M?*'B:'SOBIJQ7G]^W2M*9%CA;;G6@%X_>?UK[.\& CP;IH/:'M]37QK#&8]?
MP1TD_K7V5X-8'P?II!SF'C\S1/5W*6QN4445F,444"B@ HHHH *I3_\ '\?^
MN:_S:KM4IO\ C_;_ *YK_-J:$PIV* *6@"G./F-49AUK0F'S&J,PK2)+,B[%
M7-(Z"JMV.*N:2.E5+8E;G41?ZL?4_P Z?4<'^J'U/\ZDK U"BBB@ HHHH JZ
MC_QXR8ZUQ9;]Z<XZUWDBAEVL,@]15">*TMP";0.6; ")DUTT:J@FFCEKT'5:
M:=CGXIEC3(%8^HRL\C-@BNV7[.>FGR#ZQFJ\[6X8_P#$LD/OY7_UJVCB%%WY
M3">$E)6YCR[49&V'@US,LC"[7@]?2O9Y'LY4W+I3,,D?ZGTX]*H&.Q>Z2-M+
M$98\,\.!_*NV&8**^$XI9;)OXRYX)VM8Q$XR!QGUQ_AFNNK)L((HEM_*C5/W
MA^Z,?P&M:O'J2YY.2/;IQY8I!1116984444 %%%% !1110 4U_O)_O?T-.J&
MZE\B'S2,[.<>O!HW#8EHK ;Q2@) MF/T8?XT#Q+*P^6P<C_?7_&MO8U.QC[>
MGW-J7K5.8=:QKGQB(21)9,#Z;U_QK-N/'L:@_P"@,?\ MH/\:I8:J]D2\317
MVC6NEYJ]I QCZUP-U\1(@>; CZR#_&MCPSXNEU&X54T_9%GE_,''X4YX:K&-
MY(4,12G*T6=^.E%-1@R CI3JYCI"BBB@ I#S2TAH$)C%1-Q)P3GMWJ7I41XN
M.M.]@V$W9/#T#.W[Q_.L73=*M+JP2>99'=L\F5A_(BK/]B6&W'E/_P!_G_QJ
ME8+7+K[SG!. /SJG*["3;EA[5D:EI%I'JFF1H)0LDS!@)WY^1CZ^U23:!IY.
M"LF>O_'P_P#C511G(DG+$#)YSSGL:T+%CY:J68\X/-<.;6-M;U"R$96.& RH
MPF?.?Q-;V@QWJW<;QR1_9?)3<&.6)/6JE>UB$KLZ\=*6@=!16!N***!10,#2
M4II* "J$O_(0M_\ =?\ I5^J$O\ R$+?_=?^E-"99<_+BJ$XX'UJ\_2J4XR!
M5QW(EL<[=?\ (=L_J_\ 2NPM?]2*Y"['_$]L_J_]*Z^U_P!2*TJ;&=/<FI12
M4HKG.@**** "@T4&@!*C?J:DJ.3H:!,RK08O+W/_ #UJQ_%45O\ \?=U_OU+
M_%6DNA)'-_QZR57M(U\X95MWEKSCV%69O^/:2JL<WDRL6[1)_(4@'+MCO)&9
M@,CJ336.V\D]XQ_.H+T$328Z96EE)%YS_P \J"R&8Y)^M7=#7,S&LZ1OF:M;
M0TPI-2P-D4444@"BBB@ HHHH **** "BBB@ I#2TAH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "EI*6@"&XY"#&=S8SZ=_Z504
M;KZ8?],U_K6C.,QGVR1^59\)_P")E*/^F:_UJD)D9&#6=?WJZ?+)<NC.%C V
MKC/+ =ZU95Q(:P=?DCB@F>:-I$"IE5."?F%,1#K,O[RV;IE2V/PK9\)1;-,+
MXP6 S^&?\:XUIF<MO8M^\? )SM^4<5WOA^,Q:9L/0-Q],"G+84=S4HHHK,L*
M*** "BBB@ HHHH **** "BBB@ HHHH ,BC.:K-/Y48/)SSDUG0:JTVN):@$+
MM+'^7]:=@-JBBBD 4444 %%%% !2'I2T&@!HJO>2>7!GWJS6=K)/V5=N>M7#
M62(EI$9]N.!]S\Z1[XA<[XQ6:,8&<_E3)1E>I_*NQ4HGGRKS+%SJ<FP['@/K
MNS_C7/ZIK$ZQ\M:G\2/ZU)>#"'!S]:Y;6%8QGT^M=5.A!LS^L3,+7+R.><F6
M6!3[/7IOPQO8;KPZ4C.71L'%>$ZRC?:#P?P->O?!10-!N@!C,AP<8K/%4E&%
MT=&'JN<M3TX"G"D[4+_6O*N=XM%%% !0:*#0 E%%% $$Q+1NJ'8[#&[&<5Y1
M)\%_.UZXU.366,L\C.P\OU->JM4+_=JT[:$GCTO[/UN;S[0NM.K$DG$=>DZ&
M$\,:'#I\]Q]H\D8#E<5=E8J.*Q;\$L<UIRW6Y#FUI8[&*7SHDD7HPS3ZHZ1S
MI</^[5ZL7HS1.Z%%% HI#"BBB@ JI)_Q_/\ ]<T_FU6ZJ2?\?TG_ %S3^;4
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MV">_/Z"O-[!1)J42X.?M#Y!%>F6&19(#VR/R)HGT% L4445F:!1110 4444
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M\/36DYV7/G#/=%_PKT?X=6RV^@,-@4[N<"N-O+2.WU*Y6+< NT\G/K_A7?\
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M;;KM@4>Y_G7FNB><VKL;@8;+$8[C)KTR,8C%95-QPV'4445F6%%%% !1110
M4444 %%%% !1110!'/G[-+CKL/\ *JPD;80, = ,=!5J89A<?[)_E5-3U^M5
M$""YGD$9PV..U<]?W,H4X<Y]ZWKE"5.!7/7J'G(K6Q#;N0^$[RYE\5,DUQ(Z
M%&.UFR.E>@5YYX779XP_X P_2O0ZSEHREL%%%%0,**** "@T4&@!*;+]VG4V
M7[M %&/_ )",_P#UR7^M7#U-4H_^0E<?]<5_K5WC<>Q_G5"N9>OLITF9=PW
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M5>;40B*"$-"[,1@Y+#GCTKI9=3FO=2U. S.+9[,21(1@J"F<'MFO//%K7O\
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M3 R-?M1>:7>VY\X":, F!BK_ ($<BN"\/^'8?#-O<P:;8:KLN!EU:5R"<\D
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M%8FP4444 %57)^W2#/'EIQ^+5:JH_P#Q_P G_7)/YM0!E:Q<"UTW5YW6%A'
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MYA_X$W_H1J6N8U"BBB@ HHHH 1ONGZ57F_UT7^_5AONGZ56G_P!=#_O_ -*
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M<G\:N6=PC3?+D\^E:6T(.XMC^Y7Z#^52U#:_\>ZD]P/Y5-7&;!1110 4444
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M>2?5O_0C5FJ]@"+),C!RW_H1JQ6!L%%%% !24M)0 "H9#\Y^E3"H7Y>@!N2
M<'M4)D8.FZ+Y6SG%3XHY[$XH RKG4F2!7C@)YP0:SKC57")FU;>RYSV')']*
MZ"4#VR.@JE,"_!V[>XK6-C*2918 L>F!@Y-+9&4ZAGRU*''SXYILT;#I@YZ@
MFKFGJ[2*!P.E:2DK$1B[F[1117,= HHH%%  :2E-)0 5EW=U#;WEK)/*D2$,
M SL ,\5J51O(8GAW3PI+MR0K@'%-"9G:M9Z#KMKY6J?8;J/.0)61MOTSTI@;
M3+"R6"TFLX(8\ (CJJC\!39;71GB#SV*DMC( (Y_"LJ]M-&MY&3^RD<(X!;S
M&Z$'GK[5M$A[$&IZA9+J5IOO+<#Y\XE4\8'O75Z (ETM$MY!(@ ^85Q<@TO:
M)+33HV <@AUY'T-=MHD@DT]'10BD<(%QBM:WPF5+XC3I124HKC.D**** "BB
MB@ -87B1/W$3=MU;M9'B-=VFGV:M:+M41AB%>E(Y%KA4&&(4GU-9NL7.V';;
ML&<X^[S6DR@G+#],U1N0$;*J,_2O<BKNY\O5=DT<O*7W9,<F>_[L_P"%,67!
MQME'UC/^%;=RS$<'%9%U(W]]JZHG%)2_F*%]''G>'7)/(SBFVDB(X&X$G'0^
M]1RR$O@[3SU(J: HI#;5XYSBJGT"GN>Q^ D(\-B1OXY"1]./_KUTU8OA"$P^
M$M/!ZM'O_P"^B3_(UM5\M4=YL^XI*U./H%%%%9F@4444 %%%% !1110 4444
M %(:6D- !1110 4444 %%%%  >?:FR1K(NUNE.HI7L!CS>'T=LPW$D7TY_K4
M2Z#<JQ_T^0CH/I6[15*3 Q6TBZVX6Z<@<C)'6HUT*\)_>7S =\"MZBGSL#&@
M\.QI<"6XN))]I#*K<8-;(&.!112; ****0!1110 4444 %+24M !4+0D,[)@
M[R"0>.<8J:B@"HT,S@@K&!ZAR?Z50N=(N)P<&,?4G_"MJBJYK"M<QM*T::QG
M\R8QG_=8G^@K9HHI-W!*P4444AA1110 4444 %%%% !1110 4$9!![T44 ,\
MH8 W-Q[TAA7U('M4E% $7V=?[S?G2&V4_P 3?G4U%.X$)M4(QN;\Z9)I\$V/
M.4R = U6:* "BBBD 4444 %!HH- "4'YJ*!QTH ;Y8I/*!I^**8#/)7O49M$
M)YJ>BD!4;3+=^JG\Z=:V,%H7\E-ID.6JS13 !TI124HJ>H!1113 *#110 T@
M]JI:GI=KJUA)::A LT$BX9"*OT4T[; ]3S:Y^!?A"<YC@N(3ZI,W]359O@+X
M=X5+S4%7N/-'^%>I45M]8J]S+V-/L>3-^SWX7=\FYOR/]]?\*GM_V?\ P=#(
MKLEU+CLTN,_EBO4J*7MZO<?LH6M8YWP]X)T7PON_LBU\MC_$S%CC\:Z&EHK)
MMMW;+44M@%%%%(84444 %-9%;J*=10!$8 >F!^'_ ->F&V8]'3_OC_Z]6**
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU=_\! K_ -?+_@_>,UCQ)KWAZSAAU(6,]Y=W:6]O/9VD\JJ"C.S- I9R1L(
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M&.U#:Y+6U_X;]4RH.TD[[-?=K_P/4P/AYKUWXBT=;D)!!IUO&EM%$P)N"Z*
MS/SA >RXSCG/.*Y/5M(6RNM5UN^T>#7+5;J2X_MW3]1"W=FBMR@4C&8\$8#=
MN1G(KTNST'3=/OFO+*V\F=X4@=D=L.J#"[AG!('&XC..]9]YX$\.7^H27MUI
MY:69P\RK/(D<K#N\:L$8\=P<U7M%[3F1G&+4.5_UI_7YG/W/C37(IM;OK9=.
M?2='NH8VC>-_/GC=(V)#;L*PW\?*<]..IL7'C#5UNI[V*.R&DPZJNEF)HW-P
M6+!/,SN P&8?+C) SFBQ\*:/-XZUHZJ$N+R6>&_A@264*L0140R+PC$/&Q .
M['7BNA?PIHKZW_:S6?\ I?F"4GSG$9D P',>=A8#C=C/O1>"Y;KHOTO^OH%I
M:KK_ ,/;]&87P^BU5+C73?7MG-"-5N R0V;QL9/ERP8RL O^S@G_ &J[6LZT
MT'3['5KG4;2.6*XNCNF"W$GENW'S>7NV;N!\V,^]:-9R=[>B+2LWZL****D8
M5D^*-&&O^%[_ $W.UYXCY3_W)!RC?@P!K6HH]!K1GF^E:Q_PFVJ:9/*F4T;3
MVN;N,]%O'#1[#CNH60_\"%4/"PU2Y\0>$YK&?3K.!_#S/' +.601Q[H=R;C-
MDG/1CT'4-UKT;3] TO2C?'3[1(#J$S3W14G]X[#!/)X^@P*R-8TOPKX=TBPO
MM3WZ?:Z.JPVT\=S,C1*Q4!"4;<RDA<@Y''-;QJ+FT7]-2_5JWD9.+M;^M+?Y
M:^;,J#QCKL][I5T(].72]3U26R2+8YGC5/,&XMNVDDQ]-O'O5;2_%OB[4;?0
MI,:*O]N"41'R)?\ 1B@+98>9\^0IX!7![FNG3P7X?_M:/58[(_:$F-S&5N)/
M+61@076/=L!.3G Y[TNF:=X>%U#I^G1?O?#[;8X]TG^CF1,]2?FRK>^,U*<;
M;?U_P]BG=NZ_K<X]_%UQ/-::O)8VG]H6VCZFQ?\ >%1)!(BD*-P&QBN><GI@
MCG/1>'=?UFYUN"PUQ;%OM>FK?PM9QNGE\@,C;F.[[PP1COQ6B/!VA",QBQ^4
MQ7$./.D^Y.VZ4?>_B//MVQ3(YO#UI=WEZC;)M"M?LMP^)#Y$6U9-N.C<!3D9
M/:CFC:UN_P";_5K^MSE;V[_Y?HF<]#H>F^+O%WB;_A*(!='3YH[>TBD8@6\1
MB5O,3GAF8L=W7Y?:NKLIDLO#-N^FR7&O1QQ*(I(YHGDN!TSO)5"??(Z>M5-1
M\*^'O$\D6I7EH9GDA $L4TD)EC/(5MC+N'/1L]:VX((K6WC@MHUBAB4(B(,!
M0.  /2I;]U+T_#_,%J[G,^"O$.IZW;W/]IZ9>0^7=W*+<2F#8 LK*L>$<MN
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MQ7:77A[2[V6^DN;7>^H6HM+D^8P\R(;L+P>/OMR,'GK52M'I^ DG>S\OTO\
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ME_;I;027\Z>; 53<%M5B(D#9?YR<J>NW;7K%%4JFMVK@U=61RWP^Y\-W./\
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M/:S6<S1&XNB3OX7_ %C@!,(<@[CP:[G5/&$.GZI-I]MI.J:I-;HLEP;"%&6
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!R&OBYT?QO8>(18W5]9?8I+*9;2$S20DNKJX1>2#@@X![5G:Y!
M/XSD\/'4_#]S%IXU9RT,ZDLT(@D >50/W8+'&TGTSUQ7H%%7&5DO+_.XFKW\
M_P#*QY'XD\,7</B6X@L[1[>V6&!-'DM-(DNFMMIRPCD65$@;=R2^ 1CD@8I=
M5T>9]<8WFB7]UK)\06\Z:A':NT8M!(A'[P94*H'*9X/..]>MT54:K33[?YI_
MIJ3**::_K9K]3R6W\&1R6^GW,VBS"ZG\1W O'\IPSVK22G#_ /3(C;U^4Y]Z
M[7P18R:98:E9&WDMK:'4YUM(G0JJPY!79G^').,<>E=+14\[:M_73_+\1N-W
M?^NO^?X(****@H**** "BBB@ HHHH **** "N.\6:->:OXR\/?9;F_L8HHKO
MS+RR5<QY"8!9E91G!ZCG'%=C6'XHUZZT*WL/L&GI?W-]>+:QQ27'DJ"RLV2V
MUO[OIWJHWYE;^KZ!T.&_L.^MM*:#6K*_U/R];\S67\EI#J$/ED1NJJ/G4?N\
MHH."IXJ"TTADTF+[5H.H'01K]Q-/I[6KL[0E,1,8<%G0-@[<'MQQ7<Z1XGN9
M]3OM/\0:?#I5S9VZ73,EX)HC$Q89+E5P04.01^-:::_H\NEMJ<>K6+V"'#7:
MW*&)?J^<?K6G-)?UZ?Y:=B&D_P"O7_Y+\CS#1-%U6.6W.EZ9>V&)-8-M]HA9
M/)\P)Y.XGIG'&?3VJC/H9DM;M=%\-ZI:R'PQ<V]R9+*1?.NB8\C)'SN<'YAG
M=V)QQZY/XAT6UTZ+4+G5["&RF.(KF2Y18Y/HQ.#^%96H>/-%T[Q/8:1/J%@H
MNX'E:9[U%\O&W8,'KOW''(SCC-.,I7LEY?@_\QZ+7SO^*?Z'*ZAX:O=-DUBU
M\,:?/;076BP-(L"E!-,)3Y@#=/-,>1G.>1FH=5TJ.;10/"V@7FGZ4-0A>]MK
MG3I629 C D6FY790VS<!C=C/S8Y[J'Q7IT4,\FLWFGZ8([F:&/S;^(B18VP6
MSG@\C*GE<X-7KG6]*LK2"ZO-3L[>WN"!#-+<(J2D]-I)P<^U+GEO_7<7*EI_
M6UF8_@&RGL/#)BF,_EFXD:!)K-K7RXR<A5C9W94'. Q! ["NFJ*UNK>]M4N;
M*>*X@D&4EB<.K#U!'!J6LY-MW925D%%%%2,*R/%D$MSX,UF"WC>662QF1(T4
MLS,4(  '4UKT4GJBHOE:9Y]#=7/B2#PYI=II&IVPL)H+B[N;VS>W6,1+]U=X
M!9F/' Z9S7-WVA70T'2GNM+N9Y(1>*+6ZTF6[ART[,IVQL)(I",;7QC!ZBO6
M=6U2VT72+K4K]BMO:Q&60@9. .P]:Q]*\1:U<ZA;1:OX9EL+>\0M#<17'VCR
MR!D"8!1Y9([Y(SQFM^9MW7K^!BHJ*5_3[O\ ASE)-/,NL&?Q)X<U*ZN);:S_
M +,^S*\ILR /,3SL_NV#\EF(W#N>E)#I-V/$T;'2[P:\-9>:74_(;RVLLMA?
M-^Z5V;5$><AN<=Z[^'Q!HUQ#=2V^KV$L=GG[2Z7*,L&.N\@_+T[U!_PEWAOR
M6E_X2#2O+1BC/]MCPK 9()W=<<XI.3?3^M/Z?<?*K<O];-?K\CS>UT:2+0M%
M7Q)H6H7UG'I,D4%M':/(UO=&0G+(!E&*XPY Q@\C-;&A^$'U#Q1'-XOTW[;<
M6VBV*B>="R?:%,F_!Z%AQGOS[UW!\0:,)+1#J]B'O5#6J_:4S< ]"@S\P^F:
M6;7=)MK\V-QJEE%=JAD-O)<(L@0#);:3G&.<TW4EK\_U_P _R!Q4OZ]/\OQ9
MYCI>@B7Q!X?BO_#UX^HI=W7]LWD]FYAG#1R %G(VNIR .H ..,XIUGH$5EX3
MET^R\/2VVJ0ZW$\[1::R>9"+W>A$@7#J$P>"=H':NJT[XB:?JVG3SZ:]A/<0
MW_V4VXU*($Q^<(Q-D]B#N [\ $YKH8]?T:;4?[/AU:QDO=S+]F6Y0R97[PVY
MSD8Y]*KGFFG;;]-?N"23NOZZH\_ATF['B:-CI=Y_;PUEYI=3\AA$UD2V%\W[
MI79M41YR&YQWI?!_AJ31_P#A#[R#2Y[2[D2XCU*3R65BI5BHEST&X+C/3M7?
MG7]'&I'3CJUB+T,$-M]I3S QY VYSD^E:%0IM1M_6UAN-V_ZZW"BBBLB@K \
M=V\]Y\/]<M[2&2>>6QE6.*)"S.Q4X  Y)K?HH&G9W/*M-M[RZ\0:2]NWB;4%
MMXYA,-;L3!%;@Q$;HSY:9?.% ^;@GIUI;+P=%IWPQT5[+1'BU:673VO-L#><
M=LT;-O'4!<$G/0#VKU2LOQ'KD?AW0;C4YHFF$6U5C5@NYF8*H)/ &2,D]!6W
MM7S77=?@V_QN9>S5K>5CS+[#':^(M#_M#2;R/73XB=KF_D@;9-&?,*8E^ZPV
M[<*"=N#P.]W1_"8MH_#MP=&D%Q<:C=Q:D9+<DO;N)L+*"/N$[, \<C'6MWP]
MI,4?B)KK5?"_]ESJ'NX9X=2>YM59N'(4[5C<YSD+R">>M=+'XCT26P>^BUG3
MWM(W$;W"W2&-7)P%+9P#DCCWIN3227]= :YI-_UU?ZGF</A^2T\"ZCINDZ$]
MEJ4>HDWA33&'VBU^TLP567:)EV$?(KYQD<4^R\,R7C:3;W%C/<:4VN-*;9M*
M>T@AC^S.#B)W=EC+]FV@DGC!KTRRUW2-1\O^S]5LKOS S)Y%PC[@N Q&#SC(
MSZ9%13>*- MUB:XUS38A.@>(O=QKYBDX!7)Y!((R/2A3EVW_ .!_E^8W%._S
M_&_^?Y'GEGHFHVUY!;QZ==I:6CZS#;KY+;8XFV^4HX^Z>=OKVI;7PQJ.EV=@
MGANPFL;N[\,S1W,BHR;KD+'Y?F,>CY+XSSU]*]+M-6T[4+B>"PO[6YFMSMFC
MAF5VB/HP!R/QJ>YMH;RUEMKJ)989D*21N,AE(P014<[2^7^?^=RK*]_._P"*
M?Z'FW@VWTVW^(<"Z3H]WI:C1")TN;=H2\GFIDX;[Q]7Z-ZG%>FUDZ/X8TG0I
MI)M-MY%EE18VDFN))F"+T4%V)"C/W1@5K43DI/3^M6R8QY;_ -=$OT"BBBLR
MPKR35;:ZB\1^*DDF\6V8O+@&!=*TXRP3@P(N2WE-SD$<,.G;K7K=%5%V;\U;
M\O\ (#S?0/",6H>)XI_$F@QK]ET6Q6)&C)BBF4R;E4G@E>/4C/O6?%I$T:6#
M>(-&O;W2$O\ 4FEM%M'E(D><F&0Q@9*[=V&Q@;@?>O6*S-7\/:;KIA;489&D
M@W>5+#/)#(@888!XV5L'N,X-6ZC;N_ZN0H)*WI^"L>8>$_#5OK=KIAU#2I+B
MRCTJ\5!.A94D-T=H)Z%P.1SGC(J[;Z'$9O!>K>)/#SWDG]FM#?2/IK7$JS;8
M_+,JA2V1M;DCCVS7IUC8VVF6$-E80K!;0($CC3HH%3T_:N^G];_Y_@A<G?\
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M\3Z1LLM!U&&UAU"Q9)+F!XY92+A2^(BNX*H&2Q]^PS6+9Z+K'_"<M/<K-%J
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M&N5"H%0F$JIQWYXXS6;XPU[4=-\2>3=:Q>:!I(ME>&\MM-%TLLI8[ED8HVP
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M):PRQPLID*$.-Q (RF#WY[UD:3X(O[)1#>V<-P$\-+8!]RLIFW.609YQR.<
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M7DL^PLN#M\QV"YZ9&*B\ >$X_#7ANQ$T-Q#J+6D<=TDEY)*JL!R I<HO/]W
MH'Q!L)8K46FFZE<WERTR_88TC$T1A.) VYPN02. Q)SQFI[OQK:6TZQ1:;JE
MTZVZ7-PL-M\UK&Y^4R*Q#9X/RJ"W!XHO-W\_^#^&XDHI)=O^!^)4\;6%_J;)
M:G09]7T]HR1]BU'[)+'+R/FRZAD(/3GGL:S[+2O$?AZ31K]=,76+B+21874-
MM/'$8V#!E(WE5(Z@XQTR!6W!XUMKG5;RTBTO4O(L97BN;]HT$$15-Y))?=C!
M'134$?Q"TLVTDUW:7]EBW6Y@2XB4-=1LP53&%8\EF4;6VGYAD"DN9*R7]-/]
M&QNS>O\ 6J_5(T/"&E7.C>%;2SOM@N1ODE5&W*K.[.5![XW8S[5MURLOC^R@
MA FTS4TO/MJ636'EQF99'0NF</M*D#J&/Z'&QH>N0:]9RSP0SVSPS-!/;W"@
M212+U4X)'<'()&#2DFVY?U_6H*R27]?UHS2HHHJ"@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#$UG1]5NK^*]T37'TZ98S%)%-#]H@D7.
M0?+W+AA_>!''!S6#<_#."YT^U$]U;7>H0W4UW)-?:>D\$KR_?!AR !P,8;(Q
MU/-=S15*36PFKG-Z)X/31=2L[N.XA(M[*2U,4%HD",7D$A8*F HXQC!]R3UJ
MIX'F37!/_:Q.EKJ)U-;'[,-XG.?^6N[[N23C;GWQ7744<\KW_K>_YBY5:W];
M6_(Y:T\%_9;;0XOM^_\ LF^FO,^3CS?,$@V_>^7'F=>>G3FM3P_HO]A6=S!]
MH\_S[R>ZW;-NWS'+;>ISC.,]ZU:*.9L=E_7S_P V%%%%2,**** "BBB@ HHH
MH P=5T769M3:]T+Q UAYD826WN;;[3"<9PRKO78W/.#@\<5@W/POM)+335AG
MM)[FRCE1GU+3DNHY?,?>S>62H5MV2,'@'&#7>452DUL*US \/>%D\/WMS/'<
MK(L]O! (TMTB"^4&&0$PHSNZ  "LVQ\!S6FH0&;6#/I]E+<365K]F"M$\P8'
M=)N^< .V!@=>2:[&BAR;O?J"22LCF-+\'?V;_P (W_IWF_V'9R6O^IQY^]57
M=][Y<;>G/6M3PYHW_"/Z!;Z9Y_VCR-W[S9MW;F+=,GU]:TZ*)2<M_P"M_P#,
M%%+8****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !63KFE7VH_9YM)U>73+JW8E6V>;%(",%9(\@
M-['((['K6M11L!QC^ [J:*:ZGUL-K4E[%>K>K9A8D>-2BCRMW(VD@Y;)SUJQ
M9^"6MVTV:?4S/<VNI2ZE<2>0%$\CHR$!=WR ;AC[W3WS75T5?/+^OZ\D2XI[
M_P!;_P";.'U#X=&]LYH/MUE,DM]<79COM,6XC!E;/'S!@R]F# 'N*L0>"+[3
MO+_L;Q#+;,]G#:7<LMN)I)1'G:ZDL-CX)&2&&,<<5V%%"G)*PVDW=_U?4P[/
MPS%!9:U:7,[7$.KSR2R#;M**Z!"N<G/3KQUZ5S,/PFL_[+N+&YETW:T*1126
MNCPPN2KJX:5N3(<J,CY5/.1W'H5%)3DMO+\-@LOZ\SC+#X?K:"T;[1I\+V^H
MQWK+I^EI:QL$1E";58G/S$[F9O8"M_1M&_LB;4Y//\[[?>M=8V;?+RJC;U.?
MN]>.M:E%#G)[_P!;?Y(.5?U\_P#-A1114C"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH XGXB_\ ,._[:_\ LE<37;?$7_F'?]M?_9*XFO;PO\%?UU/ALU_W
MR?R_)!11174>:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %>H^#O^13L_^!_^AM7EU>H^#O\
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M]"6N_+?][I^IQX[_ ':?H=[7FNJ_\AB\_P"N[_\ H1KTJO-=5_Y#%Y_UW?\
M]"->UQ'_  J?J_R/CH;E6BBBOBS4**** "BBB@ HHHH **** "BBB@ HHHH
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MS%)ZD-%%%<8PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH]CB'??[_P"O(KVE%%+[;=>>T_VF;S6&&D\P[B/3-"WMTAC*7,RF($1XD(V
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M44 %%%% '$_$7_F'?]M?_9*XFNV^(O\ S#O^VO\ [)7$U[>%_@K^NI\-FO\
MOD_E^2"BBBNH\TEM'6*]@D<X59%8GT -:$-]#'JFI3B4JLT<PB8 \ENGTJM8
M6L4T<]Q=%Q!;J"PC(#,2<  GI]?:G-:07CQ#2O,WL&WPS,/W>.<[\ 8Q],8K
M*7*W9G53YXQ3CWNN[Z&C;:E9FPCMYGC,AM3$SRA]JD2%MIV\X(QTS5*ZU$#7
M(;N,QR>08\&-656V@?WB3VQDTD6E,OVH78*-% )DV,&5LLHSD9!')Z4ZZT2<
M7]S%9H7BBE,:%W4,Q'89QN..PJ%[-2O<VDZ\J:7+M9>>G_#$J26%E=3WMO=B
M8LKB&'8P8%@1\Q(QQGL3FK,U_9AGN%O!-NL5MQ;[&!W;0.XQ@$9Z]:RDTJ\>
MV$ZQKL*[AF10VW.-VTG.,]\8JY/H/EW$:+,H5K7SB1(CG<$+$8!Z<=?YTFH)
MZL<)5VO=AY]=WUW_ . 7CJ-IYMW-'<FX:ZGBD2U$;;N'!*G(QG' P34T,L-H
MLUQ+>F2,ZE'(V8W!3[Q.01][U STKGFTN\2W%P8@$P&XD7< >A*YR ?4BK&I
MVVKI%G4Y))5B;80UP)/+)[$ G;TI.G#9/^M"UB*NLI0V\GUOKOYLBT^YACN+
MF.X8I#<QM&7 SLY!!Q]0*LV+:?IUY!(;SSG!?>\:-L5=I '*@DY/IBHX-&DN
M]+AN+4;I7F>,JTBKG 4@ '&3R>!FJT>F7<L!F2+Y1NX+ ,=O7"DY./85H^1W
MU,(NK#E:A?JM&:,VHVYTF2&.8^8UI#%@ C)5R6'Y5936;.-XY&<R$/;,WRG/
MRQD,>>X)%9\^B3%@UF T2Q1.[RRH@5G7.,DCWJ!-(O7=U\D(R2>61)(J9;T&
M2,GZ5'+3:>O]:&GM,3&2:CTLM'Y_\$NP36T"3VS:KYHGB=5D"/LB)93W&><8
M.!^=27U_:-:30QW7GM]CBA#;&&YE?)ZCT]:R;:PN+R:2.! 6C4L^YPH4 X))
M) [U(FD7DI;RTC?:VW*S(0QQG"G/S''89JG&%]7^1$:M9QM&&^G7_,L6VIK:
M:-'"BPR2BY,C1S0JX*[0/X@<=#TYJZ=1LII+X/-&?M)CD1KA9-J@9_=G9SQG
MC''%9\FDLNCPW:LA>1V!7SDZ +C SG/)XZ^U,;1KY9$C,*EW8H )%/S 9VGG
MAO8\TFJ;UN.,\1!*/+=671]4U^I<EO;>\_M-);F*)KAXW20QN$;;G/ W$9SW
MJ>XU&TFA<PS6\/G0QQ%2DI=,8]]N!C.1S[52T_19;I\W $2-%(Z;I41B5!QP
M3G&1UQ53^SKG=$ BMYLOE(5D5@S<<9!QW'-'+"]K_P!?TANK74>9QWOT?K_[
M<:]YJ]K<7MC<I*X%K.-Z%>9 ""9>!C)QR/I4!:S>&\M3J$($TR3)+LD*X&X%
M2-N<_-GICWJJFBW9\II1'$DK84M,@)^;:<+G)Y]*7^QKF2YFBMS%)Y;..9D5
MB%)R=I;(Z4)4TK)@YXB3YG"]_)]5;\BSJVIP7MK*L+ME[UY0A!&5V@ ^G8U-
M'<V+7K7GVR))HX(D@$J/M#A "QPIZ8X]ZRAIMT;3[2(AY>W?]\;MN<;MN<XS
MWQBDM=.N;R&26%4\N,@.\DJH 3TY8CTI\D%&UR?;5G/F<;MZ[/S=_P!35M=0
MM[6!$:[$DB&X)D17Y+Q@*>0#R:+.[AETM+;S&5Q:R1O+L9A$#(&&< G:1QQG
MK68=*O!;&?RU*!2W$BEBH."P7.2/?&*6.VO[.XE:'S(9;= SM')@J#C'(/\
MM#I2<(/9_P!?TRE6K1M>.GH_+_Y'\RUKP"M8()?-VV:#?@C/+>O./Z5DUKKH
M^H7%]')J.YE>9(YI/.5W7<0,'DD'ZU4O],GL69I%'E>845ED5\$=C@\''8XJ
MH2BERW,JU.I)NIRM+^E^A3HHHK8Y HHHH *]1\'?\BG9_P# _P#T-J\NKU'P
M=_R*=G_P/_T-JX<;_#7J>YD?^\R_P_JCG?'/_(<A_P"O9?\ T)JYNND\<_\
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M]@,=/:I'UP22-OMOW;M-O7S.2)"#@''!&.M/O]/M6U*_=9GA@@D(<+"/E);
M51NY_3I3'T>""-Y;F\98]Z*A2'<7#+N!QN&.*T?UN[:?_I/]=#-/#N*T_/K_
M ,.1+J%J(G@-DWV<LKJHF^8, 1DMCG.>F!27^J?;DE40^7YD_G?>SCY<8Z5:
MB\.3-(R.TF?.:%&CA+KD=V.?E'(]:S[6R\Z6<3N8DMU+2,%W$8., 9&3DCO6
M<UBE%0DK)^BVU_ N+H-\R>WJ3"_M7@M5N+69GMUVAHYPH/S%NFT^OK3+[4C>
MQ[6B"$SO,2#Q\V.,?A5I]'MHH&N'O7\D1I("L&6.XD8QN[8]:CDTF.W:9KJY
M*PQLBHZ1[BY9=PXR,<=>:<X8IQ<96L]_A_'[A1E0YKK?Y_UU+45TFI+)YZ0[
M/,1@CW0B92%"DY(P0<=!S4.H:JDE_F)-R17;S*V[&\';QTX^[^M3?9H/^$Q6
MW\N,P[P-NWY2-OI5>'2(+G8\%XQ@.\.[0X*E5W=,\@@>OX5O)XB2:C:]VGMT
M:_"]O^&,H^RBU)[6NM^O_#$+ZC'+;S1RP,=\S31E9,;&/KP<C\JMMXB9[A)V
M2=G$BR.C7),9P<\+CC)]<XID&FV]W:#[*[%FN GFRIMVKM)/ 8CM4UAIMH62
M=;@S0R+,A\R#!0K&3G&3ZYJ:<<7=<K5M.W3_ (=%3>'L[K;U_KH4[/5?LD03
MR=^)6DSOQU0KCI[YI/[4_?"3R>EJ;?&[_9*[NGOTJWI^GVBWMN[2M-#/&Y0-
M .H!R"-W&.HZU#9Z,+V/S8I)S$TGEHRV^XYQR6 /R@9ZY-0H8MQC&+^6G1)?
MDRG*A=M_KYEN>> 6=Y<2>29[B%4WQW ;><KT3&5Z<YK*M[R-+5[:ZA::%F#K
ML?8RMTR#@]O:KG]B(/*BDNBMU*KE8Q%E05+#!;/?;Z4LNEVOD>>\K01QP1,P
M1-Y9G!]2/2JJ1Q$WSV2MIT\Y._3[]=NI,)48KEO?[_1?TB :E#^]B-F%M9$5
M?+C?:PVG(.[!R>O;O4R:[LF5_L_RI-'(BA^BHI4+T]^M,DTB.W,C75T4B#JD
M;I%N+Y7=DC(P,$>M1C2\ZV^G^=G8S+O"\M@9X&>I[#-1?%P:76_EOO\ \-T+
MMAY)^GGY?\#S)#K3M9+"PG#K%Y0V7!5"/4H!R<>^/:H;N_ANLRFU(N6V[I#)
ME<CN%QQGW)J[:Z3N:\MT5FD^S!Q]HB\MHSO7)(.<<9Y!Z4RVTJVNH5CAFW,U
MTL7GE".-I)PN>F1]:MPQ4TDVG?TW3:^_S\]R5*A%MKIZC)-93SKB:"W:.6X9
M78M*& 8,&R!M'''2E768H9UDM[0IFX6>4&7.XCH!QP.3ZU5NK.**UCN+:=IH
MG=D.^/80PQVR>.:IUS2Q&(IRLWJO3KK^)K&C2DM%^?H66N]VGFVV=9O-W9]L
M8Q4Z:ILGMY/)SY-N8,;NN0PST_VNGM6?16"K5%JGV_#8U=.#5FC6EUQYH0'$
M_F;54@7)$9QCG9CKQZX]JFDU*UDLTFG@\QVO)9A&LV"F=I /!R/RZ5AT5O\
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M_P#@?_H;5PXW^&O4]S(_]YE_A_5'.^.?^0Y#_P!>R_\ H35S==)XY_Y#D/\
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MIJ3&C",FT:/]MW*C$"QP*(_+01[OD&X-D$DG.1WH369HY \<,"$2B4A5(!8
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MC=U>_77Y["LMBS9ZA#''^^D;<9V8'!)4%2-WYD5!>R0C3;6WCN1.T;N6*JP
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MJ-VEW) T88".".,[AW48/X54HJE!)W,Y5YRAR/;_ (;_ "1LZ=J=E$+!KP7
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MX*@YYYZD>E5:**Y)SYW>UAA1114 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7I6E?\@>S_ .N"?^@BO-:]
M*TK_ ) ]G_UP3_T$5]3PY_%J>GZF<RU1117VAF%%%% !1110 4444 <3\1?^
M8=_VU_\ 9*XFNV^(O_,._P"VO_LE<37MX7^"OZZGPV:_[Y/Y?D@HHHKJ/-+=
MG>I;PSP7$+303A=RJ^Q@0>"#@^I[=ZU)-4L[K3[M[BVPKR0*D"3X8!489!(/
M\N]8%%9RIQD[_P!?UH;T\1."LMM>WG_FS?EU6UN-,\R\MQ(QNRRPQS;2BA%
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M;'EB4@.3Z\XK1L;=K"V9=3C\I9YX@L4RX)PV2V#VQQ^-6K.S-G?0"> 12/J
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MG!R<\ _0U5@LOM=[/&I90FY@L:;F;!Z 9&:B<<4XQB]W=6T[7?WW#0=::E'
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MTZ=7?\PLC1M]7>V@5(H\,L1C#$YZMNZ8_#%$.JK;-FVM_+S*LA&_(& 00..
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MDI>1U*MG;D8 !'WO6L6KC)25T85*4J;LPHHHJS(**** "BBB@ HHHH ****
M"BBB@ KU'P=_R*=G_P #_P#0VKRZO4?!W_(IV?\ P/\ ]#:N'&_PUZGN9'_O
M,O\ #^J.=\<_\AR'_KV7_P!":N;KI/'/_(<A_P"O9?\ T)JYNOR7,O\ >ZGJ
M?L>!_P!VAZ!1117 =@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\]>.M,DOY93<EE3_ $D@O@'C!SQ5:BB6(JRWE_7]-A8****P&%%%% !1110
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M_KV7_P!":N;KI/'/_(<A_P"O9?\ T)JYNOR7,O\ >ZGJ?L>!_P!VAZ!1117
M=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=)X&_P"0Y-_U
M[-_Z$M<W72>!O^0Y-_U[-_Z$M=^6_P"]T_4X\=_NT_0[VO-=5_Y#%Y_UW?\
M]"->E5YKJO\ R&+S_KN__H1KVN(_X5/U?Y'QT-RK1117Q9J%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\AR;_KV;_P!"6N;KI/ W_(<F_P"O9O\ T):[\M_WNGZG'CO]VGZ'>UYKJO\
MR&+S_KN__H1KTJO-=5_Y#%Y_UW?_ -"->UQ'_"I^K_(^.AN5:***^+-0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#[*CZU1[_F']E8S^3\5_F<317;?\*Z_P"HI_Y+_P#V5'_"NO\ J*?^2_\
M]E1]:H]_S#^RL9_)^*_S.)KU'P=_R*=G_P #_P#0VK$_X5U_U%/_ "7_ /LJ
MZG1]._LG28;+S?.\K=\^W;G+$],GUKEQ5:G4@E%]3ULJP6(P]=SJQLK=UW1Q
M_CG_ )#D/_7LO_H35S=>AZYX9_MJ^2X^U^3MC$>WRMV<$G.<CUK-_P"$!_ZB
M7_D#_P"RK\\QN68NKB9SA"Z;[K_,_2L+C\/3H1A*6J\G_D<=178_\(#_ -1+
M_P @?_94?\(#_P!1+_R!_P#95Q_V1C?Y/Q7^9T_VEA?YOP?^1QU%=C_P@/\
MU$O_ "!_]E1_P@/_ %$O_('_ -E1_9&-_D_%?YA_:6%_F_!_Y''45V/_  @/
M_42_\@?_ &5'_" _]1+_ ,@?_94?V1C?Y/Q7^8?VEA?YOP?^1QU%=C_P@/\
MU$O_ "!_]E1_P@/_ %$O_('_ -E1_9&-_D_%?YA_:6%_F_!_Y''45V/_  @/
M_42_\@?_ &5'_" _]1+_ ,@?_94?V1C?Y/Q7^8?VEA?YOP?^1QU%=C_P@/\
MU$O_ "!_]E1_P@/_ %$O_('_ -E1_9&-_D_%?YA_:6%_F_!_Y''45V/_  @/
M_42_\@?_ &5'_" _]1+_ ,@?_94?V1C?Y/Q7^8?VEA?YOP?^1QU%=C_P@/\
MU$O_ "!_]E1_P@/_ %$O_('_ -E1_9&-_D_%?YA_:6%_F_!_Y''45V/_  @/
M_42_\@?_ &5'_" _]1+_ ,@?_94?V1C?Y/Q7^8?VEA?YOP?^1QU%=C_P@/\
MU$O_ "!_]E1_P@/_ %$O_('_ -E1_9&-_D_%?YA_:6%_F_!_Y''45V/_  @/
M_42_\@?_ &5'_" _]1+_ ,@?_94?V1C?Y/Q7^8?VEA?YOP?^1QU%=C_P@/\
MU$O_ "!_]E1_P@/_ %$O_('_ -E1_9&-_D_%?YA_:6%_F_!_Y''45V/_  @/
M_42_\@?_ &5'_" _]1+_ ,@?_94?V1C?Y/Q7^8?VEA?YOP?^1QU%=C_P@/\
MU$O_ "!_]E1_P@/_ %$O_('_ -E1_9&-_D_%?YA_:6%_F_!_Y''45V/_  @/
M_42_\@?_ &5'_" _]1+_ ,@?_94?V1C?Y/Q7^8?VEA?YOP?^1QU%=C_P@/\
MU$O_ "!_]E1_P@/_ %$O_('_ -E1_9&-_D_%?YA_:6%_F_!_Y''45V/_  @/
M_42_\@?_ &5'_" _]1+_ ,@?_94?V1C?Y/Q7^8?VEA?YOP?^1QU%=C_P@/\
MU$O_ "!_]E1_P@/_ %$O_('_ -E1_9&-_D_%?YA_:6%_F_!_Y''45V/_  @/
M_42_\@?_ &5'_" _]1+_ ,@?_94?V1C?Y/Q7^8?VEA?YOP?^1QU%=C_P@/\
MU$O_ "!_]E1_P@/_ %$O_('_ -E1_9&-_D_%?YA_:6%_F_!_Y''45V/_  @/
M_42_\@?_ &5'_" _]1+_ ,@?_94?V1C?Y/Q7^8?VEA?YOP?^1QU%=C_P@/\
MU$O_ "!_]E1_P@/_ %$O_('_ -E1_9&-_D_%?YA_:6%_F_!_Y''45V/_  @/
M_42_\@?_ &5'_" _]1+_ ,@?_94?V1C?Y/Q7^8?VEA?YOP?^1QU%=C_P@/\
MU$O_ "!_]E1_P@/_ %$O_('_ -E1_9&-_D_%?YA_:6%_F_!_Y''45V/_  @/
M_42_\@?_ &5'_" _]1+_ ,@?_94?V1C?Y/Q7^8?VEA?YOP?^1QU%=C_P@/\
MU$O_ "!_]E1_P@/_ %$O_('_ -E1_9&-_D_%?YA_:6%_F_!_Y''45V/_  @/
M_42_\@?_ &5'_" _]1+_ ,@?_94?V1C?Y/Q7^8?VEA?YOP?^1QU%=C_P@/\
MU$O_ "!_]E1_P@/_ %$O_('_ -E1_9&-_D_%?YA_:6%_F_!_Y''45V/_  @/
M_42_\@?_ &5'_" _]1+_ ,@?_94?V1C?Y/Q7^8?VEA?YOP?^1QU%=C_P@/\
MU$O_ "!_]E1_P@/_ %$O_('_ -E1_9&-_D_%?YA_:6%_F_!_Y''45V/_  @/
M_42_\@?_ &5'_" _]1+_ ,@?_94?V1C?Y/Q7^8?VEA?YOP?^1QU%=C_P@/\
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MJ/\ A"?^HA_Y!_\ LJ/[%Q__ #[_ !7^8<R.5HKJO^$)_P"HA_Y!_P#LJ/\
MA"?^HA_Y!_\ LJ/[%Q__ #[_ !7^8<R.5HKJO^$)_P"HA_Y!_P#LJ/\ A"?^
MHA_Y!_\ LJ/[%Q__ #[_ !7^8<R.5HKJO^$)_P"HA_Y!_P#LJ/\ A"?^HA_Y
M!_\ LJ/[%Q__ #[_ !7^8<R.5HKJO^$)_P"HA_Y!_P#LJ/\ A"?^HA_Y!_\
MLJ/[%Q__ #[_ !7^8<R.5HKJO^$)_P"HA_Y!_P#LJ/\ A"?^HA_Y!_\ LJ/[
M%Q__ #[_ !7^8<R.5HKJO^$)_P"HA_Y!_P#LJ/\ A"?^HA_Y!_\ LJ/[%Q__
M #[_ !7^8<R.5HKJO^$)_P"HA_Y!_P#LJ/\ A"?^HA_Y!_\ LJ/[%Q__ #[_
M !7^8<R.5HKJO^$)_P"HA_Y!_P#LJ/\ A"?^HA_Y!_\ LJ/[%Q__ #[_ !7^
M8<R.5HKJO^$)_P"HA_Y!_P#LJ/\ A"?^HA_Y!_\ LJ/[%Q__ #[_ !7^8<R.
M5HKJO^$)_P"HA_Y!_P#LJ/\ A"?^HA_Y!_\ LJ/[%Q__ #[_ !7^8<R.5HKJ
MO^$)_P"HA_Y!_P#LJ/\ A"?^HA_Y!_\ LJ/[%Q__ #[_ !7^8<R.5HKJO^$)
M_P"HA_Y!_P#LJ/\ A"?^HA_Y!_\ LJ/[%Q__ #[_ !7^8<R.5HKJO^$)_P"H
MA_Y!_P#LJ/\ A"?^HA_Y!_\ LJ/[%Q__ #[_ !7^8<R.5HKJO^$)_P"HA_Y!
M_P#LJ/\ A"?^HA_Y!_\ LJ/[%Q__ #[_ !7^8<R.5HKJO^$)_P"HA_Y!_P#L
MJ/\ A"?^HA_Y!_\ LJ/[%Q__ #[_ !7^8<R.5HKJO^$)_P"HA_Y!_P#LJ/\
MA"?^HA_Y!_\ LJ/[%Q__ #[_ !7^8<R.5HKJO^$)_P"HA_Y!_P#LJ/\ A"?^
MHA_Y!_\ LJ/[%Q__ #[_ !7^8<R.5HKJO^$)_P"HA_Y!_P#LJ/\ A"?^HA_Y
M!_\ LJ/[%Q__ #[_ !7^8<R.5HKJO^$)_P"HA_Y!_P#LJ/\ A"?^HA_Y!_\
MLJ/[%Q__ #[_ !7^8<R.5HKJO^$)_P"HA_Y!_P#LJ/\ A"?^HA_Y!_\ LJ/[
M%Q__ #[_ !7^8<R.5HKJO^$)_P"HA_Y!_P#LJ/\ A"?^HA_Y!_\ LJ/[%Q__
M #[_ !7^8<R.5HKJO^$)_P"HA_Y!_P#LJ/\ A"?^HA_Y!_\ LJ/[%Q__ #[_
M !7^8<R.5HKJO^$)_P"HA_Y!_P#LJ/\ A"?^HA_Y!_\ LJ/[%Q__ #[_ !7^
M8<R.5HKJO^$)_P"HA_Y!_P#LJ/\ A"?^HA_Y!_\ LJ/[%Q__ #[_ !7^8<R.
M5HKJO^$)_P"HA_Y!_P#LJ/\ A"?^HA_Y!_\ LJ/[%Q__ #[_ !7^8<R.5KTK
M2O\ D#V?_7!/_017/_\ "$_]1#_R#_\ 95TMK!]FLX8-V[RHU3=C&<#&:][)
M<!B,+4G*M&UUW7Z,B33V):***^G("BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>wald-20221231_g3.jpg
<TEXT>
begin 644 wald-20221231_g3.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X@O@24-#7U!23T9)3$4  0$   O0;F]N
M90(   !M;G1R4D="(%A96B 'U  ' !4 $P + "%A8W-P          !)14,@
M<U)'0@    $             ]M8  0    #3+4A0("
M                                             !!D97-C   !1
M '1B6%E:   !N    !1B5%)#   !S   " QD;61D   )V    (AG6%E:   *
M8    !1G5%)#   !S   " QL=6UI   *=    !1M96%S   *B    "1B:W!T
M   *K    !1R6%E:   *P    !1R5%)#   !S   " QT96-H   *U     QV
M=65D   *X    (=W='!T   +:    !1C<')T   +?    "AC:&%D   +I
M "QD97-C         !IS4D="($E%0S8Q.38V+3(M,2!W:71H0E!#
M
M                                     %A96B         DH   #X0
M +;/8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !%
M $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +(
MMP"\ ,$ Q@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R
M 3@!/@%% 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!
MV0'A >D!\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B
M JP"M@+! LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#
MH@.N [H#QP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$
M!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&
M)P8W!D@&609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L
M![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)
M>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI
M"X +F NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-
MJ0W##=X-^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )
M$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2
MPQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;
M%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8
MU1CZ&2 911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ
M'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4'[\?
MZB 5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"
M(_ D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH
M#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN
M+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PPI##;,1(Q
M2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W
M-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[
MJCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9 YT$I
M06I!K$'N0C!"<D*U0O=#.D-]0\!$ T1'1(I$SD42155%FD7>1B)&9T:K1O!'
M-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*
M39--W$XE3FY.MT\ 3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3
M]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF
M6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A
M]6))8IQB\&-#8Y=CZV1 9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#
M:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q
M.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ
M>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!
MS8(P@I*"](-7@[J$'82 A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HID
MBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3
MMI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SW
MG62=TIY GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF
M_:=NI^"H4JC$J3>IJ:H<JH^K JMUJ^FL7*S0K42MN*XMKJ&O%J^+L "P=;#J
ML6"QUK)+LL*S.+.NM"6TG+43M8JV ;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[
MI[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&
MQL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1
MOM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N W 7<BMT0
MW9;>'-ZBWRG?K^ VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI
M1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50
M]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M__]D97-C
M     "Y)14,@-C$Y-C8M,BTQ($1E9F%U;'0@4D="($-O;&]U<B!3<&%C92 M
M('-21T(
M                                                    6%E:(
M     &*9  "WA0  &-I865H@            4        &UE87,
M 0                               EA96B         #%@   S,   *D
M6%E:(        &^B   X]0   Y!S:6<@     $-25"!D97-C         "U2
M969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#(#8Q.38V+3(M,0
M
M                                            6%E:(        /;6
M  $     TRUT97AT     $-O<'ER:6=H="!(97=L971T(%!A8VMA<F0L(#(P
M,#0 <V8S,@       0Q$   %W___\R8   >4  #]C___^Z'___VB   #VP
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M$    .^KM;NT
M                            10' VMW:
M                                                    (H#@;6[M
M
M                $4!P-K=V@
M                                        "* X&UN[0
M              ^+;JHN0TX![ZKM&0[53N?[5>[N;/"IF)?.#NG+T0Z'$>U2
M!:+7%_/WK$W"^ACY\WS[YF2
M    !% <#:W=H                         V\>V0RAERC&?D#FZHDTRU"
M:L:(N2?,7)Y,-6U$-BF>#+,S<&8IM+M7.=*QJSG-=:A<M7I_2Q>
M                                 B@.!M;NT
M      ::458I;6C56:1U=1JMQN2LVIFATJW 6-HNUIS*5 DW43K)4QS&2WF;
M&_3,%M"N^M+O3=*TZL> J
M  10' VMW:                         /E.*C2-6TU=I55=&[:%=U:%3,
MRV,7WV\W*9%M\O"D"B:M2_<);A<9'M_B<FS,.M2NKM7NKD]6G5CR%<
M                                   10' VMW:
M        -,C3U3ZXB%4*05AB/EHEWEE],U$G2C,R7J*837"N#$W#V95VMGH9
M/N3P8A15P;3+L[0ZHNHU:-=NH*H
M        B@.!M;NT                         ?*=U#IS<?:OXB[2;MOL
M84/Z]5H]%O.A.73 JYG8?<EM9J_AGNW\TD6Z#%<L:GT@8ET([EK-[N;VB8(,
MD:O+/]^_,6\                                         !% <#:W=
MH                         T4YJ/3"ITP*!7K2AZ'@4G@=?)*N>7:/?!;
M_?GZGG]DC&=DTL7P=OZQ,(N2H[&JRCL5AC^'G4<S'8S<H^+L79H^:=5K.
M                                       B@.!M;NT
M           /GW0?+(;VL8]S Z]T#NHKM@<WQ,6W=CN&8UOJ^5/SIPRYA6KV
M5]IBV'U-AZHD?[!-1/'UCKV779F?F-Z6,.XVOU.LC*[3'/DJ=?6Z>$5@
M                                    10' VMW:
M        &G4-G'UD)QXX?E8Y:TT:K?R3G\P2U-TK8&91>7YP@>1X][EO-P]O
MG1O7MVJK3VJ/+?)G+D;>]1[$J42KA0OV<;L0SK)4Z]CZ8$W0
M                            (H#@;6[M                   !\'T^
M'U\'U\^@ &G'?D1QR8ODXYZ[6_5ZY+SV?8'&H1A9])Y?F."U^7=_02NU">B9
M]&*D4UJ1S3 G35HU6/4DF@5P5OWN^?V+9[D&>NN]2WGS[5?
M                            B@.!M;NT                  (5%>+,
M4AH#.DMRC')M4N?F8'.,%FJ)N:U:=5,  ;>-_)%A+RM9MJKO9!=_D_+%38?/
M&O$VZ@$O2M;!ZG*\NU%9ZH?<Z9*-0L;U^4<HJMLSI(-G?Y2H#',<&S<J[IL_
MT1K?HWZ#:_OS[9S@   'S[M&C;IOP:9K$TZI@)
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M?\\ST)JI[<< C\"O1XDNN7^9813M#=67M&R]'L7@       $4!P-K=V@
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M?,QSM&]7+M&U/1[%X       !% <#:W=H                  @5M5S=O\
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MYVC>KEVC:GH]]+SN!^.Q<6O"RT>H]TU_45N@K     10' VMW:
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MJA4K;J+<         #2:GSZ 'SZ   'WX #X?7P?7SZ'WX  'T?'SZ
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MYH[JGAY=YJMAN_[/TVP>HLHU ]S.D*&Q^7+=S:M"NUM3B<[$QP*.V8"D
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ME9LHN%G.=T[<\/U;]JJV\[)IAU18?CW;8+#,NE@ZK-W%2B/GT
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M)<G&^>[O;]"*@=@W&O5.:BR9C9EL$(EF*X]S,;MZ-:@
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ML&9D,K91Z]7Z1Z/]@LR;6'Z%ADDWOV1UU9&6UNVX
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M[DQDPY?"YN/(0                                B@.!M;NT
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MQ7(ONY&19+D.II-GN[#-&S#]K/\ ;HY:%=58KE3ELYL'C&)2$2
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MB7DY#9M@L84ZA3(                               $4!P-K=V@
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M?$5WC<"CE,\EIU6Z@                               (H#@;6[M
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MV6HY,816[1R8CL\NW'+F^5)LNU3U,,NS!2Y6[M;MJH
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MY<YLSP*9)3/%X1&Z'*WMK=LU@                               10'
MV@        ;0<6"%RB#P N(?H)C;$QHT%R/FP45?..47./#"FB7>"3,'A!;<
M?:**N-QPXP->H-_E!SHB7$0TEZB"PHJM<+CE.)HUDV]&DKQ]P4Y&KFE.1S(J
M7+T:B0N;&V6KFWH+=OYOA$8L*XGRR*-S=*[F]S2I&(^1,Q1HIM\G=+-P
M                           "* __Q  Y$   !@ # PH& @$% 0$
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M!J<PS@ZJ8-B*W'1PR,3*2)-)>"*=1U6'8%,Z)]@B UQL4Z19B9S-,9*A"_\
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M5K 0M82%*IIII@K2:BEQM5!$,J45)[:XZ^: -P8V^\_S?N-=XIZ(2V3E74I
M4$D  [Y,9C+*>.LD_1BJ5L)X$6NF+IRSQ)=,954_-6Q=F(L]$)RLQ-.']I?
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M2G0+/52Q<.]HZ%&"[,.K><4;UK->2/B&#PF)/M4BM3\>MT-M6EJ"$@!*8N;
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MOZR,)) -B96F<1=0?A"<H0-Y)-GA&/!:U$%R5:Z@=W091611:WU,I;7\;'.
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MVDEM38NOH@V5)'#;!/!CP>LJLMS5N1=XLP,S_.0WBF6DD92?6B4 UE"C5VG
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MCBD=58.<)L$)>96++K*C?1:=PWV5:%4/YV>XVPO_ $5WTHI6&[]R *ZHO/\
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MM(FIUAIWKB\J^Y8>4%@;1MM0J"FVG5$AA3!N%<'3$](O9%Q$K.RRWU2SUZ7
M$+RA,N^A%BFU#SJXD9\D9<MY*;3=FS3/6WKAH"E"VGWBDX\*X+3,.2BILSJ
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M+A)6KXRCB)A.[:OQ.IW4*'D,.([I"T\Z:0F7EVENO*44!"!?IU[@W3JA"'W
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MVO1^M9_N(Q'^Y'_\(Q^Z31_^$NB-'_[;7__$ "P0 0 " 0($!@$% 0$!
M  $ $2$Q05%A<8$0D:&QP? @,$!@T>%0\7#_V@ ( 0$  3\R=7J__&MW;YCJ
M]7_XUN[?,=7J_P#QK=V^8ZO5_P#C6[M\QU>K_P#&MW;YCJ]7_P"-;NWS'5ZO
M_P :W=OF.KU?_C6[M\QU>K_V+\/.9X,S,S/!\+\/O_O\8W=OF.KU?^JS'&3=
MN=-T)512Y8<T>H)3Z_DH>V8ARY_^^![M/EJG7?!POOSU)U+K@]XOU#RCIWUI
MOM;&<QV<"!*\RYMTL^O-,>&0CSNN;B?Q?=V^8ZO5_P"HP^-T\>.7,T8N;IV=
M&KH]$:>BJK1>9\TK9ZKGE=2]MS1L:)=QR_,-$7;X1/\ C8N:O9->O9/GWOWC
M50WW*8;.]-EU6P<Q"&RM1Z3^+[NWS'5ZO_5*_L>36<K><FAO2&&M-J/N0Q!8
MXE^8CIW'.:_6N)]@^)]3)X1YOB/!N@_N6ZER#&XG5\++;'<T*6/S2WG9G)ZY
MZW_%]W;YCJ]7_JY][V)EXUQ7X:"EX(MH.4U=*K ?UWA<+8TYQ37AAAMQWV\J
M@W<M+A><>7?C6SA-%U!18QHN_'0RGUM?XNW=OF.KU?\ JGFGL3ZK@0\":LM@
MZ.<9;A-8PMA[[/VXC=P7U&AWC'7!.?!WUBU'4?,'=F(Z:W9#0Z>&CM!7T-O\
M7W=OF.KU?^K[[PL>'V.9-1R)BK##U$#R^&M2T12+G5_J:S"+8[F]\IA;R79#
M0[>&CT^9J'\73=V^8ZO5_P"J+/C\)I> (>&L\UZQZ,F/RJGD,S?&D:",[\X.
M/PF(Z7[4F@Z'AHJ8+^+IN[?,=7J_]55=S]IJ^1X^N]Q/0DTOVIA\W^S2?6YI
MFMX>TGHWMXWU[^+F[M\QU>K_ -7T3AW&V\$X]?<^*$TAWKI-G<X1-CF4E.G%
M$RTO(JGV5*P.M.&>3//7\^Z?6/@#&AHGV7 \/;'T?I_%[=V^8ZO5_P"KY?V?
M"0^%^LC&HSNI[)4Z5@N>AJMI6H. 9WM P6>DMX$.VJU^8J/2F <;8YP;OQ6,
M.B#=:@[%>&B8<Q^Z<?XMN[?,=7J_]7!HD(4 HH$Z.V?AB=Z/:Q=T\/RF7@0J
MAITA+O1\FND = G9UFJ;SPK5WJ^#@V$-,]*(/+,UQ\_A("CB/]&+8-Q8\M%Q
MU_@W-$=R._\ %MW;YCJ]7_J/A<_)DO%GG,&*]_:!T;O<W(^1[F+<'J/[F,1I
M@5088@J9TR''.V):W=]3ZREGNK1_W7YF;3V&%K <6GK#N ^CEC_%MW;YCJ]7
M_J_YA=N40\8.:<TU[S^D5\R BK/VS@F3!>2]/F6:-U5[YF.;ILO>JO648&G&
MO>4U#L6&6F<:][N?=)@Y6[L6YZ0 'J8^I*XU]Q_24 K<164)O_%MW;YCJ]7_
M *K=RNL:TB,[DJ+,I:NWC/.MS&8K*&^6OZVX0KT2@KH<)M4TJN.J96ZHMHD:
M)9K![*;>-:J'HF>8ZHGD^Y+C9S(^;-#5XB]V3M?P$1OG7NRW6N3\4)IE59W-
M<L"HK&QU!.J -2A[&O?7^+;NWS'5ZO\ U4WH=.[<@%!TQNGG*0)9T-?* -,X
M7 :$LAY3^HK %1UN]82OM/ZE/X$&B>3\B!T$&]B!&LZV3H?ZOXMN[?,=7J_]
M5T-?^4T]":/!]><TS2GM34FMZS2>)8\ ?7</XMN[?,=7J_\ 5UW#VY3F,VD"
M%A\+[537^[P'K-,)M-3CX*^TX?Q;=V^8ZO5_ZRVSPZ?"? ^U/:>\^4T0T\"P
MQ,+)?M7\6W=OF.KU?^T./:O ?HBRGS\)MPB8QXD7W?#^+;NWS'5ZO_'-+1WM
M-PKP,*LUPAU]"L>L+#-S-RC4"VQ_<;.JM#6AK7G")F>N^L>F>_YL19:_JEB[
M5!;^!=-YCP4M/"++#X4\40$,)09IA_O%8X^W^L MP0FU9I_!]W;YCJ]7_CDV
M2P3D$C7U:)S:Q>?HF8=43B?),,8N:^DNS4]^/F"\STZ"4='VV_H#BJZ2&AG$
M%C85DSUEM5?766!0Z5N)*#SE.&EK3[!P,?F@QIKSAC=X:V_I,E89W?W+'7J?
M8KG"#+M1HAI5]@01T14"F-=;-HHWT;(SFK[7ZK'J:6O+>,W-G9L/X/N[?,=7
MJ_\ (*UL%X,&7=R<,S12_"TF)O*7 Q[MJJE4U)(F-YO NT,:6?MA6J&6P+XR
MY!OM1J(-&WZ L^+CA;0/2"A!B7*T$+C ;(4J7*!8/[XH_-TB-\( NV/N9V&;
MSSQQX=8+TJ6''W$J'B7C>8>49NBXYILT1LH'O?B-9<RYL*VL^RX?JNSP51&^
ML%KFL\A_@^[M\QU>K_R#?HM[7O$61: -1G=P7&&)F2+9-U4N,1SHIR*R]4MH
MKU4IJKK=+]SFS1:5"W5S^AJ/K$6?:P@\"S]0R-,[[+.PFEC/7H #%E9A=]\-
M%ZK% L46]4YCBU!*CDW-HIU.QVJC?7YLQ8X&8N,N=N!MH_(Q<P*LU<G:WIXF
M?>GQY[P9?M_=/I.$W1<J>UW-4/[TF)8X7GR?TG7.H\X6&[\1^/G]<(\@NCM"
MV8*6O#^25*E2I3F$!$K0=L@T-7^:I!&$11X(W'\4^?/GL.<!#18C@"_HNMR@
MUI8&^;^&W/GP0%>Y=!E,TM^-^2KCW_'GSI#VT,&%599FJ_9[NWS'5ZO_ !WA
M&M%!NM9J)695=Q>]Y4$.6-JF0VNCAC"Q EHVC6PV[-AP;X8Y*YE13G7"6 0:
MUM^@)]UP3XS0<IN<GR_OFJ"@XI\PNLPMXXJ5'?.\>\U)JK$%=0T,\$OSO LQ
MF^#N$S=B&L[+P'2:_@ 6K0\<TH;)2Z,<6#7ULKTF7B. $]8U+TZ=*KTG/->9
M^CIP-2CRA[_Y^NGNT6CSNF?R4*%"A0X,2X[?*JN_)5K2U+E=/\Y<EK%ZBM_$
MH4*%"@6$T7.UAU_0)@F%(]<K\%"@0M) MBM/+XT"LX/R>)0(' ;* NH<O[/=
MV^8ZO5_XXWV#0DSR 7VL+T!A+(NV1YY@67,MFHK0W1&H9]#J7=#UJ5>3P;7"
MP4TV@TI"' .** W U%[BFRJUF(PJ *'FMO\ ,6O!Q8WVJ:SI,1*#2EF[:-TM
MN2QA1)FHFC/0/F84=-(U1K?X8;WISB#,(>CK5URK/@UD:T,=N@97JF5N[FY*
MAP:O;DH9DZ/(@.LG@%QBD=ZB<T;MZN,25@+&+,9_1H&M[,N,S'R O^_VIITV
M?+<?U\9TT_&O--=5:/SGM_7(YG&CH/;]LQW=OF.KU?\ C@>4M\*=\G$IJ#;5
MV";L(* 2M5[JZRPCS+8P,M*!*L\8XUPG$A(&[OMK/N_S"(&46]OS-P^C3633
M,,H%1KD^(%9$E],S3P8QQ=%S0(%)0JBNJ_10^9X, =V-:ZO&F <-4KOW5N)'
M3KF%4 % 0!:\SJ3,Q.0N4\LD#=CV5W=>L8ZKUJ!*ER"</T5Z:2X8/F54-\S0
M6Z=6,$@V5S_]G&EZ$$&&5X)"@,(/$#(^<R2WM1O_ /7?C:5]M:'R>&_VXL8.
MJU++]G\.W]<CF<:.@]OVS'=V^8ZO5_XW#)-5=D+9; TVJQORJ.-961(F!JQO
M0%3"H:.>?H&#JUKV-G-WK/+E*D<ZZ\F:4/R,8[7OI+AP#-"^(65UBSD/_H9]
MI8@M0!.0Q#_'Y7/P\&LS4T30\'Y^8+J1X,0#=EX-RU3+;I9R"L :7O#RWNI5
M&P>L;EK,MNQ^18WP;' )P6N$N*>-<LTO*%?. -+I7RAL%8X&T.D'NH]9I08]
MHHJ,IJ].Y! .R"?H"QA[SZB'ZFW[.:SJ7!<:%_U+E\=9H$JP/M^$0US%R@WZ
M(Y5>XGVZ.7@(YJ>#C/4&%( #2C'(1^';^N1S.-'0>W[9CN[?,=7J_P#&(F_8
M@.+KG$<#AE7%L6D NAO3O/3 <H!G2R8#[6<PKI[37TKL,@-]X($LX"[8>Q/O
MJ_B;Y?QH%O0X\0T8F*?/G9MJ7EM$6= _&-W*&CN3O-1BGOI 64XC9>MIK<%N
MJMTE/E*RD-+OZIQ+5.X%E\L\894F.59@Q,5](R)=;L#0)>R;&LOT5-:ZN,=R
M:LI/.]F $%R"UYGZ'2?V0K?[TGV?#]F-7H:Y!;SR0]^WC@>R:A/PJA/'F_!E
MI>U*&_WYBA@KPI%M!_650*/[6_#M\,^Z_8CR#A[3-K^'GSK*OO@C7L)"FS^B
M1S.-'0>WYL:=89E-*D7M9^&[=D&4VT.6J7,:_3W=OF.KU?\ C9E]*BBP5M%5
M58H60'HS3S67-"#2WT+N^T1*KZ!KQE%UMC+:+-Y0L5YL<IQ[BM2;*&3A#.HA
MKPSH8GS/RZ1'T8_)#UDX=8!$EE?^L-?*+[\F"S>I0MQ.\]4^TW32ZGO/77A
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MQG64TRRD)&R]$&W/@/K=9FN4GI3VFV.2"9R-,9-7;Y5F+:4YO@".3KPCZT;
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M12-7IA=]<S)J5I7R>[&\TQ(Z"*)>3SXJ1X33AV.QN%11(XPG'!-YP)4* #3
M8Y:>D#]9F$>4R'C\Q/0FN+R]/!+$XX\Z2WCS3.1.VI:!QTX$',S,9?UY1<>-
MO$=.5("(&XBU-B0E:; %!136W!ZPDMC5MLM:QPN&R2YDUYU[ZY9ZK$K:[NX<
M'.XEJ9D[M<==1"5L K@U >##*Y"*TMJ<[MN>>O\ !-W;YCJ]7]G1VM7JL>K,
MPW!T+X#!63;EMCF&O24*U-N:G[1UE>&8D +:QL%=XW8P'M2Y[+=YC"(.=:KU
M?-,(P)'!'W0?%P,ST/P$NP31R>4LE6C#N7?GB::ZP+QVYRA=">!ZQ[10WDK[
MJ:0@,3^D@LZRO?>.5VMCM,1;J5F\9F9]O!+\#_Y<JC7 [X]ICWWNLVO>CF0D
M &59HPM="1<BNHPUB$2#1*:U3C,]DG:6H;WR%G)1CT?W-4L=4FFJ<Q[0BK7*
ML=:,.@3%Q1^;^0$](L"7JY+TPQHWXPY"M;7_ +B4S..#FBU+'(/>6W%T?F4^
M%N,]HMW#0:=\4O4J5[V".JO!L_><Z>F0L$>$^[RB)HFN9.I"<7^A4YUD@>3/
M2(L'S(WM12+PDT=\U&?.$?<N9[)M:L4TUO?I 8:<+LVXRX,<I)$..::2K:BK
MRX_@F[M\QU>K^STW_JA8?70\'*?1VJ]4-9L!T#$OPOA,/6Y/E7\O,3#UJ[:+
M@Z@"I48!MU_XB6#J*OG,^A.YB)]3K RQ4#OJ$>8(VP'53'E75;NM:"(.8@%3
MGI7UAY%M6ZSU*ZRZ396KQM2^L/1M?&IM5@V.%_W&&%,**W%KM#!PXX\U$+<*
ME&8'&MG$%:])<'3^F STQ:CM"BUC,H,9M+NW*M5;0YY\[V4!T(*T!DH[>&ZM
M^Z@<"^>:^%L"#V8]R[*RY5;\3(.LHDVFB'W3UT=1H34A-]401B;GKX<9>_,V
M+#+NQ_%2U,ZOJ;(/'C40IX_%O:4R*4=DBK:5F/?)K8&TSL)>A')4<!QT(Z7*
M)>%(YZIH.1*(9>EM#NM;6L@7@G I0-A=I0 &QH:=OX)N[?,=7J_L[6FI/47*
M3=)"9.?P!^D-;8]W\DHE1B=_24>?]KDRG%-Y.ZGKGP="=2OK_5#)X*!R)\B*
MULV^<?:<(Z/-E\ZB!LG$'EVG-V;-G@I>21IA:XX^D8Z!ORN0XKT#\PP"%:%Y
MR9+L-+I9\I]&65:.;&^7K.8SO]\_!K_1-9_ZXSC7A'XX&56(&S8.,*9]Z!62
M%*16A-F"C(R\-)BN6_33W/!D//$TN7T8?O!GWE^&L??[CL9MT< UA,E(B,$>
M^FG-*:T!LVU8K>\7W55\!V@9<O-X]@\[7E*FWCVCY5/17K#6[_1'K.QZ*7P[
M/U^LSLGF&/:*U3-K^?\ @N[M\QU>K^S4_4/KE2JL^-,KESC;YP,:AO[I*RDK
M =)O=C6=*=T2BB\:IT<]T-A8',')+@<U>R>HZD)ACA.J:'M(.:**\YQ67ZF7
MK!XH5MOP<B'HC-BB9JK<$4X?%!6UK-PXF@KXIOF4NT\\S1N"OW[>\!+N^ /F
MH;GF8I]=J@%XM<'K=.,4>^=]@Q5.G2%&B8F75LYU^&'%<PK0V,YB0NF#5S+1
M%CS79R@8\92=1-6NJ#/.&EL"QN-"N.L' %MCF'A@W/,Q\I](JFW:^<$U-I)Q
MML.LRB*=]2IPDJ4&\')B*QPA.BC@MX>GJP?7:4U4L:/I)X)F=K9=[X1PYW.B
MV">S[P..ILBK!;*J];,IOPA%L*#@+FM[K&GC9]J#\3@E9SLRG/PLW,X+86>E
M-13&1 H%[("UI,%&071O-<?-B KSQ(8.7C[(UJ8.@4K+N;0,LU=FDH(EUX,<
M0YKC>+EY?'F;S'MHQ467I5JG9U/+^";NWS'5ZO[,6_[#(WUH N?L/"ME:RT*
MWW>SLTUX+<9;K"#=;V:_TBH!#8 .!*.L:ZU"VW5Y>C$=5M>H0*SS>LZI3J(?
MN^<DX09YV^;%<;,MK'OPQ&?_ "97<IKM-"*:FG&EKTC6SR]XS:?^RKQ.?Z4<
M.C1R>\!<WA 6V T=68!U.F.W+.?O.9/>$%5M5&06\WY^"+&E![@AXZ*4KZ)@
M05%4W7:N)KRCB R16S2\YY80N5L'CNE3_(G%3G0XD$W\%0U\./>+*P(CA3Q3
MH_Q4G+UHH7UB\1*.\N4X>"GA66LX4/-]HLUJL$K- MW\_P"H?%O-C=O4+]IB
MDKE=)4("AE YFO\ !=W;YCJ]7]I6M6ME5ZB A7#P(;<_@W:GDRV)<(KM-8:F
MW&8L*]-#KRAG7U5]KW7=ZZ3'7R$L+)OJPQ!BQY&6I Q<@AB>&W.G>?PE"9,[
M_P#3PA#<7MZL#ZJ(C M-D&I&9I.A-@^<GO4XU-6:V@@IP'?^8O+)CK]YKT@7
M77<8@&(M*BADWCAFV_K+2!,WF!(T<&4R;\R+ZMAN4V':2H\%GY>U,GI8I0UM
MJA]%WB_4,[754LY'- :>*S,JF-/] 3T-<DK+)/*(GDXZ2S"?U32*N@PV*5)I
M[MQZ.*!+0+WZOO&Z]R!H,.-0VQ&VK P="-G(C&?>5DM9K88KQB_VC0M7&5KK
MY*;S,UXA0C YB+="OCTRKT$7'O#%O/QBKZP?$9FFAG=/5(=3?UY&#SB^!/X,
M-#^";NWS'5ZO[0/N.G0/)#J[ X0 XW;+EWB7YDVC:<;"Z/7#C)E;>X^1,$ZW
M)?9M:&H;C<<%[K;BC=[A\H9F^(#CA'9&F78K1S#GD1SO>"@ !6@?U+A<I7&^
MZ!0CT#CO"(W[DB8@'=27(.#2ICX*39:/?*K5-GOA?\ D96OHEP_/!(&6_#+O
M/1+S7X"I:J#!PE&:)K<0*RWDHZ3*/TK=?K045<Y0FD2,P9'55!L^!HLRF9[K
MGF;/9K'&*?VJ4;?*$%%<J\/0>U"9P 6KVD>R G\D%4GB*LP 3@9BYM[,AM;'
M'6Q+4M1-88;5G"E%G?346T25!@S 2#A.L)*ZD;(\SVF1Q$AH.1(OFX,%]6S>
M=:]I6#N&X3:.9)HUD(_<G:&676-EXU3I*Z=A=Q#%( U*J1"S>H^-6Z_,/Q-O
MG,3V>\XH,R@,O,ML:^M?,0UE^@;,$(RAS%_6\]#\O\$W=OF.KU?V@G!4#P2I
MNO4M<MXKIR2 'TW.*ZL>-RR7/- H>,T%U'HFO(-#I%U591>1ER^<OPE/(;_K
M ]'W.(!!%&&O5PV78-IG6P2)*A5&FR %E"I<BLD^%"O/<]IJJ\3=$@F"*>&I
MRC60-WBU_('XT!V[:NN<O45=U"CKY#J$J*)V>H"9;BIJBEAH=!%',-Q5Z8AJ
MKX^G^H\Z+_R"%>?C_I#O7[K[K*%!6OEX;+UN#@GO$!.T!%,EBVT5D.[T!B"R
MRTY&WE@A=!>=T%=U7%EM['!X-*YP6(.#1KPE6% Q6!CA4/';K!!POE42MY<9
M8,LW6D!>(NQ2O#+[-*:KA?GM+#Q@V<B6(T.%UE_W:;!-WR4><-GCC.U+]U/J
M<W^";NWS'5ZO[45#"(9<#+H9JZO$ ^LZ^B-A8-JQ0MTWZ^LXQ<-DQX!PXE&]
MC9K[LPR@HN&5O75NXPX(&' CO(2_4>L349L'S24!=)A,3#I.8CL?_E,W;QAM
M767;^L':*UG9/$*G6-3##?>$V,XLDI8>67=T(AOK+@=-&&Y0+IO_ &BQ!^),
M8^S#I7U ]H:BG1_$#\%M;?JP/=S],Q3_ '?";OD)!<N#+3I4*+7<F0(?CC0^
MUXHMES7&[=[?Y*UJ\H%A:0H8\W_4-O'ESZ1H>!OY^U>L?M(FXMIT9FA6E'@Z
M3[>\T_TO/=?P3=V^8ZO5_:DO:A-"E(&EXOTSB-VGHV %TM/.6%;K"^>X';$-
M#^.EY0JY[2D@K;O=@]HJ'NX\V?;$L^:XOH^9GK)_ZC_B0O4.FC]TC32):EXK
M>A<<%DLBO-U)!4[Z!-*.O">[,%O=+7KTFCF&53K<N Z[ .IF.K/SU_(F7?1_
MPE/'(P9:$W!+OR@N%O:C@MQ(GK!U #9V^8S6%Q--+VFI1@*SH(>.(V1+&[CA
MKYS_ &(24%*UH9KM&;<.S+8'@5O:#'MYM;RT!N9[# 1EK(8&KRTEJ@RI+,E+
M?(N;>[I2P#K-!UC'<;4\B;M)Q]4PYOZ1G@F^-/.'4!H^44I>:F^-HH6[+V$0
M.-6319G1CH0PAF@/<#XCGP*ZD PVZP-F(5C:M.I_4X?3VFD4X:]LR.&T"TT#
MI[[2N%K6G!B8V+]:++TWO(OK%*.OODOU&N$M)=FB3"><$.R[C0NLV0&Z.1[_
M ,$W=OF.KU?VN$H06L;?%]G4GG$$?-QV@E/9\CHUH; \WJ:!UFF1<$(=J)\
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MBCVS4:EADB<(;J\+&7E^$3?PU&DI9"62^.TMI$TF$B+F9=)J\ ;@>#@,3!\
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M%"(R,U%A<8&Q$"!"4%)@<I&A(S1 P=$5)&+A,$."DJ+P\723LL+2X@8U4U2
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MNRR05QT+)9(Y>2JYOO5%5NHYFR-:';+%?M"&4N+VX+BV>81BIY>3@.W+7Q7
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M@*FJ8(XVAS\)L3F#L[NI1[I4C3QI>GT'G\D-V=S\-M__ /S>JG="EDY,M_\
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M)V;+!XK4%:PF'+R@=&4G!7U1"'I),XW+MI F)E%\+2FE](WKVTZ80VZE8HK
M'$>6ICB]<*6$"\<8,VW=2JF=!E#DPAL7E TZH$RV1>I_>&YEMTD)!PYN\O$D
M]%/9$CRRNC[XG/!7_4N?#%A66^^Y,S2"BYI='0DA54BNZE,=\3#Z9!F^\E9
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M6!RASDU^@KLBP)E#+<RV;U5S#A!U: !:QB2H1/SQF6%-2Z;]'4ME84V02JF
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MI2JX, OQ5[RC:1]:E#XM1"+3#JE!+2PD+<1?*FZ$M+4@ZM\KXR335RQAZT"
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MD? 0H;'!T2 PX?% 4&!P_]H " $!  $_(?.;O_C>><W?_&\\YN_^-YYS=_\
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MS6A%^8BSA5X 3U]_[FG1XCD3:*F"DJI<+CS2I-"0("VI\[5()FR[E[XJ*D&
M,%J.TVQLU&"(6^*<0CE6O!'M/O%&ZLJ4M.RMP[+VXIB.=#9Q\)TJTPE6[=,?
M7YIPWP=(M0C,U?>JQ9;*;Y]Z&"T8+-\WXTA\@1$ @1$ODB^M9'PU(!-:@B#I
M0PPK)YN*9ET*I:&1P%ADW+XD1=."M(N%$UW1E1,MJ3M8:9(9@&8E.L,UGR3
M6O5!&]Z1&FZYC*)M1OK-U)-S@Y.#Q,/']4[.:LL]Q?#C6CU@Z?ET?;^Z_IZ
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MMI90@$#@O*F8H=I*ET,YW+4IT1@"@-D!$T0#BN"JLQL[RV4<SB&%FI9^ 4)
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MZ@I)%E?!PV>%9]K_  5^"1@S6NEU4+)RE<T4"H(('0TX[ X%"PM7==I9*;%
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M$VAU14H1)86B/M8:V:XZZ<_.V:*[B1TU:"YD.5K3Y+1B,<Q\C3W_  1",B0
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M9: D"#-$$  @@1:!H&Q;_A<\YN_X9@\D#<82>I4#\V,QSJB)IQFI_FVC*XN
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M-27R!M!]C6!S#.B&9. OPI&R+#<Q!+,I!F]2A48A&6I/M&$BPEB<M[8J#@P
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MPT)%?%1CK]5GT_'_  >><W?\-R>;TY=?FOB12US#V*NGA326WHU%-8KSSW]
MFG7WH7E,B5HU/-6&3%6+8WVI+):@T5+O2-,59I7!HX*."A&B6IIM4=HZU%*R
M6Q03II3 U=%7T[\Z3:U(4[J=D\::78:A8EH&9:@U ME]J6UL4$XMZDJ>Q0+/
MH0DY:9GC4^E0VHG1H&U !:]6):M%.(-)G6:)HT4*-E9/*C3O0OT_X//.;O\
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M!0$!       !$0 A,4$046%Q@?"1H;$@4,$P0-'A\6" _]H " $" 0$_(?\
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M9XP!DPD0EPW4%]3+CZH:!P8Z_>1';BD($\PTU]@>I$"AXI!T( *#R0P?)4,
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M@% L%GI+U$&#PQ"\C"7\-M!#I@UV" 48*&88$M+A1^LJIK8 :PVYI;$*Z@R
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M(4+W#E9B)A3@P> @"@1_B5K@GT?$!E&09(]I10[!OQ"@X@4>Z(&L!\3Q&\#
MP0&P(&F&.\. TD*0J@P&0D+DOH5$01"N7UH*P@P_PY2T9PYM>R=64 Z/$M@A
M0525K/F&1['ACI.1=O[FX7V_N>#^T $_#O#"M72BOO#]M$ ]8]]*^=H-%$UR
M87!57<^U$(K#=0\$U54)S_,V/Z"F4B.A4*K\2=ZP'3KU0S4TKYM+I V-#VCX
M!A2E?7I&8$(@L7I#%2+,UDFY,-$9NRF_HXXLTXKCN@_%(&MX8O&?G.B'0H=+
M=VZQ#_)0@L[YO0NK$+D:U.^G2:5>9RP 0(BE7#?[:+:VBU/\0'S'&%! )1@J
M*2ZU)0HX\B(5:O\ B.W< 9WE!>8G=#4S'"<KU[PWT/1>(<>DVE]Q 8P !#10
M_;1] .IT(&\IMHQ$87T$<-1 >*$ #8,#7CG485H7*&\/GM"92@+_ ")Q+2T!
MA^VX^HXAU![S!IE0M2L JX:0"D(%<?B \F .8Q*MX2]Y@#:9=!H--]!#!#]M
MQZ:'2VF8=59;Z8\XF9:&L%A*# ><Z/3P=H:P0ZG3YT$/VT?7C40F=_I9Q!BL
M;"CZ ZP^>T%B808B+PR\$,_J8\XA^VC1/Z#./T7SHYWC\.< B;>>NG&\-MO!
M'XH^)>T>)WVU/VW&CT0AT\]QIY[_ %#SVB%)Y[S^OQ/Z_$0AQ!Y[13/G$PG\
MP0P7\X^@V^Q__\0 +1$!  $# @0%! ,! 0$      1$ (3%!46%QL? 0((&1
MH4!0P=%@X?$P<(#_V@ ( 0,! 3\A_P#E)8O08Z>:!DGOO'\'$$WH!:#EYM2#
M\_\ C!_$#^%0:UQ* 8.<3^<U&91ER'PL)_""JT^CCOE0U'G-<09:6&I@+I2)
M=C1I@IXWJXQ>W/\ @[ADHK48(O!=IQ:>H39]S10&T&6VE%XBYUL$X,VK"%-_
M;%*0>'\&??RJ^>>GI388S4IG62H(.]*-IPHK4X(UBY'\&S-H_%8G>E@]^E/5
M0^'ZK.6K;/9H:F6.E? .A_ FWDN(,4RQF";:5",9+L/QKQJ64A&"%;<:N6%D
MU0(";S-MS%7.[6(:F@OV-RE0!>E@UJ7).S92G\K\Q +WL1,M0O;X\?/'WJZ&
M!;G:HT7GV>2Q]JPBI>#HTJLW 2@(684)$3(C4[AG2TFS@#+&AZDJF!L7(T2V
MF;XSPJ\X()>X#,EOUUHQ*H*8EU@L,[C YHM.[&4A)<BO$RM(+G^*KGF''WI,
M^M8/+0SS4H;RS1(/%T"G8%<58.)X'6'+[4^NX0LV+"$FV4=T: @6%#A(1%U"
MF8 0A6P7:49^+UJP9=A%I-SJPWH[6^@P!GI_M8CQ#7?E2 2*GT/(4X[X?0]]
M/-O]B6*1=H4VBU ?$2'9*@NY,G*GPOU4Z!IO.BQ/(6MK49F."8)6D5DL%W!Q
M1A,!." R@/65V Q3R3-S(;;+"]8%VZU3<X5EK-&J:&!K6 6-3^E!,I%[>E!.
M2P6)M.[Q^F[Z>0\-_L,M*T375TJ5S>-*EF2WJ#G6M 66OXP"8F[M-1QLH1B%
M]G677I3,E"8 ,$8;TS!3S"P!*;8(,5 7&.YH4NS8Y%BP>]!R;"0F])@T! B+
M02E8-FTTB9%?/YHL!V+%OMSIX.@2V%^D_KP[Z>0\-_L(<*<+<JAMDE9#33+2
M"PPS4R]4BR.;,M)!Q"A$DOX89T]52V9I$P,J&K.U8?1& 2XDM0,/: Q>(;RT
M5$!D<<*3+*=&_)4G^#,S &2M* 9:&_9Z4F8=+$)6. +OFDQ(1Q9B^;N<%MV;
M*6C/$&%PD,)M0GB8T>%_BFI2&]SA/B?\_P!'G[Z>0\-_KP9(!NAUJ!5VH_@T
M\TYHJ;[7[UJ#+B_]P;[U,S#M)/2I\]X'VHJ6+5 Z-2: +P.:TCFFXL"4$1?K
MX82:T!HY)@Y"WK4XI0-+MBR.>%%;%PB=-6T=+'"\VE 3898B36Z$B\H<+$FE
MJ3%V='70Q;KH)5V1L:6V1+&8![G/"D&ALDWE1 R,S@O4YGH F!!'UHMC8TB\
M7(_[&GG[Z>0\-_KXD5O)[Q3I:<%^E:)9$QZ;TAO39/M2#3X/W6B]1^JN!PM-
M.&_DYDX5AXF^6<Z:\I(+=JS1YSHH1$K%HLZU+',L8J43U=F+5ISRI86IG;^N
MKAD,EI?DQUJ)B1%[.+RO4K*I2P LL'#7<FH)_P"F.<]WLC3T H\+,$6/;2G
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MH(.2U7 U -PF)W#%J?SW;N]/O-=;8QYO8S^-Z%SA2'<H 7$N$6F$6:N1 N6
MF)AXZ5]8HW+*P8.D(#5Q*P5-D.@8]A_5+(=.!TL,CD<&6KS!+MDER+$@FW*M
M948XP.!QP.D?-&FS^7KDOW#,\%Z,X18#FZ2YDS=VQ4.0(ZMI\3_KWT\.^^]?
M^/?3Z?6*QYN\;E3L;D3%002%A8 8CO%+?LVADM4] G.D84KY8Y10:[?[6'%W
MAD0YW;:U.]NZE&C+,/9;:H(4L6)$J ]6N@2[LPD,F.BUZ39\0A/Q'P7[;"DB
M BP<)F.AEAO6/"(0OBZZZ4ZA=J-P1!)_2U (NXTA181&N4>*%J;^5I"9ZD6'
MK%J+5FL$+.74&ME>UJ$BV&LT"'LC0R#H@^_W$N_'G[3E2 A& 7CBFOI1;)R9
MQ#M.Q44/6#HPBVV::'.P/-%0\+15X7D"'H_=2(P3(UQIRV<T-;]&P29I<DOQ
M0D=^LI7^RAFRHSEPL-:C1I$2Z26YM8OMI3*<*&N$\J3%K)TI_G1%8S !*O/+
M$;/HIP6X7*+[..Q( 6!B5.10<8:!97Z8B)=>VC!;#\*Y&WQ;'/-#2Q<EQPDU
MJFUW@T3UNJFDQM^JGVL:OW_OW"(K7T\V+U_%9C: EH5&N(+]]*M5(BPZ4>+R
M1/(JT4M[=^U02,<[U$XBZ[4@2CMHXB+-JF/&<;_BA(=DJ(:6ER$0IZC?AZU8
M&$("YAB34X;4Z!2X@P$<9!( 0*4$07@#:J<9@O%H'WM.#9E#F3%M!=1EL $$
M8NTUL8#/IJ?]-%BU(G+\5*N;5]ZE=[Z#4M8F?M^#F5,K&\>U;][>%O)\YZ4[
M.J6X,59N# =:1(B$0AFU\_NB!CF2,_WSIDLYXQ[YJ"I!QZ-$2(!$2Y3F:)BG
M,QQ?6NZ;J"&(R+*M"Q.+%)M);P1*C)RN@K0H$1739YZ9]*DEKL?ZJ=0V5WM
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MO,E,L/'CZ]^>(T,^5BI[\3Z\I]>E$BK&P-3OXX<90(NX"BTV%75L=<4 ,0E
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MOE,.AXX& W*FZ>ZW_P![Y"^E\ -&=:S.W!<P72*&A4$(N5P=.X<.;>!!ST,
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MORZ Q^]2^A9=-!#$&@^0<[S^#J=2?=THA0M> P&]&]_7WY]_CF&:WE3(963
MA#P00+8&B]IW[_ )],8-,1PTLF9U0G)%-9>$# L^GY.NSYXC(%@I/K(?6SAG
MM@^$P,CZE9?PY<J8'-(%UC*9Z]\6VW<8O+SQ743\8'3^F_PT?A_;\C[;_8>'
MYUH DK7 -<@A 0C7_;7^N6?.7Y_!\V9]&&/F_OPXH0J(&$"T 5'@W[I]F?\
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MU <]6H4*5@OG>36+VJ@[,>T,/"0UIN4ENA1R29>Q>(08X82@"!0*(C@<.U=
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M, &IG8-/Z-['.9$6T$")5M?,61C\)X4PP4P:.'8Z?\<443@L4YA>E[R!@5#
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MM^70ZL@8W$;YR?;[_@ &Y*.2R63O"_?B,%!A7H @@BZ!1HGC\2 2DR"*9*7
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MXL/+SYOB),/ @ H9R:^<U_5US_P'^.?^ _QRV57="0S T#6&]3OBKO\ :<K
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M@$" ")4O'0K\@>>#0<?1IZCC_6OQ^/KH-FLYPW7,]SU%UU:$?77G\0K#Y50
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M282(T"(R/ Z8F+0 !%W6)GQSQP481 F^1HG'XA(.2LN-QQ>GHS,0,4".36U
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M#3BD(<)\("((!+<*,J9W-)+E8;71YH!##">"A!B=(B7I31LV$Y)RWA 0I>?
M>$,%0-$.-+\"XP6 LEW$YJM%14 K\?!CU'X(!#3(U9,:P@NE.7A0"4N+] X"
M%78PT\H,;,O83B)#$80" I@ )+%XH\LJ(>52H0$.D!1P7/5\%I9P&=\OO<41
M(-;B?*.SC_\ -L(HRT[S^O\ _& X;-"EKMF@.^(!2T4HJ0#:=$"/4W6\V)[Z
M4X#.BZ7( 'X1*!CBNDYL\/7<,4)PJS9R 4NV&#X.(5Q@#2&,!T$"V2EX(AY(
M%CD(H 1 $(:,'P:ON2O;7D&Z,R< $<P6[4*<&Y@!ILZN%KIX77=JJPV^#]]N
MW/+!&2?,[-<6*#*D#C+-BBU0(R/I 8 # K9  U2@Q[&QJAY?)T)P4&FQ."Y8
M@HCX02M-', -GBEMT.3&<F/5O,IEO WA/I2X ,R#+*-(6Y%&UKT>'J,RPD@#
M"@EHIO@PQ-!FP-D%K))9&*B)&@-!^".Y.^/:A+X5L<EB!3F#%WHBK+-A93AW
M*'#OT!8[A'##[4" "!'W(B<_OC@[XWM;N.NSEA/_ (X:J&V</Z8(JV$CN]T5
MY Y] :8WII@KP%.U#8H+KJC3# T\6C3$SD-9\\.-&#+6VNE>'/6]F# +:S'9
MC(;QUG6>"4(]9T(LPN%]"OKD(K,FT_69X*7L+ @P7*@4*4S(29DA@03@4"87
MB@)8$<]'3XWIHYXY54:)>XZ<]R7SP8MQ97 U@CV+@=+I_!@<.UQX&/WWP*%6
M05!P)YN<XR8XLFQ332Y=R^5[QR%L ZTRE9  RLG?,J.-)G5@%:NFQ.*Z(1,0
M8V! J !H.(@+<:A+304#EB\+H=LW)"-"+&-.-TA$4 P@:B6E2]L)6F!(8:$8
MAU]#,RDH*FOSIPH(KV+" 6RJ4U55L7%49*&&![G;*-:,)1;4:<+$OA0*NBYD
MCQ*%/_*J,!B0J8N %32P; TSR&%H/?"4,9D!0HX-B@]D!2E(3@E N+T8^7'%
MXQ#-3M"=VC^XX<J4L(VBA*-D\#4XT*50&;@*C GLAGO(C A@"Z#E#O5EV:R&
MUK\ <A*- U1S#,.EBS9!X5$X1$-%?TLEP1T61L0$#Q*+ &L(C) V'@&55K0B
MIT1#A@UOMT&TSG!F3N<3-&="$[7Z3YGN"#V3!%8;0[4RXY5/\J1&5!DKB(K'
MC%EYN*2RX,('EA3FSLJJ*BBXIH(HJ%""6QFA !,H\HQ'&-<B&^RIB_#V7PPH
MG$\)4UEVF0#FA5C*,98NL@F7NX435O <9 DL"I,D0 9F,5F/<$Y*J3]QIY+)
M+)G3&XCYTJ*JD%JOPO>(NM$&I PQ, &'!?\ +X'1+<ABBKK@K+F>]&$  V,%
MXS*F0%5(@3M, LA3.K3I>H"WF8L?NA*I"T8KC?(FH""BP!* "4%RCE(.QW'A
M!0!H.#^ S$]G%EAEW-IR]8R:*/D#(4]V_P#6 U8-C!I[ZA[37'-Y$RFC/@?B
M1G@]T[+:%7E:2U,. ! 5H$2M94!?E<!5P4F;(OV-+T <T@\'L'@%D/LE,M%.
M-E<XX(D3&0NI*':>B)!):Q*>$*-H.U!GB)3*[V>>$F_C)G'>T?G/+Y:DE(0R
M3>Z8(CVSD=*W)8&P5XR -<!F2-[Q(>T<5YI@5E2TJLO&Z53Z1$4":VV((AD0
M0E+5A^Q*9K.^2=,F*)UJ):B3,0<<.X(%C>S]<^-<*XN^_8=<F4B<E-%Q%0<V
M.=X$,<5R:N@321&L5J\1@QV\COX N&C410<"+@BN0J%*2P0QO>"FH8B 6'&1
MI%&!!7$S3#*H<QE(0"HH2MA@D,DX9-8)$=Z!]P$R IQ1'+ 5D4?<8"F*XXT\
M!%P)$U,<%D? =9D+7R<O<@M7V%,"X2,LT1Y10"<J8TS%862)3@9%BW-")2.0
M0:B!(+MT)A$V.MWZS#.2TH+'2D,%VH77F2\!HM"9@%$LGC5Y)C*#(Q""@ XW
M.!J]Y3^PJCBB*0U$":Y:E&""&Q'$ :SD&"X/CU=3/$-$7!5H3,BPQG F3&>!
MJ4B&X!<.IW( -VO_ .=$<S]D<3 5.'^W660-P[Z.,!M(0AI FBBH.T!-J7%
M294(!U,<!U R+&1F;DU6<< 9;BQNA+C33%G,NIH4!099U;M14<EI%H0E<#R
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MVX4,F19,E'*(1:!(HM'0X7IP\*A0;:3[X38^7:L%'.3$[ZI//SF<CX?L\Q@
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MR'2F0;S(>YH)7(QC@(@T/^+5ML>!@?##C(Z<4BS&0 R1CC!0*S,>CSI>%P.
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M$%BA*6^1;8V8<YQQ@ H*TQ,OAC&SSGD="AH0(;8C0TJIPGZJ6&:"K@*,,@R
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MZ".'$M.GX1"P1:A0CY##Y%& ='9'AP&!M[1!E3"IN1>23 4(EINI0SC..6U
M@[E54'E0;O3$B Q1PJNU0#%Q;PKT@68;<+?!ZZ&< S_MOKZDT>>;"+3I?4Z^
M_P!KR3:5C0>"BX[RS[\*K754255,:='^>/2L,,@H- 4C*O4XY$/4)2IJ2 '(
M$7B'T(\D6V".B/' DRI9":"SAPN"SG;IR-J*IP H9QU>(LS& @Z*N7JWO $
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M&G*(C:%*L(AK6^'),G-06N@/5!1>)MM<D BJ-()DN9P+/9 ,0CQ9!^@.SP2
ME4,"@R,DBFH%8H*@!:YZ)52E&TF$!#$1(F&%YD. &B$B9P"\I.^E@?% 1T19
M 1R:YX;)&VD0A'84Y5D/OJ2+JJ,+13DT)IO"((G %("\J@\I3.3_ "4MMZXY
MLA_#* H3I0H<AC/M/8$"7!!##"+R*(A+0E!F\<E9U/U01-.4F06I^5%IO6D
MGA)&B4U&+$4["".1YKM):VG83J!A <U>07&T5!IQIY$EJL-0J C<@:4Y4T$
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M3>7>C/J2\#-' (*L9W_<\$Q4K\^-NJ\<L%"BYAT?L_6<JOH0\RK KERW7#4
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MZ[Y%@%/AHWC^3XX;LI1VF3^N7SG&G.%2 REM4GK8_P"K*%1,WK4S/M\7F1P
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M0BA\9[+WIG"A=L&>H;J_:;F.%#(P>TP3>YA*>177"JHBGM@P:)X#6^-00!D
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M3%%+4\^,OZ_&3OF;CL,+GU#WXQWUQXC&,G9^AG[=$VR95-5S$\3H^N/CAQ)
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MM9-QS@VDKOXX"R39,9D=SX_7DXWC7O*_OP<.2"SXQXY*4%.MW&C/K]>!$1#
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M?KS76VC=>UZSUWU.:/5_5_US=^/Y/^AA_\0 +!$!  (! P(& @$% 0$
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M#=P-<[UIB:PV3PV>W_AFPR@HDS8T[/.<^L6,'+$-L3G8<X0XU4"L(L7 )P5
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MTJLNO;/G1]!?3O\ VS).-])<[DE;2C[GK.E9@P1/FGW[>ECNL!H9.I3W/O\
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M .X1D-*HBF8[ !*((J26=*'X;0VQPQ!;2!P6"0;HM*4AD)C9%HM\HZ-H8H2
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M%P2]M,H0D%-2.6[QDRM0K#&&)B,);=9.4])B2,*0E(B5*#8458BFH: 9 !(
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M1DTQ04\@F/WJ(0!$[$EN.'059&5MJ=HF+?.TBK@6$B)8[B/R?\WU8(!.IVW
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M&O7?_L%$!'!HB;]]NL;]M*K%+-99C:]^WQ,G,0^M5Y>_EI2/ QYU^WCYG_6
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MO^"B\T9C<&=M8B"2F)!*I2U=X4DC4!IRI[0@/860.HI2-UE&VM6BI0M[R@@
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MTTI9F/*B?5[:COCEVCK]\]!'+U5Z?/\ 6'7?Y[/S7_=)486NB .ZP'5C4&,
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MC*H1:DM-&)PV.0 ( (39+U8.X$=:.<P)$)6"X4@N=1#')/K5M5F0NFK!5 B
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MYA<YEJS4)1<2#> N;+261A<WI&01@V94>-NT]M(G+*',2AQ0^S$8TP*93O-
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M>44:9+,1/S&KF6/.);+HC8#>=\:(924&4EFH;-CY8VTHJA6Q_P TS7<?1/\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>wald-20221231_g4.jpg
<TEXT>
begin 644 wald-20221231_g4.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X@O@24-#7U!23T9)3$4  0$   O0;F]N
M90(   !M;G1R4D="(%A96B 'U  ' !4 $P + "%A8W-P          !)14,@
M<U)'0@    $             ]M8  0    #3+4A0("
M                                             !!D97-C   !1
M '1B6%E:   !N    !1B5%)#   !S   " QD;61D   )V    (AG6%E:   *
M8    !1G5%)#   !S   " QL=6UI   *=    !1M96%S   *B    "1B:W!T
M   *K    !1R6%E:   *P    !1R5%)#   !S   " QT96-H   *U     QV
M=65D   *X    (=W='!T   +:    !1C<')T   +?    "AC:&%D   +I
M "QD97-C         !IS4D="($E%0S8Q.38V+3(M,2!W:71H0E!#
M
M                                     %A96B         DH   #X0
M +;/8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !%
M $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +(
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M]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M__]D97-C
M     "Y)14,@-C$Y-C8M,BTQ($1E9F%U;'0@4D="($-O;&]U<B!3<&%C92 M
M('-21T(
M                                                    6%E:(
M     &*9  "WA0  &-I865H@            4        &UE87,
M 0                               EA96B         #%@   S,   *D
M6%E:(        &^B   X]0   Y!S:6<@     $-25"!D97-C         "U2
M969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#(#8Q.38V+3(M,0
M
M                                            6%E:(        /;6
M  $     TRUT97AT     $-O<'ER:6=H="!(97=L971T(%!A8VMA<F0L(#(P
M,#0 <V8S,@       0Q$   %W___\R8   >4  #]C___^Z'___VB   #VP
MP'7_VP"$  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_" !$( B@$Q ,!(@ "$0$#$0'_Q  X  $  0,% 0$             " 8'
M"0$$!0H+ P(! 0 # 0$! 0             ! @,$!08'_]H # ,!  (0 Q
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MCZ(4L+,!6<2T]TXG'%#*:.2!& 2=&1W(4MU"K ]GN\J,*\DNQ#AHEC5W62:
M<(=Q'[I&$B(ZV?9RPL9MT4/A5[ 5VC"?.3*]B43(G#1V/(+%BZU[.?6WF;'8
MG<I&#NM<J5+=OBQ%F(_)KB5G5%[Q=:[(U]XIU5^TYA@]#^9P,[JFH13%W[-S
M<Q#1,D\?'>I@[+%%EKP>3F(J8R\M&3&'7PE#?3L!R\N'-3C$[6U8Q=S3JOM
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M%GJYJCG]*TC:V1M)HL\O"SO9Y>$6>M]*(1\X*4 CE\)*"SW-W&W\Q>@>OQ
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M-<<EP:@DI$X\K-9H+<II'';E_MY-8N6YG76D/A>#@^:F+A[K:[K?()
M      .&YGAJS1 QW 8J\JELH8V]OE!IB(@[=JM[U3;&54V2.D3''S\ZN?,3
MLF9,\?$V?I#(%1$Q JR&6+>&/7?9)[4JP,R\V&OFCX"; 515%+U1KB%Z@
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MJG4P*G4QS-HWPM4       Q6\*MEL8RYE(I*2\0I>V@*@  *4IJI::QW"L@
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MSM)5?>&8U'1BM;=)2UF:>NO:['6WE/W?^BU7.>K6V8;Y      6IK*I
M  !Q/&52K:EE4BEE4BEE4BEE4BEE4BEE4BEE4BEE4BEZH)BFOG5*)I95(I95
M(I95(I95(I95(I95(I95(I95(^7U+5             <?R"%'*Q4M1RL11RL
M11RL11RL11RL11RL11RL11RL11RL11RL11RL11RL11RL1PW,EX"8
M
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M'_C9M9G_ )3._G>%Q5@(7*3E9WC:I2?A#HV6<#;Q[)8H3'L8AY(!<E+3.!.
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MS=YE3*M*OP\>]TBC?NR/0E-UJ2BQ$8P.SQ4W&J4(X6L,)E]EU]Y@(=\AYM*
MA'2F!VEMJ1\[LO)XW54%]Y>I7[\CULM7>=0U9^-:2RXZ/>(1_4TGI=N7^I(]
MA[,VO4/]^U4_]XWZV(X$B^EO1Q<Y:'8I*6W>4N*TMKTECI&6EKR"^\$^,\\V
MPB[CK#BW4:U>=[VM^M[7M>UKV^#=24_JK^7R#[=GR"NZDEJ[#HJ%-J)<D6V[
M(+=9Y3"%*5>S0Q"HQQRP[K[Z+./,,7<CUTUMR3GF;RC+2&&'+?&Q[W2*-^[(
M]"/K33R4W%OO056VTC:\;STL:AK*M<\Q0/-;ZC'ZR'%[0S=+*O<U;'E!?>7J
M5^_(]8[//>;:HYI0XW+'4=9(BBE@DD<M:G2-H\,X\JH?[]JI_P"\;]:+V#CE
M*L.WRN2;==F1KGE4&8_8=Q]\Y(BAG7;4%]X)\4A]L9I3K@C3ASECBJD+$J ,
M2''JC-!#:(B74T!!-/297-&2PRQ(D\R9"<:F^&U#$ZXAUL*X<=*V/>.&N_*+
ML2\*)"2EF +Z',@2VFR%J+LLF(Y[.06>&L70DE=\A0A$K>[T]&#OVG?T;(6U
M)J?/("9+DN0^V&.WD#:N<EQZ3LT8Z"DB6L6),A.V-N*.C;QTRX]:,:-CSVY%
MIQ]ER>2CGOI7,C-(E5NJF';K4@>\ZE;@;0<G)HBV6'5]:Y>X29U+</1#CPTP
MLM27!T3UEV:(_AL@^W9\K7O:_&RR'W.&O</ZE+K</5=UR]DIO<DB]TWO<A^]
M[7OK7KYE..N.WXN?&Q[W2*-^[(]/&_"UO@07WEZE?OR/BP_W[53_ -XW\4+[
MP3XDP@AE39C5EJF2VTU:UK6M:U/V>4RZD>\9(G%#E2"HIVX$&)5H5[EZ*>C3
M;E2RFH^)=#*:?5<7I'2[)QSGNFSQCK@4B.865&IQA^PHW-Z(3M'&Z#A"!^E7
M6O'U+A18Z\5%N"OND//@W>D!BZZ3)+'9BG0PU#$R3URPC+'(DH\< XQZ=;<)
MA)8YXTI]G'R+.'O71$.67Q5*L$L0H@KX0J @QA&UP\A9@J+8.@[DG"$-&0+E
MS2BAA8I0Y89%90EU;,2EAR+D#KDNGO1CCJH.]@H^4 0W'M"XTL6[ Z6-WK(W
M'\));*S:-[JQ^M6/UJQ^M6/UJQ^M6/UJQ^M6/UJQ^M6/UJQ^M6/UJQ^M6/UJ
MQ^M6/UJQ^M6/UJQ^M6/UJQ^M6/UJQ^M6/U&WCKK<V+ZH/G.<W5C]:L?K5C]:
ML?K5C]:L?K5C]:L?K5C]:L?K5C]:L?J/O%W>OLR[PVX<W.K'ZU8_6K'ZU8_6
MK'ZU8_6K'ZU8_6K'ZU8_6K'ZU8_05X?<(VLC>+L\G>ZL?K5C]:L?K5C]:L?K
M5C]:L?K5C]:L?K5C]:L?K5C],*@^>SROAD,V(9<94((T&WRVO@.LM/)T/)2E
M";)1\)#+3:W74>=VFE+2XKTNL,O\OF_Q.0?;L_DX][I%&_=D?!X>B"^\O4K]
M^1\6'^_:J?\ O&_BA?>"?^+9!]NSY"L;DAMFG%Q*+K9IF,+?1S6T,:0"]:HH
MU+?,O:.)4S8BF!W25\MF\67S;,TY'%MK;;O>,)LZAJNDE_.K1Y-W7&:&B75D
MV:?<!4P.3KO%F6;YER "!D:W?7CWND4;]V1ZAE(V:=E',(1SC2&(^]CG-VVT
MKJP[]WXVUFWGFEPZ$W4A-07WEZE?OR/6U=NSB+NRMT*;CUH9?0XPY=UA0C[+
M;#<@,]I1RJA_OVJG_O&_6PGCMFVOZ;/_ -)RU.,DJ%MM"FN0W),/_H[:@OO!
M/C/D-#(UNL+=6C6Z0]8=AY^XS]B1V"+>EI]3CQ+5_7N&N?MJ8/;<L*EZGG4L
MLNO*BR2# F2R?(ASDL//4$1NPQ"K^I@ADE*EL>19EQB(]BWH#,N4Z>W?\_(/
MMV?(9^XS[;UEJAUJ613983C0NX5(-K:+O5SP4N.&H*)0Z*&VB/*;'4ZEYLD
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M83*#Q2K1#,ACUHG(G6DC"L.V>TQA+2UV &)2W!L=.1" F@%7<?+EU&-B!IR
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MAK\7$I?'8E9BY[+LF<RB3W?P1G4L$,O*OGV&%/-2!N4Y(_D\EOG?PL4RG&8
M)I94Q*$34D7)E?QWA'_C9M95C&0EY',$C=H917:&45VAE%=H917:&45VAE%=
MH917:&45VAE%=H917:&45VAE%=H917:&45VAE%=H917:&45VAE%=H917:&45
MVAE%=H917:&45VAE%=H917:&45VAE%=H917:&45VAE%=H917:&45VAE%=H91
M7:&45VAE%=H917:&45VAE%=H917:&45VAE%=H917:&45VAE%=H917:&45VAE
M%=H917:&45VAE%=H917:&45VAE%=H917:&45VAE%=H917:&45VAE%=H917:&
M45VAE%=H917:&45VAE%=H917:&45VAE%=H917:&45VAE%=H917:&45VAE%=H
M917:&45VAE%=H917:&45VAE%=H917:&45VAE%=H917:&45VAE%=H917:&45V
MAE%=H917:&45VAE%=H917:&45VAE%=H917:&45VAE%=H917:&45VAE%=H917
M:&45VAE%=H917:&45VAE%=H917:&45VAE%=H917:&45VAE%=H917:&45VAE%
M=H917:&45VAE%=H917:&45VAE%=H917:&45VAE%=H917:&45VAE%=H917:&4
M5VAE%=H917:&45VAE%=H917:&45VAE%=H917:&45VAE%=H917:&45VAE%=H9
M17:&45VAE%=H917:&45VAE%=H917AE&GQ<"6Q(?_ #-2N%<R]<R]<R]<R]<R
M]<R]<R]<R]<R]<R]<R]<R]<R]<R]<R]<R]<R]<R_ES*YEZYEZYEZYEZYEZYE
MZYEZYEZYEZYEZYEZYEZYEZYEZYEZYEZYEZM^;>_"N97,KF5S*YE<RN97,KF5
MS*YE<RN97,KF5S*YE<RN97,KF5S*YE<RN97,KF5S*2K5_!..-LH4X[UB+V[Q
M5FUH=0AUM@H8F[R1W'$,MK=<ZF!LDR7P+%#7)N';X+G[?B7^=_PK?*WYJ_E^
M:W^_\%FS>H6,6\66(M4\F)5DLVQQ9:1,R$>=.7$>RN5,D"AJ*_XU9I>4Y$AL
MS8-Y;/)C2%O,Y=)-, D'QY,TY*MNN8I+R<VZ422K,)9R8(;8[DR48=E=8L7<
MW*RGK_!<_;S3XF@Z+N/,>(\4MDA9+_B"T(EU)TMGH$:MM#3GB"R,AETX";8D
M)*2CV6O$J/5>_.3XALV&<,(>\0&QDL[J0RL>/&A"5H\0DJ#?/OWO$Z(Y^EY[
M9L1\YV!G5S:'UJ\[_._G.9FU"'/!*?S.*9/A0;/9X(-(NA/I\0$O;1(=LH!<
MQY[(F%>)(:$*LXK.^#3-K+SARUAQD YX&6:" ZYXB#\_DBO^(C(JU)?9SX1^
M[8S?G;Y6_-7\O5,Y.N/D68F/[V+<=;##MXCQ_-BTO%>(#;%KI;)\1+!++8*>
MSJ38'$*7WR9U'IK@GB.(4 630&72ADMTEPK+6 \E8QUYGQ)&(279@GQ"4 V6
MF0?S\)#T&RPUXC+<%(,K_4)+Z(GIH>=E$[9QR8SM,2[*M78S$,N?$A!/2W^_
M\'H36E/SHPA@ 4@Y]A;1++)*.%N'"M*:TIX<*TIHP2Q8SH]"BAXY$K0T(\R:
M*,:T\^,-RN>)(#$FR 37P7/V\QO#Q#, 6,MGPZDQ$K2(G&9B6DDFY.WX>'MP
M4D%0V!2&H-HS$<6-QTJ540UX<2H^EYH/!9P04D:O].9SEM)I_$\M.1#CFL>'
MLVT"6'3WALZJ0>NR=CV:R40N'*Q&!.@FBVB_._SOYY)A+\])&GT_@$E((D"S
MX'#K,%$RD^'AN4Q;D>_'6Q1T?$S(!A[PYE6T.C ,8?D JA#PNWLPL6Q-I=PB
M0*BI/='8&=RX%L KP\E#''2W&H!ZV3,SR_.WRM^:OY>J5QZ17,HGH1K%\E#-
MZJ(/X??W6;GHP"4:B%1*4>'\HQ<SDL822Q#1T;:4PV0,R N987X;+5'QK=AH
M=UC(Y*:ODF$/3LB8>EOP[(&<62%(8/+3#CYTHUX<.#EV):;\.95 [HMA<$V4
M_&S UL/+3!ICD7P@TI;A,GC^!K@Y  [U-_O_   #4F2M:@A(W+;2BUOE0<LW
M"17()"RA9*UNCQ4XR0S(4T)DCSLJI^:&E%8S&,!20DZMD1H&\-.$=<-;P@.:
M'?-6<N#DG7UOW+"R7;WCD-0\F;<Q\^T9D;,8ZRB\!*N1S1)8033+BS$?!<_;
MRR$PL-R*<%$FWG)"0)I^9)L8.VR-DSI*$WM%E%.=;66K)"4I%IR;?;'*.4K(
MR4,MNKO.+44^(ZYDBVA=^L$YXE9;!/<1"&^+*)XIUS;,KR9"7A.#\K*[)DQG
MSO\ ._D#*EAIW3O6)=QV-32\@=Y(JF694^Y26WY&6-CY%^@CB5OEAF]PFH;Y
M[CLO(,<_6C*7%.7'4F3G-PR^HV2<;!&)%8FSWB##F+3I*])#2LH<<;1<2.*<
M,#:(=JWRM^:OY>H]3@\NDE\24F-3+1%YZ20V+>]I>15= EGI0FT4&8PW/R#2
MM1JYB3:X,JM/R3#9+QK,Q+O):8I4[*)4Z5<B7+N<['A1<D<01MSG)@Q/42[.
M2TJT\V!3\S)W4.N[TW(,;EY1F0N,K<:'Z]()Z<IWTM_O_ "!"@H4T)^0Y^WD
MMEIVZ%.7C0;L[>D18#26D-IAXQ"'6TB@BAMN-#/1@+]F;.])C];[E7AHS0AM
M28H!#JW[=(C+7?7=+3:5N.IM'A6M=-GX((@Q)"T1\40XDMNT/&I;=:3YW^=_
M*X@ET6;NF,CT-MLI9C(X>ZU,<AGYTZ(,^M+KPP8H:+M""8^P.6Z6\\( ^4RM
M^X@MUV<NXQ'!V=)4^&(2RD=]4/%+NW=33$<\:02A0 *V7!UM--,-H99JWRM^
M:OY>I0(;A""UMBC,K6ZTU' ,7<NS(Q39[=FTM"LM#L#5MQ^*;TS'@C64EAU0
M+0^Y4P"&*E*!W68[GBLN\B-BT-7;2RTE5EIN %<A15V(\$9-DCK!#<T:^0Q2
M(J,;:=8;Z9'?[?U-_O\ Q;$J01)DA)5,%-M2"W.I%.)184=Y)##)"/A.?MY/
MZ[,/7:%:F-N_S]D;RB7T$LRW(;6)%(/;DY#G]*/4A"U\N64ZUK;!D7&$[J5;
M(44->Y(<P87*-68'F-^!HMU+FM-#6$.?<;0.:-/:6DHCVST2YNX\[_._F0V0
M])RUF"XV42.VIOILNH(-E]R*G+$F;8J./6PPD*T;+),:5<2/G$BNM4B*>?*&
MM>PAJX(,5Y$1,O%&V>) GB&!WG#(N5Y;UVT:M"-?E;Y6_-7\OA9'=S8L6;L
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M\K>AQX9KAS>H@4V4(Y^C?JOI^=[F@MWOQN='J_INAQMRW%OT\+4M;+/]3G4
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M<FQ"37N>MU]H=-M8J7/[KSM-_OY%6=0MDEIDEDA.IID3;H<LWM+VN:ML*'9
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MJ1EUJC]UTEDN-2W[Y;BXZQB2D25LNJ<OI8Z;=:*/E6G>GD>0*[%C'&%0+:-
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M> \GO(T,B7T2%%+I?ITM:ZWZ['C[Z-9-J5)X]0OHFC[R1? RW-C_ &5^=/\
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M=*WN+F@3>J*'E0AFJG6GHZ5'$=Y)]J2:4F0Z458KGG$E0N*#9J,OS')>YQU
MF6H::JBD7;<QQ60V !=0>/.5;8IHJ<TV7MFBM2U!J4DIUDVGC[I#3E9UD**.
M!1]=P1;!RL\M++"M#FT-=40N(S($JHD1;:@I[I"TB*W-/4Q%'EM)(SQT[3UR
M[DTD4CH_!XXD5>;=;2,_"Y4 XHZ>JVZ2GK.62UVW3%*AI  !%3SLWY/F%"5-
M[G3;G1P4]<U9/0R05E9'3TT$U.BRRO)6,MC#MR1-$4BW)=U%"*=6F"FJJF&N
MI*%DI*Y)Z61JPJ(Y8:M8^]YW%7B5D8,K=%S3T"+3Y%4RRF*KGD$5**N%IIH]
M=&I,PT!=OFJZB^Z."XH(H<MJG@5'Y46JX$J658):F'8$05BZ:UCG9HM7'58V
MH832Y-RH2R253+)4/3TPG"0QK3OIOJ0.[M87YH<@XRRE$F80O/2GESZ(5C5&
MD%;^"75@)%*[ E#'F7%M>(Z&FGCK9Z"IY;7[%+%-3LRL8YMAI*@/8&-%B5R&
MXVTG%&D\\^;MD[1I5=PW5@EFWXIS#=X"J(W.B1E5FX%DLU(@JZ+DFF.EG,D5
M5RY]JFT22Q1-&3+W-]:<VVH7'#%)2PJFULF"NU1O)-)MK#,\\%/LZ21KFLT6
MF[=5BV6O+)#)/$^69BE?%:,H'BF[G$\4H#@J=)24!RI&@C%)'42UD-5+N2SF
M&* 4QIQ>33%*S*=_X U7 %N==:$',8:^AH9*5*CN;>Z']&GBJ#$+QR?IQHRE
M7#=[<TE&]=% E16%JN5:2!9I)1!$DG)6FEED2(DWBC5.FY%KT>K,I)ZJFDI9
M9@D5+)1:>4O-4+&^J%=R(QF.(M+NIS5XZ:.-9J3)J4Z(J@R03CE<W.CE,*.H
MX\5>&ZD6YPYV$&W5P5\[S:K;*T,44IYNDZ]0D/PETZ>N^,NI135,&_2F6N:.
M=(V77&]2@I)%7=0Z@L3RE#97ZRJT0FKU55K*JL>*D"["R"6LFY)W&:9M2K$
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MFKW2)HX2J=[3Q/)I&MCQO.1[L/5.SZ =@U-/'3\%U#7HV]72M[VX8D_H4$T
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M0Q*T05IE4"0ERO.5%)"$:12-2JV13Q5%0J'3'6R02I>5OSNIAY<>QYZ>OAK
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M^SA_HI]G#_13[.'^BGV</]%/LX:X.KJ7Q2>H>\\8>^\8_P"7]0FJDWHZCD"
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M<NL]?]??3JO;@>KIZ,3?1;LQ-]%NS$WT6[,3?1;LQ-]%NS!NK"X/D]X8[!V
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M?_9^%]COIF9?R_"^QWTS,OY?A?8[Z9F7\OPOL=],S+^7XC]CA*&]C6YE;_\
M=^*;V,>G9I_[#%%['7]T*^GRV'9K,R;3/4)*Z-)KI([1 0MJ*ZVN5LAXVI?8
MMZ=FO\OQ3>Q<?%79K_+\0^QGTW-/Y?B'V,^FYI_+\0^QGTW-/Y?B'V,^FYI_
M+\0^QGTW-/Y?BG]BYN;\:[-?Y?BE]BWIV:_R_%%['EFR>2GCJ6DJ\R$3FI61
MDV"M([, (FU:TCMPM?JI?8MZ=FO\OQ![&!\5;FG5_P#L_$/L9]-S3^7XA]C/
MIN:?R_$/L9]-S3^7XA]C/IN:?R_$/L9]-S3^7XD]C^6K(526LI)Z^HJHH;]U
MY/'/1)%NE;A2S"WP61K.MUBC]C35%34SO>6:0YAJFJ:B0]+&W'J50%%@,4&4
M)EG*98:.3,ZFNAJ*F.(Z=_13TTZ!':]N=U$<;7--[%^((_IV:]?_ .S\0^QG
MTW-/Y?B'V,^FYI_+\0^QGTW-/Y?B'V,^FYI_+\0^QGTW-/Y?BG]C!N+<:W-/
M"#_L_P F*7V+>G9K_+\4?L=,^9K6O R5F9&)10)%)+NDT:LNH3+MZ$>YOJT]
M=-[&/3LT_P#88A]C2:6U<VMS/P6Z\OPOL=],S+^7X7V.^F9E_+\+['?3,R_E
M^%]COIF9?R_"^QWTS,OY?BG]C+!>LUN:7XF_^H8IO8QZ=FG_ +#%'['E6"KJ
M*)]ZKS%29:9M+E=%'(-!/>DD-X5&*;V,>G9I_P"PQ'[' 7-["MS*W_[OPOL=
M],S+^7X7V.^F9E_+\+['?3,R_E^%]COIF9?R_">QPF-U< UN9?!-_P#9^*;V
M,>G9I_[#%'['6C$U-#:&LS)GU551%31FST<:Z0\JE^=<+<@,>!IO8QZ=FG_L
M,4_L94.+7%;FE^F_^H87V.^F9E_+\+['?3,R_E^%]COIF9?R_"^QWTS,OY?A
M?8[Z9F7\OQ#[&GUD'G5N9]7Q9?BF]C'IV:?^PQ1^QWE-+305<CM69EL&.=F5
M C"D+EQ;G QJ/ QQ2^Q;T[-?Y?BG]C L+<*[-?Y?B'V,^FYI_+\0^QGTW-/Y
M?B'V,^FYI_+\0^QGTW-/Y?B'V,^FYI_+L4WL7X"W].S7^7XI?8QIBC>1K5N:
MWLBEC:] !>PX<1\>*/V-+#64\53$LM;F8D"3('4.%HG4-8\=+L+]!.*7V+>G
M9K_+\0^QGTW-/Y?B'V,^FYI_+\0^QGTW-/Y?B'V,^FYI_+\0^QGTW-/Y?B#V
M,&U__P ;FG6"/]G^7%+[%O3LU_E^*+V.&3-)I(*<QUF9%%:*/=8S%J-65=/1
MH5S?J'3BE]BWIV:_R_%/[%QQOPKLU_E^(?8SZ;FG\OQ#[&?3<T_E^(?8SZ;F
MG\OQ#[&?3<T_E^(?8SZ;FG\OQ3>Q<\;\:[-?Y?BE]BWIV:_R_%/305.45W(I
M#222R02'2260S(CVN.M1?P#^I $KWI(Z/B\'M\/?@#42QL+78]9\)\OMGCTV
MZ[8(X=/DMTWP1QZ./3?HM\?O "/ 1<>\8:?#?AY\'B>C!XCI'O%&NVG58:K>
M"_3;R>V0+\!Y3Y,=/@]\ H\"BPX\>@>7V^KI\GQXXCP^]4-:S"X!LUND7Z#Y
M?>=?1[Y5!;OB  6MT7/7;R_B;QKFF31T]?4B]Z?+DKS-4L.(XR!!#8]_N;?2
M]PH2&FAC@B0?!CB4(@_4!^) U+WIMQ%^FQZK]?A]LV^/'3@]'3Y,&X\(]X .
M-^ MQ/2?C]LB_@Z\$6%[F_ 6Z;_%U^] (\!%^CB/,>/O&%O#?AY\'B>CRX(N
M.D>\ U&P+6XD<>%^FWM]?M$<.GR>]  '  < !X />$6\/5[T E>])'1\7@]X
M>GH\N.GWJ@%C=K #4?"?"?C_ *K%3U$K2,M%3U<B)3/4%"NN?>(@VX58NSR!
MC&.,0W2H,M//61466+D\VI#*]AS'R\W+7>IOJV2;IMB3F8%.]8SYE_VA5PCR
M& 15+5(KU-R84KEI13"8:1%I%/W'%)R>7V0UEQ1TD*1214#"Y B30%=,MCO.
M>%JB8K>Y7"RHV7S&F5:CA-R6P>C,G$W/)V1-5SK,98\;^^-)'F='#6S256]&
M<SJ<Q]SY8(,MI$9M_8C!$LX7N(DCB1(]>XZ<E]Q&ARSW6T:#2EN4MR0UWP3-
M(-?*]_NC@1\I^#B7+(*$?]H7H7KK<@T?@2**'2RHE4DS3M2S1:N3)NF.&758
M4V8/#DD5&J )J63<17SX5+:E.[!2.D:6C;\+IY/&X,&1U5T8=#*PNI'D(X^]
M;30"(BIYSIJC8A=N\95^ZDB/2#S]6@\&./<M<KJJK,:@TBR4DF6T-0:6E2GI
M6T$THJ!3I)4.O"U1/*R#B#C1[JK!E?\ V>W;<KV]*\CY#?NO.K=Y:C;Z8N%1
MW&V(J1AE5)5R5-; 6Y7F=3F$B245)7@QCNXYK6$\_?0F/927:Q'5Q-6P#,@U
M8H4SYAS5S8Q<]^#220SZ.%@[66P/ON1>Z%2FE*BNFBCCRZCW0TE7$)G Y470
M)3B"TSR :I%BC.#&<^_[15RS&Z\M;+0]8L6[_I.0>Y(I'CO^#[FPR]VM@EZ$
M>R6GY:U7(90\3TE([-4O*3J1ZHQF37W.QM8)P"U+41K:VM#Y6JMR6ECYM$:>
MSQQB)LTW)8-#Z/P.0*NGH7;J=.U5Q=&W5PG:J$MU6E5BOZ)'OI*./+U,%-5"
M.H22IS*DDS*GES#,<R[H9VIU-X(Y*G43!/5L["*55P5%!!6K+1K1R:*4NM)0
MF4((2(VA6K,CF,=SWPW#AAI-0Y9$%W&VE7DTCLVWWFMN +D$Z5 %A>\=8*2O
MJGRW=9+4<.7%A#E+JVL_EJX&1W*"WNB03IBX^UX![<<4Z[R\GIIG5(JBJLVT
MDNX1#MCOV:>\<6G=MJ1<2TDI3)H3EDBLC(*HU%:91EC?G(Y.1QPF#NH"Q!;=
M&)'&YDR-5,TKZ(A&UGVK'N('.<F.S:R6O>UE@AY>]/EU#1T+1/4E;..63I$_
M,J7@Y1.-P[JPP*TS;FI4CGB6@E')DJ!:44,X+TZ]\W,A(EIH^)[G"HZ??<C6
MO#TTU15U$T8GIXHFUT]/1)(VO?JV.EA#I40M(\NMC&C.%S&6CK!GAA8"I$A5
M-]ZLCG"HCS VIC+SD4S"#N6K!H@JYAFB4GNJ6FI3+'7UVC?,CWD.V&XRN6+<
M[G/B*KE?*J"*K1X1N1MFFE>24\CW2].8$DU<#>FK('L,=Y/&L@OTC4.*M^DI
MYK#J(/M1CE+Q+ TOPC"C,ZQ^"P9V/QGC[?)1F.Y2235-1+&)::&&3<A@I!*V
MK>JW.@QTX&J-W>:YVPQC&8N<R&:&$J*JW=+\I*\^RS[7)S-T<W:X82"H@H*Z
MN8TE>\CQ57X1/%&K.8ZEWJ-QU,&J*8R3$+;6RNL52U1EM$M>5HQK6FS)V9LO
M@D)=;QP(LJZ#?5$5U"S+CHGB22WBEASE/E5KJ?*/?1TE15SF6*@BKI8XZ1&D
M4)-5S[S;(6FC.K65:;CM06>7$T,^:PU.1QY+.Q0U4M**;+M+T9N7,$M0<QY3
MM$HT>]O$H,-2I310M3U!CG5ZW,8YLQII<RKJOGFI:" !X89I[W6>?21$R7CW
MJ+,:VG78RL(4Y)#31R9LT B9(@IO3P2Z67NE4+\XG&[RF@E>BFY0-,[B+^CS
M3"[=TGI6AEDYQ[HS<3[YJ6&KHHLRY1-'.IS:OK)(7BJ::)=?*>2T,2E[<5%5
M' M.J"G),=%/E(AR<PTM/)#'05&;:\PT1$ZA2ZF@6D:I,UT5%BEF!*XFBEVL
MUA=10SWR]'J)9&>*$1MHDBI>=!!?O5U$(I-E@K'H\KJ5H5>-+TGN>+KG54YU
MW+QS,"+1GF98+'NQMQ!X@CK'O6TT(BM4\YTU(Q"[=XRK]U)$>D'NFK0>#''N
M6F5U55F50:-9*63+:&H-+2I3TK:":45 ITDJ'7A:HGF:,<02]+'F6U0325M7
M.@J**CIZDU%%#0K,X855=S8NXV.PYDFW;1HS4:&FH,W2HDWXVK<RJIQJJ=Q6
M<U,E'1;85&D[F'.B#3%"-1]C^HQP;GN)%#&_>FW*]N1R6O?3JMQU^WY/;Y)R
MZ=0J3UDT:)04NZ#)51"5K<I+*%@$($KR:=3K%&3AT7-1F^8<JDU::L96K5=C
M*ZD2BB&5"G>,_D1*('7N^G'N;!ETO)((Z?5&\=HC(*>KS&.-^:]5*W$5#!WB
MB3>;7J"MD@A5L]"FMCCERDGE-!IY"CR1*JV)V[.VGNRC5WV-@Q[2:.3 "GTA
M1^0"E@(O$ )LMA<^^>FCBA$D-6T,RM79@D]= V:S3Z7Y1R6DA22.$MJ_*2;6
MU&B;D5#44'**7W.I=V"++I<T--)OB_\ 1%@2+D\DK%72-]V14:?@1-44E'/D
M<L512+N4U3429K KJC(Q AIX>Y0(2=9G4<-H:FR/E7NEF%@\47NS^5F"Z93+
MN=[T=S_(<T<./OE66#=CT0.VE*BH!U00OJ98V5G%V$W<;+JD&E</0/%[EU<E
M'I>)Z2.JDJYI)8:!N\UTQ:*"#9[H%CLMNC#TT=?2B.>OJ))EY=-4\@V!ET*N
MV]M")C/4I&-H,@&WNR2.C9/41+0T32U]/2Q1!K5 C,>9:9I-UB!NMK=&XRZD
M7IPV4LNYSO<B..*#58=^L<DHW+=9/1;A_69849>C4RAA\0Z>CP8J8+GI-QQQ
M/$Y\ ==7^&]_5[\*/TK >O$M.-1;6MT-R>^U@=9Z]7$XFI[*5T#FV0CO2+\%
MT]1X6PR.OA0AAZO?F)4/5)H"D_\ %PZ;>K$\.I;V-Q<7Z;'R^3IQ40<>K6HN
M?U])Q^KWP!^,8F@5^@\Y-=O!XUKWQ40D'I!(L?CQ)$U@.",IL.K@.BW@ZO?Z
M$'6>"^<XGIPHZ%5ETCXM/#%1#^MP/KQI9>JUB.SV_ />20IIXC6R@C^Z#QZ/
M!BIA_P 6)X6/@#IJ_P -[^KW]OC/;BH@#'OK.I-QPYUNL>7%1 0>IB+?KOPP
MZ./"C!AYUO[X8>./5\)V5+V\IM>V*F'_ !8J8+_^(HOYSQQT>^ /QB^)8%=1
M879-8!Z0/A <./5PQ/ /BMAX38<%B*< >-M*]'AM[_2OZ1L/7B:GZ;\"I%SQ
MOPX7/7UXJ(?\0 ]?#!5E\*D$>KWYA53QTR: #U@V;IZ.'Q8G@OX;C$L!;R,F
MH_YG  ^(6]OR>\J( W0>>NKP\;&_GQ40\>GB,/%(!^;96 _PDV]^4C'C,54>
M<VQ44]AU!EMZN&*F#];JOUVQI/E%CZ_?RPH1Q"NR CRA3QZ^KPXJ8?\ %B:%
MB?@JZ:B?*O3YQQ_%F/E=/W;:E36)X4N98EXC3)IYR'K*Z+<ZZTJBAO39=102
MJ==5F]0NJ35(O%(:8:[H.=)MKSUWAH.6RP9G,M%'+2(XDHJR9&:'6KV6:,:7
MU@ W"\)!P#T\<.84E1(V=5)CO!R*-NY&%+G2]4KC3SNE0R71SH%)":.CY=7U
MU:LDB1QFQ18XX^/1WW-D+7YH302TR54TM744BOE=-4%'D@2*0 QSB-Q(ZS1]
MZ"EW X<ZTE2H+(AG:G84\<KB^U+)?F.O0]Q93>YL"<2R(]8*HH'0#:-(9%D6
MHY]XG9HF$2F^NZG@&!Q2UB'W-DJ:6KDA/Y;0[(7@9"HI]*AUJ#(RN3IT=>'E
M.8Q9?33U>Y#LK*VF-*B:&W-:/E!MS0J\Y=(MB@O0PM414RFGEC)/!,OE%43M
MS<ME/&-1=5U=&VQQ6TE?4B-5JYJ.2&2'E%M3I>!FC!6]N%K]\  ;>UWJ#JZ3
M?@ /*20!B1D0][2PL4"C_>N.>[>$ A?U<,01#RZ 3YSQP!;P=7FQ!$W_  "_
MG''$K<.FGF8O$X\"L>=$? ;D>3 *](*MWRLILRGR@\/> &9QJ+-WD2=&MO"3
MT*O6?(,;M8\2-)9N=J*J6TQ0]Y<VLHZ;V%\14\:Q,O/A>.6$ZHDEX3(JK= ^
MF4? 8$7.(15Q-),B:71OR:LRCFB2TM2% @@(#NSHITDX@V 2VTT9VW,=^;)W
M.UM=M2CG<VW'CA]ZF=@BRM^4A8]Z)+<'4]&OA;K]Z^S2W(#)^5GMUAO@)X.&
MHXH#.B5U)0-.S(Y+SR0Q-*=V[:(7J$3FW9W#BRA=6(XM"W,A>9*=0 .%B5.J
M1SS47K;A<8H.Z,P6)90NMW(B;GJ4.VAC>2427:\=-4&PV[8UT<U/*%LK:X75
MT66.3;/-TN'((&DJZL+D#BH6:+3JMWKJW1(GD-CPZ5]XI=V8)&@Z7=N@>0=9
M/4,2&0G_ $*$I"H\%AQD^-C_ ,.**&,)#N[J%&X&31$KKMJ0T@5WZ6MHX](.
M*;<T0/.-$JR';22&,-4)IO3H^\71CKND,S6YAQ1HBQG291;GRAF'<6559X]
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M]D_,ZG9DB.45C9, >X;U)+!8N+"F)^NQ.#G@)]EZ%M1B6<?*81B.<M+CT,H
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M'$E&#59_$)O$C]4X; 0B4M!(DS)>"PL,"-IP*% HR!;VYU$ PEOJX'$8,#3
MP)"EX,.DZH,+MBDF6YYR;AP+S&K%KC/X@E[H7ZXG,5<IMD*O*WC7JD7]4H^3
MG7/4NMD5[X=LIN\4[TI':<#94A(K#1X)$5K&ID[!8IIV<?:K+)D3+R8+DT=,
MZ ]@V+B4 J-9:U_Y$P#]\(&[L%A,.QBER%="@,'DHX1<8)?HC'9RZ>3?8R,J
M4WW7DF3"*-I#;N4TK"B"MF6X1)ZLN7+:3VKTD-'!FAF.?DKP&S&5;@,Z*M^N
M*;:4KZH^H<$\K$81A!)%*=,8* 'L&Y(9Y)6]9- V_-0V ++;;>2TW.\D..9<
M:8'([UI<Z+EK"2)(!08D*;<'0Z&+3L610WJ2_KBLZ1LKK#@]HC)VM@D)#-Q*
MUK/W8EUMDVN=SC]DI#K(720U6O0O13,X42*Z9PNP7R"8*5I59_(C')7]@R.4
M4_S ,%$Z*<XQK%9!.8"J"L1N,L7))1DA6'+U<$A$+$81ZB:<#(M9L@&_<#2@
M.,%P&!!; !W6PW) U5-K2R$AUFQ"X"HFX14Q<6P,D'!"45@ 701E.N *0(@K
M17PL7FD[<!ZL:<761TCJL$)8P*%5+UQ%OB/)0D4"@MPXI?A@4:Y$JA*E;R.?
M_D?%/UR69YW/,X$-B *#1)A;7HY(:\FX)_? $/*9J(,B*ASDXS;8#;N -*,!
M%BH=KM)0\\L,E@ 3&@&AQ#6=%NNL$3Y0*,=+(A)2?",/SOLVA3G#_:"Y<S4@
M@ CN!$_/-&-*V"#BP!O6=)V2;%Q*5082 )./[/$CS+)V;36=\E1T H])0:4N
M'2%/:F%<]ZRE$[>!H N0X0X/Y(G"YE@\"$VVZ9),IL!UL'@Q"IR3:K!FT;.#
MIBF7ECD3(',$]F+(><YU,V0EH8MR3M$#FW(EGF7)/07+I1#*S*RVW@Q)(31$
MMX8)46CIG+W5%DAI)IQ:=]PLC*\];>J\EOS _OF7,9K>5%&I3 Z0,@I8<%21
MA'$-<8A5]L?YHK^O%>*Z_P#C)4LRJO*C_6>%?;/"OMGA7VSPK[9X5]L\*^V>
M%?;/"OMGA7VSPK[9X5]L\*^V>%?;/"OMGA7VSPK[9X5]L\*^V>%?;/"OMGA7
MVSPK[9X5]L\*^V>%?;/"OMGA7VSPK[9X5]L\*^V>%?;/"OMGA7VSPK[9X5]L
M\*^V>%?;/"OMGA7VSPK[9X5]L\*^V>%?;/"OMGA7VSPK[9X5]L\*^V>%?;/"
MOMGA7VSPK[9X5]L\*^V>%?;/"OMGA7VSPK[9X5]L\*^V>%?;/"OMGA7VSPK[
M9X5]L\*^V>%?;/"OMGA7VSPK[9X5]L\*^V>%?;/"OMGA7VSPK[9X5]L\*^V>
M%?;/"OMGA7VSPK[9X5]L\*^V>%?;/"OMGA7VSPK[9X5]L\*^V>%?;/"OMGA7
MVSPK[9X5]L\*^V>%?;/"OMGA7VSPK[9X5]L\*^V>%?;/"OMGA7VSPK[9X5]L
M\*^V>%?;/"OMGA7VSPK[9X5]L\*^V>%?;/"OMGA7VSPK[9X5]L\*^V>%?;/"
MOMGA7VSPK[9X5]L\*^V>%?;/"OMGA7VSPK[9X5]L\*^V>%?;/"OMGA7VSPK[
M9X5]L\*^V>%?;/"OMGA7VSPK[9X5]L\*^V>%?;/"OMGA7VSPK[9X5]L\*^V>
M%?;* !T ?U_PY%/H'F$4Q,$[N#84?J4"8CCBBQQD+0P.5\ QAE!2H3RRNB8[
M ^X;-5O2/; V#B .0 ! !:P?7=0(ALHHZ([8"D*A $8  H(-V'P=![I2>R58
MJ^JR7)M7%" =$ $1!]+DQ.F-4JS6/>0,VV6D0%ZA!"J& 3$R3B4" !ABL%/>
MR IRXLE*56.W1%  K2,E,()/=JCI4TR$.Q DB"<@RY+]H0QBYA+*O..-+#H
M.R'ZS)XT5J31R8#:TB<,G;Z$+=$$[8VJ2/3Q9RC4CF4+VZ%M:4;V"43V&+<!
M&3_;2QS( ,D@MD1Q:2@_",6Y.$]#^_\ O
M              Y;E/W/^1P7GM77FHIB9'L!0>&.RXPWW*\"5?@\JN2Q2HD9
M&Y49)\N,H</.N=($6*7*-'82DX3F!"P>1"7AI(I(9&J7E6"N4BFYE.8;@,2%
MB5%U$<%5CF"<OJ-^$5. (VT8:VWN/!RERCB%ULV/8@AF,%EW?"VI/U12D!,>
M\)1R=]V?REG]OC,=%D$Y)[2X%E8,7V"MOZC-9BE5PEO@$4 A3ETKI.\$XJ.
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MHFRXNX QTH6W6BA<QNM$N-'4THIA%W% *;C)0"JS3&IRCF:Z-VENH+,1E\@
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M1&_064&=W$J #5'>NLB)O+8#VKDSK(B:Q+Q/:7;R:664I,1^#*OPWR!L 17
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M0PX,I'$I22!5@%-4*N%<P^8ABE"B*Q<, KZH?EF%CB>S 0N1$1U K(('_(&
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MN1$)A1Q0)&@3!X)O+1?K%# "API);Q*?ZY_'?5:)P1<:<2'+20MJ2L>5E_\
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MF PRJ- 0X%M3E$#,\2<EBS.B(1C" !5B,D:;J*B:,E+"6?*ZE@37Y->=.=+
M);40DH@NYY+BE'@U1WPZNZ3HB V:"@*'IYC,H; !Z:%A]_F.KGF.ONEZ\1!
MBDL^0B8!6UB650G"O,T*KLU(^B)(/9*,M4#25"N0[;ES$U*]Q,@2,-\!(R([
M_G8/U>F[YOMG\X_I\$@*%T<T%3Z7H<)_,1"65R*0DZ!F2!]D@ XTDK;2AGF=
MO@$I6ZM;C8RN#2F,OH.$CG+SB"5? DP2Z2(%#2ENT+)$G5!@6>*#:8VW:2!B
M_P"+1@K3_P"8,:84)MA4=T]B207<^B*[GT07<^B"[GT07<XNY]$%W/H@NY^
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MAVSQ/PSQ/PSQ/PSQ/PSQ/PSQ/PSQ/PSQ/PSQ/PSQ/PSQ/PSQ/PQ!Z35=/EB
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MB:$EUJ".3UZ/-<^ E)X,71$"8,(2;+("HM?(-6I)F&1Q<$ IVF*-TK=R"81
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MO\._P[_#O\%RR@6V,GZ$2$I(DFR>3N<8L/L)+4+&UA:']$R2KAQ*?J""&O\
MT1PA0L'113Z_^#JU:M6K5JU:M6K5JU:M6K5JU:M6K5JU:M6K5JU:M6K5JU:M
M6K5JU:M6K5JU:M6K5JU:M6K5JU:M6K5JU:M6K5JU:M6K5JU:M6K5JU:M6K5J
MU:M6K5JU:M6K5JU:M6K5JU:M6K5JU:M6K5JU:M6K5JU:M6K5JU?Z%6K5JU:M
M6K5JU:M6K5JU<:U9"$!LTF$8W"=<\5U_\9*O%=?^B+K-D*@'M31OA^@G ?K"
M>NI)PY@>##O"!D7L%^V>Z-3:!\C(D)^ RNRH%7QX@ESBR."Q*.6566[=D,_
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M!30P[OS#@/JX3"$RY4Y,$D,6#)/S@GYP?+U_D/\ ?I#%AIL4CQ5I36$X*,,
M,EX* XK3.(L8SE"&*T6<<\!S4=Y0&M1@G;4Q";I)$D@@D-/=S1;B,+P:*KW@
M<*W]M)Q<96@9!"0:4&/ C18<:@!R69$57B89W+$TQH*CNWRI,'*E'GB<I@DY
MT?TA& DGM[^4!]K<A>>(GX([N'E6,HV+V_<;%=/\A<\YT_6_W^Y%I.(T3=NI
M @2V\4RV1,"$<( P_P"DR&@?U7&.!-1:H$[B%D!D$C%@5"29P"]"*E"K&%=Z
M)B"^-*_)@<QYIB0DA79(Y5_A7[( %9*XA)T K7,;0GU*,A<K#D$VP/9>G@Z*
M(H,Q9F1:&F?AB>B5F,!4\G%2DPBH(B.% ,U9=92R(>/#4[;W$)K;H'%2<\@E
MO8'$RM<IXX9D-3$&YV;5+A=DM/,A";/<_F^O_ L<2O45,D!;CH'ZG?ZO2FI9
M5O'KOTAS1"6+9"WZ&:-;'HJ4J]_V @6,L,J F1MZULI6#,!-;03$(!$E3)P<
MF1"*($Z$PER5B,IB+6!T@+#C6F5@+*#Z@+ 8NMW4<PPA>?0SC(JDZ9S*9NVP
M=Y-[D#JUY_8,!S(DH$JO]BE6=8P_-34ORGBL&8E<1"$;#80"STF&[ ?\5G$9
M ,(".E>O\A_OTM5=)EC ^57&.!3F%#A:-@IDK%A^7,5V\=+\4A9?W2O^6?@Z
M8P+<9TE2P@G'O"^9SKZ,5OIP:#"!2CE[X 0#G%-/N#"+(LL&,G.5[!SOGJR,
MBR)0C)]+T8]R0X*P,%'TV(,D<=!8;N3)AV#4I:$*L.#.)ZLII&QT$TO\.H<5
M$UV8., D#A<DB%\*!S1N]XYYSI^M_O\ <58 E2;;&YMJ;'HE(/*E*6=F$)(Y
M:X+A/UKQMP9B@R;1,1/^L"&'+3$2C(DY"8@$$K;*$]@@MNI,.D;#"@.H/W,$
M^P E@$>VBDF\.&>T"XY4'8RUP@12''Y;L/8[&=D#[B_HJZQ(L(R#'"]#!!(4
M]9I.)GY)IA&0L6AX0)2I=-&!O6"GA)LV1$F+R<[8CFCZ:%3^J^2(L'"#;600
MNM)8?-F>@G4%A% :C$^WS?7_ )9/VBB@<1-:YCI)XL@&Y_D[@%87FW4-4 I%
M0Q+[?V[F[QS\/?ZO1L@6@+ZL8GEZ.4U*'^&/"5 ,Q(>+[(#M_! 7F!0!=BEF
M1G4=9T\$(A:PCL%4A/1G[<2JM*HH3BPD#A-(:LO@9C!85RS][+C 2X!M<5Q)
M?)I\?BHJ.#R+%1I_<J5Y%WHO)-IL!&*U".RX+)&L_IQ-!/C0AG08X&DMV6C,
M=QI)9=B"F)F/6/HOV/\ R'^_4FG:8\\SXO!'-K1%#E$;GKQG#*<C[XK-9HEL
M679 R- ZC$P6/&CS>RH[GE4?Q=4FT)F 4SP,+B-C0?"&.[].XVVL@'BOP1@T
MHN[97)93-Y#$L[1C"$H,V4^@?,9\3(W?#N%'MF+$ F'!*@\]2$9$9FR2!6+?
M7SG3];_?\*8W.Q&E=T@TA)LM1X5TG"TL*8:$]AC1/?Q/-K5I)I,T-T0Q&$(L
MA(KXCNL,/!:01PK9.KSP/&NOPA1ASLUP1F;6TKC)B%T\6@Q[&F)AF(=OL):-
M7DKJ"("0V/P?-]?^7!^&VWO'R6R1,(/.JBM/!.X!!@I<*PC.!Q!,2.5%/6)<
MP9D/=M*SA$^T%^%O]7LG)])R?2<GTDHMPJ$[%)JQ=Y/I/L_D/]^I$-*"%1J&
MMFB'NG)R??YSI^M_O^$6 $@)$YH1+ 2_T?F^OZ46":DA/USR?[YY/]\\G^^>
M3_?/)_OA/!$D)^9^NUW^K])_(?[_ $7G.GZW^_\ 6^;Z^AZ5$.-KD]UEEEEC
MA2$CU/K?L9/;EEEEF].A'HUB[#GV>*Z/NV_H-KRXJYJL.%KQJ3:@X_K2(M05
MRJ.>P1@^P_D@Y!T"(^0!2X<0PF%!Z\CK6^%O]7Z3^0_W^B\YT_2J!6@)7H&?
MX//\'G^#S_!Y_@\5D\3"ECK_ ">G]_Q).4Y+>Y<?,>U.G3IS'FD@"6"06X%C
MA]B0U&\H:^CG^$_&?X3\9_A/QG^$_&?X3\8TO"[P98^<>GF^OIXO?[O-=/8[
M?@S>*Z/NV?H-,HDDLA4"(QG DR1 O5;PB<.&[W_0#?,M7!D"4J<*$J" -!&;
M1>3%U$_4OPM_J_2?R'^\5$DJY)#@=29VV#ML';8.VP=M@Z:3E*YOV6*"7%0_
M8>T888;G48B)*9K7IYSIZ.'B/J:?GG:^7;.U\NV=KY=L[7R[9VOEVR&(14%2
M<?/V;ZV2K/:YSG$IFO\ *?U\/<N_O]'1I)9V^Y'N3)DR9,YI613W&_9X3H?H
M5?M/YOKZ>+W^[S73V.WX,WBNC[MGZ#< IL[$QN)J?=JX">;&NSC_ !\/\?#_
M !\/\?#_ !\"I"1$HICE?[]-_J]!U2H(64#&[]JA0H4?Y59["S&EJ(V%CW/<
M($"! @O(2 520:&.3U_D/]^]IY_O\/%#YSIZ> Z^[^7^#F&SYYYSI\/<N_O^
M)R0\)T/T*OVG\WU]/%[_ '>:Z>QV_!F\5T?=L_0:*T^\,T <Y.<%0IL^2I";
M2_D:/:R.>*RH%^<LO0=M,W,ZXHH80+8F8]6BO3^+_M[O,=7IO]7O$\KT>SSG
M3X)O\A_OWM//]_AXH?.=/3P'7W?R_P ',-GSSSG3X>Y=_?\ $Y(>$Z'Z%7[3
M^;Z^GB]_N\UT]CM^#-XKH^[9^@WGZ&8KF=F%4D!6L 1&P*&!?Q2S#2)3"-0]
MFO\ %_V]WF.KTW^KWB>5Z/9YSI\$W^0_W[VGG^_P\4/G.GIX#K[OY?X.8;/G
MGG.GP]R[^_XG)#PG0_0J_:?S?7T\7O\ =YKI[';\&;Q71]VS]#NSWPQ!U1 R
MH!08EN)RCM!Z@&B3  @ !8C8CR)KUU_B_P"WN\QU>F_U>\3RO1[/.=/@F_R'
M^_>T\_W^'BA\YT]/ =?=_+_!S#9\\\YTSYV)W?",6X>/A=R[^_XG)#PG0_0J
M_:?S?7T\7O\ =YKI[';\&;Q71]VS]#J)8%(N/)I$^+NLWK]3:;S\/8&(4K<*
MVRV6V<"".@F\X*^4VK],0 :?Z#W;MV[=N@@ 5,BT\>C$I%AH\[:X^2M7H]VA
M:1J'B96%>[[6K5JUGRP?),^GWRA+0&4(50%$L(8( )W[R63HD@Y$Q]S5JU:M
M5SPL  6$'I;?KCZ+=T&D9IV(9GKN./55(F:9Z'N-6K5JU/?H20.6,[B%10RB
MEP59C%=;Y$']H%N5Z+VS15P@%H'U^UJU:M8/R\BI+B7/I[* 2L*%ZGCL!J]&
M*+PD9D5\_<NW;MVZ"-^C <=OIB:#0-+[9 U,4U]&)DD0(ATCGW;MV[=.RLSD
MB!+MD39P(KNF@6C0)*CR,S1<J8OE$UD<+(<R9Z*/<NW;MVZO=K'39%>EBE-R
M,DWD)!D40?1[$^,%:K0^X:M6K5K,\&)9):(\^GLTNP- Y!EQ&_7I[EO+P)[3
M+VM6K5K!5!!4R,3A2_3VK3GN'H!Q0E)Z7N;T)#*4F/'N:M6K5K*_*AQ%*^9Z
M>R,AT%2BAP:1LAF+][M@3S[MV[=NW#4X066L+SF3F9E!)!"=C>!D%!\3Y$(4
MH5^_$=NW;MUSIJ8^R^EBFI-D_@(HTJH>C%#"0E(KY^Y=NW;MV,0E*1?R[/3%
MIG4&L@9 6B/T5(IA 5I"MN13&SU0)0.JP?OD)"271RQN.N6)))LG4]>F2>QC
MAPU),82P2K8+KUX!39V)C<3SK*%1*4D?P$<SKG*%1"4(ZAST1OCV/&K8DBR1
MIN_9\B6K=@Z-U\ZR01"R$VQN#F.>F2*@4663J3B>)W[/ORLKKVJVB6<_D/\
M?HP$@L0['4]B\DFQ FUPZ8W#UQ0%4 M70=5R1!$1L32.H>_L)'LP0I*@ )2O
M55WZB,@BJ ,RW'0Q=X(!!+ R/R=>WM<MB@1&&6!9+U]5!*@&UH,T6?,WS76K
M]!)A&%&&838]SD]D.I^-!")Z5HX]82$DNB;8W!VYR1D$DWV^>("5 ZM'L82
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MD^4&&&5SL.Q98.72E=&&;ZA)NVU9X02*>G]_I!)!V !DNB*@A/7([=_J1HM
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MDA^F$MH<@3^\X_9R&O<RSZ[S#SSJ3"I>^P[I?:DTV/#CQ6_N*>3W5D6"I-M
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M>$9\C]O1FK_3/",\(SPC/",\(SPC/",\(SPC/",\(SPC/",\(SPC/",\(P(
MZ ?K4B.N=W^7XSN_R_&=W^7XSN_R_&=W^7XSN_R_&=W^7XSN_P OQG=_E^,[
MO\OQG=_E^,[O\OQG=_E^,[O\OQG=_E^,[O\ +\9W?Y?C.[_+\9W?Y?C.[_+\
M9W?Y?C.[_+\9W?Y?C.[_ "_&=W^7XSN_R_&=W^7XSN_R_&-=%QKM/_\ */\
M_\0 )!$  0,%  (# 0$!        $0$"$P #$!(@!% 4,$!@<(#_V@ ( 0(!
M 0("_P"$5?))))))))))))))))))))))))))))))^4  (F0-1A:  Y?[@(F5
MH <#77E_IK[D7;????????>RY7[IG:T][]]]PM,?=?ONU4I:1_(
M      [\BFNEDE>O5FEPQ[7RS6J?Q*EVW5[**U\K>GN3TMY\DDDDDDDDDDEI
MZW)))99;=Q]R22265ERY<DDEEE2YTB>D\BFT%:UNB-"MS9I<[HZK-/X1^]NK
MV;3F.5[>U=1))))-$T31/X+EJ"""""""""""W:6Q!!!! RRZS!!!! VR^U!!
M!! EGFXVVW!)R?UN^QM+TVEZ2E_ *& *% ?F<FNNNNNNNNNNJ(-====40:ZZ
MZZHBIKKKKJ.E=Z1WV-I>FTO24OV7*MX      'YG(-0    U%0  (BH  $14
M   ]6Y222222U54DDHJJ22455)))Y>YOI7?8VEZ;2])2_>5HGDFB:/XP
M            /4$DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD_P"-@
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MT1(B05)QH2!C@9*QP? C,#)"8G*BX5 30)-@<(#2\4.R_]H " $" 0,_ O\
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M@>>@>19+T3G GH8=!?\ A^$XZ%:VR'*%LRUMDF'%782>K%(%<U=8SA3.@$(
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MZYM(V42SY%DUL\'B\B%<A"-X%^GHAR<XX(9/&\15R $XR#(696TUN:K" -.
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MSP>_ZYX/?]<\'O\ KG@]_P!<\'O^N>#W_7/![_KG@]_USP>_ZYX/?]<\'O\
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MB/VA?V8Y#'FG1SA;R. )^WX-+M._,JBBJXN5NHU!1-ICEG)?T;PK.C.;G_\
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MU>&*4I.K^Y>ZU39@R.C*?U!CIO"&G9A?XKU;@9KAJ06*@-A)7B!#8CIN-GG
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M @#='Y9CU-3"^23N#UJDC_A9WU8?O8:!T=6V'B4ER:VG.>DGYO5S/^BN=T'
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M'IBDI&"E80"JK +@@/&$]G; A$V/PBTA6ANS@=01.B(_#TRPUY9T954!5^(
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MMX&CZ<D?JE(Y+9M)!,P]E1:R YBXI:L2:X6B*R!7N:Q@%]A2%W-L(O=4._\
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M0O0KY$?)[WIE^3:\\1?#"I#(#W4 M$A?735;O%<=)!!4P[#%(0L-J_0,1MB
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M&MR >.R:5TA:;/)86\I"Q?AL/>J)D5S(NN.-M$D&6E9,,U!DK)K-X&6?"/\
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M,,7CDZ:^Y9K@2M9I6:T_B6"P14OG+XU4_1QMFLD07LUVR$ \N?\ ?3W/N]4
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M,)'BQJZ==N!*=NW(@I)+@:%^/GEJ1)!QN1I8XJ;>2U9@N"M.\M^(F3)DR;B
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MDD5<]S[O1Y$FN,+)>,79 LA@[,XX2R+<((1%$Y,!.ZH BJ- &U6!OC ! $!
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M-[S>[AWW=FS\126Y^TZ;**,QM%6KYCUSUQB=+MV[ELMF<[2!3OH'7(/PNX8
MKH)][I89T9LSJ4$@J3[PVXZGW2<FJZI!PZE$IX[7T37-J)T%6;K*U1$9_P!]
M/<^[T%!INA34;VV>$E1H.HG&.>4!X* H'[^R!CP4JQB,?/#L"SA%?LK;BCO
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M'E4M[$1TCPY,(U(V*UF47!.,!J!9$MJ:(\TT\^OV7V?641+PZ\R67QB=WN=
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MT$;XG2JN"5X8&O/,.T@ .&VJ: L# -X_3\4MK!^!V.CIBR2*IOH7%+B$.XH
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MDG0AKXNS.*BBW5 CU&_ 'C1#4@W/)[%IM?\ ,A(0]1^@J$I_[D@/&L68=Z!
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MZ[\!)&)D YA;J[K=7= C CF)9<Z" ^Y0.0)$,<ENKNMU=T,  6A@,7*P\ X
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M$0 ! @,'! (# 0$!       ! !$A,? 005%A<8&1H;'!T2#Q,$#A4&!P_]H
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M0'+13MBC&Y<Q?)$,9&Y9D'%I\G"1/*!,L"1,@Y1(EG=78K[ K[ K[ K[ K[
MK[ K[ K[ K[ K[ K[ K[ K[ K[ K[ K[ K[ K[ K[ K[ K[ K[ K[ K[ K[
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M"))$CDS/^+UW<GM?#/-_ 1<S/B1(8FPN6D#!W-,1+  ID!B Y(&B(-<!  <
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MH&805PDL\@(GPPIF6C@]>4PS1P/@W],K6"9C@+LB20QYS3%=P=F=T8'!=IO
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M P($!@,! 0$!     0 1(3%1D1!!(##P\4!A<8&QT5"AP6#A<(#_V@ ( 0$
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MM'A55J"RRQ!+$3&1OJ9:W]=K>(^=D*BH6B@HS3F>E!S8 <-X80BT6= +\7@
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MGFUOP1$7 ;"$VI02JP :6_.9@X9>NR#;A\2_$R?>/]14QEPA4]<"WCD"P P
M!T(U3)R4N-6^=TP:BYHFD.)+TYPP>F+>$&538D"-S:N)PI-10E:!YZ_>E^U)
MI1TGLD8HBP5?9![%CB<K^:M@)@M?CE,TO&PPFD@O0#U;'Z(.%BBX7O&:-9@Y
MDP(N<F>D&&E?)K52\ ; ,*;H6/ )R6N? *R][S&?5I9I\J-\'Z77/&06.%N*
M&8N7ZU C?!##0C+6)2IG+.\D+[4'M=;3!GB#':X!2,5^KPCHN*(=&%LN9V;=
MO(MAYJ,8-%3FR(D!,@4P!"H;JJDG!Q8>"3>C54_3N#^"N5W)82$^M/PJ0^.N
MC9 PHQ=*FU-Y,Z F#["251G)"K)%IA&)EAO0XD\<ZZ<$N'#0\.K^U( +70-B
M.^4CE\*,OSJ7;/\ I8 2'$/];*W) L+^%*V(5^GNZC5:NX^)C1HT:-&C1HT:
M-&C1HT:-&C1HT:-&"4)4!6&@2T%640!@5?F%ZK $=@#S(T:-&C1HT:-&C1BG
MQ2T45OV"$ T"C;)XZBL'"I+H;&Q\R-&C1HT:-&C1HT9F4I8R5735:CFM6)4@
MN - 50+=YMQHT:-&C1HT:-&C.F/(&@KN(@'/GEU]QR!,=#SZ%AP;R?0>QMU$
M0/)1=SE<N[P][V:%L+.7^*@=^#9@/+9&M/5F,F[&8"NNW/ZO.5O 0G'B)'UO
MI%.ED4 P!M_Q.G56R>C!+ "< 24BR0+]>K?IMO*;#?UZJ[[7B$]! ZT%*B!5
MT72!2.HH_)%*>XXT<[Y\RY733Y_4[UFP_59TE?,W0[9K71^RZP3MG0O+FO6Q
MKHT.@A1B<@ 79AL0:4>56_6J_7Z_O%YJF@M#?UZ_K,U59?W?P-:]ZB@7:NSW
MOO5=M]MX DU )D01*;"666C4_P":9Z2<PW+4B".PEE:T(U/=A%21<;LL!4<J
M'(2@(LJP$E"K(^)GU.20@M,I-*",W870ARLILJ5L!U*=W//S+&F9M>@BSFDX
M\QE,Q^OD&LF, #\VAE=^L7HJ%D(HX*P?9V$C!_D\C LTJD1 2W4I.WW=!@(Y
M9&^[TY(4<AB5%2(>/45]518(M.&;-$*[2LP0'Z0MT*/@+<>?-58XF0(X%R+!
MF"#(@*#YUBEDB.#:@>NC4##IH90E%=U2+B&K)UB6%!Q'9"&K'A'X*>%6F<M%
M^894IKR;E<''+<^)3=0-@DJ9.Z=JOEF5M*4IK&61<<T;86900/L!)'4<[&G4
MT()5J-3F@*)U[_<I^YFG<M\BM^H.=,WV[.GSVJF]$<B\)=!SB;)Q#4T%&(V6
M>IV3M)0;JV*YYS,+,3&W2' WI#>@N29*9U,5;O*O8#X"SNY,X98&@J7YV"Q.
M*(?0'4HCX8AZ])=@/)!DJ&*?5(?[J<2R:B6;G)+-SDEFYR2S<Y)9N<GKM"3M
MA8K$,*TSBS<YEFYR10U0^LLW.99N<DLW.26;G)+X/++C :LKVPL-+%#5P97V
MMDH;-SDA8D?3+\Y;,(7<'87UR<V;M]5EFYS+-R/%+N[%@  #*%)E- K9M>]5
MM18:H?>6;G)!'1'Z,]<Z2PU0^\IN<^KCJ[/K2PU!BO250U0^K+-SDAP([GYK
MM!$3$LW.99N<D7#D[]]'U479J%:OII@K?P4&EFDW3]@Y9K)!2"0@WH9-(]@U
M@*'X[N*)>P<'(=H#A*&7C^>A")!2DZIO:*W:<R!8,>IG4:8[L3.3<?2I"?-?
M4[TO?SJ+%G&145*J*T((;]78Q:&F\ZF,R,BA.N ]BLH([S":JB<M4+J:)!:7
MD*NQ3^@K8#M1.5+HN!D,+E@02' J#<_<Q$:4^<TVYDI=*XPL2/.U5EI7?M9I
MHH-QFLIK+D%[X=L0]3_Z[L"L=H3/!R:-"ON"MUY1*/*?%=?,&LT)3&JGHGF$
MEJKRZ;AJVM.WE7*Z8L3NVDPRV&HK!V3G_"AJ5:+0ER$.7-FM$TV)Q0QE6ZH^
M5S1H" <JVMKE57YJY5UMR]_)K?E,'<F@&H.I9"+-V8U9B?3BB"B(:5H5DQKY
M$P2M)F=.,-BV"#+K)X/?L 4/2,MYUFV5S'X5#"@9$#,N0-*UEN")4H&H);O(
M1:3@=0Y*](@1]A_P2W$R:]T7901= CRY6%UZ0:ZAI0^:>(9:#2HM:(XZTU#_
M *D O/P.!+VB@O-]SPZ9R7#G\X&/TH@(@(9S^_PBM.Y0B AS8!1%XY.F();:
M^[>5?B\),WFGN;CJ0GO?AG C/L<W40/1@HT&NB&2/80J!/5A-A5/G#(?:MYI
M;=:*.KB_'H#DN2>@_;T[3+;,-H[UL _O&ESP#%GM!\SQWIIR!* ]DO-3_P!8
M/0H+# ;HP<'FM6:%%\9TX<N)3VI!B/V&3ER3>E>N7Y.H'[XY3%*+"G19"TZ#
M4PQ?O"L2!';?"=(98644L1NI8F79Z,OKS:&BIY.8"WFZPJ$R>#!==*'&Y5&/
M$,UHO:YPE5!X'(X_8KEB2^F:.O\ 'T:D".QHM/5&<16XHCW++$ 1B&-$QTU"
MX%(M8BVB!SQ?)46V_E2]_ 9?[(I0Y<8<2QA;%2'A%6F*M/?H>_0PUCVPYUQN
ME.AQ?8=.SK_IY9^.^3=U]V?KUY<OL.G9C)>7?+S']?\ 9T^SMM+,*FOS:J_L
M4^DSWGWR[_VS,BY75ROUC F%U,+]8]^DOJ_U6/?H>_0]^A[]#WZ'OT/?H!2C
M.^>-3@%)2M@D;"*=?AG873D)[]#WZ'OT/?H>_0]^A[]#WZ'OT/?H>_0]^A>6
M"^$#/;+!2R1'OOC!N>GU2JRE]^A[]#WZ'OT/?H>_0]^A[]#WZ'OT/?H>_0>F
M2K(?(JB>4NC,J.P\*\L%::ANY[]#WZ'OT/?H>_0]^A[]#WZ'OT/?H>_0]^@G
MI8M[\R#AL:'RS(&@>-K";J9)K=.*]$$%J.+(A/ 2/4,      4=%T"I:W^2,
MHUI1H)R:2(_@9H-65JE:HYL^4I0E"F$J:ZXY-/PI%@@F^RF=)$@U"XI @H2V
MW;$3WG 9,)P!A5C&&H!+R]":# Z^2$U73YG$JOJ[J:*DN=(R X, _;<C!=9B
MRW)U4Z*[QQ,+?U129H<.S-<EF(B.-@#0&)?(*^0)1\CS;Q@%=05(1 $45T(*
M"60#0Z;<O&LXI E5K[WIZJSV2+1MAQ7S11B44<"2?9^2WVG]V7($,23XB$4X
M.D%54;?+[;3&O=B8Q5$8\BJ42J%4;9/!L$X0\4E/0 Q0,#+9!U;!74V\>)-"
MX\D9OK4R5MU?MAO#7W6%*!J*$X8NT#=4&")<\7TR&F:@0@&9\5F0Q,@2*$D(
M&PQ0<)6R=(2PDQ=K+V8(VU_V)(:+JD0E%&X7&VI*D8Y15[SD\:O*E,["\"$U
M$AF7(I"4:&!&--=&0# 4Q!&40T[1L1N<L?P!'/O$[= A@-E/V^)R9,F3)DR9
M,F3)DR9,F3)DR9,F3)D8&?VC=:RP#-_*'D&ZE&+4M&+6WOFWS<F3)DR9,F3)
MDR9&DB;KEEG8%Q=9CPABH%!:+(Y7S<F3)DR9,F3)DR9&[O6N,892#AC"S#&W
M9=DU76RUOS,F3)DR9,F3)DR9*^A3<R($I+$2[&_,%NH,[4IB=R8 V(0Q!G]A
MB0#&"B=24!=+!19CT (-!CVV8E( ^WIBOK7#.-LC1 4?UA,K=>3R>KFOOKA!
M&*4=NOC3*#=J_H6UD*BIQ48YLKH6-$,Q6,WH>UO>E0)K]5L8=%B"X),BN5,%
M/K?S1J:&G3F:+H"I^K3^!AW(H]>YC9"5A, J)U<8Q.D.BSNRS/S5#2L9#2PC
M%#JS"',S7$L@LC0$)XX%&FCTQUB\I.FO$<Q/(2C0&Y4D]J#QGDC+-7]5E^PR
M<C745N<%DB<Z)NCN)9T=M@D(L'AT*%0+!C2%X!R6GAHU0A<$;G&':WV^6EMS
MB+&6;-D%+<O,P[=N"@3Q5( O^*_O.FC( 63=:Y5"#,84616BY/5IE5<HILJ
M"LI!34'$-G)V4$R6:Z;^+\,4IA/7R%(B&A\K&*7;?A@QG,),9)@RM-17M0G3
M/2IE-XU :)?)@*SWY4(A6$VSBZNZ1P%WCM29TSY1+*W%+#1&-NEO#>1;'K$,
M-O/:W';7%J'3Z"4PDD0;]RE Z]Q8XF$/HJPUDT4\^2-@JW(H+U5I42C.3\TH
M3U 5[.$%HA3++W30F-8NF*;#08!Z220.S4[=3RDK#PX^"F74)YI!/0()-/(
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M9:SWV#LRKMX&<D\.L6K'Q5TWHCH8"8Q0.SHN1)9SIQ\(RY34'O #0KO]]_
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MQX\>/'B[0B2N%+1E&:AQJ#"@#1& P=O-X\>/'CQX\>/'CQ+/Y<H-D2L74QK
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M;$>V(]L1[8CVQ'MB/;$>V(]L1[8CVQ'MB/;$>V(]L1[8CVQ'MB/;$%@>X'V
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MU#/H#1"J[R@;H@D15VW_ +'C8$64G3.+'%?I'& 8^\ZC9C%IJ6VXGN_^&/T
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M7F(1%KG('/ECK+=5)/=ZXG2YFSC_ /4WD$/:I(%#EK6$XP"#@^FG^?PKN5&
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MH>C.E6GYTB%4=N02/5QJ @R]6BU;?"V;-FS4_+YU=ID(H#9CIP'_ %@?)P>
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M4^0;B;0P]6"VK.6X*;N<20*2G;51@Y@6> $BD]0.Y-P2:.L41V8('@&
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M3$*?2 A%:X:!H78$+-C$Z!@(%M!G'16PKO97ROG61TA$NJJ-2R59;)K7R F
M/"[U;8S87_,TP+/(MZN,69 <E-MB%!U$H &O(IA+BA,6:"@#6KJ$0;&PIS*K
MR5$I<OA9,D0%2ZK9"X5LM;["- +.")847\S'&*(0L&DR!NVVUJ*0@;H=H57
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M2:G?DYU@<#_Q7(A(PDDBX$:M23$DQ,9QK&E23$DQ,9QK&G\DF))B8SC6-/\
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M.PH%YSY)Q!),2?[W>Y&UQ2 #R\$J  !J6 224SR.)PD2L2B"+^C>Q4H9 I:
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M-R)O$Y9Q\XU =].&W^<+Q^#_ )*!*@&*V#UKQ;O/WT:\6[S]]&AT(=!%Y?\
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M$&P:QO3W*<. 5;MC8E7( 58 5"H8GN& N$P$M&+,$5 VUV2DO57;>I18 E?
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M^WLO#5[[>R\-7OM[+PU>^WLO#5[[>R\-7OM[+PU>^WLN$$?_ )W_Q  L$0$
M 0(% @<! 0$! 0$!   !$2$Q $%18?!QD8&AL<'1X?$0(#! 4&!P_]H " $#
M 0$_$/\ OX/6*9/G-.C_ +">1ZX":?XB>>& 6W*Q[_YCSK_F(_1]/_!;GCZ?
M_&2G% 6N;!3)=H@END%>L*RT)K$VG/$$"[S:M2@4;3I?PQ$&2F9$13QFL5I$
MXHM2!9\)C76DUNK:<01.>9F5#K6K6A;? &=Y-*BGCDV\<-)AR[ST3E-Z3&N
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M977+_"R1$NK?EXY,\@T#YSO6!Q,:V]Q,[7M&N)IV-BWK'O\ TO7RYVWQ)2)
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MVSKWVQS;&VSWVQ D\-"PQ*$BHPR:.W^D80@A<1D?!)P]!4I==7_XO%Z\58.
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M-3"05)HB&&<FLQ30,IEQ%S9M%%)7E&@I-Y%U])Z,<QH?X'#0JE1L%"9:" K
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MY_L$"B $JZ 81*B1AA!.RD>HIH__ ! 04%N(-I9F. :;;&. :;;&. :;;&.
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M,;$HH 45P(R0)(09/F/':K3$;#BP1G0JTDZH$4"HB0A$1R2B4D[*:8L.AZ8
M&9 )28E%"5A66XJL1,)RRPLHI28$$PJ=3$A$A-.%C(%%$T9L0%0?Y,!H0HDR
MB@%6Q(J01 E)'%Y8B)S%[0N. E" 0(R@5 I *(M$B<GC[80 E #=W:&ZP%VF
M"=*0G4 45;H<C%S$LD6Q5C0IAM-=H<0@"L HCJ*P5S5:!C#M! "0B0$K5N@
M*J *X,FH@2"44NB]6X6A,-&:EE2F@S$PNJ" LR8=@HB"$HF$8&XB((B((G\F
M"&Q(5@F%6"K,"2H)B$"8L2)1=#KN(IA6H40$J6FS.K#5"N$0(1$W-RCLDC<I
M_ !%6"%,4+("2"W0KBK ]JQ7BI BC/>^)R)')"V(;B;8*G]7@MLB++(0,P1:
MHD!(B#<"U7>:.N%%%P8C*%P,D2B4J#%QU/7" $JP%"KNP!JJ 56,!30;Y!$P
MBP%M&812N)I0E(AH8#,-7)%F*XA CL0HP3*JDF+P2(8P[@0 E$!0E;W0 %5
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M2-PJ"@:C,HE9@H&@&@4-OX10&  RD6YC$B(&YA26^S4[C1 T)B#$2TP2 L*
MB(A*J!"&00)7\9:6RM6-$2LJ!FT% "$IS$1!O<"MJZJPX90!@RX*"P5"4Y)
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M1\8WO(^,*MW&]Y'QC>\CXQO>1\8WO(^,;WD?&-[R/C&]Y'QC>\CXQO>1\?\
M>V-[R/C&]Y'QC>\CXQO>1\8WO(^,;WD?&-[R/C&]Y'QC>\CXQO>1\8WO(^,;
3WD?&-[R/C&]Y'QA59?\ \[__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>wald-20221231_g5.jpg
<TEXT>
begin 644 wald-20221231_g5.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X@O@24-#7U!23T9)3$4  0$   O0;F]N
M90(   !M;G1R4D="(%A96B 'U  ' !4 $P + "%A8W-P          !)14,@
M<U)'0@    $             ]M8  0    #3+4A0("
M                                             !!D97-C   !1
M '1B6%E:   !N    !1B5%)#   !S   " QD;61D   )V    (AG6%E:   *
M8    !1G5%)#   !S   " QL=6UI   *=    !1M96%S   *B    "1B:W!T
M   *K    !1R6%E:   *P    !1R5%)#   !S   " QT96-H   *U     QV
M=65D   *X    (=W='!T   +:    !1C<')T   +?    "AC:&%D   +I
M "QD97-C         !IS4D="($E%0S8Q.38V+3(M,2!W:71H0E!#
M
M                                     %A96B         DH   #X0
M +;/8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !%
M $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +(
MMP"\ ,$ Q@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R
M 3@!/@%% 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!
MV0'A >D!\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B
M JP"M@+! LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#
MH@.N [H#QP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$
M!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&
M)P8W!D@&609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L
M![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)
M>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI
M"X +F NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-
MJ0W##=X-^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )
M$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2
MPQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;
M%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8
MU1CZ&2 911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ
M'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4'[\?
MZB 5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"
M(_ D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH
M#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN
M+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PPI##;,1(Q
M2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W
M-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[
MJCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9 YT$I
M06I!K$'N0C!"<D*U0O=#.D-]0\!$ T1'1(I$SD42155%FD7>1B)&9T:K1O!'
M-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*
M39--W$XE3FY.MT\ 3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3
M]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF
M6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A
M]6))8IQB\&-#8Y=CZV1 9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#
M:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q
M.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ
M>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!
MS8(P@I*"](-7@[J$'82 A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HID
MBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3
MMI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SW
MG62=TIY GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF
M_:=NI^"H4JC$J3>IJ:H<JH^K JMUJ^FL7*S0K42MN*XMKJ&O%J^+L "P=;#J
ML6"QUK)+LL*S.+.NM"6TG+43M8JV ;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[
MI[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&
MQL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1
MOM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N W 7<BMT0
MW9;>'-ZBWRG?K^ VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI
M1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50
M]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M__]D97-C
M     "Y)14,@-C$Y-C8M,BTQ($1E9F%U;'0@4D="($-O;&]U<B!3<&%C92 M
M('-21T(
M                                                    6%E:(
M     &*9  "WA0  &-I865H@            4        &UE87,
M 0                               EA96B         #%@   S,   *D
M6%E:(        &^B   X]0   Y!S:6<@     $-25"!D97-C         "U2
M969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#(#8Q.38V+3(M,0
M
M                                            6%E:(        /;6
M  $     TRUT97AT     $-O<'ER:6=H="!(97=L971T(%!A8VMA<F0L(#(P
M,#0 <V8S,@       0Q$   %W___\R8   >4  #]C___^Z'___VB   #VP
MP'7_VP"$  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_" !$( ?@$R@,!(@ "$0$#$0'_Q  V  $  0,% 0$             "0<(
M"@$"!08+ P0! 0$! 0$!               ! @,$!?_:  P# 0 "$ ,0
MS^                                                      .$YN
MG"V5T<PV[BN??*VK+CGPL+Z-= J<86=SFK788(W9C."KW@<6_GHGZ8LV/">E
M=9M ]W^YR<-N!GWN7..H)AW28$PE[N&99BN?^Q&:N,Y1WY_.*E@:S%-_G!2:
M&:E:_A35Q,X?7' QL+/0BMZQ2?GFYSVW#7G]UBZ*X[!FMTST]"_\\&\'NL9Q
M6S#HCWFO02_7Y[4L]F66-<0                 !Q!RX !H:M.!.?<-S(
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MQS4G",>O:7>BY
M     0X3'PX2^2OIKH\R_*PV_)KV0]^S?>Q3G$XF\PUBR=WFLF1A^]K,M=B'
MT]C,R8U=FE9CXUR =+[ITFZQZ?F9^HY7BN53(S_1^?\ 1?E$2L5V>F5VQN^+
M,EA"#0>S(V8M%UDL]:VNY36 1%W*)%W-2B"Y1DR;1DS4FPN1BRS>4TQ3.V2Y
M0Z!_L]DW*%7O!+DA:Y<F-UQ:<HH_8+@
M               !#A,?;S+XIVGIB''S.[\L]*J;60]OTUN^O1%S*IJ&OC)I
MRP0UBE\$&_99HT0V="G05IJ7 #I/=N-NL<%,;K/=#CRLO/VF;M/T;=U\-J,>
M4W::BXI],06-N$[+52PYQR94ZK5+JRX!$7<HD+,U-,C0+)?&3]_G$F8UA$C+
M<7'EZSD@)N%:WW(K287TC&12:QC:]S[DL0OO-8!
M
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MY/,-'IY/,-'IY/,-'IY/,-'IY+=KB6@
M.+\2;VV?$F9IH'$        !Z!?GZ>@7.OGZZ:Z7D         UTU/46\NGU
M%O+IG707D         ] KS]?0*G3S]1>8        #734]FZ\FS:\F>@*
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M0,?]-S$?EB!2S*V:V:+D+D !KIJOLW7DV;7DNX    &R-62J-7MF2O=MW<=
M6C>0KZ]7D*\/7Z!&"KZGWDG99<,2>8QASZF8-YPOH]><+SUZ6_F_>D#YOVGH
MK8/&</A866%>I]BXVL5Z,P[^0"/^J5+:I?0Y<\//@"A/8\56V/AZLT3E\;BO
M]S.3WW"3GC28D=N#Y?7Y75ITHD7<HFYN'C[@  <7XDWML^),S30.(
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MO']71J)GJ!5^M_\ 9\Z\$=*   -QM :Z W&T "GM0J>3G;#?#8Y?&V%H
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MG"HU1J<U&O8 %';TZ@KA1T_"U[\= :C1KHH (HQ6>C!.-?C8=?C/ %@
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MG6@[   *=5%IY.=L5\%CM\3H%        -=-3]]I-VUI,\]TPOH
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MCN^L  #0U:;#Z."YT    6=7BV=6Q%9!>/ID%XSV\:H  XDY9LX\Y-\_PG)
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M@O'TR"\9[>-4        "R6)N62)O.\CX:P         ABF=ABB9O=MW4
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M?D0(E^1 B7Y$")?D0(E^1 B7Y$")?D0(E^A@[#PQ,G]]F^P
M                !M#0  &[4--0:!MW!M  !KN           !M#0
M   &NH:@                                      __Q !.$  ! P,
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ML#@&!L#PN6B@0,F^:"=%2#LDV.,"O%SIMR:*:G S74"-)OQ%.V%R@]X-AC'
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MT7R[().6:CX 8"Z2(D:21?#YY_((Q;Y;2&2QBG12$9'F$M%G&[N_ MC 7;T
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ME*[TN*_\4I7>EQ7_ (I2@NYCC8!8YK"I';"O(?;]26FRTW3?[%6O:]=!A?\
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MI"9$Y@5;MM9"'I6.'#3(O&L("59-T$Q\I'RK5WH\MHIM*M55_ _I4?Z0RG8
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MKJ% 1VFUUE1,2%"A-  M[-EOU/+?/A'PQ_HBV1GR=!1VX-I3K[:9)&6#L&#
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M@L#F>05P6!S/(*X+ YGD%<%@<SR"N"P.9Y!7!8',\@K@L#F>05P6!S/(*X+
MYGD%<%@<SR"N"P.9Y!7!8',\@K@L#F>04O!HIVR4OF31"$N-N;+_ /:7_\0
M5A   @$# 0,&"0H$!0 '!P(' 0(#  01$A,4(045(C%!TR C,#)1@H/1U!!
M0F%Q@82%TN0D,U*10U!B<K$T4V!CDZ'!1'.2H^'B\ :B)51P@)##\?_:  @!
M 0 3/P/_ +6CKPHU''U\*ND2.4:UU1R 12S(8WPZCIZM4;:E T%H88V6X-NX
MBDCM<3F21MIPZ42#HL02,9FTHUL!K\7,GG:NAV=A%2E6;,:QL6RO#!V@_M40
M5I"J_P! 9D4G[67[:N51)8VC 8ZECDE725.5(<Y^T&KB.-$DVQG"-#HFE++_
M  [YUB,X*\.)PA&IM@C.R ]0;HXX]1ZZ?!90W82.&:]..O'R@Y% KHB%K!).
MVL><=0C(&.T_)]8ZQ]U#L^WT5LII?&29T+I@CD?C@\=.!VFA@1B./5T2IZ>6
MT\/1V_(/JH]7R YP?0?KK/$X] [:/ ?((IGVVDX/C(XVB3!_ZQT^6V77-)CL
M1?JZV/T4#-@XQ5Q!,9FE.R!B?91ND6#-'TIFC4A@W]6 >(^WT4#G_BME.FR)
MZO&/&L3^S=Z[<?9\@KT_97;C[*U# /H)[#6>./3CK_[8>S:AQT\HVMU+NLF!
MV8:#2.+$+< 8U#&2'6ZGM4GFX@DYCD<H&!XZ-7"F.23B7K)XFK<F)+GE#3 !
M%=3AE9($\7KT\51SYNO:Q^@#&*7)TWLLVXSD8(.K9-+(G7F41KYIKDZ:*WN)
M'U<IJ5V\\<R11OI.MM).G@#5S?\ .&+H)"NWVN%Z3B1VQI3SST0NE0N8K.Y&
M7U3RD.#+(QC8J#D.ZZ<JL:1M+_\ J"/D\<E;&XTI#'R>Z_Q"'2(RVOI'BN&S
MJ><+;-/_  \LCQY(CR4$DF5 RN<4+EHV6V;FA7.U8D+LT=V!;*KQ..NGFWI+
M>ZR!C;#H:\G)*X_F[)AJCS5NVB8)#!+.RH_T-J(]D6[%<\#U5;W<4=WF9[Z-
MUWJ>*1(DE2VBVS;/J7H@9:K[E#?DM;Y3:J+UYPHQ_,=SA%(U^:!I46_+"7MA
MRP>EJDN+:2&1D *Z4,,R8<'/%3A7TQE;G^89%^D5V2[,_0RWIJ"ZU7#Z)9WD
MBWE<_P")J1OZ=.C'"GF\=;\GYN ?'X&SVKV\$3OITC:MA!JQ7/T7+3[5-12[
M5DC0Q[0^<N.!9VSLW2-$N-T2ZG EZ+S<.LJJ8U9P"J:7?-"<EMVDWK:JMP//
M55CBFQEE4R:L=*C=+>K&4MKB6*0RKT48S1P8;@_3TZM,V#SAQX2Q:%2WSMNF
M'=M8..!/4I W@<GQR7L]O;O/,1T,LDDDDNS7&&C4?RD9#'(5GEY/6&$@B7Z>
M#)-$CMK"Z0,$)IJ:\P\:1R.^I9B%$1)8ZF[:GN,0G1L'+KJ;06V89RPXD9-1
M3N)M#OR2G!B3Q4.VG.0":N)VDFCDD6R?A)PQ@73)D %@J9ZJW@ILXD@Y,S+&
MS?RI?'N7ER<D*3U5JVD?.-O$L$+9!(?BL-RT@TE]K*!VDR9UB:X\84;5Q#1J
M5C8?U*:DN-375SNTSJCQMQNSGS4P<>BC?;1Y%>29&@:UR>B%1&SI_P 4ALAD
MQ'P:&";(EZ76F6T1%N!Z>,\:W\W*M+AAKD4'$4DWG20MC2?\-.W:E[<2Q66U
M4[%M>T:1I40+P V8X'-&]VKR*\DRO UKD] *B-G3_BD-D,F 7(2#=)[YH..6
M.=4$.K:#IP>:2Q%/YINFBC-W*O7TM4+]N=-SQ''_ +8>D$8(_M1DG(BN=;/M
M QEUGI,V49BA!TZ=/"MI,#/:E=!BX2 1@KPU1!'_ -5;6?Q$/'H ;72_6>,H
M=OKHRW!Q<X"[993-MT;2-/0D'1++U,P+/(<PZ=.C7JVG5]+7K[=6:US$VW'5
MUF3,N&&H";::6XC!IGF.\2QL[(^3)F)D:20KL-GC4:%Q>-M+6?3M8CKN&QJT
MKTUQ(,<&%"6X5[7!4]"591(PRB$B1V!*KG.*.U42..II8DD6&4^DR(V>W--M
M%Q&K%EC81NBR1AF8B.0.@U-PZ1J>6X?;Q3M9[81Z]N79X[8KH9XUXCB.-*7=
MWT^:#)*\DFE<G2FK2,G XUKD!B$Z-'*- <1MJ1V'31L9RN#3/.VWFC:1TD&9
M?$LK2R$&#9><>RC+<S"2WD9&>)DGFD0ABBY.G5PQG'"@\SZ _G;-9972+/5X
MM5Z/1'1.*?.EM+!UZB&!5U5E92"K $'(H23G90W#O),N&E8/K>1V+2!WRWG5
M(9)5N9W;69")';0=?379: C89-) H&221@/H[29Y'5,\="D)GCC-/K1XV[=$
ML3)*FKAK"N ^!J!P*DUK'(H&F4LPCF>65ETC5+J+  ,^ *!D=M+<= ,KN8XM
M6&,<>E#I7H]%<1O.\>R9E:)9480I,5.>C-%(HSC)%%I(Y%!^CM(7C=D[=#,4
MSQQFH]<26\W'IJL3*&)));::]3$LV6.:<R(T9;&K2\3H^'TKK7.EM*Z@<"FV
M@TPQDE(F5'598E+-A)0Z])N'2-;>Z.PN93$7D&J<Z\F"+HR:T&C@O$YVMP-X
M@01*J$+*%3 @BXQ!&Z/7Q.6:4- L,8B0),LBSCQ8"MXSI@#7JIBZR&&)56*"
M *C JP71)JD0Z>TGY,R!^$>Q!90XC=A%XL.Z%@@"@X HZV42DYVBP,YMTDU=
M(.L096Z2D'C5Q!'=6[#Z4<\$BLLD4BY5ACZ^/4>2%F N;EM0WJZ:5(V!4-D1
MKJ3(7&%U!P\CZ[F4(LDGC'<C4(TZ*X08X*.-=-E$I.=HL#.;=)-72#I$&5ND
MI!HE]20DN=(35LNN1^EHUC40&Q2%RID;K/39M(P  BX11P50/\H=@JC[6; '
MD RETU<5U+G4N1Q&1QIF"ZY#U(N?.<X.%'$X\FS!=3'Z*YZS]0XT9HP(F/ "
M0ZN@2> #8R?).P51]I/#Y9&Z4CL0H5$&7;B1G PO6V!_ED<B.T,G]$JJ28W_
M -+X/A02I*HD3SD+(6 =?I+UCMH]0'I-02)+&V#@Z7C+*<'@<'K\.21$:9^O
M1$K$&1L?13)\/;1[P4_K$.K:%/\ 5IQ3RHDL^CSMC&S!I-/TM ..WP3U >DU
M#(LL;:6*-I="5.EU96P># @\1_EAGV.94A<6<&=:99VZ(7/^-JXZ*U$:[]#L
MB)#Q9>"[4]K!EP>D#4%P=T+:E#0&82$B:.)VEC*D',1SQ(JYO;E[JZ;?;E9S
M<2;4RKNS!(X 3AH^PX%!I-<JVD8,D#%RRC1%',VHXX1<26/&\N&M[.VY/@?8
MQW5U)(<ZI)1+I"^<J#2AR UI*)[2<'.SGMI 3JC?2>WW VNNW-M*BS2*DC94
ML8Y%'5G5D=8J>(POJ33GH'LZ0P:]-U<:8E:(=FS>>=>CUB!?Z1C4'.[ I<\#
MDG&\[ JR='!/3ZM5S+LUB@M>3;+CQ==<C@8"ZLGB>PUMIE%M()(TD>'0XUH_
M08"49&G3GK+->330\FP0HT@:QA:0IE@O2"+Z:@ODEY7M%)8)<7%OJX(QZ\HH
MZ/\ A[6(O?7\=CRG?9;2TMMO3PP=$H>B6R-I&"'JYFT.$81Z@1M1&SZGT#1G
MM.>JKV]M[*RMI80DDDNUN)X6DCV4D9T)XP.7&&":GL)]I9W\EXSK!LGXD#Q;
M.Y_H'4KC35E)M(U"@LEK)TV\=)@*@X'4RE^#<+.^6>_L&+!8GOHM711\\>B"
M!D]%@(V]6>LDR8#8+C''1':AHU9>@/%#/2 )EE0V[IL'$BB-@'Z:J=,@*\*_
M,EJX+B:>Z6)=26L0( 4>F0>;AFTF14J+(>.W39B15=<%6D,R=1!*JX';5PQG
MCY0@!&I-*[-5<C7I9@^AB&7&.+<IV\G*MS#*^SWB."":39 ,#T)5610X+1D*
MY3?9!;-R9+,^UY0D@$FRW^-3(%73D[*,<15Y?"'E"_9&T3;E!J!.S.2.CTM!
M +MT*Y0E,2!+J".XAMTV;><R31#6>&M^.A%+TLC"#,(AUR3.S9.EIXTPI"G5
MJU ##6[NUG=QQ6QG0<?&#/1SC3T=0(1UXI<3*9MI>F&>631)M4TYC:(-C5G/
M2%<K7HM(LM"DL5E;F1DURO"T?2+8&T!8QA6>N496CY.L7MRJ2:Y5'$%F##/F
M1^<K:@:Y.EAY31[074;RS6TEK)<-%$<>.5\.NC+84X'^5-+/LN;.&#HTXWW1
MU\-&OZ=79DVA6$.S16ZJ-))B5B=13_2=7"KO:;."12X9]29.A A(&AB:NMH8
MY;F2%)##;IC(1SG2^G@,EF4X4G4VREM%7.Q;@.GJ63Z8 ;3G(-#4K37%\%X3
M/Q&E,M+]#*IH#:F6K42;6-51':)LG2&CVD?276'R>/"IS)O4S7$\4!6-1T="
M/)#DZ@W'J9<U(-2,LMJ9#%(/I*0=#>D9IC+LMJMZL$>F265G767Z;.[8^H#%
M6^MK:2.::UC.K)R04NHI(_,<9*R+D8%L[&=#,L.S=^)"EFFAE*=("*71J65&
M"7)<W5[L=!G*]6S*I+&_$(,.%0R.KU@B42Q1;6YM7=L"0Q[*Y&M5 )BX=$YK
ME"?=XK>Q1EBA.P),MQ*[ZI"8PZ+%H9]()*V<LNFYBWN#=Y^3F4=3SZ-18H&M
MR6'$Z:0SG8(L*R6[1-F/,C1"$SB573;*2 <!JN-IO-]%!_-E3JV>%&U"L$.#
MHZ3#!O2Z[/:Q"1PS#SN)V:#1]9P.-1?R]4>.DO%O3@X)'#@>-378EY2OEUJD
MFF.$G8-T]6R<I((AJPVF3%XS@0;>#>&UNO%@B] !4)+$=F:#?PIFD"Z)22VG
MSM4>DR*G /JP<58Z]B\>S?3P=$(8<0>C7LXZCNQ/RFT3/@3L8BT:, IVB:CL
MF8!QU9P=9:?D^*[(E.<$:WQPQPIPR1:H9;6.#2VOH9VYUDYJS+[&<W.R$2EO
MZ")X9LG9N$UHRB3"BRF4/8E[9Y(H)HY'665CP1]C'*BEU(FTAZ8R;[<"6\N)
M9&'^&J"7;Q(VK.J/I)CB>4%N&DO9RNLVUNL*,%X='6Y7B<ZNRN4(IY+2VDMI
M9+=X%V:%F<RPOUKP1HS]+-6%PES:RA3PDC92=/H:-^DC#B!U#_*(I)PMM9H-
M,4;=&',H0('QE202.NO&O)97$);HS IC3)$4C9D=SXI&T]:FQ5TM$UXU731O
M'$-XP-(TIC#/QX@#9RJ1FZ>XF>ZDV)8-QPB1B1>DV6&E<RF11)9W"%94U1)(
MVH<0JXT,LLNINH&^@WBVN(-*C1,I23J8,Z^+;B[>;P(LK:.VM85'FQ0JD<3,
M!QZ4@SV?6;=HU?:0$L@)DBE70<](:<^AA\DFO5<6\4XN(XX]*,IZ1E5PY4%9
M.!R*.TVYNQ;-"KXT;/2'T29VFKH 8K,FTC>*RCMBTWB](74F1H9SI[,\*5I]
M,L6T1]$&803)T?IA%_U5+&QNVC> Q20POH,85G.H295E7H$/@LT7)T7.D\88
ML(9)9(&TAL\3MY-GV!]*@7-JW.UK$#QAB>&-8Y BG2NTD7::5_E5?Q[83P:;
M=-3,(GQ,&"R!UBPS:AP!J_CD;DV^N+D(LHDC0&72L<442XP7 9O%LW1Y-CG$
M%E<6<DL@Q%*BE8NGL^#NY0N3TCQY/5T@;:*5%W.LD<:FXBSJC8*>DJ<<+@VO
M)\2W]V%.4CN)I(,JN>MEFD?3P!SI=+C7L\1B0$9C1VST^'1KIZUY2>$0;=AI
MV>S"EY VK6) G0/G4IFTO#)I CAS%EI,+DZQ&O'&3C)9I],2070G83X@)#%>
M"[,2#/60.-2-+TIXTTF>STQD=)@LF)2IU&7CID"1KUP7" @9'6T; X901]%A
MQ45R<KP[Q.ARKW9V4(;B%+C#AN*@)EM5Y%<\[@,XDV+3QQO$$SYQ52SXZT5V
M43Q-+_#H[&26V725>4K(^E9=FN53I#)Q>V"7%Y:O(<S;JS0RCCDD=.,=7FGI
M5/R:EW97R6T:HC)IU(MSIA6(P;)5\7&P9 VIKE#C3+L,[U%AB!/L$D!&HC /
M25B#!&\5G;));-!&<Z0[?0UX@RH#'QK-P8R[N=UNHYWP1&9.*H0OB^OKP*Y4
MM!<Q%X$6))XM4,X#;..->,8QHZV#:1RC91\VWCR\2^S@BVD+1<473QD4Y+1D
M'5;AEM(,@*([<. ^-*@LS!>Q0O0U/_E3P++M8(WRXB=LZ#+'B,] %<:U?I8&
MAOX;;P21#:?U8+Y.GL%*C@S/+M/&(3YJC:=3<>%26ZW$<ZH-*R1ZL[.0* O
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M7<IJ(#P[,O%*44N87Q(HSE1@U);3)#M!UQ[5D":Q_3G-/;RK!(?0DQ79L?\
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MVK>1]/E?PGDB,'_S\K[2\\D1C@>H_8?*_G4WDCP(^[ROX=/*^SN/!_!S5]]
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MP66V:Z$3;JMRR=-8#+C7CZ@>B37)%Z)[#E.VM(<QP*BM+L;B..)8\[;48_\
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M01U>1_.IO(W[,EB>4E>+8;TR8(0+M&'$+K"ZC5A?K)R9RQ=%R(KI"FWTA?\
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MMZE^&HN=CM551Y^C.GAUZ/NK>I>I6!/_ +-4[F--,>O5TE1^/2X<*CN)&?2
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M\7/=UO%SW=;Q<]W6\7/=UO%SW=;Q<]W6\7/=UO%SW=;Q<]W4;'9:[HRL@U$
MXZ8R<5SD!JT+ISC9\,USF.ZKG,=U7.8[JN<QW5<YCNJYS'=USF.ZKG,=U7.8
M[JN<QW5<YCNJYS'=5SF.ZKG,=U7.8[JN<QW5<YCNJYS'=5SF.ZKG,=U7.8[J
MMJ#%M+B^GN$&UQC&B1<G'77.8XZ%"Y_E?57.8[JN<QW5<YCNJYS'=5SF.ZKG
M,=U7.8[JN<QW5<YCNJYS'=5SF.ZKG,=U7.8[JN<QW5<YCNJYS'=5SF.ZKG,=
MU7.8[JN<QW5<YCAM$*9_E]F:4ZEUH@#8/:/\YSI1$ZM<C=?'Z*CBWI4<:\=W
ME>.[RO'=Y7CN\J+7G@0..IFJ;DS;M-;1$!9M>U0\6UIAESE#7,O[BN9?W%<R
M_N*YE_<5S+^XKF7]Q7,O[BN9?W%<R_N*YE_<5S+^XKF7]Q7,O[BN9?W%<R_N
M*YE_<5S+^XKF7]Q7,O[BN9?W%<R_N*M[3=HY+G9RK<ILLNV8;DP1=+@3TAT3
M7-UK)L6;Z&O;+JX=N!7-=KW]<UVO?US7:]_7-=KW]<UVO?US7:]_7-=KW]<U
MVO?US7:]_7-=KW]<UVO?US7:]_7-=KW]<UVO?US7:]_7-=KW]<UVO?US7:]_
M7-=KW]<UVO?US5;'2D:EF/"?/ "I4 VT,I__ (=*4C[)@\1QZ&XT_) =H2XS
MLV83@,5ZLBN9?W%<R_N*YE_<5S+^XKF7]Q7,O[BN9?W%<R_N*YE_<5S+^XKF
M7]Q7,O[BN9?W%<R_N*YE_<5S+^XKF7]Q7,O[BN9?W%<R_N*YD)TH@RQX7&>
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MM!$UK/=G*N]V\V-$1=MH\K.W %1@"<W$<MW-&H-W)!)K_AX^(V0FA/7UNP<
MPWTL\S.T:RQF[33:6\R:V;9MKZ,;=+:8C+QS[X;5K:6?1'HE*O.1$^#LM(QC
M2<U;6M^D_)N#XA[BZF7=+E9 /\#UBA&D^%^'DKU;&O4'@P74XY,L8UO2/XE%
MUMIC!XZ ,#3V @M<3-<WS310O*81"ABMM.TR$N6#NO35<<*EFGV26$D]GJG6
M$-LN<1M- ;3IT,XSQK:.;M;BYF5 ='F"-25_JR,]59&II[H[% H/61J+X''2
MI;LS6O9L9Y7$UYID/F22ZYPC9&EV'2'G5RDS36/+$RV[&659)< 2:QM(FAZ.
MH;,-TMG*LCM>;;?KMM<B<$5-LQBQTN@NO/'32R2&^C#LZ17#IYA&4Z2+QXX_
MU5MFQ:0126\1O.*<1KGP5./Y;5=RS"W2RL76/?)P(Q)X]V(C5.'0;)SPIY9!
M;/+%%!(L\$G!EA<7"DZPQ #=?"K=F>%7R?Y;-Q(QCK[? ]DU?EY\.UC$LK2R
MZM "%DSG3C@<YP *Y5Y.DL8WR<:8W<D._:5]'&L_)FL^2_-K/R_X*+PG3I,
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M8TU-C 3T<?N^O/"HIIMK;I.8C= (R;*5M2@GIC9\<:@!7K"OQ<WD.2U5[G9
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M,2!)')<0!E740 J\!-UU9AZA"I("<C3L\9RPZR6#;KXGG/'4JR/+M/7C]#<
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M<  J\ 3Y$&&+TV(7T>FG[C__ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _9L\_/O_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P"KRGO^Q'__
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
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M-9/K>HX N0-Z^C+ //4IO1&^'?+#N;2K-Y1)ZV2^@-E1D9%!N@*^AG"R#&&
M)@\675<]+G:I6DLH:#0;%*%[KELS8A_$9;BZ ;=86G<!VFN[7NBIC<B$B&^[
M,98Z,I(G'P5[O X /F<30U0:1*REDP8">EQLQ$#_ %&)/!]6<M$64-TB=^53
MQG$X P86@FP/P5"!\08]1)9FLZKN7I<OVMG':L^3 8>Q16RF[C;Q$ 2-[3((
M5SZF-4[9?*1;.LW?W/1/X1+NEK)O;6GC0 G@TXZ(+,2&"=[;T!2IK%W,5U4
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M@J*,?8>I'JW[<N-P<F3>NN"JK]+D+\;H%^"\,T*.7@9RA$T"!$R&N8H ^4O
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M>J$VT!IC\!+.T*F"36Z,0/=B5VU$ 1-O-BK8Y8X>E$XHTG+<#C8ZE2R:4H5
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M0:G$ &F O*8=$&H;0A8D$ZC*93*93*93*8SG[?Z^?:)ZW];?D(:)D+"7Z:1
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M/_Z.?_T<^5>C((T4\N<!ZE2[2$K;7X_'CQX\? ,4ZU;O ]GMGK7,F)MN?#C
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M29N\N'0828#HU]V<U7E8EERY 0')PT:FB-)<4"W2%G4!B6,=2*%X".2<D(%
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MEX'9!\HD/.UZ&A_(&B+FKGSE1R=6K0!1<!7%BA+2H#(Q-E0D?* #YA%4@<H
M%4",3M*YHE(OAB:<'A(,:ADDJ:'I7NKQR+C02SDF Q%2N4@T'"JQPX$4;T(D
M"*LDZ/\ W]5+QDJ!/PIHW.FNJ0L?,CV7<V'*C8"HX8EL%I/)@<@=DWZ*V\[5
M6H2T*40!C-(6RFSU0R'DN[.%EXM5^EC)UVSRD/YZ0!Y5'4E3;U5H)"!DP%WX
M:IV%*B!K<9[965Y 0E'6ZXHB(-GW)U#&M>#M"]?Q+:^3\Y3+&."VJ"++Q7/L
ML@J#$QU8D(,A+200Z*&U$Z$!3#W/&KOY<<_B=\4?VI0&OU.\A62H=#5:F&84
M0NK=*1/31^R 8_U)!Z;6/"1&AQ$CZA44M>7=A84'HD1AC2EW2)YM28RFB !H
MT3(C512R_P O",>E8S)U5+BSUD)=TXD"9-C'5L6M0B+H5=[[AE]X58B B&PE
MY.5(3961,7_6&XNX,P4=AC>0I_"QA2DH3<@T."JALCFDJ(1'"5PX6I!Z/5N'
M$>JKFR(@I^$#*'3@37I8J%X )47F$9YPNS1QPR8[RBVGL&0-.H\U85AF!8)2
M II@D,T4F2FL.GH!#8%L<-:C.KE&,W -D0_<8^;.+/B#$!I1]0$]K*A\MZ<7
M'QI>MSY)HT'2#JK9/;3\:3,,  X<##)#M;_+QRQ*+C/KI+&L?/IG"C(S0$(.
M!5!5N X@2Y"=1KN5!0B0>78@-46WZA6,VH?>PUG=)'"J:=AVTBFV<^,:!>XG
M"-JT?*6"W5CXFJ>-_P#CYA0F]X7:IU*@_+L!@DH4-ZCBQPO@+/@3WVBZ0A\2
MC=VB&::6:=H<PZ^G0I]&/Y:"M%!R'(:":L;(Y:&9UF40H9MW<S\U&6##'PFM
MI(=._EBWC#T"C+W9T]"V%-S:GF>+:2I2Y2&%+2C%W(K!"1FD:,D./)#[A+51
M#DVVG%:B5@4'X>=9V:EP9,3(=Q&!0RHRY:Q:&UVI<RJF#R2N0M75WQ-HPF<[
M1-Q:#5%E^4 $2!PD[E+MY\%)(1Z8+,OQ$*.4AGI?SF'2KO'I]TXZ( JTM_2'
MQH@TAQO@BC($)EX:P&IL(_XZKO$SC8H/^$CR[J$E_#@(U12N-I!Z5F>OW)2^
MP9=*!SS\1I]NRQ SI6W.35=@FLQ BO(:&8^LRI@!Z;.1SPG5+.PBV,N.3^H]
M#W,D+V,5:R(KA>*2_<R8V*.$71CSG(+B\'"DHCTMK48_A0KOX7.K\GT#82^,
MUJEYI LA=C6CI9A _;HQ<L!!388EA4;9<4)$QG^6F=)TQ!*VU#@PV*8LEQ@X
ME1!PW&+PC?"\$(7F8:!!^'$#Z 3(A/=3I6QL#/=>@8ATDKZ97*%9<K8&*T\,
MC(W.)&'!4(O*P.RCP1:2"@*3/CHZ6IZ$2D[*@#X9G37F3-B+4E#U&@^>T%_.
MK7V6,NRAA4!S9)ZM[E$FC5>2(7Y^08W%;%)=?5-O*CAC3)S@$6=0&U O#0Z/
M1Q-S5F8NU2KUB2$!7L<&+- MQYK\&-C=:;YDU023^&-1('+55*,6P )^)2[Q
M$T1MPOKS5V>#^+5^W8C4"O>@=:/.9B\F-K*,R/,"[80 IH50\,*PZJ=5&NRR
MFT,V*ST'IC5X9:(E!%@<4$%,HC7,>=E3Y6Y$)@'9T7O@,-M#)DB7ZXI&^:L_
M<8XA4PM!/&;TSIDEP>4&A6\Z4J>Y2.+1^A*!M,4?(*0GL7F6G@;GPJNRSN;D
MU36^(TJ5*E2I4J5*E2I4J5*E2I4J5*E2I4J5*E2I4J5*E2I4J5*E2I4J5*E2
MI9M2PY2>^7'I4J5*E2I4J5*E2I4OJ*#[_ G*E2I4J5*E2I4J5*E2I4J5*E2I
M4J5*E2I4J5*E206,;O4W?(A0&WF8Y"*3L.[L36V:N8?B82*,B.S RQ.U5%GW
M8*;C4SZ*E2I4J5*E2I4J5*E2I4N06@^WP.4J5*E2I4J5*E2I4J5*E2I4J5*E
M2I4J5*E2I4J5'(_P_P#DJA=(!W788(%VA/);,&"M '@2YLHL;,NV%-%BWGW-
M?0XDKP;(.Y9*Q3(TL_5O\YW5'=4-40"ZIA'36#4:E6UINDU!Q>V>/;NOT0HT
MQS=-/'?OWVW>7D4TB:MW5_UNI\DK0>BN+_!]O(\[OR?^ '!.I\DK0>"NY^YA
MZ(6P&5>M[6YKXR I((,K51Z9!OP(G?(N-/CXX\&YC2CO% 93A)/-"!E-7X=C
M10558S1C$C&$0']4?. D- MWPL!U'RF_8\\+*\FFK5-AH-$^?^'T7V/(^[OR
M>&+.GY@VMVA8H1(^'^B=L#:MYLG3ZEU'!X%]%$<DDN3D=$G@AMV+P(74 )TP
M<.+P/!*Q*68MZ#7F'NR86EGA^[[T=2<-/H'_ "6+1^;Y::SQ#@D^,_)?'/*O
M%17GD>/_ $A@@;BOT<&#4 2WA<.>--J.60O.Q<+]^-J#4@C9*"WVFD$-MRJ8
MB&3*C69.^]HM'%,3CW3,N40Z5D=S 4;[I]):PXML-?12FS2PW+NB/V^^H+*?
M\_J?)*T'A7:YK+TV7;82ZN5MW$G(9#-XB5>R9U$?+*,@X%GQJ+ J:A1AJ7E0
M9^QM;,:3N";_ ("Q.6F0R0A"U+S*V8C>BQ22P)#2>X.W>)'&2EG:=4&T0"D#
MB!0K^?X3SG%\/HOL>1]W?D\-[7;;<3N$Z,9>,2"3AJ,4H.+I,NG,-_\ =X>8
MYJ'T.'7?G/ EPO&"Y)VKB)1D5(.$EYPR'9A76S-8O3I5&% =S>]1<43NDN#0
ML>8C?3@)QG<,RL<6.";ZK\ <_P#V62XCZM#$3O=@=U%7542'Q@(MA4TWM*QY
M";P_FY#M9_O^E$$8!12*'T_N]+U(&2_> GTK:VJ*:J'/?^O@)^J*,T2]E&75
M,1JJBE%R)JW)*6^NO_Y_*C$H,HY4Z$[Q?D!4Z;OZ% IK.;S@#Z+4V<<DH:::
M<,QA6.(.E(Z4@;L@F,L<E%G*  #0 _PKCZ2E-3_X@(%!;R08,$PY_4^1QM;%
M/_PI"J7R)I3+TQ9G,2?7E%>@81 V0:>FC9HT;=&C9LT:-&Q9HV[-FW1HQAPX
M*J@%U0.:E?3'#QX\>/'CQX\>/'CQX\>/'CQX<[&\X&3<2]7K-'IAQX\>/'CQ
MX\>/'CQX\>/'CQX\>?&QA9<;,2N7IP\>/'CQX\>/'CQX\>/'CQX\>/"K_ABY
M *'62*K8_P"51K.Q<\?3TGX8\/\ EJJ-9V+GCZ>"_#'AQJM](*8J$E=1L-YJ
M*^B:='TT&#!@P8,&#!@P8,&#!@P8,&#!B,J?85<  O1 $5@(9 <B9.,TZ=.G
M3ITZ=.G3IT,E?VDM-4XKJPKM;#&N?@"-9V+GCZ4\"S\,3G%JN"9AHK 4$@44
M#8FI4*#5.C^O[G1_7]SH_K^YT?U_<Z/Z_N=']?W.C^O[G1_7]SH_K^YT?U_<
MZ/Z_N=']?W.C^O[G1_7]SH_K^YT?U_<Z/Z_N=']?W.C^O[G1_7]SH_K^XW$[
MI(V)G74'M9O-!%I &V#0;&QB4E)24E)24E)24E)24A#O;:34U#F@K5&@.B;D
MT'M\ 1K.Q<\?3EGX8C.+5T/A^-#V/@H;[]:\&QH>QZ%&LP$B'UWR,.I@:-7T
M:!;/@/BU.VD+! O>#EZ [K<?C.TS/EO8X\JX.IP4(!\XQKSG-%SM6]94IC;&
M6/'P)%[;,N$9TX'8N>/G6 +H]Q126$4H,U/$(!9A]C)F3%B!C;C91K$TX!9Y
M/49:K.E-%UR_EV38*%7&:TOYC;3K6&<8:OQ-\18I U;!#*NI0(6\QO;W!HOC
ML^B) FGA81!LO*!4IGB$M3(.;8/_ '+$L4Y1O\Z"Y% JRL9S1%*:83ZO) *D
MK#R.Z$<NNB(W[9+!.%5!!0E[\F[_ *R<:GW#&EN"C09KHIT"R:,N2+U-]CE1
M^"JD7V@B8XI9>82Q*9S49*<3/?:!2S''[9C#"P2^ 92]5!F*G8$&J+V=9&15
MI;:@"=;UAKZ' >&GI0VE:YV8U (*.R!?SP$K$#:=\U6&R48 >N! $(GIU96L
M864(91<'2-I[LQE;.:U:.]^F@XAS;[CCTI9@*$ M)8917&)1*5 3,]\-4\JA
M"C**-7S3EA#M0'S'%JZ'P_&A['D-39 0/=\ ,%\+[?\ 8% &3K05@>#FZL-H
M&4+02HKP6X@D$SZ:WYP6>'LOGJGUN-W8GXX?]N40 JH!;$]NJR Q-QV"T:F,
M_(EG+S#&!:QZ8-]^M>#8T/8]"C6/)3TE&YER FR$,\Y(!R0W* 7=S.A]8=E0
MN?$.Z,<P!,SLG,4:TA!@=LCI01'A#2:[6]RV+Y2><^>Y[<,%JUPFF/L/%B"U
M%X$=BYX^?F#FA,X$>R,!R W6K>4M.%%U@ *-RF;JPEL(Z2.@"(K->IBA4"Y#
MM'E5$AX?-SO%XC;(1KX0*I@M*"\-JA,CS$WN!!I)!P8+XT[1,"BG)G(CI&W_
M *0$B8#AAM1'8$!A>.T&F-0N4O.,IFCH\1/401NM"@(*JF"2X7EOK]$8Q'$]
M0&-]1PWEQ+PT//\ L3\8958*2LD!IJBLJU+CCW+DD:Q_'*>9".EB@J0MR"P3
M,D7UG-2&1!MR?[2^X2@GN%, P0_G$#-F0!PN4\@2#1">6D'+:B# 4($*CPQV
M>)GQRL+18LT%0Z'6 0XMF^DHJ'8C0G/R_H@T#BC4G,L3)2R'4(X\@0@FLB^8
MGP/+I$D\@]IS^Y>S #%EYK+,%%VMPK4H")!PTM0<-;2BGY_=7%.X1U[,V<6K
MH?#\:'L>5BB!0 :JP!U6/APMU(5,J@]4R0-\S+&8G+ U7@-;T9NQZ=D-]I[Y
M FV94QTE_ B\#+<*:FQ.7*^&@<*D*4/&&'!*_P ,J,@H< L>3ZUX-C0]CT:-
M8<PR<C9H G/!F?"F4\'L7/'@97KM&1(0F"=(!A+("Q)GPSW?#I/DN7+ES,2
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M[%XJJ0LH$:]*3Y1SH<U>Z*F^L'=8W-7I)UA7@BS.NAM(\O\ L'S@(HBL"Q5
M+>%*BW1 0TQUD>42MW2IC3073ANRQGHQ4+%IT/RMF+5#4U5=%,/'-$ VHR9?
MSB$Y.4*0"\#@D&F=F5V+$ISBV!N]5;\L/18,I^W&TQ[!KMD%.,_ T<O&O"I7
M3@G#A,4!%#8C2/,3(]9@,L-*R9&G4;.TY53_ )&!!C4U;HQ'*KE6U=5W5X/?
M.3P1&@5"*(V)A$T1V92IZHLK2FTKWQ,3D++/N#3W:PZ@JP/K0I.-C;:)#8K:
M@[+4#6A4MW+3ZX,NM7 0%2HM_H8ZC,52BK*K:O-77X''7GE1:$7)KLQE'DF
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MB"!9HN3F,$2Y@@NF:-P"S-BCT.VFJU(LA,GJ*W(,]-OG(:1ZVGLC/(UKY.#
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MV252(<LK4:Q>!-W389!S($8&$OGHV^6NK$'&R'+NI1^KQ^21DEI 8"SG[&"
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M)KZ3358=,$"%;JNX>P/0T!08-@$&(/JE62,MQ,=>9+ #^66R$LWW2*9!X"*
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M 0$!      $1 "$Q44%A<8&1H='P$" P0+'!\>%08'"0_]H " $!  $_$/\
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M^?.RH/ 4RRSL\L1.>H#)5(.57TN391'G(N4^5@)?!'?\5Z*:5:Z2O#<X4D9
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MK_SUG##Q!A$^!V9XD!'9V 2O@+&K8$#1IB37V51FSNX""Q2XTAF@,PNOH0P
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M &WEC]A$0)W<Z4T)Z>CT#T1KK2^3!$!9D'D'!FA2HCK[8%P#9075FUU>8N^
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M7>;FE@&(PL\R;OJW&IU6VG3;'&^M6[$^:OS6;Z4FZ3,D"4;X11T.F#X5'/\
MLKCS;6,*%^"E"*@ 06#POI^9^CQ(2M,$[KBUS^\O;:9P-U1N1#RM+KFV.'M;
M@UGS5D&;5I5X*=A^UC>[OJK X7G6$YO+5F)^UHW3'M7W/;/^U"<8NP7@5)KX
M/2I-?!Z5)KX/2I-?!Z5?B6T4:+3MI05K]QM]MIO;%RJ,<Z3&;8_M>0?/M_;$
M[EN5]^XP#E1@<=/_ +[4GPO9QM[GS-L?AZ?SEY$0%)@"MM0+LTMXKO8C".L3
MIX(C"(P-[621WE_$04%"ZA06O 8%8EM-8^58NDSD\@XU:?M>Q&T^:T751]\>
MW=ZCQ9V"#B-^SVP[&.$&_P#N5@_]O*A<5CB8D=@4;@IJX&(,D/AZYNJ,]X:G
M72WA<[Z\TX&Z;]614;,!A)5%ZR;"(!J"K2#R+0?B-)4RK"P,9$Q&7^C6QEH.
M"=+=(116L[+#KZR]0#VE85?/6$2CP.EZ,25F3?LD8,A8J:&D"B*8@>E$1":"
M>#"9=M,["3VZTBA%4W3R"/ 52D8FR)$$0K<00H"F6H#@!]>0O_:O@O<[_G"K
MUU'#T6$Q(]3$;3YJV#TTXPN!/I\#\!2G1H.[1:L-T48VAQ;[]KO'*O=[?]QY
M4GT>+;4!>/%A56N3&N7*'\)H*/[BI<RE;L$""EW@/BONN6.=]'EV5/W^V"QF
M$$G="4D:81-&.:!966-Y-0@@NA2X^T[<B1AAP%R-"Z:/82* :H FP0CNJ=,L
M?@0DZF1DN>DFA^H*"!%6"4/%5B&,4+*,MQ4]61BHZ*A$DL,CE&A8HX(*X1&-
M'[J%X$ 1JPP$?4+&#@U-\P@UI[^M10[7;>R;K6^]'D+Y@"Q"8,5!0@2BD:[>
MG]O6HJ8J&'K_ (*1(F4(OA2,,5Z+)"5Z4Q,U&SO@?Y@GC?9$6B)E8^3Q*[E8
MK$;-36WJ$D>RB!C@600[6>35DJ9#5IP"EP@2V$EZ2P:.]=W8,;1B2%$  D%6
M00C(<R@"X,JV"Q'838<8AC^<\*X8QB8UH'0X>&(VGS5V'?[&C!?M?Y^.A=!C
M7#&,3&N&G2:,?)-R4AB,7B(%KA(5P;'##HB7:@(HE2J^XP$H 0 A*F,32*.T
MQX=<GT>)H+(M-S<\QHQK$X^>?RE'0O,8EI0-U(@(."R49T81P%7O>EN!+4$)
M(D(D6!8)B69BD3A-FAA)L?!#9DB[B4@!B)BQP)R+-"SIBH?YI<;FJU0Y=ZL]
MWGT+*XE[YZ;&3&*"1&(#*$RE3]TDMFLK($"!;?#B)HL"%",'!N)8*84*1D*$
M0D-< QS+[<&CP$]AL#5Z2-#9NRB!:$)C20?!H^I@%6@6U2BO*PED DJ4+^UP
M!,\BG8Y_RE<[0!@0Z%$Z@CG.R!? 8+8IW B8C5HRBU*7$6J[H=".N![,M1XS
MCK(YC]>/#>AS8+%U4 %6"ACQKQ1;' OG*"4,DDWP%$,) -J$X"FHGD7=@+JH
M1 %7 +O N;Z$L!F]H5MB0"VV4)4!4T J[#'EMBC- =3,[!%"4C9BP,,+ PPN
M0X+JJ4*D,)E$Y+@.1IOEY)QUD<Q^O$&]=]3G>NV?[/*"2_7-4A% )K $.0%4
MF*$F%2H3\Y?6<JH7!6(N(2C@GH3)&L+<<:.>.X4))5X@+R0+$9 F68K#64&U
M<&R".D([ALNAH %7BBX_I9W]=#02Z &4GR),J.>TT)]+2OFS[.S"&<VF2NS7
MG3?!$6H$K^<L*X8S@8U,6T$QO(\,1M/FN[ZCEY&*S)H8G<17#&<#&N&G0:<?
M(24 D(@A%NV "5#!>U10>)^P32(Z+! )<;<+80E9Q!*1  UF,]<%0(J^0^@=
MRW*^ZGB7-%FDWEIQTUP ;@#EX38-:\8Z>4\YI#B2V8/'(H36@)!*?!<,%8&D
M$*?)):0UD"J*#NNF5!K9\$C6C1;=/]A9%P.@X98W,$))+$.9T(3:V&/@B]!A
M6=2 5X1B E^'(PAY,M75?OPPFD3G_58_-^*>[;8"4R::$$6)F+Y8%!5QI%T$
MVE%*,0%L1E0T$INRYSO\HJ H@!A!@B7$T.)1>[ !4TX30'HJ6>,8(3W->FG&
MX.CMAW#!P9#[6HA"/(*'"R-AK#H_0I$H1%;J2/ ZWA<[ZK@NWX<O-JU NTX7
M''',8T2%);7L_9TX.-D.H*@WJ+*$=)[P'\0WS)!2*@C4:6TY  T<*BN2<)#I
MX1CA 4\\$BA!2.)IV\X_0$\Y-T55/VEIJ'%W0-W4M&"C><RU6J5GS0N46 RE
M[]7EQQH# &P,Q^0=H5:[!+%[3;7$IJ6#1>H)F"8B8O R&P;QG>K&0!A!(F"[
M"7@79>L[2VOMF/O?OD&(!;& L1;=!;4:J@HHEP4)7:XU W0=$QRJ#(SP,<Z@
MF8)A-RRFQ;N;C0!A;3Q\N(VGS66T$;O^^EA!#9</<0 : B19M0@,()1P:@0&
M"42)2P!0)@4-8"2 JB4"@HJ&4)57%6:2+>CJX_XCT!QQG/J20$001$1!Q"BY
MJ 1"). F($,(I5K2(R,BE5==FD3>IQJ"X $1  ((0@%8\%V#AK:6 FK%(#4S
M+&398.4AB-[LA P\);@ !((187L0]!5,HRH*ENJJN/G-SL%YS[R$LPAUY"!>
M>\#/(;:QU( 7"H)DH,DIN53[&@E0$NLIOQ;$*9 \=E(A[NG ('F!3(C(]NAR
M]\IX>>C&=38<P:AS>72@QNN1WB,)KZT; NT< AE*TT'PYO+HT<>Y=V0:(ZUP
MM<\5U:-'G<;$KBR*<Z%),:$J2+S>CR V-)*9:$!($W(3%VS+$8RZ56%T%AP
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M(WB/A$/LWN$#5)Y6+<(>7+,EM/:7[UR5TRL\WOU*I+=\%W*JXQP+9+RA2&A
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M01H"+6\HFAQ;=%/J912)1 2*1M2NG-LQY:))./)3-410A^]Z,+(D!8N(A70
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M" J((H%OM[>S]V0K3>>*K80)+6ZK>LD5^T)$ H@5#(15O7CB+I;H"1JI/":
M E#&&\)VH(V+$<U6)8KZN$4FJN]EZ]S>LIFEB)UA9*2S[8-ZU5%A2)MC<B0E
MVA6(>,[B(&!A"ZVE%(;UKC9C]EV,?B55Y!&&\L917@B<9\RWK*;E%M0MUBV
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M4^LI%*8VQLO0I!&WC"I2R/K"(HA/Y^@[,8CFSMGX7?KZ#R@0285;N'-MXT$
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MS>F->\[[-Z1P/+V VVT">L"@ BZX8!  NZL@DU1NE?\ AL]UVQ*?".+=*_\
M#9[KMB4^$<6Z5_X;/==L2GPCBW2O_#9[KMB4^$<6Z5_X;/==L2GPCBW2O_#9
M[KMB4^$<6Z5_X;/==L2GPCBW2O\ PV>Z[8E/A'%NE?\ AL]UVQ*?".+=*_\
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MS@.6PJ@D.]U:R]Y0:!@]9RQ(%4M( S+R)<R:T$;#0V]J0=^R7E5L#S>L+[C
MH0[*49UF87)M+O;E?8#":$JO854EVU@Y%LR+#TXHTE@29DD$"9%0* 9VQ.)L
MODI "0H*<%FDQ<@U@9^Z0SS>-""H *,PEG#N5 F=C!A:QG*$T=9)4[2+,'L:
M1+AB7E:3; H020%F1 >K*L7)>99(UL39!HF255@0$UA*9>J!)Y.20]DG#O\
M]* 26 ). F?X2LK6,W>9O()WD G, Q77K*_,<7QQGMG *F+$M:6)9S)SMLBL
MJRLIMIP QP &P#"*RA8I0MO-]M]]^-\)6L,Q+"XDD!\K/O#J<ERYD2Y<@AF)
MS$FPBLK65O. &.  V 805*)<DDBPDDD-9/**RK:Q>5YN+C<9C.'4X4ZGN4Y?
MN-L5U, Y8.=KD'M8V!GL@K42[E[F)#;,':>,5E.X*G#D%RX>TY/>8K* :LH#
M!RS165+M&5DS*32PE+9*"HD $R2[=Y<GOBLH>\H2:TV"[8,("U)24A@"[R#S
ME;TTVBLJ9<N;2YGMQARS.6D&<LPF!W&S^#!HJJ4D^P4J,I%VK &TVS#"P,X#
M@*2X'^W):"2FL)2K-9@QN8E[C"=$:KLYD7<@$"TY*+/=B6=GHTTCL%(#8L[!
MRQ$P[L)6B;"*)2 LUAV2++9@@B<L,OUC2()N8IK$-(J44 IGJ@&9SG.*U&Q#
MAF6TB6[3@"\.'9K2 28_V7M3[,I*832P(L)(=R[XA["*,5 :@?1EP#6FD$E0
M<!B6; DDR@Z&;5;0_M.U5+56E;6=YO+V84:,4B"E@+20[9=XO.^ NC9G K&L
M;?:4)C(!L;\X4I!"@Z7857L<4: ;+W! N!$Y/"2*@ 4$-6K!G*G8!A?@Q(8!
MX.C#,4$E)#D&TI%H<M/O8D6O %&JJ$A)4Q8,HS9/M"^;R#G*%:*8  8[36=+
M-\+.XQ[X!HR0"4@!2V!>J)4822)VLHEY$O9%:C2 I#5DJ)%I)FUI8@-.8:ZU
M_P"&KI;W3V$!B+PH."XL =F/"'HZS (:J6K D5JS3O\ 9%AE/&< 41(+R)8A
MF/M@@N0S-+%G$*JH=)J@JJ.*I 9S<78A)/?/"$%#,6:NY=VJU2VXMWM#T1:2
M 5/6D>S_ +:;,.T[=]DS#T18%F,@P(JA@SRF7!!.!=V,@JC#$500H7$$"L)W
MEPG#<]H-'>02'M!*6KDJ #6E+,P%^V%Z,@U6DE#2()-BMLF?.^'H@![)(295
M2SU4L"]I=W)O=C%:C 75(#I4/9+DD)9BTDVBX@VR+PA5&:M=I) +@XE^K<&G
M"=$R2:KL'!>T(8O)IJ%C9FT&'HJH:J%2*G!,ZHDF<F+S?,O 51%3J";5"P@'
MM!B6!F0\V(,\H7HZG99ZQN+L\K6DVWNO\]\[,,8=.K]1ATZOU&'3J_48=.K]
M1ATZOU&'3J_48=.K]1ATZOU&'3J_48=.K]1ATZOU&'3J_48=.K]1ATZOU&'3
MJ_48=.K]1ATZOU&'3J_48=.K]1ATZOU&'3J_48=.K]1ATZOU&'3J_48=.K]1
MATZOU&'3J_48=.K]1ATZOU&'3J_48=.K]1ATZOU&'3J_48=.K]1ATZOU&'3J
M_48=.K]1ATZOU&'3J_48=.K]1ATZOU&'3J_48=.K]1ATZOU&'3J_48=.K]1A
MTZOU&'3J_48=.KQ/F=.KQ,.G5^HPZ=7ZC#IU?J,.G5^HPZ=7ZC#IU?J,.G5^
MHPZ=7ZC#IU?J,.G5^HPZ=7ZC#IU?J,.G5^HPZ=7ZC#IU?J,.G5^HPZ=7ZC#I
MU?J,.G5^HPZ=7ZC#IU?J,.G5^HPZ=7ZC#IU?J,$@V!N]_66D#$M#IUT[SR@,
M9!2238'/+U2*):P2&#%IN,!AB8- M(*B4L YF;)99B+?3"2JP/\ <M?G&C7A
MQ&6>8@H4 Y$MHRSS&_\ [9-HVCQ\R/;3\R?$>9*"H*+LW[SP&_9&A7*0<E@'
M#V5GE<T\<H-"H-,%PY 8D%E$!GF[,#8\G>!0K+L,6<CM,0&MD9AL3(0*&D)2
MXJA4W)$@[6.[X)$SYT!UI&<)0E 9+S+ER\4OX5+\A\1YDT96EQ:[ 2MDTR;W
MYXC0TAL ,GDI)DP-Q-RDG87LC1KP%Q/:39(XS(!=K<6@T2W:K;\21OFPV$SD
MUH@@@D&1!((S%OF'LJ_I\?,FQ?RC^]/F0A2R0EG#2R) X$AXT2BUCE02V!+,
M^\/A!HU@D526 ):<C9X]U\:->J9%CPYC?&C6"U53NS--V!\"-\*04A)4X))[
M)#$,T^]Y?<?]>)$;1&C.*>/+ICDZ4$*221(@WW$9=-L> M200"P-LA^HC2+U
MC)FLN#"["#2+/O&_ 6N+AG+"YHTBP7"C:_>X5X@;FL@4BPW:,@PL,N\3LD]E
MWG00E0)L!NC_ %-%\6[[PORBC4A:16=22!*3N#.>7F2M20R2TWL%LKR'N&Z!
M2+%BKFL& 3A<  #:+KX%(H!0D:UI(F&#2NLRN$"E6"[@VR-DPUS&S."2HDFT
MDD[27/F3,* 9RS.0'8XEAW145\/YD\\QOBJ4A3M-( 922YK)-@)-D_,%%+L6
M<$'8>ML:1;N[EP786A@."0(TBLK /9%S![+6 !-\&F61<[N[!_=8# =@/C?&
ME6[R=W'9!:0!9P9$ ..9@DDDF_\ ^:$@!R0)@7W[ >^*R=8;CRZ8Y/63K#<>
M73')ZR=8<3X ]"*R=8;CEETQR>LG6&X\NF.3UDZPW'ETQR>LG6&XY99\#%9.
ML..673')ZR=8<<LL^!BLG6&X\NFV.EE6$'?EEGXQ7&/CRV]&5<8CCRV]&5<8
MCCRV]&5<8CCRV]&5<8CCRV]&5<8CCRV]&5<8CCRV]&5<8CCRV]&5<8CCRV]&
M5<8@;^6WJRNG'QY=9035ME:.\,XD#C%9,IC.V7"SC*R*Z<?'EUC%9./ \M_!
MXKC$<<LMK;+HK)Q''++;NBLG$<9<.LHKIQX'E%<8CCRVQ7&(X\MO1E7&(X\M
MO1DDA5A%H%]_<(KC$<>6WHRKC$<>6WHRKC$<>6WHRKC$<>6WHRKC$<>6WHRK
MC$<>6WHRK)QX'=9TU\5TX^/+K**R<>!Y=-;%9,IC.V7"SC*R*Z<?'EUC_P!
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M&5IF,7M ,"F;W$L'8%RSJ"K2YN:V?=&G5/LB8,IM,@V=QPD=ZE5E%3,[/;:
MSSQPNLCRCV$?^M'_ '#SHH@M!4Y*NUV4U950[D$A1!^$&%>3I2H)K*)4552
M&"4AP^9-@%DKY0F@*P"D@=BL7!,ZQ$JH):4R0PO/F3:-H\8I/^93_P#G0?V>
M;R/\8_(?%,+%:F2X+@I"622P "BJLP 8G$&33D(IR%4B$F3,XG,*4FPBPO)S
MAFX\J#4J@+ *,#\I] $@@BT1I5R<@L7#I26,L1D!LE9*-*NVMA<FZRZYI870
M5J4 "9!F# 6!A8)L)3]!%J?G1XGT>NMP])-HVCQA/LC;_@CT 2"X)!Q$CZ:;
M4[5> ]$+4  &#$%VF6L?9C;9A&D,I)+ )F 7 >1WS9K-L&D4H$%INYOF0IK6
MM -CY^LH)T0%X6MQ?^*HV;)YAFM'H42@E1)L(;&\17HG#I#3>1<NJZ;>S9(3
MO$H"J+LR ( FQFIDN2'F :P%F,[Z12%.4R45J-EH)<.7X3R9RWG\H("4.6_W
M:/\ N$.,1O$.,1O$)I5)!2E8 +ZKSM8F8?(B-.MR=),JK>[[3,XE)Q(M(AP7
M!C_44CDZ0.0$V)9A8P9A:9@ N27<PXQ&\0%)!!*@ ""22& Q,*4E?E=.4J2H
M:.@FD@CV,0XN\WD7XQ^17BGS5$&92DDM,ASE,S'5\>5_BJV(?<KU:+4_.CQ/
MJTVC:/&$^R-O^"/5IM3M5X#^#%&@%PECM-Y<W]\51GOV<NF#51GOV<NF#51G
MOV<NF#51GOV<NF#51GOV<NF#51GOV<NF#51GOV<NF#51GOV<NF#51GOV<NF#
M51GOV<NF#&B0JU()<&TVBR=UDVC1IQ5OZP\<3&C3BK?UAXXF-&G%6_K#QQ,:
M-.*M_6'CB8T:<5;^L/'$QHTXJW]8>.)@T22&+D&1!,CMZ\3"*.CHWJ)"79VO
M:SS>34B:.E"E>R00[.SL0=X@>4T$NV+KCEETVR/]30:XW'++IMD4ZT+I%%*F
M2:C%I. Q#9OOADZX_*<L\^([V3KC\IRSSXCO[.N-QRSSXB&&L'>P!1:8=W 8
MSSE.R&&L,I*XR_08-?$KE";&Q6633NF^4,+E)W*-K99FYKYWLG7 -X8F<MF.
M%XV0R=<?E.6>?$=[)UQ^4Y9Y\1WI*4S>LQ20P(L,\;7E.S?$L>!RRSX&)8\#
MEEGP.$2QX'++/@<(ECP.66? X1+'@<LL^!PB6/ Y99\#A$L>!RRSX'")8\#E
MEGP.$2QX'++/@<(ECP.66? X0&<%[)S!R.&? P*M4!V-8W$R9(&3R(QADZX_
M*<L\^([V3KC\IRSSXCO9.N/RG+//B.]DZX_*<L\^([V3KC\IRSSXCO9.N/RG
M+//B.]DZX_*<L\^([V3KC\IRSSXCO9.N/RG+//B.]DZX_*<L\^([P0&8UC,N
M 0SI O<3+'9C$L3N'.)8G<.<2Q.X<XEB=PYQ+$[ASB6)W#G$L3N'.)8G<.<2
6Q.X<XEB=PYQV93-HNNOL)_\ E7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>wald-20221231_g6.jpg
<TEXT>
begin 644 wald-20221231_g6.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X@O@24-#7U!23T9)3$4  0$   O0;F]N
M90(   !M;G1R4D="(%A96B 'U  ' !4 $P + "%A8W-P          !)14,@
M<U)'0@    $             ]M8  0    #3+4A0("
M                                             !!D97-C   !1
M '1B6%E:   !N    !1B5%)#   !S   " QD;61D   )V    (AG6%E:   *
M8    !1G5%)#   !S   " QL=6UI   *=    !1M96%S   *B    "1B:W!T
M   *K    !1R6%E:   *P    !1R5%)#   !S   " QT96-H   *U     QV
M=65D   *X    (=W='!T   +:    !1C<')T   +?    "AC:&%D   +I
M "QD97-C         !IS4D="($E%0S8Q.38V+3(M,2!W:71H0E!#
M
M                                     %A96B         DH   #X0
M +;/8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !%
M $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +(
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M]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M__]D97-C
M     "Y)14,@-C$Y-C8M,BTQ($1E9F%U;'0@4D="($-O;&]U<B!3<&%C92 M
M('-21T(
M                                                    6%E:(
M     &*9  "WA0  &-I865H@            4        &UE87,
M 0                               EA96B         #%@   S,   *D
M6%E:(        &^B   X]0   Y!S:6<@     $-25"!D97-C         "U2
M969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#(#8Q.38V+3(M,0
M
M                                            6%E:(        /;6
M  $     TRUT97AT     $-O<'ER:6=H="!(97=L971T(%!A8VMA<F0L(#(P
M,#0 <V8S,@       0Q$   %W___\R8   >4  #]C___^Z'___VB   #VP
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M Q    "_P
M
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MR ]3=>\_58D+>]OK'=9=;FS\9W/17I*0_5H[>*Q8%: R25K2Q=MNR^-R7+H
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M_0'Q4$P5$QI6"S^!,_?S]#/WX!@^_ R      ??G[,>G%/%"?-VHX<GZ^?0
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M-87 !^@_)^LN&&-UVHPD Z)0\C&B250@B8)KU!" _P"V.7.YQ9SF+:&[_OR
M,      !U.WUM"#Y-U)3;U1Y2;S$[)9#C\N/L!M>_.?V7PO?B--,F&0QG6,?
MCCGD1*T$,84X56%WWMOR^_/76'IN\L#!N?KRM,DNT!];U(\/%?T0=5(E$8\*
MPOFU'@AO1T'U/;#@-!RFB_0+XEVT;/\ 6'L\>>/4  T.IB\IP!0FE=G*V9-H
MTK87([)JA8@Q^>G!*.U""-CT0TSZ.E;&IOZXZ).">!QB]XY1G5%#+GG[=NOI
M'$<DUB_9'YG@NU65=G3:K@ @3OJ_EH5^5^F'K';X]H/*+>1Z?631=?/M=C=Z
MZ\9>Z86S7"N5L7U2M=MY_%?&F+D[C_>[I:D#;KNVL=^E/A1+:>10ME3EL-UW
M&*&BF3SW0OV]**63G+6&;==JH&9M2</%+"?7L] %#$/2B_\ B]+TFY]HR^D@
MPJ0MX;.T ^(@ #K=D##?C. 0ZU7/0K_)GSUOSZ%9C/GK?KT)PQY[G:]!G]AY
M]/>] @QF@9L=] "BQN%W<"ECO%Q?\YQ4M5>SY]R5M% L%!B#I19@/N2+[:I%
MPPQ+.O0 9QW'=AEI?<=/]!KO?<F WC?U( X^0,        !TNZ8Q$SI\ROV4
M1F#B.2W%\@-TP!9.>HK_ +0A<\VYISAEQLUGQ1BLQ@[0A-&&L1L-E8<6VNHY
MJ9'XSN,..K3<?$KY!9BIZ!9UKW1[W&OC[%*;>'N>DE@\1,NGZ&1Y .?4   U
M#Y],X^?F.[$9Q)6,WUTV?41VK/C+J_S#Z^XT<K^8U5PQN[W\LE5C7#A/Q&GK
M><2H_II_5Z#NAF.V:Y=%\9%DL#ROK$MMUR\#ZP;8-M7L_F+97S9]@RC!&'Z<
M20Q#;XG8_;3F;Z8EY&B\F=W;?:ZLHV>CY!D.RXYNY(@UG"13ZW]P&N #; !G
M(          #*.?1ZXPO6%/&1L9/IO+I(4-5Q.</ (F'C:Y="1G/4SA72$K=
M<=)@!/8V.NDM(V#[SU<\-%W_ !E>S0H]=^DHXP=J^,30$=CAM='&C1%QWPI0
M&H            ?C]MOTRO/RLO@>NMG;,UBI'N>TK'5A';7UUL7;; >FW+%C
M[CKJI;OTL]?8[6-9TG,VN![!YUGZ[-5Q7->MDCBK:.XUUF0U^!UAV<V\NU7#
MSN<V'N*O"G&2S1^(9)G-->8#(     !$2GLV_'A16PRMCS]G")='YR.CIM"!
MLDSG<VU@:0"R[P[:UPG;S(&N\"3!+=AC%6+*VB#KI7626SW^]=ZRLK\B'Y-:
M\4C;_P#EUQ563:WEKO3I6@52Q/\ K;K6+<E/,<4T1$>]G\-ZK&X6<_SC6IW+
MS*/^^_6O$V2U[^>/2FN]&PEOF4M;IN]MG7]N\64M?7[.>'Z UV
M  &JNJ.*FI+().L.*6)R/^S&(%=9#1K5 LUJ$J#:U->=6YYDXICG5B6&QX)U
M47L0]KH[\ZKV.M9';G7BU"R9BN&T:T'5P+[MO%!'59T-.4+['K0)KTJ6R>2^
M<';380..@           !I>Z&"/CAD--A ,VLAJ1\\D@'W(@Z:O# C?6=W)G
M+=$-?Z8P@J!OV#$=&4D#,[,B7!;37$:>SR"F<QU]F0L!GFL/J ;HXKZ9P 8
M                                         /A]
M
M                XL'[&J<T04NE_3>>EKAR8W;0W/D\4CXT1WTE"& K5WYN
M4$C3'IR=4(RE#>ZN\&C[TD5K]]2?OK$2DF(9!WXOT&NIFG4/O-73%4F7;ZWC
M-:[K9]CS7'8<W^6KMYXJ9+Q&68*6N38:BNN3=1KS7$JV4<8 [E0F4;ZQ=>DZ
MI;C36);;2._6'+[C*ZD<&%[)Y.2.Q-L\I7!B[XLYY@
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M,CLV@551=7%0EE;(?ZS_ (N'M!<'+90,[@
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MB-E4;RLI<QI4WK9KWM$>0MZ]NFFW <^8
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M)-FI# .G:%PR:=.%0W'?4"W8[;E2:W#F4N\@DG8@%0S>%C\X3OR:B-=[6O\
MSI)=MWU.%588-/+V,5QO]]PBH K"4,-%Y%>V]*>HDV@K%@E;8JJ<[E#L6#*V
MGK"D*RR?U,U30MAU;V)7_#[)OCE^QCYXD.] 44^E7RT&S/&?(8^71*8''?=[
ML%'687BIMS[DR]$VR0RX;@R1.4"N4O58SMU[I]X5J.'G0+Y5G.Q J=V2REXE
M@G<ZMCV.GJ^U#=C,<\%")0RZ^F;27^N"=N+AU*BF9+0?3Q,_6[>J=+WQ"U_)
M,ZA 7VMNWYHTHF_)":?,/G>GNISR1/-83IA$M\;ED$2[5L3E>3GLNJ7]2L@Y
MLL:;?U02;&O8N6-BN6]-7_@=-#\_K\:'E6NF98KRY)-/@H2GUU#8\ID:C'I6
M/97F!VC=ENU7DG1>1ID3F/G'ZH;0R:6^+Q2L4+C;!GG3HM+GVJ.7;,KTLV*W
MV+=,>Y9DKF.6$<;;(O&9.-^U7IL/5J[GC5QNS=55M5R.-@"Q(=+N]/GFB(RA
MZ<7GS'XKJN$=TD;BP-T:9(&VR2<-:R.SX!<L4/+:SL_I)FC<1!3TS5^*\(H:
MUN3]OQN,%M+_ -G]'>D939K8CI8F:Q(IXCYJ(U&ORHT/%.0U-;<Z+\ZB\[7(
MM?MWU<;1>7AV4"4[,+'&:P!ZXX<=J8;7S+AA-Y!J:\Z6K$?K68S"YS%S3T+7
MZ3M[J$QVGT=43)[%T=]J<\UQ?6WRTYG$;+I=A>@FS+HA+@)-ZO8!A%@TWV96
M7[]A?QYO8>\[2#=_I^//TE_>+[G7,^.DUE^3,4_76=SQ;IC$QDD3B\U!;9[^
MS(#WF9TD0P""Z8AZRWXA@>'U0RXU;YF,A-8<SKB>6CBT8+@'&-6X2]WWW8W8
M3.JH870KB\%YK9ED>$[+#ZZ]EM 0B=%"UGD&-%R#GU8%.QHFMS&$%W;:J6ZN
M!4HF5CE<@[I6NH7)7$_'W_2$A=\[=PB\4_([O:'N+;WYWGHL4FM-F3ZOO74Y
MXX?8M\@?V,NFJN?KK\G37DXN3C#RVX_Y?&,KDDI6(75RE-V%&Z1SPT6_"K<$
MFU5RRA Q"EI84\&GIVK[8')Z=R71:J,]W5WQ#G7T1NK]'N\A6NY%-XXI;F\5
MKVNJL23H!N?"@.E%?*>W:W6Y_EA"'^8"XH* =\'1[W3US17CHD>B6\2=<I(%
M U.%#H[W=2QR-P77 XI"5TMXSBD)2N%]1F.A*GIHMP^5FW+/K^]>_*[9@T5R
MFH^8O53VY/XMY)%?JAF; I"VLQWP0W73W8:RJ<FE]MQ^R1F7H'9"ASFE56^O
M$.$O<9+OZ$A]5)05)M?Y=LVU=SVA,\T3Q6>NI-3QUZ6G[IH-H?2R-[0%XY*Z
M^?Z'9-0\HE<>FNNF. ::([".N3;Q=/T%9^XUM+J9C[-9YK#F4X^AGGO2?7P\
MEOUH_+DUW7K]C$>4[%_6%Y^MD\MN,*SW60X]L+.+"3O^,VO\E5BX<*;2$AM%
M[A.%[#CHI_=L7I^:B?\ -=[VGVB/Q[:WL]3H[_,=+J"WT.>4YWO_ ,41/AM>
M_;+3<_&VMI_9*F_YU+X?YH>?,Z7QRAQ^L8N[9NC9].U[8HE? O;%$?\ 9BW\
MZJBU^S%ZC]T5?WC2]3V**78ZXM\Q>PEX?79)^U\[^@O/K9^;IZ6';GE>]AN;
M;3/\?X_>N/+E3=*G^VY55CSL;]UZ2MZLG68O#U$5:2V^P?LZ91$Y65>\YO[<
MKR._]/7V_=;]&3AH_/:6;<8MWLI].;,+T@6.R1Y1&\WSP_W'1KK?D?VE>@\S
MKK+U+#%]*#Z/KX 6<CH]['<\^?LP!\K6_G9E#I"4-5Y,T8'$=7'IT.PLS5M'
M9NK6)RC5%Q])2)2^OI.:D5?N P6KYJ6.F/QNN:JAV7GKH^H1+EWW! ^%2R.7
MR3;5 [*5]X4%S36[KKT$NX>K@HL;;SJG*SE=!X49Z[HV[2EN*T%9NJ"?;VVG
M=!V]"P&G.VZD])*L>XQ)7<6FW[SS43E2WJZ\U41?GT94^ME=G%))\WO/.F6S
MZ'-6WL>LMY)7K<P?KL^&S.&B*G%X_*]+IBI/1T]<^+[3;S<MHNR1%\ND)PH^
MV:[(5UESX#*&"V?@$1_*Y? 0_P"+EQF$0XERY@03]+WS&6_"\\0(6+B&$.%Q
MYP0<7GA,H9\7/D,(2+MQ@AHN/(90KF6S\YPBXLOW&48Y5BY3"-_M9N<RCVH+
MV]DQ#H7'Y/M]8;[QS27>J$_8YOGWGOF>SU^QC7S"YA8IYU/1_FYY>*[7X\M>
MEVRTOKI]''?$Y:>/JT"A)JZ%R++%@;>ZS;%JF_-&RPQXR:(9GG W$7:"A?L%
M$J+]&=-M2NKZ&^M\S228._5.,V5+JFUI^RB;5.LS)R=Q<RA6#4G* K;3'Y#I
M<SST,)-5P^#.D,V"FUXTZ& !(K#6'G72MWFI\MB?\09.ME/4FU72#A6I6L5/
MMV/<KUNPL41=].2W+8WT9@]C1K"ERC=ZKS]>2I6IKAO+E7-*RO3GVI6F=4#P
M[M5]3;165._0EA6W9UPZBT]%2XMEUMRNQ;I].C\L71*]]H\]4FUV1T:H*.K-
MU^U68.OS./\ I<E@[XYQ>3MB"I%;)W0WY4-)IYT5,C^U;G39C,"+8;?60H$W
M_6E%GL1E\4BQC/G-Q!T4Q5C2^NK:F^/VZ.2*O@E.ZNN8E^*6?Z$1?2EZ^!$1
MS2W_ (")GK2V_DQ$9DY7_P!XS%1Q2N&=8F?S+0!$GUY=/IF)+M2Q?0B=ZTM9
M@B7Y98ON<1,]&73B,Q.=J5C]8(HL?+CQY(AOU+J!$;W9:_N2*/8Y0NQC,9>V
M2(=G.$'6S,;'MC;<EP=GCL<GWEQG)?LYM<>6M9MGR6R8PZO_ )^>G\P6;0-4
M=/5^U!/MYN;W[IJAPEVIGK3;)[C9FLGN]D;LIU,#FJ6'<.8I8QZ^ASA736C'
MH]]?GPM\\:3JW5O+',Z%\B]JK+K-ZUO9LL=N?QAF<E>I[>]PD [I@ /GT-0
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M XHSN0FG=#?SJI#C*T#9'([8[1U_AGLG43 PK1UOT9YS@_(=D_'[
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MAOLY(5CC -N\H:PJ=86=?G46%.1<37(6O.-/OT#<            ^?0/GS]
M?#Z!\/H'Y^_0/R?H#\_?H'P^@?#Z!\/H'SZ ?G[] _/WZ!\/H'P^@?#Z
M       ?G] ?CB['Y#A_'9^!A.ML/&&!,Z!@C._H,+Q9_P#(86/:2/X;0;I5
M8@X-MH'?L\ILFA10RQ%^L=F>-;EE_/',!"1V4N7;K5*L,.1YMN5.Q]%B+LYV
M@&TRQ;]SI!%H]A/]G*MS8JRO8VS@C.G+?!&=_08 SH&",Z!@C.@8C)\_*'#]
MY@.'[R_0/H  !\/H    'P^@?#Z!\^@    'SZ ?/H
M
M
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MHM2_<MS=[!\:R)932T8CIVH9YK7BY;(G+U>U2GS4
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MH;"Z\J^O.%7ILYI&]NT9;ZE%JT?*?1?CWS3+6>/L6*Y7*OS]?L>:J# #(
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MM)V-SOON_CBSG2*6@ITZW3DZ \7(9-;3?LB;36REW>IVZ-\F &<@
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M"[)KJ**=[M=3DZ1_OW"*>MQN,=[UP'FY" 9
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M'R9R!^=L?HQ&5#]    ?/G%C'-]^?3 !G8
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M&]T<>6R/N6E/JZWL=+N\]@ W
M                             , !D , !D  ^?0P &0
M       ^?0/R?H#Y\_0'P^@ &#X?0/S]^F<?C[^C&?GT,X #/Y^_0#Y] _/W
MZ8/S]^@?C]?3)^?OT#\_H
M
M
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MSIV,(&-VBPG;),%K'3LC;(TRMFKM&2J*3[4B.<&_)8AI+N4R+ (6.8L68SD
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M/BNT^CW=ZCMA6D5=API5O7&:84_7;8K' =)U=!E >QLN_B>.5,V):SYXSRX
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M-V<_/.SA=ZZP_(_Z79HU'>*V6\AG$CGXO+)ZN201BRN'TLCOVRND/&5JXO\
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M.+])<UYOXA%S3]7$L63^]@I8YNZ$<S3]>7NJMD5,((*IPV00J_.2<WM;IO\
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M#--T5XUTYLA>D1(BJGQ,:\+O@4K)0G1I'<65W2Z4953B)2;-&YJOIXFZX*L
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ME<K"-5ODZ;LU]2]=_P#K7-/_  2KK)L'Y#9(>6<LF_JY&2OU!,1<B_') S#
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MYLRP?6.[LMH;.L4>30[B8;<6%TY()0$CI$[/S3VQ8A1Y1Q)'E INQ@A2:T-
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M;<9N5=2CCH6$!L_FTJ/*AWO54PS8I"TE;:G&AX16L%>([8?EWM9J%NI=5J7
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MC#:*X8&U++4"F760110O21S?A90*41Y]HFL=$_9& UB,3\81XIOZH_(H2L6
MBZ''$I.("$-VCSB%S12>!0 -VX0Z_C3-?\H4E(U0.(]@AT?-/LA[(5R,3"OF
MCVPY5.S:3QAS:2E2O,G+MA?)2@GRPO:I5/5#@\\.4IUPZ!VF#6MU/1"*MT3:
M;*\T7#/S0V;*[*=715M<JUA"F^I4%0*:5PA12HHV:X5KPA-^U2[SPC=7(^B+
M[A8%5ZZ9PVW:[-,--5ILVVW#L56&VPVAU:5!.ZA."?-#2O/#*LN,,+M4-_K[
M(2JQ1K6F'G@5/>X6>RD-*SQX0-NHH8W!$='[/RC:%.5VTE(VMD9[SA#,O;3
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M. C2[)38E2?>QF5 C%>ZWTQIA&#957P9%VS04!KSL=^$/"82$(.M3R2I205
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MQ^R&TMU;\+WJFXJ%=ZS7&O7&C5*S\+-+KB/@91.B6;\6PD)\Y317DNB<:4O
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M3[(>S%#B:>J'%U.=%J ]4+7\]<5/RW/O0W7M6]]^&4W#BM__ )L6T H/??\
MF0&_+?\ >AN7)ZT*]L-2?E:5#6C?*ROV0G1 [67?L3&DI!M+J[]6&'J()W)Z
MHTK( 77*/>[UQZJURC2LI]"][8F6IDS$P'@II"D!(#810W]E?<R;2?G'UF)9
M%>U7MB72?E+^]$NA,-CSGVPRGSJ]L:,96I1J=IU/H2X!&AV?I'_^;$BVA"ZW
M)JO&J;3SN$:*8O&^KGI%]#Y8E&&0.@@#TYPCUCU&)5*_CJ6?6J)-KT^V&4)
MX" (EB[7I/OT\@#@ C1#:CUOS/\ SHT*S]+,_P#.C0K/TTS_ ,Z-"L_33/\
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M+G/U1S[4QWS>LU4>]7,32G1X0M\!6!I*J&'FA,PLI-0>]G/L3"9G9%$_BSN
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M>2/2(Z?WH"N6G\W7FC?'U(M^:J*5^5!' XJBE+D_G%)WC?N[=T+3=K2B[O\
M<5L<JVM.17GY5BF*]RKARCSCC'5OKN$>).\@\J,OCF%JIU.PM0"Q:K;0:IA2
M[6L=E;94 !N!^T&%SG*"L.]MP^+G!F,\*AO?QH*^:,KZ_L1N8,*Y>UYS"CR3
M&M("1BEM"DY#-1RBX&B>6D).71$&D'J\\=/^*-R#]D>-_B,=?KCHGN=-/KCQ
M2/JCW;@OYK2-IP^3=VFD+91J9A*PRE5[N1351Z@<A$[_ ,,[[8G?^&<]L3G_
M  SOMB<_X9WVQ._\,[[8G/\ AG8G?^&=]L3W_#.^V)[_ (9WVQ/#]6=B>'ZL
M][8G1V=[.^V'-2D9*+2EW>1.43Z?U9WVQ/C]6=]L3X_5G?;$_P#\,]&DK'$U
MM5WJ[S@4GS@F-*N5.9*7:G<=W6?/&E-84BU!5+NU"2;J7<*DTX1/I_5G?;$^
M/U9V)\?JST3X_5GH?U^.096W3RJPB;L4<T=[N*MZJC.)\?JKT3X_5G8GQ^K.
M^V)[_AG?;$]_PSOMB>_X9V)[_AG8GO\ AG8G?^%>B>_X5WVQ/_\ #.^V'F2E
M]3:*.>#U@3O37D^6' VZ?S:SG\0Y+'9^0F$T:>F6*%NTI;<6M*[54VNL'.*.
MI"$LMNMJVTXW+3V*&5<H;=3<[KDWI%=78 1U;6)A1&!I1-:GAGAVP56TY(KP
MX"-[TP?VX>;:&>VH)]<3.N5P925>G*$?[2X447F$IK4X;\!W :)?2FX95U*,
M(;6@.3:1C05VN!QWP11W1)V#SJ*3Y(*JR\FTVH<Q-$%0INWXQ5=\\*8 8]^>
MJ"0#K:C<?!B'$-LS4LRFY2J .)15.)V1_.'P^S-!+E&5;*'.2I%<LQ=AQC)
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M5M5PKG$E-(X!4PS7]U#4T%H!JWK&ZU&[WJF.XQHW2>[GM[_\F).<:PJ"J:9
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MK@VG9*U&M;J<OC0PTI#@!ZQLYX_R@5.U08\G+R0C,W)*>'"*VUP\\)!K3&$
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M[O%6L#:!<5%-=H#  QSE*/<YRDI^<:1_W>589[=6VE-?+3W"E'_M6>2 #_\
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M*$,#P+BM[J;1<>OJB9#QFV_>[2"V$TS[:QSE =PY8]G6(27S*,:QJ;YP;!"
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MU0XAP(6IM10H*M<1@I"J$T4DYI.(A]FR7)2^O6)M94D54'#6B" 03=2%!:%
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MCCTPU;5#KCV+BU UQ6<XE6I9*S<O5C%1^$HU4:;JG#=_[D.--Z1T:XM3(?\
M>7VG4V.L.$8I"ADH9&)B5EN^I4,2TE*$N,-NI6%ZYUY20M1)2!:, .N$R#83
MH"9T2T)9U:O"+(L6NY(P52IIR<H+7?.CIG1[K^WL6RKM[EBM^')@(?+DIWHZ
MP[.3,F$T-4N)5+D%8Z3:LXU*9>5T,Y(+2VI=->X^'C:%E2K.M2JQWJJ;T3I"
M=F5-+<4&G&IMUTX+ Y00L'+.'T2\XVXVY1P7,O!/+87A4(7E<,1"926<G&I=
MD2DB261J;B7EFB:NKNI6G)SK D#+::1*M!;[BPXSJF"RMRP)(-+C1._""S.R
MS&BQ(H;F)I^6$O,!)"IM"6L%E9.2LLH66](4_!$VID%25Z/<9NGZKIR$AH%-
MU,588PDAGO14O:@8A&JL%HZAD(2V[+:(=7K5H8F6GFVFV2T@S.M0EMM5*)M0
M55.,*D_P/*Z0;G1-)4KOQUIF9[Y;EM52U*KJ!3M<A&I#NDM+]_2^ULZJYCE&
MF"O!JCO%R5TTDN*,RM:'9=Y;26W$IHDAQ*J;->3 DWG7M$RFC9QF9<4A+;DJ
MFB)AI82;@,0I&%T3"0)?0^D91<P#18G9U[7:QM'0"BJG"&I5")1B9:?>1-O3
M#LTX[@'U)=Y"EYJM_P#?\9__ 'BSTQ)%YZ8#IEUV%82A!2%$<*F/[2:17,$D
MK9$R3:WN^7F5#A&GM)?K"HT]I+,?]X5$_,&YIL\KB@'A$Z_\[^43C_SOY1-/
M?.B;?^=$Z_\ ._E$_,?/_E&D9GYX]D:2F\>"Z'R&F$?VATJT>M^\>D5],:>G
M71U/T5Z8TOI5/^::>J-+S+PWIF"'!Z14>0QK?CL+P^8L'UQ.VD[G? J\_)B=
M<IQ0H*3YQ$^]3J6/9$],?._E$],_/'LB?FO/_P#K$[,GL4/9$_,CY7\HTA,?
M.'LC2$Q\X>R)^8^</9$_,?._E$],?._E$[.MS1J-8'><KI;J#=PC2CNDM2F]
M96^  @\%6U)&^)N82JE31545W@*I$\_\[^43TQ\[^43TQ\[^43S_ ,[^43S_
M ,[^43K_ ,Z-)339W%"_7&E)M:.(7CY<(TK-_2?RC2LY\_\ E$[,$=,'UBD3
M[RDG>%1//_._E$\_\[^43KWSOY0^MVP-VWFM*E5?<:2FVF&IHI;0AV@2FB<$
MCA&EYXI_WQI&E](7G_&-(TO/ _[\QIG2"M_OYC2L]U^',:2G0BOCS6-,Z1'^
M>J-.:2\LRN--Z0"N(?52-.:0/'PYC3>D"@?_ !!C3&D!7?KC&G-(>284(TYI
M#]8.$:<GL/\ &C3D]V:\X]D:6T@D;O#&-.3YZB\<(TS/U_WY$::GZ?[]4:8G
M^JKZC&E)Z[?X8QI6<;/20Y3ST$:8T@<?'&G_ $C24RXN_ ERXV_]8GICYW\H
MFYDIIX2KFQ3KPSC2,Q:BEV.&T,LL:1/S'SOY1/3'SOY1I&9 /7GZ(FYCY_\
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MZA8!R41UYQK TY5]I/,1=M+2KLQAH7I"J+OM&'-IU[B81JW3RJG&G&#6!=U
M0K#A!HV]1+@]2AUCU1+-3S=M'5*N\&H;J@B-$MT/1#GMC1J4^1SVQ))^:K[T
M2Z6V'0E"E6[BH=?Y!]Y087JAX3FTP'FAAM;ZG25*6A"UG#I$$PTV*,N+P2FF
M*K1AD<H2E*D2K%U !G_?_'S7[MN."OK=W])<^JCN8DX 1^CCZZXS2\H^8),<
ME2J_(='\XS"[8Y,N@T_R4_?QC].F:'C5"<?*8YD^]Y2&J5AUUI7?TR5:M:D5
MRSM(K!4M:I=V]2L5';&9S/EC=(R:?]9=3'Z=4?,C]$)_XEN$A1/@@%#"O.P[
M(92V^XE3SA14)L4KP::$G',^4=SQBHX_8.YX]KZXCIQQA1MN&6=<HY[:+S3,
MET8_9&)44I &\U&$(4SK&$BQ7+00FVBNN$!MMC)>]?"GVQM7G5I!RKQ\D*-"
M:Y^2L7%Z84R4WDE26KJ)SQ%?5'B_MCC]L>,5ZA'-TF\GSM-QE?=&]'V0H)3K
MW#<HT&9S,*2M.J;2"A04.2C>(-%.S##">N]./[,<B=F5-*'#6)"$D?-K"DCD
M UR][3!_.2V(ZE0@HLQ2<@O*I$;E-_6<]P/^^K'[*8_2)GZ\.:K\=F+#NO+@
M"085K$H:QIN/$<4PP=5HQL/+<6,YA8L0!^TKR0I*UH0 ^UP0\DVU'P@# V$O
M%UKK9=VV_0:>2/\ R%/_ **!X5Y[5IJ,FDKW?&5ZH_\ +G<L_>X-WA)C'_.5
M%1.2K9[X:3_WJ6IM CG+;Y0XBO5'3F?WJH2'$R,_-)80H52'UOK.L[4)RKO-
M=T-L*F5(#CKCX*TMI.02@*3M'B<*06Y2;;-IU;:RR^V><$[5O!2:F'$KDY]H
M/LI2W:&ZJ\(D$[5+ZFF$2DQ,)##H6IEI3@35:>44@T\L2S[3+\@]<5MJ2A+E
M[>S4C?F!'1FO6W&)FWFF:C=>L)/HAH!F292EMM- 7GC1*:GI.+Q48E97O)QR
MU26DK0ZRDJH%I45FZT9@C'=2*"8DV^_99\<JQ";UIJ,2E;=<.E2,3J3GCDHQ
M+R=&W%I5[[?LK(Z5.2*F&$IU-R4J%P3COSQA=2D6U":W6YCA]M(;4'$N@)4L
M;2@HWVI4.:-QSA*DU3O-V P[AH<ZQO@D8P<%#D<W+:)ZXQVK4).0_HX1))\@
M7[8D_K0UJTE*E;\QZ#[O?";O>G?6(PK>:?)C&UIE/SEJ5'-2VCYN'V?W_P ?
M-?NVXZ*OK'N_I3GU$11;ZN0UO[5<$P=K8*4;DIQRCQ'\:H\<OU)C,7-_,.SZ
M#Z(RU6L5\9L45^T/3'*51M/:XK'T1A2;</G1'Z3=Y5-QC^-/GU0-EMA=_9>,
M/+"?^[2Z0.QQ<(HD37GV(227);5@?YZ:0KP.CV/QK@IQ0#CQ[0;40,;B#\7F
MCR9#N>,5''[!W!6DPU@-^V,(0::P^3'?!&-8.&$*!&I1DK_$R/7OC?,,BO"J
MQ"P'=2T^*;L-6O#C=1788GTO-JK1I(JHUQ^32,0"K([R:8QAK%-XG(H5M!0[
M1!VPZVD)_P -D@"D= >N.4%5@&_6.$^812Z9GYM0X@LLM$4[;J0RI:Q9X' 7
M&W:5Y\8P*A6G"HR\D"H#BZ_.C"J4;_AY=<8!<ZE]?8ENP>LQ6UJ?0HDY*%18
M$]@K"$KHM* A=*&J$XX[Q2#4]\->:N7DC7;*\G*6DJ60-6>C01O6CZ[GN"?]
MN6?V4QX^9^O'O9T@^',*[-V,+66A@FI./DW0FDQI$]]KXZM6#(^9M?+B=E'I
M.?%$RS>NUC801J.4@(V$U!QWP*%JLK,=8K>T3V&\>:-I2M!H":;U&2W>6" ^
MP]8E!Y2@5X8=1P@V_P#9SJ:\#J_;&!OF?WJL86.^&)J9[S4K\_+A9JUUJ;X;
MT=D-ZMDN.NV#DA3IN7;P%=T'POX9F'2GX!<6E/J@+(F6&2QT:(%JA7MW1H]^
M9;:5:M30%H)W5)&,2SDM-R<G?:NE=4XL%-:5QHK#JAB9>[X0I:3+A! "2$[5
MRD\8EYMIQ+*WKGPV$6H*01LK4:[7".$UZVXH$B>8VN%54'I,)*UMNL/6IS*4
M*Q\U:PU=,%8;#>-Q56FUU<3!2.]]$J;7PN3+64QSJK 1N:5^\5#TD'M8IMPB
M576\&BPI89X]<.7-K:;3X!"M54 [@ FX[_3#(U9-&3<-O&BC:G*&=06G 4BX
MJUB3@HT/GCDTV>SL]QQ@](?%.8KVCU1O56G$UBS#BE7K@M?.IZX:0HL .NS%
MV*:_FT<:BE8PQ/F[@H/<N-MI>EQ:IPT35M5:5/5"U3:FPI'@1X.X_P"(K ^2
ML,VET) VZZNW '+&#4V-K)^,I7I_O_CYK]VU'15]<]U-TPJ86H$\E"2A KUF
M%E:U9DP<'1JO+FF/%'ZZH\>KZHC_  WD_5,-52:D.W<E*N4+=]2!'/<+A[$X
M#UQS7%']F/T@?NXY(F'RL_!C<TKZ\>(9^NJ!^?\ L@8A 4.U+J5?9'O4X*D\
M [G\Q>!C,&GRJX=SQACC]@[F8?;/[0BT JJK&F1S@BT@D&N 'EIE"DU)&8/K
M@$.!*$_!IK*]F_.*VM/-.$#>$+"CZH'+61JS^C<E*/F>F&?QIQ-*8[)(H<?9
M"D$+.SK'-E))QQQ],.,NNL(<04I-'48G5Y\H).75&*@5FN_.N,= 1QC/6.$^
M4)I":MRKV&.-\TI(P&\D(AQ*'&7!44JH(-V'G\T+N0D9T*?7"J)O)5UBZ#4*
MU9';C7[(22U*.LH73X?V 4K&)[Y9]/\ U@\B83EU#^4&C3+K2UG/9&)A>T$&
M:NSL-VR#[(;L<0F7<=57!2G"YD-W)]Q^FJ^JF-)R4L\'I@EIZ8;;6 58;*E
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M&KP\M(&.VNIR-51@V,.V-T W@CLI'P_2V! *@E]%>H>R#J]=,/7J71058ZH
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M4M!W0I0J:FW"IZS&CWGW6&M6I:'D!*L\141L)<<4JAQP4HFD2SCY6L.W(4E
M&%*8QH:9*:TNU[8_AC1;[*53##BU%]"JH;752.3SAA6-%O2>O9[U0O7(*&V[
M;,+0.;A M%:USLKB!Y8T:].&7:[W+P>2E+C6(1@I)."-GR1HI]UJ8GWYIJCR
M$ZMMTBUHU2:E-*5C62=9H3@!5[W;N)&"J\FF^N4:&>*7&K5JUS?+I[XBHJDI
M5M)WB%.H3>O:;7:X$=2N-,\8JM*$)*=<4N+!4KEK3OPAYG4MN)'A@ALDTY2"
MD"TI%,?)"*/(2-8O%=</?$J2#5*_7'@F$B]:C3;KCLTI4PT&UA2,DG'CC[E"
M5NE7A2K$@>R%6884-,8K<#YX3X)S,#F+WCJ'"#;>+5=D;CEU034\KV08ZNX>
MV,5<3!VB"$^V,^YG&>HEOKK_ +_X^:_=M1TW_6CN],>KW-5);5503G0BD-NT
M-=2LFT(38$N:T5RV;DTXQ+E#<O6^Y=VL45!1(RV?LAM;+::*9+15JRNM<=UU
M<P<HM21LME-!AV<8F%!U8HI:,*II@FF64*6*YT417K,*M<.(<4+R#NK=NA2G
M:(O4X<UK5F:9)2,DI';!\&3LJZ!]D;J*[G&D D)>VNK;IC'2/K[GCD?6BI'V
MQZH&Z.FG[?R.CT*-:HFK]NM<2/BC"G7";M6:V\5#+TY]48K=6I:NU1K%Z+><
M,/ZK'**:F@H,U9"!3N'FI!\P@QQ^P=S<U*?6>]Q^G+]2825D8VB$VWJ2T!T0
MK!2O)!JZW8AT@'DA- LI\E86H7N6VD85Z7\H?JH -DV@#:YJ -_I@8 #^<-!
M1\YA-G=%.FK>KJZD]TT 3B?3!!3Z0K=Y^XJXA!V!F%J& '&#514D8X$6[OC<
M8\_DPC(F#@>4,ZQLNS&"$\$<80%E-=E65>,"]#PHML4MMW"G5" 95ZM&S@;S
MN!&T-G@<(HZIQ 2A3N*D5SIQIE"4M-I"$JKAC2Y1M.T0=U(4DE#M.-:0:CW!
M.V*]4"N%82*TY4)\$X#4\.!'6#C#9-IY:<1;N,;OLCRPYM#<8SW]S*TUC!(&
M,<D8#NXDQ^CRW[Q?]_\ 'S7[MJ-SKWIL[O2'NB<4A(^5W+76%^^2[HN:5]J5
M?"32-=)+Z/OJ*_!/*\\3NN YNK4#3XT."ZF2H(IGGNAVUP%+90K%+H3@2 <O
M)"=6KBC"!<*6^BD)H,@=T=(0X$IUJ0M!.+@UHR&^TBL=-7K[GCD>ON8=L3#*
M?EBOF&,.ZQ5PR!^WV=V8:EA:5EQTT&%,!UXPZV]JZ4<:-R% BH(]RSWNJ3::
MUAK=KGUN5<=(.Y20!3=!Y2B;1UPE/:<3Z>Y_6TKN]%/J'=""*\Y"2?/2L)2D
M:N5.RD)S4]P%?/7W'Z<OU)A.)R5O[/+$O+NLJ)2HK*PYM8;)"OLS@ZUD(6&;
MSM&WD@DY\,=T7,S"GK@VD^#0D\I2>N"HILO54UJ:9]O<SBGNM_9C HG(T]<;
MC  RJL5N%/+@84M^N:G!;11'*WUX1V8PI52@%8/2QRC$5] AO5L-@!(RP&^%
M5MP5]L#7@'%IU*@@C@HH4#YJ0TTB]NU#3::M@*.X&NWNJ:PR5O*;NU=ENK4U
MBI6?5OK7A#8(":@*I<%>R$JUCA4XZL_G%.*J:#<&^3UQQW9^XQ;YAWI,"XJR
M$-^>*6PK#()W4WB&TIO2;P.8=ZDB.L^00: "B0,R>[\4?;&0Y1XGV>Y_1I;]
MXO\ O_CYK]VU'CW?JH[O2'NA@JU9/J]TJIW5Q'F,2S34T@6E:-D+KSK=Q[F4
M;XXP5!8<\& ,%'68W'=A'$]S%Z^^PC9  "D]O7#VJ_W:0GTYP\ZJ] 6 IPG9
M5E45WY]GN2L!L:Q5J+DV)Y5_ ;H=UK;UYW ME*J6*&[B/@T[B3!IV0,MYC_#
M]!CM[O _6/=X#U0EM?4XA*QZ8EV;[JDAM.U@!:<.3A#2&?@MUM]),'\U*?6>
M]Q^G+]28[(.R@IHGFVIQH1"42SMV(30IN13('%-WFBYS'G8*PPW<<\(-56W*
MWVW8VUZDT\O<Z/I[F77 &UD=WGC<>ZK:$=I3G4P4-C:-5;(%-PC*M:\3[(Z6
MU"N53$[AY.J%7)!M"MRA'*K#6>%0,^O'$1O6KUPA+K13X9&L"5)0:VJ3U@X^
M2D=\KLQ6!S*' (.8[3OC5LZVK8"0%.IH3<XMQ6)4I6[!/"&UK*UI+>IW!(Y1
M(&P/@DYPRXRRA.K:2NE2 >6KXWK@ ^XY:21Y8QW))]48*_JL*WP*JNQ/ 1O3
M10W=<<AST<1&%-W=S5<J.D?<_HTM^\7_ '_Q\U^[:C=,.?43W>/N14)%:"!2
MN ' #N?R@^X,&#"O3"\,("5)F%%-3N%]P4GKP\W<%:)#:?E&JZ?"L!IVQ+.Z
MA*2=9;LG';(Z@=FN6$*"$H%Q)WX\D==*P_+-HM&K1K+EA"4IU:+1C@BGJSA>
MLH!>OFJ7OLWVC+'//W"4_CP0RI9K>&TJN(1U*/*[(/@U+V>K >N!<>*N[OC@
MGW&X'ZQ[C*W.L+V:?%I7]J&5:NE#83K*[L2;?1%P1S;Z74ZZ8=SR1XJ4^L][
M@8=_+]282;Z\JN%/BPC6)RM)H,<*U'#.&J/+J&J&Y+HXC*E",3C&RLJ 54W$
M8C#KMWTC?CZ>YO7W'$-)'.5CZH)5-;2E7<VP;2CN%WJ@XU/=V0<U;X-VK3F<
M]\<23YXF%H?2E2JNH2E"U 5LOKL]0H<>=!/9#EJA6AIL]A[=T$8K*!QPP\T
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M.H;6RX47MJ-5-.CGMDBI'_\ P\__Q  N$ $  @(" 0,$ @,! 0$  P$!$2$
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M@D01(!2A+25"-KHCT_\ =8\^+%@Q84J5.@@0("O,HI9$JR?U!2>C#'H_^+K
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M\\3Y7OQWDXK)9[,(&K<3=K]0(=8ZZ,3;+7)W7\>N1:ZU'@>$9@SR$@5?\-X
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M@!42*C.R(8*[SO%K[I<Y+W:'*)-C[/G+7=+A"'&_9R]$0IHX.3$-^L9&YV^
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M.!B$8)9/;_G)*H"&2F)_4X[=PH!!MTUQ..';&-VX,O[!ZC0H.&)T9-0V/FV
M8-\.*@^X61&2N[^<T&PP8T[#76)B_)?(+$I/Y>'$U,:CALF)"T#VR^A"PDTH
M3.;CG6K_ #.,&1F*SC/,3$Y2I<<\9'7CF(PRACB3EH HAO!FL[-@G K)5=L1
M]I>!"S.6'F.F"I U# (.SAWDU=0(A#V<_?'VHL1Q@?*.<%/5RF:+D3$A.5$
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MT7AYQU&5K ?/>KIE4/5CYEY;<?'W[STN7P)D?^4X/ARY%EW]F;<J]W8W'L&
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MG]<885NOP>23P>-U_!@"TAR%EB$$ZQPGE(DZMK-^,O\ \+U>&"Q%!DC((NC
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M?P]D);FLB[NM^@U_\7!RLH:Q10^41@\^KS"_S]!Q@F8'>*!^F=Y#WS6'_/7
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M"3.>D2B+1HF'?G&:H*-K!CUWAN-2WAYLY;!9PV@"_2&O1>+FR1+H\*-BZ S
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M$MZM#512U/:L+16BDRV"NW#D8)>9$KO^JZFAU%)1SN6G0%<*J.=PB/YBO_\
M@U/7[>$]3J^LYM)L08A#;FC ,*NC16X1"4J,&7 7"_5)7=UDU9B*@C$$1<0W
MAO.X\8$3QZ%LPLFZ][5K9;08Q7TP,!.'F$3IQ&MS(TVX(44!6$'8AI:@4]PR
M9'U":>A*I@5Q;8:2)!PJ-8B,D5WI1SM%&*Q:_7);FYD3HK Z"5%5T^@]*$9"
M&!)G89O8%C3&,&N_?)BH D4 &71/2""@*PO);PR]F- &P%!9 ,Y)%,6H#1RF
MOQJL(=#+)BNS$2@PS@."0%N2\.IO28;Y: H7EV,F%)C+?H89I!T[T)!GQ6I!
M,JP;[&,<Z  Z72A".;_]D<!^B.0_YQ?^?=_%S&)2LFS!  @" - <?^$9'TC)
MNN>\I/M)@?H$)F)@&!(7('6 _P#P]$LU343R</#_ )W,@+!ANA3A$A'!X=H*
M#_\ RU)DG_\ ")/I.29)DG>2=F29)DG>29)WDF29.29.29)DG>>3)/\ !8%Z
MQ!<XEJ*A/0U@"&)*U;+PAO5.W7>L^T))9.K8I":\*_K'D=Q!RZ.^+"0F%IV<
M_:<089SSG-:>W!\BGO.I/Z::=0Q6$RM1&)$_MDE+@R.N6]<1BC!YE$Q[8>!<
M-*1N1;&0IJ39@4=MAAS$3FU7S_6:#<\AZU],W$=RM"R$C3>.?PZ "9=M9"2$
M$5"*6(3'Q]()!7@#TUF^$@Q2.CNS=)#5X@4 !8T##R%TI$G33;],Y?8GUDW^
MV/)&,+2?U;Q2'HLI;P:&6,$N,(DD6 L],85*R/J"T.BH80IHC/82/N9>\XD!
M/!8[XQ_WV(%@1XC,!&"XWUC%0/C9:@+MQ<QIWE;9CFV)QD&<HJ <@'QDPC+(
M656@3DE6LQ?%C$8OY#KH"<4RM$T/2EBL*B2?JC"Y! 4FA*/LSG[T'L%?G'@V
M3_ \>K\)B2.%-*0< !8!'L;'_P"LZP(JZSC%2BV,$!M EFJ((MB,CD@TZ"J4
M>^ E(SWH> A-9KGU/I69%KB2ED3XU6%$B!C22.$S6<^,<*&!&R0'GI( 5@"L
M5J1>VBL3C!:$)>*"<C@Q+D+#.A>I0TYI1<_11(3HE<,J;JL)M&&'!$B>EQI=
MK0W>/1O-&NI#%[AR-IGQR,XKWY:_.(GDRG73MC;),3";="3(3<5RCF,**!UU
M)2 J)()RS6D@$*XR*X(SO-!S+8,USK.?K]\_&4I.+WSF]\1A!Z]GG/D7XSIM
M;&71$U\N(K6H!ETI.T9"!!+SW) ]CF_"@;[7\'GEGVF*];,@</5*HF-Z)7+#
M=[0'"()5,@1Q;Y5-W+6.2!6),D:LFF1E$@F^5YWB'&B&,DVX,<%ZD59IIH'<
M9.IE;FAIGGD/3+ 5B5RDD("O7."P"E]-8W@N:]\Y0N2YJ64]'1@,"?8#6V1I
MH8PWJ*U-CFN9&"S+6'9_TXB\!650D1 TA";NIR&@H\R([I[=/>-+C=]>WOQA
M8;V@0!O3K!XQ>J-]DO2C+;=</1+0[K5PQBV[$P%%,SL5A"12U4EA1B+<5ZU9
MS!$S46S1CFE]-50<"PX.*"B-W0-MUAP/9>PQTT0$C+60^BLF5)UE2[\X^**L
M"3T4CJL0EE6A(RF9A)ZA'..K,S $1ZO5WB/1%H^2,6G3'QRV-POP62E6&09N
M4>N2&16)U()H5!AZL(-DI@G@*0^,I/1'W_WRL+0< S)9"X;7).4V0_HO'IF(
MD IE['9,?JNO_P!=$4[,)HZ\=5A"*DRO$L$*4JD<YOO)!X$(B=P3BA0<48 #
MYT!;D57*L%$(4T5<,VX&4G=R +,D(D)Q.-U33=B811H8S,3[4)JQ":=C49HW
M_*'M1])Q)7<9H>',JW3H(\QBU0\I,!;LCU. :IX JB@?A4Z.<B<R&_RL^9 O
M#BB0:=*9EV6 !C< 45/SP*U(X7\#:8TJQQ@8#<6-H?CG.9WJ/C!&KB^BI\3'
MKD'?AQ(6 >1,(QE2BM00FIY+)4ASI(#@" @(/G#4MG9N?,5A]?O'X<,"XHB9
M, [TY@BJ?*+/>8R2(;E'KE(M78B;':)XOVR40QS\L8[2&1RT()^%]8R$D8HL
M9F!I]?\ F',8?R<J@Z)$,=A)X<3GGC.)X :,AH^&<+9? I2@#E20T^MH)YP_
MFUTJB'(5<,9"XLHX.FL]%..G\2LRK_+F^7TD"50G<=PWEZ4PND87=RY";&(U
M1CJB)$ 709$ZX9/Q*(+O@0,(D3@=PEE&Y651]>"$D32 SA9<!P )P6K:AYZ:
M$%8M.QDLA(JFF)/IGX#8O]DX^@5\8!I6P=MG^!C=X&R;GL@E<^$28DL[92&Q
M8<D9$46L1"+N=0Y.3H*PT;(H245N\EZ@.%XR%F>48ZC"D#=RP5"_6EA! =!C
MQ&02L#,4IN1[QT&!DH'%PR:;>^'6-$PR4@'Q@*\@Q]A+@23-@NJ.%YPPRHWT
M=@1\X!CL7LL=9$QA:B&F26D=*=8$^(AM4G57!8$C4?='1\966Y'I_3CB=!^W
M!,%=Z2DLBU4<S.,@(^RB*=HP8Y&0]\G6AS_M,#_Z\@@VXB4 F9^D]8EH"DML
M2A;Y?&:F@9@N4CSY^S&(8;,"CT-/7-&W2))$Z,4#)J<\8J]3"*@11LC$>R$(
MF^08$\F&"ZP-<X %+@^,18(+- @,%0V:\9:$$D-[!\+CL3Q)&L0DA)+"1R4
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M.344-5K@=T7@\@I ("-X9T'6/K,[#9&A:0+YC-2]VK)&)WU<W"&R1;@[](N
M^&TX:0E- 8=,FN*S(O%<;Q-DP0YJBG+@GA0E\C<,2/;6"7KNAT#IA:<9Z)G]
MB&PENU:R])@REP^GEMV8_P ,*=0^ :B156\;7TV"D'33@#QCI[+$PC4_Q3C
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M'VBG*)DE4,7N"<#T,E WKW)'C#^$=<4^8O'>-+,;I8ZE#Y7A77&H\U?S""<
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MO@:4B&AM,9NJOC%!]E,(<2D\H2^+Q;':6X6(FQ)HL#CLSPC,!<2A.3CV5N_
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M"$1-1M\B<AP9D2<;P;_P_6=.;J"Q<:+1[.,Z2<$0SSJ._;XD9+UI T.+/;D
MXJMW> B-H417,2X<SWEDFE".EC2<1.:OJ"# )+O;6#X?X9 ??Y,^9OF(_G$&
M,;/>>_\ F03:J*>LGG$[+!PC?KZ8&XHL0/5RI@:.OEW]LBE5[3FQD3GCW^V+
MV8G]5XJR$9/5B#\B)W.#J<>NDQZDQ-#QDUIN.CI.')1YQC.$4_,9#W.6^7T
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M0Z/O2\W0684!RXG3* '@))"[N[GG.DV0-DDH1<4B-\%#!TA*(UQA-05VQ51
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M:(Z89BYLF_5C6=1D"/99>$+4 D?$_P 86[A7?KXQ61.#SB$@H#PH0Z:,C)M
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M_P"X[]L/=,"28+*^+*%WO"1%,+VW]F"3/' OLIG(.C\=_9E*.T?M<^%D?O\
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M90$.P0R:!>$K>!EAZMYQ7WQZ7T#F\&>(^,.O/&?&.#Q8%QGA?&+\'QG:?;/
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M6$E3--8A>C0H], D$'[<8LRL]_Z\(R==+\847( @>*Q3;?KUD68PQHE-F/\
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M2^6F7/0XB>%8&)&E,(F?DU*AA1^!D7)VVSLUB.Y'1",=!1SR%$V 0*K&R3%
M%3!'9AQ8!")M&Q*R@P/*8K9G)%W!5M\O(AZAOU'N@A4[J!LY35%X1%\<9NCL
M6'9</Q,N++B_0JSR[04,$:D"B]&6;;&1.+S^W:/>@]:09PW#.".X3&-853SS
M-950['1G#_\ @$G_ ,HZ5(Q<^+ $WC%"U'*[6*A*;82A-@3AS8A'J,1'85FL
MIF[L!F>IX.'?KB&AHU8VAOCB2AIK EL.AST#LTL!R#Y((&,X%O  (+<2/4?(
M0P1*@GB(<:(+'T1))PA&#?DBK-/T2=9<AM,P-).Z"F9.- ZH6$"N24A"<F<7
M);EX03$C C(N*'*$9$@% Y9&A5Q,F5"*/80F1=QLC3,@(?!F,9OU&#ZR=9ZC
MO,T11P]3XT%A4<)KI?E6*W:/_J&O_!RQ>+EQ0J*:F@801;2)OS/3H,2Q:EV3
ML3NS9PQB0%0957H(D&"3D?;E0%N W(ZN<(U#AF?/0RV.+LSS4R8+>(57W!CF
MFB*A+R$EIK.HS 0,9,6;>;RR4Z\PD?&,\:2,J#F;J_!.%APVS/NEUJE8.1Z5
M FW2#E@=LM64LNB-FL#C(IBFU"S2:<J5F%5+*G48S*LK)F];O)S@14YA74*<
M7./$GZ*V ) / 7<@>YN@8$J6TV<(13$[2J&XN]9'4")TU/!% T _^^G_ (E%
M=QJ2K$XCE!W\A8L4S86L,<NXNN$Y4*;8#BJMH:BWH2U@:/+ I!>5*!UX,BYP
M'+35N]LY!/?/3I&G8>O<_A"WR)F/S&$W P,YR?4*42R-J$LP+1*//K&0(P>A
M.^" 0C% @)DQ5)"6<Q@(2)24,=OJ&LB0CDQL>XBU9C!+IPPWR-XT6VA=S(B:
MDVNJ'B[SFN6;-9;J!+43/*4;J#JY$@OFI%9'!71/%,@.7"DAGN*+@1JIC@/_
M $"?_P".1D/\:J&0_P *H9#<9'ZU#_""&*M+"!ZG<=>V;/.#D$=D 7U[^H1^
MI'D_QJH?YU50,C__ #$,_23(?1.3A+AR<F<G(9.3DY.29#)R&3]$_4GZS]$Y
M/T3DY.3DY.3_ (A.3DY.3D__ +TE-ANJ C0//-8L7 : 5";IL2'TONS[.N<?
M@HL95I>:KFZ^!A F##P?]=830?KQDI!]N Z'T&)V98-X1,=Z$EY,BS?H/Q+[
M_A@4-=L'H/YQ=('F;Y$,VH5IO$_##DD)U(?4LS[1\81Y1@^X?NR.,[/N8Y:)
M^A&%F/:G I^%AGX+U..*_:LK(4Z29/H)4&.!/ZF!>KTX!9Q5GEI;ZR,7>$VH
M8]$Q77 F: >K]H!S_G\?\YC_ (#'_ 81_0P<WQ/ZRL/Z"_9>>HP&IZ)9R ]<
M#^DRA14U9]K[L+AR0+[-4^'/^(Q_R&#'"(M>XU5<P?&/UAY^_P#B 5LQF[:=
MWNRH<,3#TJAZR >.86NG ZHP'-9,.DE=+_&?!&&?'VRF1&:"?3($JR]#QZ8L
M2^Z)Z9ZK=-^?Q@_J G3^7*8,T3Q]LG2A+8Q\5ED'SM5UBYTIF?W[G*19^4@1
M[9RG S8>V_QEK'F0A[9.W F2E'MCA/'6K$$4AN G'ID0L:TI^'*69$1?"_OS
MDDI[$<I$>6')"8<H/#!:,_XW \6V('^1URXVNL*2!L\B^EP1**S9GVRRG]OH
MQ?9==::B.XIR4G:WMA=1.".%37YCA3]OXR;7[_3/W_\ 7T^0?N^,&)5ZBPJV
M8@9A!X3Z9^H_K#[C<<#W5H!VH-N57ZA^,P7!([GQZ986+Q_KD1[U+^,;:\LP
MO_\ ??32LEV#_B:C>-JO+.%9%/>2<"C(V",EF# O#)_VR[7VP2Y0&FIP"2&X
M$>\G&;Q$G==]>^=258%>4<AV,!NZ_P!#B34G.WPW@\_9_H6,9#T@CY'JS&D1
MX(^@@>I@SQI[K^.R&ONH3?K@2.R4?Q6"4!W0^[^<LV\4S4HXH /7%A'$L,?;
M$TL=F+9#9CR2?[_G_!ARN0[SU9YQ&.STUMX27%"XZPZG+'29;W$(@%H6N,D<
MJA1$TMQWA!:\L"^6L/HQKK[W^'#*:=]48VM4%<D?GSG!Z*37C+.,-&O..E$F
MCO\ T9&*.,.MY;D0L?QG((E")\3O*$+C "L6X!_3!=C['XP3=ZF/6-9('57#
MR<8ZXVDWE*90@W\_G(^?[><AR7GC[A/SCHQ)TB'LYR4**O$H_C"4IW$8PYB9
M_3*P-J8F)7S_ !D3S<N_??C(H=,KA4D>0DD83Q[\89Z$+^Y=[<,&0ID-#FD!
MIP8!$0DRBC*M,A2#'F1K8$LF;:T,K55]B0.;J,NY^I%;C;)57&6(O1D [;!>
MJ<K6 1J!-V*C!EAEPD.DI]LOLP.LUK"#E(-WWR068K#KM[R:!PW-K<E>,!1U
ME27#]\9PT<DZSZL?&L ;0A7+O!34\Q^<$Z^/ 4W)4+]"CAP__?7F5@2546KJ
MO.3$MK.UC)U2ROIYK^W_ !LLR-/H24[^F3QAU8:O,^N-(.%P$P/8,!-TKO<!
M^?G!%."Y+]_.5!*)(B?KD(9VA;BU'PP3*DG$Y- OJ3^<=*2]L?;63K-X&;$$
M>8US5XB>;,H<:WPR+35 SEO?M@J^W$7^[6?WR5WO[@P+<\_N?G/,%P/C'X6N
ML29E&"*8\"/OD<C]'K^B_P!0"0/)EXRP7Z!':Q'S&3Z?-/U?5A%,J:>ZM1.'
MH)FD/IX2<$QS++JC9.V*R)Z2HJ)@@(;WFWID4>\ONP0YCC9ZG^(>ES$7G*N"
M0[??"J4BE(9G\8U& 0BFYKSE$54.L<BD!?'AZY+=DO<57GQD&0RD0?WHR =3
MQ%ZW.-^C*MCT766I^B#\(^^L 6<%1R"P2CENL=^LD4'24=\YY&"K/<-^_3(>
M_P ]F-%^/H9<8D,9=X=9-^'87*$4OZ8U+J'8YG%5(BS//^\EJ#"U5[7NLFV:
M%VM]^'-(>%E5P<3@2*>'<Q/1Q4QC;-M_8F-<N&\@<@'0NJL,EWWJB.GT).(\
M$F[%%)MMPE<2 PT!P#SDB5.?@L&MS)R[P1)@WJ@#A.LCG+.L2S@;3=9*P9%!
M/(/#6$E@OG222HG\'/-/C'R7V,GHBPF ^AC,"3@_GQ"2O7\N\959$(4(AXX9
M>KDTAX#CUPY/@";R'J&#AD*"/VCG(YKU;?\ 8^V62"R* )7@HRQ3NHNO:\;E
MGB14C\X;_P#WW_;Y<'59QG>GJ;&9C+Z>>OLPS5D.:\KS5@RS6 8B7F@TO7*H
MML]''D8C"*B,-RQ!W/9./VAD:/F+7C)]-X/\+Z)Q$4M0[I$?<P%11SPM>*IX
MQ)UCRK[9&:[PST+ DN3[.3#L^3^^<TT$<0QZP^67.8E;S^7/IDJ&2+(GI8]K
M';#JM]QR)J4!^P(8"GD*SUS[.(3Q,\\SUYR<,PU#[1<YWQ(*'^L8XG9_+'8]
M8'[9Y88B989/XC-E>!V5E)),L^,A7!H-9Z\<'T?TG "%-C<F3IFX[,VOXK&:
M![&#)3HF/?(?(M<N'\?X)19H8QIE0 \XI)$WJ?Q@7IK9J<FHAM!/P9/"9:2G
M_K) ZKZB"9OSE&AXJ9^A6F$@Z555APQ([X-G)_;><46=[ G^DSC)GZ-7]BW]
M8W,^9DW+EC^.77"/]>^2D>?TQ_/C$9$6T_'VXQ-/RI<3[ Q\IWGPVO-5LXMJ
M2Z!VT]<\*YJF!$RA<?LQ;@R04;F+835YQV@1)Y*O14:VS1W "!&FW?6\D$]@
M%JH$?XR8K^=MXE#(+#B2S2:Z,G";RD 8/0T^Z\&)3:*4;#9XC"/$UB:MH8[;
M8C_O_6?M?]8E"SW/XQTBZS3TS[(P\+F"%_3>4-+L . Q\-VF@_MB@D_K"T?\
M,D#>Y);7ST&C(AM*(OP*R",)I^,\N?@Q"Q$A>H^9JV$X*"/+S_>"WP?_  )>
M3W_;IG#CY2TX.S,)<_20>+XQ=GTXL\F'DF1%Z3\8$:'V/623*-8.AF)%;1OY
M#G-XW+?!1@NR@ZO+AN$^<A\S V?J?0)*[C61BM6N*OOXQ8,#"M+BED-X:ZRY
M361E#641X?M9L.D??%>(D$=,*3I(HGFLG:*S P,,H/-@B7M2/%Y%QE;*<.@!
M_FT?LQ.PQ#ZK]QUA--B:#[)YP!F.EM^_W#)Y,$LOPK&ESH]'"0'D2_C$D"O.
M2[SI>2\XU&WO?%C]*RXP2N4&4[8/.2R62[P6&(SY+]G)9O+T].\:*D 2/UG_
M  >R"?R8DE2!&))OTQ,(A/\ 1)EJ)"('I!SBP9!@21S_ ->V5,"$R+6VK+Q"
M)6J]/.110)]LW\*2,NX:(]T93):PP(DGAC"-OF))9X36&LBL$>K^V;!HWRPN
M!4'*20I^^,2:*>>X:$]N:X.T>LC/5@ZQC:V">7GQDW/;6KF04GKWR$HP&PFK
M:1M(,WA)F]C6CX[YR]G%1:""6SX&'L9D(J;_ ,B1EU1R<%$%4=8K!R#LX M"
M32^.,&L18M$!N2<<%70""2:N[%1&!,K^2_T>?.2UD=L8MP*ZT5CQ!W_K&@C)
MR#K"%&=$NREH(B'9C*5 H%B"V]P)*7@OL'\F#^N_JR' R6_?]?D,E-#Y'R3C
M8R=J7]$&0(B7U$A??#SDW'8_TL[_ (G"R*^PR U6F%96L@8$FX OKC:K[*RX
M_P#@BE[0[R-P)UEH9')+;W]/59]+O'_@BJT1SQ%KQ DI&G:#;>\=L!7%4]!C
MT&=3# O?'Q"3\$Y [-Z5X8'%;TR.7;V(H[*D+K#P":Q1K(1X?NSQH'WX,@ZQ
M88\*H"!9@@\N3H)U!#LM5&)NLCU(2PP'7#E!>;P>#A3O 8]*FQJ$>"&YH(B-
M%.N*E#17NEQP1"32C1+5^N+:(O6-\'T*'JFF45B(0: 4^K^61R=Z+;MSX6#$
MR:+[Q.^F'Z6*JQNIR6MM(DQC+@S5GVQYM[.0'0R\K$,$"J!SJ;R93.&0%6&4
M3$.2?28F<";H6]O^##*%D&,,- /N^(,L^']I)?9P@*"!8"O1A]'*<SN8PMU0
M;HAYEPSY,D7H=)2.5LQC[MDNF#+V5U(T%3EAK*XY]G8U& /%P)OH??[?17#%
M^SDQQ(>MYT$/5O*TGL4]>F1#KBAS#OK@/5, 3K;\8,!HS"')>O&;:(D $E>S
M&J[SF"?D1R57N>,'>E)M&/Y@PT@1<YS$2^KM47!%=4; @R>U.[+-(K-V(DY_
M&\K@ER1+!?G<X[6A74IY03ECPS=56CGQ&&J3#!.UH?2,&I\SH5L+OSC;'F,^
M^:'6.H<1#_&<K/\ !0$Z9:R?\*9\D&0%..SXRF$DM&R"72Z'G(AZ-2/B]QP4
MCOCX1A40.G[P%^^1!5?10Y^YFN?F(_G!FA['X7$C*'"5]"<X73/@T*[3@V8?
M9'WX?_O]5]6^YQ1P&\1P/.[E+])O$?Q]%N8,I]) _?Q@<HDC^8RF$4*6! ZQ
M8J-P2DRJ.<3G!V21_P!P-K+WC<X+B).=X*IDPT!-@=S%LB]#6A;&WS!\Y=Q$
M80]S(0?U6']KGA$L PA(SFPVH] L9+$#VIM@J86,+Q106Y_@NO(>Y,CJ37VF
M1&K%GYQ+')P+ULR$\GZ(JGTAGB'R)ES4!N8;#.U8::BKU\0A'VP[ST0>KH[7
MDQ@U0B7:07@#!7 [9/7*<A?\[+S!UWSBK<6)F_Y>V:J1RP?C)&OA#C$"8X.,
M&_\ 8P"OS52'D(U2'G/$_DSU7]G_  Y3$8IB@S(H+LIOEO"5L=H".ZT8K$DB
MK8C"24] A*>KUB(DPU>_ HBO]AVQ-1Y5Y$T I$.Y[,C!Q2'$Q/M?ME^(:LSR
M",GIT/4/WQ'9]/@E>Y,TP9KHTZQ?=Y&6:H$MC+D]H\Y!.\_IGV^#HQ*FUOWY
MSAPB_<SCD5QJD\B=X+64RIF=I$"O483ZLL*WTK0E;A7?HRU\6-DFJPZ[XRET
M\)+$7;E+1BV"(-0B41PSQ$SS=6I_Y5DV#34_%H*G%[5-+CEH ]P&0ZV0'AR
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M16M [K)AF+9BI#?1$Y2*BL<A*_D\8^)Q5*$]IL0ABQ4=V22^IK#H:P.X,U3
MX0](&LW< O#@P"JXW(*E;H,M@BY[B837)C1-44EGZ,4,+WN$B49.OZ [P"^*
MY#"N(K7:,TLAM0-U%XUV"%HN0D#,P1ZY(2V3+"NM;S:>5L!\L5PVLQ.&H539
M@&@%G;48&-*0*!-]0202Y/4B8<R%O =8LPD?!H*+$TB2\9%@/XI4C2L>,$*6
MJ?-MH6^N,5@KY]_<D7O(E:R3A084X *;5+N#&+3PBAJ1,3;A:8E5[O%0=+D&
M'#F3B'[N(QO:K6_ =LC4$;QPF,\K[RF4^&,B JO+8\F(U;FA.\E:G-="1MIU
M/OQCK99O;@PRY_\ @$)GO:/I_L_7LQDM2IXN>,<KA$W<'H&^?QC'23M$_E_O
M!*]W"/[Q!BST6Y:D4()/9.(&H!R<P<#)CADP G 3)SNKQCL3(ODU[3(Z&-G5
M<S?WQK=K4=B82@5H&36+ ["CVK7G!DU*&B>JCC,CC-X"\4K,H*+DB'H#6GF^
M_.0/Z8:.V^''^YSC^F/T_3&1&XQ[9!@B 5)XZMLP6QFI@3=PTX7U)YY?X PY
M])R .0_#.7/U@TU0=]]0\Y&C(;!/5WT?!BX;:Y9"?V7EW$1&00,_P#DO5-:2
MZ8FE/6;VC1;$=R[9(N\('(?$E,ZD ]\I4M+L7\Y>_P ,IA'DBZ7&KWB,+].K
M%AEWA&APX<CME2I(4NLAY!#QC8N0=X9DQ +R;42G B)9G)XRN>F9\_W_ (I6
M6@"0$G; M(P;)^TP.=]H623"=2UA(B%YA !<B8Q--/!_@,R!+@]L59W0\F!'
MGQ,V!"0M!X,8<5DH Z)P>07HR/,L6L.5H;3BRPHZ0APJDS^,ON7;:N\Q ?+(
M-@CB7]40@<8CBJA*-5%=&$D/ #&G,EY<,\YY@ZB4"!ZQ^QUTB#T07SIFUD]6
MJ&TKHNKF]X^ 9%58IF@\J3$:*%&HN3&2*XDRP(S,=8QRKB(U9" 0TD#'?E#O
M50734^AB4VNECX(](=V& B!:U#CD8@6!<8!":.V\J 4'-9'4B&!,24V<-QDB
M8K@K/A/47AL5'IDL/!ZG'OD[4&%12]@]UK.3$1&^4><T3T"B.'SA6AI/KG%#
MC+B4;B9](_8SE>-"B6%T1;D1:!HL+>ZEZV,Z%\]?G*6^WV,2W; [9!1G-IPQ
M',J&\!LMF_:_/XQ_2HT_Z9,5@G)NDQOZ_P#WSD0&R;[7UG!I-7*XP9YL"3SB
MM/"?7![5YG.&?2"&@2*$/3D<8D:S6>^<DKN(QD'DESRW:'"XZR#>.U1H$>R[
M?([]GM,.F 'LY#9YVQ&&9EZC7&<-G#:> $_*PR#1U0('!2OH,I Z!\ (VVV(
MI@6M]&*A""!C5'63^BLEV97;DT?&2'ZIAH[S6?S^U?Q](!V C=G61$Q;USUI
M<7D"A3O+?A@=Y'0J8UA%%OR/\8,3YKZ7;)''*Y@Q'5,6;QSP<DG""$\N01,+
MQLM\+^FFGOB[H^8IN39'$8DW$/0.?9C%$8]B#JD;P0;9,1) P0320KVK)0:\
M?FC+3Y$C)!@2P<]95A<NZ-DF.0C6)$^*BY4XBI7#JP9DO?$4>A6+JT]_]#"H
MXEO5CSN!\1)_/^# 6@8QE<0(<@>3 36>O<_+>2S.*290@%(+2E=P9.90@;72
MDF7XK#)&K!S!<DFY53D7L,R($*R:<J9W>@VA"NB9Q9R23L<HBU&4DHYQI*J9
MB3-=><CEMTEX*&.Y8R573E&DC%ZS3XO$9"DA@8G"Q$3$7X;YK%N64%3"5QHQ
M<0*LW ;R^=;A @<-KH<IN)&O2&/*=8]4X*$)O".5FW.'2!^,I :&^L+ZR!:X
MCEBK0H88#.M X3A ?(9/:L$OQ40TG)>/&[G<3%)1P[<K=-!1%>)1:RU95[L
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MADFXDA?2BXWFYA!37T,N31!1#I.?ME(3(34<NN,:4Z20TQNWH[PIC?9D_@Q
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MKSD8B7B0341>(\38YSD*'$^:O#>#ICB'6C,4XD\D$'3O)&;BD]I3:XG;K!!
M-+X,T2FI$L$;K90$_P"0;PQN;M6JZ5[R2NK4B/WRH .OF,<*-R#WFWN,H),H
M&H/P?(X-* K811<!8R;G+V!;/,CI1,3AX3/MWD3U\9' 8!/$)P["USWA/2N\
MG36:M@&6RST1DC2+]?)B-6V\_P"0,3$*7*S$-*9+@ =/JT7[OH8'TY8Y_P#@
M80#-B>N0&/7Z#'KB/QA"RW$PTZ!8XFUN0?EZ8D,(R@9II$5<*.,0I(_R/DQ:
ML(5GE&?N9$V)H-D7X:^LJ9V:]W$(,%!<XU\>N._H$V&4:#)=42@4J85VGSDR
M0>$OYF\F],F0'I.*54@%XM&RM:G"RK6'PD8"EXBT=9$Y&,\0S5PYKR1"H_(P
M>:,,FGBC9^*CGC&'A L((U>]9JRCM/J.QTXC@NOK@^OT&"Y\&,53S'50^,['
M?))SAD],=9X>B>")L$^G^!<;+G",PT-M. =6F@<S\>^'4!*X+JI=11FP(@&5
M7% %L/7)<0$0'@E'C*SA,PNGE>+BME/,LX[W QK((ADD%2 ]AD%!22'4WIWP
MZR#-I/G!PWMQIU@.-&O=QN.8]LD*]-)P$U/JG%%W(,#>U>2/&7Z'%L_U\Y"9
M4??NZ"?M@9>96W0?3'E(H6)0Y6G?(XG(<=B!5H7:!XWDW9P $<OT0&(629(C
M$@$@!J(TQ^I&TJX$0.:QNC%>ASB7OKJ*"+@-TSAQP%!1%I;"Q]LL+04C":\I
MVY3#PUAEQA #]&&+-1[?P,3)\QX'AR3'1?T7D0]!_C-,F+R6>6&/5^@?4:_^
M ^."S=-.>H!_.!ACC8]&F"IU@9X%C.#2^S!;QO6";6;E92E@A?;SEXF=@2!4
M(\PF\&$OU_8RPLVQC; +A;D.>PJ,S&BP1MYQ6&V^S@ 0["8<4YF1/,_]Q'\(
M^E _.+8?4G\XUC[\W2 [._7&O QQ-0<%P]02,B4#[CP-^F".*< ?C( N\1C_
M ,&2*K[/.>H%N&)/IMV^V*]OXQ8]&6[_ /?HRN<K_6/*L5FEEF_>L\D[4)&X
MB;H<D"46&[ ;$1Q;A&2LT*3@FD>CBS.O%9II>AGS ZX),5KO8GLY.I-L/+VU
M98LZ?03#6" !/^1T0\$?XK7 K[<UG.J#X\QO^LC&^L6C#;+<@^02N.+D0Y I
ME*G,ID0VO_(K#=Z>N<I8P7$#QAJ)$TC>!(L;DL_.?>93D&C(-W1B*S8^[3 @
MD#2-"A+#0.,*C=CE!/K4O8P=&\>>$/&2@].1TX/0$1Y[PV-A-P+4@EB]8Y6S
MX,JZCX/&LX(&-$>4Q4-'BF>96KFO3&&LK5.:O)=(")="*]A8)ZR/BO#:B9,:
M-@9,$+)*^J[P7O##5SB_.,1]IJ6*9G N;?A%<]85Q].H6A -LDS=!GD+"/S-
M>N2LPX'Z^\JN<4.F0(^ON6=YK% EU@H-:Z>V-M[U]#ZS_P#!;E/WX_W/J+YO
MBPL>,=\G_P!'AYSMU4N0?@*GU9NBZ404!8 6.1B+:$(_5CX=9(NQEA^(8!%*
M&0NT460 -<N7EVK[M(VXF<L;+M7:NU^C2@=D?.$J[=XKK$Q =%7VPD_43OBO
MD\^SH^V$FO 'W?VSI$'N]WG'9\FXS2=KE0=/.>QCA^N/XQK4T/\ &<0/,9H)
M7QB\F>LTQ].<L/VN%H]&*2U>,$L^B8<MWDV4;S2,XHB-5K'()X,M^<3_ '&/
M*9>'*[1Q@^P1]_7 X1E(LXFZRA)-LT#I\#HO"$_S6\J]$73;9Z!.F1C$"ZY[
MFX@9&S5B)4%0C0'@QX7M/CC)&)]WQDE/XQ'_ )B,Y>73)PYP2Z1[/9AYB9V=
M_2L'9@WF*[:.+(]B,D:C#A7ERZS_ %G)]L.8C:E"<#6?)Q:PH]\<E)7#R8-1
MF4PD5L6F^LI!,"YI:4C\F;TC'J87:<AE:$HX0GBZ"=\XI:!0@/4B>.\MF7VW
MX><P'GS^8A_(R2?U/WC4$LA#$J>5.-NFAF$UT5Q7G>2.X(Q9JT[>^.,G52;
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M?Q@**&D>3VR5![B!P.@O6722JG>[?5]7S[]9_C+UW,O?\85)D2$;8([S]?\
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MGB_J1"8C!(J"9H+VMQKWS.H4/T#5- @*C*L3RH%*")CUWG7_ /P[_\0 /Q$
M @$# @,& P8& 0,#!0   0(#  01$B$%$S$0%"(R05$&,V$5(",T0$(D,$-2
M4W&1-6!B!U"!)6-PDJ'_V@ ( 0(! 0P"_P"Q-!KJ<5H-<M_:M#5I/9ZXR*T-
M]*T-6AJ:YC5M.'8C<9[-0[ C-THQLO6LT;F,;'6*[U%[FA<1GUKF"C.GUI9
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M$,BI(Q!TBU@TIE :E&F1E'3LC9E;#Q.M"1.FH9_^:_::%>E #UK%!CZTQRM
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M:RAX]2+Q-HY[D.K:V^"897XM9Q?T^(;6DAH2' J]_-3]O6*.G T]*T+I^EN
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M='B!XCQ%""PC5XX]0==1^$WE%T\;-(8?^:G^<_:ADCCEC&#6&_NQ6!Z[U_H
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M0^E#ZD4?UDGFDK@T(:Q96&TTBPR:8XZC@N)=]PHA"V3QLU2WD$:Q0$ZRW$_
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M/I7-^E%L]164'1!4S2,N(R$JWAGMTCC2?P<WVJ7O<GEF2(-P]V.HSMG[//\
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M<40SC3_U_?1#_P"HGMJA]45=V+O4?-A[9V3(0M7SS'HODUVQ:*]4'&NWR4*
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M.1HLFV>J.P =\K:\SH^-R^-WL_&[33N0.D_3 (%!ER479PILIDN)0^U)7!#
M5T-POMO1VK=9M"_ %M8 /]R7G-C[S.L.4(3W5,;8%3&&:B>5:\*'L1<6C>0U
MCZ;:/;@BUC_RO:'-G90A.%X335AIO.GJLA[=9T-K$RJTX DS_241(WC:%$\C
M@>&]%S&\WN#6SLDD*T:QS>%H&EDG 3?:*_6,8II+3NAK'5W1:-KMHO<'?I(=
MP,_,G1Z51_;V<%,:'8?,5[Q"F\O@^Q,Z#'<@CHB% ']*.G_^?]/C\R01VHVE
MH_\ [O2WFC9_M7<P#C>F[:-;]T6LW^-27"<'&=@#B"?ZK9QC8";8TW#.2B^^
M[*3_ "#EU1/R=G5VD"*0;-MGR:VQ;_X0?S.W06W'#[3(LQ'W?]FTDMSW0!:3
M>RQ;:LIRMG=ROBU=OM 6N!W"6C5%"NCLK.-K;(!O:1-<BXPKS7#==?8/CA-@
M-^L[=%FQC -O1L:P._%#9&PF<0(O%PW7FV33Q$60[216""UC!N@ZQ_$Z+-L_
M9;'_ "V#!FWL\=G67_7L_P#4ON/:[P/L#&2 ONVC3X%<5M*W$%':MR&*X^SN
M(6^BW'_<6**:+Q-[8FP;UG8.>T@X&0H)NVNH^GW2OQ+BMI="^ZZ?8Z8$?B+W
MAQ[(JKS=F%5<)]*: X?I4)EH9WF!4HX  5/BB[/*JNB>S-%KGD/^N&U#1QR4
M_P RG5=D%3P5IB!GEY*TI#L:Y(M!1H4RS$!N$C-&RU-IO#/?"#073B"9B5 Y
MJGO^GR@[%%;.Q-&6<>:?=B>L6AP,<\#N36X@"8&W-,K9MO%MZM7$87>(0R:9
MD[!S3=O77V03X4'>IQ-?0>*!TE[OU%0#(B.8\Y1LGBU&R'4Y0KG^2=#ID>JA
M.=.4]ZLG!T&[7O4F_AK"EW-$0&T5I@W8#ER44XIT4Y)FU-,]B B0MZ#[SMX3
M& 6@/5=^RO,+KOUKO/XJFBJ.C?\ 393G=RB 4['N5P"=X5FW6B;P/A"@@DS>
M(*^.[9IK/"J$.:74Z2OU5>]-+B2'@7A!)@TP3+,TI@0ZM=FU'5;O+C'Q4<4Q
MH![<?B5=\E.WW(C13OA$98:.&GGHC8?71M7/U7/U7[+"4]LD0%:7NM]V[LX_
M3-N.C?H.2NQI T7J]Z+@VE19F8GQA3I+'_R[02W%TAI+2#VCDGL(;.9U\#SP
MS3186CFQ+FNM'D-U=EYH&Z\VM:0&N:#0%C@T\%=\M &S1 IM.2MK(6H K$@1
M[T#=+VB@(%X]QA3U7,J= V:-^C]E.F3HZ,$[.Q#I?\/F" >W0,; ?*&FTX7-
MNY;UST4D"R>X##ZP8=NU9GH7W1O<[HX WRHZUC9NMJ'[C1)\D[JO+2QW-AJ/
MFH5I:VVNZ\;2MHYU'%UW/[*P,*]SP7#S6[@/;F16?'R4Z0;5N7_$=E<>>Q"]
MG&!^,4/DK;(%D.NDO(;+7&L$2V(@K6(+NL1?Q=O.>]1Y#UT-9B/'!<-BN)EF
M )R5XNF*R8GC@K,85FO'*FGAXK@AH&2^T&B>V-$Z+N1R46G^/L%--8SVJ$XU
M#'AAYR?!-#;EYP=J[ 1H>X:]T7I)VX[%=;'F@>W]D?',(V)JZ "2RS(@FS/V
M(QQ5;K+1FL9,EKG/)C<6T.Y$68#_ )/:@'6=UAE420,:&81LR^];QTNLZ1+=
MD8'-0M^D6<NDQ26]Z(Q%=A]D/<ZXYN&L>K&WP4\_8&)*X4[4<QNT.'5)U<MI
M"RF:_P!T*)CHQAMF%F=(M+3.O^T!PX=H5ZV$AUV-?+EX)]F#<<X-=9AIKK.(
M!-ZH5F',M&VAO20Z#F0=QX(32# _EL$[/J0B?-%O;U47"3P<\]]YK?RHM:@/
M%1/-&[7AI=18]51DI3(F;1K3RDU0QY:*Z+HPY*;3_'V3P6SV!4<1@K7Y&?E3
MK0N=#0'VC"+K0:39D&2 **U=:LN-DL_ENNDC").U727#F/4*6V;7RP?SK@@$
MNLC#<9E]S:G-;+FN9<=A!LRS5I]:Y=)V$T6JX],ZT:,"\_RP;VO=E@C4BN*_
MA+%NI-W5;E-8PQT72 :)XT9D8D*/=M]ECG"6AA%T.-S%WV8RQ1K&K/:*:(R=
M";SKLW\E,78@FH4U+G-KXILGM6(3<T&VGZ4]C6D;&Q[DRTC2VT.7U7/4!S 6
MBZ7VN,9:I;WIK60VZ!3H9N\SN3VDN ;7ZN=,$7=:$P-/%8*8[$T)]Q!SHSS1
M=3LE"._13>KN*C0[&X8.:.,X\S-=%53R0:*WO<IM/+V'ON:N6]$C4OB/#VK;
MY"[Y$)LS:'7M[2VRG5UXCR3OEGRE]G9.LW BQM'!S*4CWH,M^E_@;.V?9N?_
M "W#I.B>+G5ZS@157.G8ZS-M\L-IBZ/Y;J/F,Z&D(65D2UX(??N-D/SQZPQR
M5L&%WRPMM+1S7BA:&DW6WP[NPP0^365YHH Z!@,JH :&&'?'/Y@&75S[$-B<
M-F!3!0Y$?NKQ!BMH"*]3,;T']5QNG?J<$S$[)3ZZ+PF<(S*NS3[P\DVZT .
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M#8KJ^:<ZO%"BE=-_BW1T'_D?I:# =U:BZ<]A5JYEFX-:&]9S0*F:3&:'9Q3
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MKVIL3O-E>]&UCC8&2IKJYD:)C(RU>;+G$NYNM!:H/Q)3D2(G)""O?V%'^">
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M=S;FR;*Y^&M!&THSX0*&QFVMFKJ98]1ORY(,6HQB;C<P;554<#%>%;[XK5W
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MP0OH-+O!')S2T]A_P0F/-6RTM0PTV3BMK(<W[R&QM-&6J:\$/6&/"$,<O'Y
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M6/+P8VW@"#L[PF%HN6ANMUW0*Y1P7_5$QRN+_J'-_I*VGI3R?P!6MD]_5@R
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MXISH=-W&[MCFCU0IN+H4(.6'DYH[<%M;^^G;\R996=! ;-P8TE-;+.(0AHV
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M&,4W$M029>@UR;Q*FI\P8[#@J5#1*A@SRBMJT\3+6&@P9=4.9/+1.@Q^!=2
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M@15%=FEJPOZ>\$WX:$C-V\VPZI)<SJ&<:($, &0 !/2,2]!3&9(6HLQA,A
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M!M78OG2Y@D&HYT[;4)LD[9DU,N5BJ P%6R=JMM13A5&J4QE"Q*=,F(7<MDO
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M<,4,A\%KGYP/P8 M)U1=<X@/9$%'G1WA\B ')@6\[GVQ\<LBVEF-_9BK&#%
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MCJJ_/YQ"'H ON>6)GCZW.GUP/(WB-<J7=.(/'+/PGV]\8OBEL]1!^<0L'Q^
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MF;26<5PQ25VHX/2?,YZ08K.HDRXV,!2PYYDV. ,<D.)TC@TO,7&&$++UF_I
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M8P__ $NFHY[2/SISRGN1*4( -KRPT&2(V2<DDV-_A #=4(G,6+X5A?8,Q-Y
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M803XM/5Y$&(UX;'(<2","L$$[ 9:-AUG_L 48+61[W#*KJ,1:;.KXPCKDKX
M@L)<O_/":Y$:$6"9.4&L\,LG-D%3/2,-#.L;#G08=,[DV6@ R"C2,'OT< !U
M6TEA,M?R V@=&B&AIERR%\5,#"C2DSO&=;'@E4G);)EOG2S((0@I=RP!"U4$
MLX1),%$8L,?'?EO@:87HG*YQB04G4(P&F=%(OZ:;,Z)UALRF4N4GEP)HO(Z
M4Q,H0.&(JBV&=<K4ZKC%T( I3>9$2]EU*6D(?_@8SIT.3II&U&#$C9N2,&02
ME)I.<!^04V$&P\P 7(&/ZK4FZ>?&F*YU*82#N N"/:*NR9 @P,$&')@^^BZ=
MG/B=1&*QQ&10,>^&(8KGP"(71</4YBS*R;-Y!DS4?\C4Y$6V,F2'8\\+NRI!
MN.2\<CC8'Y!ZA%%TDTP,43F8=$P 7B"H$AN9',4S"<#5!UU34G2AABKC+;$R
MFFX3VJC@Y-_%"V6SK="++A4$Q(@_CHSJ&0,Y,,1)#FB64("L:S86+&E^SQ",
M,2JG2)P695^Q(.8-<)ORX"8S1@3R8[14*0 95ST;_N?"I2(CD8^?_ 0#XH1J
M($"C%7%M2^UMXI,5%RRJA7-89.S!<?$[!O+& JQ<DF3@7U341]9#J6+9J3$<
MJF)!Q(H)L3T)@ZN22F 64<=?N<PU:C+/0Q.^@J\"8R3EN(W\O#EN.%.PI/Y^
M-PB$3 _U)QRK%-AS:B=AGH# &V"R%N1/>\(X<WYDN<A$RQ1C1AAIR+(",4:P
MNP<?U#OJA>IR*'?L(OCH-@)P41-$(;7TNE"6 5(ZF$B17#@0$XO8.F2.]&7E
M=3EUL&8M<"9#HQ6$HPLM; U ,#)[5)#)[["B9/K:,IS>9<>T!=Q%56P U*W+
M3DYH<\J*E-B\Y-B );(4PCP"C^ O?07Q#.4_BNB&S$/9-$@(N?+KVC8T9%F1
M(OLAA+$A6JC0MZ5(TT"2E+\742\9>7B8[R&CX;*5*B[=%*3BZK.QR\#J\A8?
M+8:BB;(&PV1&)JUMZ]-P$#[L0KR\821C:FKLSQL$:E&W,N/!2[06<DX)P$ ?
M_!H*_9?Z2K-K&1[JI&6R2&E[GR-&L-W8FB%"@87N35?(-R(.]I,U=:JS+2D0
M=S'!LC%Q#0EA,#"?!W+2X@95ND#)C<0,EYT"K/$E6Y)AJ/5:DA8:\;NI9-4F
ML7P7>'YNME3\ H)E 68KXZJB-;<9:'&,T;0Q.*T5"QBZ8M$!2,A9>/<?S60.
M;F$0*J4+ +"F-3A# %GP T0XL@C)*\?@.DAMK@PIKY;%L2LD<5MHH#B")JF)
ML,=3KFFZ4E5H#DB5.A$0T:ZA<.,[JR!5K56!5D*S<03FT*<D(1G'ED__ *G]
MR%SP/#6!$3 /=M!:<'"J',#J2@.4_P#P!4N>6\?#";0&%#G5ZQAZ9=S.XIX&
M&?/>09 /!%RT92600Q1"HQJN%VPVF."3L\/4)59Q0:*J(.,; !+D'5C)AE K
M8DP</9QI+QM4H9#Y3.$%A)R:)L6*P"5($!WCK'O[( DK+&ET8FZ>8F1W&T<H
M9Q<DA'O7""& U"3\W*AJ'G<&C$9.^[?UI@1"S&3_ &;I/]]UC#@XV^:#3LP[
M(8L(PB)<=U$#(,84;!JDU-0$8RP"KL5W3AD]' [TGHB4R"" P"9.X.E8B OB
M=K&ZK(#MRJ(9.D&;\X\EFPJI.C9FH$Z*@F/P.! 08Q0@H2?1*<E$LC_PO+F<
M)_FRGWR5/C[J_P (GWS6<?ZR*P/\9$N,1FH_A)P+_DV^ 40 &  DA,$4  @"
M !0!H-<5@?X@R^V0W63^V>C+ZQD=9'_\0/$4B6"-@"$_@ %'FAZ"(4<68"GY
M_&'_ .$8 3P!DBD#L[+"' C_ "'@#DO\@:ER+@ZDT.Z() :#_P"6,*(__B*3
M),D_])R3_&<D[_B?YG^9,D_PFYSR9/\ $_X29/\ ^Y)@CJ\DUDASGDR3O(=Y
MY#!-(^37SGB?]UG_ &#/,9YC/$O.22,\3YSS9Y,AWGD,AWB6TSR9XV#4#ZYS
M3DC_ "3% 5] 7 JP]C<<G 5Q)D9&2(2SE,%48)K6+IQR?K04@  J&B7& YY(
M H;@NY";]H;8!S 6)R2KP?*UH".4/.)BI)-$>[6 GN=I8$:00$,U&2A(!2[0
ML20(%FLH"(8E(!!$T,*ND,2A9>:@KSF,I/519"3T?.*=LA-06QS58F!)1;IQ
MGQ.*>G-6$O0&^N<\4;4:=;+>#-TX<&)':_3!H0,ZB_CNO.//'U9Z@]L0SZY;
MC@6D@< 3KJ-XCL=(G"H3,I-+B+J>;_K%/MEP? ,'WQ:BE,*L!,RU[]\,Z2G^
MEEE"*OC)RYO:NDE:M^V$\5LBC-42(C'!RIH"7P' W(8)"D#!+(/-<BX@'.AI
M%DX.>'/8BF2)*+APTU"OB$V*D)(YR8J#+( ,)I!+Q0%";BF 16-%I\YRZ+=?
MT6--2O DN P,HID-8[5U;(HDD5DWN72[1560.=YJ.(^1-U@+X5&>Y<IVDE Z
MP8!D +&1"PB>=9S%#"C\7%Y(F3)<W 6?DB<DTH2K$Q(WXG!#_P Y0*DY5LC/
MK04F6_4$\YZJ?6]:7O..(4187<@H1$DF(N"MH$#PB/\ ^JX#]>,9D3J-G4)]
MC634-/3IA(32,=\X.B"%!D.8<YMHS&$78(X4E\X&P"JU] .>+RQFNB*K6H4+
MNE:XSF?"L>/MQ)Q")9=L8P3,5@95U8)IP*EPEX$%E(N5@20("*SJ9%6TP%?[
M*P ES!-"Y.;(ESGB;PV,28B+&:F*XJ>2)2]6N+>C8"6F1A1'0BF"T$ULR52B
M&ZPF7$^YG&C^N, <-HS2:;_MY&AY.&[^C-A$#HA)E\VOIC*;DE@NC!:2$DDG
M('"7$)Y@!)3D"8\(DL\54X:FIW@J3[EM>#@HX).'V?R9']9Y"+9'=3*X[:WF
MFX2C%@406U2008!(+.O<<0DOW/4R$1000QG5@(6UGK)H8W4_$E@I-23DG11F
M4-*4EN14,X"X(MX"A7[)A@J)>V]#XRXT2.]23Z.&-HK0_8K5D$QE)] 8R  >
MJE6'-&YRA$ D6N E0X()8HC.@U<$9%BC'2RQ8I93#)+AVV"40*A?0EPYQH3=
M!;%.6>#Q$G%DF9=RBS"96+\I:5>*!-\6PWYK(X)$4E!5U_J,8FH;$. :%N "
M+RJG0K0A"R!/%63VTK*E J[).Y0PV,M*8A,R$9/E&YR,-8W]49C00[ ";-,D
MVO<M", F2F,P*7F-0B.9C)H8+AC($M-&^,M;&9RR"L&X%X'7TR91M25G8<)$
M%A.Z"(])+:6M$XHJX*1Y(#  .]932<)PN,-L+%+AZNCB%.M&.*L LN,DFV)E
M6OOC0;M1.<"=,SF*%^A)_H](6HTR.M"+%J(>@KRR5)$QN% 2#B0@3DBQ%]E6
M"4-!#RQ8N]<098SUNS)5= Q"!QTHL46N5RZS H"^G6.OZDQ^2 B0J9EAB@^.
M9VI@G@=QFD(<V$TWY7)$[X;87MMA14!I&$\PQ,D1D3HI.FNH&Z43-V4;U.@5
MQ6())@@^B^/_ -5<=!Z82I ($F]E)3)#'.L"WR\7S4TV2R##:-.(@RL0$#3>
M%^<#BM 2B+,96N4V!Z"P#/;+1L?0[8H*T@C#)!XN1((&UT$8R8C7]!;0P!6+
M;+,V)*F8#*LR4#D$:!,-Q&MK=1Z9N;=)MPV#+LXR/^')&DHD3!>AN&A#2P(^
M(9L5)<0"/5X"T;\.$0Z,Y4MWO8(W61L$>OO[992Q+UK66@F64N4!-G3."WD2
MGZGKZ;P%P-0P11N*WD3)8H!A" 2]QE.8543&UP/L,0JB)[L"$,*&'*G&F^]F
M!.RX,N]CC:'Q@20R56\"F4B+?H1[,Y?X)F"2R DE0$R\Z[RP.6$G&5@I9F:%
ML<28MC"A\3E][TP]%%4.3'"+: M+?)[8X<XBR29I240N%,(/A6[G-M90+7,8
MX?7]\1<D5I0H9DU=Y4_EFDE0EAO7E2Z'M%H4)[)CDJ1)^D2Q,IH2P5+K0C+S
M;$&KZR;38$J= %C2VG#;]MTS$_>I SF):B#MU/8,-W%DE/0(VF6CB"5)"-._
MP40GG.!,U8Q=^5NO-8G!FE<L7R,@\AH:9B$U%LRD*4$U<^H8,*E4)9C.\A'5
M&.$TWF!$BDG@#P$Y,$W1' G# BUQ,+J;$B@:"F!R(JU':OD3'T"M?,PX@]P%
M>F*6!*&2,]JBF2E\JV12D.I 9@2D['MS@FD:"*HD@UF!W@39HP!)DHT)E:<2
MC4H(%C>Z3$Q@NL,\P(B+=X(+D(@O97+P6$S"Y#)2<6)=%DJ776JLH@4YZ$.3
M=/;C@J=4#NF<:>H3<H&&0C4(C6,AI!3%! N9#IK$##)%I&]B-FG  -/5 )T-
M!V52'M/C"94A(@HFYPL/6X,(<,<C71Q@9^JC"3A&Z]%\$O?)?HJ6$OE(,#J,
M=#ZH $";.>L61OTW&+F0F]Y3<4_5+[3_ /JN.+%!)$"KX%'V"QE4[#"1!M"S
M L8C<1$$CA7K!%. 1B1BMA5XP2!HS*L@!(X[S*9.@98%@)H5<$"&1A0Q9R >
MF>!4*5B(G#C7?C(LJ&V4L0XRPSW&'-81*A-, >CLQ ^JE^OC(NP[.Q0&\+<
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M0#<)'LP]><)2D=XE:PTOHI6A?S@AZ(K/J1#Z&#@:ESG#1&X8+DL3K;(9&(R
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MVT4=FB =C@V*J&C+C4HA(J2IQDV/X\4))!+V)T!PVP)1!#C&!1#,490V3<F
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MC)ZGV9"*X#RCC1,T[_%@#!R(3SD[:1!-*6T+9X,0:"_5-\%EG:\DE6@\"C.
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M' &BQD=$ @J#-[!I2!.T_-X7($+E+:CXR0J>0R"D1#U,/;:PA>!)2- @+8M
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M@<L,!(2D48J=Y43. OV1(O<$KPNTC7PZ0@D-641562_ L$2M!PSI+62QDIH
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M$\(VZ5L+M(3@ZN84Z(""461/.*K#<%&8C-$:97I P'8PA#@.\,D' QJ)&[=
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MS:*2" !$]L0DJO3K \,W&-DT*R;RKEJCU>..(R57FL""^3&*(+I2C(D$35I
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MCE3B^ B!D"9J.9<4 M$NI&^-\8L)'!*,;9QR$,ES&COP" UW!WI&,+?MFQ:
MN8P@IJ-0'W$^>I)(I<XZMXBL#$SDJ   6<B99$=?"GD5CVGV5(H'TR CQ;K]
M]< F:8CE(>L0<8O)\H7 V2@TW^ 7CWR;U.>"!Q*R<>V$F@RM8E8[ML/+*+=
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MT5DJ"$(8XP4L'TXRH%5H>-MR6]F2D202@O 2?3#LA&VTMT^3OK&1-)UGK"9
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M*7A>)&_XEU]<G^O^LG^N3_7)_K_K)_K@??(X R3%\:K^ =_P:_G9Z8R](@)
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M"NK)IDX55[PVT!H:PPS)H&# .B'')M*#4&V!97:R[@8.2ODV3UN-U2S&Q#%
M_P#.9@?X1/\ C!D'7^,'7^$'_P#AH,@R'6*<9X/JYXOJYXOJYXOJYX_KGC^K
MGB^KG@^KG<3GC^K@R$'>\7[P(B'Y>,\&_+GC?ERR8OU<\#Z36 :'YUGCG_>%
MT5B+1R&Y%,B2FL 5$TF7KWSVC77,PF'F<LF\T;K)]SN<\3\]8MPUY<$C @0O
MMG/%]7/%]7/%]7/%]7/']7/%]7/%]7/%]7/%]7/%]7/%]7#6/JY#(,@R#(__
M ([D[_\ P[%)'?XR;C[9YL3Y/F\AS4]X@PGQG2/4R/OUS@?U>(,NC(^/G(^/
MG(_Q\V>0R.>@^^1^DY"JWD9B3YQ W\\9#U],AQ_*#(=-]?Q_5Y#(_O\ S(_L
M_P!9'(Y#Q^^V0\?OM_&$Q=\\9#(9#$G$^EY'_77\&/'U,CZ>O^IP+_\ >,&&
M_P!H6P02UD0O./J*L!.8>\P(9U1 4+"#(C2)L:3&X%^1'+(%>7-P\B@CT'_K
M&HK<H&LQ3/:I_?/2CP57^W)6N_3?!0 +[/;#P"B]:E.A@TM%$[P0&ZA,*,7M
M/Y&CESZNIR<\87(^N]=QDYQ6 ,?-.EBJG)PDN:FTB>3PAAR%!:+JX/=!WK"9
M2EN'4&;Z4],<^\A]S&<QW!]<@*O?Z XH(5Z_S2O&&R_\LA,SSC1!'ARYO]KG
M I.7Y&9>G1QO_9C!+2*W>)G&3V>]E5*3ZX<3BA&#+TDAT[(3@: ="#5#6:"I
MSI?&<Z9R8^]XDK]CQ_ B<D.5[*8$NZ:LEG_K/@UUWFHUR6>F74L^#?SY\96@
M(()[Q&TR\Q@"3!>_4]X#@Y.(T. D6_J< $[ @!U)&N4\,T^/O_#CE"N]]A22
M[=VN3YC%IG@)&N'G"*E[V-S>/6#Q?.3ED5^G0%:XQQ"I7J//!C@V(8=H P),
MRXSNK+-J;+>Z,IMLF $\"'$67K'+28Y4UXQ<6< Z1$$[EB^=TQ-!)$;=M>AH
MPZ;)W:EC95WYQ962]"$R)]\=17:)=H2\?;%YU*W7LIA^GG"@$28TV^T@K(AD
M-BEX%? ],M2=EMDZ0_MC8 [A82%YQ?&,<**7L0!?&2*IL0M]<!]3);]5<!3G
MV1!DB@"6#X02(V1QB0!!T%PD>6.7HE(=)8\HT+G3SK$H3%S;ZNA],5-'J/QS
MQSMT*V)JB8(K2!IPT)#:T6V,%@8G61]1%(ETN'6;QJ%A2]1H]'",OTHA:(A0
M%8OSB5-WII^W)1^D*)?7$I:X57U;ZYI"]!ALUO',O]?*W#Z'#/'TD&8WS]<8
M87CW="@D%WI,CIB$" H(P%<GB.1.>Z^I*MX[_&I0VE7?Q&*35*0$$<-#Y&G
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MN??%=0<KN,*)N.^^\=F7EX'UQN.!/?\ J8!Z'XR,W:]J,GI: ]_=E#OC-)(
M-L,I[4QZ8BSH1G@TG1"FES1PYUO1B%HQ";*P\;0E071&A7TUBCLX.!A!R:['
M!SD4-=)'EF1 E-CQFVP]]LD6(5NQ>)D>I31+)*:DM[R#9K0]&KG<10.#AL2W
M)4XI!PA&\U5PFBAP)@D5=.2Z*7ATHA90FC'$9*I 10B>X]HM8:K-STTL0(\R
M44J@P!58SC?"&93V,#G,* N4:*024F<\'M8)J#[N .C/W3\\<&SP_L<-R#BY
M6$+ZJ5BS='K#ZLP$^;2'5!DP9(H($4G;<J>F;&;-\P)S.IIPP=4J2X'4(B:-
MK@4DE,IF@+>N4II&VV]?*VGN:I8=6'L(8]AA796FN]$4S@3[4_X=X78/8/Y/
M_P !V:.0-^B$X]7[9*2UF!1N SD(?,P/VR%6I7L,AP8@RI?64 TWC(O!ASY<
MG.;4\0)?IFZ!DP72H=JD7BC6F&&6A8Q$EA.@$DI=+Z1KQBJ!:U9PS"8F!,.,
ME8,B)!:H#GF7"^L!%$UL;>:RKVPKP3(9F-*%+7D7'X,+R"*_UFDUDB.HP\9_
M7.\6*W\ C\88 &X^<5":QF4+#D4Y8)MD,V1:)'NK,D$PCSF!.S%VMK+H'N*:
MU9"/G#PV3>.I?Q4\.%X:MO9ARIW#(.&B"J"2@2R G(X*!1$)@,!'7M349/1'
M F^92.HO#?AH$B>1$&;*(&'BPW5UAIY22F>3]O+D76$$DUYBOG%42PB8CFKB
MS"#:Y(VQ:#O['9GQ>W)2=>%N/S],"-W@/X&\WD8[\Y.A1B"+V-CC-L>*\W4[
MQ^IADZ?Y.*V%B'186+.C 6(T8UD-R^F$/T%PP$BBA_U@RG:.)3@C</&5V7%-
MMO1H$KVR4ZZ%7:)Z0*7DO$W+H6CC;Z8N6X$182'(O6#!J7TA<86@+<X76K8\
M#IC2O1A]H2E6@]*/",D6PV3@B^CR,%1M*Z0!6,3O!H^0Z)$%@#,36%0#1@7.
M[1("$WD;2X/9/#P QL!]_J\90I.@,A*.P_)B*NCE/0!$QZ7%BBUJ6:+40!!<
MPUXLC;K&!V!@4X<3*, 5G!4P)IN<+R8XX4@GN[,(,ZWWF.4**GF[>9(A[:RI
M4FA%34Q3CVDP+$X:=X)>3] K!"T*(ZY&W)<VHA41)@+&4['61CQT$!%U+<E)
M#3-$>" /0@%BD;0Y(Z^S@RIKN6\0:MK-^*@) '-\)/V'V?C <C@_9Y(^F*JA
MI^[E[3Z8/+I/:84]!SHHS+= %EQC12&3Y+4:\AA<-KGJ2QI>7/29(F0!*2O?
MTQ!%&#"'163"!'B,$ M1ZP!+CO2R>"[]F,#[OC],_><)FG_W#]_FST1$K!*"
MWB,'(()3%%*08[7'/WYQ+,P7H$GS*_;C&S]?OC*?O6/KR9'SD07O$IF<)ZK/
M( E1-ZOTQ\SEQ#:5T9J#K"J#TPJ+](#,=><]"8V5%QWO#D&@#KXC""D:!+9#
M\>,M..3,1*\!60(1PA2*;$0&!@RI'C&A._7]\5BOQIQ7.\GX_.)"Z]+1D9%?
M%#CQ)+3UQDMM#3+&&I*)2, S(NH%S4 % :M.!BU3I<] 8(%8X/5IHBNV1B=V
MD()W49@\!B STH(;0(O8<T,.JXE (24$N-T*I&9J9O9A&9/)K,Q,XF-(SAEV
M$U=Z)@>DQX](/Q"<B^N+QM@P]K"RO 20WC$C*:&W(O\ W&)2Z";F& Z\8Y%D
M ./@8SYD/.<)B;&CZ8QSZHB^;_UBK;'@_.#A[K8J.\5 F"(F#&31E=S>DEG;
M.JR#F3!#Z8#L??( ;@@:>7,8:_D%RN2#$$OUROUFBXEGI5ZXL(TP( (D;VT8
MY)*X,&4%05ZXUED6J!02A3NS'&R(38&9L-R)$<QDQJ3 9S#^0!A-0D?BL4G[
M/L8 N6W/C>7#MEC(Q+(-OG(KDM^,B:(KD T=P KP'>$L<Y8>,?*IN5/J$R4<
M=DBD!L]E.L&RA0/@,6.&JXP%T9&JRBSF:QET#K,EX8R!I8$K(X OGW''#HJ^
M&>)QH,*]Y.P,"( Z&!R3I$XVG1*0@1:%@*H<(DP2Z\W=IH[FEJ,:&#DY%'-6
MIG%@4'M:H>FX>-9,D.P5&VF(S,KBC%F%Y$F,;(A##MR1?F8(536%Y$&A+S&I
MZQV09^IC 6.J1* YE/SE?W8*,QH558\;<;21(3=F1TJNG)(.BK5%$:"2T8/"
M#:R$+-9669QT:\HW>;X,GK$&TGU O9\X\&+3C#6P&F%><-X:B%A'[@>F18@D
M*HW-FY->V52XTD%VW$0*> X_UXXR)B]?OSFT!$\'W3)1-$I;W ??&RV%$IT(
MKQO-X4X2X#-T#>$;5E8^A8#6KQ)1J8/;(OT)OK_]YXTD3I)^CK!!H /8("LO
M!9@(#J,_I\5HR4_OG/U?OG-GKCPYK#<P/;:>AMP@)38%IR$UD< LY-@=6C9*
MWO()=3 X N&PY"G&6L; CY VOHV\8V)&3T!_K$<"46!I,G=QA_D%@@B1!X.Q
MC-&2P)(&'9O+;(!._8UGP+E@'B^V%J'%P<6'X*'LKRF#?/J9:0T?;&PH9F.3
M<<\XW0@"U$) @"C1&C*V<J=(;>D$.QCOK2UU8HB)NH%G B@H]0L^V,3IA$$;
M::YOC%&]7> CHA=["3C%>3P*3TW)W'65#P1)T(R73U&0V.1QGP9N<"8*GIR_
M ,QF(&T4PK6$H8 "N/@2!=FL:O@7$U>WV8TN!&&5CT /;"'[8XMO:GRQ0PX'
MFF8HP=&=RF+QA=!4[=')T\]9N*)D? [G&)!=DB=P2QE'1ZX.>YSJH$)<DVP2
M)%L@-P0>^OKB3_\ 3&&OY*(,:%E7+.^\C9^R,FQ"$W"5C["^4I- (3;BYLB$
MJ<,3,NS>1FZ5%0D=F]HUC9Z7FQ8!U[.**"@@C14@U$O=9.X BQ(1^,0C C#B
M -Q4.3J0G 1;D++F< /M*RA6"SDC +;1)%B-$H.O]<WB !! 1P4Z3T_@D_[E
M]@+;N+O!2%YQ7&;M9$@29$J$ZR@!:&XU>.JX"*)>]'>\@1!P=L7?*]G*1(#L
MQ!7BUB<'D'H" )10(XC+7/") E'L,F;QBE:-:5HK!Y'H*R+<-)B%*Q1)X9/$
M8F$"H1D[-%Y.KIOF\7 GL<V;I _(Y;L:= %;)%5NEU6@SM;)+P6S(I]H8*$S
M(3D,(P@,T-)P:V,9 &TS=U'PB"6W%9F4JHV+QBM+5X4CJ,(%Y 0](?[KQQT#
M*4I$E%^7YR _) 46.C7UP\%X&C@:'7F,BS3;YCF,2%-QKPPE\(<X@=(8)@9S
MHA9>G,M?%N#J_*6L;5DAQZ%1]B87S $&KS*CE1Q&'@H"6Y! /,XK_P!D!-Z8
M\Q\4X J>SWR10^+P=<K((;T#Q]<H<F8QC#IP>#%-U3[/8@?6'#"!\V7YKUS?
M_P"XX^']G])P;P,ECR?T/MEXCQDIN#!29ULKO]O)T%Z0<3W ^S%*D_X(+3D
M",7D)B]!NVB*X!$&5:[)%4-UV.$9$AU#E$B?*GI6%$H _IXK!X3PCD3:)-AS
M$XY^\5^R!%T)/= C"Q,+*U0GUO@(7>26RGYP@WD/3JX_I#ZN1_R(^8_76<WJ
MQ]\[_#7I[N:<G/J9RG/YRZ2?IB5[((.;?H*V2L\2<MMV#H=MFV ]0XB"))2L
M\3CC+F0$ 4 EV*-,"40]<U"H@B.\]65_Q,BFWFC-5D(R"<>HA*5JLA Y2?JB
M/G(/,-0)<L5"@M3AQKA#*$89B!,<A:7!(+L%?#YR4=0$Q#I@GOX,3 LYF0J
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M*J1V0B6RSJF5?&F1F457&:3PP*X=(+(X$A1EJX(/(UA3;P?V=#R8N0'P%NH
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M/!WD2 @[XW#YQ,E2!F8O[+/(*"2_!O'"7!Q*:#IU<:]\-'\P)Q9FA>C5:26
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MQ_C7^#B2E)C7C)\8,XWD&09!GN^N R, M%V3%_.0OSD#*[Q<,"FGK(,,Z_\
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MR#_&"9S7\1.\@R)R#(,@R,@_B#?_ /6W_\0 +!$!  (" 0,#!0 # 0$! 0$
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MG.Y_5B$QG,1<3'9YSD;.^0'#UC.SB1+#OFDSDVG[[R+R,,?\'^]\I_9$ZD-
MF+WK(0CPZB:_UGM&EOH6AR\5E4(1YK,I@7V/QDY-<@!4P0D<8YQE9%&82D#E
M=,5&!6T*0IX"6.$).698SRZ7HV]2^3#8D:\,0GI_>F(6$E)*&#:(@1+><]Y'
MO_/YP:_K1_A1R]1?3CTR&-IS9E$0JRB(57EFL*,Z8\]IZX <.@DYP%!XOA#6
M)8V">)K%'EUVQ,(,HO362]Z0SU)$IPXVZQM-K(O0TT]6X.9R<E)*',R7@;YG
M TG4GU_>&!25U37;&) IUQYZ8G]&'?VPR*/)2%+;JN!\ 9=4O[C/>>BEVWU(
MA.%QA* WTC)263<1,_\ F+E!TBO#=/?TQ9D*7A0>,*I -3&I^I]/X]LHYRSS
MD82WF^X^9PVA9:[37TKKSAFB>=+(T]$?K!)U0)1%N,1Y56<J/;'2Q23Z1C /
MM9":P=$;?D.W?6*'^Z8HE?GCSA_CSE')/$\JB (6M]9S?)FIU-EQXPG.-[?H
MUC>@.M0:6$&<ELY$7+%E=NSG'GE.H R(U!)=!PH1RB)XVU]WS">'NN_2_4>F
M(K/2&C(\2O.0G,TD0'R&CMG\#HP5>#[&7\_['U;A\?)/WR))+9T7K_:R.RA1
MR>%L?[\Y0(!@MCIB]BR$4R'^TWD1BI?;_>+#P?W_ #+&J3'>?&OSBC\L!D O
MAGQ#BU"I,'=V6)*E$%)9:6)Q&D+1Z8DZ(,/?"+UQ/C!-X.[1Q@%&F6H&R_ W
MYRNA1L9$5&QG@QYY+ W\P_+#YU5F6!!M8B-X<WB9RJ"Z BP>7)+10$^S/@R<
MV4C2I!$Z$L3%9:2C"@(N>-=+R, -K?B,**+1V?4^AK$GMDW.Q\8G*L$>O]ZY
MU%&%Y7^&UQ7;/-[<Z\F"D4<F#G_6>L]I:Y=09^7&&&)>D%A=Z%6$8:_QY]/S
MDR)7=$C>VHO7; \S&9'@PIDOSA%F #P^-G&A.GCU?MD [!"4QY5\><7B#BX:
MD.G?!1GE*+*<D3ZSD'(!VS<BBID#%&.&W8Y$*T)WD+QWSXQ\OUD8G^N,_DX@
M^K@&T==5#'M[X&P>I..V;<ITE_638MM'2S]X+NH>X>\_$X*[2QWN %N$WS&A
MYM*B\G;^/G)!$/\ K(1<>V(Q!!58WO$#,)Q'0NUU:QSCYV)E^+>#P%$>7GK@
M.:OO@_G%4@-WH7HC-+)N&6)&NC#UPU%BX!+U;3P&1S#?4#IY?]8E;.),!*Z,
MEHH*=8;-(I5JS%5@H[ &* -5PCK$?F\<^P(URPJ-!63]>T,Y%$,E' BLFQ*8
M[?WYR&HU'^(Y.=G]K);_ #CHYYRE9U8XP,(1@^C#6,4C%#N3CO@06KN"@N7?
M_?U9GE!84;_'TL0%+ I40@CN9P /H&L<0*.F(\+_ #7AA6QGX _R_P!8YF;K
M/3FR$:1X?TP9&:FTG"CUN%.? ?"\.R8Y-9<DR?EQ@(*+QXC^<@ZZ/EYGM&,<
M/I(2"1 +16!$2Z9.K[E)ZS@3_>,Z@1U^^3A-Z?MGNE]CZW_AKD'/G"P4"#B(
M_KZY'>1\8:L"\UA?]G!.G8A3KE*$\#J<!1D31&Q\F.'*O3A!( H]6.(O-'0M
M[>YAS+IL;_&#ZY Y!O8$?MA3UIB+G^B&(RR+W<$9&0(FG]ZF0EI6%H3;(V0G
ME.+M FI09NN]7(<]G5X;1H:0SVRQHL@!$=Q&>9$=.,X N9?4AVSSZ9"HR#LM
M<OQEX,PLM*R>D5&$QH]<D(_Z1BZ#)]O\_;/;/;*_O3!VIXR'.29#MD/H5!;/
M)[5DCB??(]'JL^OP?Y.='\+* 93227CG)X69$#(JM29%+32,P2SA2\C>:"UP
M>G3!T*')I77$A6B6NSA'"!?59)9$A':HK"9"/<N;+[)G$P*>B^FY[L:DLB#*
M6 G9!,1AQ4])K\9\Z>G'Q]8]6@K5_KD1WEG!=$98T<Q?$9RPVM<Z)7>3-/%I
M$V6E@]D<9UN >XE3/KYP#N[# F+JN]XG*6TUZIIX_>&JD&T1*B9H'$1AEI*K
M!$;D2.%RE80R62&P@C"*0MNMX0R=MI$A2MD#O>5P>U="">H&+CK61 96MAZ%
ME.XO$<F1@['H&#M.1>[?W5Q!0 ">*/;G#49PW>OG-ZI1L F$[D4\.(T2J;)F
MO[SA!! *1 / ]\&1NS4)74N\&/C^_OC()XOMA_@KR7KDO_OP>/\ '_6;==OL
MPKSZ$7A[F23J R)^-<A&#V)KP/ICR_*04A9A,,7$>G#E7 (T@@BH7[G&*CCK
MBL%"7[3KM^,H-U?CI_<9(%P1 <NT)!!!.L;0+EN=0/Q1U>,3_:,B2YHLV 1X
MUB8W<]<<]V7P?6&<A(K4!PN"+.@.L]7+88.@SI:>S6 .U5NNFIGFH-YQ.(&Y
MN99M2_7G*%V*)1=R$5@]UJ8:T29-@U6@^$)AACH2QA (F !/2&?^LE(X9\"Q
M;H\282D7+/($R3OD;G)S;2 ^#<>&<:JAR ]5_F8H@=V\1LO5O,9)8EQNN<4"
MI03UR6^V"0OC)2]&3[^N7QH'?C+2Z1[>^$=R2'+L?W&?//M_CO\ ^!_E&0Y#
M_D]<6$/C[+S0<;=8SZ )6YFG*"8>SLFQ#(ZZ<0P*'3;281-L?.(^X1'"!+5"
MS9-XQL&*BB5NM19B\):./'VO#)7!N<&Y/0*X]6.(&RHG1-WA$XVJU32X$4E8
MWB1<S9&$"I-0OJ8U! I92*#W)C/G_P ?6(01*DWF@+]<*^@ )3'?":5Z\HT7
M8Q7#T#I6-C&],3H@-\!CG9(J=;7$%R<ZH?JK#&Q%=MY-\I0$=\+!0@>^ N?/
M(.MD1D(AB@(/%%8G4>7]L8J=Q;4QK!4/5\=L"9.U_1A,*C^Z8F(^;MVPE!@C
M!$0>_P#&(BM//ZR"9P/9&1)C9'#>L("",?ZNW;&)9$/C_&N<@Z9!TR#(,@R#
M(.F5T,KH9Z'T]/\ SB-BZ" -KIUP/R ++MP)>,T(_OK^L@I?1I^[BY4:!?O!
MG%B1 &BW.S^?WC;VB,%UB1CBF?5-Z, UTOY,2HI"E3HP7BI4S_S_ %B,DK;]
M8\_YA)"8ZYKGZ>,CD)C268YR.^"9BXW&>N%O5$YM F6SG(/]X6."Q[9'TAY_
M\ / =I^V+**04-"@E*%0W02I/ U<M#$%,#:&2980Q<Q#.GG] DZMT<I+#N.3
MMSID3)QA8&NZBL.JD\UA>K*-'#QZPX<#."217L\40;.2,+H+)%P;ZAW*PY%D
M)EW1Y31HHDX&Y> ]D@:7"BMX,6(0L>(D3*,]^3S:1Q0*F6QD.H9_3/X(M$7_
M #49#Z&31Y7_ %@E'-OLE\84(W)/ R^3(8.JA[L9WN&%-;C!+$GRSEQE]1@+
ML0O+//IFQ>!3VP71_9&0Q_CX=/QE";GXYSJ(T[V?E4\Y-*^E5K,>.G;!\D^A
M?YUXK"O+^UCQVRR8C7QFCW/,R/W,; _&6AY/0GYR3_7">\/]&#HZI]<734,^
MV1/\!@H 5ZF(1XUYR5M_9XZ8+Q7]_:RC7N>(X/26\2(]/&JQ\??JQ99_\)7H
M839",6P28/@@>@,TG2[,[6_ !!T*/+*L&1W EF4S \J)-%S('R BVF(ZI1"#
M:.8M)LGB0=)2-P[".8++3K21<4V,!1P<VY]H.4XM@)CKY27$*X@+.-<NJF24
M12Y!?</4$?5+%%&@77/W+D"HVES3MCKPE_8)0J-)>* <O=0%B)J"TQ R:#A.
MP,]L$#<BH_\ '\:[?0>=-GI7W^O?Z\1A(!TO_P#$-$O&,Y&1AP>4T>V&X/#X
M5ASI]]L=)>IA(FQUSL9)B>B$\RUGRZ'[(Y_Q/[R%9DJ 'JUCLC+2L]%R)D#1
MI*\$XJ MB&/,9)<U\'G LE<H$/G"^_C*&@-O3-=W9OUS\Z]+?B7&4*V*3R#)
MGR.S[DP.?"#\CDG4_P#N>73<%??(5=-&O]9!@'=Q@ 6:6>_7MBQ @JO?!<2P
MM GWQ(_J2@ ."G?KLR<#V./:B?QE1QZD?9)^V 17J)$>3#>$E&#SSCA(^U^W
MUV>'!TD)6@)'0W0T=,"? UDH'&,W1,NT)&W :W&!S:F+NR=XJY*)JA"_-WB2
M8%*>W7*0*S6#<@]M%$:R2#B*1HD,$NL3.0*+A5C1XZQTPF2,\GH502 [[8',
M!*]2.)P4R,1S;"-7:_OAZ-,F.B]'R5B*!M02FT^&L@IX)&S3\8<<03Y/MZ_Z
M(18]05./UIGP$D[K+OW<GU.FLC#*[@AUC6.^JJBDSZ!SZC.'-;*TEU7O)TP!
MEQ)FIX>C?GC6+FXR!/\ [9_ *_7UP";%$6&D#_6>I5.->F+#[2V9F4KOB(*W
MD41"\@9GRXGM>(.M(G2U'2,.Z8X=0$-2,*)%\N""@6LG#=I:G-P'# -S%//"
MZT)J,@QI1+W<1N=O3(?;8D$F$A1W4G3"U7$2@=:#X,$(0(%!1HX^FCX<<:0!
M84D^S>111=A0=E*F^Q-.49>92#1.2DD?2,I31?A^,<IM+<I'Y9&N#RGX_P"8
M)^YC9 3MP>,G!'Q]7"@GM7&%/.@FH2#I#."@I+B"*TKDTR'5RNB+)>&:I&H0
M(]+G(N<CV0A""#O?-85@=NQROE>(<2C J!<NAG&GU+407Q';C(4\$K^/]8K"
MC&*;YXC 1P:A8(D+E6<5CB6^P!W:;AT;P$LP$KL([:PHS J&6^?YR1!M[92(
M'91]\VGAT\>CI])_^Q0#,ZUXRI)5.LI<9%8HT5\ZZ9:!R4L<"(VOI&$&*:8D
MNF]QAU"&,3PD4DV#KMG-L !$ XI=[?3INKN&!C@J*:ED>4OSA908SG_L./ME
M:J#L2 7?F(CSGSGV^CX#B5=/=MC.'F(YR(LGQE)Y'@PD:-$QB%*&(B@)=;1L
M3RR.@M)#9>!3-0B-.3'4DQVEA#EIZ*Z*Q\W30+R3Z;PJ'T5?UD)R\TQ0%]9G
M&DC#>3Z0O29IZY.E?2)CK?Q&1H#:*E^3%*LPC=?WVQCEZG/MAS@I[2XZU\8T
M23PXP6*2L&NFD>WC)T)X%NJ,.4V2>Q.CGZ4R234XR ^Z*$L>[OB@"THVF%YR
M1(6[GSQ1@<<)2-62%">/;_*[N1=,Y_?Z<_O]/T3DY)DY)DF29)DF29)DF3_@
M[#G\<X*L($D#+NSOQPB.L-.+LS53O+".E[(NS?'C&T1TB/U&1 23"3[8.N4,
M%FRYZ1)K)P,O3[9*W/3[Y<FODC]XU$.OM';#8B3[H7'%W[84"V&@AJ5!!,6;
M,$%_:/I\!Q%>2H0(($Z#<=27((F,0D)A.CO$P888&Z5.'.6[EL@'A/B"">HA
M-=)M>2+A[_[>'%$D7JV&<@PA#P[?;G #9O!(6&#N2+<!%S^,6!E?4H+)? [9
M./%U!*CH4)WYR@>". U,MP4]^V Y8F2(FR/8GG!O)/-.,:'GZ9"C(CK3#@HI
M#50XQ $*O; &OH\M[R,D3=WKQC0F#SQ$XY%ZW0CVRBY7]L@[)8FC /PQ$M$C
MTUI_BRJ%\]>\93P1<7HB>>,2.VD5XZA,8*D><>'ITPAS0EP#J1*4]\_;"*&N
MC^O!80,]OTP&S+'C82I1116A-N/59#2C$ VMT'7'@8"CQ(D1UI.AL(S9UJ0Z
MD"#OR1G\WD?W\Y'C)X1\XP?SEM1_>?\ !*;;16&$ZIY#" N;5!+S&AID\'?4
M]7"./*>I\8XP9H)S\@>\%8@E$,+HV2>KDJ.GXQ) \O\ ?.%=#6$(RZ/#K("1
MQ^L'3)Y@VVQ?+A":@-3,ZH0Z<,2,C5ZT?3XCDA%T368 5,8(!!SO(U2D1)!+
M3&X>#XQ(#.B(Q2G<@9B;5)$-B4S=5#-;-Q&&EXO7[E!KB^F5:39+QO']1-T3
M3"W7J21@C-GE@4F7KQ@V$D)(YXG&MT/I=28EHX<>C;"CI#.CS'KCP60@2QG<
MF&AZF\$S_MO#.6,5Q_O"FN2X*P= 0=<*@%*1"8Z>DXLJ@7)\3AVA!_P<303;
M$GK@*#[/R1!)17M,S'.$ZA*_,69<;&LMVB, 0.GKC3L]H[FO0\G;ZSTZ_K-B
MB]]*Z\851/.31_G!'Q*\G+OYP7TC"#H!+B+5>#<DZY1136I4Q0D$U>\(0(*7
M#<QE,"^:R!2PG5.F&@$@ H$P]M-8J8@M-!^Q@_=N1 YZALX5DLH66&0]@OB
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M<QJL2QIC66"*Z$<_&&2$](!,V8A0&BR'+:H3 ="SIA&?2L9/ FR9UPF H )
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MGQG\^/H_GQG\^,_GQ_@/#^KZ/!^I#(_P0@DR44(5"],TB<7&13&T8S *I/H
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M'U'Q3OTP@U*(B!(F?Z'&Q+6]$3#MBC9:$W;6NVS%:G>5-^O5P CPAT0?+_\
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MW<%MFR\_ +^,;5T8'4OIY9( \-[J'S_=\B>R':(P:-20>4ONO_AM>X-*ER^
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M1.J\=)Q)OTY]L<^7LEP:3K%,,EV]LI[S?2.<C>)MP_O&$"-91$@:EG&D-?\
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M)![AX^L#O C^7/I\X$O!!D *),RU%<XQ!&SNK3H_#>:.SAAV+NH"J"L8]3=
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M8YES?M7\*B#*X#3UP  [ ^Q_>0ZXG&B#YM )B+3;UG&:K%B.A6NW3MAV?IG
M?#QEEYXT(EX&L.38(CB3J9G53%],!%@I(FPU(B2??($QA&&M)K6!^G(:/[R8
MM:A"3KM&1@<Y7\>3+CUG<GKM-FJ*XQY(0;N*/2,16"ZX3+Z]>W;'WE$(*V:)
ME]F00+=41PK!$N%;HFS;&6+ZN)GW)G>P^Q1UJ-.0@"(J!!KEWAJ$+9#KN8)B
M[R\8@7JR]%PM91S^;7[Y$S-JM^N"#[/O]2?3[>4A26P!4:@]/.-OQ)/Q^<2
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MKB//0U.<_P#[7]9R5-+?#%Y9-+1>>-&7%=#TZ_&)4@I;ZXODLFH@LX)UOBL
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M1+G!+#8Y?T01#Q&!)T2E2BQZR]>V$P(0A+J9+2C.^*P^64"%DE:8C;TP@"!
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M[48M3&ECHQ5^GC%.\$01XY<@74^I/PRH-V0SMNL*>D9,-0/=K$#*V ?.*LC
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M3R84E3,MLH)NN\IZ;"+8CBY[98C9KL KX^;RRSJ(Q1K(40F.$3\@6EO*+"X
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MZ+Z8^+:6"94/%N)GCN8I=/#"'7<ESQXR92-B?S@2E=<ZS]O\R1*TUZ/Z^D9
M_?OBJ$:_7"-DAC:F4)O7V8S0VY<R#F]D]=X5)4FF-]\DSU1E^YR)7@K"Y9+
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M$=2HF!J<>6=0A.8=\";:0L4CV(JUG6!VMZB&"S$55N%SDULP:B)8'J=]<A,
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M-]\V7=NIX_8RDHC<Z'NR!)[%?<K!9)0W5/7!8+F*FB<6(D^.-?54M:(92R1
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MDG<ZDM=KG(SY6B$-C1H3C7;)%)5XY&/ZS2T&\[*N:3!,0R&/6X3Q;.L(/O\
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M?@+J]&*&^#N]'%!0)U0M.E1GJG?%& >W7\1])D^W#.D\BO'D?#>WEMZN[/\
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M'(>C\')Z'X.3T/P<AZ/P<2H$0)%:41LS<9=X2()#A 0LF[R?^U_WR?\ M?\
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MPP8K74@ 3BQ*ZNY(S$![)HJC]O&!@0/)A%AUXN96Z@8.A(Z-;V:8XNQZF/7
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M]^892>U>CI$\[Q[#."X[F*/P5^.=*GL;_3]?MP1PG7W/I_GBL85M$^HKOXX
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M!()H)L-)CS!:JP_ 5=$30O1,$7)R,2! -!X(;K "NP8.,/-<7E'WWV%4*$O
M*"UZ\I>; MUI"$$5+L*FN\H5 Q&JZI'+0A+"Q0LYEONL68!@9!0,LYM!<B >
MA+"GK<F=\\:P/Q=G827O@@'\[_J"P S<!,J]2?'+=.WFAJT6">HKIQ"Z ,B:
M)88\.[9$$,."DQ@,3TY 'YT_G_7^*.P]Y_IY0)2U2_CV?6^/.')*)LD2MY=4
M?,08\83I014A,$!AU?3PUI+\3 .KIU/3N#(9(F0 ]GS#9Y>2$3NP#Q)DT7S]
MMZ9&I\!OQ7J^U<->*/!>?!3Z5-4'KA\9&(=((!L@%,ZZ>#1'U 8I90J">C>
MI$XJ <8B<AD $FL4I, Q?*##J-TE4[:3L&$"K8+Y#K?QYGX<AD: [*$$LKH$
M\PSPI #*96X:D1PJ8F2.3&0%2"IXR48F+:@JH"!C.)Y00[1+DU$!L/-0.!'
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MZ\F_JH0##@N/)/(08,5 I6\CC1U$$6$1:NN@RQ'347L0[9D\A>]]<T\XS="
M\W+11W<)RE>H.MKF*+&:2.@03B,(FM9[9US$* <FY1/X,!@R2"B"<21J81!
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MLD6:!RB$.Q,J+.9!W=2&Q_L 2M&<'\0VHA3,-W=L9XX[Y$\CZHOW_7,XM,8
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MBZB(-P@@X1Y^)JJ%7%5\R7>0B#!1D?MP7Z%&O#(\)@,SIP874#A )3IH">
ML%N!I!!))N [!9CYL<+YNRB&Z@4)VZ9!'B/&,E!D@A(&#*2L-$Z!ZP> .D%A
MPH85S<VE4620)E4IP&B;#Y<R!04[P1F1*U35[!@!T+YM&!IB0C:X/#"" -4D
M+!4"Q$<B+3-U:PXT&0)!4<":(:)G"* /"B,1*/5($2L,+IP6C$7,[0FI:F7N
M07*[0$20T 0!1XJ]!0F<D0 X;E+1A-3B)!H07JD!?9UAH=V17L[*;& +1*%
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MR<""CX2QK*X^7N?/#-\ Y;Z1'].,5"R'(E4BS-[\<1DT1E?-(*8AOQP +I[
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MD,*=",=;C1R+D9K!$EZ*L1_]=GE/22$&6XB7::1 *:&5,*\/:IH8&G#HRD5
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M\;TDB\)%3IZ[/*HT$Q@*(D(>X*((8/ CU6J(K>%"3H%WA4&NG^B-&'D.&^V
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MP1*O*F1H)O48G"6JMD@FBT74C7NN:B@H;13X/&<T25,Z,JA>@%*,!L98^04
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M#LZBT1L4:;^4?R+460,#@^*(&.P6$A+J"H4'^Z8P(T)%4H)HF\9GG92D-#?
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MMXTHR3:0: 2@ Z1>5LBDQAL@(":!P!9.E%8E#"0^%"ZA'LJ(H J8"( ? ?\
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M<H)S=1:F*ZJU$N(RNH$Q$KTHC-23708N"P/0R-;'4 >'8 Y0E+2?0*\+ (-
M((Z;R?4*DX566&6#,XI1*T;K: P\'K>7P%]%3(6$A(\$_P"),H*B-P:KPL3C
MM2\R68UZ"X7J+2T#P8QI.<+PKK$6U-/,&C9OCB-% >HRC2%?0*,G!W241:*A
MYZ3M;O$HU)"[@,U!6-/*X5R41B(K1 ($]C@JL(Y GA3B<T'%D? )1FO)*SH
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M@";\JCC.T)+,7MH5R@.#AX\F2]IH;%1;=!"HWE.>Z$*XKJP#LH5)-UPD 1%
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MR(Z"5[<6Y2N9*A&"BJ@/"C]B%Q%4%18H&=B%WM5%P6@2T)E6[, DYM_N"6L
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M(4HM>WN/*^*\%^*"BF>Q&;.&CK5+7FL@DE'9A > ,U3;!G@5/(0X&;&R5 H
M$NB%DNQ*"J\,!(!^]_(P*9IW+/B?'SS$'N5@$1S1DLKI#B>(X;AR .U!21!X
M0H2L (5%$;<M\7.-4FI)F)ZWOJN/VG&%XLU?I3Q^L9]>78I8^3OC#_<XIC&A
M]#%G8>-+CV-XP<IHIK.R>_-A^-'F +JV6'GW$[+86C&=%\SSW4^$6KB&T&#S
M$,<]&OOAIGEB^NC^/7-@^(GW%_7QNV7UK_CAP"CA@D&ZBXJW'QS0" )Z0+5
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M_P .5M\_._O_ ,%?A2?FH#W])\<#4DJ$5>FZ1UR_'"%06BU\#KX^O)@/&?\
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M13Z5D>?+?%_KF<LR^%$?M;R%PZ-6%>O4%L*9R&BT@TJE:QJK$?!J$>+4M 2
M#37+YG=X3UF'2,2QX8)"N&4S5'UF9/7B"LEVA(W2NJ*J!(Y)HZBF"J\11"%P
MA$ G5 M$:T F[5(I31575U?@PX!<>XCEDP3"#LU]@8R6D"PY&=K\[L%,W"E$
M/ %-VY(?&:O0@>L,XBH'/ L=CMIR9$/@EF;L8=QX'(</JYC-$GZ4NE_")5"L
M42HMZ$5@QJK DN-54/7&S3+Z<* K#P$Y$47#,TE+9;:"();!WTKC5T1J B'L
MDGZ95K4(R3#8]'V8YGX$E-+XZ]\C!505>B1HV6Z9EW<J"+?#.%P,6AP87.F
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M&F#8+AM<C.!-4*: Q4&$. +S0'5(4V4(\=$ GCD@D36)AW6=[]EY/P"5&[!
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M>R\AW"^Y_1![!^N\AW"]6>/7/@/P<AZ/Q_8IVGU#D/7]J#V#]2_TAZ/P<@6
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MVY)1V;.#'::/QZ!>=PJX16%3OE@1-6^9+47))A.1PY,4)577O5OCOMS7[?\
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M<I)'&O:7 MPQ1(%00.HET'"7'D&(&<3N$V+P=-QO8LH$Z/%/3NG$Z!)6I$W
M%50%9]!=2!>272M>5GN>U^1'IN#'"[!R2((!!B:6]\A#_,O@E9+#,"!M*B)C
M/M<: <+90"3;1-!A PNILHN@A- F.?D,7C7JEJ21>@#51!,N#R!CA,]4>&&P
MUH1O:+_>WT0)+=.97+QW$^M(BAN;-=;W!?O+?/<.O_U>C]']N;2@"!VJ'W_G
MGCW],I:R&HL"FDV#J&M-?V*:J[8,C ^EG#%XR#@D[5A:#$OE&CWRPA[W CI1
M *]#IR"W Z.BC\0N18KW$"QH*:X.82F3IKDL2 'JA'U/[IZX0J<. FV('8>
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M]=51<M@\E=FZ(F%SZ(0!^B%@^O87%*XV%*X'#:F0 <"<-P#NK G!Y@D+O$"
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M_P!839%414X/ U3TN&)4 !(1E!O,6:K*M$*GH6NYQCQ -"O@*GCIDG=%$]Z
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M2B(*KH3A,'Q'=1),J42!P^]V!*^"6JQB=)3C"H6" T$,HBY132I @5 V8JH
M@DQ2<1HD*52C,!$*/:%]\O$CH6884#9%TK4+0P50L-%1T(Q01SD.+3&EF)4M
M1C1VX6EC#$(:$1TA!'%.&!9A6'M(8Z2/UX[6$5#=7= C6]"4\2Y!)#&"S0 &
M@5)P@0BR(!24H/>@\+$OA2)*)5P;JL 9Q>5%QSZ-,R+0I$XE@_FR)(Z*8548
MTW31$S@T $29!7>"%Y&^IHK$!HN$U.)-M@*( 3TFBNM>72S-0#Q60<)+I3B-
M1Y0[]@'Z3BL#KX BDD"-Z8SY.,2,,UFF#F==3)_P3+)H3B0D"R,%? >/;_9
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M%H4$'EU+5DZ_D_K_  W_ $<CL<6SB&J@ !'R3MWY[AT*:Z.Q7A? M5*&Q.T
M@"'?)04+H=@H'\*R1/)TSPYO456!5,6%35WK.P,HK5G#O02ZB*"F.T4@=0IY
MJVQ/P[F5>609$B"5@SK"0-,\\>32NDY((ITKE:\",0?,04-"L*!IW.'] 7HE
M)MK(:>A3\#71L0*KW   MG QD2^L@ 0JDX(![B,K@J36>NH^=#LQ"]+1&&_
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M.LH0 #4C4'V29+PR_' ]7J 4 *ZX>'CH7<5M_L# +),X(834@0"")V"8,G?
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M"*#71$+$H#@80H!_+;$8DP' RF!&'*YD.04Y>QP"Z(**L"H0GXWM  D "H"
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M)./+K<BI58EV@4K='2.;58;15\,N3)@(,LS^A#[1.O-YT,2A,\N<U:D %SD
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M>FZ:F@N I,+I,5(7.)UJ'B1E+CZ#:I?]2I!!2%L\KUM@SPN.*<:+6=KJX#<
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M$-\J0!00$O-Q2)!IGH9[AD77%W=$HD0&+7M$J!3<&J+&$ )>H#C.'5QB!$5
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M*K0%5BG28<LIZ^8I,-ZIT"/+007:8:E' 5\2<651YD2AL$\7@DX>(1)E0%[
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M'G2MK97-6*4$CV2Q=7$<C 1:K&U*%"F&G7+#20'((&@4Q]! <1F#SPN;PD/
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M#N?8C;5VJ^.,."$TJ UOFRYG#: UM8@A^2 \->1"><FCI!*[PAAM:VFXP)%
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M?)X-=2]37I:@V^3_ $*!Q3J5.)880=D"-&/#$<KA&OV)!1HR+=Y"T&1-.JA
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M71M)+2=ZQE#,P$((V(4E?]N6U4]#6C:R(Q"A7KBU" .JT,0)#*/T+B:&)?R
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M.QK-WU#<.H'UI_0P&9?/[O,:NO/O_'\WAD$DM?\ 'S_/GD0H_).VNV:0)1>
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M%?O9]IP! -ZG1XZ,^TXLJ &;\'E/;^.)+T[$H'V(?I]>!7J21Y/7Q]H\8/9
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MG&NA5"I>H T=-KCD0=D4GG10??.@.S)J%@ *L$TD5#N+SM=['=$W9.(%JA2
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MK^C]W^GT_P <1+-[8/WNL/F3A%S'Z_#]/'&EQ]9U^W$HF])\??/SR-P^.O\
M3^Q]^1\?IQ'Q^G% #0<)I[Z9U\?MP@*"G8R_L?OP2M(J_MG7Z_G>0::]?^<\
M>,W1/WG/I_C[\1453&+/M,X$$6^T//X'R/ ?=/\ DY'D?9G+OCZ&7QU'UV$>
MW>0Q2AK7\_?[<_\ 2X"47W1S^!\0D/RK^NG*46=U0^W^N"*!>M6OB?K]N7_
M_?@9 CU7%NS\@_2OT^>#\_<3?I%R  1BU/OX?Q/IG!HHLQLGX--Z_#R^!\S]
M@<.[95^/7RO?-!OT:GW@_P"^2KT.X#?G\_'! ?(O;FB)>^W[G/O??_1?QPL*
M!G7V\8S@+(-_GHX,H'O._P!.+I#3/89^.&H>T.3<*45\Q[\^#XX Z/Z=?V_8
M_JHW4+Y?VKP; .VVFC,: @X]KS!N.,A200[$M&./06/&X8+$Q(1 H4L+5L0O
MRGC'$+ J7G%$Q%'#0!*T.>"5X25H!UD>0Y>=GB!YIV2O*H$6X3QY;._'$0_W
MU $-N<PA12]B.%U5U;P+3#B10JTA@L![WZ7V4G!J$'<>_/R?2[89P!8E@"G0
MRPQ0?2AVG!NKC&C!]+@/UXX$:?1Z5Y:")A2)0PJ(/ 3PDB4KVSDPB'P&/K[?
M!WO7$;C!Q[4M!^)IX\\$]RQ?!.ZS)Y]<10\3[]]>Y-_YWI^CP:JW$-H+ J$"
M-4^_LW1O@/!Q!/R; ]*RX]9<(WV!1,J;'/)4=)!<K3QAA&U/@RX;S#8^B)N>
MK>DV\.;C-I87*T,@X6KKQ-TBZ*N$^,;WDQEO+6 :'0IN TMA3Q2W"A9@.24?
MXM6[R>PU:B15&A[,A,\,P6Q*50B@7FDNUW?W7^6W[E+E7A^A$5.DG%@,\_XY
M:QX6SK[A6>@\GC,B,B*-(#2.73[@WAWMUCE\%:Q<BDJ%12&VH7@#AN10!FR"
MJP N++O\MP/Q+4/)E\UI]'T++'B95,Z,4I>U/(S56Z.BD:1RDT@)59^1;(@[
M/%D EHL>'I;DM*\.BGUHRQ+=<0005?\ V1:=7W*GK:3:.7I(+:)_Q]R>O\O!
M-1U7I_UR/I_#QZ'E$^]/]<3J JB^>;6+[XHTSXW_ &<_AO\ OG\-_P!\_AO^
M^?PW_?/X;_OG\-_WP!)1[[[^M_SSZOYX.J=>;UG^?V\\NU]'+I\?7]KPAU^$
M//J9SX/T<?!^CB^@?NS_ !QZL]-25\&>OK_OLF'Z@UM?A_3OQP0C+5\P]XN2
M=0TOW7N,>M/GXYGI_)_KF>G\G^N#00[\1^\Y\'Z./@_1Q>DWP6^*W/6_IP90
MAV$,?WSW.!Y#ZM_>2<(*#KUGLWSUZX+@;KV!^W$>'>M/]?ZYGI_)_K@Q:WJ@
M9^/]<^#]'#X3]'^CGP?H_P!//@_1Q\'Z/]'!6-.B6_X.?PW_ 'Q0>_S_ +>(
M\,$&>+_/CGAK4/7DOTW@8'P'/$8=]^OI\_TZOO\ N_U\6VI&-^OCZ\>+;A[Y
MXOJ:D^$7XUX7I"1P>KP/[1JP!N766W7% X%+N75QU4G,7_)8E#+%18CBYY&A
MKDWO:D)RZIE^H!.Z:A%"4@1538-4AYY(.B)\117-<IQ@_P#$;>H8HA= 2HMC
M,R]Q[/K@U0]P/D6CHI7+>7K4^$1]0Z<A!*RCNRGD29RZ/&/N1C]QZ_)I>E;:
MFI0)+?$TE;ODQGT^!WUX<L; CA8H1RDAX2WB7;X4PXF?8U8>EQPAN<V*=,\8
M. \F!<<?5U.O#OUX^>&A]#_E=$]CP?IM>$P5%()J&\BME()(TY806Y)F+\NB
M/F]-S+Y6#4.L@'PVQ5R>>"+,3QP7FG_794(OGX%6AC.,8K9@NX-HJHZFW-->
M1%+).MYQUP["=0&B0R33& ^7@M6V4@"K!AL'B3C H)F:P8Y9Y/F<^)/V:AW-
MO#X:_FN3<B]8X_LF81T.-F(8FAW*]I1UF00>:%DXW+4S2P%-;]DW>[O2SGF+
M]#&U^J#+)@0)#4QJ:3"&).8E=U?\<&D,UP&$^'\(U1^E#C=MK'8JTA5$HAP<
M((D51Q;D <,()LBH4QD?(#^A<X>W2?J(=BHHW<JFLN<:T1G; E@_JLB6GG8;
M7#X8!_*N/3O/_=7*X&-)<&+^@GB !,CM7_D=SZ?Y?Z>/Q_G^?;E^S]?]<N*E
M#.YGOUF7O@H>G_@)+!GOO]N$6A=:+F13V#%[/$VIQAK9<19U1J?1B^1"XHFU
M,&/J&N%!Y893GJ^(DJQN VE6<KE7J[67<PM.:3F'$>%_6HA&%&0D>P54$AG*
MF^U^8#.#+LFV4Y":]/8R*2@2!L"4P53M*?J4D%7"'(,7/-&#YB+G(%GY'BOE
M^**0IQFP^QL:SBG*Z/96CQ] N2U6+3"\06[)S"]-OYD_$-$8X"@ _(%PU9J*
M/!M*1EV&)QLYZ!W 9O6?&<@]EY#T?@_OAW"^Y_0U#WSOM48ZB=?7K^=C2Y_/
MMP8C3&_UZOO^[_44O9/?GZG[G 7F9B+G<MD /@K3^EU.;H*4!+@<I[W%YR"Q
M7R7)[@SU4ZCP&"C<)-Y6"@E.#RM#FW ^D4TA'H>6<QB,%#NIL 9NGPVY">E&
M"!K@DEUG'6$B@*%&/TZU<4(;H 'XWOEI=" V$I(LR)\,H&J1/ 8=O%GN0>Z.
MGE9B5!+6RPHB%$*UV;C7 FI."9IPA,P8)DQ?E4U.19?&WT>T\8.N"Z*QE,:(
M]D2"D*F0T8CJ\RC0D"_JC!#>0SZ3M$UX\6*^0  'KQ]KX/'_ #J-0LE06=SZ
M7>? >NCKURG:?8_USX&=8?'^C\'KGDA=V'GO\^??/@/P?3]LY^ G1UZ^G/\
MP#_7P?CGP/P< Z#Z!_KY>4[\G@\]^//GWS]0\'FWQYK?=>*=A^H>>_SR%L+)
M9LME]7?KP#H'T#^>7GP/P?/^W\OOGP-QPT]<^!^#Z?MG(>C\<IV')T=>OIQ!
M[!C2^'W]>9S"V1+[D[^>0]'OH[W?U?R^^*=I]0^/CX/P<A)">IGO]^ = ^@<
MZ,99AE[GJ^>0]&M<.Y+]9GTY\!^#D.H3U#W?WWZ\^!^#QU^/^1"UO)]OZ?Z_
MJ\3:G^?SR11Q'=NW_4^G!%/[/Y_G@(P\^/E_H=NCIP^=_)_WQH*Q<VT'P_SP
MVX805>AD$6BJPL,C3-!#R 4^")MP &)AQ[8W)]M,8A%@JMG'T;^+$!AS<00&
MX^\(L3G;8*<#/*X=$!=H0+3@?TM,-O2W/R@-]#>4O 5*@.*\<FA4J-(HJ&H
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MF1!!/ Q10%K>,B$/-WM>\I58TWKVFE"(ODD>E\=6?'%;5H$Z1*9)BK9:\&!
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MSOERF/:I]\S^?88T/L'KU?KQP7URD%R^^&W'[_\ OS_'B:%/"*'C5@3S+/7
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M*C>D$ "1W2(1IT992T&&$Y;-PN,$:.^@0_$O%] U01H(ZX1VE!$+22J-":
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M:O?N>2<*$^=2^?QO F??#]?V<4TXAO<%!4$Z1<]*R!\!A-E&J KA(#7>(_?
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M1_SG#E=3.P 51*5/$8Q;TO9M@%044TRA//$ 2//5*Z2+7P.#::I\%4! 7L*
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MB"G5Y1AJ5QJ(K*X7'P\%.5CB :!!\F;7=Y!/_6E3)J#JJ*)O4 *7#ZW?K_\
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M(THB;-K+VK(5*!G:^R#= 3L1,*-:% +P[,PO(SLP=&^SQRS:"-I[#MV%*QJ
M9<*%/)U M6Q?7<$]\,W$F>GH_7@Q?.#^_P#]RC<Q(6.+T8*ITJ#%40;0-2S(
MM5;6U((\4(=G;)GSQ,D=-1;)K"/EVG1RX%E/]?#XZZWC%'W]=&6_.=?=G%3>
MFN\S[>9\GK.,I*=+K:PN9]O'N<(%N%WWF^GY^E\(AUQ$!>T\]0SKOKYK-":K
M0$OF//H.['E[35;)/SB<3(LLW$OQ=]B('SSM.M $E\10E%/'*/\ $YUH#HV8
MPG%?*A;00#9!<M$GH#P?:4F70AVEA:O<5$H40\IR^D10^;QC[,^I)VV\A*-4
M%)V[S!^'HXN*)@AJ!A,K>K.WCI 43U?HL '9W;YB,LPTK,(^5]O&Y80%!WZ5
MGAPR7@0[K"+?N_@(G#A^QV$LDD(*5C[9S0M4U,$(T2#RZ/B#3R_3'OO%>N*B
MA$>;I$@M*4\)M>$!7H) *Q:MD\<*RB'BI*A@#XA!'JVZ_P#)S(<8+.2R_P#>
MP!-=@AZ4X"+(1A4IA7 I.VP1G"(TC-00$L?'FIA%9S[@*"@@$?@<$DX 6(()
M$<9'?SB(8;.Y?QXZ[/OQ32- T@U9P].=^/<L:EB^/,>[+MQ\>>)Z9H;E!@0I
MNO#(Z33: 8<J,GD: @J%(A"%[((Z<"Z9U@VP4[F[X?;\;]^"M6]1A]N'V@T>
M9@BQP,'9HK)DF?;B:=@Q$ P+,1R]&1IY!>^BID[&AGCPBY*\F79]HAX#^O1^
MC^W*[LE:N@#6\!73(\4;B:TB"!2*#%>V-=<QQ5T1%H4Q]!0;S&AU72L8JWBG
MG9;86F*R\6D*5C;)"7Y!6J4Z?QTL&T%V@$J0]FVD]K1,/8D^JJNWGF9 =@.\
MQU"M\&/->+5"FZ13!,[>Q.4&NAT!4+3Z5/UO6$J4$,,P'1+M6R^7Y\S]?.;S
M&\.=>O7>SR?MV94VE@VV'OO5%Z\<"^I!H1\@C!S*/#I#A4FA1728)2$JO7!&
M"),#2\I1$"BBTD :-Z7TWC7@F4CJT IIE6X247Q()]!L1!=0>^ HVC%:T"DW
MN*A.9BC@,O!0D!='7T[6#!@U"P@$I[7ET$9ERKH,B<-Y8:@C?TT3Q,H*L$D*
M>":+%,X'NY#5Q*Z:&(4%VMJ"3V0A&#;BVXVJ%W@K@@"TXR81B4"R(P!MRD"I
ME3("J(>("*'WZ4"VV=%M\ ;"$5R\<P"5:Z$K0\2V,*^'="\1=D>K7M7O]Y?1
M>%BF^0Q]%._0\^7.)?A 'O@A,=LB_HIK:@U4"@*'@4>0;R+)-3X(W E$@^4X
M!8YVQQ8NB![R9\S-L*%8*$@B#7735WZ01TN6X XM#(!.GH=%$1F)RH7^[U@P
M9-@_GA*8X B,AIM+]_Q#UL$,TZ3"G8),PX+H5%!;%Z+,NIHEYO(#@GRGUTQP
MU7+?\%?KG7$J7*V?Y/C_ .X!%Z/KU[V=S_W@:PG)9"ATH56!<F\$(7(E*AB*
M H@#5/<)>M9?/U_[K>@8&)='D5N8B+7&4K0/NG^GB3QPHL N[Y^C^3DY4 +\
M9X^O&)==,R:[+\_!U.B- X-?70_3XXE\ R9EZGCI]_3SQ(P4'R(2$ JTB\G/
MV6NLB,U:W!.7<%2@6HP 90>AJ3"7DE4]EK2>]O(#P *&#51.MMZ/%\##4U4I
MK4@^#NG'X-#C=S>X'@14GE>%#\ZE0"U4)M1@#OM!]Z#.QX6-3L9V*IY\AU=7
M.0ETN4VUWL%U*X^>,LET1:SFE2^)7F"H4Z@0=>)I/CQCRPMZ,Q+NAWAVX/%T
M2#*<PC<'*KCEN8\T3;EZP3G-:$I/2^.3<@$R,1F&? ,M>."@7;(#!K\BAYUE
M9=F$Q 4<#3)'KB*[;1\%#V:(':*/J7%20K0<4=R^.-(5=A;I4(@8 *=@">%J
MD@J1P;O X+DG4_@6GP.D56$1M"GU )#)IT6II!&05*@+4T0X<ZY7NI0 ]F@[
MGIBS R'1RCR^0\\?N.)X5-1%O9&$;L)\'N5[*BGO?#X>0AX;!;Z\J?$-XP"U
M P#$^_CXGVX6;IIFL=:J-F*\7Q:]0.5I)%" (2!/=$5]FLW(]Q\)Q0@!&#._
MGUXV;\9Q- ;14C.S&R?#UKUR9C&6O #K"K_KJ^_[O]/KRVV!8H,0/8;-CX:V
M4C9#2@$88J/ I!@XA6D0Z,*AQNNXH1A *NT)CRP_,#P'#F7)O9.0%5"K1A4H
M=&#.4,XS7P"8(4@!;G#ZH#,5H=TAAF@L*G#[Z,4EP>.ZM^-CT+ P.R*0JQ0L
M8<@Q\$0M9\'%8)#AI@TU/6>Q(*- Y(+75_;-\3]?IRAZ"F=?$O<^DNW@#%ZI
MB%G2+%[(YQ]A5PIX6AFL"V/(5\!6AY28 !'30;U5!.P%T#6-27IM %EE&[02
MB%@SDME#+4%!?8&W!F,4>.-'67,B- )WG.2OL*R<56HGI4)/@ #IAC07"1GS
M"4B$R);24./#V1DI#:J%!3QO*\#"EW5>3B5'#3),GR"[!H'^"(..@)W);>YW
M7;^EBW )B'@9E,Z40IRGW#J:LHW@8L<L(EKL>05H)4B/:B0=+Q=N@TA$<N4;
M*G7@$]ZJG<(ZF0A=@L23%0++-<;@E!0IHLE9DIX0"5O';Y332)= ,$6@I7?L
M3!3O @#;$/!^L%M1AP ]Q](<J+XJ8!9#!CV0" (P%76"J *JJ[L0X&TV<92R
M50CPD4#@B 8[3L\EH-$^C>N"F4H:+,4!]%W@JL@O#6!"'L^/'*WVGAP'H=!2
M=5Y&(;F:JX7U+Z;V<'IVPL3$J,B*$0Y1U=$1'M:#XKDW>N#TE#O0K\*THWY?
M7!/L!_/Q_P#=:%[/KGU[Q_/&(0B1@CD#OP3Y/GE*(=C);"=B.)>-G""W? ID
MK)QIVK+[+^S&TSLVX2K30]-JX,WY?=)0?I'XX"4._;*D_;/SUP!)27V[W>O)
MG<))Q$!2C,ML)6;YN<8 88VSYJJ]L#KSRW@38L.H.Q+4KTBLSOA%G"T8"W J
MEXP$"ZH9 ;>+EB 0A() CM45CCKA9-4[*4-/>Z7./FCOZCIA0*O46'%S%_V5
M08L 0"'(O&5@%X4<W4] >!UJC7119W+?@[SE"(&'7X\_7V,VWFA#( ,5TF,7
M?7OX&2.WD%43N0GK[<C@54B-2AZ[Z\%KO*)<("5M#'/BC?1Y8^]V6D=/5Z90
MWHFUCHY2B(D,3M$ETCR<CV-**2R"!$.%<T=WD "("U2&@4V33>6B0*H[P,=0
M2L?+Z^[Y6!N=X1@ !W+6EX+NV$D"R ;[?!7&_(..X-$=J*N-IO98!<B@8H%%
M(#M0X2E3,=LL4N@SS.+XR((L\D,-W?%9)P#GB140A("9M*0,/R%  L>P:-0K
M3U^*$%&TS(@AR=M!T[&:XAA065P\#(LHJ.C#@:#1PO8_K! +72AGER<R\A ;
M1>2X(&4(QIE=$5@BMP++XBCG->.MXF*QFX5#3B29R'@=9;'6,3ZQX5!29H#
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MI\./SO-XZ^GB.[_G@S6.II!7KZ7;/F]3O3\D)ESY+@]>KQ(* T[?L2;W_CO
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MFG4-- Q*4]C))&"!<HQ$M!V5#%T;.'*(A$G[0CZB#CH,KDO[$,/+ZA /N)9
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MXD1&D;=F><W0X1 %,.W/PY],O=X1QL5/P;5Z\Y)Y[X<IOP0>P-\9<._DX#H
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ML1V:'-4+!+T'#6#I,50/!I$1 \W'T:]9EOT!H$%86K<G?UL @6$I!%O#32-
M &Q@' ^]!=09 .$H%.&Y@ZDDU\_?V^4.:18 103HS#T9O@\@BH"/TWK&P_\
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MLW$VB/UWR< 5?/4*G(H.&2#CR>Q@9B$6E1%[H7*P>Z*U)0KQ2(KU6D.AA=E
MV[V5O&NH!U)#<_\ /ZD4U%ZRY?G.OO.H@\%2N$ 0\N@.#3Y60U+C@EB4O'1+
MPO92%L92ZL-1YJJ14W5!0&&[V:NC10)60'([$;@[<-:"=A54?!J/)AX NR.%
M<9B"I2&<,5043U\=*U(VM%"C>66\H_#:! *B$-1\IP5M$]*ALUP69K)QX%2
M1>"6^B>U 4!L"DU6]"\V2K!6*!P$SBE0:T$7SPI7>)WCM6.T,$&#<'C.E(S1
M"C0"D O-0HGZ3I:1=.^M_P!1<+RIUJ)C!$:]GU_4H2&( *@DH,-BX V@T"
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MZ-N,$$)40K*F;!.;(6<(@>!FV1&&@72 %&N/+JWE(2FSR"\$9_'I .VF38D
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M:=$!6=&;W@H()N+<9K=6DBZ(S 1.DT,4 (-XX8GTLH+": 6@+?#/6IZS-8/
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M#62EDMHHBT[3N<+=+8OJLQ8!:@*O&ALT.I1#A BH,0Y=H3,KZG3X'].#&ZQ
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M7E#781?!R1 [<(SCZL"=FX#$@0X1<-)F1%!QJ:9[1H I$U)  :" 1Z[X&BJ
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M 0G$PZ[F=K.[&?6SSVEW9L\/V;[_ /.-@0V> +X^L^O)W4\OCQZ#XZ^F\H1
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M%A8 4ZIP:I0%HT&:Q5>7MS87#Q!PTO/0'TY5^:U?/V@C%B@X%<*P-Z?INH<
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M$@D P7T!FN/67<X+N-I*C5$</9R/0/)O7V?)W'C*%3HD0>@6GITS?,K3*2X
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M,>NI-Y;%+T@(A;[@@;[,XJU!NJE:,A"GSXS@]RAKTMT,>$"'GU0YX4PPP+"
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MX2\2("?ML"* VD#1GYSG<'MP[,H71M>W1%DI2HPYBL4"Z;!;PU0[6G=*/#!
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MY:B)QXH$(%%;OUXZ)02ZAL3QT'T<A8D+ >-! G;"3@OH F%/*F8=RKWT1!'
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MA^W@US;:E7(0<$L%H(J@+85VZO.K^>7^C@\'E/HMV-]-/='T\+?<[L/QUQ=
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M'B3. 4!@J\]DVF@BWF/G]S_/F_-YA/-^K>]7YOVY[F^S^QY\C]7_ '?,XR^
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M1&$6&1SB#8'"8:U6)<='8N$SES=-'RPAE!67<I,](''VJ*&2.V" ]9NW#QG
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M**<Q,?@SWYY#N.YER<H9QAT]8WG*.JH5AR=O>?L7D"( DZK4)* 6D1-0GV9
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M<#<Y1 <"S1M@N 426H,CN\1)Z4#45!8'0P=TJFVUV-TC( 1 X6'+%TZD<U4
M,$5. KP "*HF(:,5K[>OXV/D_OCINM^\9_<_]-(03'6<Y_)*GU>46 \ ?OYW
MUPTA3R'Q[]S[?0\[J8>O^OS>^.]_H^'S[^G!,,/HZG^GVX*@D*SHH27>]7F
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M?KSVOO\ ]<]KKO\ Z_>[ST?GXZ^_[OT?GX_?UOJ_+_OGH_+_ +O[B<]#[O\
MOD_Z#C\\P_T/SY]<$-?8?]^N7T?D_IG+Z?G_ 'R^C\^O?K\O+Z/M\>?CXR\J
M>/L?ZY7U]@_H]?\ *9HQD'QFWB@#H,@!529;*OF\AFRDXB*5@43H^VYYIMSN
M9VII,)7$G',T!D!&%K]7Z- 1D$ 0VG!@SC$R'":J 0 "J $"LZG(@ SO;_UM
MSN<<"*&BD9CWRQ*J^60"%>L_.>)4>/"1E$^!W\^LMXT0VA1>F_GD (!KF  -
MP @#!QYS:FUQ5^W\_+[OW]?IP)VORWE]:RT9,=Z_]^WOK])\^N(.4$SE_/\
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M"$Z TS5<$;Y>A(V8^$0+# TQ5"@[XPAM(JFL:<HR\6*9!LN/QW* 6E /?"H
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M/UY\)G36:3XZFF<=#0%)(@R*92FA1&OF"2<:LW)T4 F'.1R?3,X4Q1G92!$
M@!@5Y/0(R*V10PI8XI>5(D2A2H,!+A 5A."!BN&04%*@-JW5V-'>G0ZTAG5J
MB/QG-:F464E55Z5Q]YIFA'"4<P:!JQ9HQ&$5:#>A"A467S/J&&WR+)X Z)!+
M 4C%=TX- "JC!@E3 [%2O/8G$,0QM(145K:9-!MXRAI+R4)%2%!!E2<239Z4
M- 0" +%>7<HL%FBYFB329SV\-'P=WK]QUK^"H3=AXSY]:O#HEE1A2/DS!"SC
MS :S4,(P5J-A>7CJ= BJH@A*"LFH<<_H(KA(0%,RVLC13D\B@ QL=N5NCK!)
M#A30!0 H4N;@+<X<IP%2 34B-(<G32'KC3D+I 2(N#"<P D"A&( ]V^-OIXU
M#* 0.S,Q"(@SIU#_ /0/ VVR")C/%Y$@K@#+:H*1BN47GA"!XB #-@$#4WQ1
MO#&9D%,_/ QHE,%4<&P!&<SC$G80#D"R12DJV#Z5:$I"4=M(5X'RLJ/HW5&0
MJJLBQ,%PGD@*L$M. :,FB9C(-!*>:)KC/ 'W '13/\'>*F0)4@TR9<.$0\8S
M7$!R9NQR=]^9R40F%(( F9EX6U,<ADF,$,* :U!.W<X[O!J@%%982"ER9#A:
M'%#B^MC#8^?OV3"![CZ!^F(=IP8/19*6)K$4 %-).0:@ :+D$.4^DSRB5$%1
M(U-U[);WNL/,U.K5TXLS3,G>7B'_ #M J,=%1!0N%:Y9A%@R,81"7/S>(;:9
MD!R.<&9$F=>^0*++MK,O5P5Z[>*,!)$<KI?\\!Y:T@H#8T9$$&XG%E:2W=?@
M -C,$(&CO'$&WZ?O^>-45(Z\=M\_.+.N "VI,1Z"ZM8?3)[Y>3QM$QE&]B(S
MXKP0D"9RL ($(Y#=X7C$P<&&A/@Z(;UPPKBK"C1#!\#O[<03(XZ/A"3)YIG!
MQ]%6&P&(( ",$PB(/"^@;0;-HQ29[#87I8CD;52V1R!^($>FXA85*P3C#7&S
MP_( P574-43M2)JENMN(2AF%B 22S+$[3#VS#Q26(#DBU./UO 84,)ISBHI]
M%XN)C)7@.ZH(Z%@.)ZT-2DH )8(USECF$HHC,+@2S&$]_B<.#?&4!%LPH5%D
M.)PY3@DJ1H8*YI4%O!B&BH78&GO8;^>>77GOZ_[_ .YQT&4BL$:*:6SSP\0U
M^()!CZ&('!LKUPF0@$[!10XK5I JEN&#G'5'.^%9BP. 0%VO9H'D_3&&!4A*
M*ATYO%":U!XC90:1 #4.)00S(3.S.TQ2%W8(4U,')#- ZU-Y3F08%S!)-,EI
M,ZX>)*0(Q4$/<3U?''GR-TBR&!9@4>RG#<@KVXR7"60/!>!(3E'D$=HDV%WY
MI_'@CU.33O@6J-07$,*BJ&S7'_K.6);8(QR")QLC>63 S,B5*PKK $FF]-L;
M+C0"*$<L".A0=@ 2TN3EF@P(H+#0 W:LTN$.3D0)E)+0#/E<8=+B<104O8"S
M.'*7CMD  HV$)HFEE8O-X48806H940XU+#.86T@8T2(@W)# .7"6R%&N$%E#
M(Z1=,AG+4M\$1N[CH5IQI0A!MGC>^9NB@MV4$P:C/%F^/U^4"D_IDI#ZYY!
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M&^._V<:)4'0U#$,IO7J=\+# 7P)"RQR,Q DUOBB!B5L'/"-JS4U>!R:J#G
MB+2#=L5.0QJ4(B_C'04M2JW'$HGGSQ(RGY_UP'(I7%&-CC08\&KP],9&15A
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M -<]!^_^?WY>>C]_3]KR?+^S_O\ 'C,>7]_7],QY_<?]_CQE+.O\Z_U]V_(
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MYS91.\"U!-B0I.A J4@2A+80,$$GISST%9Z'F4$(6\*C6U1+,HRT>!H @@&
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M"ODQ/$"V!0W/>9Q U\($(Z]B(+J!A1G208H8)2H;@66W.0)0YXBBEHM9>$"
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MD!H%R.@<R("JE@ 73'!2[X!,RJ0V)A4NRIV,O YA8";F"5BK='$0HG"W!JT
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M6W*N"-RZ]\4-!CS_ %_?#T!$47(!5%P9EQ7 \-1UG&1<N63W<:TX#&:P8(!
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M;1X*P$(("[PE+@ !S(<$$D.5 @H%Y 7H[XB\_5 @4113AH$.'T[,=^4D2D"
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MNMH79JTX>H1@,P0Q5$S*DUZ^KD@=!4S@4SZ6\P0YNI\A2,$R %K!F( *6!Z
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M8C3**&WY)'B)H$P(EXNP0&5ZCP(:UJ8 ,<Z5,@?1X@)4%<5&&.YNIX'FA/L
M,"R#Y_+PP Q4)V46N2!,-RUT@#6J:B"'>%R\CJU(]E=\$\0[9:0NP68:)\DO
MCR1 *VT!U<T4&[[N"%"[AEU.&89X!E@J .U]@B#V"NL+O'*EC,K&%=/2)GA=
M<0C"-&*8G%2IZ1K>6 -7D$0LI0>A=<E,H8%ID'E?&\<R!B@"QN0Z8T9W_P#
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MR@06#389G^$L)D(EE0" [9/CC&+\A<:8($P9[?3-@,*!L!X9!TSDI@-&  <
M%=J-SA;H+TJD@(IBA@N:EXA<=%ZD@RS)$6]&G&%F2FDL)9, V7+Q/!EA[!&
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MV)A,FA,\*%B)C])<:N+XY?.16(""4\>R )WQ>^H 9(5!Q6C(>P+!(H"K!&
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M$ A@KD';R%-.M5E(%Q5P8N:N]!@781 IF+\8I."@4D7-A%9 C7QKDP7L#"0
M>V"]8&G$](Z;%2$(1BH3)XO74<EA*Y0;0VL5C#'1)8:"(8K.GBI,@BE4 TJB
M5$CA^!&M**RY &-1<6<#"M9"-&=8QG.MO @!# _G_$_26!VG$E!#=PP81IG0
M'1K@$HJ6IU(9+C-.]O%&$5QV9)K&LZGUXT$'R)JN2,)YL>GF6BOC5\$'IG.'
M7F33EP J0N&%6JB"U$Y "FH$:E8F<NG#QM@MCH@!(BSD*T8'$Q(.@^&T6"8Q
MGZIS+.[I"$(T?@-?8\90;"5'>#%2(-PXI69E'N94NU,5^V^)-<M)2#B#8QER
M+]R(?P2B]X"&=!G?HD3L7"T4(:UC3:6XG+><34&AD>AEU;>90JRF8X  *"L&
M)5&MBJ %@BX3D+ @BD2]4!A$+(B!5@,8IR"K((M"E#1LWQ:Z9#(VL!)$6"+4
MO$1BP< 08NPBS8\"5U-32JC)FO;JXXYH(!A( B@586U=\L]!:U&F"!!JQTW>
M_P!7_7WQRIOQH]_5/2>_7,:K7%D%4 N,2Z7CSF'0R6'-,*M96#"V=HH ^J*@
MMS2+<"J[# BT 1Q8  (%#!"WHD5B3H..6E7*TQ\/63OKV<W-D?"8PMU*[G[5
MX<1?8((0C@0ODUXXL[/%%&$18*+%0=+QB+DJ((R9C.76--WQA8@DT@@YCY!1
M227C,QSM@:S(OFS =KJ)$]D)E=8 D=S+>7P\;,?G77]^W- 6AA68#UC'S^3@
MK!,0S?%Z-IY>9]?V?[_'#1-0G_B^CT$IE!GGC%7!RA""P$B4]<-&"=2F:'V#
M2 8G VRJ  XJYZA""<1 6V>%2-+1-17B#WK%$>R*D$%GB\LBY3PP-1<Z!;>"
MK)8(5D0JMCL [,,MQX:B0) 8(,@X#+;9!+*A(R;!*\:2#"4%DN!;RXF%'D$W
M$Z[A5$67NUKS: 4/>UI7;&<"8O&WPI+!04+&9[#]5LE-V^Z^MDS_ "+" E%1
M2@W)YO[<$RN!B"!AOS"Y6G(#8%LJ$$R5DZ9D4XS(2:*H#!A0(DS3N1%8P1@A
MR!55R0!+$@9"(\9@-""Z&YY$[G8(9&+C '#)OD?RA=9HA!9(I<QJ<2T*R@F<
M-P%@6$[8$1Z=VQR1=C33&^,] BIE2'MH5-#&)"-<D1=ADN#!9I\\O:+W# 62
M.<N-TN XH6)%"% %)%&M>!QRC(0%0FT/D&GI3'$%C8;""SLI@ 2R)R'-[3HM
M91P"&G/2%TV4LZ; H("@+E]<,D+$A(P6"(.,";I'G;J42T%5,@ZR)9DF0B8(
M)4BL@1<)VTD&RY.#;(W9,VG",= $-$"9ER"W.>,3+HN<IEZM^_WOZ:>J7XI>
M1&W&-N>@Q);OT_7B$BXMS-GC.)Y/L\8$!,N47'MG^1\J;"H):<T(PQG2%5)S
M3\)!37Q=>5?AX_=*1,<E$3:O?"Z/)1$,S2HP?>+GB;A.LAAP:_'W]\5CAL4N
M.LH^1Q3;R((@!:F9.G]].>"BQ+!8BL-;=^L\N2Y1&F$'WH!1[G)+$%6$$5QG
M >W6GD!M> 1AJHZW0U]:%,+A;[0[^,4QS/B"-/7MGXW]LN!5]W.3KXSC$/?&
M<K#-OA&YYZO^>1K_ +^[5[]9^>?C_P *"M@YFYCBGLQ%9M@^2?O1&.4J**<%
M[8W(CIS->_ZXH,B@2*KD0%\4]HK#];-B%3/,?<S9BLD,@,1ZA1,11R4"+@H%
M82'!4W#8BDI(+E@>75^(64L6<"A-57#I47!%T!1V)FK5P(U?AD5BJ;+B#5#(
M0+H<@72"H;S.O%@V)!FEWMNKO9QD" T\( G>I-OZ?'K^_7CJZ.L8@;:66X-N
M6@!DZI&5@4^"G?$8:S $E;>\LMF\\251JW4M-R.UO5QR.@BK$1G%1,51SP;B
M"#4'($ JA4*[QOE+@I#4>S1F9QAO,!0AX!!%)+K*>_0JE4#1N(6+8D7Y3B.3
M ()*2%5V(,HVBV-W,K,M (,Z!)P-VG&/34<@J1DL?E-T#AU8.Z=!KQYXN^ D
M>NK;C3]/>'B,= +(>'O"LZ2DG*#5*%+#H,E< *+J0383! YX1*H5WK9PS@;Q
M5,**@D)Y=]KPI "@*2J3 7%*"<4TH&!B@O0FI#@!ML6*LH;5Y[/'!@405 !7
M1BF3@WDY; 5B%E"Y(+NL<T10&@HV@E8/9\K>$5(ASPOV8Q\/=_\ %JD5$WZ/
MSI/#>)2FP3Z[G]V?7A("I8?:Y,_;YQ.,9 HYR!#&33QX-W")5#ISHZZ&3\F.
M+,20),\*4<I, LJDI'P#H$A:()7D)CDT.F O?\>/*0@)@1(N0^\S?VSC/!VB
MC(,#&XAC,Y2N$F$$""3-"JP*<)H3+=%PX,3LG?BZ-9@+$UX8E"-)CC%4XD0R
M*XK1K?/(-D0E,@3)-C!?+*< L R<JLJ!IK7)O;QR!0A,-,3OW?IOB0C!'+Z#
MO[8QZ\/E+O/H-_?6G?#1\'_AQ\O^2G,&1R; B),B#-*AP58$J*.%Q:D$& S/
M#P$0BJ1YI/91G@QXJ:40$,$CETF+QCI.%3:+R!D+44XW'C;M :B0+!*=Q35:
M@P!7 +0H@EKACU3,&P*<P0PRJM8IQ.1&:P4 3.,SAQT3BL&J%:]X$XZZEQ4H
M 99NU\EMO$I.CJYJB=R:\ !Q%MA/7V/ZJVZ>]P=8OCP;)R-BR!%QE%5IB7-'
M@K.>BJ4]JF99XSQ@%-*N#)I<T 4[#3C  MDS13&I\XO!7I$J)5%"%<O;C'=V
MD0QG-"'?4-H8*:X>00B9")*(&4<3[[L-V"0"3.,@Q(6G7#$80QD: HJC"2P6
MBB?D'&JW)G)D.\XM:!65L%MNSKH)X@V$_@E#+!PN.^N G --H'P9ZSGQDX(1
M0C4D %$&3*H?%XF9]& !AB&R9#NG+F,8(@<K!3=5)AX]6?@$8A40<R&32<PV
M5@.6$06!$(00JF41U$("(I"()')@*:4:* !JW&EXV,*.T,@[0&,X\[RX'J&"
MR92 OQ+:R<M%+4BU<(X6#G-8QIQY L4J@@LT'&!0GZNF;ZX&FNGZ8_/ YR.1
M1#"Q2/5"SLO!EH"%#3C8!X?..G?&0RZR'3V[[^GCB>DD/&RM_,TZX02-+J0F
M2?59.^ &(GE4$,P+6"F#,[L 19B-L/?=PN/QQ[7!T&6:K@OGN<&EDQI^FLYW
M_9R+._Q_<\3&UGD^#$W>OW,\BE$8.J!N.&A1/ \8P5-:"I.0L  KM%1'L"*Q
M8S@8]N<WP8!PCFAJH9,-R8.,< &O0R@OB,X>2]#UPHZ^001SS%N&D3LSO^_&
M>& /'_AZ=Q^YQ@!8LB*5 (LR6V',3A5";)6 1&F*@DJ3&9(B5"(2I:0[X\(J
M1! @T:&&[A"G$M$<B*HD&H3-,29X=X18\9"H# .K\#>4 A<)$R#$<47$+.00
M;7P4T&.4]P9XL?$A 5 %A/5F.T9B'"8HJ]D]Q5@"H)#9,(ATD@QAO")<$S:,
M+,K[^KG?*TA40T81\@Q]W]8% *A&5RXT'CU:\DA$-8"?W6)P#8,!T08R]EOD
MU<\NJ*@.DE6+!&'SYWT,-"F1.- 3_9P,DN"8UP8&!@AVWS+2@,I*HG0$,0RG
M$;!,E"9!U<X\P#IY1:9AKG0.S 9<7C2H!2:@9* */.36^2)OEZ'3+5"NX&MA
MK5=6H.<OCK&_!.&YJ"%!%9$OEN3W@. *H,*><LSU=>;.%@1-:I4+V- #.NN!
M9+"S,6FJJC<TO+ )'_YV$P8(4R<'\Z$]>#:F F%2'H@8@V#3K46"R<0F<\4H
MF5(!=I5%335A1$"3M8XF@G O,G&40 9%+RTXX\2KFY'#0$2O;824KE.  AS$
M>X;ZB&7NI!"C,8BW.G6;ZWC_ ,3;$D_OTX&01%2]<%MI]C@J$;LAD9%<YT6X
MKB<  %0*VB@#&:N9[XE/C%,FF_H3>[O'!$6U%]SY2/@QK/$82!SG0,F3)J/V
MQQUJ!B5$(Q$JR!(LBZ8?2*T^$4>/-<#<RP-1T9L?J#O/ C,A(D&L3YDOGB,0
M<)"G<>WO&?IHP4 %X2VX'LUF3-X&:Y0!)%X%!C#O%488J-D#QAXT,OQQ3 ).
M2!6I]BFDPEK)\6"N<+%Z *5%1E"V1&JJF<(/6O.9_P"<?A/NDIWGV<8$.%,>
M:NV<. ^)Q=.Z  0?0@7PTZ3AE2MQ@T#I(&VO! ,8  GL$!,9:8#A,8E" A04
M&DVF<.2U9A,.!!5)(Y*(IT</20=X@R8T6-3IV$%K\-'%#*FGA,9LAS'X4M:9
M34-&+V@E(/H$LJKBN2-""(R$!.Q5%(?!.78I6([ ",*K+@E:'(F(+CG8F?1_
M<?JU-E%_<^%7'QXXXV&].=9_CB F@?*%^_9K\<#H0I\KG\'63?,<L<ZJ0E>I
M5?>=<)I+Z T[D(",55!#C"8J-@"JRHG20GDB@+T&L:*M(P:QCE<#!@DPE(N/
MM],EXAX6R!E$&#61S'!Q5P',JPODRGR>,<8Q(F9%<C,B?'WX<E.RHB4?AQQ-
M;0CP=!7:$7$3#KCRR98"I15R$K!QIY4!U> &N<!45F1M[JQ(4HL& (XDO#>,
MEYHW$C<)4@Z)XQ'C JR$"XSV.!!D6M(F5 O@'O;G$XDKYQ L'TQ<Y7B*Z**P
M@)9+7IWV/#24 .,$QXW%GR1UQ)T_;X];S?\ >R#V*>=G6_[M_P#)(I./P^T[
M^E.0.7,8&XPN^_/VX$ ,;\I933O)GRYQF-WTS?J<Y/CS\/ A*_W^Z]MO$%E:
MW<TCG6<^??&8%Z!0&>==?UX($ 0 0 T$->OCA S^'T0R7/USB<POL'\=>?\
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M,(.I N0Q]4_SP!%Z,<&']N=2SB;8/^0^7G])Y!.NQ'X3SQD 5M"5D]\1:AW
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M':,97$#N'N2$ 3! 5<A#@ , O6UI.$7:X5AFD=SNA63KM.).%>4J0"S5M"Z
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M<$*:B<$!0+E2'QPK*+-E!40@H,7*'%I=4)LT9VF+GBH+)4@%!L0RFYGCRL(
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MUVHF.5'$#<D06\.%8H"6<)J:I4 !RVYO,/[WU^GY!^_,' %C>1AA90TFW6>
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M3U/>;EX@.B;@:WFF:>S&#P0$MRS4F'P"47,[XU#RF53!*(%9<D:T,EJJB>3
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M2!#!0C?$=/-)=V,F $Q26TRBF=@L<+O:R?0Y[,?&&K]I.L@]<L"CUJ./.?\
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M]( !)4' ]! +P( U1@HT$TB&0K8=B^P-R,"O:[!*CFP I!) )D5]S$**5J9
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M42X'#9.7**=1:"*G@JBN!+$%4 "R4XT%#%(@6 &,P""*3DH7ZUJ)1$", 3@
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M)O/=S:VT367'Y+]> [5\U4^OT\>>?(SVGCQ',[_?@!H?']^_W]')X'V/[WQ
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M)_?^GWY3R?<Y3R??E/)RGD^_]\G*>3^_]/ORGD^_*>?[_4XI*9^,YXEY_O\
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M(QK<=SXEY)XZ2O8>[CYZ['D7DBH<O(82(Q(3AM-[K-( Y0P,M94(#G,A*7&
M<-MSZ>3E I'E\DPZ_'# 'CFZ%(=A.S6"AI0BOI:$",G50+AY$!=FY(+&@>':
ME8B%)\H761504KHP,&7P60"1PP%%,6!EP P(!)P%PFM>=]>7 ($<LQ!<4Q"X
MN&(LQ&[NH41(ED?H,.L +;0.-Q$"!UF>2\0,F=F(#F=P92>*R(@LLKF &L(]
M7/%X !Q<Y(90)1XD "V$3CB#BH ,A5C8SP+B VPMA<5J D&0@KCB=.&CKPI@
M$(" %UP7!SFP72+KV.>'O\HHK(%7WD%G-3D"S@6:0AA1%,ZKCRC-0"T9!"8
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M $3C*'&,9F52Y2#EBLRLVT4 *,""C]/O;@ ""(A;8'A)V19HT>16A"'3K@D
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M6H,1!J!JAIE.8U\L#??0IV;B"H)P$>UJD*"JKGQ$*BK)H/L$,HH6"8($&$]
M2BR"4+GA6D2(*HH-K+BI&:>,@I8A#3&NTI% Y>:=JBT2 2"Y8'C/(*#U6BLN
M#$\C-@=K"VFDZPT!H*DAE08%L\H+)>"G%4]3R@B" 1%> L)\&XS(S)L44S^A
MV;3]%8QY%RY.3&(A0A4+<#1)".#IHBP"V'< J<F<RB(K C:!9&T@P)Q1U#Q2
M,,O"T[$MY/RC9<07M 3E\PE FS ,A7& 7I6>"4HS-5:<D64,N URW13$*PRC
M%A957!NB0FOHGI5!^LXPRT)@T4(QHC0(1<TL2"L7!@;S-8$Z>005# I@#G#4
M3H>$HI<-$E9+35!V]UJK,4)0:AD+(17(UY!TL6 !95!VE4*$J5)U"<C1$LQQ
M#5A3V!@"+&#H0.F&L@*%4C)G*SE'&?%)J:%,!E&*U*);B*-8%J6P&!5W$+,7
M"UA\]:(K.+[T HF*!0H:F'7*KT$T".$C88M')-B^BZ:@+ UU 48JV_&NM8U_
M^Z8^:?M_/&A+^);7[.CK@@"Q0,) FR@Y+*2W6O$D14(TI8K[,$\%-6B:5$)E
M[FV;&EY 6N\/"5HN SE&.S%*%Q-L-+G/C@'O.E5$V45L-,<)HBPP(BVG:D9H
MXV2%":2\LC0IMV-"M3.U@55+A",@R<8?$Y:!0A@I<=:T:X="6QF=D)L4Z/\
MG'! CY2Y&6LB006JBH=D2@%8"VJN1(WR\"9)(0ML4X'P/*!R (9!&,FM\!68
M1:=(P#,$I=\)$1$S#<W4%RJ&[ PZCZ(&JV?!5ZXRA"Z<PE1J5:@42I8L"/$#
M%9% KX4X ?T'PBR@K 76$XII@"X1\- Q E;G&!8P98<HQ5\!GAA!*E&;85+[
MQ,P, > XB#386K2I@>[=RN6"</$&<M(B1@63CL-4@"@-(QJ%2;X^D"W8'<@@
MB6(8PALG="L*1:NE .6]8\Q-!02!##R-R@BQ-#E\#A634E5C&+AH:)92!!-
M+A3,<7H6UF<@)B-( R(3B0R%H/@M2Y!)1U'AH>3XMK!,()NU"]HH4"!P99#,
MA5&R1@902ZP?+(8"V*,QDE]":P01$ ZU1!CGAV&C%L#Z]$2P %FDB*.L"Z$
M.)Y19SNWVZ*)BE"H<!3\>":)MN5HY0#N"#Q'%4#3,S!QF I4+QB!P *T&G#T
M!E%!) &8**1)$G>'<@;F*&8HE7"<;Q(U+ 95P*VT2XY"F9R<P" -2(*!Y063
MR0$"<H0IL2M3GQ_^^6'MGSB_XX^^=8] >-;_ .YX22!"]>CYOO.I6',BD!&$
MHA6553C(N=OQP\HD8=4RI>C?(SRSP-@VD"^O \"P[^0JL:EH2=J)REC+1")E
M(F-J:G #*.TA$")8[+$MXJ@+0+22*Q,C#GOA8G"1)B(J2(,:L%Y>RD- #(.B
M(^F\\A&81_PQB:->)PQD\J$HO@(Q,B"XY?UY:3J,XS=@LM+ (KLW!&HJ4I2U
M1RL[ S_G_&#B-22*[H/'V'HXS@*:X<J=01@,F,O&QFXK \ 00@N%.WB!-H$T
M/V@@;G+E5P)>T"D"!VCEESE : )$1FI4KTO!UR1AD(3:D8)(/$F<84!=/,DV
MP<$K/ <4T DCB(J_2Q2RJ*)8,YSD?P<K P+O-+<0T$(M&E0:@A5EP51:K5O
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M8E@XH^ SU_NH&,0Q!Y2Q$$D8XKH*F9IVX,UBV RT=,EF)2+FR!6DPXH* A5
M/),@Y15]X$=7+.*7,:'B2=%9H9EM51XT<;,;2CUQAE.4E$48Z@]MLA6, .3C
M]I)025 H&ZYKO4J1E-F R^1,)A>8X,$P^04&@)!+ #D#TJ;P'*@B&<6"/1-!
M5B0B5 < '-_3 'W*N\&<'OZX]P2>$0!Q"DN'!$VT<-:R0W$\E!B+B@1P\A71
MS%@$O56(>XG +A:.TAQAS_Q#@DUS04++*RHEN8FC-(S_ &?W'[;X)4"@, V$
M%N01W=]<LRT>M F&T(FL'B\0X* 1J:<>MS4W@G)=D&@1C'6/Y2<N(/8&6"C%
M044FIR@&89'#0&7;&Y(8\8?@A("4*0EJMT6$EYG"0/?E0"]91F,&7,902/U-
MQ5/;#HX3[A#4<4KNU6 ,IB,$ ELT9% I%['&=#CMBVHFA "8#S#]TQ\ C$$E
MB3S0BT$GA*,WNC9,9G)-R0&Z%A]AX.7U)Q88>IV3A4= $YDWE\Z;WG3CKHX%
M2_NW3/V\O07_ ."9,S'C:'^>!AG0/4@YF<:?BO$N;%"J@0@F]7K;X01"X4@B
M'RPOX/!$613X>)-1V@!A#/O=[>GNKMXTRY-DUM]@ZX(3-H;3N8N]_C,.PI!#
M)G?8DU;YOQQMK!)D0ZH"]S(0='#\)"V1C !GMF3O?%ZX03O5 $QH:[S@1M56
M-VY$S0JSJ<$Z5*:@@PNP0,(WD$"$-F#7S]/CB(HK'0 ZKE?A2\9&<2F!%ULU
MCE(35JI"BR1,V(.)EXUDP1@2PX(S?*FD)$6$4R232H+Q"@ P$DJ# 0;"'(5_
M831!((Q&A !T\+$E("T08H)45^4TA&9F![*1@09!QP9,%0-IRDG(R4 V<5WN
MS!Z *#Z%^7AD'R',"Z#. QKY^_EXM42,!N,EMW ,[ \DKH)1@ 0:?#QHX<.E
M38,,:[4?9C@AD&((J0T+13@+XO (02"(Q4F*5#6O281;/7]^_KGJ9D$<,E\Y
M##E8A>&]],BY<%GC\X<9>05AABI+\F3\Y^G&5 5B4F!-US88]TFEHR!$R55N
M'!EL>.!&PJT0QIA4%^@D8N@)"D2' W(Z:3=+PT@4[A(= Q[>E:-A *=[!!HT
M.];;]6HUK&L"&2BJ*8G!$G)^<0S615787$_<0]D2#*\1X)M#*"T)DK<!+XS"
MG&X70?,<NU"56T8C@9X(1P3PJJ+#PAFKVM:[N=^_C/ "JPUT;,XR8OOQXY97
M!(WBU9NGQ\>?_@,4P4OW/]<'0RCZ[U^,>.&N1+A& IKLP;3O7EAJ+A%,T73*
MF'VQ1^Z!B80B5<%HYG%"E"$%D,9+BF2-%Z>7[7& ]!,,4"M3C=, (EB:(Z(,
MW,<=*?-8V'77R'^9_AA<CU>M\R#LH.V84+7#\>^#T9G=EQOZS^WD.FX2];$[
M#@"<922*&BAF-2U^:%<21R*%,%%;' U6 "FKT$07,+!+HS8QK20AH!108D,+
M&B@H$H! 2)D =D0@0&RTJ!.S/"]>%F:Q0-6IHH144Y<86UZ E(Y)!</;,%>Y
M6:N=5I14= @%9&R$Q8&3":@B<YNA3 J0!I73P)KE5%0=9%D108ZRR8@A(0#@
M QP\" >"<2&)-YET?G!K]N/F!$$HD!2I0 ;XS@$L;EB@NPS4:96\@,QQ,*,9
M50 !W4E,Y1E I6O4.P.I',),BL"UT<"U='6N! 2I:8]9_KOQPA1"Q1@I9,#Y
MQZ9QJ'T!F&#2$B/6^^4<HDQ>AI)#K69HO%V"B 23"U(NV.^@1;$!FHZ"[G4"
MA# ,H&$8.LJ_:EICE;0D!L4L/Y1RW>MHU*(E*YJSH605>"(N22=,3/OUZSWP
M&13T+LC04Z"FIQLL9J:Y6"BCD"AHG,4T"R@PHAE)PD"XR%Z*BS$2(9<O#4,+
M!\U+9E(,@A"(I4"OGPI(JQ!+V&1PAXSW/?CB1EJOWP3ZVK?XXL>J+Y:I]>O=
MP_\ P?W[?QPEP,(T8RZ\;^IZX JA0U"& +U7(0+JASAH!=DIT#+E@6\7L)=H
M*N8F@T 1'!YT@[I"),ZHJN&?O/<\@%(4-310,>1M@0HABL0S5UR=J@-$$Q7A
MG3/5G*.7TH%9Q&!$3@0OA 6+)*]E1$8A>&AX1V&A*U62&H#9,TLVO0:@*H7E
M1REO6R$C"6IAP@\N_5;8T?@IM(X("$\<CDJNE5:4L4]44(.2XS)S2! $+H8B
MVF!P%N@D$2MON(=63%6[AR4).+RJ:H8@%2U[<V!P2LS:J5Z&B1(LJM&T*3:H
MBQ#Y&D(G?,F=!%$I%4.2E1[>U^P,-#R@(>[[,YAXXMDQIBM3."PNJQ%!TZ2
MAU<!Q$49A_:>OG\<@J7*HT((6F0F<T1,&L0OAJ1Z +>TEO$[O)XB0-=&/GY&
M*5VY2&,QTI[F9UKDHK45UI 87=\QUJC$$OAKXFGY]>YQP)),6.&:7<'$&[XD
M05#JS@BFF6QUA.:V+$!5P=#E-==6<6T  &8ES[.:(^>69-$X5RD,QKY#FGAF
M8*"Q@K&M:UVHFUK,!L697"R@WG&T6(%XFLT0A6&"U"\5@ *" 9<@A9>ON%>
M=+"!5D44P*L%$SRYG3!1+J-N@U$*T,$:0)*%"BRR,OJ$!\NZ*:@!4(66*LXC
M*R$@62_ ,4.%QT&F( 0DUE$5K."H2 (5.L>]^\NWBB] WY_CB9,*6H:C\?N>
M?_AB ?<,U%QH_CNJ\@-/'>61ZQ-]?Z1KJC5[^G3,^CZ A> 1SRA4:"( #Z)1
M9Q@"0229"6G7,)6<R5X(I-@?"K()98# ZV%I>I#@C4M5@!D"C5=;>%<K/1,T
M-#(%,G3MJ5V.,C=,!)YUS" LF8?$@PWFB/ 1J_=NL5V0W8<;,+1$3,(8HQEG
MR;((IYDPG(S:-_'(*4I)4W^B.1BM=)9]2)D#^A):$BX7:\X6H9+C0:4\2).<
M 5:YBV@H9@#CU2P*>)%%A3,7XSQ\ B, F"2'!,G76.$##BCS 9D:7#)EUS9"
M0%!D*$PJQ+ V\41HI$!)@B,Y!7*Y>=]A/S$&MO,0%"B#GEQ2(TM A$8X$ \$
MYA[<[Q_OY\?P7I2("HB2L8FF6;\IT%M^,!#+%Z.?.6H D83-1SJ;GC''0HFD
M]95:QKYZ.N**XK:-A[7A^WQP-$0;!;<V.#XR_0X\H9.!TZX3HF/SPZHF<C"R
MLK6W-KGSPTNM9%UO+>[[\[6#=RH;,=M8T9_V?H2U!,:$OG)U,$X8#V)<*.?+
M?S>IR,%F,8:I6;;!L,=< BH6X@2G:T 20\,*C.3:6XGTGVUKOB!TA =.<UNA
MG]C@OT125(I1!#"+  *"C!(>0T*F96$+QJR5&Q*4DI51PP).00"N$*:A48@[
M!HNG6SX\PSK#\>4*39N;UG;[\SQCDN)[['K^/I/? +FRA 9E:-Z]_P#Q1B^P
M72@?(W'F>>%PX$#M#Q-C]RH6<@&IB;'>A?D/2;,MS,/ICJI58FT<<6&J BNU
MA%080Y6)S3*B!A6H V8;I"TIP&P=NDF@V&<L,PJ<'@G+*Y70&?@[Y14604V
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MX9<OK*#L7#D"US'<O#-@ 8*C[<:.!B@5CP$1<86\RU'L%E1<1&#."FL)&K6
M '"H@*I#,R#R&#!T%.1<9B&27.W JLHY<XBQE4"86EB)H:$>(/8$HT>Q#4BD
M7(*.Z! E,&N^K'4U<KE&E2%6PJD@1Y-;&:TGQ5)RJ""3(4:HA4!\D\!B_7_Z
MY?W_ /"7?_YP-$__ "AX_IKG]^T_@^W/[]OU@=?S]_T -=_K/Y^W_/TU^D/'
(KZ>/_P"8_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693578856352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVER<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Waldencast plc<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10 Bank Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">White Plains<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag', window );">Document Financial Statement Restatement Recovery Analysis [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001840199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">Y9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A ordinary shares, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">WALD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">86,460,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Redeemable warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Redeemable warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">WALDW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">21,104,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10 Bank Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">White Plains<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Michel Brousset<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">546-6828<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtRestatementRecoveryAnalysisFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693571398192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Costa Mesa, California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693574196592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,693<span></span>
</td>
<td class="nump">$ 12,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">54,384<span></span>
</td>
<td class="nump">21,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">6,273<span></span>
</td>
<td class="nump">4,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">91,043<span></span>
</td>
<td class="nump">59,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,328<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">639,165<span></span>
</td>
<td class="nump">79,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">334,620<span></span>
</td>
<td class="nump">44,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset, net</a></td>
<td class="nump">16,384<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">1,090,075<span></span>
</td>
<td class="nump">184,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">2,041<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">20,095<span></span>
</td>
<td class="nump">15,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities (including related party liability of $9,914 as of December 31, 2022)</a></td>
<td class="nump">26,123<span></span>
</td>
<td class="nump">12,683<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">72,505<span></span>
</td>
<td class="nump">40,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">159,229<span></span>
</td>
<td class="nump">103,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">18,311<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">17,882<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="nump">22,250<span></span>
</td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">571<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">290,177<span></span>
</td>
<td class="nump">145,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (NOTE 18)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">796,038<span></span>
</td>
<td class="nump">100,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(156,780)<span></span>
</td>
<td class="num">(64,849)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL CONTROLLING SHAREHOLDERS' EQUITY</a></td>
<td class="nump">639,239<span></span>
</td>
<td class="nump">39,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">160,659<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="nump">799,898<span></span>
</td>
<td class="nump">39,239<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">1,090,075<span></span>
</td>
<td class="nump">184,586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">19,259<span></span>
</td>
<td class="nump">18,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">23,873<span></span>
</td>
<td class="nump">12,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities (including related party liability of $9,914 as of December 31, 2022)</a></td>
<td class="nump">9,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693578993248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party liability</a></td>
<td class="nump">$ 26,123<span></span>
</td>
<td class="nump">$ 12,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized (in shares)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party liability</a></td>
<td class="nump">$ 9,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized (in shares)</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued (in shares)</a></td>
<td class="nump">86,460,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares)</a></td>
<td class="nump">86,460,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued (in shares)</a></td>
<td class="nump">21,104,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares)</a></td>
<td class="nump">21,104,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693574284224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue (including related party net revenue of $17,219 in the Successor period)</a></td>
<td class="nump">$ 92,373<span></span>
</td>
<td class="nump">$ 73,760<span></span>
</td>
<td class="nump">$ 142,472<span></span>
</td>
<td class="nump">$ 94,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold (including related party costs of $5,128 in the Successor period)</a></td>
<td class="nump">60,657<span></span>
</td>
<td class="nump">30,868<span></span>
</td>
<td class="nump">55,037<span></span>
</td>
<td class="nump">29,096<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">31,716<span></span>
</td>
<td class="nump">42,892<span></span>
</td>
<td class="nump">87,435<span></span>
</td>
<td class="nump">65,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">88,926<span></span>
</td>
<td class="nump">55,549<span></span>
</td>
<td class="nump">82,968<span></span>
</td>
<td class="nump">60,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,796<span></span>
</td>
<td class="nump">2,606<span></span>
</td>
<td class="nump">6,092<span></span>
</td>
<td class="nump">4,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Loss on impairment of goodwill</a></td>
<td class="nump">68,715<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">159,437<span></span>
</td>
<td class="nump">58,155<span></span>
</td>
<td class="nump">89,060<span></span>
</td>
<td class="nump">64,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (loss) income</a></td>
<td class="num">(127,721)<span></span>
</td>
<td class="num">(15,263)<span></span>
</td>
<td class="num">(1,625)<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">6,230<span></span>
</td>
<td class="nump">6,652<span></span>
</td>
<td class="nump">11,118<span></span>
</td>
<td class="nump">6,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of derivative warrant liabilities (Note 10)</a></td>
<td class="num">(6,793)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt (Note 8)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,317<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainOnPPPLoanForgiveness', window );">Gain on PPP Loan forgiveness (Note 8)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,824)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainLossOnNoteReceivableWriteoff', window );">Loss on write-off of loan receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,555<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(798)<span></span>
</td>
<td class="num">(971)<span></span>
</td>
<td class="num">(817)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (income) expenses, net</a></td>
<td class="num">(1,361)<span></span>
</td>
<td class="nump">5,681<span></span>
</td>
<td class="nump">8,349<span></span>
</td>
<td class="nump">6,292<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(126,360)<span></span>
</td>
<td class="num">(20,944)<span></span>
</td>
<td class="num">(9,974)<span></span>
</td>
<td class="num">(5,764)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(5,803)<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">9,602<span></span>
</td>
<td class="num">(3,394)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(120,557)<span></span>
</td>
<td class="num">(21,057)<span></span>
</td>
<td class="num">(19,576)<span></span>
</td>
<td class="num">(2,370)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="num">(24,990)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Class A shareholders</a></td>
<td class="num">$ (95,567)<span></span>
</td>
<td class="num">$ (21,057)<span></span>
</td>
<td class="num">$ (19,576)<span></span>
</td>
<td class="num">$ (2,370)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share attributable to Class A shareholders (Note 15):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (2.63)<span></span>
</td>
<td class="num">$ (2.45)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (2.63)<span></span>
</td>
<td class="num">$ (2.45)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Shares used in computing net loss per share (Note 15):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">86,460,560<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">86,460,560<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</a></td>
<td class="num">$ (36)<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="num">$ (32)<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(120,593)<span></span>
</td>
<td class="num">(20,961)<span></span>
</td>
<td class="num">(19,608)<span></span>
</td>
<td class="num">(2,354)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interests</a></td>
<td class="num">(24,997)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Class A shareholders</a></td>
<td class="num">$ (95,596)<span></span>
</td>
<td class="num">$ (20,961)<span></span>
</td>
<td class="num">$ (19,608)<span></span>
</td>
<td class="num">$ (2,354)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_GainLossOnNoteReceivableWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Note Receivable Writeoff</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_GainLossOnNoteReceivableWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_GainOnPPPLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on PPP Loan Forgiveness</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_GainOnPPPLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693577541296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 92,373<span></span>
</td>
<td class="nump">$ 73,760<span></span>
</td>
<td class="nump">$ 142,472<span></span>
</td>
<td class="nump">$ 94,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">60,657<span></span>
</td>
<td class="nump">$ 30,868<span></span>
</td>
<td class="nump">$ 55,037<span></span>
</td>
<td class="nump">$ 29,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Supply Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">17,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">$ 5,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=us-gaap_SupplyCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=us-gaap_SupplyCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693570332240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>As Reported</div></th>
<th class="th"><div>Restatement Adjustments</div></th>
<th class="th"><div>Waldencast plc</div></th>
<th class="th"><div>Obagi Global Holdings Limited</div></th>
<th class="th">
<div>Obagi Global Holdings Limited </div>
<div>As Reported</div>
</th>
<th class="th">
<div>Obagi Global Holdings Limited </div>
<div>Restatement Adjustments</div>
</th>
<th class="th"><div>Class A Ordinary Shares</div></th>
<th class="th"><div>Class B Ordinary Shares</div></th>
<th class="th">
<div>Ordinary Shares </div>
<div>Obagi Global Holdings Limited</div>
</th>
<th class="th">
<div>Ordinary Shares </div>
<div>Obagi Global Holdings Limited </div>
<div>As Reported</div>
</th>
<th class="th">
<div>Ordinary Shares </div>
<div>Class A Ordinary Shares </div>
<div>Waldencast plc</div>
</th>
<th class="th">
<div>Ordinary Shares </div>
<div>Class B Ordinary Shares </div>
<div>Waldencast plc</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Waldencast plc</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Obagi Global Holdings Limited</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Obagi Global Holdings Limited </div>
<div>As Reported</div>
</th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Waldencast plc</div>
</th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Obagi Global Holdings Limited</div>
</th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Obagi Global Holdings Limited </div>
<div>As Reported</div>
</th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Obagi Global Holdings Limited </div>
<div>Restatement Adjustments</div>
</th>
<th class="th">
<div>Accumulated Other Comprehensive Loss </div>
<div>Waldencast plc</div>
</th>
<th class="th">
<div>Accumulated Other Comprehensive Loss </div>
<div>Obagi Global Holdings Limited</div>
</th>
<th class="th">
<div>Accumulated Other Comprehensive Loss </div>
<div>Obagi Global Holdings Limited </div>
<div>As Reported</div>
</th>
<th class="th">
<div>Noncontrolling Interest </div>
<div>Waldencast plc</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,002,000<span></span>
</td>
<td class="nump">8,000,002,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,187<span></span>
</td>
<td class="nump">$ 98,533<span></span>
</td>
<td class="num">$ (37,346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,055<span></span>
</td>
<td class="nump">$ 96,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (38,859)<span></span>
</td>
<td class="num">$ (1,513)<span></span>
</td>
<td class="num">$ (37,346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (2,370)<span></span>
</td>
<td class="num">$ (9,171)<span></span>
</td>
<td class="nump">$ 6,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,370)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Non-cash contribution of trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends paid</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,044)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,044)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,002,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(19,576)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(19,506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends paid</a></td>
<td class="num">$ (2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">8,000,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,002,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 39,239<span></span>
</td>
<td class="nump">$ 89,290<span></span>
</td>
<td class="num">$ (50,051)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(21,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_DistributionOfBusiness', window );">Distribution of Obagi China Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jul. 27, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,002,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,645,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jul. 27, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (61,038)<span></span>
</td>
<td class="nump">$ 4,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
<td class="nump">$ 87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (61,213)<span></span>
</td>
<td class="num">$ (86,094)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_StockIssuedDuringPeriodSharesTrustProceeds', window );">Issuance of Class A ordinary shares upon release of Trust proceeds (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,478,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_StockIssuedDuringPeriodValueTrustProceeds', window );">Issuance of Class A ordinary shares upon release of Trust proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements', window );">Issuance of common shares in connection with the FPA investment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements', window );">Issuance of common shares in connection with the FPA investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">332,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_StockIssuedDuringPeriodSharesSubscriptionAgreements', window );">Issuance of common shares in connection with the PIPE investment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_StockIssuedDuringPeriodValueSubscriptionAgreements', window );">Issuance of common shares in connection with the PIPE investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common shares in connection with the Obagi and Milk Business Combination (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,237,506<span></span>
</td>
<td class="nump">21,104,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common shares in connection with the Obagi and Milk Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">292,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(120,557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120,557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95,567)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,460,560<span></span>
</td>
<td class="nump">21,104,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,460,560<span></span>
</td>
<td class="nump">21,104,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 799,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 799,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 796,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (156,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_DistributionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Distribution of Business</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_DistributionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Foreign Purchase Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_StockIssuedDuringPeriodSharesSubscriptionAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Subscription Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_StockIssuedDuringPeriodSharesSubscriptionAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_StockIssuedDuringPeriodSharesTrustProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Trust Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_StockIssuedDuringPeriodSharesTrustProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Foreign Purchase Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_StockIssuedDuringPeriodValueSubscriptionAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Subscription Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_StockIssuedDuringPeriodValueSubscriptionAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_StockIssuedDuringPeriodValueTrustProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Trust Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_StockIssuedDuringPeriodValueTrustProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693577839120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Dividends paid (in dollars per share)</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693565836000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (120,557)<span></span>
</td>
<td class="num">$ (21,057)<span></span>
</td>
<td class="num">$ (19,576)<span></span>
</td>
<td class="num">$ (2,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7,736<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_DepreciationDepletionAndAmortizationOperatingActivities', window );">Depreciation and amortization</a></td>
<td class="nump">26,982<span></span>
</td>
<td class="nump">8,190<span></span>
</td>
<td class="nump">13,904<span></span>
</td>
<td class="nump">13,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">740<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities', window );">Change in fair value of derivative warrant liabilities</a></td>
<td class="num">(6,793)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_NonCashLossFromChangeInFairValueOnInterestRateCollar', window );">Non-cash loss from change in fair value on interest rate collar</a></td>
<td class="nump">592<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,317<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainOnPPPLoanForgiveness', window );">Gain on PPP Loan forgiveness</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,824)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">677<span></span>
</td>
<td class="nump">767<span></span>
</td>
<td class="nump">1,139<span></span>
</td>
<td class="nump">798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_AmortizationOfRelatedPartyLiability', window );">Amortization of related party liability</a></td>
<td class="num">(12,186)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(5,823)<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">9,374<span></span>
</td>
<td class="num">(3,044)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Loss on impairment of goodwill</a></td>
<td class="nump">68,715<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) Loss on disposal of equipment</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainLossOnNoteReceivableWriteoff', window );">Loss on write-off of loan receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,555<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of impact of business combinations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(204)<span></span>
</td>
<td class="nump">3,524<span></span>
</td>
<td class="num">(5,057)<span></span>
</td>
<td class="num">(16,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Related party accounts receivable</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">6,382<span></span>
</td>
<td class="num">(13,008)<span></span>
</td>
<td class="num">(6,010)<span></span>
</td>
<td class="nump">4,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(213)<span></span>
</td>
<td class="nump">658<span></span>
</td>
<td class="num">(1,097)<span></span>
</td>
<td class="num">(1,919)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other assets</a></td>
<td class="num">(250)<span></span>
</td>
<td class="num">(352)<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="nump">1,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties', window );">Accounts payable</a></td>
<td class="num">(1,021)<span></span>
</td>
<td class="nump">9,635<span></span>
</td>
<td class="nump">9,647<span></span>
</td>
<td class="num">(7,391)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Related party accounts payable</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(724)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current liabilities and other liabilities</a></td>
<td class="num">(39,336)<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">2,493<span></span>
</td>
<td class="nump">4,135<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(74,977)<span></span>
</td>
<td class="num">(10,037)<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
<td class="num">(7,431)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Capital expenditure on intangible assets</a></td>
<td class="num">(247)<span></span>
</td>
<td class="num">(248)<span></span>
</td>
<td class="num">(863)<span></span>
</td>
<td class="num">(653)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditure on property and equipment</a></td>
<td class="num">(1,340)<span></span>
</td>
<td class="num">(661)<span></span>
</td>
<td class="num">(424)<span></span>
</td>
<td class="num">(1,054)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_AdvancesForNoteReceivable', window );">Advances for note receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ProceedsFromTrustAccount', window );">Proceeds from trust account</a></td>
<td class="nump">44,883<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(544,367)<span></span>
</td>
<td class="num">(909)<span></span>
</td>
<td class="num">(3,787)<span></span>
</td>
<td class="num">(1,707)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from PIPE investments</a></td>
<td class="nump">118,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ProceedsFromForwardPurchaseAgreements', window );">Proceeds from FPA investments</a></td>
<td class="nump">333,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from term loan</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of term loan</a></td>
<td class="num">(4,348)<span></span>
</td>
<td class="num">(1,375)<span></span>
</td>
<td class="num">(72,455)<span></span>
</td>
<td class="num">(9,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from revolving credit facility</a></td>
<td class="nump">14,117<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of revolving credit facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(44,000)<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherDebt', window );">Proceeds from PPP Loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(6,304)<span></span>
</td>
<td class="num">(742)<span></span>
</td>
<td class="num">(6,383)<span></span>
</td>
<td class="num">(1,017)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(2,044)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="nump">629,465<span></span>
</td>
<td class="nump">3,883<span></span>
</td>
<td class="nump">5,162<span></span>
</td>
<td class="nump">14,319<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="nump">10,121<span></span>
</td>
<td class="num">(7,063)<span></span>
</td>
<td class="nump">4,904<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash and cash equivalents</a></td>
<td class="num">(36)<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;Beginning of period</a></td>
<td class="nump">6,477<span></span>
</td>
<td class="nump">13,444<span></span>
</td>
<td class="nump">8,572<span></span>
</td>
<td class="nump">3,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;End of period</a></td>
<td class="nump">10,163<span></span>
</td>
<td class="nump">6,477<span></span>
</td>
<td class="nump">13,444<span></span>
</td>
<td class="nump">8,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW DATA &#8211; CASH PAID:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">5,550<span></span>
</td>
<td class="nump">5,053<span></span>
</td>
<td class="nump">10,014<span></span>
</td>
<td class="nump">5,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures in accounts payable and accruals</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_CapitalContribution', window );">Capital contribution of trademarks</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_DistributionToShareholderForDispositionOfBusiness', window );">Obagi China Distribution to shareholder</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,113<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of promissory note to warrants</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=wald_ObagiMergerMember', window );">Obagi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of Business Combinations, net of cash acquired</a></td>
<td class="num">(465,010)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of ordinary shares for Business Combinations</a></td>
<td class="nump">277,824<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=wald_MilkTransactionMember', window );">Milk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of Business Combinations, net of cash acquired</a></td>
<td class="num">(122,653)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of ordinary shares for Business Combinations</a></td>
<td class="nump">$ 200,087<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the net carrying value of derivative instruments reported as assets and liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_AdvancesForNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advances For Note Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_AdvancesForNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_AmortizationOfRelatedPartyLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Related Party Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_AmortizationOfRelatedPartyLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_CapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_CapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_DepreciationDepletionAndAmortizationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation, Depletion and Amortization, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_DepreciationDepletionAndAmortizationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_DistributionToShareholderForDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Distribution To Shareholder For Disposition Of Business</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_DistributionToShareholderForDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_GainLossOnNoteReceivableWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Note Receivable Writeoff</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_GainLossOnNoteReceivableWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_GainOnPPPLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on PPP Loan Forgiveness</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_GainOnPPPLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Accounts Payable, Excluding Related Parties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_NonCashLossFromChangeInFairValueOnInterestRateCollar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Loss From Change In Fair Value On Interest Rate Collar</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_NonCashLossFromChangeInFairValueOnInterestRateCollar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ProceedsFromForwardPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Forward Purchase Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ProceedsFromForwardPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ProceedsFromTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Trust Account</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ProceedsFromTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=wald_ObagiMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=wald_ObagiMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=wald_MilkTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=wald_MilkTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693576214592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">ORGANIZATION AND DESCRIPTION OF BUSINESS</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successor</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast plc (&#8220;Waldencast&#8221;), formerly known as Waldencast Acquisition Corp., is a Jersey company. Waldencast was originally incorporated on December 8, 2020 as a Cayman Islands exempted company and a blank check company solely for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. On March&#160;18, 2021, Waldencast consummated an initial public offering of 34,500,000 units (the &#8220;IPO&#8221;), with each unit consisting of one Class A ordinary share and one-third of one redeemable warrant (&#8220;Public Warrant&#8221;) to acquire one Class A ordinary share (together, a &#8220;Unit&#8221;), at $10.00 per Unit.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Business Combination (as defined below), on July 26, 2022, with the approval of Waldencast&#8217;s shareholders, and in accordance with the Cayman Companies Act (the &#8220;Cayman Act&#8221;), the Companies (Jersey) Law 1991, as amended (the &#8220;Jersey Companies Law&#8221;) and Waldencast&#8217;s amended and restated memorandum and articles of association, Waldencast effected a deregistration under the Cayman Act and a domestication under Part 18C of the Jersey Companies Law (by means of filing a memorandum and articles of association with the Registrar of Companies in Jersey), pursuant to which Waldencast&#8217;s jurisdiction of incorporation was changed from the Cayman Islands to Jersey (the &#8220;Domestication&#8221;). Upon the effective time of the Domestication, Waldencast Acquisition Corp. was renamed Waldencast plc.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2022 (the &#8220;Closing Date&#8221;), Waldencast acquired Obagi Global Holdings Limited, a Cayman Islands exempted company, and its subsidiaries (collectively, &#8220;Obagi&#8221;) and Milk Makeup LLC, a Delaware limited liability company, and its subsidiaries (collectively &#8220;Milk&#8221;) (the &#8220;Business Combination&#8221;), as described below in &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Business Combinations.&#8221; Following the Business Combination, the Company (as defined below) conducts its business through the following reportable segments: (i) Obagi Skincare and (ii) Milk Makeup. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi is a global skincare company that develops, markets, and sells proprietary-topical aesthetic and therapeutic prescription-strength skincare systems and related products primarily in the physician-dispensed market. Obagi provides cosmetic, over-the-counter (&#8220;OTC&#8221;) and prescription products. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk Makeup develops and sells cosmetic, skin care and other beauty products. The brand creates vegan, cruelty-free, clean formulas from its Milk headquarters in downtown New York City. Milk&#8217;s products are offered through its U.S. website, www.milkmakeup.com, and its retail partners including Sephora in North America, Europe, the Middle East, Australia, Cult Beauty, and ASOS online.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Business Combination, Waldencast is organized as an &#8220;Up-C&#8221; structure, whereby the equity interests of Obagi and Milk are held by Waldencast Partners LP (&#8220;Waldencast Partners LP&#8221;), a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cayman Islands exempted limited partnership and indirect </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsidiary of Waldencast, which is an entity that is classified as a partnership for U.S. federal income tax purposes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Predecessor</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi Global Holdings Limited is a holding company incorporated in the Cayman Islands that conducts all operations through its wholly-owned subsidiaries. Obagi is a global skincare company that develops, markets, and sells proprietary-topical aesthetic and therapeutic prescription-strength skincare systems and related products primarily in the physician-dispensed market. Obagi provides cosmetic, OTC and prescription products. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the Board of Directors of Obagi approved (i) an increase in the number of Obagi&#8217;s authorized ordinary shares from 50,000 to 25,000,000, (ii) an issuance of 4,000,000 ordinary shares to ZhongHua Finance Acquisition Fund I, L.P. (&#8220;ZhongHua&#8221;), and (iii) a two-for-one stock split of Obagi&#8217;s issued and outstanding ordinary shares (in combination with the share issuance to ZhongHua, the &#8220;Stock Split&#8221;), all of which became effective on December 2, 2020. Obagi was held by a single shareholder, and the share issuance to ZhongHua was deemed akin to a </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock split. All share, per share amounts and related shareholders&#8217; equity balances presented herein have been retroactively adjusted to reflect the impact of the Stock Split.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2021, ZhongHua, Obagi&#8217;s sole shareholder, transferred its shares to its affiliate, Cedarwalk Skincare Ltd. (&#8220;Cedarwalk&#8221;), which became the new sole shareholder of Obagi. This transfer between affiliates did not result in any change of control.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the Business Combination, Obagi carved out and distributed all of the outstanding shares of its subsidiary, Obagi Hong Kong Limited (&#8220;Obagi Hong Kong&#8221; or &#8220;Obagi HK&#8221;) to its shareholder, Cedarwalk (the &#8220;Obagi China Distribution&#8221;). All sales of Obagi products in the People&#8217;s Republic of China, inclusive of the Hong Kong Special Administrative Region, the Macau Special Administrative Region, and Taiwan (the &#8220;China Region&#8221;) prior to the Business Combination had been conducted through Obagi Hong Kong and its subsidiaries (the &#8220;Obagi China Business&#8221;), which were not acquired by Waldencast in the Business Combination.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast has prepared the accompanying consolidated financial statements pursuant to generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for the Business Combination, Waldencast was deemed to be the legal and the accounting acquirer (referred to as the &#8220;Successor&#8221;), however, Obagi was deemed to be the predecessor entity for financial reporting purposes (referred to as the &#8220;Predecessor&#8221;). Under the acquisition method of accounting, Waldencast&#8217;s assets and liabilities retained their carrying values and the assets and liabilities associated with Obagi and Milk were recorded at their fair values measured as of the acquisition date, which created a new basis of accounting.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This change in accounting basis is represented in the accompanying consolidated financial statements by a black line, which appears between the columns entitled Successor and Predecessor in the financial statements and in the relevant accompanying notes. The black line signifies that the consolidated financial statements presented for the Company after the Closing Date (the &#8220;Successor Period&#8221;) are presented on a measurement basis different from those for the period prior to the Closing Date (the &#8220;Predecessor Periods&#8221;). As a result of the application of the acquisition method of accounting as of the Closing Date, the financial statements for the Predecessor Periods (which only includes Obagi, including the Obagi China Business, through July 27, 2022) and for the Successor Period (which includes Waldencast and its subsidiaries from July 28, 2022 to December 31, 2022) are presented on a different basis of accounting and are, therefore, not comparable.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context requires otherwise, the &#8220;Company&#8221; refers to Obagi for periods prior to the Business Combination and to Waldencast together with its consolidated subsidiaries, as the Successor for periods after the Business Combination.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693577780768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTATEMENT AND RECLASSIFICATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionTextBlock', window );">RESTATEMENT AND RECLASSIFICATIONS</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">RESTATEMENT AND RECLASSIFICATIONS</span><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restatement of Previously Issued Financial Statements</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, management of the Company (&#8220;Management&#8221;) and the audit committee of the Company&#8217;s Board of Directors (&#8220;the Board&#8221;), conducted an internal review, with the assistance of legal and accounting advisors, pertaining to certain accounting practices used by Obagi in connection with the recognition of revenue from sales of Obagi products to its Southeast Asia Distributor (the &#8220;SA Distributor&#8221;) in Vietnam, transactions with other Obagi distributors, both within and outside the U.S., as well as other accounting issues. Management and the audit committee identified misstatements in the previously issued consolidated financial statements as of December 31, 2021 and for the years ended December 31, 2021 and 2020 (Predecessor Periods) as described below.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the Company has restated the accompanying consolidated balance sheet as of December 31, 2021 (Predecessor Period) and consolidated statements of operations and comprehensive loss, cash flows, and shareholders&#8217; equity for the years ended December 31, 2021 and 2020 (Predecessor Periods) from amounts previously reported.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Restatement Adjustments</span></div><div><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A summary of the restatement adjustments are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:6.91pt">Net revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; The Company identified misstatements primarily relating to distributor fees and the recognition of revenue from three of Obagi&#8217;s distributors: the SA Distributor, Obagi&#8217;s exclusive supplier for the physician-dispensed channel in the U.S. (&#8220;Physician Channel Provider&#8221;), and the distributor for Obagi&#8217;s U.S. e-commerce platforms (&#8220;U.S. Online Marketplace Distributor&#8221;). The following table summarizes the impact of the restatement to net revenue:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributor fees for services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(39,146)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SA Distributor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physician Channel Provider </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US Online Marketplace Distributor </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(267)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total net revenue adjustments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(63,597)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,283</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Distributor fees for services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; Obagi&#8217;s distributors charge fees for certain services they render. The Predecessor (Obagi) had recorded these service fees as selling, general and administrative (&#8220;SG&amp;A&#8221;) and research and development (&#8220;R&amp;D&#8221;) expenses. Management subsequently determined these service fees should have been recognized as a reduction to net revenue, as the additional services provided by distributors were not distinct from the distributors&#8217; purchase of Obagi products. This resulted in an overstatement of net revenue of $39.1 million and corresponding overstatements of SG&amp;A expenses and R&amp;D expenses of $37.1 million $2.0 million, respectively, for the year ended December 31, 2021 (Predecessor Period). The misstatement had no impact to net income or cash flows for the year ended December 31, 2021 (Predecessor Period). There was no similar accounting misstatement identified for the year ended December 31, 2020 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:10.5pt">SA Distributor </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211; The Predecessor historically recognized revenue for products sold to Obagi&#8217;s SA Distributor upon shipment of the products. Management determined that the SA Distributor revenue should have been recognized when Obagi had no remaining performance obligations and received substantially all of the consideration related to each purchase order in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">(&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">606&#8221;). This resulted in an overstatement of accounts receivable of $24.8 million as of December 31, 2021 (Predecessor Period), an overstatement of net revenue of $14.2 million for the year ended December 31, 2021 (Predecessor Period), and an understatement of net revenue of $1.7 million for the year ended December 31, 2020 (Predecessor Period). </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Physician Channel Provider</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> - The Predecessor historically recognized revenue for products sold in the physician dispensed, or Direct-to-Physician (&#8220;DTP&#8221;), channel upon the transfer of products to the Physician Channel Provider. Management determined that although the products were transferred to the Physician Channel Provider, the Physician Channel Provider did not obtain actual control of the products until immediately prior to selling through to the physician customer. Therefore, revenue should have been recognized only immediately prior to transfer of products to physicians (i.e., when the products were sold to the physicians) rather than when they were transferred to the Physician Channel Provider. In addition, the Physician Channel Provider charged fees for certain services rendered by it (as discussed above) and the Predecessor recorded these service fees as SG&amp;A and R&amp;D expenses, instead of as a reduction to net revenue. As a result of these items, there was an overstatement of net revenue of $8.2 million, an understatement of cost of goods sold of $0.4 million, an overstatement of SG&amp;A of $7.1 million, an overstatement of accounts receivable of $14.8 million, and an understatement of inventory of $2.0 million as of and for the year ended December 31, 2021 (Predecessor Period). For the year ended December 31, 2020 (Predecessor Period) this resulted in an understatement of revenue of $8.6 million, an understatement of cost of goods sold of $2.6 million, and an overstatement of SG&amp;A of $4.9 million.  </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">U.S. Online Marketplace Distributor &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> The Predecessor agreed to nonstandard payment terms in its contracts with the U.S. Online Marketplace Distributor and allowed for payments over a period of time that exceeded 365 days until final payment of an invoice. Management subsequently identified misstatements to revenue recognition relating to the significant financing component of such </span></div><div style="padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">arrangement, timing of revenue, and incorrect accounting of shipping activities. The net impact of these misstatements resulted in an overstatement of net revenue of $1.8 million, an understatement of other income of $1.0 million and an understatement of deferred revenue of $0.7 million as of and for the year ended December 31, 2021 (Predecessor Period) and an understatement of net revenue of $0.1 million for the year ended December 31, 2020 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Other net revenue adjustments &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Other net revenue adjustments were individually and in the aggregate insignificant for the years ended December 31, 2021 and 2020 (Predecessor Periods). </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:6.34pt">Cost of goods sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; The following table summarizes the impact of the restatement to cost of goods sold:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:39.749%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physician Channel Provider</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory obsolescence provision </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(583)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other - adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total net cost of goods sold adjustments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,673</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,471</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Physician Channel Provider </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; As described above in (a)3, Management determined that it should have recognized revenue and cost of goods sold for products sold to the Physician Channel Provider immediately prior to the transfer of products to the physicians, which resulted in understatements of costs of goods sold as set forth in the table above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Inventory obsolescence provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; The Company did not appropriately adjust the inventory reserve for obsolete inventory. In connection with the restatement, the Company corrected its historical inventory obsolescence provision. This resulted in an overstatement of cost of goods sold of $0.6 million for the year ended December 31, 2021 (Predecessor Period) and an understatement of $0.7 million for the year ended December 31, 2020 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:10.5pt">Other net cost of goods sold adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; The Predecessor historically recorded certain promotional products in marketing expenses. Management determined that it should have recorded such promotional products in inventory and cost of goods sold, which resulted in understatements of costs of goods sold as set forth in the table above. The other net cost of goods sold adjustments related to the understatement of cost of goods sold were insignificant both individually and in the aggregate for the years ended December 31, 2021 and 2020 (Predecessor Periods).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:6.91pt">SG&amp;A </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; The following table summarizes the impact of the restatement to SG&amp;A expenses:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributor fees for services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(37,075)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physician Channel Provider </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,065)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,891)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(732)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other - adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(974)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(546)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total SG&amp;A adjustments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(44,523)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3,138)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Distributor fees for services &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described above in (a)1, the Predecessor had incorrectly recorded certain payments to distributors for services on a gross basis in net revenue which caused an overstatement of SG&amp;A expenses.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Physician Channel Provider &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> As described above in (a)3, the Predecessor had recorded fees for certain services to the Physician Channel Provider in SG&amp;A expenses as opposed to a reduction to net revenue, which cause an overstatement of SG&amp;A expenses. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Computer software &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> As described below in (j), the Predecessor historically capitalized certain computer software expenses that should have been expensed as incurred. This adjustment resulted in </span></div><div style="padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">understatements of SG&amp;A expenses of $1.3 million and $0.5 million for the years ended December 31, 2021 and 2020 (Predecessor Periods), respectively.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Prepaid expenses &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described below in (h)1 through (h)2, the Predecessor historically capitalized certain expenses primarily related to marketing and advertising activities. Obagi should have expensed these items in the period in which the expenses were incurred. These misstatements resulted in an overstatement of SG&amp;A expenses of $0.7 million for the year ended December 31, 2021 (Predecessor Period) and an understatement of $1.8 million for the year ended December 31, 2020 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:10.5pt">Other SG&amp;A adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> As described in (b)3, management determined that it should have recorded certain promotional products in cost of goods sold instead of marketing expenses, which resulted in an overstatement of SG&amp;A expenses as set forth in the table above. The other SG&amp;A adjustments were individually and in the aggregate insignificant for the years ended December 31, 2021 and 2020 (Predecessor Periods). </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:6.34pt">R&amp;D </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Distributor fees for services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; As described above in (a)1, the Predecessor had incorrectly recorded fees for certain services in R&amp;D expenses as opposed to a reduction to net revenue, which caused an overstatement of R&amp;D expenses.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Prepaid expenses &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described below in (h), Obagi should have expensed certain costs that were previously capitalized related to R&amp;D activities. These misstatements resulted in understatements of R&amp;D expenses of $1.2 million and $0.5 million for the years ended December 31, 2021 and 2020 (Predecessor Periods), respectively.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Other R&amp;D expense &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The other R&amp;D expense misstatements were individually and in the aggregate insignificant for the years ended December 31, 2021 and 2020 (Predecessor Periods).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:6.91pt">Other expenses (income), net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> - As described above in (a)4, the Predecessor did not adjust the transaction price for a significant financing component in its contract with the U.S. Online Marketplace Distributor. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:8.01pt">Accounts receivable, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; The following table summarizes the impact of the restatement to accounts receivable, net:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:69.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SA Distributor </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,821)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physician Channel Provider</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,796)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncollectible loan receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,512)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total accounts receivable, net adjustments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(44,629)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">SA Distributor &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described above in (a)2, the Company restated revenue for products sold to the SA Distributor and adjusted the overstatement of accounts receivable, net. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Physician Channel Provider</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; As described above in (a)3, the Company restated revenue for products sold in the DTP channel and adjusted the overstatement of accounts receivable, net.  </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Uncollectible loan receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; The Predecessor did not record the loss on the write-off of a one-time uncollectible loan receivable related to the Obagi China Business in the period it was deemed uncollectible. This resulted in an overstatement of accounts receivable, net of $2.5 million as of December 31, 2021 (Predecessor Period) and an understatement of a loss on the write-off of the loan receivable of $2.6 million for the year ended December 31, 2021 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; The Company identified misstatements related to certain distributor receivables, aged accounts receivable and other accounts receivable. The aggregate impact of these misstatements resulted in an overstatement of accounts receivable, net of $2.5 million as of December 31, 2021 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:6.34pt">Inventories </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; The following table summarizes the impact of the restatement to inventories:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:69.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physician Channel Provider </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory obsolescence provision </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other adjustments  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total net inventory adjustments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,272</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Physician Channel Provider </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; As described above in (a)3, the Predecessor historically recognized cost of goods sold for products sold in the DTP channel upon transfer of the products to the Physician Channel Provider instead of immediately prior to transfer of the products to physician customers, which resulted in an understatement of inventory. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Inventory obsolescence provision </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; As described above in (b)2, as a result of misstatements in inventory, the Company had an overstatement of inventory of $0.1 million as of December 31, 2021 (Predecessor Period). </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; As described in (b)3, management determined that it should have recorded certain promotional products in inventory and cost of goods sold instead of marketing expenses, which resulted in an understatement of inventory of $0.3 million as of December 31, 2021 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:106%;padding-left:6.34pt"> Prepaid Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Marketing costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; The Predecessor capitalized and amortized certain expenses related to marketing activities that did not meet the criteria for capitalization. Obagi should have expensed these items in the periods in which the expenses were incurred. This resulted in an overstatement to prepaid expenses of $2 million as of December 31, 2021 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">R&amp;D &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> The Predecessor capitalized and amortized certain expenses related to R&amp;D activities. Obagi should have expensed these items in the periods in which the expenses were incurred. This resulted in an overstatement of prepaid expenses of $1.1 million as of December 31, 2021 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Other prepaid expense adjustments &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The other prepaid expense misstatements were individually and in the aggregate insignificant as of December 31, 2021 (Predecessor Period). </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:8.57pt">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The ot</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">her current assets misstatements were individually and in the aggregate insignificant as of December 31, 2021 (Predecessor Period). </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(j)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:8.57pt">Property and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; The Predecessor historically capitalized certain internal use software costs that did not meet the criteria for capitalization. Obagi should have recorded these expenses in the periods in which they were incurred. This resulted in an overstatement of property and equipment, net of $2.4 million as of December 31, 2021 (Predecessor Period), however it had an insignificant impact on depreciation expense for the years ended December 31, 2021 and 2020 (Predecessor Periods).</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(k)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:6.34pt">Other non-current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; As described above in (h), the Predecessor historically capitalized prepaid expenses and included the long-term portion of such expenses in other non-current assets. Obagi should have recognized these expenses in the periods in which they were incurred. This resulted in an overstatement of other non-current assets of $1.2 million as of December 31, 2021 (Predecessor Period). </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(l)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:8.57pt">Accounts payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; The Predecessor historically did not appropriately accrue for certain costs incurred in the period. These misstatements were individually insignificant, but in the aggregate resulted in an understatement of accounts payable of $1.3 million as of December 31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(m)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:3.57pt">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">   </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:106%;padding-left:10.5pt">Deferred revenue &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">As described above in (a)4, the Company identified misstatements to revenue recognized for the SA Distributor and the U.S. Online Marketplace Distributor. Obagi should have recorded deferred revenue for payments received in advance of the revenue recognition. These adjustments resulted in an understatement of other current liabilities of $0.7 million as of December 31, 2021 (Predecessor Period).</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Accrued payroll and related expenses &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company identified misstatements to accrued liabilities for employee related compensation matters and other expenses. This resulted in an understatement of other current liabilities of $0.2 million as of December 31, 2021 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Accrued distribution service fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> The Company identified misstatements to accrued distribution service fees which should have been classified as contra-accounts receivable. This resulted in an overstatement of other current liabilities of $1.2 million as of December 31, 2021 (Predecessor Period).</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(n)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Tax Accounting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; The Company recalculated its income tax expense and related liabilities as a result of the restatements. The tax impact of the restatements was a decrease to income tax expense of $1.7 million and an increase to income tax expense of $1.7 million for the years ended December 31, 2021 and 2020 (Predecessor Periods), respectively. There was no impact to the balance sheet as of December 31, 2021 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(o)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">&#160;&#160;&#160;&#160;Accumulated Deficit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; The cumulative impact of the restatement adjustments for the previously reported periods increased accumulated deficit by approximately $37.3 million as of January 1, 2020. The effects of the restatement adjustment to opening accumulated deficit as of January 1, 2020 primarily relates to restatement adjustments associated with the SA Distributor, the Physician Channel Provider, U.S. Online Marketplace Distributor, and prepaid expenses as described above in (a)2, (a)3, (a)4, and (h), respectively. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to enhance the clarity of financial information for users of these financial statements, the Company has elected to make certain reclassifications to its consolidated statements of operations and comprehensive loss. As such, certain amounts in the prior periods presented have been reclassified to conform to the current period financial statement presentation. These reclassification changes do not constitute errors because they represent changes in presentation from one acceptable method to another acceptable method under U.S. GAAP. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Reclassifications</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categories of the reclassification adjustments and their impact on previously reported consolidated financial statements are described below: </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(p) The Company chose to reclassify depreciation and amortization expenses presented historically in the Predecessor Periods as a separate line item to cost of goods sold and SG&amp;A expenses. Depreciation expense of property and equipment was reclassified to SG&amp;A expenses and amortization expense of product-related intangible assets (e.g., supply agreement, formulations) was reclassified to cost of goods sold. These reclassifications align the historical presentation in the Predecessor Periods to the Successor Period presentation in the consolidated statement of operations and comprehensive loss.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Cost of goods sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; The following table summarizes the impact of the reclassification adjustments to cost of goods sold:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">(q) The Company chose to reclassify amounts related to the effect of foreign exchange rates on cash and cash equivalents and present them as a separate line item from the change in cash, cash equivalents and restricted cash. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(r) The Company previously did not present gross profit. The Company has changed the presentation in its statement of operations to present gross profit, which resulted in cost of goods sold being reclassified from being grouped with other operating expenses to being part of the separate gross profit presentation.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Consolidated Financial Statement Adjustments Tables</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the effects of the restatement and reclassification adjustments to the previously issued consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEET</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.479%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">As Reported</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Restatement Adjustments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Restatement Reference</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">12,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">12,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">63,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(44,629)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">f</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">18,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">19,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">g</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">21,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">7,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(2,979)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">h</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">i</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">104,429&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(45,392)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">59,037&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">3,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(2,386)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">79,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">79,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">44,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">44,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1,209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">k</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">TOTAL ASSETS</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">233,573</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(48,987)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">184,586</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CURRENT LIABILITIES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">11,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">l</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">12,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">15,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">n.m.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">15,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">12,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">m</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">12,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">39,740</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">1,065</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">40,805</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Long-term debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">103,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">103,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">n.m.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">TOTAL LIABILITIES</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">144,283&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">145,347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">SHAREHOLDERS' EQUITY:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Predecessor common shares, 25,000,000 shares authorized; $0.50 par value, 8,000,002 shares issued and outstanding as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">100,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">100,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(14,798)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(50,051)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(64,849)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">TOTAL SHAREHOLDERS' EQUITY</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">89,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(50,051)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">39,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">233,573</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(48,987)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">184,586</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n.m. - not meaningful</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE (LOSS)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restatement Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restatement Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">206,069</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(63,597)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">142,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b,p,r</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross profit </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(48,708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c,p</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(899)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d,a(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,904)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">j,p</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating expenses </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">187,995</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(53,364)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(45,571)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">89,060</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,699)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,625)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,156&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n.m.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,118&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on PPP Loan forgiveness</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on write-off of loan receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses (income), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,011)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total other (income) expenses, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,843</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,506</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,349</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Loss) income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11,231</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(21,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(70)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,506)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,576)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares used in computing net loss per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,576)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(102)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,506)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,608)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n.m. - not meaningful</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restatement Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restatement Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">84,145</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,283</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">94,428</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b,p,r</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross profit </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">65,332</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,969)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c,p</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,421)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">j,p</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating expenses </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">92,118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(24,625)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,689)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">64,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7,973)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,501</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total other (income) expenses, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Loss) income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14,265)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,501</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5,764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,094)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9,171)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,801</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares used in computing net loss per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9,171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,801</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9,155)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,801</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,354)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CONSOLIDATED STATEMENT OF CASH FLOWS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars)</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restatement Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restatement Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(19,506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(19,576)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gain on PPP Loan forgiveness</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,824)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,824)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n.m.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on disposal of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on write-off of loan receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">f</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(23,790)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">f</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,057)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">g</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">h</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,097)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,711)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">i,k</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">l, q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current liabilities and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,782)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">m</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash (used in) provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,541)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,529</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditure on intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(937)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n.m.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditure on property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Advances for note receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash used in investing activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(5,360)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,573</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(3,787)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash provided by financing activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,162</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,162</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,872</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">q</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;Beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,572</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,572</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;End of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13,444</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13,444</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SUPPLEMENTAL CASH FLOW DATA &#8211; CASH PAID:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NON-CASH INVESTING AND FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures in accounts payable and accruals</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENT OF CASH FLOWS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars)</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restatement Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restatement Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,743)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(961)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">f</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16,661)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">g</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">h</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,919)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(998)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">i,k</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">l</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,391)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current liabilities and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">m</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash (used in) provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(7,251)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(7,431)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditure on intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditure on property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,054)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash used in investing activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,887)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">180</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,707)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash provided by financing activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,181</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,181</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;Beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,391</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,391</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;End of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,572</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,572</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SUPPLEMENTAL CASH FLOW DATA &#8211; CASH PAID:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NON-CASH INVESTING AND FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures in accounts payable and accruals</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital contribution of trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693577683104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The accompanying consolidated financial statements include the accounts of Waldencast and its consolidated subsidiaries. The Company consolidates entities in which the Company has a majority voting interest. The Company eliminates intercompany transactions and accounts in consolidation. The Company separately presents within equity on the consolidated balance sheets the ownership interests attributable to parties with noncontrolling interests in the Company's consolidated subsidiaries, and separately presents net income attributable to such parties on the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a registration statement declared effective under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or do not have a class of securities registered under the Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This may make comparison of the Company&#8217;s consolidated financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Significant estimates and assumptions reflected in the financial statements include, but are not limited to, revenue recognition, fair value of assets acquired and liabilities assumed in business combinations, stock-based compensation, and valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and assumptions that it believes are reasonable at the time. Due to the inherent uncertainty involved in making assumptions and estimates, changes in circumstances could result in actual results differing from those estimates, and such differences could be material to the Company&#8217;s consolidated balance sheets and consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company maintains its cash balances in accounts held by major banks and financial institutions located primarily in the U.S. and considers such risk to be minimal. Such bank deposits from time to time may be exposed to credit risk in excess of the Federal Deposit Insurance Corporation insurance limit.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable primarily represent amounts due from distributors, and third-party logistics companies, directly and indirectly from major retailers, and from group purchasing organizations located both inside and outside the U.S. The Company mitigates its credit risks by performing ongoing credit evaluations of its customers&#8217; financial conditions, requiring customer advance payments in certain circumstances. The Company generally does not require collateral. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 (Successor Period), two U.S. customers accounted for 50% and 19% of accounts receivable, respectively. As of December&#160;31, 2021 (Predecessor Period), three U.S. customers accounted for 41%, 14%, and 10% of accounts receivable, respectively. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period from July 28, 2022 to December&#160;31, 2022 (Successor Period), one vendor exceeded 10% of inventory purchases. During the period from January 1, 2022 to July&#160;27, 2022 (Predecessor Period), three vendors exceeded 10% of inventory purchases. During the period from July 28, 2022 to December&#160;31, 2022 (Successor Period), the Company purchased approximately 27% of inventory from one vendor. During the period from January 1, 2022 to July&#160;27, 2022 (Predecessor Period), the Company purchased approximately 23%, 12%, and 12% of inventory, respectively, from three vendors. During the year ended December&#160;31, 2021 (Predecessor Period), two vendors exceeded 10% of inventory purchases. In 2021 (Predecessor Period), the Company purchased approximately 45% and 11% of inventory, respectively, from two vendors.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 (Successor Period), two</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vendors accounted for</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15% and 12%,</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, of accounts payable. As of December&#160;31, 2021 (Predecessor Period), one vendor accounted for 24% of accounts payable. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company considers highly liquid investments with an initial maturity of three months or less to be cash and cash equivalents.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company&#8217;s restricted cash represents funds that were not accessible for general purpose cash needs due to contractual limitations. As of December&#160;31, 2022 (Successor Period), the Company&#8217;s cash, cash </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equivalents, and restricted cash balance of $10.2 million shown on the consolidated statements of cash flows consisted of $1.5&#160;million of restricted cash and $8.7&#160;million of cash and cash equivalents. The restricted cash balance represented cash in a savings account held by a major bank located in the U.S. and provides collateral for corporate credit cards obtained by the Predecessor for its employees. The Company is required to hold the restricted cash in the bank&#8217;s savings account. Following the acquisition of Milk, the Company had an additional $0.8 million in restricted cash held with a financial institution as collateral for a lease deposit. The deposit is refundable at the end of the lease in November 2030, provided that Milk does not default on its lease payments. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 (Predecessor Period) the Company&#8217;s cash, cash equivalents, and restricted cash balance of $13.4 million as shown on the consolidated statements of cash flows consisted of $0.6 million restricted cash and $12.8 million in cash and cash equivalents. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company&#8217;s products are produced by third-party contract manufacturers (&#8220;CMOs). Inventories consist of finished goods, work-in-process products and promotional products, valued at the lower of cost or net realizable value using the standard cost method, which approximates actual costs determined on a first-in, first-out (&#8220;FIFO&#8221;) basis. In order to track inventory quantities, the Company uses a perpetual inventory system. Promotional product is charged to cost of goods sold at the time the product is shipped to the Company&#8217;s customer.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has in-transit inventory at any given period. Assessment of in-transit inventory is required to determine inventory balances accurately at period-end. Inventory is recognized when the Company holds title and bears substantially all of the risks and rewards of ownership. In many transactions, the transfer of title and the risks and rewards of ownership are dictated by contractually specified shipping terms, which may take the form of free-on-board (&#8220;FOB&#8221;) shipping point or FOB destination point.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If historical costs exceed the net realizable value at the balance sheet date, the Company adjusts the inventory to net realizable value (i.e., if impairment is identified, the Company records write-downs of inventories to cost of goods sold in the period in which it occurs). The Company evaluates the carrying value of inventories on a regular basis and determines the need to write down carrying values by considering historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost, and the remaining shelf life of goods on hand. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Obsolete, Scrap and Expired Inventory</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inventory provision is set up for inventory that is expected to become obsolete or have a decreased value due to market trends or product upgrades. It accounts for losses that may occur when the inventory cannot be sold at its full cost. The Company regularly monitors any inventory that is not expected to be sold prior to the expiration date and historically slow-moving inventory based on the remaining shelf life and incorporates these considerations into its reserve analysis. Additionally, each period, Management will evaluate whether any additional write downs are required in addition to the calculated reserve amount (generally, by stock keeping unit (&#8220;SKU&#8221;) and/or lot). Specific reserves may relate to known matters, such as quality concerns or a discontinued product.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Sales Returns</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the Company has not experienced a material amount of product returns. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain arrangements may give the Company&#8217;s customers the right to return products. In addition, when customer arrangements do not give the Company&#8217;s customer the explicit right to return products, the Company may accept returns on a discretionary basis. The Company records a return asset for products returned by customers measured at the former carrying amount of the inventory, less any expected costs to recover the goods and potential decreases in value. If the returned inventory is not considered re-sellable, it will be written off to cost of goods sold. When customers have the right to receive a refund for defective or damaged products (as opposed to a replacement product), the right is accounted for as a right of return under ASC 606. When customers have the right to receive a replacement product for defective or damaged products, the right is accounted for as a warranty under ASC 460-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Company accrues for replacement costs.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivatives </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accounts for derivative instruments in accordance with ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 815&#8221;), which requires additional disclosures about the Company&#8217;s objectives and strategies for using </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">derivative instruments, how the derivative instruments and related hedged items are accounted for, and how the derivative instruments and related hedging items affect the consolidated financial statements. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses interest rate collars to mitigate interest risk associated with its variable rate credit agreements. See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_145" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Financial Instruments&#8221; for further discussion of the interest rate collar. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Terms of debt instruments are reviewed to determine whether they contain embedded derivative instruments that are required to be accounted for separately from the host contract and recorded on the consolidated balance sheets at fair value under ASC 815. An evaluation of specifically identified conditions is made to determine whether the fair value of warrants issued is required to be classified as equity or as a derivative liability. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Liabilities</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for Public Warrants and Private Placement Warrants (each as defined below) as liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 480&#8221;) and ASC 815. Specifically, the Public and Private Placement Warrants meet the definition of a derivative but do not qualify for an exception from derivative accounting since the warrants are not indexed to the Company&#8217;s stock and, therefore, are precluded from equity classification. Since the Public and Private Placement Warrants meet the definition of a derivative under ASC 815, the Company measures the warrants at fair value at inception and at each reporting date, with changes in fair value recognized in change in fair value of derivative warrant liabilities in the consolidated statements of operations and comprehensive loss in the period of change. See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_145" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Financial Instruments&#8221; for further discussion of the warrants, including the FPA Warrants (as defined below).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the interest rate collar and warrant liabilities were estimated using inputs based on management&#8217;s judgment and conditions that existed at each reporting date. See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_151" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a><a href="#if2fc25067f8b45fc8cc165df93f3be1c_151" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for further details.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company&#8217;s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and all other current liabilities approximate their carrying values because of the short maturities of these instruments. Additionally, the carrying amount of debt approximates fair value due to the adjusting interest rates of the Company&#8217;s term loan, which approximate current market rates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Capitalized Software and Website Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212; The Company capitalizes costs related to (i) internal-use software (ii) cloud computing arrangement (&#8220;CCA&#8221;) implementation costs, and (iii) other software-related costs (e.g., website development costs).</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For internal-use software, both internal and external costs incurred during the preliminary project stage are expensed as incurred, and qualifying costs incurred during the application development state are capitalized. Capitalization ceases no later than the point at which a software project is substantially completed and ready for its intended use. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For CCAs, or hosting arrangements, the Company evaluates if the CCA includes a software license that will be accounted for in addition to a hosting service. The cost of the arrangement (i.e., license or service cost) of a CCA that includes a software license will be capitalized as an acquisition of an asset (similar to internal-use software) and amortized over its useful economic life, whereas the costs of a service contract are expensed as incurred.  </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs related to website development are expensed as incurred during the planning stage, content development stage, and operating stage. The Company generally capitalizes costs incurred for activities during the website application and infrastructure development stage, and graphics development stage. Costs incurred for website hosting services from a third-party vendor are expensed over the period the services are received.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Internal-use software costs and website development costs are amortized on a straight-line basis over their estimated useful lives, which is generally three years or less. Management evaluates the useful lives of these assets and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; At initial recognition, the Company measures prepaid assets based on cost (i.e., amount paid). In the accounting period or periods in which a good or service is used or received, the asset will be reduced by a proportionate amount and an associated asset (e.g., inventory) or expense (e.g., marketing) will be recorded.   </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Prepaid Inventory</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prepayments are required to begin production of inventory at certain of the Company&#8217;s CMOs and inventory suppliers. Vendors are tracked to determine prepayments that have been made and when the associated inventory is expected to be delivered to the Company (i.e., when the Company takes ownership of the inventory). Prepaid inventory is triggered by invoices received from CMOs (i.e., the vendor). When the Company submits purchase orders, the CMOs may request a prepayment amount (deposit) based on agreed-upon percentage in the vendor contracts to start the production process.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Prepaid Marketing and Advertising</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally expenses the costs of advertising and marketing as costs are incurred, except for costs associated with producing advertising. While production costs (i.e., costs to develop promotions for a specific campaign associated with an identified new brand or new product) are incurred during the process of production, the Company has elected to expense certain costs when the associated advertising takes place. In the event that the advertising is not expected to occur (e.g., decision has been made to not launch a promotion) or a 12-month period elapses without the associated advertising occurring, the associated production costs will be expensed.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Property and equipment are stated at cost, net of accumulated depreciation. In the case of a business combination, acquired property and equipment are recognized at their fair value as of the date of acquisition. Following initial recognition, property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of respective assets. No depreciation is charged to construction in progress. The estimated useful lives of the Company&#8217;s assets are as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ESTIMATED&#160;USEFUL&#160;LIVES</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gondolas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lesser of useful life or term of lease</span></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Intangible assets consist primarily of trademarks and trade names, a supply agreement, customer relationships, formulations, and developed technology. Intangible assets acquired in a business combination are recognized at their fair value as of the date of acquisition. Following initial recognition, intangible assets are carried at cost less accumulated amortization and impairment losses, if any, and are amortized on a straight-line basis over the estimated useful life of the asset. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, for each asset group held for use with indicators of impairment, the Company compares the expected future cash flows generated by the asset group, which represents the lowest level at which cash flows are identifiable, with its associated net carrying value. If the net carrying value of the asset group exceeds expected undiscounted cash flows, the excess of the net book value over estimated fair value is charged to impairment loss. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; When the Company acquires a business, the total purchase consideration provided is allocated to the identifiable assets and liabilities of the acquired business at their estimated respective fair values. Any excess consideration of the fair value of purchase consideration over the fair values of assets acquired and liabilities assumed is recognized as goodwill.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgments and assumptions are required in determining the fair value of assets acquired and liabilities assumed. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows, useful lives and discount rates. Measurement period adjustments are reflected at the time identified, up through the conclusion of the measurement period, which is the time at which all information for determination of the values of assets acquired and liabilities assumed is received, which may not exceed one year from the acquisition date. The Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with a corresponding offset to goodwill. If outside of the measurement period, any subsequent adjustments are recorded in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Goodwill represents the difference between the purchase price and the fair value of assets and liabilities acquired in a business combination. The Company reviews goodwill for impairment annually on October 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and at an interim date if events or changes in circumstances indicate the occurrence of a triggering event. The Company reviews goodwill for impairment by initially considering qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill, as a basis for determining whether it is necessary to perform a quantitative analysis. If it is determined that it is more likely than not that the fair value of reporting unit is less than its carrying amount, a quantitative analysis is performed to identify goodwill impairment. Determining the fair value of a reporting unit involves the use of significant estimates and assumptions. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company capitalizes costs related to the issuance of debt instruments, as applicable. Such costs are initially recorded as a direct deduction from the applicable debt instrument and amortized over the contractual term of the related debt instrument in interest expense, net using the straight-line method, which approximates the effective interest method, in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Trade accounts receivable are stated at net realizable value. Receivables are unsecured and represent amounts billed to and currently due from customers that have yet to be collected. Payment terms are generally short-term in nature and are less than one year. In certain circumstances, the Company offers extended payment terms to customers. When the period between the transfer of control of the products and payment is greater than one year, the Company adjusts the promised amount of consideration for the effects of a significant financing component. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains an allowance for doubtful accounts, which represents allowances for customer trade accounts receivable that are both probable and estimated to be partially or entirely uncollectible. These allowances are used to reduce gross trade receivables to their net realizable value. The Company records these allowances based on estimates related to the following factors: (i)&#160;customer-specific allowances, based upon past collection history, historical trends, and identification of specific customer risk and (ii)&#160;formula-based general allowances using an aging schedule. Determining such allowances involves the use of significant estimates and assumptions. Payments of accounts receivable are allocated to the specific invoices identified on the customer&#8217;s remittance advice or to the customer&#8217;s account, if unspecified, until an invoice can be determined by the customer. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to trade accounts receivable.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company recognizes revenue when control of the promised goods or services is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to for those goods or services. In that determination, under ASC 606 the Company follows a five-step model that includes: (1) determination of whether a contract or an agreement between two or more parties that creates legally enforceable </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rights and obligations exists; (2) identification of the performance obligations in the contract; (3) determination of the transaction price; (4) allocation of the transaction price to the performance obligations in the contract; and (5) recognition of revenue when (or as) performance obligations are satisfied. Net revenue excludes taxes collected by us on behalf of governmental authorities.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue is primarily generated from product sales to distributors, retailers, physicians and directly to consumers (&#8220;DTC&#8221;) via its e-commerce platforms. Distributors may resell products to retailers, physicians, or end consumers. To determine when to recognize revenue under ASC 606 in cases where products are sold to distributors, the Company analyzes various factors including its ability to direct products physically held by the distributors, when title and risk of loss transfers, and who ultimately manages the relationship with the end consumer. The Company does not recognize revenue until control of the products is transferred to the distributor.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, and when facts and circumstances change, the Company assesses whether it is probable that the Company will collect substantially all of the consideration it will be entitled to from a customer. If the Company determines that it is not probable that the Company will collect substantially all of the consideration from the customer, the Company recognizes revenue only when one or more of the following events occur: (i) the Company has no remaining obligations to transfer goods or services to the customer, and all, or substantially all, of the consideration promised by the customer has been received by the Company and is nonrefundable, (ii) the contract has been terminated, and the consideration received from the customer is nonrefundable, or (iii) the Company has transferred control of the goods or services to which the consideration that has been received relates, the Company has stopped transferring goods or services to the customer (if applicable) and has no obligation under the contract to transfer additional goods or services, and the consideration received from the customer is nonrefundable.  </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that each of its products is distinct and represents a separate performance obligation. The transaction price is equal to the consideration the Company is entitled to &#8211; which could be either a distributor, retailer, physician, or e-commerce end consumer. When measuring revenue and determining the consideration the Company is entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Product sales revenue is recognized net of provisions for estimated volume rebates and discounts, markdowns, margin adjustments, early-payment discounts and returns. The Company estimates variable consideration using the expected value method and adjusts the transaction price when control of the related product is transferred to the customer. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s distributors charge fees for certain services rendered by the distributors, including packing and shipping, marketing and advertising the Company&#8217;s products, monitoring product reviews, regulatory services, providing customer service, and generating data and analytical reports on product sales. Distributor fees for services are recognized as a reduction to revenue because the services provided are typically not distinct from the distributors&#8217; purchase of products.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, customers are required to pay either in advance or between 30 and 90 days from delivery or invoicing. However, in certain circumstances, the Company offers extended payment terms to customers. When the period between the transfer of control of the products and payment is greater than one year, the Company adjusts the promised amount of consideration for the effects of a significant financing component. When contracts contain a significant financing component in which the Company is effectively financing the customer, a portion of the transaction price is recognized as other income.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price to each performance obligation based on its relative standalone selling price. Standalone selling price is the price at which the Company would sell a promised product separately to a customer. The Company typically has an observable standalone selling price for each of its products.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has different contracted shipping terms with different customers that dictate the timing of payment, passage of legal title, transfer of physical possession, and assumption of the risks and rewards occur. For distributors, other than the Physician Channel Provider, and retailers, depending on the contract, the Company considers transfer of control to have occurred either once the delivery of the product has occurred or once the product has been picked up from the Company&#8217;s designated warehouse/distribution center by the customer&#8217;s shipping agent, unless the Company is responsible for shipping the goods, in which case transfer of control passes upon delivery to the customer. For DTC </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales and sales to physicians through the Physician Channel Provider, control transfers upon shipment to the end consumer or physician. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shipping and Handling </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for shipping and handling activities as fulfillment activities instead of as performance obligations and recognizes these costs as SG&amp;A expenses. Costs related to shipping and handling for the period from July&#160;28 to December&#160;31, 2022 (Successor Period), and the period from January&#160;1 to July&#160;27, 2022 (Predecessor Period), and the years ended December&#160;31, 2021 and 2020 (Predecessor Periods) were $2.0 million, $0.6 million, $1.0 million, and $0.2 million, respectively. Amounts billed to customers for shipping and handling are included in revenue.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Promotional Products</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In situations where promotional products, such as samples and testers, are provided by the Company to its customers at the same time as a related saleable product, the cost of these promotional products are recognized as cost of sales at the same time as the revenue for the related product is recognized.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates royalty revenue from products sold under the Obagi brand name in Japan and Hong Kong through license agreements with local operators. Under these agreements, the Company provides the local operators with a license of intellectual property and receives a royalty based upon a percentage of net sales of Obagi-branded products sold in Japan and Hong Kong. Because the license is the predominant item to which the sales-based royalty relates, the Company recognizes revenue for the sales-based royalty when the local operators make sales of the products.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs to Obtain a Contract with a Customer</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the incremental costs of obtaining a customer contract as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. The incremental costs to obtain contracts primarily relate to sales commission and sales-based bonuses. Total capitalizable costs to obtain a contract were immaterial during the periods presented.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts do not typically give rise to material contract assets or contract liabilities because (i) payment is typically closely aligned with the timing of the Company&#8217;s performance or (ii) the Company performs prior to customer payment, and the Company has an unconditional right to payment that represents an account receivable. Similarly, the Company does not recognize material revenue in reporting periods from performance obligations satisfied in previous periods. The Company applies the exemption in ASC 606-10-50-14(a) related to disclosure of the amount of transaction price allocated to unsatisfied performance obligations for royalty contracts. Because of the short-term nature of product sales contracts, the Company typically does not have other material amounts to disclose related to the transaction price allocated to unsatisfied performance obligations. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cost of Goods Sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;Cost of goods sold consists of inventory and promotional product costs, including when inventory and promotional products are sold or written down, and product-related intangible asset amortization and depreciation expense.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;R&amp;D costs are expensed as incurred. Costs associated with research and development activities may include materials, equity and facility costs, personnel costs, contracted services (i.e., the costs of services performed by third parties in connection with the Company&#8217;s R&amp;D activities), and direct costs (e.g., appropriate allocations for general and administrative costs). Substantially all R&amp;D expenses are related to new product development and design improvements or increased functionality in current products. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may capitalize acquired assets associated with R&amp;D activities (e.g., materials, equipment) if both of the following criteria are met: (i) the Company reasonably expects that the acquired assets will be used in an alternative manner and anticipates an economic benefit from the alternative future use and (ii) the use of the acquired asset is not </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contingent on the further development of the asset after acquisition date (i.e., the asset can be used in an alternative manner in the condition in which it existed at the acquisition date).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Advertising costs are expensed in the period in which they are incurred. Total advertising costs, included in SG&amp;A expense on the consolidated statements of operations and comprehensive loss, were $11.7 million, $6.8 million, $9.2 million and $5.9 million for the period from July&#160;28 to December&#160;31, 2022 (Successor Period), the period from January&#160;1 to July&#160;27, 2022 (Predecessor Period) and the years ended December&#160;31, 2021 and 2020 (Predecessor Periods), respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company measures the cost of share-based awards granted to eligible employees, directors, and consultants based on the grant-date fair value of the awards. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Replacement Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Closing Date, in connection with the Business Combination, the Company assumed Obagi and Milk&#8217;s legacy incentive award plans and outstanding unvested options granted under those plans (&#8220;Replacement Options&#8221;). Because the options were deemed in the money on the replacement date, a Hull-White lattice pricing model was used to estimate their fair value to capture the optimal timing of exercise. This pricing model requires the use of assumptions including the volatility of the underlying stock, the fair value of the stock, dividend yield, risk-free rate, and exercise multiple. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Founder Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value and derived service period of the stock options issued to founders (&#8220;Founder Awards&#8221;) in August 2022 based on the Monte Carlo simulation, as they were deemed out of the money on the grant date. The Monte Carlo simulation model requires the use of assumptions including the option&#8217;s expected term, the volatility of the underlying stock, dividend yield rate, risk-free rate, and expected exercise behavior. For expected exercise behavior, the Company assumes that the options are exercised after 50% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock is equal to the price of the Company&#8217;s ordinary shares on the grant date.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to recognize the effect of forfeitures in the period in which they occur. Share-based awards are classified as equity, unless the underlying shares are classified as liabilities or the Company is required to settle the awards by transferring cash or other assets.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for awards with service or performance conditions using the straight-line method over the requisite service period, which is generally the award&#8217;s vesting period. Compensation expense for employee stock-based awards whose vesting is subject to the fulfillment of both a service condition and the occurrence of a performance condition is recognized on a graded-vesting basis at the time the achievement of the performance condition becomes probable.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accounts for income taxes using the asset and liability approach. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes represents income taxes paid or payable for the current period plus the change in deferred taxes during the period. Deferred taxes result from differences between the financial and tax basis of the Company&#8217;s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether a valuation allowance is required often requires significant judgment including the long-range forecasting of future taxable income and the evaluation of planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made. A valuation allowance of $7.9 million was recorded as of December&#160;31, 2022 (Successor Period), a valuation allowance of $14.1 million was recorded as of December&#160;31, 2021 (Predecessor Period), and no valuation allowance was recorded as of December&#160;31, 2020 (Predecessor Period).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for a tax benefit from an uncertain position in the consolidated financial statements only if it is more likely than not that the position is sustainable, based solely on its technical merits and consideration of the relevant taxing authority&#8217;s widely understood administrative practices and precedents. If the recognition threshold for the tax position is met, the Company records only the portion of the tax benefit that is greater than 50% likely to be realized. As of December&#160;31, 2022 (Successor Period), 2021 (Predecessor Period), and 2020 (Predecessor Period), the Company had no uncertain positions in the consolidated financial statements.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no amounts accrued for interest and penalties as of December&#160;31, 2022 (Successor Period), or December 31, 2021 and 2020 (Predecessor Periods).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Income (Loss) Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Basic net income (loss) per share attributable to shareholders of ordinary shares is computed by dividing the Company&#8217;s net income (loss) attributable to holders of ordinary shares by the weighted-average number of ordinary shares used in the income (loss) per share calculation during the period. Diluted net income (loss) per share attributable to holders of ordinary shares is computed by giving effect to all potentially dilutive securities. The net income (loss) per share that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Noncontrolling interests represent the portion of Waldencast Partners LP that the Company controls and consolidates but does not own. The Company recognizes each noncontrolling holder&#8217;s respective share of the estimated fair value of the net assets at the date of formation or acquisition. Noncontrolling interests are subsequently adjusted for the noncontrolling holder&#8217;s share of additional contributions, distributions and their share of the net earnings or losses of each respective consolidated entity. The Company allocates net income or loss to noncontrolling interests based on the weighted average ownership interest during the period. The net income (loss) that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss. The Company does not recognize a gain or loss on transactions with a consolidated entity in which it does not own 100% of the equity, but the Company reflects the difference in cash received or paid from the noncontrolling interests carrying amount as additional paid-in-capital.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and incur expenses and about which separate financial information is regularly evaluated by the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) in deciding how to allocate resources. Similar operating segments can be aggregated into a single operating segment if the businesses are similar. Management has determined that, following the Business Combination, the Successor has two operating and reportable segments: Obagi Skincare and Milk Makeup, reflecting the manner in which the CODM operates the Company. The Company&#8217;s CODM is its Chief Executive Officer. The Predecessor had one operating and reportable segment.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;) using the modified retrospective transition method on the date of the Business Combination. The Predecessor planned to adopt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 842 during the annual period ended December&#160;31, 2022. Waldencast had no capital or operating lease obligations prior to the Business Combination. The Company elected the package of practical expedients available upon transition to ASC 842 that allow (i) historical lease classification of existing leases, (ii) no reassessment of any expired or existing contracts containing leases, and (iii) no reassessment of initial direct costs for any existing leases. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of the new standard impacted the Company&#8217;s accounting for operating leases. Upon adoption, the Company established an operating right-of-use asset of $13.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and a corresponding operating lease liability of $16.6 million. The Company does not have any finance leases. See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_142" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further detail.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of ASC 842, the Company recognized rent expense for operating leases on a straight&#8209;line basis (including the effect of reduced or free rent and rent escalations) over the lease term. The difference between the cash paid to the landlord and the amount recognized as rent expense on a straight&#8209;line basis was recognized as an adjustment to deferred rent in the consolidated balance sheets.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Debt-Debt with Conversion and Other Options&#8221; (Subtopic 470-20) and &#8220;Derivatives and Hedging-Contracts in an Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 also removes certain settlement conditions that are required for equity-linked contracts to qualify for scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company adopted ASU 2020-06 on January 1, 2021. Adoption of the ASU did not impact the Company&#8217;s financial position, results of operations or cash flows.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU No.&#160;2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic&#160;848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was effective for the Company in the annual period ended December&#160;31, 2022. This ASU provides relief that, if elected, will require less accounting analysis and less accounting recognition for modifications related to reference rate reform. This update provides optional guidance for a limited period of time to ease the potential burden in accounting for reference rate reform on financial reporting. The amendments in the update apply only to contracts, hedging relationships, and other transactions that reference the London Inter-Bank Offered Rate (&#8220;LIBOR&#8221;) or another reference rate expected to be discontinued because of reference rate reform. Waldencast adopted this ASU prospectively effective January 1, 2022, which did not have a material effect on its consolidated financial position, results of operations and cash flows.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022, Waldencast adopted ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes&#8212;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2019-12&#8221;). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. Waldencast adopted this ASU prospectively, which did not have a material effect on its consolidated financial position, results of operations and cash flows.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards, Not Yet Adopted</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU No.&#160;2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements&#8212;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU adds an impairment model known as current expected credit loss that is based on expected losses rather than incurred losses. It recognizes an allowance as an estimate of expected credit losses, which may result in more timely recognition of such losses. In 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 326), which defers the effective date for entities in the &#8220;all other&#8221; category and public not-for-profit entities that have not yet issued their financial statements reflecting the adoption of credit losses. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, and early adoption is permitted. This guidance is effective for the Company for the annual period beginning on January 1, 2023, and interim periods within the annual period beginning on January 1, 2023, with earlier adoption permitted. The adoption of this new standard will not have a material effect on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The guidance requires an acquirer to, at the date of acquisition, recognize and measure the acquired contract assets and contract liabilities acquired in the same manner that they were recognized and measured in the acquiree&#8217;s financial statements before the acquisition. This guidance is effective for interim and annual periods beginning after December 15, 2022, with early adoption permitted. The amendments in this update should be applied prospectively to business combinations occurring on or after the effective date. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements, but does not expect it to have a material impact.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The guidance expands public entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. The guidance also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. This guidance is effective for interim periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. The amendments in this update should be applied retrospectively to all periods presented in the financial statements. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements but does not expect it to have a material impact.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2025, with early adoption permitted. The amendments should be applied prospectively however, retrospective application is also permitted. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575467600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">BUSINESS COMBINATIONS</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">BUSINESS COMBINATIONS</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2022, Waldencast consummated its initial business combination with (i) Obagi, pursuant to an Agreement and Plan of Merger dated November 15, 2021, by and among Waldencast, Obagi Merger Sub, Inc., a Cayman Islands exempted company limited by shares and an indirect wholly-owned subsidiary of Waldencast (&#8220;Merger Sub&#8221;), and Obagi (the &#8220;Obagi Merger Agreement&#8221;), and (ii), Milk, pursuant to an Equity Purchase Agreement dated November 15, 2021, by and among Waldencast, Obagi Holdco 1 Limited, a limited company incorporated under the laws of Jersey (&#8220;Holdco Purchaser&#8221;) and a subsidiary of Waldencast, Waldencast Partners LP together with Holdco Purchaser, (the &#8220;Purchasers&#8221;), certain members of Milk (the &#8220;Milk Members&#8221;), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as representative of the Milk Members (the &#8220;Equityholder Representative&#8221;) (the &#8220;Milk Equity Purchase Agreement&#8221; and together with the Obagi Merger Agreement, the &#8220;Transaction Agreements&#8221;).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Obagi Merger Agreement, at the effective time of the Obagi Merger (the &#8220;Obagi Merger Effective Time&#8221;) Merger Sub merged with and into Obagi (the &#8220;Obagi Merger&#8221;) and the separate corporate existence of Merger Sub ceased, with Obagi surviving as an indirect subsidiary of the Company. At the Obagi Merger Effective Time, all outstanding ordinary shares of Obagi, $0.50 par value (&#8220;Obagi common shares&#8221;) were canceled and exchanged for (i) 28,237,506 Class A ordinary shares of Waldencast and (ii) cash in the amount of $345.4 million.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Milk Equity Purchase Agreement, at the effective time of the Milk Transaction (the &#8220;Milk Purchase Effective Time&#8221;) the Purchasers acquired from the Milk Members all of their equity in Milk in exchange for (i) 21,104,225 limited partnership units in Waldencast Partners LP (&#8220;Waldencast LP Units&#8221;) (ii) 21,104,225 Class B ordinary shares, which are non-economic voting shares of Waldencast and (iii) cash in the amount of $121.6 million </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;Milk Transaction&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Waldencast LP Unit and Class B ordinary share held by a Milk Member is redeemable at the option of the holder, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, if such option is exercised, exchangeable at the option of Waldencast </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into one Waldencast Class A ordinary share or cash, </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in accordance with the terms of the Amended and Restated Waldencast Partners LP Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon consummation of the Business Combination </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast became organized in an &#8220;Up-C&#8221; structure, whereby the equity interests of Obagi and Milk are held by Waldencast Partners LP, which is an indirect subsidiary of Waldencast plc.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Business Combination, Waldencast was deemed to be the accounting acquirer and continues as the SEC registrant. Obagi and Milk were deemed to be the accounting acquirees, however Obagi is considered the predecessor entity for purposes of financial reporting. Waldencast was determined to be the accounting acquirer based on evaluation of the following factors:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">The owners of Waldencast have the largest voting interest in the combined company;</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">The original owner of Waldencast, Waldencast Long-Term Capital LLC (the &#8220;Sponsor&#8221;), and its affiliates nominated the majority of the initial members who will serve on the board of directors of Waldencast (the former owner of Obagi nominated one director, and Milk nominated no directors); and</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Waldencast&#8217;s existing management holds executive management roles for the post-combination company, whilst Obagi and Milk management team members report into the current Waldencast executive team.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the Obagi Merger Effective Time, Obagi carved out and distributed the Obagi China Business to Cedarwalk pursuant to the Obagi China Distribution. Following the Obagi China Distribution, the Obagi China Business continues to be held by Cedarwalk, which also owned 24.5% of the fully diluted Waldencast plc Class A ordinary shares as of the Obagi Merger Effective Time. Prior to the Obagi China Distribution, the pre-tax losses for the Obagi China Business were $8.0 million, $3.7 million and $2.3 million for the period from January 1 to July 27, 2022 (Predecessor Period), the year ended December 31, 2021 (Predecessor Period) and the year ended December 31, 2020 (Predecessor Period), respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 17</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Transactions&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on ongoing transactions with the Obagi China Business following the close of the Obagi Merger. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurement period adjustments will be recognized in the reporting period in which the adjustments are determined.  </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obagi and Milk Purchase Price Allocation:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Purchase Price:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">345,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">467,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">277,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">477,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash repayment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total purchase consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">781,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">325,651</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,107,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Account receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">505,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">662,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total identifiable assets acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">579,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">212,609</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">791,925</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities assumed:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">66,145</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22,030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">88,175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net assets acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">513,171</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">190,579</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">703,750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">781,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">325,651</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,107,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">268,263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">135,072</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">403,335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill recognized for these acquisitions is attributable to improving the product offerings, expanding into additional markets and the expected cash flows resulting from these efforts, and assembled workforce. Goodwill recognized is not expected to be deductible for local tax purposes. During the Successor Period ended December 31, 2022, the Company recorded a non-cash impairment charge of $68.7 million within the Obagi Skincare reportable segment. See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_133" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Goodwill&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional details.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_178" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 19</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Segment Reporting&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for amounts related to revenue and earnings associated with Obagi Skincare and Milk Makeup subsequent to the acquisition date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related party liability</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company recognized a liability with respect to a related party supply contract executed on the Closing Date between Obagi and Obagi Hong Kong. The fair value of the related party liability was determined using the present value of after-tax cash flows related to unfavorable discounts provided to the Obagi China Business included in the supply agreement. As of the Obagi Merger Effective Time, the Company recognized a related party liability of $22.1 </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million. During the period from July 28 to December 31, 2022 (Successor Period), the Company amortized $12.2 million of the related party liability into the related party revenue recognized on the sale of products to the Obagi China Business. The Company had a remaining related party liability of $9.9 million, included in Other current liabilities, as of December 31, 2022.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Useful Life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks and Trade Name</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">414,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">559,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer/distributor relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tretinoin distribution and supply agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formulations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Intangible Assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">505,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">157,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">662,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible assets acquired in connection with the Business Combination are classified as Level 3 in the fair value hierarchy. The estimate of the fair values of the acquired amortizable intangible assets were determined using a multi-period excess earnings income approach by discounting the incremental after-tax cash flows over multiple periods. Significant estimates used in the determination include estimating future cash flows over multiple periods, terminal value, and discounting such cash flows at a rate of return that reflects the relative risk of the cash flows.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction Costs </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Business Combination, Waldencast incurred transactions costs of $9.4 million which was incurred during the period from July&#160;28, 2022 to December&#160;31, 2022 (Successor Period). Transaction costs consisted of advisory, legal, accounting and management fees, which are included in SG&amp;A expenses on the consolidated statements of operations and comprehensive loss. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unaudited ASC 805 Pro Forma </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma combined financial information presents the Company&#8217;s results as though the Business Combination had occurred on January 1, 2021, for the years ended December&#160;31, 2021 and 2022. The unaudited pro forma consolidated financial information has been prepared using the acquisition method of accounting in accordance with U.S. GAAP.</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma net revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">162,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(86,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(145,152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Pro forma net income (loss) attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,519)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma net income (loss) attributable to Waldencast plc</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61,790)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(118,633)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited pro forma results include adjustments such as inventory step-up, amortization of acquired intangible assets, and interest expense on debt financing in connection with the Business Combination. Material, nonrecurring pro forma adjustments directly attributable to the Business Combination include:&#160;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; Cost of goods sold related to acquired inventory step-up of $10.0 million was removed from net income for the year ended December&#160;31, 2022 and recognized as an incremental cost of goods sold in the year ended December&#160;31, 2021. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226; Transaction related costs of $66.1 million were removed from net income for the year ended December&#160;31, 2022 and recognized as an expense in the year ended December&#160;31, 2021. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated pro forma financial information was prepared in accordance with accounting standards and is not necessarily indicative of the results of operations that would have occurred if the Business Combination had been completed on the date indicated, nor is it indicative of the future operating results of the Company.&#160;</span></div>The unaudited pro forma results do not reflect events that either have occurred or may occur after the Business Combination, including, but not limited to, the anticipated realization of operating synergies in subsequent periods. They also do not give effect to certain charges that the Company expects to incur in connection with these acquisitions, including, but not limited to, additional professional fees and employee integration.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693576987152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">REVENUE</span><div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates its revenue from customers by sales channel, as well as by revenue source and geographic region, based on the location of the end customer, as it believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Sales Channel</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue is primarily generated from product sales. Direct Sales revenue listed in the table below includes (i) sales to physicians through the Physician Channel Provider, (ii) DTC sales via the Company&#8217;s e-commerce platforms, and (iii) sales directly to retailers. Distributors revenue includes products sold through distributors other than the Physician Channel Provider.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue by sales channel was as follows for the periods indicated: </span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Skincare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk  Makeup</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Sales Channel</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59,102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,090&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,283&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1 to July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Sales Channel</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,729&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,759&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,524&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,760&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period from July 28 to December 31, 2022 (Successor Period), three customers accounted for 29%, 18% and 16% of the Company&#8217;s revenue, respectively. During the period from January 1 to July 27, 2022, (Predecessor Period), two customers accounted for 44% and 20% of the Company&#8217;s revenue. For the year ended December 31, </span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 (Predecessor Period), two customers accounted for 44% and 17% of the Company&#8217;s revenue. For the year ended December 31, 2020 (Predecessor Period), one customer accounted for 57% of the Company&#8217;s revenue.</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Physician Channel Provider is an authorized wholesale distributor and service provider for the Company in the U.S. Revenue from sales to physicians and e-commerce customers made through this provider are considered direct sales revenue. The Physician Channel Provider is also a distributor of the Company&#8217;s products to other channels, such as the spa channel, and the related sales are considered distributor revenue (in which instances it is referred to as the &#8220;Spa Channel Distributor&#8221;). Revenue generated from products sold to physicians and the DTC channel via the Company&#8217;s e-commerce platform through the Physician Channel Provider was $26.3 million during the period from July 28 to December 31, 2022 (Successor Period), $32.2 million during the period from January 1 to July 27, 2022, (Predecessor Period), $58.8 million during the year ended December 31, 2021 (Predecessor Period), and $51.6 million during the year ended December 31, 2020 (Predecessor Period). Revenue generated from products sold to the Spa Channel Distributor was $0.3 million during the period from July 28 to December 31, 2022 (Successor Period), $0.4 million during the period from January 1 to July 27, 2022, (Predecessor Period), $3.6 million during the year ended December 31, 2021 (Predecessor Period), and $2.5 million during the year ended December 31, 2020 (Predecessor Period). </span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Geographic Region</span></div><div style="padding-left:22.5pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue by geographic region, based on the location of the end customer, was as follows for the periods indicated: </span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:82.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.095%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Geographic Region&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">North America</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of the World</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:49.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1 to July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Geographic Region&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">North America</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of the World</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,729&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,759&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,524&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,760&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period from July&#160;28 to December&#160;31, 2022 (Successor Period), the two countries that accounted for more than 10% of the Company&#8217;s total revenues were the United States and China, respectively, with net product sales amounting to $54.3 million and $17.0 million, respectively. </span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period from January&#160;1 to July 27, 2022, (Predecessor Period) the two countries that accounted for more than 10% of the Company&#8217;s total revenues were the United States and Vietnam, with net product sales amounting to $43.8 million and $14.9 million, respectively. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2021 (Predecessor Period), the countries that accounted for more than 10% of the Company&#8217;s total revenues were the United States, China, and Vietnam, with net product sales amounting to $76.7 million, $16.2 million, and $18.6 million, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020 (Predecessor Period), the United States was the country that accounted for more than 10% of the Company&#8217;s total revenues, amounting to net product sales of $63.4 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693577701504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">GOODWILL</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">GOODWILL</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated goodwill acquired in the Obagi Merger to its Obagi Skincare reportable segment and goodwill acquired in the Milk Transaction to its Milk Makeup segment. The fair value of each reporting unit was determined as of the Closing Date as part of the Business Combination (see &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The following table presents changes in goodwill by reportable segment:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Skincare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk Makeup</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Goodwill</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance as of December 31, 2021 and 2020 (Predecessor)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">44,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">44,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elimination of Predecessor goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44,489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44,489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi and Milk Business Combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">268,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">403,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(68,715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(68,715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance as of December 31, 2022 (Successor)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">199,548</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">135,072</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">334,620</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates goodwill for impairment on an annual basis on October 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and at an interim date if indicators of a potential impairment exist. The goodwill impairment test is conducted at the reporting unit level. The fair value of the Company&#8217;s reporting units is determined using a combination of the discounted cash flow method under the income approach and the guideline public company method under the market approach. Fair value estimates result from a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions that have been deemed reasonable by management as of the measurement date. Under the discounted cash flow method, fair value is determined by discounting the estimated future cash flows of each reporting unit, which includes the Company&#8217;s most recent projected long-term financial forecasts for revenue, earnings, capital expenditures and working capital. The discount rate used is intended to reflect the risks inherent in the future cash flows of the respective reporting unit. Under the guideline public company method, fair value is estimated using market multiples of various financial metrics observed for the reporting unit&#8217;s comparable public companies. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual impairment test performed for fiscal 2020 and 2021 (Predecessor Period) and fiscal 2022 (Successor Period) did not indicate an impairment of goodwill at the time they were performed. However, subsequent to the Business Combination (see &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Business Combinations&#8221;), the Company concluded that qualitative factors and relevant events and circumstances indicated it was more likely than not that the fair value of the Obagi Skincare reporting segment was less than its carrying amount. This included a decline in financial performance of the Obagi Skincare reporting unit compared to results projected at the time of acquisition, primarily as a result of the subsequent identification of the matters underlying the restatements adjustments, see &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_1097" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restatement and Reclassifications.&#8221; Therefore, the Company performed a quantitative goodwill impairment test for the associated reporting unit. As a result, during the Successor Period ended December 31, 2022, the Company recorded a non-cash impairment charge of $68.7 million within the Obagi Skincare reportable segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693577515344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS&#8212;NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS&#8212;NET</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">INTANGIBLE ASSETS&#8212;NET</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following as of December&#160;31, 2022 (Successor Period):</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:34.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average Useful<br/>Lives (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademark and trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">559,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,840)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">541,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,349)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supply agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formulations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,526)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">663,208&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,043)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">639,165&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following as of December&#160;31, 2021 (Predecessor Period):</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:34.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average Useful<br/>Lives (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademark and trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,004&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,842)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,404)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supply agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formulations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,077&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(54,503)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79,574&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the period from July 28 to December&#160;31, 2022 (Successor Period), period from January&#160;1, 2022 to July&#160;27, 2022 (Predecessor Period), and the years ended December&#160;31, 2021 and 2020 (Predecessor Period), was $24.0 million,</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.7 million, $13.5 million, and $13.3 million, respectively. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected amortization for each of the years between 2023 through 2027, and thereafter are as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ending December 31</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">359,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">639,165&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693578111424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">DEBT</span><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.226%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.383%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.119%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Successor)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Predecessor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 Term Loan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Predecessor 2021 Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Predecessor 2021 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Predecessor 2018 Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Predecessor 2018 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Predecessor PPP Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20,095)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,442)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159,229&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103,423&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Successor 2022 Credit Agreement </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Borrower, a wholly-owned subsidiary of the Company, together with Waldencast Partners LP and certain of its subsidiaries as guarantors, entered into the 2022 Credit Agreement with the Lenders and JPMorgan, as administrative agent for the Lenders. The 2022 Credit Agreement provides the Company with access to a term loan of $175.0 million (the &#8220;2022 Term Loan&#8221;) and a revolving credit capacity with borrowing capacity of up to $50.0 million (the &#8220;2022 Revolving Credit Facility&#8221;), of which up to $7.5 million may be available, at Borrower&#8217;s option, to be drawn in form of letters of credit (&#8220;2022 Letter of Credit&#8221;). The 2022 Credit Agreement is secured by the assets of the Company. The 2022 Credit Agreement restricts the Company&#8217;s ability to make certain distributions or dividends, subject to a number of enumerated exceptions, which restrictions will not apply at any time the Company&#8217;s Leverage Ratio is below 2.5X.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Credit Agreement matures on July 27, 2026, four years following the funding date. The Company may elect to borrow either alternate base rate borrowings or term benchmark borrowings. Each draw that is an alternate base rate borrowing bears interest at&#160;an Alternate Base Rate (as defined in the 2022 Credit Agreement) plus the applicable rate of 2.5% per annum. Each draw that is a term benchmark borrowing bears interest at the Term SOFR Rate (as defined in the 2022 Credit Agreement), which resets periodically, plus 0.1% and the applicable rate of 3.5% per annum. As of December&#160;31, 2022, borrowings under the 2022 Credit Agreement consisted entirely of term benchmark borrowings at a borrowing rate of 7.9%. The carrying amount of debt approximates fair value due to the adjusting interest rates of the term loan, which approximate current market rates.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2022 Credit Agreement, the Company incurred $6.3 million of debt issuance costs. As of December&#160;31, 2022, the Company had unpaid principal of $170.7 million and $14.1 million on the 2022 Term Loan and the 2022 Revolving Credit Facility, respectively. The 2022 Term Loan and the 2022 Revolving Credit Facility had total unamortized debt issuance costs of $5.4 million as of December&#160;31, 2022. As of December 31, 2022, the weighted average interest rate was 6.6% for the 2022 Term Loan and the 2022 Revolving Credit Facility. The current portion of the 2022 Term Loan and the 2022 Revolving Credit Facility was $8.4 million and $14.1 million, respectively. The current portion of the unamortized debt issuance costs on the 2022 Term Loan and the 2022 Revolving Credit Facility was $1.2 million and $1.2 million, respectively. The accrued interest was $0.1 million as of December&#160;31, 2022. Unamortized debt issuance costs on the 2022 Letter of Credit is $0.2 million, of which $51,000 was recognized in other current assets and $0.1 million was recognized in other assets in the consolidated balance sheets.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled maturities under the Company&#8217;s 2022 Credit Agreement as of December&#160;31, 2022 (Successor Period) are as follows :</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unpaid principal</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184,769&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Waiver and Consent and Amendment to the 2022 Credit Agreement</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Borrower entered into a technical amendment to the 2022 Credit Agreement to cure a technical error and clarify when the first amortization payment under the 2022 Credit Agreement is due and payable.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Borrower entered into a waiver and consent agreement with JPMorgan and the required Lenders to, among other things, waive certain defaults or events of default that had or would have resulted from the failure to deliver certain financial information and related reports. In June 2023, the Borrower entered into a subsequent waiver and consent agreement with JPMorgan and the required Lenders, pursuant to which they agreed to, among other things, (a) continue to waive certain defaults or events of default that had or would have resulted from the failure to deliver certain financial information and related reports and (b) suspend the testing of certain financial covenants in the 2022 Credit Agreement.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, the Borrower entered into a subsequent waiver and consent agreement with JPMorgan and the required Lenders, pursuant to which they agreed to, among other things, (i) waive any default or event of default that has or would result from the failure to deliver the financial information and related reports with respect to the fiscal year of the Borrower ended December 31, 2022 and the fiscal quarters of the Borrower ended March 31, 2023 and June 30, 2023, respectively and (ii) suspend the testing of certain financial covenants set forth in the 2022 Credit Agreement. Such waiver would remain in effect until September 15, 2023.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Borrower and Waldencast Partners LP entered into the second amendment and waiver to the 2022 Credit Agreement (the &#8220;Amendment&#8221;) with JPMorgan and the required Lenders, pursuant to which they agreed to (i) waive any default or event of default that has or would result from (a) the failure to deliver the financial information and related reports with respect to the fiscal year of the Borrower ended December 31, 2022 and the fiscal quarters of the Borrower ended March 31, 2023 and June 30, 2023, respectively, (b) any inaccuracy or misrepresentation in certain historical financial statements previously delivered to JPMorgan and (c) certain historical breaches of the financial covenants and (ii) amend the 2022 Credit Agreement to, among other things, modify the existing financial covenant tests. The Borrower is required to deliver certain of the financial information described in (i)(a) above by December 31, 2023 (the &#8220;Waiver Expiration Date&#8221;). Failure to deliver the required audited financial information and certain other deliverables on or prior to the Waiver Expiration Date will result in an event of default under the 2022 Credit Agreement (unless otherwise waived or extended). The Amendment also (i) included additional restrictions on the Borrower&#8217;s, Waldencast Partners LP's and certain of their subsidiaries&#8217; ability to incur certain types of additional indebtedness, make certain acquisitions and investments, create certain liens, dispose of certain assets and make certain types of restricted payments, (ii) established a minimum liquidity covenant of $15.0 million, which is certified on a monthly basis, and (iii) introduced additional financial reporting obligations, in each case until the earlier of September 30, 2024 or such earlier time that the Borrower elects to test the financial covenants in the same manner as prior to giving effect to the Amendment. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Borrower subsequently delivered unaudited financial information and related reports with respect to the fiscal quarters of the Borrower ended March 31, 2023 and June 30, 2023. In December 2023, the Borrower entered into a subsequent waiver and consent agreement with JPMorgan and the required Lenders, pursuant to which they agreed, among other things, to waive any default or event of default that has or would result from the failure to </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deliver the financial information and related reports with respect to the fiscal year of the Borrower ended December 31, 2022. Such waiver shall remain in effect until January 15, 2024.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Predecessor 2021 Credit Agreement </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Obagi replaced its Predecessor 2018 Credit Agreement (described below) for a new financing agreement with a syndicate of lenders, including TCW Asset Management Company LLC as administrative agent for the lenders (the &#8220;2021 Credit Agreement&#8221;). The terms and conditions of the 2018 Credit Agreement and the 2021 Credit Agreement limited the ability of Obagi and its wholly-owned subsidiaries to declare dividends or make other distributions, directly or indirectly, to its shareholder, subject to certain enumerated exceptions, including, but not limited to, dividends up to a specified amount if Obagi was able to achieve certain &#8220;Consolidated Total Leverage Ratios&#8221; thresholds. Due to the aforementioned restrictions, substantially all of the net assets of Obagi&#8217;s subsidiaries were restricted.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Credit Agreement included a term loan of $110.0 million (the &#8220;2021 Term Loan&#8221;) and a revolving credit facility with borrowing capacity of up to $40.0 million (&#8220;2021 Revolving Credit Facility&#8221;). Both the 2021 Term Loan and the 2021 Revolving Credit Facility were due to mature in March 2026. The 2021 Term Loan and 2021 Revolving Credit Facility bore interest at the LIBOR plus an applicable margin, as determined by the Company&#8217;s leverage ratios, and were subject to LIBOR succession provisions. In connection with the issuance of the 2021 Credit Agreement, the Company incurred $6.4 million of debt issuance costs. The 2021 Credit Agreement was secured by the assets of the Company. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 (Predecessor Period), the Company had unpaid principal of $109.2 million, and unamortized debt issuance costs of $3.9 million on the 2021 Term Loan. The interest rate was 8.5% and there was no accrued interest as of December&#160;31, 2021 (Predecessor Period). The current portion of the 2021 Term Loan and 2021 Revolving Credit Facility was $2.8 million and $15.0 million, respectively. The current portion of the unamortized debt issuance costs on the 2021 Term Loan and 2021 Revolving Credit Facility was $0.9 million and $1.4 million, respectively. The outstanding debt under the Predecessor 2021 Credit Agreement was paid in full as part of Waldencast&#8217;s acquisition of Obagi. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Predecessor 2018 Credit Agreement </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, and subject to amendments in March 2020 and November  2020, Obagi entered into a credit agreement (the &#8220;2018 Credit Agreement&#8221;) with a syndicate of banks, including Wells Fargo Bank, National Association (&#8220;Wells Fargo&#8221;) as administrative agent for the banks (the &#8220;Syndicate of Banks&#8221;). The 2018 Credit Agreement included a term loan of $90.0 million (the &#8220;2018 Term Loan&#8221;) and a revolving credit facility with borrowing capacity of up to $35.0 million (&#8220;2018 Revolving Credit Facility&#8221;). Both the 2018 Term Loan and the 2018 Revolving Credit Facility were due to mature in December 2023. In connection with the issuance of the 2018 Credit Agreement, the Company incurred $2.9 million of debt issuance costs.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon settlement of the debt with proceeds from the Predecessor 2021 Credit Agreement, the Company recorded a loss on extinguishment of the 2018 Credit Agreement of $2.3 million to loss on extinguishment of debt in the accompanying consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2021 (Predecessor Period), which consisted of expensing unamortized debt issuance costs.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Predecessor PPP Loan</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company received loan proceeds in the amount of $6.8 million under the Paycheck Protection Program (&#8220;PPP&#8221;) from MUFG Union Bank (the &#8220;PPP Loan&#8221;). The PPP, established as part of the Coronavirus aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;), provided for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The PPP Loan accrued interest at a rate of 1%. The PPP Loan and accrued interest were forgivable after eight or twenty-four weeks as long as the borrower used the proceeds for eligible purposes, including payroll, benefits, rent and utilities and maintains its payroll levels. The Company used the proceeds for purposes consistent with the PPP, and in 2021, received approval from MUFG Union Bank and the Small Business Administration (&#8220;SBA&#8221;) for forgiveness of the full amount of its PPP Loan, inclusive of accrued interest of $74,000. The Company recognized a gain on PPP Loan forgiveness of $6.8 million for the year ended December&#160;31, 2021 (Predecessor Period). </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the Company was notified by its lender that the SBA had requested additional documents relating to the Company&#8217;s PPP Loan. The Company provided the required documentation and no further communication has been received in response.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693574140704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">LEASES</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for real estate properties for office and warehouse space with initial terms of approximately 8 and 11 years, respectively.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s lease contracts include options to extend the leases for up to 5 years. Our lease agreements generally do not contain any residual value guarantees or restrictive covenants.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if a contract contains a lease at inception of the arrangement based on whether the Company has the right to obtain substantially all of the economic benefits from the use of an identified asset and whether the Company has the right to direct the use of an identified asset in exchange for consideration, which relates to an asset that the Company does not own. Right of use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of any changes in market conditions but generally, these termination options are not exercised and not considered in the determination of the lease term. Lease liabilities are recognized at the present value of the future lease payments at the lease commencement date. ROU assets are recognized on the balance sheet based on the lease liability adjusted for any initial direct costs, lease incentives received, and prepaid rent. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate used to determine the present value of the future lease payments is the Company&#8217;s incremental borrowing rate (&#8220;IBR&#8221;), because the interest rate implicit in most of the Company&#8217;s leases is not readily determinable. The IBR is a hypothetical rate based on the Company&#8217;s understanding of what its credit rating would be, and resulting interest the Company would pay, to borrow an amount equal to the lease payments in a similar economic environment over the lease term on a collateralized basis. Lease payments may be fixed or variable, however, only fixed payments or in-substance fixed payments are included in the Company&#8217;s lease liability calculation. Variable lease payments may include costs such as common area maintenance, utilities, or other costs. Variable lease payments are recognized in operating expenses in the period in which the obligation for those payments is incurred. The Company has elected not to separate non-lease components from lease components and accounts for them as a single lease component. The Company has also elected the short-term lease recognition exemption for all leases that qualify.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company historically accounted for leases in accordance with ASC 840, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under which operating leases were not recorded on the balance sheet. Adoption of ASC 842 was not required in interim periods preceding December&#160;31, 2022. Upon consummation of the Business Combination, Obagi and Milk adopted ASC 842 as a matter of policy alignment. The period from January 1 to July 27, 2022 (Predecessor Period) does not reflect the impact of ASC 842 adoption, as the Company did not adopt the standard as of an interim 2022 period.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease expenses of $1.4 million were composed of operating lease costs. The Company does not have any finance leases, short-term lease costs or variable lease costs. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company&#8217;s operating leases was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:77.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022<br/>(Successor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for new operating lease liabilities:</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:77.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022<br/>(Successor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliation of the undiscounted future minimal lease payments under non-cancelable operating leases to the total operating lease liability recognized on the consolidated balance sheet as of December 31, 2022 was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:77.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed Interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,865&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total reported lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,923&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosures Related to Periods Prior to the Adoption of ASC 842 </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Obagi China Distribution, the Company leased office space under three non-cancelable operating leases expiring between September 2023 and February 2032. Rent expense related to the Company&#8217;s operating leases was $0.9 million, $1.2 million, and $1.1 million for the period from January 1 to July&#160;27, 2022 (Predecessor Period) and the years ended December&#160;31, 2021 and 2020 (Predecessor Period), respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments as of December 31, 2021 were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575464032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">FINANCIAL INSTRUMENTS</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Collar</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To mitigate interest rate risk in connection with the variable rate loans under the 2022 Credit Agreement, the Company entered into an interest rate collar with Wells Fargo for a notional value of $160.0 million and a fixed cash payment of </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.8 million. Under the terms of the interest rate collar, the Company is required to pay Wells Fargo if the monthly SOFR-based interest falls below the defined interest rate floor of 2.55%; conversely, the Company is entitled to receive payment from Wells Fargo if the monthly SOFR-based interest rate rises above the defined interest rate cap of 5.25%. Settlement in cash occurs monthly, if contractually required, until termination of the agreement in October 2024, and the variable interest rate is reset on the last day of each month. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This derivative instrument has not been designated for hedge accounting, therefore the change in fair value is recognized in current period earnings. The fair value of these contracts, included in other non-current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $0.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of December&#160;31, 2022 (Successor Period). The non-cash loss from change in fair value during the period from July 28 to December&#160;31, 2022 (Successor Period) was $0.6 million, recognized in other expenses, net. No payments or receipts were exchanged on the interest rate collar contract during the period from July 28 to December&#160;31, 2022 (Successor Period) aside from the initial fixed cash payment of $0.8 million. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liabilities </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Waldencast&#8217;s IPO, the Company issued 11,499,950 Public Warrants to third-party investors. Simultaneously with the closing of the IPO, Waldencast completed the private sale of 5,933,333 warrants (the &#8220;Sponsor Warrants&#8221;) to the Sponsor. Also, in connection with the IPO, on February 22, 2021, Waldencast, the Sponsor and Zeno Investment Master Fund (f/k/a Dynamo Master Fund, a member of the Sponsor (&#8220;Zeno&#8221;), entered into a Forward Purchase Agreement (the &#8220;Sponsor FPA&#8221;), which was subsequently amended by the assignment and assumption agreement entered into by and between the Sponsor and Burwell Mountain Trust (&#8220;Burwell&#8221;) on December 20, 2021. Under the assignment and assumption agreement, Sponsor assigned, and Burwell assumed, all of the Sponsor&#8217;s rights and benefits under the Sponsor FPA, pursuant to which, Burwell and Zeno committed to subscribe for and purchase 16,000,000 Waldencast Class A ordinary shares and 5,333,333 warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;Sponsor FPA Warrants&#8221;) in connection with the closing of the Business Combination. In addition, Waldencast and Beauty Ventures LLC (&#8220;Beauty Ventures&#8221;) entered into a Forward Purchase Agreement on March&#160;1, 2021 (the &#8220;Third-Party FPA&#8221;, and together with the Sponsor FPA, the &#8220;FPAs&#8221;), pursuant to which Beauty Ventures committed to subscribe for and purchase up to 17,300,000 Class A ordinary shares and 5,766,666 warrants (the &#8220;Third-Party FPA Warrants&#8221; and together with the Sponsor FPA Warrants, the &#8220;FPA Warrants&#8221;) for an aggregate commitment amount of $173.0 million, in connection with the closing of Waldencast&#8217;s initial business combination. Finally, in connection with the Business Combination, Waldencast issued 1,000,000 warrants to settle $1.5 million working capital loans with its Sponsor, the terms of which are identical to the Sponsor FPA Warrants (the &#8220;Sponsor Loan Warrants&#8221;). The Sponsor Loan Warrants and Third-Party FPA Warrants are collectively referred to as the &#8220;Private Placement Warrants&#8221;.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, all of the above-noted warrants, totaling 29,533,282, remained issued and outstanding. For the period from July 28 to December&#160;31, 2022 (Successor Period), the Company recognized a gain of $6.8 million from the change in fair value of the Public Warrants and Private Placement Warrants in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the Domestication, Public Warrants and Private Placement Warrants each entitle the holder to purchase one share of the Company&#8217;s Class A ordinary shares at an exercise price of $11.50 per share. Public Warrants may only be exercised for a whole number of shares. No fractional warrants will be issued and only whole warrants can trade. The Public Warrants became exercisable 30 days after the completion of the Business Combination. The Public Warrants will expire June 27, 2027 or earlier upon redemption or liquidation.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem the Public Warrants:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">in whole and not in part;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">upon a minimum of 30 days&#8217; prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption, based on the redemption date and the &#8220;fair market value&#8221; of the Class A ordinary shares;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">at a price of $0.01 per warrant if, and only if, the reported last sale price of the Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption the warrant holders (the &#8220;Reference Value&#8221;) equals or exceeds $18.00 per share (as adjusted).</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">At a price of $0.01 per warrant if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted); and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">if the Reference Value is less than $18.00 per share (as adjusted), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price and number of Class A ordinary shares issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants.</span></div>The terms of the Third-Party FPA Warrants are identical to the Public Warrants. The Sponsor Loan Warrants and Sponsor FPA Warrants are also identical to the Public Warrants, except that they and the Class A ordinary shares issuable upon the exercise of such warrants were not transferable, assignable or salable until 30 days after the completion of the Business Combination, subject to certain limited exceptions. Additionally, the Sponsor Loan Warrants and Sponsor FPA Warrants will be exercisable on a cashless basis and be non-redeemable, except as described above, so long as they are held by the initial purchasers or their permitted transferees, thereafter they will be redeemable by the Company and exercisable by such holders on the same basis as Public Warrants.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693659149296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">FAIR VALUE MEASUREMENTS</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s financial instruments that are measured at fair value on a recurring basis by level within the fair value hierarchy as of December&#160;31, 2022 (Successor Period): </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quoted Prices in Active Market</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Other Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Other Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate collar</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities - Public</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities - Private</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private derivative warrants are classified as Level 2 financial instruments. The fair value of the Level 2 Private Placement Warrant liabilities has been measured based on the fair value of Public Warrant liabilities. The interest rate collar has been measured at net present value by projecting future cash flows and discounting the future amounts to a present value using market-based observable inputs including interest rate curves and credit spreads.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For goodwill (see &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_133" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Goodwill&#8221;), fair value assessments of the reporting units and the reporting units&#8217; net assets performed for goodwill impairment tests are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain long-lived and intangible assets at fair value on a nonrecurring basis when events occur that indicate an asset group may not be recoverable. If the carrying amount of an asset group is not recoverable, an impairment charge is recorded to reduce the carrying amount by the excess over its fair value. Except for the initial valuation of long-lived assets in connection with the Business Combination (see &#8220;</span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_127" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business Combinations&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and impairment of goodwill discussed above, no long-lived assets were remeasured at fair value on a nonrecurring basis during the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575269904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL BALANCE SHEET DISCLOSURES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">SUPPLEMENTAL BALANCE SHEET DISCLOSURES</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">SUPPLEMENTAL BALANCE SHEET DISCLOSURES</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Net</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 (Successor Period), accounts receivable, net consisted of accounts receivable of $20.3 million, less allowance for doubtful accounts of $1.0 million. As of December&#160;31, 2021 (Predecessor Period), accounts receivable, net consisted of accounts receivable of $19.4 million, less allowance for doubtful accounts of $0.7 million. </span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the allowance for doubtful accounts were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:57.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.270%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">July 28 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1<br/>to July 27,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for bad debts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-off of uncollectible accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">994&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,061&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, and as amended in December 2021 and April 2022, Obagi Cosmeceuticals LLC, a wholly-owned subsidiary of Obagi, entered into a non-recourse, uncollateralized short-term promissory note, not in the ordinary course of business, lending a third party $2.5 million (the &#8220;Predecessor Loan Receivable&#8221;). This Predecessor Loan Receivable had a maturity date of December&#160;31, 2022 and carried an interest rate of 1.00% from July 30, 2021 to September 29, 2021 and 8.00% from September&#160;30, 2021 through maturity. The outstanding principal and accrued interest were due upon maturity. As discussed in &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_1097" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Restatement and Reclassifications,&#8221; the Company wrote-off the $2.5&#160;million loan receivable in 2021 when it was determined to be uncollectible. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Successor)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Predecessor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,384&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,611&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Successor)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Predecessor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer hardware, software and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internally developed software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gondolas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,928)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,328&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,198&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for property and equipment for the period from July 28 to December&#160;31, 2022 (Successor Period) and the period from January 1 to July 27, 2022 (Predecessor Period) were $2.9 million and $0.5 million, respectively. Depreciation expense for property and equipment for the years ended December&#160;31, 2021 and 2020 (Predecessor Period) were $0.4 million and $0.1 million, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense pertains to property and equipment utilized as part of the Company&#8217;s SG&amp;A activities and therefore has not been allocated to cost of goods sold.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Successor)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Predecessor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued salaries and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued sales returns and damages</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued marketing expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued distribution fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,123&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,683&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accrued distribution fees related to service charges such as e-commerce shipping and handling costs. The related party liability of $9.9 million as of December 31, 2022 reflects the remaining unamortized fair value of the related party inventory contract executed on the acquisition date between Obagi and the Obagi China Business (see &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span>. Business Combinations&#8221;). This related party liability will be amortized into related party revenue upon the sale of products to the Obagi China Business in subsequent periods.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575438096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK BASED COMPENSATION</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">STOCK-BASED COMPENSATION</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Successor Incentive Plan</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2022 Incentive Award Plan (the &#8220;Plan&#8221;) provides for incentives to be provided to selected officers, employees, non-employee directors and consultants of the Company in the form of options, stock appreciation rights, restricted stock, restricted stock units, stock bonuses or other stock-based awards granted under the Plan. The Plan was adopted by Waldencast&#8217;s Board of Directors in June 2022, was approved by its shareholders in July, 2022, and became effective on July 27, 2022 in connection with the closing of the Business Combination. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum number of ordinary shares available for issuance under the Plan as of December 31, 2022 was 16,134,716</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;Share Reserve&#8221;); </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Share Reserve automatically increases on January 1st of each calendar year (each, an &#8220;Evergreen Date&#8221;), prior to the tenth anniversary of the effective date of the Plan in an amount equal to the lesser of (i) 3% of the total number of ordinary shares issued and outstanding on the December&#160;31</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> immediately preceding the applicable Evergreen Date and (ii) a number of ordinary shares determined by the Board, including zero. All and up to the number of ordinary shares reserved for issuance under the Plan as of the effective date of the Plan (subject to an equitable adjustment in the event of a change in capitalization or change in control event) may be granted as an incentive stock options. As of December&#160;31, 2022 (Successor Period), the Company had 2,749,579</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares reserved for future issuances under the Plan.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combination</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Closing Date, in connection with the Business Combination, the Company assumed Obagi and Milk&#8217;s legacy incentive award plans and outstanding unvested awards granted under those plans. The Company assumed 5,906,300 stock options and 1,776,827 restricted stock units as replacement awards pursuant to the Obagi Merger Agreement, as </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">well as 237,724 stock options and 2,808,131 share appreciation rights as replacement awards pursuant to the Milk Merger Agreement. The total post-combination incremental stock-based compensation was $18.3 million, which is expected to be recognized over the remaining requisite service periods, where $47.7 million represents the fair value of the equity awards as part of the equity purchase consideration. The awards that were replaced had been contingent on a performance condition and as such, the Company is required to use an attribution model in which compensation cost for each vesting tranche is recognized as if each vesting tranche were a separate award.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Founder Awards</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022 the Company granted a total of 11,500,000 stock options to the two founders of Waldencast that vest based on service over the six-year period from August 2022 through August 2028. The options were granted with four vesting tranches, each tranche with a different exercise price, subject to their continued employment with the Company. Additionally, the Company granted 692,000 founders service-based restricted stock units that cliff vest in August 2025, subject to their continued employment with the Company. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incentive Awards</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company approved incentive awards to employees of Waldencast, Milk, and Obagi. The long-term incentive awards (the &#8220;LTI Awards&#8221;) are restricted stock units that vest based on both a service condition and meeting either a net sales or earnings before interest, taxes, depreciation and amortization (&#8220;EBITDA&#8221;) target in calendar year 2022. These LTI Awards were granted to employees in November 2022. The performance targets for the LTI Awards</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were met for Milk in 2022. The Company granted LTI Awards will vest one-third each year beginning on February 15, 2023, subject to continued service through such dates. As of December&#160;31, 2022 (Successor Period),</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">694,537 restricted stock units had been granted. In May 2023, the Board approved a modification to the LTI Awards by waiving the performance conditions for most Obagi and Waldencast employees, other than the former Chief Executive Officer of Obagi and the Chief Executive Officer and Chief Growth Officer of Waldencast. See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_187" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 21</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subsequent Events</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Waldencast One-Time Stock Grant</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company approved a one-time stock grant for certain Milk employees that were not eligible to participate in the LTI award program. A total of 10,000 awards were approved under this program. These awards are service-based restricted stock units that will cliff vest three years from the grant date, subject to continued employment with the Company. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the period from July 28 to December&#160;31, 2022 (Successor Period) was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of<br/>Common<br/>Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>intrinsic<br/>Value (in<br/>thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of July 28, 2022 (Successor)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,452,155</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2022 (Successor)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,452,155</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable as of December 31, 2022 (Successor)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,451,538</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest as of December 31, 2022 (Successor)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,452,155</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.50&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,118&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value per share of the awards granted for stock options during the period from July 28 to December&#160;31, 2022 (Successor Period) is $3.58.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock option awards was determined on the grant date using the Monte Carlo simulation model for Founder Awards and the Hull-White lattice pricing model was used for replacement awards based on the following weighted-average assumptions:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:57.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28<br/>to December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Founder Awards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Replacement Awards</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.87% - 2.92%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;2.79% - 2.80% </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7 - 9.9</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.77% - 44.76%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The risk-free rate is based on U.S. Treasury securities with maturities equivalent to the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The expected term for founder awards is based on the assumption that the options are exercised after 50% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The exercise multiple is selected from the commonly used exercise multiple range of 2.0x to 2.5x assuming on average the options holders would exercise the options when the ratio of underlying stock price to the exercise price reaches 2.3x.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">For founder awards, the expected stock price volatility is the median historical volatility of Waldencast&#8217;s volatility peer group with a look-back period equal to the contractual term using daily stock prices; for replacement awards, the expected stock price volatility is estimated by adjusting the observed equity volatility for leverage.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.43pt">Waldencast has not paid any dividends historically and does not plan to declare dividends in the foreseeable future and therefore assumed a dividend yield of zero.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity for the period from July 28 to December&#160;31, 2022 (Successor Period) was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant Date Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of July 28, 2022 (Successor)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,173,364</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(370,945)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2022 (Successor)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,802,419</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized compensation cost as of December 31, 2022 (Successor Period) for stock options and restricted stock was $32.5 million and $11.4 million, respectively. These costs are expected to be recognized over a weighted-average service period of 4.8 and 2.9 years for stock options and restricted stock, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Predecessor Incentive Plan</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Predecessor established a Stock Incentive Plan (the &#8220;Predecessor Incentive Plan&#8221;), under which stock options, stock awards, and restricted stock units (&#8220;Predecessor Restricted Stock&#8221;) of the Company could be granted to eligible employees, directors, and consultants. Under the Predecessor Incentive Plan, the Company was authorized to issue of a maximum number of 1,500,000 shares of Obagi common stock. Incentive stock options were required to have an exercise price at or above the fair market value of the stock on the date of the grant. The Company&#8217;s stock options and Predecessor Restricted Stock granted during the period from January 1 to July 27, 2022 (Predecessor Period) and the year ended December&#160;31, 2021 (Predecessor Period) had service-based and performance-based vesting conditions. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options vested over five years, with 25% of options vesting in four equal quarterly installments at the end of each three-month period through the first anniversary of the grant, and the remaining 75% vesting in a series of five equal annual installments over the five-year period measured from the grant date. The Predecessor Restricted Stock vested in five equal annual installments at the end of each year, over the five-year period from the grant date. Award holders had a ten-year period to exercise the options before they expire. Notwithstanding achievement of the service-based condition, the options and the Predecessor Restricted Stock did not vest or become exercisable until a qualifying transaction was consummated prior to the expiration date. A qualifying transaction consisted of either a change in control event or an underwritten initial public offering by the Company of its equity securities on a U.S. or foreign exchange, which occurred upon Waldencast&#8217;s acquisition of Obagi. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the period from January 1 to July 27, 2022 (Predecessor Period) was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of<br/>Common Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>intrinsic<br/>Value (in<br/>thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of January 1, 2022 (Predecessor) </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">800,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,200</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of July 27, 2022 (Predecessor)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">774,800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,659&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the year ended December&#160;31, 2021 (Predecessor Period) was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of<br/>Common Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>intrinsic<br/>Value (in<br/>thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of January 1, 2021 (Predecessor)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">800,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2021 (Predecessor)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">800,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,456&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value per share of the awards granted during from January 1 to July 27, 2022 (Predecessor Period) was $15.55 for stock options and $38.90 for Predecessor Restricted Stock. The weighted average fair value per share of the awards granted during the year ended December&#160;31, 2021 (Predecessor Period) was $15.55 for stock options and $38.68 for Predecessor Restricted Stock. The unrecognized compensation cost as of December&#160;31, 2021 (Predecessor Period) for stock options and Predecessor Restricted Stock was $9.4 million and $12.4 million, respectively. Prior to Waldencast&#8217;s acquisition of Obagi, the Company did not expect the occurrence of a qualifying transaction event to be &#8220;probable&#8221;, and therefore no expense had been recorded.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock option awards was determined on the grant date using the Black-Scholes valuation model based on the following weighted-average assumptions:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1<br/>to July 27, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended <br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock per share value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The risk-free rate is based on U.S. Treasury securities with maturities equivalent to the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The expected term is the estimated length of time the grants are expected to be outstanding before it is exercised or terminated. This number is calculated as the midpoint between the requisite service period and the contractual term of the award, as the Company does not have any historical data that would provide a reasonable basis to estimate the expected term for the option.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The expected price volatility is based on the average of the historical volatility of comparable public companies over a period consistent with the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The Predecessor historically made distributions to its shareholder but the Company does not plan to declare dividends in the foreseeable future and therefore assumed a dividend yield of zero.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Predecessor Restricted Stock activity for the period from January 1 to July&#160;27, 2022 (Predecessor Period) was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant Date Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of January 1, 2022 (Predecessor)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">243,307</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,754</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,219</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of July 27, 2022 (Predecessor)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">234,842</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.90&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Restricted Stock activity for the year ended December&#160;31, 2021 (Predecessor Period) was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant Date Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of January 1, 2021 (Predecessor)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">243,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2021 (Predecessor)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">243,307&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.68&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693696629792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">SHAREHOLDERS&#8217; EQUITY</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successor&#8217;s Share Capital</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company&#8217;s Memorandum of Association (the &#8220;Constitutional Document&#8221;), its authorized share capital consists of 1,000,000,000 Class A ordinary shares, 100,000,000 Class B ordinary shares and 25,000,000 Preference Shares, each having a par value of $0.0001. As of December&#160;31, 2022 (Successor Period), there were&#160;86,460,560 and 21,104,225 Class A and Class B ordinary shares, respectively, issued and outstanding. The Company did not have any Preference Shares issued and outstanding as of December&#160;31, 2022 (Successor Period).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Class A ordinary share is entitled to one vote per share. The Company can, at the discretion of its Board of Directors, declare dividends and distributions out of the funds of the Company lawfully available therefor. In the event of a voluntary or involuntary liquidation or wind-up, assets available for distribution among the holders of Class A ordinary shares will be distributed on a pro rata basis.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each Class B ordinary share is entitled to one vote per share and will vote together with holders of Class&#160;A ordinary shares as a single class. Class B ordinary shares are non-economic shares that are not entitled to dividends. Upon a liquidation, dissolution or winding up the Company, the holders of Class B ordinary shares will not be entitled to receive any assets of the Company, except to the extent of the par value of their shares, pro rata with the distributions that the Class A ordinary shares.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As outlined in &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Business Combinations,&#8221; Class B ordinary shares were issued by the Company to the Milk Members in connection with the Business Combination, giving rise to noncontrolling interest in the Company&#8217;s controlled subsidiary, Waldencast Partners LP. As such, the Constitutional Document prohibits issuances of additional shares of Class B ordinary shares, unless issued to a noncontrolling interest in connection with the Company&#8217;s Up-C structure. Class B ordinary shares are convertible into Class A ordinary shares on a one-to-one basis at the option of the holder. If such option is exercised, the exchanged Class B ordinary shares will automatically be surrendered and retired for no consideration. If the Company issues or redeems Class B ordinary shares, Waldencast Partners LP is obligated to issue or redeem a corresponding number of Waldencast LP partnership units, such that the number of issued and outstanding partnership units at any time will correspond and be equivalent to the then number of issued and outstanding Class B ordinary shares.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Predecessor&#8217;s Share Capital</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Predecessor&#8217;s equity structure consisted of a single class of ordinary shares. In November  2020, the Obagi Board of Directors approved (i) an increase in the number of the Company&#8217;s authorized common shares from 50,000 to 25,000,000, (ii) an issuance of 4,000,000 common shares to ZhongHua, and (iii) a two-for-one split of the Company&#8217;s issued and outstanding common shares  all of which became effective in December  2020. The Company was held by a single shareholder, and the share issuance to ZhongHua was deemed akin to a stock split. All share, per share amounts and related shareholders&#8217; equity balances presented for Predecessor Periods have been retroactively adjusted to reflect the impact of the Stock Split. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December&#160;31, 2021 the Predecessor had 25,000,000 ordinary shares authorized and 8,000,002 shares issued and outstanding. Predecessor&#8217;s ordinary shares had a par value of $0.50 per share and each share was entitled to one vote.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Predecessor was able to, at the discretion of its Board of Directors, declare dividends and distributions out of the funds of the Company lawfully available therefor. Payments of dividends and distributions were limited to realized or unrealized profits of the Company. The Company did not pay any dividends during the period from January 1 to July 27, 2022 (Predecessor Period). In the years ended December&#160;31, 2021 and 2020 (Predecessor Period), Obagi, through a wholly-owned subsidiary, paid $2.0 million (approximately $0.25 per share) and $2.0 million (approximately $0.26 per share), respectively, in dividends to its shareholder.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575464032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">NET LOSS PER SHARE </span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the weighted average ownership percentages during the period to calculate the net loss per share attributable to public shareholders and the noncontrolling interest holders. The following table sets forth the computation of basic and diluted net income (loss) using the treasury stock method: </span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.950%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from<br/>January 1 to <br/>July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except for share and per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(120,557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,576)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributed to Class A shareholders - basic and diluted EPS</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(95,567)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21,057)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,576)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,370)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86,460,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average diluted shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86,460,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.11)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.63)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.45)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.30)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents potential ordinary shares outstanding that were excluded from the computation of diluted net loss per share of common share because their effect would have been anti-dilutive:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:41.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from<br/>July 28 to December 31, <br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from<br/>January 1 to<br/>July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended <br/>December 31, <br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended <br/>December 31, <br/>2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,533,282</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,452,155</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">774,800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">800,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,802,419</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">234,842</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">243,307</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,787,856</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,009,642</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,043,307</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575269904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX BENEFIT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAX BENEFIT</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">INCOME TAX BENEFIT</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Predecessor was domiciled in the Cayman Islands. Following the Business Combination, the Company, domiciled in the Bailiwick of Jersey, is subject to taxation in the U.S. and various states jurisdictions. ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 740&#8221;) indicates that the federal statutory income tax rate of a foreign reporting entity be used when preparing the rate reconciliation disclosure. As such, the Company and its wholly-owned subsidiaries use the statutory income tax rate in the Bailiwick of Jersey for the Successor Period and the Cayman Islands for the Predecessor Period, which was 0%. The Company&#8217;s consolidated pretax income (loss) for the period from July 28 to December&#160;31, 2022 (Successor Period), the period from January 1 to July 27, 2022 (Predecessor Period), the year ended December&#160;31, </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 (Predecessor Period) and the year ended December&#160;31, 2020 (Predecessor Period) were generated by domestic and foreign operations as follows:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:41.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from<br/>July 28 to December 31, <br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1 to July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(125,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,676)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,079)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(126,360)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20,944)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,974)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,764)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the period from July 28 to December&#160;31, 2022 (Successor Period), the period from January 1 to July 27, 2022 (Predecessor Period), the year ended December&#160;31, 2021 (Predecessor Period) and the year ended December&#160;31, 2020 (Predecessor Period) consisted of the following:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:39.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1 to July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current provision (benefit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(363)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(350)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred (income) expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,557)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,823)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,374&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,044)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income tax (benefit) provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,803)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,602&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,394)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income tax expense related to the following:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:41.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1 to July 27,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit at Bailiwick of Jersey for Successor and Income tax benefit at Cayman Islands for Predecessor statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S./foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State income tax benefit, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Permanent Items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(141.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction bonuses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PPP Loan forgiveness  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">True-Ups</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax (benefit) expense </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(96.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of each reporting date, the Company considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As part of the Business Combination, the Company determined that there was sufficient positive evidence to conclude that it was more likely than not that additional deferred taxes of $28.1 million would be realizable through the reversal of existing deferred tax liabilities listed below. It therefore reduced the valuation allowance accordingly. As of December 31, 2022, a valuation allowance of $7.9 million has been provided for on the deferred tax assets related to the Company&#8217;s investment in Waldencast Partners LP. If or when recognized, the tax benefits related to any reversal of valuation allowance will be accounted for as a reduction of income tax expense.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards. The tax effects of temporary differences that give rise to portions of the deferred tax assets and deferred tax liabilities as of December&#160;31, 2022 (Successor Period) and December&#160;31, 2021 (Predecessor Period) are presented below:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest to foreign related parties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other temporary differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-deductible interest carryover</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below market contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in Waldencast LP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">34,580</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16,532</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,794)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed asset basis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,025)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(46,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(48,886)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3,020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net deferred tax (liabilities) assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14,306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13,512</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,944)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,060)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(22,250)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(548)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses and tax credit carryforwards as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Successor Period) and  December&#160;31, 2021 (Predecessor Period) were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:49.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.805%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.805%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.585%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expiration Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expiration Year</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, federal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, state</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2039-2042</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2039-2041</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax Credits, federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2038-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2038-2039</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax Credits, state</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#8220;IRC&#8221;) annual use of the Company&#8217;s net operating losses (&#8220;NOLs&#8221;) and R&amp;D credit carryforwards may be limited in the event a cumulative change in ownership of more than 50.0% occurs within a three-year period. The Company has not undergone an analysis to determine whether this limitation would apply to the utilization of the NOL carryforward. However, as the </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">federal NOLs do not expire, the Company does not believe that any potential limitations to federal or state NOL&#8217;s, or federal credit carryforwards, if applicable, would be material to the financial statements.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits, and uncertain income tax positions must meet a more likely than not recognition threshold to be recognized. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line in the consolidated statements of operations and comprehensive loss. There were no unrecognized tax benefits as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022 (Successor Period)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or December&#160;31, 2021 (Predecessor Period). The Company does not expect material changes to its unrecognized tax benefits for the twelve month period following the reporting date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (Successor Period) there were no active taxing authority examinations in any of the Company's major tax jurisdictions. The Company remains subject to examination for federal and state income tax purposes for the tax years ending 2018 through 2022 (Successor Period).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the tax years beginning on or after January 1, 2022, the Tax Cuts and Jobs Act of 2017 eliminates the option to currently deduct R&amp;D expenses and requires taxpayers to capitalize and amortize them over five years for research activities performed in the U.S. and 15 years for research activities performed outside the U.S. pursuant to IRC Section 174. Although Congress is considering legislation that would repeal or defer this capitalization and amortization requirement, it is not certain that this provision will be repealed or otherwise modified. If the requirement is not repealed or replaced, it will decrease our tax deduction for research and development expense in future years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693577234816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">RELATED PARTY TRANSACTIONS</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Waldencast</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Prior to the Business Combination</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sponsor Shares</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Sponsor purchased 7,187,500 Class B ordinary shares for an aggregate purchase price of $0.025 million, or approximately $0.003 per share (the &#8220;sponsor shares&#8221;). In February 2021, the Sponsor transferred 20,000 Class B ordinary shares to each of the Company&#8217;s then-serving independent directors, Ms. Sarah Brown, Ms. Juliette Hickman, Ms. Lindsay Pattison and Mr. Zack Werner (the &#8220;Investor Directors&#8221;), resulting in the Sponsor holding 7,107,500 Class B ordinary shares. In March 2021, Waldencast effected a share capitalization resulting in the Sponsor holding an aggregate of 8,545,000 Class B ordinary shares. As such, the Sponsor and the Investor Directors collectively owned 20% of Waldencast&#8217;s issued and outstanding shares upon consummation of its IPO. In connection with the Business Combination, 8,625,000 sponsor shares held by the Sponsor and Investor Directors converted automatically, on a one-for-one basis, into one Class A ordinary share in accordance with their terms.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Agreements</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with Waldencast&#8217;s IPO, in February  2021, the Sponsor and Zeno (a member of the Sponsor) entered into the Sponsor FPA, which was subsequently amended by the assignment and assumption agreement entered into by and between the Sponsor and Burwell in December 2021. Under the assignment and assumption agreement, Sponsor assigned, and Burwell assumed, all of the Sponsor&#8217;s rights and benefits under the Sponsor FPA, pursuant to which, Burwell and Zeno committed to subscribe for and purchase 16,000,000 Class A ordinary shares and 5,333,333 warrants for an aggregate commitment amount of $160.0 million in connection with the closing of Waldencast&#8217;s initial business combination. In addition, Beauty Ventures entered into the Third-Party FPA with Waldencast in March 2021, pursuant to which Beauty Ventures committed to subscribe for and purchase up to 17,300,000 Class A ordinary shares and up to 5,766,666 warrants for an aggregate commitment amount of $173.0 million, in connection with the closing of the Company&#8217;s initial business combination. Members of the Sponsor or their affiliates will begin to receive a twenty percent (20%) performance fee allocation on the return of the forward purchase securities in excess of the hurdle rate, calculated on the total return generated from forward purchase securities (whether by dividend, transfer or increase in value as measured from date of issuance), when the return of such securities (less the expenses of Beauty Ventures) underlying the Third-Party FPA exceeds a hurdle rate of five percent (5%) accrued annually until the fifth anniversary of the issuance of such securities. In the event of a transfer and subsequent sale of any forward purchase securities prior to such fifth anniversary, the performance fee for the period between such transfer and such fifth </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anniversary will be calculated based on the proceeds generated by such sale. The FPA investments were consummated substantially concurrently with the consummation of the Business Combination.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Placement Warrants</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneously with the consummation of the IPO, the Sponsor purchased 5,933,333 Private Placement Warrants at a purchase price of $1.50 per private placement warrant, or $8.9 million in the aggregate. Each Private Placement Warrant entitles the holder to purchase one Class A ordinary share for $11.50 per share. The Private Placement Warrants may not be redeemed by the Company so long as they are held by the Sponsor or its permitted transferees. If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the  Private Placement Warrants will be redeemable by the Company and exercisable by the holders on the same basis as the Public Warrants. The Sponsor, or its permitted transferees, has the option to exercise the Private Placement Warrants on a cashless basis. The Private Placement Warrants are identical to the Public Warrants, except that the Private Placement Warrants: (i) are not redeemable by the Company, (ii) may be exercised for cash or on a cashless basis so long as they are held by the Sponsor or any of its permitted transferees and (iii) are entitled to registration rights (including the Class A ordinary shares issuable upon exercise of the private placement warrants). Additionally, the purchasers agreed not to transfer, assign or sell any of the Private Placement Warrants, including the Class A ordinary shares issuable upon exercise of the Private Placement Warrants (except to certain permitted transferees), until 30 days after the completion of the Business Combination. In connection with the Business Combination, each of the 5,933,333 Private Placement Warrants converted automatically into a warrant to acquire one Class A ordinary share.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Registration Rights</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the sponsor shares, Private Placement Warrants, and warrants that were issued upon conversion of the Working Capital Loan (as defined below) (and any Class A ordinary shares issuable upon (i) the exercise of the Private Placement Warrants, including the Working Capital Warrants (as defined below) and (ii) the conversion of the sponsor shares) are entitled to registration rights pursuant to a registration rights agreement dated March 15, 2021 (the &#8220;Legacy Registration Rights Agreement&#8221;) requiring the Company to register such securities for resale (in the case of the sponsor shares, only after conversion to Class A ordinary shares). The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of the Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company is responsible for the expenses incurred in connection with the filing of any such registration statements.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sponsor, the members of the Sponsor and certain of the Company&#8217;s shareholders, Obagi and Milk and certain of their respective affiliates entered into an amended and restated registration rights agreement, dated July 27, 2022, with the Company (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company agreed to register for resale, pursuant to Rule 415 under the Securities Act, certain Class A ordinary shares and our other securities that are held by the parties thereto from time to time, subject to the restrictions on transfer therein. The Registration Rights Agreement amended and restated the Legacy Registration Rights Agreement and terminates with respect to any party thereto, on the date that such party no longer holds any Registrable Securities (as defined therein).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Company filed a registration statement on Form F-1 to register up to 121,120,063 Class A ordinary shares, consisting of (i) 8,545,000 Class A ordinary shares converted from the sponsor shares; (ii) 80,000 Class A ordinary shares converted from the sponsor shares held by the Investor Directors; (iii) 20,000 Class A ordinary shares issued to Aaron Chatterley in a private placement exempt from registration pursuant to Section 4(a)(2) of the Securities Act, and Rule 506 of Regulation D promulgated thereunder, in connection with the consummation of the Business Combination; (iv) 28,237,506 Class A ordinary shares issued pursuant to the Obagi Merger Agreement; (v) 21,104,225 Class A ordinary shares issuable in exchange for 21,104,225 Class B ordinary shares pursuant to the Milk Equity Purchase Agreement; (vi) 11,800,000 Class A ordinary shares issued in the PIPE investments; (vii) 33,300,000 Class A ordinary shares issued pursuant to the FPAs; and (viii) 18,033,332 Class A ordinary shares issuable in respect of the private placement warrants, pursuant to the Registration Rights Agreement.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related Party Notes and Advances</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, Waldencast issued a promissory note to the Sponsor (the &#8220;January Note&#8221;), pursuant to which Waldencast could borrow an aggregate principal amount of $0.3 million. The note was non-interest bearing and payable on the completion of the IPO. There were no borrowings outstanding under the note at the closing of the IPO.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Waldencast issued a promissory note to the Sponsor, pursuant to which it could borrow up to an aggregate principal amount of $1,500,000 from the Sponsor (the &#8220;Working Capital Loan&#8221;). The note was non-interest bearing, unsecured and due and payable in full on the earlier of (x) March 18, 2023 and (y) the date Waldencast consummated its initial business combination. In October 2021, Waldencast drew down the entire available balance of the promissory note and the Sponsor deposited $1,500,000 in Waldencast&#8217;s operating bank account. As of the Closing Date, there was a total aggregate principal amount of $1,500,000 in outstanding borrowings under the Convertible Working Capital Note. In connection with the closing of Business Combination, the Sponsor elected to convert $1,500,000 of the Working Capital Loan balance into warrants at a price of $1.50 per warrant for a total of 1,000,000 warrants (the &#8220;Working Capital Warrants&#8221;). The Working Capital Warrants issuance was exempt from registration pursuant to Section 4(a)(2) of the Securities Act, and Rule 506 of Regulation D promulgated thereunder. Borrowings under the Convertible Working Capital Note are no longer available.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Waldencast issued working capital promissory notes to the Sponsor on (i) in May 2022, for up to $600,000 (&#8220;May Working Capital Note&#8221;) and (ii) July 2022, for up to $450,000 (&#8220;July Working Capital Note&#8221; and, together with May Working Capital Note, the &#8220;Non-Convertible Working Capital Notes&#8221;), in each case, for working capital purposes. As of the Closing Date, there was a total aggregate principal amount of $1,050,000 in outstanding borrowings under the Non-Convertible Working Capital Notes. In connection with the closing of Business Combination, the aggregate outstanding balance under the Non-Convertible Working Capital Notes of $1,050,000 was repaid to the Sponsor. Borrowings under the Non-Convertible Working Capital Notes are no longer available.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Administrative Services Agreement</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast entered into an agreement whereby, commencing on March 15, 2021, through the earlier of the consummation of a business combination or a liquidation, Waldencast agreed to pay the Sponsor a monthly fee of $10,000 for office space, administrative, financial and support services. Waldencast incurred approximately $65,000 in administrative expenses under the agreement through the Closing Date, but ceased to incur these fees following the completion of the Business Combination. As of December 31, 2022 (Successor Period), the Company had $0.4 million in related party accounts payable in consolidated balance sheets. The Company ceased to incur these fees following the completion of the Business Combination.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lock-Up Agreements</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to a Letter Agreement, dated March 15, 2021, between the initial shareholders of Waldencast Acquisition Corp. and Waldencast (the &#8220;Letter Agreement&#8221;), such shareholders agreed not to transfer, assign or sell any of their sponsor shares until the earlier to occur of: (A) one year after the Closing Date; and (B) following the Closing Date, (x) if the last reported sale price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share sub-divisions, share dividends, rights issuances, consolidations, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within any 30-trading day period commencing at least 150 days after the Company&#8217;s initial business combination or (y) the date on which it completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of its public shareholders having the right to exchange their ordinary shares for cash, securities or other property (except with respect to permitted transferees) (the &#8220;Letter Agreement Lock-Up Provisions&#8221;). Any permitted transferees would be subject to the same restrictions and other agreements of the initial shareholders of Waldencast Acquisition Corp. with respect to any sponsor shares. Such Letter Agreement Lock-Up Provisions expired on July 27, 2023.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to the Sponsor FPA, Burwell and Zeno agreed not to transfer, assign or sell any of their Class A ordinary shares according to the same Letter Agreement Lock-Up Provisions. Any permitted transferees would be subject to the same restrictions and other agreements as a purchaser under the Sponsor FPA. The Sponsor FPA lock-up period expired on July 27, 2023.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Waiver and Agreement</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the consummation of the Business Combination, the Company waived certain provisions as contemplated by the Letter Agreement and certain other agreements related thereto (collectively, the &#8220;Waiver&#8221;), with respect to any securities held by an Insider (as defined in the Letter Agreement) as of the closing the Business Combination (the &#8220;Lock-Up Securities&#8221;) that would disallow a pledge by such Insider of the Lock-Up Securities in a transaction for the purpose of financing such Insider&#8217;s payment obligations owed in connection with the closing of the Business Combination. In connection with such Waiver, the Company entered into that certain Waiver and Agreement, dated as of July 25, 2022, with Burwell (the &#8220;Waiver and Agreement&#8221;), to permit a pledge by Burwell of its Lock-Up Securities to be used as a portion of the collateral under a loan to finance Burwell&#8217;s payment obligations under the Sponsor FPA in connection with the closing of the Business Combination. Pursuant to the terms of the Waiver and Agreement, in the event of a foreclosure, any such lenders or a collateral agents will be required to execute a joinder to the Letter Agreement pursuant to which they will be bound by the transfer restrictions of the Lock-Up Securities (including the foreclosure of or other exercise of remedies under any such loan documentation) in the Letter Agreement for the duration of such agreement. We also agreed to provide any such lender or collateral agent with customary registration rights in the event of default, foreclosure or other exercise of remedies following the respective Lock-Up Periods (as defined in the Letter Agreement).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnification Agreements</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Business Combination, the Company entered into indemnification agreements with each of its directors. The indemnification agreements provide, to the fullest extent permitted under law, indemnification against all expenses, judgments, fines and amounts paid in settlement relating to, arising out of or resulting from an indemnitee&#8217;s status as a director, officer, employee, fiduciary or agent of the Company or any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other entity which such person is or was serving at the Company&#8217;s request as a director, officer, employee or agent. In addition, the indemnification agreements provide that the Company will advance, to the extent not prohibited by law, the expenses incurred by the indemnitee in connection with any proceeding, and such advancement will be made within thirty (30) days after the receipt by the Company of a statement requesting such advances from time to time, whether prior to or after final disposition of any proceeding. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transactions with Cedarwalk in connection with the Business Combination</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Obagi China Distribution, the Company entered into an Intellectual Property License Agreement (the &#8220;IP License Agreement&#8221;), a Global Supply Services Agreement (the &#8220;Supply Agreement&#8221;), and a Transition Services Agreement (the &#8220;Transition Services Agreement&#8221;) with Obagi Hong Kong, which is owned by Cedarwalk, the former owner of Obagi and a beneficial holder of 24.5% of the Company&#8217;s fully diluted Class A ordinary shares as of the closing of the Business Combination.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the IP License Agreement, the Company exclusively licenses intellectual property relating to the Obagi brand to the Obagi China Business, and the Company retains the rights to such intellectual property to conduct the Obagi-branded business worldwide except for the China Region. The Obagi China Business pays the Company a royalty of 5.5% of gross sales of licensed products. During the period from July 28 to December&#160;31, 2022 (Successor Period) net revenue generated from related party royalties was $0.2 million. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Supply Agreement, the Company supplies or causes to be supplied through certain Obagi CMOs products for distribution and sale in the China Region by the Obagi China Business. The term of the Supply Agreement is perpetual, subject to termination for material breach and failure to cure or termination in the event that the IP License Agreement is terminated. The Company anticipates it will continue supplying the Obagi China Business with products at an agreed-upon markup, net of agreed-upon discounts as applicable until the Obagi China Business has been added as a party to Obagi&#8217;s CMO agreements, at which time it will then order directly from the CMOs. During the period from July 28 to December&#160;31, 2022 (Successor Period) net revenue generated from supplying products to the Obagi China Business was $17.0 million</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the related cost of goods sold was $5.1 million.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 (Successor Period), the Company had $0.3</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million in related party accounts receivable from the Obagi China Business in the consolidated balance sheet. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Transition Services Agreement, the Company provided Obagi Hong Kong and its affiliates certain transition services to enable them to conduct the Obagi China Business as a going concern in the China Region. The transition services were provided for an initial term of up to <span style="-sec-ix-hidden:f-2134">twelve</span> (12) months, with an option for Obagi China Business to extend the service period for up to an additional <span style="-sec-ix-hidden:f-2135">twelve</span> (12) months solely as to certain R&amp;D services. Obagi Hong Kong did not elect to extend the services and as a result the Transition Services Agreement expired on July 27, 2023. Services under the agreement were to be charged at the reasonable, fully-loaded costs of providing the services, but such services were to be provided at no charge for a certain period of time or up to a specified dollar value of services (the &#8220;Threshold Amount&#8221;). The Company determined that the Threshold Amount may be applied towards a combination of the Company&#8217;s services or inventory purchases made by the Obagi China Business under the Supply Agreement. Due to the fact that the Threshold Amount had not been reached at the time of expiration, the Company received no fees from the Obagi China Business during the period ended December 31, 2022 (Successor Period).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Predecessor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operational Support Services Agreement</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, Obagi Cosmeceuticals LLC (&#8220;Obagi Cosmeceuticals&#8221;) entered into an operational support services agreement with Obagi Holdings Company Limited (&#8220;Obagi Holdco&#8221;), Obagi Hong Kong and Obagi Shanghai Cosmeceuticals Co. Ltd., a subsidiary of Obagi Hong Kong (&#8220;Obagi Shanghai&#8221;), pursuant to which Obagi Cosmeceuticals provided certain services, including administrative and product related services, to the other signatories party thereto. The agreement terminated with respect to Obagi Hong Kong and Obagi Shanghai in connection with the Obagi China Distribution (as defined below). Under the agreement, which automatically renewed for a one-year term on January 1, 2021, Obagi Cosmeceuticals received service fees in an amount equal to the sum of its costs incurred in the performance of such services plus five percent (5%). Total service fees paid to Obagi Cosmeceuticals were $1.1, $3.5, $4.6 and $0.9 million for the 2022 Successor Period, 2022 Predecessor Period, for the year ended December 31, 2021 (Predecessor Period), and for the year ended December 31, 2020 (Predecessor Period), respectively. There were no service fees paid to Obagi Shanghai in the 2022 Successor Period, as the agreement was terminated upon closing of the Business Combination.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Exclusive Marketing Services Agreement</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Obagi Holdco and Obagi Shanghai entered into a non-exclusive marketing services agreement, pursuant to which Obagi Shanghai provided certain sales and marketing services to Obagi Holdco in the People&#8217;s Republic of China. Under the agreement, which terminated upon closing of the Business Combination, Obagi Shanghai received service fees in an amount equal to the sum of its costs incurred in the performance of such services plus five percent (5%). Total service fees paid to Obagi Shanghai were $2.1, $2.6 and $0.6 million for the 2022 Predecessor Period, for the year ended December 31, 2021 (Predecessor Period), and for the year ended December 31, 2020 (Predecessor Period), respectively. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registration with National Medical Products Administration in China</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Cedarwalk paid approximately $4.1 million to register Obagi&#8217;s products with the National Medical Products Administration in China in exchange for 8,000,000 shares of Obagi common stock. This non-cash capital contribution was recorded as additional paid-in capital in Obagi&#8217;s consolidated statements of shareholders&#8217; equity for the year ended December 31, 2020.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Obagi China Distribution</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition to the Obagi Merger Agreement, prior to the Closing Date, Obagi Holdco distributed to Obagi and then Obagi distributed to Cedarwalk all of the issued and outstanding shares of capital stock of Obagi Hong Kong and certain related assets pursuant to distribution agreements in the Obagi China Distribution, as discussed in &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Business Combinations.&#8221; The Obagi China Business had been conducted through Obagi Hong Kong and its subsidiaries. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milk</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milk subleases from Milk Studios Los Angeles LLC certain space in Los Angeles, CA on a month-to-month basis. Milk primarily uses these facilities for corporate offices and as an in-house studio. During the period from July 28 to </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022 (Successor Period), the Company incurred administrative fees of $0.1 million, which is recorded in SG&amp;A expenses in consolidated statements of operations and comprehensive loss.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575337568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">COMMITMENTS AND CONTINGENCIES</span><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Commitments</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase commitments represent unconditional purchase obligations to purchase goods or services, primarily inventory, that are enforceable and legally binding on the Company and specify all significant terms, including fixed or minimum quantities to be purchased, price provisions, and the approximate timing of the transaction. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into a certain development and production agreement with a third-party vendor in which the Company is committed to purchase from the vendor certain units of Skintrinsiq devices totaling $5.7&#160;million. As of December 31, 2022, the Company&#8217;s associated future minimum payment was $1.4 million over the next 12-18 months. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into an unconditional purchase order with third-party product manufacturers for the delivery of inventory in which the Company is committed to purchase from the manufacturers certain product inventory totaling $8.2 million. As of December 31, 2022, the Company&#8217;s associated future minimum payment was $7.0 million over the next 12-18 months. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Except for the SEC investigation described in &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_187" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Note 21</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Subsequent Events</span>.&#8221; the Company is not involved in any material litigation nor, to management&#8217;s knowledge, was any material litigation threatened against the Company, which if adversely determined could have a material adverse impact on the Company other than routine litigation arising in the ordinary course of business,<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575355936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">SEGMENT REPORTING</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports segment information based on the management approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of our reportable segments. Prior to the consummation of the Business Combination, the Predecessor operated its business and reported its results through a single operating and reportable segment. Following the Business Combination, the Company determined that it has two operating and reportable segments: Obagi Skincare and Milk Makeup. See. &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obagi Skincare </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- this segment consists of the business of Obagi. Obagi&#8217;s business activities include developing, marketing, and selling skin health products. These assets and activities are conducted by Obagi Global Holdings Limited and its wholly-owned subsidiaries.  </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milk Makeup</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - this segment consists of the business of Milk. Milk&#8217;s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Milk generates revenue from the sale of cosmetics to retailers, including off-price retailers, and sales DTC via its website. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Central costs include operating expenses related to corporate overhead expenses such as personnel-related costs, professional fees, interest expense related to the 2022 Credit Agreement, and the change in the fair value of derivatives. These costs are not used in evaluating the results of, or in allocating resources to, the Company&#8217;s segments.  </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the segments are the same as those described in &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_124" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of financial measures of the Company&#8217;s segments to the consolidated totals:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022<br/>(Successor):</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Skincare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk Makeup</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the performance of its reportable segments based on segment gross profit. Segment gross profit is segment revenue less segment cost of goods sold.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles segment gross profit to net income (loss) before income taxes for the period from July 28 to December&#160;31, 2022 (Successor Period):</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"><tr><td style="width:1.0%"></td><td style="width:85.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from<br/>July 28 to December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,793)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(798)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(126,360)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(120,557)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not evaluate performance or allocate resources based on segment asset data, and therefore such information is not presented. All of the Company&#8217;s and the Predecessor&#8217;s long-lived assets are located in the U.S.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693574347440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE BENEFIT PLAN</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">EMPLOYEE BENEFIT PLAN</span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a Section&#160;401(k)&#160;retirement plan and pension plans for employees in the U.S. and the United Kingdom. During the period from July 28 to December&#160;31, 2022 (Successor Period), the period from January 1 to July&#160;27, 2022 (Predecessor Period), and the years ended December&#160;31, 2021 and 2020 (Predecessor Periods) the Company&#8217;s contributions to the plan were $0.3 million, $0.4 million, $0.6 million, and $0.5 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575385744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">SUBSEQUENT EVENTS </span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023,</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company granted an aggregate of 2,290,000 stock growth incentive awards</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;SGI Awards&#8221;) in performance share units to certain Waldencast employees, in an amount up to 200% of the target share units allocated to the program, which are based on meeting the respective Company&#8217;s net revenue and EBITDA targets for the year ended December 31, 2025. The SGI Awards had a grant date fair value of $8.88 and require a one-year post vesting holding period once the shares have been awarded.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Incentive (&#8220;LTI&#8221;) Awards</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the LTI Awards were modified to waive the performance conditions for most Obagi and Waldencast employees, other than the Chief Executive Officer of Obagi and the Chief Executive Officer and Chief Growth Officer of Waldencast. Based on the financial statements prepared by the Company for the period ended December 31, 2022, the Board has certified that the applicable performance goals have not been met and, accordingly, that the 2022 RSUs granted to our founders will not vest.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Leases</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Obagi entered into two leases for office and warehouse space in Texas as part of their plans to  relocate the headquarters from California. Obagi&#8217;s corporate headquarters were located in Long Beach, California until September 2022, when Obagi moved its headquarters to Houston, Texas under a lease that will expire in July 2032. In January 2024, Obagi will relocate its headquarters back to its Long Beach offices, where it occupies facilities totaling approximately 28,300 rentable square feet under a lease that expires in June 2026.  Obagi entered into a sublease for the office space in Texas once Obagi relocates to California that will run through December 2025. The Obagi warehouse facilities located in Conroe, Texas are subject to a lease that will expire in February 2031 and Obagi plans to sublease those facilities subject to finding a tenant. ROU assets as of December 31, 2022 associated with the office and warehouse were $4.0 million and $2.5 million, respectively. The Company is in the process of assessing whether or not impairment exists.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction with the SA Distributor</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, as part of the Company&#8217;s strategy to internalize distribution channels in key markets, certain of Obagi&#8217;s subsidiaries entered into and consummated a Purchase Agreement (the &#8220;Vietnam Purchase Agreement&#8221;) with Obagi Vietnam and the SA Distributor, pursuant to which, among other terms, Obagi acquired certain assets of Obagi Vietnam from the SA Distributor and in return, the SA Distributor received forty percent (40%) of the outstanding equity of Obagi Blue Sea Holding, LLC, a subsidiary of Obagi and the parent company of Obagi Vietnam. The Vietnam Purchase Agreement also provided the SA Distributor with a potential earnout payment based upon the net revenue of the business of Obagi Vietnam during the twelve-month period ending on December 31, 2026, subject to setoff for any owed obligations. The Company currently does not anticipate that any such earnout payment will be payable. The SA Distributor does not currently have any active participation in the Obagi Vietnam business other than as a silent shareholder. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Credit Agreement</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_139" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; Borrower and Waldencast Partners LP and JPMorgan, entered into a waiver and consent to the 2022 Credit Agreement in May 2023, August 2023 and December 2023. The 2022 Credit Agreement was amended in September 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subscription Agreement with PIPE Investors</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Company entered into subscription agreements (the &#8220;Subscription Agreements&#8221;) with certain investors (collectively, the &#8220;2023 PIPE Investors&#8221;), pursuant to, and on the terms and subject to the conditions of which, the 2023 PIPE Investors collectively subscribed for 14,000,000 Class A ordinary shares (the &#8220;PIPE Shares&#8221;), in a private placement at a purchase price of $5.00 each per share, for aggregate gross proceeds of $70.0&#160;million (the &#8220;2023 PIPE Investment&#8221;). The Subscription Agreements relating to approximately $68.0&#160;million of proceeds were consummated in September 2023, and the closings of Subscription Agreements relating to the remaining approximately $2.0&#160;million occurred in November 2023, following receipt of regulatory approvals (the &#8220;2023 PIPE Closings&#8221; and the date on which such Closing occurred, the &#8220;PIPE Closing Date&#8221;).&#8221; No Class B ordinary shares, warrants or other securities of the Company were issued in connection with the 2023 PIPE Investment. As a result, the Company had a total of 122,076,410 ordinary shares issued and outstanding, including 101,228,857 Class A ordinary shares issued and outstanding and 20,847,553 class B ordinary shares issued and outstanding, as of December 31, 2023. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SEC Investigation</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, the audit committee of the Board, engaged in a review of certain accounting practices applied to the Company&#8217;s financial statements for the Predecessor Period and Successor Period through December 31, 2022. The Company proactively and voluntarily self-reported the review to the SEC. In connection with this matter, the Company  received a document subpoena from the SEC in September 2023. Although the Company is fully cooperating with the SEC&#8217;s investigation and continues to voluntarily respond to requests related to this matter, it cannot predict when the SEC will complete its investigation or its outcome and potential impact such outcome may have on the Company&#8217;s business. Any remedial measures, sanctions, fines or penalties, including, but not limited to, financial penalties and awards, injunctive relief and compliance conditions, imposed on the Company could have a material adverse effect on its business, financial condition and results of operations.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Nasdaq Capital Market Listing</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s securities are listed on The Nasdaq Capital Market. In May 2023, the Company received written notice from Nasdaq indicating that, as a result of not having timely filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, it was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the SEC. In July 2023, the Company obtained an extension from Nasdaq permitting it to regain compliance provided it filed this Report no later than October 30, 2023. On October 31, 2023, the Company received a written notice from the Listing Qualifications Staff of Nasdaq (the &#8220;Listing Qualifications Staff&#8221;) indicating that, based upon its non-compliance with the filing requirement as of October 30, 2023, the Listing Qualifications Staff had determined to delist the Company&#8217;s securities from Nasdaq by opening of business on November 9, 2023 unless the Company timely requested a hearing before the Nasdaq Hearings Panel. On November 7, 2023, by requesting a hearing (the &#8220;Hearing&#8221;) before the Nasdaq Hearings Panel (the &#8220;Panel&#8221;), the Company appealed the determination of the Listing Qualifications Staff to the Panel and requested that the stay of delisting, which otherwise would have expired on November 22, 2023, be extended until the Panel issued a final decision on the matter. On November 22, 2023, Nasdaq granted the Company&#8217;s request to extend the stay. Accordingly, the Company&#8217;s securities will continue to trade on The Nasdaq Capital Market until the Panel issues a final decision regarding its listing status following the Hearing scheduled for February 8, 2024, or, if earlier, upon receipt of confirmation from Nasdaq that the Company has regained compliance with Nasdaq&#8217;s continued listing standards. On January 3, 2024, we received an additional notice of non-compliance from the Listing Qualifications Staff due to the Company not having filed interim financial statements for the period ended June 30, 2023 with the SEC by December 31, 2023, as required by Nasdaq Listing Rule 5250(c)(2). The notice indicated that the Panel will consider this additional notice as part of its determination regarding the Company&#8217;s continued listing on The Nasdaq Capital Market. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Online Marketplace Distributor Contract Termination</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Company entered into a termination agreement with the U.S. Online Marketplace Distributor. The termination agreement provides the U.S. Online Marketplace Distributor with a termination fee in exchange for the return of all existing inventory purchased from Obagi, deactivation of all online marketplace listings by the U.S. Online Marketplace Distributor, and full satisfaction of the remaining outstanding accounts receivable balance within defined payment terms. The termination agreement includes contractual protections designed to ensure that the Company is only providing a return credit for valuable inventory which excludes short-dated or damaged products. The termination of the U.S. Online Marketplace Distributor shall enable the Company to fully control the online marketplace distribution of Obagi products, including both product quality and customer service.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575233760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock', window );">SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY)</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) </span><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parent company financial statements for Waldencast Plc should be read in conjunction with the Company&#8217;s Consolidated Financial Statements and the accompanying notes thereto. For purposes of this condensed financial information, the Company&#8217;s wholly owned and majority owned subsidiaries are recorded based upon its proportionate share of its subsidiaries&#8217; net assets (similar to presenting them on the equity method). Waldencast plc has no material operations of its own and conducts substantially all of its activities through its wholly owned subsidiaries. Waldencast plc has no significant assets or liabilities other than derivative warrant liabilities and cash, most expenditures paid by Waldencast plc are allocated to its subsidiaries. Waldencast Finco Limited, a wholly-owned indirect subsidiary of Waldencast plc, is the borrower under the 2022 Credit Agreement. The terms and conditions of the 2022 Credit </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement (see </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_139" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for definition) limit the ability of Waldencast plc&#8217;s wholly owned subsidiaries to make certain distributions or dividends, subject to a number of enumerated exceptions. Due to the aforementioned restrictions, substantially all of the Successor period net assets of Waldencast Plc&#8217;s subsidiaries are restricted. Since the restricted net assets of consolidated subsidiaries exceed 25% of the consolidated net assets of the Company and its subsidiaries, the accompanying condensed parent company financial statements have been prepared in accordance with Rule 12-04, Schedule 1 of Regulation S-X. This information should be read in conjunction with the accompanying Consolidated Financial Statements.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following condensed financial statements have been presented on a &#8220;parent-only&#8221; basis. Under a parent-only presentation, Waldencast plc&#8217;s investment in its subsidiaries is presented under the equity method of accounting. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC<br/>(PARENT COMPANY ONLY)<br/>CONDENSED BALANCE SHEET</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,215&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in subsidiary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">823,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL ASSETS</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">827,151&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CURRENT LIABILITIES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intercompany payables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL LIABILITIES</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,253&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHAREHOLDERS&#8217; EQUITY:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successor Class A ordinary shares, $0.0001 par value, 1,000,000,000 shares authorized; and 86,460,560 outstanding as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successor Class B ordinary shares, $0.0001 par value, 1,000,000,000 shares authorized; and 21,104,225 outstanding as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">796,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(156,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL CONTROLLING SHAREHOLDERS&#8217; EQUITY</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">639,239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL SHAREHOLDERS&#8217; EQUITY</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">799,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">827,151&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC<br/>(PARENT COMPANY ONLY)<br/>CONDENSED STATEMENT OF OPERATIONS </span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the period from July 28 to December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before equity in undistributed earnings of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity in undistributed earnings of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(102,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(95,567)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(95,596)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC<br/>(PARENT COMPANY ONLY)<br/>CONDENSED STATEMENT OF CASH FLOW </span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(95,567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity in income of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,793)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from trust</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfers from subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfers to subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses paid on behalf of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,982)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3,282)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,137</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH - Beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH - end of period</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.5-04(Schedule I))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480922/205-10-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693568055552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Waldencast has prepared the accompanying consolidated financial statements pursuant to generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for the Business Combination, Waldencast was deemed to be the legal and the accounting acquirer (referred to as the &#8220;Successor&#8221;), however, Obagi was deemed to be the predecessor entity for financial reporting purposes (referred to as the &#8220;Predecessor&#8221;). Under the acquisition method of accounting, Waldencast&#8217;s assets and liabilities retained their carrying values and the assets and liabilities associated with Obagi and Milk were recorded at their fair values measured as of the acquisition date, which created a new basis of accounting.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This change in accounting basis is represented in the accompanying consolidated financial statements by a black line, which appears between the columns entitled Successor and Predecessor in the financial statements and in the relevant accompanying notes. The black line signifies that the consolidated financial statements presented for the Company after the Closing Date (the &#8220;Successor Period&#8221;) are presented on a measurement basis different from those for the period prior to the Closing Date (the &#8220;Predecessor Periods&#8221;). As a result of the application of the acquisition method of accounting as of the Closing Date, the financial statements for the Predecessor Periods (which only includes Obagi, including the Obagi China Business, through July 27, 2022) and for the Successor Period (which includes Waldencast and its subsidiaries from July 28, 2022 to December 31, 2022) are presented on a different basis of accounting and are, therefore, not comparable.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context requires otherwise, the &#8220;Company&#8221; refers to Obagi for periods prior to the Business Combination and to Waldencast together with its consolidated subsidiaries, as the Successor for periods after the Business Combination.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The accompanying consolidated financial statements include the accounts of Waldencast and its consolidated subsidiaries. The Company consolidates entities in which the Company has a majority voting interest. The Company eliminates intercompany transactions and accounts in consolidation. The Company separately presents within equity on the consolidated balance sheets the ownership interests attributable to parties with noncontrolling interests in the Company's consolidated subsidiaries, and separately presents net income attributable to such parties on the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Significant estimates and assumptions reflected in the financial statements include, but are not limited to, revenue recognition, fair value of assets acquired and liabilities assumed in business combinations, stock-based compensation, and valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and assumptions that it believes are reasonable at the time. Due to the inherent uncertainty involved in making assumptions and estimates, changes in circumstances could result in actual results differing from those estimates, and such differences could be material to the Company&#8217;s consolidated balance sheets and consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company maintains its cash balances in accounts held by major banks and financial institutions located primarily in the U.S. and considers such risk to be minimal. Such bank deposits from time to time may be exposed to credit risk in excess of the Federal Deposit Insurance Corporation insurance limit.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable primarily represent amounts due from distributors, and third-party logistics companies, directly and indirectly from major retailers, and from group purchasing organizations located both inside and outside the U.S. The Company mitigates its credit risks by performing ongoing credit evaluations of its customers&#8217; financial conditions, requiring customer advance payments in certain circumstances. The Company generally does not require collateral. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 (Successor Period), two U.S. customers accounted for 50% and 19% of accounts receivable, respectively. As of December&#160;31, 2021 (Predecessor Period), three U.S. customers accounted for 41%, 14%, and 10% of accounts receivable, respectively. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period from July 28, 2022 to December&#160;31, 2022 (Successor Period), one vendor exceeded 10% of inventory purchases. During the period from January 1, 2022 to July&#160;27, 2022 (Predecessor Period), three vendors exceeded 10% of inventory purchases. During the period from July 28, 2022 to December&#160;31, 2022 (Successor Period), the Company purchased approximately 27% of inventory from one vendor. During the period from January 1, 2022 to July&#160;27, 2022 (Predecessor Period), the Company purchased approximately 23%, 12%, and 12% of inventory, respectively, from three vendors. During the year ended December&#160;31, 2021 (Predecessor Period), two vendors exceeded 10% of inventory purchases. In 2021 (Predecessor Period), the Company purchased approximately 45% and 11% of inventory, respectively, from two vendors.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 (Successor Period), two</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vendors accounted for</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15% and 12%,</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span>respectively, of accounts payable. As of December&#160;31, 2021 (Predecessor Period), one vendor accounted for 24% of accounts payable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company considers highly liquid investments with an initial maturity of three months or less to be cash and cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company&#8217;s restricted cash represents funds that were not accessible for general purpose cash needs due to contractual limitations. As of December&#160;31, 2022 (Successor Period), the Company&#8217;s cash, cash </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equivalents, and restricted cash balance of $10.2 million shown on the consolidated statements of cash flows consisted of $1.5&#160;million of restricted cash and $8.7&#160;million of cash and cash equivalents. The restricted cash balance represented cash in a savings account held by a major bank located in the U.S. and provides collateral for corporate credit cards obtained by the Predecessor for its employees. The Company is required to hold the restricted cash in the bank&#8217;s savings account. Following the acquisition of Milk, the Company had an additional $0.8 million in restricted cash held with a financial institution as collateral for a lease deposit. The deposit is refundable at the end of the lease in November 2030, provided that Milk does not default on its lease payments. </span></div>As of December&#160;31, 2021 (Predecessor Period) the Company&#8217;s cash, cash equivalents, and restricted cash balance of $13.4 million as shown on the consolidated statements of cash flows consisted of $0.6 million restricted cash and $12.8 million in cash and cash equivalents.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company&#8217;s products are produced by third-party contract manufacturers (&#8220;CMOs). Inventories consist of finished goods, work-in-process products and promotional products, valued at the lower of cost or net realizable value using the standard cost method, which approximates actual costs determined on a first-in, first-out (&#8220;FIFO&#8221;) basis. In order to track inventory quantities, the Company uses a perpetual inventory system. Promotional product is charged to cost of goods sold at the time the product is shipped to the Company&#8217;s customer.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has in-transit inventory at any given period. Assessment of in-transit inventory is required to determine inventory balances accurately at period-end. Inventory is recognized when the Company holds title and bears substantially all of the risks and rewards of ownership. In many transactions, the transfer of title and the risks and rewards of ownership are dictated by contractually specified shipping terms, which may take the form of free-on-board (&#8220;FOB&#8221;) shipping point or FOB destination point.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If historical costs exceed the net realizable value at the balance sheet date, the Company adjusts the inventory to net realizable value (i.e., if impairment is identified, the Company records write-downs of inventories to cost of goods sold in the period in which it occurs). The Company evaluates the carrying value of inventories on a regular basis and determines the need to write down carrying values by considering historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost, and the remaining shelf life of goods on hand. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Obsolete, Scrap and Expired Inventory</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inventory provision is set up for inventory that is expected to become obsolete or have a decreased value due to market trends or product upgrades. It accounts for losses that may occur when the inventory cannot be sold at its full cost. The Company regularly monitors any inventory that is not expected to be sold prior to the expiration date and historically slow-moving inventory based on the remaining shelf life and incorporates these considerations into its reserve analysis. Additionally, each period, Management will evaluate whether any additional write downs are required in addition to the calculated reserve amount (generally, by stock keeping unit (&#8220;SKU&#8221;) and/or lot). Specific reserves may relate to known matters, such as quality concerns or a discontinued product.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Sales Returns</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the Company has not experienced a material amount of product returns. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain arrangements may give the Company&#8217;s customers the right to return products. In addition, when customer arrangements do not give the Company&#8217;s customer the explicit right to return products, the Company may accept returns on a discretionary basis. The Company records a return asset for products returned by customers measured at the former carrying amount of the inventory, less any expected costs to recover the goods and potential decreases in value. If the returned inventory is not considered re-sellable, it will be written off to cost of goods sold. When customers have the right to receive a refund for defective or damaged products (as opposed to a replacement product), the right is accounted for as a right of return under ASC 606. When customers have the right to receive a replacement product for defective or damaged products, the right is accounted for as a warranty under ASC 460-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Company accrues for replacement costs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivatives </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accounts for derivative instruments in accordance with ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 815&#8221;), which requires additional disclosures about the Company&#8217;s objectives and strategies for using </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">derivative instruments, how the derivative instruments and related hedged items are accounted for, and how the derivative instruments and related hedging items affect the consolidated financial statements. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses interest rate collars to mitigate interest risk associated with its variable rate credit agreements. See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_145" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Financial Instruments&#8221; for further discussion of the interest rate collar. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Terms of debt instruments are reviewed to determine whether they contain embedded derivative instruments that are required to be accounted for separately from the host contract and recorded on the consolidated balance sheets at fair value under ASC 815. An evaluation of specifically identified conditions is made to determine whether the fair value of warrants issued is required to be classified as equity or as a derivative liability. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Liabilities</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for Public Warrants and Private Placement Warrants (each as defined below) as liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 480&#8221;) and ASC 815. Specifically, the Public and Private Placement Warrants meet the definition of a derivative but do not qualify for an exception from derivative accounting since the warrants are not indexed to the Company&#8217;s stock and, therefore, are precluded from equity classification. Since the Public and Private Placement Warrants meet the definition of a derivative under ASC 815, the Company measures the warrants at fair value at inception and at each reporting date, with changes in fair value recognized in change in fair value of derivative warrant liabilities in the consolidated statements of operations and comprehensive loss in the period of change. See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_145" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 10</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Financial Instruments&#8221; for further discussion of the warrants, including the FPA Warrants (as defined below).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the interest rate collar and warrant liabilities were estimated using inputs based on management&#8217;s judgment and conditions that existed at each reporting date. See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_151" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 1</a><a href="#if2fc25067f8b45fc8cc165df93f3be1c_151" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for further details.</span></div>The fair values of the Company&#8217;s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and all other current liabilities approximate their carrying values because of the short maturities of these instruments. Additionally, the carrying amount of debt approximates fair value due to the adjusting interest rates of the Company&#8217;s term loan, which approximate current market rates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Capitalized Software and Website Development Costs</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Capitalized Software and Website Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212; The Company capitalizes costs related to (i) internal-use software (ii) cloud computing arrangement (&#8220;CCA&#8221;) implementation costs, and (iii) other software-related costs (e.g., website development costs).</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For internal-use software, both internal and external costs incurred during the preliminary project stage are expensed as incurred, and qualifying costs incurred during the application development state are capitalized. Capitalization ceases no later than the point at which a software project is substantially completed and ready for its intended use. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For CCAs, or hosting arrangements, the Company evaluates if the CCA includes a software license that will be accounted for in addition to a hosting service. The cost of the arrangement (i.e., license or service cost) of a CCA that includes a software license will be capitalized as an acquisition of an asset (similar to internal-use software) and amortized over its useful economic life, whereas the costs of a service contract are expensed as incurred.  </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Costs related to website development are expensed as incurred during the planning stage, content development stage, and operating stage. The Company generally capitalizes costs incurred for activities during the website application and infrastructure development stage, and graphics development stage. Costs incurred for website hosting services from a third-party vendor are expensed over the period the services are received.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Internal-use software costs and website development costs are amortized on a straight-line basis over their estimated useful lives, which is generally three years or less. Management evaluates the useful lives of these assets and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_PrepaidExpensesPolicyTextBlock', window );">Prepaid Expenses</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; At initial recognition, the Company measures prepaid assets based on cost (i.e., amount paid). In the accounting period or periods in which a good or service is used or received, the asset will be reduced by a proportionate amount and an associated asset (e.g., inventory) or expense (e.g., marketing) will be recorded.   </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Prepaid Inventory</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prepayments are required to begin production of inventory at certain of the Company&#8217;s CMOs and inventory suppliers. Vendors are tracked to determine prepayments that have been made and when the associated inventory is expected to be delivered to the Company (i.e., when the Company takes ownership of the inventory). Prepaid inventory is triggered by invoices received from CMOs (i.e., the vendor). When the Company submits purchase orders, the CMOs may request a prepayment amount (deposit) based on agreed-upon percentage in the vendor contracts to start the production process.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Prepaid Marketing and Advertising</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally expenses the costs of advertising and marketing as costs are incurred, except for costs associated with producing advertising. While production costs (i.e., costs to develop promotions for a specific campaign associated with an identified new brand or new product) are incurred during the process of production, the Company has elected to expense certain costs when the associated advertising takes place. In the event that the advertising is not expected to occur (e.g., decision has been made to not launch a promotion) or a 12-month period elapses without the associated advertising occurring, the associated production costs will be expensed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; Property and equipment are stated at cost, net of accumulated depreciation. In the case of a business combination, acquired property and equipment are recognized at their fair value as of the date of acquisition. Following initial recognition, property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of respective assets. No depreciation is charged to construction in progress. The estimated useful lives of the Company&#8217;s assets are as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ESTIMATED&#160;USEFUL&#160;LIVES</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gondolas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lesser of useful life or term of lease</span></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets, Net</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets, Net</span>&#8212;Intangible assets consist primarily of trademarks and trade names, a supply agreement, customer relationships, formulations, and developed technology. Intangible assets acquired in a business combination are recognized at their fair value as of the date of acquisition. Following initial recognition, intangible assets are carried at cost less accumulated amortization and impairment losses, if any, and are amortized on a straight-line basis over the estimated useful life of the asset.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span>&#8212;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, for each asset group held for use with indicators of impairment, the Company compares the expected future cash flows generated by the asset group, which represents the lowest level at which cash flows are identifiable, with its associated net carrying value. If the net carrying value of the asset group exceeds expected undiscounted cash flows, the excess of the net book value over estimated fair value is charged to impairment loss.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; When the Company acquires a business, the total purchase consideration provided is allocated to the identifiable assets and liabilities of the acquired business at their estimated respective fair values. Any excess consideration of the fair value of purchase consideration over the fair values of assets acquired and liabilities assumed is recognized as goodwill.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant management judgments and assumptions are required in determining the fair value of assets acquired and liabilities assumed. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows, useful lives and discount rates. Measurement period adjustments are reflected at the time identified, up through the conclusion of the measurement period, which is the time at which all information for determination of the values of assets acquired and liabilities assumed is received, which may not exceed one year from the acquisition date. The Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with a corresponding offset to goodwill. If outside of the measurement period, any subsequent adjustments are recorded in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Goodwill represents the difference between the purchase price and the fair value of assets and liabilities acquired in a business combination. The Company reviews goodwill for impairment annually on October 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span> and at an interim date if events or changes in circumstances indicate the occurrence of a triggering event. The Company reviews goodwill for impairment by initially considering qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill, as a basis for determining whether it is necessary to perform a quantitative analysis. If it is determined that it is more likely than not that the fair value of reporting unit is less than its carrying amount, a quantitative analysis is performed to identify goodwill impairment. Determining the fair value of a reporting unit involves the use of significant estimates and assumptions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Deferred Issuance Costs</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Issuance Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company capitalizes costs related to the issuance of debt instruments, as applicable. Such costs are initially recorded as a direct deduction from the applicable debt instrument and amortized over the contractual term of the related debt instrument in interest expense, net using the straight-line method, which approximates the effective interest method, in the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, Net</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Trade accounts receivable are stated at net realizable value. Receivables are unsecured and represent amounts billed to and currently due from customers that have yet to be collected. Payment terms are generally short-term in nature and are less than one year. In certain circumstances, the Company offers extended payment terms to customers. When the period between the transfer of control of the products and payment is greater than one year, the Company adjusts the promised amount of consideration for the effects of a significant financing component. </span></div>The Company maintains an allowance for doubtful accounts, which represents allowances for customer trade accounts receivable that are both probable and estimated to be partially or entirely uncollectible. These allowances are used to reduce gross trade receivables to their net realizable value. The Company records these allowances based on estimates related to the following factors: (i)&#160;customer-specific allowances, based upon past collection history, historical trends, and identification of specific customer risk and (ii)&#160;formula-based general allowances using an aging schedule. Determining such allowances involves the use of significant estimates and assumptions. Payments of accounts receivable are allocated to the specific invoices identified on the customer&#8217;s remittance advice or to the customer&#8217;s account, if unspecified, until an invoice can be determined by the customer. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to trade accounts receivable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company recognizes revenue when control of the promised goods or services is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to for those goods or services. In that determination, under ASC 606 the Company follows a five-step model that includes: (1) determination of whether a contract or an agreement between two or more parties that creates legally enforceable </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rights and obligations exists; (2) identification of the performance obligations in the contract; (3) determination of the transaction price; (4) allocation of the transaction price to the performance obligations in the contract; and (5) recognition of revenue when (or as) performance obligations are satisfied. Net revenue excludes taxes collected by us on behalf of governmental authorities.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue is primarily generated from product sales to distributors, retailers, physicians and directly to consumers (&#8220;DTC&#8221;) via its e-commerce platforms. Distributors may resell products to retailers, physicians, or end consumers. To determine when to recognize revenue under ASC 606 in cases where products are sold to distributors, the Company analyzes various factors including its ability to direct products physically held by the distributors, when title and risk of loss transfers, and who ultimately manages the relationship with the end consumer. The Company does not recognize revenue until control of the products is transferred to the distributor.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, and when facts and circumstances change, the Company assesses whether it is probable that the Company will collect substantially all of the consideration it will be entitled to from a customer. If the Company determines that it is not probable that the Company will collect substantially all of the consideration from the customer, the Company recognizes revenue only when one or more of the following events occur: (i) the Company has no remaining obligations to transfer goods or services to the customer, and all, or substantially all, of the consideration promised by the customer has been received by the Company and is nonrefundable, (ii) the contract has been terminated, and the consideration received from the customer is nonrefundable, or (iii) the Company has transferred control of the goods or services to which the consideration that has been received relates, the Company has stopped transferring goods or services to the customer (if applicable) and has no obligation under the contract to transfer additional goods or services, and the consideration received from the customer is nonrefundable.  </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that each of its products is distinct and represents a separate performance obligation. The transaction price is equal to the consideration the Company is entitled to &#8211; which could be either a distributor, retailer, physician, or e-commerce end consumer. When measuring revenue and determining the consideration the Company is entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Product sales revenue is recognized net of provisions for estimated volume rebates and discounts, markdowns, margin adjustments, early-payment discounts and returns. The Company estimates variable consideration using the expected value method and adjusts the transaction price when control of the related product is transferred to the customer. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s distributors charge fees for certain services rendered by the distributors, including packing and shipping, marketing and advertising the Company&#8217;s products, monitoring product reviews, regulatory services, providing customer service, and generating data and analytical reports on product sales. Distributor fees for services are recognized as a reduction to revenue because the services provided are typically not distinct from the distributors&#8217; purchase of products.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, customers are required to pay either in advance or between 30 and 90 days from delivery or invoicing. However, in certain circumstances, the Company offers extended payment terms to customers. When the period between the transfer of control of the products and payment is greater than one year, the Company adjusts the promised amount of consideration for the effects of a significant financing component. When contracts contain a significant financing component in which the Company is effectively financing the customer, a portion of the transaction price is recognized as other income.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price to each performance obligation based on its relative standalone selling price. Standalone selling price is the price at which the Company would sell a promised product separately to a customer. The Company typically has an observable standalone selling price for each of its products.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has different contracted shipping terms with different customers that dictate the timing of payment, passage of legal title, transfer of physical possession, and assumption of the risks and rewards occur. For distributors, other than the Physician Channel Provider, and retailers, depending on the contract, the Company considers transfer of control to have occurred either once the delivery of the product has occurred or once the product has been picked up from the Company&#8217;s designated warehouse/distribution center by the customer&#8217;s shipping agent, unless the Company is responsible for shipping the goods, in which case transfer of control passes upon delivery to the customer. For DTC </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales and sales to physicians through the Physician Channel Provider, control transfers upon shipment to the end consumer or physician. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shipping and Handling </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for shipping and handling activities as fulfillment activities instead of as performance obligations and recognizes these costs as SG&amp;A expenses. Costs related to shipping and handling for the period from July&#160;28 to December&#160;31, 2022 (Successor Period), and the period from January&#160;1 to July&#160;27, 2022 (Predecessor Period), and the years ended December&#160;31, 2021 and 2020 (Predecessor Periods) were $2.0 million, $0.6 million, $1.0 million, and $0.2 million, respectively. Amounts billed to customers for shipping and handling are included in revenue.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Promotional Products</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In situations where promotional products, such as samples and testers, are provided by the Company to its customers at the same time as a related saleable product, the cost of these promotional products are recognized as cost of sales at the same time as the revenue for the related product is recognized.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates royalty revenue from products sold under the Obagi brand name in Japan and Hong Kong through license agreements with local operators. Under these agreements, the Company provides the local operators with a license of intellectual property and receives a royalty based upon a percentage of net sales of Obagi-branded products sold in Japan and Hong Kong. Because the license is the predominant item to which the sales-based royalty relates, the Company recognizes revenue for the sales-based royalty when the local operators make sales of the products.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs to Obtain a Contract with a Customer</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the incremental costs of obtaining a customer contract as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. The incremental costs to obtain contracts primarily relate to sales commission and sales-based bonuses. Total capitalizable costs to obtain a contract were immaterial during the periods presented.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div>The Company&#8217;s contracts do not typically give rise to material contract assets or contract liabilities because (i) payment is typically closely aligned with the timing of the Company&#8217;s performance or (ii) the Company performs prior to customer payment, and the Company has an unconditional right to payment that represents an account receivable. Similarly, the Company does not recognize material revenue in reporting periods from performance obligations satisfied in previous periods. The Company applies the exemption in ASC 606-10-50-14(a) related to disclosure of the amount of transaction price allocated to unsatisfied performance obligations for royalty contracts. Because of the short-term nature of product sales contracts, the Company typically does not have other material amounts to disclose related to the transaction price allocated to unsatisfied performance obligations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods Sold</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cost of Goods Sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8212;Cost of goods sold consists of inventory and promotional product costs, including when inventory and promotional products are sold or written down, and product-related intangible asset amortization and depreciation expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;R&amp;D costs are expensed as incurred. Costs associated with research and development activities may include materials, equity and facility costs, personnel costs, contracted services (i.e., the costs of services performed by third parties in connection with the Company&#8217;s R&amp;D activities), and direct costs (e.g., appropriate allocations for general and administrative costs). Substantially all R&amp;D expenses are related to new product development and design improvements or increased functionality in current products. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may capitalize acquired assets associated with R&amp;D activities (e.g., materials, equipment) if both of the following criteria are met: (i) the Company reasonably expects that the acquired assets will be used in an alternative manner and anticipates an economic benefit from the alternative future use and (ii) the use of the acquired asset is not </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contingent on the further development of the asset after acquisition date (i.e., the asset can be used in an alternative manner in the condition in which it existed at the acquisition date).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span>&#8212;Advertising costs are expensed in the period in which they are incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company measures the cost of share-based awards granted to eligible employees, directors, and consultants based on the grant-date fair value of the awards. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Replacement Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Closing Date, in connection with the Business Combination, the Company assumed Obagi and Milk&#8217;s legacy incentive award plans and outstanding unvested options granted under those plans (&#8220;Replacement Options&#8221;). Because the options were deemed in the money on the replacement date, a Hull-White lattice pricing model was used to estimate their fair value to capture the optimal timing of exercise. This pricing model requires the use of assumptions including the volatility of the underlying stock, the fair value of the stock, dividend yield, risk-free rate, and exercise multiple. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Founder Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value and derived service period of the stock options issued to founders (&#8220;Founder Awards&#8221;) in August 2022 based on the Monte Carlo simulation, as they were deemed out of the money on the grant date. The Monte Carlo simulation model requires the use of assumptions including the option&#8217;s expected term, the volatility of the underlying stock, dividend yield rate, risk-free rate, and expected exercise behavior. For expected exercise behavior, the Company assumes that the options are exercised after 50% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock is equal to the price of the Company&#8217;s ordinary shares on the grant date.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to recognize the effect of forfeitures in the period in which they occur. Share-based awards are classified as equity, unless the underlying shares are classified as liabilities or the Company is required to settle the awards by transferring cash or other assets.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense for awards with service or performance conditions using the straight-line method over the requisite service period, which is generally the award&#8217;s vesting period. Compensation expense for employee stock-based awards whose vesting is subject to the fulfillment of both a service condition and the occurrence of a performance condition is recognized on a graded-vesting basis at the time the achievement of the performance condition becomes probable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accounts for income taxes using the asset and liability approach. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes represents income taxes paid or payable for the current period plus the change in deferred taxes during the period. Deferred taxes result from differences between the financial and tax basis of the Company&#8217;s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether a valuation allowance is required often requires significant judgment including the long-range forecasting of future taxable income and the evaluation of planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made. A valuation allowance of $7.9 million was recorded as of December&#160;31, 2022 (Successor Period), a valuation allowance of $14.1 million was recorded as of December&#160;31, 2021 (Predecessor Period), and no valuation allowance was recorded as of December&#160;31, 2020 (Predecessor Period).</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for a tax benefit from an uncertain position in the consolidated financial statements only if it is more likely than not that the position is sustainable, based solely on its technical merits and consideration of the relevant taxing authority&#8217;s widely understood administrative practices and precedents. If the recognition threshold for the tax position is met, the Company records only the portion of the tax benefit that is greater than 50% likely to be realized. As of December&#160;31, 2022 (Successor Period), 2021 (Predecessor Period), and 2020 (Predecessor Period), the Company had no uncertain positions in the consolidated financial statements.</span></div>The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Income (Loss) Per Share</span>&#8212;Basic net income (loss) per share attributable to shareholders of ordinary shares is computed by dividing the Company&#8217;s net income (loss) attributable to holders of ordinary shares by the weighted-average number of ordinary shares used in the income (loss) per share calculation during the period. Diluted net income (loss) per share attributable to holders of ordinary shares is computed by giving effect to all potentially dilutive securities. The net income (loss) per share that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Noncontrolling Interests</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Noncontrolling interests represent the portion of Waldencast Partners LP that the Company controls and consolidates but does not own. The Company recognizes each noncontrolling holder&#8217;s respective share of the estimated fair value of the net assets at the date of formation or acquisition. Noncontrolling interests are subsequently adjusted for the noncontrolling holder&#8217;s share of additional contributions, distributions and their share of the net earnings or losses of each respective consolidated entity. The Company allocates net income or loss to noncontrolling interests based on the weighted average ownership interest during the period. The net income (loss) that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss. The Company does not recognize a gain or loss on transactions with a consolidated entity in which it does not own 100% of the equity, but the Company reflects the difference in cash received or paid from the noncontrolling interests carrying amount as additional paid-in-capital.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and incur expenses and about which separate financial information is regularly evaluated by the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) in deciding how to allocate resources. Similar operating segments can be aggregated into a single operating segment if the businesses are similar. Management has determined that, following the Business Combination, the Successor has two operating and reportable segments: Obagi Skincare and Milk Makeup, reflecting the manner in which the CODM operates the Company. The Company&#8217;s CODM is its Chief Executive Officer. The Predecessor had one operating and reportable segment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recently Issued Accounting Standards, Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;) using the modified retrospective transition method on the date of the Business Combination. The Predecessor planned to adopt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 842 during the annual period ended December&#160;31, 2022. Waldencast had no capital or operating lease obligations prior to the Business Combination. The Company elected the package of practical expedients available upon transition to ASC 842 that allow (i) historical lease classification of existing leases, (ii) no reassessment of any expired or existing contracts containing leases, and (iii) no reassessment of initial direct costs for any existing leases. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of the new standard impacted the Company&#8217;s accounting for operating leases. Upon adoption, the Company established an operating right-of-use asset of $13.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and a corresponding operating lease liability of $16.6 million. The Company does not have any finance leases. See &#8220;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#if2fc25067f8b45fc8cc165df93f3be1c_142" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further detail.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of ASC 842, the Company recognized rent expense for operating leases on a straight&#8209;line basis (including the effect of reduced or free rent and rent escalations) over the lease term. The difference between the cash paid to the landlord and the amount recognized as rent expense on a straight&#8209;line basis was recognized as an adjustment to deferred rent in the consolidated balance sheets.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Debt-Debt with Conversion and Other Options&#8221; (Subtopic 470-20) and &#8220;Derivatives and Hedging-Contracts in an Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 also removes certain settlement conditions that are required for equity-linked contracts to qualify for scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company adopted ASU 2020-06 on January 1, 2021. Adoption of the ASU did not impact the Company&#8217;s financial position, results of operations or cash flows.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU No.&#160;2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic&#160;848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was effective for the Company in the annual period ended December&#160;31, 2022. This ASU provides relief that, if elected, will require less accounting analysis and less accounting recognition for modifications related to reference rate reform. This update provides optional guidance for a limited period of time to ease the potential burden in accounting for reference rate reform on financial reporting. The amendments in the update apply only to contracts, hedging relationships, and other transactions that reference the London Inter-Bank Offered Rate (&#8220;LIBOR&#8221;) or another reference rate expected to be discontinued because of reference rate reform. Waldencast adopted this ASU prospectively effective January 1, 2022, which did not have a material effect on its consolidated financial position, results of operations and cash flows.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2022, Waldencast adopted ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes&#8212;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2019-12&#8221;). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. Waldencast adopted this ASU prospectively, which did not have a material effect on its consolidated financial position, results of operations and cash flows.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards, Not Yet Adopted</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2016, the FASB issued ASU No.&#160;2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements&#8212;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU adds an impairment model known as current expected credit loss that is based on expected losses rather than incurred losses. It recognizes an allowance as an estimate of expected credit losses, which may result in more timely recognition of such losses. In 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 326), which defers the effective date for entities in the &#8220;all other&#8221; category and public not-for-profit entities that have not yet issued their financial statements reflecting the adoption of credit losses. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, and early adoption is permitted. This guidance is effective for the Company for the annual period beginning on January 1, 2023, and interim periods within the annual period beginning on January 1, 2023, with earlier adoption permitted. The adoption of this new standard will not have a material effect on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The guidance requires an acquirer to, at the date of acquisition, recognize and measure the acquired contract assets and contract liabilities acquired in the same manner that they were recognized and measured in the acquiree&#8217;s financial statements before the acquisition. This guidance is effective for interim and annual periods beginning after December 15, 2022, with early adoption permitted. The amendments in this update should be applied prospectively to business combinations occurring on or after the effective date. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements, but does not expect it to have a material impact.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The guidance expands public entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. The guidance also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. This guidance is effective for interim periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. The amendments in this update should be applied retrospectively to all periods presented in the financial statements. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements but does not expect it to have a material impact.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2025, with early adoption permitted. The amendments should be applied prospectively however, retrospective application is also permitted. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -SubTopic 50<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482610/350-50-25-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -SubTopic 40<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482633/350-40-30-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_PrepaidExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_PrepaidExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575334144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTATEMENT AND RECLASSIFICATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Summary of Restatement and Reclassification Adjustments</a></td>
<td class="text">The following table summarizes the impact of the restatement to net revenue:<div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributor fees for services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(39,146)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SA Distributor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physician Channel Provider </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,191)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US Online Marketplace Distributor </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(267)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total net revenue adjustments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(63,597)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,283</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Distributor fees for services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; Obagi&#8217;s distributors charge fees for certain services they render. The Predecessor (Obagi) had recorded these service fees as selling, general and administrative (&#8220;SG&amp;A&#8221;) and research and development (&#8220;R&amp;D&#8221;) expenses. Management subsequently determined these service fees should have been recognized as a reduction to net revenue, as the additional services provided by distributors were not distinct from the distributors&#8217; purchase of Obagi products. This resulted in an overstatement of net revenue of $39.1 million and corresponding overstatements of SG&amp;A expenses and R&amp;D expenses of $37.1 million $2.0 million, respectively, for the year ended December 31, 2021 (Predecessor Period). The misstatement had no impact to net income or cash flows for the year ended December 31, 2021 (Predecessor Period). There was no similar accounting misstatement identified for the year ended December 31, 2020 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:10.5pt">SA Distributor </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8211; The Predecessor historically recognized revenue for products sold to Obagi&#8217;s SA Distributor upon shipment of the products. Management determined that the SA Distributor revenue should have been recognized when Obagi had no remaining performance obligations and received substantially all of the consideration related to each purchase order in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">(&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">606&#8221;). This resulted in an overstatement of accounts receivable of $24.8 million as of December 31, 2021 (Predecessor Period), an overstatement of net revenue of $14.2 million for the year ended December 31, 2021 (Predecessor Period), and an understatement of net revenue of $1.7 million for the year ended December 31, 2020 (Predecessor Period). </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Physician Channel Provider</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> - The Predecessor historically recognized revenue for products sold in the physician dispensed, or Direct-to-Physician (&#8220;DTP&#8221;), channel upon the transfer of products to the Physician Channel Provider. Management determined that although the products were transferred to the Physician Channel Provider, the Physician Channel Provider did not obtain actual control of the products until immediately prior to selling through to the physician customer. Therefore, revenue should have been recognized only immediately prior to transfer of products to physicians (i.e., when the products were sold to the physicians) rather than when they were transferred to the Physician Channel Provider. In addition, the Physician Channel Provider charged fees for certain services rendered by it (as discussed above) and the Predecessor recorded these service fees as SG&amp;A and R&amp;D expenses, instead of as a reduction to net revenue. As a result of these items, there was an overstatement of net revenue of $8.2 million, an understatement of cost of goods sold of $0.4 million, an overstatement of SG&amp;A of $7.1 million, an overstatement of accounts receivable of $14.8 million, and an understatement of inventory of $2.0 million as of and for the year ended December 31, 2021 (Predecessor Period). For the year ended December 31, 2020 (Predecessor Period) this resulted in an understatement of revenue of $8.6 million, an understatement of cost of goods sold of $2.6 million, and an overstatement of SG&amp;A of $4.9 million.  </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">U.S. Online Marketplace Distributor &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> The Predecessor agreed to nonstandard payment terms in its contracts with the U.S. Online Marketplace Distributor and allowed for payments over a period of time that exceeded 365 days until final payment of an invoice. Management subsequently identified misstatements to revenue recognition relating to the significant financing component of such </span></div><div style="padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">arrangement, timing of revenue, and incorrect accounting of shipping activities. The net impact of these misstatements resulted in an overstatement of net revenue of $1.8 million, an understatement of other income of $1.0 million and an understatement of deferred revenue of $0.7 million as of and for the year ended December 31, 2021 (Predecessor Period) and an understatement of net revenue of $0.1 million for the year ended December 31, 2020 (Predecessor Period).</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Other net revenue adjustments &#8211; </span>Other net revenue adjustments were individually and in the aggregate insignificant for the years ended December 31, 2021 and 2020 (Predecessor Periods).The following table summarizes the impact of the restatement to cost of goods sold:<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:39.749%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physician Channel Provider</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory obsolescence provision </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(583)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other - adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total net cost of goods sold adjustments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,673</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4,471</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Physician Channel Provider </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; As described above in (a)3, Management determined that it should have recognized revenue and cost of goods sold for products sold to the Physician Channel Provider immediately prior to the transfer of products to the physicians, which resulted in understatements of costs of goods sold as set forth in the table above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Inventory obsolescence provision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; The Company did not appropriately adjust the inventory reserve for obsolete inventory. In connection with the restatement, the Company corrected its historical inventory obsolescence provision. This resulted in an overstatement of cost of goods sold of $0.6 million for the year ended December 31, 2021 (Predecessor Period) and an understatement of $0.7 million for the year ended December 31, 2020 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:10.5pt">Other net cost of goods sold adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; The Predecessor historically recorded certain promotional products in marketing expenses. Management determined that it should have recorded such promotional products in inventory and cost of goods sold, which resulted in understatements of costs of goods sold as set forth in the table above. The other net cost of goods sold adjustments related to the understatement of cost of goods sold were insignificant both individually and in the aggregate for the years ended December 31, 2021 and 2020 (Predecessor Periods).</span></div>The following table summarizes the impact of the restatement to SG&amp;A expenses:<div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributor fees for services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(37,075)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physician Channel Provider </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,065)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,891)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(732)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other - adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(974)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(546)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total SG&amp;A adjustments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(44,523)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3,138)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Distributor fees for services &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described above in (a)1, the Predecessor had incorrectly recorded certain payments to distributors for services on a gross basis in net revenue which caused an overstatement of SG&amp;A expenses.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Physician Channel Provider &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> As described above in (a)3, the Predecessor had recorded fees for certain services to the Physician Channel Provider in SG&amp;A expenses as opposed to a reduction to net revenue, which cause an overstatement of SG&amp;A expenses. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Computer software &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> As described below in (j), the Predecessor historically capitalized certain computer software expenses that should have been expensed as incurred. This adjustment resulted in </span></div><div style="padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">understatements of SG&amp;A expenses of $1.3 million and $0.5 million for the years ended December 31, 2021 and 2020 (Predecessor Periods), respectively.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Prepaid expenses &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described below in (h)1 through (h)2, the Predecessor historically capitalized certain expenses primarily related to marketing and advertising activities. Obagi should have expensed these items in the period in which the expenses were incurred. These misstatements resulted in an overstatement of SG&amp;A expenses of $0.7 million for the year ended December 31, 2021 (Predecessor Period) and an understatement of $1.8 million for the year ended December 31, 2020 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:10.5pt">Other SG&amp;A adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> As described in (b)3, management determined that it should have recorded certain promotional products in cost of goods sold instead of marketing expenses, which resulted in an overstatement of SG&amp;A expenses as set forth in the table above. The other SG&amp;A adjustments were individually and in the aggregate insignificant for the years ended December 31, 2021 and 2020 (Predecessor Periods). </span></div>The following table summarizes the impact of the restatement to accounts receivable, net:<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:69.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SA Distributor </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,821)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physician Channel Provider</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,796)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncollectible loan receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,512)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total accounts receivable, net adjustments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(44,629)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">SA Distributor &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As described above in (a)2, the Company restated revenue for products sold to the SA Distributor and adjusted the overstatement of accounts receivable, net. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Physician Channel Provider</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; As described above in (a)3, the Company restated revenue for products sold in the DTP channel and adjusted the overstatement of accounts receivable, net.  </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Uncollectible loan receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; The Predecessor did not record the loss on the write-off of a one-time uncollectible loan receivable related to the Obagi China Business in the period it was deemed uncollectible. This resulted in an overstatement of accounts receivable, net of $2.5 million as of December 31, 2021 (Predecessor Period) and an understatement of a loss on the write-off of the loan receivable of $2.6 million for the year ended December 31, 2021 (Predecessor Period).</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Other adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> &#8211; The Company identified misstatements related to certain distributor receivables, aged accounts receivable and other accounts receivable. The aggregate impact of these misstatements resulted in an overstatement of accounts receivable, net of $2.5 million as of December 31, 2021 (Predecessor Period).</span></div>The following table summarizes the impact of the restatement to inventories:<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:69.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.149%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physician Channel Provider </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory obsolescence provision </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other adjustments  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total net inventory adjustments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,272</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Physician Channel Provider </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; As described above in (a)3, the Predecessor historically recognized cost of goods sold for products sold in the DTP channel upon transfer of the products to the Physician Channel Provider instead of immediately prior to transfer of the products to physician customers, which resulted in an understatement of inventory. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Inventory obsolescence provision </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; As described above in (b)2, as a result of misstatements in inventory, the Company had an overstatement of inventory of $0.1 million as of December 31, 2021 (Predecessor Period). </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8211; As described in (b)3, management determined that it should have recorded certain promotional products in inventory and cost of goods sold instead of marketing expenses, which resulted in an understatement of inventory of $0.3 million as of December 31, 2021 (Predecessor Period).</span></div>The following table summarizes the impact of the reclassification adjustments to cost of goods sold:<div style="margin-top:12pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"><tr><td style="width:1.0%"></td><td style="width:37.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the effects of the restatement and reclassification adjustments to the previously issued consolidated financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEET</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.479%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">As Reported</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Restatement Adjustments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Restatement Reference</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">12,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">12,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">63,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(44,629)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">f</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">18,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">19,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">g</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">21,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">7,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(2,979)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">h</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">i</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">104,429&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(45,392)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">59,037&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">3,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(2,386)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">79,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">79,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">44,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">44,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1,209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">k</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">TOTAL ASSETS</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">233,573</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(48,987)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">184,586</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CURRENT LIABILITIES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">11,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">l</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">12,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">15,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">n.m.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">15,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">12,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">m</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">12,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">39,740</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">1,065</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">40,805</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Long-term debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">103,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">103,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">n.m.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">TOTAL LIABILITIES</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">144,283&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">145,347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">SHAREHOLDERS' EQUITY:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Predecessor common shares, 25,000,000 shares authorized; $0.50 par value, 8,000,002 shares issued and outstanding as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">100,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">100,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(14,798)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(50,051)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">o</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(64,849)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">TOTAL SHAREHOLDERS' EQUITY</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">89,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(50,051)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">39,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">233,573</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(48,987)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">184,586</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n.m. - not meaningful</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE (LOSS)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restatement Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restatement Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">206,069</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(63,597)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">142,472</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b,p,r</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross profit </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(48,708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c,p</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(899)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d,a(1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,904)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">j,p</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating expenses </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">187,995</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(53,364)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(45,571)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">89,060</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18,074</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,699)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1,625)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,156&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n.m.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,118&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on PPP Loan forgiveness</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on write-off of loan receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses (income), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,011)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total other (income) expenses, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,843</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,506</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,349</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Loss) income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11,231</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(21,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(70)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,506)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,576)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares used in computing net loss per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,576)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(102)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,506)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19,608)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n.m. - not meaningful</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.778%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restatement Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restatement Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">84,145</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10,283</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">94,428</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b,p,r</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross profit </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">65,332</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,969)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c,p</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,421)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">j,p</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total operating expenses </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">92,118</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(24,625)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,689)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">64,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7,973)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,501</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">528</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total other (income) expenses, net</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,292</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Loss) income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14,265)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8,501</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5,764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,094)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9,171)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,801</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,370)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares used in computing net loss per share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9,171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,801</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9,155)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,801</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2,354)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CONSOLIDATED STATEMENT OF CASH FLOWS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars)</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restatement Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restatement Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(19,506)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(19,576)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gain on PPP Loan forgiveness</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,824)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,824)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n.m.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on disposal of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on write-off of loan receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">f</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(23,790)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">f</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,057)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,359)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">g</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">h</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,097)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,711)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">i,k</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">l, q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current liabilities and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,782)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">m</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash (used in) provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,070</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,541)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,529</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditure on intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(937)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n.m.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditure on property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,923)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Advances for note receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash used in investing activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(5,360)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,573</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(3,787)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash provided by financing activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,162</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,162</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,872</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">32</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">q</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4,904</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of foreign exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">q</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(32)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;Beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,572</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,572</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;End of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13,444</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13,444</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SUPPLEMENTAL CASH FLOW DATA &#8211; CASH PAID:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NON-CASH INVESTING AND FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures in accounts payable and accruals</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENT OF CASH FLOWS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars)</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Predecessor (Obagi)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restatement Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Restatement Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9,171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,743)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(961)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(15,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">f</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16,661)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">g</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">h</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,919)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current assets and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(998)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">i,k</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">l</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7,391)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current liabilities and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">m</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash (used in) provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(7,251)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(7,431)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditure on intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditure on property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,054)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash used in investing activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,887)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">180</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(1,707)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash provided by financing activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14,319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,181</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5,181</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;Beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,391</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3,391</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;End of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,572</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8,572</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SUPPLEMENTAL CASH FLOW DATA &#8211; CASH PAID:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NON-CASH INVESTING AND FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures in accounts payable and accruals</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital contribution of trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575310432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Estimated Useful Lives of Assets</a></td>
<td class="text">The estimated useful lives of the Company&#8217;s assets are as follows:<div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ESTIMATED&#160;USEFUL&#160;LIVES</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gondolas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lesser of useful life or term of lease</span></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Successor)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Predecessor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer hardware, software and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internally developed software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gondolas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,928)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,328&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,198&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693577887648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Summary of Purchase Price Allocation</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obagi and Milk Purchase Price Allocation:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Purchase Price:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">345,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">467,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">277,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">477,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash repayment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total purchase consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">781,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">325,651</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,107,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Account receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">505,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">662,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total identifiable assets acquired</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">579,316</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">212,609</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">791,925</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities assumed:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">66,145</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22,030</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">88,175</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net assets acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">513,171</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">190,579</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">703,750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">781,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">325,651</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1,107,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">268,263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">135,072</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">403,335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock', window );">Schedule of Intangible Assets Acquired in Business Combination</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Useful Life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks and Trade Name</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">414,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">559,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer/distributor relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tretinoin distribution and supply agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formulations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Intangible Assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">505,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">157,500</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">662,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Unaudited Pro Forma Consolidated Financial Information</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma combined financial information presents the Company&#8217;s results as though the Business Combination had occurred on January 1, 2021, for the years ended December&#160;31, 2021 and 2022. The unaudited pro forma consolidated financial information has been prepared using the acquisition method of accounting in accordance with U.S. GAAP.</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma net revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">200,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">162,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(86,930)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(145,152)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Pro forma net income (loss) attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,519)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pro forma net income (loss) attributable to Waldencast plc</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61,790)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(118,633)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693571400976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Revenue by Sales Channel</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue by sales channel was as follows for the periods indicated: </span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Skincare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk  Makeup</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Sales Channel</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59,102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,283&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,090&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,283&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1 to July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Sales Channel</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,729&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,759&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,524&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,760&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue by Geographic Region</a></td>
<td class="text"><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue by geographic region, based on the location of the end customer, was as follows for the periods indicated: </span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:82.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.095%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Geographic Region&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">North America</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of the World</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,385&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:49.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1 to July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue by Geographic Region&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">North America</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rest of the World</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,729&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136,759&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,524&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total:</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,760&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94,428&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -SubTopic 10<br> -Topic 280<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575334144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text">The following table presents changes in goodwill by reportable segment:<div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Skincare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk Makeup</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Goodwill</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance as of December 31, 2021 and 2020 (Predecessor)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">44,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">44,489</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elimination of Predecessor goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44,489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44,489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obagi and Milk Business Combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">268,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">403,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(68,715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(68,715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance as of December 31, 2022 (Successor)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">199,548</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">135,072</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">334,620</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693577844160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS&#8212;NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following as of December&#160;31, 2022 (Successor Period):</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:34.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average Useful<br/>Lives (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademark and trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">559,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,840)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">541,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,349)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supply agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formulations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,526)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">663,208&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,043)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">639,165&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following as of December&#160;31, 2021 (Predecessor Period):</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:34.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average Useful<br/>Lives (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademark and trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,004&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,842)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,404)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supply agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,654)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formulations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,592)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134,077&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(54,503)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79,574&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Expected Amortization Expense</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected amortization for each of the years between 2023 through 2027, and thereafter are as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ending December 31</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">359,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">639,165&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693577331120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt Instruments</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.226%"><tr><td style="width:1.0%"></td><td style="width:51.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.383%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.119%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Successor)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Predecessor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 Term Loan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Predecessor 2021 Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Predecessor 2021 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Predecessor 2018 Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Predecessor 2018 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Predecessor PPP Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179,324&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20,095)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,442)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total long-term portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159,229&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103,423&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-Term Debt</a></td>
<td class="text"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scheduled maturities under the Company&#8217;s 2022 Credit Agreement as of December&#160;31, 2022 (Successor Period) are as follows :</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unpaid principal</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184,769&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693571510960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Supplemental Cash Flow and Other Information Related to Leases</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company&#8217;s operating leases was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:77.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022<br/>(Successor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,166&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for new operating lease liabilities:</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:77.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022<br/>(Successor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease Maturity</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliation of the undiscounted future minimal lease payments under non-cancelable operating leases to the total operating lease liability recognized on the consolidated balance sheet as of December 31, 2022 was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:77.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed Interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,865&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total reported lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,923&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments as of December 31, 2021 were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693571325616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s financial instruments that are measured at fair value on a recurring basis by level within the fair value hierarchy as of December&#160;31, 2022 (Successor Period): </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quoted Prices in Active Market</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Other Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Other Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate collar</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities - Public</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities - Private</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693567650192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL BALANCE SHEET DISCLOSURES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Change in Allowance for Doubtful Accounts</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the allowance for doubtful accounts were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:57.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.270%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">July 28 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">January 1<br/>to July 27,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for bad debts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-off of uncollectible accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">994&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,061&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">671&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventories were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Successor)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Predecessor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,138&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventory</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54,384&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,611&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">The estimated useful lives of the Company&#8217;s assets are as follows:<div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ESTIMATED&#160;USEFUL&#160;LIVES</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer hardware and software</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 - 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gondolas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lesser of useful life or term of lease</span></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Successor)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Predecessor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer hardware, software and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">752&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and fixture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internally developed software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gondolas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,928)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,328&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,198&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Successor)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Predecessor)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued salaries and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,876&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued sales returns and damages</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued marketing expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued distribution fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,914&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,123&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,683&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575263456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the period from July 28 to December&#160;31, 2022 (Successor Period) was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of<br/>Common<br/>Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>intrinsic<br/>Value (in<br/>thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of July 28, 2022 (Successor)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,452,155</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance as of December 31, 2022 (Successor)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,452,155</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable as of December 31, 2022 (Successor)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,451,538</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest as of December 31, 2022 (Successor)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,452,155</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.50&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.3</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,118&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the period from January 1 to July 27, 2022 (Predecessor Period) was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of<br/>Common Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>intrinsic<br/>Value (in<br/>thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of January 1, 2022 (Predecessor) </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">800,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,200</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of July 27, 2022 (Predecessor)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">774,800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,659&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity for the year ended December&#160;31, 2021 (Predecessor Period) was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of<br/>Common Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>intrinsic<br/>Value (in<br/>thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of January 1, 2021 (Predecessor)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">800,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2021 (Predecessor)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">800,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.10&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,456&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions, Stock Options</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock option awards was determined on the grant date using the Monte Carlo simulation model for Founder Awards and the Hull-White lattice pricing model was used for replacement awards based on the following weighted-average assumptions:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:57.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28<br/>to December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Founder Awards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Replacement Awards</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.87% - 2.92%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;2.79% - 2.80% </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7 - 9.9</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise multiple </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.77% - 44.76%</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The risk-free rate is based on U.S. Treasury securities with maturities equivalent to the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The expected term for founder awards is based on the assumption that the options are exercised after 50% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The exercise multiple is selected from the commonly used exercise multiple range of 2.0x to 2.5x assuming on average the options holders would exercise the options when the ratio of underlying stock price to the exercise price reaches 2.3x.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">For founder awards, the expected stock price volatility is the median historical volatility of Waldencast&#8217;s volatility peer group with a look-back period equal to the contractual term using daily stock prices; for replacement awards, the expected stock price volatility is estimated by adjusting the observed equity volatility for leverage.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.43pt">Waldencast has not paid any dividends historically and does not plan to declare dividends in the foreseeable future and therefore assumed a dividend yield of zero.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock option awards was determined on the grant date using the Black-Scholes valuation model based on the following weighted-average assumptions:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1<br/>to July 27, 2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended <br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock per share value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The risk-free rate is based on U.S. Treasury securities with maturities equivalent to the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The expected term is the estimated length of time the grants are expected to be outstanding before it is exercised or terminated. This number is calculated as the midpoint between the requisite service period and the contractual term of the award, as the Company does not have any historical data that would provide a reasonable basis to estimate the expected term for the option.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The expected price volatility is based on the average of the historical volatility of comparable public companies over a period consistent with the expected term.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The Predecessor historically made distributions to its shareholder but the Company does not plan to declare dividends in the foreseeable future and therefore assumed a dividend yield of zero.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity for the period from July 28 to December&#160;31, 2022 (Successor Period) was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant Date Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of July 28, 2022 (Successor)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,173,364</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(370,945)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2022 (Successor)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,802,419</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.16&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Predecessor Restricted Stock activity for the period from January 1 to July&#160;27, 2022 (Predecessor Period) was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant Date Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of January 1, 2022 (Predecessor)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">243,307</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,754</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,219</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of July 27, 2022 (Predecessor)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">234,842</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.90&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Restricted Stock activity for the year ended December&#160;31, 2021 (Predecessor Period) was as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Grant Date Fair Value<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of January 1, 2021 (Predecessor)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">243,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2021 (Predecessor)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">243,307&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.68&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693577701504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text">The following table sets forth the computation of basic and diluted net income (loss) using the treasury stock method: <div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:42.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.950%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.270%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from<br/>January 1 to <br/>July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except for share and per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(120,557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,576)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributed to Class A shareholders - basic and diluted EPS</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(95,567)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21,057)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,576)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,370)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86,460,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average diluted shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86,460,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,000,002</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.11)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.63)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.45)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.30)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents potential ordinary shares outstanding that were excluded from the computation of diluted net loss per share of common share because their effect would have been anti-dilutive:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:41.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from<br/>July 28 to December 31, <br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from<br/>January 1 to<br/>July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended <br/>December 31, <br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended <br/>December 31, <br/>2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,533,282</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,452,155</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">774,800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">800,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,802,419</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">234,842</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">243,307</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,787,856</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,009,642</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,043,307</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693579116352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX BENEFIT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Consolidated Pretax Income (Loss)</a></td>
<td class="text">The Company&#8217;s consolidated pretax income (loss) for the period from July 28 to December&#160;31, 2022 (Successor Period), the period from January 1 to July 27, 2022 (Predecessor Period), the year ended December&#160;31, <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 (Predecessor Period) and the year ended December&#160;31, 2020 (Predecessor Period) were generated by domestic and foreign operations as follows:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:41.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from<br/>July 28 to December 31, <br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1 to July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(125,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(17,676)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,079)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(126,360)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20,944)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,974)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,764)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the period from July 28 to December&#160;31, 2022 (Successor Period), the period from January 1 to July 27, 2022 (Predecessor Period), the year ended December&#160;31, 2021 (Predecessor Period) and the year ended December&#160;31, 2020 (Predecessor Period) consisted of the following:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:39.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1 to July 27, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current provision (benefit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(363)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(350)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred (income) expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,557)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,777&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,823)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,374&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,044)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income tax (benefit) provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,803)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,602&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,394)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Components of Income Tax Expense</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income tax expense related to the following:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:41.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from January 1 to July 27,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit at Bailiwick of Jersey for Successor and Income tax benefit at Cayman Islands for Predecessor statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S./foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State income tax benefit, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Permanent Items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(141.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction bonuses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PPP Loan forgiveness  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">True-Ups</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax (benefit) expense </span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(96.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of Deferred Tax Assets and Deferred Tax Liabilities</a></td>
<td class="text">The tax effects of temporary differences that give rise to portions of the deferred tax assets and deferred tax liabilities as of December&#160;31, 2022 (Successor Period) and December&#160;31, 2021 (Predecessor Period) are presented below:<div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:70.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest to foreign related parties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,660&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Formation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other temporary differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-deductible interest carryover</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below market contract</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in Waldencast LP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">34,580</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16,532</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,794)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed asset basis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,025)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(46,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(48,886)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3,020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net deferred tax (liabilities) assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14,306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13,512</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,944)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,060)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(22,250)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(548)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock', window );">Summary of Net Operating Losses and Tax Credit Carryforwards</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses and tax credit carryforwards as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Successor Period) and  December&#160;31, 2021 (Predecessor Period) were as follows:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:49.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.805%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.805%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.585%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(As Restated)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Predecessor</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expiration Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expiration Year</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, federal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating losses, state</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2039-2042</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2039-2041</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax Credits, federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2038-2039</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2038-2039</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax Credits, state</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Do Not Expire</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Operating Loss Carryforwards and Tax Credit Carryforwards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693577198848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Reconciliation of Financial Measures of Segments to Consolidated Totals</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of financial measures of the Company&#8217;s segments to the consolidated totals:</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:56.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022<br/>(Successor):</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obagi Skincare</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milk Makeup</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Segment Gross Profit to Net Income (Loss) Before Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles segment gross profit to net income (loss) before income taxes for the period from July 28 to December&#160;31, 2022 (Successor Period):</span></div><div style="margin-top:12pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"><tr><td style="width:1.0%"></td><td style="width:85.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from<br/>July 28 to December 31, <br/>2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Successor</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on impairment of goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,793)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(798)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(126,360)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(120,557)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575312480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Condensed Balance Sheet</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following condensed financial statements have been presented on a &#8220;parent-only&#8221; basis. Under a parent-only presentation, Waldencast plc&#8217;s investment in its subsidiaries is presented under the equity method of accounting. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC<br/>(PARENT COMPANY ONLY)<br/>CONDENSED BALANCE SHEET</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CURRENT ASSETS:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,215&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in subsidiary</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">823,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL ASSETS</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">827,151&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CURRENT LIABILITIES:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intercompany payables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative warrant liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL LIABILITIES</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,253&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SHAREHOLDERS&#8217; EQUITY:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successor Class A ordinary shares, $0.0001 par value, 1,000,000,000 shares authorized; and 86,460,560 outstanding as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successor Class B ordinary shares, $0.0001 par value, 1,000,000,000 shares authorized; and 21,104,225 outstanding as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">796,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(156,780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL CONTROLLING SHAREHOLDERS&#8217; EQUITY</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">639,239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL SHAREHOLDERS&#8217; EQUITY</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">799,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">827,151&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock', window );">Condensed Statement of Operations</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC<br/>(PARENT COMPANY ONLY)<br/>CONDENSED STATEMENT OF OPERATIONS </span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars, except share and per share data)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the period from July 28 to December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before equity in undistributed earnings of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity in undistributed earnings of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(102,379)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(95,567)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(95,596)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock', window );">Condensed Statement of Cash Flow</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:85.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WALDENCAST PLC<br/>(PARENT COMPANY ONLY)<br/>CONDENSED STATEMENT OF CASH FLOW </span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands of U.S. dollars)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period from July 28 to December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(95,567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity in income of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivative warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,793)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from trust</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfers from subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfers to subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses paid on behalf of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,982)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3,282)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,137</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH - Beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH - end of period</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3,215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedCashFlowStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedIncomeStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693578896352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 18, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList', window );">Financial Designation, Predecessor and Successor [Fixed List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Successor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of units issued in IPO (in shares)</a></td>
<td class="nump">34,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per unit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,460,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares | Class A Ordinary Shares | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_StockholdersEquityNumberOfSharesInEachUnit', window );">Number of shares in each IPO unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_StockholdersEquityNumberOfSharesInEachUnit', window );">Number of shares in each IPO unit</a></td>
<td class="nump">0.3333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates designation of financial information when substantially all business or separately identifiable line of business transfers from one entity to another entity. Acceptable values are "Predecessor" and "Successor".</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 27<br> -SubTopic 10<br> -Topic 852<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481435/852-10-45-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:financialDesignationType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_StockholdersEquityNumberOfSharesInEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity, Number Of Shares In Each Unit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_StockholdersEquityNumberOfSharesInEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693566479072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTATEMENT AND RECLASSIFICATIONS - Summary of Net Revenue Restatement Adjustments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue adjustments</a></td>
<td class="nump">$ 92,373<span></span>
</td>
<td class="nump">$ 73,760<span></span>
</td>
<td class="nump">$ 142,472<span></span>
</td>
<td class="nump">$ 94,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SG&amp;A expenses</a></td>
<td class="num">(88,926)<span></span>
</td>
<td class="num">(55,549)<span></span>
</td>
<td class="num">(82,968)<span></span>
</td>
<td class="num">(60,421)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D expenses</a></td>
<td class="num">(1,796)<span></span>
</td>
<td class="num">(2,606)<span></span>
</td>
<td class="num">(6,092)<span></span>
</td>
<td class="num">(4,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,738)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">60,657<span></span>
</td>
<td class="nump">30,868<span></span>
</td>
<td class="nump">55,037<span></span>
</td>
<td class="nump">29,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">54,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">26,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=wald_PhysicianChannelProviderMember', window );">Physician Channel Provider</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue adjustments</a></td>
<td class="nump">$ 26,300<span></span>
</td>
<td class="nump">$ 32,200<span></span>
</td>
<td class="nump">$ 58,800<span></span>
</td>
<td class="nump">$ 51,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=wald_USOnlineMarketplaceDistributorMember', window );">US Online Marketplace Distributor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_MinimumThresholdPeriodForContractRepaymentOverTime', window );">Threshold repayment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">365 days<span></span>
</td>
<td class="text">365 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (63,597)<span></span>
</td>
<td class="nump">$ 10,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SG&amp;A expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,523<span></span>
</td>
<td class="nump">3,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">899<span></span>
</td>
<td class="num">(454)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
<td class="nump">4,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfDistributorServiceFeesMember', window );">Misstatement of Distributor Service Fees | Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SG&amp;A expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,075<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfDistributorServiceFeesMember', window );">Misstatement of Distributor Service Fees | Restatement Adjustments | Distributor fees for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,146)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SG&amp;A expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingMember', window );">Misstatement of Revenue Recognition Timing | Restatement Adjustments | SA Distributor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,220)<span></span>
</td>
<td class="nump">1,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember', window );">Misstatement of Revenue Recognition Timing and Payments Recorded for Services | Restatement Adjustments | Physician Channel Provider</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,191)<span></span>
</td>
<td class="nump">8,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SG&amp;A expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,065<span></span>
</td>
<td class="nump">4,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="nump">2,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember', window );">Misstatement of Revenue, Nonstandard Payment Terms | Restatement Adjustments | US Online Marketplace Distributor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,773)<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_OtherMisstatementAdjustmentsMember', window );">Other adjustments | Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(267)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SG&amp;A expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">974<span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,882<span></span>
</td>
<td class="nump">$ 1,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_MinimumThresholdPeriodForContractRepaymentOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Threshold Period for Contract Repayment Over Time</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_MinimumThresholdPeriodForContractRepaymentOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=wald_PhysicianChannelProviderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=wald_PhysicianChannelProviderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=wald_USOnlineMarketplaceDistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=wald_USOnlineMarketplaceDistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfDistributorServiceFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfDistributorServiceFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=wald_SADistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=wald_SADistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_OtherMisstatementAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_OtherMisstatementAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693579106080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTATEMENT AND RECLASSIFICATIONS - Summary of Cost of Goods Sold Restatement Adjustments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total net cost of goods sold adjustments</a></td>
<td class="nump">$ 60,657<span></span>
</td>
<td class="nump">$ 30,868<span></span>
</td>
<td class="nump">$ 55,037<span></span>
</td>
<td class="nump">$ 29,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total net cost of goods sold adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
<td class="nump">4,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Restatement Adjustments | Inventory obsolescence provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total net cost of goods sold adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(583)<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Restatement Adjustments | Other adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total net cost of goods sold adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,882<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Restatement Adjustments | Physician Channel Provider | Misstatement of Revenue Recognition Timing and Payments Recorded for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total net cost of goods sold adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 374<span></span>
</td>
<td class="nump">$ 2,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfInventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfInventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_OtherMisstatementAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_OtherMisstatementAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=wald_PhysicianChannelProviderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=wald_PhysicianChannelProviderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693568007376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTATEMENT AND RECLASSIFICATIONS - Summary of SG&amp;A Expenses Restatement Adjustments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Total SG&amp;A adjustments</a></td>
<td class="nump">$ 88,926<span></span>
</td>
<td class="nump">$ 55,549<span></span>
</td>
<td class="nump">$ 82,968<span></span>
</td>
<td class="nump">$ 60,421<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Total SG&amp;A adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,523)<span></span>
</td>
<td class="num">(3,138)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Restatement Adjustments | Misstatement of Distributor Service Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Total SG&amp;A adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,075)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Restatement Adjustments | Misstatement of Revenue Recognition Timing and Payments Recorded for Services | Physician Channel Provider</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Total SG&amp;A adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,065)<span></span>
</td>
<td class="num">(4,891)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Restatement Adjustments | Misstatement of Capitalized Computer Software Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Total SG&amp;A adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Restatement Adjustments | Misstatement of Capitalized Marketing and Advertising Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Total SG&amp;A adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(732)<span></span>
</td>
<td class="nump">1,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Restatement Adjustments | Other adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Total SG&amp;A adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (974)<span></span>
</td>
<td class="num">$ (546)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfDistributorServiceFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfDistributorServiceFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=wald_PhysicianChannelProviderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=wald_PhysicianChannelProviderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_OtherMisstatementAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_OtherMisstatementAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693567417920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTATEMENT AND RECLASSIFICATIONS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 27, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>distributor</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>distributor</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors', window );">Number of distributors | distributor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D expense adjustments</a></td>
<td class="nump">$ 1,796<span></span>
</td>
<td class="nump">$ 2,606<span></span>
</td>
<td class="nump">$ 6,092<span></span>
</td>
<td class="nump">$ 4,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses adjustments</a></td>
<td class="num">(6,273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,965)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net adjustments</a></td>
<td class="num">(8,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,198)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets adjustments</a></td>
<td class="num">(535)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">26,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense adjustment</a></td>
<td class="nump">5,803<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="num">(9,602)<span></span>
</td>
<td class="nump">3,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Increase in accumulated deficit</a></td>
<td class="num">(799,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,239)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 120,557<span></span>
</td>
<td class="nump">21,057<span></span>
</td>
<td class="nump">19,576<span></span>
</td>
<td class="nump">2,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=wald_ObagiCosmeceuticalsLLCMember', window );">Obagi Cosmeceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Increase in accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,906)<span></span>
</td>
<td class="num">(39,239)<span></span>
</td>
<td class="num">(60,847)<span></span>
</td>
<td class="num">$ (61,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,057<span></span>
</td>
<td class="nump">19,576<span></span>
</td>
<td class="nump">2,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D expense adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(899)<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,699<span></span>
</td>
<td class="num">(1,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Increase in accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,506<span></span>
</td>
<td class="num">(6,801)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Restatement Adjustments | Obagi Cosmeceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Increase in accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember', window );">Misstatement of Capitalized Research and Development Expenses | Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">R&amp;D expense adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfCapitalizedMarketingExpensesMember', window );">Misstatement of Capitalized Marketing Expenses | Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfResearchAndDevelopmentExpenseMember', window );">Misstatement Of Research And Development Expense | Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember', window );">Misstatement of Capitalized Internal Use Software Costs | Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_OtherMisstatementAdjustmentsMember', window );">Other adjustments | Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember', window );">Misstatement of Revenue, Nonstandard Payment Terms | Restatement Adjustments | US Online Marketplace Distributor and SA Distributor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember', window );">Misstatement of Employee Related Compensation Matters and Other Expenses | Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfAccruedDistributionServiceFeesMember', window );">Misstatement of Accrued Distribution Service Fees | Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember', window );">Misstatement of Income Tax Expense and Related Liabilities | Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="num">$ (1,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Misstatement Adjustments, Revenue Recognition, Number of Distributors</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=wald_ObagiCosmeceuticalsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=wald_ObagiCosmeceuticalsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfCapitalizedMarketingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfCapitalizedMarketingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_OtherMisstatementAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_OtherMisstatementAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=wald_USOnlineMarketplaceDistributorAndSADistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=wald_USOnlineMarketplaceDistributorAndSADistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfAccruedDistributionServiceFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfAccruedDistributionServiceFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693570124560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTATEMENT AND RECLASSIFICATIONS - Summary of Accounts Receivable, Net Restatement Adjustments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable, net adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainLossOnNoteReceivableWriteoff', window );">Loss on write-off of loan receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,555<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable, net adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainLossOnNoteReceivableWriteoff', window );">Loss on write-off of loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingMember', window );">Misstatement of Revenue Recognition Timing | Restatement Adjustments | SA Distributor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable, net adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,821)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember', window );">Misstatement of Revenue Recognition Timing and Payments Recorded for Services | Restatement Adjustments | Physician Channel Provider</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable, net adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,796)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember', window );">Misstatement of Loss On Forgiveness of Uncollectible Loan Receivable | Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable, net adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainLossOnNoteReceivableWriteoff', window );">Loss on write-off of loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_OtherMisstatementAdjustmentsMember', window );">Other adjustments | Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable, net adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,512)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_GainLossOnNoteReceivableWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Note Receivable Writeoff</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_GainLossOnNoteReceivableWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=wald_SADistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=wald_SADistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=wald_PhysicianChannelProviderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=wald_PhysicianChannelProviderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_OtherMisstatementAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_OtherMisstatementAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693574631712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RESTATEMENT AND RECLASSIFICATIONS - Summary of Inventory Restatement Adjustments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total net inventory adjustments</a></td>
<td class="nump">$ 54,384<span></span>
</td>
<td class="nump">$ 21,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total net inventory adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember', window );">Misstatement of Revenue Recognition Timing and Payments Recorded for Services | Restatement Adjustments | Physician Channel Provider</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total net inventory adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfInventoryMember', window );">Inventory obsolescence provision | Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total net inventory adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_OtherMisstatementAdjustmentsMember', window );">Other adjustments | Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total net inventory adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=wald_PhysicianChannelProviderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=wald_PhysicianChannelProviderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfInventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_MisstatementOfInventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_OtherMisstatementAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=wald_OtherMisstatementAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693568000208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTATEMENT AND RECLASSIFICATIONS - Summary of Reclassification Adjustments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationLineItems', window );"><strong>Reclassification [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">$ 7,700<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="nump">$ 13,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Reclassification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationLineItems', window );"><strong>Reclassification [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,656<span></span>
</td>
<td class="nump">$ 4,656<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693566224176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RESTATEMENT AND RECLASSIFICATIONS - Consolidated Balance Sheets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,693<span></span>
</td>
<td class="nump">$ 12,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,738)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">54,384<span></span>
</td>
<td class="nump">21,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">6,273<span></span>
</td>
<td class="nump">4,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">91,043<span></span>
</td>
<td class="nump">59,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,328<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">639,165<span></span>
</td>
<td class="nump">79,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">334,620<span></span>
</td>
<td class="nump">44,489<span></span>
</td>
<td class="nump">$ 44,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">1,090,075<span></span>
</td>
<td class="nump">184,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">20,095<span></span>
</td>
<td class="nump">15,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">26,123<span></span>
</td>
<td class="nump">12,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">72,505<span></span>
</td>
<td class="nump">40,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">159,229<span></span>
</td>
<td class="nump">103,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="nump">22,250<span></span>
</td>
<td class="nump">548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">290,177<span></span>
</td>
<td class="nump">145,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Predecessor common shares, 25,000,000 shares authorized; $0.50 par value, 8,000,002 shares issued and outstanding as of December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">796,038<span></span>
</td>
<td class="nump">100,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(156,780)<span></span>
</td>
<td class="num">(64,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="nump">799,898<span></span>
</td>
<td class="nump">39,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">$ 1,090,075<span></span>
</td>
<td class="nump">184,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Predecessor common shares, 25,000,000 shares authorized; $0.50 par value, 8,000,002 shares issued and outstanding as of December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,979)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,392)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,386)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Predecessor common shares, 25,000,000 shares authorized; $0.50 par value, 8,000,002 shares issued and outstanding as of December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,051)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,051)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (48,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693577756976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RESTATEMENT AND RECLASSIFICATIONS - Consolidated Balance Sheets (Parenthetical) (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized (in shares)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued (in shares)</a></td>
<td class="nump">8,000,002<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares)</a></td>
<td class="nump">8,000,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693563513824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTATEMENT AND RECLASSIFICATIONS - Consolidated Statements of Operations and Comprehensive (Loss) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 92,373<span></span>
</td>
<td class="nump">$ 73,760<span></span>
</td>
<td class="nump">$ 142,472<span></span>
</td>
<td class="nump">$ 94,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">60,657<span></span>
</td>
<td class="nump">30,868<span></span>
</td>
<td class="nump">55,037<span></span>
</td>
<td class="nump">29,096<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">31,716<span></span>
</td>
<td class="nump">42,892<span></span>
</td>
<td class="nump">87,435<span></span>
</td>
<td class="nump">65,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">88,926<span></span>
</td>
<td class="nump">55,549<span></span>
</td>
<td class="nump">82,968<span></span>
</td>
<td class="nump">60,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,796<span></span>
</td>
<td class="nump">2,606<span></span>
</td>
<td class="nump">6,092<span></span>
</td>
<td class="nump">4,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">159,437<span></span>
</td>
<td class="nump">58,155<span></span>
</td>
<td class="nump">89,060<span></span>
</td>
<td class="nump">64,804<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (loss) income</a></td>
<td class="num">(127,721)<span></span>
</td>
<td class="num">(15,263)<span></span>
</td>
<td class="num">(1,625)<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">6,230<span></span>
</td>
<td class="nump">6,652<span></span>
</td>
<td class="nump">11,118<span></span>
</td>
<td class="nump">6,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,317<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainOnPPPLoanForgiveness', window );">Gain on PPP Loan forgiveness</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,824)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainLossOnNoteReceivableWriteoff', window );">Loss on write-off of loan receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,555<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(798)<span></span>
</td>
<td class="num">(971)<span></span>
</td>
<td class="num">(817)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (income) expenses, net</a></td>
<td class="num">(1,361)<span></span>
</td>
<td class="nump">5,681<span></span>
</td>
<td class="nump">8,349<span></span>
</td>
<td class="nump">6,292<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(126,360)<span></span>
</td>
<td class="num">(20,944)<span></span>
</td>
<td class="num">(9,974)<span></span>
</td>
<td class="num">(5,764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(5,803)<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">9,602<span></span>
</td>
<td class="num">(3,394)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (120,557)<span></span>
</td>
<td class="num">$ (21,057)<span></span>
</td>
<td class="num">$ (19,576)<span></span>
</td>
<td class="num">$ (2,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (2.63)<span></span>
</td>
<td class="num">$ (2.45)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (2.63)<span></span>
</td>
<td class="num">$ (2.45)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Shares used in computing net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">86,460,560<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">86,460,560<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</a></td>
<td class="num">$ (36)<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="num">$ (32)<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (120,593)<span></span>
</td>
<td class="num">(20,961)<span></span>
</td>
<td class="num">(19,608)<span></span>
</td>
<td class="num">(2,354)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=wald_ObagiCosmeceuticalsLLCMember', window );">Obagi Cosmeceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,057)<span></span>
</td>
<td class="num">(19,576)<span></span>
</td>
<td class="num">(2,370)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Shares used in computing net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,069<span></span>
</td>
<td class="nump">84,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,243<span></span>
</td>
<td class="nump">54,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,991<span></span>
</td>
<td class="nump">3,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,053<span></span>
</td>
<td class="nump">13,426<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_OperatingExpensesAndCostOfGoodSold', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,995<span></span>
</td>
<td class="nump">92,118<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,074<span></span>
</td>
<td class="num">(7,973)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,156<span></span>
</td>
<td class="nump">6,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainOnPPPLoanForgiveness', window );">Gain on PPP Loan forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,824)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainLossOnNoteReceivableWriteoff', window );">Loss on write-off of loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (income) expenses, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,843<span></span>
</td>
<td class="nump">6,292<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,231<span></span>
</td>
<td class="num">(14,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,301<span></span>
</td>
<td class="num">(5,094)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
<td class="num">$ (9,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Shares used in computing net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (32)<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="num">(9,155)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Reported | Obagi Cosmeceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,708<span></span>
</td>
<td class="nump">19,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Reclassification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,364<span></span>
</td>
<td class="nump">24,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,248<span></span>
</td>
<td class="nump">8,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,904)<span></span>
</td>
<td class="num">(13,421)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_OperatingExpensesAndCostOfGoodSold', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,364)<span></span>
</td>
<td class="num">(24,625)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainOnPPPLoanForgiveness', window );">Gain on PPP Loan forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainLossOnNoteReceivableWriteoff', window );">Loss on write-off of loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (income) expenses, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Shares used in computing net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Reclassification | Obagi Cosmeceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,708)<span></span>
</td>
<td class="num">(19,969)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63,597)<span></span>
</td>
<td class="nump">10,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
<td class="nump">4,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,523)<span></span>
</td>
<td class="num">(3,138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(899)<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,571)<span></span>
</td>
<td class="num">(2,689)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (loss) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,699)<span></span>
</td>
<td class="nump">8,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainOnPPPLoanForgiveness', window );">Gain on PPP Loan forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainLossOnNoteReceivableWriteoff', window );">Loss on write-off of loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,011)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (income) expenses, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,506<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,205)<span></span>
</td>
<td class="nump">8,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,699)<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19,506)<span></span>
</td>
<td class="nump">$ 6,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.44)<span></span>
</td>
<td class="nump">$ 0.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.44)<span></span>
</td>
<td class="nump">$ 0.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Shares used in computing net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19,506)<span></span>
</td>
<td class="nump">$ 6,801<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_GainLossOnNoteReceivableWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Note Receivable Writeoff</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_GainLossOnNoteReceivableWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_GainOnPPPLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on PPP Loan Forgiveness</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_GainOnPPPLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_OperatingExpensesAndCostOfGoodSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Expenses and Cost of Good Sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_OperatingExpensesAndCostOfGoodSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=wald_ObagiCosmeceuticalsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=wald_ObagiCosmeceuticalsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693568512320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTATEMENT AND RECLASSIFICATIONS - Consolidated Statement of Cash Flows (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (120,557)<span></span>
</td>
<td class="num">$ (21,057)<span></span>
</td>
<td class="num">$ (19,576)<span></span>
</td>
<td class="num">$ (2,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_DepreciationDepletionAndAmortizationOperatingActivities', window );">Depreciation and amortization</a></td>
<td class="nump">26,982<span></span>
</td>
<td class="nump">8,190<span></span>
</td>
<td class="nump">13,904<span></span>
</td>
<td class="nump">13,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,317<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainOnPPPLoanForgiveness', window );">Gain on PPP Loan forgiveness</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,824)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">677<span></span>
</td>
<td class="nump">767<span></span>
</td>
<td class="nump">1,139<span></span>
</td>
<td class="nump">798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(5,823)<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">9,374<span></span>
</td>
<td class="num">(3,044)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of equipment</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainLossOnNoteReceivableWriteoff', window );">Loss on write-off of loan receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,555<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(204)<span></span>
</td>
<td class="nump">3,524<span></span>
</td>
<td class="num">(5,057)<span></span>
</td>
<td class="num">(16,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">6,382<span></span>
</td>
<td class="num">(13,008)<span></span>
</td>
<td class="num">(6,010)<span></span>
</td>
<td class="nump">4,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(213)<span></span>
</td>
<td class="nump">658<span></span>
</td>
<td class="num">(1,097)<span></span>
</td>
<td class="num">(1,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other assets</a></td>
<td class="num">(250)<span></span>
</td>
<td class="num">(352)<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="nump">1,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties', window );">Accounts payable</a></td>
<td class="num">(1,021)<span></span>
</td>
<td class="nump">9,635<span></span>
</td>
<td class="nump">9,647<span></span>
</td>
<td class="num">(7,391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current liabilities and other liabilities</a></td>
<td class="num">(39,336)<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
<td class="nump">2,493<span></span>
</td>
<td class="nump">4,135<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(74,977)<span></span>
</td>
<td class="num">(10,037)<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
<td class="num">(7,431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Capital expenditure on intangible assets</a></td>
<td class="num">(247)<span></span>
</td>
<td class="num">(248)<span></span>
</td>
<td class="num">(863)<span></span>
</td>
<td class="num">(653)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditure on property and equipment</a></td>
<td class="num">(1,340)<span></span>
</td>
<td class="num">(661)<span></span>
</td>
<td class="num">(424)<span></span>
</td>
<td class="num">(1,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_AdvancesForNoteReceivable', window );">Advances for note receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(544,367)<span></span>
</td>
<td class="num">(909)<span></span>
</td>
<td class="num">(3,787)<span></span>
</td>
<td class="num">(1,707)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="nump">629,465<span></span>
</td>
<td class="nump">3,883<span></span>
</td>
<td class="nump">5,162<span></span>
</td>
<td class="nump">14,319<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="nump">10,121<span></span>
</td>
<td class="num">(7,063)<span></span>
</td>
<td class="nump">4,904<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash and cash equivalents</a></td>
<td class="num">(36)<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;Beginning of period</a></td>
<td class="nump">6,477<span></span>
</td>
<td class="nump">13,444<span></span>
</td>
<td class="nump">8,572<span></span>
</td>
<td class="nump">3,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;End of period</a></td>
<td class="nump">10,163<span></span>
</td>
<td class="nump">6,477<span></span>
</td>
<td class="nump">13,444<span></span>
</td>
<td class="nump">8,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW DATA &#8211; CASH PAID:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">5,550<span></span>
</td>
<td class="nump">5,053<span></span>
</td>
<td class="nump">10,014<span></span>
</td>
<td class="nump">5,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures in accounts payable and accruals</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_CapitalContribution', window );">Capital contribution of trademarks</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(9,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_DepreciationDepletionAndAmortizationOperatingActivities', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,053<span></span>
</td>
<td class="nump">13,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainOnPPPLoanForgiveness', window );">Gain on PPP Loan forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,824)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,073<span></span>
</td>
<td class="num">(4,743)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainLossOnNoteReceivableWriteoff', window );">Loss on write-off of loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,790)<span></span>
</td>
<td class="num">(961)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,359)<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,654)<span></span>
</td>
<td class="num">(2,150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,323<span></span>
</td>
<td class="num">(998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,495<span></span>
</td>
<td class="num">(7,523)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current liabilities and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,275<span></span>
</td>
<td class="nump">2,478<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,070<span></span>
</td>
<td class="num">(7,251)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Capital expenditure on intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(937)<span></span>
</td>
<td class="num">(652)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditure on property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,923)<span></span>
</td>
<td class="num">(1,235)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_AdvancesForNoteReceivable', window );">Advances for note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,360)<span></span>
</td>
<td class="num">(1,887)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,162<span></span>
</td>
<td class="nump">14,319<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,872<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;Beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,444<span></span>
</td>
<td class="nump">8,572<span></span>
</td>
<td class="nump">3,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;End of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,444<span></span>
</td>
<td class="nump">8,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW DATA &#8211; CASH PAID:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,014<span></span>
</td>
<td class="nump">5,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures in accounts payable and accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_CapitalContribution', window );">Capital contribution of trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">Restatement Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,506)<span></span>
</td>
<td class="nump">6,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_DepreciationDepletionAndAmortizationOperatingActivities', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainOnPPPLoanForgiveness', window );">Gain on PPP Loan forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,699)<span></span>
</td>
<td class="nump">1,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_GainLossOnNoteReceivableWriteoff', window );">Loss on write-off of loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,733<span></span>
</td>
<td class="num">(15,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(651)<span></span>
</td>
<td class="nump">2,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,557<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,711)<span></span>
</td>
<td class="nump">2,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current liabilities and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,782)<span></span>
</td>
<td class="nump">1,657<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,541)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Capital expenditure on intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditure on property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_AdvancesForNoteReceivable', window );">Advances for note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,573<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rates on cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;Beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;End of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW DATA &#8211; CASH PAID:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures in accounts payable and accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
<td class="num">(186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_CapitalContribution', window );">Capital contribution of trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_AdvancesForNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advances For Note Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_AdvancesForNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_CapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_CapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_DepreciationDepletionAndAmortizationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation, Depletion and Amortization, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_DepreciationDepletionAndAmortizationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_GainLossOnNoteReceivableWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Note Receivable Writeoff</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_GainLossOnNoteReceivableWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_GainOnPPPLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on PPP Loan Forgiveness</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_GainOnPPPLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Accounts Payable, Excluding Related Parties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693565939104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jul. 27, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th">
<div>Jul. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 15, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 10,163<span></span>
</td>
<td class="nump">$ 6,477<span></span>
</td>
<td class="nump">$ 10,163<span></span>
</td>
<td class="nump">$ 13,444<span></span>
</td>
<td class="nump">$ 8,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">8,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,693<span></span>
</td>
<td class="nump">12,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum', window );">Period after which production costs will be expensed for advertising that has not yet occurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShippingAndHandlingCosts', window );">Shipping and handling costs</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">11,700<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">7,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,944<span></span>
</td>
<td class="nump">14,060<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, accrued interest and penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use asset</a></td>
<td class="nump">$ 16,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,384<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 19,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_CustomerPaymentPeriod', window );">Customer payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_CustomerPaymentPeriod', window );">Customer payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Internal-Use Software and Website Development Costs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=wald_MilkMember', window );">Milk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=wald_FounderAwardsMember', window );">Founder Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent', window );">Percent of award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=wald_InventoryPurchasesMember', window );">Inventory Purchases | Supplier Concentration Risk | Vendor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=wald_InventoryPurchasesMember', window );">Inventory Purchases | Supplier Concentration Risk | Vendor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=wald_InventoryPurchasesMember', window );">Inventory Purchases | Supplier Concentration Risk | Vendor Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable | Lender Concentration Risk | Vendor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable | Lender Concentration Risk | Vendor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=wald_CustomerOneMember', window );">Customer One | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=wald_CustomerTwoMember', window );">Customer Two | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=wald_CustomerThreeMember', window );">Customer Three | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_CustomerPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Customer Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_CustomerPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognition Period for Deferred Advertising Costs, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShippingAndHandlingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shipping And Handling Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShippingAndHandlingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=wald_MilkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=wald_MilkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=wald_FounderAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=wald_FounderAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=wald_InventoryPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=wald_InventoryPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=wald_VendorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=wald_VendorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=wald_VendorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=wald_VendorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=wald_VendorThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=wald_VendorThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_LenderConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_LenderConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=wald_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=wald_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=wald_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=wald_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=wald_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=wald_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693579974288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=wald_ComputerHardwareSoftwareAndEquipmentMember', window );">Computer hardware and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">ESTIMATED&#160;USEFUL&#160;LIVES</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixture | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">ESTIMATED&#160;USEFUL&#160;LIVES</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixture | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">ESTIMATED&#160;USEFUL&#160;LIVES</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">ESTIMATED&#160;USEFUL&#160;LIVES</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">ESTIMATED&#160;USEFUL&#160;LIVES</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=wald_GondolasMember', window );">Gondolas</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">ESTIMATED&#160;USEFUL&#160;LIVES</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=wald_ComputerHardwareSoftwareAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=wald_ComputerHardwareSoftwareAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=wald_GondolasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=wald_GondolasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693567751136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATIONS - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 28, 2022 </div>
<div>USD ($) </div>
<div>director </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 27, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_CommonStockConvertibleConversionRatio', window );">Stock conversion ratio (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pre-tax losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,360<span></span>
</td>
<td class="nump">$ 20,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,974<span></span>
</td>
<td class="nump">$ 5,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Loss on impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,715<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 68,715<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,373<span></span>
</td>
<td class="nump">73,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,472<span></span>
</td>
<td class="nump">94,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,123<span></span>
</td>
<td class="nump">12,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,657<span></span>
</td>
<td class="nump">30,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,037<span></span>
</td>
<td class="nump">29,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=wald_ObagiChinaBusinessMember', window );">Obagi China Business | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Pre-tax losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_CommonStockConvertibleConversionRatio', window );">Stock conversion ratio (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=wald_WaldencastPlcMember', window );">Waldencast plc | Class A Ordinary Shares | Obagi China Business | Related Party | Cedarwalk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership interest in fully diluted Class A ordinary shares (percent)</a></td>
<td class="nump">24.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=wald_ObagiAndMilkBusinessCombinationsMember', window );">Obagi and Milk Business Combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=wald_ObagiAndMilkBusinessCombinationsMember', window );">Obagi and Milk Business Combinations | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Related party liability from merger</a></td>
<td class="nump">$ 22,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=wald_ObagiMergerMember', window );">Obagi Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares exchanged</a></td>
<td class="nump">$ 345,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_NumberOfNominatedDirectors', window );">Number of nominated directors | director</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=wald_ObagiMergerMember', window );">Obagi Merger | Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares exchanged (in shares) | shares</a></td>
<td class="nump">28,237,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=wald_MilkTransactionMember', window );">Milk Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares exchanged</a></td>
<td class="nump">$ 121,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_NumberOfNominatedDirectors', window );">Number of nominated directors | director</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=wald_MilkTransactionMember', window );">Milk Transaction | Limited Partnership Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares exchanged (in shares) | shares</a></td>
<td class="nump">21,104,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=wald_MilkTransactionMember', window );">Milk Transaction | Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares exchanged (in shares) | shares</a></td>
<td class="nump">21,104,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember', window );">Obagi Skincare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Loss on impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,090<span></span>
</td>
<td class="nump">$ 73,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember', window );">Obagi Skincare | Obagi and Milk Business Combinations | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Related party liability from merger</a></td>
<td class="nump">$ 22,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_CommonStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Convertible, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_CommonStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_NumberOfNominatedDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Nominated Directors</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_NumberOfNominatedDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=wald_ObagiChinaBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=wald_ObagiChinaBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=wald_WaldencastPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=wald_WaldencastPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=wald_CedarwalkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=wald_CedarwalkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=wald_ObagiAndMilkBusinessCombinationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=wald_ObagiAndMilkBusinessCombinationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=wald_ObagiMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=wald_ObagiMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=wald_MilkTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=wald_MilkTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=wald_LimitedPartnershipUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=wald_LimitedPartnershipUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693565507536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BUSINESS COMBINATIONS - Summary of Purchase Price Allocation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 334,620<span></span>
</td>
<td class="nump">$ 44,489<span></span>
</td>
<td class="nump">$ 44,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=wald_ObagiAndMilkBusinessCombinationsMember', window );">Obagi and Milk Business Combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Total Purchase Price:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="nump">$ 467,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Equity consideration</a></td>
<td class="nump">477,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt', window );">Cash repayment of debt</a></td>
<td class="nump">140,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase consideration</a></td>
<td class="nump">1,107,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Fair value of assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">17,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash', window );">Restricted cash</a></td>
<td class="nump">1,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Account receivable, net</a></td>
<td class="nump">19,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty', window );">Related party receivable</a></td>
<td class="nump">526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="nump">61,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses</a></td>
<td class="nump">4,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">9,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">662,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="nump">13,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total identifiable assets acquired</a></td>
<td class="nump">791,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">25,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other current liabilities</a></td>
<td class="nump">18,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Lease liabilities</a></td>
<td class="nump">16,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="nump">28,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed:</a></td>
<td class="nump">88,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">703,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase consideration</a></td>
<td class="nump">1,107,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">403,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=wald_ObagiAndMilkBusinessCombinationsMember', window );">Obagi and Milk Business Combinations | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Total Purchase Price:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Related party liability</a></td>
<td class="nump">22,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember', window );">Obagi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,548<span></span>
</td>
<td class="nump">44,489<span></span>
</td>
<td class="nump">44,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember', window );">Obagi | Obagi and Milk Business Combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Total Purchase Price:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="nump">345,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Equity consideration</a></td>
<td class="nump">277,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt', window );">Cash repayment of debt</a></td>
<td class="nump">136,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase consideration</a></td>
<td class="nump">781,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Fair value of assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">15,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash', window );">Restricted cash</a></td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Account receivable, net</a></td>
<td class="nump">15,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty', window );">Related party receivable</a></td>
<td class="nump">327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="nump">31,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses</a></td>
<td class="nump">4,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">1,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">505,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="nump">4,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total identifiable assets acquired</a></td>
<td class="nump">579,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">18,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other current liabilities</a></td>
<td class="nump">12,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Lease liabilities</a></td>
<td class="nump">6,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="nump">28,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed:</a></td>
<td class="nump">66,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">513,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase consideration</a></td>
<td class="nump">781,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">268,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember', window );">Obagi | Obagi and Milk Business Combinations | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Total Purchase Price:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Related party liability</a></td>
<td class="nump">22,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember', window );">Milk&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,072<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember', window );">Milk&#160; | Obagi and Milk Business Combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Total Purchase Price:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash consideration</a></td>
<td class="nump">121,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Equity consideration</a></td>
<td class="nump">200,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt', window );">Cash repayment of debt</a></td>
<td class="nump">3,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase consideration</a></td>
<td class="nump">325,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Fair value of assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">2,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash', window );">Restricted cash</a></td>
<td class="nump">819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Account receivable, net</a></td>
<td class="nump">3,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty', window );">Related party receivable</a></td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="nump">30,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses</a></td>
<td class="nump">520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">8,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">157,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="nump">8,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total identifiable assets acquired</a></td>
<td class="nump">212,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">6,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other current liabilities</a></td>
<td class="nump">5,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Lease liabilities</a></td>
<td class="nump">10,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed:</a></td>
<td class="nump">22,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">190,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase consideration</a></td>
<td class="nump">325,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">135,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember', window );">Milk&#160; | Obagi and Milk Business Combinations | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Total Purchase Price:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Related party liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease obligation assumed in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Cash Repayments of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables, Related Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Leases, Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=wald_ObagiAndMilkBusinessCombinationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=wald_ObagiAndMilkBusinessCombinationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693577004672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BUSINESS COMBINATIONS - Schedule of Intangible Assets Acquired in Business Combination (Details) - Obagi and Milk Business Combinations<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jul. 28, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total Intangible Assets</a></td>
<td class="nump">$ 662,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember', window );">Obagi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total Intangible Assets</a></td>
<td class="nump">505,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember', window );">Milk&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total Intangible Assets</a></td>
<td class="nump">157,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Name</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total Intangible Assets</a></td>
<td class="nump">$ 559,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Useful Life</a></td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Name | Obagi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total Intangible Assets</a></td>
<td class="nump">$ 414,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Name | Milk&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total Intangible Assets</a></td>
<td class="nump">145,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer/distributor relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total Intangible Assets</a></td>
<td class="nump">$ 36,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Useful Life</a></td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer/distributor relationships | Obagi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total Intangible Assets</a></td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer/distributor relationships | Milk&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total Intangible Assets</a></td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=wald_TretinoinDistributionAndSupplyAgreementMember', window );">Tretinoin distribution and supply agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total Intangible Assets</a></td>
<td class="nump">$ 38,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=wald_TretinoinDistributionAndSupplyAgreementMember', window );">Tretinoin distribution and supply agreement | Obagi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total Intangible Assets</a></td>
<td class="nump">$ 38,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=wald_TretinoinDistributionAndSupplyAgreementMember', window );">Tretinoin distribution and supply agreement | Milk&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total Intangible Assets</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=wald_FormulationsMember', window );">Formulations</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total Intangible Assets</a></td>
<td class="nump">$ 28,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Useful Life</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=wald_FormulationsMember', window );">Formulations | Obagi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total Intangible Assets</a></td>
<td class="nump">$ 27,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=wald_FormulationsMember', window );">Formulations | Milk&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Total Intangible Assets</a></td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=wald_ObagiAndMilkBusinessCombinationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=wald_ObagiAndMilkBusinessCombinationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=wald_TretinoinDistributionAndSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=wald_TretinoinDistributionAndSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=wald_FormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=wald_FormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693576899120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATIONS - Unaudited Pro Forma Consolidated Financial Information (Details) - Obagi and Milk Business Combinations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Pro forma net revenue</a></td>
<td class="nump">$ 200,547<span></span>
</td>
<td class="nump">$ 162,583<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Pro forma net income (loss)</a></td>
<td class="num">(86,930)<span></span>
</td>
<td class="num">(145,152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Pro forma net income (loss) attributable to noncontrolling interest</a></td>
<td class="num">(25,140)<span></span>
</td>
<td class="num">(26,519)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent', window );">Pro forma net income (loss) attributable to Waldencast plc</a></td>
<td class="num">$ (61,790)<span></span>
</td>
<td class="num">$ (118,633)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Pro Forma Net Income (Loss), Attributable to Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Pro Forma Net Income (Loss), Attributable to Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=wald_ObagiAndMilkBusinessCombinationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=wald_ObagiAndMilkBusinessCombinationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693570344928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Revenue by Sales Channel (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 92,373<span></span>
</td>
<td class="nump">$ 73,760<span></span>
</td>
<td class="nump">$ 142,472<span></span>
</td>
<td class="nump">$ 94,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember', window );">Obagi Skincare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">61,090<span></span>
</td>
<td class="nump">73,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember', window );">Milk Makeup</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">31,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">90,385<span></span>
</td>
<td class="nump">70,729<span></span>
</td>
<td class="nump">136,759<span></span>
</td>
<td class="nump">88,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales | Obagi Skincare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">59,102<span></span>
</td>
<td class="nump">70,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales | Milk Makeup</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">31,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales | Direct sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">60,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales | Direct sales | Obagi Skincare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">30,276<span></span>
</td>
<td class="nump">39,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales | Direct sales | Milk Makeup</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">30,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales | Distributors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">29,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales | Distributors | Obagi Skincare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">28,826<span></span>
</td>
<td class="nump">31,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales | Distributors | Milk Makeup</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">1,988<span></span>
</td>
<td class="nump">3,031<span></span>
</td>
<td class="nump">5,713<span></span>
</td>
<td class="nump">$ 5,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties | Obagi Skincare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">1,988<span></span>
</td>
<td class="nump">$ 3,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties | Milk Makeup</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelDirectlyToConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=us-gaap_SalesChannelThroughIntermediaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693579995104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 92,373<span></span>
</td>
<td class="nump">$ 73,760<span></span>
</td>
<td class="nump">$ 142,472<span></span>
</td>
<td class="nump">$ 94,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">90,385<span></span>
</td>
<td class="nump">70,729<span></span>
</td>
<td class="nump">136,759<span></span>
</td>
<td class="nump">88,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">54,300<span></span>
</td>
<td class="nump">43,800<span></span>
</td>
<td class="nump">76,700<span></span>
</td>
<td class="nump">63,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">CHINA | Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_VN', window );">VIET NAM | Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,900<span></span>
</td>
<td class="nump">18,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=wald_PhysicianChannelProviderMember', window );">Physician Channel Provider</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">26,300<span></span>
</td>
<td class="nump">32,200<span></span>
</td>
<td class="nump">58,800<span></span>
</td>
<td class="nump">51,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerSalesChannelAxis=wald_SpaChannelDistributorMember', window );">Spa Channel Distributor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Customer One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Customer Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Customer Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Geographic Concentration Risk | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Geographic Concentration Risk | CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Geographic Concentration Risk | VIET NAM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_VN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_VN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=wald_PhysicianChannelProviderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=wald_PhysicianChannelProviderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerSalesChannelAxis=wald_SpaChannelDistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerSalesChannelAxis=wald_SpaChannelDistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=wald_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=wald_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=wald_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=wald_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=wald_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=wald_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693565848912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Revenue by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 92,373<span></span>
</td>
<td class="nump">$ 73,760<span></span>
</td>
<td class="nump">$ 142,472<span></span>
</td>
<td class="nump">$ 94,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">90,385<span></span>
</td>
<td class="nump">70,729<span></span>
</td>
<td class="nump">136,759<span></span>
</td>
<td class="nump">88,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales | North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">56,630<span></span>
</td>
<td class="nump">44,443<span></span>
</td>
<td class="nump">79,122<span></span>
</td>
<td class="nump">64,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales | Rest of the World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">33,755<span></span>
</td>
<td class="nump">26,286<span></span>
</td>
<td class="nump">57,637<span></span>
</td>
<td class="nump">24,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 1,988<span></span>
</td>
<td class="nump">$ 3,031<span></span>
</td>
<td class="nump">$ 5,713<span></span>
</td>
<td class="nump">$ 5,904<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=wald_RestOfTheWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=wald_RestOfTheWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693566436080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL - Schedule of Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,489<span></span>
</td>
<td class="nump">$ 44,489<span></span>
</td>
<td class="nump">$ 44,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Elimination of Predecessor goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,489)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Obagi and Milk Business Combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment loss</a></td>
<td class="num">$ (68,715)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(68,715)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">334,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334,620<span></span>
</td>
<td class="nump">44,489<span></span>
</td>
<td class="nump">44,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember', window );">Obagi Skincare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,489<span></span>
</td>
<td class="nump">44,489<span></span>
</td>
<td class="nump">44,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Elimination of Predecessor goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,489)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Obagi and Milk Business Combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment loss</a></td>
<td class="num">(68,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">199,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,548<span></span>
</td>
<td class="nump">44,489<span></span>
</td>
<td class="nump">44,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember', window );">Milk Makeup</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPeriodIncreaseDecrease', window );">Elimination of Predecessor goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Obagi and Milk Business Combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 135,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,072<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693574337856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment loss</a></td>
<td class="nump">$ 68,715<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 68,715<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember', window );">Obagi Skincare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment loss</a></td>
<td class="nump">$ 68,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693566161792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS&#8212;NET - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 663,208<span></span>
</td>
<td class="nump">$ 134,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(24,043)<span></span>
</td>
<td class="num">(54,503)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 639,165<span></span>
</td>
<td class="nump">$ 79,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademark and trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Lives (Years)</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 559,328<span></span>
</td>
<td class="nump">$ 46,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(17,840)<span></span>
</td>
<td class="num">(17,842)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 541,488<span></span>
</td>
<td class="nump">$ 28,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Lives (Years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="nump">$ 39,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,349)<span></span>
</td>
<td class="num">(16,404)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 34,651<span></span>
</td>
<td class="nump">$ 22,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=wald_TretinoinDistributionAndSupplyAgreementMember', window );">Supply agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Lives (Years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 38,900<span></span>
</td>
<td class="nump">$ 25,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(3,325)<span></span>
</td>
<td class="num">(10,654)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 35,575<span></span>
</td>
<td class="nump">$ 14,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=wald_FormulationsMember', window );">Formulations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Lives (Years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 28,900<span></span>
</td>
<td class="nump">$ 22,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,526)<span></span>
</td>
<td class="num">(9,592)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 27,374<span></span>
</td>
<td class="nump">$ 13,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Useful Lives (Years)</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=wald_TretinoinDistributionAndSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=wald_TretinoinDistributionAndSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=wald_FormulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=wald_FormulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575239472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS&#8212;NET - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 24.0<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="nump">$ 13.5<span></span>
</td>
<td class="nump">$ 13.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693577756848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS&#8212;NET - Expected Amortization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 56,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">56,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">56,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">56,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">53,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">359,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 639,165<span></span>
</td>
<td class="nump">$ 79,574<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693578908128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Long-term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">$ (5,445)<span></span>
</td>
<td class="num">$ (6,300)<span></span>
</td>
<td class="num">$ (5,310)<span></span>
</td>
<td class="num">$ (6,400)<span></span>
</td>
<td class="num">$ (2,900)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">179,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt</a></td>
<td class="num">(20,095)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">159,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=wald_A2022TermLoanMember', window );">2022 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt</a></td>
<td class="num">(8,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=wald_A2022RevolvingCreditFacilityMember', window );">2022 Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt</a></td>
<td class="num">(14,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=wald_A2021TermLoanMember', window );">Predecessor 2021 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=wald_A2021RevolvingCreditFacilityMember', window );">Predecessor 2021 Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | 2022 Term Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">170,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | 2022 Revolving Credit Facility | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">14,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Predecessor 2021 Term Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Predecessor 2021 Revolving Credit Facility | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Predecessor 2018 Term Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Predecessor 2018 Revolving Credit Facility | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Predecessor PPP Loan | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wald_A2022TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wald_A2022TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wald_A2022RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wald_A2022RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wald_A2021TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wald_A2021TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wald_A2021RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wald_A2021RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wald_A2018TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wald_A2018TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wald_A2018RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wald_A2018RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wald_PPPLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wald_PPPLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693566860224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 27, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="nump">$ 5,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(2,317)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_LineOfCreditCovenantTermsMinimumLiquidity', window );">Minimum liquidity covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=wald_A2022CreditAgreementMember', window );">2022 Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total unpaid principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=wald_A2022CreditAgreementMember', window );">2022 Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_DebtInstrumentCovenantLeverageRatioMaximum', window );">Leverage ratio, maximum</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=wald_A2022TermLoanMember', window );">2022 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt issuance cost, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=wald_A2022TermLoanMember', window );">2022 Term Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=wald_A2022TermLoanMember', window );">2022 Term Loan | Line of Credit | Variable Rate Component One | Alternate Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=wald_A2022TermLoanMember', window );">2022 Term Loan | Line of Credit | Variable Rate Component Two | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=wald_A2022TermLoanMember', window );">2022 Term Loan | Line of Credit | Variable Rate Component Three | Applicable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=wald_A2022RevolvingCreditFacilityMember', window );">2022 Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt issuance cost, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=wald_A2021TermLoanMember', window );">Predecessor 2021 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt issuance cost, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=wald_A2021RevolvingCreditFacilityMember', window );">Predecessor 2021 Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt issuance cost, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=wald_A2018TermLoanMember', window );">Predecessor 2018 Term Loan | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | 2022 Term Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issuance cost</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total unpaid principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | 2022 Term Loan | Line of Credit | Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | 2022 Term Loan | Line of Credit | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Predecessor 2021 Term Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total unpaid principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Predecessor 2018 Term Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total unpaid principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Predecessor PPP Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total unpaid principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityDecreaseForgiveness1', window );">Line of credit facility, forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | 2022 Term Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | 2022 Revolving Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total unpaid principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Predecessor 2021 Term Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Predecessor 2021 Revolving Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total unpaid principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityDecreaseForgiveness1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in line of credit facility from forgiveness by the holder of the line of credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityDecreaseForgiveness1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_DebtInstrumentCovenantLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_DebtInstrumentCovenantLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_LineOfCreditCovenantTermsMinimumLiquidity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of Credit, Covenant Terms, Minimum Liquidity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_LineOfCreditCovenantTermsMinimumLiquidity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wald_A2022CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wald_A2022CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wald_A2022TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wald_A2022TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_VariableRateComponentAxis=wald_VariableRateComponentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_VariableRateComponentAxis=wald_VariableRateComponentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=wald_AlternateBaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=wald_AlternateBaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_VariableRateComponentAxis=wald_VariableRateComponentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_VariableRateComponentAxis=wald_VariableRateComponentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=wald_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=wald_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_VariableRateComponentAxis=wald_VariableRateComponentThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_VariableRateComponentAxis=wald_VariableRateComponentThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=wald_ApplicableRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=wald_ApplicableRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wald_A2022RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wald_A2022RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wald_A2021TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wald_A2021TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wald_A2021RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wald_A2021RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wald_A2018TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wald_A2018TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wald_PPPLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wald_PPPLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693565835664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Scheduled Maturities (Details) - 2022 Credit Agreement<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 22,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">7,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">11,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">143,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total unpaid principal</a></td>
<td class="nump">$ 184,769<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wald_A2022CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wald_A2022CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693566462848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 27, 2022 </div>
<div>USD ($) </div>
<div>operatingLease</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_LesseeOperatingLeaseExtensionTerm', window );">Operating lease extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_NumberOfOperatingLeases', window );">Number of non-cancelable operating leases | operatingLease</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_LesseeOperatingLeaseExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Extension Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_LesseeOperatingLeaseExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_NumberOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_NumberOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693658950608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Supplemental Cash Flow Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities:</a></td>
<td class="nump">$ 1,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities:</a></td>
<td class="nump">$ 4,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">7 years 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">5.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693566417200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Operating Lease Maturity Schedule (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 3,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">3,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">3,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">2,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">2,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">9,194<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">24,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed Interest</a></td>
<td class="nump">4,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total reported lease liability</a></td>
<td class="nump">$ 19,923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693571361072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Operating Lease Maturity Schedule Prior to the Adoption of ASC 842 (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2022</a></td>
<td class="nump">$ 1,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">1,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">1,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2025</a></td>
<td class="nump">1,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2026</a></td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">1,911<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum lease payments</a></td>
<td class="nump">$ 8,870<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693566510144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 28, 2022</div></th>
<th class="th"><div>Dec. 20, 2021</div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
<th class="th"><div>Mar. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,533,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of derivative warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,793<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_BeautyVenturesLLCMember', window );">Beauty Ventures LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares | Burwell and Zeno</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares | Beauty Ventures LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=wald_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,499,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination', window );">Warrant exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ClassOfWarrantOrRightRedemptionPeriod', window );">Warrant redemption period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice', window );">Warrant redemption, number of trading days at or above trigger price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ClassOfWarrantOrRightRedemptionTradingPeriod', window );">Warrant redemption, trading period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption', window );">Warrant redemption, period between end of trading and notice of redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger', window );">Warrant redemption, stock price trigger (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=wald_PublicWarrantsMember', window );">Public Warrants | Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ClassOfWarrantOrRightRedemptionPricePerShare', window );">Warrant redemption price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger', window );">Warrant redemption, stock price trigger (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=wald_PublicWarrantsMember', window );">Public Warrants | Share-Based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ClassOfWarrantOrRightRedemptionPricePerShare', window );">Warrant redemption price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger', window );">Warrant redemption, stock price trigger (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=wald_SponsorWarrantsMember', window );">Sponsor Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,933,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=wald_SponsorWarrantsMember', window );">Sponsor Warrants | Burwell and Zeno</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=wald_SponsorWarrantsMember', window );">Sponsor Warrants | Beauty Ventures LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,766,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=wald_PrivatePlacementWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination', window );">Warrant exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=wald_InterestRateCollarMember', window );">Interest rate collar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative notional value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities', window );">Fixed cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFloorInterestRate', window );">Interest rate floor (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCapInterestRate', window );">Interest rate cap (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Fair value of derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Loss from change in fair value on derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCapInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cap rate on an interest rate derivative such as an interest rate cap or collar. If market rates exceed the cap rate, a payment or receipt is triggered on the contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCapInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFloorInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Floor rate on an interest rate derivative such as an interest rate floor or collar. If market rates falls below the floor rate, a payment or receipt is triggered on the contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFloorInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4CC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Period After Completion of Business Combination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Period Between End of Trading and Notice of Redemption</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Redemption, Number of Trading Days At or Above Trigger Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ClassOfWarrantOrRightRedemptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Redemption Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ClassOfWarrantOrRightRedemptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ClassOfWarrantOrRightRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Redemption Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ClassOfWarrantOrRightRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Redemption, Stock Price Trigger</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ClassOfWarrantOrRightRedemptionTradingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Redemption, Trading Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ClassOfWarrantOrRightRedemptionTradingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=wald_BeautyVenturesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=wald_BeautyVenturesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=wald_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=wald_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=wald_SponsorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=wald_SponsorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=wald_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=wald_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=wald_InterestRateCollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=wald_InterestRateCollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693578124576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=wald_InterestRateCollarMember', window );">Interest rate collar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Assets</a></td>
<td class="nump">$ 198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=wald_PublicDerivativeWarrantLiabilitiesMember', window );">Derivative warrant liabilities - Public</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="nump">7,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=wald_PrivateDerivativeWarrantLiabilitiesMember', window );">Derivative warrant liabilities - Private</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="nump">11,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Interest rate collar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Assets</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Derivative warrant liabilities - Public</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="nump">7,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Derivative warrant liabilities - Private</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Interest rate collar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Assets</a></td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Derivative warrant liabilities - Public</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Derivative warrant liabilities - Private</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="nump">11,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Interest rate collar</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative Assets</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Derivative warrant liabilities - Public</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Derivative warrant liabilities - Private</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative Liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-10<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=wald_InterestRateCollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=wald_InterestRateCollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=wald_PublicDerivativeWarrantLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=wald_PublicDerivativeWarrantLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=wald_PrivateDerivativeWarrantLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=wald_PrivateDerivativeWarrantLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693565864496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 29, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent', window );">Accounts receivable and notes receivable, before allowance for doubtful accounts</a></td>
<td class="nump">$ 20,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInNotesReceivableCurrent', window );">Increase (decrease) in loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="num">$ (2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansReceivableBasisSpreadOnVariableRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Related party liability</a></td>
<td class="nump">$ 9,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInNotesReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of amounts due within one year (or one business cycle) from note holders for outstanding loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInNotesReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansReceivableBasisSpreadOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage added to reference rate used to compute variable rate on loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansReceivableBasisSpreadOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable and Notes Receivable, before Allowance for Credit Loss, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693580019392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Change in Allowance for Doubtful Accounts (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Ending balance</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=wald_WaldencastPlcMember', window );">Waldencast plc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Beginning balance</a></td>
<td class="nump">1,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-off of uncollectible accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Ending balance</a></td>
<td class="nump">994<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=wald_ObagiCosmeceuticalsLLCMember', window );">Obagi Cosmeceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Beginning balance</a></td>
<td class="nump">$ 1,061<span></span>
</td>
<td class="nump">671<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-off of uncollectible accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,061<span></span>
</td>
<td class="nump">$ 671<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=wald_WaldencastPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=wald_WaldencastPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=wald_ObagiCosmeceuticalsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=wald_ObagiCosmeceuticalsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575558480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">$ 11,138<span></span>
</td>
<td class="nump">$ 1,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">43,246<span></span>
</td>
<td class="nump">20,042<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 54,384<span></span>
</td>
<td class="nump">$ 21,611<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693567728384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 11,256<span></span>
</td>
<td class="nump">$ 1,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(2,928)<span></span>
</td>
<td class="num">(678)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">8,328<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=wald_ComputerHardwareSoftwareAndEquipmentMember', window );">Computer hardware, software and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">724<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">608<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internally developed software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">889<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=wald_GondolasMember', window );">Gondolas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">6,040<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 2,051<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=wald_ComputerHardwareSoftwareAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=wald_ComputerHardwareSoftwareAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=wald_GondolasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=wald_GondolasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693578228432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued salaries and related expenses</a></td>
<td class="nump">$ 9,069<span></span>
</td>
<td class="nump">$ 6,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_AccruedSalesReturnsAndDamagesCurrent', window );">Accrued sales returns and damages</a></td>
<td class="nump">2,651<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued marketing expenses</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">2,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_AccruedDistributionFeesCurrent', window );">Accrued distribution fees</a></td>
<td class="nump">1,621<span></span>
</td>
<td class="nump">760<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">26,123<span></span>
</td>
<td class="nump">12,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">9,914<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">9,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">$ 2,773<span></span>
</td>
<td class="nump">$ 2,084<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_AccruedDistributionFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Distribution Fees, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_AccruedDistributionFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_AccruedSalesReturnsAndDamagesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Sales Returns And Damages, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_AccruedSalesReturnsAndDamagesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693565536400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 12, 2022 </div>
<div>segment </div>
<div>individual </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 27, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 27, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals', window );">Number of founders | individual</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted in period (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.58<span></span>
</td>
<td class="nump">$ 15.55<span></span>
</td>
<td class="nump">$ 15.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Stock options, unrecognized compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=wald_ObagiAndMilkBusinessCombinationsMember', window );">Obagi and Milk Business Combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost', window );">Incremental stock based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure', window );">Fair value of equity awards in business combination | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=wald_ObagiMergerMember', window );">Obagi Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod', window );">Stock options assumed in business combination (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,906,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=wald_MilkTransactionMember', window );">Milk Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod', window );">Stock options assumed in business combination (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=wald_ShareBasedPaymentArrangementFounderMember', window );">Share-Based Payment Arrangement, Founder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches', window );">Number of tranches | segment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=wald_PredecessorIncentivePlanMember', window );">Predecessor Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock | 2022 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,134,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod', window );">Anniversary period, annual increase in shares issued under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage increase in shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,749,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Restricted stock, unrecognized compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.90<span></span>
</td>
<td class="nump">$ 38.68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Obagi Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod', window );">Equity instruments assumed in business combination (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,776,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Share-Based Payment Arrangement, Founder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares)</a></td>
<td class="nump">692,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Long-Term Incentive Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | One-Tim Stock Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Predecessor Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments', window );">Number of annual installments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Restricted stock, unrecognized compensation cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation cost, weighted average service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember', window );">Stock Appreciation Rights (SARs) | Milk Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod', window );">Equity instruments assumed in business combination (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,808,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation cost, weighted average service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Share-Based Payment Arrangement, Founder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Predecessor Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Predecessor Incentive Plan | Share-Based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments', window );">Number of annual installments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Predecessor Incentive Plan | Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments', window );">Number of quarterly installments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of equity issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Business Combination, Assumed In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares, Anniversary Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Annual Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Quarterly Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Business Combination, Assumed In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Number Of Individuals</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Payment Arrangement, Business Combination, Incremental Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=wald_ObagiAndMilkBusinessCombinationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=wald_ObagiAndMilkBusinessCombinationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=wald_ObagiMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=wald_ObagiMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=wald_MilkTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=wald_MilkTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=wald_ShareBasedPaymentArrangementFounderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=wald_ShareBasedPaymentArrangementFounderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=wald_PredecessorIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=wald_PredecessorIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=wald_A2022IncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=wald_A2022IncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=wald_LongTermIncentiveAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=wald_LongTermIncentiveAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=wald_OneTimStockGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=wald_OneTimStockGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockAppreciationRightsSARSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693565074160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=wald_WaldencastPlcMember', window );">Waldencast plc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Common Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">20,452,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">20,452,155<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">4,451,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">20,452,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">9.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited. weighted average exercise price (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">9.50<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">4.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual life</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm', window );">Granted, weighted average remaining contractual life</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted average remaining contractual life</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, weighted average remaining contractual life</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 39,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="nump">21,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, aggregate intrinsic value</a></td>
<td class="nump">$ 39,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=wald_ObagiCosmeceuticalsLLCMember', window );">Obagi Cosmeceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Common Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">774,800<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">774,800<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 41.10<span></span>
</td>
<td class="nump">$ 41.10<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">41.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited. weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice', window );">Vested, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.10<span></span>
</td>
<td class="nump">$ 41.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm', window );">Granted, weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm', window );">Forfeited, weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,659<span></span>
</td>
<td class="nump">$ 16,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue', window );">Granted, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue', window );">Forfeited, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeiture In Period, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighed Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Vested In Period, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=wald_WaldencastPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=wald_WaldencastPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=wald_ObagiCosmeceuticalsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=wald_ObagiCosmeceuticalsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693569881568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Fair Value of Stock Options Valuation Assumptions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple', window );">Exercise multiple</a></td>
<td class="nump">230.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent', window );">Exercise term, percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Dividend yield</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple', window );">Exercise multiple</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple', window );">Exercise multiple</a></td>
<td class="nump">250.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=wald_FounderAwardsMember', window );">Founder Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">2.87%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">2.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, minimum</a></td>
<td class="nump">39.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, maximum</a></td>
<td class="nump">44.76%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=wald_FounderAwardsMember', window );">Founder Awards | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=wald_FounderAwardsMember', window );">Founder Awards | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">9 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=wald_ReplacementAwardsMember', window );">Replacement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">2.79%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple', window );">Exercise multiple</a></td>
<td class="nump">230.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk -free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock per share value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 38.68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Multiple</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Exercise Term, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=wald_FounderAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=wald_FounderAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=wald_ReplacementAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=wald_ReplacementAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693577058320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Restricted Stock Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=wald_ObagiCosmeceuticalsLLCMember', window );">Obagi Cosmeceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue', window );">Exercised, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock | Waldencast plc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">3,173,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(370,945)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">2,802,419<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding beginning balance, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">9.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding ending balance, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 9.16<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.90<span></span>
</td>
<td class="nump">$ 38.68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Obagi Cosmeceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">234,842<span></span>
</td>
<td class="nump">243,307<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,754<span></span>
</td>
<td class="nump">243,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,219<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,842<span></span>
</td>
<td class="nump">243,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding beginning balance, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 38.90<span></span>
</td>
<td class="nump">$ 38.68<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.19<span></span>
</td>
<td class="nump">38.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.68<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding ending balance, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.90<span></span>
</td>
<td class="nump">$ 38.68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercised, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=wald_ObagiCosmeceuticalsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=wald_ObagiCosmeceuticalsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=wald_WaldencastPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=wald_WaldencastPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693570336720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS&#8217; EQUITY (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 27, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 28, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized (in shares)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued (in shares)</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_CommonStockConvertibleConversionRatio', window );">Stock conversion ratio (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split conversion ratio</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Dividends paid (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,460,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,460,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_CommonStockConvertibleConversionRatio', window );">Stock conversion ratio (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,104,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,104,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_CommonStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Convertible, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_CommonStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693577033488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Basic and Diluted Net Income (Loss) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (120,557)<span></span>
</td>
<td class="num">$ (21,057)<span></span>
</td>
<td class="num">$ (19,576)<span></span>
</td>
<td class="num">$ (2,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="num">(24,990)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributed to Class A shareholders - basic EPS</a></td>
<td class="num">(95,567)<span></span>
</td>
<td class="num">(21,057)<span></span>
</td>
<td class="num">(19,576)<span></span>
</td>
<td class="num">(2,370)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributed to Class A shareholders - diluted EPS</a></td>
<td class="num">$ (95,567)<span></span>
</td>
<td class="num">$ (21,057)<span></span>
</td>
<td class="num">$ (19,576)<span></span>
</td>
<td class="num">$ (2,370)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average basic shares outstanding (in shares)</a></td>
<td class="nump">86,460,560<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average diluted shares (in shares)</a></td>
<td class="nump">86,460,560<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (2.63)<span></span>
</td>
<td class="num">$ (2.45)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (2.63)<span></span>
</td>
<td class="num">$ (2.45)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693566460336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities</a></td>
<td class="nump">52,787,856<span></span>
</td>
<td class="nump">1,009,642<span></span>
</td>
<td class="nump">1,043,307<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities</a></td>
<td class="nump">29,533,282<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities</a></td>
<td class="nump">20,452,155<span></span>
</td>
<td class="nump">774,800<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities</a></td>
<td class="nump">2,802,419<span></span>
</td>
<td class="nump">234,842<span></span>
</td>
<td class="nump">243,307<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693565070320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX BENEFIT - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Decrease in valuation allowance</a></td>
<td class="nump">$ 28,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">7,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,060<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693578855232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX BENEFIT - Schedule of Consolidated Pretax Income (Loss) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (125,281)<span></span>
</td>
<td class="num">$ (17,676)<span></span>
</td>
<td class="num">$ (15,320)<span></span>
</td>
<td class="num">$ (13,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(1,079)<span></span>
</td>
<td class="num">(3,268)<span></span>
</td>
<td class="nump">5,346<span></span>
</td>
<td class="nump">7,479<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">$ (126,360)<span></span>
</td>
<td class="num">$ (20,944)<span></span>
</td>
<td class="num">$ (9,974)<span></span>
</td>
<td class="num">$ (5,764)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575982336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX BENEFIT - Schedule of Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current provision (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current provision (benefit), total</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="num">(350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred (income) expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(4,557)<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">7,597<span></span>
</td>
<td class="num">(2,473)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(1,266)<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
<td class="num">(571)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred (income) expense, total</a></td>
<td class="num">(5,823)<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">9,374<span></span>
</td>
<td class="num">(3,044)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">$ (5,803)<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">$ 9,602<span></span>
</td>
<td class="num">$ (3,394)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693571527584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX BENEFIT - Schedule of Components of Income Tax Expense (Details)<br></strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at Bailiwick of Jersey for Successor and Income tax benefit at Cayman Islands for Predecessor statutory rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">U.S./foreign tax rate differential</a></td>
<td class="nump">20.70%<span></span>
</td>
<td class="nump">17.70%<span></span>
</td>
<td class="nump">30.50%<span></span>
</td>
<td class="nump">47.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax benefit, net of federal benefit</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent Items</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense', window );">Noncontrolling interest</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(6.10%)<span></span>
</td>
<td class="num">(16.90%)<span></span>
</td>
<td class="num">(141.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent', window );">Transaction bonuses</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent', window );">Transaction costs</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(11.30%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent', window );">PPP Loan forgiveness</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">14.40%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent', window );">True-Ups</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent', window );">Goodwill impairment</a></td>
<td class="num">(11.40%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total income tax (benefit) expense</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(96.30%)<span></span>
</td>
<td class="nump">58.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Goodwill Impairment, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, PPP Loan Forgiveness, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Transaction Bonuses, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Transaction Costs, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, True-Ups, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693565498128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAX BENEFIT - Summary of Deferred Tax Assets and Deferred Tax Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties', window );">Accrued interest to foreign related parties</a></td>
<td class="nump">$ 1,660<span></span>
</td>
<td class="nump">$ 581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_DeferredTaxAssetsLeaseLiabilities', window );">Lease liability</a></td>
<td class="nump">2,434<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_DeferredTaxAssetsFormationCosts', window );">Formation costs</a></td>
<td class="nump">1,509<span></span>
</td>
<td class="nump">1,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">13,117<span></span>
</td>
<td class="nump">4,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory reserve</a></td>
<td class="nump">1,731<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_DeferredTaxAssetsTransactionCosts', window );">Transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other temporary differences</a></td>
<td class="nump">646<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Accrued compensation</a></td>
<td class="nump">1,377<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D tax credits</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Non-deductible interest carryover</a></td>
<td class="nump">3,350<span></span>
</td>
<td class="nump">1,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_DeferredTaxAssetsBelowMarketLeaseContract', window );">Below market contract</a></td>
<td class="nump">2,373<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research</a></td>
<td class="nump">2,538<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Investment in Waldencast LP</a></td>
<td class="nump">3,466<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">34,580<span></span>
</td>
<td class="nump">16,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill', window );">Goodwill</a></td>
<td class="num">(285)<span></span>
</td>
<td class="num">(2,794)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed asset basis</a></td>
<td class="num">(370)<span></span>
</td>
<td class="num">(226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Lease asset</a></td>
<td class="num">(2,025)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangibles</a></td>
<td class="num">(46,206)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts', window );">Inventory</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(48,886)<span></span>
</td>
<td class="num">(3,020)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_DeferredTaxAssetsNetBeforeValuationAllowance', window );">Net deferred tax (liabilities) assets</a></td>
<td class="num">(14,306)<span></span>
</td>
<td class="nump">13,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(7,944)<span></span>
</td>
<td class="num">(14,060)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">$ (22,250)<span></span>
</td>
<td class="num">$ (548)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479692/805-740-25-9<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 740<br> -Section 25<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479692/805-740-25-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Accrued Interest to Foreign Related Parties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_DeferredTaxAssetsBelowMarketLeaseContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Below Market Lease Contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_DeferredTaxAssetsBelowMarketLeaseContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_DeferredTaxAssetsFormationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Formation Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_DeferredTaxAssetsFormationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_DeferredTaxAssetsNetBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net, Before Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_DeferredTaxAssetsNetBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_DeferredTaxAssetsTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_DeferredTaxAssetsTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693570179296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAX BENEFIT - Summary of Net Operating Losses and Tax Credit Carryforwards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 50,772<span></span>
</td>
<td class="nump">$ 20,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">39,366<span></span>
</td>
<td class="nump">9,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693550176000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 28, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 20, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 18, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 15, 2021 </div>
<div>USD ($) </div>
<div>tradingDay </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 01, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 27, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,373<span></span>
</td>
<td class="nump">$ 73,760<span></span>
</td>
<td class="nump">142,472<span></span>
</td>
<td class="nump">$ 94,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,657<span></span>
</td>
<td class="nump">30,868<span></span>
</td>
<td class="nump">55,037<span></span>
</td>
<td class="nump">29,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember', window );">Milk&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Licensed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,385<span></span>
</td>
<td class="nump">70,729<span></span>
</td>
<td class="nump">136,759<span></span>
</td>
<td class="nump">88,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Licensed products | Milk&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=wald_SponsorWarrantsMember', window );">Sponsor Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued (in shares) | shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,933,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=wald_PrivatePlacementWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination', window );">Warrant exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,104,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,460,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage', window );">Performance fee allocation percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ForwardPurchaseAgreementHurdleRate', window );">Hurdle rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod', window );">Hurdle rate accrual period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_IndemnificationAgreementAdvanceExpensePeriod', window );">Indemnification agreement, advancement period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Milk&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdministrativeFeesExpense', window );">Administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Supply Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Licensed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_RoyaltyPercentageOfGrossSales', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Cedarwalk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Product registration payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued (in shares) | shares</a></td>
<td class="nump">5,933,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,933,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ConversionOfStockToCommonStockConversionRatio', window );">Stock conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination', window );">Warrant exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Class B Ordinary Shares | Milk Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock registered (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,104,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock registered (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,120,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Class A Ordinary Shares | Forward Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock registered (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Class A Ordinary Shares | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock registered (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Class A Ordinary Shares | Obagi Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock registered (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,237,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Class A Ordinary Shares | Milk Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock registered (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,104,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Class A Ordinary Shares | Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock registered (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,033,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_SponsorMember', window );">Sponsor | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdministrativeFeesExpense', window );">Administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod', window );">Lock-up shares, earnout period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger', window );">Lock-up shares, stock price trigger | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays', window );">Lock-up shares, threshold trading days | tradingDay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays', window );">Lock-up shares, threshold consecutive trading days | tradingDay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays', window );">Lock-up shares, threshold period before commencement of consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">150 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_SponsorMember', window );">Sponsor | Related Party | January Note | Notes Payable, Other Payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Outstanding borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_SponsorMember', window );">Sponsor | Related Party | Convertible Working Capital Note | Notes Payable, Other Payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_SponsorMember', window );">Sponsor | Related Party | Non-Convertible Working Capital Notes | Notes Payable, Other Payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_SponsorMember', window );">Sponsor | Related Party | Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,107,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_SponsorMember', window );">Sponsor | Related Party | Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock registered (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_InvestorDirectorsMember', window );">Investor Directors | Related Party | Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_InvestorDirectorsMember', window );">Investor Directors | Related Party | Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock registered (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_SponsorAndInvestorDirectorsMember', window );">Sponsor and Investor Directors | Related Party | Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares) | shares</a></td>
<td class="nump">8,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ConversionOfStockToCommonStockConversionRatio', window );">Stock conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember', window );">Burwell and Zeno | Sponsor Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember', window );">Burwell and Zeno | Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember', window );">Burwell and Zeno | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember', window );">Burwell and Zeno | Related Party | Sponsor Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember', window );">Burwell and Zeno | Related Party | Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_BeautyVenturesLLCMember', window );">Beauty Ventures LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_BeautyVenturesLLCMember', window );">Beauty Ventures LLC | Sponsor Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,766,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_BeautyVenturesLLCMember', window );">Beauty Ventures LLC | Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_BeautyVenturesLLCMember', window );">Beauty Ventures LLC | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_BeautyVenturesLLCMember', window );">Beauty Ventures LLC | Related Party | Sponsor Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,766,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_BeautyVenturesLLCMember', window );">Beauty Ventures LLC | Related Party | Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_AaronChatterleyMember', window );">Aaron Chatterley | Related Party | Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock registered (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_CedarwalkMember', window );">Cedarwalk | Related Party | Class A Ordinary Shares | Waldencast plc | Obagi China Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership interest in fully diluted Class A ordinary shares (percent)</a></td>
<td class="nump">24.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_CedarwalkMember', window );">Cedarwalk | Related Party | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_ObagiChinaBusinessMember', window );">Obagi China Business | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_TransitionServicesAgreementPeriod', window );">Transition services, initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_TransitionServicesAgreementExtensionPeriod', window );">Transition services, optional extension term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_ObagiChinaBusinessMember', window );">Obagi China Business | Related Party | Supply Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_ObagiChinaBusinessMember', window );">Obagi China Business | Related Party | Licensed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_ObagiCosmeceuticalsLLCMember', window );">Obagi Cosmeceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ServicesAgreementRenewalTerm', window );">Services agreement, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_ObagiCosmeceuticalsLLCMember', window );">Obagi Cosmeceuticals | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ServicesAgreementFeePercentageOfIncurredCosts', window );">Service fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_PaymentsForServicesAgreementFees', window );">Total service fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=wald_ObagiShanghaiMember', window );">Obagi Shanghai | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ServicesAgreementFeePercentageOfIncurredCosts', window );">Service fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_PaymentsForServicesAgreementFees', window );">Total service fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdministrativeFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for administrative fee from service provided, including, but not limited to, salary, rent, or overhead cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdministrativeFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Period After Completion of Business Combination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ConversionOfStockToCommonStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock to Common Stock, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ConversionOfStockToCommonStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ForwardPurchaseAgreementHurdleRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forward Purchase Agreement, Hurdle Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ForwardPurchaseAgreementHurdleRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forward Purchase Agreement, Hurdle Rate Accrual Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forward Purchase Agreement, Performance Fee Allocation Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_IndemnificationAgreementAdvanceExpensePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indemnification Agreement, Advance Expense Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_IndemnificationAgreementAdvanceExpensePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_PaymentsForServicesAgreementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Services Agreement Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_PaymentsForServicesAgreementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Stock Price Trigger</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Period Before Commencement of Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_RoyaltyPercentageOfGrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Percentage of Gross Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_RoyaltyPercentageOfGrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ServicesAgreementFeePercentageOfIncurredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Services Agreement Fee, Percentage of Incurred Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ServicesAgreementFeePercentageOfIncurredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ServicesAgreementRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Services Agreement, Renewal Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ServicesAgreementRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_TransitionServicesAgreementExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transition Services Agreement, Extension Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_TransitionServicesAgreementExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_TransitionServicesAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transition Services Agreement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_TransitionServicesAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=wald_SponsorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=wald_SponsorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=wald_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=wald_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentAxis=us-gaap_SupplyCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentAxis=us-gaap_SupplyCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=wald_CedarwalkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=wald_CedarwalkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=wald_MilkTransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=wald_MilkTransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=wald_ForwardPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=wald_ForwardPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=wald_ObagiMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=wald_ObagiMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=wald_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=wald_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wald_JanuaryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wald_JanuaryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wald_ConvertibleWorkingCapitalNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wald_ConvertibleWorkingCapitalNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=wald_NonConvertibleWorkingCapitalNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=wald_NonConvertibleWorkingCapitalNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=wald_InvestorDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=wald_InvestorDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=wald_SponsorAndInvestorDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=wald_SponsorAndInvestorDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=wald_BeautyVenturesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=wald_BeautyVenturesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=wald_AaronChatterleyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=wald_AaronChatterleyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=wald_CedarwalkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=wald_CedarwalkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=wald_WaldencastPlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=wald_WaldencastPlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=wald_ObagiChinaBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=wald_ObagiChinaBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=wald_ObagiChinaBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=wald_ObagiChinaBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=wald_ObagiCosmeceuticalsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=wald_ObagiCosmeceuticalsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=wald_ObagiShanghaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=wald_ObagiShanghaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693580151184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=wald_SkintrinsiqDevicesMember', window );">Skintrinsiq Devices</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Initial commitment amount of purchase commitments</a></td>
<td class="nump">$ 5.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Future minimum payment</a></td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_InventoriesMember', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Initial commitment amount of purchase commitments</a></td>
<td class="nump">8.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Future minimum payment</a></td>
<td class="nump">$ 7.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Skintrinsiq Devices</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Purchase commitment period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Purchase commitment period</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Skintrinsiq Devices</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Purchase commitment period</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Purchase commitment period</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=wald_SkintrinsiqDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=wald_SkintrinsiqDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693579999664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING - Narrative (Details) - segment<br></strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693580010736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 92,373<span></span>
</td>
<td class="nump">$ 73,760<span></span>
</td>
<td class="nump">$ 142,472<span></span>
</td>
<td class="nump">$ 94,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">60,657<span></span>
</td>
<td class="nump">30,868<span></span>
</td>
<td class="nump">55,037<span></span>
</td>
<td class="nump">29,096<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">31,716<span></span>
</td>
<td class="nump">42,892<span></span>
</td>
<td class="nump">87,435<span></span>
</td>
<td class="nump">$ 65,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember', window );">Obagi Skincare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">61,090<span></span>
</td>
<td class="nump">$ 73,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">44,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">16,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember', window );">Milk Makeup</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">31,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">15,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">$ 15,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=wald_ObagiSkincareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=wald_MilkMakeupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693580106176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING - Reconciliation of Segment Gross Profit to Net Income (Loss) Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">$ 31,716<span></span>
</td>
<td class="nump">$ 42,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,435<span></span>
</td>
<td class="nump">$ 65,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">88,926<span></span>
</td>
<td class="nump">55,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,968<span></span>
</td>
<td class="nump">60,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,796<span></span>
</td>
<td class="nump">2,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,092<span></span>
</td>
<td class="nump">4,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Loss on impairment of goodwill</a></td>
<td class="nump">68,715<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 68,715<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">6,230<span></span>
</td>
<td class="nump">6,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,118<span></span>
</td>
<td class="nump">6,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of derivative warrant liabilities</a></td>
<td class="num">(6,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expenses (income), net</a></td>
<td class="num">(798)<span></span>
</td>
<td class="num">(971)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(817)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(126,360)<span></span>
</td>
<td class="num">(20,944)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,974)<span></span>
</td>
<td class="num">(5,764)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (120,557)<span></span>
</td>
<td class="num">$ (21,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (19,576)<span></span>
</td>
<td class="num">$ (2,370)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693575785936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLAN (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Company 401(k) retirement plan contributions</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693546615840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>lease </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU assets | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,460,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,460,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,104,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,104,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_TX', window );">TEXAS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_NumberOfLeaseAgreements', window );">Number of leases | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_TX', window );">TEXAS | Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU assets | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_TX', window );">TEXAS | Warehouse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU assets | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">CALIFORNIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,076,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,076,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued in private placement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Subscription agreement proceeds | $</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 68,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,228,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,228,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued in private placement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,847,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,847,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Vietnam Purchase Agreement | SA Distributor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_BusinessAcquisitionEarnoutPeriod', window );">Earnout period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Vietnam Purchase Agreement | Obagi Blue Sea Holding, LLC | SA Distributor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Ownership percentage acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | SGI Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent', window );">Maximum allocated target share units, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Post vesting holding period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_BusinessAcquisitionEarnoutPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Earnout Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_BusinessAcquisitionEarnoutPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_NumberOfLeaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Lease Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_NumberOfLeaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Allocated Target Share Units, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_TX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_TX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_WarehouseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=srt_WarehouseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=wald_VietnamPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=wald_VietnamPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=wald_SADistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=wald_SADistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=wald_ObagiBlueSeaHoldingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=wald_ObagiBlueSeaHoldingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=wald_StockGrowthIncentiveAwardsSGIAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=wald_StockGrowthIncentiveAwardsSGIAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693566273216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Balance Sheet (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,693<span></span>
</td>
<td class="nump">$ 12,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">91,043<span></span>
</td>
<td class="nump">59,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">1,090,075<span></span>
</td>
<td class="nump">184,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">18,311<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">290,177<span></span>
</td>
<td class="nump">$ 145,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Successor ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">796,038<span></span>
</td>
<td class="nump">100,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(156,780)<span></span>
</td>
<td class="num">(64,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL CONTROLLING SHAREHOLDERS' EQUITY</a></td>
<td class="nump">639,239<span></span>
</td>
<td class="nump">39,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling Interest</a></td>
<td class="nump">160,659<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="nump">799,898<span></span>
</td>
<td class="nump">39,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">$ 1,090,075<span></span>
</td>
<td class="nump">$ 184,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized (in shares)</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares)</a></td>
<td class="nump">86,460,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Successor ordinary shares</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares)</a></td>
<td class="nump">21,104,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Successor ordinary shares</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">3,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_InvestmentInSubsidiary', window );">Investment in subsidiary</a></td>
<td class="nump">823,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">827,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_IntercompanyPayables', window );">Intercompany payables</a></td>
<td class="nump">8,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative warrant liabilities</a></td>
<td class="nump">18,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">27,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">796,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(156,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL CONTROLLING SHAREHOLDERS' EQUITY</a></td>
<td class="nump">639,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling Interest</a></td>
<td class="nump">160,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="nump">799,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">$ 827,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company | Class A Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized (in shares)</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares)</a></td>
<td class="nump">86,460,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Successor ordinary shares</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company | Class B Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized (in shares)</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding (in shares)</a></td>
<td class="nump">21,104,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Successor ordinary shares</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_IntercompanyPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intercompany Payables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_IntercompanyPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_InvestmentInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in Subsidiary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_InvestmentInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693568498272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 92,373<span></span>
</td>
<td class="nump">$ 73,760<span></span>
</td>
<td class="nump">$ 142,472<span></span>
</td>
<td class="nump">$ 94,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">88,926<span></span>
</td>
<td class="nump">55,549<span></span>
</td>
<td class="nump">82,968<span></span>
</td>
<td class="nump">60,421<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (loss) income</a></td>
<td class="num">(127,721)<span></span>
</td>
<td class="num">(15,263)<span></span>
</td>
<td class="num">(1,625)<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeDisclosureNonoperatingAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of derivative warrant liabilities</a></td>
<td class="nump">6,793<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(126,360)<span></span>
</td>
<td class="num">(20,944)<span></span>
</td>
<td class="num">(9,974)<span></span>
</td>
<td class="num">(5,764)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">5,803<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="num">(9,602)<span></span>
</td>
<td class="nump">3,394<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Class A shareholders</a></td>
<td class="num">(95,567)<span></span>
</td>
<td class="num">(21,057)<span></span>
</td>
<td class="num">(19,576)<span></span>
</td>
<td class="num">(2,370)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</a></td>
<td class="num">(36)<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Class A shareholders</a></td>
<td class="num">(95,596)<span></span>
</td>
<td class="num">$ (20,961)<span></span>
</td>
<td class="num">$ (19,608)<span></span>
</td>
<td class="num">$ (2,354)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (loss) income</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeDisclosureNonoperatingAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of derivative warrant liabilities</a></td>
<td class="nump">6,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">6,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income before equity in undistributed earnings of subsidiaries</a></td>
<td class="nump">6,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromSubsidiariesNetOfTax', window );">Equity in undistributed earnings of subsidiaries</a></td>
<td class="num">(102,379)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Class A shareholders</a></td>
<td class="num">(95,567)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive (loss) income &#8212; foreign currency translation adjustments, net of tax</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Class A shareholders</a></td>
<td class="num">$ (95,596)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedIncomeStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedIncomeStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromSubsidiariesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) of subsidiary attributable to the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromSubsidiariesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeDisclosureNonoperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeDisclosureNonoperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm139693566798944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Cash Flow (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (120,557)<span></span>
</td>
<td class="num">$ (21,057)<span></span>
</td>
<td class="num">$ (19,576)<span></span>
</td>
<td class="num">$ (2,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities', window );">Change in fair value of derivative warrant liabilities</a></td>
<td class="num">(6,793)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(74,977)<span></span>
</td>
<td class="num">(10,037)<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
<td class="num">(7,431)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ProceedsFromTrustAccount', window );">Proceeds from trust</a></td>
<td class="nump">44,883<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(544,367)<span></span>
</td>
<td class="num">(909)<span></span>
</td>
<td class="num">(3,787)<span></span>
</td>
<td class="num">(1,707)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="nump">629,465<span></span>
</td>
<td class="nump">3,883<span></span>
</td>
<td class="nump">5,162<span></span>
</td>
<td class="nump">14,319<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="nump">10,121<span></span>
</td>
<td class="num">(7,063)<span></span>
</td>
<td class="nump">4,904<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;Beginning of period</a></td>
<td class="nump">6,477<span></span>
</td>
<td class="nump">13,444<span></span>
</td>
<td class="nump">8,572<span></span>
</td>
<td class="nump">3,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;End of period</a></td>
<td class="nump">10,163<span></span>
</td>
<td class="nump">6,477<span></span>
</td>
<td class="nump">$ 13,444<span></span>
</td>
<td class="nump">$ 8,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(95,567)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromSubsidiariesNetOfTax', window );">Equity in income of subsidiaries</a></td>
<td class="nump">102,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities', window );">Change in fair value of derivative warrant liabilities</a></td>
<td class="num">(6,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_ProceedsFromTrustAccount', window );">Proceeds from trust</a></td>
<td class="nump">6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="nump">6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Transfers from subsidiaries</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDistributionsToAffiliates', window );">Transfers to subsidiaries</a></td>
<td class="num">(300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_wald_PaymentsOfExpensesOnBehalfOfSubsidiaries', window );">Expenses paid on behalf of subsidiaries</a></td>
<td class="num">(8,982)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(3,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH</a></td>
<td class="nump">3,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;Beginning of period</a></td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#8212;End of period</a></td>
<td class="nump">$ 3,215<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromSubsidiariesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) of subsidiary attributable to the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromSubsidiariesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the net carrying value of derivative instruments reported as assets and liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDistributionsToAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDistributionsToAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_PaymentsOfExpensesOnBehalfOfSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Of Expenses On Behalf Of Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_PaymentsOfExpensesOnBehalfOfSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_wald_ProceedsFromTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Trust Account</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">wald_ProceedsFromTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>wald_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>wald-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:wald="http://www.waldencast.com/20221231"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="wald-20221231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">us-gaap:SupplyCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfDistributorServiceFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfDistributorServiceFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:SADistributorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfRevenueRecognitionTimingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:SADistributorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfRevenueRecognitionTimingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:PhysicianChannelProviderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:PhysicianChannelProviderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:USOnlineMarketplaceDistributorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfDistributorRevenueNonstandardPaymentTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:USOnlineMarketplaceDistributorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfDistributorRevenueNonstandardPaymentTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:OtherMisstatementAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:OtherMisstatementAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:SADistributorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfRevenueRecognitionTimingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:PhysicianChannelProviderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:USOnlineMarketplaceDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:USOnlineMarketplaceDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:USOnlineMarketplaceDistributorAndSADistributorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfDistributorRevenueNonstandardPaymentTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfDistributorServiceFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfDistributorServiceFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfCapitalizedComputerSoftwareExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfCapitalizedComputerSoftwareExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:OtherMisstatementAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfCapitalizedMarketingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfCapitalizedInternalUseSoftwareCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfAccruedDistributionServiceFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">wald:MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">wald:InventoryPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">wald:VendorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">wald:InventoryPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">wald:VendorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">wald:InventoryPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">wald:VendorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">wald:InventoryPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">wald:VendorThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">wald:InventoryPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">wald:VendorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">wald:InventoryPurchasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">wald:VendorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:LenderConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">wald:VendorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:LenderConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">wald:VendorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:LenderConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">wald:VendorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">wald:ComputerHardwareSoftwareAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">wald:GondolasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wald:FounderAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">wald:LimitedPartnershipUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:CedarwalkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiChinaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiChinaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiChinaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiChinaBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:TretinoinDistributionAndSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:TretinoinDistributionAndSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:TretinoinDistributionAndSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:TretinoinDistributionAndSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:FormulationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:FormulationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:FormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:FormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelDirectlyToConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">us-gaap:SalesChannelThroughIntermediaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">wald:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:PhysicianChannelProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:PhysicianChannelProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:PhysicianChannelProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:PhysicianChannelProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:SpaChannelDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:SpaChannelDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:SpaChannelDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerSalesChannelAxis">wald:SpaChannelDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wald:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wald:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wald:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">wald:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:VN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:VN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:VN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:VN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:ObagiSkincareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:TretinoinDistributionAndSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:FormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:TretinoinDistributionAndSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">wald:FormulationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2018TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2018TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2018RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2018RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:PPPLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:PPPLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">wald:AlternateBaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="wald:VariableRateComponentAxis">wald:VariableRateComponentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">wald:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="wald:VariableRateComponentAxis">wald:VariableRateComponentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">wald:ApplicableRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="wald:VariableRateComponentAxis">wald:VariableRateComponentThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">wald:AlternateBaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="wald:VariableRateComponentAxis">wald:VariableRateComponentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2021RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2018TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2022RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:A2018TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:PPPLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:PPPLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:InterestRateCollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:InterestRateCollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:SponsorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BurwellMountainTrustAndZenoInvestmentMasterFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-20</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BurwellMountainTrustAndZenoInvestmentMasterFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:SponsorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-20</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BeautyVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BeautyVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:SponsorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BeautyVenturesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:SponsorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:InterestRateCollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:InterestRateCollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:InterestRateCollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:PublicDerivativeWarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:PublicDerivativeWarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:PublicDerivativeWarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:PublicDerivativeWarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:PrivateDerivativeWarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:PrivateDerivativeWarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:PrivateDerivativeWarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">wald:PrivateDerivativeWarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <instant>2021-09-29</instant>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">wald:ComputerHardwareSoftwareAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">wald:GondolasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:A2022IncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:A2022IncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockAppreciationRightsSARSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiAndMilkBusinessCombinationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">wald:ShareBasedPaymentArrangementFounderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-12</startDate>
            <endDate>2022-08-12</endDate>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
        </entity>
        <period>
            <startDate>2022-08-12</startDate>
            <endDate>2022-08-12</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">wald:ShareBasedPaymentArrangementFounderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-12</startDate>
            <endDate>2022-08-12</endDate>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">wald:ShareBasedPaymentArrangementFounderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-12</startDate>
            <endDate>2022-08-12</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:LongTermIncentiveAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:OneTimStockGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:OneTimStockGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wald:FounderAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wald:ReplacementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wald:FounderAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wald:FounderAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:WaldencastPlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:PredecessorIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:PredecessorIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:PredecessorIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:PredecessorIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:PredecessorIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:PredecessorIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:PredecessorIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">wald:PredecessorIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:InvestorDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorAndInvestorDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BurwellMountainTrustAndZenoInvestmentMasterFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BurwellMountainTrustAndZenoInvestmentMasterFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:SponsorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BurwellMountainTrustAndZenoInvestmentMasterFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BeautyVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BeautyVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:SponsorWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:BeautyVenturesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:InvestorDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:AaronChatterleyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:ObagiMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:MilkTransactionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">wald:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">wald:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:JanuaryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:JanuaryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:ConvertibleWorkingCapitalNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:ConvertibleWorkingCapitalNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:ConvertibleWorkingCapitalNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:ConvertibleWorkingCapitalNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:NonConvertibleWorkingCapitalNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:NonConvertibleWorkingCapitalNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:NonConvertibleWorkingCapitalNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">wald:NonConvertibleWorkingCapitalNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-15</startDate>
            <endDate>2021-03-15</endDate>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-15</instant>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiChinaBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiChinaBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SupplyCommitmentAxis">us-gaap:SupplyCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiChinaBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiChinaBusinessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiCosmeceuticalsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiShanghaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiShanghaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiShanghaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiShanghaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:ObagiShanghaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:CedarwalkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">wald:CedarwalkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">wald:MilkMakeupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">wald:SkintrinsiqDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">wald:SkintrinsiqDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">wald:SkintrinsiqDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">wald:SkintrinsiqDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">wald:StockGrowthIncentiveAwardsSGIAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">srt:WarehouseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">wald:ObagiBlueSeaHoldingLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:VietnamPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:SADistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">wald:VietnamPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">wald:SADistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840199</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="distributor">
        <measure>wald:distributor</measure>
    </unit>
    <unit id="segment">
        <measure>wald:segment</measure>
    </unit>
    <unit id="director">
        <measure>wald:director</measure>
    </unit>
    <unit id="operatinglease">
        <measure>wald:operatingLease</measure>
    </unit>
    <unit id="individual">
        <measure>wald:individual</measure>
    </unit>
    <unit id="tradingday">
        <measure>wald:tradingDay</measure>
    </unit>
    <unit id="lease">
        <measure>wald:lease</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-43">0001840199</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-44">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-45">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-46">2022</dei:DocumentFiscalYearFocus>
    <dei:EntityAddressCountry contextRef="c-1" id="f-47">US</dei:EntityAddressCountry>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-48">Y9</dei:EntityIncorporationStateCountryCode>
    <wald:StockholdersEquityNumberOfSharesInEachUnit contextRef="c-96" decimals="4" id="f-579" unitRef="shares">0.3333</wald:StockholdersEquityNumberOfSharesInEachUnit>
    <wald:ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption contextRef="c-361" id="f-1576">P3D</wald:ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod contextRef="c-390" id="f-1814">P10Y</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-401"
      decimals="2"
      id="f-1815"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <wald:TransitionServicesAgreementPeriod contextRef="c-501" id="f-2134">P12M</wald:TransitionServicesAgreementPeriod>
    <wald:TransitionServicesAgreementExtensionPeriod contextRef="c-501" id="f-2135">P12M</wald:TransitionServicesAgreementExtensionPeriod>
    <wald:ForwardPurchaseAgreementHurdleRateAccrualPeriod contextRef="c-516" id="f-2150">P5Y</wald:ForwardPurchaseAgreementHurdleRateAccrualPeriod>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-15"
      decimals="INF"
      id="f-2183"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-15"
      decimals="INF"
      id="f-2184"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <dei:DocumentType contextRef="c-1" id="f-1">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c-1" id="f-2">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-3">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-5">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-6">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c-1" id="f-7">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-8">001-40207</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-9">Waldencast plc</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">10 Bank Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-11">Suite 560</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">White Plains</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-13">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">10606</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelName contextRef="c-2" id="f-15">Michel Brousset</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c-2" id="f-16">10 Bank Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-2" id="f-17">Suite 560</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-2" id="f-18">White Plains</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-2" id="f-19">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-2" id="f-20">10606</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-2" id="f-21">917</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-2" id="f-22">546-6828</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-3" id="f-23">Class A ordinary shares, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-24">WALD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-25">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-4" id="f-26">Redeemable warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-4" id="f-27">WALDW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-4" id="f-28">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-29" unitRef="shares">86460560</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-30" unitRef="shares">21104225</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-32">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-33">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-34">No</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-35">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-36">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-37">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-38">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-39">true</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentFinStmtRestatementRecoveryAnalysisFlag contextRef="c-1" id="f-40">false</dei:DocumentFinStmtRestatementRecoveryAnalysisFlag>
    <dei:DocumentAccountingStandard contextRef="c-1" id="f-41">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c-1" id="f-42">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="c-1" id="f-49">34</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-50">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-51">Costa Mesa, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-52" unitRef="usd">8693000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-8" decimals="-3" id="f-53" unitRef="usd">12794000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c-7" decimals="-3" id="f-54" unitRef="usd">1470000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-8" decimals="-3" id="f-55" unitRef="usd">650000</us-gaap:RestrictedCash>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-9" decimals="-3" id="f-56" unitRef="usd">19259000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-10" decimals="-3" id="f-57" unitRef="usd">18738000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-11" decimals="-3" id="f-58" unitRef="usd">285000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-12" decimals="-3" id="f-59" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-7" decimals="-3" id="f-60" unitRef="usd">54384000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-8" decimals="-3" id="f-61" unitRef="usd">21611000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-7" decimals="-3" id="f-62" unitRef="usd">6273000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-8" decimals="-3" id="f-63" unitRef="usd">4965000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-64" unitRef="usd">679000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-8" decimals="-3" id="f-65" unitRef="usd">279000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-7" decimals="-3" id="f-66" unitRef="usd">91043000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-8" decimals="-3" id="f-67" unitRef="usd">59037000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-68" unitRef="usd">8328000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-8" decimals="-3" id="f-69" unitRef="usd">1198000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-7" decimals="-3" id="f-70" unitRef="usd">639165000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-8" decimals="-3" id="f-71" unitRef="usd">79574000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-7" decimals="-3" id="f-72" unitRef="usd">334620000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-8" decimals="-3" id="f-73" unitRef="usd">44489000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-7" decimals="-3" id="f-74" unitRef="usd">16384000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-8" decimals="-3" id="f-75" unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-7" decimals="-3" id="f-76" unitRef="usd">535000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-8" decimals="-3" id="f-77" unitRef="usd">288000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-7" decimals="-3" id="f-78" unitRef="usd">1090075000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-8" decimals="-3" id="f-79" unitRef="usd">184586000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-9" decimals="-3" id="f-80" unitRef="usd">23873000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-10" decimals="-3" id="f-81" unitRef="usd">12680000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-11" decimals="-3" id="f-82" unitRef="usd">373000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-12" decimals="-3" id="f-83" unitRef="usd">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-84" unitRef="usd">2041000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-8" decimals="-3" id="f-85" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-7" decimals="-3" id="f-86" unitRef="usd">20095000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-8" decimals="-3" id="f-87" unitRef="usd">15442000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-11" decimals="-3" id="f-88" unitRef="usd">9914000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-89" unitRef="usd">26123000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-90" unitRef="usd">12683000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-91" unitRef="usd">72505000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-92" unitRef="usd">40805000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-7" decimals="-3" id="f-93" unitRef="usd">159229000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-8" decimals="-3" id="f-94" unitRef="usd">103423000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c-7" decimals="-3" id="f-95" unitRef="usd">18311000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c-8" decimals="-3" id="f-96" unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-97" unitRef="usd">17882000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-8" decimals="-3" id="f-98" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-7" decimals="-3" id="f-99" unitRef="usd">22250000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-8" decimals="-3" id="f-100" unitRef="usd">548000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-7" decimals="-3" id="f-101" unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-8" decimals="-3" id="f-102" unitRef="usd">571000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-7" decimals="-3" id="f-103" unitRef="usd">290177000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-8" decimals="-3" id="f-104" unitRef="usd">145347000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-7" id="f-105" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-8" id="f-106" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-107" unitRef="shares">25000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="2"
      id="f-108"
      unitRef="usdPerShare">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-109" unitRef="shares">8000002</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-8" decimals="INF" id="f-110" unitRef="shares">8000002</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-8" decimals="-3" id="f-111" unitRef="usd">4000000</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-112" unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="4"
      id="f-113"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-114" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-7" decimals="INF" id="f-115" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="4"
      id="f-116"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-117" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-118" unitRef="shares">86460560</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-119" unitRef="usd">8000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="4"
      id="f-120"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-121" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-122" unitRef="shares">21104225</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="-3" id="f-123" unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-7" decimals="-3" id="f-124" unitRef="usd">796038000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-8" decimals="-3" id="f-125" unitRef="usd">100113000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-7" decimals="-3" id="f-126" unitRef="usd">-156780000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-8" decimals="-3" id="f-127" unitRef="usd">-64849000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-7" decimals="-3" id="f-128" unitRef="usd">-29000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-8" decimals="-3" id="f-129" unitRef="usd">-25000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-130" unitRef="usd">639239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-131" unitRef="usd">39239000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-7" decimals="-3" id="f-132" unitRef="usd">160659000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-8" decimals="-3" id="f-133" unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-134" unitRef="usd">799898000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-8" decimals="-3" id="f-135" unitRef="usd">39239000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-7" decimals="-3" id="f-136" unitRef="usd">1090075000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-8" decimals="-3" id="f-137" unitRef="usd">184586000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-138" unitRef="usd">17219000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-139" unitRef="usd">92373000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-3" id="f-140" unitRef="usd">73760000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-16" decimals="-3" id="f-141" unitRef="usd">142472000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-17" decimals="-3" id="f-142" unitRef="usd">94428000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-13" decimals="-3" id="f-143" unitRef="usd">5128000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-14" decimals="-3" id="f-144" unitRef="usd">60657000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-15" decimals="-3" id="f-145" unitRef="usd">30868000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-16" decimals="-3" id="f-146" unitRef="usd">55037000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-17" decimals="-3" id="f-147" unitRef="usd">29096000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-14" decimals="-3" id="f-148" unitRef="usd">31716000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-15" decimals="-3" id="f-149" unitRef="usd">42892000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-16" decimals="-3" id="f-150" unitRef="usd">87435000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-17" decimals="-3" id="f-151" unitRef="usd">65332000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-14" decimals="-3" id="f-152" unitRef="usd">88926000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-15" decimals="-3" id="f-153" unitRef="usd">55549000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-16" decimals="-3" id="f-154" unitRef="usd">82968000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-17" decimals="-3" id="f-155" unitRef="usd">60421000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-14" decimals="-3" id="f-156" unitRef="usd">1796000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-15" decimals="-3" id="f-157" unitRef="usd">2606000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-16" decimals="-3" id="f-158" unitRef="usd">6092000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-17" decimals="-3" id="f-159" unitRef="usd">4383000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-14" decimals="-3" id="f-160" unitRef="usd">68715000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-15" decimals="-3" id="f-161" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-16" decimals="-3" id="f-162" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-17" decimals="-3" id="f-163" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:OperatingExpenses contextRef="c-14" decimals="-3" id="f-164" unitRef="usd">159437000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-15" decimals="-3" id="f-165" unitRef="usd">58155000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-16" decimals="-3" id="f-166" unitRef="usd">89060000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-17" decimals="-3" id="f-167" unitRef="usd">64804000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-14" decimals="-3" id="f-168" unitRef="usd">-127721000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-15" decimals="-3" id="f-169" unitRef="usd">-15263000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-16" decimals="-3" id="f-170" unitRef="usd">-1625000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-17" decimals="-3" id="f-171" unitRef="usd">528000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="c-14" decimals="-3" id="f-172" unitRef="usd">6230000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-15" decimals="-3" id="f-173" unitRef="usd">6652000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-16" decimals="-3" id="f-174" unitRef="usd">11118000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-17" decimals="-3" id="f-175" unitRef="usd">6281000</us-gaap:InterestExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-14" decimals="-3" id="f-176" unitRef="usd">6793000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-15" decimals="-3" id="f-177" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-16" decimals="-3" id="f-178" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-17" decimals="-3" id="f-179" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-14" decimals="-3" id="f-180" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-15" decimals="-3" id="f-181" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-16" decimals="-3" id="f-182" unitRef="usd">-2317000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-17" decimals="-3" id="f-183" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <wald:GainOnPPPLoanForgiveness contextRef="c-14" decimals="-3" id="f-184" unitRef="usd">0</wald:GainOnPPPLoanForgiveness>
    <wald:GainOnPPPLoanForgiveness contextRef="c-15" decimals="-3" id="f-185" unitRef="usd">0</wald:GainOnPPPLoanForgiveness>
    <wald:GainOnPPPLoanForgiveness contextRef="c-16" decimals="-3" id="f-186" unitRef="usd">6824000</wald:GainOnPPPLoanForgiveness>
    <wald:GainOnPPPLoanForgiveness contextRef="c-17" decimals="-3" id="f-187" unitRef="usd">0</wald:GainOnPPPLoanForgiveness>
    <wald:GainLossOnNoteReceivableWriteoff contextRef="c-14" decimals="-3" id="f-188" unitRef="usd">0</wald:GainLossOnNoteReceivableWriteoff>
    <wald:GainLossOnNoteReceivableWriteoff contextRef="c-15" decimals="-3" id="f-189" unitRef="usd">0</wald:GainLossOnNoteReceivableWriteoff>
    <wald:GainLossOnNoteReceivableWriteoff contextRef="c-16" decimals="-3" id="f-190" unitRef="usd">-2555000</wald:GainLossOnNoteReceivableWriteoff>
    <wald:GainLossOnNoteReceivableWriteoff contextRef="c-17" decimals="-3" id="f-191" unitRef="usd">0</wald:GainLossOnNoteReceivableWriteoff>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-14" decimals="-3" id="f-192" unitRef="usd">798000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-15" decimals="-3" id="f-193" unitRef="usd">971000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-16" decimals="-3" id="f-194" unitRef="usd">817000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-17" decimals="-3" id="f-195" unitRef="usd">-11000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-14" decimals="-3" id="f-196" unitRef="usd">1361000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-15" decimals="-3" id="f-197" unitRef="usd">-5681000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-16" decimals="-3" id="f-198" unitRef="usd">-8349000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-17" decimals="-3" id="f-199" unitRef="usd">-6292000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-200" unitRef="usd">-126360000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-201" unitRef="usd">-20944000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-202" unitRef="usd">-9974000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-203" unitRef="usd">-5764000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-204" unitRef="usd">-5803000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-205" unitRef="usd">113000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-206" unitRef="usd">9602000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-207" unitRef="usd">-3394000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-208" unitRef="usd">-120557000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-209" unitRef="usd">-21057000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-3" id="f-210" unitRef="usd">-19576000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-3" id="f-211" unitRef="usd">-2370000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-212" unitRef="usd">-24990000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-213" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-214" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-215" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-216" unitRef="usd">-95567000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-217" unitRef="usd">-21057000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-218" unitRef="usd">-19576000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-17" decimals="-3" id="f-219" unitRef="usd">-2370000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-220"
      unitRef="usdPerShare">-1.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-221"
      unitRef="usdPerShare">-1.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-222"
      unitRef="usdPerShare">-2.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-223"
      unitRef="usdPerShare">-2.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-16"
      decimals="2"
      id="f-224"
      unitRef="usdPerShare">-2.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-16"
      decimals="2"
      id="f-225"
      unitRef="usdPerShare">-2.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-17"
      decimals="2"
      id="f-226"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-17"
      decimals="2"
      id="f-227"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-14"
      decimals="INF"
      id="f-228"
      unitRef="shares">86460560</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-14"
      decimals="INF"
      id="f-229"
      unitRef="shares">86460560</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-15"
      decimals="INF"
      id="f-230"
      unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-15"
      decimals="INF"
      id="f-231"
      unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-16"
      decimals="INF"
      id="f-232"
      unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-16"
      decimals="INF"
      id="f-233"
      unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-17"
      decimals="INF"
      id="f-234"
      unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-17"
      decimals="INF"
      id="f-235"
      unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-236" unitRef="usd">-120557000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-237" unitRef="usd">-21057000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-3" id="f-238" unitRef="usd">-19576000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-3" id="f-239" unitRef="usd">-2370000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-14" decimals="-3" id="f-240" unitRef="usd">-36000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-15" decimals="-3" id="f-241" unitRef="usd">96000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-16" decimals="-3" id="f-242" unitRef="usd">-32000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-17" decimals="-3" id="f-243" unitRef="usd">16000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-244" unitRef="usd">-120593000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-245" unitRef="usd">-20961000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-246" unitRef="usd">-19608000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-247" unitRef="usd">-2354000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-248" unitRef="usd">-24997000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-249" unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-250" unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-251" unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-14" decimals="-3" id="f-252" unitRef="usd">-95596000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-15" decimals="-3" id="f-253" unitRef="usd">-20961000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-16" decimals="-3" id="f-254" unitRef="usd">-19608000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-17" decimals="-3" id="f-255" unitRef="usd">-2354000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-18"
      decimals="INF"
      id="f-256"
      unitRef="shares">8645000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="-3" id="f-257" unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-19"
      decimals="INF"
      id="f-258"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-3" id="f-259" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-20" decimals="-3" id="f-260" unitRef="usd">174000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-21" decimals="-3" id="f-261" unitRef="usd">-61213000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-262" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-23" decimals="-3" id="f-263" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="-3" id="f-264" unitRef="usd">-61038000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <wald:StockIssuedDuringPeriodSharesTrustProceeds
      contextRef="c-25"
      decimals="INF"
      id="f-265"
      unitRef="shares">4478054</wald:StockIssuedDuringPeriodSharesTrustProceeds>
    <wald:StockIssuedDuringPeriodValueTrustProceeds contextRef="c-26" decimals="-3" id="f-266" unitRef="usd">44882000</wald:StockIssuedDuringPeriodValueTrustProceeds>
    <wald:StockIssuedDuringPeriodValueTrustProceeds contextRef="c-27" decimals="-3" id="f-267" unitRef="usd">44882000</wald:StockIssuedDuringPeriodValueTrustProceeds>
    <wald:StockIssuedDuringPeriodSharesForeignPurchaseAgreements
      contextRef="c-25"
      decimals="INF"
      id="f-268"
      unitRef="shares">33300000</wald:StockIssuedDuringPeriodSharesForeignPurchaseAgreements>
    <wald:StockIssuedDuringPeriodValueForeignPurchaseAgreements contextRef="c-25" decimals="-3" id="f-269" unitRef="usd">3000</wald:StockIssuedDuringPeriodValueForeignPurchaseAgreements>
    <wald:StockIssuedDuringPeriodValueForeignPurchaseAgreements contextRef="c-26" decimals="-3" id="f-270" unitRef="usd">332997000</wald:StockIssuedDuringPeriodValueForeignPurchaseAgreements>
    <wald:StockIssuedDuringPeriodValueForeignPurchaseAgreements contextRef="c-27" decimals="-3" id="f-271" unitRef="usd">333000000</wald:StockIssuedDuringPeriodValueForeignPurchaseAgreements>
    <wald:StockIssuedDuringPeriodSharesSubscriptionAgreements
      contextRef="c-25"
      decimals="INF"
      id="f-272"
      unitRef="shares">11800000</wald:StockIssuedDuringPeriodSharesSubscriptionAgreements>
    <wald:StockIssuedDuringPeriodValueSubscriptionAgreements contextRef="c-25" decimals="-3" id="f-273" unitRef="usd">1000</wald:StockIssuedDuringPeriodValueSubscriptionAgreements>
    <wald:StockIssuedDuringPeriodValueSubscriptionAgreements contextRef="c-26" decimals="-3" id="f-274" unitRef="usd">117999000</wald:StockIssuedDuringPeriodValueSubscriptionAgreements>
    <wald:StockIssuedDuringPeriodValueSubscriptionAgreements contextRef="c-27" decimals="-3" id="f-275" unitRef="usd">118000000</wald:StockIssuedDuringPeriodValueSubscriptionAgreements>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-25"
      decimals="INF"
      id="f-276"
      unitRef="shares">28237506</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-25" decimals="-3" id="f-277" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="c-28"
      decimals="INF"
      id="f-278"
      unitRef="shares">21104225</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-28" decimals="-3" id="f-279" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-26" decimals="-3" id="f-280" unitRef="usd">292250000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-29" decimals="-3" id="f-281" unitRef="usd">185656000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-27" decimals="-3" id="f-282" unitRef="usd">477911000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:ProfitLoss contextRef="c-30" decimals="-3" id="f-283" unitRef="usd">-95567000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-29" decimals="-3" id="f-284" unitRef="usd">-24990000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-27" decimals="-3" id="f-285" unitRef="usd">-120557000</us-gaap:ProfitLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-26" decimals="-3" id="f-286" unitRef="usd">7736000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-27" decimals="-3" id="f-287" unitRef="usd">7736000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-31" decimals="-3" id="f-288" unitRef="usd">-29000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-29" decimals="-3" id="f-289" unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-27" decimals="-3" id="f-290" unitRef="usd">-36000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-32"
      decimals="INF"
      id="f-291"
      unitRef="shares">86460560</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-292" unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-33"
      decimals="INF"
      id="f-293"
      unitRef="shares">21104225</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-294" unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="-3" id="f-295" unitRef="usd">796038000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="-3" id="f-296" unitRef="usd">-156780000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-36" decimals="-3" id="f-297" unitRef="usd">-29000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-37" decimals="-3" id="f-298" unitRef="usd">160659000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-38" decimals="-3" id="f-299" unitRef="usd">799898000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-39"
      decimals="INF"
      id="f-300"
      unitRef="shares">8000002000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-39" decimals="-3" id="f-301" unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-40" decimals="-3" id="f-302" unitRef="usd">96055000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-3" id="f-303" unitRef="usd">-1513000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-3" id="f-304" unitRef="usd">-9000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-3" id="f-305" unitRef="usd">98533000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-3" id="f-306" unitRef="usd">-37346000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-307" unitRef="usd">-37346000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-46"
      decimals="INF"
      id="f-308"
      unitRef="shares">8000002000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-309" unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-3" id="f-310" unitRef="usd">96055000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-3" id="f-311" unitRef="usd">-38859000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-3" id="f-312" unitRef="usd">-9000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-3" id="f-313" unitRef="usd">61187000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-51" decimals="-3" id="f-314" unitRef="usd">-2370000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-52" decimals="-3" id="f-315" unitRef="usd">-2370000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-53" decimals="-3" id="f-316" unitRef="usd">16000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-52" decimals="-3" id="f-317" unitRef="usd">16000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="c-54" decimals="-3" id="f-318" unitRef="usd">4058000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="c-52" decimals="-3" id="f-319" unitRef="usd">4058000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-17"
      decimals="2"
      id="f-320"
      unitRef="usdPerShare">0.26</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash contextRef="c-51" decimals="-3" id="f-321" unitRef="usd">2044000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-52" decimals="-3" id="f-322" unitRef="usd">2044000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-55"
      decimals="INF"
      id="f-323"
      unitRef="shares">8000002000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-55" decimals="-3" id="f-324" unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-3" id="f-325" unitRef="usd">100113000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-3" id="f-326" unitRef="usd">-43273000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-3" id="f-327" unitRef="usd">7000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-3" id="f-328" unitRef="usd">60847000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-60" decimals="-3" id="f-329" unitRef="usd">-19576000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-61" decimals="-3" id="f-330" unitRef="usd">-19576000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-62" decimals="-3" id="f-331" unitRef="usd">-32000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-61" decimals="-3" id="f-332" unitRef="usd">-32000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-16"
      decimals="2"
      id="f-333"
      unitRef="usdPerShare">0.25</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash contextRef="c-60" decimals="-3" id="f-334" unitRef="usd">2000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-61" decimals="-3" id="f-335" unitRef="usd">2000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-63"
      decimals="INF"
      id="f-336"
      unitRef="shares">8000002000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-63" decimals="-3" id="f-337" unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-64" decimals="-3" id="f-338" unitRef="usd">100113000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-65" decimals="-3" id="f-339" unitRef="usd">-64849000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-66" decimals="-3" id="f-340" unitRef="usd">-25000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-67" decimals="-3" id="f-341" unitRef="usd">39239000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-68" decimals="-3" id="f-342" unitRef="usd">-21057000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-69" decimals="-3" id="f-343" unitRef="usd">-21057000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-70" decimals="-3" id="f-344" unitRef="usd">96000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-69" decimals="-3" id="f-345" unitRef="usd">96000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <wald:DistributionOfBusiness contextRef="c-71" decimals="-3" id="f-346" unitRef="usd">13113000</wald:DistributionOfBusiness>
    <wald:DistributionOfBusiness contextRef="c-68" decimals="-3" id="f-347" unitRef="usd">188000</wald:DistributionOfBusiness>
    <wald:DistributionOfBusiness contextRef="c-70" decimals="-3" id="f-348" unitRef="usd">71000</wald:DistributionOfBusiness>
    <wald:DistributionOfBusiness contextRef="c-69" decimals="-3" id="f-349" unitRef="usd">13372000</wald:DistributionOfBusiness>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-72"
      decimals="INF"
      id="f-350"
      unitRef="shares">8000002000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-72" decimals="-3" id="f-351" unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-73" decimals="-3" id="f-352" unitRef="usd">87000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-74" decimals="-3" id="f-353" unitRef="usd">-86094000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-75" decimals="-3" id="f-354" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-76" decimals="-3" id="f-355" unitRef="usd">4906000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-356" unitRef="usd">-120557000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-357" unitRef="usd">-21057000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-3" id="f-358" unitRef="usd">-19576000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-3" id="f-359" unitRef="usd">-2370000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-14" decimals="-3" id="f-360" unitRef="usd">7736000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-15" decimals="-3" id="f-361" unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-16" decimals="-3" id="f-362" unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-17" decimals="-3" id="f-363" unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <wald:DepreciationDepletionAndAmortizationOperatingActivities contextRef="c-14" decimals="-3" id="f-364" unitRef="usd">26982000</wald:DepreciationDepletionAndAmortizationOperatingActivities>
    <wald:DepreciationDepletionAndAmortizationOperatingActivities contextRef="c-15" decimals="-3" id="f-365" unitRef="usd">8190000</wald:DepreciationDepletionAndAmortizationOperatingActivities>
    <wald:DepreciationDepletionAndAmortizationOperatingActivities contextRef="c-16" decimals="-3" id="f-366" unitRef="usd">13904000</wald:DepreciationDepletionAndAmortizationOperatingActivities>
    <wald:DepreciationDepletionAndAmortizationOperatingActivities contextRef="c-17" decimals="-3" id="f-367" unitRef="usd">13421000</wald:DepreciationDepletionAndAmortizationOperatingActivities>
    <us-gaap:OperatingLeaseExpense contextRef="c-14" decimals="-3" id="f-368" unitRef="usd">740000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-15" decimals="-3" id="f-369" unitRef="usd">0</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-16" decimals="-3" id="f-370" unitRef="usd">0</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-17" decimals="-3" id="f-371" unitRef="usd">0</us-gaap:OperatingLeaseExpense>
    <us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities contextRef="c-14" decimals="-3" id="f-372" unitRef="usd">6793000</us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities contextRef="c-15" decimals="-3" id="f-373" unitRef="usd">0</us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities contextRef="c-16" decimals="-3" id="f-374" unitRef="usd">0</us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities contextRef="c-17" decimals="-3" id="f-375" unitRef="usd">0</us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities>
    <wald:NonCashLossFromChangeInFairValueOnInterestRateCollar contextRef="c-14" decimals="-3" id="f-376" unitRef="usd">592000</wald:NonCashLossFromChangeInFairValueOnInterestRateCollar>
    <wald:NonCashLossFromChangeInFairValueOnInterestRateCollar contextRef="c-15" decimals="-3" id="f-377" unitRef="usd">0</wald:NonCashLossFromChangeInFairValueOnInterestRateCollar>
    <wald:NonCashLossFromChangeInFairValueOnInterestRateCollar contextRef="c-16" decimals="-3" id="f-378" unitRef="usd">0</wald:NonCashLossFromChangeInFairValueOnInterestRateCollar>
    <wald:NonCashLossFromChangeInFairValueOnInterestRateCollar contextRef="c-17" decimals="-3" id="f-379" unitRef="usd">0</wald:NonCashLossFromChangeInFairValueOnInterestRateCollar>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-14" decimals="-3" id="f-380" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-15" decimals="-3" id="f-381" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-16" decimals="-3" id="f-382" unitRef="usd">-2317000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-17" decimals="-3" id="f-383" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <wald:GainOnPPPLoanForgiveness contextRef="c-14" decimals="-3" id="f-384" unitRef="usd">0</wald:GainOnPPPLoanForgiveness>
    <wald:GainOnPPPLoanForgiveness contextRef="c-15" decimals="-3" id="f-385" unitRef="usd">0</wald:GainOnPPPLoanForgiveness>
    <wald:GainOnPPPLoanForgiveness contextRef="c-16" decimals="-3" id="f-386" unitRef="usd">6824000</wald:GainOnPPPLoanForgiveness>
    <wald:GainOnPPPLoanForgiveness contextRef="c-17" decimals="-3" id="f-387" unitRef="usd">0</wald:GainOnPPPLoanForgiveness>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-14" decimals="-3" id="f-388" unitRef="usd">677000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-15" decimals="-3" id="f-389" unitRef="usd">767000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-16" decimals="-3" id="f-390" unitRef="usd">1139000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-17" decimals="-3" id="f-391" unitRef="usd">798000</us-gaap:AmortizationOfFinancingCosts>
    <wald:AmortizationOfRelatedPartyLiability contextRef="c-14" decimals="-3" id="f-392" unitRef="usd">12186000</wald:AmortizationOfRelatedPartyLiability>
    <wald:AmortizationOfRelatedPartyLiability contextRef="c-15" decimals="-3" id="f-393" unitRef="usd">0</wald:AmortizationOfRelatedPartyLiability>
    <wald:AmortizationOfRelatedPartyLiability contextRef="c-16" decimals="-3" id="f-394" unitRef="usd">0</wald:AmortizationOfRelatedPartyLiability>
    <wald:AmortizationOfRelatedPartyLiability contextRef="c-17" decimals="-3" id="f-395" unitRef="usd">0</wald:AmortizationOfRelatedPartyLiability>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-396" unitRef="usd">-5823000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-397" unitRef="usd">90000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-398" unitRef="usd">9374000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-399" unitRef="usd">-3044000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-14" decimals="-3" id="f-400" unitRef="usd">68715000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-15" decimals="-3" id="f-401" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-16" decimals="-3" id="f-402" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-17" decimals="-3" id="f-403" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-14" decimals="-3" id="f-404" unitRef="usd">2000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-15" decimals="-3" id="f-405" unitRef="usd">-35000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-16" decimals="-3" id="f-406" unitRef="usd">-52000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-17" decimals="-3" id="f-407" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <wald:GainLossOnNoteReceivableWriteoff contextRef="c-14" decimals="-3" id="f-408" unitRef="usd">0</wald:GainLossOnNoteReceivableWriteoff>
    <wald:GainLossOnNoteReceivableWriteoff contextRef="c-15" decimals="-3" id="f-409" unitRef="usd">0</wald:GainLossOnNoteReceivableWriteoff>
    <wald:GainLossOnNoteReceivableWriteoff contextRef="c-16" decimals="-3" id="f-410" unitRef="usd">-2555000</wald:GainLossOnNoteReceivableWriteoff>
    <wald:GainLossOnNoteReceivableWriteoff contextRef="c-17" decimals="-3" id="f-411" unitRef="usd">0</wald:GainLossOnNoteReceivableWriteoff>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-14" decimals="-3" id="f-412" unitRef="usd">204000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-15" decimals="-3" id="f-413" unitRef="usd">-3524000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-16" decimals="-3" id="f-414" unitRef="usd">5057000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-17" decimals="-3" id="f-415" unitRef="usd">16661000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties contextRef="c-14" decimals="-3" id="f-416" unitRef="usd">-265000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties contextRef="c-15" decimals="-3" id="f-417" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties contextRef="c-16" decimals="-3" id="f-418" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties contextRef="c-17" decimals="-3" id="f-419" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-14" decimals="-3" id="f-420" unitRef="usd">-6382000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-15" decimals="-3" id="f-421" unitRef="usd">13008000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-16" decimals="-3" id="f-422" unitRef="usd">6010000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-17" decimals="-3" id="f-423" unitRef="usd">-4441000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-14" decimals="-3" id="f-424" unitRef="usd">213000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-15" decimals="-3" id="f-425" unitRef="usd">-658000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-16" decimals="-3" id="f-426" unitRef="usd">1097000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-17" decimals="-3" id="f-427" unitRef="usd">1919000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-14" decimals="-3" id="f-428" unitRef="usd">250000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-15" decimals="-3" id="f-429" unitRef="usd">352000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-16" decimals="-3" id="f-430" unitRef="usd">-612000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-17" decimals="-3" id="f-431" unitRef="usd">-1159000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties contextRef="c-14" decimals="-3" id="f-432" unitRef="usd">-1021000</wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties>
    <wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties contextRef="c-15" decimals="-3" id="f-433" unitRef="usd">9635000</wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties>
    <wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties contextRef="c-16" decimals="-3" id="f-434" unitRef="usd">9647000</wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties>
    <wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties contextRef="c-17" decimals="-3" id="f-435" unitRef="usd">-7391000</wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="c-14" decimals="-3" id="f-436" unitRef="usd">43000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="c-15" decimals="-3" id="f-437" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="c-16" decimals="-3" id="f-438" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="c-17" decimals="-3" id="f-439" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-14" decimals="-3" id="f-440" unitRef="usd">-724000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-15" decimals="-3" id="f-441" unitRef="usd">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-16" decimals="-3" id="f-442" unitRef="usd">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-17" decimals="-3" id="f-443" unitRef="usd">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-14" decimals="-3" id="f-444" unitRef="usd">-39336000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-15" decimals="-3" id="f-445" unitRef="usd">1481000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-16" decimals="-3" id="f-446" unitRef="usd">2493000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-17" decimals="-3" id="f-447" unitRef="usd">4135000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-14" decimals="-3" id="f-448" unitRef="usd">-74977000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-15" decimals="-3" id="f-449" unitRef="usd">-10037000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-16" decimals="-3" id="f-450" unitRef="usd">3529000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-17" decimals="-3" id="f-451" unitRef="usd">-7431000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-14" decimals="-3" id="f-452" unitRef="usd">247000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-15" decimals="-3" id="f-453" unitRef="usd">248000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-16" decimals="-3" id="f-454" unitRef="usd">863000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-17" decimals="-3" id="f-455" unitRef="usd">653000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-14" decimals="-3" id="f-456" unitRef="usd">1340000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-15" decimals="-3" id="f-457" unitRef="usd">661000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-16" decimals="-3" id="f-458" unitRef="usd">424000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-17" decimals="-3" id="f-459" unitRef="usd">1054000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <wald:AdvancesForNoteReceivable contextRef="c-14" decimals="-3" id="f-460" unitRef="usd">0</wald:AdvancesForNoteReceivable>
    <wald:AdvancesForNoteReceivable contextRef="c-15" decimals="-3" id="f-461" unitRef="usd">0</wald:AdvancesForNoteReceivable>
    <wald:AdvancesForNoteReceivable contextRef="c-16" decimals="-3" id="f-462" unitRef="usd">2500000</wald:AdvancesForNoteReceivable>
    <wald:AdvancesForNoteReceivable contextRef="c-17" decimals="-3" id="f-463" unitRef="usd">0</wald:AdvancesForNoteReceivable>
    <wald:ProceedsFromTrustAccount contextRef="c-14" decimals="-3" id="f-464" unitRef="usd">44883000</wald:ProceedsFromTrustAccount>
    <wald:ProceedsFromTrustAccount contextRef="c-15" decimals="-3" id="f-465" unitRef="usd">0</wald:ProceedsFromTrustAccount>
    <wald:ProceedsFromTrustAccount contextRef="c-16" decimals="-3" id="f-466" unitRef="usd">0</wald:ProceedsFromTrustAccount>
    <wald:ProceedsFromTrustAccount contextRef="c-17" decimals="-3" id="f-467" unitRef="usd">0</wald:ProceedsFromTrustAccount>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-77" decimals="-3" id="f-468" unitRef="usd">465010000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-78" decimals="-3" id="f-469" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-79" decimals="-3" id="f-470" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-80" decimals="-3" id="f-471" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-81" decimals="-3" id="f-472" unitRef="usd">122653000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-82" decimals="-3" id="f-473" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-83" decimals="-3" id="f-474" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-84" decimals="-3" id="f-475" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-14" decimals="-3" id="f-476" unitRef="usd">-544367000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-15" decimals="-3" id="f-477" unitRef="usd">-909000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-16" decimals="-3" id="f-478" unitRef="usd">-3787000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-17" decimals="-3" id="f-479" unitRef="usd">-1707000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-14" decimals="-3" id="f-480" unitRef="usd">118000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-15" decimals="-3" id="f-481" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-16" decimals="-3" id="f-482" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-17" decimals="-3" id="f-483" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <wald:ProceedsFromForwardPurchaseAgreements contextRef="c-14" decimals="-3" id="f-484" unitRef="usd">333000000</wald:ProceedsFromForwardPurchaseAgreements>
    <wald:ProceedsFromForwardPurchaseAgreements contextRef="c-15" decimals="-3" id="f-485" unitRef="usd">0</wald:ProceedsFromForwardPurchaseAgreements>
    <wald:ProceedsFromForwardPurchaseAgreements contextRef="c-16" decimals="-3" id="f-486" unitRef="usd">0</wald:ProceedsFromForwardPurchaseAgreements>
    <wald:ProceedsFromForwardPurchaseAgreements contextRef="c-17" decimals="-3" id="f-487" unitRef="usd">0</wald:ProceedsFromForwardPurchaseAgreements>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-14" decimals="-3" id="f-488" unitRef="usd">175000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-15" decimals="-3" id="f-489" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-16" decimals="-3" id="f-490" unitRef="usd">110000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c-17" decimals="-3" id="f-491" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c-14" decimals="-3" id="f-492" unitRef="usd">4348000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c-15" decimals="-3" id="f-493" unitRef="usd">1375000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c-16" decimals="-3" id="f-494" unitRef="usd">72455000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c-17" decimals="-3" id="f-495" unitRef="usd">9370000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-14" decimals="-3" id="f-496" unitRef="usd">14117000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-15" decimals="-3" id="f-497" unitRef="usd">6000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-16" decimals="-3" id="f-498" unitRef="usd">20000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-17" decimals="-3" id="f-499" unitRef="usd">29000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-14" decimals="-3" id="f-500" unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-15" decimals="-3" id="f-501" unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-16" decimals="-3" id="f-502" unitRef="usd">44000000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-17" decimals="-3" id="f-503" unitRef="usd">9000000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromOtherDebt contextRef="c-14" decimals="-3" id="f-504" unitRef="usd">0</us-gaap:ProceedsFromOtherDebt>
    <us-gaap:ProceedsFromOtherDebt contextRef="c-15" decimals="-3" id="f-505" unitRef="usd">0</us-gaap:ProceedsFromOtherDebt>
    <us-gaap:ProceedsFromOtherDebt contextRef="c-16" decimals="-3" id="f-506" unitRef="usd">0</us-gaap:ProceedsFromOtherDebt>
    <us-gaap:ProceedsFromOtherDebt contextRef="c-17" decimals="-3" id="f-507" unitRef="usd">6750000</us-gaap:ProceedsFromOtherDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-14" decimals="-3" id="f-508" unitRef="usd">6304000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-15" decimals="-3" id="f-509" unitRef="usd">742000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-16" decimals="-3" id="f-510" unitRef="usd">6383000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-17" decimals="-3" id="f-511" unitRef="usd">1017000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDividends contextRef="c-14" decimals="-3" id="f-512" unitRef="usd">0</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="c-15" decimals="-3" id="f-513" unitRef="usd">0</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="c-16" decimals="-3" id="f-514" unitRef="usd">2000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="c-17" decimals="-3" id="f-515" unitRef="usd">2044000</us-gaap:PaymentsOfDividends>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-14" decimals="-3" id="f-516" unitRef="usd">629465000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-15" decimals="-3" id="f-517" unitRef="usd">3883000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-16" decimals="-3" id="f-518" unitRef="usd">5162000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-17" decimals="-3" id="f-519" unitRef="usd">14319000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-14" decimals="-3" id="f-520" unitRef="usd">10121000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-15" decimals="-3" id="f-521" unitRef="usd">-7063000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-16" decimals="-3" id="f-522" unitRef="usd">4904000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-17" decimals="-3" id="f-523" unitRef="usd">5181000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-14" decimals="-3" id="f-524" unitRef="usd">-36000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-15" decimals="-3" id="f-525" unitRef="usd">96000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-16" decimals="-3" id="f-526" unitRef="usd">-32000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-17" decimals="-3" id="f-527" unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-85" decimals="-3" id="f-528" unitRef="usd">78000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-529" unitRef="usd">13444000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-86" decimals="-3" id="f-530" unitRef="usd">8572000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-87" decimals="-3" id="f-531" unitRef="usd">3391000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-532" unitRef="usd">10163000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-88" decimals="-3" id="f-533" unitRef="usd">6477000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-534" unitRef="usd">13444000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-86" decimals="-3" id="f-535" unitRef="usd">8572000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid contextRef="c-14" decimals="-3" id="f-536" unitRef="usd">152000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-15" decimals="-3" id="f-537" unitRef="usd">3000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-16" decimals="-3" id="f-538" unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-17" decimals="-3" id="f-539" unitRef="usd">9000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet contextRef="c-14" decimals="-3" id="f-540" unitRef="usd">5550000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-15" decimals="-3" id="f-541" unitRef="usd">5053000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-16" decimals="-3" id="f-542" unitRef="usd">10014000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-17" decimals="-3" id="f-543" unitRef="usd">5449000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-14" decimals="-3" id="f-544" unitRef="usd">406000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-15" decimals="-3" id="f-545" unitRef="usd">43000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-16" decimals="-3" id="f-546" unitRef="usd">86000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-17" decimals="-3" id="f-547" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <wald:CapitalContribution contextRef="c-14" decimals="-3" id="f-548" unitRef="usd">0</wald:CapitalContribution>
    <wald:CapitalContribution contextRef="c-15" decimals="-3" id="f-549" unitRef="usd">0</wald:CapitalContribution>
    <wald:CapitalContribution contextRef="c-16" decimals="-3" id="f-550" unitRef="usd">0</wald:CapitalContribution>
    <wald:CapitalContribution contextRef="c-17" decimals="-3" id="f-551" unitRef="usd">4058000</wald:CapitalContribution>
    <wald:DistributionToShareholderForDispositionOfBusiness contextRef="c-14" decimals="-3" id="f-552" unitRef="usd">0</wald:DistributionToShareholderForDispositionOfBusiness>
    <wald:DistributionToShareholderForDispositionOfBusiness contextRef="c-15" decimals="-3" id="f-553" unitRef="usd">13113000</wald:DistributionToShareholderForDispositionOfBusiness>
    <wald:DistributionToShareholderForDispositionOfBusiness contextRef="c-16" decimals="-3" id="f-554" unitRef="usd">0</wald:DistributionToShareholderForDispositionOfBusiness>
    <wald:DistributionToShareholderForDispositionOfBusiness contextRef="c-17" decimals="-3" id="f-555" unitRef="usd">0</wald:DistributionToShareholderForDispositionOfBusiness>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-77" decimals="-3" id="f-556" unitRef="usd">277824000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-78" decimals="-3" id="f-557" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-79" decimals="-3" id="f-558" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-80" decimals="-3" id="f-559" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-81" decimals="-3" id="f-560" unitRef="usd">200087000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-82" decimals="-3" id="f-561" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-83" decimals="-3" id="f-562" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="c-84" decimals="-3" id="f-563" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c-14" decimals="-3" id="f-564" unitRef="usd">650000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c-15" decimals="-3" id="f-565" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c-16" decimals="-3" id="f-566" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c-17" decimals="-3" id="f-567" unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="c-1" id="f-568">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Waldencast plc (&#x201c;Waldencast&#x201d;), formerly known as Waldencast Acquisition Corp., is a Jersey company. Waldencast was originally incorporated on December 8, 2020 as a Cayman Islands exempted company and a blank check company solely for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. On March&#160;18, 2021, Waldencast consummated an initial public offering of 34,500,000 units (the &#x201c;IPO&#x201d;), with each unit consisting of one Class A ordinary share and one-third of one redeemable warrant (&#x201c;Public Warrant&#x201d;) to acquire one Class A ordinary share (together, a &#x201c;Unit&#x201d;), at $10.00 per Unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Business Combination (as defined below), on July 26, 2022, with the approval of Waldencast&#x2019;s shareholders, and in accordance with the Cayman Companies Act (the &#x201c;Cayman Act&#x201d;), the Companies (Jersey) Law 1991, as amended (the &#x201c;Jersey Companies Law&#x201d;) and Waldencast&#x2019;s amended and restated memorandum and articles of association, Waldencast effected a deregistration under the Cayman Act and a domestication under Part 18C of the Jersey Companies Law (by means of filing a memorandum and articles of association with the Registrar of Companies in Jersey), pursuant to which Waldencast&#x2019;s jurisdiction of incorporation was changed from the Cayman Islands to Jersey (the &#x201c;Domestication&#x201d;). Upon the effective time of the Domestication, Waldencast Acquisition Corp. was renamed Waldencast plc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 27, 2022 (the &#x201c;Closing Date&#x201d;), Waldencast acquired Obagi Global Holdings Limited, a Cayman Islands exempted company, and its subsidiaries (collectively, &#x201c;Obagi&#x201d;) and Milk Makeup LLC, a Delaware limited liability company, and its subsidiaries (collectively &#x201c;Milk&#x201d;) (the &#x201c;Business Combination&#x201d;), as described below in &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 4&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Business Combinations.&#x201d; Following the Business Combination, the Company (as defined below) conducts its business through the following reportable segments: (i) Obagi Skincare and (ii) Milk Makeup. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Obagi is a global skincare company that develops, markets, and sells proprietary-topical aesthetic and therapeutic prescription-strength skincare systems and related products primarily in the physician-dispensed market. Obagi provides cosmetic, over-the-counter (&#x201c;OTC&#x201d;) and prescription products. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milk Makeup develops and sells cosmetic, skin care and other beauty products. The brand creates vegan, cruelty-free, clean formulas from its Milk headquarters in downtown New York City. Milk&#x2019;s products are offered through its U.S. website, www.milkmakeup.com, and its retail partners including Sephora in North America, Europe, the Middle East, Australia, Cult Beauty, and ASOS online.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the Business Combination, Waldencast is organized as an &#x201c;Up-C&#x201d; structure, whereby the equity interests of Obagi and Milk are held by Waldencast Partners LP (&#x201c;Waldencast Partners LP&#x201d;), a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cayman Islands exempted limited partnership and indirect &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsidiary of Waldencast, which is an entity that is classified as a partnership for U.S. federal income tax purposes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Obagi Global Holdings Limited is a holding company incorporated in the Cayman Islands that conducts all operations through its wholly-owned subsidiaries. Obagi is a global skincare company that develops, markets, and sells proprietary-topical aesthetic and therapeutic prescription-strength skincare systems and related products primarily in the physician-dispensed market. Obagi provides cosmetic, OTC and prescription products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, the Board of Directors of Obagi approved (i) an increase in the number of Obagi&#x2019;s authorized ordinary shares from 50,000 to 25,000,000, (ii) an issuance of 4,000,000 ordinary shares to ZhongHua Finance Acquisition Fund I, L.P. (&#x201c;ZhongHua&#x201d;), and (iii) a two-for-one stock split of Obagi&#x2019;s issued and outstanding ordinary shares (in combination with the share issuance to ZhongHua, the &#x201c;Stock Split&#x201d;), all of which became effective on December 2, 2020. Obagi was held by a single shareholder, and the share issuance to ZhongHua was deemed akin to a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;stock split. All share, per share amounts and related shareholders&#x2019; equity balances presented herein have been retroactively adjusted to reflect the impact of the Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2021, ZhongHua, Obagi&#x2019;s sole shareholder, transferred its shares to its affiliate, Cedarwalk Skincare Ltd. (&#x201c;Cedarwalk&#x201d;), which became the new sole shareholder of Obagi. This transfer between affiliates did not result in any change of control.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the closing of the Business Combination, Obagi carved out and distributed all of the outstanding shares of its subsidiary, Obagi Hong Kong Limited (&#x201c;Obagi Hong Kong&#x201d; or &#x201c;Obagi HK&#x201d;) to its shareholder, Cedarwalk (the &#x201c;Obagi China Distribution&#x201d;). All sales of Obagi products in the People&#x2019;s Republic of China, inclusive of the Hong Kong Special Administrative Region, the Macau Special Administrative Region, and Taiwan (the &#x201c;China Region&#x201d;) prior to the Business Combination had been conducted through Obagi Hong Kong and its subsidiaries (the &#x201c;Obagi China Business&#x201d;), which were not acquired by Waldencast in the Business Combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Waldencast has prepared the accompanying consolidated financial statements pursuant to generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accounting for the Business Combination, Waldencast was deemed to be the legal and the accounting acquirer (referred to as the &#x201c;Successor&#x201d;), however, Obagi was deemed to be the predecessor entity for financial reporting purposes (referred to as the &#x201c;Predecessor&#x201d;). Under the acquisition method of accounting, Waldencast&#x2019;s assets and liabilities retained their carrying values and the assets and liabilities associated with Obagi and Milk were recorded at their fair values measured as of the acquisition date, which created a new basis of accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This change in accounting basis is represented in the accompanying consolidated financial statements by a black line, which appears between the columns entitled Successor and Predecessor in the financial statements and in the relevant accompanying notes. The black line signifies that the consolidated financial statements presented for the Company after the Closing Date (the &#x201c;Successor Period&#x201d;) are presented on a measurement basis different from those for the period prior to the Closing Date (the &#x201c;Predecessor Periods&#x201d;). As a result of the application of the acquisition method of accounting as of the Closing Date, the financial statements for the Predecessor Periods (which only includes Obagi, including the Obagi China Business, through July 27, 2022) and for the Successor Period (which includes Waldencast and its subsidiaries from July 28, 2022 to December 31, 2022) are presented on a different basis of accounting and are, therefore, not comparable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless the context requires otherwise, the &#x201c;Company&#x201d; refers to Obagi for periods prior to the Business Combination and to Waldencast together with its consolidated subsidiaries, as the Successor for periods after the Business Combination.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList contextRef="c-14" id="f-569">Successor</us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-89"
      decimals="INF"
      id="f-570"
      unitRef="shares">34500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <wald:StockholdersEquityNumberOfSharesInEachUnit
      contextRef="c-90"
      decimals="INF"
      id="f-571"
      unitRef="shares">1</wald:StockholdersEquityNumberOfSharesInEachUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-91"
      decimals="INF"
      id="f-572"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-92"
      decimals="2"
      id="f-573"
      unitRef="usdPerShare">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-93"
      decimals="INF"
      id="f-574"
      unitRef="shares">50000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-94"
      decimals="INF"
      id="f-575"
      unitRef="shares">25000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-94"
      decimals="INF"
      id="f-576"
      unitRef="shares">4000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c-95"
      decimals="INF"
      id="f-577"
      unitRef="number">2</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-578">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Waldencast has prepared the accompanying consolidated financial statements pursuant to generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accounting for the Business Combination, Waldencast was deemed to be the legal and the accounting acquirer (referred to as the &#x201c;Successor&#x201d;), however, Obagi was deemed to be the predecessor entity for financial reporting purposes (referred to as the &#x201c;Predecessor&#x201d;). Under the acquisition method of accounting, Waldencast&#x2019;s assets and liabilities retained their carrying values and the assets and liabilities associated with Obagi and Milk were recorded at their fair values measured as of the acquisition date, which created a new basis of accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This change in accounting basis is represented in the accompanying consolidated financial statements by a black line, which appears between the columns entitled Successor and Predecessor in the financial statements and in the relevant accompanying notes. The black line signifies that the consolidated financial statements presented for the Company after the Closing Date (the &#x201c;Successor Period&#x201d;) are presented on a measurement basis different from those for the period prior to the Closing Date (the &#x201c;Predecessor Periods&#x201d;). As a result of the application of the acquisition method of accounting as of the Closing Date, the financial statements for the Predecessor Periods (which only includes Obagi, including the Obagi China Business, through July 27, 2022) and for the Successor Period (which includes Waldencast and its subsidiaries from July 28, 2022 to December 31, 2022) are presented on a different basis of accounting and are, therefore, not comparable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless the context requires otherwise, the &#x201c;Company&#x201d; refers to Obagi for periods prior to the Business Combination and to Waldencast together with its consolidated subsidiaries, as the Successor for periods after the Business Combination.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ErrorCorrectionTextBlock contextRef="c-1" id="f-580">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;RESTATEMENT AND RECLASSIFICATIONS&lt;/span&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restatement of Previously Issued Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, management of the Company (&#x201c;Management&#x201d;) and the audit committee of the Company&#x2019;s Board of Directors (&#x201c;the Board&#x201d;), conducted an internal review, with the assistance of legal and accounting advisors, pertaining to certain accounting practices used by Obagi in connection with the recognition of revenue from sales of Obagi products to its Southeast Asia Distributor (the &#x201c;SA Distributor&#x201d;) in Vietnam, transactions with other Obagi distributors, both within and outside the U.S., as well as other accounting issues. Management and the audit committee identified misstatements in the previously issued consolidated financial statements as of December 31, 2021 and for the years ended December 31, 2021 and 2020 (Predecessor Periods) as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result, the Company has restated the accompanying consolidated balance sheet as of December 31, 2021 (Predecessor Period) and consolidated statements of operations and comprehensive loss, cash flows, and shareholders&#x2019; equity for the years ended December 31, 2021 and 2020 (Predecessor Periods) from amounts previously reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description of Restatement Adjustments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A summary of the restatement adjustments are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:6.91pt"&gt;Net revenue &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2013; The Company identified misstatements primarily relating to distributor fees and the recognition of revenue from three of Obagi&#x2019;s distributors: the SA Distributor, Obagi&#x2019;s exclusive supplier for the physician-dispensed channel in the U.S. (&#x201c;Physician Channel Provider&#x201d;), and the distributor for Obagi&#x2019;s U.S. e-commerce platforms (&#x201c;U.S. Online Marketplace Distributor&#x201d;). The following table summarizes the impact of the restatement to net revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.148%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.414%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distributor fees for services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(39,146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SA Distributor&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Physician Channel Provider &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US Online Marketplace Distributor &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total net revenue adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(63,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;10,283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Distributor fees for services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2013; Obagi&#x2019;s distributors charge fees for certain services they render. The Predecessor (Obagi) had recorded these service fees as selling, general and administrative (&#x201c;SG&amp;amp;A&#x201d;) and research and development (&#x201c;R&amp;amp;D&#x201d;) expenses. Management subsequently determined these service fees should have been recognized as a reduction to net revenue, as the additional services provided by distributors were not distinct from the distributors&#x2019; purchase of Obagi products. This resulted in an overstatement of net revenue of $39.1 million and corresponding overstatements of SG&amp;amp;A expenses and R&amp;amp;D expenses of $37.1 million $2.0 million, respectively, for the year ended December 31, 2021 (Predecessor Period). The misstatement had no impact to net income or cash flows for the year ended December 31, 2021 (Predecessor Period). There was no similar accounting misstatement identified for the year ended December 31, 2020 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:10.5pt"&gt;SA Distributor &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2013; The Predecessor historically recognized revenue for products sold to Obagi&#x2019;s SA Distributor upon shipment of the products. Management determined that the SA Distributor revenue should have been recognized when Obagi had no remaining performance obligations and received substantially all of the consideration related to each purchase order in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"&gt;(&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ASC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;606&#x201d;). This resulted in an overstatement of accounts receivable of $24.8 million as of December 31, 2021 (Predecessor Period), an overstatement of net revenue of $14.2 million for the year ended December 31, 2021 (Predecessor Period), and an understatement of net revenue of $1.7 million for the year ended December 31, 2020 (Predecessor Period). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Physician Channel Provider&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; - The Predecessor historically recognized revenue for products sold in the physician dispensed, or Direct-to-Physician (&#x201c;DTP&#x201d;), channel upon the transfer of products to the Physician Channel Provider. Management determined that although the products were transferred to the Physician Channel Provider, the Physician Channel Provider did not obtain actual control of the products until immediately prior to selling through to the physician customer. Therefore, revenue should have been recognized only immediately prior to transfer of products to physicians (i.e., when the products were sold to the physicians) rather than when they were transferred to the Physician Channel Provider. In addition, the Physician Channel Provider charged fees for certain services rendered by it (as discussed above) and the Predecessor recorded these service fees as SG&amp;amp;A and R&amp;amp;D expenses, instead of as a reduction to net revenue. As a result of these items, there was an overstatement of net revenue of $8.2 million, an understatement of cost of goods sold of $0.4 million, an overstatement of SG&amp;amp;A of $7.1 million, an overstatement of accounts receivable of $14.8 million, and an understatement of inventory of $2.0 million as of and for the year ended December 31, 2021 (Predecessor Period). For the year ended December 31, 2020 (Predecessor Period) this resulted in an understatement of revenue of $8.6 million, an understatement of cost of goods sold of $2.6 million, and an overstatement of SG&amp;amp;A of $4.9 million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;U.S. Online Marketplace Distributor &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; The Predecessor agreed to nonstandard payment terms in its contracts with the U.S. Online Marketplace Distributor and allowed for payments over a period of time that exceeded 365 days until final payment of an invoice. Management subsequently identified misstatements to revenue recognition relating to the significant financing component of such &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;arrangement, timing of revenue, and incorrect accounting of shipping activities. The net impact of these misstatements resulted in an overstatement of net revenue of $1.8 million, an understatement of other income of $1.0 million and an understatement of deferred revenue of $0.7 million as of and for the year ended December 31, 2021 (Predecessor Period) and an understatement of net revenue of $0.1 million for the year ended December 31, 2020 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;5.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Other net revenue adjustments &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Other net revenue adjustments were individually and in the aggregate insignificant for the years ended December 31, 2021 and 2020 (Predecessor Periods). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:6.34pt"&gt;Cost of goods sold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &#x2013; The following table summarizes the impact of the restatement to cost of goods sold:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.749%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.148%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Physician Channel Provider&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory obsolescence provision &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other - adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total net cost of goods sold adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,673&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,471&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Physician Channel Provider &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2013; As described above in (a)3, Management determined that it should have recognized revenue and cost of goods sold for products sold to the Physician Channel Provider immediately prior to the transfer of products to the physicians, which resulted in understatements of costs of goods sold as set forth in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Inventory obsolescence provision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &#x2013; The Company did not appropriately adjust the inventory reserve for obsolete inventory. In connection with the restatement, the Company corrected its historical inventory obsolescence provision. This resulted in an overstatement of cost of goods sold of $0.6 million for the year ended December 31, 2021 (Predecessor Period) and an understatement of $0.7 million for the year ended December 31, 2020 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:10.5pt"&gt;Other net cost of goods sold adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &#x2013; The Predecessor historically recorded certain promotional products in marketing expenses. Management determined that it should have recorded such promotional products in inventory and cost of goods sold, which resulted in understatements of costs of goods sold as set forth in the table above. The other net cost of goods sold adjustments related to the understatement of cost of goods sold were insignificant both individually and in the aggregate for the years ended December 31, 2021 and 2020 (Predecessor Periods).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:6.91pt"&gt;SG&amp;amp;A &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &#x2013; The following table summarizes the impact of the restatement to SG&amp;amp;A expenses:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.148%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.414%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distributor fees for services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(37,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Physician Channel Provider &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer software&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other - adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total SG&amp;amp;A adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(44,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(3,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Distributor fees for services &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As described above in (a)1, the Predecessor had incorrectly recorded certain payments to distributors for services on a gross basis in net revenue which caused an overstatement of SG&amp;amp;A expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Physician Channel Provider &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; As described above in (a)3, the Predecessor had recorded fees for certain services to the Physician Channel Provider in SG&amp;amp;A expenses as opposed to a reduction to net revenue, which cause an overstatement of SG&amp;amp;A expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Computer software &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; As described below in (j), the Predecessor historically capitalized certain computer software expenses that should have been expensed as incurred. This adjustment resulted in &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;understatements of SG&amp;amp;A expenses of $1.3 million and $0.5 million for the years ended December 31, 2021 and 2020 (Predecessor Periods), respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Prepaid expenses &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As described below in (h)1 through (h)2, the Predecessor historically capitalized certain expenses primarily related to marketing and advertising activities. Obagi should have expensed these items in the period in which the expenses were incurred. These misstatements resulted in an overstatement of SG&amp;amp;A expenses of $0.7 million for the year ended December 31, 2021 (Predecessor Period) and an understatement of $1.8 million for the year ended December 31, 2020 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;5.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:10.5pt"&gt;Other SG&amp;amp;A adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; As described in (b)3, management determined that it should have recorded certain promotional products in cost of goods sold instead of marketing expenses, which resulted in an overstatement of SG&amp;amp;A expenses as set forth in the table above. The other SG&amp;amp;A adjustments were individually and in the aggregate insignificant for the years ended December 31, 2021 and 2020 (Predecessor Periods). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:6.34pt"&gt;R&amp;amp;D &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Distributor fees for services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2013; As described above in (a)1, the Predecessor had incorrectly recorded fees for certain services in R&amp;amp;D expenses as opposed to a reduction to net revenue, which caused an overstatement of R&amp;amp;D expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Prepaid expenses &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As described below in (h), Obagi should have expensed certain costs that were previously capitalized related to R&amp;amp;D activities. These misstatements resulted in understatements of R&amp;amp;D expenses of $1.2 million and $0.5 million for the years ended December 31, 2021 and 2020 (Predecessor Periods), respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Other R&amp;amp;D expense &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The other R&amp;amp;D expense misstatements were individually and in the aggregate insignificant for the years ended December 31, 2021 and 2020 (Predecessor Periods).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:6.91pt"&gt;Other expenses (income), net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; - As described above in (a)4, the Predecessor did not adjust the transaction price for a significant financing component in its contract with the U.S. Online Marketplace Distributor. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:8.01pt"&gt;Accounts receivable, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &#x2013; The following table summarizes the impact of the restatement to accounts receivable, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.651%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.149%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SA Distributor &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(24,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Physician Channel Provider&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Uncollectible loan receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total accounts receivable, net adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(44,629)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;SA Distributor &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As described above in (a)2, the Company restated revenue for products sold to the SA Distributor and adjusted the overstatement of accounts receivable, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Physician Channel Provider&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &#x2013; As described above in (a)3, the Company restated revenue for products sold in the DTP channel and adjusted the overstatement of accounts receivable, net.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Uncollectible loan receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2013; The Predecessor did not record the loss on the write-off of a one-time uncollectible loan receivable related to the Obagi China Business in the period it was deemed uncollectible. This resulted in an overstatement of accounts receivable, net of $2.5 million as of December 31, 2021 (Predecessor Period) and an understatement of a loss on the write-off of the loan receivable of $2.6 million for the year ended December 31, 2021 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Other adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &#x2013; The Company identified misstatements related to certain distributor receivables, aged accounts receivable and other accounts receivable. The aggregate impact of these misstatements resulted in an overstatement of accounts receivable, net of $2.5 million as of December 31, 2021 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;(g)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:6.34pt"&gt;Inventories &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2013; The following table summarizes the impact of the restatement to inventories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.651%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.149%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Physician Channel Provider &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory obsolescence provision &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other adjustments  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total net inventory adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Physician Channel Provider &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2013; As described above in (a)3, the Predecessor historically recognized cost of goods sold for products sold in the DTP channel upon transfer of the products to the Physician Channel Provider instead of immediately prior to transfer of the products to physician customers, which resulted in an understatement of inventory. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Inventory obsolescence provision &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2013; As described above in (b)2, as a result of misstatements in inventory, the Company had an overstatement of inventory of $0.1 million as of December 31, 2021 (Predecessor Period). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Other adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2013; As described in (b)3, management determined that it should have recorded certain promotional products in inventory and cost of goods sold instead of marketing expenses, which resulted in an understatement of inventory of $0.3 million as of December 31, 2021 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%"&gt;(h)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:106%;padding-left:6.34pt"&gt; Prepaid Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Marketing costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &#x2013; The Predecessor capitalized and amortized certain expenses related to marketing activities that did not meet the criteria for capitalization. Obagi should have expensed these items in the periods in which the expenses were incurred. This resulted in an overstatement to prepaid expenses of $2 million as of December 31, 2021 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;R&amp;amp;D &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; The Predecessor capitalized and amortized certain expenses related to R&amp;amp;D activities. Obagi should have expensed these items in the periods in which the expenses were incurred. This resulted in an overstatement of prepaid expenses of $1.1 million as of December 31, 2021 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Other prepaid expense adjustments &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The other prepaid expense misstatements were individually and in the aggregate insignificant as of December 31, 2021 (Predecessor Period). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:8.57pt"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &#x2013; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The ot&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;her current assets misstatements were individually and in the aggregate insignificant as of December 31, 2021 (Predecessor Period). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;(j)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:8.57pt"&gt;Property and equipment, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &#x2013; The Predecessor historically capitalized certain internal use software costs that did not meet the criteria for capitalization. Obagi should have recorded these expenses in the periods in which they were incurred. This resulted in an overstatement of property and equipment, net of $2.4 million as of December 31, 2021 (Predecessor Period), however it had an insignificant impact on depreciation expense for the years ended December 31, 2021 and 2020 (Predecessor Periods).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;(k)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:6.34pt"&gt;Other non-current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &#x2013; As described above in (h), the Predecessor historically capitalized prepaid expenses and included the long-term portion of such expenses in other non-current assets. Obagi should have recognized these expenses in the periods in which they were incurred. This resulted in an overstatement of other non-current assets of $1.2 million as of December 31, 2021 (Predecessor Period). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;(l)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:8.57pt"&gt;Accounts payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &#x2013; The Predecessor historically did not appropriately accrue for certain costs incurred in the period. These misstatements were individually insignificant, but in the aggregate resulted in an understatement of accounts payable of $1.3 million as of December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;(m)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:3.57pt"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:106%;padding-left:10.5pt"&gt;Deferred revenue &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%"&gt;As described above in (a)4, the Company identified misstatements to revenue recognized for the SA Distributor and the U.S. Online Marketplace Distributor. Obagi should have recorded deferred revenue for payments received in advance of the revenue recognition. These adjustments resulted in an understatement of other current liabilities of $0.7 million as of December 31, 2021 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Accrued payroll and related expenses &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company identified misstatements to accrued liabilities for employee related compensation matters and other expenses. This resulted in an understatement of other current liabilities of $0.2 million as of December 31, 2021 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Accrued distribution service fees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; The Company identified misstatements to accrued distribution service fees which should have been classified as contra-accounts receivable. This resulted in an overstatement of other current liabilities of $1.2 million as of December 31, 2021 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(n)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Tax Accounting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &#x2013; The Company recalculated its income tax expense and related liabilities as a result of the restatements. The tax impact of the restatements was a decrease to income tax expense of $1.7 million and an increase to income tax expense of $1.7 million for the years ended December 31, 2021 and 2020 (Predecessor Periods), respectively. There was no impact to the balance sheet as of December 31, 2021 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;(o)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;&#160;&#160;&#160;&#160;Accumulated Deficit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &#x2013; The cumulative impact of the restatement adjustments for the previously reported periods increased accumulated deficit by approximately $37.3 million as of January 1, 2020. The effects of the restatement adjustment to opening accumulated deficit as of January 1, 2020 primarily relates to restatement adjustments associated with the SA Distributor, the Physician Channel Provider, U.S. Online Marketplace Distributor, and prepaid expenses as described above in (a)2, (a)3, (a)4, and (h), respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In an effort to enhance the clarity of financial information for users of these financial statements, the Company has elected to make certain reclassifications to its consolidated statements of operations and comprehensive loss. As such, certain amounts in the prior periods presented have been reclassified to conform to the current period financial statement presentation. These reclassification changes do not constitute errors because they represent changes in presentation from one acceptable method to another acceptable method under U.S. GAAP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description of Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The categories of the reclassification adjustments and their impact on previously reported consolidated financial statements are described below: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;(p) The Company chose to reclassify depreciation and amortization expenses presented historically in the Predecessor Periods as a separate line item to cost of goods sold and SG&amp;amp;A expenses. Depreciation expense of property and equipment was reclassified to SG&amp;amp;A expenses and amortization expense of product-related intangible assets (e.g., supply agreement, formulations) was reclassified to cost of goods sold. These reclassifications align the historical presentation in the Predecessor Periods to the Successor Period presentation in the consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;Cost of goods sold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &#x2013; The following table summarizes the impact of the reclassification adjustments to cost of goods sold:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.148%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.414%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;(q) The Company chose to reclassify amounts related to the effect of foreign exchange rates on cash and cash equivalents and present them as a separate line item from the change in cash, cash equivalents and restricted cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(r) The Company previously did not present gross profit. The Company has changed the presentation in its statement of operations to present gross profit, which resulted in cost of goods sold being reclassified from being grouped with other operating expenses to being part of the separate gross profit presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%"&gt;Consolidated Financial Statement Adjustments Tables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the effects of the restatement and reclassification adjustments to the previously issued consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CONSOLIDATED BALANCE SHEET&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In thousands of U.S. dollars, except share and per share data)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.479%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Predecessor (Obagi)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Restatement Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Restatement Reference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;CURRENT ASSETS:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;12,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;12,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;63,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(44,629)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;f&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;18,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;19,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;g&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;21,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;7,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(2,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;h&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;4,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;i&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;104,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(45,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;59,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;3,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(2,386)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;j&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;79,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;79,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;44,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;44,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(1,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;k&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;TOTAL ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;233,573&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;(48,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;184,586&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;LIABILITIES AND SHAREHOLDERS' EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;CURRENT LIABILITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;11,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;1,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;12,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;15,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;n.m.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;15,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;12,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;m&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;12,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;39,740&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;1,065&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;40,805&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;103,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;103,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;n.m.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;TOTAL LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;144,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;145,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;SHAREHOLDERS' EQUITY:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Predecessor common shares, 25,000,000 shares authorized; $0.50 par value, 8,000,002 shares issued and outstanding as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;100,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;100,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(14,798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(50,051)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;o&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(64,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;TOTAL SHAREHOLDERS' EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;89,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(50,051)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;39,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;233,573&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;(48,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;184,586&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n.m. - not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE (LOSS)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In thousands of U.S. dollars, except share and per share data)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor (Obagi)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restatement Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restatement Reference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenue &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;206,069&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(63,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;142,472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;b,p,r&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross profit &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;r&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(48,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;r&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;118,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(44,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;c,p&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;82,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(899)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d,a(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;j,p&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total operating expenses &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;187,995&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(53,364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(45,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;89,060&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18,074&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(19,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(1,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n.m.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on PPP Loan forgiveness&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on write-off of loan receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expenses (income), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total other (income) expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,843&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,506&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8,349&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Loss) income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;11,231&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(21,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(9,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(19,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(19,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares used in computing net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(19,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(19,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive (loss) income &#x2014; foreign currency translation adjustments, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(19,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(19,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n.m. - not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In thousands of U.S. dollars, except share and per share data)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor (Obagi)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restatement Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restatement Reference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenue &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;84,145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;10,283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;94,428&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;b,p,r&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross profit &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;r&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;65,332&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;r&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;c,p&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,421)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;j,p&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total operating expenses &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;92,118&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(24,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(2,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;64,804&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(7,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8,501&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;528&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expenses (income), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total other (income) expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Loss) income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(14,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8,501&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(5,764)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,094)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(9,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,801&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(2,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares used in computing net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(9,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,801&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(2,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive (loss) income &#x2014; foreign currency translation adjustments, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(9,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,801&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(2,354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;CONSOLIDATED STATEMENT OF CASH FLOWS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In thousands of U.S. dollars)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Predecessor (Obagi)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Restatement Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Restatement Reference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH FLOWS FROM OPERATING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(19,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(19,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Adjustments to reconcile net loss to net cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash (used in) provided by operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;j&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gain on PPP Loan forgiveness&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;n.m.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Loss on disposal of equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Loss on write-off of loan receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;f&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Changes in operating assets and liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(23,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;f&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;g&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;h&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,097)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other current assets and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;i,k&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;l, q&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other current liabilities and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;m&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net cash (used in) provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,070&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,541)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,529&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH FLOWS FROM INVESTING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital expenditure on intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;n.m.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital expenditure on property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;j&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Advances for note receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net cash used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(5,360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,573&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(3,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH FLOWS FROM FINANCING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net cash provided by financing activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,162&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,162&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,872&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;q&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,904&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effect of foreign exchange rates on cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;q&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#x2014;Beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,572&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,572&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#x2014;End of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;13,444&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;13,444&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;SUPPLEMENTAL CASH FLOW DATA &#x2013; CASH PAID:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;NON-CASH INVESTING AND FINANCING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital expenditures in accounts payable and accruals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;j&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CONSOLIDATED STATEMENT OF CASH FLOWS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In thousands of U.S. dollars)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Predecessor (Obagi)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Restatement Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Restatement Reference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH FLOWS FROM OPERATING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Adjustments to reconcile net loss to net cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash (used in) provided by operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;j&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;n&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,044)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Changes in operating assets and liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(15,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;f&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(16,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;g&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;h&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other current assets and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;i,k&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other current liabilities and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;m&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net cash (used in) provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(7,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(7,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH FLOWS FROM INVESTING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital expenditure on intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital expenditure on property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;j&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net cash used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,887)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;180&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH FLOWS FROM FINANCING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net cash provided by financing activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;14,319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;14,319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#x2014;Beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,391&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,391&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#x2014;End of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,572&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,572&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;SUPPLEMENTAL CASH FLOW DATA &#x2013; CASH PAID:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;NON-CASH INVESTING AND FINANCING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital expenditures in accounts payable and accruals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;j&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital contribution of trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ErrorCorrectionTextBlock>
    <wald:MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors
      contextRef="c-86"
      decimals="INF"
      id="f-581"
      unitRef="distributor">3</wald:MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors>
    <wald:MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors
      contextRef="c-8"
      decimals="INF"
      id="f-582"
      unitRef="distributor">3</wald:MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="c-1" id="f-583">The following table summarizes the impact of the restatement to net revenue:&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.148%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.414%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distributor fees for services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(39,146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SA Distributor&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Physician Channel Provider &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US Online Marketplace Distributor &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total net revenue adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(63,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;10,283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Distributor fees for services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2013; Obagi&#x2019;s distributors charge fees for certain services they render. The Predecessor (Obagi) had recorded these service fees as selling, general and administrative (&#x201c;SG&amp;amp;A&#x201d;) and research and development (&#x201c;R&amp;amp;D&#x201d;) expenses. Management subsequently determined these service fees should have been recognized as a reduction to net revenue, as the additional services provided by distributors were not distinct from the distributors&#x2019; purchase of Obagi products. This resulted in an overstatement of net revenue of $39.1 million and corresponding overstatements of SG&amp;amp;A expenses and R&amp;amp;D expenses of $37.1 million $2.0 million, respectively, for the year ended December 31, 2021 (Predecessor Period). The misstatement had no impact to net income or cash flows for the year ended December 31, 2021 (Predecessor Period). There was no similar accounting misstatement identified for the year ended December 31, 2020 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:10.5pt"&gt;SA Distributor &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2013; The Predecessor historically recognized revenue for products sold to Obagi&#x2019;s SA Distributor upon shipment of the products. Management determined that the SA Distributor revenue should have been recognized when Obagi had no remaining performance obligations and received substantially all of the consideration related to each purchase order in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"&gt;(&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ASC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;606&#x201d;). This resulted in an overstatement of accounts receivable of $24.8 million as of December 31, 2021 (Predecessor Period), an overstatement of net revenue of $14.2 million for the year ended December 31, 2021 (Predecessor Period), and an understatement of net revenue of $1.7 million for the year ended December 31, 2020 (Predecessor Period). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Physician Channel Provider&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; - The Predecessor historically recognized revenue for products sold in the physician dispensed, or Direct-to-Physician (&#x201c;DTP&#x201d;), channel upon the transfer of products to the Physician Channel Provider. Management determined that although the products were transferred to the Physician Channel Provider, the Physician Channel Provider did not obtain actual control of the products until immediately prior to selling through to the physician customer. Therefore, revenue should have been recognized only immediately prior to transfer of products to physicians (i.e., when the products were sold to the physicians) rather than when they were transferred to the Physician Channel Provider. In addition, the Physician Channel Provider charged fees for certain services rendered by it (as discussed above) and the Predecessor recorded these service fees as SG&amp;amp;A and R&amp;amp;D expenses, instead of as a reduction to net revenue. As a result of these items, there was an overstatement of net revenue of $8.2 million, an understatement of cost of goods sold of $0.4 million, an overstatement of SG&amp;amp;A of $7.1 million, an overstatement of accounts receivable of $14.8 million, and an understatement of inventory of $2.0 million as of and for the year ended December 31, 2021 (Predecessor Period). For the year ended December 31, 2020 (Predecessor Period) this resulted in an understatement of revenue of $8.6 million, an understatement of cost of goods sold of $2.6 million, and an overstatement of SG&amp;amp;A of $4.9 million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;U.S. Online Marketplace Distributor &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; The Predecessor agreed to nonstandard payment terms in its contracts with the U.S. Online Marketplace Distributor and allowed for payments over a period of time that exceeded 365 days until final payment of an invoice. Management subsequently identified misstatements to revenue recognition relating to the significant financing component of such &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;arrangement, timing of revenue, and incorrect accounting of shipping activities. The net impact of these misstatements resulted in an overstatement of net revenue of $1.8 million, an understatement of other income of $1.0 million and an understatement of deferred revenue of $0.7 million as of and for the year ended December 31, 2021 (Predecessor Period) and an understatement of net revenue of $0.1 million for the year ended December 31, 2020 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"&gt;5.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Other net revenue adjustments &#x2013; &lt;/span&gt;Other net revenue adjustments were individually and in the aggregate insignificant for the years ended December 31, 2021 and 2020 (Predecessor Periods).The following table summarizes the impact of the restatement to cost of goods sold:&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.749%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.148%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Physician Channel Provider&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory obsolescence provision &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other - adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total net cost of goods sold adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,673&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;4,471&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Physician Channel Provider &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2013; As described above in (a)3, Management determined that it should have recognized revenue and cost of goods sold for products sold to the Physician Channel Provider immediately prior to the transfer of products to the physicians, which resulted in understatements of costs of goods sold as set forth in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Inventory obsolescence provision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &#x2013; The Company did not appropriately adjust the inventory reserve for obsolete inventory. In connection with the restatement, the Company corrected its historical inventory obsolescence provision. This resulted in an overstatement of cost of goods sold of $0.6 million for the year ended December 31, 2021 (Predecessor Period) and an understatement of $0.7 million for the year ended December 31, 2020 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:10.5pt"&gt;Other net cost of goods sold adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &#x2013; The Predecessor historically recorded certain promotional products in marketing expenses. Management determined that it should have recorded such promotional products in inventory and cost of goods sold, which resulted in understatements of costs of goods sold as set forth in the table above. The other net cost of goods sold adjustments related to the understatement of cost of goods sold were insignificant both individually and in the aggregate for the years ended December 31, 2021 and 2020 (Predecessor Periods).&lt;/span&gt;&lt;/div&gt;The following table summarizes the impact of the restatement to SG&amp;amp;A expenses:&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.148%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.414%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distributor fees for services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(37,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Physician Channel Provider &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer software&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other - adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total SG&amp;amp;A adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(44,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(3,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Distributor fees for services &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As described above in (a)1, the Predecessor had incorrectly recorded certain payments to distributors for services on a gross basis in net revenue which caused an overstatement of SG&amp;amp;A expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Physician Channel Provider &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; As described above in (a)3, the Predecessor had recorded fees for certain services to the Physician Channel Provider in SG&amp;amp;A expenses as opposed to a reduction to net revenue, which cause an overstatement of SG&amp;amp;A expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Computer software &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; As described below in (j), the Predecessor historically capitalized certain computer software expenses that should have been expensed as incurred. This adjustment resulted in &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;understatements of SG&amp;amp;A expenses of $1.3 million and $0.5 million for the years ended December 31, 2021 and 2020 (Predecessor Periods), respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Prepaid expenses &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As described below in (h)1 through (h)2, the Predecessor historically capitalized certain expenses primarily related to marketing and advertising activities. Obagi should have expensed these items in the period in which the expenses were incurred. These misstatements resulted in an overstatement of SG&amp;amp;A expenses of $0.7 million for the year ended December 31, 2021 (Predecessor Period) and an understatement of $1.8 million for the year ended December 31, 2020 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;5.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:10.5pt"&gt;Other SG&amp;amp;A adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; As described in (b)3, management determined that it should have recorded certain promotional products in cost of goods sold instead of marketing expenses, which resulted in an overstatement of SG&amp;amp;A expenses as set forth in the table above. The other SG&amp;amp;A adjustments were individually and in the aggregate insignificant for the years ended December 31, 2021 and 2020 (Predecessor Periods). &lt;/span&gt;&lt;/div&gt;The following table summarizes the impact of the restatement to accounts receivable, net:&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.651%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.149%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SA Distributor &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(24,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Physician Channel Provider&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Uncollectible loan receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total accounts receivable, net adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(44,629)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;SA Distributor &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As described above in (a)2, the Company restated revenue for products sold to the SA Distributor and adjusted the overstatement of accounts receivable, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Physician Channel Provider&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &#x2013; As described above in (a)3, the Company restated revenue for products sold in the DTP channel and adjusted the overstatement of accounts receivable, net.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Uncollectible loan receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2013; The Predecessor did not record the loss on the write-off of a one-time uncollectible loan receivable related to the Obagi China Business in the period it was deemed uncollectible. This resulted in an overstatement of accounts receivable, net of $2.5 million as of December 31, 2021 (Predecessor Period) and an understatement of a loss on the write-off of the loan receivable of $2.6 million for the year ended December 31, 2021 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Other adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; &#x2013; The Company identified misstatements related to certain distributor receivables, aged accounts receivable and other accounts receivable. The aggregate impact of these misstatements resulted in an overstatement of accounts receivable, net of $2.5 million as of December 31, 2021 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;The following table summarizes the impact of the restatement to inventories:&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.651%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.149%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Physician Channel Provider &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory obsolescence provision &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other adjustments  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total net inventory adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Physician Channel Provider &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2013; As described above in (a)3, the Predecessor historically recognized cost of goods sold for products sold in the DTP channel upon transfer of the products to the Physician Channel Provider instead of immediately prior to transfer of the products to physician customers, which resulted in an understatement of inventory. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Inventory obsolescence provision &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2013; As described above in (b)2, as a result of misstatements in inventory, the Company had an overstatement of inventory of $0.1 million as of December 31, 2021 (Predecessor Period). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;padding-left:10.5pt"&gt;Other adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x2013; As described in (b)3, management determined that it should have recorded certain promotional products in inventory and cost of goods sold instead of marketing expenses, which resulted in an understatement of inventory of $0.3 million as of December 31, 2021 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;The following table summarizes the impact of the reclassification adjustments to cost of goods sold:&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.727%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.148%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.414%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.150%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the effects of the restatement and reclassification adjustments to the previously issued consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CONSOLIDATED BALANCE SHEET&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In thousands of U.S. dollars, except share and per share data)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.479%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Predecessor (Obagi)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Restatement Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Restatement Reference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;CURRENT ASSETS:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;12,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;12,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;63,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(44,629)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;f&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;18,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;19,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;2,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;g&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;21,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;7,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(2,979)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;h&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;4,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;i&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;104,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(45,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;59,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;3,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(2,386)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;j&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;79,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;79,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;44,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;44,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(1,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;k&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;TOTAL ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;233,573&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;(48,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;184,586&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;LIABILITIES AND SHAREHOLDERS' EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;CURRENT LIABILITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;11,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;1,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;12,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;15,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;n.m.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;15,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;12,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;m&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;12,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;39,740&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;1,065&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;40,805&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;103,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;103,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;n.m.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;TOTAL LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;144,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;145,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;SHAREHOLDERS' EQUITY:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Predecessor common shares, 25,000,000 shares authorized; $0.50 par value, 8,000,002 shares issued and outstanding as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;100,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;100,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(14,798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(50,051)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;o&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(64,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;TOTAL SHAREHOLDERS' EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;89,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(50,051)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;39,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;233,573&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;(48,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;184,586&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n.m. - not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE (LOSS)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In thousands of U.S. dollars, except share and per share data)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor (Obagi)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restatement Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restatement Reference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenue &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;206,069&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(63,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;142,472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;b,p,r&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross profit &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;r&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(48,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;r&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;118,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(44,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;c,p&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;82,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(899)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d,a(1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;j,p&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total operating expenses &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;187,995&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(53,364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(45,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;89,060&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;18,074&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(19,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(1,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n.m.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain on PPP Loan forgiveness&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on write-off of loan receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expenses (income), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(817)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total other (income) expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,843&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,506&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8,349&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Loss) income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;11,231&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(21,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(9,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(19,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(19,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares used in computing net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(19,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(19,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive (loss) income &#x2014; foreign currency translation adjustments, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(19,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(19,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n.m. - not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In thousands of U.S. dollars, except share and per share data)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.778%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor (Obagi)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restatement Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restatement Reference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenue &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;84,145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;10,283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;94,428&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;b,p,r&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross profit &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;r&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;65,332&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19,969)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;r&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;c,p&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,421)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;j,p&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total operating expenses &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;92,118&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(24,625)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(2,689)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;64,804&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(7,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8,501&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;528&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expenses (income), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total other (income) expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Loss) income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(14,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;8,501&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(5,764)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,094)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(9,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,801&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(2,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares used in computing net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(9,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,801&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(2,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive (loss) income &#x2014; foreign currency translation adjustments, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(9,155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,801&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(2,354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;CONSOLIDATED STATEMENT OF CASH FLOWS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In thousands of U.S. dollars)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Predecessor (Obagi)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Restatement Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Restatement Reference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH FLOWS FROM OPERATING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(19,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(19,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Adjustments to reconcile net loss to net cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash (used in) provided by operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;j&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gain on PPP Loan forgiveness&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6,824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;n.m.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Loss on disposal of equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Loss on write-off of loan receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;f&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Changes in operating assets and liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(23,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;f&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;g&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;h&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,097)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other current assets and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;i,k&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;l, q&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other current liabilities and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;m&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net cash (used in) provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,070&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,541)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,529&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH FLOWS FROM INVESTING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital expenditure on intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;n.m.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital expenditure on property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;j&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(424)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Advances for note receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net cash used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(5,360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;1,573&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(3,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH FLOWS FROM FINANCING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net cash provided by financing activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,162&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,162&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,872&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;q&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;4,904&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effect of foreign exchange rates on cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;q&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#x2014;Beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,572&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,572&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#x2014;End of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;13,444&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;13,444&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;SUPPLEMENTAL CASH FLOW DATA &#x2013; CASH PAID:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;NON-CASH INVESTING AND FINANCING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital expenditures in accounts payable and accruals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;j&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CONSOLIDATED STATEMENT OF CASH FLOWS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In thousands of U.S. dollars)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:98.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Predecessor (Obagi)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Restatement Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Restatement Reference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH FLOWS FROM OPERATING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(9,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Adjustments to reconcile net loss to net cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash (used in) provided by operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;j&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;n&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3,044)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Changes in operating assets and liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(15,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;f&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(16,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;g&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;h&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other current assets and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;i,k&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(7,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other current liabilities and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;m&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net cash (used in) provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(7,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(7,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH FLOWS FROM INVESTING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital expenditure on intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital expenditure on property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;j&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net cash used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,887)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;180&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(1,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH FLOWS FROM FINANCING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Net cash provided by financing activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;14,319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;14,319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;5,181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#x2014;Beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,391&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;3,391&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;CASH, CASH EQUIVALENTS AND RESTRICTED CASH&#x2014;End of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,572&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;8,572&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;SUPPLEMENTAL CASH FLOW DATA &#x2013; CASH PAID:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;NON-CASH INVESTING AND FINANCING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital expenditures in accounts payable and accruals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;j&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capital contribution of trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-3" id="f-584" unitRef="usd">-39146000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-98" decimals="-3" id="f-585" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-99" decimals="-3" id="f-586" unitRef="usd">-14220000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-100" decimals="-3" id="f-587" unitRef="usd">1709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-101" decimals="-3" id="f-588" unitRef="usd">-8191000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-102" decimals="-3" id="f-589" unitRef="usd">8591000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-103" decimals="-3" id="f-590" unitRef="usd">-1773000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-104" decimals="-3" id="f-591" unitRef="usd">60000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-105" decimals="-3" id="f-592" unitRef="usd">-267000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-106" decimals="-3" id="f-593" unitRef="usd">-77000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-107" decimals="-3" id="f-594" unitRef="usd">-63597000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-108" decimals="-3" id="f-595" unitRef="usd">10283000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-5" id="f-596" unitRef="usd">-39100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-97" decimals="-5" id="f-597" unitRef="usd">-37100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-97" decimals="-5" id="f-598" unitRef="usd">-2000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-109" decimals="-5" id="f-599" unitRef="usd">-24800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-99" decimals="-5" id="f-600" unitRef="usd">-14200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-100" decimals="-5" id="f-601" unitRef="usd">1700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-101" decimals="-5" id="f-602" unitRef="usd">-8200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-101" decimals="-5" id="f-603" unitRef="usd">400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-101" decimals="-5" id="f-604" unitRef="usd">-7100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-110" decimals="-5" id="f-605" unitRef="usd">-14800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-110" decimals="-5" id="f-606" unitRef="usd">2000000.0</us-gaap:InventoryNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-102" decimals="-5" id="f-607" unitRef="usd">8600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-102" decimals="-5" id="f-608" unitRef="usd">2600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-102" decimals="-5" id="f-609" unitRef="usd">-4900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <wald:MinimumThresholdPeriodForContractRepaymentOverTime contextRef="c-111" id="f-610">P365D</wald:MinimumThresholdPeriodForContractRepaymentOverTime>
    <wald:MinimumThresholdPeriodForContractRepaymentOverTime contextRef="c-112" id="f-611">P365D</wald:MinimumThresholdPeriodForContractRepaymentOverTime>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-103" decimals="-5" id="f-612" unitRef="usd">-1800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OtherNonoperatingIncome contextRef="c-103" decimals="-5" id="f-613" unitRef="usd">1000000.0</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-113" decimals="-5" id="f-614" unitRef="usd">700000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-104" decimals="-5" id="f-615" unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-101" decimals="-3" id="f-616" unitRef="usd">374000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-102" decimals="-3" id="f-617" unitRef="usd">2552000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-114" decimals="-3" id="f-618" unitRef="usd">-583000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-115" decimals="-3" id="f-619" unitRef="usd">665000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-105" decimals="-3" id="f-620" unitRef="usd">1882000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-106" decimals="-3" id="f-621" unitRef="usd">1254000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-107" decimals="-3" id="f-622" unitRef="usd">1673000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-108" decimals="-3" id="f-623" unitRef="usd">4471000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-114" decimals="-5" id="f-624" unitRef="usd">-600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-115" decimals="-5" id="f-625" unitRef="usd">700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-116" decimals="-3" id="f-626" unitRef="usd">-37075000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-117" decimals="-3" id="f-627" unitRef="usd">0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-101" decimals="-3" id="f-628" unitRef="usd">-7065000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-102" decimals="-3" id="f-629" unitRef="usd">-4891000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-118" decimals="-3" id="f-630" unitRef="usd">1323000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-119" decimals="-3" id="f-631" unitRef="usd">472000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-120" decimals="-3" id="f-632" unitRef="usd">-732000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-121" decimals="-3" id="f-633" unitRef="usd">1827000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-105" decimals="-3" id="f-634" unitRef="usd">-974000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-106" decimals="-3" id="f-635" unitRef="usd">-546000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-107" decimals="-3" id="f-636" unitRef="usd">-44523000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-108" decimals="-3" id="f-637" unitRef="usd">-3138000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-118" decimals="-5" id="f-638" unitRef="usd">1300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-119" decimals="-5" id="f-639" unitRef="usd">500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-120" decimals="-5" id="f-640" unitRef="usd">-700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-121" decimals="-5" id="f-641" unitRef="usd">1800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-122" decimals="-5" id="f-642" unitRef="usd">1200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-123" decimals="-5" id="f-643" unitRef="usd">500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-109" decimals="-3" id="f-644" unitRef="usd">-24821000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-110" decimals="-3" id="f-645" unitRef="usd">-14796000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-124" decimals="-3" id="f-646" unitRef="usd">-2500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-125" decimals="-3" id="f-647" unitRef="usd">-2512000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-126" decimals="-3" id="f-648" unitRef="usd">-44629000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-124" decimals="-5" id="f-649" unitRef="usd">-2500000</us-gaap:AccountsReceivableNetCurrent>
    <wald:GainLossOnNoteReceivableWriteoff contextRef="c-127" decimals="-5" id="f-650" unitRef="usd">-2600000</wald:GainLossOnNoteReceivableWriteoff>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-125" decimals="-5" id="f-651" unitRef="usd">-2500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-110" decimals="-3" id="f-652" unitRef="usd">2029000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-128" decimals="-3" id="f-653" unitRef="usd">-82000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-125" decimals="-3" id="f-654" unitRef="usd">325000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-126" decimals="-3" id="f-655" unitRef="usd">2272000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-128" decimals="-5" id="f-656" unitRef="usd">-100000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-125" decimals="-5" id="f-657" unitRef="usd">300000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-129" decimals="-6" id="f-658" unitRef="usd">-2000000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-130" decimals="-5" id="f-659" unitRef="usd">-1100000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-131" decimals="-5" id="f-660" unitRef="usd">-2400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-129" decimals="-5" id="f-661" unitRef="usd">-1200000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-125" decimals="-5" id="f-662" unitRef="usd">1300000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-113" decimals="-5" id="f-663" unitRef="usd">700000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-132" decimals="-5" id="f-664" unitRef="usd">200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-133" decimals="-5" id="f-665" unitRef="usd">-1200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-134" decimals="-5" id="f-666" unitRef="usd">-1700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-135" decimals="-5" id="f-667" unitRef="usd">1700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-5" id="f-668" unitRef="usd">-37300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-136" decimals="-3" id="f-669" unitRef="usd">4656000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-137" decimals="-3" id="f-670" unitRef="usd">4656000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-138" decimals="-3" id="f-671" unitRef="usd">12794000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-126" decimals="-3" id="f-672" unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-8" decimals="-3" id="f-673" unitRef="usd">12794000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c-138" decimals="-3" id="f-674" unitRef="usd">650000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-126" decimals="-3" id="f-675" unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-8" decimals="-3" id="f-676" unitRef="usd">650000</us-gaap:RestrictedCash>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-138" decimals="-3" id="f-677" unitRef="usd">63367000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-126" decimals="-3" id="f-678" unitRef="usd">-44629000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-8" decimals="-3" id="f-679" unitRef="usd">18738000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-138" decimals="-3" id="f-680" unitRef="usd">19339000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-126" decimals="-3" id="f-681" unitRef="usd">2272000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-8" decimals="-3" id="f-682" unitRef="usd">21611000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-138" decimals="-3" id="f-683" unitRef="usd">7944000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-126" decimals="-3" id="f-684" unitRef="usd">-2979000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-8" decimals="-3" id="f-685" unitRef="usd">4965000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-138" decimals="-3" id="f-686" unitRef="usd">335000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-126" decimals="-3" id="f-687" unitRef="usd">-56000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-8" decimals="-3" id="f-688" unitRef="usd">279000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-138" decimals="-3" id="f-689" unitRef="usd">104429000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-126" decimals="-3" id="f-690" unitRef="usd">-45392000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-8" decimals="-3" id="f-691" unitRef="usd">59037000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-138" decimals="-3" id="f-692" unitRef="usd">3584000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-126" decimals="-3" id="f-693" unitRef="usd">-2386000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-8" decimals="-3" id="f-694" unitRef="usd">1198000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-138" decimals="-3" id="f-695" unitRef="usd">79574000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-126" decimals="-3" id="f-696" unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-8" decimals="-3" id="f-697" unitRef="usd">79574000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-138" decimals="-3" id="f-698" unitRef="usd">44489000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-126" decimals="-3" id="f-699" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-8" decimals="-3" id="f-700" unitRef="usd">44489000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-138" decimals="-3" id="f-701" unitRef="usd">1497000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-126" decimals="-3" id="f-702" unitRef="usd">-1209000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-8" decimals="-3" id="f-703" unitRef="usd">288000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-138" decimals="-3" id="f-704" unitRef="usd">233573000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-126" decimals="-3" id="f-705" unitRef="usd">-48987000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-8" decimals="-3" id="f-706" unitRef="usd">184586000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-138" decimals="-3" id="f-707" unitRef="usd">11375000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-126" decimals="-3" id="f-708" unitRef="usd">1305000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-8" decimals="-3" id="f-709" unitRef="usd">12680000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-138" decimals="-3" id="f-710" unitRef="usd">15382000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-126" decimals="-3" id="f-711" unitRef="usd">60000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-8" decimals="-3" id="f-712" unitRef="usd">15442000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-138" decimals="-3" id="f-713" unitRef="usd">12983000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-126" decimals="-3" id="f-714" unitRef="usd">-300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-715" unitRef="usd">12683000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-138" decimals="-3" id="f-716" unitRef="usd">39740000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-126" decimals="-3" id="f-717" unitRef="usd">1065000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-718" unitRef="usd">40805000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-138" decimals="-3" id="f-719" unitRef="usd">103423000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-126" decimals="-3" id="f-720" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-8" decimals="-3" id="f-721" unitRef="usd">103423000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-138" decimals="-3" id="f-722" unitRef="usd">548000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-126" decimals="-3" id="f-723" unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-8" decimals="-3" id="f-724" unitRef="usd">548000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-138" decimals="-3" id="f-725" unitRef="usd">572000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-126" decimals="-3" id="f-726" unitRef="usd">-1000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-8" decimals="-3" id="f-727" unitRef="usd">571000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-138" decimals="-3" id="f-728" unitRef="usd">144283000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-126" decimals="-3" id="f-729" unitRef="usd">1064000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-8" decimals="-3" id="f-730" unitRef="usd">145347000</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-731" unitRef="shares">25000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="2"
      id="f-732"
      unitRef="usdPerShare">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c-8" decimals="INF" id="f-733" unitRef="shares">8000002</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-734" unitRef="shares">8000002</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-138" decimals="-3" id="f-735" unitRef="usd">4000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-126" decimals="-3" id="f-736" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-8" decimals="-3" id="f-737" unitRef="usd">4000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-138" decimals="-3" id="f-738" unitRef="usd">100113000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-126" decimals="-3" id="f-739" unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-8" decimals="-3" id="f-740" unitRef="usd">100113000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-138" decimals="-3" id="f-741" unitRef="usd">-14798000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-126" decimals="-3" id="f-742" unitRef="usd">-50051000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-8" decimals="-3" id="f-743" unitRef="usd">-64849000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-138" decimals="-3" id="f-744" unitRef="usd">-25000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-126" decimals="-3" id="f-745" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-8" decimals="-3" id="f-746" unitRef="usd">-25000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-138" decimals="-3" id="f-747" unitRef="usd">89290000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-126" decimals="-3" id="f-748" unitRef="usd">-50051000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-8" decimals="-3" id="f-749" unitRef="usd">39239000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-138" decimals="-3" id="f-750" unitRef="usd">233573000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-126" decimals="-3" id="f-751" unitRef="usd">-48987000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-8" decimals="-3" id="f-752" unitRef="usd">184586000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-139" decimals="-3" id="f-753" unitRef="usd">206069000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-136" decimals="-3" id="f-754" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-107" decimals="-3" id="f-755" unitRef="usd">-63597000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-16" decimals="-3" id="f-756" unitRef="usd">142472000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-136" decimals="-3" id="f-757" unitRef="usd">53364000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-107" decimals="-3" id="f-758" unitRef="usd">1673000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-16" decimals="-3" id="f-759" unitRef="usd">55037000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-16" decimals="-3" id="f-760" unitRef="usd">87435000</us-gaap:GrossProfit>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-140" decimals="-3" id="f-761" unitRef="usd">48708000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-141" decimals="-3" id="f-762" unitRef="usd">-48708000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-139" decimals="-3" id="f-763" unitRef="usd">118243000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-136" decimals="-3" id="f-764" unitRef="usd">9248000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-107" decimals="-3" id="f-765" unitRef="usd">-44523000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-16" decimals="-3" id="f-766" unitRef="usd">82968000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-139" decimals="-3" id="f-767" unitRef="usd">6991000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-136" decimals="-3" id="f-768" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-107" decimals="-3" id="f-769" unitRef="usd">-899000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-16" decimals="-3" id="f-770" unitRef="usd">6092000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-139" decimals="-3" id="f-771" unitRef="usd">14053000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-136" decimals="-3" id="f-772" unitRef="usd">-13904000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-107" decimals="-3" id="f-773" unitRef="usd">-149000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-16" decimals="-3" id="f-774" unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <wald:OperatingExpensesAndCostOfGoodSold contextRef="c-139" decimals="-3" id="f-775" unitRef="usd">187995000</wald:OperatingExpensesAndCostOfGoodSold>
    <wald:OperatingExpensesAndCostOfGoodSold contextRef="c-136" decimals="-3" id="f-776" unitRef="usd">-53364000</wald:OperatingExpensesAndCostOfGoodSold>
    <us-gaap:OperatingExpenses contextRef="c-107" decimals="-3" id="f-777" unitRef="usd">-45571000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-16" decimals="-3" id="f-778" unitRef="usd">89060000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-139" decimals="-3" id="f-779" unitRef="usd">18074000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-136" decimals="-3" id="f-780" unitRef="usd">0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-107" decimals="-3" id="f-781" unitRef="usd">-19699000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-16" decimals="-3" id="f-782" unitRef="usd">-1625000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="c-139" decimals="-3" id="f-783" unitRef="usd">11156000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-136" decimals="-3" id="f-784" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-107" decimals="-3" id="f-785" unitRef="usd">-38000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-16" decimals="-3" id="f-786" unitRef="usd">11118000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-139" decimals="-3" id="f-787" unitRef="usd">-2317000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-136" decimals="-3" id="f-788" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-107" decimals="-3" id="f-789" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-16" decimals="-3" id="f-790" unitRef="usd">-2317000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <wald:GainOnPPPLoanForgiveness contextRef="c-139" decimals="-3" id="f-791" unitRef="usd">6824000</wald:GainOnPPPLoanForgiveness>
    <wald:GainOnPPPLoanForgiveness contextRef="c-136" decimals="-3" id="f-792" unitRef="usd">0</wald:GainOnPPPLoanForgiveness>
    <wald:GainOnPPPLoanForgiveness contextRef="c-107" decimals="-3" id="f-793" unitRef="usd">0</wald:GainOnPPPLoanForgiveness>
    <wald:GainOnPPPLoanForgiveness contextRef="c-16" decimals="-3" id="f-794" unitRef="usd">6824000</wald:GainOnPPPLoanForgiveness>
    <wald:GainLossOnNoteReceivableWriteoff contextRef="c-139" decimals="-3" id="f-795" unitRef="usd">0</wald:GainLossOnNoteReceivableWriteoff>
    <wald:GainLossOnNoteReceivableWriteoff contextRef="c-136" decimals="-3" id="f-796" unitRef="usd">0</wald:GainLossOnNoteReceivableWriteoff>
    <wald:GainLossOnNoteReceivableWriteoff contextRef="c-107" decimals="-3" id="f-797" unitRef="usd">-2555000</wald:GainLossOnNoteReceivableWriteoff>
    <wald:GainLossOnNoteReceivableWriteoff contextRef="c-16" decimals="-3" id="f-798" unitRef="usd">-2555000</wald:GainLossOnNoteReceivableWriteoff>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-139" decimals="-3" id="f-799" unitRef="usd">-194000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-136" decimals="-3" id="f-800" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-107" decimals="-3" id="f-801" unitRef="usd">1011000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-16" decimals="-3" id="f-802" unitRef="usd">817000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-139" decimals="-3" id="f-803" unitRef="usd">-6843000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-136" decimals="-3" id="f-804" unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-107" decimals="-3" id="f-805" unitRef="usd">-1506000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-16" decimals="-3" id="f-806" unitRef="usd">-8349000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-139" decimals="-3" id="f-807" unitRef="usd">11231000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-136" decimals="-3" id="f-808" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-107" decimals="-3" id="f-809" unitRef="usd">-21205000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-810" unitRef="usd">-9974000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-139" decimals="-3" id="f-811" unitRef="usd">11301000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-136" decimals="-3" id="f-812" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-107" decimals="-3" id="f-813" unitRef="usd">-1699000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-814" unitRef="usd">9602000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-139" decimals="-3" id="f-815" unitRef="usd">-70000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-136" decimals="-3" id="f-816" unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-107" decimals="-3" id="f-817" unitRef="usd">-19506000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-3" id="f-818" unitRef="usd">-19576000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-139"
      decimals="2"
      id="f-819"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-139"
      decimals="2"
      id="f-820"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-107"
      decimals="2"
      id="f-821"
      unitRef="usdPerShare">-2.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-107"
      decimals="2"
      id="f-822"
      unitRef="usdPerShare">-2.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-16"
      decimals="2"
      id="f-823"
      unitRef="usdPerShare">-2.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-16"
      decimals="2"
      id="f-824"
      unitRef="usdPerShare">-2.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-139"
      decimals="INF"
      id="f-825"
      unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-139"
      decimals="INF"
      id="f-826"
      unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-16"
      decimals="INF"
      id="f-827"
      unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-16"
      decimals="INF"
      id="f-828"
      unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss contextRef="c-139" decimals="-3" id="f-829" unitRef="usd">-70000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-136" decimals="-3" id="f-830" unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-107" decimals="-3" id="f-831" unitRef="usd">-19506000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-3" id="f-832" unitRef="usd">-19576000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-139" decimals="-3" id="f-833" unitRef="usd">-32000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-136" decimals="-3" id="f-834" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-107" decimals="-3" id="f-835" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-16" decimals="-3" id="f-836" unitRef="usd">-32000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-139" decimals="-3" id="f-837" unitRef="usd">-102000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-136" decimals="-3" id="f-838" unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-107" decimals="-3" id="f-839" unitRef="usd">-19506000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-840" unitRef="usd">-19608000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-142" decimals="-3" id="f-841" unitRef="usd">84145000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-137" decimals="-3" id="f-842" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-108" decimals="-3" id="f-843" unitRef="usd">10283000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-17" decimals="-3" id="f-844" unitRef="usd">94428000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-137" decimals="-3" id="f-845" unitRef="usd">24625000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-108" decimals="-3" id="f-846" unitRef="usd">4471000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-17" decimals="-3" id="f-847" unitRef="usd">29096000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-17" decimals="-3" id="f-848" unitRef="usd">65332000</us-gaap:GrossProfit>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-143" decimals="-3" id="f-849" unitRef="usd">19969000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-144" decimals="-3" id="f-850" unitRef="usd">-19969000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-142" decimals="-3" id="f-851" unitRef="usd">54794000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-137" decimals="-3" id="f-852" unitRef="usd">8765000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-108" decimals="-3" id="f-853" unitRef="usd">-3138000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-17" decimals="-3" id="f-854" unitRef="usd">60421000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-142" decimals="-3" id="f-855" unitRef="usd">3929000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-137" decimals="-3" id="f-856" unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-108" decimals="-3" id="f-857" unitRef="usd">454000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-17" decimals="-3" id="f-858" unitRef="usd">4383000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-142" decimals="-3" id="f-859" unitRef="usd">13426000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-137" decimals="-3" id="f-860" unitRef="usd">-13421000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-108" decimals="-3" id="f-861" unitRef="usd">-5000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-17" decimals="-3" id="f-862" unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <wald:OperatingExpensesAndCostOfGoodSold contextRef="c-142" decimals="-3" id="f-863" unitRef="usd">92118000</wald:OperatingExpensesAndCostOfGoodSold>
    <wald:OperatingExpensesAndCostOfGoodSold contextRef="c-137" decimals="-3" id="f-864" unitRef="usd">-24625000</wald:OperatingExpensesAndCostOfGoodSold>
    <us-gaap:OperatingExpenses contextRef="c-108" decimals="-3" id="f-865" unitRef="usd">-2689000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-17" decimals="-3" id="f-866" unitRef="usd">64804000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-142" decimals="-3" id="f-867" unitRef="usd">-7973000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-137" decimals="-3" id="f-868" unitRef="usd">0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-108" decimals="-3" id="f-869" unitRef="usd">8501000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-17" decimals="-3" id="f-870" unitRef="usd">528000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="c-142" decimals="-3" id="f-871" unitRef="usd">6281000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-137" decimals="-3" id="f-872" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-108" decimals="-3" id="f-873" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-17" decimals="-3" id="f-874" unitRef="usd">6281000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-142" decimals="-3" id="f-875" unitRef="usd">-11000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-137" decimals="-3" id="f-876" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-108" decimals="-3" id="f-877" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-17" decimals="-3" id="f-878" unitRef="usd">-11000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-142" decimals="-3" id="f-879" unitRef="usd">-6292000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-137" decimals="-3" id="f-880" unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-108" decimals="-3" id="f-881" unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-17" decimals="-3" id="f-882" unitRef="usd">-6292000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-142" decimals="-3" id="f-883" unitRef="usd">-14265000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-137" decimals="-3" id="f-884" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-108" decimals="-3" id="f-885" unitRef="usd">8501000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-886" unitRef="usd">-5764000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-142" decimals="-3" id="f-887" unitRef="usd">-5094000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-137" decimals="-3" id="f-888" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-108" decimals="-3" id="f-889" unitRef="usd">1700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-890" unitRef="usd">-3394000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-142" decimals="-3" id="f-891" unitRef="usd">-9171000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-137" decimals="-3" id="f-892" unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-108" decimals="-3" id="f-893" unitRef="usd">6801000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-3" id="f-894" unitRef="usd">-2370000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-142"
      decimals="2"
      id="f-895"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-142"
      decimals="2"
      id="f-896"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-108"
      decimals="2"
      id="f-897"
      unitRef="usdPerShare">0.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-108"
      decimals="2"
      id="f-898"
      unitRef="usdPerShare">0.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-17"
      decimals="2"
      id="f-899"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-17"
      decimals="2"
      id="f-900"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-142"
      decimals="INF"
      id="f-901"
      unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-142"
      decimals="INF"
      id="f-902"
      unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-17"
      decimals="INF"
      id="f-903"
      unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-17"
      decimals="INF"
      id="f-904"
      unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss contextRef="c-142" decimals="-3" id="f-905" unitRef="usd">-9171000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-137" decimals="-3" id="f-906" unitRef="usd">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-108" decimals="-3" id="f-907" unitRef="usd">6801000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-3" id="f-908" unitRef="usd">-2370000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-142" decimals="-3" id="f-909" unitRef="usd">16000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-137" decimals="-3" id="f-910" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-108" decimals="-3" id="f-911" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-17" decimals="-3" id="f-912" unitRef="usd">16000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-142" decimals="-3" id="f-913" unitRef="usd">-9155000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-137" decimals="-3" id="f-914" unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-108" decimals="-3" id="f-915" unitRef="usd">6801000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-916" unitRef="usd">-2354000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-139" decimals="-3" id="f-917" unitRef="usd">-70000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-107" decimals="-3" id="f-918" unitRef="usd">-19506000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-3" id="f-919" unitRef="usd">-19576000</us-gaap:ProfitLoss>
    <wald:DepreciationDepletionAndAmortizationOperatingActivities contextRef="c-139" decimals="-3" id="f-920" unitRef="usd">14053000</wald:DepreciationDepletionAndAmortizationOperatingActivities>
    <wald:DepreciationDepletionAndAmortizationOperatingActivities contextRef="c-107" decimals="-3" id="f-921" unitRef="usd">-149000</wald:DepreciationDepletionAndAmortizationOperatingActivities>
    <wald:DepreciationDepletionAndAmortizationOperatingActivities contextRef="c-16" decimals="-3" id="f-922" unitRef="usd">13904000</wald:DepreciationDepletionAndAmortizationOperatingActivities>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-139" decimals="-3" id="f-923" unitRef="usd">-2317000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-107" decimals="-3" id="f-924" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-16" decimals="-3" id="f-925" unitRef="usd">-2317000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <wald:GainOnPPPLoanForgiveness contextRef="c-139" decimals="-3" id="f-926" unitRef="usd">6824000</wald:GainOnPPPLoanForgiveness>
    <wald:GainOnPPPLoanForgiveness contextRef="c-107" decimals="-3" id="f-927" unitRef="usd">0</wald:GainOnPPPLoanForgiveness>
    <wald:GainOnPPPLoanForgiveness contextRef="c-16" decimals="-3" id="f-928" unitRef="usd">6824000</wald:GainOnPPPLoanForgiveness>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-139" decimals="-3" id="f-929" unitRef="usd">1179000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-107" decimals="-3" id="f-930" unitRef="usd">-40000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-16" decimals="-3" id="f-931" unitRef="usd">1139000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-139" decimals="-3" id="f-932" unitRef="usd">11073000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-107" decimals="-3" id="f-933" unitRef="usd">-1699000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-934" unitRef="usd">9374000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-139" decimals="-3" id="f-935" unitRef="usd">-52000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-107" decimals="-3" id="f-936" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-16" decimals="-3" id="f-937" unitRef="usd">-52000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <wald:GainLossOnNoteReceivableWriteoff contextRef="c-139" decimals="-3" id="f-938" unitRef="usd">0</wald:GainLossOnNoteReceivableWriteoff>
    <wald:GainLossOnNoteReceivableWriteoff contextRef="c-107" decimals="-3" id="f-939" unitRef="usd">-2555000</wald:GainLossOnNoteReceivableWriteoff>
    <wald:GainLossOnNoteReceivableWriteoff contextRef="c-16" decimals="-3" id="f-940" unitRef="usd">-2555000</wald:GainLossOnNoteReceivableWriteoff>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-139" decimals="-3" id="f-941" unitRef="usd">23790000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-107" decimals="-3" id="f-942" unitRef="usd">-18733000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-16" decimals="-3" id="f-943" unitRef="usd">5057000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-139" decimals="-3" id="f-944" unitRef="usd">5359000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-107" decimals="-3" id="f-945" unitRef="usd">651000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-16" decimals="-3" id="f-946" unitRef="usd">6010000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-139" decimals="-3" id="f-947" unitRef="usd">2654000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-107" decimals="-3" id="f-948" unitRef="usd">-1557000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-16" decimals="-3" id="f-949" unitRef="usd">1097000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-139" decimals="-3" id="f-950" unitRef="usd">-2323000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-107" decimals="-3" id="f-951" unitRef="usd">1711000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-16" decimals="-3" id="f-952" unitRef="usd">-612000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties contextRef="c-139" decimals="-3" id="f-953" unitRef="usd">8495000</wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties>
    <wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties contextRef="c-107" decimals="-3" id="f-954" unitRef="usd">1152000</wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties>
    <wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties contextRef="c-16" decimals="-3" id="f-955" unitRef="usd">9647000</wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-139" decimals="-3" id="f-956" unitRef="usd">4275000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-107" decimals="-3" id="f-957" unitRef="usd">-1782000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-16" decimals="-3" id="f-958" unitRef="usd">2493000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-139" decimals="-3" id="f-959" unitRef="usd">5070000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-107" decimals="-3" id="f-960" unitRef="usd">-1541000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-16" decimals="-3" id="f-961" unitRef="usd">3529000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-139" decimals="-3" id="f-962" unitRef="usd">937000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-107" decimals="-3" id="f-963" unitRef="usd">-74000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-16" decimals="-3" id="f-964" unitRef="usd">863000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-139" decimals="-3" id="f-965" unitRef="usd">1923000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-107" decimals="-3" id="f-966" unitRef="usd">-1499000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-16" decimals="-3" id="f-967" unitRef="usd">424000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <wald:AdvancesForNoteReceivable contextRef="c-139" decimals="-3" id="f-968" unitRef="usd">2500000</wald:AdvancesForNoteReceivable>
    <wald:AdvancesForNoteReceivable contextRef="c-107" decimals="-3" id="f-969" unitRef="usd">0</wald:AdvancesForNoteReceivable>
    <wald:AdvancesForNoteReceivable contextRef="c-16" decimals="-3" id="f-970" unitRef="usd">2500000</wald:AdvancesForNoteReceivable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-139" decimals="-3" id="f-971" unitRef="usd">-5360000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-107" decimals="-3" id="f-972" unitRef="usd">1573000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-16" decimals="-3" id="f-973" unitRef="usd">-3787000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-139" decimals="-3" id="f-974" unitRef="usd">5162000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-107" decimals="-3" id="f-975" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-16" decimals="-3" id="f-976" unitRef="usd">5162000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-139" decimals="-3" id="f-977" unitRef="usd">4872000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-107" decimals="-3" id="f-978" unitRef="usd">32000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-16" decimals="-3" id="f-979" unitRef="usd">4904000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-139" decimals="-3" id="f-980" unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-107" decimals="-3" id="f-981" unitRef="usd">-32000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-16" decimals="-3" id="f-982" unitRef="usd">-32000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-145" decimals="-3" id="f-983" unitRef="usd">8572000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-146" decimals="-3" id="f-984" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-86" decimals="-3" id="f-985" unitRef="usd">8572000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-138" decimals="-3" id="f-986" unitRef="usd">13444000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-126" decimals="-3" id="f-987" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-988" unitRef="usd">13444000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid contextRef="c-139" decimals="-3" id="f-989" unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-107" decimals="-3" id="f-990" unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-16" decimals="-3" id="f-991" unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet contextRef="c-139" decimals="-3" id="f-992" unitRef="usd">10014000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-107" decimals="-3" id="f-993" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-16" decimals="-3" id="f-994" unitRef="usd">10014000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-139" decimals="-3" id="f-995" unitRef="usd">97000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-107" decimals="-3" id="f-996" unitRef="usd">-11000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-16" decimals="-3" id="f-997" unitRef="usd">86000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:ProfitLoss contextRef="c-142" decimals="-3" id="f-998" unitRef="usd">-9171000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-108" decimals="-3" id="f-999" unitRef="usd">6801000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-3" id="f-1000" unitRef="usd">-2370000</us-gaap:ProfitLoss>
    <wald:DepreciationDepletionAndAmortizationOperatingActivities contextRef="c-142" decimals="-3" id="f-1001" unitRef="usd">13426000</wald:DepreciationDepletionAndAmortizationOperatingActivities>
    <wald:DepreciationDepletionAndAmortizationOperatingActivities contextRef="c-108" decimals="-3" id="f-1002" unitRef="usd">-5000</wald:DepreciationDepletionAndAmortizationOperatingActivities>
    <wald:DepreciationDepletionAndAmortizationOperatingActivities contextRef="c-17" decimals="-3" id="f-1003" unitRef="usd">13421000</wald:DepreciationDepletionAndAmortizationOperatingActivities>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-142" decimals="-3" id="f-1004" unitRef="usd">798000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-108" decimals="-3" id="f-1005" unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-17" decimals="-3" id="f-1006" unitRef="usd">798000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-142" decimals="-3" id="f-1007" unitRef="usd">-4743000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-108" decimals="-3" id="f-1008" unitRef="usd">1699000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-1009" unitRef="usd">-3044000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-142" decimals="-3" id="f-1010" unitRef="usd">961000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-108" decimals="-3" id="f-1011" unitRef="usd">15700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-17" decimals="-3" id="f-1012" unitRef="usd">16661000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-142" decimals="-3" id="f-1013" unitRef="usd">-1593000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-108" decimals="-3" id="f-1014" unitRef="usd">-2848000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-17" decimals="-3" id="f-1015" unitRef="usd">-4441000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-142" decimals="-3" id="f-1016" unitRef="usd">2150000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-108" decimals="-3" id="f-1017" unitRef="usd">-231000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-17" decimals="-3" id="f-1018" unitRef="usd">1919000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-142" decimals="-3" id="f-1019" unitRef="usd">998000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-108" decimals="-3" id="f-1020" unitRef="usd">-2157000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-17" decimals="-3" id="f-1021" unitRef="usd">-1159000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties contextRef="c-142" decimals="-3" id="f-1022" unitRef="usd">-7523000</wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties>
    <wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties contextRef="c-108" decimals="-3" id="f-1023" unitRef="usd">132000</wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties>
    <wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties contextRef="c-17" decimals="-3" id="f-1024" unitRef="usd">-7391000</wald:IncreaseDecreaseInAccountsPayableExcludingRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-142" decimals="-3" id="f-1025" unitRef="usd">2478000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-108" decimals="-3" id="f-1026" unitRef="usd">1657000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-17" decimals="-3" id="f-1027" unitRef="usd">4135000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-142" decimals="-3" id="f-1028" unitRef="usd">-7251000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-108" decimals="-3" id="f-1029" unitRef="usd">-180000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-17" decimals="-3" id="f-1030" unitRef="usd">-7431000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-142" decimals="-3" id="f-1031" unitRef="usd">652000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-108" decimals="-3" id="f-1032" unitRef="usd">1000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-17" decimals="-3" id="f-1033" unitRef="usd">653000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-142" decimals="-3" id="f-1034" unitRef="usd">1235000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-108" decimals="-3" id="f-1035" unitRef="usd">-181000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-17" decimals="-3" id="f-1036" unitRef="usd">1054000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-142" decimals="-3" id="f-1037" unitRef="usd">-1887000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-108" decimals="-3" id="f-1038" unitRef="usd">180000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-17" decimals="-3" id="f-1039" unitRef="usd">-1707000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-142" decimals="-3" id="f-1040" unitRef="usd">14319000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-108" decimals="-3" id="f-1041" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-17" decimals="-3" id="f-1042" unitRef="usd">14319000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-142" decimals="-3" id="f-1043" unitRef="usd">5181000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-108" decimals="-3" id="f-1044" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-17" decimals="-3" id="f-1045" unitRef="usd">5181000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-147" decimals="-3" id="f-1046" unitRef="usd">3391000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-148" decimals="-3" id="f-1047" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-87" decimals="-3" id="f-1048" unitRef="usd">3391000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-145" decimals="-3" id="f-1049" unitRef="usd">8572000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-146" decimals="-3" id="f-1050" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-86" decimals="-3" id="f-1051" unitRef="usd">8572000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid contextRef="c-142" decimals="-3" id="f-1052" unitRef="usd">9000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-108" decimals="-3" id="f-1053" unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-17" decimals="-3" id="f-1054" unitRef="usd">9000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet contextRef="c-142" decimals="-3" id="f-1055" unitRef="usd">5449000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-108" decimals="-3" id="f-1056" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-17" decimals="-3" id="f-1057" unitRef="usd">5449000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-142" decimals="-3" id="f-1058" unitRef="usd">186000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-108" decimals="-3" id="f-1059" unitRef="usd">-186000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-17" decimals="-3" id="f-1060" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <wald:CapitalContribution contextRef="c-142" decimals="-3" id="f-1061" unitRef="usd">4058000</wald:CapitalContribution>
    <wald:CapitalContribution contextRef="c-108" decimals="-3" id="f-1062" unitRef="usd">0</wald:CapitalContribution>
    <wald:CapitalContribution contextRef="c-17" decimals="-3" id="f-1063" unitRef="usd">4058000</wald:CapitalContribution>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-1064">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The accompanying consolidated financial statements include the accounts of Waldencast and its consolidated subsidiaries. The Company consolidates entities in which the Company has a majority voting interest. The Company eliminates intercompany transactions and accounts in consolidation. The Company separately presents within equity on the consolidated balance sheets the ownership interests attributable to parties with noncontrolling interests in the Company's consolidated subsidiaries, and separately presents net income attributable to such parties on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Emerging Growth Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a registration statement declared effective under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), or do not have a class of securities registered under the Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This may make comparison of the Company&#x2019;s consolidated financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Significant estimates and assumptions reflected in the financial statements include, but are not limited to, revenue recognition, fair value of assets acquired and liabilities assumed in business combinations, stock-based compensation, and valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and assumptions that it believes are reasonable at the time. Due to the inherent uncertainty involved in making assumptions and estimates, changes in circumstances could result in actual results differing from those estimates, and such differences could be material to the Company&#x2019;s consolidated balance sheets and consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company maintains its cash balances in accounts held by major banks and financial institutions located primarily in the U.S. and considers such risk to be minimal. Such bank deposits from time to time may be exposed to credit risk in excess of the Federal Deposit Insurance Corporation insurance limit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable primarily represent amounts due from distributors, and third-party logistics companies, directly and indirectly from major retailers, and from group purchasing organizations located both inside and outside the U.S. The Company mitigates its credit risks by performing ongoing credit evaluations of its customers&#x2019; financial conditions, requiring customer advance payments in certain circumstances. The Company generally does not require collateral. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 (Successor Period), two U.S. customers accounted for 50% and 19% of accounts receivable, respectively. As of December&#160;31, 2021 (Predecessor Period), three U.S. customers accounted for 41%, 14%, and 10% of accounts receivable, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the period from July 28, 2022 to December&#160;31, 2022 (Successor Period), one vendor exceeded 10% of inventory purchases. During the period from January 1, 2022 to July&#160;27, 2022 (Predecessor Period), three vendors exceeded 10% of inventory purchases. During the period from July 28, 2022 to December&#160;31, 2022 (Successor Period), the Company purchased approximately 27% of inventory from one vendor. During the period from January 1, 2022 to July&#160;27, 2022 (Predecessor Period), the Company purchased approximately 23%, 12%, and 12% of inventory, respectively, from three vendors. During the year ended December&#160;31, 2021 (Predecessor Period), two vendors exceeded 10% of inventory purchases. In 2021 (Predecessor Period), the Company purchased approximately 45% and 11% of inventory, respectively, from two vendors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 (Successor Period), two&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vendors accounted for&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15% and 12%,&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively, of accounts payable. As of December&#160;31, 2021 (Predecessor Period), one vendor accounted for 24% of accounts payable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company considers highly liquid investments with an initial maturity of three months or less to be cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company&#x2019;s restricted cash represents funds that were not accessible for general purpose cash needs due to contractual limitations. As of December&#160;31, 2022 (Successor Period), the Company&#x2019;s cash, cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;equivalents, and restricted cash balance of $10.2 million shown on the consolidated statements of cash flows consisted of $1.5&#160;million of restricted cash and $8.7&#160;million of cash and cash equivalents. The restricted cash balance represented cash in a savings account held by a major bank located in the U.S. and provides collateral for corporate credit cards obtained by the Predecessor for its employees. The Company is required to hold the restricted cash in the bank&#x2019;s savings account. Following the acquisition of Milk, the Company had an additional $0.8 million in restricted cash held with a financial institution as collateral for a lease deposit. The deposit is refundable at the end of the lease in November 2030, provided that Milk does not default on its lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 (Predecessor Period) the Company&#x2019;s cash, cash equivalents, and restricted cash balance of $13.4 million as shown on the consolidated statements of cash flows consisted of $0.6 million restricted cash and $12.8 million in cash and cash equivalents. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company&#x2019;s products are produced by third-party contract manufacturers (&#x201c;CMOs). Inventories consist of finished goods, work-in-process products and promotional products, valued at the lower of cost or net realizable value using the standard cost method, which approximates actual costs determined on a first-in, first-out (&#x201c;FIFO&#x201d;) basis. In order to track inventory quantities, the Company uses a perpetual inventory system. Promotional product is charged to cost of goods sold at the time the product is shipped to the Company&#x2019;s customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has in-transit inventory at any given period. Assessment of in-transit inventory is required to determine inventory balances accurately at period-end. Inventory is recognized when the Company holds title and bears substantially all of the risks and rewards of ownership. In many transactions, the transfer of title and the risks and rewards of ownership are dictated by contractually specified shipping terms, which may take the form of free-on-board (&#x201c;FOB&#x201d;) shipping point or FOB destination point.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If historical costs exceed the net realizable value at the balance sheet date, the Company adjusts the inventory to net realizable value (i.e., if impairment is identified, the Company records write-downs of inventories to cost of goods sold in the period in which it occurs). The Company evaluates the carrying value of inventories on a regular basis and determines the need to write down carrying values by considering historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost, and the remaining shelf life of goods on hand. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Obsolete, Scrap and Expired Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The inventory provision is set up for inventory that is expected to become obsolete or have a decreased value due to market trends or product upgrades. It accounts for losses that may occur when the inventory cannot be sold at its full cost. The Company regularly monitors any inventory that is not expected to be sold prior to the expiration date and historically slow-moving inventory based on the remaining shelf life and incorporates these considerations into its reserve analysis. Additionally, each period, Management will evaluate whether any additional write downs are required in addition to the calculated reserve amount (generally, by stock keeping unit (&#x201c;SKU&#x201d;) and/or lot). Specific reserves may relate to known matters, such as quality concerns or a discontinued product.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically, the Company has not experienced a material amount of product returns. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain arrangements may give the Company&#x2019;s customers the right to return products. In addition, when customer arrangements do not give the Company&#x2019;s customer the explicit right to return products, the Company may accept returns on a discretionary basis. The Company records a return asset for products returned by customers measured at the former carrying amount of the inventory, less any expected costs to recover the goods and potential decreases in value. If the returned inventory is not considered re-sellable, it will be written off to cost of goods sold. When customers have the right to receive a refund for defective or damaged products (as opposed to a replacement product), the right is accounted for as a right of return under ASC 606. When customers have the right to receive a replacement product for defective or damaged products, the right is accounted for as a warranty under ASC 460-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Guarantees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the Company accrues for replacement costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivatives &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company accounts for derivative instruments in accordance with ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 815&#x201d;), which requires additional disclosures about the Company&#x2019;s objectives and strategies for using &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;derivative instruments, how the derivative instruments and related hedged items are accounted for, and how the derivative instruments and related hedging items affect the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses interest rate collars to mitigate interest risk associated with its variable rate credit agreements. See &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_145" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Financial Instruments&#x201d; for further discussion of the interest rate collar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Terms of debt instruments are reviewed to determine whether they contain embedded derivative instruments that are required to be accounted for separately from the host contract and recorded on the consolidated balance sheets at fair value under ASC 815. An evaluation of specifically identified conditions is made to determine whether the fair value of warrants issued is required to be classified as equity or as a derivative liability. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrant Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for Public Warrants and Private Placement Warrants (each as defined below) as liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC Topic 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 480&#x201d;) and ASC 815. Specifically, the Public and Private Placement Warrants meet the definition of a derivative but do not qualify for an exception from derivative accounting since the warrants are not indexed to the Company&#x2019;s stock and, therefore, are precluded from equity classification. Since the Public and Private Placement Warrants meet the definition of a derivative under ASC 815, the Company measures the warrants at fair value at inception and at each reporting date, with changes in fair value recognized in change in fair value of derivative warrant liabilities in the consolidated statements of operations and comprehensive loss in the period of change. See &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_145" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Financial Instruments&#x201d; for further discussion of the warrants, including the FPA Warrants (as defined below).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the interest rate collar and warrant liabilities were estimated using inputs based on management&#x2019;s judgment and conditions that existed at each reporting date. See &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_151" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 1&lt;/a&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_151" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the Company&#x2019;s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and all other current liabilities approximate their carrying values because of the short maturities of these instruments. Additionally, the carrying amount of debt approximates fair value due to the adjusting interest rates of the Company&#x2019;s term loan, which approximate current market rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Capitalized Software and Website Development Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014; The Company capitalizes costs related to (i) internal-use software (ii) cloud computing arrangement (&#x201c;CCA&#x201d;) implementation costs, and (iii) other software-related costs (e.g., website development costs).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For internal-use software, both internal and external costs incurred during the preliminary project stage are expensed as incurred, and qualifying costs incurred during the application development state are capitalized. Capitalization ceases no later than the point at which a software project is substantially completed and ready for its intended use. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For CCAs, or hosting arrangements, the Company evaluates if the CCA includes a software license that will be accounted for in addition to a hosting service. The cost of the arrangement (i.e., license or service cost) of a CCA that includes a software license will be capitalized as an acquisition of an asset (similar to internal-use software) and amortized over its useful economic life, whereas the costs of a service contract are expensed as incurred.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs related to website development are expensed as incurred during the planning stage, content development stage, and operating stage. The Company generally capitalizes costs incurred for activities during the website application and infrastructure development stage, and graphics development stage. Costs incurred for website hosting services from a third-party vendor are expensed over the period the services are received.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Internal-use software costs and website development costs are amortized on a straight-line basis over their estimated useful lives, which is generally three years or less. Management evaluates the useful lives of these assets and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Prepaid Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; At initial recognition, the Company measures prepaid assets based on cost (i.e., amount paid). In the accounting period or periods in which a good or service is used or received, the asset will be reduced by a proportionate amount and an associated asset (e.g., inventory) or expense (e.g., marketing) will be recorded.   &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Prepaid Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Prepayments are required to begin production of inventory at certain of the Company&#x2019;s CMOs and inventory suppliers. Vendors are tracked to determine prepayments that have been made and when the associated inventory is expected to be delivered to the Company (i.e., when the Company takes ownership of the inventory). Prepaid inventory is triggered by invoices received from CMOs (i.e., the vendor). When the Company submits purchase orders, the CMOs may request a prepayment amount (deposit) based on agreed-upon percentage in the vendor contracts to start the production process.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Prepaid Marketing and Advertising&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally expenses the costs of advertising and marketing as costs are incurred, except for costs associated with producing advertising. While production costs (i.e., costs to develop promotions for a specific campaign associated with an identified new brand or new product) are incurred during the process of production, the Company has elected to expense certain costs when the associated advertising takes place. In the event that the advertising is not expected to occur (e.g., decision has been made to not launch a promotion) or a 12-month period elapses without the associated advertising occurring, the associated production costs will be expensed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Property and equipment are stated at cost, net of accumulated depreciation. In the case of a business combination, acquired property and equipment are recognized at their fair value as of the date of acquisition. Following initial recognition, property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of respective assets. No depreciation is charged to construction in progress. The estimated useful lives of the Company&#x2019;s assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ESTIMATED&#160;USEFUL&#160;LIVES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gondolas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lesser of useful life or term of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Intangible assets consist primarily of trademarks and trade names, a supply agreement, customer relationships, formulations, and developed technology. Intangible assets acquired in a business combination are recognized at their fair value as of the date of acquisition. Following initial recognition, intangible assets are carried at cost less accumulated amortization and impairment losses, if any, and are amortized on a straight-line basis over the estimated useful life of the asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, for each asset group held for use with indicators of impairment, the Company compares the expected future cash flows generated by the asset group, which represents the lowest level at which cash flows are identifiable, with its associated net carrying value. If the net carrying value of the asset group exceeds expected undiscounted cash flows, the excess of the net book value over estimated fair value is charged to impairment loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Combinations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; When the Company acquires a business, the total purchase consideration provided is allocated to the identifiable assets and liabilities of the acquired business at their estimated respective fair values. Any excess consideration of the fair value of purchase consideration over the fair values of assets acquired and liabilities assumed is recognized as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant management judgments and assumptions are required in determining the fair value of assets acquired and liabilities assumed. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows, useful lives and discount rates. Measurement period adjustments are reflected at the time identified, up through the conclusion of the measurement period, which is the time at which all information for determination of the values of assets acquired and liabilities assumed is received, which may not exceed one year from the acquisition date. The Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with a corresponding offset to goodwill. If outside of the measurement period, any subsequent adjustments are recorded in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Goodwill represents the difference between the purchase price and the fair value of assets and liabilities acquired in a business combination. The Company reviews goodwill for impairment annually on October 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and at an interim date if events or changes in circumstances indicate the occurrence of a triggering event. The Company reviews goodwill for impairment by initially considering qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill, as a basis for determining whether it is necessary to perform a quantitative analysis. If it is determined that it is more likely than not that the fair value of reporting unit is less than its carrying amount, a quantitative analysis is performed to identify goodwill impairment. Determining the fair value of a reporting unit involves the use of significant estimates and assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Issuance Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company capitalizes costs related to the issuance of debt instruments, as applicable. Such costs are initially recorded as a direct deduction from the applicable debt instrument and amortized over the contractual term of the related debt instrument in interest expense, net using the straight-line method, which approximates the effective interest method, in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Trade accounts receivable are stated at net realizable value. Receivables are unsecured and represent amounts billed to and currently due from customers that have yet to be collected. Payment terms are generally short-term in nature and are less than one year. In certain circumstances, the Company offers extended payment terms to customers. When the period between the transfer of control of the products and payment is greater than one year, the Company adjusts the promised amount of consideration for the effects of a significant financing component. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains an allowance for doubtful accounts, which represents allowances for customer trade accounts receivable that are both probable and estimated to be partially or entirely uncollectible. These allowances are used to reduce gross trade receivables to their net realizable value. The Company records these allowances based on estimates related to the following factors: (i)&#160;customer-specific allowances, based upon past collection history, historical trends, and identification of specific customer risk and (ii)&#160;formula-based general allowances using an aging schedule. Determining such allowances involves the use of significant estimates and assumptions. Payments of accounts receivable are allocated to the specific invoices identified on the customer&#x2019;s remittance advice or to the customer&#x2019;s account, if unspecified, until an invoice can be determined by the customer. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to trade accounts receivable.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company recognizes revenue when control of the promised goods or services is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to for those goods or services. In that determination, under ASC 606 the Company follows a five-step model that includes: (1) determination of whether a contract or an agreement between two or more parties that creates legally enforceable &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rights and obligations exists; (2) identification of the performance obligations in the contract; (3) determination of the transaction price; (4) allocation of the transaction price to the performance obligations in the contract; and (5) recognition of revenue when (or as) performance obligations are satisfied. Net revenue excludes taxes collected by us on behalf of governmental authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenue is primarily generated from product sales to distributors, retailers, physicians and directly to consumers (&#x201c;DTC&#x201d;) via its e-commerce platforms. Distributors may resell products to retailers, physicians, or end consumers. To determine when to recognize revenue under ASC 606 in cases where products are sold to distributors, the Company analyzes various factors including its ability to direct products physically held by the distributors, when title and risk of loss transfers, and who ultimately manages the relationship with the end consumer. The Company does not recognize revenue until control of the products is transferred to the distributor.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, and when facts and circumstances change, the Company assesses whether it is probable that the Company will collect substantially all of the consideration it will be entitled to from a customer. If the Company determines that it is not probable that the Company will collect substantially all of the consideration from the customer, the Company recognizes revenue only when one or more of the following events occur: (i) the Company has no remaining obligations to transfer goods or services to the customer, and all, or substantially all, of the consideration promised by the customer has been received by the Company and is nonrefundable, (ii) the contract has been terminated, and the consideration received from the customer is nonrefundable, or (iii) the Company has transferred control of the goods or services to which the consideration that has been received relates, the Company has stopped transferring goods or services to the customer (if applicable) and has no obligation under the contract to transfer additional goods or services, and the consideration received from the customer is nonrefundable.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that each of its products is distinct and represents a separate performance obligation. The transaction price is equal to the consideration the Company is entitled to &#x2013; which could be either a distributor, retailer, physician, or e-commerce end consumer. When measuring revenue and determining the consideration the Company is entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Product sales revenue is recognized net of provisions for estimated volume rebates and discounts, markdowns, margin adjustments, early-payment discounts and returns. The Company estimates variable consideration using the expected value method and adjusts the transaction price when control of the related product is transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s distributors charge fees for certain services rendered by the distributors, including packing and shipping, marketing and advertising the Company&#x2019;s products, monitoring product reviews, regulatory services, providing customer service, and generating data and analytical reports on product sales. Distributor fees for services are recognized as a reduction to revenue because the services provided are typically not distinct from the distributors&#x2019; purchase of products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Typically, customers are required to pay either in advance or between 30 and 90 days from delivery or invoicing. However, in certain circumstances, the Company offers extended payment terms to customers. When the period between the transfer of control of the products and payment is greater than one year, the Company adjusts the promised amount of consideration for the effects of a significant financing component. When contracts contain a significant financing component in which the Company is effectively financing the customer, a portion of the transaction price is recognized as other income.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price to each performance obligation based on its relative standalone selling price. Standalone selling price is the price at which the Company would sell a promised product separately to a customer. The Company typically has an observable standalone selling price for each of its products.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has different contracted shipping terms with different customers that dictate the timing of payment, passage of legal title, transfer of physical possession, and assumption of the risks and rewards occur. For distributors, other than the Physician Channel Provider, and retailers, depending on the contract, the Company considers transfer of control to have occurred either once the delivery of the product has occurred or once the product has been picked up from the Company&#x2019;s designated warehouse/distribution center by the customer&#x2019;s shipping agent, unless the Company is responsible for shipping the goods, in which case transfer of control passes upon delivery to the customer. For DTC &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sales and sales to physicians through the Physician Channel Provider, control transfers upon shipment to the end consumer or physician. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shipping and Handling &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for shipping and handling activities as fulfillment activities instead of as performance obligations and recognizes these costs as SG&amp;amp;A expenses. Costs related to shipping and handling for the period from July&#160;28 to December&#160;31, 2022 (Successor Period), and the period from January&#160;1 to July&#160;27, 2022 (Predecessor Period), and the years ended December&#160;31, 2021 and 2020 (Predecessor Periods) were $2.0 million, $0.6 million, $1.0 million, and $0.2 million, respectively. Amounts billed to customers for shipping and handling are included in revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Promotional Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In situations where promotional products, such as samples and testers, are provided by the Company to its customers at the same time as a related saleable product, the cost of these promotional products are recognized as cost of sales at the same time as the revenue for the related product is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates royalty revenue from products sold under the Obagi brand name in Japan and Hong Kong through license agreements with local operators. Under these agreements, the Company provides the local operators with a license of intellectual property and receives a royalty based upon a percentage of net sales of Obagi-branded products sold in Japan and Hong Kong. Because the license is the predominant item to which the sales-based royalty relates, the Company recognizes revenue for the sales-based royalty when the local operators make sales of the products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Costs to Obtain a Contract with a Customer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the incremental costs of obtaining a customer contract as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. The incremental costs to obtain contracts primarily relate to sales commission and sales-based bonuses. Total capitalizable costs to obtain a contract were immaterial during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts do not typically give rise to material contract assets or contract liabilities because (i) payment is typically closely aligned with the timing of the Company&#x2019;s performance or (ii) the Company performs prior to customer payment, and the Company has an unconditional right to payment that represents an account receivable. Similarly, the Company does not recognize material revenue in reporting periods from performance obligations satisfied in previous periods. The Company applies the exemption in ASC 606-10-50-14(a) related to disclosure of the amount of transaction price allocated to unsatisfied performance obligations for royalty contracts. Because of the short-term nature of product sales contracts, the Company typically does not have other material amounts to disclose related to the transaction price allocated to unsatisfied performance obligations. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Cost of Goods Sold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;Cost of goods sold consists of inventory and promotional product costs, including when inventory and promotional products are sold or written down, and product-related intangible asset amortization and depreciation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;R&amp;amp;D costs are expensed as incurred. Costs associated with research and development activities may include materials, equity and facility costs, personnel costs, contracted services (i.e., the costs of services performed by third parties in connection with the Company&#x2019;s R&amp;amp;D activities), and direct costs (e.g., appropriate allocations for general and administrative costs). Substantially all R&amp;amp;D expenses are related to new product development and design improvements or increased functionality in current products. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may capitalize acquired assets associated with R&amp;amp;D activities (e.g., materials, equipment) if both of the following criteria are met: (i) the Company reasonably expects that the acquired assets will be used in an alternative manner and anticipates an economic benefit from the alternative future use and (ii) the use of the acquired asset is not &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contingent on the further development of the asset after acquisition date (i.e., the asset can be used in an alternative manner in the condition in which it existed at the acquisition date).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Advertising costs are expensed in the period in which they are incurred. Total advertising costs, included in SG&amp;amp;A expense on the consolidated statements of operations and comprehensive loss, were $11.7 million, $6.8 million, $9.2 million and $5.9 million for the period from July&#160;28 to December&#160;31, 2022 (Successor Period), the period from January&#160;1 to July&#160;27, 2022 (Predecessor Period) and the years ended December&#160;31, 2021 and 2020 (Predecessor Periods), respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company measures the cost of share-based awards granted to eligible employees, directors, and consultants based on the grant-date fair value of the awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Replacement Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On the Closing Date, in connection with the Business Combination, the Company assumed Obagi and Milk&#x2019;s legacy incentive award plans and outstanding unvested options granted under those plans (&#x201c;Replacement Options&#x201d;). Because the options were deemed in the money on the replacement date, a Hull-White lattice pricing model was used to estimate their fair value to capture the optimal timing of exercise. This pricing model requires the use of assumptions including the volatility of the underlying stock, the fair value of the stock, dividend yield, risk-free rate, and exercise multiple. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Founder Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value and derived service period of the stock options issued to founders (&#x201c;Founder Awards&#x201d;) in August 2022 based on the Monte Carlo simulation, as they were deemed out of the money on the grant date. The Monte Carlo simulation model requires the use of assumptions including the option&#x2019;s expected term, the volatility of the underlying stock, dividend yield rate, risk-free rate, and expected exercise behavior. For expected exercise behavior, the Company assumes that the options are exercised after 50% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of restricted stock is equal to the price of the Company&#x2019;s ordinary shares on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to recognize the effect of forfeitures in the period in which they occur. Share-based awards are classified as equity, unless the underlying shares are classified as liabilities or the Company is required to settle the awards by transferring cash or other assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense for awards with service or performance conditions using the straight-line method over the requisite service period, which is generally the award&#x2019;s vesting period. Compensation expense for employee stock-based awards whose vesting is subject to the fulfillment of both a service condition and the occurrence of a performance condition is recognized on a graded-vesting basis at the time the achievement of the performance condition becomes probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company accounts for income taxes using the asset and liability approach. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes represents income taxes paid or payable for the current period plus the change in deferred taxes during the period. Deferred taxes result from differences between the financial and tax basis of the Company&#x2019;s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether a valuation allowance is required often requires significant judgment including the long-range forecasting of future taxable income and the evaluation of planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made. A valuation allowance of $7.9 million was recorded as of December&#160;31, 2022 (Successor Period), a valuation allowance of $14.1 million was recorded as of December&#160;31, 2021 (Predecessor Period), and no valuation allowance was recorded as of December&#160;31, 2020 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for a tax benefit from an uncertain position in the consolidated financial statements only if it is more likely than not that the position is sustainable, based solely on its technical merits and consideration of the relevant taxing authority&#x2019;s widely understood administrative practices and precedents. If the recognition threshold for the tax position is met, the Company records only the portion of the tax benefit that is greater than 50% likely to be realized. As of December&#160;31, 2022 (Successor Period), 2021 (Predecessor Period), and 2020 (Predecessor Period), the Company had no uncertain positions in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no amounts accrued for interest and penalties as of December&#160;31, 2022 (Successor Period), or December 31, 2021 and 2020 (Predecessor Periods).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Income (Loss) Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Basic net income (loss) per share attributable to shareholders of ordinary shares is computed by dividing the Company&#x2019;s net income (loss) attributable to holders of ordinary shares by the weighted-average number of ordinary shares used in the income (loss) per share calculation during the period. Diluted net income (loss) per share attributable to holders of ordinary shares is computed by giving effect to all potentially dilutive securities. The net income (loss) per share that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Noncontrolling interests represent the portion of Waldencast Partners LP that the Company controls and consolidates but does not own. The Company recognizes each noncontrolling holder&#x2019;s respective share of the estimated fair value of the net assets at the date of formation or acquisition. Noncontrolling interests are subsequently adjusted for the noncontrolling holder&#x2019;s share of additional contributions, distributions and their share of the net earnings or losses of each respective consolidated entity. The Company allocates net income or loss to noncontrolling interests based on the weighted average ownership interest during the period. The net income (loss) that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss. The Company does not recognize a gain or loss on transactions with a consolidated entity in which it does not own 100% of the equity, but the Company reflects the difference in cash received or paid from the noncontrolling interests carrying amount as additional paid-in-capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and incur expenses and about which separate financial information is regularly evaluated by the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources. Similar operating segments can be aggregated into a single operating segment if the businesses are similar. Management has determined that, following the Business Combination, the Successor has two operating and reportable segments: Obagi Skincare and Milk Makeup, reflecting the manner in which the CODM operates the Company. The Company&#x2019;s CODM is its Chief Executive Officer. The Predecessor had one operating and reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 842&#x201d;) using the modified retrospective transition method on the date of the Business Combination. The Predecessor planned to adopt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 842 during the annual period ended December&#160;31, 2022. Waldencast had no capital or operating lease obligations prior to the Business Combination. The Company elected the package of practical expedients available upon transition to ASC 842 that allow (i) historical lease classification of existing leases, (ii) no reassessment of any expired or existing contracts containing leases, and (iii) no reassessment of initial direct costs for any existing leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The adoption of the new standard impacted the Company&#x2019;s accounting for operating leases. Upon adoption, the Company established an operating right-of-use asset of $13.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and a corresponding operating lease liability of $16.6 million. The Company does not have any finance leases. See &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_142" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 9&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further detail.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the adoption of ASC 842, the Company recognized rent expense for operating leases on a straight&#x2011;line basis (including the effect of reduced or free rent and rent escalations) over the lease term. The difference between the cash paid to the landlord and the amount recognized as rent expense on a straight&#x2011;line basis was recognized as an adjustment to deferred rent in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Debt-Debt with Conversion and Other Options&#x201d; (Subtopic 470-20) and &#x201c;Derivatives and Hedging-Contracts in an Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2020-06&#x201d;), which &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 also removes certain settlement conditions that are required for equity-linked contracts to qualify for scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company adopted ASU 2020-06 on January 1, 2021. Adoption of the ASU did not impact the Company&#x2019;s financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU No.&#160;2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic&#160;848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was effective for the Company in the annual period ended December&#160;31, 2022. This ASU provides relief that, if elected, will require less accounting analysis and less accounting recognition for modifications related to reference rate reform. This update provides optional guidance for a limited period of time to ease the potential burden in accounting for reference rate reform on financial reporting. The amendments in the update apply only to contracts, hedging relationships, and other transactions that reference the London Inter-Bank Offered Rate (&#x201c;LIBOR&#x201d;) or another reference rate expected to be discontinued because of reference rate reform. Waldencast adopted this ASU prospectively effective January 1, 2022, which did not have a material effect on its consolidated financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2022, Waldencast adopted ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&#x2014;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2019-12&#x201d;). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. Waldencast adopted this ASU prospectively, which did not have a material effect on its consolidated financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards, Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued ASU No.&#160;2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Statements&#x2014;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU adds an impairment model known as current expected credit loss that is based on expected losses rather than incurred losses. It recognizes an allowance as an estimate of expected credit losses, which may result in more timely recognition of such losses. In 2019, the FASB issued ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 326), which defers the effective date for entities in the &#x201c;all other&#x201d; category and public not-for-profit entities that have not yet issued their financial statements reflecting the adoption of credit losses. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, and early adoption is permitted. This guidance is effective for the Company for the annual period beginning on January 1, 2023, and interim periods within the annual period beginning on January 1, 2023, with earlier adoption permitted. The adoption of this new standard will not have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The guidance requires an acquirer to, at the date of acquisition, recognize and measure the acquired contract assets and contract liabilities acquired in the same manner that they were recognized and measured in the acquiree&#x2019;s financial statements before the acquisition. This guidance is effective for interim and annual periods beginning after December 15, 2022, with early adoption permitted. The amendments in this update should be applied prospectively to business combinations occurring on or after the effective date. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements, but does not expect it to have a material impact.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The guidance expands public entities&#x2019; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. The guidance also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. This guidance is effective for interim periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. The amendments in this update should be applied retrospectively to all periods presented in the financial statements. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements but does not expect it to have a material impact.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2025, with early adoption permitted. The amendments should be applied prospectively however, retrospective application is also permitted. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-1065">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The accompanying consolidated financial statements include the accounts of Waldencast and its consolidated subsidiaries. The Company consolidates entities in which the Company has a majority voting interest. The Company eliminates intercompany transactions and accounts in consolidation. The Company separately presents within equity on the consolidated balance sheets the ownership interests attributable to parties with noncontrolling interests in the Company's consolidated subsidiaries, and separately presents net income attributable to such parties on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-1066">&lt;div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Significant estimates and assumptions reflected in the financial statements include, but are not limited to, revenue recognition, fair value of assets acquired and liabilities assumed in business combinations, stock-based compensation, and valuation allowance for deferred tax assets. The Company bases its estimates on historical experience and assumptions that it believes are reasonable at the time. Due to the inherent uncertainty involved in making assumptions and estimates, changes in circumstances could result in actual results differing from those estimates, and such differences could be material to the Company&#x2019;s consolidated balance sheets and consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-1067">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company maintains its cash balances in accounts held by major banks and financial institutions located primarily in the U.S. and considers such risk to be minimal. Such bank deposits from time to time may be exposed to credit risk in excess of the Federal Deposit Insurance Corporation insurance limit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable primarily represent amounts due from distributors, and third-party logistics companies, directly and indirectly from major retailers, and from group purchasing organizations located both inside and outside the U.S. The Company mitigates its credit risks by performing ongoing credit evaluations of its customers&#x2019; financial conditions, requiring customer advance payments in certain circumstances. The Company generally does not require collateral. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 (Successor Period), two U.S. customers accounted for 50% and 19% of accounts receivable, respectively. As of December&#160;31, 2021 (Predecessor Period), three U.S. customers accounted for 41%, 14%, and 10% of accounts receivable, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the period from July 28, 2022 to December&#160;31, 2022 (Successor Period), one vendor exceeded 10% of inventory purchases. During the period from January 1, 2022 to July&#160;27, 2022 (Predecessor Period), three vendors exceeded 10% of inventory purchases. During the period from July 28, 2022 to December&#160;31, 2022 (Successor Period), the Company purchased approximately 27% of inventory from one vendor. During the period from January 1, 2022 to July&#160;27, 2022 (Predecessor Period), the Company purchased approximately 23%, 12%, and 12% of inventory, respectively, from three vendors. During the year ended December&#160;31, 2021 (Predecessor Period), two vendors exceeded 10% of inventory purchases. In 2021 (Predecessor Period), the Company purchased approximately 45% and 11% of inventory, respectively, from two vendors.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 (Successor Period), two&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;vendors accounted for&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15% and 12%,&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;respectively, of accounts payable. As of December&#160;31, 2021 (Predecessor Period), one vendor accounted for 24% of accounts payable.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-149"
      decimals="2"
      id="f-1068"
      unitRef="number">0.50</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-150"
      decimals="2"
      id="f-1069"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-151"
      decimals="2"
      id="f-1070"
      unitRef="number">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-152"
      decimals="2"
      id="f-1071"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-153"
      decimals="2"
      id="f-1072"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-154"
      decimals="2"
      id="f-1073"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-155"
      decimals="2"
      id="f-1074"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-156"
      decimals="2"
      id="f-1075"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-157"
      decimals="2"
      id="f-1076"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-158"
      decimals="2"
      id="f-1077"
      unitRef="number">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-159"
      decimals="2"
      id="f-1078"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-160"
      decimals="2"
      id="f-1079"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-161"
      decimals="2"
      id="f-1080"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-162"
      decimals="2"
      id="f-1081"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-1082">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company considers highly liquid investments with an initial maturity of three months or less to be cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-1083">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company&#x2019;s restricted cash represents funds that were not accessible for general purpose cash needs due to contractual limitations. As of December&#160;31, 2022 (Successor Period), the Company&#x2019;s cash, cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;equivalents, and restricted cash balance of $10.2 million shown on the consolidated statements of cash flows consisted of $1.5&#160;million of restricted cash and $8.7&#160;million of cash and cash equivalents. The restricted cash balance represented cash in a savings account held by a major bank located in the U.S. and provides collateral for corporate credit cards obtained by the Predecessor for its employees. The Company is required to hold the restricted cash in the bank&#x2019;s savings account. Following the acquisition of Milk, the Company had an additional $0.8 million in restricted cash held with a financial institution as collateral for a lease deposit. The deposit is refundable at the end of the lease in November 2030, provided that Milk does not default on its lease payments. &lt;/span&gt;&lt;/div&gt;As of December&#160;31, 2021 (Predecessor Period) the Company&#x2019;s cash, cash equivalents, and restricted cash balance of $13.4 million as shown on the consolidated statements of cash flows consisted of $0.6 million restricted cash and $12.8 million in cash and cash equivalents.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-5" id="f-1084" unitRef="usd">10200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCash contextRef="c-7" decimals="-5" id="f-1085" unitRef="usd">1500000</us-gaap:RestrictedCash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-5" id="f-1086" unitRef="usd">8700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash contextRef="c-163" decimals="-5" id="f-1087" unitRef="usd">800000</wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-5" id="f-1088" unitRef="usd">13400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCash contextRef="c-8" decimals="-5" id="f-1089" unitRef="usd">600000</us-gaap:RestrictedCash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-8" decimals="-5" id="f-1090" unitRef="usd">12800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-1091">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company&#x2019;s products are produced by third-party contract manufacturers (&#x201c;CMOs). Inventories consist of finished goods, work-in-process products and promotional products, valued at the lower of cost or net realizable value using the standard cost method, which approximates actual costs determined on a first-in, first-out (&#x201c;FIFO&#x201d;) basis. In order to track inventory quantities, the Company uses a perpetual inventory system. Promotional product is charged to cost of goods sold at the time the product is shipped to the Company&#x2019;s customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has in-transit inventory at any given period. Assessment of in-transit inventory is required to determine inventory balances accurately at period-end. Inventory is recognized when the Company holds title and bears substantially all of the risks and rewards of ownership. In many transactions, the transfer of title and the risks and rewards of ownership are dictated by contractually specified shipping terms, which may take the form of free-on-board (&#x201c;FOB&#x201d;) shipping point or FOB destination point.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If historical costs exceed the net realizable value at the balance sheet date, the Company adjusts the inventory to net realizable value (i.e., if impairment is identified, the Company records write-downs of inventories to cost of goods sold in the period in which it occurs). The Company evaluates the carrying value of inventories on a regular basis and determines the need to write down carrying values by considering historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost, and the remaining shelf life of goods on hand. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Obsolete, Scrap and Expired Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The inventory provision is set up for inventory that is expected to become obsolete or have a decreased value due to market trends or product upgrades. It accounts for losses that may occur when the inventory cannot be sold at its full cost. The Company regularly monitors any inventory that is not expected to be sold prior to the expiration date and historically slow-moving inventory based on the remaining shelf life and incorporates these considerations into its reserve analysis. Additionally, each period, Management will evaluate whether any additional write downs are required in addition to the calculated reserve amount (generally, by stock keeping unit (&#x201c;SKU&#x201d;) and/or lot). Specific reserves may relate to known matters, such as quality concerns or a discontinued product.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically, the Company has not experienced a material amount of product returns. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain arrangements may give the Company&#x2019;s customers the right to return products. In addition, when customer arrangements do not give the Company&#x2019;s customer the explicit right to return products, the Company may accept returns on a discretionary basis. The Company records a return asset for products returned by customers measured at the former carrying amount of the inventory, less any expected costs to recover the goods and potential decreases in value. If the returned inventory is not considered re-sellable, it will be written off to cost of goods sold. When customers have the right to receive a refund for defective or damaged products (as opposed to a replacement product), the right is accounted for as a right of return under ASC 606. When customers have the right to receive a replacement product for defective or damaged products, the right is accounted for as a warranty under ASC 460-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Guarantees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the Company accrues for replacement costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c-1" id="f-1092">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivatives &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company accounts for derivative instruments in accordance with ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 815&#x201d;), which requires additional disclosures about the Company&#x2019;s objectives and strategies for using &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;derivative instruments, how the derivative instruments and related hedged items are accounted for, and how the derivative instruments and related hedging items affect the consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses interest rate collars to mitigate interest risk associated with its variable rate credit agreements. See &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_145" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Financial Instruments&#x201d; for further discussion of the interest rate collar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Terms of debt instruments are reviewed to determine whether they contain embedded derivative instruments that are required to be accounted for separately from the host contract and recorded on the consolidated balance sheets at fair value under ASC 815. An evaluation of specifically identified conditions is made to determine whether the fair value of warrants issued is required to be classified as equity or as a derivative liability. The fair value of derivative liabilities, if any, is required to be revalued at each reporting date, with corresponding changes in fair value recorded in current period operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrant Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for Public Warrants and Private Placement Warrants (each as defined below) as liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC Topic 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 480&#x201d;) and ASC 815. Specifically, the Public and Private Placement Warrants meet the definition of a derivative but do not qualify for an exception from derivative accounting since the warrants are not indexed to the Company&#x2019;s stock and, therefore, are precluded from equity classification. Since the Public and Private Placement Warrants meet the definition of a derivative under ASC 815, the Company measures the warrants at fair value at inception and at each reporting date, with changes in fair value recognized in change in fair value of derivative warrant liabilities in the consolidated statements of operations and comprehensive loss in the period of change. See &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_145" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 10&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Financial Instruments&#x201d; for further discussion of the warrants, including the FPA Warrants (as defined below).&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-1093">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the interest rate collar and warrant liabilities were estimated using inputs based on management&#x2019;s judgment and conditions that existed at each reporting date. See &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_151" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 1&lt;/a&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_151" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;1&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; for further details.&lt;/span&gt;&lt;/div&gt;The fair values of the Company&#x2019;s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and all other current liabilities approximate their carrying values because of the short maturities of these instruments. Additionally, the carrying amount of debt approximates fair value due to the adjusting interest rates of the Company&#x2019;s term loan, which approximate current market rates.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock contextRef="c-1" id="f-1094">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Capitalized Software and Website Development Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014; The Company capitalizes costs related to (i) internal-use software (ii) cloud computing arrangement (&#x201c;CCA&#x201d;) implementation costs, and (iii) other software-related costs (e.g., website development costs).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For internal-use software, both internal and external costs incurred during the preliminary project stage are expensed as incurred, and qualifying costs incurred during the application development state are capitalized. Capitalization ceases no later than the point at which a software project is substantially completed and ready for its intended use. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For CCAs, or hosting arrangements, the Company evaluates if the CCA includes a software license that will be accounted for in addition to a hosting service. The cost of the arrangement (i.e., license or service cost) of a CCA that includes a software license will be capitalized as an acquisition of an asset (similar to internal-use software) and amortized over its useful economic life, whereas the costs of a service contract are expensed as incurred.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Costs related to website development are expensed as incurred during the planning stage, content development stage, and operating stage. The Company generally capitalizes costs incurred for activities during the website application and infrastructure development stage, and graphics development stage. Costs incurred for website hosting services from a third-party vendor are expensed over the period the services are received.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Internal-use software costs and website development costs are amortized on a straight-line basis over their estimated useful lives, which is generally three years or less. Management evaluates the useful lives of these assets and tests for impairment whenever events or changes in circumstances occur that could impact the recoverability of these assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-164" id="f-1095">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <wald:PrepaidExpensesPolicyTextBlock contextRef="c-1" id="f-1096">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Prepaid Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; At initial recognition, the Company measures prepaid assets based on cost (i.e., amount paid). In the accounting period or periods in which a good or service is used or received, the asset will be reduced by a proportionate amount and an associated asset (e.g., inventory) or expense (e.g., marketing) will be recorded.   &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Prepaid Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Prepayments are required to begin production of inventory at certain of the Company&#x2019;s CMOs and inventory suppliers. Vendors are tracked to determine prepayments that have been made and when the associated inventory is expected to be delivered to the Company (i.e., when the Company takes ownership of the inventory). Prepaid inventory is triggered by invoices received from CMOs (i.e., the vendor). When the Company submits purchase orders, the CMOs may request a prepayment amount (deposit) based on agreed-upon percentage in the vendor contracts to start the production process.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Prepaid Marketing and Advertising&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally expenses the costs of advertising and marketing as costs are incurred, except for costs associated with producing advertising. While production costs (i.e., costs to develop promotions for a specific campaign associated with an identified new brand or new product) are incurred during the process of production, the Company has elected to expense certain costs when the associated advertising takes place. In the event that the advertising is not expected to occur (e.g., decision has been made to not launch a promotion) or a 12-month period elapses without the associated advertising occurring, the associated production costs will be expensed.&lt;/span&gt;&lt;/div&gt;</wald:PrepaidExpensesPolicyTextBlock>
    <wald:RecognitionPeriodForDeferredAdvertisingCostsMaximum contextRef="c-1" id="f-1097">P12M</wald:RecognitionPeriodForDeferredAdvertisingCostsMaximum>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-1098">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; Property and equipment are stated at cost, net of accumulated depreciation. In the case of a business combination, acquired property and equipment are recognized at their fair value as of the date of acquisition. Following initial recognition, property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of respective assets. No depreciation is charged to construction in progress. The estimated useful lives of the Company&#x2019;s assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ESTIMATED&#160;USEFUL&#160;LIVES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gondolas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lesser of useful life or term of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-1099">The estimated useful lives of the Company&#x2019;s assets are as follows:&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ESTIMATED&#160;USEFUL&#160;LIVES&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gondolas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lesser of useful life or term of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer hardware, software and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and fixture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Internally developed software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gondolas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-165" id="f-1100">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-166" id="f-1101">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-167" id="f-1102">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-168" id="f-1103">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-169" id="f-1104">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-170" id="f-1105">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="c-1" id="f-1106">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&#x2014;Intangible assets consist primarily of trademarks and trade names, a supply agreement, customer relationships, formulations, and developed technology. Intangible assets acquired in a business combination are recognized at their fair value as of the date of acquisition. Following initial recognition, intangible assets are carried at cost less accumulated amortization and impairment losses, if any, and are amortized on a straight-line basis over the estimated useful life of the asset.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-1107">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&#x2014;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, for each asset group held for use with indicators of impairment, the Company compares the expected future cash flows generated by the asset group, which represents the lowest level at which cash flows are identifiable, with its associated net carrying value. If the net carrying value of the asset group exceeds expected undiscounted cash flows, the excess of the net book value over estimated fair value is charged to impairment loss.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-1108">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Combinations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; When the Company acquires a business, the total purchase consideration provided is allocated to the identifiable assets and liabilities of the acquired business at their estimated respective fair values. Any excess consideration of the fair value of purchase consideration over the fair values of assets acquired and liabilities assumed is recognized as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant management judgments and assumptions are required in determining the fair value of assets acquired and liabilities assumed. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows, useful lives and discount rates. Measurement period adjustments are reflected at the time identified, up through the conclusion of the measurement period, which is the time at which all information for determination of the values of assets acquired and liabilities assumed is received, which may not exceed one year from the acquisition date. The Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with a corresponding offset to goodwill. If outside of the measurement period, any subsequent adjustments are recorded in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-1109">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Goodwill represents the difference between the purchase price and the fair value of assets and liabilities acquired in a business combination. The Company reviews goodwill for impairment annually on October 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt; and at an interim date if events or changes in circumstances indicate the occurrence of a triggering event. The Company reviews goodwill for impairment by initially considering qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill, as a basis for determining whether it is necessary to perform a quantitative analysis. If it is determined that it is more likely than not that the fair value of reporting unit is less than its carrying amount, a quantitative analysis is performed to identify goodwill impairment. Determining the fair value of a reporting unit involves the use of significant estimates and assumptions.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:DebtPolicyTextBlock contextRef="c-1" id="f-1110">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Issuance Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company capitalizes costs related to the issuance of debt instruments, as applicable. Such costs are initially recorded as a direct deduction from the applicable debt instrument and amortized over the contractual term of the related debt instrument in interest expense, net using the straight-line method, which approximates the effective interest method, in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-1111">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Trade accounts receivable are stated at net realizable value. Receivables are unsecured and represent amounts billed to and currently due from customers that have yet to be collected. Payment terms are generally short-term in nature and are less than one year. In certain circumstances, the Company offers extended payment terms to customers. When the period between the transfer of control of the products and payment is greater than one year, the Company adjusts the promised amount of consideration for the effects of a significant financing component. &lt;/span&gt;&lt;/div&gt;The Company maintains an allowance for doubtful accounts, which represents allowances for customer trade accounts receivable that are both probable and estimated to be partially or entirely uncollectible. These allowances are used to reduce gross trade receivables to their net realizable value. The Company records these allowances based on estimates related to the following factors: (i)&#160;customer-specific allowances, based upon past collection history, historical trends, and identification of specific customer risk and (ii)&#160;formula-based general allowances using an aging schedule. Determining such allowances involves the use of significant estimates and assumptions. Payments of accounts receivable are allocated to the specific invoices identified on the customer&#x2019;s remittance advice or to the customer&#x2019;s account, if unspecified, until an invoice can be determined by the customer. Balances that are still outstanding after management has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to trade accounts receivable.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-1112">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company recognizes revenue when control of the promised goods or services is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to for those goods or services. In that determination, under ASC 606 the Company follows a five-step model that includes: (1) determination of whether a contract or an agreement between two or more parties that creates legally enforceable &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rights and obligations exists; (2) identification of the performance obligations in the contract; (3) determination of the transaction price; (4) allocation of the transaction price to the performance obligations in the contract; and (5) recognition of revenue when (or as) performance obligations are satisfied. Net revenue excludes taxes collected by us on behalf of governmental authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenue is primarily generated from product sales to distributors, retailers, physicians and directly to consumers (&#x201c;DTC&#x201d;) via its e-commerce platforms. Distributors may resell products to retailers, physicians, or end consumers. To determine when to recognize revenue under ASC 606 in cases where products are sold to distributors, the Company analyzes various factors including its ability to direct products physically held by the distributors, when title and risk of loss transfers, and who ultimately manages the relationship with the end consumer. The Company does not recognize revenue until control of the products is transferred to the distributor.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, and when facts and circumstances change, the Company assesses whether it is probable that the Company will collect substantially all of the consideration it will be entitled to from a customer. If the Company determines that it is not probable that the Company will collect substantially all of the consideration from the customer, the Company recognizes revenue only when one or more of the following events occur: (i) the Company has no remaining obligations to transfer goods or services to the customer, and all, or substantially all, of the consideration promised by the customer has been received by the Company and is nonrefundable, (ii) the contract has been terminated, and the consideration received from the customer is nonrefundable, or (iii) the Company has transferred control of the goods or services to which the consideration that has been received relates, the Company has stopped transferring goods or services to the customer (if applicable) and has no obligation under the contract to transfer additional goods or services, and the consideration received from the customer is nonrefundable.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that each of its products is distinct and represents a separate performance obligation. The transaction price is equal to the consideration the Company is entitled to &#x2013; which could be either a distributor, retailer, physician, or e-commerce end consumer. When measuring revenue and determining the consideration the Company is entitled to as part of a contract with a customer, the Company takes into account the related elements of variable consideration. Product sales revenue is recognized net of provisions for estimated volume rebates and discounts, markdowns, margin adjustments, early-payment discounts and returns. The Company estimates variable consideration using the expected value method and adjusts the transaction price when control of the related product is transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s distributors charge fees for certain services rendered by the distributors, including packing and shipping, marketing and advertising the Company&#x2019;s products, monitoring product reviews, regulatory services, providing customer service, and generating data and analytical reports on product sales. Distributor fees for services are recognized as a reduction to revenue because the services provided are typically not distinct from the distributors&#x2019; purchase of products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Typically, customers are required to pay either in advance or between 30 and 90 days from delivery or invoicing. However, in certain circumstances, the Company offers extended payment terms to customers. When the period between the transfer of control of the products and payment is greater than one year, the Company adjusts the promised amount of consideration for the effects of a significant financing component. When contracts contain a significant financing component in which the Company is effectively financing the customer, a portion of the transaction price is recognized as other income.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price to each performance obligation based on its relative standalone selling price. Standalone selling price is the price at which the Company would sell a promised product separately to a customer. The Company typically has an observable standalone selling price for each of its products.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has different contracted shipping terms with different customers that dictate the timing of payment, passage of legal title, transfer of physical possession, and assumption of the risks and rewards occur. For distributors, other than the Physician Channel Provider, and retailers, depending on the contract, the Company considers transfer of control to have occurred either once the delivery of the product has occurred or once the product has been picked up from the Company&#x2019;s designated warehouse/distribution center by the customer&#x2019;s shipping agent, unless the Company is responsible for shipping the goods, in which case transfer of control passes upon delivery to the customer. For DTC &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sales and sales to physicians through the Physician Channel Provider, control transfers upon shipment to the end consumer or physician. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shipping and Handling &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for shipping and handling activities as fulfillment activities instead of as performance obligations and recognizes these costs as SG&amp;amp;A expenses. Costs related to shipping and handling for the period from July&#160;28 to December&#160;31, 2022 (Successor Period), and the period from January&#160;1 to July&#160;27, 2022 (Predecessor Period), and the years ended December&#160;31, 2021 and 2020 (Predecessor Periods) were $2.0 million, $0.6 million, $1.0 million, and $0.2 million, respectively. Amounts billed to customers for shipping and handling are included in revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Promotional Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In situations where promotional products, such as samples and testers, are provided by the Company to its customers at the same time as a related saleable product, the cost of these promotional products are recognized as cost of sales at the same time as the revenue for the related product is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates royalty revenue from products sold under the Obagi brand name in Japan and Hong Kong through license agreements with local operators. Under these agreements, the Company provides the local operators with a license of intellectual property and receives a royalty based upon a percentage of net sales of Obagi-branded products sold in Japan and Hong Kong. Because the license is the predominant item to which the sales-based royalty relates, the Company recognizes revenue for the sales-based royalty when the local operators make sales of the products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Costs to Obtain a Contract with a Customer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the incremental costs of obtaining a customer contract as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. The incremental costs to obtain contracts primarily relate to sales commission and sales-based bonuses. Total capitalizable costs to obtain a contract were immaterial during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s contracts do not typically give rise to material contract assets or contract liabilities because (i) payment is typically closely aligned with the timing of the Company&#x2019;s performance or (ii) the Company performs prior to customer payment, and the Company has an unconditional right to payment that represents an account receivable. Similarly, the Company does not recognize material revenue in reporting periods from performance obligations satisfied in previous periods. The Company applies the exemption in ASC 606-10-50-14(a) related to disclosure of the amount of transaction price allocated to unsatisfied performance obligations for royalty contracts. Because of the short-term nature of product sales contracts, the Company typically does not have other material amounts to disclose related to the transaction price allocated to unsatisfied performance obligations.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <wald:CustomerPaymentPeriod contextRef="c-171" id="f-1113">P30D</wald:CustomerPaymentPeriod>
    <wald:CustomerPaymentPeriod contextRef="c-172" id="f-1114">P90D</wald:CustomerPaymentPeriod>
    <wald:ShippingAndHandlingCosts contextRef="c-14" decimals="-5" id="f-1115" unitRef="usd">2000000.0</wald:ShippingAndHandlingCosts>
    <wald:ShippingAndHandlingCosts contextRef="c-15" decimals="-5" id="f-1116" unitRef="usd">600000</wald:ShippingAndHandlingCosts>
    <wald:ShippingAndHandlingCosts contextRef="c-16" decimals="-5" id="f-1117" unitRef="usd">1000000.0</wald:ShippingAndHandlingCosts>
    <wald:ShippingAndHandlingCosts contextRef="c-17" decimals="-5" id="f-1118" unitRef="usd">200000</wald:ShippingAndHandlingCosts>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c-1" id="f-1119">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Cost of Goods Sold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&#x2014;Cost of goods sold consists of inventory and promotional product costs, including when inventory and promotional products are sold or written down, and product-related intangible asset amortization and depreciation expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-1120">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;R&amp;amp;D costs are expensed as incurred. Costs associated with research and development activities may include materials, equity and facility costs, personnel costs, contracted services (i.e., the costs of services performed by third parties in connection with the Company&#x2019;s R&amp;amp;D activities), and direct costs (e.g., appropriate allocations for general and administrative costs). Substantially all R&amp;amp;D expenses are related to new product development and design improvements or increased functionality in current products. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may capitalize acquired assets associated with R&amp;amp;D activities (e.g., materials, equipment) if both of the following criteria are met: (i) the Company reasonably expects that the acquired assets will be used in an alternative manner and anticipates an economic benefit from the alternative future use and (ii) the use of the acquired asset is not &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contingent on the further development of the asset after acquisition date (i.e., the asset can be used in an alternative manner in the condition in which it existed at the acquisition date).&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c-1" id="f-1121">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising&lt;/span&gt;&#x2014;Advertising costs are expensed in the period in which they are incurred.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense contextRef="c-14" decimals="-5" id="f-1122" unitRef="usd">11700000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-15" decimals="-5" id="f-1123" unitRef="usd">6800000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-16" decimals="-5" id="f-1124" unitRef="usd">9200000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-17" decimals="-5" id="f-1125" unitRef="usd">5900000</us-gaap:AdvertisingExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-1126">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company measures the cost of share-based awards granted to eligible employees, directors, and consultants based on the grant-date fair value of the awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Replacement Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On the Closing Date, in connection with the Business Combination, the Company assumed Obagi and Milk&#x2019;s legacy incentive award plans and outstanding unvested options granted under those plans (&#x201c;Replacement Options&#x201d;). Because the options were deemed in the money on the replacement date, a Hull-White lattice pricing model was used to estimate their fair value to capture the optimal timing of exercise. This pricing model requires the use of assumptions including the volatility of the underlying stock, the fair value of the stock, dividend yield, risk-free rate, and exercise multiple. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Founder Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value and derived service period of the stock options issued to founders (&#x201c;Founder Awards&#x201d;) in August 2022 based on the Monte Carlo simulation, as they were deemed out of the money on the grant date. The Monte Carlo simulation model requires the use of assumptions including the option&#x2019;s expected term, the volatility of the underlying stock, dividend yield rate, risk-free rate, and expected exercise behavior. For expected exercise behavior, the Company assumes that the options are exercised after 50% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of restricted stock is equal to the price of the Company&#x2019;s ordinary shares on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to recognize the effect of forfeitures in the period in which they occur. Share-based awards are classified as equity, unless the underlying shares are classified as liabilities or the Company is required to settle the awards by transferring cash or other assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense for awards with service or performance conditions using the straight-line method over the requisite service period, which is generally the award&#x2019;s vesting period. Compensation expense for employee stock-based awards whose vesting is subject to the fulfillment of both a service condition and the occurrence of a performance condition is recognized on a graded-vesting basis at the time the achievement of the performance condition becomes probable.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent
      contextRef="c-173"
      decimals="2"
      id="f-1127"
      unitRef="number">0.50</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-1128">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company accounts for income taxes using the asset and liability approach. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes represents income taxes paid or payable for the current period plus the change in deferred taxes during the period. Deferred taxes result from differences between the financial and tax basis of the Company&#x2019;s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether a valuation allowance is required often requires significant judgment including the long-range forecasting of future taxable income and the evaluation of planning initiatives. Adjustments to the deferred tax valuation allowances are made to earnings in the period when such assessments are made. A valuation allowance of $7.9 million was recorded as of December&#160;31, 2022 (Successor Period), a valuation allowance of $14.1 million was recorded as of December&#160;31, 2021 (Predecessor Period), and no valuation allowance was recorded as of December&#160;31, 2020 (Predecessor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for a tax benefit from an uncertain position in the consolidated financial statements only if it is more likely than not that the position is sustainable, based solely on its technical merits and consideration of the relevant taxing authority&#x2019;s widely understood administrative practices and precedents. If the recognition threshold for the tax position is met, the Company records only the portion of the tax benefit that is greater than 50% likely to be realized. As of December&#160;31, 2022 (Successor Period), 2021 (Predecessor Period), and 2020 (Predecessor Period), the Company had no uncertain positions in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-5" id="f-1129" unitRef="usd">7900000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-8" decimals="-5" id="f-1130" unitRef="usd">14100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-86" decimals="-5" id="f-1131" unitRef="usd">0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-7" decimals="-5" id="f-1132" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-86" decimals="-5" id="f-1133" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-8" decimals="-5" id="f-1134" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-7" decimals="-5" id="f-1135" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-86" decimals="-5" id="f-1136" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-8" decimals="-5" id="f-1137" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-1138">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Income (Loss) Per Share&lt;/span&gt;&#x2014;Basic net income (loss) per share attributable to shareholders of ordinary shares is computed by dividing the Company&#x2019;s net income (loss) attributable to holders of ordinary shares by the weighted-average number of ordinary shares used in the income (loss) per share calculation during the period. Diluted net income (loss) per share attributable to holders of ordinary shares is computed by giving effect to all potentially dilutive securities. The net income (loss) per share that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy contextRef="c-1" id="f-1139">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Noncontrolling interests represent the portion of Waldencast Partners LP that the Company controls and consolidates but does not own. The Company recognizes each noncontrolling holder&#x2019;s respective share of the estimated fair value of the net assets at the date of formation or acquisition. Noncontrolling interests are subsequently adjusted for the noncontrolling holder&#x2019;s share of additional contributions, distributions and their share of the net earnings or losses of each respective consolidated entity. The Company allocates net income or loss to noncontrolling interests based on the weighted average ownership interest during the period. The net income (loss) that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the consolidated statements of operations and comprehensive loss. The Company does not recognize a gain or loss on transactions with a consolidated entity in which it does not own 100% of the equity, but the Company reflects the difference in cash received or paid from the noncontrolling interests carrying amount as additional paid-in-capital.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-1140">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and incur expenses and about which separate financial information is regularly evaluated by the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources. Similar operating segments can be aggregated into a single operating segment if the businesses are similar. Management has determined that, following the Business Combination, the Successor has two operating and reportable segments: Obagi Skincare and Milk Makeup, reflecting the manner in which the CODM operates the Company. The Company&#x2019;s CODM is its Chief Executive Officer. The Predecessor had one operating and reportable segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-14"
      decimals="INF"
      id="f-1141"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-14"
      decimals="INF"
      id="f-1142"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-15"
      decimals="INF"
      id="f-1143"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-15"
      decimals="INF"
      id="f-1144"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-1145">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 842&#x201d;) using the modified retrospective transition method on the date of the Business Combination. The Predecessor planned to adopt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 842 during the annual period ended December&#160;31, 2022. Waldencast had no capital or operating lease obligations prior to the Business Combination. The Company elected the package of practical expedients available upon transition to ASC 842 that allow (i) historical lease classification of existing leases, (ii) no reassessment of any expired or existing contracts containing leases, and (iii) no reassessment of initial direct costs for any existing leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The adoption of the new standard impacted the Company&#x2019;s accounting for operating leases. Upon adoption, the Company established an operating right-of-use asset of $13.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and a corresponding operating lease liability of $16.6 million. The Company does not have any finance leases. See &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_142" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 9&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further detail.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the adoption of ASC 842, the Company recognized rent expense for operating leases on a straight&#x2011;line basis (including the effect of reduced or free rent and rent escalations) over the lease term. The difference between the cash paid to the landlord and the amount recognized as rent expense on a straight&#x2011;line basis was recognized as an adjustment to deferred rent in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Debt-Debt with Conversion and Other Options&#x201d; (Subtopic 470-20) and &#x201c;Derivatives and Hedging-Contracts in an Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2020-06&#x201d;), which &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 also removes certain settlement conditions that are required for equity-linked contracts to qualify for scope exception, and it simplifies the diluted earnings per share calculation in certain areas. The Company adopted ASU 2020-06 on January 1, 2021. Adoption of the ASU did not impact the Company&#x2019;s financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU No.&#160;2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic&#160;848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was effective for the Company in the annual period ended December&#160;31, 2022. This ASU provides relief that, if elected, will require less accounting analysis and less accounting recognition for modifications related to reference rate reform. This update provides optional guidance for a limited period of time to ease the potential burden in accounting for reference rate reform on financial reporting. The amendments in the update apply only to contracts, hedging relationships, and other transactions that reference the London Inter-Bank Offered Rate (&#x201c;LIBOR&#x201d;) or another reference rate expected to be discontinued because of reference rate reform. Waldencast adopted this ASU prospectively effective January 1, 2022, which did not have a material effect on its consolidated financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2022, Waldencast adopted ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&#x2014;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2019-12&#x201d;). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. Waldencast adopted this ASU prospectively, which did not have a material effect on its consolidated financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards, Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2016, the FASB issued ASU No.&#160;2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Statements&#x2014;Credit Losses (Topic&#160;326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU adds an impairment model known as current expected credit loss that is based on expected losses rather than incurred losses. It recognizes an allowance as an estimate of expected credit losses, which may result in more timely recognition of such losses. In 2019, the FASB issued ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 326), which defers the effective date for entities in the &#x201c;all other&#x201d; category and public not-for-profit entities that have not yet issued their financial statements reflecting the adoption of credit losses. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, and early adoption is permitted. This guidance is effective for the Company for the annual period beginning on January 1, 2023, and interim periods within the annual period beginning on January 1, 2023, with earlier adoption permitted. The adoption of this new standard will not have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The guidance requires an acquirer to, at the date of acquisition, recognize and measure the acquired contract assets and contract liabilities acquired in the same manner that they were recognized and measured in the acquiree&#x2019;s financial statements before the acquisition. This guidance is effective for interim and annual periods beginning after December 15, 2022, with early adoption permitted. The amendments in this update should be applied prospectively to business combinations occurring on or after the effective date. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements, but does not expect it to have a material impact.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The guidance expands public entities&#x2019; segment disclosures by requiring disclosure of significant segment expenses that are regularly reviewed by the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. The guidance also allows, in addition to the measure that is most consistent with U.S. GAAP, the disclosure of additional measures of segment profit or loss that are used by the CODM in assessing segment performance and deciding how to allocate resources. This guidance is effective for interim periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024 with early adoption permitted. The amendments in this update should be applied retrospectively to all periods presented in the financial statements. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements but does not expect it to have a material impact.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which provides qualitative and quantitative updates to the rate reconciliation and income taxes paid disclosures, among others, in order to enhance the transparency of income tax disclosures, including consistent categories and greater disaggregation of information in the rate reconciliation and disaggregation by jurisdiction of income taxes paid. The amendments in ASU 2023-09 are effective for fiscal years beginning after December 15, 2025, with early adoption permitted. The amendments should be applied prospectively however, retrospective application is also permitted. The Company is in the process of assessing the impact of this ASU on its future consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-174" decimals="-5" id="f-1146" unitRef="usd">13000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c-174" decimals="-5" id="f-1147" unitRef="usd">16600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-1148">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;BUSINESS COMBINATIONS&lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 27, 2022, Waldencast consummated its initial business combination with (i) Obagi, pursuant to an Agreement and Plan of Merger dated November 15, 2021, by and among Waldencast, Obagi Merger Sub, Inc., a Cayman Islands exempted company limited by shares and an indirect wholly-owned subsidiary of Waldencast (&#x201c;Merger Sub&#x201d;), and Obagi (the &#x201c;Obagi Merger Agreement&#x201d;), and (ii), Milk, pursuant to an Equity Purchase Agreement dated November 15, 2021, by and among Waldencast, Obagi Holdco 1 Limited, a limited company incorporated under the laws of Jersey (&#x201c;Holdco Purchaser&#x201d;) and a subsidiary of Waldencast, Waldencast Partners LP together with Holdco Purchaser, (the &#x201c;Purchasers&#x201d;), certain members of Milk (the &#x201c;Milk Members&#x201d;), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as representative of the Milk Members (the &#x201c;Equityholder Representative&#x201d;) (the &#x201c;Milk Equity Purchase Agreement&#x201d; and together with the Obagi Merger Agreement, the &#x201c;Transaction Agreements&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Obagi Merger Agreement, at the effective time of the Obagi Merger (the &#x201c;Obagi Merger Effective Time&#x201d;) Merger Sub merged with and into Obagi (the &#x201c;Obagi Merger&#x201d;) and the separate corporate existence of Merger Sub ceased, with Obagi surviving as an indirect subsidiary of the Company. At the Obagi Merger Effective Time, all outstanding ordinary shares of Obagi, $0.50 par value (&#x201c;Obagi common shares&#x201d;) were canceled and exchanged for (i) 28,237,506 Class A ordinary shares of Waldencast and (ii) cash in the amount of $345.4 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Milk Equity Purchase Agreement, at the effective time of the Milk Transaction (the &#x201c;Milk Purchase Effective Time&#x201d;) the Purchasers acquired from the Milk Members all of their equity in Milk in exchange for (i) 21,104,225 limited partnership units in Waldencast Partners LP (&#x201c;Waldencast LP Units&#x201d;) (ii) 21,104,225 Class B ordinary shares, which are non-economic voting shares of Waldencast and (iii) cash in the amount of $121.6 million &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(the &#x201c;Milk Transaction&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Each Waldencast LP Unit and Class B ordinary share held by a Milk Member is redeemable at the option of the holder, &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and, if such option is exercised, exchangeable at the option of Waldencast &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;into one Waldencast Class A ordinary share or cash, &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in accordance with the terms of the Amended and Restated Waldencast Partners LP Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Upon consummation of the Business Combination &lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Waldencast became organized in an &#x201c;Up-C&#x201d; structure, whereby the equity interests of Obagi and Milk are held by Waldencast Partners LP, which is an indirect subsidiary of Waldencast plc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the Business Combination, Waldencast was deemed to be the accounting acquirer and continues as the SEC registrant. Obagi and Milk were deemed to be the accounting acquirees, however Obagi is considered the predecessor entity for purposes of financial reporting. Waldencast was determined to be the accounting acquirer based on evaluation of the following factors:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;The owners of Waldencast have the largest voting interest in the combined company;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;The original owner of Waldencast, Waldencast Long-Term Capital LLC (the &#x201c;Sponsor&#x201d;), and its affiliates nominated the majority of the initial members who will serve on the board of directors of Waldencast (the former owner of Obagi nominated one director, and Milk nominated no directors); and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;Waldencast&#x2019;s existing management holds executive management roles for the post-combination company, whilst Obagi and Milk management team members report into the current Waldencast executive team.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the Obagi Merger Effective Time, Obagi carved out and distributed the Obagi China Business to Cedarwalk pursuant to the Obagi China Distribution. Following the Obagi China Distribution, the Obagi China Business continues to be held by Cedarwalk, which also owned 24.5% of the fully diluted Waldencast plc Class A ordinary shares as of the Obagi Merger Effective Time. Prior to the Obagi China Distribution, the pre-tax losses for the Obagi China Business were $8.0 million, $3.7 million and $2.3 million for the period from January 1 to July 27, 2022 (Predecessor Period), the year ended December 31, 2021 (Predecessor Period) and the year ended December 31, 2020 (Predecessor Period), respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 17&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related Party Transactions&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for more information on ongoing transactions with the Obagi China Business following the close of the Obagi Merger. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Measurement period adjustments will be recognized in the reporting period in which the adjustments are determined.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Obagi and Milk Purchase Price Allocation:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.604%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Obagi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Milk&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Purchase Price:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;345,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;467,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;277,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;200,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;477,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash repayment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;136,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related party liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;781,434&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;325,651&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,107,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value of assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Account receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related party receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;505,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;157,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;662,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;579,316&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;212,609&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;791,925&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;66,145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;22,030&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;88,175&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;513,171&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;190,579&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;703,750&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;781,434&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;325,651&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,107,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;268,263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;135,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;403,335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill recognized for these acquisitions is attributable to improving the product offerings, expanding into additional markets and the expected cash flows resulting from these efforts, and assembled workforce. Goodwill recognized is not expected to be deductible for local tax purposes. During the Successor Period ended December 31, 2022, the Company recorded a non-cash impairment charge of $68.7 million within the Obagi Skincare reportable segment. See &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_133" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 6&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Goodwill&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for additional details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_178" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 19&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Segment Reporting&#x201d; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for amounts related to revenue and earnings associated with Obagi Skincare and Milk Makeup subsequent to the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related party liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company recognized a liability with respect to a related party supply contract executed on the Closing Date between Obagi and Obagi Hong Kong. The fair value of the related party liability was determined using the present value of after-tax cash flows related to unfavorable discounts provided to the Obagi China Business included in the supply agreement. As of the Obagi Merger Effective Time, the Company recognized a related party liability of $22.1 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million. During the period from July 28 to December 31, 2022 (Successor Period), the Company amortized $12.2 million of the related party liability into the related party revenue recognized on the sale of products to the Obagi China Business. The Company had a remaining related party liability of $9.9 million, included in Other current liabilities, as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Obagi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Milk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trademarks and Trade Name&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;414,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;145,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;559,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer/distributor relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tretinoin distribution and supply agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Formulations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;505,300&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;157,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;662,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible assets acquired in connection with the Business Combination are classified as Level 3 in the fair value hierarchy. The estimate of the fair values of the acquired amortizable intangible assets were determined using a multi-period excess earnings income approach by discounting the incremental after-tax cash flows over multiple periods. Significant estimates used in the determination include estimating future cash flows over multiple periods, terminal value, and discounting such cash flows at a rate of return that reflects the relative risk of the cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transaction Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Business Combination, Waldencast incurred transactions costs of $9.4 million which was incurred during the period from July&#160;28, 2022 to December&#160;31, 2022 (Successor Period). Transaction costs consisted of advisory, legal, accounting and management fees, which are included in SG&amp;amp;A expenses on the consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unaudited ASC 805 Pro Forma &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma combined financial information presents the Company&#x2019;s results as though the Business Combination had occurred on January 1, 2021, for the years ended December&#160;31, 2021 and 2022. The unaudited pro forma consolidated financial information has been prepared using the acquisition method of accounting in accordance with U.S. GAAP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma net revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;200,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;162,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(86,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(145,152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Pro forma net income (loss) attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(25,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(26,519)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma net income (loss) attributable to Waldencast plc&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(118,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited pro forma results include adjustments such as inventory step-up, amortization of acquired intangible assets, and interest expense on debt financing in connection with the Business Combination. Material, nonrecurring pro forma adjustments directly attributable to the Business Combination include:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022; Cost of goods sold related to acquired inventory step-up of $10.0 million was removed from net income for the year ended December&#160;31, 2022 and recognized as an incremental cost of goods sold in the year ended December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022; Transaction related costs of $66.1 million were removed from net income for the year ended December&#160;31, 2022 and recognized as an expense in the year ended December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited consolidated pro forma financial information was prepared in accordance with accounting standards and is not necessarily indicative of the results of operations that would have occurred if the Business Combination had been completed on the date indicated, nor is it indicative of the future operating results of the Company.&#160;&lt;/span&gt;&lt;/div&gt;The unaudited pro forma results do not reflect events that either have occurred or may occur after the Business Combination, including, but not limited to, the anticipated realization of operating synergies in subsequent periods. They also do not give effect to certain charges that the Company expects to incur in connection with these acquisitions, including, but not limited to, additional professional fees and employee integration.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-175"
      decimals="2"
      id="f-1149"
      unitRef="usdPerShare">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-176"
      decimals="INF"
      id="f-1150"
      unitRef="shares">28237506</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-177" decimals="-5" id="f-1151" unitRef="usd">345400000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-178"
      decimals="INF"
      id="f-1152"
      unitRef="shares">21104225</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-179"
      decimals="INF"
      id="f-1153"
      unitRef="shares">21104225</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-180" decimals="-5" id="f-1154" unitRef="usd">121600000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <wald:CommonStockConvertibleConversionRatio
      contextRef="c-181"
      decimals="INF"
      id="f-1155"
      unitRef="shares">1</wald:CommonStockConvertibleConversionRatio>
    <wald:NumberOfNominatedDirectors
      contextRef="c-175"
      decimals="INF"
      id="f-1156"
      unitRef="director">1</wald:NumberOfNominatedDirectors>
    <wald:NumberOfNominatedDirectors
      contextRef="c-182"
      decimals="INF"
      id="f-1157"
      unitRef="director">0</wald:NumberOfNominatedDirectors>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="c-183"
      decimals="3"
      id="f-1158"
      unitRef="number">0.245</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-184" decimals="-5" id="f-1159" unitRef="usd">-8000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-185" decimals="-5" id="f-1160" unitRef="usd">-3700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-186" decimals="-5" id="f-1161" unitRef="usd">-2300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-1162">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Obagi and Milk Purchase Price Allocation:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.604%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Obagi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Milk&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Purchase Price:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;345,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;467,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;277,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;200,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;477,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash repayment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;136,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;140,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related party liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;781,434&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;325,651&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,107,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value of assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Account receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related party receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;505,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;157,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;662,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;579,316&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;212,609&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;791,925&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;66,145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;22,030&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;88,175&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;513,171&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;190,579&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;703,750&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;781,434&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;325,651&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;1,107,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;268,263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;135,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;403,335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-187" decimals="-3" id="f-1163" unitRef="usd">345398000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-188" decimals="-3" id="f-1164" unitRef="usd">121629000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-189" decimals="-3" id="f-1165" unitRef="usd">467027000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-187" decimals="-3" id="f-1166" unitRef="usd">277824000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-188" decimals="-3" id="f-1167" unitRef="usd">200087000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-189" decimals="-3" id="f-1168" unitRef="usd">477911000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <wald:BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt contextRef="c-187" decimals="-3" id="f-1169" unitRef="usd">136112000</wald:BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt>
    <wald:BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt contextRef="c-188" decimals="-3" id="f-1170" unitRef="usd">3935000</wald:BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt>
    <wald:BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt contextRef="c-189" decimals="-3" id="f-1171" unitRef="usd">140047000</wald:BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-190" decimals="-3" id="f-1172" unitRef="usd">22100000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-191" decimals="-3" id="f-1173" unitRef="usd">0</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-192" decimals="-3" id="f-1174" unitRef="usd">22100000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-187" decimals="-3" id="f-1175" unitRef="usd">781434000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-188" decimals="-3" id="f-1176" unitRef="usd">325651000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-189" decimals="-3" id="f-1177" unitRef="usd">1107085000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-193" decimals="-3" id="f-1178" unitRef="usd">15850000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-194" decimals="-3" id="f-1179" unitRef="usd">2092000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-195" decimals="-3" id="f-1180" unitRef="usd">17942000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash contextRef="c-193" decimals="-3" id="f-1181" unitRef="usd">650000</wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash>
    <wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash contextRef="c-194" decimals="-3" id="f-1182" unitRef="usd">819000</wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash>
    <wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash contextRef="c-195" decimals="-3" id="f-1183" unitRef="usd">1469000</wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c-193" decimals="-3" id="f-1184" unitRef="usd">15214000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c-194" decimals="-3" id="f-1185" unitRef="usd">3866000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c-195" decimals="-3" id="f-1186" unitRef="usd">19080000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty contextRef="c-193" decimals="-3" id="f-1187" unitRef="usd">327000</wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty>
    <wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty contextRef="c-194" decimals="-3" id="f-1188" unitRef="usd">199000</wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty>
    <wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty contextRef="c-195" decimals="-3" id="f-1189" unitRef="usd">526000</wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-193" decimals="-3" id="f-1190" unitRef="usd">31026000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-194" decimals="-3" id="f-1191" unitRef="usd">30945000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-195" decimals="-3" id="f-1192" unitRef="usd">61971000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c-193" decimals="-3" id="f-1193" unitRef="usd">4307000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c-194" decimals="-3" id="f-1194" unitRef="usd">520000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c-195" decimals="-3" id="f-1195" unitRef="usd">4827000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther contextRef="c-193" decimals="-3" id="f-1196" unitRef="usd">359000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther contextRef="c-194" decimals="-3" id="f-1197" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther contextRef="c-195" decimals="-3" id="f-1198" unitRef="usd">359000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-193" decimals="-3" id="f-1199" unitRef="usd">1245000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-194" decimals="-3" id="f-1200" unitRef="usd">8436000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-195" decimals="-3" id="f-1201" unitRef="usd">9681000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-193" decimals="-3" id="f-1202" unitRef="usd">505300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-194" decimals="-3" id="f-1203" unitRef="usd">157500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-195" decimals="-3" id="f-1204" unitRef="usd">662800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets contextRef="c-193" decimals="-3" id="f-1205" unitRef="usd">4811000</wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets>
    <wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets contextRef="c-194" decimals="-3" id="f-1206" unitRef="usd">8232000</wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets>
    <wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets contextRef="c-195" decimals="-3" id="f-1207" unitRef="usd">13043000</wald:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets contextRef="c-193" decimals="-3" id="f-1208" unitRef="usd">227000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets contextRef="c-194" decimals="-3" id="f-1209" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets contextRef="c-195" decimals="-3" id="f-1210" unitRef="usd">227000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-193" decimals="-3" id="f-1211" unitRef="usd">579316000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-194" decimals="-3" id="f-1212" unitRef="usd">212609000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c-195" decimals="-3" id="f-1213" unitRef="usd">791925000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="c-193" decimals="-3" id="f-1214" unitRef="usd">18699000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="c-194" decimals="-3" id="f-1215" unitRef="usd">6442000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="c-195" decimals="-3" id="f-1216" unitRef="usd">25141000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther contextRef="c-193" decimals="-3" id="f-1217" unitRef="usd">12912000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther contextRef="c-194" decimals="-3" id="f-1218" unitRef="usd">5483000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther contextRef="c-195" decimals="-3" id="f-1219" unitRef="usd">18395000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation contextRef="c-193" decimals="-3" id="f-1220" unitRef="usd">6461000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation contextRef="c-194" decimals="-3" id="f-1221" unitRef="usd">10105000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation contextRef="c-195" decimals="-3" id="f-1222" unitRef="usd">16566000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-193" decimals="-3" id="f-1223" unitRef="usd">28073000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-194" decimals="-3" id="f-1224" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-195" decimals="-3" id="f-1225" unitRef="usd">28073000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-193" decimals="-3" id="f-1226" unitRef="usd">66145000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-194" decimals="-3" id="f-1227" unitRef="usd">22030000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-195" decimals="-3" id="f-1228" unitRef="usd">88175000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-193" decimals="-3" id="f-1229" unitRef="usd">513171000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-194" decimals="-3" id="f-1230" unitRef="usd">190579000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-195" decimals="-3" id="f-1231" unitRef="usd">703750000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-187" decimals="-3" id="f-1232" unitRef="usd">781434000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-188" decimals="-3" id="f-1233" unitRef="usd">325651000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-189" decimals="-3" id="f-1234" unitRef="usd">1107085000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:Goodwill contextRef="c-193" decimals="-3" id="f-1235" unitRef="usd">268263000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-194" decimals="-3" id="f-1236" unitRef="usd">135072000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-195" decimals="-3" id="f-1237" unitRef="usd">403335000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-196" decimals="-5" id="f-1238" unitRef="usd">68700000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-192" decimals="-5" id="f-1239" unitRef="usd">22100000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-197" decimals="-5" id="f-1240" unitRef="usd">12200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-11" decimals="-5" id="f-1241" unitRef="usd">9900000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock contextRef="c-1" id="f-1242">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Obagi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Milk&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trademarks and Trade Name&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;414,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;145,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;559,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer/distributor relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tretinoin distribution and supply agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Formulations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;505,300&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;157,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;662,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-198" decimals="-3" id="f-1243" unitRef="usd">414000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-199" decimals="-3" id="f-1244" unitRef="usd">145000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-200" decimals="-3" id="f-1245" unitRef="usd">559000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-201" id="f-1246">P14Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-202" decimals="-3" id="f-1247" unitRef="usd">25000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-203" decimals="-3" id="f-1248" unitRef="usd">11000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-204" decimals="-3" id="f-1249" unitRef="usd">36000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-205" id="f-1250">P11Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-206" decimals="-3" id="f-1251" unitRef="usd">38900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-207" decimals="-3" id="f-1252" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-208" decimals="-3" id="f-1253" unitRef="usd">38900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-209" id="f-1254">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-210" decimals="-3" id="f-1255" unitRef="usd">27400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-211" decimals="-3" id="f-1256" unitRef="usd">1500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-212" decimals="-3" id="f-1257" unitRef="usd">28900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-213" id="f-1258">P8Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-193" decimals="-3" id="f-1259" unitRef="usd">505300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-194" decimals="-3" id="f-1260" unitRef="usd">157500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-195" decimals="-3" id="f-1261" unitRef="usd">662800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-214" decimals="-5" id="f-1262" unitRef="usd">9400000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="c-1" id="f-1263">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma combined financial information presents the Company&#x2019;s results as though the Business Combination had occurred on January 1, 2021, for the years ended December&#160;31, 2021 and 2022. The unaudited pro forma consolidated financial information has been prepared using the acquisition method of accounting in accordance with U.S. GAAP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma net revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;200,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;162,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(86,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(145,152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Pro forma net income (loss) attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(25,140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(26,519)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pro forma net income (loss) attributable to Waldencast plc&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(118,633)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c-215" decimals="-3" id="f-1264" unitRef="usd">200547000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c-216" decimals="-3" id="f-1265" unitRef="usd">162583000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c-215" decimals="-3" id="f-1266" unitRef="usd">-86930000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c-216" decimals="-3" id="f-1267" unitRef="usd">-145152000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <wald:BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest contextRef="c-215" decimals="-3" id="f-1268" unitRef="usd">-25140000</wald:BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest>
    <wald:BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest contextRef="c-216" decimals="-3" id="f-1269" unitRef="usd">-26519000</wald:BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest>
    <wald:BusinessAcquisitionProFormaNetIncomeLossAttributableToParent contextRef="c-215" decimals="-3" id="f-1270" unitRef="usd">-61790000</wald:BusinessAcquisitionProFormaNetIncomeLossAttributableToParent>
    <wald:BusinessAcquisitionProFormaNetIncomeLossAttributableToParent contextRef="c-216" decimals="-3" id="f-1271" unitRef="usd">-118633000</wald:BusinessAcquisitionProFormaNetIncomeLossAttributableToParent>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-216" decimals="-5" id="f-1272" unitRef="usd">10000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-216" decimals="-5" id="f-1273" unitRef="usd">66100000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-1274">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;REVENUE&lt;/span&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disaggregates its revenue from customers by sales channel, as well as by revenue source and geographic region, based on the location of the end customer, as it believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue by Sales Channel&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenue is primarily generated from product sales. Direct Sales revenue listed in the table below includes (i) sales to physicians through the Physician Channel Provider, (ii) DTC sales via the Company&#x2019;s e-commerce platforms, and (iii) sales directly to retailers. Distributors revenue includes products sold through distributors other than the Physician Channel Provider.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue by sales channel was as follows for the periods indicated: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.604%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28 to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Obagi Skincare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Milk  Makeup&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue by Sales Channel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Direct sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distributors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;59,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.604%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from January 1 to July 27, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue by Sales Channel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Direct sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distributors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;136,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;73,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;142,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;94,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the period from July 28 to December 31, 2022 (Successor Period), three customers accounted for 29%, 18% and 16% of the Company&#x2019;s revenue, respectively. During the period from January 1 to July 27, 2022, (Predecessor Period), two customers accounted for 44% and 20% of the Company&#x2019;s revenue. For the year ended December 31, &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021 (Predecessor Period), two customers accounted for 44% and 17% of the Company&#x2019;s revenue. For the year ended December 31, 2020 (Predecessor Period), one customer accounted for 57% of the Company&#x2019;s revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Physician Channel Provider is an authorized wholesale distributor and service provider for the Company in the U.S. Revenue from sales to physicians and e-commerce customers made through this provider are considered direct sales revenue. The Physician Channel Provider is also a distributor of the Company&#x2019;s products to other channels, such as the spa channel, and the related sales are considered distributor revenue (in which instances it is referred to as the &#x201c;Spa Channel Distributor&#x201d;). Revenue generated from products sold to physicians and the DTC channel via the Company&#x2019;s e-commerce platform through the Physician Channel Provider was $26.3 million during the period from July 28 to December 31, 2022 (Successor Period), $32.2 million during the period from January 1 to July 27, 2022, (Predecessor Period), $58.8 million during the year ended December 31, 2021 (Predecessor Period), and $51.6 million during the year ended December 31, 2020 (Predecessor Period). Revenue generated from products sold to the Spa Channel Distributor was $0.3 million during the period from July 28 to December 31, 2022 (Successor Period), $0.4 million during the period from January 1 to July 27, 2022, (Predecessor Period), $3.6 million during the year ended December 31, 2021 (Predecessor Period), and $2.5 million during the year ended December 31, 2020 (Predecessor Period). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue by Geographic Region&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue by geographic region, based on the location of the end customer, was as follows for the periods indicated: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.095%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28 to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue by Geographic Region&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;North America&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rest of the World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.099%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from January 1 to July 27, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue by Geographic Region&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;North America&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rest of the World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;136,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;73,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;142,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;94,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the period from July&#160;28 to December&#160;31, 2022 (Successor Period), the two countries that accounted for more than 10% of the Company&#x2019;s total revenues were the United States and China, respectively, with net product sales amounting to $54.3 million and $17.0 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the period from January&#160;1 to July 27, 2022, (Predecessor Period) the two countries that accounted for more than 10% of the Company&#x2019;s total revenues were the United States and Vietnam, with net product sales amounting to $43.8 million and $14.9 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2021 (Predecessor Period), the countries that accounted for more than 10% of the Company&#x2019;s total revenues were the United States, China, and Vietnam, with net product sales amounting to $76.7 million, $16.2 million, and $18.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2020 (Predecessor Period), the United States was the country that accounted for more than 10% of the Company&#x2019;s total revenues, amounting to net product sales of $63.4 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock contextRef="c-1" id="f-1275">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue by sales channel was as follows for the periods indicated: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.604%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28 to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Obagi Skincare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Milk  Makeup&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue by Sales Channel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Direct sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distributors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;59,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.604%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from January 1 to July 27, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue by Sales Channel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Direct sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distributors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;136,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;73,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;142,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;94,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-217" decimals="-3" id="f-1276" unitRef="usd">30276000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-218" decimals="-3" id="f-1277" unitRef="usd">30192000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-219" decimals="-3" id="f-1278" unitRef="usd">60468000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-220" decimals="-3" id="f-1279" unitRef="usd">28826000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-221" decimals="-3" id="f-1280" unitRef="usd">1091000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-222" decimals="-3" id="f-1281" unitRef="usd">29917000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-223" decimals="-3" id="f-1282" unitRef="usd">59102000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-224" decimals="-3" id="f-1283" unitRef="usd">31283000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-225" decimals="-3" id="f-1284" unitRef="usd">90385000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-226" decimals="-3" id="f-1285" unitRef="usd">1988000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-227" decimals="-3" id="f-1286" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-228" decimals="-3" id="f-1287" unitRef="usd">1988000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-196" decimals="-3" id="f-1288" unitRef="usd">61090000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-229" decimals="-3" id="f-1289" unitRef="usd">31283000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-1290" unitRef="usd">92373000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-230" decimals="-3" id="f-1291" unitRef="usd">39649000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-231" decimals="-3" id="f-1292" unitRef="usd">68181000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-232" decimals="-3" id="f-1293" unitRef="usd">54343000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-233" decimals="-3" id="f-1294" unitRef="usd">31080000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-234" decimals="-3" id="f-1295" unitRef="usd">68578000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-235" decimals="-3" id="f-1296" unitRef="usd">34181000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-236" decimals="-3" id="f-1297" unitRef="usd">70729000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-237" decimals="-3" id="f-1298" unitRef="usd">136759000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-238" decimals="-3" id="f-1299" unitRef="usd">88524000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-239" decimals="-3" id="f-1300" unitRef="usd">3031000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-240" decimals="-3" id="f-1301" unitRef="usd">5713000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-241" decimals="-3" id="f-1302" unitRef="usd">5904000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-242" decimals="-3" id="f-1303" unitRef="usd">73760000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-243" decimals="-3" id="f-1304" unitRef="usd">142472000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-17" decimals="-3" id="f-1305" unitRef="usd">94428000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-244"
      decimals="2"
      id="f-1306"
      unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-245"
      decimals="2"
      id="f-1307"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-246"
      decimals="2"
      id="f-1308"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-247"
      decimals="2"
      id="f-1309"
      unitRef="number">0.44</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-248"
      decimals="2"
      id="f-1310"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-249"
      decimals="2"
      id="f-1311"
      unitRef="number">0.44</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-250"
      decimals="2"
      id="f-1312"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-251"
      decimals="2"
      id="f-1313"
      unitRef="number">0.57</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-252" decimals="-5" id="f-1314" unitRef="usd">26300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-253" decimals="-5" id="f-1315" unitRef="usd">32200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-254" decimals="-5" id="f-1316" unitRef="usd">58800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-255" decimals="-5" id="f-1317" unitRef="usd">51600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-256" decimals="-5" id="f-1318" unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-257" decimals="-5" id="f-1319" unitRef="usd">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-258" decimals="-5" id="f-1320" unitRef="usd">3600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-259" decimals="-5" id="f-1321" unitRef="usd">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-1322">&lt;div style="padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue by geographic region, based on the location of the end customer, was as follows for the periods indicated: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.705%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.095%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28 to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue by Geographic Region&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;North America&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rest of the World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.099%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from January 1 to July 27, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue by Geographic Region&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;North America&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rest of the World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;57,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;136,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;73,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;142,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;94,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-260" decimals="-3" id="f-1323" unitRef="usd">56630000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-261" decimals="-3" id="f-1324" unitRef="usd">33755000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-225" decimals="-3" id="f-1325" unitRef="usd">90385000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-228" decimals="-3" id="f-1326" unitRef="usd">1988000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-1327" unitRef="usd">92373000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-262" decimals="-3" id="f-1328" unitRef="usd">44443000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-263" decimals="-3" id="f-1329" unitRef="usd">79122000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-264" decimals="-3" id="f-1330" unitRef="usd">64040000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-265" decimals="-3" id="f-1331" unitRef="usd">26286000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-266" decimals="-3" id="f-1332" unitRef="usd">57637000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-267" decimals="-3" id="f-1333" unitRef="usd">24484000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-268" decimals="-3" id="f-1334" unitRef="usd">70729000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-269" decimals="-3" id="f-1335" unitRef="usd">136759000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-238" decimals="-3" id="f-1336" unitRef="usd">88524000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-270" decimals="-3" id="f-1337" unitRef="usd">3031000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-271" decimals="-3" id="f-1338" unitRef="usd">5713000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-241" decimals="-3" id="f-1339" unitRef="usd">5904000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-3" id="f-1340" unitRef="usd">73760000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-16" decimals="-3" id="f-1341" unitRef="usd">142472000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-17" decimals="-3" id="f-1342" unitRef="usd">94428000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-272"
      decimals="2"
      id="f-1343"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-273"
      decimals="2"
      id="f-1344"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-274" decimals="-5" id="f-1345" unitRef="usd">54300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-275" decimals="-5" id="f-1346" unitRef="usd">17000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-276"
      decimals="2"
      id="f-1347"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-277"
      decimals="2"
      id="f-1348"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-278" decimals="-5" id="f-1349" unitRef="usd">43800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-279" decimals="-5" id="f-1350" unitRef="usd">14900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-280"
      decimals="2"
      id="f-1351"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-281"
      decimals="2"
      id="f-1352"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-282"
      decimals="2"
      id="f-1353"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-283" decimals="-5" id="f-1354" unitRef="usd">76700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-284" decimals="-5" id="f-1355" unitRef="usd">16200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-285" decimals="-5" id="f-1356" unitRef="usd">18600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-286"
      decimals="2"
      id="f-1357"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-287" decimals="-5" id="f-1358" unitRef="usd">63400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GoodwillDisclosureTextBlock contextRef="c-1" id="f-1359">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;GOODWILL&lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocated goodwill acquired in the Obagi Merger to its Obagi Skincare reportable segment and goodwill acquired in the Milk Transaction to its Milk Makeup segment. The fair value of each reporting unit was determined as of the Closing Date as part of the Business Combination (see &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 4&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). The following table presents changes in goodwill by reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.604%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Obagi Skincare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Milk Makeup&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance as of December 31, 2021 and 2020 (Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;44,489&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;44,489&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Elimination of Predecessor goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(44,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(44,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Obagi and Milk Business Combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;268,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;135,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;403,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(68,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(68,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance as of December 31, 2022 (Successor)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;199,548&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;135,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;334,620&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates goodwill for impairment on an annual basis on October 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and at an interim date if indicators of a potential impairment exist. The goodwill impairment test is conducted at the reporting unit level. The fair value of the Company&#x2019;s reporting units is determined using a combination of the discounted cash flow method under the income approach and the guideline public company method under the market approach. Fair value estimates result from a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions that have been deemed reasonable by management as of the measurement date. Under the discounted cash flow method, fair value is determined by discounting the estimated future cash flows of each reporting unit, which includes the Company&#x2019;s most recent projected long-term financial forecasts for revenue, earnings, capital expenditures and working capital. The discount rate used is intended to reflect the risks inherent in the future cash flows of the respective reporting unit. Under the guideline public company method, fair value is estimated using market multiples of various financial metrics observed for the reporting unit&#x2019;s comparable public companies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The annual impairment test performed for fiscal 2020 and 2021 (Predecessor Period) and fiscal 2022 (Successor Period) did not indicate an impairment of goodwill at the time they were performed. However, subsequent to the Business Combination (see &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 4&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Business Combinations&#x201d;), the Company concluded that qualitative factors and relevant events and circumstances indicated it was more likely than not that the fair value of the Obagi Skincare reporting segment was less than its carrying amount. This included a decline in financial performance of the Obagi Skincare reporting unit compared to results projected at the time of acquisition, primarily as a result of the subsequent identification of the matters underlying the restatements adjustments, see &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_1097" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 2&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restatement and Reclassifications.&#x201d; Therefore, the Company performed a quantitative goodwill impairment test for the associated reporting unit. As a result, during the Successor Period ended December 31, 2022, the Company recorded a non-cash impairment charge of $68.7 million within the Obagi Skincare reportable segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-1360">The following table presents changes in goodwill by reportable segment:&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.604%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Obagi Skincare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Milk Makeup&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total Goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance as of December 31, 2021 and 2020 (Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;44,489&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;44,489&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Elimination of Predecessor goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(44,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(44,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Obagi and Milk Business Combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;268,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;135,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;403,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(68,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(68,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Balance as of December 31, 2022 (Successor)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;199,548&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;135,072&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;334,620&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-288" decimals="-3" id="f-1361" unitRef="usd">44489000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-289" decimals="-3" id="f-1362" unitRef="usd">44489000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-290" decimals="-3" id="f-1363" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-291" decimals="-3" id="f-1364" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-86" decimals="-3" id="f-1365" unitRef="usd">44489000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-8" decimals="-3" id="f-1366" unitRef="usd">44489000</us-gaap:Goodwill>
    <us-gaap:GoodwillPeriodIncreaseDecrease contextRef="c-292" decimals="-3" id="f-1367" unitRef="usd">-44489000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillPeriodIncreaseDecrease contextRef="c-293" decimals="-3" id="f-1368" unitRef="usd">0</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillPeriodIncreaseDecrease contextRef="c-1" decimals="-3" id="f-1369" unitRef="usd">-44489000</us-gaap:GoodwillPeriodIncreaseDecrease>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-292" decimals="-3" id="f-1370" unitRef="usd">268263000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-293" decimals="-3" id="f-1371" unitRef="usd">135072000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-1" decimals="-3" id="f-1372" unitRef="usd">403335000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-292" decimals="-3" id="f-1373" unitRef="usd">68715000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-293" decimals="-3" id="f-1374" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="-3" id="f-1375" unitRef="usd">68715000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill contextRef="c-294" decimals="-3" id="f-1376" unitRef="usd">199548000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-295" decimals="-3" id="f-1377" unitRef="usd">135072000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-7" decimals="-3" id="f-1378" unitRef="usd">334620000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-196" decimals="-5" id="f-1379" unitRef="usd">68700000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-1380">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;INTANGIBLE ASSETS&#x2014;NET&lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net consisted of the following as of December&#160;31, 2022 (Successor Period):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.120%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.627%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average Useful&lt;br/&gt;Lives (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trademark and trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;559,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;541,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supply agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Formulations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;663,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(24,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;639,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net consisted of the following as of December&#160;31, 2021 (Predecessor Period):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.120%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.627%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average Useful&lt;br/&gt;Lives (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trademark and trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17,842)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supply agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Formulations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(54,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense for the period from July 28 to December&#160;31, 2022 (Successor Period), period from January&#160;1, 2022 to July&#160;27, 2022 (Predecessor Period), and the years ended December&#160;31, 2021 and 2020 (Predecessor Period), was $24.0 million,&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$7.7 million, $13.5 million, and $13.3 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected amortization for each of the years between 2023 through 2027, and thereafter are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years ending December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;359,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;639,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-1381">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net consisted of the following as of December&#160;31, 2022 (Successor Period):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.120%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.627%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average Useful&lt;br/&gt;Lives (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trademark and trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;559,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;541,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supply agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Formulations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;663,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(24,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;639,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net consisted of the following as of December&#160;31, 2021 (Predecessor Period):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.120%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.627%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average Useful&lt;br/&gt;Lives (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trademark and trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17,842)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16,404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supply agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Formulations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;134,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(54,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-296" id="f-1382">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-296" decimals="-3" id="f-1383" unitRef="usd">559328000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-296" decimals="-3" id="f-1384" unitRef="usd">17840000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-296" decimals="-3" id="f-1385" unitRef="usd">541488000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-297" id="f-1386">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-297" decimals="-3" id="f-1387" unitRef="usd">36000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-297" decimals="-3" id="f-1388" unitRef="usd">1349000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-297" decimals="-3" id="f-1389" unitRef="usd">34651000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-298" id="f-1390">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-298" decimals="-3" id="f-1391" unitRef="usd">38900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-298" decimals="-3" id="f-1392" unitRef="usd">3325000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-298" decimals="-3" id="f-1393" unitRef="usd">35575000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-299" id="f-1394">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-299" decimals="-3" id="f-1395" unitRef="usd">28900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-299" decimals="-3" id="f-1396" unitRef="usd">1526000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-299" decimals="-3" id="f-1397" unitRef="usd">27374000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-300" id="f-1398">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-300" decimals="-3" id="f-1399" unitRef="usd">80000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-300" decimals="-3" id="f-1400" unitRef="usd">3000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-300" decimals="-3" id="f-1401" unitRef="usd">77000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-7" decimals="-3" id="f-1402" unitRef="usd">663208000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-7" decimals="-3" id="f-1403" unitRef="usd">24043000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-7" decimals="-3" id="f-1404" unitRef="usd">639165000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-301" id="f-1405">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-301" decimals="-3" id="f-1406" unitRef="usd">46004000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-301" decimals="-3" id="f-1407" unitRef="usd">17842000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-301" decimals="-3" id="f-1408" unitRef="usd">28162000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-302" id="f-1409">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-302" decimals="-3" id="f-1410" unitRef="usd">39370000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-302" decimals="-3" id="f-1411" unitRef="usd">16404000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-302" decimals="-3" id="f-1412" unitRef="usd">22966000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-303" id="f-1413">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-303" decimals="-3" id="f-1414" unitRef="usd">25570000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-303" decimals="-3" id="f-1415" unitRef="usd">10654000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-303" decimals="-3" id="f-1416" unitRef="usd">14916000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-304" id="f-1417">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-304" decimals="-3" id="f-1418" unitRef="usd">22863000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-304" decimals="-3" id="f-1419" unitRef="usd">9592000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-304" decimals="-3" id="f-1420" unitRef="usd">13271000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-305" id="f-1421">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-305" decimals="-3" id="f-1422" unitRef="usd">270000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-305" decimals="-3" id="f-1423" unitRef="usd">11000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-305" decimals="-3" id="f-1424" unitRef="usd">259000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-8" decimals="-3" id="f-1425" unitRef="usd">134077000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-8" decimals="-3" id="f-1426" unitRef="usd">54503000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-8" decimals="-3" id="f-1427" unitRef="usd">79574000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-14" decimals="-5" id="f-1428" unitRef="usd">24000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-15" decimals="-5" id="f-1429" unitRef="usd">7700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-16" decimals="-5" id="f-1430" unitRef="usd">13500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-17" decimals="-5" id="f-1431" unitRef="usd">13300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-1432">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected amortization for each of the years between 2023 through 2027, and thereafter are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years ending December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;56,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;359,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;639,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-7" decimals="-3" id="f-1433" unitRef="usd">56675000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-7" decimals="-3" id="f-1434" unitRef="usd">56675000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-7" decimals="-3" id="f-1435" unitRef="usd">56675000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-7" decimals="-3" id="f-1436" unitRef="usd">56675000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-7" decimals="-3" id="f-1437" unitRef="usd">53350000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-7" decimals="-3" id="f-1438" unitRef="usd">359115000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-7" decimals="-3" id="f-1439" unitRef="usd">639165000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-1440">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;DEBT&lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.226%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.383%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;July 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;July 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Predecessor 2021 Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;109,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Predecessor 2021 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Predecessor 2018 Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Predecessor 2018 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Predecessor PPP Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;May 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;179,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;118,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(20,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15,442)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Successor 2022 Credit Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Borrower, a wholly-owned subsidiary of the Company, together with Waldencast Partners LP and certain of its subsidiaries as guarantors, entered into the 2022 Credit Agreement with the Lenders and JPMorgan, as administrative agent for the Lenders. The 2022 Credit Agreement provides the Company with access to a term loan of $175.0 million (the &#x201c;2022 Term Loan&#x201d;) and a revolving credit capacity with borrowing capacity of up to $50.0 million (the &#x201c;2022 Revolving Credit Facility&#x201d;), of which up to $7.5 million may be available, at Borrower&#x2019;s option, to be drawn in form of letters of credit (&#x201c;2022 Letter of Credit&#x201d;). The 2022 Credit Agreement is secured by the assets of the Company. The 2022 Credit Agreement restricts the Company&#x2019;s ability to make certain distributions or dividends, subject to a number of enumerated exceptions, which restrictions will not apply at any time the Company&#x2019;s Leverage Ratio is below 2.5X.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Credit Agreement matures on July 27, 2026, four years following the funding date. The Company may elect to borrow either alternate base rate borrowings or term benchmark borrowings. Each draw that is an alternate base rate borrowing bears interest at&#160;an Alternate Base Rate (as defined in the 2022 Credit Agreement) plus the applicable rate of 2.5% per annum. Each draw that is a term benchmark borrowing bears interest at the Term SOFR Rate (as defined in the 2022 Credit Agreement), which resets periodically, plus 0.1% and the applicable rate of 3.5% per annum. As of December&#160;31, 2022, borrowings under the 2022 Credit Agreement consisted entirely of term benchmark borrowings at a borrowing rate of 7.9%. The carrying amount of debt approximates fair value due to the adjusting interest rates of the term loan, which approximate current market rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of the 2022 Credit Agreement, the Company incurred $6.3 million of debt issuance costs. As of December&#160;31, 2022, the Company had unpaid principal of $170.7 million and $14.1 million on the 2022 Term Loan and the 2022 Revolving Credit Facility, respectively. The 2022 Term Loan and the 2022 Revolving Credit Facility had total unamortized debt issuance costs of $5.4 million as of December&#160;31, 2022. As of December 31, 2022, the weighted average interest rate was 6.6% for the 2022 Term Loan and the 2022 Revolving Credit Facility. The current portion of the 2022 Term Loan and the 2022 Revolving Credit Facility was $8.4 million and $14.1 million, respectively. The current portion of the unamortized debt issuance costs on the 2022 Term Loan and the 2022 Revolving Credit Facility was $1.2 million and $1.2 million, respectively. The accrued interest was $0.1 million as of December&#160;31, 2022. Unamortized debt issuance costs on the 2022 Letter of Credit is $0.2 million, of which $51,000 was recognized in other current assets and $0.1 million was recognized in other assets in the consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scheduled maturities under the Company&#x2019;s 2022 Credit Agreement as of December&#160;31, 2022 (Successor Period) are as follows :&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unpaid principal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Waiver and Consent and Amendment to the 2022 Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, the Borrower entered into a technical amendment to the 2022 Credit Agreement to cure a technical error and clarify when the first amortization payment under the 2022 Credit Agreement is due and payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, the Borrower entered into a waiver and consent agreement with JPMorgan and the required Lenders to, among other things, waive certain defaults or events of default that had or would have resulted from the failure to deliver certain financial information and related reports. In June 2023, the Borrower entered into a subsequent waiver and consent agreement with JPMorgan and the required Lenders, pursuant to which they agreed to, among other things, (a) continue to waive certain defaults or events of default that had or would have resulted from the failure to deliver certain financial information and related reports and (b) suspend the testing of certain financial covenants in the 2022 Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023, the Borrower entered into a subsequent waiver and consent agreement with JPMorgan and the required Lenders, pursuant to which they agreed to, among other things, (i) waive any default or event of default that has or would result from the failure to deliver the financial information and related reports with respect to the fiscal year of the Borrower ended December 31, 2022 and the fiscal quarters of the Borrower ended March 31, 2023 and June 30, 2023, respectively and (ii) suspend the testing of certain financial covenants set forth in the 2022 Credit Agreement. Such waiver would remain in effect until September 15, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2023, the Borrower and Waldencast Partners LP entered into the second amendment and waiver to the 2022 Credit Agreement (the &#x201c;Amendment&#x201d;) with JPMorgan and the required Lenders, pursuant to which they agreed to (i) waive any default or event of default that has or would result from (a) the failure to deliver the financial information and related reports with respect to the fiscal year of the Borrower ended December 31, 2022 and the fiscal quarters of the Borrower ended March 31, 2023 and June 30, 2023, respectively, (b) any inaccuracy or misrepresentation in certain historical financial statements previously delivered to JPMorgan and (c) certain historical breaches of the financial covenants and (ii) amend the 2022 Credit Agreement to, among other things, modify the existing financial covenant tests. The Borrower is required to deliver certain of the financial information described in (i)(a) above by December 31, 2023 (the &#x201c;Waiver Expiration Date&#x201d;). Failure to deliver the required audited financial information and certain other deliverables on or prior to the Waiver Expiration Date will result in an event of default under the 2022 Credit Agreement (unless otherwise waived or extended). The Amendment also (i) included additional restrictions on the Borrower&#x2019;s, Waldencast Partners LP's and certain of their subsidiaries&#x2019; ability to incur certain types of additional indebtedness, make certain acquisitions and investments, create certain liens, dispose of certain assets and make certain types of restricted payments, (ii) established a minimum liquidity covenant of $15.0 million, which is certified on a monthly basis, and (iii) introduced additional financial reporting obligations, in each case until the earlier of September 30, 2024 or such earlier time that the Borrower elects to test the financial covenants in the same manner as prior to giving effect to the Amendment. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Borrower subsequently delivered unaudited financial information and related reports with respect to the fiscal quarters of the Borrower ended March 31, 2023 and June 30, 2023. In December 2023, the Borrower entered into a subsequent waiver and consent agreement with JPMorgan and the required Lenders, pursuant to which they agreed, among other things, to waive any default or event of default that has or would result from the failure to &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;deliver the financial information and related reports with respect to the fiscal year of the Borrower ended December 31, 2022. Such waiver shall remain in effect until January 15, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Predecessor 2021 Credit Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, Obagi replaced its Predecessor 2018 Credit Agreement (described below) for a new financing agreement with a syndicate of lenders, including TCW Asset Management Company LLC as administrative agent for the lenders (the &#x201c;2021 Credit Agreement&#x201d;). The terms and conditions of the 2018 Credit Agreement and the 2021 Credit Agreement limited the ability of Obagi and its wholly-owned subsidiaries to declare dividends or make other distributions, directly or indirectly, to its shareholder, subject to certain enumerated exceptions, including, but not limited to, dividends up to a specified amount if Obagi was able to achieve certain &#x201c;Consolidated Total Leverage Ratios&#x201d; thresholds. Due to the aforementioned restrictions, substantially all of the net assets of Obagi&#x2019;s subsidiaries were restricted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2021 Credit Agreement included a term loan of $110.0 million (the &#x201c;2021 Term Loan&#x201d;) and a revolving credit facility with borrowing capacity of up to $40.0 million (&#x201c;2021 Revolving Credit Facility&#x201d;). Both the 2021 Term Loan and the 2021 Revolving Credit Facility were due to mature in March 2026. The 2021 Term Loan and 2021 Revolving Credit Facility bore interest at the LIBOR plus an applicable margin, as determined by the Company&#x2019;s leverage ratios, and were subject to LIBOR succession provisions. In connection with the issuance of the 2021 Credit Agreement, the Company incurred $6.4 million of debt issuance costs. The 2021 Credit Agreement was secured by the assets of the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 (Predecessor Period), the Company had unpaid principal of $109.2 million, and unamortized debt issuance costs of $3.9 million on the 2021 Term Loan. The interest rate was 8.5% and there was no accrued interest as of December&#160;31, 2021 (Predecessor Period). The current portion of the 2021 Term Loan and 2021 Revolving Credit Facility was $2.8 million and $15.0 million, respectively. The current portion of the unamortized debt issuance costs on the 2021 Term Loan and 2021 Revolving Credit Facility was $0.9 million and $1.4 million, respectively. The outstanding debt under the Predecessor 2021 Credit Agreement was paid in full as part of Waldencast&#x2019;s acquisition of Obagi. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Predecessor 2018 Credit Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, and subject to amendments in March 2020 and November  2020, Obagi entered into a credit agreement (the &#x201c;2018 Credit Agreement&#x201d;) with a syndicate of banks, including Wells Fargo Bank, National Association (&#x201c;Wells Fargo&#x201d;) as administrative agent for the banks (the &#x201c;Syndicate of Banks&#x201d;). The 2018 Credit Agreement included a term loan of $90.0 million (the &#x201c;2018 Term Loan&#x201d;) and a revolving credit facility with borrowing capacity of up to $35.0 million (&#x201c;2018 Revolving Credit Facility&#x201d;). Both the 2018 Term Loan and the 2018 Revolving Credit Facility were due to mature in December 2023. In connection with the issuance of the 2018 Credit Agreement, the Company incurred $2.9 million of debt issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon settlement of the debt with proceeds from the Predecessor 2021 Credit Agreement, the Company recorded a loss on extinguishment of the 2018 Credit Agreement of $2.3 million to loss on extinguishment of debt in the accompanying consolidated statements of operations and comprehensive loss for the year ended December&#160;31, 2021 (Predecessor Period), which consisted of expensing unamortized debt issuance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Predecessor PPP Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company received loan proceeds in the amount of $6.8 million under the Paycheck Protection Program (&#x201c;PPP&#x201d;) from MUFG Union Bank (the &#x201c;PPP Loan&#x201d;). The PPP, established as part of the Coronavirus aid, Relief and Economic Security Act (&#x201c;CARES Act&#x201d;), provided for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The PPP Loan accrued interest at a rate of 1%. The PPP Loan and accrued interest were forgivable after eight or twenty-four weeks as long as the borrower used the proceeds for eligible purposes, including payroll, benefits, rent and utilities and maintains its payroll levels. The Company used the proceeds for purposes consistent with the PPP, and in 2021, received approval from MUFG Union Bank and the Small Business Administration (&#x201c;SBA&#x201d;) for forgiveness of the full amount of its PPP Loan, inclusive of accrued interest of $74,000. The Company recognized a gain on PPP Loan forgiveness of $6.8 million for the year ended December&#160;31, 2021 (Predecessor Period). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023, the Company was notified by its lender that the SBA had requested additional documents relating to the Company&#x2019;s PPP Loan. The Company provided the required documentation and no further communication has been received in response.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-1441">&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.226%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.383%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.453%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.119%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;July 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;July 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Predecessor 2021 Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;109,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Predecessor 2021 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Predecessor 2018 Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Predecessor 2018 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Predecessor PPP Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;May 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;179,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;118,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(20,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15,442)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;103,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-306" decimals="-3" id="f-1442" unitRef="usd">170652000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-307" decimals="-3" id="f-1443" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-308" decimals="-3" id="f-1444" unitRef="usd">14117000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-309" decimals="-3" id="f-1445" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-310" decimals="-3" id="f-1446" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-311" decimals="-3" id="f-1447" unitRef="usd">109175000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-312" decimals="-3" id="f-1448" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-313" decimals="-3" id="f-1449" unitRef="usd">15000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-314" decimals="-3" id="f-1450" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-315" decimals="-3" id="f-1451" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-316" decimals="-3" id="f-1452" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-317" decimals="-3" id="f-1453" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-318" decimals="-3" id="f-1454" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-319" decimals="-3" id="f-1455" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-7" decimals="-3" id="f-1456" unitRef="usd">5445000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-8" decimals="-3" id="f-1457" unitRef="usd">5310000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt contextRef="c-7" decimals="-3" id="f-1458" unitRef="usd">179324000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-8" decimals="-3" id="f-1459" unitRef="usd">118865000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent contextRef="c-7" decimals="-3" id="f-1460" unitRef="usd">20095000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-8" decimals="-3" id="f-1461" unitRef="usd">15442000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-7" decimals="-3" id="f-1462" unitRef="usd">159229000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-8" decimals="-3" id="f-1463" unitRef="usd">103423000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-320" decimals="-5" id="f-1464" unitRef="usd">175000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-321" decimals="-5" id="f-1465" unitRef="usd">50000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-320" decimals="-5" id="f-1466" unitRef="usd">7500000</us-gaap:DebtInstrumentFaceAmount>
    <wald:DebtInstrumentCovenantLeverageRatioMaximum
      contextRef="c-322"
      decimals="INF"
      id="f-1467"
      unitRef="number">2.5</wald:DebtInstrumentCovenantLeverageRatioMaximum>
    <us-gaap:DebtInstrumentTerm contextRef="c-323" id="f-1468">P4Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-324"
      decimals="3"
      id="f-1469"
      unitRef="number">0.025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-325"
      decimals="3"
      id="f-1470"
      unitRef="number">0.001</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-326"
      decimals="3"
      id="f-1471"
      unitRef="number">0.035</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-327"
      decimals="3"
      id="f-1472"
      unitRef="number">0.079</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-328" decimals="-5" id="f-1473" unitRef="usd">6300000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-306" decimals="-5" id="f-1474" unitRef="usd">170700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-308" decimals="-5" id="f-1475" unitRef="usd">14100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-7" decimals="-5" id="f-1476" unitRef="usd">5400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="c-329"
      decimals="3"
      id="f-1477"
      unitRef="number">0.066</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="c-308"
      decimals="3"
      id="f-1478"
      unitRef="number">0.066</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:LongTermDebtCurrent contextRef="c-330" decimals="-5" id="f-1479" unitRef="usd">8400000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-331" decimals="-5" id="f-1480" unitRef="usd">14100000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c-330" decimals="-5" id="f-1481" unitRef="usd">1200000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c-331" decimals="-5" id="f-1482" unitRef="usd">1200000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c-14" decimals="-5" id="f-1483" unitRef="usd">100000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-306" decimals="-5" id="f-1484" unitRef="usd">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-332" decimals="-3" id="f-1485" unitRef="usd">51000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-333" decimals="-5" id="f-1486" unitRef="usd">100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-1487">&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scheduled maturities under the Company&#x2019;s 2022 Credit Agreement as of December&#160;31, 2022 (Successor Period) are as follows :&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unpaid principal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;184,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-334" decimals="-3" id="f-1488" unitRef="usd">22490000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-334" decimals="-3" id="f-1489" unitRef="usd">7963000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-334" decimals="-3" id="f-1490" unitRef="usd">11264000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-334" decimals="-3" id="f-1491" unitRef="usd">143052000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c-334" decimals="-3" id="f-1492" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-334" decimals="-3" id="f-1493" unitRef="usd">184769000</us-gaap:DebtInstrumentCarryingAmount>
    <wald:LineOfCreditCovenantTermsMinimumLiquidity contextRef="c-335" decimals="-5" id="f-1494" unitRef="usd">15000000.0</wald:LineOfCreditCovenantTermsMinimumLiquidity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-336" decimals="-5" id="f-1495" unitRef="usd">110000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-337" decimals="-5" id="f-1496" unitRef="usd">40000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-338" decimals="-5" id="f-1497" unitRef="usd">6400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt contextRef="c-339" decimals="-5" id="f-1498" unitRef="usd">109200000</us-gaap:LongTermDebt>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-339" decimals="-5" id="f-1499" unitRef="usd">3900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="c-340"
      decimals="3"
      id="f-1500"
      unitRef="number">0.085</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c-341" decimals="-5" id="f-1501" unitRef="usd">0</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:LongTermDebtCurrent contextRef="c-339" decimals="-5" id="f-1502" unitRef="usd">2800000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-342" decimals="-5" id="f-1503" unitRef="usd">15000000.0</us-gaap:LongTermDebtCurrent>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c-339" decimals="-5" id="f-1504" unitRef="usd">900000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c-342" decimals="-5" id="f-1505" unitRef="usd">1400000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-343" decimals="-5" id="f-1506" unitRef="usd">90000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-344" decimals="-5" id="f-1507" unitRef="usd">35000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-345" decimals="-5" id="f-1508" unitRef="usd">2900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-346" decimals="-5" id="f-1509" unitRef="usd">2300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-347" decimals="-5" id="f-1510" unitRef="usd">6800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="c-319"
      decimals="2"
      id="f-1511"
      unitRef="number">0.01</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c-348" decimals="-3" id="f-1512" unitRef="usd">74000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:LineOfCreditFacilityDecreaseForgiveness1 contextRef="c-348" decimals="-5" id="f-1513" unitRef="usd">6800000</us-gaap:LineOfCreditFacilityDecreaseForgiveness1>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-1514">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;LEASES&lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for real estate properties for office and warehouse space with initial terms of approximately 8 and 11 years, respectively.&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the Company&#x2019;s lease contracts include options to extend the leases for up to 5 years. Our lease agreements generally do not contain any residual value guarantees or restrictive covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if a contract contains a lease at inception of the arrangement based on whether the Company has the right to obtain substantially all of the economic benefits from the use of an identified asset and whether the Company has the right to direct the use of an identified asset in exchange for consideration, which relates to an asset that the Company does not own. Right of use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of any changes in market conditions but generally, these termination options are not exercised and not considered in the determination of the lease term. Lease liabilities are recognized at the present value of the future lease payments at the lease commencement date. ROU assets are recognized on the balance sheet based on the lease liability adjusted for any initial direct costs, lease incentives received, and prepaid rent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate used to determine the present value of the future lease payments is the Company&#x2019;s incremental borrowing rate (&#x201c;IBR&#x201d;), because the interest rate implicit in most of the Company&#x2019;s leases is not readily determinable. The IBR is a hypothetical rate based on the Company&#x2019;s understanding of what its credit rating would be, and resulting interest the Company would pay, to borrow an amount equal to the lease payments in a similar economic environment over the lease term on a collateralized basis. Lease payments may be fixed or variable, however, only fixed payments or in-substance fixed payments are included in the Company&#x2019;s lease liability calculation. Variable lease payments may include costs such as common area maintenance, utilities, or other costs. Variable lease payments are recognized in operating expenses in the period in which the obligation for those payments is incurred. The Company has elected not to separate non-lease components from lease components and accounts for them as a single lease component. The Company has also elected the short-term lease recognition exemption for all leases that qualify.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company historically accounted for leases in accordance with ASC 840, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, under which operating leases were not recorded on the balance sheet. Adoption of ASC 842 was not required in interim periods preceding December&#160;31, 2022. Upon consummation of the Business Combination, Obagi and Milk adopted ASC 842 as a matter of policy alignment. The period from January 1 to July 27, 2022 (Predecessor Period) does not reflect the impact of ASC 842 adoption, as the Company did not adopt the standard as of an interim 2022 period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease expenses of $1.4 million were composed of operating lease costs. The Company does not have any finance leases, short-term lease costs or variable lease costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to the Company&#x2019;s operating leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28 to December 31, 2022&lt;br/&gt;(Successor)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28 to December 31, 2022&lt;br/&gt;(Successor)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reconciliation of the undiscounted future minimal lease payments under non-cancelable operating leases to the total operating lease liability recognized on the consolidated balance sheet as of December 31, 2022 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Imputed Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total reported lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disclosures Related to Periods Prior to the Adoption of ASC 842 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the Obagi China Distribution, the Company leased office space under three non-cancelable operating leases expiring between September 2023 and February 2032. Rent expense related to the Company&#x2019;s operating leases was $0.9 million, $1.2 million, and $1.1 million for the period from January 1 to July&#160;27, 2022 (Predecessor Period) and the years ended December&#160;31, 2021 and 2020 (Predecessor Period), respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments as of December 31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-349" id="f-1515">P8Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-350" id="f-1516">P11Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <wald:LesseeOperatingLeaseExtensionTerm contextRef="c-7" id="f-1517">P5Y</wald:LesseeOperatingLeaseExtensionTerm>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-1518" unitRef="usd">1400000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-1519">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to the Company&#x2019;s operating leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28 to December 31, 2022&lt;br/&gt;(Successor)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28 to December 31, 2022&lt;br/&gt;(Successor)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c-14" decimals="-3" id="f-1520" unitRef="usd">1166000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-14" decimals="-3" id="f-1521" unitRef="usd">4081000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-7" id="f-1522">P7Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-7" decimals="3" id="f-1523" unitRef="number">0.059</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-1524">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reconciliation of the undiscounted future minimal lease payments under non-cancelable operating leases to the total operating lease liability recognized on the consolidated balance sheet as of December 31, 2022 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Imputed Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total reported lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments as of December 31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-7" decimals="-3" id="f-1525" unitRef="usd">3309000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-7" decimals="-3" id="f-1526" unitRef="usd">3430000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-7" decimals="-3" id="f-1527" unitRef="usd">3504000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-7" decimals="-3" id="f-1528" unitRef="usd">2899000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-7" decimals="-3" id="f-1529" unitRef="usd">2452000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-7" decimals="-3" id="f-1530" unitRef="usd">9194000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-7" decimals="-3" id="f-1531" unitRef="usd">24788000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-7" decimals="-3" id="f-1532" unitRef="usd">4865000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-1533" unitRef="usd">19923000</us-gaap:OperatingLeaseLiability>
    <wald:NumberOfOperatingLeases
      contextRef="c-88"
      decimals="INF"
      id="f-1534"
      unitRef="operatinglease">3</wald:NumberOfOperatingLeases>
    <us-gaap:LeaseAndRentalExpense contextRef="c-15" decimals="-5" id="f-1535" unitRef="usd">900000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="c-16" decimals="-5" id="f-1536" unitRef="usd">1200000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="c-17" decimals="-5" id="f-1537" unitRef="usd">1100000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="c-8" decimals="-3" id="f-1538" unitRef="usd">1544000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="c-8" decimals="-3" id="f-1539" unitRef="usd">1625000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="c-8" decimals="-3" id="f-1540" unitRef="usd">1456000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="c-8" decimals="-3" id="f-1541" unitRef="usd">1490000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="c-8" decimals="-3" id="f-1542" unitRef="usd">844000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="c-8" decimals="-3" id="f-1543" unitRef="usd">1911000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="c-8" decimals="-3" id="f-1544" unitRef="usd">8870000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="c-1" id="f-1545">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;FINANCIAL INSTRUMENTS&lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Rate Collar&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To mitigate interest rate risk in connection with the variable rate loans under the 2022 Credit Agreement, the Company entered into an interest rate collar with Wells Fargo for a notional value of $160.0 million and a fixed cash payment of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.8 million. Under the terms of the interest rate collar, the Company is required to pay Wells Fargo if the monthly SOFR-based interest falls below the defined interest rate floor of 2.55%; conversely, the Company is entitled to receive payment from Wells Fargo if the monthly SOFR-based interest rate rises above the defined interest rate cap of 5.25%. Settlement in cash occurs monthly, if contractually required, until termination of the agreement in October 2024, and the variable interest rate is reset on the last day of each month. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This derivative instrument has not been designated for hedge accounting, therefore the change in fair value is recognized in current period earnings. The fair value of these contracts, included in other non-current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was $0.2 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of December&#160;31, 2022 (Successor Period). The non-cash loss from change in fair value during the period from July 28 to December&#160;31, 2022 (Successor Period) was $0.6 million, recognized in other expenses, net. No payments or receipts were exchanged on the interest rate collar contract during the period from July 28 to December&#160;31, 2022 (Successor Period) aside from the initial fixed cash payment of $0.8 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrant Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Waldencast&#x2019;s IPO, the Company issued 11,499,950 Public Warrants to third-party investors. Simultaneously with the closing of the IPO, Waldencast completed the private sale of 5,933,333 warrants (the &#x201c;Sponsor Warrants&#x201d;) to the Sponsor. Also, in connection with the IPO, on February 22, 2021, Waldencast, the Sponsor and Zeno Investment Master Fund (f/k/a Dynamo Master Fund, a member of the Sponsor (&#x201c;Zeno&#x201d;), entered into a Forward Purchase Agreement (the &#x201c;Sponsor FPA&#x201d;), which was subsequently amended by the assignment and assumption agreement entered into by and between the Sponsor and Burwell Mountain Trust (&#x201c;Burwell&#x201d;) on December 20, 2021. Under the assignment and assumption agreement, Sponsor assigned, and Burwell assumed, all of the Sponsor&#x2019;s rights and benefits under the Sponsor FPA, pursuant to which, Burwell and Zeno committed to subscribe for and purchase 16,000,000 Waldencast Class A ordinary shares and 5,333,333 warrants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(the &#x201c;Sponsor FPA Warrants&#x201d;) in connection with the closing of the Business Combination. In addition, Waldencast and Beauty Ventures LLC (&#x201c;Beauty Ventures&#x201d;) entered into a Forward Purchase Agreement on March&#160;1, 2021 (the &#x201c;Third-Party FPA&#x201d;, and together with the Sponsor FPA, the &#x201c;FPAs&#x201d;), pursuant to which Beauty Ventures committed to subscribe for and purchase up to 17,300,000 Class A ordinary shares and 5,766,666 warrants (the &#x201c;Third-Party FPA Warrants&#x201d; and together with the Sponsor FPA Warrants, the &#x201c;FPA Warrants&#x201d;) for an aggregate commitment amount of $173.0 million, in connection with the closing of Waldencast&#x2019;s initial business combination. Finally, in connection with the Business Combination, Waldencast issued 1,000,000 warrants to settle $1.5 million working capital loans with its Sponsor, the terms of which are identical to the Sponsor FPA Warrants (the &#x201c;Sponsor Loan Warrants&#x201d;). The Sponsor Loan Warrants and Third-Party FPA Warrants are collectively referred to as the &#x201c;Private Placement Warrants&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, all of the above-noted warrants, totaling 29,533,282, remained issued and outstanding. For the period from July 28 to December&#160;31, 2022 (Successor Period), the Company recognized a gain of $6.8 million from the change in fair value of the Public Warrants and Private Placement Warrants in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the Domestication, Public Warrants and Private Placement Warrants each entitle the holder to purchase one share of the Company&#x2019;s Class A ordinary shares at an exercise price of $11.50 per share. Public Warrants may only be exercised for a whole number of shares. No fractional warrants will be issued and only whole warrants can trade. The Public Warrants became exercisable 30 days after the completion of the Business Combination. The Public Warrants will expire June 27, 2027 or earlier upon redemption or liquidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may redeem the Public Warrants:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;in whole and not in part;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;upon a minimum of 30 days&#x2019; prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption, based on the redemption date and the &#x201c;fair market value&#x201d; of the Class A ordinary shares;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;at a price of $0.01 per warrant if, and only if, the reported last sale price of the Class A ordinary shares for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption the warrant holders (the &#x201c;Reference Value&#x201d;) equals or exceeds $18.00 per share (as adjusted).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;At a price of $0.01 per warrant if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted); and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;if the Reference Value is less than $18.00 per share (as adjusted), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants, as described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price and number of Class A ordinary shares issuable upon exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the Public Warrants.&lt;/span&gt;&lt;/div&gt;The terms of the Third-Party FPA Warrants are identical to the Public Warrants. The Sponsor Loan Warrants and Sponsor FPA Warrants are also identical to the Public Warrants, except that they and the Class A ordinary shares issuable upon the exercise of such warrants were not transferable, assignable or salable until 30 days after the completion of the Business Combination, subject to certain limited exceptions. Additionally, the Sponsor Loan Warrants and Sponsor FPA Warrants will be exercisable on a cashless basis and be non-redeemable, except as described above, so long as they are held by the initial purchasers or their permitted transferees, thereafter they will be redeemable by the Company and exercisable by such holders on the same basis as Public Warrants.</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:DerivativeLiabilityNotionalAmount contextRef="c-351" decimals="-5" id="f-1546" unitRef="usd">160000000.0</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities contextRef="c-352" decimals="-5" id="f-1547" unitRef="usd">800000</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities>
    <us-gaap:DerivativeFloorInterestRate
      contextRef="c-351"
      decimals="4"
      id="f-1548"
      unitRef="number">0.0255</us-gaap:DerivativeFloorInterestRate>
    <us-gaap:DerivativeCapInterestRate
      contextRef="c-351"
      decimals="4"
      id="f-1549"
      unitRef="number">0.0525</us-gaap:DerivativeCapInterestRate>
    <us-gaap:DerivativeAssetsNoncurrent contextRef="c-351" decimals="-5" id="f-1550" unitRef="usd">200000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet contextRef="c-352" decimals="-5" id="f-1551" unitRef="usd">600000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities contextRef="c-352" decimals="-5" id="f-1552" unitRef="usd">800000</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-353"
      decimals="INF"
      id="f-1553"
      unitRef="shares">11499950</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-354"
      decimals="INF"
      id="f-1554"
      unitRef="shares">5933333</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-355"
      decimals="INF"
      id="f-1555"
      unitRef="shares">16000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-356"
      decimals="INF"
      id="f-1556"
      unitRef="shares">5333333</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-357"
      decimals="INF"
      id="f-1557"
      unitRef="shares">17300000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-358"
      decimals="INF"
      id="f-1558"
      unitRef="shares">5766666</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-359" decimals="-5" id="f-1559" unitRef="usd">173000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-360"
      decimals="INF"
      id="f-1560"
      unitRef="shares">1000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-360" decimals="-5" id="f-1561" unitRef="usd">1500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-7"
      decimals="INF"
      id="f-1562"
      unitRef="shares">29533282</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-14" decimals="-5" id="f-1563" unitRef="usd">6800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-7"
      decimals="INF"
      id="f-1564"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-7"
      decimals="2"
      id="f-1565"
      unitRef="usdPerShare">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <wald:ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination contextRef="c-361" id="f-1566">P30D</wald:ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination>
    <wald:ClassOfWarrantOrRightRedemptionPeriod contextRef="c-361" id="f-1567">P30D</wald:ClassOfWarrantOrRightRedemptionPeriod>
    <wald:ClassOfWarrantOrRightRedemptionPricePerShare
      contextRef="c-362"
      decimals="2"
      id="f-1568"
      unitRef="usdPerShare">0.01</wald:ClassOfWarrantOrRightRedemptionPricePerShare>
    <wald:ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice contextRef="c-361" id="f-1569">P20D</wald:ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice>
    <wald:ClassOfWarrantOrRightRedemptionTradingPeriod contextRef="c-361" id="f-1570">P30D</wald:ClassOfWarrantOrRightRedemptionTradingPeriod>
    <wald:ClassOfWarrantOrRightRedemptionStockPriceTrigger
      contextRef="c-362"
      decimals="2"
      id="f-1571"
      unitRef="usdPerShare">18.00</wald:ClassOfWarrantOrRightRedemptionStockPriceTrigger>
    <wald:ClassOfWarrantOrRightRedemptionPricePerShare
      contextRef="c-363"
      decimals="2"
      id="f-1572"
      unitRef="usdPerShare">0.01</wald:ClassOfWarrantOrRightRedemptionPricePerShare>
    <wald:ClassOfWarrantOrRightRedemptionStockPriceTrigger
      contextRef="c-363"
      decimals="2"
      id="f-1573"
      unitRef="usdPerShare">10.00</wald:ClassOfWarrantOrRightRedemptionStockPriceTrigger>
    <wald:ClassOfWarrantOrRightRedemptionStockPriceTrigger
      contextRef="c-364"
      decimals="2"
      id="f-1574"
      unitRef="usdPerShare">18.00</wald:ClassOfWarrantOrRightRedemptionStockPriceTrigger>
    <wald:ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination contextRef="c-365" id="f-1575">P30D</wald:ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-1577">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s financial instruments that are measured at fair value on a recurring basis by level within the fair value hierarchy as of December&#160;31, 2022 (Successor Period): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Quoted Prices in Active Market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant Other Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant Other Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate collar&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative warrant liabilities - Public&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative warrant liabilities - Private&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Private derivative warrants are classified as Level 2 financial instruments. The fair value of the Level 2 Private Placement Warrant liabilities has been measured based on the fair value of Public Warrant liabilities. The interest rate collar has been measured at net present value by projecting future cash flows and discounting the future amounts to a present value using market-based observable inputs including interest rate curves and credit spreads.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For goodwill (see &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_133" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 6&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Goodwill&#x201d;), fair value assessments of the reporting units and the reporting units&#x2019; net assets performed for goodwill impairment tests are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain long-lived and intangible assets at fair value on a nonrecurring basis when events occur that indicate an asset group may not be recoverable. If the carrying amount of an asset group is not recoverable, an impairment charge is recorded to reduce the carrying amount by the excess over its fair value. Except for the initial valuation of long-lived assets in connection with the Business Combination (see &#x201c;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_127" style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 4&lt;/a&gt;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business Combinations&#x201d;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) and impairment of goodwill discussed above, no long-lived assets were remeasured at fair value on a nonrecurring basis during the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-1578">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s financial instruments that are measured at fair value on a recurring basis by level within the fair value hierarchy as of December&#160;31, 2022 (Successor Period): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Quoted Prices in Active Market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant Other Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant Other Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate collar&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative warrant liabilities - Public&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative warrant liabilities - Private&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DerivativeAssets contextRef="c-351" decimals="-3" id="f-1579" unitRef="usd">198000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-366" decimals="-3" id="f-1580" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-367" decimals="-3" id="f-1581" unitRef="usd">198000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-368" decimals="-3" id="f-1582" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities contextRef="c-369" decimals="-3" id="f-1583" unitRef="usd">7130000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-370" decimals="-3" id="f-1584" unitRef="usd">7130000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-371" decimals="-3" id="f-1585" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-372" decimals="-3" id="f-1586" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-373" decimals="-3" id="f-1587" unitRef="usd">11181000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-374" decimals="-3" id="f-1588" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-375" decimals="-3" id="f-1589" unitRef="usd">11181000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="c-376" decimals="-3" id="f-1590" unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-1591">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;SUPPLEMENTAL BALANCE SHEET DISCLOSURES&lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 (Successor Period), accounts receivable, net consisted of accounts receivable of $20.3 million, less allowance for doubtful accounts of $1.0 million. As of December&#160;31, 2021 (Predecessor Period), accounts receivable, net consisted of accounts receivable of $19.4 million, less allowance for doubtful accounts of $0.7 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the allowance for doubtful accounts were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.635%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.270%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;July 28 to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;January 1&lt;br/&gt;to July 27,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for bad debts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Write-off of uncollectible accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, and as amended in December 2021 and April 2022, Obagi Cosmeceuticals LLC, a wholly-owned subsidiary of Obagi, entered into a non-recourse, uncollateralized short-term promissory note, not in the ordinary course of business, lending a third party $2.5 million (the &#x201c;Predecessor Loan Receivable&#x201d;). This Predecessor Loan Receivable had a maturity date of December&#160;31, 2022 and carried an interest rate of 1.00% from July 30, 2021 to September 29, 2021 and 8.00% from September&#160;30, 2021 through maturity. The outstanding principal and accrued interest were due upon maturity. As discussed in &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_1097" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 2&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Restatement and Reclassifications,&#x201d; the Company wrote-off the $2.5&#160;million loan receivable in 2021 when it was determined to be uncollectible. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventories were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Computer hardware, software and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and fixture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Internally developed software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gondolas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for property and equipment for the period from July 28 to December&#160;31, 2022 (Successor Period) and the period from January 1 to July 27, 2022 (Predecessor Period) were $2.9 million and $0.5 million, respectively. Depreciation expense for property and equipment for the years ended December&#160;31, 2021 and 2020 (Predecessor Period) were $0.4 million and $0.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense pertains to property and equipment utilized as part of the Company&#x2019;s SG&amp;amp;A activities and therefore has not been allocated to cost of goods sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued salaries and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued sales returns and damages&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued marketing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued distribution fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related party liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accrued distribution fees related to service charges such as e-commerce shipping and handling costs. The related party liability of $9.9 million as of December 31, 2022 reflects the remaining unamortized fair value of the related party inventory contract executed on the acquisition date between Obagi and the Obagi China Business (see &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 4&lt;/a&gt;&lt;/span&gt;. Business Combinations&#x201d;). This related party liability will be amortized into related party revenue upon the sale of products to the Obagi China Business in subsequent periods.</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <wald:AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent contextRef="c-7" decimals="-5" id="f-1592" unitRef="usd">20300000</wald:AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-7" decimals="-5" id="f-1593" unitRef="usd">1000000.0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <wald:AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent contextRef="c-8" decimals="-5" id="f-1594" unitRef="usd">19400000</wald:AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-8" decimals="-5" id="f-1595" unitRef="usd">700000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="c-1" id="f-1596">&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the allowance for doubtful accounts were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.547%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.635%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.270%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;July 28 to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;January 1&lt;br/&gt;to July 27,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for bad debts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Write-off of uncollectible accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-24" decimals="-3" id="f-1597" unitRef="usd">1061000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-67" decimals="-3" id="f-1598" unitRef="usd">671000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-59" decimals="-3" id="f-1599" unitRef="usd">368000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-27" decimals="-3" id="f-1600" unitRef="usd">-67000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-69" decimals="-3" id="f-1601" unitRef="usd">390000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-61" decimals="-3" id="f-1602" unitRef="usd">303000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs contextRef="c-27" decimals="-3" id="f-1603" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs contextRef="c-69" decimals="-3" id="f-1604" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs contextRef="c-61" decimals="-3" id="f-1605" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-38" decimals="-3" id="f-1606" unitRef="usd">994000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-76" decimals="-3" id="f-1607" unitRef="usd">1061000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-67" decimals="-3" id="f-1608" unitRef="usd">671000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:IncreaseDecreaseInNotesReceivableCurrent contextRef="c-377" decimals="-5" id="f-1609" unitRef="usd">2500000</us-gaap:IncreaseDecreaseInNotesReceivableCurrent>
    <us-gaap:LoansReceivableBasisSpreadOnVariableRate
      contextRef="c-378"
      decimals="4"
      id="f-1610"
      unitRef="number">0.0100</us-gaap:LoansReceivableBasisSpreadOnVariableRate>
    <us-gaap:LoansReceivableBasisSpreadOnVariableRate contextRef="c-8" decimals="4" id="f-1611" unitRef="number">0.0800</us-gaap:LoansReceivableBasisSpreadOnVariableRate>
    <us-gaap:IncreaseDecreaseInNotesReceivableCurrent contextRef="c-16" decimals="-5" id="f-1612" unitRef="usd">-2500000</us-gaap:IncreaseDecreaseInNotesReceivableCurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-1613">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventories were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;54,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryWorkInProcess contextRef="c-7" decimals="-3" id="f-1614" unitRef="usd">11138000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c-8" decimals="-3" id="f-1615" unitRef="usd">1569000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c-7" decimals="-3" id="f-1616" unitRef="usd">43246000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c-8" decimals="-3" id="f-1617" unitRef="usd">20042000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="c-7" decimals="-3" id="f-1618" unitRef="usd">54384000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-8" decimals="-3" id="f-1619" unitRef="usd">21611000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-165" decimals="-3" id="f-1620" unitRef="usd">944000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-379" decimals="-3" id="f-1621" unitRef="usd">752000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-380" decimals="-3" id="f-1622" unitRef="usd">724000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-381" decimals="-3" id="f-1623" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-382" decimals="-3" id="f-1624" unitRef="usd">608000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-383" decimals="-3" id="f-1625" unitRef="usd">70000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-384" decimals="-3" id="f-1626" unitRef="usd">889000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-385" decimals="-3" id="f-1627" unitRef="usd">1041000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-170" decimals="-3" id="f-1628" unitRef="usd">6040000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-386" decimals="-3" id="f-1629" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-387" decimals="-3" id="f-1630" unitRef="usd">2051000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-388" decimals="-3" id="f-1631" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-7" decimals="-3" id="f-1632" unitRef="usd">11256000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-8" decimals="-3" id="f-1633" unitRef="usd">1876000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-1634" unitRef="usd">2928000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-8" decimals="-3" id="f-1635" unitRef="usd">678000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-1636" unitRef="usd">8328000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-8" decimals="-3" id="f-1637" unitRef="usd">1198000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-14" decimals="-5" id="f-1638" unitRef="usd">2900000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-15" decimals="-5" id="f-1639" unitRef="usd">500000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-16" decimals="-5" id="f-1640" unitRef="usd">400000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-17" decimals="-5" id="f-1641" unitRef="usd">100000</us-gaap:Depreciation>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-1642">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued salaries and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued sales returns and damages&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued marketing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued distribution fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related party liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent contextRef="c-7" decimals="-3" id="f-1643" unitRef="usd">9069000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c-8" decimals="-3" id="f-1644" unitRef="usd">6876000</us-gaap:AccruedSalariesCurrent>
    <wald:AccruedSalesReturnsAndDamagesCurrent contextRef="c-7" decimals="-3" id="f-1645" unitRef="usd">2651000</wald:AccruedSalesReturnsAndDamagesCurrent>
    <wald:AccruedSalesReturnsAndDamagesCurrent contextRef="c-8" decimals="-3" id="f-1646" unitRef="usd">0</wald:AccruedSalesReturnsAndDamagesCurrent>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="c-7" decimals="-3" id="f-1647" unitRef="usd">95000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="c-8" decimals="-3" id="f-1648" unitRef="usd">2963000</us-gaap:AccruedMarketingCostsCurrent>
    <wald:AccruedDistributionFeesCurrent contextRef="c-7" decimals="-3" id="f-1649" unitRef="usd">1621000</wald:AccruedDistributionFeesCurrent>
    <wald:AccruedDistributionFeesCurrent contextRef="c-8" decimals="-3" id="f-1650" unitRef="usd">760000</wald:AccruedDistributionFeesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-11" decimals="-3" id="f-1651" unitRef="usd">9914000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-12" decimals="-3" id="f-1652" unitRef="usd">0</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-9" decimals="-3" id="f-1653" unitRef="usd">2773000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-10" decimals="-3" id="f-1654" unitRef="usd">2084000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-1655" unitRef="usd">26123000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-1656" unitRef="usd">12683000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-11" decimals="-5" id="f-1657" unitRef="usd">9900000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-1658">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;STOCK-BASED COMPENSATION&lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Successor Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2022 Incentive Award Plan (the &#x201c;Plan&#x201d;) provides for incentives to be provided to selected officers, employees, non-employee directors and consultants of the Company in the form of options, stock appreciation rights, restricted stock, restricted stock units, stock bonuses or other stock-based awards granted under the Plan. The Plan was adopted by Waldencast&#x2019;s Board of Directors in June 2022, was approved by its shareholders in July, 2022, and became effective on July 27, 2022 in connection with the closing of the Business Combination. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maximum number of ordinary shares available for issuance under the Plan as of December 31, 2022 was 16,134,716&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(the &#x201c;Share Reserve&#x201d;); &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;provided, however&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Share Reserve automatically increases on January 1st of each calendar year (each, an &#x201c;Evergreen Date&#x201d;), prior to the tenth anniversary of the effective date of the Plan in an amount equal to the lesser of (i) 3% of the total number of ordinary shares issued and outstanding on the December&#160;31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; immediately preceding the applicable Evergreen Date and (ii) a number of ordinary shares determined by the Board, including zero. All and up to the number of ordinary shares reserved for issuance under the Plan as of the effective date of the Plan (subject to an equitable adjustment in the event of a change in capitalization or change in control event) may be granted as an incentive stock options. As of December&#160;31, 2022 (Successor Period), the Company had 2,749,579&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares reserved for future issuances under the Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On the Closing Date, in connection with the Business Combination, the Company assumed Obagi and Milk&#x2019;s legacy incentive award plans and outstanding unvested awards granted under those plans. The Company assumed 5,906,300 stock options and 1,776,827 restricted stock units as replacement awards pursuant to the Obagi Merger Agreement, as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;well as 237,724 stock options and 2,808,131 share appreciation rights as replacement awards pursuant to the Milk Merger Agreement. The total post-combination incremental stock-based compensation was $18.3 million, which is expected to be recognized over the remaining requisite service periods, where $47.7 million represents the fair value of the equity awards as part of the equity purchase consideration. The awards that were replaced had been contingent on a performance condition and as such, the Company is required to use an attribution model in which compensation cost for each vesting tranche is recognized as if each vesting tranche were a separate award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Founder Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022 the Company granted a total of 11,500,000 stock options to the two founders of Waldencast that vest based on service over the six-year period from August 2022 through August 2028. The options were granted with four vesting tranches, each tranche with a different exercise price, subject to their continued employment with the Company. Additionally, the Company granted 692,000 founders service-based restricted stock units that cliff vest in August 2025, subject to their continued employment with the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incentive Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Company approved incentive awards to employees of Waldencast, Milk, and Obagi. The long-term incentive awards (the &#x201c;LTI Awards&#x201d;) are restricted stock units that vest based on both a service condition and meeting either a net sales or earnings before interest, taxes, depreciation and amortization (&#x201c;EBITDA&#x201d;) target in calendar year 2022. These LTI Awards were granted to employees in November 2022. The performance targets for the LTI Awards&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were met for Milk in 2022. The Company granted LTI Awards will vest one-third each year beginning on February 15, 2023, subject to continued service through such dates. As of December&#160;31, 2022 (Successor Period),&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;694,537 restricted stock units had been granted. In May 2023, the Board approved a modification to the LTI Awards by waiving the performance conditions for most Obagi and Waldencast employees, other than the former Chief Executive Officer of Obagi and the Chief Executive Officer and Chief Growth Officer of Waldencast. See &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_187" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 21&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Subsequent Events&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Waldencast One-Time Stock Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, the Company approved a one-time stock grant for certain Milk employees that were not eligible to participate in the LTI award program. A total of 10,000 awards were approved under this program. These awards are service-based restricted stock units that will cliff vest three years from the grant date, subject to continued employment with the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity for the period from July 28 to December&#160;31, 2022 (Successor Period) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Common&lt;br/&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;Value (in&lt;br/&gt;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance as of July 28, 2022 (Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,452,155&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance as of December 31, 2022 (Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,452,155&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable as of December 31, 2022 (Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,451,538&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested and expected to vest as of December 31, 2022 (Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,452,155&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average fair value per share of the awards granted for stock options during the period from July 28 to December&#160;31, 2022 (Successor Period) is $3.58.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock option awards was determined on the grant date using the Monte Carlo simulation model for Founder Awards and the Hull-White lattice pricing model was used for replacement awards based on the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.811%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.813%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28&lt;br/&gt;to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Founder Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Replacement Awards&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.87% - 2.92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;2.79% - 2.80% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.7 - 9.9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise multiple &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected stock price volatility &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.77% - 44.76%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The risk-free rate is based on U.S. Treasury securities with maturities equivalent to the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The expected term for founder awards is based on the assumption that the options are exercised after 50% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The exercise multiple is selected from the commonly used exercise multiple range of 2.0x to 2.5x assuming on average the options holders would exercise the options when the ratio of underlying stock price to the exercise price reaches 2.3x.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;For founder awards, the expected stock price volatility is the median historical volatility of Waldencast&#x2019;s volatility peer group with a look-back period equal to the contractual term using daily stock prices; for replacement awards, the expected stock price volatility is estimated by adjusting the observed equity volatility for leverage.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.43pt"&gt;Waldencast has not paid any dividends historically and does not plan to declare dividends in the foreseeable future and therefore assumed a dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock activity for the period from July 28 to December&#160;31, 2022 (Successor Period) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value&lt;br/&gt;per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of July 28, 2022 (Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,173,364&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(370,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2022 (Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,802,419&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrecognized compensation cost as of December 31, 2022 (Successor Period) for stock options and restricted stock was $32.5 million and $11.4 million, respectively. These costs are expected to be recognized over a weighted-average service period of 4.8 and 2.9 years for stock options and restricted stock, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Predecessor Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Predecessor established a Stock Incentive Plan (the &#x201c;Predecessor Incentive Plan&#x201d;), under which stock options, stock awards, and restricted stock units (&#x201c;Predecessor Restricted Stock&#x201d;) of the Company could be granted to eligible employees, directors, and consultants. Under the Predecessor Incentive Plan, the Company was authorized to issue of a maximum number of 1,500,000 shares of Obagi common stock. Incentive stock options were required to have an exercise price at or above the fair market value of the stock on the date of the grant. The Company&#x2019;s stock options and Predecessor Restricted Stock granted during the period from January 1 to July 27, 2022 (Predecessor Period) and the year ended December&#160;31, 2021 (Predecessor Period) had service-based and performance-based vesting conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The options vested over five years, with 25% of options vesting in four equal quarterly installments at the end of each three-month period through the first anniversary of the grant, and the remaining 75% vesting in a series of five equal annual installments over the five-year period measured from the grant date. The Predecessor Restricted Stock vested in five equal annual installments at the end of each year, over the five-year period from the grant date. Award holders had a ten-year period to exercise the options before they expire. Notwithstanding achievement of the service-based condition, the options and the Predecessor Restricted Stock did not vest or become exercisable until a qualifying transaction was consummated prior to the expiration date. A qualifying transaction consisted of either a change in control event or an underwritten initial public offering by the Company of its equity securities on a U.S. or foreign exchange, which occurred upon Waldencast&#x2019;s acquisition of Obagi. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity for the period from January 1 to July 27, 2022 (Predecessor Period) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Common Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;Value (in&lt;br/&gt;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of January 1, 2022 (Predecessor) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;800,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of July 27, 2022 (Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;774,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity for the year ended December&#160;31, 2021 (Predecessor Period) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Common Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;Value (in&lt;br/&gt;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of January 1, 2021 (Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;800,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2021 (Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;800,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average fair value per share of the awards granted during from January 1 to July 27, 2022 (Predecessor Period) was $15.55 for stock options and $38.90 for Predecessor Restricted Stock. The weighted average fair value per share of the awards granted during the year ended December&#160;31, 2021 (Predecessor Period) was $15.55 for stock options and $38.68 for Predecessor Restricted Stock. The unrecognized compensation cost as of December&#160;31, 2021 (Predecessor Period) for stock options and Predecessor Restricted Stock was $9.4 million and $12.4 million, respectively. Prior to Waldencast&#x2019;s acquisition of Obagi, the Company did not expect the occurrence of a qualifying transaction event to be &#x201c;probable&#x201d;, and therefore no expense had been recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock option awards was determined on the grant date using the Black-Scholes valuation model based on the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from January 1&lt;br/&gt;to July 27, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended &lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected stock price volatility &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock per share value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The risk-free rate is based on U.S. Treasury securities with maturities equivalent to the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The expected term is the estimated length of time the grants are expected to be outstanding before it is exercised or terminated. This number is calculated as the midpoint between the requisite service period and the contractual term of the award, as the Company does not have any historical data that would provide a reasonable basis to estimate the expected term for the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The expected price volatility is based on the average of the historical volatility of comparable public companies over a period consistent with the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The Predecessor historically made distributions to its shareholder but the Company does not plan to declare dividends in the foreseeable future and therefore assumed a dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Predecessor Restricted Stock activity for the period from January 1 to July&#160;27, 2022 (Predecessor Period) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value&lt;br/&gt;per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of January 1, 2022 (Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;243,307&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,754&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,219&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of July 27, 2022 (Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;234,842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Restricted Stock activity for the year ended December&#160;31, 2021 (Predecessor Period) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value&lt;br/&gt;per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of January 1, 2021 (Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;243,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2021 (Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;243,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-389"
      decimals="INF"
      id="f-1659"
      unitRef="shares">16134716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c-390"
      decimals="2"
      id="f-1660"
      unitRef="number">0.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-389"
      decimals="INF"
      id="f-1661"
      unitRef="shares">2749579</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod
      contextRef="c-391"
      decimals="INF"
      id="f-1662"
      unitRef="shares">5906300</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod
      contextRef="c-392"
      decimals="INF"
      id="f-1663"
      unitRef="shares">1776827</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod
      contextRef="c-393"
      decimals="INF"
      id="f-1664"
      unitRef="shares">237724</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod
      contextRef="c-394"
      decimals="INF"
      id="f-1665"
      unitRef="shares">2808131</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod>
    <wald:ShareBasedPaymentArrangementBusinessCombinationIncrementalCost contextRef="c-395" decimals="-5" id="f-1666" unitRef="usd">18300000</wald:ShareBasedPaymentArrangementBusinessCombinationIncrementalCost>
    <us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure contextRef="c-396" decimals="-5" id="f-1667" unitRef="usd">47700000</us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-397"
      decimals="INF"
      id="f-1668"
      unitRef="shares">11500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals
      contextRef="c-398"
      decimals="INF"
      id="f-1669"
      unitRef="individual">2</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-399" id="f-1670">P6Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches
      contextRef="c-397"
      decimals="INF"
      id="f-1671"
      unitRef="segment">4</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-400"
      decimals="INF"
      id="f-1672"
      unitRef="shares">692000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-401"
      decimals="INF"
      id="f-1673"
      unitRef="shares">694537</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-402"
      decimals="INF"
      id="f-1674"
      unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-403" id="f-1675">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="c-1" id="f-1676">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity for the period from July 28 to December&#160;31, 2022 (Successor Period) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Common&lt;br/&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;Value (in&lt;br/&gt;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance as of July 28, 2022 (Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,452,155&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance as of December 31, 2022 (Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,452,155&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable as of December 31, 2022 (Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,451,538&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested and expected to vest as of December 31, 2022 (Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,452,155&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity for the period from January 1 to July 27, 2022 (Predecessor Period) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Common Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;Value (in&lt;br/&gt;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of January 1, 2022 (Predecessor) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;800,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of July 27, 2022 (Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;774,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity for the year ended December&#160;31, 2021 (Predecessor Period) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Common Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;Value (in&lt;br/&gt;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of January 1, 2021 (Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;800,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2021 (Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;800,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-24" decimals="0" id="f-1677" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-24"
      decimals="2"
      id="f-1678"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-27" decimals="0" id="f-1679" unitRef="shares">20452155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-27"
      decimals="2"
      id="f-1680"
      unitRef="usdPerShare">9.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm contextRef="c-27" id="f-1681">P8Y3M18D</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-27" decimals="0" id="f-1682" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-27"
      decimals="2"
      id="f-1683"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-27" decimals="0" id="f-1684" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-27"
      decimals="2"
      id="f-1685"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-38" decimals="0" id="f-1686" unitRef="shares">20452155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-38"
      decimals="2"
      id="f-1687"
      unitRef="usdPerShare">9.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-27" id="f-1688">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-38" decimals="-3" id="f-1689" unitRef="usd">39118000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-38" decimals="0" id="f-1690" unitRef="shares">4451538</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-38"
      decimals="2"
      id="f-1691"
      unitRef="usdPerShare">4.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-27" id="f-1692">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c-38" decimals="-3" id="f-1693" unitRef="usd">21816000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-38" decimals="0" id="f-1694" unitRef="shares">20452155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-38"
      decimals="2"
      id="f-1695"
      unitRef="usdPerShare">9.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-27" id="f-1696">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-38" decimals="-3" id="f-1697" unitRef="usd">39118000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-14"
      decimals="2"
      id="f-1698"
      unitRef="usdPerShare">3.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1699">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock option awards was determined on the grant date using the Monte Carlo simulation model for Founder Awards and the Hull-White lattice pricing model was used for replacement awards based on the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.811%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.813%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28&lt;br/&gt;to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Founder Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Replacement Awards&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.87% - 2.92%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;2.79% - 2.80% &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.7 - 9.9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercise multiple &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected stock price volatility &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39.77% - 44.76%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The risk-free rate is based on U.S. Treasury securities with maturities equivalent to the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The expected term for founder awards is based on the assumption that the options are exercised after 50% of the period between the later of the vest date and exercise price achievement date and the end of the contractual term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The exercise multiple is selected from the commonly used exercise multiple range of 2.0x to 2.5x assuming on average the options holders would exercise the options when the ratio of underlying stock price to the exercise price reaches 2.3x.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;For founder awards, the expected stock price volatility is the median historical volatility of Waldencast&#x2019;s volatility peer group with a look-back period equal to the contractual term using daily stock prices; for replacement awards, the expected stock price volatility is estimated by adjusting the observed equity volatility for leverage.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.43pt"&gt;Waldencast has not paid any dividends historically and does not plan to declare dividends in the foreseeable future and therefore assumed a dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock option awards was determined on the grant date using the Black-Scholes valuation model based on the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from January 1&lt;br/&gt;to July 27, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended &lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (years) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected stock price volatility &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock per share value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The risk-free rate is based on U.S. Treasury securities with maturities equivalent to the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The expected term is the estimated length of time the grants are expected to be outstanding before it is exercised or terminated. This number is calculated as the midpoint between the requisite service period and the contractual term of the award, as the Company does not have any historical data that would provide a reasonable basis to estimate the expected term for the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The expected price volatility is based on the average of the historical volatility of comparable public companies over a period consistent with the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The Predecessor historically made distributions to its shareholder but the Company does not plan to declare dividends in the foreseeable future and therefore assumed a dividend yield of zero.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c-404"
      decimals="4"
      id="f-1700"
      unitRef="number">0.0287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="c-404"
      decimals="4"
      id="f-1701"
      unitRef="number">0.0292</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c-405"
      decimals="4"
      id="f-1702"
      unitRef="number">0.0279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="c-405"
      decimals="4"
      id="f-1703"
      unitRef="number">0.0280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-406" id="f-1704">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-407" id="f-1705">P9Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple
      contextRef="c-405"
      decimals="2"
      id="f-1706"
      unitRef="number">2.30</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="c-404"
      decimals="4"
      id="f-1707"
      unitRef="number">0.3977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="c-404"
      decimals="4"
      id="f-1708"
      unitRef="number">0.4476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-405"
      decimals="4"
      id="f-1709"
      unitRef="number">0.5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent contextRef="c-14" decimals="2" id="f-1710" unitRef="number">0.50</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple
      contextRef="c-408"
      decimals="1"
      id="f-1711"
      unitRef="number">2.0</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple
      contextRef="c-409"
      decimals="1"
      id="f-1712"
      unitRef="number">2.5</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple contextRef="c-14" decimals="1" id="f-1713" unitRef="number">2.3</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="c-14" decimals="INF" id="f-1714" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="c-1" id="f-1715">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock activity for the period from July 28 to December&#160;31, 2022 (Successor Period) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value&lt;br/&gt;per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of July 28, 2022 (Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,173,364&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(370,945)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2022 (Successor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,802,419&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Predecessor Restricted Stock activity for the period from January 1 to July&#160;27, 2022 (Predecessor Period) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value&lt;br/&gt;per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of January 1, 2022 (Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;243,307&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,754&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,219&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of July 27, 2022 (Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;234,842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Restricted Stock activity for the year ended December&#160;31, 2021 (Predecessor Period) was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Grant Date Fair Value&lt;br/&gt;per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of January 1, 2021 (Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;243,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding as of December 31, 2021 (Predecessor)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;243,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-410"
      decimals="0"
      id="f-1716"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-410"
      decimals="2"
      id="f-1717"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-411"
      decimals="0"
      id="f-1718"
      unitRef="shares">3173364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-411"
      decimals="2"
      id="f-1719"
      unitRef="usdPerShare">9.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-411"
      decimals="0"
      id="f-1720"
      unitRef="shares">370945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-411"
      decimals="2"
      id="f-1721"
      unitRef="usdPerShare">10.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-411"
      decimals="0"
      id="f-1722"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-411"
      decimals="2"
      id="f-1723"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-412"
      decimals="0"
      id="f-1724"
      unitRef="shares">2802419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-412"
      decimals="2"
      id="f-1725"
      unitRef="usdPerShare">9.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-7" decimals="-5" id="f-1726" unitRef="usd">32500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-413" decimals="-5" id="f-1727" unitRef="usd">11400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-414" id="f-1728">P4Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-415" id="f-1729">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-416"
      decimals="INF"
      id="f-1730"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-417" id="f-1731">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-418"
      decimals="3"
      id="f-1732"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments
      contextRef="c-419"
      decimals="INF"
      id="f-1733"
      unitRef="segment">4</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-418" id="f-1734">P3M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-420"
      decimals="3"
      id="f-1735"
      unitRef="number">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments
      contextRef="c-421"
      decimals="INF"
      id="f-1736"
      unitRef="segment">5</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-420" id="f-1737">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments
      contextRef="c-422"
      decimals="INF"
      id="f-1738"
      unitRef="segment">5</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-423" id="f-1739">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-423" id="f-1740">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-67" decimals="0" id="f-1741" unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-67"
      decimals="2"
      id="f-1742"
      unitRef="usdPerShare">41.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-61" id="f-1743">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-67" decimals="-3" id="f-1744" unitRef="usd">16456000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-69" decimals="0" id="f-1745" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-69"
      decimals="2"
      id="f-1746"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-69" decimals="0" id="f-1747" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-69"
      decimals="2"
      id="f-1748"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-69" decimals="0" id="f-1749" unitRef="shares">25200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-69"
      decimals="2"
      id="f-1750"
      unitRef="usdPerShare">41.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm contextRef="c-69" id="f-1751">P8Y7M6D</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue contextRef="c-69" decimals="-3" id="f-1752" unitRef="usd">639000</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="c-69" decimals="0" id="f-1753" unitRef="shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <wald:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice
      contextRef="c-69"
      decimals="2"
      id="f-1754"
      unitRef="usdPerShare">0</wald:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-76" decimals="0" id="f-1755" unitRef="shares">774800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-76"
      decimals="2"
      id="f-1756"
      unitRef="usdPerShare">41.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-69" id="f-1757">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-76" decimals="-3" id="f-1758" unitRef="usd">19659000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-59" decimals="0" id="f-1759" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-59"
      decimals="2"
      id="f-1760"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-61" decimals="0" id="f-1761" unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-61"
      decimals="2"
      id="f-1762"
      unitRef="usdPerShare">41.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm contextRef="c-61" id="f-1763">P9Y1M6D</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue contextRef="c-61" decimals="-3" id="f-1764" unitRef="usd">16456000</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-61" decimals="0" id="f-1765" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-61"
      decimals="2"
      id="f-1766"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-61" decimals="0" id="f-1767" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-61"
      decimals="2"
      id="f-1768"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="c-61" decimals="0" id="f-1769" unitRef="shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <wald:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice
      contextRef="c-61"
      decimals="2"
      id="f-1770"
      unitRef="usdPerShare">0</wald:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-67" decimals="0" id="f-1771" unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-67"
      decimals="2"
      id="f-1772"
      unitRef="usdPerShare">41.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-61" id="f-1773">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-67" decimals="-3" id="f-1774" unitRef="usd">16456000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-15"
      decimals="2"
      id="f-1775"
      unitRef="usdPerShare">15.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-424"
      decimals="2"
      id="f-1776"
      unitRef="usdPerShare">38.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-16"
      decimals="2"
      id="f-1777"
      unitRef="usdPerShare">15.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-425"
      decimals="2"
      id="f-1778"
      unitRef="usdPerShare">38.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-8" decimals="-5" id="f-1779" unitRef="usd">9400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-426" decimals="-5" id="f-1780" unitRef="usd">12400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-427"
      decimals="4"
      id="f-1781"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-428"
      decimals="4"
      id="f-1782"
      unitRef="number">0.0068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-428" id="f-1783">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c-427"
      decimals="4"
      id="f-1784"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c-428"
      decimals="4"
      id="f-1785"
      unitRef="number">0.4300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="c-427" decimals="INF" id="f-1786" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:SharePrice
      contextRef="c-429"
      decimals="2"
      id="f-1787"
      unitRef="usdPerShare">0</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c-430"
      decimals="2"
      id="f-1788"
      unitRef="usdPerShare">38.68</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="c-427" decimals="INF" id="f-1789" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-431"
      decimals="0"
      id="f-1790"
      unitRef="shares">243307</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-431"
      decimals="2"
      id="f-1791"
      unitRef="usdPerShare">38.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-432"
      decimals="0"
      id="f-1792"
      unitRef="shares">1754</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-432"
      decimals="2"
      id="f-1793"
      unitRef="usdPerShare">68.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c-432"
      decimals="0"
      id="f-1794"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue
      contextRef="c-69"
      decimals="2"
      id="f-1795"
      unitRef="usdPerShare">0</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-432"
      decimals="0"
      id="f-1796"
      unitRef="shares">10219</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-432"
      decimals="2"
      id="f-1797"
      unitRef="usdPerShare">38.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-432"
      decimals="0"
      id="f-1798"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-432"
      decimals="2"
      id="f-1799"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-433"
      decimals="0"
      id="f-1800"
      unitRef="shares">234842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-433"
      decimals="2"
      id="f-1801"
      unitRef="usdPerShare">38.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-434"
      decimals="0"
      id="f-1802"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-434"
      decimals="2"
      id="f-1803"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-435"
      decimals="0"
      id="f-1804"
      unitRef="shares">243307</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-435"
      decimals="2"
      id="f-1805"
      unitRef="usdPerShare">38.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c-435"
      decimals="0"
      id="f-1806"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue
      contextRef="c-61"
      decimals="2"
      id="f-1807"
      unitRef="usdPerShare">0</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-435"
      decimals="0"
      id="f-1808"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-435"
      decimals="2"
      id="f-1809"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-435"
      decimals="0"
      id="f-1810"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-435"
      decimals="2"
      id="f-1811"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-431"
      decimals="0"
      id="f-1812"
      unitRef="shares">243307</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-431"
      decimals="2"
      id="f-1813"
      unitRef="usdPerShare">38.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-1816">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;SHAREHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Successor&#x2019;s Share Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company&#x2019;s Memorandum of Association (the &#x201c;Constitutional Document&#x201d;), its authorized share capital consists of 1,000,000,000 Class A ordinary shares, 100,000,000 Class B ordinary shares and 25,000,000 Preference Shares, each having a par value of $0.0001. As of December&#160;31, 2022 (Successor Period), there were&#160;86,460,560 and 21,104,225 Class A and Class B ordinary shares, respectively, issued and outstanding. The Company did not have any Preference Shares issued and outstanding as of December&#160;31, 2022 (Successor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each Class A ordinary share is entitled to one vote per share. The Company can, at the discretion of its Board of Directors, declare dividends and distributions out of the funds of the Company lawfully available therefor. In the event of a voluntary or involuntary liquidation or wind-up, assets available for distribution among the holders of Class A ordinary shares will be distributed on a pro rata basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each Class B ordinary share is entitled to one vote per share and will vote together with holders of Class&#160;A ordinary shares as a single class. Class B ordinary shares are non-economic shares that are not entitled to dividends. Upon a liquidation, dissolution or winding up the Company, the holders of Class B ordinary shares will not be entitled to receive any assets of the Company, except to the extent of the par value of their shares, pro rata with the distributions that the Class A ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As outlined in &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 4&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Business Combinations,&#x201d; Class B ordinary shares were issued by the Company to the Milk Members in connection with the Business Combination, giving rise to noncontrolling interest in the Company&#x2019;s controlled subsidiary, Waldencast Partners LP. As such, the Constitutional Document prohibits issuances of additional shares of Class B ordinary shares, unless issued to a noncontrolling interest in connection with the Company&#x2019;s Up-C structure. Class B ordinary shares are convertible into Class A ordinary shares on a one-to-one basis at the option of the holder. If such option is exercised, the exchanged Class B ordinary shares will automatically be surrendered and retired for no consideration. If the Company issues or redeems Class B ordinary shares, Waldencast Partners LP is obligated to issue or redeem a corresponding number of Waldencast LP partnership units, such that the number of issued and outstanding partnership units at any time will correspond and be equivalent to the then number of issued and outstanding Class B ordinary shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Predecessor&#x2019;s Share Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Predecessor&#x2019;s equity structure consisted of a single class of ordinary shares. In November  2020, the Obagi Board of Directors approved (i) an increase in the number of the Company&#x2019;s authorized common shares from 50,000 to 25,000,000, (ii) an issuance of 4,000,000 common shares to ZhongHua, and (iii) a two-for-one split of the Company&#x2019;s issued and outstanding common shares  all of which became effective in December  2020. The Company was held by a single shareholder, and the share issuance to ZhongHua was deemed akin to a stock split. All share, per share amounts and related shareholders&#x2019; equity balances presented for Predecessor Periods have been retroactively adjusted to reflect the impact of the Stock Split. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of December&#160;31, 2021 the Predecessor had 25,000,000 ordinary shares authorized and 8,000,002 shares issued and outstanding. Predecessor&#x2019;s ordinary shares had a par value of $0.50 per share and each share was entitled to one vote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Predecessor was able to, at the discretion of its Board of Directors, declare dividends and distributions out of the funds of the Company lawfully available therefor. Payments of dividends and distributions were limited to realized or unrealized profits of the Company. The Company did not pay any dividends during the period from January 1 to July 27, 2022 (Predecessor Period). In the years ended December&#160;31, 2021 and 2020 (Predecessor Period), Obagi, through a wholly-owned subsidiary, paid $2.0 million (approximately $0.25 per share) and $2.0 million (approximately $0.26 per share), respectively, in dividends to its shareholder.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-5"
      decimals="INF"
      id="f-1817"
      unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-6"
      decimals="INF"
      id="f-1818"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-7"
      decimals="INF"
      id="f-1819"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="4"
      id="f-1820"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="4"
      id="f-1821"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="4"
      id="f-1822"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-5"
      decimals="INF"
      id="f-1823"
      unitRef="shares">86460560</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-5"
      decimals="INF"
      id="f-1824"
      unitRef="shares">86460560</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-6"
      decimals="INF"
      id="f-1825"
      unitRef="shares">21104225</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-6"
      decimals="INF"
      id="f-1826"
      unitRef="shares">21104225</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-7"
      decimals="INF"
      id="f-1827"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-7"
      decimals="INF"
      id="f-1828"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockVotingRights contextRef="c-436" id="f-1829">one</us-gaap:CommonStockVotingRights>
    <us-gaap:CommonStockVotingRights contextRef="c-437" id="f-1830">one</us-gaap:CommonStockVotingRights>
    <wald:CommonStockConvertibleConversionRatio
      contextRef="c-7"
      decimals="INF"
      id="f-1831"
      unitRef="shares">1</wald:CommonStockConvertibleConversionRatio>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-93"
      decimals="INF"
      id="f-1832"
      unitRef="shares">50000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-94"
      decimals="INF"
      id="f-1833"
      unitRef="shares">25000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-94"
      decimals="INF"
      id="f-1834"
      unitRef="shares">4000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c-95"
      decimals="INF"
      id="f-1835"
      unitRef="number">2</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-8"
      decimals="INF"
      id="f-1836"
      unitRef="shares">25000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-8"
      decimals="INF"
      id="f-1837"
      unitRef="shares">8000002</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-8"
      decimals="INF"
      id="f-1838"
      unitRef="shares">8000002</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="2"
      id="f-1839"
      unitRef="usdPerShare">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights contextRef="c-16" id="f-1840">one</us-gaap:CommonStockVotingRights>
    <us-gaap:DividendsCommonStockCash contextRef="c-15" decimals="-5" id="f-1841" unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-16" decimals="-5" id="f-1842" unitRef="usd">2000000.0</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-16"
      decimals="2"
      id="f-1843"
      unitRef="usdPerShare">0.25</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash contextRef="c-17" decimals="-5" id="f-1844" unitRef="usd">2000000.0</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-17"
      decimals="2"
      id="f-1845"
      unitRef="usdPerShare">0.26</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1846">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;NET LOSS PER SHARE &lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the weighted average ownership percentages during the period to calculate the net loss per share attributable to public shareholders and the noncontrolling interest holders. The following table sets forth the computation of basic and diluted net income (loss) using the treasury stock method: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.950%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.270%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28 to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from&lt;br/&gt;January 1 to &lt;br/&gt;July 27, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands, except for share and per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(120,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(24,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss attributed to Class A shareholders - basic and diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(95,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average basic shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86,460,560&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average diluted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86,460,560&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents potential ordinary shares outstanding that were excluded from the computation of diluted net loss per share of common share because their effect would have been anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from&lt;br/&gt;July 28 to December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from&lt;br/&gt;January 1 to&lt;br/&gt;July 27, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended &lt;br/&gt;December 31, &lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended &lt;br/&gt;December 31, &lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,533,282&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,452,155&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;774,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;800,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,802,419&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;234,842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;243,307&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,787,856&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,009,642&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,043,307&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-1847">The following table sets forth the computation of basic and diluted net income (loss) using the treasury stock method: &lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.925%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.950%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.270%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28 to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from&lt;br/&gt;January 1 to &lt;br/&gt;July 27, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands, except for share and per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(120,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(24,990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss attributed to Class A shareholders - basic and diluted EPS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(95,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average basic shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86,460,560&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted-average diluted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;86,460,560&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,000,002&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-1848" unitRef="usd">-120557000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-1849" unitRef="usd">-21057000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-3" id="f-1850" unitRef="usd">-19576000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-3" id="f-1851" unitRef="usd">-2370000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-1852" unitRef="usd">-24990000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-1853" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-1854" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-1855" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-14" decimals="-3" id="f-1856" unitRef="usd">-95567000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-14" decimals="-3" id="f-1857" unitRef="usd">-95567000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-15" decimals="-3" id="f-1858" unitRef="usd">-21057000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-15" decimals="-3" id="f-1859" unitRef="usd">-21057000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-16" decimals="-3" id="f-1860" unitRef="usd">-19576000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-16" decimals="-3" id="f-1861" unitRef="usd">-19576000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-17" decimals="-3" id="f-1862" unitRef="usd">-2370000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-17" decimals="-3" id="f-1863" unitRef="usd">-2370000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-14" decimals="0" id="f-1864" unitRef="shares">86460560</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="0" id="f-1865" unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-16" decimals="0" id="f-1866" unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-17" decimals="0" id="f-1867" unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-14" decimals="0" id="f-1868" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-15" decimals="0" id="f-1869" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-16" decimals="0" id="f-1870" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-17" decimals="0" id="f-1871" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-14" decimals="0" id="f-1872" unitRef="shares">86460560</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="0" id="f-1873" unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-16" decimals="0" id="f-1874" unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-17" decimals="0" id="f-1875" unitRef="shares">8000002</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-1876"
      unitRef="usdPerShare">-1.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-1877"
      unitRef="usdPerShare">-1.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-1878"
      unitRef="usdPerShare">-2.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-1879"
      unitRef="usdPerShare">-2.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-16"
      decimals="2"
      id="f-1880"
      unitRef="usdPerShare">-2.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-16"
      decimals="2"
      id="f-1881"
      unitRef="usdPerShare">-2.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-17"
      decimals="2"
      id="f-1882"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-17"
      decimals="2"
      id="f-1883"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-1884">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents potential ordinary shares outstanding that were excluded from the computation of diluted net loss per share of common share because their effect would have been anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from&lt;br/&gt;July 28 to December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from&lt;br/&gt;January 1 to&lt;br/&gt;July 27, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended &lt;br/&gt;December 31, &lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended &lt;br/&gt;December 31, &lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,533,282&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,452,155&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;774,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;800,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,802,419&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;234,842&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;243,307&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52,787,856&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,009,642&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,043,307&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-438"
      decimals="0"
      id="f-1885"
      unitRef="shares">29533282</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-439"
      decimals="0"
      id="f-1886"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-440"
      decimals="0"
      id="f-1887"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-441"
      decimals="0"
      id="f-1888"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-442"
      decimals="0"
      id="f-1889"
      unitRef="shares">20452155</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-443"
      decimals="0"
      id="f-1890"
      unitRef="shares">774800</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-444"
      decimals="0"
      id="f-1891"
      unitRef="shares">800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-445"
      decimals="0"
      id="f-1892"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-446"
      decimals="0"
      id="f-1893"
      unitRef="shares">2802419</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-447"
      decimals="0"
      id="f-1894"
      unitRef="shares">234842</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-448"
      decimals="0"
      id="f-1895"
      unitRef="shares">243307</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-449"
      decimals="0"
      id="f-1896"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-14" decimals="0" id="f-1897" unitRef="shares">52787856</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-15" decimals="0" id="f-1898" unitRef="shares">1009642</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-16" decimals="0" id="f-1899" unitRef="shares">1043307</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-17" decimals="0" id="f-1900" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1901">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;INCOME TAX BENEFIT&lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Predecessor was domiciled in the Cayman Islands. Following the Business Combination, the Company, domiciled in the Bailiwick of Jersey, is subject to taxation in the U.S. and various states jurisdictions. ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 740&#x201d;) indicates that the federal statutory income tax rate of a foreign reporting entity be used when preparing the rate reconciliation disclosure. As such, the Company and its wholly-owned subsidiaries use the statutory income tax rate in the Bailiwick of Jersey for the Successor Period and the Cayman Islands for the Predecessor Period, which was 0%. The Company&#x2019;s consolidated pretax income (loss) for the period from July 28 to December&#160;31, 2022 (Successor Period), the period from January 1 to July 27, 2022 (Predecessor Period), the year ended December&#160;31, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021 (Predecessor Period) and the year ended December&#160;31, 2020 (Predecessor Period) were generated by domestic and foreign operations as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from&lt;br/&gt;July 28 to December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from January 1 to July 27, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss before income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(125,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(126,360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(20,944)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,764)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes for the period from July 28 to December&#160;31, 2022 (Successor Period), the period from January 1 to July 27, 2022 (Predecessor Period), the year ended December&#160;31, 2021 (Predecessor Period) and the year ended December&#160;31, 2020 (Predecessor Period) consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.001%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28 to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from January 1 to July 27, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current provision (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred (income) expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,044)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of income tax expense related to the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28 to December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from January 1 to July 27,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit at Bailiwick of Jersey for Successor and Income tax benefit at Cayman Islands for Predecessor statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S./foreign tax rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State income tax benefit, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Permanent Items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(141.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction bonuses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PPP Loan forgiveness  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;True-Ups&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total income tax (benefit) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(96.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of each reporting date, the Company considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As part of the Business Combination, the Company determined that there was sufficient positive evidence to conclude that it was more likely than not that additional deferred taxes of $28.1 million would be realizable through the reversal of existing deferred tax liabilities listed below. It therefore reduced the valuation allowance accordingly. As of December 31, 2022, a valuation allowance of $7.9 million has been provided for on the deferred tax assets related to the Company&#x2019;s investment in Waldencast Partners LP. If or when recognized, the tax benefits related to any reversal of valuation allowance will be accounted for as a reduction of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards. The tax effects of temporary differences that give rise to portions of the deferred tax assets and deferred tax liabilities as of December&#160;31, 2022 (Successor Period) and December&#160;31, 2021 (Predecessor Period) are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest to foreign related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Formation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other temporary differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-deductible interest carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below market contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized research&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment in Waldencast LP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;34,580&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;16,532&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed asset basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(46,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(48,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(3,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net deferred tax (liabilities) assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(14,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;13,512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,944)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(22,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses and tax credit carryforwards as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Successor Period) and  December&#160;31, 2021 (Predecessor Period) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.214%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.805%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.805%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.585%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Expiration Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Expiration Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses, federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Do Not Expire&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Do Not Expire&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses, state&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2039-2042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2039-2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax Credits, federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2038-2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2038-2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax Credits, state&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Do Not Expire&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Do Not Expire&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#x201c;IRC&#x201d;) annual use of the Company&#x2019;s net operating losses (&#x201c;NOLs&#x201d;) and R&amp;amp;D credit carryforwards may be limited in the event a cumulative change in ownership of more than 50.0% occurs within a three-year period. The Company has not undergone an analysis to determine whether this limitation would apply to the utilization of the NOL carryforward. However, as the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;federal NOLs do not expire, the Company does not believe that any potential limitations to federal or state NOL&#x2019;s, or federal credit carryforwards, if applicable, would be material to the financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits, and uncertain income tax positions must meet a more likely than not recognition threshold to be recognized. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line in the consolidated statements of operations and comprehensive loss. There were no unrecognized tax benefits as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022 (Successor Period)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or December&#160;31, 2021 (Predecessor Period). The Company does not expect material changes to its unrecognized tax benefits for the twelve month period following the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, (Successor Period) there were no active taxing authority examinations in any of the Company's major tax jurisdictions. The Company remains subject to examination for federal and state income tax purposes for the tax years ending 2018 through 2022 (Successor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the tax years beginning on or after January 1, 2022, the Tax Cuts and Jobs Act of 2017 eliminates the option to currently deduct R&amp;amp;D expenses and requires taxpayers to capitalize and amortize them over five years for research activities performed in the U.S. and 15 years for research activities performed outside the U.S. pursuant to IRC Section 174. Although Congress is considering legislation that would repeal or defer this capitalization and amortization requirement, it is not certain that this provision will be repealed or otherwise modified. If the requirement is not repealed or replaced, it will decrease our tax deduction for research and development expense in future years.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-15"
      decimals="INF"
      id="f-1902"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-14"
      decimals="INF"
      id="f-1903"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-1904">The Company&#x2019;s consolidated pretax income (loss) for the period from July 28 to December&#160;31, 2022 (Successor Period), the period from January 1 to July 27, 2022 (Predecessor Period), the year ended December&#160;31, &lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021 (Predecessor Period) and the year ended December&#160;31, 2020 (Predecessor Period) were generated by domestic and foreign operations as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from&lt;br/&gt;July 28 to December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from January 1 to July 27, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss before income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(125,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(17,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(126,360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(20,944)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(9,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,764)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-14" decimals="-3" id="f-1905" unitRef="usd">-125281000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-15" decimals="-3" id="f-1906" unitRef="usd">-17676000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-16" decimals="-3" id="f-1907" unitRef="usd">-15320000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-17" decimals="-3" id="f-1908" unitRef="usd">-13243000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-14" decimals="-3" id="f-1909" unitRef="usd">-1079000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-15" decimals="-3" id="f-1910" unitRef="usd">-3268000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-16" decimals="-3" id="f-1911" unitRef="usd">5346000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-17" decimals="-3" id="f-1912" unitRef="usd">7479000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-1913" unitRef="usd">-126360000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-1914" unitRef="usd">-20944000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-1915" unitRef="usd">-9974000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-1916" unitRef="usd">-5764000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-1917">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes for the period from July 28 to December&#160;31, 2022 (Successor Period), the period from January 1 to July 27, 2022 (Predecessor Period), the year ended December&#160;31, 2021 (Predecessor Period) and the year ended December&#160;31, 2020 (Predecessor Period) consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.001%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28 to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from January 1 to July 27, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current provision (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred (income) expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,044)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1918" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1919" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-1920" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-1921" unitRef="usd">-363000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1922" unitRef="usd">20000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1923" unitRef="usd">19000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-1924" unitRef="usd">58000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-1925" unitRef="usd">-19000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1926" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1927" unitRef="usd">4000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-1928" unitRef="usd">170000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-1929" unitRef="usd">32000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1930" unitRef="usd">20000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1931" unitRef="usd">23000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-1932" unitRef="usd">228000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-1933" unitRef="usd">-350000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1934" unitRef="usd">-4557000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1935" unitRef="usd">38000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-1936" unitRef="usd">7597000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-1937" unitRef="usd">-2473000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1938" unitRef="usd">-1266000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1939" unitRef="usd">52000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-1940" unitRef="usd">1777000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-1941" unitRef="usd">-571000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1942" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1943" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-1944" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-1945" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1946" unitRef="usd">-5823000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1947" unitRef="usd">90000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-1948" unitRef="usd">9374000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-1949" unitRef="usd">-3044000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1950" unitRef="usd">-5803000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1951" unitRef="usd">113000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-16" decimals="-3" id="f-1952" unitRef="usd">9602000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-17" decimals="-3" id="f-1953" unitRef="usd">-3394000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1954">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of income tax expense related to the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.584%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28 to December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from January 1 to July 27,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit at Bailiwick of Jersey for Successor and Income tax benefit at Cayman Islands for Predecessor statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S./foreign tax rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State income tax benefit, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Permanent Items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(141.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction bonuses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PPP Loan forgiveness  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;True-Ups&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total income tax (benefit) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(96.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;58.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-14" decimals="3" id="f-1955" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-15" decimals="3" id="f-1956" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-16" decimals="3" id="f-1957" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-17" decimals="3" id="f-1958" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-14" decimals="3" id="f-1959" unitRef="number">0.207</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-15" decimals="3" id="f-1960" unitRef="number">0.177</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-16" decimals="3" id="f-1961" unitRef="number">0.305</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-17" decimals="3" id="f-1962" unitRef="number">0.477</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-14" decimals="3" id="f-1963" unitRef="number">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-15" decimals="3" id="f-1964" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-16" decimals="3" id="f-1965" unitRef="number">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-17" decimals="3" id="f-1966" unitRef="number">0.082</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-14" decimals="3" id="f-1967" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-15" decimals="3" id="f-1968" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-16" decimals="3" id="f-1969" unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-17" decimals="3" id="f-1970" unitRef="number">-0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense contextRef="c-14" decimals="3" id="f-1971" unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense contextRef="c-15" decimals="3" id="f-1972" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense contextRef="c-16" decimals="3" id="f-1973" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense contextRef="c-17" decimals="3" id="f-1974" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-14" decimals="3" id="f-1975" unitRef="number">-0.061</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-15" decimals="3" id="f-1976" unitRef="number">-0.169</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-16" decimals="3" id="f-1977" unitRef="number">-1.410</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-17" decimals="3" id="f-1978" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <wald:EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent contextRef="c-14" decimals="3" id="f-1979" unitRef="number">0</wald:EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent>
    <wald:EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent contextRef="c-15" decimals="3" id="f-1980" unitRef="number">0.086</wald:EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent>
    <wald:EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent contextRef="c-16" decimals="3" id="f-1981" unitRef="number">0</wald:EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent>
    <wald:EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent contextRef="c-17" decimals="3" id="f-1982" unitRef="number">0</wald:EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent>
    <wald:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent contextRef="c-14" decimals="3" id="f-1983" unitRef="number">0</wald:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent>
    <wald:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent contextRef="c-15" decimals="3" id="f-1984" unitRef="number">-0.113</wald:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent>
    <wald:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent contextRef="c-16" decimals="3" id="f-1985" unitRef="number">0</wald:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent>
    <wald:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent contextRef="c-17" decimals="3" id="f-1986" unitRef="number">0</wald:EffectiveIncomeTaxRateReconciliationTransactionCostsPercent>
    <wald:EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent contextRef="c-14" decimals="3" id="f-1987" unitRef="number">0</wald:EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent>
    <wald:EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent contextRef="c-15" decimals="3" id="f-1988" unitRef="number">0</wald:EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent>
    <wald:EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent contextRef="c-16" decimals="3" id="f-1989" unitRef="number">0.144</wald:EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent>
    <wald:EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent contextRef="c-17" decimals="3" id="f-1990" unitRef="number">0</wald:EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent>
    <wald:EffectiveIncomeTaxRateReconciliationTrueUpsPercent contextRef="c-14" decimals="3" id="f-1991" unitRef="number">0</wald:EffectiveIncomeTaxRateReconciliationTrueUpsPercent>
    <wald:EffectiveIncomeTaxRateReconciliationTrueUpsPercent contextRef="c-15" decimals="3" id="f-1992" unitRef="number">0</wald:EffectiveIncomeTaxRateReconciliationTrueUpsPercent>
    <wald:EffectiveIncomeTaxRateReconciliationTrueUpsPercent contextRef="c-16" decimals="3" id="f-1993" unitRef="number">-0.018</wald:EffectiveIncomeTaxRateReconciliationTrueUpsPercent>
    <wald:EffectiveIncomeTaxRateReconciliationTrueUpsPercent contextRef="c-17" decimals="3" id="f-1994" unitRef="number">0.011</wald:EffectiveIncomeTaxRateReconciliationTrueUpsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-14" decimals="3" id="f-1995" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-15" decimals="3" id="f-1996" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-16" decimals="3" id="f-1997" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-17" decimals="3" id="f-1998" unitRef="number">0.034</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <wald:EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent contextRef="c-14" decimals="3" id="f-1999" unitRef="number">-0.114</wald:EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent>
    <wald:EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent contextRef="c-15" decimals="3" id="f-2000" unitRef="number">0</wald:EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent>
    <wald:EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent contextRef="c-16" decimals="3" id="f-2001" unitRef="number">0</wald:EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent>
    <wald:EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent contextRef="c-17" decimals="3" id="f-2002" unitRef="number">0</wald:EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-14" decimals="3" id="f-2003" unitRef="number">0.046</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-15" decimals="3" id="f-2004" unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-16" decimals="3" id="f-2005" unitRef="number">-0.963</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-17" decimals="3" id="f-2006" unitRef="number">0.589</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-14" decimals="-5" id="f-2007" unitRef="usd">-28100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-5" id="f-2008" unitRef="usd">7900000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-2009">The tax effects of temporary differences that give rise to portions of the deferred tax assets and deferred tax liabilities as of December&#160;31, 2022 (Successor Period) and December&#160;31, 2021 (Predecessor Period) are presented below:&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.283%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest to foreign related parties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Formation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other temporary differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-deductible interest carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below market contract&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized research&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment in Waldencast LP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;34,580&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;16,532&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed asset basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(46,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(48,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(3,020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net deferred tax (liabilities) assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(14,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;13,512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,944)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,060)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(22,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <wald:DeferredTaxAssetsAccruedInterestToForeignRelatedParties contextRef="c-7" decimals="-3" id="f-2010" unitRef="usd">1660000</wald:DeferredTaxAssetsAccruedInterestToForeignRelatedParties>
    <wald:DeferredTaxAssetsAccruedInterestToForeignRelatedParties contextRef="c-8" decimals="-3" id="f-2011" unitRef="usd">581000</wald:DeferredTaxAssetsAccruedInterestToForeignRelatedParties>
    <wald:DeferredTaxAssetsLeaseLiabilities contextRef="c-7" decimals="-3" id="f-2012" unitRef="usd">2434000</wald:DeferredTaxAssetsLeaseLiabilities>
    <wald:DeferredTaxAssetsLeaseLiabilities contextRef="c-8" decimals="-3" id="f-2013" unitRef="usd">0</wald:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-7" decimals="-3" id="f-2014" unitRef="usd">0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-8" decimals="-3" id="f-2015" unitRef="usd">4108000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <wald:DeferredTaxAssetsFormationCosts contextRef="c-7" decimals="-3" id="f-2016" unitRef="usd">1509000</wald:DeferredTaxAssetsFormationCosts>
    <wald:DeferredTaxAssetsFormationCosts contextRef="c-8" decimals="-3" id="f-2017" unitRef="usd">1629000</wald:DeferredTaxAssetsFormationCosts>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-7" decimals="-3" id="f-2018" unitRef="usd">13117000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-8" decimals="-3" id="f-2019" unitRef="usd">4995000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-7" decimals="-3" id="f-2020" unitRef="usd">1731000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-8" decimals="-3" id="f-2021" unitRef="usd">81000</us-gaap:DeferredTaxAssetsInventory>
    <wald:DeferredTaxAssetsTransactionCosts contextRef="c-7" decimals="-3" id="f-2022" unitRef="usd">0</wald:DeferredTaxAssetsTransactionCosts>
    <wald:DeferredTaxAssetsTransactionCosts contextRef="c-8" decimals="-3" id="f-2023" unitRef="usd">1358000</wald:DeferredTaxAssetsTransactionCosts>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-7" decimals="-3" id="f-2024" unitRef="usd">646000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-8" decimals="-3" id="f-2025" unitRef="usd">1148000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c-7" decimals="-3" id="f-2026" unitRef="usd">1377000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c-8" decimals="-3" id="f-2027" unitRef="usd">831000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-7" decimals="-3" id="f-2028" unitRef="usd">379000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-8" decimals="-3" id="f-2029" unitRef="usd">379000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetInterestCarryforward contextRef="c-7" decimals="-3" id="f-2030" unitRef="usd">3350000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetInterestCarryforward contextRef="c-8" decimals="-3" id="f-2031" unitRef="usd">1422000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <wald:DeferredTaxAssetsBelowMarketLeaseContract contextRef="c-7" decimals="-3" id="f-2032" unitRef="usd">2373000</wald:DeferredTaxAssetsBelowMarketLeaseContract>
    <wald:DeferredTaxAssetsBelowMarketLeaseContract contextRef="c-8" decimals="-3" id="f-2033" unitRef="usd">0</wald:DeferredTaxAssetsBelowMarketLeaseContract>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-7" decimals="-3" id="f-2034" unitRef="usd">2538000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-8" decimals="-3" id="f-2035" unitRef="usd">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInvestments contextRef="c-7" decimals="-3" id="f-2036" unitRef="usd">3466000</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsInvestments contextRef="c-8" decimals="-3" id="f-2037" unitRef="usd">0</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-7" decimals="-3" id="f-2038" unitRef="usd">34580000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-8" decimals="-3" id="f-2039" unitRef="usd">16532000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill contextRef="c-7" decimals="-3" id="f-2040" unitRef="usd">285000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill contextRef="c-8" decimals="-3" id="f-2041" unitRef="usd">2794000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-2042" unitRef="usd">370000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-8" decimals="-3" id="f-2043" unitRef="usd">226000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-7" decimals="-3" id="f-2044" unitRef="usd">2025000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-8" decimals="-3" id="f-2045" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-7" decimals="-3" id="f-2046" unitRef="usd">46206000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-8" decimals="-3" id="f-2047" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts contextRef="c-7" decimals="-3" id="f-2048" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts contextRef="c-8" decimals="-3" id="f-2049" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-7" decimals="-3" id="f-2050" unitRef="usd">48886000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-8" decimals="-3" id="f-2051" unitRef="usd">3020000</us-gaap:DeferredIncomeTaxLiabilities>
    <wald:DeferredTaxAssetsNetBeforeValuationAllowance contextRef="c-7" decimals="-3" id="f-2052" unitRef="usd">-14306000</wald:DeferredTaxAssetsNetBeforeValuationAllowance>
    <wald:DeferredTaxAssetsNetBeforeValuationAllowance contextRef="c-8" decimals="-3" id="f-2053" unitRef="usd">13512000</wald:DeferredTaxAssetsNetBeforeValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-3" id="f-2054" unitRef="usd">7944000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-8" decimals="-3" id="f-2055" unitRef="usd">14060000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities contextRef="c-7" decimals="-3" id="f-2056" unitRef="usd">22250000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-8" decimals="-3" id="f-2057" unitRef="usd">548000</us-gaap:DeferredTaxLiabilities>
    <wald:SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock contextRef="c-1" id="f-2058">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses and tax credit carryforwards as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Successor Period) and  December&#160;31, 2021 (Predecessor Period) were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.214%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.805%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.805%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.585%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Expiration Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Expiration Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses, federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Do Not Expire&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Do Not Expire&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating losses, state&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2039-2042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2039-2041&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax Credits, federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2038-2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2038-2039&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax Credits, state&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Do Not Expire&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Do Not Expire&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</wald:SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock>
    <us-gaap:OperatingLossCarryforwards contextRef="c-450" decimals="-3" id="f-2059" unitRef="usd">50772000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-451" decimals="-3" id="f-2060" unitRef="usd">20880000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-452" decimals="-3" id="f-2061" unitRef="usd">39366000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-453" decimals="-3" id="f-2062" unitRef="usd">9772000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-450" decimals="-3" id="f-2063" unitRef="usd">283000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-451" decimals="-3" id="f-2064" unitRef="usd">283000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-452" decimals="-3" id="f-2065" unitRef="usd">121000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-453" decimals="-3" id="f-2066" unitRef="usd">121000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-7" decimals="-5" id="f-2067" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-8" decimals="-5" id="f-2068" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-2069">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Waldencast&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Prior to the Business Combination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sponsor Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Sponsor purchased 7,187,500 Class B ordinary shares for an aggregate purchase price of $0.025 million, or approximately $0.003 per share (the &#x201c;sponsor shares&#x201d;). In February 2021, the Sponsor transferred 20,000 Class B ordinary shares to each of the Company&#x2019;s then-serving independent directors, Ms. Sarah Brown, Ms. Juliette Hickman, Ms. Lindsay Pattison and Mr. Zack Werner (the &#x201c;Investor Directors&#x201d;), resulting in the Sponsor holding 7,107,500 Class B ordinary shares. In March 2021, Waldencast effected a share capitalization resulting in the Sponsor holding an aggregate of 8,545,000 Class B ordinary shares. As such, the Sponsor and the Investor Directors collectively owned 20% of Waldencast&#x2019;s issued and outstanding shares upon consummation of its IPO. In connection with the Business Combination, 8,625,000 sponsor shares held by the Sponsor and Investor Directors converted automatically, on a one-for-one basis, into one Class A ordinary share in accordance with their terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Forward&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Purchase Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with Waldencast&#x2019;s IPO, in February  2021, the Sponsor and Zeno (a member of the Sponsor) entered into the Sponsor FPA, which was subsequently amended by the assignment and assumption agreement entered into by and between the Sponsor and Burwell in December 2021. Under the assignment and assumption agreement, Sponsor assigned, and Burwell assumed, all of the Sponsor&#x2019;s rights and benefits under the Sponsor FPA, pursuant to which, Burwell and Zeno committed to subscribe for and purchase 16,000,000 Class A ordinary shares and 5,333,333 warrants for an aggregate commitment amount of $160.0 million in connection with the closing of Waldencast&#x2019;s initial business combination. In addition, Beauty Ventures entered into the Third-Party FPA with Waldencast in March 2021, pursuant to which Beauty Ventures committed to subscribe for and purchase up to 17,300,000 Class A ordinary shares and up to 5,766,666 warrants for an aggregate commitment amount of $173.0 million, in connection with the closing of the Company&#x2019;s initial business combination. Members of the Sponsor or their affiliates will begin to receive a twenty percent (20%) performance fee allocation on the return of the forward purchase securities in excess of the hurdle rate, calculated on the total return generated from forward purchase securities (whether by dividend, transfer or increase in value as measured from date of issuance), when the return of such securities (less the expenses of Beauty Ventures) underlying the Third-Party FPA exceeds a hurdle rate of five percent (5%) accrued annually until the fifth anniversary of the issuance of such securities. In the event of a transfer and subsequent sale of any forward purchase securities prior to such fifth anniversary, the performance fee for the period between such transfer and such fifth &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;anniversary will be calculated based on the proceeds generated by such sale. The FPA investments were consummated substantially concurrently with the consummation of the Business Combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Private&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Placement Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Simultaneously with the consummation of the IPO, the Sponsor purchased 5,933,333 Private Placement Warrants at a purchase price of $1.50 per private placement warrant, or $8.9 million in the aggregate. Each Private Placement Warrant entitles the holder to purchase one Class A ordinary share for $11.50 per share. The Private Placement Warrants may not be redeemed by the Company so long as they are held by the Sponsor or its permitted transferees. If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the  Private Placement Warrants will be redeemable by the Company and exercisable by the holders on the same basis as the Public Warrants. The Sponsor, or its permitted transferees, has the option to exercise the Private Placement Warrants on a cashless basis. The Private Placement Warrants are identical to the Public Warrants, except that the Private Placement Warrants: (i) are not redeemable by the Company, (ii) may be exercised for cash or on a cashless basis so long as they are held by the Sponsor or any of its permitted transferees and (iii) are entitled to registration rights (including the Class A ordinary shares issuable upon exercise of the private placement warrants). Additionally, the purchasers agreed not to transfer, assign or sell any of the Private Placement Warrants, including the Class A ordinary shares issuable upon exercise of the Private Placement Warrants (except to certain permitted transferees), until 30 days after the completion of the Business Combination. In connection with the Business Combination, each of the 5,933,333 Private Placement Warrants converted automatically into a warrant to acquire one Class A ordinary share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Registration Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of the sponsor shares, Private Placement Warrants, and warrants that were issued upon conversion of the Working Capital Loan (as defined below) (and any Class A ordinary shares issuable upon (i) the exercise of the Private Placement Warrants, including the Working Capital Warrants (as defined below) and (ii) the conversion of the sponsor shares) are entitled to registration rights pursuant to a registration rights agreement dated March 15, 2021 (the &#x201c;Legacy Registration Rights Agreement&#x201d;) requiring the Company to register such securities for resale (in the case of the sponsor shares, only after conversion to Class A ordinary shares). The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain &#x201c;piggy-back&#x201d; registration rights with respect to registration statements filed subsequent to the completion of the Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company is responsible for the expenses incurred in connection with the filing of any such registration statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Sponsor, the members of the Sponsor and certain of the Company&#x2019;s shareholders, Obagi and Milk and certain of their respective affiliates entered into an amended and restated registration rights agreement, dated July 27, 2022, with the Company (the &#x201c;Registration Rights Agreement&#x201d;), pursuant to which the Company agreed to register for resale, pursuant to Rule 415 under the Securities Act, certain Class A ordinary shares and our other securities that are held by the parties thereto from time to time, subject to the restrictions on transfer therein. The Registration Rights Agreement amended and restated the Legacy Registration Rights Agreement and terminates with respect to any party thereto, on the date that such party no longer holds any Registrable Securities (as defined therein).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, the Company filed a registration statement on Form F-1 to register up to 121,120,063 Class A ordinary shares, consisting of (i) 8,545,000 Class A ordinary shares converted from the sponsor shares; (ii) 80,000 Class A ordinary shares converted from the sponsor shares held by the Investor Directors; (iii) 20,000 Class A ordinary shares issued to Aaron Chatterley in a private placement exempt from registration pursuant to Section 4(a)(2) of the Securities Act, and Rule 506 of Regulation D promulgated thereunder, in connection with the consummation of the Business Combination; (iv) 28,237,506 Class A ordinary shares issued pursuant to the Obagi Merger Agreement; (v) 21,104,225 Class A ordinary shares issuable in exchange for 21,104,225 Class B ordinary shares pursuant to the Milk Equity Purchase Agreement; (vi) 11,800,000 Class A ordinary shares issued in the PIPE investments; (vii) 33,300,000 Class A ordinary shares issued pursuant to the FPAs; and (viii) 18,033,332 Class A ordinary shares issuable in respect of the private placement warrants, pursuant to the Registration Rights Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Related Party Notes and Advances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, Waldencast issued a promissory note to the Sponsor (the &#x201c;January Note&#x201d;), pursuant to which Waldencast could borrow an aggregate principal amount of $0.3 million. The note was non-interest bearing and payable on the completion of the IPO. There were no borrowings outstanding under the note at the closing of the IPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, Waldencast issued a promissory note to the Sponsor, pursuant to which it could borrow up to an aggregate principal amount of $1,500,000 from the Sponsor (the &#x201c;Working Capital Loan&#x201d;). The note was non-interest bearing, unsecured and due and payable in full on the earlier of (x) March 18, 2023 and (y) the date Waldencast consummated its initial business combination. In October 2021, Waldencast drew down the entire available balance of the promissory note and the Sponsor deposited $1,500,000 in Waldencast&#x2019;s operating bank account. As of the Closing Date, there was a total aggregate principal amount of $1,500,000 in outstanding borrowings under the Convertible Working Capital Note. In connection with the closing of Business Combination, the Sponsor elected to convert $1,500,000 of the Working Capital Loan balance into warrants at a price of $1.50 per warrant for a total of 1,000,000 warrants (the &#x201c;Working Capital Warrants&#x201d;). The Working Capital Warrants issuance was exempt from registration pursuant to Section 4(a)(2) of the Securities Act, and Rule 506 of Regulation D promulgated thereunder. Borrowings under the Convertible Working Capital Note are no longer available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, Waldencast issued working capital promissory notes to the Sponsor on (i) in May 2022, for up to $600,000 (&#x201c;May Working Capital Note&#x201d;) and (ii) July 2022, for up to $450,000 (&#x201c;July Working Capital Note&#x201d; and, together with May Working Capital Note, the &#x201c;Non-Convertible Working Capital Notes&#x201d;), in each case, for working capital purposes. As of the Closing Date, there was a total aggregate principal amount of $1,050,000 in outstanding borrowings under the Non-Convertible Working Capital Notes. In connection with the closing of Business Combination, the aggregate outstanding balance under the Non-Convertible Working Capital Notes of $1,050,000 was repaid to the Sponsor. Borrowings under the Non-Convertible Working Capital Notes are no longer available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Administrative Services Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Waldencast entered into an agreement whereby, commencing on March 15, 2021, through the earlier of the consummation of a business combination or a liquidation, Waldencast agreed to pay the Sponsor a monthly fee of $10,000 for office space, administrative, financial and support services. Waldencast incurred approximately $65,000 in administrative expenses under the agreement through the Closing Date, but ceased to incur these fees following the completion of the Business Combination. As of December 31, 2022 (Successor Period), the Company had $0.4 million in related party accounts payable in consolidated balance sheets. The Company ceased to incur these fees following the completion of the Business Combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lock-Up Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to a Letter Agreement, dated March 15, 2021, between the initial shareholders of Waldencast Acquisition Corp. and Waldencast (the &#x201c;Letter Agreement&#x201d;), such shareholders agreed not to transfer, assign or sell any of their sponsor shares until the earlier to occur of: (A) one year after the Closing Date; and (B) following the Closing Date, (x) if the last reported sale price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share sub-divisions, share dividends, rights issuances, consolidations, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within any 30-trading day period commencing at least 150 days after the Company&#x2019;s initial business combination or (y) the date on which it completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of its public shareholders having the right to exchange their ordinary shares for cash, securities or other property (except with respect to permitted transferees) (the &#x201c;Letter Agreement Lock-Up Provisions&#x201d;). Any permitted transferees would be subject to the same restrictions and other agreements of the initial shareholders of Waldencast Acquisition Corp. with respect to any sponsor shares. Such Letter Agreement Lock-Up Provisions expired on July 27, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, pursuant to the Sponsor FPA, Burwell and Zeno agreed not to transfer, assign or sell any of their Class A ordinary shares according to the same Letter Agreement Lock-Up Provisions. Any permitted transferees would be subject to the same restrictions and other agreements as a purchaser under the Sponsor FPA. The Sponsor FPA lock-up period expired on July 27, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Waiver and Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the consummation of the Business Combination, the Company waived certain provisions as contemplated by the Letter Agreement and certain other agreements related thereto (collectively, the &#x201c;Waiver&#x201d;), with respect to any securities held by an Insider (as defined in the Letter Agreement) as of the closing the Business Combination (the &#x201c;Lock-Up Securities&#x201d;) that would disallow a pledge by such Insider of the Lock-Up Securities in a transaction for the purpose of financing such Insider&#x2019;s payment obligations owed in connection with the closing of the Business Combination. In connection with such Waiver, the Company entered into that certain Waiver and Agreement, dated as of July 25, 2022, with Burwell (the &#x201c;Waiver and Agreement&#x201d;), to permit a pledge by Burwell of its Lock-Up Securities to be used as a portion of the collateral under a loan to finance Burwell&#x2019;s payment obligations under the Sponsor FPA in connection with the closing of the Business Combination. Pursuant to the terms of the Waiver and Agreement, in the event of a foreclosure, any such lenders or a collateral agents will be required to execute a joinder to the Letter Agreement pursuant to which they will be bound by the transfer restrictions of the Lock-Up Securities (including the foreclosure of or other exercise of remedies under any such loan documentation) in the Letter Agreement for the duration of such agreement. We also agreed to provide any such lender or collateral agent with customary registration rights in the event of default, foreclosure or other exercise of remedies following the respective Lock-Up Periods (as defined in the Letter Agreement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indemnification Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Business Combination, the Company entered into indemnification agreements with each of its directors. The indemnification agreements provide, to the fullest extent permitted under law, indemnification against all expenses, judgments, fines and amounts paid in settlement relating to, arising out of or resulting from an indemnitee&#x2019;s status as a director, officer, employee, fiduciary or agent of the Company or any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other entity which such person is or was serving at the Company&#x2019;s request as a director, officer, employee or agent. In addition, the indemnification agreements provide that the Company will advance, to the extent not prohibited by law, the expenses incurred by the indemnitee in connection with any proceeding, and such advancement will be made within thirty (30) days after the receipt by the Company of a statement requesting such advances from time to time, whether prior to or after final disposition of any proceeding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Transactions with Cedarwalk in connection with the Business Combination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Obagi China Distribution, the Company entered into an Intellectual Property License Agreement (the &#x201c;IP License Agreement&#x201d;), a Global Supply Services Agreement (the &#x201c;Supply Agreement&#x201d;), and a Transition Services Agreement (the &#x201c;Transition Services Agreement&#x201d;) with Obagi Hong Kong, which is owned by Cedarwalk, the former owner of Obagi and a beneficial holder of 24.5% of the Company&#x2019;s fully diluted Class A ordinary shares as of the closing of the Business Combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the IP License Agreement, the Company exclusively licenses intellectual property relating to the Obagi brand to the Obagi China Business, and the Company retains the rights to such intellectual property to conduct the Obagi-branded business worldwide except for the China Region. The Obagi China Business pays the Company a royalty of 5.5% of gross sales of licensed products. During the period from July 28 to December&#160;31, 2022 (Successor Period) net revenue generated from related party royalties was $0.2 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Supply Agreement, the Company supplies or causes to be supplied through certain Obagi CMOs products for distribution and sale in the China Region by the Obagi China Business. The term of the Supply Agreement is perpetual, subject to termination for material breach and failure to cure or termination in the event that the IP License Agreement is terminated. The Company anticipates it will continue supplying the Obagi China Business with products at an agreed-upon markup, net of agreed-upon discounts as applicable until the Obagi China Business has been added as a party to Obagi&#x2019;s CMO agreements, at which time it will then order directly from the CMOs. During the period from July 28 to December&#160;31, 2022 (Successor Period) net revenue generated from supplying products to the Obagi China Business was $17.0 million&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and the related cost of goods sold was $5.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 (Successor Period), the Company had $0.3&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million in related party accounts receivable from the Obagi China Business in the consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Transition Services Agreement, the Company provided Obagi Hong Kong and its affiliates certain transition services to enable them to conduct the Obagi China Business as a going concern in the China Region. The transition services were provided for an initial term of up to &lt;span style="-sec-ix-hidden:f-2134"&gt;twelve&lt;/span&gt; (12) months, with an option for Obagi China Business to extend the service period for up to an additional &lt;span style="-sec-ix-hidden:f-2135"&gt;twelve&lt;/span&gt; (12) months solely as to certain R&amp;amp;D services. Obagi Hong Kong did not elect to extend the services and as a result the Transition Services Agreement expired on July 27, 2023. Services under the agreement were to be charged at the reasonable, fully-loaded costs of providing the services, but such services were to be provided at no charge for a certain period of time or up to a specified dollar value of services (the &#x201c;Threshold Amount&#x201d;). The Company determined that the Threshold Amount may be applied towards a combination of the Company&#x2019;s services or inventory purchases made by the Obagi China Business under the Supply Agreement. Due to the fact that the Threshold Amount had not been reached at the time of expiration, the Company received no fees from the Obagi China Business during the period ended December 31, 2022 (Successor Period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Predecessor&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Operational Support Services Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, Obagi Cosmeceuticals LLC (&#x201c;Obagi Cosmeceuticals&#x201d;) entered into an operational support services agreement with Obagi Holdings Company Limited (&#x201c;Obagi Holdco&#x201d;), Obagi Hong Kong and Obagi Shanghai Cosmeceuticals Co. Ltd., a subsidiary of Obagi Hong Kong (&#x201c;Obagi Shanghai&#x201d;), pursuant to which Obagi Cosmeceuticals provided certain services, including administrative and product related services, to the other signatories party thereto. The agreement terminated with respect to Obagi Hong Kong and Obagi Shanghai in connection with the Obagi China Distribution (as defined below). Under the agreement, which automatically renewed for a one-year term on January 1, 2021, Obagi Cosmeceuticals received service fees in an amount equal to the sum of its costs incurred in the performance of such services plus five percent (5%). Total service fees paid to Obagi Cosmeceuticals were $1.1, $3.5, $4.6 and $0.9 million for the 2022 Successor Period, 2022 Predecessor Period, for the year ended December 31, 2021 (Predecessor Period), and for the year ended December 31, 2020 (Predecessor Period), respectively. There were no service fees paid to Obagi Shanghai in the 2022 Successor Period, as the agreement was terminated upon closing of the Business Combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-Exclusive Marketing Services Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, Obagi Holdco and Obagi Shanghai entered into a non-exclusive marketing services agreement, pursuant to which Obagi Shanghai provided certain sales and marketing services to Obagi Holdco in the People&#x2019;s Republic of China. Under the agreement, which terminated upon closing of the Business Combination, Obagi Shanghai received service fees in an amount equal to the sum of its costs incurred in the performance of such services plus five percent (5%). Total service fees paid to Obagi Shanghai were $2.1, $2.6 and $0.6 million for the 2022 Predecessor Period, for the year ended December 31, 2021 (Predecessor Period), and for the year ended December 31, 2020 (Predecessor Period), respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Registration with National Medical Products Administration in China&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, Cedarwalk paid approximately $4.1 million to register Obagi&#x2019;s products with the National Medical Products Administration in China in exchange for 8,000,000 shares of Obagi common stock. This non-cash capital contribution was recorded as additional paid-in capital in Obagi&#x2019;s consolidated statements of shareholders&#x2019; equity for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Obagi China Distribution&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a condition to the Obagi Merger Agreement, prior to the Closing Date, Obagi Holdco distributed to Obagi and then Obagi distributed to Cedarwalk all of the issued and outstanding shares of capital stock of Obagi Hong Kong and certain related assets pursuant to distribution agreements in the Obagi China Distribution, as discussed in &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 4&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Business Combinations.&#x201d; The Obagi China Business had been conducted through Obagi Hong Kong and its subsidiaries. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milk subleases from Milk Studios Los Angeles LLC certain space in Los Angeles, CA on a month-to-month basis. Milk primarily uses these facilities for corporate offices and as an in-house studio. During the period from July 28 to &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2022 (Successor Period), the Company incurred administrative fees of $0.1 million, which is recorded in SG&amp;amp;A expenses in consolidated statements of operations and comprehensive loss.&lt;/span&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-454"
      decimals="INF"
      id="f-2070"
      unitRef="shares">7187500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-454" decimals="-3" id="f-2071" unitRef="usd">25000.000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-455"
      decimals="3"
      id="f-2072"
      unitRef="usdPerShare">0.003</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-456"
      decimals="INF"
      id="f-2073"
      unitRef="shares">20000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-457"
      decimals="INF"
      id="f-2074"
      unitRef="shares">7107500</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-458"
      decimals="INF"
      id="f-2075"
      unitRef="shares">8545000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="c-459"
      decimals="2"
      id="f-2076"
      unitRef="number">0.20</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-460"
      decimals="INF"
      id="f-2077"
      unitRef="shares">8625000</us-gaap:CommonStockSharesOutstanding>
    <wald:ConversionOfStockToCommonStockConversionRatio
      contextRef="c-460"
      decimals="INF"
      id="f-2078"
      unitRef="number">1</wald:ConversionOfStockToCommonStockConversionRatio>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-461"
      decimals="INF"
      id="f-2079"
      unitRef="shares">16000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-462"
      decimals="INF"
      id="f-2080"
      unitRef="shares">5333333</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-463" decimals="-5" id="f-2081" unitRef="usd">160000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-464"
      decimals="INF"
      id="f-2082"
      unitRef="shares">17300000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-465"
      decimals="INF"
      id="f-2083"
      unitRef="shares">5766666</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-466" decimals="-5" id="f-2084" unitRef="usd">173000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <wald:ForwardPurchaseAgreementPerformanceFeeAllocationPercentage
      contextRef="c-467"
      decimals="2"
      id="f-2085"
      unitRef="number">0.20</wald:ForwardPurchaseAgreementPerformanceFeeAllocationPercentage>
    <wald:ForwardPurchaseAgreementHurdleRate
      contextRef="c-467"
      decimals="2"
      id="f-2086"
      unitRef="number">0.05</wald:ForwardPurchaseAgreementHurdleRate>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-468"
      decimals="INF"
      id="f-2087"
      unitRef="shares">5933333</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-469"
      decimals="2"
      id="f-2088"
      unitRef="usdPerShare">1.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-468" decimals="-5" id="f-2089" unitRef="usd">8900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <wald:ConversionOfStockToCommonStockConversionRatio
      contextRef="c-469"
      decimals="INF"
      id="f-2090"
      unitRef="number">1</wald:ConversionOfStockToCommonStockConversionRatio>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-469"
      decimals="2"
      id="f-2091"
      unitRef="usdPerShare">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <wald:ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination contextRef="c-468" id="f-2092">P30D</wald:ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-470"
      decimals="INF"
      id="f-2093"
      unitRef="shares">5933333</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <wald:ConversionOfStockToCommonStockConversionRatio
      contextRef="c-471"
      decimals="INF"
      id="f-2094"
      unitRef="number">1</wald:ConversionOfStockToCommonStockConversionRatio>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-472"
      decimals="INF"
      id="f-2095"
      unitRef="shares">121120063</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-473"
      decimals="INF"
      id="f-2096"
      unitRef="shares">8545000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-474"
      decimals="INF"
      id="f-2097"
      unitRef="shares">80000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-475"
      decimals="INF"
      id="f-2098"
      unitRef="shares">20000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-476"
      decimals="INF"
      id="f-2099"
      unitRef="shares">28237506</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-477"
      decimals="INF"
      id="f-2100"
      unitRef="shares">21104225</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-478"
      decimals="INF"
      id="f-2101"
      unitRef="shares">21104225</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-479"
      decimals="INF"
      id="f-2102"
      unitRef="shares">11800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-480"
      decimals="INF"
      id="f-2103"
      unitRef="shares">33300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-481"
      decimals="INF"
      id="f-2104"
      unitRef="shares">18033332</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-482" decimals="-5" id="f-2105" unitRef="usd">300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ShortTermBorrowings contextRef="c-483" decimals="-3" id="f-2106" unitRef="usd">0</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-484" decimals="-3" id="f-2107" unitRef="usd">1500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-485" decimals="-3" id="f-2108" unitRef="usd">1500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-486" decimals="-3" id="f-2109" unitRef="usd">1500000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-486" decimals="-3" id="f-2110" unitRef="usd">1500000</us-gaap:LongTermDebt>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-486"
      decimals="2"
      id="f-2111"
      unitRef="usdPerShare">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-486"
      decimals="INF"
      id="f-2112"
      unitRef="shares">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-487" decimals="-3" id="f-2113" unitRef="usd">0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-488" decimals="-3" id="f-2114" unitRef="usd">600000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-489" decimals="-3" id="f-2115" unitRef="usd">450000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebt contextRef="c-490" decimals="-3" id="f-2116" unitRef="usd">1050000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-490" decimals="-3" id="f-2117" unitRef="usd">1050000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-491" decimals="-3" id="f-2118" unitRef="usd">0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:AdministrativeFeesExpense contextRef="c-492" decimals="-3" id="f-2119" unitRef="usd">10000</us-gaap:AdministrativeFeesExpense>
    <us-gaap:AdministrativeFeesExpense contextRef="c-493" decimals="-3" id="f-2120" unitRef="usd">65000</us-gaap:AdministrativeFeesExpense>
    <us-gaap:AccountsPayableCurrent contextRef="c-494" decimals="-5" id="f-2121" unitRef="usd">400000</us-gaap:AccountsPayableCurrent>
    <wald:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod contextRef="c-492" id="f-2122">P1Y</wald:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod>
    <wald:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger
      contextRef="c-495"
      decimals="2"
      id="f-2123"
      unitRef="usdPerShare">12.00</wald:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger>
    <wald:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays
      contextRef="c-492"
      decimals="INF"
      id="f-2124"
      unitRef="tradingday">20</wald:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays>
    <wald:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays
      contextRef="c-492"
      decimals="INF"
      id="f-2125"
      unitRef="tradingday">30</wald:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays>
    <wald:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays contextRef="c-492" id="f-2126">P150D</wald:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays>
    <wald:IndemnificationAgreementAdvanceExpensePeriod contextRef="c-496" id="f-2127">P30D</wald:IndemnificationAgreementAdvanceExpensePeriod>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="c-183"
      decimals="3"
      id="f-2128"
      unitRef="number">0.245</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <wald:RoyaltyPercentageOfGrossSales
      contextRef="c-497"
      decimals="3"
      id="f-2129"
      unitRef="number">0.055</wald:RoyaltyPercentageOfGrossSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-498" decimals="-5" id="f-2130" unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-499" decimals="-5" id="f-2131" unitRef="usd">17000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-499" decimals="-5" id="f-2132" unitRef="usd">5100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-500" decimals="-5" id="f-2133" unitRef="usd">300000</us-gaap:AccountsReceivableNetCurrent>
    <wald:ServicesAgreementRenewalTerm contextRef="c-502" id="f-2136">P1Y</wald:ServicesAgreementRenewalTerm>
    <wald:ServicesAgreementFeePercentageOfIncurredCosts
      contextRef="c-503"
      decimals="2"
      id="f-2137"
      unitRef="number">0.05</wald:ServicesAgreementFeePercentageOfIncurredCosts>
    <wald:PaymentsForServicesAgreementFees contextRef="c-504" decimals="-5" id="f-2138" unitRef="usd">1100000</wald:PaymentsForServicesAgreementFees>
    <wald:PaymentsForServicesAgreementFees contextRef="c-505" decimals="-5" id="f-2139" unitRef="usd">3500000</wald:PaymentsForServicesAgreementFees>
    <wald:PaymentsForServicesAgreementFees contextRef="c-506" decimals="-5" id="f-2140" unitRef="usd">4600000</wald:PaymentsForServicesAgreementFees>
    <wald:PaymentsForServicesAgreementFees contextRef="c-507" decimals="-5" id="f-2141" unitRef="usd">900000</wald:PaymentsForServicesAgreementFees>
    <wald:PaymentsForServicesAgreementFees contextRef="c-508" decimals="-5" id="f-2142" unitRef="usd">0</wald:PaymentsForServicesAgreementFees>
    <wald:ServicesAgreementFeePercentageOfIncurredCosts
      contextRef="c-509"
      decimals="2"
      id="f-2143"
      unitRef="number">0.05</wald:ServicesAgreementFeePercentageOfIncurredCosts>
    <wald:PaymentsForServicesAgreementFees contextRef="c-510" decimals="-5" id="f-2144" unitRef="usd">2100000</wald:PaymentsForServicesAgreementFees>
    <wald:PaymentsForServicesAgreementFees contextRef="c-511" decimals="-5" id="f-2145" unitRef="usd">2600000</wald:PaymentsForServicesAgreementFees>
    <wald:PaymentsForServicesAgreementFees contextRef="c-512" decimals="-5" id="f-2146" unitRef="usd">600000</wald:PaymentsForServicesAgreementFees>
    <us-gaap:PaymentsForFees contextRef="c-513" decimals="-5" id="f-2147" unitRef="usd">4100000</us-gaap:PaymentsForFees>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-514"
      decimals="INF"
      id="f-2148"
      unitRef="shares">8000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:AdministrativeFeesExpense contextRef="c-515" decimals="-5" id="f-2149" unitRef="usd">100000</us-gaap:AdministrativeFeesExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-2151">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Purchase commitments represent unconditional purchase obligations to purchase goods or services, primarily inventory, that are enforceable and legally binding on the Company and specify all significant terms, including fixed or minimum quantities to be purchased, price provisions, and the approximate timing of the transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into a certain development and production agreement with a third-party vendor in which the Company is committed to purchase from the vendor certain units of Skintrinsiq devices totaling $5.7&#160;million. As of December 31, 2022, the Company&#x2019;s associated future minimum payment was $1.4 million over the next 12-18 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into an unconditional purchase order with third-party product manufacturers for the delivery of inventory in which the Company is committed to purchase from the manufacturers certain product inventory totaling $8.2 million. As of December 31, 2022, the Company&#x2019;s associated future minimum payment was $7.0 million over the next 12-18 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Except for the SEC investigation described in &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_187" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;Note 21&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Subsequent Events&lt;/span&gt;.&#x201d; the Company is not involved in any material litigation nor, to management&#x2019;s knowledge, was any material litigation threatened against the Company, which if adversely determined could have a material adverse impact on the Company other than routine litigation arising in the ordinary course of business,</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LongTermPurchaseCommitmentAmount contextRef="c-517" decimals="-5" id="f-2152" unitRef="usd">5700000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:PurchaseObligation contextRef="c-518" decimals="-5" id="f-2153" unitRef="usd">1400000</us-gaap:PurchaseObligation>
    <us-gaap:LongtermPurchaseCommitmentPeriod contextRef="c-519" id="f-2154">P12M</us-gaap:LongtermPurchaseCommitmentPeriod>
    <us-gaap:LongtermPurchaseCommitmentPeriod contextRef="c-520" id="f-2155">P18M</us-gaap:LongtermPurchaseCommitmentPeriod>
    <us-gaap:LongTermPurchaseCommitmentAmount contextRef="c-521" decimals="-5" id="f-2156" unitRef="usd">8200000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:PurchaseObligation contextRef="c-522" decimals="-5" id="f-2157" unitRef="usd">7000000.0</us-gaap:PurchaseObligation>
    <us-gaap:LongtermPurchaseCommitmentPeriod contextRef="c-523" id="f-2158">P12M</us-gaap:LongtermPurchaseCommitmentPeriod>
    <us-gaap:LongtermPurchaseCommitmentPeriod contextRef="c-524" id="f-2159">P18M</us-gaap:LongtermPurchaseCommitmentPeriod>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-2160">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;SEGMENT REPORTING&lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reports segment information based on the management approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of our reportable segments. Prior to the consummation of the Business Combination, the Predecessor operated its business and reported its results through a single operating and reportable segment. Following the Business Combination, the Company determined that it has two operating and reportable segments: Obagi Skincare and Milk Makeup. See. &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_127" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 3&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Obagi Skincare &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;- this segment consists of the business of Obagi. Obagi&#x2019;s business activities include developing, marketing, and selling skin health products. These assets and activities are conducted by Obagi Global Holdings Limited and its wholly-owned subsidiaries.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milk Makeup&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - this segment consists of the business of Milk. Milk&#x2019;s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Milk generates revenue from the sale of cosmetics to retailers, including off-price retailers, and sales DTC via its website. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Central costs include operating expenses related to corporate overhead expenses such as personnel-related costs, professional fees, interest expense related to the 2022 Credit Agreement, and the change in the fair value of derivatives. These costs are not used in evaluating the results of, or in allocating resources to, the Company&#x2019;s segments.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies of the segments are the same as those described in &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_124" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 3&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of financial measures of the Company&#x2019;s segments to the consolidated totals:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.604%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28 to December 31, 2022&lt;br/&gt;(Successor):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Obagi Skincare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Milk Makeup&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the performance of its reportable segments based on segment gross profit. Segment gross profit is segment revenue less segment cost of goods sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles segment gross profit to net income (loss) before income taxes for the period from July 28 to December&#160;31, 2022 (Successor Period):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from&lt;br/&gt;July 28 to December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on impairment of goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value of derivative warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expenses (income), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(126,360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(120,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not evaluate performance or allocate resources based on segment asset data, and therefore such information is not presented. All of the Company&#x2019;s and the Predecessor&#x2019;s long-lived assets are located in the U.S.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-14"
      decimals="INF"
      id="f-2161"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-14"
      decimals="INF"
      id="f-2162"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-2163">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of financial measures of the Company&#x2019;s segments to the consolidated totals:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.604%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.579%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28 to December 31, 2022&lt;br/&gt;(Successor):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Obagi Skincare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Milk Makeup&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;61,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;92,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-196" decimals="-3" id="f-2164" unitRef="usd">61090000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-229" decimals="-3" id="f-2165" unitRef="usd">31283000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-2166" unitRef="usd">92373000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-196" decimals="-3" id="f-2167" unitRef="usd">44973000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-229" decimals="-3" id="f-2168" unitRef="usd">15684000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-14" decimals="-3" id="f-2169" unitRef="usd">60657000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-196" decimals="-3" id="f-2170" unitRef="usd">16117000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-229" decimals="-3" id="f-2171" unitRef="usd">15599000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-14" decimals="-3" id="f-2172" unitRef="usd">31716000</us-gaap:GrossProfit>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-2173">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles segment gross profit to net income (loss) before income taxes for the period from July 28 to December&#160;31, 2022 (Successor Period):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from&lt;br/&gt;July 28 to December 31, &lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Successor&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;88,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss on impairment of goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;68,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value of derivative warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expenses (income), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(126,360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(120,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:GrossProfit contextRef="c-14" decimals="-3" id="f-2174" unitRef="usd">31716000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-14" decimals="-3" id="f-2175" unitRef="usd">88926000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-14" decimals="-3" id="f-2176" unitRef="usd">1796000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-14" decimals="-3" id="f-2177" unitRef="usd">68715000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:InterestExpense contextRef="c-14" decimals="-3" id="f-2178" unitRef="usd">6230000</us-gaap:InterestExpense>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-14" decimals="-3" id="f-2179" unitRef="usd">-6793000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-14" decimals="-3" id="f-2180" unitRef="usd">798000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-2181" unitRef="usd">-126360000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-2182" unitRef="usd">-120557000</us-gaap:ProfitLoss>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c-1" id="f-2185">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;EMPLOYEE BENEFIT PLAN&lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors a Section&#160;401(k)&#160;retirement plan and pension plans for employees in the U.S. and the United Kingdom. During the period from July 28 to December&#160;31, 2022 (Successor Period), the period from January 1 to July&#160;27, 2022 (Predecessor Period), and the years ended December&#160;31, 2021 and 2020 (Predecessor Periods) the Company&#x2019;s contributions to the plan were $0.3 million, $0.4 million, $0.6 million, and $0.5 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-14" decimals="-5" id="f-2186" unitRef="usd">300000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-15" decimals="-5" id="f-2187" unitRef="usd">400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-16" decimals="-5" id="f-2188" unitRef="usd">600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-17" decimals="-5" id="f-2189" unitRef="usd">500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-2190">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;SUBSEQUENT EVENTS &lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023,&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company granted an aggregate of 2,290,000 stock growth incentive awards&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(the &#x201c;SGI Awards&#x201d;) in performance share units to certain Waldencast employees, in an amount up to 200% of the target share units allocated to the program, which are based on meeting the respective Company&#x2019;s net revenue and EBITDA targets for the year ended December 31, 2025. The SGI Awards had a grant date fair value of $8.88 and require a one-year post vesting holding period once the shares have been awarded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-term Incentive (&#x201c;LTI&#x201d;) Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, the LTI Awards were modified to waive the performance conditions for most Obagi and Waldencast employees, other than the Chief Executive Officer of Obagi and the Chief Executive Officer and Chief Growth Officer of Waldencast. Based on the financial statements prepared by the Company for the period ended December 31, 2022, the Board has certified that the applicable performance goals have not been met and, accordingly, that the 2022 RSUs granted to our founders will not vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Texas Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, Obagi entered into two leases for office and warehouse space in Texas as part of their plans to  relocate the headquarters from California. Obagi&#x2019;s corporate headquarters were located in Long Beach, California until September 2022, when Obagi moved its headquarters to Houston, Texas under a lease that will expire in July 2032. In January 2024, Obagi will relocate its headquarters back to its Long Beach offices, where it occupies facilities totaling approximately 28,300 rentable square feet under a lease that expires in June 2026.  Obagi entered into a sublease for the office space in Texas once Obagi relocates to California that will run through December 2025. The Obagi warehouse facilities located in Conroe, Texas are subject to a lease that will expire in February 2031 and Obagi plans to sublease those facilities subject to finding a tenant. ROU assets as of December 31, 2022 associated with the office and warehouse were $4.0 million and $2.5 million, respectively. The Company is in the process of assessing whether or not impairment exists.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Transaction with the SA Distributor&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, as part of the Company&#x2019;s strategy to internalize distribution channels in key markets, certain of Obagi&#x2019;s subsidiaries entered into and consummated a Purchase Agreement (the &#x201c;Vietnam Purchase Agreement&#x201d;) with Obagi Vietnam and the SA Distributor, pursuant to which, among other terms, Obagi acquired certain assets of Obagi Vietnam from the SA Distributor and in return, the SA Distributor received forty percent (40%) of the outstanding equity of Obagi Blue Sea Holding, LLC, a subsidiary of Obagi and the parent company of Obagi Vietnam. The Vietnam Purchase Agreement also provided the SA Distributor with a potential earnout payment based upon the net revenue of the business of Obagi Vietnam during the twelve-month period ending on December 31, 2026, subject to setoff for any owed obligations. The Company currently does not anticipate that any such earnout payment will be payable. The SA Distributor does not currently have any active participation in the Obagi Vietnam business other than as a silent shareholder. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022 Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in &#x201c;&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_139" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 8&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#x201d; Borrower and Waldencast Partners LP and JPMorgan, entered into a waiver and consent to the 2022 Credit Agreement in May 2023, August 2023 and December 2023. The 2022 Credit Agreement was amended in September 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Subscription Agreement with PIPE Investors&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2023, the Company entered into subscription agreements (the &#x201c;Subscription Agreements&#x201d;) with certain investors (collectively, the &#x201c;2023 PIPE Investors&#x201d;), pursuant to, and on the terms and subject to the conditions of which, the 2023 PIPE Investors collectively subscribed for 14,000,000 Class A ordinary shares (the &#x201c;PIPE Shares&#x201d;), in a private placement at a purchase price of $5.00 each per share, for aggregate gross proceeds of $70.0&#160;million (the &#x201c;2023 PIPE Investment&#x201d;). The Subscription Agreements relating to approximately $68.0&#160;million of proceeds were consummated in September 2023, and the closings of Subscription Agreements relating to the remaining approximately $2.0&#160;million occurred in November 2023, following receipt of regulatory approvals (the &#x201c;2023 PIPE Closings&#x201d; and the date on which such Closing occurred, the &#x201c;PIPE Closing Date&#x201d;).&#x201d; No Class B ordinary shares, warrants or other securities of the Company were issued in connection with the 2023 PIPE Investment. As a result, the Company had a total of 122,076,410 ordinary shares issued and outstanding, including 101,228,857 Class A ordinary shares issued and outstanding and 20,847,553 class B ordinary shares issued and outstanding, as of December 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;SEC Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, the audit committee of the Board, engaged in a review of certain accounting practices applied to the Company&#x2019;s financial statements for the Predecessor Period and Successor Period through December 31, 2022. The Company proactively and voluntarily self-reported the review to the SEC. In connection with this matter, the Company  received a document subpoena from the SEC in September 2023. Although the Company is fully cooperating with the SEC&#x2019;s investigation and continues to voluntarily respond to requests related to this matter, it cannot predict when the SEC will complete its investigation or its outcome and potential impact such outcome may have on the Company&#x2019;s business. Any remedial measures, sanctions, fines or penalties, including, but not limited to, financial penalties and awards, injunctive relief and compliance conditions, imposed on the Company could have a material adverse effect on its business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Nasdaq Capital Market Listing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s securities are listed on The Nasdaq Capital Market. In May 2023, the Company received written notice from Nasdaq indicating that, as a result of not having timely filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, it was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the SEC. In July 2023, the Company obtained an extension from Nasdaq permitting it to regain compliance provided it filed this Report no later than October 30, 2023. On October 31, 2023, the Company received a written notice from the Listing Qualifications Staff of Nasdaq (the &#x201c;Listing Qualifications Staff&#x201d;) indicating that, based upon its non-compliance with the filing requirement as of October 30, 2023, the Listing Qualifications Staff had determined to delist the Company&#x2019;s securities from Nasdaq by opening of business on November 9, 2023 unless the Company timely requested a hearing before the Nasdaq Hearings Panel. On November 7, 2023, by requesting a hearing (the &#x201c;Hearing&#x201d;) before the Nasdaq Hearings Panel (the &#x201c;Panel&#x201d;), the Company appealed the determination of the Listing Qualifications Staff to the Panel and requested that the stay of delisting, which otherwise would have expired on November 22, 2023, be extended until the Panel issued a final decision on the matter. On November 22, 2023, Nasdaq granted the Company&#x2019;s request to extend the stay. Accordingly, the Company&#x2019;s securities will continue to trade on The Nasdaq Capital Market until the Panel issues a final decision regarding its listing status following the Hearing scheduled for February 8, 2024, or, if earlier, upon receipt of confirmation from Nasdaq that the Company has regained compliance with Nasdaq&#x2019;s continued listing standards. On January 3, 2024, we received an additional notice of non-compliance from the Listing Qualifications Staff due to the Company not having filed interim financial statements for the period ended June 30, 2023 with the SEC by December 31, 2023, as required by Nasdaq Listing Rule 5250(c)(2). The notice indicated that the Panel will consider this additional notice as part of its determination regarding the Company&#x2019;s continued listing on The Nasdaq Capital Market. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Online Marketplace Distributor Contract Termination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Company entered into a termination agreement with the U.S. Online Marketplace Distributor. The termination agreement provides the U.S. Online Marketplace Distributor with a termination fee in exchange for the return of all existing inventory purchased from Obagi, deactivation of all online marketplace listings by the U.S. Online Marketplace Distributor, and full satisfaction of the remaining outstanding accounts receivable balance within defined payment terms. The termination agreement includes contractual protections designed to ensure that the Company is only providing a return credit for valuable inventory which excludes short-dated or damaged products. The termination of the U.S. Online Marketplace Distributor shall enable the Company to fully control the online marketplace distribution of Obagi products, including both product quality and customer service.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-525"
      decimals="INF"
      id="f-2191"
      unitRef="shares">2290000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent
      contextRef="c-525"
      decimals="2"
      id="f-2192"
      unitRef="number">2</wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-525"
      decimals="2"
      id="f-2193"
      unitRef="usdPerShare">8.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c-525" id="f-2194">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <wald:NumberOfLeaseAgreements
      contextRef="c-526"
      decimals="INF"
      id="f-2195"
      unitRef="lease">2</wald:NumberOfLeaseAgreements>
    <us-gaap:NetRentableArea contextRef="c-527" decimals="0" id="f-2196" unitRef="sqft">28300</us-gaap:NetRentableArea>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-528" decimals="-5" id="f-2197" unitRef="usd">4000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-529" decimals="-5" id="f-2198" unitRef="usd">2500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="c-530"
      decimals="2"
      id="f-2199"
      unitRef="number">0.40</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <wald:BusinessAcquisitionEarnoutPeriod contextRef="c-531" id="f-2200">P12M</wald:BusinessAcquisitionEarnoutPeriod>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-532"
      decimals="INF"
      id="f-2201"
      unitRef="shares">14000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-533"
      decimals="2"
      id="f-2202"
      unitRef="usdPerShare">5.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-534" decimals="-6" id="f-2203" unitRef="usd">70000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-532" decimals="-6" id="f-2204" unitRef="usd">68000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-535" decimals="-6" id="f-2205" unitRef="usd">2000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-536"
      decimals="INF"
      id="f-2206"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-537"
      decimals="INF"
      id="f-2207"
      unitRef="shares">122076410</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-537"
      decimals="INF"
      id="f-2208"
      unitRef="shares">122076410</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-538"
      decimals="INF"
      id="f-2209"
      unitRef="shares">101228857</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-538"
      decimals="INF"
      id="f-2210"
      unitRef="shares">101228857</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-539"
      decimals="INF"
      id="f-2211"
      unitRef="shares">20847553</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-539"
      decimals="INF"
      id="f-2212"
      unitRef="shares">20847553</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock contextRef="c-1" id="f-2213">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) &lt;/span&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The parent company financial statements for Waldencast Plc should be read in conjunction with the Company&#x2019;s Consolidated Financial Statements and the accompanying notes thereto. For purposes of this condensed financial information, the Company&#x2019;s wholly owned and majority owned subsidiaries are recorded based upon its proportionate share of its subsidiaries&#x2019; net assets (similar to presenting them on the equity method). Waldencast plc has no material operations of its own and conducts substantially all of its activities through its wholly owned subsidiaries. Waldencast plc has no significant assets or liabilities other than derivative warrant liabilities and cash, most expenditures paid by Waldencast plc are allocated to its subsidiaries. Waldencast Finco Limited, a wholly-owned indirect subsidiary of Waldencast plc, is the borrower under the 2022 Credit Agreement. The terms and conditions of the 2022 Credit &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agreement (see &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#if2fc25067f8b45fc8cc165df93f3be1c_139" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 8&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for definition) limit the ability of Waldencast plc&#x2019;s wholly owned subsidiaries to make certain distributions or dividends, subject to a number of enumerated exceptions. Due to the aforementioned restrictions, substantially all of the Successor period net assets of Waldencast Plc&#x2019;s subsidiaries are restricted. Since the restricted net assets of consolidated subsidiaries exceed 25% of the consolidated net assets of the Company and its subsidiaries, the accompanying condensed parent company financial statements have been prepared in accordance with Rule 12-04, Schedule 1 of Regulation S-X. This information should be read in conjunction with the accompanying Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following condensed financial statements have been presented on a &#x201c;parent-only&#x201d; basis. Under a parent-only presentation, Waldencast plc&#x2019;s investment in its subsidiaries is presented under the equity method of accounting. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;WALDENCAST PLC&lt;br/&gt;(PARENT COMPANY ONLY)&lt;br/&gt;CONDENSED BALANCE SHEET&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In thousands of U.S. dollars, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CURRENT ASSETS:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment in subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;823,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;TOTAL ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;827,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;LIABILITIES AND SHAREHOLDERS' EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CURRENT LIABILITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intercompany payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;TOTAL LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SHAREHOLDERS&#x2019; EQUITY:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Successor Class A ordinary shares, $0.0001 par value, 1,000,000,000 shares authorized; and 86,460,560 outstanding as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Successor Class B ordinary shares, $0.0001 par value, 1,000,000,000 shares authorized; and 21,104,225 outstanding as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;796,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(156,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;TOTAL CONTROLLING SHAREHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;639,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncontrolling Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;160,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;TOTAL SHAREHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;799,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;827,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;WALDENCAST PLC&lt;br/&gt;(PARENT COMPANY ONLY)&lt;br/&gt;CONDENSED STATEMENT OF OPERATIONS &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In thousands of U.S. dollars, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;For the period from July 28 to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value of derivative warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before equity in undistributed earnings of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity in undistributed earnings of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(102,379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(95,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive (loss) income &#x2014; foreign currency translation adjustments, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(95,596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;WALDENCAST PLC&lt;br/&gt;(PARENT COMPANY ONLY)&lt;br/&gt;CONDENSED STATEMENT OF CASH FLOW &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In thousands of U.S. dollars)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28 to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CASH FLOWS FROM OPERATING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(95,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments to reconcile net loss to net cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash (used in) provided by operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity in income of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value of derivative warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net cash provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CASH FLOWS FROM INVESTING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Proceeds from trust&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net cash provided by investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CASH FLOWS FROM FINANCING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transfers from subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transfers to subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses paid on behalf of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net cash used in financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(3,282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CASH, CASH EQUIVALENTS AND RESTRICTED CASH - Beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CASH, CASH EQUIVALENTS AND RESTRICTED CASH - end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="c-1" id="f-2214">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following condensed financial statements have been presented on a &#x201c;parent-only&#x201d; basis. Under a parent-only presentation, Waldencast plc&#x2019;s investment in its subsidiaries is presented under the equity method of accounting. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;WALDENCAST PLC&lt;br/&gt;(PARENT COMPANY ONLY)&lt;br/&gt;CONDENSED BALANCE SHEET&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In thousands of U.S. dollars, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CURRENT ASSETS:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment in subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;823,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;TOTAL ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;827,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;LIABILITIES AND SHAREHOLDERS' EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CURRENT LIABILITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intercompany payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;TOTAL LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;27,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SHAREHOLDERS&#x2019; EQUITY:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Successor Class A ordinary shares, $0.0001 par value, 1,000,000,000 shares authorized; and 86,460,560 outstanding as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Successor Class B ordinary shares, $0.0001 par value, 1,000,000,000 shares authorized; and 21,104,225 outstanding as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;796,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(156,780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;TOTAL CONTROLLING SHAREHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;639,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Noncontrolling Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;160,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;TOTAL SHAREHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;799,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;827,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-540" decimals="-3" id="f-2215" unitRef="usd">3215000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AssetsCurrent contextRef="c-540" decimals="-3" id="f-2216" unitRef="usd">3215000</us-gaap:AssetsCurrent>
    <wald:InvestmentInSubsidiary contextRef="c-540" decimals="-3" id="f-2217" unitRef="usd">823936000</wald:InvestmentInSubsidiary>
    <us-gaap:Assets contextRef="c-540" decimals="-3" id="f-2218" unitRef="usd">827151000</us-gaap:Assets>
    <wald:IntercompanyPayables contextRef="c-540" decimals="-3" id="f-2219" unitRef="usd">8942000</wald:IntercompanyPayables>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c-540" decimals="-3" id="f-2220" unitRef="usd">18311000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-540" decimals="-3" id="f-2221" unitRef="usd">27253000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-541"
      decimals="4"
      id="f-2222"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-541"
      decimals="INF"
      id="f-2223"
      unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-541"
      decimals="INF"
      id="f-2224"
      unitRef="shares">86460560</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-541" decimals="-3" id="f-2225" unitRef="usd">8000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-542"
      decimals="4"
      id="f-2226"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-542"
      decimals="INF"
      id="f-2227"
      unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-542"
      decimals="INF"
      id="f-2228"
      unitRef="shares">21104225</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-542" decimals="-3" id="f-2229" unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-540" decimals="-3" id="f-2230" unitRef="usd">796038000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-540" decimals="-3" id="f-2231" unitRef="usd">-156780000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-540" decimals="-3" id="f-2232" unitRef="usd">-29000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-540" decimals="-3" id="f-2233" unitRef="usd">639239000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-540" decimals="-3" id="f-2234" unitRef="usd">160659000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-540" decimals="-3" id="f-2235" unitRef="usd">799898000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-540" decimals="-3" id="f-2236" unitRef="usd">827151000</us-gaap:LiabilitiesAndStockholdersEquity>
    <srt:ScheduleOfCondensedIncomeStatementTableTextBlock contextRef="c-1" id="f-2237">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;WALDENCAST PLC&lt;br/&gt;(PARENT COMPANY ONLY)&lt;br/&gt;CONDENSED STATEMENT OF OPERATIONS &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In thousands of U.S. dollars, except share and per share data)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;For the period from July 28 to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value of derivative warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before equity in undistributed earnings of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity in undistributed earnings of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(102,379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(95,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive (loss) income &#x2014; foreign currency translation adjustments, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(95,596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfCondensedIncomeStatementTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-543" decimals="-3" id="f-2238" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-543" decimals="-3" id="f-2239" unitRef="usd">0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss contextRef="c-543" decimals="-3" id="f-2240" unitRef="usd">0</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet contextRef="c-543" decimals="-3" id="f-2241" unitRef="usd">19000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-543" decimals="-3" id="f-2242" unitRef="usd">6793000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-543" decimals="-3" id="f-2243" unitRef="usd">6812000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-543" decimals="-3" id="f-2244" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-543" decimals="-3" id="f-2245" unitRef="usd">6812000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromSubsidiariesNetOfTax contextRef="c-543" decimals="-3" id="f-2246" unitRef="usd">-102379000</us-gaap:IncomeLossFromSubsidiariesNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-543" decimals="-3" id="f-2247" unitRef="usd">-95567000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-543" decimals="-3" id="f-2248" unitRef="usd">-29000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-543" decimals="-3" id="f-2249" unitRef="usd">-95596000</us-gaap:ComprehensiveIncomeNetOfTax>
    <srt:ScheduleOfCondensedCashFlowStatementTableTextBlock contextRef="c-1" id="f-2250">&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.220%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;WALDENCAST PLC&lt;br/&gt;(PARENT COMPANY ONLY)&lt;br/&gt;CONDENSED STATEMENT OF CASH FLOW &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(In thousands of U.S. dollars)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Period from July 28 to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CASH FLOWS FROM OPERATING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(95,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjustments to reconcile net loss to net cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash (used in) provided by operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity in income of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in fair value of derivative warrant liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net cash provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CASH FLOWS FROM INVESTING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Proceeds from trust&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net cash provided by investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;6,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CASH FLOWS FROM FINANCING ACTIVITIES:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transfers from subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transfers to subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses paid on behalf of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net cash used in financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(3,282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,137&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CASH, CASH EQUIVALENTS AND RESTRICTED CASH - Beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CASH, CASH EQUIVALENTS AND RESTRICTED CASH - end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;3,215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfCondensedCashFlowStatementTableTextBlock>
    <us-gaap:ProfitLoss contextRef="c-543" decimals="-3" id="f-2251" unitRef="usd">-95567000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromSubsidiariesNetOfTax contextRef="c-543" decimals="-3" id="f-2252" unitRef="usd">-102379000</us-gaap:IncomeLossFromSubsidiariesNetOfTax>
    <us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities contextRef="c-543" decimals="-3" id="f-2253" unitRef="usd">6793000</us-gaap:IncreaseDecreaseInDerivativeAssetsAndLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-543" decimals="-3" id="f-2254" unitRef="usd">19000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <wald:ProceedsFromTrustAccount contextRef="c-543" decimals="-3" id="f-2255" unitRef="usd">6400000</wald:ProceedsFromTrustAccount>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-543" decimals="-3" id="f-2256" unitRef="usd">6400000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromContributionsFromAffiliates contextRef="c-543" decimals="-3" id="f-2257" unitRef="usd">6000000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:PaymentsOfDistributionsToAffiliates contextRef="c-543" decimals="-3" id="f-2258" unitRef="usd">300000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <wald:PaymentsOfExpensesOnBehalfOfSubsidiaries contextRef="c-543" decimals="-3" id="f-2259" unitRef="usd">8982000</wald:PaymentsOfExpensesOnBehalfOfSubsidiaries>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-543" decimals="-3" id="f-2260" unitRef="usd">-3282000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-543" decimals="-3" id="f-2261" unitRef="usd">3137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-544" decimals="-3" id="f-2262" unitRef="usd">78000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-540" decimals="-3" id="f-2263" unitRef="usd">3215000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>130
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MDGW.0G(76OD+UUZ!LY" 7,^SD'SKK/YE9S6]SD("FNA92.X")G_9,4V/LY"
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MGM(!T3O(U]:'=$N7[*8C%D_*DB?6Z?W\$W2LWW31M>2L$BL^Q(I-WGL#FFZ
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M)@  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;*U:76_CMA+]*X2[*+)
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MOT)+OY)<[9-0,/DVD3@QFLRFX>SS@S]>!CZ$2_EX#*;+$&8?838/%N/E@PR
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MI=?H7C@@RD%2&HH7MA>77.G.MMM4SUX4)D"?KSA7>\-<4$_S\ ]02P,$%
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MK];BOJRU.THF&;XER3A4D/G +,H%'ZP\JC7A?'=\ QS*8(_IZ8$;!-I==R&
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MX-\O"YXG[]^("QR?=G?U?U!+ P04    "  D-3!8J9:(,M4,  #T(@  &0
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M!92!DCWF;$*L$?PC@@>+F$ON1_\!:N-X(F#<LNB3!>!/4K,;^'^.4P>I@ZF
M0/Y[&/B,75_J#:-,7$<Z(&(30HR,,?N%C2Q?,^PI?B3BF&];[&0C<PQE;0V(
M,F:&YNH^&^8#M >E/<WPH75/<WR#?9GO(2,;V=B#YKI0=ZJS*V&W%0T9.5#
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M%2KMW?33;KJ[VV@HN-JQ5>.XA9<!4B\00(/F=IC.R9^JR_91FOZPH;F91%T
M/D[%K%VVZJ=%R?N6"YX4,^_;@:.K^:GC[-)J7(5H9TJ\^KD:FHBTAB!=#;8(
MO]80M/<GE?I3254T)LA>N@AK/$-%NVH1[;(H$!%MV1OMAWU:LBD_--NTSP]
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M?!0;(^-.7%-MJB!6X('GCM3BR],N(.*P='/GF*=ZJ7$O!56(5#\2J/2_#Z@
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M90U63Q_I4[!E?U<FU?LGPV&X;,[+MK@L@@S$@,I@ Y(<%#(^8-R:P<0?4&H
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M^B6*N!;E_#T)O9^_?><.TQW59853 5F5X'\7V:II"L J9LV/ROH(-B,'+4#
M?+IIA';U@QG'<'Q@%! 'UXQX;!S%^S#UTUI3@7^#1,<1GQ V](%5>GYCNW4(
M&T?ZWVF< A\#H6Z!XC<D!/!VX1BMZP#NF?R$T4E%P*N+5^]\:F8!'A=;(TU+
MJ80&XY7YI\AH^:,WDAY,^;?'0)!! V]K"93PBML!E6SF((E&"$*> W.F76D2
M@O%.Z,X<RI\XHDP69'@1\W=;?G&2-<2S&$?LX08E#!M!:3@-L *C14.SR)]P
M+$>13#*J)MX;"$V/^^@1'YT X=A+\@^VXTV.0,($ I3U*!+X+UB1$@*)G 2D
M@+HONXK]W@58IX[RC)VA\#"N754JL]C)96EPP_IA&;*?=-6;84:6+Y;^LF1J
M#=M]?DWBQ@*XG]WT76Q; &QH&);+$@4+7A\1.B#,^62( 6 P8DP!57#+B0_!
MO#IJZJ-%@[S@2??=<T^Y?K$M^._$6? I7 8H XZ!\@=PX&4<G61^81-=$A,3
M_"@TF$3D*,>2LH I?N^=))C#Y6,":FK1>^7<SF=9N<28ORE;(C+,]Q08YD<,
MI:LC42"N;\#HM$<%X-O%ACY*KFD.$FTMKI?/Z0,1-TB.*/Z2G#W'/"R? VR*
MEF+I/A8=;TC2I;6KOC(M"P\B"\\#3G#*K$&09PCY8%DG9$(V./XUNB&*" )"
M\G++D?\>)3B8&Y65:!,R'ID!0311#!K>G(G(*'.;X!*#TBBV,5U'YA+GRE2:
M,\;*-O)C@"[;3[8;;CD@I5G@$8M12LK)@)VR!*-Z:<.]"'CS[-T"KL@B(5WE
MK=G2ZR]OMR1,@DCXD! 4F1M4Z(4R$$BKW[)A%TA.TEI\3$;^PE)]02,;(H=(
M4AGL# RZVT+N6%P"/C"( 8O^14 /;+=J34%>:Q<<+X0 X\R:]44^)OH*(BP
MF)L:C2-PCU3&4Z"TKQB-*4$*?8'L  >K[,CUK'<3Q\4ETR/S\G#_3:M:PB)V
M0Y:4,!YN$044Z.BC37/-91Y!A#O6IGLOEZ.<WB@GTG?6D[5$$4$&-718*7F"
MUTRU(ZU[YDU?=)JMP<(/R1._#0FU&["@/(\B;B5QN8M-Y\!I+DWTE\'"5H3
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MU3P [Y5"N(M$;,PXKA($N"U$@=,9<_#*& ,L9,DF#TESD7(DW4G0D2W ["Q
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M_5@D^;W)+6;5CI(\ D6/$+,5IP"7K4$Q3Y5&^R!;M6:[QGZ)T>>*K00$W6Q
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MZV,2%%#O2RX4[OV=YQAPIJ&ZP=E-#7.M4&/JTVQ^)!VDY8:J239@B(PT4!C
M:$830YM^T:%QJE0UX5CZ-UC*A^;%O>3H2QFIK 9.N/#UH<&;83*A6E76URV5
M6[8HUOM:R,=7Y&*T+L!!]"OEA9S 1,<3B85@:B-29]E63H_NF.Z0[(;;^215
M$,0#T1F7SI*F?DS%48JK(Y^6":O.9%G.>!EJT*ETGC6W..]F<<<ZMW;+.&DQ
M_/-1VTT48:/&*:Z>.M0 F\R4U1%3T2%[IW7)U.:%WY%2](C]6)EQQV]XZ4]H
MKDO-IDX/"N1@U]"E]J?T2<PHEZ6M3(* :!H7^&D=!X4+RHV'_O+1PP(*!=Y
M1.KXBYD,I2?SD;:F$=N4Q/5&BL1IPB23YSI)Q',$X /+%\$?P(85PO@2I47D
M%V."BH@[FJT;D0;( 1"9S -)-ZLX?T:B(GK"J6'!=!G:,L=38Z99&=4&CSM^
M'^*=4\:%]_WQ;7[C1LK3!T*3I9T,5FA#70NEJ5G:1AEQQ26I6"1.EI*$3_&)
MG5>]06@F969A>@2FV&J:CD(;L&C%$6LC<"0C9KK4YYVE+;?)/I)JH0$^U_;(
M=78+MFIAJRRI&@/)<'(X]J3]:(!0H<4]/CYX'A333<.- :WUWS7!I2VD>M#&
M77$N&]WWW'*3))HYS(;-HL(>2[)%J&S8/<GNG1Y."!71BA0$(,,P>C.8/ 0M
M+/%@XEA>B1K-SP-VX=F'A\K<=SVH5/#%,)"X^^XPCLZS&Q"1Y#V*_Q[N7938
M%'YVR/=S,L#T?7LKE7^=N94);QR466"Y.PJ@A5V;:LDMY6"WUE3.6OEN-OHF
METOIM^91"!$711*+]T.OPV=;0CR8S"_MVN;1*N@8)C-_HUF]VS6X,'EI:HT^
M2<> )![[33QAZ\6'<U^0>UT:GC]W!);%!HLR,!_?(=;0]8CVDP ,MMP'PXA'
M&8RAF+&N+\+NH(<'CFVM0P)(J'B$I-S'8\FLXYK'=, 89>]&6$FL,/3M_F6Y
MD1C[:M3)#JXNQ<6E+HS6(F?&[\-'(E;3$8$<)8FWY,/XB4RDE3&#*>8*"3S1
MZC?K)L/DG\P(99W@@H\CZ;+P+1HQ$@>-2V'X\!B'J,CV6;/38C@ZTASKWKR,
M\LUT>@);$Q[%RTF'M5-T97 )U";*5Q@%#+S-Z/UZ?8%\;6&\_7.T4FT0S7](
MQ#]78P9U?9%DU-.Y2#[\@$C]:\'S+G%0=MW=JK6I\;M4$-?4026Z8-1)I8$M
MC%>Q03JLTJF;:#I.+ 39*&#?9ZRK1\I9^C*(LT>GGDT?V]L" [,I5.CX C5Y
M(G!NP3=1AP&0,S9S8W40%E*EI!7X8V#26K@$G/%.<$CN2!BB,^:< 8--(C%\
M7=?0?#'=!!K8Z7#C8BN E$?KZ?X:I[OSVN 0RR@,PW7F0A6!%J*O*?*(C:DC
M&G\QVO$OP/9X'. P*DB)V8;'O<=BC/L5_;R#X,_Z$0E[3 #><FR,E#1:('P?
MQ'Z3LW2)H"&]?O)$T['Z_1+Z+3:Q= V*.]*8K#"#$D[%/L4O.*7 4P)81L23
MW33<]<40&T>6)0<;_+5KRF-23'&]'@W,TKFY<7#.5B$6YB=W)/ $PXA-FL@(
MBC*+4LGFIZIQ4"*$%< ?!;3 &POO=FJZS7$],LW9HA]7U#7B$RTXQ:NM=D<:
MS/'O"07)?*F8'H-_.WVFY"N%)#6H[;=434:",PH'C:ENRHU2I$;3->_PG::_
M6R*V4M1E7%H-\DB(S8L.C#UH ?'8Q@D6T];DG[1(5H<\SN)RV7I0Y3D!61@W
M)!/D:&$_YHO2*<@G.&>.Z[B]N.%\?/(]#O*A-'*P#2UMD49JV\$.Y YACLN3
M(9^8UXFQ&[ T[,F(LM^&XU+:CZ2TK+V'%,O0MWT1 16?[[9B4M(\8I5A7E#&
MB-?OM B%V+XF%^E45YK%W]HPJ*H'6E<Y1,S WWF!,Z[%V7QP3$CZQS$@;.=T
MS@35K4O/,49#J';YI^8&BW[(5?__&.WG8[2_><XF@UG' 'WVS:3-.9'@FJ#
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M5U GV<\26%*U" 4$>\9Z:&"2. C=HIP^2@J;N!$2UD'7EV\$?B$$'!$";#%
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M1=,=@DL52PJE<BTS_1^"AP2VG0&_%==WKJH :==Q59>*O @Y!);@F'0! #G
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M"7)G<$!2&GJN1[D4.S$&00//<SX'SR9OVT._VA>#7P[!C5X$@K,#@BA[3SU
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M<5/HLV^X.\5G),WS9$B0#)_[[3%LGX$)RGJGS4_::>^K5 \I8T]3I*>.DOR
MH4V"O-B^6PY#C07D(;:)IV7F?8_'F++*M<X]IQ?5Y>Z' >BIB:B\UM4A-];\
M$@O>P"B,J1CR!=8WQZ>3$UPO\UQPWNFP?7(9>&7PG^R[XTP']]%"+A)RZY8B
MA6RLKZ;=:G>Q?U_?9_OM]5\%;F"B-I+A:QR=34Z.1JCJ\:9=OP1;QMOMR@;<
ME>,CVC8R0S;@^]HBXLV+*.C^W''Y7U!+ P04    "  D-3!87LS9]E4$   *
M"@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6RU5FUOXS8,_BN$KS@T
M@)!8\EO2:P*D+^LZ[(KBTNTP#/N@V$QBU+8R2;ZT^_6C[,1U<6FQ =N71)3)
MAP])D=+Y3NE'LT&T\%06E9EZ&VNW9Z.123=82C-46ZSHRTKI4EH2]7IDMAIE
MUAB5Q4CX?CPJ95YYL_-F[U[/SE5MB[S">PVF+DNIGR^P4+NIQ[W#QI=\O;%N
M8S0[W\HU+M#^LKW7)(TZE"POL3*YJD#C:NK-^=E%Z/0;A5]SW)G>&EPD2Z4>
MG7";33W?$<("4^L0)/U]PTLL"@=$-/[<8WJ=2V?87Q_0?VABIUB6TN"E*K[F
MF=U,O;$'&:YD7=@O:O<C[N.)'%ZJ"M/\PJ[5C0(/TMI85>Z-B4&95^V_?-KG
MH6<P]M\P$'L#T?!N'34LKZ25LW.M=J"=-J&Y11-J8TWD\LH596$U?<W)SLYN
M[Q[F=S>W%S]?PWRQN'Y8?/PP%EQ\NKM^.!]9<N#41ND>[*(%$V^ <0&?564W
M!JZK#+/7 "-BUM$3!WH7XEW$*TR'$' &PA?B';R@"S=H\((W\&Z4RG9Y48"L
M,KBMK*S6^;) F!N#UL!5;M)"F5HC_#Y?&JOIT/QQ+ ^ME_"X%]=(9V8K4YQZ
MU"D&]3?T9A\_\-C_]$X,81=#^![ZORW9NV#'J;[CH9\TV22-046S(U74I\9B
M!FH%=H.P4@4U?%ZM2<WM426Q7*+NJ@FGBSI-T1BEX1YUKK+!&9S>5F2M:D/U
M,0/XVC05@=YH90S,T[0NZT*ZG3MR^J!E1C-*/S;EM$Z"2I8(/(03B*()"\28
M5J<\8>/0'[C-D+-P/(;+IK6(CD;"H_E@-OG6 .<0Q,SW?;)A03@90!"R..*P
MJ+?;XAGD6B/23+(003!F$Z<8D)>(%",6)1&X65'O(6$,8J_$623B 8B$!4D(
M]Q1"1>=-^#!V" -($GA05A9$,8X#)OR&MPB9'P:.=QQ,&(^C_RS]'$[O-6;X
M?Q7 )\ZARV38Y5^X."@?/!9OIM\'BC-(7,)B%OHA94RP21Q_GW]2%2[C3M6G
M$I$J#]F$QZ\KX-0$&\<!G$Y8-"$.G+*;\'X)1 /"R5<TZ:K J? ^58781R&+
M_*8*"6%0^>:ETC;_JW$!^$07I'$9UTWFMTTJ8:55"3_5Q)F.H%7_Z/RSU\:R
MJNF>A(,^@;1XR0'@2 596PGB\8Q2&T WB(]4WVG1PG\#9$>GYD2$0Y_NG**@
M,!F<),.D)_%@&+V(#LYM!2];-$VVV-RYQ?,0KI^<0%1D/W<N9RC3S>'4MIR7
M:'>(E>,7T+96]7KCA*0+CIX?*TOA2.W:8'_8S7>G][=#"EP?]'+0(M,PB%E,
M+4M2V%M'O77<6R<04:M'/CR\$ AHQG >]1KTV( ?]>YG.O3KYA5BJ&GKRK97
M=;?;/73F[?W^HMZ^DCY+O<[I7!>X(E-_F$0>Z/;ET0I6;9O;?JDL=5BSW-!C
M#;53H.\KI>Q!< ZZY]_L;U!+ P04    "  D-3!8EDNJ)7(0  #5-P  &0
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M)4T1M"Q YX6AY+8+-K#^=V3R#U!+ P04    "  D-3!8HK"[P<X'  "K$P
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M/UG)YN%,:SDV1ZQ%FPX-%7G(_6]3K0V_^J0<G5N:_?A2%-7Y-!Q!E6/*:_#
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M%_961'&!H7E1"IE%(LRS$AXJLZK$7%&UC&-!OJ7(1J_R%<4)4(/3A3^$7$%
M82PY>!3DW'@%D55%S(SPJ-TGHL[BJB$RR[.ZQ(:PO1QK%?KQQ8QM4)*$2K&
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M?X8/>''A314^FLV-QXP2'@O!H1D=P/N%09HT"Q+0?46]_ M02P,$%     @
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M*BGGI%>/5QAS.LDL2D8M50=^*RN10$KQHW6D:Y_87>Q2\;J?3[3L@?CS??7
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MR$5MM,AI%RVWR@ZB1C%]2D1%)EDT8AO8([Z&XVSOW/IYA('7'\=E0*A.G;Q
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M(&F4C:#?NLKC[!1)JSV1#F%CT<?L@+EMOH<R^K&"!9>365B/J5?.DY*9Z$X
M]XF(@F HU%F76/C\3''0GO:EY9@W<U9.P2 "UD.M5KR##V^ZTW*DB^-;3[I/
M FD9'4<?%F*EN(BMLON.YY5V[*1DOL[V&R47K%78$AZQ1A+PZ;#2QU;K?ZY
MF:;/N.D4UP1RA [-P%'ZWU7/:82A[/R[123^.IF(/;V&"CU%I6W('<@>:6H[
MXMI"LLY? G4! *H9E&HC24/@9XQ:\YM5+RX: $&4[:JA%7)9+&VA<I:>0<)U
M,P\W/\;L<H$? Y+<UH&:-@!)OJ4:A$4J=I$^U4*(#"3^O"CGF%1R(\+0X^Y\
M5+2 _J$?L]AR:VE>K2I36H$*6<]V1_1H&L*%O>?HQ_-)0SQL56\ZB2?8CKJZ
MZ.-V3)DS/&15&YUXNV]R*")U7,3L/O XS]DW7P^7%!_=IB%IATV+YS9^GPX?
M8Z,A(,A<:*#8#3 0B)3)/34I.J)R"&$V$+\25 W*AZIV9PWDY:DX.YV>>=/6
M4C<4-M+*V?@*UX!H8!T&GWR-U9=-E:V<^&I):MM?&3VRA(*$>0"Z7,?3"^S'
M73U&FQ OW)3-['NI4:R]XL"VN"L(U?@RGDYGCP>&7.F$K'W%#N?@V</^:!L4
MLO-OP&&"JAWVBA DD(#))+Y^I'YM,;7!TNW;VS=A28OV@8TP)SANHS:</][.
M81<*2Q](*B?7\9A2C.E1='(&Z-%4,3XX>M#:8=X1#C7\4I36R,_3!RPS=G3G
MP\:#;6*2J,(?A:8ZD71G.T\>.CVW&1XUY.."8Y*B0DTO-,X^-!O\$!<G:@OI
M0-!(&(\N7&F-W06!A&VZO,C/%;EZ@\4LH;DS#/P2>R*U->6'@1OU73^A$G(2
M!7:=X8$=3*.#6_M6.M;&KZVVA6OCUJ;]FPC;13?5HA=;^\>I-L'6/,FVM[==
M[.O*#^M!B$>IC4D]10W6/Z?850@8 +*^K+#A: OL0F>*^[*G7\Y<2G5-T=4%
MZ]/^K/:^#9FI"]!8YGFT'_<!O(9KI39XD6JYB])B9R&"K ;X+QZ$RKAV)3+7
M)K E\P;#W+R HV4JMR )"%5 <<"ZHX58;+'FCL1>B/R>&N85JNS<1\HW5JI>
M4V^H9/$4V!+AKM#1+,<(.9#A0+1K<;YAATSY05L*4)E[ZRV!['>77D+ZT,0=
M.V0; 81P#A4I'",HAM\UZ_2'Y7E7GJ'FI"47+)CXSK+?84CZ71&BJ0&]I0K?
M4T(F_2_'$:/HU;=PV99O753K]:"5@!_:LIW=S [NM!7%M'V&+1I1;WMO@U]D
M%MNS)U>63:>6,[BH"UY?1O$U(<[0VOM=SIK[T:J!#7$_D-QBQ4U4$O8^&%C"
M[<:_@%5\C,C!6!4&25B9Q (. WQ R$J#2;$#2W^681C/CC<,1V'TQZQ#,+H5
M0F,U_BM!::&(=-%R*U3:$L$>#3GNC%XUF:>06EIE?T!-U@\*XZPZ PW'WMIU
M";]HASQ=[&,:IH#51,*\571$XNFB6JW;SK0K7Q"=OI&Z)5&F(,9.Q8%NU\4'
M<.#-XDVTP6E>4")L5!/%;72!NKU<HD&FJ5<P7@V*@)##T8"0R&SK>KO%PJ"Q
MA!HU)U]L6:HUQ'DU<]+;W+PN:-7\K&D:$JNI08L*(@I)W6' E4ZU1<^EI()K
MEI&<?%5[@M75SW"Y2>7H]*Y*<  $"'5+C?VS9MJ_%BD&N9=A_UC;,)ZK#C94
M,&%8A>PN,I7:+C]K#HU^FV8I\$_'\UV1W)__N@UG^&X;U?1W.)H:I))Q9P4]
M;DS$N7@NK  V1[' ,X+0&G)( )#>CDB>@@7-DGP3AMH"<Y4U/.:K^VU*MVL7
M]0"*TTH<F$R0WL7R^^AT?D;=HCU\&S2^0J&TZ>2KLQ97FH*+4;-BYF2(,ABZ
M@HHJ5$#V<=%0IT_^7HG,(%9NXN;)9#H:C\,9:70MZ6^0RM@V+7]LJL4YCA9A
M/P$R4_[0S1K!![:&ZJ(B6V]B(>5'M"ST2N1VRI<^: [^VHHD5R,5*(2P\]9V
M,O_,3I^AQ\<OR&]0.Q$=$-H'^.IB?!Y\Y:9I L,*060FD7R3V4$S\FLFT)"(
MC80%'6&=M9$ZH>]HVML-55H<_5S)I$T<ZHKWT8'KDCPD32-F=JB3&N#<T&](
M^%H\.'DB)O&D@:W5L$!W#=]C0SX.J\(>)K#.0%8P3:[]VZZK=O> !U74&Y9;
M75@AJ^/P>;[O:>WO.#N6[=(S36HTZL^U:(G:=+GQL&^Q/UW%Y*9A&$5W:&Z.
M0!5=F=(\JQ4V'2Y:D7B['M28RCT8P?T6T];;*Z );Y*C@,)'H/;?R#V*@?WH
M1/>P<J-#1>-M&8((B8*U#/V4_RQPMHX+:![!OL#WR'IMT_GO\(2ZK[6MY4%0
MS;R$I#)SDWK<]&C1N]$6:]/'Q1&N8W,:7FIHY#&,:NTF.V6[M@2N6 ]![-O<
M*"1[V/"PE=<VL&>(E8M7K6/K[:,V;(45JCI1]HD@3T*0&*7*X*CN#F4BD^E*
M^O%&!Z,]^W [[@Z$)M8/8W(^QI.H%,EB<SO8U+L*B,ZX40,&>&7=6;'K;[*V
MBHA'#[W0X<ROIC"U)LU%Z06C2Y!=6,8L8<F?-1J=SIR<'LA)<Z=::KSE;[#
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MP8NBA,B;?EU+ 18'%\#WRP)$VOZ!!_C72+_\+U!+ P04    "  D-3!8"S$
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MRH1O.R:A/ACK5(J"^5T+3C_O%UIG%C2-"DJ4X&A/H#:"9H20>Q!J0Y#:[$_
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MG;ARM #O9Q:.$'_0 ?W'CF_^!U!+ P04    "  D-3!8/Q"CJ,P(  #[%@
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M6G<!4RXME.+Q&E3_8#B@*R&:AE *WD+\AN54Y9!W+]("8 @\'HT01J[J!A3
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M!ZZWG0+9#P"4<$2W7HM97#'<"=Q)@\1N7%<2C/<OHC=\QR^.\GFQ-&*&@L$
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M,E&TKI()D4(V*>PKA=/"W!NT,/F,1?_F#0,;<*C,!_# =.LZS<B*;8.'!E>
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M$4TL(!B#? G/!]5LD@OXJG0%BG[D@;4V2O9N@\Q1'A#=IA IH3&YAD;;8^P
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MLD=RO;60@I0R<[$9V0F9KG5/$HSU0H[/TOUP\)"?!=<*1DDMT.)&J5(Y[$T
M)?UOP+[_)SCV7<8[JG6OW:(FG(3#?C*BV 5L?'(Z>S@QXN+*^V"UZ 7X @CJ
M-^SP%K1\.'\":&F;><-&XB<C(60U*2,\TBPC1=9T%>94P2\E.ENQ E$TE]!M
MG"=A9[FXK;UCW#\E[GF JZ\W]R5:_!MHOT8?9W7:AWREPDL36LFJ'<X?+HR3
MKG>8B)&7''Q%X5'L(Q&&6=$80O<+*(D6QX^'J?1L<OCR\6-GX['5K;@I@.W-
MRZG3U'NOC>Y4%\Y!#<H0<*K&RGW/4I_$-](##9S"&*= )!@L]4.%+K)()7NJ
M%N"L5<X*'HM=]_QXUEZ,P#TN,!67:M?3;E8Y&G52D4R7G7%)'Z5>>IUF]EC9
MMK1'!WK>^C(U-%QH%DP^LP-*UB@Y@_V"<U)8MUB?E0F:>RTC/Z9\^0N,(^TK
MK'F@OCZ\9;G?-A299[B7G!IYR6ZBK?1])1@MLLX2GUESF#&.NLEO#5 CF6A[
M<=3;#Y'+?'9Z]G0RZB/SI/'T[/&HQ<=5B^<A[\E_]\8D0/&E;M["89O6%V4S
MD/QQ^XP@O2^U1D943?HQ41,&G=C0%2Q"K]QFZ2PVEZE"]:OUWQUJ]TX9GE@=
M+2YRC29+DK=U+(1Y_9LRDANQ@ P1+U"?,XO5T.XM5* 8S.5+!F7O1+(><?>'
MT7;(+D3!;C;:@8TT#BZ?-OHFJK,C7?*;< ]9(J'L5>OJ$28;FZ5Y2*H*%[ZQ
M U,YGUB=2F"(V*)02&K8K>0RB</_++;0T-;6)X8R>38BL'=8;B<4]O @A3T\
M/?MADDATSQB60EWSIZBK7MKB/9CU8XB#Z)LO@8\"1Z<,[A[9P((!$QJ5,BI6
MM,.51JTR,\)B+\1&83;_ XE;DXVGKYKK"+T_0Z-ZW%3,!/4P'"210^X'(0S6
M7,[N J%2&2?/(F)10L^3)+2LECK'99U[;LH:X]9G+@7]UD?IX'B;F.5;$% "
M\S#@9#NIF=5H&Q^?8.ZA3QHYJ4'<&\;>0TTQ%\^14DDS:UJKN1,Y?IY>34E/
MGXA+QYZ(B5K[LK&#8 M'U#6]0\E+0SK^;9-AS6"^/9AZ1_9T5YYT7"Y_DT;R
MZ,_F;E&@3#I<%<6P(E_9U+@X_A]G:=_'T3PT;^-H/TZ2PX9WGYF%)RT34VW;
M^YC(\]ER2B.B WQ&1L9?\/EXJUF<(7B)$8AN>YUW/Z$\LS,"-T'Y@UR":96N
MC"5W5;E)U=-#GJ!=BFZ7/4?(=-!XM! T,=0L:K_F?FL>)+RH^07*OVR61'ET
M5[V7@:3_Z.J\P89E?K#>OL<0W1S?OZKX/_Y6+>(VM6&C[0_CP+3U:N3B_.A-
M\C]*5J/9" \H-/0R;=/G/X-6NW87KBA0.('D^N4>YBCX;]%JPZN2GIW/[SV
M-\/CSW_>I6OWEOJJ8B'L"EX]F_[P^!['-_5#6^UP2*S4 16:_MRX%) 8'X#?
M5U75Z@><X*:JO]#RGO]?4$L#!!0    ( "0U,%A;*<WC9!8  $E3   9
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MM8,"49I@G-XQMPF^'A1.' _E4%/!;%.65>3MS!0<&:&)."-4D=1-'Y\A_J$
M]ZZXR%Y=*$88[:"$B@TJ"A.#?X7,*2'9G)C1!,%!,;9BS5GV,,2:3_31" V.
MDQ<2$$!!;1?[&HJ1^IH"8VD[&"U&[,AY\25>'Q+&_":*:?UQ:)KF_'>6IE'I
MX=10']J=AALCU8NEIUOLJ/_I;5'<:$7Q'<$R3K DQ*E'%?H;^E5&?FKX @[T
MZ;GQ%JTV(6QS^EV-N,_3B-EM&.W7BCT,JA9#80_%E^%XN"_IV\;$PEDFE:LF
MH!TE71#+\%'ERHBZ.2T_AHJG729 @CUD9%X2Y>HEN2S[SGF1\(<EBYS](08!
MYO@NOT\Q*S2P7$=$X6,56N]B2EFJV;&!D VE\-;MR52+W+9)+X?"2H-E/&T8
M%\=J%;_R&-\0=T+'-(%D2E^"K0/@RFGD*TK_LHR*.=2W1FOAY.2NE7LE$;-\
MKN^TJ3AU .:ZI,]<+\0\9*X2!TX-VK6,7*ZMXJGIE-'US!Y#33FZ5PD)-]$[
M"5AOJTB68;\]F-YB/S_ I0^G77HKKWL![7*&97UD6_FC\JL?5D7:5>SA$I+E
MV?C?U!S'!'S6\7."@"+SJ:0T@%-Y+F!S-<GQJ=(#3U)+>=4M]EA49O)]$_^;
MCMVJ]O3$JV[AQ]!<S\)?6[,]@XH^.^9>R0D0&&&:" X5))/=#L)C2]M%^(#F
M;0[40VA586!CQKV9Y!ZBT4^F]C#9AA\1G8H1#]J.V378O(*#?%V^5(XJ:-((
ML"4A5^5-%A6GV'MUW@[U)XA28?)8\]APB>>P)K4XI4Y5+ZU[+:NL+#DU0M'Z
MFBD;D" I]S=J*&B56!63JX8N Q[) >MM\I(V^/<NY,!$<BO1<5^>YVV/-YW(
M]K*\K@DP>SSNX&H*<]F*'4.>B[0L]M5&B_L+QFO"G-YZY $>R,,P]&T;HU%Q
MOWO^3%<A*:6'BK959:&.#B)OG.^ _+?HP23ER42 \&BEZCI)G5F',W"M&?KL
MV$N^U2"IZ3;+R6$Z?_/&A:?IGM/>N-B%5 0[:.#23H*M^;0]0?%@!9N"\.Z*
MAQ"R4]!CF9:P/9,L>ADB3-7U6=ZG\"R3\<GT^M&+!@@\>M*A;16%7DW"UMVH
ML&W-,2VU',VP_./#=RJVXI:A;:235 ^LB5ZO2U84&.;6*;5WAB;*)&99FN>T
M QRS0[5IB'*=:;CB['97TM XN/EBD.Y;;+W ';LU^U$WZ2O<0PS+99HKU]RU
ML]&2QJ'"0.S=-,I>&4SH& '+X,_C'A&TX^\T7,:P0>8FE12F&Z/4"^38NE'>
M*;_F* =+6A&O+N&P,>E]47-3FHK+6QTN#R!S>H'LN8&INW/"">J&:^\1\OVQ
M41?*<&$^0^3U4" [M"_,;EC'^ ;[U&8?C*4 YUC+OU1UOZV<6B^MTDU=.%5Y
M;)R4IDCWZEF46-%H\NEY7+\ZGTA#GDQS6MGB#\FC>D-SKSF0(4PHXBR>3DKV
M<9\>-&]5\3:941]/.4Q'3Z IO:(I#6<?H^C2D)_"+T9;]F+6SR\HNF "]4U\
MW$<2#%OS @#W%^#EG ]-D6SF:9BT2XI\S $IKZX?]YU7L-6WAED1@)ZRI,9P
ML4D(7#-@&K!EYW(K%)K=+*=,?_9L8?;L-:H 1+-28>6@&BLOYD>A^1.64-K=
MZ>UUO<WSDOD#@'?K?5O&4Z6SRN%YV#GQI'+'Z2%#9'Z5WMWQ\+@K7W%M<;5S
ML+4<0$7_D_LX"<7'%< !0Z_'^H(+]I'$6J-N[\_?!56&JBK#SK-V0K>'\W"[
MF)0,NQ)9*T^_I!1O#WL<MZ]2L;5:VU)/%=ZCSIY]-6U$ZY#VB?KV)D@R*MKV
M?*N"<2NHOJCN^E-4>W!4WEM&-#7=# XL(/IF;]A%4+9,IU4Q;*7[G3AK:B82
MO)<7"'>RP%9-\* Z8$\L4UO6K2)?9TOTD!2FYA![-V37N][<"=[&.G9LHSVM
M0+A%U!/"MK"[5=DU_79EIXLAE WV.4-WHZ]=G'^:]5N[PLC?1A_WE;6>12;W
M[8[J[<3M)2'C^86BT0(T-OZW.D3$$RS"9,9@&N:@N3EO!KB.6__M.:E+*1FB
M::+JSO+N3DY5OKI^4+<\+=4]3-S6>U5Y!U^)L3K:ZLOS%?M_ C7$$>-%N65'
M1QUK"T;B?W4YOKHX/QW=GIV*CZ.+T>7)F1C_?G9VVQ4738QW.2.L(B2?I+W)
M)1D.Y?$TQR4E]GR% </COF#<<S(5QGHCEY"GC#I'J%NGI3OW;VA[C1UY5'\1
MB=%X?'8[%B=?;F[X+#U?OA$G=(20;9,^R*\KX,^\VK4QP;CM5AVOOD6](II2
MO]S.=?3Z(?H\VH9HKJ59KM?0Z3MA^)IG^74H0CHMC$"SK*#$@IDP#<TUC,W2
M@*<%MDUT/O#0TSWL**AWKCA])LM0QF99CA@X2!YB87I!B4-KSQBZK=D NH'M
M:%8 '',"3;<\BMG06Z$\F 2T5#L7M!Q+<WR>@N6C\S^%H1D!K67-V-7#7J Y
MGEW+J;S\#;'@ <XJ(!+;#^JOR\NRY)\FK]:GJ]F!1Z>S31VK_TN8OB]NKVY'
M%Y6F :86YL?[;@/;UP)?';SV;4S:%1?GHX_G%^>WYV=C?K%B_/OHYNSWJXO3
MLYOQ_XBS__UR?ONOVEI:#[]IE+L,'YDJH5-#LSR'-_HLW1%S92FNKXN3<M9D
MOV4LF*?)[!6%5T3922$,B-LWZ7QY,EP,Z=*VS34USN-P$L^YV$(=![X%3D$I
MWD*-8ZVIM/V\%6B>K6-F.JS#UC4?$[SH3$&IQ] MZ-^J%5!=GU:[U>4V=Q%^
M[_3OV'[=ACYO:JSS-$R::!6OU?&,4F=M;1A0/9^-QXQM7$$^MM>KGS>=>('9
M+?AH*P(,3,YT-%W7Z5]Y2X0K!"MZ\2%ZR\4\'1K,!/R=JJ)^^;19/5U&2.;!
MJX(/?'#9:PN@V#Q2;;U\-6H.CY/KOJ)ZBJK 0;JZ9AAM::MK&-=JL5+\/9((
MYG0ZBU-_GRKWF*$#Z:5BX-J:;\/RVPT47Z<::B;OZ<6L;V6V-S"=XWHHOE!B
M[S5Z/]#,0&\&@P&9"$>;BMKJ-GM<CW7_BM/2A0SI'/#=:M[%F>:EIZM/XNKZ
M[*9\V8F&/+GZ?(TQSR['YW^<B<'%U7A\_&(HV@GU^U%I#7N?#U.7K6T+B%%W
MX01!!X+JETA"$JEM:K0E=++)K!R"&KL\>C#1EEHF'(<C^F^\4P*:=@?CRM"+
M[VDV$**G$RC/TWU6(OXV-I0U+^4<\%*( 9 S;4O D&R_V5R::DOA(YJY/JV_
M_\T05PL"HS%=/X#)1UI((02B"4QH"\8.TE+41V[:U N>HSL(EH:E!3J_S4,^
M\R<&KKI4@9,@+NQP3[970&Q 87V@A,GU.L0CQ"WZ"$?1Z;6@NNV G.VX"I34
M@:9[70(Q +B[M CZ" X 5P1<2F)SU=!E. :6@A;6*Z<]. 40^,+P$<)5>4)^
MIZ%7<7[?'"\"J@"2#:]N7?U5=W\CQHZFU]?7Z";D:L4,>N*ZS<#5?-,^WFA:
MW:_&[91$>JM1G7$=QP'947\50C2[ETI>Q^6Z@X8B0$*Z 5%+*-ZHWZ]24:YJ
MU4H6J/DO, O?MKJD37-T(MH^@ 3\YJ*MI F?'VYA&R$L2(75,CJ32 9OGVJ\
M@7K> .%@ JG!C>II,!70C?826-T)C-\%N)!_<TB&_CW]>,,V,-/CZJ.'C_7S
M2]E%N#?B8X@T6#E,/%]1\$ [?:B79>6A;5<?,/>Q C7> :WWV<AFD_8 6WMN
MT+'Y]-2E7/6@4]=CJO:DDGB6E'1F^JC* ?.-O*:N$K$J:/][PVKIYLDF(-*T
M='/GG%V]\K@?!56$5#\3J/3_'E !V4'4NEZGWG DE HHL_#[\,6D/,@IS\4I
MD#(150-W$Z1<\$"K%^F@K  @.5!_GPM2CLVI'8 ./+DZ]4 0Y>J8O;$=H@ M
M9BMO<6P!W 2GM_9A$_%KE[')I@T@.J%Q(#(%)F. VCUB$*&/2 086(@:ZO8.
M7!H USRK:_T^;-_ 7\?TMR"2"WT:&QZF[NX.Z9NM<.O 8&X"X]OS;#ZI[_:'
M<WY'V&T18+74@0--[XOF>$@/6FA(KQDC42/[L.A^.P8&FJ%X07N*/@N5,F0*
MD9<;P?:0F&X,#0[E^M"W58RW])\>T0]8S4\.Z(:[:3;NEF".V3K.]MDZD-_V
MH'TR&O\N/EU<_7-/='YQEO#<6-N:X*>;J\\5RES^)D8GM^=_E'6)33SN0^%1
MMRQ(E=QD&L]E8S;E>2$N;'%Y;%#:V''GS><F,#4G0=X<2L>9A0O%RI]&99]!
M8:OK]:(L]TYI/K\1JHY.@EQ[5 /3*[8-' CZ:B"*)^J>U:%X=.2\6@Z]%9CF
M(;_\5M?-$%^;:HGY-#;=9='5#V*0(!I5J.(8";Y5=7G35Y"$8UA //KM!"I!
M6NB8HIWC'7>*D;AG.5C=P*5:P(R$J1MHM'D($?A#?@:V[7CBGLD[I:F]!<G6
M[J*Z8?+I1OJQ!2+\L?:7< USL]3F:S82,DJ-3#'7Q%=BU;:WHUK6#-2^"T#P
M'!Z--NP6&-T.+':@Z=,,G@ 31J"K=,ZQU7L'2&^##:<]O_SC;+SAM"=E/8C%
M&,7%"I"0)CW[!8/ @C!A7FR6 ]\%?F]IO.RMV-($ Y,/DMI! .\;V.P4T3<R
M?W48$3Q7=DU$G21I4B%U74NJ0A_:@,DW94/&XW(H,JIR$&R.JD'KTOET?CFZ
M/.D+:3Q.6P_-FT5K>C#<+E50=TY^'UW^=@;Q\YB:&ID*57^,+@  X_)G=<:W
M-^<G! W\/>W*^!YU!\KYE2\I4IWQ'@SY:(5HX.OLA_2FISJ).MVZH]!)2KZ6
MN<G!<RI;?Y2S.$G*EZ'*TQ7,WKSNXM6=)W=_ED2=CHF<VFM[(.K6^,OU]05C
MZ.BB4:< OH[J?4:^?3TZ/WW3HEFLK3Y"5WVJZ2=2"-UHR@'EY>75Y2ONN.51
M6$^_!?6X2%[]%$ GLC!63:?9*IPSP_;8I0V"*0C3_=GTX9#<[>^C#S7Y6Z=\
M_UWV4"9,3LD=*"L[!-.]H-FAH,_]:#Y _F=S> 2:*XJO4PGEY3@;N)3=&0[E
M#K3E-S!<S:5[G4T_S0$$F9IO^T!9),1VSY8?U& XZ(/*4XRP@1$<BK"#@+80
MJ ./\95 --A$6.2&7)PU$/CF=&71*PE/!5BJ2OLD2@RVP&H,RWDFO&(&IJ-*
M6H:O6"U5JXU-"'DIP+H.'[-DJO,<<#4MA[B40= *[N/83\!)>J^PW",IN82G
M_Q24! .WC.Z&0GGKF3@)D/6-==C%G1\$;)1G=[M7=UX,;-L0\V6PUI5LT$ 9
M[>HV12)U];< F>&[RG=<!675%*K^^%UU.AE8!E!DYI&DHSC$DG6GB9SJJN\7
M\5ZW?MYP(;,9_X@CO06/>:E?.JSOUK\3.5(_C]@\KGYD\G.(-"[)Q5S>H:D^
M])PCD:D?;E071;KD'TN<I$61+OCCO<2,,WH W]^EH+#E!0U0_WKFA_\ 4$L#
M!!0    ( "0U,%AX-]7"J0,  .T'   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;'U5;6_B.!#^*Z/L:M65N.:%M[0%)$JA&ZFTJ,">3J?[8)()B3:)
ML[93VG]_8P?2]@[XDGC&,\^\>F:PX^*73! 5O.99(8=6HE1Y;=LR3#!G\I*7
M6-!-S$7.%)%B:\M2((N,4I[9GN/T[)REA34:&-Y"C :\4EE:X$* K/*<B;=;
MS/AN:+G6@?&<;A.E&?9H4+(M+E&MRX4@RFY0HC3'0J:\ ('QT!J[U[<=+6\$
M?J:XDQ_.H"/9</Y+$T$TM!SM$&88*HW Z/>"$\PR#41N_-YC6HU)K?CQ?$"?
MF=@IE@V3..'9GVFDDJ'E6Q!AS*I,/?/=#]S'T]5X(<^D^<*NENUZ%H255#S?
M*Y,'>5K4?_:ZS\,'!=\YH>#M%3SC=VW(>'G'%!L-!-^!T-*$I@\F5*--SJ6%
M+LI2";I-24^-ENOY?/S\%SS-8!G</P:S8#)^7,%X,GE:/ZZ"QWM8/#T$DV"Z
MA(L5VV0HOP]L18:UNAWNC=S61KP31EP/YKQ0B81I$6'T&< FCQNWO8/;M]Y9
MQ#L,+Z'MML!S/.\,7KM)0]O@M4_@C<.05X5*BRTL>):&*4KX>[R12E#;_',L
MXAJO<QQ//Z5K6;(0AQ:]%8GB!:W1MR]NS[DYXVVG\;9S#GTTE2JEAL0(UA+C
M*H,'ZFP)/(:QE*CD,7_/(A[W=Y4@8&.JJDUE!U.*;B<\+UGQ]NV+[[G]&PG,
MF <FD(X0\XS>O+R&Z7(5S,>KZ1VLE]/9^@$>@I_44%J[4B@@82+:&:4B LEC
M98@VO"$3$F:5*%)5[:_C]%6?)5W_ =V]R)R%"44DWHP(_J[2D@:'^B1SSXN(
M9TPVN ](KSGA601I7@K^@EI%LRD(H2-L(HX1N #R--?L3.O!0M!@%.H_%EM0
MT" -.0TMJ9.VSU.=">JN:ZJ09E+_8KXA,X<>/L%WX8(NGJD*N@;?X2(H")!7
MDJQ*(I=5&)*_7-!Y(3#" _6_W+;>$_LY1U_AJM.A;[_K'4\U]+T.F!)[-R<S
MW7-\Z#L0%&2S8%GV1J/QA49^B1\JZOM7X+:<COM>C!Z13H-^HB1>R^FZX+9A
MQ17+H#R:>@K!=5M>MZ</+;_?,Y6DL1]6>969%HZ0FCM,F=D'%U[KRO,I;[T^
M?<^5\ROXK;;G&USWRH=C+]C^,()S%%NS:"28J5)/XX;;[+)Q/<+?Q>M%.&=B
MFQ:2^BPF5>>RW[5 U,NE)A0OS4#?<$7KP1P3VL<HM #=QYRK Z$--!M^]"]0
M2P,$%     @ )#4P6*_.HBJX!@  2P\  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL?5=K;]LV%/TKA!<4*:#$(O5.DP!.VFX9UM1HTA;#L ^T1-M$
M95$CJ:;Y]SND9-5)'7^Q2)GW?>[AU?F#TM_,6@A+?FSJQEQ,UM:V9].I*==B
MP\VI:D6#?Y9*;[C%5J^FIM6"5UYH4T]9&*;3#9?-Y/+<OYOKRW/5V5HV8JZ)
MZ38;KA^O1*T>+B9TLGWQ2:[6UKV87IZW?"7NA/W<SC5VTU%+)3>B,5(U1(OE
MQ61&SZY2=]X?^"+%@]E9$Q?)0JEO;G-374Q"YY"H16F=!H['=W$MZMHI@AO_
M#3HGHTDGN+O>:G_O8T<L"V[$M:J_RLJN+R;YA%1BR;O:?E(/?X@AGL3I*U5M
M_"]YZ,^FT824G;%J,PC#@XUL^B?_,>1A1R /7Q!@@P#S?O>&O)=ON>67YUH]
M$.U.0YM;^%"]-)R3C2O*G=7X5T+.7EY]OKNY?7=W1ZX_?KBZN9W=WWR\O2/'
M]WQ1"_/Z?&IAPYV<EH.^JUX?>T$?9>2#:NS:D'=-):JG"J9P;O20;3V\8@<U
MOA7E*8EH0%C(V %]T1AQY/5%+T7<&;PQAERKS4(VO ='4Y&9,6B"6?E?)XWT
M;_^9+8S5 ,Z_^Q+1FXGWFW'-=&9:7HJ+";K%"/U=3"Y?_4;3\,V!(.(QB/B0
M]LN[OH>(6I)YI\LU<$GF6I:"S.I:E3ZH?3X?U+K?YX\+OI(^01]D_>UE<V?D
M^*8A=JTZ@\/F->D%O="]LKP>?I\J."/7W*Q)J=#FE=!]-8Y(%"=!5.1844:#
ME!58Q6D6A"PC[U @^_A,A&59D+,8( F#,,](C'U!::]=BY8_@DFLRU<E%I;0
M* THL!H%1900&D,HSL@G47,K*M)R#0.UY M9.U.,!30,R:O?<D;9F^VV#Z?=
MAO,\A"RG01S%+AB6!&E"73 01!!Y0MYSJ<EW7G?"^<0=] PH"J%I40U)<3DO
MW4+@-<XB ..4)$&>A%BP("R8>X%08P;O 599N@"\5(I#.2U@-$X+X+I4'3*@
M12F@#.T=D 9XAS9&8R0B3U-""S@7/LO#3PE$DN%,01*6DIOF.QQ26@KCVC/$
MJRB$(PE):5!D%/5%VF5%Q _<( :GXB *,\B&6.70]-&NA0;):>U*,^0@2@IR
MXG_G&E>/<\#EP:6@]26D 8.-'+E-21&D.84GEC<KZ1P<E"0AX(,2T20+$CS3
ME 4YGO[..5'+D\Z,9^$+<)('+&* !7 0#8X-_S-X>N)_^X*CQHV52\EW[&T+
MAV(D61%$-'7EH2Q(0X?<K$!&6$+^&A#E4@;);N-*/13&(-N/O4Z$R\M2=V(G
M=S0/4B0^#6)4&GBB,7V6OWI'.2P70'<2Q'GD1*,"QH5#Z>XI*$LIH2% B1Y(
M@P0(>"N60KM(9%.JC2"6_W@BP_(@S"*7D'[1YZ3>%]@1T@X_$Y<*0#5RD,WS
M@&8)N17VE]0E2#X%;&@1!D@BR<(HR #A^?X&V[;7MKE^MM;O2E4/LJZ=W11U
M32/7(U$"?UVWQ- ;H>D/L' RLG!RF(4Q(E5=[5MX!X2S/K+9-C+9D'V7SCY^
M/FAO/S__:MASRQ?/+;]P\%<_IHCJY#E;WVM>8=[#+.@!Z+?DE@,"2!F-@S!T
M]4,YAU62%'X%[G@47",R/ZP(/:VDXZ%%!VX =]0^5K.6K7&X]2+4/T#!_6Y0
M<*^%E8U"MD8-VZO9=&U;@PA66@A/ E$>%#N,/&R309.;U[K!,&Z&('9F/!&P
M_F"^->ES\FL&CT8&.1HYY&ADD0/(24?DI >1\[GA724=QX+EO+\<T&B,JF7E
MJ?<]0-*4TGO7C]XO(.:PG?NU($N%._I!-BO2C59;6/5JT54.D'BU'"W*GQ:)
MQYEC)W"- V_+FT>?]>R-074-AE_7\AY)J[4_M7? 6O.*J-)S%18-^9,WG1M@
M^KD.OS#II?O""#<\@HQ*L5F XX;QCWHPN#GPE+C(]L>SD\7],8%-R$(('QRN
M.)QS'J^\>;XS_FT$HJK\_=QSM#LD&[_3%10+#.MV33Z?WIV2WV>S^2GY&]X/
MSN\LG[7:\5C]I^OY&(2[F+7 _=JY]G,S38+Q!%@$ A-0^M.3 U4?U\HX[7F*
MH2;$PC4K3=AK4+\Q9P>%N.T;SE] 5I%&X>_&:D"G#]H*%-N28W_U..4,]P4M
MGCM]6.M77N/RQ'!B25N7B.<8HT)60!V6U%UQ4?1Z7W=-=SYP0#$K_QEGB"]*
M_ZTSOAV_%&?]!]+/X_UGY@>N5Q*T4(LE1,/3#)2K^T^W?F-5ZS^7%LJ"S_QR
MC:]=H=T!_+]4RFXWSL#X_7SY/U!+ P04    "  D-3!8S$([&1$$   ""P
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M4MV+J^L8N72OG*DTM.]=<T&/5%36@.9G4II-QR[0/WLG?P)02P,$%     @
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M.KI5>5DI%T;F[H*PD(:N&^YQ3?<[5%: WB^E-+N%=5#?&$?_ E!+ P04
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M:%)0CNWE(TFJ$%<M\X$>B-=$L(H8NF/4'HI:BE&S7L/K5(I#"C.-[[R$N&X
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M3C2&>VKQ9G"P\=:N1175K@2U66NKD*F4V9N-8]1+&L&*<I;RV#[)$1?B'BM
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M:4%J")U,*'4&E;)H9*RI4:A*/@,E<O0 .>I$Q!?&B53$L)$BA]^J[!G8"+0
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M662%+'6F2E;)Y<G@S#LZ3XC>$/R6R4?=&3/R9*[4-WJY6IP,7#)(YC*M28+
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M7-<5$N2??3Y;B4&_1 +-D5Z)5)X,@ HMJP<Y.'WSDQ>Y[P[8&[3V!H>DG]X
MA(MU+IE:L@M5:I5G"U'+!9M5LH83&W^&UTKW+]AA\;?W$F*+E2B?W_R4<"]^
MIUG:5;.R:K*-FIS4,)0"5H-S):M,+=BR4@7[=9T_,YZP6C&LF2SFLFK7C0UO
MUFDJM0;?S/",G-<"1+E&56 >B;#2XH8=SBYDGX!G*2HF*==>:?5ZV9@H%]_C
M=/LY'R4RY4Z6LC*1F3^S!6*BZRPU0A$45("2H5R"  5',Z$QFZ/LZ:.-%.OJ
M[,?<_OLAYPY\A/UGFGV!:63HZ.7;58D J+6&T5C+SLIT?*9T8G-)/C5KCS20
M\.-KF9'W-R1-LY_9T..APQ-O9,:Q$\61'8:.SUT[]!T>^"/V81.AH>>X\126
M8#Y*1@R40<1B)XBG[%;5(K=B(\>/K #N.M,@,,.I,XWM*'3B*!@=@%C80BS\
M88C-*O60F?V&<GQ;+*3NP]9AN82MU8Z\;B3_3T%$Q273E$&(-HFP ,G*NUV(
M'(S$_SY^+M95)<NZL_[#.2K',JM'1^P#Z"J3Y:;F\G=[1D,_ FH,TF 6\Z8L
M3 ",Z19)#6W O-AE/B<R[C..P W]$."YE$L)2Q9L:'-OQ.03VCDMMU8, R<,
MXQ'S$T PG,: &Y#8*@98>01(AYQY3ASC<QA[KRW8]P1,$PYA4Y=-'3\."/0N
M8?D3^LTM'K;AZ83,@#QQ?8*[Y_GXG3J1RTUD'']Z$/Q1"_[H/]A?BY4JL6R:
MWCJ=PGL;L[X2<%@ZE8!T1VK'Y<U*H+/-S8:"_/T3@/@^%O9E^@$$\/;'^SX@
M^A%PM75TL[1,U.Q<9'GVF*7?*!:_RDK+9U,(MS*HM/3S7HCG0I3L2N>$/,/6
M54CFK&L%]VE_;A/PE^^,OHYOQI-F[R:-AGN1+0$<+%H&A'!W'(/2B\W#=\<A
M'H%]LR#)7AGLL!()#B>7&Y@UCO!Q0+(VOPE^DS''+]81WE'-N*IEH9EK9H?N
M&& S3VZ>WCBDYR<%C65=(5>0*=!?PUI=TW>/_3("MPNJ[N_%O2COR%+V(/*U
ML"<BRC11ID!Y9/F&7C2>VD'@$5\CZK82I1;V(#57Y5IC!]L&,1E'>\+;Y4N5
MKKM<0\\;^Z,]C+/9#%V(,!OG'<YM)5:YE] +3"R[*M?R[==5/S4"E(Q,Z#TB
MQ8*ER*&L[J?>CGRCY"]*+1ZS/&<96N:L*FBYR(M@GQ<=JTQCTUOQFD(0F"AB
MJ2.SU-/(1B=,:$D.U+JXK77QX5IGS]V4E>V^0!$XTUHB (2\G?GK3,P!USKK
M[WX.*Z/29ZH<@)3:VH>\7JF*+&C@!>BBY@';M,*LRA $5"X0V?YYTR(L&J-(
MGM@:NS.?;XVEOMOX^/T.:N/TCS4]%?5S..&5IOVGZXPCQ.Z5JIZI;37]$[W$
MY6OWH3=-D>:++?(1MZ:*-1O*2E0F'-@]G2AR\0P3CUU+@3 WX<(6X01^T";J
M55FC3F1T_M]V%X[G)LS>@6QQ[#FA.R7)?&HV\\VY!]6(#HE@1]OO>3&XI],0
M<@%A6YWM&9FZ"=]C,&A_B? <'QW/9^1 M2=Y(AP</,<+DC8@M-T"3=92"$#'
MDD#/ES>B6+V[-#%L$._CO$%_**9OL0NN80+\WH8T%57UK!YH#6$(&C GP#*:
M>RP&('V#TZ8(PW9$T8_]UO +L<H ]^Q?,(C\%55Z#Y(0/=8VT _082H(:O+O
M(E_ (P&MUS.H"Z*HI;25HP\$/EJW!'9%D,QW\Z0#AZ-MV1KR!-L'&KP8W1/[
MD#V!VLBBBZU,HZ^*7?K.48%LGMBOX' Y./NR9!A$#G>CT8YG=JE?-H,]GG1A
M.PP2)TDB<S!TZ>Q(:;5#/>R0CYHH8*MR?#( "1=Z'(9K^-R[R\7V'$D<;M2G
MH&L.'3RYPT-[!@V#Y%"_F;0U./G1&DS*/[>@N;:@H7I$M??"Y"@2"2D(7#^*
M:M%;A ]KZ\6E.;RU,+!9WJCX+Y5.<W72O0W95R/[YU^6S?XZ^:*8GA5J#7"A
M=\_L?8QM>/=,]T7*:9LW5$X7AQ]@3*%:;+@EIKF+C'5?3/?+,L:#Q<<Y".CF
MKC]]R]V FV,-R6YFO$X"[-C $Y^(DK=$^>I]AZE1YB%V+VU^-=>7UI/.C7(A
MJSMS;TYW@PB>O5QN9]NK^3-[([TEM_?Z'P4:..SFN5R"%;UT.,!6;^[*[4NM
M5N9^>J[J6A5F>"\%O"8"?%\J53<OI*#]A\7IOP%02P,$%     @ )#4P6 ?4
M T+_ P  ]@@  !D   !X;"]W;W)K<VAE971S+W-H965T-#8N>&ULE591;^(X
M$/XKH^QJ!5)4D@ !NH#4=KN]GHXN O;NX70/)AF"5<?.VJ:T__[&2<C2BJ+=
M%[#',Y^_&7_V9+Q7^M%L$2T\YT*:B;>UMKCL=$RRQ9R9"U6@I)6-TCFS--59
MQQ0:65H&Y:(3!4'<R1F7WG1<VN9Z.E8[*[C$N0:SRW.F7ZY1J/W$"[V#8<&S
MK76&SG1<L R7:+\7<TVS3H.2\AREX4J"QLW$NPHOK_O.OW3XF^/>'(W!9;)6
MZM%-[M.)%SA"*#"Q#H'1WQ/>H! .B&C\J#&]9DL7>#P^H'\M<Z=<ULS@C1+_
M\-1N)][0@Q0W;"?L0NW_P#J?DF"BA"E_85_[!AXD.V-57@<3@YS+ZI\]UW7X
ME8"H#HA*WM5&)<LOS++I6*L]:.=-:&Y0IEI&$SDNW:$LK:953G%VNKR]F]T^
MK&!Q._^V6-T_W$%KQ=8"37O<L83OO#I)C75=847O8(41S)2T6P.W,L7T-4"'
MB#7LH@.[Z^@LXA=,+J ;^A %470&K]MDVRWQNN]EBQD)RL(""Z4MEQG\>[4V
M5I,V_CN5;X76.XWF[LNE*5B"$X\NA$']A-[TTX<P#CZ?X=IKN/;.H4\7F"B9
M<,%9*5^U@:]<,K(P 3-D9D=;.FN=DP&KX$9)HP1/F<445LHR84ZE=7;CTVFM
MM@@;)>@.NZIQ XRNY%N"FX9@?D304NB-R@LF7SY]&$;AX+,!<T3:K2?'Q&U)
M_!+FJ+E*8:-5#G_NQ M$0^=/HL!\C;H1!K3N):&HG6$R-6WXMF89A^4CEPG3
M"#,N'F'&'G%75#6!!WKL-#ZAW"%\A#CT@U%  \*+AET:C"*_.^@2:6-= IE2
M*5%6(H5>SQ_12MCWXV$/XL"/^P.XT\H8*+3:<$O18>R'X< -^GY_-*J !V$,
M9T31;T31_TU1'"1=D9A7)*A*+L=[F:@<H?47+;7A&ND-QX-QQ9[QI#C.$WBM
M ^N>BD8(V)PK9,<E(3:2V/":C2C9K"LVM=$Z-@2L2S44OWSPRUV2H#$45XFE
M_5HU;X3QT_O-D=4'M*3F0&GYD*%$34*A,& I/;O</1*N?\!PZ(^BF%X0@TPG
MV](E)2T)5929$](H!E=QH /B)'NNRX5:2'LN!,1#VJ]/1V&1+HD%?*8F:] O
MZQ3[43> FRV3F:L/; @!GI@@L1)&2ND]553V3&M&R*2&-4G"<BIA*Z;]NW0'
MJ([Z@$OFJL[M:H?68#1L-^IX_SP^0BN,8K\;!^U23\ZS,@9^OS]HGQ)TYZ@7
MY:BSLN,:NN [::NVU%B;IGY5];*?[M47P8SIC$L# C<4&EP,2)JZZK+5Q*JB
M[&QK9:E/EL,M?9B@=@ZTOE'*'B9N@^939_H_4$L#!!0    ( "0U,%B8M*#G
MT@8  # 1   9    >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;*U8ZW/B-A#_
M5W9HIH497_ CO/*:<0AIW"% ,;F;FTX_"%N 6B-12<ZC?WU7LG$@Q]&[3C_<
MQ997N[]]_'8E+I^%_%.M*-7PLLZXNJJMM-Z<-YLJ6=$U4:=B0SE^60BY)AI?
MY;*I-I*2U&Y:9TW?==O--6&\=GUIUR;R^E+D.F.<3B2H?+TF\O6&9N+YJN;5
MM@M3MEQIL]"\OMR0)8VI?MQ,)+XU*RTI6U.NF. @Z>*J%GKG-VTC;P4^,OJL
M=I[!>#(7XD_S$J57-=< HAE-M-% \,\3[=,L,XH0QE^ESEIETFS<?=YJO[.^
MHR]SHFA?9)]8JE=7M6X-4KH@>::GXOF>EOZTC+Y$9,K^#\^EK%N#)%=:K,O-
MB&#->/&7O)1Q^)8-?KG!M[@+0Q;E+='D^E**9Y!&&K69!^NJW8W@&#=)B;7$
MKPSWZ>OXL=\?Q/%X"OWQZ'8PB@>W<!>-PE$_"H<0C>[&TX=P%HU',+Z#3^$0
M1?IA/(/)L _U23@=C&:X\V$2CC[#>#3\W(#ZC,PSJAJ738WXC)5F4F*Y*;#X
M7\'B^? @N%XI&/"4IOL*FNA8Y9V_]>[&/ZKQEB:G$'@.^*[O']$75-$*K+[@
M*_KZ H%Q15.X8YSPA)$,(EY0P]38+5-))E0N*?P6SI666'2_'PI$8>;LL!E#
MQ'.U(0F]JB'3%)5/M';]XP]>V[TXXL19Y<39,>T[3MR0#)V@$)OR.03SJ*+#
M,&<K"@N1(=D97T)2V5I4 5.::(J\U@I6Y(G"G%(.5@'7*&BH"C_^T/5]]V)#
M)"Y^$#Q[M2O>A:$@4Z?PB'HE"NY(;'785#CPB61H.B%*PR9+S':O<Z& \2>J
MM#&/C\ 0A,KGBJ6,2$;QL]J!DELC&CVB?^5,O\*:ZI5 B OL)HG(N48?3[^@
M1<1QC\@5X:DRLH^G\2FD&!,BE0/T):$;#6J%R %%8(,VBK<4&=R T&["TJ7K
M.7[:EB^$<3R8Q=!_G%K6%:_GT"=J9?4DYL$ ?2*9C>X)!([OM6 F-(8]R:4)
M%1"E*'XL/D5[T:@B\0I=/W!Z01MFXQGV@=+T"2YW'*_EP3 *;Z)A-(L&,82C
M6XCOL17<CS$.T_@G&/SZ&,T^5TAWA,_1HJ8R$>L-X9@Q\FJ;!72=WIF//DL$
M;]HT/!,I":+*&)FSC&F3&Z_K!)Y70MI%< ((RV\%>S#*C)=@SB'.DX0J)23T
M,XP!A"!DBD6)SMKH8VI.W%/7=3U35(!!S*D#GH,KVW^E() <\RO9WS2]L)'O
MMIVSMNNTVB[@W,/ZYJDI?O*51':_P'+S_V'Q/<=SSQS?;WT3%BRK-&6&,5@B
M&\+2#U@'"=DP4S*=7MMQ@RZ$29*O\XP83N#$8PG34/=:;:?3=1M[7P6218))
MKZ0K,[HQE8SC.X4Z-D:%X\'O-<H4XL293<?#833Z^4CFH!WT'#_HP4B@(JXE
M$LEX9 L)BQ>P+3KM5J]4>D31"3K4<[J][H$2^FH1O]7\D=;;JEIOZQM;;[QM
M@B8M8VP!MFNI0TWXN,K_N?G@4<<V/%QGV.D64JSAEQR;J]\%+0X4T @/CI(^
M49Y3V[4]_P)B:E/DP))R]"RSEDB*QQ=F9J(E^%:V:$ZBB "FM:R6[>>Q+:AB
M\?PMY\6" QRM>SWHKPA?FDJ#!6$E7XSSZ?&&@@7<"U"IM3BG.,>K:M7DQ0IT
M\5 254LHQ+'^=05O?V\Y)1 &3@[C*IOGAA642(Z^V7SL39M"_^![M]4]UW>"
M#A+)1-_P"NJ]%O:?3J,,V#X#2^J]"ZV!S):\' S)*V!JN,J*DPQ)_\B+P:"*
M*",&$P!+W_Z>]C?[O7;C"$G:%4G:_X4D=L[=X;GB$$>.:CQ\4/D>XC1@\JU\
M0(7W<#<<?XKA;CI^@/%D,,4#-+:XL#^+/I93L,K;R5OFPK>0&]628K=+6$9M
M^*TPKIIG.^AM..JY"1/C#3RTB">&AV:8O^Z0R=YY;*V?[U1960?OJZHLJO]*
MIKIE4U&2%N&_0;+$?1>M:/1Q$'\1K8D4":68%AM^+3%,2)TS'(('C15'O'?&
M"OGW]LJKSCM[,T.$!96EP7>4-</W30)SLL_-P,69.'C9F!)6=J2:(^V<KDBV
M^)+)>/#I^CM!*Q.Z/2[O^U#'0YN1[M^'HY\'&"SKCU-X9>;5QW"(!ZYBFDTQ
MD-.H/\,+G?T>.%[0^9X-'^"&+ADW+<C@+B="I_M].BA/=W9OCZ2'VD1SYQ:[
MIG)I[^H*[#F[N-!6J]7/ 6%Q"WX3+WY+>" 2D2O(Z *WNJ<=G*&RN)\7+UIL
M[)UX+C3>L.WCBA*L<". WQ="Z.V+,5#]2'+]#U!+ P04    "  D-3!88/2K
M\HX%  "9*P  &0   'AL+W=O<FMS:&5E=',O<VAE970T."YX;6RMFFMOVS84
MAO\*X0U#"Q31Q9<XF6,@L<3-0),8\;H"*_:!D9A8B"2Z)&TGPW[\*$J6+%MF
MK.[X0ZS;>8[(5^$17W.T8?Q%+"B5Z#6)4W'564BYO+0L$2QH0L096])4G7EB
M/"%2[?)G2RPY):$.2F++M>V!E9 H[8Q'^MB,CT=L)>,HI3..Q"I)"'^[H3';
M7'6<SO; 0_2\D-D!:SQ:DF<ZI_++<L;5GE52PBBAJ8A8BCA]NNI<.Y?8[68!
M^HH_([H1.]LH:\HC8R_9SC2\ZMC9'=&8!C)#$/6UIA,:QQE)W<?W MHI<V:!
MN]M;.M:-5XUY)().6/PU"N7BJC/LH) ^D54L']CF=UHTJ)_Q A8+_1=M\FL'
M;@<%*R%94@2K.TBB-/\FKT5'[ 1TCP6X18"[%^ Z1P*Z14#WU(!>$= [-:!?
M!/1/#1@4 0/=]WEGZ9[VB"3C$6<;Q+.K%2W;T'+I:-7!49H]67/)U=E(Q<GQ
M_<-OUW?3OZ[_F-[?H>L[#WG^?/(PG>G]>XQNOLRG=_Y\CCYX5)(H%A]'EE1Y
MLV@K*'),\ASND1P.NF6I7 CDIR$-&^(]<WS?$&^I]I:-=K>-OG&-P%O"SY S
M_(1<VW70S\A"8D$X%<574PO-P#NV/D-=6P/MXQ3/3/%HH"B.IKC'*?[I%.<X
M!9LI]X$L*<TMJO5\MWS<NAK;/8*=Q$0(Q)[07++@!7W[K,ZCJ:2)^+OA'F]R
M6*\9E@VZEV)) GK54:.JH'Q-.^-??G(&]J]-$D+"/$B8#PG#0+":O+U2WIZ)
M/L912M(@(C'RJ(B>4Y)5CT]HQFE( RH$XXBD(9JO@F+O&XY>:8@^1T(V/@#&
M=&T? $B89^Z(LH5-<D/>!P:"U>3NEW+WC:V\6R6/E&?_SL7X&9 X5G(^OB%*
M@@7:$,Y)*IN$-8+;"@L)\W)87\.R][+UV!E9ZUW](--A(%A-OT&IW\"HWX0E
MB7J[*\0C*[E@//I'"?@AVAYM*O<W1FI;\08'_>WV;?VI=[L'F=4_-2L^O+!?
MNZK6\>=EQY^WZ/A(B-7[G6XDMNWT\X-6]1K['#*I?YATJ'.Z>UT.E+2FS+!4
M9F@>N/5[B5C&D40!2]>4YW.HK)(UJ6*DM55E>/A0[ND!F<Z'A&$@6$VTBU*T
M"Z-HT]E]DS;&H+;:0,(\2)@/"<- L)J,CEU-1FW(Z4%! U(8E.:!TGQ0&H:B
MU57>L1R<$U\;5VDDR_JGRI_Z1WZO#!;LW4&RV^LWU*Z)^2Y:ZPE)\T%I&(I6
MU].M]'2->LYX%%"T5))F>FH!0Q;'A M]4(OY$?V[8[0T"ILG&>R^>!](:KR1
MUI)"TGQ0&H:BU26M;!K':!,4 _$UNN>AFM+S-S0_KANH20-*\T!I/B@-0]'J
M"E=.C=,#+;6@3@PHS0.E^: T#$6KJUP9-([9H?G1&;X9VUIN4(/&:7!H[.UG
MSZH!S8RA:'4Q*[?&:6/7G.8:F)&MA82D><ZAMS(<] 9V?W @(V1>#$6KRUAY
M/X[9_-FKJ>K%Z$BU56>.S&S-&5JK"DGS0&D^* U#T>K*5]Z2,P2MN:#F$BC-
M Z7YH#0,1:NK7)E1CMF-.OA51(W0^N>0;':;S9 :M;YX[V>'B3EM:P%!/2A0
M&H:BU1<'5"Z4:_0__L_/6@79)*,Y>5L906D^* U#T>HR5C:3:[:9ON8R&<JH
M&=!V@ 6E>: T'Y2&H6AU82N_R74ARZ@+:<Q,0&D>*,T'I6$H6EWERH)RS1;4
M#Y71@GFQ,_[:9UWUV1^$06TF4)H/2L-0M%Q%:V>E84+YLUX3J@HD6Z4R7W18
M'BW7G5[KU996=7F^:/66\.<H%2BF3RK4/CM719/GZT#S'<F6>MWB(Y.2)7IS
M04E(>7:!.O_$F-SN9 G*U;CC_P!02P,$%     @ )#4P6. B3*B "0  *E(
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M,<98;B,<R&$"IHS(NU,L#V%EA!V/O+_?2Q:8R"O^3]VXRBMNUU>LW/B6KU&
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M1@,FDP[F_EP(O6LD#RBV1@W_!U!+ P04    "  D-3!8YO-RN-$*  #4;0
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MMYH"KQ7"8V/1ML)H2J3#MB[($AD(IN@RVN@R,NIR-IGDR_KF:Y%\3^ZRG=V
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M*2_3_)Z,DT5:)5GZ/R&CN()Y4DP>F^L\XD\\RQN'A\0O?MT/\DIOH)4>ZOE
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M(K-_"5E'BUUZ''\0&@_W:3,"BD61&8#O-T+HIXXYX1=_=,;_ 5!+ P04
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MBAOTDW:]\YS>;]?WS1: +H)=1=S<1_S*;"7Z*.J!0?\=, W3;'*H7?YED_:
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M:BF6FFRAX&1Z>MT"+&%MGP&6/5]=-DJQ@LJ^"%BF/=0MP)K61IG*&_Q8+6_
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M8\RJ$UC,VAV=Y35W^@#Y6(!\C%)P JM8VV)8\@Y<-]!N$;V\]7COM<?]%)S
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MK1_+J"[89UU)J8"TB Q'LR:;5%H%0+D9-SKY])JT0(FJX"5JTG!0:RY)-54
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MV:,F*6#240"5IZ%(PP9+/NKA?'1DX2X%76WV6;@!ILF#P%<?>$PAP\1-5(<
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MANK[IK:Z'#8*X&0XKN^&M/UUK<MA<Q?3Z-%K#LLP1^/ZW@HY+A^),23&D9@
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M61#%$CA:$^YM" =$0@\)MI1Z<HJ?$4]_$S<B(@MH64KT O@K6.V/'W"U],W
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M6[G,PW"]R-=>A*'AS-&PT7;RO78SI.$:L(]:(-U.C@A?T5 @'Y8*JG154]\
MWW=H^XED4=(5/3&I>JQDN%9=+7"]03U?,B;?)KK12OOD]E]02P,$%     @
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M6^93<1KN6*".K,/(IU(UHXTE=A&C;MK)]RQDVT/+ISP8S";IOH=H-@ECZ?&
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M'PE=<IC%?& *:5PAS*@R=%D:L@\8<L US43"P3B+4=R@'[7KO9?T0;N^:[<
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M1E9,WXO-9ZCBZ5B]3##E?M&FQ'8-.%LI+8J*;$Y04%X^R7.5AQV"T6DFX(J
MWTH(*T+XFM#=0X@J0O2:$.TA="J""]TO8W>)2X@F<5^*#9(6;=3LPF7?L4V^
M*+?W9**E>4L-3\>C\<-P?#.Z^IJBX622/DQ.CLYQ@"_'Z0/ZB,9$2F(KB4X3
MT(0R=6:LCY,$G1Z?H6-$.;JEC)F*J[ZOS7&LJ)]5KJ]*UWB/ZPZZ%5PO%$IY
M#GD#__HPO_<_?G*8'^ # K[)8YU,O$WF%3ZHF$#60F'P >$VQDT!':9_6;$6
MPKV]].3MWH,&>OIV>OM ,L+Z9H5.+]RC=R-$OC&7 Q&>HQ'7A,_IE $:*@5:
MH82JC FUDH!^#*=*2],R?C9=HM)+U.S%MM$+M209##S3)Q7(-7CQR5'0;5\V
M%> ]Q9+W%$O?2>Q%J:*Z5-$A]7A8"*GI'^):MYB9S[JN%G'5:JI+*=EUDG8:
MK6,<]?WU;K9+2(!W,+U6[R4H:0 %8:OS$I4VH\(:5<;M[S3" N3<32"%,K'B
MNOR,:VL]Y(:NM[^R)V;XE;/JGTPY.6^)G%.N$(.9D6RW>J8?RW(:E1LMEJ[=
M3H4VS=LM%V: @[0 \WXFA-YNK(/Z+T'\%U!+ P04    "  D-3!89=\2N]X"
M  ":"0  &0   'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6RMEE]OVC 4Q;^*
ME595*VW-/Y) "Y$H=!W2AJI"MX=I#R:Y$*M.S&P#[3[]["2-:$D#0GL!.[GG
M^'<N)'9WP_B32  D>DYI)GI&(N7RRC1%E$"*Q25;0J;NS!E/L513OC#%D@..
M<U%*3<>R?#/%)#/";G[MGH==MI*49'#/D5BE*>8O-T#9IF?8QNN%![)(I+Y@
MAMTE7L $Y./RGJN96;G$)(5,$)8A#O.>T;>O!AU=GQ?\(+ 16V.DD\P8>]*3
M4=PS+ T$%"*I';#Z6L, *-5&"N-/Z6E42VKA]OC5_4N>766980$#1G^26"8]
MHVV@&.9X1>4#VWR%,H^G_2)&1?Z)-F6M9:!H)21+2[$B2$E6?./GL@]; KOU
M@< I!<ZA K<4N'G0@BR/-<02AUW.-HCK:N6F!WEO<K5*0S+]*TXD5W>)TLEP
M-)[VQW>CFV^WJ#^9W$XG9R=MQW:NQ[=3]!G=/B]5NR%&_91Q2?[BO/7G0Y"8
M4'&A*AXG0W1^>H%.$<G0-&$K@;-8=$VIV/0*9E1RW!0<S@<<0X@ND6M_0H[E
M.#7RP>%R^ZW<5!VIVN)4;7%R/_<#OSO&X@VA%*DT:)1)G"W(C +J"P%2H"$1
M$65BQ0']ZL^$Y.K?^+LN=+%*JWX5_81>B26.H&>H1U  7X,1GIW8OG5=UX+_
M9/:F(6[5$+?)/51]=>L"%BH_5^DWQCKT?#_PNN9ZF[S1^TCR5D7>VD?>JB,O
M5-X>\D;O(\F]BMS;1^[5D7L'D3=Z'TGN5^3^/G*_CMP_B+S1^TCRH"(/]I$'
M=>3!+KGK>M8[\D;O(\G;%7F[D7R:@-K&YQ)X'7][A]_U.K;]OO6-2QP9H%,%
MZ#0&&*LSRP!S_D*RA=YP5IFL2]+9>>/X;L?VWR?9+0LZ7M"JJ@I$<VOGU*>6
M[Y@O2"80A;G269>!ZA@O3@+%1+)EOIG.F%1;<SY,U.$)N"Y0]^>,R=>)WI^K
MXUCX#U!+ P04    "  D-3!8Y7DCJ"0'  "+3   &0   'AL+W=O<FMS:&5E
M=',O<VAE970W-"YX;6RUG%%OVS84A?\*X15#"S2U*,F.G3D&5HO$,J1#T+3;
MP[ 'Q69BH;+D2732#OOQHV35-"6%LM;3E\2R=;]K\U!7]-&U9D]I]BE?"R')
MYTV<Y)>#M93;B^$P7Z[%)LS?I%N1J%?NTVP32K69/0SS;2;"51FTB8>NXXR'
MFS!*!O-9^=Q--I^E.QE'B;C)2+[;;,+LRUL1IT^7 SKX^L3[Z&$MBR>&\]DV
M?!"W0G[<WF1J:WB@K**-2/(H34@F[B\'/],+[I<!Y1Z_1^(I/WI,BH]REZ:?
MBHVKU>7 *=Z1B,52%HA0_7L4"Q''!4F]C[\KZ."0LP@\?OR5SLL/KS[,79B+
M11K_$:WD^G(P&9"5N ]WL7R?/OTBJ@\T*GC+-,[+O^2IVM<9D.4NE^FF"E;O
M8!,E^__AYVH@C@*H_TR 6P6XIP9X58!W:H!?!?BG!HRJ@-&I >,J8%R._7ZP
MRI$.0AG.9UGZ1+)B;T4K'I1RE=%J@*.DF%FW,E.O1BI.S@/V]@,Y(]=I\G F
M1;8A@;B3Y&4@9!C%^2OUTL?;@+Q\\8J\(%%"/JS371XFJWPVE"I[P1@NJTQO
M]YG<YS*)Y1OBT=?$=5RW)7QA#_]UEZAPY]GPX/3LM"6<V</?A9DUG)^<G4[,
M\*$2[*":>U#-+7G>LSPETE62RVRGCG))_KQ6.Y K*3;Y7VW*[&E^.ZTH7A?Y
M-ER*RX&J3KG('L5@_N,/=.S\U*83$A8@80P)XR"8H:]WT->ST><?DW"39C+Z
M1ZQ4F51:1WF^"Y.E(,LTEZT'WQXX+H'%Z>1Q?C;R_=%L^'BL7<M>8\]QS+V"
M-I9':WNQ-I9?9_&6O=SIT5[&^/B'\?&MX_.;.N4NPRS[$B4/1 W5+I%M8[*'
MC(YRT_.IY_JU0;'FZCNA6W+2R61<$X(A<W(0S)!B=)!B9)7B6N3Y!5GLLJPH
M1-MBUJH%0WI/XL,II9C!;?*,&D-UIA9$T_J<M>;O*T]+3JJ.$[<F#S(G!\$,
M><8'><9V>0P57I-$M$HQ;L[:T=1UIS4IK+GZ2M&2T_%\UZM)@<S)03!#BO.#
M%.=6*8J%"_E02'&=ADF;"M;XOJ=I)"Q PA@2QD$P0]')0=$)=!DV0>J+A 5(
M&$/". AFZ#L]Z#O]7N>V:?,\,VDLCA;6]'TU1,(8$L9!,$-#ZNAON$YWW7TO
M'M/XL5@N+C*QBB3AX3**(_FE]8NL%=CW0(72 BB-06D<13.%/K(R*+0<5SB4
MS$A: *4Q*(VC:*;,VON@UJ_>WU*5*[*Y_/=IHR[;WT%O+:$F!Y3&43132^US
M4+O1<:.*L5@J0=.LM-;LZV,[K/<!BZ0%4!J#TCB*9HJLS1KJ8^LRTAQ90&D!
ME,:@-(ZBF3)K(XC:G:#_85K:B;V5ACI%M,4J\J;U4P6#)N4HFBFA-HNHW2TZ
MT5>U4WK+!G65:)NM-'6;ND%])13-U$T[2]1N+7W+D@AJ.D%I044S'>))4TJH
MH82BF5)J2XE:'8WFBJC?-U>HQ02E!5 :@](XBF:*KGTF.L6ND)#VS )*"Z T
M!J5Q%,V\:*^=*-?N1'U#F;:3>U_"AUI2%:UV4<UIU&EH5HZBF5IJL\FUNASS
M\@A5TE5%^5]B7MY13]R*Y4Z]6';4M$H*M9^@M !*8U :1]%,X8]:;\"]-]CF
M&VSW#;;]!MM_\SV<*5<[4Z[=F;KN+LE>2WN),Q[5>@D6]D2])6MF;=19J'F$
MHIDZ://(M;?ZM-?99Q?%:H=>"V9[]MY')]1K@M(8E,91-'-6:*_)'6&+,-1H
M@M("*(U!:1Q%,V76?I3;IWNI5=@6N\>G]+Q>@Z$>4TO21@V&VDLHFBF#MI?<
M#GNI7H.?OVQSRKH7ZCA!:0&4QJ TCJ*9DT ;4RZVV<F%6E%06@"E,2B-HVBF
MS-J*<CMZGKI+;K.WJ7[]W)ZCMUK-A-29TO-Z3S4T*T?1S!\ :*_(Z_"*.FLN
M; UL?R=]CU0H+8#2&)3&431SAF@'RL.V.WE0OPE*"Z T!J5Q%,V46?M-7D>[
M4V=!]II=3?6";,_16ZUFPC:_%YJ4HVBF#$>_R.KP@^SUF$YZK8'MR7H?BU"'
M"4IC4!I'T<Q)H,TH#]O)Y$'=)2@M@-(8E,91-%-F[2YY';]IZRZYS>:@1LF%
MFD3="1DT(4?13 FT\^-U.#^=Y1:W_(5V,T%I 93&H#2.HIDS1)M2WCFV%D-M
M)R@M@-(8E,91-%-F;3MY]GZH$VKQI+L60]VC[H0,FI"C:*8$VA+R.BPA6RV^
MN;DY>=$+[5J"T@(HC4%I'$4S;[6@G2C?@19:'VHG06D!E,:@-(ZBF3)K.\GO
M:&CJ++058&PIM/8<O=7J3,B@"3F*MI=@>'1;IN(V7>_"["%*<A*+>X5WWIRK
M,TBVO_/5?D.FV_).37>IE.FF?+@6X4IDQ0[J]?LTE5\WBIL_'>X_-O\/4$L#
M!!0    ( "0U,%BEUX1?H!$  /L7 0 9    >&PO=V]R:W-H965T<R]S:&5E
M=#<U+GAM;+7=;6_;1KK&\:]">!<'72"-1>HY)S&0F/.(IC62=,^+@WVAR+0M
M5!)=BG*:13_\4C+C\8CT6$S_VQ=-+&M^(RGW+0UYB>3K+WGQV^8FR\KHC]5R
MO7ES<E.6MZ].3S?SFVPUV[S,;[-U]9NKO%C-RNK'XOIT<UMDL\O]H-7R-.GU
M1J>KV6)]<O9Z?]M%<?8ZWY;+Q3J[**+-=K6:%5_?9<O\RYN3^.3;#1\6US?E
M[H;3L]>WL^OL8U;^>GM15#^=/BB7BU6VWBSR=51D5V].WL:O[#39#=C?XY^+
M[,OFT=^CW5/YG.>_[7XPEV].>KM'E"VS>;DC9M4?=]EYMESNI.IQ_%ZC)P]S
M[@8^_OLW7>Z??/5D/L\VV7F^_+_%97GSYF1R$EUF5[/MLOR0?]%9_82&.V^>
M+S?[_T=?ZOOV3J+Y=E/FJWIP]0A6B_7]G[,_ZA?BT8 D>6) 4@](CAW0KP?T
MCQTPJ <,CATPK <,CQTPJ@>,CATPK@>,CQTPJ0=,#@?$3PR8U@.FQ\X0][[]
MR_7V%73_3[ZOEW16SLY>%_F7J-C=O_)V?]D7W7Y\52:+]:X_/I9%]=M%-:X\
M2\6[3]&/T<^SHICM*C7Z(<W*V6*Y^4?T]VBQCC[=Y-O-;'VY>7U:5M/M!IW.
M:_K\GDZ>H(?1^WQ=WFPBL;[,+EO&I^'QX^?&B_#X. D I]7K]/!B)=]>K'=)
M4+3;]<NHWWL1);TDB7[]F$8__/T?;2],F$FS><7$SS+I<X]F^3)*QL\RXOA'
M$P<8>3S3"S JS'S,;A]>XGZ T6'F_:PXZDF9YYBOQSPG>_1+$T_:&:\<^P^]
MV]^[_2?=SV5DUINRV%:?6&7T_S]5=XA,F:TV_VIYE._NM4&[MOL@?K6YG<VS
M-R?5)^TF*^ZRD[/_^5L\ZOUO6XF36$IB@L0DB2D2TR1F2,Q"F-<3@X>>&(3T
MLU_7LU5>E(M_9Y?5,JGJC\5FLYVMYUDTSS=EVZ?8NWMPM =WR\F[LU&_UWM]
M>O>XW)MW&@X&0_].:?"A=2WCEAG[\<'#DN2,BL1TRZLZ.'Q5#3FC;<Z83!_-
MZ)73\*&<AL%R.M\6Q>ZM]7974]5R/K^*EOGZ^L<R*U;[^FHKJ"#9]7WV'AL^
M?E:]WO2P\L@I17/*N"KVY*#TR"D5B6D2,R1F(<PKY=%#*8^"I?QV/B^VU;OB
M8ET5;[9IK=R@T+5R1\TR.GP#2,D)!8E)$E,DIDG,D)B%,*^\QP_E/0Z6]\]9
M&<VKK=BOB_5U5*T!MNO6"@\B72M\W*SP\;2?# Z*G)Q3M,P93R:C@P\$2<ZI
M2$R3F"$Q"V%>^4X>RG<2+%_Q1UD5[G:QN=EORE7KC*=6%T&G:P5/&M5T^ X]
M::RJ#NXAFL:/23\>'Q3DLXXBGY@F,4-B%L*\*IL^5-DT6&4?MY\WV>_;786)
MNZS]'3(H=*TO$DM)3)"8)#%%8IK$#(E9"//Z(.ZYW=X]=-]9S4%M@6HIJ@E4
MDZBF4$VCFD$U2VE^>SQ*A>+@!\7[Q7JQVJZBY>+W[>)R47Z-YGGU@3%K_\@(
M8YV;@]125!.H)E%-U=KC)58\[!UN<FMT4H-JEM+\JD]<U2?!JM\':>=%5A5\
M]/:ZR++5$VNDL-.YX$DM136!:A+5%*II5#.H9BG-[PN7,\9LT!BC22.JI:@F
M4$VBFD(UC6H&U2RE^>WA(L<XG#E^RLO9,MJN;V>+R^BV6*SGB]O9LK4QR,#K
MO-:\?8&3P7@T/=B%@\XJ4$VBFD(UC6H&U2RE^27O8M$XG(NVKI2B/Z/]!T-^
M5?^JM070=!354E03J"913:&:1C6#:I;2_$9QH6L\8I=.: 2+:BFJ"523J*90
M3:.:035+:7Y[N- V#J>V/V5W63&[SJ+=MX_S%[NO-N_V.[5VQKT4]Q]_%>;E
M0>YY'IZO<\6CT2VJ2513J*91S:":I32_XEW.&X>#WOW*Z=/NZV,_Y;-U:Z&C
M"2^JI:@F4$VBFD(UC6H&U2RE^0WA(NEXRJZ0T( :U5)4$Z@F44VAFD8U@VJ6
MTOPCCEQ0G023ON_[!G+8[-HCM?9X/].D\5WN%)U3H)I$-85J&M4,JEE*\VO?
MI=!).(5.&P=PO(CF]_W06O5H#)VTQ*E)L^K1>!G5)*HI5-.H9E#-4II?]2Z%
M3HY(H1^V$([:J1H6.U<^FD>CFD UB6H*U32J&52SE.9WB,NC$S:/3M \&M52
M5!.H)E%-H9I&-8-JEM+\]G!Y=!+.HTU]A-=NIVK6V@]H#%UK<?QHI=1[V1N-
M#I=*: R-:A+5%*II5#.H9BG-KW070R='Q-!/+Y6J&_XY*Q:SS\LL^E#U0G2>
MKV[S]>XCXY?J?G]&;Y=5IZQWOWDWV]S?I[5?T,P:U5)4$Z@F44VAFD8U@VJ6
MTORN<IEUPF;6"9I9HUJ*:@+5)*HI5-.H9E#-4IK?'BZS3L*9]?U>J8?V>/'T
M,FO<NC!*#C/K)^XW/OP>7_AQ=:YE-(U&-85J&M4,JEE*\VO9I=%)ES2ZRP+J
MTY>\^NW';+ZM[AG]<E>MHW:G(HSD8CU;SW<'X>\'_/#Q%_FA[9Q9[\*/K/.G
M!AISHYI -8EJ"M4TJAE4LY3F=YJ+N1,VYD[0F!O54E03J"913:&:1C6#:I;2
M_#,9NIB['XZYCUY4U<[A8JD7'RRJPO-UK7A4$Z@F44VAFD8U@VJ6TOR*=^%V
M/QQN_X6EUTV1[?=>W=XN%_.'>[1V"QJ)HUJ*:@+5)*HI5-.H9E#-4IK?4RXZ
M[R?H(JN/YN:HEJ*:0#6):@K5-*H95+.4YK?'H_-%!X/'#HNL?NLBJW^XYRH\
M7^>*9T\#S9X'FCT1-'LF:/94T.RYH/\;47C?1>']<!2^7V1]R.[RY=UNEU2]
MM)*S^6*Y*+^VECZ:C:-:BFH"U22J*533J&90S5*:WR N0>\/V143&H6C6HIJ
M M4DJBE4TZAF4,U2FM\>+@KOAT^:_5U'7X3-SCURKWG?0Q\TSZ2-3BI03:*:
M0C6-:@;5+*7YQ>^"[OXQ0??1AU^$M<YEWW*BZ^;A%^B< M4DJBE4TZAF4,U2
MFE_U+A+OAR/QBVH;(9MGFTU>W%\]*GBP=ACK7/1HBHUJ M4DJBE4TZAF4,U2
MFM\<+L7NLREV'TVQ42U%-8%J$M44JFE4,ZAF*<V_]IA+L0?A%/M[KCZ&'JJ-
M:BFJB4'S,/+^]'!%)]$Y%:II5#.H9BG-KWR79@_":?9W;2B'S<ZUCZ;3J"9J
MS;N,VZ19^VCJC&H:U0RJ64KS:]^ESH/P =L=MY/#6N>J1T-G5!.U]KCJ6][P
MT2P9U32J&52SE.87O<N2!^$L^<CKK865SL6.YLVH)FK-O][AM+'+2J*S*E33
MJ&90S5*:7^^/KBL<3I(;NX4ZI<IAO',;H*DRJ@E4DZBF4$VCFD$U2VE^L[A4
M><"FR@,T54:U%-4$JDE44ZBF4<V@FJ4TOSU<JCSX+Z3*8;-SCZ!'6:.:&+1<
M.;IY(2N)3JI03:.:035+:7[QNU1Y@*;*8:USV:.G!T<U,6A)O!NGV93HG K5
M-*H95+.4YE>]2Y4'75+E>.(=^?,Q6R^JVW_.RZP](T!#9E1+44V@FD0UA6H:
MU0RJ64KS>\6%S ,V9!Z@(3.JI:@F4$VBFD(UC6H&U2RE>>TQ="'S,!PRBS_*
MQ?IZN]C<[+NCVGAX:I,A#'5M#%1+44T,F]ERTF^LG= Y%:II5#.H9BG-+WB7
M+0_#V?*WD\SL/Q?^C+[C_,CA"3HW AHTHYI -8EJ"M4TJAE4LY3F-XP+I(?L
M8=!#-)%&M135!*I)5%.HIE'-H)JE-+\]7'0]#$?7[^\O,A=]SHMJ["[!F\^J
MZ9Z([FK,._YFW-P=>1Z>M'/9H]DTJDE44ZBF4<V@FJ4TO^Q=@CT,)]C-':^M
MY3YHE/NNV@^+?=!<;S<.S@D_GLXUC ;+J*903:.:035+:7X-NV!Y&#[A]_&7
M6@]#G=<TP^:^^7%O-$P.2QX-BUMF;6S2H@DPJFE4,ZAF*<VO8Y< #\,)<+=-
MVNJ&7\J;K(B^!<=O-YNL_7""\+R=RQY-B5%-H)I$-85J&M4,JEE*\_O(A<G#
M,;NEBZ;)J):BFD UB6H*U32J&52SE.:WATN=A^'4^<@E/QHOU]KC1<LP/EPF
MH:$QJDE44ZBF4<V@FJ4TO]1=:#P,IF[?NZ(*K*305!G54E03J"913:&:1C6#
M:I;2O/X9N51YU$-74B,T6T:U%-4$JDE44ZBF4<V@FJ4TOSU<!CWJ>BGJUJ9
M<^91\Z#AYGF_T"D%JDE44ZBF4<V@FJ4TO]9=?#P*'\]\L)2Z>/*$2$=]]R(\
M6>>>0,-E5!.H)E%-H9I&-8-JEM+\YG'A\HB]-O4(/4 :U5)4$Z@F44VAFD8U
M@VJ6TOSV<"'T*!Q"=_ON11CKW!RDEJ*:0#6):@K5]*CYU8&X6M8>+FP-.JNE
M-+_L76X]HG+K,-2YY)]-D%-T0M$R8=R;QN.#*T=(=%:%:AK5#*I92O/KV.76
MHTZY]47HJ+8C-@W0L!K54E03J"913:&:1C6#:I;2_.9Q8?6(#:M':%B-:BFJ
M"523J*903:.:035+:7Y[N+!Z% ZK.VX:H*$UJJ6H)E!-HII"-8UJ!M7LJ/FU
MAJFWU>)7O<NM1^'<NL.6 1I(UUIPRP!-F9^?4*(3*E33J&90S5*:5\)C%QV/
MPP<D!S8*+BXNCM\<"$_3M<!1+44U@6H2U12J:50SJ&8IS6\;%RF/8W1S8(R&
MRZB6HII -8EJ"M4TJAE4LY3FMX=+H<?A%+K;YD 8Z]P<:,J,:@+5)*HI5-.H
M9FKM\8&-H\8I^"TUIU_T+CT>AP]-/GYK( QU+OCFR:L/MP;0"<6X>53UX=8
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MJ'Y_E>?EMQ]V$WS)B]_V#_OL/U!+ P04    "  D-3!81)Y)DGH"  !:!@
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M<KJ;.+ZSK[C/5FNA*MQHO,$KF('XO+ECLN36E$56 .$9)8C!<N)<^9>)'ZH
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M]0)U?\F8?)_HEMC]T-*_4$L#!!0    ( "0U,%BAEHX!K L  +Z5   9
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M08((%@SQ71AB]N,."#V,-5-[;W@.-EN1-.B348PWL 3Q&B^8/-,+BA^$$/&
M1HC!>JQ-S5O73 5ICS\#./#2,4IN947I]^3DP1]K1I(1$/!$@L#R9P_W0$A"
MDGG\FT.U(F8B+!^_TV?IS<N;66$.]Y3\%?AB.]8&&O)AC7=$/-/#-\AOJ)OP
M/$IX^A<=\KZ&AKP=%S3,Q3*#,(BR7_R6/XB20'+J!58NL"X5M'-!^U)!)Q=T
M3@6],X)N+NB>"CIG!+U<T+M4T,\%_=2L[.FFUMA8X,F(T0-B26])2PY2?U.U
M="2(DE)<"B:O!E(G)LO7Q6+N/#I/+],YNIO.IT_W#EI^<YP79#\L[^=_+%^?
MG27ZBIXP8S@I&_39!H$#PF]DZ^O21I\_W:!/*(C0RY;N.(Y\/M*%3"T)H'MY
M&G=9&M:9-+KHD49BRY$3^>#7Z.^;]?V/]':S?OB1WFG6FU8#0)>>%,98[\;<
M68U$&[P6:IM?D&585MT#:9;_OB,M9/7/RNUF^31F,KIQ5NY<GKQ9(Y]=+C=J
MY&ZS? FQO/=A7?0C*]K%.]).>>TSO&<@6("/%IB)'^B%X8CC;"#]>RZ[H@<!
M(?^GKN@S;J>>F\PRMSS&'HPU.8UP8'O0)K_^8O:,W^H,5PFS5<(<E;"92IBK
M"'94-IVB;#I-],G4\^@N$ES.V!X$>[PB@.3HB"(JH-SX!:U KBGD12(7!CCR
M ,E3Y-/=2JQW1,[6&:>NP+(,>FD&R:IC/[&,MB'?F7VY<AKSO+9R5,*<:O[F
ML'.:_TQE2%<1[*@DND5)=)M+XGJ',V"W_(2,BL&-4:\U6"7,J:;?K]BK,J"K
M"'9D;Z^PM]=H[T/DR<\!+I=(/F1'-\FZB% <E=[W.I<;N==.%"IA=J\ZPG1/
M'72JG;Y6>\U4YN4J@AWYW"]\[G_@LP!)%4BNB&OM;)1?:Z=*F*T2YF0PTRCY
M;K2,P8GM*D.Z]2'-(N21GX/"ST&CGS;(T%Z TS4=O,G/?%YKZZ RF%G#RE@\
MJ+P+E3?!;DSG6A>J :LS:+6/>=K'5934D0/#PH%AHP-'2^RZ1]\HO_:-4@FS
M5<(<E;"92IBK"'94':;Q<Y?"^)\^P7*PHLI12K.5TAREM)E2FJN*=EP^I4TN
M\Z+A)4[+AP1X%9"@?J#)2>6A<C@T.R>#?'.\J^M )<VIN8/3Z4!I0%<5+3-7
M+VUFAL VZ3XU1^D74K9]5K06>^'3= ?XI-TQ;V?9CO9/3+;!_HC9)H@X(K"6
M2*/5EU,ZR_:LLQ-!XW3+=$6%H&%ZN 7L TLZR.MK*K_A\Y,D0/&?@\E_4$L#
M!!0    ( "0U,%BS H* -P0  *X5   9    >&PO=V]R:W-H965T<R]S:&5E
M=#@T+GAM;+U878_:.!3]*U:V6K529_(!),,L( %AU:Z8%L',]F&U#R8Q8-6)
MJ>U ]]^OG61"0H)G:*.^0)SXG.M[XFN?>'"D["O?(23 ]XC$?&CLA-C?FR8/
M=BB"_);N42R?;"B+H)!-MC7YGB$8IJ"(F(YEN68$<6R,!NF]!1L-:"((CM&"
M 9Y$$63_31"AQZ%A&\\WEGB[$^J&.1KLX1:MD'C:+YALF05+B",4<TQCP-!F
M:(SM>]_V%"#M\3=&1UZZ!BJ5-:5?5>-C.#0L-2)$4" 4!91_!S1%A"@F.8YO
M.:E1Q%3 \O4S^Y]I\C*9->1H2LD7'(K=T+@S0(@V,"%B28\?4)Y03_$%E/#T
M%QSSOI8!@H0+&N5@.8((Q]D__)X+40)(GF: DP.<UP(Z.:!S#G O +HYH)LJ
MDZ62ZN!# 4<#1H^ J=Z235VD8J9HF3Z.U7M?"2:?8HD3H]738C&?/<P^/8[G
M8#*>CS]-9V#U839[!/['U73^>?6TG*W #9CN8+Q% ,=@3.1D@7& @)QVP*?)
M6FP2 L9!0)-8</#61P)BPM])U-/*!V_?O -O%/!Q1Q,.XY /3"&'K@9@!ODP
M)]DPG0O#[($'&HL=![,X1&$#?JK'>R_A?3W>=C0$IM2\$-YY%G[B:!E]%-R"
MCOT>.);C-"6DA_^5D%O@>!?A_NNCVYIL.L4TZJ1\G0M\Q<M?H@#A UP3]/YL
MHDP9"K$ <\HY^&=)"0&R<(^0A?\V38<L7+<YG%H,[_D>!FAHR-6.(W9 QNCW
MWVS7^J-)RC;)_);(*C)W"YF[.O;1!&UQ'.-X*]<ZHI1MDDY+<:UT&9F;DJD]
MY##R+&M@'LJ*M!2PHDBO4*2G5426XPMR]&H9V-9Y"E-MD&MG2#UB6;-*FFZ1
MIJM-\PLD(8H#R 78DZ I32W^VK?>)IG?$EE%-Z_0S?NUZY+7ILQMDODMD55D
MOBMDOOOY=2FCZ%4*T;7/"E$;YUI)6B*K2-(O).EK)5DP>L"I.U:3; U#Z4;7
MHM'Z]&O"W+C>F2[:8-?JTA)911?;.CE.2[^6,2S0#=UL -V ))8.-OT(D*4I
MOP*R<FTTB%9-IO-57!_X6I7:8JO*5#+F]D_N;#E!69%^OWNN2;U3O>Q\_5A^
M-%?GE*NCS?7S&FXQF%(>R64Z$3B I'D.:&FN77Y;9?/;8JM*>#+@]B]VX':K
M%KQ5-K\MMJK6)Q=NMV##[;IU;MCO\E[E\G2]6G76.W7<NV9':9^<LZVWSE?L
M4'JFJ^="KYY.__RCHJF3U;F0\\E&VR_XZ!_<>UIUUSF;9B?SM5VJN9^LL*VU
M@*_94%IUMSF;O@#\AE[E LAR-4L'7!%BV_2@D(/TA65G7<7=XC!RG![!F:?N
MV4GF V2R>#D@:".AUJTG-6;9X6#6$'2?'I>MJ1 T2B]W"(:(J0[R^892\=Q0
M 8HCVM'_4$L#!!0    ( "0U,%C1]XYTJ@(  (8&   9    >&PO=V]R:W-H
M965T<R]S:&5E=#@U+GAM;*U5WT_;,!#^5ZP,32 Q\KMC+(U4VB*0"E2D'0_3
M'MSDVE@X=F:[+?#7ST[2J$! /.PEL<_W??[N?#Y'6RX>9 Z@T&-!F>Q;N5+E
MF6W+-(<"RQ-> M,K2RX*K/14K&Q9"L!9!2JH[3E.SRXP858<5;:IB".^5I0P
MF HDUT6!Q=,Y4+[M6ZZU,]R15:Z,P8ZC$J\@ 34OIT+/[)8E(P4P23A# I9]
M:^">#4/C7SG\(K"5>V-D(EEP_F F5UG?<HP@H) JPX#U;P-#H-00:1E_&TZK
MW=( ]\<[]HLJ=AW+ DL8<GI/,I7WK5,+9;#$:ZKN^/82FG@J@2FGLOJB;>/K
M6"A=2\6+!JP5%(35?_S8Y&$/X ;O +P&X'T6X#< OPJT5E:%-<(*QY'@6R2,
MMV8S@RHW%5I'0Y@YQ40)O4HT3L7)?#J=C*_'-[/!!)T/)H.;X1@EE^/Q#(VN
MDN'D-IG?C1/T#5VQ#3#%Q1,Z'('"A,HC;9TG(W1X<(0.$&%HEO.UQ"R3D:VT
M-+.!G38RSFL9WCLR1I">(-\]1I[C>1WPX>?A[DNXK1/29L5KL^)5?/X[?+=B
MA1EYQJ;2CM&0,\DIR7!=>"Q#4P%29Z,V\"6Z( RSE&"*$FT$7>5*HM^#A51"
MU^F?KGS4 H)N >;NGLD2I]"W2K.7V( 5?_WB]IR?7=GY3V0O<N6WN?(_8H_O
M]34UIU\*GH+L//N:H%<1F+:RB5W7]4\C>[,?1(=7V/O1.KT0%[3B@@_%Z8,A
M^G)D:,5Y=UW6^'!OU\#W@MXK;6^]=)L,O&YQ82LN_%#<C"M=,61WL;K4A6]R
M$@;^:?!*W5LOS^VY[BMU]EZ7,!WZ&HL581)16&J<<_)=TXBZZ]43Q<NJ<2RX
MTFVH&N;ZH0!A'/3ZDG.UFYA>U#X]\3]02P,$%     @ )#4P6.Z+JG(X!
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M/C"OOAZG-6=0$P.E"13-S)DV,8%]C<V>9R10FP*EA5 :K6F-,Q+WQ>$B5)-
M:0)%,Q.E-4E@G_779R1_+J.LD-GLJ<M)"52>0&DAE$9KVN9)B=],&=220&D"
M15NEK)_?2UF$41&=GLS+.TQ>R-FL7(NR3!2^G%]9/TLR>:M2Z+P[<WO]%\^'
MSCOJE,_W->;T9*'ZM8]1=J=R2&;R5B'+688>R<JK:I]_*-*%^L/OD9NT*-)Y
M]?!>1E.9E2]0O[]-T^+YA[*"QS3[5C7[]/]02P,$%     @ )#4P6"R+_Z'5
M!P  .3T  !D   !X;"]W;W)K<VAE971S+W-H965T.#DN>&ULS9MK;]LV%(;_
M"N$50PNDMD7)MRXQX%C9U@UM@KJ7#\,^T#)C"]7%$^DX^?>C+C9%2SX2.QK8
ME\26R9?D(Y)ZCXYTO8^3[VQ#*4?/81"QF\Z&\^V[7H]Y&QH2UHVW-!*_/,9)
M2+CXFJQ[;)M0LLHJA4$/]_O#7DC\J#.]SHX])-/K>,<#/Z(/"6*[,"3)RRT-
MXOU-Q^H<#GSRUQN>'NA-K[=D31>4?]D^).);[ZBR\D,:,3^.4$(?;SHSZYWK
M3-(*68FO/MVSTF>4#F49Q]_3+^]7-YU^VB,:4(^G$D3\>Z)S&@2IDNC'/X5H
MY]AF6K'\^:#^:S9X,9@E870>!]_\%=_<=,8=M**/9!?P3_'^=UH,:)#J>7'
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M ?'[8QSSPY>T@>/;TM-_ 5!+ P04    "  D-3!8OC:XT#P&   %,   &0
M 'AL+W=O<FMS:&5E=',O<VAE970Y,"YX;6S%FEUOVS84AO\*X0U#"S2V1#G^
MZ!P#B95BW98FJ-ON8M@%8S&Q$$GT2-J.@?WX41\138>FH_8$ODDL6>>E^)B'
MXBN>T9KQ!S&G5*+'-,G$66LNY>)]IR-F<YH2T68+FJEO[AA/B52'_+XC%IR2
MJ A*DP[VO%XG)7'6&H^*<S=\/&)+F<09O>%(+-.4\,T%3=CZK.6WGDY\CN_G
M,C_1&8\6Y)Y.J?RZN.'JJ%.K1'%*,Q&S#'%Z=]8Z]]^'03\/**[X%M.UV/J,
M\J[<,O:0'WR,SEI>?D<TH3.92Q#U;T4G-$ER)74?_U:BK;K-/'#[\Y/ZAZ+S
MJC.W1- )2_Z*(SD_:PU:**)W9)G(SVS]&ZTZ=)KKS5@BBK]H75WKM=!L*21+
MJV!U!VF<E?_)8P5B*P#W]@3@*@#O!*B&[0%!%1#LMK OH%L%= LR95<*#B&1
M9#SB;(UX?K52RS\4,(MHU?TXRW_WJ>3JVUC%R?'TR_7DCY.+\^EEB";75S>7
MGZ;G7SY>?T(GZ .).?I&DB5%[ Y-)9L]H.M%_FN)XC0I?KASH89,=?9-2"6)
M$_%617^=ANC-SV]'':GN,F^K,ZONZ**\([SGCD[1%<OD7*#++**1)7[BCN\?
MB@_=\3YV"'04WIHQ?F)\@9V*(9VU4>"_0]C#V-8A=_CORZ2-<']O>/CRUGU'
M;X)ZQ 2%7K!OQ,P)IR<7*M<B-&&IFH!$-1(X)]D]59."1+<;M'W=#=D4I\_7
MA$?H[S^5)/HH:2K^L8V/LOVNO?U\(GPO%F1&SUIJIA.4KVAK_,M/?L_[U<86
M4BP$$C.X=VON79?Z^/*1\EDL*$K5E!8O$FI#5TKX7J&1S_FK,6X'H\YJ&XFS
MG:9(@,0,)*<UDM.7(9&4I^_00AVI46;C<OJ<B]<^W>'B;*PI%R Q@TNOYM)S
M<@GC51S1+$*;F":V*?"BC.]MX]B!X6RA*0P@,0-&OX;1=\*XBK,X7:8V"L[
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MI_+8\;A'YIM4BE45G+5@%<;E_^!;]47L!5#[2 "M F@C8$"/! RJ@$$SP[&
M814P; 0,K2,!HRI@U&S2X$C N H8=^WTI J8= V85@'38G3+X2C&T@ED,+M(
MQ!-)\J,S6KY1"**(SH8PC'/MWLDD^S3,XN3LCEW=NNS3!\>]O7OYTY3:DW?$
M_?7^_6]_DE<.ET$8I:_)"](GZ3)(>$K"F-S'H4S?9#NS[8]A%&423"_Z,FM,
MCNS/J\3796)Z)+%-/HI8+E/BQ@N^:(F_T<>/3L4[^OC)J7CW1/NI!M#/1F$W
M%/1Y**ZIEOB+V)Z1@?6&4(M:U??=]KWH*0Z?9Q2[H-#]D3L*=/3 GS?1&:&3
M"GA_YY!7+UZW?5_=VV4_8SJUS^L.MEK +42_2X^G58^/4IB>\FDN]]K51E%4
M,MC]8 <%=G $>Q,%:4K$ [F38OZ5_/4A^YR\EWR5_MWV(RQAPW98?F(\3]?!
MG%_VLC-?RI,M[\U>_F2/K7=MRD/"'"3,1<(\),Q'PA@(I@AON!/>4$>?W8C5
M*KO8J'ZMP48N11+^RQ?D5?B\MVU:N"ZIHX*:7TEM9W1D%:^+_G9?7=KTINI"
MPMRN7?"067TDC!UV8:2T7Y'$:">)D582G[/K3)XDF0:,5:$%F\Y+HX[CXR"S
MNDB8AX3Y2!@#P12!C7<"&W>?<]Z0=9"0;1!M>*&NA8BB($G)FB?E$:_)?_KS
M_K4VFZGJD# '"7-+V&3O]V"=C1I3%3*ACX0Q$$P1W&0GN(G1C ;0G#:AJ>9*
MV%09V6R:LQOS'#*GBX1Y2)B/A#$03)'==">[J<&U59BFF]-GT.G!26_8>EFE
MS6PZ32%A[F$/ID4':&.J0B;UD3 &@BF:>;O3S%L#S8B-3&40+\+X\91PM%C3
M"0D)<Y P]VU'=2&3^D@8 \$4==E6;0Q:9A?WW:8E/=547A5M?Q2;U_30A"Z4
MYD%I/I3&4#157GN^LVTF+X,93(\VUIA]6F/(A"Z4YD%I/I3&4#158[36&.UT
MBLR=TC=D*V2NK22O9K47++0T8UDA:0Z4YI[XWD3,6Y6&;(,/I3$4355:;<K;
M6NMU5IKQ<Q%O>5*6=0,9BI/S&-2=KVC[\UCSOA":T(72/"C-A](8BJ:JJW;>
M;;WU7JHK74>A/-!8JZY:#.O&7:$^H_'L!+7;H30/2O.A-(:BJ;JJ[7M;[]\[
MX39<\'B1DG40+G(GJU5-4*\>2G,JVOCXM9O;<DCS%O#T(3ZTV0Q%4\>]=M5M
MO:W>&/<?-#;U28QU ;73H337;C/4:=-1;S]JW!02U"M'T50AU6ZYK;?+RX<1
MKLBG)+MM"Y+OY.ZX6J ^.)3F0&DNE.9!:3Z4QE T57VU:6Y/D8_"V$CK]P9*
M<Z T%TKSH#0?2F,HFJK VH*W33SX[D\_Z+'&4CRTNFWK^=6\ X1Z[%":!Z7Y
M4!I#T=0G0VLSGNK->/2#$/ITI@*L:"?+TM"L+I3F06D^E,90-%5\M55/]5;]
MCU2G]4AC@1U:]-/Q<&R-QLWY#9K7A=(\*,V'TAB*IDJL=NII-Z?>N!2DYQKK
MC';6&=2/A](\*,V'TAB*INJL]NFIWJ<WK CI:<;JTK>MO>KB0-O@0FD>E.9#
M:0Q%4Y56>_:TBV=O6A'20XT%!S7YH3072O.@-)\>UD\:E[(,E5!55^W<4[US
M7UH?UUV,-SW)6%)0^QY*<Z$T#TKSH32&HJGJJ^L'=(PTWBBT4 "E.5":"Z5Y
M4)H/I3$4355@77B@)PH//VB\Z;'&4IP<-]Z:]PO0$@.4YD%I/I3&4#159W6)
M@1H\F(_PW: UB(IVVG>#5A>@- ]*\Z$TAJ*IXJNK"]2DNM#1=X-6%NAA98':
MMC6DS>*W \WK0FD>E.9#:0Q%4]<2J.L* X.Z@HGOIN>:ZFQP^)C_$9U!\[I0
MF@>E^5 :0]%4G=4EA$&W$D)'WTU/,U:7OFU'?#=H&UPHS8/2?"B-H6BETOI[
M2QNM>/)8+'.5DKG8Q+)<6F>W=[>4UE6Q@%1COVN?>^6"6#6F7)_K8Y \AG%*
M(OZ0(:VS238-)>625^4;*=;% DI?A)1B56PN>;#@27Y ]OF#$/+Y39Y@M_#8
M[']02P,$%     @ )#4P6!HQ@/=/!    A(  !D   !X;"]W;W)K<VAE971S
M+W-H965T.3,N>&ULK5A=CYLX%/TK%ENM9J1.^ J0S"9(,X&J7;7=:-+9/CO@
M)*B L[9)NO]^KX$P"3$DU68>)L:<<^Q[N%QL3_:4_> ;0@3ZF:4YGVH;(;:/
MNLZC#<DP'] MR>'.BK(,"[AD:YUO&<%Q2<I2W3(,5\]PDFO^I.R;,W]""Y$F
M.9DSQ(LLP^S?9Y+2_50SM4/'2[+>"-FA^Y,M7I,%$:_;.8,KO5&)DXSD/*$Y
M8F0UU9[,Q]"T):%$_)V0/3]J(QG*DM(?\N)3/-4,.2.2DDA("0P_.S(C:2J5
M8![_U*):,Z8D'K</ZA_*X"&8)>9D1M/O22PV4VVDH9BL<)&*%[K_2.J '*D7
MT927_]&^QAH:B@HN:%:38099DE>_^&=MQ!$!=-0$JR98UQ+LFF"W"6X'85@3
MAFW"L(/@U(0R=+V*O30NP +[$T;WB$DTJ,E&Z7[)!K^27";*0C"XFP!/^%_#
M;^CS7XL%FH<O:/'QZ25$#^@9\R1".(]1D*2%(#'Z"BG[*8]H1M#=9\KY/;H+
MB,!)"JT']+H(T-V[>_0.Z8AO,",<)3EZS1/!WT,GM+]M:,%!D$]T ;.68^M1
M/</G:H96QPP=](7F8L-1F,<D5O!G_7SO$C_HYYM6CX .=C>>6P?/GZU>Q8!$
M V2;[Y%E6)8JH'[ZGT4Z0);720^N']U4T,/KZ4:/&7:3@':I9W<E8)$1A@5E
MCZK4J+A#-5<6T4>^Q1&9:E E.6$[HOF__V:ZQA\J6V\I%MQ2++R1V,D#&#8/
M8-BG[LM7.X576F5_Q71+IOSD[/P'TS(<QYOHNV-G%3C+--JP0"4W=CSW%!:J
MU&S/:% G83I-F,Y582(L!$N6A<#+E"!!44ZAKN6"T10H:RA6@H#)0F5'-8)S
M,K'A>&RTW#B'M1#!1438ASB)WVWB=W\M?JCJ$/TLQ=#W5)7M#4UCPCA4]&7Y
M!0CG"Y4-[KD-8\=QVTFA@*F20@%3)85*K3,IO,84[X:FQ/7'L,,6[SQM5;8H
M8"I;%#"5+2JU3EM&C2VCWIH<D)S"6J.S*H]N695O*1;<4BR\D=C)(Q@WCV#<
MFYG?RQ4NB1_P#CZ/:U*_D?7J"E;\7,!R2A:L.UA>5=WWJF<U/GMO1N[0-1RW
M7;440$/^6:W$O!(77L:=&&,:;RM6H]>:<+6"70:BJ^J%A'T&XB0J6"(2L.:"
M';5V3^F=788$ER%A+^0T\J.UNOEK27&H2'5:7(K=O#875$AE,EP+#*\ GIIB
MO9EB]9I2;5;R0R7?$E9Y4+H1PU<=LZ->M3'5"-Y)L1V89ML5!<P:N';;$R5L
MZ+0=4<",@=UAQ]MRVNQ=+/J''=O_,\2^SA %3&6($G9NB )V;HA^M->%G<.Z
M/&3@**)%+JHM6-/;'&0\E=OW5G\@#SC*/?2;3'4Z\@6S=9)SE)(52!H##[*6
M50<.U86@VW)'O:0"]N=E<T,PK!(D .ZO*!6'"SE <^SC_P=02P,$%     @
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M&7 -4-]7C,E]1T_0EWOIOU!+ P04    "  D-3!8B,@7\?(#  "V$   &0
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M7!%D,!.E!)$_:YA EI5*<AW_-J)&.V=)/'S>J3]6YJ69-\)A0K._TT0LQL;
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M4M!0\T4\D?E_M"]CW1Z*,JEX6H*A!VG,BE_R6AIQ @ >,\ K 5Y7P* $#.J
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MLEAWD4-,?=(/IV=_M43IP!S:8\Z5GQ3GN+/RB$MEUHT[Z+:W<X$Q[!?F9.A
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M%$_SRRTE4)'K 'B_YEP=;G0#U1'E[']02P,$%     @ )#4P6!5OS6V_!0
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MC;/,H,RK[7_\V!1BQP$&3SB@Q@$=Z^ W#OZQ#D'C$-25V:+4=4BQP),S1C>
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MGA&F#.3W<TK%KPOUKJM]&3KY'U!+ P04    "  D-3!89P*?1=,"  #D"0
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M)AB)Z21FD)A)8A:)V20F2,QYQD9/V&[B^]N':6_W9_#[^V_U<"(']4C,)[&
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M'!TT&IPIEC@WX8>.FJ":1+44U3)4RRFM&33'9HF!<K_O!_FP6JY7E?;'_GV
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M<U'-0S4?U8)7_L4/>]IM\>/<I$N(OHX(U6)42U!-HEJ*:AFJY9363*MC^<5
MN?WXP\VB6*^U3UI8W<Z71?5#DR\OJD ++E!-1S4#U4Q4LU#-1C6!:@ZJN:CF
MH9J/:@&JA:@6H5J,:@FJ251+42U#M9S2F@EV++@8O%7!Q0 MN$ U'=4,5#-1
MS4(U&]4$JCFHYJ*:AVH^J@6H%J):A&HQJB6H)E$M1;4,U7)*:P3:\%AP,507
M7-RL[N]7AW7NVNIQL]X4R^W5V=W%R]_5 W0--E334<U -1/5+%2S44V@FH-J
M+JIYJ.:C6C \K:,8]/N]J\&@76B+CANA6HQJ":I)5$M1+4.UG-*:H74LRQBJ
MRS*>YQ$_7C*/J)8ZIQ/:F8%J!JJ9J&:AFHUJ M4<5'-1S4,U']4"5 M1+4*U
M&-425).HEJ):AFHYI343;'!,L+?JS!BBG1FHIJ.:@6HFJEFH9J.:0#4'U5Q4
M\U#-1[4 U4)4BU M1K4$U22JI:B6H5I.:<U .W9F#-6=&< \(KF-^P;5=%0S
M4,U$-0O5;%03J.:@FHMJ'JKYJ!8,3WMGIN.K<6\T[K7G$=&R#52+42U!-8EJ
M*:IEJ)936C.TCF4;VX>JT&I<A9W-).7QG3.)U'14,U#-1#4+U6Q4$ZCFH)J+
M:AZJ^:@6H%J(:A&JQ:B6H)I$M135,E3+*:V96\<NCN'HK68/T5X.5--1S4 U
M$]4L5+-13:":@VHNJGFHYJ-:@&HAJD6H%J-:@FH2U5)4RU MI[1FH!U[.8;*
M;=(?HK+ZLJKNB^6LU+Z4I58L%JO9<P7B0UG-RN6FN#O[!EQJMW.>H;4<J&:@
MFHEJ%JK9J"90S4$U%]6\O=;OU6;F>K\-FI-R/CIF@&HAJD6H%J-:@FH2U5)4
MRU MI[1F3AWK-H;JS??V8W6[*+5J5X3XSWTR_7(VE]"R#5334<U -1/5+%2S
M44V@FH-J+JIY>ZV52[U1.YC0%@U4"U$M0K48U1)4DZB6HEJ&:CFE-8/IV*PQ
M5#=KU(.IF,VJQV*AJ()28YW3"2W70#4#U<Q73L)(^U$6U;G%+1;Z.FQ4$ZCF
MH)J+:AZJ^:@6H%J(:A&JQ:B6H)I$M135,E3+*:T96,<BC:%R7_.'C[/9ZG&Y
M66L/Q8_B\^+\Y!Y:F8%J.JH9J&:BFH5J-JH)5'/V6GUE6VM)FXL.Z*&:CVK!
M7JN_O=!P,FRO\$/K+5[__L?H@ FJ251+42U#M9S2&MEQ=>RLN%)W5HCE;7F_
MG'^9[V\1%7=5^?26)+]JQ>VWW4VDI_<G>?GZYQ7_Y8K-&_6174,$U0Q4,U'-
M0C4;U02J.:CFHIJ':CZJ!:@6HEJ$:C&J):@F42U%M0S5<DIK9MBQPN)*76'Q
M\_KG^2T>7[H$4BM=+X%034<U ]5,5+-0S48U@6K.7E-= J$#>JCFHUIPYILQ
MF+;+DM AH]>__S$Z8()J$M525,M0+:>T9GP,CO'Q-[;S-I>%_Y?FSQ=_OO@5
M?/H[(RBB!2V20#4#U4Q4LU#-1C6!:@ZJN:CFH9J/:@&JA:@6H5J,:@FJ251+
M42U#M9S2FLEV+)*X>M[SR^]MND(+)%!-1S4#U4Q4LU#-1C6!:@ZJN:CFH9J/
M:@&JA:@6H5J,:@FJ251+42U#M9S2FH%V+)G8/E3.]-W>SY?S]:8J-O-OI5;^
M]5 NU^<KD-12YP0C-1W5#%0S4<U"-1O5!*HYJ.:BFH=J/JH%>ZT^2]?OM=N/
MT"$C5(M1+4$UB6HIJF6HEE-:,YB.+1)7RDV])].%\O'A8?%#VS7YS3>[%11G
M(PHMD$ U'=4,5#-1S4(U&]4$JCFHYJ*:AVH^J@6H%J):A&HQJB6H)E$M1;4,
MU7)*:V;9L4#B:OQ6LX9H@P2JZ:AFH)J):A:JV:@F4,U!-1?5/%3S42U M1#5
M(E2+42U!-8EJ*:IEJ)936C/0CDT35^JFB:#<:%7YK5P^GE\7B/9+H)J.:@:J
MF:AFH9J-:@+5'%1S4<U#-1_5@KW6F"F<#/K7[;E"M%\"U6)42U!-HEJ*:AFJ
MY936C*-CO\25NMK@9K7>:*LOVMUJ=;O6UJO%^7U5:*\$JNFH9J":B6H6JMFH
M)E#-0347U3Q4\U$MV&OUO;VC_F#:#B6T0P+58E1+4$VB6HIJ&:KEE-8,I6.'
MQ)6Z0Z)] \N;SW9+*VZUAVIU^SC;G%]C@99*H)J.:@:JF:AFH9J-:@+5'%1S
M4<U#-1_5 E0+42U"M1C5$E23J):B6H9J.:4ULFQT[+08]=[H!M:(W!9]@VHZ
MJAFH9J*:A6HVJ@E4<U#-134/U7Q4"U M1+4(U6)42U!-HEJ*:AFJY936#+1C
MP<5(77"1K'X4BVV4J=^_0XUT#B^TWP+5#%0S4<U"-1O5!*HYJ.:BFH=J/JH%
M>ZW?KTT9[CK<VVT8Z*@1JL6HEJ":1+44U3)4RRFM&4N#8RPIMR^?S!G>E+=%
M];U8_'DVG="*#%334<U -1/5+%2S44V@FH-J+JIYJ.:C6H!J(:I%J!:C6H)J
M$M525,M0+:>T9H8=*S)&;U61,4(K,E!-1S4#U4Q4LU#-1C6!:@ZJN:CFH9J/
M:@&JA:@6H5J,:@FJ251+42U#M9S2FH%VK,C8/E1=E$7/ZS6TJKS;%V7LWOBW
M^+';A'QV$8?:ZYQCI*:CFH%J)JI9J&;OM?JBM*N35@6!CNF@FHMJ'JKYJ!:@
M6HAJ$:K%J):@FD2U%-4R5,LIK9E/QZ:,4;>FC*B:?]N]TV*T*/;O-?)'46TO
MPUX(*[0R ]5T5#-0S40U"]5L5!.HYJ":BVH>JOFH%J!:B&H1JL6HEJ":1+44
MU3)4RRFM&6K'RHS16U5FC-#*#%334<U -1/5+%2S44V@FH-J+JIYJ.:C6H!J
M(:I%J!:C6H)J$M525,M0+:>T9J =*S-&ZLH,L5X_;O/LG_.EMOY:;$?X97NI
M]OSH;(J=;LT?70]W?YI33C?J83L'U(7#&NBP)JI9J&:CFD U!]5<5/-0S4>U
M -5"5(M0+4:U!-4DJJ6HEJ%:3FG-[#GV8XQ>Z\=8KN>WY?[6U?-[.I9G.S+4
M4.>+)[0C8W3:"S"];M^",= Q352S4,U&-8%J#JJYJ.:AFH]J :J%J!:A6HQJ
M":I)5$M1+4.UG-*:P73LR!BI.S*BQVKVM5B7VD,UGY6[W5C/ET1/ETFWJ\6B
MJ-;'S^ZNF/ZAO5==-:'U&:BF[[5)+;[ZOXW:Z86V8J":A6HVJ@E4<U#-134/
MU7Q4"U M1+4(U6)42U!-HEJ*:AFJY9362*_QL15CK-RD_$%N5K,_M=EJ^:VL
MUD]75KL+K'.YM(<:19NM>3SU6%W#YO4!#71 $]4L5+-13:":@VHNJGFHYJ-:
M@&HAJD6H%J-:@FH2U5)4RU MI[1FU!S[*L;JO@KCK[*:S7]>**V^:-_W:_K^
M[J62>L"NETJHIN^UQJ72Z;42.J:):A:JV:@F4,U!-1?5/%3S42U M1#5(E2+
M42U!-8EJ*:IEJ)936C/ !L< 4S=;[)>@:^7/("NK^>KL/2BUU#F9T%Z+5[[*
M84^[+7Z<RUL#?1TFJEFH9J.:0#4'U5Q4\U#-1[4 U4)4BU M1K4$U22JI:B6
MH5I.:<VT.G98C)5;BD][F!;%>JU]TL+J=KXLJA^:?+JNVOZ-/U_\65^>?C;0
MT%X+5--1S4 U$]4L5+-13:":@VHNJGFHYJ-:@&HAJD6H%J-:@FH2U5)4RU M
MI[1FR!U[+;8/=SZ_Q6H/4X%&:CJJ&:AFHIJ%:C:J"51S4,U%-0_5?%0+4"U$
MM0C58E1+4$VB6HIJ&:KEE-8,M&,1QEA=A/&\'N.YIJFL.FRV4KN=\PSMP$ U
M ]5,5+-0S48UL=?JZVD&_7[O:C!HW95TT'%=5/-0S4>U -5"5(M0+4:U!-4D
MJJ6HEJ%:3FG-K#KV6XR5VXU?F&'\V)YA/)M6:,$%JNFH9J":B6H6JMFH)E#-
M0347U3Q4\U$M0+40U2)4BU$M036):BFJ9:B64UHST8X%%^/)6TTGDGNM;U!-
M1S4#U4Q4LU#-1C6!:@ZJN:CFH9J/:@&JA:@6H5J,:@FJ251+42U#M9S2FH%V
M;,T8JULS_OYT(EJB@6HZJAFH9J*:A6HVJHF]UMB>-^CW![W>>-B>3T2;-%#-
M0S4?U0)4"U$M0K48U1)4DZB6HEJ&:CFE-</JV*0Q5C=I7#B?N/T;<U5]+ZKM
M,P_=&Q_OJO*I)_YLEJ&-&JBFHYJ!:B:J6:AFHYI -0?57%3S4,U'M0#50E2+
M4"U&M035)*JEJ):A6DYIC;B;'*LW)KTWFFR<D-O";U!-1S4#U4Q4LU#-1C6!
M:@ZJN:CFH9J/:@&JA:@6H5J,:@FJ251+42U#M9S2FH%V+/B8J L^_O9DH]KM
MG&=HCP>J&:AFHIJ%:C:JB;U6GVP<#H>]W9_67",ZKHMJ'JKYJ!:@6HAJ$:K%
MJ):@FD2U%-4R5,LIK9E5@V-6J5LN+I]K/'DKRK,)AO9]H)J.:@:JF:AFH9J-
M:@+5'%1S4<U#-1_5 E0+42U"M1C5$E23J):B6H9J.:4U4^[8 3(9OM44(]KW
M@6HZJAFH9J*:A6HVJ@E4<U#-134/U7Q4"U M1+4(U6)42U!-HEJ*:AFJY936
M#+1CW\?VX=M,,2K=SGE&:CJJ&:AFHIJ%:C:JB;W66,_8GYZ=8B3'=5'-0S4?
MU0)4"U$M0K48U1)4DZB6HEJ&:CFE-;/J6.4Q45=Y7#[%&'XN[N::7U9W974V
MO-!N#U334<U -1/5+%2S44V@FH-J+JIYJ.:C6H!J(:I%J!:C6H)J$M525,M0
M+:>T9L =^S\FX[>:743K/U!-1S4#U4Q4LU#-1C6!:@ZJN:CFH9J/:@&JA:@6
MH5J,:@FJ251+42U#M9S2FH%VK/^8*'=C_P>SBVC[!ZKIJ&:@FHEJ%JK9J";V
M6J-\<3H83D:]<7MV$6WV0#4/U7Q4"U M1+4(U6)42U!-HEJ*:AFJY936S*IC
ML\=$W>QQ^>SB)6_OHAZL<X"A=1^H9J":B6H6JMFH)E#-0347U3Q4\U$M0+40
MU2)4BU$M036):BFJ9:B64UHSY(Z-()/KMYIA1#L_4$U'-0/53%2S4,U&-8%J
M#JJYJ.:AFH]J :J%J!:A6HQJ":I)5$M1+4.UG-(:@38]=GY,E5NP__X,H]KM
MFF>HIJ.:@6HFJEFH9J.:V&L7O+T+.JZ+:AZJ^:@6H%J(:A&JQ:B6H)I$M135
M,E3+*:V95<<ZCZFZSN,_V"*M_5%4VXNUS?DH0]L^4$U'-0/53%2S4,U&-8%J
M#JJYJ.:AFH]J :J%J!:A6HQJ":I)5$M1+4.UG-*:<3<XQMW@C>8:IVCY!ZKI
MJ&:@FHEJ%JK9J"90S4$U%]4\5/-1+4"U$-4B5(M1+4$UB6HIJF6HEE-:,]".
MY1]3Y5[L_V"N$>W^0#4=U0Q4,U'-0C4;U<1>:^R5GO:&VS^#]EPCVNN!:AZJ
M^:@6H%J(:A&JQ:B6H)I$M135,E3+*:V95<=>C^U#958]K);K5;6-I<9EV-ET
M4DJ=TXG4=%0S4,U$-0O5;%03J.:@FHMJ'JKYJ!:@6HAJ$:K%J):@FD2U%-4R
M5,LIK9E@Q[:/Z>BMI@_1=@]4TU'-0#43U2Q4LU%-H)J#:BZJ>:CFHUJ :B&J
M1:@6HUJ":A+54E3+4"VGM&:@'=L]ILK-UA\^WM[/E_/UIBHV\V^E5O[U4"[7
M+TP8HG4>J*:CFK'7QO6)KU8]H(F.:*&:C6H"U1Q4<U'-0S4?U0)4"\_\A(];
M"T@C=,08U1)4DZB6HEJ&:CFE-=/F6+TQ55=O?)S-5H_+S5I[*'X4GQ?EV9A!
M6S9034<U ]5,5+-0S48U@6H.JKFHYJ&:CVK!7JM'R%6[1#E$AXQ0+4:U!-4D
MJJ6HEJ%:3FG-1#H6;$S5!1O>:O;G_WA\V*^3^%4KBVJY>MQH#V4U7]V>S2>T
M1 /5=%0S7OG6];4?V^_6V2A"^S)0S48U@6H.JKFHYJ&:CVH!JH6H%J%:C&H)
MJDE42U$M0[6<TIJ9=>S+F"JW+Y]DUOII">!#-9^5VJ::W]V5NR46_]#>JU;_
MH<T9J*:CFK'7&I-Y@_9D'MJ'@6HVJ@E4<U#-134/U7Q4"U M1+4(U6)42U!-
MHEJ*:AFJY936"*SK8Q_&M;H/HQU8FZ_;_WQ=+6ZW<57<SI=WVFWQ8[?%>/^A
M7IQ=$Z@>I6MFH9J.:L;UF9:']@TH=$0+U6Q4$ZCFH)J+:AZJ^:@6H%J(:A&J
MQ:B6H)I$M135,E3+*:V96<=>C&MU+\;+F35;+=?E[/%IO42W_$(K,5!-1S5C
MK]7S:WB27VC1!:K9J"90S4$U%]4\5/-1+4"U$-4B5(M1+4$UB6HIJF6HEE-:
M,[\&Q_Q2[CM6Y-?SK2WM<_EE597;-+N_+Y?[0J?5EQ?3[6R@H948J*:CFO'*
M-[L_ZKWT33+1%V*AFHUJ M4<5'-1S4,U']4"5 M1+4*U&-425).HEJ):AFHY
MI35S[MA_<?U*_\7Y/<7;CYUB^;@K, Q6FW+[X>X_Z^U?/BT\_%4+-U_+ZO#A
M^71#"S)034<U ]5,5+-0S48U@6H.JKFHYJ&:CVH!JH6H%J%:C&H)JDE42U$M
M0[6<TIJ!=RS1V#[<^?P6Y#U,!1JIZ:AFH)J):A:JV:@F4,U!-1?5/%3S42U
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MBFH9JN64U@S!8W/']?2M[H.A#1ZHIJ.:@6HFJEFH9J.:0#4'U5Q4\U#-1[4
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M^#QPOU^;O.K]-K@:-2>O;EYYA=T#CFTX03F3Y2R6LUE.L)S#<B[+>2SGLUS
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MY]5FL[I_>OBU+&[+:O>$[=]_6:TVAP]V WQ?57\^?3D?_C]02P,$%     @
M)#4P6"B7!_:- P  AA   !H   !X;"]W;W)K<VAE971S+W-H965T,3 R+GAM
M;+58VV[;.!#]%4(M%BW0M4SZ$B=K&TCLM#50NT:=[CXL^L!(8YN(**HD9:=
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M*!N ^ULIS6%B$[2_E_@W4$L#!!0    ( "0U,%B^7P<D:00  &48   :
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M9\;$ "E>HWTF[NCA5UP+\A1?0C->_@6'.M8R0++G@N8U6*X@)T7UB;[51IP
M),\PP*X!]FL!3@UPN@#_!8!; ]PNP'T!X-6 4KI9:2^-BY! \RFC!\!4M&13
M#Z7[)5KZ10JU45:"R6^)Q(GY*KY>QI_OP5U\^^7N_N;S-?@9W.&$%@G)""IS
M2=?@$RF0'$$96&+$]PQS-;K"&[EE! >"@@4M.,U(B@1.P3T5*./@?80%(AG_
M(#F_KB+P_MT'\ Z0 MQOZ9ZC(N534T@-:B5F4J_WJEJO_<)Z/;"DA=AR$!<I
M3@?PBW%\\'_X:!P/[1$"4YK?9,!^SL"5/<H8X>0"./ G8%NV/21H'/[;/KL
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MM (+!2G)RE_\5AFQ!Q \>H!= >S/ IP*X*@ _PC K0"N"G"/ +P*X'T6X%<
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M1!3R2E'"8"&0K(H"B\<I4+X=6ZZU6[@AZUR9!3L*2[R&6U!WY4+HF=VI9*0
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MHLDD&49EZ>=1>J_RZBBYQ2S.LS=/BXC65D S<51S*ZTQ ;:VNP!-NE'-1[4
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M\V+V<F+<)GF>3)<7QRH:J;2\0?'SNR3)G[XI-_"8I'\N=_OB?U!+ P04
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M,MO6#Z2^S\HRV]0OUS1:T;PJP'[_D&7ECS?5,ZZ/3TV_^A]02P,$%     @
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MD4+MWT3)9IF+ZJ.^EC885BM@'P])8JM]?CK/HNWI%VM.O[;S^1]02P,$%
M  @ )#4P6#J;0#48 P  F4   !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<\W;2T[<0!2%X:V@7@"N6^^*@%$F3",VT&K,0_1+;4>!W:<% SBE##)!
M_D=6V?+U&7VR[#I7O\;M>GX^[*>GY^-T\;K;[J?KU=,\'W\,P[1Y&G?KZ?)P
M'/?G*P^'TVX]GY>GQ^&XWKRL'\?!.Y>'T]<9JYNKKS,O[MZ.X_],/#P\/&_&
MGX?-[]VXG_\Q>/AS.+U,3^,XKR[NUJ?'<;Y>#:_;S]/3\'ZPR_/DU<7M_?7J
M='MOJV'I0%X"^>4#!0D4E@\4)5!</E"20&GY0%D"Y>4#%0E4E@]4)5!=/E"3
M0&WY0.941@>(U&$-T-J4:P-X;0JV <0V)=L 9INB;0"U3=DV@-NF<!M ;E.Z
M#6"W*=X&T-NKWAZ@MU>]/4!OW[UL _3VJK<'Z.U5;P_0VZO>'J"W5[T]0&^O
M>GN WE[U]@"]O>KM 7H'U3L ] ZJ=P#H'53O - [=!]+ 'H'U3L ] ZJ=P#H
M'53O - [J-X!H'=0O0- [Z!Z!X#>4?6. +VCZAT!>D?5.P+TCJIW!.@=NX_=
M +VCZAT!>D?5.P+TCJIW!.@=5>\(T#NJWA&@=U*]$T#OI'HG@-Y)]4X O9/J
MG0!Z)]4[ ?1.W<]*@-Y)]4X O9/JG0!Z)]4[ ?1.JG<"Z)U5[PS0.ZO>&:!W
M5KTS0.^L>F> WEGUS@"]L^J= 7KG;K,)0.^L>F> WEGUS@"]L^J= 7H7U;L
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M;W!S+V%P<"YX;6Q02P$"% ,4    "  D-3!8D ^G1^X    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  D-3!8
MF5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( "0U,%AHV;(U?@<  "@G   8              "
M@0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  D-3!8
MXFX1+3\"  #"!0  &               @('!#P  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ )#4P6-8N/6+]!P  LBL  !@
M     ("!-A(  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M "0U,%AWK[3<P00  /HB   8              " @6D:  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    "  D-3!8FY#DWV<(  #8)@  &
M            @(%@'P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ )#4P6%)@[#M$ P  OPL  !@              ("!_2<  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( "0U,%C@D H XA$  # 3
M 0 8              " @7<K  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    "  D-3!886G C8H"  #9!0  &               @(&//0
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ )#4P6& PH-,]
M#0  ^4X  !@              ("!3T   'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( "0U,%BIEH@RU0P  /0B   9              "
M@<)-  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ )#4P
M6&UL%R1K'0  F'D  !D              ("!SEH  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    "  D-3!8D"@%S?$H  "DA@  &0
M        @(%P>   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( "0U,%CS^<JXT!   +PN   9              " @9BA  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ )#4P6(I*^8Y$!P  !1D
M !D              ("!G[(  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    "  D-3!8&&'*V_0&  #Z$   &0              @($:N@
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( "0U,%A>S-GV
M500   H*   9              " @47!  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ )#4P6)9+JB5R$   U3<  !D
M ("!T<4  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  D
M-3!8=E;PY&D)   D&   &0              @(%ZU@  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( "0U,%B&N)00@@H  .$<   9
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M970R,RYX;6Q02P$"% ,4    "  D-3!8ODC1QXD$  #%"@  &0
M    @($!$@$ >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M "0U,%A@2$/.Y0T  (TF   9              " @<$6 0!X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ )#4P6)\\'*^Y&0  4EH  !D
M             ("!W20! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    "  D-3!8"S$ @ 8$  !K"0  &0              @('-/@$ >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( "0U,%BIPE[%M@8
M !T0   9              " @0I# 0!X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ )#4P6,7*AO;A @  <08  !D              ("!
M]TD! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  D-3!8
M_)2.008/  #X*   &0              @($/30$ >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( "0U,%@_$*.HS @  /L6   9
M      " @4Q< 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ )#4P6"<O!OZ .   _,8  !D              ("!3V4! 'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  D-3!86RG-XV06  !)4P
M&0              @($&G@$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( "0U,%AX-]7"J0,  .T'   9              " @:&T 0!X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ )#4P6*_.HBJX
M!@  2P\  !D              ("!@;@! 'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    "  D-3!8S$([&1$$   ""P  &0
M@(%POP$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( "0U
M,%@2D=W1" ,  'X&   9              " @;C# 0!X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ )#4P6+6=/-HA!   A@D  !D
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M=#0R+GAM;%!+ 0(4 Q0    ( "0U,%@FD:J@=0@  (4;   9
M  " @0K= 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
M)#4P6$KU$6E^!   X@H  !D              ("!MN4! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    "  D-3!86F.7T%D(  "\&   &0
M            @(%KZ@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( "0U,%@'U -"_P,  /8(   9              " @?OR 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ )#4P6)BTH.?2!@
M,!$  !D              ("!,?<! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    "  D-3!88/2K\HX%  "9*P  &0              @($Z
M_@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( "0U,%C@
M(DRH@ D  "I2   9              " @?\# @!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ )#4P6+_9+E:8!   J!L  !D
M     ("!M@T" 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "0U,%AN]\!W&P,  )(,   9              "
M@7XL @!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ )#4P
M6*QO;)"+"P  =F8  !D              ("!T"\" 'AL+W=O<FMS:&5E=',O
M<VAE970U-BYX;6Q02P$"% ,4    "  D-3!8W;;GS/0"  "9"0  &0
M        @(&2.P( >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0
M   ( "0U,%B:_&^@(1   ,F1   9              " @;T^ @!X;"]W;W)K
M<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ )#4P6/+TS-3H$   >)(
M !D              ("!%4\" 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q0
M2P$"% ,4    "  D-3!8"=X.BK@-   [L0  &0              @($T8 (
M>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( "0U,%B WBCW
M-P,  #,/   9              " @2-N @!X;"]W;W)K<VAE971S+W-H965T
M-C$N>&UL4$L! A0#%     @ )#4P6"_#X@=,"P  JW\  !D
M ("!D7$" 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    "  D
M-3!8 )G.V\D-  "ZE@  &0              @($4?0( >&PO=V]R:W-H965T
M<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( "0U,%C2(I.B"@4  #DC   9
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M970V."YX;6Q02P$"% ,4    "  D-3!8$#W4+C$%  #?)0  &0
M    @(&9I@( >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    (
M "0U,%AQ@E#Y!0,  .8-   9              " @0&L @!X;"]W;W)K<VAE
M971S+W-H965T-S N>&UL4$L! A0#%     @ )#4P6(\27*EB!0  FAX  !D
M             ("!/:\" 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"
M% ,4    "  D-3!8C:9LL,H"   >"   &0              @('6M ( >&PO
M=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( "0U,%AEWQ*[W@(
M )H)   9              " @=>W @!X;"]W;W)K<VAE971S+W-H965T-S,N
M>&UL4$L! A0#%     @ )#4P6.5Y(Z@D!P  BTP  !D              ("!
M[+H" 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    "  D-3!8
MI=>$7Z 1  #[%P$ &0              @(%'P@( >&PO=V]R:W-H965T<R]S
M:&5E=#<U+GAM;%!+ 0(4 Q0    ( "0U,%A$GDF2>@(  %H&   9
M      " @1[4 @!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%
M  @ )#4P6 ZB/EO1 P  LQ4  !D              ("!S]8" 'AL+W=O<FMS
M:&5E=',O<VAE970W-RYX;6Q02P$"% ,4    "  D-3!869*42=H"  #>!@
M&0              @('7V@( >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+
M 0(4 Q0    ( "0U,%CXMZ43S0(  ,\'   9              " @>C= @!X
M;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ )#4P6)\O6LN<
M @  W 8  !D              ("![. " 'AL+W=O<FMS:&5E=',O<VAE970X
M,"YX;6Q02P$"% ,4    "  D-3!8H9:. :P+  "^E0  &0
M@(&_XP( >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( "0U
M,%BP?-O5,@0  -0<   9              " @:+O @!X;"]W;W)K<VAE971S
M+W-H965T.#(N>&UL4$L! A0#%     @ )#4P6#UQW:U6!   11@  !D
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M=#@W+GAM;%!+ 0(4 Q0    ( "0U,%B4N(V=$0\  -_'   9
M  " @0,( P!X;"]W;W)K<VAE971S+W-H965T.#@N>&UL4$L! A0#%     @
M)#4P6"R+_Z'5!P  .3T  !D              ("!2Q<# 'AL+W=O<FMS:&5E
M=',O<VAE970X.2YX;6Q02P$"% ,4    "  D-3!8OC:XT#P&   %,   &0
M            @(%7'P, >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+ 0(4
M Q0    ( "0U,%BA>DNM P8  *,K   9              " @<HE P!X;"]W
M;W)K<VAE971S+W-H965T.3$N>&UL4$L! A0#%     @ )#4P6,3/NX9%!P
MA$P  !D              ("!!"P# 'AL+W=O<FMS:&5E=',O<VAE970Y,BYX
M;6Q02P$"% ,4    "  D-3!8&C& ]T\$   "$@  &0              @(&
M,P, >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+ 0(4 Q0    ( "0U,%@6
MAX?ZV0,  $L5   9              " @08X P!X;"]W;W)K<VAE971S+W-H
M965T.30N>&UL4$L! A0#%     @ )#4P6.?.CF\B P  =@L  !D
M     ("!%CP# 'AL+W=O<FMS:&5E=',O<VAE970Y-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "0U,%AG I]%TP(  .0)   :              "
M@2=2 P!X;"]W;W)K<VAE971S+W-H965T,3 P+GAM;%!+ 0(4 Q0    ( "0U
M,%CHL(I-4SH  *01!0 :              " @3)5 P!X;"]W;W)K<VAE971S
M+W-H965T,3 Q+GAM;%!+ 0(4 Q0    ( "0U,%@HEP?VC0,  (80   :
M          " @;V/ P!X;"]W;W)K<VAE971S+W-H965T,3 R+GAM;%!+ 0(4
M Q0    ( "0U,%@B@05:< (  &H&   :              " @8*3 P!X;"]W
M;W)K<VAE971S+W-H965T,3 S+GAM;%!+ 0(4 Q0    ( "0U,%B^7P<D:00
M &48   :              " @2J6 P!X;"]W;W)K<VAE971S+W-H965T,3 T
M+GAM;%!+ 0(4 Q0    ( "0U,%@6AF<3S00  +<3   :              "
M@<N: P!X;"]W;W)K<VAE971S+W-H965T,3 U+GAM;%!+ 0(4 Q0    ( "0U
M,%C8"1.1L (   $(   :              " @="? P!X;"]W;W)K<VAE971S
M+W-H965T,3 V+GAM;%!+ 0(4 Q0    ( "0U,%@=Y=*V&0P  #6F   :
M          " @;BB P!X;"]W;W)K<VAE971S+W-H965T,3 W+GAM;%!+ 0(4
M Q0    ( "0U,%B/=UO+^ D  $%=   :              " @0FO P!X;"]W
M;W)K<VAE971S+W-H965T,3 X+GAM;%!+ 0(4 Q0    ( "0U,%A0MRG.RP8
M ,XH   :              " @3FY P!X;"]W;W)K<VAE971S+W-H965T,3 Y
M+GAM;%!+ 0(4 Q0    ( "0U,%B5J!YJ.@<   4Q   :              "
M@3S  P!X;"]W;W)K<VAE971S+W-H965T,3$P+GAM;%!+ 0(4 Q0    ( "0U
M,%@>[$'X60,  +(6   -              "  :[' P!X;"]S='EL97,N>&UL
M4$L! A0#%     @ )#4P6)>*NQS     $P(   L              ( !,LL#
M %]R96QS+RYR96QS4$L! A0#%     @ )#4P6( F>VRL!P  \4<   \
M         ( !&\P# 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( "0U,%@Z
MFT U& ,  )E    :              "  ?33 P!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( "0U,%C'A96L>@(  "<^   3
M      "  437 P!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !V '8 ?"
' ._9 P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>544</ContextCount>
  <ElementCount>558</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>166</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - COVER</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/COVER</Role>
      <ShortName>COVER</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONS</Role>
      <ShortName>RESTATEMENT AND RECLASSIFICATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - BUSINESS COMBINATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/BUSINESSCOMBINATIONS</Role>
      <ShortName>BUSINESS COMBINATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - REVENUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/REVENUE</Role>
      <ShortName>REVENUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/GOODWILL</Role>
      <ShortName>GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - INTANGIBLE ASSETS???NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/INTANGIBLEASSETSNET</Role>
      <ShortName>INTANGIBLE ASSETS???NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/FINANCIALINSTRUMENTS</Role>
      <ShortName>FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURES</Role>
      <ShortName>SUPPLEMENTAL BALANCE SHEET DISCLOSURES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - SHAREHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SHAREHOLDERSEQUITY</Role>
      <ShortName>SHAREHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/NETLOSSPERSHARE</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - INCOME TAX BENEFIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/INCOMETAXBENEFIT</Role>
      <ShortName>INCOME TAX BENEFIT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SEGMENTREPORTING</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - EMPLOYEE BENEFIT PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/EMPLOYEEBENEFITPLAN</Role>
      <ShortName>EMPLOYEE BENEFIT PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLY</Role>
      <ShortName>SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSTables</Role>
      <ShortName>RESTATEMENT AND RECLASSIFICATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONS</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - BUSINESS COMBINATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/BUSINESSCOMBINATIONSTables</Role>
      <ShortName>BUSINESS COMBINATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/BUSINESSCOMBINATIONS</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - REVENUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/REVENUETables</Role>
      <ShortName>REVENUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/REVENUE</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/GOODWILLTables</Role>
      <ShortName>GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/GOODWILL</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - INTANGIBLE ASSETS???NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/INTANGIBLEASSETSNETTables</Role>
      <ShortName>INTANGIBLE ASSETS???NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/INTANGIBLEASSETSNET</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/DEBT</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/LEASES</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESTables</Role>
      <ShortName>SUPPLEMENTAL BALANCE SHEET DISCLOSURES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURES</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/NETLOSSPERSHARETables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/NETLOSSPERSHARE</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - INCOME TAX BENEFIT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/INCOMETAXBENEFITTables</Role>
      <ShortName>INCOME TAX BENEFIT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/INCOMETAXBENEFIT</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - SEGMENT REPORTING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SEGMENTREPORTINGTables</Role>
      <ShortName>SEGMENT REPORTING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/SEGMENTREPORTING</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables</Role>
      <ShortName>SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLY</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Summary of Net Revenue Restatement Adjustments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails</Role>
      <ShortName>RESTATEMENT AND RECLASSIFICATIONS - Summary of Net Revenue Restatement Adjustments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Summary of Cost of Goods Sold Restatement Adjustments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails</Role>
      <ShortName>RESTATEMENT AND RECLASSIFICATIONS - Summary of Cost of Goods Sold Restatement Adjustments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Summary of SG&amp;A Expenses Restatement Adjustments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails</Role>
      <ShortName>RESTATEMENT AND RECLASSIFICATIONS - Summary of SG&amp;A Expenses Restatement Adjustments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails</Role>
      <ShortName>RESTATEMENT AND RECLASSIFICATIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Summary of Accounts Receivable, Net Restatement Adjustments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails</Role>
      <ShortName>RESTATEMENT AND RECLASSIFICATIONS - Summary of Accounts Receivable, Net Restatement Adjustments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Summary of Inventory Restatement Adjustments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails</Role>
      <ShortName>RESTATEMENT AND RECLASSIFICATIONS - Summary of Inventory Restatement Adjustments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Summary of Reclassification Adjustments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofReclassificationAdjustmentsDetails</Role>
      <ShortName>RESTATEMENT AND RECLASSIFICATIONS - Summary of Reclassification Adjustments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails</Role>
      <ShortName>RESTATEMENT AND RECLASSIFICATIONS - Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Consolidated Balance Sheets (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsParentheticalDetails</Role>
      <ShortName>RESTATEMENT AND RECLASSIFICATIONS - Consolidated Balance Sheets (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Consolidated Statements of Operations and Comprehensive (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails</Role>
      <ShortName>RESTATEMENT AND RECLASSIFICATIONS - Consolidated Statements of Operations and Comprehensive (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Consolidated Statement of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails</Role>
      <ShortName>RESTATEMENT AND RECLASSIFICATIONS - Consolidated Statement of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - BUSINESS COMBINATIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails</Role>
      <ShortName>BUSINESS COMBINATIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - BUSINESS COMBINATIONS - Summary of Purchase Price Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails</Role>
      <ShortName>BUSINESS COMBINATIONS - Summary of Purchase Price Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - BUSINESS COMBINATIONS - Schedule of Intangible Assets Acquired in Business Combination (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails</Role>
      <ShortName>BUSINESS COMBINATIONS - Schedule of Intangible Assets Acquired in Business Combination (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - BUSINESS COMBINATIONS - Unaudited Pro Forma Consolidated Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails</Role>
      <ShortName>BUSINESS COMBINATIONS - Unaudited Pro Forma Consolidated Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - REVENUE - Revenue by Sales Channel (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails</Role>
      <ShortName>REVENUE - Revenue by Sales Channel (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - REVENUE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/REVENUENarrativeDetails</Role>
      <ShortName>REVENUE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - REVENUE - Revenue by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails</Role>
      <ShortName>REVENUE - Revenue by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - GOODWILL - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails</Role>
      <ShortName>GOODWILL - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - GOODWILL - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/GOODWILLNarrativeDetails</Role>
      <ShortName>GOODWILL - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - INTANGIBLE ASSETS???NET - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS???NET - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - INTANGIBLE ASSETS???NET - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/INTANGIBLEASSETSNETNarrativeDetails</Role>
      <ShortName>INTANGIBLE ASSETS???NET - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - INTANGIBLE ASSETS???NET - Expected Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails</Role>
      <ShortName>INTANGIBLE ASSETS???NET - Expected Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - DEBT - Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/DEBTLongtermDebtDetails</Role>
      <ShortName>DEBT - Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - DEBT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/DEBTNarrativeDetails</Role>
      <ShortName>DEBT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - DEBT - Scheduled Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails</Role>
      <ShortName>DEBT - Scheduled Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - LEASES - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/LEASESSupplementalCashFlowInformationDetails</Role>
      <ShortName>LEASES - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - LEASES - Operating Lease Maturity Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails</Role>
      <ShortName>LEASES - Operating Lease Maturity Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - LEASES - Operating Lease Maturity Schedule Prior to the Adoption of ASC 842 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details</Role>
      <ShortName>LEASES - Operating Lease Maturity Schedule Prior to the Adoption of ASC 842 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - FINANCIAL INSTRUMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/FINANCIALINSTRUMENTS</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails</Role>
      <ShortName>SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Change in Allowance for Doubtful Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails</Role>
      <ShortName>SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Change in Allowance for Doubtful Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails</Role>
      <ShortName>SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails</Role>
      <ShortName>SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails</Role>
      <ShortName>SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - STOCK-BASED COMPENSATION - Fair Value of Stock Options Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Fair Value of Stock Options Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - SHAREHOLDERS??? EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails</Role>
      <ShortName>SHAREHOLDERS??? EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/SHAREHOLDERSEQUITY</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9954533 - Disclosure - NET LOSS PER SHARE - Basic and Diluted Net Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails</Role>
      <ShortName>NET LOSS PER SHARE - Basic and Diluted Net Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9954534 - Disclosure - NET LOSS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9954535 - Disclosure - INCOME TAX BENEFIT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails</Role>
      <ShortName>INCOME TAX BENEFIT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9954536 - Disclosure - INCOME TAX BENEFIT - Schedule of Consolidated Pretax Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails</Role>
      <ShortName>INCOME TAX BENEFIT - Schedule of Consolidated Pretax Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9954537 - Disclosure - INCOME TAX BENEFIT - Schedule of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails</Role>
      <ShortName>INCOME TAX BENEFIT - Schedule of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9954538 - Disclosure - INCOME TAX BENEFIT - Schedule of Components of Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails</Role>
      <ShortName>INCOME TAX BENEFIT - Schedule of Components of Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9954539 - Disclosure - INCOME TAX BENEFIT - Summary of Deferred Tax Assets and Deferred Tax Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails</Role>
      <ShortName>INCOME TAX BENEFIT - Summary of Deferred Tax Assets and Deferred Tax Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9954540 - Disclosure - INCOME TAX BENEFIT - Summary of Net Operating Losses and Tax Credit Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails</Role>
      <ShortName>INCOME TAX BENEFIT - Summary of Net Operating Losses and Tax Credit Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9954541 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9954542 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9954543 - Disclosure - SEGMENT REPORTING - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SEGMENTREPORTINGNarrativeDetails</Role>
      <ShortName>SEGMENT REPORTING - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>9954544 - Disclosure - SEGMENT REPORTING - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails</Role>
      <ShortName>SEGMENT REPORTING - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>9954545 - Disclosure - SEGMENT REPORTING - Reconciliation of Segment Gross Profit to Net Income (Loss) Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentGrossProfittoNetIncomeLossBeforeIncomeTaxesDetails</Role>
      <ShortName>SEGMENT REPORTING - Reconciliation of Segment Gross Profit to Net Income (Loss) Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>9954546 - Disclosure - EMPLOYEE BENEFIT PLAN (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/EMPLOYEEBENEFITPLANDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLAN (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/EMPLOYEEBENEFITPLAN</ParentRole>
      <Position>106</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>9954547 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>9954548 - Disclosure - SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails</Role>
      <ShortName>SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables</ParentRole>
      <Position>108</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>9954549 - Disclosure - SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails</Role>
      <ShortName>SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables</ParentRole>
      <Position>109</Position>
    </Report>
    <Report instance="wald-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>9954550 - Disclosure - SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Cash Flow (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails</Role>
      <ShortName>SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Cash Flow (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables</ParentRole>
      <Position>110</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isUsgaap="true" original="wald-20221231.htm">wald-20221231.htm</File>
    <File>wald-20221231.xsd</File>
    <File>wald-20221231_cal.xml</File>
    <File>wald-20221231_def.xml</File>
    <File>wald-20221231_lab.xml</File>
    <File>wald-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>wald-20221231_g1.jpg</File>
    <File>wald-20221231_g2.jpg</File>
    <File>wald-20221231_g3.jpg</File>
    <File>wald-20221231_g4.jpg</File>
    <File>wald-20221231_g5.jpg</File>
    <File>wald-20221231_g6.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://fasb.org/srt/2023</BaseTaxonomy>
    <BaseTaxonomy items="1956">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="51">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>136
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "wald-20221231.htm": {
   "nsprefix": "wald",
   "nsuri": "http://www.waldencast.com/20221231",
   "dts": {
    "inline": {
     "local": [
      "wald-20221231.htm"
     ]
    },
    "schema": {
     "local": [
      "wald-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "wald-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "wald-20221231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "wald-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "wald-20221231_pre.xml"
     ]
    }
   },
   "keyStandard": 459,
   "keyCustom": 99,
   "axisStandard": 44,
   "axisCustom": 1,
   "memberStandard": 69,
   "memberCustom": 86,
   "hidden": {
    "total": 15,
    "http://www.waldencast.com/20221231": 6,
    "http://xbrl.sec.gov/dei/2023": 6,
    "http://fasb.org/us-gaap/2023": 3
   },
   "contextCount": 544,
   "entityCount": 1,
   "segmentCount": 166,
   "elementCount": 916,
   "unitCount": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1956,
    "http://xbrl.sec.gov/dei/2023": 51,
    "http://fasb.org/srt/2023": 3
   },
   "report": {
    "R1": {
     "role": "http://www.waldencast.com/role/COVER",
     "longName": "0000001 - Document - COVER",
     "shortName": "COVER",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.waldencast.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-46",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-46",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYParenthetical",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-16",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "0000009 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS",
     "longName": "0000010 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONS",
     "longName": "0000011 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS",
     "shortName": "RESTATEMENT AND RECLASSIFICATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ErrorCorrectionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ErrorCorrectionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "0000012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.waldencast.com/role/BUSINESSCOMBINATIONS",
     "longName": "0000013 - Disclosure - BUSINESS COMBINATIONS",
     "shortName": "BUSINESS COMBINATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.waldencast.com/role/REVENUE",
     "longName": "0000014 - Disclosure - REVENUE",
     "shortName": "REVENUE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.waldencast.com/role/GOODWILL",
     "longName": "0000015 - Disclosure - GOODWILL",
     "shortName": "GOODWILL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.waldencast.com/role/INTANGIBLEASSETSNET",
     "longName": "0000016 - Disclosure - INTANGIBLE ASSETS\u2014NET",
     "shortName": "INTANGIBLE ASSETS\u2014NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.waldencast.com/role/DEBT",
     "longName": "0000017 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.waldencast.com/role/LEASES",
     "longName": "0000018 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.waldencast.com/role/FINANCIALINSTRUMENTS",
     "longName": "0000019 - Disclosure - FINANCIAL INSTRUMENTS",
     "shortName": "FINANCIAL INSTRUMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTS",
     "longName": "0000020 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURES",
     "longName": "0000021 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES",
     "shortName": "SUPPLEMENTAL BALANCE SHEET DISCLOSURES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.waldencast.com/role/STOCKBASEDCOMPENSATION",
     "longName": "0000022 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.waldencast.com/role/SHAREHOLDERSEQUITY",
     "longName": "0000023 - Disclosure - SHAREHOLDERS\u2019 EQUITY",
     "shortName": "SHAREHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.waldencast.com/role/NETLOSSPERSHARE",
     "longName": "0000024 - Disclosure - NET LOSS PER SHARE",
     "shortName": "NET LOSS PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.waldencast.com/role/INCOMETAXBENEFIT",
     "longName": "0000025 - Disclosure - INCOME TAX BENEFIT",
     "shortName": "INCOME TAX BENEFIT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONS",
     "longName": "0000026 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "0000027 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.waldencast.com/role/SEGMENTREPORTING",
     "longName": "0000028 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.waldencast.com/role/EMPLOYEEBENEFITPLAN",
     "longName": "0000029 - Disclosure - EMPLOYEE BENEFIT PLAN",
     "shortName": "EMPLOYEE BENEFIT PLAN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.waldencast.com/role/SUBSEQUENTEVENTS",
     "longName": "0000030 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLY",
     "longName": "0000031 - Disclosure - SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY)",
     "shortName": "SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSTables",
     "longName": "9954473 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS (Tables)",
     "shortName": "RESTATEMENT AND RECLASSIFICATIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9954474 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://www.waldencast.com/role/BUSINESSCOMBINATIONSTables",
     "longName": "9954475 - Disclosure - BUSINESS COMBINATIONS (Tables)",
     "shortName": "BUSINESS COMBINATIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.waldencast.com/role/REVENUETables",
     "longName": "9954476 - Disclosure - REVENUE (Tables)",
     "shortName": "REVENUE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.waldencast.com/role/GOODWILLTables",
     "longName": "9954477 - Disclosure - GOODWILL (Tables)",
     "shortName": "GOODWILL (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.waldencast.com/role/INTANGIBLEASSETSNETTables",
     "longName": "9954478 - Disclosure - INTANGIBLE ASSETS\u2014NET (Tables)",
     "shortName": "INTANGIBLE ASSETS\u2014NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.waldencast.com/role/DEBTTables",
     "longName": "9954479 - Disclosure - DEBT (Tables)",
     "shortName": "DEBT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.waldencast.com/role/LEASESTables",
     "longName": "9954480 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSTables",
     "longName": "9954481 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESTables",
     "longName": "9954482 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES (Tables)",
     "shortName": "SUPPLEMENTAL BALANCE SHEET DISCLOSURES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONTables",
     "longName": "9954483 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.waldencast.com/role/NETLOSSPERSHARETables",
     "longName": "9954484 - Disclosure - NET LOSS PER SHARE (Tables)",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.waldencast.com/role/INCOMETAXBENEFITTables",
     "longName": "9954485 - Disclosure - INCOME TAX BENEFIT (Tables)",
     "shortName": "INCOME TAX BENEFIT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.waldencast.com/role/SEGMENTREPORTINGTables",
     "longName": "9954486 - Disclosure - SEGMENT REPORTING (Tables)",
     "shortName": "SEGMENT REPORTING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables",
     "longName": "9954487 - Disclosure - SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) (Tables)",
     "shortName": "SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
     "longName": "9954488 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:FinancialDesignationPredecessorAndSuccessorFixedList",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
     "longName": "9954489 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Summary of Net Revenue Restatement Adjustments (Details)",
     "shortName": "RESTATEMENT AND RECLASSIFICATIONS - Summary of Net Revenue Restatement Adjustments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-111",
      "name": "wald:MinimumThresholdPeriodForContractRepaymentOverTime",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails",
     "longName": "9954490 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Summary of Cost of Goods Sold Restatement Adjustments (Details)",
     "shortName": "RESTATEMENT AND RECLASSIFICATIONS - Summary of Cost of Goods Sold Restatement Adjustments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-114",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails",
     "longName": "9954491 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Summary of SG&A Expenses Restatement Adjustments (Details)",
     "shortName": "RESTATEMENT AND RECLASSIFICATIONS - Summary of SG&A Expenses Restatement Adjustments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-118",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
     "longName": "9954492 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Narrative (Details)",
     "shortName": "RESTATEMENT AND RECLASSIFICATIONS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "wald:MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors",
      "unitRef": "distributor",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "wald:MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "wald:MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors",
      "unitRef": "distributor",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "wald:MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails",
     "longName": "9954493 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Summary of Accounts Receivable, Net Restatement Adjustments (Details)",
     "shortName": "RESTATEMENT AND RECLASSIFICATIONS - Summary of Accounts Receivable, Net Restatement Adjustments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-124",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails",
     "longName": "9954494 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Summary of Inventory Restatement Adjustments (Details)",
     "shortName": "RESTATEMENT AND RECLASSIFICATIONS - Summary of Inventory Restatement Adjustments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:InventoryNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-128",
      "name": "us-gaap:InventoryNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofReclassificationAdjustmentsDetails",
     "longName": "9954495 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Summary of Reclassification Adjustments (Details)",
     "shortName": "RESTATEMENT AND RECLASSIFICATIONS - Summary of Reclassification Adjustments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-136",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
     "longName": "9954496 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Consolidated Balance Sheets (Details)",
     "shortName": "RESTATEMENT AND RECLASSIFICATIONS - Consolidated Balance Sheets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-138",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsParentheticalDetails",
     "longName": "9954497 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Consolidated Balance Sheets (Parenthetical) (Details)",
     "shortName": "RESTATEMENT AND RECLASSIFICATIONS - Consolidated Balance Sheets (Parenthetical) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R58": {
     "role": "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
     "longName": "9954498 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Consolidated Statements of Operations and Comprehensive (Loss) (Details)",
     "shortName": "RESTATEMENT AND RECLASSIFICATIONS - Consolidated Statements of Operations and Comprehensive (Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-16",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
     "longName": "9954499 - Disclosure - RESTATEMENT AND RECLASSIFICATIONS - Consolidated Statement of Cash Flows (Details)",
     "shortName": "RESTATEMENT AND RECLASSIFICATIONS - Consolidated Statement of Cash Flows (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-139",
      "name": "wald:DepreciationDepletionAndAmortizationOperatingActivities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "longName": "9954500 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-85",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails",
     "longName": "9954501 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-165",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-165",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
     "longName": "9954502 - Disclosure - BUSINESS COMBINATIONS - Narrative (Details)",
     "shortName": "BUSINESS COMBINATIONS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-184",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails",
     "longName": "9954503 - Disclosure - BUSINESS COMBINATIONS - Summary of Purchase Price Allocation (Details)",
     "shortName": "BUSINESS COMBINATIONS - Summary of Purchase Price Allocation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-189",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails",
     "longName": "9954504 - Disclosure - BUSINESS COMBINATIONS - Schedule of Intangible Assets Acquired in Business Combination (Details)",
     "shortName": "BUSINESS COMBINATIONS - Schedule of Intangible Assets Acquired in Business Combination (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-195",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-200",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails",
     "longName": "9954505 - Disclosure - BUSINESS COMBINATIONS - Unaudited Pro Forma Consolidated Financial Information (Details)",
     "shortName": "BUSINESS COMBINATIONS - Unaudited Pro Forma Consolidated Financial Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-215",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-215",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails",
     "longName": "9954506 - Disclosure - REVENUE - Revenue by Sales Channel (Details)",
     "shortName": "REVENUE - Revenue by Sales Channel (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-223",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.waldencast.com/role/REVENUENarrativeDetails",
     "longName": "9954507 - Disclosure - REVENUE - Narrative (Details)",
     "shortName": "REVENUE - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-274",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails",
     "longName": "9954508 - Disclosure - REVENUE - Revenue by Geographic Region (Details)",
     "shortName": "REVENUE - Revenue by Geographic Region (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-260",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails",
     "longName": "9954509 - Disclosure - GOODWILL - Schedule of Goodwill (Details)",
     "shortName": "GOODWILL - Schedule of Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:Goodwill",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillPeriodIncreaseDecrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.waldencast.com/role/GOODWILLNarrativeDetails",
     "longName": "9954510 - Disclosure - GOODWILL - Narrative (Details)",
     "shortName": "GOODWILL - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R71": {
     "role": "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails",
     "longName": "9954511 - Disclosure - INTANGIBLE ASSETS\u2014NET - Schedule of Intangible Assets (Details)",
     "shortName": "INTANGIBLE ASSETS\u2014NET - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.waldencast.com/role/INTANGIBLEASSETSNETNarrativeDetails",
     "longName": "9954512 - Disclosure - INTANGIBLE ASSETS\u2014NET - Narrative (Details)",
     "shortName": "INTANGIBLE ASSETS\u2014NET - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R73": {
     "role": "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails",
     "longName": "9954513 - Disclosure - INTANGIBLE ASSETS\u2014NET - Expected Amortization (Details)",
     "shortName": "INTANGIBLE ASSETS\u2014NET - Expected Amortization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
     "longName": "9954514 - Disclosure - DEBT - Long-term Debt (Details)",
     "shortName": "DEBT - Long-term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-316",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.waldencast.com/role/DEBTNarrativeDetails",
     "longName": "9954515 - Disclosure - DEBT - Narrative (Details)",
     "shortName": "DEBT - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-328",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:DebtInstrumentIncreaseAccruedInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails",
     "longName": "9954516 - Disclosure - DEBT - Scheduled Maturities (Details)",
     "shortName": "DEBT - Scheduled Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-334",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-334",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.waldencast.com/role/LEASESNarrativeDetails",
     "longName": "9954517 - Disclosure - LEASES - Narrative (Details)",
     "shortName": "LEASES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "wald:LesseeOperatingLeaseExtensionTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "wald:LesseeOperatingLeaseExtensionTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.waldencast.com/role/LEASESSupplementalCashFlowInformationDetails",
     "longName": "9954518 - Disclosure - LEASES - Supplemental Cash Flow Information (Details)",
     "shortName": "LEASES - Supplemental Cash Flow Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails",
     "longName": "9954519 - Disclosure - LEASES - Operating Lease Maturity Schedule (Details)",
     "shortName": "LEASES - Operating Lease Maturity Schedule (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details",
     "longName": "9954520 - Disclosure - LEASES - Operating Lease Maturity Schedule Prior to the Adoption of ASC 842 (Details)",
     "shortName": "LEASES - Operating Lease Maturity Schedule Prior to the Adoption of ASC 842 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
     "longName": "9954521 - Disclosure - FINANCIAL INSTRUMENTS (Details)",
     "shortName": "FINANCIAL INSTRUMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails",
     "longName": "9954522 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-351",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-351",
      "name": "us-gaap:DerivativeAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails",
     "longName": "9954523 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Narrative (Details)",
     "shortName": "SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "wald:AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "wald:AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails",
     "longName": "9954524 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Change in Allowance for Doubtful Accounts (Details)",
     "shortName": "SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Change in Allowance for Doubtful Accounts (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails",
     "longName": "9954525 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Inventory (Details)",
     "shortName": "SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:InventoryWorkInProcess",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:InventoryWorkInProcess",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails",
     "longName": "9954526 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Property and Equipment, Net (Details)",
     "shortName": "SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails",
     "longName": "9954527 - Disclosure - SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Other Current Liabilities (Details)",
     "shortName": "SUPPLEMENTAL BALANCE SHEET DISCLOSURES - Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "longName": "9954528 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-398",
      "name": "wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals",
      "unitRef": "individual",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-398",
      "name": "wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals",
      "unitRef": "individual",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails",
     "longName": "9954529 - Disclosure - STOCK-BASED COMPENSATION - Stock Option Activity (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-27",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails",
     "longName": "9954530 - Disclosure - STOCK-BASED COMPENSATION - Fair Value of Stock Options Valuation Assumptions (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Fair Value of Stock Options Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "1",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "1",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails",
     "longName": "9954531 - Disclosure - STOCK-BASED COMPENSATION - Restricted Stock Activity (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Restricted Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-69",
      "name": "wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-69",
      "name": "wald:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails",
     "longName": "9954532 - Disclosure - SHAREHOLDERS\u2019 EQUITY (Details)",
     "shortName": "SHAREHOLDERS\u2019 EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-94",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-16",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails",
     "longName": "9954533 - Disclosure - NET LOSS PER SHARE - Basic and Diluted Net Income (Loss) (Details)",
     "shortName": "NET LOSS PER SHARE - Basic and Diluted Net Income (Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
     "longName": "9954534 - Disclosure - NET LOSS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "shortName": "NET LOSS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails",
     "longName": "9954535 - Disclosure - INCOME TAX BENEFIT - Narrative (Details)",
     "shortName": "INCOME TAX BENEFIT - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails",
     "longName": "9954536 - Disclosure - INCOME TAX BENEFIT - Schedule of Consolidated Pretax Income (Loss) (Details)",
     "shortName": "INCOME TAX BENEFIT - Schedule of Consolidated Pretax Income (Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails",
     "longName": "9954537 - Disclosure - INCOME TAX BENEFIT - Schedule of Provision for Income Taxes (Details)",
     "shortName": "INCOME TAX BENEFIT - Schedule of Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails",
     "longName": "9954538 - Disclosure - INCOME TAX BENEFIT - Schedule of Components of Income Tax Expense (Details)",
     "shortName": "INCOME TAX BENEFIT - Schedule of Components of Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails",
     "longName": "9954539 - Disclosure - INCOME TAX BENEFIT - Summary of Deferred Tax Assets and Deferred Tax Liabilities (Details)",
     "shortName": "INCOME TAX BENEFIT - Summary of Deferred Tax Assets and Deferred Tax Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "wald:DeferredTaxAssetsAccruedInterestToForeignRelatedParties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "wald:DeferredTaxAssetsAccruedInterestToForeignRelatedParties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails",
     "longName": "9954540 - Disclosure - INCOME TAX BENEFIT - Summary of Net Operating Losses and Tax Credit Carryforwards (Details)",
     "shortName": "INCOME TAX BENEFIT - Summary of Net Operating Losses and Tax Credit Carryforwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-450",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "wald:SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-450",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "wald:SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "longName": "9954541 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-467",
      "name": "wald:ForwardPurchaseAgreementPerformanceFeeAllocationPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "longName": "9954542 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-517",
      "name": "us-gaap:LongTermPurchaseCommitmentAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-517",
      "name": "us-gaap:LongTermPurchaseCommitmentAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.waldencast.com/role/SEGMENTREPORTINGNarrativeDetails",
     "longName": "9954543 - Disclosure - SEGMENT REPORTING - Narrative (Details)",
     "shortName": "SEGMENT REPORTING - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R104": {
     "role": "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails",
     "longName": "9954544 - Disclosure - SEGMENT REPORTING - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details)",
     "shortName": "SEGMENT REPORTING - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-196",
      "name": "us-gaap:GrossProfit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentGrossProfittoNetIncomeLossBeforeIncomeTaxesDetails",
     "longName": "9954545 - Disclosure - SEGMENT REPORTING - Reconciliation of Segment Gross Profit to Net Income (Loss) Before Income Taxes (Details)",
     "shortName": "SEGMENT REPORTING - Reconciliation of Segment Gross Profit to Net Income (Loss) Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:GrossProfit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.waldencast.com/role/EMPLOYEEBENEFITPLANDetails",
     "longName": "9954546 - Disclosure - EMPLOYEE BENEFIT PLAN (Details)",
     "shortName": "EMPLOYEE BENEFIT PLAN (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true,
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails",
     "longName": "9954547 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-526",
      "name": "wald:NumberOfLeaseAgreements",
      "unitRef": "lease",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R108": {
     "role": "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails",
     "longName": "9954548 - Disclosure - SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Balance Sheet (Details)",
     "shortName": "SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Balance Sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-540",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R109": {
     "role": "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails",
     "longName": "9954549 - Disclosure - SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Operations (Details)",
     "shortName": "SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-543",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    },
    "R110": {
     "role": "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails",
     "longName": "9954550 - Disclosure - SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Cash Flow (Details)",
     "shortName": "SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY) - Condensed Statement of Cash Flow (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-543",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "wald-20221231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital expenditures in accounts payable and accruals",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r59"
     ]
    },
    "wald_ObagiCosmeceuticalsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ObagiCosmeceuticalsLLCMember",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Obagi Global Holdings Limited",
        "terseLabel": "Obagi Cosmeceuticals",
        "label": "Obagi Cosmeceuticals LLC [Member]",
        "documentation": "Obagi Cosmeceuticals LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for bad debts",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r453"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r526",
      "r704",
      "r1086"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "us-gaap_ContractWithCustomerSalesChannelDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerSalesChannelDomain",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with Customer, Sales Channel [Domain]",
        "label": "Contract with Customer, Sales Channel [Domain]",
        "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary."
       }
      }
     },
     "auth_ref": [
      "r1009",
      "r1133"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r1164"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETNarrativeDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofReclassificationAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r82",
      "r86"
     ]
    },
    "us-gaap_ContractWithCustomerSalesChannelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerSalesChannelAxis",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with Customer, Sales Channel [Axis]",
        "label": "Contract with Customer, Sales Channel [Axis]",
        "documentation": "Information by sales channel for delivery of good or service in contract with customer."
       }
      }
     },
     "auth_ref": [
      "r1009",
      "r1133"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r273",
      "r288",
      "r461",
      "r462",
      "r463",
      "r764",
      "r989"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r85",
      "r766"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "stpr_TX": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "TX",
     "presentation": [
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TEXAS",
        "label": "TEXAS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets Acquired in Business Combination",
        "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]",
        "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other temporary differences",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r1164"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r85"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]",
        "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]",
        "documentation": "A table containing detailed characteristics of finite-lived intangible assets acquired during a business combination. Finite-lived intangible assets are assets that have no physical form, but have expected future economic benefit, and are expected to be used over a defined period. Acquired finite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the Entity) and in total. Additionally, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period are also disclosed."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash contribution of trademarks",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized Software and Website Development Costs",
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r156"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r366",
      "r765",
      "r838",
      "r862",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r882",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r901",
      "r904",
      "r905",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r926",
      "r1028"
     ]
    },
    "srt_CondensedBalanceSheetStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedBalanceSheetStatementTable",
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Balance Sheet Statement [Table]",
        "label": "Condensed Balance Sheet Statement [Table]",
        "documentation": "Disclosure of information about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r329",
      "r1049"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Debt Instrument, Increase, Accrued Interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r1089"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r1164"
     ]
    },
    "srt_NorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NorthAmericaMember",
     "presentation": [
      "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "North America",
        "label": "North America [Member]",
        "documentation": "Continent of North America."
       }
      }
     },
     "auth_ref": [
      "r1204",
      "r1205",
      "r1206",
      "r1207"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r1164"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r90"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CASH INVESTING AND FINANCING ACTIVITIES:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_IncreaseDecreaseInNotesReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInNotesReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Increase (decrease) in loan receivable",
        "label": "Increase (Decrease) in Notes Receivable, Current",
        "documentation": "The increase (decrease) during the reporting period of amounts due within one year (or one business cycle) from note holders for outstanding loans."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other current assets and other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Common Stock Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CondensedCashFlowStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedCashFlowStatementTable",
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Cash Flow Statement [Table]",
        "label": "Condensed Cash Flow Statement [Table]",
        "documentation": "Disclosure of information about condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r329",
      "r1049"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liabilities",
        "label": "Derivative Liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r693",
      "r863",
      "r864",
      "r865",
      "r866",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r895",
      "r897",
      "r898",
      "r943",
      "r944",
      "r946",
      "r948",
      "r949",
      "r951",
      "r952",
      "r986",
      "r1198"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails",
      "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r329",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r511",
      "r516",
      "r517",
      "r518",
      "r519",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r705",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1089"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/REVENUE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r569"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1040",
      "r1041",
      "r1042"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/DEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r96",
      "r99",
      "r147",
      "r148",
      "r150",
      "r154",
      "r198",
      "r199",
      "r998",
      "r1000",
      "r1094"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/EMPLOYEEBENEFITPLAN"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EMPLOYEE BENEFIT PLAN",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r202",
      "r203",
      "r204"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited, weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL INSTRUMENTS",
        "label": "Financial Instruments Disclosure [Text Block]",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails",
      "http://www.waldencast.com/role/GOODWILLNarrativeDetails",
      "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails",
      "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r408",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r487",
      "r488",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r996",
      "r1057",
      "r1195"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares exchanged",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r41",
      "r200"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares in connection with the Obagi and Milk Business Combination",
        "verboseLabel": "Issuance of ordinary shares for Business Combinations",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "documentation": "Value of stock issued pursuant to acquisitions during the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r41",
      "r200"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected stock price volatility, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash consideration",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r664"
     ]
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1091"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected stock price volatility, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock registered (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r163",
      "r164",
      "r200",
      "r840",
      "r926",
      "r956"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r690",
      "r736",
      "r737",
      "r738",
      "r998",
      "r999",
      "r1010",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product registration payments",
        "label": "Payments for Other Fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/DEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Long-Term Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1091",
      "r1166"
     ]
    },
    "wald_CustomerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "CustomerThreeMember",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Three",
        "label": "Customer Three [Member]",
        "documentation": "Customer Three"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r272",
      "r321",
      "r445",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r668",
      "r671",
      "r672",
      "r694",
      "r1022",
      "r1127",
      "r1182",
      "r1183"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UNITED STATES",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current provision (benefit), total",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r648",
      "r654",
      "r1091"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of revolving credit facility",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r1089"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/NETLOSSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares in connection with the Obagi and Milk Business Combination (in shares)",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r200"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Expected Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "wald_VariableRateComponentOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "VariableRateComponentOneMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate Component One",
        "label": "Variable Rate Component One [Member]",
        "documentation": "Variable Rate Component One"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Deferred Tax Assets and Deferred Tax Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "country_VN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "VN",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VIET NAM",
        "label": "VIET NAM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r163",
      "r164",
      "r200",
      "r594"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Provision for Income Taxes",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares exchanged (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r40",
      "r96",
      "r200",
      "r521"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Expense",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Consolidated Pretax Income (Loss)",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1091"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of derivative warrant liabilities (Note 10)",
        "terseLabel": "Change in fair value of derivative warrant liabilities",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityNotionalAmount",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative notional value",
        "label": "Derivative Liability, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability."
       }
      }
     },
     "auth_ref": [
      "r942",
      "r945",
      "r947",
      "r950",
      "r1168",
      "r1169",
      "r1170"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails",
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r483",
      "r484",
      "r485",
      "r766",
      "r767"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r690",
      "r692"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options granted (in shares)",
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r690"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails",
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r85"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "negatedLabel": "Accounts receivable",
        "verboseLabel": "Total accounts receivable, net adjustments",
        "negatedTerseLabel": "Accounts receivable, net",
        "netLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Purchase Price Allocation",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r315",
      "r316"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1025",
      "r1026",
      "r1027",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1095",
      "r1096",
      "r1171",
      "r1197",
      "r1202"
     ]
    },
    "us-gaap_SupplyCommitmentArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplyCommitmentArrangementMember",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supply Commitment Arrangement [Domain]",
        "label": "Supply Commitment Arrangement [Domain]",
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each supply commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r223"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of term loan",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1084"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r170",
      "r171",
      "r172"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1061",
      "r1091",
      "r1166"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from term loan",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1083"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r112",
      "r662"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Debt, Type [Domain]",
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails",
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "negatedTerseLabel": "Less: valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Assets",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294",
      "r693",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r888",
      "r889",
      "r941",
      "r946",
      "r948",
      "r949",
      "r951",
      "r952",
      "r986",
      "r1027",
      "r1198"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsCurrentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance cost, current",
        "label": "Debt Issuance Costs, Current, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage increase in shares available for issuance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventory",
        "label": "Deferred Tax Liabilities, Inventory",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r1164"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Related party liability from merger",
        "terseLabel": "Related party liability",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r117",
      "r665"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Post vesting holding period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity consideration",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Useful Lives (Years)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation",
        "documentation": "Amount of lease obligation assumed in business combination."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of derivative asset",
        "label": "Derivative Asset, Noncurrent",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis",
     "presentation": [
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real Estate, Type of Property [Axis]",
        "label": "Real Estate, Type of Property [Axis]",
        "documentation": "Information by type of real estate property."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r263",
      "r962",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Useful Life",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain",
     "presentation": [
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real Estate [Domain]",
        "label": "Real Estate [Domain]",
        "documentation": "Land and any structures permanently fixed to it."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration received",
        "verboseLabel": "Subscription agreement proceeds",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Goodwill",
        "label": "Deferred Tax Liabilities, Goodwill",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r118",
      "r119",
      "r1164"
     ]
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of units issued in IPO (in shares)",
        "verboseLabel": "Issued (in shares)",
        "netLabel": "Issued in private placement (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Debt, Type [Axis]",
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative warrant liabilities",
        "label": "Derivative Liability, Noncurrent",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Intangibles",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r1164"
     ]
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r1163"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other Nonoperating Income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r321",
      "r445",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r668",
      "r671",
      "r672",
      "r694",
      "r880",
      "r991",
      "r1035",
      "r1127",
      "r1182",
      "r1183"
     ]
    },
    "us-gaap_DeferredTaxAssetsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Waldencast LP",
        "label": "Deferred Tax Assets, Investments",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Lease asset",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r1164"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities (including related party liability of $9,914 as of December 31, 2022)",
        "verboseLabel": "Related party liability",
        "netLabel": "Other current liabilities",
        "totalLabel": "Total",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r1022"
     ]
    },
    "us-gaap_DerivativeCapInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeCapInterestRate",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate cap (percent)",
        "label": "Derivative, Cap Interest Rate",
        "documentation": "Cap rate on an interest rate derivative such as an interest rate cap or collar. If market rates exceed the cap rate, a payment or receipt is triggered on the contract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r655"
     ]
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per unit (in dollars per share)",
        "verboseLabel": "Purchase price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ParentCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ParentCompanyMember",
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Parent Company",
        "label": "Parent Company [Member]",
        "documentation": "Registrant with controlling financial interest in one or more subsidiaries. Controlling interest in subsidiary includes, but is not limited to, primary beneficiary of variable interest entity (VIE). Controlling interest in subsidiary excludes broker-dealer with controlling financial interest in subsidiary but control is likely to be temporary."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss from change in fair value on derivative instruments",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r1056"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Net",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r411",
      "r412",
      "r414"
     ]
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CN",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CHINA",
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding borrowings",
        "label": "Short-Term Debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r220",
      "r1022",
      "r1192"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r655"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentGrossProfittoNetIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other (income) expense, net",
        "negatedLabel": "Other expenses (income), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "us-gaap_DerivativeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLineItems",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Line Items]",
        "label": "Derivative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r225",
      "r794",
      "r1022",
      "r1090",
      "r1107",
      "r1173"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r69",
      "r145",
      "r146",
      "r408",
      "r963"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeTable",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Table]",
        "label": "Derivative [Table]",
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r127",
      "r128",
      "r129",
      "r130",
      "r133",
      "r136",
      "r139",
      "r141",
      "r143",
      "r680"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r69",
      "r145",
      "r146",
      "r408",
      "r836",
      "r963"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixture",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesChannelDirectlyToConsumerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesChannelDirectlyToConsumerMember",
     "presentation": [
      "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Direct sales",
        "label": "Sales Channel, Directly to Consumer [Member]",
        "documentation": "Contract with customer in which good or service is transferred directly to consumer."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "wald_ObagiChinaBusinessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ObagiChinaBusinessMember",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Obagi China Business",
        "label": "Obagi China Business [Member]",
        "documentation": "Obagi China Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "negatedTerseLabel": "Prepaid expenses adjustments",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r464",
      "r465",
      "r982"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Fixed asset basis",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r1164"
     ]
    },
    "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodPercent",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent of award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period, Percent",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ApplicableRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ApplicableRateMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Applicable Rate",
        "label": "Applicable Rate [Member]",
        "documentation": "Applicable Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1078"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/NETLOSSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "wald_VariableRateComponentTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "VariableRateComponentTwoMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate Component Two",
        "label": "Variable Rate Component Two [Member]",
        "documentation": "Variable Rate Component Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "wald_SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "SummaryOfOperatingLossCarryforwardsAndTaxCreditCarryforwardsTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Net Operating Losses and Tax Credit Carryforwards",
        "label": "Summary of Operating Loss Carryforwards and Tax Credit Carryforwards [Table Text Block]",
        "documentation": "Summary of Operating Loss Carryforwards and Tax Credit Carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income (Loss) Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64"
     ]
    },
    "wald_MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MisstatementOfLossOnForgivenessOfUncollectibleLoanReceivableMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Misstatement of Loss On Forgiveness of Uncollectible Loan Receivable",
        "label": "Misstatement of Loss On Forgiveness of Uncollectible Loan Receivable [Member]",
        "documentation": "Misstatement of Loss On Forgiveness of Uncollectible Loan Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]",
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r333",
      "r339",
      "r346",
      "r446",
      "r449",
      "r618",
      "r619",
      "r620",
      "r649",
      "r650",
      "r673",
      "r674",
      "r675",
      "r677",
      "r678",
      "r679",
      "r682",
      "r684",
      "r685",
      "r686",
      "r718"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]",
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r333",
      "r339",
      "r346",
      "r446",
      "r449",
      "r618",
      "r619",
      "r620",
      "r649",
      "r650",
      "r673",
      "r674",
      "r675",
      "r677",
      "r678",
      "r679",
      "r682",
      "r684",
      "r685",
      "r686",
      "r718"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "wald_RestOfTheWorldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "RestOfTheWorldMember",
     "presentation": [
      "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rest of the World",
        "label": "Rest of the World [Member]",
        "documentation": "Rest of the World"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r333",
      "r339",
      "r346",
      "r446",
      "r449",
      "r618",
      "r619",
      "r620",
      "r649",
      "r650",
      "r673",
      "r674",
      "r675",
      "r677",
      "r678",
      "r679",
      "r682",
      "r684",
      "r685",
      "r686",
      "r718"
     ]
    },
    "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Adjustments",
        "label": "Revision of Prior Period, Error Correction, Adjustment [Member]",
        "documentation": "Cumulative increase (decrease) to previously issued financial statements for correction of error."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r342",
      "r343",
      "r344",
      "r345"
     ]
    },
    "wald_SkintrinsiqDevicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "SkintrinsiqDevicesMember",
     "presentation": [
      "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Skintrinsiq Devices",
        "label": "Skintrinsiq Devices [Member]",
        "documentation": "Skintrinsiq Devices"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofReclassificationAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification",
        "label": "Revision of Prior Period, Reclassification, Adjustment [Member]",
        "documentation": "Cumulative increase (decrease) to previously issued financial statements for reclassification. Excludes adjustment for reclassification from amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Obagi and Milk Business Combinations",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r996"
     ]
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL BALANCE SHEET DISCLOSURES",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/LEASESSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities:",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r714",
      "r1021"
     ]
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of promissory note to warrants",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r59"
     ]
    },
    "wald_VendorTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "VendorTwoMember",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vendor Two",
        "label": "Vendor Two [Member]",
        "documentation": "Vendor Two"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ForwardPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ForwardPurchaseAgreementMember",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Purchase Agreement",
        "label": "Forward Purchase Agreement [Member]",
        "documentation": "Forward Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "CA",
     "presentation": [
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CALIFORNIA",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "wald_A2022RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "A2022RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Revolving Credit Facility",
        "label": "2022 Revolving Credit Facility [Member]",
        "documentation": "2022 Revolving Credit Facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFIT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAX BENEFIT",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r628",
      "r636",
      "r639",
      "r646",
      "r651",
      "r657",
      "r658",
      "r659",
      "r845"
     ]
    },
    "wald_OtherMisstatementAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "OtherMisstatementAdjustmentsMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other adjustments",
        "label": "Other Misstatement Adjustments [Member]",
        "documentation": "Other Misstatement Adjustments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofConsolidatedPretaxIncomeLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentGrossProfittoNetIncomeLossBeforeIncomeTaxesDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (loss) before income taxes",
        "negatedLabel": "Pre-tax losses",
        "terseLabel": "Income (loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r174",
      "r226",
      "r373",
      "r393",
      "r399",
      "r402",
      "r785",
      "r798",
      "r992"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current provision (benefit):",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsBusinessCombinationAssumedInPeriod",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options assumed in business combination (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Business Combination, Assumed In Period",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Business Combination, Assumed In Period"
       }
      }
     },
     "auth_ref": []
    },
    "wald_A2022TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "A2022TermLoanMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Term Loan",
        "label": "2022 Term Loan [Member]",
        "documentation": "2022 Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred (income) expense:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, accrued interest and penalties",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_InventoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoriesMember",
     "presentation": [
      "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventories [Member]",
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale."
       }
      }
     },
     "auth_ref": []
    },
    "wald_MisstatementOfDistributorRevenueNonstandardPaymentTermsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MisstatementOfDistributorRevenueNonstandardPaymentTermsMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Misstatement of Revenue, Nonstandard Payment Terms",
        "label": "Misstatement of Distributor Revenue, Nonstandard Payment Terms [Member]",
        "documentation": "Misstatement of Distributor Revenue, Nonstandard Payment Terms"
       }
      }
     },
     "auth_ref": []
    },
    "wald_PrivateDerivativeWarrantLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "PrivateDerivativeWarrantLiabilitiesMember",
     "presentation": [
      "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative warrant liabilities - Private",
        "label": "Private Derivative Warrant Liabilities [Member]",
        "documentation": "Private Derivative Warrant Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r630",
      "r631",
      "r639",
      "r640",
      "r645",
      "r647",
      "r839"
     ]
    },
    "wald_MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MisstatementOfCapitalizedMarketingAndAdvertisingExpensesMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Misstatement of Capitalized Marketing and Advertising Expenses",
        "label": "Misstatement of Capitalized Marketing and Advertising Expenses [Member]",
        "documentation": "Misstatement of Capitalized Marketing and Advertising Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "verboseLabel": "Inventory",
        "netLabel": "Total net inventory adjustments",
        "totalLabel": "Total inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r981",
      "r1022"
     ]
    },
    "wald_ClassOfWarrantOrRightRedemptionStockPriceTrigger": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ClassOfWarrantOrRightRedemptionStockPriceTrigger",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant redemption, stock price trigger (in dollars per share)",
        "label": "Class of Warrant or Right, Redemption, Stock Price Trigger",
        "documentation": "Class of Warrant or Right, Redemption, Stock Price Trigger"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ShareBasedPaymentArrangementBusinessCombinationIncrementalCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedPaymentArrangementBusinessCombinationIncrementalCost",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental stock based compensation expense",
        "label": "Share-Based Payment Arrangement, Business Combination, Incremental Cost",
        "documentation": "Share-Based Payment Arrangement, Business Combination, Incremental Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsParentheticalDetails",
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities and other liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "wald_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer One",
        "label": "Customer One [Member]",
        "documentation": "Customer One"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/COVER",
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r283",
      "r284",
      "r285",
      "r321",
      "r351",
      "r352",
      "r359",
      "r361",
      "r367",
      "r368",
      "r445",
      "r495",
      "r497",
      "r498",
      "r499",
      "r502",
      "r503",
      "r534",
      "r535",
      "r538",
      "r541",
      "r548",
      "r694",
      "r840",
      "r841",
      "r842",
      "r843",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r882",
      "r903",
      "r926",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r1048",
      "r1088",
      "r1099"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss attributable to Class A shareholders",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r296",
      "r298",
      "r306",
      "r783",
      "r805"
     ]
    },
    "wald_CapitalContribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "CapitalContribution",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital contribution of trademarks",
        "label": "Capital Contribution",
        "documentation": "Capital Contribution"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r69",
      "r145",
      "r146",
      "r408",
      "r963",
      "r1051"
     ]
    },
    "wald_ObagiBlueSeaHoldingLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ObagiBlueSeaHoldingLLCMember",
     "presentation": [
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Obagi Blue Sea Holding, LLC",
        "label": "Obagi Blue Sea Holding, LLC [Member]",
        "documentation": "Obagi Blue Sea Holding, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultiple",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise multiple",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Multiple",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Exercise Multiple"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ProceedsFromForwardPurchaseAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ProceedsFromForwardPurchaseAgreements",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from FPA investments",
        "label": "Proceeds From Forward Purchase Agreements",
        "documentation": "Proceeds From Forward Purchase Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "wald_PrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "PrivatePlacementWarrantsMember",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement Warrants",
        "label": "Private Placement Warrants [Member]",
        "documentation": "Private Placement Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "wald_DeferredTaxAssetsTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "DeferredTaxAssetsTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Deferred Tax Assets, Transaction Costs",
        "documentation": "Deferred Tax Assets, Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "wald_PrepaidExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "PrepaidExpensesPolicyTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses",
        "label": "Prepaid Expenses [Policy Text Block]",
        "documentation": "Prepaid Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising",
        "label": "Advertising Cost [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r871",
      "r873",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r895",
      "r896",
      "r897",
      "r898",
      "r914",
      "r915",
      "r916",
      "r917",
      "r920",
      "r921",
      "r922",
      "r923",
      "r941",
      "r943",
      "r948",
      "r951",
      "r1025",
      "r1027"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "wald_A2021TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "A2021TermLoanMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Predecessor 2021 Term Loan",
        "label": "2021 Term Loan [Member]",
        "documentation": "2021 Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease costs",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r712",
      "r1021"
     ]
    },
    "wald_USOnlineMarketplaceDistributorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "USOnlineMarketplaceDistributorMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Online Marketplace Distributor",
        "label": "US Online Marketplace Distributor [Member]",
        "documentation": "US Online Marketplace Distributor"
       }
      }
     },
     "auth_ref": []
    },
    "wald_TretinoinDistributionAndSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "TretinoinDistributionAndSupplyAgreementMember",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails",
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Tretinoin distribution and supply agreement",
        "terseLabel": "Supply agreement",
        "label": "Tretinoin Distribution and Supply Agreement [Member]",
        "documentation": "Tretinoin Distribution and Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "wald_SpaChannelDistributorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "SpaChannelDistributorMember",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Spa Channel Distributor",
        "label": "Spa Channel Distributor [Member]",
        "documentation": "Spa Channel Distributor"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lock-up shares, stock price trigger",
        "label": "Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Stock Price Trigger",
        "documentation": "Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Stock Price Trigger"
       }
      }
     },
     "auth_ref": []
    },
    "wald_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment",
        "label": "Effective Income Tax Rate Reconciliation, Goodwill Impairment, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Goodwill Impairment, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unaudited Pro Forma Consolidated Financial Information",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1053"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.waldencast.com/role/LEASESSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r1021"
     ]
    },
    "wald_PaymentsOfExpensesOnBehalfOfSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "PaymentsOfExpensesOnBehalfOfSubsidiaries",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expenses paid on behalf of subsidiaries",
        "label": "Payments Of Expenses On Behalf Of Subsidiaries",
        "documentation": "Payments Of Expenses On Behalf Of Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ForwardPurchaseAgreementHurdleRateAccrualPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ForwardPurchaseAgreementHurdleRateAccrualPeriod",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hurdle rate accrual period",
        "label": "Forward Purchase Agreement, Hurdle Rate Accrual Period",
        "documentation": "Forward Purchase Agreement, Hurdle Rate Accrual Period"
       }
      }
     },
     "auth_ref": []
    },
    "wald_JanuaryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "JanuaryNoteMember",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January Note",
        "label": "January Note [Member]",
        "documentation": "January Note"
       }
      }
     },
     "auth_ref": []
    },
    "wald_DistributionOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "DistributionOfBusiness",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Distribution of Obagi China Business",
        "label": "Distribution of Business",
        "documentation": "Distribution of Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareCashPaid",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYParenthetical",
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends paid (in dollars per share)",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r529",
      "r546",
      "r680",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r802",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1103",
      "r1104",
      "r1105",
      "r1106"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for doubtful accounts",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r413",
      "r450"
     ]
    },
    "wald_MisstatementOfCapitalizedComputerSoftwareExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MisstatementOfCapitalizedComputerSoftwareExpensesMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Misstatement of Capitalized Computer Software Expenses",
        "label": "Misstatement of Capitalized Computer Software Expenses [Member]",
        "documentation": "Misstatement of Capitalized Computer Software Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "wald_MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MisstatementOfRevenueRecognitionTimingAndPaymentsRecordedForServicesMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Misstatement of Revenue Recognition Timing and Payments Recorded for Services",
        "label": "Misstatement of Revenue Recognition Timing and Payments Recorded for Services [Member]",
        "documentation": "Misstatement of Revenue Recognition Timing and Payments Recorded for Services"
       }
      }
     },
     "auth_ref": []
    },
    "wald_BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "BusinessCombinationConsiderationTransferredCashRepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash repayment of debt",
        "label": "Business Combination, Consideration Transferred, Cash Repayments of Debt",
        "documentation": "Business Combination, Consideration Transferred, Cash Repayments of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails",
      "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009"
     ]
    },
    "wald_MinimumThresholdPeriodForContractRepaymentOverTime": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MinimumThresholdPeriodForContractRepaymentOverTime",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold repayment period",
        "label": "Minimum Threshold Period for Contract Repayment Over Time",
        "documentation": "Minimum Threshold Period for Contract Repayment Over Time"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1091",
      "r1165",
      "r1166"
     ]
    },
    "wald_MilkMakeupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MilkMakeupMember",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails",
      "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails",
      "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Milk",
        "terseLabel": "Milk Makeup",
        "label": "Milk Makeup [Member]",
        "documentation": "Milk Makeup"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails",
      "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009"
     ]
    },
    "wald_IntercompanyPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "IntercompanyPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intercompany payables",
        "label": "Intercompany Payables",
        "documentation": "Intercompany Payables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r1091",
      "r1165"
     ]
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "presentation": [
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage acquired",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "wald_StockGrowthIncentiveAwardsSGIAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "StockGrowthIncentiveAwardsSGIAwardsMember",
     "presentation": [
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SGI Awards",
        "label": "Stock Growth Incentive Awards (SGI Awards) [Member]",
        "documentation": "Stock Growth Incentive Awards (SGI Awards)"
       }
      }
     },
     "auth_ref": []
    },
    "wald_DebtInstrumentCovenantLeverageRatioMaximum": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "DebtInstrumentCovenantLeverageRatioMaximum",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leverage ratio, maximum",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r112",
      "r662",
      "r1013",
      "r1014"
     ]
    },
    "wald_MilkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MilkMember",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milk",
        "label": "Milk [Member]",
        "documentation": "Milk"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, weighted average remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r275",
      "r797"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, weighted average remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "wald_AlternateBaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "AlternateBaseRateMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alternate Base Rate",
        "label": "Alternate Base Rate [Member]",
        "documentation": "Alternate Base Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r1013",
      "r1014"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r243",
      "r246",
      "r795"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, weighted average remaining contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "totalLabel": "Deferred (income) expense, total",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r210",
      "r247",
      "r653",
      "r654",
      "r1091"
     ]
    },
    "wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriod",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lock-up shares, earnout period",
        "label": "Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period",
        "documentation": "Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r609"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "negatedTerseLabel": "Property and equipment, net adjustments",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r786",
      "r797",
      "r1022"
     ]
    },
    "wald_A2018RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "A2018RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Predecessor 2018 Revolving Credit Facility",
        "label": "2018 Revolving Credit Facility [Member]",
        "documentation": "2018 Revolving Credit Facility"
       }
      }
     },
     "auth_ref": []
    },
    "wald_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets, Lease Liabilities",
        "documentation": "Deferred Tax Assets, Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "wald_PublicDerivativeWarrantLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "PublicDerivativeWarrantLiabilitiesMember",
     "presentation": [
      "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative warrant liabilities - Public",
        "label": "Public Derivative Warrant Liabilities [Member]",
        "documentation": "Public Derivative Warrant Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ClassOfWarrantOrRightPeriodBetweenEndOfTradingAndNoticeOfRedemption",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant redemption, period between end of trading and notice of redemption",
        "label": "Class of Warrant or Right, Period Between End of Trading and Notice of Redemption",
        "documentation": "Class of Warrant or Right, Period Between End of Trading and Notice of Redemption"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "wald_TransitionServicesAgreementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "TransitionServicesAgreementPeriod",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transition services, initial term",
        "label": "Transition Services Agreement Period",
        "documentation": "Transition Services Agreement Period"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Error Correction, Type [Axis]",
        "label": "Error Correction, Type [Axis]",
        "documentation": "Information by type of error correction."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r342",
      "r343",
      "r344",
      "r345"
     ]
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r183"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Addresses, Address Type [Axis]",
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]",
        "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]",
        "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r342",
      "r343",
      "r344",
      "r345",
      "r365"
     ]
    },
    "us-gaap_AccountsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableMember",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable",
        "label": "Accounts Payable [Member]",
        "documentation": "Obligations incurred and payable to vendors for goods and services received."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1077",
      "r1087",
      "r1191",
      "r1194"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Address Type [Domain]",
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]",
        "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r342",
      "r343",
      "r344",
      "r345",
      "r365"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.waldencast.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1040",
      "r1041",
      "r1042"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.waldencast.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1040",
      "r1041",
      "r1042"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r1041",
      "r1042"
     ]
    },
    "srt_CondensedIncomeStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedIncomeStatementsCaptionsLineItems",
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Income Statements, Captions [Line Items]",
        "label": "Condensed Income Statements, Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r329",
      "r1049"
     ]
    },
    "srt_CondensedBalanceSheetStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedBalanceSheetStatementsCaptionsLineItems",
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Balance Sheet Statements, Captions [Line Items]",
        "label": "Condensed Balance Sheet Statements, Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r329",
      "r1049"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH\u2014Beginning of period",
        "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH\u2014End of period",
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r183",
      "r317"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.waldencast.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1040",
      "r1041",
      "r1042"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r325",
      "r724",
      "r725",
      "r726",
      "r727",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r899",
      "r901",
      "r933"
     ]
    },
    "us-gaap_SalesChannelThroughIntermediaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesChannelThroughIntermediaryMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Distributor fees for services",
        "terseLabel": "Distributors",
        "label": "Sales Channel, Through Intermediary [Member]",
        "documentation": "Contract with customer in which good or service is transferred through intermediary."
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "srt_CondensedCashFlowStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedCashFlowStatementsCaptionsLineItems",
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Cash Flow Statements, Captions [Line Items]",
        "label": "Condensed Cash Flow Statements, Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r329",
      "r1049"
     ]
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1092",
      "r1093"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OfficeBuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OfficeBuildingMember",
     "presentation": [
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office",
        "label": "Office Building [Member]",
        "documentation": "Building designed primarily for the conduct of business, for example, but not limited to, administration, clerical services, and consultation."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1208",
      "r1209"
     ]
    },
    "srt_WarehouseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "WarehouseMember",
     "presentation": [
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warehouse",
        "label": "Warehouse [Member]",
        "documentation": "Facility designed for the storage of goods or equipment."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1208",
      "r1209"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Name",
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Future minimum lease payments",
        "label": "Operating Leases, Future Minimum Payments Due",
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234"
     ]
    },
    "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Statement of Operations",
        "label": "Condensed Income Statement [Table Text Block]",
        "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r1070",
      "r1094"
     ]
    },
    "us-gaap_SupplyCommitmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplyCommitmentAxis",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supply Commitment [Axis]",
        "label": "Supply Commitment [Axis]",
        "documentation": "Information by arrangements in which the entity has committed resources to supply goods or services to a customer."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r223"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Balance Sheet",
        "label": "Condensed Balance Sheet [Table Text Block]",
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r1070",
      "r1094"
     ]
    },
    "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsBusinessCombinationAssumedInPeriod",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity instruments assumed in business combination (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Business Combination, Assumed In Period",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Business Combination, Assumed In Period"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Statement of Cash Flow",
        "label": "Condensed Cash Flow Statement [Table Text Block]",
        "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r1070",
      "r1094"
     ]
    },
    "us-gaap_PaymentsForDerivativeInstrumentFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForDerivativeInstrumentFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed cash payment",
        "label": "Payments for Derivative Instrument, Financing Activities",
        "documentation": "The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r987"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CONTROLLING SHAREHOLDERS' EQUITY",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r167",
      "r168",
      "r189",
      "r884",
      "r900",
      "r927",
      "r928",
      "r1022",
      "r1035",
      "r1090",
      "r1107",
      "r1173",
      "r1202"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r326",
      "r327",
      "r508",
      "r536",
      "r727",
      "r984",
      "r986"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferredAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredAbstract",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Purchase Price:",
        "label": "Business Combination, Consideration Transferred [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDerivativeAssetsAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDerivativeAssetsAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in fair value of derivative warrant liabilities",
        "label": "Increase (Decrease) in Derivative Assets and Liabilities",
        "documentation": "The increase (decrease) during the period in the net carrying value of derivative instruments reported as assets and liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/LEASESSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities:",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r713"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "verboseLabel": "Accounts payable adjustments",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r1022"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUCCESSOR CONDENSED FINANCIAL INFORMATION OF WALDENCAST PLC (PARENT COMPANY ONLY)",
        "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]",
        "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r329",
      "r1049"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Taxes Paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r56"
     ]
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net carrying amount",
        "terseLabel": "Net carrying amount",
        "verboseLabel": "Outstanding borrowings",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r222",
      "r517",
      "r532",
      "r998",
      "r999",
      "r1193"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation cost, weighted average service period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interests",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r292",
      "r321",
      "r445",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r667",
      "r671",
      "r694",
      "r1022",
      "r1127",
      "r1128",
      "r1182"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, weighted average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised, weighted average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited. weighted average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r134",
      "r136",
      "r138",
      "r871",
      "r873",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r895",
      "r896",
      "r897",
      "r898",
      "r914",
      "r915",
      "r916",
      "r917",
      "r920",
      "r921",
      "r922",
      "r923",
      "r941",
      "r943",
      "r948",
      "r951",
      "r986",
      "r1025",
      "r1027"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r731"
     ]
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Internally developed software",
        "label": "Software Development [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued salaries and related expenses",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r983"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising expense",
        "label": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r731"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r731"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r240",
      "r241",
      "r244",
      "r245"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails": {
       "parentTag": "wald_OperatingExpensesAndCostOfGoodSold",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentGrossProfittoNetIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "negatedLabel": "R&amp;D expenses",
        "verboseLabel": "R&amp;D expense adjustments",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r627",
      "r1190"
     ]
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Internal-Use Software and Website Development Costs",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r731"
     ]
    },
    "us-gaap_ProceedsFromContributionsFromAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromContributionsFromAffiliates",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers from subsidiaries",
        "label": "Proceeds from Contributions from Affiliates",
        "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r406",
      "r993"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Capital expenditure on property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r724",
      "r725",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r899",
      "r901",
      "r933"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Registration Statement",
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeographicConcentrationRiskMember",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographic Concentration Risk",
        "label": "Geographic Concentration Risk [Member]",
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r963"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r318"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.waldencast.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "wald_BusinessAcquisitionEarnoutPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "BusinessAcquisitionEarnoutPeriod",
     "presentation": [
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnout period",
        "label": "Business Acquisition, Earnout Period",
        "documentation": "Business Acquisition, Earnout Period"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ShippingAndHandlingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShippingAndHandlingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shipping and handling costs",
        "label": "Shipping And Handling Costs",
        "documentation": "Shipping And Handling Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities, net of impact of business combinations:",
        "verboseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1091",
      "r1165",
      "r1166"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party accounts payable",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "wald_A2022IncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "A2022IncentiveAwardPlanMember",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Incentive Award Plan",
        "label": "2022 Incentive Award Plan [Member]",
        "documentation": "2022 Incentive Award Plan"
       }
      }
     },
     "auth_ref": []
    },
    "wald_MisstatementOfCapitalizedInternalUseSoftwareCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MisstatementOfCapitalizedInternalUseSoftwareCostsMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Misstatement of Capitalized Internal Use Software Costs",
        "label": "Misstatement of Capitalized Internal Use Software Costs [Member]",
        "documentation": "Misstatement of Capitalized Internal Use Software Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Capital expenditure on intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_ReclassificationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationTable",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofReclassificationAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification [Table]",
        "label": "Reclassification [Table]",
        "documentation": "Disclosure of information about reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r408"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.waldencast.com/role/COVER",
      "http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Redeemable warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share",
        "terseLabel": "Warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r1025",
      "r1026",
      "r1029",
      "r1030",
      "r1031",
      "r1032"
     ]
    },
    "wald_StockIssuedDuringPeriodSharesForeignPurchaseAgreements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "StockIssuedDuringPeriodSharesForeignPurchaseAgreements",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares in connection with the FPA investment (in shares)",
        "label": "Stock Issued During Period, Shares, Foreign Purchase Agreements",
        "documentation": "Stock Issued During Period, Shares, Foreign Purchase Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails",
      "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentGrossProfittoNetIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "terseLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r321",
      "r373",
      "r393",
      "r399",
      "r402",
      "r445",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r694",
      "r992",
      "r1127"
     ]
    },
    "wald_MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MisstatementOfEmployeeRelatedCompensationMattersAndOtherExpensesMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Misstatement of Employee Related Compensation Matters and Other Expenses",
        "label": "Misstatement of Employee Related Compensation Matters and Other Expenses [Member]",
        "documentation": "Misstatement of Employee Related Compensation Matters and Other Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, Net",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ReclassificationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationLineItems",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofReclassificationAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification [Line Items]",
        "label": "Reclassification [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "wald_BurwellMountainTrustAndZenoInvestmentMasterFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "BurwellMountainTrustAndZenoInvestmentMasterFundMember",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Burwell and Zeno",
        "label": "Burwell Mountain Trust and Zeno Investment Master Fund [Member]",
        "documentation": "Burwell Mountain Trust and Zeno Investment Master Fund"
       }
      }
     },
     "auth_ref": []
    },
    "wald_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Two",
        "label": "Customer Two [Member]",
        "documentation": "Customer Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails_1": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of long-term debt",
        "negatedTerseLabel": "Less: Current portion of long-term debt",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.waldencast.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r906",
      "r907",
      "r910"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.waldencast.com/role/GOODWILLNarrativeDetails",
      "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r996"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted (in dollars per share)",
        "terseLabel": "Diluted net loss per share (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r336",
      "r337",
      "r339",
      "r340",
      "r342",
      "r351",
      "r359",
      "r360",
      "r361",
      "r365",
      "r686",
      "r687",
      "r784",
      "r806",
      "r990"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r480",
      "r996"
     ]
    },
    "wald_ShareBasedPaymentArrangementFounderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedPaymentArrangementFounderMember",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Founder",
        "label": "Share-Based Payment Arrangement, Founder [Member]",
        "documentation": "Share-Based Payment Arrangement, Founder"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r721",
      "r722",
      "r723",
      "r725",
      "r728",
      "r846",
      "r847",
      "r848",
      "r908",
      "r909",
      "r910",
      "r930",
      "r932"
     ]
    },
    "wald_A2021RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "A2021RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Predecessor 2021 Revolving Credit Facility",
        "label": "2021 Revolving Credit Facility [Member]",
        "documentation": "2021 Revolving Credit Facility"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAnniversaryPeriod",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anniversary period, annual increase in shares issued under plan",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares, Anniversary Period",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares, Anniversary Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/REVENUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue by Geographic Region",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyInstallments",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of quarterly installments",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Quarterly Installments",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Quarterly Installments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.waldencast.com/role/GOODWILLNarrativeDetails",
      "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill [Table]",
        "label": "Schedule of Goodwill [Table]",
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r996"
     ]
    },
    "wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "BusinessAcquisitionProFormaNetIncomeLossAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails": {
       "parentTag": "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pro forma net income (loss) attributable to Waldencast plc",
        "label": "Business Acquisition, Pro Forma Net Income (Loss), Attributable to Parent",
        "documentation": "Business Acquisition, Pro Forma Net Income (Loss), Attributable to Parent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r907",
      "r910"
     ]
    },
    "wald_MilkTransactionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MilkTransactionMember",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Milk",
        "terseLabel": "Milk Transaction",
        "label": "Milk Transaction [Member]",
        "documentation": "Milk Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Accounting Standard",
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtWeightedAverageInterestRate",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Debt, Weighted Average Interest Rate",
        "documentation": "Weighted average interest rate of debt outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "wald_EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "EffectiveIncomeTaxRateReconciliationTransactionBonusesPercent",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction bonuses",
        "label": "Effective Income Tax Rate Reconciliation, Transaction Bonuses, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Transaction Bonuses, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r329",
      "r522"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r329",
      "r522"
     ]
    },
    "wald_DistributionToShareholderForDispositionOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "DistributionToShareholderForDispositionOfBusiness",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Obagi China Distribution to shareholder",
        "label": "Distribution To Shareholder For Disposition Of Business",
        "documentation": "Distribution To Shareholder For Disposition Of Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/COVER",
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class A Ordinary Shares",
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1202"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r329",
      "r522"
     ]
    },
    "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of annual installments",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Annual Installments",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Annual Installments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r329",
      "r522"
     ]
    },
    "wald_RoyaltyPercentageOfGrossSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "RoyaltyPercentageOfGrossSales",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty percentage",
        "label": "Royalty Percentage of Gross Sales",
        "documentation": "Royalty Percentage of Gross Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r329",
      "r522"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Related party accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable, Related Parties",
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails_1": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, net",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "wald_ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ClassOfWarrantOrRightExercisePeriodAfterCompletionOfBusinessCombination",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise period",
        "label": "Class of Warrant or Right, Exercise Period After Completion of Business Combination",
        "documentation": "Class of Warrant or Right, Exercise Period After Completion of Business Combination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r690",
      "r692"
     ]
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory reserve",
        "label": "Deferred Tax Assets, Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r1164"
     ]
    },
    "wald_StockIssuedDuringPeriodValueForeignPurchaseAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "StockIssuedDuringPeriodValueForeignPurchaseAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares in connection with the FPA investment",
        "label": "Stock Issued During Period, Value, Foreign Purchase Agreements",
        "documentation": "Stock Issued During Period, Value, Foreign Purchase Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "wald_FormulationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "FormulationsMember",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails",
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Formulations",
        "terseLabel": "Formulations",
        "label": "Formulations [Member]",
        "documentation": "Formulations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermPurchaseCommitmentPeriod",
     "presentation": [
      "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase commitment period",
        "label": "Long-Term Purchase Commitment, Period",
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r1164"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentGrossProfittoNetIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense, net",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r229",
      "r303",
      "r377",
      "r703",
      "r911",
      "r1033",
      "r1200"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails": {
       "parentTag": "wald_OperatingExpensesAndCostOfGoodSold",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of goods sold (including related party costs of $5,128 in the Successor period)",
        "verboseLabel": "Cost of goods sold",
        "netLabel": "Total net cost of goods sold adjustments",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r765"
     ]
    },
    "wald_CustomerPaymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "CustomerPaymentPeriod",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer payment period",
        "label": "Customer Payment Period",
        "documentation": "Customer Payment Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Estimated useful life (in years)",
        "terseLabel": "ESTIMATED\u00a0USEFUL\u00a0LIVES",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r988"
     ]
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails",
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Customer/distributor relationships",
        "terseLabel": "Customer relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "wald_ObagiMergerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ObagiMergerMember",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Obagi",
        "terseLabel": "Obagi Merger",
        "label": "Obagi Merger [Member]",
        "documentation": "Obagi Merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "documentation": "The amount of inventory recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r274",
      "r980"
     ]
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentAssetsMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Assets",
        "label": "Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other current assets."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r142"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Dividends paid",
        "terseLabel": "Dividends paid",
        "label": "Dividends, Common Stock, Cash",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "srt_CondensedIncomeStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedIncomeStatementTable",
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Income Statement [Table]",
        "label": "Condensed Income Statement [Table]",
        "documentation": "Disclosure of information about condensed income statement including, but not limited to, income statements of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r329",
      "r1049"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Supplemental Cash Flow and Other Information Related to Leases",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1176"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r200",
      "r792",
      "r830",
      "r835",
      "r844",
      "r883",
      "r1022"
     ]
    },
    "us-gaap_OtherAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets",
        "label": "Other Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other assets."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r142"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/INTANGIBLEASSETSNET"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTANGIBLE ASSETS\u2014NET",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Domain]",
        "label": "Title of Individual [Domain]",
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails",
      "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r511",
      "r516",
      "r517",
      "r518",
      "r519",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r529",
      "r705",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1089"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r218"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails",
      "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r158",
      "r159",
      "r220",
      "r222",
      "r329",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r511",
      "r516",
      "r517",
      "r518",
      "r519",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r705",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1089"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails",
      "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r96",
      "r99",
      "r147",
      "r148",
      "r150",
      "r154",
      "r198",
      "r199",
      "r329",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r511",
      "r516",
      "r517",
      "r518",
      "r519",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r529",
      "r705",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1089"
     ]
    },
    "us-gaap_PurchaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future minimum payment",
        "label": "Purchase Obligation",
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDistributionsToAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDistributionsToAffiliates",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Transfers to subsidiaries",
        "label": "Payments of Distributions to Affiliates",
        "documentation": "The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "wald_StockIssuedDuringPeriodValueTrustProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "StockIssuedDuringPeriodValueTrustProceeds",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A ordinary shares upon release of Trust proceeds",
        "label": "Stock Issued During Period, Value, Trust Proceeds",
        "documentation": "Stock Issued During Period, Value, Trust Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]",
        "documentation": "Entity or group of entities consolidated into reporting entity."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r329",
      "r667",
      "r668",
      "r671",
      "r672",
      "r729",
      "r974",
      "r1073",
      "r1074",
      "r1075",
      "r1126",
      "r1129",
      "r1130"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r584",
      "r614",
      "r615",
      "r617",
      "r1016"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillDisclosureTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/GOODWILL"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GOODWILL",
        "label": "Goodwill Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill."
       }
      }
     },
     "auth_ref": [
      "r466",
      "r469",
      "r479",
      "r996"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]",
        "documentation": "Information by consolidated entity or group of entities."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r329",
      "r667",
      "r668",
      "r671",
      "r672",
      "r729",
      "r974",
      "r1073",
      "r1074",
      "r1075",
      "r1126",
      "r1129",
      "r1130"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r1005",
      "r1133",
      "r1195",
      "r1196"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r135"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r366",
      "r765",
      "r838",
      "r862",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r882",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r901",
      "r904",
      "r905",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r926",
      "r1028"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails",
      "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r765",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r978",
      "r1003",
      "r1023",
      "r1057",
      "r1124",
      "r1125",
      "r1133",
      "r1195"
     ]
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails",
      "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r765",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r978",
      "r1003",
      "r1023",
      "r1057",
      "r1124",
      "r1125",
      "r1133",
      "r1195"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Allowance for Doubtful Accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1110"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofReclassificationAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period [Axis]",
        "label": "Revision of Prior Period [Axis]",
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r365",
      "r447",
      "r448",
      "r650",
      "r683",
      "r685",
      "r686",
      "r687",
      "r706",
      "r719",
      "r720",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r837"
     ]
    },
    "us-gaap_NetRentableArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetRentableArea",
     "presentation": [
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rentable square feet",
        "label": "Net Rentable Area",
        "documentation": "Net rentable area for properties owned."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofReclassificationAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period [Domain]",
        "label": "Revision of Prior Period [Domain]",
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r365",
      "r447",
      "r448",
      "r650",
      "r683",
      "r685",
      "r686",
      "r687",
      "r706",
      "r719",
      "r720",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r837"
     ]
    },
    "us-gaap_ErrorCorrectionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ErrorCorrectionTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESTATEMENT AND RECLASSIFICATIONS",
        "label": "Error Correction [Text Block]",
        "documentation": "The entire disclosure for reporting error correction."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of warrants (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred shares, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r534"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r736",
      "r737",
      "r738",
      "r998",
      "r999",
      "r1010",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/DEBT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEBT",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r319",
      "r504",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r520",
      "r527",
      "r528",
      "r530"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total other (income) expenses, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1135"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory note",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r840"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from revolving credit facility",
        "label": "Proceeds from Lines of Credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r1089"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.waldencast.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease remaining term",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1175"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Options Activity",
        "label": "Schedule of Stock Options Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/LEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r127",
      "r128",
      "r130",
      "r140",
      "r328"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (in dollars per share)",
        "terseLabel": "Basic net loss per share (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r336",
      "r337",
      "r339",
      "r340",
      "r342",
      "r348",
      "r351",
      "r359",
      "r360",
      "r361",
      "r365",
      "r686",
      "r687",
      "r784",
      "r806",
      "r990"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Liabilities",
        "label": "Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total purchase consideration",
        "terseLabel": "Purchase consideration",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r18"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails",
      "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "verboseLabel": "Total unpaid principal",
        "totalLabel": "Total unpaid principal",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r222",
      "r531"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansReceivableBasisSpreadOnVariableRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansReceivableBasisSpreadOnVariableRate",
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Loans Receivable, Basis Spread on Variable Rate",
        "documentation": "Percentage added to reference rate used to compute variable rate on loan receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseAndRentalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseAndRentalExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense",
        "label": "Operating Leases, Rent Expense",
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromOtherDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromOtherDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from PPP Loan",
        "label": "Proceeds from Other Debt",
        "documentation": "Amount of cash inflow from debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r484"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of assets acquired:",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities assumed:",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "verboseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r173",
      "r286",
      "r791",
      "r831",
      "r835"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r276",
      "r796"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance cost",
        "verboseLabel": "Aggregate principal amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r150",
      "r505",
      "r705",
      "r998",
      "r999"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition of Business Combinations, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_LenderConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LenderConcentrationRiskMember",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lender Concentration Risk",
        "label": "Lender Concentration Risk [Member]",
        "documentation": "Reflects the percentage that borrowings or credit lines from one or more lenders is to a specified benchmark, such as total debt, segment debt. Risk is the materially adverse effects from loss of financing arrangements with a particular lender."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "wald_VendorThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "VendorThreeMember",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vendor Three",
        "label": "Vendor Three [Member]",
        "documentation": "Vendor Three"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset, net",
        "verboseLabel": "Operating right-of-use asset",
        "netLabel": "ROU assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "wald_StockIssuedDuringPeriodSharesSubscriptionAgreements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "StockIssuedDuringPeriodSharesSubscriptionAgreements",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares in connection with the PIPE investment (in shares)",
        "label": "Stock Issued During Period, Shares, Subscription Agreements",
        "documentation": "Stock Issued During Period, Shares, Subscription Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive (loss) income \u2014 foreign currency translation adjustments, net of tax",
        "verboseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "wald_MisstatementOfDistributorServiceFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MisstatementOfDistributorServiceFeesMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Misstatement of Distributor Service Fees",
        "label": "Misstatement of Distributor Service Fees [Member]",
        "documentation": "Misstatement of Distributor Service Fees"
       }
      }
     },
     "auth_ref": []
    },
    "wald_GondolasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "GondolasMember",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gondolas",
        "label": "Gondolas [Member]",
        "documentation": "Gondolas"
       }
      }
     },
     "auth_ref": []
    },
    "wald_PPPLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "PPPLoanMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Predecessor PPP Loan",
        "label": "PPP Loan [Member]",
        "documentation": "PPP Loan"
       }
      }
     },
     "auth_ref": []
    },
    "wald_CedarwalkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "CedarwalkMember",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cedarwalk",
        "label": "Cedarwalk [Member]",
        "documentation": "Cedarwalk"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "wald_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Warrants",
        "label": "Public Warrants [Member]",
        "documentation": "Public Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock split conversion ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_GoodwillPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillPeriodIncreaseDecrease",
     "presentation": [
      "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Elimination of Predecessor goodwill",
        "label": "Goodwill, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r1111"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromSubsidiariesNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromSubsidiariesNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity in undistributed earnings of subsidiaries",
        "negatedTerseLabel": "Equity in income of subsidiaries",
        "label": "Income (Loss) from Subsidiaries, Net of Tax",
        "documentation": "Amount after tax of income (loss) of subsidiary attributable to the parent entity."
       }
      }
     },
     "auth_ref": []
    },
    "wald_AaronChatterleyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "AaronChatterleyMember",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aaron Chatterley",
        "label": "Aaron Chatterley [Member]",
        "documentation": "Aaron Chatterley"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityIssuedInBusinessCombinationFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of equity awards in business combination",
        "label": "Equity Issued in Business Combination, Fair Value Disclosure",
        "documentation": "Fair value of equity issued in a business combination."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareReconciliationAbstract",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used in computing net loss per share (Note 15):",
        "verboseLabel": "Shares used in computing net loss per share:",
        "label": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails",
      "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails",
      "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net revenue (including related party net revenue of $17,219 in the Successor period)",
        "verboseLabel": "Net revenue",
        "netLabel": "Total net revenue adjustments",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r375",
      "r392",
      "r397",
      "r398",
      "r404",
      "r406",
      "r408",
      "r567",
      "r568",
      "r765"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Issuance Costs",
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "wald_ReplacementAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ReplacementAwardsMember",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Replacement Awards",
        "label": "Replacement Awards [Member]",
        "documentation": "Replacement Awards"
       }
      }
     },
     "auth_ref": []
    },
    "wald_LineOfCreditCovenantTermsMinimumLiquidity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "LineOfCreditCovenantTermsMinimumLiquidity",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum liquidity covenant",
        "label": "Line of Credit, Covenant Terms, Minimum Liquidity",
        "documentation": "Line of Credit, Covenant Terms, Minimum Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total identifiable assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "wald_EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "EffectiveIncomeTaxRateReconciliationPPPLoanForgivenessPercent",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PPP Loan forgiveness",
        "label": "Effective Income Tax Rate Reconciliation, PPP Loan Forgiveness, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, PPP Loan Forgiveness, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ConversionOfStockToCommonStockConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ConversionOfStockToCommonStockConversionRatio",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock conversion ratio",
        "label": "Conversion of Stock to Common Stock, Conversion Ratio",
        "documentation": "Conversion of Stock to Common Stock, Conversion Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "wald_LesseeOperatingLeaseExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "LesseeOperatingLeaseExtensionTerm",
     "presentation": [
      "http://www.waldencast.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease extension term",
        "label": "Lessee, Operating Lease, Extension Term",
        "documentation": "Lessee, Operating Lease, Extension Term"
       }
      }
     },
     "auth_ref": []
    },
    "wald_DeferredTaxAssetsBelowMarketLeaseContract": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "DeferredTaxAssetsBelowMarketLeaseContract",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Below market contract",
        "label": "Deferred Tax Assets, Below Market Lease Contract",
        "documentation": "Deferred Tax Assets, Below Market Lease Contract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SEGMENTREPORTING"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT REPORTING",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r385",
      "r396",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r408"
     ]
    },
    "wald_DeferredTaxAssetsAccruedInterestToForeignRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "DeferredTaxAssetsAccruedInterestToForeignRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest to foreign related parties",
        "label": "Deferred Tax Assets, Accrued Interest to Foreign Related Parties",
        "documentation": "Deferred Tax Assets, Accrued Interest to Foreign Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityDecreaseForgiveness1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityDecreaseForgiveness1",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, forgiveness",
        "label": "Line of Credit Facility, Decrease, Forgiveness",
        "documentation": "Amount of decrease in line of credit facility from forgiveness by the holder of the line of credit."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1085"
     ]
    },
    "wald_MisstatementOfInventoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MisstatementOfInventoryMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory obsolescence provision",
        "label": "Misstatement of Inventory [Member]",
        "documentation": "Misstatement of Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "wald_SponsorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "SponsorMember",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sponsor",
        "label": "Sponsor [Member]",
        "documentation": "Sponsor"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SEGMENTREPORTINGTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Segment Gross Profit to Net Income (Loss) Before Income Taxes",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78"
     ]
    },
    "wald_USOnlineMarketplaceDistributorAndSADistributorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "USOnlineMarketplaceDistributorAndSADistributorMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Online Marketplace Distributor and SA Distributor",
        "label": "US Online Marketplace Distributor and SA Distributor [Member]",
        "documentation": "US Online Marketplace Distributor and SA Distributor"
       }
      }
     },
     "auth_ref": []
    },
    "wald_OperatingExpensesAndCostOfGoodSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "OperatingExpensesAndCostOfGoodSold",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses and Cost of Good Sold",
        "documentation": "Operating Expenses and Cost of Good Sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Account receivable, net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities assumed:",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SEGMENTREPORTINGTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Financial Measures of Segments to Consolidated Totals",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r80"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "wald_LongTermIncentiveAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "LongTermIncentiveAwardsMember",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Incentive Awards",
        "label": "Long-Term Incentive Awards [Member]",
        "documentation": "Long-Term Incentive Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r80"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "wald_VariableRateComponentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "VariableRateComponentAxis",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate Component [Axis]",
        "label": "Variable Rate Component [Axis]",
        "documentation": "Variable Rate Component"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total antidilutive securities",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "wald_IndemnificationAgreementAdvanceExpensePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "IndemnificationAgreementAdvanceExpensePeriod",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indemnification agreement, advancement period",
        "label": "Indemnification Agreement, Advance Expense Period",
        "documentation": "Indemnification Agreement, Advance Expense Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r87"
     ]
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Activity",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer Benchmark",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r1050"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to Class A shareholders (Note 15):",
        "verboseLabel": "Net loss per common share:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "verboseLabel": "Total Intangible Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "wald_NonCashLossFromChangeInFairValueOnInterestRateCollar": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "NonCashLossFromChangeInFairValueOnInterestRateCollar",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash loss from change in fair value on interest rate collar",
        "label": "Non-Cash Loss From Change In Fair Value On Interest Rate Collar",
        "documentation": "Non-Cash Loss From Change In Fair Value On Interest Rate Collar"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/COVER",
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r283",
      "r284",
      "r285",
      "r321",
      "r351",
      "r352",
      "r359",
      "r361",
      "r367",
      "r368",
      "r445",
      "r495",
      "r497",
      "r498",
      "r499",
      "r502",
      "r503",
      "r534",
      "r535",
      "r538",
      "r541",
      "r548",
      "r694",
      "r840",
      "r841",
      "r842",
      "r843",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r882",
      "r903",
      "r926",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r1048",
      "r1088",
      "r1099"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "wald_SecuredOvernightFinancingRateSOFRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "SecuredOvernightFinancingRateSOFRMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Overnight Financing Rate (SOFR)",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "documentation": "Secured Overnight Financing Rate (SOFR)"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lock-up shares, threshold trading days",
        "label": "Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Trading Days",
        "documentation": "Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "wald_AccruedSalesReturnsAndDamagesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "AccruedSalesReturnsAndDamagesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued sales returns and damages",
        "label": "Accrued Sales Returns And Damages, Current",
        "documentation": "Accrued Sales Returns And Damages, Current"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitureInPeriodWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited, weighted average remaining contractual life",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeiture In Period, Weighted Average Remaining Contractual Term",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeiture In Period, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ClassOfWarrantOrRightRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ClassOfWarrantOrRightRedemptionPricePerShare",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant redemption price (in dollars per share)",
        "label": "Class of Warrant or Right, Redemption Price Per Share",
        "documentation": "Class of Warrant or Right, Redemption Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplyCommitmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplyCommitmentMember",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supply Commitment",
        "label": "Supply Commitment [Member]",
        "documentation": "Supply arrangement in which the entity has agreed to commit resources to supply goods or services to a customer. Excludes long-term commitments."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r223"
     ]
    },
    "wald_GainLossOnNoteReceivableWriteoff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "GainLossOnNoteReceivableWriteoff",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on write-off of loan receivable",
        "negatedLabel": "Loss on write-off of loan receivable",
        "label": "Gain (Loss) on Note Receivable Writeoff",
        "documentation": "Gain (Loss) on Note Receivable Writeoff"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "wald_VietnamPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "VietnamPurchaseAgreementMember",
     "presentation": [
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vietnam Purchase Agreement",
        "label": "Vietnam Purchase Agreement [Member]",
        "documentation": "Vietnam Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails": {
       "parentTag": "wald_OperatingExpensesAndCostOfGoodSold",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentGrossProfittoNetIncomeLossBeforeIncomeTaxesDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "negatedLabel": "SG&amp;A expenses",
        "verboseLabel": "Total SG&amp;A adjustments",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_DerivativeFloorInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeFloorInterestRate",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate floor (percent)",
        "label": "Derivative, Floor Interest Rate",
        "documentation": "Floor rate on an interest rate derivative such as an interest rate floor or collar. If market rates falls below the floor rate, a payment or receipt is triggered on the contract."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherSundryLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Related party liability",
        "terseLabel": "Other",
        "label": "Other Sundry Liabilities, Current",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r89"
     ]
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Category of Item Purchased [Axis]",
        "label": "Category of Item Purchased [Axis]",
        "documentation": "Information by category of items purchased under a long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Imputed Interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in process",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Uncertain tax positions",
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r629",
      "r638"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentTable",
     "presentation": [
      "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Purchase Commitment [Table]",
        "label": "Long-Term Purchase Commitment [Table]",
        "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160"
     ]
    },
    "us-gaap_LongTermPurchaseCommitmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentLineItems",
     "presentation": [
      "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Purchase Commitment [Line Items]",
        "label": "Long-Term Purchase Commitment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liability",
        "terseLabel": "Total reported lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentGrossProfittoNetIncomeLossBeforeIncomeTaxesDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "negatedTerseLabel": "Net income (loss)",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r295",
      "r297",
      "r313",
      "r321",
      "r334",
      "r344",
      "r345",
      "r373",
      "r393",
      "r399",
      "r402",
      "r445",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r666",
      "r669",
      "r670",
      "r687",
      "r694",
      "r785",
      "r799",
      "r850",
      "r902",
      "r924",
      "r925",
      "r992",
      "r1019",
      "r1020",
      "r1034",
      "r1082",
      "r1127"
     ]
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial commitment amount of purchase commitments",
        "label": "Long-Term Purchase Commitment, Amount",
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/NETLOSSPERSHARE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NET LOSS PER SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r362",
      "r363",
      "r364"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r586",
      "r587",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ]
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "presentation": [
      "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]",
        "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]",
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pro forma net revenue",
        "label": "Business Acquisition, Pro Forma Revenue",
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r661"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Pro forma net income (loss)",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r661"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHAREHOLDERS' EQUITY:",
        "verboseLabel": "SHAREHOLDERS\u2019 EQUITY:",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Business Combination, Acquisition Related Costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.waldencast.com/role/NETLOSSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_OtherIncomeDisclosureNonoperatingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncomeDisclosureNonoperatingAbstract",
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income:",
        "label": "Other Income, Nonoperating [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss attributable to noncontrolling interests",
        "terseLabel": "Net loss attributable to noncontrolling interest",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r216",
      "r295",
      "r297",
      "r344",
      "r345",
      "r800",
      "r1082"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Write-off of uncollectible accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "verboseLabel": "Noncontrolling Interest",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r224",
      "r321",
      "r445",
      "r495",
      "r497",
      "r498",
      "r499",
      "r502",
      "r503",
      "r694",
      "r793",
      "r884"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/REVENUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue by Sales Channel",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_PaymentsOfDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDividends",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of dividends",
        "label": "Payments of Dividends",
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r731"
     ]
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from PIPE investments",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Valuation Assumptions, Stock Options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership interest in fully diluted Class A ordinary shares (percent)",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title of Individual [Axis]",
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals."
       }
      }
     },
     "auth_ref": [
      "r1102",
      "r1180"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, weighted average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "As Reported",
        "label": "Previously Reported [Member]",
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r330",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r345",
      "r365",
      "r650",
      "r683",
      "r685",
      "r686",
      "r706",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r837",
      "r1054",
      "r1058",
      "r1059",
      "r1060",
      "r1098",
      "r1108",
      "r1109",
      "r1172",
      "r1178",
      "r1179"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r198",
      "r199",
      "r200",
      "r283",
      "r284",
      "r285",
      "r367",
      "r534",
      "r535",
      "r536",
      "r538",
      "r541",
      "r546",
      "r548",
      "r840",
      "r841",
      "r842",
      "r843",
      "r1002",
      "r1048",
      "r1088"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r84"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total income tax (benefit) expense",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r263",
      "r406",
      "r407",
      "r865",
      "r868",
      "r870",
      "r935",
      "r937",
      "r940",
      "r954",
      "r962",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r979",
      "r1004",
      "r1027",
      "r1133",
      "r1195"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails",
      "http://www.waldencast.com/role/GOODWILLNarrativeDetails",
      "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails",
      "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r370",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r408",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r486",
      "r487",
      "r488",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r996",
      "r1057",
      "r1195"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1162",
      "r1167"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Gain) Loss on disposal of equipment",
        "negatedLabel": "Loss on disposal of equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Information Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/GOODWILLNarrativeDetails",
      "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails",
      "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentGrossProfittoNetIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on impairment of goodwill",
        "verboseLabel": "Loss on impairment of goodwill",
        "negatedNetLabel": "Impairment loss",
        "netLabel": "Impairment loss",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r468",
      "r474",
      "r480",
      "r996"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETExpectedAmortizationDetails",
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r766"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r467",
      "r780",
      "r996",
      "r1022",
      "r1112",
      "r1119"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r767"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest, weighted average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r406",
      "r407",
      "r865",
      "r868",
      "r870",
      "r935",
      "r937",
      "r940",
      "r954",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r979",
      "r1004",
      "r1027",
      "r1133",
      "r1195"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income, net",
        "label": "Interest Income (Expense), Net",
        "documentation": "The net amount of operating interest income (expense)."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITNarrativeDetails",
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax rate",
        "verboseLabel": "Income tax benefit at Bailiwick of Jersey for Successor and Income tax benefit at Cayman Islands for Predecessor statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r635",
      "r656"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S./foreign tax rate differential",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r1162",
      "r1167"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to Class A shareholders",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r185",
      "r227",
      "r270",
      "r295",
      "r297",
      "r302",
      "r321",
      "r334",
      "r336",
      "r337",
      "r339",
      "r340",
      "r344",
      "r345",
      "r357",
      "r373",
      "r393",
      "r399",
      "r402",
      "r445",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r687",
      "r694",
      "r801",
      "r902",
      "r924",
      "r925",
      "r992",
      "r1033",
      "r1127"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes."
       }
      }
     },
     "auth_ref": [
      "r1162",
      "r1167"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributed to Class A shareholders - basic EPS",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r336",
      "r337",
      "r339",
      "r340",
      "r348",
      "r349",
      "r358",
      "r361",
      "r373",
      "r393",
      "r399",
      "r402",
      "r992"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/DEBTNarrativeDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on extinguishment of debt (Note 8)",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "terseLabel": "Extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r91",
      "r92"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent Items",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1162",
      "r1167"
     ]
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplierConcentrationRiskMember",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Concentration Risk",
        "label": "Supplier Concentration Risk [Member]",
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r194"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedMarketingCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued marketing expenses",
        "label": "Accrued Marketing Costs, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.waldencast.com/role/LEASESNarrativeDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r493",
      "r494",
      "r570",
      "r579",
      "r610",
      "r611",
      "r612",
      "r739",
      "r763",
      "r825",
      "r872",
      "r873",
      "r934",
      "r936",
      "r938",
      "r939",
      "r953",
      "r975",
      "r976",
      "r994",
      "r1002",
      "r1015",
      "r1024",
      "r1027",
      "r1122",
      "r1131",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES (NOTE 18)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r153",
      "r789",
      "r881"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.waldencast.com/role/LEASESNarrativeDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r493",
      "r494",
      "r579",
      "r763",
      "r825",
      "r872",
      "r873",
      "r934",
      "r936",
      "r938",
      "r939",
      "r953",
      "r975",
      "r976",
      "r994",
      "r1002",
      "r1015",
      "r1024",
      "r1131",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.waldencast.com/role/LEASESNarrativeDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r493",
      "r494",
      "r570",
      "r579",
      "r610",
      "r611",
      "r612",
      "r739",
      "r763",
      "r825",
      "r872",
      "r873",
      "r934",
      "r936",
      "r938",
      "r939",
      "r953",
      "r975",
      "r976",
      "r994",
      "r1002",
      "r1015",
      "r1024",
      "r1027",
      "r1122",
      "r1131",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributed to Class A shareholders - diluted EPS",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r350",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r361"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.waldencast.com/role/LEASESNarrativeDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r493",
      "r494",
      "r579",
      "r763",
      "r825",
      "r872",
      "r873",
      "r934",
      "r936",
      "r938",
      "r939",
      "r953",
      "r975",
      "r976",
      "r994",
      "r1002",
      "r1015",
      "r1024",
      "r1131",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r69",
      "r145",
      "r146",
      "r408"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax benefit, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1162",
      "r1167"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1161"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock, unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1161"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock per share value (in dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r1022"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.waldencast.com/role/SEGMENTREPORTINGNarrativeDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.waldencast.com/role/SEGMENTREPORTINGNarrativeDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r1005",
      "r1133",
      "r1195",
      "r1196"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r1162",
      "r1167"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery and equipment",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "wald_DepreciationDepletionAndAmortizationOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "DepreciationDepletionAndAmortizationOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Operating Activities",
        "documentation": "Depreciation, Depletion and Amortization, Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recently Issued Accounting Standards, Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableOtherPayablesMember",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Payable, Other Payables",
        "label": "Notes Payable, Other Payables [Member]",
        "documentation": "A written promise to pay a note to a third party."
       }
      }
     },
     "auth_ref": []
    },
    "wald_IncreaseDecreaseInAccountsPayableExcludingRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "IncreaseDecreaseInAccountsPayableExcludingRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable, Excluding Related Parties",
        "documentation": "Increase (Decrease) in Accounts Payable, Excluding Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofSegmentGrossProfittoNetIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in fair value of derivative warrant liabilities",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r14"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r451",
      "r452",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r529",
      "r546",
      "r680",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r802",
      "r995",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1103",
      "r1104",
      "r1105",
      "r1106"
     ]
    },
    "wald_ClassOfWarrantOrRightRedemptionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ClassOfWarrantOrRightRedemptionPeriod",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant redemption period",
        "label": "Class of Warrant or Right, Redemption Period",
        "documentation": "Class of Warrant or Right, Redemption Period"
       }
      }
     },
     "auth_ref": []
    },
    "wald_NumberOfNominatedDirectors": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "NumberOfNominatedDirectors",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of nominated directors",
        "label": "Number of Nominated Directors",
        "documentation": "Number of Nominated Directors"
       }
      }
     },
     "auth_ref": []
    },
    "wald_MisstatementOfCapitalizedMarketingExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MisstatementOfCapitalizedMarketingExpensesMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Misstatement of Capitalized Marketing Expenses",
        "label": "Misstatement of Capitalized Marketing Expenses [Member]",
        "documentation": "Misstatement of Capitalized Marketing Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNumberOfIndividuals",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of founders",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Number Of Individuals",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Number Of Individuals"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdministrativeFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdministrativeFeesExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Administrative expenses",
        "label": "Administrative Fees Expense",
        "documentation": "Amount of expense for administrative fee from service provided, including, but not limited to, salary, rent, or overhead cost."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r901",
      "r1201"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails",
      "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net product sales",
        "verboseLabel": "Licensed products",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r214"
     ]
    },
    "wald_StockholdersEquityNumberOfSharesInEachUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "StockholdersEquityNumberOfSharesInEachUnit",
     "presentation": [
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares in each IPO unit",
        "label": "Stockholders' Equity, Number Of Shares In Each Unit",
        "documentation": "Stockholders' Equity, Number Of Shares In Each Unit"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ClassOfWarrantOrRightRedemptionNumberOfTradingDaysAtOrAboveTriggerPrice",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant redemption, number of trading days at or above trigger price",
        "label": "Class of Warrant or Right, Redemption, Number of Trading Days At or Above Trigger Price",
        "documentation": "Class of Warrant or Right, Redemption, Number of Trading Days At or Above Trigger Price"
       }
      }
     },
     "auth_ref": []
    },
    "wald_NonConvertibleWorkingCapitalNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "NonConvertibleWorkingCapitalNotesMember",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Convertible Working Capital Notes",
        "label": "Non-Convertible Working Capital Notes [Member]",
        "documentation": "Non-Convertible Working Capital Notes"
       }
      }
     },
     "auth_ref": []
    },
    "wald_GainOnPPPLoanForgiveness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "GainOnPPPLoanForgiveness",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on PPP Loan forgiveness (Note 8)",
        "negatedTerseLabel": "Gain on PPP Loan forgiveness",
        "label": "Gain on PPP Loan Forgiveness",
        "documentation": "Gain on PPP Loan Forgiveness"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "wald_WaldencastPlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "WaldencastPlcMember",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Waldencast plc",
        "label": "Waldencast plc [Member]",
        "documentation": "Waldencast plc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax liabilities",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r633",
      "r788"
     ]
    },
    "wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Leases, Right-of-Use Assets",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Leases, Right-of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "wald_TransitionServicesAgreementExtensionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "TransitionServicesAgreementExtensionPeriod",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transition services, optional extension term",
        "label": "Transition Services Agreement, Extension Period",
        "documentation": "Transition Services Agreement, Extension Period"
       }
      }
     },
     "auth_ref": []
    },
    "wald_LimitedPartnershipUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "LimitedPartnershipUnitsMember",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Limited Partnership Units",
        "label": "Limited Partnership Units [Member]",
        "documentation": "Limited Partnership Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "wald_InvestorDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "InvestorDirectorsMember",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor Directors",
        "label": "Investor Directors [Member]",
        "documentation": "Investor Directors"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ComputerHardwareSoftwareAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ComputerHardwareSoftwareAndEquipmentMember",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEstimatedUsefulLivesDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESPropertyandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Computer hardware and software",
        "terseLabel": "Computer hardware, software and equipment",
        "label": "Computer Hardware, Software And Equipment [Member]",
        "documentation": "Computer Hardware, Software And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "wald_BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "BusinessAcquisitionProFormaNetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails": {
       "parentTag": "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Pro forma net income (loss) attributable to noncontrolling interest",
        "label": "Business Acquisition, Pro Forma Net Income (Loss), Attributable to Noncontrolling Interest",
        "documentation": "Business Acquisition, Pro Forma Net Income (Loss), Attributable to Noncontrolling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ServicesAgreementFeePercentageOfIncurredCosts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ServicesAgreementFeePercentageOfIncurredCosts",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service fee percentage",
        "label": "Services Agreement Fee, Percentage of Incurred Costs",
        "documentation": "Services Agreement Fee, Percentage of Incurred Costs"
       }
      }
     },
     "auth_ref": []
    },
    "wald_AccruedDistributionFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "AccruedDistributionFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued distribution fees",
        "label": "Accrued Distribution Fees, Current",
        "documentation": "Accrued Distribution Fees, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, voting rights",
        "label": "Common Stock, Voting Rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r242"
     ]
    },
    "wald_ConvertibleWorkingCapitalNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ConvertibleWorkingCapitalNoteMember",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Working Capital Note",
        "label": "Convertible Working Capital Note [Member]",
        "documentation": "Convertible Working Capital Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESChangeinAllowanceforDoubtfulAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lock-up shares, threshold consecutive trading days",
        "label": "Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Consecutive Trading Days",
        "documentation": "Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares reserved for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "wald_VariableRateComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "VariableRateComponentDomain",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate Component [Domain]",
        "label": "Variable Rate Component [Domain]",
        "documentation": "Variable Rate Component [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares called by each warrant",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL CASH FLOW DATA \u2013 CASH PAID:",
        "label": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "wald_OneTimStockGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "OneTimStockGrantMember",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One-Tim Stock Grant",
        "label": "One-Tim Stock Grant [Member]",
        "documentation": "One-Tim Stock Grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unamortized debt issuance costs",
        "terseLabel": "Unamortized debt issuance costs",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r1132"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "wald_BeautyVenturesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "BeautyVenturesLLCMember",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beauty Ventures LLC",
        "label": "Beauty Ventures LLC [Member]",
        "documentation": "Beauty Ventures LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r1022",
      "r1199"
     ]
    },
    "us-gaap_AdjustmentsForErrorCorrectionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsForErrorCorrectionDomain",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Error Correction, Type [Domain]",
        "label": "Error Correction, Type [Domain]",
        "documentation": "Type of error correction."
       }
      }
     },
     "auth_ref": [
      "r336",
      "r337",
      "r338",
      "r342",
      "r343",
      "r344",
      "r345"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r582"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialDesignationPredecessorAndSuccessorFixedList": {
     "xbrltype": "financialDesignationType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialDesignationPredecessorAndSuccessorFixedList",
     "presentation": [
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Designation, Predecessor and Successor [Fixed List]",
        "label": "Financial Designation, Predecessor and Successor [Fixed List]",
        "documentation": "Indicates designation of financial information when substantially all business or separately identifiable line of business transfers from one entity to another entity. Acceptable values are \"Predecessor\" and \"Successor\"."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "wald_ObagiShanghaiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ObagiShanghaiMember",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Obagi Shanghai",
        "label": "Obagi Shanghai [Member]",
        "documentation": "Obagi Shanghai"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r508",
      "r536",
      "r727",
      "r985",
      "r986"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of shares available for issuance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "wald_ForwardPurchaseAgreementPerformanceFeeAllocationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ForwardPurchaseAgreementPerformanceFeeAllocationPercentage",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance fee allocation percentage",
        "label": "Forward Purchase Agreement, Performance Fee Allocation Percentage",
        "documentation": "Forward Purchase Agreement, Performance Fee Allocation Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details": {
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234"
     ]
    },
    "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Intrinsic Value",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r69",
      "r70",
      "r145",
      "r217",
      "r963"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.waldencast.com/role/LEASESSupplementalCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r716",
      "r1021"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162",
      "r221",
      "r642"
     ]
    },
    "wald_VariableRateComponentThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "VariableRateComponentThreeMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate Component Three",
        "label": "Variable Rate Component Three [Member]",
        "documentation": "Variable Rate Component Three"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "wald_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdPeriodBeforeCommencementOfConsecutiveTradingDays",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lock-up shares, threshold period before commencement of consecutive trading days",
        "label": "Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Period Before Commencement of Consecutive Trading Days",
        "documentation": "Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Period Before Commencement of Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r489",
      "r490",
      "r964",
      "r1123"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r620",
      "r851",
      "r1095",
      "r1096",
      "r1097",
      "r1171",
      "r1202"
     ]
    },
    "wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Restricted Cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details": {
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022",
        "label": "Operating Leases, Future Minimum Payments Due, Next 12 Months",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r977"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details": {
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234"
     ]
    },
    "wald_PredecessorIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "PredecessorIncentivePlanMember",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Predecessor Incentive Plan",
        "label": "Predecessor Incentive Plan [Member]",
        "documentation": "Predecessor Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details": {
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "wald_ServicesAgreementRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ServicesAgreementRenewalTerm",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services agreement, renewal term",
        "label": "Services Agreement, Renewal Term",
        "documentation": "Services Agreement, Renewal Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details": {
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details": {
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturitySchedulePriortotheAdoptionofASC842Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average diluted shares (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r361"
     ]
    },
    "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeighedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, weighted average remaining contractual life",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighed Average Remaining Contractual Term",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Weighed Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value of options granted in period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "wald_MisstatementOfAccruedDistributionServiceFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MisstatementOfAccruedDistributionServiceFeesMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Misstatement of Accrued Distribution Service Fees",
        "label": "Misstatement of Accrued Distribution Service Fees [Member]",
        "documentation": "Misstatement of Accrued Distribution Service Fees"
       }
      }
     },
     "auth_ref": []
    },
    "wald_PaymentsForServicesAgreementFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "PaymentsForServicesAgreementFees",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total service fees paid",
        "label": "Payments for Services Agreement Fees",
        "documentation": "Payments for Services Agreement Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/NETLOSSPERSHAREBasicandDilutedNetIncomeLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (in shares)",
        "terseLabel": "Weighted-average basic shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r590"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "wald_InterestRateCollarMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "InterestRateCollarMember",
     "presentation": [
      "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails",
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate collar",
        "label": "Interest Rate Collar [Member]",
        "documentation": "Interest Rate Collar"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Ending balance, weighted average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r590"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r41",
      "r265",
      "r300",
      "r301",
      "r302",
      "r330",
      "r331",
      "r332",
      "r335",
      "r343",
      "r345",
      "r366",
      "r446",
      "r449",
      "r550",
      "r618",
      "r619",
      "r620",
      "r649",
      "r650",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r685",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r720",
      "r826",
      "r827",
      "r828",
      "r851",
      "r926"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/COVER",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class B Ordinary Shares",
        "label": "Common Class B [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1202"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "wald_VendorOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "VendorOneMember",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vendor One",
        "label": "Vendor One [Member]",
        "documentation": "Vendor One"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r330",
      "r331",
      "r332",
      "r335",
      "r343",
      "r345",
      "r446",
      "r449",
      "r618",
      "r619",
      "r620",
      "r649",
      "r650",
      "r673",
      "r675",
      "r676",
      "r679",
      "r685",
      "r826",
      "r828",
      "r851",
      "r1202"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "wald_NumberOfOperatingLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "NumberOfOperatingLeases",
     "presentation": [
      "http://www.waldencast.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of non-cancelable operating leases",
        "label": "Number of Operating Leases",
        "documentation": "Number of Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsParentheticalDetails",
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend",
        "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected stock price volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of tranches",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Tranches",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk -free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "wald_AmortizationOfRelatedPartyLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "AmortizationOfRelatedPartyLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization of related party liability",
        "label": "Amortization Of Related Party Liability",
        "documentation": "Amortization Of Related Party Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/LEASESOperatingLeaseMaturityScheduleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected stock price volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r571",
      "r576",
      "r690",
      "r737",
      "r998",
      "r999",
      "r1010",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r732"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares",
        "verboseLabel": "Predecessor common shares, 25,000,000 shares authorized; $0.50 par value, 8,000,002 shares issued and outstanding as of December 31, 2021",
        "netLabel": "Successor ordinary shares",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r790",
      "r1022"
     ]
    },
    "wald_A2018TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "A2018TermLoanMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Predecessor 2018 Term Loan",
        "label": "2018 Term Loan [Member]",
        "documentation": "2018 Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Maturity",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1177"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r571",
      "r576",
      "r690",
      "r736",
      "r1010",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r586",
      "r587",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1174"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r583",
      "r585",
      "r586",
      "r587",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsParentheticalDetails",
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r882"
     ]
    },
    "wald_StockIssuedDuringPeriodSharesTrustProceeds": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "StockIssuedDuringPeriodSharesTrustProceeds",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Class A ordinary shares upon release of Trust proceeds (in shares)",
        "label": "Stock Issued During Period, Shares, Trust Proceeds",
        "documentation": "Stock Issued During Period, Shares, Trust Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r265",
      "r300",
      "r301",
      "r302",
      "r330",
      "r331",
      "r332",
      "r335",
      "r343",
      "r345",
      "r366",
      "r446",
      "r449",
      "r550",
      "r618",
      "r619",
      "r620",
      "r649",
      "r650",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r685",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r720",
      "r826",
      "r827",
      "r828",
      "r851",
      "r926"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating (loss) income",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r393",
      "r399",
      "r402",
      "r992"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsParentheticalDetails",
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r164",
      "r882",
      "r900",
      "r1202",
      "r1203"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r534"
     ]
    },
    "wald_AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "AccountsReceivableAndNotesReceivableBeforeAllowanceForCreditLossCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable and notes receivable, before allowance for doubtful accounts",
        "label": "Accounts Receivable and Notes Receivable, before Allowance for Credit Loss, Current",
        "documentation": "Accounts Receivable and Notes Receivable, before Allowance for Credit Loss, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r583",
      "r585",
      "r586",
      "r587",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r20",
      "r45",
      "r674",
      "r677",
      "r720",
      "r826",
      "r827",
      "r1080",
      "r1081",
      "r1082",
      "r1095",
      "r1096",
      "r1097"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofNetOperatingLossesandTaxCreditCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "wald_CommonStockConvertibleConversionRatio": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "CommonStockConvertibleConversionRatio",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock conversion ratio (in shares)",
        "label": "Common Stock, Convertible, Conversion Ratio",
        "documentation": "Common Stock, Convertible, Conversion Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.waldencast.com/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r690",
      "r738",
      "r998",
      "r999",
      "r1010",
      "r1011",
      "r1012"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised, weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercised, Weighted Average Grant Date Fair Value",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Exercised, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted stock units granted (in shares)",
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofProvisionforIncomeTaxesDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax (benefit) expense",
        "negatedLabel": "Income tax expense adjustment",
        "totalLabel": "Income tax (benefit) expense",
        "negatedNetLabel": "Income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r248",
      "r344",
      "r345",
      "r381",
      "r634",
      "r652",
      "r807"
     ]
    },
    "wald_EffectiveIncomeTaxRateReconciliationTransactionCostsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "EffectiveIncomeTaxRateReconciliationTransactionCostsPercent",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Effective Income Tax Rate Reconciliation, Transaction Costs, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Transaction Costs, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "wald_A2022CreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "A2022CreditAgreementMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails",
      "http://www.waldencast.com/role/DEBTScheduledMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Credit Agreement",
        "label": "2022 Credit Agreement [Member]",
        "documentation": "2022 Credit Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r598"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "negatedTerseLabel": "Other non-current assets adjustments",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding beginning balance, weighted average grant date fair value (in dollars per share)",
        "periodEndLabel": "Outstanding ending balance, weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r598"
     ]
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TrademarksAndTradeNamesMember",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails",
      "http://www.waldencast.com/role/INTANGIBLEASSETSNETScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trademarks and Trade Name",
        "terseLabel": "Trademark and trade name",
        "label": "Trademarks and Trade Names [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r882"
     ]
    },
    "wald_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier [Domain]",
        "label": "Supplier [Domain]",
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r882",
      "r900",
      "r1202",
      "r1203"
     ]
    },
    "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumAllocatedTargetShareUnitsPercent",
     "presentation": [
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum allocated target share units, percent",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Allocated Target Share Units, Percent",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Allocated Target Share Units, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested, weighted average grant date fair value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r601"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier [Axis]",
        "label": "Supplier [Axis]",
        "documentation": "Information by supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Goods Sold",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "wald_InvestmentInSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "InvestmentInSubsidiary",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in subsidiary",
        "label": "Investment in Subsidiary",
        "documentation": "Investment in Subsidiary"
       }
      }
     },
     "auth_ref": []
    },
    "wald_EffectiveIncomeTaxRateReconciliationTrueUpsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "EffectiveIncomeTaxRateReconciliationTrueUpsPercent",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "True-Ups",
        "label": "Effective Income Tax Rate Reconciliation, True-Ups, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, True-Ups, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.waldencast.com/role/REVENUENarrativeDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r69",
      "r145",
      "r146",
      "r408",
      "r963"
     ]
    },
    "wald_MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MisstatementOfCapitalizedResearchAndDevelopmentExpensesMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Misstatement of Capitalized Research and Development Expenses",
        "label": "Misstatement of Capitalized Research and Development Expenses [Member]",
        "documentation": "Misstatement of Capitalized Research and Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r588",
      "r607",
      "r608",
      "r609",
      "r610",
      "r613",
      "r621",
      "r622",
      "r623",
      "r624"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r215",
      "r296",
      "r298",
      "r304",
      "r781",
      "r803"
     ]
    },
    "wald_SponsorWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "SponsorWarrantsMember",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sponsor Warrants",
        "label": "Sponsor Warrants [Member]",
        "documentation": "Sponsor Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseTermPercent",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise term, percent",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Exercise Term, Percent",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Exercise Term, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss attributable to noncontrolling interests",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r122",
      "r126",
      "r296",
      "r298",
      "r305",
      "r782",
      "r804"
     ]
    },
    "wald_MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MisstatementOfIncomeTaxExpenseAndRelatedLiabilitiesMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Misstatement of Income Tax Expense and Related Liabilities",
        "label": "Misstatement of Income Tax Expense and Related Liabilities [Member]",
        "documentation": "Misstatement of Income Tax Expense and Related Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "wald_DeferredTaxAssetsNetBeforeValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "DeferredTaxAssetsNetBeforeValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax (liabilities) assets",
        "label": "Deferred Tax Assets, Net, Before Valuation Allowance",
        "documentation": "Deferred Tax Assets, Net, Before Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "wald_DeferredTaxAssetsFormationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "DeferredTaxAssetsFormationCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Formation costs",
        "label": "Deferred Tax Assets, Formation Costs",
        "documentation": "Deferred Tax Assets, Formation Costs"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetInterestCarryforward",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/INCOMETAXBENEFITSummaryofDeferredTaxAssetsandDeferredTaxLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible interest carryover",
        "label": "Deferred Tax Asset, Interest Carryforward",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "wald_RecognitionPeriodForDeferredAdvertisingCostsMaximum": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "RecognitionPeriodForDeferredAdvertisingCostsMaximum",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period after which production costs will be expensed for advertising that has not yet occurred",
        "label": "Recognition Period for Deferred Advertising Costs, Maximum",
        "documentation": "Recognition Period for Deferred Advertising Costs, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restatement and Reclassification Adjustments",
        "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]",
        "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r62"
     ]
    },
    "wald_ForwardPurchaseAgreementHurdleRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ForwardPurchaseAgreementHurdleRate",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hurdle rate (percent)",
        "label": "Forward Purchase Agreement, Hurdle Rate",
        "documentation": "Forward Purchase Agreement, Hurdle Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSParenthetical",
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESNarrativeDetails",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r724",
      "r725",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r899",
      "r901",
      "r933",
      "r1181"
     ]
    },
    "wald_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited, aggregate intrinsic value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Intrinsic Value",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period, Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.waldencast.com/role/EMPLOYEEBENEFITPLANDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company 401(k) retirement plan contributions",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Tranche One",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "wald_MisstatementOfRevenueRecognitionTimingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MisstatementOfRevenueRecognitionTimingMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Misstatement of Revenue Recognition Timing",
        "label": "Misstatement of Revenue Recognition Timing [Member]",
        "documentation": "Misstatement of Revenue Recognition Timing"
       }
      }
     },
     "auth_ref": []
    },
    "wald_StockIssuedDuringPeriodValueSubscriptionAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "StockIssuedDuringPeriodValueSubscriptionAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common shares in connection with the PIPE investment",
        "label": "Stock Issued During Period, Value, Subscription Agreements",
        "documentation": "Stock Issued During Period, Value, Subscription Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/GOODWILLTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r996",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121"
     ]
    },
    "wald_InventoryPurchasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "InventoryPurchasesMember",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Purchases",
        "label": "Inventory Purchases [Member]",
        "documentation": "Inventory Purchases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r550",
      "r1095",
      "r1096",
      "r1097",
      "r1202"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash (used in) provided by operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before equity in undistributed earnings of subsidiaries",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r321",
      "r334",
      "r373",
      "r393",
      "r399",
      "r402",
      "r445",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r687",
      "r694",
      "r798",
      "r992",
      "r1127"
     ]
    },
    "wald_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested, weighted average exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Vested In Period, Weighted Average Exercise Price",
        "documentation": "Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Vested In Period, Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "wald_ObagiAndMilkBusinessCombinationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ObagiAndMilkBusinessCombinationsMember",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSUnauditedProFormaConsolidatedFinancialInformationDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Obagi and Milk Business Combinations",
        "label": "Obagi and Milk Business Combinations [Member]",
        "documentation": "Obagi and Milk Business Combinations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BUSINESS COMBINATIONS",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r663"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "wald_MisstatementOfResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MisstatementOfResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Misstatement Of Research And Development Expense",
        "label": "Misstatement Of Research And Development Expense [Member]",
        "documentation": "Misstatement Of Research And Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "wald_MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "MisstatementAdjustmentsRevenueRecognitionNumberOfDistributors",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of distributors",
        "label": "Misstatement Adjustments, Revenue Recognition, Number of Distributors",
        "documentation": "Misstatement Adjustments, Revenue Recognition, Number of Distributors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSNarrativeDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL SHAREHOLDERS' EQUITY",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "negatedTerseLabel": "Increase in accumulated deficit",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r124",
      "r265",
      "r266",
      "r301",
      "r330",
      "r331",
      "r332",
      "r335",
      "r343",
      "r446",
      "r449",
      "r550",
      "r618",
      "r619",
      "r620",
      "r649",
      "r650",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r685",
      "r696",
      "r697",
      "r701",
      "r720",
      "r827",
      "r828",
      "r849",
      "r884",
      "r900",
      "r927",
      "r928",
      "r960",
      "r1034",
      "r1090",
      "r1107",
      "r1173",
      "r1202"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1040",
      "r1041",
      "r1042"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184",
      "r185"
     ]
    },
    "wald_ProceedsFromTrustAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ProceedsFromTrustAccount",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from trust account",
        "verboseLabel": "Proceeds from trust",
        "label": "Proceeds From Trust Account",
        "documentation": "Proceeds From Trust Account"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r320",
      "r533",
      "r535",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r547",
      "r550",
      "r681",
      "r929",
      "r931",
      "r961"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedStatementofCashFlowDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails",
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Tranche Two",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedBalanceSheetsDetails",
      "http://www.waldencast.com/role/SUCCESSORCONDENSEDFINANCIALINFORMATIONOFWALDENCASTPLCPARENTCOMPANYONLYCondensedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r280",
      "r321",
      "r373",
      "r394",
      "r400",
      "r445",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r667",
      "r671",
      "r694",
      "r787",
      "r894",
      "r1022",
      "r1035",
      "r1127",
      "r1128",
      "r1182"
     ]
    },
    "wald_PhysicianChannelProviderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "PhysicianChannelProviderMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofCostofGoodsSoldRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofInventoryRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofSGAExpensesRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/REVENUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Physician Channel Provider",
        "label": "Physician Channel Provider [Member]",
        "documentation": "Physician Channel Provider"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "wald_AdvancesForNoteReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "AdvancesForNoteReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Advances for note receivable",
        "label": "Advances For Note Receivable",
        "documentation": "Advances For Note Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "wald_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivablesRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party receivable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables, Related Party",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables, Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "wald_ClassOfWarrantOrRightRedemptionTradingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ClassOfWarrantOrRightRedemptionTradingPeriod",
     "presentation": [
      "http://www.waldencast.com/role/FINANCIALINSTRUMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant redemption, trading period",
        "label": "Class of Warrant or Right, Redemption, Trading Period",
        "documentation": "Class of Warrant or Right, Redemption, Trading Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.waldencast.com/role/REVENUERevenuebyGeographicRegionDetails",
      "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "wald_SponsorAndInvestorDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "SponsorAndInvestorDirectorsMember",
     "presentation": [
      "http://www.waldencast.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sponsor and Investor Directors",
        "label": "Sponsor and Investor Directors [Member]",
        "documentation": "Sponsor and Investor Directors"
       }
      }
     },
     "auth_ref": []
    },
    "wald_SADistributorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "SADistributorMember",
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofAccountsReceivableNetRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSSummaryofNetRevenueRestatementAdjustmentsDetails",
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SA Distributor",
        "label": "SA Distributor [Member]",
        "documentation": "SA Distributor"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grantee Status [Axis]",
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r583",
      "r585",
      "r586",
      "r587",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ]
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://www.waldencast.com/role/DEBTLongtermDebtDetails",
      "http://www.waldencast.com/role/DEBTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Shell Company Report",
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "wald_ObagiSkincareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "ObagiSkincareMember",
     "presentation": [
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSNarrativeDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSScheduleofIntangibleAssetsAcquiredinBusinessCombinationDetails",
      "http://www.waldencast.com/role/BUSINESSCOMBINATIONSSummaryofPurchasePriceAllocationDetails",
      "http://www.waldencast.com/role/GOODWILLNarrativeDetails",
      "http://www.waldencast.com/role/GOODWILLScheduleofGoodwillDetails",
      "http://www.waldencast.com/role/REVENUERevenuebySalesChannelDetails",
      "http://www.waldencast.com/role/SEGMENTREPORTINGReconciliationofFinancialMeasuresofSegmentstoConsolidatedTotalsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Obagi Skincare",
        "verboseLabel": "Obagi",
        "label": "Obagi Skincare [Member]",
        "documentation": "Obagi Skincare"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grantee Status [Domain]",
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r583",
      "r585",
      "r586",
      "r587",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.waldencast.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.waldencast.com/role/SHAREHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r367",
      "r534",
      "r535",
      "r536",
      "r538",
      "r541",
      "r546",
      "r548",
      "r840",
      "r841",
      "r842",
      "r843",
      "r1002",
      "r1048",
      "r1088"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1040",
      "r1041",
      "r1042",
      "r1044"
     ]
    },
    "wald_NumberOfLeaseAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "NumberOfLeaseAgreements",
     "presentation": [
      "http://www.waldencast.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of leases",
        "label": "Number of Lease Agreements",
        "documentation": "Number of Lease Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
      "http://www.waldencast.com/role/SUPPLEMENTALBALANCESHEETDISCLOSURESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Lives of Assets",
        "verboseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails": {
       "parentTag": "wald_OperatingExpensesAndCostOfGoodSold",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.waldencast.com/role/RESTATEMENTANDRECLASSIFICATIONSConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r378"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://www.waldencast.com/role/COVER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r1040",
      "r1041",
      "r1042",
      "r1044"
     ]
    },
    "wald_FounderAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.waldencast.com/20221231",
     "localname": "FounderAwardsMember",
     "presentation": [
      "http://www.waldencast.com/role/STOCKBASEDCOMPENSATIONFairValueofStockOptionsValuationAssumptionsDetails",
      "http://www.waldencast.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Founder Awards",
        "label": "Founder Awards [Member]",
        "documentation": "Founder Awards"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "SubTopic": "50",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482610/350-50-25-4"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "SubTopic": "40",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482633/350-40-30-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "a",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(19)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)-(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-5"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "740",
   "Section": "25",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479692/805-740-25-8"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "740",
   "Section": "25",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479692/805-740-25-9"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "25",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//250/tableOfContent"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r208": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r209": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r210": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r211": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r212": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r213": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r214": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r215": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r216": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r217": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r218": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r219": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r220": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r221": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r222": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r223": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r224": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r225": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r226": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r227": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r228": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r229": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r230": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r231": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r232": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r233": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Subparagraph": "(Note 3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481418/840-10-55-40"
  },
  "r234": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "27",
   "SubTopic": "10",
   "Topic": "852",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-27"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "(m)",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.5-04(Schedule I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480922/205-10-S99-6"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-23"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-11"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "(a)",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>137
<FILENAME>0001840199-24-000006-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001840199-24-000006-xbrl.zip
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MDG4QK W-VG'EY'1X-C@Z'IIGIED].;:&Y_5A?4"K)CYV',#WP3>Z_H7IA6[
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M7N ^'W-?K2A+FN:.>WP@F<E'F!ZSJ'4=!T?[&1GQT;L?SWRX&7'EH7OF/8#
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MH]O+2FDU+.KGRI(G:YAPR&I02-&936\RL%V.E>TLR]F^M)3E65235GK;Y:0
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M!KL" ( ([^(5T2R?AY[AQ>+:"%9G. %>+1]5:I53S0JKS HK \;7@B[B!MT
MFUE'P#L_^/R=.!9U3>('QM0Q%]'WE(16;?+N0^LG,0/^O3C-/O].@_B&/Z4F
MUI!8ANT:=N ;YI@P>-=?M%:II%5%&N:C]8=Y0[=]>ZPF%'5Q>,3(Y*2^=QXH
MZA0+KE"6[XNE%/R\WRGSZ>QI[+,KXOO DW>'3SFES>\__W%6JYY^\H5EMMW
M,UKNR+']\2\[)^4/OX?,]BW;C(;!=DV/367IF.$Q^+\1<>W_Y7__4OQ0^+71
M1\.R&#94$/^Y@?M5XV*(RL'G:L6X).X/HQ<P2H.GA.G['U>+'U>%+">T VH<
MGU36CK4+/NY-^&>'];W'F*+&C:&^CW$8[AUBNWYF8\[GG3OLGGD/H 3SDI<Z
MF/J_GD:7;WO(O><'Q/D?>]KTK/DCCA!()Y63PDGUPWGU]!?C^.BD?')6.RM
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MB@07#&;PE"%E\(G4&,-_;;<D;H\E\+7*)W%[_D?UTR_&HQV,X3@5W].C9LC
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M"&P(/CCIOBUP8W"_$MH<*S31X!#,(\$KN-P_/M@P:'"Y"7 G=BJ0@#0PI&A
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M!GH/.@JN]DL(F00$I$R8Q1M42>;'+K=A36P7;32/Z."I_(GP+#+AREN:FR
MY!R$$\^RAVC-N-L)8 @YV.&_G];1Z3I.@FEH906M95),(^OW^UN>K4#J!J&Y
M<4E<"'/O#AN':*\X6TBFQ$0++A-.DKXEP5LF2,>E8-X[T:^LA5  $V0XM!U[
MSDT*(,B &"=<>)H+F0T$X/B'4&>(7WPDOO!7\6\>IH 1XL&V,T,S $*1?_&
M*6">@W&K'_WA\%2_Q$_U)6@PQH*;R3/X6Y20"!DO>?CCF/*@+QC#V(X@H'2Y
M.^2\*@_&)S3B=Y-&2>3T>#@*7^73HA%(S!/-W7+Z5 =)\86)@=17+>%F5WY@
M'"_/K3LDT3[E$T:KAU3&IE.TXR@A<03/,DGHBW!9_):(9!/9%;[:%*(^TQ:Y
M %DYL'BA]^C"T;$]Q5,?/!YB^_%T%W<QIJ224Z.]=\JN@$Y'WCUMVQ,D]34&
M[LF9FD<(TYU9&86<F 2:I5-K+<KMB[+9X%L+FPM^NNDQSR4/-@M]HV&#"+N8
M- X%D]T"1?0FMAE-1^.,L19>'L)S"*1L#;"'< JJ$\^(_;0HD2_D)_[S']43
MB-$6SRX94\*,!^*$U/A/7@-7Q8D(<51+-2^I7KY*JD_.?J-4M1@S$Z/YY?8^
M+3,PEB(7]CS+N"5N.(1@1M#6]QC7V":R*J/0D7P8Q>E24\Q788AT?=70^IB#
M/B9F&9_R)/?4FSHT)K2[5%;-8,TCOS JE[KOQ@5927(=[_$5:9,_\']ZF(00
M9Y$/$0\7U,DM@?#[^1.YE^X3^Y&X&C Y ,:STMFNH6#2?O YKBIL1Q-+73F'
M@Q^  *Z>GYTD6;C58(IN?+;IJO+\ZW.7#V9U'<K[577PNJ1=E[1G7=*N#7VV
MAK[S9_NJ7#U/&_M>H]LK-[T_RS4DJJ)S1.J,?"9]0!/'(SQD$\- AGN\G UG
M1%D\U8Z%6K[OF3;_BTYMBT+>S8-[5_P33[%LGR*;[H4!MQ*^=OK;QT+KMO$T
M.&R%S)O"7\8MM6P3JWOXI(C)RX3Y9(8YBYC3^-QO;K*.O_4MBAJU5'.0*B\G
M$#4&&-M#9@T#QJ.:!:6?UR(LG&?T*'NP<6)<%I$W\;.(Y3U71 Y1$'5FRR;%
M6/KF$CRB$HR7-VCMSP,GT4J<)TPJ+RR=+]M)GBA"[/K1>B&V%MZFA'=]M<1T
M\\SH&ID:]-M7+!RE<FU/9]:Y2*JY1%37U,*5:UQ:)2XJ$6PU/7]" ]O4TQ/Y
M2 N7;)F>44U+3!1D1L>2DX139C_@LHHW+3@3X?5Z$XVXB$8#8ON D$236#?V
M5(]Q!1+C:RL=2'9^XB+4V!1K<>4@KFYOA5]\PAC*&%=+:?M2$N;OJ: N">04
MC[;Y([DHMPG!ITN=:,DL6MU+C$S]L6$R7/MET2G&H9"7:EGF)4NY( 73A1OR
MN*0T-S[\05SP"YX'J<1Y5:<2^0I0UC4_E9DC"YZGA$$>+POR=?6J(F*[]9K=
M)8G%,V];J]:.:^<;'+!;#_#BVO\;KQ.*LAF<8XYJ!"(6 8&D<9,#;BC#156]
M<+ LQYD?+4'$9!ZNT;)B7X6X875Z7H@)[C068WZ ._@<VQ^YMBTB>65I-Z^K
MYNNM<"W[1+PX%DZ'KAW$JX<3G4M>7FN_K[#+U7:@D.Y#9O*5,,^LQ!)S$$M.
M32_)NO,>.!1$06#U6*QQ7%B;E>Q/D.!#;NY+,2-3DHO/%Z<5XK5:S\R):!QM
M'T=WQ+?(WVG8X (4\;O1"SP3C0'[00,T!EI$VQ>1" =$.6!D?M,"PR6TJQ;-
M+VMV\J)%7VM)LQ;S!L0LH[YG#'I\B)O4>X@$N=/FU[W3IL]#SGGK)ZWQ.4 A
MJL;O/5>[_W3IAIBW6KX  !<YSIO(::EN7ZJ+:]E7KG^[N5]6NC$5EX^BR_4Z
M9@5%S)>H+CAG/@>)S>6LD#@E8VBS"2JCF)/DA?E(Z\GUJZ5Y4A]-9*:./E/U
M\[2!96KJDR,F]4M4',C?X=^>#>AZ /F&C$9_^CS\B^\W H?"7 07MAT*@[''
MU^_QE;]^P$)Q1/XD6M[(OH"X@!?&X0<,Q*>UFKUJ8&8*S$0-T4LU1O/2HGIJ
M/D"++0>Q84/IYSP%1'#E/O8*:)*IC5H950FFB<*55D,[B>T+]9O+9='#AC1^
MU&1\L5U#L@'YDV.]J^@7+^[F]Y]Q3P=&H]3.(8_#T)$K!^>UPKPB0JOS]B6?
MBO%6*O6]]/><5UO-^2\)#V2;7-EJX]GZ)3Q5(R!/!$2,[.)\;US;AL),(687
M&LTUL%&QX*;P S^" 1LP_%(7X@Q_WMS%HCZ\?;3I@>OQY<UP,G;B_2#:L7[\
MI^A:BAV2T>8Q8E$8B!_^4[A'C\*<*FXIY&.KG7G#0MXP..Y:F.I(E[PW;QTH
MZI4,\0NV"W9'?#6NEXQZ;7Q"3Y3B\TZ+G@OAM8TW+2W>D?\IQL"()V<";['=
M^81 *CB=8H=2;,V#/;#A>8+?R:NK+H=\\;KJ2F.!(^>QXHX@UX#\A]"?30:\
M?Q;NQ, ;8B44*.H(CEVO>"]-#FP+O@C[4/,VJC/CD<Q*\W:E '('CN-:2?@O
MQ2 8$ ^V@W?B]N%=@U(4Y> F!13T' S<O+U;\@;DL<0UG^_&YLO+?/J,#AX:
MWRE$7XFWYK1;*#I:RDW#>/]1KNYF5%(E%_(G;Y52=;@X;3MP)"93,!!$K-K#
MI7SHR$5G,=Y7W_*8+QL.P]4B(8@Z784^;U&&X[?P)JM]Q?J^H8C=G(63<9/[
MY"S84(F:1PK1$0;@$[#W:/,7.[N7HI[F?!J3-[U/C_(,^\(A0N8;(R3HE?1>
M/8($2NQ?\$!L1RP%=H6^Q.\C&J\G'9-HMC].W<#RJ'@X_L1CP'BG(7'9+@0+
M_67]A*.&Q?!Z\+9,S&5,Q RE10(BC AV[?<&4JZBO>?89E995-#YH,TFZB8?
M5^+/;^:'[('.H@TGY(^B*8?0SA?WG0&W[%/1]3KNO<*SN2:8,5#8RY!1$HH9
M\L:$XO85+H0)IDT%3W;O /BP/5;(1I0_$-=V3CS(&@&$J2)XT7\:(>EC577<
MLE?<?&E<(P"\:NR2K47DSR@O \RK/<&0J62,F/<8C.=/QFCNW]2<]V!.HI31
M$6'QSAZH-A0#HP>Z.OO<^UX0-=T+8DFC MT+0JU>$"L\1TXZ$VE]:;Y1'5A>
MM#G)_1I$)03O58^C+GUJ9/B%2Y M_9,7_I?/=SUSJ#6B8B(#UQ?A;COS\((N
M,ZF\^"+>A4.TJJ?)_JVI9\0V5DS.@_^83(55%=9/Y)?IETX^"[,"RY"M;N=O
M_(O8OC Q#F.^U<T#9*U3N3-.ZO-6/R%JN&J+W1*C > 5A00S%'L:[5DH(VQY
MY2[$(BGWNGZX8(SBC1%Y!_)YBI/TD_#W+/+17#X#W'\J';]$ !U@+\V'>",N
MW(^!VY%!&"3R)],,&3%G\:X(#@4+([>'>1),RCA63BU3:LEJ/1+PP#7IX5-O
MBHE=##MBN"'?( &?  *TAQC9!$DDXY)H1C&XQB8D"W&#B";@I1XA9"@[GO=C
M<2O,Q7@.$1:-BNT^> [$%<SV93H7NC)2C#>\Q-?UP\&_9<]HN90^_H 'PFP/
M C3LJ\?W3TFV6<.8#O(^,XQV",51]F7WXJBA"^&-69!PO<,=QKIQ]',MO^I&
M?E4OWL0BXO[XGE.'QE^I3<H,2#-!P<"]A%+0?..72+OF6V&L5K"]#Z?JF8=3
MUOI;3-?U%M,Z!MN/+::;C6^XNW2C^Y=QU^FWC&[K2Z-[U;[[8EQWNM_AG^6;
M3N</_+O7;_1;MZV[_D[L.-U/;IN3V/D)8TB9((N6GCCK@#O0>O$O<_L=^1KZ
MQ/\EMCN2>T[Q/OF4N#RK'LH=N$3K@T05QPW\9R3<9I=RCBBNZS@_/C1P&B:Y
MDY)LJ,^'+[F_4G*'3=R&E?O0U>_(-R_PG_T*O($'=@^B#A2=V#,!:1*QO1#&
MDG)OXHB;B;:"<&6$^62_9!D1+?XLB-O%7Z,P^\GO/W$OB66[)MAN^.1LX:.?
MGKWDQPEYLDDSN'7WR6\B''KZ,_;^>O(S<N'QA#^,&<8N,N", CRQUW-R]V>Y
MPSD_2T2+$"@.?"IWDQ-!A;@LIA<1:3(2G$LQ"A@7Q'P8QSE+Y![O5)I(;/#E
M1+,Z/G6&F[^&6'Z&L2'?V@,40V8J\VU@XXT.>2L=.N+3;-<B9A-ORL4@MYG
M'LF)36'Y1A1#W YQ(K<8QLDY$4YBB#??!!YG"R%LMD6TQT?T&53+KQ.,8#3?
M,6<%+]:W='JR_?V3[3R]FDR)&6^J%TD;S#/Y@>CA*0.'7+PQ8K3I"18Y+MNX
MN,1/IT. @4 2HWP+EX *>#QY1KSF"2R.M-;1)<^NFMLT!!KXEN_;+S-?P?.-
M7-<3O-SX*]JP4]#0+VW%N[B[T(I=+K4$LY<@"BBJ4>0JQHD&7LP&H8C4(CQI
MOKL/)L2))6M1):1<M!;Q>8F;3G##R?G"-]YY/7+T5OP<W&;5 G.OQ;QY,1-S
MC!&<B$CB. ]WXG;I$.E&[J+Y+KOQ+MPR#%CLAK^X4S:>+S@,+<C-"U)N"H\E
M&3,>/TG+FV*@8Z7#.%B&J'$LIX6T&;>(40VN$Z71]DN)J5_<*-J6L]MB'>DP
MXFD3U&RJ?F& M6<H5MP+SN8<"A.Q/3I5$<5'07=ZGUY<&H+74<9OYS[7]TN+
M_#TBEU,/B8AH1#W<4X\7DQG8?"UX8C_G)T<;SCP2N9GXT+'-%"(@90I0];7:
M;B&:1>\G-GR'[-BDU(K8)-M]0%)C]*0^1>R,& 9\%^SH#G->:/'2Y!;MJ,P,
M_":OW'@NF$[F25+;V9),R';7S[,TE#;NIH4OYI.XKH]5/7C<L2%4LOAJ4QDS
M"WA$# =20YSW,$6$K>64O9Q018?$=D*QB$?,>"ZLN^2D&>_AY3%>#LZ\!^+X
M*?4%X<4\F>CX(]I!:)EE+S,QY9P8_>=6YX,SQ3GVE)F>YYY3AJ7!#QY.SZ*N
M:G%MPZO:J9I*4;OM\5($N)>+O81%I0"Z/Q#0W,TRRFL' G"5PR'\%%T1+[B+
M+QTZ(1+1.@W=$FU$;.3^9;T.QAR2%/)87 W#EQ@ADZ I@JW*AH__3'"L\^C/
M!!?G$AYH3""EG)=.+^UM$3/K<T6VZ""(%U=X R>*AZ6_E)K[0,6)\>.TP+=A
M84-W2!X\QFLMQ.0W;PKAI@,5C^DX97MZF&;G(@+.!+\&II"7A_FR>E!$)V)]
MB^OQ2@/.LL8\7L2VQC_0GY)$C]N0B>W+(F8W4LJIYUHB'^$\5 !>4\Y9"[_)
MTPZ<KPDG?*5!O*9,XR-[?"2&7!)X<?CBR6E27&;'>(TR.E)AE!FO34:&:'Y]
M0'[R#39*R1V)2_)2GH]X: - CL^N0]>R?+.N<WYN53$L1#XFLP=Q)2V\#9_F
MQ/_*6?&H6HF[:=XAIM5\\YI"%%V!UQ1R07^G8F5I0'Y@=4<BQ,"A"Z<XG2PV
M7WS V),O3'VQ7L1:6)PX7_^.C7<DI89.U(6/2/#OI5A#'T2EEJPU>X1'EPQ>
M5LK?0+Q4>ET@7PZ0+HLI)=EXSOV)^3CQKJ*<9F79S)SGGQ?/V&XI64 SX$M[
MGR\,>Z:&1ZR=AP!N$(I*(5YN(5YHOL(X59T=[4$"-S>.#Q.K.F,7U1$S$O .
MJ!_7<2#:!?G!8//>BE$54EQI-2_O6WA&_=#X@\Z,]EQ$_$&U3U>'1A>T,/JX
MZ$ZQ_''73ML]?%H?]*RZO/W@0ETXKRW>R[KPHSSKPD]T7?CVWT77A>=1%W[?
MZ/:-]I+ZQS55Y?S@=1^[K86(R[^VW6_=&M5#HWW5NNNW^W\9G6OCJMUM-?N=
M;J\$0=1=N],U;AMWC2^\!-YHW%T9C:L_V[U6]Q7E\.F8[TR5(M'E8](XW([>
M+'MZ>J3.#FM\&*YX@RQ/=J7O41?;8=_&]2F9BB$G]W:'?5+B'BCK+\ L%+(N
M%4+6V1$.0\/"Z)_Y&D(%@5!3(0@)X]0(+>STL1I"*P&R3FZ=?R*] *LW1P:U
MVAJ109YA0 U2[>OK5I<O>&OW^NUFC[O[UK_N(1YH71G]]FVKW[B\:;UR'5S^
MB][6-0U[GV4>YYAEUHYUEJFSS)WK /.,Q446KO67T;Z[[G1O&[@<6:=46XI:
M>A3W%J%))O6*!&07XN NQ;(":NUH!*Q>$B57<$6[EV*.WG:Q;(-:6">0?[?3
M74#URV'X+H!;O?2N2XF/94G8$9JO5^/3:HCQ;SX/!>Y%=;^&N8;YVC"_4@_F
MB4G/-[5YR772HMON_6%<-SAKO^.-E/D=+[B_-==@;]JN01^($XJI\V3Y7LF8
MS9N7F02R(+X(%*NW[&BCLJ'G.-XC7BEGZ^7NY/&"(5ZQ4HK*&IY6KO#:@ F6
M8! WL3P%I^-#W\#9^E"0"[P4 VXV$PW&925PM)C_Z8+&=!W&H=' -3+VD"]X
MDB_)^S\/%[YC58F-: 7#R]=L9H837$V.E0J/E#?QYXND^+X&V,./9X%\&31V
M[0MPPX"H[TNRX(+7T%D/E/EX!@''809/EWK,EUI&S7JQ"FL:R@_YD%X>AKM"
M4Q8MP KG7\O7:,KJO5]*R8XLT?8-4WO*V]"+!;RX;+04/5Q653Q9'%9*5?RZ
M43M%D_AC8P@CZI<65B'QE1-B603OR>YZO(4B+R61QF48KV/C$SH^UK),[""8
MEQ"_OCU2.VYQ$R]O!?%(F?#*%M&[:":V7N7-8<3K?!*-G^;+744A"V_"C)+F
M0A.O%O<9G!?Q+ %[U$Q&;I0,@L=NG:+HB%\CVEW3:+DFG" ;U\\USXNN3C5F
M%-"5JX7F;\Q[.#$<%)I2Z?0MERB!Z$=)Y@7VJ<6".%!XU=1#HB/6]15?_<CE
M^PRSF)GQE2Y(<HYJD1J];[>WV%"M<\UY#?1*J]U1^D/.X0$%"6D*U5JHRT';
MG2_V:D?+6I'"8Y[C/ZDGD\M:U]UM2<D22"X2#RWP0A/5V U'YE3:W%ZK*3L,
M<$-'DPN/YPO(I?=,USJNO=)8W/_]C9W6WNU:<=&,"<0]B:YZF8R-T1ZB-4:Q
MAVX4J,BF;%("MNP&[&)S++'#L.'/?*R+!-F]HK^6#(Y61T7BW!5PP%?@-<QP
M(@RHB]MAB^[;?-NDQ< IBAEX9P,<-='+.TSCZK5A%WI#\3XOHDI;ZFU9ZFAO
M+I!9O-M]9QZBI0UV,XI+W[0]GEKL!S<+2U3JF38]<G\/N1YH%JF0+%CVY:[Q
M4<-0L?*#_H1OLT2[[N126ID41(OU$LU$Y5.D:1<]FWH_X"%H9^+F3;>0Z(73
M6&9\LY[X6^0.4CS7&Z::1\YKV=>V[$K+\'K>$""Y>#*1C\Y73XK=KW TEB^<
M%.F(=+;2:#](+VO1(8&?4U83<.*(?0MXEA &O"V:$/6<DN<BX^Z'S+V.M)G2
M*2RN]DMF>M$\_T+2&/V\&U(4?A2;.X@5;])K<HF*QN[Q6IMGFM&AG$3KNM)B
M&SR4UP#7M^)%<0]_F3U'.O)<;X(G3=G01H@7DLNGHYT@!(K@82X=<1449H1@
M:KL;TFHLZ[936NBUPU>F.,3&QL4CW%XIP/ A'AS3\P,9/V!84A8+&:4S F7#
M[L1X%&X[3$08%C5M2W2@]6D0.-0JR7N^)BA92K5$ZRZ7M.422SWQ*0"(";]5
M@A 2&SDY<@.)1%^AA7VGGF&CEH(FYD/LH=A:8D!YMZ)4AC%+HCS=P(BC=^PY
M?,L_C#QM?Q+9K^02HM"7V[.ARB0X$-D!IP2^B1M.^A.>%%%@J0]9\(MBQP^Y
MR#ED*:)J)Q3@.]]Q8K:XLT=J%[40)U8H4EB6[8OU65%1M0@0'L3VA9RC2X-3
M&J=9[-&3RXP%PTCGJX?%RO '4(MHB7^"'>.DE,_W?N065"QGCNUE:B_(1.,<
M7;2V2O@G>@<R77^F?/V9XA:44=ZH5F[OD/1(L7_E&U^7I(>*NQR *?5!J#Y.
M#\Q=-K^9=&/@V'%&069:2+9$AGAQXD9S$,IP$((MYA4?CRZ-=_!%:<WGI78E
M<D"GSG= 3?9@2@1QT>;E,YYRR YV);G0FT\NSEO("@Y!;J,GEZ*C6Q47>_%@
M1@TJ_)AWMBA?CRXW . =1M;*A3 AQH T%<S:N"D&QNZX GQG0CR9,T(8S'LN
MX:2B*^87Y:)[>'D,K'"/.=GI-1Y>OOF<[,;-.:6!#W^**4C>)>$1I$W+%MR-
MAV'B3X]W2N,-F; E&HOFBC&6MEFTS[7<9QGD,:*IC@"29$C&\%$ZL4 T+)UI
M7IW[/,F4YW!=EE#@Q"A\M./Q/>@FHFN"X^#%LW3KS!W!BNQ;*'9AYY#!L@&?
M!Q!1>+]"H=+:&_7-XR.>V#)0ZAY\K1W=,V4$HDWWY.9)DWE[_SF;Q2V#K/.(
MLS*1'LJ<@W!2DD](<\0&1$Q&SU]D@559^M0D$IX!CLCS31S/G9AC:J3U+CUD
MDD<">8VI$^^_&FU8'^L84K-4VFV\EG._.DY1+$[YXG@#T(J6;!9?,N[CMN%\
MR;27GBK9C< %&^.(]O>R9>[0#B(^%!V>'_):77O>&CUNIC_OH"](]5FD%A/R
M;U[K%>T'/+8'-H0AU)NBC>/[NDZI&Y5CV3S\!U_,S2I82NY97+"W))0541A^
M\(!$Q_B*ZLZ2&:UH!FLGU$06@4!T33DH>,#E4CZE$=%T+/*;WPY[A^#^/8R?
MH^HQ*J8:3/@.P#>;3Q!"-!7SRS'/%^UG%]VY)(K>4%<@R)A/5TPQYW ?/%ML
M!XS3%Q"'S"=6",Z!6>40'!*>RR--ONE@*1U:KCU_]2I^?3>BP,Y3:,<)$E;Y
M^#P+<SF=,9G2(-XN6\3()M_7D5L]/$[<N-Z/CWTBN( 4 L2%DL#AE'L\\_TI
M'P%Y7CHBY_OL+<Y>B<TOL HQLN@?>7>V>'YT3BXC3TN#'>'M^PD]2N=)D;Z)
M;H[14/'3',RSYB>\1YLV/U6E'5Z^#N^&3XNB>+KSV13A!?NHRTT.@$8L\?9\
MEFR7W:)Q\[3A*<45!J:HO)#-;3V6;)0:-\I-7":W>X@WY,&J.;14W)3.R3(1
M4T;T2935<DX,+B_#I650123%C ^R56&GWY0-"'\Q+!:.^.ZJF+F*R5]_ O<S
MYX:1UYL(5MI_PEU+T6EE5##Z7%8\M1,ZMMJYX?H&QT'.<"WW@XKUUDJ)B.U*
MCK)6!S74P7B'<]I9K<$;+>G&G;US6NZ2DN.J?4N!E&GI[&5<0/U/,IE^,KY'
M=%3;M6!4V6PG- :K_RPRP3W2I$M-+HZ4,_?^O%LWKG7@A7T\M\7S0[&8WQ=$
M*=_T>Z%+-S**>69)A1 $.GS<IV?DEJ)%)VBO</3<$"LD0D:?Q+^QD<$$UI';
M"N-2(SPA6KT:S6C.$N5JLI9S,$O8IOE17OIF8.F;'56UBYD^/V0\,9:3HOC#
M<(C;&[B!L',/O,/#3/!8XB&Z9]I*J9_J\C-=?J9\^9E:*X4WNRQUZ]^ZLBG%
M\J_?T66IQNH:Y7?U@%6MNH W%FF\<;2C/DKWC()!@I&&O^_A%3R,S_  \7D0
M%F2T(#:Q><X PI''4@(W</\ 8P:^_: 5-V?@U7!B.DQ6M&#IE#AGCLM2M,SV
ME3!.EV\E:_43M7<KVI0D=R']8/^2:,Z07F8A/@^GIL-@WH5E%JT*+"57!>)\
MFHBC,/SZ$66*0Q /DZDY%VMJ40?/3OG0RYUIY"WFI6!RF8W<E#K>>R83D8KI
M?@JA76P)Q&31,_B;[USS"88.QBYTY_N;<395@A-G3D)7+' FV!Z<[]H+3Q3+
MBX:41KN<N514_(I5#"RYI>RB.L@W3(&#OP>\"*@[2$&N8<$+Z1#>(]J#+> 2
MCMKN1"WO$R"&#,+'=W'FR<Q\A[XXO> ;=\$#'W[!,:%\"R$8:R[-6&BB@MF?
MEPD2?W%/\OG6QD_V,9?E=,F9OL2ZQ216)2.X;$6W'"@RKQ*,%NVXSU5N[?56
M5PTL+J$/MA?ZN!S-]DTL<[2X@8+TB:^SHC)EA00+P UJZ> J+6=8%EHEI_B9
MV$Q)XC"Q_G>N%)@I<S,HYH8DUG&W,5Q9MJ@5O$>3,+/\=1B8?'@9K.NS/#/D
M. +[.?4 C B3'IV"QJ ]K%5J]4.CX6#A\6@<V=JH1]5\]7YRP[-XLZBT$5[<
M%3&QD2$BG=<@IW0W_<XF<65#']Y-Z'%,79$91NXC*K&,&NE(3Y+0&Y9 _WRG
MS<2#GE8K+%,.>=M5.L!I$%S"8 D.@T"BBYH.V(HV0>:ZS]\GTOZ$2RG!XP.^
MN(O/T//12+(8<XO!+1-N#,8O_W?HBB82,(@V'<KQCI?)SFNMDBN5!S3>.=;C
M71R6V-3D &VCYL-HQ![8$5N@+2!I3'QYJ=BV+%F1*CR(*/GB6'7L'ZAU@CE-
M;,G)US0N7EA:O60S^C/U*OMN\.28+-DPKQ33/\1].FY<HSF*7(]WYG*H-:)1
MN[AT%"7CI\T$,26IRO,HYIF0)7*+ZT;9A\97[Y$^I T8!-88R_)*> P(N0U;
M_L7<HO%K&&Z.F J&A9E9?7&"98V[5N!AN-U;*[=6KP)8HM^\[]R*3XYB<8PP
M7)D[SJ>=!IXUFW\Z[UHX#-GB6;:+P9&,FZ8AXZMFY-*O^:+RB&WTQ69%'A*,
M\(VO4=NW:JD*:7ZT!:=N<:1VBZ.".X*E$>=2JXH3!)YC6SS(6VYBN7VY@@"5
MQY_U:HFW9.$0R!C!R6@S-?O@TQ&CH_C%K3".MF1DSIM;6"*L2UTYK[H4Y7Y8
M=@1Q(KI'!S6#?QRG?>.&,/##MY[QI=&X%PNZDK>+]GN.*NOE0V60DN@<%'^L
M_QPOUG@Z;%A@3+"K!G^B.>-EPKP9Y<!VYR,0'9>1ZBO&F'NHR.J#J; %887=
MO,6^]KQ3J*P_Y;T)YB\YL?TG3A;4%XF.:&MM>[(<1K'_&' <8J\>D1!8D!F8
M49\7TV-,_.4E3,2 ^#9&H3Z?M8JGQQSBBER%1_9Q0]4E2!0IG^BGQ!/ 2"/
M$=JBI2W>%;MHP/TENX&I.T^L$NG?4C@G<!#W#QJ 8W33V]/CWL<Q*&+\B-<;
M"UIA3G3]#6,J%&O.8]C)!8$TP;U8J-9!'!$9& D-'-L?HUYZN/+, P,8S!\H
MUCE.8PO]"L,_)]I,AQ+&^[Q@]C3?"QWB$H^O=17YI 13/->85,&E>EV*DH5(
MP/,T@<M7TD"'QIT7H"!CQ>5![;,6J237LL1T$28N<'NYB7$<"[UL%5=L?!TW
MJ!T2FSFR:;/C)!I#TZC]<-HS1M.=SP5U\_;",5L\%0SQG-R0Z2("'168 QU-
MV:'1HS3:ZGG#4U.O;<6-T4?UN)R>XKF/E2J_/>EE14OUDUS%R1;;;3_3AW\/
MTLU4QR2T!;98+\,[MG%22[98IV)9C(G+:GFA8S("6;5Z/3%]$#>OQKF1R52,
M?&,HZ \7U84D"&?T2;$%7]#WN#T8;D[(FX9CAVVZS 8DJ$/> N#9\.B6,/"J
MU3,>&T&$)/Z6L5*5/_;WT*5&O9+X95&)>1[].P%W"J,071J,&2?ZTG><KS6"
MX_#^$Q#66"B.;_^,_L1%(HL/1F-*N+U..G-A4:*ZCJ24>&L/L6H";"R:M,<X
MU^9O,!$^F%L_-'5ODR>GU.'?'L-+D&</9CQC31CT9%@4.<,$ 8M?\"B7=T?I
M1)*46D$2<"A0GA7P<L !<;A[!>^)Z[*7B)>_%X8M8&/_?_;>O;F-(\D>_2J(
MN[L35D238TE^S3CB1M"4-=:,--(U->/8_:\!%("V&MV8?I""/_VM/)E9E=5H
M@*(L2C2%7_QVUR* ?M0C*Q\GSZG,DFE=XI=A;79%U\.Y&?/TJN'C<Z;TK5EI
M%#<WR =_C%S^9X_9^>Z(V3EB=NXF9N?N^@$_AE32;O +V0?@&<BNDXUC[B>E
MP:/2"'-O#((-#9&8U771>#.-")"4,[PYG?H()>:LB:8EY??3*L].@#B:J!A6
MPM1O(4#L!M=PU8JCQ)%HR::5^1C0.]+!%IY$XD)7!<B#O:4/BRG:G41R36EF
M4NK-_0EKOF=1>=L+0RW!MC_XBC4GXWB0&.?.3@&G_]KQG&$<,':?1C,[@P1>
MJB82 ]E]T;C4NN)-XXJ0(KL]!!.!FW!G3@#) I+'T+$ET@'D$F(N<O2"&(&]
M]04[0Y*\6!3E6'J"*PI*#6J<G5!E1"(G#LR @G6Z#7RX)AN_DXO/^VY5:UW3
M$"K+H]##<5";HQ[=JYR)W[3*2$/D2)T/R7\C'P?C0KHQ_AX%2$%ID,T(^'\]
MI<^?GCRF!Y+__LKF:YGR:-BX7$^9%U@H=^V\+7P@BZ#!3'MD41:DNG<&RWKK
M9'>F##BT(<%PZM+LKK":2A&"F;O$_:2?<#XX)[?+WTQ(F5&VX;(9)1<NE>C.
M2;7,R?8A[]+Q8->4YGZ_HLUG79], D8@>MZ"\)2S;WOLS+MG-D6B:"S_G[8]
MA'J"C[QF;B.[<^%WRY#A$%,[0LR%R*O)D78Z0F]&2UP'2HWA2!R<WW3@2\X/
MQ&LIV!"'VO5GN0D8%;A()>S#1](DA<EA->R6K0Z5?R=S/B5R4*.+58[)W[3\
M-O=G'+W##6I[/PJ97P!7AAHRX2VH[VWI'Z92-;O=1'.HCMB']H<)<W:.?3FI
M\.DCLPC7I?#;A1._:/B0$B"D_\@U#?%EU:!A6.0S.AATWB@[JJG2:XO\'T$\
MZQ8O]/&!]-B MZ<:<HO6ZRY5Z'^GVLA=U JY?V#[U]&2J41D2G<V*)N\V]A/
MX]@S.=0$]# #__;&VC-L>_N&B(1:0SN%B]O8]8W;VFC.UMS29_CK[6_2I*N2
M?O:!^X_/Z"#^ #6:3]9U[!]AO.N8%@' H$[!6J6[#(7;#@Z(H/5X/89ER%VY
M>ABC!72_AO5Q@MYW@J([)@%VPP3DB 9G5#8/Q &A$Q?5=8D\(X)J69]T]8EP
MJIH8E.B[:!50E>0X@[<Y@U1-D_)L](4E\A/&AU6Q:6.%<+/:MH7W>*K %@8[
M:U6_=K1 &M>1ZA%A+8BL&]02N0\6EZY>-OEF%7EUKX"LN2* 0UD>-_''6@(V
M26LB?C1 !D)'O[E7_J(G0-B0:-=Q=FYM=I -<4 ^;>I"XNJPKR2=2Y\*L>QQ
M#FYQAP#O9OQ7,DT)S0091RFK&\J<U.91!0=.2G(D,E!)&"Q(Q""TW!$%/Q&X
M09T=D*Z. I4HG0";V_1(PAVG_\-/O]I$AK0PQ]&E$&8&\99D[L=WZG%N/N+A
M-2^6*)K$[<*![":H5QRGXQ:VBBDI[7/I@]-?;H]3\.&GP%NH3FLVE ;QFX#+
M__XX*5U^Z7]P'/;;."1:K@;DG1880M)SU$V@_ON&&Z@GC.42-@52;:4:!J?A
MCG/UX>?*1YR%NW0VT=@1[;7.#.HK!NF@^CTM]<V6 "SJ05_F0@.*,%;3GJ!$
M.$[<+=@V;I0W$\=504(G#ZI?=MI,PP2W33>8+OJ!3/SGE/+?7UF^DA)QDIC7
MW0(IDR!MQ:%0?9FBIB1&BG@F +(8G1UN03U"L^YT\I3339G<0?I/B"T1R)\(
MPU+-0SNE@7@F$H$ BG-"F&* OH*\E.SJBMP0* !H];KX#04!2E^6=;4DJFSZ
M,:&#?I-N?C1X+2B3J9K:T)6Z#&R0+@<%:GNH-_@J5-[IG@Y5#'1% 4B!R% (
MB@QMS-15SMO_-H[86&&$+RQ3= J21%,\EQM*C3I<\9.*7'P>T U3<4QQ!B(K
M+86HT:*G,S@%<U*I"SW#J;._?UA^0:GXMA,A%E//*P9HJLG_^F7JMPXM";H6
M]V'NJ;S2$[Q'#3!O!W77D9HK<;P86(5PQCA"#H94R.X=_UR/LV]''*$_,OH9
M(UE024 W7UO65^4VR(BH12+VN+*M%?TX4 @G<J%HX^0Y%TPI%"J/W ::5!Q9
MZZSTMT0Z*/!O@8C#L,Q%.K&T(RYT\]%CN4JI_'M"8'ISZ2K5+H?Z-C7:]L*_
MPE0I,Z51\IYEOK4\IJKP2/2I==,>BZ%WV/>1^8?,)&DLD988EO*(K@LP0Q3\
M<>X1E9E:%<V&U+C:'L5G;W*)\',14>7S='](\MDWO_SEV/QR;'ZYF\TO1\O[
MOI8WL982!D"73CH4<.K']@(E1+N&_$P9$87'\^F3,XX!G@H[YNLFGSN_NM;4
M9$J^MDKW/#72/>I&G*MD_"OA-+_(%\X[>R,_/W]U$7]OI?F46RUO5,G7#TQE
MVR4H_4&R?>$WQ^34AU]MML8H1S7HYD\H3-PROJ:@(YD[/\BY3<]SN'<+*8(8
M_ 4Q&>F_!S\)SK+_ A42B> #[/8SPO00.&_!;1SH1:,(5Z(-.)C;F#6C0K25
M"/%W6/?ED@/:L-"9+6;RHC[_^>RXA&YG"5%1>!F)BIB20X46Q8C!?Y3^.,K5
M4,, )T(X,C+IB.,TW9I'G[3PJ8J.(#ZBCTX]&)N-\P=#HI=CA432M!W+;KJ(
MUU(=SKH),6RKD30:YUGT#:$ZZ;=0B?28Q[[UF1^DAU#"UJQ!X]W49653;;$'
MZP#N-2J2"#1!<Y?0L9D/Z.P3RNZ8OT VG5.)F>1]'?TX_&U@_O,-4@VTCIT_
ML&8D3,B:-YFNXVQ2YM,:>6%7719-#;9G[E2IYL3Y^CFEX6/;\&AW!!HLZ</8
M=14-N&2^W-N-SO0[)^.RD(X&5U>!WD%)[XE9B-FLW2Y2F(U9O8D2DX;D]G4M
M/8D=!&^T%JIO0FQ;>5_-5O:EU,9ERBY"R2N_'$U]!Z]I:<Q#@S-G-"!>%BJM
MG.PVM=82*!!"C2?)DKE;8_"JM'"423F)<^*1ZY#)\Y4+[W1R4;#03VA]32VV
M3.U5W;R1(L-:='1)AHB^VKG9JO)K37MMD16@[]*'$1"+;CM ^]Z!,I*<]EG>
M=H-IC%,8^=>5_*98"V-?!R%MHE%3-FBCEP F8:XOR.P*KVV<&TU0QE6E[-7S
MIJ"4-J2%J=E[*^$35KNNHV3TPJQ3HWV"=B11NLJ5S&6G5DSGC,Q)8.JV@N!-
M_:MJ/=(6U8<'6T]\ W 5PAUNT7?^2UX24R:-9]&&X$T>/V9T$QV%OTZ^R!^$
M+48SA3J+H4)J:VJQW;-L=%J4><".$B?HDJ_[QY(<[O>3+Z8/#"O GM6D:TDM
MR.C8"J/_[(&XC6"?CFN!S7TZ]S+3"!K (RIS/MUJ<CE6[)0%@-M^*MML.?G"
MG2Y/,[,J:3VJG"!M=^+ 0!7BP>GD"?>+8KS"'-"L-DW=1T*[>+&TC)(T")EA
MG91*98[UPI63WY)C=UG64[LQ^15:5C/$%K*6AC<BYI!N$W=CB+L(3CWB=9]"
M9EV7 )?ZJ#XA/55UBDA5>\T5)A1:F!J80:5,%VR8O#J7KW<XQ)-V6_^OII;R
MDS&#64(G,> &2\J$F%-FQQ6O!+P#&U!B^8DHE,DC%/!U<(@2PO'[1X7RKM:O
MRNE@L&0RF&!ML ^,KG:9&12 4%Y;^$VM TZL$W[)N(IY0G3T]U/AWIV*YUUJ
M]QP(UJAR4FHVYC4(PK1*E[2+E-O/NFI\EI9RO*]75X9D;5CX%U>BE>T$7EI;
MW[G&(33*B.D44!%TZ2I%HRN* M=?(59<[!9GT[8??HZD7S_]0MPUMDXJK6/T
MN^&Q%,!Q.9T&*(>2,4S9?[+T<>FH-0-J>6]C\?O9R(./#V!,E@5;85M;&?:B
MHK>JLU.S9 5?E\0D^9#:;8SRNXPJN$Y\K(NSR9/X%>6X<R \' MFI_GLS1*'
MWHDLUP7^W_<?:_$.?&MP+L0.^$^QG:)?V<6UFM!%"EMD[V?RT7>TA'88NB=?
MT+<E<8X_7/!9')3%-).>[5Y762CIRGR3;_===5>Q+,GP;UW>"!/E\!$?AKP^
M_K'_0L!7, DCZ=]D)C!C:L5?*<F_Y8WJ@)Z2'?#OPG65]Q2>K4$!]>-;_)_7
M0MWRXO6_J<JP(7_P.7O(&9-MXT_@D")*2F&09!K,G*,#21J3Y!?-EMY(B#W7
M1A,MW0[LL\!5(W?=G";A&CHJR2O$L?@;G%/(? Q:J?0"5WDB?23WV_=(HZS(
MWF7I2F<#(NQ\8=2B6%4YRN)#V$Y918%@[XM26&'M3^LZUDW:8!P(R6'XCNW+
MT%"+ UC6'%)&-[ &9XHW/AP/V8#^2=^H%^V?HF$EX[A^R!>=NB7SS03*[-BU
MY*TSZD;^42[SAH92-=SP2O+11=W[/U*4==86^:!.$48C#!R&A3E7]"(YQ=ME
M&2E+L:Y;/@^*+H6# GW'9"H%JY4I.SBGV R)5Q0)MJ@9_YY-=^('78+B7W8"
MWS3- -#-U'57!-4!K$@'M0W1E6961+LX70-N^+)6'C%$]%&:+:$[DY.%-44D
MP $>]C(OXXV!TPR72F8SU^B+V69X&>?#N)+&[;!"RE5,"(PFO*A65)/(BYE]
M#ER&\'GM&DYB8HG%/FL7TD:+*=8PD9$0;R>&[RF:=#]C1YHJIG:WY8U 8W<#
M(_;AZ<WO7H5!VH;SB)Z>Q]U?&6,1S ,= ]*#2@;!'JITN/SJ3X*6P/?'1L9;
MF3 5&1HA6_!!]8D-&#(+ZXMXO7A A;FS/ MRAI,G<9R_6^@IXFZNR')1:><=
M<#4^)F5G9A;I<B4O=IR-V^A#16$,Y4_+()3/:=@&^%=44.KUNH;D'_O'6F$G
MIV?A Z)JYFQ5(D77V-PYON1C3BK\A)YPL_<^IPKGR\BN-J(;K,05QK--,X@H
M)?J)J-?%+(,V3L>*L4&UQU2163,SI9+)*1.$P#>"F3(;#*).Q+?8 CH/?@;5
M8I1[NR )F40M'&HDN>,C+GH?+OKAET=@]!$8?3>!T9^ <'3<7*K[750,*U"A
M*[9K/NR/"NF<T*#\/_TK8R$^5K6#&\E_-4U;T%"OHVQ0%/5C@;X%>YWX+J>@
M;0J!0$2S?.-L3HE$[RC_HX(KHSU*MAU)Z,PUYZ6E ?R;,<:_Y0.1>,FU)>]M
M\<A<L$2+E.0H]B8,;";ME%A=B4FPX]RCY'T4M9II/DE$Z@L)G#?DU\DW GP+
M$FYHQJ$79W1''"4:2KIO7K'H:]'%(3%2#CGYA*T<*2$B"U)OG*E)9"#V16M^
M:M.L;1#V5L^3[AIG0L1VY8[VP9_R+R'%() P3?E)@H=TR:6>L2_!DS G[7DQ
M_>T0)\$/2>ED):&NA84'N3;@ D9N2:X>\P7:9!3Z,)6?(:1"XHP&9%&OI2N>
M>/=6U)6L^ 3QV =A]JH% 7NG^>RZ#;+:[$J&C=2^O];9;? P?_3ZIK8R:\YQ
M=]'N)(.MSH7-3HHR LVT7;R#Y')*14]K)+%6(J4@6R,+#1 !T1A!:F-F(J#E
M8O(Q\0N5AUWVJ31G2U>%;1B1G: /HMVG)*9FN^W'"^IQ*Q.P7J\%IS<*!> X
MB=XK>[B4\179BZC6TJ66GRC$>TR0YN^3?+B_+3$R@&)<T^"TVV1Z#KQL.R;_
M42PF.130,C6HLU5-^XFNF8)3U)0'+[[,IZYDNC4L$]&87*"<4$^\U;H:%20@
MY8W8[3XH4_L#K%Z3Q,CL4P,][LHF?BVM!67I/9.>%RTIOFYYBQC_(.UP/E3P
ML9!&++!.2&%Q_-91)B"T*1WV,^@T%3%D>O(VB*?SQ:Y6-0GW61%5G?K=MU)0
MJ=QHX8HN;H&^U3[^#LU:_K6I@/_"+_M:I8P.F0[_,#:M*D>,O.S&CT]FM'A,
MTWF&;,/2[]1\4\S+;=(@/@2'SO---_%;8O:F5-+ME?Q^8""E^6<7U4MO@7A;
M,E;#8NWU4\RQ-1N>-:$KD6\A2.A5.@3L=]!L48TX,PLJL[Z!#U,**H?S8\U
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M8#Y;#,$4X3(RC?9JF4&%#CEU^/"G.)%XC\CS+4F<U)_WRX[PG_L:1(-T<+S
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M<7H_0B B^?BH2X.))#B4I 9TYS6$>>S=3O#8$$-:(%8%0\-AWKOCY'VH7!X
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MUM(!N^D[VP11NI@H]AN-FA]&VK^"B4B(U,=Y"W1G3QA30:@2M%289 L.O'A
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M2!N*'W>817([Q9HB6<293BX2A,1IH/N--_?/O_*FG*Y(=V7*E$V/N(DE>CB
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M5ZZ<![ _5V9C:<*F)2*CR3TH+;P8+4FSX>[0,EJ4E/EOZ=U]U#7#@J6\V Y
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M:^,W7'5"+;-7><C7';JL=M*@(Q,_$,*('2@WJ]KY%Z8D $1PN?<@L*B2CTW
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MW_LNF$'Z+I)=YSF DV*'\#R)<B\N498NC=?AE-ML4PK4%!SZQ7ZB*9D HEU
M#&@[ =$PX7(C974'H84DR6AKSY-T@U#HQR^OCPN'AO3)Q"48S:0'@)M"-JUM
MU-4W+/_)>NSID4\!*^;IA)*P/WMK!%^9JCRM0L4XE(]-1DD:7HJ[UDXR7ML6
M?IDLT"/D#EDBX$R)W;38Q &1Z2@7%TH9\]1OBGCS]-!;$]#SW?!3#T79W 4Q
M\%N"X7?;V,.M]8"*GK>07<^V>=8],]ON1,JJ-H++2D2;"C0<O3@]!:4+C/K/
M*B"T^1@E53Z;[2=:\YY]Y(0V6Y'JR]V9MS"9C"Z.ZPH#L@"9G^-YSN(8R?(]
M@0^+>3)@F-IA'8.V%IZT\+JXP5FJ%6$!6?!\JIZ3G&-=?9P+4XB<H'7=;JP<
MG@TP,4U2DAB(WC?YWL]D_5WP*"?Q*'^\X%$N>)0+'N6]-DUQ-CM3*8ALJ JH
MV>24R+H-N76JA!%;C]VR0/ZP2978G+A]T"5L':>*0<#7_;E;9XVI17";#+NC
M'5>6>+@$Y'^K]RU\0J" 3Z"":1#/)Y<&GU&"&1Z]3B\VE'GC+/GZ4,VG2-HB
MTVB_$Y0W_:."L@'-;P:$O3)4?I1FQ&6I9\PN6YWL7$K8;A!_\*L3=KT[4&4+
M93E-7Z1>+A]5 ,-)7_?D:OH9APGB(:E/(P$,%7F$A:.@\? I>([C\7-*1?FG
MUYAIH2Z;!4_:+C$[;ME_<[P6>=4J$;#O&<!^-">"H?'.#X!_S'Z6ZV O=X6
M4/!$AE_AXO*>Q5 J8^3>-7\'<"CM'\K'<9H0&C&AE?E;V(H.JV+DFHIK<4"L
M4Z@5XL?GVIR)#BRUS#B6/ZEH\ #F;94/>J5YJL23LSQ$S'(.OJQ?U6Z("&G?
M3RIYX\NFCI0"6:JE-A&DH)3C/H]*8AQU'T<U3C/]-@=!E!U%ED!$2,;['W&]
M8;&A28,.:H[NIC;>F30;H12#^NM=,%T$0\GI!$O9W)MRX=L?/7]B7 G=?=CH
M]Y0T00/!M5%<XU<X65)X)B&?+LU4-=,83\1_N>' 6AWP'^_0[L K%FG4A>8)
M3FHC4-.T*^)=6K[5K,,&_2])0<0#!@>Q#7XJ2HN[T(>SU/;P$].0(&J:F;N4
M65:E"]:8(LK)Y@Y4*V!BJ;69 T7T]$D:2F752JVX[I7)N&OI)(8N*IP*C>;=
M_*E^[A3L.931O_56''5&,CW7;VF ?/;BY;,,MI#<"Z?B(UOPF5JD%V)'7G(.
ME#D)!E[)":]YZNO/N1R$_41=[O'JGWSTT1\1? ^*O P)':65.V\MKT&:D0RD
M<^F4$_5$GL::D?AA=F6#+Y< 36$6&0&,$IW/6)\Y,(^W.C\GI5(K-(PW/?Z?
MZG_,Q4J&9CO11F=_%#[6-6%R-EEB*W^79)'7X*59U9F(*Q6562/F;Y,@5>'&
MT%9+AHD5;6P+M5D7F4@RBXE9-_UZVM/UU\&_NW?.AB70XVPF.G'5D@2$%G.\
M]'HJFKW7'&85=LVI\*G)7:[TN/5F XRG2]8O/6JE# I0+#+<7^8Q\7?R@6.Q
M9&VPRXZ!^<%R-BDZ3]]TSZN:3K>-KY_-MU3\WLW4;,).^LWRYD2'\7/C:R"Q
M2NT31P!Q#N-$/$G?K*0_D.9J4S1CRX&<M1O28MKT]3T.7\5NTIDKW8G2"]YN
MH_]@G<;).3.EJM2B& =4+[[0I/JPRL:#1]9#LCYQ_8)(UU="6;\DO*FI/YR
M:Y0E'_,!'D:W1AETA\L+@)B??*DV9ML?<5'T826 5+?-^+O,;7L=CNX4^4FG
M[*,AA,B.64K?1]-CHEUE^%ZM;H^;OHOC%I=LJ&;9ACA!0UQ%P*(\08FB):XT
MY!\(B&9()R,TL@#9809]@6[6C_&0DVM-S)R06.P.WW=,[+/ *VT0)4L#2.B?
M<&U;.1CEH;\A#USI6S2 W!($1.*, HB34@[^]O$.S#KO:5CJ^W,PKPD+N<1?
M+\LM6U3&"/+5?QLA"/FZ^=K"NG*@R&]?/?N0L'M-*G*5J+J6%H\4>M_:^./+
M5^5<I39QNB0+$ 2]R\GJ-I7$L70S=-S3Z$/NV(TH!LAMQ:_^NU"/JW.**4?@
MTXV>P/1A^4O\\XNXC,/\@X\7/L# $DO9XH\2#3II'ZM$884J+C JK?1>Z1"W
MRW5; =XLPK:$B%"W$4?K:5700)WL4ED>?QR>W93-FRP(A-8]3B+:R6W'L!R<
MY>]3>C;DSJG8.R.4]PWDN>D26[2,K1X$E9G;3DNC+X_10_B*88+><4X+_>"
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MT$HY(1T*/Y0>8!,.$ N>#O'56NI!I:K:EFO,)9.Q[_)U(&9KJ'H'JM;D<Q*
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MRR392?RV)_D@>G^M10O^[.(SC<I(;YK]M"]./.;.%!D-?\R^_7=T.".GF8W
MJ0=Y^_7^/5Y->^IP+(#F1!;9D+P>7O8L_M075 .>O@0^U1Y&.SR]B1XT?BCC
MN GDWN'>O]709=A[/Q'O@165F)S@-.Z;==_%];@/OPWMWX_[7/\/J]>D<^,
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M71&:LOQ3:TRJSHWV-Q6"7T$XN,9%+BS[(/1"OOJKD+AG1,E,>$FS$FU[GB*
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M7)  %R3 >R(!YI9MSOM:=+;4)"8-K>.[F46MDSF5,C\=K^0]1<>)71DF3DO
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MJK.F1<&WX 2[U@&S3L]#?>P [TUKJ/ >2%"M*D .E/Y*C8Y$$S^*:,3UJ5@
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MT&+2NPVC+SPA,@,UF LB*VY:.&F>8+K'NFZUGL&V3O-Z5$+='Y 'O6$(.@*
MX18=$<?4AIDHH49L\H#_(C[P0'2, M^2?V:PVTSH:CP>:(!W<MFPR0TZ)VX=
M?1:?/"[E2V@SJJ5XHWT7S.C0"VE%ABO,4LG@)V$,O9<(U82\/NHV>B82.W7J
M'J B0^J#2#3/1K$RA,G];;?/5Y>M'3?7E4[T=0"AH,XW60*<@D;$1DU]EFO@
M*7[@.7@V*3>\PXZ_T?K-L*Z%B#*:M1KCV $')]:16@< XQ]=IJ+K\U_ :R6!
M BZ:]?6]Y9[Q928LB)'BNH[&',B]483;H^<;YUY@B4I4*_R*?6 011RRAH $
MR.?''7\.UN@Y4%ED=JGE=U2,!F)R:H-@9V4DC(W J-9.N\;-K%8"''J+O90!
MCF[-8RP\F%"C=ZL"KFV(1N<FS'P;<ZA1@J0$03P=CJ&F16V*05U+KU9IBSZ!
M+ZU%GT]9Z9+NGQ!,.7BOK3"Z_!@;@3/V+:"NOF:R[:B$2<WA15%TRQ3,;*.U
M!0:YJ==B-C+?$'!(L&'=4KEFXWZG:] 4^M9SYX]?60,TMHA5=B@G5K#K8S;<
MI@I%WN>-$&D),.:!J4W'C4&34'2)7]RP<1*=*KV^X8R7L2XJ9W4.^^C;DOB+
M/2>8.A;&-,DHY3/<I/$73"5"HGD6JQ*6B6Q^;#*\?RF>EVC=Z0#CZ,_OS(Z8
M.+;N!$QK)KOI=MHY9-/;G;_T1-0H$#\E7ULK=X!.R2/Z_6!,2/%NVV@0&*VG
MK(3Z^O%;*$[I#A+%,GES2DRKH) C74O>:#Q6XLH]W,+/?;X8AB>VR<60_/$7
MQ1]58F01U<+DONR8&AZ&L!8AD7D2O"YZK101S> 0_-5SL!M^>-YE5 H^^A"=
ML>M=,]R:7[@+98U\>0H8O8I.7+T-W?+_?OSITS^NXHON:'F^&_IH\?I2CB>S
MF.15RAG4LXPGN! QP*X7"[9&/PG[">H[YTB6K!O13).K&57LDE;><G+_<XPL
MJW3X*@C. X[MP*M<[Q*[ANI\ VT;1V<GRK@>X27'HND?)(PNMZY0\L*@KU>I
M! 8;W >E/VI%'KQFMA?PQKB?BA=%=/4,"QESIE?_1.0U QW/S=L,C<]CB[.P
M0+0T#8A[^LSR.VOPAQZKM:<).P>3<SI=O>D1WPB-(GF-DN;D+*5?_,-MLQV)
M9F[]6ILDG%^3NRK+P,;D%!6DJ6FTJ^B 3S=!3LEZ+4AGT6/3YITG=CR3C](R
ME:*K/U_ 0"?!0'^\@($N8*!'#P9Z7/)+BW"6+3BIU*:FP,V^7(_$C;BAP+X#
M[>YRC@-&+46 JE:R(3&3U#!/;' 'TS6=4&'RL@@^@P^;C&SF?=>_9OXM^$25
M?%V*!)Q1S<LD)F7GTA12RW69XS)V];];;>N[N')I[>V;-[ZT(A D/ J? *1$
M40M7:H<73D, 70 \H;1T[W+MY#,XEE6XB+1IU*MGK1><I2KIXCQ:/5_]I#U=
M?9-8V"MNXO=^SZZ>6NKPYB;I004/\T9LZ=)LM/(UM12,$9$_UB )#'$S,FD/
M!Y:2J<P#/HR*/I[?.&B/* CEN@)YEKMA*#>5#E@,25@76U"_RD*P(V8C:G3)
M'H#S_2:U%/9QY=Q9GV0CZ78T5:';,+Z@.1/M4K+%I52*Y%_AQ,@X^ZG1E+K>
MB>IA+'*&#G7)P*(HQL\@D5>=)H(3(2#1X?0WDM>BCTM\*EZ-W(D88\RIBITO
M%1'#19+*A=MUJCA0PZ9V$BCH8U[9*Q"#\2:[HT[XQMWOJG4:+MV:-0K6AAEG
M"6KJ7T@91>\7:L!B</H.Z'@J9*IK>LG,O%M<1#,AD$O;A8K&U"YBEXW$ MU-
M61:7/K#0:FH;,@H:^+^MH^Q?O%OD!ZJK[;"8$<:+3=<2BQZ?]'<6P/(HRYQH
M^"'(%.18W23&<&Y-7>$J(F(\LVFT79@V@U):[M1Q0'#(AH/'HWJI\'F8+8TB
MF2/E@*XWVSRO0>.M#$A1+*EK4A)@24NK7-9#5M9 [II+T6::AL2(=VX. ^:+
M<H8:LI+1C5Y3 4X1#'5R'L&,C:*7B"VK=G>!@"J78G("]60J)\_;$+<4LK58
M]IFC\X[SNYPF>_J/B4H^>?Q@)B!#Q+&IC!N##S:F?CQV4@U!;V6WJ_#ONJ]&
MYG0Y83S<Y%B04?90J=S?3,8F]?Q'WY+FD9Z/$2FRI2H2MY>()+1W3=^IP ZC
MYOJ-. !")MGU;J\KOT#3SK@YX.#9)=13X*/K[>]W!MN<4FN20,XVE2;0 #]A
MM?1BVH2429!;3Q3*9I8[N7Q&_-2NJ,/#)^>R,787O^ZY9L>%OCOO9W-KHL9K
MXVI=@&"TNJW@(:ZZ\3-Q4\H@]4\+L./2254$7:W)398M4;Y6DJ\D&\GL2Q(Q
M]T^V]!UBLKL/U_$D#<QT GTTAYIS!!JIF3W94@Q$=S_P;ZROVL9")L4A\N1N
MR\5'8 ![\7'3@JXL^$[37X"W#"G ;@'YOW8 E%W ]//G]+)4$5#ZOJ3M3'*_
M"WB0+!E "U)+RCSJA!9C,LV%[O%4QOVQ/ )&+?^@8WD^2G-%"IWGW((U1H$3
MC#R/3D&Z)A(F4N9(6$_1P4!PQ)F$ 6*?>>MY[M<WL+.R['TL-G)KO^T$<_<J
M][R,A163W:"@EK4?DT_)X7Q-4)YKR$"E$]"3^\V=3:VF*4,QJPR36D/OM8VY
M)%#-J52(U' :>;FF==KES#JVZ&G '!;8[R<[ G$JUWO!=59"\<376NC$EQ8G
MO%R,J%FMS[;O@CD;*IV)A*DEKYA[*A)]KK.GYQ&MGBQB%SB!35CO( --"T'@
MA90KY&2%!U;2#S-8)9E"ABR>@0'Q8U4,49TWAB*_M#12H/X:4RI;F$SVQVA]
M-_0ALV3DS%W7<3^1B=$,U]A5P(NW8"(L(?DS[&CG#O$^7(-<UNKN#@%7)8RR
M]K!R?FO+PK6&\5E7BASW-I$2T92A@U86'B++49F?(2)Z8DQX6[&JYNIFUUT3
MC&F.938)VWB\02M7B=05%)PPR*DVZJU"M'YD95&\1Y*K:5/#%/)\#%Q*A''@
M#KOIH#,N8K_(K;$!LH5=.?1%G+-.6$_H<_GSH7*MG+^,5/Y)I^RCL2H_T.NP
MX^R/'\\R:[G6*N=S26T3=]&'[/J'>8Z,B.]H&6Z/,M,R3'(:37@G<9R:3%HZ
M+3@^8I2,AD==G\LO+_*SE<E25?GFX@T3F22'O!F&N&B&;;UV+II'KV.EUSOR
M)SD2<!GJ[=EE77Y@W#\:. [@L5Q8+M*+U"1R*%XR<$&XOL68>P_0(2]VMUO:
MA<DZ/1,[8%GTY=N[.@ ,9]>: K=U,=$BH)+P*&)7"Y>Y("=.(B?^=$%.7) 3
M%^3$>VT:X!,)V<VQ^S"$/3,!%\B%T-X@ZIQ.V26<V)9L8=!XM+B-" ^(!#K_
M"IY>>_.$6.:,DFZ0EL9$NLL0-E=J=>:5"5RY8(V'..9!F/;$20K"=5M K(QH
MT2DR7_-'FFVW#D@CZ97<EZ:&G->> UTY;(%G*/XOL>6)GTG-2LAA93]*[HU5
M;YUODUJ=@"\-JV,W*?N79=WDS:UU"K-)KVUQ)PH+XAMP(VX<<^>Z2&U>0M2)
MPUGZ;+<3<6FAY--'XWL08^":P:R4E6H@J*E/873I)J*\#T$9;9++<R:>!^N1
MNBI<;;%6FN&T3X!*,M)^<P-L0IC9.!5EMLC09.'0<RO7*]%/NGQ<FJ"YS!I4
M4Y#1)2I$AVWH+&TUYU,$/Z4@-RV0NO8)4@&<.MP[Q([C?&V/NO0!C=&61AT/
MD2G4;!32O(<4CB+W*PPUD#("+H-;68*LNO4<].% XPHXO6;CH'&!)K] ?X,=
M,$C+IVR3Y*HAT:7KNK/U*SS#X(Z@\.\)N^;T;8\%BD_9"2=^O:D/HSP\)G@,
M '[0]0Y*>2VX(NW1E H#9PO6L"64W;7'V98\Z[PJTF)P@0R'G8&D!M(M.7^I
MS9B$*TF[.4Z@ZE"+B>V$3EE*@HP<:=V-M090QC"^K"CO%!\+HA)G802RY><J
M.E0-I#>-^T1T5,1<W]+FCS'<% HM<NE>CNN(&CTM/O JEPXZ12@%SA^;?2WO
MGJ)0I&.$SJ)VN9U4171!ZB)AMV^X#O"\XAUV<4&]Y'B)MC9)/6NGX9>?/[NJ
M3BT&.!4G#CCZ'D!4.&I\6([WK%._R5Z%<7AYW\=[7F4,ZL33,.UNT/V1!,.^
M[IY]=X5$D@3=Y++<![Z?'MJ0J& SUH0LF!X2>8@BX^R\I=,S_:'';7G*\N8I
M)ZM<(;9TE%M7^UJ\TL":EYVN(K#F-YJ\:[4.S5]BCG25B]6OH*=0&HB7(MQT
M:#@Z_ZS)/7V3UBXU*W9I*;HLWS!VA B<1I42&6[IX7"RT K1LJ$0L[;"5\_9
ML6B]\<;W?3Q;GQ#Q'1^F4SL-&-F?(Z/Q:!)AKZ@605Z%JR;1^(>Q3_7TOB;"
M^5E1<:E;58LR2>\":6;FER8*?G)@:#6DPI7G-<D[K,AMV+.V >MRN.X<P T2
M8E--FI FL0=P#D;_59?JN[,96-Q&C)*6W.&FVQ,1XMK*IO!VE'V$TMRS&>.4
M)7KNBIY8_4KU/I/*/D;Z1)T5;>$1MF,7L/!C<O7>>%(X]W@CI"EUC*#B+P8!
M,_.&'C<=.2DD,Z@0%?W+Q3+F)TK$N&/$B82%KNDP!GXMJIL_!$]"HFHA@I1)
M1#R_3>_HGV]%^1L:)87][8DBPXNXR^S.L%LH<G?P2S\C3'RXTQ)KNKYN%07(
M"F\;474B1DB/)[.DE=^N7V5R&,5C.&N:GBBY;?SHVCOH,0B."N"F R71')W;
MGD#EWH /B/<F WE,D0040;NS,+E:>[@-]5VC-0B?[(@'5;OFW<KX2SFHH';%
M;C+A]1<W?YEVGFUW-ME'7^B.2U[&VTK>9?[E+8]TRODZ _M;D#N<'GE$'=I[
M*[VVJ=51^RJGP_M.-YFEM\PJ3)2'>- $I\P74]\B$BN28.\YS>IQ:\,X/#H]
M::1LI0)7<7._#L?490U+M>">/W?I&ZU\(<ZDD*$/MQS^.E=-;LA*A/&!.86U
M<$KQX\6IMD=-[V(M-8L%3Y;)&%+W=H>H=&HY3I4985C3.- 3RWD\IYI8*TG%
MT]4KBLYC/,$.#6\ZBB7ZP/1OHSK]76Z9'VI^8@BM:2!Z4@"!A5NYW*=<XDWB
M*P_(*11=YPJ(T!5<+5MFMR7,:&3,7";?YF!;-/UAF0'S@_I#;@9Z=]OC&O@_
MN/[0TD.:!,6(J$:)R#&RN*EIG3I&-21<QV9P]'TI@&VV7,'=18L=U]L'ZP_+
MLS/.>IR9I<O))#-%B:9?\?S%O"/6^6#SH9O"S"0;S-]/H^UBG>9'&I4\>"#^
M%\)%>MGO4L#)<DVO* !^AJ5T97B_YP):.V/])KHP2^WF6F:L> E3GMA#7;^[
M+3&?G+@A2]EJ0L5#<2KOL4MOWLGPW$/+SOW$7S[A"U46&V+5=/SR\RL.C;Y\
M]8S_X]F+E\\J"76HZ0+F#LI_1-:H_3DJ +BL[%AFQ+Z8B#$]CLNS;B^BLY5!
M#&#2*PD#[&H[JBVMZT,2G+J4]T]-_^\^NI3W+^7]2WG_O3:-V4CJ29-V/?/B
M26-6'#%XYI!S6W'^.*_44B&^#W*1P(CN-K4C%_GH.]7?YC^&_2SZK:_[KMZ4
M!E23*M;\R&EZSE/D$'5FE0M::+@R<+P_B3,5WKNPQ ;!41NDU9F+R,O&=J=8
M+_V#9Y4(+P6V_LO7+]" %78 XI(&,Q 3"BX3@DK&ED(^6+BMM.U2N_3%=3#E
M!AQGEJFAO+C3O=4^E'[S.H0#[NP$6^)4OJ (2AK39(3EHEFU1-F?O<.2O9Z.
M2DHD*7H"+!?7BYUC;0>2]9YI;?]SBE/Y<44\9K_CHY+!!;0.?&HPTVQN\74^
MN^,0YQ/ G_Y^SMAU^M1=3M<X&/^/V2\HT<>+P!FT*+A (C?$[4'1"B&QJ49,
M)2;K,02COJ0HN3^DKQ,,VL,)-XXM)/YQRDF,R^ZX-"=U8H5>&B1%RC8F([?9
M:#\9YXE58S%U!H$=I4@I%BTMEFAXQ9>*%I,6<B[#K,X8DPJ7OICZU_&?ZK[H
M2>F[,8@K+1D%5U2M5NM=W4A-EK?EK'\$<.V"#*^0NLSIHJEABYXL<&?^8*F/
M=<*'YK>(H7PS9%@KAP0%^;?:#GY3:>&S>>\?8LPF24,&\VSH""IG9S@.8]@/
MU<HHJ%,RV I[N=83)5=NV.N5$A*FWY 9CN)/B452&X[EOBGA054/I:6^#[W'
MPTLJ"\,95N]*'3'^!#7<!Q#V(&Z9;9<9EAN7*6NTV4&TUFCDA$:\9*X0 W#B
M2H_+M_9R6&TU-'\G;1?ZP=_BZ$MDFL8_#;K)LU.,"M'V/?'3D!5R%5[!/?]3
M<'@\EA U4QZV\YK .^;8X%'D<+M3$F Z?$T96!I:=HF1_M"')YIM)$:F.VJX
M[7I?71@#NT,=';PQPMLP$8.<T4]77VF92F_'7*#.N#UT-S*8H6:22X:%F*OR
M6Y($WCH]>[VI ZQ]'?=RQ\IA!%-PRB\F2WIMNRG@T6/@>KO:]-.-%23%!QL:
M@OG7+5'1HVXR""IJ##=05#"LZ7X:F60KCO]NHFPU TKI9)EX"W+M<JD?PV]S
MZA3B)^GEG$+JVW==%*J_ G2#,2,I8TH MX,B_]F:%$Q-C;4/9:;\;3-K[47E
M .*)V=^@!<J?"[Z-,T;,$+!DX:ECCXDA&!F&QLCX/2["2LX>QR;2IU1\),4_
M X+-V(RL .( 9D[BP!YGQ2J)\ICE8W3]XD"FC9;C]MXVG0JDY-T76/+:VGI^
MS%P,MYI<C_[%, AP*"VR-#-Y +*H.[4 R\(OBZZA!4!FAIA26;XNFQ>"'S4M
M70@]@%WI(F./.-YY?4.M4B(2")L,HZGF9#EUF:^,G#.BX#KBF*Q.N@-\190/
MSN24R"43=!%2? U8X(:4+UH63B>M#RDN<T1F!M;AU7>[ *\Q.MF0;50'-[G&
M#&>?&>>,[%U_C'7&5WAPDVAD OGL>-;3:7'H&U#"I4NXAWBO[50E:+!(4$;?
M0\<%P*^Q&0E_R&-4E29NWVT(@>R9])/;3W4VI[($Q9LXQ.BJ<TGC/$'!3E2&
MPH0B6EJC!18Y+MGXELUV:WH-N_K^2/.)<=LV.YBYFE E["-2<6&B)M^:1'7
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MA!]W3TFQU%U$NQ$A?BM@@^O0AFTSE@6%07L(3O1"C\>#I.$4QDE$#B1L!VO
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M:D;Z/RQXH462MS^@851\"..PBGFBJ#HE86N'3'4R_G$]$X^6'.BQF*O,D2W
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M5-[67F^GLX-2G*CK'<] JY)/G*EBC@*LFQA<^+&AGW=&KFOJAA.ZVG=0#Z]
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M&!S"Q71AT /',%?S?<Z&CPH\N; VE-5U9)+S* >O<B/!J,&DB^BV0F_&PQG
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M]CTZ%W 9.D6\=0D^$YV.))I)<7W-MD5$O9W)B7\3NHYPN4H7- ]<GM6<(3P
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M_(TZ7R0\C.7"$7]2^Y* R=AGC^U:*11MRA TK_SJ"^'"51LQP'16U>1G9LV
M.446AYXP_XD( >&SN,>N<2J%(XO\ JL-R>&E1Z*>D-3&5N;!''/>&R,3\UE\
MPY-]/MOYX_/L\=EO.'^O78@BK?):F^=GSDP$CN[ 0+T?MXM+<4]FU+(F=4EA
M[*8!W)82HEHV!@QW5WEV+6+3\6X8\!!5KX7A%H.(V&&6YZ2)1E1DOMUCMDL
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M3I53EI.B+;)OFB;*/N32"=-FK&VDTBK&JRO$6!'BUH%->[:@X6<M>$D7NM8
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M33:GU2*=Q]/?;\7^#G'=PSG[*YVS0E3CJ'<[E@39YF5-Z0J8"BHWY^5E=JF
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M4J%2NUFV,DI##8B[?7O*6R2$1@M1A=37Z7+FQ;%+]TY&%+C Y0N'?08IY#!
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M@<T,CRSS3]@-SD;]U_\Y^^S);SWP=RF=J)>)_26]B\M5=@F!) Z>(002J0%
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MT?EKTSV3J_H^S'P*T!Y+V3-#5V47/7ZPCRFW.H60D_BK^N9!J4_JQ(NTJ#D
M[NA?H6F4BZ4\THQW SWXM O[(&OF)8:8\YI=@LT,[*"4B57'E0VPFZ-Q-P.4
MCF:,5I>V"\UR6GO<$I]KDI*9E3O [X1\D5Z9?S!<:[2O6HZ*_-+2!G6>]S,0
MQK?)0WJIK$] @[44F.)"^YL]>D^>:))W5PA.9+U)IO'X'F^5DQ]2ZX!<HMI
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M=U928'3!)>OSO.F7GB=B[TR^\1*/"?^4?,EU<D:;T46V7.3PU;?P=Q*+"A2
MW^SN=\E/_V5^K@]+795&,D911%Q7R+ T/4"4"PH]+I4)TDG&M:A&@(>4@J&)
M,H *G%.))QA7*\D72ZHY!E!DCEB7G#_OXN<*,3)O]<N(F:(.2G*L2_9SR4$O
MVG<:P>?@PY%:HMP519PA]3*_E7]S?(RBK7M*%<MI9AR:J@9'*T%DGIR]?IJ:
MN A7(P].-MEFLJ4()?$7#@]33TAJ;P^%Y)X]^$PR-FUVD7-\#.H8OA-7H98
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M^\FIRW::S/+(@/ 2;2.FGTJ*.R%!H5&AEYT3@+/U/-'R- BENKUD 3J&8:N
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MD,_?!3?Z^U_D]VU3D&F]SE'\DN6@,?GCC=/A2SW9)\:O=Z "6U/D5U' ]_W
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M-GM\"S"X(5 %&DZZ37C_B' >1(M4HR\3[1ZF$J/=<$=Q&^>GCTT[\_O]Y#0
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M9K0AZSDY/B(V'#LX@A@2@;2R% U7.)%3QG-,%S7+C<' Y7+124[;#QVO0K\
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M%"RP8D@G+3E^)M[9T870-VE;WC^LJ6V9O@$DBZ?3?H732T$*DK$!EPN,350
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ME3MIP1!GR/!U+G(330]9S-FL8>*9S:DMQ;-Q_6$N.^ZAZZ:^+.CU<!J#HRJ
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MNUTXY9K_G6K78;_&4<VE>60W..??DJK[P1$16OZ^7)]R3\]@"O99FE]O)X#
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M5I&B7J/Z,8W/>D9+?^R>"#ZC^"<X"\[5R:2-S$&JCZ\Y[0M]1*QF<_B&!4Y
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M SH#HVB(@\1(C?<S@W: T=,)M9&\"D/:0QLQD]%2(:F)(=+HT$7$P85^+%]
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M'6NPKS1"NI.4D<4U)3R%'R%50HRGJ]'3A!N$.6]$QCEGC?%&E<2N+F(RWPU
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M7"^E'T&9#TMKIB?*$5H=%@T;;:^(,*,DXW*:9[EYF;9V> 6H3BDJ$U7L:/C
MPJ-PYB^9\:#2A=X48-DU8D##"31-RE)PR1A/X[8CM_8<\9!ZB8%[$#=EFOIY
M0,WJZ08)4/"X/S=7CHPTSP1&ZK&#JZQ^HE??(!Q?OJ+F6F\TS!&!4$1+:K:0
M[((2V_JYUKO 9")2%5Q.P&>#(%/(XH2 [VI2$%K]=Q?<10 1%__5[!*KQZ1I
MGG#UD$,"SJ0/Z#*<2\+]A.\(-24AEJQZM*VYM)AEOOG<U&D2DVM;J]K2'R;-
MC,@9-5I,EPLX"/%""7PL<BBVS02\48="R47J3:1#VB802HZ3' A6STWM/]YB
MZ.;45'))#S:KE5__P2 E>+)T"B;*^_[?-,B"B43(=L+_U(P?\$!LQ';!A9OO
M__>"W@\_$\EZ'8$5AQW;AI,\C<B?"E[74J=_K7B4Q*?*0-6%H(&9_"<F5I7F
M<O-B_K/..!6K:2X?BT9<J_\N$19;;,3C][B4W# O9CE1H4Q4%/]9H^,@_0,=
MW@<<P/]2&9#]%^L(U]K(A\-ZAO4Q4K;#I?=XU:!8^>V)3PC2@#E!]CSPS0I[
M.U1<RL)<]Z7$/>%>)G2S[E;!EL[!/C*H'NPS,*" 9Q>)Y!KXR#OC8+"UGFN.
M!5$:]E-RSZ*]25X3)U =)WD31S2GUJ@\(CIT-.\K^FX9O(7_/<_&"H_DV[<7
MICLU;#(5';E?"(.+<V$JAMGB<?YQO[>/Y'A@E5!=#EED637Y+M-J15E1:Y ,
M"3,8LH(BOQM([U=3,.@6:B>.+RKVDHFRO7;I[QKU@]SHDO0T>MQ*+X$%;%/C
M-8T09Q:X4N#9*WKMT)W'P!JIA\$2+T4&$MK^3H8%L0,Y77V^Z>,]V^H?&0L_
MH+0IFALR>$J5CO;@]!?\JM":/:&YX6E:!8R*V!)@C"U$R_ZTXN#T+!C5:<IE
M$6:%>J!@F+2R;:C.0I*_)-8!S!JN25!7R.PG'94TR5;!F2"R$^BVQU.&+( "
M0;X&X9-<:@27*3%U[31Y[_:>+B3:P-2WV%?&%//HM-L,=MMX:I(4UO6MD+M&
MS1F:0S6I,%8O28V&+L;;Q5P=%K68Z>#),B7E?));.4,('I'PP!\37"U8/-3R
M+]Y<?KCH!0>G?[M=<%M^YS$>2>U928K#I4\2H]H^B7N3WB250)<:35!-FA4;
MQ1 SGRY3YA2#])BAE*<!Y&M"2CS<3A%JZ'0<1-I*;GX&.JXT>>U)#?M/R,*:
M6.IHI7;B D,V-5(7-2/AZ&K>@>.VND&P[KMA9JT-$KJ/7.))77 >TR<$CZ5J
MN=BEM&$OJ_+O3K?,3?+LZ8("22A:UTEF21(+\'.Q #GD?P94_XA.WFQ1X'SD
M^L&/2H4UW;H 6433*4<VG:-MUU!3R]@ZX_8KDTW"Q8I%,F$U^T([1)Q(0,/V
MX,!+I@2W=.-0!:VZ0Q'DA ,)FU!1&7[;0,TK^<:DXDHT]J.R5!JHJ*LF.1P?
M$XD2:8/,W2K3<M PR\I+G$I=:@ ]<]LT;E['O;WG18==G#4MU!B6B\CTA,_*
MT!XCHY_L+"E:9-R4,J(T-L@OG )Q*J?Y.*><D---YT4T*< T"4V[F(LHBV+X
MX&("QX,I %_]%@;_P*C(OZA9QAMX9T3_#ZPHHO5[4Q81DHK^,YIA3=6_ZGF4
M@#Y_%V%8%K_ /6C"X/]&552$P<>Z++FO.0AF< X;2_\%,XG Q5&A-*KY5TXX
M]$^3*$E)4BD5=/XJM#U_; .@JUY !6-DZJ$J(#K+.9$&I-*$DQ?275R]1GPZ
M;4LU\TQ[="E<PFQ=:*+STS2Y*1OJI;=QS<<@9P.(7/!'721EG R%4@.[TBH"
M!V-ILKDEJ3Q8<Z_#O2@]1C@L_V>-_7-GU$0G&:)_K>91:LH/]*PZ]-!*]-!9
MAQ[JT$,=>FBC0^/8%I[R2]QFEDX]-L*'L':VQJ)939@-COJ)]$(ZZ#/QJ(3@
M2&N;5UCSRG?K\SF\,4/+A')_,"OLT!1-&QK9M7M:6ES&7 ,A+66Q*719$^Z8
M)"1@LERIH>+NLLZUNQ,>QY6*D-+?E'S\7XX)PYY]Y!:W.V!-M5FK)GZ6D)?Q
MAR2/B%L @ZNEK$LP2FNTN5G$B74KPPB0T,I:_EWFHD=1F8 =(S W)&#"--+(
M<-53/L[AI;7-$QHQ:.JJ]>'?;U[N]<\"Y,944[CB,9K%K; %1FQ)^!5(<4)D
M(F1HX^9Q.+_"9&:!/@2FY<?*G-3V.:X(*U@'ZASI3?@%G#!?MV2A;I7,@<&,
M'1GP:<1L(46!9S!3Z*YQ\!M$A@[9C6DIHQ]"D\,NT-@(>SA!1S(6"A7%,;Y1
M@A0FDNWSE_1:#2.,CC>Z!J(GP90WXDE@HS=IDM;HPICA-PN=)XF"%/87_P,4
MT353[IC]#-&[I/76RYT7F.D 18()0=(M G[ IN#YD)*&UPMNI",P#1D0LXXW
M)<:11A=*(50%, ""<1$D [S%3#/S_\1OQJ@M;C?8L^ DM"V,LXUZ('\:[: W
M! M011AQH F8I'&R(^F$7XE7B()T']6XYOC8#NA#A/@Y'1F$PLU6\3OZL##S
M1C$;FP7!4B/PS?*"$U-.X\&%XXB]/ ^#UY\NP(N\O+H(75I W;V'?:J1BKDJ
MLN3Z8LQ%IIZS).- "ACGO3J=GT9SFL9#8L$>E(_!;A,#-8?)C/Q(\N64#HDQ
MJ+01;85WUU@616R/(0K"D"F_P@!!7"G]"XD9^$\Y-?4(2:^ R@QUO2C\)1HI
M^O^31!Y=$J>E5R&61AC^PP=$,248^$T&21;:'B4<:$945UY&2W03E+S1A5V:
M84RL,S3TW15A%2<W%I(#<0R*H^]#+=P$F# 2FQ>F2UB;Y!F$2V':YEK;UYP&
MIMW&VTU?%%4>&D5=JN0_=<%]._^HLZ'<E_96P/(Y*8P?%FA)1%3P/TQNX!J8
MPCU1X:4.JCU*<4RA[BG,WC_/6@J(-&Z/E[W4<7B-[K =?$8)$JE16Z@\$X-<
MB@I9WX\<U;$+H;;?"'_ FW]QCJ'><JJ(4]1IL0,S+J6-06&IA)X+)02R[' *
M'C-FU!694&,SV**,U\Q\8NNU458M"(QS&L@N[,"@A&8"63&P(HTRK+!TH=S?
M-H>B ZB8>B4.=]3DR'A/A,0AGP[NY.5$305)5N;13!>K1Z69#QP).@YL?IEK
MP,@7JG T9R-) C'>6X8-U@3'Q_2!)]M(EM8!IDM["^?&X==19&NJ5\_N#OR+
MT2"OHZ2P(&!:L[?Z5>?#ROGF99[ W@67U+J7IF!_!M_D+]GX7O,NPD_X/M*W
MC*M;>L&%D1=MR3J3 0]X3YIZ$"+F!A[CJAIDC[Y!/GR-(?&4I6:?%BI]LF4I
M,3F%(X06,#Y>E-)_L,OVE1NX%UO?+*E18QA$!1MYI@1/TMP4YL>&/R6SJ'+,
M:Y!H7#,)0/I. %<S@BCJ3E+O\HN/Y[V 3Q?]!T5AB9H#1IY?@R[0/"H(RR^4
M;FWG;;X[0F=%\'M&LC!#%'-C0/@VH@1P#1PR%KZ9G&02AQ,$6+/P(@96_Z:)
MW'E&9:+\8(:62RS"H'G]8+%Q&3IL=:+"-8@:'("]STK-&&[8F"5-S:N1XHY=
MSNWL0H%,KW@B=[1:"<F6!+M(XDP<>)SUDFCPQ;L/AH:&U_^:7)3F;*8.+\W2
MOF1Y@)9%P1CL?]8(\B+TQ6&/=UM_O=3"3LES#*]X5S-;E,0HBI7:GD#:N5-'
MU(5%>L![CC@+8OP[*P[>.*7)!!Q'GNHX9[)GN?Z23,;\.\%>\?1&,$;XT2*O
MJ9Q=_&E8M"L-;5EBOM)"'0GA!JVD% O+]SDKP,MH9T\^)&8HL%-/1+4R^H6-
MG8*!Q2#7S+ XBTI>5MLDCTBC\448!!"@KS,*7X<C[H8*!'2B8$ZF@M_/EAZ(
M:YRI,;GBZ)>SIX?^<8+&UP9]<[;7 ,!;BDP^%%)[#ZST=>C"DL54KAGK.E)P
M:4?)E+)VH)ETUE6;R ZOBD!Q,[ATJW+9R&7_9H4-6BUF0K&@4T&1UG68="U+
MMZV?Z1)<.)=,**J) C<$ 8Y*!L!KH#(J =LVD&=%(2#45V%SNOIBBF(8$&,_
M':V+5]3O*-Q46)I4-75M7'X]JT-769/UP*] =/H-VKUSI-]9,#Y3[E@JUV#V
M< &6+Q]J<[ITQ]0&*EM>H\^T!LD@S* 68OV*39LI'!$O8$+%L]@B.2D_6YU.
M]AEO&+MCI>',F?&!KS-OD?00N-VS+DVA2C_>W"4I>>-M,=N!%&DS5%<)1VI0
M>E,U-FH_BC%*R $M8B,J*?>)EPA^?>1(+?[!I"4S!Y7HOM4EXD(D :[]-8;[
M5PF$?@_=-73N&A*5(A!>_WI)*@1QY\UI! =4R6S <F8_S)R@DJ*'2#?;Y@9R
M- O)F!VO2AL=QN-R,!&"#W&XG=%,7."%->0><>;4\*[H-T74]Z$B)>SXB\M7
M-Z(B%<4&XV@*'C<YA/ ]L+/=X\WO,+Q2VJ.\4=:3I7(2<8[!]1C9F;'Z(-1_
MR5&?FT3N 7OV3>E72#57:$OS#^0$TABU';LDPBNDA (),P1^IN[/':[T8FET
M<.FCHM-VWCQB X(, /Q^G)3T>H25W_9^4&5LY?@^<S']*K=8VE3(R$I_4"R!
M=(M<*S$6,>>$/2"%XTM\$/P=>2$K7(_?E?>HY; =71A2AC(RAMAR: .=/@09
M(%ML!QA89RR<[7> @0XPT $&-CHT5IOKR]V[ 7(O&Q%;6D+C0X&*=D*[I SS
MPM6%UMXC!7YM0DAD%+A7#,?"XB*:A^*>X__?,Y<'_)N#T<KG01.N +X.=\'M
MP220Z[R,\F(Y+J?=G-A$K3Y=2,46_9?<4Y\($$O5PUQ$>SZLO,@8<TFVA% =
MCX&'(O!&"7!2J4<UP<3NPOIF\Z1LC5CP76E3\A:92R(#_SU)KA/N?TY&8M-Y
MJ[,1AA7QNE84)]403 OJ!X,!%B9T%D%?UF^C;!)-.?A(B'7P</+"0?VR22@5
M!B#&\/_';,?R#<INNSLFXVYQ6^AL8=C+J TG8>$QOG^3Y+Q+E4V'29+<,0I<
M5P6631J"[8 H?VQWC\&4QAU8CG!J-+%C)3FBI*L5Q*<$Q_%&@3-HG'4PVV<B
M5DY,NVR$JR1WQ1AU% /JKXI>:+N1KQNU+ W2Q+4XWF6%(V'WBB4Y\_P=7:)A
MB0_I?("71#W*;7RLY;U6 3,[=>OS;52_,%34GDZW?6>8P\4L32PG!_8[T<X4
MV]-\$[AF,,53$1NF%URT$AF]1:*+,\V!EZP+'SR>/,P XZM)JIEK<H3WXOZ:
M9 /B,4RY27NDQ461B04-BI!0:Q3XIL!PU/9C<INQS* N*EV/PS6S2TZJDQNM
ML];E:5UI;<V34HS@P4E:%TMA2%I*_&Z;#,R5UA;X=U5*-,!<H53PMFIR_K=H
MHC0H>2AJ!\30,8+&QC!Q7F@)1'(+TUKPB=,7]%+2EX*CPLCAI#?8377CY)+$
MYD2<_K%NE,%KZ4JPDW)VW4";,":U;<,_>(#KK%J* R>NC1"ZN!A!$[%O;MS+
M0LUJIAN@GN8\7(F"1 L.8+L.WHH-<41L%[2Y[D](86Y!9=D$DN':=$%[)N&R
M(E73DE.20$-C"]V#;C0[Q=>PTPJBKQKG2K91DVX52R/ I(_.^4C2BP50>^,L
M:Q20TM5P=@PFMJ$0-%:B9@#EALK,_"6*I\C=2^FK&_T,+%G2B &86ZF&M3QZ
M:OK(X>6U$DD@V 1"+CJ1DUBE=*9M-C/GOJ:%IB\9U53@Z_6A:97A5AW0B"B2
MK5/6NY-F6!%]P06R$1@3H;8DS!S%OM:ZA=$&'-.5ZWJ*7 J-1*^OY9TH(XHN
M!L8(E<(F:)-%Q5Y&CG;T8F>N0@UMDCB%4TM6IA8RZ_,U,Y9Z,AQ.Q\4QL5D2
M RVIF@P7#Z!X=/#T<H3NF9)+HR5KW$B:NYFU)KVUZU>  5&0'\,-(;V.&OI^
MP"Q9F4]5L"(C*-=IC#7>\>HH.SZ1;7==?RA ![@/N,_@E.J@*F=YFG*RC!9U
M.N"X$?CAL"XX J_WB,5HZ+EIY<1ZT-KWXWZ&13WV\X4ZZ912M[F%IM0"*Y=X
M@D!ZB)*\8KXPSG-17M%Z8D@QM -G^_?V>RER<,$^K,3#-K8%=P4GQ%EJ=O[0
M;!2-24!+#6"7R,0;XAE2;'RY?@+V.N5>F2"+6&#G7G'+KO+2($RJD_''VKGA
M_*C6UXPFEB05A\TL#9QRWTF!A*1@-B7"<+ZS0(.R/=3-J-0*4W*F ZFE,*K8
M8J6  )P:C9C3<DQX\UFAY#O4O:+B+&1KL%\G7=EZQ==1 HXZMMY$PT48@+$1
M>84I0XX0ANU%NJ%U!.G;"K]0(/LX5S%'&O"A"PP-H11?Y.+2:'!*99U/4 -Y
MX9!K>8.J\#V-9UELB[C_V.KGBZAP^':68Y&!N:)T[$-.*R$'R'73WA@..L/S
MH U6,!R*&XZ3O,EXBX>PBX6QW9SC<=N1L+ES67D=&7)68*;R6:I,D0+N3(_!
MQSHL(PRI=SES#<YC3]0HF[<RG,+>B%?&Q%K;J1<*K21&YK"X.<C;CT ^P@K0
M.A/K57HF\5WCBKDI$":1IQ1V6;$')AXSUK NV ;C?PK)G/M5VQJ4*R#@0DX3
M8JK@?= 1L=U5X#[ZG2IR+J^< "AC!R_TZ9/61<$5)\PI$HAWYY0QD?R(];]Y
MPZUT2![.AR03@_W]4ZV34) 9-2'X,$84^))R#>M'VVR=44]#.(V#VEP:)])N
MD,H\.)3+,%@*NQO\'=MQM$23B!%*-E1 R\D& P]<Q]ZQQP+]?^0,X8. QO$(
M YPY(P,H3WV- *G8<T?\R5@;SG <NOP1A,H@3J,_:A%X/#J87;>>#YF.C@F=
M>2!SWGB3XTZ*83TMB;D1@: X;^_$<@2=Y^Q'!REPN+0CN;B2.C)%3]1OJQ8S
M5?+X"3ND+VNC(C?85Q_ JNG+G$PSCER:?WL0D)9A:R5$:>P5+C=_QU]+7'L;
M8;$;T J\)WV_6M%T:>E^EY;NTM*/(RV]Q05_;RDX?HG18X5CW+'B9YTR$J^&
M:U@)WRG%038E&6+&)Y3@*IQ_5./&ROZ<Y?-4Q5C]-2=:H]9'8"(-KV&JC1&T
MFSL8X04?Z9!IZL0VXN"NU4L>)X!DU) <+ =G*_.2K)@Q2KCA@E3C)AEG6.J"
MJ;^M!_A-JU<?@/Y_!;WW]R$;O-/;_94Z[0UH&3XX_(FPO5=549.)M M!H=]F
MICQ_Z@7X7NC(S84E'PN#W[$S;C:," XQC"BV2(NCSZDNU_IMMG>AR[5*O6!"
MT"M>BA"'DTNHI##@PW4T3L@.HR.#[LY$I>25.*]^>VD(^X51-@8C;DA%3642
M)WA@X&'.+V;IL"</_T>>QL,<"T$BY"U$S$8^SP@YO?K'(5-YG YZQW\S"0#;
M_R= YG5*K7FC[ 7D:]@>0$(LC$QC&O)IWIJPX=Q\;V0@S#$S(A<J'WU5/!(D
M3<:A+4PL^=]#"M!H5JJ?]3]^D5X%/R<4/-FC'_TBSQ>SM(6"DU[('UOSJK?/
M)E95P/_&^LWR<8\^^JF*ES\[.N@='AZM_'B_UU_YV;K'#HY[!X/#;_[8_G'O
M[&#U3]W'_D0KP:L!"XZ;^3\_'/Q@K5G20S\/9E^"OK^+J)J6:$]IN1]$8:^S
M7B\$#_0>%(416%F9'9XTQZK@U+[)- ^V2\FPZPN C*#H7O-=\F&N=>0;4?3>
M0MQR#K##P+A &-F>3&P(5B\X0-NY5.UW[ ND!+U247#N9,%A=?Z=J"J+IH$^
M)F^Y_/X.@K(3RR+3?RK3)=OAZV1_1/_SJ&;M>CZO:LPUA<%5[VWO7KO^".?_
M(BJ&*@6_X:E,^!N(^2,\W*Z8OWU[\51T&C/)O%1I- =7[:G,NM/DO_WKJXR5
M1SC[5]D8&4D"ZL" 3KK3OF7'I_XT-3H'B\[+)+J,AD_--#<$ZD]EPD]3I;.,
M&_?T'YHV[[X6S"-<@HMH@91F;TKBFWHJLSX\>[HJG0H^AZJF896=M;[KLW[*
MJOW7-+^.4JW8RZ=FM#]-Y?Z4[76=W-62'CP5+?=/1)PLGLIL$=/U1%6Z2/C@
MZR3\$4[_*R3\$<[VJ2MQ,E>>:&+T&Y@MCW#63]E.?Z\0%$K;';SH_?O)9$<1
M'>?,_:E,^RDK=T1](" ,B\BPBNC5%_I_2,Z%",EWG_[]5-7^$\/#?(,8Y",\
M^@Z\5Z[Y+MB^X[/^>F?U$9YN1\Y?8\5V%Y#9Z=D^3>/=$7+=/CRX>OF^%[SX
MQ\LG8\/KF3^5^3Y-X]T1]4NI>PK>7CX5]=9%9)ZD4K^",4<S)"V[K%0O>%O%
M3T:KFZD_E0D_>;7^V[^"#Y;@_HG%7KX5O/<13GV%X/]$Y;Z[1B[P<NO(!2X-
M_]XE2*!P[+WZL^;VQ+M ,>!7M!M^#DL\.+,35V;BIO2?2_NELX*FO?=Y I#2
MKHUNJEE+[__JKB-)L/%0.2R2:^0(N<YOVIA^D_A_?KB=&>>@_\-VMD1I/RUO
M/KUZ%QQB@]3W'U]=?7C[[U<O@ZM/YZ]?!Q<?WKU[]?[3U2[(YWMDI_TI>)]7
M#OO8_;?X\/%M\5$O^/W\[<M7[R_.KS[)L;@*/ER^^GC^Z<W[7X/S]R^#UV_>
MG[^_>'/^-OCXZM]O7OU.?[S\^.'J\M7%IZO'(0;TQ)^3"MX_O&-VTG)W8&^T
MFAO'$'-E%J4+[ /I<A%'0O!J.J7;QJ9,^U/J%A'$Z0&__DA4="[UK!"HO*G4
M-#CT-9N0Z$I^+#3ML)&#$!OEP .H,R.\($\3[MAF>\(1=9XTG"6BNXK[WA8*
M:4ZI54N2>:\_)<9_^;DSD)Y^\VONA8&]".V42L/M"F.5QS6'+'^>*_,7>)+\
M$::B_UBHD:)N"L^2Y\O,*#C@JO095)[)0^R7G1<X [JJA]A\(=>O>FZXP0?[
M@T%@/@XN09KR.'A&W8,'IR%_#D,R?7X/N*?PX'E Q'/2A?JNC#IUEFK^0B+H
M_>)21)KVQ#C79PDLPEI<[_HEN2P4-@Q:/6GG"W;:458C(T[?3IQ7XD3^\-RP
M?'++;681;2Y.G[X%_]@/GJEH..&=%89]%$$D#T("[^6QRE#,D&?P7X4FG[SK
M.G>LC"NUW-F@8V5L+DS'ROC=9>\;-0M\A-:#=',@%M\Y>"I[:9Y36UKG@A9.
M^Q&2L)MN)>"<E&&@8-Y(-0C_O*8.N:7I:4#]XYVVW3VA'UOY&G2R3.>CH$8N
M.&H)@P3*2?FYE'YSPN[+[;QQ9,+FG=<5MIW6+1V()SY/>P%U[6-Z>=UZEII"
M)".\SAU*<DWU74VHFW&1_\%S$/;#U2,'PP1>0!W+:#RX[L$PPA;4LEKZQ7!1
MR'LU/^.]7RI&FH*%K]E!19[*5.[>*@_ED;+7]I'&ZE.Z,8Y<<Q^1[5EFXEIS
MVFJ*B(P?[U_P3A08B]JS?2V#?"N#O#*#U(^1L8)@I*4BVCT>C;$Y+:<R-XKB
M/:)F;3G\G[BF#E@4W8(WM#'.W=$A.GE4#M&'&^P-H.:/PZ.Y8^"%.M],X<I8
M$"TJV5J..7T^!#-3VMA<Y,6L%Q*Q8L 8!MW6L1>X#ZSRL>+^T>CA)-REQKH=
MK@4J3QNST3J%8YGL46\9T"$@X0MIBYJF9+6!FJMPM$C.B,WBIMS4 9^!K=/K
M)(WMPZY!&\)*[U&SF-;'N:\SC[Y>,/LZ53M'0]VYF_PZ,/Q3"H,C7R,<W@Q-
M\K'*)#2.RFX"B[PW+O)Y-0FU_[,7%]AR/J WZ=X=U(XA4Z.DLESWX@J9Z%.)
M738,-3IW#*'1QJ"*TYQC4,-HQKTPJ!<):?6D@)TK*S7#<PV329/_4",5T+TW
M"5TT<Z&W;S.(>=N:8;0/3H<1[MQDR3W1XIYK\G?AL1P;E=,?_,(/NP)]1,U3
M#8DG<X;L0@.&Q@P-^2B,LECL28=$;'9V@[<O'(+/& W KU+WD2+/Y9Z!RPF<
M)6QKG\FWKA.8PWB!+09&1"W,;/C4"7%(9(+8R28XV&<W2_?=Q%L?CAC=]3PZ
MVY:,[G:\;-G+BA,BGYOHCA]..S1J4$6W)CP!9S";Y%4>1],(V9-I?'BGX2J+
MUQH-,R5]%6KXD+ZI1Y#C;5OR> ?[^R[I/P=O9Y-%F0R32'JSH.Z8*U 7<,/-
MY_->CD_I#>FXT \T52IU3(E*.MO46BSCEQP?28,0MD_X)40KFVG.7K?)Z2Y(
M8H,OFY4Z.O-,0YOE-]QH3[J?\4)C"[S,;1;&FH2U#7>C*(,;$#AL%E34*JT6
M>Z-"P4;S+\W#2)?AFR8@\G_648%-_G [8AA&A4/!:?YO7GP.+K![;W#!O5E2
MD&\:N2LB!VTB@@^G[=:"\4!>RBU4ERBN\,+/4U9Q(+,/-\X?_FY#8MP$RS 4
M.]'%*P5GNXAPL]Z#'I\$YV 6@"T>&G8^/&GODC@&!?^*;OIS5&]P"N [%]@(
MXP7=LORR\ZL/5])<Z6N.U0/9>A^5,>YW0">\Y+:R.A2W(A)W$#ID^3IDIBLN
M="B/(LG4XRNI*J5\7FICN;S(P04);8@;^_5QHQG\ ??P%9,*U3-96#'8)KH;
M&!YY"EIJ98WN(MK>U,)%.R?VQ]1ELS3=A"0$B-U+QYGI%EJ@ ULK[7HM!Q*]
M]JD;/9+4'C?)-53E;E\<_.G5>?#2WC4X"BGK"+%/659*YU-I6T4&-#_(:\-]
M#9_05Y),HOOL:.M;,'2O0=,EEI[FKA>(-O9E+ZEW*36QD?WF9>:S+KM(SK^>
M_!2;07E!U89$T/Z)@\F]?-K2##JZO"XRO*\CP_"?3@=L6LM7%YCR.*_'<-""
M PDXPU]>HPT_V-]['3R[P!%Q7.4U_#IX3[T,?P[V]_M[A_#T$XY/Z^Y6[H]_
M.G>>/CB4QS\#)]M2]!J_&K1E+S@X.-@;')_L'QT\UVF?+ ]2,-]A/I0 HF9F
MN)0]RHWH-FM1ZC5$HA%A'PEN%>K$ALS^F%7$+K=J95;F^UPW@WN&O![PEO[A
M[TY^2AR26T;SO0*VM]@,?VGP>/U8[AX\[N^?G6"FO**(\>.=@0H&#QCS)CG]
MW@BD3<^L8P218OJH_.[(Y8,NE@YG!LOQQ]6YJ+L')P_WVX*36V2@8MXM>'7#
MR9HMM*\WE#:9D.2OOWI>VV-Z*VT 8OO$EA;>&(WA("+F'ZB#*>@P FMP8VLT
M%3,)PC Z SZZH:]<+]#13C',FI4U1VUTE]/0-BJO%C/$E,+C9U%"360M=DY:
M[IB^B!A2 5L#.[SD9<0]Q,&X4V M2O,J;A9;:CN:V^Z"UT==+B6P"+\I5(2)
MCH)B!]SW47J1VM"4R8-P (<;,2Y,(V$=N:%H #?6 8-L!#M#=B,ZFK;K;YGF
M\ST,,W#_3;3L*2"%#1FS<8YFK_FNE[@*_69=;E_<3(TY6F(;=IF%*C$YAD_%
MY71WM!>\L7TFT8, G2E CL3YV7"28_M9-K5C-97VOLW^[C@RN. H3.CEQW8A
M6/4F"]Y1M!/-?5Z)W_,"9OP/EFJWOQ:M0H12?_'AWV]>[O7/0AOMGV$_>MQ9
M;CLL?@HCGG"?S1TVM0W5IK Q-4)HYOC*.9RZ7N!XRA3=Q[BVR)I^*QZ-HIZA
M4PC>7[&(HT60)B,EXHOM:IU'AH$$?YLMETTPG4.ELUFZV(.3Q0%5?+XTJ+7>
MW'611_'>-9TJYPSR;P/."Z 4>;/@9, D2D?<BQ>7&27,]G/5Z0UY#H\!!=&-
M)%IM)1W2'4=W55S?_FB..4;;)H_;PJ/Z4IR8G4H'=1)]'0(.P/.I\JGNUVZ[
MMVL]HP-6&*+FGGMI#FO3"WZ?H+\WS6'B&(+$_KD8DY8N\C%'(O2TEYJU&K'
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M$!Q%,.H%YH9U1!;KHD "BDK7EX&]14^Z;;<QYEESM1/\9 4E_)/:V'=PP)E
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MKN2Q%'0DD,XOG&1O>1$I,4%,F$4FY(C(9HNYL31J5TAL=R_X)H@K2AKU^<*
MP1)_HG=N?N=S]NK++!$,'OJ$UAU]W2ZL9JBZ9<]JZ?79_>0AZ(Y0?2;AK)P<
M<OMX D3?.%6?4;9\^&[SAYY)HQK;G(8.-1F!N@95,L+G5A5A!@ 5@,%].55[
M"-4M$MT/*6N-%80KU.#_4_J+H^'I+NVXYDC6Q;A4FSNLK5!4BYE@--U20ALZ
M1*;,S\IAHC08" WKN8$I3+E? N.NS)?31&$--!/L*(_0TB+%O,>;T>AUH7CM
M0AY/YPK!V-<IPDXP5(1!K&D]=0J+S0FA8(<3@') SO@Z!!9II _<51,D"$*4
MCXN?3["70UP/_3UK00<&.0R)R5:HZ#N@_CY#1)/QW4_'.2I@14BWVHM/5-\A
MBA#AX?6W"(5J<$]6D:9*,VW"2JQ40[KI F+*X:;.\#YUX"QC+JT1\T3.C1%9
MHLL4;8%(*_UO) K5S*;PWV5['#[T0X3,48U8KS2Q^&>LIV@9]Y,VB#Q=;CT.
M[Z:JL]NUY09W_5?>U^3RF\MAR]PH?;UV")25")2C#H'2(5"V$X&R-8@3WSHW
M4<+=B<#X$8QR$I&9W!K!,$A6CE\</MD\3W^  8P1U@/A-E)*!BV<A<VY^BZA
M2!&5&-Z:8Z/6/4(+0N<6'I^I<5XA8A:N46/BRIXQI#J-AHK_R2+$13*:2L@\
M'81I%-WD!3\8!Q1ZW!2A9Y<)*X?(GP&<.@0Y0]WYU6DM1FE<0X#!;#%(5[<#
MZ7J3(3?9:V.?K,\PL_\I+69RG^'AN">GE!J9-N3#OHA*S^IR3808Q"!:> E=
MW=>,'BH,#?! Q(A)GPNW'DJD9<1C3E0#74SU.K:SV[5*\[D0T1"@K87%O57$
ML<DXEOR[M.YOC0='I<?"#?51E2"<,+IO4%2W-5 6MU"@N32[P 3L.P7]4PTL
M;'@#2ZK)#2JY:X3/6%HH/T@+9MD"!'XHWFHJ251;I?&[2M,2#F,QSH,74?8Y
M#-YK6/VY4YUJ6B?;KYL7(8K>1\U$8RH&DJ(1>>E.J#F7KK:O]T\N&=9VMVZ0
MX'*Q D]N%%1'OH_7OFUN=<VGB]]Q@U0%XS$=6W1PX>W;B[ONRAKA&O17"A?'
M\EQ]BI$Q1T/?^B0*@! 7-::94$<F[:C<.R%ZM:HM.!"ZI&TOEW6YY;]IT[H$
M5#WJM=6"?ICI#H"HD"V2]2.WIR%@6I&3]:F!LM]8AV^/PKZ\I!MX5P[VPF&A
M=D4&N<0IGDT0OEF1#Y6*33#1 9$=]TX-A,PY#+!,Y-Z\^^WUKT@C I^BKO60
M(?TUKS54"L9)NGIQSI:'_T0ZW?"_8VPWZ=3PT@&SX]2#PKVC0;Q6UP5Y,!RK
MTN7\62[AX.L%V<*L,VST%4>!6 ^,0*FR\L/!L3 Q",6Q$&#[K_Y=:0!E(Y2E
M?VR]O"PWYQLYANI,,S2X9<6\7 XY,ZN&-8I!AO+$+2\*8UZ^N7SE MMWXU0W
M<^E("^+:6QA[-04R#BE: R-[@(1<]HO+W&="1"D)&T[_8+NN9S#7U*9NFT^E
M17^COVWAMDX(E[T328*QJ\QL[==_.!$.XY.6!JH;:D^C^9K '9->@6LI#>\?
MAK I^+\KZVV6UH8>3P4D=CTPG869E1O"":.!Q%X\EGHV.05 =1[UX(64'IHI
M(8L)V50R8.,Q7*NE5;_XJQ,'UFQ@VMYTC;$!U_0DEY8940,0;;-U_"FW,0S^
M#7\@(G@P<SY+;0R_A0-!L2H<?VYIE9GV3"3")*U='AS'H',JB=SLY52(MN0U
M5ZC5<G!8W\% 7A1Y328@W00EUO9<5XFS#"M$UE/(=+=\(28'D(4?CT^=9:'V
MK[+:FC%$DRTF+4=KA<UVY[%49F7)O/)'-G 'AK 'ZEM O2IO["C6\;\NMTO[
M?L5/NW0[N*2/M@&?W\S0(033S2,_<FO$'?'<C=MW0%SC6"UEF*VX<%U0!-RM
M$AYN2^]QX9#9)%,I68V?U<*R>SLX!9\]Q\4K-&($DAUTB4^EE60;5>A2.K ]
M2";Q+$W7TL DF("7?I&U19<E@2PP4)U2*MKXAC'4$$:X0'U/C9^>'>[_[;G6
M&:YO*11N9@0OD';R2D5$P4J4/>#PAI)'M<1L/NWFC(N%A%QE:3JL-=<L(L%5
M/&.U,2MQW&<YYI'0(511D2$+@ZXJX-I-TTL3*7)T]U"9M.D(L[38L>WG4LU5
M>J/V")RAB=VEH5">+:4QCD/74("=S$<CH8>'19@CU,-"-,@@'^I^S&"$$UT"
M=D_!<IE*<!?X2PW)\"9(D5PDYY::"%K2QBK%N6(2!OL:[KJ4,27_C1*Z>WRA
M8-APUOYRV(42"<9P<TE-4U(<B7/'8B\<SA3DV1XL%]T&F 60@J_&^) W#:7=
M+LH2,>\Z(5D"9<$!K2AT,\=!Y)^-+P+NTHR4 =V.\&B"]C"#X2W"@#V_$N[:
M0V&D-!]2NP =!]*I"N7TZJD4_)#>P@D1B7 S"U=C#?"[4L_,5RSE6>;2RYFM
MT=&(_MV!"%:""(X[$$$'(MA.$,'6TEAX%I/CC$M*?U97M-2F=SVG7_<B)%K0
MC?@P3R\4"('+^6E8@\DMRZ^%NB]QBK-V@4+J?5[A:AGCB2$5NN\DW$(8L(N"
M>8&]NC/=B7VY-MJ_$\05MYQ\FA8R1)X*IK;D_*F*G?A@T^YC:T?:8_L$AV.F
M]Z7R3+[N<*!9[CB$[J4L7?[8CD2[KXK(ZL(LN^&D-A27FO/ =-_@0(.^P)&-
ML @DB=-N%[1PU9Y?703'^\?WZ^;=M>[N6G=O2^-K8EQY^-[76T?X\DA[7V_#
M+;_A6K_-AY_W?IM1!$F7?>S 77SI>(Z1)J9PT#Y,U\J1)<$.@M>N26AKRR ,
M]Q^%%+S8L<\]_PS]7V;G][(,S;?:% /Y\-X3I3 /W7/T=3'L-R)T5(F4LU2*
M02WV.'XB534<D=:I@>6R#FQ$@.%:^,G/P;/SY]26@("8EG+6)<U@PJAG+YXW
MV$_=[X3/OCS'3@D$9,#9&TI']'9M5H$(XE<D,=2?=91R%?L7#G'_V!]@$L+D
M'WA-8Q0JR8WPG\'<V -Y3$JV*OF/^ ?8BQC19B@"I2D+H?;2FIZ7?U*HW.EK
M3'^0KG_Z3PXZ4C>"=:F9GIL8SF ?/V ,!M*%H6E"95R+X&!_S_E(QXJXB2VC
M3BKL3 C+US_:YU_SEG!?&1:Y:TOM9KO%8#>/Q7.G$"8SMC4#/A4!,KGZ2&+O
MU!JGT,NE.UDTUX*:=:^:-EN6&F^99-K4HZ[!-5B'0U^>P<+4TD-[0I:?;DG"
MXOM!2P5GKVA9N1U&J4!H!>RGQP1^!:QBM0B>H<S,JB6L\0QMX(J,3#D]2L%F
M/5MS( .M_"XQN%@ZS&E(69,MVI\IX.EKU<P#4FF35SYG)<GQJ'3ITNV*Y=RA
M@[[(BUEO:=(4$/34@&"G[S!5[#))X>8&]//@(9CJ5C(FZG&[Z[H+SJ+7'*@9
MYY1<8_#Z\IPT88P :@UOA?OC15UPQU78@?]7@:=VG^MC):6C[BK@R?4=!.H[
MGAF*,&NGL7  /LY*2=#;6;H4AXB]T"54OTK>=T"<+AL2U-XMSI!_>3>ZB9M+
M2WGWC'O)+[V>*[ :_',M%\NP6#=$[[6RVN0E],.E=WB,EZO:\RW]RK?65CVS
MM>N+4]5WZZES,DB63,">'R9VUR$R5TBEMD7+J50[.I+KLQ/L@ARO((AM@Y:$
M.KFH4U:4,-$($,MT$1F1PIIRMVO:2I"-2Z6/=>(F,^NDG^GE%ELCO:SE"0ZG
M _+P/F^1H!/#O)L8$UZG\7# *L8A\[T(=OL>V>VBR9;:/8']1>%96B*/!X\X
M^C=X59E\\1.<&[S+ S3CIV]YX1VKZO%9%DG\/S_<'LXY//CA(='#<J9.6L\4
M8M-!@L3V_.B0])N:J2W&/[?/Z;VJ-,IE![3>>P>0D)3!6&6X,13/+_)ZC 2C
M<"#%W<H-"KY48[JH=#^JJ\^@N-#%TP\H/:@#^.:P)#!Z\UB=K.%$-07V-=\U
MW4>I[CD9?5:@(>[UV&]V*QT<;Q'^'G?L4J:Y.W+XH2Z:HB0RYNQR285("3$7
M"=TYNM^310GW,+7@*[CZ%%%2J,UODBA0>Q3\*(9T:5:86(![UO82=3JB2:M'
MYQ&F!NKE)]US\OGS(+<=>&%4^!(\';'-',&YN/0$W#EB3MX+99GAEMHQQBO#
M]MBZP6Y4:+I=D^A+9Q=*QQ$73?$YSN<9_W.,D1$*6XF]C:&XQ9Z&Z3B_8Y!6
MJ9E,V=#%PFMG_.+GZ&Q7A_A8B?@XZ1 ?'>+CL2(^MD7[OV&\WV^]JQX7X*^X
M"O@"6*'\M0U )3[ZS\$%0W Y6$1EWZ+Z&=8@,?[(A1-X.%_7WM!EE*T]V,)5
MC<^D95E+1S3=Q:SE,]N]$JZ,:1ZKE-"$Y-4SC,^NP?H)FRN,?ILX!/,FGI#)
MPOH/ULN9<ZC=O& (LI/3]:IIM1<"IH!_3OW7R4.<V'8*?NWMNV0B;LYN$_:X
MYCMRU8@HT..,+W?P'G5AGX6^&/QWBVU RXS@$PH6(2-RD1MHB38OT=G'Y@,+
M'=5:/1.#[)Z3EUF72B.Y#=4R@S@E2I.R6S1)9J4)0I3*3BJ4;%NRJFL<)<,:
MXY6/E+,ZQ&NF^]F&*R9:6NBNCC'=+G"A)NT0*+$Q>.PYPITTKX";/[[+4]?,
MVY6U]LDVO?]5_6B"O8"1$8\,F/"0N 0OX+'4="8W4"\= G'5J0"5;]O]7N Z
MJJ8*88T"2<H6R]XSQHV-+B(()KX&GN-%9.SZ%B7!A0&VCV'KXW? *_N4$R,D
M[&B:3(EICY@]J[67-*W-\DV=ZVI<ZV2XJ\V]4$EYX8&>1:6M@$R*>(\[%3E[
M,5?7X#PHKE]HT3%YT0@RR$7FC8 H+^5BE,:V7*NAM5U3'U+Q*-R:OK-W95ZP
M/,DE'W,)&[D+DO*&2Z 8#8DUK[=:<=Y]K'5W4SRH\?3Q44"V&M5$14,J"#TO
MDR@,7M68FP^#MQB50LY.Y"8V )IW21R#.+V*RHJ$I%K,D+H8+HX-Q"5Q)];P
MD6^3%()*M O*FL<^#8'!@(\;X5LC'";20J4LA*H54Z\9M4"##U6R18.7WH_T
M!JQX8FLTR%/JH5M=D]]UWYPK9R=#DGXJ9'>"DAOWC&SR#."WVYH_2H5DHU>D
M;OE%N22VEJY4<0,_+E>P]*_]ID]2T!RXYM39JL287:M0KPZ^=^TTOXYCZH$D
M*Z#_^<V 2=J%9([T!Q$%*9"A_<LPA4V[06.,OXJ!:L,] 1X1TCO4U.M,$&O-
M.GNG9RC^::G%J3ANI!(S"Z&S9D_[:SA@SIZF?LN>[DQJL(3SO$CC.6C'0'!T
M.ISB]RIM#,J)!%BOVS@ 3=.QM?OIN2G30,-DZ?G2;S62#!3AE(ZD.RVS3YB>
MJ[+PMMTJ%IH:B,6*L)!MY&JS:S0!OPFGWE2G+ =LX!_W>P/+=;$#.M7*_++Z
MPP 7_3$,")%9LXQ?RY\3)RWI%- 3WO?=!Z3T<N[\YC:CD/B59G*1M\O,)Z%=
M,1P<S;Z^X"F \,\4G@2OW%HS2N([R"$6*E#IF,&-ZRW=+76ORPOO9S(BYM$U
MA56M7823TE)8QF3E.I7;O)@HGLW5, 80W0UFW:C06P L>V3>8I*IGNG@"^D
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MYKBKA]_IP)MFCI(R%ZM7QX(P'7S3]'O0J2?FL&O7D8(?R9RHAR7Q9CYG+LV
M0QTK BVSTCRU2X]<RE+UHZY^9[B3MGZ24,YQI%_KX]%I-&E<=3O#*IWR4LFB
MV0B=##N55D+C,=J6C!#%M!>6/4\$&1R:"&+RCM,.4&T4L7@=!HA8@VW=:)C=
M ?+_5_CA:NU$/+D##NSE.Y#)"MC>NMNQ#DTM.6H+)&=^I6P4928K#7G=_CV"
M8A9A%VU,M4@*CZPC#-/#IITH@-?%G9_)$Z@A.4AD$#E,E(8(>WH@'(<-$A*
MCM=IY(D1NI58QB]?(?$$]\6>Z#A,E_*!# =G\3J!RVG(ZBM$A-3FNIA\E)V
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MU)9\9\*;XC5S$^^6^?>=O$5W<\&'76:\P(V8$^,?C)E2"()_WPFI&.31:NW
M-T82RI^6 8XPLXX\@ L<P7 2GC-([5_@23BVN@?^<K'BY^5][+D>_$34=\'R
MU ,G(DR]_O9*;O,?G:\=X]9SJ#D. SY?K;!PTUC[3@)(7^%^ 5[8$ =S%EUL
M< -G7*U#['PSO:=%7GWZY_O7U];$ %S,V,ISC3L6,2,(#3\,%O!2>!DLZ+*.
ML0VZ+!52'*%XZED$9!/@BW:=]^N-H>14TAGYQ$T/:R4#:LOC^.K+8K7?CQ_"
M?K?05XJ364K ER?F!U)_Y_AQ:"Q8P"*LAC0B\M3G_83F4;B2Z2(QRL:9 ?*5
M<>ZB!AQ&X*SHA']WD+23)4C@Q=+P/9<ZW#N+B+$5,$#<,;YL+'Y'Q!7$<$SX
MP<-18G6'(L$6?>PE!"3A(:!?1 R(!]"6MQ#ZM=BN0UP<W?P19PJ@2)/J1W8(
MAR?J^%&5W36J!$[5'O]&[58VBJ*5_RZCO$YUP:ZG0//?KYTY+/#"\>^<^_B7
MWXJP <"HB-B$825DYO/'@0R\F2,(Z"B,B/M>$)7CKV!/3FWV8BPC-O_K+__E
MS>VY:P^ZP]%\/.T/YN[8=:WA8#:?].:]*;/<_S<"L4^B-YP;K^"%R(%_^<W)
MT/C$Q$?(-<IHZ*@;%9"A^XDUK>N5WJSN)U:_)A"*VE#7=F(UA-J^CF&Z5YCN
M%:9[A=4 9KI76+F[7?<*T[W"=*^PO?C6O<)TK[#:9BKM[17V+F]]_H5:G^M^
M87J'#[K#BTC]"Z-D:=RLX&G7T0W#FMQ&9S0Q+?O$7+P:949HHFL2T0W[9K??
MU42GB>XI YP#LSMNOJ0[)@>L@;E<=N_H'B,/@Z.:Y&2UQA2KJ/<$@UF.E?HS
MC/S9I=5]CLQA3W<ZJCF6[+[9'^O*SYICJ=<SK8$NHJXYEJS>H',>5FK@C=Y$
M7Y#N&O;S-3O-KLK17<,T#3>=AEO?-4R3<-M)6+='>QARKA]F=7NT2W67Z?9H
MVK*O+Y)T>[3:(TFW1ZLW>G1[M!;[Q71[--WCYGAOFFZ/IKE#<X=NCZ:90S.'
M;H^FVZ/I]FBZ/=H#M$>CADV%R@W>,6TTZ5C%AFG#?J?[& W3MG:#ZVYE!/)=
M#4:=87%7=E]I[';(KG;T@=K860L[N06[,2_ALPW]AG1]V]7I#9;;/NU#=UT3
M<-H"X,\0T^/1#JU85MU<7C'Y*N2G>A>&L]CX&BIYNBUOS61W[%ZO.0V$^MVA
MWFRS-GL8=>G63+HUDV[-5"LPZM9,NC73X\),MV8J=_7IUDRZ-9-NS;07W[HU
MDV[-U+ L">EH6)"C(0ZW"X+WG?8R8UK'';[>KO?!P.R>6A-=C[C4GAPV3<)M
M)V%[8G8GQ_:MT"2L2;@^I[8'YJ1OM9B$C\DD;E7\?SSI')M-^-AXK4F$O_DI
MR$>:QDYL.(HEC)IW4)VG?$P^30/YHC>^V%93CY=PU40ZZ'9V)Y2V%-TU]GJT
M(/5JV[,A$IL&2G(53VQ2$[#T?,H]0-P'(/AU$<9Y"I*<*$@_NO*>&UX ]UX2
M1OC5UHN2T' !&N&*13&MVA\IJUYY\/R,K2/F>I0?Q).,5B'(@/_P#^ 9T1CG
MF@8),LR>BED2TT_C=+W&M*AL"B)_1V<D7V'2S^ ]\*)Y1%"A3_)->P%'-[P+
M]\]7Z.6;Q)F.7I:O1=E.)>?<,R<2UU0IU#3NEIZ[K 3KW;%@M;OJXE<_'AVL
M5_>; ,W "+\M;IX_;G4F!9:]^H]Z2  MBVX9[NK6BVFL*/[H+O(2=AW.YW*-
M7HZ7%K#F9L)A":IW)P FFPL(J@#TKSA:JGB\8[P'/,#=D1 ^2]Y<HN?*9$CY
M2B 5@*HWAQL[2' ^:UJ^JY+%1>XD["K[F5Q=4F2>6*C.A85M)1M35L/ 1PIR
M0]C+?W#,JEBH?(&[)>/<ZCHQL*!SSTE<>2LRN\_P+^LT<I>X/3+B8C[)%G/M
M@-89@7>>^OX.6M0C4;MC/1)U$S)Z).JC$]_#C42M1S;Q5P;77K PC7<T3=HG
M"7HS ])&T4;BY'+2B[OCTS)2VY4$JS?[.)NUAWKRJTXOUNG%#00C3R^.=7ZQ
MSB_6^<4ZO[@!<-/YQ3J_6.<7-SO2UO+\XLSUL%!<#TZYZT&GNEU(JMO8-B?#
M8WM(-2G539-PVTEXV#7[=INS-34)MYV$;=L<]-M<]G&Q"<>]4>?$YNTZX5@G
M'+<WX7@P/CH17R<<7]+P8VR\IPFD&8Z3%J0H?WWWW\YJ_?+&8#_6+(@93U >
M]S83E(?=3O^1.B^V(1-R"XR'I"@7H+PC19FMUGYXS_+,0DSP@[=DN;#/^DJR
ML\GSDF/I]8)5O[.$_HAXR5()BRG#D[S5IBD2CG>GX,J#\H=M]>';YT82 3 =
M-2\Y;ZBXCL(YP(+W4YPS)C=@;60]PS+A?.ZYK,1A)U_/GQWGN;DBW]DKMJC<
MA9[*C&>5Y/=E/!^$I=X@[UYJ'I(]KL)XW!EO(NA(% _S%3B2#H3N(,>ND6&F
M'(E6_HI6L/5F@O,6'54G*#]<E]3-=.1MM%=AG>3P)B<>W)RT-KF#7UC,G BX
MCQJ_@MG@AVM,>KZ<A,%!3Z>UZ<T^SF;[G;%5_;5.&-0)@SIAL+9@U F#.F%0
M)PSJA,'FP$TG#.J$09TPV&R_=\L3!@O^AEF)OT'GIUQ(?LK0[$[JUC=-9UAI
M"CYB'*39&]<M$4=3L*;@(SIPF*/NL;,KFT3!EYLB.#DZTT6G".H4P=9G@/6/
MSIQM=P*8SA#<I _=LO9AZ*/I:[0E"='X0FDUKXM)B,/-F=1]G8*XRVNU <-#
M,A!5$%>DML6.#Y\R-8&O)---YIC92JX8/K"Q*1R9[/HI4K)LX*DZV.@1T!C@
MI_@+V7?Q62_OF[F95K5YZ@,ZF?8/3NL[]NS]1SB[E2=F8FZCD@I6S!J;14#*
M@3&]WYQR+;<!Y![L&^U=G1NF&T%V)[H1Y"9D="/(6C:"K$WFYGMD!@:2[ V7
M@2::=9>3MJG'R.O-ZC'R]0S'Z[1-G;:ITS8; BN=9*?3-G7:ID[;?/+ E$[;
MU&F;.FVS-F'EG;R:.1M8F;-!YPM=2KZ095J6[NRH2;BY)#PT[;%N[*@IN+D4
MW#?'/=W7L85)FZ.13MK429LZ:7.++_;,#]=)>1<Q1W[8V7WKM13;-79ZM" ]
M<M.QH<POGMYC/EO>URV,#+RA?]V;_7=@:[+=*6=\1G'$YE[@!"ZFK<$=0''4
M__ZOL6V-7L;&C$T33#K[0 6UM!LG,99P.A;!Y^)@D9.PV,3<OCOF^S2Z><9'
M.SN^ 8I#%-[!ZI1!ET:XZWD4KHP_X;>Q\1;P&,J\-M])8$ECZ?ASW$MVLKD7
M SL9]\R)#NY_5N=QJG^$<6P OM_\P/YOJ1<O*8<0COP: *XS;"XK#T1O5F?8
MU"]RHC-L=(:-SK!I"*QT/H3.L-$9-CK#1F?8M"BQ1 -"9]@\I"-*>AW8EM=A
MIGH==)3W0J*\MMFSVASEU13<=@HF/[7]4M.PIN'&TG#;I?#%YMI0:*1FB#U_
M!'IW5/?P*&Y9<X:3%GIJ<&!$UM^IB>^-_A;CN+*5B0@%WT5>PJ[#.450UQ&[
M]< ZQW OFS,>?,W"O;SYB8@#X[-'QH);$8M]Y\"9 !>?/W\V_@AA1V]#V/LM
M"P#D.A)[6?%"O5D=B:V?ATU'8G4D5D=B&P(K'3?3D5@=B=616!V);5$ 4@-"
M1V(?T@=TD,]!1P N) )P-33'=G^+8UOA_=?4VW;JU3%83<--I^$V2V =?ZV1
M6*I[_+4Y5;5O=\=(3>,.PYENN A@T9GA& O2N6EJQE@91Q&'KD?ATSLO6=**
M\UP7ET6HF9[.BUD9#6) S]7!$=#:A#ME$NB?:IB8SO8%(.C=(F'HL.=E!>?T
M9G78LW[N+!WVU&%/'?9L"*QTD$J'/7784X<]==BS1=$^#0@=]GR, M1"BKJ/
MOH=HV_>@G>\7XGRWS<%@4#,_K0X?:0K6(5!-PY=#PVV7PCH,6B/$ZC#HV<*@
M_@$Z.(5)[7QR/0VWGP'N@S#)5Y.+Y3/I2UL0ZYGTU:..NI7 T3/I]4SZQR*^
M4V;2U[F"^U."W<BOW@=NN&+/\V'U'_6P^DN+M^O-MB:3H5E.Z*=-5F@6;$Y/
M26@M2'1Z@4XOT.D%.KV@.7#3Z04ZO4"G%^CT@AH';H0?P!-^ #U'_I+C65=C
M:]3.@CY-NVVG74M/C]?DVUSRO1K;XW:*WF/6.,GPJQ\R@\ZJT\K(.=<6N;)(
M'96?=97"8-F"^;[<=\G;'QO?EEYL."O ?@*T$<1>C)7$>6MFC*-W.W8^WW=.
M(7,XA-*T&5X%^PH,FHT;N/=&$L&Q? HW4N3]F=7IJDLL6, BQ\_G[_)#_$PW
MYGHA16CN\2%8Z!+NO-4*P!EYCM\>* C2/(02-T9*JX2\.2DZ=F#-->\C+HK8
M374H=(2E[[@*'#L;' T_? 2BJTT F4>.C6_.#^/J=SCGW$NR,+*A0\B7%>C4
MF]4A9!U"KAEL= A9AY!U"%F'D&L!&1U"UB%D'4*N1>14 T*'D!_2\R(\ 0EZ
M J;2$\ V/0$ZDG$AD8R).>S:.A:G*;BQ%'S5,WN3EG8VUM3;=NJU;',R&;98
M .=>RPNK2K_JC>W.I#YRZ1PP**E(?WA#N!XV\)OYG+E8UTVJ=02&4*499)<>
MN2ED/1EV>E54W7@2/34BTV2,#L:=R<X+Z%*Q>CX?1 N2CQ0_@_0N4 K21&FZ
ML6<*O,DG%C@ NRAB\3H,$%P&VY*TF#+$Y=*O9B$=A&=XR'T(=P?E+/4Z_;)M
ME/7W.&H;R$R_8MH4,UQR!6-F2<E/BP/N\YR4I/#@.L)4"8"@$P7PSMA4OKMU
M_%1D4/E^>.<$+C,IF6ICND.8PD&<>W?)W.]PNC#!K>!DMBA<1,Z*.J.4Y+AX
ML[_^LK_OP[#_RWXJ/9-/\F,87+^[N?ELO/4"@([G^,8'YL0IX+ %&53O >\@
M/@B50.F(93A8ZB<<Z6O&NWG$1!(K<6[\"KX!"EDAO1@SEK!H!6M3II3C H7/
MZ NB^']TOG8,A"#UV)DRWV-(PDLG,5R0]3AM)) PGF<PSMX%3&BD,9NG/O&
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M%<"]0UDHY??_J)LKS]SON2<W1B1'VCEL@V*&*;_QBQ7B:@9P3L>H;HPZDXQ
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MUBE<^!&3SJV-,?$98*I[2IE"=[G=7%1=<KBQY'8+K#;T.#V2!'N'BSO9[4M
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MK^EZS5LLPJY_=WPJLOVZQ"O^M1>[((2Q8<(Y!50N?V+097 T=&P<VN$A5R8
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M[,!P9)J*<&*FTC>B% =)R% 83W'%E+N&../*#8!4Y[[!+/8(+\28 PH1X/F
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M"_.]<$,<K[\4C/V\20&C<.W61M04:/D0STKJ&&V0T1A \S!1B'P4E,6\ 0(
M<P8\H1O'!6W\WX!;('1*?)1*Q@[EB/(-95HCFB@HU#*WW!Q>"RJ+GS*.WPW(
MH[\/28L>I+BY$T7W9-JL^%3X7+V1NS:Y%*9<23'Y5O4]JGL+J*.&P_MQ9&H?
MGA"34_@1R:E#:9<[!/4QASSZB!4;PB<IX"8VSM5'#RD,"$Y!8H;;5F@9KQ5L
M'D)!/,N06[LI]V<=E/W*/97%U?.LQTR@\*0C01*SS.X&>VWJ!8YJV4L#$3-F
M96HY*"7),IPI50C"U"/#V*'T*7ZI+E(/'4P!:DQ3GVQ:GE"RM0)W>&8K@,6;
MGR$_K:@"(,7 X=XA]@/]AQXKY%_*'.YYBD61!FH'XD;/"Q0\EA6D8'S1N?6X
M[-]3<T+">HIZT0QUMYE:E@'*-@*;QT*Y:,YJTE;P,]@+?3JC^HE_9(?? 613
M1681:SQZFZ7'DIDI]CZ3)\_+ 7 ?=)4524%>+9G0Y-G6Z-!@+AF94?@O[N3R
MPV#!^R;D1I-L_R/S[T@-0_4S0E+'*H>R^GR*'X<1F87B!YQPB^X([M,1EM2,
M2PHU*9PG/V6U)](54G9R\EBLUT""A*@B#%14[*%8TD"SC'X%-=-[P46"D%<8
M&Z<D*WA[9MUF<(/5(G3\A%-T?B.^,!I!M94\<4I]N:@EWK[CJUW;.N!M373
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M)1MNB0X?*;>RYQ@$A(/Z/J-:>(K,P<[6Y'7@#9 S+U[!^X&?Y&M2+M!LLT<
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M\(#DA0HBM,[C13)2@)94<"_])AMES?.20%'%26C@5?'7RF20?(-;MA]6?7
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M*70Z[&Z,GG? UO\A?::RPR'^M*OB+>^=P_OA"C.S;#>F+'?;;%NN;M 3?CF
M-L[,C-'01?*Z95& L%;Z.M/25T)5__KI[1>A1CR_YI/:BGN8._B2O-8LM[ +
MO_)#7@)E=P:#7U\BQD3V5[9[)H< \IE%Z"_-&T"BUZ;D.+B[TET!93!J5R5F
MH);ORG76N*=!QQ[\BNE163(@'XFT%+.[*(-?-O!,19-,#FI3^']*',5Y&U(O
M;WT(=->7$ZU8A2#B#F-TLHK\,Q\3QV;.?=9LBK"H\[G.:!GU!S*?JWMVTTB@
M5T5]G$1IP6]0#ZM)VB/G!%=F"\UH+ER6EETF674GL!TI399.:=(I33JEZ2>-
MQ+?"$'XC#>&WBN7< N7]SWR,B5**&V2='$5;!/248?-*?P9,S,S<7DMDX\S"
MU';^S+W:(\TN*=HW3VJ>=B?&W])$TAF_" S>+%F93)JWY:00"E9L\;FZHOZ#
MFV<Q+$"*(8\Y2;='?FA3.&&4 95R/N2F#V7CX?O<><+K,YR%XP6BT*FP]PK3
MF^<L,5%\@6F_R_LUMCC@8ZNLKCK69-_+-X:<4"W%9J%KR50('O0IJ7_M&#C,
M%!8PL][RE#-1M,ZPQ>QLL366=],;L;5Y!#&'RQ9:E=P"#(&92IM]WL^$VR>B
MSSF9Y[(_+[G1 @H*TEAJ0"-7"3"19]LGEN^&>Q_:X?,2+KQVB*X9CU3G):!8
M:)85O:,O:6.:C^2F8,-36CH0I8KVJ84ZK/C26,K&!KS]8$9_8EJ=PL"9AV#A
MAU.LWG/<*,R&'K'@UHO"@#LY2CJPH)-WC8UQT./=,=[)81 Y\Q%#R\),#^=X
M454DQFWSV0XX&&:!U8DTK2HV<Q<:_P#A$E,H?6-J'W:<YGX0*F[,6^PP,9;'
M%=UZ\SD]V%::IR+1,'/YII\:3%<;-OJ&<Q)5$[X-?KQ/23::C+(8*,0"LISY
M,>.CIS=':REMG)P[_!/UQK@'C0+ @ZF&:MMQ$RPZV"-^CF/'/9%:AK-+;K,&
M/\@AE&S'<S.VW=$\O86<::(!^;U224JL4,GN6(!,DQV-O&LW9P(JH"ZDJYNP
MZK]3;T8=/Z*LH3>P'ZQ$O"-GGO";-9_KF ,N%RIJ7(\7O"+,Y$@##,V(GC#H
M5$/5HM#O9$/ZA*4W]<E!P(E5WR#@^V]O/AC#CO'Z_9<WK[Y]^O+5-+Z^^?C^
MTQ?CP\W'FW=O/KSY^,VX^?C:>//A\Q^?_O?-FZ^',^(:NT %BVN?S3G;%?CP
M^DD8L?S4-YVG,=[*WEX$R[AC$QA>TXQRV=7H*PL\($*E)V(+I!\U[<F:^,E6
M:EPLR91 9T5)<PN1.*VT#N"15]E";E8 EYB"1YP-ER,UD,C4 1J>(W/2N%Q]
M<2@T 5)BG])]A5.7KLDWMH[9"_F'ER"2UKYS_\(+Z-STT$NQF/!YH7^&QNV"
M:2$01(CA7^>NFTZ7NV^2"/Z=R3>+KSOTU6_);/N[7K\#0JCRZV['.O&[_HFK
M[MKLI-,=G+J?I][KP.I,>H=MZ#="&D<<T 82V5]_Z?V2._6(\U_8ZQ^&5>15
M% :;Y,$IXTPB\B.P8L8FXMP[CM3% _URT$]+3L^=I+4Z_\WBHH__64C> @SV
MD/=VBT/79: @OA1BDZ3J&C1$+&HP\ PO:\811QHI;[)[YY.X=W[+[O$#B*<2
M7D=0U4_ _&=6/\,.CR8^T5^S9B2V4T7ZX+E+YAN_PSFP1.DD&MHX]DD8V@^Z
MLXJL<N -K!K#JW:D]FKIL;FQ)<%(GWZ%7?:-]^_?&U*</<@UT"3P_(]'9M@T
M\<XMR)O%A/U^C>%5.RKC3"A*%P4'_ARK-5 2?5YZOK=>,^.= Z)H P#UDN(U
M9+C!L,;PJAVM<8;+$\4*MQY]]RF+O#P(/]93*!UIYWP,@^LWJ[4?WC-FU,;"
MJ?4:ER"XWS*0VT 0:1(Y-19"=13:XQK#JW9TILV1O[V*L(>U$X3&US#]SVG<
M=KDVR:3&\*H?J0EN>R!F:Z"\^>I$SA*=<'=!C<5T#1EMV*TQO&I'9H+1+O=2
M^WOJ>RQ)F/$_GOL=5JNQE*XAL^E;3=]JQT#@#R^8Q<Z]\=E)$B\.]=5VG,6F
MKS9]M1T.@/\/#F'\R:+@1'?VQ=YJ/1T_.AN?-5#0W#A1&!BOEG"GL<AG]S46
MTC5DML&HQO"J':T]L K90''SU5L!M[UV=$[$<7>:76-XU8[(#O'V_T8)]C6K
M<#LR5;11%1WEAZI(5SP'U?#!Y%B/"@O<\J$*3E8F(NO3?@^I16_ NXI5I<#Q
M<>1_=X(4JT*Q@+YC?(@ZV3FI[#4?M6@/J*!.S!K%#L<XH-#PF8,\9RJUG/CB
M:>KY5'HJRE2G$5;L8>7H'V)VWJ?HO__+[O5>PI=7GV^^O# ^?>$C^CY'H0NR
MS?AO9[5^:;QS5EB9<O7Q?[^^>6%\?O><S\XTECC,)?K.VTCY3AI@;W_Y8L-S
MP\!SL[>Z?/2U;$6P8.$B<M9+FH3X :M*>6=,K(,M0&".0@9>H<SU^R?\CMI%
M_O$YZYU5\K5LI65BM7W(02&[=_,6B-G<P%NV]%R?YKL"%JQ)<4XA#0/<B4&/
M#W)@:]Y1L6RO:SF,$ OF33''G%<LIE/>4P ;EH$8]1DO\P^0]194'IQ- P7L
M^_?7,77#GC(G%;-XL"<"=7O@T"XA(I^I!\[:3LHJ)YJ '48K.%'IYL,HF8>^
M%^8-IG6_GAW]>NQ*X.A^/;I?3\W[]=2EBO-SA)6IU%(DY;U&2T33QFTA^\F\
M@P_6V' FID$VB*#M2R^;( NXPS$L$=Y[O%/":T\,GP8Y^?^S]^9=C6-9ONA7
MT8K.Z@7W"2<V<T17K4401":9,7"!K.BJ?]Z2K6.L#%ER:8 @/_W=TQDD2\80
M V!TW^NL "2=:9\][]_^0$6CA]BC>10P/.)O98SBNK^+TSN<95%,8H-:D%/U
M9Y:B-*E,C>%*0D85E(I1,T$2Z9_539-HUA)4@ R==ZB!!,K5C3$(7P%5*53
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MI>OLT6Z/NFNELMD@F*?(9 /Q1IDY(^X*<@#4TU&RX=<F*IY1%Q?#E>7$\E&
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M _2Q@KF!2A4"?6;(8[C;8D48@9F4.&*SY3ADG]\;F^<6,_043IQOOG$4&/_
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MYM:QX(Y\-#BDW*?V_/W1*4*G:D6S;1*L9 44.-2_ EHD=A?!<8T#D&YP@^(
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ML$^!G&2_L*@XK5 P"'B@%\X?DGTB2L'NUT?4A[50JLX;;I-1:-DFEZ@@>^]
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MXZN_3V[.!C;1R%0(Z%68CPH-+8Z",B<&*LJF^1JW:D0\1 8.A:T;.P>P3E]
MR/&!-X7Y3'*G=3>Y[NO3];GM)QU2@DV%C?,6_NU:4X04S>P1%5_:KA%"?]+N
ML?N:0OW:YA03ELRRBE^8033MEPT%\$JM+/&1>Z@,6S'9RTF]FF\$;]VJZ$GH
M*O3N7RJI,8213'2V),<A$<E&OMQU:W>*PUNZ4MQ4A(TS VO+JRD'QH;(*B:(
MG,G-08$)@ QT7X\1.7PE0LL7E3T5WN$ZBTQ0-BB!^#-I (,HN"$PXAC]0VEF
M+TG=_8*^CT1,;VZS0*H.M>O-T4D9D!N/B8MC+$3"-\ZEJF?/S3&&W-S,RFTT
M=QM#4D8?:S%G:47F[A 4K48_Q90+=+; A0SD%[6%X;M&C;OSVI:8N-/K@I.'
MKC@&@!]S]U83<SHLN)MV-&Y-L7.N7AQ<KP(QHX?990/#BFM!4@JO"*?6',4(
MUHZIE<!!83=NL$E/3-+1Y'JN5359>4XWN^5G@-=\2*],)X.MEJ04-RO0J"5O
MTC#<> N<[K/W"?V2Y]1#T3M3IM7ED6Y!>9JEA<BXPQ&H[K(J"HP554V=Q5]U
M<9REH;=&@^36/62@.Y0CR[?--T"W$">[2U%#=+V'JA+YPWV%MWP0A0B"2S<C
ML_D@J<1*8=XB\.*(&R+1M8;SNR,Q_A#*HR^^I#C8:(G<A5\RBH"_Q[V!+9E+
MV#3'+X#(33)N!:YD4V1 KUA+=W1E<T<42B[,$, \+?-<X,4IVU -BZCN2(1M
MU=F6)@1G<U7+&3[0[V,ZX,+D*#?/XBU/P_LX<SL"K;/DJ/V1M0Q"D0Y0.XA2
M@H'/HR_2O3[0ZEW^$BRO=:_O'_1W_=U=RH^BJR8SL#I+JEO<9^0XGXM15ESY
MPL:3AOC&3_W-WMZF32D%TV]XEPGD"$\??MT,^KWMG<H,1G8&^[?. /3D["LG
M,.@-*A,@33;4BNP4!"3RG!U_;X<)I'4SHB_-$>/EI[+3V^R[4P%JE8 VTFY-
M2#7J 618AZZ98H2*OD\:QKQF]>EN<S3;N>"/:R[632CMIG'\+WG5 0,7HR*"
MV(;PYZZ*" Z]-:17TY0Q3%,)SX^C,8R\ME-,UINVO&5=#5&MKUW8'YA/9<Y2
MM 6QD>K+N^TB^OHZ( DR8?K:GA(E4W- (YY=(8N:'Q_U@CR/P$.==EI.::^N
M50P?7>L/UIM-34V[>LJ5./'\M)KLY*IQG++&4[*'K\GKM@+B[*,CJKQK:OV#
MW3I(Z80]P&@8TILC\N:LE]V#P2)QY#N;#YIZDW!RT^:JDHG&G[> [\12Z^PH
MRI9C/Y0%X"K!-6E/&Z5%ODRTNC,#N"C]K;U6(F^MKW*=S55EHB7!& N6-M@'
M:I)$V., 7 /F./5@^X#)1/E$DE)H8)W_:#STBVJXYO,WY\_-_)IIR?6&L@-"
M.\S%^X9?Q*XK&7I]2W)!';\^N7AS2-[SRJ3%-=62<;', NA ?RL3FN:6SPFF
MY#K#?C#2G-358N?'<3-!G!@MK(_"$VQ/U6, -9]04=DG76B@.;CNJ&534UUK
M#0NI]!NH5_X2 .%@1YI#LLW@(=VJ5?YBV)QS,NYU A&++>PIPZL2A:&N?[A+
M\-]M8O/PCYUO)=J_@WC[U%"2:!>M[ZE<.7NA&L\3';]W/E/]31WD,8.#^A\X
M/=/'U( VPH_,,H4]IBK$S5W6,STL*N%,SUU8OSVLO]>%];NP?A?6OUNASGP]
MCF6&V) 4N2Y7'% TMF:MS+/$27#%-=#4,'K*W@Y?W(8BFLR7;F7-+*?P<RBK
MEM>U'R\FQ-$CPH08T#;P69]FZ&P?J:7;ES[4_H%T%%EE:H'F>A6NB$TVU$5.
M%.P;8\9L3JF%4VHS[T80.<O9*8.E3:&2W)HYY#0!]YT.<AB4B7+VWR?8NMGV
M;?7.J^I>)2EY08]S2K:'SU(XF[L?ODE')>F"3DQ.>(%-TK<9VY5.V<;#'WVI
M98.O@@W^"2/B= API*CG7T\464?5.C331!S;;"9HM1'#96>5;AGI"V %,&F)
M7@=%D45#4.LD,5PZ4V(KPH11+2A]RJ=@>L+2U6P\AE#@0_GXAI)<4LI+P<@[
M*MHX8_*$8,VLJ=OCLJJ8GH(3Q=<JQ)P763GBII]VG#$0!]5V91&<&_8<3L6A
MB$T;T\18%Q8TQ#;'Y%Z9:#ME="=2DWB&#G0,+L)GJ:0B^L(>HDJ#3=X1S#U7
M5TZE%YX@_1WL#8SQ"]'KM:P"X9TZ(2ZJGV^[T&R%':DPR*Z#^/-\E?_1IR/O
M_#-8JLBBWA5ACQ^Y+ ,4[MRYW+QN#C,%V_Z2+>S"*:*F$C%T8.#P1(-(K%3B
M %8A[#VZ4"0^C"%@3EYQ:7;(4",9>6:1*SI,C:]/(*%.,RGV..8&^L7^(;T&
M8W/'8!-0_HH;L?^HO3KG@H6 YO=YA&WFWP01:5*D$*E84!G8)1DE$76JKU_K
MRE9)8US;<UU\22<G)^9%#"99M(E"3;T]F$/P)WS2B;+SY3N3 @O$X[WQ+A!4
M@S<R%ZB\O=[KWBU/8=X=;I:T3B8ED,5/LE@L/,$NX+3;K .OI*IQTAS5-V)^
M@1QWV3=&0T2+("4B=0I_QB 33';)5(I@$Z^_PXR5V]/F)*HH?B;* -]B#)F*
M;X1'HB)C<E,0%  "/7#'VY3^M^=V9LY-+3&E45(;<^[I[!2&H0["W7^IKA-N
M]>4E PJ@9VR#_(F,N^$=%I(\REUUITH54I;N]OS%C%_NF%X92*LPF@MP@*,V
MB*0LC)24E^58$<\?NR;?GTYS)28$<BQ"?8%4O4!@77QNU(T<;XE9!*U+(C"P
MRK(,=7!"F]Y.\??A:]IMQ;'(D%4Z]K@[ 9CYC6T\LV":2F2'?91Z/"<(?3^;
M<&OW]BOY8\S$=M#2P>ZK!_)IS-F*_>W>#NZ%C=:=N-!)UY,(Z0?%?@T9R:]
M(E&1E NQ).! &M:&29-(6GEB%YBL@07731@%.<6Y&)_R3I<$7-'SCQ@0;U28
M'"#ZH"G9WF<_^*ME*&ZK([AO37 M%%='#?+G,+M8.<TP&RL \7.>EG\%2Y&>
MS1?Y;K1'^1L=03T,0;50U'OXAXI-NI;OO55Q-%/>F[+( N9A6K%?BHQ,A/J[
M4=$JV*%4@JW/HU(?72O#*>%_8_9XQ.+SPD.HN#QPL]#/A7AVE PZ0I,1R];Q
M-_8/H'\ K\@XL8.2%&!G3#XGJ#"8D@RJ5>*B>.#C\F^I1FGR79D,?$S()M]+
MNSJ3IZ2#8@T06+<P)X(:G:5@=@S1*\-95:P"REYH-1NAY9C M)_/^NTN<*4C
ML5[LQE15=NL_XKQN2G.) RJQP&HZBLH3R;K8*;JNI<P$Z?.K$F$>R+ S.,$G
M!A%RI%;@*CF6@#YOS&Y($TDU'2H\3DQ/YH T)FU\"/(P^(]WQ* XB";Y&5F?
M@-HN K1UPD&(:FL\PR8/&NA%A]5=QV9@O1Y1[H)R]D!=A#G&F"K"MIF&\OP*
MB$Y_#I]38W;.P0YJD"TR,\2EXDQ/NS\"6VAH_?#.9LB.TIZT7XXN;C_8[^+V
M7=R^B]O?#0E?0,A/!?[TA$#(O?,B*,I5\$G>'X/=>+<<&%A3F5\IE$)^?:R%
MU.%(UYMG:B$V^JP<QBT0Z9TOZD=;<KD:%:W'R4H+0S%16)6LK'&$>2M\B!F%
MP7/KH912G&O0#_))-&/K+@NX*!,]EQSGQ%]'E(= >I2D@C/.FQ[J>D(AR'$D
M-(B?43F7E4G!-$)SP_A.F0VZKSO_TN,B(J[P$[L->V"-I"H<GR?$>V0"4M1*
MEJ44%?\5&&P3G9**!1<X7DDEQXQ.38$&JT&ZHW>D\(-)@0V8YL-P^ G[I6.R
M9K09='Y\I'$*V-/#S 7MJ[=8\MK?W/C=6PMBK(R^G!A)1>RH\@8WKP""RCB_
M(I2HRI3X2[/DR]<IYR-#"^;&_8X>^O^2R2[%8642@+RB )1.0W;@R)!2.=KI
MQG5;9IZK:;0AT[<?JP6$83$E+(;J90G28;D%(0I*Y3V[HOV-WWV+#4VH'@PY
MC&XU,W]TYI#G _%+T8N1=^[6'WRI',#\MPCX*"T0*9<F<^'TW[[1+ECAN.@6
M4](>0C>0D10<[#"2(9TA)+:(<I?DAC>:BE;!,7I839U5F8&%I?@ZKQ\]AE=!
M% N E=T+N/:@_2:ZB$AG+OE.P5%+EZ@I.40D@,_C7J<EEITH!&! -D"E8JP?
M5]3BFYYW&#(4"7?!,&"K(W)$A58R%M;W!,N<I02OQ!7VE(Z@B^=S3/U)K]O8
MA>0-@'%0YI3%QN%A[;Z9("#,B/L0:_]-XW SG0;+^6NJ-,B=ID;%,0X6S_@)
M>D1-C9-1AE8RX\7F&K +DI.Q.*M6%Z>E+0FX?@6."EC-;XB+(M 0&L2SQ&]6
MLAYU&;/$?_*J(YYS(B67S, 7Y^0)%0<]Q@L:'O$V2.5 >6Y_ZS,(LKW5%A&9
MD:(D_8W[_(0N]9HG5X%U8F:3\"%_/D_(9U4AB-WMU#7=3M'A;5G6Z-%.X+0)
M; F/W<E01&L@O!+0*<*#"S,D!U%21LR_X*"/TEED;QUHG1DQ7]20./IC3Q"9
MKN'UDB)]K89YA!7C#Z@ +'!87E]?]ZZ#& ,L05[T8#$/V?R.KK ):< 5=E@Z
MJO%X)2K>>XJ0U)1:/%ES"OIV.T>AL>,$@2M*C+ 0$#N3AL^)W:GBYTDQIEX:
MU63]QRE-[H@?<TA\RE;LK@"/N2 4L0K[-='KN01Y=A4B?Z9(L. _3U @=,[#
M'VF78$R<@3:&K."8H@9I:L'9V86Z)$^-L'MKX8)X*!CPRF<<01T)CR.;11NK
M2[&LQ:9)LYL*6!:]*R^[70F)GIPLB&HY![L?G9"UH!E>K<^5*<N\<2$9YNTR
MH8[+Q.9--(R;=WZG'^QWDH82G%+M:FZ8DX*1,OFG[7)'=II+M/B9ZS3[K/_=
M=*X&-9(9C_N(XXL44TYP3\A9$X%,4LDE%9T1-EQ'(3^00F:9VF!\1%+88WV/
MJ3 I33;X)],.CU/)7!.EE1ZH<D>3PQU)@*T=HRCC0W:BF-%/KG*)EL#O1BHL
M02"^6DKH=Z3S;4@G4U>1NM9V'KK1RCRO^*V;^40<<Q\6E#>3:,8&LODSF:3T
M!4:)-#5W"CNY"&!J!6+'%5<=[_B!! !Z)IZ9. VT>K*()SC8N,A6T!3!=*DL
M+73G8 ?M4Z(*;--4L5=S5_-!.NK._6'.O4DUI00]W>H2#G$,!\>ENJ@J(BY0
M=\Q/X9@9$EGS=X?;Z_ C>[W:[GJH\E$&YBF\06CLF%N,_8]':"M8X5\3Y=I%
MSHI&F:OPE;3:0^AA\SZQ#QU%"+*(Y(Z9CP[M2?(#/?U*["%2<6*R6;A:+%-!
M8>"%F^.,E+Q#@HD*;474W:+_X'JLVQ<T;#@W:V>))ETR4B('&)Q9V:!4+HDB
M>I:F+,#^#G4C:5V_8$*OV(RC1FXZ",.AKNL,70OLR2T3,\6A*JYQN0M7V"6?
MMB>?'G3)IUWRZ:-//EU67#[0-7)9J([#HBQP(FHQINAGQ@&1CR9@#O)YE EW
MR5$B!8"QCJ6%="[XQE?K\CWAAD[>2I9A@@X+!TX@"%-NVC*;87FQ!$B:7'>=
MIO(@EBC9%B'"36+' ?0A:-@8BI2*S])1/]A-*2Y,77K4XE[P!,X3U=$,&XY'
MW3$_)H44L8B &02FIAO30T@IQ$-W&0DJCKFNQ6Y7F:AQEF*GABUCJQ'3'/40
MP+WE"38O32+Q]&\[F^:(#F?\5CQ@K%!&)M6.Z;Q0=YB! 0Z/"@D821<P6LDA
MY]J=59,+!YL;;]&99S(-*<1I#;7N"OQ(TUM*?.$(F?Y=WQOS-C[$^2Q,*YMT
M3:ND=#8^0I:\(V.UT=%P33H">#"GJ^.YIR9)#*LT(UBEPL(JU?O/B'5)SGB+
MT$703MN;V\C8G.S)\XW?409.R_A2@UKIG&3#3LK<(S.&"R),YV@[@RXY]L'H
MA&XR<@8)&6/*D* 2J I\G<]MB/ IWXTJBYO%!0H7A9F\+QS1#@I;\1U893J:
MSH)1L4A1MNWRHN0JC:_8)T1QR8":&Z;)9<H24[YY%:6Q]:+$P34U%LPPE4F)
M$R<L8128>EC"1>"&4SH<Q4+; 6>PF/@.)CH^?:EK+A9\FVA_%=+9&E)-*KB=
M\Y703K$TG:%3_RQ83G-@*11&Y*J[T22(,A>9:5+M2EZIS:8,2L(2MJU):W.M
M%%:[0LIFV+EI5[4R/.?C-O4.SE]EJ$32\MJ^ W^J5'*<H>79WSS<V+*)>)B<
M5YNO'I'EZMW6BDJ ;COB.-*IXL'>L'0VP304P6:XO8S<JV0TI@L/9NYD*]L/
M/TMN='WF=GJ$D5GX3L%[6YM=$4M[:^'ZVL[ZO'!Z(K?OCMELS>TAGL92;V4T
M.DG(YJ0V)Q1+2EN7OO88-,S*&6%/4-O51=I*V)9'<PUGQ&*71BABP=@:  (K
ME.2.Y7J-=WKBMSEMR:J@6&[B5!B2=ZLIYV^Y\R;\9V,-:.QIW8U\+D&5ZU^Q
M8)F;#"&UV)9#TA %L]((+#RZLMGL[5-IH%>RE1VXF"J!"[)DF<A$3:N<>6I>
MTY,/6+$]FD1J/-^RDN=L_OX+Z$J@%LD?UQOOA ,SW#*=^XQ5[Y\WU/UB2.AJ
M&N@"[ _)::=\8:K=HO(J3=0;@-5EIV^"(*9-U\9<"1[JC,7-!M, 7PR#3E'K
MOD2CFKNE.71')#^02-KYE>D(RZVJZ%1U-V>GSS"FSL&&1]13)<C (HAF]-+W
M8V+-@ITFO&B:]YW$4A9 1X_?AAY-NV]#D-(97IF$,-LB<#'OJ4@W8D0=9WF0
M.A7'ST\ C C"5W$=(A3)C77:B91QH2B<*OJ*4V)Y]N!CY;>I;NPHX4=20J4
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M,L4+A_G@631S5XY"Q9AEA>ODP0PO-9TQ 2%/49@$G9,['_CO+%8%"\VH$E7
MWZ!C-QI'C,"!"@GL M@6!=7[9PKH5R&QTT>+%/A?.HN87; D0XLA*(H PP[(
MGHZ_3*(A?F>[-]C=@/_LFRS!,\K8MBM <Z+Z(6!X:39+#:';\7'X*%D!XZ.]
MFF(%2/@\FI8Q7&J5EOFB>VP,DF;OT8Y_(*KGHI2N O,BYIU&_=[.)KF$6M\E
M3])/^[T#5T<E,T K1%)ZVOH%NB1%K%B&2K$9D+F9S@+S&D7&3WTS2W%<72S.
M7\,0#5[F(4IUR>:"^U'"=4Z]&(M%N2SFAJY1D_< U0GX$ RI%4T13XK$Z>T9
M=,YW><$"^<.P:\L.Y=\VCI:(O$R*M?-"!276I-?(^LQ<))4-+$IV=,B.V"]'
M'+LP4$-_V! J":<<OH0O8;:=ZY2BLY&U^;<L3E<G<6(0>1%UOLXMZR9OS2C(
M)Z2:T0K:N5V7<+.UW27<= DWCSKAY@G(ZUND#JED.$=T*4N%V6W\E+@H_,:(
M>+029P7SV<4\\"5E8G+"0C$G "1)W"0K:'@JE*?(-Y$S-S#1NPA(-!'1EF[C
M[TX:.:5BLA(0LG_B,LH+2;P4/]\:[Y VG[]U4CNBA(A3C!W^]+AH(" 1*:&'
M_)<A;2B>GZS%%R<F)0RQ$_'F]@%]SRX(C_>;9^FO:5I)O9'*J!JT\1S6??$?
M;$E.$W%IT33)VG'TS(4.J170N>\4<')CFDMIV2W1)>UEU?HP_C#Z3PF&XP+5
MES6IA2;N@IE\'W,6JZ-F-]8*1;UQWIH%8[:_W=FQ+MF=N0SOC!C>"ERF"]>B
M8)*L1F;]A?P12<(0K+4L)"*N0]_H_'-HOK&F:"U 2(!QA+'UH8K3ZW7X%67X
MW_#M8OSTVY@O"E1V\R[+A%TFWS0[@_W0,$-3)2$V?VVAU9U<3H96R_B;GK"1
MP9"N&X5V>'?Z.PT!GG=@X8]NO ;ZM2$B$[G)%#(U7'^9VRFBV5[SJ*,6 HM"
M7_.:Z$.CP.YWG8C2!(.?)+6<?<*XO):K+>>[SDRT2J-51W9]6Z?!9QTX*D#O
MQFHPN">(/ #B5DXZGR!'0]>V_:O0;^N::V$YUQ@GU4.+<-GW671Y>;.!SFG9
MW<;3E,I80DN8HXF\@!-F=S+7,3MN?M%.J_*_31 2I<J(- B+KMH9.V=:/VZ7
M+,^P\'F[O^.$<L_MDX>CHN=]4MJO$635L$O$;N^P+;J&X3 .KN'-IVFT;,DJ
MZ#*?JID(_,/4Q@SK\7U-8J+J.=!/0+\?A\%EQ+AQD:#*.<]SO-'!Y7!"C]50
M<F*R%(AJ%&UYN)@7^<*,?D-0F,&> /JX;&@I_M,0^*?P-ROUS;3JWXTX_?HF
M+I0NG-25B>?/N1"F$L$UK32:B6A;'+'$8G.ZK?"_E2HW#EERG0-%-9 CZAA:
M(8H3<;^%>]=\6OCQ93@_:W5H="02A:[R([R%,XJ &A52/(\4B:5MH%O*#R5L
M?)J"#WQ=CX]"VCD+5Y[*:M=7(JYU8H"M\!)0_@9S[Z"%E5&:$HJBMQO]"I%+
M]L.@[_<Q?7.W%;?*;X#]KN=!SA.WM7684.?D]BO6;O87IUXT?&:<\O5KR.Z;
MS^A[)2Z&6TI21:F$#3D,,MBQ(R ]V*18W5 &7X.*!TK@%*QKFE5EYUV&<2X2
M:'LM6%\;K!NN6V,:>$V(M^QL[N(S0-08O\8WWV#4>EK&ES8:2:MOSR!9,LJ+
M&W.U;A$]%X.RJ["R+OPH2X3W*L,+::X\?!:_"D2UN>T/!CNW^S4X0X2*98CQ
MSKT[GT]<GPJ)) TR.)>BA%/"6OF^OW]+GH^L5%3.TY/38P<')*?O$.C!K0E#
M+5N&,>=7K-A?$57V]_U-<AL,EMHGS3J7L#OJ0R_DTRO!&6]UARPAJAXP%6!I
MW\E!YSJIND[<:IT/:2&*U6%XA8E%J^!'^6C*1,02=Y*-38$ R0GX(<THN*WT
MQ=<:OJLNZZ(3W*U;M.-16J)X3;,LO:Z5F( E/XIFE4K&GS9[6SH/@+5+FLHU
MP2,FL)5H"N0%F6X:T&D6W'!,*FFQ.778&.B9'$"@!O)\"!W6K8JP:CD-*S$2
M)Z=2?VXUB((50:&)_;O3Q#)'SEKB[0??)ZQCE(E&3VNBO";WG,5IOY5@,%2A
MT1T)#*Q4%1H"5HO8HIJ6$%XS8JB?M2_KO%&2K+POV&PDC&_6K=%Q74VL0_NL
MRQQHSQS8Z3('NLR!IYHY\$"W9G%6/S#VCV"Z#E7&#&O@<O8P@RF$&FJ,54HO
MN JBF&/[0:R3O,F"L>S_0RJ:JLN90T4L"-B<P[\EW2"=88HT\NHA]H?#(K82
M+85#4C$KKCB:V21 @</I^TO+"AK+RF]'K%M1?L0> ()OKHL/7!5YSF^II6B.
MW[I;H6(N%"U2[7)PY[DHN*3WG/R;M83*^3Q*'>.EJA'9+GB@;ZJ(;/Q^@=C4
M<:.JZ&R-+IGD?Y2K#^RXZ'FO[W/*DLFB'8"&Y+^G*O?@N?_U2BW1ZZYE?Z28
MN:[EY7757T*7[X,;7:\W8'P15NY^VA72TWUK\,&F,S"!/!.:)#8@@<'J-[=W
MJM^D)Q=\%+]9ATIIFT>E..P#J(FW$4_NM/E+.&T#XXD\X;G=+,%BSJ62^^M9
MW>;.\JQNJ;5\';]SJMG=V0@/N^-4:DM$[I*I61"%-0ILN?/+C?$ %__1N*Q<
M0]UO%#]^ZRVA6]IZ[1[<WW67TI=M'_^[@__=8FQ&^$??=P*.E+'7N<4L:1V&
M8!>);+]"P9U=@2[B.#Q7X/I\4O/!9=N5@JG7IW)<.%OBC$E30@LR1I#REY.Z
MSZ IG!(T:NV4+@M*<QS]IXS"P)96F]CR+*CA3WA36-\$;N=8&7R6/D],%]*,
MJ:<; AQ[L+TCX !!Y51!?L'X";5HX[+(&5%^+H=-J1(F)V(>[65WISH>1KJJ
M9&,R*RS3MCOL[MJ1R)XW!@%OI*CZ")9.,Y#,FK&B]![=V6/Y)!,MC0WR@*#K
M#WQF*>(RND6JU9:G-\HN:@5N_CMLB?+';+5P.$XKF6OO% 9G74@')UO-L_=:
M5Q"7MM)3V]YN=DL-@^\0<V_9,P<4F,UZOF0LN:_<.14\RNJP-+9J6_,<3%D;
MX65)QR^]M<-U2O^]P30GFY/MWC2));Y>KUVIZFU<^[+N17RS8ER?[?6#R5C&
M1EV4A$Z(A3FN2I>I_]0?]#:=HCO*N A")!LI(^!?@Y:P@?7XU C(EU_J GW$
M?>(XG+90)=D@C86+$C*4](&ROZBB.$DB#2?11$!\05;1:M8%H@&M'_P#\0;*
M=!<P3_S3UN:&\R==@N[(#C#H8X7;U]^IY,G?EA6/FU9Q,*/*;EWM6J>JBHXI
M1=7U=NGP>'TO2.JT+9NS9QC@BF 8!$H%YSLKA\!+J@0]":XT^="9<+F=Q.69
M?C]JJCBWJ&-8'^*[N4MF3B!M8!=!_].%"/7LG^9J!&#TR4U+Q<@U1R94/=&)
MZA0KV4Z6(@QK-SEO]V$!C:E+U?O<\\Z12]1YDZ?Y\:GIA\6PXHQ+X%J76]PL
M6@S;$]#$O1VW<[N!OOEH?'.XSK=&"3A35Y&ZECYS*<V53-_^X-69(OR(8X1X
MT+_3,SMS=DZ;XWBVTY1T9=L*1\(J\Q)F%8RQBK.EGCY1@::9 PNZCS!HQ9JI
M]@,2XEZ"JK[CQ4'6;HNAW.Q'NRV5REX"K*CV9FLG^F^.9OLH:8QZG9_6R(I"
MD.>,4,2&O[U3OGW"R41*6W4/36:@#)698>5MK?)\HD9NUJ!'$+:. @N=>YI"
M:WEVI M)E3Y(F#2S8"^U$>FCKBX"-/H6GMS;^9OFQ9J,SR73D)3TV0RD$\4S
M:B0T54'")>$&(@:82R*F7>W=N=&YZ)U- WD< ?U8OYI'S%GT*5['X-&L(X^^
M;) ]>>>%=+'M]MCV;A?;[F+;3RBV_1B]$9\"9$><D;="KL>V$,R2R=?D'+S&
MK4&O!':E-27:UDH(:OYXR7&?4P4KM3AUU2U3CC,?1/2:"S=<":3Q23D@HTT6
MSWQW8-C[DR2/4!MPBRXDA[H^V76G_X6.5[5M4K704 M8,P,3C>32.M)PPRA'
ML,)K5%>IE:]16/0<Z_*Z@E085 QH T?' 4'&XB-32_<DEH\:NVP6W'#)!9C7
ME^*;2*_;Z]%JF8F-?L_5O"RT?4QQ#-3M^O'I0#5%-S$0[>\+G "M"4+74&S%
M]Z=MMK4YBJ]^VM*_\5!4B,F X#*R10,=45] &);G!^^FF<L.\/[!Y+$3(=M1
MTD\;*[J(NDP7[X5DU6B#?0V=>77;Q,3-*/.E\12B.=Q(W6:[S)1OBRQCK"'+
MR+((W T ':B*4D65HZ$@/8U*<HS]F4:)(((ULK_Y'-8"D4GT1X>8OZ%YI[&5
MJJ5QK3RA!CKBK(Y<:=K5Y1:$9P@G%IF0B=T#/.0P'94X:=KR]38F:3@/&')&
ME-!';)P"0SO4--(),:'H"%5]VW&:]3VO]VQO*K^L'ZYT;/>KN[!P"ZI>:<<R
M--X+;MN^E.18!4YX:\"_Z9X]>*A^Z=*4K:TN"%\5?*&:)K#5@IZ\4B&Y.T'E
MU$5\5-L91V.E+VEH'8Q6A+J6DUV,"UX5#NAK68&U %@] !M&DL+X1IDWQ\&U
MW_ YT#KR@L(E.OSM>W^6X:5XY9!+L4[!>5XHGR.Z2MSBC:XL.TK(B0OW)XM8
M_):%B W;=X32,&4.A5)&YF/];BF>5[T!OF0#P#_PYJ<WBE( PG(4D;LG$^8N
MO 0.8$8N9\'B(CZM[QR=2AQ-*?LWCH)A%&/UY(C?\767Y'P2S7P2P86'@H#D
M>I$!)=HY:/A]K$-T8E*$FG$C%YZKN+E=>D2* '4OP/@[Q]:<"5N$?T2CP*.X
M91/,RAM -&ZG%L^ J>D-(]4AX/HQ0TM"0\A>X47B>,RWB(KXB3H,A6@=]GB;
M%#0J@F=D:JIP,0#7,@/.9A%M9AJ$IA<N_(?":UN;ZW7@+@)XGQ5Z H824$6S
ME>&RO\:<D0'S)F@!#:]N?+VI#DJCUAJCY:5=?AI?PRYJ":RJ!>?TT.+O#IEJ
M_1T<9+LW>!A!J-N99<RFN2/>@TJ0.PI,7;8/]Y@+OU9!4+J&U2%V)XR5M[=C
M4CR!*8*YPE<4Z>Q=<&VHY0A(';AHR;"$WALQ']BTTARQSN^O)RE"Y_KR0'S#
MW0_T3_BR9PKKYKP>%3&=<A@_S76_^[F&,35!@\8W 0E%8>2$(.S4R#[#'![,
M0\,VZIJQPH4> Y$4)!P0EU+_PJH6>M)Y_;,4M!Q;Z\]N#:JJUP$*K2BOV)?
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M0#NFDY'0Q.GK :">&X[#!*V,&_-)U0));"=V9F$NZG^("2-;DM($G]TX'AS
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M?*VO?35UFP.$IFS<+J3)DC=#84)]90=.3KUW\'3B]BB^Z\(;%M6Z)IJU<6W
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MZ R^#+[YP]N7AJ]&8N1J"5NHV=BNHCYDTC-@:U;.&1H_P(N5\)X>+ETI4LE
M<:"'!<DO'"0O%<\IJPMB4.[1N+J 12[/O8+E?(A3!8:X5B#N2*S\C(@3:41<
M.R/F;%$+FXM-@UN0U^17I6!M2TI% 67^=CU2 8RE&4N7G//(S=)RR_(7C.<8
MSY6<J,G-<TK+DBZ,YQC/E9Q=RLUS:KTR13NC%D3QT*R%X(&"ZQ091'#H.B5M
MW#C'H[;PE1O\J&S<ZL4_28[@%Q*MPO^=FF_]O^,_=D24HF)-L70\$Z3J9Q=!
M(>\;^O)N3OTY5B,D<AK[5@@.8?,58XQ1LO+W?R4F2"<((J 7"@!_NQ859:TU
M=LE!RU,^(\09$VAF,^P/R+;;CH^O[CN@C0D_&CZ:<C/3-NR):5CX^? /2-?:
MS?;+Q?^$%P65:LZDV412A:XVT\>*.IOHDXG85:>SGCR3QTB<_+<H]#K1M^9K
M?;8T7M'UV$7&CVMCAHGSV;#>C0^O\\L6#1>F?1V'U2XB]E)T-JN&HOC.@1['
M%H;CDA+US]@R0"Y\"C^30<VS<',7K*Q_.WY 6J?_0@+0SHR[!0/-AD(,8SWY
MZ<R@)8?+I2&/_!'$RK<5#'XJRUAZZ'/TER^1]#)M<FWRI2\+PWW%@ HE#N!I
MQP(CU Q^O8':C1# +50]X9W#7]^07^U8C,'O>OI-3]C_:^%&_/>,JJU.28Z_
M!@]W]X^W@^<7[NGA-FUX6!/>\G;T^#QZ&-X-7N[ON.<7_)_?[Q]?GKG1-^[Y
MM\'W^]]&F K?GTF>3?O"W?_7'\.7?S:5&%=#F_/GS@I?8^J!$/GCYOD&VW.8
M%5V/Y]#/"0++CPPHQ[K&^)0D1,*FJ!&?R]*-*$F9^#S/9=63KWKX=Y*BE/ZL
MRHW:[=;D61E=&5V[-YJNU^19M<Q6! W/*I]XU8M@H)>9MVKAG5?F\>^:*:JR
M&^$Y'@/]DG"'SV/#Z)E,F.=8O<U_</?_6IG^Q]_'[B_]OPS\,WMB>#ZWM"8W
M>^O3:3[#"G&Q$_J1#DX"/@4JYS-VLP$EO4)N_;:]IC%&5) V<O$S&^X'%\R@
MSC+0_"@!]@:0&TK%K^>E(KZ(Z[PG"G";0=$!?E8(>!D61^3TDV%.KX<V^?NM
ML31]PV+4/9VZD\EJL;(@+DPH>H=FYL3T&45+HV@P86XKKTU^'NB7AT/3-!BQ
MCQ%[NT:>BXKD&45/INB+@P4J%[>2UZ'-P%9F=O'!J@WI@%U<(^OW>369(,]S
MW%)8J1;(/Y.EUBRB#1;.RLXB;]M'&H8G2O!4IX_2I^?.%FO,WGU?[\#2U\'#
MX/'V/NS,_,?*^N DG><D09**K'(^B39G+"O.1IR\^]7T(_O5L-^U<.QGWYG\
M*+S_3>W".K6NHL)*M7(V_V4^N\SU];G0<.'Z^FR0R%Y>G^_=Z\D':<7U^N&.
M<X+^T)D+G+C3!C4E*^RU3C_91%9),=DNU=(+($_K:J>CH>9D4<"4Q#$ET2M-
M2:3,6XCI!WW_O 6F'9AVN)!VZ)U'.V0?2W)@]!+3'>?5'4Q0,$$1"0I)N) 9
MV16P&:DEVS29,&#"@ F#\EXZ5\>V)&;LV*["?CC>W-T5._VNR$MBD14%-+(M
M8\YV,F<NWI0H,^F[$C/IF3A@XN!"XD"F31S(3!PP<<#$P:5,]ZQS0B]DNBO$
M=!?D(K/0+LB<])534%&B0=.8YFSZ8.AY*\.>!-,PPNX7)^K;"%))W&J)F<U%
M%C(\\KD7=P4-8JZ#\3?-5-QU J$N*'YRSC]/3[A)ZIZ$V[MA30.I [1'T[N5
M"[(&/Y,S#3)OA+Y/(7GS%FATU4Y?X15-YX64J6]E'%:1W5(TS;W/:C 1&RZG
MW92.;RIF.K-38J?$3HF=4BF+/J0]JV4.*;D_#6N%3M!Q,>NYBW6<PNMZ<MDZ
MPQ;5V&(2@)T2.R5V2NTYI5S:=,_:K(JUJ58;;4I?B(B*L!--6W/SI"'BP:<)
MJ3^.0DZF#:QAHX!GWDU_SOESQ'U[&N!?O2'/AX&]7)&"8A9Z2@L]?7-<?&/[
M:>5.YH:'!J\N"F8CYPY#Z9V^+/.R()3>*-2T_8L5Z)$]*V:/ZI$#QY]4&SU\
MPA3M5&0HJLQF9*?$3HF=TD7B9 45\D9<:P(H9"EU<3T#&M5 8^* G1([)79*
M[3FELP3-RE.M(JA6.=71I0UH]$6[J(B@U:]PZ\0(VM/PZ;YP"(U5;QT(H3VO
MQM[$-9>D=/3D^)DF=?JBR.MEQL]8'J;J^-F^LT^J##EM:@QMZ18&(99P9:?$
M3NG2XOC4X%D151R3U;"W7M3X7J_')':]4,9D 3LE=DKLE-IS2F>)G)6D5U70
MJWH983-6>,8*SRH-FXW&QJO)&?:4^]VT?G!?5QZ^LN?!2INQ:9-EY*P:+6<H
M;:L#>U\T;3#YU\KTR/*K_#&T;J<OZ;PD:[PJ=%D-&A4QM".G3O3+]J$G%8?6
M[,JSELN+8^/LJY,7.I87(B\*"B])*I,7YY4760:XGR@O>OA<&RPO&';V! CS
M8R>?!Z,+&%@]B9=4^A/_#%ZL#HB=$CNE2XOJ+)/XJQ#58J<OZBK?59..((-7
M<^"U)Z19.;RD3E_1-+XG%J[J8"6 K 0P&V,\(I^S#NW.;F2&@^6AV"FQ4V*G
MQ$Z)G1([)79*^4XIUQ!I.;$-:L\0Z2?7F9G^ [;%<CL.<J??4WFUF^S*S3X(
MFH&(L3H[I6+SXA-QJ?)97>GT)87O]9+) L;JS0!1(OI4/HB@:$X2>%6E6F'0
M%P^B(L94OWHY$C"]'AL>@E=<+)'MD6JWDV).M0U!LSP4.R5V2NR4V"FQ4Z+I
ME,HLDAI,_V<5#(7P7IP!I@1<T;">#',ZM&^-I>D;%JFQ),; ;<P6^(Z"Q"EZ
M1NZ;.4%!3O4[FCBO-KD*2:_FMG2[G;[&:S++U]<,E$QTL%-BI\1.J3VG5&:%
M$G5J6*N+&J8O/D1%S*E^=4WA8#YNLG)=9$\^.-_%%[."+DMCS1^L[(F"0"]+
M%[!38J?$3HF=$CLE=DKLE-@IG:TX3<Q8;##RY\@%1]%%<^PKFF]H:$^<!8+R
M@]#4O@TM[1<PM(-[#^SIR\;LWGBEC\@?S5Z,GVFN(O3/)V?D4526P/!VA@JI
M\^&MU^E3707#X':&6JJSP:T'&W2283"*\$9?M(J*"!C-55=:*J=\'3P,'F_O
M0ZOM#DW08HQ<3A9Y3A(DJ<@DFK'C3I%[[3O+SP ^S[',*0<O1.E,H70"Y9PI
M)$M'9@K=DB%PI-@MF",T6OF>;]A D+QCA'IBIZ]W>:4K\&KW/*LORSGT5"U"
M&VO\+6_"(>.[UQ/N:7Z!E*$%?NY8F"C>_;]6IO^!]:6U DH\.2[1AK[OFN.5
M;XPM].(\.C;<P'4L_%RO0WPKS!Y^FGZ4,.[WPOTB3N\I":K, I**?"J3^'LD
MOGQ.B2^??7 <D_A,XJ=C_9P27TD;K,<D?A42GS$\8_@UPROG8?A\E4(]M=/7
M>EU>D)D5R&0"DPG%7SI?/B@Q<'M/P/1"TJ';Z8MJE]?T(NW/C#L9=]+RTOFX
M,]%]4S%W)AE0*YB=9;S'>(^6E\[%>EEF@IY?'^I8'W8%OJLF>9)9RTPF,)E0
MJ4S(LFWB_#(!"EIZ/5[O,0^:%4 <*X"(/A*=E4JD7=F52!FN$9YT<$"[AQV#
M@8Q_,W56F&&V<5#9O=G+L9=C+\=>CKT<>[EZO!Q]QL;9*CA597,"IU2L3!!8
MW30Y)*2N)'0B_H,+W CN[V/WEWZP3O97RQD;%O<;_@1^)X][,!>FCZ89RD7H
M.])+%/J>@A+://4G%V%_$'F>XV8I$SKZREGD&[L(NPB["+M(21>A3W'0U'72
M""VUW8_R#\->&>X'%W2C"-R5X7$N6CHN-EX2Z<3*:56?./2>2N5>Y97*ZPBS
M+ B=OL[CU\?_WU^Y6<W9L7P,R\?LS<=D60MZ[GR,+(B=O@+<PK(QI69HR[%=
MV-69C&8R^GPR6DELPZ)"1DN=/A2=J_O[KIB09L*""8LS%[PJ6<<374ALR)V^
MR*NBW+""6,:UC&N+<&UB>,"9R]1E0<'ZO/5,6>>K,X'2;(&22YZ<J34]I_)7
ML8S1>55.:G_F,[ RVU,S/NGSW>B07^F0&RV1C1^5&QN684\0Y\T1\CE@*<-'
M, XO-F[?XZX>'1]QTFDIGN/$H6Y>89CN*N-UVS7HL7'3AMDU&&KKA]I&GE(^
M=S8Q*(6N(%2WTY<U7E:HGBK+ -AL,4'+-1J)EGSBBNH1+K*@U4%<T>=(4N&<
MUGT(=GK1(7%46=%A[J)#I7O.HD.]JJ+#0CJE>#BZ/BA(4S9']H%?2,?T6,D=
MK8.D6W4-)CGV2PX:!RK)HL *P6C+7K>,B?(Y>XD11%0Y>Z*(G3V=UU/&D[6V
M&(/!^0"<LZZ'JZQR2)2:5SG$S"4Z62,/9ZA4ULV+<J??%7E13VY09.82"S.V
MIP;F$?F<Y7A>"1'%[3E!AT8!T27CJ"Y_R4A-VO1&!<G#[+AB>44*K\&P7ENL
M%QGNUK9CS^4UJEF[Q)Y<9V;ZL-,YMZ$+2\IX62NR=H2!LN:@;) L8OJ.4HSE
M$WQ9&^T*"#ZUWH*//F_X AXV?0_,/LD^R3[)*O@R:,1OCHO_:7.3E>LB>_+!
M^2Z^F&40[;CI+"NC JP.!D*1@%J)>9CZ65:G6>_I"&%9.PJOP5!;!]2R4V*G
M=*%3RN5:'YDY,?+GR+UU%DL7S9'MF6]H:$^<!0(?.[18;D.#Y07LE>"6 WOZ
MLK%>!FOCY1'YH]F+\3/- 8>5Q\E>F>9 C99K,,@GHDF7@KQ6"\C3YPU2X6'6
ML'C#L:\GAC<G_$!JI(!5G!EXFE.T,-P?'IM6<M:0?OT$+6OH;O@U&HG:7.9!
M8@S&MGFP4>W>BS/ E( K&M:384Z']JVQ-'W#(B9$[A243KKYU.0ZX^9P6R/1
MU3B9R$ZI#J=$RS4:B98R'<KJ-$:O+AJ#/G^/"A^R8)9R:KY=A#GNS#=SBNRI
MQRTQAKFKOQWBEB?DDJ$8NUPC;C5&2P=F:JQO%UWJ%CNQP#UKEA#6+"$)G;YP
M(R6C*MP2N1R9[[$IZ"'T8XE4%E-L1[*#78.AMGZH;>0I%:S[WU:5:_T8TYF@
M(O.:DY((-;""HA3O"V= 8NS.E -U:"E8=5^1V)%J(';H<S:I<&!I3H)F&91Y
MAR9H,<:>H5S>J,QD&TA[1F6JZAE'94IRZ:,RJVG7:M<$E\1<9AHFN$A*_4=E
MYA4L+$M!X368Y-@O.:@<LBNIG;Z(=8R8LOZ4R8Y+YZ&;Q"OYO+/$7%FJ)F)*
M7:QO95[2BNP,9J"E'[2Y,)N8XGJF:9>2UNG7>71?+1F!EFLPAMS/D(DYM%3H
M#KW3[PJ\KC"69;%*:HIM+M&P4=ZTS>3PU[9.VZQF2'/])S(5RB12,O6K;DE&
M6J[!L-Y<K+?M;'-%4;J)<?.E3Y:3>IV^V.-5K<@B2 :].D"O36*%EFNT#6/Y
MQ%OU$X-EH>;BC3[/E@IOF>;*GO,/T#M.#>H$!1MQP!I%V348:NN*6G9*[)1J
M86-G'4Y_MKEB,FPC31;$YJZ[H!%OM%R#X3ZS;WD^W$NTXYX^OY *7[/58Q"Z
M58Q!D&4R!B&YW9V-0;ALRKA^2H%UF#;\&@RU=4!M(T^I8*ZVFGYDF>Q %%):
MQ2CJ1V9 :C:[TW*-1J*EH)];D=A1:R!VZ',VJ7!@:4Z6GC(&061C$ J-0>C*
M9QR#('?9& 3Z6FNV(4!+:XVLL3$(K<Y;T'(-)CGV2XXC"P@N)#ET-@:!WAQ[
MDW@EGW>6F#9$U1@$N=?I=Q5>5WIL# (#[1JTB4$W%8,V@4M%Z/13LH,-QR0M
MUV@9;^1BC<18&QK$N (553U>DI-BG-D^+&S8OHD$; 8!+04EC6IN8PV4[;T&
MPWISL=ZVL\WG#2:FXI7>I*O B'V1%]3D1*UZ-.DRZ#&Q0N\UVH:Q?.(M,6.P
M?/$FUUR\T>?+4N$?TUQ6PV80L!D$M&GQROO7ZA]ZI^4:#+5U0"T[)79*-5A
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M-%.GAW61<J,?L$ASS%?CRS?0L[YW*09Z5X *%N5&VD^.DZVN8,2% :\[+9%
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M@?1*EN_"5ME"[UX%-*Y(DA1WIKNO<+U\; /*FL;F^07_T=E#_?*.N38U;.M
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M2!)BJ#A5-C6U(<C-(F8MD\WSY<;A/-+2 *!@$$A:H^T.1 !D9FV X00YDI$
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M&ONO4==F&COF+*V5=YSO(.:7[S@C-XKS$>=%W3/<V*]F?-@:@BK=EKM#GIH
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M(E?M6H8M1,.PTSITRR'%$7^D> [.W#O[A9A^K[ /K&#XX\$)Q74GDLR)"!3
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MFTN*KDJJMMS81#TDSL";GA]_Y-PU-EQJ\WN$EN^)^8B<=(=ONY.HU5\KI@Z
ML-R%KAC*>%I\R]?BQ^G.P<*W0O$X9B.=5F/2:L;DVYQ]=/L4I7J"6?!TMOV8
M1=C=5P2SZ+3W9!;[;B61670:DTZS%\U7%<Q", O!+/:@T$'AO**[)Z_8<R>)
MK*)'646T\(,/5B'<.A5Z\AS<.I28+&EC$572='3LK#=8F8\MY'Q_CW#TB#6$
MH^<TCA[OX&>6\DMYCK7#$7%S^W5;4_B3KD[4*9Q2>2:WF]6,F'<+1W5A_.YN
M8ULVP!Q@E2T.&E P^L?;<V2SCM:3<\>T3PK<(OPOFL7,45HS1S:06*/$-00C
MBQ@^)^!CPZ-MN2 V-JH(&Q,V7H6>+"19J JZM%BCOFO4RTXJJ!ZL M[J@GI-
M<NFMYJ>VJS,^L+:+/Q-'('V5D/[TU5C=E,E:%:K&$H0H"+%6]5/==@'U4_Q1
M!2]K".JL+W667_'4[110\22Z?NPQXA>CT"9Y(;JEO1+IPS+8V=M18_ NX8>Z
M--^8)M'G[Y)MPGN7M)6BI*A_;2Q[172;#4.3C 7VWJMM"_ B^EGEFQ)\&;RB
M0&]+=BN7SJ4\X9VPET]U]<F_H:EW06#7WRV>E%]Q!-AM3+I15V\M6KC6$^.*
MGRM< IYEMYI2IEF))M<UPL1,XXA/BHG]<\!$7M:H)T64HUX?3QD8\*,,G$.\
M)72G>T5>G"X/[!2?N@!KU=C,EH1U>CC/#B5%@H87=G/42$\,JW&9!OQKN4'P
MW!LF92NV;6JSC:T 8)^,I-;Y44:#/8UB,DQRV_Q%7#+G[FU!XN=,XH5:>X43
M=G;ENAYSE 37$5SG'+A.24&\4OE/AF##N+A(8 U8 "]K"%8D6-&Q(Y8GYD2]
M%N5$@]:HVIR(.FE^HZ"!/U7M=?)/^A]V@IGYFZ?<>5^ZYUDIYK.FTXT-*#LX
MA?JG-U=-Z4+2#5M:$06+WQ>;97C+>#]XXYJ^4?PJB/ G\<=J=[QS98=%]A\Y
M!^GUX:1KP])P*Y],@NZ^5_+Y35/M%P #M2$"OW+0I.7_1)D!4FSLY)]L[2XZ
M$N9$E_?UHMT?;%U6X+\O7L'!6GDF%S.3*#\OE 7L]Y.R?%/>K<9OX6/"&8,P
MW09'XB$7BW(."6]FL 8^8K#YA9^ _(F)3\&>%&[V(KV8R'__2UMT%O,.Z%?#
MQ6C6ZR_FH_F\/>BKBW%WT9V1]OQ_AXW)$W(+3!; ^8R8/?#/WY13V8#T<J4X
M'-JB<8=Q]T?=B_:(21WXBJA3V_O8Z?H5^ZO6Q3CF1ZT+G!(9Q,$ ::&[7EN\
MG\HS?7?[>/?MYFKZ='TE/3[!']^O;Y^DNZ_2W?WUP_3I!KZ7IK=7TN7=]_N'
MZW]=WS[>_'$M?;M[?$QD6-P<[L.-+MDOQ@;64"W$Q!_-QR9(S>52,2U9(K_F
M!$4E5M31HG&O.X.D*K;R,=\!J7#TN2^5QG-\U=HBG]R_?';+IC2=;I?^Z+/#
M>!V6C3QI2QC3%[*O?7;5;#&6Y<1.G#<[7S?I5UNJ!?MN/&J.6\E?MYKM?X3$
M?J2@JYM6SQ524A(TD6B]342U2):8E8%S9]P$#ID)SGF6;;>;P^%HKV73O^N5
ML=ENL]?K5V6SG69KM.^&Q&9W;38;&NP(!^_.-QCFXT69YQ^N-%5=DA-)LG\3
MQ90(Z&&J=$7F!$O!I6Y;ECJM3BMD1Q8/OMT6)3>S(^-A=V\24&:)91FF].%N
MICQK'PL%643X51YB4TMZ(&O#3&N@<]8 >B#SI6)9V@(VA/J_@%(\E"Q;L0GF
M(DE^6E(D]44 :QM8#V1!,,LK>9K]68.*LB<*+34/(Z]8)EGRY B3O!)]0Z0]
M'<AG'4&I=HPD5XBDUTE/$GE@:/35-%;HH<,U_]3LETO@T\:*F->_G/#(U+)
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MKICO-S996< "\/VF02<:N 'PW/3?;4S:/;D3,ZJF%NW<JHZ71TE8.Q(VINO
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MA_R]T=88O!-^G&+22A#(=_HC8/S=XM[$/'[[_7ZIZ/:U"^DX@N@W)OT.1Q:
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M$,*X,1G(HU:4$$0:NZ#*LZ/*?((J:WK-WN39AL,V)AVY.VSQ(:AJ9?S%HT#
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M_9ARL\(!;ZSP+%PE"X)%?I*6TC6YWIIS2>D,+F2]EHZTMM(B7XA.%EK>KDY
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M&"+C&(VB^8"<A2M$O%!08(9#%^I-RT-W,:0UBD\5<*_E!.K,?@52E2!LD:K
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MVW2OBMWC[68%"\VW\6E;^7R$LV@+N K=GC+?'YSXWEAJ<XU83_##+TMC_C.
M+SV&H@!VHDYM]T-<F !VK6%IV]R0DP!AZ\):31KF>OSQ_?OTX=_2W5?I\>;W
MVYNO-Y?3VR=I>GEY]^.6>OSO[[[=7-Y</WJX'H*@BRBYP HT28MU*&I2<+['
M ;,?@=H65@?@CB^)@SP(I$.1^$0H>V]J^EQ;+V%%T)!#("NE4BNRK:12+2K>
MGUX(=8>O8 OOV&AO[FV0J.X,,M#T+1L^6&&EF@3'66Y4(MG.3ZDG'8[V)W!K
MHL\5RZ;^= T^#2UF;6:6IFJ*"337E/#%E^RUP<<L"=Y!ISZ@H_[M19N_T!>Y
MC[XHEJ1(*^4OP]3L=^G50$J&1UE0.[PL66HK.(!-UX('G%.BE:);C/];KNN?
MG0)>.0]>4'@]BZP5$Y9;ODMK>!L%QIMFO\"OR-\;W Z@,FXV=.R9L@08$LEZ
M(01^@-\;;SHQK1=M[6T<]F$S\4;C$;8AP:LH%/ %$I D-;6,Y3)X7+KA '3^
M3PK$97K2N"/HQ,8[Q?*$[4U8&P"_NY.XPP70 C# 6!-3\<&*\#;)"]$M[95(
M2\.R/.Z=)N^"3"E \@[V]OI([H:EX0\^F60)OWPEG]\TU7X!W*>J1^!73.9^
M:OD_46:P_8V=_)-MWA+QT97.2.(I]NM%NS_> F#@OR]>_L-:>287,Y,H/R^4
M!>SWD[)\4]ZMQF_A8\(9@S#=!D?B(1>+<@X);V:P!D7.8'CT"50O8N)3L">%
MF[U(+R9*Q/_:K8,-&Y,G2DR,]=M(*?_\32FG1C?3L1H3*0Z'4B1R)UXB=RLK
MD:^!N3PC'_W=--Z NSK<DP-I_$B8L=1N=3[,/GYH?Z1.-6"Z_[-9K8'7FK9T
MMS&E+QL+5K LZ1$_VJPM:3JW\=%.J]V1/N /<,%.Z_/_W'UYQ"_I/]N?/TKD
M%UFM@5L3%P;/# 9,-B*;7YC&2IH1_,Y$L68"FP=1@ ^ U&#B" YMF/#UJV:%
MM 3%4ZY1,NBJ8JJ6A!\L0=QHKR K B^"?2H@>4 RV2^&A?H$_/-% 5&A&_@7
MD,OPBF?-LAD!^L(&C<6E@ALCM-LWBA=*G116 ,2-R50(!RSM<;<+\@^D$OP:
MQZL&011^W 64C =4#6<KL+XBP2LM*N8L_Q=L?P2WXF_ ;4<>>'TO^/J/$NP]
M$;BX0BX ,R7%O6EWAJS%X FH''_5H'7A=TL '^[  "O6V-@NO@&I,DA178D*
M3J>MER?9@_MUSL(4 ?;>-3Y@(P#UBV1D UU#HJH5*AIT,_BFP'XTT'%,@(,Q
M1S8:UL=0%Z2_@7WB/86/P99,/(?L*)<K E^P/;^!JB(I'F#INRT+N%[@+F1'
MMZ4O5S5 /Q,1$H\+YB5=GZFQ"_C->C.#3_'7$>R7@WH;0X[$FY+I52DJ'BX&
M.[S]*NQK&QA3#+GM_/V6<L8[;X]GI$\O<&LKY1W^]],YO:E93G3"ASCEM\//
M5@9SAR*Y OCU0KP;]2P)QL$ HAK].H7:="/U:X?Y68C!B' ,AY'//^\B2,1"
M;;Y9VGBIV@H474M#E6-&YLK&(N[)UP9J'W@X%VWGH6RH+:8-F)&,$#D08/+/
MF?G;)+Q2+B?##XO<+:YAR1725<"M,(BX%:(HZZC__&!M1"-I=P!K?[!K\DYY
M(E6$[B7@& #KC9J+FD\_6=P#^! Z:-$BIM3SH_G8E'Z?3N]=08$DJH.50H4Y
ML&U*K,0]/;/)@?."ID*-2291J*AG7H<5,]=A>X:)&]%B3-/8S;G6ON?N +I&
M;P0(S@T\"3L#.D*NL%FJ#ITPA8BI*-X6FU+ I9BR<[ 3' 'E;#'-HR(S<6@R
M!0B=%S95#V1DU034;_AS;L!K<6U96BB:*;TJRPW%'7@KNA>4N:-5X$Z6FC+3
MEDQ3H;MB^YBYZB/ 888.$MRJ#!LRYC\O9@K*!(00V.T*>Q.NA2]BF* LE\8;
M=6F@C%,)P(BJ,<HO9Q-A*8T+6M0;Y(,)5@$^;1LF>L=I>J:I(3^*OWF0MC.R
MU  &EJ,Y*<#16>*F+_*:TM6&.BWP TU_88)Y ZN:MJ+I@(N:_FHL7QD, ./P
M^H/OPG=[6P292W4XAL^:.=^LD#DBRV3(P5"%\<\0[C"LP<7C$,=QPZ!N$F3#
M;,T9D? A$]'#.4BJO-IR+3'-K%#O3- 7D]<UC,X2]L('S?IY"3BBV?BW  L?
MQIF6PQ@W.^_*2$(#W2 0F/N70D%",'!@;G[UF)&F@Y6U">COUF;VE\MN74JF
MALKVB>;L1*!D_:3(!V2-RB?<$FR;/J!8+PSA\"_$;WD6=KT":R/P343)7R'M
MPO\8"Z%K.&@?3N5^(4A [\PU#(_H/]D+%J$S:O:&[7P)!@62B+]5AT%36>52
M$MA1IL6HE1X0(( TJND8: 09@%_@JX +4O^B8SU3#1P)&/]$972&"AP\X5A[
M 9"A[_C7G###$M__E< [8;=7;$7I1K<V)J7R2\-<.[XH/(OS*143-5'=H^PN
M!CT"5P;RGSFQ/8U !1% KT!%MP&ZL@W3X;GVBV:J%^C,?H?;1[-=FUM!@TP%
MN3FW85EJX>G>/^EZ#*U, JBX).Z2]!L,$*_!,#!!8%!UW3"?8<7_*&%$ TWT
M!:\-4(K^%C1\^G</YT)(#S+[F04N$.E]?+$0Q8&/4_4*WZ4_&S1JPQXAGI2F
M^$1_#'=J ,NV')@&" (P7-4<X<\4,[J4\P,P&%\IAJV5=U^S8\(T+!'#>W\F
M.B(P $XUX "HRCA:'V8\+%&^(>W4 6.G%,I7@)JK&3%9*D&W+4N=5J<C?0#N
M@(0-:,/&UWT$F__-8)?MW8J+X:BPPI.)61/Z!E\1S24;!S,G.CNE,.P$/P#5
MN^WE2:"#UY/(H\:DWXID2?R#HFS>S?5;!6\.D\>C=:?_H.IOE%$@4EMKYAY<
MOH..GWQ;;>G#/5 0B=S7BTE(L3?6;Q<+E&&K,>E%IS7\0\Z_LT[!.VO#=?7B
M=K87,G4+WET'=A>'Z=F0J0[LZVICNNXEQY5$!=K_;(!W=T8.&P-])0>#,W0B
M@:FJPF>HUA#T6+5;%*A@?<%]&.:[*RM1<"1M0=$W"CS9]C>!NV(;Z S=#:30
M+-N$==@N#@!$4&]VWZ2BF]@T?E%+$);.30*]@DF@VYATAO$DX,.)@L*_UY+N
MK 1H]0N&5@^@U2V$T0X*WED?6%FT#_2^C'98\.X&\;L+85F8O<JNZR1 R2&\
M>R<*,!CJ#\\GST'_RL49;O1T]: $M!T5#/XAZ ?]HC2Z@M7-(9;)QB@O&7##
MO\D=;JO#97-B;L0P/EMQ2+,5JV*0I/BA%HN2]RN=T@GF,H*0/G^VT,C+"@8%
M&W=#-.Z*XE.#@HVL42M!PG*!+M$TRE,A4!*;!'X8YN%!(\MIPK&7@1ZP-PXS
MRP<%&[\C,'X[,<9O[,FC-R@=$#!W1HUL#1A)3,\?=>H2;7$##?0O@:-S$&G9
MSG9G@847>!!4Q*4&>U6IPF/9H:03^$RC*1N@3&YHPCN-$J!:O()7OUB8\K'$
MZ &+3"3&6@H-[<7B5V3432S^!="N&Z,ZC;JUB?WY\*#XR!<.>O$5T]\E11DO
MHF))BXVNNHEQQ,E)4*@"2;.+D,DZKGZT?3"XQ9;0P:IB@1@6+[1-)T!.(U4L
M.)'*ZW<Z5/Q@.+Q/9F]-Q^_X,CI16. 5%@Q:HK" @[V<5V%!G 2 CWLINB03
M$'%RHPH%@O'D%Q#3S&.WS93=-!^XZO_.4U8=KJKNGV!>W2 @[WL8;VE&C2@)
M0+JDZ?TOQIN>H<J,PF2Q--XL-^&$J$7#)GSN_(=%CVPS:LTR.><>&/:\?=5X
M_47?<507F]J7BFEB_N,?F#Z8_WB#QF34C$8.(L=+UD=IRD 2HGM:B/N%1O/R
ME5?8L>>O\3)^E$#.CY=NL9W-XU5%^#D(5(69.TDUQ$VAF-/T9V.&:0Z$KH_K
M!(U/_!E-9URME\8[V<Y_T*Q0:<>+L52=&HGP89T=XJX]A6;KB$WIJX')EJ[;
MFR9W.LG? -WOVO)GV E-BV:P5(#E=< 9<R%3>]"-1R?:B,&M.KKTLT8?6#[J
M?XAZ@ZT!M(6&,FE*LT"G3B8JH-\W/P]URM)0#Z4O$'^M9K2;@\=+ +C;\*;H
MPNRJ^*0P+,+8P@X%C"L%%%LGO8M=M/,/=M&H)0<S48FNNIE<[*>PDUOCE6JY
MH-QV6[*+BBK3K?$2_4P9E2P4FLFO4Q1C2[@).-M1YU2MMD(",$W:=U*=VO%N
MH5VV0FD"=\25P,782K<9]4%Y1 +X?E29NP,\A_*$,?*$:&M)[[@'R]H,UUN\
MK!U3U_,.7I?F]]GA6CQ15<^-&]U+]$N.4SU!7+"S>,^/>S3M9'4\N[P^(('4
MS=QFU13L'ZZJX^?(NJX;+-79+-"'8Z+/\H-3-GOY_<[ZB %R[[!>^C?P!1"P
MFO4"BSX;A@I<]LTP?UZ .(*7T61G?P=,-UL9CK[B?B&SRA:OJ!%8#PA0Y$2&
M10O=L&N%2>"^_T/%+ZN#\>OEO*)(^OR*V"]^R6<@0&^YU1OXF 7D#;)_114_
MY(]P#-/"OD>R\S<LRW,!\/7FZYU75CU3X.0T78 ._:7)WP"\GX&L@K\WBM/9
M)*RS;; \1L%4FC6A6_%_8KT#GUTU0?N,  BUC_D+R'BW@)C!G8(;)VB'JT%I
MKH[_0VP]LF8_C!653JKC8?5_H9Y1@991<:R#-\+>F:!.2S51O6+5F($[4UA!
M\[,&'SCY4>CMA$NV:+4;S6R(^=V6V>!A8N 1K^X!S(.-T\4%7L=><@&:IT^.
MSGJN=LY*FT.6 J"(!<AA.]WO9T2AE0XS)!P,.>#:RZ6KR[+<<Z8KO3$+:>&W
ML:&(O]INK</0G'ZR8+3KOV[WFI0WJ2"N6?;\>]"5#'O#8"*8&ZBH(#)3L@>
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M@L\.MW]D?MN^;G_T[7NLN]UJ-2;=B(;I^/\/P= %_;]*W<#7C0FZP<;!S 7
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M"Q1N:_GW>I%8'D Y;"Z@SB2*[,25SN)T<)]'_3,DB05/@J"U0+9R#JIXLWR
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M WY=J/B7B%'#*6 &B,#HYQI0IK_*6'\C*#=HVJ#2PE4'A/&G?'L63%T9@*<
M_=S%:/@3KT94B*BIT9*,>4VY$-Y!V0I%HBW#@Q+<0ZI3.D1)L'95F8=!P_C7
M,O+BL3=*!LNLN^C>U8YO7_]@IZR!NLDB!=V'/;#(SE1 Z_%)3X0Q,R\YZBV_
MXZ6- F*+PB-LUGD88Y5_Y 6(-O[F"K_T0C')MMJQ4D 3TNFG^?P2T5$$+U$$
M>MJN!NAIYL :]0Z>QKL_;S]]^7!["X;"'^\^?;G^\>GKE]M5$*@;;J7B5@/M
M4VXU\#6P_K$$N>#T"G)>D$V7,XX"Z)%L\T3>5]ZGQ>44EKP3;(X--GL4+UU>
M^@/KN@:YR@.G*&F_^2[)TS]8=(]2FUZA_"]"^#5M%,$\W0'ODV1FML#F$8_?
M+N_HGJQC_Y\;]PEVQ?H4^^0Z8+_8C'(@1D)^R0RW.X5ORAV'L#I1!O\X#7W_
MZ0KA]L8$34@HG$\9[$:9E)+,(:FVH&H7FN$K+<*5FK/:C_136/MO$\Q0;@=%
M1<LW,%6GF(N7[.BNV_=?H3\>A5;3^LSWQ-82 $<J*Q)4T3EJHRI'FE>0/9+@
M_P?<\.Q);8884<XQ4GESO'IXU6;:*T$QPWO>^HNH*SNZG=I>]7&<;*G,[)G1
MSM","<))?XYC.O$OI _C-D$11I\9MXBYGG3+&UK")#_?$-4AO\+]K/8O*846
M.VG+!AF>R*=QX9*D3H(:5B@?7*38ZA-+S9A30N'$U(;G5KB2?&2\E6H!4_N-
M0Q03K:U';G\DB9;)-]16GH5W^)O&BNMV181F$HV/LF?%>:8>6BD8DG1$7($Z
MST3,8$.5>^%\E.ZE<(.X2?$AQ7(DEI_B;IY*)ANQ:J\;8>;O6"BB?%#0#AXX
M"C3/WE"B,\W@*;RSZT5^$])KM<D!%2X7%-ZEX$BV\_1$WBYKP04D=GL>9*!3
MV"@^@5^>@:2D?N$@A+Y&E!\TQIYG+!FR $-L4!N"MI''R@ +02+GODH=RHA>
M)%:ESH8B:2,TCWP11V._>*M&7D""E^MJ)#4:*[_B[@8D-5HM3V1[3U ]'(:?
M%ALG!9Q?)UJ=Y*W"]4XW* B6LZMQ2.X+?&'17G4:M:'3MYU6SP85/;]C-PB/
M8UT7G;R>URAN2IY9*(.,W*->'GEB0[.,%3M$9'&@#=+ *SK-VK#5[M3;J]$K
MSE&@KK^B-@A6>EB_A7*7GQIRA73%[R?Z0Q+Y5KB]J;N8Q-1$Y!;QLBXD0OH.
M3R.>RH:BNS%MOV),"_8-J)/-1MMVG$Z>,%71B-#<$*(:UTB>@A6:G12(VI_A
MTS_QJ42'\7;9O$'%-J^U?O.XQ'N7E7C2;8<.)/C^%7JKPAE8] \AQZ==(Q</
M)!C[C4H)QG9MV'2::V!]UD7=G59SXCRG0,N)'$T>28)^V<CZ!XQ2Y]F-)TH5
M$J$U93X9RJXN_SC0\Q@D,\48A&1.%XARVV1M0NVSGPBLBTKP* \X295DOU@T
M\DBCE8*Z>!W:5KWDP9%V7U8(]ILKA. C+$K7<S7>3%CV.WITRB+I=CK%2+KZ
M/A9K=[+Z]V7)150Q1CSTK^Q?!-=1O=FO9[P>%%GF.R-W]7C5!:>4EY?E>D(D
M5(X\C46+\CU?] "T?<1Z26J9<>_RI$(.OR+$ZY_SJQOIM,"\^!'&%/"^!/M)
M9(4HI4RV5Y"68X+BK<NWXB.45["WSL;5'IW[H[/0S3\%:\#JM?4^$N ]T+BL
M><W4W*FD59EAZO%. [PRX/;##>9:41/78%'/'@\9PUN,CIJ2"&J)(;Q8]9F5
MP*X:0*]H_X&J^7P9S4/1XZ6P,#FWU@3<?^UZDQJ9I+.YX+JD'\ $Y&,8Q6]V
MHYA.NRKQJ#6=+5X2$"G#8"W<"0QC\B8Z&<ZES"'NUH[NL:^.4+)5GQV%5H:<
MD'C'WVYS>"US=H<ZN\B#344,:#S$-2&$SR$\_ .8U;H1J-&?/]^DO *W<PQ!
M1VE_/W5FG4PH)X 2S&8H]H00(0 9 6U*06X1#).AA<=IR,M18,D/3%:>W(58
MI@*/\,LCS)'>*RX5HADN2"Z+"[+D_2O5/SGJ!D]G5@&4[1.^R#>\E[,KK?5U
M5VA]<F9V(M+W64_?.<!ZBCJHZFLI[J":'-UK"I(8GC\6SR=LHG*75;W[3&N\
M \8FV76B4XKVIRC$DGU9YP:W_>)*CUFKT!PH>CXP8T8'T09:,'>F6)VK"#SN
M0M>"*)S5V#J9#3YY'FKA#'0QE(S^4QIE?VU(1P0\W(C:H2T7,M&*-Y$3LI5_
MZ68*YY*HG3#Z#1N[$7#XSU0L//O$>ZV]7]WZF.JXM.I[]NKW)IHJU_*DD: F
MHUQSF"7%LP16"C3>YS4OSEJZ.&ME/6M_> '=-;+1Y5?9^>\;BS ;&*CRW5.Z
MHR+_BA)K5XXFU_JUH=.NYWV/JL_=9*GZMJ8-6C!I5H9DW+@PL)DF@+KU+4\J
MJXX#]/0KS/X3%>62;0M/B>R#DO[,',0X5H3 3]GMYXF46%O],0IG-YP><(\5
MK,4[*E53+;Q9_.$7F#%RASYA?4;Z>.1)%GHV![5AOP!J7_HU-T0[\^OL5'.=
MW49MV*KW5OMO43247&JN8WQ%EMH$EJNW5B]574F\4)KB3*I &KDEE955U"C]
M-><9S"/-H)0EC=:+'E,I &N>+.S,_MK6FJ#Z3QM3-$T51:J*HM<P5105F,LE
M55%@8FIAOFKK9/-532N.9VG%T9.M.)H]TXLCB_;% 38Q,/"D1W4KTY^#,)#T
M,A?ZYSXD&RC7#GNE1IUN58LU (69B^?1!TQ'\A(Z6-*M(N:.O+L4KH6L'5(%
M_^*Q5+]7?0R7 A@R9%"W,OM6KDGW:,K&2Y]A0U8YHT_H-*)VAASQY%HD+5T'
M8PWN!/X&KQC33590T-%U3J<QZ$K&+2Z)R3AS5 H8&*0C9EWSZF^4F+O3,ZQ5
ME-A+C17KW*Y@S;X[C]D;^</;L1?/???IC1?0/.FAMV)XH>:B'D>A># FQ([2
MYO(_"Q5OT*VWNBW4\A81_'\L7RP4P#HI@+\MQOF_=;KU;J.]\L^->G/EW]8-
MVW3JG=Y@IV'7_ZWM],UD^\Y6P_Y&Q, ) D@.J9F<2LJF(+)]X\Q_6<TTSR(E
M9ZF.$]P+L/&*Q"H*1X?+&,MY5 J5W)-RR^4VX+$7O%E*E5A5 ]=4.Z,-0.',
M,38O>1=^A, /J0W8P-1W[NCG?12"MG\EYC@:,0:&1L6X??.J,S?SFRW(8./B
MMZ"/RQVC-&5-Z'\5I:SB6^,&\Y]E&A"I>5FR*K/:AG4*:_[/O9:H+XU:$E=J
M;>6B NF*GEQX[9O[1";:CU#83-(&9O'O41AOF9O>TJRH%A7MV*U!/^?R+[[;
M2O*:5?*(2LF*S"NS\L8PRODR2O_8C,*+..RN,S",8ACE=!AE<&Q&Z=2&[6[/
M;CCY>/G+,<IYV20KV@'QTH&UNJ-:NU-N[85<?^JLL4'9*H 8NM'WEB(JO#,T
MWWJ95Q'STL+K8(P_H,>T/!=U:T.GU[/[3KZ<NB07%5/RLUXWV]J!A@@W*C(O
M2H0](,)&PV[T]Q;EA@@K380;E(07)<(^Z!,@"0?-9H6(\&(\41&;<PV12D'8
MW6(GC6);.^+4^6B%1D&E'B68"'?^N]SX^.OD/>Q[><89@,7:ZMK-IE,A1?Q
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M7BP!W=%R&O-O))KU#2C:KB4CIX@%XB_'! I"7Q);XMY'C'%M^SJ6"^$#_,'
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M.,D&67R'=K=M8$W"XRIU$8I\P-I\=QZS-_*'MZ!KSGWWZ8T7T'SHH;=B>*'
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M%B1'$-SM(%9! (E:U64@)-_B"5^A+XX*3+6J<[A'79*7,#M8#*AB03B#>4^
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M\3*@&;^S/)ET9>+J@%)D01X]+W3#Q#EI+\KK!(_(N5C#3"AF1L2A4A$'LZF
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MEKE7/;6MC@=[F7LU'&_UV.+W>NJH6>Q1+7;4;<:?G?CX,QIT76)725#FHR?
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M#M"8DWLHT]_5T_BXJ/-OIMDX[A.BN"3O*1O0I6X"OQ=\SHK$92]K$_[!<0-
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M,Q;,])*TQ,5&<0L0'NB1 "T?S#\U6\<7O\-/![3$+F"?F$J'0![2MXC_D.;
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M"Z\Y-,;=1R(4\X:I:F[XFR,]_O[_:,O5;]<2DO(%W!I8NM M8)@L&R>@.S1
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M9RF^9VMY=KKH/XJC;33SJ6OF&O/P.92QK,-N.M'.CXWK?97#HC9M4&HRJ!H
M]KP!4+8JPU7J@Z:4P2!5(: V#6HUJ5]0*FW1R>"N*GK3!A5BF38J:>-F+F6/
MS5QQ3MGQ^GU0&9!GT^?5H$^]O^NW5_2I075XG$W[15WX[( >Y-[0IP;507(V
MC'I,J9?FF,[FF,XA#[8>?>K,8HN#Y,/68E"M,4;587;6.-=Q9HQX0*^I-#I4
M"5:M#K6S8=6C,,C-,9W;,9U#,JD!#:K&:3H@:-"@\J*_)C8\.">6]YKJ#!HT
MK+RPK6'1>IOAYIC.[9C.(<N4;K'PNUBES ;6!CBH:E>L[N.\A^]<S?4>3'1J
MY;<-\,-QC@(?5EP(UP 'G:P].>XQXL/W*[UK[$=C/RJJ7#R:$>3#JBL7:P8<
MA)O"L]%-3^..YW%""3TMF/0JM*JD<;4JS37=EEZHYW\%81>%"1B((;J0ANSB
M2,^\)T::45V?-+>M9=@*+[E6 =)K#''H?V_C/BG]O;I/A:T$].8GS66?@4CQ
MZ0Q1-ZH/[-]O]_LI[B>8)B<"X.1(('#;T:&G]O9#B-N_/=U]NS,=U_8HH_D
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M=)-R?V_*H[N@Z89\!>E&6^$SMN^,J4]GT1^HPJ(3'H*M?F5+T'/FS*/)-==
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M"='">T7,P!].-,=Y0S+3B*[IEP(AD/=&Z0U!/@7.:$T,N*F0M\]]![@>XS_
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MKJX:%2@Y9@2&>1EYYJ$ .>+/.. 4O/2S?UUT)'W>)&Z['"<VR4_ZZ!RG]P+
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M\FP'B_!@B1=6Z?U;DP0!; O339-"TKW6QI&Q2NL_7G0MRO<CZ)J"D8W:</-
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M:QI^*L(NX?B]R@@H#\=/;\C[:'N)H7ZB+>\FEL">SCI-A]!.F_$XMKN&#,!
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M(T]^B*LGFL6^/RCBU]8YZ^"5W%]>CQXOORIWH_O'?RN/]Z.;A]'%X]7MS4.
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M+'9CZ)+%CPO?5N]=;XMFE#7JQ;@+8>MW4M\YJH:J@L*F4X 1.LH%\B=LEZ4
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M7B.8P9FF.U)DFK:&3F:*/*6KAYCCHIG*6.ITDU"G(P4063%7\,X9:#AORK\
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MLB[,@TQTN*#>LMP'&1C4X<\$PY:%@$\@/VR'YD)&A[UQ,15IC!&XH!=2MU>
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ME0:AK%PO>!0+>Q+/-N<_\>E%29[$48Z>'Q0*O<N?O!0DMM'8C+!8ZE-(\@7
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M(GF.E,J8E>M(7U+"8Y7?>.AI9@$3*F^J6>5KJZ+BE=51V.IH;]GJJ*+=JR'
M V\OH(I6 29O4A$;:E*%O]<F"0'=7SEL1Y8>'Q<3C(HI2BV=VK#?5P?-C:FE
M"C(5PHU[YC+-P38.0"61(0)KD<BJ O&P242"%(CC:PC0M2FC6QN"&!E48N1]
M,0)]->AKPBZIAD/>">$F>C5,LY(@ZRM5 H17 6 1U,7IHE<;=ON@7W4JB?&N
MN'"5:."CHI>N$A=KTX.$Y]H"H@^$H#9;92KE. 8!<1%THLKJ0J6\:HZ#/6A,
M0QN+>;5')CA.-J,4[$<,?R5)YAL _%\([Y&.80V4(;?3/SBPUY DF. &&M9B
M$NZ"([*2(=M!BUOJ\!?TD3OAX9Q/QRA*-J20.&$07&]L*VCI=T6 30YPC2!_
MOUX;]@;]#5"_$AL%U:<EX<RB/.<X$V6*'?Z@64"&D.2()E,.^/A<'R!R&\Q2
M/B?DX\\](NI=_O0<3<[TN/+8S 5>@J]W;/+Z256UL(CM8XI;LZNVNHM::F$A
M^P[I-P<N?K'Q /*?-1.?1)Y""R"LVSYF/1#TCY,1;1,TQ\BFPLRHXEREB5RE
MKG922E,*ZR_;N, JY2\GY4^W&9^<)7/_XFE_CFRZS"(MEQ<R_JCOO*)KGA:T
MA':X"D6]J*-S<,2<+C$UF^EGRL@TLQH,RO;2D<DQP7>FC< U<-:7;'L/[^-[
MU64GZM_/'A*)@^D]75<<>-5OU]9)0ROSP*O&8+V)5WA58+T0#$>6?CF;F_8;
M8^?,8L X[DS84DKF9+^3,O^IWRGAZ*L.GWQU^?WN^O;?EY?*^>7-Y;>K1^7N
M>G2SWO0K.N8AL QWCNFQ#G8/?6#$U[E+LUUOG/SXQ/]VF&<X?!35''"!#S\'
M?$& X <\/90)K'&C]!I0_>\6S:/XOP 2W9Z=*5]]1_:&WS2G5%U<18/[<MZ4
M!JZ#2_(UFCVY1G1Z5;"*W.H;TQR<NZS#?E,WT:!'X8]ZVDI@<J:Q/]+QC;%/
M9H%LLDK@? 7^6FPJ<$+R+PP%_@ID:S'](O)*)&*L6,7TZ2<+D&7%*M7($.%^
MMS:LGRVZ\.008;7@(3H?<H@>'B)[WGK10W0_Y!!]/,1BN#H\!")HL8/T/N0@
M SS(8G@Q/ BH%G/D2R_,?-NJ].\=G/1OUM><=QD,D.7S8U-$_2!MRN6@C%,N
MA:A_^/W\X?)_?L<YEY?_@G\^*.O)^4'ZE,M!R:=<%DP-?_#@MD^Y)3")Z(*'
M,&OER@K4 9#8+36G._YTNN.]?.BHL^A\S"<,X]%X,$5[>G+8$PT?FN8,R'P&
M@\Q-"HU.L[-D!.4#_NX<$2MF8V 8D0\W/7\+'[G3WO"CT:OFZ)=_^8;W=F6Y
MP%>HD(OB+H_/FG4[)Q7J5XI$7EE<Z5I-\D0F6@Y ?6^JS4%=!:@ORA\7*0)K
MI5X]-'FQJ@&CS1IN+6^XR6&CT GBD)@X]/#KE4(WY8IQ*Y]0[X_Z&PAG"(5(
MWYTPQ]/@D3\T$T3E1,/T%FDRJ'S$MZ+-<)",XL_Q!YG(:-%<TR7(V)2H^ KO
MVR$>?M=^&C-_-A*>%?T16"/S:#&T>5S SPD-;Q4X"((C1,(F2NU%]/N[]*%X
MM%@,DM*%$TSSFCLVD/-,#BK')P.?SHRQZ @NH4DMV"96V"67-,?+\ZO'KR/Q
M]K#X#PVCA%TD&\=W^,CC$"F49PW8"V<TZ$Q*#A++54X!9@3 5:_XO;G-'T04
MH Z\,$=[8O3E5SACD#21RG%:M6'_K+\8!Q:3<F$+. U7R57>" +O=>A;WW,]
MV!Q@4.+$]VP&I R?RTZ&OF8^,F>6,EA8]YU@L'  BG9M: -S081**F3*',N%
M7YA+B/O,!UI*Z]Y&OD(3T4@> 9(!-H\9LSAG9LG*XFKH4QX[QZ%/S03 JJ%/
M'[&7(QKZ1*93JD75.B"+ZAH#&CB#7KD*E,<3H3E=/UX%*M,HIE#NN9WU71,V
M%K%H.*;4!<C#.;-U8VIPO>550X D^U+@7&.#^T=1Y9BA(.##25!"INN-?)"M
M!T*+>UV?#395+G^RB4\POYU.#5 \@_G-@9,WZT'\GG_W*U?^(RN$.SA3SJ6*
M13-2@RE;("\]QEMIS!TV!R%%0YJCME>BE4*Z/M7D,#RW 7X@Y5S2G@7XGC6/
MOM3F<T!&8@91*#[9H!QQR8C!.9*.,U#PX&0J31W%Y),G\TT-5R*G^/W#[VY@
M&,(=V;X#>R4>!3=HF"8MAX+Y;'U\+0V!/K*? -5K!M=X*.07X!"&*%2![Z1?
M4 PUSZ(R$0Z+VG8WP[HGD^J&K+#;*<$P&".<H@&"N19H@"EJ<:<V]%[M1:V8
M]L0Y@4TT2+0)#(5A$P-0 >?:A'+#^57BC&3-\83E!*8&CTS!J7'\,8]Z(Z[C
M>.6_?'@2T9JB11=P?_ 6R]"2T]W#P<RQ7Q$[BP2GD=DKYTR;/*N1Q10<B6HJ
M#VSN!=?21"L-Z)'?S<S&@#<:=;'E8<N_V=@5W%+%V8@(P30@D'"R)8)D/^<&
MI3:*N%F]U3Q3X@ZOMD0$^D$ B8678M(&OAF_",\C(._2MO%- -_)Q)_CL.*I
M-A$)]WP\(*KIP)(<&^QA> 7L)]N;]-?46\2V6 2BGC1S;A@\:5$"QP@TT>(.
MGR[8VGVUE>;M<<3"BHOP8#A&VTL#.H>WRP%N$=_LGBEIE :J)6:VX"\EOQ=(
MG$!;LFCX O)R" ,B>!3>M^.CO'%L_^DY1NW"^A87'5!(Y(8BV I:HV,SB5H:
MY76,_V03Z@:4AV/?V-@1:-7B(5#^PH#0@B/S.=61UT?> +*2+#HX%P.I":+T
M_O;W(.N#QE,N"$/\V@;YBB=X-4 H1^ 99PK%8ZF=9C\_\A4TF")&=X\\]W;Z
M.[ \W'):4&N +<?/4M!,!+6*!^<ZB=Z(6]AC'ZAA]<";$DT9,(((/Q [AK[Q
MSC2:6H 7"YR"=#) >U08(L6=[*?A>NX&VD.9-?Y'T)Q<<9<!CCZ,E*]8N(\1
MTTC_F7(??+F:C\7L7-&/2]W%H;+8LX ]O9%D0?YHP1G^PQ1= @6A-0'EW6(F
M8=4/]J8 -'X ,U #C[%4WL-E_;%KZ(;F(&^)\UU+I\FU.*B< AS*G0^[1:84
MJ"A*U(W]+X-Y0$LICP4V&MTF9W7R:6E%Q.]75>:^X_KH\40;!]VQ*KJT@2B$
MF8(N,BF0M0EY_/3@F(('!J:*?!DI*8MOHTW SQSF^8ZEICWA ".EI#J0)-X;
M6@D3.G]1SWJKGNMV/?>!\('Z1W@B[A037F_MB=U._V5[D<1V_I2#R0)I'O$!
M\,X4A_@GB6%VZ)-4&#DP0X"=HV_Y@6F@/I'74%6NKR]4+HLYOKPM&H)HHU&3
M0L[<DM#GK"\;2Q0 B8V,\,7061I2</31E+F-OAJT$9GF6' ,>#/Y8H6WWI\+
M8S+JC!>''@L +^*&'J91Y?N-6XV8\IYR99=\6RGQM"P_;K->1]V=F2_L%+#<
M>U[TY08V+N[2MA9$>U>-Z@: _R#526.BNWA%$WL,7(\74\3%T,1W\.;,2-HK
M4)XQ,>9<U=<\6H225I,@)\UFC)?_AGJ?"%[$[RU8-7P1&=6XJ,;C*,CZ^ O)
MP\7O+WY!X=6%C@I4NQ37,'$GY,A&+S=SSI0]$1 %)2-I<!= \6 ]!'2S)T?-
M/=C(14$V\7%:$]Z^$"E+7+&[\C W2^3MSM_+ZM[N1@ODP0UP3J7_@4YNNNRS
M74?>"U+55S;V/A(>JM"/E'/;<8!3.TDG[1TP1PM="]=W]-4_[[[;SI,&FDK"
M4B9GL!.H;HRK3X%?,LDYD-)"3_/(?P(>0/]!*T3-XA;GZ^FKO"(7GG'O*ZP8
M<].T5K=1EN0#ELKGB8E^$\>@X&X4$JB@W%W=72I7%KIW;>=0/*+Q2U5C;O@8
M$KI1R&B!+S-F*:1#SXV;"5*7-R0DE1/L2RP-:;X%L2#A;!SN<K&8)<&S>85V
M2"8$?1#1F_"+2/ $M$1A? @B2KY&B>Y)'G[,[83".6"MYK(<,-#R;Z>48RA]
MQI20X%ZYKL_T*RMB.A=UZS7K6/;:QB2N]$2N"Q/,*F6DR));F3D0O5D"#M]2
M> %HD(%>CWU&*$]_(M1]#S^69@!\/]D@G:75RD]G"0%WAR\*UTF!0[,V[)RE
M08#\N*"(\Y.K7+L.DOZ"=N 3QG1WZ5$6CQ O1>CFG $;L8.1Q-6!>V&:WA:_
M_6[DU*W:L%=/\;7Q>@WI<#O)H;JHJ2_L@'1"5WAJ"%I;=L+171!DS0\%&<ZE
M[B\%&2!"@!3D5(UZ51;D95@\,S%M] (2)JT"2)Z9)K*)-@-KYT/!VD&'ZE*H
M3LB8) C>V"]1 (:M^\EK,R>?&A"I#["R@6\1:%XPM)N.S1<"\%(MDQ="N7?H
MDZ3L0+*&Q:/!;F)2*;J8@DEM 7'(E0L+B*PPXN8"8FK\9/KI?YACI_+$+AH/
M63+A/"D35-E,RD7?-;?7708@XC&,N(N3$X5!&\3;A#-;+.']36,U9\H(K7]X
MG6]Z<8V$9TQ2+&V=7.Q6;PF8X3TSVR(P<_!&\ON*R]U>3HNVK>V0(T#QS>&$
MSF93K?>Z:KNQ2)2+*)%4#\3%DN(50@FU C&EN?CU]-_U>@9K7$_A':YY/0T<
M=U=OJ,UF7^VG-!9878M+OR;Z[\*G'[S7Z1MK7$WAS6V"/ U*2U?[[9[:Z2S6
M>RY>SR2=H69247J8MY5T@%;9N\NR=UM5]FX)]G)<V;N'E*;[<'DA=#,18SH$
MQ]>(<D]?#-MW,3AFN&B322U?\]$-.@%Q87@>"R*,E&B*GMDG8!8Z=W[@&K C
M>"*(4$\F6)]%!1G$_+&!#*6AAN5(R12 U-Q8F1.UV#V!A$6RQ<-BTI/,#(J'
M!,%"TJ17"]=Y <YN>9ICH)>+F=-3/O).Q&G%^<2^ 14H=VY1D3=<!:0G,,ZX
MNAY&US5%MR=40H.^M+G-+"T2M <46_0O*R,39S$]/<>6A#=-?1,V.[&#]I*1
M9)++BP"J1A1II>N<,NHI$RMZ<$SDL2VZ'RPRPA \M\#EG47.AZBA6:*GCVY,
M/)ZN*,]!85.,E)M,Y!#&]P$7AA^"K*=>B]0G) A[8R+0Q.,6J'QBIHF@JO!N
M)I%'1D\!7A:>9 :;@J5F3'-]LMB 3NBNX$_L3T"6VQS@;Z+)%E'755C*HVBN
M:<P,?G0U@IO!;_@H$TI;QY__Z5L\U L0PZ1P#FD @)'(6%?Q?'8D)SP(4]N^
MJ8O(,<(9$!H'IN@OS'&9PJ93].$BA_7"XT9W%KQ"E(FAW4CJDQTT&3S4C"J
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MO<4$4FUEU)[>ISR]*_IY?U@W[SS'DC5%J*=D?M%>BT+&DQUK7X385T>*](,
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M"*I,6]:(;-U1UO2&(6.2.V_1 "P*GF&6A'=4.(;!M<3N%6K_3!R#I-=D.O[
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M6P+K#01CZ2:/7%<E)VGI8%049\I[[E17H;N^D(!;Y0S55:W*;QA4%7!U-H'
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M0_'[QB)P#8(B>']). T'RQYWN%O;G-4N=G'#AKO4")=D%IEFO[1^AP#C%R=
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MYEY4*Q/IY/7/CGO_]:(65:%6=8.:M%!WCG7JIK)HLF^Q[\FSMA)9KPKRA<>
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MC40QN?B\W@[1\+(GQU57B&)20N1RSK/T7O;F/BDAW&C(ZBO#4@HB@/*/>&4
M:K8Z++@"7VYB*"-6B[H0S9QOJNKNO<A2.8'.8*D_*V6("2'->:2J(3W-V:T1
MIP&Q%EA-QM(G89PW;A](5M$5@IKS/E6#FK2%LHTU$F":RZ+O>_,0DV4'/X3*
M2)81$$*6<_^PM!HM1(FU*#5$R9U 68_IWR]WA@5(G(#9#9CZRU=A;2$<.3=7
M#$>S%R8Z",ENR[XSPX@ Y1KGFP(Z0G1R[JD8G90F6A-M)% \?T_]25-27PA,
MSBL5)Q)J^L3APS")5BN7A="8;A+!LXOG7XFJ$+N2A_#8X>&ZA77D3^/=]GQ\
MXD Z;]['9H!CO?.2:**:F,H1%4*:\UNED*8-(-9"HB]?UL;T"='*P5?9%JJ1
M/:%Z!%1'Q &;U \7V+#]%6W8GQF3]H>W5P>9P>+F1%*0?[I100I8\RCT$3"
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M[9X78N*9[GV )_XL?#()9EVI%M3:Y XGR_*B;%Q=7%V!<0Y?.H_8H&<M(\!
M,#6K*VDQ1S=1Z2Y7KO^"\1B[U-]%#[=!?S,>[LP08 I ?-F]HN0)=17,ZU/7
M0018#'8O"")L=R("TY?K(A:M%]SX!#MS+WG\Q)@3S!_#*]<'-<GM?2CX-P%K
M5TJIDR?LNG?TAC$,W)1$00BP_0U[/KV.RA^DO8-M#R8WD6=7RT=-8CJ(0QM8
M]9>83)_\ZCX6%-1BYE/M=#G&C[[[2-<B=IA\8U+W9?@BUFNBFEITD4VF:YA
M]LA\8:]]$T+OSM,_;T#F;$RJ>ZI 0+,.9Y5KANGKEWR7Z+H$JQ2AV7QZ'E=
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M+O._G@/O 1BN2_.W'_X?4$L#!!0    ( "4U,%B>;LY'*3P  #MT @ 5
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M5\F+4*G_R^/VC2?T^<4@+Z6014#%!"D!5FBH)COP#AEPB=H9*X64K9L O,A
M^]2%XE]E,34C7F?50YMO2-1>H[/WE2S'Y??9Y3\9Q.!=J=W$C-(2E&.!3&JI
MQ>\IVR(P(ZYV+V'W6/O4<*,G"Z*/+.F_>;F1*A_(P(M4*4%0TM0.N_5\F4"0
MB"4QF7),K0^X[F)<?6I$TI.UTEM:]7+!U#;18WK=MX%T)NE8*-Y*]5"4KZWU
MI26S1^80?6T/(UI7YW<RD)5V)-G_KHF784[_'*;;;=P'*C,NBA$02VUB)$4
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MB/Z/'W.Z&.5)N7O$90L[O=%[VMCC[8?8R.Z2G2<>OQM^OG]XJ)Y%1L%\#"F
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M]%N]%OZ\5B:1"V:R4TF!#;7$S["ZKYH5<!>*TE;&F-I?./8XGC[E!1JRH9$
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MRIK,M?M U=[:V4L8"#Y&*#8979MI%]5^5[D7TIYJ2DLB^KJ$6KW?!9&*#+Z
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M/5$SUSI>T ;YLU:F1R#O$=*K!\ZBTBIQD,&Y:BC1*\+0@?7.A,1BB.UOR!_
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MP\QK[HLR$*T6H+V@'X0:B6\=-K@?T;-7AH8"[R'W]3JZ.\\MGK/+63B049$
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MP0"V[&[@,:,)@@Y'%FKI6'%T?HF"P&*LMS-..=_:T/A;6?>Q0?=B=H"[U=W
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M7$U4X0:\L8XGG9CJ-B3UD53H^T\^5(U3"RJGS43:N!+B'7[-[\M/F*[RNKN
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M46 ["*KU"-S?Q^?__AW_G2^_K5J$"Z><(E-6FD6NL,G@ BFE#=(['J+FJML
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ML#0?P'S];LVKN73COM]Z-:\<]L %!I<@I9HU9$, Y\F@RNB4"R5FIGQC36P
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M:]MH#<JU(%]<+*_SJL?Y>5HGF4TG%R1G^M S\ESS+,\O1MK:DEV-*S 4H&J
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M8T)&EL@L<ZT3JAY&]+R4IB\% V3:W81X'L"YC/HX84J*68 2D?9)42.ZEAS
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M[X?C\0><])1$2=FNA"*3J1H%9"'.:2FC)<PX2D,TMNY%M37H8V+4+OS6P3N
MS^$<S\KGR3#]^^I^\O.W0$OCN_'X O.[P9=1&(Q#JF[I(2H3ZK5SPBI;FHT$
M;\E<%"P%9636J)J+0ZR![^G3J3-O=* _>0OKZ^%@W,_36^WAX!,F)(/DLSM@
M8TH!'4%4+!2*M:O,5J@E+-D;QU,J\7[9:$OJ+ =X5-QI[(\.U*E>GX?Q^*S\
MJY9R#B9GHT]5+?GL8C*>A$&FQ;*78_ NQ0"R%E*K*L;ELM=@;8@6N2\VM4Z
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M"*/RBN)[E(#)Y*)3-M:VELA_6LH[G;%C'<OO3'E'"4]CI=2.*9MJX"3 >XM
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M2"!D&YFT3KOJ,V[7@?EU/,(Z\JA8*' #[!9.R;8]RW=8N'XSNB <R"G<C.Y
MZ0%UQ/E028:1Q1#;RV:DN4QTU<818\I(E& -AMD>B F&1@8^95.]X="!M&53
M.L&AE&4;$0R@) _/2Y;79H$'G9P@@D&9_1U5::WMR^QOBH:1"6IKCS-=C63_
M7DAMF3T:I]V;\ %2#]Z.)WX2Q_[BW60VGUZVDT+:R CMJ1(YD,25)S*KMC39
MDB@= _R)R+[V*-,U4'X=-Z2&+"I6LRUAM4O.,+UMNEXF>N05:&=?\2-GJW^T
M/#OIL):!W)6:ZSB,8U-%09IG)MT!;%O5-<487="V[1Q=TE*4PY=9*,(41_]
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MPX]F.A]/SM]-<C/][J]7?7W*KE@(U)7R6AYH">8-L:"!:&]DI-I'JZKG/G?
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M1ZT&U17S3Y^"M<AY6;X%70 .Y']M!'<89ZJ**#NH1W\Y#. C;0:J=2QIMY%
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MW_6:@AC )[P#:A2BU2J+2&)&!T<J5-X07"Y3)4V2H)5^6'E><^L_4OGO2O
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M$ME0\+8-G=L6O%W_=?D2,(C\'__M_P-02P,$%     @ )34P6-)@#@"9Y ,
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M+R<P2,C(+U^\Q$%!P:$G)B"F_W\L3QT %C*"+#PA',P; !8+!@X+YJD'( ,
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MLJ%&V.^55X9T^E/2TH>6 8\$?M6]:,KF":O-"8YPY:KSY0X9&X&6C,_3D">
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MRRE,*>#]?&**'SDACV6ET%<2\2+3S(SEZS_NO NH6H*X%*N8VKHCG&+3UI\
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M']-QO]IC:A<QCD4EFU!F]DQQ9"*;N>/5%EHLJD3'>A3Q"4RW.=1_ZPU_%62
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M.7K=7"T1])T;+<#Y<-93(U=9"3;1I(53Q>'#=_G'ZPE5I]2VZZH@'<E-C#]
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M&DRBC#K ^=_M>F87(/\\>,B9PF#,JZ27#B]+D:PM3?0TXL A5QU";*IQ#&C
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M#E'.0.<'!6,J+U<D1M:_(L+W9=<9OEB+AV2H%:[+^;2+R<-K\F6FC8V3/&\
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MOOE_WX[N$6U]Q8YM4&1B;QU_$O)U_5=M+9"O%]#G9#XVZD^(/9$U99]V5G
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MBNXV<H:1?4EG. OA>>,2!\.N6 +\X*)N5H%CMK5>?'ZHM<R5;\/]Q $2K^S
M\$Z_LQYX=J !\F0 HV!C,U-Q9]%'MNJU= ISB.9&.VEZ_RQ/W'P+%2PGO550
M$>0Z;!!!G\SA9:,W<AP:@1?^=NBF\(6&_Q8 Q'T7:@_YIEWH%0OB-*;WB,+6
M'A E2.P0%"P3SWLHIM#*Y#6GC$$(>+<3@V)?R%SX!B!KS/E/B=0XW"^!,T=R
MKKL#X8Z-BP^U.:O>?0XX&QN!@1.<RNT9\FF65!7:>.R2/.D&7^,23.I*GOH^
M3<46'Y_*6IM 'N5ESHYKV@*-CL1=*E%B-$_7)[**?O(,^\?P.3# R]E*[<W(
MOXZUQ<RIN+/;)\4-MH8.LRY$75A$[B57T.M_]2[;O9G*QOR<."ZD*8*_LVUW
MUO:W]S4@7_,Y2VR>^9>,S/XR;F/R&-Q/.]H42H)X?X3U0N-5DV,Z2/7OQ8E-
ME9VUW:L"F73"$*75$0Y_97Q&:7Y-[NI]Y?9\[:6QSM$M<K\.MB[S;,QVE<GM
M><93['7U=J^EQ=J_MM0K'5WU=]M%#-J/9LD]/R\;3."1M11][CE56]S:!P-:
M%,K9;LJIE ODC\@</LON7*H*A(^3>-Q5H"N)9/_MNTU/,! '*FN#S,;^B,W@
M21%B.$FO 0VO[XHZ BFDD\'1@[RFYK%[")EDJR[C%@[!B2I W;.S<+O%H8K%
M/_O<= ]VN# -U&*.F?N\ =[*9%P539M$!T1FQTG?>+TY(R;TGSC*DK*B_ZM9
M4;6=6<;-MIAIZR;*YM]F/-HB)-"Z?9H*C8#[]4W,2-?U"':K1]<^ Y/F=%[L
MTR+8?!> %5*E 31>+K:E&V!S2ZS)L+@KV_-&W]84L,Q'K:X#!\/*&AICGH;+
MT?)#NE8J^#><WIWJ<8(60I]Y2[4]$'H]LX+K=8X?]1+R=4;1S/8H1Y8[/,W+
M$N\T$8XE5"Q7^+*$XK>64<^1#U\IYF@@T[;G%%J8,#M<=;;UWO8:S$.=^,&$
M@3J)HX,-MKK,$)1<Y+9.\9K6J09A) -K(LG3L<J8#*:VVUI80]VR_-.'YC!X
MZ*Z&?@[SN;->K'\%<\/YAW[T'70K?=!>Q%R,0IL2@X!CSIV:']0NJW2<SLJ?
M[824=I*Y^,H6/,9EZ=W)/1)SQF6;.GZ", /<+Z(?2ZXN.G)3 !4=X4'<RF0L
M-]),1*1U:WBVVN87>G0Z/MU+#=MBOM P'-.V!,%>+W%&!::W"<GH^.N7><O7
MR"]>7OK/HW)G&A[0N-5A+N'8-'TM2Y1I^:I=C(.Y2G/.L!PJ^Z:J\79O@\U&
MB.5"'Y]R,)Q9G#X4+$)?D-A*HB4]YW?&@+R^%1,J[$=U2=A:(Q=VBC96G'&]
M1KTX6I.XX&Q#[MW,(^"HUA 4JGJ?CY=OOGD\0OPY;\2>ZDZ=";[U80I7_BL)
M@.=FG["[K 4O1W"BN_P<W==43[Q<QY(-UJ*KS6%-5<2MMG@"WRDXFYT_G\.H
M_BKJYN9&2CL%1O]X-&F5S&1.%"@PXA05!X172P7"L_'-%O<1?9W)Z^1K]ZM/
MBX ZW_Z^6O&3A:L/<*CXY?>H@571RP7>%/Q@C<JD#6-BON5NAR@(FT)'WNL=
M DLD,K1^7U1F IV05&-[UVV:9XHBH!JMC3E]CKH3+Z660*^ Y6]%!M24"I%9
M@8Q_$N#.V-HSW5'KIRIOVNG/Y1)5P+,G>S51K%XE9UAY(IU>S!C(_'_[G?#)
M/ITP"Y!56_%Q#N0PYQ;Y% ^#GU1&]@KLP::P I+H[NV%TF.]4?6+7LQ$-%8H
MOC#%%]0),,CU)FG8@VP@'<=3\.XV:&9=5T1E:%B!>*097@9YGNKK@^@$2@R=
MJ&2[U)FGPG]0H#)!FE6BO3IDMVPF0ZO!2B8%N/C5D*P]GU*JJX"<5:JU.F;G
MR.&@6#65G6J((;VM&QO>QNOXTFZ.'U(I-& Z>8-*Z8CHI<*FSD+%CH%,3.6#
MV6Y^SR]+MNS)$8T2EI^C /;8D1MA\/(@1X)/O2OX8DK83:P5"DCGI1SQ"AY_
M ZC,7:^2(F5HS#+94)C!ZO04:^F$_&J!\[ZWU[';UH(TF#1R_-',.E-L5YH5
M\?0;@=$%O,(I0DW9?. LSBQVU7J=_O1W9J'CL?)\0:*ZN?13#"B(IP2N)^\$
M)9T_>?CV$8V-AU-W)+3\+$IT8+8QUH"$N#[)FP\R\H:.&N38.7W]L6-73"!9
MWD@S(49*W9BH*1EPKICX#4]U1<$#$I_#E.>BPIK3@L"U=_ .$!^?,:^]EUBJ
M)V=;;)6LX=S#SOA=E[+.1X27+!ITUFSK6,ZT C,+];'$?*;@"T[0!F=\CM&;
M"@X"?)7M7H9\]MOF!-.$V-Q4(\@:%STP6)A&;.:&PE-Q5<'7(@2OX5<30KV_
M;Q(CC0EC>RS+7@SD%BVMKVD50%(8<"*98%*34LH3Z:*O)(/X F@0?:C9Q(^:
M6;4,I8[&EG>XJ=UL'9/#A++=V_2BI'_VFM=)8*V^ANN%40N.BU:U$PZ-%X0F
M6""5*K$OU#7C;0 ?:\R!K_J-I4;<H1*-;X"+W\OH])M::"IBR'IFBR*?$RB_
M\A(2_A-T>05QNJ=D_42(<L2R598E=4$6(WH#"*'C/;S[;C.QND"7<J*8ZJ*#
M2ZKTQEQK8V TF'3/-8KU&BELJ)HOR^64=@NYT^:5I&GVCQ[I^#PB&,P.L@X7
M"?/#F.S"3+W@<I+&Q6E!+B]8L5"U5K$: _+AN+')%B[U>TR-%S-75 -#T3Y$
M=Z&=[%S1MZ>?X0NJ:>DAY".K$Z)AB.+**<]?5W[.T]-1K:]E!THPVV$+[B\[
M$A[#:KPY';+):B_N0E^A)2RPC:QMZ[K@C7?BB#Y^7ZB$ 1CPVV#3^S78T7K?
M2*EFM],Y4^A2)E>,*S'(S\V(\(?A92:$ZKD Z_#[G^8*J ]&/.>2\"9WRS35
MQ\I,(EV-/-6XKH8$!I-]8@>_ZYO]*<-+G$]'$"1F&V*92"6Y;L\4"\\V_W#
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MD*$)'F#H"9R^M5H.GA#+T-&8Y2BY'F(\JZPZ,PT 20Z;?I Z#2)\2&4S]$]
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M)H9PI+5.<R'=T8R7CP*C1K,R@/N/'R%#G0=N*H6-1)_#$M+(AYDP,[5CG$]
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MLT?9YYF<++7HJ8..OS]7G YVL2ER_@477A"W-7RU.OQQ9A0D<(X7KJ,:,J]
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MRP^8L;+ #5]T2UB9'N2&2).H989$XV$^5B%)ASA>>(FS5M"J(_OCS$7-V[^
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MMZ([4U>\,#9W7TG&1PO:X[)K1+%"14XYM]M@7@=Y\DF*X(;$#H!87$[.3I>
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M)<V3=YT<C,-&7,!2S^"6?,BV8E0WFG.C61>V]Q<0QFIA\:6$PR#BSKVBM84
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MUG*L9$6'M9_YI+>E%B1$N 76I1Z.[T*TGQCC*KRITO4T (DSCZ8"8:;[Z'7
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M5QISM[I=ANL"*CB;3MG*T+@[[50]-MR0"20R1W.%4RJ<J&-N/^H"4\.5?L[
M2(>BZYI8:!W*^XQ>F=E4<2\J&R)C+W&Y#BBTV9>6D2-AV!$^+X%/D6/U;JBW
MWAF3?._:]C#"K(FZ<%VYQNL#><%BFK=U9(+IJNQ^;D_J^GZKN![!6/U6,"^B
M\[P7-HG>*T6WP"'QSGF^MHNSD0,^P_?*_I="2F!@DJQ#3- -%=*0Y&>U>;!
MK!0[M1A:,.*UG$)QCN5>3IXR,$EY+UF;LM]'Y:A)3_"[4--Z]JC%#>5!]B3A
M^13DOD?D:)5LIY1?^='(@T>0:>E6[_:,QRM<I:K&_-FPYM=@-?N=%H%$A%UE
MH-YISWK>C\7DRI,7AGG+KIGMQ33[$7=J,19W<LYDSW3(6\VX0#0@6")0Y,O,
MC?%Y5?'RB0>N3:5A]24);O"'5#-7<KW76G$#K^UBNT/=Q T985'C]^;'XGW3
M[!V=([VI*^,DYEAQQ9>\<V$BOV2M(6D5.]G=A'8(0J]2>6,A,N:XL^H"OK&Y
MB#[I\18SWOSV@KCS3IW["'?Q?*('?/4%OX/Z]A]079"9M@5EXNBGK;BV'CIX
MM1BXF*)DJHA(W/%\-TZT>.VK>[Q';\R6A:_;KSLB4!:X-+YD]0CA(*5: C47
M*5K[EZ!"@$D!%)I)MAS>1 8>!?B]F8=BBP/'OS/BV+T+HL=CARK1,Z\KVX#!
M2NOQ&;M4%N4+L#].?13A96CK3_8NPP73%7TV00RV>Y&I'B^G@$\7Z(F)+16U
M89W$WZ%+:@Y[@PN%H$)2S6^9 ]$L7VC.OE_(* -L<GZ)SF4K-[0NI+WXNB?M
M@_.6? EE(\>:6$U"":L6/.X%'8M-?NJ(2N.8>M4].2X*>ETP-W2T6"<9]EK1
MIM,!ZE+H$C,38F)X@'YEG@9M.]QO5+;57V/':IHC!"=#:PC/ ,.0UUQ:5);I
M<LYXWO%QL)+B!\7W,Q=2BZ7Z9 <8%@K>Q<EC<J[:* T8G7BD*$&Z@L:D:DN<
MVQ$Z,)6,K5PN!EWF_40\[=878_QW@RHI1G5@=!N+('_3(<W-5=O!BY?55]G4
M9VMIK_4O^,8N0ND]-/9+U[M9UEQ&J4_U3;V:!FC>AJBGZ[[TN<U^;V^+0F P
M_WG,TC(G.P>\#HGS=16=-J[VLE!>*HT"?UC)LDTI5,&YEGM2U^:(P?S\4XW-
MGA/]X[QCVD'?E+@WR2+'TO@(-A8)6Y /#HGCRD&^!+AEBYT_;D%"I?I(UR ]
M''$Z7;UNU-<N/SX0F%%*QJ4%P$_1U/0218+ Z_P^WLSW&WBNE"D=&IL/CV=9
MC55YCX>;\2;F*>W #F9P-^-J8..I@8,6EC.(72FS)(7'Y:L9MG*J_,X_;.<-
MA2#$GXAE6+161_,-H3KK:*^5*/FPB:):1$'))-$\-I54]XYJ0&_CIOYHP)\6
MAF7.26B3+)43=N9N:#@V[,/+O?.4U*[E/>'P#C[13Q**Q:D:>V^($ZA4V1OE
MF'Z6\>;S@]!JVQA-&QU!R.A.NZ\TNJV0T%*"O!E098]@[4^I;FZ); XK")NZ
MB!E%A&A5'1.4I5VR\_/N.)V4A\QO=3CI!#LD3'PY-S"_'8/H<1L</'%0W'WU
M*G%'!9ORS$=2<^/^0T>[F[UM.B'=1PM;6N8)CT/@\PISC,[EKXVN&O6BHV:?
MS3OM\LNNV!-L>Q;E&Z/VW.\5VD8LCS+#*)3>DQ>X7LB&U/[NU)KPOA4Z:!)<
MQ.&\+'\"3Q<([2P,;-5;HG.46-(M\PKX.%<:98AMRKK=%#5(Z2NTS##Z?B\O
M.UY2W14TIO%AA&.*?GB AGYI[[*KV*=^?N-.4I[;.GB%; 1<HK28(O)6>>^>
MEG>W &_^UZ1:P#_JX%@B()RD?]+BH>H&'Z'1,F2@;U%/_.%'F#%"$QIU>OHL
M7+RL;B]8\CWV]/DO@.XQQL/[G,:D["$#95HM!#GT'[S3%'//S6"7=/CV,F=L
MGF1QLV:3#[/PQN5>Y8$@P_7Z.9*E'3MZG;RD48ZP @GLRFR;^9=Q,H70#3*I
M2\J60%<\ET ^S%'6'5S/@?CM@#=>$:I+I.H4VI.#4)( Z]B9;]E?K*W16AK&
M\5S&+NW;_@)"G91?!E]&G^B>\//OXIDG'+SS/'-S#J5/I!QLJ-M=C#PC?]"8
M/$1\ZE9LGDN"O\B8G%GG K6W+%=C!H&!.)B8Z 7#Q!HIE$N_9:U]*$;B)BJ/
M)R)PD/;5^*?+B$=^>J1EI<=V:G#5H'[>-%Q[A\K*%W%=XY=BN9K88\/W)FX7
MT6YHS#<U]7)WAZ!.)SVO<WV*O"'_1)_S)BCLD\B@)MR/N<C^GG?-SB-FB:!V
M,(M\+^SN4%Q%84QI6D1"1P.$L\OICAV+M:D1\LX%+Y,VJJ;F[5M9K2B%B.E8
M63(LZC5+-V!0C'8^L5>Z06/G%0<%^'@U6W NK$J ;8=?LA\8&BSE4/L*<Y?*
M[,8XXIFA7?&9X2]@.< L%-0AY)^!P\6?\_M0XK#6>\JNICO$C=*8"RS%3@@^
MS!+=OV%.4DR<34UH:B(186M%W8UQJSJ,/5_Z];UZW$ HOQQT.=9>"I.J/E_1
M3<,HO![^CE$D'6<?FFQ\!10CZ=YY5\N1<$11LL![M&D=;UD_S&L<L[S>[80E
M2]N?X HY@@W;;N*[G=A7=4R:(,2C*V JT0LK''GZN/P25KLC.NZHKK)#(A)8
M&DF+(PYQ:R>_EV)A3UY^\IQAX9GNR/).N,4<>@($'<CGQ5MI4KO,>8&:_[P<
M;W =L$W_,J/>\!?@\!=@_1=@Z:T<SWTF;3-UZG0#N=D5&2:[,!YLS@;9^'I[
M@O%&+XKUN6A=Q%<^T4GD\52BDU5*7T;^S%_-1_P%F-,ZW$BL/=;M/V8,9^X?
M6C\'D/!?R.7X?&\2P?\O25F?G EV+"UV6N DOXI729)N#/[N;88HCCBY(?3^
M=5L!,T7R<C)H;<O6G/>;=W_I(O$F8!3IL98W*PD<HB0G(Y/0:N\.AN)Z/&_8
M>;Q27D%6FIT&RFE3HX2:47D\!NU&^5W:;2[)ZN? HZN\0@9YC^#.)_^-O;<,
MBC.(V@6'0(#@$-R#.\%=$SRX.PDZN+L3W"%(T. 0& CN[L%MD$$'EP$&=S;?
MK=JJ^V/O[G[?O;6U6[4_GJKW1]=;7=U]GO.<.J=/LY>,489;![DXI\^TKXYQ
M-P7JD$F_B121%+*W^%9Y9.!9X[?]"L"0?V%(%ZIFXX $_/C(ZT*@AWCO-YU2
MY7/?C)N 6CVF=5X:7W5/Y5@O%,J#[X TA8";OSEN7UQ#Y0Z'R19L&9-I--6'
M0J>'TEF;YB%?;F!HFYB_9^J2/@*&7'J*\IC7 J6L7*-KCOE?6-W!?$H3XIPP
MSOI^I#8S.^8MSD9 B_9(<J1H"T(+Q)@J]IKUF,R8?U$IU\&13^3N9'"..HB:
MP(H-_USE/:*H9:2!S[E.\$H99"+69]TYIVR%[B+NUX[\M[4_33ZKND+[(*!M
MEG9Z8UEG>IEC,^'I)P*Z4%0A)-Q05%KJL&2%OP)??/.\?A_G,<R\ K88ZXS]
MC96^N==:N] 7&Q9=GJ*)7ZLAX@G"AKC")FR/;\5ISM?"XW,,&O= /K\W8CUR
M# UI>T(%7&E1+"P3QC%W;H_C*"J#WMQY@LG*H7.C1/'HJPT9>.U?IKONQGBX
MZ"+$W$9ZA! )*GX?\@NOA>D?I1^+O@TS2RG1(X_002*@K44B]8=W;01732([
MF _ATD?DNKCPY_,--5+\-EZ3L;U4<#R7WQ%UX:'Y8[$99[V[72X,QC$Y:BMM
MW7+PTDAY(:.U]*"8B:9-7LC-'-K28B:)) &0<SV %\J^NRO1A9C5[:T?PZ+.
M>-I_-N&O3X[K3X)I]QBO" JPLH'(%6[E@UB0]I;M!*  5:[YVA]S0>+U-;&
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M_&-*)&D%R?$$AX(0E!/[?;_HD!K_\/SJ</634(D.:Z/-4B-X7\B1I&U?:,I
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M;?SI34U-8Z7+L7Y"2$TSJ$066#P14G',)**)FB9^'B#O/DYL/2-(%X@W+^#
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MY4'%R5#CD^K)$RU*1:8>% !E:W7JP /OPUK)=YT:4KZF$CO/]:_4^#':GHB
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M3^HK&?%4&@M/[ 1I>: R&9_?K&S-N/= +Y14#E\NP=%/C3UB6(+0VX%XVU?
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M%^@LGIOV.455%D$&7RN.J3 &@(J$(RMUA,F-2M/4G(!N,\OT33)Y*#9<!A$
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M>GH,>*-@>GA+3<Y+C5F3(#ZQ-A??DB[]4]^?_M-&\]_CPBG.1#1#*?I)J&R
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M9!WA3@QN_4?\TA8IV^>.R;M(IFJSB]__J__ %[2\ >)  2N2HX7%:F\ BJN
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M>P9!5R^[I<0?07<>]Y!S)Q""*MGS"%[94\D?W2SME%>)RC? NN0C:OG_T8$
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M2G,M$]4 <&O9*%0XKMC2K!-B\KY;_^E?>*/3T)7H]#<=M=;2K]7A,R^ZE:+
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M@FP14="EZV^#<L8BC -Y!- =*$K05)'-_%F#+K.3M[!Q_@9ER-6$)LF%FLP
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M6.P2"/QO&,S\WS!XYQ^2^BX _U;W'1=ER=BEVQDB7WU_ ]C'C?%8>$PL#YZ
M8UO*&D_I[-+9[I L4.,+"C,\$=V<CY-?Z4>CJUT2UEI_7A#D)JZ8Q-C^.1(4
MY!V_(A?D<DAG*K#"]<X*<"ODMI@/0F84Q"=H_#+7YN=;4A619ZQP-^)?$<40
MIV97A/=K181C@QN"WI&YG552!)+?.L<<LQ.?,Z&:R5Y;*4W7Z8PNE*W[P+T:
ME$EF784);GH#8%DW1*DUA>A'G33-Z*N(C%BU*9I,:^A9G+] :Z(MS6L4>W="
M'/=[OCF%N(D3P#1M&*8_.^"/LOV@LXHIH/NQ(T>,-;3K#%Z)#G'0^A>:(/=5
MZG.":7=EAE8OO]OO1M0><<1KA,*P6/!,EGDER*>R,,7P:Y&UMQ,NC6+EO@$N
M"K$P5;S07JLH9]COP2-XK&*">?9HGAYJ\/Y[=%D()K6TA/WS\%0/Z=VE(0EV
MR/Y,0Z?2Z+W6DZVI'(T.][ F_9)>$%OB^\R;U>:@4+(]PW Y<>4ZKVI5D%M!
MR0IT'7I$R /,*.7 +XBRY%%2E9-Z ^A%6UH(GZJH$1_8UBO[EH,@D"T'R'57
M'BXP]&K;M6]O^\6,2&P;N0"M-R#LZ[E\8^U<8THJ\(C245<A+9 &FUD=-5M:
MFXP;0Y]"#\Z+A( "U<M]?[Z1]*_C_D^U/1JHO?3,@ ,Q%:$]!I!"^&G'8Q>:
MXV+KI@?-"DNSONM4NH-.PJB\[_$J0/_E"G5V+@DBT TJV@:SP_["VY <(D/A
M!M' U]:T1%.&XRF_F^'[VC!CB@NCO/-1GLO33L?+6-DP4=DI+KSU+.Y;A';N
M]QR?WY<OJQ6 H*:/*H6ZCPZ=J[/]01Y05<OA\;P"NO<]!O"6V"F($42]MQ0E
M%LB1-UG3?:5'(OXQ*[.*'W1G3&5,5.HZ;.6PZ2,I1$*2Q4+TS!<:VF,TC076
M->LAK[AM0.TL0VTR5W6RV(+2,]942JS9$Y\Y1G7$6V5%!XA:_3724U3$/79&
M)FD@]]!CC>\E8?BS9#G4ZTHY(]6ODV/.]"5K5<LM!NR<^+*;$(7]\V5'N@,[
MYUQC#-.^3^M7DLD,=6?VI(/NH&BY5_3LQT4F"J:>$0^C'29D83'-93L?W2(0
M_T).V?(JK$<!8L.!.\.#I+J'# ^?;9<R+T$Q4E:T6S:O*4J\V]X2@5AL%6OW
MPS(B2K%[3VJO%KV!XH-CSX";+@D-Z'%U]UDS)D6@Z>Y5::B!,7G/;WE*& ]N
M-J:@&F0K,!U6(FQ^J=6WF *I52D%-4U/W$U<=>51+'6D0?BFU&XC84.JR,3'
MQL!C$GN?GR)^Z3'Y)I,9FTV@.46:Z]$J5WGDA .[G-EG?/KBFF9!P0LCZ$?.
MT Y*2^K%4RU44W *=8T4/%H'R53]7TNV6W&1XR<3@\1Y=K&#G>MN7_HV%M9
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M )=4O,;NEJ8CU+,-'<1RN+K@ 7(N+YN*#ML3:-M&QI)/:FKZ>XUAOG9Q37G
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M_AZZ=U+$S;GE_BU5CW,Z^_QMA&*+^%G%&!I8),8ZQ'S_G2;R%^ +4JWI8CU
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ME'M"SW@F61FLL,72<69?'%ITD)5>/#N[N\!+M\EROX65*$(JD,!B9TV/$RY
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MT]G0."<QMHM%@RHYH%G_%@$O,Y&;YUY'OWJP=%;/9/MQ#)C 21T=BV1+A=^
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M);B0%=+P#3^A4L$*(!Y.F#.%*2BU_]L_L;4*2 &>$V8J:NSQ+;,*H!4H@50
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M&6]3F<1?3[F20S4:=V9Q:G7A2<WJE=<C[@NOXI4!8C<#K]4V^ZW?8ABO/%N
MW;8_FUDNMDW?\:DKZL$F*1T,QDV8^GTH!\31L/WL\9V0!:LW>.@9H!FW@;9H
MQ5NP&S<RAU/>$3!^=TMJ,1M8DQ7B<AC%<)B#)):_A@-AE1V][4 K[8+=>16_
MULC-(QG/UVY=.)SGK/&J[4^MT$)"+MMKU-9>8KA)3P0Y__B?SX,"S5-<+O:3
M+^<"<6$[*H#]V'EIL?F(3#:6+CNPI%D72Z'[Y&+-&7\)^G!2WG.U6C_K#Y8R
M+Q5[*IK6M;"+F;M&,%Y!Y8*E\YT?T-M'F?\1^V[T YK(-</-_CMH& JJV0](
M=DN"KS;:5#G7?8S?WS*HN.%53.2/'G1Z4=^S1[H*CZ, B,S#AU\T<-3 8?/J
MIB;XN"'?K&[P(#F1PX!5H1N'BHZSIO9(ITA2%0Z>/%+U0JHT.PRN?DKC,D*Z
MM:)>?*$G,(R:Z(3,;6IP\M+8F2,V=A;E+;6R HM^''&][PS?5,XX!V9MI*_O
MQQ7LD\/'MD8<%'9^DFE6UD(;G$6 N,D3KCY@-=?GJDC(IAO#(_S@ECDZ=&T>
M-10^L<>-R1F7Y=#+W]KP^>Q*E2B6STC?L\O>P9:D^JW<'F7YS)XF/H[8Q:?V
M=J7DB1MJ]NYAHKT@J2!1QKJ#*3X45YH;]EOM!A.:UHKH9Q4_/R!N']R0R@IF
M+:H[5TN>'SODSNS!J&JL/#N/]R-1/[E&=ZK$?\"5*V6T2F) BAV]X<2&C"WU
M]U3+WC2FQ1U"9U]\7!PEK:"CV[&( R$#IQES*!31!;/+*V"\H^ !2&8K$Z:E
M8B@%[,T1'-^%[=XAD23KBV)!;^Z'J]U-%3<Z^0M0K5'/<\0K/H>-[[?28Y_>
M^>7,7SV;YORMT4D\G).(ZYQS.U"$4(5[QC,C2B^8I95@]!2F9\$LG3/0%#>'
MNA'.*1+4A.4F=D?;RZ<FM,;-2F) LZ,? D"LUQ;G[;U*_R$ 24XT"YT=771C
M=["NK72 -WO@ME-W_6?Q1$ /)TB-\ 2(^?L@()'5\Q(98&R TNSP0($E193L
M]9%=K4;H/;ZHTE7"77; #DY-%ZV\2O-B9#X,[LQLB-"Q'G"X-3"15MDD$3G#
MK;'^^/RQU+\.>?=B(=Z*%8*XA,8B+IWX_^8P'[%&A !,Q'XNIQHTI]2+)H(9
MKS43HJ8BFSH:,PZ0_Q&7KT"WG.>(>S5:[^Y/[Q"*>@5G>MJ'+_X5_A=U@JC?
MA#3M),81KL$]C=\WGZ"-U'+;CF5&0I=!. J\(W^^?KMLT60[KO&[:T_.S7*Y
MB T[P-)C"6G *_#[:]#E -1]B+T?,8JOJ82,U)6YIFGYT*ZZ#W,7 8MO-!*&
M,USXM&KQE5_7E4GY[:RU0CLT#IU<%4@]0+SC->\2<K0S[YUIB#KN$@FD#*/R
MZX%_(%LS/?&IXW=U"^,S;HSO'&QK23?D>RD(?=/"5S.%BFOGG0)6,XL>D&SS
MIYK5%K+,2>?0NS6$?J:8B9R3O2B@$F%GBQI!V/Y:@E:R$/O4%)H)D"B\"^6L
M,=9TC=8'3[R"M.5F*.NHLK//"G9Q=2=K733N03BUEGQB( 4:N?D"". '#3?V
MMQ2SJ]AP]P'S2,_2B+F9V%SM-=C:$-_)EW>=1H+C9/R8F1YHC:RHZ+B6RBYA
M_C2)'HG #NT@C)39L1+_#)P6L_055TA&P$C%QF\KKH&7[V=)@H)(Q9L/UNP$
M";78^RO<1D,(CKXTBY"!2G6>6F$VA8E*=FA^:<J7R<9A^T?LL71 ]6V!EF<@
M+?TN?K9/"1SA[/7([2'<K\T#TZO"-I=2 ^31LQ'6I#XI>RU14('W\-Z [=I%
M-Q*-/XR3D7/IJS;N.5G XQITVC>U9+&PL(26UH7$,9>$X;2V:QIM'1D;/C5P
M9+M27CA>>Q=P^+CEN7:"-4,;2V"LL"NVXYI)<<VG*Z@++ '[<X/X+%[4ECC[
M"%X5GZ*=X>/IM26%H3PV1FV[CJ^T78_$P^J*LD.6P%SG!PCKY \LJ<!B_JSQ
MK2YOYU?@K;1$3XZ9L40I&1!&[9*E*E.G&D">FP4<1XV1/!'Q=]V00>1O^WN/
M<"5D:7ZX0O+R+UY:[5T\W=WN'K*;[G(6:*ZM$(" 1WBF'WL/#:!"*>:&P$6F
M:GPE!_[!V;12\W)P<P-Z @0L\P\^K)X)?%C\[D61QYE-P>)IXA6Z0D]][,M/
M?Q[4BO^I"QL,=DS1$V/A;Q9_[0N>C+*+G'7WF+&@XUI(;,G1VQQ?T_M@+0]=
MS,J1C9P,Z/)UQ7[#Y*O,ABRT;A+CQ3G^DQ1SP5P@.>/*_=H<\8W@;JGY[Y0-
M^:6>0H\"U\,0'Q9#6L&G)-6'.)$:W!N+"3=)4Z48T:@PUB<V(Q4YD<7@\YD4
M8KHL=S&Z(B7M5K]U+@]+W$5A'!DB9_(V*%5ZZ4=CTWYJW3ZSBE1]H$:Z#5-R
MG\1V<$E:B(012(GT;5I:^VJH$HE^_/\Y)6D[6*T8E.8_>?>DTMKW5ML!A%=V
MWG,S@BM0FIHAJ-)-28)E*0(-0*,<3_R',O0%0$>=849=\P_E7*V5W7)79)GY
M\UUO<"29\.V"SME-TN21^VO6/(,Y8O_.0_7K]Z,Y.:LQ92KXA:3+=GJ1^1<6
M!08<6>D2 :!^W"]N/R"<,C1 3U-!*\A*_DCWZ_O&UKP1[OP2HYOX4!'RH4H8
MOAH#:EHLXE;-A+AH*I]Z5,X[Q=U'(YN)+"N5^G>D-=Q[1K2@P.-6$%7IE)4C
M8&**N2WZV<@!5"F_8"DQ$R2T.KCXUY8(WKJ3JGH79868H+1MLM_S%:03",*X
M+HA";AGN;D^X7\21KY??$A;I(&Q=MBBHEY@'D[+HHG+]]A)>#6_^+;\Q(*NS
M\R-+$VB.07?0#;-5QA]0_9 <N(>9"+S#8<IO7^JVHHNF,N-^3M.TJ30%V/Z6
MFC+*,!!I4CW[A\*?R!]V8A)ZW 58K8_^1=F21 7*?&OVL]MHMGG$>VT&('.R
M:ZA K:KU=WR8-@LG$A<%1Z\OT7L*=$B>ID;RE@O'[4U#!SDW(.H+KO+[=4;B
M-C16K!4ODEZ)%C<BH(BO//!<&,<LYD.-G22I=ZH0MJI5)OHXO?LD81=TWR'H
M4N.K650TU^H+Y[S+;TWU&[/M#$G78E#-JENK:M,_E"ILEF0B1D&&044T$LDW
M:*X1"+)KJ:("L(I>4"'+V%NY*BD@\OUT0D $/ODK451/,53Y&\Z2I6"'LDVS
MX\8MR^$U/]_YR1DWW'*\198#ZLD=/T\#\R@F&H,9@F&8T;<]QT7'5-G&TO8,
MA*I:PFUC?XI^NJ06A3T-';!##?1?"KRW'+-HON:&IE&L\7)E_50#DM;5V:67
MO $U%B@GD^%P3J+8JF(5T5"3?R&_QNNM\0EX=4).%8G(=4ZU-'-F$>O>%_A<
MY"L4[OK;126"(WZ#.D#XO^0\^MH-Y]Z+R(>$:HKL1#1564]0$KU<A24D9_?K
M!;YR<J-Y"+!O,^@-4!I+?:L*+DLAF92-EZQ.EQ].I A7$7KZK\R:/KA9+ M3
MK-Y9. ^I6K6V\(G4_71*8G=E>JN:FOH/1:S=YI8/)43;&<(:_6Q!%]L8TZJ2
M829)66?@\^K"-33S'+LC&[N>_[D* !J;# Q?M?1OTZ;Z''%'WD"V3$9Y'G\]
M3J9JZE3"&CDNTZN#.L8EV _ &OU#?RDRY;_#"K+^J-ENPU5M+*"L^+6;H<2>
MQ9VD(.0_N%CGBC]VZ5;@#?W5[AAUM*7"0?T$,IO)?#LHBE?#GQ;U%/\U8%[@
M4GRBO_EJ+>ZG6E<.\K,IYVD0IH0W;PW9S!C,E18]UPKT<M9?X:N?*.FQZ/SR
M?NE'*_1E+,]2V^-]<959@*6P6KG2XY;R,CA^&)-A'Y] ?>,:OXHGI20WSFG1
M+(8E"D::G%Q@WU2K;D9SCC$@=HBRJ)>Z"(^*9L*,KIO8VQ*XN5O22>'VX9Q
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M!!E'"1H 17"LS+PX+<UYB,_;ZHWI4299ZE!0@#L7I+2E-=&+;MW&BW)=Y >
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M[2>^K&GC)";J[FF:Q^Q1L1$PXC30,-^&]JZH:@-FJBZ;N!L4J;J9DA+%BL5
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M6VXA!M T^9J>%%$/%9FP%96^ 7C04%2W0M/TG!#<WY6 UG>==8V?A3)MLL;
MQ*,-6HQN@F\YWN*P37X^<T0KPYNH.5X7$M/\N/,/Y=OA4BUCFM)3\,)QH#VA
MVMVRU=EA1'U!EP8*O''9WN-7]?T_% (IL,=_@/@JBRG]HKC](X<$P3G>3522
MEU"//KY 38N]_=I7^N%3<2Z[;C"622+"C&69:(L!N>'1:_6[A]SSX,OU)E]Y
M_:;_K6;S"@^DGKMN&]J:_2/U[XI4$C_X9=XHFO>EGE728U30X)R#)ZQ)7.;M
MLT L6.O VX),IG'LAX4*$&K=Y9:]4B(%]1J03*(\<:;^&JGGS.\LX5M&O;'>
ML73)L,6>#NA4W7+<)!VBR:"4S&1%I^/\(A,G@=[Y(7-AQ'V*9F%PG!7ZZ%<B
MT:R&?'1^K4SAB)>':Q]_9N:_I-5Y;72'Z_&AC5D!R^\;)B8_ZYN^:28LZC#P
M.),X24=UF<T&16=AZ(70/Q3THQS7T+B-%DUYSM^Q.W>?*VN:!0Z+]SN8I%YA
M?'H(5[PF_U;:O"S,BPWOJ397=UPHZ5%*M;;%H6E2?:WL8+V.DO>*/Y5SR:DV
M73G:;F3G"BN>\1N@7]N7=6'3DG(Y:9-2:G1__VRSIVFK60<H0_!LAQD7A+?2
M]'H=]K=\@.6UL R/YF(::]9/P2J&9I<YRE<]O;%];N\\2Z:$ZE_U)"4(63B^
M$![9M)%=DB1#3B;O] (&2M*SOVVUHE)8K!^)O6KTKH_NY80V+]H6C)'K*CA#
MUPI==/^FVF7GN'VG+YS6PYK*^R5\WJ)WMXBO'Q =+D54=40U&AKL@M>2M6QD
MX).OM;UXT8:.*;Z7DIA_!<(Q??BZ"ZRKJP/_BNCFKK*:P276I%:!FH2KL$@-
MLZG2?S9NH '7NQ0G@3DWQ761+X)7%=]:\]5-6L;3*9^EP)2KAZAE3XI:"YBL
M?M/?3MOCO2;J# _[Z9@]*M7*'EPY\:1!#Y^HI-J(IIL8X=_/.<);9\_+0K H
M9L7O.=@2@$HF6!Q26KS1+YQ)Y@N.R[6Y^JFP2\WOSGB^(;"A-W_/'#3L\YXW
M':5+5[?60BXO>W&'BBV.=6>J!X*71G#&HZU!@_M1LPC;3Y?S>_6D)T(ZIVKK
M_UU2] O6BLU#'-"GS 1@^KG[+@'DFXEJ. L#,)IYT'GZ%?BC>TWLI@V^8'5?
M'48$BV7\L5CIA=P]T!N"-.48[:BRQ;\_#QKWVV2M48X?QO[ZPQYD8CIT(*=$
M8JCP_RO5_W\5LO2*+(YU^/6S[93,7:G'&8K:4Y,OR:81Y>Q28OO=G/#B&CUO
M$IU,;/*#Z!/9?BT4Z=9V\8@U;G:Q=W'=YOOEGJ(F2:2[V/<$.+-#RW,_\O$T
M,+^L[!<$G4BVC6P2N3FZ*')@ET>,Q,]Z"J]W<I-BOLO5M!3J><-35#E4.7J.
M?Q"S2WAN:)YPFH7*Q/3NVQ[$"R%ZK;F:O^N/%Y'YHAQ'M64Y!@1Q-<[UA#CM
MV^O50(F8GH=QO[^OL>6EFF"-*6T@(VS-A.-]-_+8NO!+.^L#SF4VHXKLN^(&
MC%$<^^;7<6,T77W>RH"X58]5RZXA@F\LTCXIZM4B#'\KOOTD^(T8/>/0@P'9
M5-M+%H>>8KNR]=P0-E%N4L;OTJZV+!80V[!%%4:HDE+P\*[Q6:?PB1$G+A^7
M>V73U\MTP,V#>;#)/ ;[TCZBJ8&P5U;YA<91RMCJV]K;LIJA8O#'.UW_-E$\
MG$''#I#/>I14+Y4(J^]0O$=>J&%U7RD55=5.W*_EVE;4*MCG:K8+QLZ1J.5L
MEA1:*%LRB<U!:$?<;P"R^;^J$JUG+ ?Z)&R?.LK:6J ODI6.;(L2^UZ;^Z(O
MK9?:I780=4;52!_?J@;.\%Z B)B?"!ROFK5B8JHQI2IRLUXT4NVR,&%,2"H+
M@"0(8OR:-S8MZL*Q-L[ IA>/?2V>=DKM.60WUW0 L;9/-)7BHY_U#&1J,*,5
M=N9P" @FT+A_%AX 17* =(9;")7LI]F*RX!\2;NJ&2_1GP2\YY!4,[/]GI=9
MJ#$7=TF+?AJ.#^Z)O6_R&U6^$+EU:M9T0"L0\?!' T_Z'XINKH9R8YC:=AO_
MEFN."6.6O()2,T?9X^0E@Z?L+,=,?8*IU1N$\YJI.?06MHGST>5I7K"902&;
MB.+=+3G7./_$ !HSKU/^D$(>] JSK0;XIVRV) @S]VNU6@!-]9WZCG6!&%&O
M8E;DU\U7K_VV;].6RMJN]'7]_P_VWC(HKBCJ%FR") 1W=PT:W"$$#\&=1H-+
MX^X2'!H+$!R"NS;:0'!W=W<:=YU\4_55S;QY4^_-FU=3,U7S8_VZ5?><?>Z^
M>Z]U[][G)(-T@06_Y?=?=W,(R6TU)[.<%X!>SE#PRN:QX%I=I:&5H NORO(;
MH&<)*#03K)6&=IH\)0<Q W_NY8#4=:ZT?KNAR9T35F[!N*VG'BU\'9Y*>.#[
M[BRJ*W5Y*2[PLK"?> 46T<OHEA"2.4=84BPRYI_3E049Q]#%F,0K=+-6!SMC
M</=/P&>FW\/[\5>@^*.L5'4/0EG=BR6H(<'_M&NOM9JIGU9RP:]6.^.9N"^B
M076)6ZCQ,MZ.Q5;R>.6\CR$]&(B#\;M  9]F^$]2'^0HP<!V1XWM^\P=74A?
M59Z"!39!=+L97/[ESWCJ".J800<R<291,V4^.UP>E= P";Y0ZN;6V9VLW><V
M-<7(SCD.2)[ZE5-GW<S#6@;H3.\?CS,%]S#.K</BQU%K]#XU SYL)WRN>(WO
M.!U:=YQPV29"I+\O$JF9$?Z7XK^7F9#]-<=@F^;&2G%A^X%<GV1$R(43X!;@
M<5@N+.7,$UH[?XO5Z9DO()<3NC\B(_KM&^_ 4*;&WQU4TMN]E#-J8H[D5^S0
M=87SFS1%7LN4=XZ_!['C<>.WD^D\$QT&13C.=-P[,+*>5.D55+04GZ16_P:"
M'$6/?QOPO=R^!H_0^D"-T!TX4HJ?OR2!N!54]Y;DN?#+Y^;='$>.,^<2."-0
M2\AQ":3I?@&03N+@RN(\.K04[,X4ZZ9,H&V>A0F2Z>K4A#\U;\LU>2^=ZU/[
MX,B<G(.[(5+%ELP^O&FWEW(WOC\^^?1&TN.[&5J\+ %7) +<&PBC,O8;_@+Z
M.'RA-"7"^+6B%6:W3Y^FY#VUOJ/@SX9L+5U$</;;1CM# 8X!2.)1/2VGN>Z;
M:#@:YR=6M:^G74IK*_5HM7)_J-!G;$-7(6UPPGS?@IZVZ,8R;9S=7?.Z0)LV
MQ>]3O'2EFQI#=ET930BC'Q3A]QEVA;Y8BWF\ ?Z%AU>"\]_G2\5/5LW+A;K:
M_F6+V30C#X_9;7LN,' 13ZS%^>G>W) VA7;(B-LM[ZUM@Y0/I/[7,%&<9]@(
M;1P)">=[PI/&=4Q[E[XGNM?0LA)H-8NRN"/+P2#3MZ/>O)_M,O&43,4K@6/(
M- 63$,C<M;8=; M+7\ZNCD0@VT8:2(FT38E=S@7N!W/(M41I$I,>/8O$7P]'
M>;=IT*;M#:M"$F1AO(PV@Y(A72G\'Z7?[6?<X#GM=R:\% (KQ%0B46)A".W!
MHY KZN@H<6OU'->5CSM!'SII*@5VZJNPK77YH7.N'@Q9]G5'=Z*JUI?#J$%+
M.VSCK-O+Y"LP3<4<[&X&>'N5^QCWPJ$Y'$L#NS*RX:YSX##WI+$Q6"],EBB"
M6H.0$<G=.3!10;T],#?I#?!!L;E@U"S/*N(V1FQDVN#H4C:O\XDCEA:'T>-5
MNW\ JY/A#&T4'-OE!V^(8AWKU/(SQ;$<S=ZNEDA>AH3?B1!:WCQ X:CL.L C
MW_=*F2"&;OE84;8&E'#$&[F406W_7B!6=TJ+DH%)B*>*C( $V-@J".N_ZB'>
M5IE"T+7/]@3A7N@3F<?#?D8OQAH!.+ON'V(I49W32$H80\- 4I[7_CCV=%-I
M&QYN*OP)PC0D :%\,2MBS]X/,;$LP0V\!N*KT?%MI?<E,-#U=H&NN#=;KCW=
MC)_K?")F!)9.;"JDUL_L;[]P1@":Z>&@$,<J&1E>MY4AYND-3]#!07QOD?"<
MLIS8LKML@KX43@[6@X<1L8NJ.X:>6\'$LX)OE<>^DGD(R.4XAGIO[\/<2>LW
MX7L-7=G; #"2Q["),^H.EM+BH!V!C*.4 ]>S"M![D&5G<N=)W0P6&7'987M%
M1-6XVE@>B!(,QBWI'-4QQ%U?-[!*'#5J:%"UOL-W@!('LG^*8%-_B/\=L/1=
M,H#PJGX_&F=QN%B?K )OSRNEAZ3YF9GL93;J\"1[43<.R)S')0<2^8LHNN73
M0_,.&MSDY&0-K"(SL%I::71:>LDQT-&N*,B$#*]($LO9M3M-2J_\BC;]TT@)
MD.TL.LDGD,F;U)-J[!&H9*N?]<67]V#KL>&NX\X;C-^S=#.2_/+PRV2$(X'0
MR(+2[08["KS=I"*%1_F?NXS3_!DDH8TD(C1."A4G3Y*K5_A\D&AY:((JZ#(I
MS YZYRFKTHD*T#,1$/GT".E=+8SR=BQ<]BV]9"3;",CPK,1-,NS9T&+.N6_5
M>P.$V#M6>;3*$/OE8CDD1\909#@A&#%CJ]=A-C%4B:#I1ED?2#<^4WD)A/=3
MS10:?'Q8@LR$<J)+4%DA2Q,^#0<'23LHB B3Y/:!W'1'RJR'#H).097#5''<
M4:W8GYV ;(0[^Q6>+Z'-Y1X8XC.PJ@I32$O<\EHO6^DPM= @MXI^QVF^_2_A
MP(N,UZM"P97F^]AB"6>TCMN.L.W +)B:1@(16MMZ$BGZG\]T&XE<N0_IO_@'
M'VP,Y*Y_M C!V+],UUOMIW5]PI</*(717LJ'J/:JN-<LY;0::P%,+S34.M-0
M'0R_-DCV^J*(<W)??L:JH8N'LU\MH<V@GWSXN$-_'U_)$.[7UT(X$$C[.N8F
M[DQ_;,^=1*_?C_[O"<@,^3GX*2]CD-NT%%:0IQ8>":)M*XB4_[A$T='E[XE;
M&3C2&ATTN\3UW;P#?Q%&'!0Y)9#YL[8 M/Z<KQ7O&4$Z.9;G2.BQ(D@N0B3^
MS-16&%RXL%:Q6M&8(OAP[WOBN"]+EQ+D>"48# -_9DY,[],MJ(JIN):/RF2G
MWP'*V>\(CG.^Q(W8J=V%V7KWC1C7!%]9%# KD=L$*T!\%:Z;="_'^L[72=SE
MO6F;L/='U:A8X,+98$/(<18 ]<MOW2U".)L*N(<7.B14MQ[EM-,JPO-;JUVA
MW_>%3PR\+N;R_=&LL%NY&[[MGBI,(YE3%7Q^0(A3Q#A]U7,YB[[2,\^]0-&L
MGZU/E_>PM3-I#2+RF8'#/X>6Q^P\))2A,H5VE1?MDR$1080UMIY@&'HV\N8U
MXF3U:MT@AVCSF<P=L\]_)0!$7ZO,]Z0&X-,$+%:TI(O/#2)9=&=D/'?KX%N?
MI+='E'&+-7R?DAQZ0 CH2GC"Y'B3, B*]["W!5A>6?AW;T^6NJG,;BB6W0*)
M\7*KG>-:<S;2HMZBU1KEO%VB0O/,TND-_I80?:3,Y7Z\6^NI&Z,;_2S\+@#C
M]Y7>3I;0#(1N\NP[[]V\FV N@J[,4S7YF$]&+\MR@U,/?"O\:9"T3;)"_6]]
M\DXIS]64<,BG&[Y@R>:I_'3EV83W,PC8PZ@Y5L-\OTOV'1,"I4D(CQ,3[(ZR
MN#N"-U_#JH"LF>4MD5U7+T56LL$]VB'K+/*9?S'2I+9%%.%BS4^%,MOP]G&>
M)69$5PM9[(N 4<TNUT#FWWIZ^G1]HY>]5S&EK4,;P4.D60%385MVQ2?!,$'N
M"M:@505<AP&2;R:.J-_K7L]WI&OK^%;$J)[RTOR&Q$=BU?] DX0]2U:MZ^3-
M'T5>9NMKM9<-.TG_O-?,ZI1;WL.4>90@W7GI#([>MU"^:*@HHKUM;-15R)AK
M= 8.EZQT4B\URYHD83*D)KEC;Y]EWX "G!#)A\1=O-#PNM<] GUDSDVTH*L4
M2\OB%BU@.DHIEN0?^GDB-=3Q@\?S/%HJ%VTWL9$$WX PZCZJ3\'#T)CH/QSF
M%D\JHC]B&?D7I,5^/O^]_I9N[#Q17,5?<Z%9M(6F]$T^"BA$TM% N!FJO<<.
MQZM6G?FKUDZ&YF,^.KQIZ-,O88ZM3$/9<[\0$Y0%:R5GVS3?QD04> N/W/>)
MCD]]8YBMC2O\$4U$N"^)*%D54D8V631 0Q2%TD/.KJ,49MOID?S>]V<]G++;
ME$G1IPSQ75E?]IK9[Y4@A_4JWA9LB?Q!XVK09/6&^+P6>;DD7)D(/X6CQ4'V
M6(EOW#L3>M=#S.,\2IA*_A<,TM-T66,?8*XJNSI)8E9)"C]C]O?=A*$#:B1^
MER^GLQ6>6U'%PB;T*;<QHK,TEG-"\N$K*P9E]-NT4D X]1V*7Y<Q"7E(L>9=
M^T ISW]I&PR5+[A7DIAEZZ@C/<9$B>4'?LB%C(CW?#=K5M:)<G#':/%3T[RN
M(K?6C8T(S>:?GA".PCD<*+<SDC!GX.*R[_RR/_P4G" PCOCT27?S/Y:3ZWP^
MBJ?JQ!MY"DV4E6GU>IBBEE8U-7:),F#7U.H#G*[Q#/87 8&=*<A]7N6JE=HJ
M3WNZK4KNVM3O_D7Y9#2<8">DS7JC@8FL#D9^A%M5=%.O4;S]AC< )GO^A72B
M!?LB]KQRZ.(<%<'9PC#YEL-4F#(RC"0 ;AC=\4#C7\;9] [!55']_">2$?#_
M++9W#4G]NV9^]MRNGX?[9CQ$_5SO,'X#!)ZN@[/9UKWR*Y%V^XIR#A\#:UK;
MIBOLV1<X&I.UI^2#OGQQ2TSF5VZ[![B5MBB%U*.0'(]*?*^'\!&@*X_%][<
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M;U0@2;D7'3PF%Q L5[#8G95WC1)D8@O'O5,D<^)L9G20<;VM5!11ZC$\CY?
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M[O3P9V@]$>8-0/GG)2F4EQ5,U_Q+Z'@.^&7)K,PUUEY2>$/:'AS7K<>SD_9
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M,7DNE$RK6-W+;[CB*>N3,/L3$SCP?C;&G3@VFGL=U:K%UBL\-<W;E9'ZBP?
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MUC[)+EFU/XI4MG,9*K^O:V*7LYS;<QBAO#P<R.% X_H0#:TI,6+#.3:F-J#
MU5U;L^/#MH-1M;>:U"KEV%\A#X\4JJ8.+0=.Z5[*#7_TI9]G]<' VW^AOH^N
MLDV?*K"PL;(=M7"<_O@5N/D9O]B$V_]>0.T5P/"&D[WD\-WW[IW&^=5MOG"Q
M9B<@*ZN)2MKWQF9;==F4K%8;-Q70E*SZ</DM4/]9\M!"VEMD<G Z&)RE\7=.
M8O9:;VLN']6F).M\G6:-L;.?5+)D[!T26>MFLFDA<;?9Q3LMJ(%JXV3AT8ZX
MDMM4R)*ZJ*MXG+=&+4;C&Y?9RWY U-RMJCN!"%W$5848F4-*I OPJTI'MI
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ML/M@G1FHV0X)4UB=MF]AW,8D4AG&1/X4J01Q*##*!8MY^+%\6,CSVX>=C%<
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MBUFH\BW/.K *0]BP;TZ7MQ)C+U>:,A[B^AE6+(6SVNDEN^4$TZ%V^#?-9 .
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M+F=PH-Q_"D>J&3,@U9*F;XU.$S;8'JG<[D@QF9V%N?4QI-^R0X"4O(M3F*B
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M9N]</,SL^>?J[ ,W%;0 FY YC=]-\FIY<>9"-+#Y[D,62!D;-D+3&K<^W$Q
MCZ![^-Y-D'B@Z=Z[9'D==HR?8Q.I%:R6?726O" U33HK)*P$2KCL^K4RPHBE
M5#;6<*_A6/DM<5%XU$RWH#']2RL+KHP!(*?1DB*C4H928!<IHN*KGW39K+[7
MG&SGA64Z6>=S%,0/PI1JQ#H3-7@'*2^HQL&[G\;$4E$NOC )@PS_"R-VD78'
M#V*V?/'A3Q,VUG]V/02&]0>;SD4&<%*M%]$O#(]*5+I8T+PAQ596MIO^:L%<
M;JNC ,M#NJR2>SI;G@P1C5? UPC?#+WX.N2<!!)J@_'WK.OPT.>+3PU3  "
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M,9&S[3/-6ZU2^:+UY!GYOG[L8+U:GM7%:EF<]KSTQP5$;G2S\]PIOMPKW<A
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MF$QV+$S##TK*.:H5Y3F5NS1_\B-O<ZT^1/WYNZ'6]F7H(W1'O=\?TB5>54]
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M5P_P<$>(;0ZU9F7$W@8&TK'H:DI'_] [X)*;?*6)=S6@(>?@]C7$)S7Y)&R
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M0.J512O><Q]W*IZVYX$ZK-#W50%#E9@Q19;'&2 6!4>T*>8A%)LJ83<<-)F
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M /GHNCKH/EA^%[9;3Z+,?,&OE9/L;<\U%OGE7:0PA%WHE.2,JYJM-@18QJ,
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MA[;V.4_#,'B9I &9@1\LUUE(S?81K6MKZ,LGJJBO(ON243,7RO%-V.=D#FY
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M@X_"*@TR6#\G-UW->(UC$^S$(GM-!/-F:_\^X$?3[SJ,5T#$G#1,V(Q)H2#
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M-W(QV%\98BH54M-U6,!F"M9"<D!X^'WZT2:=4KI"HPZ\8UO900,9_6BL3CU
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MSS0C,T<SJ_7Z>GLIPB?)."*>Q%I*OT)/1X!WX <8$%PHP^\9$URUSJF?=28
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MLZR6 )OLK!-Q?ZJG1M\V7G6M?2AE4^QL15K<R#;=4\\9B9\; J.T#1$I:"#
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M*UPJJ&-^W15?KZ?.:BXL$.7;FK%HI[K_@1#J%+K-JBU3,'U*,56I[LLD/(@
M:W:)TQ:W*UE&VOZ$_DBZ%^PE_V,KQ&9O&I*^K*W#T=@8^U5RT>/W($WB7>>K
ML[[T15)&B1N3[8=E48=ZA3[VB*@P&BK&93_BJJP$2.K,5&VX+()H[?3U_G.+
ME4:O?=0>Z403#\UCZH4MBOD:==I&_LUJ89C@4"&*)YC7]];)-A'N#H,Y8YV+
M_W9,QA!)]Z08I=;#B4QHVK1U\H^;S8:N!Q1'PF5_#B>-V0@-2P^$Q&G;4<$R
M"_L:Q.B<[.EY%.*D21UT:$ZM)L\R"(631&@@+_C[49W/-U_X[^NXBRQO9>:
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MG=38<G0PH]72P)7,DN"@PE!H@T$=W9_V+K;B<)] \Z2]_3&D=3BSNE7%<7(
M0EJ:F2*__XB04];U[Q\= $!+%JJXTNN!5?50*&&$I !7:1VA/NC2[*%U"S!%
MVR#?\_+DSN:ZJ+H<>=?\E?Q1^(-D#S-"Y%9'/7S/<W+=.$JNVX*,( $VVC?
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MH&M;\C* %0+KN>@_C*FL*--6T#[.9Y$'$J4=*29>P.I_[I+]A83P))TIZDF
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M./GB^,[/+':*FTV;+XB8\"5\O=<[27=J;V('^_[T+]HU[;'*,4NR,OBU'IO
M];5M@\T);*VG''-^4=W;\@_0S%9*YI<==;G"6!"%^.,P=LJ1\Q\ ^KHC:)2#
MH]?IY5[-MJ>1H=BZ5'70&^:0OLR@E89"GHI"^_-$.":Z2ZJ(_D^+<I7-J3N6
MR!KF DH"'4*[:U+RA."%3+68MR@+,VVX,JI7D [<Z'()N>F-N*4E7O67P*9/
M_50-ZBU?#J$$VI,GWN AW?+ZGU[\^N7O7RIBV^E^O)8_RWW''[!Z3QLA.CJ1
M,C[A,&#23M^Q"O+<9<57;B=\^#N2;R<L=Q!5UO'=]%&]%>E(P$W@C\7=Q^<X
M3]FF;COA;K4)])*HJ3F@4\PI,5(&DY)'$-JL$B;YS7](>6OS\F47]&R@SQMW
M%6\GJ@2?H)!4 4:K6L8L28=/Q?5;'[S1QA_EY!4/H/V2J[&-]?6GGXY(H5W3
M$TS+GMT8D+::A9NKD^L*'M ='?+6^1GM%)JR*T>YU38T15!_A9FMZ0/D+S8A
MVZ'Q;3S\T4TPN\S=9?8J>[Z-USQ$WC/C&;^F &07[$O.IEL()831)47+FB5>
MR0C-5HL(FK:<X].T\D#:EP[R!1M^3]]=/?O9R\Q3P(P6-,Y2I<EWY/"QV8]W
M-S:.62/Y_E25:+PXZL]PK(8;S$EQ!/',J69' =")@<>%K;<5.2KD/E-;8=/2
MJ#OI;A:(69[*7HQQ\J;BS1'8L9 &&V?)EF$@:+>IM%E]X"=<X;]OY8:VP*(*
M,PT*1:[ZR"NV[_X4SMC8AHSMF5_U-%M4R'W.]JX$?F0UH:_+UTS^!IH97C.>
MO<5F_#)H_DYI"L^V^2UVM_*)JCF=N3QDYNG F[Y#DF*BI1AIGH!L_'6#<>\0
M/3XV9V4Y(>'/*W" KV,Z%J2OR*Q;<N^TR=S<J"^?M#-&\MXS)039(R^MR4^F
M,+S3K.IX6Z<.6.20\DH1#46\O4GVZA_E<5445;%VRLH(?Y&K,K#3\@16H-:<
M-1-WW2^-M:3!I?@*:72Y@E4('%,1QX2#!=U7XG97E_ZD+ZAKU-7',T:F.?L>
M=>&A_1BS<&S:64ZMX?K<1_PALE:[ZG%1:L'OBW/-:(6.?E_=Q K,$8=U*:KD
MR7J=JIZ6F$1LN=RWRN:O0;+!R>I*"XX@0,Z5:Z2=5F 2AULYS_\_&W7Q%]DE
M/DY,/.LT]W*)6[AC;IX/WTQB+'0E$7",=OU8"G/@JQ% $1@/U9[W<_L[?+S@
MCD8X\R77_D$?&R[C@OWC#&W&V(4$X0U'PT?KK]<$_')D=/"O>0=X4!)/3KBE
M@%"AWJ_*.1Q\(/&N+ZW/XJXF*R4GI5/<W/N\-?Q.5D2RQ);_VC:CUZ*M)RAU
MF<S-672BN[/%0F4,-\!B/ZF) %R 'H!\!:_<:6NR_FS72_M,:_&B#B=)9D[C
M/$,MC5(-97P2TV>\KX''9*@VF_Q/*>>4R?\H$OWO/21+;")861IU'5/0XPYG
M\F<2$Z'H'VWN5*$'N1L4@ZV\*[:MY8KS%Y?I/(FP@84P[W1Z>XSM3J?BC2LF
MI&O*:/J#X1*?D;P'OHES$6:W\%U4I^$,015L_3^5L78:M)#N>1$]>ZDN?%M*
M?3FO&+5G+J'7EL^A=&-50WTU7 8@I) 3)=N[B]#*DW\ U%J>RD>'K\V&4/<8
M]A:N1CZC2:PW,RNJ&LW<45,0236%Y"C\4WW[PD?;O_9UMNHBIMM&TGB\&AY;
M.=MQ8_@_#R(#F%7]Y J;5E5J&LN;6FQG74*.^;_]<AH>"5#AXE*6;_UR7/ZC
M29!"7>(:B9*J59'%=A$DXVMYI<]6!=?@FSBQDDO:WV3^E+,?,9%&0MQO@ ^\
M%N$G%6]/T(C>:9/\!72M0"MJ,T':@?/ Y4?,K6>V,AX#Q%MYFRN\G@?_>BV4
M&( 4LV"J'7:!3>B_!Z0)^3S\CI#>_2I/"CF=_>9^A^DJMV >(:JNT=#@&_*=
MV=4I*5/(?V[(ZN?Q">-A6K5Q@\@_@.+50XR%059<3X'\9*G<EZXE0O-TKYK6
MC4F<6S)3@@\2.S[&[+9K2TW_ 'B! T,A-T,&D^5$$+[39*HXOL1_ ,9,[\M0
M]/V](Z.=WR778L%XFSP=AUDATT.>]#5[E)+X0;6S$RZH_7\JT:ILDK_3):@V
M>4V,]*>[4T63V5L)_AXR\5=^EY+36J=+"2[VLAI9W%R7JH6? .WN?TP_Q3P5
MW3J3PW(I'$A",CA??M%0B(F'QD>[;>&(UU:7?'(0<O.)A*J= *=/P,,9J=3"
M.6.@F:<GI$]=()YG["BHXDHK<J:[:&[.0G8S#6@(HQ:S+US;9I0+H^[36=*L
MWF]6]U?*9^6LMTFM^K;&5J1I9\P)$>=M\PMC)P[!PU]JN7??JIS^!D:(*%MA
MAO7:+E/NDAGP[NLV:R?I[<W\ RALD$H0>W]S?O 6EK:S&_'QZ/5WBY1*/@</
MI\92M;3=3,H=P1H@CA)R4JGF7%<Z#FKB%2*">Y44=O():MT="_9@AU*=:LX*
MEO@+:;]6M5]X"@3""&:S1VT=\-2_C39R%>LM1:&LEFPX4\4D!]QY892Y7P3E
MY,_M276.M":'6*\.A;6!J4LK%ES2&=\5KM A#=$8<<U0G&^?)4.<>Q\KL=]P
M+PDVK L<E_]3'K/JOCI;6F*F,XO,NE60!MS/^+2'+,6%-6\4=L"V9?I%\!VS
MH.,.66FSW'*I^"@]PMB)4/QNO=LEN<X&_,3Y!!F3;TN93G1X>$SSZS$W#+(/
MX#*>-=I[%_[%3;R0*/;,3]*7Y&W >SX^P9?HP@')Z)CUP)OAY[ZI K^#-\DO
M\$ZUP=W'.GZA'_,I6EPHI%5%ZN![%N/Q0^\P_^+ZKX_G;E^ODH^GZ;B&?<W_
MNJ4W;&3O>']*+R3Y^+#O=\0B0 RXD1(GBOW3[BZW0^01,B(LRZ;V#W#.?"!W
M.,YB(GZ\PM:^WR*LIB2G2_W;1=4ZC[,C9H15\8[3XUJWV!!D*R$ 3F2*+4TB
M&'DB>_CA5#WY^</YM($B^_"-]?3G:OKIH5-W#'R]-4-O=M$J^<D>_HU"2AE'
MCI<)#T#8OC;8_Z?NL8>C9X5!OY7]CRW>H1 >_1R,>@'R'$U?UD#I)</OBW=V
M9"WQG,Q51(P'*G_,0OL>BO,4#0?J^W^_$:V [UCQU9?![MFQ8?$W)(&[3@;5
M#_J5W\Q?K[3$25_Z/:T0F9PX/V<6/)Y0T.E._YRJQ4JW"MFUZ^62]*=O@PP=
M,;C0/B6DI$V6<3=TGG_5J%L^#U@L-0(9B;?59H.YQMHII#62LNRA(YF.#E9M
M2V":,)$H<^]E#2YD-BYE3=1UBI:</SRO)9WODX:/_WZ*IG_TW#405B/"TX=#
MIPERNZ<Z?W"+MY)!O=M83QG(KXIC+*LMJAZUE;L[%R]J+5L;GS_>)QD8B92=
MN,Q^G,.; F&1<J!L8O4%#SN<4G*WMBS@_0,,7O?7CNB9.]9O(G^8[Z<KL)!T
MD6<R6QZ=ZQTV9&^YVOCK7YY=G@U[ZFK;Z^DA'(O!_=')MT)EP9>0D6[\I9SO
M?H-'$-2+_IBZ=3P'IY#1Y-C2T?>OY@6D_XZFZ=K9M7H??W76^V7@#!#7QD]]
M!6\VVSZG, ?;WC]E,:Q0*9HJBRE\WX[:MY$HHS=GL&.3>!C!5D6)?1'EA;0:
MP?[*Q6P9MR4+/T(%=#O>K>_1X7!#=DO:KI4CS]F@*Z<&B\9M&O"Y<6_2-H/.
M!G'!D:ULL9R%H[P5=-J(QJO6:%9Y0_LED&[[U1^M+3NP;)/'0P5Y0:;&>"12
MQ]Z';;[#/KH4E]7!O^<'KU4N-<UF1:_U>B#?.).L PW0! FD?@)D)FLR$"E2
M(0#8]N0\T>(Z[H5R&L*ZXP<9H.F:G/84H #G>*%%%G=_?HTFWVINE>:N5DB:
M=_61+JXL(%$'#P7ITTA*!5N_N6L/V]4IW-":/WT%FK9[_, P';&HZF7.^</\
M6U^F"N'&9/IF&P22*"L0O9. ;W._&&C!NZ'H!@W+X$3?:[KHUH[ZC@Z.AN(S
M8A289+-.NW<PQ/)L>ES\%6:NU*4..=.#S1),C+4J[K.46PHED@0#\MN4%ZKR
MN$/?\&(5F5:0VB-^PYX\G6<^-$Q23$80(^&(39_^AWP.>JYZ(..Y@X3PN]A*
MZYI:>_=UO%E]NUC?SRO1[835]K1]B4K(W\/RC*@< "^C'@GQJ]H=UX3Y9H7_
M -;9T3R3HV%ZAD]H'W>V<2<9X87S0/+:Z9S710/+BJJRC,!2V#@Q\T]]D<\2
MS]_%39(-1N,#E_=:]>_+&&)XT'C6>8GOIGFK3)W),X">)-%D":D]3MBT"3Z"
M!VYGA#+"%5Z!H!^GK?6*/YLGMR3O90N72N(,Y^@H;4?RC+];#O5Q D)<D_I_
MV10^]MJB@V)A=L!C^(H.6^W+^!E83@O/<6,](UH#9RB!3TPY Z3])E17M^C^
M/([9L\E,L\$[\;/[JP4P"&>O CLX;I/['#2H60_EAX.*'6]B,K5I%/,L9Q]:
M_-9.XWU4I^E:,+'YK]DC_70KK(E6U$$GVB.[9&/GQ:U+Z=3XW5.E&.N):#@#
M9@@!X +<X)Q8U]\]?"E#?YM";H[!9<!"I,3)EJ^LQ30$*HLX-=6M21]NT-C$
MCXJ6_0)WSK\"0_YB&BEV1H#&JCUE_"GGNY<-&M ^T;3<B*(X-)?UT,]ER:FZ
M5XMT<?B721')I<8"GB+SB) H-CFDQ+QAQ@U?O-BVM)JO_@%2:H997*MF#Z++
MN 03ZDTM4D-SK@_YB??]Y^<T#;ZJURU7_X<VAC CT 7S(4R^@4U&-8W.LEJ+
M"]PM__\<TT@LM$2T J=9;,XF(W'_V-K2UIP.1<.E&ZK&1S'B3%/"$*"J>UXG
M&<'^CV"$G\&N$LL.U>R?W9/O:DP:ESZ@FSF[,2@D<!(LNTP\HGB@3/0!A*J-
MM#N:EEAYSIDFA">??^YG:OF&8MB06TAR"VB)FG\#J.?< [*F6Z\/\U:AX);"
M_>.1>^%$Q>4)MO'M3&IK&2OZS#KQ?78EKQ4VK?E O5C)]):KC)@_CJ@ZNM:-
MAG3G)2,929,!"TBY]&&IL5R 3,A,+RW53H"%@.WRW(MP[:QK:0+.QHG$ JI#
M9IKC?GC:5#VQYKW"P561@H/G7HBK0>#]8<IK]6O&:X7%ZW\76BS?6IG_XN(Y
M<W:3Y'@QJX(HQJWS--:ZR5]B4.W6 0DOVW=M;?#'OK$3EDX^2UQQ7GE1EM^M
MG8DN<=9LY)UNEY%[U7&OM0Q:V2A"S-E(,I/^F -B@7$-DO+(MD]NURK9[F2W
M(S#D9N'M5DTH;H@[T$+&KA*5@LZN_3ZYQYC;DAOU0^%$>#]:3KYZ@LXM[ZN,
MP@WG/9D.F]_T/T#@%%=<VRCQ3<?#YKFJ=0]]_7+75[.*KOO[D1-&DAV;I1\E
M:00K-%Y/4>Y]?0RT\38C+J""^N#"1T?-!?<H=C.[9B+2X9>,NN8=:ZFF..ZA
M2<+S@O2;> V'IVS1ZQA>YO8 >O'RZH,_K8/J;=RHS>P;Z$8TDJ1DX"?]3^Q'
M7T(&J>.WF2LC1]\H,]1[PIO]>5G.]H)>V[9D#KJ2,P,]<[8Y<*U(QF>5F*65
M/SX&?,$3=-_DI90-F(M930J9![,>(N1I6S.(<G #L[27D2-)_?AK=7_K,9K4
M&"G8$]OBBE=W3+#+RS0_=!78(\E_J*!EP5H9Q0$6O$AK62AJC!E3ZKN@]>F^
M+?S(DD ;NZ$33ORT0R93ZN[#'^\FJCZ0[G,P4UZ^+NGTDP[/\/.:A06&*8OL
M4Y^H@-C2+.GCRF)_AQ\1$3I9YMHY5V>);3&)J2I%1T-PN$C=;RY)M=QSL*1D
MUI((MO=]M<O*RI9FNO SC#FJ%NO75!%/,FP*B:<SK'C" [,U'$$2B[!#@&?:
M97&PAZ:NH2W3BIUQ_JBCC5NH4J)4SH-E0UX?<YT*8<FTM/-:851FSI''%ZD]
M13\)C[CFB -U\-NM14QQ3M"//@I%O7^ L!!1MDWLV!JW7%)O@[ OKT4DYBK(
MLC9XW'G> '+G61&&+\T_K5VTA;2ZYH?O_86'@*:$QBPS;;TVNC&C!V,+3[TG
M_7A^I5OI*(XFTH$?O*8=:AW.X;Q+=!%.#O-+:!2%B\LQ07T59DC;+FU4Y/&8
MGM",J#_/Q)>[$1<S_A(3ZS648W 9LG!$0?#H/GG"CRMNS;M:8AL]K?Q*$:)T
MSPRH054&UYJ,6Y$^S7X(LOS]?OQN5LY?J@9!8?"GX>AR$%M!5O<2TX,P^+P9
MP5%$ 6Z4/'.X,TF3Q(\L)_;W0(FC)7"';/G,3ZYBU@2Y1.]!K;'C66<I.G("
MTX%!(H[JJ9X\OS\NGY'*Q*Y@U4^7,GP7C"Z?M];ETRD?L2^&]%Z>:=\L=Y:F
M5C5$2K+\\7#@4O_Z?>ELFH55$8_\ZNT,H2 P0^LTJ-.03ZF<3G5:V'!K>5 R
M-T'BVGW &[^GE/"8"O04V'3%!CJ7-4_>LL\,%RFD8N+#;_^&!,GDQ?PT/ \]
MKC1W+/<%P@IPMLA%/N]Q\-0>T?+1 LR?<I5^K_TY_31,JJ\V3C_\&B;D I,4
M,A(],_DT9:6Z%7R#P2\]CECXR]-0=(Y51-RN7+'2IH)@.'O3O[2V6%.?>(#=
MT!.%!<N'^G3M,-OW?1)H1,BPM\*6L*)8T1VS(HSN'.R^GZBXV8@GB"*F-CMV
M)OO&0C[9C3^D]: &*[(CZM#@GF'%V]+BG+V508B&:R=RT_1"D8GK#P*T &8-
MO:M-_JQR2W<@,HY.%P<V-1&'S=8*"@\^48]\20T4R!^!KM4E7C#7!#:_15/#
M":[I@4C;EM=3VS^ CL IA!+"9/9%;QQ;,B-%ZMH@/M.=((S_,[!D>5>SM4/J
MIK2M;<O1::@!\G[#I=VY,WP_&&AT=13+SJN=!<64!K89/FUW&\AI;3!#@11M
M\;2?50>%0F R@H)4U[\#KQ*MMZSSMI[U1F=:(V>SOC:5_2[N$UZSHG82']]#
M+EUT!POKMMC%T;RMO!&XQ+%633)%] G0RY'THU#NYC<EKPPT"$R^?AJZVMJR
M]=#V5%5P))>VZ+2ABH>=$6/N7S /]Z&$;P1$%#\Z5@3:G/H40Z<#65,]M&("
MEG^A+]^.9TPQ3=*&CZVG/<GN,;6_:_YS2:+\\W1A7<K,TCCB!.3][@1X_S.$
MTXASFXDC# +A%);/<06EV$%%NRLZVI;M35MQZ4:LVJ7$R7)H]W/ IJ@HA:,?
M^9E=FDC)W\+!U38=X(S(_7G)8:MV,M5DKRD7*LSF)''V0W)(A";BX5,"R8BO
M,H[RU:SBU<VCJT9+=WU$OYY%WE3('!!=4&%*V@FB[;*];=EQ;C74 O4,AX$:
MK-FKQR$R-!M, YYMW\ZIQC3>-TS/ #XW_ /L"(& (.9<6S)TH%WE98-_"X4B
M?0OZ_OCG:VITN&@)AZ%L/P\#PR_Q0KU;8,\U?4^"6>4Q*21]I77X8G_9<-'M
MFK=[ #^*/!Z]8!MQC%: 3N4_203ERZX&B6/.%#K_M)6M# 2S,',T$U[+',9=
M%$\/@,]O+>HAB*L)>#83#_B*WA:$N9A=_.^>:FEOUF1G4 )3_8HQO,!K%)C?
M1(Q*RPJ]*:8W2[OCFJN;)[;&78J^($TSJJ#MO>DZN;AVWGXL7>/AJ'&KUML!
M@P:A(G\_K;GY/C-+M2?CF:8-4<J1T3E#BEU\*\;VK?*S!PW9=&KV%UB;@61V
M<>)E=MZU7:>MGRRC<:<JW3(1YA^Y_C#?)'*"CJ^Q[K=)SMQ\OYSU3/N[I03:
M\!D*ZW:54:%&/46KB=D;YWD=2?;G"26,\&>%<=K<0-$9P1M-"<FS5$['$.RV
MZP;\C5!-[V'#_F*N_:NMJ(,%/W%79]^?/77WE82Y![;*'Z7>1J*F:+512Z8/
MR9/Z^XFWETYWJBTGU=O:&SJ7Z71X@4;UHV(5=#_!J+'G9&D;%P=EM $Z8(/N
MRO:BQGN(AP V_J.98?NU/[QUYZINDTS83L"*"^%&,-=2U/7&.W'RPJQO?#=+
MA+="QX]WN8N]W,:(=4@O"V;JAH H#Y=P"8S^)'C>FF/9C1PC6MP@;I:JM>+8
MI8C< $6Z3]*%\1:)BPZ)V</=YC("D]8E1NJMR!K^8Y81YS^72&LO7U=K7N3
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M-J/&)X0^O*BQ$6Q&T,\-!.+UUNONZOVD8:LR6VU\S"W;",8]5DM"K:A,Y+<
MKPT3_I2ZI"3IC+WI3]K7W_\2% NVAY<J#N]10S]#]VS;W?MGT']%]-/2Q-O&
MJLQ-/ ;O;(+4ZD/8L4'1%OY"IXHNJA]H%&A)J$L4>T]&ISJCWO;,3:"M@^VU
M%VQ'S2MBXZQ+,X?B&,'%VA'$,2')98%+R(,.DDFI M6(>Z_L8QCI#\D*1$>M
M.JM3\9).K"N$3W44I1O%.7X0.8!YY&B'O3/<OVCA'NT,S%934[V)[R>Q(6V
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M0NA<F$;$CI'!&+:7%"%-1]EF[,6+F3^DR/4&UVIJ[$IW;P?IG&L,6&1)PYT
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M;+E&,VBHQ]/F+G*H$ES6Z-O)!,E=O-;U4?$L?RV&THO'FLS9H_7NNV_;$Q_
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MHP[!*&H:VT!CT ZH7DD0BSOUM2P>6K[L;SL/]SR-0MFMG\>%9R<9&=)(J[?
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MRN]DVO^&1.6XAO:/+OA;U@[:#A.V%+&\P?ZP+^.,AK=7&2G*".O^RO%LK.R
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M5G<DTW'RTK9?00X'PR&KE>VBY^E0M]#,[" !0&V4<7W=U<QT(?CGSYIO<OI
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M=TL.28Z^1P!V5\G&2'W5%'-WNQ!LWGY]!-*73691/D// NDMC>7"L''.UQG
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M<[3-2D%\)1O.>X6]Y6T? D)06D-X ]XHM>*LC;YB%=-&*H0QM&,_"6G7^A=
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M6Q_I)NJL;-,]X*),>W5@6E5C<9M>OFR";FSEG)3[7%!.P1 W9KA';9QR-K\
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M]G'2!G!O*4Q;S#*;@WG-2A(VZ^^(%\ Z_<.C)<4Q>,=!I:0\'-2:D;9GD.L
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MIC1Y9BBA7O0>8 W7BX:X?9[ (VZI+8[K!=&'V?X//Z<<2HB5CYRBAEK7M?<
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M"BZ]F@*P;F:/[8H*!AH$U?'D,8D*&2_Z8$BWA^O.2HP+G(UW%)*G41@.567
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M"I3*JQR/-]->CMU0.&0OS,M.>:36I9K56NA,AUTVR/T4C>XV+^GK1RF!5>X
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M9IDG4X8[ATYI@1.3C%Y(L_7M]K8*#5OK?16J@[J<F)S-!#%4(<<F0<B+EW>
M/\?]7R14^%)[#%;AHO.Q<5&DOWL8;N?(,\8P6475+N*E@!-[UGA9OG_L59+R
M(LP",9E>V3XC LEK:C8:6![82P(7+P24_C4WH2 L[?EWDV>D:T[Z (<7$FI
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M\?_I?O_[>_?Y%\_[[]WWO2?KCZ7M<?=,'B1:4QUW(5"7_PC!NVK<RU7;^Q#
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M]E" \&:T@.\"M)_/,?[]]IR)8.EZTE%N>HP4S0-1:HG-H? 2R27MP8YV'^_
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M<,H?5,U,B=VVGC[>$+2<A'Q# 0=47Z_&D6K:>O2*=[?>K4U'.)8<Y8?+T3S
M]I8,[OC+X==K*G"3)\4P*:%[IC80[3;U-*;[64J"[9<Z1?!.GMHL-.1Y&@)%
M*S_Q8MPO#4)!-JVM_VD\]EYZ#7*] U^W-$7=U]!"MSV'R3<$XX10EKN\Z7S9
ME9QD9DNZ8TE/@;/L5./@@CM]<>28/FJ#Y_9GLI/0>]8M1*I\,'R-\?3&NA3S
M]&%"]CBIE.?RJR #MV8^KIC@H.%'06_O'D9=N*G.3]7YHY6MBP+F5U$ 65V\
M+UEIDG&"<J2;3IF>.[;I%Z%L+43>*PG\RFJ">KW4$*G#;$G"TN:PM^QUVP/T
MD8,?<1?UIB39_GKL\ZC?SDK:@?:B"O$I7C(\VO%G:4DK(_VCW;,B)\AJ)1:L
M9VJE@5<#Q]K61DGIU6'<<D\*,J[@!<6TXTFC@*AO32CSUK?2Y9H$S2':&$FQ
M!;6X,+B"S#OEKCO>4L;F,T[&SZGW<W.^?N;0GY2<=1GI*M D&]PTBA&656X:
M#OC^BLCP9'(\O]6.3<BNWF/9N+VIF9&HOT-H2&ZUC3D3.H^.(4XTPVWLB10A
M$6:"8U_ R<X-8UTC41GYT?,I15D']<1LP=1Y(SOOLIOJ'JG?;W4G,;IO@8<M
MC(R6E#:S9M>RX&KHB!DHYOD2*4W19"FU2>?8P($-UE9R?G[((>2#7F1:AU#H
MYJ968?L&FZQJ9D69_D'E5MTI9?!*8Z3"'C+>GD M^@#<P-^95ZFY[>]'ID-]
M&;_VX!9R@3K\?()[1&:P4(XZ;G1%L;3Y E=H78P.Q(%(=U"QGX;JJL28].&,
MV ^UT2YO19X+8@:'=,O6B*F?/."OCE@=PM1E5W0GJ'QK,:ZB^2%]#L^WE?EX
MJW547352EG>>5](]PW+'T$[XEG"Q3?S0U*KAT%4[)T7QR#"LR@1W+$-;R24H
M4C^V$0J%SK$9O&_;O**[.B;WE^6/UU9__%DH:#SKZ^L48O^N$MGQPQ\DRZ$>
M\Y_4"4ZRT;08/ $^/8>WQQ-=+>.4D><MZ:Y92KTLS%W<.Z)G?"4[)^>T _W%
MF\A2F;7E]ME1"&3(*1MEJIR;PW]C76>!S:82PS;_UV!/S0+,2!E+V$6#E6>E
MK]NWIB9!#?NQU$KI^?#7S5+B*+;L^TOD0JVAW8$D4]PV$39\C<F5!Y;CYT6O
MLK]=,/R$IS"0.YDO,Y[TO1(G6I&>K0I$8Z1,S'_Z:/9O:62600%APM K.X6K
MFQH)$UD6!@?8Y2@ AH,"4@,O4BB0K H*H_TF^0SI38.]?WRMY_L^L3^D&MF'
MC#Z!4+L@RF?KWPMW9!E"OM6A@-P<I"P*.%&;5M)IO:]^?^7KX$)![$*!W&@>
M>35Z-?4N0A;T(*,J*( 6!5PR@?_X8SLW_V+,!HU-8T_4"<[!Q$BSAR@ =Q.9
M#CUG1],XI3_^T+ 6!VD7S1\0;!6"#CS8$?WT2**)*W'P@0$**,OX0QLV%?BB
M4@>^#)K4!"\C#,Z3%!#,Q1>!D&4X"C"1_$-;KY+0W;(:T@DN*X%TG<$/GT//
M- R."5% %P39'?J'=KTEP^]AAD%,WJ" R'W(JCUX#P;?8$0!$2C@*AKTQQ_O
M1Y6.\V=1P&-D=PL*H%_\?]- QJ9:/?+55;0/4J$-!<1_1Y/BORM5]9\T+#E>
MX(+PN63&1D"_H@"N !3@B_:<2@H(-+C=ROV'7P55Z:%%ZKOGV'^J]O]<M05Y
M0T>[6\ETY.Q\_0?5GR[?K[$HO(9JUXN+;:KF%M'9BM[R;^U)B7IWI>4#^V!V
M:7G.]F)B>3M(LKI[-NF!8U*H-MHS?L9&IAN<W[A6X[?  R:3.)ERQR2V^43T
M/YO,"?VN$OC9)/W 8-D>!>QYHH!1]+ >0ZY'B;Y#B1WA=3U/;\7-KL*]__(T
MD"G-XE4$\3D%!/$8?(Q&>IV@:W7]_5:U'TJ2)Q)XUW/_]BHK$&G; @GO0*O@
M[_VAC> VP948_ #[>LI\"2'&;^#74P#ZL^L_N_ZSZS^[_K/K__6NU6/\%Z!;
M.FLUEP;)=5Q4\\PVG*_Z'=R9W0*'4[0^9_$\%^ESA1\^S0;?5V9[$!/:!0G3
MX'%>(*B8DP-/5YV7<6T?. 8E+>UJR(K;!GQ3;*,E&VILA(@&\U;Q&YR)0#:>
M7,?*ZTB'QFRY_LA7U\$I/[T&7FH'.MQ%/\$+4P?XWF?T>$71X_U+F$,'?B4"
MA,]U %$3!_VH(3@_18?DNW]>^.>%?U[XYX5_NU!M>*KEQ.KYF]GZ[F"5]QQ)
M=TRSTNM*?MQY052K%%R,9G+J=-,S:#*X?>\_S;[]*7_*?R+*RL-_.'WE[X(9
MR/"[8>J)R]!'FHH9R"5A#J0'#24 #!G<__:./^6?1%I6^M]N7.$RI"J]Q,C,
MXH[ZQYD(E/GO?Z7G_PJA9:7]ZZ=M9=L 6L(&Y7^T6L""48X6^./W;PG3(Z+^
M^^WA_P;Y;;/B-%D@ #=.S0(^09 %2-'0#P>WQU4@)U-OS[G7KBOR9JSLO<Q,
MO DM4HHM,H\PM8[1T<(;4\^J'&T:_&E]@YY"G29#N'YLEFLE' L<6!"M&6+F
MZ!;(4"C71JC(D H,*R?( (Q\N-K^= D/:5F KMS@4=G31)"VL6=TGUG_W1'H
MJ(J47+GHI<B/JJ''],.%F+<[ES5H J'O2*]N.:N?W6,39LHB#.>(?!<1I:P<
MV#OXWWWNTO]0N!7-,?[YCXSBM/\F._R_)")V7$J%_0,^-P/!#=/V%V1 3*#-
MTKI29;-^#>(7IB53@4%[LOWYJ*1&-3;Y!'@7<IRGA^$1&$CNFYA*34TMW)&+
MV-!^\P_+X[>\>KZ)7EZS<Z,V)ZG82DH\WW+FD/ %Q:H,7/?5CI^0;YZL0UH#
M,*V<N3""9A3@JUG5Y+<9ETB]GXK'_;<^HBJB -QBCJO3!76"X_PR2#$WL#^<
M\F+EF5-.:.U+PNP-CTIY_4H'FYQ-U95-;;%N<49(D>X(?(+^\EM>SY7E:C*R
M%CQ'Y/ C;L<F05M45O?JM\ED_V5!$^'+*8X]>08Y=H;:G\H90.I5<T",^3IA
M)QP32/ MISU(KO:J),(#=ST5!2A6JO$2"7=9H)5=*"?R?Z3M_P_%1QS+\T$L
M8=0DSHU P)DTMV4QX?M:8 $&S\U0[1SF$OV:POK:5?'G#L+/S$O(+_.L^G@,
M[NMK2U?Q0P]AK=]B#S8$1/H$8VS\N6?>8<TR9&81015Q&=+C_G?]ZIW8G=!3
M7U&$1';D3FAN[GY79OOG_$B"N+$9-2U_NK#>3:_Q<E+(,/9X90X%6:_SU=[%
M(+9XCI'E_N&MYR^2QBX&1L[PCHIPS</2 QD]_QC95!TA!!,79!$9L6<>\,%!
M3%QM("N/5.;GI_9R&':WE?Q/!RN!GY^RXT@TC%:+^O"N%"]"US0GC%815K9B
M)/[(F_#^O #R427QQ[\K4&2T90"F!OAFL!:1ML%Q!9"1)>3>_69= >3@R2@W
M>F69U&BY/*LPGM<S7A$0%<AY5% E;(@"/JCQNQ*]_PXIN&[V&!K5U@@H#Q/4
M_ZN-*:F(&!GLC/$C5W31)K9VF9UG(\J)?6U7;Z[MJF^[;9 ?%D%PC*<F[*O@
MH*TD+<-,K7C]L9),>DH+2\:PLOV7#TP#,VH[W/C@18#!:HBE?QRRPC5T\R7Q
M>49"VBJXB,KH8O#6!3.X%W+^2YS*" 5 N#'2I!-2AU\(C(AVNIO?D D:L^(S
M"ZYV]%''E@&T_U9Z\_^WX!.2 3+OX.^3Y6)W!F]@OY*:9:"\A9VE"=. [I!U
MC<H_[7LG>RIGN&%V'Y1E04@L=*H?>_5X(O6, "F^CSQVA37,KYLVTC<;'+!#
MFO-&M77OID<IDRGI+OUG \B@'O?$9>0C4#H?JG677'N))TZW@MQ#_)K)20,E
M ZQ_M-MK<\U6#>T$:;_);/<N>"TPEE_,D,GUPK[-[#G:2L<S6XO0C5\7@UAC
M_AC@ <O!_$>Z+ :[H&7+*VXZM./B^(>5P&EP?8+!!9D[!_( TGB%#Q J#P6*
M,O7S\R3;O5#1=@R14TS^P'W[6YW!F@X9WST4T!Q[/JXW=:B=\/*JL^,T]CPP
MIX0:'>\R?P=4*7E&"WR -)<6U)"7G]4WUL"UG:(F(B&Q)$=W)%9+6T!'R?B*
MG"E\K&)TH=@0^VH#7,5=DL$W>#BRFM/UHJ4WD9+/PS*JT6V(K3SK81L"?#JF
MG*@Q(ONINA1T1J1KQ-:N'/%(/MJMTY[TE,B?KCCG1MNR& IHU*XSN2IJD?I9
M$SP/P]C6EF&55"6<G1P,B:KX_!-7>Y4/_9SIGC>D92P8@'P#V\H9C>W[RU02
M.]'O&^85/V>G<43@2,^/&9HBHQO)+#-<WO.7$IE(TQ,Y-O$]<W4]U*"JS>?C
MJWI#.<$1!*G4-4UCL<X6N&W*:91:#=F#/;B8G-6YNKLDC (<4,""7H6=TTI!
M<@CNV<71\-4L\G ,JERBU<)G=]PQ1S2JU4,QGC]4XBQ\F^>0%VK%9&476YYH
ML[-7@C1L"AUZ&2I;C8L)$S B2N$,8LCJWK'R^JX*@W*_L[C&RG\[H/M)5B8W
MAKSQU-C]=VI=&L*6>?(ZGAR#*4>#<;VK@=BOPP.50N;S\FED&'^<@)*%%4$*
M_9XDQ$^C-58)KVJ$2X^SEHIN?6F^6ZG_T0LS0L K7$7V\62?T0Q_PIO:#7OE
MYID143QQ5H0DCTT\[N< U3MO5-;_E4.1:8O^YYZ6E985(%0W:9L)[RM5"^@
M<[1)7F4X"$@(N'0A*S"*Q4W9TNP4>K^>@_:SW"7L/%15!M)0 !DPG%[>AVB1
M[*Q% 4XH()B34EZ+[0&?.$8 Q8V79$[_$LW_)T+&P U$37IL"R2RSZ;>[G@E
M9R1/>8OZ3F 9[LC#DD/-ND00P]IPU1KH22&E1IS42=%CZKY/8C]UDS2R/PD;
MSE&"M _@]Z%'Z<RC3120SBJX=AT<1VI3LO$Z '4K7NM#T3QU$/.ZH:9S)3'P
MNLHJ6&2#V5RCH+M%<E,=1P@9?3#1!KZG]\%_D:<MJS?HW1;4V-[I!F!VW,<-
MDQO(=((^-)\:+:**SM>>+0M1)Q6%4&MG;$+7#>ZM"V2UQR\^A[TS-D_@?\Y@
MGW#)WJIQ8.E!5M*0>&5<XHUPYN8Q,PR684@/^TVR?NM;L4$M8O/=%U@:H6<W
M@:/&1G0'P@-T2GQ>R4WW%,0JDDTD^?(Y9N;='QN6SQAG<S$;1CI)%D+75+-K
MHIS"_9?4LR_;<]$>)3/@W4!=8ZW*0>_2?D&"[L%K#N;8FP<D:SR)[_D+IL"V
M1:H1)9&CFUZ=Z8F@&<*-[_^%2B6VC[-5DI9(CW,1G1T:2F?#)'M,.-ATF<3W
M3J+!N_F!TNE=5XM()TT-)OE&*X%7ET/'13@[UNV.0D;(F\P<.]NOH:R]]+\6
MH<QWC:VGW#LA\^ +G(+C1#,F@>DM9]LY*G_P-RN9?_6?5E?+O[V8,\]?O1C:
M8TH9/[PKIQ1GK[%",<;H3_C=<)8@H9);GWB_<#/M4#TD=-#=HD1B#'W=;W02
M-CQ,=N,ML^?^UYTQW$<S1)+=KK!+TJ<UMH^T=2'FW(L/C![C-YO6E<2<U"4]
MG[,UVHE[%#,H^.EDOWJ<0WO(HNZC3CE/=).$_64T"L#M]H:P-GW(0@%-S#+"
M$D](J'1G;U]&;_31CQZLYTWKI+CF=AO5.0???TD#4%.H"\[JNOK?*=BNP)T?
MM<ZRR#3V4\:C,+'"6IUSMDW <42NN'%?!<=T^"B31//5REC5A\UO$B//L1KI
M%X8+O^*W9IHJVM>;][DFA77+"P40(# ;F1<J%KY-GYOHZ400!JZU7X+,TGZ9
MS$U/74X(QU;)"<17![I_JCWY WLDBG>;R#9?*CVXG^C($8UGQ_%+LLAB#.<E
MF6\5N&X)!;S*#C!Q\=?DV!<.V5G;V@V]NEMNYJ.#VP;CKJ($+TVB@+.Z7S-
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M2HD#>-Y@OZ@Q6+[]Q1S4T5*_4O[M>"GLD^$3&FGCY@M;@_W"Z5"J=C3#3>5
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M6Q/2+^U!WZSP#8G/QQ*=B-(K*Y%<"^B&N$%A\+]LE67$7AF#T?%R"XUS5U"
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M:3GS%SNSRM_@^FI6_D#L\YM<QB2JR6*A?2M]=!15RAFXM?WK4>D3OUGNB=H
MQYG@PMHCX8*&:9;JJ:!BN[:L4A&BC%<QDUTMI"#1X6I[J<0P;9'27W7<]ND2
MW<-A&#.$YPK]5FQC"])+?#0S\BQ9[&Q+_BN>Y_;;$SPY=TR<]%A<"3#]$D^-
M*:"SO,S$4@& N+GII69YM,;=V\NEN!H3-T'M7WP(\-IN\CWPW*&]),>YK_I.
M/YF<'QP&JY;R_B5KP2(C!&7 %C(K<M G,2-6T1&N$WOTO6Q/]&X2Q81DAB2W
M6Q)GY=*M!.[OY/(O*C-^^-;.H !?5D*-)[E_Y,E0I(CZ_ [XFB9?@PI(W?QP
M_F/7ZN\D1>R?E&@S8\GN/&2MJ]I6>O^ 8Y!7 B)0Z5(VSH[;;O.8/EK%BI<:
M$IO*OZQF  HH0FB?,B^$%Q2(DF&_N:T$C3NFK"FZGVO0FGKF;C3":E@;+W%I
M01A*$V1F.UPW>_[4A-KT%#0U_AJ+"_[XF +W%[</"G@0!YXE\OH8F3>YJQ1A
ML IZ%:YW-Z;>Z9?D)?6Y.L_[IRDKW==%-C=2_T9-9>2O'XD>\LV3'T*B(^JR
M4&3*G%,E%22C!0NX?P>TV/$<65/,=69AF2$^L6,]W/;D65G[>(3)\HVSJC4'
MG^G'IHV";2_I?/-CG<6-7^HM'A*Y;FA0@Y/M/*ADS;<J-;>+K2M97I))<V\:
MX1:/QKR[6!JN9T2 N.E+)W[4NMLQ\Z+A5OFI6 TUM=#:40$!VGSMX46-XCG2
MI$U2RZ%<P> KNU^MU$&J&4BAMROPT0MUE>D=.FKVB0=F>,A"EU,BO1#;#H5C
MO;RI2--/5$,0I=>BB>';E&^TW,9<%$+=-@Q) B0K'=5%N4*_U1E?9JR_Q/MW
M=9I2%A;X_\AG)\%C26XJ>;>[P\6;U^96C:@^[0Z7TX_:*(7(E%U<C#7*<[WI
M<(@1';$HE+9Y).+"DC%HG3Z0^HA8F6V>CRC-EB$LZ AFG\P_4PYZ+6'YT5K]
M]MV;&BSN0N7B63_N=@]16_@)6^D =W!;AH(F7IEJ]EI %TGZ;/]Q4++2LB]O
M&6[DBSGXSN!4A^$GN]U-.:[4K/ON96C=%NODP*9J'/33-%^@$2=26B^)*O1C
M_;?3^[&C2>W4V-N=$DMASS)HQD\#)L43=]4?Y]OE8._BMHYPWT_[I1$^M^'"
M5R!8P$SRQ7S/T2L"TE7$ZK9B6Y'!_<1;R,*S%=I4.?*<^[PHS;M(7GGYZX1#
MCM_>162TG*?MTC[/NCT**#!(+>;=J^W/8+O'QK<?.4"?<)2) M3A,M^R5P=_
M:#.DE[/\:P5G>,@8_:"I)S:I!-68]$N29><<:9?*#ST@Y5L:$9HT("&M#DI[
M#4+91R;X]:N@9,/9:6^%IQ5ZUK<'PA2&.I&5RIJ%\?*;#NX-K4B>HN6ZVVFI
M4^<>C[7\A7@5<K#JWS@.UWZT2I3%H8F9FH$M'!(\.SQ/B&%U7:OGZ, -8J"'
MT(18\=--2OWZE1[8^YOBO$KW>8DC%[LSDH>&+<"J\Y6^.['[6&-='Y1%BK(*
MR/R9W.'59F:)Y!IE<99[,85/NJ)3J;)F7$9-81_>LL0-O4<;,B\=X1K*P2U'
M>H!HJ7<AU0WATIW+,+*ZFY<U.;6A5)=5H:][X(\/ZH<*;*OT."V'5$[<EI#9
MBBP:7XZ1TUXPXGC+,MIUL'+.VJ8^:FA0K1N/1[<)PWAGYE>@W=&5.QO<$J;U
MQ&1GC;5/8_2-,[R6J9MX6]!SH/Q]X?B2I# F@<#;67O$5#T<!]+)CKRE*V2S
MS;W]F+PJ:)MD9VSV@ZKUR'/D,3^"FN^Z1!9F]]?]X5>I-XN%SGSWCAL,W&+!
M4\R686T5>;J7$VE426/DAY=Y\%EDM#U9+%M.^#H<3W_H4VF1MASI9C0*V!R?
M2;D3,?(JIGM O3+4C@GO3HC;Z2ELI5*69(=L3C8N1HW"[WG'^7&Z3LO)5^?/
MS.*\CD_OV8>**FTQYGPD/DXXT"[_7M1T5YQB[EW"2L']CIYVL#;MV5L*96(]
MFUD[QS",XK>5S0EG;S_$^?8Y%A=$Q4C!HKQ'N(V -X8P$FV7(9Q5GN%*%$ -
M^D9%])$9&JLB[?W,AIATM='>8^.*V7_(6-IVYONDAAKU(6S%XU>Z71!ENMD
MX^83\U2EOV0I"HMLNF5SHYJ;I9X#1SP%2CVC:A+R;+_BQ:6UDD)/)/+A]D_
M&H03(\Y%#>)W(7-%[BJJ4/F050@;0;G.T_+R6OPNZE2LU)'*2></JQ]!I0*M
MC %QO<V/3@1=8=':6<5I \?:9OPNZ5:L$:R+-"B@6C-6'[2/@_TH; E9%WA$
M"CLV:92UMS*4S7AN*WQY']G1*,ELN0S)*P6=3 X@N[0[B)7><\1@1>Z>IJC9
M+^@YUT;,W4(!5=^JA+@6@O7QLMZ;W^<Z?-O",Z;+5C*) D*)$)HH8*O2Y56,
M]!LL]Z8WAD7E:2T%*6P%P7$J+4.?87"NS+*@#LO\#GN*AT=+%ZK'%* -%/!3
M#M$GK?_VU]^JIV[/.XU9P,=;D5=:MG4>T=JVQZ40N!Q&G\&9X>+:=V5=\0(:
M=<<!HN\G;0Z72U,O55(PIKB.BZPY<=Z$+/5'F]P]5RZNOS%<$^S40=\F:\\\
MG6G?]>@^#SN;-,42><;LR \,J-LV]Q?M.?*X!*D9'!P,D@=-'42-8J-JDW@.
MONN8<QU.5.:76FND/URN=K^5LVCS5HD^* NMJ!*]>U8D>+;R419$W[MXN'8P
ML'>>M#95_NZ+E3%3/GR=]51:N'&=->!CLDT\LE#=UVP=NM%FKH[U]0UZIDG^
MH5;6P?T,/H_TR\R6/EU$0]X+,L /<KP':8*$PT0U]\5C?3_I.-H7S%MBS9DO
MB7U^%:?4F$BI,%Z/ Y]X=8W/&@[;8ZH??NAGS@5INE0&OY:UNJ,L22K<;$'H
MLQLX'B$W&9"LBYO3%LN9GK];K??=I^:PPR.J6HRU;9+ZL8ZW9+%VP(M6XJ]"
MX]%-TSPU(GYL&3X]'D0\$XA/>C\A/1A7EF+V)T,]M"?Q]H0DGCHUAJG;NDL3
MZWKRWI!!%+!;O&H5.3(^(Y?-K6]LUFWW1:.:TJI@$+XTL6^[:KE6RC&SKK)#
MD,7*<U>1S/D/^$U5KK<]B^AADG0"L"]LNC$W\+U8\ QV*'GUG>EQ]1=P? O_
MBG_6^X.9'F>G06VQ]SV601.=+<:/4\]_.)Y_U(!^&">AV:>*"1/-U)N;96*?
MA#4_$"<AG5GSS/":(%W7VVZP?Y'WT<).$Y*6B@+$];*BZ,7?CMX=&V']PCPE
MQ>:D]\QUF$,]RE1U2H/C^;&0NEI^G^&0EG 74PRG0-U!?<A2%]J9J.]963CU
M,6[?'-()Y<-T8I+<2<SEZ;<(N)_R/#OD9S?+\HI(X3O?Q"0/9XX9V[>?6#+G
MY(=E0A^/=)>@^33K?98L'1<'N%4P(4;*6+<Y^:-5BY40/%>JWKQI3@JGYNGD
MUGU8L8@W_F"G=4>2HNEK-Z>"C_>J!>:.% 5PF:/0I!DS$,"G9<Q,Q<R50P%/
M\""G!A=J%SD,H*F_['9D?QYX=I9#N=)>>JLJWKJ86BICH*&4*VY)_DQUZ;UP
M@;R2,!Q!#3'1F8Y[OPVI*'!-%BBQ>94_?P]6(6OMC (6GD2J5(IBO8WI=\94
M[YC!E9S+FR03M,57:%J=6%G%T7V]P3$87KW/,W9B*%;%Q^Z/D-MV;.?[J2&:
M!>GD!9U*'L \CAC'6+[PW]&%83UOAOE(H^FT,6@'MQ]VO74R'"BCI$GY7Z_H
MD"GL97$G@YE>WPGV&-6W<*E:Z\<T;Z;#8D(!7A2!/QO "S\^<=DZ8B6^S=^J
M(76VT/5V[ )2F(=7)"(T5-T_>_FH]7)N8^P,Z#JDFJUKC?IJ@1VRFEXZUAF"
M*BN"W]H_9'E]HR_B9<=K:-;K8/H?UHEW1762EB82QB*P8U<NWRX3,:6:YK<9
M6J,1#FSFZ:?4)GZ$E;9B$K5%]T\3RY<-7E6E+S0I"2B&V8GQ0L^7!=42OU"P
M]]C).O%C%@#*/YEY5S7/P<&\6%4)7,\N)B28H<,:7#?T\&6 ?RYZ__>%H:*.
M=C%5 ]P=N!ETV1=J^/KCLMML4O=\V3@.50+E"GQ^+/ ,D+$B>BBS?/3:L7N!
M+J+..0.MUTM](<C9^*:-8U"1K>X'09V1V806VILIK\TJ%?W%QK:/27:<\9@#
M9'AU'!ZVN>VI&A8_C*\E>O!M&!^\_6U3C0'T5F-@%<M-;5/85C8(]K:F;NIC
M4.CWAWJ]/_2X^@\X$SFI.0XXA9E]_"7AAY,9I6'81J>*(\HYW*.?:^,G?WEP
M5UJHS^E8/-9XDXMIQURA?C<M:IE*W#7+[VN>(.R-$PF(BXUYJ'#IP[:A%D%_
M0>!A07N"QT*#BD[DD.1XX-I_ 2M&"T9SH%!Z[%/GE+0VK61<C#KUV:9-*<QZ
M?/D+32=:BR'P3RHZ 6$\VU%?2COR9!L[<?F>\=/?6-><X%/'#QA1"?^*>0/+
MJ'D3*E/JNI#$)4?>1Q,OHOE,-[I=T'[00RV8W7?(8S#P<%J4O5?#[AWH50=1
M?ND#%O,V W77!Z;1^BP%O.X*16ZX5RU'Q>"AI?N6V;3+-$S>C1@>ORY41V?L
M_CT,9 3M\ W'A*. L>K!02R]B=MG1SSM1:-E'X99N=.+<L)HPGO=N]=@.Y G
M>M%KLY$_0"NZM'G3^PJVO42%(\PKT,3E#A;)8U@W(_?N9)C5K$CXG"PHZM'C
MP%;*5S0$!FZ!5T4LQKC6U=(KI #^#[6OJR@@H"$\4YF8([5SP6-O6XO/FK8[
M)EEM[6 9H^[-C>$\^C3:KM1 WJH8AA-2D@=<&[4%CXR0='+(58BV<3.>%=&F
M-YQCPT,[I@^R:#Q_/' QSCECOHWF?FO<_U33'X6(PNCY$-%6R6!6&7+"3!?V
MF%,J7X)K).6X6V]Z=IVL/=R%Z$!7:[H]K(>CDHX8^T:,(K:ND?!=9I?%V_@+
MEV/1].&XDM'5X.>"H=2($YCV/KW)WF5;CCAKAN@#[/A6(=>6F]X2]H';.:78
MUH5""BYV/3&Q6V\*C(UL=$*UBW+3N]P=L.X5#:C,^^5LY)4KUM($704XANI6
MBN;1^"C5F8I@U-YTG/#1?!H>8!63\*LXW1/\"+9T?>#=';2?T""VA,.3KD:\
M.A;'IC[HWL]VO-K(0U#S]C%D<J?7-O]U Q/+D\Q-C5+T2G5^!P7(-%B&I-H3
M_F[6V(B%$'R?4 +=UY_NL<!E+)LZ+<S2V;U[ Q1[U/?N5TDAF<27)RGL=,]:
M!5OPNW8$QNF_!)6<-1U8U;PLO[RK_-K7L"4V&X>^.,O2XDZ"7V)ZC]  VTF8
M7YB#74?>%3-L;I%S@RVK5OT=2R@R"7NG"QN>]6:./6;KE,/38W@KSO;MA-#X
M:A%W268[:[>.XNT?PECD"6O'1)+)1!(B,_"!S>8^PMZ<M)P%_/IT %J3E'#D
M?%FY]H*0P43BY4N&FCXWSJLAW6,7OJSKK6^B@)+?E=8:]-O#=_97<D!?U?)S
M4< ^"J"_<E!8'<6(+M3%T^/32!Y_=+\Y,V#"@:I1TEXWUK]2-/<,=WRMLWPD
M=OL+$8L?9O#2+A;-,@K0WJA<*I<<UWQC.*O HC%1<S.TNP9T1X\;!1"\J8\W
M_:!^K"_.^<@$X^(N)X1"0XRX_O#^KU,**_64O2[$>#+W$"9&-&=?Q:=9A:Q7
MSD]U]2:[J$2ZK-DX.:[FQEI;R:XB923C28)5@[M3;<[]*3_PW-=X**!9R2PG
MUG/"+Y:B8OT)@G.4)R0$<4(!QV/P9.-?TC81EG@W(Z3:K8>Y4O5=U[N*Y&XN
MD"/K^ Z+:$OQ' NK48 :"L!$ PR9P!^KH+.'D%\263"CO^6U,,AWH%D:B5=.
M!KMC?I<YZVHY*$#O>A=KV%-H4V^,;>FLU.(-&OZ*N015[^!N"=G#DR<1S&7#
M1L%4B YH@O7W^T'VNA-?5 SJ]QOSIW5%[3-?.=Y/F .Q]WW9<YB\59KRH8-H
M>-U.[M9XQFI[9X0,*:G76L@D+"%F6?\S:S??8$55C(Z1!>_L\D)I]>G_P]I;
M1L45;MN"A2= ".X6W(,[%!(\N%-(@KN[%1(@N+L&#5*XN[L$=W=WMR;GWG/Z
MGCZON]^/]V./4:-&C5V[=GW?6G.M->?<Z;+&\_&<_8IH@,9O(H[[ZD[R7$<I
MX-CHEQ2N*+N+^[1I#9DD]6&%@F-J *GNLBV=6K? :($,L DK1[/Q^SV<F1KR
MM.4;:H+YMT&"8:;WY]M7P*^"28J_G;OG#P QKH<[X"JP?S;N;E=AO'J54'>@
M2-<\2GJF7Y71Y&*Z7# H=J)%#7QWY_^WB^=6T.TE??,1 Z2E88[?\M-1+</"
M-7U=[ 9I.G+R'++W]*7_T+(@0@^S/Y?9P!P/)LJU?S???+KOR4O' .\"03?]
M ,G(YDY&\\59V9CYV'?)8_>J&&/W.%&#6U"RX^F U[</-$0YLI+,*X3-AID:
M E/C[CXK_P;$^LHV5H=GN8RL5>9PEY)R(H3FK(KZ(M=*(X6 ]3#+;<E%&=U]
M#KE!26J9BHNO@-]Z??=3\<%9_Y*L*Y)<3S-^Z?%<:?Z#\/.NLI,^7,=:2P?/
M>P#6VURW<T?A/8EC(%[IQ,J&HIT+AF1IN'ZJ&NS"&FXOHA\8HF_1^KYNUHF1
M2Z5A)F-"QI%8&VRB#H-[(!T#QM\GJ_,?:4RY50HQ8"=C!YILV]8OWYJ;&Y3_
M2:0HHGA6:-"4GG .$AE?T>F(&Q1V6IR@WB6<H4IT-:Y?*2JCN(EAKO\>I&V]
M?ZR#/-Z'G6X K?T^7O=[G%*6,?4F3(T#OJ&><6O=%U(IXE0F;ECFI=VR35"G
MM$RR)2T;HXR-NNVZ40ASB;^MI?M5WVS*]0<D<"PB/!065"\8XM92,@%:*+&R
MLX].FA:)Z7'H^W[T49=^G%T4-P2J(M1*N1XY\J7&@C%L<NH008OF5,P^]7_H
MS%7QDD(?O7D6GKQ5W2M/UEEU%K*_GD>1[&B;U/!I?]UIEL@R==_)M;ZVP@<%
MCSN_Q['E)N)5]4I1S=%,J@9E,2@;-4;U&!!W%6SJR,SI&!8=Q)P<0 G)JJ3*
MMRVLGG-%H<UU GL;O#(^C4FG.%>@S^4YL"2\ N23PO-ENXN1T=I+(Z7;)[_!
M1)>K?Z),'VFM,)_%]U^":8**HB%$/&27<TQZSW,/YXZEK"CN>,O^M_PO0?'Y
MY_[]\.GT*H_=_9D&&AHX05(FQ,J'N.TI"]>E^Q6;OD"\TK#FPB$@:1<V^L_5
MUJS2!(6+;$NY=)A)BUK"RP+E@N&2U!94M*R-+?_+P@<MI#U\XQB9O/2G(_2B
M077$^?VPW8@6.K^%PRA=CHSLJB$CZTH#RY(-<4<&%+;8($MOK)4AJA2-H/"(
MS30XX*;"D)=^)44(I-YE\8^[&B0?'M[?QC73)E8Y8#-Z9Q!Y6\5#[2?,L424
MMUQVJF"9I5WS(,^6Y5OI,/FM(6)G?0%5)*"/'"MV"L5?6B_S&C+8,]$V"VZW
M,(_Z7XJ$_HJ:_@U**NN(,A%$R^6: [9/3YL#$HY$V@PCMK]Y$G(B_: F3@;&
MZP^517]W\#R3K*VM$U\J<0$V?_>QQ\'M$ZRI*S+#X5*[G!,?K+V4J^(/\*'Y
MY8\JX*[.Q17$%!'M90$7FCK/-#PS^^DBN--'<L^=N*;2H&6H,3\/.[YD?Z:$
M:9XI[]TE0[U&G:W/LX;OW13$A;\N,6H_>V.]I#,XN91S.\);=3/6=Y5(3&GV
M"?C;O%'V*9CON4):Q@8_H$L*#0[%;CF.T&,28EGSCFQJ_)@JOFS>)$(CJ3!"
MY)<&N@"G_]TD6EU>_V>;4O7![X1PPBCS1OI9+\FEV8*H!I,A.Y[ @K&"/M[E
M?D,W1/3M2NTB.(H7TI3]V!-&(U(B,4R5?X%NI0FE/U":7+;%BXD7*1)2A@M8
MY=ZW$ M50J("P"N@!/R,F(+!EL+X)WI[J4"N\N\CC#.GB;_XL"OH-E##?9TC
M=;\N;11:E(>OX$!]T>Q,F?BL1*%_9XO0?"DR6'*"&0RBAJK0#>-%7&?GGCL0
MJHSB*M.#N#@667/_C<C_.=14 C[4/N!K2;P"U%:E 4/-CY7/]*,[+?[2=[&4
MUSM;M2$=R&%N) Z5L]FZ) EZ>6XF(1-?9J[?#TM_ V':< V_%9CM'3SMA/I-
MY0-<QJ)_#@WJ V_VEK5J]XQ\$2MP*=#YU)0#_6#J& 9CHKJO[ML>IFV$91M5
M?W?&WDA&B&*/T8^:Q\^IA?^()"N(_\RS>:K:0A0-/]*9$#%DMR*,*P ,S*\6
M:8PU>7%[2_@_99"+S:.8;1A]^%\!5<K=S@>,D?>[SQ8I'G$1O2$TI0Y"_](:
MY$N]E)T73!H]QD'UWW6]"-^*$#2E2LT;:&3,XR5G NG6Q6WE\^QF*\PJ>[*:
M("USV.,GR0DF<UPTR+:NA],M%N,<('J/,5:^5,-&G1#/ FZ$&/<9RMY( [K%
MZ@PBV$4?\J[G)<<"!B-"P=@&Q0+:(YDB6)S+=ZW[E4IS/$3GD5V8([*#J]IA
MVY[GD=8?>!_4HZ1/\ZKESG^PGNSQ*5\CF>$_F%P,P-L.BAK8=A07*'$HV<U1
MXN 8?Y\/GQR[(ADIKCD;>_('KJGVSW^228T:JO.=VFU2UUD?NSL'GJK%J@53
M=>1A^L6I<_^+ ?6IY%GB6:7M+VC\PY'Y!JR*$I]7]]4_]$>WNT9,&YYCY[%'
M2R&%\B/][))<Y(+Q"2(E1A"BF_'G(Z+NFJ1UFV5@J88G]T".0BC0:@+;6*Z0
M-K3B<$4/;-TC?HI$1!$>TTLZ/U8+GZZ4-:H\4&$&Y"8%LQ+?<^AI%9QQ K\K
MS58HJR[!=9'=!QVW(R.'$;X" NQG$\G'^)&1^E3;7P&&QHTMPOG/%QT^6L>B
MT WW;G\IHSPN#K:7K$85-[VZ"-_@')5YZ/ %4:.L0@6<&=U%GJ<?U)/O3/A^
M+6?6MXBYZX.+]6[%OJL[N/.A9(?08WS[!SVJ[!5 ,@&>97^Q4BLJR3Q_^"\J
ML#(,N5;FT8)NV>>,VD52Y9U&A/<#6X6'VC9^,\?-I#L8Q 5VE&?.*;/6O015
M,<6=YPM-1&9<^^Z="4A).#N6:_9>4, \^P?*D>&VCS_J[%;>+M\L[&-UO]QZ
M,T#%1V[R!.H&DG/VU.VT$(BC6+V)ZV<9^;A3OU<*F9297"$@\"38@(+J_]#T
M>Q?BC&/9^S"0BVM#INWC$-FDK2*^[-AD8&=7D:AD'!PM-83=C[#R\XB**M/3
M<?^:*PFO>7$M!./WJ-N#VLM/.P+PK/J+TZ#V(N- 4PBU9)A6##<K"T'K+1'O
MK'(.273;80Z8MZX"P03Q1X#0PXOGY'X%N$@OJT"=]E^FX^&W\A/%LO\@+YL-
M@-S>':!&WZNPO0(@H<^O@'TA8C#XN\WG[GM"S?V8K\8!PXG*C3+MN@J6=))]
MLM,S^U#=C3[Z/5]RK#?3D)U+0I=)9-O.>0\>TG!<6!>Y.<=;O]A6WBJP9"3O
M<A3FRX4Z\(N.&2?=)T?;XNSWR/0JI&?GE?8\X@?K9$,NI&_4C,G#Z\!<D\,[
ME8[GM?T?\L 3BX!(\]FF$#/+8_[P;L8!D\7]YNN2/>QU*XSC[_ZI,4*65QW7
MI?$5PZ.I,D#2AYD\@WV)Z&M(2,^)>>T;F(SJ_)_<KV3JE<CGTSVSJP'!*_ I
M6%0(=>QM8:#^;466<=P%>.4MW$6)%4K]SAO^\[M:1B8[E![L%'1VN=)"M>TW
M9JWAPY51,#>#DI<K7*3+/ON E;X9&6\818_>4J3C^L=L@&NO%+N^G+VK1]$'
M17#@TH^5)7KT5*O.;F1Y!;CK\U+S,15,M,%K]K,!"BF0D%'&;N3X#T+LN[Y#
MZ7C3F1G:_66.^^!B0H[4BJ;QV]J+\4$DWXY]'>- V]!KFQV+],#1C??LM<SW
M:)TQ[]%R]9:WD%UV\QSQT> ,.OH9W$A.\0\2>BT<"FI? 9%.3^!T&84%PH6R
MS:<#\_9_<+]I:?\*HX_(W7Q(8]7@Q!]E-DGB 0Z<V%QU^"I,,5I;*+ )6YEC
M7G*.0QTS]%1C*WRX8*T"K]]+&G><"S)J+%(4%3W-'^M+VC$RIL.]2LT34C9-
M-W;,8OCBE.E\=/X4Q32<N/%[C-,QIS:%/ 8,6\ODZC8M5DN91XL/+P*HG55*
M>:^Z\ N90AFD62R,8>V2IOWJ$-TC6BXU9KT9IS^=#:.[;>E)V'Y=CV7X) X5
MM>:TY2V>E]JMK#TDF/.<=5.;<(LF'M4;D&A )J@-M>I&$J"E'5U))IK_QRB<
M$IX/#@EO'RF&&04847>%;6=FV30)S3%&9('0=;FLX^HLD]J4F%8?K6* Z(,R
M79/%;KRR6'KL?S]SND[&E^[B3I/=\#]=7/Y+8O, _!]T:^4]JF^'UC,/+3TC
MX5/GVF(VR;#.Z[WPDGCDA5=85/Y@@9OTSXO4;M3!-\WV7\A-Q_[8^3_3L_6Z
MW"QX/4I9@#ULP%NG,7P:,T+]?.6"2<>JEKH[ IRC9JHQ%HOMNII;0\.I&GY"
M@(\%',WN:(SA.E]HITKJ'.]? 7DVIGS@BC66M'#_/(>':*1BS? Y@LSH*ZRF
M]6W%G'91G'OO&Y8'5=49>,=;CL*_$R;E?PV4/[![7<JQCX8+H7 @)_<-3:6I
MI*7X[0 YT1OH/-!$IM0_Z<];%<2_ LP+1ZAA379/+Y4I)^$OQI?Z R+D^*:1
M((Q?(X;X?_85CK L29'L<.#RD!]^#0%2L>#I/XIS$5]=D3 _3,"93"U- &?J
M)FH.Z264+[G6M:K_UWY<_]$R%'.B3H2R=][(X]!Z  I._2+P7;L,L;!ERV]A
MTZJX9-P.]^5[6F[V5E7ZIL5<9A$S3U?,_=1'1/]1Y<R1"]\#1#E]7"*=SZ&3
MZMM_&,6FPK&*4O.\DFIG431BR$AJ80_-K(E N(D%B:^#R5;U&B^;3SLBCX_[
M=AXYD5O[V3H7R60,D8V9N/D5D"F]Z1@)>U . GDEZIA]%0XZU14AX!D "IDO
M9;R;MB8/II[-8"'N](Q9BO\<%GM8_R+R(_X6IB+B$-GWZ6==&@V&-?45Y.HQ
M]*H4X\L9/Z_1:<;LY5@R;'WL!_^TIP;"CWDN9K=B7Z9]M&BR_YU7CEC"K01<
MM-E5,V\3655^&@%(4"]SA'M[*X-8O19ZVX"T15\J\V/?(I,_R>4X\.J33H"]
M%O/(['.U_*Z.%?H2>;FB&!;E?P!L\N?>!Z4)KF7@7W"F%_,7@84FU5;\_BXQ
M9( KA[+#YVY"Z%US,%O\V. =[\N9N$N:81H(34L]TH>[60C)X1%="6D;;8_3
MZSXR-HW8Z9W?VDJ5K'2^VK)3&"V\X72XC(IY:CB\5&OFC&X/.KK_7 T-88VN
M(XV^,P &J&<,PA /8U)J *CT-CCR>*1*S8KQZHOW!F\(5X8">HT(W3WC"_%?
M 07 Q^PB2,[B :(SLR8!#\-',;)J??FK1.!1")TUN],;[+1/^$]!/R+\ L^I
MQJ!/5'&O71_$I&4F=IL-J4&HO^-2VWJ7$/ERML:<[A60CRJAT0=VT%[>#9RW
MLOH5LVF_^/L+$LE*%[W#V",08H$I[*YWE!Q#L[*=)M=+H<SW-/:\TGHM;58=
M&&L^0)'\K;AA]</)1^FB!R%7D-/P/H.]C6\"R\]%BLLQ :_":%=W,^P1I;U<
MSA\?\@3O8)UX;HIKDA!K*Q97M>_I1.)$_:1.IB?W:+<7T$XU2I*F=I7#+'5?
MCD$/\@\)/;1'2O]5 L+_-TT?=Q,3H.:=]PH@KGH%U)O?/]:(*@V!ENBNYWWO
M5<7FHYFV]<I[\-W"'3XCU5>AV@/15+:G2M Y/CB1!<*N]3;;I5W=0K#K:V/8
M,*11MA<SI;O:QAF-P#'?R=T\I-SXK!:? K1^@*8RS,0TT4;L3)"6H, L<2.U
M7\4+/@Y<[7>43!@TJ\4@!:<C18&&%%Q,]I6'LCN9>CHEH]&;0&PFU+AC<LTI
MX9^J)ZU@6>1*BQ.00=14C9\,CR+,HLU0D;QD$X>CZ[41CG7#,@^"'K.;;^4=
MK7324=:$]J_+1.2O19_'-=26]O(J*#$5-5+_L3!58U^ )/_0V-:H&K[EI[[_
MUMC"$"A.,4)*F3XEO*Q,F*C0[[*&1:96%/DKH=.0+"YX1(KL65AC??BM8PUX
M*IP"MV@TUM;?N%?/G"UTCFOUQLBVG4KB^@9LKF2KD"NI-]WSX8OGA%3*G""%
M&\CC)(AX*8VGB=$UN0V%I;=>C[#S>F(GG M6?$-6SU^OL&_VFR>2S],(ZF4=
M(AI/Z 0,61L%T8=W,Q.X.\Q"A%\![R,7#&127:UR?/FKX[6)1C[!V!+:0E%X
M$Q47L=BIL<0V-:3SSG'T#)46&]&D7%NK("S[<+D3-\_*9HW&+B:36?5/<*+P
M7LJ59X @5$BIT<3W<=SOF $"A>S^P_XO*2FE/XBZ@0?J>\!XP1R?':R'C]M*
M_S<:@R+J>W(?>EE_4=7=Y^\-=F'U?%99FPZ-O+M)?.YZ*L)KFQ5[>6:'LR\G
MK^0X\HTS]*>6CA!&BW2=PF6R2^\JR],W7V!<RK1<4%32)!9+=84]48+V-B&1
M'JF?I&H(O$!H"(1UCOC*1\^YC4#$#5VCJ-8RT/!'"IGY).A1>*I42N<I8J>J
M]!?B'^DZ]$%D?X)4TC,+AOV%].VXZ.S.DQWQ%-O^Q5#:>X>I;VE><)9ZOH2V
M=#Y9W+@P<Y-S(RD/ZJLD6O,ELA0[PM>0QD%0BL0;^J:3_K?>GL'SWBM@Y24P
M\VOLJ<1?"3&4VLV[$UW<'9V!-NX!HL@\Y1@!8J2>ZAB=V%KF3%-;M_TGG4,1
MF^NS5\#?@3%8<<*&^.*)PJX:)U;B<\9() U=4=HK8)4'M_AG*-HKX+L>'V7+
M0'2\#&J=_*V$\FVCFM?$G3L!1\M;(>' I&J$(R?Z;>T5@&.0,E Y7@8QJEG9
M((N2@F&?"%1LB'LY\L*\[A%%B?]MYC*:,$8TA78?;$EF6U;31XW@>YEPNE"Z
M8EBK$_,!?6?]>&V1O:CI)P;?-_?G@_&S!P8S1-+.8E2$@F$+:HG)LNI%D&\A
MO[TLU82NX \?AZ=#=1$@N]YIYO.[20_TNK>H=G<E7_AB7%!T SS?R51[,2Y1
M@__U3]8_X+?>LXFV^U3GK]C3M# _9E,8<MF:P-.N<5%^;T-*Z,8ZSV_^#ZH6
M;2CSY1'<QXD#R"2N!FW@K[L"/EI5S\$,INA$XON8A,=J:]XUI),FDG?3U&./
M!AR>W7@*II6+% /$F<;%I"P5#",-4KN%!U[FN<0XM1+P)X.X@\QSA;0+B_)#
M]5XLH,_YNE:;ZDDP<U_H<A>\UI0@Q5_;(_;@N&/)&JK]AN1<(1B6WJ TF#^;
MT<I[H-8AJW(F3N07)Q$K)I/E'?/$+X3^"=Q B*E9E*@5ZY?*'3%$Z,N)&@\\
MR&@)6)J&9")DA]?]?S;SWH.W/ME<@??5#_Z'Q)F=RMZ;8QK@=F14/7GR::YH
MP(4NT/X)&FH_;*=X'_*IJM;/XZ>Q!6@8)WCH%QP(RF&BQ#53(K);\),%.65>
M273GNQB-H0'J/]8PT#E_V ^=JQ+F\3 UM7='J_NEQOBC>AJ(SCQFSO>^U#*M
M>C9"BE%\4S/;U6Z#E@9RVK=B+VXYQ@Y,>,/S>6-V_R*N.,,_5@DB2):PT:K*
MDGB32[/_\+&0^V=/#\ A\@I0D,'68T;'+TMI/Z?A(R>]YH;0BLF9L=%-VOK'
M4!.35IV,W"M3G!.%>2;:##9D>;E/TU<-8.V54-+/71!_5V.9)Z*_R_FJ?"FY
M#&S2O!5DFN#BW$]]N>/HTQG!WN"Z/-:8K<#^FH-Q.&*%#$?=T,,_BUHK<P+>
M<3[=@&"^ H:Z(FT8VSI_G.O&':%SQ8_]%@&FN[5*I[$\]>B4VZR<CRBW3X2^
M,ZX/-IUXS+S/F%X/W6ZM<A$CA5FIHT\\HT*)_-0K^#WE@+XG15J6?-]L8/!]
M^=O>_? ?NKB_'BK_/DXLS2K]R'Y@44[BNGDHA&E4H]8[3RDZNVT=6$0@!0XY
MO@-V^\S$;0\S;G^KL\0?C+Y&CXS3)?R&,4!<8[XF;E4*$WVSP1<9>W4HLK@4
M2%F6NL-#;@U'<8MC<HQ;2=';($X=^+T/<ZZ4 YXEJ%JXUY#4WW\A(POD-R?!
M^?5BT"$SZ0J2MX8X>&D@ 3>ODME%58-56221)].F@!U"4_COLH(LNT"@5D9Q
M%;P9X 4;\*+Y4MT>(7J1TOT&N""%WL?ZYB2.TV2:V('@29:#S?M9D':"'YMG
MVZDZZ$O=NZ.WU"TL_!^<1>_]!Z4_[OB 7_9(#/X+53LA!*FP 4M4F":"V34_
M81^VMCRFT#L1_:(CTMN+E<R')9@=.333 T;5WB!9K?#^_>2W<7R:FY:U!<I^
M!A[R"+8[=7&R49<ON6AC0U]-<2L&J00X9RZ*5CJ-/1<I6NN^6'5H-I"<I"2K
M&W6,V874;14]K6C ND 7Z0YLL38H^]FEC"4+H$9$A-"4R/RGW1F<>O!PTX9M
M@2EA2(' 2#?;N]S&,+;GU=B"?2W1/%;)&/EF*('Z8I&*2+O"FFKI2;U.S!A6
M#/[(SN+G?(OD%-S/ZR: +;@Q\C-(8E7--Z[V=\0Y85-4[_2-'8-A+B]IKHN_
M,A@CF82HQ6C"5 &XA7C51F-?"H-LW4KVM_"*&QE24^SV)"[R:$WA\_[J:7Z^
ME>7Y4)+B?SF?G_:U;ZHVK @DIN#R(;^%+1A"$$M*<6R!6GOOVWEVFETV9\*,
M)R$<W'T/;<NUO+YID5,S<4IQ)6*R:'M(I:9<BL=U4T>XF5(*4]8W&7+8)_U/
M\RO2]O1;J3K2,FZ!,%Q_]&NL.?B*0Y64:*%]9YV<//!##3B44@5CZD%<#>B4
M(U'A#O&#^".7EI M X'C4&1;&-(>SRK."L<(YR'2!Y:"C@V"]G8<@\.44>EF
M9\D%YE^4+E1> A8E9A;N(8FUV_,^4(:Z;C=E,J%)ZD13ZB-Z2!NIH'.X%%ZT
MZE-K/L0';60F!%Q<K!_;7.>_+CJ!,/7K8M A_Y4*BS\_>=4]ACXM0%2EYA@G
M3?Z^3($.2P0:M,8UXZ!4TJUG!Z3990J?JEIOES?9\(((8GG+!LBUVG"W3"*$
M^-=FZJ/?\4^+&@=BAXUTT6IOKG)8"!/.U?BM&,5P%RPE]UJF5V1^C0 B%F.5
MIF)U#0B$3:#;0\]+MG':2P&^74CM-":O@06Y0) B'^A45XYDCCC]PS$NPI/E
M,(^=:KFM*DX=)5P#C6\538C^B)DF3NU/8GQB)D8F,9P_FW\$V/G!J<K0')5^
M&?.\C,KU/+ 'XS>8V(9S#<6.Y9E9O>,+-7B,_XMKICC;SD]R;V'N5:9[+?_)
M[)4 /GD,_$4X6L=&?%I+Y+R<ML<^8$+\&N9A=*B!!7"\>!=%F*U9%FU)HR^)
M0%X#R=&H_,O0UQB9B!M)^>K,9_-TAFYSZ.8D!.XELUBM4X0=)_ZUB/F^.^5&
MM'2!G@G_V@&<0R9@GN%2S=4E:<(*[J;:DL97C1<0&&*N:^;G*$Q1193>T>MV
MJGEH?#-"RRI%&UUUZ7P#(3>@Q7]@&<ZN*T;Z(HX.W0538SUCOS3!]P9BE13^
M;7)!<9!Y"A:5SY=Z$NQ[P = G'9H(R1S6.,\XXGL_&6YY Y42_)(PU EM*H_
M4OUJ")$R, J1_5$*-<),,VS O9S79,6#IQMT4<3:2&XCRR0T-.YW 92>BM,.
M;GWRUETRX-^IR*N;PM;,/):$84*3P:C>A"A1QMG8F- YSXUD.D3N*^WQ3752
MZ(0W43JD.2A8U8?K'2OE5.RI3#TH[YRS/*]K"80]I.L$/;E13[==D:N9M_B0
M#; RVZ\^H!5C^9;_<^ (H,/[..H=S_Q;+S$+?LO'UD.%2APE-?L>Q-,C'\)S
M)$<#0[>K9.BKR_U^%Q9_M'Y:F\QXNJYR5R"( BR]1PFS2)Y5I S]1-3D$3+#
MR1ICA VHV/?UCY4Q-.(-]*RAL;O<3+$<+]_WS\A*:2@HK@Y!@,DSHZ5'PVU*
MK584<R#ZG\Y4B2Y.'UJV2V('HS\AP_ !V'K,50GZ]5U=Y!%EZBCH?>QDWR<O
MU&3XER[<:Q7,6>>,"L5'USZS3201?"VOU&"DJO+#/8,F+_K]!,<)TL';^"@0
M$C/7#X@ (PZV5(]#M@Q?!B7>K6%?$OQ"R&B=KI;T0#5W#X@Y4$L]96R_OPQ6
M.?<]U='U(=-A1%\1)@,(?M?6]I=9H*B>S/E&Z$?D1B*J4QM,&BLO(?8NU];7
M+F2FKM-(9H-]_V^_A2WW7_V6[Z[10#L,YV503?0&QW)^IC'$M$E%'#? 78D'
MNUX%5Q\S4UFSL6=TSGFQW(3[L7DFEH:: ?AUFB *K;*([:K,GNYD=VC:69:P
M.>_6L(_*X^7H%1# 8M31.R\QP_:"56<_+(& %>U$#O8J+J+&C&M+^N5%Z+9"
M9"]/SIV_(/ESS1HVS5'PFK 2_8Y/7D"R,(LFEW-Z,VVCR LZ8[?B[OV[L[GH
MM@@1B<G(EQ;'Z=#U=U\%T2<[#L9/WT!U,+!_9MJS1L*MZH267CDR2U$,*SGK
M_[>' [6[D$IA079L'7= J]MN,+)^Y3S,A2YVM?LP)9.U5$QR=?]N3S"^24PI
M%@:K.A12#RH@M6>5T IWI.\$NWFVN[1##F@ORUFRSH[,;"GKZV.\<EF+[?Q!
MI :^8IBI@']S/?D[!%.HIF"K_'9*&N6ZBUOX.PLQ''GT'3TN\:^!EWB17<GZ
M-$+<OJG,,T@174,)O7;O1+59B<DE%4OFK4;F'KUQ""V7K72'&*82[O_S9RF(
M"R.T8"K \/_RX>(BO@K$NB;U4(E3@-4ST3OEVI6TBGL%8'@[<6">P%)-O^O=
M>=J/,3N3C>3YZN/X0<WT+Q[Z+T?,?_#8A>]_9]E-^!!LA\C3X'O3Y,/PQY\J
MIGZA3LD($5*Q8EU^*'S:GZEEUL*Y4#:+VBX:P6Q'D%:4DJ9S_SON:Z=A5Q3Z
M0'I3I)61:%&L(67V6ZA*F&P]*J1-C/VX7$">L^$.9_W]J('?!L9!+-<UAV8K
M])U+@,R(L'K]I<2=>J$BR$N_S.&S@7S%ULBCP)W.*M7.4^3M[!.=!WC^%=#Q
MI[]TP(F)C[U^;#ODFH[6P[VE[^B7A<:NI\!:.D[G8ULEHV<ML'M88_.\-# A
M9*!V>9%1C/'O=07^(V3/B%EGIXL!OGQ#R$=8?P7,YA,8"Q !3]\6DT:V#VU-
M*)=ZY,OS*^#Z@"V/W&LCZ 7J[3,01-KED/Z1EZX:F]:055^2F;Q(R<K(DTZ$
M#7!OZ;A\BDYGOYA"")8XX%A&#(O\7^6A_]&<-ODWYR6V2/.,$$#9C<LK("/T
M%> )OM[/GQ!]!3"JO]R] @ZGB_Z>/6O!@4LS\1]O3((K,3-3A,!K),_NX]F9
M[ $#V*)P1:#GI=@P!V5%,:G_A&Y"1I]\2*\16A@Q <O^3RFBN.P/--#DT!GU
M3T74D^NQIS3 S+N_7^,KM%<K<2KR\>VZ<R-EJG[Z$WZ2O#)XX; .8>HQ)(52
M@<.%*<_+#A']EY,O')SP6T20S0[/3@@!&(B$3ZD83Y!/.]Q-72G70^S+R^O&
M6';/"\GK0CY?FR)L*HV+=="_[2A)_?\.B*99L+_##!W)SPM_][ ?496JF:;'
M%<X?JYI4)*@S\)=DGB).ME_E8-XG-2B.MOK;7A@.H;O<PUEJ:J6"[ @$-_BF
M2SY*TP[:QU11L4^XH,>]P=9_[685+K4*72'])/2"/U-3BN4I\N+ZP #+Q9,A
MWE= N^^+?C&7WS%>U4V3[]L-?XL_CG%J@RV21\.4 3F,&_:5KHB#\BUN#O>?
M[U3-!/'W+[P.']NZ3.[43<3T9HK!+(E3S*O]$6BMF&:6]DY(JT\.KX#@8LXV
MI*MW[[C@3TX7-,N!E-!-=+0R&%J@_OIO9V<N86B$J!)6-H2HI)+90C]S[E20
MH93>4D/Z?_Q7_VMYT/_741WWO^Y%_^\<_S!#"=%6# %(T]J)TT#1Y/7@9L%F
M)V+J^[S=SO]-9[__TT=N7@XF($YI(TP!6E$FA$7HO1@3S=\G!=3_\^W_8Q[O
M_V:3@L*W82@%#++43^A[%"91J?E@=O%R9_/8QH(TU@!=/R(W0R2XV%T.,I5=
M_YT[86!7D! 6W)\(K[A=1=HK<CT&E+[2PTG_4%W_ZYQ"/0;$7K1_(UF*%S\;
M->]CK>U^KM%*6'TFUP2WA,^/,ZNX(L2_7X9]>1L-TZYI?!R;1N\Q,[6<4Z<W
M#HYF4W\"LGJ,X>@M@@ZM"-6Z]Q\@D#A-M?L8>6H[F]13[^N*,!0$+*VN/OST
MMT7WA?,&7:8@740&6V6RU.4+:OQEV-W%SZ5Z^BF861ZL"K=L5V,;G$4I%VL"
M]7C!2?S36$,_LAP/&CXDINV.[QE)^_*MXYY\.2-V&_1S6FA6C0?JEY2FTSX[
M\A3H3>=/PBY*<ISJ>C.A5P9F"T,/JR]0(W>]O2N/&XQA+MYXKX ?P>HR<:&>
M78]5.P4CCS.*QQUC'.I=#_F0@KDY,WQ,S@0EG8.ZJ%30E!E\1DC>##-:H"VS
M+0KS''R3K'KG _ G4U9K:\3:"*$X]W9=<\K2$06A]W$B.2FQ.>>XI\ ZA)-O
M]X?6XKZN57]RKC.-IJ2+OA23)'6I+**4:/S]BPN&G-SAT$5%WUV@E.Q-SH<M
MY]X3OA&<T0PX)_2*S,>280!1Q1A_K,+>0JZ6S/RRC'FL&YM%[.F0C4(LNLC:
M9J:MNUW(2:SDGYH]< WY3^T^;\83_NWH]M@AO@U+0P/87:+'G6Q\^2#'9ZW>
MV?[W+M0+N;5A5>4VS(%I%Y);Y6L/Y_(IXW:'95N)>]P+^U>3UZ\ MJ3F\X)@
MQR:WO)9(J5CG ,[B=X$\\'U*J0:6;<."WI*]7O \37:;1 ;B^'%:U9Q<;#U&
M'Y8K:M7#V1@"F2,;DL[F^ )9V=J+H^\D.E'-8_8M3%\!YHV36^'9'L&+SYB5
M@6*4/U5'EZ#"G/LXB"N*[WA7U=MJI\GJ4[:MU":.E7IW'#4D5[!"/BEVF0B8
MK3#-Z$VO/L$BOJ6GH9>/*VP:YU0MZX?<WZ<"PFX37<QL; 32<R^*_,*.1J 3
M[,4[ 1_&='E*=+X_B6VDHR^X5%P@L\H@A89SBH<G,2]^GM]2VF(]8T69D!<X
M+*D\*PL\J5:HM24(!54FTMO=%.J*DWI&5&$S,?.B+J'$E^6;.;N+1=5,;K!T
MXU8L'1T-NS$,=R=03\686R?*BGJUE1V*E 5F-=>>/5=K)7S9M)L;J<_&IL3,
MV&)"6->J49>?@G" C#,Z]3@IX]<9JTN)<(M1A/;:0VHT!VI/.LS>(KS:E!.2
M%;UL?5M;[&!M;7A>@FQ>[6\\:@ Z&%&4[<G@%4 FV/ *^';_"K@"J:?=.0\N
MK'9G$$;*G]4]D=>Q+*8.A>90Z.U'O0NI]"4@ZJZB[=AR*KWYB.'JT=TK2S!<
M;^"&5!BX,^%AP\,2B*BCSD_<QY'GD+OO1\]C3=JYK]=<9WN$+/1)N9^'W :6
M<*=:R7&R3>^.++$U1A<<WE9&'O;GR:+,-:R;\1B;WDMD0>I[^E5J5H*A?;:$
M?B'3]AC-D/^AY@NQ1Y,-]!WI 8E!<P1H#WN.@?7+GX],<E+HJ,>G/CS SP4F
M6::"A- ?;$3K*)GT+QGGAFB_2 D:5')Q1PIT_BZ$>!)E:_8AJ]U4_H2<P VS
M<$R51/7# !1E4'-V@#0 AXDB)>E]>JL[KA?#@\G[%YH=1R"!14Q'CIZ%HMFQ
M2;$H7XES-.\ AGA> \,6\R=Y7%SN0TUOLG.Y,K>UU*1KUR//<!N1AJ9:[**.
MK(409QX&T:=2P6\XT6'J-E;YKNZ3BI/5'J[.2_M1[#=1)U'W=K6*$5(=HY(=
M%)/Z9Y^#/OD=8$Y&QCO!@/K#^7\P?+7O]ZD[F<H8".'YY;$H?P>^([&3WG\%
MZ.H5[)C<32?=T?6N>E"HNSBK71[K-V6[*6K:\T*C /%- BT9'8'$A^[BT8@+
M^T-&%K:,.8_!Y.PAW2CSB T/:C?U*< ;$0V+GQ C)PKG8@)XON0(5$-[%+LQ
MZX8BQK75#QI[=0HRQJN&)J#4P)@-3:(P0]:8[=#T)G%XNV,I68K3U:<VQGY%
M9\5#HV?/FY<2.ZV(5*OO&Q"PWO03?<'!#.UO\=ZG97)9ZVSNV9]G#C4-'71>
M4&4:".1D#1WK-LB'=0J'G<-RLR)\/AM2V#SU<$39_6K<?0P-:^[J$M+RRXH>
M$"!LB%8=Y5].PG#6/Y-;&<]Y>D!KSCE^)WW9!W#GEQR9J%"O\<^)C]-OR]5U
M4*!^-^7*O&?&DS+G\#9:YT!A=!:U5U^*M#D%&C,M^K%.^X)O6OAB1.K^1?;]
M(78;9#S6\U:7>*I:'L55<%9V<JU9)OE=!KQ1Z#>U=<5$'@:'L5> 'O4+MMAS
M:>J'E5\FEH+3!K2UDEW>%Q>T_%784GO=A8JS91RS&JX@J4FCFH29]V$)&291
MESHR]-1) &^="(=JI_U%++C;H&8>@YP.RNL42$(DO3D:MHD-9>^.R8'401_A
M,Z^J@\3Q&X@BN2.QC4F4/WPAW,Z;K='YK#0CV&-6P%3(E%.P,$(>_-5ZXLNO
MI/ G@ZQ>;L*M2RV<5M)S,<CT:$9DKL!*ZO>;QT+\]]@\OB9(^!_9Z&R#&&0<
M(NBL^!3/]'[6!&+GB[<VI?#]J4/3!B5GD$+S!D,'+@#67:^QZDI<]21F\Z6<
M9)3ILW%O*<:(KZ@I"0P^'&:N6T::6RTZV=P9MO'Y71_?'][FQ+:>C]:/F[L'
M)G_PVW^PSK3ZS:Z.UI"@&HW$"H\,'86 @+ O]?MNMEN!L\;#""5I!M_H"+OS
MO4&4#$V\ <\* 0R\_$E:I-QC@L4Z&&V@"#2_*,^KVW5CT0#7?-Y%1Z5LWB\D
M&A9]0?BBFON"/;Y5VUSGP=_CQ>ZP]#GE%<"7I5!0ACO7C(PB6'T*>ZT%[M#+
M&Y!6TSJ</7G+'0EMYZT5.7U>!F"LW(<XKMJ;"ED+"[;>+X,@NV 9'CJL>H0,
M7N.?_'H;,O/LBS16C,?6)V4FM1:AB^\WI-#(5BISY53;!9CE%=Q.=51W ]G#
MA<L^+&<FS>9SIC?WP5:#[7P1Z"3TZ]D7@4BF-Q^M*&N*WS,:N>5$[T0O-97.
M&!OK:T?W:J3$TRRJECW!O0(03@GD"Z[;GC[6K]<0J8/.876Q&J6.&*EES67,
M,!>:0W?%J40V;T.<40NV#\=6-A%D0.?@GPR)&JGR.AQ9XT9^*W;\2M89$N\T
M$S\&*!!^(YJ_+DVP>6]:99;= <'[!DIHDF?:^.*8G%3AY/1MT'[D3T3]OL(!
M,<+92S$P'6Q$4:J*-;:01VP\UJ@-WU7>ASPO>"VMV-H$[@)WO*>Z>:D!GP'S
MU<],GKQ=$U^Z6%\!>_6'!46U6E;Y&;>,)C@)UOELPRX8#?V #'E"J/8-B)KL
MRDKHF1AE6_'37Z)G(-86JBFO:E 74B;&_**$62EHR(Z=J\*SDM_/&?%'9#-!
M0,=ARO7#9:)>$#YV"X-#:'Q#1?TJ:9*NK)4-_?=;PAU*(#//<<9T'N=IP=K7
M6NJI)Z.RGIO#(5S'K<J**=+R&+SQ!743EB#;#A^ 6Q(, O>HAXKZ0]U/I[(/
MKJ6:BU]#9:I!C\+XHM09ZU@^5CTWD=Y NL76LS<\=0U&^]T8-#+%1"[SIV*,
M+C>;4Z$2M00URME'GOL&$O#'<6K2I@1[$7O!?_"6Y3[\L8MZE6=4W&$1]UC4
M(F9F]H7@^NMO/BF^H]GELJ>/RC#K.RTN&XQ$UB+"\.DV^" Q#&AKI&R?X:=U
MJ*/Z49XQ[E)YM0GLP4/5F=-J5XXAU<:8S4<7^2F1Y?GL.AK,,&-^-)_E!KS^
M,IFJ/X[+@O=E#)#FY!5,WWFB\@-_I'H36-_>#;:(ZTRW-7D4O0-TW66S[;SD
MKN%B_F#"$KYF\P[<\R7":0^Q8Y[H-/TI'KWK@NO[M.>Q<([^_)E32**<%[5$
M8R!G^"98T'697%_4NK-\M6_083(BOZ<OC,.I,>.&YB@P%J6H43,XQ\%6HUR>
MC<^GW9B$B55HU+3B+#^2*Z(FI^A'?7."J\VZ+V4<73>:(G)H)\M' E24(Z>-
M1IRS_)"'U9LJS5= WKV?DN<N6C*@W8'8&1LF?&ZL!<=ONW&O3>:EU=?,O/$5
MT+5X98S3M5>C4C\K>WV<]B=<;8U5U/B\(G9[")ZU'.EE]/T;$&O2&JW^X_A(
MI+6K6!VA4<H4L>^W)+7=9'?IYE%KO>;Y=E;3&7N7NFQ&>JZ#SA":0EPU^1#V
M[V5WNJ\ V='9#/)MX"T%88XW,A3$G.8*?SS#)L^"Y"S5/,7P(E]9?')AYX1M
MW(:0W0.%[[?FQZ=WJA^1/BCM=A-CI/1Z\8XBG%WRVR+Q&*+U-1(-U(_$.(Q'
M"D]Q:5U9 84FKG(\'1^_^!Q@L-^*23UOEG?P9PCZ0U=RA'_N;"6:8/A<(_#@
M51I1_*'Z?&DX'+U" 37.:C@WH)^'T '4F[TS#I:5N39?$9=CFGFIKKNWV!G^
MS6]0.N:1I_/N:GOB6D )1!%JD+RI<@F_L5@;\]6+\_Q4M;H-^ZY)L>Y/;F](
MVZ*?(MH%Y2M G ;)*"CY<HMV#:OCQ*) 'NX._*@EH,9'?O,C::E7;4.>T?";
ML%.D<[N<G"W/J4R^V0HQCL+^@Z->R]FC583 !#@G&4- ZKX2<AHV54!@]0SN
MFBMP/FF#C H\Z=CQSZ0T)W!F+F O".;WO"5)%2G8G[DT2_"]]!GV[M\B',9=
M7?1FK)WJ&3AZ*FQJ]HO!2)J]^]L7,.36!DVGR&@13VH_SYQ_D+.$DL3UV*'P
M[PMN'3<JWK;]O#Q>Q.S?.;O.6]X^X!RHIM>K7!*D$/P"4I.MWUN"X\$3^+T3
M#K%^!:0^:[W4\8 6V^Z]@].N>(E3-TYQ7%-?T'_"C4_N1*Q,T.+ZVJ %@X;E
M7(WU^UST$A<:FVACAKHX3_,'[,HD"*7)8GBRW9@0OIY2*F1Z1F34*"N>E04U
MRU-HQ6__2M[Z <6@+/4^@:U?;6ZHWF&\:J9VS8\>Y+I6&ZX?2/GNIS^4T!I
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MM^]H:(!![Y^?R<I%6 D+;JO)]44[R1-0MGCO:LFJ/'PKAS^E!QLA.1'Q2O>
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M(_T3SN2MRWN SNW3VJGC.[U-_0AT?O:._MD"/%BR&I)Y>$HHX_2[^]?@1^\
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M-5W% C.W56P!G#$U]?11WZ?S=6?F+!->S.J^+P>^^T$?(<)"(BYI=9!_UOI
M=CZGW0-@K7W'RLP?)A'=AN U'8)M;&>'"R*9G/ZDY2\W6OOAC=0\&E9%">J
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MUGA0L.JR#L7@6FL(0S6D3,9K,:9OS, S/6A7?:3+8.Z9UR1M$F=[ \$OJ:T
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MP) JIL5*C\'A@02;'GCIAW(=,'3IRMW:SOR9@3T-F8^35T-7.JW4E@#;)]8
MV942"=K+4II7PW;/E]# X+9U+G2R%#_?Q,]L/2XI\#DGZEN+'&2A?<K2)$?6
M-5LLJALJR'V\>;YZ2'VV[]QUSH6TA8JMIM3W/F8;(&[Y1:@\GY34K]L[JS%D
M,3W7-T"L#E^Y6APO0"PY';CBIJB3_OG,EQ:=E_K))E&F%S%1!$>CI>J3N.)=
MMNH5L[Q7LY.0XH09-!Q@VL+.K-!B\>_@D-%,3EF?\D<?_>,SY-H3(_PK^,A9
MX_QI3L8T/0OM=VVH?\N^1.7BIBF]A1%I?)KQ<NZ$&\\WG=T#B$K+.CH$#[P9
M(>U7>HF]E&N.5E[DE1H@>Q1(<IU&]DACNG*UI;X]H"2>4K3'#'VGVZ+T#@<*
MNDOE)!+A,2AL.#LVH(*3MC0)_(+O%(TPJ8X(2BP9K4>G+3'&'8L.V,Q$]BNZ
M6+OE9]I(:@T0+HVQ'-[R E@^?RWWJ91Q>B+BA2 +\"DWEAH2Y!JM_%-BX@-I
M&2&42C"E%==F2;?JSCU<HL,WPGM;9I5T(WEVD!EF .^(.K *,BU4=+%PXJLJ
M]DB;[DWL$Q&S_AOM.1^7G8P6(CJ7C!QW<J.'BD:(I/=#OKI]L"0)XRBW<NYO
M<-^S. [S2'TGF#-ZQ7&\HU,?!',TRC!:?].X0^:=1AU$VRSI4W90:;SV.*,$
M@IO:ZY;L]X1V$7-'>Y_#?(X3)3?? H;,NG*&9F$-;990R@KN#SA@V92$_('6
MPQSWZD;5HM=BK.*72ECA5Y;/C26Y]:K=5B MM,MY87LV/) I2@_"<RR@>?T@
MT'( &Y<I[TW(])X^#W<?E>JB(N_;$PI)FYEGN#=PL<ELLI6S#5-G)8W!",AD
M"*5BLYJGM]LT+X$-=J>6TGYR$SGF<F2AJH(Z37][$JAJV3D-E1^8G)1[EVH!
MAE=E/3\HOQ H0Y37I[_H,1<F 7&W?__#]RU/D&U7BDB# S-_[ 2[N<E?!<Q.
M;%0;-T N&<8U.X)CS#/7G,:89="2H>C8&"M\9F@?X65W;(@<P%T*&*3V"*"@
MUK-YP\W"V-H$XXU"Z=LT /:2XNZRSROOJO5].-&R9^S:!H4UQPTN+D'QM<J<
M^01%/V<3M+_/3/VJFE?D+@V?&;6^-.I4VL;WDEBGH* ]G:.$&Z@AVN\!"(4]
M62F+C,^*ZLR5B6AEP?1'2G;Z,D'0TAWT[S(7/,7^A<R2W/_:_M! 9=7]DE#]
M'F ^]I#5N;U]I]Y1W<DGA\W7A?U2,[MTOUZ2T4V@N3N0D>^H%IH-V^ +N >8
M/=2,<D([^ENMU3<?7\GL/=3KOY0ZJH!W9#(&EW0T3X?KM16#C<IT44[F0O$;
M?@K7%8:)7;*H#&,MJ3JGD^&Y9R\_6>+X9&^<Y&4V%:K/M.HTYH8(_?J@=^V[
M,G*7*C+<9G#Q*7SGM"2DP!KXV(GOY557^DV>INIW<2\S8[14RT<*^Y7H$9%Q
MV57"KO**D5+5[^XKY%X?98E9/;572F2,EWT\G\!#_$_#PA(=Y3[[\XU.%??!
M@2';A+(RNNK/AUE./E0QC_M_E*@[@PM/?J.)^ZS;QR+1YQ@'HD ^A+W9YK>N
M51#5Z!JFKX-^=31EN^+;56(X':)6>^J<:F8'_J5Y[G\]6@5RC[?4[^SZ$%LV
MH=NL?N(.<\D'_M(>60<DEU\LI4^:B=[,)NRWB%H)LM!DW=PT+CK09HP'6:>>
M9@#M3UC#;?0,^#=2+UM]*"9^ZNY[2NQ=7.U=[NU2DD;RP_2C6:N>,INW3H<.
MN0!!/XM4B$/E4QD^^Q?SH(,D3/S2%MQH+4V/[#$,F "\RI*T#41/!1?M#]SN
M ;]Y7K)I&]<8HDS11]&@"G.SHKPL_*SW4JTS1,6@I+23? ?BF#?.&JNE76_\
MSRK2""OUIQ[ 57C8( ]$$!QWI:46\VB"6IOS@U)&PJAGMH>,.38_#8M1JDP(
MOD2YK9)-&F9S-[#F2.=W:DI+@-RO0D63C@C1*GK#>8P"):"4"O5LA^HX6KTY
ME5;JB$%:+T!4<0(K=QM]4GKV4*"@ZLWRJF^>M20K.HT586>J?R96)!D$ZK*+
M,;T/PH\2+%]HK%.FCEH@)L]N(_QB&2:IDT;2;C<R<AMF@CVI"IDQDUY"O(W)
MP!QA-T#N-P'#D^+B[@%7.Y] ?E:U[_0&#VN R2V-V7[D%>_$1^S"E'?N''GB
M=CD6Q>UFSFO?) [+K3L2)W>Q-@@CEUB:W27I>)B<:)2Q5GTJ4_'C^X5<+IZD
MEL&_R(?4<KI8/?TF_1C)#+I85"$OMYQ.$7-XMQU3D A'FF"D>C]$+0-JP<W?
MNP_F;GR'X2T,F6J>QFB6-AG ,K$!#&H\X8^$?EI!Y=^-)NEE;'Y\O#@,YWQF
M"&U>I\L@U<0S)O%T<;FC#/OF_Z1$MZ!!5[TQB0LG-R,C.J2M=D58=+"[W\",
M1UD+#/K&:P]E8?4.7_2$#G2(6>X.%-]*/;_5,B,M@]<Z>2D3NXN_\(U6M=;Q
MQY:ZLNE"B,\-<\;S;3@!H_J&\S>XXYZ]6Z54>V*0T0.7L#A]4A!%YNN3,1K%
M]&[=G1>9/W3YPX^<3D-#?*9K(=>UDBN*@?.YY!B#5![MZ?J'RFF_NRY$R*-?
M8P75-!R*!$>2G+CX"D4UX*?3Y!3[@=!9<PF#S*/]/[4"MO$]G::$EZ>5FY_@
M+PKF*GFB'>$K"_S$5$R_);T>N_.I6<F=L0*E;CF<ZAN.N4=U^EX.\ZL)F[B)
M6/I-?$%R*D8^/ I]==U^_J20!S+;,I7(4>\M3^V$+P@3X",PS%7"$#+R6:"4
M&N%2J*UCM-U2I &M_SCK*7BG^CTYUF*NQT>WH"J'Y_4070Y>1N/=GN?3$Y]=
MWL!SH:?]7YN0K!!SD 3><-(N[N.Z'/Q$ ]C#?^J]H"]H^#E]8'(MP8]<]OXY
MXSYR\V,=RO=7WV&JB/]5$I<.'*3+IO$,&C!(TS8WU0.&J+OL'-\#!%\J4G($
MQ8*;B!M/T\0P.':RJ7VIWSN/!H)?,7X,6%\<K_A3^&R7:,;RCJ(R_Q-<S*MX
M(>0:>^HA;?]QXG\SB/4=.66+A&IL879ATI27JB;*D:OC>;_,9L0Z1%_:G)6>
M&2^V+^;[!CU\60-A;N?2X.\9+ZD*L0XI:-=Q?H]Q=^8P]X'60(F#JGU0#5O@
M=%SHN_*K#O-0-9?;5Q.:6JT<VL::KN[N10/LQ[9I2I;^ 1GD YCD%!1'1O45
M4SZ9ZHCDZ0GM*%)MP_<&Q4X6QS@/X+T*[Q[P!7)B?(K@O'M]'G;6(W-*;*'[
M+:^_?.<J8[1!D=0 1?&?:Y74FO_1$#SH9+P'C$K<H>X!^ZE]\TU1=_AWK7E/
M,^\!G9J;E_0%$,ZR$Q57&NN."&51_23#O-=/'>5#" )+BD53*L:H>UD QR:E
M4W!#XWY![T6SE\],RKB ] (D'@#6TGE4]ERBN:2\ZHG(5]??H]\NWFU+_'[,
M=XKD9/=JLO?5W8[330BJ.LHO="TWRL(]V'HW^G&F;X(MI$(AJC&G?37.9TRG
M=>;U/$-;W !KHDU/O)%^8_CMFN9;VRG%8O[;,K.(>-)'MC]Z4FN'!9(2E5F+
MQ?<4LBT6^^VCUB"ZE"]]"?K\*)#KT-[\("'.191&>WGQ2,/GW+S??>7,4:DS
M%XT7UM;#:^1^O):&Q"<D?,B@YYEU0K?I#LTF/<)[9$TOKLEIT*\/^=XK!9Y5
M%DU5T_[0J*GJ;?MHJX7VCD>KC NLD,.3?TF;]3G6L8$;3F)(@#D]3XC?!WK.
M7TXYX^T.X!FX+'W*,_M'T&CU);30:6MIC&:HV:5\+8E;P;7M$U;Y(-*SNT=(
MD/^;8YVI6J!MW*[VX$)\CV:[ABQ=T S!:55 ?5M?T\O'],\QFI/\ 8$D+8,X
M,Y":<K3SS@M?,:94:]</0MW)(ZPU@)P.=G&/!9D]N3G&JMH4X>,0]ZJ[M[&:
M+1\E8M,/R8M$^.KMNL?'97'HM#C&8IVN?#=(J";$>D*.*(7[S8HPAB,T-$LX
M1 6=>$Z;W;B5=LP=XN @>#8V/< S>6C5'JY<8C:"D<%XJ73X!##@;LHN)GI.
M5KCA/]/+4REF''6%H"@4+G3SR6" VFP)%?%9/N+7'[*ZU$^9>[O^;L.!_]GY
MZ K[Q @%0< A'EF>= R?Y9REH!JIQA%76;C1O.@0</F+.N/9TOP0[A!KF@*,
MPZ[C,6CH2L]KVFGOUM'I@(\/YBS%51\:]EOMJ[KK(\VWJ.I,UIA96]QK1N:4
M"XIM<E&Z')60,,>Y9'F:^=P5&\@S-+F;77!NX?1<K6LESRL6F.BS%_%JTMOX
MI)@1*DR$9XQ.+V%IQU,B*+17'0.!9S;[Q*CG#_MRY,O9.P4EA .5$M7._,W(
M"U0FRG&R-Y8 %IL,5!;D6*WZ+A--[2,E!B_5KLU46SU1"IVR2:+\:8OZXG#A
MX"#I$.?9[S!45/OK]Q*<(8 FW$),'-#</>X]M%[=P%?OLID$Y"WWMWZ/1WK3
M[>"T_?%<<LHY:VX][L\S5<DFL!F=WORN:=KY\LFU.G,+A*7YW1(37[,2.ONW
M"''V1?FA$)5*OC?!W._+[P/$.K#/;VQ6W!X+)$TTZ$R?&KGEB0 4XDFA6<4*
MUGK4'AJ>2?-DNM?BVSZO&9NR7J5$V8()%CT3/1>]E;E>N=P#+*:HX&;*&0-!
MIZ%=UY[5 7#4HOF/Q:(J[,KU0+*MU[@LYH_Y/0>O]+ KEZE&=,ODL*:9AGB&
M\%?=L$'H[)N%G83 BDSNA>-,;6H53BNU-^_SLIQZMUGS5"WV73)X["&+_:QI
MXV(99-$Z7GYI@SMR>E.UEMO1R5L>'3=Y^NZ#=7!G#W/4\-<VNR-SK0_$J2B
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M'B?KK\;YWSP\D<%#![MO7AV8/]%O;LC(7?+["/7X<M/?ZBK=63]R %H>:"C
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ML<!"TV2*GHDG4/X0;X@MI6O'TI=KSAK[9KRMX2R_JBE-C.@#74.GQBB8;[.
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MP-6L^(_2%\N3Q^9YU;N4+YAGUEH<KM7+??@#HN$\B]0 6=$-:B)5^EG&A.$
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M?NUH5^-4:LQ5>#N,R7>""5-Z1Q.467]'WYAF'[;<J_-S*R[VW88U%0X\9'I
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MUY/F/2M"B:O]A_4S;YEQ.[#'(PRH1J#_GI&JX6?UJ13Q@"7X@%N"W3'MYY9
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MH1CK"4+L3^ATSC?;5ND+<W<P-Q?3RQ=KJ.]#C(>-&3F%EEZK2=.8-&U)X'M
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MINAHQ0HN !4V=[)\^/FL#&;+I6KG8N1']TNPU\E1P=>S)> 9*WV.*O,^KZ]
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M6LHK?5SNB<H8!6V+R>.<ZI-:A\1Z":6LD$(\##Q3KC5M!$QSB2%>,I9;EB3
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M(;9$O(S^56]F;VBL=$$U]?"KG[U\IRA3LY7(5.[SW-R:3$:A\\/^]Z[,+V3
M5R26W?V5?3^"E=34OL^GL6N:? *]H=+6>_P_5N"'NQ,.D9Y^2P)]=T6>][T@
M8'6EIYL.*7WE4+4J:-D3;"%<?G3M\8SO+7F<?I6^D(-FQ5WV#^^XHU6/&*XT
MV _'/!3-#7#!9*=Z0O+JO'"5=+X/J?';_*N(9S?9$C39__ GO.+J(.F#R[>P
M?2[5/>CD8ZE#&+\QR*/4-5O"E^(I=IJ;\3*H4^A;FJBZ^4$W2Q2HLE+4>_C:
M-PJ5X]=X?"T[0%IV:LG/4,%U)"%K>\3OT- ^0)K,&O3@K8$FQNL\[HU(<L5T
M.]E(_Y+$45P7M&\1:$NW&&M?YN\-#,=#GN)89FQB$6CY:>3<&YZ\:S?),5'=
MPSY18.+1E00-JRN/46Y\#>%Z+G)8= =IM]18^PV)>+?(C,P)]$<=)"UP&G?T
M=>7-; M*=,%' ;C4W;@E&Z;F<3T]PG?@M'D\&2;YFB6&D+KN#\QLCT;'G>_W
MFO##0(?7025R:59LW!+C_MHN-/(U)];UF-Z#L".#N\Q*-.G9U$+MO3J>C.\_
MC>+,5C^,0U>R$LO0^T<IA[IFU^[ZU:W8<@.C4G4Z"&<8?XQD(P[6#6_Q#0RV
MHJZ,4#[9/YZ8"F_D'I:KG.5+,-5SI@T0\B;/+RPL11H#/2PLB)(ELW;OD1>'
MZ-)R$I9SBLLB'7G9-: Y6[!'<SA?_P[N'<U!GF/4?&&P%"I79V'!'CPD]W%:
M3IU+*GCHZ<%#IC8MNBA^;UCQ50*G>2TVYG1?@[4(,Z7@OE#.1OUXJ/+*LX9!
MM6AYBI\_-C0:JAP;E%18=UWN2%I>*37B;[LIN2CV^>F.NUN]<Y,L%>8H6BPD
M'6GM??2UR_&D2U&I(:W(RDZ(D5_",JYYG*E>;7!!W.13^J\-BQZS+6MZH>I,
M-:G;[>CT[N2)[CT,L( 8T.Z10#?$=JS_XH9'_E=@! .8=S.94OF/>1KWW=I;
MR3)-:V<ZWM[QS_.QR;-EZ^SAT4DQ93-3$=++GR=D1MUXOXHS6R5UKRH8)@LJ
M684N& VG=VKW$!TOU,M6RJ'*(S;AY0B-+'5HE+'<[<@KWN:!NP'5P60KJSJ!
M^7!.AC':+W=8VZ7%6DXUK'1"UGI--;<P^#G<KDB^CC!(6;%L]5S!U;_(&QHX
MDV'-%B#^3!-70)=E7%HFS(O7D$T2][;$*/EKJ7U?K#;"9?F]$>SJE2@7S:*[
MLBD=V,H<^L'("SER]("O@?15-FU?O4]PVJ%,W1D/K%"MCU\+?&ZH!#..VDY^
M/MC%VER/3^*H2_EH2F0CCZ(;?/!3/Z4Z8G7LS4 4FT+E43&ABEJ9>,L%8%\?
MJ=R?.O?LK./!6>IWH U7HF!.>6O+ZH<-H\3+C68ODE VAOV#FGH&EF=4WUS;
MD/RB4JWE 5?)TN8!<X+TV1(BYQ-$<T3YD"D'6#9\4+1G*%N5CO/0)\UUO*WJ
MX_' BJ_CTQU(OD=\7-KB6H9=*'Y]2@TS\YDR'L$66\"Y4V"7G>'=M,_"Z^Q(
M>3TBF.U:SE5B\E!9KH.]=9B$6;4) ZPR91GOD2G@@SEZ45"0.\0_W]=P6\/;
MP[4(14/95W@H7V>.?CK"-]L&KKHF57S=_WM[;/[.FK:VLE297]@EUIOV3./R
M#8)/WA"MVFT$&JR.K29-\[Q<0G A[C+<Z_%JOB;.]J-(3U>?(UYU^R:%5_W7
M^*W;+D.I1U.5DC&S70_VNAT,&VH15X-4E^V2M[L&U6(^_/,H[EP]^X;_X2F&
M1X^?[_Q*@@LWAJ;* P=')#UMQ3E_Y&G+I^5FFV=3%RGL8&?!759!*W:Q:8FJ
MI$1G5TU0$S*?K9<Z&5MKA&#=K7B\TB.G;A,6$S\#:^H<GK&PMMY$+JT7*I.W
M)1)]( F+K!6LW\P#Y$JG'- V,R-O(X V5S,DDS2^P:Z[NLMR#V8E\.CE\]LU
M*7.[(2H5X@<F:80T.!ZI+&.8<U:RL^"]#0T)"+6>2RV(^'^#42O>7"<*LQ9&
MQZ4=^2Q\0-H,I[R@*/3/E;#M[W9:+/6=U*#WS*>K![.7-LEJV[M'WFXIK_(6
M/3?GO!M7(WCJ^O*@$ZQAA+M&Y4@93!O9<+O\_I"4QT1V%8Q3K39%AR-6#4X6
MQ_.-'/OA6.\"8$X?Z3JCE*$-]>#N9/:H"DS4WHCK5MO*WAHQ[=V ;D&K,#"!
M#0M)3TZ_8C]2_>QHZ94EU0I^HA0 \S=7\6_,CC)SS\CE&6U$)8&V,P@JB[AH
MTN\OBZ/RVAVMQ!J\'H-$E?$!K\AGS..BTW:G/SC3A?33/Z4]PH*9T"\H8N>2
M8-P3)6X.ZG%@9Y%1/;1(8[/A#5*7:D+I,=VL3U6/ 8.8J7#Q7C&ZW,QGT2JS
MYJ\[5WJ \0(-0"]&LIM:2%!E.2IZ7J'2)WJG\2W=VV4V$CKQ;S\R,J,>3SO)
MO70>F4_U"2*7*N'>IEM:/3;@S^#C=]S@7&XX,[/>O?'')(VL'=HOGIFP^2SD
M9.^SV?DL5\^7[OO0&?W<]W[\>I&$T8!!M\\20UI5)XI5;?-Y4:5$UO0 (?]S
ME]"LM^K@;&!L8]==CA:#&]VRCU\23NX5Y6O1:9B^G]#J[\5>  1'"UD.$+<>
M)'WEZ:/Q,6@!"HH3,MI2,Z*P#I"RY)@J->#)G#?"#3=1"EIS:_6_,J<>:M_'
M:RG=6I/&F+9S:WC<B+=YTD_*P5C.Q;PB;\6)^374)LNM4ZQ+P-O361)R=GB#
M!.2@W5)S[EF7B)RI@JJBRL2D&,<W_,*?.GJZ+=.HT!%>Z_(E)W@*S?#=*[ <
MU=_B_Z+"K!<.,K;ZJNWJ$3>Y0]6SM^&SM0!-C(/Y?K[_%$%U1<9D4E$6J6@\
MM>:)2@CPPBUGWTEFK1U[=>+]M@_3T+_JY5;AMH8M571//K=-BW/:I0YZV!)9
M>#UR*9*B6[,ZT].A_(B/+%1E!=)G[)51VWJIF9;4))+?YJKGL/LCXG;_(C"P
M=4AL*-=:S2A?Q] 05]. SC3,/[HQW>:  &OBU6^2Q4B>MM:7$HMMJ9X57(U
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M % [8@QT<OU=]^+7!RP "8 .P +@ T@ E  Z #. '< #$ "\ 8@#I $* !6
M)D /8 RP -@"G !N &^ 'R 8$ Z( 20 4@%9@#Q $: ,4 FH S0#V@$]@$'
M*  "F ?\!&P ]@#'@$O W?/"@H="A<*$PH<BA:*&8H1BA^*%$H82AY*%4H+2
MA#* ,H>R@P)">4,%0(5#Q4*E0F5#%4%50#5 M4/U0XU!S4*M0.U G4+=0L-
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M<"%OQ902F6+S,M2,,=J9K<F3ZR]O+O[14Z%.L;'&E%$\\GI8Q(7LA8U[B9\
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M]TZ;1;9BD66.U&]M6<RHW^R 8@,RQ>0HYBHKNW=D[$\Z7EL2?<+68-R0NFR
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MJ3TEB^,^[PS9EL-&4DRG%?C,-!03[D9O\\HGN&M@#*].F$@J2Z?;CH]#EEW
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MVH0)RK>O&ZT^WQ61>0)4W<YK74YYT5[V**]2>--J:Z.95FP3]/U;B]9-I)F
M;UQX4O;W,,X6><9_652Y__Z-GM101Y7AE;9_,X>>;#M0041] X[Z/&SIW*['
MBYU<8) Z+YUN"<G?+S0C%L6P7+IVT:X7J^[!_Y%OU!U=Q4@B%%.* 0-1*NXM
M98+R.=.#</AXVX%P[22%=%I(@_^Q,^S/3>3V*KS8[)6%DP*"*GO,9\VUS['-
M9NE<,T<F;5Z]U\O?VX30LQ"T#EJ/F?2K<\VB65<239NPKJI$"'('$=]HZ">_
MAF?50S-H)F0(8L%^[]S)).+.]]O59T&Z\8)O,T4ZFQ]DAG #?FN'0J%^[;D=
MK71+?T\UPOUN?+>#>M$K#%@B9<X.[</:,EZ%I2V\+XDZR:CH9LN/(11>+C5$
M#32V).- =Q<X88P0$[5,4EWOH3X/:MUWS\)<XF8M/4A?;:M)0ZWJONK H6WT
M$&>7^2&83R-8(FKW78VQ#3ZLO-MT WRDNS!'?MN _CXH&,3XBE.<8K=ACP;#
MK[_7&D_V??E4.P\?ITJ(IHEA=Q+EMJ8G"#V?M.@Q(JM#[LSD=?03H*!H+SH"
M'4C8/Y[66W:<KB1!I9;]!,"%NFD7AJ8EF^EB-!-@R\XI[(^0W&'W]K]S4#>C
M.QZIK6L=":+LR)K+?K1L]EKFD-FY-A^OX/""[&@II<P4%R :@C?M%KI=$[$+
MFE6]JP0E@67#AU1RZN\&^PR? -+J?P,0B,9D3F0NAI6HZ>YL:B&&9^L_1OEF
MWY4("5R*TA6*U^4O5QW$/LEM(*9B39!%PX9OK?0$^.Q<]R)"\2>XMJF-Z D0
MK![ 2^>;:D]RWE8EJW]P;3QNJ[7V1HNWH@394WB$9"$K2O-&+J2N@2J[JE<G
MW':T\OQ>8 ?Y0F0L[EJJU<'/]8N.5H*%H/MH9$2:]]K@VA?(ERS/9+%#(4ND
MW*ZO3=[X><4WWAI!']8QY23C\,+'LTY9+G^F#!.J<?R4H*L\;OZ^P+#&:#:Z
M *2*1 S!=?LLBB8:C)JHY*QIT7\>*X.4F,#(O,X)DNF0B2VVX8#.GRW)'E_?
MS^.-11#J)52[Y?AVRNLUKK[K:Y6[*(M:6L=@$4=>7[%7"Q[F3EF->#=, .[
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M>V5(*U] 7*#5NY<,EX7JXP)M+JA&7]A386JAN'PS&QE['FR<R.%LH'/U][_
MD1:8;?%?&LQ^38?L?;3?]%34KL=N"0UCS(*4H<[:@IQ;5*4X2PGH6]M/#S[R
M(?'^FKH-V#7:R8M4L-@W HNIRL/ ]RA:<8YZG0)_$U5I]WGAV)6QYC0-I"M:
M:HGR?##*B!'!SJD9F(NX3_]:J!WGI&*X5Z*'AP==Q]*0N:,%Y.8!E(.@2&S9
MOKNEC#%;XKL*D<61IKY=%F\UJ19900XQXO-VO^(\HWVHUL!EWC/DS?;XYO4Z
MH;.LZ617#,O8_%0RWV+VU[2>OB:X--Q)^6;V@&5-?MWVGEK2IQ%BB]+]U8]G
MM*F;O4Y%]JPY>!@&?HEX4F#WK33US?%6=5*+WKZ.%/H@QA,K*WL!-/6M#[HU
M8LF%L6[/M- )3:F:C.INA'-WT=1,#4RS\,RZDW""8#!SV8H0M 5!<'9&$Y6@
MI*PM=VL=XC*+"_>)L3R1R="(?2>\*]4ZD;J(18$O5?4<NA9X$3)#'JNW8)@N
MH2$WV\>OVGML,>0V!EG(FN.^4?CZ!V8"E;]910*/0*61#YN/A=^'LE37<@FR
M9DGV"XDUOW++.?!J=Z,O.U/E#TP="]7=ZD5R8ZIK"1VSHG ;7@UH@=F5N<*;
MIJZH1WPRFXX$T:$1]2,J)@ODS=$DW1%22Y?RY05'0=5*J\-&YQ%Q>[-,9&W&
M:KQ-.\IGFBS>XBS>D'^N(M[ZO-;<9IX!E0N.'H&@WO/*712[R/QU<T-7^#6-
M(>PM'-'VH?;#XE7,$6%3#&>\7['6\3Z4OK9>?<0[6$L[M5\50=,?(0I1&S'9
M\&-P>\=ED96 <@1]">P"J@^=WZ1#%Y<WUN_#VT^"SBN^M&)/8?OZ;]7>"6*5
MX<MZ1%]IYV4 C3**[^P(->W$=9U^+1O[OS-WYKKV+RS'972)4.1M1-1,-'^2
MR0=:5;B*H4V[X=1<#<DS4HEMZ6[LO=2[Q<LQ'^(R!;Y&Z&ENF8M+! C]",GW
M+4#A=&&ULIL"TSWD_L3V8QSXQ]LE9$C9+*C?]LBP>(HWC)97$\J-F;1!?B1G
M?[9CXZH*NT\-K^#2ARHMX:(0JJ"@F%AN" !KCEE5J8'9)EHZBLA.@H-_0-<8
M5E-ZJU=)+GN",+"\<ES&)RJ:Z4+2R,L-Y!V^%D> Q=M:2_ELJ$I+Y?45:O&A
MB26)RM DS)_]<W $O6]^JF 554GJ:/ 10Q-/4Y#VQ]<-S#=;]->,OZR6:[5#
M]:'@5)\H8$J>F<[G\C45).#-2[M 7UX&Y/G'1'=T-S2YRNI@W>&-A/9Z4R1A
MN,NG&U6Q^H_5'R>[-+ESBNT]?A1J3Z_^RE!=MX?/\)44^;6 <:TQDX#L;-5I
MN1,GJ*"=7-1WF\W-LWK?#2J,KVJR5-#2C,Z"\^0KY-,7"M%:B-[PT;2QJ]#L
MS7+M8 /2J^JI.^Z%/]0;YGCQK;>RN4\RBC 6A'&O^F0IAT<BUPGUG+2)6G%Y
MF5S'RE^]%1[XY*,((;MNQ7&9]:_8^4ZQ!3G4M^0I+3=4@-3M:XO5W?GV*!PJ
M^K?_]$N?S/CE?/'(ELMQO[MQ8RQH?C[<M=?C-KP6K.N?'NRQ0J^ZGW54&PQI
M*LQ+^13&]=\F)7B.^!TGM%%<)C_.O76 4Q-B*&68 2F.,:K'?X=UIU^U[VSF
M#2IU8*"BV64(HKA,^3M+9(OVMNS=^K\1,)H>Y,EQTY;C?D=V@N(%B/Y?#/\]
M5<_*RFA?O57?NXU :95*:NYV0U,,7EXHL76V0%.NW1C@S2!@"U/37X J5J2<
M^ZU2OG SMJB%N\HE"8UONL#8XCAVSBC;_]<T50^C#\?W%^"4 E$HV@\Q0'>B
M*K)?P<>.,%HH;8EE-!1./?2]S*/>C43I%=@-342SP>G2YD@M^*R_VGN0=+'I
MO=Q#.!8@ZMT"=8LH19NDO;Y^,"X,V.S@ZZXQB=K.5SY#=T-3>C<LR/Y #Y:C
M66C"\T0<4GZRCQ#UL[O/;B/;L$[=?Q_NN"*U-VH(,6I/ _,^L^5_NM<S2L/M
M(X 9'>G9]6BVK-$S%27>6?4VJ6;H&A%RM]N/__:%_'W[6<SUPNE_&<9BY7WQ
MY%HCWWP+R:-,=(FUV>98>;-;O42>%"#XV?F?(9%<*MX?F P,8/X(NK)GRV/9
M?T>R_0NL]@=F+&^VR-?C#XS(1-$U)#5ZJ^-S(#=G 2XX2[SRS692V4DO;)B
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MS%06^!O2C2=,7VQ*4"HHEUPM.7[.FZD&_GP[0E:_SO>U6_ZC<OLGC/7$.K)
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M]_O+NN9''IVG3!:O!#(X73$;(*PDG^@@MM^B)TP 4+Z:0K?R>!"Y5D@.72_
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M[+<4VHV8_Y3$/L3,BZO_:+P[V]W?,C(6_]+Z .T/ )MO:WLZY0^ B2!F5F"
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M4U?VDFG/+[;K"?S23:WWBMH>^CL# QXRY]P<;C!+#AU*LD)SHY@O/"_80J/
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M-70KLA V"7Q";K>R4'>=&^!@(%EOJ]!-X(2.Z^,CQ)-Y#&XO==*S3R7&[7F
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MU3YN<*3S?=_$E4YY]49=]5OC0Z4+^J'1LP9.83 &S4.?4$-9*!,'OWB&KV-
M-H"C:EX$7_5STR9[WCP]@ 0*&(W"(=*-H2YWJE*W8%:%0W0GTZ$T!)U%X0
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M_('_2QSV[/*V7HD?U$/%+PPO4<2[/(T?[_DQ:(V<XL.G.6'JPYKS\/I +!Y
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M?_WK6RY#"WB2O[*%FVQ+2T*R5XAI8#B.8\J>+=+<KD.UG(Y)L&[P'V-EVUZ
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M.Q#CHY])J#I2KNR2GU1" LMOVK\0>PXKM*+&,^&E0,Q&.Y1EH AK6RU=X!@
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M2R)2!%/,LC&2: @SS3T..?E0'1>QU1K.5N,^E];]OJ5.P:G=J$#.>,8*/6'
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M%TI%-E8UH7R)R,\IA;PO\S\VJC48?K07>QYT$-UX^6LM^;Y-.PEY$]/^\]3
M\&I94WA^NQ"T^2;'XU3##: 3)G+Q7HWWJ/1'IKXYLI\\\X82/?Y.1)_@]_H9
M1*IV!Q!$EC4,M)D62R*OKB1$PBE _B(Y-C24B+(<&":0ZJ[D9V2]8IOG(WB
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M3DJ*?5P<F&E*"JRZ$]D49V,#;A:G,A:.QDE4"3.XI,!VSXQRS4JB$BZ'\1(
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MJ+^U%ME=!VDANLJ&-1U!S3Z=03B,MW)M]#(+(P_56;?M\G[5)]=R5V\I[_'
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M? [!U)X>EJA)W"=N( C_HMSF247/JDI,A8H!UOW)7,M$*M24WE-\I<H?ZH:
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M [:0)9@EG0U8>97'B\F!FZ!HSC-&'6_BNX45KP5'(!S Y@>N6=/UMYC2#(<
MJJ9A'ET@]G!(,C %QRF/3;KKX24PI#^4+ !9 C,IAS2AC6C%]US,]_ ,)S[-
M0^M'@F1H$R279 (@  E&*N/&G^>(F0%U &>6XZ:O<1"*DT>#(:R$?DHK$F$C
MH-YX^A?>!:E*3"\41&(F*V+<I3VY"W!E!\ >L[NB&>T<(]B6B%J?41W ZYOM
M(0-$Y]+VV4+&2.L2-;638(^UYN3&MP49.+![98K$?E+M08]QGQT0_WY&^O_[
M:^$4^Q(%!254@;UP'X4T]TQ=NSD)5Z)%Q$"&4SV:B8]@,LE&J&$L0@5CN5IX
M+$(]WFF5'EX<3@*>62L\-FRQ3Z#A=L*)-G*REP9PCX8DNH" B-6F6D!/LQW8
M3D54[$'  VBI)IG*X*^8HZ7JD:"3!PF-$L!KB">#>W_"X17N@="C)L]9QE=0
MISJ:9,IHZ^/9;>@ESM;"0 [%EXKU=T04EO.\KXAW^' !<"KB;$K0)_3?A.(]
M0WBC'/"L3$QF- [>-57I(3E(&'MW;R93=]^_^1008&G=^E"Y4U,!IBIU2E<-
M45I&*1(,]:JYX$>IWHE>CWGJO[[Y#U-5_@6<P''7YAJ*LTTR&YZI+JB$B7.8
M@-S&/ET1?GZ.3,9 I<)J&@OZ,0V5'[6;10<\FIH]K*G?_D08CD"G&ULG14]L
M.?E6=_\B>SG(OQ*FC:&IC>>9NYR48YIMT5>JX ,OWYN,$G(&3N?_FBA,^!O:
MER99ZILD$WY-1L^+@N!/[E]*!D"+VRHMCI$WN80WB6;8N88;S>:OH:G#^)TX
MI0Z4DBB=33\D3WSX7E[.F+<&*1&3ZDL@D7 UB*;2TVTVE V@SK:M8?3^"3(!
M2*#C$ZA)N*X9_KP6@P2H20F=Y704[+Y6*!@,EE2Q^,Z$9Q3V_#$5=1[MEVNR
M=9>30-T&)0-'WV?+JLBPRC!GPQ6IOPG/B'9]B8>%)[P'V-%W.!$HH*5\TAK9
M+9$FK*EP'2W1?83VF*W_H!E-+0BWP*$3Y-M!Q<@E)@0)W.US'_&)B)</9$5+
M2E>GTKMB?'@WWWB+%$RG(B..W_0]9TMY &$=!&*70WX.WR6.,:-WC#J&AYW%
M2M&)JT6;K*+U8 ;GG;(+3A<@#[XJPS?X*=\O^)\Z?)I,OSY+XZI\#;+C 8YA
MM46XKNU^3G"^?U&2M;?M^$I-3!UM_<>%EC-[ SY;YA5!EQJY.,%<;)&+U ;"
MDRP!I8JC/00LQ=\4DQCY$!>K A1$PJGGFGY) ^K';.&M(J9=[H$U5DB@5$2Z
M9,$M *T=.Q2__?'/@G,$HI<)/:<"4O7X;_PD )25"4'CMJT$7@*",#B).5$W
M3,O^40RO/L@FZM)9?I>__4OHE02''A@#DT!,K$"8@@:K. V,N8B@K95/)P/B
MZC]^QX2Y_1>PMK"&M('21-Q63#\-^PGJ2:W35C#;EK"O_H"&AJMAJ3$5EPH\
MRB.4Y-;^\DD-K@6>"K?NV7G,A-DCN@L/46.-F'?U1W#M#<BTA-I\5F?#.V>H
M"1';U"<1W50B+K@BVC#)XR\ M+EG-V"-P]$/-U0C6>R+$EZ@4UV.!N9!,.7<
M*17AL$5N*PXY&16-_82)^;;!+CAOZH_R*J<AKU:,U(0"1^, ?X*U*%[F&LEI
M/W&>L?JGKP+R WE#HKS\%\MY<<PGBO1.3G' 8&WR( 8)#U4^$]HEG>(8AM]6
MTZ+PDEESEV/*F]ILY23T@(YL"+@[*?F%KD5DM&OUZ[8C *S]TB-Y]1EXK($U
M[$\VP7:7P2@VTXBO<BNJ01DV]DWI46-F(HGS8=E6AM]X9@#[T(P#'B4^Y-L;
MS8<37:I%?Y"7 *+4!#S(4YN24QW0FJ-(V1V><?SA1*28-_30Z2'!6+ZAV'D)
MFENG\!4!5(R'*PXJ19+@FOJ1%4H3RO(#U;'U]+P?6/L0:A77"I]T!*:CUG@Z
M\/82\%4O_?1,+D7+/8VX:$9"+[0[0#]*/T' XCT7.[Z+M;R#PX52_//E?4<T
MX"B5S-1?AD'*5&A4Y@R98\V\ZIZ9-0D_:H0;7,P"(;[/3!93*L%CTF,H6:XW
MW3_2S?J&O:"#0>3-F]YJ D(E <"O# FC="5W7BD<>4GHAF4.G\3O<)X7A *H
MO]Y.\G)HRX+[_:66Y+WU6K+AQ[E02GK#,0 X'\/T;[ &(ZB1"B?J@*&&&B1O
MI=C\K,+]M!9N(D?6\5-3/+.HC*-T*&3?2SJ]MW._)MEUQ<@JD_P%>"T5>L4:
MBIJA0.']@L6B301+!JTFVO&(NM4]?*DR%U@%'7T@:#LM5V#Y#(KHDUNT_*+)
MXP4 /F+2*(S=?/3JG7P73!"%0C$L"GD7D02A](EPM-):P_>WAU43'?9+;%'*
M[.4,L:*E :ACN:>9[K.$;J,WP9C,^6[BXN_@L#G#,U9O,29Z#G<2)HC\O/F;
M8MT0]K*<?.!7>0 N>E=$O+B!S)Y,CPLMM>1O+&TS!OS=H5TJ-(2@&/W=(KE1
M)/5DBR1;&:RA 5#Q/B+E:4@=\N@-V>#@$%P3E6VDT$CPDF1R#0:2I.1A?X2T
M!*C!6!]M&$-L)+W-&LO1GU$;@I6$NT$MH9E1]R=2KGDO,2W%Z^UX+V"@>_=M
M 4X,ZWJXW:.T__JU35S$_+OBGRU,?!4W4Q>MC_/MH-@13VR$52W4^5M>L>)*
M*&T)I.9%8:>)0O!>BH>[,4^I'#,!V^81";\BP$_61)*JV4^*@&9F3:&;8Y'D
M,_- 62+K<NQ!#_88E;V/V4U1_FF49)22MU,S]B](Z-R?/O1:4#?IRE650H61
M-2M /+K"D._9IJ,C3N-%_-,$,42<GAC,S-Y.C\;_BX; [B\@^N=7N((CQ&-&
M#QXN<D:6]5Z^A3LCZHGR+6-7N'@  C?DM2T <.Y!Y<S<$2]M&H#@LB+N4P+
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MWI'2 M\ZVH6V>])MICD>#.Q"\9O-I*NQM7L0/K>B8F2?MI_Q?I+$NWF'^.S
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M8UOSF*,M^I#@=5<A;&ANJ)1;D*7*F(0&)PTA3T5:84@#0X$W1&.&Y2!OE/R
M2<-M?%+'D'E9O7XF0+3@,)3#R;-/!B@M[8KEMR(P>L3G_(%1;2K;R6&3E[02
MA@4U:J#6"ZVG'"96PVT9"\]@PL'AV=_I&IP]AS>6CR[.1'&;.TW;O\?'_[W/
M+3UJ'V,3-QBV/:2+K[K*5ALAE?8;>2!VJPCE^FK ;REYU*IB6UGP>X+7(XP-
M7V1GH/'U.J?.G(?6K<RL([+0PHCGKGHQEHHG*N&TW15V([KU6*'R2:<//X*S
M6W=)F&HKKDE3+BRV^TQCA\FKV%%[K7JC7>)&UU<L4&,@J:-'NQ":A,^R=)VB
MOMMQ+8>C5+AU^ AKNUQ!LI'Z*5O8YA/5YM.F$R"Z]?M&7UU%%.E31S6_5J]8
MS4Y&_:7FT%6$V^+XV6,UF,)W<8^ 4K:C;,#\9X/^<CTEI^ZO]K-=C:78GS>R
MMF#^QY@L?-]FF<#JJX.?/;^'XS7_?%C[=*,J3+8 )J XQ<>L)>VY3V(01MOY
M?/;P+:!G4;7OY\<[F,TG[%GOI:3U@NM7RLQ:3@W%^6!9%JQ'G0"F^L];;7?U
MW6_5-UP/_XY29P/] ZU (! .B 3\%V#_@5D<:D[ ?T>I@ZA*FH>N%_<X3&X@
M+N+%_S-+'?07\!)YCBE1S8-4O$(:!K%3MYPYA&LI@5@1*;P-J KF7<!Y,:4%
M?CY6I$04G)NRG[DOI('VG':_\I,W_A 3N5]?+ZP]P6X4^=Z)'?!8M4QVTO!'
MX^(BWJ81[9V26%#= 1GZ5$#@''735Q+QP*K[0C]5JH_-"'YIAZK'W?;E9"==
MN&\#[_\"(I&J#+!63S],MZ->-\Q]8$!@+EV@]@G%F_$JZ>B5IS:A1IC-PR.D
M#BT>&B-51<8=GHU6,(5O<1)W^1I<"@_:<!;\SC%X6AE:O9JOE;?[Y+_FKAYD
M8M_G:ID82K@R9%-53/*Q]SY-40\NF43+KVUWF5! !S+DA5ADQ&W%%CFP J<7
M-\NOBY=6;I"##"'8+\-[AR> Z_,]K]"Q.K<D3)<(;F@2H@D9M=B0^>2RV$>6
M=0'W:9 ]YB]@S[3V\_>- 9?]_NMX20D<NU5VN;GWD'K2$P*<ONMS #Z.FE"%
M:>O4F$7+*S'?!3/G8'.[SF"%NGRI=.WM\#<I !)#.5?<R;=K9K22_8;G]X_'
MX#LG/)N<*B9PJ0HE2*.,04P\9141N83\*6KUH)+50(=8'/W%15><:<9RTH'
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M*!G"(WOJT_'.NIQ@^??9G<##.7Y)NS+O2O</+31";1'=!8X/=# C8ET4.0)
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MLW9_#!A]8+&(46^WFGCG2#H653.\D/!]L'3BT@X;RUC3+ 7L#"$H=.(%BCE
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MO"K45VI H&^<F\1&0G+J?,=L![!=Y,]((^;(D-E,GPS41R^DI E%%?NMQI&
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M_P VPBC+3O/Z_P#\8#ALT*6NV: [X@%+12BI -IT0(]3=;S8GOI3@,Z+I<@
M?A$H&.*Z3FSP]=PQ0G"K-G(!2[88/@XA7& -(8P'00+9*7@B'D@6.0B@!$ 0
MAHP?!J^Y*]M>0;HS)P 1S!;M0IP;F &FSJX6NGA==VJK#;X/WV[<\L$9)\SL
MUQ8H,J0.,LV*+5 C(^D!@ ,"MD #5*#'L;&J'E\G0G!0:;$X+EB"B/A!*TT<
MP V>*6W0Y,9R8]6\RF6\#>$^E+@ S(,LHTA;D4;6O1X>HS+"2 ,*"6BF^##$
MT&; V06LDED8J(D: T'X([D[X]J$OA6QR6(%.8,7>B*LLV%E.'<H<._0%CN$
M<,/M0( ($?<B)S^^.#OC>UNXZ[.6$_\ CAJH;9P_I@BK82.[W17D#GT!IC>F
MF"O 4[4-B@NNJ-,,#3Q:-,3.0UGSPXT8,M;:Z5X<];V8, MK,=F,AO'6=9X)
M0CUG0BS"X7T*^N0BLR;3]9G@I>PL"#!<J!0I3,A)F2&!!.!0)A>* E@1ST=/
MC>FCGCE51HE[CISW)?/!BW%E<#6"/8N!TNG\&!P[7'@8_?? H59!4' GFYSC
M)CBR;%--+EW+Y7O'(6P#K3*5D #*R=\RHXTF=6 5JZ;$XKHA$Q!C8$"H &@X
MB MQJ$M-!0.6+PNAVS<D(T(L8TXW2$10#"!J):5+VPE:8$AAH1B'7T,S*2@J
M:_.G"@BO8L(!;*I3556Q<51DH88'N=LHUHPE%M1IPL2^% JZ+F2/$H4_\JHP
M&)"IBX 5-+!L#3/(86@]\)0QF0%"C@V*#V0%*4A."4"XO1CY<<7C$,U.T)W:
M/[CARI2PC:*$HV3P-3C0I5 9N J,">R&>\B,"& +H.4.]679K(;6OP!R$HT#
M5',,PZ6+-D'A43A$0T5_2R7!'19&Q 0/$HL :PB,D#8> 956M"*G1$.&#6^W
M0;3.<&9.YQ,T9T(3M?I/F>X(/9,$5AM#M3+CE4_RI$94&2N(BL>,67FXI++@
MP@>6%.;.RJHJ*+BF@BBH4();&:$ $RCRC$<8UR(;[*F+\/9?#"B<3PE367:9
M .:%6,HQEBZR"9>[A1-6\!QD"2P*DR1 !F8Q68]P3DJI/W&GDLDLF=,;B/G2
MHJJ06J_"]XBZT0:D##$P 8<%_P O@=$MR&**NN"LN9[T80 #8P7C,J9 54B!
M.TP"R%,ZM.EZ@+>9BQ^Z$JD+1BN-\B:@(*+ $H )07*.4@['<>$% &@X/X#,
M3V<66&7<VG+UC)HH^0,A3W;_ -8#5@V,&GOJ'M-<<WD3*:,^!^)&>#W3LMH5
M>5I+4PX $!6@1*UE0%^5P%7!29LB_8TO0!S2#P>P> 60^R4RT4XV5SC@B1,9
M"ZDH=IZ(D$EK$IX0HV@[4&>(E,KO9YX2;^,F<=[1^<\OEJ24A#)-[I@B/;.1
MTK<E@;!7C( UP&9(WO$A[1Q7FF!65+2JR\;I5/I$10)K;8@B&1!"4M6'[$IF
ML[Y)TR8HG6HEJ),Q!QP[@@6-[/USXUPKB[[]AUR92)R4T7$5!S8YW@0QQ7)J
MZ!-)$:Q6KQ&#';R._@"X:-1%!P(N"*Y"H4I+!#&]X*:AB(!8<9&D48$%<3-,
M,JAS&4A *BA*V&"0R3ADU@D1WH'W 3("G%$<L!611]Q@*8KCC3P$7 D34QP6
M1\!UF0M?)R]R"U?84P+A(RS1'E% )RIC3,5A9(E.!D6+<T(E(Y!!J($@NW0F
M$38ZW?K,,Y+2@L=*0P7:A=>9+P&BT)F 42R>-7DF,H,C$(* #C<X&KWE/["J
M.*(I#40)KEJ48((;$<0!K.08+@^/5U,\0T1<%6A,R+#&<"9,9X&I2(;@%PZG
M<@ W:_\ YT1S/V1Q,!4X?[=99 W#OHXP&TA"&D":**@[0$VI<4!)E0@'4QP'
M4#(L9&9N359QP!EN+&Z$N--,6<RZFA0%!EG5NU%1R6D6A"5P/(#2<HQ!,2.)
MUP:$W804$%&5$1,PYJ2_85\J1@]CUP#-Y( T#@2+"."?HVH@!J>?YCDAA*RN
M8+0MS@"LP5%  1!G*5UW:VE^UG HZ"&H"'KA!B/'HC\^P2",%5DO"&47=#XS
M#$ !CD8]H G3.>$!0: L!U++2!.(HB-%")'%)  :T"&PX$6M)P="9!H#=X";
MN*S#F&8(4IN8-"("A<-8@R</5.T]EA#-,X(VUE0*G!)-,,9=/^L!J087'33]
MQ)@LT<%.Q,&IF"%S,*,N":E1L5'!V0'OQP\ 2Q (I: -5H+<7EG$ABXY%(UG
M \C/EM"P%Z+01F"G!+!L"$D\)H'1?7'OI--H9 0N*99/*!B3C6^T;P[P"*S@
M&#!#=ULZ+QB!*V$/$##&J4X$?+!)"I$:FALF)J >?GDV)4 % LWIF5WB\2D)
M<LD*F2J"$JG'<E3%^6'.'K[ZXO6)-/91QBV'NUD4;8X .!@;W1&6)D7,1%:2
MKF6 1#%2ZRF<\+;;*9G\1Z\\QO8&P4/D3:71PJX/E;K"ERGLI6I%.F8"5@A)
M4+H@ 612T N1O.N8R*F@D'41/FU!?B6E0F1/#PP X+@PK3*62 F Y ADARW$
MR2(LJS P3%#)+@IE8#;@PLT$ 5A -<#(-L64Q"&<Z^&-4:)YT:SK1, L+T7
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M8GX9IH. -9<,F>!9:$FTF6>/5.O'*#X$J15S##$16>GD:O"@HIFLUDS\!CD
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M!B\<&V %0(QXIFJ#P9&2^%A *\T;,TZ4 ,JX0?</.AH#7VSP-P[_ )>#>DM
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M 0E9 ^'82#VV3)Y6H67@,KL2*UOJ39F1H F&^-:M[1NEA8=3$R2$YH#Q_(_
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M?KQ!*H44B)Y2, H@\!(8'0SUEPB6U3#N)-T'F7-17A4\?>JAZ6)2R;7N,YJ
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MF]RIMIR"T[5E8@!0L@MX2-<6)OG_ %'/(=#.JYG5QOBXIA-&0B_*0O?>^$?
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M[$A1)H@F<_.:/)5"C,((PJFD;YA1^T=L[: *+E7HXW.0TNXS"@A=D<UF.2
M8B@SII-FWIR %-)8=T4Q;!EWY:C9&CM1[I$H9[7E:^#,H9(, 15)&.:%E$1&
M)D44'1K<G!="H R&, 8U_&N *,Q3T/6-34^>&E@Z$3]>N/5D96!:$4*';XW.
M*BST/9T$0*W*Y$4TF@6;@1(; O"@9\B0ID1@D,EX,$*RP5RB)T8@%M5P8!*$
MM45' QPP/#5YD*# .*MAY?8D70-R>1 @ 0+Q1^ C9:- AT#*X#@">/$=+4"*
M*")P:0I; :4G DUJO(T(XL<JF0N,X[2-U$$DO+J;S*-/?"#OF$I(66*E158
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M;F]_3AK(4.O)9-3O9:-Y1J3:9O=?!X_]%:@ZUX7WG]> +#5)-D/3PZ*08 ,
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M.3IYTO2\/?8_5@U^4D,7_#>>YY;^6PC)MU,ZZH,?.Y!Q<"5(.,]-.NI'--
M*CQ>!0P<*@JA'[5K)_I^4B4\--5?2(>V5,O-\B#)<FCA9:#DN'_5P*#HI9.Y
MLLE7$/+I?T<HI5X0AR^1Z^0);,(E_0AH <1]K&20R/@)^VCA$,33CH!#0*CH
MT0+FWF3$0*>8QO9OC) >4H!^C^>,A?*TWWT4*1=+1L9O]R=B=YAL@-IZTXDY
M5Y[F(T79(\Y7H?MC$].N\^OY]JZ0K:-*XR*B8?>DF[_>?_YWH<KOGXSWS>EW
MO !,9]+'#C2O;@\=7ZTW:8HX!!;=4Y&.S?X=&@C)5R3XEV[.*E!C:77T^1E,
MG:&)N^ST]*.UJ5G?P_"^0B!)S22-I%&Z\DZI*,NKU<'T1!YW^6_NISK?9.P[
M-X[ RNPCESJ9'I,WRJ<YOA=86R+WF[?Q0C^YTTGC2ZA\1O[PA2(?%&J%K&0E
MXTE*+0/X$/]C1%U!O3*+ KR*@PM-&#?AP>2/,F_/$@OPFOQH5B5BPQ?UN^U0
MT![(C6?R+Y-^FI8@A^Q@LE=6/!LY D9E=&DO&/A]GP==V2-Z:*>#)!_/*MU'
MDKILN_^-8?Y$UNHOG><JUZM=4>PA/4\D[9UJ8),0G"23H@-LH%415ZMX8),[
ML9N%0UFK)?@A%].$Z!('17AL#"WCG5W.)-_WL6?8'%,XX\)PK9MO2BX.C23W
M+,\,D0S&@#D([_<JJ;M1IBZT*B;E)P.IV'HV!XDL@%MU+V614ZBB%PP'CLY?
M3_O9]%0R:X(A2&_,<&I" :N@')\AD>,W=QHUA]6AY-PL,(X57"9G-1OC+G]L
MP@W&>FEZY_[E*([N,=SAKP4?Y=ZC-[OB/3W%+KJVA5CR9_5L,K10%F4&^4[W
MBGXO^$N$^GAW+B_T\>Y\X.R.IYX=\!A]H+GY>/-@'-?OR)\ULA4_M74Q-M=M
MWG3?KQ_LO7SVUUYU 1&B=NGG\\97T%NHEP /GZA7E>_]\JQ5K';3<%X_JGC"
MT10Y%R.*+_/$DY<\<-'\:_EXHIB_1%H)P(Q-9Y#FGET[C<OV1^Q:[&<O0_)C
MJ<Q>%/ +@+I"2YQ&GR:AFYYX-9&%NO8-%]YN"S>A4!SN.W.\MQY[)A\-W)!&
MPM6;Y8![G^)YL'I^]LW0[4XK,(%R #U *P,757RYXOI,)-:,\0W.R0A[C]%<
M4JDA@B4HT(A^DRMLFM@2K(*[!F 4@,,)?>=KUI7C,,AH:91CDJ^M=P\(*0/K
M3'_97-Z)X#G]7KD?%%NX T?,BK)<L MYD2,0;;[:Y%1U8),70(3)\#F_7[!W
MWMCN^<#!^=W>T29K8ZE5\LY413B #V?ORO5O#+R8YA$8]BB4*&5AJ<R)@0^9
MO/+OX(4@.#XA83@++T/H[8D.ZML2FJMDP*KT,7F0TW%[P] ,@+(TUUK+G[UI
M&HN]\-I5!LLYY*,92>X85*"AE'5#RBSN_&>%I @[3FBKMK+*;_1O4]@K0K/Z
M]+B1J*&*^?/V=_6'R)DU:)$E@./A4BG)6(NDWBEAQ\"^.!B^;8O$BDWLBH1!
M=FR<8!1YFBR\^K->-JN,/IL_J:_"*UXXH#_T78+0EP_93 ;0'^.K+C%7B@11
MP &S"++NU@1EB41,/#Q]J==!*MI><KBR9 T;]VB!RD4)]PYA.:#K$)19_O^Y
M.-TP\NBA"%8AL?['H[&5RC/P"2UB]%GZG<A?SH!GK #:[O6]^T57]O2^UT5]
M.UD5T:]".H.+)F.=O!A<3--=+]53\<.OQ33^>/65 G);D @G%Z9YAMU+BW\R
MP.M\:^QZ0\FL<$581/5\O5Q0D+BDD5@GC[I(M>G4R4K"=04CU& R&0/$W#0N
M9C^XF/;)8#![EWC=E,5L*5S#?M)/0(V"HW0M313'I@?1QT-E#3AQ!"=M"V^^
M,TD*!9!-72/4L:.Q"@=4"@2EQC:FOHD08@+F+:)!Z\,)=(E1K>E?ZT6TYN2P
M%<080S42TWJCM#)GXF<PT^9KT10B@>%I87HZ:P3A,O"P5"[T&>O>OA1 DJ)Z
M+(,LZ^A/CQ%<P,3PH#F?)-R<A[Y;$57]:&S]_IS+U=HFL'FV54=Z1DWM?VG'
M(4Q%BEN!Z&"T51*K[GP!!%R598V=?6\0?GJ<ZWO=M;GT501KP[3 YO)>A-/O
MKY@@Q<@-#X)>,+GY?F9(S#4+,9D &;JG^SY76V]:$5.*&4W(:)_27 +&2Z>F
M)LE>27 H91Z4Y.@#Q O&3UOB06* ?L7W:S,YZ)RL_0W2,7SK;$G MVD^ZF\R
M:2R,;W"EH-UX(/-Y1_RX:7.(G?.HOPS[MA=F*?T-+>+*O9@$%9@ ED#FQ.+6
M*T-=YM*1[]4OBP/OS=#I*+[)SA#%?[TXF>#&9Q OM<PS(,3D(Q\6/C]#ZYM%
M/']*'L=L@;<04^@5Q0$O[Y.O="0Z0RJ5MM0BY('(L>VDI*<YVBW02Z,PHA8H
M"?1)OV/E0M/F(VJ,>8,!4:B'2F)JO8JU\_R<WL#>]C^$ZT-IN"BSO'7]-I3<
M/H50L7C_>+45CSAW7*9$.V.?;/0++"1N?Z8B[^!Q)9N[77V^$\W//C46'\FP
MQ"N2C7DK$:J-]UZ:?."0]JO"%^IP^A&2$?[*) **Q))89&T3=KQ8*515/8RW
MJB;\,^,\ &\+PG9SEFC-)/-4ZCQBTTV#&B8K19GL/_XC_BZ_8,OKMR>NI-DL
M;/_4)YB;PAM$C"HL_\,\1LC9$'0,5NBU2F?>A$VCZP+-XJCK.:=7<E2@@'KP
MQQ;)3Q1 YI;O*9+<T(+K2-*2SVG O=@?534.75*,N*CJA@61>XNKZMG*#?*Z
MV%A-)%]59LNH];_FI?5!;(8EK9TJ)%V4CW1W96#*T=R$0'7APY3V,T0(..E@
MLJ/H#WC#]%74*\L=V77JV^2I6 GW,NE%T9"#_R2LSLJ7K+U+:&+OTM?BZB[0
MXWHZ3;JSP<C.O*A.Q5GD!9#RV5O,$/@)E$$="_IATU1,TU^,I),J07XXS<\H
MT3&,C!+.QR6;!1BN!M7D<*/1['GY\XW'C7*A\3D/7F_B;MI)C,8J(8EH#:)+
M *Q!'%+6T.,<#B9%+H5.<=6*S,66<3_?1#31?M$LA=@>WO96+8+^6)XX&1K?
MQ /Y1/ HLS(F>D(SYML<&!+,"Y8#SDB==T>5-$26%V'B[RA42?6Y88H]K#56
M#W*2+.^ .*=]5Z]X9]P-O,STJW$0I+$!X.$FZ."U:NZ\-<.@XZ/_K@)*JY\(
M2QL!IB$Y2PO!:^("<F[/XU1A2]\8YA[_PRA,\N?M*PW>"5^K]^+!Q/EJB*G_
M7XC.L48.'K=%^ H/3J[?OP"@R T<Z\.2P+VCLJ-<.S-BW&@L/@6L7!5D_11D
M)=&$TN[B=%(1&TE&7'1J8I64BA/9]TD:H6(U9IC3X<2U>$YC3,H,PL=$L&IH
M+KK4)I'9L2D4A&M3@(T")%J()T"NDHJ5QXW4G[&*[5DX*[PIPP:J<\PQ<3&Q
M.S6Y[(JJ00C,( R,=@SJR!)$FH#Q26+B1'[M'RKSY5(IJM-8&N[<\.*OL 1,
ME*926: *S!</-_9@]E1;3U'QU#E1Q^%.>G@]0I:-(LEJ!IXDJP_&2T#%U3X.
MW,:O20@CKY>&KC'^R3C7S\6+I%M78SQ$3='6S):OBD_X,8<WR'=Z$-SZ9ZH@
M0#-(O%YQ_/;Q],_6V.W)=4=2J#]DB])H)R'H?F XIZ@R7('"5GWOGXG0AP>M
M*M!XO"H53WP?$"+4X"FD0#TO&/P4G G)>?P3?*!^<+;\F";<97XO=E:>1G&#
M;=IE^G$)I]EV]['K[K9%B0)@M*!4/*>T9<F4%LL]R6-@)4DMH"/CA#SS8V'Z
MM>1;:_(D\X.9.=P0O'I2"Q/2)!U):@A=A-D(UDT?&3*=I#Q$%6J#JO^Y^@-3
M1JP$=V9<DY>!X9]C)!3 ,88;9Z4)7L%#5CD-LXIF3P::I=DDNU1_TCL)I@0\
M.BB+EU ,4:^,1,Q(([JU24P5A,-*/IX5M*I#1LK#C%R"P@)-Q_I89*R(ONNL
M(&HSV0#A+N:@8Y(T[RN(_9.(&E2R?=! 0KOB_W&?!PWTO5=Y8!6@F]LS8FWV
MQDD3GAECQ<%(H!TSJ S7'H?%D.LD5/V0455J5!X31)C,7-W>U%Y1O7I$(@_1
MT/\>(ON06FJFRAQV%CH[AT<^TX#ZFV.;VIO>@IIF50+*]NESXC=)">A<S!O8
ME?@Y][M\#0SMMI;+JCG#MQC9;.<R9V-5*4=8SXP:LH2&J XJF@.-S//H)<3[
MUS.JT:8/AS/EU)$9.6$Q>O:SOPO5B*M0D4%2M.73_6F*IQ"Z-[T3V&'->>A(
M4AA&^,6]G]118XS/^+_^]@!8AL$ZF<W2<9REAA4@U.K$^' !A&3UVT^K6;QZ
MA;GT 87A(! )7.I+8]FAZ98..+23[AO00;4]Q]RJ@4@)C82^Q&. 2)L66$Z)
M.5O-UM%X(#=M^L^4KW*I\L\:_59XIRAV4'-D$ %4RPUZ]-?_74]*(I1Q^R]&
MC?L29'$#7.4.9'XCR+UF)57*=E\ A8''5#;KK==7645(5DYR[2%"[\C'[PDW
ME7BHE=40:EORXOZ/+X"84%2)(=:@LQ(-"R:XKL=5S%DYXT".I]S.K$]V7*@Y
M%,>N+GX,+8>;[%?P-U$<Z9NJT[DCPR%81.YOX:TDGF&WELCL\'"ZF,;OZ99\
MQ-3J*>$H!&;P.?7Y[%+)R%,"%5Y%"%?DEU.#81MA#V\0/0B=&?[I3L#'&L-@
MQPX0B?;:(9]4!ICZAC9'GTO[S0Q' HU"5)2RH-% JZ*'9!=.C:B7@PHY]6=X
MW/Y&5'C//C4O;AAW#PVJ@QT1D HH7Z,%Q&TY*W%(8=6!T. U<E>5,DK(]VKR
M>6_<D*N JS1M<,?W^[0XW_IRHF]"I&W4G>$)3?357,K!S#2T051P33)\HNI0
MR2]81OBP.+<ONY4L\VGDL%I%)AIT_6+-8G,>:B@HHSN'KJ]<-XF8E:&&T+\\
M7"+W./A&B.AO3_'10Z*4U?.B]^'KV>"SR;!8C[+?<NOM9'T3\8E;UT?<54JZ
M!//9N6RPDTU<+=03@<K"7!(&D^Z9]:0Z1)BF=K]W7-+MGV\TM.:G 6JAV+^:
MU:+UH3W/U-2I:.82#5A<A$X-N$*ZRZR#@^?8V 7W@?+9,6E'^5.Z[6>4K&Q1
MIEH'Q;K4*6\5>PE:V/UY;M%+,$:E<C+>ZHS_SL[ZEC:-?&)W6N"]&6ZDWNNT
M9NE[QAR9YUP,G](*7GE/RE-B14<@8T&/IC+>ZAXFR?853_US3?="D_*@JA16
MV J)S)Q\\QUI;D_]/VRIN=EA.T$H5MO4_(#/%I$B37D]D%D2@!0!# 9V""2O
M;Q;Z0J*)^A5>+]^>/94K+\E&RYG_'34=3RG,\&Z&^@OQ_EX\'KB;+)I4:VC7
MBN6,5+';*S<=,[-.I.=3O34(4IP M)#Y\2XUC5LSL5^;C:"_HH F^BU-,2R=
M"-O 'CP,YQBQA4V\ -@>%-C0R-"CA-*)L_]*K=&@ZU+;<"]64'P#J,"A"MD3
M^$$GP>\,E7JECYK%5\)I6!(ECY+90<G"\VI340RUWL#)%\#5S=;T?[^#"TV!
MY!$(">(7 "G3O)R?N"P\M_06"3[<S1$1*)OV"VTQRX<.N>+I\U8*B;6MY=7,
M_@T^$@GL\"+BU"YS9IUC"%N^W3M^VJP&'5.&S)7_C+Z+ZDI"?E*+).E5T(/)
M2BJ#2/TN^"-KVM;T5^@$77,F")(:Q\ME(0.O!\>4]O'EA*\D<K5*6/5VT_RV
M9:J$$+]&==4^I 9K'\V@9M/BI<$_4Y?J,2"[72CPQ#C\J*D(S9+=T8'**\-3
MD7V)\?J_PLRZX0.QUJE51Y!T7"2.^K0QH*64'X<=&"44WZ%"\8NA?W\Y\H!
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MDLK6LVC&86B72@XFL4=38:0* "TI'3@36#MYB"*2[ XP1'K$O J*!2:%<LF
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M]+$X?6/QW^Y_\Y[,?O?2E 82 I5"M,XCEF]#T3&+*@9@)!A%XMK1%1M9$2&
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MC]YP=#TZ>'_./?21]^V;^$/#Z:QJ./O;M76\1>MF<D^[\H]O!VS9SPOZ\_\
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MDTB$L:E@1PH:T=D3@+RN\M6!"3&ZQIU@"024I26HHN=1#S^GE9#IDB&:E9$
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M>\N\>^L7#L=C=/C9ZZS>H%V_1-MS00B@@.N)<8>!CK>IHJDRF;J)[0IH$D&
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M 0U %S "S $;P!%P [P ?^ U$ )$ G% ,I !Y (%0"E0!=0"34 [\!'H!T:
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MMO_51_'!VZ- P=B<9HK_9?Z_,U5M[\5EX%&0]M!;[WO2] \S#);ZUF6@HKD
MIJN/3\'G=6*X4;1LD"C6S A7BOCW%%/9B"-\.]4EC+FA2$_%_Q\2L_:R?>LR
M\+=\"M*Z?:-<@(I^1*]4+N)?H9O$PL-H=T2-/VT*4W6NEQ'\_(9*.R(*- 7(
M2R>E*L65QW*GJK?U'OLMV;7P!WX92!4Z^S'-R\+S@DG*^DI3Z F*)RJ?GJ Z
M:59>T;RM8L(JIYJS8W,*W4*,J>LM^8M3&N&TD+B%U+1!5!KXRBQ]0;28/NEZ
MJ\!>\>4)MN3V(--+-DSE[(E&'!&%RJ:>+^=%&:;67 $>FY;@]& .-9;G$PH<
MVPX1VN[XM4Z-"??!-856#=*[@TM\6<%[/<_XC+)^*%=OVKORZ!O.?8/ZVQ$G
MY.'HT;)Y'?.9C2/%0;COW0G1T&3R5'5A1>JG3BZ2H["TK6H)BG&0V>< '[/(
M; ]&16A,_7F7*M?B/3TWK7C=@+2JIHYX)N7!C-<:FE@=JE5DOG^@!^2[&V\"
MXZ@K] 4O16LAKO(?J[(Q27C58X&&=#LB]EC*!H,]RY)L4X&:G@T27V<;'U;B
MHA,4#DID *"0KBPE8\#?2F_TO7ZK@OI;JVJ,2',S=M@/U ++LN$?R(7.+F$C
M4RZ0=ZC7XZ:M?>CW=9!2I?#88W]%1V[9.79Y2Y'_9,0_=5)"J-1B=C@(B,>)
M=>0:H/I80EF@)%@Q9\,T;$OHN?-C3=%LIR4;7"",\^;-;A$S\9%]ZSKI'QLE
M9-?;;@R-;06&_J+4(2^ZHU/%-BQ,P+/<;Y:[7U,Q@5]B@$2$O^42L]9*X?R<
M^T7<X#-T-HB*$)VF$"&O19H&^@^C[0OVN[&O,D'_/CJ_RO,7*%^T(W73+;&I
M7JOE;?=D! $ @EI&J6V%5R%K;G;7JF,8@71V!UFT'U%Z[DP_R=:\B?*HDD@>
MM=?7%&0;X@^-_30X*=_YNX+,1\C6N[)FW4^")SJ8GG;'65$4FY57I!)V-;?&
M50C"[?TR$L-Y>CL%Z@6S[Z$IK,'J81;Q;EO2E/D%8G3KTFG3'OS?YL3K9!U2
M,0E)] & @LKUIPO+@>2&RS+\A!=$ >\W.H,9K"<B(,8LQ^0A%?@<@%;54+N2
M:@X^_&W*C2YPQ5I8!F:E![.-+O%TS_Z2(FF=E5N^CVI)BI"3[Z7SLT%X]5<?
M$09_ 6SEQ,]#O.P<NKZA^/->+8J6>GH\F+E_+D?6KW^YGP-QM[F2G(5EFIST
MFER=J2P][H+LM$_[]NE-D76C(D=\@$:B1_PCZZ2>QI5[J)1D29]TXKY52S .
MJI9]FBI>E?A0Z*D/6%)5?I:HW:,:TJ:")GN9&RT[I<X4?G"P\3"M].$E)Q-:
MW;E3IS'/R4IA _6.UN2/;?NL!>)'(*9VOFC$_01#3]AO:?;MG*&$K-?ZD(]T
MP\XO[]#++RE?#$6IL220T\LU3U(=,YTD;J]IDT<*#&^K8K1(:07XSQ1RJ4WK
MGE0UA]>(L)U:3[YJU'OZZM3$6R71_-PPM3PU3Q<X/^;G,V52;RVO@*,PGL6.
M^',E[UBPE_7UDZ,? 8%.Q9JE6V<O=@7NJ"&C*(C=D;G+JK,[$@H#74L>B%R^
MXT$-#?^F-OI)%67!F UGSES]RWD"<,-J $^PLWG MU!A[7?N*7U]\^XIO0HC
MI>;.J2W;,+>2;8[J>LZ0"Q4SYD0,(JN87]EI6I:<?B3VN/COP>H.[&8<7 I_
MD_5CS#Y>Q[-]BC=/UY8J6JO-QT> 8&8@(_,%^)J+//,9M>'94#I)W@7+M^\O
MTTR5N=+4;[OLQF(C[TR8I=Q8G;-B:VYK[F)1ADWM.9OUON46HV9?/Q^".GM]
MV?-5.::,/L*HY-J_I,&4937HK,-E;P7^4GWZF<C4-S+?K<2=JUO_IDY,AGC'
M4ZF6L==?7^"/&&4R3=3+D(B< *FN&(8W;D:J)SZ_KFL8;.YTWP7)<[KDPXPJ
M"98,]'SYM48Y:GG>],]W'P=FH,9:/6L/'DA"Y=0UF;AP>@I\X]X?73P"+2A&
MH4R]%]-X=R3E]Q!SJPSZ(<VB)*D!"_"3T'O2A1\3,G,=F%\>B#QS?-^5@.3\
MK;,"CB0WP!MIT92'VUAZTW#CNHNK"IIC_K5RRDUI_ 6)!/3Q&#7VI>QU+IMK
MD[[A_.S]56$H!S[AM[6W+M<@ANKDZ$YCT<U0*=;-:<-,Q<O.!?/R@\L[//35
M$YZ7RI>GJ%F?CWCOIPV%K=?A62P3.S*WF'X>QYM[.W+4<3B1+=^T"9+L@#2D
MP8TV=A'QK?7SZT> N3O'GK7X\L5L)@G.UP\&4=LFZWPDII>F5\1$2=USMBX-
MYR)*) +'KQ/@-R#W0O=SB7YAT?&MJEVW<1O\AN_&1#/F;G$1_<O",[&K 9J1
MHXM;9W]J;?+EE6CW3,C]>ZZ4#F[]7)LXX9=+(.9-RK;3[?9W2Q>_@ P:3[<W
M:=YK&2V=1A&2ZFS,=6@$D_&AX2( 7B.BRG%'C3ZJ;5504B-G/CW!SAY^?JZQ
M$?VP/*^3X-!K+!*Y::6!IR7MF+Z?*.3[>L)89>7K>VP]B=V^LW7-3@>I.X_G
MF7W+0YG+N:$"R->Y')FCSF?<L*-?ZJ,CMU]$^B]$7SO4O&3NR&5AC-)=("D\
M=T]]+6N(Z,^B?;'0Z;>XSDW^8)4(NI@^\!?\Z%2#3/?CS4 NVN[TTCI'JR9Y
M>6J^)GG)<-]%SXGYT6V+*O@VI<V:O)+3MZC]I=)3,\-P=8'J UY'5!P^[_=.
M;;,U5/B;SF?7\?K*B+/),F5)91UI!^7@"8YV;K8MG.H]*U_4)0&172^=QK[S
M=?FGN7]GYS5)SNG*3*5FW:J>_I;>WYU]%D[,4_B1FR7C^F8LK'5Q\.@18!..
M[!O:@M?>6[FDCL$N9%2XS77V7VA_*>^_$)6JC,2T]G1R1FLUB5Y:QA9_9&"D
M"GLG6'6K$5$!3I8I+\V@S\5<<6[:L1P+^MYE4]FI:GZ^X3M5^DRBK 6-)V<J
MO<*LE>N[L)6/0SU.06W'FJ1V[,%P@29&F>&FW1[8?><\XE1Y9F/H+.,W;CLT
MO;T-</V1?E6$XL.;M?RC)IK'DD>L7@15;5KG]#:@!EW>ND>IC;N;:?%\7KIF
M93YQV4D=L*^MT?&(]$0#Y[:?\SV8#K!-&]H?PNP=)#=^"_B!-;WQO6>UN;(N
MO0K=_,Z/F$(C.<.V?HV22U@/7-')YG#Y]H< TFUXI?.H8Y/^9>=+&54.SA?-
MS.GP@S3SH.GM7#(CD3C8@9,(J!U[!<[Y3\.G'7YU!1F/0)FU/3\>_7:&/[A/
M2 A[9& >6:O(6BC2WBU)79,%63<?1N"^H6]4)=)Z7JGIJEX -@]IK4%?<0$_
MER352"^_<6+^"-GSU43FUG6#9]M;^P(PRR.P7!TLI'_-^G!UDC6-QXQIY-3P
ME.VY^@M_*ZFWE+X,=NQVE[XZ&LN^U7X9NVC8N$U"T@BAGC/6CWA=;FU^$#KZ
ML6S160;R_"+<>R_26BB$@=43YJ&WU)[+]?[IB$ )!/6""]MOE?Q7 YP]ZG@_
M0F^RW_5C40D@OC<&QH?"2NF_A@ZGU:7;NML<EG56EF3\6-.WD=G!U'=.IE/4
MJ)_SXUT&RU\ZJAQ7GK14%NTQX+=XR("FPTCXS686JARWBYF4I#9?!)!';S0X
M@7_F/N49R_["3YC 9(^ DE#$-M=<2>$YF*ZW(##KZR:NATB3?9K=V)3%[-7A
M18RP/FC<D-J!/[7EU-A6U2D]$533<N!E<TC@++\F$!^+APZ/\?9H[!Q1W-3.
MUI^KK/E(\;G695M6>-8=99VBKPL^"?Z+/O65Y55FZ9 PV2'EM8^76H6;&RTY
M! ;[@6%[^^6T I+U/?JQVA)+KGS(#SH"'WW=WSCTY8S/B\WKY_ (L4"/#(QF
ML"P-&:UR(-/?GCAHZ1DL";^ZM[9O<7GK$<D2^+JZ:;RDC,[WW0O/M?DIW;6*
M#9L,J\8D30.JJG")Y5-^%Y#R(KY?KMUE7#Y%NSXY8=++M:744>>X0G*[R)?V
ME<7"\ZTET5@KX\^%XSM/]/D7'-.>+@G&$H.>VK1W)K5:]:95L>/D=:_L;U,G
M8XG<\.O-V\@I*ZWQ?$J.P16.C@0%>F)+OGK;"BY>&O/\/[.5,GOS0_UT!Q^O
MND> (:IBRMBN\83@X^PK](FH^.MWJ2_85PR=9THRIHJ;$PV= FI:'OSGECX9
M/@(A BJ$S@(2.\70SBRPPW7ME3?W)_L$NS7:-^?)!P+@D6/WCL[*&\%XI?6)
MB2,Y \>Y>?#BD#/M]STY\VI4>Q\A!GL!*INC&/5YAV72#O.&[N;KS%Q[KO8*
M$70[_7.#->\<<?7R]*)\1B.Y[M&+KVKM5."OR:H*FMI:=C\7PZ$DTMB#<)7M
M2T3[##>_F\H/[0/,SG(^X1=?D2^E#R"_#5_GSQHRA7@U\4!^:5=D(A<6<>1
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M0)=]OU_A:^7(PLSX'@XJ-8@)M^CY-G@G<3\Z/"'-Q[R??SJJN='H2G++>F1
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M00Z<L$<A^.>9L$(1X8>G]WZSZ[F8AW-(Q V*A*[+[WIU%GOOL#3Z" Q;OQ2
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M;GGI,,9'J&_OV+;&FLD?4EZ0>EDNG>AE8!42#K98+%Z!5D!1:NM+M[I-)86
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M(KR!@6%X %S[PR)\B)0G++?=_009<*Z2A&B7\>\TAMC)4/?0M[I<]]4+/"C
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MC7JG6Q!>>DN 18P7EI./53H7?5<8NKQ%5I[-RD*U=][/')\[%&P5PE'B+YM
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MC\MSPCYA$ NM+9<E52SGP">+ >*@=70S5'(;)TO 5C>1ZCFRB!-+I651:.N
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MS0%7=JW]9LOFT*,OS&(K<ED@6>1!KKNOH&\FR+UR%TLJ^+N)VCC-,[*9-64
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M=&;8L(-#R8>0$5A<&BV;'0_I*U0=?P%%Z2^BZC<@[NH@O1@_'@-?'E]MB_^
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M_-M'_7461S.5#6NOS4W4)T:1=P5.PZ%^VVI@X)N/G4];?7[PGYM3V2EGG95
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MO6A*F"L-_\ /6CZ;1LD40MSS-,.@YHX\TN9:T=@2!^GC6 C-@GP7B4TWXLW
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M1[JT"5K$MI-&75\,,] .J/\]-WG3;"2Z)BW1<[#$>E:4[*@J5ESFB^(K#>T
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MNG3\>?;\BD [:)M9U,-DS9@Q_Z#KT33TTGOU"30LT)C("(C,HGBY#RN<(TX
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MT@*QF6(^5X^=F6Z6J(A](W/RW9G]78*.6#]Q(V;W"SM]ZA:EM$6E3EZ]&5B
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M'+%NW5XJ+EL$;R,XK9 Z?.A-X 6E=AQS%*,SG,?D2WAPJN:IL$%/*20U^/8
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M.]/"C325X]!3"]I93Q.6#,:"S8K!DNM !HZ%@ZZ\U^@;-T)7;@$_H)G/0?/
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MX[[>M\<FHY)">Z>T/:^\>;_CDU!UOP\<LM.'!D=MS\7IU0*Y56_-=]8*L_R
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MG"!!7#01PF#0D5!0_\D0K=R,<M"WD(0428M9MT;,8SYXUHZNI/_@:6]";3G
M7_H<8";4C731_B*&E3,?!E4<:GS*JTJUYID9*(6;M$P:98 G/.-]@E4:=7EW
M=/6_#6U\Q:9/"^M8E) 0\&Y6AL>D0<DS#1Y[;Y[:Y)*^/>TT"D1DL*1?7"0B
M=$&Z$;.(I;VW'X,.#BF3>) Z$.:=)"Z-\0)K8Z31$F6F0>UORRK;)H_PH;UB
M8C!&)5>Y!*=L!1#4-&P%^/!$*0J884;!1G.2>W*?!-W;WZ34G4^!&9IZH#P0
MXU1# =J;76\?!;F,\F@/(AC59W3G*I5)+(.^\; ^X(4&\B-,2IBYQ$#W!L>V
MW>I_D!S$"VNYGMFZ5YJ:EW2#&.('4FJ:!#Z@9(4I665KL3Z0U*E2" 1;*[=]
MSB98*YUXM'[S^UJ7^391F.P6^/&R4Q# K(+)$"Z>LG(L:&'X17PGD$^$TSG]
M+E5B3U(YWR#_B @FF[\,CPT/S'RB/E9?6K Y==I1%R%75&[+JR%K=8Q%9N7I
M=,4/P!-]/Q.^BZNG#3>!XO(<[E/<TC/)%)_38#S12^T#(I(FXOTZ1$/3GKY.
M^"Y96)5''EE(M8O7I_$_HD?'";9+)MR(0L'#H=5Z];@PN=VB*-2AFZ^,R/[C
M&/^/PK*G>WC%&)['C"ZJN0IU7.%M47$;J>S/5\W+9'M#,Q.WY(1\+<SW+)_*
MO%8J+T_3,PJ<F7'C1%G%_/4QH33'H;1Z1"/5HRG'>NW3?GG=X/Z1%*^/T(YD
MMQ([!BZ'U"U;,NB1E =KI\^ZV3V8%*W$@27;;@.]?\F8!K=C,)2QO+=_"OT/
MMUHW' "*MVLTA%TR7.>KH"'D2*_?-N+/QG()7/%&ID;\][)'E[!AA8_V']&S
M^2X_ML#*DTLR?H5] $O6'DJ."_ HNSH'-Y/<*EDV+KJ.30U"(U(*4G_ZOW'H
M5V[FE?'D#G)>Z,#+:W&N6);MD&YLW U&.:)NB>>;G=B14).G.PF8\/C% O/I
M*OJHZQ5Q4(G*Q<6L7'Z_&K:_9LY0Q/,RE[)4M5YT#@ZPVQ\9DN/WY"W-UU7%
M>Z8O6)L]2N:+0VKS207C7H+$,H3(3M6\YYU,OK_\Z8W_FT0(NR5:G4=5[AI:
M@LE=!.AXRM4<< P&/-!+J^>D?[Q?%^PL,/J;S7C41?5=X=!B0HS\A96Z;/+N
MBWA1-SF>\4F7K_TZV3>2N5G_1?DORG]1_C]#Z0-<!"CY:(SP:G.L],X$WN&Y
M?6((^O*2^MT?7 +M_V1WGSC\3_;2GN-_;7\M>*?T=UBM1A*3)/ANLUZ,D\L=
MYH%WF(ZJZ26%9E:=RRD1_H)MR@D81>!OA\_, _)P X>WH(\)<)GGW,N=?G/T
MW$9^0N"O+ZCY9P8N29\A=1LD"_H,<QD/1,'*3ZWW8O[J-?E+PK)YZ9WI*L,A
M30L<#RHD_R7Z4^?#@Z:.=PNF8[!,'9R6R&,6KC@%K,,\0KS/.SSV>L!8<,38
M_CY2P@=F:F)T4F&F4T\VQ@^^HKLT;,J=6+:2E+5%X4LY U6#C>5F,U?%. 4I
MC,TFVRNW.MYRZC\T%F7=S:LSNAS>7HGR4 U,11QDJ,) LEY55=&&!VR;6W<!
M"'C"<&[9H5"119PY6INE4']XR]4[)M4-HL%S9^ F]\$?=Z?VU:RBDHC=RBLE
M-3C6Z/AVZ6*<.51PJPV \RF[2@QSV9O_:*)G6R39''H$YVGD%HP5.U;W/WNA
MMN*Q>^ZQZ%PV(A_A!Z4YWD7,,NM!^E6D*L@Q&X$/G^[9\#Q.A<_O_E#4N$@:
M1-EYK$VYEU#5.29Y@\>V)RH^&A?U.F014 *EA0H__>A&^^!(5U ^;D =5WOL
M?@>Q3QMJ @C$G7.DYH66O>ZKATKT&CD)F6)21<I')&-_'^>1.=6O4DF<B8S"
MH+QRC8!X9(,5&:/TOF5&5MQM^O: T-V\+W^3K)CO/$N O;QN,]ZK8Y(=/3DX
MX^/_HRQ>'66MFI<=KSUDZJ"4HF/+^N<[EJN%.W 3TY;JGH\NY?*O'9[U^P1S
M6G!U4$P3S)5SW^7UL'E;)#0F1C03+L/DY0MR'HRXAS$FQ4V!<E"T0;Y-0-%J
M.AVHO5 /P( ?4_DJ4E7FJ<''%/2E1'4,IY*C/DNCH0E1_\T"(Q'RD/?[U$+&
M@3('Z&^2]BFT,8Q@!"\)4@B2S3H:B!PD?6]B+K>TSU!I(IJ>E:>Z4TK68$&Q
M;[VD@W+@2#3GV4C=5;CX*3M$%E7@" .,<_4PY929[1])ESY(B[MF=DS(E"T-
M*RC/-7.+\DXOO,E,4G79O&WI1UGLUR<Y17LL(&E0]:J;3B%(Z>E5_Q3Y[N7K
MA/A[!I8.5E<)R?N^EPS3993$(\7K:SS7#\7G=*XHW&&8LL#M8"HAGBW9@*;\
MP%Q-(]FO+U6CL2K.99%A,";QV&)"=+9Q^Y)<R&SF>SJGYOTN*V1FA4TX5$>(
MJIE48XQ/JN67\^>=647;/*SX4 G:TA1@UIK4D1SM=#=^X\3O0\JG(')-(_]S
M&&JS ND!71\P)P2%O*>,@9YFSDHR[#[:Z?0-Y5+,6[?M*S,LPA2&GOMXZ:+Z
M];+F(!;:L\N((^X./RFHGKP'"??"-+9EPXT#XHJ/5$(!/Z7GNB1V:\CT$MO2
M-OCC&:<32EL]=*;)\2MXKUXB*'0%7*%W3>_X%RWW18)+6-RH!]Y=[&P5TF[*
MJ-BQC.8 H'SQN+%Y/-A)$^-6^7:\Q=A\B5G7CU=*Z7=V@EYKV4JNM[GA 2EM
M.FM@VBS"4$\E"[\>E/(W27Y:IZC=O.%BN*7[+H^K8@9Z>K;'!&#6<VTP=<\"
M=^_E9./Q6Q_/%5J7UL@G?5!%BZ#2E0CQ2GQKO4B]&QOI*PUI!/>6=,63.8-C
MD-P'B\!;!:T0[/)3MB\'7):-V-Z?+TA_QV0@'G.^_N!1',UISAI)<T#[R>P1
MX)(529KY+G@ZR5GQ4A4]A28>RFOX<0D[NYK]-..DN579KX+[U+%J<0L=*E0E
MPVN;"G'.-&%IEP.D'(4@+,2-<$4"=*/A$4:N7AI[BE4C3L9V+#!P \.TP25%
MP<9$SEN"MIY;9]SJ/L?0X^C2;+FC>[@%X];R#8P?#T9PDEJ?6W:E(ZJBH#"A
MWNLG2QF#^6C#S-E//"G$@[>$BL<5E6->R\PP8'(=6/^4;S%/J<@Z0MH'RJWM
M*8A^=+IN-Q7YZ(THLHM*J8\44XHMQ-[7G?4,*R#DHG[H^G^E9U0/T5O:&-L+
MJ-),0, -<J3,!^XE_@ P,Y:&&!NU8?N_WPU /U<_%4)OJ5#SZ0:#1]7M7!4.
M5P^$HN5:]W(E4/MUAZ&/:7^\1BA\?SE(B-#NOOM4G2V#K2>>-KH4W97CI%>(
M)7AI:GQK[D@[>_GJEZ2@ZX.W+4(LT07U68[9E:;,*=\@C04_TX[5V@8Y0NZ?
MCR0D2#+TGMW]N4:1<F$DT#18NFH<T@U<5Q+W22@XIWX[)M(I/E?L#S>Y;;4.
MF*Y)BPFT. Y/?EW,[/@UV#K<X&T_3P62YR.OGE$CU6WI%(/BK.-Q;](&&]/.
M4ZS"GUVD*9QYN/?I2AM7=M!R6E=B%]0SX/*P<V[%45X*RH3$C4V0&5T<F0G<
MV_>"-C83WO08JMH$J/S\+/J=JSK+@0:#X7BT!V4>%WE#>V/JX244M7R9(",7
M6I2M*$97BJ!O/COP5KFU1E^M1+(UW8.GEEIOIA4[IS644MIT9YZ^/W/J1W$*
M5BDXW)@Q)JLT :?-#$*83(![AA),!A0I;>3#&!)[*O?#@PVBEF!9LK"NIV#,
ME*7GU)RG/,W:J#X/A$=]JE)![6O;CF^?D\F40X7V#WH!G*K_L4G;F;801@O>
MGO\AR#,%U'/HA&YNBOSE=3U8QOT@3W43\SZ\DC IG&'U=+\]QRN1?*MDOK>J
ML&*!. +[7C=<YO%7&/ZU4CY23CP-[),YIIKRZ\43VHDK38IGC1NO9?+0U+;U
MS\K/6I;$X]P\8IW%P6J9QK7$I>#N@,.RG=%R<8+2;BJDETI+SRLKGMI9+/ET
MCLQ5!530VE;+IL?+HMA?6,JE>@ZDG1@R=DA_P<X<8GS^<)[K(N>P2=R!$%G<
MG?XD2<(8>' )$ P*38&]4?<L515&3A<KONIMU6UDTLOZB!#%EC^AKG3*"W?;
M-C8/G?VQ.D8R[>HV!\9_EUPIQ(D!4("Q4GF.G;A+E50I1MFIH]9;$H W7F\.
M#$;KL]F<<FP+6_HH)6ST>,@/[$:=N_P_0H?6]^((@V%*1CFF3R"VPL"AN;<>
MLWIN:LXF[-6W%VXZ]11,S\H. ^#R65^ Q*?YX0%WS&IJCGU?/Q><:^VS970-
M8H'3Y8RT&]HKB%=,##0W"]__=6\8@F4'AC:$*#ZN'%15%L;C[;ILJMQ*B:4X
M5=<7D)4%?8J\W8K*"3AFLR^C7\0]6W,,VV;W!#T\IBQU:Z#(^#-]'B_?'VM$
MEQV4WKYE:E6"_YV-?^QW:WDH0*](P\4SY^BD[[F":G$[3[0X6[)KS8!!;,-D
M5QLBPUQ38Y(EV#CY+H@_OV)LNVHG>=Q$V"A%/W2K=0FK%MKX+4[8>/-G>*;A
M"HVY"P$&S8!D&IQKVKQRJ2HGR%"?20>ENC1U:IST0"OZ2X0K*JQ<L*7/8;V7
M\,$D(5X:H8IGJX*#O4O;MF\A:8T*TZZSCS,ZS0_'#<GB8/0-1?X7=2/R=9'#
M@>XS!5&CV704KCH*/TWAU.\#\'ABG'/.LPX*9$Z.8ZF2N9W&MFOKF'_IITB$
MF0FSOMK.;C1$62C.CG_5#43:.B'#\-IJDFBPY#9>3SO,,^LAM&9@$(Y^CN(J
M.OJ&6L+"RMVVS%YUK%I>\04-G_T 'CJ/)H+1A<3@%:RK)7"E[HL;L#(C'<6F
MU)NMH BAL!7;C)UI9 B'RHZPU X9_N;=(L$\Z<L.K!-O%50CX]OL@Y@F?UFY
M>JCNB94R)7%D\/J0*E_1[L[23W*5]T_RMR?G]2O>5I2=[9[64N ]:U98M;)R
MWG6O1]$1#!;/VT1'B0?!\DJ$(G4Y.<:ZD]A?IN3'A#X?I[\,YH0#?0RS:;M/
MTU,-1C\V*Q-NM&-M)81D9^R"4%P-Z!5BZ%(7L:(1"JA8G<O#YK%!5(9H"36]
ML8.49I%GPO.<&#NUV6G7BZ\9,SZF50VUNE7%]ROS^1Y\7%(?XO&(L%;BBGI"
M8?WD#^VAVW)0C)%I@TA>;MA8+^JYB6=K<HZMDVUQB6Z#F:#YM*'"I+]UJ, N
MXQA9@U[,+^4^%ZJL280JSM5*21SUZ/DI)^_W;6@?U]SF\.H=<\M1Y$Q@P] =
MNI9$$\]ZON_]*U(#K+[:KH4ED9EF0U7 ]5S>7#3FM'"NR$0=QFLY*H GXM])
ME8VX+(4@/,0>J:86<P<\#K;8]=CGK^9Q2T]SNSL$7&?4$C?3TB/;#-$Z&1F\
M:4'5 )KJJX:LR(O&YJH81@1<\A.+7?"=[X$A[3;9?L^0+FVN&,NE?+/QX<&0
M59(Q[U<W^OK;_6\1VBGP/LYR_-3J5(56O<+$ NI6<$-B.:9NH)KU9,#&)%<I
M  )K&+^3;N0:!]!Q]N&(/SUT1-]8XW"C6Y+5U;H1FW@/H_=A81JV0>Q8U14V
M-9+U!^#9/G7X?>>N0+6.%(0>CX)?R;<?K/HA[[O3B;9T^FL_'M0 SU$2H-"?
MG)&S#UI/X,5CPX(95.(J?.+Z*HK?QB9VWS\].;9Z$*1PKFMZ@%%>6TP!*&T?
M\!@XK0>>ZZ6IA0]A2PT69#3B.@P&C.M(-7R,G?3<$M(#]W*6JW)4KXP:15LS
M6&9CDLUT;WW3U_R,-R[Q'VA3',4=!Y6Z>3XX,HYC#G:-J/NT?KRCOF8BKQ![
MQEBD;;TBJY>E/R+W=4FUL-&P]TQ.%@\U&Q$<7JH0$"N*4=K=HT*V<HQ$.Y)+
M'"$[N>"L9='RT]4AWH<JB]97[)0RXX4ET:K;>$5Y$TWKD?;1KM[#&A141-,Y
MYQ-[6O1?<DGW] JN-*&Z-0,"X0H& PFVP*R =,7^S-^2_@L$/HZ+'O,ZZ;;R
MJM9D0X4J#C$)@=TX1>"UX-J7_O.?$@IG7B8P#ENL7>YBLH25L\,9169G'>D$
MGB6[R.QCMILM%HHT7@:ID(LONB8<E7MWP,%6.N#OZ\4<YT*2CP;$PM0R,\R>
M?)C(PNL;Q[G2@ETU@IB?P>=H>U)WWKW1G;[[LP2X8>6_0.*Z3$3#*(%)9@TC
MM#>6I<FH>E0O9Z]Z(*JEOH04XPV7O-=QIH;-<0%9]8BJ7*@[/[<FID:RH9UH
M_AOQ;0%45]!EC5X([N[N3G"XN+M<N+@%=W>7X')QE^#N[@3W !>WX 0('A(D
M!%Z^F?EFYDW]\\][5:_^U^=4GZKN/KW7WGOUZFZY=#O^=7%4GYLH7..\_#[@
M]6,W,<B>A;$V1B\NSL#>.M-W\^"%9O6[@_Z*NG;3N&/WGR_QG GX2-K?:ZKH
M:^6:EUOF2/'/?4NE.M #M<:F,GM:,NN_>F\O*<O9QX_&J_TQN@2&F><%\GTW
MJO'D$_F4G(,NHZ%BK[B0MJPNC3)"4^GEIL:J)7]4EM'=I8JIFH.'Q2[/!.%5
MJ61+D^'./KAROKJ+'R-&9[676!L'S[.KTE@CD/C9GRMI*CFAYZ(U+Z^("W=-
MM<*>44;^Z+)Z X1^_B&-&Q>^H@66U6'R%*59(B_S3Y34MRZ4J/4)4T1-J- ;
M_ST!HJOH8-$#Z3#@U+58.0@C"Z!4YZ;FXON6XZB%TBHJ+8^S5.%07 S;9QLT
MVW7+Q3(3B*EMIH15%E:<T935PY5Q,(F_RRUL\"=0:EJ:G_J062DKPP"/U[LH
M=8PRHU64R(.TOH4WHPI2N$54.!=2PLNES^3'<1SZTLQ*8]O2\L-X.6K<R-X"
MPM9_E*IT##'6+_>2A0?2W!EC5MA*9N0<H.+:&SOVD++'UN(H/9Z#6M'Q;DD0
MXDVV3Q+ZAK4+><C/2KZ1<]N^,V%6AB[7,QQ-W^78%3:C#K>,MM6K'YAJVRM)
M1RL8>1XO5[7C$SN/GWQ0]+??C#F\*K95FQTSX2I'.PV7.M"U[=C]6F]Q-@TO
M+:]EM%0?N**=OJ UITI>O@Y!X&!AMY8M%#OP-8>0!'G]Q%M19JY*4"?SLY*U
M;V.EY[\(^H8U_+NYYMRVC(/9W*_F;KNE&W2.4B)F 93 SC'WZ*0HV;S?N4_&
M,\]-UKJ[]J!0J$B?MO][,9E-:9.4(6FDB$J><@YZ1: -5T)R'] N=2O-GEVA
M@:=/D*55=81+F*\0]%)QUI6C"6.QHZFL8E>DG4$=TYZ&L^B1)XOE;N<-2V[$
MYU*J[+%54N)!>W(VR]%D\W*V1I6JDN$##%7<.9"400X8^OPI-A/YB(D]-92S
M-TNTK8^!.3KQ8/Z@KHD0_C#>H1+C7@(\$A;4.[V5RI.I;/EL=KS[SY=?I_!2
M5DL-M98(@F!T=6A+4P[*?^F9<&@#)1:.N\?04!R9NY=J2K4^CXDSG-A\F+WE
MM;U;=;R0Y;AE]!?=@JN$R/F X<Y..&%5:A")F']IT<XXG-O5.!CS1WA\8P5"
M-PF,-1WSEA6:&=TC+<E<\-E$XI3&9DHQ>>I]6(+-A4?:0#0[5$!GWEKX<W_A
M0J9.X\W<Y)URJWBNU$+_GCAK;*D[Q2GF QVG=UI]DP6SR.14]G:4>KX&#SH0
MW9@MS5J[()(ES5I;J^6:-8JUT!"SME8H;_I[&>;:KXPSYW3FH6"-6A:PM,YL
M62=0 B^QY:,./%[YIPVX'WV*8L7*:2=86HY#%,4-=@+3LE7K+.-S]3\1/G)D
M_!"L9BS6J\A38=4REE0L::Y[#L4_G0'A1-I P)O7BD8#P$5M8[A6)6L\2Y \
M7F<LG_/W# 8U!^7M\.D_"^P)X$LM?5%X09V4.>[<S>SJF>^@^D4!/@BA*_OP
M8T49%V[^YY*,BFV[.RVJ3.GN.3U[?JM%\IS]$X)4Y0*NXSOP%^X-YDV&3VEE
M?HEZY4NB4^Z+I@9 ?'P4]%1A,BU0BT1."0NT;;.PDJTF/+W;C@.GT(-6M*TM
M_3S?P#!/<TE6E]V''D<M WNHP]:Z;N?H=Y238GMGT?2[<#JTSB8E,54$>3[/
M]#^K+R6%%7ITK)P8W[HI42%8]S\>#X#2-"OE[S.]DTO.9_S\;!3J]*-]L;BW
ML<:B:,MU4N. I]T<ERDJ\^]DJ;,&':K<:"((Z#T]O'@] Z.BE'J<,C-E&_RJ
M">,+T7'&K_B0[K\?E=NWYUV:B_0H;=0P6^@GST\1L-38;US=GG-?R4[.A28C
M+WY$K[W!F\*D^B)DQ-4WE%O+-E?5LI:*')FCT9L90R&LJ=!BW$:F!24!Y_%7
MA.%7'",8]616E-,EOZH[.ZLLMMD7IYX/;?5C3?#F$7/%)+I'YO$Y3D3$4@JM
M"IZFE,I:VJE\MM>0-D]EHLFU0'>$M)(C9M&3V('9[H>-#6-64&D<EMZU&$V+
M7J?]AL4/%\CX9F6X/L-(&$QWZ_+=K;;-_]<,ZMFV-.G6[TFES@@RS5'J]:@\
MJ43^\/S,<+XE\Q(&^E*HI,X!^JU:#745'VBC;)D%"0K-6JG?6$YAZ'":CZ[%
M2XG(DROOO<%N]ATUNMIK[EXC&>J@#78'^![@)S)XL)5<C.L3X_"GRKG/7DV1
M(%C3Y;D=QEG1%/"7 'KL8@R["M!Z]D_J#X) >6Y&FA/^&5[9'AV[WN-:[;5V
M!E+%99ZR/F;5V?E:Z"P7(^!6>^LT"3>Z*%4/1.QQ$B']Q0A;E V"Y:E>6@=K
M8)*PI_HLVIC%RGN<K@0F/X /7(+FV [4*DNG))?Q4 ,?U39"=8E_075D[#H2
M5K'-N>LL"+6<\\_*'I<Z>5[:MF%EJLH*WBZM,&_LLSPV0V@[_2')8F%)>?$:
M_P&PT%VVD^8>F"> IC5\C99G_[U62E7J$M#F@WVUU.:$,E6J)UG$OXNF!4.V
MR5?DY\B_Z\Y%*-Z%=/2M9*@#OZN*XCD7)QYW*8*K&@27ZT,-NYL6A%P-Q,@8
ME&,Z6V6J..:J2O1K#7/:7^LMRUC;Q3])JXQBLC/GQC(JXXH_<W)866C\ EJH
M'W.**1VX>@/XB[,["0\^YOK:GW50Q>ECT\7J+^K%G!!DBHDR4Y$=BV!^Q))7
M2?#"QH'OU4.7'W8$$)YJ$!;!1,>5?Q4J?I<,73J'%'WD9'E?=*PIEHR*319T
MN[EZ,9[+; ]2'J$=J:H9G7E-4RNTZ&FS']_OOH7 Q?FJQ(LS8W;T1,JMCM_P
M#US-NZ_MVIY\7:^,%-!/U=6+W%Y3QIDFC:8 ,<7,';9$.:3\/2NP,5?*J(66
MV.[ER@]!!5&]7$_'C>546*HI]VX]L(D++,AVIZ*M/Q2<E :8XBV2;.I'BBQ=
MPE"E0X<$$#L%[^QCLDS5TCH#4,U3\T?8ZD52G!BR"O+TL^.#=4V%/097QA]&
M[?! B<QD]OAXOK"0=YLWF!=  Y^:!'T6$CH>SO!Y)R,.IXG(N1XUJB@A.COR
M(X45_5QC!!TV^&OJ..Y7(5GV(%H\SV9B8_KD,J;RH]@'"PNK,XC::2'KCV@*
M0=^]JW$;=$5E;;(&N=1K?!E' 0#9!@Q<(+O#W' TY).#7+O),PXQ77MXM"[,
M>#)O9X #FC3^2H67L,.<?[C*A:"K73S_V:,/L#$0M"1%(IL1X5KRD<X&[/+9
M<WQ;:U3TLBFY7?AV-2:5+;Q'!FUX#:,=X_R+;RQGU2Y>VPU+=X8,B 8^);W8
MS6PH#B?K;''N=(P701=2;W>-DB<GP:>X^*$EFF2M1*W)31D>V*Z"S3"+U/^U
M>C639XZ<T94Z!'<J9M&(8?U#$7GO^6((H2ZY*.%AG)*'YEG'CVR-Z4E=29T
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M#%\2";5/,4_8&_>X_BUKU$K:R.[8)FH^UON:EAR0RDPA_(K9W32S4Q]N$A%
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M3; PG^E4VPHJQB["!<+\[BK69V=UWAYS\>OEW5=%%+L#OI9P\1Y,BK_8S=X
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MPO;)X26I(,M9<*);TP?,Y,VORKODX\6^(CBN'T+D_CP_HOP&_7@0<*G^_0;
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MBI.VK[^V7J=)O[HSV'[Z$F'ZRGKXOIKR,1YM=X*"A]GI^;U6\8]31DQ1Q3=
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MB']YS_U33^9MW]W/+-'<#\8&-=KDR6+$9I[&*1@O,J\8D\O1GZ5O7_[5<7\
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M1E"2U\*Y(P(#E?;)GC@MXH!*,D'?C;0#TJ'3"QQ3S3-5#ZA2\FI<;D*EY_\
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MZ_L3RC;UK@< JLO&^LBW\SIO=^M8._??/!5<#JV+ONGX/S0^FKG?3!6%**Q
MO?NHR\;WE$6?=NX:6?^583P9J+OM2^0F]31>,F-GVYW_SYN3\\1_HE2LLQ0/
M^FE2N?E#+Y=#\=W@;ZM_:7ARAU&6XH/V++77Z4JU57\ ?4S1Y+EB(3$R/"_^
M /"G>MZ/2B=>1#>5V,[U^1->>Z8 (VGVN9&% _+;I<M''21U[[]-:^BU_>,O
M.R'J2^3)E2H)*:6 @5S6V^I<HF"Z&Q(>NY]_ )]D3!CL#)I\@:H]-%O N!6F
M-#XC*EWM"#QFW(+E$S?FC##R%!5G(:4>GL_#^H9^3W*K6_=Y(V!6F$GX2U,"
M;;[L"M1&XGTG":TPB"81VTQQ^-4[=+\GL0>^3EO<<LCX_*Z*C1R5$8Q?RL3@
MQQ81\"DD!73#V<#153"G6F.432W!MC[&S\#)$J&UJ#&5OL=VZ0>)[?IH-$]E
M3AQ+,9D^8KE=4=!+]/=M^HR*T,C]B*>6(Q];QA6/$LF[W\^;$)/O$LF-=&#
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MEXZS%AA3W)![8"+QQMPWJJ(8.*4J\SN/9H![@,/"AL7(^*TXU)X:BZH.5N_
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M^3)$[SNJ-GM4+#I_\?N'*;?"K3&DK/0&\,!V;M<FK?;(@J!SC_C76FTWVH$
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M4LJ-)81&..M45**2$NS,QB$*"D[][$%&%9VH646>$'B?;CP@ R%"C@M+!D4
MGE>4(/HI$2L\&?;.DJ"6 YL"00A,"HHO'HM3*AV1K<"=5P41Z\P 4 4D4P2A
MP>:*IN1AM'7:&^LR<P% Z<8P#2!AEE4136;W1&H93-[//2S2!%%-Q@T5/PFI
M#ULJZJ(X&$X3]Z%Q3)SJ3C7U]^>29T/LRJ0Z;#3?+MC3U[<(36@98-Q.FA=T
M.WJV=2(>":*A&1Z;G5*O(W<;C$;.9W?H,/^J$\>6D,JSFL\J<(3C;U^IED/.
M$8XA[M<%XQ S>VJ2MAS90D@?H<-"+O*%;MSAW209EKZB+J H52Z$@**_K22H
M0I756,ZSFS],PU94+!!.M<4_L?X&3.HG"\I#.,Q":*<X;B">$@XM*5IF49 Q
M+-9I5E#0H/NI)C7KJ B]N T6%9V8@6EE$CD-EJ\9"KRLD(V',+<1A?@:-S*R
M:DZN$+1'=W>,.E>6\H_U#M2\?H)ID"T* ;BT-%8K8@4Q<8PP/ ^L"P-C)^H[
M1\30=)* 0]$2EBB&($(-N/[HP1BL <RX#V50+_R)R8,7;441WRD5*2&/I:3]
MRO'3Q_R+=C9IOMD[<$6PG9 #10!2L)!8DV'9.$R0F2&RS+;&[1W4:0E2?+'&
MVW#WW\[)CUF'75W48C20Z] H6=@X;C."^(XV>JTT<@!UY?X(I*OP.Y6^WF!)
M[9U$A4XK9@NPZEQ&AT_D=!TLE#HO607H=>=JR)PDJ;_RR;V_SJE)FGYXOYVM
M221X3B2;,XDE$S!.\Z"HB,O,>,R'('V[=7)[->296T^DV"LU3_U2T#,L1SKR
M"ACY^"1.N:"PL>>*0%$CCASGI7MJ@'ZT7^ 5^?+,(*-M)$D<N[Y$5-5U7>=N
M_<.-RZ&- #.PV[2 0[NUPIGP]T/*PGXBA068>?ST%55IZL_[[W@,:(CW8)]/
MGK/8E\J?)Q\FLAZ$@;F95NUZEL P,LGE;'1\-->NG$:J=)4M$K&@5?$"; F+
ME&F)2"2[!M56QV .9N K(!4;T!%G8DO*+@8=.#_M?/M 9"#_A!2!VG E&CYH
M=H(^'RMK5JE*/S+-N8F<(ITCQ=]"'B,,LSC5QVF70W#3^*5-*W,!J796?VIP
MOS&*UJ-%HCD6'9<M2@+?1V]9X@M& #OTF==RFJ\PCH"0[M>.--%'%I/@<+^)
M'N&O2SA!,,#G,3;W]:XKV,*.%#-'5UL=Y;HJW7.DXO/B:)C:N\<A"IY</H&P
ML?F!<E&0MV,"40G:*KZ_8.>WGXYX=RQ?:JZ1^4YD:76?D(X_E;,M7WP;LOM!
MLW>G+A90M 9RD?H^D4@L=D?V5/CS+$*]^S%+IJL. ,@C1NH[.TWJ?93/.1!L
MRW\B<@:A:^-<Q( 3:9@=XG2W%VOEHUVLK*=W*J-7MO5H\FWI:<1Q@7U2V%*:
MHS!#8(QD@*Q" :^=8L2O!Z8&1N0RY<1WDG6EEJ;AY$AZ3KNV$?L2+B6G@PD8
M:?)61IQ7$#I/5BNAK)68Y/2G-I^AQN=-E:*2^E%IYB1T\E%-(AL)[CU%<4L]
M21#)3G^'"R7@T5^-B][_A5Y96/0*<'\T_BFZ)MH0UJT(!9:Y/Z< @>;M^+D/
M#9R'8^UKIJR.>0&HI8_YBC?P\FA=W/V__7C'KLUF],SSD?UW'W# $<QW9;(:
M-]_4;[P]$Y?96_OWT^=7O\S<'GQ8.W[UX&Z\Z$7]> 6\'_[_PL)(!QOO3/!M
M=GL%O X"R%$!8!!0 '"(/[N/_#Y0P<#1 1 H:,20BAA,('W[OS8> 0<# P=_
M!02I7?WSI:Q_A0<0@-0841S+#R+UR2\\.0\&0L?#MZ1[3Z=UZ]/=&S3L^QQG
M5_.?;WWJGR=R>?JQ**TE<?6OZ]G^BK J3OA0JVYA/])\-669.UCNNJ$[3J='
MY^F5.+?I_8]R++X[2E&D?'0C<I0B3U'7;OO-J;;-415=T31A5MN&S51/96C_
MB*ED>T%]6JM<:3K@UMU<7'A+*8<N.BL8L/]?;^EN%-=#H@A!T+=/H@A!(C8\
M_7[7ER+'EF/-7FKLV?;IG<R\A:>T7B^U/AP&S(&C54W[]]]0%JCCLJ0J]$96
MD):\\87%;D5NRZNZF3)SRL^IM)M_KL7'C'CA#;%C @"DM " J"H P/\QZ7?U
M%]7($R(JI"@P51.D]G_8%?]7TGWS'*D"\Q>F?UWBEU_H/][IO^$5$.WW?[$^
M,,P5GA] 84>-?>FMPGH7<Y\<^-OF99=4?OS*35A2[I9BDF;@Y7@9<GW:\8Y-
MO+*PVON5LE49\R!(N;AZ14">PS._D+(S+L?X,7+ELG[O<'@D,9/+525HH-'N
MU$<%>6>E,?+ACWQHLA5IQW%=]TMT+)4 !U_6RD!#%B5!IJ]19DEXJ$8 G%8
MO*OE=_V J?;N4>*Z<4^+0OOJ>5F+ HX:<A3-U@_ID%BX'ZK[H)I*.>682\)6
MM>;%J:Y$$\POS+=GM^=J4"W48Q#Q\;C8(J4_BQ7K_B$], !Y%BSNI*G42>5!
MTJILZ7RH,DG2JOT4M'BB?=L[]A+U?ZY?,/NM<PN^=6XP2&AH&.!;'__3O\$
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M-V@!\]%ZDNT0/D8.120R-+:+LXU:^I%YNVQ#NI-]63%':L1*Y1$'K%8++1^
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MU"G!$M%#2['*9*]I\P8Q0/C30P3"D:I.T _J.+F10']0Y2+K\""Y)%6VHH0
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M8P-^4+ED&#$.AHV_Y0B:8ZP62%(H2)7^OL9I.E)\?<9*/?]6B(4-YG_C[2V
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M.,"EW3KDFU+@A>5OZW:ED;,^LV,E<3A.Y@WPCL ?N,V0DT9(1Y7P]]2&^=B
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M?'?[9YYM&]!,^*1]^;P:UQ<'MB''&J5&S%90M,P^^>@\+:%,G%(XEV!6>\:
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MK$DJNET#X%_ UHOUZ*/L"M?3H!K+Z.6W[W]_DZ02T=P+$>?'="MLH?$2^&+
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MZMA6]:Q6]<Q--C9PH!\4VC.XQCZYQAZ)D_Z[0309>(-,A^E#5(@5_]S.W#A
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M""  ;* $ $U7+';T'=MJ-=VKP7G(]*!KP #%@+A(N6/>%L1Q1+I_$PM-$8:
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M=R!T\EIFR6.@HRA%R><8>RS(SHWIQ6'*SAMGS4HY43=E G,/Q:?E*#20FKJ
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MC*WP'E_-:>CSI9SQ2Z&:L4N;A@)'.AB#6ED!?<(54T'DIK8@K7*W6.L@4-Y
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M7L5T+H61;U=K_>(BYC.*X:]_?=4@8]6OY/>6(^)6N='C-+0(_L:I;)#IQ/Z
M % (XF2; /\,ZSAH/RL@^1GVI&\9=U,14H?'AS*9"XS4..2Y3-.ZDR(1T!<^
ME35_\]'"1XO&GZ:!69^N*;=[VK TOX=^*"*>RO_25'^?-(K2P1^@<6% N*MG
M67VI^7GW68^M1SZQ\CW;9[4S)LX_-_J7>@]Y:#R.OO5]L>EX%0+617.I('D;
MLRW<%GX!^:[EA4/^"SCVQFS35G:C]1CC-+]N 3QU/L:88K;)1G+])^QO71>V
M4Z/F>26*D]=C9^/Y>9L?>Q$8%KW^]$G /:]MG^VYN_0G.IVQ]]OT$\G #:DX
ML[M-87S42CR;M2RN]NP$%_+)Q!(U*FCM(%ZYB'5\L(S3K>[Y=$I_VBPJ-F8%
MU0@3:ECK5H&$4K?6-(*E7'"V;%-P[)&DJ70>6)J&;2 7-8XMOECB=<)MKD6^
M+],7.2C)Y*1:-Q1B?<)MGDW)J.[$^H09><Z[99HWI7H19US14Y U,";X(D%W
M@21**T^NTJ//(JOU,6^M<YK?#(.]BS[Z!X@CB/'(?6$VRJ1J81=;&O3Q&^^/
MO$K_#;:.0]+ F:]'!Y_6JGN1XSV<LP$)S7XDNGBT][/#BC):,QF>.'3MB1.+
MBG9H^%XKOU;<Q:7E:D3E<]: N0Y^?JRSE8T?]?AB14"/)WZ628M]"Q?V.0<C
MG^I4Y?#(./Y']7"S!V=!8?K,<TV7/8Z6@'2+KHGWK1P?8A.'1>K$DZ[)9/OX
MJY+H?Y_ZLZ1]3>8/\KE\\SO0$_Y7Q"0"^HL#65_;M1BNR; ZJ,\+/[<2B7W-
M%/ME8J:@8]&YH'#J&ON(T/$(%H#P&#I+$*VV?31IHZ8O^?8[EB(3\KOXLJPV
MB?Z/29^ PW=/6MYKDR@F?LY2-KY>^[LAC+#CNYZM2 KRF>>_ Z7Y;G_<4%]4
M7:TR;:C(Y;^'AY_M?NWFBHQ+LZ(&!^I-G"[[BB2VY/SX;<(= @+6-4A,2<Z#
MO1)8JF%&S2VWNK4 E+GHH:M!A5R3>(;?YVK"3W9&O<+W9).H_=(,#&OXE6"W
M%E=&2BH^52>/CY?(;BHD3L(^BN37< OJ/\WGH,Y)?=)T<Y\?(V<@8[C?20<7
M,D=H^/*1O'@]K)9Y,2.UJV7#GRR@\:G-U-+L[I)[:;1?_J2GD.*=K5>(+S>^
M'_?7WHYY0<!UG^A'5(>M <_9(ZKE:?H90AV/RM+0F.R:LX-.C[7YCBS_IP[#
MQVLZ8BL>_ 1.>Y<\'B:ELSFLI-:K=12Z"2-P9ZN:ZV82;C "OK6U'9.['CLV
MWE,;$W47.DP3Q?31U4YL,ZOW+1(^O\7QX-PMJ3+H+RB@=5RN>B(K[3"Q]]S1
M&XUX9!I3H4O>6=-WJ> \= AQ(?3+MNS-!,/(*L[N<=7RS2!2K<\XY%>6$VT_
M,<]U&F>H#5B^R]PF3+&^Y#%9?DB<)0F?H%N*[+S^+Z :Z+DDA?:61GV*>$&:
M-^&[]RGRP4L<#!L7\..2K?58'P<+P%"JOLNH0&6O_>C(NBM,*!Y:V=5YJ'1G
M(\Z7_?K8-0/(7-1]_*>LZ0HQ?- O]E)4-PO%6#S>N'LO)<IV/F/&;G=Q%__L
ME=-IGY9*^=)(]I'>^@1N\8%@^O1-OC^T6"']D]$OP%R!B!B.OS\PL-OF$DLS
M&K@UE7#30Q'W,T[/.B/,K-XNHXJE3T;',(DHT()8+]H(;M?#3PZ]O4'XDL[>
MF;*)H=K!>75_ZOU,26EE1BYQZ-/!$K$0$9O DM$=@P>(&;?>>M\L_1#&E!L.
M70[:!_FROP 6M7+8D5OK%S4_JLY2A2D!-!+GJ#*FJ[1I*.@@6$H@;\>IVGYE
MW'N);W>4J+\SRJA-:T7%ND7EGMCZ;?_.9Y$EA<8]:Y_,?;^(>+WGSPYV'J5<
M7 OZYOI^.4>X\6 U.2<GO&?LRR_ ]69+^\MI/L]/'@U'1@?B;R+./OYL$1,R
M,^/_DDP8NS#XTW&CO*_AB_D?,16^,_\DNQO_3'FCF+),;N^^'DA3:X7#BZWH
M+MV*C0SAQ]E_)Y7\ Z#))MZ"*#0/:'.H]YT/=!U\T:I]_%]0F7\25&@UL[!5
M/33<GZXZDN>?PG.O\MG[=\I??+@?)]WYA-IJ*CF;CBP.61OTJ="LFT_\K(A7
M]78\YH1<0?G/QS_456?Y+#>VD\LL#8H+\S4>;+I$FYI66Y857#?,Y"2RY_.L
MEY&XY*6&<?W@+>+0D"1.1$?%M*\W4;SQI1,I!,6:C])CM:=F\^&D?1JZ9C?S
MAFN^=U>7EG>]%(-$ S\[V/&6'*;\@XQ*N\<HB.\9&[K$DTXO<^;B4J2 6=J<
M<?YM0O7Q3[=H\8+P-%1 E&9*1(1.$.6*USV>TN6$)@V]!X>U7S5:O>.I/JG2
M9AKTIT<\2M]P_[GJ#Q7E.,>I2LLJFAAT3'UH'>U=R1TQH#WCR]0J,?;.&&C4
M0YQJWD3#]47$5@E,!VQT>T(RE-Y-T/6UB9FNV[4S#-D%Q?+0)U+$"<U>,Z9E
MLSZ-$*-W*58"Y9U:I Z/D_-HPAC@^KY9S8$QC1DTGL(NL%=V7SGBDFI4."E]
M:!@\M-)2#,QZMD^?3&8^'SQAE22GRV%+S73#J$DLJZ%%*(>1F<IZ<TT,A4V7
M(,8?PQ]F6;&K-U^]]?]/LM\\6KJ?94&UC?"-26;%IYD."ZT.2V\N.F;^15%+
MYWJ?;;%"0V/Q .90K&\ID&+V5^OQEWK1.$-2VL%IT0[G54D;K[9GXO^*SK]O
M%, &+6\B/[HU37T(_Z#E$,P%K,2(XM^S3P!&B;@-]6FT\:@=9\$D^ KM#H;
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M1$4;-06;!X^5J+ 3<2XI.7BAD#*QEWB/6P*Q)%5P7V."X.*^GY!S6[Z3J$-
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M#9"\+"IRR!A(_.#0MJ[X97:[4U2:\@8%64?-L=DWCS'OW53 =[3;1ZHX<)L
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M('D=>"4>*Q^K%=9D.9/#0>K)"/ZU*CN@/4Q-T'3.FRP+5W0\FV;SL$"I[GZ
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MK#67H=4X@$=,(EYLNC\IG?J[GJ0U(U!</1)4QJ.0NI76\Z?&QQ,5XV/DZQN
M@@'[,S6E\4JIR+$V0HK$%P?(CFDP%U,\ZCPV+D;H0-D85V@S@R@H.5 J*<K
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MPMLP@ D3" ""8,%@(/#_R3:%":#D^#L)<U+1Y550P\#\+@8%NZBR\3]R38&
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M+Z U0L2AJ(WG.M]FUT\C"!J"A-;FZ:2N8,O2C6%!G4X5![E7K4EB$:21S&>
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M2K0R(\(B8<);D)=%#3B-N#9HIV-S'Z- 2[EY3;,7BM4\_7XWN:D/03'<Q0\
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M9='+RABT4B!N+XV*&-V);F>M4A>_28L6,5^\PK.?U]2&&:CNJ*NR9("+05Q
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M 5)$?[ PK9[D/+K_T<-L5MP[O5@H?XVZT<W@_H+\VL3\XT2KS>NIV8FE*.N
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MULNDF>AQ2K&>8W-)?EP,'(#D=TPR G@[(&29K8;A0U%0UXP,&C-!T A51#&
M/ 8 K4P"5JO"LK)O^_6V.O)W]^+F'(6@]H>D4GW);5<EK#@(2@/@B ?>/'QD
M3OD.%A7*P*+VU2V83CL6PH_!.%DPPKJK>G$N+$KM7Q#4;^,35$4UHZ.YF=CE
M!+8\A<P,-#,^XL0Z>K/DQA$1$6$N"FO5EY54;BD[P-0HP8W&D4,>:3X.BD*U
M?##R>89EF&\TL3?ZB>$C\O=VL:;I<1LS,F5UVK$GZ7&QE]+Y6'BIJ!$V,084
M!*U4H7=C_MAN E37J9;3,259X'H4R.=M,:,ZDLR0W%'+3='7T3-9UK&[#VJ,
MLN@%)A%1L%I5]IX/A<8$80L(.(!,AK\7T*GC:<I(&%WMKGZ4G"WJ%?SAXD6M
M5#^<07G$+=YQ48@$INJ:?A8F*0F3C,*H9%@WH[RZ*F0C1=-?.78F7Z LIK*&
MU[>/S%6R$D5EX$!NN[02'XZ+[L]6*2R*F3]$ #A*,%6E=\J8XYUEC>$7U!52
MY%[PQC!C"IGT,5TV)H!T 8!6)Q@VEI-N ?94XE:NU9+SJ* 5D;P@[2N@5<6'
M0E@"H)%IL9R_@-XTY!&W";4IP'<6'_K%K@")[!Y-'TW;44.\!@A!&**.['QG
MH/]$51Q/)"Y"@/6:4=HI&8DM?<I'?LMPYKVM;,2SL?&U\0H9U$,V%:M:;2#9
M[5,XK[@HP!&*H.XED,L-0T13L*9TQ3TT.B F>RBBAR:17;>X<78::$?&B1?D
M?_+DR?GS^QVU6GLDBZ8A/()JI((/'1RJ.8X;?/XVO3!'#N?WKN\"A[AC$R"=
MD,5-J00E !@!3-%K>X;?0-9$915]6CNH7Y6HA*X G:?I0]O)20R$:1@/8(4!
M!2FH 0 E !MEU+$NS:="JSX JS!"7UNHR.OV@4Z?LT18E;U1C1U_KSHUPEF#
MZ<*Q%JX<9L=%XWN?#4HN7DF?-,2BFHW'-U\21X!&GB*L^<A]N:W<\,: +H3F
MS6.7!R6/$QEGI,\ D<Q&E58V-Y_/?_H],VOVI?GYRX"F-S^K:YZ^]PJXM^U1
M^5T)SM3TYA^^_UOR&>"Y)A.][<^[(O]3$ ;?. /DG_4"!/\\O$])?H'L;Z?W
MR2"<8@!E _L]W^2(PC_.[N__Y?"^SY^G]RG^.+U_!G@9-<.7NBGY\0Q06W"C
MAMSM%!F\@K?RJ]L]=1A[N<%U%'9]SZK@VL-?CF4PRAI/V& @D?NYLFUM52.Z
M3CIO'TC7-M_$"_.2O]D#H=)RQJA==:ZSQ*S&&U(^I$D(*)[Y-.\+U W.3F=H
MJK1D7@*X!$N6ER7JM/E,V@^W'>D:A6 ]\ @G[L!4*TWK 6424\>;$GY&]^/1
M36LE59YT+4LW"8E&Y]6+%:\H%VOQ\Q[P2/BK0^3K6!W!*AQL]<CML>>V$00(
MT5,AXV_:N<G!]+&,(7F(- RFMO+OL1K[VFUX!Y17QJ]8/^.3_JG'S3-U6UU"
MC%+J\1N48;.5O'67\9[ 0H$_<:1FH>_V>ZEXV0Q+Y]'*("'GEE$S^D2;L/6M
M*:!J-0[';MA@I#%VG%\%854/'/TZPR&F99(5$%,Z<<?F;0^C'*9/FI-8%H=V
MLX;5F%3S U54H=O5SHGBJ#CC>-,K;)2^-WA+@^N-O&G[3(_I3AJ+T_?KI+.]
MXC EAADQA26[2FPIZ3TE_K&DM*$F=ODQQ)Z\DTFQG<V=K$[(TBUT3*JL^%:0
M '!>"NFY%5R:(7 -XCJ64-%!YV3")%ZJPW[06D:"O UKJ'X<JM2-S&<6?BLB
MD>]"K;XO W<T7E+W;_8#J_77JET7-G5N[!OT,^JD_L;-GNH L)(1M_&6QUCF
M#$K0;6U<WI#?V3P#1.5]N=.;D_=;855']U[^/KKLNNYQJM'#LE#-BM=3':CI
MS:TEJ+O_T6ZLE-S)?T9D?*FU?87'G]']J.9Y0&H'SXW79;,9Z#=-E9.+MN;Y
MOWY4+#'*C:5O?5V/'7(K/CHYZ"K\?/3CZOERI#15UW@W=NEU\=U@G'_.MM3P
M]C!CVI1FJ47@;@?:?_'WM;8ZB;SCHQ\*67FE.7I2AW^5-'$XH^BV'BMUN%$6
MJOOS)K_1U/#? N1M#I0-ONO=#7I=')(\W?OQFX/.53%T1]BY)X6ENUN?[O2N
M2TZ&A 7C7.3V_^3_J2YOUJ+FIJUY]NO7.?G[\M?"KNENH&9?_^DH;-?UZU_"
MZST5U/4WDZLQ=2ELW8W-RF@/<;FAVSC+^#)O],7ZN:?7%ZE+&@Z7*!Z_W3H(
M=BC__6!HE UW9_Z'84&!^:<MVX=_#,77!Y;!N-NA?\1LE\QQRKPE^Y>A?/I0
M+_6_.>C_DG@&^"F>US1\!@#$J=_J49<<N#B5M'/UNJYJX]YO.8:IGJ,/"GK_
M!XO. .LYZFL.W%269M::S'M#YGG?'-KW2KBF=FZR0+$#!$C:S_Z,+;$U>E+C
MH>1\HZ7Z;[J 0Z> X5^"R=!/2YF)V -ZBDV%F0N,; OOL#MWU5MS J6%MB^?
M 2:_'FQZ[7,CE;ZP&_,(D5^]$\O]Q)"/.>[745<R+>EX<!6FLR5/3R=%MS'9
M<*>J9?AW\*X1.16-'$CM%O0)+I+9#5ED8R! B13-+N14OL\Z9FPI/CX^TX@U
MGFR%]W4G:'I3J\.=JGFU,"GIW.3*X"?.K-BDFTQ]KK=C'!!HYQ6$LII /"49
M.7NZ/$$"RZ^2A,B0@K5EP+/M:M!)>"5RC(&)=@HKE6@6M)S-B/I]@!I.Q FE
MSXOGYS1-Z*')UNB3='Q2:$P?6ZF"I8U!T22):TM7DRD3)J"-YCD-J"9SJ>*8
M7-G*9 /@)8=BPBJYI:1RRJ@1-3\=Y9-(EI380NWD*BVZ\FK1XEXT,2D2E%*F
M->J#48%J84PAU8FVX;]TY!\&I2"O54UTM.]&ORJ48+RZ'M[9.QFRWL'C,*SJ
MI9G8DJ-95L(+2W4^-/7K_DJD/=;+/E6_^F'F[:*4 FK5*\WE#N_DQ%"K#6K_
M1&[JC[&C:PA  8D:Q#0R:K9!4WVJ-%%E6+=QSOB6G:A4DJ:,ORFRTD*B!N#,
MJ%^<5F&:,OFFAEFMW#XCD;NC3TC;00T ?3M"2W.;3Q#3JNPW]X2A^$DT6F(&
M:IYMC$=QHXKH\IVI 4I%FD+&+1(F7BJ]<-H,@$FK4\@44]Y")1X3+<6B1$1W
MTZ@HPT"&G!3(7$ZD>P7_;FJDJ 2Y/NLK-$V&6]P"%*$D'>G!VI#S;+4(2,/@
M0,^BJH,= Z,\E0#FP MQ<1;=3TKU/?2CU9/<;LCUW695^X@'8+& 3U19T9%*
M$?PJH^EHJR6^![]NF8Q4P*:%$(E9#T00)DI$;3Y*_MC@3C?.CP+X,<Z F*;7
M'!1Z]HED9;4#@*DY!Z+;9[%>R6_P5;:[(%]ZQ1C9F((>#E4]>Z* J+@)-0WW
MI3)KOFP#=\&43W;YH=9_,-#-RYE K0PJVFUI\#0KW#B%C"TR$KM+B,CX%!43
M0$LMFBS9V2V>G8:!/1%5E15>J5.C8C/6I*?-,A2C,C$QU2JNO%.9R'D>'CPU
M9^^#,.P$F,PQS/$2M8IF$*_Z2@"CUA3-"&7'2"X-4#&%, >(&G6#.@5*K14K
MJ_>&2LC)N%EX[6^B45XF +57D>/=]K$U+$QP37)N4JV6@4P7EQH0QA)99[B"
M]C&EX532*(2J*-N\'.>%FX.9<AF:MB-H\$ 3)8"3*4*ZNX2WAYI>0B7)HDAM
MQ%\D+'%NP_;GI;J1]F\*#MEW/P<.B'^?VTETVJU;X!C6^:8 _]>U2P[-<ID=
M Y[_B9/_$NV4P[9-J1[\&.7+;'C),]7UB1*54]+MH0@$'.6Z9EVAM<R71+!0
M@A+CIW.+RW6P,',#HBC=(S M# 2C!^#/ (F*6NJA+,^OH)BPQ?#[:FAUYU@+
M@H:S)E.#$M6C2A1$JY":7-2(LY[RD0]>8X@5VAYV;VF-3!E%U"2'&FK8/P8O
MNR7'E$737A0D BAB286 4D-@M"Y&Q>!7V)CW[[CQ6*,+W"F<6N*0 N C02BK
M8?ET#D$:Q?09,NG:R81'4!O[/G\Y/L)*,$@P;ZP0HI^#?V-B4&,"UPK6$]U/
M>7O?.SD]ZMW)V/>D)8LW-;,P%2&'/-+0Q%]^QE3-_E'#V_J+I*=3E=/:$I.\
M^5&91D[?\#HI>\%ZQM_=,#VU \[F:NS9Q7>3VDS!$$PJE=JZ:%FO[&$'20-6
M-8@SYYH")5R FF(:52\".#:2U$;$FTSV*ZH86<<.+0EF/>[.N9M,8XF WWOO
MEB1$V'@I43,>T&N!LZ5\C<=U*A-R8TT+ %,[9$Y_2\?BS1_",DR-7 C>0E/W
M68X%=L_O"_\39 EB/10@K^-M%"MQ:^ C XX#"H/$+]6-UC6_#OLKECJG?91W
M-MM/]$IHOKOS%XQ_'6,/P7"BS9<\/9*0M(!'Y:R04KEFZ;>[S?^(BC+)+;:I
MYQ]VMT<R'S=+'%,@?2F-Q9W%$HSWZ1!*3 PO''(=O I^_A5K9COSGG]?N)S[
M:D'^;P+!J+WQVMY"Y&-0CD)XL3TUIR_K%6">(J6634#X<9MMFTD4GMM]3*-+
M4#BZ3XOU!KRST_P(6LJ!H((OD4K*59BSHK/J@)%VX/?"C!CI5'Z$UC2.OT0#
MG$B17.S'=8E&E%,>0%*GO*'+;$PR!J4",IEIJ8Q3*GF9@-=W+Y>K,@IV5$<2
M'R4;<EUPX ]&1P [(V^@R/+!$6(F;XOT\3D^AR^]]R,0*2FH.%0RTOBV5@*6
MW#CD#IH>3&_')VKAKPH!K]Y>I!?]XR?ZW#, YI,FB !UM:MRQ1HGX0?1="HF
MHAI*TW%QZAI VF2J/.3Y#'U;+H 7@VK&\)E!&Q%I261@9C)/_BK6)ZV'$)2[
MCH UDZF63DEL9.J2JK5C&_>:K0XN=XJ%TIT^QSS4*6O2BUANNF_(3J<C\-33
MADF $?9U9WH66,@28DS,P?9YKQ?+5!E+9PB$=EW@QRXK9(6VYX50N;D*S5I_
MK5JF6S448&LJ7!25O10:IQIZU)&J;Y^/LY.)_VV'GJTQB[PI(CNC7=0,37LB
M8+,X1^,0](5_2%VWW2=Y=.X+_-7HJ,1@^( UAKUW/E-B+,%-Y^ ,T.E%2W\0
M)PK&YM?UO]V]ZYTH_?KN0JAO\]W%A;6$AL5O2QQ>!=^;C]<\O[>W#-"YO/Z;
MR>[2OM,ANZ"XZ[7_9[N(=WX&9$4&=I8]$8TJS.4 (:GX+[<<_HV'?V@FM04S
M8L[ ?E*3Z6:ME$(PTXB94J=DBOU'*J"2%?HTF'I-/Z\.MJ-7Z*%40/V<T#^J
M^#?M+JJ <8\T0L6_+?V^ZAJCQ W$IJ?=@NN*0U><"W/6^?&FHM"8\CN^-+;I
M,GDGR=WV-!^,9GQI;LK-BA1\ZQ4W; S8_4ZT'D222Y%/BS_5HYTHLC!J_M;B
MK@Y9>':H*B3>*R(?FG^R>CDH]( #<YJWWZOX?0A5,+4R!9X4R&;K<RB=W<92
M^ J[#(APE/WRS]\7;EL./ /TN9 7Q3-$>KF-+[:+42K7,_I:%#(-"H!7!V/X
MY^/L/?*,NG&^U%DX*ERZN>V!&FH,UZI_6:-G\_17(HM8X>\A%;P^GO"&0C-
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MOV/W.RS/ *%_SB 0K[*J6PAY>P^-^PFS%.\B?_&H&-K%WSOUV0/-3PY9XV<
M,AJVT:((Z!LTJI#?59:\3[T1U\NH-DJT7V!I4\0&W_E*;J,:4N<%.G6@!K]7
MUM]_8JA?_$9^V3.YC1N7/N^<:@$!]CVX,?6;>?404^$DC#)0E5:!4@0U<<Y8
ML$E7A"P7R7,M0'6H#HT#&JFYLWJ/IEY1N2Y*U[3FF%1KS+QQ"[L$S.A[(\Z
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MPD>O9:*M'_?[<CF&AN_Z3G\]G:Z?SHXMF2Q,&'17]4DQ;L0VI*)2DE-JJG.
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M$.2QT-Q=&T">@]:WCOM.0IFR;$XU[4MGED7I@_;.0^(=RI#ZOJ36O;R8%<^
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M%3C3.'>X)+@2N-:X,;AUN,MX$'AT>*_PW/$R\+KQ#O Q\/GPC?%#\2OQ%PC
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MD++V5MF\H#*0/1"!@7QZUW4=0'T"7A?9*M\1-'S;:0<;S&O!++ZJJ?B.K,<
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M")/08*Z7++;T<4_2I4]ZAF68^:O#47-(=WX&?LY_0('Q9NXO\^?_VB)H RW
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M&(9-Y<M(DJAD!+6M;T9]<5912;%)74.Q:<%H[;SU"5)5'!^%B-Y\RI[$6.B
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M2OV]H=4S+REKB(TYP<&0_#\7H;[M[M$DU75P5H^E>J#R8J45FV>W^Y!F^W(
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M^K:3'@5AFE&/MB$K0(MQ<A.>DYC)JR<LFF]&)A-FM;5!A1J,&$7YK52%%FK
MRQ@ESDWM'*5+XM,9N(D*+A]J@HZ)179?P'UVD?4+'R$";X(H#R<8VYT!6E/N
MJ$-E[J]1)N]-6";<$+6I)#F>ZUO*\):RO3(>NGYMKHAN8H@#EQJLB4-XM OG
MX(1N$W4J^5*(ENS,&$/R?M('U)<]XO"8E(Z*P8R32I;<CJ(A<=@,8N<CLM5D
MQTIDF;0Q[?QQFYN]P;++;U80R0/S'!]/TTL# H=%L&#50JO=6FK*B UJ([Y1
M9-D(1%R&K>)QK&<TUV+)AT=*6R&:5H](P:!+TV/XA!DF?K&E#CRB6@G]JC@3
MC<3DMB8B)]2,!R7QCHT.0MCQ>(Z^*\=-+/;&J;^9;3P@LO-DP\ZVE@CNCI05
M)HX"5SO.E*3L6[B1HCZ^QZUDJ!?"AR6MT*^CL]%83,X. 4EN1VD(;M3C<;OQ
MAA=VMN)?<,;F:@6/!%E*><5,='+2F6:CCWR<!Q-M:$FB"8KP)W817IUL&VYA
M:,N)VZ"CTELMC[KVQ-O.(WX4E]/2XJX/EY36S*?.,_>2[NEV4.6B!SL(.("H
M)+:M_7:DNF1YM'V&C^G/G\49^25UD2NFTV0ECDF4R3EGD@J<I)^3"4[IT*BP
M88C^PR8,QV)ZP(*L.CE[;)SA#@C'+ 8];#A2S&Y@DYXGJ\.%1((>CB)<6-ZJ
MYW-2$$N'G7PMD?=$WH#H(!=! ]6BS7;N%[85) Y_,_M2>#G+3:.Y)P!)TDZ=
MW-.U-XWTFI]'TZ7[^54.X=SF^U&$ KMQ].9E3[@304;]>*18W"P>2Y^3UX8D
M#Y*BCD4O:?]^!,XFCX!C#L$'ZO+_5T6)HTW^2T?->GC_?\.T_I.B-L-AC]$\
M')PMV6@MV J5-F7JF(6!S*());:\S1:]9/VM%<7_K>HA]['^7VV??R'J]P2$
M-.C$O$)!4R9=YB114ZJM6%5GN/)7?V-3M0#2O:P<M8 4=9?MCTJ*1+P&:Z)(
M[F2ZBRMNU-8JN\J#:RG)'WX"ZG0Y[1\;]ZK\#B?,PAOCK \N=&5JOJ\(#,4N
M]AN'H=/Y;DI^/W\0EU+;V0\._K[TZ(A*J)U96.0BJ]-S0"O2#%]6+49\KN>W
M&[YJ;M_>_4@6>!O<FBNUQG<RO49^3'V=77;E\6!]6NGW8\S\+?+.05-MM]_P
MQR<@F^U->ALX]D4H]C;9(Q6M-$I>_EVQ]#$M5Q<B31.@:69FTO9I5B>_JI.B
M.U':L8SU'HB_A]4SI"8$(<D(1S@C679KVIFPLCK7+^4*RWI.DD1I&</W-;Y^
MT!+);64^.U,;1)#?R2$S6+3 UED))(FHFF<(,).(E7V!=8<'!/@D4C1]HE!Y
MW1YS/TA>RY:GSSA@8F*T-8Y/M,&2%=M7(7M#X0O>AJ@')GCFYT6W:CZ>AB6M
M,?263/"DB]1@'AF1MY#FG'*VVPF?JL=NHRE=!J[*1H_#33N<1))"AZN1W'A
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M1!1*%2ZG:I"3Q;Y&/FPOX(.-_&H=V6>:\J+2=!TZQN[UMH*V2I5UBHO^26D
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M@OT_--4X+S2=/RQT_L]NI3*NOZ*[_<4LQ^VK5@G5FZX\I9N5]DJ?-1>R/U2
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M;1O*^C]VL>X^=+0O)XUAKL-=219D0WQA81*:9EZ09$8@T:PB;Q700]BFP76
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M41K^><XB)ZK:L^$<FL S+X57+:, 3CE7F,F6G6LE;<ILFQPCI(-'$N,%:MY
M[U%2V _*T>.SWBZ]U\/1J(NK>U"[9>HX1'J&^X::!'-T;@Q).)+]>+;(&%RF
M,[-8 ]&V-^Q;=9U?L!AK,2U':,XRB.HN]8V_8G8X2TBA-;.PI6:J7=Y5*W#U
M6570NSDW$[P@(FRL47(E'X3%IFG1:>K6F$JSQ&0?H:"4,9&O=H\1TL+D/[$U
MD\,E4"D> N2MS3KB88!P=9>DC^JE"3*B]E!#-5R."?,,(E?[A?3.P_SN]I=W
MFYD*\GAV^..Y2]8W5;*0DSN2;0US&4"RPU]V]?=@*02YW0"O^APK2"*5B A&
MMF:%SR%9O$DS8ID!"DP*%+ HZ3G^]*/N[,D;TM(^F719DA0QK,JYAAPY+OG?
M1(.>O<8MTV:8;WV:C!,D/909OI4TUGJ>4 3K:%E:DH.@Q(8*J \M47H[4E@)
MM=' >UXLY-ZCOO,4R5JMN:MZB=$DC22!/,LV\$L6,^_R+9*EH8_.:7U)-(0]
M&!#R^,=%&WU6(9)UG/)9+?:(6Z*P^2Z,2O;$,;"9"NSQUD!M(RK-ME@H:%&H
M? NOF34/:*;6>!9=<V(_U6/C!"E7HHFKL\RT0CVU, 8.C;RX:=DB_F%L?=D]
MU0_Q,WB 92$/+NQ)8JNB14R#\<%2$!:]F1Q-<]8M!_.R>98[);=E'4BA[^A'
M(!/8O:2Q.M^%H3E4D2-9G5;34\],?3PL5? F.U)V8>/HC-62 R_1+N=T.(0U
M+FO*9JM#V0L"[1,,(U\N/H+#3AX;)T94M-BWGZ4ZQ<P1E4@]2CDAK(NXP54*
MM5B9T39D&JUE%@)5_@7T9IJV OWXG&YO+/B'3-V;5'[ DM1.;QLN_.O0(/I3
M2\R4W,(O$XXS2D;DI^B63LF)/O-]&.L&M0]JDS QH]3JK%H1HETB,LFX)JQ.
M!JH;U5F:@&#598SJXB%#4T\X-*K3UE3*8;HX;RI5@"!3&/Y6$<!C6;+XT*:6
M*]LC14=64)+ H+B8D.:6FKIU!DM[M%KFV&:!!YT(.WPDDZCJ9KDQ#NHU*X;,
M&]6W(R0AY3_U:N$2D4MF=7#F6N=:B:5E"*V0JB7F8C\)3*!BN_)?.W1[<CPP
MY37<HG);Q<%G7+Z6 .7+;4&;TPT+O5&[2^G=3VI3%T(O4(,U:DG*068S,/D(
ME*$4DJ"[D:^4 [Q S?P0Q<8LKJ16$4"B,"'YD'P;OR+RSD])C%*!R&3KV&>4
MH7O+Q>]1@%K2]E.-I'P? 1&9%&> 2*-_M\HI^LD*]@N4=H[&2#3S@_!YG$-W
M\>Q-(W3\)LSMJV,>Y%AFQY(8WG1QS6-/2P=29'AAF7O33^:9ZGBX+M;ZEKEM
M%.[/O-6"3&J$7Z?.HA*O++?:-5:ZT^&*4<1<O,574KEA32DH;7:\@)S%Q'WN
M?3&MG:W^H-)-)VUW5]JYD?8&F'@H94+1WF"QXD7&%6GD1 ZW$6XIXO'RW3!#
M.?.!ZVWPV7FK*-S2H*<G=:1@<:I",5M..7?!$(HM?=Z,BWM#WLH[Y?)-N?/O
MT/;5:ZORL=PQR;R:=?%2)'KS20N,/G%L%=R'^?Z"$K"=?#J$9MI17@X;OHM%
M"^3OC_'GB"^^E$Q")[MVG"'6>[BHJ("TQMIY8I",E>IW^Q<-XV%?GPSO^*,X
MEJHYDB=S)VU/[>J_%0M*M;"=S:L?]^6>NG9 +Y(E',!-+-5EDZ5\L$/:2T\[
MQP8BN+HZ@T(X3D?HCUZ@(INB.F\?O83+ H$S,ZO.*L@DF)&%!E2V^!0G!XZH
M&&%^P41J1*)E4]S6C8>5-<Z.9U7@DC#J9(6FECS<9)'4I%R$7>AT?).LO)[
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M/_^X-B@VJ^::=NTQ@FPU^+/"X;#QN)Q+)M*MTB>"1F1FR[WA$$DESUD>'B)
M^?]9U?(+X(TE;@$WMP<%"B<%M9Y-K )Q/GEJ,,*V$QZ-6[GU[(@&%^@$W]1M
MMJX#LE^\]6S^<8:H B]C.O#\2T5%86,PR+OQ5R<;PUPP9A63+X;$,!_M_H_2
M.MQ-95;'GXS6R<D>3-F:8 ^K5O89%]Q/]@U6+7PK!VQ,)%:6,.IO.Q7GG6QK
M(3,K*UX7[OB+#>8L+'3K;Y@OA&KR!L?[P+8N(^D+W#!N98+\$&;D<U$/1D;9
MM2^D\,@_OMOX:,KQP2DUOM_A2).UZ^W=3*P,RRDKB^O^E,F<7_S*&PMJ O,"
ML-X!XYH(?96),!$H.>/M'+J<_VO,_52OLX\^(0UL)B&Y'QKO6ED)^+$P^P)H
M:LI^:JR>'KK_8&KS(UTT::')!4'8/B)#OA+NA-1E/MC>F-'/TG[O>W2E7^95
MLO,T2<.JJT=C><I21Q2,UV369]W%[!= CWICMH N,_>C<8[.J=C PK]YS'%R
M]:7+\\7CD0WOW79<?"9=FX7J'&27-?,\:;<6GU1.B&D[VMZ7NZG.@](^E/WK
M8*GF6U_Y=UN,4M,[B[3_KIO^'5S&@)3<R2I97ND/72=YWJW9_Z_O^!]!QI-"
M8D/7_JHEBA#&\L>'BVJ[3;Y'QHFGPL.)%X!0^L$+(%SUYGM;9[G?ZF4V_X_/
M ?R/)T[ISQ0B%?(6GDGE FKE0Z48CMR^Y2[IZZ#HC9,UJY\ZN_QMS22=\RT3
M%Y6#3A[_.CCG4 3 .@<E=9VL%?[4V7_=UOS*?[Y5Z:)RU-C#4>.AW/7S^C\$
MR[S> 0L?9V=.7P#'>UTG/RIOG'K]-E>,_#9O2KN<?KE?=XWN'CRWZ:[O/]EV
M?%XWFN\"_U)-?U":2G_VX/^]9<PLW>4UO\U%Q8>.KY7\"0_E*\WA3&;$0.8C
M4E\%%ZA6;E1I3(-#FYCR,%A,@_.L9#M^)_;IFCG96"\*@D+)] +8I"W5?A@N
M").+$OLY7*;M;_:*)CY7]><PD>3300H)N@3^L147P@P!*$BP6X19WD)^[P5@
M7A<:H)5-\TN5YFA%X.W3<B["')[#%DSA\@BS@X4E.F:29V%M2[*.</A,+#'*
MKM)VD^(7KF0:+EOO-_N&HW;4(L)<5XKJ2JG&N$R36B9S*;-TPA*+E/-Q#+5/
M@A.B'>7PX=\2"99K7P#VI&F#QXD@AI9=\=K;_21SJU; ";H>HV)PDJC @C@%
MUA?:L%E:BV,36;_PAO9+QJ;6;(,#( =57WE\DIR@:8'MCE=4,^E.1]2)/"$M
MFFD<039CF(2&4,M"KZ$](LSJ;UY,VX-D(YN![0;J6&WRJ6V>KCO=/M18&:EM
MXH^+]%1E1I1!RT#T-+AG%O8V0GX!_$PH2U+5#T7SCH;E6%'ZXNYPBWB4,A]C
M('2\D^+*5X><KQ6&/2/,77/6"TUK<+X<A>1^/I4#;.\Z9H"33=/25LZ^D!0L
MLUK93.=I6!S%2'M M1MPIXA3*-X-MGR#H!8^"0D9:K$=K,]!32;RK;!6YE(2
M&R3)XQNYX&?KAX%&[GN4(LQD2I'F8+IRTQFN8G1D 1%DVKRF+[LA+P"?DU!S
MZ'!!\Y=<K4]W%98H.:P!;P]1;FNW/GCPA[/GQ8% O\NV)(2U*QAU&"LS!.E8
MC/WR/5C+VI9I/HB@ F?]ATK]@L8$:5*K97^ UJB<O"29^@E^1[9KG2#)#"4&
MPDYRLI)#!@H B9G#SF:3PZ6/!#@XF[O2,@_5Y7?]K.*E3K$[6[N K*L2K];)
MWM5&2(1SM"S??89BO&.&W+:B5Q<Y-T0=Y.8D(F6UA]%N)0I"F#12*]3VFN.;
M;4_6C"G+B=6/;)N_W0K&$$KR,%T@ <'CK&"%_V'[D[L]9@3:6I9?(K?P,>FR
M #I/X TM?K71/4RZ8SFVON;P$1<>YS!1+TT@NXHP@M/"^KX$K>(7"G,-7"YA
MN1$@O QEBE4WW"EOU^K[9)Y(7 LHAHKXR!E)R<76>_,C;7T4QC-*JJKDG]X!
M[YSH?^HV.F%DT-A7,IO*3SF$ADMC"N:=?')B=K7OP4@DWV+9X.T_"B_@Q1PD
M$&.3LR=(NF'KO5C[IOFK(#%W]Q-E/%8)PK0.>6W+QC+=F<)&*Y]>@VM@8F"L
MF>61,S/*KHM 9,R8R,"!O0CWAE.$%L/'1.NXRF(9 ]<YSUK0FFJ3;OV!9!8?
M(RF9C<_8W3HFQQO% 48F/O0K2&T=_32HNJYP?_A.!=0?NN2$8H?S'@76W,"<
M I=(?'F_0ZS7&VZ.P$I2X3ZPW&O?=S7=EH OB_?01B*15#\!VUG Y*KP<[^4
M&\%CS*LO/DWQ_;6)684#H(G"_;TG(E;+(VA/M676^'$^7TGALM$J(6'Y'.:0
M_8 O=YK]PPB[#YEHFLR(UY*^DLU8PCKR92>AW9&J39TC#EOWTC I@[!LLC&S
MUT$-OKNX-HP6@K8VC+86 -!]33GSO7N_($ROV=26EDC^(-B9;H7+M#=LM@)Q
M1T*C=^,P&=C6M%K,6'[;!,NTJ&@"T%$6)==9^IZ^U-@4DY? )B!9B7/J& ]4
M\=I-]%;T<N1E\H]E-';EJ;7-W'>+M(X=.!9<P,*V>B;S.ZAK)U+E!W<@4.C/
M(1@;K_=$KAIMBF3")GTE^C)763@)PHC6XB+'*%PPTY]M'KA+:V=)+ESJ\1\.
MHZG:(-'#AR@W-5D-?MTGP @N$FRJ3\]LKT<)TF*NS97?$G(^:IT#\8YR#K"=
MZ;6P[\#5>.^"4]S/"B-.>X9/*\O12EM%*S=!33Y@/$4\NBL17L_II,B-/0E6
MUY4+O=E7+<DAYX^;)Z8@)^P$)?KODOL^D18<=YO'Y9]NT V^V%CZ-W9'[+\O
MG?0T$'G'\9D^'<UW5-<S9_0Z9?6B:0NB =EA#^,X[X-'L&N.J[Z\&5^E3Q8:
M?QN](N7I196IO#V&N+&^1VVVLH?W,=@T;E+#$HDD.B1YSQ\%/%&><_X:7:SO
M/#HM8GDW]Q P9TFJ1+9>+2+IW.XBE-C(EA*;7YQ?57DP2[?@XZ@W'.J5VGA6
M_U/+FOE[^U"#((6UD1MTP<]L@+XQK^!C@!*^"=;\NTN3]GC'B0[P$Q<WEPV5
M7E%\EE<%Y04P,I:(H\Y.R"NX=5OCNN!'@BH@3<$$Q*XE_0INM?S7DB5S<5X^
MO8 R^SKT3$V!<JWL2PKAN"T-"7/^)W/URZ]_IBTOL9#T/1&.Q%\I(V<4[()W
M2--9Y_6%7;7P:BWWA??/JCI4B0^Z52PO -Q.G<LG]^KVWM?SC+=$@^/\5FC0
MR]-M#;S2S^4Z2>@K;O$ET;C(%%H&#INZZ3G1IXQ(>:V.&'UY=L"#YMRDP+&L
M<8AH%M%?Z3'^]LZXUYN6(^#FNFOF9@0'@E3R%#[Z.YLFB" _=%1OSXX^",<B
M7;KI;HI?H;C@O^?$UFU^^VD^&"OG,C>.4"/$L<,7^/F==7E^G/RN'-T1.MN6
MT6P/ ;YY_02%Y-=I1WBE%5^B&?OYL :E#8V[W (M\^@??]]$*7=A;"80FT->
M&JG!A;;)]1)IRFU7@)FAV'RI3-G_ ]+O4.0E(B1VLML7;DQ)F1:VPS*V]Z6(
MLP;7'F$VJAK)$GXWO__36(N%K[VY#:$@L)EMA]YF051PN?Y0:+*(07UGXAY,
M93+2SW4*\C!4'K 4A5_PD"04,&_%E-RAAY'BHM.@H+8L]!0QK-^ZG_5^_;M(
M\L:2%FHS-!"_C9]CB:M.\=)-Z&MB8T_.<MJA4^$<?H"E/XU%PH]A?_#)U[GK
ML'-M1B$]8O"0%O]>8+'X2H5F;]5EH,C[T4(H,\XV^DN\UFYUR?7'HC<J81>[
MSY]K,P^;GXD3/%6L8%ILZ<Q:WVBZC+1+".==U)_3ZQS!-&HE]XK)J0_ZQ6Z+
MQ/18-MGGXCF6NX[,ZJ&W+,:64$;RCA#E^6)J-C6$<W:75+(/[@CLZ-TTS9F_
M #!4M>/BX9O>ZY(U?7>K7%-@MA!(LJ4/XPF<'^.'836K@_&0(O?)Z[_PH"B:
M_M+VBMPGG-(('-K!(4(W'G%M ')>' 18CC$@8^@,9 U4%2Y8.*K&?P*S-1S!
MA. TX *\O*ELO?=4)'<5OM&QS.!\GJ&BDN,=_IP'PAOY-4T076.EHY_ 2T;D
M3>O/K-6O,-R$RWK 8A\:)N]$LF<JK(3#5JYHYE@5B]K9G*6PTPQG*VROE)HH
MS0FL&76^/TU>-VF*&GI_5,:]#L+(M\6U7:%D_44 8]6P.@;;,6$)Q+5H9%<9
MN9:@,)*[*>V(>>#2R]+0_63:R67R$:W!M)^]IBU&S[@BX\L8D<QPU#$J^#;T
M!;!"HY]M\P+X)D1@5DUN:S7 SY!%Z,VG63/G?J@#81=9:7/: =/YYF-.J"SS
MFY,+V!N\XAXIGEPL:O6T#.47V*77IK=/=QA%)H<Q+]:?/CIV@';@-!2M?25L
MLD4C!I54ZZ)[4_45)_]X_YM.'E1W=7*MF.P]6;%\-.JB?9-;L/>;"F7 >1J7
M:X]_M)Z9AX)"^ )^)9&^"5Y&.J,.%@7&^-0\9N7]W?IS#SK6WVM ,Q*>F2@K
M<5YCTJ60:V#[^95GY;-@I (AH:89G$C=T)FN[V@^STBVF?K+1XL_P4(MVA]W
M8%Q( 4'T&A#.7$D*(06 =8D6EVU[F,[.-6L_9>(3:W Q6E]>2\=GL MMM4;*
M3"#3=C?3)*);T+;/7U:.%K%@0S?T+84?P9"L))A)X0U]V@:XMKYQ$1@!=AMX
M:RI_ H>F$.!2TQ#&)6*@D_^6F=A:AX@^79^^3+! Z9-^Y1Q&8><AB;:5(-?0
M 9]7](S!!&'O8N((1]6:UZ*C* ,CW<P8W?>J;>CHM?(K]H'T^A)/;ZI>;[*6
M%!O+*(EP#2P"Q[EX9'<39![/R9L-)5CZD19N)6#2S;8V1DR<9O<NSH1(\&/W
M@TPS@]P57]L]B*D&9I S2I^^V9=?@ RA):(B >3\K)1)G3(;?;G!SI9"V/S)
M'!4H?DR#VI5R[#F'L&P:1)*.L,=&%ZT/T8_-'_[-#H >N%/PY7,C=([(U+$=
ME,"(PE7N9A89*@6M"=;4IM QY&3W,+5BN+*\E/<;P<,,7GER_GRU2DR+M /1
M4.\.9B(P(0JUNO-ER#-=&V *'7;WF-2W/-TLH0!$,[@^'8L.;1* :@E%28$Q
MW1F:Z=>NZ.H3%-[\:;3C/C=P=2<VZ1_C)E/'7?N'=\L%&(IM7:MYTI6O/;T9
MK%OF4V RY\D0O,KB19^@W[HTB@?DV>F=RTO"2 $WDG<93"*U9\M[MC0;9E)%
MYQ4C9$B?"W@8\N0G%#S<'-Y_2900ZQ.QB";<4A$R-$"0RLP@7#@M8NIQJ#>/
M)=P=FMX+^'M>2>NZ?P%(UYQE/^N&SXD2I.RVM<N'D,SXF>H(!>V2_@@R_OE9
M115+]5-0SRF<VOFL\<?FZM_99DX1.A"PHWLK+$.M P4AIE?;0*0.OQ><A-E[
MX+3YAY/)T*4P;]6R92/]0;?(TMN]*,)U))5H:TG.80M;HCB%*0O#-3'*J20M
MYIIQY'B6A61'&4VN+5LPJ*^VU2;(:\OE#LN%.-4TCV%=.QN=>-SD*OWV%\FX
M3HRF,V+1%M)'_.?/00>;'^^^-G3<?3W4]-N\/-[WSQP*^258_KWZ[1CL")+I
M"X!$4X3[:/?:\TB2+=^XOK^^^OER<9OM=#Y\#XK;Z6+\*_FD$:;;(.>*V]<F
M+.R$-!?ID_R<WU*U6X3>/:':V[<!)8-#><4]?[@9HG!0A[[<$,=',BN=4#+K
M&%0]Z1BRH9EW+<E[R8S1LE..=&!#B@^.612LQTBTQ>+M,2U')4$?UM5; 0Z#
M1!2BJD=3.-EM>8V;= W-O0=:X=1X1R-&P)#<7?4>^LJEMY1$*1=1.!"N-$J#
MVZ#XVK]GG+]H>?;?:7EU?<NEP;9GXNH(KIV @.%;+F<O3QWHZSZUD]$<S=AS
MC;5A.NP1%A&[79-U>@W\*U$M@1B[3A&\_ACOGE)'.@6.&AF2N3Q$N(+P8TH"
MN"]XTL$<'?IXL=)[9LVE'T@_94+FM>6R\X6\/(X>RGT^E^KAO0#JM2[,E3E/
MYV>T/HBRDS,+1Y+<!F[8I1(QQA;H<->ENN<F!=2)HPSRLA=.*3:W>N'T4]WS
M2N[OOC>"U(R7^9@@.9(3QV_Y'!N_#[%;R4^1ZF^[G<XW4^)'%-)/M\YQKD"A
M/+&:K=:G@Y\O\,X'>'K.N93+!2!OYYDF'Q,_&LT6.-=>7IE5ZIU96@GZ>?7/
M4$%DR4+PGXUE*_>%E1T']FS#8?A:45R%@(QP*-.EOW@JN(AR4-"BLQ7HH%"8
M+9]_H,2ZEKNO_Y''I'_ .WB>N3EX 60JWP3\$< U'S<7%8=O=7*_5TIMO@OO
M:L3RMZ.\GQ.%EOB>JOU<^,_BX9^+?Q1+): WR%Q\6)N@^H=RSP /QZF+RN6G
M^7:QMF;KGSIGSR?KV>O_"I2).GI@#^;<QJ),=S96=CP'M>M<S+<W_K,7FE7T
MN/(_9?!4"QO9WZRLKS1[5JZ7O[?[IR\HQ31=*^IA\F?,A9Y'_^6?%VT-GZ(B
M:D)#NN^T/27I4$<Q"Z@O,7WM_=J^_[\8-NMK<1_."YW>BY[_#\<^3RP-C<BF
M2!/G5LD\W4>/8^/R1@B^\\@.BS65+TC@865Y:&-A\LV/0FTX$KBC=A\[XO,H
M.A>"&<26^E40RYN#)AW_>8>*A[)E_9_:=?47]I;6:PNC4ZV5R=EN?\$3?\&\
MO^%R2^MUG=&IMO\"I_T%VVV;S:6=%:5>QN!3IAIU0/T;)SP957RY<ZQ:BX9N
M=7F6GJ,.TJFF#6;-[UG2' )DW)1CCZIL:Y\()OC$\O['4QSB"=+FBW .!&[9
MA>"HS6(9)Y(7VFI4K@S6Q?IU^96O""9F_63<W%\ . ;K_/]1LOD?!8__5?"?
M9_#^1X%:Q"=_SY_UJ\51BQDV,:Z\T$5^Y;YW84-/P-,JQ_0=EO2B7U$'QUVT
MK6U.$?^,(/OO@N?_.N,/04!$[LB-"TZN7\",L(L\3U6SN$I\8E!VQ>^B[!Z.
MVNUIZ7>B>O>P>]>\7[_X\ZZYVLUHW&_U!M3VP_[&V 1Z-G0W56O\[YB1^/36
MF1F)/I=]!4F/]+.QG,;EU,AII?_5+\9RT@%9/"\2!_3=6*S"MVERA-\477;#
M;A=$+I@Y_"D\\G,/#A'J7P"%\*.V@H-%4_H/KVC'[8<JUW;#BU7<?WQ3/V2^
MRPP8.Y\R\GT%5%M_@QHDA]FU^8N@N+#0I\=8=?EMFYZMD(H<Y<H+H"V\^J'U
M!1"+=KU\^O"XNMA:;?4&?%>Y[LM[5UWC\\/\\7"I>H3!G9V8O"M+2,Y1F'D#
M+1-<I1+"5PF$^07=%3/^VXK%SJE? ,=2-8<\7\9#5:IF^V+QH-_F2[NZ.C"K
MRG9C! :KNKX^EC;:H1UM!=3F&9CKSTF@BCMVK0B.N_*CQZINR@GIF]^H&DFI
M329%WPM GQI^$[/YP=CBRM4PG]47 +7(ZS'KZN];6=5?JY]93C6C@-5G>9@"
M&=:G%=ADE%%QVUK^W=F/I9B%U%!LV[5P!PJQ6<C7JL IG!\Z @$^0];%9Y=/
MOFD_S(>?K"*/0C)<W@0I#*@N^64?-'N<+?8QPFAY_.;AKT!:WB\ U\-GEK,[
M3%=9E^GMO<Z0Q7HJT?A@Z@?]"-A*J$K G6GXLWO*58[8K_K!@.NBA'6L'P@O
M@(/X\\UG(Z&49;V :\N4(G!(P$U#P,2K8> ,\M8'^S/=/=-25TRO:IO;J,:F
M,"IBUU42=#\_38"SL]O"&U5#^^^Q?>QYLL;R4D.]HCD9SM=B*5/&FSW/T :Y
M[@0C)+GY+,&'$^O0I"J_?1R8^N@?54)=]RLRK.!^RQS366FX"F?C\AAW+PS5
M3#%GJF?2]\BDF\<$<^)LV:JZC^>\MXW.*O"[XMM9*U^2>#[PW+6^@8AJ3[-*
MD,L/#VU&L6:/SWB<&-6=/3N] +Z(^E ,DLV&1K\ )C 7'!.I'A]?&QUTIEZ+
M^=M)]11N=_-Y/25)4I(2"2SV)D[@F1='.]]:GTXY)3PN7'2F_7+-0-%M1%H$
M*9O+(PW")!;'8G5%,9<-NDT+#.H^^_-<#5$"AS'RY7[)G;X 9N(8OV01S\[<
M.*M4;93U!G#+P66+V3942P<*G3XHS#X-8"E"XA^6LK&61'TY;UJ)F6DA=>->
M,+HL<0'SZ$CU#3R=_K5S"11IUG4"8;01 44\ZMLI*ZMB#Y5[\S@O ,^XOMI0
MN<SI5"A8@CYG"FH9YT^;'X-)';*"97.776L<Y\+.BUXE['9TGFM=L^[B 2P7
M/)&D]6CZUO4^\]KGU-CO V4%G2*V-6.ELUO?:5[N9/3E3<M'TR$>=0. 9A&1
M:%H=TOP[B5Z.\5#\R]/3<G>(9)G?3LEYL?K]AU@95K4QOB8*!JT%<XDGP\X,
M)G07MAF!LUQR6HXE8A?V3H?^NSZ2^Q+:,+8":+-Q^)T#].D9?+JV6$^IQ-!R
M.H<H0'XG-N%XNEP=-T65R)MV]KPA]Z<.&@56U^*HBB&-$02HQ6$5S<:Z8[1<
M%CZR.=PJT;F_Z:P\:=?)W'D1(R4#?4@MI(,?_23BWLXF2^0I+7 J<(BUMO2J
MZ>Y</=/E!:"J[-,0=//:["M]CN2#LO'I0\-N4QJ9C6EK4EU,Y>3X*1=ESWPU
M!.EO?NV]+;4W81UCO7=V3?6'50[[(-F6%. ZNZ)]0?SPV3KG$O^0=049#CA!
MY<&=I!?G696XO )JBIZ@BD+*V_"!5(OG+W?C<OE<>L&M[OG_Z8$>E!5;_E8-
MP3&X3SRF@5/'IY-N:?'U':_NQ3W-3[;EW9GE5O;;78Y.2C:15#*RJCH9@XJH
M&QPVQ>./KL72UA?KC:F1$74T.#*\_+^J%:GQ?'P!E(J6?9C$GRB?I"!$>I:A
M"^*S72[ Y6T]':+$C\E-EK/'K**0.^7Q2J:#U8I?T!WV1?H=XMXOC8X2!(H=
M>9A"G2_?Q-=ZRB^O-AQ],J>9LM#DU\\]P&^Z:BX.QQ1Z[_<">&NOWM?AR(86
M:BM9UJKMJ2]BQD(Y;FM=FD.^:S4^#%M0]H0A]%G+E=JY#FH[&_OYZ$N5$ O5
M@CNBVQ'QE-X?]I:@BUQL==H7:XPK@"DP\9H))=/,OJE5B_"PP-#P]HO;8^[\
MWZQ."E)($;TFP.+I4C6>E2OYM02S#DL]?_[I\?,?2>0:J62AZ!4VO'>9K)!_
MP'&EWF+#R5 ^U=V,/(RC")' 9/Q1X6<5. ]87V<6P:U\.,:&.ZH_O9=DZ,>;
M^&7--]7YC_%'@UY/'C3&^%%>%2(?OC_9,9!)9D-=+:#^V2^ )9X3&$U57/D=
MGZE%#?+AI7,_SSNJOYDB1F$^XW'I?>FFYGB"]Y*8[O1O#TZMFJ[A('#I@SLO
M8)E5]HFWF.200Q X)0 7>&_*T8<73RL?4@!)LY_D7@!]>Z)_Q%%AU8/5$4CC
M<Z&8"G=/>$Z@-* #O3/MP=1)<23:DY ">&W TJ*CK.<^3>?EQ^\HIXNJ!\UI
MS=;DJ:LU+4"<7EK6@ J=T[1$9R0GNZ+L#E&'D7M=\8Y<$C='"I /*_';5>N(
M3"<XO]&?"_>X!4D[6Y@O#;TU;VQ+>A(DOYL9W524'<([ZB960QI_BGK,\"!$
M;Y$9TB1/S+Z=&[^Y3G0/3W\5 UL-Q12EI&*L:OPYM$< ?3<.H,#V:3,,4EU7
M8KYJ$75Z;?S)J+I$ SI*$-;YA=PKVL-EQLMCMKTI&NBB["?NT[HS%1]+%-<"
M=W9M_(>O'&QT3OSV7*<_=3CA_X<*1$SC/GRSZVDB$3L)QW#\4%^'&5!6E<OT
M84+],]4'I&7UM5"Q%1G5N]SWUIOJ[0V_M6RN[&P0V\8C=J,3!WU04,5ZY-;-
M[I_(5CR]4J>J(MY]DYWV0'#I[U'=)48SU%QS+WY&D22L]8.JK)$R=OFH4D[W
M9Y&9W^?_EV7,"(W'\8TAFO.D$!VN4!C+[U"4KT,$_=M'<Q>AL71(O_@K#E]D
M1/>K>H$MEHPA#X,#X;)#SG5=0<A%Z_A[[4GSMBHWBGFWU(OR_P2>_/_@^G\/
MXC]XD DKY BE,@T1:LXKBPX6P37LB.A<N:TO_)O'G(/GNXOHBA!UP&X1EXO!
M'F(E6K' \N7$?[LNCW]B1_\-V)0ST-#2E;6-N$@\&$G$2/'[-I!0M.Q]_W]&
M0_\D* #&+@KXO)RF6>J1!U@2S7\\%%+'*S>(61PZ*MG92":W'WJ?O-L^>K6^
M[W5QG;>8!8\I]*7,\>UJP\(T-B'85TL$],[TLZ"4P=A#U('QFB[7\T[KYY\$
MXU];JBR?!MQ>7[!\"7#Y%\%R7^45079/U\I1A[KS5,>W..XM>#,4> ;K]@P#
MZ4?VJ^Q5%"T$$YZ=3VZ&U0$&B_:;B[PK/Z'_%H'.D*)L8>IEM@B@5 VC@>MW
M" Q7U'@S$M+O<N3(\QA'D<O.76^%%SC@4_<_V-<_ .,RF4)8O0RL RN#CUJM
M.LP14SMZ&O:N&DG37P#KO?]K;?XG<%"AT!0?.Z19@&O\F-B,HZW."[6;U(IE
MEI@<$>OWT2^_#CE%?338Y'OL)84B301@T?LT\9Y@I3TP5(]-37SEJ[_^R:58
M-4&GQ.<#B':O!?EF3X-\LRZ:?HJN@R]\VU;7?GHTMUZ<.OUVD8W#]LK.J??_
M QCL4BP1-Q3+'7E>V3AU]*^/H:-<WD'W_M#)K' CF-PY] @R*D\_++,NK J6
M*[??D0K9?HZ*]U$D^61IL>2-_5G:U]=B?(\K4V//J*_3GYGN OH4C 9$?L^'
M W!T): ,/\__7U3R @C^U)MBJ=OGC'FZ2&[]7*?\JONVA90K1^%M"!/0=<6@
M92=(84X@:OJU+!)S.<.WHN&]MENIE-WYZS5E<EJ%;'I:*2"3K1X+08SKD$+W
MEA]LPJ]VIF7MP]?YUH&3^?)NC)0H2G$46([$B%1Z)L@GP+Y']=_/#$WHC/*B
M'+#SG,:[%,2\3Y0?<LR-BNB$EIAPX3G51U3E]QT'02%BC,(%@Q1ZQV-6Y16O
M"\C-15R,:JH')FZ<QFFJU;R9EH0X7@!*KY@_[.Z] /[:&74TL85'-&3Z^A5Z
M,1)2Q'9WM/]7VKA19V<O"#D65O/P?]GX/ML7BP;D=HI5IUF]JX8^N4@X= _D
M<HT(G>7^<X*5<_Q,Y^0D685OO"/)O)2C"DXR9?WW]*:%+IR >EDDG&[S4%>]
M.OVJ:K>Z118C953'980BO3;%(>2/[BG?Y&C;5R<$< ,Q0X %]@G$F(S$)Z4\
MT<?-G?- *-,D+[_: P)(R<D9G/\E@BN 7Y%S,,GZZ+":PNR$#&U2!V+?3*N7
MQN+;V-A'YU3__@N\_@J&([SRJ# *^QE_!UHD>LIRZ.[NSJ3(!-9'US$-!XKD
MI@5P\<!)=)6/764&"\##(]TRPKXE#'1!PQ.J[,LTW;";T_&*3WW,A;=Q8AQ'
MHC&]OU@2GFXWTBW.M25157&#Q9<VS?W6?7]Y4*SDEUB4&%T%#M+&$GXX\\F:
MU*MSQ!0+UHLU BW/!)\R?8X!GWI(#S2-G0_$/;=R7^/*>3R%&GFM*ZI/X75_
M%96T_3:Z:OO-3&TK5%EV&<QR2%DUFO*63U3@C,KQ589#5'.:E#^;8>JD+S/1
M?$%6I52%=7TX)6\CZ8_,=Z*D]7TJ;ED4 8S;%M5F64BU[PRL#,6K("GBDUZ)
M<URN0D?&<N]Q^5 X6B22 F3SEWSMK&;(AX:LLN>!_@3G)4Y[R7L8,46#:[\:
MO=]450E4Z^GN'%Q"(_J4W^3Q#J_AP.8GJ,X)NRF]:ML['E.,3XT>*:@HH]+)
M6N/'"2JSI3!7I[/9+[) -XO]A#P>RA=3R.M>#Y*E9NLMU:228__8+$?N?ALQ
M0 )'WUL')LB=+K<)10;;)_6]IDPX=*BHWR5M>L=+-!U?#9<CCQ4B:_E*1'!P
MAM&@(#"KDN[DK++NQ$4  TL78:444=32(QCU$#C\P13#)Z0O2CJR"K-'B'2/
MEO/X^+*\O(5.@8#P_2KW:GT>@P^CVAS/(0%"XR.($Z-=Q*>@E:G9^2U76AZR
MS^L#=S>N]08<WHJ?ULS?/6_,I656;:[KFP%:)B@3_:[K$Z0A[^EP[9\IWP M
M&#Y"H>U(@#Y_UAON!GM6JW.>%=!XVG(3N#J?S+TI-;K#[7O8?&5AMK0//?--
M/-[664.TN<($Z-UFP6-ZR [ESHGE.KN.N%@W- JGX)=Q>$(GZ'<H"4&8VTUD
M-0?-B$7*+*R8(T$".7A^P*(9O%WDG^!1ZRC"026N;#CGPMT/:;N==^DM3/-/
MT%,0S2I=P%YE=R%3AFDX_C;)/=@$<5S8.; 4=_<.YJ4/* >*:L>7%K<)XZ-B
MZ9-^VG*9*6SG?O?#P3JY?S'-XHU%PFD&T,+6DX+F4/<5M[+Y&!Y;.XFE/GTW
MKCV9?!HE)+<>8V9YM$[8"-Q\VK1(ZRRC7$]<.W/$WG$UJT07=L]Q=DS05YPJ
MJUGP:0@B-@^R&BC 47#"Z=C)D&V]U-J] ^NZCK/-C XLB%X[ W&]?IH!M;:_
M.61<%J=(.%P/X..R7BKTI! 1H:K4] /6_9C7OVSKCCR#^'$Y(5V;<,N\'XS\
MA/7ZZQKJ3K[!$KX]5!$@/P2@[ANI) SRCPRFKH]@/A7ZD]N+,=B_4;JQ%WO]
MBZF#4241X$JH3 =.,@\>JY25'R2I,X=E^N&'9T&D,IRS521*!RNGSCLSMA0Z
MVXY7?N?C16Z2@9X%&^'0F^&#1@VN"LE*(&(>@@\6+R#E(_R>J4Y;BHR_]T1^
MQ4MC E]6%72/7DQCX;((2<:>82TIU@C3UQ]"W$'N08JQ86MD<@W-C$SDC$^=
M_$KH590HS?.)QW9 >T'6M/MJ*K.\,&,&S$W?4/A./IO=E3COZJ8%@$PP>Z1G
M.7DF9&1E$0!UCU5LU4W,ZZKSK_IV3B@KVQXEXXWFU3H-.G9&H"3^H79>A%.4
M:GZ/0^<B&X4H5 ]Y@[43.UR7W,R-?S1&B\DZO1LN#]<M8(F@A%U65@NK'[D%
M(%<009"IR4[*3Y S)R]U+?R<HYN;KZ[1,OK# *.H=W:PPDPDJ  _1IU.K8J0
MIC!,1<G9U]UFG,F9.Q]W\M[#)$M 2%<FC]77IG)Z Z]>NV_T?&=N5W\Y9TI:
MEU7_)&A_EW@Y<DM[Y6/\+X@0FB>>SK<A=/9M72?&3]HZ5I2<77%X.9-QC4(5
MZ9UQLM^FPXACJ:TU M=A!C/KZNEH!<$['T@LN4;H) QCY?(/;&$!M;)U??C?
MT=-@MQ3*B)&9X=QCR;F#=?F%E[YRFMOX*!U$\+#C5=Z>FO5GRBSG2%HPSC)F
M?6@:^$"H^./5EB]!:1VM"&8N#2"NHA4>4C'?>-N,.T;W"EC&OL#4/5,DARPD
M-^-BE%U6T"!--EY-.,9V:]80J1).Z2*J_4<FWR"OFAZ>1C]0TC6B/>". 5;D
M^EG?N;J6SHNLY7<,WM4UZR8=Z\VY_W*7"CN5+MFR2K:.I&$;F8U1K<?>WHWD
M?B;=<J^I6SU5'[6UA3<CAL+R%PIUPQ5AN@SF!S&T-;8F[]ML>B0-<JP$M]?S
MA5H+><!/T:TN7\<,-.[])*)DWC^$X%!TU*9:Q.._4G:%ISNH9FL<0)_R_[!P
MS"6/BF@13TK=UZCO$^KJ5:,$1,PO,#12 O,T(:Z^<5#GH@2BY@C_"DB5,LJY
M_!986*",9,/ARCD?K>8@O?"3IC\MC->N/R:86.LGS&XP66J32GP5)&+VZ!Q.
M5.NB@&OC_$>[8\2<[.6]2S&YT,G&\4YC6Z; .7VTRXC@?#"OQ1P1*;@PDX1<
M?CI94"B.GQ*F)=JY5-ZB'V<$6YN8G,02K#]IIU3L*ZSYQC.=J9-< 2:RI^>4
MDFI[KUIGL%-B:XA' 0PTD+=PIS$;,1+RRC@F5P:E^Z]/Y(6&UM*QKY-;D]8F
MV#%$RWF#X8#(51*2[JTQ'A]9,K!D*%)*V>%[#3.R7I.Q1QA%Z S-3&#K7Q3&
MN#@&FLMKCP=%.I8JH"63R+ZBS=@WXB?7G@^D?AJBCM>M&QRQ;9(@X[*)0>,+
MS &C>>=D[$#&M&:411+KIG:N\@W"27DR/&='TS_RB\A;J@4KORIMR/4SV<GG
M/ J:WTI:DTB:7% PT:?2-RUIQJP ";'-D-0VLR5Q\JT%&K]:[H,+-1AG2#C8
M$<^)5"J=)L1Q(1?F$,BJ\Z.RF+_SOISW2)VT@+EZ3AR*1?75VUXVDRJ)B3=S
M@T*U;UQC!CJ:Z^J!<O5- AM^[SCB0\QM.K#A*H%MF1H_V-7;(1AU4KLU3:/Q
M XN!>&%Q_>[]Y8X+/^&P;N<;R#E%)$YW-;,TLFP]@U[3)_1\2Z7VVD\Q?#>8
MPKQLVDW#A?&^=G75EEV6MR9^/$W5( J%G*ER+&^SXOJUJF7*JN-),'L5P)IW
M3.WZ8]EG8?T0\,*"84X[6LYJBA"L@U85K];1U>BT$[?C?8*D 4*(56EYI'AQ
M[U^5[V>=&%^FY=N3F14/<Y*9I5M2[G.5:7%[#_TFA=[#=\RU'VU==]'QU-/V
M%'EIAE#XU$[8%@OD>NLF"5!KS2G#WRHB4WH!GW@L>J78Y9=33K@L*(-/')%"
M)5<^:T"KY^1RKDY$&YMN5?&%*<+&GG_JS(*78\A=Z5M&#3J/,HKE+-+)'5QB
M7.TF75MVT4Z^J>K(&5/VS=F!]AI3=-S9S>J#DCJB<^7G\B3'D7&\PU34KO@Y
MJRK1*03NZBR]O#><MV4EZOQ^O#H7P8+I-SDL:PJQ  FY'U;K?(#P>NX2T$\&
MY\L6@5SZM+N'A9#-@SO1^1I78HIFGZNGJ^ME/:S#N#64Z3#:^A ZRB[#XYN:
MI4>7T:8%U&A)V/DZ>;UN*D5)/R.Q9/SPF(X3'@-3#K.=;*%+ <=R?5V+]Q_5
M[X"#C?J(*(;BT4\Y<PF'?G3#G_!31@D0@?%9^@*1KO''AEEO9T_J($:#LP6<
M0Y3U*Q);RGH3=:#^;D/N*F1!];#GJK4TG:OIMP7QSG59P@[UE@]27'?%!/Y\
M*_+;+X!R%3BX%X#B6WME.UV-$W@+ZS 9DB8WV_=66>]Q0HEP$6AH5<)XBI70
M=+@=4L[ET%5:!+>[[^T8!@8Z6MF:%,1.298SIV;,T[H2P9SAU&=MM3EQ;>&.
MR;<::SAF,S^:HNUVH?RZ !=Q$X!0($6@)^HC:_*99O</%@WT(@ ]%#*_?#*'
MA"N R4O0$:'_O3)#QA6]X"[?(2)[^V[I9$#)U[;6J%H(Z^#X!2"G=U^^0/"K
MM2,DKBQ_9MP9\&#C D_Y1W/=]/KK'_'J&F=P,@]Y<TB)/9@L&(4'X=2E'S+W
MZ>VE ARKVZ? PP&$N&,-MX9[P3ZS$8)YPEV=*4'!W8(7@!TUVL>5-KEZZ@PD
MG3B[W26[ Q[M%AF8!DFW@665W&4(KP<RML&VQS8=$J4U)<G9)'<VS2]OEOG:
MW]P&>4%VK8)D..%:&7G#K)PC=I+:.I EW<-6B6Y(4?Y>EM;0D%Q>Y^T3YB?;
MJ T%\-F/0'PBKN(T><L;[:MR)(PX_."* @NN^.Y@@6 !'! 7P439:6I?%E<.
MA0HBRI9 2.0Y0]2K;(&9NOAB06KK":2*6)H_B.0;$I)=:0MUP M@PM5P\IA]
M5&J75I20%!2K!H\W!,RS E?4O3W4G #&#\HQT@7F?P/DY2P@I3^)6<^_DT5:
MGY?^?=AOJ X6/AA?JON5#V2N$*'FGS(&5C*WLV3)O_?ZT;VKLL&H=WO%WJML
M+*VA#S)P3:ZC$.YH*O6,K6/U.$G@H J^[4TLS<&9 -OS,ZX.OE:4"97!)(NV
M8'*6W*G,#Y,8C1.V!YWZ'QNQE.Y0GP2+2T=MOWM].= Y\)71:)B0BY='I^:L
M<C<^XU=@2!2ZJ?NA8[UKG+ES(LH!*_ZDGQX)VOQBM$NBPA?J1NZ/*QG'&'QK
M52F#F20.=MVI=*X3/ YH*F:Q%.+F($S![0S2/:4$^N0D4R0FN5Y>)O<85R %
M' I#_'2LM0OW2=8QGKJ_I$X488R5:4F&L&5+(XB^<F*B@+](-.R3;W+"ALXG
M*<)P]/+&R4REY&P/I?14*CD(R ;>>7!7"<>JQ>B+83HUFGJ!L$XS]@M@MIH0
M &^1F',N9 (1_=*X]R!P)VQ"GU0YIXM-W>*-[&KYWFHEN-)UT&86D7NZUAZD
M#<I_ ;CJ$R.=#/,&4&1N,EQ<3WSN:&QWKJ]HH<F7?P%$BG,8#DYC)JT7!8,7
M!+:B)/JS0I2*2V4EM)WEQG[E;]6BEN5'6C$& ESHH-J5<T0(<H4?598>3E@B
M"L((8Z2&Z>/)"ZQX:#(X$;2"G3'DO!T?O($S%A *+HKR'$OVTH2VSZ)F!6D\
M:?Z4'P893*YM[]_!##F%_M)G62H..M.I+X1BYI*9E#AN?$;7[I 5N"0(&>$S
M5U:.AK]U>>CJN"PI2K=W3$R-^88\4I?<R,18Q.?G4@+S)ZW?$V33OO 4EVAW
M5S4P;:KH*V?N;"EE;7;4:*X+)2+/Y#G8E@;#[I%E)B)N%[I7DP"YKRNGZ,53
MO:;[XQU^3"(.&@POX[KSU"6.3F1I?#+P_FQ74%_A<+>\MZN2M393=#KLV03F
MF_)LT4G3@P9E)09PN# +>].E-$5.?.3"<TD@%/ATFWK/F]46&5(0"V%4ZV:\
M_SJ?37/WD?<$BV:$B%)H5-?MDW?E9:N"6^"! 1Y[C*@'G=C0U$C>MM%ZL1;"
M$"B3+@OR^5Z_2CEM^_R[=23(O$S82TWZ<G1S5V6W(KA@J[>=P .RY574_LI9
M9J="8L]P?;Y&-F<B:E_=U<5/LW_(L>YP*)  ^=.K J7<3-BT?7O/-=9<CAT%
MUK6KR+D8SEN!:%BYN+\:/R(?FY3<1D0JHGCI *4)RN([)!ZTH;/QY"W'4@XI
MR]*?DCS?F:OQN=0=?[:"C6ZJ%)5M>COC&KPID3>H!Q%23+1R.!FU%^&%9;'8
MW@YV@^?:7D..3KF<*);W"_ZJ+6^R\FYX(7&$;:*O6%'YWFP&(++@PS<9WU-Z
M0>1%I!Y?FKMB3WI/*1#2E[=!56?WV'%'$3T3@$->7=^X2#949S 8)M5 HN^C
M3ZS3G.Q$VVZ=F1?N(3ML*-]V 5<M<0W'XI439-&20*97R#G%D\F6+IQC$M&7
M>\B4/V*>M#31Q(1GA?I5WC.L]_AD5WGDLN%U^T6Z(+].8O_Q2AN/F?K,Z<F
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MU^AKEOH<FW*\]>_)/0"VX;J1&V+&CE^Z^#!TQ5H:_>$YJ17(/V,C:L^)HW;
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M\S2A"XJIR-IAE;E5'&!0M#!(6;?</ G-./P9X^@Q@'&O'R&9H$1GS-<IX:3
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MAG^5V+#9LTF))<%1*X)LIV[>E'J-W21M$MES)[7D]V(@O./IR1=KR! KU:*
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M6A:Z)=V[9L"L.EXY;W"81H@WQ@G3%Z% ?!7+:1::S5 14&Y02*E>2L,J6NZ
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M^0-P"N9I<+J6_V"\L"[Q'G^+0DWQBL![-UT&6^X3?-&[$/F()>V$3W2,! "
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M1B5?5FMZ)X?#Y1$$4^Y"9Y#E'#2?#>9]* [Z;G,Y$O3+2KI'M)[E5"1;;%7
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M  P@,  0# @! 0WVU_&')<  *"0L(LPJ1E=_]LA.RO]\[2;1T#'@W]^[(?D
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M/DRA(VU1 >A5!>"T]^:QNIO:-&#U='0^1NK9%)41I'5@;]!?_ ,2[+PY2J7
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M2Y$G[>VYRFR';43WA2X"<ID=?UWQHS;0F#,<<1P0GF7HZNR\]MRY42$*!GX
M***E#IZM:JZ18 79;C[CW]1A8!PF[GX I T#V^OF^H.5(=I"!_/8U^)TX&>&
M!WX_K06KPJQ2,SQDB2"VT69$F$[$FBN^KC'@JZ'%NTYUB/-J2KF 2;Z6S^L.
M1MMRW*EFL]>O=Q4).?04-.;?ON23UT*'NG?4?./\U(IZLF^W+C-FRN89J=5H
MH4)$7TR\K7-=44]KC6Y4Z:5L<69G.Y+<3OD!"&C@L4H8AQ%=[)Y8C=B,1D_J
M2YC_$MSFF3@BJ[/F)M(L3 ,>@4[W_(XVX^0C&'WF1>3AIX1X[O[3B2_D:,2
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M>QS:+7#'J><=(&G0Y75_NEC[/Y,J3B  G063S H'U?"?(P#(^( ?+%)NN\(
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M,]>6TPA;$Z'0Q@\CYO"R,F1;8U__<6/1=X @'/%QP#[/&A$>74W"!NPA:N
M$'>I5=ZU:Y*"<0H "U??JZ_KQKRC9=P)0@(#L@#(!-U40-@+6,@DG &JX02+
M4GITQCI(O2U^'ST;![(A\(\_F09GN!ZW*>Q:+&TS%A%)4FM)8>4!L#+39O9!
M=J,489 (J-23+<P\I>[QN\X'7\](0&.;A3^&VYP/'([*4TD:#QZ9M?<,?KM4
MO4ZI:IS_[D[:OHS]?KSM*,$0?H=+=%I&EN=<A=/7TC3_KX:O911X*64<OP^[
MM\ %KE,Z4BT>IY2H]O]N&XOP&T!;7HE6I(YJ^^^15'68U@FT;MVG,"/L9&BD
M3T:B;R;NWP7F!E9\%KWG;B(&SK_Z-JV/<S4/V OX.JE8.)6S<R?36&(4C>^H
MI6?))+*'_PFCE_M)+9T^\/\2M97O%LCY_Y*)U%;,.^"J%_4I?.7E6>7((@?G
M^L_PMK=TH3ZO)U3,5=, 8>'Y?IE9<49U4:J1Y;JM2@P*..1YUOEW <B2MQ]*
M: )VD!7^I>%(9K"-).98K(&6:?:[\^GV<#)7P.</<4;J);#%V,?;2 Z&[+&G
M$22#I4:#@L843Y#U"P#ZC2LL'J[L<.8*(/RM#HZ'WJO<T:63%712>WRNR@#
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M+X]$46LJBC1;9A@9I+TXY>V)N_;PAK *_C5C")\XM"B.6 GUS@P%%%U,[1I
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MA?X@!>8N_\YVRS3\JF^KY\QQ$#U;$<UNFC^]BI&U/^4:1W<8K\Y=)]%AQT0
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M!PJ9^@<'*1!A?9-L#K];"+(U5EQ7B3Y7Z]8+V+PL?"ZF.6:G@I=X%"=&21/
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M1?DLXU=HJA,SL[9CFM 3!""Z!KSHH 9YE%)#5 LVOS9>V5&96$(_99*55F$
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M4C+0GA4+,+87\6N-+?UDWHC=_NN[COB3]*?. !(0C6X3*B8LQ<D&C(R&B%0
MJ-!!GAC1!)33@H*BPE12M?$MDE@/CK9_44^1.6=_3X(CH B$>#_#AS*P!,T&
M'4P2M5AOAIJ:*E5;_RUBK90D: .(#0"A2@!USO6#PYK30#8#,%YN%K,EHUW*
MB+63$$P1VE8 . C;V!=ZA:]8R(2>=E3>>O]IHL=[LB.D =5]!V;@VSU)V5PW
M%T"('F26-\+X0>.!!$T%YYCQ(T$_8X*(AQKEU\-NF'>@8L3PS8'+[:B7]\&@
M.Q]93YFKMUO>X''B&C5:314IZ)0,1"P_*WZ^=W$P/?3!TXR$NLJI:1)_OE F
M9["_FB7*-5^.,Y])MF,M'L;'DY1I!9?%=<$EM!O#CFG3-'8C( / .  $0# N
MVT+1N,[Y;A%H60=4NA'('P'JP:'-9!QL<\\H?W5M!K'W4)&%M>G@T>+'.*?!
M S)Z-0.M81R7@:R86?M7KY<8.Z@/N:QU,VC?>URJ6E&]%"A9HPA@14*?Z9%H
M<K!^8JWGI,7J9N,PPI/)-,-P#$U49X;%,;Y&>@QZ:N).FD9%"2@73/L][K):
M?V!T.!)3T9?[Q86OV%\3LIB@19'D<60GN FA;X$<H(G]$DKI0!A#1L3=\/LH
MY,2G>2_/WGZOX,W>W"%OGT0X>RY!>H??<A)5B,L1DTC(RPEL/'_^D-1KVE39
M1HY<82W)-/**04T(O5^G *J RD@A9D,4J@N2N*)<KJ] ^7IN0.^ DB01  F/
MVL<HQ G\/ ?1NL0E&VZ5"Y;$P^'B/)-7VJH<-?,VP<F)H*T9A!1V5@ML93)N
M8;4OYH6BP6)_9K!@FN@+\"[KJ6Q<8U$5HT^+B.5_D'&+KB<_8N&PMZ(Y.6N]
M$KA].C8D^EKF>!@GD*D.R+:M4!Y-J/=9?C8$%0E^9 T?#9(DHL<7(,'"U Q
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M%J3TWU2A4=H]M8*U=/^4_CCE,9<L[=U#QC8?XZI%).AFZ!]\/Y@;\3;\"6L
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MU@L.%,!/G9B2P+P(<:(P3(!J8$Q"+=4O.7?H6#Q&(*MEK2E;-JXLD9P5%
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MBVFDK^_]IL>4^J^_.)#J6I7I(+4^KG+XR#*@O.$-S3H%A'@D4RV JQK(&D7
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MPTF2[NNR__ H+ET1:2.S5FT'S=*'660CKE06X]3R/YS4=L5XE%-0803*!A#
M*]_+5[ V_ :\]I/6^:?Q%0_!3M$@-@XK=P:<G@<3=;DCRZ CGS\JC48;_C\F
M0,4N*,$9Q;%9O%XN6<5,[:2@B6FN0JU*_C^[!;4^P0,&D@]]_O'F=S] &AL
M!$(@8 @:& V,!/Q[=Q80):>QN*ISXCD23GX=KEK@]"88"J/BD#!)ZN&2=/F&
MQ\T#=PVJ[YU1T2AHX#5R4_]KVQ80$"@&^ W0?DH$;F0<U"];Z:>Q7#)M'='I
MD.RFP3;VZ1/DKL&)YJJ0ZRYBZ6R9 DDGO$)GY"@R(O5/IE&BR3GMA("80$SC
MT;Z6IBCSE(+Y&CF0L=#8SJ.D0 D-W="39YPTXK+83;1;*YL$[YT&*549&HV^
M)Z*2A+Z%ZQ%>&'U?PF586*FWWS8*P9>G*E#$&"Y \%UM6N.V!E[;;Y7@8$-S
MSW&[-[K?4])\1$P>]%Q$R<R@<\981Q,F%.CCRWUAM;\#23#H+J$K<S'2K471
M:$3VXM:/S-NU_#2&]"2\XII_O!!#^NC$G48BD(W83?ID]7#",(,VDV&M7!AA
M02Z/:5F<KRR!FB(<[74! "KPUZY?"^).#7T]"<0!OD S0LQ,>MUZC-!?+'!.
M/G^[H$TT"<,VZE&E8XQ$;+N41%,>3(3H5G4B7B836NU+1BB$= %<!$]-H)$X
MH"2O-?-J%UA ]D/W:NC.DX0BG+,%#_@.3Y\"%UDQ<BKCX46:\W5&!U%4@?@I
MM"\,&M#QE%CX62,B^=!K%/LC"QC)@G)5C3LANJKT^">RRAX5U .?TYR^>WA@
MT29N. :AZ>C+2].I*!"A!$(Y4$U]^Q<("^FKH.41#G*;KU\N1 5S6#PI()!8
M 4A?!U4&]QZ$UF\R9FWSD4YE!U4F4FOJ>G)!@;+?*UZ7$WAB<IB@,6BBHD=0
M!3JVM#3<FC$K[4=5A:"Q.E3XC. _2"! $?B8(9J=7EML:0=H).]%Z ) *H.D
MO1YYL='8G[1HH[ZW2M&5GYD??UFKSRR.R#$V*VHX#?:95S66S3)UH:%=QH_P
MFMB"&1EC5!7CA5U7\YG>Z,?XTVKN8(==#*H:H&9;CK=4ENP2S+$NL 88XIMY
M)>2-$X>(/U]%XU[I_U[!Z91<';=8,Y]XC(=89=U7>CVOJ&:"Y&U2A(H:R3)N
MBNX<37V(D;.+%T$E]#9V-W8Z94I?L]:4\J!PU3@]+F4:^VOMV)"\5<2MCOEV
M,0_"MY+KV\Q;*M$%8J]#)6R*8\P.MY*(>/<P R%UA$Q;'SLY8P'U_T_X/R<$
M:-%*HPWU?L%.N&X@'RD8_G]S7_\]8: ]\V+N["'!B8CP55A4?6!&:U'A<VU?
M!@."70Q+7COH3916X2(.^-2<\(A\,X74+>""^J?N(=E3.@])X$A,N_Z>2'\^
M])T7H59L!S.M!G\)]XG1.7,46C\#!M-(2R\244%WC\1J]>"Z!X,F"\;J(%QF
M@@K>$09 ,QG4K[ZD,+G XY*B;Z*),0#1E,#6I#X'<08S5,Y(>_-=EE5@8CJ%
M^)+XVTJC9'69\CM_?\8)>Z%7UQ)JUEJ\7%OK!2W/*&3HL"#U7NDWY0/CRQ;7
M1JW^RC5![2"  F@"VE)GC$KX]-AJ@_V3(29 J7K%H*-ONA.#6(&4GJ"G'$_L
M[3\[3*%5[@U,60@>DYY>1D =J,=-,S;$+PG%(_',D(W?<'DG#4RI1=O?K@U,
M25 9E_-T#!I-1;)^-AIE3OQJKD8O'%&[)K(\TB*U0%MO/ZV'Z#54:6T^.$%(
M\;ZT75PI[*(36/\-:$N*?-E.G\6*I>-YSL\UM1O^!LGU7S+)'P,_I(6S"-^1
M=HQ)II'_>#+>**3\"_(W*(,H$*J8AAWN;WL*AO,_<*G7XOY*>[V^]VO2\NQ#
MY'=?&3,.LLZL&0$*@RE9(U%Z\M>W?7%"!C1PU"2$(@>X1;(1@E%$*D'B'.?4
MU$;X58RQ] WSYM1'YWLEX7M#K-"'^%'K]=$[-_8O_NK*O[3[\OVW+]YZ7G21
M8]P^2YG]F'I^8-CZHR3G1TVXQ,^A79ZS73^A?ZID>";U$?"DYC<@Z]#_D*.S
MC;"MQLQ:T4NSC?#[?R5QXK[E("F@3H%Y62/@:0"9P0%31JAF7+UH_[&^=/+S
MEE/LA=5)&%)Z Q=?WRT[/8T]'OSK1S)]V!X:>67)3RMD=>_/.USF_#G^DG3_
ME>2%9Z[G<'._B#BI-@"6"0O#<TBW_NR[)]0@_[)XV7W]/JYRW_L/Z,TC*&>W
M3;]4_S<@XVC",^W0(\?SEVF%X-I_+V?IT2Y%T7Y)\:W#T[6C)5URU%"Y>OPF
M)ZO<F>\[_>HOQY,K/*20IZ@W+"\$N$9ASARK#%HA08X8J/49""D6#B8@F8Q-
MA Y:4FAC"KX\D*HY P'P^_60\:XTS\R)!2VHR)P3E5[0:.4+,#* +B1Y1<11
MS8C:ZH2*")MX.&Z:N5T[/N_/^&1N)3%$U$6QV],)IJG[L(!CC**D;FF_(<PK
MDZFD6BBSYTQ&92$.SU'I2:GJH,$X$27:1$3M.MW+CES2NM)6U&8A]HQ6V1)Z
M.J(0?L;4OGH;>@Y?I 5QXW%VD9YNS@"!9_",HH)D24X:OGE*Z,HTK088U+(,
M'HX)J3(U1M[(R5=66(+V'*)E:.TVEX)9T)<%,PTH8XV2Z"?%%(R_3^[Z?G_Q
MSNK>"01@4F/9'M@H03[._/G>?0L !D63?A3)G.TXX%*9/,4HGDINRETF-'2?
MPX:Q,:X?V+TQ7GE#/*%\/P(R@S#@!8J\]%X,1:>2B,#X-(X>BB/:T3$Q;B+8
MDOYKYC=@<^DW8.&LX"_M@!_J:G7;FJFJ(6/+YC%!4\UK =%;1N!-8TTI8Z(B
M:6.XF*'DNBONU95<3!5 XNI[":U#5.\8,R@%A9,/F4OY.YR% #8V_6CCQB:"
M]@)JG4J=1H+G*@FXZ@@P1M"P 5/2',PP-D(:"+L*^@W>*4E()Q)4:N,[+%16
MGP64W//H("+KBM-P:!0C*.T_54GRB7OFT;"$%]?^M+SH_$D_V9+<VA#NOH4#
M9DB"@WL)2YW1#[W&4_CAT=M$3'6O]U\M?4U1T:Z-]4A;_EF5BY1E+Z:WO_5L
M>65@?PHG&(-?R;<@[?Y&K/;T8\P^O=^#MH$7#%#&I(D:P1&HHL9%U3MD=N^M
MNJA3Z\.6A/-I)Y.6BW)((:\,:$ +5"'HN<=$R5R*D>&[^ U8-OPA+/9]]6]%
M._@:"US%,$MF(0?=R:MTC3FD=HLW75V)_E$_*8'\.@V:>#-$%/(JR==456R3
MF "%YJ[H>B(L@RAQEN:!$9Z<,K8-QE7+0@'#@R+OF.2$D#Q2-W:;XC1=VI!]
M B4;NJ7U\(9%_X9[@U_)^RLC7U[0+3.L>KFKISME/<<UCT01J+&:L/L-6%PR
MNIUN3E[:$ Q;]J];[Q=KRKY^QM;_/C"TO?/.?'_Q5U_S+^[LG,N<]Z134!U&
M=2@EF!*]NW8Y23] )GA'2EZ(7)Z1IK<[G)"O9^NX3)S2&J:B9V2B*O(_EI%_
ML:"&'^S$='_4O)&[[-CP1QYD"PJ(0+.MY703X9<-$>!<:H.#Q9<0LQ^BXU)4
MVO/!+Z:CXY(HJ&!ED=G"F?OD7D$6M!3KSX=N6%N^9>^<O2MTX<C>4C/J9D)#
MHR;/"I7#I<G(S" U:BXZ-=H." _.@T*)NF&H20D@M4MASHB]-<,'A=^ <,O?
M@)==\=KWK5]+_"?7G!;1M%3]\]>X_ZR]VWS_G*R>^(;\=YYD7MJNX*=DA\4H
M[](:SLW?F#\7'-#<3LR_833., O^1NG;$OQ-9XZBUYEB6.89LR3=+MQK,(#*
M^^P%L5(*N<W-2UY+K[^:&?^+>JS*9)1]3GCPO[="[%XIR?!12GC0/W?@]M6R
MT.58&W\@'$WBD&#[RNS"H>MSB\7I<Q%7S%RES\M+MR;1MQG[2=[\AK:6JU'L
M:Z:Y<CNKKZO>>3!\]([SID]VOVE^O5CP<T]PY_^>XLH?=ZI/#)9R$_=SEP4N
MTN&0SYYR4&]Q54TPII A]9']<VU_DNT$A_3A[UD*HI^?/XLF"W;KDIE;UOWZ
MX?R'S@YI\<7SDIE)]\GPK2'8*GOB-5^:;[6?&($@\J%?_/O&AE77S;NZ8>X5
M0]I5X;CGSUYH)!P -]NBQ&GQB)%@:YI-GO;-PC)F^DZ4J.+N0_HBB--,H-^D
M"#FZV9#=]Q1$_9-9,<4L"X6)($MB>0896R\]N]/F.?N7\K.19O6"N3:501]R
M[Q?L,O9\EV#OU,08=19JYDH41I+EO=:71^(L.Y/E?9?EU'T6'7L"5- S,91(
M/6HLW._?TIT:C!]?\B@M=V9^WK.*5,\\L_\[F=4DF./O17>J;-YBX\H2=)EY
M9O9^_+8V C<A:G.RZT8^^_SKEJ/9^TFLK[3)\N[E:8JN/%_WWV1RCL^VYYR
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M#1AJ$^!A<\T'B6:2CL3%>42D<#$-"$O3:Y2_).O1LR\_,Q%!V\#B:FHQ4".
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M%Z'!8?,Y!Z>G40*G+-$HA7W-T=K)K_R]=3^P!@@57LQ :GXCL\%\*?B?F=V
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MPET=1S1+[*&$CI$%P":I"A&>&A)9Y.JWSX]]73US+I^\($<J\[NJY5JE4Z^
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M[36K7+YP_-U4.7+!3D(V)'RZ3WJ-M"0R.@BJ!H.I3L%[VTYNO;7>?*D$,(,
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M>+47!V 1,Q*=>,DP\60NQR__F.)N+637M+')=0Y(\CN?_#=02P,$%     @
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M2  7<E(N!ACV*S[GE/OLW]&NQ\7_.'OI11WJ!WKUHGF5]U[(D3'V7G+V(K^
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M@N?^_5<"B'VMYKZJFHA87HSJ62+KLB11)4@B[[5OOZQX";NSW@ I7<W+[KH
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M^45#Q<U).47S=T#%^RH?UH -PYB$</;?BB\Q[VI.$XO4CH39),UBA@%6W<#
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M6?MIT%@KBJ/#&\ Q_TAL<"-Q>7"3EB[GFUOMGZ5-2G!9$H'TBQ91B6X]D[B
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MX%\;V6YYL'A]ZF,:;@1^VX?Z!E@R/A^5-#ZQ>,>N8@9X3MT(1-"Z\VZML_C
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MKU&K9M_S;=U7!LV:L<YXA3ARCO2Y%V/8W&*]Y%2YFU77F3O\B3V>#,#(??D
MF D-^\\01_BQ^6+T+B\'\)&7;+]%0P#_V/D?@_Z;@5?_43^"?_UC^/\G2NI_
MA\"I];=F[J.L/9(.E"6R#/M4M\GI_*!H<(P90WVFG7I,K9#NM%JV%'TDQ,.B
M7YEH4SF:O9J0T/"SO\E^?AB<C.H9G+@T3?9NF-4[MRYEOM!(ETAT=C5+)S[%
M-0241EK'LRJJ%S$59H>\A$JS$(TT3P3L&PNNCY5'FANLYU3PN1.M<YVK>:(B
MNZ5\E7GD>T3+"T+.X^O>5@WHY-.W2>6ZL.VI1TQ.JY9Z YA>(063!5QF$_ME
M7*\]^Q:6R1/T?/$5'G*G1U<R!J4\7G=<S9?='+QOH#*]7M^]0E%L2_8KR-,E
MP?GTHMKKZ^O@)QTH^ 80-=*SUL[78 .E@UVYO,L.#Z><V<;+YB6N#J(;!.H?
MF6"^B0HJR)27QHQYH)O6.J(1&:?GB4#OK>:2-:L$;;:G;\Q9=$2> >6M9$9W
M<"_S0]#6.\QG=;#DNGWA2W%CTKQ"8F"I5GKA4PL.MF,%Y!+NOFRG,1>ULK=?
ML9A[&>WWR6UFU9__^HWQOXA:T!EV_B?1TD_:A"_ ]2W5=U>Q=6QPGLZ3Q9QJ
MVW<LNHY.BNN_EY>R+V<C+4E9MXG=;:)@T_=F/Z0= VHU(CC\/J2@;H+.MWY?
MGWV6-?;ME3=3[^):0)0>%JT@J>.Q-5\425V;DZ)'LH#V5.GX<GGM?WC@2UGD
MX#VQP%1TFCD)WN;</U_]AC4#DQ)Z PC^G;VG41>S+?NC44Y)L+6TH?NA\DJ_
MZ!PUPG,:3LPY?[+MGTW) VB//-,3=(8T6OD2\'25+0;4=W)'A7T\3 %;S=]>
M*\[DXR[=>&A,D/YR?GGX6))2<[-YWMW]9[R^RB*+;]@4[]U)\WM4!M(]V(*W
MM4W'",NE:9*&N]6&NLV7;-G-=H]F&%JI=WMF92++U4<LM$$A$:_,T2KZBA[T
MFM:VLZF>NQ//7$/'KJE:CUHJ @]+[ER35=5:)[7W6UX.PCG\U8JKS(O[S*<>
M$47Q,.JCU<S3)NMH2S7\N.[:9OT^PJO"0ME=<.BI5JV%_DX:S>');>461HC%
MOZ#R#GAG4OQ;-=)YH2/':X&U0YXIO;FO;S\)H+$]IRW?VY0Z*C8]N'/S HS(
M;^V'4@2S\.L26SN)QO2D[J%JF/[-KI@?1 TK8.T/EQ948JK8*NT&?9IM,25\
M5#+7"U*H:[NS[[_=]-K;K!,0N"%>]J>]EM=YGM'&34?_&N%O6.$H_]!.B_7I
ME!VJ?[&0#B+3M5JJ;U#4YJG2'C:F[=-DNZZC?3JLV)!_<M*C1WD8\!J(=U ^
M[MT1L];G6KA8R6$J.MS*:O-E^@7&2%Q>H,UOLQ2SI:B0X;P.]_9;P_9ZKOL;
M/]-K3$#!-8G13 G.Z[ UNZ_;TN["A3IDLM)7@MGOL,EGLHE]DEB97YDM&LG<
MDA1E6D8DBM*\NW/H'ML[BU^F>Q#W"BJ5@E+R*!L-+]6X( DU(H+M1?Q.D"$G
M^M7F586OV^$.*MJ%-:D9CNA"G35Q^%[G4#0'SW1<VE'CKY:*5GHTM(:4/!J?
M.A_,P-KU-@/:1D-RRN.RF6MAF6LM@0]63B#C!IF  0#[OR#SGLYI1&XJQ62E
M1?DT@GORN_K)AF,=3+"49L*#5:^"28XRAFROZ>)H]"@\7@O3P$"O;^EJ+^?K
MQO<'[R.$1FL,YEC?V9Y1H>[?M#4]S$'!5($/!.F+C#N:E/G#R27[;&[@.#4J
M6E?>&$E<,!Z+TZ)(6O7OE5<, B:CE#B1_=/D4K>]:V3>0ETT3F.BWYY]Z.)6
M$ 69PVG%R2)\7Q%QVMA:(4##9C+]L<8;@+#3EC Y><]'P[Q@9<,S[W%%<#*U
MMC%FA.D1/5=7N' 5>&R:ND\1?GGCUFZYXMEK,:\L\-X73D<*:WVR@N/P&!YD
MV>@-,&"RO#)3YSG("KT[J[9U5SVGTVXEK_R8W7.*'7M\",J=OHI3-\PB77H#
MH ]:+2\U=*_>5SZMP]>>(7T$ID457R6+?7PB!I:<J"B9<WL=K#+KV[NL>B!I
M:IT,S'<I,:.0NE=F+5NI5!1XOGBKN);20-997,AP&.<-Q<[1@'0@?5CA0I_;
M!N2,C' L35U!FJK,CN"@96>_D8Y-NT4^8.%?XPJ#B!>AR@_\9LB0FNO\C4-G
M]AJ$::&0?NU=#696^?K!97J25,NTG)QCRVZNDV\>DW+7\UI*KU4!2.EQ-(AO
M8F0L#O58-'DJH]"=7_]L^I=_P,F/2XV#V1N;U%$7^S"%9EE]4C>Y1U>W,2KR
ME1Q.E^=0>(-O(S D_G3?U_.>_$_^]N"9R;,(@XOH,/A"6M\=SN'J-"VTO^J'
M'\H4-H+0U&=$:T)DM$J=O&HT[O_F9L0&AT^XR1=)AXTC_WKI2,,\JESC\H93
M/X,"1 ,?JHQ3F44W*X$-O"DU2QPM)8JJ_OT!QE0>@]JU'O-!<XN-GJ:8RR)Y
M&)U+U8JHM<=)[]]_W-I\SJ^W8<(R2#"^^&@9;[V.>O/ASWKSZDNN>DOLPOXK
M"_5GFG4OJTEF4^Q?G#_2%,WFK#E_N#-^7E5GU^=) '<&SB8?[$ <Q63&AENY
M'M1JA95P$>>:BO]V>#[K06)<E=?)/<>&E* &3LKB0B!YQV*(P,0N=9Y[H'JX
MUCJO=J6GSG2')5E1G!+I+ YSBT/E1^\\8_#I<(O)OQX Y)[JU4+HQ\L=]9I
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M<R6=K&S:FQZ9#_H(U?PDBR$4IXIX[=RJ7HOCCN_*E5*O5GY\ADC9M/OYQAM
M_[DGBL6J!<+8SD-$]&!76_H3D!X-TADKY-/*1_#I]\N[[NVB.V4AC"PEC%%W
MGXLE70=T$G##*[^BY^:MW'I1'?X;0,[N]TW:=INCO=C4W%\T.LHTO;4F>];Q
MR ^PG2!/?)US+(>L7VM/"V^ 3QV]@0\F"Z+?.-Y3*^+\5+[;>U XGUUUS'B]
MIIV8S_X>-M35I3 ,;J3CU/+C]+O0IVHJ5$A0Q4H/<(31$-0=4\77%=AV+JF?
MHWOF>% =&QI+T5U>N035+U+&4FP']1Y\NZE*\1>%[J2*.\Y.\U49+U-"TWAG
MM@Z9 BAVM.8->[\>]W24PK7RZ2#K8\_8JZ[8=_NA]!SVO9"##^;!M:_QJ^:+
M)Z.3SC^!"?EY&RJ'A_9]RX?^,V9_-*#M"/8]4#'C_.7LW__^-I3ES5RZ%I9E
M0Q7O#'-Z=I;*Z1UFVM?5C0:YROCYDZWZ^^PQ"9[&('TQYXHBK6PN&H94'+Q:
M?U[S;X5P-)4:$K.Y<T2>"U@=^^L^T53MVU[R+[G,#!48O2#_]G]QO$ ]DO3V
M&-S#TGXLW<GW;''>]!,A!IKW<D&;W02ARM@L?%Z+==K[Y_;/ZN=VYK;3M#4&
MC*X_-W7KF+4.'T\Y#3_%XWUNHC[)=H@^'%8D&NV$W'"GL)2=XZB<ACP)_=DZ
M0J9-A"'&1"G&?#_$BA3'08B&P% [[<\XO;;6EOCX[LOV5KADN\JZA4JKMO(E
MKI(/3P>F.@(IOU(L<5/9S&RWB8"XGX/> -.0!C%=]FYB;.$?BQ\"DU:+B4HX
MGP@;VUE%0*VKKS(#@&@D#0OM[!C_L8G'"F]>"2TP/T'ZH:P>)'?'NKKFBX]B
MS<=O#4\EBD&V6<Y>'/,OW,MDIM99,MIU9 ^.L>>>3Z@ME\YWH!NG-T!5A'KA
MCBN*L2RZF M@[%_0>,_/*IKKX(O:>FEN!$Q0(4E?/_'>/"W+D%"^R;I/KTOY
MJGV:OW50-O9)KX><5R.:'IY0M#"_/#=T5_7^5N:@P:Z.DL[Y)!/\Z48ERVCZ
MF "&=W;)$^@\3W>5GL AC%[.RZ0A:DI2IY(0+I,:#SEA6I]#VE^$W*#N+2GM
MKX^<L,WOSD\AC3URGKL[LS^,49#FXM/[IZ=]:#@I>YRNVQ=O?<S)*H/=@A\]
M7W^OB)JO;Y4X<W%'SGRD.#I_=%8]:!HY-GR8V.(O]IY7^215V>>Z,*W4_6K^
M G>!LT>!USOZ:,W2'4+\CQ=P^T.-LR??W]3.K9$]QS4$=1JG>XG1*O4M]N4B
M1P*][9?P+M"IW@#+-7W;:L&TK*#JK5VZI$WPJ=ADQ=[IPTWT?:9V*MK(2?!8
MG''JG<JBQ*'A<]@BNFY^K6*>-M>NYW2:V/*XT53Z>X^["<+%V[.&AQ3:&L%
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M_O;_TW#8S>Z^B2]PB4!\%X;F/X L\B<\IKQJ_<9_4C\/MFS=W;)ZR>(DDRA
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MW*&>>WV#>.NB8B &,+UPZ=!"B3OTL><=J$;>UUM*E^50S\>Z3=@W8OC)6M4
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M:2V-:8T8%05)"B@-=)QN%%M7V;='K+D+FYZ0?T : +\LKZI3FY4V?T*X\._
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MM>"/G-KT8Q7<E]L6D%SBR,ZA'D'7SJ9UG,#,:D0OO4'YMIUIS]@@KUL/GW.
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M7IO0 ^F9]Z\HS8'Z=G\Y<$.>ZVVM%D_L=;X7KHM^>D6];9PY.LA)GJI+7>1
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M;C6S%6DKXDFK2Z]MW-/8NL&"8>K$;5209HOMB>,5@61[8W22T6!6@I5$7;#
M3DF#.K%/Q$/G8[>7@-_(DT'5P_^_8C-SKEX1;MC]--'I5_UV/\-\<+B#KZ H
M$P^ZBM!_4FBWOE^/GA;T7US#+<V*_B48O%YU='+@H[O4E',O>50M%6S@PI--
M2L+MMZ?=<3>3[\)[,;I_69JZ6I2^46OF?@_L!1"]9'NW%"]:EAX9[%$&0]6X
M[TRQ\E1@JHP#6&Q0&2+23ZM[T6\2FO"VW6!Q=HY)F=3P-/8LJS=B\H+0-CY-
M277&8V)R0:#P'416I%]HDAJTA^L(<\JIQA_.^F?PE?\+QL@3C0Z"Y/TA!K*
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M89T&F!]:=N.+^JCI+93H%/YKEI]LV>^GYE";SS/N[)(<XIM?3":CXKVB&=(
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MY*2F1;#(_IUASW+JNX[$N9 <IF^^[KML:IG\@ _UM+ $1F*.4W:C>5V)^_T
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MI;U"2(JSG:7SBHI,GT(L.9]P%T2:U'GH:R(!&F''7M[^*=B?9&@?ASOXD&^
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M)9RMR/N3UE@3S32VZ(#CI.DU)>'MORL0"/.0*GEY2W%K)KBL^/NB272E_P/
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M]R^B"Z.MA+_&" 3T<#$Y;#8F4^OS<;QU$%XX&5;AUB 6H/'T,OU61-U"+\&
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MQVT*[>O-SG(-+^V&<0D-_"JA$UPMWF ??M#D?&!T2,3B9.(IW%15$M NYG*
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M"_/Z45"_D_B;2,C6(%WUJMEGI]VR^3VQ <&CW2M7,0E=CH3#;+,J__8Q^@Q
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MT98T!JDI:7%7X+6I:;4?WLAH[K4N63X?G[X]#4\?='@N_M/)_-0G;<*SX7-
M#NIRY>1I[MY!X/^E34S?XB25E/<'^?[%FKT\J69Y)_>9HB,17\IQ@L9@?M2C
MD?7P[@C?20'U0R,(VP[DK?(FP+A5PU-\^L\VIV A0N:1(<JGTCED[6;WL.T4
MT?=H;8B?D4<7A.V8XT+=;,B9:3\/>^4([?CI\?%!ESC19KCW$#T0PA;,HF>H
MX?>-YW!D5RV*XY&!T<U^XT9-[6D32'YDU?SE:[]ULH?^,I%\Q;C1::6/.$O)
MAO.BT&@9 :@H2/:;P!PR'I%,;VYN*&F;%CY':2O+(397.-=[%)4DIFS1'.6P
M:DA\?E0T2E!>+>&GY=J,]I"@0!^%_(IYW*AMWX?7VU@7Z*_AX\[^?9F9#%$9
M5L;Q4U)36]^BE-0G37\^W+'/Z-!Q5\=8\Y&>0H;89,]#^,'MRK6P2=SO[,5A
MM:P2#ZU58?@CV8[:"5OQO5OZZ^<2;_YH>S5H^/H8BK_'NH#,,O8I>,%CENE2
M:+!/)P0D3.5*P/F0&YLIJ3D4W'K#V (B$)=;A_1:K(TM>?-X*5ID>.;&QS;7
MX8;>U:QT7NN3OO[&[%;5P,'HO*%1M]Z^_E"P$<Z 179KRLBB*D%F0[DZC,]N
M_S:7YB4Y:" UP<$*:0Z7=UP65]<T*:=QYK,CH,W)8:1_];8MROY]5KY@;.:W
M1(O!F27XT$Q?*(.6-G6O5-!2/57Q>,SS9[9?J2>"2@2?O-;RJSH,U"&Q;8!>
MR6*JH^JUO[&*3DZ+I[0X1%Y^TAVS/<HNP'1B:DMB"523,T>&*+<TT*GFXI!L
M?)U"3F+DA6O9R)N#R-"6F2;JXPANF@:OSW^Q..);I[.L+(0;3A*J8;[7),C7
M']J-WGHYQ2I,QY-WIBWX>!PIF @H^;[VCYPT>@DQ!1TLF%@8)_<3$IIH)/-R
M&8TUU[]/JT?2O(0D2SYU%M!X_X,\BX_L"\K@N9ZMJ']O +ZD3LDYP>&HZJ*E
MF59U5U,<=G""&&U6%/U8D\BQF!#_-AT5NI'16J?YLX W:['CEUNX9%NA\:D*
M"\>AQC:F*FG=4?-D67+RN/I)W#MWAR=51]C UG+GO?F09P4*GY'<WEJ!!(4=
M>>O!T2=J'JH+RH!#F===/:O\T#4UA@WVJGMO%6.ROUC;TPW(5\DIB^L) ?U1
M1 _L@\:] 1QZ\N'VJO&GQ^3WW^D%)"S .>>)/[>)I@.Z(XK1?>S" P)26-3M
M0QFE_(OTC(;WK6;5M1[UVD8W[X3C316HZU[N1CE:MQDLZOJD80)Y)VO\7U<E
MQ!/K:R[\Y"::=F0?C:)]_,8(IP=KYK[<9%$Q:7;J2D. JU%TU5_UM*7-M>NS
MM*V^CE&Q_;G(2"6M,S6P#589'$Z;K$9,H2Z9W) ?N61\]O"M4OW3(X82IW0J
M$BX#U31QIM"NOU@1'_[V8UE28F'CX.'@XQ,#2/#Q\8EPL;%Q<+'PJ*C9A/%I
MV!7T1!1AUNZ40 []X,2"VBG69S8>(4G)=3W3($XA)8.4POK>C3,">=O0(E'/
MXIES+F4HO('6ZI6;U\>^33$51,+?)2PB;&PLXA>X?[%.2*?8F2CW(]B&/!C_
MZ\)Z-]Q:S 0?D?P7Z%TJ_H^/SP0&3I89\(%(2IVEV:;(([T4T+K;$U[WU9:^
M"Z</[D?Q9OX/D[;X5$,R\0/ABR;-W'U1J^.C\09XXN<JWKXH*W16M([:GQJZ
MVX@?\F]V63JQ\S+^8OW CEWIN\D75@,JG+TIU-5$X[X0>MC_\:'(: TQ^O#X
M_BSJ?V#0/YCA^46ZD4)[0,P%:?WI5?3I,-1N6$6PT GRNXPTL.^F0&3O=V/0
MOA*+ZON?!'(Q_ZJ8Q;FP=+&$9C/*K"I8=A;[AH*)'ZT*HK^/_]YA.Q![XNJ2
MI"&GTD<=_)R'7H]GB!%A_Q=K#OD72YRFZ"^6H='O;ZKQ#R\M+ZWLSRMA^G_&
M,>ZE,8C]W\0LQX<K']:Z$Q>;+P%K[K^WM9N+<EUJ2A\)#?M)HFU2$X!"U2!#
MF3&7,,JP<& 2C!Q04N^WBF.&60VN$*VV6.%63?,+^_ UM,@BQ0^WXL<'TCD5
M!^VW"%Q&55EE'K7WZ.K;A)5$C3UV<\6UJ<I^?]L.P]R2^-]?V40L%?^%,I[F
M&_T>TDJ;Y/_SBIBRJK\&_?Z"BNVNKFM7\97 8:K8PS89R]ROVK]8&;AJ?RK_
M)8A^.!SY[VJS(?[:[I4ZL\@S&'71COJ+Q'1OL.8L,0DKMJ-'5-KG1(MO&0$'
MH)/_/XSX#TS_?^%>Q3(-11![9ZW0S811$S?SG4J ]8VCG25F<2"YGH,NW?<?
M@:+]<NXD8O7V\+KO]/?5O_A[_\Z:^Z[G%M^"ON=6.\O^^)?)_%^BS'^(.?\A
MC@?^(^[)_2->YOTCFB!#15N2QV6#!EF&OWXM(,[,AUBX@YF).S["\73&WMPI
M=<B),G&]IY\@/9?-AH P^4L#"#H+Y"Q2J@+'>@0E068IJZ<@M<LFK4[ZQ*)S
MQS-*@L<2*?#K6VSVUMG'=8.CT3U7]71M;!U1SK.CB%+D$Q?>>2T9 Z^_6%*[
MC!)]R<8 FZ,(%KZO6CHX,&IQ9,A-V<FV]0%*$H N[MB#XPMND'_=:1U\MJKP
MH1 D9N9S%7?E^?3>^@ I>)('6%^\76'SE'KK_O4@0IJ;VV6CTO.'<O_@=.M)
M5$8>RG.9XG/!9PRF_*$L,[U40[ 2S%--EY%MHF_"%# +W23B9LXM,]>-^ #<
M0&CK\!3*;)RN"8L]JS,SM8R1@E-5E%M\YY*=^ES"DZ>HG@%QO$]I:^5AO!,J
MA5=F.F@YT1JMWZ^*HC1*#J_N<S/_U)ZRN(V86^$Y.8+<^63BUO&$ME0:\4G*
M7 &*M6BW@K'G+_NB5':C6N4-KGR5K8'1(2+"5J]XG7+=)5>A%?H.>,D9 R$U
MZSYEZK7>O3UC8@.=;FM5\B[D70IAY!-W6\R1Z]8@1E( FTY.')H(EO%RW54W
M_2$AUE%:^V%EG4JKAU*R.P;@3EBIMN>(67'_.8@79"^I*KI%0&V(<16/?V*7
MI*(S=#B.3Z8CW) S@N('@ ]7 I3]>%Y8FT?X6M_@UD*%_M2=X@3@B<G[HFG?
M.8BJ_U)JDA /WE7_'1__!^\OEMO*S,%?K&AOR[<[=T3_#LR29);PVN%LRW\P
M%3ECB#C!FEI+_@SL313MNJ^;[40 C_@-..@9P<9OE<'&MC)3O]20E5O&4UV+
MMPU40ZE^XC].4_.:1(W>-;4*;=*]L\]P+; "U57(-YQ]5<1U2:.$I7S2=U!\
MQ_K.FL@-3,2>SQOCUZ<.=74XM>_FH2=R(U3EMW5_GMVW+_QT@_I*EM]O/7;%
M_3MVL-2&X-/2'/=F.1=P8GP/O\Y/Q,Q7]WL;%;)?K\(DETX5#L$-JN45KE4^
M3N2B;8PM??8E*&,3\$CX%*11.W%R%>^9:'1()JS8V^V(,C9_%[3V9'<P .7S
M!#4X"5SRB>,_O!A(^C-!\1?KZXO=OJ0)H.-,9:I*#+^5AW[<2V9N1J,MV!BZ
M5QSJ0USJ4B-1;EW#!Y@;X>/;:D>\:NY-RAG&;B@)78GSZ'137^J.-VIUYBO,
M('7[TU80L0.KH_X$^EBH[6*BH?M*I\O)]O5)(^ZLKR)C(YB8O"+'E>6-MUCS
MNQXY/]:\$,?$Y84Y]54<S-//N98F5Z<;V\3$QY2_?.DSU&!BCDS )WK:.<.2
MT7ND56E/]-[Q:S.Z>!<XYZQ3VGNPA_,3]G::F__.0<R&0AT0&GSIGY8?E8X+
M_>PA?@YRWMJ)G2'18>1-YS).C@VBC$RK[FUFD7U1H2L_>>?Y$17G*^DS3Z!8
M.];MOQ4BU\#%VNC6\KKM_/CT/)8U RME)4S@$2'(0I<7QFP]^]F@25.GP+$^
M>A))O19P'UVK-$8L*[@*\L8P;E^SU-&"^CTC' /**VV(1RAE)Q,X(J\&L6^!
M%0Y6%[H*0F&_9\A:+T''X3FWT==*@@_TG0E]WU6[7@G=3%4O4O]XH'Y(?/(7
M:_(?KF=1W%N->IF7[WG:7SPQ*75CH^.TSWA?RR5VU][EPUGR%\O(][0_YOOA
MZ<.WQ"RNY^>67U;+SA#1Q[>%BIY7;]X?J^N\K_RQ&LLB=5??Y2,:N/<?XM1,
M5T7[C:V:SGO,7IVHU]Z_LK:JXT$X#XE%/'+![X>F/+ODNU[9MTX4&-6)FNU-
MHD7-OD_137E^4+71/O 2 $,THU#:08-T&[>RDT<-)XM&BRR+6<MLG%HBIBGD
M5!./%O,HT=YJUZYV;PM1+ZY#^>5>M>P$"$0)WF0F./_A+:19CWITI)FZ!G1
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M[(EX,W42@QMTRGV#&SYD3Q7^N.)C+&N)<75(JLN)I@/3&Q$;_UTG>\%.OV.
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M[5L##<0GEI>?6L%7BF4KD]  S#08],W*KF.6C^%,M?ESSAPC,C$Z2&@];>K
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MLB6M\PZE!_"3U^(A2I]8JTU@\_$#.3<=LKG )LVE1"_U-K7T>RKY[<W3G+F
MLNCH>6[S5*6G1R?VDT_.C(!72FAY3=1T2K)*V9Z78'@C*O\O%OSCIX&S3/]\
M0++Y_3K/&#'=62^M.YZ)_]9 Q<5G,.'70YF0H@@ZMJP;?)-"#"YJD42"#24<
M]\; [2&3Z%6+F4I)3M867DLC=>C7=B]/<_#/06Q<W/0HY623[ '1DBUJEZV!
MTGEK8BV[E7+]:B#V',!UQ]7DHYPM?OWL)UTT'\&Y&5%LH6)C'B 41^T+R@K[
MU_R/6$9"S\&_6#A!(TN%2'GOJ/%265O#8E>V^1M]#/#"1#,P]7&&#WKB$LPK
M=B2I]"R5W&3WL7MGYR]&?-8RV[;\WE7IU80EA2;T'O45$#QG<GKJKHN1=LY;
M#'6:: N?='(A_FY1EOU61YCG5\?2Z\6B"\'< /)J!PW 430VVABG439RS>V2
MR*.\+8QXAT(.ZYUU!/7A9*84A@>I2(S[FL8Z2]$L[2S2_, 0WI 5 (H1V73(
MX.63QYAZ-3-]ZX7X39=?*[I*C[B0Q%GXD3C>+=J[MZ5<U.),[8R#X'60$$9L
MOS=0M '+$Y&EMZE+G-C><>@"M9P(NF'ZPR#A7MKBEC#\!GW3I/SBR=)J!%G@
MG7;2B59+N$&)*B=Z,]DR-MM^./Q$5% "+K&M1YO'%F&NF/+)!0:*SRSD$100
MKO#FAV1(]UCESR-6$T=J%/YBU5G@"DRP4V891IAB0 ,_G+D/HBCZ2[)*)I^P
MAV?-A<!J!VI"4AO\S3*#U+RA)<OJ1SSTKW%L39WJ'4R^5!"+ON-QVIZ,3":9
M%KE@MX'/ 7^9)X3A)0_SEH&,&-G-UB-R>(SGMZ)VDO,,1$HGK^,M:HEVG/+\
MI$$ZW@3'FS_Y4YXJ)A!Q7CCBKVFUA[&V%*-0,:=2@#>07DCJM#F7&M[*$'>V
M#K0MVBR%E%HV,8[RA=3@>K<6U:A,&\(P-9UL%I\^"<D/HA:J!BA5'"L""?--
M'Y7S>A/K<6+#"I">%VH*+ ;OE0IMJ5.H(!M15UN@!OK;MW#=%-@S(&Y=WEQ
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M7I<^.CW C]9,MUU#[L7Z+YE'LE<X3+AD5]=4!Q^S+'S5JNK28(55)@ON^6)
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M8\4B(G?L!,6 63^02O_%FO[ :[JL 18SMRH+[>^&E9_-/C<(;YM 6#;1K^K
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MVK*BYY?K5IU=<ZS^8I64I66]Q7-I;TC6112;R1$12"E]8'S7%XAW?UBQ)V1
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M\;O29VVMZUD6FP@RHJFDTA!?N\W@[:)"LR@4V_=)4YQL^5$O+I8G23DYF^,
M,_22_JY7O'_E9>[T[A+-Y/^8XZK\.@9T^UY?WN7Z'X'G7XJ/5;]48A;_I#[Q
M2(9 %($8NT6">7_J/*^*,AW68J('/YN,JW'%BQ#E!>^/?%:**7@V")^C5<-
M# 8E#4_M]Y48S<9_MDPC* 92M*R]#?6G1#(B^X$:5D]S"/39G%1;W#,/_ *)
M'K U>!J=/0GRSVZ63%\[@+U]_4B)BNY)OTL-*.- -;I+BU7.A77=[:$ABAKU
M+E8LI_W$O])26?(B7-8W#7.ASSG?QL7^H\ISM15DP!LX&Q!P2!]^F'HJRV'L
MLS]'^+-*?%J,2Y;UO/='GV RK)IP9 L3PA'%,<&W8OZSF=U'V]O&NJBY$CQG
MM5LTSSO/Y"<D>6D F,W)==>C;WQ&'+RY]M.9DCJN!C G@-4=T/U*(^Y:1\[5
MFK97/6L)!@F7IOLY(?I;% VA7L4!P'?G$VR>1CG1F!S!^6B)HQ[PO0G$#^Q1
M<Z75-8&())G!D%S?>DXS%/U(9A=K>AAKG\436CP<<EQYI>;>$X"P#96\5L_!
MYA)8U,+7BK@<9+_7LF6K3SO+SIMMN?\J9>JXIC-R' VM7V(J(S2OBG7L*:9S
MSSEM_P1]7\#,Z8M^$V<PJ+4FUN<Z< *:0 #TO#N!!B7$S^N.PWVR%,5\DJG%
M&.H*:%%+!/3TO'[?3YD.0+-L+TQDJ.J'KNF\MC(FTQ_LB+[:Y37\M?F,Q+%[
MA43KY/]JWDF#_^%"X6OEUU-%V<.J^5/#IH7T1PJO65XT\NX9_ +]T'R?\WPW
M:\HG_.FOH61?_TGU'*VA("+F3(-?ATH5_G!%G-$U:4$ZN];[\R&4,^-TVBCZ
MF)MUSH5)1P:*;H8VK_Y2^<KPG%<5(<F(F6\P2F!-/&-52(F^F^4J&[]UEI0M
M",CD(5,^)I@C5:QW)&!C[3SLE$*3*?W*7XX70SU6\Q!3*T(M;4$8WO PLXK'
M[7Q.S\AR1@D!CSGTZ%F7&*S%W%''"0D@&*^DYZ*4$ >%C:D@'7)%T_!;U_A$
MDP@[Q%*:L_D-M1&L<>-)58AW+?U;"]L,%IA[O4F[X?=U>HCL(\Z-Z- RABJ"
MV99]R!Z]K/IZB. 62F:X+MH1_H(W<##X]F-Y^0WI_^)/,G3=:_JBP)RC27ME
MQW0707;_VH[VJ'@=J2BP2'LRRWTM([)$?]&>%^AQK5XYD:DKK,41_U8KK4&F
M$O*>VV+HPX] W4Y(# --'5.:WK,%)A6IKX\:8E\)[ WD4L@O255!!!<>.G$:
M=6D]U L8R.MGR!;YTN@T2<:_,P,+2'NV6$(B_,6X>-&J>.N7_L[+0@TZVN8Z
M/I/*T+B7-/O<%#6"%^["Y.Z&L[G'YY!*N@?9)_2< KMYVL=*@3D(B/[>'V!/
MF%([^L,.X_ZJ02N'4-&EY;G=#Z>0([';Q#H&#F-;!)9PT$SUZZ!6*[->(!YW
M-433<O#NV7WVE\G0(.O0U9\Y5%9VBTP(-IN*)P+M/"4O?<.JB:ADZGY7L^N#
MKS\5T0/8O#[K"-/_F(N;9TB6+-M<.2S]+QD(_)<,<@0_++<\?]"SX*<4^/_7
MV .]V /]/BHH?9VX,Y+HO2BTUV]42!3'Y'#LUDIF74C6N3D+*.G8G8AC^.$7
M+!QNNKI5HZELY\;OOX>C=-IQ.2<*-=]+)^O>83E:)>W;LF[MM""AM&$+J:C?
M#^Z^Z>@D#UER]).Z^7/Q?'O[,MY*A!&A"6*X'&+X4XN>D=Z*T%$UPJ(>*F-W
M9G;-INE(&C+2F4U>]7&6._&6CN;QZ+R!NCQ__(_@)N''UU^\X?0&T@]=*KA:
M@K0R!& [JM%ZZ?MQQTL&C>QCAEO.1W&/8?F,18J&+7^N!PV^^)RI^9U8KH<]
MT>M/7/]'D,LX24X5^H\@F_"C\#^"8)9,@1KR'_W0,!,TA=,Z"/1#U5?YQ&&]
M01R#8=&I^FC"%!POX!U<"OE,Z#>J>'H]C&L9E:PNG^P^2<@HTQWH#01@ (2<
MTC1JX0ZA8[G@7\-SMN8,)Z:M?/@PZ-V53K'8PF6AFT2A?'=#Z1,+E(M_OD&Q
M""$S6R$F_,Y-NS5:I(V_:JBR^;)=,]'V>T]ML,:5DAD*D2)/>F\ZCV=.49,/
M^C$96VA1HE=GT/I$57F#DS1#9!YS>W5!L$$DJ>:BZ#'VCV BB?PK_O\MIW7_
M?R6%B!(,\^L+.HGIZT3 V5"RZ[[<S;96T_Z+M23V^0F?_Z]&ZC+O]COG8MD]
MAK\_4]R"3&^V5#X^*PSC9;FL.U-_^VI7]$SS_T9NJ7R06/(Y&X@*EPL/YF49
MOM>\_S]/^5\_TE($S=^4J-0]*PSF9;[LN"D!-^R^6$M@/%[ZV$TK_+\^.',G
M=+4Z+D/21VOW_^8T>+>_GL3\?\M(<KUG ^OJL;(G)DG_1Y 9S>S)^8GI5;)U
M_992<&@WG@HQRJJF FEFJ.#'R?&:2@2^+K?TTF.Q@M#36YKXFK&FSX0N3=>T
M_K7NNP7IU$PL;5I5_7*^[TQ6PWF9)+VTIX[3K.E&R ]RJ7'-DF9.3HNV;YEE
MTBG^9--!\!<C90H4<M0O 5G>H]*NL?7P^A9O2^@P'XA+*]KY 4N.3KR#'O D
MD_4Q%U"RV8JTF#^WY.YG6B,&:]*N+1.=$^8AI#\OW2"]3.Y#CX7S9]NHND 7
MY&J,#:Q$S'!>7#<%@4K-1U1<0HPQ6/=WT,:J!W^V'!ZY4M#X@26_.G#FPB9,
MU()B /KC7P*^&/#QZ;%45NDI#UWEUNXD[34HC)9%)DJ]S#,I@-)VFF'+@VE+
M-'\6.ECOL3X5< :\,NZV.#-BC'P< X)U\E/_-JPR1:JF^"Q#*HJ-XOMIXF..
M)A+-*=LWH)90VA0K[RT"B*%+?K4>4"QN(==?E[NF0@AZ0YMBG&Y[PCD+9&(;
MXL^&[#Y!'H[Y._2_L6"LU39:25S/H)'_^EH\:D(0Y3*QT5Q!3.39#'/U-9 T
MW.GC@XV2V.QWMV)2Z"-[D+W6G?Q+;B,N77L?<^83&PM:VN4 >O!99A74J.QI
ML<BV7D B=R9V3 ZH+59F@H\"(0TJ=9LQ\LUEF"5C,5FBO/,DSOZG@%GBYJI6
MG:V:F65EM&\"AK/;)TEBVAEJ]+H..'>TU4J=#)(EI.6(BJ*(Z]K1;1/G;1UW
MU9I&,B8B^<"LFC1*\Z]'83VL,@+&E&1 ,*%)50[.R++$UL;Y\($4MLE/QK#R
MV4-!0UF +-N0@,/<]B/I;TLJ@%FK-R4UG8'BR6L\M0(Y4#X66%U^L2MX?)(4
MM_S3J4/1"\,LL;2J[?UVV7NRRU"XXS7_$8::Q%Z8JJD2-EY#XC" Y=T(01TE
MD:SE -U:[(^?UHP=X2]JD,.+I&KQ&MKMVTCOA-8^W]<5CI[;FE;>R[35,FMY
M57FZ.E_XX8<FNV3MCVEOR3PSX8D/%DOT/R?,66;[+UORWOFD>L>.BN[9:"R7
M&H$9=.X?K4 +2D]<%>3)E345WH)Q7M&CC,V\[9)!=,R'<2-ZH_<MELS=6U/T
MCF3+'06>.+H[E)GBAHDN5+0%>*WT!W>L.P5RG&<(L.7.)L3>'H#[W$<;#*JV
M?ABEGZJYFG)R9P'4@F]_92[['V1G9/B_  >@<OP_^1''6H$]<S  '?-[:91J
M3&$FUDD<4J)"K)0 2'4_0INJ;/T!5O!;A$5\MMIFB]EN.X!\ X-+9!@SMI6X
MV^:34BAB5(-^KB&B-<%V-C5..]]CX. 4EQ+E[N83&NC7_7#>U<\%PGI6Z,VM
M*>O*/SMHS(3BO@%<1E+/ORT?3(?:FH\<_IK-P.QD R"K4(TOT(SNC"4WV^W$
M44G+)7YD;/^ \, 8I'UDOT5Z/4KZ<M()\T,S!1T*[:W<6*XT4H7E=$[*@W'!
MV^"1L8^.3<;3GZ'?UI"U)[=#/W/2<G("P%_ NN(U'4BN62/[^U49[X7+4=QA
M\*>)GR1V9XY!'9*';"//M#QC=$9'#X(RGJ@=P5O4JDG(?"OP;<S\2YX# U]@
M0G.9S47%1ED*5$9#DD)=%_BFHS2KOJOF)LI<X3G9;%.Z:G@EW"EGGM-._3G&
MP=?A.;F>]*WP3<_XD8YPG8L#LM396:]Y^R%QG(7.B'FORTQNA-271\<H7?"$
ME-1Z_E7K2K=;MO^IGK!DL=3]G'=B";],RW)KOK4>&7^0,SZTG&AM/4OB G8,
M[(NP@;U+Q2%;Q=T\3AXT&"S]GY[VGKD6&0DFR<!VN9RF?%MD J9HJ1O25_.<
MU!'4E7P0U,KDP=!Y%$E="+CRBG,HM\C&0[TU$*:\?#=N+W@C6;4_@\)LJ9<>
M)./KM%L<_)>1@EPZE<\LS?!1.$G)^8V,5S3</])@\6YQ<_4+,.^WI1/UC$4/
M*_MC[&"X'#P4_[[F IJ1%7R\4J-![OR14EP1N%,E-=>3:53EOG(=V\4!3,4X
MF(P6JM=[B9 '].?%OM=PW8N!=A7O/,E(R62U9VN6[ES 4GPREKS;^.W@R)KI
M1:$K;,*'K92$)'9T=S4E ,9),'OV_,R.3@9DXRP*%^9#")<Y4!_G3Z]@J,\0
MKP"?8YD'^@] %//L5$VGO776\"]K-_-W>"M]]%+ 0/&98[-Q\S0R8&"0]E>V
M&>AF:2Z!S; D.DF.D]Y5!:E=\O[>FR'^UZNS3M;"KEA?-1"4-J/ AY7(-.W&
M?4C2=R^I,$MU27<9UN>C=?B*=M6XG-1<?I"*/,F6D-76H4'8///9ZHB]0NZB
M-A3=DFVXJ/)G<8FI'U\K.9<>KO%Y]*8[AC+@R"$GS.$X!KI@ B P?:<+&1]O
M*,W&TZ8[9<YBY4=0]:V%CC@]NH H$Q?]P(&KGJYS07RU'N0+XUNPE$[C'!K7
MX:9H&8.XN_-+8EN'F+E)6Y'96: L\J\6@>/F63DHZ/-FB3.@V5-1M=+\&=>E
M<:T>RR;B5;T*/RHY*2G9QOI12T^4[H>EEEJ*<C!W95>*] ,B?I94OVWYE0_I
M>$K^R=G-.*R BUF^])OM"EZ$!6F!^L!<!KZ)%OI5M\EXY'ZWF)67)3PP_T6D
M:A*QJC?U54DSJBP[9>KO;<4YE;C"6@/(4FK!CRD&*Q##C4Q_6LK[)#OKQ<;^
MZA\^L1-XA2IS.Z352"5TV&D_(@[-?;&0$6K)XOP0%B )4HV"0?9C>,!BE9C/
M(MZ(\*BU[-#SB 8?H<B5#PT[[;_@\_9/8]/XF^M^.,(I*E_>5%<UP=#SND"T
MCG!Z#[I7?1IQ2,$\MGUZ$]7$$<W/2,$$,6/\TERD>.G%S2#,O18W=0%K$AJ7
M,.DH=W28E6AU!X(1S9P6C,3S?8:L^5._E0)4BHHH.CK%CA]^C\F."F>A(O7J
M/'"_1!Z&?0^]=A;(1SX,2VXF=X"FX*0&]J-UQ>:2IK[6)_\X\QAB/4M0[U*]
M[ANW2 KBS:O_\]8#:)1=GBG9:B,DW)RAK=)-#&*PEN-_XG<($)",>E^+V-6M
M;%$:A48:7Z":H-+*%32E48?3\AIT[PZM[1"TXX$L4;WY[@U)1A3WB>@9.OFD
MDB?&M(%Z-I3[T'XW8@"0OP2/?J5K:UAKJ@T9L91$R[B*0(JPR/8T/[3Y,S[.
M9/'2</(63+,%+VU*:P3:C]QG70H3)K+A7258R7CA'1UGQ%6<C\[.ND^/O8"J
M$OLG^I!*?G9/D!LN<*#BHI.@TY,2Z\LG2H!181K_=,6MN[BDTE9FF4WI'_RZ
MX7NK35LGBQ%4=*DF)GCD%W*JC7':P/O:H*TN<ZQD%UT0^3[)Y2:$\ZYK<_<[
MT8;\<<ZJS&=!LX<)V<>$2%!H71_Q%?]E,'#;M\G<>"Z37 UV G2F'2=4NL*M
MV10)6E>B'%J7B8Y50!89,J3IX#^ JO]BM9%]HW8F$OVEYN& /!+>QML&)4M0
MY$Z^G9+PK@ZXQ$\HE>=F=?AG^"LCI02[A!<,51DO[L^THC(*.S ?9;1HVS!E
M)D4JV6ZWTV\A.5 G"@#MM"/")T?>KML7-8"]K$BI^0SE,T=F@!_,C6;L7CVV
M -"^B,K+L34X#\'-K'7U-(?'J/=W-I9-8FN3RID7LZ-EDX1.,_^(8_BR+.6/
MC/2D^T%!(/N:V!-!2K?])%NH8UVXLSD>1J'?+719C)*J@DT4QV8C2G"O\5)=
M2;.\:A;#QF8-S9,O,W.-)J((N'6%81<YBAW<;E6)B!PAS@*]JFU=6XTDS@WG
MZ&X^B2KH$92N1MN&4U8N>M/Z.^!I,::,CUG-FPZF@O^V;!!'WQHS469-CI1O
M2'IL"'&FO3RP3)/P3M"]O;#OQF4CC1^-U$?SD>U@9ZLKE2\(DACMA2<%-)M$
MJQWT#12.EKQ['BU6.O$GH;? G]4 B+;GC851;TMF./6.H?6C)TO%1-&3;UV9
M 18*(P> <>8G<Q*ZQV>2J/M259)G]LO&@%'F NV$5RT2W\QE5R(R7+RH CJI
M5]\&21_UU5)9)M"/J>FXNYHJ/-0! )GG"V$O4;DNJK%F_IK1P2H4V%C^J^CI
M;RXMCZH!CM:M,^7T+=%3#$2Y8TXM$^)E_#MEB[EJW[#"?/D0*^30G(<(A;5&
M.P@G*1-2JD<FC=VG/R9#5O%1XV<VC.;,\#B-DC926W=G^6[&E:K&9$B;4-EN
MRJC-V<;&?/N!A0F&.8<[ \\,L/4Y?_6ZW7E32J+UF=XML)\)+7">G7[VR&CS
MVGL3U,8JW=2)3@"70[<MQ"5BC4:,=>Z+9;2,Y#\LG5"*(TJD3]=Q=N"VSIZ7
MK)X6;3WM:!Z3M-+A,2QC/:]U&0VA+-F9O/1* &04!N6SIDO/? &E!8H16$CF
MY1[@I "UE;IHM!^0MZ\P?UJB2:+\T\JV7IE)%>0]+U&<(/ 19"W[ZPG)CZ 1
M=0 8,^D@S 6NK.FAMH13J8/#'KD[)YB;8,F7855GKT?+;&;A]7IS,JIZI1RG
M )#7R!,,%]D@!)IC2'8O09P/0Z>03RC Y^.-OTRK%2;5L"]W6!N," =LA!J5
MSKK-Q=H:#?/E0K(S<E7[YAC#I=^(01I6N*U]/D:]/JQ,,*FL-?ZP1(N6_2P+
M&!HE;"TIH42GI>=.U8F# )@5B+'CRK[T:.AF46H5@Q'_T5!\UE2INE/'8M"@
M+-Z"2GA13\>[FO[VMU\/[9T^JZT&])(BX&>>GU!T^T2G>2]:J3@9Q"._S4SN
M0)<CHUN_LW/N0(SF56H!VNO>"^[_I*)S</99,S%T\?!$?#WMMS$77W1C9<:J
MSG%VS6=+"DR13,$F+2A(]#"4L>M=)X<%-@=->)B@:;40-#=#W+)NYN+<K*O?
MNDV>@Z#]XB<?C:DS7NN5FD!53CQOJI4IX_=]$V:@\Z42XK@\"9-LFZDW@T(5
M0  ]>N\:.TT]YWME)FV\>PYXM 1;UDO)C5PCPUD^\J4:4N['/_&29FCR&D)?
M*561#2Q<:L-.==RI2:#D*CKW$H@@19;/"^ T6,'+^DW.(+GY=T[E5R%S,8&U
MP:%ZQ13TV$Q+&^R&>_A'QB)LV(Q39G9^RC3;[5/,*"T3C.N&%5:1]6"?\3>I
M1D$(CY9L6[ED&=I05<C1!1'39?+6O<J+J&:U,5 =M7WQ\O,7G<I#?C[?M(R6
MV+>N.IKOFP<U6'M343H!P]O0HRS":-T/TP2S^O7]N90*43HJ)PGFLR_^5DSY
MZ!UCT_IQF1HYPU^$O_%2!L=E,%NJ_'TF>2F3Z&HAZ#)/,\B?/10S#9GJ5$(H
M[BW36@PY.D96KJ<_[% BJU[2Y"D(5$]O^I3TE$?LJDO[H9%#5^)1>I-*3[MF
M/.R1?L!;I[0L1.-Q<<S=4VD^4)5(]"W>V#^^6DIZ&D;;*;4HE[#HN#-7OLOB
MAPAN_< $<R$C5HW-[D/FX:L@L^?FF?K%J&2L63G)\-W&FVU]3/$ *RH]*UKI
M%T5-V;24V$X?D_,GEV4'$5IJM, KB@55#KY(W2;],=EC6LP,/!8%,8K@J5"%
MK[OKE, A[<N5JJ.];< 5G]BHZ@Y(N1#4!<W[#HK)4V&*1\[/2N"S_$;:5K(]
MZZL7'WKF6AY19\ZU$NHVOLCRVMN-Z(VE;E0+1,0>@.='COT>;!',\\_.>/2J
MR7S15[KJ/ZG1@/O=2+TUE"OW<*;?R2NF:A> +O&S!5UWB)4MP<=;V8PZ!%5&
M>$B=*@VT[R@\&5C@(*A;6[)"];99QTOZW!=>!BP,N?9UM&^D50,$2)'+D^CB
M-\<3L@GVHAG9]D(IDZ:?OD6C&F/DB^BKQFV\].OH!EW%EI<&*F>;8WJV%A >
MKX^RG=6QC9TY>&9?B3_#H9:U+[8N'S.X\GF=/]C2'V9R'N7V8U9N+S<IS\_U
M2#N>R*F<H)>%TEY8UTMN984.27V+,ES^W2@5__4>Q2IPVP(M$[\P^F8/H*(V
M].S A6]>D$UWNC+(^TNE4.>NRW;@!J5A7P;JX%.)L,5,\9HS_--S]O9C.:-U
M4[$^![^*;#_*;I&\["P+;5&>;341WJ/<3$^)RR1^1&SW2>6;]$W#_'DUI<<:
M' ,G? !-0FG4#B;QH<KG>+5*O^#N0(>;)^ZOX&>AY]'4;&UU_M1HOE7.8P_=
M6?7(UN59_LF@9SRB?P@!%I3.AN0DS:S/@?W (-9,XZ6'"=_,&=AF^%Y2%]&G
M.&%RHI+/O4C^$=S7EI1B8!BP#UU27?;B X%'P++4KQ%DR#(\=32O$4"[ET"6
MZN[L%3/.YVM F@"S88U8;9A3MCM_CA+L6T+&G^]*?2#TP/9!$D@H?3Y\->DI
MX*Y\)0D@=)0G7<3_N^*<03NA;'<)VN]L<5IL/B)[+R$N#5,!YS6EV4L82A47
M0SJ4^DVPWR,/1NRTHMZB]/1(1AX(9 =G+_JS1]"-K4\-]51D.Z7'$YS&P2@%
M6!]XVH%URAR #;HG:_1/F;CY4ZA3H3A1PLO_U&,]M"86&C<63Y^!GYC0<R,>
MOR/WJM8MEMI^8:\KO0Q^S)#W9IO9Q#@] [1^P>V%*?))"DV5G71$S]DA%::P
MV/>I2T'7OG&3K>20_M)4I['Y-TGBP#:19BYY/*2=7(8.[(9(3#E@,;=S$(])
M#(T5>)*I!>[_]D!RIO!WH;=D==59;6MK6A5:]] XWDM0585/*XU@3?\ +R1,
MN@N020$L%!KKRHB-2'8W&1EUQ2O6UZ,X&0!:G*D)2MIX_'K;#0]8IV8VUS 1
MASD?%!>+G1Z$_]#,1!.S%K?%?=/,1OTC@(5_3A(&TNYSSKZVT7$]2)(1I+);
MO]@&?Y&-\39.JS9XU)3TC^!G)W8F=M6+J93&=D;0:U7;N#,*UR+I8)/GPC4"
M:04667[F$$R^[D/+?Q!GZ/=@.M-?!=].K14JAUW)"8YUYFD'K6IQ=1_M:G5+
M\:XL%1Z2:).6^*QQKJ$>SS>N$CB3@<^3Z=3S?L_22311Z6;,]!%\-!YO,?>.
M0^FK$?%T ^X._A[HUL7YP(22P!W]W1,ON%B^,GE511)Z^38PE,GE<3L7%<AC
MIV<?JD_/+MM4+Q5&);4HO>2$Q#@J,"B?+"=?5V 5R!A(PD6>S1^\7TN^JKM-
MORG]\-'T'\%-\N5?J[\'9UQW*K??A46KI,YKQ2Q<[8U/A&W;[=X,^S[GO/AQ
M74P[VG(?&$5;@WOGRERUD*.C/<O]R=E)E ;VX3:9!O^B>EA[FNJH83(Y^8DO
MC"W+_S<7\RC(R<^C[-P6QS!B\W,],Z_0V&_X4.TXJT';'2DJ'R-J:ESD+BDU
M/$\!W%BJ<L<;5>VE#YPF.$BM-2';,T%MRM[/I TW">6C1'+GW">NB00%)8[?
MY>V>S_E4R*C.Q44(V(63FP9.L(6],C8IK2%3E?(MTOX)'^NGP([1XT7&V"5C
MO^A#CUW] "?O1E7$[D$K<@+Y7/<%VYU?KL\.]%/J&E=R/6&E(+4.6?"(>Y2;
MM)+/)=B@@2Q;TZ2OO7Y$!8R4DZQ+8YDKM\ 2QQ!.R/*R&Y5]XT(+5=9WYG ^
M;/SZ=(8G!*=4'WL&B^9ZT%R?/IK0MJJAV3?K;2POV29"/T2+:;/^B9@2+\E5
MXY6^]XW-8;;L6/6KV[UJ_?>^!$^7V@T)>UB0'6[0OI5!TWEG%<F^;%/9('+D
M1EFJH<8$['YBXKSPE,41=?JL.BEDW=%Z4 [#NM_9[)@W6".SG# D:<FB!W?U
M0,6\P[GOI";_5$M$5&8'D..!S*HH$;")\01%%7Z:N8WTN^!@6" *IOM%FLY+
M^?&DX??.#^JO!X:W=06\27<)0"H1JP_0KL;/K*5#ZTWP%#'UQ("/4J\\RZP0
M?,(2QZ8SK!3^)C'V1<J/$7EA@5Q?\]Z$+>QU_.&6I_C;\*LU+79D@#/Z*L#X
M;)TTB"\OHQD+>#%0IA0\J/:4G+BG'!KTD>G53G)BZ(N?G?5/FT@HAJTJ&DSJ
M DL^H+ZT/MGEXB$VV3QOUS*Y)R1&O315K6TA @9;P%.UY:+:SZ+6 #/'EN2/
MVWL(,&P1R[2;;199:OH?O"QQWN:BP/(8>!RI27N5AM,/R]DI\!R/24L,R-\X
MYLC!,:];]Y'S&\;U? J@%ON6:GIEJ#W'FU'T,<W&[FX*MJ3C?HP%2OJ99_]3
M<ABMDZ1#=!Z%W.D5>C8EQNHX!D!N7HI<7>Z70 S*8SI"^B*:%9(.50/N7V4F
M#IDQ90C)OW&SH#?6DW>Z1VA&0B 8W!;\+,O_Y@&)O(JJ"K)QU>PLQM0\W@UT
M'Q?9(BZR7=;^3'*/O@'P*>,@-=%[DW&MTYC3+"E519F3\.>6]_I&^JFLEEZX
MV:?*]DGWX=)SNU(B/+'B/=_P.=DMD,&NS<*BF9Q]2,,\2]GP?$))=A*FT<%*
MQ8)M8XMA7+)XDRZ@\YB@,_.%\C*6\LE+A+.HKB[O6VD<3>(OSEQGXW1=T#N/
MS(]U^;3I4JL;(^T%C-\3 -FN 3T$78W1O^U0VPX\K5(OGVK.6%78##$0=; -
M1]NB*4UE%*=2M*DM_M NG:HAYOI:"L21<UL>O%3J (%^^2J?FM%%^F)9CR0H
M'X6Y5_#0]VW-*G^21T6!FDXY4<8UY#4,!\5LAD!ZZ$$_R^.<6)+[>0?<\Y3E
M*%JGE%+;(#"+%DY"O5/YUTC21.DQ:2[ML&2U,,"$%<2,$'E3=>(WT(X-L7NC
M&(E1-32M8OB"1JO#/HT>$\BQ=4ZS*V6A2-'A?:U+D4[I5N<_S0;:6["S#&38
M8'!YHY RQ L6AZ!G^4> TG6]/UTG\4(; +;L9JE ?B3/,G26'!"<A52L6I6@
M+<L*=*M^:)9^I O&^'7QFF3>!WE)7O5R(CQY#?\PW'NQ_^BFWHO<>6Y8!RE0
M%1'5?+MIO*9F]ON0L4;O#?IMA2&&'U7.7L'8>9&6#Y8R&1F>/8S*%8Z:P4C3
M%N]P/]<VNR+]1T!U-'\2O63E_'#7C+77<BD JL"<Z(*9'^-Y97@,.9%Y;Y9T
M4O0+__R[MU?0=[VU/Q]>O\2"31@4JC2-;^V(".X^'E-@76E]7U9=N@OB-^>C
M)98KD=F:(C"$1;,D#$(7*=U0YLAJM?(E[4A8F+YDLLV:"RB0AIJ!)=47W@O[
M"%UR;\;6KP[L?]9_5L10J4Y "X1;O7DRQV*I+X"*P6#!)R1,# -!FC]1B!;
M0'VYW(Z]'I4V74]L2JD..L9SERZ3]!G\@G (>(RTH,UQ2T\CO,Y:SO&B_TQ
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M1[@Q\H7X6%NSG4_\&*H7/M#7E 4O2]X'3.\N,K1T 49N K9JW=(7D^B4E22
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MS!^[PFH7FK]0;//?S;C?J6^"KQ0FGNPW>:@#*PW17@'Q@PL='&#(4@L<H/O
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ML4$VO:TGD1GQM_KD* ,'ZE&<86+\TH%&?%D$&=?ZH)K:JX\TA-4.K(O)0L7
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MIA_A*O9X()8C\\5>.4&!]-!?0D40._U69:U/Z3K^VL2PWP5[BDV:YNHC#6B
M>5LEAP-;W0E3=)CM+]?(SZ"1>RPNVI(ETT_7U=^NGCS?%\K[XG_88\L=9^[)
M4H8U^1))FO;R):TS*5X>K \Z#7GZ0D$Q$ZX_UG 0RW'[6"&(4V'2[:CWPQ7-
M\U,M\H*,Z[&A9)Q8LZUN119J&P?BM31]'2WKU09QDSAKCZ8 I$P95=YNW?F:
MP2V#0BC'/=:D\U%O VS5VM(J"$$B83!'5&"AIC?BZI;[D"5%/Y>CIW(#6!]M
M&;.!B4$[R6^#?FC?]83^RKB-OJT1N!:XW4F_C>XXU<[+GEV.-CFQN!Z;+_$W
MK+DQ )F8RMCOP]*BA(KG5=ELZL[S&P+3SO,)5BA;Y(5G_^>83?DH^ABJ\;LY
M.VE>_PXP\%5^%U:?-K-6<]6Q T1 06<W!DZ?#"I^V673=_,@>5AY3E*%3_LI
M,U@V:1/_O@M#07>+O/T\S&J3W::5W0@E:C]EGR+"(WE%(H4./0])7BEBHK)B
MWS7HNX/8?_.OR41!R23YX>:-X$6P%_(7_>7J%.@;?^A(%8^IH="H91=D<L"9
MQ[),[ZKJ>:_I^!QIFLYA$4]IGP-\EBR?H+LEKFGA^%VN?7#/'OG_(CXTT2,K
MM*WAPB=9=FIR5;\!_4*/=P3$_;I/\T!A0^21Z5HSG_E>JGQGA(0YY3GP3B:*
ME2O<9=O>8YV.DS]X]4/FTEH:@"XL\D/8K=C#<;J+8E$0%A8JOP+%1MU,]?;D
MU>W'9H0YSP&>39T5SP$ V#&\Q8>]/P9&]9=BLY)D0O=U=0(GS^U<[85']<D_
MXMYC-?YMNCX,J1$5/DG;_U\-'?EMYL' :?=B;#4RV>/(H@O?M;Q8\O;_&E>D
M_JF,7@[4,ON/RB>?='CMQWPZ27*0V<X-9IN56V/R>6C%_-=* X9HEG8+M]L5
MO_L?8=_E:E_W]-&'U0G*M?$SC98,U>$G>'NS%E:YB;BTXSJ!2]=_"A?T;6V6
M8SWGP),0ON_R13V/+;Q+:%7+/KND^XQ055X6O/@IIBV]%>LL-\Z_G<V9>Z):
M]W^+ @M,5L3 K?]_1*/_(_I_K(ZR.:W_7ZO_TZ&_W+C@@]7B_X=5?A02-%K(
MXV9.59UR2YBBW J^.W5)UQ_R/^HM]"[UC9*B?#M.BU.O_U5:7_=]XD9'S1Z%
M!HSW97#BR\1#U[2P40K-,PW>Z<G0'822.2V<FYIYT-X8V& [E2N\2IQ_JN%L
MB#EG**S_-D#\]DW"+KXT?=GN#!ZK\=2'7V:F%&LS=3M,U5&@I31(@V^4YW[T
M6#S^4?WZHOCQ^KG]HJ?P.N/5P*)O*>8A%^Q4XHJ3L>1Z>Q!9 8@6XUQ3?[,R
M7]]O)QPA-;.XY'+6JW%OQ[SQ3%.4I7IB1W,N_BG'9+T<-#CA!>;I@,1XL;81
M(9[]I5 >^CY^=,VMO:;?\WBVJ<N!1A;]W&#;7G3XAJH<?-VO*&X]B39+XY-"
M$)?ASO58ZYZ_!O#6$/]]I\_>C#, =)O7#B Z*3Y2[0YS/E)9U3#_E.(AE11%
M7,/E*,9]NZC#_2_TE/<&:KW<+!:C4"7'?]F9R],EI,/3E1A9B))-Y!Y]&+)7
M)N^=^I__38U6BJ6#9_#LE%W:'EL>?0[/"&Q<<F_9PD5"YM^*AQ\H6!4C%BE8
ME6T?:1GD,ZJ*V_%YT>;JW;P*51';)>I6>.&IK$<B:3C[*A[_8(LWK+*$NIU7
MW[T[>2'V2$R'JM48JV%8M-B:3?G,M*>CF!!/42RYXF+,^J5XN3M[[K+O?C@D
MP..O^I$G!85DK@X/2-&/Y+>94Z2(LFG:%,BF5L0"@3E\NO[!1(KDB\5K=LIO
MZJ?<T[B70DE,-SB+GK'?1;UGJG[ZP#6W/&-;%,XZ-G2_FY59GS_UT+^U:05X
M2Y67D8;:B'!M&",JP,71@S<?,M/ $ZX\-L53L=\9XJ:J?DX"[@ZY.9*<6N^L
M]+3>V_QYZ&&(7]R#:-;,T63YPZ>T1QX"*BO'Q.(X*8")P+"DZ>.G;_5O0UFH
MN!TZ9Z]39#F4K8A[;!"A'#K:D<9I)F[2[;'_S:/Y1C,W]9&:&#-S\Z.7SL9Z
MWQV2F$8>C#@\?ZY<D$=, R ?Z5LEQ!LJ:=<BNKDVJ1"P5Q7N;Y75-_Q4%]./
MF![FKRT4)M_\:&PO-LLZ>[-\Y:^=DR5]P,@WLGC]G04_I.^-W3YFK1202HL7
M<+!I@U/)S:$PNU9U?+7FK[%Z=X]5=2/8G)L,@GZKQ>\H=LE[,@N@JJ@R!QIO
MU691CB@)RQ=VKLG<8W7'SM%C@.B$$.%[+$%NCK"9ZQ1IMHR+I;#5WHVDJT6W
ML=@Y\K.K.UR]P7NLBO]4',+^6S/[72=++*!6 1,R^"GE'LORSDK797@X0LFT
MC5"3+GCJ?[3/V35=?NB&'<F'_>Y/&<_[\]\[>1P.3@T[DD78 +I%P51YV:!+
M0VQ<0J;Q!T(A&_E 6!7/L0E\%6\J8U.,*GDJ^K)\K1I*%I$\DU0FL;&FGA?8
MG%F7D?_SS!.L$::F%W9<B&LM]+>:VR=*]7](9O7*T*@5>_>%49SGGWH2G&6C
M>(Z*JK"FZ/HIV&9GDLK[H0S.1#AO$:9FF+E!$UA IP]J\:GRY>QS]"+ZY,>4
M^PD,W"IWQ/(I!1M14D))#IK#(?1VRF8[:520T]4R'; 0UB!^+[CFU(Y>13$[
M.<)=/^T>ZW.2Q%](@P12HKZ<$[K)"D]3XP[XH3I)7-9O93A%WY$[!Y3Z*EF(
MF"9C^Q95V@#DX9VEC$Q& ]0XMM(^Q,S56L$[VNW<';6H#3QG/K!2Z$Y%X>4K
M@GCUV!37"-F% GHJ*EZC!R!12# T</XW@:/QHNU4/9,?2:/)J-\[.%G=5R9E
MFJMR1UX#O#YG5P*I24;9M-2)KT-S*^2-TZ>C"U-\>B43$$$D'I&AAR,25MKC
M^JA!/<H9=U;TT DY<R7].G]K:B]4!+N2^<UAY??A3ZQ.#4EZK!6$)!(T(+5"
M:M.L;MS>Q?)[K #1"P'B=U"\]-3SM<%*%ZW";^@IRB&8GO0*P#69ZF 8(+&X
M1F6,8GJ57%0.R;G8C'<S0#'Q_]#^(?$B,\/O::/,W.#8E!/AX+?0[Y^X*JB6
MO[5V&.S-<2KO,[00N,EX1&_GJ/@<NDR/M/#F<V4USI9-9X6#U?:ZN+<A5)BH
M6:IADN&FBI!SDP\J+MVH\%Q-RD+G%?743*\8*L<A%EO=2."<NZM^%#C*9&3Z
M@%,==YSDZP+ R.55I9[N-M3>Z)GI!\-FTW"8F<L'#X^O<M;2XB4W6C :\57M
M=WQ81I%J@I!JG'>2XH+'+CH2L?W KM 7ZK&93@TM!<% R0@R <B\C*G:WTD=
M$Y<C!-#XV8M5#[&Y>J-*AIR,4',V;;NWUI##]-SSIF2$T_PYXT4$F4N+G\M9
M(PP,Q2LM36 /AKZP?(R&1/\K5PY_.=;/D&4Y#_LQPF6(T.'2>A\19*N<7D_J
MU9O,]UI<[AXKN+IW\B=XJ'2+/CWS"=MF!3<N[EJYR%!]A*ADH?58Q4^)+#J/
M"Q/C2WQ;50/DEQF_Y^!NIV+9-6-]W._:I7^G'O9B6_OWFK8[:J4"VY:6OETB
M7]UA-,2J;26X0DEFEE2] E1A;"S$%*#,M2"88<1__7?8U<)=Y]5?QT537A[4
M*:H0.,.<K")2B_'[MS7G-< (\9Z&\V"!)E8 WMR=Q0[T#EI#TH-9(TWBB7&
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M^LR\[F\)'V/Z%FIS_->D>],-9<:JI(8C[>LP$B%,PN+;U"B>P&^P4B9M7/I
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MSQN1;2!_1$_Y^>&7RGMY?W(\JU&E*F "5X#41.>'DE$<%+]+/!P'L ?EN1;
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MG7@9^M>>P<)10=K5V <R_]R#Q?F_3S;BUXWK!57EP9U(Z3-*H.7>AGAG@Q6
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MCC\C.Z8<UC=5$2ZCQ/OWV$?&][,7J,WPE56D9B[!;%0)-H&4>N;H2B"2D+-
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MB=QQ:!JPZDO_44D@Z4=3UB0.PLSG2GQ)4$$M] PAPLFXOLA:$2,?2=I4>;.
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M]C_:ML 0X!ZY.23W:KQU,A1XAZJTW(\0AK*&G6*#6E-,(&$U)M)]3,S.=.3
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MF04!P\&>+@.HH^7&/.WOL9+XY)PC UFVJD)M(\/+YD/6#TL4/857NKM [+V
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M9I8%DZU?PJLC4RA\92KL?6NQ)L_/XU9YV(<WP-#LVS" '1<.  \/#X> "(\
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M)DVH8+!O"MQ"*.6=Z?;>KT^8!URRBSGZS+BSIR5?I2Y^OM</6(1C]/>T)#Y
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M2%&!=<&#8M234TIY8GV&(P<)WF2_ ][1";\+;2,_Z-<CE_GWO/MA[L5DSRO
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MX9UCF@&Z])(GG&LB+E6S5YPWY<+HULT4,-N$IC!RJ8]\C))<.6)AJCA@US&
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M09Z(_P (_5]L <DG_!G2!2\2@^6<@Y+.KUD-"<&6]I88\@=8@P.T=)Q!3$V
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MG2L>1PQ<+]))\9RC/Z4LE4P,#N,)*"H]7#^>M]- @CUZP1!EX?P/XY&2+:4
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M"7%1: (F0 S0[O&$Q#K09@:3@(#9%-Z)\9,"0A#<\_"?&$01H0\"GPQG)YJ
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MX+>Q**D (,"'#(0JDDV;\]8QIZZGT/S,#(;3LCM0[C1EY.D(.^#7W4R3 V,
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M8)>9$KO^JZFAU%)1SN6G0%<*J.=PB/YBO_\ @U/7[>$]3J^LYM)L08A#;FC
M,*NC16X1"4J,&7 7"_5)7=UDU9B*@C$$1<0WAO.X\8$3QZ%LPLFZ][5K9;08
MQ7TP,!.'F$3IQ&MS(TVX(44!6$'8AI:@4]PR9'U":>A*I@5Q;8:2)!PJ-8B,
MD5WI1SM%&*Q:_7);FYD3HK Z"5%5T^@]*$9"&!)G89O8%C3&,&N_?)BH D4
M&71/2""@*PO);PR]F- &P%!9 ,Y)%,6H#1RFOQJL(=#+)BNS$2@PS@."0%N2
M\.IO28;Y: H7EV,F%)C+?H89I!T[T)!GQ6I!,JP;[&,<Z  Z72A".;_]D<!^
MB.0_YQ?^?=_%S&)2LFS!  @" - <?^$9'TC)NN>\I/M)@?H$)F)@&!(7('6
M_P#P]$LU343R</#_ )W,@+!ANA3A$A'!X=H*#_\ RU)DG_\ ")/I.29)DG>2
M=F29)DG>29)WDF29.29.29)DG>>3)/\ !8%ZQ!<XEJ*A/0U@"&)*U;+PAO5.
MW7>L^T))9.K8I":\*_K'D=Q!RZ.^+"0F%IV<_:<089SSG-:>W!\BGO.I/Z::
M=0Q6$RM1&)$_MDE+@R.N6]<1BC!YE$Q[8>!<-*1N1;&0IJ39@4=MAAS$3FU7
MS_6:#<\AZU],W$=RM"R$C3>.?PZ "9=M9"2$$5"*6(3'Q]()!7@#TUF^$@Q2
M.CNS=)#5X@4 !8T##R%TI$G33;],Y?8GUDW^V/)&,+2?U;Q2'HLI;P:&6,$N
M,(DD6 L],85*R/J"T.BH80IHC/82/N9>\XD!/!8[XQ_WV(%@1XC,!&"XWUC%
M0/C9:@+MQ<QIWE;9CFV)QD&<HJ <@'QDPC+(656@3DE6LQ?%C$8OY#KH"<4R
MM$T/2EBL*B2?JC"Y! 4FA*/LSG[T'L%?G'@V3_ \>K\)B2.%-*0< !8!'L;'
M_P"LZP(JZSC%2BV,$!M EFJ((MB,CD@TZ"J4>^ E(SWH> A-9KGU/I69%KB2
MED3XU6%$B!C22.$S6<^,<*&!&R0'GI( 5@"L5J1>VBL3C!:$)>*"<C@Q+D+#
M.A>I0TYI1<_11(3HE<,J;JL)M&&'!$B>EQI=K0W>/1O-&NI#%[AR-IGQR,XK
MWY:_.(GDRG73MC;),3";="3(3<5RCF,**!UU)2 J)()RS6D@$*XR*X(SO-!S
M+8,USK.?K]\_&4I.+WSF]\1A!Z]GG/D7XSIM;&71$U\N(K6H!ETI.T9"!!+S
MW) ]CF_"@;[7\'GEGVF*];,@</5*HF-Z)7+#=[0'"()5,@1Q;Y5-W+6.2!6)
M,D:LFF1E$@F^5YWB'&B&,DVX,<%ZD59IIH'<9.IE;FAIGGD/3+ 5B5RDD("O
M7."P"E]-8W@N:]\Y0N2YJ64]'1@,"?8#6V1IH8PWJ*U-CFN9&"S+6'9_TXB\
M!650D1 TA";NIR&@H\R([I[=/>-+C=]>WOQA8;V@0!O3K!XQ>J-]DO2C+;=<
M/1+0[K5PQBV[$P%%,SL5A"12U4EA1B+<5ZU9S!$S46S1CFE]-50<"PX.*"B-
MW0-MUAP/9>PQTT0$C+60^BLF5)UE2[\X^**L"3T4CJL0EE6A(RF9A)ZA'..K
M,S $1ZO5WB/1%H^2,6G3'QRV-POP62E6&09N4>N2&16)U()H5!AZL(-DI@G@
M*0^,I/1'W_WRL+0< S)9"X;7).4V0_HO'IF(D IE['9,?JNO_P!=$4[,)HZ\
M=5A"*DRO$L$*4JD<YOO)!X$(B=P3BA0<48 #YT!;D57*L%$(4T5<,VX&4G=R
M +,D(D)Q.-U33=B811H8S,3[4)JQ":=C49HW_*'M1])Q)7<9H>',JW3H(\QB
MU0\I,!;LCU. :IX JB@?A4Z.<B<R&_RL^9 O#BB0:=*9EV6 !C< 45/SP*U(
MX7\#:8TJQQ@8#<6-H?CG.9WJ/C!&KB^BI\3'KD'?AQ(6 >1,(QE2BM00FIY+
M)4ASI(#@" @(/G#4MG9N?,5A]?O'X<,"XHB9, [TY@BJ?*+/>8R2(;E'KE(M
M78B;':)XOVR40QS\L8[2&1RT()^%]8R$D8HL9F!I]?\ F',8?R<J@Z)$,=A)
MX<3GGC.)X :,AH^&<+9? I2@#E20T^MH)YP_FUTJB'(5<,9"XLHX.FL]%..G
M\2LRK_+F^7TD"50G<=PWEZ4PND87=RY";&(U1CJB)$ 709$ZX9/Q*(+O@0,(
MD3@=PEE&Y651]>"$D32 SA9<!P )P6K:AYZ:$%8M.QDLA(JFF)/IGX#8O]DX
M^@5\8!I6P=MG^!C=X&R;GL@E<^$28DL[92&Q8<D9$46L1"+N=0Y.3H*PT;(H
M245N\EZ@.%XR%F>48ZC"D#=RP5"_6EA! =!CQ&02L#,4IN1[QT&!DH'%PR:;
M>^'6-$PR4@'Q@*\@Q]A+@23-@NJ.%YPPRHWT=@1\X!CL7LL=9$QA:B&F26D=
M*=8$^(AM4G57!8$C4?='1\966Y'I_3CB=!^W!,%=Z2DLBU4<S.,@(^RB*=HP
M8Y&0]\G6AS_M,#_Z\@@VXB4 F9^D]8EH"DML2A;Y?&:F@9@N4CSY^S&(8;,"
MCT-/7-&W2))$Z,4#)J<\8J]3"*@11LC$>R$(F^08$\F&"ZP-<X %+@^,18(+
M- @,%0V:\9:$$D-[!\+CL3Q)&L0DA)+"1R4 $PAT@8),@5DZ$X,'@4YQY!1(
MM .(?3L&9,=^;W#.8H(@]$:PR$@*!Y*22$J!0&0CH%Y3' HC+)R$EZVYM"=I
M'WQ(("A8$G,2]D7BJ?6Z(X=9PMXZC\R?6HU63%/&M-2W)-?05'U^V?Q]/B4)
M.\8,O&)J0OW_ +QVZW1[:5&O^8[,@UB$W;OU-&3<(G<[M;#U'TCPTI>JSO'N
M;D,CAJ(=D5F^R7$+$#D#Y&/QU0LU62Y8N-7H=QDI@!+D1.LL^9M(;1_I@TO"
MQF;A;[:Q9\2 %*G4KGQB#<4R\$$C2S=:RK2X$.O:<4S6%-B"&^_UPA)@G-P*
MX6C :P8='1 OAS@[A&I!<!M9ZR D :&9K ]F""'7"M=QD#[(<,J\J/J\M3GI
MBOD"(*:B^Q2(2CE.$-]S)$I4:3IO^IQB97<(0NEK1]S-MWGY)IKU#DI8< 7^
MK"#G+Z'DHOC[L"#3J!BR*!*4!%9_''XSM+D3(N)SU/7> ]!P?8O5*!W'93$D
MY,!/"@X3/%<9+N\9,Y*Q%[&1::]H(2D<S,+YRY9F]!FELA7)]AR>D*=L@[ Q
M33H*TDX!"QSG.6SVA5LQ=6$Y.:-)F1/&!]V=D?CN1>/[BRVN?2K"ST3&0F@L
M1"R*ZD<_ Z1_^NQ7"BV@Z![J< B8JT[!6)NW.344-5K@=T7@\@I ("-X9T'6
M/K,[#9&A:0+YC-2]VK)&)WU<W"&R1;@[](N ^&TX:0E- 8=,FN*S(O%<;Q-D
MP0YJBG+@GA0E\C<,2/;6"7KNAT#IA:<9Z)G]B&PENU:R])@REP^GEMV8_P ,
M*=0^ :B156\;7TV"D'33@#QCI[+$PC4_Q3C 2.8M/Y8&UM;V6I1R3$/6"(XD
M"-!G'99:;:_XG^<<3/O"Z#4D[<BHH0>(5[8Z .5ML@VZ_P 2GVS^/HP6/!2^
M?%?]R4@?7 F;Q5USRB>PXKUS@+.V]"*>[.C!0>'&6ABLC6PSVG))V.4OEWQF
M91*(>(!CQE^16R@\JDN2:L[#]\0Z-U'>N.LVG^?T?&:+_"B[@$81@%K?^XN5
MEHXRP43X>+K0,76ME5\8AU#'JY WZ9:U\,#P"_?+BM#!RG!F-!2_7"NG^00"
M:TQK%VHX2.TAU+6HUE521>[#L[PMZ[D#^6,1ZDG<B@IQ-]Y, @Y#J1MSQ%3:
M\H%P&%M0-@YY39@$>R/I-DB6W/;<"=8\YHRHVF5B<H&0D9L[IDLW( D>0QRR
MB\D:?;AJ'BA#O^IDC>4GDFX@V82DH-%\2^[CW<3%+ O6+8X#+8^6L< ZIE"8
M@Q'&\B!"Y2C.E0AR4@G%[$-F(## \ 6#T3DW3.= A;((UD(C5/\ ]:<_ ?\
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M97>M@FJXLZPTV&(3Y">-\UA6X1:$8PS$P/?IEL'( *SGRGE>+5B2805AD/\
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M \_QPO/%^K/<&#(%6$UOI@^,&.OEM[Z%CAO*18BI]6!_XIJ3,UYG"*6%#8F
M5LG58:CJO/R^6\7#$>&C7F8 3# 63-9_!M@A!@GA54=VGYYP04RDS#9ONXTQ
M6W^8G[Y_I#'V";.,&B597_//LM"!XFLX)XN<GEY:Q!G9;[A0='5UBZ!MD$OL
MCSSFH$#.*4V%X:RG4F\4PKV7W8H"G%L6=KK(+2.Z"$.^,C)%"*GDO)X$2<9!
M6)RV[]Q[X&2T-5Y'ZZR^-2S0R,=PX08R^MT_@Z,1@7P#">*?$Y.;19<RX*'T
MXP@3X'L,+N<>1$6MO8T^$]K RCH(42023ZN34QL=[!!Y-9MPM6">)P,(CWE=
MWH&,P4Q]"C6:HQZ8PVV%+ZO'FM*I?&!DE9"LU=6HLL1\O%G6"[ +XUC8:L&%
MU+NF3QRCIWE&.'P*'(HE%P'IG$X*D[-H"C\=Y%*2X+!!5PZD+64=,:1ZQ%%>
MGG)EDX* "Z$E*S0R682HX#+I&#R\YYBO'3\C J"D(EXP2\TW^<+HCT0I.BU)
M]6*:VQ1 4V>U87C@Q)O1O F)G$*5?#0: "K</L0I2+)C3A%UFZ,F2+>I0] X
MQRL0#;*)! H!ZXQ?GWTN";X.:P^OZ3MC._C[X<G1M32G424[[QF*[E#*739Y
MF:#"IQ$:L&HR-:9$U)B-N#SG,S>QE#@*GTQ;;/9*&_YC@*I*YCW+B\0C9B$(
M/7QPD[?84Y,4C A2PO$;8))*=.$2D6=_!W0(<#CI,"T4_(T*?1Q$+BFQ*Y"-
M)/.)5$L0 7: 8 DG>5"O7DNR;0=,(1J8;%I9H)O"(P_$9E%+GO%D \VX@FH2
M,<<Y]A2JSYVTX'^CW&A+14DN"V$2MU"%SH"C6-&AOY+.@])88&%Q@5Y,O%-+
M4B'G% R,9-'U#6#)W@!QG>=;45]_%TBM!BUN6<2:N[BBZ#K(< *O)_&2&NN<
M#'I._/YP&+%KB"DDAJLJO*8L,,,?I_WP0SBE42='6,(5 (#5N3KW5BZKC)3L
MK ;%LOB\VI/L&&1*U]E$?;#(=_PP7A/@R^^&O3^&%YE'"$6.\4O/^$VB=Y5(
M3XD&&<4&>[)_UJG#E<<"9+8[VAR[J!7"7$3FO4&)%VIH=%I Y#>7"8K%0N Q
M0=;&LIC(1&FP#!U.>.QZQB?C5^"^F1DOT3YK.?P?N85#.D/?#@[*S0Z'?HRU
M%;FFJG(:B!S 2?>?; 1NL5 .RE ODPC89DF#547<M$F1[JJ/>^:=%>,@?0T8
MDA\_)HRO,!>:[7![$2,BE9+.&FFF=5HPZ2;D4CM=BP>2<[]]LV E Z0LO6)7
M<M('4Z%]8=&BU\;J!LTVW+D!3=H$PGX,%IT7C913NE)!LA/JO$D!350CQ* )
M\F(P<7"X$?D?.-!@H(=LIK)%Q07>F;O>.W^\ZDE5!B$@&(BF\@1":,XI7UM'
M>\J?MF/(BN:&9QDICL*8;+'6/Q&]?G-G3XU[9/\  1LX#X6<,!;@UQM1RY\Y
M?#"C<YU6LWDV;^UC^/IX5^VO\\@#26-)3W)>_P!7 &$N*('L& Q9=T59)"1(
M\,K'"(A,EW*)D<F3HQQ9 2"C.&$QL3 K\!2Q<5EF6AW+REPWWB)\3D +1#9!
MA;WE !-ZI&P<-8,%35F))P)MBM2N@<1P&+4H H66 KB[R?Q4W,QV]5S.\35U
MC0^5WZSA@3+/$0Z&$E)(K\Z9\XR/M9+S2_AYR:J&)\E !Z%D*\90*.;%0?"U
MC80?/.OPC 4*S0SHF7@. ;S9G]:#K)PTNV88$(>,DHH2/0#%#!H5D%-<+,2Z
M\N4!^M9L*0.(@ZK_  _6=.$C@31/>;UL0>[P >35R=\3?<,H$[:8J3G(L*8(
MI(;:3TF<D%D>IP F]Y93%7IB=S=[C-?H?G"0&=T\W]MZ_*9+/R*\_+#$9'+Q
M%K[8..)2F-KQO-1X/Y<U5Z;T-Y>()-VPYTE-+[1$5Z_1H0DH'=AO3#@'R#F,
M9'W29QFBBAW9W$Y'%1"0HLK+R3H)R--</9+1Z9.QE^AWA54Y?L85A->XT_C&
M.PLGJRD9/1YL$7P^<W#6KQD4J^+PH(>_SG(YR)L&>+\Y;\KE,Y/Y+DE)Q3OV
MQ?4'R?.21<? [8YY1]G]>V&V>6OMU.+S*CU.<U.OS..CT'XP5#S]LZ'&E/\
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M4FKI+\8TZCXQ&*[ C7+V1^<?H,CTD?Q]**<(QS[X-(AY*S?6 $K6 +N?$9Q
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M'-1OUQ%N.$E=A]\,V<8;=#'-F2",^7BAK?$XWE!U_)A%TS^]_P" 1&U'R9*
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M -6-H^B,/I'U/JXC[11<%!%/Y##45N_[K)8:X#+P7HZ29$388DTFT(!O 0*
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MPQAK@')')=)(JLG,TC,D(?DJAICC8XR: H'T:1+':X)*-+Z1F5(1@(\R=BH
ME= ,BW4NRPI%?J+3!B+E4.",1D;4RHX0/4R+4B7&9-(,'T,A!(20.MFF,;D/
MUG>$(&4U>,=Q(6\1J"S'H@REIQP\F$%KFRE5(#HX%M)+Y:9<]#B)X5@8D:4P
MB9^34J&%'X&1<G;;.S6([D=$(QT%'/(438! JL;),4 5,$=F'%@$(FT;$K*#
M \IBMF<D7<%6WR\B'J&_4>Z"%3NH&SE-47A$7QQFZ.Q8=EP_$RXLN+]"K/+M
M!0P1J0*+T99ML9$XO/[=H]Z#UI!G#<,X([A,8UA5//,UE5#L=&</_P" 2?\
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M  JAD-QD?K4/\((8JTL('J=QU[9L\X.01V0!?7OZA'ZD>3_&JA_G55 R/_\
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M?Q_SF/\ @,?\!A']#!S?$_K*P_H+]EYZC :GHEG(#UP/Z3*%%35GVONPN')
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MIX=S$]'%3&-LVW]B8URX;R!R ="ZJPR7?>J(Z?0DXCP2;L44FVW"5Q(##0'
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M8?#J7<RS_.R$!(X,+-7[#G-V#6#8&F*R\-WO"GM#DNY(Y4)F(UF0J4P#1LR
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M<I&0F0^64N0UD?9"HXI0%U]L;QAD(HJ QRE=%QH8%)<^'6,4CE'$.3[G_P"
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M^&6P#!<*-H9'*A@C_",>U-A.C-1#E3W+#+HTL+ 26!&AT0<G(28&1!EE3+V
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M?2<,"GL<>,[I84!16=6.=N"\,D,N,+OX JS1Z.03JG_!CH0]LXS(/\)9\.2
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M-H/\C\$XD>P6?4EQTJ6P0_8YRH<K_K)]S>#+VQ^3^&*\]]['HP;P?HIS:_\
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M _1ABS4>W\#$R?,>!X<DQT7]%Y$/0?XS3)B\EGEACU?H'U&O_@/C@LW33GJ
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MKG%#ID"/K[EG>:Q0)=8*#6NGMC;>]?0^L_\ P6Y3]^/]SZB^;XL+'C'?)_\
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M#>LD>ME-11Z<G^19[7=O1%?$@YW$.6WEXE#'RI%B&7MH],X,HUU!'PZ>)"$
M/%.$69@=HL<RSM7BA:9R<PB2=CDX2 )'(<=?AO,W#[N*H;98PN=VO_SD_;GS
M95P$*E.NZQ(NZ]0-]Z0_BI5V6CDB8/1XCQ)+XH+K\/A]Q(\6;V"+5BV/J4J=
MH($U\T!9.((J<U)()4BNE>/63A8YT?RM7KUJ/S&O4CLU;"LT:'7L9ATZ4744
MC!LX^]CZ5_S7IC%:1[44!QM135Z4HY?B&U<V3^\UU_WH^E:?I17.^*,8>L$
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M\&M _.)@!8A:,&#CU*,,YH!<'-7=Q+%*B0A6JVXES95C,)4_<L^"LEZM^\C
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M4<::')/H:#0^F:,%JTZ7#(G>%B#G2M/ 8\*<4S(I /7P;5A-O=])7#8PH4*
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MG1Z51_;V<%,:'8?,5[Q"F\O@^Q,Z#'<@CHB% ']*.G_^?]/C\R01VHVEH_\
M[O2WFC9_M7<P#C>F[:-;]T6LW^-27"<'&=@#B"?ZK9QC8";8TW#.2B^^[*3_
M "#EU1/R=G5VD"*0;-MGR:VQ;_X0?S.W06W'#[3(LQ'W?]FTDMSW0!:3>RQ;
M:LIRMG=ROBU=OM 6N!W"6C5%"NCLK.-K;(!O:1-<BXPKS7#==?8/CA-@-^L[
M=%FQC -O1L:P._%#9&PF<0(O%PW7FV33Q$60[216""UC!N@ZQ_$Z+-L_9;'_
M "V#!FWL\=G67_7L_P#4ON/:[P/L#&2 ONVC3X%<5M*W$%':MR&*X^SN(6^B
MW'_<6**:+Q-[8FP;UG8.>T@X&0H)NVNH^GW2OQ+BMI="^ZZ?8Z8$?B+WAQ[(
MJKS=F%5<)]*: X?I4)EH9WF!4HX  5/BB[/*JNB>S-%KGD/^N&U#1QR4_P R
MG5=D%3P5IB!GEY*TI#L:Y(M!1H4RS$!N$C-&RU-IO#/?"#073B"9B5 YJGO^
MGR@[%%;.Q-&6<>:?=B>L6AP,<\#N36X@"8&W-,K9MO%MZM7$87>(0R:9D[!S
M3=O77V03X4'>IQ-?0>*!TE[OU%0#(B.8\Y1LGBU&R'4Y0KG^2=#ID>JA.=.4
M]ZLG!T&[7O4F_AK"EW-$0&T5I@W8#ER44XIT4Y)FU-,]B B0MZ#[SMX3& 6@
M/5=^RO,+KOUKO/XJFBJ.C?\ 393G=RB 4['N5P"=X5FW6B;P/A"@@DS>(*^.
M[9IK/"J$.:74Z2OU5>]-+B2'@7A!)@TP3+,TI@0ZM=FU'5;O+C'Q4<4QH![<
M?B5=\E.WW(C13OA$98:.&GGHC8?71M7/U7/U7[+"4]LD0%:7NM]V[LX_3-N.
MC?H.2NQI T7J]Z+@VE19F8GQA3I+'_R[02W%TAI+2#VCDGL(;.9U\#SPS318
M6CFQ+FNM'D-U=EYH&Z\VM:0&N:#0%C@T\%=\M &S1 IM.2MK(6H K$@1[T#=
M+VB@(%X]QA3U7,J= V:-^C]E.F3HZ,$[.Q#I?\/F" >W0,; ?*&FTX7-NY;U
MST4D"R>X##ZP8=NU9GH7W1O<[HX WRHZUC9NMJ'[C1)\D[JO+2QW-AJ/FH5I
M:VVNZ\;2MHYU'%UW/[*P,*]SP7#S6[@/;F16?'R4Z0;5N7_$=E<>>Q"]G&!^
M,4/DK;(%D.NDO(;+7&L$2V(@K6(+NL1?Q=O.>]1Y#UT-9B/'!<-BN)EF )R5
MXNF*R8GC@K,85FO'*FGAXK@AH&2^T&B>V-$Z+N1R46G^/L%--8SVJ$XU#'AA
MYR?!-#;EYP=J[ 1H>X:]T7I)VX[%=;'F@>W]D?',(V)JZ "2RS(@FS/V(QQ5
M;K+1FL9,EKG/)C<6T.Y$68#_ )/:@'6=UAE420,:&81LR^];QTNLZ1+=D8'-
M0M^D6<NDQ26]Z(Q%=A]D/<ZXYN&L>K&WP4\_8&)*X4[4<QNT.'5)U<MI"RF:
M_P!T*)CHQAMF%F=(M+3.O^T!PX=H5ZV$AUV-?+EX)]F#<<X-=9AIKK.(!-ZH
M5F',M&VAO20Z#F0=QX(32# _EL$[/J0B?-%O;U47"3P<\]]YK?RHM:@/%1/-
M&[7AI=18]51DI3(F;1K3RDU0QY:*Z+HPY*;3_'V3P6SV!4<1@K7Y&?E3K0N=
M#0'VC"+K0:39D&2 **U=:LN-DL_ENNDC").U727#F/4*6V;7RP?SK@@$NLC#
M<9E]S:G-;+FN9<=A!LRS5I]:Y=)V$T6JX],ZT:,"\_RP;VO=E@C4BN*_A+%N
MI-W5;E-8PQT72 :)XT9D8D*/=M]ECG"6AA%T.-S%WV8RQ1K&K/:*:(R=";SK
MLW\E,78@FH4U+G-KXILGM6(3<T&VGZ4]C6D;&Q[DRTC2VT.7U7/4!S 6BZ7V
MN,9:I;WIK60VZ!3H9N\SN3VDN ;7ZN=,$7=:$P-/%8*8[$T)]Q!SHSS1=3LE
M"._13>KN*C0[&X8.:.,X\S-=%53R0:*WO<IM/+V'ON:N6]$C4OB/#VK;Y"[Y
M$)LS:'7M[2VRG5UXCR3OEGRE]G9.LW BQM'!S*4CWH,M^E_@;.V?9N?_ "W#
MI.B>+G5ZS@157.G8ZS-M\L-IBZ/Y;J/F,Z&D(65D2UX(??N-D/SQZPQR5L&%
MWRPMM+1S7BA:&DW6WP[NPP0^365YHH Z!@,JH :&&'?'/Y@&75S[$-B<-F!3
M!0Y$?NKQ!BMH"*]3,;T']5QNG?J<$S$[)3ZZ+PF<(S*NS3[P\DVZT . <7@=
M6)F<XQCBNF\AI.8_$596S#:D"EQNM&66Y6]T60# :ML[M6SA.:L!KB[= =2<
MT3J37BH /FL6GL52.+A'FC7MP0(/(0I='&:*]((1C1.:A1[-53]00:U3:8?E
M]CP0R]IO5O";O!! &0'$"'B#,&J#9EFH8_+&.C*5A\W:ZHU:W\JJ\(#N*FS9
M_P"GV4-B(U[2AFI&!$@'<C)><C$1WE!C3 .ZL[90<7<_V3Q%<$,(R&Q&D[-Z
M>#49X*[$G8FF\(.#A%>*>9+MITN.7_4B>$\D2TP?PX\T+1U\O-UMV!>RFHP1
MOD6CIETP<\8PG.)5?TZ,M4E-B0<E#>Y 0C:-BO;[$GBA10H]BOBJ?J"HOYGE
M[,P(7 (-)K&S*B;4<--K\EM;:WZI>Z)C&7-RZN^5('JKK1RE=$V/Z L3RTG#
MAI<X@3N]N9&Z%XH' _&'%,JUS=4SLX(:D@S &_WK,FO>LENP]$<9WII1&U?R
MM=K;Q'\R'4X8[JE!G6F9YZ;KJG  6@PF@X]ZNV=Y_C\ \UTL:T=2H=0Y79_=
M:T-PR$F,@2"0,I4>6AK8G;5.(P5T:#[&5W]PM_[K:H]BOZBKP[+P1#8Y)Q?_
M (^SL7)<0HW:6M+6VA Z0-.+0[K1NF$Y$32LCP3O#T66@H8:-Z"*WU]HN"8
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M"Z&W[VA-^4W>5QE53PT$A6>O_36.!S5JUMHP$!PBZV=];RM+*\YN5ZS9(/\
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M(G.:W=J_KK/:CSC_ *;V-_2:VM_2:QY9'UK>H[L*$<K#(C<@V\Z_-#*HV/\
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MN8[BYT"W^'UB$7"1B#2[G2("=KPQ/XVOS>ZU/M)$6XU+.EO \KAFI93(BO\
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MC(IH)%T9M=7 9^U5U=E<.6B>\+>511\EQ\MWI8PO\M8>:&U3!>-XAK0!C)=
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M>2X#W+BCN&CZ)A01(M7 UWRAF>DVI/;>33(%K:O<)VU/S@_*0'<B8![2C[3
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M28Y-9/BJHRH\C,;=RW^7!==;5T-Q/+/1S5T/GJ+6+II,W<$,4-H!\4PRTM:
M1V:!31O\KH]K8FT#O,NN.M 3+!S>D=1+=?U3J@4V]Z(+^E&30Y-V9]RZ.UGP
M:S=4MM7/$N#?H-&S/<CTRU$Q%&O(8 /1NX47I_2._:)5@\VEED0779/\K1P
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MVPOJCW+ZH]RS+&@3V!'T2)\5]4>Y</R7#\D!%ST8V<%]4>Y?4'N7U1[D3,-
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M>(AC6XYX>0#Y/ZW^61&D- KNX+>C$T&7%6=F&#VNV25P^;G!3'B/%I[%3O\
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M+@2';-FL; 6> C=>1DG2I%,7#2,H=W"'4EUK.KRBMD".!C,TPP-QB09$AG%
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M:?3$S22>%G(E]2QD";T-(4X*TB$R8-R2CKIQR12W(3$48LO"5.R\6254/Q!
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M?0RM (HH/8;=D8P>+V>83EOT<XF+%;G3A%/4XP0>A_Y#P([(>F57QYK(ON[
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ML.SWJ^^*&P!OV?6<"E9[O]<"1GV*86&OY?DD>IDHB-ZT(Y!!/IXQ5I&Z4O>
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M@L=(E>""$R63FZX0M"!UH!-QB)#G2"D$7D&@LQ1@1! A+'V5B/7&$ EA*:Y
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M._N1,)HSMP*@-?B9->()&<^6,Z5R=G(>N<.*!#\A<G2<LR\M>_[\X-,%W%=
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MD@6?<<XEP9<*P4!,E<XC#Y,A1L^<[W+[9S<(ZTGKA]/!LE&0V>-1D)!DXS5
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M4GUYR/%1-W*LD\RD'!0L09;'R1;\5HHPD@*ZM':.< 1?PD'=U#NC4X@Q&F
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MC);F"?>4 @)XQUT*S0YA'/6&MP(!FD20=NMY!"I)T2GES[N3$J4=1([&L'4
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M@UQ-OK],!)PO/EQN-OB_MFS@GS]?_.1KS_65#G/ VF5<(^[^9J/_ &<1[/\
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MO-U'A<04O E@*%4OIC4Y@Y2<S5"836AAG[]BC62 ['E*K*'\HZJA!4%TJTH
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MUY! )SRXJVU#&(MI)04)&4GOH_5! \:P,XV5B8D68+:4:Y80KH)D .K,9DF
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MR[F4H1;.0*-)4$U#)AU>T-_7I:D?&\^*<+HG#&8EYRR5]#&0+AEEGVF13 5
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MXG!#_P Y0*DY5LC/K04F6_4$\YZJ?6]:7O..(4187<@H1$DF(N"MH$#PB/\
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M>B'!>W<@_&0Q#]0^XG#CTMO]\(@UJ_8EC4T[Y/I^ABF]RGC(\6-3.,E&P$8
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M0"E?7"QH;!+*YDTI#?=8*H54B?+CE\CILP&N7C')S%A>(JA(D-W\X.U8@B!
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MN,8VW-5JT 0?VD*JI)$2';-W*2H$SJ./Y83J>[:R4T'MT^80FJ\--" 1E_\
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MI,R%N_94.NH)CX"PS:G KR./ /R&T\*M@,YNS[1V]7GY],*[68'SH27&8,;
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MCEA_.V8S.6TX7)]3QX)6?R$MHD4^M9LR8)O+^T^$$I!B(,U.(M>G&L<P.>B
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M*7%JWT=BRVV!B*WL/M/W8-,7++/-YJ3=O$T75L*-0P2J82*/ #@O0K?X*(F
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M;;!8?P1T;&_>%\ZZO\'F2.*ZE%OV3:+EZ1 V<#+GZ_DQ.FV%]I#M_2NBD?H
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M;.E4_)@V"TY007_BB^=($(<C)S:/:Z:%#)WYAN'-* Y!^&=ZT0F>PI.$9)8
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MU?/ZA#YSU$SA#+#[@]\\7<J9:/F/OZWSF0&L'1_OO0.?-Y5Z"95XY]7FTY3
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MY?M1))YK*^L8DOY?:JG\_*M0[Z6,05=B"T047G[?63*Z8CJ.9C?KTY:N)VZ
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MTUI-!L+^--[W?2)!PHQ_,ZX\R,IBPZ&G]$K@?K,7*CHGFPAC.P7C% $B.:<
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M]%*J9<DR\*&.1EU=:1_DWI"QC+M9A[GWQMSTY])VLHT$)3)X<7!O]&.>A&-
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M$1O?^5\ *D#5OXR\9X"S#0\?PRSMR71NL3U8>PB=%1*O5SE)%R&!I7#>O?&
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M(-NU\JQFPIP:;S[CG*]/(BI>3^S#!/[1Z/[WD+GP-!-?C& Y&C5:>V,=" ?
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M7I'*Q:W>"3)%5)O,F,?<MRLKF"MN6&V@;RRK?UK)DI"BIK!2Y'23=!LA8N=
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MF.<B C7K SS#JI/?.QG@.ZUZXHW<$GV([Y(((.II]3%C>61G3SD8F3+LUK&
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MQ;ERN!)*)BY+#2TE)1X_K(J$G+M? 0.SF.DL/R0O^$R'UJW.^:2;FB HMT3
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MD3N)QLB>B7&S,_60)E/2><J-+A>5 Z#F5LYAB=KV/@HC_7;%*R OZVW^]U>
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M_'/'%^MC%!SYF ,\O$FJ<$4> *?'P:*_.)FE(&O:ARU^;!?@>S)-C=8WJ_L
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M,MU0N!LH*P<EP?>RIM/!=BV]05W:^+;BAW1Y$ZCH>3N1;EE/^;)T@^0D]9^
M(2EJ5>KK7!-R^@#7I"&Y&I"+G,GFY1JML-8+A)@X\7'02D3K;V->A0BZ3"[,
MJZ  *G#H!>A"<OYAH33ZP8Z%J\=??S6W:L1![PX42'B.D'2_2ECG?-XDF#VD
M>_SE7_H\5G +D<4[S#J,SDM+?DJ0QVC!G78@H%=S^@1\6:!-J:&/7D^KT %0
ML^W6'R2D]27,.M.XC"5!%Q\KE<:9!XE5D"^0U(@=J&*CR<(&7DGT*0(9H,Z&
MQ5B]D]XUZ?UT+2D'?XZ5<QP_@WN32+!'2I!P55,!XZH#5KCCK>Q:5MB9VMQ
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MOE45>T?,S/DKDG(5YZL/>,6MBZ.#-OOJN9@A5?4D"DPC.U@.N'RESL8 9E!
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MS052%EZ8A7S-TO1EHJJ8,3T4K'_P,'7^G)D9\95@IT[C,14V+AXS:2!NL?V
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M".-YOVC_ WC_3(6J2OIPI2+::5?U@5RZR0J3-YZ]0N(F,,-^=[U2X4PK,.X
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M[DK-G]TX"#'E#!]1QM) #S1([0R,D;<9K@1?M];_4AAT)([(':]FUJ"!D_N
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M)".N%8QF]%W))]6ZX9Q BG:-I'C:^"S]6'HC46Q%#(.C4*W$8T0#^&\Y![0
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M:7A7XZT?0S?TO_3CP4:C&>IESN?AHK(D6\@#8!HK!.ZI$X?7+_-2_'F+R(/
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M$AU17*2C&CQ6Y?42(A6"G$#7KC79W( GB*4)($MXQ3(%74 U!1S2L+(0*Z+
M0UM*,G'QEI%R3&'T(180.10$215V4#'(WB_0(]%"5 8=O15>(*%;36I%LA$9
MBH( MM<G[A&>KVD7!T%8*?EP*@#R*<!N>B DE65#FQ1#NBJB 4SPR_M%UM26
M@N.I)PA'V,6A!DE"(B@<P. 5O,A16Q#05B-(G22AI5Y+*CQ-8^BKT)8($5PX
M^G<8'S(D 4"*3@4K [^P<4HD H!\:?A03.E,:> Z;8)EHJ:;NANUL2\\]I2(
MU$^32PY%]T34 O"S*.4+&J*#=8.0XF@KF C0%A.NX1 WB?& U;636<U01FA1
M3E'<,5[%%A#D 3B?<^G1.+6$([PC7?9'3/MW>]_NMU*#]#@PE'W/[\:\H+29
M\H><_/V -,O4]"PU:*.@P9!+H&,F1QB:XA*GN9V3XJ36A,%"JZM(J$2@!IDW
MB\H!20@PR&8V&=<L5HU'Z@('[$9Q<)AHB1E*=DZ!.^9H3V?--H/?A/9Q%"0
M:$27JQ*=E.KPUL2DR K89[S+!Y[1PG@$5P "  ,I0A H*=[",O2>H;A#"@50
M%"%,5#K9UG N \2 :8Y!8==XS(5Z[[X: BG0/W.0L>+'0H*J !JDV<?*WG2I
M5#I)GD)S3(V+13Q1-S'B#6,8ZFQ8>HA-+Q6WR#WPV8UZ(B@XXG=GN"CZ&7P]
M<IW8BL0*@45(1$C@H YCHJBI5-BX!$,0MZ<#=4ED3HV>:- 1R&'2BIHWA<[[
MZSR](QEV#PJHX2DZ2[\3?/!%A!/$E!.LU\@LJV66KI6#20(715&*B3&%@0@
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MDZJK5GT9=(*A;!%$ADWFHEL:$%8 ;A:>?H@C A'<D$5$CW=)0 G6U3L+RU!
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MS^.H":+$H$+B'!H0MOR"31"V)3L5]%OVWA6ZX(A4\!+B,Z3C[[I!$#>T4KS
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MAV@@7&]'7&J>0)O+B-V)!:X%.FA%@E0P@4)<*$<>WSZG%[ :J>9\C;TQ$!0
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MJ-Y3GNA"N*ZL [*%23=<) $10%T68^VT<,#0\";:\@)V3ATUK0JW81 3+P*
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MX< HX8)!NHN*MQ\<T @">D"U0 SP/)F^;U]4/O\ YX*A_P!_O_/KQ #8:5"
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M--!AXV.O@!1A'F=7ZVY  94J>PU17N:IUF!'B0W;@BJD@V&] ][^OA.9X8=
M@/D&5!H0!@M1*%',A,"I'99*A(%0 W:K"#0"F!I5\QJ%* !$@1*C3CBKW'(&
MB,1A"GCB.8("R@U93H&"''H#(V%!?M=P\%45]U=:&$25 2!!Y3=S(\3$.2L!
MYHT'0%6H#H!I<1=?C=2HK6[6T3OYH#ZU5FY24. ,9PM?@\ 2>$PBB(#"$+11
MQP71(!Q!= B1D#@&2!X($\A1T. SYCU>NS/OQ-B'$4;0RB]EVGEY*P06"V#
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M7GW<'84]*L#PSV#2_C"E>HI,Q=G& (V/=)4\C<\'KIX&\ S;5<^(4=ONZKQ
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M.CU%1WCL\@":"-4N;+9]9_!'Q*)VY6I$\8]C3'2"BQ.HL(6TPB07S#8IV("
MH!&P1>0:P*59PR!,".+5;2T[T0XR[OX23KX@^H(#/&^WE1$ !P %?#&@8WH
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MX>+(JVB!1DT6&[O!0%%(F ""P8!2='HX$.$ *&D-FUN%\YP\7EJ5664+M(Z
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M4H\_R2X5T?<XT'7B&EIO&0R+E')^\/H !\7RTWR$*8((07JY<T]U:*A_BJ#
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M[EXF3AS X#R #Q?WO]T*,55#DW]D;SP;8)D4\+:0!7_Y6FWPGYO^^"%6$O\
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M-"AUP#&JJP"I4 L6(T=S[T7(=@P?:($X0I[PP!R9US'FTMB ] &,4&.@Y_\
MJ]'Z/[<1*L6OOMEI!9U5ZZ>+:,V#4$^+%8)@D 3B0B1HR2A1JW_T!F; ,$31
M53BYKBC_  K/ &$)P%VJ%84;* $WM'JG/2@)0Q*"UZZ;5^O#2#FZPF4@3 7@
MM%=VO/+()B&H1KG=SB1M]T$!=;+<")SJ2>?-*#_R!@*IN#8]O,FN',YA1'GG
MNCYG<.J"I*1"L!;$PE0L"0AJH )P(.L9X';5I(+ !,$<VNA8H&G$.:#K?:[$
MHAA\MX XQ4H,6L4/+L\7RN>LO?J*019]H%XD14-5Z,AT5W9?@WNM  $U500"
MLOEUQ%'14 SUP),A2N1!&#'1.6*M<.;!R$KXD'  !XNN:1XR028(($XJT,[9
M//7YC](]/]24B(M+Y?\ '.MA$=@"#;*DTU+O"?&N-W#%@ 0JM@Q0!58Q*V(/
M?#S<QT#=RN6D.@[&<>8T4ZR,%H.,*G-@<R%X\HRG0$,">I36G+CW/]6/X_[_
M.(OC6 <'QW;,8V\.H>,X]CJVA%"R,T*$.CAT[+W'TU[9*TIE)WN3RE9"A;15
MG]?[=OO^!=\?KQ^N7Z_;_7Z5G.A0:1Z5?L(/.!9N/36<Y<&=03)7J_GX"RB7
MU.5)IY1NCFX#R)K>OF72GD:SDX O("R-^\Z6$"*VKC"O8D4=)HN><HF9F&R7
M-YK:!#9F8FBHOFG/^#U4?:2\ N$YQNS"AQP(71RH%1^GU_&0HZ9BS)+'MS3=
M%B(;%M1VKP'U)C.M*HJ_G_+$6Y5I&W _\M9#J= N3MD"=-GIH?7A7DPT;IRY
M.;+2AAOZZAK/$,-)'Y NZNDX\!'?-#'#J5?GG@K;S(TBI?B)6_)N<,%9#*;Z
M_GC\3TD2@+-I\N[1=M,#WL"1I)?+LR9LAF45^'I[K"]W"4W[NTD_?+EE<)8!
M][=\\!L%8@P)?R@Z%YC/KT/E&OG$YGX2\B; ?0)Z<&IA_F'D@-6NVFR W0;F
M.>=LR)GE+.5B%UFVNF=0N_6"OBW8,!9$(Y;W?5SW8G(K-VM87M!?4NBZ]BHW
M:.@57N0U<<X-0M_0D5Q.F1-3_\G@HG*85YUY%U@FLLDR"UZGS-J$N[6M4 *\
MGF]L$NED%@N=^N^P'1DF\12KK'R'_9Z,^L[T_(]+^OR?OJYR.%^CP/WW95I_
M%/,ZN)/!169Q];YF]]V+'O8PI##7E"B$C^-$/CHX,ICL<VN=#?%_!VM8 JVZ
M=8*/(%65Z2.R>DG?D=)>$BU,;A+9M7W2AJ!#2K3%I[)>0AT3V)_*]X!,QQ=K
M:ICB3VH1 ^M\\HR!^AS>,*Z7KMQR4=;+@+#XRS?;^59(*1M=#PYR$:K:JD0;
MUK'<]8;,E5<SY4$2A]G$IB>J<X=H47E)5 N#(K@^3Z=9;HFG0_V0\ ;9@\D&
M$"&3);[])PJ;XBQ!4U707\U_(%K2/& _\1A<L()S/D&,HWI("K*9FO<.6Z.I
M00+#F6!P,1A?/U U>?_27Z7?&DJ/;)#Z^*;E'(^M#5VA5]8<I@PE./D)U"DC
MO(_U/SV8$MS(U4=([A8OU+GX"JO@C8JW?="WE@LHMXP<'VG6@4>>E"IOF;$8
M/8BFI%B1^N;SM%"'NSQ J3<C*&'F<N'H.&YU'IIU6?FV__4'EH6MV,??07_L
MTH<I0U*RK$)5YX@A6_3YK9B L28 U&]VF&#T@Y:::<G4=+F RBU!<NM3-RQ%
M<><\,*X'M@Y&C15(.T@]A$@R!VZ21<(++"/U?OMW/]'(&AO(?VG1WUZQ8VKG
M",XXSYX@(S3RTY)R?>A"]\JPC,#KGH]K/OC>JP-E(YV52,<[Z<T^F=0!W1/^
MY=W1FG*5^4!\LT>^N@2K':+Q+HKB%?(TU.K/GC'P3H,Q+;4A6#Q2DKHS<VEW
MH(+ATNW.5P)SE#,B:\SD&QTD)@\DH&G*R(81#4]I>R7KWYNA;M(,[\^,"OAC
M$.QE7R+(E'F4[],LJ GBUZK\+":U;RCQUR)5XJUPEWG2]5ZH0_,"WS5S6AY3
MURK%'T9)&^J;6Z\=$:S8JE&Y6!@Y/](\'O[3"2*?,T>JEI0XFI]CX5DB7+H:
M%<A%GHD7C92V:F7IZ)$88'\;4!BNO(5/@,S9<"L(:1&;? S!0\CN-M9,K4<3
M5)>R_ON_G@I4_0[2V?CR<'LVO?7GUFJH^M :%54? Q519F>W8_12K&G^GPGD
MR0(--'G\(Q14@S)<+2]8ZE?!2UKD9 J/"J/%$^P.Z2W8;Z/'W BP)KG*LX@?
MM%L.W7]]H9#F65F;?'F*SN>Q(<G$B<:$13"A&C&GV7AL\! L/V'42O>@RZ/8
MUT_P:3<=Y^OL7)]I/LNA-5,=;*0H%1&2-;[^8;DH6<C:\JR^JYHK3;6'AO\B
MD\4$?_WENEW6X1<FJAD2%_^I]XKGM9$89&2FJ=TH([=HGRZ;(&CMX4>B($*A
MV+U)_?T@NA)?F'1PO]3?:(*W+E1;D,@DW6L6LZ?R73Q_\N/?^VWK)!0)87A.
MN)"^"*X2]1YA0QE?HA*>O+#&)ARDS35?>;LGH3P ]Q-%@ ?L@@=M.GJ\"<H&
M1@_]5 <K)7XD\PM28J8,I^6%PN1$&[E#Q0&F^)<QHF<IH!YF(RHX!^,0)/O5
M6/*\!XL)07\:2R 8E!F%FV3<97&SYQW5AC"$<['56&58F"O$X%U[D8W2^#2F
MZ.;0])1:5IGPA"OMZL;6R3KS-A_4/$3R&,->;KO6XV$.*?ZB&9);BY=Q#+9!
M,!=\_^QLXF0&)@./M'^;(XA$[')X:(HAV6@<>O7%*TQ0TUK9!]RS$H1,GQ<D
M4_W"#$SL]U.I+55O360;GUYJQ(\5?(]-&Y:7R#"*$G>;"J,9&!CA1ICAJZA5
MRLU"&AXQMMEIG_B]X3JB8G=I!'K'<62;VX\R_!%D J&^:WOLAGT%.R!<?I*<
M!RSI+ZG2&Z' 0V!C:-,P8@;T+CS;\*Z5;.E/KRDVDX=VU1KA8F8?.'H."((L
M<[9&8X.6^*&/]"-X60L3:P+>64JY1RDX9B\Y>=!_[ZTMNZN- WULX9:-W2W!
MHP\#M,,B4*4[#JM5A@5;,E:_3E:\OQJ9=OF*;MFJZD&>"02?XTX(X\=^;Y$9
MVELM4'AEQ_2N<EV%AVR'E-&SG^<;XH/I'_X!1V!D1B@S\^+_IMH1T^&OH2%U
MO&W7/ +5S^#1(7\AA 9.)I>#XS#^SFQP\_>BKEK)1 JUZRZS],UF_T*GU!:5
MDG QRB6/UMCPHO9I0;=5,SXT6C/$5,+_K3G)L9^8H,>="+42O+* ]QZ3U=\2
M*M>LM#3,8MY1@B@E]JSL\NM#Q*GT-N(L@&3[I&4X&C:9OO;?K^@T_M@5]ULN
MN[SR"8D"&EP13<&IO,$1#!4U&.M.$Q87%OU6H'[3R(J6?D;K)UU 4&-$?&EC
MD \DZ*8"$7%ZL!KSIZ&Z!BJ$4^F2!);E08)67-/%2OEM'.@Q60YF+9UOD*>:
M0J2X/TY_E>^?CA*/Y%SL[[Z)_J,A 5K]W&K1L.+RYN3V#^<<9"!FU:6?-S[?
MO1+6GD[WI*R,57I0C22(]^<%C;!/E?,:E//@7Z=][ZY;$VD>=14RU0MR9H6&
M&1JE/^0I32++-K55D6V:#\P_)9R&,'LF3B;5;2Y"M,%?GOUW+=:-NZJ15\DO
MYGEE#480.$#O]@8Z9"#'RBEV0:_64&@VVH/'X$#VZ3<QM)*P*@TA+ON*=\@6
M5+&AD-[[[-\<8=P$RKEU/MN<'@$I/JY?)SO7]IR)MANYFN01KS3QP9"#W/8P
M);.DI&#Q;#3"3;/ZW>J77=_!S+%KF7P.,G,4'X,Q.V'X6VOHMC<NZ=0=,U[Y
MH;?5-\D&5XM4@;.\: <C%'0=-"O&3O+U%-AMQL/HR9FM2^M+.KXD&24]<8;T
M*P RIKL&;PZ&%1@W" >+#23*%$O7Q[C_&,'U%"I]OEKUO/;G(I5N@0[MGG"9
M6+_1ARM<L'Y"[HIBRR7_UTY<Y^1\EO] !&7NCL8^-@1VZ'82I4HY,DFR_!SW
MA :$S$ =[%52FXOC##?< *&$?HAI\938CL^Y\J7=Y)7+6[T'20L?=Q*[+0UW
M?4 I3!I!(XLQ@C#]6!\)#91Y+<S.I3?[N0A+-U"I129,VK$7Y+%4;0=UL[RQ
MA1(H&'%]O)T>W0TX0$L,^ <TT3I;7KC4_KWL.][ T;,[@G;'ICDZ)-1DO%*F
M6^[_X$PJ^NVPU,>$8Q9;V#^(\@XJN!.;HL=1:4SWUB$PY_#6W"]N#&@Z%UK;
M+>CE/D8[B/]!7U9I+*F!WSZX_[E  9$9N_9UV3)X33/WU6,AM]L'%- OC.NO
M;YRH%E54"RUC0P9HH$0-^-1$-_B.CKX?3ZY(%[H'I1&61OX'^40QE266]D#G
M,IKH;DV,6^U*LH6+-/\\XXA-"1&"UN3F&09+AMJ+S;Y^SHMCA3L=?4M)#UA-
M8'OF^3[?<(AFH?4JTU?S+:25)AT%[Q+/0Z&7%ZY=<--4K'^\\/M>KMB#I5O.
M_X#+J]_NK_[A?*:"&[6#?-*,O_W!7-BPJWV68E']XFCT8"FUPKS)]M+W35;+
ML%$ZTI%.^BTT*]457XI-4\X62-WI.Q#FFX \Q(.NO'Z.O6=1 !3&9'L!Q"1[
M\[>/9B-?[$0-O1$ZCI4(I/4'J,I=1NX#TT4BV#459*C?)U-=,C)'R MJYNR,
M6*M#RTY\6IX@:<9':J3X?PR[9(W\N&S!ZV:&?=W4G.6CXV",-P7NE?T*/XS0
M./(,7&!SF1_:K4N]>+:LHU,N6"$8Q,5K/_KS#3M8H80[:(T63U=9C7QZJGG.
MC_?8G;_[^86 IOVME;)FEV'3TT&^,T-5!2?+>YH;7#3-C5\NQ89BSI3B!EK(
M[2MEG\T"9FD0?@HF4**^X6:KV#FTCV6 >$STC2C1U4^H>D]VN"'.FM-8[8X%
M:T(TG@R]=C,7,BYA]OPP0:P@?5S!=SNKS3)##LE.KWX"W6ZX/(]C89ZX>SE<
M7QH/:L -Y;#U!VXN,[TB^).2![>I2VM\I'^ @UFFC9XY,\3FO-?=!F!ER>&9
MNM(XT46HJ_#M&]/$*TMM289_R+JCQ[9!+D<C7MQU.PUOA[8Q[:9[@'W#/8C
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MF:U;2PK@K2^72CGOEG ($+LQ9RN8.W,L"D"D3,YJGMUXM[QO</[?[J\DEW_
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M6ZR?Y+W2YQ']\5?XC%+ XR1EYZ]*C^(?(;D2;;-,6P=N#)2;,K@_YS;*OS^
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M#Z,KAN?%6Q$(,5">'?D@_KOZ3I1T90Z'89K$E^$</KP=Z)Y6>$D1Y.I U^-
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M7^M3RZK4;R] "TTD,&T-U]0,KJ:Y@7R=@_R;GHO;9.&+3A9E+Y(!"^ Q9^+
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M*K0%5BG28<LIZ^8I,-ZIT"/+007:8:E' 5\2<651YD2AL$\7@DX>(1)E0%[
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M'G2MK97-6*4$CV2Q=7$<C 1:K&U*%"F&G7+#20'((&@4Q]! <1F#SPN;PD/
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M#N?8C;5VJ^.,."$TJ UOFRYG#: UM8@A^2 \->1"><FCI!*[PAAM:VFXP)%
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M?)X-=2]37I:@V^3_ $*!Q3J5.)880=D"-&/#$<KA&OV)!1HR+=Y"T&1-.JA
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M71M)+2=ZQE#,P$((V(4E?]N6U4]#6C:R(Q"A7KBU" .JT,0)#*/T+B:&)?R
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M.QK-WU#<.H'UI_0P&9?/[O,:NO/O_'\WAD$DM?\ 'S_/GD0H_).VNV:0)1>
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M%?O9]IP! -ZG1XZ,^TXLJ &;\'E/;^.)+T[$H'V(?I]>!7J21Y/7Q]H\8/9
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MG&NA5"I>H T=-KCD0=D4GG10??.@.S)J%@ *L$TD5#N+SM=['=$W9.(%JA2
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MK^C]W^GT_P <1+-[8/WNL/F3A%S'Z_#]/'&EQ]9U^W$HF])\??/SR-P^.O\
M3^Q]^1\?IQ'Q^G% #0<)I[Z9U\?MP@*"G8R_L?OP2M(J_MG7Z_G>0::]?^<\
M>,W1/WG/I_C[\1453&+/M,X$$6^T//X'R/ ?=/\ DY'D?9G+OCZ&7QU'UV$>
MW>0Q2AK7\_?[<_\ 2X"47W1S^!\0D/RK^NG*46=U0^W^N"*!>M6OB?K]N7_
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MB<8C7>4(J@_C/1L0UT.LZK$(W92$,B-T/^QU*@6Q-G\\(19 ML?P(\[HP4,
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MK)#^'04.([M?^+T^_JF],CLPN/*ZUMJN?*_;4AWJ[PO;B+AFVBHS^)\ZTC_
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MC4]GUP8B/O><V/W'QESV!]7!N<!'%%J6"KH0M8*XV5H5RF3212>\/EEO@MG
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M>3R=<3$4&=LT"[\/B_YD7US;-29Z,&IB6]Y:LS5J\D$K]F&-;6!DG$(Z^JM
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ML0_M@'VBSOV*PYO.V?W1YR&.H3"%B/'$B"_&DJHZ0'K'PJXB>NEP-]A.3_[
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MMJ1&[#UV7&ND6BQX?J+1T<I RQ$Q!AZ)]N!I>"HDJD=-;%/OUGTT!*<@#84
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M'9H<U0L$O0<-8.DQ5 \&D1$#S<?1KUF6_0&@05A:MR=_6P"!82D$6\--(T
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M%;9$4\X0$(%2KNJ;4D>H59--,7$@H*J5*L%F=!Z2KV)6#.^B@G K!4EF!2,
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M$#BH14*\>=SP:?&UJ$SNMM[Y4VH]+"T8AM,3G>V BP :6#!-BI%S:R;L6&$
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M$+X 2W:*- -=-D.$:?*)&9-]Y-Q&<T(\0OHW0S@B '1(V1(#,.E55J%T0XG
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MQ4OR1Z[41^GG3E3WJK?&)]7_ $\*J3KSO[%Z]^^O@%GXZ7#2EA,AN]<O.8L
M\"Z]NH2FEMH2^J])?GQG?UX<4( &D<\$WZ]5SK;Q%$0"/M] _CSP;=BP&$C.
ML[ '#FM9@UC8L\JVUX]K:JO*5#MPP'@UCT4:E( E%'0AT6S)3A3Z*RQIC!Y
M7Q\F@$LF-^:KJ^Z]<%8G7SZ7_P YWF?KX]=_?KQO$% %][GF<ZOK_AY<!D^-
MF&_S#?/7!9<=TN=PGS\_CC!BKV"1NB 13Z<,JX^4NA)PA$!*79J^39"(YDBK
MQ7(58-#\PUK XY4*L$+R(^[H81163A. ;[HHP5/-5+56-MGEOCQ(G0$\"OZ=
MOK#F7=B$X] "C)1[P.2P4J"4J^X93[/-()*82D0(G8B+>^19=5-" *)4%F-
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M7RCP>ZVBD,84ZII#$O$MQ-CVP)B*=DIU.94,Q11RGAF>?C#@$0%"$#AH[@>
M^FJPR,9T-(":SW>D7,&9UGOVOG-;PU'<L?K/6_Z[ZXI5Q9BK1S\L_7SS!FXL
M)Z4C/0C7J<340A9%VI2@>A9'CJ\*OTQWBJ=UN?3KUX='D GJ[]_^N&GTW]'E
MS,Q?Q.=!:3?>KU]'@PT[_9_S,R=;W#!1I<.^^2!,P97X[Y:"*O\ 8NQY2"AE
M'AHG%MY$J:A-V!!E+#AG3"<.1(T  @(H,*C=&269J:4]RL](Q5K@%!T!0"0
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M[G9?Z=9:#;V]$![XBE(E0^2E?63FDRYGRL\>8\$2C1\_\:GLORS@CY+\-_\
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MHHT/SC?8++CLD)V\.4W]@C6BXC2>F/R"=&"I3;90K]5"/K%DKUS%@OP;DB$
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M-W]428 ^,H>8QWJ.$<%G^WH+7UHHE;:\%/2_&+=E3LPM@^IA+/:V6#7H896
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M:=:3+H96C\N+^VM/.['!<N4.F^=;6_'UY OKA%<7=\#3+E5]!<QP2#?[,"3
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M3H&[%\!K$?K5P[<_>H 9-AFOD/S7!X42C/#/;D5.Y4-BXHQLS 5=L,3<S3>
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M:UQ,(;Z 5L5QOV,<O+>C5SIH/T;2'2?+)9*V,M%UH)", )(E6)_/!J[2V<(
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M&-M:"!4FDTB2@5*X<K6,K84!I$C4\,R0Y7/JS?0?:"%![BKHEA=]((AGF!$
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M !,QX4-:VO"*"@[]8-94AI%T]PJ*&.\'SJ7]CUQ5.<VQ=3'=+!L%P(!COKH
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M-[K!-[Z4&E86R=;GK4H3"M89;8!.Y(#PY@Z_6A722TC#HB\T*>Z'.93WO8>
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M9<Z8B $DF.XW'-C@%"986U-?Y%P<.;Z[E>?U6+[GRQD5,3EM/J5H.8WE7JM
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M8YBGZ&>TF-;Q#K-\X/)5LTK+M"2&/1(_H%*S\<AN[RJK4@3L1^>V54F@-E^
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MPPACHYE2Z3\" 2E/,T@8CI7,) Z)<A%.FT;'II(MYMH];U%KU\3@!@UP\-E
M=ZSD;=4%=FKHF]B>I<\+I\X2YT*2)SVS:G)0\7(AX:52.=W;TUG*0P=83##'
MXOEZ5BZ*91WP:)8U[S6PYFC+QWDUH9;BTWPZ?3\OS$V3*,QB%IA#E#SF$$58
MF%4*#+%2BF=!1H)8>CU.Z17^V*2R=OT]'XSTV^&6SN5HN[%OG]3B>.2)TY$U
M!6"#@WHS#"PT"^NSDRLB]%^79I72N,'U"P0^&W) PXY/'_=5NG6H<Y-^P8_K
MZ&0O'>-\>K(?%%U6Y;LBO9[QPB2"NY[5G]KE;)9_U2,#+9[KU9N)H#22+(DA
MD9)!Q$W " I"F$5)RDD8AUE$[!?O>\,YMJ%O Z#)$5 M8FJ?:$EUSS6V@'R]
M[E\O>BYG)A_LDWZ0R]IR?WUOL_H_BAX=PRCXYN@HV)JK_[):S-Y\1VJ;Q]'M
M+CL/H^C^H38H7OTU<-S.Z+USCN]Z]-?\@)LCO7.XO8?2?W,=Y^'YPRQ7.:>Z
MO;HLK]G@F4]SGLMRO5;/HB#DL0GO,;4K48899&D00Q2K2%+$5""<%@CMFAW;
MX'_WR\\_7W[Z.[AY#^ZN?_IX_?[ZZO+C/;B\NKKYY>/]]<>?P.W-A^NKZW>6
MQ3 =.\%R3NN=VKY'X35@L$8,6LC@<S_[($XT^9K;V34Z[)S,B8B=N93;W:^4
M>*W-:&.75RM@F&&9*)C$+(6(I"ED&,4P%7%,(BI1PISR[P\+?VRBV8+[HR1@
M<WM7/*TSOMH;,((9EG4:MA4)?\Q,;)WZ<"S)V-S CVM1L9>.\9Z2K1N*,U-Y
M7,^>EHOR@_PJIV$3BYYJ?U[[]QR*% N(T@!!JAB!B1!4(((QYE:UZBW:&MM0
M]4,%#H2.0\XQ-NW&!T\<]2SFZ[0H9L'# +T #6,]A/M;<.([,<J>EEXG+\IA
MDP^F13ER2]=JT)<S\7,^_7W/J:2R>;L#D8:,9$0K!%<0:=V C,01Q$$2AR))
M@H#&;G6A3[8Y-LVHZQR:Z#V#&^P[>^@246Y)O,4*OG\Z>Y87&R8[UY$^3:EK
M16FOU Y:6[KCR]JAR+0U1Z?+39]^U,"%IZUMVRU!;7]KQW21Q5Q/GQ?/MU.S
M++.1 &>]EH@XPTB(! II\EJED81$(@&9XBA14180Y%0SZ'238Q/N=^4B?S2Y
M*,$OI53+*3")/:MLA_7I6L<LD:<I#T*2B3 *H40QA4@[U1#+C,$@Y!E5E*@(
ML8GV]=G\=4C?;+H_VEO,VWFR3-U!Q\QB%HS;.=]^6>QYD&S!7H *[LML8ST>
M'+"GR5=VSM,-#IN<TYJ G=R<]G=V7"#7CD.UR%!'*)D5B/G,K#E4H>498PG1
MZ@X)S6*M]2J"C',&"4E2AE2:1([!K\=:&YW,UV&*:Y"=0OB/$VRY".R+MIXE
MQIDQ]Z54&R9\K7P>;6O8A4H;LW?6%:UNZB8;JPS96I/J@DGY[.%&O=?.Z(SG
M=+H1Z7BO6RCW_^KM_)'FLXEV:&2 TP@BQ0.(1)!!A@6#<8IHQI,L#+/(165\
M@AN;**V0;H5/?Z[!.DJ3UTZT4[+7ZIJ^US>[]8JS_/5!GR>U] IM4''M@]27
M6MQ+&QV/=4YIJ9__&S4;3(N;XI/9*]K:(EK]LFQ^6X:31(HL3 ()E=!_($2Y
M=@(IA90(G$K%4IHYS?H[H1B;&+_;#D*8*_"M@>PE(*%;3]D)<>_\]ZRX%7[#
M> -2?P*@0GGQ8AM_XYIR=9''VA-G$>GK#&DG#,,>*CV'IIU3IF<]S$TVRV)A
M3K4*4YA'O*%3DZ;I[HN4BY5[75[1>A_^0SZ3U_IGY81D61 1B6&:$NW1AB*%
MF%(&<1 GBE+-'[>:-W=I?&PBN<(/&@- 90%8FW !6B/ 9V,&J.RP=&8[]<]Q
MC>R;];ZET3OAUJ)X#G/'M% _=T,'];_6&MBIR4&D[QPR6L4[ZQG=_,,/\]G#
MO2P>WTJV^)DNED65 O23?%J5"=(*JSW3)^.:FBIE]]_F$Q9(E> TA@&+E0G]
M"2$+]#^3*-$_"4(AD=69P'- C$WX]"N*W!R^3M3;^7M]$]JSIAGXT. 'QH +
MT)CP?%'73-1@_7ETYU#ER:'K!&%0?^X<DEZZ<V<]:^ D(GNKX/Y4S,MRDF!%
M$58$JC!%$*F,FIPA"JJ,Q0))'H5IZ+9+VP/*\6WKUDD>YXT_\E"77'=/:-IG
MSV8"JS3-4A@ALTH=X 3B,,8P(2R@DB&J<#!(#A@__3K$X/?3&/O1<K?M=7NG
MYY'40_Z6(]7M*VM'D([E=%>\=LZ5(PC'=0:B.\7>LJ=8-#6:JCKUE;>%]EYR
MT19TGHDJWTO]NPF3*"0\DMI1R$QU^D! PD@ >< QT7.G&*=.E2%?Q8JQ#3@-
M5B!KL*]?<,?B1; ;CT;?O3V/6#T7Y:EON #M"]304=U8IR4[$=4YAE(]]ATZ
MWN(]%C;\T<OYV'?3  5^', ,/,E>'4VJ ->#_XLSC;_.I_IIVJQG4WAO@F*,
ME0F.%@E+]-S;A!"),(8)SDB,921DP :9H3E#']LX:EX$;F9N934OKW>VOZX@
M#S2)<W\#>I[;]=JOXY_R;=2UWR!@SQGZ-0E5+=,13 4[]]QKSQ#=@?\Q)HZ=
M.\3;?+([@HZ'YO-9OI#FE)"XGBTTNGP]4#_.BT7^WQ7R9@PV*]SO]<<_$2B-
M>1 &,$4FM[Y* T@#HH<WFK",1U&$8JLSLN?!&-L I3^PU/&4?3?Z[4:4_DGM
M>72H#8"5!6!M0CWKN0 K?V#3FF;;S5CB\=C^64SZ.M'?#<2PA_W/(FHG#\!Y
M3W-31"'SR0?])DQOO\QGLD[K/<%!PAE.)0R#2$+$4@89T\Y[(#/$4!I&66"U
MO;+OX6-3KPH?J  V6<WMM&PO<<<5ZEPZ>M_2MV;"6DJ.F;Q'($K)__(P__JC
MOJW6!OV7M23L?=@@'_HQ,]K/]^@U'?)V_$J+:OW N#NKHT+WW^9MO@ZN6&)*
M= I.(HAXPB%1,8%$!$P*F48DM?I&+=H:VR?;HJTF-.O#;4>#3ISY/?XI>V:M
MYR_["&%=LG"<8,XA^X8_!@?*NM'EU7-+MF%'R=$D&R<>,5QR#3M;MI)J6-[2
M;=K7I#4M/TDN\Z^FF?:5%9E") AA$&29R><@(<6I@H3$.$B1HAPYI0D]U-#8
ME+3%"=9 W69R!QFUFZOYX*EG[=Q#40\9TDX1X6DR=;"90:=+IXQ].2$Z>;TO
M[ZK* )!@@K!($ZBD5@"DG2E(<!S#B,22:.\J)JG5X>?CS8Q-"0X-;"X9%DX0
MV]6C&EE.A0&8.M>#<F7L=9VG/AVGW2P4+C[3<'DE["PX[2EYR"3Q29:+(C<K
MC%4@\"^S7"OOW2]M2ED]O40ARV"0"@&1[G)((^TN*1IS&9& HM1I7_=H:V,3
MR3584 =)5W#!#QJP:S3M<9;MO"=OW/6LF$=IZ\&9LN+%DT=UO*U!W2HKLU_Z
M5G8W=5.2M_*ID#RO1[& 9UD:)01&V*PI1[%)6A6GT)2;89*SC,=.N:@W'SXV
MG=C$UL8_NLG#%G5V:M"5D)X__DU8_C[Q?<9Z^J*W'CWH![S/J)??Z]YKNI:3
MW]BCGXE/<I$7U2[]V[SDTWFY+.0E*ZOJT=8ES:V?.*(W= T3O)$SJ?(J35J#
MTVLM<V=VO)4TMV]YX,KFSI3L%CAW?T3'5+S-Z<?W\^*]E.6$!4'&4CV.)2F+
M(**AA"Q3"H91*I.8DC1S.V+]XOEC&]1NB[E8\@4HY$-N^*P&M_9$J&.^UQ=,
MVJG+&?STK" M,J#F11.B;A!Z3-BZWW1?V5E?/'W85*S[3=O)NWK@LHZ!T/R+
M%,NIO%'FB/-FKJ]5PN$LHU&DD(")*1^&TB2 % <))"@-6<HHCGGB%,!\LLFQ
M?? M8I.P:?NX_V92/<?XX]/$VXF!7SI[U@<[)GM-^6S/EZ\HV],-#AL=:TW
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M RLP8.T7IH_P>GIAV@];/8M--Z*<5J9/\]!I9?K(8P=;F3YMVN;*M,75':M
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M#0VV=^QF^.:FLN.=';; ?J5%;K)J?*(+:0+1YC.SKZ;)E^VBB,12(BI@$*
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M/D24,4@"S"$+]00@PH*IB+B5R#K:GLL'-E MQ17<*M%>]4^'6NF6+*,D4UF
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M!JIS;]G]:>-M-7M;^&+GV?_NOLN?A<V"K@N??"O*/]ZOE"S6]F\S0G)%J4@
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M*CL\G*'+!LW!JQQM* ;FQ->CL&>)PXCT\5,O&QH/;W:T(1K)Y[ULJ +YQT%
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MO8X)8 AS$,LXH80E1.5>S7-]%9@:+;3ZVWVKG07V7]8&8(WHWL\*,RR.WNF
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M%R<279>E6I<WBZ^KI<W6MTZ#>=R/ZX7\H)[4?/GX4.4@9T*H.&8@1QH!1(4
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M5<KFQ;/'+6%SS*R#TC5'+^J9A&E&^@<KU2V?%_?UHILE@J@4,4 S\\VB#&>
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MA7. .(P!2S*SI%9:FS5V@J3T:J_83XVI39CFE<_]UJP]X7=;8 X/ZL S8&U
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M+.<PYC)) 4EH E"6$, PU$#&QG3&,DUSIXS22Q69&@O8=\IODN\]!&YNP!C
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M\:MH7_7 /:Q\T K9O,I)[OA=JWS@.-JNRNL!?8XJU4(N5[>+MH4WRO-8<48
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M%=@L&#,J -*$ $)@ BC$6,&<Y")U:F[<)61J%%6K&;5Z1D91#U_C%)(.[E<
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M'XY2# .M Z22,$RY>VQ6<U]CVWU7T@(K+MC("XS 'F%$9_!MYMV.4>N90QL
M.U\HV!LYC\BK[A <*.2JS:?G%V'E!DEC:-69)H:+J7+392>8RO&5EJ9U?G#Z
MB8F\^._-PM[83S3BDE"NH0J3P%;B5) E$8$$\Q#A %'-O!PKCW4R-@8MS_,K
M(<%OA9B^6?V/P>EHKUX(4M]&IR\^_J9B P!=V7O'NAC6:&M0\L#R:GJVA?ET
MJ[7-0%%9<<: LY1B[V'GMHNB?MN2S3,F[(\?%O.UV<P_*O,%S5>3A#&L YE"
MA)@AA5C$D#!;V"C@' G%<,B<PK<N%V5LU%$3%/!"4@_3X;)1<;#)!L.Z9P;:
MZ %J*0QSHV-7ERM0'Y!2G2M0*C38R'C8?(.-T$ F8<\CY6<]=@)NHW%Y60_#
MV9Z=(+%CFG;38CO+]4;QU39[U@>63;.GUZ5B\F%>MYC1) Y3(;2.(+*U07%
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M'-4IB7>CITX^=:DCVZ?I?+I2GZ<_#'F:$9^_3 ^I,WMDR]6#/L*\VPM;1&5
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M99%_WS-,X)(1<6/-@7#NF3YW,B\ .RG!5A6PU07P7)DJ4T.NSA6H%.J.)3M
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MMBF.5M5/NY[+S]NXL3QKIC(V<+9:3FV2S(\L^S8)>$0$U@Q2J5.(P\#8G['
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M>O6K]?,/7Q;D^FFQO%%+8X@4A76K= &?S#9K+NR9JJVXF^^?)L)\#Q@)!GG
M,<0B3"!+(YODCT>)2(4DB=?]D+\(8R.,3],_RS-)\%HHTR[PU6,0W(R-?J'M
MFV"J,%F;SG(K_DY"D8T&8*M"]_&S_O!U'%;K(<"[1-OZ W0J"+=%2VW]AEB6
M!_GNN:-P3@*11 H*E*:V?(2 Q!;())1R1GDLT]0K6=F)?L9&84_BFY+K69X'
M]FG]^CK+/51M&)=EM4^SQ1_Y0O^P^J:6.U&_7]7,YAJP[BNYJI[G.*>&P8W?
M.@"W9Q(K_7SR#56_SCR-2'3FL'.\EX&=<AI5/72\:7Z\JU(T=_,?9L8LEG9U
MCE/*!,($(A8HB$D80\IU E62,+.1BK@]Z>VB!DVM4Z>/?O@$(34)+RTZ4T?8
MC1\N!^Q=R\RX8-=!>9DCF/165Z;>USL7E#FB]OE*,L=>:L<@]VIEUU:SL;-E
M4^6'MU\R)8L.LM6.I;/)B1$+%$G)0R@"6^J3Q@H:8R6$/(PB&1MR2;'3:4Q[
M$<9FMGR\?OH[^/3YX1]/X-/7AR_@[O[7VZ?GN_N?P?7'Y[M?[Y[O;I_^EQ_O
MM!@7-S+J%^V>&<H(7YB"E?BV&O9/5@-#5'\#&R5J^S"7A##>[-4>Q(XHK84
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M=E-M\B<S'@H0SY2+Y[$7.,$QH@02S<VRD288TB2-8)3&L0Y2R504M?#?[V,
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M:CZX*)8L%8JF3H58O'L>V_)VOYC#/']AOGY-^7I5UNJT]>+-,"U_]S3SW<?
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M(>:1AC0().12"AZ%,0X(]CWC\1=C:HQHON#8_ZBG!?SN1T'#@CKR45&EA.'
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M;XA,TX>Z]YY<>M/!&^63/E3P? KIHR=;W@B_?&79JC#W5H8ZOBYS-G_0-G7
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M=0/KR&HJ)>&)64TC9)?40$.>X-16(TV"6*8D%$ZE-'J29VHKZF&F,ZL3>%B
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M8NT6_OFT6AJB>6'W]JS:GOQ9+_"9#!7AA(0PCK0A@5!02 .;J5^SB L>Q3K
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M#_*.Y9F8$:I#&2<A9%%@+\ZT@%QR!&E(8Y'81"-)[+,E].Q_:GL]:_?/C>2
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MN*%6Q68:L\IL,K%[GG-U&1XW3AD)]('99X/WB2#97RI5?BT,K4H;L%5GH "
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MXV0_C=[E6X).F P\M?W@\+H7.*MVJPN!X]9&NPDXJ\CN%<#YAUJ>_;<-X?_
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MWQ\^OK]]_/R_P>U__G[W]%^^U0B/@'4EEBYP#4PCI4!7X'I=>N44Z^MZ"<H
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M"5M^FD** V.Q*1R0." )9V169NKXO&:KM1LQCB2]#PT<ZC <([Q3S]EB89F
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M84J]7-F;.IL:C56R@I=:V-JIW7'KX@2PV^%K7[ -S$$U8ALY02'H%:A$[>\
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MO&Y]%MW#$S:@^ I3M*XU;KC"ANVCL(75E[J./6#K;8ON,BEJ%D:,!!P+F-+
ME//0!&+33CM-4\D3)&(<.0XR.%IC:IO<5_XDQ<N\[("U+5 WA.\UQ*^RQAP+
M_4]!;*<Y>@(W]#G$#V8=A@*<1<5;F__C%49NW'^6Q>-6_.<O[5*583)0;K2M
M+<6'E\(DP\DB7XK2.%\]%"^K]7VQ-/W>5S.9! (+3F'&B;;:8FU6D%";;DF2
M1&&$4BSMFH0YKCLUU6&(IEJJYC6HO++7!NY\08N?8%72#UZ>]?&\D'.CORMG
MK&8(/-<<@5_R17VE97VVJZ@L(A[#"&!H%51.B*NH!A79H*+[JG)_K*YJK!OB
MA\'7I7)D$)S'JB7QA[=CB8DS:NU%)_:W&[$,Q9G'_<(4]Z]WV!^^R%>C4[]H
MW?Z<K^E\.Y35&*C2#/U>K')1&JS+197#^)$6B^7+NJ)''_:9P %#,$E3K,^@
M,H;$3!2A*!0<\4")!%EO&[W)F=IN<JN%"%^>Z^W@"LB*6--R6%/KH+WZ"\IB
MTQ@5_H'WDIH7<,A,.1*[9@?L\7-5IU#KOVLIW8\O)8>M9U1IC;0CC2 UMYW*
M&\BM&UC_5<;;U[PALK?=^;OK1$/<O],?^;>7;S,<(9Y$2=E]41^SF$H@X2&&
M*E0(Q3%*LMAJOQR;\*GMK(;4$_'N*_"MHG=B@>]&_!.)?W<0ZO]Q8? K\/N%
M1V5Z\? #N?VKA,4;LO_/BHX?"&/T(/GA^AW.?Q_R5=7XK2R9;=K+S((T(B2D
M#+(LT8<Z2CC$."4P"G&"XR!$22H="J!:EG*+*XXX<G-+;%F5SNAC#MX_Y0L*
M&M(=S@5G8+8XDO5 ;:R)D?M(^4/'X2C4'Z61SC?.:+F=5MIQ:#V"G/GJ>.>*
M=MKW#@L7+NTX/*6J'_NT+&3^N'B@/S[^,$I;OI,+J?+U3"4)$I&,(*&*0Q0$
M&.*,9)!%F8H1"RE)G'JQ7%AO:O9V3:?CX)0+F-I9PQZ1&E@9UI2"FE333P;4
MQ()?:G+/QX3<1ZK8 >-KM,J%U<8=L6+'^M&H%<NO3<")8"CCVMSY8SG7MYGG
MZY^[YTA&E, D8#!.50 15REDE!(8XT3R+ T20M\N8;Z5]*DIMH;8:DY45<4&
M7C>43\&AT/XHO(%+P9N _W6="IO'9HO!OX17P4IT4_0KM!/^K^M9L!+(H+X%
M.PHZ3B&3ZZJWGNF_=?U*\[E):3+-MS8SS^H&.1_R^8LF8I9%:93)C$/,3;]8
MI1)(580A0R*F$5,HX,*E0Y8S!4X;U(B#10"MF_1KI6/ZW]7)265HN>8 0" J
M)L#'^Z^.8\Z<)66W\0R*_\#[QW&_R T#50O"[=S$FH<K4'/A<8!:5P!]#5=S
M7G_<P6M=X3D:RM;Y1FZJ4<A\]G&QUFKV6HC"=//6/]X5#\OOBUF* H:P8I#@
M+(5(2 8QHPB2)$P$D2PF06)CUK>L,3G[NR03U'1> 4.I*6<WM-IIL#9 VW64
M)Y@&UD*=$+)6,Q88G% D*\G_[7'Y^C_TMRL=HG_8JHZV>XZB'"R8:EY_FTL[
M1%:NC8OUB]0'R5?34[J0(E]_HKPTKYI9K($^P,N80,HY,^5;$62Q$I +CA#+
M1) E5B^[Y7I3>_$-P6!#,:A(!@W-#O$#"Z@M(BU^ 1Q8);1C=WF*:R<0'0(R
M?L$<*3C3\8%T"]'8(],:KK&XS7BA&WN>]L(X#E_KZ(^M2YKN5-WU^8M\-@//
M%H\W"[4LOI7/DSXI5[_<-F/G&4E(8D(],8[-R!*AK;"0PB@+!%4XDEH[.SE7
MN]$Q-85]W*S]4[Z@^A,Z![]+NGHQM3';[OO'7=H?S&G9L62WJPPMO:+#2V9H
M%^=.V5XS]F##!-CAXJIT=-97#-DOOR>FOGR/':D8UY'8#ZHCKV#/VW6==7(X
MR7S&4Q5AI3A,%3'MG+(04I2F4*4\CAGC02BM:@G/+S$]W5A2"$H272>('.%G
MI[SZH3*P7MH#Y+)!VF$JQSGFO4W8.%I@Y&D9YQ@\GGQQ]DKW)LC:'LM795[-
M?9$OBRJY_F-1+(OWRZ*0O(PS;'J U\]K2)!B<9+"**':8 HB EG$!,R$H(+2
M2*#0*C>F*P'3TP8K?5BIPHO7K@W3.TNA76N,@>W@.J4BW]@Z)0.;:M62![!E
MXFH'=H_*IR^&/?H]=UIVM*;0?4#9[1S=ZSX]DG;8Y5 J.PREWE71TS_TNUZ.
MV&S"J ]+\]'=RUKK@(5IR_FG-#U>]#6OLJ"/\HLT3;'+07.+<NSF"YV;7AOA
M3"DBN$P0E('6I8A+ FF8*I@1A!.$ D%4ZIS4,PG6IJ:@*\[*N3FR2>30I]57
M_?$5^%XS!6C%%2@:M@#?\@7FN>K27G,2\G!)&IH$P1/:A3PD%=TU640[S^''
MG>?PC_(YW('I"C1 @1HIL($*[& %#%B>,X\F)7^?F4G38&S\S*5I\-V6V30M
M"GWW7:JSC^^U0GK27%P_%K+D;#6+8A+@-$8P#B,%D>(,LC#-8,10D&&.$TRL
M.I/VH&%J._5N/R9>Y=O479CRA=F.%Y51"+[GZR>P?I+@T_VU_I79R4N-.T S
MIO/RLP@S#B^5H;<_BZ9!3?U#PPC8<C*\$'QU;_(BC EU<NHB%(]MG2["V;W%
MT_E;3Z3=TT7>[5L_7;Y5QV/PR_/SO+P3G;^C<Z-ROSY)N?Z0K_A\6<;VML$U
MDB5*GU-#F*0J,6EJ$<0XPY"GB"@F4QECMX.JP^)3VZ"^_OW^_O;C[Q\_F\&V
M[ZYOKS^__PB^_NWCQP?PX>;K^]N[KW__\M$Q%]=)&)9'N8$@'GJWV2$;U'2#
MDG"P0SGX:YA(9@?,?!U07)8>]PC1 90C([_+/;HDX8E7<V^C-#\OUZ:[D,Q?
MRXZ]B,0!"G$$.=+*"[&40(H$@FF8I@G*4L72P+7#P=G5K-ZG\9L<-/0"M32C
M7M?&T=60[)(Y=A9D"W.X'V;CZ* -3II(8*@$7_SBY))8YP.OD8S23K@Y9M-=
M@J,]B>[LMT?,G;O$P7[*W,6K.S8_V-8X5&;F]<OZ:5GD_R7%3$4H3(7,((UX
M )$B"619B"%)(I2%B))8.!E[+6M-S;9[O^=PH!LZW;T*-D#;&7*>X!M89^Z6
M1C5'4+"EU&,/A,MP^.I_T++2N+T/+K-\U/? XBON54P?ZGUD)[NLFH= 9!S%
M.&8P4V8P39QPB"6*8")X1+2Q11,J;,N8SBTR-5W1T+F;<^DV8:(5TG;EX NH
M@;5")XR<*IDN@="IE.GL34>K9;K$UFXQT\5KN^9)+(NU"8R\6Q;%\GN^>#3Q
MB@0'24!AQ#)M&M XAHQ% C*"29I$ 2.9U53MEC6F]IKO!)( VU#IF@=P#*5M
M0+X70(-'QC5UV[DQ/N/09]GV%A ^7F'DR.Q9%H]#I.<O[> D:?JG:1N!Y8M2
M7YA*C\>%L0YNA-8DN<J- BD'5*VN^3]?\J(,L=[JCTVU3J[M"=-.0HIRI-7J
M8*;5:A:++,VH3" BF9FXJ"+(4A) '"-SME 4R\@ZKCD\O5/3.<<S&UW":"/(
MU\+1,RVI#:P(&V;!#K=FDGO#+]AEN)K%IT]'-<ME-M .TZ#F^JH:Y+<Z-<EO
M8L^#@T-K6L_%2)ZQ"3T?;OZV\:35ZK@;@8SQ/(#C8;KG2AQQV9&[*7Y>+JID
ML&I,Q,[TPH\_9,%S?;D9BAFD*(U@JK" 2,H(4B++ I8D322/A9"C]$^T('9J
MYLB&L.YNT$%E:WN4FH;$!C^3]<Y6U@S#BN-ZUL[N0%#3";'F>@(=#QUD\]8]
M#FU(_=?H:N@ NK<^ABYK=MM^FO%ZGS1096IPW7"\_.!:J;(/@ES-J$*49H&
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M'IR@-$0A@RQ!%"*>I%!;S!BF5! >9TH;SDY#1NR7GMHFLC^SJTL.C0/L=KZ
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M#(<029)"AB)]]"52"Y*D*I9.A5 6:TYMSSKL>'$%'O0:'8<>VV!NYW#SC.3
M6U%7$/OT'[\$B_\6XF=7?*LNX)<@:&GD??&K7AMSG+#AM2;4'[SHS^I?FNXA
M35.((-#&=!H@R#!-M)&=A9#&S$Q\0 0+@IB(K$IX_)(U-=55V@>_O#1]))YW
MNDML<XKIAC4_O3Q<16FG[L87T, :\4+/CU/>B=(6K'D#6^;&; 72$>]AVX.X
M$C6%EB$=@;1L(]+U[AV[YC6=FVXW";QQQE&(> 93% 40X11#EA ,>:)XP)7
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M@,N#VIM:##E.PQ&2^.YJQRXF;Q4E"R48$R/X4-NI:MH#@BX94O+.!)=SP-;
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M[%( GXO"H'426T?G4[KZ-JJO#29>A=Z&"NJS?7S*VKW OYX9AL2*DMZ 4-F
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M%(2N#8F3>:<NK$NHZ^4=\6WA<DM*ZV]ZY/:FZ!)!RI1M3I%##H8$J:2$&%0
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MK(G@>P"@NRY[3^PV8\PIK3-XER@8\3%#M$8 9ZRD[(S6JO6-I>>I60E$;L=
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ME.W:Z<!V=-,#T-6I;(_MK_3.!&4R<%Z+!5"2Z>6I>@4N(GW+)M9ZQUQ"QFI
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ME?HKD+4:LG;E4&!;^N@!Q/;R=YS.AQ0.?UZ,;7A2'$"K@LCG% E'7P_%+,3
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M!E2V &&HT2X=E@,VEV\CZK!.:!<,W=,K?C"CC>!^_;;,H^G%I+0E3;[0:7N
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MKW;:4?E"\PL.'*<?UI;JK(W*&@TZ1%YJ(T?$E"UD$WGK><_[;K-ZB?WD&/_
MQOX@[&^@H;&X0=E(E585S\J3LEC>6D9!,-0&^:)QQ(IT=;.K^%>8V+@SICHK
M>@1A[4;]/+P7C,FHV6EMP^BJX;U@JP!5K)<EE^)-;\+3O\3HJWUR,MT-]P3
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M6Y99HK<T7Z[NK$:4)B$'9]@Z,M 01)_X&HC)92FJJ7JC8>R[8>PNL0;NM1L
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MAQ6=!8?6:JVAU0R#D:*-Q#(**"6=?!!%8G<:LW4A-@)7^'7 U<<:8X+3-W:
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MK?NSWZ6B'_@<(M='8'( DR>.]+VLC01Q]:U2_S9\Q:W9ES23Y.['4GM+B.+
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M [_]Y(G;O;<1^%'LZNKFZ78_<I:MCBHYP.S(3..U+%Y&#9(6$@(C_U.9D7R
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M=JO91<(#,X5I"=)S RHD0::JY.3WR)PE?9I+ZR'S3]$T>2RD(0*>A-<1XN@
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M_[%=3E*!=*F2P%+-C%-8R&[C = 6[8O67(6\/QP>?5=/9THS=+3C;@]@X;?
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M*:G=DT_'[O_H<:\EAL;%WD(<&P(5S3<>75[UU,K6%),"**\BJ.08>-1U>II
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M#U_)SN:+S6&)%2J)(#2D7*MJ2U(0"E+2;()F3AG'^9/1U-V/'0\  ^ELWD2
M8ZO^\H7Q?/'K=)$C_7^YX:%P'H+V$C+6=J/U -8Y'T$&%5+A#L.6('A@@7$R
ML"/!H850QP;&!M+K,OS[N<F"!30Z :L#=I1/!ER1&4K1UA+,=3%J%S_Q\%+C
M%%\>UW<T$O38L/GE8O'/?'[^>Q42B>7CXF)97[[]OWDVOVYF\#NEQ'GQV\4L
M;3@42H2BA06FBJ6$@5OPC L(3'F=#/-,;>=M]EI^G)++(\%K>(6,#KF,%ZOO
M?R<V+DAUKU^_V/#@DW?>A-I#05,6JD(&7X("GQBE#;$PIK8;S?'  N-45AX+
M-@V$.C8PSG"Q'HF^HL\[SU?WRRZC",%N>HTIZQP$SATY5VZUS3E&O]TXYGL_
M?IPG)T<"Q>$"'1L2+W+"!7WUQU6HKNMAE$D@;:J#R%4D%Y<I<O?!L1!2RL9N
M!89;'SQ.L^8CP> 0(8X-@+<!/TU??)[.\)>+Y;2.9+YR;!2;HXP*=#3U2$D9
M8H*I.F0A"^<"CVF["9X/K3!.X^4C0:*)6/O QGSY)<=\L9I&/+^Q\3EI&2\*
MP59H*^\M8-8"+,<0@Q+9E.VRG<=6&:<K\E$QTD"\7>#DPV><??J,TPW]VK 4
M6:XA42TM"8J!#R("L]9S::SRN ,\?O[PD=H2'Q,6!TBS@\*'[:XN+@^>.<]<
M: D\$S^J'@L&4P*!W2A.:$#A;C6&'>RJ]2YUXY9%'.\J:&"]=8;(C8$:XU1]
M P=H(G$@$@<G,NW$F 7)D(S*#7G)WT/Q^U#Z?@16>PB_,_AL7')@MBA&.W)T
M=6YV\N3?98F H38-DBJYYN,$[U+1#WSVT>LC,-E#R!W 9%UVO8X)SG&Y?%L^
MK.;QC[7Y9*=IHRX2(I.F]C;QX%S*@-)B-$$F&5JW>7V0F'%;-QQ_5VNCE0[@
M=9/^C;TA3\I;%!16%I*+X0F")@EE'8O5BL>H6WNANU2,7#'31KWSIK+N 2WS
M+U_FLS4?OUQ=G*7:#R!2$E+?E2BT!8*+",H&45)@*<?6P?9=*L9%RZ%ZO0V3
MPX3<%TS.KCB0V90L#%A?-W%>:ZU]KIW5'0:*^H3$UK7I=ZD8-_<:#B;["+D;
MF*SE<16;11-E9@QL;::E,B]U!"JGK[+BUFO-MRO1W!DE-X@8-Y09!"3[BK@'
MC%S*XQ]86ZNNWB[>3S]]7JUWXCK2"!57) =#/C&G !3121"9_F16*:U:/_I\
MD)AQ&TH=/_QMHY5>X765=W(N'',&HO !E&(90O0&7 HH8B1'V[R_RB/D=!'B
M'*KP;6"TA_3'OJS8E)=M^+BZED/EL0B.X*04H+PK@"X7\,'KE&1A)=W*HQZO
MW?OYXSO$PSZ:NZ=*[P QC@V$=XOI-W*S[\XQKM/'6ZQ(Y$$EA:!-(,DXHP ]
M:I R9LF4+?QVGX('$/'X.EV$N6VAT5"P'>PZ5_?W9_&_+J;+Z5HSU9=Z1,$\
M>5",T=*6;"V0:S7 4E E,N%$:MUV^@%2QNUH>/R IH5&.@56_7*1KZZ0DPDI
MDN.$K,@^5,0(+C,/&C$X)93&YH?&3Q(U[E;61/5;P&E_/8R]JZVK!W[/BT_Y
MZO5-LB(P:RDEU;ZVT\MD:I*DA$@Y*@M&,KU#(=?-C^X/"P?H[4X)QMY"'!L"
MOT_/_[CA?Z^V71,<2K3 )$N@6"1G2\(A$V$9M7(EJNTJ.^_]^''#F &A<+@P
M.]AJ/ER$Y31-<?'] ]:=^OJ*A%O-32D9#$5=%+!+#\ZF"#D4%[ERWOC6]T</
M$C/N=((1[B6;:*4'>%V37PO@WI8;4MO87PFIU(F:8*VM!6S.4C*!&6KSEL@S
MIM*\_??35(U\;]E&_;=!U587':#K=CIY=38>1##)U];FF9%'C[5;>LTJI6;D
M@;EDKO5PO_LI&1E%C?4];R[\#B#TVW2&LSC%\U>SY6IQ41FY3!O(?6M9 B2A
M$531ZU=]#J+R/--/9,'677 ?(&6<]S'C[7TM--(!L-8BHI679[/T(2^^3>-T
M]NEMN8>[Y4?ZR.7]/]K8:8S1!^/JLZ'UW:'V)$JI@6M!^X&BQ".V3O=;TC^N
M'VP"J-M]X\;2[M@9Y&^7+?+>W7[J</6&J:#D=3*;PLQ)IF7]P)$3/]%G+$IR
M>VN8Z0.IY./KC NH\90_'T83';C+7W-8W;)/@S840ZFS3TZ"<K) \$6#S"*A
M8RDE(QL[O;M4C/,4<;S=]T ]=(>D&\^N4C&&R^Q!6)[JK94@BX@!8F2:L9B*
MP/9#S.ZG9>RY\X?I^%'(["GPL?>U_XFS"\JWW\Q7^>I<-VDG-7)(O(J$B0+H
M)0>TTJLH@U5ZNT8K=SZZ)^WOJZYY,]F-K?D7\]FWO%C56<G_F"_^H*U\,X?V
M!C\Q69MX+)45O!R6%G0.8'R,UCAF9-KNR>H6BXU[7MX>':WE.S9>WLQGC[)T
M5<P0C8E)>@'%< N*2TN[<&9@6/9U9&UD;CO,;+G@N 6O[7$SA)P["$\^?)XO
M5A_SXDN56$T/UONO#"6G@AF(9K("\IXU6O-UP*-P2B0RCM:Q[KV$C--58<2+
MEH.UT2.DKOH,Y) U$Q$T1@8J!$M!71TB&I5,)3J30NLZI =(&?D@_' E/P6;
M/23> 7#6;O0=?J]F]';U.2\V7__H2!,8EP81F-"<V*E=[4S64)#V:Z:ED*5U
MZ?03)'4&I'W4/A].!QU ZO5\]FEUV]2*$,6B#K1%8YTI)04X%2(8X<AU2\H6
M8FM'=!\=(S6'&6]W.U@9'0+JRN1$=-IP5WN\1E!697"%#"2*'%@(F2S.# RI
M'K:VPS7\!&3V$'<'H'G*J?+"F4J48%J&M:<]XQ"0Q%0"1Y;JFUS7.MSN>F-K
MH?4=][5=5##R*(FW_YS1YWR>?EU;5\PH;-(&K/%$N"WDBW7*H'GFP4D1:4O>
M!CM/C(OX:='MT/%,)H_L+^Y><')UM1=89O7A=HC6@E+1@T_2@]6\]B,OY*=5
M2Z2,/3[D ,7=I_X]I#CVV> _?HPQ>W<>KP:J$O_<Q@!96I*#XA)02F*'^\2%
M-EGD[8KL[_GP#G2]CY;F#44VHLI3GDY>YT]X_G*VNIH.SDUA&;D&4S,U)6G+
MI(W,0RS,IX)!AT<?YBQS_(]/\V]_H8^^-'GZXMK:[UEP.P0\@T:$API[9)Q<
M4GW5"L):807ZRW?6BE,4A-9PX)Y%E24B+X_U%WP:)#=7&\=''*RN>0/9C;T=
M/-CJV6E&OYHE)*Y2O>^J+7PYAZ2=$+5]JT6VU9YP4 ?M092^O[*V:I*]B^3&
M5O_MYN]%<LN8SF"\)?P+K^MC> T"-7/>B,CD=L5Q^W30;[X%M%/V(7(:.>1_
MMYBGB[AZN[BL \R;PE+*FJ4M]0E8KL?!"*CKFXW(A3-6YJS<(^Y]V[C_OK6W
ML_MGT,&QB?#[ ,]U&6F^*@HM3&*MQP)!@3!Y.0J%/9$.3!CA*#J.<;L#\^T0
M=)> \?**PW5Z%R '"KB#\\P-(U<5#SQ:%2F5+H:1O=1WIF0B&5)D2IFL4I*M
M7P/\1,#HZ#A4H7=>,NTKW;VA\2TOPKS9$]ZO7\^_UQ9QT]7UXP;FBI3,0*:(
MB.1!P1(6&\'K8(5WE*3+UO<C]]&Q'52>44NU@Y71@;>YPT-MTO/IYN."S!RC
MJ-1#SKZV+V424&0#!76601,T>.M2ZB>)&OO)[J%Z?PI(!RFA0U1MN& R)18T
M L_U17.L;3&-*9 M9IFR]3ZWGK5P/R6=X><P=3\!ICUDWP."KMIY7YT)?,B?
MUD^I+L=0),VE90*\4Y1^9K*S0%DG2,&D,2ZRF%HW$GV4H.WP](R:;[533P]8
MNZ1]$UV&>J%AZ\@M%RPHICS4@7T470H11(Y:EJTR^EVP=9. 3MKH'Z[8VY#9
M6\ICG^W5YC^_XQ_YXNO5G97T64I=P"NLQ)-7#9%X"4%YHU0M+=WN2/?V)X^L
M^_TU=+M7TM[BZB++>L"+OB:#>$76L9Q@*5;&Y,&AKP]Y+8.@K2-/2C80M);6
M'FE<V0^:MH/.,^J;U%1)/>Q"-UJX7%2[H;]\)MDO7RV7%SF]FMU@<L*C%HZ'
M C'41U0\*$!G!8B4:J]X&]7M1VI-&RD]15\_ ZD.1\8CG96:JJD+SW>#NQ=D
MLU-2U%IM[W/,TV\YO?V)/>N2-ZXX$'E]R4L\AJ(E^&P2I;LF:]W\X&D7 L=]
M7GDL&#965%^N\-UB&O.[O%C;V$1E9E*($K@+M5A("T#M*3G6S-BD!+>I>6S^
M "WC/L$\%K;V%W\7[NS&+)5+)_WV8K5<X2Q-9Y\FR1KME&'@O4N@$N4QOD0!
M,D9>>/&&->^K_!@]XPXD&110S=30F6_*BUAU](F^<5T/6VBMF[X7F6 Z&$J7
M:<L'95,"'X4&(366)&+)MOFAYXXTCMLZ_FB^K+FZQCZ8N'PSOR2R-RQ^G-\P
MM>N?OJ^ZG"1N0B &0/(ZN]=;K#TZ$%))TLM2O#?;M7[>:=EQV_D.@JV!93\V
MJAYJ-D;V4^:++SB+^;><S\[7'T,<7MO5A$61%1<%/%I#QL,Y..G)@I!CSJ[X
MLB7$]J=AW!::P^'M2%KI%7S_>;%(YYF,*4^(9&ME+I"X=_7% (?@$L4/4159
MN'#!I(- =KW6N!WAC@^F/:7</VC.8EQ<X#D9Q72>)HP5(Y1)P&6N31,99<(N
M"(@Z!X;.15&V>Z:SX\+C=EP9$T[[R[^#D/_>\5@O_R0'.UWF=8;\XX?+S4^7
M?))T9&A<@<*\ ,4M&5 @_QME(LDFAY$UG[*\#Z$C=TH8-O$<7'-CN[['.5R;
MVSK%H=CTZWE>K</5JZM=^EZ8SM:J_O_+^[+FMG)DS??Y%1/SCMO8EXB)B9!E
MN481MN0KN[JGGQA8$C9OTZ2;I%RE_O63X"++DB@=DC@Z4-\*EZS-YR0R/R0R
MD=N(T^2%1;;FQ&29;!.(+\.(E6'9LZ"TOS\3?)=S4(>@@:N@>_0;!A!8 SIT
MY16M0R1OK^?CZ9?U4M?701?PQ^I'BY'@1D-&4S66T0320;$Z,NY$%6, *TU@
MU>-:G2@;N/:RWSN2^K)I '&_=BE\YR.<?)M=3Y<C#=P%FAG)4J#UH="\+34'
MQ&0:I>=:.5%[",TN6@8NX>D5557XWT04X;85V)O9?#[[ S=(Z2CGI.1<$^54
M&7TBD4=6Q3+Z1'(/G&:H/C'K(1D#I]SWJY6.Y'H#*NCC?!8!TN(=<JXHT7))
M<YE+ YYM8[F1L4QGDX$X5J(?SFL2J) DY\Q"++.X3>VV>\]3-7 Z:Z^PJBR3
M!E#V"^UER),TF1.5I4>ST"-K/"N)Y-JEC(XWN]^)N$JOM/V0\[JN^X_F<Q.'
MV*-^QVT&$T0T_)9C6)SZR032FYO[7O%(>V>#XNCR 7K&,H5,G(J!<#S*,WZI
M*-1.O3B2Y&Y8?%VA@"&DV8"*.TG?QM,QVI(HOA\ESK$X^_,[3!<P$BKD[- +
MH3&B&RPUZFK.@*!!@)O2)NUX[?E_.XGI!KC7%2ZH*X$6H!1C\4*V[0I/K^>%
MMR/E3?#&2F(58[@*[DGI*$\H2]09)E(4M6< /DY)-Q"]KB!!1=X/?=]Z!26N
M#U<0U],)QO]:R>9T-EVBAX*K^24;\^R?U^/ES9F?3V?7RTWPPVCPB1M&RK!Z
M(HUCQ$JJB<N:)9\\T/O=;'?<M!Y-2K?TV-=U\S^ D%X])']F>GZ>C[]\@?G(
M6QF=TYF$5#K\V<"(LU02[97(7M%H(+P,1A_0U@VTKS P,+ 87SV*/R,0%U]G
MDX1B*8FE;_T-VKG&!F>B)U;@XJ5 $]<[HT@Y;ZA2H).*+P/DQ\CKAN77%51H
M1)C_/G NOX@.73&[[S*#Q:@-"YS85,9Y6VV(BTP0YRT+X)6+M%L.2]^4=@/Y
MZXIQM"?B?Q^\K[]\ WDVAY)1"]/US/G+O(--40@&4.J)@2.;0#A4"TD2@;9:
MS-0KR5YZ)^R[AFY[Y'7%<5X3+(;>/>?3!-^FXSQ>Y^[>)M"=I!\E/K&Y:MGX
M)EE'Y#L'7$F(Z"X+5 L!@!B68F >%Q:[.9#[O+4;0E]72*A?UC=PU_5A/)W-
M<4>=3_&9L%C>5KW\3 Y_<W,QFT;<COCJ21EMOOJ5D73),J.1B8&708NED579
M1M9+=(V9L=K5'IIR,+'=H/DZ8TXO(\&AU=_5[,9/EC=W"[1^F\\6BU*\M1C1
MS&T6 >V>($3A7R:6Y5P"LS1+J:61W8I*GGQ--Q2]KFA19>8VH-&*/3&]AA*\
M+S;$'+GTM_'RZ^GU8CG[!O.S/^/DNE@ )XL%X)_TV?\Y,A97Q 00E=PF0.&8
M+/%::H47+)OJ#0P/(+,;_EYG\*AOJ;418)^A>LZ_S6;I;LO:3VBZCH17(4((
MQ"&WB$P,B"_M%Y(I!FJ(5J3:)<"[J>D&M-<98*HD@R;PM V6K3MZE'C9!2QO
M0V8ZL12"(\D50]1:=&Y*+BZ3( $M5,VK-\)XBIYNS3!>5R2INASV1Y5;HVH*
MR^-MK!5?QH4MVVUQMX2T.#?:.@^ ^X(YA0YS4NC<&& D"=!<.[07[S<UVV%G
M/?NJ;G!YA3&<NDP>VBQ_8C5G?R[1+5Z7&9=E666S2S(187*IZ(N6V,@8$=S(
MD U%GG6[D^C^SFX@>H7!DY[8/C2:'BSF"J: /RDIE2-@2;  ABB[:A%) PD<
M>:<4X'D=$^.Z6T?-I][2#3&O,!)1C;7-8>0=P%W']7P:R\&;BIVW&-GH*.2@
MB,UX[J*GFHD3&@ADGZ1$-X&F?!AHGGIM-Q2]PKOZ_I@_-*P^^IM5#^-WL_EC
MBRSIL!ZL%8+XX$OS_I1+U, 3*YUP44/6AG="TG-OZ@:>5WB-7I7%#5PTW5G/
MBGQ'O04(EC \<XF409"0%!#!M$W9)K3SJ]?I_$I"-^B\SFON8[A=#2S_^R\/
M.(NK^\?J1ZN?E']U!?E_EK]_OSK_Y?E_W(ZV_8\X^[9^P>GEAP_GGS^<77S^
M='+Q]O3RXO/YQ6]G%Z?G9Y_>PM*/)XM?U[ 8EY+OY_1,AZ?^Y2?-]U>S>?@#
M:-2@'XIUFB#]K^.;-JY'5Y1+G-M0<1S#XNUX$2>SQ?4<3L)B=8\XXLH'AD8O
M84IR(D&A7@DLD"2C53QE)GBLO#'W(K!6==>VN<K/EZ];:'OA00K%B7$ES!VR
M1 U+&>&>0=#,NF1J%T \0]*PS9_[0\^N>K :DAEX.N%5F3^SGN2N)2XZE411
M71*?J2$NE;%HH700%M)+WJD.XIEIA+<O'!8L544X.Y:?+8!@,[+!L!R<BD@Q
M+:TPB_OH168DQ9R=#T*EV&G 3A<8##UH\$!AW1?W 9P;6. ?QM/QM^MOMU,Z
M9 ZZ]..R @F7DI% C2 Q*9VYX<6&JR#R7UXZL- /$=FL!O^&%KS_\P[ASD0T
MV:4C48M<:EW*L+&82F<%+JG+5-S/GSQ,\'=?.DQG_FJ"/YA_#7BVN\^\-S>G
MZ.)]F<UO+G/QZ;:_D5;*,3,JHS"<9%NFK@KTXIWA999%5E#*2K*HG49Q(*G#
MCGWHPZ9X2=DU#=$=B]R,K*(T4BL8)5GPTJ$JX3(A<>(I39&Y8&-OS2_V)+55
ML[<BC#I#MYY,A[YG_O2/\70Y'T\7XW^^A=4=Z':>)V2K!7-E+BP>$59&8H/U
M).?5(>,9U??2-79%*G:\H54\593MK#:C&U!TY],?R*39?'R[@!@C=65C:9Y,
ML2(%VA$LDA"258G'($)M%?: B%;/S_I@JB.'!H"TFVD_+^@#+\H:M7?,J5B[
MOO1\*?,=M02!7J^EU1L2=R!KV#E*PQAKA\FD:9AM>CMFY1/54A,F2H,^*$W4
M!'Z@3#H6R[2+6#O3]3F:6CT:#P1!9Y =()$&$+9=QV68C+^L.QUGJSQ72:+!
M"?@!4+M;F3D1$ (-W@LPM:<,/J2BU3.Q#HJ.Y'H#N"D<6C[*H4VJ'$LI4<60
M,Q;0=Z&6$JNT)%0HE\ X=%_Z./V>HJG5HZ^>9JHFD7:#_)_.?BL1\JNSCY=7
M)3Y^45KME5KD(T+\SSZS4H!_/]HKA?<W4\:OX/ML7F*SM[%89AQ%<''B0KF2
M%8@XAU @4:"A%2 J^#D,NE9+Y1VT'*N-MIT8+[^O*MNG7S8O6HQ<RC9$)0FJ
M48&+1/B[J 5N,)NCY5FG7#M=82<Q34R;/PX']Y5.'<8W<)YM%[)F3_%%;E>2
MO#/>HS$'&C6S=!(M.BH385)1-.:,E]53T793,ZQ=U"N&CF3]ZSFRKB#.IG$\
M&:^>/<OOQE./7_O)!_ E6V8QRUL.+&>EV\9L,DXE&?#S;.DGBXH'725*>CH>
M^^!3WX>J]#;*S"A)R:.1A087<8  =@$M>N954J+ZG(*>#M5/\2NDZ]4XUWMO
M.)^N1B 6J;RYV?QP?7^#FRI%'3D)BADB<?,2FWPD0*FW/ @A8NWC]@ R&SV(
M]\'.@^D-/0NK@2/Z$XIHE=^^'<^TW?RK6!DM#HPW>/BD54Y(MB1D/#1,4!&0
MBS%W2Z?9!WE/$30PQOJ&PX.11K5DTP+0UK1OXAR*:49CR2_1*1')A2/.,D%
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ME_[-/@JE%;6,Q1DI>:2Q0-_[1 3HD#-//M+:=28/J6AD#LIQXKW?PODX7K>
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M5#HKC>?&L,G?CSGZC%Z[09\+SYJ<B6=9$AT!K(HF"-LI%?EYF#WZ_@:P54O
ML\K<;A QMPG])EE.-<FBY,\DG8@WW!,/:/JXXKO[&ETG=E,P*&HJ2/89J!S
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M?IWM_/-J6"<=&:64B!C1V*,"%6_FG-@,V4HJ@^.5O.J]Z!JFJN0%O.W^I-.
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MKVK5<<\Q@.B9BD1Q$$1"1 9J_$SQZ*C)7"5>N]=41]*:/*&K(>1A-*FZN%I
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MD5E!BKTRNK&67(=E874+Y@KN3HY'%].OQ%>V-](U%P(;L:LHA_$%1@NQEY5
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MDQ"F2XX7,1/.HUN4%%C-X.@QE<;((H;\2.YM\THQ;R:?&X*U^.E0X@?UP<0
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M26-Y&MW-289@FM*-YGC^M,C"L;(:O&-UC%_-Z1]AD3%AXD=8F?_ACDG"N(A
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M&QZ\@+5YWMWCW*+$4->JNGD7S)I]'WYH,U,?FTL=FW&:1BXJ3.:HLFG"9HV
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MHZ^JB8!E5!96P,18I),7&U+7PM D,IJ3Y?EW2.BWPZIK=TH<,M\-7D0LFW=
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MJ<3\VZ$/_.05)2>P)7[>*DD$\I(!,S CKVC/TL(N3):Q19:EA51>><KM!N]
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M5B%ML [>,73<M/DKMD&F^&T1.41D#EY)['/""$WBZV=/@='=FL8)9(6%6C;
M 4(GRL1^,X8PQ7D[7/T39$DW.*])(LCB#+:X%DP#.:0(F8I':[5FM(.9 #FD
ME\*UICICHQKE! BAID-RT2M?>)KF6H9PXWYFE,B_ZH!OA#(@S.A5+F%<PI_
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M:/,J,S17;H$P\+4N.?!4!YK106Y=,KZRVAZ_]#JB*.4>,*'.$FY_X=60*U;
M*4'B+'_73$](YMAJ2YS((XTE&_Q%N5)N[0WSRSK\ER,E[BD9LG:LTPYO^"(!
M;3O*\\4&H3S7*7I6<(TO8=6?IR9KX),7>BY79I4ONP(0C=M7.6@<^K^@'Y4
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M0>Z4,;]R0MS#((<]C.XH.KIV-?]@(7NQ>.K.F1V1A0)+G?[\\[.2HWCM7W-
M7B9XA9ZZJKUK8H$C+FELO510]6ND&3#;F"MDSVKHR0JFW&!./J](KV;J$/5V
M*A>FT5734WTM6^:Z MMT@9:![393//.:RR92$,Q08Y%FL6ME776#$ZVCV"&>
MK)IC_JNLPUW+ZX4 9B:HR1ZIU2QA#W.'5'4A)G&SHE1+.U,R_#!.55IW6D:J
M,M$25>4J2XP=B]V7Z6F15S%?DZ&E<D8;-P\B-4$G:8GXD-MS$_SQX1%+S9WC
M=EZ:K6EA&)QD$&F%N@]B["('R_"A0SXV$JJ#1NL)5K1T0HJGW5X3I-AA7S*2
M#H<Z <-'9@@4$P-Y>%*(1$_=/Z6#*M=%JP%6X:B/G^2BU/Y753.R^EN92FAY
MH;S,/I!F#ORKF#4@<@/$$;GU@8#E&>4;!O>6OO/=C8*Z2]KP'PX.NC]]B<Q,
M]-<?S--7^\/!X-GSH=X/G^_OOWJUMZ>BYX/G+U[H4!]$ZG^?O_CAFSQ]NUSX
MEQODPM_A#-?CV7PZ?'_<.SDZ/+\(/KP_^@9<L??3B^[>FLM/#X_IG8X__H::
MSP>T[.5.=IL5[E]8[L79Z?''HX=97<HQ]C*HKC]/8P['NL;CKLL;#W0H\46L
M3\NP*4QZ'PIW!9A2D;$XZ7<:<S095CU<K1Q]-P>DA8WBDL.=/!UQW+CC[>=O
M$M_XR@+-V;UV/KO=D72\P[!!^U#<Z^S1K]P'YUYNT':TUG;";<F33MDNA_XK
M0V+8I%SN34F/OS!TOLT7TD_7JU]V.*W,4T_B^4;QYQ%\,'KO#S*EH=4#@9-F
M%XUZ=BP*$I9.EBZK6NP[9^3".2/.W]W9,**79;6WQ=W P=7)BW9>7=[07AQ:
MD+ NM-+R'$Z)J.-!F&DF805N*U .47(-"DC=E<"*&K9N,?LJ8>%037DGN1:=
M^[455GR\YB(QHT@&>$N\%P&@O%,A-29:)>S<HE.P]PO+"==R!@\PENN.+L.,
MI>:&N+;U,>WC)]])EG<#;1UB#:GFXB%71L\Z&-#)-0LD\GA+5)ZK<$Q7J1"H
M2(SOY&-B7*2,?>*N98*LWIB"C!4\=M;;/7K?.SP[/#GJ!1_.3H]ZQQ_/>@\P
MZW)(QF#0%,\2G<"1\(&>:4'$._%G%\>MN79HM90\XFIIS/.XEC-WK?N<I&EU
M%AJ95&/S-+P,TFD)69BIC*=O=-PT>%P#C!6)<&L+9&(2".7&[SK!V?E'6R5W
MW1PTQ7/%.L2RP[QVHPX/&;6N'_+R%2LK4]5X_&I'4'IF4+A5EDMBT%Z>%=:-
MABN[@_/N#&GWGI1-.X8FHV?(L$PI#="[(3%-QG/J73"\OJL<X!*,5MH<1,H8
M<Q))DX'$S:^'DCI+/NL&/>)(N QERKM\%H,O!G0TF%"G'+HCTA*5]7#63!G+
ML?&%9%P),O'[7WXB9]6,+?NA;QR5E3&"$-0JXOQYK;Y!-N FZ!JOFD-#)'C2
M6#NT$5=@6%J>@6KW"8'!G*-T>+B,+TVYE:K-35[0[]WSJUBDI#00,.:'*M<4
MQP$+:IO7#8[JQZB:K&'=G!J>8B4SIIZ_VAV#TP234 )E'):<!_]<(X8TPTZ6
M2%M2ELV[--I![KH*S^ F^N+G5A<8&*R)T9& <H9*<(G<Z )?T';SW8E(+O5T
MH0LM[2T]_GN*=K/.4[Y4E@^NR;!&$E'-T*[7F4Q8S"0>=56;>%&.B!>R_DJC
MGRU7-Q^,'T5N1DBRR><=3!86$RMC(CPW\$C>*3TFUS=*C1IXJS:&S"=W>'BD
MFWH6UGKBUMA[,85>1\W("V\%CAF::W.-F;?O#X_^?OKQ(OC0.^N?'F^'$;,$
MA2CC]2#J%U!B9"$X'Z-LV\QXCK)S_RV0G#OZ<P@Q29(1K@/K#0@0MFZ0,-M[
M.CC8W2/?"5]BZ!CQOAV+Y\'<95C,5*DD;YD_Z6X]_/%P=V^#LB?KI/PS[>0W
M9# ()&8MXL(1/!2X"L]%#A;C!]8DD1OI&TFG/OZ^].O\S$%/^^H:>'*G2"0/
M/];^US,D4!F0,2TR6R@!_# +U@C\R69ZQE\9:/E'H3*B(E)[;]W&M-#?-GBK
M0^5GCJHD20LB@GIMR&(4ZX]RU54C,\$Z6+&#5<R#2X4WJH#'-,V=<9>7TU1+
M8\77K32&6R\TB2Q78&NCH!$ 6@@.LF@F^V1L!CS16AIT.")U\975M_34F@N:
MD,G4/"%S9602=K/<&H?D VIZH7&PLW=PC^?VD@L#OWAR2Z1QGDY?[^YW7^'G
MM"%<P>-$*MJ(XPXH-%T_C3T)(E6. "+5DT7!),7.N8\<104[OZF,M./>02?X
M?P4YB?C'.>D\$5![!ZR-C\F7\W]KN)] /3)$DLZ)#LH))2G6D(."F\PCPCT1
M8#F5LA;W3J)-*VA> ["#8)V0)%FA;LW=X!TP*Y\50ECL4L^TQ!5H1=7/RMO#
M!?BDHT3;2,WO4,F1DM"5ZBYP")=AO,L,W>N!N4I?*2EYT(J9!#V_H;\4]-(P
M9]J4G!<U+PJG"*\ZI',3-QTT8-RZ2T(8^7576M2+Q;CFN]4]MKK!IP)IU>7H
MB=BC=T0$'CNY] ZAT!>[?\?=^=^O=O_.&:3*H^I43Y:[2E+)-58-QT9?E35!
M$;V$KH/H%D"9#:=.?^9>&!*N=WSF@T"L]P'O(M5/%K THBVWSI0P*DX^6WE3
M/'H05W&3!G!T4')LY!CC/^/W^DM]UXS4X]G>YW[@3)O<\X[5,AQYN$_TWPZ+
M3%X@<U,8%EDY"*-DC<6A))*-0T: 686C8BH8ZEF%5NC4H JUL>[=@#E8?S8V
MUS[6YE:P6\[D*6W6,L8WJ.RDR(^G1[H4&1\(=$_U0E1PP%;6K<G;7GM6H]2M
MO(W+A%7OCBH^,W$I1R1&Y$X(G[D;B899>\T-$WVDPU1JIUYSU%;L#Z?MUE_3
MTL:<.=^-NHQ_-J2C%&&2/N<^0BCS<@-!TT37P?Z-^K):QG\'*7_L)Q*'9-]=
M.>#Q]1* 1;)XT@GD-5WPCN[EL@QCH).Y)J%QBPJ<C6?./.YVE9$]<"Z%(V$\
M+C.H707_N4:_#>61 [(ODGCB#5O1=XM+]S:YLE^(=#XP.7XC[9Z<7O363[[<
M#BJ QH $N^Z]&^LFSCKOK8/H;"*RG.D2Q_\%J];<OEKZ>AMW%M]#9>(B6[3<
M0;:T.#.<^\JO4K?<(-G)*F#[Q_V$PQ)E!PDQTE/W1F+&(,3!12.^[FLM-+E.
MTCO[^+X7[#U]B\A+"=1\?_@0VPS 5CXKZ-1<((D+]B*NWB/SD<S&"?O10&R@
M+J L?[I6C&44MUMB D26RU=\U 8VBSPDLG8SJIH%Y[B@2GY71215-P):JQ@4
M*!=Q"T4O K<TN*&XR7++0M7O6=KIN%.&C&;JH"KE>R;1%]BTX[*8L3/.ZSFH
M.[&N3SYG_L&N",NE=X,9/3<'*L9M.8:&!"I*IVZ+^-V38)22&"(!D(^KX<0<
M0.1\]M=DQ1)G7O&#)%JN;84 :L!DZ99U,MI1FP3>J@5)VT1PG:))!B -0%_I
MLF&&];2<=8)WW%@4LP] !TP,L.'+"EZQ$Z2]C8ZGSK2F PEA+$A N?:VZ]'W
MCY4FG"UYMD'9DHW0+<Y?F[E\!9\)HC]IDTAKH J2UQ,#U$V83N?E.,X22U/[
MT9?Z+3$&! GY*S1?XDGB"(! E>T</"G'-R$* H>#+M>-Q;)<93%79Z>@/K]/
M+FF\RNJL3IHU1\67@OBK#;P':<*O&%^1. Q.?0M)[3FE5B,,1L9Y0!O.'.43
MW,J >_C$A7;Q0U=W'"#[(=F;LD"]ELZ0:!FK68?$F6; ):G<):,Y">TF0I=7
M>BQ^!(1'!?6)=)?1R^@^*Y[;F"@/P):"1)C*W;@F4>.+;ZO",'5(J-2'^Z1C
M0EFZ/6U0GB(ZCV![<!J1(Y>^JE=?2PE*Y,<1I4N["QV6J1^+SR>P+*0FD]>S
MD!3W]94N\=_D5>GR( S*BQ-DG%N@Y\IE8W:_%3O+X"[/Q(LQ63X'0'><=3/,
M'!V%8V &VACZT4K#Q-J)N#!Z_3Q :J!;D==^8%7#R&5YSE1SS\UP-WE.%=O"
M32M[Q[5GRT2+8.=^U^D4 ,=_.Y9TOA%HLLPJW]ZYV@HTE^)&$$R-7PED6&MS
M]J._GYQ^>M\[_J7W6^_DXN'Y^X?UBL5:#J :'EG%4A<"IJNZK#<K&J0G0%F-
MP,1NLIK4Y>CMT)4,);GK7E.#.C;ZU0EOU1_@H09<X>#+'WQ UE]U3[7]CPY.
MW<'9WU0'YQOLR6UGZRYOB>9KSRMQ 6F!OFJ_/3R1T9=P%E<O@1T;!M2M"_JN
M]3"M\R[9D;42Z TK_5O^0FT&DOID*7#7IE)N"DA=@.)H,X4E^IG -;D-[TCY
MRCML\XK#6K_%P09^&VW5T=IU6V:,$MU,%K7Z<@K@9#M?CA21LPBN]S3HX)J&
MKG<9RXVAJU9:]2MZ#+GC'C"ZBAOQI\^3=-K8F_L=#G#+O2$/?P:87[TJ+*F7
M&$NS_C"76C^ GHJRNLHWOH[JO<ONX"W<Y;M<BF^\^09H]BZ7+TZM?NW_\28R
MEGS$^6N3\+OSC]XT1P$MP:*R@I>O*V.H^U0,HIR6DT?^R>[K+G_U8QY=_^[9
M0??%BV<KOW[:W5OYW4VWW7_6W?]I__YO^ZK[XOG!K6[[(^]$MF!XR\P0_) .
MP9(M\M<?]G^HS%'N=/OZ:2"=?/PSOL&E;G7K78FC0\"<Z5K49YHH ._Z'K^O
MGTT_XS9O:I8RVOY>0T,S\=V38?GTBP-R0 \?,L,0K1,U*3O-/)QSWNS5/5+A
M;:GPG-O'D$)^),%'$FR'!(_)6'RDOOM<W8]L=WUCDW!9=.;9RX-:S\#'P"$'
M#I^O#AS^.$BC.?UGG$_BO_U_4$L! A0#%     @ )34P6 L;-JDB6 8 NQE#
M !$              ( !     '=A;&0M,C R,C$R,S$N:'1M4$L! A0#%
M  @ )34P6"[D=<_A(0  _),! !$              ( !45@& '=A;&0M,C R
M,C$R,S$N>'-D4$L! A0#%     @ )34P6)YNSD<I/   .W0" !4
M     ( !87H& '=A;&0M,C R,C$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( "4U
M,%@]OJ:A9B ! (C)#  5              "  ;VV!@!W86QD+3(P,C(Q,C,Q
M7V1E9BYX;6Q02P$"% ,4    "  E-3!8TF . )GD P"P- 0 %
M    @ %6UP< =V%L9"TR,#(R,3(S,5]G,2YJ<&=02P$"% ,4    "  E-3!8
M;++T5_VU 0!;+0( %               @ $AO L =V%L9"TR,#(R,3(S,5]G
M,BYJ<&=02P$"% ,4    "  E-3!8\1VG_ IF @":= ( %
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M2P$"% ,4    "  E-3!85X=(2 ZX 0"!;1( %0              @ $]1AP
M=V%L9"TR,#(R,3(S,5]L86(N>&UL4$L! A0#%     @ )34P6(Q@.%BL90$
M-!D0 !4              ( !?OX= '=A;&0M,C R,C$R,S%?<')E+GAM;%!+
M 0(4 Q0    ( "4U,%C56?T6Z@8  *\D   ;              "  5UD'P!W
M86QD+3(P,C(Q,C,Q>#(P9GAE>#$R,2YH=&U02P$"% ,4    "  E-3!8VE+O
MS? &  #.)   &P              @ & :Q\ =V%L9"TR,#(R,3(S,7@R,&9X
M97@Q,C(N:'1M4$L! A0#%     @ )34P6"21QWT@!   D!   !L
M     ( !J7(? '=A;&0M,C R,C$R,S%X,C!F>&5X,3,Q+FAT;5!+ 0(4 Q0
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(  "ZL!\    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
